Diet	O
and	O
gene	O
expression	O
:	O
delta	B-geneN
-	I-geneN
5	I-geneN
and	I-geneN
delta	I-geneN
-	I-geneN
6	I-geneN
desaturases	E-geneN
in	O
healthy	O
Chinese	O
and	O
European	O
subjects	O
.	O

AIM	O
:	O
To	O
compare	O
the	O
composition	O
of	O
fatty	B-chem
acids	E-chem
(	O
FAs	S-chem
)	O
in	O
diet	O
,	O
and	O
the	O
expression	O
of	O
delta	B-geneY
-	I-geneY
6	I-geneY
desaturase	E-geneY
(	O
D6D	S-geneY
)	O
and	O
delta	B-geneY
-	I-geneY
5	I-geneY
desaturase	E-geneY
(	O
D5D	S-geneY
)	O
genes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
Chinese	O
and	O
Europeans	O
.	O

METHODS	O
:	O
Three	O
-	O
day	O
dietary	O
records	O
from	O
20	O
subjects	O
from	O
Beijing	O
,	O
China	O
(	O
n	O
=	O
10	O
)	O
and	O
Kent	O
,	O
UK	O
(	O
n	O
=	O
10	O
)	O
were	O
analysed	O
.	O

Expression	O
of	O
PBMC	O
D6D	S-geneY
and	O
D5D	S-geneY
genes	O
of	O
the	O
subjects	O
was	O
determined	O
using	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
The	O
dietary	O
intake	O
of	O
Chinese	O
subjects	O
contained	O
less	O
saturated	B-chem
fatty	I-chem
acids	E-chem
(	O
SFAs	S-chem
)	O
and	O
monounsaturated	B-chem
fatty	I-chem
acids	E-chem
(	O
MUFAs	S-chem
)	O
,	O
but	O
more	O
essential	B-chem
fatty	I-chem
acids	E-chem
(	O
EFAs	S-chem
)	O
than	O
that	O
of	O
Europeans	O
.	O

Levels	O
of	O
expression	O
of	O
PBMC	O
D6D	S-geneY
and	O
D5D	S-geneY
genes	O
of	O
Chinese	O
subjects	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
Europeans	O
.	O

A	O
significant	O
positive	O
correlation	O
was	O
found	O
between	O
dietary	O
intake	O
of	O
total	O
SFAs	O
and	O
total	O
MUFAs	O
and	O
expression	O
of	O
PBMC	O
D6D	S-geneY
and	O
D5D	S-geneY
genes	O
,	O
but	O
a	O
significant	O
negative	O
correlation	O
between	O
dietary	O
intake	O
of	O
linoleic	B-chem-C4-1
acid	E-chem-C4-1
(	O
LA	S-chem-C4-1
)	O
and	O
alpha	B-chem-C4-1
-	I-chem-C4-1
linolenic	I-chem-C4-1
acid	E-chem-C4-1
(	O
LNA	S-chem-C4-1
)	O
and	O
the	O
expression	O
of	O
PBMC	O
D6D	S-geneY-C4-2
and	O
D5D	S-geneY-C4-2
genes	O
.	O

CONCLUSION	O
:	O
Intake	O
of	O
high	O
SFAs	S-chem-C3-1
and	O
MUFAs	S-chem-C3-1
appears	O
to	O
increase	O
expression	O
of	O
PBMC	O
D6D	S-geneY-C3-2
and	O
D5D	S-geneY-C3-2
genes	O
,	O
whilst	O
high	O
EFAs	S-chem-C4-1
intake	O
appears	O
to	O
decrease	O
expression	O
of	O
PBMC	O
D6D	S-geneY-C4-2
and	O
D5D	S-geneY-C4-2
genes	O
.	O

A	O
follow	O
-	O
up	O
study	O
of	O
the	O
expression	O
of	O
D6D	S-geneY
and	O
D5D	S-geneY
genes	O
in	O
Chinese	O
who	O
live	O
in	O
European	O
countries	O
with	O
high	O
SFA	S-chem
and	O
MUFA	S-chem
diets	O
would	O
be	O
of	O
interest	O
.	O

Role	O
of	O
organic	B-geneY-C9-2
cation	I-geneY-C9-2
/	I-geneY-C9-2
carnitine	I-geneY-C9-2
transporter	I-geneY-C9-2
1	E-geneY-C9-2
in	O
uptake	O
of	O
phenformin	S-chem-MU-1
and	O
inhibitory	O
effect	O
on	O
complex	B-geneN-C4-2
I	E-geneN-C4-2
respiration	O
in	O
mitochondria	O
.	O

Phenformin	S-chem-C4-1
causes	O
lactic	O
acidosis	O
in	O
clinical	O
situations	O
due	O
to	O
inhibition	O
of	O
mitochondrial	B-geneN-C4-2
respiratory	I-geneN-C4-2
chain	I-geneN-C4-2
complex	I-geneN-C4-2
I	E-geneN-C4-2
.	O

It	O
is	O
reportedly	O
taken	O
up	O
by	O
hepatocytes	O
and	O
exhibits	O
mitochondrial	O
toxicity	O
in	O
the	O
liver	O
.	O

In	O
this	O
study	O
,	O
uptake	O
of	O
phenformin	S-chem
and	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
tetraethylammonium	E-chem
(	O
TEA	S-chem
)	O
and	O
complex	B-geneN-C4-2
I	E-geneN-C4-2
inhibition	O
by	O
phenformin	S-chem-C4-1
were	O
examined	O
in	O
isolated	O
liver	O
and	O
heart	O
mitochondria	O
.	O

Uptake	O
of	O
phenformin	S-chem
into	O
isolated	O
rat	O
liver	O
mitochondria	O
was	O
higher	O
than	O
that	O
into	O
heart	O
mitochondria	O
.	O

It	O
was	O
inhibited	O
by	O
several	O
cat	O
ionic	O
compounds	O
,	O
which	O
suggests	O
the	O
involvement	O
of	O
multispecific	O
transport	O
system	O
(	O
s	O
)	O
.	O

Similar	O
characteristics	O
were	O
also	O
observed	O
for	O
uptake	O
of	O
TEA	S-chem
;	O
however	O
,	O
uptake	O
of	O
phenformin	S-chem
into	O
mitochondria	O
of	O
organic	B-geneY
cation	I-geneY
/	I-geneY
carnitine	I-geneY
transporter	I-geneY
1	E-geneY
(	O
OCTN1	S-geneY
)	O
knockout	O
mice	O
was	O
lower	O
than	O
that	O
in	O
wild	O
-	O
type	O
mice	O
,	O
whereas	O
uptake	O
of	O
TEA	S-chem
was	O
comparable	O
between	O
the	O
two	O
strains	O
,	O
suggesting	O
the	O
involvement	O
of	O
distinct	O
transport	O
mechanisms	O
for	O
these	O
two	O
cations	O
in	O
mitochondria	O
.	O

Inhibition	O
by	O
phenformin	S-chem-C4-1
of	O
oxygen	S-chem
consumption	O
via	O
complex	B-geneN-C4-2
I	E-geneN-C4-2
respiration	O
in	O
isolated	O
rat	O
liver	O
mitochondria	O
was	O
greater	O
than	O
that	O
in	O
heart	O
mitochondria	O
,	O
whereas	O
inhibitory	O
effect	O
of	O
phenformin	S-chem-C4-1
on	O
complex	B-geneN-C4-2
I	E-geneN-C4-2
respiration	O
was	O
similar	O
in	O
inside	O
-	O
out	O
structured	O
submitochondrial	O
particles	O
prepared	O
from	O
rat	O
livers	O
and	O
hearts	O
.	O

Lactic	O
acidosis	O
provoked	O
by	O
iv	O
infusion	O
of	O
phenformin	S-chem
was	O
weaker	O
in	O
octn1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
that	O
in	O
wild	O
-	O
type	O
mice	O
.	O

These	O
observations	O
suggest	O
that	O
uptake	O
of	O
phenformin	S-chem-MU-1
into	O
liver	O
mitochondria	O
is	O
at	O
least	O
partly	O
mediated	O
by	O
OCTN1	S-geneY-C9-2
and	O
functionally	O
relevant	O
to	O
its	O
inhibition	O
potential	O
of	O
complex	B-geneN-C4-2
I	E-geneN-C4-2
respiration	O
.	O

This	O
study	O
was	O
,	O
thus	O
,	O
the	O
first	O
to	O
demonstrate	O
OCTN1	S-geneY
-	O
mediated	O
mitochondrial	O
transport	O
and	O
toxicity	O
of	O
biguanide	O
in	O
vivo	O
in	O
rodents	O
.	O

Phillyrin	S-chem-C3-1
attenuates	O
high	O
glucose	S-chem
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
through	O
the	O
activation	O
of	O
LKB1	S-geneY-C3-2
/	O
AMP	B-geneN-C3-2
-	I-geneN-C3-2
activated	I-geneN-C3-2
protein	I-geneN-C3-2
kinase	E-geneN-C3-2
-	O
dependent	O
signalling	O
.	O

Phillyrin	S-chem
,	O
an	O
active	O
constituent	O
found	O
in	O
many	O
medicinal	O
plants	O
and	O
certain	O
functional	O
foods	O
,	O
has	O
anti	O
-	O
obesity	O
activity	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
provide	O
new	O
data	O
on	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
the	O
role	O
of	O
phillyrin	S-chem
in	O
the	O
prevention	O
of	O
high	O
glucose	S-chem
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
.	O

We	O
found	O
that	O
phillyrin	S-chem
suppressed	O
high	O
glucose	S-chem
-	O
induced	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
.	O

Phillyrin	S-chem-C4-1
strongly	O
inhibited	O
high	O
glucose	S-chem-C3-1
-	O
induced	O
fatty	B-geneY-MU-2
acid	I-geneY-MU-2
synthase	E-geneY-MU-2
(	O
FAS	S-geneY-MU-2
)	O
expression	O
by	O
modulating	O
sterol	B-geneY
regulatory	I-geneY
element	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
-	I-geneY
1c	E-geneY
(	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
)	O
activation	O
.	O

Moreover	O
,	O
use	O
of	O
the	O
pharmacological	O
AMP	B-geneN-C4-2
-	I-geneN-C4-2
activated	I-geneN-C4-2
protein	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
AMPK	S-geneN-C4-2
)	O
inhibitor	O
compound	B-chem-C4-1
C	E-chem-C4-1
revealed	O
that	O
AMPK	S-geneN-C4-2
is	O
essential	O
for	O
suppressing	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
expression	O
in	O
phillyrin	S-chem
-	O
treated	O
cells	O
.	O

Finally	O
,	O
we	O
found	O
that	O
liver	B-geneY
kinase	I-geneY
B1	E-geneY
(	O
LKB1	S-geneY
)	O
phosphorylation	O
is	O
required	O
for	O
the	O
phillyrin	S-chem-C3-1
-	O
enhanced	O
activation	O
of	O
AMPK	S-geneN-C3-2
in	O
HepG2	O
hepatocytes	O
.	O

These	O
results	O
indicate	O
that	O
phillyrin	S-chem-MU-1
prevents	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
by	O
blocking	O
the	O
expression	O
of	O
SREBP	B-geneY-C4-2
-	I-geneY-C4-2
1c	E-geneY-C4-2
and	O
FAS	S-geneY-C4-2
through	O
LKB1	S-geneY-C3-2
/	O
AMPK	S-geneN-C3-2
activation	O
,	O
suggesting	O
that	O
phillyrin	S-chem-C3-1
is	O
a	O
novel	O
AMPK	S-geneN-C3-2
activator	O
with	O
a	O
role	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
obesity	O
.	O

Enhanced	O
heterodimerization	O
of	O
Bax	S-geneY
by	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
mutants	O
improves	O
irradiated	O
cell	O
survival	O
.	O

B	B-geneY
Cell	I-geneY
Lymphoma	I-geneY
-	I-geneY
2	E-geneY
(	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
)	O
protein	O
suppresses	O
ionizing	O
radiation	O
-	O
induced	O
apoptosis	O
in	O
hemato	O
-	O
lymphoid	O
system	O
.	O

To	O
enhance	O
the	O
survival	O
of	O
irradiated	O
cells	O
,	O
we	O
have	O
compared	O
the	O
effects	O
and	O
mechanism	O
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
and	O
its	O
functional	O
variants	O
,	O
D34A	S-geneN
(	O
caspase	B-geneY
-	I-geneY
3	E-geneY
resistant	O
)	O
and	O
S70E	S-geneN
(	O
mimics	O
phosphorylation	O
on	O
S70	O
)	O
.	O

Bcl	B-geneY
-	I-geneY
2	E-geneY
and	O
its	O
mutants	O
were	O
transfected	O
into	O
hematopoietic	O
cell	O
line	O
and	O
assessed	O
for	O
cell	O
survival	O
,	O
clonogenicity	O
and	O
cell	O
cycle	O
perturbations	O
upon	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
electrostatic	O
potential	O
of	O
BH3	B-geneN
cleft	E-geneN
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
/	O
mutants	O
and	O
their	O
heterodimerization	O
with	O
Bcl	B-geneY
-	I-geneY
2	I-geneY
associated	I-geneY
X	I-geneY
protein	E-geneY
(	O
Bax	S-geneY
)	O
were	O
computationally	O
evaluated	O
.	O

Correspondingly	O
,	O
these	O
results	O
were	O
verified	O
by	O
co	O
-	O
immunoprecipitation	O
and	O
western	O
blotting	O
.	O

The	O
mutants	O
afford	O
higher	O
radioprotective	O
effect	O
than	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
in	O
apoptotic	O
and	O
clonogenic	O
assays	O
at	O
D	O
(	O
0	O
)	O
(	O
radiation	O
dose	O
at	O
which	O
37	O
%	O
cell	O
survival	O
was	O
observed	O
)	O
.	O

The	O
computational	O
and	O
functional	O
analysis	O
indicates	O
that	O
mutants	O
have	O
higher	O
propensity	O
to	O
neutralize	O
Bax	S-geneY
protein	O
by	O
heterodimerization	O
and	O
have	O
increased	O
caspase	B-geneY
-	I-geneY
9	E-geneY
suppression	O
capability	O
,	O
which	O
is	O
responsible	O
for	O
enhanced	O
survival	O
.	O

This	O
study	O
implies	O
potential	O
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
mutants	O
or	O
their	O
chemical	O
/	O
peptide	O
mimics	O
to	O
elicit	O
radioprotective	O
effect	O
in	O
cells	O
exposed	O
to	O
radiation	O
.	O

P21	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	I-geneY
1	E-geneY
(	O
Pak1	S-geneY
)	O
mediates	O
the	O
cross	O
talk	O
between	O
insulin	S-geneN
and	O
β	B-geneY
-	I-geneY
catenin	E-geneY
on	O
proglucagon	S-geneN
gene	O
expression	O
and	O
its	O
ablation	O
affects	O
glucose	S-chem
homeostasis	O
in	O
male	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
gut	O
endocrine	O
L	O
cells	O
,	O
the	O
Wnt	S-geneN
signaling	O
pathway	O
effector	O
β	B-geneY
-	I-geneY
catenin	E-geneY
(	O
β	B-geneY
-	I-geneY
cat	E-geneY
)	O
/	O
transcription	B-geneY
factor	I-geneY
7	I-geneY
-	I-geneY
like	I-geneY
2	E-geneY
mediates	O
the	O
stimulatory	O
effect	O
of	O
insulin	S-geneY
on	O
proglucagon	S-geneN
(	O
gcg	S-geneY
)	O
expression	O
and	O
glucagon	B-geneY
-	I-geneY
like	I-geneY
peptide	I-geneY
-	I-geneY
1	E-geneY
(	O
GLP	B-geneY
-	I-geneY
1	E-geneY
)	O
production	O
.	O

In	O
several	O
other	O
cell	O
lineages	O
,	O
insulin	S-geneN
is	O
able	O
to	O
stimulate	O
p21	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	I-geneY
1	E-geneY
(	O
Pak1	S-geneY
)	O
.	O

Here	O
we	O
determined	O
the	O
role	O
of	O
Pak1	S-geneY
in	O
gcg	S-geneY
expression	O
and	O
the	O
effect	O
of	O
Pak1	S-geneY
deletion	O
on	O
glucose	S-chem
homeostasis	O
.	O

Insulin	S-geneN
stimulated	O
Pak1	S-geneY
activation	O
through	O
increasing	O
its	O
Thr423	S-chem
phosphorylation	O
in	O
gut	O
gcg	S-geneY
-	O
expressing	O
cell	O
lines	O
,	O
associated	O
with	O
increased	O
gcg	S-geneY
mRNA	O
levels	O
.	O

This	O
stimulation	O
was	O
attenuated	O
by	O
the	O
Pak	S-geneN-C4-2
inhibitor	O
2,2	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
dihydroxy	I-chem-C4-1
-	I-chem-C4-1
1,1	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
dinaphthyldisulfide	E-chem-C4-1
(	O
IPA3	S-chem-C4-1
)	O
or	O
dominant	O
-	O
negative	O
Pak1	S-geneY
.	O

Both	O
insulin	S-geneN
and	O
cAMP	S-chem
-	O
promoting	O
agents	O
activated	O
β	O
-	O
cat	O
Ser675	S-chem
phosphorylation	O
,	O
which	O
was	O
attenuated	O
by	O
IPA3	O
or	O
protein	B-geneN
kinase	I-geneN
A	E-geneN
inhibition	O
,	O
respectively	O
.	O

Gut	O
gcg	S-geneY
levels	O
were	O
reduced	O
in	O
male	O
Pak1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
associated	O
with	O
impaired	O
glucose	S-chem
tolerance	O
after	O
an	O
ip	O
or	O
oral	O
glucose	S-chem
challenge	O
.	O

These	O
mice	O
had	O
lower	O
circulating	O
active	O
GLP	B-geneY
-	I-geneY
1	E-geneY
levels	O
after	O
a	O
glucose	S-chem
challenge	O
as	O
well	O
as	O
reduced	O
distal	O
ileum	O
GLP	B-geneY
-	I-geneY
1	E-geneY
content	O
after	O
insulin	O
treatment	O
.	O

Finally	O
,	O
the	O
Pak1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
reduced	O
brainstem	O
gcg	O
level	O
and	O
abolished	O
β	B-geneY
-	I-geneY
cat	E-geneY
Ser675	S-chem
phosphorylation	O
in	O
brain	O
neurons	O
after	O
insulin	S-geneN
treatment	O
.	O

We	O
suggest	O
that	O
Pak1	S-geneY
mediates	O
the	O
cross	O
talk	O
between	O
insulin	S-geneN
and	O
Wnt	S-geneN
signaling	O
pathways	O
on	O
gut	O
and	O
brain	O
gcg	S-geneY
expression	O
,	O
and	O
its	O
ablation	O
impairs	O
glucose	S-chem
homeostasis	O
.	O

Significant	O
receptor	O
affinities	O
of	O
metabolites	O
and	O
a	O
degradation	O
product	O
of	O
mometasone	B-chem
furoate	E-chem
.	O

Mometasone	B-chem
furoate	E-chem
(	O
MF	S-chem
)	O
is	O
a	O
highly	O
potent	O
glucocorticoid	O
used	O
topically	O
to	O
treat	O
inflammation	O
in	O
the	O
lung	O
,	O
nose	O
and	O
on	O
the	O
skin	O
.	O

However	O
,	O
so	O
far	O
no	O
information	O
has	O
been	O
published	O
on	O
the	O
human	B-geneY
glucocorticoid	I-geneY
receptor	E-geneY
activity	O
of	O
the	O
metabolites	O
or	O
degradation	O
products	O
of	O
MF	S-chem
.	O

We	O
have	O
now	O
determined	O
the	O
relative	O
receptor	O
binding	O
affinities	O
of	O
the	O
known	O
metabolite	O
6beta	B-chem
-	I-chem
OH	I-chem
MF	E-chem
and	O
the	O
degradation	O
product	O
9,11	B-chem
-	I-chem
epoxy	I-chem
MF	E-chem
to	O
understand	O
their	O
possible	O
contribution	O
to	O
undesirable	O
systemic	O
side	O
effects	O
.	O

In	O
competition	O
experiments	O
with	O
human	B-geneY
lung	I-geneY
glucocorticoid	I-geneY
receptors	E-geneY
we	O
have	O
determined	O
the	O
relative	O
receptor	O
affinities	O
(	O
RRA	O
)	O
of	O
these	O
substances	O
with	O
reference	O
to	O
dexamethasone	S-chem
(	O
RRA	O
=	O
100	O
)	O
.	O

We	O
have	O
discovered	O
that	O
6beta	B-chem
-	I-chem
OH	I-chem
MF	E-chem
and	O
9,11	B-chem
-	I-chem
epoxy	I-chem
MF	E-chem
display	O
RRAs	O
of	O
206	O
+	O
/	O
-	O
15	O
and	O
220	O
+	O
/	O
-	O
22	O
,	O
respectively	O
.	O

This	O
level	O
of	O
activity	O
is	O
similar	O
to	O
that	O
of	O
the	O
clinically	O
used	O
inhaled	O
corticosteroid	S-chem
flunisolide	S-chem
(	O
RRA	O
180	O
+	O
/	O
-	O
11	O
)	O
.	O

Furthermore	O
we	O
observed	O
that	O
9,11	B-chem
-	I-chem
epoxy	I-chem
MF	E-chem
is	O
a	O
chemically	O
reactive	O
metabolite	O
.	O

In	O
recovery	O
experiments	O
with	O
human	O
plasma	O
and	O
lung	O
tissue	O
we	O
found	O
a	O
time	O
dependent	O
decrease	O
in	O
extractability	O
of	O
the	O
compound	O
.	O

Hence	O
,	O
we	O
provide	O
data	O
that	O
might	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
pharmacokinetics	O
as	O
well	O
as	O
the	O
clinical	O
effects	O
of	O
MF	S-chem
.	O

Arsenic	S-chem
activates	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
Gi	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
signaling	O
to	O
inhibit	O
stem	O
cell	O
differentiation	O
in	O
adipogenesis	O
.	O

Dysfunctional	O
lipid	O
and	O
glucose	S-chem
metabolism	O
contribute	O
to	O
metabolic	O
syndrome	O
-	O
a	O
major	O
public	O
health	O
concern	O
that	O
enhances	O
cardiovascular	O
disease	O
risk	O
.	O

Arsenic	S-chem
(	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
)	O
exposure	O
may	O
increase	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
disease	O
risk	O
by	O
impairing	O
adipose	O
tissue	O
differentiation	O
,	O
function	O
,	O
and	O
insulin	O
sensitivity	O
through	O
pathogenic	O
mechanisms	O
that	O
remain	O
unclear	O
.	O

We	O
hypothesized	O
that	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
signals	O
through	O
the	O
Pertussis	B-geneN
toxin	E-geneN
(	O
Ptx	S-geneN
)	O
sensitive	O
,	O
Gi	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
(	O
GPCR	S-geneN
)	O
to	O
impair	O
adipogenesis	O
,	O
as	O
previously	O
demonstrated	O
for	O
its	O
stimulation	O
of	O
vascular	O
oxidant	O
generation	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O

Because	O
both	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
and	O
GPCR	S-geneN
ligands	O
inhibit	O
progenitor	O
cell	O
differentiation	O
into	O
adipocytes	O
,	O
we	O
investigated	O
the	O
hypothesis	O
in	O
a	O
model	O
of	O
low	O
-	O
passage	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSC	O
)	O
.	O

As	B-chem
(	I-chem
III	I-chem
)	E-chem
(	O
0.1	O
-	O
1.0	O
µM	O
)	O
suppressed	O
dexamethasone	S-chem
/	O
insulin	O
-	O
induced	O
hMSC	O
adipogenesis	O
,	O
as	O
indicated	O
by	O
decreased	O
transcriptional	O
promoters	O
of	O
differentiation	O
,	O
decreased	O
fat	O
droplet	O
formation	O
,	O
and	O
decreased	O
expression	O
of	O
differentiated	O
adipocyte	O
markers	O
,	O
such	O
as	O
adiponectin	S-geneY
and	O
perilipin	S-geneY
.	O

Preincubating	O
hMSC	O
with	O
Ptx	S-geneN
prevented	O
90	O
%	O
of	O
the	O
suppressive	O
effect	O
of	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
.	O

Selective	O
competitive	O
antagonists	O
of	O
Gi	S-geneN
-	O
coupled	O
endothelin	B-geneN
-	I-geneN
1	I-geneN
type	I-geneN
A	I-geneN
and	I-geneN
B	I-geneN
receptors	E-geneN
were	O
~	O
60	O
%	O
effective	O
in	O
blocking	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
inhibition	O
and	O
combination	O
of	O
antagonists	O
to	O
both	O
receptors	O
were	O
85	O
%	O
effective	O
.	O

In	O
contrast	O
,	O
antagonists	O
to	O
the	O
sphingosine	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
phosphate	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
(	O
previously	O
shown	O
to	O
mediate	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
vascular	O
effects	O
)	O
or	O
the	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
were	O
ineffective	O
in	O
blocking	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
effects	O
.	O

These	O
studies	O
suggest	O
a	O
majority	O
of	O
arsenic	S-chem
-	O
inhibited	O
adipocyte	O
differentiation	O
,	O
and	O
metabolism	O
requires	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
GPCRs	S-geneN
and	O
that	O
As	B-chem
(	I-chem
III	I-chem
)	E-chem
effects	O
on	O
GPCR	S-geneN
signaling	O
are	O
tissue	O
and	O
context	O
specific	O
.	O

This	O
may	O
represent	O
a	O
significant	O
mechanism	O
for	O
the	O
contribution	O
of	O
arsenic	S-chem
exposure	O
to	O
increased	O
metabolic	O
and	O
cardiovascular	O
diseases	O
.	O

Iron	S-chem
and	O
zinc	S-chem
bioavailability	O
in	O
Caco	O
-	O
2	O
cells	O
:	O
influence	O
of	O
caseinophosphopeptides	S-geneN
.	O

A	O
study	O
has	O
been	O
made	O
of	O
the	O
influence	O
of	O
two	O
pools	O
of	O
caseinophosphopeptides	S-geneN
(	O
CPPs	S-geneN
)	O
obtained	O
from	O
α	B-geneN
(	I-geneN
s	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
β	I-geneN
-	I-geneN
casein	E-geneN
(	O
CN	S-geneN
)	O
fractions	O
,	O
and	O
of	O
three	O
specific	O
CPPs	S-geneN
(	O
β	B-geneY
-	I-geneY
CN	E-geneY
(	O
1	O
-	O
25	O
)	O
4P	O
,	O
α	B-geneY
(	I-geneY
s1	I-geneY
)	I-geneY
-	I-geneY
CN	E-geneY
(	O
64	O
-	O
74	O
)	O
4P	O
and	O
α	B-geneN
(	I-geneN
s2	I-geneN
)	I-geneN
-	I-geneN
CN	E-geneN
(	O
1	O
-	O
19	O
)	O
4P	O
)	O
,	O
on	O
iron	S-chem
bioavailability	O
(	O
ferritin	S-geneY
synthesis	O
)	O
and	O
zinc	S-chem
bioavailability	O
(	O
retention	O
,	O
transport	O
and	O
uptake	O
of	O
zinc	S-chem
)	O
in	O
Caco	O
-	O
2	O
cells	O
.	O

α	B-geneN
-	I-geneN
CPP	E-geneN
and	O
β	B-geneN
-	I-geneN
CPP	E-geneN
pools	O
did	O
not	O
improve	O
ferritin	S-geneY
synthesis	O
,	O
but	O
the	O
three	O
specific	O
CPPs	S-geneN
showed	O
an	O
increase	O
in	O
ferritin	S-geneY
synthesis	O
in	O
Caco	O
-	O
2	O
cells	O
versus	O
iron	B-chem
sulphate	E-chem
,	O
β	B-geneY
-	I-geneY
CN	E-geneY
(	O
1	O
-	O
25	O
)	O
4P	O
being	O
the	O
most	O
effective	O
.	O

In	O
relation	O
to	O
zinc	S-chem
bioavailability	O
,	O
α	B-geneN-C9-2
-	I-geneN-C9-2
CPPs	E-geneN-C9-2
,	O
β	B-geneN-C9-2
-	I-geneN-C9-2
CPPs	E-geneN-C9-2
,	O
α	B-geneY-C9-2
(	I-geneY-C9-2
s1	I-geneY-C9-2
)	I-geneY-C9-2
-	I-geneY-C9-2
CN	E-geneY-C9-2
(	O
64	O
-	O
74	O
)	O
4P	O
and	O
β	B-geneY-C9-2
-	I-geneY-C9-2
CN	E-geneY-C9-2
(	O
1	O
-	O
25	O
)	O
4P	O
increased	O
zinc	S-chem-C9-1
uptake	O
.	O

However	O
,	O
this	O
increase	O
was	O
of	O
the	O
same	O
order	O
as	O
the	O
increase	O
due	O
to	O
the	O
presence	O
of	O
zinc	B-chem
sulphate	E-chem
.	O

Discovery	O
of	O
a	O
synthetic	O
Aminopeptidase	B-geneY-C4-2
N	E-geneY-C4-2
inhibitor	O
LB	B-chem-C4-1
-	I-chem-C4-1
4b	E-chem-C4-1
as	O
a	O
potential	O
anticancer	O
agent	O
.	O

APN	S-geneY
inhibitors	O
have	O
been	O
considered	O
as	O
potential	O
anticancer	O
agents	O
for	O
years	O
.	O

LB	B-chem-C4-1
-	I-chem-C4-1
4b	E-chem-C4-1
is	O
the	O
first	O
synthetic	O
APN	S-geneY-C4-2
inhibitor	O
to	O
be	O
evaluated	O
for	O
both	O
of	O
its	O
anti	O
-	O
invasion	O
and	O
anti	O
-	O
angiogenesis	O
effects	O
.	O

As	O
a	O
potent	O
synthetic	O
APN	S-geneY-C4-2
inhibitor	O
(	O
IC50	O
=	O
850nM	O
,	O
versus	O
bestatin	S-chem-C4-1
of	O
8.1μM	O
)	O
,	O
LB	B-chem-C4-1
-	I-chem-C4-1
4b	E-chem-C4-1
was	O
determined	O
to	O
have	O
more	O
significant	O
block	O
effects	O
to	O
cancer	O
cell	O
invasion	O
and	O
angiogenesis	O
than	O
bestatin	S-chem-C4-1
.	O

Besides	O
,	O
it	O
is	O
able	O
to	O
be	O
easily	O
synthesized	O
with	O
a	O
high	O
total	O
yield	O
,	O
while	O
the	O
reported	O
synthetic	O
methods	O
of	O
bestatin	S-chem
are	O
much	O
more	O
complex	O
.	O

Dexamethasone	S-chem-C4-1
suppresses	O
histamine	S-chem
synthesis	O
by	O
repressing	O
both	O
transcription	O
and	O
activity	O
of	O
HDC	S-geneY-C4-2
in	O
allergic	O
rats	O
.	O

BACKGROUND	O
:	O
Histamine	S-chem-C9-1
synthesized	O
by	O
histidine	B-geneY-C9-2
decarboxylase	E-geneY-C9-2
(	O
HDC	S-geneY-C9-2
)	O
from	O
L	B-chem-C9-1
-	I-chem-C9-1
histidine	E-chem-C9-1
is	O
a	O
major	O
chemical	O
mediator	O
in	O
the	O
development	O
of	O
nasal	O
allergy	O
which	O
is	O
characterized	O
by	O
nasal	O
hypersensitivity	O
.	O

However	O
the	O
regulatory	O
mechanism	O
of	O
histamine	S-chem-C9-1
synthesis	O
by	O
HDC	S-geneY-C9-2
remains	O
to	O
be	O
elucidated	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
examine	O
the	O
changes	O
of	O
histamine	S-chem
content	O
,	O
HDC	S-geneY
activity	O
and	O
HDC	S-geneY
mRNA	O
expression	O
in	O
the	O
nasal	O
mucosa	O
of	O
allergy	O
model	O
rats	O
sensitized	O
by	O
the	O
exposure	O
to	O
toluene	B-chem
diisocyanate	E-chem
(	O
TDI	S-chem
)	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
dexamethasone	S-chem
on	O
the	O
above	O
mentioned	O
allergic	O
parameters	O
.	O

METHODS	O
:	O
Rats	O
were	O
sensitized	O
and	O
provocated	O
by	O
TDI	S-chem
and	O
the	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
were	O
scored	O
during	O
a	O
10	O
minute	O
period	O
after	O
provocation	O
.	O

Histamine	S-chem
content	O
and	O
HDC	S-geneY
activity	O
in	O
the	O
nasal	O
mucosa	O
were	O
determined	O
using	O
fluorometric	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
expression	O
of	O
HDC	S-geneN
mRNA	O
in	O
nasal	O
mucosa	O
was	O
determined	O
using	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

RESULTS	O
:	O
In	O
TDI	S-chem
-	O
sensitized	O
rats	O
,	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
such	O
as	O
sneezing	O
and	O
watery	O
rhinorrhea	O
were	O
induced	O
.	O

Histamine	S-chem
content	O
,	O
HDC	S-geneY-C3-2
activity	O
and	O
HDC	S-geneY-C3-2
mRNA	O
expression	O
in	O
nasal	O
mucosa	O
were	O
also	O
significantly	O
increased	O
after	O
TDI	S-chem-C3-1
provocation	O
.	O

Pretreatment	O
with	O
dexamethasone	S-chem-C4-1
significantly	O
suppressed	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
,	O
up	O
-	O
regulation	O
of	O
histamine	S-chem
content	O
,	O
HDC	S-geneY-MU-2
activity	O
and	O
HDC	S-geneY-MU-2
mRNA	O
induced	O
by	O
TDI	S-chem-C3-1
in	O
TDI	S-chem-C3-1
-	O
sensitized	O
rats	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
increased	O
synthesis	O
of	O
histamine	S-chem-C9-1
through	O
up	O
-	O
regulation	O
of	O
HDC	S-geneY-C9-2
gene	O
expression	O
and	O
HDC	S-geneY-C9-2
activity	O
in	O
nasal	O
mucosa	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
nasal	O
hypersensitivity	O
.	O

Repression	O
of	O
HDC	S-geneY-C4-2
gene	O
expression	O
and	O
HDC	S-geneY-C4-2
activity	O
by	O
dexamethasone	S-chem-C4-1
may	O
underlie	O
its	O
therapeutic	O
effect	O
in	O
the	O
treatment	O
of	O
allergy	O
.	O

Carvedilol	S-chem
modulates	O
the	O
expression	O
of	O
hypoxia	B-geneY
-	I-geneY
inducible	I-geneY
factor	I-geneY
-	I-geneY
1alpha	E-geneY
and	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
in	O
a	O
rat	O
model	O
of	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
beta	O
-	O
blockers	O
has	O
emerged	O
as	O
a	O
beneficial	O
treatment	O
for	O
congestive	O
heart	O
failure	O
.	O

Hypoxia	B-geneY
-	I-geneY
inducible	I-geneY
factor	I-geneY
-	I-geneY
1alpha	E-geneY
(	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
)	O
is	O
tightly	O
regulated	O
in	O
the	O
ventricular	O
myocardium	O
.	O

However	O
,	O
the	O
expression	O
of	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
in	O
chronic	O
heart	O
failure	O
resulting	O
from	O
volume	O
overload	O
and	O
after	O
treatment	O
with	O
beta	O
-	O
blocker	O
is	O
little	O
known	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
plays	O
a	O
role	O
in	O
the	O
failing	O
myocardium	O
because	O
of	O
volume	O
overload	O
,	O
an	O
aorta	O
-	O
caval	O
shunt	O
was	O
created	O
for	O
4	O
weeks	O
in	O
adult	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
induce	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

Carvedilol	S-chem
at	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
per	O
day	O
after	O
surgery	O
was	O
given	O
.	O

The	O
heart	O
weight	O
and	O
body	O
weight	O
ratio	O
increased	O
from	O
2.6	O
+	O
/	O
-	O
0.3	O
in	O
the	O
sham	O
group	O
to	O
3.9	O
+	O
/	O
-	O
0.7	O
(	O
P	O
<	O
.001	O
)	O
in	O
the	O
shunt	O
group	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
dimension	O
increased	O
from	O
6.5	O
+	O
/	O
-	O
0.5	O
mm	O
to	O
8.7	O
+	O
/	O
-	O
0.6	O
mm	O
(	O
P	O
<	O
.001	O
)	O
.	O

Treatment	O
with	O
carvedilol	S-chem
in	O
the	O
shunt	O
group	O
reversed	O
the	O
heart	O
weight	O
and	O
ventricular	O
dimension	O
to	O
the	O
baseline	O
values	O
.	O

Western	O
blot	O
showed	O
that	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
,	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
,	O
and	O
brain	B-geneY
natriuretic	I-geneY
peptide	E-geneY
(	O
BNP	S-geneY
)	O
proteins	O
were	O
upregulated	O
and	O
nerve	B-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
beta	E-geneY
(	O
NGF	B-geneY
-	I-geneY
beta	E-geneY
)	O
downregulated	O
in	O
the	O
shunt	O
group	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
that	O
mRNA	O
of	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
,	O
VEGF	S-geneY
,	O
and	O
BNP	S-geneY
increased	O
and	O
mRNA	O
of	O
NGF	B-geneY
-	I-geneY
beta	E-geneY
decreased	O
in	O
the	O
shunt	O
group	O
.	O

Treatment	O
with	O
carvedilol	S-chem-MU-1
reversed	O
both	O
protein	O
and	O
mRNA	O
of	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1alpha	E-geneY-C4-2
,	O
VEGF	S-geneY-C4-2
,	O
BNP	S-geneY-C4-2
,	O
and	O
NGF	B-geneY-C3-2
-	I-geneY-C3-2
beta	E-geneY-C3-2
to	O
the	O
baseline	O
values	O
.	O

Increased	O
immunohistochemical	O
labeling	O
of	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1alpha	E-geneY-C4-2
,	O
VEGF	S-geneY-C4-2
,	O
and	O
BNP	S-geneY-C4-2
in	O
the	O
ventricular	O
myocardium	O
was	O
observed	O
in	O
the	O
shunt	O
group	O
and	O
carvedilol	S-chem-C4-1
again	O
normalized	O
the	O
labeling	O
.	O

CONCLUSION	O
:	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
and	O
VEGF	S-geneY
mRNA	O
and	O
protein	O
expression	O
were	O
upregulated	O
in	O
the	O
rat	O
model	O
of	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

Treatment	O
with	O
carvedilol	S-chem-C4-1
is	O
associated	O
with	O
a	O
reversal	O
of	O
abnormal	O
regulation	O
of	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1alpha	E-geneY-C4-2
and	O
VEGF	S-geneY-C4-2
in	O
the	O
failing	O
ventricular	O
myocardium	O
.	O

[	O
Change	O
of	O
dopamine	B-geneY
transporter	E-geneY
activity	O
(	O
DAT	S-geneY
)	O
during	O
the	O
action	O
of	O
bupropion	S-chem
(	O
in	O
depression	O
)	O
]	O
.	O

Bupropion	S-chem-C4-1
has	O
an	O
antidepressant	O
effect	O
through	O
blocking	O
the	O
dopamine	B-geneY-C4-2
transporter	E-geneY-C4-2
.	O

By	O
99mTc	O
-	O
TRODAT	O
-	O
SPECT	O
,	O
we	O
measured	O
the	O
baseline	O
DAT	S-geneY
activity	O
of	O
depressed	O
patients	O
.	O

After	O
3	O
weeks	O
'	O
bupropion	S-chem
treatment	O
we	O
studied	O
the	O
change	O
in	O
DAT	S-geneY
activity	O
,	O
which	O
corresponds	O
to	O
the	O
occupancy	O
of	O
bupropion	S-chem
.	O

The	O
average	O
occupancy	O
of	O
bupropion	S-chem
on	O
DAT	S-geneY
was	O
similar	O
to	O
the	O
international	O
findings	O
at	O
20.84	O
%	O
in	O
9	O
depressed	O
patients	O
.	O

Crystal	O
structure	O
of	O
the	O
pyridoxal	B-chem
-	I-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
-	O
dependent	O
serine	B-geneY
dehydratase	E-geneY
from	O
human	O
liver	O
.	O

L	B-geneY-C9-2
-	I-geneY-C9-2
serine	I-geneY-C9-2
dehydratase	E-geneY-C9-2
(	O
SDH	S-geneY-C9-2
)	O
,	O
a	O
member	O
of	O
the	O
beta	O
-	O
family	O
of	O
pyridoxal	B-chem
phosphate	E-chem
-	O
dependent	O
(	O
PLP	O
)	O
enzymes	O
,	O
catalyzes	O
the	O
deamination	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
serine	E-chem-C9-1
and	O
L	B-chem-C9-1
-	I-chem-C9-1
threonine	E-chem-C9-1
to	O
yield	O
pyruvate	S-chem-C9-1
or	O
2	B-chem-C9-1
-	I-chem-C9-1
oxobutyrate	E-chem-C9-1
.	O

The	O
crystal	O
structure	O
of	O
L	B-geneY
-	I-geneY
serine	I-geneY
dehydratase	E-geneY
from	O
human	O
liver	O
(	O
hSDH	S-geneY
)	O
has	O
been	O
solved	O
at	O
2.5	O
A	O
-	O
resolution	O
by	O
molecular	O
replacement	O
.	O

The	O
structure	O
is	O
a	O
homodimer	O
and	O
reveals	O
a	O
fold	O
typical	O
for	O
beta	O
-	O
family	O
PLP	O
-	O
dependent	O
enzymes	O
.	O

Each	O
monomer	O
serves	O
as	O
an	O
active	O
unit	O
and	O
is	O
subdivided	O
into	O
two	O
distinct	O
domains	O
:	O
a	O
small	O
domain	O
and	O
a	O
PLP	B-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
that	O
covalently	O
anchors	O
the	O
cofactor	O
.	O

Both	O
domains	O
show	O
the	O
typical	O
open	O
alpha	O
/	O
beta	O
architecture	O
of	O
PLP	O
enzymes	O
.	O

Comparison	O
with	O
the	O
rSDH	S-geneY
-	O
(	O
PLP	O
-	O
OMS	O
)	O
holo	O
-	O
enzyme	O
reveals	O
a	O
large	O
structural	O
difference	O
in	O
active	O
sites	O
caused	O
by	O
the	O
artifical	O
O	B-chem
-	I-chem
methylserine	E-chem
.	O

Furthermore	O
,	O
the	O
activity	O
of	O
hSDH	S-geneY
-	O
PLP	O
was	O
assayed	O
and	O
it	O
proved	O
to	O
show	O
catalytic	O
activity	O
.	O

That	O
suggests	O
that	O
the	O
structure	O
of	O
hSDH	S-geneY
-	O
PLP	O
is	O
the	O
first	O
structure	O
of	O
the	O
active	O
natural	O
holo	O
-	O
SDH	S-geneY
.	O

Opioid	O
activity	O
profiles	O
indicate	O
similarities	O
between	O
the	O
nociceptin	S-geneY
/	O
orphanin	B-geneY
FQ	E-geneY
and	O
opioid	B-geneN
receptors	E-geneN
.	O

Nociceptin	S-geneY
(	O
orphanin	B-geneY
FQ	E-geneY
)	O
is	O
the	O
recently	O
discovered	O
peptide	O
agonist	O
for	O
the	O
orphan	B-geneN
receptor	E-geneN
opioid	B-geneY
receptor	I-geneY
-	I-geneY
like	I-geneY
1	E-geneY
(	O
ORL1	S-geneY
)	O
.	O

Despite	O
the	O
high	O
sequence	O
homology	O
between	O
ORL1	S-geneY
and	O
the	O
opioid	B-geneN
receptors	E-geneN
,	O
most	O
opioids	O
lack	O
affinity	O
for	O
the	O
nociceptin	B-geneY
receptor	E-geneY
.	O

The	O
affinity	O
and	O
functional	O
profile	O
of	O
opioids	O
possessing	O
activity	O
at	O
the	O
nociceptin	B-geneY
receptor	E-geneY
was	O
determined	O
using	O
[	O
3H	O
]	O
nociceptin	O
and	O
nociceptin	O
-	O
stimulated	O
[	B-chem
35S	I-chem
]	I-chem
GTPgammaS	E-chem
binding	O
.	O

The	O
mu	B-geneY-C5-2
-	I-geneY-C5-2
opioid	I-geneY-C5-2
receptor	E-geneY-C5-2
-	O
selective	O
agonist	O
lofentanil	S-chem-C5-1
potently	O
and	O
competitively	O
displaced	O
[	O
3H	O
]	O
nociceptin	O
at	O
rat	O
brain	O
receptors	O
(	O
IC	O
(	O
50	O
)	O
62	O
nM	O
)	O
.	O

Lofentanil	S-chem-C5-1
exhibited	O
full	O
agonism	O
for	O
enhancement	O
of	O
[	B-chem
35S	I-chem
]	I-chem
GTPgammaS	E-chem
binding	O
to	O
human	O
recombinant	O
ORL1	S-geneY-C5-2
receptors	O
(	O
EC	O
(	O
50	O
)	O
50	O
nM	O
)	O
.	O

The	O
related	O
piperidines	S-chem-C5-1
ohmefentanyl	S-chem-C5-1
and	O
sufentanil	S-chem-C5-1
and	O
the	O
nonselective	O
opioid	B-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
etorphine	S-chem-C5-1
were	O
less	O
potent	O
nociceptin	B-geneY-C5-2
receptor	E-geneY-C5-2
agonists	O
.	O

The	O
kappa	O
(	O
1	O
)	O
+	O
kappa	O
(	O
3	O
)	O
-	O
opioid	O
receptor	O
agonist	O
/	O
mu	B-geneY-C6-2
-	I-geneY-C6-2
opioid	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
naloxone	B-chem-C6-1
benzoylhydrazone	E-chem-C6-1
was	O
a	O
pure	O
antagonist	O
at	O
both	O
rat	O
brain	O
and	O
human	O
ORL1	S-geneN-C6-2
receptors	O
.	O

The	O
nonselective	O
opioid	B-geneN-C5-2
receptor	E-geneN-C5-2
partial	O
agonist	O
buprenorphine	S-chem-C5-1
and	O
the	O
nonselective	O
opioid	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
(	B-chem-MU-1
-	I-chem-MU-1
)	I-chem-MU-1
-	I-chem-MU-1
quadazocine	E-chem-MU-1
exhibited	O
pure	O
antagonism	O
at	O
rat	O
brain	O
receptors	O
,	O
but	O
displayed	O
partial	O
agonism	O
at	O
human	B-geneY-C5-2
ORL1	E-geneY-C5-2
receptors	O
.	O

Thus	O
,	O
opioids	O
displaying	O
full	O
agonism	O
at	O
the	O
nociceptin	B-geneY
receptor	E-geneY
are	O
also	O
opioid	B-geneN
receptor	E-geneN
agonists	O
,	O
whereas	O
opioids	O
that	O
are	O
antagonists	O
or	O
partial	O
agonists	O
at	O
the	O
nociceptin	B-geneY
receptor	E-geneY
show	O
antagonism	O
or	O
partial	O
agonism	O
at	O
opioid	B-geneN
receptors	E-geneN
.	O

In	O
addition	O
,	O
the	O
stereospecificity	O
required	O
at	O
opioid	B-geneN
receptors	E-geneN
appears	O
to	O
be	O
retained	O
at	O
the	O
nociceptin	B-geneY
receptor	E-geneY
,	O
since	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
quadazocine	E-chem
is	O
inactive	O
at	O
both	O
receptors	O
.	O

These	O
findings	O
illustrate	O
the	O
structural	O
and	O
functional	O
homology	O
of	O
the	O
opioid	O
recognition	O
site	O
on	O
these	O
two	O
receptor	O
classes	O
and	O
suggest	O
that	O
opioids	O
may	O
provide	O
leads	O
for	O
the	O
design	O
of	O
nonpeptide	O
nociceptin	B-geneY
receptor	E-geneY
agonists	O
and	O
antagonists	O
lacking	O
affinity	O
for	O
the	O
classical	O
opioid	B-geneN
receptors	E-geneN
.	O

Bioactive	O
microconstituents	O
and	O
antioxidant	O
properties	O
of	O
wild	O
edible	O
mushrooms	O
from	O
the	O
island	O
of	O
Lesvos	O
,	O
Greece	O
.	O

Crude	O
composition	O
,	O
fatty	B-chem
acids	E-chem
,	O
sterols	S-chem
,	O
total	O
phenolic	O
content	O
(	O
TPC	O
)	O
,	O
individual	O
polyphenols	S-chem
and	O
terpenic	B-chem
acids	E-chem
were	O
determined	O
in	O
five	O
wild	O
edible	O
mushrooms	O
species	O
(	O
Lactarius	O
deliciosus	O
,	O
Lactarius	O
sanguifluus	O
,	O
Lactarius	O
semisanguifluus	O
,	O
Russula	O
delica	O
,	O
Suillus	O
bellinii	O
)	O
from	O
Lesvos	O
Island	O
,	O
Greece	O
.	O

In	O
addition	O
,	O
the	O
DPPH	S-chem
scavenging	O
capacity	O
,	O
the	O
ferric	S-chem
ion	O
reducing	O
power	O
(	O
FRAP	O
)	O
and	O
the	O
ferrous	S-chem
ion	O
chelating	O
activity	O
of	O
mushroom	O
methanolic	O
extracts	O
were	O
assessed	O
.	O

Among	O
sterols	S-chem
,	O
ergosterol	S-chem
predominated	O
at	O
concentrations	O
9.2	O
-	O
18.0mg	O
/	O
100g	O
fw	O
.	O

Total	O
phenolic	O
content	O
of	O
mushroom	O
extracts	O
ranged	O
from	O
6.0	O
to	O
20.8mg	O
GAE	O
/	O
100g	O
fw	O
.	O

Up	O
to	O
19	O
simple	O
polyphenols	S-chem
were	O
determined	O
in	O
mushrooms	O
extracts	O
,	O
the	O
more	O
abundant	O
being	O
p	B-chem
-	I-chem
OH	I-chem
-	I-chem
benzoic	I-chem
acid	E-chem
,	O
p	B-chem
-	I-chem
OH	I-chem
-	I-chem
phenylacetic	I-chem
acid	E-chem
,	O
o	B-chem
-	I-chem
coumaric	I-chem
acid	E-chem
,	O
ferulic	B-chem
acid	E-chem
and	O
chrysin	S-chem
.	O

In	O
addition	O
,	O
the	O
triterpenic	B-chem
acids	E-chem
oleanolic	S-chem
and	O
ursolic	S-chem
were	O
detected	O
for	O
the	O
first	O
time	O
in	O
mushrooms	O
.	O

All	O
species	O
exerted	O
antioxidant	O
activity	O
and	O
ferrous	S-chem
ion	O
chelating	O
capacity	O
.	O

Principal	O
component	O
analysis	O
revealed	O
good	O
correlations	O
between	O
TPC	O
,	O
DPPH	S-chem
and	O
FRAP	O
but	O
not	O
with	O
metal	O
chelating	O
activity	O
.	O

It	O
seems	O
that	O
mushrooms	O
polyphenols	S-chem
exert	O
antiradical	O
and	O
reducing	O
activities	O
,	O
but	O
they	O
are	O
not	O
strong	O
metal	O
chelators	O
,	O
the	O
observed	O
chelating	O
ability	O
being	O
probably	O
due	O
to	O
other	O
classes	O
of	O
compounds	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
the	O
bioactive	O
microconstituents	O
and	O
antioxidant	O
activity	O
of	O
wild	O
Greek	O
edible	O
mushrooms	O
.	O

Mechanisms	O
of	O
cefadroxil	S-chem-C9-1
uptake	O
in	O
the	O
choroid	O
plexus	O
:	O
studies	O
in	O
wild	O
-	O
type	O
and	O
PEPT2	S-geneY-C9-2
knockout	O
mice	O
.	O

The	O
choroid	O
plexus	O
uptake	O
of	O
[	B-chem-C9-1
(	I-chem-C9-1
3	I-chem-C9-1
)	I-chem-C9-1
H	I-chem-C9-1
]	I-chem-C9-1
cefadroxil	E-chem-C9-1
was	O
studied	O
in	O
peptide	B-geneY-C9-2
transporter	I-geneY-C9-2
2	E-geneY-C9-2
(	O
PEPT2	S-geneY-C9-2
)	O
wild	O
-	O
type	O
and	O
null	O
mice	O
as	O
a	O
function	O
of	O
temperature	O
,	O
transport	O
inhibitors	O
,	O
pH	O
,	O
and	O
saturability	O
.	O

At	O
normal	O
pH	O
(	O
7.4	O
)	O
and	O
temperature	O
(	O
37	O
degrees	O
C	O
)	O
,	O
the	O
uptake	O
of	O
1	O
microM	O
cefadroxil	S-chem-C9-1
was	O
reduced	O
by	O
83	O
%	O
in	O
PEPT2	S-geneY-C9-2
(	O
-	O
/	O
-	O
)	O
mice	O
as	O
compared	O
with	O
PEPT2	S-geneY-C9-2
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
further	O
reduction	O
was	O
achieved	O
in	O
null	O
animals	O
by	O
reducing	O
the	O
temperature	O
to	O
4	O
degrees	O
C	O
,	O
or	O
by	O
adding	O
saturating	O
concentrations	O
of	O
unlabeled	O
cefadroxil	S-chem
or	O
p	B-chem
-	I-chem
aminohippurate	E-chem
(	O
p	O
<	O
0.05	O
)	O
.	O

Glycylsarcosine	S-chem
coadministration	O
could	O
inhibit	O
the	O
uptake	O
of	O
cefadroxil	S-chem-C9-1
in	O
PEPT2	S-geneY-C9-2
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
p	O
<	O
0.01	O
)	O
but	O
not	O
PEPT2	S-geneY-C9-2
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Although	O
a	O
proton	O
-	O
stimulated	O
uptake	O
of	O
cefadroxil	S-chem-C9-1
was	O
demonstrated	O
in	O
PEPT2	S-geneY-C9-2
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
pH	O
6.5	O
versus	O
pH	O
7.4	O
;	O
p	O
<	O
0.01	O
)	O
,	O
no	O
pH	O
dependence	O
was	O
observed	O
in	O
PEPT2	S-geneY-C9-2
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Kinetic	O
parameters	O
for	O
cefadroxil	S-chem
(	O
without	O
p	B-chem
-	I-chem
aminohippurate	E-chem
)	O
in	O
wild	O
-	O
type	O
mice	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
5.4	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
34	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0.0069	O
microl	O
/	O
mg	O
/	O
min	O
;	O
in	O
the	O
presence	O
of	O
p	B-chem
-	I-chem
aminohippurate	E-chem
,	O
the	O
parameters	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
4.1	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
27	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0.0064	O
microl	O
/	O
mg	O
/	O
min	O
.	O

In	O
null	O
animals	O
,	O
the	O
kinetic	O
parameters	O
of	O
cefadroxil	S-chem
(	O
without	O
p	B-chem
-	I-chem
aminohippurate	E-chem
)	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
2.7	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
110	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0.0084	O
microl	O
/	O
mg	O
/	O
min	O
;	O
in	O
the	O
presence	O
of	O
p	B-chem
-	I-chem
aminohippurate	E-chem
,	O
only	O
a	O
K	O
(	O
d	O
)	O
=	O
0.010	O
microl	O
/	O
mg	O
/	O
min	O
was	O
observed	O
.	O

Based	O
on	O
kinetic	O
and	O
inhibitor	O
analyses	O
,	O
it	O
was	O
determined	O
that	O
(	O
under	O
linear	O
conditions	O
)	O
,	O
80	O
to	O
85	O
%	O
of	O
cefadroxil	O
's	O
uptake	O
in	O
choroid	O
plexus	O
is	O
mediated	O
by	O
PEPT2	S-geneY
,	O
10	O
to	O
15	O
%	O
by	O
organic	B-geneY
anion	I-geneY
transporter	I-geneY
(	I-geneY
s	I-geneY
)	E-geneY
,	O
and	O
5	O
%	O
by	O
nonspecific	O
mechanisms	O
.	O

These	O
findings	O
demonstrate	O
that	O
PEPT2	S-geneY-C9-2
is	O
the	O
primary	O
transporter	O
responsible	O
for	O
cefadroxil	S-chem-C9-1
uptake	O
in	O
the	O
choroid	O
plexus	O
.	O

Moreover	O
,	O
the	O
data	O
suggest	O
a	O
role	O
for	O
PEPT2	S-geneY
in	O
the	O
clearance	O
of	O
peptidomimetics	O
from	O
cerebrospinal	O
fluid	O
.	O

The	O
design	O
and	O
realization	O
of	O
a	O
large	O
-	O
area	O
flexible	O
nanofiber	O
-	O
based	O
mat	O
for	O
pollutant	O
degradation	O
:	O
an	O
application	O
in	O
photocatalysis	O
.	O

This	O
work	O
demonstrates	O
a	O
novel	O
multifunctional	O
nanofibrous	O
mat	O
for	O
photocatalytic	O
applications	O
based	O
on	O
TiO2	S-chem
nanocables	O
functionalized	O
by	O
Ag	S-chem
nanoparticles	O
and	O
coated	O
with	O
a	O
thin	O
(	O
∼	O
2	O
nm	O
)	O
graphitic	S-chem
shell	O
.	O

In	O
this	O
mat	O
,	O
which	O
was	O
realized	O
by	O
an	O
electrospinning	O
technique	O
,	O
each	O
component	O
serves	O
a	O
unique	O
function	O
:	O
the	O
carbon	S-chem
coating	O
acts	O
as	O
both	O
an	O
adsorption	O
material	O
for	O
capturing	O
pollutants	O
and	O
as	O
a	O
charge	O
-	O
transfer	O
material	O
,	O
the	O
Ag	S-chem
nanoparticles	O
act	O
as	O
a	O
visible	O
-	O
light	O
sensitizing	O
agent	O
and	O
also	O
as	O
a	O
charge	O
-	O
transfer	O
material	O
,	O
finally	O
the	O
TiO2	S-chem
nanocable	O
mat	O
acts	O
as	O
a	O
UV	O
sensitive	O
photocatalytic	O
matrix	O
and	O
as	O
the	O
flexible	O
substrate	O
for	O
the	O
other	O
functional	O
components	O
.	O

This	O
multicomponent	O
nanocable	O
mat	O
exhibits	O
excellent	O
photocatalytic	O
activity	O
under	O
simulated	O
solar	O
irradiation	O
for	O
the	O
degradation	O
of	O
model	O
pollutants	O
including	O
RhB	S-chem
and	O
phenol	S-chem
.	O

The	O
significant	O
photocatalytic	O
properties	O
are	O
attributed	O
to	O
the	O
synergetic	O
effect	O
of	O
the	O
three	O
functional	O
components	O
and	O
the	O
unique	O
charge	O
transport	O
``	O
freeway	O
``	O
property	O
of	O
the	O
nanofibrous	O
mat	O
.	O

In	O
addition	O
,	O
the	O
porous	O
carbon	S-chem
coating	O
infiltrated	O
into	O
the	O
nanocable	O
matrix	O
endows	O
the	O
mat	O
with	O
excellent	O
flexibility	O
and	O
enables	O
robust	O
,	O
large	O
-	O
area	O
(	O
10	O
×	O
10	O
cm	O
)	O
fabrication	O
,	O
representing	O
a	O
significant	O
advantage	O
over	O
previous	O
brittle	O
ceramic	O
nanofibrous	O
mat	O
photocatalyst	O
substrates	O
.	O

This	O
study	O
provides	O
new	O
insight	O
into	O
the	O
design	O
and	O
preparation	O
of	O
an	O
advanced	O
,	O
yet	O
commercially	O
practical	O
and	O
scaleable	O
photocatalytic	O
composite	O
membrane	O
material	O
.	O

The	O
as	O
-	O
prepared	O
photocatalytic	O
mat	O
might	O
also	O
be	O
of	O
interest	O
in	O
solar	O
cell	O
,	O
catalysis	O
,	O
separation	O
technology	O
,	O
biomedical	O
engineering	O
,	O
and	O
nanotechnology	O
.	O

Esmolol	S-chem
reduces	O
autonomic	O
hypersensitivity	O
and	O
length	O
of	O
seizures	O
induced	O
by	O
electroconvulsive	O
therapy	O
.	O

We	O
evaluated	O
the	O
clinical	O
effectiveness	O
of	O
esmolol	S-chem-C4-1
,	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	B-geneY-C4-2
1	I-geneY-C4-2
-	I-geneY-C4-2
adrenergic	I-geneY-C4-2
receptor	E-geneY-C4-2
blocking	O
drug	O
,	O
to	O
control	O
the	O
sinus	O
tachycardia	O
and	O
increase	O
in	O
arterial	O
blood	O
pressures	O
induced	O
by	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Each	O
of	O
20	O
patients	O
,	O
ASA	O
physical	O
status	O
I	O
-	O
III	O
,	O
participated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
study	O
,	O
involving	O
four	O
match	O
-	O
pair	O
trials	O
(	O
placebo	O
versus	O
esmolol	S-chem
)	O
during	O
ECT	O
.	O

Each	O
patient	O
acted	O
as	O
his	O
or	O
her	O
own	O
control	O
(	O
total	O
number	O
of	O
ECT	O
procedures	O
,	O
160	O
)	O
.	O

We	O
administered	O
a	O
4	O
-	O
min	O
infusion	O
of	O
either	O
placebo	O
or	O
esmolol	S-chem
at	O
the	O
rate	O
of	O
500	O
micrograms.kg	O
-	O
1.min	O
-	O
1	O
.	O

We	O
then	O
induced	O
anesthesia	O
with	O
methohexital	S-chem
and	O
succinylcholine	S-chem
.	O

After	O
administration	O
of	O
electrical	O
stimulation	O
for	O
ECT	O
,	O
the	O
rate	O
of	O
infusion	O
decreased	O
to	O
300	O
micrograms.kg	O
-	O
1.min	O
-	O
1	O
for	O
three	O
additional	O
minutes	O
and	O
was	O
then	O
discontinued	O
.	O

Statistically	O
significant	O
reductions	O
in	O
mean	O
heart	O
rate	O
from	O
minute	O
2	O
until	O
minute	O
15	O
and	O
in	O
maximum	O
heart	O
rate	O
(	O
the	O
mean	O
of	O
each	O
patient	O
's	O
maximum	O
heart	O
rate	O
after	O
seizure	O
changed	O
from	O
152	O
+	O
/	O
-	O
23	O
to	O
115	O
+	O
/	O
-	O
24	O
beats	O
/	O
min	O
)	O
occurred	O
in	O
patients	O
given	O
esmolol	S-chem
.	O

During	O
and	O
immediately	O
after	O
infusion	O
,	O
arterial	O
blood	O
pressure	O
also	O
decreased	O
.	O

Finally	O
,	O
the	O
length	O
of	O
seizures	O
decreased	O
,	O
as	O
manifested	O
clinically	O
from	O
48	O
+	O
/	O
-	O
18	O
to	O
39	O
+	O
/	O
-	O
14	O
s	O
and	O
on	O
electroencephalogram	O
from	O
86	O
+	O
/	O
-	O
41	O
to	O
67	O
+	O
/	O
-	O
28	O
s	O
.	O

We	O
conclude	O
that	O
esmolol	S-chem
effectively	O
controls	O
the	O
hyperdynamic	O
response	O
to	O
ECT	O
and	O
reduces	O
the	O
length	O
of	O
seizures	O
.	O

The	O
significance	O
of	O
the	O
latter	O
to	O
the	O
overall	O
effectiveness	O
of	O
ECT	O
is	O
not	O
known	O
.	O

Different	O
mechanisms	O
of	O
acquired	O
resistance	O
to	O
fluorinated	B-chem
pyrimidines	E-chem
in	O
human	O
colorectal	O
cancer	O
cells	O
.	O

5	B-chem-C4-1
-	I-chem-C4-1
Fluorouracil	E-chem-C4-1
(	O
5	B-chem-C4-1
-	I-chem-C4-1
FU	E-chem-C4-1
)	O
,	O
5	B-chem-C4-1
-	I-chem-C4-1
fluoro	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
deoxyuridine	E-chem-C4-1
(	O
FdUrd	S-chem-C4-1
)	O
and	O
5	B-chem-C4-1
-	I-chem-C4-1
trifluorothymidine	E-chem-C4-1
(	O
F3	B-chem-C4-1
(	I-chem-C4-1
d	I-chem-C4-1
)	I-chem-C4-1
Thd	E-chem-C4-1
)	O
are	O
antimetabolites	O
which	O
are	O
metabolized	O
to	O
their	O
corresponding	O
active	O
forms	O
which	O
inhibit	O
DNA	O
synthesis	O
via	O
inhibition	O
of	O
thymidylate	B-geneY-C4-2
synthase	E-geneY-C4-2
(	O
TS	S-geneY-C4-2
)	O
.	O

To	O
investigate	O
ways	O
of	O
overcoming	O
5	B-chem
-	I-chem
FU	E-chem
-	O
resistance	O
,	O
we	O
established	O
acquired	O
-	O
resistant	O
colorectal	O
cancer	O
cell	O
lines	O
against	O
these	O
three	O
drugs	O
by	O
continuous	O
and	O
step	O
-	O
wise	O
escalation	O
of	O
drugs	O
,	O
and	O
analyzed	O
the	O
cytotoxicity	O
and	O
the	O
mechanism	O
of	O
resistance	O
to	O
the	O
drugs	O
.	O

When	O
cells	O
were	O
incubated	O
with	O
the	O
3	O
drugs	O
for	O
72	O
h	O
,	O
the	O
resistance	O
ratio	O
to	O
parental	O
DLD	O
-	O
1	O
human	O
colorectal	O
tumor	O
cells	O
was	O
65.2	O
for	O
DLD	O
-	O
1	O
/	O
5	O
-	O
FU	O
,	O
9.7	O
for	O
DLD	O
-	O
1	O
/	O
FdUrd	S-chem
and	O
448.6	O
for	O
DLD	O
-	O
1	O
/	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
cells	O
.	O

DLD	O
-	O
1	O
/	O
5	B-chem
-	I-chem
FU	E-chem
cells	O
did	O
not	O
show	O
any	O
cross	O
-	O
resistance	O
against	O
FdUrd	S-chem
and	O
F	B-chem
(	I-chem
3	I-chem
)	I-chem
dThd	E-chem
.	O

However	O
,	O
DLD	O
-	O
1	O
/	O
FdUrd	S-chem
cells	O
showed	O
3	O
-	O
and	O
9	O
-	O
fold	O
increased	O
resistance	O
to	O
5	B-chem
-	I-chem
FU	E-chem
and	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
,	O
respectively	O
,	O
and	O
DLD	O
-	O
1	O
/	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
cells	O
also	O
showed	O
about	O
90	O
-	O
fold	O
resistance	O
to	O
FdUrd	S-chem
.	O

Analysis	O
of	O
enzyme	O
activities	O
and	O
gene	O
expression	O
associated	O
with	O
pyrimidine	S-chem
metabolism	O
indicated	O
that	O
a	O
significant	O
decrease	O
in	O
orotate	B-geneY
phosphoribosyltransferase	E-geneY
activity	O
in	O
DLD	O
-	O
1	O
/	O
5	B-chem
-	I-chem
FU	E-chem
cells	O
,	O
a	O
7	O
-	O
fold	O
increase	O
of	O
TS	S-geneY
mRNA	O
in	O
DLD	O
-	O
1	O
/	O
FdUrd	S-chem
cells	O
,	O
and	O
a	O
37	O
-	O
fold	O
decrease	O
in	O
thymidine	B-geneY
kinase	E-geneY
activity	O
of	O
DLD	O
-	O
1	O
/	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
cells	O
were	O
the	O
major	O
mechanisms	O
of	O
drug	O
resistance	O
.	O

These	O
findings	O
were	O
closely	O
associated	O
with	O
the	O
cytotoxicity	O
of	O
5	B-chem
-	I-chem
FU	E-chem
,	O
FdUrd	S-chem
and	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
against	O
the	O
established	O
5	B-chem
-	I-chem
FU	E-chem
-	O
,	O
FdUrd	S-chem
-	O
or	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
-	O
resistant	O
cells	O
.	O

When	O
DLD	O
-	O
1	O
/	O
FdUrd	S-chem
cells	O
expressing	O
increased	O
TS	S-geneY
mRNA	O
were	O
treated	O
with	O
FdUrd	S-chem
and	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
for	O
only	O
4	O
h	O
,	O
the	O
resistance	O
ratios	O
of	O
DLD	O
-	O
1	O
/	O
FdUrd	S-chem
cells	O
to	O
parental	O
DLD	O
-	O
1	O
cells	O
were	O
markedly	O
different	O
for	O
FdUrd	S-chem
and	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
,	O
suggesting	O
that	O
the	O
cytotoxicity	O
with	O
short	O
-	O
time	O
exposure	O
to	O
F3	B-chem-C4-1
(	I-chem-C4-1
d	I-chem-C4-1
)	I-chem-C4-1
Thd	E-chem-C4-1
is	O
due	O
to	O
a	O
mechanism	O
other	O
than	O
TS	S-geneY-C4-2
inhibition	O
,	O
although	O
the	O
cytotoxicity	O
of	O
F3	B-chem
(	I-chem
d	I-chem
)	I-chem
Thd	E-chem
in	O
the	O
short	O
-	O
time	O
is	O
low	O
compared	O
to	O
that	O
of	O
long	O
-	O
time	O
exposure	O
.	O

In	O
conclusion	O
,	O
F3	B-chem-C4-1
(	I-chem-C4-1
d	I-chem-C4-1
)	I-chem-C4-1
Thd	E-chem-C4-1
,	O
an	O
antimetabolite	O
that	O
inhibits	O
TS	S-geneY-C4-2
activity	O
,	O
may	O
be	O
effective	O
against	O
5	B-chem
-	I-chem
FU	E-chem
and	O
/	O
or	O
FdUrd	S-chem
-	O
resistance	O
in	O
colorectal	O
cancer	O
cells	O
caused	O
by	O
amplification	O
of	O
TS	S-geneN
and	O
/	O
or	O
deletion	O
of	O
orotate	B-geneY
phosphoribosyltransferase	E-geneY
.	O

Dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
activation	O
leads	O
to	O
an	O
up	O
-	O
regulation	O
of	O
glial	B-geneY
cell	I-geneY
line	I-geneY
-	I-geneY
derived	I-geneY
neurotrophic	I-geneY
factor	E-geneY
via	O
Gβγ	O
-	O
Erk1	B-geneN
/	I-geneN
2	E-geneN
-	O
dependent	O
induction	O
of	O
Zif268	S-geneY
.	O

Glial	B-geneY
cell	I-geneY
line	I-geneY
-	I-geneY
derived	I-geneY
neurotrophic	I-geneY
factor	E-geneY
(	O
GDNF	S-geneY
)	O
is	O
a	O
potent	O
growth	O
factor	O
essential	O
to	O
the	O
development	O
,	O
survival	O
,	O
and	O
function	O
of	O
dopaminergic	O
neurons	O
(	O
Airaksinen	O
and	O
Saarma	O
2002	O
)	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
GDNF	S-geneY
expression	O
remain	O
elusive	O
;	O
thus	O
,	O
we	O
set	O
out	O
to	O
identify	O
a	O
signaling	O
pathway	O
that	O
governs	O
GDNF	S-geneY
levels	O
.	O

We	O
found	O
that	O
treatment	O
of	O
both	O
differentiated	O
dopaminergic	O
-	O
like	O
SH	O
-	O
SY5Y	O
cells	O
and	O
rat	O
midbrain	O
slices	O
with	O
the	O
dopamine	B-geneN-C5-2
D2	I-geneN-C5-2
receptor	E-geneN-C5-2
(	O
D2R	S-geneN-C5-2
)	O
agonist	O
,	O
quinpirole	S-chem-MU-1
,	O
triggered	O
an	O
increase	O
in	O
the	O
expression	O
of	O
GDNF	S-geneN-C3-2
that	O
was	O
temporally	O
preceded	O
by	O
an	O
increase	O
in	O
the	O
levels	O
of	O
zinc	B-geneN-C3-2
-	I-geneN-C3-2
finger	I-geneN-C3-2
protein	I-geneN-C3-2
268	E-geneN-C3-2
(	O
Zif268	S-geneN-C3-2
)	O
,	O
a	O
DNA	O
-	O
binding	O
transcription	O
factor	O
encoded	O
by	O
an	O
immediate	O
-	O
early	O
gene	O
.	O

Moreover	O
,	O
the	O
D2R	S-geneY-C4-2
inhibitor	O
raclopride	S-chem-C4-1
blocked	O
the	O
increase	O
of	O
both	O
GDNF	S-geneY-C4-2
and	O
Zif268	S-geneY-C4-2
expression	O
following	O
potassium	S-chem
-	O
evoked	O
dopamine	S-chem
release	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

We	O
used	O
adenoviral	O
delivery	O
of	O
small	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
targeting	O
Zif268	S-geneY
to	O
down	O
-	O
regulate	O
its	O
expression	O
and	O
found	O
that	O
Zif268	S-geneY
is	O
specifically	O
required	O
for	O
the	O
D2R	S-geneY
-	O
mediated	O
up	O
-	O
regulation	O
of	O
GDNF	S-geneY
.	O

Furthermore	O
,	O
the	O
D2R	S-geneY
-	O
mediated	O
induction	O
of	O
GDNF	S-geneY
and	O
Zif268	S-geneN
expression	O
was	O
dependent	O
on	O
Gβγ	O
-	O
mediated	O
signaling	O
and	O
activation	O
of	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
.	O

Importantly	O
,	O
using	O
chromatin	O
immunoprecipitation	O
assay	O
,	O
we	O
identified	O
a	O
direct	O
association	O
of	O
Zif268	S-geneY
with	O
the	O
GDNF	B-geneN
promoter	E-geneN
.	O

These	O
results	O
suggest	O
that	O
D2R	S-geneY
activation	O
induces	O
a	O
Gβγ	O
-	O
and	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
-	O
dependent	O
increase	O
in	O
the	O
level	O
of	O
Zif268	S-geneY
,	O
which	O
functions	O
to	O
directly	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
GDNF	S-geneY
.	O

Live	O
-	O
cell	O
imaging	O
of	O
p53	S-geneY
interactions	O
using	O
a	O
novel	O
Venus	O
-	O
based	O
bimolecular	O
fluorescence	O
complementation	O
system	O
.	O

p53	S-geneY
plays	O
an	O
important	O
role	O
in	O
regulating	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
,	O
such	O
as	O
cell	O
cycle	O
arrest	O
and	O
/	O
or	O
apoptosis	O
.	O

Dysfunction	O
of	O
p53	S-geneY
is	O
frequently	O
associated	O
with	O
several	O
pathologies	O
,	O
such	O
as	O
cancer	O
and	O
neurodegenerative	O
diseases	O
.	O

In	O
recent	O
years	O
substantial	O
progress	O
has	O
been	O
made	O
in	O
developing	O
novel	O
p53	S-geneY
-	O
activating	O
molecules	O
.	O

Importantly	O
,	O
modulation	O
of	O
p53	S-geneY
interaction	O
with	O
its	O
main	O
inhibitor	O
,	O
Mdm2	S-geneY
,	O
has	O
been	O
highlighted	O
as	O
a	O
promising	O
therapeutic	O
target	O
.	O

In	O
this	O
regard	O
,	O
bimolecular	O
fluorescence	O
complementation	O
(	O
BiFC	O
)	O
analysis	O
,	O
by	O
providing	O
direct	O
visualization	O
of	O
protein	O
interactions	O
in	O
living	O
cells	O
,	O
offers	O
a	O
straightforward	O
method	O
to	O
identify	O
potential	O
modulators	O
of	O
protein	O
interactions	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
simple	O
and	O
robust	O
Venus	O
-	O
based	O
BiFC	O
system	O
to	O
screen	O
for	O
modulators	O
of	O
p53	S-geneN
-	O
p53	S-geneN
and	O
p53	S-geneN
-	O
Mdm2	S-geneN
interactions	O
in	O
live	O
mammalian	O
cells	O
.	O

We	O
used	O
nutlin	B-chem-C4-1
-	I-chem-C4-1
3	E-chem-C4-1
,	O
a	O
well	O
-	O
known	O
disruptor	O
of	O
p53	S-geneY-C4-2
-	O
Mdm2	S-geneY-C4-2
interaction	O
,	O
to	O
validate	O
the	O
specificity	O
of	O
the	O
assay	O
.	O

The	O
reduction	O
of	O
BiFC	O
signal	O
mediated	O
by	O
nutlin	B-chem-C3-1
-	I-chem-C3-1
3	E-chem-C3-1
was	O
correlated	O
with	O
an	O
increase	O
in	O
Puma	S-geneY-C3-2
transactivation	O
,	O
PARP	S-geneN-C3-2
cleavage	O
,	O
and	O
cell	O
death	O
.	O

Finally	O
,	O
this	O
novel	O
BiFC	O
approach	O
was	O
exploited	O
to	O
identify	O
potential	O
modulators	O
of	O
p53	S-geneY
-	O
Mdm2	S-geneY
complex	O
formation	O
among	O
a	O
commercially	O
available	O
chemical	O
library	O
of	O
33	O
protein	B-geneN
phosphatase	E-geneN
inhibitors	O
.	O

Our	O
results	O
constitute	O
``	O
proof	O
-	O
of	O
-	O
concept	O
``	O
that	O
this	O
model	O
has	O
strong	O
potential	O
as	O
an	O
alternative	O
to	O
traditional	O
target	O
-	O
based	O
drug	O
discovery	O
strategies	O
.	O

Identification	O
of	O
new	O
modulators	O
of	O
p53	S-geneY
-	O
p53	S-geneY
and	O
p53	S-geneY
-	O
Mdm2	S-geneY
interactions	O
will	O
be	O
useful	O
to	O
achieve	O
synergistic	O
drug	O
efficacy	O
with	O
currently	O
used	O
anti	O
-	O
tumor	O
therapies	O
.	O

A	O
physiologically	O
based	O
pharmacokinetic	O
model	O
for	O
the	O
oxime	S-chem
TMB	B-chem
-	I-chem
4	E-chem
:	O
simulation	O
of	O
rodent	O
and	O
human	O
data	O
.	O

Multiple	O
oximes	S-chem
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
use	O
as	O
countermeasures	O
against	O
chemical	O
warfare	O
nerve	O
agents	O
.	O

The	O
current	O
U.S.	O
military	O
and	O
civilian	O
oxime	S-chem
countermeasure	O
,	O
2	B-chem
-	I-chem
[	I-chem
(	I-chem
hydroxyimino	I-chem
)	I-chem
methyl	I-chem
]	I-chem
-	I-chem
1	I-chem
-	I-chem
methylpyridin	I-chem
-	I-chem
1	I-chem
-	I-chem
ium	I-chem
chloride	E-chem
(	O
2	B-chem
-	I-chem
PAM	E-chem
)	O
,	O
is	O
under	O
consideration	O
for	O
replacement	O
with	O
a	O
more	O
effective	O
acetylcholinesterase	S-geneY-C3-2
reactivator	O
,	O
1,1	B-chem-C3-1
'	I-chem-C3-1
-	I-chem-C3-1
methylenebis	I-chem-C3-1
{	I-chem-C3-1
4	I-chem-C3-1
-	I-chem-C3-1
hydroxyiminomethyl	I-chem-C3-1
}	I-chem-C3-1
pyridinium	I-chem-C3-1
dimethanesulfonate	E-chem-C3-1
(	O
MMB	B-chem-C3-1
-	I-chem-C3-1
4	E-chem-C3-1
)	O
.	O

Kinetic	O
data	O
in	O
the	O
scientific	O
literature	O
for	O
MMB	B-chem
-	I-chem
4	E-chem
are	O
limited	O
;	O
therefore	O
,	O
a	O
physiologically	O
based	O
pharmacokinetic	O
(	O
PBPK	O
)	O
model	O
was	O
developed	O
for	O
a	O
structurally	O
related	O
oxime	S-chem
,	O
1,1	B-chem
'	I-chem
-	I-chem
trimethylenebis	I-chem
{	I-chem
4	I-chem
-	I-chem
hydroximinomethyl	I-chem
}	I-chem
pyridinium	I-chem
dibromide	E-chem
.	O

Based	O
on	O
a	O
previous	O
model	O
structure	O
for	O
the	O
organophosphate	S-chem
diisopropylfluorophosphate	S-chem
,	O
the	O
model	O
includes	O
key	O
sites	O
of	O
acetylcholinesterase	S-geneY
inhibition	O
(	O
brain	O
and	O
diaphragm	O
)	O
,	O
as	O
well	O
as	O
fat	O
,	O
kidney	O
,	O
liver	O
,	O
rapidly	O
perfused	O
tissues	O
and	O
slowly	O
perfused	O
tissues	O
.	O

All	O
tissue	O
compartments	O
are	O
diffusion	O
limited	O
.	O

Model	O
parameters	O
were	O
collected	O
from	O
the	O
literature	O
,	O
predicted	O
using	O
quantitative	O
structure	O
-	O
property	O
relationships	O
or	O
,	O
when	O
necessary	O
,	O
fit	O
to	O
available	O
pharmacokinetic	O
data	O
from	O
the	O
literature	O
.	O

The	O
model	O
was	O
parameterized	O
using	O
rat	O
plasma	O
,	O
tissue	O
and	O
urine	O
time	O
course	O
data	O
from	O
intramuscular	O
administration	O
,	O
as	O
well	O
as	O
human	O
blood	O
and	O
urine	O
data	O
from	O
intravenous	O
and	O
intramuscular	O
administration	O
;	O
sensitivity	O
analyses	O
were	O
performed	O
.	O

The	O
PBPK	O
model	O
successfully	O
simulates	O
rat	O
and	O
human	O
data	O
sets	O
and	O
has	O
been	O
evaluated	O
by	O
predicting	O
intravenous	O
mouse	O
and	O
intramuscular	O
human	O
data	O
not	O
used	O
in	O
the	O
development	O
of	O
the	O
model	O
.	O

Monte	O
Carlo	O
analyses	O
were	O
performed	O
to	O
quantify	O
human	O
population	O
kinetic	O
variability	O
in	O
the	O
human	O
evaluation	O
data	O
set	O
.	O

The	O
model	O
identifies	O
potential	O
pharmacokinetic	O
differences	O
between	O
rodents	O
and	O
humans	O
,	O
indicated	O
by	O
differences	O
in	O
model	O
parameters	O
between	O
species	O
.	O

The	O
PBPK	O
model	O
can	O
be	O
used	O
to	O
optimize	O
the	O
dosing	O
regimen	O
to	O
improve	O
oxime	S-chem
therapeutic	O
efficacy	O
in	O
a	O
human	O
population	O
.	O

Transcriptional	O
control	O
of	O
the	O
arginine	B-geneN
/	I-geneN
lysine	I-geneN
transporter	E-geneN
,	O
cat	B-geneY
-	I-geneY
1	E-geneY
,	O
by	O
physiological	O
stress	O
.	O

Cells	O
respond	O
to	O
physiological	O
stress	O
by	O
phosphorylating	O
the	O
alpha	O
subunit	O
of	O
the	O
translation	O
initiation	O
factor	O
eIF2	S-geneN
.	O

This	O
adaptive	O
response	O
inhibits	O
protein	O
synthesis	O
and	O
up	O
-	O
regulates	O
genes	O
essential	O
for	O
cell	O
survival	O
.	O

Cat	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
,	O
the	O
transporter	O
for	O
the	O
essential	O
amino	B-chem-C9-1
acids	E-chem-C9-1
,	O
arginine	S-chem-C9-1
and	O
lysine	S-chem-C9-1
,	O
is	O
one	O
of	O
the	O
up	O
-	O
regulated	O
genes	O
.	O

We	O
previously	O
showed	O
that	O
stress	O
increases	O
cat	B-geneY
-	I-geneY
1	E-geneY
expression	O
by	O
coordinated	O
stabilization	O
of	O
the	O
mRNA	O
and	O
increased	O
mRNA	O
translation	O
.	O

This	O
induction	O
is	O
triggered	O
by	O
amino	B-chem
acid	E-chem
depletion	O
and	O
the	O
unfolded	B-geneN
protein	I-geneN
response	E-geneN
(	O
UPR	S-geneN
)	O
,	O
which	O
is	O
caused	O
by	O
unfolded	O
proteins	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

We	O
show	O
here	O
that	O
cat	B-geneY
-	I-geneY
1	E-geneY
gene	O
transcription	O
is	O
also	O
increased	O
by	O
cellular	O
stress	O
.	O

Our	O
studies	O
demonstrate	O
that	O
the	O
cat	B-geneN
-	I-geneN
1	I-geneN
gene	I-geneN
promoter	E-geneN
/	O
regulatory	O
region	O
is	O
TATA	S-geneN
-	O
less	O
and	O
is	O
located	O
in	O
a	O
region	O
that	O
includes	O
94	O
bases	O
of	O
the	O
first	O
exon	O
.	O

Transcription	O
from	O
this	O
promoter	O
is	O
stimulated	O
8	O
-	O
fold	O
by	O
cellular	O
stress	O
.	O

An	O
amino	B-chem
acid	E-chem
response	O
element	O
within	O
the	O
first	O
exon	O
is	O
shown	O
to	O
be	O
required	O
for	O
the	O
response	O
to	O
amino	B-chem
acid	E-chem
depletion	O
but	O
not	O
to	O
the	O
UPR	O
.	O

The	O
stimulation	O
of	O
transcription	O
by	O
amino	B-chem
acid	E-chem
depletion	O
requires	O
activation	O
of	O
GCN2	S-geneY
kinase	S-geneN
,	O
which	O
phosphorylates	O
eIF2alpha	S-geneY
.	O

This	O
phosphorylation	O
also	O
induces	O
translation	O
of	O
the	O
cat	B-geneY
-	I-geneY
1	E-geneY
mRNA	O
,	O
demonstrating	O
that	O
stress	O
-	O
induced	O
transcriptional	O
and	O
translational	O
control	O
of	O
cat	B-geneY
-	I-geneY
1	E-geneY
are	O
downstream	O
targets	O
of	O
a	O
signaling	O
pathway	O
initiating	O
with	O
eIF2alpha	S-geneY
phosphorylation	O
.	O

Our	O
studies	O
show	O
that	O
the	O
increase	O
in	O
cat	B-geneY
-	I-geneY
1	E-geneY
gene	O
expression	O
by	O
cellular	O
stress	O
involves	O
at	O
least	O
three	O
types	O
of	O
coordinate	O
regulation	O
:	O
regulation	O
of	O
transcription	O
,	O
regulation	O
of	O
mRNA	O
stability	O
,	O
and	O
regulation	O
of	O
mRNA	O
translation	O
.	O

Cyclooxygenase	B-geneY
(	I-geneY
COX	I-geneY
)	I-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
both	O
play	O
an	O
important	O
role	O
in	O
the	O
protection	O
of	O
the	O
duodenal	O
mucosa	O
in	O
cats	O
.	O

Although	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
often	O
cause	O
ulcers	O
in	O
the	O
duodenum	O
in	O
humans	O
,	O
the	O
role	O
of	O
cyclooxygenase	S-geneN
(	O
COX	S-geneN
)	O
isoforms	O
in	O
the	O
pathogenesis	O
of	O
duodenal	O
ulcers	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
examined	O
in	O
cats	O
the	O
1	O
)	O
ulcerogenic	O
effects	O
of	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
SC	B-chem-C4-1
-	I-chem-C4-1
560	E-chem-C4-1
,	O
ketorolac	S-chem-C4-1
)	O
and	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
celecoxib	S-chem-C4-1
,	O
meloxicam	S-chem-C4-1
)	O
inhibitors	O
on	O
the	O
gastrointestinal	O
mucosa	O
,	O
2	O
)	O
effect	O
of	O
feeding	O
and	O
cimetidine	S-chem
on	O
the	O
expression	O
of	O
COX	S-geneN
isoforms	O
and	O
prostaglandin	B-chem
E	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
level	O
in	O
the	O
duodenum	O
,	O
and	O
3	O
)	O
localization	O
of	O
COX	S-geneN
isoforms	O
in	O
the	O
duodenum	O
.	O

COX	S-geneN
inhibitors	O
were	O
administered	O
after	O
the	O
morning	O
meal	O
in	O
cats	O
once	O
daily	O
for	O
3	O
days	O
.	O

Gastrointestinal	O
lesions	O
were	O
examined	O
on	O
day	O
4	O
.	O

Localization	O
and	O
expression	O
of	O
COX	S-geneN
isoforms	O
(	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
)	O
and	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
level	O
(	O
by	O
enzyme	O
immunoassay	O
)	O
were	O
examined	O
.	O

Results	O
were	O
as	O
follows	O
.	O

First	O
,	O
selective	O
COX	B-geneY
-	I-geneY
1	E-geneY
or	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
alone	O
produced	O
marked	O
ulcers	O
in	O
the	O
duodenum	O
but	O
did	O
not	O
cause	O
obvious	O
lesions	O
in	O
the	O
small	O
intestine	O
.	O

Coadministration	O
of	O
SC	B-chem
-	I-chem
560	E-chem
and	O
celecoxib	S-chem
produced	O
marked	O
lesions	O
in	O
the	O
small	O
intestine	O
.	O

Second	O
,	O
feeding	O
increased	O
both	O
the	O
expression	O
of	O
COX	S-geneN-C4-2
isoforms	O
and	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
level	O
in	O
the	O
duodenum	O
,	O
and	O
the	O
effects	O
were	O
markedly	O
inhibited	O
by	O
pretreatment	O
with	O
cimetidine	S-chem-C4-1
.	O

Third	O
,	O
COX	B-geneY
-	I-geneY
1	E-geneY
was	O
localized	O
in	O
goblet	O
and	O
Brunner	O
's	O
gland	O
cells	O
,	O
Meissner	O
's	O
and	O
Auerbach	O
's	O
plexus	O
,	O
smooth	O
muscle	O
cells	O
,	O
and	O
arterioles	O
;	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
was	O
observed	O
in	O
capillaries	O
,	O
venules	O
,	O
and	O
basal	O
granulated	O
cells	O
.	O

The	O
expression	O
of	O
COX	S-geneN
isoforms	O
in	O
the	O
duodenum	O
is	O
up	O
-	O
regulated	O
by	O
feeding	O
,	O
and	O
inhibition	O
of	O
either	O
COX	B-geneY
-	I-geneY
1	E-geneY
or	O
COX	B-geneY
-	I-geneY
2	E-geneY
causes	O
ulcers	O
in	O
the	O
duodenum	O
,	O
suggesting	O
that	O
both	O
isoforms	O
play	O
an	O
important	O
role	O
in	O
the	O
protection	O
of	O
the	O
duodenal	O
mucosa	O
.	O

Addition	O
of	O
eicosapentaenoic	B-chem
acid	E-chem
to	O
gamma	B-chem
-	I-chem
linolenic	I-chem
acid	E-chem
-	O
supplemented	O
diets	O
prevents	O
serum	O
arachidonic	B-chem
acid	E-chem
accumulation	O
in	O
humans	O
.	O

Previous	O
studies	O
reveal	O
that	O
supplementation	O
of	O
human	O
diets	O
with	O
gamma	B-chem
-	I-chem
linolenic	I-chem
acid	E-chem
(	O
GLA	S-chem
)	O
reduces	O
the	O
generation	O
of	O
lipid	O
mediators	O
of	O
inflammation	O
and	O
attenuates	O
clinical	O
symptoms	O
of	O
chronic	O
inflammatory	O
disorders	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

However	O
,	O
we	O
have	O
shown	O
that	O
supplementation	O
with	O
this	O
same	O
fatty	B-chem
acid	E-chem
also	O
causes	O
a	O
marked	O
increase	O
in	O
serum	O
arachidonate	S-chem
(	O
AA	S-chem
)	O
levels	O
,	O
a	O
potentially	O
harmful	O
side	O
effect	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
design	O
a	O
supplementation	O
strategy	O
that	O
maintained	O
the	O
capacity	O
of	O
GLA	S-chem
to	O
reduce	O
lipid	O
mediators	O
without	O
causing	O
elevations	O
in	O
serum	O
AA	S-chem
levels	O
.	O

Initial	O
in	O
vitro	O
studies	O
utilizing	O
HEP	O
-	O
G2	O
liver	O
cells	O
revealed	O
that	O
addition	O
of	O
eicosapentaenoic	B-chem-C4-1
acid	E-chem-C4-1
(	O
EPA	S-chem-C4-1
)	O
blocked	O
Delta	B-geneY-C4-2
-	I-geneY-C4-2
5	I-geneY-C4-2
-	I-geneY-C4-2
desaturase	E-geneY-C4-2
activity	O
,	O
the	O
terminal	O
enzymatic	O
step	O
in	O
AA	S-chem
synthesis	O
.	O

To	O
test	O
the	O
in	O
vivo	O
effects	O
of	O
a	O
GLA	S-chem
and	O
EPA	S-chem
combination	O
in	O
humans	O
,	O
adult	O
volunteers	O
consuming	O
controlled	O
diets	O
supplemented	O
these	O
diets	O
with	O
3.0	O
g	O
/	O
d	O
of	O
GLA	S-chem
and	O
EPA	S-chem
.	O

This	O
supplementation	O
strategy	O
significantly	O
increased	O
serum	O
levels	O
of	O
EPA	S-chem
,	O
but	O
did	O
not	O
increase	O
AA	S-chem
levels	O
.	O

EPA	S-chem
and	O
the	O
elongation	O
product	O
of	O
GLA	S-chem
,	O
dihomo	B-chem
-	I-chem
gamma	I-chem
-	I-chem
linolenic	I-chem
acid	E-chem
(	O
DGLA	S-chem
)	O
levels	O
in	O
neutrophil	O
glycerolipids	O
increased	O
significantly	O
during	O
the	O
3	O
-	O
wk	O
supplementation	O
period	O
.	O

Neutrophils	O
isolated	O
from	O
volunteers	O
fed	O
diets	O
supplemented	O
with	O
GLA	S-chem
and	O
EPA	S-chem
released	O
similar	O
quantities	O
of	O
AA	S-chem
,	O
but	O
synthesized	O
significantly	O
lower	O
quantities	O
of	O
leukotrienes	S-chem
compared	O
with	O
their	O
neutrophils	O
before	O
supplementation	O
.	O

This	O
study	O
revealed	O
that	O
a	O
GLA	S-chem
and	O
EPA	S-chem
supplement	O
combination	O
may	O
be	O
utilized	O
to	O
reduce	O
the	O
synthesis	O
of	O
proinflammatory	O
AA	S-chem
metabolites	O
,	O
and	O
importantly	O
,	O
not	O
induce	O
potentially	O
harmful	O
increases	O
in	O
serum	O
AA	S-chem
levels	O
.	O

Steroidal	B-chem
glycosides	E-chem
from	O
the	O
bulbs	O
of	O
Fritillaria	O
meleagris	O
and	O
their	O
cytotoxic	O
activities	O
.	O

Steroidal	B-chem
glycosides	E-chem
(	O
1	O
-	O
18	O
)	O
,	O
including	O
10	O
new	O
compounds	O
(	O
1	O
-	O
10	O
)	O
,	O
were	O
isolated	O
from	O
the	O
bulbs	O
of	O
Fritillaria	O
meleagris	O
(	O
Liliaceae	O
)	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
were	O
determined	O
by	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
NMR	O
analysis	O
,	O
and	O
by	O
hydrolytic	O
cleavage	O
followed	O
by	O
spectroscopic	O
and	O
chromatographic	O
analysis	O
.	O

The	O
isolated	O
compounds	O
and	O
their	O
aglycones	O
were	O
evaluated	O
for	O
cytotoxic	O
activity	O
against	O
HL	O
-	O
60	O
human	O
promyelocytic	O
leukemia	O
cells	O
and	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O

Morphological	O
observation	O
and	O
flow	O
cytometry	O
analysis	O
showed	O
that	O
5β	B-chem
-	I-chem
spirostanol	I-chem
glycoside	E-chem
(	O
2	O
)	O
and	O
a	O
cholestane	S-chem
derivative	O
(	O
17a	O
)	O
induced	O
apoptotic	O
cell	O
death	O
in	O
HL	O
-	O
60	O
cells	O
through	O
different	O
mechanisms	O
of	O
action	O
.	O

Furthermore	O
,	O
the	O
(	B-chem
22R	I-chem
)	I-chem
-	I-chem
spirosolanol	I-chem
glycoside	E-chem
(	O
11	O
)	O
selectively	O
induced	O
apoptosis	O
in	O
A549	O
cells	O
without	O
affecting	O
the	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
level	O
.	O

Auranofin	S-chem-C4-1
,	O
as	O
an	O
anti	O
-	O
rheumatic	O
gold	O
compound	O
,	O
suppresses	O
LPS	O
-	O
induced	O
homodimerization	O
of	O
TLR4	S-geneY-C4-2
.	O

Toll	B-geneN
-	I-geneN
like	I-geneN
receptors	I-geneN
(	I-geneN
TLRs	I-geneN
)	E-geneN
,	O
which	O
are	O
activated	O
by	O
invading	O
microorganisms	O
or	O
endogenous	O
molecules	O
,	O
evoke	O
immune	O
and	O
inflammatory	O
responses	O
.	O

TLR	S-geneN
activation	O
is	O
closely	O
linked	O
to	O
the	O
development	O
of	O
many	O
chronic	O
inflammatory	O
diseases	O
including	O
rheumatoid	O
arthritis	O
.	O

Auranofin	S-chem
,	O
an	O
Au	B-chem
(	I-chem
I	I-chem
)	E-chem
compound	O
,	O
is	O
a	O
well	O
-	O
known	O
and	O
long	O
-	O
used	O
anti	O
-	O
rheumatic	O
drug	O
.	O

However	O
,	O
the	O
mechanism	O
as	O
to	O
how	O
auranofin	S-chem
relieves	O
the	O
symptom	O
of	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
fully	O
clarified	O
.	O

Our	O
results	O
demonstrated	O
that	O
auranofin	S-chem-C4-1
suppressed	O
TLR4	S-geneY-C4-2
-	O
mediated	O
activation	O
of	O
transcription	O
factors	O
,	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
and	O
IRF3	S-geneY-C4-2
,	O
and	O
expression	O
of	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
a	O
pro	O
-	O
inflammatory	O
enzyme	O
.	O

This	O
suppression	O
was	O
well	O
correlated	O
with	O
the	O
inhibitory	O
effect	O
of	O
auranofin	S-chem-C4-1
on	O
the	O
homodimerization	O
of	O
TLR4	S-geneY-C4-2
induced	O
by	O
an	O
agonist	O
.	O

Furthermore	O
,	O
auranofin	S-chem-C4-1
inhibited	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
activation	O
induced	O
by	O
MyD88	S-geneY
-	O
dependent	O
downstream	O
signaling	O
components	O
of	O
TLR4	S-geneY
,	O
MyD88	S-geneY
,	O
IKKbeta	S-geneY
,	O
and	O
p65	S-geneY
.	O

IRF3	S-geneY-C4-2
activation	O
induced	O
by	O
MyD88	S-geneY
-	O
independent	O
signaling	O
components	O
,	O
TRIF	S-geneY-C4-2
and	O
TBK1	S-geneY-C4-2
,	O
was	O
also	O
downregulated	O
by	O
auranofin	S-chem-C4-1
.	O

Our	O
results	O
first	O
demonstrate	O
that	O
auranofin	S-chem-C4-1
suppresses	O
the	O
multiple	O
steps	O
in	O
TLR4	S-geneY-C4-2
signaling	O
,	O
especially	O
the	O
homodimerization	O
of	O
TLR4	S-geneY-C4-2
.	O

The	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
TLR4	S-geneY-C4-2
activity	O
by	O
auranofin	S-chem-C4-1
may	O
be	O
the	O
molecular	O
mechanism	O
through	O
which	O
auranofin	S-chem-C4-1
exerts	O
anti	O
-	O
rheumatic	O
activity	O
.	O

Dose	O
-	O
dependent	O
inhibition	O
of	O
platelet	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
and	O
monocyte	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
by	O
meloxicam	S-chem-C4-1
in	O
healthy	O
subjects	O
.	O

We	O
evaluated	O
whether	O
therapeutic	O
blood	O
levels	O
of	O
meloxicam	S-chem
are	O
associated	O
with	O
selective	O
inhibition	O
of	O
monocyte	O
cyclooxygenase	B-geneY
(	I-geneY
COX	I-geneY
)	I-geneY
-	I-geneY
2	E-geneY
in	O
vitro	O
and	O
ex	O
vivo	O
.	O

Concentration	O
-	O
response	O
curves	O
for	O
the	O
inhibition	O
of	O
monocyte	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
platelet	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
were	O
obtained	O
in	O
vitro	O
after	O
the	O
incubation	O
of	O
meloxicam	S-chem-C4-1
with	O
whole	O
blood	O
samples	O
.	O

Moreover	O
,	O
11	O
healthy	O
volunteers	O
received	O
placebo	O
or	O
7.5	O
or	O
15	O
mg	O
/	O
day	O
meloxicam	S-chem
,	O
each	O
treatment	O
for	O
7	O
consecutive	O
days	O
,	O
according	O
to	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
design	O
.	O

Before	O
dosing	O
and	O
24	O
h	O
after	O
the	O
seventh	O
dose	O
of	O
each	O
regimen	O
,	O
heparinized	O
whole	O
blood	O
samples	O
were	O
incubated	O
with	O
lipopolysaccharide	O
(	O
10	O
microgram	O
/	O
ml	O
)	O
for	O
24	O
h	O
at	O
37	O
degrees	O
C	O
,	O
and	O
prostaglandin	B-chem-C9-1
E2	E-chem-C9-1
was	O
measured	O
in	O
plasma	O
as	O
an	O
index	O
of	O
monocyte	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
activity	O
.	O

The	O
production	O
of	O
thromboxane	B-chem-C9-1
B2	E-chem-C9-1
in	O
whole	O
blood	O
allowed	O
to	O
clot	O
at	O
37	O
degrees	O
C	O
for	O
60	O
min	O
was	O
assessed	O
as	O
an	O
index	O
of	O
platelet	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
activity	O
.	O

The	O
administration	O
of	O
placebo	O
did	O
not	O
significantly	O
affect	O
plasma	O
prostaglandin	B-chem
E2	E-chem
(	O
21	O
.	O

3	O
+	O
/	O
-	O
7.5	O
versus	O
19.1	O
+	O
/	O
-	O
4	O
ng	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
S.D	O
.	O
,	O
n	O
=	O
11	O
)	O
or	O
serum	O
thromboxane	B-chem
B2	E-chem
(	O
426	O
+	O
/	O
-	O
167	O
versus	O
425	O
+	O
/	O
-	O
150	O
ng	O
/	O
ml	O
)	O
levels	O
.	O

In	O
contrast	O
,	O
the	O
administration	O
of	O
7.5	O
and	O
15	O
mg	O
of	O
meloxicam	S-chem-C4-1
caused	O
dose	O
-	O
dependent	O
reductions	O
in	O
monocyte	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
activity	O
by	O
51	O
%	O
and	O
70	O
%	O
,	O
respectively	O
,	O
and	O
in	O
platelet	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
activity	O
by	O
25	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Although	O
the	O
IC50	O
value	O
of	O
meloxicam	S-chem-C4-1
for	O
inhibition	O
of	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
was	O
10	O
-	O
fold	O
higher	O
than	O
the	O
IC50	O
value	O
of	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
in	O
vitro	O
,	O
this	O
biochemical	O
selectivity	O
was	O
inadequate	O
to	O
clearly	O
separate	O
the	O
effects	O
of	O
meloxicam	S-chem
on	O
the	O
two	O
isozymes	O
after	O
oral	O
dosing	O
as	O
a	O
function	O
of	O
the	O
daily	O
dose	O
and	O
interindividual	O
variation	O
in	O
steady	O
-	O
state	O
plasma	O
levels	O
.	O

Redesign	O
of	O
carnitine	B-geneY
acetyltransferase	E-geneY
specificity	O
by	O
protein	O
engineering	O
.	O

In	O
eukaryotes	O
,	O
L	B-chem
-	I-chem
carnitine	E-chem
is	O
involved	O
in	O
energy	O
metabolism	O
by	O
facilitating	O
beta	O
-	O
oxidation	O
of	O
fatty	B-chem
acids	E-chem
.	O

Carnitine	B-geneY-C9-2
acetyltransferases	E-geneY-C9-2
(	O
CrAT	S-geneY-C9-2
)	O
catalyze	O
the	O
reversible	O
conversion	O
of	O
acetyl	B-chem-C9-1
-	I-chem-C9-1
CoA	E-chem-C9-1
and	O
carnitine	S-chem-C9-1
to	O
acetylcarnitine	S-chem-C9-1
and	O
free	O
CoA	O
.	O

To	O
redesign	O
the	O
specificity	O
of	O
rat	B-geneY
CrAT	E-geneY
toward	O
its	O
substrates	O
,	O
we	O
mutated	O
Met564	O
.	O

The	O
M564G	S-geneN-C9-2
mutated	O
CrAT	S-geneY-C9-2
showed	O
higher	O
activity	O
toward	O
longer	O
chain	O
acyl	B-chem-C9-1
-	I-chem-C9-1
CoAs	E-chem-C9-1
:	O
activity	O
toward	O
myristoyl	B-chem-C9-1
-	I-chem-C9-1
CoA	E-chem-C9-1
was	O
1250	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
CrAT	S-geneY-C9-2
,	O
and	O
lower	O
activity	O
toward	O
its	O
natural	O
substrate	O
,	O
acetyl	B-chem-C9-1
-	I-chem-C9-1
CoA	E-chem-C9-1
.	O

Kinetic	O
constants	O
of	O
the	O
mutant	O
CrAT	S-geneY-C9-2
showed	O
modification	O
in	O
favor	O
of	O
longer	O
acyl	B-chem-C9-1
-	I-chem-C9-1
CoAs	E-chem-C9-1
as	O
substrates	O
.	O

In	O
the	O
reverse	O
case	O
,	O
mutation	O
of	O
the	O
orthologous	O
glycine	B-geneN
(	I-geneN
Gly553	I-geneN
)	I-geneN
to	I-geneN
methionine	E-geneN
in	O
carnitine	B-geneY-C9-2
octanoyltransferase	E-geneY-C9-2
(	O
COT	S-geneY-C9-2
)	O
decreased	O
activity	O
toward	O
its	O
natural	O
substrates	O
,	O
medium	O
-	O
and	O
long	O
-	O
chain	O
acyl	B-chem-C9-1
-	I-chem-C9-1
CoAs	E-chem-C9-1
,	O
and	O
increased	O
activity	O
toward	O
short	O
-	O
chain	O
acyl	B-chem-C9-1
-	I-chem-C9-1
CoAs	E-chem-C9-1
.	O

Another	O
CrAT	S-geneY
mutant	O
,	O
M564A	S-geneN
,	O
was	O
prepared	O
and	O
tested	O
in	O
the	O
same	O
way	O
,	O
with	O
similar	O
results	O
.	O

We	O
conclude	O
that	O
Met564	O
blocks	O
the	O
entry	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
acyl	B-chem-C9-1
-	I-chem-C9-1
CoAs	E-chem-C9-1
to	O
the	O
catalytic	O
site	O
of	O
CrAT	S-geneY-C9-2
.	O

Three	O
-	O
dimensional	O
models	O
of	O
wild	O
-	O
type	O
and	O
mutated	O
CrAT	S-geneY
and	O
COT	S-geneY
support	O
this	O
hypothesis	O
.	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
amino	B-chem
acid	E-chem
is	O
able	O
to	O
determine	O
the	O
substrate	O
specificity	O
of	O
CrAT	S-geneY
and	O
COT	S-geneY
.	O

Purification	O
and	O
structural	O
characterisation	O
of	O
phospholipase	B-geneN
A1	E-geneN
(	O
Vespapase	S-geneN
,	O
Ves	B-geneN
a	I-geneN
1	E-geneN
)	O
from	O
Thai	O
banded	O
tiger	O
wasp	O
(	O
Vespa	O
affinis	O
)	O
venom	O
.	O

The	O
Thai	O
banded	O
tiger	O
wasp	O
(	O
Vespa	O
affinis	O
)	O
is	O
one	O
of	O
the	O
most	O
dangerous	O
vespid	O
species	O
in	O
Southeast	O
Asia	O
,	O
and	O
stinging	O
accidents	O
involving	O
this	O
species	O
still	O
cause	O
fatalities	O
.	O

In	O
the	O
present	O
study	O
,	O
four	O
forms	O
of	O
V.	B-geneN
affinis	I-geneN
phospholipase	I-geneN
A	I-geneN
(	I-geneN
1	I-geneN
)	E-geneN
were	O
identified	O
through	O
a	O
proteomics	O
approach	O
.	O

Two	O
of	O
these	O
enzymes	O
were	O
purified	O
by	O
reverse	O
-	O
phase	O
chromatography	O
,	O
and	O
their	O
biochemical	O
properties	O
were	O
characterised	O
.	O

These	O
enzymes	O
,	O
designated	O
Ves	B-geneN
a	I-geneN
1s	E-geneN
,	O
are	O
not	O
glycoproteins	O
and	O
exist	O
as	O
33441.5	O
and	O
33474.4	O
Da	O
proteins	O
,	O
which	O
corresponded	O
with	O
the	O
34	O
-	O
kDa	O
band	O
observed	O
via	O
SDS	O
-	O
PAGE	O
.	O

The	O
thermal	O
stabilities	O
of	O
these	O
enzymes	O
were	O
stronger	O
than	O
snake	O
venom	O
.	O

Using	O
an	O
in	O
vivo	O
assay	O
,	O
no	O
difference	O
was	O
found	O
in	O
the	O
toxicities	O
of	O
the	O
different	O
isoforms	O
.	O

Furthermore	O
,	O
the	O
toxicity	O
of	O
these	O
enzymes	O
does	O
not	O
appear	O
to	O
be	O
correlated	O
with	O
their	O
PLA	B-geneN
(	I-geneN
1	I-geneN
)	E-geneN
activity	O
.	O

The	O
cDNAs	O
of	O
the	O
full	O
-	O
length	O
version	O
of	O
Ves	B-geneN
a	I-geneN
1s	E-geneN
revealed	O
that	O
the	O
Ves	B-geneN
a	I-geneN
1	E-geneN
gene	O
consists	O
of	O
a	O
1005	O
-	O
bp	O
ORF	O
,	O
which	O
encodes	O
334	O
amino	B-chem
acid	E-chem
residues	O
,	O
and	O
67	O
-	O
and	O
227	O
-	O
bp	O
5	O
'	O
and	O
3	O
'	O
UTRs	O
,	O
respectively	O
.	O

The	O
two	O
isoforms	O
are	O
different	O
by	O
three	O
nucleotide	S-chem
substitutions	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
two	O
amino	B-chem
acids	E-chem
.	O

Through	O
sequence	O
alignment	O
,	O
these	O
enzymes	O
were	O
classified	O
as	O
members	O
of	O
the	O
pancreatic	B-geneN
lipase	E-geneN
family	O
.	O

The	O
structural	O
modelling	O
of	O
Ves	B-geneN
a	I-geneN
1	E-geneN
used	O
the	O
rat	B-geneY
pancreatic	I-geneY
lipase	I-geneY
-	I-geneY
related	I-geneY
protein	I-geneY
2	E-geneY
(	O
1bu8A	S-geneY
)	O
as	O
a	O
template	O
because	O
it	O
has	O
PLA	B-geneN
(	I-geneN
1	I-geneN
)	E-geneN
activity	O
,	O
which	O
demonstrated	O
that	O
this	O
enzyme	O
belongs	O
to	O
the	O
α	B-geneN
/	I-geneN
β	I-geneN
hydrolase	E-geneN
fold	O
family	O
.	O

The	O
Ves	B-geneN
a	I-geneN
1	E-geneN
structure	O
,	O
which	O
is	O
composed	O
of	O
seven	O
α	O
-	O
helixes	O
and	O
eleven	O
β	O
-	O
strands	O
,	O
contains	O
the	O
β	O
-	O
strand	O
/	O
ɛSer	O
/	O
α	O
-	O
helix	O
structural	O
motif	O
,	O
which	O
contains	O
the	O
Gly	B-geneN
-	I-geneN
X	I-geneN
-	I-geneN
Ser	I-geneN
-	I-geneN
X	I-geneN
-	I-geneN
Gly	E-geneN
consensus	O
sequence	O
.	O

The	O
typical	O
surface	O
structures	O
that	O
play	O
important	O
roles	O
in	O
substrate	O
selectivity	O
(	O
the	O
lid	O
domain	O
and	O
the	O
β9	O
loop	O
)	O
were	O
shortened	O
in	O
the	O
Ves	B-geneN
a	I-geneN
1	E-geneN
structure	O
,	O
which	O
suggests	O
that	O
this	O
enzyme	O
may	O
only	O
exhibit	O
phospholipase	S-geneN
activity	O
.	O

Moreover	O
,	O
the	O
observed	O
insertion	O
of	O
proline	S-chem
into	O
the	O
lid	O
domain	O
of	O
the	O
Ves	B-geneN
a	I-geneN
1	E-geneN
structure	O
is	O
rare	O
.	O

We	O
therefore	O
propose	O
that	O
this	O
proline	S-chem
residue	O
might	O
be	O
involved	O
in	O
the	O
stability	O
and	O
activity	O
of	O
Ves	B-geneN
a	I-geneN
1s	E-geneN
.	O

Combined	O
effects	O
of	O
organochlorine	S-chem
pesticides	O
heptachlor	S-chem
and	O
hexachlorobenzene	S-chem
on	O
the	O
promotion	O
stage	O
of	O
hepatocarcinogenesis	O
in	O
rats	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
combined	O
effect	O
of	O
organochlorine	S-chem
pesticides	O
heptachlor	S-chem
(	O
HEP	S-chem
)	O
and	O
hexachlorobenzene	S-chem
(	O
HCB	S-chem
)	O
by	O
using	O
a	O
medium	O
-	O
term	O
rat	O
liver	O
bioassay	O
.	O

Male	O
F344	O
rats	O
were	O
initially	O
administered	O
diethylnitrosamine	S-chem
(	O
DEN	S-chem
,	O
200mg	O
/	O
kgi.p	O
.	O
)	O
;	O
after	O
a	O
2	O
-	O
week	O
non	O
-	O
dosing	O
period	O
,	O
they	O
were	O
given	O
diets	O
containing	O
HEP	S-chem
(	O
5	O
or	O
25ppm	O
)	O
,	O
HCB	S-chem
(	O
70	O
or	O
350ppm	O
)	O
,	O
or	O
their	O
mixtures	O
(	O
5	O
and	O
70ppm	O
or	O
25	O
and	O
350ppm	O
)	O
for	O
6weeks	O
.	O

All	O
rats	O
were	O
subjected	O
to	O
partial	O
hepatectomy	O
at	O
week	O
3	O
and	O
killed	O
at	O
week	O
8	O
.	O

We	O
observed	O
additive	O
or	O
synergistic	O
effects	O
of	O
HEP	S-chem
and	O
HCB	S-chem
in	O
groups	O
treated	O
with	O
mixtures	O
of	O
these	O
pesticides	O
.	O

Number	O
and	O
area	O
of	O
preneoplastic	O
foci	O
positive	O
for	O
glutathione	B-geneN-C3-2
S	I-geneN-C3-2
-	I-geneN-C3-2
transferase	I-geneN-C3-2
placental	I-geneN-C3-2
form	E-geneN-C3-2
(	O
GST	B-geneN-C3-2
-	I-geneN-C3-2
P	E-geneN-C3-2
)	O
were	O
consistently	O
higher	O
in	O
these	O
groups	O
than	O
the	O
sum	O
of	O
individual	O
values	O
in	O
the	O
groups	O
treated	O
with	O
HEP	S-chem-C3-1
or	O
HCB	S-chem-C3-1
alone	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
HEP	S-chem
and	O
HCB	S-chem
had	O
additive	O
or	O
synergistic	O
effects	O
on	O
cell	O
proliferation	O
induction	O
within	O
the	O
preneoplastic	O
foci	O
and	O
cytochrome	B-geneN
P450	I-geneN
(	I-geneN
CYP	I-geneN
)	I-geneN
2B1	I-geneN
and	I-geneN
3A1	E-geneN
induction	O
,	O
which	O
may	O
lead	O
to	O
more	O
efficient	O
metabolic	O
activation	O
of	O
HEP	S-chem
and	O
HCB	S-chem
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
we	O
conclude	O
that	O
HEP	S-chem-C3-1
and	O
HCB	S-chem-C3-1
have	O
additive	O
and	O
synergistic	O
effects	O
on	O
the	O
development	O
of	O
GST	B-geneN-C3-2
-	I-geneN-C3-2
P	E-geneN-C3-2
-	O
positive	O
foci	O
and	O
that	O
higher	O
risks	O
are	O
associated	O
with	O
a	O
combination	O
of	O
residual	O
organochlorine	S-chem
pesticides	O
in	O
foods	O
than	O
with	O
individual	O
residual	O
organochlorine	S-chem
pesticides	O
.	O

Genome	O
-	O
wide	O
integrated	O
analyses	O
of	O
androgen	B-geneY
receptor	E-geneY
signaling	O
in	O
prostate	O
cancer	O
based	O
on	O
high	O
-	O
throughput	O
technology	O
.	O

The	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
is	O
a	O
steroid	B-geneN
hormone	I-geneN
receptor	E-geneN
that	O
functions	O
as	O
a	O
ligand	O
-	O
dependent	O
transcriptional	O
factor	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
prostate	O
cancer	O
.	O

Recent	O
advancement	O
in	O
high	O
throughput	O
technologies	O
including	O
microarrays	O
and	O
deep	O
-	O
sequencing	O
provides	O
unbiased	O
genome	O
-	O
wide	O
knowledge	O
on	O
the	O
AR	S-geneY
signaling	O
including	O
datasets	O
for	O
androgen	S-chem
-	O
regulated	O
gene	O
expression	O
and	O
genomic	O
binding	O
sites	O
for	O
AR	S-geneY
.	O

In	O
the	O
present	O
review	O
,	O
we	O
will	O
briefly	O
summarize	O
the	O
main	O
features	O
of	O
the	O
AR	S-geneY
signaling	O
as	O
well	O
as	O
the	O
individual	O
AR	S-geneY
target	O
genes	O
identified	O
by	O
the	O
integration	O
of	O
multiple	O
datasets	O
in	O
prostate	O
cancer	O
.	O

Cap	O
analysis	O
gene	O
expression	O
(	O
CAGE	O
)	O
is	O
also	O
featured	O
as	O
a	O
unique	O
transcriptome	O
method	O
,	O
which	O
particularly	O
determines	O
the	O
androgen	S-chem
-	O
dependent	O
transcription	O
start	O
points	O
in	O
prostate	O
cancer	O
.	O

Vitamin	B-chem
E	E-chem
supplementation	O
alters	O
HDL	S-geneN
-	O
cholesterol	S-chem
concentration	O
and	O
paraoxonase	S-geneY
activity	O
in	O
rabbits	O
fed	O
high	O
-	O
cholesterol	S-chem
diet	O
:	O
comparison	O
with	O
probucol	S-chem
.	O

Vitamin	B-chem
E	E-chem
and	O
probucol	S-chem
are	O
well	O
-	O
known	O
antioxidants	O
that	O
prevent	O
cells	O
from	O
the	O
oxidative	O
stress	O
,	O
which	O
is	O
a	O
risk	O
factor	O
of	O
atherosclerosis	O
.	O

Male	O
rabbits	O
were	O
fed	O
either	O
0.03	O
%	O
vitamin	B-chem
E	E-chem
or	O
0.05	O
%	O
probucol	S-chem
in	O
a	O
0.5	O
%	O
high	O
-	O
cholesterol	S-chem
(	O
HC	O
)	O
diet	O
for	O
8	O
weeks	O
.	O

Vitamin	B-chem-C4-1
E	E-chem-C4-1
and	O
probucol	S-chem-C4-1
significantly	O
suppressed	O
an	O
increase	O
in	O
plasma	O
total	O
-	O
cholesterol	S-chem
(	O
total	O
-	O
C	O
)	O
and	O
low	B-geneN-C4-2
-	I-geneN-C4-2
density	I-geneN-C4-2
lipoprotein	E-geneN-C4-2
cholesterol	S-chem
compared	O
to	O
HC	O
-	O
control	O
group	O
.	O

However	O
,	O
plasma	O
high	B-geneN-C3-2
-	I-geneN-C3-2
density	I-geneN-C3-2
lipoprotein	E-geneN-C3-2
-	O
cholesterol	S-chem
(	O
HDL	S-geneN-C3-2
-	O
C	O
)	O
and	O
HDL	S-geneN-C3-2
-	O
C	O
/	O
total	O
-	O
C	O
ratio	O
levels	O
and	O
plasma	O
paraoxonase	S-geneY-C3-2
activity	O
were	O
only	O
significantly	O
higher	O
in	O
vitamin	B-chem-C3-1
E	E-chem-C3-1
group	O
after	O
8	O
weeks	O
.	O

Hepatic	O
ACAT	S-geneY-C4-2
activity	O
was	O
significantly	O
lower	O
in	O
both	O
vitamin	B-chem-C4-1
E	E-chem-C4-1
and	O
probucol	S-chem-C4-1
groups	O
than	O
in	O
HC	O
-	O
control	O
group	O
,	O
while	O
HMG	B-geneY-C3-2
-	I-geneY-C3-2
CoA	I-geneY-C3-2
reductase	E-geneY-C3-2
activity	O
was	O
the	O
highest	O
only	O
in	O
the	O
probucol	S-chem-C3-1
group	O
.	O

Total	O
fecal	O
sterol	S-chem
content	O
was	O
significantly	O
higher	O
in	O
probucol	S-chem
and	O
vitamin	B-chem
E	E-chem
groups	O
than	O
in	O
the	O
two	O
control	O
groups	O
.	O

Some	O
atherogenic	O
signs	O
were	O
discovered	O
in	O
the	O
aortic	O
fatty	O
streak	O
of	O
HC	O
-	O
control	O
group	O
,	O
yet	O
not	O
in	O
other	O
groups	O
.	O

Hepatic	O
mRNA	O
expressions	O
of	O
apo	B-geneY-C4-2
B	I-geneY-C4-2
-	I-geneY-C4-2
100	E-geneY-C4-2
and	O
apo	B-geneY-C4-2
C	I-geneY-C4-2
-	I-geneY-C4-2
III	E-geneY-C4-2
were	O
significantly	O
lower	O
in	O
probucol	S-chem-C4-1
group	O
than	O
in	O
other	O
groups	O
.	O

Vitamin	B-chem
E	E-chem
supplementation	O
was	O
found	O
to	O
alter	O
the	O
plasma	O
HDL	S-geneN
-	O
C	O
-	O
related	O
factors	O
;	O
meanwhile	O
,	O
probucol	S-chem-C4-1
supplementation	O
was	O
very	O
effective	O
in	O
enhancing	O
cholesterol	S-chem
metabolism	O
,	O
except	O
for	O
a	O
negative	O
effect	O
that	O
reduced	O
plasma	O
HDL	S-geneN-C4-2
-	O
C	O
concentration	O
.	O

Angiotensin	B-geneY-C4-2
II	E-geneY-C4-2
suppression	O
in	O
humans	O
by	O
the	O
orally	O
active	O
renin	S-geneY-C4-2
inhibitor	O
Aliskiren	S-chem-C4-1
(	O
SPP100	S-chem-C4-1
)	O
:	O
comparison	O
with	O
enalapril	S-chem
.	O

Renin	S-geneY
is	O
the	O
main	O
determinant	O
of	O
angiotensin	B-geneY
(	I-geneY
Ang	I-geneY
)	I-geneY
II	E-geneY
levels	O
.	O

It	O
,	O
therefore	O
,	O
always	O
appeared	O
desirable	O
to	O
reduce	O
Ang	B-geneY
II	E-geneY
levels	O
by	O
direct	O
inhibition	O
of	O
renin	S-geneY
.	O

So	O
far	O
,	O
specific	O
renin	S-geneY
inhibitors	O
lacked	O
potency	O
and	O
/	O
or	O
oral	O
availability	O
.	O

We	O
tested	O
the	O
new	O
orally	O
active	O
nonpeptidic	O
renin	S-geneY-C4-2
inhibitor	O
SPP100	S-chem-C4-1
(	O
Aliskiren	S-chem-C4-1
,	O
an	O
octanamide	S-chem-C4-1
with	O
a	O
50	O
%	O
inhibitory	O
concentration	O
[	O
IC50	O
]	O
in	O
the	O
low	O
nanomolar	O
range	O
)	O
in	O
18	O
healthy	O
volunteers	O
on	O
a	O
constant	O
100	O
mmol	O
/	O
d	O
sodium	S-chem
diet	O
using	O
a	O
double	O
-	O
blind	O
,	O
3	O
-	O
way	O
crossover	O
protocol	O
.	O

In	O
3	O
periods	O
of	O
8	O
days	O
,	O
separated	O
by	O
wash	O
-	O
outs	O
of	O
6	O
days	O
,	O
each	O
volunteer	O
received	O
2	O
dosage	O
levels	O
of	O
Aliskiren	S-chem
(	O
low	O
before	O
high	O
;	O
40	O
and	O
80	O
or	O
160	O
and	O
640	O
mg	O
/	O
d	O
)	O
and	O
randomized	O
placebo	O
or	O
20	O
mg	O
enalapril	S-chem
.	O

Aliskiren	S-chem
was	O
well	O
tolerated	O
.	O

Not	O
surprisingly	O
,	O
blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
unchanged	O
in	O
these	O
normotensive	O
subjects	O
.	O

There	O
was	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
plasma	O
renin	S-geneY-C4-2
activity	O
,	O
Ang	B-geneY-C4-2
I	E-geneY-C4-2
,	O
and	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
following	O
single	O
doses	O
of	O
Aliskiren	S-chem-C4-1
starting	O
with	O
40	O
mg	O
.	O

Inhibition	O
was	O
still	O
marked	O
and	O
significant	O
after	O
repeated	O
dosing	O
with	O
maximal	O
decreases	O
in	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
levels	O
by	O
89	O
%	O
and	O
75	O
%	O
on	O
Days	O
1	O
and	O
8	O
,	O
respectively	O
,	O
when	O
the	O
highest	O
dose	O
of	O
Aliskiren	S-chem-C4-1
was	O
compared	O
with	O
placebo	O
.	O

At	O
the	O
same	O
time	O
,	O
mean	O
plasma	O
active	O
renin	S-geneY-C3-2
was	O
increased	O
16	O
-	O
and	O
34	O
-	O
fold	O
at	O
the	O
highest	O
dose	O
of	O
Aliskiren	S-chem-C3-1
.	O

Plasma	O
drug	O
levels	O
of	O
Aliskiren	S-chem
were	O
dose	O
-	O
dependent	O
with	O
maximal	O
concentrations	O
reached	O
between	O
3	O
to	O
6	O
hours	O
after	O
administration	O
;	O
steady	O
state	O
was	O
reached	O
between	O
5	O
and	O
8	O
days	O
after	O
multiple	O
dosing	O
.	O

Less	O
than	O
1	O
%	O
of	O
dose	O
was	O
excreted	O
in	O
the	O
urine	O
.	O

Plasma	O
and	O
urinary	O
aldosterone	S-chem
levels	O
were	O
decreased	O
after	O
doses	O
of	O
Aliskiren	S-chem
>	O
or	O
=	O
80	O
mg	O
and	O
after	O
enalapril	S-chem
.	O

Aliskiren	S-chem
at	O
160	O
and	O
640	O
mg	O
enhanced	O
natriuresis	O
on	O
Day	O
1	O
by	O
+	O
45	O
%	O
and	O
+	O
62	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
placebo	O
(	O
100	O
%	O
,	O
ie	O
,	O
87	O
+	O
/	O
-	O
11	O
mmol	O
/	O
24h	O
)	O
and	O
enalapril	S-chem
(	O
+	O
54	O
%	O
)	O
;	O
kaliuresis	O
remained	O
unchanged	O
.	O

In	O
conclusion	O
,	O
the	O
renin	S-geneY-C4-2
inhibitor	O
Aliskiren	S-chem-C4-1
dose	O
-	O
dependently	O
decreases	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
levels	O
in	O
humans	O
following	O
oral	O
administration	O
.	O

The	O
effect	O
is	O
long	O
-	O
lasting	O
and	O
,	O
at	O
a	O
dose	O
of	O
160	O
mg	O
,	O
is	O
equivalent	O
to	O
that	O
of	O
20	O
mg	O
enalapril	S-chem
.	O

Aliskiren	S-chem-MU-1
has	O
the	O
potential	O
to	O
become	O
the	O
first	O
orally	O
active	O
renin	S-geneY-C4-2
inhibitor	O
that	O
provides	O
a	O
true	O
alternative	O
to	O
ACE	S-geneY-C4-2
-	O
inhibitors	O
and	O
Ang	B-geneN-C6-2
II	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonists	O
in	O
therapy	O
for	O
hypertension	O
and	O
other	O
cardiovascular	O
and	O
renal	O
diseases	O
.	O

The	O
potassium	B-geneY
channel	I-geneY
subunit	I-geneY
Kvbeta3	E-geneY
interacts	O
with	O
pannexin	B-geneY
1	E-geneY
and	O
attenuates	O
its	O
sensitivity	O
to	O
changes	O
in	O
redox	O
potentials	O
.	O

Pannexin	B-geneY
1	E-geneY
(	O
Panx1	S-geneY
)	O
,	O
a	O
member	O
of	O
the	O
second	O
gap	B-geneN
junction	I-geneN
protein	E-geneN
family	O
identified	O
in	O
vertebrates	O
,	O
appears	O
to	O
preferentially	O
form	O
non	O
-	O
junctional	O
membrane	O
channels	O
.	O

A	O
candidate	O
regulatory	O
protein	O
of	O
Panx1	S-geneY
is	O
the	O
potassium	B-geneY
channel	I-geneY
subunit	I-geneY
Kvbeta3	E-geneY
,	O
previously	O
identified	O
by	O
bacterial	O
two	O
-	O
hybrid	O
strategies	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
physical	O
association	O
of	O
Panx1	S-geneY
with	O
Kvbeta3	S-geneY
by	O
immunoprecipitation	O
when	O
co	O
-	O
expressed	O
in	O
a	O
neuroblastoma	O
cell	O
line	O
(	O
Neuro2A	O
)	O
.	O

Furthermore	O
,	O
in	O
vivo	O
co	O
-	O
expression	O
of	O
Panx1	S-geneY
and	O
Kvbeta3	S-geneY
was	O
shown	O
to	O
occur	O
in	O
murine	O
hippocampus	O
and	O
cerebellum	O
.	O

Kvbeta3	S-geneY
is	O
known	O
to	O
accelerate	O
inactivation	O
of	O
otherwise	O
slowly	O
inactivating	O
potassium	B-geneN
channels	E-geneN
under	O
reducing	O
conditions	O
.	O

We	O
subsequently	O
found	O
that	O
Panx1	S-geneY
channel	O
currents	O
exhibit	O
a	O
significant	O
reduction	O
when	O
exposed	O
to	O
reducing	O
agents	O
,	O
and	O
that	O
this	O
effect	O
is	O
attenuated	O
in	O
the	O
presence	O
of	O
Kvbeta3	S-geneY
.	O

Apparently	O
,	O
Kvbeta3	S-geneY
is	O
involved	O
in	O
regulating	O
the	O
susceptibility	O
of	O
Panx1	S-geneY
channels	O
to	O
redox	O
potential	O
.	O

Furthermore	O
,	O
the	O
Panx1	S-geneY-C4-2
channel	O
blockers	O
carbenoxolone	S-chem-C4-1
and	O
Probenecid	S-chem-C4-1
were	O
less	O
effective	O
in	O
inhibiting	O
Panx1	S-geneY
currents	O
when	O
Kvbeta3	S-geneY
was	O
co	O
-	O
expressed	O
.	O

The	O
influence	O
of	O
Kvbeta3	S-geneY
on	O
Panx1	S-geneY
is	O
the	O
first	O
example	O
of	O
modulation	O
of	O
Panx1	S-geneY
channel	O
function	O
(	O
s	O
)	O
by	O
interacting	O
proteins	O
,	O
and	O
suggests	O
the	O
physiological	O
importance	O
of	O
sensing	O
changes	O
in	O
redox	O
potentials	O
.	O

Down	O
-	O
regulation	O
of	O
LRRK2	S-geneY
in	O
control	O
and	O
DAT	S-geneY
transfected	O
HEK	O
cells	O
increases	O
manganese	S-chem
-	O
induced	O
oxidative	O
stress	O
and	O
cell	O
toxicity	O
.	O

The	O
extra	O
-	O
pyramidal	O
symptoms	O
associated	O
with	O
manganism	S-chem
often	O
overlap	O
with	O
that	O
seen	O
in	O
Parkinsonism	O
suggesting	O
a	O
common	O
link	O
between	O
the	O
two	O
disorders	O
.	O

Since	O
wide	O
deviations	O
are	O
observed	O
in	O
susceptibility	O
and	O
characteristics	O
of	O
the	O
symptoms	O
observed	O
in	O
manganism	S-chem
,	O
these	O
differences	O
may	O
be	O
due	O
to	O
underlying	O
genetic	O
variability	O
.	O

Genes	O
linked	O
to	O
early	O
onset	O
of	O
Parkinsonism	O
which	O
includes	O
ATP13A2	S-geneY
and	O
parkin	S-geneY
have	O
already	O
been	O
suggested	O
to	O
promote	O
development	O
of	O
Mn	S-chem
toxicity	O
.	O

Of	O
the	O
other	O
Parkinson	O
-	O
linked	O
genes	O
,	O
mutations	O
in	O
LRRK2	S-geneY
,	O
an	O
autosomal	O
dominant	O
gene	O
,	O
represent	O
another	O
likely	O
candidate	O
involved	O
in	O
the	O
development	O
of	O
manganism	S-chem
.	O

In	O
this	O
paper	O
the	O
effect	O
of	O
shRNA	O
LRRK2	S-geneY
knock	O
-	O
down	O
on	O
Mn	S-chem
toxicity	O
was	O
examined	O
in	O
control	O
and	O
DAT	S-geneY
transfected	O
HEK293	O
cells	O
.	O

Results	O
demonstrate	O
that	O
LRRK2	S-geneY
down	O
-	O
regulation	O
potentiates	O
Mn	S-chem
toxicity	O
in	O
both	O
control	O
and	O
DAT	S-geneY
-	O
transfected	O
cell	O
as	O
well	O
as	O
potentiates	O
DA	O
toxicity	O
.	O

Combined	O
treatment	O
of	O
Mn	S-chem-C3-1
and	O
DA	O
further	O
augments	O
cell	O
toxicity	O
,	O
ROS	O
production	O
and	O
JNK	S-geneN-C3-2
phosphorylation	O
in	O
LRRK2	S-geneY
deficient	O
cells	O
compared	O
to	O
controls	O
.	O

Consistent	O
with	O
studies	O
demonstrating	O
that	O
LRRK2	S-geneN
plays	O
a	O
role	O
in	O
the	O
phosphorylation	O
of	O
p38	S-geneN
,	O
our	O
results	O
similarly	O
demonstrate	O
a	O
decrease	O
in	O
p38	S-geneN
activation	O
in	O
LRRK2	S-geneY
knock	O
-	O
down	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
null	O
mutations	O
in	O
LRRK2	S-geneY
which	O
cause	O
Parkinsonism	O
potentiate	O
Mn	S-chem
toxicity	O
and	O
increase	O
susceptibility	O
to	O
develop	O
manganism	S-chem
.	O

Discovery	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
small	O
molecules	O
that	O
block	O
the	O
human	B-geneN
immunoglobulin	I-geneN
G	E-geneN
-	O
human	B-geneY
neonatal	I-geneY
Fc	I-geneY
receptor	E-geneY
(	O
hIgG	S-geneN
-	O
hFcRn	S-geneY
)	O
protein	O
-	O
protein	O
interaction	O
.	O

The	O
neonatal	B-geneY
Fc	I-geneY
receptor	E-geneY
,	O
FcRn	S-geneY
,	O
prolongs	O
the	O
half	O
-	O
life	O
of	O
IgG	S-geneN
in	O
the	O
serum	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disease	O
.	O

Small	O
molecules	O
that	O
block	O
the	O
protein	O
-	O
protein	O
interactions	O
of	O
human	B-geneN
IgG	E-geneN
-	O
human	B-geneY
FcRn	E-geneY
may	O
lower	O
pathogenic	O
autoantibodies	O
and	O
provide	O
effective	O
treatment	O
.	O

A	O
novel	O
class	O
of	O
quinoxalines	S-chem-C6-1
has	O
been	O
discovered	O
as	O
antagonists	O
of	O
the	O
IgG	S-geneN-C6-2
:	O
FcRn	S-geneY-C6-2
protein	O
-	O
protein	O
interaction	O
through	O
optimization	O
of	O
a	O
hit	O
derived	O
from	O
a	O
virtual	O
ligand	O
-	O
based	O
screen	O
.	O

Dasatinib	S-chem-C4-1
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
354825	E-chem-C4-1
)	O
inhibits	O
KITD816V	S-geneY
,	O
an	O
imatinib	S-chem
-	O
resistant	O
activating	O
mutation	O
that	O
triggers	O
neoplastic	O
growth	O
in	O
most	O
patients	O
with	O
systemic	O
mastocytosis	O
.	O

Mastocytosis	O
is	O
associated	O
with	O
an	O
activating	O
mutation	O
in	O
the	O
KIT	S-geneY
oncoprotein	O
(	O
KITD816V	S-geneY
)	O
that	O
results	O
in	O
autophosphorylation	O
of	O
the	O
KIT	S-geneY
receptor	O
in	O
a	O
ligand	O
-	O
independent	O
manner	O
.	O

This	O
mutation	O
is	O
inherently	O
resistant	O
to	O
imatinib	S-chem
and	O
,	O
to	O
date	O
,	O
there	O
remains	O
no	O
effective	O
curative	O
therapy	O
for	O
systemic	O
mastocytosis	O
associated	O
with	O
KITD816V	S-geneY
.	O

Dasatinib	S-chem-C4-1
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
354825	E-chem-C4-1
)	O
is	O
a	O
novel	O
orally	O
bioavailable	O
SRC	S-geneY-C4-2
/	O
ABL	S-geneY-C4-2
inhibitor	O
that	O
has	O
activity	O
against	O
multiple	O
imatinib	S-chem
-	O
resistant	O
BCR	S-geneY
-	O
ABL	S-geneY
isoforms	O
in	O
vitro	O
that	O
is	O
presently	O
showing	O
considerable	O
promise	O
in	O
early	O
-	O
phase	O
clinical	O
trials	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

Pharmacokinetic	O
analysis	O
suggests	O
that	O
high	O
nanomolar	O
concentrations	O
of	O
dasatinib	S-chem
can	O
be	O
achieved	O
safely	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
significant	O
inhibitory	O
activity	O
of	O
dasatinib	S-chem-C4-1
against	O
both	O
wild	O
-	O
type	O
KIT	S-geneY-C4-2
and	O
the	O
KITD816V	S-geneY
mutation	O
in	O
the	O
nanomolar	O
range	O
in	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
kinase	S-geneN
assays	O
.	O

Additionally	O
,	O
dasatinib	S-chem-C4-1
leads	O
to	O
growth	O
inhibition	O
of	O
a	O
KITD816V	S-geneY
-	O
harboring	O
human	O
masto	O
-	O
cytosis	O
cell	O
line	O
.	O

Significantly	O
,	O
dasatinib	S-chem
selectively	O
kills	O
primary	O
neoplastic	O
bone	O
marrow	O
mast	O
cells	O
from	O
patients	O
with	O
systemic	O
mastocytosis	O
while	O
sparing	O
other	O
hematopoietic	O
cells	O
.	O

Computer	O
modeling	O
suggests	O
that	O
the	O
KITD816V	S-geneY
mutation	O
destabilizes	O
the	O
inactive	O
conformation	O
of	O
the	O
KIT	B-geneN
activation	I-geneN
loop	E-geneN
to	O
which	O
imatinib	S-chem
binds	O
,	O
but	O
it	O
is	O
not	O
predicted	O
to	O
impair	O
binding	O
of	O
KIT	S-geneY
by	O
dasatinib	S-chem
.	O

Based	O
upon	O
our	O
results	O
,	O
further	O
evaluation	O
of	O
dasatinib	S-chem
for	O
the	O
treatment	O
of	O
systemic	O
masto	O
-	O
cytosis	O
in	O
clinical	O
trials	O
is	O
warranted	O
.	O

Moreover	O
,	O
dasatinib	S-chem
may	O
be	O
of	O
clinical	O
utility	O
in	O
other	O
disease	O
settings	O
driven	O
by	O
activating	O
KIT	S-geneY
mutations	O
.	O

GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
expression	O
in	O
human	O
tumors	O
and	O
human	O
normal	O
tissues	O
:	O
potential	O
for	O
in	O
vivo	O
targeting	O
.	O

UNLABELLED	O
:	O
Peptide	B-geneN
hormone	I-geneN
receptors	E-geneN
overexpressed	O
in	O
human	O
tumors	O
,	O
such	O
as	O
somatostatin	B-geneN
receptors	E-geneN
,	O
can	O
be	O
used	O
for	O
in	O
vivo	O
targeting	O
for	O
diagnostic	O
and	O
therapeutic	O
purposes	O
.	O

A	O
novel	O
promising	O
candidate	O
in	O
this	O
field	O
is	O
the	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
,	O
which	O
was	O
recently	O
shown	O
to	O
be	O
massively	O
overexpressed	O
in	O
gut	O
and	O
lung	O
neuroendocrine	O
tumors	O
-	O
-	O
in	O
particular	O
,	O
in	O
insulinomas	O
.	O

Anticipating	O
a	O
major	O
development	O
of	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
targeting	O
in	O
nuclear	O
medicine	O
,	O
our	O
aim	O
was	O
to	O
evaluate	O
in	O
vitro	O
the	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
expression	O
in	O
a	O
large	O
variety	O
of	O
other	O
tumors	O
and	O
to	O
compare	O
it	O
with	O
that	O
in	O
nonneoplastic	O
tissues	O
.	O

METHODS	O
:	O
The	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
protein	O
expression	O
was	O
qualitatively	O
and	O
quantitatively	O
investigated	O
in	O
a	O
broad	O
spectrum	O
of	O
human	O
tumors	O
(	O
n	O
=	O
419	O
)	O
and	O
nonneoplastic	O
human	O
tissues	O
(	O
n	O
=	O
209	O
)	O
with	O
receptor	O
autoradiography	O
using	O
(	O
125	O
)	O
I	O
-	O
GLP	B-geneY
-	I-geneY
1	I-geneY
(	I-geneY
7	I-geneY
-	I-geneY
36	I-geneY
)	E-geneY
amide	O
.	O

Pharmacologic	O
competition	O
experiments	O
were	O
performed	O
to	O
provide	O
proof	O
of	O
specificity	O
of	O
the	O
procedure	O
.	O

RESULTS	O
:	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptors	E-geneY
were	O
expressed	O
in	O
various	O
endocrine	O
tumors	O
,	O
with	O
particularly	O
high	O
amounts	O
in	O
pheochromocytomas	O
,	O
as	O
well	O
as	O
in	O
brain	O
tumors	O
and	O
embryonic	O
tumors	O
but	O
not	O
in	O
carcinomas	O
or	O
lymphomas	O
.	O

In	O
nonneoplastic	O
tissues	O
,	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptors	E-geneY
were	O
present	O
in	O
generally	O
low	O
amounts	O
in	O
specific	O
tissue	O
compartments	O
of	O
several	O
organs	O
-	O
-	O
namely	O
,	O
pancreas	O
,	O
intestine	O
,	O
lung	O
,	O
kidney	O
,	O
breast	O
,	O
and	O
brain	O
;	O
no	O
receptors	O
were	O
identified	O
in	O
lymph	O
nodes	O
,	O
spleen	O
,	O
liver	O
,	O
or	O
the	O
adrenal	O
gland	O
.	O

The	O
rank	O
order	O
of	O
potencies	O
for	O
receptor	O
binding	O
-	O
-	O
namely	O
,	O
GLP	B-geneY
-	I-geneY
1	I-geneY
(	I-geneY
7	I-geneY
-	I-geneY
36	I-geneY
)	E-geneY
amide	O
=	O
exendin	B-geneY
-	I-geneY
4	E-geneY
>	O
>	O
GLP	B-geneY
-	I-geneY
2	E-geneY
=	O
glucagon	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
29	I-geneY
)	E-geneY
-	O
-	O
provided	O
proof	O
of	O
specific	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
identification	O
.	O

CONCLUSION	O
:	O
The	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptors	E-geneY
may	O
represent	O
a	O
novel	O
molecular	O
target	O
for	O
in	O
vivo	O
scintigraphy	O
and	O
targeted	O
radiotherapy	O
for	O
a	O
variety	O
of	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
-	O
expressing	O
tumors	O
.	O

For	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
scintigraphy	O
,	O
a	O
low	O
-	O
background	O
signal	O
can	O
be	O
expected	O
,	O
on	O
the	O
basis	O
of	O
the	O
low	O
receptor	O
expression	O
in	O
the	O
normal	O
tissues	O
surrounding	O
tumors	O
.	O

Dandelion	O
leaf	O
extract	O
protects	O
against	O
liver	O
injury	O
induced	O
by	O
methionine	S-chem
-	O
and	O
choline	S-chem
-	O
deficient	O
diet	O
in	O
mice	O
.	O

We	O
investigated	O
the	O
hepatoprotective	O
effects	O
of	O
the	O
extract	O
of	O
dandelion	O
leaves	O
(	O
EDL	O
)	O
on	O
a	O
murine	O
model	O
of	O
methionine	S-chem
-	O
and	O
choline	S-chem
-	O
deficient	O
(	O
MCD	O
)	O
diet	O
-	O
induced	O
nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
.	O

C57BL	O
/	O
6	O
mice	O
were	O
fed	O
for	O
4	O
weeks	O
with	O
one	O
of	O
the	O
following	O
diets	O
:	O
control	O
diet	O
(	O
Cont	O
)	O
,	O
MCD	O
diet	O
(	O
MCD	O
)	O
,	O
MCD	O
diet	O
supplemented	O
with	O
EDL	O
at	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
·	O
daily	O
(	O
MCD	O
+	O
D200	O
)	O
,	O
and	O
MCD	O
diet	O
supplemented	O
with	O
EDL	O
at	O
500	O
mg	O
/	O
kg	O
body	O
weight	O
·	O
daily	O
(	O
MCD	O
+	O
D500	O
)	O
.	O

Hepatic	O
function	O
was	O
assessed	O
by	O
evaluating	O
the	O
following	O
parameters	O
:	O
liver	O
histology	O
;	O
plasma	O
levels	O
of	O
alanine	B-geneN
aminotransferase	E-geneN
(	O
ALT	S-geneN
)	O
,	O
triglyceride	S-chem
(	O
TG	O
)	O
,	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
,	O
and	O
reduced	B-chem
glutathione	E-chem
(	O
GSH	S-chem
)	O
;	O
expression	O
levels	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
;	O
and	O
levels	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
pJNK	S-geneN
/	O
JNK	S-geneN
protein	O
.	O

Histopathological	O
evaluations	O
revealed	O
that	O
addition	O
of	O
EDL	O
to	O
the	O
MCD	O
diet	O
dampens	O
the	O
severity	O
of	O
the	O
clinical	O
signs	O
of	O
NASH	O
.	O

Moreover	O
,	O
EDL	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
serum	O
levels	O
of	O
ALT	S-geneN
,	O
hepatic	O
TG	O
,	O
and	O
MDA	S-chem
,	O
and	O
in	O
the	O
expression	O
levels	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
;	O
on	O
the	O
contrary	O
,	O
the	O
levels	O
of	O
reduced	B-chem
GSH	E-chem
increased	O
.	O

At	O
the	O
post	O
-	O
transcriptional	O
level	O
,	O
EDL	O
significantly	O
decreased	O
the	O
activation	O
of	O
procaspase	B-geneY
-	I-geneY
3	E-geneY
to	O
active	O
caspase	B-geneY
-	I-geneY
3	E-geneY
,	O
and	O
the	O
phosphorylation	O
of	O
JNK	S-geneN
.	O

These	O
results	O
suggest	O
that	O
the	O
beneficial	O
effects	O
of	O
EDL	O
on	O
NASH	O
are	O
mainly	O
due	O
to	O
its	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Helenalin	S-chem
-	O
induced	O
apoptosis	O
is	O
dependent	O
on	O
production	O
of	O
reactive	O
oxygen	S-chem
species	O
and	O
independent	O
of	O
induction	O
of	O
endoplasmic	O
reticulum	O
stress	O
in	O
renal	O
cell	O
carcinoma	O
.	O

Helenalin	S-chem
,	O
a	O
sesquiterpene	B-chem
lactone	E-chem
,	O
exhibits	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
tumor	O
activities	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
helenalin	S-chem
could	O
induce	O
apoptosis	O
in	O
human	O
renal	O
carcinoma	O
Caki	O
cells	O
.	O

Helenalin	S-chem
increased	O
apoptosis	O
in	O
dose	O
dependent	O
manner	O
in	O
Caki	O
cells	O
,	O
and	O
also	O
induced	O
apoptosis	O
in	O
other	O
carcinoma	O
cells	O
,	O
such	O
as	O
human	O
renal	O
carcinoma	O
ACHN	O
cells	O
,	O
human	O
colon	O
carcinoma	O
HT29	O
and	O
HCT116	O
cells	O
.	O

We	O
found	O
that	O
helenalin	S-chem-C3-1
markedly	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
-	O
related	O
genes	O
,	O
such	O
as	O
regulated	B-geneY-C3-2
in	I-geneY-C3-2
development	I-geneY-C3-2
and	I-geneY-C3-2
DNA	I-geneY-C3-2
damage	I-geneY-C3-2
responses	I-geneY-C3-2
(	I-geneY-C3-2
REDD	I-geneY-C3-2
)	I-geneY-C3-2
1	E-geneY-C3-2
,	O
activating	B-geneY-C3-2
transcription	I-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
4	E-geneY-C3-2
(	O
ATF4	S-geneY-C3-2
)	O
and	O
/	O
or	O
the	O
CCAAT	B-geneY-C3-2
enhancer	I-geneY-C3-2
-	I-geneY-C3-2
binding	I-geneY-C3-2
protein	I-geneY-C3-2
-	I-geneY-C3-2
homologous	I-geneY-C3-2
protein	E-geneY-C3-2
(	O
CHOP	S-geneY-C3-2
)	O
.	O

However	O
,	O
down	O
-	O
regulation	O
of	O
ATF4	S-geneY
and	O
/	O
or	O
CHOP	S-geneY
expression	O
by	O
siRNA	O
had	O
no	O
effect	O
on	O
helenalin	S-chem
-	O
induced	O
apoptosis	O
in	O
Caki	O
and	O
HCT116	O
cells	O
.	O

Helenalin	S-chem
increased	O
production	O
of	O
intracellular	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
.	O

Furthermore	O
,	O
ROS	O
scavengers	O
,	O
N	B-chem
-	I-chem
acetylcystine	E-chem
(	O
NAC	S-chem
)	O
,	O
and	O
glutathione	B-chem
ethyl	I-chem
ester	E-chem
(	O
GEE	S-chem
)	O
,	O
reduced	O
helenalin	S-chem
-	O
induced	O
apoptosis	O
.	O

Taken	O
together	O
,	O
helenalin	S-chem
induced	O
apoptosis	O
via	O
ROS	O
generation	O
in	O
human	O
renal	O
carcinoma	O
Caki	O
cells	O
.	O

Possible	O
Therapeutic	O
Uses	O
of	O
Salvia	O
triloba	O
and	O
Piper	O
nigrum	O
in	O
Alzheimer	O
's	O
Disease	O
-	O
Induced	O
Rats	O
.	O

Abstract	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
Salvia	O
triloba	O
L.	O
and	O
Piper	O
nigrum	O
extracts	O
in	O
ameliorating	O
neuroinflammatory	O
insults	O
characteristic	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
in	O
an	O
experimentally	O
induced	O
rat	O
model	O
.	O

Adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
classified	O
into	O
Group	O
1	O
(	O
n	O
=	O
10	O
)	O
:	O
normal	O
healthy	O
animals	O
serving	O
as	O
the	O
negative	O
control	O
group	O
;	O
Group	O
2	O
(	O
n	O
=	O
60	O
)	O
:	O
the	O
AD	O
-	O
induced	O
group	O
.	O

After	O
AD	O
induction	O
,	O
animals	O
in	O
the	O
AD	O
-	O
induced	O
group	O
were	O
divided	O
randomly	O
and	O
equally	O
into	O
6	O
subgroups	O
.	O

The	O
first	O
subgroup	O
served	O
as	O
AD	O
control	O
;	O
the	O
second	O
one	O
,	O
which	O
served	O
as	O
positive	O
control	O
,	O
was	O
treated	O
orally	O
with	O
the	O
conventional	O
therapy	O
for	O
AD	O
(	O
rivastigmine	S-chem
)	O
at	O
a	O
dose	O
of	O
0.3	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b.w	O
.	O
)	O
daily	O
for	O
3	O
months	O
.	O

The	O
third	O
and	O
fourth	O
subgroups	O
were	O
,	O
respectively	O
,	O
treated	O
orally	O
with	O
the	O
S.	O
triloba	O
extract	O
at	O
a	O
dose	O
of	O
750	O
and	O
375	O
mg	O
/	O
kg	O
b.w	O
.	O
daily	O
for	O
3	O
months	O
.	O

The	O
fifth	O
and	O
sixth	O
subgroups	O
were	O
,	O
respectively	O
,	O
treated	O
orally	O
with	O
the	O
P.	O
nigrum	O
extract	O
at	O
a	O
dose	O
of	O
187.5	O
and	O
93.75	O
mg	O
/	O
kg	O
b.w	O
.	O
daily	O
for	O
3	O
months	O
.	O

Levels	O
of	O
brain	O
acetylcholine	S-chem
(	O
Ach	O
)	O
,	O
serum	O
and	O
brain	O
acetylcholinesterase	S-geneY
(	O
AchE	S-geneY
)	O
activity	O
,	O
C	B-geneY
-	I-geneY
reactive	I-geneY
protein	E-geneY
(	O
CRP	S-geneY
)	O
,	O
total	O
nuclear	B-geneN
factor	I-geneN
kappa	I-geneN
-	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
,	O
and	O
monocyte	B-geneY
chemoattractant	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
MCP	B-geneY
-	I-geneY
1	E-geneY
)	O
were	O
estimated	O
.	O

The	O
results	O
showed	O
that	O
administration	O
of	O
AlCl3	S-chem-C3-1
resulted	O
in	O
a	O
significant	O
elevation	O
in	O
the	O
levels	O
of	O
AchE	S-geneY-C3-2
activity	O
,	O
CRP	S-geneY-C3-2
,	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
,	O
and	O
MCP	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
accompanied	O
with	O
a	O
significant	O
depletion	O
in	O
the	O
Ach	O
level	O
.	O

Treatment	O
of	O
AD	O
rats	O
with	O
each	O
of	O
the	O
selected	O
medicinal	O
plant	O
extracts	O
caused	O
marked	O
improvement	O
in	O
the	O
measured	O
biochemical	O
parameters	O
.	O

In	O
conclusion	O
,	O
S.	O
triloba	O
and	O
P.	O
nigrum	O
methanolic	O
extracts	O
have	O
potent	O
anti	O
-	O
inflammatory	O
effects	O
against	O
neuroinflammation	O
characterizing	O
AD	O
.	O

Peptidyl	B-geneY
-	I-geneY
prolyl	I-geneY
cis	I-geneY
/	I-geneY
trans	I-geneY
-	I-geneY
isomerase	I-geneY
A1	E-geneY
(	O
Pin1	S-geneY
)	O
is	O
a	O
target	O
for	O
modification	O
by	O
lipid	O
electrophiles	O
.	O

Oxidation	O
of	O
membrane	O
phospholipids	O
is	O
associated	O
with	O
inflammation	O
,	O
neurodegenerative	O
disease	O
,	O
and	O
cancer	O
.	O

Oxyradical	O
damage	O
to	O
phospholipids	O
results	O
in	O
the	O
production	O
of	O
reactive	O
aldehydes	S-chem
that	O
adduct	O
proteins	O
and	O
modulate	O
their	O
function	O
.	O

4	B-chem
-	I-chem
Hydroxynonenal	E-chem
(	O
HNE	S-chem
)	O
,	O
a	O
common	O
product	O
of	O
oxidative	O
damage	O
to	O
lipids	O
,	O
adducts	O
proteins	O
at	O
exposed	O
Cys	S-chem
,	O
His	S-chem
,	O
or	O
Lys	S-chem
residues	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
peptidyl	B-geneY-C9-2
-	I-geneY-C9-2
prolyl	I-geneY-C9-2
cis	I-geneY-C9-2
/	I-geneY-C9-2
trans	I-geneY-C9-2
-	I-geneY-C9-2
isomerase	I-geneY-C9-2
A1	E-geneY-C9-2
(	O
Pin1	S-geneY-C9-2
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
the	O
peptide	O
bond	O
of	O
pSer	S-chem-C9-1
/	O
pThr	S-chem-C9-1
-	O
Pro	S-chem-C9-1
moieties	O
in	O
signaling	O
proteins	O
from	O
cis	O
to	O
trans	O
,	O
is	O
highly	O
susceptible	O
to	O
HNE	S-chem
modification	O
.	O

Incubation	O
of	O
purified	O
Pin1	S-geneY
with	O
HNE	S-chem
followed	O
by	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
mass	O
spectrometry	O
resulted	O
in	O
detection	O
of	O
Michael	O
adducts	O
at	O
the	O
active	O
site	O
residues	O
His	S-chem
-	O
157	O
and	O
Cys	S-chem
-	O
113	O
.	O

Time	O
and	O
concentration	O
dependencies	O
indicate	O
that	O
Cys	S-chem
-	O
113	O
is	O
the	O
primary	O
site	O
of	O
HNE	S-chem
modification	O
.	O

Pin1	S-geneY
was	O
adducted	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
treated	O
with	O
8	B-chem
-	I-chem
alkynyl	I-chem
-	I-chem
HNE	E-chem
as	O
judged	O
by	O
click	O
chemistry	O
conjugation	O
with	O
biotin	S-chem
followed	O
by	O
streptavidin	O
-	O
based	O
pulldown	O
and	O
Western	O
blotting	O
with	O
anti	O
-	O
Pin1	S-geneY
antibody	O
.	O

Furthermore	O
,	O
orbitrap	O
MS	O
data	O
support	O
the	O
adduction	O
of	O
Cys	S-chem
-	O
113	O
in	O
the	O
Pin1	S-geneY
active	O
site	O
upon	O
HNE	S-chem
treatment	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O
siRNA	O
knockdown	O
of	O
Pin1	S-geneY
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
partially	O
protected	O
the	O
cells	O
from	O
HNE	S-chem
-	O
induced	O
toxicity	O
.	O

Recent	O
studies	O
indicate	O
that	O
Pin1	S-geneY
is	O
an	O
important	O
molecular	O
target	O
for	O
the	O
chemopreventive	O
effects	O
of	O
green	O
tea	O
polyphenols	S-chem
.	O

The	O
present	O
study	O
establishes	O
that	O
it	O
is	O
also	O
a	O
target	O
for	O
electrophilic	O
modification	O
by	O
products	O
of	O
lipid	O
peroxidation	O
.	O

Lower	O
Adiponectin	S-geneY
Levels	O
at	O
First	O
Trimester	O
of	O
Pregnancy	O
Are	O
Associated	O
With	O
Increased	O
Insulin	S-geneY
Resistance	O
and	O
Higher	O
Risk	O
of	O
Developing	O
Gestational	O
Diabetes	O
Mellitus	O
.	O

OBJECTIVETo	O
evaluate	O
the	O
associations	O
between	O
adiponectin	S-geneY
levels	O
and	O
1	O
)	O
the	O
risk	O
of	O
developing	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
,	O
and	O
2	O
)	O
insulin	S-geneY
resistance	O
/	O
sensitivity	O
,	O
β	O
-	O
cell	O
function	O
,	O
and	O
compensation	O
indices	O
in	O
a	O
prospective	O
cohort	O
representative	O
of	O
the	O
general	O
population	O
of	O
pregnant	O
women.RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
performed	O
anthropometric	O
measurements	O
and	O
collected	O
blood	O
samples	O
at	O
1st	O
(	O
6	O
-	O
13	O
weeks	O
)	O
and	O
2nd	O
(	O
24	O
-	O
28	O
weeks	O
)	O
trimesters	O
.	O

Diagnosis	O
of	O
GDM	O
was	O
made	O
at	O
2nd	O
trimester	O
,	O
based	O
on	O
a	O
75	O
-	O
g	O
oral	O
glucose	S-chem
tolerance	O
test	O
(	O
International	O
Association	O
of	O
Diabetes	O
and	O
Pregnancy	O
Study	O
Group	O
criteria	O
)	O
.	O

Insulin	S-geneY
was	O
measured	O
(	O
ELISA	O
;	O
Luminex	O
)	O
to	O
estimate	O
homeostasis	O
model	O
assessment	O
of	O
insulin	S-geneY
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
,	O
β	O
-	O
cell	O
function	O
(	O
HOMA	O
-	O
B	O
)	O
,	O
insulin	S-geneY
sensitivity	O
(	O
Matsuda	O
index	O
)	O
,	O
insulin	S-geneY
secretion	O
(	O
AUC	O
(	O
insulin	S-geneY
/	O
glucose	S-chem
)	O
)	O
,	O
and	O
β	O
-	O
cell	O
compensation	O
(	O
insulin	S-geneY
secretion	O
sensitivity	O
index	O
-	O
2	O
)	O
.	O

Adiponectin	S-geneY
was	O
measured	O
by	O
radioimmunoassay.RESULTSAmong	O
the	O
445	O
participants	O
included	O
in	O
this	O
study	O
,	O
38	O
women	O
developed	O
GDM	O
.	O

Women	O
who	O
developed	O
GDM	O
had	O
lower	O
1st	O
-	O
trimester	O
adiponectin	S-geneY
levels	O
(	O
9.67	O
±	O
3.84	O
vs	O
.	O

11.92	O
±	O
4.59	O
µg	O
/	O
mL	O
in	O
women	O
with	O
normal	O
glucose	S-chem
tolerance	O
)	O
.	O

Lower	O
adiponectin	S-geneY
levels	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
developing	O
GDM	O
(	O
OR	O
,	O
1.12	O
per	O
1	O
µg	O
/	O
mL	O
decrease	O
of	O
adiponectin	S-geneY
levels	O
;	O
P	O
=	O
0.02	O
,	O
adjusted	O
for	O
BMI	O
and	O
HbA	O
(	O
1c	O
)	O
at	O
1st	O
trimester	O
)	O
.	O

Adiponectin	S-geneY
levels	O
at	O
1st	O
and	O
2nd	O
trimesters	O
were	O
associated	O
with	O
HOMA	O
-	O
IR	O
(	O
both	O
:	O
r	O
=	O
-	O
0.22	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
Matsuda	O
index	O
(	O
r	O
=	O
0.28	O
,	O
P	O
<	O
0.0001	O
,	O
and	O
r	O
=	O
0.29	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

After	O
adjustment	O
for	O
confounding	O
factors	O
,	O
we	O
found	O
no	O
significant	O
association	O
with	O
HOMA	O
-	O
B	O
and	O
AUC	O
(	O
insulin	S-geneY
/	O
glucose	S-chem
)	O
.CONCLUSIONSPregnant	O
women	O
with	O
lower	O
adiponectin	S-geneY
levels	O
at	O
1st	O
trimester	O
have	O
higher	O
levels	O
of	O
insulin	S-geneY
resistance	O
and	O
are	O
more	O
likely	O
to	O
develop	O
GDM	O
independently	O
of	O
adiposity	O
or	O
glycemic	O
measurements	O
.	O

Inhibition	O
of	O
gentamicin	S-chem
binding	O
to	O
rat	O
renal	O
brush	O
-	O
border	O
membrane	O
by	O
megalin	S-geneY
ligands	O
and	O
basic	O
peptides	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
coadministration	O
of	O
cytochrome	B-geneY
c	E-geneY
and	O
a	O
20	O
-	O
residue	O
basic	O
peptide	O
,	O
N	O
-	O
WASP181	O
-	O
200	O
(	O
NISHTKEKKKGKAKKKRLTK	S-geneN
,	O
pI	O
=	O
10.87	O
)	O
inhibits	O
renal	O
accumulation	O
of	O
gentamicin	S-chem
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
effects	O
of	O
ligands	O
of	O
megalin	S-geneY
,	O
an	O
endocytic	O
receptor	O
involved	O
in	O
renal	O
uptake	O
of	O
gentamicin	S-chem
,	O
and	O
basic	O
peptides	O
including	O
N	O
-	O
WASP180	O
-	O
200	O
and	O
its	O
mutant	O
peptides	O
on	O
gentamicin	S-chem
binding	O
to	O
isolated	O
rat	O
renal	O
brush	O
-	O
border	O
membrane	O
(	O
BBM	O
)	O
.	O

Gentamicin	S-chem
binding	O
to	O
BBM	O
was	O
inhibited	O
by	O
megalin	S-geneY
ligands	O
,	O
basic	O
peptide	O
fragments	O
of	O
cytochrome	B-geneY
c	E-geneY
,	O
and	O
N	O
-	O
WASP181	O
-	O
200	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Klotz	O
plot	O
analysis	O
showed	O
that	O
N	O
-	O
WASP181	O
-	O
200	O
inhibited	O
the	O
binding	O
of	O
gentamicin	S-chem
in	O
a	O
competitive	O
manner	O
.	O

By	O
substituting	O
glycines	S-chem
for	O
lysines	S-chem
in	O
N	O
-	O
WASP181	O
-	O
200	O
at	O
positions	O
9	O
and	O
15	O
,	O
the	O
inhibitory	O
effect	O
on	O
gentamicin	S-chem
binding	O
to	O
BBM	O
was	O
reduced	O
,	O
which	O
may	O
be	O
related	O
to	O
a	O
decrease	O
in	O
the	O
alpha	B-geneN
-	I-geneN
helix	E-geneN
content	O
in	O
the	O
peptide	O
.	O

Gentamicin	S-chem
binding	O
to	O
BBM	O
treated	O
with	O
trypsin	S-geneN
,	O
in	O
which	O
megalin	S-geneY
completely	O
disappeared	O
,	O
was	O
significantly	O
but	O
not	O
completely	O
decreased	O
compared	O
with	O
the	O
native	O
BBM	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
BBM	O
with	O
trypsin	S-geneN
led	O
to	O
a	O
decrease	O
in	O
the	O
inhibitory	O
effect	O
of	O
N	O
-	O
WASP181	O
-	O
200	O
on	O
gentamicin	S-chem
binding	O
.	O

These	O
observations	O
support	O
that	O
megalin	S-geneY
ligands	O
and	O
basic	O
peptides	O
including	O
N	O
-	O
WASP181	O
-	O
200	O
decrease	O
renal	O
accumulation	O
of	O
gentamicin	S-chem
by	O
inhibiting	O
its	O
binding	O
to	O
BBM	O
of	O
proximal	O
tubule	O
cells	O
,	O
partly	O
interacting	O
with	O
megalin	S-geneY
.	O

In	O
addition	O
,	O
the	O
alpha	B-geneN
-	I-geneN
helix	E-geneN
conformation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
inhibitory	O
effect	O
of	O
N	O
-	O
WASP181	O
-	O
200	O
on	O
the	O
binding	O
of	O
gentamicin	S-chem
to	O
BBM	O
.	O

Beta1	B-geneY
adrenergic	I-geneY
receptor	E-geneY
-	O
mediated	O
enhancement	O
of	O
hippocampal	O
CA3	O
network	O
activity	O
.	O

Norepinephrine	S-chem
is	O
an	O
endogenous	O
neurotransmitter	O
distributed	O
throughout	O
the	O
mammalian	O
brain	O
.	O

In	O
higher	O
cortical	O
structures	O
such	O
as	O
the	O
hippocampus	O
,	O
norepinephrine	S-chem
,	O
via	O
beta	B-geneN
adrenergic	I-geneN
receptor	E-geneN
(	O
AR	S-geneN
)	O
activation	O
,	O
has	O
been	O
shown	O
to	O
reinforce	O
the	O
cognitive	O
processes	O
of	O
attention	O
and	O
memory	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
beta1AR	S-geneY
activation	O
on	O
hippocampal	O
cornu	O
ammonis	O
3	O
(	O
CA3	O
)	O
network	O
activity	O
.	O

AR	S-geneN
expression	O
was	O
first	O
determined	O
using	O
immunocytochemistry	O
with	O
antibodies	O
against	O
beta1ARs	S-geneY
,	O
which	O
were	O
found	O
to	O
be	O
exceptionally	O
dense	O
in	O
hippocampal	O
CA3	O
pyramidal	O
neurons	O
.	O

CA3	O
network	O
activity	O
was	O
then	O
examined	O
in	O
vitro	O
using	O
field	O
potential	O
recordings	O
in	O
rat	O
brain	O
slices	O
.	O

The	O
selective	O
betaAR	S-geneN-C5-2
agonist	O
isoproterenol	S-chem-C5-1
caused	O
an	O
enhancement	O
of	O
hippocampal	O
CA3	O
network	O
activity	O
,	O
as	O
measured	O
by	O
an	O
increase	O
in	O
frequency	O
of	O
spontaneous	O
burst	O
discharges	O
recorded	O
in	O
the	O
CA3	O
region	O
.	O

In	O
the	O
presence	O
of	O
alphaAR	S-geneN
blockade	O
,	O
concentration	O
-	O
response	O
curves	O
for	O
isoproterenol	S-chem
,	O
norepinephrine	S-chem
,	O
and	O
epinephrine	S-chem
suggested	O
that	O
a	O
beta1AR	S-geneY
was	O
involved	O
in	O
this	O
response	O
,	O
and	O
the	O
rank	O
order	O
of	O
potency	O
was	O
isoproterenol	S-chem
>	O
norepinephrine	S-chem
=	O
epinephrine	S-chem
.	O

Finally	O
,	O
equilibrium	O
dissociation	O
constants	O
(	O
pK	O
(	O
b	O
)	O
)	O
of	O
subtype	O
-	O
selective	O
betaAR	S-geneN
antagonists	O
were	O
functionally	O
determined	O
to	O
characterize	O
the	O
AR	S-geneN
subtype	O
modulating	O
hippocampal	O
CA3	O
activity	O
.	O

The	O
selective	O
beta1AR	S-geneY-MU-2
antagonists	O
atenolol	S-chem-C6-1
and	O
metoprolol	S-chem-C6-1
blocked	O
isoproterenol	S-chem-C5-1
-	O
induced	O
enhancement	O
,	O
with	O
apparent	O
K	O
(	O
b	O
)	O
values	O
of	O
85	O
+	O
/	O
-	O
36	O
and	O
3.9	O
+	O
/	O
-	O
1.7	O
nM	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
the	O
selective	O
beta2AR	S-geneY-MU-2
antagonists	O
ICI	B-chem-C6-1
-	I-chem-C6-1
118,551	E-chem-C6-1
and	O
butoxamine	S-chem-C6-1
inhibited	O
isoproterenol	S-chem-C5-1
-	O
mediated	O
enhancement	O
with	O
apparent	O
low	O
affinities	O
(	O
K	O
(	O
b	O
)	O
of	O
222	O
+	O
/	O
-	O
61	O
and	O
9268	O
+	O
/	O
-	O
512	O
nM	O
,	O
respectively	O
)	O
.	O

Together	O
,	O
this	O
pharmacological	O
profile	O
of	O
subtype	O
-	O
selective	O
betaAR	S-geneN
antagonists	O
indicates	O
that	O
in	O
this	O
model	O
,	O
beta1AR	S-geneY-C5-2
activation	O
is	O
responsible	O
for	O
the	O
enhanced	O
hippocampal	O
CA3	O
network	O
activity	O
initiated	O
by	O
isoproterenol	S-chem-C5-1
.	O

Orlistat	S-chem-C4-1
,	O
a	O
new	O
lipase	S-geneN-C4-2
inhibitor	O
for	O
the	O
management	O
of	O
obesity	O
.	O

Orlistat	S-chem
,	O
a	O
weight	O
-	O
loss	O
agent	O
with	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
recently	O
was	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
obesity	O
.	O

It	O
inhibits	O
gastric	B-geneN
and	I-geneN
pancreatic	I-geneN
lipases	E-geneN
in	O
the	O
lumen	O
of	O
the	O
gastrointestinal	O
tract	O
to	O
decrease	O
systemic	O
absorption	O
of	O
dietary	O
fat	O
.	O

In	O
several	O
trials	O
lasting	O
up	O
to	O
2	O
years	O
,	O
orlistat	S-chem
was	O
more	O
effective	O
than	O
diet	O
alone	O
for	O
weight	O
reduction	O
and	O
maintenance	O
of	O
lost	O
weight	O
.	O

Orlistat	S-chem-C3-1
treatment	O
also	O
results	O
in	O
modest	O
improvements	O
in	O
total	O
cholesterol	S-chem
,	O
low	B-geneN-C3-2
-	I-geneN-C3-2
density	I-geneN-C3-2
lipoprotein	E-geneN-C3-2
,	O
blood	O
pressure	O
,	O
and	O
fasting	O
glucose	S-chem
and	O
insulin	S-geneY-C3-2
concentrations	O
.	O

The	O
major	O
adverse	O
effects	O
are	O
gastrointestinal	O
,	O
usually	O
occur	O
early	O
in	O
therapy	O
,	O
and	O
tend	O
to	O
decrease	O
with	O
continued	O
treatment	O
.	O

Because	O
orlistat	S-chem
may	O
decrease	O
the	O
absorption	O
of	O
fat	O
-	O
soluble	O
vitamins	S-chem
,	O
a	O
standard	O
multiple	O
-	O
vitamin	S-chem
supplement	O
is	O
recommended	O
daily	O
during	O
therapy	O
to	O
prevent	O
abnormalities	O
in	O
vitamin	S-chem
serum	O
concentrations	O
.	O

The	O
potential	O
for	O
severe	O
gastrointestinal	O
discomfort	O
and	O
the	O
modest	O
degree	O
of	O
weight	O
loss	O
may	O
limit	O
the	O
agent	O
's	O
clinical	O
utility	O
.	O

Its	O
long	O
-	O
term	O
safety	O
and	O
effectiveness	O
for	O
weight	O
maintenance	O
,	O
cost	O
-	O
effectiveness	O
of	O
treatment	O
,	O
and	O
overall	O
reduction	O
in	O
obesity	O
-	O
related	O
morbidity	O
and	O
mortality	O
remain	O
to	O
be	O
determined	O
.	O

[	O
Protein	O
profile	O
and	O
vitamin	B-chem
A	E-chem
in	O
children	O
of	O
school	O
age	O
in	O
Ivory	O
Coast	O
]	O
.	O

The	O
purpose	O
of	O
this	O
transverse	O
prospective	O
study	O
was	O
to	O
determine	O
blood	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
change	O
in	O
vitamin	B-chem
A	E-chem
deficiency	O
in	O
children	O
of	O
school	O
-	O
age	O
(	O
262	O
children	O
,	O
aged	O
7	O
to	O
15	O
years	O
)	O
.	O

Blood	O
vitamin	B-chem
A	E-chem
has	O
been	O
determined	O
by	O
HPLC	O
with	O
UV	O
detection	O
.	O

Proteins	O
have	O
been	O
measured	O
by	O
radial	O
immunodiffusion	O
according	O
to	O
Mancini	O
.	O

Results	O
showed	O
that	O
96	O
children	O
(	O
36.6	O
%	O
)	O
presented	O
a	O
vitamin	B-chem
A	E-chem
deficiency	O
(	O
vitamin	B-chem
A	E-chem
<	O
200	O
microg	O
/	O
L	O
with	O
a	O
retinol	B-geneN
binding	I-geneN
protein	E-geneN
/	O
transthyretin	S-geneY
molar	O
ratio	O
=	O
0.29	O
+	O
/	O
-	O
0.06	O
)	O
while	O
166	O
(	O
63.3	O
%	O
)	O
children	O
presented	O
normal	O
blood	O
concentrations	O
of	O
vitamin	B-chem
A	E-chem
(	O
vitamin	B-chem
A	E-chem
>	O
or	O
=	O
200	O
microg	O
/	O
L	O
with	O
a	O
Retinol	B-geneN
Binding	I-geneN
Protein	E-geneN
/	O
Transthyretin	S-geneY
molar	O
ratio	O
=	O
0.40	O
+	O
/	O
-	O
0.08	O
)	O
.	O

This	O
study	O
showed	O
that	O
the	O
retinol	B-geneN
binding	I-geneN
protein	E-geneN
and	O
the	O
immunoglobulin	B-geneN
A	E-geneN
are	O
lower	O
in	O
children	O
with	O
vitamin	B-chem
A	E-chem
deficiency	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
isolated	O
increase	O
of	O
alpha	B-geneY
-	I-geneY
1	I-geneY
glycoprotein	I-geneY
acid	E-geneY
has	O
been	O
observed	O
in	O
boys	O
with	O
vitamin	B-chem
A	E-chem
deficiency	O
.	O

The	O
vitamin	B-chem
A	E-chem
deficiency	O
observed	O
in	O
this	O
survey	O
is	O
due	O
to	O
a	O
micronutrients	O
deficiency	O
in	O
the	O
diet	O
which	O
is	O
essentially	O
based	O
on	O
glucides	O
.	O

The	O
positive	O
correlation	O
between	O
vitamin	B-chem-C3-1
A	E-chem-C3-1
and	O
immunoglobulin	B-geneN-C3-2
A	E-geneN-C3-2
concentrations	O
might	O
be	O
the	O
result	O
of	O
the	O
vitamin	B-chem-C3-1
A	E-chem-C3-1
inductive	O
effect	O
during	O
immunoglobulins	B-geneN-C3-2
A	E-geneN-C3-2
synthesis	O
.	O

The	O
isolated	O
increasing	O
of	O
alpha	B-geneY
-	I-geneY
1	I-geneY
glycoprotein	I-geneY
acid	E-geneY
in	O
boys	O
with	O
vitamin	B-chem
A	E-chem
deficiency	O
has	O
been	O
assigned	O
to	O
the	O
ecosensitiveness	O
of	O
the	O
unfavourable	O
environment	O
.	O

We	O
therefore	O
concluded	O
that	O
,	O
in	O
Ivorian	O
primary	O
-	O
school	O
-	O
aged	O
children	O
with	O
vitamin	B-chem
A	E-chem
deficiency	O
,	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
which	O
are	O
modified	O
are	O
respectively	O
retinol	B-geneN
binding	I-geneN
protein	E-geneN
,	O
immunoglobulin	B-geneN
A	E-geneN
and	O
alpha	B-geneY
-	I-geneY
1	I-geneY
glycoprotein	I-geneY
acid	E-geneY
.	O

Design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
hybrid	O
compounds	O
of	O
imidazole	S-chem
scaffold	O
-	O
based	O
2	B-chem
-	I-chem
benzylbenzofuran	E-chem
as	O
potent	O
anticancer	O
agents	O
.	O

A	O
series	O
of	O
novel	O
hybrid	O
compounds	O
between	O
2	B-chem
-	I-chem
benzylbenzofuran	E-chem
and	O
imidazole	S-chem
has	O
been	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
against	O
a	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
benzimidazole	S-chem
ring	O
and	O
substitution	O
of	O
the	O
imidazolyl	S-chem
-	O
3	O
-	O
position	O
with	O
a	O
naphthylacyl	S-chem
or	O
4	B-chem
-	I-chem
methoxyphenacyl	E-chem
group	O
were	O
vital	O
for	O
modulating	O
cytotoxic	O
activity	O
.	O

In	O
particular	O
,	O
hybrid	O
compounds	O
46	O
and	O
47	O
were	O
found	O
to	O
be	O
the	O
most	O
potent	O
derivatives	O
against	O
5	O
strains	O
human	O
tumor	O
cell	O
lines	O
and	O
more	O
active	O
than	O
cisplatin	S-chem
(	O
DDP	S-chem
)	O
,	O
and	O
exhibited	O
cytotoxic	O
activities	O
selectively	O
against	O
breast	O
carcinoma	O
(	O
MCF	O
-	O
7	O
)	O
and	O
myeloid	O
liver	O
carcinoma	O
(	O
SMMC	O
-	O
7721	O
)	O
,	O
respectively	O
.	O

Glucagon	B-geneY
receptor	E-geneY
antagonism	O
improves	O
islet	O
function	O
in	O
mice	O
with	O
insulin	S-geneN
resistance	O
induced	O
by	O
a	O
high	O
-	O
fat	O
diet	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Increased	O
glucagon	S-geneY
secretion	O
predicts	O
deterioration	O
of	O
glucose	S-chem
tolerance	O
,	O
and	O
high	O
glucagon	S-geneY
levels	O
contribute	O
to	O
hyperglycaemia	O
in	O
type	O
2	O
diabetes	O
.	O

Inhibition	O
of	O
glucagon	O
action	O
may	O
therefore	O
be	O
a	O
potential	O
novel	O
target	O
to	O
reduce	O
hyperglycaemia	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
chronic	O
treatment	O
with	O
a	O
glucagon	B-geneY
receptor	E-geneY
antagonist	O
(	O
GRA	O
)	O
improves	O
islet	O
dysfunction	O
in	O
female	O
mice	O
on	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
8	O
weeks	O
of	O
HFD	O
,	O
mice	O
were	O
treated	O
with	O
a	O
small	O
molecule	O
GRA	O
(	O
300	O
mg	O
/	O
kg	O
,	O
gavage	O
once	O
daily	O
)	O
for	O
up	O
to	O
30	O
days	O
.	O

Insulin	S-geneN
secretion	O
was	O
studied	O
after	O
oral	O
and	O
intravenous	O
administration	O
of	O
glucose	S-chem
and	O
glucagon	S-geneY
secretion	O
after	O
intravenous	O
arginine	S-chem
.	O

Islet	O
morphology	O
was	O
examined	O
and	O
insulin	S-geneN
secretion	O
and	O
glucose	S-chem
oxidation	O
were	O
measured	O
in	O
isolated	O
islets	O
.	O

RESULTS	O
:	O
Fasting	O
plasma	O
glucose	S-chem
levels	O
were	O
reduced	O
by	O
GRA	O
(	O
6.0	O
+	O
/	O
-	O
0.2	O
vs	O
7.4	O
+	O
/	O
-	O
0.5	O
mmol	O
/	O
l	O
;	O
p	O
=	O
0.017	O
)	O
.	O

The	O
acute	O
insulin	S-geneN
response	O
to	O
intravenous	O
glucose	S-chem
was	O
augmented	O
(	O
1,300	O
+	O
/	O
-	O
110	O
vs	O
790	O
+	O
/	O
-	O
64	O
pmol	O
/	O
l	O
;	O
p	O
<	O
0.001	O
)	O
.	O

The	O
early	O
insulin	S-geneN
response	O
to	O
oral	O
glucose	S-chem
was	O
reduced	O
in	O
mice	O
on	O
HFD	O
+	O
GRA	O
(	O
1,890	O
+	O
/	O
-	O
160	O
vs	O
3,040	O
+	O
/	O
-	O
420	O
pmol	O
/	O
l	O
;	O
p	O
=	O
0.012	O
)	O
,	O
but	O
glucose	S-chem
excursions	O
were	O
improved	O
.	O

Intravenous	O
arginine	S-chem-C3-1
significantly	O
increased	O
the	O
acute	O
glucagon	S-geneY-C3-2
response	O
(	O
129	O
+	O
/	O
-	O
12	O
vs	O
36	O
+	O
/	O
-	O
6	O
ng	O
/	O
l	O
in	O
controls	O
;	O
p	O
<	O
0.01	O
)	O
,	O
notably	O
without	O
affecting	O
plasma	O
glucose	S-chem
.	O

GRA	O
caused	O
a	O
modest	O
increase	O
in	O
alpha	O
cell	O
mass	O
,	O
while	O
beta	O
cell	O
mass	O
was	O
similar	O
to	O
that	O
in	O
mice	O
on	O
HFD	O
+	O
vehicle	O
.	O

Isolated	O
islets	O
displayed	O
improved	O
glucose	S-chem-C3-1
-	O
stimulated	O
insulin	S-geneN-C3-2
secretion	O
after	O
GRA	O
treatment	O
(	O
0.061	O
+	O
/	O
-	O
0.007	O
vs	O
0.030	O
+	O
/	O
-	O
0.004	O
pmol	O
islet	O
(	O
-	O
1	O
)	O
h	O
(	O
-	O
1	O
)	O
at	O
16.7	O
mmol	O
/	O
l	O
glucose	S-chem
;	O
p	O
<	O
0.001	O
)	O
,	O
without	O
affecting	O
islet	O
glucose	S-chem
oxidation	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Chronic	O
glucagon	B-geneY
receptor	E-geneY
antagonism	O
in	O
HFD	O
-	O
fed	O
mice	O
improves	O
islet	O
sensitivity	O
to	O
glucose	S-chem
and	O
increases	O
insulin	S-geneN
secretion	O
,	O
suggesting	O
improvement	O
of	O
key	O
defects	O
underlying	O
impaired	O
glucose	S-chem
tolerance	O
and	O
type	O
2	O
diabetes	O
.	O

Drugs	O
in	O
Development	O
for	O
Relapsing	O
Multiple	O
Sclerosis	O
.	O

Drug	O
development	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
as	O
with	O
any	O
other	O
neurological	O
disease	O
,	O
faces	O
numerous	O
challenges	O
,	O
with	O
many	O
drugs	O
failing	O
at	O
various	O
stages	O
of	O
development	O
.	O

The	O
disease	O
-	O
modifying	O
therapies	O
(	O
DMTs	O
)	O
first	O
introduced	O
for	O
MS	O
are	O
only	O
moderately	O
effective	O
,	O
but	O
given	O
the	O
lack	O
of	O
competition	O
,	O
they	O
have	O
been	O
widely	O
accepted	O
in	O
clinical	O
practice	O
.	O

Although	O
safety	O
and	O
efficacy	O
continue	O
to	O
be	O
the	O
two	O
main	O
metrics	O
by	O
which	O
drugs	O
will	O
be	O
judged	O
,	O
the	O
newer	O
agents	O
in	O
the	O
market	O
also	O
face	O
challenges	O
of	O
a	O
more	O
comparative	O
nature	O
-	O
are	O
they	O
more	O
efficacious	O
than	O
the	O
currently	O
available	O
drugs	O
on	O
the	O
market	O
?	O
Are	O
they	O
safer	O
or	O
better	O
tolerated	O
?	O
Do	O
they	O
offer	O
any	O
practical	O
advantages	O
over	O
current	O
treatments	O
?	O
Fingolimod	S-chem
represented	O
a	O
milestone	O
following	O
its	O
approval	O
as	O
an	O
oral	O
drug	O
for	O
MS	O
in	O
2010	O
,	O
offering	O
patients	O
a	O
far	O
more	O
convenient	O
administration	O
route	O
.	O

However	O
,	O
association	O
with	O
cardiovascular	O
complications	O
has	O
led	O
to	O
a	O
more	O
cautious	O
approach	O
in	O
its	O
initial	O
prescribing	O
,	O
now	O
requiring	O
cardiac	O
monitoring	O
for	O
the	O
first	O
6	O
h	O
as	O
well	O
as	O
subsequent	O
monitoring	O
of	O
blood	O
pressure	O
and	O
for	O
macular	O
oedema	O
.	O

Natalizumab	O
,	O
amongst	O
licensed	O
drugs	O
,	O
represents	O
the	O
current	O
benchmark	O
for	O
efficacy	O
.	O

The	O
risk	O
of	O
progressive	O
multifocal	O
leukoencephalopathy	O
during	O
natalizumab	O
treatment	O
is	O
now	O
more	O
quantifiable	O
.	O

Other	O
monoclonal	O
antibodies	O
are	O
in	O
various	O
phases	O
of	O
development	O
.	O

Marketing	O
authorisation	O
for	O
alemtuzumab	O
has	O
been	O
filed	O
,	O
and	O
whilst	O
trial	O
data	O
suggest	O
that	O
its	O
efficacy	O
outperforms	O
both	O
licensed	O
drugs	O
and	O
others	O
in	O
development	O
,	O
there	O
is	O
a	O
significant	O
risk	O
of	O
secondary	O
autoimmunity	O
.	O

Its	O
once	O
-	O
yearly	O
administration	O
,	O
however	O
,	O
seems	O
particularly	O
advantageous	O
.	O

Rituximab	O
is	O
unlikely	O
to	O
be	O
developed	O
further	O
as	O
its	O
license	O
will	O
expire	O
,	O
but	O
ocrelizumab	O
,	O
another	O
monoclonal	O
antibody	O
directly	O
targeting	O
B	O
cells	O
,	O
is	O
currently	O
in	O
phase	O
2	O
development	O
and	O
looks	O
promising	O
.	O

Daclizumab	O
is	O
also	O
moderately	O
efficacious	O
but	O
may	O
struggle	O
to	O
establish	O
itself	O
given	O
its	O
monthly	O
subcutaneous	O
dosing	O
.	O

There	O
are	O
new	O
oral	O
drugs	O
in	O
development	O
,	O
and	O
it	O
is	O
likely	O
that	O
BG	B-chem
-	I-chem
12	E-chem
will	O
be	O
licensed	O
this	O
year	O
.	O

This	O
has	O
been	O
licensed	O
for	O
psoriasis	O
so	O
there	O
are	O
good	O
safety	O
data	O
in	O
humans	O
that	O
may	O
also	O
hold	O
true	O
in	O
MS	O
;	O
however	O
,	O
its	O
three	O
times	O
daily	O
dosage	O
will	O
probably	O
impact	O
on	O
patient	O
compliance	O
.	O

Laquinimod	S-chem
has	O
lower	O
efficacy	O
than	O
BG	B-chem
-	I-chem
12	E-chem
but	O
appears	O
safe	O
and	O
could	O
find	O
a	O
place	O
as	O
a	O
first	O
-	O
line	O
agent	O
.	O

Teriflunomide	S-chem
has	O
just	O
been	O
licensed	O
by	O
the	O
US	O
FDA	O
and	O
may	O
challenge	O
the	O
current	O
injectable	O
first	O
-	O
line	O
therapies	O
as	O
it	O
has	O
a	O
similar	O
efficacy	O
but	O
the	O
advantage	O
of	O
being	O
taken	O
orally	O
.	O

However	O
,	O
risk	O
of	O
teratogenicity	O
may	O
caution	O
against	O
its	O
use	O
in	O
some	O
women	O
of	O
child	O
-	O
bearing	O
potential	O
.	O

This	O
review	O
will	O
examine	O
drugs	O
that	O
have	O
been	O
recently	O
approved	O
as	O
well	O
as	O
those	O
that	O
are	O
in	O
late	O
phase	O
2	O
or	O
3	O
development	O
as	O
treatment	O
for	O
relapsing	O
MS	O
,	O
highlighting	O
their	O
mechanism	O
of	O
action	O
as	O
well	O
as	O
the	O
clinical	O
trial	O
and	O
safety	O
data	O
before	O
discussing	O
their	O
potential	O
for	O
success	O
in	O
an	O
increasingly	O
florid	O
and	O
complex	O
DMT	O
armamentarium	O
.	O

Nonsedating	O
histamine	B-geneY
H1	I-geneY
-	I-geneY
receptor	E-geneY
antagonists	O
.	O

The	O
chemistry	O
,	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
adverse	O
effects	O
,	O
and	O
dosages	O
of	O
the	O
nonsedating	O
histamine	B-geneY-C6-2
H1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
terfenadine	S-chem-C6-1
,	O
astemizole	S-chem-C6-1
,	O
loratadine	S-chem-C6-1
,	O
and	O
acrivastine	S-chem-C6-1
are	O
reviewed	O
.	O

Terfenadine	S-chem-C6-1
and	O
astemizole	S-chem-C6-1
are	O
chemically	O
unrelated	O
to	O
histamine	B-geneY-C6-2
H1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
such	O
as	O
diphenhydramine	S-chem-C6-1
and	O
chlorpheniramine	S-chem-C6-1
.	O

Loratadine	S-chem
is	O
structurally	O
related	O
to	O
the	O
antihistamine	O
azatadine	S-chem
,	O
and	O
acrivastine	S-chem
is	O
a	O
side	O
-	O
chain	O
-	O
reduced	O
metabolite	O
of	O
the	O
antihistamine	O
triprolidine	S-chem
.	O

Like	O
other	O
histamine	B-geneY
H1	I-geneY
-	I-geneY
receptor	E-geneY
antagonists	O
,	O
they	O
competitively	O
block	O
histamine	B-geneN
receptor	E-geneN
sites	O
rather	O
than	O
inhibiting	O
histamine	S-chem
release	O
.	O

All	O
four	O
drugs	O
have	O
relatively	O
long	O
half	O
-	O
lives	O
and	O
are	O
rapidly	O
absorbed	O
after	O
oral	O
administration	O
.	O

Terfenadine	S-chem
,	O
astemizole	S-chem
,	O
and	O
loratadine	S-chem
are	O
metabolized	O
extensively	O
in	O
the	O
liver	O
;	O
terfenadine	S-chem
and	O
astemizole	S-chem
are	O
both	O
97	O
%	O
protein	O
bound	O
.	O

Terfenadine	S-chem
60	O
mg	O
twice	O
daily	O
has	O
been	O
shown	O
to	O
be	O
as	O
effective	O
as	O
conventional	O
antihistamines	O
for	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
.	O

In	O
clinical	O
trials	O
,	O
astemizole	S-chem
10	O
mg	O
daily	O
was	O
comparable	O
to	O
or	O
better	O
than	O
chlorpheniramine	S-chem
for	O
treatment	O
of	O
chronic	O
rhinitis	O
.	O

Both	O
terfenadine	S-chem
and	O
astemizole	S-chem
were	O
effective	O
for	O
treatment	O
of	O
chronic	O
urticaria	O
.	O

For	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
,	O
loratadine	S-chem
combined	O
with	O
pseudoephedrine	S-chem
may	O
be	O
preferable	O
to	O
triprolidine	S-chem
-	O
pseudoephedrine	S-chem
and	O
acrivastine	S-chem
-	O
pseudoephedrine	S-chem
combinations	O
that	O
require	O
more	O
frequent	O
dosing	O
.	O

Acrivastine	S-chem
must	O
be	O
administered	O
more	O
frequently	O
than	O
the	O
other	O
nonsedating	O
antihistamines	O
.	O

None	O
of	O
these	O
four	O
agents	O
impairs	O
psychomotor	O
activity	O
.	O

Infrequently	O
reported	O
adverse	O
effects	O
include	O
dry	O
mouth	O
,	O
skin	O
reactions	O
,	O
and	O
weight	O
gain	O
.	O

The	O
absence	O
of	O
substantial	O
sedative	O
effects	O
and	O
the	O
less	O
-	O
frequent	O
dosing	O
schedules	O
make	O
these	O
agents	O
good	O
alternatives	O
to	O
the	O
classic	O
antihistamines	O
for	O
treatment	O
of	O
seasonal	O
and	O
chronic	O
rhinitis	O
and	O
chronic	O
urticaria	O
.	O

The	O
platelet	B-geneN
P2	I-geneN
receptors	E-geneN
as	O
molecular	O
targets	O
for	O
old	O
and	O
new	O
antiplatelet	O
drugs	O
.	O

Platelet	O
activation	O
by	O
ADP	S-chem
and	O
ATP	S-chem
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	O
and	O
thrombosis	O
,	O
and	O
their	O
so	O
-	O
called	O
P2	B-geneN
receptors	E-geneN
are	O
potential	O
targets	O
for	O
antithrombotic	O
drugs	O
.	O

The	O
ATP	B-geneY
-	I-geneY
gated	I-geneY
channel	I-geneY
P2X1	E-geneY
and	O
the	O
2	O
G	B-geneY
protein	I-geneY
-	I-geneY
coupled	I-geneY
P2Y1	E-geneY
and	O
P2Y12	S-geneY
ADP	B-geneN
receptors	E-geneN
selectively	O
contribute	O
to	O
platelet	O
aggregation	O
.	O

The	O
P2Y1	S-geneY
receptor	O
is	O
responsible	O
for	O
ADP	S-chem
-	O
induced	O
shape	O
change	O
and	O
weak	O
and	O
transient	O
aggregation	O
,	O
while	O
the	O
P2Y12	S-geneY
receptor	O
is	O
responsible	O
for	O
the	O
completion	O
and	O
amplification	O
of	O
the	O
response	O
to	O
ADP	S-chem
and	O
to	O
all	O
platelet	O
agonists	O
,	O
including	O
thromboxane	B-chem
A2	E-chem
(	O
TXA2	S-chem
)	O
,	O
thrombin	S-geneY
,	O
and	O
collagen	S-geneN
.	O

The	O
P2X1	S-geneY
receptor	O
is	O
involved	O
in	O
platelet	O
shape	O
change	O
and	O
in	O
activation	O
by	O
collagen	S-geneN
under	O
shear	O
conditions	O
.	O

Due	O
to	O
its	O
central	O
role	O
in	O
the	O
formation	O
and	O
stabilization	O
of	O
a	O
thrombus	O
,	O
the	O
P2Y12	S-geneY
receptor	O
is	O
a	O
well	O
-	O
established	O
target	O
of	O
antithrombotic	O
drugs	O
like	O
ticlopidine	S-chem
or	O
clopidogrel	S-chem
,	O
which	O
have	O
proved	O
efficacy	O
in	O
many	O
clinical	O
trials	O
and	O
experimental	O
models	O
of	O
thrombosis	O
.	O

Competitive	O
P2Y12	S-geneY
antagonists	O
have	O
also	O
been	O
shown	O
to	O
be	O
effective	O
in	O
experimental	O
thrombosis	O
as	O
well	O
as	O
in	O
several	O
clinical	O
trials	O
.	O

Studies	O
in	O
P2Y1	S-geneY
and	O
P2X1	S-geneY
knockout	O
mice	O
and	O
experimental	O
thrombosis	O
models	O
using	O
selective	O
P2Y1	S-geneY
and	O
P2X1	S-geneY
antagonists	O
have	O
shown	O
that	O
,	O
depending	O
on	O
the	O
conditions	O
,	O
these	O
receptors	O
could	O
also	O
be	O
potential	O
targets	O
for	O
new	O
antithrombotic	O
drugs	O
.	O

Innovative	O
approach	O
for	O
improvement	O
of	O
an	O
antibiotic	O
-	O
overproducing	O
industrial	O
strain	O
of	O
Streptomyces	O
albus	O
.	O

Working	O
with	O
a	O
Streptomyces	O
albus	O
strain	O
that	O
had	O
previously	O
been	O
bred	O
to	O
produce	O
industrial	O
amounts	O
(	O
10	O
mg	O
/	O
ml	O
)	O
of	O
salinomycin	S-chem
,	O
we	O
demonstrated	O
the	O
efficacy	O
of	O
introducing	O
drug	O
resistance	O
-	O
producing	O
mutations	O
for	O
further	O
strain	O
improvement	O
.	O

Mutants	O
with	O
enhanced	O
salinomycin	S-chem
production	O
were	O
detected	O
at	O
a	O
high	O
incidence	O
(	O
7	O
to	O
12	O
%	O
)	O
among	O
spontaneous	O
isolates	O
resistant	O
to	O
streptomycin	S-chem
(	O
Str	O
(	O
r	O
)	O
)	O
,	O
gentamicin	S-chem
,	O
or	O
rifampin	S-chem
(	O
Rif	O
(	O
r	O
)	O
)	O
.	O

Finally	O
,	O
we	O
successfully	O
demonstrated	O
improvement	O
of	O
the	O
salinomycin	S-chem
productivity	O
of	O
the	O
industrial	O
strain	O
by	O
2.3	O
-	O
fold	O
by	O
introducing	O
a	O
triple	O
mutation	O
.	O

The	O
Str	O
(	O
r	O
)	O
mutant	O
was	O
shown	O
to	O
have	O
a	O
point	O
mutation	O
within	O
the	O
rpsL	S-geneY
gene	O
(	O
encoding	O
ribosomal	B-geneY
protein	I-geneY
S12	E-geneY
)	O
.	O

Likewise	O
,	O
the	O
Rif	O
(	O
r	O
)	O
mutant	O
possessed	O
a	O
mutation	O
in	O
the	O
rpoB	S-geneY
gene	O
(	O
encoding	O
the	O
RNA	B-geneN
polymerase	I-geneN
beta	E-geneN
subunit	O
)	O
.	O

Increased	O
productivity	O
of	O
salinomycin	S-chem
in	O
the	O
Str	O
(	O
r	O
)	O
mutant	O
(	O
containing	O
the	O
K88R	S-geneN
mutation	O
in	O
the	O
S12	S-geneY
protein	O
)	O
may	O
be	O
a	O
result	O
of	O
an	O
aberrant	O
protein	O
synthesis	O
mechanism	O
.	O

This	O
aberration	O
may	O
manifest	O
itself	O
as	O
enhanced	O
translation	O
activity	O
in	O
stationary	O
-	O
phase	O
cells	O
,	O
as	O
we	O
have	O
observed	O
with	O
the	O
poly	O
(	O
U	O
)	O
-	O
directed	O
cell	O
-	O
free	O
translation	O
system	O
.	O

The	O
K88R	S-geneN
mutant	O
ribosome	O
was	O
characterized	O
by	O
increased	O
70S	B-geneN
complex	E-geneN
stability	O
in	O
low	O
Mg	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
concentrations	O
.	O

We	O
conclude	O
that	O
this	O
aberrant	O
protein	O
synthesis	O
ability	O
in	O
the	O
Str	O
(	O
r	O
)	O
mutant	O
,	O
which	O
is	O
a	O
result	O
of	O
increased	O
stability	O
of	O
the	O
70S	B-geneN
complex	E-geneN
,	O
is	O
responsible	O
for	O
the	O
remarkable	O
salinomycin	S-chem
production	O
enhancement	O
obtained	O
.	O

Contrasting	O
effects	O
of	O
N5	B-chem
-	I-chem
substituted	I-chem
tetrahydrobiopterin	E-chem
derivatives	O
on	O
phenylalanine	B-geneY
hydroxylase	E-geneY
,	O
dihydropteridine	B-geneY
reductase	E-geneY
and	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
.	O

Tetrahydrobiopterin	S-chem
[	O
(	B-chem
6R	I-chem
)	I-chem
-	I-chem
5,6,7,8	I-chem
-	I-chem
tetrahydro	I-chem
-	I-chem
L	I-chem
-	I-chem
biopterin	E-chem
,	O
H	B-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
]	O
is	O
one	O
of	O
several	O
cofactors	O
of	O
nitric	B-geneN
oxide	I-geneN
synthases	E-geneN
(	O
EC	B-geneY
1.14.13.39	E-geneY
)	O
.	O

Here	O
we	O
compared	O
the	O
action	O
of	O
N	B-chem
(	I-chem
5	I-chem
)	E-chem
-	O
substituted	O
derivatives	O
on	O
recombinant	O
rat	B-geneY
neuronal	I-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
with	O
their	O
effects	O
on	O
dihydropteridine	B-geneY
reductase	E-geneY
(	O
EC	B-geneY
1.6.99.7	E-geneY
)	O
and	O
phenylalanine	B-geneY
hydroxylase	E-geneY
(	O
EC	B-geneY
1.14.16.1	E-geneY
)	O
,	O
the	O
well	O
-	O
studied	O
classical	O
H	B-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
-	O
dependent	O
reactions	O
.	O

H	B-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
substituted	O
at	O
N	B-chem
(	I-chem
5	I-chem
)	E-chem
with	O
methyl	S-chem
,	O
hydroxymethyl	S-chem
,	O
formyl	S-chem
and	O
acetyl	S-chem
groups	O
were	O
used	O
.	O

Substitution	O
at	O
N	B-chem
(	I-chem
5	I-chem
)	E-chem
occurs	O
at	O
a	O
position	O
critical	O
to	O
the	O
redox	O
cycle	O
of	O
the	O
cofactor	O
in	O
phenylalanine	B-geneY
hydroxylase	E-geneY
/	O
dihydropteridine	B-geneY
reductase	E-geneY
.	O

We	O
also	O
included	O
N	B-chem
(	I-chem
2	I-chem
)	I-chem
'	I-chem
-	I-chem
methyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
,	O
a	O
derivative	O
substituted	O
at	O
a	O
position	O
not	O
directly	O
involved	O
in	O
redox	O
cycling	O
,	O
as	O
a	O
control	O
.	O

As	O
compared	O
with	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
methyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
,	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
formyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
bound	O
with	O
twice	O
the	O
capacity	O
but	O
stimulated	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
to	O
a	O
lesser	O
extent	O
.	O

Depending	O
on	O
the	O
substituent	O
used	O
,	O
N	B-chem
(	I-chem
5	I-chem
)	E-chem
-	O
substituted	O
derivatives	O
were	O
redox	O
-	O
active	O
:	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
methyl	E-chem
-	O
and	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
hydroxyl	I-chem
methyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
,	O
but	O
not	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
formyl	E-chem
-	O
and	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
acetyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
,	O
reduced	O
2,6	B-chem
-	I-chem
dichlorophenol	I-chem
indophenol	E-chem
.	O

N	B-chem-C9-1
(	I-chem-C9-1
5	I-chem-C9-1
)	I-chem-C9-1
-	I-chem-C9-1
Substituted	I-chem-C9-1
H	I-chem-C9-1
(	I-chem-C9-1
4	I-chem-C9-1
)	I-chem-C9-1
biopterin	E-chem-C9-1
derivatives	O
were	O
not	O
oxidized	O
to	O
products	O
serving	O
as	O
substrates	O
for	O
dihydropteridine	B-geneY-C9-2
reductase	E-geneY-C9-2
and	O
,	O
depending	O
on	O
the	O
substituent	O
,	O
were	O
competitive	O
inhibitors	O
of	O
phenylalanine	B-geneY
hydroxylase	E-geneY
:	O
N	B-chem-C4-1
(	I-chem-C4-1
5	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
methyl	E-chem-C4-1
-	O
and	O
N	B-chem-C4-1
(	I-chem-C4-1
5	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
hydroxymethyl	I-chem-C4-1
H	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
)	I-chem-C4-1
biopterin	E-chem-C4-1
inhibited	O
phenylalanine	B-geneY-C4-2
hydroxylase	E-geneY-C4-2
,	O
whereas	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
formyl	E-chem
-	O
and	O
N	B-chem
(	I-chem
5	I-chem
)	I-chem
-	I-chem
acetyl	I-chem
H	I-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
had	O
no	O
effect	O
.	O

Our	O
data	O
demonstrate	O
differences	O
in	O
the	O
mechanism	O
of	O
stimulation	O
of	O
phenylalanine	B-geneY-C4-2
hydroxylase	E-geneY-C4-2
and	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
by	O
H	B-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
)	I-chem-C4-1
biopterin	E-chem-C4-1
.	O

They	O
are	O
compatible	O
with	O
a	O
novel	O
,	O
non	O
-	O
classical	O
,	O
redox	O
-	O
active	O
contribution	O
of	O
H	B-chem
(	I-chem
4	I-chem
)	I-chem
biopterin	E-chem
to	O
the	O
catalysis	O
of	O
the	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
reaction	O
.	O

Histone	B-geneY
deacetylase	I-geneY
3	E-geneY
is	O
required	O
for	O
maintenance	O
of	O
bone	O
mass	O
during	O
aging	O
.	O

Histone	B-geneY
deacetylase	I-geneY
3	E-geneY
(	O
Hdac3	S-geneY
)	O
is	O
a	O
nuclear	O
enzyme	O
that	O
removes	O
acetyl	S-chem
groups	O
from	O
lysine	S-chem
residues	O
in	O
histones	S-geneN
and	O
other	O
proteins	O
to	O
epigenetically	O
regulate	O
gene	O
expression	O
.	O

Hdac3	S-geneY
interacts	O
with	O
bone	O
-	O
related	O
transcription	O
factors	O
and	O
co	O
-	O
factors	O
such	O
as	O
Runx2	S-geneY
and	O
Zfp521	S-geneY
,	O
and	O
thus	O
is	O
poised	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
skeletal	O
system	O
.	O

To	O
understand	O
the	O
role	O
of	O
Hdac3	S-geneY
in	O
osteoblasts	O
and	O
osteocytes	O
,	O
Hdac3	S-geneY
conditional	O
knockout	O
(	O
CKO	O
)	O
mice	O
were	O
created	O
with	O
the	O
osteocalcin	B-geneN
(	I-geneN
OCN	I-geneN
)	I-geneN
promoter	E-geneN
driving	O
Cre	S-geneN
expression	O
.	O

Hdac3	S-geneY
CKO	O
(	O
OCN	S-geneY
)	O
mice	O
were	O
of	O
normal	O
size	O
and	O
weight	O
,	O
but	O
progressively	O
lost	O
trabecular	O
and	O
cortical	O
bone	O
mass	O
with	O
age	O
.	O

The	O
Hdac3	S-geneY
CKO	O
(	O
OCN	S-geneY
)	O
mice	O
exhibited	O
reduced	O
cortical	O
bone	O
mineralization	O
and	O
material	O
properties	O
and	O
suffered	O
frequent	O
fractures	O
.	O

Bone	O
resorption	O
was	O
lower	O
,	O
not	O
higher	O
,	O
in	O
the	O
Hdac3	S-geneY
CKO	O
(	O
OCN	S-geneY
)	O
mice	O
,	O
suggesting	O
that	O
primary	O
defects	O
in	O
osteoblasts	O
caused	O
the	O
reduced	O
bone	O
mass	O
.	O

Indeed	O
,	O
reductions	O
in	O
bone	O
formation	O
were	O
observed	O
.	O

Osteoblasts	O
and	O
osteocytes	O
from	O
Hdac3	S-geneY
CKO	O
(	O
OCN	S-geneY
)	O
mice	O
showed	O
increased	O
DNA	O
damage	O
and	O
reduced	O
functional	O
activity	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Thus	O
,	O
Hdac3	S-geneY
expression	O
in	O
osteoblasts	O
and	O
osteocytes	O
is	O
essential	O
for	O
bone	O
maintenance	O
during	O
aging	O
.	O

Immunomodulatory	O
properties	O
of	O
multi	O
-	O
walled	O
carbon	S-chem
nanotubes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
and	O
allergic	O
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
immunomodulatory	O
activity	O
of	O
multi	O
-	O
walled	O
carbon	S-chem
nanotubes	O
(	O
MWCNTs	O
)	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
healthy	O
donors	O
and	O
mite	O
-	O
allergic	O
subjects	O
.	O

Freshly	O
prepared	O
PBMCs	O
,	O
stimulated	O
or	O
not	O
with	O
Toll	B-geneN
-	I-geneN
like	I-geneN
receptor	I-geneN
(	I-geneN
TLR	I-geneN
)	I-geneN
1	I-geneN
-	I-geneN
9	E-geneN
agonists	O
,	O
a	O
T	B-geneN
cell	I-geneN
mitogen	E-geneN
(	O
phytohemagglutinin	B-geneN
A	E-geneN
)	O
or	O
mite	O
allergen	O
extract	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
MWCNTs	O
.	O

Secretion	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IL	B-geneY
-	I-geneY
2	E-geneY
,	O
IL	B-geneY
-	I-geneY
5	E-geneY
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
,	O
IL	B-geneN
-	I-geneN
12	I-geneN
/	I-geneN
23p40	E-geneN
or	O
IFN	B-geneY
-	I-geneY
γ	E-geneY
was	O
quantified	O
in	O
the	O
culture	O
supernatants	O
by	O
ELISA	O
.	O

Basal	O
secretion	O
of	O
all	O
the	O
cytokines	S-geneN
was	O
not	O
altered	O
by	O
MWCNTs	O
in	O
PBMCs	O
from	O
both	O
healthy	O
donors	O
and	O
allergic	O
subjects	O
.	O

In	O
PBMCs	O
from	O
healthy	O
donors	O
,	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
and	O
IL	B-geneN
-	I-geneN
12	I-geneN
/	I-geneN
23p40	E-geneN
secretion	O
in	O
response	O
to	O
the	O
TLR4	S-geneY
agonist	O
,	O
lipopolysaccharide	O
was	O
however	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
MWCNTs	O
.	O

Significant	O
increases	O
in	O
the	O
release	O
of	O
these	O
cytokines	S-geneN
were	O
also	O
observed	O
in	O
PBMCs	O
stimulated	O
with	O
a	O
TLR2	S-geneY
or	O
TLR3	S-geneY
agonist	O
.	O

MWCNTs	O
also	O
increased	O
the	O
release	O
of	O
IL	B-geneY
-	I-geneY
2	E-geneY
and	O
IFN	B-geneY
-	I-geneY
γ	E-geneY
by	O
PBMCs	O
stimulated	O
with	O
a	O
T	B-geneN
cell	I-geneN
mitogen	E-geneN
.	O

In	O
contrast	O
,	O
MWCNTs	O
inhibited	O
allergen	O
-	O
induced	O
IL	B-geneY
-	I-geneY
5	E-geneY
secretion	O
by	O
PBMCs	O
from	O
mite	O
-	O
allergic	O
subjects	O
.	O

As	O
well	O
,	O
MWCNTs	O
altered	O
the	O
capacity	O
of	O
PBMC	O
-	O
derived	O
monocytes	O
to	O
differentiate	O
into	O
functional	O
dendritic	O
cells	O
.	O

All	O
together	O
,	O
our	O
data	O
suggest	O
that	O
according	O
to	O
its	O
immune	O
cell	O
target	O
,	O
MWCNTs	O
may	O
either	O
promote	O
or	O
suppress	O
immune	O
responses	O
in	O
humans	O
.	O

Further	O
investigations	O
are	O
necessary	O
to	O
fully	O
understand	O
the	O
complexity	O
behind	O
interactions	O
of	O
engineered	O
nanoparticles	O
with	O
the	O
immune	O
system	O
.	O

From	O
an	O
inborn	O
error	O
patient	O
to	O
a	O
search	O
for	O
regulatory	O
meaning	O
:	O
a	O
biotin	S-chem
conducted	O
voyage	O
.	O

This	O
article	O
summarizes	O
some	O
findings	O
of	O
a	O
research	O
that	O
I	O
have	O
pursued	O
for	O
the	O
past	O
25	O
years	O
,	O
whose	O
roots	O
are	O
immersed	O
in	O
the	O
field	O
of	O
inherited	O
metabolic	O
disorders	O
,	O
and	O
deal	O
with	O
different	O
aspects	O
of	O
the	O
vitamin	O
biotin	S-chem
,	O
starting	O
with	O
a	O
patient	O
with	O
multiple	O
carboxylase	S-geneN
deficiency	O
(	O
MCD	O
)	O
.	O

Several	O
of	O
MCD	O
clinical	O
manifestations	O
resemble	O
those	O
of	O
infant	O
malnutrition	O
;	O
we	O
demonstrated	O
that	O
about	O
one	O
-	O
third	O
of	O
infants	O
with	O
this	O
common	O
nutritional	O
disorder	O
were	O
indeed	O
biotin	S-chem
-	O
deficient	O
,	O
and	O
that	O
this	O
deficiency	O
is	O
metabolically	O
significant	O
,	O
by	O
studying	O
urine	O
instead	O
of	O
blood	O
,	O
studying	O
urinary	O
organic	O
acids	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Remarkably	O
,	O
the	O
metabolic	O
abnormalities	O
became	O
apparent	O
only	O
after	O
protein	O
feeding	O
was	O
started	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
may	O
contribute	O
to	O
the	O
worsening	O
of	O
malnourished	O
individuals	O
when	O
they	O
are	O
abruptly	O
fed	O
.	O

Afterwards	O
,	O
we	O
studied	O
biotin	S-chem
deficiency	O
at	O
the	O
tissue	O
level	O
.	O

Carboxylase	S-geneN
activities	O
and	O
masses	O
were	O
significantly	O
reduced	O
in	O
liver	O
,	O
kidney	O
,	O
muscle	O
,	O
adipose	O
tissue	O
,	O
intestine	O
,	O
and	O
spleen	O
,	O
but	O
brain	O
and	O
heart	O
were	O
spared	O
;	O
their	O
mRNAs	O
remained	O
unchanged	O
.	O

On	O
the	O
other	O
hand	O
,	O
holocarboxylase	B-geneY-C3-2
synthetase	E-geneY-C3-2
(	O
HCS	S-geneY-C3-2
)	O
mRNA	O
levels	O
were	O
markedly	O
low	O
in	O
the	O
deficient	O
animals	O
,	O
and	O
increased	O
upon	O
biotin	S-chem-C3-1
injection	O
.	O

Over	O
2000	O
human	O
genes	O
have	O
been	O
identified	O
that	O
depend	O
on	O
biotin	S-chem
for	O
expression	O
.	O

To	O
probe	O
into	O
the	O
``	O
logic	O
``	O
of	O
this	O
enigma	O
,	O
we	O
have	O
started	O
comparative	O
studies	O
among	O
evolutionarily	O
distant	O
organisms	O
,	O
such	O
as	O
mouse	O
and	O
Saccharomyces	O
cerevisiae	O
,	O
and	O
we	O
are	O
now	O
looking	O
for	O
biotin	O
effects	O
on	O
specific	O
genes	O
and	O
proteins	O
,	O
such	O
as	B-geneY
HCS	O
and	O
hexokinases	O
,	O
and	O
on	O
their	O
proteomes	O
.	O

Crystal	O
structures	O
of	O
protein	B-geneN
phosphatase	I-geneN
-	I-geneN
1	E-geneN
bound	O
to	O
motuporin	S-chem
and	O
dihydromicrocystin	B-chem
-	I-chem
LA	E-chem
:	O
elucidation	O
of	O
the	O
mechanism	O
of	O
enzyme	O
inhibition	O
by	O
cyanobacterial	O
toxins	O
.	O

The	O
microcystins	S-chem
and	O
nodularins	S-chem
are	O
tumour	O
promoting	O
hepatotoxins	O
that	O
are	O
responsible	O
for	O
global	O
adverse	O
human	O
health	O
effects	O
and	O
wildlife	O
fatalities	O
in	O
countries	O
where	O
drinking	O
water	O
supplies	O
contain	O
cyanobacteria	O
.	O

The	O
toxins	O
function	O
by	O
inhibiting	O
broad	O
specificity	O
Ser	B-geneN
/	I-geneN
Thr	I-geneN
protein	I-geneN
phosphatases	E-geneN
in	O
the	O
host	O
cells	O
,	O
thereby	O
disrupting	O
signal	O
transduction	O
pathways	O
.	O

A	O
previous	O
crystal	O
structure	O
of	O
a	O
microcystin	S-chem
bound	O
to	O
the	O
catalytic	O
subunit	O
of	O
protein	B-geneN
phosphatase	I-geneN
-	I-geneN
1	E-geneN
(	O
PP	B-geneN
-	I-geneN
1c	E-geneN
)	O
showed	O
distinct	O
changes	O
in	O
the	O
active	O
site	O
region	O
when	O
compared	O
with	O
protein	B-geneN
phosphatase	I-geneN
-	I-geneN
1	E-geneN
structures	O
bound	O
to	O
other	O
toxins	O
.	O

We	O
have	O
elucidated	O
the	O
crystal	O
structures	O
of	O
the	O
cyanotoxins	S-geneN
,	O
motuporin	S-chem
(	O
nodularin	B-chem
-	I-chem
V	E-chem
)	O
and	O
dihydromicrocystin	B-chem
-	I-chem
LA	E-chem
bound	O
to	O
human	B-geneY
protein	I-geneY
phosphatase	I-geneY
-	I-geneY
1c	I-geneY
(	I-geneY
gamma	I-geneY
isoform	I-geneY
)	E-geneY
.	O

The	O
atomic	O
structures	O
of	O
these	O
complexes	O
reveal	O
the	O
structural	O
basis	O
for	O
inhibition	O
of	O
protein	B-geneN
phosphatases	E-geneN
by	O
these	O
toxins	O
.	O

Comparisons	O
of	O
the	O
structures	O
of	O
the	O
cyanobacterial	B-geneN
toxin	E-geneN
:	O
phosphatase	S-geneN
complexes	O
explain	O
the	O
biochemical	O
mechanism	O
by	O
which	O
microcystins	S-chem
but	O
not	O
nodularins	S-chem
permanently	O
modify	O
their	O
protein	B-geneN
phosphatase	E-geneN
targets	O
by	O
covalent	O
addition	O
to	O
an	O
active	O
site	O
cysteine	S-chem
residue	O
.	O

Cerebral	O
D2	B-geneN
and	I-geneN
5	I-geneN
-	I-geneN
HT2	I-geneN
receptor	E-geneN
occupancy	O
in	O
Schizophrenic	O
patients	O
treated	O
with	O
olanzapine	S-chem
or	O
clozapine	S-chem
.	O

We	O
report	O
the	O
results	O
of	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
prospective	O
trial	O
on	O
D2	B-geneN
and	I-geneN
5	I-geneN
-	I-geneN
HT2	I-geneN
receptor	E-geneN
occupancy	O
and	O
the	O
clinical	O
effects	O
of	O
olanzapine	S-chem
versus	O
clozapine	S-chem
in	O
a	O
sample	O
of	O
neuroleptic	O
-	O
refractory	O
schizophrenic	O
patients	O
.	O

Receptor	O
occupancy	O
was	O
evaluated	O
in	O
different	O
cortical	O
areas	O
and	O
in	O
basal	O
ganglia	O
using	O
[	B-chem
18F	I-chem
]	I-chem
fluoro	I-chem
-	I-chem
ethyl	I-chem
-	I-chem
spiperone	E-chem
(	O
[	B-chem
18F	I-chem
]	I-chem
FESP	E-chem
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

A	O
total	O
of	O
15	O
neuroleptic	O
-	O
free	O
patients	O
completed	O
the	O
study	O
undergoing	O
a	O
baseline	O
and	O
a	O
post	O
-	O
treatment	O
PET	O
scan	O
(	O
olanzapine	S-chem
,	O
nine	O
patients	O
,	O
one	O
female	O
;	O
clozapine	S-chem
,	O
six	O
patients	O
,	O
three	O
female	O
)	O
8	O
weeks	O
after	O
starting	O
treatment	O
.	O

PET	O
data	O
were	O
analysed	O
both	O
by	O
regions	O
of	O
interest	O
and	O
on	O
a	O
voxel	O
-	O
by	O
-	O
voxel	O
basis	O
using	O
Statistical	O
Parametric	O
Mapping	O
(	O
SPM96	O
)	O
.	O

Olanzapine	S-chem
and	O
clozapine	S-chem
induced	O
a	O
similar	O
and	O
significant	O
inhibition	O
of	O
[	B-chem
18F	I-chem
]	I-chem
FESP	E-chem
binding	O
index	O
in	O
the	O
cortex	O
.	O

In	O
the	O
basal	O
ganglia	O
,	O
receptor	O
occupancy	O
was	O
significantly	O
higher	O
with	O
olanzapine	S-chem
than	O
with	O
clozapine	S-chem
(	O
p	O
=	O
0.0018	O
)	O
.	O

By	O
contrast	O
,	O
no	O
differences	O
in	O
receptor	O
occupancy	O
were	O
detected	O
at	O
the	O
level	O
of	O
the	O
pituitary	O
gland	O
.	O

Clinical	O
outcomes	O
,	O
in	O
particular	O
a	O
full	O
extra	O
pyramidal	O
tolerability	O
,	O
were	O
similar	O
.	O

In	O
this	O
sample	O
of	O
neuroleptic	O
-	O
refractory	O
schizophrenic	O
patients	O
,	O
olanzapine	S-chem
and	O
clozapine	S-chem
showed	O
a	O
different	O
pattern	O
of	O
occupancy	O
of	O
D2	B-geneY
-	I-geneY
like	I-geneY
receptor	E-geneY
despite	O
a	O
common	O
lack	O
of	O
extrapyramidal	O
side	O
-	O
effects	O
.	O

Antiarrhythmic	O
effects	O
of	O
(	B-chem-C5-1
-	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
epicatechin	I-chem-C5-1
-	I-chem-C5-1
3	I-chem-C5-1
-	I-chem-C5-1
gallate	E-chem-C5-1
,	O
a	O
novel	O
sodium	B-geneN-C5-2
channel	E-geneN-C5-2
agonist	O
in	O
cultured	O
neonatal	O
rat	O
ventricular	O
myocytes	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
Epicatechin	I-chem
-	I-chem
3	I-chem
-	I-chem
gallate	E-chem
(	O
ECG	S-chem
)	O
,	O
a	O
polyphenol	S-chem
extracted	O
from	O
green	O
tea	O
,	O
has	O
been	O
proposed	O
as	O
an	O
effective	O
compound	O
for	O
improving	O
cardiac	O
contractility	O
.	O

However	O
,	O
the	O
therapeutic	O
potential	O
of	O
ECG	S-chem
on	O
the	O
treatment	O
of	O
arrhythmia	O
remains	O
unknown	O
.	O

We	O
investigated	O
the	O
direct	O
actions	O
of	O
ECG	S-chem
on	O
the	O
modulation	O
of	O
ion	O
currents	O
and	O
cardiac	O
cell	O
excitability	O
in	O
the	O
primary	O
culture	O
of	O
neonatal	O
rat	O
ventricular	O
myocyte	O
(	O
NRVM	O
)	O
,	O
which	O
is	O
considered	O
a	O
hypertrophic	O
model	O
for	O
analysis	O
of	O
myocardial	O
arrhythmias	O
.	O

By	O
using	O
the	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
configurations	O
,	O
we	O
found	O
ECG	S-chem
enhanced	O
the	O
slowly	O
inactivating	O
component	O
of	O
voltage	O
-	O
gated	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
currents	O
(	O
I	O
(	O
Na	S-chem
)	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
0.1	O
-	O
100	O
μM	O
)	O
with	O
an	O
EC	O
(	O
50	O
)	O
value	O
of	O
3.8	O
μM	O
.	O

ECG	S-chem
not	O
only	O
shifted	O
the	O
current	O
-	O
voltage	O
relationship	O
of	O
peak	O
I	O
(	O
Na	S-chem
)	O
to	O
the	O
hyperpolarizing	O
direction	O
but	O
also	O
accelerated	O
I	O
(	O
Na	S-chem
)	O
recovery	O
kinetics	O
.	O

Working	O
at	O
a	O
concentration	O
level	O
of	O
I	O
(	O
Na	S-chem
)	O
enhancement	O
,	O
ECG	S-chem
has	O
no	O
notable	O
effect	O
on	O
voltage	O
-	O
gated	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
currents	O
and	O
L	O
-	O
type	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
currents	O
.	O

With	O
culture	O
time	O
increment	O
,	O
the	O
firing	O
rate	O
of	O
spontaneous	O
action	O
potential	O
(	O
sAP	O
)	O
in	O
NRVMs	O
was	O
gradually	O
decreased	O
until	O
spontaneous	O
early	O
after	O
-	O
depolarization	O
(	O
EAD	O
)	O
was	O
observed	O
after	O
about	O
one	O
week	O
culture	O
.	O

ECG	S-chem
increased	O
the	O
firing	O
rate	O
of	O
normal	O
sAP	O
about	O
two	O
-	O
fold	O
without	O
waveform	O
alteration	O
.	O

Interestingly	O
,	O
the	O
bradycardia	O
-	O
dependent	O
EAD	O
could	O
be	O
significantly	O
restored	O
by	O
ECG	S-chem
in	O
fast	O
firing	O
rate	O
to	O
normal	O
sAP	O
waveform	O
.	O

The	O
expression	O
of	O
dominant	O
cardiac	O
sodium	B-geneN
channel	E-geneN
subunit	O
,	O
Nav1.5	S-geneY
,	O
was	O
consistently	O
detected	O
throughout	O
the	O
culture	O
periods	O
.	O

Our	O
results	O
reveal	O
how	O
ECG	S-chem
,	O
the	O
novel	O
I	O
(	O
Na	S-chem
)	O
agonist	O
,	O
may	O
act	O
as	O
a	O
promising	O
candidate	O
in	O
clinical	O
applications	O
on	O
cardiac	O
arrhythmias	O
.	O

The	O
circadian	O
clock	O
circuitry	O
and	O
the	O
AHR	S-geneY
signaling	O
pathway	O
in	O
physiology	O
and	O
pathology	O
.	O

Life	O
forms	O
populating	O
the	O
Earth	O
must	O
face	O
environmental	O
challenges	O
to	O
assure	O
individual	O
and	O
species	O
survival	O
.	O

The	O
strategies	O
predisposed	O
to	O
maintain	O
organismal	O
homeostasis	O
and	O
grant	O
selective	O
advantage	O
rely	O
on	O
anticipatory	O
phenomena	O
facing	O
periodic	O
modifications	O
,	O
and	O
compensatory	O
phenomena	O
facing	O
unpredictable	O
changes	O
.	O

Biological	O
processes	O
bringing	O
about	O
these	O
responses	O
are	O
respectively	O
driven	O
by	O
the	O
circadian	O
timing	O
system	O
,	O
a	O
complex	O
of	O
biological	O
oscillators	O
entrained	O
to	O
the	O
environmental	O
light	O
/	O
dark	O
cycle	O
,	O
and	O
by	O
regulatory	O
and	O
metabolic	O
networks	O
that	O
precisely	O
direct	O
the	O
body	O
's	O
adjustments	O
to	O
variations	O
of	O
external	O
conditions	O
and	O
internal	O
milieu	O
.	O

A	O
critical	O
role	O
in	O
organismal	O
homeostatic	O
functions	O
is	O
played	O
by	O
the	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AHR	S-geneY
)	O
complex	O
,	O
which	O
senses	O
environmental	O
and	O
endogenous	O
compounds	O
,	O
influences	O
metabolic	O
responses	O
controlling	O
phase	O
I	O
/	O
II	O
gene	O
expression	O
,	O
and	O
modulates	O
vital	O
phenomena	O
such	O
as	O
development	O
,	O
inflammation	O
and	O
adaptive	O
immunity	O
.	O

A	O
physiological	O
cross	O
-	O
talk	O
between	O
circadian	O
and	O
AHR	S-geneY
signaling	O
pathways	O
has	O
been	O
evidenced	O
.	O

The	O
alteration	O
of	O
AHR	S-geneY
signaling	O
pathway	O
deriving	O
from	O
genetic	O
damage	O
with	O
polymorphisms	O
or	O
mutations	O
,	O
or	O
produced	O
by	O
exogenous	O
or	O
endogenous	O
AHR	S-geneY
activation	O
,	O
and	O
chronodisruption	O
caused	O
by	O
mismatch	O
between	O
the	O
body	O
's	O
internal	O
clock	O
and	O
geophysical	O
time	O
/	O
social	O
schedules	O
,	O
are	O
capable	O
of	O
triggering	O
pathological	O
mechanisms	O
involved	O
in	O
metabolic	O
,	O
immune	O
-	O
related	O
and	O
neoplastic	O
diseases	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
molecular	O
components	O
of	O
the	O
circadian	O
clock	O
circuitry	O
and	O
AHR	S-geneY
signaling	O
pathway	O
may	O
represent	O
useful	O
tools	O
for	O
preventive	O
interventions	O
and	O
valuable	O
targets	O
of	O
therapeutic	O
approaches	O
.	O

Sergliflozin	B-chem-C4-1
etabonate	E-chem-C4-1
,	O
a	O
selective	O
SGLT2	S-geneY-C4-2
inhibitor	O
,	O
improves	O
glycemic	O
control	O
in	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
rats	O
and	O
Zucker	O
fatty	O
rats	O
.	O

The	O
low	O
-	O
affinity	O
sodium	B-geneN-C9-2
glucose	I-geneN-C9-2
cotransporter	E-geneN-C9-2
(	O
SGLT2	S-geneY-C9-2
)	O
is	O
responsible	O
for	O
most	O
of	O
the	O
glucose	S-chem-C9-1
reabsorption	O
in	O
the	O
kidney	O
and	O
has	O
been	O
highlighted	O
as	O
a	O
novel	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

We	O
discovered	O
sergliflozin	B-chem-C4-1
etabonate	E-chem-C4-1
,	O
a	O
novel	O
selective	O
SGLT2	S-geneY-C4-2
inhibitor	O
,	O
and	O
found	O
that	O
selective	O
inhibition	O
of	O
SGLT2	S-geneY-C4-2
increased	O
urinary	O
glucose	S-chem
excretion	O
and	O
consequently	O
decreased	O
plasma	O
glucose	S-chem
levels	O
.	O

In	O
this	O
report	O
,	O
we	O
examined	O
the	O
antihyperglycemic	O
effects	O
of	O
sergliflozin	B-chem
etabonate	E-chem
in	O
normal	O
and	O
diabetic	O
rats	O
in	O
comparison	O
with	O
those	O
of	O
a	O
sulfonylurea	S-chem
(	O
gliclazide	S-chem
)	O
and	O
an	O
alpha	B-geneY-C4-2
-	I-geneY-C4-2
glucosidase	E-geneY-C4-2
inhibitor	O
(	O
voglibose	S-chem-C4-1
)	O
.	O

Sergliflozin	B-chem
etabonate	E-chem
increased	O
urinary	O
glucose	S-chem
excretion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
inhibited	O
the	O
increase	O
in	O
plasma	O
glucose	S-chem
after	O
sucrose	S-chem
loading	O
independently	O
of	O
insulin	S-geneN
secretion	O
in	O
normal	O
rats	O
.	O

Sergliflozin	B-chem
etabonate	E-chem
also	O
improved	O
postprandial	O
hyperglycemia	O
in	O
neonatal	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
rats	O
;	O
whereas	O
gliclazide	S-chem
did	O
not	O
improve	O
it	O
.	O

In	O
rats	O
with	O
mild	O
or	O
moderate	O
streptozotocin	S-chem
-	O
induced	O
diabetes	O
,	O
the	O
degree	O
of	O
the	O
antihyperglycemic	O
effects	O
of	O
sergliflozin	B-chem
etabonate	E-chem
correlated	O
with	O
the	O
severity	O
of	O
the	O
diabetic	O
condition	O
.	O

Sergliflozin	B-chem
etabonate	E-chem
did	O
not	O
affect	O
the	O
plasma	O
glucose	S-chem
level	O
of	O
normal	O
rats	O
as	O
seen	O
with	O
gliclazide	S-chem
.	O

Chronic	O
treatment	O
with	O
sergliflozin	B-chem-C4-1
etabonate	E-chem-C4-1
reduced	O
the	O
levels	O
of	O
glycated	B-geneN-C4-2
hemoglobin	E-geneN-C4-2
and	O
fasting	O
plasma	O
glucose	S-chem
,	O
and	O
improved	O
the	O
glycemic	O
response	O
after	O
glucose	S-chem
loading	O
in	O
Zucker	O
fatty	O
rats	O
.	O

In	O
addition	O
,	O
sergliflozin	B-chem
etabonate	E-chem
did	O
not	O
affect	O
the	O
body	O
weight	O
or	O
food	O
intake	O
.	O

These	O
data	O
indicate	O
that	O
sergliflozin	B-chem
etabonate	E-chem
could	O
improve	O
glycemic	O
control	O
without	O
its	O
use	O
resulting	O
in	O
insulin	S-geneN
secretion	O
,	O
hypoglycemia	O
,	O
and	O
body	O
weight	O
gain	O
,	O
and	O
may	O
provide	O
a	O
unique	O
approach	O
to	O
the	O
treatment	O
of	O
diabetes	O
.	O

Vesicular	B-geneY
monoamine	I-geneY
transporter	I-geneY
-	I-geneY
1	E-geneY
(	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
)	O
mRNA	O
and	O
immunoreactive	O
proteins	O
in	O
mouse	O
brain	O
.	O

OBJECTIVE	O
:	O
Vesicular	B-geneY
monoamine	I-geneY
transporter	I-geneY
1	E-geneY
(	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
)	O
mRNA	O
and	O
protein	O
were	O
examined	O
(	O
1	O
)	O
to	O
determine	O
whether	O
adult	O
mouse	O
brain	O
expresses	O
full	O
-	O
length	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
mRNA	O
that	O
can	O
be	O
translated	O
to	O
functional	O
transporter	O
protein	O
and	O
(	O
2	O
)	O
to	O
compare	O
immunoreactive	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
proteins	O
in	O
brain	O
and	O
adrenal	O
.	O

METHODS	O
:	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
mRNA	O
was	O
detected	O
in	O
mouse	O
brain	O
with	O
RT	O
-	O
PCR	O
.	O

The	O
cDNA	O
was	O
sequenced	O
,	O
cloned	O
into	O
an	O
expression	O
vector	O
,	O
transfected	O
into	O
COS	O
-	O
1	O
cells	O
,	O
and	O
cell	O
protein	O
was	O
assayed	O
for	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
activity	O
.	O

Immunoreactive	O
proteins	O
were	O
examined	O
on	O
western	O
blots	O
probed	O
with	O
four	O
different	O
antibodies	O
to	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
.	O

RESULTS	O
:	O
Sequencing	O
confirmed	O
identity	O
of	O
the	O
entire	O
coding	O
sequences	O
of	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
cDNA	O
from	O
mouse	O
medulla	O
oblongata	O
/	O
pons	O
and	O
adrenal	O
to	O
a	O
Gen	O
-	O
Bank	O
reference	O
sequence	O
.	O

Transfection	O
of	O
the	O
brain	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
resulted	O
in	O
transporter	O
activity	O
that	O
was	O
blocked	O
by	O
the	O
VMAT	S-geneN-C4-2
inhibitor	O
reserpine	S-chem-C4-1
and	O
a	O
proton	O
ionophore	O
,	O
but	O
not	O
by	O
tetrabenazine	S-chem
,	O
which	O
has	O
a	O
high	O
affinity	O
for	O
VMAT	B-geneY
-	I-geneY
2	E-geneY
.	O

Antibodies	O
to	O
either	O
the	O
C	S-chem
-	O
or	O
N	S-chem
-	O
terminus	O
of	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
detected	O
two	O
proteins	O
(	O
73	O
and	O
55	O
kD	O
)	O
in	O
transfected	O
COS	O
-	O
1	O
cells	O
.	O

The	O
C	S-chem
-	O
terminal	O
antibodies	O
detected	O
both	O
proteins	O
in	O
extracts	O
of	O
mouse	O
medulla	O
/	O
pons	O
,	O
cortex	O
,	O
hypothalamus	O
,	O
and	O
cerebellum	O
but	O
only	O
the	O
73	O
kD	O
protein	O
and	O
higher	O
molecular	O
weight	O
immunoreactive	O
proteins	O
in	O
mouse	O
adrenal	O
and	O
rat	O
PC12	O
cells	O
,	O
which	O
are	O
positive	O
controls	O
for	O
rodent	B-geneY
VMAT	I-geneY
-	I-geneY
1	E-geneY
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
a	O
functional	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
mRNA	O
coding	O
sequence	O
is	O
expressed	O
in	O
mouse	O
brain	O
and	O
suggest	O
processing	O
of	O
VMAT	B-geneY
-	I-geneY
1	E-geneY
protein	O
differs	O
in	O
mouse	O
adrenal	O
and	O
brain	O
.	O

A	O
case	O
of	O
Ehlers	O
Danlos	O
syndrome	O
type	O
VI	O
.	O

Ehlers	O
Danlos	O
type	O
VI	O
is	O
a	O
rare	O
autosomal	O
recessive	O
connective	O
tissue	O
disease	O
involving	O
primarily	O
the	O
skin	O
and	O
joints	O
.	O

The	O
main	O
feature	O
of	O
the	O
condition	O
is	O
neonatal	O
hypotonia	O
and	O
rare	O
complications	O
are	O
ruptures	O
of	O
arteries	O
and	O
the	O
eye	O
globe	O
.	O

A	O
4	O
year	O
old	O
girl	O
with	O
a	O
typical	O
clinical	O
presentation	O
and	O
molecular	O
diagnosis	O
of	O
EDS	O
VI	O
is	O
presented	O
.	O

Sequencing	O
of	O
PLOD1	S-geneY
gene	O
revealed	O
a	O
homozygous	O
deletion	O
in	O
exon	O
13	O
(	O
c.1362delC	O
)	O
,	O
leading	O
to	O
a	O
frameshift	O
and	O
truncation	O
of	O
the	O
lysyl	B-geneN
hydroxylase	E-geneN
,	O
an	O
enzyme	O
necessary	O
for	O
collagen	S-geneN
biosynthesis	O
.	O

Early	O
diagnosis	O
allowed	O
treatment	O
with	O
high	O
doses	O
of	O
ascorbic	B-chem
acid	E-chem
in	O
order	O
to	O
prevent	O
complications	O
,	O
genetic	O
counseling	O
of	O
the	O
family	O
and	O
prenatal	O
diagnosis	O
of	O
an	O
unaffected	O
embryo	O
.	O

Hyperglycemia	O
slows	O
embryonic	O
growth	O
and	O
suppresses	O
cell	O
cycle	O
via	O
cyclin	B-geneY
D1	E-geneY
and	O
p21	S-geneY
.	O

In	O
pregnant	O
women	O
,	O
the	O
diabetic	O
condition	O
results	O
in	O
a	O
three	O
-	O
to	O
fivefold	O
increased	O
risk	O
for	O
fetal	O
cardiac	O
malformations	O
as	O
a	O
result	O
of	O
elevated	O
glucose	S-chem
concentrations	O
and	O
the	O
resultant	O
osmotic	O
stress	O
in	O
the	O
developing	O
embryo	O
and	O
fetus	O
.	O

Heart	O
development	O
before	O
septation	O
in	O
the	O
chick	O
embryo	O
was	O
studied	O
under	O
two	O
hyperglycemic	O
conditions	O
.	O

Pulsed	O
hyperglycemia	O
induced	O
by	O
daily	O
administration	O
of	O
glucose	S-chem
during	O
3	O
days	O
of	O
development	O
caused	O
daily	O
spikes	O
in	O
plasma	O
glucose	S-chem
concentration	O
.	O

In	O
a	O
second	O
model	O
,	O
sustained	O
hyperglycemia	O
was	O
induced	O
with	O
a	O
single	O
injection	O
of	O
glucose	S-chem
into	O
the	O
yolk	O
on	O
day	O
0	O
.	O

The	O
sustained	O
model	O
raised	O
the	O
average	O
plasma	O
glucose	S-chem
concentration	O
from	O
70	O
mg	O
/	O
dL	O
to	O
180	O
mg	O
/	O
dL	O
and	O
led	O
to	O
decreased	O
gene	O
expression	O
of	O
glucose	B-geneN
transporter	E-geneN
GLUT1	S-geneY
.	O

Both	O
models	O
of	O
hyperglycemia	O
reduced	O
embryo	O
size	O
,	O
increased	O
mortality	O
,	O
and	O
delayed	O
development	O
.	O

Within	O
the	O
heart	O
outflow	O
tract	O
,	O
reduced	O
proliferation	O
of	O
myocardial	O
and	O
endocardial	O
cells	O
resulted	O
from	O
the	O
sustained	O
hyperglycemia	O
and	O
hyperosmolarity	O
.	O

The	O
cell	O
cycle	O
inhibitor	O
p21	S-geneY
was	O
significantly	O
increased	O
,	O
whereas	O
cyclin	B-geneY
D1	E-geneY
,	O
a	O
cell	O
cycle	O
promoter	O
,	O
decreased	O
in	O
sustained	O
hyperglycemia	O
compared	O
with	O
controls	O
.	O

The	O
evidence	O
suggests	O
that	O
hyperglycemia	O
-	O
induced	O
developmental	O
delays	O
are	O
associated	O
with	O
slowed	O
cell	O
cycle	O
progression	O
,	O
leading	O
to	O
reduced	O
cellular	O
proliferation	O
.	O

The	O
suppression	O
of	O
critical	O
developmental	O
steps	O
may	O
underlie	O
the	O
cardiac	O
defects	O
observed	O
during	O
late	O
gestation	O
under	O
hyperglycemic	O
conditions	O
.	O

Single	O
-	O
walled	O
carbon	S-chem
nanotube	O
surface	O
control	O
of	O
complement	O
recognition	O
and	O
activation	O
.	O

Carbon	S-chem
nanotubes	O
(	O
CNTs	O
)	O
are	O
receiving	O
considerable	O
attention	O
in	O
site	O
-	O
specific	O
drug	O
and	O
nucleic	O
acid	O
delivery	O
,	O
photodynamic	O
therapy	O
,	O
and	O
photoacoustic	O
molecular	O
imaging	O
.	O

Despite	O
these	O
advances	O
,	O
nanotubes	O
may	O
activate	O
the	O
complement	O
system	O
(	O
an	O
integral	O
part	O
of	O
innate	O
immunity	O
)	O
,	O
which	O
can	O
induce	O
clinically	O
significant	O
anaphylaxis	O
.	O

We	O
demonstrate	O
that	O
single	O
-	O
walled	O
CNTs	O
coated	O
with	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
activate	O
the	O
complement	O
system	O
through	O
C1q	O
-	O
mediated	O
classical	O
and	O
the	O
alternative	O
pathways	O
.	O

Surface	O
coating	O
with	O
methoxypoly	B-chem
(	I-chem
ethylene	I-chem
glycol	I-chem
)	E-chem
-	O
based	O
amphiphiles	O
,	O
which	O
confers	O
solubility	O
and	O
prolongs	O
circulation	O
profiles	O
of	O
CNTs	O
,	O
activates	O
the	O
complement	O
system	O
differently	O
,	O
depending	O
on	O
the	O
amphiphile	O
structure	O
.	O

CNTs	O
with	O
linear	O
poly	B-chem
(	I-chem
ethylene	I-chem
glycol	I-chem
)	E-chem
amphiphiles	O
trigger	O
the	O
lectin	S-geneN
pathway	O
of	O
the	O
complement	O
through	O
both	O
L	O
-	O
ficolin	O
and	O
mannan	O
-	O
binding	O
lectin	S-geneN
recognition	O
.	O

The	O
lectin	S-geneN
pathway	O
activation	O
,	O
however	O
,	O
did	O
not	O
trigger	O
the	O
amplification	O
loop	O
of	O
the	O
alternative	O
pathway	O
.	O

An	O
amphiphile	O
with	O
branched	O
poly	B-chem-C3-1
(	I-chem-C3-1
ethylene	I-chem-C3-1
glycol	I-chem-C3-1
)	E-chem-C3-1
architecture	O
also	O
activated	O
the	O
lectin	S-geneN-C3-2
pathway	O
but	O
only	O
through	O
L	O
-	O
ficolin	O
recognition	O
.	O

Importantly	O
,	O
this	O
mode	O
of	O
activation	O
neither	O
generated	O
anaphylatoxins	O
nor	O
induced	O
triggering	O
of	O
the	O
effector	O
arm	O
of	O
the	O
complement	O
system	O
.	O

These	O
observations	O
provide	O
a	O
major	O
step	O
toward	O
nanomaterial	O
surface	O
modification	O
with	O
polymers	O
that	O
have	O
the	O
properties	O
to	O
significantly	O
improve	O
innate	O
immunocompatibility	O
by	O
limiting	O
the	O
formation	O
of	O
complement	O
C3	B-geneN
and	I-geneN
C5	I-geneN
convertases	E-geneN
.	O

Lipoxygenase	S-geneN
and	O
urease	S-geneN
inhibition	O
of	O
the	O
aerial	O
parts	O
of	O
the	O
Polygonatum	O
verticillatum	O
.	O

Over	O
expression	O
of	O
lipoxygenase	S-geneN
(	O
LOX	S-geneN
)	O
and	O
urease	S-geneN
has	O
already	O
contributed	O
to	O
the	O
pathology	O
of	O
different	O
human	O
disease	O
.	O

Targeting	O
the	O
inhibition	O
of	O
these	O
enzymes	O
has	O
proved	O
great	O
clinical	O
utility	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
scrutinised	O
the	O
inhibitory	O
profile	O
of	O
the	O
aerial	O
parts	O
of	O
the	O
Polygonatum	O
verticillatum	O
enzyme	O
against	O
LOX	S-geneN
,	O
urease	S-geneN
,	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
and	O
butyrylcholinesterase	S-geneY
(	O
BChE	S-geneY
)	O
using	O
standard	O
experimental	O
protocols	O
.	O

When	O
checked	O
against	O
lipoxygenase	S-geneN
,	O
the	O
extracts	O
revealed	O
significant	O
attenuation	O
.	O

Of	O
the	O
tested	O
extracts	O
,	O
the	O
ethyl	B-chem
acetate	E-chem
fraction	O
was	O
the	O
most	O
potent	O
(	O
half	O
-	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
:	O
97	O
µg	O
/	O
mL	O
)	O
followed	O
by	O
aqueous	O
fraction	O
IC50	O
:	O
109	O
µg	O
/	O
mL	O
)	O
.	O

Regarding	O
urease	S-geneN-C4-2
inhibition	O
,	O
n	B-chem-C4-1
-	I-chem-C4-1
butanol	E-chem-C4-1
was	O
the	O
most	O
potent	O
fraction	O
(	O
IC50	O
:	O
97	O
µg	O
/	O
mL	O
)	O
.	O

However	O
,	O
the	O
extracts	O
did	O
not	O
show	O
significant	O
inhibition	O
on	O
AChE	S-geneY
and	O
BChE	S-geneY
.	O

In	O
the	O
preliminary	O
phytochemical	O
tests	O
,	O
the	O
aerial	O
parts	O
of	O
the	O
plant	O
showed	O
the	O
presence	O
of	O
saponins	S-chem
,	O
alkaloids	O
,	O
flavonoids	S-chem
,	O
phenols	S-chem
,	O
tannins	S-chem
and	O
terpenoids	S-chem
.	O

The	O
current	O
findings	O
could	O
be	O
attributed	O
to	O
these	O
groups	O
of	O
compounds	O
.	O

All	B-chem-C3-1
-	I-chem-C3-1
trans	I-chem-C3-1
retinoic	I-chem-C3-1
acid	E-chem-C3-1
protects	O
hepatocellular	O
carcinoma	O
cells	O
against	O
serum	O
-	O
starvation	O
-	O
induced	O
cell	O
death	O
by	O
upregulating	O
collagen	B-geneY-C3-2
8A2	E-geneY-C3-2
.	O

As	O
a	O
therapeutic	O
or	O
chemopreventative	O
agent	O
for	O
various	O
cancers	O
,	O
all	B-chem
-	I-chem
trans	I-chem
retinoic	I-chem
acid	E-chem
(	O
atRA	S-chem
)	O
has	O
been	O
reported	O
to	O
inhibit	O
growth	O
,	O
induce	O
apoptosis	O
or	O
cause	O
differentiation	O
.	O

It	O
was	O
found	O
that	O
atRA	S-chem
could	O
protect	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
against	O
cell	O
death	O
induced	O
by	O
serum	O
starvation	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
atRA	S-chem
could	O
enhance	O
cell	O
adhesion	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
cell	O
cycle	O
and	O
apoptosis	O
.	O

Using	O
an	O
Illumina	O
Human	O
HT	O
-	O
12	O
v4	O
expression	O
microarray	O
,	O
207	O
upregulated	O
and	O
173	O
downregulated	O
genes	O
were	O
identified	O
in	O
HepG2	O
cells	O
treated	O
with	O
atRA	S-chem
.	O

The	O
most	O
upregulated	O
genes	O
are	O
cytochrome	B-geneY
P450	I-geneY
family	I-geneY
26	I-geneY
subfamily	I-geneY
A	I-geneY
polypeptide	I-geneY
1	E-geneY
(	O
CYP26A1	S-geneY
)	O
,	O
histidine	B-geneY
triad	I-geneY
nucleotide	I-geneY
binding	I-geneY
protein	I-geneY
3	E-geneY
(	O
HINT3	S-geneY
)	O
,	O
miR	B-geneY
-	I-geneY
1282	E-geneY
and	O
cytochrome	B-geneY
P450	I-geneY
family	I-geneY
26	I-geneY
subfamily	I-geneY
B	I-geneY
polypeptide	I-geneY
1	E-geneY
(	O
CYP26B1	S-geneY
)	O
,	O
which	O
showed	O
more	O
than	O
fivefold	O
greater	O
expression	O
.	O

Using	O
Gene	O
Ontology	O
analysis	O
,	O
the	O
greatest	O
significance	O
was	O
found	O
in	O
extracellular	O
-	O
matrix	O
-	O
related	O
molecular	O
functions	O
and	O
the	O
cellular	O
component	O
in	O
upregulated	O
genes	O
.	O

The	O
upregulation	O
of	O
collagen	B-geneY
8A2	E-geneY
(	O
COL8A2	S-geneY
)	O
was	O
further	O
confirmed	O
using	O
quantitative	O
RT	O
-	O
PCR	O
and	O
western	O
blotting	O
.	O

Knockdown	O
of	O
COL8A2	S-geneY
blocked	O
enhancement	O
in	O
the	O
early	O
stage	O
of	O
cell	O
adhesion	O
by	O
atRA	S-chem
treatment	O
.	O

Re	O
-	O
expression	O
of	O
COL8A2	S-geneY
in	O
COL8A2	S-geneY
-	O
knocked	O
-	O
down	O
HCC	O
cells	O
reversed	O
the	O
effect	O
of	O
small	O
interfering	O
RNA	O
-	O
COL8A2	S-geneY
.	O

In	O
addition	O
,	O
COL8A2	S-geneY
could	O
increase	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Thus	O
,	O
COL8A2	S-geneY
was	O
identified	O
as	O
the	O
key	O
protein	O
involved	O
in	O
the	O
enhancement	O
of	O
cell	O
adhesion	O
of	O
atRA	S-chem
under	O
serum	O
-	O
free	O
conditions	O
.	O

In	O
conclusion	O
,	O
atRA	S-chem
protects	O
HCC	O
cells	O
against	O
serum	O
-	O
starvation	O
-	O
induced	O
cell	O
death	O
by	O
enhancing	O
cell	O
adhesion	O
,	O
and	O
COL8A2	S-geneY
plays	O
an	O
important	O
role	O
in	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Life	O
-	O
threatening	O
hypoglycemia	O
associated	O
with	O
intentional	O
insulin	S-geneY
ingestion	O
.	O

There	O
are	O
reports	O
of	O
insulin	S-geneY
overdose	O
by	O
injection	O
,	O
yet	O
little	O
is	O
known	O
regarding	O
the	O
potential	O
harms	O
of	O
intentional	O
oral	O
ingestion	O
of	O
insulin	S-geneY
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
massive	O
insulin	S-geneY
ingestion	O
and	O
ensuing	O
hypoglycemia	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
previously	O
published	O
cases	O
of	O
hypoglycemia	O
caused	O
by	O
intentional	O
insulin	S-geneY
ingestion	O
.	O

A	O
51	O
-	O
year	O
-	O
old	O
man	O
intentionally	O
ingested	O
three	O
10	O
-	O
ml	O
vials	O
(	O
total	O
of	O
3000	O
units	O
)	O
of	O
various	O
insulins	S-geneY
:	O
one	O
vial	O
each	O
of	O
insulin	S-geneY
aspart	O
,	O
lispro	O
,	O
and	O
glargine	O
.	O

Four	O
symptomatic	O
hypoglycemic	O
episodes	O
,	O
with	O
blood	O
glucose	S-chem
levels	O
of	O
48	O
,	O
25	O
,	O
34	O
,	O
and	O
40	O
mg	O
/	O
dl	O
,	O
occurred	O
approximately	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
hours	O
,	O
respectively	O
,	O
after	O
ingestion	O
.	O

The	O
hypoglycemia	O
could	O
not	O
be	O
explained	O
other	O
than	O
the	O
ingestion	O
of	O
the	O
insulins	S-geneY
.	O

The	O
patient	O
was	O
admitted	O
for	O
observation	O
,	O
and	O
euglycemia	O
occurred	O
within	O
24	O
hours	O
without	O
any	O
additional	O
hypoglycemic	O
episodes	O
.	O

Hypoglycemia	O
treatment	O
is	O
reviewed	O
in	O
this	O
case	O
report	O
,	O
and	O
factors	O
that	O
may	O
affect	O
systemic	O
response	O
of	O
orally	O
ingested	O
insulin	S-geneY
,	O
including	O
gastrointestinal	O
absorption	O
and	O
insulin	S-geneY
sensitivity	O
,	O
are	O
discussed	O
.	O

In	O
addition	O
,	O
the	O
findings	O
of	O
our	O
case	O
report	O
may	O
provide	O
useful	O
insight	O
into	O
the	O
development	O
of	O
novel	O
oral	O
insulin	S-geneY
products	O
that	O
are	O
currently	O
in	O
research	O
.	O

Despite	O
poor	O
bioavailability	O
(	O
1	O
%	O
)	O
when	O
taken	O
orally	O
,	O
insulin	S-geneY
may	O
produce	O
symptomatic	O
hypoglycemia	O
with	O
a	O
massive	O
ingestion	O
.	O

Vigilant	O
blood	O
glucose	S-chem
monitoring	O
,	O
supportive	O
care	O
with	O
glucose	S-chem
replacement	O
therapy	O
,	O
and	O
admission	O
to	O
the	O
hospital	O
for	O
observation	O
may	O
be	O
required	O
.	O

Sphingosine	B-chem-C3-1
-	I-chem-C3-1
1	I-chem-C3-1
-	I-chem-C3-1
phosphate	E-chem-C3-1
promotes	O
the	O
nuclear	O
translocation	O
of	O
β	B-geneN
-	I-geneN
catenin	E-geneN
and	O
thereby	O
induces	O
osteoprotegerin	S-geneN-C3-2
gene	O
expression	O
in	O
osteoblast	O
-	O
like	O
cell	O
lines	O
.	O

Sphingosine	B-chem
-	I-chem
1	I-chem
-	I-chem
phosphate	E-chem
(	O
S1P	S-chem
)	O
is	O
a	O
well	O
-	O
known	O
signaling	O
sphingolipid	S-chem
and	O
bioactive	O
lipid	O
mediator	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
S1P	S-chem
inhibits	O
osteoclast	O
differentiation	O
and	O
bone	O
resorption	O
.	O

On	O
the	O
other	O
hand	O
,	O
S1P	S-chem
effects	O
on	O
osteoblasts	O
and	O
bone	O
formation	O
are	O
little	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
S1P	S-chem
on	O
osteoblasts	O
,	O
using	O
two	O
osteoblast	O
-	O
like	O
cell	O
lines	O
,	O
SaOS	O
-	O
2	O
and	O
MC3T3	O
-	O
E1	O
.	O

S1P	S-chem-MU-1
activated	O
phosphatidylinositol	B-geneN-C3-2
3	I-geneN-C3-2
-	I-geneN-C3-2
kinase	E-geneN-C3-2
(	O
PI3K	S-geneN-C3-2
)	O
/	O
Akt	S-geneN-C3-2
signaling	O
,	O
leading	O
to	O
the	O
inhibition	O
of	O
glycogen	B-geneN-C4-2
synthase	I-geneN-C4-2
kinase	I-geneN-C4-2
-	I-geneN-C4-2
3β	E-geneN-C4-2
and	O
the	O
nuclear	O
translocation	O
of	O
β	B-geneN
-	I-geneN
catenin	E-geneN
,	O
followed	O
by	O
the	O
increase	O
of	O
the	O
transcriptional	O
activity	O
by	O
β	B-geneN
-	I-geneN
catenin	E-geneN
/	O
T	B-geneN
-	I-geneN
cell	I-geneN
factor	E-geneN
complex	O
formation	O
in	O
both	O
SaOS	O
-	O
2	O
cells	O
and	O
MC3T3	O
-	O
E1	O
cells	O
.	O

The	O
inhibitors	O
of	O
PI3K	S-geneN
and	O
Akt	S-geneN
suppressed	O
S1P	S-chem
-	O
induced	O
nuclear	O
localization	O
of	O
β	B-geneN
-	I-geneN
catenin	E-geneN
.	O

We	O
further	O
investigated	O
the	O
effects	O
of	O
PI3K	S-geneN
/	O
Akt	S-geneN
signaling	O
on	O
the	O
Wnt	S-geneN
/	O
β	B-geneN
-	I-geneN
catenin	E-geneN
signaling	O
pathway	O
,	O
since	O
β	B-geneN
-	I-geneN
catenin	E-geneN
takes	O
a	O
central	O
role	O
in	O
this	O
signaling	O
pathway	O
.	O

Both	O
inhibitors	O
for	O
PI3K	S-geneN
and	O
Akt	S-geneN
suppressed	O
the	O
nuclear	O
localization	O
of	O
β	B-geneN
-	I-geneN
catenin	E-geneN
and	O
T	B-geneN
-	I-geneN
cell	I-geneN
factor	E-geneN
transcriptional	O
activity	O
induced	O
by	O
Wnt	B-geneN
-	I-geneN
3a	E-geneN
.	O

S1P	S-chem-C3-1
increased	O
the	O
amount	O
of	O
osteoprotegerin	S-geneN-C3-2
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
,	O
and	O
increased	O
the	O
activity	O
of	O
alkaline	B-geneN
phosphatase	E-geneN
,	O
leading	O
to	O
the	O
mineralization	O
.	O

These	O
findings	O
suggest	O
that	O
S1P	S-chem-C3-1
activates	O
the	O
PI3K	S-geneN-C3-2
/	O
Akt	S-geneN-C3-2
signaling	O
pathway	O
leading	O
to	O
the	O
promotion	O
of	O
nuclear	O
translocation	O
of	O
β	B-geneN-C3-2
-	I-geneN-C3-2
catenin	E-geneN-C3-2
in	O
osteoblast	O
-	O
like	O
cells	O
,	O
resulting	O
in	O
the	O
upregulation	O
of	O
osteoptotegerin	S-geneN-C3-2
and	O
osteoblast	O
differentiation	O
markers	O
including	O
alkaline	B-geneN-C3-2
phosphatase	E-geneN-C3-2
,	O
probably	O
relating	O
to	O
the	O
inhibition	O
of	O
osteoclast	O
formation	O
and	O
the	O
mineralization	O
,	O
respectively	O
.	O

Differential	O
activation	O
of	O
cAMP	B-geneN-C3-2
response	I-geneN-C3-2
element	I-geneN-C3-2
binding	I-geneN-C3-2
protein	E-geneN-C3-2
in	O
discrete	O
nucleus	O
accumbens	O
subregions	O
during	O
early	O
and	O
late	O
cocaine	S-chem-C3-1
sensitization	O
.	O

The	O
present	O
study	O
examined	O
the	O
differential	O
cocaine	S-chem-C3-1
-	O
induced	O
activation	O
of	O
the	O
cyclic	B-geneN-C3-2
adenosine	I-geneN-C3-2
monophosphate	I-geneN-C3-2
(	I-geneN-C3-2
cAMP	I-geneN-C3-2
)	I-geneN-C3-2
response	I-geneN-C3-2
element	I-geneN-C3-2
binding	I-geneN-C3-2
protein	E-geneN-C3-2
(	O
CREB	S-geneN-C3-2
)	O
throughout	O
discrete	O
zones	O
of	O
analysis	O
of	O
the	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
in	O
rats	O
.	O

CREB	S-geneN
-	O
dependent	O
gene	O
transcription	O
,	O
which	O
may	O
underlie	O
long	O
-	O
lasting	O
drug	O
-	O
induced	O
changes	O
in	O
behavior	O
and	O
the	O
subjective	O
effects	O
of	O
cocaine	S-chem
,	O
varies	O
depending	O
on	O
the	O
stage	O
of	O
drug	O
exposure	O
or	O
withdrawal	O
and	O
the	O
cell	O
population	O
involved	O
.	O

Using	O
immunohistochemistry	O
,	O
the	O
authors	O
analyzed	O
changes	O
in	O
CREB	S-geneN-C3-2
phosphorylation	O
in	O
the	O
NAc	O
after	O
5	O
days	O
of	O
cocaine	S-chem-C3-1
,	O
a	O
short	O
or	O
long	O
drug	O
-	O
free	O
period	O
,	O
and	O
a	O
subsequent	O
challenge	O
injection	O
.	O

The	O
NAc	O
shell	O
was	O
separated	O
into	O
5	O
zones	O
of	O
analysis	O
previously	O
defined	O
by	O
neurochemistry	O
and	O
connectivity	O
.	O

Repeated	O
cocaine	S-chem-C3-1
resulted	O
in	O
CREB	S-geneN-C3-2
phosphorylation	O
in	O
all	O
analyzed	O
subregions	O
of	O
the	O
NAc	O
excluding	O
the	O
most	O
ventrolateral	O
region	O
of	O
the	O
shell	O
2	O
weeks	O
after	O
cessation	O
of	O
repeated	O
cocaine	S-chem-C3-1
,	O
but	O
rats	O
challenged	O
after	O
2	O
drug	O
-	O
free	O
days	O
yielded	O
a	O
more	O
localized	O
activation	O
of	O
CREB	S-geneN-C3-2
in	O
the	O
3	O
most	O
dorsomedial	O
zones	O
of	O
the	O
shell	O
.	O

The	O
temporal	O
and	O
anatomical	O
determinants	O
of	O
cocaine	S-chem-C3-1
-	O
induced	O
CREB	S-geneN-C3-2
activity	O
may	O
indicate	O
functional	O
differences	O
among	O
NAc	O
shell	O
subregions	O
and	O
suggest	O
the	O
involvement	O
of	O
CREB	S-geneN
in	O
early	O
and	O
late	O
cocaine	S-chem
effects	O
.	O

Toxicological	O
impact	O
of	O
inhaled	O
electric	O
mosquito	O
-	O
repellent	O
liquid	O
on	O
the	O
rat	O
:	O
a	O
hematological	O
,	O
cytokine	S-geneN
indications	O
,	O
oxidative	O
stress	O
and	O
tumor	O
markers	O
.	O

Abstract	O
Context	O
:	O
High	O
malaria	O
burden	O
has	O
led	O
to	O
the	O
increased	O
use	O
of	O
insecticides	O
in	O
the	O
tropics	O
and	O
subtropics	O
.	O

This	O
study	O
thus	O
aimed	O
at	O
assessing	O
the	O
hematological	O
effects	O
alteration	O
of	O
pyrethroid	S-chem
insecticide	O
exposure	O
using	O
the	O
experimental	O
animal	O
model	O
.	O

Objective	O
:	O
A	O
commonly	O
available	O
Electric	O
Mosquito	O
-	O
Repellent	O
Liquid	O
pyrethroid	S-chem
insecticide	O
containing	O
prallethrin	S-chem
1.6	O
%	O
w	O
/	O
w	O
is	O
widely	O
used	O
for	O
mosquito	O
control	O
in	O
Saudi	O
Arabia	O
.	O

The	O
immunotoxic	O
effects	O
after	O
inhalation	O
exposures	O
to	O
the	O
preparation	O
for	O
a	O
continuous	O
period	O
of	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
were	O
investigated	O
in	O
rats	O
.	O

Methods	O
and	O
materials	O
:	O
Rats	O
were	O
exposed	O
to	O
prallethrin	S-chem
1.6	O
%	O
w	O
/	O
w	O
by	O
inhalation	O
for	O
72	O
consecutive	O
hours	O
.	O

Total	O
blood	O
count	O
,	O
blood	O
indices	O
of	O
creatine	B-geneN
kinase	E-geneN
(	O
CK	S-geneN
)	O
,	O
gamma	B-geneY
-	I-geneY
glutamyltranspeptidase	E-geneY
(	O
γ	B-geneY
-	I-geneY
GT	E-geneY
)	O
,	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
,	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
,	O
interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
2	E-geneY
,	O
tumor	B-geneY
necrosis	I-geneY
factors	I-geneY
(	I-geneY
TNF	I-geneY
)	I-geneY
α	E-geneY
,	O
alpha	B-geneY
-	I-geneY
fetoprotein	E-geneY
(	O
AFP	S-geneY
)	O
,	O
carbohydrate	B-geneN
antigen	I-geneN
(	I-geneN
CA	I-geneN
)	I-geneN
19.9	E-geneN
and	O
carcinoembrionic	B-geneN
antigen	E-geneN
(	O
CEA	S-geneN
)	O
were	O
assayed	O
.	O

Results	O
:	O
The	O
administration	O
of	O
prallethrin	S-chem-C3-1
1.6	O
%	O
w	O
/	O
w	O
created	O
significant	O
increased	O
changes	O
in	O
the	O
levels	O
of	O
total	O
WBC	O
,	O
lymphocytes	O
,	O
RBC	O
,	O
hemoglobin	S-geneN-C3-2
,	O
packed	O
cell	O
volume	O
,	O
platelets	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
mean	O
corpuscular	O
hemoglobin	S-geneN-C3-2
in	O
rats	O
after	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
of	O
continuous	O
inhalation	O
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
neutrophils	O
at	O
transient	O
reduction	O
in	O
the	O
monocytes	O
after	O
24	O
and	O
48	O
h	O
to	O
return	O
to	O
normal	O
after	O
72	O
h	O
.	O

Significant	O
increases	O
in	O
the	O
levels	O
of	O
CK	S-geneN
,	O
γ	B-geneY
-	I-geneY
GT	E-geneY
,	O
SOD	S-geneN
,	O
NO	S-chem
,	O
MDA	S-chem
,	O
AFP	S-geneY
,	O
IL	B-geneY
-	I-geneY
2	E-geneY
,	O
and	O
TNFα	S-geneY
were	O
recorded	O
.	O

CA	S-geneN
and	O
CEA	S-geneN
did	O
not	O
exhibit	O
any	O
change	O
.	O

Conclusions	O
:	O
Continuous	O
inhalation	O
to	O
prallethrin	S-chem
1.6	O
%	O
insecticides	O
poses	O
toxicity	O
on	O
hematological	O
variables	O
.	O

It	O
is	O
also	O
concluded	O
that	O
pyrethroid	S-chem
group	O
of	O
insecticide	O
may	O
cause	O
hematological	O
,	O
biochemical	O
,	O
cytokine	S-geneN
disturbances	O
and	O
possible	O
mutagenic	O
damage	O
to	O
the	O
tissues	O
.	O

Comparative	O
proteomics	O
of	O
ovarian	O
epithelial	O
tumors	O
.	O

We	O
analyzed	O
12	O
ovarian	O
epithelial	O
tumors	O
using	O
2D	O
PAGE	O
-	O
based	O
comparative	O
proteomics	O
to	O
construct	O
intra	O
-	O
and	O
inter	O
-	O
tumoral	O
distance	O
map	O
trees	O
and	O
to	O
discover	O
surrogate	O
biomarkers	O
indicative	O
of	O
an	O
ovarian	O
tumor	O
.	O

The	O
analysis	O
was	O
performed	O
after	O
laser	O
microdissection	O
of	O
12	O
fresh	O
-	O
frozen	O
tissue	O
samples	O
,	O
including	O
4	O
serous	O
,	O
5	O
mucinous	O
,	O
and	O
3	O
endometrioid	O
tumors	O
,	O
with	O
correlation	O
with	O
their	O
histopathological	O
characteristics	O
.	O

Ovarian	O
epithelial	O
tumors	O
and	O
normal	O
tissues	O
showed	O
an	O
apparent	O
separation	O
on	O
the	O
distance	O
map	O
tree	O
.	O

Mucinous	O
carcinomas	O
were	O
closest	O
to	O
the	O
normal	O
group	O
,	O
whereas	O
serous	O
carcinomas	O
were	O
located	O
furthest	O
from	O
the	O
normal	O
group	O
.	O

All	O
mucinous	O
tumors	O
with	O
aggressive	O
histology	O
were	O
separated	O
from	O
the	O
low	O
malignant	O
potential	O
(	O
LMP	O
)	O
group	O
.	O

The	O
benign	O
-	O
looking	O
cysts	O
adjacent	O
to	O
the	O
intraepithelial	O
carcinoma	O
(	O
IEC	O
)	O
showed	O
an	O
expression	O
pattern	O
identical	O
to	O
that	O
of	O
the	O
IEC	O
area	O
.	O

The	O
extent	O
of	O
change	O
on	O
the	O
lineages	O
leading	O
to	O
the	O
mucinous	O
and	O
serous	O
carcinoma	O
was	O
1.98	O
-	O
fold	O
different	O
.	O

The	O
overall	O
gene	O
expression	O
profiles	O
of	O
serous	O
or	O
endometrioid	O
carcinomas	O
appeared	O
to	O
be	O
less	O
affected	O
by	O
grade	O
or	O
stage	O
than	O
by	O
histologic	O
type	O
.	O

The	O
potential	O
candidate	O
biomarkers	O
screened	O
in	O
ovarian	O
tumors	O
and	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
in	O
comparison	O
to	O
normal	O
tissues	O
were	O
as	O
follows	O
:	O
NM23	S-geneY
,	O
annexin	B-geneY
-	I-geneY
1	E-geneY
,	O
protein	B-geneN
phosphatase	I-geneN
-	I-geneN
1	E-geneN
,	O
ferritin	B-geneY
light	I-geneY
chain	E-geneY
,	O
proteasome	B-geneY
alpha	I-geneY
-	I-geneY
6	E-geneY
,	O
and	O
NAGK	S-geneY
(	O
N	B-geneY
-	I-geneY
acetyl	I-geneY
glucosamine	I-geneY
kinase	E-geneY
)	O
.	O

In	O
conclusion	O
,	O
ovarian	O
mucinous	O
tumors	O
are	O
distinct	O
from	O
other	O
ovarian	O
epithelial	O
tumors	O
.	O

LMP	O
mucinous	O
tumors	O
showing	O
histologically	O
aggressive	O
features	O
belong	O
to	O
mucinous	O
carcinoma	O
on	O
the	O
proteomic	O
basis	O
.	O

Inhibition	O
of	O
matrix	B-geneN
metalloproteinases	E-geneN
(	O
MMPs	S-geneN
)	O
as	O
a	O
potential	O
strategy	O
to	O
ameliorate	O
hypertension	O
-	O
induced	O
cardiovascular	O
alterations	O
.	O

A	O
group	O
of	O
proteases	O
,	O
the	O
matrix	B-geneN
metalloproteinases	E-geneN
(	O
MMPs	S-geneN
)	O
are	O
well	O
known	O
for	O
their	O
capacity	O
to	O
degrade	O
extracellular	B-geneN
matrix	I-geneN
(	I-geneN
ECM	I-geneN
)	I-geneN
proteins	E-geneN
.	O

Particularly	O
MMP	B-geneY
-	I-geneY
2	E-geneY
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
contribute	O
to	O
the	O
degradation	O
and	O
reorganization	O
of	O
the	O
ECM	O
components	O
and	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
cardiovascular	O
remodeling	O
.	O

Imbalanced	O
MMP	S-geneN
activity	O
promotes	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
migration	O
and	O
proliferation	O
and	O
endothelial	O
dysfunction	O
,	O
thus	O
resulting	O
in	O
increased	O
cardiovascular	O
stiffness	O
and	O
hypertrophy	O
.	O

Furthermore	O
,	O
MMP	B-geneY
-	I-geneY
2	E-geneY
cleaves	O
non	O
-	O
ECM	O
protein	O
substrates	O
including	O
cellular	O
receptors	O
and	O
intracellular	O
proteins	O
,	O
thus	O
causing	O
cardiac	O
and	O
vascular	O
dysfunction	O
.	O

It	O
is	O
now	O
becoming	O
clear	O
that	O
increased	O
MMP	S-geneN
activity	O
promotes	O
long	O
-	O
lasting	O
cardiovascular	O
structural	O
and	O
functional	O
alterations	O
in	O
both	O
experimental	O
and	O
clinical	O
hypertension	O
,	O
and	O
this	O
alteration	O
may	O
contribute	O
to	O
sustained	O
hypertension	O
and	O
its	O
complications	O
.	O

Other	O
pathogenic	O
mechanisms	O
including	O
activation	O
of	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
-	O
aldosterone	O
system	O
and	O
oxidative	O
stress	O
activate	O
and	O
upregulate	O
MMPs	S-geneN
.	O

Therefore	O
,	O
MMP	S-geneN
inhibition	O
may	O
prevent	O
the	O
deleterious	O
consequences	O
of	O
hypertension	O
to	O
the	O
cardiovascular	O
system	O
.	O

This	O
review	O
article	O
will	O
focus	O
on	O
growing	O
evidence	O
supporting	O
the	O
relevance	O
of	O
MMPs	S-geneN
in	O
hypertension	O
and	O
the	O
effects	O
of	O
MMP	S-geneN
inhibitors	O
.	O

Particularly	O
,	O
the	O
effects	O
of	O
doxycycline	S-chem-C4-1
used	O
as	O
a	O
non	O
selective	O
MMP	S-geneN-C4-2
inhibitor	O
in	O
experimental	O
and	O
clinical	O
studies	O
will	O
be	O
discussed	O
.	O

Comparison	O
of	O
chemotherapy	O
with	O
chemohormonal	O
therapy	O
as	O
first	O
-	O
line	O
therapy	O
for	O
metastatic	O
,	O
hormone	O
-	O
sensitive	O
breast	O
cancer	O
:	O
An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

PURPOSE	O
:	O
Although	O
hormonal	O
therapy	O
represents	O
standard	O
therapy	O
for	O
metastatic	O
hormone	O
-	O
sensitive	O
disease	O
,	O
many	O
patients	O
receive	O
initial	O
chemotherapy	O
because	O
of	O
the	O
location	O
,	O
bulk	O
,	O
or	O
aggressiveness	O
of	O
their	O
disease	O
.	O

It	O
is	O
uncertain	O
whether	O
simultaneous	O
hormonal	O
therapy	O
provides	O
additional	O
benefit	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
January	O
1988	O
and	O
December	O
1992	O
,	O
231	O
patients	O
with	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
-	O
positive	O
or	O
ER	S-geneY
-	O
unknown	O
metastatic	O
breast	O
cancer	O
were	O
randomized	O
to	O
receive	O
either	O
chemotherapy	O
(	O
cyclophosphamide	S-chem
,	O
doxorubicin	S-chem
,	O
and	O
fluorouracil	S-chem
inverted	O
question	O
markCAF	O
)	O
or	O
chemohormonal	O
therapy	O
(	O
CAF	O
plus	O
tamoxifen	S-chem
and	O
Halotestin	S-chem
inverted	O
question	O
markfluoxymesterone	O
;	O
Pharmacia	O
-	O
Upjohn	O
,	O
Kalamazoo	O
,	O
MI	O
inverted	O
question	O
markCAFTH	O
)	O
as	O
front	O
-	O
line	O
therapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

Patients	O
who	O
experienced	O
a	O
complete	O
response	O
to	O
induction	O
therapy	O
either	O
received	O
or	O
did	O
not	O
receive	O
maintenance	O
cyclophosphamide	S-chem
,	O
methotrexate	S-chem
,	O
fluorouracil	S-chem
,	O
prednisone	S-chem
,	O
and	O
TH	O
as	O
a	O
secondary	O
randomization	O
.	O

RESULTS	O
:	O
The	O
response	O
rates	O
(	O
complete	O
response	O
and	O
partial	O
response	O
)	O
of	O
patients	O
who	O
received	O
CAF	O
and	O
CAFTH	O
were	O
similar	O
(	O
69.2	O
%	O
v	O
68.9	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.99	O
)	O
.	O

Time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
was	O
slightly	O
longer	O
for	O
patients	O
who	O
received	O
chemohormonal	O
therapy	O
compared	O
with	O
chemotherapy	O
alone	O
patients	O
(	O
13.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=	O
.087	O
)	O
,	O
and	O
TTF	O
was	O
significantly	O
longer	O
in	O
ER	S-geneY
-	O
positive	O
compared	O
with	O
ER	S-geneY
-	O
negative	O
patients	O
(	O
17.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=	O
.048	O
)	O
.	O

However	O
,	O
ER	S-geneY
status	O
had	O
no	O
effect	O
on	O
overall	O
survival	O
(	O
30.0	O
months	O
for	O
CAF	O
v	O
29.3	O
months	O
for	O
CAFTH	O
)	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
potentially	O
hormone	O
-	O
sensitive	O
metastatic	O
breast	O
cancer	O
,	O
chemohormonal	O
therapy	O
prolongs	O
TTF	O
for	O
ER	S-geneY
-	O
positive	O
patients	O
without	O
improving	O
overall	O
survival	O
.	O

GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
,	O
seizures	O
,	O
and	O
the	O
amygdala	O
.	O

The	O
amygdala	O
is	O
a	O
critical	O
brain	O
region	O
for	O
limbic	O
seizure	O
activity	O
,	O
but	O
the	O
mechanisms	O
underlying	O
its	O
epileptic	O
susceptibility	O
are	O
obscure	O
.	O

Several	O
lines	O
of	O
evidence	O
implicate	O
GluR5	S-geneY
(	O
GLU	B-geneY
(	I-geneY
K5	I-geneY
)	E-geneY
)	O
kainate	B-geneN
receptors	E-geneN
,	O
a	O
type	O
of	O
ionotropic	B-geneN
glutamate	I-geneN
receptor	E-geneN
,	O
in	O
the	O
amygdala	O
's	O
vulnerability	O
to	O
seizures	O
and	O
epileptogenesis	O
.	O

GluR5	S-geneY
mRNA	O
is	O
abundant	O
in	O
temporal	O
lobe	O
structures	O
including	O
the	O
amygdala	O
.	O

Brain	O
slice	O
recordings	O
indicate	O
that	O
GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
mediate	O
a	O
portion	O
of	O
the	O
synaptic	O
excitation	O
of	O
neurons	O
in	O
the	O
rat	O
basolateral	O
amygdala	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
studies	O
demonstrate	O
that	O
GluR5	S-geneY
kainate	B-geneN
receptor	E-geneN
-	O
mediated	O
synaptic	O
currents	O
are	O
inwardly	O
rectifying	O
and	O
are	O
likely	O
to	O
be	O
calcium	S-chem
permeable	O
.	O

Prolonged	O
activation	O
of	O
basolateral	O
amygdala	O
GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
results	O
in	O
enduring	O
synaptic	O
facilitation	O
through	O
a	O
calcium	S-chem
-	O
dependent	O
process	O
.	O

The	O
selective	O
GluR5	S-geneY
kainate	B-geneN
receptor	E-geneN
agonist	O
ATPA	O
induces	O
spontaneous	O
epileptiform	O
bursting	O
that	O
is	O
sensitive	O
to	O
the	O
GluR5	S-geneY-C6-2
kainate	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
LY293558	S-chem-C6-1
.	O

Intra	O
-	O
amygdala	O
infusion	O
of	O
ATPA	O
in	O
the	O
rat	O
induces	O
limbic	O
status	O
epilepticus	O
;	O
in	O
some	O
animals	O
,	O
recurrent	O
spontaneous	O
seizures	O
occur	O
for	O
months	O
after	O
the	O
ATPA	O
treatment	O
.	O

Together	O
,	O
these	O
observations	O
indicate	O
that	O
GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
have	O
a	O
unique	O
role	O
in	O
triggering	O
epileptiform	O
activity	O
in	O
the	O
amygdala	O
and	O
could	O
participate	O
in	O
long	O
-	O
term	O
plasticity	O
mechanisms	O
that	O
underlie	O
some	O
forms	O
of	O
epileptogenesis	O
.	O

Accordingly	O
,	O
GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
represent	O
a	O
potential	O
target	O
for	O
antiepileptic	O
and	O
antiepileptogenic	O
drug	O
treatments	O
.	O

Most	O
antiepileptic	O
drugs	O
do	O
not	O
act	O
through	O
effects	O
on	O
glutamate	B-geneN
receptors	E-geneN
.	O

However	O
,	O
topiramate	S-chem-C4-1
at	O
low	O
concentrations	O
causes	O
slow	O
inhibition	O
of	O
GluR5	S-geneY-C4-2
kainate	B-geneN-C4-2
receptor	E-geneN-C4-2
-	O
mediated	O
synaptic	O
currents	O
in	O
the	O
basolateral	O
amygdala	O
,	O
indicating	O
that	O
it	O
may	O
protect	O
against	O
seizures	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
suppression	O
of	O
GluR5	S-geneY-C4-2
kainate	B-geneN-C4-2
receptor	E-geneN-C4-2
responses	O
.	O

Comparison	O
of	O
cyclooxygenase	S-geneN-C4-2
inhibitory	O
activity	O
and	O
ocular	O
anti	O
-	O
inflammatory	O
effects	O
of	O
ketorolac	B-chem-C4-1
tromethamine	E-chem-C4-1
and	O
bromfenac	B-chem-C4-1
sodium	E-chem-C4-1
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
cyclooxygenase	S-geneN
(	O
COX	S-geneN
)	O
activity	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
the	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
ketorolac	B-chem
tromethamine	E-chem
(	O
ketorolac	S-chem
)	O
and	O
bromfenac	B-chem
sodium	E-chem
(	O
bromfenac	S-chem
)	O
.	O

METHODS	O
:	O
Cyclooxygenase	S-geneN-C9-2
activity	O
and	O
selectivity	O
was	O
determined	O
in	O
vitro	O
by	O
measuring	O
prostaglandin	B-chem-C9-1
E	I-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
(	O
PGE	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
)	O
production	O
following	O
incubation	O
of	O
varying	O
concentrations	O
of	O
NSAID	O
with	O
human	B-geneY
recombinant	I-geneY
COX	I-geneY
-	I-geneY
1	E-geneY
or	O
COX	B-geneY
-	I-geneY
2	E-geneY
and	O
arachidonic	B-chem
acid	E-chem
.	O

Anti	O
-	O
inflammatory	O
effects	O
were	O
evaluated	O
in	O
a	O
rabbit	O
model	O
in	O
which	O
an	O
ocular	O
inflammatory	O
response	O
was	O
induced	O
by	O
intravenous	O
injection	O
of	O
10	O
microg	O
/	O
kg	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
study	O
animals	O
,	O
one	O
eye	O
was	O
treated	O
with	O
50	O
microL	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
ketorolac	E-chem
0.4	O
%	O
(	O
Acular	B-chem
LS	E-chem
)	O
or	O
bromfenac	S-chem
0.09	O
%	O
(	O
Xibrom	S-chem
)	O
and	O
the	O
other	O
eye	O
with	O
50	O
microL	O
buffered	O
saline	O
.	O

In	O
control	O
animals	O
,	O
both	O
eyes	O
were	O
treated	O
with	O
vehicle	O
.	O

All	O
animals	O
were	O
treated	O
twice	O
:	O
2	O
hours	O
and	O
1	O
hour	O
before	O
LPS	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
production	O
in	O
vitro	O
,	O
measured	O
by	O
enzyme	O
immunoassay	O
;	O
fluorescein	B-chem
isothiocyanate	E-chem
(	O
FITC	S-chem
)	O
-	O
dextran	O
leakage	O
into	O
the	O
anterior	O
chamber	O
,	O
measured	O
by	O
fluorophotometry	O
;	O
aqueous	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
levels	O
in	O
vivo	O
,	O
measured	O
by	O
ELISA	O
immunoassay	O
.	O

RESULTS	O
:	O
Ketorolac	S-chem-C4-1
was	O
six	O
times	O
more	O
active	O
against	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
=	O
0.02	O
microM	O
)	O
than	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
=	O
0.12	O
microM	O
)	O
while	O
bromfenac	S-chem-C4-1
was	O
approximately	O
32	O
times	O
more	O
active	O
against	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
=	O
0.0066	O
microM	O
)	O
than	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
=	O
0.210	O
microM	O
)	O
.	O

In	O
the	O
animal	O
model	O
,	O
both	O
drugs	O
resulted	O
in	O
nearly	O
complete	O
inhibition	O
of	O
FITC	S-chem
-	O
dextran	O
leakage	O
and	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
production	O
in	O
the	O
anterior	O
chamber	O
of	O
treated	O
eyes	O
.	O

There	O
was	O
also	O
a	O
79	O
%	O
inhibition	O
(	O
p	O
<	O
0.001	O
)	O
of	O
FITC	S-chem
-	O
dextran	O
leakage	O
in	O
the	O
contralateral	O
eyes	O
of	O
bromfenac	S-chem
-	O
treated	O
rabbits	O
,	O
and	O
a	O
22.5	O
%	O
inhibition	O
(	O
not	O
statistically	O
significant	O
)	O
in	O
the	O
contralateral	O
eyes	O
of	O
ketorolac	S-chem
-	O
treated	O
rabbits	O
.	O

CONCLUSIONS	O
:	O
Ketorolac	S-chem
is	O
relatively	O
COX	B-geneY
-	I-geneY
1	E-geneY
selective	O
while	O
bromfenac	S-chem
is	O
potently	O
selective	O
for	O
COX	B-geneY
-	I-geneY
2	E-geneY
over	O
COX	B-geneY
-	I-geneY
1	E-geneY
.	O

In	O
the	O
animal	O
model	O
,	O
both	O
ketorolac	S-chem
0.4	O
%	O
and	O
bromfenac	S-chem
0.09	O
%	O
demonstrated	O
maximal	O
anti	O
-	O
inflammatory	O
activity	O
in	O
treated	O
eyes	O
.	O

Only	O
bromfenac	S-chem
0.09	O
%	O
had	O
a	O
significant	O
effect	O
on	O
the	O
contralateral	O
eye	O
,	O
suggesting	O
possible	O
systemic	O
absorption	O
of	O
this	O
drug	O
.	O

The	O
role	O
of	O
combination	O
medical	O
therapy	O
in	O
benign	O
prostatic	O
hyperplasia	O
.	O

To	O
review	O
key	O
trials	O
of	O
monotherapy	O
and	O
combination	O
therapy	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenergic	I-geneN
receptor	E-geneN
antagonists	O
(	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
)	O
,	O
5alpha	B-geneN
-	I-geneN
reductase	E-geneN
inhibitors	O
(	O
5alphaRIs	O
)	O
and	O
anti	O
-	O
muscarinic	O
agents	O
in	O
the	O
treatment	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

To	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
therapies	O
for	O
LUTS	O
associated	O
with	O
BPH	O
,	O
a	O
search	O
of	O
the	O
MEDLINE	O
and	O
Cochrane	O
databases	O
(	O
1976	O
-	O
2008	O
)	O
was	O
conducted	O
for	O
relevant	O
trials	O
and	O
reviews	O
using	O
the	O
terms	O
benign	O
prostatic	O
hyperplasia	O
,	O
lower	O
urinary	O
tract	O
symptoms	O
,	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenergic	I-geneN
receptor	E-geneN
antagonists	O
,	O
5alpha	B-geneN
-	I-geneN
reductase	E-geneN
inhibitors	O
,	O
anti	O
-	O
muscarinics	O
,	O
anticholinergics	O
,	O
combination	O
therapy	O
,	O
alfuzosin	S-chem
,	O
doxazosin	S-chem
,	O
tamsulosin	S-chem
,	O
terazosin	S-chem
,	O
dutasteride	S-chem
,	O
finasteride	S-chem
,	O
tolterodine	S-chem
,	O
flavoxate	S-chem
,	O
propiverine	S-chem
,	O
oxybutynin	S-chem
,	O
erectile	O
dysfunction	O
,	O
sildenafil	S-chem
,	O
vardenafil	S-chem
and	O
tadalafil	S-chem
.	O

Data	O
from	O
the	O
Medical	O
Therapy	O
of	O
Prostatic	O
Symptoms	O
(	O
MTOPS	O
)	O
study	O
indicated	O
a	O
role	O
for	O
long	O
-	O
term	O
use	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
5alphaRIs	O
in	O
combination	O
.	O

In	O
the	O
MTOPS	O
study	O
,	O
combination	O
therapy	O
with	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
doxazosin	S-chem
and	O
the	O
5alphaRI	O
finasteride	S-chem
was	O
significantly	O
more	O
effective	O
than	O
either	O
component	O
alone	O
in	O
reducing	O
symptoms	O
(	O
P	O
=	O
0.006	O
vs	O
doxazosin	S-chem
monotherapy	O
;	O
P	O
<	O
0.001	O
vs	O
finasteride	O
monotherapy	O
)	O
and	O
in	O
lowering	O
the	O
rate	O
of	O
clinical	O
progression	O
(	O
P	O
<	O
0.001	O
vs	O
either	O
monotherapy	O
)	O
.	O

These	O
findings	O
were	O
confirmed	O
by	O
the	O
2	O
-	O
year	O
preliminary	O
results	O
of	O
the	O
Combination	O
of	O
Avodart	S-chem
and	O
Tamsulosin	S-chem
study	O
.	O

In	O
this	O
study	O
,	O
combination	O
therapy	O
of	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
tamsulosin	S-chem
and	O
the	O
5alphaRI	O
dutasteride	S-chem
resulted	O
in	O
a	O
significantly	O
greater	O
decrease	O
in	O
International	O
Prostate	O
Symptom	O
Score	O
(	O
IPSS	O
)	O
when	O
compared	O
with	O
either	O
monotherapy	O
.	O

Several	O
recent	O
trials	O
have	O
studied	O
the	O
efficacy	O
of	O
combining	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
anti	O
-	O
muscarinic	O
agents	O
in	O
the	O
treatment	O
of	O
BPH	O
.	O

These	O
studies	O
have	O
found	O
this	O
combination	O
to	O
result	O
in	O
statistically	O
significant	O
benefits	O
in	O
quality	O
of	O
life	O
scores	O
,	O
patient	O
satisfaction	O
,	O
urinary	O
frequency	O
,	O
storage	O
symptoms	O
and	O
IPSS	O
scores	O
.	O

Studies	O
have	O
not	O
shown	O
an	O
increased	O
risk	O
of	O
urinary	O
retention	O
associated	O
with	O
the	O
use	O
of	O
anti	O
-	O
muscarinics	O
in	O
a	O
highly	O
select	O
cohort	O
of	O
men	O
with	O
BPH	O
.	O

The	O
available	O
data	O
suggest	O
that	O
combination	O
therapy	O
can	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
BPH	O
and	O
associated	O
LUTS	O
.	O

The	O
greatest	O
efficacy	O
for	O
the	O
alpha	O
(	O
1	O
)	O
-	O
ARA	O
and	O
5alphaRI	O
combination	O
was	O
shown	O
in	O
patients	O
with	O
larger	O
prostate	O
size	O
and	O
more	O
severe	O
symptoms	O
.	O

The	O
combination	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
and	O
5alphaRIs	O
appears	O
to	O
prevent	O
disease	O
progression	O
in	O
these	O
patients	O
.	O

The	O
combination	O
of	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
with	O
anti	O
-	O
muscarinic	O
agents	O
is	O
useful	O
for	O
relieving	O
symptoms	O
of	O
bladder	O
outlet	O
obstruction	O
and	O
detrusor	O
overactivity	O
.	O

Theoretic	O
concerns	O
regarding	O
the	O
risk	O
of	O
acute	O
urinary	O
retention	O
have	O
been	O
refuted	O
in	O
several	O
recent	O
clinical	O
trials	O
;	O
however	O
,	O
it	O
must	O
be	O
noted	O
that	O
the	O
patients	O
in	O
these	O
trials	O
were	O
a	O
highly	O
select	O
cohort	O
of	O
men	O
.	O

Men	O
with	O
overactive	O
bladder	O
and	O
BPH	O
who	O
are	O
not	O
receiving	O
adequate	O
alleviation	O
of	O
symptoms	O
from	O
the	O
first	O
-	O
line	O
alpha	O
(	O
1	O
)	O
-	O
ARAs	O
may	O
benefit	O
from	O
the	O
addition	O
of	O
an	O
anti	O
-	O
muscarinic	O
agent	O
.	O

A	O
mutation	O
in	O
the	O
FAM36A	S-geneY
gene	O
,	O
the	O
human	O
ortholog	O
of	O
COX20	S-geneN
,	O
impairs	O
cytochrome	B-geneN
c	I-geneN
oxidase	E-geneN
assembly	O
and	O
is	O
associated	O
with	O
ataxia	O
and	O
muscle	O
hypotonia	O
.	O

The	O
mitochondrial	B-geneN-C9-2
respiratory	I-geneN-C9-2
chain	I-geneN-C9-2
complex	I-geneN-C9-2
IV	E-geneN-C9-2
(	O
cytochrome	B-geneN-C9-2
c	I-geneN-C9-2
oxidase	E-geneN-C9-2
)	O
is	O
a	O
multi	O
-	O
subunit	O
enzyme	O
that	O
transfers	O
electrons	O
from	O
cytochrome	B-geneY
c	E-geneY
to	O
molecular	O
oxygen	S-chem-C9-1
,	O
yielding	O
water	O
.	O

Its	O
biogenesis	O
requires	O
concerted	O
expression	O
of	O
mitochondria	O
-	O
and	O
nuclear	O
-	O
encoded	O
subunits	O
and	O
assembly	O
factors	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
homozygous	O
missense	O
mutation	O
in	O
FAM36A	S-geneY
from	O
a	O
patient	O
who	O
displays	O
ataxia	O
and	O
muscle	O
hypotonia	O
.	O

The	O
FAM36A	S-geneY
gene	O
is	O
a	O
remote	O
,	O
putative	O
ortholog	O
of	O
the	O
fungal	B-geneN
complex	I-geneN
IV	I-geneN
assembly	I-geneN
factor	E-geneN
COX20	S-geneN
.	O

Messenger	O
RNA	O
(	O
mRNA	O
)	O
and	O
protein	O
co	O
-	O
expression	O
analyses	O
support	O
the	O
involvement	O
of	O
FAM36A	S-geneY
in	O
complex	B-geneN
IV	E-geneN
function	O
in	O
mammals	O
.	O

The	O
c.154A	B-geneN
>	I-geneN
C	E-geneN
mutation	O
in	O
the	O
FAM36A	S-geneY
gene	O
,	O
a	O
mutation	O
that	O
is	O
absent	O
in	O
sequenced	O
exomes	O
,	O
leads	O
to	O
a	O
reduced	O
activity	O
and	O
lower	O
levels	O
of	O
complex	B-geneN
IV	E-geneN
and	O
its	O
protein	O
subunits	O
.	O

The	O
FAM36A	S-geneY
protein	O
is	O
nearly	O
absent	O
in	O
patient	O
's	O
fibroblasts	O
.	O

Cells	O
affected	O
by	O
the	O
mutation	O
accumulate	O
subassemblies	O
of	O
complex	B-geneN
IV	E-geneN
that	O
contain	O
COX1	S-geneY
but	O
are	O
almost	O
devoid	O
of	O
COX2	S-geneY
protein	O
.	O

We	O
observe	O
co	O
-	O
purification	O
of	O
FAM36A	S-geneY
and	O
COX2	S-geneY
proteins	O
,	O
supporting	O
that	O
the	O
FAM36A	S-geneY
defect	O
hampers	O
the	O
early	O
step	O
of	O
complex	B-geneN
IV	E-geneN
assembly	O
at	O
the	O
incorporation	O
of	O
the	O
COX2	S-geneY
subunit	O
.	O

Lentiviral	O
complementation	O
of	O
patient	O
's	O
fibroblasts	O
with	O
wild	O
-	O
type	O
FAM36A	S-geneY
increases	O
the	O
complex	B-geneN
IV	E-geneN
activity	O
as	O
well	O
as	O
the	O
amount	O
of	O
holocomplex	B-geneN
IV	E-geneN
and	O
of	O
individual	O
subunits	O
.	O

These	O
results	O
establish	O
the	O
function	O
of	O
the	O
human	B-geneY
gene	I-geneY
FAM36A	E-geneY
/	O
COX20	S-geneY
in	O
complex	B-geneN
IV	E-geneN
assembly	O
and	O
support	O
a	O
causal	O
role	O
of	O
the	O
gene	O
in	O
complex	B-geneN
IV	E-geneN
deficiency	O
.	O

Aberrant	O
regulation	O
of	O
argininosuccinate	B-geneY
synthetase	E-geneY
by	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
in	O
human	O
epithelial	O
ovarian	O
cancer	O
.	O

The	O
pro	O
-	O
inflammatory	O
cytokine	S-geneN
,	O
tumour	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
,	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
,	O
is	O
dysregulated	O
in	O
malignant	O
compared	O
with	O
normal	O
ovarian	O
surface	O
epithelium	O
(	O
OSE	O
)	O
.	O

Several	O
epidemiological	O
studies	O
have	O
associated	O
inflammation	O
with	O
ovarian	O
tumorigenesis	O
,	O
with	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
playing	O
a	O
key	O
role	O
in	O
modulating	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

Here	O
,	O
we	O
show	O
that	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
also	O
induces	O
expression	O
of	O
arate	O
-	O
limiting	O
enzyme	O
in	O
arginine	S-chem
synthesis	O
,	O
argininosuccinate	B-geneY
synthetase	E-geneY
(	O
AS	S-geneY
)	O
,	O
thereby	O
linking	O
inflammation	O
with	O
several	O
arginine	S-chem
-	O
dependent	O
metabolic	O
pathways	O
,	O
implicated	O
in	O
accelerated	O
carcinogenesis	O
and	O
tumour	O
progression	O
.	O

Having	O
identified	O
AS	S-geneY
mRNA	O
induction	O
in	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
-	O
treated	O
IGROV	O
-	O
1	O
ovarian	O
cancer	O
cells	O
,	O
using	O
RNA	O
-	O
arbitrarily	O
primed	O
-	O
PCR	O
,	O
we	O
then	O
observed	O
differential	O
regulation	O
of	O
AS	S-geneY
mRNA	O
and	O
protein	O
in	O
malignant	O
,	O
compared	O
with	O
normal	O
,	O
OSE	O
cells	O
.	O

A	O
cDNA	O
cancer	O
profiling	O
array	O
with	O
matched	O
normal	O
ovarian	O
and	O
ovarian	O
tumour	O
samples	O
revealed	O
increased	O
expression	O
of	O
AS	S-geneY
mRNA	O
in	O
the	O
latter	O
.	O

Moreover	O
,	O
AS	S-geneY
protein	O
co	O
-	O
localised	O
with	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
in	O
ovarian	O
cancer	O
cells	O
,	O
with	O
significantly	O
higher	O
levels	O
of	O
AS	S-geneY
in	O
malignant	O
compared	O
with	O
normal	O
ovarian	O
tissue	O
.	O

Increased	O
co	O
-	O
expression	O
of	O
AS	S-geneY
and	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
mRNA	O
was	O
also	O
observed	O
in	O
2	O
other	O
epithelial	O
tumours	O
,	O
non	O
-	O
small	O
cell	O
lung	O
and	O
stomach	O
cancer	O
,	O
compared	O
with	O
normal	O
corresponding	O
tissues	O
.	O

In	O
summary	O
,	O
high	O
levels	O
of	O
AS	S-geneY
expression	O
,	O
which	O
may	O
be	O
required	O
for	O
several	O
arginine	S-chem
-	O
dependent	O
processes	O
in	O
cancer	O
,	O
including	O
the	O
production	O
of	O
nitric	B-chem
oxide	E-chem
,	O
proline	S-chem
,	O
pyrimidines	S-chem
and	O
polyamines	S-chem
,	O
is	O
regulated	O
by	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
and	O
may	O
provide	O
an	O
important	O
molecular	O
pathway	O
linking	O
inflammation	O
and	O
metabolism	O
to	O
ovarian	O
tumorigenesis	O
.	O

Herbicidal	O
inhibitors	O
of	O
amino	B-chem
acid	E-chem
biosynthesis	O
and	O
herbicide	O
-	O
tolerant	O
crops	O
.	O

Acetohydroxyacid	B-geneN
synthase	E-geneN
(	O
AHAS	S-geneN
)	O
inhibitors	O
interfere	O
with	O
branched	B-chem
-	I-chem
chain	I-chem
amino	I-chem
acid	E-chem
biosynthesis	O
by	O
inhibiting	O
AHAS	S-geneN
.	O

Glyphosate	S-chem-C4-1
affects	O
aromatic	B-chem
amino	I-chem
acid	E-chem
biosynthesis	O
by	O
inhibiting	O
5	B-geneN-C4-2
-	I-geneN-C4-2
enolpyruvylshikimate	I-geneN-C4-2
-	I-geneN-C4-2
3	I-geneN-C4-2
-	I-geneN-C4-2
phosphate	I-geneN-C4-2
synthase	E-geneN-C4-2
(	O
EPSPS	S-geneN-C4-2
)	O
.	O

Glufosinate	S-chem-C4-1
inhibits	O
glutamine	B-geneN-MU-2
synthetase	E-geneN-MU-2
and	O
blocks	O
biosynthesis	O
of	O
glutamine	S-chem-C9-1
.	O

AHAS	S-geneN
gene	O
variants	O
that	O
confer	O
tolerance	O
to	O
AHAS	S-geneN
inhibitors	O
have	O
been	O
discovered	O
in	O
plants	O
through	O
selection	O
or	O
mutagenesis	O
.	O

Imidazolinone	S-chem
-	O
tolerant	O
crops	O
have	O
been	O
commercialized	O
based	O
on	O
these	O
AHAS	S-geneN
gene	O
variants	O
.	O

A	O
modified	O
maize	B-geneY
EPSPS	E-geneY
gene	O
and	O
CP4	O
-	O
EPSPS	S-geneY
gene	O
from	O
Agrobacterium	O
sp	O
.	O
have	O
been	O
used	O
to	O
transform	O
plants	O
for	O
target	O
-	O
based	O
tolerance	O
to	O
glyphosate	S-chem
.	O

A	O
gox	S-geneN
gene	O
isolated	O
from	O
Ochrobactrum	O
anthropi	O
has	O
also	O
been	O
employed	O
to	O
encode	O
glyphosate	B-geneN
oxidoreductase	E-geneN
to	O
detoxify	O
glyphosate	S-chem
in	O
plants	O
.	O

Glyphosate	S-chem
-	O
tolerant	O
crops	O
with	O
EPSPS	S-geneN
transgene	O
alone	O
or	O
both	O
EPSPS	S-geneN
and	O
gox	S-geneN
transgenes	O
have	O
been	O
commercialized	O
.	O

Similarly	O
,	O
bar	S-geneY
and	O
pat	S-geneY
genes	O
isolated	O
from	O
Streptomyces	O
hygroscopicus	O
and	O
S.	O
viridochromogenes	O
,	O
respectively	O
,	O
have	O
been	O
inserted	O
into	O
plants	O
to	O
encode	O
phosphinothricin	B-geneN
N	I-geneN
-	I-geneN
acetyltransferase	E-geneN
to	O
detoxify	O
glufosinate	S-chem
.	O

Glufosinate	S-chem
-	O
tolerant	O
crops	O
have	O
been	O
commercialized	O
using	O
one	O
of	O
these	O
two	O
transgenes	O
.	O

Profiling	O
976	O
ToxCast	O
chemicals	O
across	O
331	O
enzymatic	O
and	O
receptor	O
signaling	O
assays	O
.	O

Understanding	O
potential	O
health	O
risks	O
is	O
a	O
significant	O
challenge	O
due	O
to	O
large	O
numbers	O
of	O
diverse	O
chemicals	O
with	O
poorly	O
characterized	O
exposures	O
and	O
mechanisms	O
of	O
toxicities	O
.	O

The	O
present	O
study	O
analyzes	O
976	O
chemicals	O
(	O
including	O
failed	O
pharmaceuticals	O
,	O
alternative	O
plasticizers	O
,	O
food	O
additives	O
,	O
and	O
pesticides	O
)	O
in	O
Phase	O
I	O
and	O
II	O
of	O
the	O
U.S	O
.	O

EPA	O
's	O
ToxCast	O
™	O
project	O
across	O
331	O
cell	O
-	O
free	O
enzymatic	O
and	O
ligand	O
-	O
binding	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
assays	O
.	O

Half	O
-	O
maximal	O
activity	O
concentrations	O
(	O
AC50	O
)	O
were	O
identified	O
for	O
729	O
chemicals	O
in	O
256	O
assays	O
(	O
7,135	O
chemical	O
-	O
assay	O
pairs	O
)	O
.	O

Some	O
of	O
the	O
most	O
commonly	O
affected	O
assays	O
were	O
CYPs	S-geneN
(	O
CYP2C9	S-geneY
,	O
CYP2C19	S-geneY
)	O
,	O
transporters	O
(	O
mitochondrial	O
TSPO	O
,	O
norepinephrine	S-chem
,	O
dopaminergic	O
)	O
,	O
and	O
GPCRs	S-geneN
(	O
aminergic	O
)	O
.	O

Heavy	O
metals	O
,	O
surfactants	O
,	O
and	O
dithiocarbamate	S-chem
fungicides	O
showed	O
promiscuous	O
,	O
but	O
distinctly	O
different	O
patterns	O
of	O
activity	O
whereas	O
many	O
of	O
the	O
pharma	O
compounds	O
showed	O
promiscuous	O
activity	O
across	O
GPCRs	S-geneN
.	O

Literature	O
analysis	O
confirmed	O
>	O
50	O
%	O
of	O
the	O
activities	O
for	O
the	O
most	O
potent	O
chemical	O
-	O
assay	O
pairs	O
(	O
56	O
)	O
,	O
but	O
also	O
revealed	O
10	O
missed	O
interactions	O
.	O

Twenty	O
-	O
two	O
chemicals	O
with	O
known	O
estrogenic	O
activity	O
were	O
correctly	O
identified	O
for	O
the	O
majority	O
(	O
77	O
%	O
)	O
,	O
missing	O
only	O
the	O
weaker	O
interactions	O
.	O

In	O
many	O
cases	O
,	O
novel	O
findings	O
for	O
previously	O
unreported	O
chemical	O
-	O
target	O
combinations	O
clustered	O
with	O
known	O
chemical	O
-	O
target	O
interactions	O
.	O

Results	O
from	O
this	O
large	O
inventory	O
of	O
chemical	O
-	O
biological	O
interactions	O
can	O
inform	O
read	O
-	O
across	O
methods	O
as	O
well	O
as	O
to	O
link	O
potential	O
targets	O
to	O
molecular	O
initiating	O
events	O
in	O
adverse	O
outcome	O
pathways	O
for	O
diverse	O
toxicities	O
.	O

This	O
abstract	O
does	O
not	O
necessarily	O
reflect	O
U.S	O
.	O

EPA	O
policy	O
.	O

Effects	O
of	O
age	O
and	O
sex	O
on	O
the	O
disposition	O
of	O
retigabine	S-chem
.	O

BACKGROUND	O
:	O
The	O
novel	O
antiepileptic	O
drug	O
retigabine	S-chem-C3-1
is	O
the	O
first	O
selective	O
M	B-geneN-C3-2
-	I-geneN-C3-2
current	I-geneN-C3-2
potassium	I-geneN-C3-2
channel	E-geneN-C3-2
opener	O
for	O
KCNQ2	B-geneN-C3-2
/	I-geneN-C3-2
3	E-geneN-C3-2
and	O
KCNQ3	B-geneN-C3-2
/	I-geneN-C3-2
5	E-geneN-C3-2
channels	O
.	O

Retigabine	S-chem
undergoes	O
phase	O
II	O
metabolism	O
(	O
N	S-chem
-	O
glucuronidation	O
,	O
acetylation	O
)	O
exclusively	O
and	O
renal	O
excretion	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
age	O
and	O
sex	O
on	O
the	O
pharmacokinetics	O
of	O
retigabine	S-chem
.	O

METHODS	O
:	O
Healthy	O
young	O
(	O
age	O
range	O
,	O
18	O
-	O
40	O
years	O
)	O
and	O
elderly	O
(	O
age	O
range	O
,	O
66	O
-	O
81	O
years	O
)	O
white	O
subjects	O
(	O
12	O
men	O
and	O
12	O
women	O
in	O
each	O
group	O
)	O
received	O
a	O
single	O
200	O
-	O
mg	O
oral	O
dose	O
of	O
retigabine	S-chem
.	O

After	O
dosing	O
,	O
blood	O
was	O
collected	O
over	O
a	O
72	O
-	O
hour	O
period	O
to	O
determine	O
plasma	O
concentrations	O
of	O
retigabine	S-chem
and	O
its	O
acetylated	O
metabolite	O
,	O
AWD21	B-chem
-	I-chem
360	E-chem
.	O

Pharmacokinetics	O
was	O
compared	O
for	O
age	O
group	O
and	O
sex	O
by	O
ANOVA	O
.	O

RESULTS	O
:	O
In	O
young	O
men	O
,	O
retigabine	S-chem
was	O
rapidly	O
absorbed	O
,	O
with	O
the	O
maximum	O
concentration	O
occurring	O
within	O
2	O
hours	O
,	O
and	O
was	O
eliminated	O
with	O
an	O
apparent	O
clearance	O
of	O
0.67	O
L	O
x	O
h	O
(	O
-	O
1	O
)	O
x	O
kg	O
(	O
-	O
1	O
)	O
and	O
a	O
mean	O
terminal	O
half	O
-	O
life	O
of	O
8.5	O
hours	O
.	O

Subjects	O
were	O
similarly	O
exposed	O
to	O
AWD21	B-chem
-	I-chem
360	E-chem
.	O

Compared	O
with	O
young	O
men	O
,	O
young	O
women	O
had	O
higher	O
retigabine	S-chem
maximum	O
concentration	O
(	O
56	O
%	O
)	O
and	O
exposure	O
(	O
20	O
%	O
)	O
but	O
similar	O
clearance	O
(	O
0.68	O
L	O
x	O
h	O
(	O
-	O
1	O
)	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
;	O
these	O
differences	O
were	O
related	O
to	O
differences	O
in	O
body	O
weight	O
.	O

Although	O
maximum	O
concentration	O
was	O
similar	O
in	O
elderly	O
subjects	O
,	O
retigabine	S-chem
elimination	O
was	O
slower	O
(	O
30	O
%	O
lower	O
apparent	O
clearance	O
normalized	O
for	O
weight	O
)	O
,	O
resulting	O
in	O
higher	O
exposure	O
(	O
42	O
%	O
)	O
and	O
a	O
longer	O
half	O
-	O
life	O
(	O
30	O
%	O
)	O
.	O

Because	O
phase	O
II	O
metabolism	O
is	O
scarcely	O
affected	O
by	O
age	O
,	O
these	O
differences	O
may	O
be	O
related	O
to	O
the	O
known	O
decline	O
of	O
renal	O
function	O
with	O
age	O
.	O

CONCLUSIONS	O
:	O
Although	O
there	O
are	O
no	O
substantial	O
sex	O
-	O
related	O
differences	O
in	O
the	O
disposition	O
of	O
retigabine	S-chem
,	O
a	O
relevant	O
decrease	O
in	O
clearance	O
resulting	O
in	O
higher	O
exposure	O
occurs	O
in	O
elderly	O
patients	O
.	O

The	O
results	O
suggest	O
that	O
decline	O
of	O
renal	O
function	O
with	O
age	O
may	O
account	O
for	O
some	O
of	O
the	O
observed	O
changes	O
.	O

Effects	O
of	O
fenofibrate	S-chem
,	O
a	O
PPAR	B-geneY
-	I-geneY
α	E-geneY
ligand	O
,	O
on	O
the	O
haemodynamics	O
of	O
glycerol	S-chem
-	O
induced	O
renal	O
failure	O
in	O
rats	O
.	O

The	O
modulating	O
effect	O
of	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
α	E-geneY
ligand	O
on	O
haemodynamic	O
effects	O
of	O
phenylepherine	S-chem
(	O
PE	O
)	O
,	O
angiotensin	B-geneY
II	E-geneY
(	O
AII	S-geneY
)	O
,	O
endothelin	B-geneY
1	E-geneY
(	O
ET1	S-geneY
)	O
,	O
acetylcholine	S-chem
(	O
Ach	S-chem
)	O
,	O
sodium	B-chem
nitroprusside	E-chem
(	O
SNP	S-chem
)	O
and	O
isoproterenol	S-chem
(	O
ISO	S-chem
)	O
were	O
evaluated	O
in	O
glycerol	S-chem
-	O
induced	O
acute	O
kidney	O
injury	O
in	O
rats	O
.	O

The	O
effect	O
of	O
PE	O
on	O
fenofibrate	S-chem
-	O
treated	O
animals	O
was	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
.	O

For	O
AII	S-geneY-C3-2
and	O
ET1	S-geneY-C3-2
,	O
MAP	O
was	O
also	O
increased	O
for	O
the	O
fenofibrate	S-chem-C3-1
group	O
but	O
not	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

On	O
the	O
medullary	O
blood	O
flow	O
(	O
MBF	O
)	O
,	O
while	O
the	O
lower	O
doses	O
of	O
PE	O
and	O
AII	S-geneY
increased	O
the	O
perfusion	O
unit	O
on	O
the	O
fenofibrate	S-chem
-	O
treated	O
group	O
,	O
the	O
higher	O
doses	O
decreased	O
the	O
perfusion	O
unit	O
.	O

The	O
ET1	S-geneY
increased	O
the	O
perfusion	O
unit	O
on	O
this	O
group	O
but	O
not	O
in	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
effects	O
of	O
PE	O
and	O
AII	S-geneY
on	O
the	O
cortical	O
blood	O
flow	O
(	O
CBF	O
)	O
of	O
fenofibrate	S-chem
-	O
treated	O
group	O
is	O
similar	O
to	O
that	O
of	O
MBF	O
for	O
the	O
same	O
group	O
but	O
not	O
for	O
ET1	S-geneY
.	O

The	O
effect	O
of	O
Ach	S-chem
,	O
SNP	S-chem
and	O
ISO	S-chem
in	O
all	O
the	O
groups	O
was	O
the	O
decrease	O
in	O
MAP	O
.	O

ISO	S-chem
caused	O
dose	O
-	O
dependent	O
increase	O
in	O
MBF	O
of	O
fenofibrate	S-chem
-	O
treated	O
group	O
.	O

The	O
effect	O
of	O
Ach	S-chem
,	O
SNP	S-chem
and	O
ISO	S-chem
on	O
the	O
CBF	O
perfusion	O
unit	O
was	O
that	O
of	O
the	O
increase	O
for	O
the	O
fenofibrate	S-chem
-	O
treated	O
group	O
.	O

The	O
study	O
showed	O
that	O
fenofibrate	S-chem
did	O
not	O
attenuate	O
increased	O
blood	O
pressure	O
induced	O
by	O
PE	O
,	O
AII	S-geneY
and	O
ET1	S-geneY
but	O
caused	O
enhanced	O
vasodilation	O
by	O
Ach	S-chem
,	O
SNP	S-chem
and	O
ISO	S-chem
.	O

Sex	O
differences	O
in	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
ketamine	S-chem
.	O

Current	O
medications	O
for	O
major	O
depression	O
suffer	O
from	O
numerous	O
limitations	O
.	O

Once	O
the	O
right	O
drug	O
for	O
treatment	O
has	O
been	O
determined	O
,	O
it	O
still	O
takes	O
several	O
weeks	O
for	O
it	O
to	O
take	O
effect	O
and	O
improve	O
mood	O
.	O

This	O
time	O
lag	O
is	O
a	O
serious	O
concern	O
for	O
the	O
healthcare	O
community	O
when	O
dealing	O
with	O
patients	O
with	O
suicidal	O
thoughts	O
.	O

However	O
,	O
recent	O
clinical	O
studies	O
have	O
shown	O
that	O
a	O
single	O
low	O
-	O
dose	O
injection	O
of	O
ketamine	S-chem-C6-1
,	O
an	O
N	B-geneN-C6-2
-	I-geneN-C6-2
methyl	I-geneN-C6-2
d	I-geneN-C6-2
-	I-geneN-C6-2
aspartate	I-geneN-C6-2
receptor	E-geneN-C6-2
(	O
NMDAR	S-geneN-C6-2
)	O
antagonist	O
,	O
has	O
rapid	O
antidepressant	O
effects	O
that	O
are	O
observed	O
within	O
hours	O
and	O
are	O
long	O
lasting	O
.	O

Although	O
major	O
depression	O
affects	O
twice	O
as	O
many	O
women	O
as	O
men	O
,	O
all	O
studies	O
examining	O
the	O
rapid	O
antidepressant	O
effects	O
of	O
ketamine	S-chem
have	O
focused	O
on	O
male	O
subjects	O
.	O

Thus	O
,	O
we	O
have	O
investigated	O
the	O
behavioral	O
and	O
molecular	O
effects	O
of	O
ketamine	S-chem
in	O
both	O
male	O
and	O
female	O
rats	O
and	O
demonstrated	O
greater	O
sensitivity	O
in	O
female	O
rats	O
at	O
a	O
low	O
dose	O
of	O
ketamine	S-chem
,	O
a	O
dose	O
does	O
not	O
have	O
antidepressant	O
-	O
like	O
effects	O
in	O
male	O
rats	O
.	O

The	O
antidepressant	O
-	O
like	O
effects	O
of	O
this	O
low	O
dose	O
of	O
ketamine	S-chem
were	O
completely	O
abolished	O
when	O
female	O
rats	O
were	O
ovariectomized	O
(	O
OVX	O
)	O
,	O
and	O
restored	O
when	O
physiological	O
levels	O
of	O
estrogen	S-chem
and	O
progesterone	S-chem
were	O
supplemented	O
,	O
suggesting	O
a	O
critical	O
role	O
for	O
gonadal	O
hormones	O
in	O
enhancing	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
ketamine	S-chem
in	O
female	O
rats	O
.	O

In	O
preclinical	O
studies	O
,	O
the	O
mammalian	B-geneY
target	I-geneY
of	I-geneY
rapamycin	E-geneY
(	O
mTOR	S-geneY
)	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
and	O
the	O
eukaryotic	B-geneN
elongation	I-geneN
factor	E-geneN
(	O
eEF2	S-geneY
)	O
in	O
the	O
hippocampus	O
have	O
been	O
proposed	O
as	O
critical	O
mediators	O
of	O
ketamine	S-chem
's	O
rapid	O
antidepressant	O
actions	O
.	O

In	O
our	O
hands	O
,	O
the	O
increased	O
sensitivity	O
of	O
female	O
rats	O
to	O
a	O
low	O
dose	O
of	O
ketamine	S-chem
was	O
not	O
mediated	O
through	O
phosphorylation	O
of	O
mTOR	S-geneY
or	O
eEF2	S-geneY
.	O

Role	O
of	O
cytochrome	B-geneY
P4502B6	E-geneY
in	O
methadone	S-chem
metabolism	O
and	O
clearance	O
.	O

Methadone	S-chem-C9-1
N	S-chem-C9-1
-	O
demethylation	O
in	O
vitro	O
is	O
catalyzed	O
by	O
hepatic	O
cytochrome	B-geneY-C9-2
P4502B6	E-geneY-C9-2
(	O
CYP2B6	S-geneY-C9-2
)	O
and	O
CYP3A4	S-geneY-C9-2
,	O
but	O
clinical	O
disposition	O
is	O
often	O
attributed	O
to	O
CYP3A4	S-geneY-C9-2
.	O

This	O
investigation	O
tested	O
the	O
hypothesis	O
that	O
CYP2B6	S-geneY-C9-2
is	O
a	O
prominent	O
CYP	S-geneN-C9-2
isoform	O
responsible	O
for	O
clinical	O
methadone	S-chem-C9-1
N	S-chem-C9-1
-	O
demethylation	O
and	O
clearance	O
,	O
using	O
the	O
in	O
vivo	O
mechanism	O
-	O
based	O
CYP2B6	S-geneY-C4-2
inhibitor	O
ticlopidine	S-chem-C4-1
,	O
given	O
orally	O
for	O
4	O
days	O
.	O

A	O
preliminary	O
clinical	O
investigation	O
with	O
the	O
CYP3A4	B-geneN
/	I-geneN
5	E-geneN
substrate	O
probe	O
alfentanil	S-chem
established	O
that	O
ticlopidine	S-chem
did	O
not	O
inhibit	O
intestinal	O
or	O
hepatic	O
CYP3A4	B-geneN
/	I-geneN
5	E-geneN
.	O

Subjects	O
received	O
intravenous	O
plus	O
oral	O
(	O
deuterium	S-chem
-	O
labeled	O
)	O
racemic	B-chem
methadone	E-chem
before	O
and	O
after	O
ticlopidine	S-chem
.	O

Ticlopidine	S-chem
significantly	O
and	O
stereoselectively	O
(	O
S	O
>	O
R	O
)	O
inhibited	O
methadone	O
N	I-chem
-	E-chem
demethylation	S-chem
,	O
decreasing	O
plasma	O
metabolite	O
/	O
methadone	O
area	O
under	O
the	O
curve	O
ratios	O
and	O
metabolite	O
formation	O
clearances	O
.	O

Ticlopidine	S-chem
also	O
significantly	O
increased	O
the	O
dose	O
-	O
adjusted	O
plasma	O
area	O
under	O
the	O
curve	O
for	O
R	B-chem
-	I-chem
and	I-chem
S	I-chem
-	I-chem
methadone	E-chem
by	O
20	O
%	O
and	O
60	O
%	O
,	O
respectively	O
,	O
after	O
both	O
intravenous	O
and	O
oral	O
dosing	O
.	O

CYP2B6	S-geneY
inhibition	O
reduces	O
methadone	S-chem
N	S-chem
-	O
demethylation	O
and	O
clearance	O
,	O
and	O
alters	O
methadone	S-chem
concentrations	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
CYP2B6	S-geneY-C9-2
in	O
clinical	O
methadone	S-chem-C9-1
disposition	O
.	O

Comparison	O
of	O
the	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibiting	O
properties	O
of	O
two	O
reversible	O
and	O
selective	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
inhibitors	O
moclobemide	S-chem-C4-1
and	O
toloxatone	S-chem-C4-1
,	O
and	O
assessment	O
of	O
their	O
effect	O
on	O
psychometric	O
performance	O
in	O
healthy	O
subjects	O
.	O

1	O
.	O

The	O
effects	O
of	O
two	O
reversible	O
,	O
predominantly	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
(	O
MAO	B-geneY
-	I-geneY
A	E-geneY
)	O
inhibitors	O
,	O
moclobemide	S-chem-C4-1
(	O
150	O
mg	O
three	O
times	O
daily	O
)	O
and	O
toloxatone	S-chem-C4-1
(	O
400	O
-	O
200	O
-	O
400	O
mg	O
day	O
-	O
1	O
)	O
on	O
monoamine	S-chem
metabolites	O
and	O
psychometric	O
performance	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
controlled	O
crossover	O
study	O
in	O
12	O
healthy	O
subjects	O
.	O

2	O
.	O

After	O
7	O
days	O
of	O
moclobemide	S-chem
/	O
toloxatone	S-chem
/	O
placebo	O
administration	O
subjects	O
were	O
hospitalized	O
for	O
24	O
h	O
on	O
day	O
8	O
.	O

Blood	O
samples	O
were	O
drawn	O
every	O
2	O
h	O
for	O
determination	O
of	O
plasma	O
noradrenaline	S-chem
(	O
NA	S-chem
)	O
,	O
3,4	B-chem
-	I-chem
dihydroxyphenylglycol	E-chem
(	O
DHPG	S-chem
)	O
,	O
homovanillic	B-chem
acid	E-chem
(	O
HVA	S-chem
)	O
and	O
5	B-chem
-	I-chem
hydroxyindolacetic	I-chem
acid	E-chem
(	O
5	B-chem
-	I-chem
HIAA	E-chem
)	O
.	O

Urine	O
was	O
collected	O
for	O
measurements	O
of	O
normetanephrine	S-chem
and	O
3	B-chem
-	I-chem
methoxytyramine	E-chem
excretion	O
.	O

Psychometric	O
performance	O
(	O
short	O
-	O
and	O
long	O
-	O
term	O
memory	O
,	O
critical	O
flicker	O
fusion	O
frequency	O
,	O
choice	O
reaction	O
time	O
)	O
and	O
subjective	O
feelings	O
were	O
assessed	O
before	O
each	O
drug	O
intake	O
(	O
in	O
the	O
morning	O
,	O
at	O
noon	O
,	O
in	O
the	O
evening	O
)	O
.	O

3	O
.	O

Compared	O
with	O
placebo	O
,	O
both	O
reversible	O
monoamine	B-geneN
oxidase	E-geneN
inhibitors	O
decreased	O
the	O
plasma	O
concentration	O
of	O
DHPG	S-chem
and	O
HVA	S-chem
.	O

The	O
overall	O
fall	O
in	O
DHPG	S-chem
(	O
AUC	O
from	O
0	O
to	O
24	O
h	O
)	O
was	O
44	O
%	O
during	O
moclobemide	S-chem
and	O
12	O
%	O
during	O
toloxatone	S-chem
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
the	O
overall	O
decrease	O
in	O
HVA	S-chem
was	O
38	O
%	O
and	O
20	O
%	O
(	O
P	O
less	O
than	O
0.005	O
)	O
on	O
moclobemide	S-chem
and	O
toloxatone	S-chem
,	O
respectively	O
.	O

4	O
.	O

Before	O
the	O
next	O
drug	O
intake	O
,	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
inhibition	O
,	O
as	O
judged	O
by	O
the	O
decrease	O
of	O
plasma	O
DHPG	S-chem
concentration	O
,	O
was	O
significantly	O
different	O
from	O
placebo	O
with	O
moclobemide	S-chem-C4-1
but	O
not	O
with	O
toloxatone	S-chem-C4-1
.	O

5	O
.	O

Moclobemide	S-chem
,	O
but	O
not	O
toloxatone	S-chem
,	O
exerted	O
a	O
moderate	O
,	O
but	O
significant	O
inhibition	O
of	O
the	O
deamination	O
of	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
as	O
judged	O
by	O
the	O
fall	O
in	O
plasma	O
5	B-chem
-	I-chem
HIAA	E-chem
concentration	O
.	O

Neither	O
drug	O
influenced	O
plasma	O
NA	S-chem
concentration	O
.	O

6	O
.	O

A	O
significant	O
rise	O
in	O
urinary	O
excretion	O
of	O
normetanephrine	S-chem
was	O
observed	O
on	O
moclobemide	S-chem
and	O
to	O
a	O
lesser	O
extent	O
on	O
toloxatone	S-chem
.	O

The	O
urinary	O
excretion	O
of	O
3	B-chem
-	I-chem
methoxytyramine	E-chem
was	O
significantly	O
raised	O
by	O
moclobemide	S-chem
but	O
not	O
by	O
toloxatone	S-chem
.	O

7	O
.	O

Neither	O
moclobemide	S-chem
nor	O
toloxatone	S-chem
altered	O
memory	O
function	O
,	O
vigilance	O
,	O
subjective	O
feelings	O
or	O
sleep	O
characteristics	O
of	O
the	O
subjects	O
.	O

Ibandronate	S-chem-C3-1
increases	O
the	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
FAS	S-geneY-C3-2
by	O
epigenetic	O
mechanisms	O
in	O
tumor	O
cells	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
aminobisphosphonates	S-chem
like	O
ibandronate	S-chem
show	O
anticancer	O
activity	O
by	O
an	O
unknown	O
mechanism	O
.	O

Biochemically	O
,	O
they	O
prevent	O
posttranslational	O
isoprenylation	O
of	O
small	O
GTPases	S-geneN
,	O
thus	O
inhibiting	O
their	O
activity	O
.	O

In	O
tumor	O
cells	O
,	O
activated	O
RAS	B-geneN
-	I-geneN
GTPase	E-geneN
,	O
the	O
founding	O
member	O
of	O
the	O
gene	O
family	O
,	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
FAS	S-geneY
via	O
epigenetic	O
DNA	O
-	O
methylation	O
by	O
DNMT1	S-geneY
.	O

We	O
compared	O
ibandronate	S-chem
treatment	O
in	O
neoplastic	O
human	O
U	O
-	O
2	O
osteosarcoma	O
and	O
in	O
mouse	O
CCL	O
-	O
51	O
breast	O
cancer	O
cells	O
as	O
well	O
as	O
in	O
the	O
immortalized	O
non	O
-	O
neoplastic	O
MC3T3	O
-	O
E1	O
osteoblastic	O
cells	O
.	O

Ibandronate	S-chem
attenuated	O
cell	O
proliferation	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

In	O
the	O
neoplastic	O
cells	O
we	O
found	O
up	O
-	O
regulation	O
of	O
caspases	S-geneN
suggesting	O
apoptosis	O
.	O

Further	O
we	O
found	O
stimulation	O
of	O
FAS	S-geneY
-	O
expression	O
as	O
a	O
result	O
of	O
epigenetic	O
DNA	O
demethylation	O
that	O
was	O
due	O
to	O
down	O
-	O
regulation	O
of	O
DNMT1	S-geneY-C3-2
,	O
which	O
was	O
rescued	O
by	O
re	O
-	O
isoprenylation	O
by	O
both	O
geranylgeranyl	B-chem-C3-1
-	I-chem-C3-1
pyrophosphate	E-chem-C3-1
and	O
farnesylpyrophosphate	S-chem-C3-1
.	O

In	O
contrast	O
,	O
ibandronate	S-chem
did	O
not	O
affect	O
FAS	S-geneY
and	O
DNMT1	S-geneY
expression	O
in	O
MC3T3	O
-	O
E1	O
non	O
-	O
neoplastic	O
cells	O
.	O

Data	O
suggest	O
that	O
bisphosphonates	S-chem-C3-1
via	O
modulation	O
of	O
the	O
activity	O
of	O
small	O
-	O
GTPases	S-geneN
induce	O
apoptosis	O
in	O
neoplastic	O
cells	O
by	O
DNA	O
-	O
CpG	S-geneN
-	O
demethylation	O
and	O
stimulation	O
of	O
FAS	S-geneY-C3-2
-	O
expression	O
.	O

In	O
conclusion	O
the	O
shown	O
epigenetic	O
mechanism	O
underlying	O
the	O
anti	O
-	O
neoplastic	O
activity	O
of	O
farnesyl	B-geneN
-	I-geneN
transferase	E-geneN
-	O
inhibition	O
,	O
also	O
explains	O
the	O
clinical	O
success	O
of	O
other	O
drugs	O
,	O
which	O
target	O
this	O
pathway	O
.	O

MDMA	S-chem
-	O
and	O
p	B-chem
-	I-chem
chlorophenylalanine	E-chem
-	O
induced	O
reduction	O
in	O
5	B-chem
-	I-chem
HT	E-chem
concentrations	O
:	O
effects	O
on	O
serotonin	B-geneY
transporter	E-geneY
densities	O
.	O

Low	O
levels	O
of	O
serotonin	S-chem-C4-1
may	O
reduce	O
the	O
density	O
of	O
the	O
serotonin	B-geneY-C4-2
transporter	E-geneY-C4-2
(	O
SERT	S-geneY-C4-2
)	O
by	O
either	O
increasing	O
trafficking	O
or	O
reducing	O
synthesis	O
;	O
a	O
``	O
neuroadaptive	O
response	O
``	O
.	O

To	O
determine	O
whether	O
3,4	B-chem-C4-1
-	I-chem-C4-1
methylenedioxymethamphetamine	E-chem-C4-1
(	O
MDMA	S-chem-C4-1
)	O
-	O
induced	O
reductions	O
in	O
SERT	S-geneY-C4-2
density	O
could	O
be	O
related	O
to	O
such	O
a	O
mechanism	O
,	O
p	B-chem
-	I-chem
chlorophenylalanine	E-chem
or	O
MDMA	S-chem
was	O
administered	O
to	O
rats	O
,	O
and	O
brain	O
serotonin	S-chem
and	O
SERT	S-geneY
density	O
were	O
measured	O
.	O

As	O
expected	O
,	O
both	O
treatments	O
led	O
to	O
serotonin	S-chem
depletion	O
1	O
,	O
7	O
and	O
14	O
days	O
later	O
.	O

However	O
,	O
only	O
MDMA	S-chem-C4-1
reduced	O
SERT	S-geneY-C4-2
density	O
.	O

This	O
observation	O
suggests	O
that	O
MDMA	S-chem-C4-1
-	O
induced	O
reductions	O
in	O
SERT	S-geneY-C4-2
density	O
do	O
not	O
represent	O
neuroadaptive	O
responses	O
to	O
decreased	O
levels	O
of	O
brain	O
serotonin	S-chem
,	O
but	O
may	O
occur	O
in	O
response	O
to	O
some	O
other	O
stimulus	O
or	O
to	O
the	O
neurotoxic	O
effects	O
of	O
MDMA	S-chem
.	O

Molecular	O
Mechanisms	O
of	O
the	O
antitumor	O
activity	O
of	O
SB225002	S-chem
:	O
A	O
novel	O
microtubule	O
inhibitor	O
.	O

SB225002	S-chem-MU-1
(	O
SB	O
)	O
is	O
an	O
IL	B-geneY-C6-2
-	I-geneY-C6-2
8	I-geneY-C6-2
receptor	I-geneY-C6-2
B	E-geneY-C6-2
(	O
IL	B-geneY-C6-2
-	I-geneY-C6-2
8RB	E-geneY-C6-2
)	O
antagonist	O
that	O
has	O
previously	O
been	O
shown	O
to	O
inhibit	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
8	E-geneY-C4-2
-	O
based	O
cancer	O
cell	O
invasion	O
,	O
and	O
to	O
possess	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
nociceptive	O
effects	O
.	O

The	O
present	O
study	O
presented	O
an	O
evidence	O
for	O
the	O
cell	O
cycle	O
-	O
targeting	O
activity	O
of	O
SB	O
in	O
a	O
panel	O
of	O
p53	S-geneY
-	O
mutant	O
human	O
cancer	O
cell	O
lines	O
of	O
different	O
origin	O
,	O
and	O
investigated	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

A	O
combination	O
of	O
cell	O
cycle	O
analysis	O
,	O
immunocytometry	O
,	O
immunoblotting	O
,	O
and	O
RNA	O
interference	O
revealed	O
that	O
SB	O
induced	O
a	O
BubR1	S-geneY
-	O
dependent	O
mitotic	O
arrest	O
.	O

Mechanistically	O
,	O
SB	O
was	O
shown	O
to	O
possess	O
a	O
microtubule	O
destabilizing	O
activity	O
evidenced	O
by	O
hyperphosphorylation	O
of	O
Bcl2	S-geneY
and	O
BclxL	S-geneY
,	O
suppression	O
of	O
microtubule	O
polymerization	O
and	O
induction	O
of	O
a	O
prometaphase	O
arrest	O
.	O

Molecular	O
docking	O
studies	O
suggested	O
that	O
SB	O
has	O
a	O
good	O
affinity	O
towards	O
vinblastine	S-chem
-	O
binding	O
site	O
on	O
β	B-geneY
-	I-geneY
tubulin	E-geneY
subunit	O
.	O

Of	O
note	O
,	O
SB265610	S-chem-C6-1
which	O
is	O
a	O
close	O
structural	O
analogue	O
of	O
SB225002	S-chem-C6-1
with	O
a	O
potent	O
IL	B-geneY-C6-2
-	I-geneY-C6-2
8RB	E-geneY-C6-2
antagonistic	O
activity	O
did	O
not	O
exhibit	O
a	O
similar	O
antimitotic	O
activity	O
.	O

Importantly	O
,	O
in	O
P	B-geneY
-	I-geneY
glycoprotein	E-geneY
overexpressing	O
NCI	O
/	O
Adr	O
-	O
Res	O
cells	O
the	O
antitumor	O
activity	O
of	O
SB	O
was	O
unaffected	O
by	O
multidrug	O
resistance	O
.	O

Interestingly	O
,	O
the	O
mechanisms	O
of	O
SB	O
-	O
induced	O
cell	O
death	O
were	O
cell	O
-	O
line	O
dependent	O
,	O
where	O
in	O
invasive	O
hepatocellular	O
carcinoma	O
HLE	O
cells	O
the	O
significant	O
contribution	O
of	O
BAK	S-geneY
-	O
dependent	O
mitochondrial	O
apoptosis	O
was	O
demonstrated	O
.	O

Conversely	O
,	O
SB	O
activated	O
p38	S-geneN
MAPK	S-geneN
signaling	O
in	O
colorectal	O
adenocarcinoma	O
cells	O
SW480	O
,	O
and	O
pharmacologic	O
inhibition	O
of	O
p38	S-geneN
MAPK	S-geneN
activity	O
revealed	O
its	O
key	O
role	O
in	O
mediating	O
SB	O
-	O
induced	O
caspase	S-geneN
-	O
independent	O
cell	O
death	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
introduced	O
SB	O
as	O
a	O
promising	O
antitumor	O
agent	O
which	O
has	O
the	O
potential	O
to	O
exert	O
its	O
activity	O
through	O
dual	O
mechanisms	O
involving	O
microtubules	O
targeting	O
and	O
interference	O
with	O
IL	B-geneY
-	I-geneY
8	E-geneY
-	O
drivin	O
cancer	O
progression	O
.	O

Preferential	O
block	O
of	O
late	O
sodium	S-chem
current	O
in	O
the	O
LQT3	B-geneY-C4-2
DeltaKPQ	I-geneY-C4-2
mutant	E-geneY-C4-2
by	O
the	O
class	O
I	O
(	O
C	O
)	O
antiarrhythmic	O
flecainide	S-chem-C4-1
.	O

Flecainide	S-chem-C4-1
block	O
of	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
current	O
(	O
I	O
(	O
Na	S-chem
)	O
)	O
was	O
investigated	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
the	O
long	B-geneY-C4-2
QT	I-geneY-C4-2
syndrome	I-geneY-C4-2
3	I-geneY-C4-2
(	I-geneY-C4-2
LQT3	I-geneY-C4-2
)	I-geneY-C4-2
sodium	I-geneY-C4-2
channel	I-geneY-C4-2
alpha	E-geneY-C4-2
subunit	O
mutation	O
with	O
three	O
amino	B-chem
acids	E-chem
deleted	O
(	O
DeltaKPQ	S-geneY-C4-2
)	O
stably	O
transfected	O
into	O
human	O
embryonic	O
kidney	O
293	O
cells	O
using	O
whole	O
-	O
cell	O
,	O
patch	O
-	O
clamp	O
recordings	O
.	O

Flecainide	S-chem
(	O
1	O
-	O
300	O
mM	O
)	O
caused	O
tonic	O
and	O
use	O
-	O
dependent	O
block	O
(	O
UDB	O
)	O
of	O
I	O
(	O
Na	S-chem
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Compared	O
with	O
WT	O
,	O
DeltaKPQ	S-geneY-C4-2
I	O
(	O
Na	S-chem
)	O
was	O
more	O
sensitive	O
to	O
flecainide	S-chem-C4-1
,	O
and	O
flecainide	S-chem-C4-1
preferentially	O
inhibited	O
late	O
I	O
(	O
Na	S-chem
)	O
(	O
mean	O
current	O
between	O
20	O
and	O
23.5	O
ms	O
after	O
depolarization	O
)	O
compared	O
with	O
peak	O
I	O
(	O
Na	S-chem
)	O
.	O

The	O
IC	O
(	O
50	O
)	O
value	O
of	O
peak	O
and	O
late	O
I	O
(	O
Na	S-chem
)	O
for	O
WT	O
was	O
127	O
+	O
/	O
-	O
6	O
and	O
44	O
+	O
/	O
-	O
2	O
microM	O
(	O
n	O
=	O
20	O
)	O
and	O
for	O
DeltaKPQ	S-geneY
was	O
80	O
+	O
/	O
-	O
9	O
and	O
19	O
+	O
/	O
-	O
2	O
microM	O
(	O
n	O
=	O
31	O
)	O
respectively	O
.	O

UDB	O
of	O
peak	O
I	O
(	O
Na	S-chem
)	O
was	O
greater	O
and	O
developed	O
more	O
slowly	O
during	O
pulse	O
trains	O
for	O
DeltaKPQ	S-geneY
than	O
for	O
WT	O
.	O

The	O
IC	O
(	O
50	O
)	O
value	O
for	O
UDB	O
of	O
peak	O
I	O
(	O
Na	O
)	O
for	O
WT	O
was	O
29	O
+	O
/	O
-	O
4	O
microM	O
(	O
n	O
=	O
20	O
)	O
and	O
for	O
DeltaKPQ	S-geneY
was	O
11	O
+	O
/	O
-	O
1	O
microM	O
(	O
n	O
=	O
26	O
)	O
.	O

For	O
DeltaKPQ	S-geneY
,	O
UDB	O
of	O
late	O
I	O
(	O
Na	S-chem
)	O
was	O
greater	O
than	O
for	O
peak	O
I	O
(	O
Na	S-chem
)	O
.	O

Recovery	O
from	O
block	O
was	O
slower	O
for	O
DeltaKPQ	S-geneY
than	O
for	O
WT	O
.	O

We	O
conclude	O
that	O
DeltaKPQ	S-geneY-C4-2
interacts	O
differently	O
with	O
flecainide	S-chem-C4-1
than	O
with	O
WT	O
,	O
leading	O
to	O
increased	O
block	O
and	O
slowed	O
recovery	O
,	O
especially	O
for	O
late	O
I	O
(	O
Na	S-chem
)	O
.	O

These	O
data	O
provide	O
insights	O
into	O
mechanisms	O
for	O
flecainide	S-chem
block	O
and	O
provide	O
a	O
rationale	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
that	O
open	O
channel	O
block	O
may	O
be	O
a	O
useful	O
pharmacological	O
property	O
for	O
treatment	O
of	O
LQT3	O
.	O

Angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibition	O
and	O
AT1	S-geneN
receptor	O
blockade	O
modify	O
the	O
pressure	O
-	O
natriuresis	O
relationship	O
by	O
additive	O
mechanisms	O
in	O
rats	O
with	O
human	B-geneY
renin	E-geneY
and	O
angiotensinogen	S-geneY
genes	O
.	O

The	O
intrarenal	O
factors	O
responsible	O
for	O
hypertension	O
in	O
double	O
-	O
transgenic	O
rats	O
(	O
dTGR	O
)	O
harboring	O
human	B-geneY
renin	E-geneY
and	O
human	B-geneY
angiotensinogen	E-geneY
genes	O
are	O
unclear	O
.	O

The	O
pressure	O
-	O
natriuresis	O
and	O
-	O
diuresis	O
relationships	O
in	O
response	O
to	O
chronic	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
(	O
ACE	S-geneY
)	O
inhibition	O
and	O
AT1	S-geneN
receptor	O
blockade	O
were	O
evaluated	O
.	O

Renal	B-geneY
renin	E-geneY
-	O
angiotensin	S-geneY
and	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
system	O
gene	O
expression	O
was	O
also	O
investigated	O
.	O

Six	O
-	O
week	O
-	O
old	O
dTGR	O
were	O
treated	O
for	O
3	O
wk	O
with	O
submaximal	O
doses	O
of	O
cilazapril	S-chem
(	O
10	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
or	O
losartan	S-chem
(	O
10	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
or	O
with	O
the	O
drug	O
combination	O
.	O

In	O
untreated	O
dTGR	O
,	O
pressure	O
-	O
natriuresis	O
relationships	O
were	O
maximally	O
shifted	O
rightward	O
by	O
approximately	O
70	O
to	O
80	O
mmHg	O
,	O
and	O
both	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
GFR	O
were	O
markedly	O
decreased	O
.	O

Submaximal	O
cilazapril	S-chem
and	O
losartan	S-chem
dosages	O
both	O
decreased	O
systolic	O
BP	O
by	O
30	O
mmHg	O
and	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
by	O
25	O
to	O
30	O
mmHg	O
.	O

Cilazapril	S-chem
increased	O
RBF	O
and	O
GFR	O
to	O
values	O
observed	O
in	O
normotensive	O
control	O
animals	O
but	O
did	O
not	O
significantly	O
affect	O
fractional	O
sodium	S-chem
excretion	O
(	O
FENa	O
)	O
or	O
fractional	O
water	O
excretion	O
(	O
FEH2O	O
)	O
curves	O
.	O

In	O
contrast	O
,	O
losartan	S-chem
had	O
no	O
significant	O
effect	O
on	O
RBF	O
or	O
GFR	O
but	O
shifted	O
the	O
FENa	O
and	O
FEH2O	O
curves	O
leftward	O
.	O

The	O
cilazapril	S-chem
and	O
losartan	S-chem
combination	O
completely	O
normalized	O
BP	O
and	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
more	O
than	O
did	O
either	O
drug	O
alone	O
.	O

When	O
cilazapril	S-chem
and	O
losartan	S-chem
were	O
administered	O
at	O
higher	O
doses	O
(	O
30	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
,	O
the	O
two	O
drugs	O
equally	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
,	O
by	O
50	O
mmHg	O
.	O

Both	O
drugs	O
increased	O
RBF	O
and	O
GFR	O
;	O
however	O
,	O
only	O
losartan	S-chem
shifted	O
FENa	O
and	O
FEH2O	O
curves	O
leftward	O
.	O

Human	B-geneN-C3-2
and	I-geneN-C3-2
rat	I-geneN-C3-2
renin	E-geneN-C3-2
and	O
angiotensinogen	S-geneN-C3-2
genes	O
were	O
downregulated	O
in	O
dTGR	O
and	O
were	O
increased	O
by	O
losartan	S-chem-C3-1
and	O
cilazapril	S-chem-C3-1
treatments	O
,	O
whereas	O
no	O
changes	O
in	O
the	O
expression	O
of	O
rat	B-geneY
ACE	E-geneY
and	O
AT1A	S-geneY
receptor	O
genes	O
were	O
observed	O
.	O

Endothelial	B-geneY-C3-2
NO	I-geneY-C3-2
synthase	E-geneY-C3-2
expression	O
was	O
increased	O
by	O
cilazapril	S-chem-C3-1
but	O
not	O
by	O
losartan	S-chem
.	O

Neither	O
inducible	B-geneY
NO	I-geneY
synthase	E-geneY
nor	O
neural	B-geneY
NO	I-geneY
synthase	E-geneY
gene	O
expression	O
was	O
affected	O
by	O
drug	O
treatments	O
.	O

Therefore	O
,	O
submaximal	O
ACE	S-geneY
inhibition	O
enhanced	O
sodium	S-chem
excretion	O
mainly	O
by	O
increasing	O
RBF	O
and	O
GFR	O
,	O
whereas	O
submaximal	O
AT1	S-geneN
receptor	O
blockade	O
decreased	O
tubular	O
sodium	S-chem
and	O
water	O
reabsorption	O
.	O

The	O
combination	O
of	O
the	O
two	O
drugs	O
produced	O
an	O
additive	O
effect	O
.	O

The	O
ACE	S-geneY
inhibitor	O
effects	O
may	O
involve	O
increased	O
endothelial	B-geneY
NO	I-geneY
synthase	E-geneY
expression	O
,	O
perhaps	O
related	O
to	O
the	O
inhibition	O
of	O
bradykinin	S-geneY
degradation	O
.	O

Adolescence	O
methylphenidate	S-chem
treatment	O
in	O
a	O
rodent	O
model	O
of	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
:	O
Dopamine	B-geneY
transporter	E-geneY
function	O
and	O
cellular	O
distribution	O
in	O
adulthood	O
.	O

Attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
is	O
attributed	O
to	O
dysfunction	O
of	O
the	O
prefrontal	O
cortex	O
.	O

Methylphenidate	S-chem-C4-1
,	O
an	O
inhibitor	O
of	O
dopamine	B-geneN-C4-2
and	I-geneN-C4-2
norepinephrine	I-geneN-C4-2
transporters	E-geneN-C4-2
(	O
DAT	S-geneY-C4-2
and	O
NET	S-geneY-C4-2
,	O
respectively	O
)	O
,	O
is	O
a	O
standard	O
treatment	O
for	O
ADHD	O
.	O

The	O
Spontaneously	O
Hypertensive	O
Rat	O
(	O
SHR	O
)	O
is	O
a	O
well	O
-	O
established	O
animal	O
model	O
of	O
ADHD	O
.	O

Our	O
previous	O
results	O
showed	O
that	O
methylphenidate	S-chem
treatment	O
in	O
adolescent	O
SHR	O
enhanced	O
cocaine	S-chem
self	O
-	O
administration	O
during	O
adulthood	O
,	O
and	O
alterations	O
in	O
DAT	S-geneY
function	O
in	O
prefrontal	O
cortex	O
play	O
a	O
role	O
in	O
this	O
response	O
.	O

Importantly	O
,	O
prefrontal	O
cortex	O
subregions	O
,	O
orbitofrontal	O
cortex	O
(	O
OFC	O
)	O
and	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
,	O
have	O
been	O
shown	O
to	O
have	O
distinct	O
roles	O
in	O
ADHD	O
and	O
cocaine	S-chem
self	O
-	O
administration	O
.	O

In	O
the	O
current	O
study	O
,	O
SHR	O
,	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
and	O
Wistar	O
(	O
WIS	O
)	O
rats	O
received	O
a	O
therapeutically	O
relevant	O
dose	O
of	O
methylphenidate	S-chem
(	O
1.5mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
or	O
vehicle	O
during	O
adolescence	O
and	O
then	O
OFC	O
and	O
mPFC	O
DAT	S-geneY
function	O
and	O
cellular	O
expression	O
were	O
assessed	O
during	O
adulthood	O
.	O

In	O
both	O
OFC	O
and	O
mPFC	O
,	O
no	O
strain	O
differences	O
in	O
Vmax	O
or	O
Km	O
for	O
dopamine	S-chem
uptake	O
into	O
synaptosomes	O
were	O
found	O
between	O
vehicle	O
-	O
treated	O
SHR	O
,	O
WKY	O
and	O
WIS	O
.	O

Methylphenidate	S-chem-MU-1
increased	O
DAT	S-geneY-C3-2
Vmax	O
in	O
SHR	O
mPFC	O
and	O
decreased	O
DAT	S-geneY-C4-2
Vmax	O
in	O
WKY	O
OFC	O
.	O

Also	O
,	O
methylphenidate	S-chem-C4-1
decreased	O
DAT	S-geneY-C4-2
Km	O
in	O
WIS	O
OFC	O
.	O

Further	O
,	O
methylphenidate	S-chem
did	O
not	O
alter	O
DAT	S-geneY
cellular	O
localization	O
,	O
indicating	O
that	O
methylphenidate	S-chem
treatment	O
during	O
adolescence	O
regulated	O
DAT	S-geneY
function	O
in	O
SHR	O
mPFC	O
in	O
a	O
trafficking	O
-	O
independent	O
manner	O
.	O

Thus	O
,	O
the	O
increase	O
in	O
mPFC	O
DAT	S-geneY-C3-2
function	O
was	O
an	O
SHR	O
-	O
specific	O
long	O
term	O
consequence	O
of	O
methylphenidate	S-chem-C3-1
treatment	O
during	O
adolescence	O
,	O
which	O
may	O
be	O
responsible	O
for	O
the	O
treatment	O
-	O
induced	O
alterations	O
in	O
behavior	O
including	O
the	O
observed	O
increases	O
in	O
cocaine	S-chem
self	O
-	O
administration	O
.	O

A	O
combination	O
strategy	O
to	O
inhibit	O
Pim	B-geneY
-	I-geneY
1	E-geneY
:	O
synergism	O
between	O
noncompetitive	O
and	O
ATP	S-chem
-	O
competitive	O
inhibitors	O
.	O

Pim	B-geneY
-	I-geneY
1	E-geneY
is	O
a	O
serine	B-geneN
/	I-geneN
threonine	I-geneN
kinase	E-geneN
critically	O
involved	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
various	O
types	O
of	O
cancer	O
,	O
especially	O
leukemia	O
,	O
lymphomas	O
and	O
solid	O
tumors	O
such	O
as	O
prostate	O
,	O
pancreas	O
and	O
colon	O
,	O
and	O
is	O
considered	O
a	O
potential	O
drug	O
target	O
against	O
these	O
malignancies	O
.	O

In	O
an	O
effort	O
to	O
discover	O
new	O
potent	O
Pim	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
,	O
a	O
previously	O
identified	O
ATP	S-chem
-	O
competitive	O
indolyl	B-chem
-	I-chem
pyrrolone	E-chem
scaffold	O
was	O
expanded	O
to	O
derive	O
structure	O
-	O
activity	O
relationship	O
data	O
.	O

A	O
virtual	O
screening	O
campaign	O
was	O
also	O
performed	O
,	O
which	O
led	O
to	O
the	O
discovery	O
of	O
additional	O
ATP	S-chem
-	O
competitive	O
inhibitors	O
as	O
well	O
as	O
a	O
series	O
of	O
2	B-chem
-	I-chem
aminothiazole	E-chem
derivatives	O
,	O
which	O
are	O
noncompetitive	O
with	O
respect	O
to	O
both	O
ATP	S-chem
and	O
peptide	O
substrate	O
.	O

This	O
mechanism	O
of	O
action	O
,	O
which	O
resembles	O
allosteric	O
inhibition	O
,	O
has	O
not	O
previously	O
been	O
characterized	O
for	O
Pim	B-geneY
-	I-geneY
1	E-geneY
.	O

Notably	O
,	O
further	O
evaluation	O
of	O
the	O
2	B-chem
-	I-chem
aminothiazoles	E-chem
indicated	O
a	O
synergistic	O
inhibitory	O
effect	O
in	O
enzymatic	O
assays	O
when	O
tested	O
in	O
combination	O
with	O
ATP	S-chem
-	O
competitive	O
inhibitors	O
.	O

A	O
synergistic	O
effect	O
in	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
by	O
ATP	S-chem
-	O
competitive	O
and	O
ATP	S-chem
-	O
noncompetitive	O
compounds	O
was	O
also	O
observed	O
in	O
prostate	O
cancer	O
cell	O
lines	O
(	O
PC3	O
)	O
,	O
where	O
all	O
Pim	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
tested	O
in	O
showed	O
synergism	O
with	O
the	O
known	O
anticancer	O
agent	O
,	O
paclitaxel	S-chem
.	O

These	O
results	O
further	O
establish	O
Pim	B-geneY
-	I-geneY
1	E-geneY
as	O
a	O
target	O
in	O
cancer	O
therapy	O
,	O
and	O
highlight	O
the	O
potential	O
of	O
these	O
agents	O
for	O
use	O
as	O
adjuvant	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O
diseases	O
in	O
which	O
Pim	B-geneY
-	I-geneY
1	E-geneY
is	O
associated	O
with	O
chemotherapeutic	O
resistance	O
.	O

Synthesis	O
and	O
antagonistic	O
activity	O
at	O
muscarinic	B-geneN-C6-2
receptor	E-geneN-C6-2
subtypes	O
of	O
some	O
2	B-chem-C6-1
-	I-chem-C6-1
carbonyl	E-chem-C6-1
derivatives	O
of	O
diphenidol	S-chem-C6-1
.	O

A	O
series	O
of	O
2	B-chem
-	I-chem
carbonyl	E-chem
analogues	O
of	O
the	O
muscarinic	O
antagonist	O
diphenidol	S-chem-C6-1
bearing	O
1	O
-	O
substituents	O
of	O
different	O
lipophilic	O
,	O
electronic	O
,	O
and	O
steric	O
properties	O
was	O
synthesized	O
and	O
their	O
affinity	O
for	O
the	O
M2	B-geneN-C6-2
and	I-geneN-C6-2
M3	I-geneN-C6-2
muscarinic	I-geneN-C6-2
receptor	E-geneN-C6-2
subtypes	O
was	O
evaluated	O
by	O
functional	O
tests	O
.	O

Two	O
derivatives	O
(	O
2g	O
and	O
2d	O
)	O
showed	O
an	O
M2	S-geneY
-	O
selective	O
profile	O
which	O
was	O
confirmed	O
by	O
functional	O
tests	O
on	O
the	O
M1	B-geneN
and	I-geneN
M4	I-geneN
receptors	E-geneN
.	O

A	O
possible	O
relationship	O
between	O
M2	S-geneY
selectivity	O
and	O
lipophilicity	O
of	O
the	O
1	O
-	O
substituent	O
was	O
suggested	O
by	O
structure	O
-	O
activity	O
analysis	O
.	O

This	O
work	O
showed	O
that	O
appropriate	O
structural	O
modification	O
of	O
diphenidol	S-chem-C6-1
can	O
lead	O
to	O
M2	S-geneY-C6-2
-	O
selective	O
muscarinic	O
antagonists	O
of	O
possible	O
interest	O
in	O
the	O
field	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Sorafenib	S-chem
:	O
scientific	O
rationales	O
for	O
single	O
-	O
agent	O
and	O
combination	O
therapy	O
in	O
clear	O
-	O
cell	O
renal	O
cell	O
carcinoma	O
.	O

Clear	O
-	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
is	O
characterized	O
by	O
the	O
loss	O
of	O
von	B-geneY
Hippel	I-geneY
-	I-geneY
Lindau	I-geneY
disease	I-geneY
protein	E-geneY
and	O
the	O
resultant	O
dysregulation	O
of	O
the	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
/	O
VEGF	B-geneN
receptor	E-geneN
(	O
VEGFR	S-geneN
)	O
,	O
platelet	B-geneY
-	I-geneY
derived	I-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
beta	E-geneY
(	O
PDGF	B-geneY
-	I-geneY
beta	E-geneY
)	O
/	O
PDGF	B-geneY
receptor	I-geneY
-	I-geneY
beta	E-geneY
(	O
PDGFR	B-geneY
-	I-geneY
beta	E-geneY
)	O
,	O
and	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
(	O
TGF	B-geneY
-	I-geneY
alpha	E-geneY
)	O
/	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
/	O
Raf	S-geneY
pathways	O
,	O
which	O
contribute	O
to	O
angiogenesis	O
,	O
lymphangiogenesis	O
,	O
and	O
tumor	O
cell	O
growth	O
and	O
survival	O
.	O

Significant	O
advances	O
in	O
the	O
treatment	O
of	O
clear	O
-	O
cell	O
RCC	O
have	O
been	O
derived	O
from	O
agents	O
that	O
target	O
these	O
pathways	O
,	O
including	O
the	O
multiple	O
-	O
kinase	S-geneN-C4-2
inhibitors	O
(	O
MKIs	O
)	O
sorafenib	S-chem-C4-1
,	O
sunitinib	S-chem-C4-1
,	O
and	O
AG013736	S-chem-C4-1
,	O
which	O
target	O
multiple	O
VEGFRs	S-geneN-C4-2
as	O
well	O
as	O
PDGFR	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
.	O

Sorafenib	S-chem-C4-1
has	O
the	O
added	O
advantage	O
of	O
inhibiting	O
multiple	O
different	O
Raf	S-geneY-C4-2
isoforms	O
,	O
which	O
enables	O
it	O
to	O
target	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
alpha	E-geneY-C4-2
/	O
EGFR	S-geneY-C4-2
signaling	O
and	O
may	O
also	O
enhance	O
its	O
inhibition	O
of	O
VEGFR	S-geneN-C4-2
and	O
PDGFR	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
.	O

This	O
review	O
will	O
examine	O
the	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
biology	O
of	O
clear	O
-	O
cell	O
RCC	O
and	O
show	O
how	O
those	O
advances	O
have	O
helped	O
delineate	O
new	O
targets	O
of	O
opportunity	O
for	O
treatment	O
.	O

It	O
will	O
also	O
present	O
the	O
early	O
clinical	O
results	O
of	O
agents	O
that	O
target	O
the	O
pathways	O
dysregulated	O
in	O
clear	O
-	O
cell	O
RCC	O
,	O
with	O
special	O
emphasis	O
on	O
sorafenib	S-chem
and	O
the	O
other	O
active	O
MKIs	O
,	O
and	O
will	O
describe	O
the	O
scientific	O
rationales	O
for	O
ongoing	O
and	O
future	O
sorafenib	S-chem
-	O
based	O
combination	O
therapy	O
trials	O
in	O
RCC	O
.	O

No	O
influence	O
of	O
moderate	O
hepatic	O
impairment	O
on	O
the	O
pharmacokinetics	O
of	O
lumiracoxib	S-chem-C4-1
,	O
an	O
oral	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
selective	O
inhibitor	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
hepatic	O
impairment	O
on	O
the	O
pharmacokinetics	O
(	O
PK	O
)	O
of	O
the	O
novel	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
selective	O
inhibitor	O
lumiracoxib	S-chem-C4-1
(	O
Prexige	S-chem-C4-1
)	O
,	O
so	O
that	O
dose	O
recommendations	O
for	O
clinical	O
use	O
can	O
be	O
provided	O
.	O

This	O
was	O
an	O
open	O
-	O
label	O
,	O
single	O
dose	O
,	O
case	O
-	O
controlled	O
study	O
in	O
which	O
eight	O
subjects	O
with	O
liver	O
cirrhosis	O
classed	O
as	O
moderate	O
hepatic	O
impairment	O
(	O
Child	O
-	O
Pugh	O
score	O
:	O
7	O
-	O
9	O
)	O
and	O
eight	O
demographically	O
-	O
matched	O
healthy	O
subjects	O
received	O
a	O
single	O
oral	O
400	O
mg	O
dose	O
of	O
lumiracoxib	S-chem
.	O

Routine	O
safety	O
assessments	O
were	O
made	O
and	O
blood	O
samples	O
were	O
taken	O
for	O
determination	O
of	O
lumiracoxib	S-chem
concentrations	O
for	O
96	O
h	O
post	O
dose	O
.	O

The	O
ex	O
vivo	O
binding	O
of	O
lumiracoxib	S-chem
to	O
plasma	O
proteins	O
was	O
determined	O
pre	O
dose	O
and	O
at	O
2	O
and	O
12	O
h	O
post	O
dose	O
.	O

An	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
detect	O
differences	O
in	O
PK	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
and	O
Tmax	O
)	O
between	O
the	O
treatment	O
groups	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
subjects	O
with	O
moderate	O
hepatic	O
insufficiency	O
and	O
healthy	O
subjects	O
in	O
the	O
area	O
under	O
the	O
lumiracoxib	S-chem
plasma	O
concentration	O
-	O
time	O
curves	O
(	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
)	O
:	O
29.2	O
+	O
/	O
-	O
6.7	O
microg	O
h	O
ml	O
(	O
-	O
1	O
)	O
versus	O
28.7	O
+	O
/	O
-	O
6.3	O
mircrog	O
h	O
ml	O
(	O
-	O
1	O
)	O
.	O

The	O
rate	O
of	O
absorption	O
of	O
lumiracoxib	S-chem
was	O
not	O
significantly	O
altered	O
by	O
hepatic	O
impairment	O
based	O
on	O
Cmax	O
and	O
Tmax	O
.	O

The	O
protein	O
-	O
bound	O
fraction	O
of	O
lumiracoxib	S-chem
exceeded	O
98	O
%	O
both	O
in	O
healthy	O
control	O
subjects	O
and	O
in	O
those	O
with	O
moderate	O
hepatic	O
insufficiency	O
.	O

A	O
single	O
dose	O
of	O
400	O
mg	O
lumiracoxib	S-chem
was	O
well	O
tolerated	O
.	O

In	O
conclusion	O
,	O
no	O
dose	O
adjustments	O
appear	O
to	O
be	O
required	O
when	O
lumiracoxib	S-chem
is	O
administered	O
to	O
patients	O
with	O
either	O
mild	O
or	O
moderate	O
hepatic	O
impairment	O
.	O

Dose	O
-	O
dependent	O
release	O
of	O
endogenous	O
tissue	B-geneY
factor	E-geneY
pathway	O
inhibitor	O
by	O
different	O
low	O
molecular	O
weight	O
heparins	O
.	O

Tissue	B-geneY
factor	E-geneY
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
is	O
released	O
to	O
circulating	O
blood	O
after	O
intravenous	O
and	O
subcutaneous	O
injections	O
of	O
heparins	O
,	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
antithrombotic	O
effect	O
of	O
heparins	O
.	O

A	O
previous	O
study	O
suggested	O
different	O
abilities	O
of	O
various	O
low	O
molecular	O
weight	O
heparins	O
(	O
LMWH	O
)	O
to	O
release	O
endogenous	O
TFPI	O
,	O
but	O
the	O
dose	O
-	O
response	O
relationship	O
was	O
not	O
determined	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
dose	O
-	O
response	O
relationship	O
for	O
escalating	O
doses	O
of	O
two	O
LMWHs	O
,	O
dalteparin	O
and	O
enoxaparin	O
,	O
on	O
the	O
release	O
of	O
endogenous	O
TFPI	O
was	O
investigated	O
.	O

Six	O
healthy	O
male	O
participants	O
were	O
given	O
50	O
,	O
100	O
and	O
200	O
U	O
/	O
kg	O
dalteparin	O
and	O
0.5	O
,	O
1.0	O
and	O
2.0	O
mg	O
/	O
kg	O
enoxaparin	O
as	O
a	O
single	O
subcutaneous	O
injection	O
.	O

The	O
study	O
was	O
a	O
randomized	O
,	O
cross	O
-	O
over	O
design	O
with	O
a	O
1	O
-	O
week	O
wash	O
-	O
out	O
period	O
between	O
each	O
injection	O
.	O

Peak	O
free	O
TFPI	O
antigen	O
and	O
TFPI	O
activity	O
were	O
detected	O
after	O
only	O
1	O
h	O
,	O
whereas	O
anti	O
-	O
activated	O
factor	B-geneY
X	E-geneY
(	O
anti	O
-	O
FXa	S-geneY
)	O
and	O
anti	O
-	O
activated	O
factor	B-geneN
II	E-geneN
(	O
anti	O
-	O
FIIa	S-geneY
)	O
activities	O
were	O
detected	O
after	O
2	O
-	O
6	O
h	O
.	O

Putative	O
therapeutic	O
equivalent	O
doses	O
of	O
dalteparin	O
and	O
enoxaparin	O
gave	O
similar	O
release	O
of	O
endogenous	O
TFPI	O
,	O
but	O
dissimilar	O
effects	O
on	O
anti	O
-	O
FXa	S-geneY
and	O
anti	O
-	O
FIIa	S-geneY
activities	O
.	O

IFN	B-geneY
-	I-geneY
gamma	E-geneY
-	O
induced	O
IDO	S-geneY
and	O
WRS	S-geneY
expression	O
in	O
microglia	O
is	O
differentially	O
regulated	O
by	O
IL	B-geneY
-	I-geneY
4	E-geneY
.	O

Indoleamine	B-geneY-C9-2
2,3	I-geneY-C9-2
-	I-geneY-C9-2
dioxygenase	E-geneY-C9-2
(	O
IDO	S-geneY-C9-2
)	O
,	O
a	O
tryptophan	S-chem-C9-1
catabolizing	O
enzyme	O
,	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
neurological	O
disorders	O
.	O

IDO	S-geneY
expression	O
is	O
induced	O
by	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
and	O
leads	O
to	O
neurotoxicity	O
by	O
generating	O
quinolinic	B-chem
acid	E-chem
.	O

Additionally	O
,	O
it	O
inhibits	O
the	O
immune	O
response	O
through	O
both	O
tryptophan	S-chem
depletion	O
and	O
generating	O
other	O
tryptophan	S-chem
catabolites	O
.	O

IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
13	E-geneY
have	O
been	O
shown	O
to	O
control	O
IDO	S-geneY
expression	O
by	O
antagonizing	O
the	O
effects	O
of	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
in	O
different	O
cell	O
types	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
these	O
cytokines	S-geneN
on	O
IDO	S-geneY
expression	O
in	O
microglia	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
both	O
IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
13	E-geneY
greatly	O
enhanced	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
-	O
induced	O
IDO	S-geneY
expression	O
.	O

However	O
,	O
tryptophanyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
WRS	S-geneY
)	O
,	O
which	O
is	O
coinduced	O
with	O
IDO	S-geneY
by	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
,	O
is	O
downregulated	O
by	O
IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
13	E-geneY
.	O

The	O
effect	O
of	O
IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
13	E-geneY
was	O
independent	O
of	O
STAT	B-geneY
-	I-geneY
6	E-geneY
.	O

Modulation	O
of	O
IDO	S-geneY
but	O
not	O
WRS	S-geneY
was	O
eliminated	O
by	O
inhibition	O
of	O
protein	B-geneN
phosphatase	I-geneN
2A	E-geneN
(	O
PP2A	S-geneN
)	O
activity	O
.	O

The	O
phosphatidylinositol	B-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
(	O
PI3K	S-geneN
)	O
pathway	O
further	O
differentiated	O
the	O
regulation	O
of	O
these	O
two	O
enzymes	O
,	O
as	O
inhibiting	O
the	O
PI3K	S-geneN
pathway	O
eliminated	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
induction	O
of	O
IDO	S-geneY
,	O
whereas	O
such	O
inhibition	O
greatly	O
enhanced	O
WRS	S-geneY
expression	O
.	O

These	O
findings	O
show	O
discordance	O
between	O
modulations	O
of	O
expression	O
of	O
two	O
distinct	O
enzymes	O
utilizing	O
tryptophan	S-chem
as	O
a	O
common	O
substrate	O
,	O
and	O
raise	O
the	O
possibility	O
of	O
their	O
involvement	O
in	O
regulating	O
immune	O
responses	O
in	O
various	O
neurological	O
disorders	O
.	O

TWIK	B-geneY
-	I-geneY
2	E-geneY
,	O
an	O
inactivating	O
2P	B-geneY
domain	I-geneY
K	I-geneY
+	I-geneY
channel	E-geneY
.	O

We	O
cloned	O
human	O
and	O
rat	O
TWIK	B-geneN
-	I-geneN
2	E-geneN
and	O
expressed	O
this	O
novel	O
2P	B-geneN
domain	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
in	O
transiently	O
transfected	O
COS	O
cells	O
.	O

TWIK	B-geneY
-	I-geneY
2	E-geneY
is	O
highly	O
expressed	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
the	O
vasculature	O
,	O
and	O
the	O
immune	O
system	O
.	O

Rat	B-geneY
TWIK	I-geneY
-	I-geneY
2	E-geneY
currents	O
are	O
about	O
15	O
times	O
larger	O
than	O
human	B-geneY
TWIK	I-geneY
-	I-geneY
2	E-geneY
currents	O
,	O
but	O
both	O
exhibit	O
outward	O
rectification	O
in	O
a	O
physiological	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
gradient	O
and	O
mild	O
inward	O
rectification	O
in	O
symmetrical	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
conditions	O
.	O

TWIK	B-geneY
-	I-geneY
2	E-geneY
currents	O
are	O
inactivating	O
at	O
depolarized	O
potentials	O
,	O
and	O
the	O
kinetic	O
of	O
inactivation	O
is	O
highly	O
temperature	O
-	O
sensitive	O
.	O

TWIK	B-geneY
-	I-geneY
2	E-geneY
shows	O
an	O
extremely	O
low	O
conductance	O
,	O
which	O
prevents	O
the	O
visualization	O
of	O
discrete	O
single	O
channel	O
events	O
.	O

The	O
inactivation	O
and	O
rectification	O
are	O
intrinsic	O
properties	O
of	O
TWIK	B-geneY
-	I-geneY
2	E-geneY
channels	O
.	O

In	O
a	O
physiological	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
gradient	O
,	O
TWIK	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
is	O
half	O
inhibited	O
by	O
0.1	O
mm	O
Ba	B-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
+	I-chem-C4-1
)	E-chem-C4-1
,	O
quinine	S-chem-C4-1
,	O
and	O
quinidine	S-chem-C4-1
.	O

Finally	O
,	O
cysteine	S-chem
53	O
in	O
the	O
M1P1	B-geneN
external	I-geneN
loop	E-geneN
is	O
required	O
for	O
functional	O
expression	O
of	O
TWIK	B-geneY
-	I-geneY
2	E-geneY
but	O
is	O
not	O
critical	O
for	O
subunit	O
self	O
-	O
assembly	O
.	O

TWIK	B-geneY
-	I-geneY
2	E-geneY
is	O
the	O
first	O
reported	O
2P	B-geneY
domain	I-geneY
K	I-geneY
(	I-geneY
+	I-geneY
)	I-geneY
channel	E-geneY
that	O
inactivates	O
.	O

The	O
base	O
-	O
line	O
,	O
transient	O
,	O
and	O
delayed	O
activities	O
of	O
TWIK	B-geneY
-	I-geneY
2	E-geneY
suggest	O
that	O
this	O
novel	O
2P	B-geneY
domain	I-geneY
K	I-geneY
(	I-geneY
+	I-geneY
)	I-geneY
channel	E-geneY
may	O
play	O
an	O
important	O
functional	O
role	O
in	O
cell	O
electrogenesis	O
.	O

Alprenolol	S-chem-C6-1
and	O
bromoacetylalprenololmenthane	S-chem-C6-1
are	O
competitive	O
slowly	O
reversible	O
antagonists	O
at	O
the	O
beta	B-geneY-C6-2
1	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptors	E-geneY-C6-2
of	O
rat	O
left	O
atria	O
.	O

We	O
studied	O
the	O
effects	O
of	O
alprenolol	S-chem
and	O
bromoacetylalprenololmenthane	S-chem
(	O
BAAM	S-chem
)	O
on	O
rat	O
left	O
atria	O
.	O

Alprenolol	S-chem-C4-1
and	O
BAAM	S-chem-C4-1
at	O
10	O
(	O
-	O
7	O
)	O
,	O
3	O
x	O
10	O
(	O
-	O
7	O
)	O
,	O
and	O
10	O
(	O
-	O
6	O
)	O
M	O
inhibited	O
the	O
cardiac	O
stimulation	O
response	O
slightly	O
,	O
which	O
is	O
indicative	O
of	O
membrane	O
-	O
stabilizing	O
activity	O
independent	O
of	O
beta	B-geneN-C4-2
-	I-geneN-C4-2
adrenoceptor	E-geneN-C4-2
blockade	O
.	O

This	O
membrane	O
-	O
stabilizing	O
activity	O
was	O
readily	O
reversible	O
.	O

Alprenolol	S-chem-C6-1
and	O
BAAM	S-chem-C6-1
also	O
caused	O
surmountable	O
antagonism	O
of	O
isoprenaline	S-chem-C5-1
responses	O
,	O
and	O
this	O
beta	B-geneY-MU-2
1	I-geneY-MU-2
-	I-geneY-MU-2
adrenoceptor	E-geneY-MU-2
antagonism	O
was	O
slowly	O
reversible	O
.	O

Inhibition	O
of	O
the	O
isoprenaline	S-chem
responses	O
with	O
alprenolol	S-chem
and	O
BAAM	S-chem
at	O
10	O
(	O
-	O
6	O
)	O
M	O
was	O
at	O
equilibrium	O
after	O
60	O
min	O
,	O
which	O
is	O
indicative	O
of	O
reversible	O
antagonism	O
.	O

We	O
conclude	O
that	O
alprenolol	S-chem-C6-1
and	O
BAAM	S-chem-C6-1
are	O
competitive	O
slowly	O
reversible	O
beta	B-geneY-C6-2
1	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonists	O
on	O
rat	O
left	O
atria	O
.	O

Differential	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
methylphenidate	S-chem
enantiomers	O
:	O
does	O
chirality	O
matter	O
?	O

d	B-chem
,	I-chem
l	I-chem
-	I-chem
threo	I-chem
-	I-chem
methylphenidate	E-chem
(	O
MPH	S-chem
)	O
is	O
an	O
effective	O
first	O
-	O
line	O
treatment	O
for	O
the	O
symptoms	O
associated	O
with	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O
threo	B-chem-C4-1
-	I-chem-C4-1
methylphenidate	E-chem-C4-1
inhibits	O
the	O
dopamine	B-geneY-MU-2
transporter	E-geneY-MU-2
and	O
the	O
norepinephrine	B-geneY-MU-2
transporter	E-geneY-MU-2
,	O
resulting	O
in	O
elevations	O
of	O
these	O
monoamines	S-chem-C9-1
after	O
impulse	O
release	O
.	O

Although	O
MPH	S-chem
has	O
long	O
been	O
administered	O
as	O
a	O
racemic	O
mixture	O
of	O
the	O
2	O
enantiomers	O
,	O
d	B-chem
-	I-chem
MPH	E-chem
and	O
l	B-chem
-	I-chem
MPH	E-chem
,	O
converging	O
lines	O
of	O
evidence	O
drawn	O
from	O
investigations	O
using	O
in	O
vitro	O
systems	O
,	O
animal	O
models	O
,	O
and	O
humans	O
indicate	O
that	O
it	O
is	O
predominantly	O
,	O
if	O
not	O
exclusively	O
,	O
d	B-chem
-	I-chem
MPH	E-chem
that	O
mediates	O
the	O
pharmacological	O
/	O
therapeutic	O
actions	O
of	O
MPH	S-chem
.	O

In	O
both	O
rodent	O
and	O
primate	O
animal	O
models	O
,	O
the	O
binding	O
of	O
radiolabeled	O
d	B-chem
-	I-chem
MPH	E-chem
to	O
dopamine	B-geneN
transporter	E-geneN
was	O
found	O
to	O
be	O
selective	O
,	O
saturable	O
,	O
and	O
reversible	O
,	O
whereas	O
binding	O
of	O
l	B-chem
-	I-chem
MPH	E-chem
was	O
diffuse	O
and	O
nonspecific	O
.	O

The	O
behavioral	O
effects	O
of	O
the	O
enantiomers	O
of	O
MPH	S-chem
have	O
been	O
tested	O
in	O
several	O
animal	O
models	O
,	O
and	O
results	O
indicate	O
these	O
observed	O
behavioral	O
changes	O
are	O
likewise	O
mediated	O
by	O
d	B-chem
-	I-chem
MPH	E-chem
,	O
whereas	O
l	B-chem
-	I-chem
MPH	E-chem
has	O
little	O
or	O
no	O
effect.The	O
contribution	O
of	O
the	O
l	O
-	O
isomer	O
to	O
the	O
overall	O
pharmacological	O
profile	O
of	O
the	O
racemate	O
remains	O
unclear	O
,	O
owing	O
to	O
several	O
studies	O
suggesting	O
that	O
l	B-chem
-	I-chem
MPH	E-chem
may	O
not	O
be	O
merely	O
an	O
inert	O
isomeric	O
ballast	O
.	O

For	O
example	O
,	O
behavioral	O
studies	O
conducted	O
in	O
rats	O
demonstrate	O
an	O
attenuation	O
of	O
the	O
effect	O
of	O
d	B-chem
-	I-chem
MPH	E-chem
in	O
animals	O
pretreated	O
with	O
l	B-chem
-	I-chem
MPH	E-chem
,	O
suggesting	O
that	O
l	B-chem
-	I-chem
MPH	E-chem
may	O
interfere	O
with	O
the	O
action	O
of	O
the	O
active	O
enantiomer	O
.	O

The	O
importance	O
of	O
MPH	S-chem
chirality	O
to	O
central	O
nervous	O
system	O
MPH	B-geneN
receptor	E-geneN
targeting	O
has	O
culminated	O
in	O
human	O
imaging	O
studies	O
revealing	O
that	O
d	B-chem
-	I-chem
MPH	E-chem
binds	O
specifically	O
to	O
striatal	O
structures	O
,	O
whereas	O
l	B-chem
-	I-chem
MPH	E-chem
binding	O
is	O
nonspecific	O
.	O

Taken	O
together	O
,	O
data	O
from	O
in	O
vitro	O
,	O
animal	O
,	O
and	O
human	O
studies	O
support	O
the	O
premise	O
that	O
the	O
d	B-chem
-	I-chem
enantiomer	I-chem
of	I-chem
MPH	E-chem
mediates	O
the	O
neurophysiological	O
actions	O
of	O
MPH	S-chem
and	O
therefore	O
likely	O
mediates	O
its	O
clinical	O
efficacy	O
.	O

Different	O
responses	O
to	O
dexamethasone	S-chem
and	O
prednisolone	S-chem
in	O
the	O
same	O
depressed	O
patients	O
.	O

RATIONALE	O
:	O
Patients	O
with	O
major	O
depression	O
show	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
hyperactivity	O
,	O
but	O
the	O
mechanisms	O
underlying	O
this	O
abnormality	O
are	O
still	O
unclear	O
.	O

OBJECTIVES	O
:	O
We	O
have	O
compared	O
two	O
synthetic	O
glucorticoids	O
,	O
dexamethasone	S-chem
and	O
prednisolone	S-chem
,	O
in	O
their	O
ability	O
to	O
suppress	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
depressed	O
patients	O
.	O

Dexamethasone	S-chem
probes	O
glucocorticoid	B-geneY
receptor	E-geneY
(	O
GR	S-geneY
)	O
function	O
,	O
while	O
prednisolone	S-chem
probes	O
both	O
GR	S-geneY
and	O
mineralocorticoid	B-geneY
receptor	E-geneY
(	O
MR	S-geneY
)	O
function	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
used	O
a	O
single	O
-	O
blind	O
,	O
repeated	O
-	O
measure	O
design	O
.	O

We	O
administered	O
placebo	O
,	O
prednisolone	S-chem
(	O
5	O
mg	O
)	O
or	O
dexamethasone	S-chem
(	O
0.5	O
mg	O
)	O
,	O
at	O
22	O
:	O
00	O
,	O
to	O
18	O
severe	O
,	O
treatment	O
-	O
resistant	O
depressed	O
inpatients	O
(	O
15	O
of	O
them	O
with	O
a	O
history	O
of	O
childhood	O
trauma	O
)	O
and	O
14	O
healthy	O
volunteers	O
.	O

On	O
the	O
following	O
days	O
,	O
we	O
collected	O
salivary	O
cortisol	S-chem
from	O
9	O
:	O
00	O
to	O
22	O
:	O
00	O
.	O

RESULTS	O
:	O
Depressed	O
patients	O
had	O
higher	O
salivary	O
cortisol	S-chem
levels	O
compared	O
with	O
controls	O
,	O
at	O
baseline	O
and	O
after	O
both	O
prednisolone	S-chem
and	O
dexamethasone	S-chem
(	O
p	O
<	O
0.001	O
)	O
.	O

Consistent	O
with	O
previous	O
studies	O
,	O
depressed	O
inpatients	O
showed	O
impaired	O
suppression	O
by	O
dexamethasone	S-chem
:	O
based	O
on	O
the	O
analysis	O
of	O
the	O
areas	O
under	O
the	O
curve	O
(	O
AUCs	O
)	O
,	O
suppression	O
by	O
dexamethasone	S-chem
(	O
0.5	O
mg	O
)	O
was	O
-	O
85	O
%	O
in	O
controls	O
vs	O
-	O
46	O
%	O
in	O
depressed	O
patients	O
(	O
p	O
=	O
0.018	O
)	O
.	O

However	O
,	O
the	O
same	O
depressed	O
patients	O
showed	O
normal	O
suppression	O
by	O
prednisolone	S-chem
(	O
5	O
mg	O
)	O
:	O
suppression	O
was	O
-	O
41	O
%	O
in	O
controls	O
and	O
-	O
36	O
%	O
in	O
depressed	O
patients	O
(	O
p	O
=	O
0.6	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
suggest	O
that	O
the	O
additional	O
effects	O
of	O
prednisolone	S-chem
on	O
the	O
MR	S-geneY
explain	O
the	O
different	O
responses	O
to	O
these	O
glucocorticoids	O
in	O
the	O
same	O
depressed	O
patients	O
.	O

Comparative	O
formation	O
of	O
2	B-chem
-	I-chem
amino	I-chem
-	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
6	I-chem
-	I-chem
phenylimidazo	I-chem
[	I-chem
4,5	I-chem
-	I-chem
b	I-chem
]	I-chem
pyridine	E-chem
(	O
PhIP	S-chem
)	O
in	O
creatinine	S-chem
/	O
phenylalanine	S-chem
and	O
creatinine	S-chem
/	O
phenylalanine	S-chem
/	O
4	B-chem
-	I-chem
oxo	I-chem
-	I-chem
2	I-chem
-	I-chem
nonenal	E-chem
reaction	O
mixtures	O
.	O

The	O
comparative	O
formation	O
of	O
the	O
heterocyclic	O
aromatic	O
amine	O
2	B-chem
-	I-chem
amino	I-chem
-	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
6	I-chem
-	I-chem
phenylimidazo	I-chem
[	I-chem
4,5	I-chem
-	I-chem
b	I-chem
]	I-chem
pyridine	E-chem
(	O
PhIP	S-chem
)	O
in	O
both	O
creatinine	S-chem
/	O
phenylalanine	S-chem
(	O
CRN	S-chem
/	O
Phe	S-chem
)	O
and	O
creatinine	S-chem
/	O
phenylalanine	S-chem
/	O
4	B-chem
-	I-chem
oxo	I-chem
-	I-chem
2	I-chem
-	I-chem
nonenal	E-chem
(	O
CRN	S-chem
/	O
Phe	S-chem
/	O
ON	O
)	O
systems	O
was	O
studied	O
to	O
analyse	O
the	O
ability	O
of	O
lipid	O
-	O
derived	O
reactive	O
carbonyls	S-chem
to	O
promote	O
PhIP	S-chem
formation	O
.	O

Although	O
PhIP	S-chem
was	O
produced	O
to	O
some	O
extent	O
in	O
the	O
CRN	S-chem
/	O
Phe	S-chem
system	O
,	O
the	O
presence	O
of	O
the	O
oxidized	O
lipid	O
increased	O
considerably	O
the	O
amount	O
of	O
PhIP	S-chem
produced	O
.	O

This	O
increase	O
seemed	O
to	O
be	O
a	O
consequence	O
of	O
the	O
decrease	O
in	O
the	O
E	O
(	O
a	O
)	O
of	O
the	O
reaction	O
when	O
the	O
lipid	O
was	O
present	O
,	O
which	O
diminished	O
from	O
112.9	O
to	O
80.9	O
kJ	O
/	O
mol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
addition	O
of	O
the	O
lipid	O
did	O
not	O
seem	O
to	O
produce	O
PhIP	S-chem
by	O
an	O
alternative	O
mechanism	O
because	O
PhIP	S-chem
was	O
formed	O
analogously	O
in	O
both	O
CRN	S-chem
/	O
Phe	S-chem
and	O
CRN	S-chem
/	O
Phe	S-chem
/	O
ON	O
systems	O
as	O
a	O
function	O
of	O
pH	O
,	O
creatinine	S-chem
concentration	O
,	O
phenylalanine	S-chem
concentration	O
,	O
time	O
,	O
temperature	O
,	O
oxygen	S-chem
concentration	O
in	O
the	O
reaction	O
atmosphere	O
,	O
and	O
the	O
addition	O
of	O
different	O
amounts	O
of	O
ammonia	S-chem
.	O

All	O
these	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
lipid	O
oxidation	O
products	O
to	O
produce	O
PhIP	S-chem
is	O
related	O
to	O
their	O
capacity	O
to	O
induce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	S-chem
to	O
phenylacetaldehyde	S-chem
.	O

Therefore	O
,	O
any	O
other	O
reactive	O
carbonyl	S-chem
compound	O
that	O
can	O
produce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	S-chem
should	O
also	O
be	O
considered	O
as	O
a	O
potential	O
inducer	O
of	O
PhIP	S-chem
formation	O
under	O
appropriate	O
conditions	O
.	O

Regulated	O
function	O
of	O
the	O
prolyl	B-geneN
-	I-geneN
4	I-geneN
-	I-geneN
hydroxylase	I-geneN
domain	I-geneN
(	I-geneN
PHD	I-geneN
)	I-geneN
oxygen	I-geneN
sensor	I-geneN
proteins	E-geneN
.	O

Cellular	O
oxygen	S-chem
is	O
sensed	O
by	O
prolyl	B-geneN
-	I-geneN
4	I-geneN
-	I-geneN
hydroxylase	I-geneN
domain	I-geneN
(	I-geneN
PHD	I-geneN
)	I-geneN
proteins	E-geneN
that	O
hydroxylate	S-chem
hypoxia	B-geneN
-	I-geneN
inducible	I-geneN
factor	I-geneN
(	I-geneN
HIF	I-geneN
)	I-geneN
alpha	E-geneN
subunits	O
.	O

Under	O
normoxic	O
conditions	O
,	O
hydroxylated	O
HIFalpha	S-geneN
is	O
bound	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
pVHL	O
)	O
tumor	O
suppressor	O
,	O
leading	O
to	O
ubiquitinylation	O
and	O
proteasomal	O
degradation	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
hydroxylation	O
becomes	O
reduced	O
,	O
leading	O
to	O
HIFalpha	S-geneN
stabilization	O
.	O

The	O
authors	O
recently	O
showed	O
that	O
changes	O
in	O
PHD	S-geneN
abundance	O
and	O
activity	O
can	O
regulate	O
HIFalpha	S-geneN
stability	O
under	O
normoxic	O
as	O
well	O
as	O
under	O
hypoxic	O
conditions	O
.	O

Thus	O
,	O
the	O
PHD	S-geneN
oxygen	S-chem
sensors	O
themselves	O
represent	O
effectors	O
of	O
cellular	O
signalling	O
pathways	O
as	O
well	O
as	O
potential	O
drug	O
targets	O
.	O

Here	O
,	O
a	O
cell	O
-	O
free	O
in	O
vitro	O
microtiter	O
plate	O
-	O
based	O
peptide	O
hydroxylation	O
assay	O
was	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
ferrous	B-chem
iron	E-chem
,	O
Krebs	O
cycle	O
intermediates	O
,	O
transition	O
metals	O
,	O
and	O
vitamin	B-chem
C	E-chem
and	O
other	O
antioxidants	O
on	O
the	O
activity	O
of	O
purified	O
PHD1	B-geneN
to	I-geneN
3	E-geneN
.	O

PHD	S-geneN
activity	O
depends	O
not	O
only	O
on	O
oxygen	S-chem
availability	O
but	O
is	O
also	O
regulated	O
by	O
iron	S-chem
,	O
vitamin	B-chem
C	E-chem
,	O
and	O
Krebs	O
cycle	O
intermediates	O
,	O
suggesting	O
a	O
physiological	O
relevance	O
of	O
their	O
cellular	O
concentrations	O
.	O

Copper	S-chem
but	O
not	O
iron	S-chem
,	O
cobalt	S-chem
,	O
or	O
nickel	S-chem
salts	O
catalyzed	O
vitamin	B-chem
C	E-chem
oxidation	O
.	O

While	O
vitamin	B-chem
C	E-chem
is	O
essential	O
for	O
PHD	S-geneN
activity	O
in	O
vitro	O
,	O
N	B-chem
-	I-chem
acetyl	I-chem
-	I-chem
L	I-chem
-	I-chem
cysteine	E-chem
had	O
no	O
effect	O
,	O
and	O
gallic	B-chem-C4-1
acid	E-chem-C4-1
or	O
n	B-chem-C4-1
-	I-chem-C4-1
propyl	I-chem-C4-1
gallate	E-chem-C4-1
efficiently	O
inhibited	O
the	O
activity	O
of	O
all	O
three	O
PHDs	S-geneN-C4-2
,	O
demonstrating	O
different	O
functions	O
of	O
these	O
antioxidants	O
.	O

Pharmacological	O
properties	O
of	O
angiotensin	B-geneN
II	I-geneN
receptor	E-geneN
antagonists	O
.	O

The	O
availability	O
of	O
selective	O
,	O
potent	O
,	O
orally	O
active	O
and	O
long	O
acting	O
nonpeptide	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
(	I-geneY
AT1	I-geneY
)	I-geneY
receptor	E-geneY
antagonists	O
has	O
provided	O
the	O
opportunity	O
to	O
obtain	O
the	O
benefits	O
of	O
selectively	O
blocking	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
-	O
aldosterone	S-chem
system	O
at	O
the	O
level	O
of	O
the	O
AT1	S-geneY
receptor	O
that	O
mediates	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
important	O
actions	O
of	O
angiotensin	B-geneY
II	E-geneY
,	O
and	O
avoid	O
the	O
nonspecificity	O
of	O
the	O
angiotensin	B-geneY
I	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitors	O
.	O

Losartan	S-chem-C6-1
was	O
the	O
first	O
,	O
but	O
by	O
no	O
means	O
remained	O
the	O
only	O
,	O
AT1	S-geneY-C6-2
receptor	O
antagonist	O
.	O

Numerous	O
other	O
'	O
sartans	O
'	O
have	O
emerged	O
in	O
the	O
past	O
several	O
years	O
and	O
successfully	O
completed	O
clinical	O
development	O
.	O

With	O
the	O
exception	O
of	O
eprosartan	S-chem
,	O
all	O
others	O
,	O
ie	O
,	O
candesartan	S-chem
,	O
irbesartan	S-chem
,	O
saprisartan	S-chem
,	O
tasosartan	S-chem
,	O
telmisartan	S-chem
,	O
valsartan	S-chem
and	O
zolasartan	S-chem
,	O
are	O
based	O
on	O
medications	O
of	O
losartan	O
's	O
prototypical	O
chemical	O
structure	O
.	O

Among	O
the	O
current	O
AT1	S-geneY-C6-2
receptor	O
antagonists	O
,	O
the	O
rank	O
order	O
of	O
the	O
relative	O
binding	O
affinities	O
(	O
highest	O
affinity	O
=	O
1	O
)	O
is	O
:	O
candesartan	S-chem-C6-1
1	O
,	O
telmisartan	S-chem-C6-1
10	O
,	O
E3174	S-chem-C6-1
(	O
the	O
active	O
metabolite	O
of	O
losartan	S-chem-C6-1
)	O
10	O
,	O
tasosartan	S-chem-C6-1
20	O
,	O
losartan	S-chem-C6-1
50	O
,	O
eprosartan	S-chem-C6-1
100	O
and	O
the	O
prodrug	O
candesartan	B-chem-C6-1
cilexetil	E-chem-C6-1
280	O
.	O

The	O
mode	O
of	O
(	O
functional	O
)	O
AT1	S-geneY-C6-2
receptor	O
antagonism	O
has	O
been	O
characterized	O
as	O
surmountable	O
/	O
noncompetitive	O
(	O
losartan	S-chem-C6-1
,	O
tasosartan	S-chem-C6-1
,	O
eprosartan	S-chem-C6-1
)	O
or	O
insurmountable	O
/	O
noncompetitive	O
(	O
candesartan	S-chem-C6-1
,	O
saprisartan	S-chem-C6-1
,	O
zolasartan	S-chem-C6-1
,	O
irbesartan	S-chem-C6-1
,	O
valsartan	S-chem-C6-1
,	O
telmisartan	S-chem-C6-1
,	O
E3174	S-chem-C6-1
)	O
.	O

It	O
is	O
very	O
likely	O
that	O
slow	O
dissociation	O
kinetics	O
from	O
the	O
AT1	S-geneY
receptor	O
underlie	O
insurmountable	O
antagonism	O
.	O

However	O
,	O
competitive	O
or	O
noncompetitive	O
antagonism	O
does	O
not	O
determine	O
the	O
antihypertensive	O
efficacy	O
,	O
but	O
the	O
slow	O
off	O
-	O
rate	O
may	O
extend	O
the	O
occupancy	O
of	O
the	O
AT1	S-geneY
receptor	O
and	O
thereby	O
lengthen	O
the	O
duration	O
of	O
the	O
antihypertensive	O
effect	O
.	O

Environmental	O
stress	O
,	O
oxytocin	B-geneY
receptor	E-geneY
gene	O
(	O
OXTR	S-geneY
)	O
polymorphism	O
,	O
and	O
mental	O
health	O
following	O
collective	O
stress	O
.	O

We	O
examined	O
whether	O
the	O
oxytocin	B-geneY
receptor	E-geneY
gene	O
(	O
OXTR	S-geneY
)	O
single	O
nucleotide	S-chem
polymorphism	O
(	O
SNP	O
)	O
rs53576	O
genotype	O
buffers	O
the	O
combined	O
impact	O
of	O
negative	O
social	O
environments	O
(	O
e.g	O
.	O
,	O
interpersonal	O
conflict	O
/	O
constraint	O
)	O
and	O
economic	O
stress	O
on	O
post	O
-	O
traumatic	O
stress	O
(	O
PTS	O
)	O
symptoms	O
and	O
impaired	O
daily	O
functioning	O
following	O
collective	O
stress	O
(	O
September	O
11th	O
terrorist	O
attacks	O
)	O
.	O

Saliva	O
was	O
collected	O
by	O
mail	O
and	O
used	O
to	O
genotype	O
704	O
respondents	O
.	O

Participants	O
completed	O
Web	O
-	O
based	O
assessments	O
of	O
pre	O
-	O
9	O
/	O
11	O
mental	O
health	O
,	O
acute	O
stress	O
9	O
-	O
23days	O
after	O
9	O
/	O
11	O
,	O
the	O
quality	O
of	O
social	O
environments	O
1year	O
post	O
-	O
9	O
/	O
11	O
,	O
economic	O
stress	O
18months	O
post	O
-	O
9	O
/	O
11	O
,	O
and	O
PTS	O
symptoms	O
and	O
impaired	O
functioning	O
2	O
and	O
3years	O
post	O
-	O
9	O
/	O
11	O
.	O

Interactions	O
between	O
negative	O
social	O
environments	O
and	O
economic	O
stress	O
were	O
examined	O
separately	O
based	O
on	O
OXTR	S-geneY
rs53576	O
genotype	O
(	O
GG	O
vs.	O
any	O
A	O
allele	O
)	O
.	O

For	O
individuals	O
with	O
an	O
A	O
allele	O
,	O
a	O
negative	O
social	O
environment	O
significantly	O
increased	O
PTS	O
symptoms	O
without	O
regard	O
to	O
the	O
level	O
of	O
economic	O
stress	O
experienced	O
.	O

However	O
,	O
for	O
respondents	O
with	O
a	O
GG	O
genotype	O
,	O
negative	O
social	O
environments	O
predicted	O
elevated	O
PTS	O
symptoms	O
only	O
for	O
those	O
also	O
experiencing	O
high	O
economic	O
stress	O
.	O

Gender	O
moderated	O
associations	O
between	O
negative	O
social	O
environments	O
,	O
economic	O
stress	O
,	O
and	O
impaired	O
functioning	O
.	O

The	O
functioning	O
of	O
females	O
was	O
most	O
affected	O
by	O
negative	O
social	O
environments	O
regardless	O
of	O
genotype	O
and	O
economic	O
stress	O
,	O
whereas	O
the	O
functioning	O
of	O
males	O
was	O
differentially	O
susceptible	O
to	O
economic	O
stress	O
depending	O
on	O
OXTR	S-geneY
genotype	O
and	O
negative	O
social	O
environments	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
is	O
important	O
to	O
consider	O
the	O
combined	O
impact	O
of	O
gender	O
and	O
ongoing	O
stress	O
in	O
different	O
domains	O
as	O
moderators	O
of	O
genetic	O
vulnerability	O
following	O
collective	O
stress	O
.	O

Drug	O
cocktail	O
interaction	O
study	O
on	O
the	O
effect	O
of	O
the	O
orally	O
administered	O
lavender	O
oil	O
preparation	O
silexan	O
on	O
cytochrome	B-geneN
p450	E-geneN
enzymes	O
in	O
healthy	O
volunteers	O
.	O

This	O
cocktail	O
study	O
evaluated	O
the	O
interaction	O
potential	O
of	O
the	O
oral	O
lavender	O
oil	O
preparation	O
silexan	O
with	O
major	O
P450	S-geneN
(	O
cytochrome	B-geneN
P450	E-geneN
)	O
enzymes	O
.	O

Subjects	O
and	O
Methods	O
:	O
Sixteen	O
healthy	O
male	O
or	O
female	O
Caucasians	O
completed	O
this	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
2	O
-	O
fold	O
crossover	O
study	O
.	O

Silexan	O
(	O
160	O
mg	O
)	O
or	O
placebo	O
were	O
administered	O
once	O
daily	O
for	O
11	O
days	O
.	O

Additionally	O
,	O
on	O
day	O
11	O
of	O
both	O
study	O
periods	O
,	O
150	O
mg	O
caffeine	S-chem
(	O
CYP1A2	S-geneY
)	O
,	O
125	O
mg	O
tolbutamide	S-chem
(	O
CYP2C9	S-geneY
)	O
,	O
20	O
mg	O
omeprazole	S-chem
(	O
CYP2C19	S-geneY
)	O
,	O
30	O
mg	O
dextromethorphan	B-chem
-	I-chem
HBr	E-chem
(	O
CYP2D6	S-geneY
)	O
,	O
and	O
2	O
mg	O
midazolam	S-chem
(	O
CYP3A4	S-geneY
)	O
were	O
administered	O
orally	O
.	O

Formal	O
interaction	O
was	O
excluded	O
if	O
the	O
90	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
silexan	O
over	O
placebo	O
ratios	O
for	O
phenotyping	O
metrics	O
(	O
primary	O
:	O
AUC0	O
-	O
t	O
)	O
was	O
within	O
a	O
0.70	O
-	O
1.43	O
range	O
.	O

Results	O
:	O
According	O
to	O
the	O
AUC0	O
-	O
t	O
comparisons	O
,	O
silexan	O
had	O
no	O
relevant	O
effect	O
on	O
CYP1A2	B-geneN
,	I-geneN
2C9	I-geneN
,	I-geneN
2D6	I-geneN
,	I-geneN
and	I-geneN
3A4	E-geneN
activity	O
.	O

Secondary	O
phenotyping	O
metrics	O
confirmed	O
this	O
result	O
.	O

Mean	O
ratios	O
for	O
all	O
omeprazole	S-chem
-	O
derived	O
metrics	O
were	O
close	O
to	O
unity	O
.	O

The	O
90	O
%	O
CI	O
for	O
the	O
AUC0	O
-	O
t	O
ratio	O
of	O
omeprazole	S-chem
but	O
not	O
for	O
omeprazole	S-chem
/	O
5	B-chem
-	I-chem
OH	I-chem
-	I-chem
omeprazole	E-chem
plasma	O
ratio	O
3	O
hours	O
post	O
-	O
dose	O
or	O
omeprazole	S-chem
/	O
5	B-chem
-	I-chem
OH	I-chem
-	I-chem
omeprazole	E-chem
AUC0	O
-	O
t	O
ratio	O
(	O
secondary	O
CYP2C19	S-geneY
metrics	O
)	O
was	O
above	O
the	O
predefined	O
threshold	O
of	O
1.43	O
,	O
probably	O
caused	O
by	O
the	O
inherent	O
high	O
variability	O
of	O
omeprazole	S-chem
pharmacokinetics	O
.	O

Silexan	O
and	O
the	O
phenotyping	O
drugs	O
were	O
well	O
tolerated	O
.	O

Repeated	O
silexan	O
(	O
160	O
mg	O
/	O
day	O
)	O
administration	O
has	O
no	O
clinically	O
relevant	O
inhibitory	O
or	O
inducing	O
effects	O
on	O
the	O
CYP1A2	B-geneN
,	I-geneN
2C9	I-geneN
,	I-geneN
2C19	I-geneN
,	I-geneN
2D6	I-geneN
,	I-geneN
and	I-geneN
3A4	E-geneN
enzymes	O
in	O
vivo	O
.	O

In	O
vitro	O
simulation	O
of	O
therapeutic	O
plasmatic	O
fibrinolysis	O
.	O

One	O
type	O
of	O
therapy	O
for	O
thromboembolism	O
is	O
plasmatic	O
thrombolysis	O
.	O

Several	O
plasminogen	B-geneN
activators	E-geneN
(	O
PA	S-geneN
)	O
are	O
clinically	O
available	O
,	O
including	O
urokinase	S-geneN
(	O
u	B-geneY
-	I-geneY
PA	E-geneY
)	O
,	O
tissue	B-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
t	B-geneY
-	I-geneY
PA	E-geneY
)	O
,	O
streptokinase	S-geneN
(	O
SK	S-geneN
)	O
,	O
plasminogen	B-geneN
-	I-geneN
streptokinase	I-geneN
-	I-geneN
activator	I-geneN
-	I-geneN
complex	E-geneN
(	O
PSAC	S-geneN
)	O
,	O
or	O
mutants	O
of	O
t	B-geneY
-	I-geneY
PA	E-geneY
such	O
as	O
reteplase	O
(	O
RP	O
)	O
or	O
tenecteplase	O
(	O
TP	O
)	O
.	O

Therapeutic	O
plasmatic	O
fibrinolysis	O
was	O
simulated	O
,	O
using	O
the	O
PA	S-geneN
at	O
relevant	O
plasma	O
concentrations	O
,	O
and	O
plasmin	S-geneY
(	O
Pli	S-geneY
)	O
and	O
PA	S-geneN
activities	O
were	O
determined	O
.	O

Normal	O
citrated	O
plasma	O
was	O
supplemented	O
with	O
31	O
to	O
1,000	O
IU	O
/	O
mL	O
u	O
-	O
PA	O
,	O
0.31	O
to	O
20	O
microg	O
/	O
mL	O
t	B-geneN
-	I-geneN
PA	E-geneN
,	O
125	O
to	O
4,000	O
IU	O
/	O
mL	O
SK	S-geneN
,	O
12.5	O
to	O
400	O
U	O
/	O
mL	O
PSAC	S-geneN
,	O
125	O
to	O
4,000	O
U	O
/	O
mL	O
RP	O
,	O
or	O
0.31	O
to	O
10	O
microg	O
/	O
mL	O
TP	O
.	O

Ten	O
IU	O
/	O
mL	O
urokinase	S-geneN
was	O
also	O
incubated	O
with	O
pooled	O
plasma	O
of	O
stroke	O
patients	O
,	O
that	O
was	O
previously	O
oxidized	O
with	O
the	O
singlet	B-chem-C4-1
oxygen	E-chem-C4-1
(	O
1O2	S-chem-C4-1
)	O
donor	O
chloramine	B-chem-C4-1
T	E-chem-C4-1
(	O
CT	S-chem-C4-1
)	O
,	O
to	O
destroy	O
plasmatic	B-geneY-C4-2
PAI	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
and	O
alpha2	O
-	O
antiplasmin	O
.	O

After	O
0	O
to	O
80	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
,	O
50	O
-	O
microL	O
samples	O
were	O
withdrawn	O
and	O
added	O
to	O
100	O
microL	O
1.5	O
M	O
arginine	S-chem
,	O
pH	O
8.7	O
,	O
and	O
oxidized	O
with	O
50	O
microL	O
of	O
20	O
mM	O
CT	S-chem
.	O

For	O
determination	O
of	O
plasmin	S-geneY-C9-2
activity	O
,	O
10	O
microL	O
thereof	O
was	O
incubated	O
with	O
150	O
microL	O
1.5	O
M	O
arginine	S-chem-C9-1
,	O
pH	O
8.7	O
,	O
and	O
100	O
microL	O
20	O
mM	O
CT	S-chem
preoxidized	O
(	O
15	O
minutes	O
37	O
degrees	O
C	O
)	O
pooled	O
normal	O
citrate	S-chem
buffered	O
EDTA	S-chem
-	O
plasma	O
for	O
30	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
.	O

For	O
determination	O
of	O
[	O
PA	S-geneN-C9-2
+	O
Pli	S-geneY-C9-2
]	O
-	O
activity	O
,	O
arginine	S-chem-C9-1
was	O
added	O
after	O
this	O
incubation	O
.	O

25	O
-	O
microL	O
6	O
mM	O
Val	B-chem
-	I-chem
Leu	I-chem
-	I-chem
Lys	E-chem
-	O
pNA	O
were	O
added	O
and	O
deltaA	O
/	O
h	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
was	O
monitored	O
,	O
using	O
a	O
microtiterplate	O
reader	O
.	O

[	O
PA	S-geneN
+	O
Pli	S-geneY
]	O
-	O
Pli	S-geneY
=	O
PA	S-geneN
.	O

The	O
PA	S-geneN
concentration	O
required	O
to	O
induce	O
25	O
%	O
[	O
ED25	O
]	O
of	O
the	O
maximally	O
inducible	O
Pli	S-geneY
-	O
activity	O
in	O
plasma	O
(	O
=	O
1	O
U	O
/	O
mL	O
=	O
45	O
mg	O
/	O
L	O
=	O
0.53	O
micromol	O
/	O
L	O
active	O
Pli	S-geneY
;	O
deltaA	O
=	O
363	O
+	O
/	O
-	O
8	O
mA	O
/	O
h	O
RT	O
)	O
after	O
10	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
were	O
320	O
IU	O
/	O
mL	O
u	B-geneY
-	I-geneY
PA	E-geneY
,	O
8	O
microg	O
/	O
mL	O
t	B-geneY
-	I-geneY
PA	E-geneY
,	O
140	O
U	O
/	O
mL	O
PSAC	O
,	O
6,000	O
IU	O
/	O
mL	O
SK	O
,	O
720	O
U	O
/	O
mL	O
RP	O
,	O
and	O
approximately	O
150	O
microg	O
/	O
mL	O
TP	O
.	O

The	O
approximate	O
activity	O
half	O
-	O
lives	O
of	O
the	O
PA	S-geneN
in	O
plasma	O
were	O
30	O
minutes	O
for	O
u	B-geneY
-	I-geneY
PA	E-geneY
,	O
30	O
minutes	O
for	O
t	B-geneY
-	I-geneY
PA	E-geneY
,	O
greater	O
than	O
80	O
minutes	O
for	O
SK	S-geneN
,	O
greater	O
than	O
80	O
minutes	O
for	O
PSAC	S-geneN
,	O
50	O
minutes	O
for	O
RP	O
,	O
and	O
80	O
minutes	O
for	O
TP	O
.	O

The	O
present	O
study	O
shows	O
-	O
-	O
for	O
the	O
first	O
time	O
-	O
-	O
a	O
combined	O
kinetic	O
in	O
vitro	O
simulation	O
of	O
the	O
plasmatic	O
activity	O
of	O
six	O
different	O
PAs	S-geneN
.	O

At	O
clinically	O
used	O
concentrations	O
,	O
RP	O
induces	O
the	O
highest	O
plasmatic	B-geneY
Pli	E-geneY
activity	O
.	O

Due	O
to	O
unselective	O
generation	O
of	O
plasmin	S-geneY
in	O
plasma	O
,	O
all	O
PA	S-geneN
are	O
of	O
some	O
danger	O
in	O
inducing	O
severe	O
hemorrhagias	O
.	O

Clinical	O
thrombolysis	O
might	O
be	O
improved	O
by	O
usage	O
of	O
more	O
physiologic	O
activators	O
of	O
thrombolysis	O
,	O
such	O
as	O
activators	O
of	O
polymorphonuclear	O
neutrophils	O
.	O

Effect	O
of	O
galantamine	S-chem
on	O
acetylcholinesterase	S-geneY
and	O
butyrylcholinesterase	S-geneY
activities	O
in	O
the	O
presence	O
of	O
L	B-chem
-	I-chem
carnitine	E-chem
in	O
rat	O
selected	O
brain	O
and	O
peripheral	O
tissues	O
.	O

OBJECTIVES	O
:	O
The	O
alkaloid	O
galantamine	S-chem-C4-1
(	O
GAL	S-chem-C4-1
)	O
,	O
which	O
exhibits	O
a	O
combined	O
anticholinesterase	S-geneY-C4-2
and	O
direct	O
parasympathomimetic	O
mechanism	O
of	O
action	O
,	O
is	O
employed	O
in	O
conjunction	O
with	O
therapeutic	O
interventions	O
in	O
the	O
stimulation	O
of	O
central	O
cholinergic	O
transfer	O
in	O
cognitive	O
diseases	O
.	O

We	O
attempted	O
to	O
achieve	O
pharmacologically	O
-	O
induced	O
enhancement	O
of	O
the	O
parasympathomimetic	O
activity	O
of	O
GAL	S-chem
in	O
the	O
key	O
areas	O
of	O
rat	O
brain	O
,	O
using	O
an	O
interactive	O
combination	O
of	O
the	O
alkaloid	O
with	O
the	O
transmembrane	O
enhancer	O
L	B-chem
-	I-chem
carnitine	E-chem
(	O
CAR	S-chem
)	O
.	O

METHODS	O
:	O
We	O
investigated	O
activities	O
of	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
in	O
brain	O
areas	O
(	O
frontal	O
cortex	O
,	O
basal	O
ganglia	O
,	O
septum	O
and	O
hippocampus	O
)	O
and	O
the	O
hypophysis	O
,	O
and	O
that	O
of	O
butyrylcholinesterase	S-geneY
(	O
BuChE	S-geneY
)	O
in	O
plasma	O
and	O
liver	O
.	O

RESULTS	O
:	O
Following	O
administration	O
of	O
the	O
highest	O
of	O
the	O
GAL	S-chem-C4-1
doses	O
used	O
(	O
2.5	O
;	O
5	O
;	O
10	O
mg	O
/	O
kg	O
i.m	O
.	O
)	O
,	O
AChE	S-geneY-C4-2
activity	O
decreased	O
mainly	O
in	O
the	O
frontal	O
cortex	O
,	O
hippocampus	O
and	O
hypophysis	O
.	O

In	O
the	O
interaction	O
of	O
GAL	S-chem-C4-1
and	O
CAR	S-geneN
,	O
AChE	S-geneY-C4-2
inhibition	O
was	O
stronger	O
but	O
without	O
any	O
statistical	O
significance	O
.	O

The	O
peripheral	O
inhibition	O
of	O
BuChE	S-geneY
was	O
found	O
to	O
be	O
dose	O
-	O
dependent	O
.	O

Premedication	O
by	O
CAR	S-chem
led	O
to	O
a	O
slight	O
change	O
in	O
the	O
values	O
of	O
the	O
activities	O
monitored	O
.	O

CONCLUSIONS	O
:	O
CAR	S-chem
in	O
terms	O
of	O
positive	O
modulation	O
of	O
GAL	S-chem
targeting	O
to	O
the	O
central	O
nervous	O
system	O
had	O
no	O
statistically	O
significant	O
effect	O
.	O

Amitriptyline	S-chem-C5-1
is	O
a	O
TrkA	S-geneY-C5-2
and	O
TrkB	S-geneY-C5-2
receptor	O
agonist	O
that	O
promotes	O
TrkA	S-geneY
/	O
TrkB	S-geneY
heterodimerization	O
and	O
has	O
potent	O
neurotrophic	O
activity	O
.	O

Neurotrophins	S-geneN
,	O
the	O
cognate	O
ligands	O
for	O
the	O
Trk	B-geneN
receptors	E-geneN
,	O
are	O
homodimers	O
and	O
induce	O
Trk	S-geneN
dimerization	O
through	O
a	O
symmetric	O
bivalent	O
mechanism	O
.	O

We	O
report	O
here	O
that	O
amitriptyline	S-chem
,	O
an	O
antidepressant	O
drug	O
,	O
directly	O
binds	O
TrkA	S-geneY
and	O
TrkB	S-geneY
and	O
triggers	O
their	O
dimerization	O
and	O
activation	O
.	O

Amitriptyline	S-chem-C3-1
,	O
but	O
not	O
any	O
other	O
tricyclic	S-chem
or	O
selective	O
serotonin	S-chem
reuptake	O
inhibitor	O
antidepressants	O
,	O
promotes	O
TrkA	S-geneY-C3-2
autophosphorylation	O
in	O
primary	O
neurons	O
and	O
induces	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Amitriptyline	S-chem
binds	O
the	O
extracellular	O
domain	O
of	O
both	O
TrkA	S-geneY
and	O
TrkB	S-geneY
and	O
promotes	O
TrkA	S-geneY
-	O
TrkB	S-geneY
receptor	O
heterodimerization	O
.	O

Truncation	O
of	O
amitriptyline	S-chem
binding	O
motif	O
on	O
TrkA	S-geneY
abrogates	O
the	O
receptor	O
dimerization	O
by	O
amitriptyline	S-chem
.	O

Administration	O
of	O
amitriptyline	S-chem
to	O
mice	O
activates	O
both	O
receptors	O
and	O
significantly	O
reduces	O
kainic	B-chem
acid	E-chem
-	O
triggered	O
neuronal	O
cell	O
death	O
.	O

Inhibition	O
of	O
TrkA	S-geneY
,	O
but	O
not	O
TrkB	S-geneY
,	O
abolishes	O
amitriptyline	O
's	O
neuroprotective	O
effect	O
without	O
impairing	O
its	O
antidepressant	O
activity	O
.	O

Thus	O
,	O
amitriptyline	S-chem-C5-1
acts	O
as	O
a	O
TrkA	S-geneY-C5-2
and	O
TrkB	S-geneY-C5-2
agonist	O
and	O
possesses	O
marked	O
neurotrophic	O
activity	O
.	O

A	O
Model	O
-	O
Based	O
Approach	O
to	O
Predict	O
Longitudinal	O
HbA1c	S-geneY
,	O
Using	O
Early	O
Phase	O
Glucose	S-chem
Data	O
From	O
Type	O
2	O
Diabetes	O
Mellitus	O
Patients	O
After	O
Anti	O
-	O
Diabetic	O
Treatment	O
.	O

Predicting	O
late	O
phase	O
outcomes	O
from	O
early	O
-	O
phase	O
findings	O
can	O
help	O
inform	O
decisions	O
in	O
drug	O
development	O
.	O

If	O
the	O
measurements	O
in	O
early	O
-	O
phase	O
differ	O
from	O
those	O
in	O
late	O
phase	O
,	O
forecasting	O
is	O
more	O
challenging	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
a	O
model	O
-	O
based	O
approach	O
for	O
predicting	O
glycosylated	B-geneY
hemoglobin	E-geneY
(	O
HbA1c	S-geneY
)	O
in	O
late	O
phase	O
using	O
glucose	S-chem
and	O
insulin	S-geneY
concentrations	O
from	O
an	O
early	O
-	O
phase	O
study	O
,	O
investigating	O
an	O
anti	O
-	O
diabetic	O
treatment	O
.	O

Two	O
previously	O
published	O
models	O
were	O
used	O
;	O
an	O
integrated	O
glucose	S-chem
and	O
insulin	S-geneY
(	O
IGI	O
)	O
model	O
for	O
meal	O
tolerance	O
tests	O
and	O
an	O
integrated	O
glucose	S-chem
-	O
red	O
blood	O
cell	O
-	O
HbA1c	S-geneY
(	O
IGRH	O
)	O
model	O
predicting	O
the	O
formation	O
of	O
HbA1c	S-geneY
from	O
the	O
average	O
glucose	S-chem
concentration	O
(	O
Cg	O
,	O
av	O
)	O
.	O

Output	O
from	O
the	O
IGI	O
model	O
was	O
used	O
as	O
input	O
to	O
the	O
IGRH	O
model	O
.	O

Parameters	O
of	O
the	O
IGI	O
model	O
and	O
drug	O
effects	O
were	O
estimated	O
using	O
data	O
from	O
a	O
phase1	O
study	O
in	O
59	O
diabetic	O
patients	O
receiving	O
various	O
doses	O
of	O
a	O
glucokinase	S-geneY
activator	O
.	O

Cg	O
,	O
av	O
values	O
were	O
simulated	O
according	O
to	O
a	O
Phase	O
2	O
study	O
design	O
and	O
used	O
in	O
the	O
IGRH	O
model	O
for	O
predictions	O
of	O
HbA1c	S-geneY
.	O

The	O
performance	O
of	O
the	O
model	O
-	O
based	O
approach	O
was	O
assessed	O
by	O
comparing	O
the	O
predicted	O
to	O
the	O
actual	O
outcome	O
of	O
the	O
Phase	O
2	O
study	O
.	O

We	O
have	O
shown	O
that	O
this	O
approach	O
well	O
predicts	O
the	O
longitudinal	O
HbA1c	S-geneY
response	O
in	O
a	O
12	O
-	O
week	O
study	O
using	O
only	O
information	O
from	O
a	O
1	O
-	O
week	O
study	O
where	O
glucose	S-chem
and	O
insulin	S-geneY
concentrations	O
were	O
measured	O
.	O

Activation	O
of	O
AMP	B-geneN-C3-2
-	I-geneN-C3-2
activated	I-geneN-C3-2
Protein	I-geneN-C3-2
Kinase	E-geneN-C3-2
and	O
Phosphorylation	O
of	O
Glycogen	B-geneY-C3-2
Synthase	I-geneY-C3-2
Kinase3	I-geneY-C3-2
β	E-geneY-C3-2
Mediate	O
Ursolic	B-chem-C3-1
Acid	E-chem-C3-1
Induced	O
Apoptosis	O
in	O
HepG2	O
Liver	O
Cancer	O
Cells	O
.	O

Despite	O
the	O
antitumour	O
effect	O
of	O
ursolic	B-chem
acid	E-chem
observed	O
in	O
several	O
cancers	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
roles	O
of	O
AMP	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
AMPK	S-geneN
)	O
and	O
glycogen	B-geneY
synthase	I-geneY
kinase	I-geneY
3	I-geneY
beta	E-geneY
(	O
GSK3β	S-geneY
)	O
were	O
examined	O
in	O
ursolic	O
acid	O
induced	O
apoptosis	O
in	O
HepG2	O
hepatocellular	O
carcinoma	O
cells	O
.	O

Ursolic	B-chem
acid	E-chem
significantly	O
exerted	O
cytotoxicity	O
,	O
increased	O
the	O
sub	O
-	O
G1	O
population	O
and	O
the	O
number	O
of	O
ethidium	S-chem
homodimer	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
mediated	O
dUTP	S-chem
nick	O
end	O
labeling	O
positive	O
cells	O
in	O
HepG2	O
cells	O
.	O

Also	O
,	O
ursolic	O
acid	O
enhanced	O
the	O
cleavages	O
of	O
poly	B-geneN
-	I-geneN
ADP	I-geneN
-	I-geneN
ribose	I-geneN
polymerase	E-geneN
(	O
PARP	S-geneN
)	O
and	O
caspase3	S-geneY
,	O
attenuated	O
the	O
expression	O
of	O
astrocyte	B-geneY
elevated	I-geneY
gene	E-geneY
(	O
AEG1	S-geneY
)	O
and	O
survivin	S-geneY
in	O
HepG2	O
cells	O
.	O

Interestingly	O
,	O
ursolic	B-chem-C3-1
acid	E-chem-C3-1
increased	O
the	O
phosphorylation	O
of	O
AMPK	S-geneN-C3-2
and	O
coenzyme	B-geneN-C3-2
A	I-geneN-C3-2
carboxylase	E-geneN-C3-2
and	O
also	O
enhanced	O
phosphorylation	O
of	O
GSK3β	S-geneY-C3-2
at	O
inactive	O
form	O
serine	S-chem
9	O
,	O
whereas	O
ursolic	B-chem-C4-1
acid	E-chem-C4-1
attenuated	O
the	O
phosphorylation	O
of	O
AKT	S-geneN-C4-2
and	O
mTOR	S-geneY-C4-2
in	O
HepG2	O
cells	O
.	O

Conversely	O
,	O
AMPK	S-geneN-C4-2
inhibitor	O
compound	B-chem-C4-1
C	E-chem-C4-1
or	O
GSK3β	S-geneY-C4-2
inhibitor	O
SB216763	S-chem-C4-1
blocked	O
the	O
cleavages	O
of	O
PARP	S-geneN-C3-2
and	O
caspase	B-geneY-MU-2
3	E-geneY-MU-2
induced	O
by	O
ursolic	B-chem-C3-1
acid	E-chem-C3-1
in	O
HepG2	O
cells	O
.	O

Furthermore	O
,	O
proteosomal	O
inhibitor	O
MG132	S-chem-MU-1
suppressed	O
AMPK	S-geneN-MU-2
activation	O
,	O
GSK3β	S-geneY-MU-2
phosphorylation	O
,	O
cleaved	O
PARP	S-geneN
and	O
deceased	O
AEG	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
induced	O
by	O
ursolic	B-chem-MU-1
acid	E-chem-MU-1
in	O
HepG2	O
cells	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
ursolic	B-chem-C3-1
acid	E-chem-C3-1
induced	O
apoptosis	O
in	O
HepG2	O
cells	O
via	O
AMPK	S-geneN-C3-2
activation	O
and	O
GSK3β	S-geneY-C3-2
phosphorylation	O
as	O
a	O
potent	O
chemopreventive	O
agent	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Heterobivalent	O
dual	O
-	O
target	O
probe	O
for	O
targeting	O
GRP	S-geneY
and	O
Y1	B-geneY
receptors	E-geneY
on	O
tumor	O
cells	O
.	O

Receptor	O
targeting	O
ligands	O
for	O
imaging	O
and	O
/	O
or	O
therapy	O
of	O
cancer	O
are	O
limited	O
by	O
heterogeneity	O
of	O
receptor	O
expression	O
by	O
tumor	O
cells	O
,	O
both	O
inter	O
-	O
patient	O
and	O
intra	O
-	O
patient	O
.	O

It	O
is	O
often	O
more	O
important	O
for	O
imaging	O
agents	O
to	O
identify	O
local	O
and	O
distant	O
spread	O
of	O
disease	O
than	O
it	O
is	O
to	O
identify	O
a	O
specific	O
receptor	O
presence	O
.	O

Two	O
natural	O
hormone	O
peptide	O
receptors	O
,	O
GRPR	S-geneY
and	O
Y1	S-geneY
,	O
are	O
specifically	O
interesting	O
because	O
expression	O
of	O
GRPR	S-geneY
,	O
Y1	S-geneY
or	O
both	O
is	O
up	O
-	O
regulated	O
in	O
most	O
breast	O
cancers	O
.	O

We	O
describe	O
here	O
the	O
design	O
and	O
development	O
of	O
a	O
new	O
heterobivalent	O
peptide	O
ligand	O
,	O
truncated	B-geneN
bombesin	E-geneN
(	O
t	B-geneN
-	I-geneN
BBN	E-geneN
)	O
/	O
BVD15	O
-	O
DO3A	O
,	O
for	O
dual	O
-	O
targeting	O
of	O
GRPR	S-geneY
and	O
Y1	S-geneY
,	O
and	O
validation	O
of	O
its	O
dual	O
binding	O
capability	O
.	O

Such	O
a	O
probe	O
should	O
be	O
useful	O
in	O
imaging	O
cells	O
,	O
tissues	O
and	O
tumors	O
that	O
are	O
GRPR	S-geneY
and	O
/	O
or	O
Y1	S-geneY
positive	O
and	O
should	O
target	O
radioisotopes	O
,	O
for	O
example	O
,	O
(	O
68	O
)	O
Ga	O
and	O
/	O
or	O
(	O
177	O
)	O
Lu	O
,	O
to	O
more	O
tumors	O
cells	O
than	O
single	O
GRPR	S-geneY
or	O
Y1	S-geneY
targeted	O
probes	O
.	O

A	O
GRP	S-geneY
targeting	O
ligand	O
,	O
J	O
-	O
G	O
-	O
Abz4	O
-	O
QWAVGHLM	O
-	O
NH	O
(	O
2	O
)	O
(	O
J	O
-	O
G	O
-	O
Abz4	O
-	O
t	O
-	O
BBN	O
)	O
,	O
and	O
an	O
Y1	S-geneY
targeting	O
ligand	O
,	O
INP	O
-	O
K	O
[	O
ε	O
-	O
J	O
-	O
(	O
α	O
-	O
DO3A	O
-	O
ε	O
-	O
DGa	O
)	O
-	O
K	O
]	O
-	O
YRLRY	O
-	O
NH	O
(	O
2	O
)	O
(	O
[	O
ε	O
-	O
J	O
-	O
(	O
α	O
-	O
DO3A	O
-	O
ε	O
-	O
DGa	O
)	O
-	O
K	O
]	O
-	O
BVD	O
-	O
15	O
)	O
,	O
were	O
synthesized	O
and	O
coupled	O
to	O
produce	O
the	O
heterobivalent	O
ligand	O
,	O
t	B-geneN
-	I-geneN
BBN	E-geneN
/	O
BVD15	O
-	O
DO3A	O
.	O

Competitive	O
displacement	O
binding	O
assays	O
using	O
t	B-geneN
-	I-geneN
BBN	E-geneN
/	O
BVD15	O
-	O
DO3A	O
against	O
(	B-geneN
125	I-geneN
)	I-geneN
I	I-geneN
-	I-geneN
Tyr	I-geneN
(	I-geneN
4	I-geneN
)	I-geneN
-	I-geneN
BBN	E-geneN
yielded	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
18	O
±	O
0.7	O
nM	O
for	O
GRPR	S-geneY
in	O
T	O
-	O
47D	O
cells	O
,	O
a	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O

A	O
similar	O
assay	O
using	O
t	B-geneN
-	I-geneN
BBN	E-geneN
/	O
BVD15	O
-	O
DO3A	O
against	O
porcine	B-geneY
(	I-geneY
125	I-geneY
)	I-geneY
I	I-geneY
-	I-geneY
NPY	E-geneY
showed	O
IC	O
(	O
50	O
)	O
values	O
of	O
80	O
±	O
11	O
nM	O
for	O
Y1	B-geneY
receptor	E-geneY
in	O
MCF7	O
cells	O
,	O
another	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O

In	O
conclusion	O
,	O
it	O
is	O
possible	O
to	O
construct	O
a	O
single	O
DO3A	O
chelate	O
containing	O
probe	O
that	O
can	O
target	O
both	O
GRPR	S-geneY
and	O
Y1	S-geneY
on	O
human	O
tumor	O
cells	O
.	O

Nitrogen	S-chem-MU-1
-	O
containing	O
bisphosphonates	S-chem-MU-1
induce	O
apoptosis	O
of	O
hematopoietic	O
tumor	O
cells	O
via	O
inhibition	O
of	O
Ras	S-geneN-C4-2
signaling	O
pathways	O
and	O
Bim	S-geneY-C3-2
-	O
mediated	O
activation	O
of	O
the	O
intrinsic	O
apoptotic	O
pathway	O
.	O

Nitrogen	S-chem-C4-1
-	O
containing	O
bisphosphonates	S-chem-C4-1
(	O
N	S-chem-C4-1
-	O
BPs	S-chem-C4-1
)	O
induce	O
apoptosis	O
in	O
tumor	O
cells	O
by	O
inhibiting	O
the	O
prenylation	O
of	O
small	O
G	B-geneN-C4-2
-	I-geneN-C4-2
proteins	E-geneN-C4-2
.	O

However	O
,	O
the	O
details	O
of	O
the	O
apoptosis	O
-	O
inducing	O
mechanism	O
remain	O
obscure	O
.	O

The	O
present	O
study	O
showed	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
N	S-chem
-	O
BPs	S-chem
in	O
hematopoietic	O
tumor	O
cells	O
is	O
mediated	O
by	O
mitochondrial	O
apoptotic	O
signaling	O
pathways	O
,	O
which	O
are	O
activated	O
by	O
the	O
suppression	O
of	O
geranylgeranyl	B-chem
pyrophosphate	E-chem
(	O
GGPP	S-chem
)	O
biosynthesis	O
.	O

Furthermore	O
,	O
N	S-chem-MU-1
-	O
BPs	S-chem-MU-1
decreased	O
the	O
levels	O
of	O
phosphorylated	B-geneN-C4-2
extracellular	I-geneN-C4-2
signal	I-geneN-C4-2
-	I-geneN-C4-2
regulated	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
ERK	S-geneN-C4-2
)	O
and	O
mTOR	S-geneY-C4-2
via	O
suppression	O
of	O
Ras	S-geneN-C4-2
prenylation	O
and	O
enhanced	O
Bim	S-geneY-C3-2
expression	O
.	O

The	O
present	O
results	O
indicated	O
that	O
N	S-chem-MU-1
-	O
BPs	S-chem-MU-1
induce	O
apoptosis	O
by	O
decreasing	O
the	O
mitochondrial	O
transmembrane	O
potential	O
,	O
increasing	O
the	O
activation	O
of	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
9	E-geneY-C3-2
and	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
,	O
and	O
enhancing	O
Bim	S-geneY-C3-2
expression	O
through	O
inhibition	O
of	O
the	O
Ras	S-geneN-C4-2
/	O
MEK	S-geneN-C4-2
/	O
ERK	S-geneN-C4-2
and	O
Ras	S-geneN-C4-2
/	O
mTOR	S-geneY-C4-2
pathways	O
.	O

The	O
accumulation	O
of	O
N	S-chem
-	O
BPs	S-chem
in	O
bones	O
suggests	O
that	O
they	O
may	O
act	O
more	O
effectively	O
on	O
tumors	O
that	O
have	O
spread	O
to	O
bones	O
or	O
on	O
Ras	S-geneN
-	O
variable	O
tumors	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
the	O
specific	O
molecular	O
pathways	O
of	O
N	S-chem
-	O
BP	O
-	O
induced	O
apoptosis	O
.	O

The	O
antipsychotic	O
drugs	O
sertindole	S-chem-C4-1
and	O
pimozide	S-chem-C4-1
block	O
erg3	S-geneY-C4-2
,	O
a	O
human	B-geneN-C4-2
brain	I-geneN-C4-2
K	I-geneN-C4-2
(	I-geneN-C4-2
+	I-geneN-C4-2
)	I-geneN-C4-2
channel	E-geneN-C4-2
.	O

The	O
antipsychotic	O
drugs	O
sertindole	S-chem-C4-1
and	O
pimozide	S-chem-C4-1
are	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
on	O
the	O
electrocardiogram	O
via	O
a	O
high	O
affinity	O
block	O
of	O
the	O
cardiac	B-geneN-C4-2
K	I-geneN-C4-2
(	I-geneN-C4-2
+	I-geneN-C4-2
)	I-geneN-C4-2
channel	E-geneN-C4-2
known	O
as	O
HERG	S-geneY-C4-2
(	O
human	B-geneY-C4-2
ether	I-geneY-C4-2
-	I-geneY-C4-2
a	I-geneY-C4-2
-	I-geneY-C4-2
go	I-geneY-C4-2
-	I-geneY-C4-2
go	I-geneY-C4-2
-	I-geneY-C4-2
related	I-geneY-C4-2
gene	E-geneY-C4-2
;	O
erg1	S-geneY-C4-2
)	O
.	O

We	O
wished	O
to	O
test	O
whether	O
these	O
drugs	O
also	O
displayed	O
high	O
affinity	O
for	O
the	O
related	O
neuronal	B-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
erg3	S-geneY
.	O

The	O
cDNA	O
encoding	O
erg3	S-geneY
channel	O
was	O
cloned	O
from	O
a	O
human	O
brain	O
library	O
.	O

Northern	O
analysis	O
confirmed	O
that	O
the	O
channel	O
was	O
localized	O
to	O
brain	O
relative	O
to	O
other	O
tissues	O
including	O
heart	O
,	O
liver	O
and	O
lung	O
.	O

Within	O
the	O
brain	O
,	O
erg3	S-geneY
was	O
expressed	O
in	O
higher	O
amounts	O
in	O
the	O
frontal	O
lobe	O
and	O
cerebellum	O
relative	O
to	O
the	O
temporal	O
,	O
parietal	O
and	O
occipital	O
lobes	O
.	O

Transient	O
expression	O
of	O
erg3	S-geneY
in	O
Chinese	O
hamster	O
ovary	O
cells	O
produced	O
outwardly	O
directed	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
currents	O
that	O
activated	O
at	O
approximately	O
-	O
50	O
mV	O
and	O
produced	O
a	O
large	O
transient	O
component	O
at	O
positive	O
membrane	O
potentials	O
.	O

Inward	O
tail	O
currents	O
measured	O
at	O
-	O
100	O
mV	O
were	O
blocked	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
by	O
sertindole	S-chem
resulting	O
in	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
43	O
nM	O
.	O

Significant	O
inhibition	O
was	O
observed	O
at	O
concentrations	O
as	O
low	O
as	O
3	O
nM	O
.	O

Block	O
of	O
erg3	S-geneY-C4-2
by	O
sertindole	S-chem-C4-1
also	O
displayed	O
a	O
positive	O
voltage	O
-	O
dependence	O
.	O

Pimozide	S-chem-C4-1
blocked	O
erg3	S-geneY-C4-2
channel	O
currents	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
103	O
nM	O
and	O
significant	O
inhibition	O
was	O
noted	O
at	O
concentrations	O
of	O
10	O
nM	O
and	O
higher	O
.	O

We	O
conclude	O
that	O
erg3	S-geneY-C4-2
can	O
be	O
blocked	O
by	O
certain	O
antipsychotic	O
drugs	O
like	O
sertindole	S-chem-C4-1
and	O
pimozide	S-chem-C4-1
.	O

Inhibition	O
of	O
erg3	S-geneY
or	O
related	O
K	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
in	O
the	O
brain	O
may	O
contribute	O
to	O
the	O
efficacy	O
/	O
side	O
effect	O
profiles	O
of	O
some	O
antipsychotic	O
drugs	O
.	O

Efficacy	O
and	O
safety	O
of	O
the	O
dipeptidyl	B-geneY-C4-2
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
inhibitor	O
,	O
sitagliptin	S-chem-C4-1
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
inadequately	O
controlled	O
on	O
glimepiride	S-chem
alone	O
or	O
on	O
glimepiride	S-chem
and	O
metformin	S-chem
.	O

AIM	O
:	O
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
24	O
-	O
week	O
treatment	O
with	O
sitagliptin	S-chem-C4-1
,	O
a	O
highly	O
selective	O
once	O
-	O
daily	O
oral	O
dipeptidyl	B-geneY-C4-2
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
(	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
)	O
inhibitor	O
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
had	O
inadequate	O
glycaemic	O
control	O
[	O
glycosylated	B-geneY
haemoglobin	E-geneY
(	O
HbA	B-geneY
(	I-geneY
1c	I-geneY
)	E-geneY
)	O
>	O
or	O
=	O
7.5	O
%	O
and	O
<	O
or	O
=	O
10.5	O
%	O
]	O
while	O
on	O
glimepiride	O
alone	O
or	O
in	O
combination	O
with	O
metformin	O
.	O

METHODS	O
:	O
After	O
a	O
screening	O
,	O
diet	O
/	O
exercise	O
run	O
-	O
in	O
and	O
drug	O
wash	O
-	O
off	O
period	O
,	O
a	O
glimepiride	O
+	O
/	O
-	O
metformin	O
dose	O
titration	O
/	O
stabilization	O
period	O
and	O
a	O
2	O
-	O
week	O
,	O
single	O
-	O
blind	O
placebo	O
run	O
-	O
in	O
,	O
441	O
patients	O
(	O
of	O
ages	O
18	O
-	O
75	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
the	O
addition	O
of	O
sitagliptin	O
100	O
mg	O
once	O
daily	O
or	O
placebo	O
in	O
a	O
1	O
:	O
1	O
ratio	O
for	O
24	O
weeks	O
.	O

Of	O
these	O
patients	O
,	O
212	O
were	O
on	O
glimepiride	O
(	O
>	O
or	O
=	O
4	O
mg	O
/	O
day	O
)	O
monotherapy	O
and	O
229	O
were	O
on	O
glimepiride	O
(	O
>	O
or	O
=	O
4	O
mg	O
/	O
day	O
)	O
plus	O
metformin	O
(	O
>	O
or	O
=	O
1,500	O
mg	O
/	O
day	O
)	O
combination	O
therapy	O
.	O

Patients	O
exceeding	O
pre	O
-	O
specified	O
glycaemic	O
thresholds	O
during	O
the	O
double	O
-	O
blind	O
treatment	O
period	O
were	O
provided	O
open	O
-	O
label	O
rescue	O
therapy	O
(	O
pioglitazone	O
)	O
until	O
study	O
end	O
.	O

The	O
primary	O
efficacy	O
analysis	O
evaluated	O
the	O
change	O
in	O
HbA	O
(	O
1c	O
)	O
from	O
baseline	O
to	O
Week	O
24	O
.	O

Secondary	O
efficacy	O
endpoints	O
included	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
2	O
-	O
h	O
post	O
-	O
meal	O
glucose	O
and	O
lipid	O
measurements	O
.	O

RESULTS	O
:	O
Mean	O
baseline	O
HbA	O
(	O
1c	O
)	O
was	O
8.34	O
%	O
in	O
the	O
sitagliptin	O
and	O
placebo	O
groups	O
.	O

After	O
24	O
weeks	O
,	O
sitagliptin	O
reduced	O
HbA	O
(	O
1c	O
)	O
by	O
0.74	O
%	O
(	O
p	O
<	O
0.001	O
)	O
relative	O
to	O
placebo	O
.	O

In	O
the	O
subset	O
of	O
patients	O
on	O
glimepiride	O
plus	O
metformin	O
,	O
sitagliptin	O
reduced	O
HbA	O
(	O
1c	O
)	O
by	O
0.89	O
%	O
relative	O
to	O
placebo	O
,	O
compared	O
with	O
a	O
reduction	O
of	O
0.57	O
%	O
in	O
the	O
subset	O
of	O
patients	O
on	O
glimepiride	O
alone	O
.	O

The	O
addition	O
of	O
sitagliptin	O
reduced	O
FPG	O
by	O
20.1	O
mg	O
/	O
dl	O
(	O
p	O
<	O
0.001	O
)	O
and	O
increased	O
homeostasis	O
model	O
assessment	O
-	O
beta	O
,	O
a	O
marker	O
of	O
beta	O
-	O
cell	O
function	O
,	O
by	O
12	O
%	O
(	O
p	O
<	O
0.05	O
)	O
relative	O
to	O
placebo	O
.	O

In	O
patients	O
who	O
underwent	O
a	O
meal	O
tolerance	O
test	O
(	O
n	O
=	O
134	O
)	O
,	O
sitagliptin	O
decreased	O
2	O
-	O
h	O
post	O
-	O
prandial	O
glucose	O
(	O
PPG	O
)	O
by	O
36.1	O
mg	O
/	O
dl	O
(	O
p	O
<	O
0.001	O
)	O
relative	O
to	O
placebo	O
.	O

The	O
addition	O
of	O
sitagliptin	O
was	O
generally	O
well	O
tolerated	O
,	O
although	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
overall	O
(	O
60	O
vs	O
.	O

47	O
%	O
)	O
and	O
drug	O
-	O
related	O
adverse	O
experiences	O
(	O
AEs	O
)	O
(	O
15	O
vs	O
.	O

7	O
%	O
)	O
in	O
the	O
sitagliptin	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

This	O
was	O
largely	O
because	O
of	O
a	O
higher	O
incidence	O
of	O
hypoglycaemia	O
AEs	O
(	O
12	O
vs	O
.	O

2	O
%	O
,	O
respectively	O
)	O
in	O
the	O
sitagliptin	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

Body	O
weight	O
modestly	O
increased	O
with	O
sitagliptin	O
relative	O
to	O
placebo	O
(	O
+	O
0.8	O
vs	O
.	O

-	O
0.4	O
kg	O
;	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Sitagliptin	O
100	O
mg	O
once	O
daily	O
significantly	O
improved	O
glycaemic	O
control	O
and	O
beta	O
-	O
cell	O
function	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
had	O
inadequate	O
glycaemic	O
control	O
with	O
glimepiride	O
or	O
glimepiride	O
plus	O
metformin	O
therapy	O
.	O

The	O
addition	O
of	O
sitagliptin	O
was	O
generally	O
well	O
tolerated	O
,	O
with	O
a	O
modest	O
increase	O
in	O
hypoglycaemia	O
and	O
body	O
weight	O
,	O
consistent	O
with	O
glimepiride	O
therapy	O
and	O
the	O
observed	O
degree	O
of	O
glycaemic	O
improvement	O
.	O

Proto	B-geneN
-	I-geneN
oncogene	E-geneN
PIM	B-geneY
-	I-geneY
1	E-geneY
is	O
a	O
novel	O
estrogen	B-geneY
receptor	E-geneY
target	O
associating	O
with	O
high	O
grade	O
breast	O
tumors	O
.	O

We	O
searched	O
ERα	S-geneY
cistromes	O
of	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
for	O
previously	O
unrecognized	O
ERα	S-geneY
targets	O
and	O
identified	O
proto	B-geneN
-	I-geneN
oncogene	E-geneN
PIM	B-geneY
-	I-geneY
1	E-geneY
as	O
a	O
novel	O
potential	O
target	O
gene	O
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
PIM	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
is	O
induced	O
in	O
response	O
to	O
estradiol	S-chem-C3-1
in	O
MCF	O
-	O
7	O
cells	O
and	O
that	O
the	O
induction	O
is	O
mediated	O
by	O
ERα	S-geneY-C3-2
-	O
regulated	O
enhancers	O
located	O
distally	O
upstream	O
from	O
the	O
gene	O
.	O

In	O
keeping	O
with	O
the	O
growth	O
-	O
promoting	O
role	O
of	O
the	O
PIM	B-geneY
-	I-geneY
1	E-geneY
,	O
depletion	O
of	O
the	O
PIM	B-geneY
-	I-geneY
1	E-geneY
attenuated	O
the	O
proliferation	O
of	O
the	O
MCF	O
-	O
7	O
cells	O
,	O
which	O
was	O
paralleled	O
with	O
up	O
-	O
regulation	O
of	O
cyclin	B-geneN
-	I-geneN
dependent	I-geneN
protein	I-geneN
kinase	I-geneN
inhibitor	E-geneN
CDKN1A	S-geneY
and	O
CDKN2B	S-geneY
expression	O
.	O

Analysis	O
of	O
PIM	B-geneY
-	I-geneY
1	E-geneY
expression	O
between	O
invasive	O
breast	O
tumors	O
and	O
benign	O
breast	O
tissue	O
samples	O
showed	O
that	O
elevated	O
PIM	B-geneY
-	I-geneY
1	E-geneY
expression	O
is	O
associated	O
with	O
malignancy	O
and	O
a	O
higher	O
tumor	O
grade	O
.	O

In	O
sum	O
,	O
identification	O
of	O
PIM	B-geneY
-	I-geneY
1	E-geneY
as	O
an	O
ERα	S-geneY
target	O
gene	O
adds	O
a	O
novel	O
potential	O
mechanism	O
by	O
which	O
estrogens	S-chem
can	O
contribute	O
to	O
breast	O
cancer	O
cell	O
proliferation	O
and	O
carcinogenesis	O
.	O

Emodin	B-chem-C4-1
-	I-chem-C4-1
6	I-chem-C4-1
-	I-chem-C4-1
O	I-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
D	I-chem-C4-1
-	I-chem-C4-1
glucoside	E-chem-C4-1
inhibits	O
HMGB1	S-geneY-C4-2
-	O
induced	O
inflammatory	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

High	B-geneY
mobility	I-geneY
group	I-geneY
box	I-geneY
1	E-geneY
(	O
HMGB1	S-geneY
)	O
protein	O
acts	O
as	O
a	O
potent	O
proinflammatory	O
cytokine	S-geneN
and	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
vascular	O
diseases	O
,	O
such	O
as	O
,	O
systemic	O
vasculitis	O
and	O
sepsis	O
.	O

Emodin	B-chem
-	I-chem
6	I-chem
-	I-chem
O	I-chem
-	I-chem
β	I-chem
-	I-chem
D	I-chem
-	I-chem
glucoside	E-chem
(	O
EG	O
)	O
is	O
a	O
new	O
active	O
compound	O
from	O
Reynoutria	O
japonica	O
,	O
and	O
its	O
biologic	O
activities	O
have	O
not	O
been	O
previously	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
the	O
antiinflammatory	O
activities	O
of	O
EG	O
on	O
HMGB1	S-geneY
-	O
mediated	O
proinflammatory	O
responses	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
in	O
a	O
murine	O
cecal	O
ligation	O
and	O
puncture	O
(	O
CLP	O
)	O
-	O
model	O
of	O
sepsis	O
in	O
mice	O
.	O

EG	O
was	O
found	O
to	O
suppress	O
the	O
release	O
of	O
HMGB1	S-geneY
,	O
the	O
production	O
of	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
(	I-geneY
TNF	I-geneY
)	I-geneY
-	I-geneY
α	E-geneY
,	O
and	O
the	O
activation	O
of	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
κB	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
by	O
HMGB1	S-geneY
in	O
HUVECs	O
,	O
and	O
to	O
inhibit	O
HMGB1	S-geneY
-	O
mediated	O
hyperpermeability	O
and	O
leukocyte	O
migration	O
in	O
mice	O
.	O

In	O
the	O
CLP	O
model	O
,	O
HMGB1	S-geneY
was	O
highly	O
released	O
,	O
but	O
this	O
release	O
was	O
prevented	O
by	O
EG	O
.	O

Furthermore	O
,	O
EG	O
also	O
increased	O
the	O
survival	O
times	O
of	O
CLP	O
administered	O
mice	O
.	O

Collectively	O
,	O
this	O
study	O
shows	O
EG	O
can	O
protect	O
barrier	O
integrity	O
and	O
inhibit	O
HMGB1	S-geneY
-	O
mediated	O
inflammatory	O
responses	O
,	O
which	O
suggests	O
a	O
potential	O
use	O
as	O
a	O
therapy	O
for	O
sepsis	O
or	O
septic	O
shock	O
.	O

Smad3	S-geneY
mediates	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
induction	O
of	O
VEGF	S-geneY
release	O
by	O
human	O
fetal	O
lung	O
fibroblasts	O
.	O

Cigarette	O
smoke	O
is	O
the	O
major	O
cause	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
yet	O
pathogenic	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
is	O
one	O
of	O
the	O
major	O
regulators	O
of	O
endothelial	O
cell	O
survival	O
and	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
COPD	O
.	O

Fibroblasts	O
are	O
a	O
significant	O
source	O
of	O
VEGF	S-geneY
in	O
the	O
lungs	O
;	O
however	O
the	O
effect	O
of	O
cigarette	O
smoke	O
exposure	O
on	O
VEGF	S-geneY
release	O
by	O
fibroblasts	O
is	O
not	O
fully	O
understood	O
.	O

We	O
hypothesized	O
that	O
cigarette	O
smoke	O
-	O
induced	O
disturbed	O
VEGF	S-geneY
release	O
by	O
human	O
lung	O
fibroblasts	O
is	O
a	O
potential	O
pathogenic	O
mechanism	O
that	O
could	O
contribute	O
to	O
COPD	O
.	O

Cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
was	O
prepared	O
by	O
modification	O
of	O
the	O
methods	O
of	O
Carp	O
and	O
Janoff	O
(	O
American	O
Review	O
of	O
Respiratory	O
Disease	O
,	O
1978	O
)	O
.	O

Human	O
fetal	O
lung	O
fibroblasts	O
(	O
HFL	O
-	O
1	O
)	O
were	O
exposed	O
to	O
different	O
concentrations	O
of	O
CSE	O
and	O
for	O
different	O
durations	O
.	O

VEGF	S-geneY
release	O
into	O
the	O
media	O
was	O
measured	O
using	O
ELISA	O
.	O

TGF	B-geneY
-	I-geneY
β1	I-geneY
receptor	E-geneY
(	O
TβR1	S-geneY
)	O
/	O
Smad3	S-geneY
as	O
a	O
potential	O
pathway	O
for	O
CSE	O
modulated	O
VEGF	S-geneY
release	O
was	O
also	O
investigated	O
using	O
biochemical	O
analyses	O
and	O
siRNA	O
inhibition	O
of	O
Smad3	S-geneY
and	O
siRNA	O
and	O
pharmacologic	O
inhibition	O
of	O
TβR1	S-geneY
.	O

CSE	O
induced	O
VEGF	S-geneY
release	O
by	O
HFL	O
-	O
1	O
in	O
concentration	O
and	O
time	O
dependent	O
manner	O
.	O

This	O
was	O
confirmed	O
in	O
two	O
additional	O
types	O
of	O
primary	O
human	O
fetal	O
lung	O
fibroblasts	O
.	O

CSE	O
induced	O
Smad3	S-geneY
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
HFL	O
-	O
1	O
cells	O
.	O

Silencing	O
of	O
Smad3	S-geneY
by	O
siRNA	O
not	O
only	O
eliminated	O
the	O
stimulatory	O
effect	O
of	O
CSE	O
on	O
VEGF	S-geneY
release	O
but	O
also	O
inhibited	O
baseline	O
VEGF	S-geneY
production	O
.	O

Suppression	O
of	O
TβR1	S-geneY-C4-2
by	O
the	O
pharmacological	O
inhibitor	O
(	O
SB431542	S-chem-C4-1
)	O
markedly	O
reduced	O
VEGF	S-geneY-C4-2
release	O
by	O
HFL	O
-	O
1	O
in	O
response	O
to	O
CSE	O
and	O
this	O
effect	O
was	O
confirmed	O
by	O
TβR1	S-geneY
siRNA	O
.	O

In	O
contrast	O
,	O
nicotine	O
inhibited	O
VEGF	S-geneY
release	O
by	O
HFL	O
-	O
1	O
in	O
a	O
dose	O
and	O
time	O
dependent	O
manner	O
.	O

Our	O
findings	O
indicate	O
that	O
CSE	O
stimulates	O
Smad3	S-geneY
-	O
mediated	O
VEGF	S-geneY
release	O
by	O
lung	O
fibroblasts	O
.	O

Nicotine	S-chem
does	O
not	O
account	O
for	O
the	O
CSE	O
stimulation	O
of	O
VEGF	S-geneY
in	O
HFL	O
-	O
1	O
.	O

The	O
ability	O
of	O
lung	O
fibroblasts	O
to	O
produce	O
VEGF	S-geneY
may	O
play	O
a	O
role	O
in	O
pathogenesis	O
of	O
cigarette	O
smoke	O
induced	O
lung	O
disease	O
.	O

Acetylcholinesterase	S-geneY
inhibition	O
reveals	O
endogenous	O
nicotinic	O
modulation	O
of	O
glutamate	S-chem
inputs	O
to	O
CA1	O
stratum	O
radiatum	O
interneurons	O
in	O
hippocampal	O
slices	O
.	O

The	O
involvement	O
of	O
brain	O
nicotinic	B-geneN
acetylcholine	I-geneN
receptors	E-geneN
(	O
nAChRs	S-geneN
)	O
in	O
the	O
neurotoxicological	O
effects	O
of	O
soman	O
,	O
a	O
potent	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
inhibitor	O
and	O
a	O
chemical	O
warfare	O
agent	O
,	O
is	O
not	O
clear	O
.	O

This	O
is	O
partly	O
due	O
to	O
a	O
poor	O
understanding	O
of	O
the	O
role	O
of	O
AChE	S-geneY
in	O
brain	O
nAChR	S-geneN
-	O
mediated	O
functions	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
AChE	S-geneY
inhibition	O
builds	O
sufficient	O
acetylcholine	S-chem
(	O
ACh	O
)	O
in	O
the	O
brain	O
and	O
facilitates	O
nAChR	S-geneN
-	O
dependent	O
glutamate	S-chem
transmission	O
,	O
we	O
used	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
technique	O
to	O
record	O
spontaneous	O
glutamate	S-chem
excitatory	O
postsynaptic	O
currents	O
(	O
EPSCs	O
)	O
from	O
CA1	O
stratum	O
radiatum	O
interneurons	O
(	O
SRI	O
)	O
in	O
hippocampal	O
slices	O
.	O

First	O
,	O
the	O
frequency	O
,	O
amplitude	O
and	O
kinetics	O
of	O
EPSCs	O
recorded	O
from	O
slices	O
of	O
control	O
guinea	O
pigs	O
were	O
compared	O
to	O
those	O
recorded	O
from	O
slices	O
of	O
guinea	O
pigs	O
after	O
a	O
single	O
injection	O
of	O
the	O
irreversible	O
AChE	S-geneY
inhibitor	O
soman	O
(	O
25.2μg	O
/	O
kg	O
,	O
s.c.	O
)	O
.	O

Second	O
,	O
EPSCs	O
were	O
recorded	O
from	O
rat	O
hippocampal	O
slices	O
before	O
and	O
after	O
their	O
superfusion	O
with	O
the	O
reversible	O
AChE	S-geneY-C4-2
inhibitor	O
donepezil	S-chem-C4-1
(	O
100nM	O
)	O
.	O

The	O
frequency	O
of	O
EPSCs	O
was	O
significantly	O
higher	O
in	O
slices	O
taken	O
from	O
guinea	O
pigs	O
24h	O
but	O
not	O
7	O
days	O
after	O
the	O
soman	O
injection	O
than	O
in	O
slices	O
from	O
control	O
animals	O
.	O

In	O
52	O
%	O
of	O
the	O
rat	O
hippocampal	O
slices	O
tested	O
,	O
bath	O
application	O
of	O
donepezil	S-chem
increased	O
the	O
frequency	O
of	O
EPSCs	O
.	O

Further	O
,	O
exposure	O
to	O
donepezil	S-chem
increased	O
both	O
burst	O
-	O
like	O
and	O
large	O
-	O
amplitude	O
EPSCs	O
,	O
and	O
increased	O
the	O
proportion	O
of	O
short	O
(	O
20	O
-	O
100ms	O
)	O
inter	O
-	O
event	O
intervals	O
.	O

Donepezil	S-chem
's	O
effects	O
were	O
suppressed	O
significantly	O
in	O
presence	O
of	O
10μM	O
mecamylamine	S-chem
or	O
10nM	O
methyllycaconitine	S-chem
.	O

These	O
results	O
support	O
the	O
concept	O
that	O
AChE	S-geneY
inhibition	O
is	O
able	O
to	O
recruit	O
nAChR	S-geneN
-	O
dependent	O
glutamate	S-chem
transmission	O
in	O
the	O
hippocampus	O
and	O
such	O
a	O
mechanism	O
can	O
contribute	O
to	O
the	O
acute	O
neurotoxicological	O
actions	O
of	O
soman	O
.	O

Trace	B-geneY
amine	I-geneY
-	I-geneY
associated	I-geneY
receptor	I-geneY
1	E-geneY
displays	O
species	O
-	O
dependent	O
stereoselectivity	O
for	O
isomers	O
of	O
methamphetamine	S-chem
,	O
amphetamine	S-chem
,	O
and	O
para	B-chem
-	I-chem
hydroxyamphetamine	E-chem
.	O

The	O
synthetic	O
amines	S-chem
methamphetamine	S-chem
(	O
METH	S-chem
)	O
,	O
amphetamine	S-chem
(	O
AMPH	S-chem
)	O
,	O
and	O
their	O
metabolite	O
para	B-chem
-	I-chem
hydroxyamphetamine	E-chem
(	O
POHA	S-chem
)	O
are	O
chemically	O
and	O
structurally	O
related	O
to	O
the	O
catecholamine	S-chem
neurotransmitters	O
and	O
a	O
small	O
group	O
of	O
endogenous	O
biogenic	O
amines	S-chem
collectively	O
referred	O
to	O
as	O
the	O
trace	O
amines	S-chem
(	O
TAs	O
)	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
METH	S-chem
,	O
AMPH	S-chem
,	O
POHA	S-chem
,	O
and	O
the	O
TAs	O
para	B-chem
-	I-chem
tyramine	E-chem
(	O
TYR	S-chem
)	O
and	O
beta	B-chem
-	I-chem
phenylethylamine	E-chem
(	O
PEA	S-chem
)	O
stimulate	O
cAMP	S-chem
production	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
-	O
293	O
cells	O
expressing	O
rat	B-geneY
trace	I-geneY
amine	I-geneY
-	I-geneY
associated	I-geneY
receptor	I-geneY
1	E-geneY
(	O
rTAAR1	S-geneY
)	O
.	O

The	O
discovery	O
that	O
METH	S-chem-C3-1
and	O
AMPH	S-chem-C3-1
activate	O
the	O
rTAAR1	S-geneY-C3-2
motivated	O
us	O
to	O
study	O
the	O
effect	O
of	O
these	O
drugs	O
on	O
the	O
mouse	B-geneY
TAAR1	E-geneY
(	O
mTAAR1	S-geneY
)	O
and	O
a	O
human	O
-	O
rat	O
chimera	O
(	O
hrChTAAR1	S-geneY
)	O
.	O

Furthermore	O
,	O
because	O
S	O
-	O
(	O
+	O
)	O
-	O
isomers	O
of	O
METH	S-chem-C3-1
and	O
AMPH	S-chem-C3-1
are	O
reported	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
in	O
vivo	O
than	O
R	O
-	O
(	O
-	O
)	O
,	O
we	O
determined	O
the	O
enantiomeric	O
selectivity	O
of	O
all	O
three	O
species	O
of	O
TAAR1	S-geneY-C3-2
.	O

In	O
response	O
to	O
METH	S-chem
,	O
AMPH	S-chem
,	O
or	O
POHA	S-chem
exposure	O
,	O
the	O
accumulation	O
of	O
cAMP	S-chem
by	O
HEK	O
-	O
293	O
cells	O
stably	O
expressing	O
different	O
species	O
of	O
TAAR1	S-geneY
was	O
concentration	O
-	O
and	O
isomer	O
-	O
dependent	O
.	O

EC50	O
values	O
for	O
S	B-chem-C3-1
-	I-chem-C3-1
(	I-chem-C3-1
+	I-chem-C3-1
)	I-chem-C3-1
-	I-chem-C3-1
METH	E-chem-C3-1
were	O
0.89	O
,	O
0.92	O
,	O
and	O
4.44	O
microM	O
for	O
rTAAR1	S-geneY-C3-2
,	O
mTAAR1	S-geneY-C3-2
,	O
and	O
h	B-geneY-C3-2
-	I-geneY-C3-2
rChTAAR1	E-geneY-C3-2
,	O
respectively	O
.	O

PEA	S-chem-C5-1
was	O
a	O
potent	O
and	O
full	O
agonist	O
at	O
each	O
species	O
of	O
TAAR1	S-geneY-C5-2
,	O
whereas	O
TYR	S-chem-C5-1
was	O
a	O
full	O
agonist	O
for	O
the	O
rodent	B-geneY-C5-2
TAAR1s	E-geneY-C5-2
but	O
was	O
a	O
partial	O
agonist	O
at	O
h	B-geneY-C5-2
-	I-geneY-C5-2
rChTAAR1	E-geneY-C5-2
.	O

Interestingly	O
,	O
both	O
isomers	O
of	O
METH	S-chem-C5-1
were	O
full	O
agonists	O
at	O
mTAAR1	S-geneY-C5-2
and	O
h	B-geneY-C5-2
-	I-geneY-C5-2
rChTAAR1	E-geneY-C5-2
,	O
whereas	O
both	O
were	O
partial	O
agonists	O
at	O
rTAAR1	S-geneY-C5-2
.	O

Taken	O
together	O
,	O
these	O
in	O
vitro	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
TAAR1	S-geneY
could	O
be	O
a	O
novel	O
mediator	O
of	O
the	O
effects	O
of	O
these	O
drugs	O
.	O

The	O
influence	O
of	O
sex	O
,	O
ethnicity	O
,	O
and	O
CYP2B6	S-geneY-C9-2
genotype	O
on	O
bupropion	S-chem-C9-1
metabolism	O
as	O
an	O
index	O
of	O
hepatic	O
CYP2B6	S-geneY
activity	O
in	O
humans	O
.	O

The	O
effects	O
of	O
sex	O
,	O
ethnicity	O
,	O
and	O
genetic	O
polymorphism	O
on	O
hepatic	O
CYP2B6	S-geneY
(	O
cytochrome	B-geneY
P450	I-geneY
2B6	E-geneY
)	O
expression	O
and	O
activity	O
were	O
previously	O
demonstrated	O
in	O
vitro	O
.	O

Race	O
/	O
ethnic	O
differences	O
in	O
CYP2B6	S-geneY
genotype	O
and	O
phenotype	O
were	O
observed	O
only	O
in	O
women	O
.	O

To	O
identify	O
important	O
covariates	O
associated	O
with	O
interindividual	O
variation	O
in	O
CYP2B6	S-geneY
activity	O
in	O
vivo	O
,	O
we	O
evaluated	O
these	O
effects	O
in	O
healthy	O
volunteers	O
using	O
bupropion	S-chem-C9-1
(	O
Wellbutrin	B-chem-C9-1
SR	E-chem-C9-1
GlaxoSmithKline	O
,	O
Research	O
Triangle	O
Park	O
,	O
NC	O
)	O
as	O
a	O
CYP2B6	S-geneY-C9-2
probe	O
substrate	O
.	O

A	O
fixed	O
150	O
-	O
mg	O
oral	O
sustained	O
-	O
release	O
dose	O
of	O
bupropion	S-chem
was	O
administered	O
to	O
100	O
healthy	O
volunteers	O
comprising	O
four	O
sex	O
/	O
ethnicity	O
cohorts	O
(	O
n	O
=	O
25	O
each	O
)	O
:	O
Caucasian	O
men	O
and	O
Caucasian	O
,	O
African	O
American	O
,	O
and	O
Hispanic	O
women	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
0	O
and	O
6	O
hours	O
postdose	O
for	O
the	O
measurement	O
of	O
serum	O
bupropion	S-chem
(	O
BU	O
)	O
and	O
hydroxybupropion	S-chem
(	O
HB	O
)	O
concentrations	O
.	O

Whole	O
blood	O
was	O
obtained	O
at	O
baseline	O
for	O
CYP2B6	S-geneY
genotyping	O
.	O

To	O
characterize	O
the	O
relationship	O
between	O
CYP2B6	S-geneY
activity	O
and	O
ethnicity	O
,	O
sex	O
,	O
and	O
genotype	O
when	O
accounting	O
for	O
serum	O
BU	O
concentrations	O
(	O
dose	O
-	O
adjusted	O
log	O
(	O
10	O
)	O
-	O
transformed	O
)	O
,	O
analysis	O
of	O
covariance	O
model	O
was	O
fitted	O
in	O
which	O
the	O
dependent	O
variable	O
was	O
CYP2B6	S-geneY
activity	O
represented	O
as	O
the	O
log	O
(	O
10	O
)	O
-	O
transformed	O
,	O
metabolic	O
ratio	O
of	O
HB	O
to	O
BU	O
concentrations	O
.	O

Several	O
CYP2B6	S-geneY
polymorphisms	O
were	O
associated	O
with	O
CYP2B6	S-geneY
activity	O
.	O

Evidence	O
of	O
dependence	O
of	O
CYP2B6	S-geneY
activity	O
on	O
ethnicity	O
or	O
genotype	O
-	O
by	O
-	O
ethnicity	O
interactions	O
was	O
not	O
detected	O
in	O
women	O
.	O

These	O
results	O
suggest	O
that	O
CYP2B6	S-geneY-C9-2
genotype	O
is	O
the	O
most	O
important	O
patient	O
variable	O
for	O
predicting	O
the	O
level	O
of	O
CYP2B6	S-geneY-C9-2
activity	O
in	O
women	O
,	O
when	O
measured	O
by	O
the	O
metabolism	O
of	O
bupropion	S-chem-C9-1
.	O

The	O
bupropion	S-chem-C9-1
metabolic	O
ratio	O
appears	O
to	O
detect	O
known	O
differences	O
in	O
CYP2B6	S-geneY-C9-2
activity	O
associated	O
with	O
genetic	O
polymorphism	O
,	O
across	O
different	O
ethnic	O
groups	O
.	O

Prospective	O
studies	O
will	O
be	O
needed	O
to	O
validate	O
the	O
use	O
of	O
bupropion	S-chem
as	O
a	O
probe	O
substrate	O
for	O
clinical	O
use	O
.	O

Association	O
of	O
MTRRA66G	S-geneY
polymorphism	O
(	O
but	O
not	O
of	O
MTHFR	S-geneY
C677T	S-geneN
and	O
A1298C	S-geneN
,	O
MTRA2756G	S-geneY
,	O
TCN	S-geneN
C776G	S-geneN
)	O
with	O
homocysteine	S-chem
and	O
coronary	O
artery	O
disease	O
in	O
the	O
French	O
population	O
.	O

Methylenetetrahydrofolate	B-geneY
reductase	E-geneY
polymorphism	O
(	O
MTHFR	S-geneY
C677T	S-geneN
)	O
is	O
an	O
established	O
determinant	O
of	O
homocysteine	S-chem
plasma	O
level	O
(	O
t	O
-	O
Hcys	S-chem
)	O
while	O
its	O
association	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
seems	O
to	O
be	O
more	O
limited	O
.	O

In	O
contrast	O
,	O
the	O
association	O
of	O
the	O
substitutions	O
A2756G	S-geneN
of	O
methionine	B-geneY
synthase	E-geneY
(	O
MTR	S-geneY
)	O
,	O
A66G	S-geneN
of	O
methionine	B-geneY
synthase	I-geneY
reductase	E-geneY
(	O
MTRR	S-geneY
)	O
and	O
C776G	S-geneN
of	O
transcobalamin	S-geneN
(	O
TCN	S-geneN
)	O
to	O
both	O
t	O
-	O
Hcys	S-chem
and	O
CAD	O
needs	O
to	O
be	O
evaluated	O
further	O
.	O

The	O
objective	O
was	O
to	O
evaluate	O
the	O
association	O
of	O
these	O
polymorphisms	O
with	O
t	O
-	O
Hcys	S-chem
and	O
CAD	O
in	O
a	O
French	O
population	O
.	O

We	O
investigated	O
the	O
individual	O
and	O
combined	O
effects	O
of	O
these	O
polymorphisms	O
and	O
of	O
vitamin	B-chem
B12	E-chem
and	O
folates	S-chem
with	O
t	O
-	O
Hcys	O
in	O
530	O
CAD	O
patients	O
and	O
248	O
matched	O
healthy	O
controls	O
.	O
t	O
-	O
Hcys	S-chem
was	O
higher	O
in	O
the	O
CAD	O
group	O
than	O
in	O
controls	O
(	O
11.8	O
vs	O
10.4	O
microM	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
in	O
carriers	O
of	O
MTRRAA	S-geneY
and	O
MTHFR	S-geneY
677TT	O
than	O
in	O
those	O
carrying	O
the	O
most	O
frequent	O
allele	O
of	O
both	O
polymorphisms	O
(	O
13.8	O
vs	O
11.4	O
microM	O
,	O
P	O
=	O
0.0102	O
and	O
12.5	O
vs	O
11.0	O
mM	O
,	O
P	O
=	O
0.0065	O
respectively	O
)	O
.	O

The	O
frequency	O
of	O
MTRR	S-geneY
A	O
allele	O
was	O
higher	O
in	O
CAD	O
patients	O
than	O
in	O
controls	O
(	O
0.48	O
[	O
95	O
%	O
CI	O
:	O
0.44	O
-	O
0.52	O
]	O
vs	O
0.38	O
[	O
95	O
%	O
CI	O
:	O
0.32	O
-	O
0.44	O
]	O
,	O
P	O
=	O
0.0081	O
)	O
while	O
no	O
difference	O
was	O
observed	O
for	O
MTHFR	S-geneY
677T	O
frequency	O
.	O

In	O
multivariate	O
analysis	O
,	O
t	O
-	O
Hcys	S-chem
>	O
median	O
and	O
MTRRAA	S-geneY
genotype	O
were	O
two	O
significant	O
independent	O
predictors	O
of	O
CAD	O
with	O
respective	O
odds	O
ratios	O
of	O
3.1	O
(	O
95	O
%	O
CI	O
:	O
1.8	O
-	O
5.1	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
4.5	O
(	O
95	O
%	O
CI	O
:	O
1.5	O
-	O
13.1	O
,	O
P	O
=	O
0.0051	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
contrast	O
to	O
North	O
Europe	O
studies	O
,	O
MTRRAA	S-geneY
genotype	O
is	O
a	O
genetic	O
determinant	O
of	O
moderate	O
hyperhomocysteinemia	O
associated	O
with	O
CAD	O
in	O
a	O
French	O
population	O
without	O
vitamin	O
fortification	O
.	O

Mineralocorticoids	O
,	O
salt	O
,	O
hypertension	O
:	O
effects	O
on	O
the	O
heart	O
.	O

In	O
uninephrectomized	O
rats	O
on	O
1	O
%	O
NaCl	S-chem
solution	O
to	O
drink	O
,	O
aldosterone	S-chem
(	O
0.75	O
micrograms	O
/	O
h	O
subcutaneously	O
for	O
8	O
weeks	O
)	O
raises	O
blood	O
pressure	O
and	O
causes	O
marked	O
interstitial	O
and	O
perivascular	O
cardiac	O
fibrosis	O
,	O
effects	O
not	O
seen	O
in	O
animals	O
on	O
a	O
low	O
salt	O
intake	O
.	O

In	O
extending	O
these	O
initial	O
findings	O
,	O
we	O
have	O
shown	O
that	O
cardiac	O
fibrosis	O
(	O
i	O
)	O
is	O
not	O
reversed	O
by	O
correction	O
of	O
mineralocorticoid	O
-	O
induced	O
hypokalemia	O
;	O
(	O
ii	O
)	O
appears	O
not	O
to	O
involve	O
the	O
plasma	O
or	O
tissue	O
renin	S-geneY
-	O
angiotensin	S-geneY
systems	O
,	O
as	O
fibrosis	O
is	O
largely	O
unaffected	O
by	O
concurrent	O
administration	O
of	O
Losartan	S-chem
or	O
Perindopril	S-chem
;	O
(	O
iii	O
)	O
is	O
independent	O
of	O
cardiac	O
hypertrophy	O
,	O
in	O
that	O
it	O
is	O
equally	O
seen	O
in	O
right	O
and	O
left	O
ventricles	O
,	O
and	O
in	O
rats	O
rendered	O
hypertensive	O
without	O
cardiac	O
hypertrophy	O
by	O
the	O
administration	O
of	O
9	B-chem
alpha	I-chem
-	I-chem
fluorocortisol	E-chem
;	O
(	O
iv	O
)	O
is	O
independent	O
of	O
elevated	O
blood	O
pressure	O
,	O
in	O
that	O
it	O
is	O
found	O
in	O
normotensive	O
animals	O
infused	O
peripherally	O
with	O
aldosterone	S-chem
and	O
intracerebroventricularly	O
with	O
the	O
mineralocorticoid	B-geneY-C6-2
receptor	E-geneY-C6-2
(	O
MR	S-geneY-C6-2
)	O
antagonist	O
RU28318	S-chem-C6-1
;	O
(	O
v	O
)	O
is	O
via	O
classical	O
MR	S-geneY-C6-2
,	O
in	O
that	O
it	O
is	O
blocked	O
by	O
concurrent	O
administration	O
of	O
the	O
MR	S-geneY-C6-2
antagonist	O
potassium	B-chem-C6-1
canrenoate	E-chem-C6-1
;	O
and	O
(	O
vi	O
)	O
may	O
or	O
may	O
not	O
be	O
a	O
direct	O
cardiac	O
effect	O
,	O
inasmuch	O
as	O
data	O
for	O
in	O
vivo	O
effects	O
on	O
collagen	S-geneN
formation	O
by	O
cardiac	O
fibroblasts	O
are	O
conflicting	O
.	O

Although	O
there	O
is	O
a	O
high	O
probability	O
that	O
the	O
action	O
of	O
aldosterone	S-chem
to	O
cause	O
cardiac	O
fibrosis	O
in	O
this	O
experimental	O
model	O
is	O
an	O
effect	O
via	O
non	O
-	O
epithelial	O
MR	S-geneY
,	O
the	O
locus	O
of	O
aldosterone	S-chem
action	O
remains	O
to	O
be	O
established	O
,	O
as	O
do	O
the	O
molecular	O
mechanisms	O
linking	O
MR	S-geneY
occupancy	O
by	O
aldosterone	S-chem
and	O
collagen	O
deposition	O
.	O

In	O
addition	O
,	O
and	O
in	O
particular	O
,	O
the	O
mechanisms	O
underlying	O
the	O
crucial	O
contribution	O
of	O
high	O
salt	O
intake	O
in	O
this	O
model	O
of	O
mineralocorticoid	O
excess	O
await	O
exploration	O
.	O

Physiological	O
oxygenation	O
status	O
is	O
required	O
for	O
fully	O
differentiated	O
phenotype	O
in	O
kidney	O
cortex	O
proximal	O
tubules	O
.	O

Hypoxia	O
has	O
been	O
suspected	O
to	O
trigger	O
transdifferentiation	O
of	O
renal	O
tubular	O
cells	O
into	O
myofibroblasts	O
in	O
an	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
process	O
.	O

To	O
determine	O
the	O
functional	O
networks	O
potentially	O
altered	O
by	O
hypoxia	O
,	O
rat	O
renal	O
tubule	O
suspensions	O
were	O
incubated	O
under	O
three	O
conditions	O
of	O
oxygenation	O
ranging	O
from	O
normoxia	O
(	O
lactate	O
uptake	O
)	O
to	O
severe	O
hypoxia	O
(	O
lactate	O
production	O
)	O
.	O

Transcriptome	O
changes	O
after	O
4	O
h	O
were	O
analyzed	O
on	O
a	O
high	O
scale	O
by	O
restriction	O
fragment	O
differential	O
display	O
.	O

Among	O
1,533	O
transcripts	O
found	O
,	O
42	O
%	O
were	O
maximally	O
expressed	O
under	O
severe	O
hypoxia	O
and	O
8	O
%	O
under	O
mild	O
hypoxia	O
(	O
Po	O
(	O
2	O
)	O
=	O
48	O
mmHg	O
)	O
,	O
suggesting	O
two	O
different	O
levels	O
of	O
oxygen	S-chem
sensing	O
.	O

Normoxia	O
was	O
required	O
for	O
full	O
expression	O
of	O
the	O
proximal	O
tubule	O
-	O
specific	O
transcripts	O
25	B-geneY
-	I-geneY
hydroxyvitamin	I-geneY
D	I-geneY
1	I-geneY
-	I-geneY
hydroxylase	E-geneY
(	O
Cyp27b1	S-geneY
)	O
and	O
l	B-geneY
-	I-geneY
pyruvate	I-geneY
kinase	E-geneY
(	O
Pklr	S-geneY
)	O
,	O
transcripts	O
involved	O
in	O
tissue	O
cohesion	O
such	O
as	O
fibronectin	S-geneY
(	O
Fn1	S-geneY
)	O
and	O
N	B-geneY
-	I-geneY
cadherin	E-geneY
(	O
Cdh2	S-geneY
)	O
,	O
and	O
non	B-geneN
-	I-geneN
muscle	I-geneN
-	I-geneN
type	I-geneN
myosin	E-geneN
transcripts	O
.	O

Mild	O
hypoxia	O
increased	O
myogenin	S-geneY
transcript	O
level	O
.	O

Conversely	O
,	O
severe	O
hypoxia	O
increased	O
transcripts	O
involved	O
in	O
extracellular	O
matrix	O
remodeling	O
,	O
those	O
of	O
muscle	B-geneN
-	I-geneN
type	I-geneN
myosins	E-geneN
,	O
and	O
others	O
involved	O
in	O
creatine	O
phosphate	S-chem
synthesis	O
and	O
lactate	O
transport	O
(	O
Slc16a7	S-geneY
)	O
.	O

Accordingly	O
,	O
microscopy	O
showed	O
loss	O
of	O
tubule	O
aggregation	O
under	O
hypoxia	O
,	O
without	O
tubular	O
disruption	O
.	O

Hypoxia	O
also	O
increased	O
the	O
levels	O
of	O
kidney	O
-	O
specific	O
transcripts	O
normally	O
restricted	O
to	O
the	O
less	O
oxygenated	O
medullary	O
zone	O
and	O
others	O
specific	O
for	O
the	O
distal	O
part	O
of	O
the	O
nephron	O
.	O

We	O
conclude	O
that	O
extensive	O
oxygen	S-chem
supply	O
to	O
the	O
kidney	O
tubule	O
favors	O
expression	O
of	O
its	O
differentiated	O
functions	O
specifically	O
in	O
the	O
proximal	O
tubule	O
,	O
whose	O
embryonic	O
origin	O
is	O
mesenchymal	O
.	O

The	O
phenotype	O
changes	O
could	O
potentially	O
permit	O
transient	O
adaptation	O
to	O
hypoxia	O
but	O
also	O
favor	O
pathological	O
processes	O
such	O
as	O
tissue	O
invasion	O
.	O

Effect	O
of	O
fenoterol	S-chem-C3-1
-	O
induced	O
constitutive	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
2	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptor	E-geneY-C3-2
activity	O
on	O
contractile	O
receptor	O
function	O
in	O
airway	O
smooth	O
muscle	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
fenoterol	S-chem-C3-1
-	O
induced	O
constitutive	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
2	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptor	E-geneY-C3-2
activity	O
on	O
muscarinic	B-geneN
receptor	E-geneN
agonist	O
-	O
and	O
histamine	S-chem
-	O
induced	O
bovine	O
tracheal	O
smooth	O
muscle	O
contractions	O
.	O

Bovine	O
tracheal	O
smooth	O
muscle	O
strips	O
were	O
incubated	O
with	O
10	O
microM	O
fenoterol	S-chem
or	O
vehicle	O
for	O
various	O
periods	O
of	O
time	O
(	O
5	O
,	O
30	O
min	O
,	O
18	O
h	O
)	O
at	O
37	O
degrees	O
C	O
.	O

After	O
extensive	O
washout	O
(	O
3	O
h	O
,	O
37	O
degrees	O
C	O
)	O
,	O
isometric	O
contractions	O
were	O
measured	O
to	O
the	O
full	O
muscarinic	B-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
methacholine	S-chem-C5-1
,	O
the	O
partial	O
muscarinic	B-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
4	B-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
m	I-chem-C5-1
-	I-chem-C5-1
chlorophenyl	I-chem-C5-1
-	I-chem-C5-1
carbamoyloxy	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
butynyltrimethylammonium	E-chem-C5-1
(	O
McN	B-chem
-	I-chem
A	I-chem
-	I-chem
343	E-chem
)	O
and	O
histamine	S-chem-C5-1
.	O

Fenoterol	S-chem
treatment	O
significantly	O
reduced	O
the	O
sensitivity	O
(	O
pEC	O
(	O
50	O
)	O
)	O
to	O
methacholine	S-chem
in	O
a	O
time	O
-	O
dependent	O
manner	O
,	O
without	O
affecting	O
maximal	O
contraction	O
(	O
E	O
(	O
max	O
)	O
)	O
.	O

Fenoterol	S-chem
treatment	O
similarly	O
reduced	O
the	O
pEC	O
(	O
50	O
)	O
of	O
McN	B-chem
-	I-chem
A	I-chem
-	I-chem
343	E-chem
and	O
histamine	S-chem
;	O
however	O
,	O
E	O
(	O
max	O
)	O
values	O
were	O
also	O
reduced	O
,	O
to	O
approximately	O
70	O
%	O
of	O
control	O
after	O
18	O
-	O
h	O
treatment	O
.	O

The	O
inverse	O
agonist	O
timolol	S-chem
,	O
having	O
no	O
effect	O
on	O
control	O
preparations	O
,	O
consistently	O
restored	O
the	O
reduced	O
pEC	O
(	O
50	O
)	O
and	O
E	O
(	O
max	O
)	O
values	O
of	O
the	O
contractile	O
agonists	O
.	O

Remarkably	O
,	O
in	O
the	O
presence	O
of	O
timolol	O
the	O
pEC	O
(	O
50	O
)	O
values	O
of	O
McN	B-chem
-	I-chem
A	I-chem
-	I-chem
343	E-chem
and	O
histamine	S-chem
in	O
fenoterol	S-chem
-	O
treated	O
airways	O
were	O
significantly	O
enhanced	O
compared	O
to	O
controls	O
.	O

In	O
conclusion	O
,	O
fenoterol	S-chem-C3-1
-	O
induced	O
constitutive	O
beta	B-geneY-MU-2
(	I-geneY-MU-2
2	I-geneY-MU-2
)	I-geneY-MU-2
-	I-geneY-MU-2
adrenoceptor	E-geneY-MU-2
activity	O
reduces	O
muscarinic	B-geneN
receptor	E-geneN
agonist	O
-	O
and	O
histamine	S-chem
-	O
induced	O
contractions	O
of	O
bovine	O
tracheal	O
smooth	O
muscle	O
,	O
which	O
can	O
be	O
reversed	O
by	O
the	O
inverse	O
agonist	O
timolol	S-chem-C5-1
.	O

Moreover	O
,	O
after	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonist	O
treatment	O
,	O
inverse	O
agonism	O
by	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
may	O
cause	O
enhanced	O
airway	O
reactivity	O
to	O
contractile	O
mediators	O
.	O

Neuroprotection	O
by	O
estrogen	S-chem
against	O
MPP	B-chem
+	E-chem
-	O
induced	O
dopamine	S-chem
neuron	O
death	O
is	O
mediated	O
by	O
ERalpha	S-geneY
in	O
primary	O
cultures	O
of	O
mouse	O
mesencephalon	O
.	O

Estrogen	S-chem
involvement	O
in	O
neuroprotection	O
is	O
now	O
widely	O
accepted	O
,	O
although	O
the	O
specific	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
estrogen	S-chem
action	O
in	O
neuroprotection	O
remain	O
unclear	O
.	O

This	O
study	O
examines	O
estrogenic	O
effects	O
in	O
a	O
mixed	O
population	O
of	O
cells	O
in	O
attempts	O
to	O
identify	O
the	O
contributing	O
cells	O
that	O
result	O
in	O
estrogen	S-chem
-	O
mediated	O
neuroprotection	O
.	O

Utilizing	O
primary	O
mesencephalic	O
neurons	O
,	O
we	O
found	O
expression	O
of	O
both	O
estrogen	B-geneY
receptor	I-geneY
alpha	E-geneY
(	O
ERalpha	S-geneY
)	O
and	O
estrogen	B-geneY
receptor	I-geneY
beta	E-geneY
(	O
ERbeta	S-geneY
)	O
with	O
a	O
predominance	O
of	O
ERalpha	S-geneY
on	O
both	O
dopamine	S-chem
neurons	O
and	O
astrocytes	O
.	O

We	O
also	O
found	O
that	O
17beta	B-chem
-	I-chem
estradiol	E-chem
protects	O
dopamine	S-chem
neurons	O
from	O
injury	O
induced	O
by	O
the	O
complex	O
I	O
inhibitor	O
,	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
pyridinium	E-chem
(	O
MPP	B-chem
(	I-chem
+	I-chem
)	E-chem
)	O
in	O
a	O
time	O
-	O
and	O
ER	S-geneY
-	O
dependent	O
manner	O
.	O

At	O
least	O
4	O
h	O
of	O
estrogen	S-chem
pre	O
-	O
treatment	O
was	O
required	O
to	O
elicit	O
protection	O
,	O
an	O
effect	O
that	O
was	O
blocked	O
by	O
the	O
ER	S-geneY-C6-2
antagonist	O
,	O
ICI	B-chem-C6-1
182,780	E-chem-C6-1
.	O

Moreover	O
,	O
ERalpha	S-geneY
mediated	O
the	O
protection	O
afforded	O
by	O
estrogen	S-chem
since	O
only	O
the	O
ERalpha	S-geneY
agonist	O
,	O
HPTE	O
,	O
but	O
not	O
the	O
ERbeta	S-geneY-C5-2
agonist	O
,	O
DPN	S-chem-C5-1
,	O
protected	O
against	O
dopamine	S-chem
cell	O
loss	O
.	O

Since	O
glial	O
cells	O
were	O
shown	O
to	O
express	O
significant	O
levels	O
of	O
ERalpha	S-geneY
,	O
we	O
investigated	O
a	O
possible	O
indirect	O
mechanism	O
of	O
estrogen	S-chem
-	O
mediated	O
neuroprotection	O
through	O
glial	O
cell	O
interaction	O
.	O

Removal	O
of	O
glial	O
cells	O
from	O
the	O
cultures	O
by	O
application	O
of	O
the	O
mitotic	O
inhibitor	O
,	O
5	B-chem
-	I-chem
fluoro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyuridine	E-chem
,	O
significantly	O
reduced	O
the	O
neuroprotective	O
effects	O
of	O
estrogen	S-chem
.	O

These	O
data	O
indicate	O
that	O
neuroprotection	O
provided	O
by	O
estrogen	S-chem
against	O
MPP	B-chem
(	I-chem
+	I-chem
)	E-chem
toxicity	O
is	O
mediated	O
by	O
ERalpha	S-geneY
and	O
involves	O
an	O
interplay	O
among	O
at	O
least	O
two	O
cell	O
types	O
.	O

Inhibition	O
of	O
dipeptidyl	B-geneY-C4-2
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
IV	E-geneY-C4-2
(	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
IV	E-geneY-C4-2
)	O
by	O
atorvastatin	S-chem-C4-1
.	O

Dipeptidyl	B-geneY
peptidase	I-geneY
-	I-geneY
IV	E-geneY
(	O
DPP	B-geneY
-	I-geneY
IV	E-geneY
)	O
is	O
an	O
enzyme	O
responsible	O
for	O
the	O
inactivation	O
of	O
the	O
glucoregulatory	O
incretin	B-geneN
hormones	E-geneN
glucagon	B-geneY
-	I-geneY
like	I-geneY
peptide	I-geneY
-	I-geneY
1	E-geneY
(	O
GLP	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
glucose	B-geneY
-	I-geneY
dependent	I-geneY
insulinotropic	I-geneY
polypeptide	E-geneY
(	O
GIP	S-geneY
)	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
hypolipidemic	O
agent	O
atorvastatin	S-chem-C4-1
is	O
a	O
competitive	O
inhibitor	O
of	O
porcine	B-geneY-C4-2
DPP	I-geneY-C4-2
-	I-geneY-C4-2
IV	E-geneY-C4-2
in	O
vitro	O
,	O
with	O
K	O
(	O
i	O
)	O
=	O
57.8	O
+	O
/	O
-	O
2.3	O
microM	O
.	O

These	O
results	O
may	O
have	O
implications	O
in	O
the	O
development	O
of	O
novel	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
IV	E-geneY-C4-2
inhibitors	O
based	O
on	O
the	O
use	O
of	O
atorvastatin	S-chem-C4-1
as	O
a	O
lead	O
compound	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

Absorption	O
,	O
distribution	O
,	O
and	O
biotransformation	O
of	O
hexahydro	B-chem
-	I-chem
1,3,5	I-chem
-	I-chem
trinitro	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazine	E-chem
in	O
B6C3F1	O
mice	O
(	O
Mus	O
musculus	O
)	O
.	O

Absorption	O
,	O
distribution	O
,	O
and	O
biotransformation	O
are	O
3	O
critical	O
aspects	O
affecting	O
toxicant	O
action	O
in	O
animals	O
.	O

In	O
the	O
present	O
study	O
,	O
B6C3F1	O
mice	O
(	O
Mus	O
musculus	O
)	O
were	O
exposed	O
for	O
28	O
d	O
to	O
contaminated	O
feed	O
that	O
contained	O
1	O
of	O
5	O
different	O
hexahydro	B-chem
-	I-chem
1,3,5	I-chem
-	I-chem
trinitro	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazine	E-chem
(	O
RDX	O
)	O
concentrations	O
:	O
0	O
mg	O
/	O
kg	O
,	O
0.5	O
mg	O
/	O
kg	O
,	O
5	O
mg	O
/	O
kg	O
,	O
50	O
mg	O
/	O
kg	O
,	O
and	O
500	O
mg	O
/	O
kg	O
.	O

The	O
authors	O
quantified	O
RDX	O
and	O
its	O
reductive	O
transformation	O
products	O
hexahydro	B-chem
-	I-chem
1	I-chem
-	I-chem
nitroso	I-chem
-	I-chem
3,5	I-chem
-	I-chem
dinitro	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazine	E-chem
(	O
MNX	O
)	O
,	O
hexahydro	B-chem
-	I-chem
1,3	I-chem
-	I-chem
dinitroso	I-chem
-	I-chem
5	I-chem
-	I-chem
nitro	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazine	E-chem
(	O
DNX	O
)	O
,	O
and	O
hexahydro	B-chem
-	I-chem
1,3,5	I-chem
-	I-chem
trinitroso	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazine	E-chem
(	O
TNX	O
)	O
in	O
the	O
stomach	O
,	O
intestine	O
,	O
plasma	O
,	O
liver	O
,	O
and	O
brain	O
of	O
these	O
mice	O
.	O

Average	O
RDX	O
concentrations	O
followed	O
a	O
dose	O
-	O
dependent	O
pattern	O
for	O
all	O
matrices	O
tested	O
.	O

No	O
controls	O
had	O
concentrations	O
above	O
limits	O
of	O
detection	O
.	O

Average	O
RDX	O
concentrations	O
in	O
tissues	O
of	O
exposed	O
mice	O
ranged	O
from	O
11.1	O
ng	O
/	O
mL	O
to	O
182	O
ng	O
/	O
mL	O
,	O
25.6	O
ng	O
/	O
g	O
to	O
3319	O
ng	O
/	O
g	O
,	O
123	O
ng	O
/	O
g	O
to	O
233	O
ng	O
/	O
g	O
,	O
144	O
ng	O
/	O
g	O
to	O
35	O
900	O
ng	O
/	O
g	O
,	O
and	O
51.1	O
ng	O
/	O
g	O
to	O
2697	O
ng	O
/	O
g	O
in	O
the	O
plasma	O
,	O
brain	O
,	O
liver	O
,	O
stomach	O
,	O
and	O
intestine	O
,	O
respectively	O
.	O

A	O
considerable	O
amount	O
of	O
RDX	O
was	O
present	O
in	O
the	O
brain	O
,	O
especially	O
in	O
the	O
highest	O
-	O
exposure	O
group	O
.	O

This	O
is	O
consistent	O
with	O
the	O
widely	O
observed	O
central	O
nervous	O
system	O
effects	O
caused	O
by	O
γ	B-chem
-	I-chem
aminobutyric	I-chem
acid	E-chem
inhibition	O
associated	O
with	O
RDX	O
exposure	O
.	O

N	B-chem
-	I-chem
nitroso	E-chem
metabolites	O
of	O
RDX	O
were	O
also	O
present	O
in	O
tested	O
tissues	O
in	O
a	O
dose	O
-	O
dependent	O
pattern	O
.	O

Average	O
MNX	O
concentrations	O
in	O
the	O
stomachs	O
of	O
mice	O
exposed	O
to	O
RDX	O
ranged	O
from	O
nondetectable	O
in	O
control	O
exposures	O
to	O
490	O
ng	O
/	O
g	O
in	O
the	O
highest	O
-	O
exposure	O
groups	O
.	O

In	O
the	O
brain	O
,	O
MNX	O
accumulated	O
at	O
a	O
maximum	O
average	O
concentration	O
of	O
165.1	O
ng	O
/	O
g	O
,	O
suggesting	O
the	O
potential	O
formation	O
of	O
MNX	O
from	O
RDX	O
within	O
the	O
brain	O
.	O

At	O
higher	O
exposures	O
,	O
DNX	O
and	O
TNX	O
were	O
present	O
in	O
the	O
stomach	O
,	O
plasma	O
,	O
and	O
brain	O
of	O
mice	O
.	O

The	O
presence	O
of	O
RDX	O
metabolites	O
at	O
notable	O
amounts	O
in	O
different	O
tissues	O
suggests	O
that	O
RDX	O
can	O
transform	O
into	O
its	O
N	B-chem
-	I-chem
nitroso	E-chem
metabolites	O
in	O
vivo	O
by	O
an	O
undefined	O
mechanism	O
.	O

Environ	O
Toxicol	O
Chem	O
2013	O
;	O
32	O
:	O
1295	O
-	O
1303	O
.	O

©	O
2013	O
SETAC	O
.	O

[	O
Efalizumab	O
]	O
.	O

Efalizumab	O
(	O
Raptiva	O
,	O
Serono	O
)	O
is	O
a	O
humanised	O
monoclonal	O
antibody	O
(	O
IgG1	S-geneY
)	O
produced	O
by	O
biotechnology	O
.	O

This	O
antibody	O
has	O
a	O
novel	O
place	O
among	O
biotherapies	O
for	O
psoriasis	O
.	O

It	O
is	O
bound	O
to	O
the	O
CD11a	S-geneY
subunit	O
of	O
a	O
surface	O
molecule	O
of	O
the	O
T	O
lymphocyte	O
LFA	B-geneN
-	I-geneN
1	E-geneN
(	O
Leucocyte	B-geneN
Function	I-geneN
-	I-geneN
associated	I-geneN
Antigen	I-geneN
-	I-geneN
1	E-geneN
)	O
.	O

This	O
molecule	O
is	O
essential	O
for	O
binding	O
of	O
T	O
lymphocytes	O
to	O
the	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
molecule	O
(	O
Intercellular	B-geneY
Adhesion	I-geneY
Molecule	I-geneY
-	I-geneY
1	E-geneY
)	O
found	O
on	O
antigen	O
-	O
presenting	O
cells	O
,	O
endothelial	O
cells	O
and	O
keratinocytes	O
.	O

Binding	O
of	O
efalizumab	O
to	O
CD11a	S-geneY
prevents	O
binding	O
of	O
LFA	B-geneN
-	I-geneN
1	E-geneN
to	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
,	O
thus	O
inhibiting	O
several	O
steps	O
in	O
the	O
immunological	O
process	O
responsible	O
for	O
formation	O
of	O
psoriatic	O
plaque	O
(	O
activation	O
of	O
naive	O
T	O
lymphocytes	O
to	O
memory	O
T	O
lymphocytes	O
,	O
lymphocyte	O
migration	O
and	O
reactivation	O
of	O
T	O
lymphocytes	O
in	O
skin	O
)	O
.	O

Efalizumab	O
was	O
approved	O
in	O
the	O
United	O
States	O
by	O
the	O
FDA	O
(	O
Food	O
and	O
Drug	O
Administration	O
)	O
in	O
2003	O
for	O
the	O
treatment	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
psoriasis	O
requiring	O
systemic	O
therapy	O
.	O

It	O
may	O
be	O
used	O
as	O
first	O
-	O
line	O
therapy	O
in	O
the	O
United	O
States	O
in	O
this	O
indication	O
.	O

In	O
France	O
,	O
marketing	O
authorisation	O
(	O
MA	O
)	O
was	O
granted	O
more	O
recently	O
in	O
September	O
2005	O
.	O

The	O
indications	O
are	O
moderate	O
-	O
to	O
-	O
severe	O
cutaneous	O
plaque	O
psoriasis	O
in	O
adults	O
in	O
cases	O
of	O
failure	O
,	O
intolerance	O
or	O
contraindication	O
of	O
at	O
least	O
two	O
systemic	O
treatments	O
including	O
phototherapy	O
,	O
methotrexate	S-chem
and	O
cyclosporine	S-chem
.	O

Current	O
clinical	O
trial	O
data	O
is	O
available	O
for	O
3500	O
patients	O
with	O
plaque	O
psoriasis	O
.	O

A	O
75	O
%	O
improvement	O
in	O
PASI	O
score	O
was	O
seen	O
in	O
between	O
22	O
and	O
39	O
%	O
of	O
patients	O
treated	O
with	O
efalizumab	O
(	O
vs	O
.	O

2	O
to	O
5	O
%	O
for	O
patients	O
on	O
placebo	O
)	O
in	O
a	O
single	O
weekly	O
subcutaneous	O
injection	O
(	O
1	O
mg	O
/	O
kg	O
)	O
.	O

A	O
study	O
in	O
good	O
responders	O
confirms	O
the	O
continuing	O
long	O
-	O
term	O
efficacy	O
of	O
prescription	O
of	O
the	O
drug	O
up	O
to	O
36	O
months	O
(	O
with	O
at	O
least	O
a	O
75	O
%	O
improvement	O
in	O
PASI	O
score	O
in	O
53	O
%	O
of	O
patients	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
effective	O
against	O
joint	O
involvement	O
in	O
psoriasis	O
.	O

The	O
most	O
common	O
side	O
-	O
effects	O
(	O
incidence	O
>	O
1	O
/	O
100	O
)	O
are	O
influenza	O
-	O
like	O
syndrome	O
,	O
risk	O
of	O
outbreak	O
of	O
cutaneous	O
psoriasis	O
during	O
or	O
after	O
discontinuation	O
of	O
treatment	O
,	O
worsening	O
of	O
arthralgia	O
,	O
minor	O
hypersensitivity	O
reactions	O
,	O
reversible	O
changes	O
in	O
laboratory	O
values	O
(	O
hyperlymphocytosis	O
,	O
elevated	O
alkaline	B-geneN
phosphatases	E-geneN
and	O
transaminases	S-geneN
)	O
.	O

Because	O
of	O
rare	O
cases	O
of	O
thrombocytopenia	O
(	O
incidence	O
<	O
1	O
/	O
100	O
)	O
,	O
reversible	O
on	O
discontinuation	O
of	O
treatment	O
,	O
monthly	O
monitoring	O
of	O
platelet	O
counts	O
is	O
required	O
over	O
the	O
first	O
3	O
months	O
of	O
therapy	O
.	O

There	O
are	O
currently	O
no	O
randomised	O
studies	O
comparing	O
the	O
various	O
systemic	O
treatments	O
(	O
standard	O
therapy	O
and	O
biotherapy	O
)	O
for	O
psoriasis	O
.	O

However	O
,	O
on	O
extrapolation	O
of	O
the	O
available	O
results	O
concerning	O
efficacy	O
(	O
PASI	O
-	O
75	O
after	O
12	O
weeks	O
of	O
treatment	O
)	O
,	O
efalizumab	O
appears	O
to	O
be	O
less	O
efficacious	O
than	O
anti	O
-	O
TNF	B-geneY
alpha	E-geneY
agents	O
.	O

This	O
drug	O
constitutes	O
an	O
additional	O
treatment	O
option	O
and	O
its	O
position	O
in	O
the	O
therapeutic	O
arsenal	S-chem
will	O
depend	O
upon	O
its	O
long	O
-	O
term	O
benefit	O
/	O
risk	O
ratio	O
in	O
relation	O
to	O
other	O
biotherapies	O
.	O

Heteromtoxin	S-geneY
(	O
HmTx	S-geneY
)	O
,	O
a	O
novel	O
heterodimeric	O
phospholipase	B-geneN
A	I-geneN
(	I-geneN
2	I-geneN
)	E-geneN
from	O
Heterometrus	O
laoticus	O
scorpion	O
venom	O
.	O

Heteromtoxin	S-geneY
(	O
HmTx	S-geneY
)	O
is	O
a	O
group	B-geneN
III	I-geneN
phospholipase	I-geneN
A	I-geneN
(	I-geneN
2	I-geneN
)	E-geneN
produced	O
in	O
Heterometrus	O
laoticus	O
,	O
in	O
Thailand	O
.	O

In	O
this	O
study	O
,	O
HmTx	S-geneY
was	O
purified	O
from	O
venom	O
by	O
separation	O
chromatography	O
,	O
and	O
the	O
PLA	B-geneN
(	I-geneN
2	I-geneN
)	E-geneN
activity	O
of	O
the	O
fractions	O
was	O
determined	O
by	O
lecithin	O
agar	O
assay	O
.	O

The	O
enzyme	O
is	O
an	O
acidic	O
protein	O
with	O
a	O
pI	O
of	O
5.6	O
and	O
an	O
apparent	O
molecular	O
weight	O
of	O
14018.4	O
Da	O
.	O

The	O
nucleotide	S-chem
sequence	O
of	O
HmTx	S-geneY
contains	O
649	O
bp	O
,	O
and	O
the	O
mature	O
protein	O
is	O
predicted	O
to	O
have	O
131	O
amino	B-chem
acid	E-chem
residues	O
-	O
104	O
of	O
which	O
make	O
up	O
the	O
large	O
subunit	O
,	O
and	O
27	O
of	O
which	O
make	O
up	O
the	O
small	O
subunit	O
.	O

The	O
subunit	O
structure	O
of	O
HmTx	S-geneY
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
other	O
toxin	O
,	O
Pandinus	O
imperator	O
imperatoxin	O
I	O
(	O
IpTx	O
(	O
i	O
)	O
)	O
and	O
to	O
Mesobuthus	B-geneN
tamulus	I-geneN
phospholipase	I-geneN
A	I-geneN
(	I-geneN
2	I-geneN
)	E-geneN
(	O
MtPLA	B-geneN
(	I-geneN
2	I-geneN
)	E-geneN
)	O
.	O

The	O
3D	O
-	O
structure	O
of	O
HmTx	S-geneY
consists	O
of	O
three	O
conserved	O
alpha	O
-	O
helices	O
:	O
h1	O
(	O
Lys24	S-chem
-	O
His34	S-chem
)	O
,	O
h2	O
(	O
Cys59	S-chem
-	O
Asp71	S-chem
)	O
,	O
and	O
h3	O
(	O
Ala80	S-chem
-	O
Phe89	S-chem
)	O
.	O

The	O
beta	O
-	O
sheet	O
consisted	O
of	O
a	O
single	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
(	O
b1.1	O
at	O
Glu43	S-chem
-	O
Lys45	S-chem
and	O
b1.2	O
at	O
Lys48	S-chem
-	O
Asn50	S-chem
)	O
that	O
was	O
highly	O
similar	O
to	O
the	O
conserved	O
sequences	O
(	O
-	O
CGXG	O
-	O
,	O
-	O
CCXXHDXC	O
-	O
and	O
CXCEXXXXXC	O
-	O
)	O
of	O
Apis	O
mellifera	O
(	O
bee	O
)	O
phospholipases	S-geneN
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
induce	O
colorectal	O
cancer	O
cell	O
apoptosis	O
by	O
suppressing	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
.	O

To	O
determine	O
the	O
role	O
of	O
14	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
3	E-geneN
in	O
colorectal	O
cancer	O
apoptosis	O
induced	O
by	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
sulindac	S-chem
on	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	I-geneY
protein	E-geneY
expression	O
in	O
colorectal	O
cancer	O
cells	O
.	O

Sulindac	B-chem-C4-1
sulfide	E-chem-C4-1
inhibited	O
14	B-geneY-C4-2
-	I-geneY-C4-2
3	I-geneY-C4-2
-	I-geneY-C4-2
3epsilon	I-geneY-C4-2
proteins	E-geneY-C4-2
in	O
HT	O
-	O
29	O
and	O
DLD	O
-	O
1	O
cells	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

Sulindac	B-chem
sulfone	E-chem
at	O
600	O
mumol	O
/	O
L	O
inhibited	O
14	O
-	O
3	O
-	O
3epsilon	O
protein	O
expression	O
in	O
HT	O
-	O
29	O
.	O

Indomethacin	S-chem-C4-1
and	O
SC	B-chem-C4-1
-	I-chem-C4-1
236	E-chem-C4-1
,	O
a	O
selective	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
inhibitor	O
,	O
exerted	O
a	O
similar	O
effect	O
as	O
sulindac	S-chem
.	O

Sulindac	S-chem
suppressed	O
14	O
-	O
3	O
-	O
3epsilon	O
promoter	O
activity	O
.	O

As	O
14	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
3epsilon	I-geneN
promoter	E-geneN
activation	O
is	O
mediated	O
by	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
delta	E-geneY
(	O
PPARdelta	S-geneY
)	O
,	O
we	O
determined	O
the	O
correlation	O
between	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
inhibition	O
and	O
PPARdelta	S-geneY
suppression	O
by	O
NSAIDs	O
.	O

Sulindac	B-chem-C4-1
sulfide	E-chem-C4-1
inhibited	O
PPARdelta	S-geneY-C4-2
protein	O
expression	O
and	O
PPARdelta	S-geneY-C4-2
transcriptional	O
activity	O
.	O

Overexpression	O
of	O
PPARdelta	S-geneY
by	O
adenoviral	O
transfer	O
rescued	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
proteins	O
from	O
elimination	O
by	O
sulindac	S-chem
or	O
indomethacin	S-chem
.	O

NSAID	O
-	O
induced	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
suppression	O
was	O
associated	O
with	O
reduced	O
cytosolic	B-geneY
Bad	E-geneY
with	O
elevation	O
of	O
mitochondrial	B-geneY
Bad	E-geneY
and	O
increase	O
in	O
apoptosis	O
which	O
was	O
rescued	O
by	O
Ad	O
-	O
PPARdelta	S-geneY
transduction	O
.	O

Stable	O
expression	O
of	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
in	O
HT	O
-	O
29	O
significantly	O
protected	O
cells	O
from	O
apoptosis	O
.	O

Our	O
findings	O
shed	O
light	O
on	O
a	O
novel	O
mechanism	O
by	O
which	O
NSAIDs	O
induce	O
colorectal	O
cancer	O
apoptosis	O
via	O
the	O
PPARdelta	S-geneY
/	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
transcriptional	O
pathway	O
.	O

These	O
results	O
suggest	O
that	O
14	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
3epsilon	E-geneY
is	O
a	O
target	O
for	O
the	O
prevention	O
and	O
therapy	O
of	O
colorectal	O
cancer	O
.	O

FGFR4	S-geneY
genetic	O
polymorphisms	O
determine	O
the	O
chemotherapy	O
response	O
of	O
Chinese	O
patients	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Aim	O
:	O
To	O
investigate	O
the	O
relationship	O
of	O
fibroblast	B-geneY
growth	I-geneY
factor	I-geneY
receptor	I-geneY
4	E-geneY
(	O
FGFR4	S-geneY
)	O
gene	O
polymorphisms	O
with	O
the	O
response	O
of	O
Chinese	O
patients	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
to	O
chemotherapy.Methods	O
:	O
A	O
total	O
of	O
629	O
patients	O
with	O
Stage	O
III	O
(	O
A	O
+	O
B	O
)	O
or	O
IV	O
NSCLC	O
,	O
as	O
well	O
as	O
729	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
were	O
recruited	O
.	O

All	O
the	O
patients	O
received	O
platinum	S-chem
-	O
based	O
chemotherapy	O
,	O
and	O
the	O
therapeutic	O
effects	O
were	O
evaluated	O
.	O

Three	O
polymorphisms	O
in	O
the	O
FGFR4	S-geneY
gene	O
(	O
rs351855G	O
/	O
A	O
,	O
rs145302848C	O
/	O
G	O
,	O
and	O
rs147603016G	O
/	O
A	O
)	O
were	O
genotyped	O
,	O
and	O
the	O
association	O
between	O
the	O
3	O
polymorphisms	O
and	O
the	O
chemotherapy	O
effect	O
was	O
analyzed	O
using	O
SPSS	O
software	O
,	O
version	O
16.0.Results	O
:	O
The	O
genotype	O
frequencies	O
of	O
rs145302848C	O
/	O
G	O
and	O
rs147603016G	O
/	O
A	O
were	O
not	O
significantly	O
different	O
between	O
NSCLC	O
patients	O
and	O
healthy	O
controls	O
on	O
one	O
hand	O
,	O
and	O
between	O
the	O
responders	O
and	O
non	O
-	O
responders	O
to	O
the	O
chemotherapy	O
on	O
the	O
other	O
hand	O
.	O

The	O
distribution	O
of	O
AA	O
genotype	O
and	O
A	O
-	O
allele	O
of	O
rs351855G	O
/	O
A	O
was	O
significantly	O
lower	O
in	O
NSCLC	O
patients	O
than	O
in	O
healthy	O
controls	O
.	O

Using	O
patients	O
with	O
the	O
GG	O
genotype	O
as	O
a	O
reference	O
,	O
the	O
AA	O
carrier	O
had	O
a	O
significantly	O
reduced	O
risk	O
for	O
the	O
development	O
of	O
NSCLC	O
after	O
normalizing	O
to	O
age	O
,	O
sex	O
and	O
smoking	O
habits	O
.	O

In	O
NSCLC	O
patients	O
,	O
this	O
genotype	O
occurred	O
more	O
frequently	O
in	O
the	O
responders	O
to	O
the	O
chemotherapy	O
than	O
in	O
non	O
-	O
responders	O
.	O

The	O
chance	O
of	O
being	O
a	O
responder	O
was	O
significantly	O
increased	O
with	O
the	O
AA	O
genotype	O
as	O
compared	O
to	O
G	O
genotype	O
.	O

The	O
AA	O
genotype	O
of	O
rs351855G	O
/	O
A	O
had	O
a	O
better	O
prognosis	O
compared	O
with	O
GA	O
and	O
GG	O
genotype	O
carriers	O
:	O
the	O
overall	O
survival	O
of	O
patients	O
with	O
the	O
AA	O
genotype	O
of	O
rs351855G	O
/	O
A	O
was	O
significantly	O
longer	O
than	O
those	O
with	O
the	O
GG	O
+	O
GA	O
genotype	O
(	O
21.1	O
vs	O
16.5	O
months	O
)	O
.Conclusion	O
:	O
The	O
rs351855G	O
/	O
A	O
polymorphisms	O
of	O
FGFR4	S-geneY
gene	O
can	O
be	O
used	O
to	O
predict	O
the	O
occurrence	O
,	O
chemotherapy	O
response	O
and	O
prognosis	O
of	O
NSCLC	O
.	O

Disruption	O
of	O
the	O
cereblon	S-geneY
gene	O
enhances	O
hepatic	O
AMPK	S-geneN
activity	O
and	O
prevents	O
high	O
fat	O
diet	O
-	O
induced	O
obesity	O
and	O
insulin	S-geneN
resistance	O
in	O
mice	O
.	O

A	O
nonsense	O
mutation	O
in	O
cereblon	S-geneY
(	O
CRBN	S-geneY
)	O
causes	O
a	O
mild	O
type	O
of	O
mental	O
retardation	O
in	O
humans	O
.	O

An	O
earlier	O
study	O
showed	O
that	O
CRBN	S-geneY
negatively	O
regulates	O
the	O
functional	O
activity	O
of	O
AMP	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
AMPK	S-geneN
)	O
in	O
vitro	O
by	O
binding	O
directly	O
to	O
the	O
α1	B-geneY
subunit	I-geneY
of	I-geneY
the	I-geneY
AMPK	E-geneY
complex	O
.	O

However	O
,	O
the	O
in	O
vivo	O
role	O
of	O
CRBN	S-geneY
was	O
not	O
studied	O
.	O

To	O
elucidate	O
the	O
physiological	O
functions	O
of	O
Crbn	S-geneY
,	O
a	O
mouse	O
strain	O
was	O
generated	O
in	O
which	O
the	O
Crbn	S-geneY
gene	O
was	O
deleted	O
throughout	O
the	O
whole	O
body	O
.	O

In	O
Crbn	S-geneY
-	O
deficient	O
mice	O
fed	O
a	O
normal	O
diet	O
,	O
AMPK	S-geneN
in	O
the	O
liver	O
showed	O
hyper	O
-	O
phosphorylation	O
,	O
which	O
indicated	O
the	O
constitutive	O
activation	O
of	O
AMPK	S-geneN
.	O

Since	O
Crbn	S-geneY
-	O
deficient	O
mice	O
showed	O
significantly	O
less	O
weight	O
gain	O
when	O
fed	O
a	O
high	O
fat	O
diet	O
and	O
their	O
insulin	O
sensitivity	O
was	O
considerably	O
improved	O
,	O
the	O
functions	O
of	O
Crbn	S-geneY
in	O
the	O
liver	O
were	O
primarily	O
investigated	O
.	O

These	O
results	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
that	O
Crbn	S-geneY
is	O
a	O
negative	O
modulator	O
of	O
AMPK	S-geneN
,	O
which	O
suggests	O
that	O
Crbn	S-geneY
may	O
be	O
a	O
potential	O
target	O
for	O
metabolic	O
disorders	O
of	O
the	O
liver	O
.	O

Dopamine	B-geneN
D2	I-geneN
/	I-geneN
3	I-geneN
receptor	E-geneN
binding	O
potential	O
and	O
occupancy	O
in	O
midbrain	O
and	O
temporal	O
cortex	O
by	O
haloperidol	S-chem
,	O
olanzapine	S-chem
and	O
clozapine	S-chem
.	O

AIMS	O
:	O
Aberrant	O
dopamine	S-chem
transmission	O
in	O
extrastriatal	O
brain	O
regions	O
has	O
been	O
repeatedly	O
illustrated	O
among	O
patients	O
with	O
schizophrenia	O
.	O

Differences	O
between	O
typical	O
and	O
second	O
-	O
generation	O
antipsychotics	O
in	O
dopamine	B-geneY
D	I-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
modulation	O
within	O
various	O
brain	O
areas	O
remain	O
a	O
topic	O
for	O
debate	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
therefore	O
to	O
investigate	O
dopamine	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
/	I-geneN
3	I-geneN
)	I-geneN
receptor	E-geneN
apparent	O
binding	O
potential	O
(	O
BP	O
(	O
app	O
)	O
)	O
and	O
occupancy	O
in	O
midbrain	O
and	O
temporal	O
cortex	O
among	O
clozapine	S-chem
-	O
,	O
olanzapine	S-chem
-	O
and	O
haloperidol	S-chem
-	O
treated	O
schizophrenia	O
patients	O
.	O

METHODS	O
:	O
Dopamine	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
/	I-geneN
3	I-geneN
)	E-geneN
binding	O
was	O
studied	O
on	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
ligand	O
[	B-chem
(	I-chem
123	I-chem
)	I-chem
I	I-chem
]	I-chem
epidepride	E-chem
in	O
13	O
schizophrenia	O
patients	O
treated	O
with	O
medication	O
(	O
two	O
with	O
haloperidol	S-chem
,	O
four	O
with	O
olanzapine	S-chem
and	O
seven	O
with	O
clozapine	S-chem
)	O
,	O
six	O
drug	O
-	O
naive	O
patients	O
and	O
seven	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
Statistically	O
significant	O
differences	O
in	O
midbrain	O
dopamine	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
/	I-geneN
3	I-geneN
)	I-geneN
receptor	E-geneN
BP	O
(	O
app	O
)	O
(	O
P	O
=	O
0.015	O
)	O
and	O
occupancy	O
(	O
P	O
=	O
0.016	O
)	O
were	O
observed	O
between	O
the	O
clozapine	S-chem
,	O
olanzapine	S-chem
and	O
haloperidol	S-chem
groups	O
.	O

The	O
lowest	O
occupancy	O
was	O
found	O
in	O
clozapine	S-chem
-	O
treated	O
patients	O
(	O
5	O
%	O
)	O
,	O
followed	O
by	O
olanzapine	S-chem
-	O
treated	O
patients	O
(	O
28	O
%	O
)	O
,	O
compared	O
to	O
haloperidol	S-chem
-	O
treated	O
patients	O
(	O
40	O
%	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
temporal	O
poles	O
.	O

Occupancy	O
changed	O
substantially	O
depending	O
on	O
the	O
comparison	O
group	O
used	O
(	O
either	O
drug	O
-	O
naive	O
vs	O
healthy	O
controls	O
)	O
in	O
the	O
examined	O
brain	O
areas	O
(	O
P	O
=	O
0.001	O
)	O
,	O
showing	O
an	O
overestimation	O
with	O
all	O
antipsychotics	O
when	O
the	O
healthy	O
control	O
group	O
was	O
used	O
.	O

CONCLUSION	O
:	O
Both	O
typical	O
and	O
second	O
-	O
generation	O
antipsychotics	O
occupy	O
cortical	O
dopamine	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
/	I-geneN
3	I-geneN
)	I-geneN
receptors	E-geneN
,	O
thus	O
mediating	O
therapeutic	O
efficacy	O
.	O

Observed	O
differences	O
in	O
midbrain	O
dopamine	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
/	I-geneN
3	I-geneN
)	E-geneN
occupancy	O
between	O
classical	O
antipsychotics	O
and	O
second	O
-	O
generation	O
antipsychotics	O
may	O
have	O
clinical	O
relevance	O
by	O
modulating	O
altered	O
nigrostriatal	O
dopamine	S-chem
neurotransmission	O
during	O
the	O
acute	O
phase	O
of	O
schizophrenia	O
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Pharmacological	O
Characterization	O
of	O
Novel	O
Endomorphin	B-chem-C5-1
-	I-chem-C5-1
1	E-chem-C5-1
Analogues	O
as	O
Extremely	O
Potent	O
μ	B-geneY-C5-2
-	I-geneY-C5-2
Opioid	E-geneY-C5-2
Agonists	O
.	O

Recently	O
we	O
reported	O
the	O
synthesis	O
and	O
structure	O
-	O
activity	O
study	O
of	O
endomorphin	B-chem
-	I-chem
1	E-chem
(	O
EM	B-chem
-	I-chem
1	E-chem
)	O
analogues	O
containing	O
novel	O
,	O
unnatural	O
α	B-chem
-	I-chem
methylene	I-chem
-	I-chem
β	I-chem
-	I-chem
aminopropanoic	I-chem
acids	E-chem
(	O
Map	S-chem
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
new	O
EM	B-chem
-	I-chem
1	E-chem
analogues	O
containing	O
Dmt	S-chem
(	O
1	O
)	O
,	O
(	B-chem
R	I-chem
/	I-chem
S	I-chem
)	I-chem
-	I-chem
βPro	E-chem
(	O
2	O
)	O
,	O
and	O
(	B-chem
ph	I-chem
)	I-chem
Map	E-chem
(	O
4	O
)	O
/	O
(	B-chem
2	I-chem
-	I-chem
furyl	I-chem
)	I-chem
Map	E-chem
(	O
4	O
)	O
.	O

All	O
of	O
the	O
analogues	O
showed	O
a	O
high	O
affinity	O
for	O
the	O
μ	B-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
(	O
MOR	S-geneY
)	O
and	O
increased	O
stability	O
in	O
mouse	O
brain	O
homogenates	O
.	O

Of	O
the	O
new	O
compounds	O
,	O
Dmt	S-chem
(	O
1	O
)	O
-	O
(	B-chem
R	I-chem
)	I-chem
-	I-chem
βPro	E-chem
(	O
2	O
)	O
-	O
Trp	S-chem
(	O
3	O
)	O
-	O
(	B-chem
2	I-chem
-	I-chem
furyl	I-chem
)	I-chem
Map	E-chem
(	O
4	O
)	O
(	O
analogue	O
12	O
)	O
displayed	O
the	O
highest	O
affinity	O
toward	O
MOR	S-geneY
,	O
in	O
the	O
picomolar	O
range	O
(	O
Ki	O
(	O
μ	O
)	O
=	O
3.72	O
pM	O
)	O
.	O

Forskolin	S-chem
-	O
induced	O
cAMP	S-chem
accumulation	O
assays	O
indicated	O
that	O
this	O
analogue	O
displayed	O
an	O
extremely	O
high	O
agonistic	O
potency	O
,	O
in	O
the	O
subpicomolar	O
range	O
(	O
EC50	O
=	O
0.0421	O
pM	O
,	O
Emax	O
=	O
99.5	O
%	O
)	O
.	O

This	O
compound	O
also	O
displayed	O
stronger	O
in	O
vivo	O
antinociceptive	O
activity	O
after	O
iv	O
administration	O
when	O
compared	O
to	O
morphine	S-chem
in	O
the	O
tail	O
-	O
flick	O
test	O
,	O
which	O
indicates	O
that	O
this	O
analogue	O
was	O
able	O
to	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Pharmacophore	O
identification	O
of	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Myc	E-geneY-C4-2
inhibitor	O
10074	B-chem-C4-1
-	I-chem-C4-1
G5	E-chem-C4-1
.	O

A	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
study	O
of	O
the	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Myc	E-geneY-C4-2
(	O
Myc	S-geneY-C4-2
)	O
inhibitor	O
10074	B-chem-C4-1
-	I-chem-C4-1
G5	E-chem-C4-1
(	O
N	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
[	I-chem-C4-1
1,1	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
biphenyl	I-chem-C4-1
]	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
7	I-chem-C4-1
-	I-chem-C4-1
nitrobenzo	I-chem-C4-1
[	I-chem-C4-1
c	I-chem-C4-1
]	I-chem-C4-1
[	I-chem-C4-1
1,2,5	I-chem-C4-1
]	I-chem-C4-1
oxadiazol	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
amine	E-chem-C4-1
,	O
1	O
)	O
-	O
which	O
targets	O
a	O
hydrophobic	O
domain	O
of	O
the	O
Myc	S-geneY
oncoprotein	O
that	O
is	O
flanked	O
by	O
arginine	S-chem
residues	O
-	O
was	O
executed	O
in	O
order	O
to	O
determine	O
its	O
pharmacophore	O
.	O

Whilst	O
the	O
7	B-chem
-	I-chem
nitrobenzofurazan	E-chem
was	O
found	O
to	O
be	O
critical	O
for	O
inhibitory	O
activity	O
,	O
the	O
ortho	B-chem
-	I-chem
biphenyl	E-chem
could	O
be	O
replaced	O
with	O
a	O
para	B-chem
-	I-chem
carboxyphenyl	E-chem
group	O
to	O
furnish	O
the	O
new	O
inhibitor	O
JY	B-chem
-	I-chem
3	I-chem
-	I-chem
094	E-chem
(	O
3q	O
)	O
.	O

Around	O
five	O
times	O
as	O
potent	O
as	O
the	O
lead	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
33	O
μM	O
for	O
disruption	O
of	O
the	O
Myc	S-geneY
-	O
Max	S-geneY
heterodimer	O
,	O
JY	B-chem
-	I-chem
3	I-chem
-	I-chem
094	E-chem
demonstrated	O
excellent	O
selectivity	O
over	O
Max	S-geneY
-	O
Max	S-geneY
homodimers	O
,	O
with	O
no	O
apparent	O
effect	O
at	O
100	O
μM	O
.	O

Importantly	O
,	O
the	O
carboxylic	O
acid	O
of	O
JY	B-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
094	E-chem-C4-1
improves	O
the	O
physicochemical	O
properties	O
of	O
the	O
lead	O
compound	O
,	O
which	O
will	O
facilitate	O
the	O
incorporation	O
of	O
additional	O
hydrophobicity	O
that	O
might	O
enhance	O
Myc	S-geneY-C4-2
inhibitory	O
activity	O
further	O
still	O
.	O

Role	O
of	O
the	O
calcium	B-geneN
modulated	I-geneN
cyclases	E-geneN
in	O
the	O
development	O
of	O
the	O
retinal	S-chem
projections	O
.	O

Transmembrane	O
isoforms	O
of	O
adenylate	B-geneN-C9-2
cyclases	E-geneN-C9-2
(	O
AC	S-geneN-C9-2
)	O
integrate	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
from	O
neurotransmitters	O
to	O
morphogens	O
and	O
can	O
also	O
regulate	O
cAMP	S-chem-C9-1
production	O
in	O
response	O
to	O
calcium	S-chem
entry	O
.	O

Based	O
on	O
observations	O
in	O
the	O
barrelless	O
mouse	O
strain	O
,	O
the	O
Adcy1	S-geneY
gene	O
(	O
AC1	S-geneY
)	O
was	O
involved	O
in	O
the	O
segregation	O
of	O
binocular	O
retinal	S-chem
inputs	O
.	O

To	O
determine	O
the	O
potential	O
role	O
of	O
other	O
AC	S-geneN
isoforms	O
we	O
localized	O
the	O
Adcy	S-geneN
genes	O
in	O
the	O
visual	O
centres	O
during	O
development	O
,	O
using	O
in	O
situ	O
hybridization	O
.	O

Six	O
different	O
AC	S-geneN
subtypes	O
were	O
found	O
in	O
the	O
developing	O
retinal	O
ganglion	O
cell	O
layer	O
(	O
RGC	O
;	O
AC1	S-geneY
,	O
AC2	S-geneY
,	O
AC3	S-geneY
,	O
AC5	S-geneY
,	O
AC8	S-geneY
,	O
and	O
AC9	S-geneY
)	O
,	O
and	O
three	O
AC	S-geneN
subtypes	O
were	O
expressed	O
in	O
the	O
central	O
brain	O
targets	O
,	O
the	O
dorsal	O
lateral	O
geniculate	O
nucleus	O
(	O
AC1	S-geneY
and	O
AC8	S-geneY
)	O
,	O
the	O
ventral	O
lateral	O
geniculate	O
nucleus	O
(	O
AC2	S-geneY
and	O
AC8	S-geneY
)	O
and	O
the	O
superior	O
colliculus	O
(	O
AC1	S-geneY
,	O
AC2	S-geneY
,	O
AC8	S-geneY
)	O
.	O

Using	O
a	O
genetic	O
approach	O
we	O
tested	O
the	O
role	O
of	O
the	O
calcium	B-geneN
modulated	I-geneN
cyclases	E-geneN
AC1	S-geneY
,	O
AC5	S-geneY
and	O
AC8	S-geneY
for	O
the	O
segregation	O
retinal	S-chem
fibres	O
.	O

Ipsilateral	O
retinal	S-chem
axons	O
remained	O
exuberant	O
in	O
the	O
AC1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
with	O
overlapping	O
retinal	S-chem
projections	O
from	O
both	O
eyes	O
in	O
the	O
superior	O
colliculus	O
and	O
the	O
visual	O
thalamus	O
.	O

These	O
abnormalities	O
were	O
similar	O
to	O
those	O
of	O
barrelless	O
mouse	O
mutants	O
.	O

No	O
abnormalities	O
were	O
detectable	O
in	O
the	O
AC5	S-geneY
(	O
-	O
/	O
-	O
)	O
or	O
the	O
AC8	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Similar	O
abnormalities	O
were	O
noted	O
in	O
the	O
single	O
AC1	S-geneY
(	O
-	O
/	O
-	O
)	O
and	O
the	O
AC1	S-geneY
/	O
AC8	S-geneY
double	O
-	O
knockout	O
mice	O
(	O
DKO	O
)	O
.	O

Thus	O
,	O
only	O
AC1	S-geneY
is	O
required	O
for	O
the	O
maturation	O
of	O
the	O
retinal	S-chem
axon	O
terminals	O
whereas	O
AC5	S-geneY
and	O
AC8	S-geneY
are	O
not	O
needed	O
.	O

The	O
specificity	O
of	O
AC1	B-geneY
's	E-geneY
action	O
is	O
linked	O
to	O
its	O
cellular	O
localization	O
in	O
the	O
RGCs	O
and	O
to	O
its	O
distinctive	O
functional	O
profile	O
,	O
compared	O
with	O
the	O
other	O
cyclases	S-geneN
expressed	O
in	O
the	O
same	O
cells	O
.	O

Histamine	B-geneY-C6-2
H1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
,	O
promethazine	S-chem-C6-1
and	O
homochlorcyclizine	S-chem-C6-1
,	O
increase	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
haloperidol	S-chem
and	O
reduced	O
haloperidol	S-chem
.	O

The	O
effects	O
of	O
histamine	B-geneY-C6-2
H1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
,	O
promethazine	S-chem-MU-1
and	O
homochlorcyclizine	S-chem-MU-1
,	O
both	O
of	O
which	O
are	O
inhibitors	O
of	O
CYP2D6	S-geneY-C4-2
,	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
(	O
Css	O
)	O
of	O
haloperidol	S-chem
and	O
reduced	O
haloperidol	S-chem
were	O
studied	O
in	O
23	O
schizophrenic	O
inpatients	O
receiving	O
haloperidol	S-chem
,	O
12	O
to	O
36	O
mg	O
/	O
d	O
,	O
for	O
2	O
to	O
29	O
weeks	O
.	O

Promethazine	S-chem
,	O
150	O
mg	O
/	O
d	O
,	O
in	O
11	O
patients	O
and	O
homochlorcyclizine	S-chem
,	O
60	O
mg	O
/	O
d	O
,	O
in	O
the	O
others	O
were	O
coadministered	O
for	O
at	O
least	O
1	O
week	O
.	O

Blood	O
sampling	O
was	O
performed	O
before	O
and	O
during	O
coadministration	O
of	O
promethazine	S-chem
or	O
homochlorcyclizine	S-chem
and	O
1	O
week	O
after	O
the	O
discontinuation	O
,	O
together	O
with	O
clinical	O
assessments	O
by	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
(	O
BPRS	O
)	O
and	O
Udvalg	O
for	O
kliniske	O
undersogelser	O
(	O
UKU	O
)	O
side	O
effect	O
rating	O
scale	O
.	O

The	O
Css	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
of	O
haloperidol	S-chem
and	O
reduced	O
haloperidol	S-chem
during	O
promethazine	S-chem
coadministration	O
(	O
27.6	O
+	O
/	O
-	O
24.9	O
and	O
8.6	O
+	O
/	O
-	O
13.2	O
ng	O
/	O
mL	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
before	O
the	O
coadministration	O
(	O
12.7	O
+	O
/	O
-	O
10.8	O
and	O
5.0	O
+	O
/	O
-	O
6.0	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0.01	O
)	O
or	O
1	O
week	O
after	O
the	O
discontinuation	O
(	O
15.6	O
+	O
/	O
-	O
14.8	O
and	O
5.8	O
+	O
/	O
-	O
7.9	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
Css	O
of	O
haloperidol	S-chem
and	O
reduced	O
haloperidol	S-chem
during	O
homochlorcyclizine	S-chem
coadministration	O
(	O
14.9	O
+	O
/	O
-	O
8.1	O
and	O
6.4	O
+	O
/	O
-	O
5.4	O
ng	O
/	O
mL	O
)	O
were	O
also	O
significantly	O
higher	O
than	O
those	O
before	O
the	O
coadministration	O
(	O
10.9	O
+	O
/	O
-	O
7.2	O
and	O
3.8	O
+	O
/	O
-	O
3.6	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0.01	O
)	O
or	O
1	O
week	O
after	O
the	O
discontinuation	O
(	O
12.9	O
+	O
/	O
-	O
7.4	O
and	O
4.8	O
+	O
/	O
-	O
4.1	O
ng	O
/	O
mL	O
;	O
P	O
<	O
0.05	O
)	O
.	O

No	O
change	O
in	O
BPRS	O
or	O
UKU	O
score	O
was	O
found	O
throughout	O
the	O
study	O
.	O

Thus	O
,	O
the	O
current	O
study	O
suggests	O
that	O
coadministration	O
of	O
clinical	O
doses	O
of	O
promethazine	S-chem-C4-1
and	O
homochlorcyclizine	S-chem-C4-1
increases	O
the	O
Css	O
of	O
haloperidol	S-chem
and	O
reduced	O
haloperidol	S-chem
via	O
the	O
inhibitory	O
effects	O
on	O
the	O
CYP2D6	S-geneY-MU-2
-	O
catalyzed	O
metabolism	O
of	O
haloperidol	S-chem-C9-1
and	O
reduced	O
haloperidol	S-chem-C9-1
.	O

Genome	O
-	O
wide	O
screen	O
for	O
modulation	O
of	O
hepatic	O
apolipoprotein	B-geneY
A	I-geneY
-	I-geneY
I	E-geneY
(	O
ApoA	B-geneY
-	I-geneY
I	E-geneY
)	O
secretion	O
.	O

Control	O
of	O
plasma	O
cholesterol	S-chem
levels	O
is	O
a	O
major	O
therapeutic	O
strategy	O
for	O
management	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

Although	O
reducing	O
LDL	S-geneN
cholesterol	S-chem
(	O
LDL	S-geneN
-	O
c	O
)	O
levels	O
decreases	O
morbidity	O
and	O
mortality	O
,	O
this	O
therapeutic	O
intervention	O
only	O
translates	O
into	O
a	O
25	O
-	O
40	O
%	O
reduction	O
in	O
cardiovascular	O
events	O
.	O

Epidemiological	O
studies	O
have	O
shown	O
that	O
a	O
high	O
LDL	S-geneN
-	O
c	O
level	O
is	O
not	O
the	O
only	O
risk	O
factor	O
for	O
CAD	O
;	O
low	O
HDL	S-geneN
cholesterol	S-chem
(	O
HDL	S-geneN
-	O
c	O
)	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
CAD	O
.	O

Apolipoprotein	B-geneY
A	I-geneY
-	E-geneY
I	O
(	O
ApoA	B-geneY
-	I-geneY
I	E-geneY
)	O
is	O
the	O
major	O
protein	O
component	O
of	O
HDL	S-geneN
-	O
c	O
that	O
mediates	O
reverse	O
cholesterol	S-chem
transport	O
from	O
tissues	O
to	O
the	O
liver	O
for	O
excretion	O
.	O

Therefore	O
,	O
increasing	O
ApoA	B-geneY
-	I-geneY
I	E-geneY
levels	O
is	O
an	O
attractive	O
strategy	O
for	O
HDL	S-geneN
-	O
c	O
elevation	O
.	O

Using	O
genome	O
-	O
wide	O
siRNA	O
screening	O
,	O
targets	O
that	O
regulate	O
hepatocyte	O
ApoA	B-geneY
-	I-geneY
I	E-geneY
secretion	O
were	O
identified	O
through	O
transfection	O
of	O
21,789	O
siRNAs	O
into	O
hepatocytes	O
whereby	O
cell	O
supernatants	O
were	O
assayed	O
for	O
ApoA	B-geneY
-	I-geneY
I	E-geneY
.	O

Approximately	O
800	O
genes	O
were	O
identified	O
and	O
triaged	O
using	O
a	O
convergence	O
of	O
information	O
,	O
including	O
genetic	O
associations	O
with	O
HDL	S-geneN
-	O
c	O
levels	O
,	O
tissue	O
-	O
specific	O
gene	O
expression	O
,	O
druggability	O
assessments	O
,	O
and	O
pathway	O
analysis	O
.	O

Fifty	O
-	O
nine	O
genes	O
were	O
selected	O
for	O
reconfirmation	O
;	O
40	O
genes	O
were	O
confirmed	O
.	O

Here	O
we	O
describe	O
the	O
siRNA	O
screening	O
strategy	O
,	O
assay	O
implementation	O
and	O
validation	O
,	O
data	O
triaging	O
,	O
and	O
example	O
genes	O
of	O
interest	O
.	O

The	O
genes	O
of	O
interest	O
include	O
known	O
and	O
novel	O
genes	O
encoding	O
secreted	O
enzymes	O
,	O
proteases	O
,	O
G	B-geneN
-	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptors	E-geneN
,	O
metabolic	O
enzymes	O
,	O
ion	B-geneN
transporters	E-geneN
,	O
and	O
proteins	O
of	O
unknown	O
function	O
.	O

Repression	O
of	O
farnesyltransferase	S-geneY-C4-2
(	O
FNTA	S-geneY-C4-2
)	O
by	O
siRNA	O
and	O
the	O
enzyme	O
inhibitor	O
manumycin	B-chem-MU-1
A	E-chem-MU-1
caused	O
elevation	O
of	O
ApoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
secretion	O
from	O
hepatocytes	O
and	O
from	O
transgenic	O
mice	O
expressing	O
hApoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
and	O
cholesterol	B-chem
ester	E-chem
transfer	O
protein	O
transgenes	O
.	O

In	O
total	O
,	O
this	O
work	O
underscores	O
the	O
power	O
of	O
functional	O
genetic	O
assessment	O
to	O
identify	O
new	O
therapeutic	O
targets	O
.	O

Toxic	O
effects	O
of	O
chromium	S-chem
on	O
tannery	O
workers	O
at	O
Sialkot	O
(	O
Pakistan	O
)	O
.	O

Chromium	S-chem
is	O
widely	O
used	O
in	O
the	O
leather	O
industry	O
,	O
and	O
tannery	O
workers	O
are	O
under	O
constant	O
threat	O
of	O
adverse	O
health	O
effects	O
due	O
to	O
its	O
excessive	O
exposure	O
.	O

Our	O
objective	O
was	O
to	O
find	O
out	O
the	O
toxic	O
effects	O
of	O
chromium	S-chem
on	O
tannery	O
workers	O
at	O
Sialkot	O
,	O
Pakistan	O
.	O

A	O
total	O
of	O
240	O
males	O
consisting	O
of	O
120	O
workers	O
from	O
tanneries	O
at	O
Sialkot	O
and	O
equal	O
number	O
of	O
controls	O
were	O
included	O
.	O

Blood	O
complete	O
counts	O
,	O
high	O
-	O
sensitive	O
C	B-geneY
-	I-geneY
reactive	I-geneY
protein	E-geneY
,	O
malondialdehyde	S-chem
and	O
routine	O
biochemical	O
tests	O
were	O
carried	O
out	O
by	O
routine	O
procedures	O
.	O

Chromium	S-chem
levels	O
in	O
blood	O
(	O
BCr	O
)	O
and	O
urine	O
were	O
analyzed	O
using	O
graphite	S-chem
furnace	O
atomic	O
absorption	O
spectrophotometer	O
Perkin	O
Elmer	O
analyst	O
-	O
200	O
.	O

Results	O
revealed	O
that	O
all	O
the	O
workers	O
were	O
male	O
with	O
average	O
age	O
of	O
33	O
years	O
and	O
15	O
(	O
13	O
%	O
)	O
had	O
skin	O
rashes	O
,	O
14	O
(	O
12	O
%	O
)	O
had	O
chronic	O
bronchitis	O
,	O
10	O
(	O
8	O
%	O
)	O
had	O
gastritis	O
and	O
4	O
(	O
3	O
%	O
)	O
conjunctivitis	O
.	O

The	O
tannery	O
workers	O
had	O
significantly	O
raised	O
median	O
(	O
interquartile	O
range	O
)	O
of	O
BCr	O
569	O
(	O
377	O
-	O
726	O
)	O
nmol	O
/	O
L	O
as	O
compared	O
to	O
318	O
(	O
245	O
-	O
397	O
)	O
nmol	O
/	O
L	O
in	O
the	O
control	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Sixty	O
-	O
five	O
(	O
54	O
%	O
)	O
workers	O
had	O
BCr	O
levels	O
above	O
the	O
upper	O
limit	O
set	O
by	O
Agency	O
for	O
Toxic	O
Substance	O
and	O
Drug	O
Registry	O
.	O

The	O
urinary	O
chromium	S-chem
excretion	O
was	O
significantly	O
high	O
in	O
workers	O
131	O
(	O
46	O
-	O
312	O
)	O
nmol	O
/	O
L	O
as	O
compared	O
to	O
13	O
(	O
3	O
-	O
26	O
)	O
nmol	O
/	O
L	O
in	O
controls	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
workers	O
had	O
hematological	O
,	O
hepatic	O
and	O
renal	O
function	O
impairment	O
because	O
of	O
oxidative	O
stress	O
on	O
body	O
systems	O
.	O

It	O
is	O
concluded	O
that	O
about	O
half	O
of	O
the	O
workers	O
had	O
excessive	O
exposure	O
to	O
chromium	S-chem
in	O
the	O
tanneries	O
at	O
Sialkot	O
.	O

They	O
had	O
significantly	O
raised	O
chromium	S-chem
levels	O
in	O
their	O
biological	O
fluids	O
and	O
adverse	O
health	O
effects	O
due	O
to	O
enhanced	O
oxidative	O
stress	O
and	O
inflammatory	O
changes	O
.	O

Response	O
of	O
nonreentrant	O
catecholamine	S-chem
-	O
mediated	O
ventricular	O
tachycardia	O
to	O
endogenous	O
adenosine	S-chem
and	O
acetylcholine	S-chem
.	O
Evidence	O
for	O
myocardial	O
receptor	O
-	O
mediated	O
effects	O
.	O

BACKGROUND	O
:	O
Reentrant	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
is	O
known	O
to	O
be	O
insensitive	O
to	O
the	O
nucleoside	S-chem
adenosine	S-chem
.	O

However	O
,	O
we	O
have	O
previously	O
identified	O
a	O
form	O
of	O
nonreentrant	O
,	O
catecholamine	S-chem
-	O
mediated	O
VT	O
that	O
can	O
be	O
initiated	O
with	O
rapid	O
pacing	O
,	O
demonstrates	O
cycle	O
length	O
dependence	O
,	O
and	O
is	O
sensitive	O
to	O
exogenous	O
adenosine	S-chem
as	O
well	O
as	O
to	O
the	O
Valsalva	O
maneuver	O
.	O

The	O
mechanism	O
of	O
this	O
tachycardia	O
is	O
thought	O
to	O
be	O
due	O
to	O
a	O
catecholamine	S-chem
-	O
induced	O
,	O
cAMP	S-chem
-	O
mediated	O
increase	O
in	O
intracellular	O
calcium	S-chem
,	O
resulting	O
in	O
delayed	O
afterdepolarizations	O
and	O
triggered	O
activity	O
.	O

The	O
antiarrhythmic	O
effects	O
of	O
exogenous	O
adenosine	S-chem
and	O
Valsalva	O
on	O
this	O
form	O
of	O
VT	O
may	O
be	O
due	O
to	O
receptor	O
-	O
mediated	O
inhibition	O
of	O
adenylate	B-geneN
cyclase	E-geneN
or	O
to	O
noncardiac	O
receptor	O
-	O
mediated	O
effects	O
,	O
i.e	O
.	O
,	O
exogenous	O
adenosine	S-chem-C3-1
may	O
modulate	O
VT	O
through	O
alterations	O
in	O
autonomic	O
tone	O
by	O
activation	O
of	O
arterial	O
chemoreceptors	S-geneN-C3-2
,	O
and	O
Valsalva	O
has	O
been	O
shown	O
to	O
decrease	O
venous	O
return	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
cardiac	O
dimensions	O
and	O
myocardial	O
stretch	O
.	O

To	O
clarify	O
this	O
issue	O
and	O
circumvent	O
both	O
autonomic	O
and	O
noncardiac	O
receptor	O
effects	O
,	O
the	O
response	O
of	O
nonreentrant	O
catecholamine	S-chem
-	O
mediated	O
VT	O
to	O
endogenous	O
adenosine	S-chem
and	O
acetylcholine	S-chem
was	O
evaluated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Group	O
1	O
(	O
n	O
=	O
8	O
)	O
:	O
Dipyridamole	S-chem
(	O
0.56	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
,	O
a	O
nucleoside	S-chem
transport	O
blocker	O
that	O
potentiates	O
the	O
effects	O
of	O
endogenous	O
adenosine	S-chem
,	O
reproducibly	O
abolished	O
sustained	O
nonreentrant	O
,	O
nonautomatic	O
,	O
catecholamine	S-chem
-	O
mediated	O
VT	O
in	O
the	O
five	O
patients	O
in	O
whom	O
it	O
was	O
evaluated	O
.	O

VT	O
recurred	O
with	O
the	O
addition	O
of	O
aminophylline	S-chem-C6-1
,	O
a	O
competitive	S-chem
adenosine	B-geneY-C6-2
A1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
.	O

Edrophonium	S-chem-C4-1
(	O
10	O
mg	O
i.v	O
.	O
)	O
,	O
a	O
cholinesterase	S-geneY-C4-2
inhibitor	O
that	O
potentiates	O
the	O
effects	O
of	O
acetylcholine	S-chem
at	O
the	O
muscarinic	B-geneN-C4-2
cholinergic	I-geneN-C4-2
receptor	E-geneN-C4-2
,	O
terminated	O
VT	O
in	O
four	O
of	O
four	O
patients	O
,	O
an	O
effect	O
that	O
was	O
reversed	O
by	O
atropine	S-chem-C4-1
.	O

Group	O
2	O
(	O
n	O
=	O
6	O
)	O
:	O
In	O
patients	O
with	O
reentrant	O
VT	O
,	O
dipyridamole	S-chem
and	O
edrophonium	S-chem
had	O
no	O
effect	O
on	O
VT	O
cycle	O
length	O
or	O
duration	O
.	O

Group	O
3	O
(	O
n	O
=	O
4	O
)	O
:	O
Adenosine	S-chem
and	O
vagal	O
maneuvers	O
had	O
no	O
effect	O
on	O
catecholamine	S-chem
-	O
mediated	O
VT	O
caused	O
by	O
automaticity	O
in	O
three	O
of	O
four	O
patients	O
tested	O
.	O

In	O
one	O
patient	O
,	O
adenosine	S-chem
transiently	O
suppressed	O
VT	O
(	O
<	O
5	O
seconds	O
)	O
,	O
after	O
which	O
it	O
spontaneously	O
resumed	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
further	O
delineate	O
the	O
mechanism	O
of	O
a	O
newly	O
recognized	O
form	O
of	O
clinical	O
VT	O
.	O

It	O
can	O
be	O
identified	O
by	O
termination	O
of	O
the	O
tachycardia	O
in	O
response	O
to	O
activation	O
of	O
the	O
adenosine	B-geneY
A1	E-geneY
or	O
muscarinic	B-geneN
cholinergic	I-geneN
receptor	E-geneN
,	O
which	O
results	O
in	O
inhibition	O
of	O
adenylate	B-geneN
cyclase	E-geneN
.	O

These	O
receptor	O
-	O
mediated	O
effects	O
appear	O
to	O
be	O
specific	O
for	O
identifying	O
nonreentrant	O
,	O
nonautomatic	O
,	O
catecholamine	S-chem
-	O
mediated	O
VT	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationship	O
of	O
pyripyropene	B-chem-C4-1
A	E-chem-C4-1
derivatives	O
as	O
potent	O
and	O
selective	O
acyl	B-geneY-C4-2
-	I-geneY-C4-2
CoA	I-geneY-C4-2
:	I-geneY-C4-2
cholesterol	I-geneY-C4-2
acyltransferase	I-geneY-C4-2
2	E-geneY-C4-2
(	O
ACAT2	S-geneY-C4-2
)	O
inhibitors	O
:	O
Part	O
2	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
7	B-chem
-	I-chem
O	I-chem
-	I-chem
p	I-chem
-	I-chem
cyanobenzoyl	I-chem
pyripyropene	I-chem
A	E-chem
derivatives	O
with	O
modification	O
at	O
C1	O
and	O
11	O
are	O
described	O
.	O

Regioselective	O
mono	O
-	O
deprotection	O
of	O
di	B-chem
-	I-chem
tert	I-chem
-	I-chem
butylsilylene	I-chem
acetal	E-chem
was	O
critical	O
in	O
their	O
synthesis	O
.	O

Carnitine	B-geneY-C9-2
palmitoyltransferase	I-geneY-C9-2
2	E-geneY-C9-2
and	O
carnitine	B-geneY-C9-2
/	I-geneY-C9-2
acylcarnitine	I-geneY-C9-2
translocase	E-geneY-C9-2
are	O
involved	O
in	O
the	O
mitochondrial	O
synthesis	O
and	O
export	O
of	O
acylcarnitines	S-chem-C9-1
.	O

Acylcarnitines	S-chem
are	O
commonly	O
used	O
in	O
the	O
diagnosis	O
of	O
mitochondrial	O
fatty	B-chem
acid	E-chem
β	O
-	O
oxidation	O
disorders	O
(	O
mFAODs	O
)	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
this	O
plasma	O
acylcarnitine	S-chem
profile	O
reflects	O
the	O
mitochondrial	O
accumulation	O
of	O
acyl	B-chem
-	I-chem
CoAs	E-chem
.	O

The	O
identity	O
of	O
the	O
enzymes	O
and	O
the	O
mitochondrial	O
and	O
plasmalemmal	O
transporters	O
involved	O
in	O
the	O
synthesis	O
and	O
export	O
of	O
these	O
metabolites	O
have	O
remained	O
undefined	O
.	O

We	O
used	O
lentiviral	O
shRNA	O
to	O
knock	O
down	O
the	O
expression	O
of	O
medium	B-geneY
-	I-geneY
chain	I-geneY
acyl	I-geneY
-	I-geneY
CoA	I-geneY
dehydrogenase	E-geneY
(	O
MCAD	S-geneY
)	O
in	O
control	O
and	O
carnitine	B-geneY
palmitoyltransferase	I-geneY
2	E-geneY
(	O
CPT2	S-geneY
)	O
-	O
,	O
carnitine	B-geneY
/	I-geneY
acylcarnitine	I-geneY
translocase	E-geneY
(	O
CACT	S-geneY
)	O
-	O
,	O
and	O
plasmalemmal	O
carnitine	B-geneN
transporter	E-geneN
(	O
OCTN2	S-geneY
)	O
-	O
deficient	O
human	O
fibroblasts	O
.	O

These	O
cell	O
lines	O
,	O
including	O
mock	O
-	O
transduced	O
controls	O
,	O
were	O
loaded	O
with	O
decanoic	B-chem
acid	E-chem
and	O
carnitine	S-chem
,	O
followed	O
by	O
the	O
measurement	O
of	O
the	O
acylcarnitine	S-chem
profile	O
in	O
the	O
extracellular	O
medium	O
.	O

In	O
control	O
fibroblasts	O
,	O
MCAD	S-geneY
knockdown	O
markedly	O
increased	O
the	O
production	O
of	O
octanoylcarnitine	S-chem
(	O
3	O
-	O
fold	O
,	O
P	O
<	O
0.01	O
)	O
.	O

OCTN2	S-geneY
-	O
deficient	O
cell	O
lines	O
also	O
showed	O
extracellular	O
accumulation	O
of	O
octanoylcarnitine	S-chem
(	O
2.8	O
-	O
fold	O
,	O
P	O
<	O
0.01	O
)	O
,	O
suggesting	O
that	O
the	O
cellular	O
export	O
of	O
acylcarnitines	S-chem
does	O
not	O
depend	O
on	O
OCTN2	S-geneY
.	O

In	O
contrast	O
,	O
in	O
CPT2	S-geneY
-	O
and	O
CACT	S-geneY
-	O
deficient	O
cells	O
,	O
the	O
accumulation	O
of	O
octanoylcarnitine	S-chem
in	O
the	O
medium	O
did	O
not	O
significantly	O
increase	O
in	O
the	O
MCAD	S-geneY
knockdown	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
pharmacological	O
inhibition	O
of	O
CPT2	S-geneY
in	O
fibroblasts	O
from	O
MCAD	S-geneY
-	O
deficient	O
individuals	O
.	O

This	O
shows	O
that	O
CPT2	S-geneY-C9-2
and	O
CACT	S-geneY-C9-2
are	O
crucial	O
for	O
mitochondrial	O
acylcarnitine	S-chem-C9-1
formation	O
and	O
export	O
to	O
the	O
extracellular	O
fluids	O
in	O
mFAOD	O
.	O
-	O
Violante	O
,	O
S.	O
,	O
IJlst	O
,	O
L.	O
,	O
te	O
Brinke	O
,	O
H.	O
,	O
Tavares	O
de	O
Almeida	O
,	O
I.	O
,	O
Wanders	O
,	O
R	O
.	O

J	O
.	O

A.	O
,	O
Ventura	O
,	O
F	O
.	O

V.	O
,	O
Houten	O
,	O
S	O
.	O

M	O
.	O

Carnitine	B-geneY-C9-2
palmitoyltransferase	I-geneY-C9-2
2	E-geneY-C9-2
and	O
carnitine	B-geneY-C9-2
/	I-geneY-C9-2
acylcarnitine	I-geneY-C9-2
translocase	E-geneY-C9-2
are	O
involved	O
in	O
the	O
mitochondrial	O
synthesis	O
and	O
export	O
of	O
acylcarnitines	S-chem-C9-1
.	O

Protective	O
effects	O
of	O
selenium	S-chem
on	O
oxidative	O
damage	O
and	O
oxidative	O
stress	O
related	O
gene	O
expression	O
in	O
rat	O
liver	O
under	O
chronic	O
poisoning	O
of	O
arsenic	S-chem
.	O

Arsenic	S-chem
(	O
As	S-chem
)	O
is	O
a	O
toxic	O
metalloid	O
existing	O
widely	O
in	O
the	O
environment	O
,	O
and	O
chronic	O
exposure	O
to	O
it	O
through	O
contaminated	O
drinking	O
water	O
has	O
become	O
a	O
global	O
problem	O
of	O
public	O
health	O
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
protective	O
effects	O
of	O
selenium	S-chem
on	O
oxidative	O
damage	O
of	O
chronic	O
arsenic	S-chem
poisoning	O
in	O
rat	O
liver	O
.	O

Rats	O
were	O
divided	O
into	O
four	O
groups	O
at	O
random	O
and	O
given	O
designed	O
treatments	O
for	O
20weeks	O
.	O

The	O
oxidative	O
damage	O
of	O
liver	O
tissue	O
was	O
evaluated	O
by	O
lipid	O
peroxidation	O
and	O
antioxidant	O
enzymes	O
.	O

Oxidative	O
stress	O
related	O
genes	O
were	O
detected	O
to	O
reflect	O
the	O
liver	O
stress	O
state	O
at	O
the	O
molecular	O
level	O
.	O

Compared	O
to	O
the	O
control	O
and	O
Na2SeO3	S-chem
groups	O
,	O
the	O
MDA	S-chem
content	O
in	O
liver	O
tissue	O
was	O
decreased	O
and	O
the	O
activities	O
of	O
antioxidant	O
enzymes	O
were	O
increased	O
in	O
the	O
Na2SeO3	S-chem
intervention	O
group	O
.	O

The	O
mRNA	O
levels	O
of	O
SOD1	S-geneY-MU-2
,	O
CAT	S-geneY-MU-2
,	O
GPx	S-geneN-MU-2
and	O
Txnrd1	S-geneY-C4-2
were	O
increased	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
combined	O
Na2SeO3	S-chem-MU-1
+	O
NaAsO2	S-chem-C4-1
treatment	O
group	O
.	O

The	O
expressions	O
of	O
HSP70	S-geneN-C3-2
and	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
in	O
the	O
NaAsO2	S-chem-C3-1
group	O
and	O
reduced	O
in	O
the	O
combined	O
treatment	O
group	O
.	O

The	O
results	O
indicate	O
that	O
long	O
-	O
term	O
intake	O
of	O
NaAsO2	S-chem
causes	O
oxidative	O
damage	O
in	O
the	O
rat	O
liver	O
,	O
and	O
Na2SeO3	S-chem
protects	O
liver	O
cells	O
by	O
adjusting	O
the	O
expression	O
of	O
oxidative	O
stress	O
related	O
genes	O
to	O
improve	O
the	O
activities	O
of	O
antioxidant	O
enzymes	O
.	O

Phenotypic	O
analysis	O
of	O
ovine	O
antigen	O
presenting	O
cells	O
loaded	O
with	O
nanoparticles	O
migrating	O
from	O
the	O
site	O
of	O
vaccination	O
.	O

Virus	O
-	O
sized	O
particulate	O
adjuvants	O
such	O
as	O
ISCOMs	O
,	O
polystyrene	S-chem
nanoparticles	O
and	O
virus	O
-	O
like	O
particles	O
have	O
been	O
shown	O
to	O
target	O
dendritic	O
cells	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
T	O
and	O
B	O
cells	O
in	O
vivo	O
.	O

Using	O
an	O
ovine	O
pseudo	O
-	O
afferent	O
lymph	O
cannulation	O
model	O
to	O
capture	O
APC	O
that	O
traffic	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
,	O
we	O
show	O
that	O
40	O
-	O
50nm	O
nanoparticles	O
are	O
taken	O
up	O
at	O
the	O
site	O
of	O
injection	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
migrating	O
to	O
the	O
draining	O
lymph	O
node	O
.	O

These	O
DCs	O
can	O
express	O
CD11c	S-geneY
,	O
CD1b	S-geneY
,	O
CD5	S-geneY
,	O
MHC	B-geneN
class	I-geneN
II	E-geneN
and	O
CD8	S-geneN
.	O

Nanoparticles	O
transported	O
by	O
DCs	O
migrating	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
therefore	O
needs	O
to	O
be	O
considered	O
as	O
a	O
new	O
mechanism	O
underlying	O
the	O
immunogenicity	O
of	O
virus	O
-	O
sized	O
vaccine	O
delivery	O
systems	O
.	O

Modulation	O
of	O
dialysate	O
levels	O
of	O
dopamine	S-chem
,	O
noradrenaline	S-chem
,	O
and	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
in	O
the	O
frontal	O
cortex	O
of	O
freely	O
-	O
moving	O
rats	O
by	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
alone	O
and	O
in	O
association	O
with	O
5	B-chem
-	I-chem
HT	E-chem
reuptake	O
inhibitors	O
:	O
comparative	O
roles	O
of	O
beta	O
-	O
adrenergic	O
,	O
5	B-geneY
-	I-geneY
HT1A	I-geneY
,	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
Pindolol	E-chem
,	O
which	O
possesses	O
significant	O
affinity	O
for	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
,	O
and	O
beta	B-geneN
1	I-geneN
/	I-geneN
2	I-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
(	B-geneN
AR	I-geneN
)	I-geneN
s	E-geneN
,	O
dose	O
-	O
dependently	O
increased	O
extracellular	O
levels	O
of	O
dopamine	S-chem
(	O
DA	S-chem
)	O
and	O
noradrenaline	S-chem
(	O
NAD	S-chem
)	O
versus	O
5	B-chem
-	I-chem
HT	E-chem
,	O
in	O
dialysates	O
of	O
the	O
frontal	O
cortex	O
(	O
FCX	O
)	O
,	O
but	O
not	O
accumbens	O
and	O
striatum	O
,	O
of	O
freely	O
-	O
moving	O
rats	O
.	O

In	O
distinction	O
,	O
the	O
preferential	O
beta	B-geneY-C6-2
1	I-geneY-C6-2
-	I-geneY-C6-2
AR	E-geneY-C6-2
antagonist	O
,	O
betaxolol	S-chem-C6-1
,	O
and	O
the	O
preferential	O
beta	B-geneY-C6-2
2	I-geneY-C6-2
-	I-geneY-C6-2
AR	E-geneY-C6-2
antagonist	O
,	O
ICI118,551	S-chem-C6-1
,	O
did	O
not	O
increase	O
basal	O
levels	O
of	O
DA	S-chem
,	O
NAD	S-chem
,	O
or	O
5	B-chem
-	I-chem
HT	E-chem
.	O

Further	O
,	O
they	O
both	O
dose	O
-	O
dependently	O
and	O
markedly	O
blunted	O
the	O
influence	O
of	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
upon	O
DA	S-chem
and	O
NAD	S-chem
levels	O
.	O

The	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1A	E-geneY-C6-2
receptor	O
antagonist	O
,	O
WAY100,635	S-chem-C6-1
,	O
slightly	O
attenuated	O
the	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
-	O
induced	O
increase	O
in	O
DA	S-chem
and	O
NAD	S-chem
levels	O
,	O
while	O
the	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1B	E-geneY-C6-2
antagonist	O
,	O
SB224,289	S-chem-C6-1
,	O
was	O
ineffective	O
.	O

These	O
data	O
suggest	O
that	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
facilitates	O
frontocortical	O
dopaminergic	O
(	O
and	O
adrenergic	O
)	O
transmission	O
primarily	O
by	O
activation	O
of	O
beta	B-geneN
1	I-geneN
/	I-geneN
2	I-geneN
-	I-geneN
ARs	E-geneN
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
by	O
stimulation	O
of	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
receptors	O
,	O
whereas	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
are	O
not	O
involved	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
Pindolol	E-chem
potentiated	O
the	O
increase	O
in	O
FCX	O
levels	O
of	O
5	B-chem
-	I-chem
HT	E-chem
elicited	O
by	O
the	O
5	B-chem
-	I-chem
HT	E-chem
reuptake	O
inhibitors	O
,	O
fluoxetine	S-chem
and	O
duloxetine	S-chem
,	O
and	O
also	O
enhanced	O
their	O
ability	O
to	O
elevate	O
FCX	O
levels	O
of	O
DA	S-chem
-	O
-	O
though	O
not	O
of	O
NAD	S-chem
.	O

In	O
contrast	O
to	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
,	O
betaxolol	S-chem
and	O
ICI118,551	S-chem
did	O
not	O
affect	O
the	O
actions	O
of	O
fluoxetine	S-chem
,	O
whereas	O
both	O
WAY100,635	S-chem
and	O
SB224,289	S-chem
potentiated	O
the	O
increase	O
in	O
levels	O
of	O
5	B-chem
-	I-chem
HT	E-chem
-	O
-	O
but	O
not	O
DA	S-chem
or	O
NAD	S-chem
levels	O
-	O
-	O
elicited	O
by	O
fluoxetine	S-chem
.	O

In	O
conclusion	O
,	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
modulates	O
,	O
both	O
alone	O
and	O
together	O
with	O
5	B-chem
-	I-chem
HT	E-chem
reuptake	O
inhibitors	O
,	O
dopaminergic	O
,	O
adrenergic	O
,	O
and	O
serotonergic	O
transmission	O
in	O
the	O
FCX	O
via	O
a	O
complex	O
pattern	O
of	O
actions	O
at	O
beta	B-geneN
1	I-geneN
/	I-geneN
2	I-geneN
-	I-geneN
ARs	E-geneN
,	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
,	O
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
clinical	O
studies	O
of	O
the	O
influence	O
of	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
pindolol	E-chem
upon	O
the	O
actions	O
of	O
antidepressant	O
agents	O
.	O

Dose	O
-	O
response	O
effect	O
of	O
tetracyclines	S-chem
on	O
cerebral	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
after	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
hyperstimulation	O
.	O

Brain	O
arteriovenous	O
malformations	O
(	O
BAVMs	O
)	O
are	O
a	O
potentially	O
life	O
-	O
threatening	O
disorder	O
.	O

Matrix	B-geneY
metalloproteinase	I-geneY
(	I-geneY
MMP	I-geneY
)	I-geneY
-	I-geneY
9	E-geneY
activity	O
was	O
greatly	O
increased	O
in	O
BAVM	O
tissue	O
specimens	O
.	O

Doxycycline	S-chem-C4-1
was	O
shown	O
to	O
decrease	O
cerebral	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
activities	O
and	O
angiogenesis	O
induced	O
by	O
vascular	B-geneY-C4-2
endothelial	I-geneY-C4-2
growth	I-geneY-C4-2
factor	E-geneY-C4-2
(	O
VEGF	S-geneY-C4-2
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
dose	O
-	O
response	O
effects	O
of	O
doxycycline	S-chem
and	O
minocycline	S-chem
on	O
cerebral	O
MMP	B-geneY
-	I-geneY
9	E-geneY
using	O
our	O
mouse	O
model	O
with	O
VEGF	S-geneY
focal	O
hyperstimulation	O
delivered	O
with	O
adenoviral	O
vector	O
(	O
AdVEGF	O
)	O
in	O
the	O
brain	O
.	O

Mice	O
were	O
treated	O
with	O
doxycycline	S-chem
or	O
minocycline	S-chem
,	O
respectively	O
,	O
at	O
1	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
/	O
day	O
through	O
drinking	O
water	O
for	O
1	O
week	O
.	O

Our	O
results	O
have	O
shown	O
that	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
expression	O
was	O
inhibited	O
by	O
doxycycline	S-chem-C4-1
starting	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0.02	O
)	O
.	O

Minocycline	S-chem-C4-1
showed	O
more	O
potent	O
inhibition	O
on	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
mRNA	O
expression	O
,	O
starting	O
at	O
1	O
(	O
P	O
<	O
0.005	O
)	O
and	O
further	O
at	O
more	O
than	O
30	O
(	O
P	O
<	O
0.001	O
)	O
mg	O
/	O
kg	O
/	O
day	O
.	O

At	O
the	O
enzymatic	O
activity	O
level	O
,	O
doxycycline	S-chem-C4-1
started	O
to	O
suppress	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
activity	O
at	O
5	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
minocycline	S-chem
had	O
an	O
effect	O
at	O
a	O
lower	O
dose	O
,	O
1	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0.02	O
)	O
.	O

The	O
inhibition	O
of	O
cerebral	O
MMP	B-geneY
-	I-geneY
9	E-geneY
mRNA	O
and	O
activity	O
were	O
highly	O
correlated	O
with	O
drug	O
levels	O
in	O
the	O
brain	O
tissue	O
.	O

We	O
also	O
assessed	O
the	O
potential	O
relevant	O
signaling	O
pathway	O
in	O
vitro	O
to	O
elucidate	O
the	O
mechanisms	O
underlying	O
the	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
inhibition	O
by	O
tetracyclines	S-chem-C4-1
.	O

In	O
vitro	O
,	O
minocycline	S-chem-C4-1
,	O
but	O
not	O
doxycycline	S-chem-C4-1
,	O
inhibits	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
,	O
at	O
least	O
in	O
part	O
,	O
via	O
the	O
extracellular	B-geneN
signaling	I-geneN
-	I-geneN
related	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
)	O
-	O
mediated	O
pathway	O
.	O

This	O
study	O
provided	O
the	O
evidence	O
that	O
the	O
tetracyclines	S-chem-C4-1
inhibit	O
stimulated	O
cerebral	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
9	E-geneY-C4-2
at	O
multiple	O
levels	O
and	O
are	O
effective	O
at	O
very	O
low	O
doses	O
,	O
offering	O
great	O
potential	O
for	O
therapeutic	O
use	O
.	O

In	O
vitro	O
polyphenolics	S-chem
erythrocyte	O
model	O
and	O
in	O
vivo	O
chicken	O
embryo	O
model	O
revealed	O
gallic	B-chem
acid	E-chem
to	O
be	O
a	O
potential	O
hemorrhage	O
inducer	O
:	O
physicochemical	O
action	O
mechanisms	O
.	O

The	O
in	O
vivo	O
chicken	O
embryo	O
model	O
(	O
CEM	O
)	O
demonstrated	O
that	O
gallic	B-chem
acid	E-chem
(	O
GA	O
)	O
induced	O
dysvascularization	O
and	O
hypoxia	O
.	O

Inflammatory	O
edema	O
,	O
Zenker	O
's	O
necrosis	O
,	O
hemolysis	O
,	O
and	O
liposis	O
of	O
cervical	O
muscles	O
were	O
the	O
common	O
symptoms	O
.	O

Levels	O
of	O
the	O
gene	O
hif	B-geneY
-	I-geneY
1α	E-geneY
,	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
,	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
,	O
and	O
NFκB	S-geneN
in	O
cervical	O
muscles	O
were	O
all	O
significantly	O
upregulated	O
,	O
while	O
the	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
was	O
downregulated	O
in	O
a	O
dose	O
-	O
responsive	O
manner	O
.	O

Consequently	O
,	O
the	O
cervical	O
muscle	O
inflammation	O
and	O
hemolysis	O
could	O
have	O
been	O
stimulated	O
en	O
route	O
to	O
the	O
tissue	O
TNF	B-geneY
-	I-geneY
α	E-geneY
-	O
canonical	O
and	O
the	O
atypical	O
pathways	O
.	O

We	O
hypothesized	O
that	O
GA	O
could	O
deplete	O
the	O
dissolved	O
oxygen	S-chem
(	O
DO	O
)	O
at	O
the	O
expense	O
of	O
semiquinone	S-chem
and	O
quinone	S-chem
formation	O
,	O
favoring	O
the	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
production	O
to	O
induce	O
RBC	O
disruption	O
and	O
Fe	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
ion	O
release	O
.	O

To	O
explore	O
this	O
,	O
the	O
in	O
vitro	O
polyphenolics	S-chem
-	O
erythrocyte	O
model	O
(	O
PEM	O
)	O
was	O
established	O
.	O

PEM	O
revealed	O
that	O
the	O
DO	O
was	O
rapidly	O
depleted	O
,	O
leading	O
to	O
the	O
release	O
of	O
a	O
huge	O
amount	O
of	O
Fe	B-chem
(	I-chem
II	I-chem
)	E-chem
ions	O
and	O
hydrogen	B-chem
peroxide	E-chem
(	O
HPO	S-chem
)	O
in	O
a	O
two	O
-	O
phase	O
kinetic	O
pattern	O
.	O

The	O
kinetic	O
coefficients	O
for	O
Fe	B-chem
(	I-chem
II	I-chem
)	E-chem
ion	O
release	O
ranged	O
from	O
0.347	O
h	O
(	O
-	O
1	O
)	O
to	O
0.774	O
h	O
(	O
-	O
1	O
)	O
;	O
and	O
those	O
for	O
Fe	B-chem
(	I-chem
III	I-chem
)	E-chem
ion	O
production	O
were	O
from	O
6.66	O
×	O
10	O
(	O
-	O
3	O
)	O
h	O
(	O
-	O
1	O
)	O
to	O
8.93	O
×	O
10	O
(	O
-	O
3	O
)	O
h	O
(	O
-	O
1	O
)	O
.	O

For	O
phase	O
I	O
HPO	S-chem
production	O
,	O
they	O
ranged	O
from	O
0.236	O
h	O
(	O
-	O
1	O
)	O
to	O
0.774	O
h	O
(	O
-	O
1	O
)	O
and	O
for	O
phase	O
II	O
HPO	S-chem
production	O
from	O
0.764	O
h	O
(	O
-	O
1	O
)	O
to	O
2.560	O
h	O
(	O
-	O
1	O
)	O
at	O
GA	O
within	O
6	O
μM	O
to	O
14	O
μM	O
.	O

Thus	O
,	O
evidence	O
obtained	O
from	O
PEM	O
could	O
strongly	O
support	O
the	O
phenomena	O
of	O
CEM	O
.	O

To	O
conclude	O
,	O
GA	O
tends	O
to	O
elicit	O
hypoxia	O
-	O
related	O
inflammation	O
and	O
hemolysis	O
in	O
chicken	O
cervical	O
muscles	O
through	O
its	O
extremely	O
high	O
prooxidant	O
activity	O
.	O

Cross	O
-	O
talk	O
between	O
constitutive	B-geneY
androstane	I-geneY
receptor	E-geneY
and	O
hypoxia	B-geneN
-	I-geneN
inducible	I-geneN
factor	E-geneN
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Hypoxia	B-geneN
inducible	I-geneN
factor	E-geneN
(	O
HIF	S-geneN
)	O
and	O
5	B-geneN
'	I-geneN
-	I-geneN
AMP	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
are	O
often	O
activated	O
under	O
similar	O
physiological	O
conditions	O
.	O

Constitutive	B-geneY
androstane	I-geneY
receptor	E-geneY
(	O
CAR	S-geneY
)	O
translocates	O
into	O
the	O
nucleus	O
in	O
accordance	O
with	O
5	B-geneN
'	I-geneN
-	I-geneN
AMP	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
and	O
thus	O
confers	O
transactivation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
a	O
possible	O
link	O
between	O
CAR	S-geneY
and	O
HIFα	S-geneY
.	O

Phenobarbital	S-chem-C3-1
(	O
PB	O
)	O
,	O
a	O
typical	O
CAR	S-geneY-C3-2
activator	O
,	O
increased	O
the	O
gene	O
expression	O
of	O
HIF	S-geneN
-	O
target	O
genes	O
in	O
the	O
livers	O
of	O
mice	O
,	O
including	O
erythropoietin	S-geneY-C3-2
,	O
heme	B-geneY-C3-2
oxygenase	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
and	O
vascular	B-geneY-C3-2
endothelial	I-geneY-C3-2
growth	I-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
a	E-geneY-C3-2
.	O

PB	O
induced	O
an	O
accumulation	O
of	O
nuclear	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
and	O
an	O
increase	O
in	O
the	O
HIF	B-geneN
-	I-geneN
responsive	I-geneN
element	E-geneN
-	O
mediated	O
transactivation	O
in	O
HepG2	O
cells	O
.	O

Cobalt	B-chem-C3-1
chloride	E-chem-C3-1
,	O
a	O
typical	O
HIF	S-geneN-C3-2
activator	O
,	O
induced	O
the	O
gene	O
expression	O
of	O
CAR	S-geneY
-	O
target	O
genes	O
,	O
including	O
cyp2b9	S-geneY-C3-2
and	O
cyp2b10	S-geneY-C3-2
,	O
an	O
accumulation	O
of	O
nuclear	O
CAR	S-geneY
and	O
an	O
increase	O
in	O
the	O
PB	B-geneN
-	I-geneN
responsive	I-geneN
enhancer	I-geneN
module	E-geneN
-	O
mediated	O
transactivation	O
in	O
the	O
mouse	O
liver	O
.	O

Immunoprecipitation	O
-	O
immunoblot	O
and	O
chromatin	O
immunoprecipitation	O
analyses	O
suggest	O
that	O
CAR	S-geneY
binds	O
to	O
the	O
PB	B-geneN
-	I-geneN
responsive	I-geneN
enhancer	I-geneN
module	E-geneN
with	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
in	O
the	O
liver	O
of	O
untreated	O
mice	O
and	O
that	O
the	O
complex	O
dissociates	O
upon	O
PB	O
treatment	O
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
CAR	S-geneY
and	O
HIF	B-geneY
-	I-geneY
α	E-geneY
interact	O
and	O
reciprocally	O
modulate	O
the	O
functions	O
of	O
each	O
other	O
.	O

Antioxidant	O
and	O
immunomodulatory	O
activity	O
of	O
selenium	S-chem
exopolysaccharide	O
produced	O
by	O
Lactococcus	O
lactis	O
subsp	O
.	O
lactis	O
.	O

Exopolysaccharide	O
(	O
EPS	O
)	O
was	O
isolated	O
and	O
purified	O
from	O
Lactococcus	O
lactis	O
subsp	O
.	O

Lactis	O
culture	O
broth	O
.	O

Selenium	B-chem
chloride	I-chem
oxide	E-chem
(	O
SeCl	B-chem
(	I-chem
2	I-chem
)	I-chem
O	E-chem
)	O
was	O
added	O
to	O
the	O
EPS	O
to	O
synthesize	O
selenium	S-chem
-	O
exopolysaccharide	O
(	O
Se	S-chem
-	O
EPS	O
)	O
.	O

The	O
in	O
vitro	O
and	O
in	O
vivo	O
antioxidant	O
and	O
in	O
vivo	O
immunomodulatory	O
activity	O
of	O
EPS	O
and	O
Se	S-chem
-	O
EPS	O
were	O
compared	O
.	O

EPS	O
and	O
Se	S-chem
-	O
EPS	O
scavenged	O
superoxide	S-chem
anions	O
and	O
hydroxyl	S-chem
radicals	O
.	O

They	O
also	O
increased	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
,	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
and	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GSH	B-geneN
-	I-geneN
Px	E-geneN
)	O
activity	O
,	O
while	O
decreasing	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
levels	O
in	O
serum	O
and	O
in	O
the	O
livers	O
of	O
mice	O
.	O

Se	S-chem
-	O
EPS	O
showed	O
stronger	O
in	O
vitro	O
and	O
in	O
vivo	O
antioxidant	O
activity	O
than	O
were	O
shown	O
by	O
EPS	O
.	O

The	O
in	O
vivo	O
immunoenhancement	O
activity	O
of	O
EPS	O
and	O
Se	S-chem
-	O
EPS	O
induced	O
by	O
cyclophosphamide	S-chem
(	O
CY	O
)	O
treatment	O
in	O
immunosuppressed	O
mice	O
was	O
researched	O
.	O

EPS	O
and	O
Se	S-chem
-	O
EPS	O
treatments	O
increased	O
macrophage	O
phagocytosis	O
,	O
spleen	O
and	O
thymus	O
indices	O
and	O
haemolytic	O
complement	O
activity	O
(	O
HC	O
(	O
50	O
)	O
)	O
.	O

Se	S-chem
-	O
EPS	O
showed	O
stronger	O
immunomodulatory	O
activity	O
than	O
did	O
EPS	O
.	O

Antithrombin	O
binding	O
of	O
low	O
molecular	O
weight	O
heparins	O
and	O
inhibition	O
of	O
factor	B-geneY
Xa	E-geneY
.	O

Fluorescence	O
and	O
stopped	O
flow	O
methods	O
were	O
used	O
to	O
compare	O
clinically	O
used	O
heparins	O
with	O
regard	O
to	O
their	O
ability	O
to	O
bind	O
to	O
antithrombin	S-geneY
and	O
to	O
accelerate	O
the	O
inactivation	O
of	O
factor	B-geneY
Xa	E-geneY
.	O

Titration	O
of	O
antithrombin	S-geneY
with	O
both	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
(	O
enoxaparin	O
,	O
fragmin	O
and	O
ardeparin	O
)	O
and	O
unfractionated	O
heparin	O
(	O
UFH	O
)	O
produced	O
an	O
equivalent	O
fluorescence	O
increase	O
and	O
indicates	O
similar	O
affinity	O
of	O
all	O
heparin	O
preparations	O
to	O
antithrombin	S-geneY
.	O

However	O
,	O
relative	O
to	O
UFH	O
enoxaparin	O
,	O
the	O
LMWH	O
with	O
the	O
smallest	O
average	O
molecular	O
mass	O
,	O
contained	O
only	O
12	O
%	O
material	O
with	O
high	O
affinity	O
for	O
antithrombin	S-geneY
.	O

The	O
rate	O
of	O
factor	B-geneY
Xa	E-geneY
inhibition	O
by	O
antithrombin	S-geneY
increased	O
with	O
the	O
concentration	O
of	O
the	O
examined	O
heparins	O
to	O
the	O
same	O
limiting	O
value	O
,	O
but	O
the	O
concentration	O
required	O
for	O
maximal	O
acceleration	O
depended	O
on	O
the	O
preparation	O
.	O

According	O
to	O
these	O
data	O
the	O
high	O
affinity	O
fraction	O
of	O
the	O
heparin	O
preparations	O
increased	O
the	O
intrinsic	O
fluorescence	O
and	O
inhibitory	O
activity	O
equally	O
without	O
additional	O
effects	O
by	O
variations	O
in	O
chain	O
length	O
and	O
chemical	O
composition	O
.	O

In	O
contrast	O
,	O
in	O
the	O
presence	O
of	O
Ca	S-chem-C4-1
UFH	O
accelerated	O
the	O
inhibition	O
of	O
factor	B-geneY-C4-2
Xa	E-geneY-C4-2
by	O
antithrombin	S-geneY-C4-2
10	O
-	O
fold	O
more	O
efficiently	O
than	O
comparable	O
concentrations	O
of	O
the	O
high	O
affinity	O
fractions	O
of	O
enoxaparin	O
and	O
fragmin	O
.	O

The	O
bell	O
-	O
shaped	O
dependence	O
of	O
this	O
accelerating	O
effect	O
suggests	O
simultaneous	O
binding	O
of	O
both	O
proteins	O
to	O
heparin	O
.	O

In	O
conclusion	O
,	O
under	O
physiologic	O
conditions	O
the	O
anti	O
-	O
factor	B-geneY
Xa	E-geneY
activity	O
of	O
heparin	O
results	O
from	O
a	O
composite	O
effect	O
of	O
chain	O
length	O
and	O
the	O
content	O
of	O
material	O
with	O
high	O
affinity	O
to	O
antithrombin	S-geneY
.	O

Thus	O
,	O
the	O
reduced	O
antithrombotic	O
activity	O
of	O
LMWH	O
relative	O
to	O
UFH	O
results	O
from	O
a	O
smaller	O
content	O
of	O
high	O
affinity	O
material	O
and	O
the	O
absence	O
of	O
a	O
stimulating	O
effect	O
of	O
calcium	S-chem
.	O

Galanin	S-geneY
attenuates	O
cyclic	B-geneN-C3-2
AMP	I-geneN-C3-2
regulatory	I-geneN-C3-2
element	I-geneN-C3-2
-	I-geneN-C3-2
binding	I-geneN-C3-2
protein	E-geneN-C3-2
(	O
CREB	S-geneN-C3-2
)	O
phosphorylation	O
induced	O
by	O
chronic	O
morphine	S-chem-C3-1
and	O
naloxone	S-chem-C3-1
challenge	O
in	O
Cath.a	O
cells	O
and	O
primary	O
striatal	O
cultures	O
.	O

Repeated	O
morphine	S-chem
administration	O
leads	O
to	O
molecular	O
alterations	O
of	O
the	O
neural	O
circuitry	O
in	O
the	O
locus	O
coeruleus	O
and	O
nucleus	O
accumbens	O
.	O

These	O
changes	O
include	O
increased	O
activity	O
of	O
several	O
components	O
of	O
the	O
cAMP	S-chem
signaling	O
pathway	O
that	O
are	O
thought	O
to	O
be	O
associated	O
with	O
psychological	O
and	O
somatic	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

The	O
neuropeptide	O
galanin	S-geneY
has	O
been	O
shown	O
to	O
attenuate	O
cAMP	S-chem
signaling	O
in	O
multiple	O
cell	O
types	O
.	O

The	O
current	O
study	O
demonstrates	O
that	O
acute	O
galanin	S-geneY
treatment	O
blocks	O
the	O
consequences	O
of	O
increased	O
cAMP	S-chem
signaling	O
following	O
chronic	O
opiate	O
administration	O
and	O
withdrawal	O
in	O
Cath.a	O
cells	O
and	O
primary	O
cultures	O
of	O
striatal	O
neurons	O
as	O
measured	O
by	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
cAMP	B-geneN
regulatory	I-geneN
element	I-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
(	O
CREB	S-geneN
)	O
.	O

In	O
addition	O
,	O
galanin	S-geneY
-	O
mediated	O
attenuation	O
of	O
CREB	S-geneN
phosphorylation	O
is	O
independent	O
of	O
galanin	S-geneY
-	O
induced	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
(	I-geneN
ERK	I-geneN
)	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
in	O
Cath.a	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
galanin	B-geneN
receptors	E-geneN
may	O
serve	O
as	O
an	O
additional	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
opiate	O
withdrawal	O
.	O

Liver	O
glycogen	O
loading	O
dampens	O
glycogen	O
synthesis	O
seen	O
in	O
response	O
to	O
either	O
hyperinsulinemia	O
or	O
intraportal	O
glucose	S-chem
infusion	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
liver	O
glycogen	O
loading	O
on	O
net	O
hepatic	O
glycogen	O
synthesis	O
during	O
hyperinsulinemia	O
or	O
hepatic	O
portal	O
vein	O
glucose	S-chem
infusion	O
in	O
vivo	O
.	O

Liver	O
glycogen	O
levels	O
were	O
supercompensated	O
(	O
SCGly	O
)	O
in	O
two	O
groups	O
(	O
using	O
intraportal	O
fructose	S-chem
infusion	O
)	O
but	O
not	O
in	O
two	O
others	O
(	O
Gly	O
)	O
during	O
hyperglycemic	O
-	O
normoinsulinemia	O
.	O

Following	O
a	O
2	O
-	O
h	O
control	O
period	O
during	O
which	O
fructose	S-chem
infusion	O
was	O
stopped	O
,	O
there	O
was	O
a	O
2	O
-	O
h	O
experimental	O
period	O
in	O
which	O
the	O
response	O
to	O
hyperglycemia	O
plus	O
either	O
4×	O
basal	O
insulin	S-geneY
(	O
INS	S-geneY
)	O
or	O
portal	O
vein	O
glucose	S-chem
infusion	O
(	O
PoG	O
)	O
was	O
measured	O
.	O

Increased	O
hepatic	O
glycogen	O
reduced	O
the	O
percent	O
of	O
glucose	S-chem
taken	O
up	O
by	O
the	O
liver	O
that	O
was	O
deposited	O
in	O
glycogen	O
(	O
74	O
±	O
3	O
vs	O
.	O

53	O
±	O
5	O
%	O
in	O
Gly	O
+	O
INS	S-geneY
and	O
SCGly	O
+	O
INS	S-geneY
,	O
respectively	O
,	O
and	O
72	O
±	O
3	O
vs	O
.	O

50	O
±	O
6	O
%	O
in	O
Gly	O
+	O
PoG	O
and	O
SCGly	O
+	O
PoG	O
,	O
respectively	O
)	O
.	O

The	O
reduction	O
in	O
liver	O
glycogen	O
synthesis	O
in	O
SCGly	O
+	O
INS	S-geneY
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
insulin	S-geneY
signaling	O
and	O
an	O
increase	O
in	O
AMPK	S-geneN
activation	O
,	O
whereas	O
only	O
the	O
latter	O
was	O
observed	O
in	O
SCGly	O
+	O
PoG	O
.	O

These	O
data	O
indicate	O
that	O
liver	O
glycogen	O
loading	O
impairs	O
glycogen	O
synthesis	O
regardless	O
of	O
the	O
signal	O
used	O
to	O
stimulate	O
it	O
.	O

Introduction	O
:	O
The	O
pharmacological	O
profile	O
of	O
eprosartan	S-chem
-	O
-	O
implications	O
for	O
cerebrovascular	O
and	O
cardiovascular	O
risk	O
reduction	O
.	O

Moderate	O
elevations	O
in	O
blood	O
pressure	O
translate	O
to	O
significant	O
increases	O
in	O
cardiovascular	O
and	O
cerebro	O
vascular	O
risk	O
.	O

Beneficially	O
,	O
this	O
relationship	O
allows	O
small	O
decreases	O
in	O
blood	O
pressure	O
to	O
be	O
associated	O
with	O
risk	O
reduction	O
.	O

Both	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
system	O
and	O
the	O
sympathetic	O
nervous	O
system	O
are	O
involved	O
in	O
hypertension	O
,	O
hence	O
targeting	O
these	O
systems	O
is	O
likely	O
to	O
be	O
of	O
benefit	O
in	O
the	O
treatment	O
of	O
hypertension	O
.	O

Angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
blockers	O
(	O
ARBs	O
)	O
are	O
used	O
for	O
controlling	O
blood	O
pressure	O
and	O
treating	O
heart	O
failure	O
in	O
a	O
broad	O
range	O
of	O
patients	O
,	O
including	O
those	O
with	O
diabetes	O
and	O
the	O
elderly	O
.	O

Not	O
only	O
have	O
ARBs	O
shown	O
good	O
efficacy	O
and	O
tolerability	O
,	O
they	O
also	O
appear	O
to	O
have	O
a	O
protective	O
effect	O
that	O
goes	O
beyond	O
that	O
expected	O
from	O
the	O
reduction	O
of	O
blood	O
pressure	O
.	O

The	O
ARB	O
eprosartan	S-chem-C6-1
is	O
a	O
nonbiphenyl	O
nontetrazole	O
angiotensin	B-geneY-C6-2
II	I-geneY-C6-2
type	I-geneY-C6-2
1	I-geneY-C6-2
receptor	E-geneY-C6-2
(	O
AT1	S-geneY-C6-2
)	O
antagonist	O
,	O
which	O
acts	O
to	O
decrease	O
total	O
peripheral	O
resistance	O
.	O

Eprosartan	S-chem
acts	O
at	O
vascular	O
AT1	B-geneY
receptors	E-geneY
(	O
postsynaptically	O
)	O
and	O
at	O
presynaptic	O
AT1	B-geneY
receptors	E-geneY
,	O
where	O
it	O
inhibits	O
noradrenaline	S-chem
release	O
.	O

In	O
clinical	O
studies	O
,	O
eprosartan	S-chem
has	O
been	O
shown	O
to	O
significantly	O
reduce	O
cardiovascular	O
and	O
cerebrovascular	O
events	O
,	O
whilst	O
avoiding	O
the	O
persistent	O
cough	O
that	O
commonly	O
occurs	O
with	O
the	O
use	O
of	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitors	O
.	O

Eprosartan	S-chem
can	O
also	O
be	O
differentiated	O
from	O
other	O
ARBs	O
due	O
to	O
its	O
noradrenergic	O
effects	O
,	O
which	O
other	O
ARBs	O
used	O
at	O
therapeutic	O
doses	O
do	O
not	O
possess	O
.	O

Eprosartan	S-chem
,	O
therefore	O
,	O
represents	O
a	O
useful	O
therapeutic	O
option	O
in	O
the	O
management	O
of	O
patients	O
with	O
hypertension	O
,	O
including	O
those	O
with	O
a	O
history	O
of	O
stroke	O
or	O
with	O
co	O
-	O
morbid	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Antidepressant	O
use	O
and	O
glycemic	O
control	O
.	O

RATIONALE	O
:	O
Past	O
research	O
on	O
the	O
association	O
of	O
antidepressant	O
medication	O
use	O
with	O
glycemic	O
control	O
abnormalities	O
has	O
produced	O
mixed	O
results	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
association	O
of	O
antidepressant	O
use	O
with	O
glycemic	O
control	O
abnormalities	O
and	O
screen	O
-	O
positive	O
diabetes	O
in	O
a	O
representative	O
population	O
sample	O
of	O
US	O
adults	O
without	O
a	O
diagnosis	O
of	O
diabetes	O
.	O

METHODS	O
:	O
Using	O
data	O
from	O
adult	O
participants	O
of	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
,	O
2005	O
-	O
2010	O
)	O
,	O
the	O
association	O
of	O
antidepressant	O
use	O
with	O
continuous	O
measures	O
of	O
HbA1c	S-geneY
,	O
fasting	O
blood	O
sugar	S-chem
,	O
2	O
-	O
h	O
oral	O
glucose	S-chem
tolerance	O
test	O
,	O
insulin	S-geneY
sensitivity	O
and	O
screen	O
-	O
positive	O
diabetes	O
according	O
to	O
HbA1c	S-geneY
,	O
fasting	O
blood	O
sugar	O
and	O
2	O
-	O
h	O
oral	O
glucose	S-chem
tolerance	O
test	O
were	O
assessed	O
.	O

RESULTS	O
:	O
Antidepressant	O
use	O
was	O
not	O
associated	O
with	O
increased	O
levels	O
of	O
HbA1c	S-geneY
,	O
fasting	O
blood	O
sugar	S-chem
,	O
2	O
-	O
h	O
oral	O
glucose	S-chem
tolerance	O
test	O
,	O
reduced	O
insulin	S-geneY
sensitivity	O
or	O
increased	O
prevalence	O
of	O
screen	O
-	O
positive	O
diabetes	O
.	O

Results	O
were	O
mostly	O
consistent	O
across	O
sociodemographic	O
groups	O
and	O
across	O
different	O
lengths	O
of	O
exposure	O
,	O
different	O
classes	O
of	O
antidepressants	O
and	O
levels	O
of	O
body	O
mass	O
index	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
representative	O
population	O
sample	O
,	O
antidepressant	O
use	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
abnormalities	O
in	O
glycemic	O
control	O
or	O
undetected	O
diabetes	O
.	O

Positive	O
findings	O
from	O
past	O
research	O
may	O
be	O
attributable	O
to	O
detection	O
bias	O
,	O
in	O
that	O
individuals	O
prescribed	O
antidepressants	O
may	O
be	O
more	O
likely	O
to	O
be	O
tested	O
and	O
diagnosed	O
with	O
diabetes	O
.	O

The	O
effects	O
of	O
norepinephrine	B-geneY
transporter	E-geneY
inactivation	O
on	O
locomotor	O
activity	O
in	O
mice	O
.	O

BACKGROUND	O
:	O
Acute	O
administration	O
of	O
different	O
classes	O
of	O
antidepressants	O
can	O
enhance	O
or	O
reduce	O
spontaneous	O
locomotor	O
activity	O
in	O
a	O
novel	O
environment	O
,	O
but	O
the	O
effects	O
of	O
chronic	O
antidepressant	O
treatment	O
on	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
and	O
familiar	O
environments	O
are	O
less	O
well	O
characterized	O
.	O

Because	O
norepinephrine	S-chem
is	O
an	O
important	O
regulator	O
of	O
spontaneous	O
locomotor	O
activity	O
,	O
we	O
speculated	O
that	O
norepinephrine	B-geneY
transporter	E-geneY
blockade	O
contributes	O
to	O
the	O
effects	O
of	O
some	O
antidepressants	O
on	O
spontaneous	O
locomotor	O
activity	O
.	O

METHODS	O
:	O
Antidepressant	O
drugs	O
(	O
reboxetine	S-chem
,	O
desipramine	S-chem
,	O
imipramine	S-chem
,	O
venlafaxine	S-chem
,	O
bupropion	S-chem
)	O
were	O
administered	O
acutely	O
(	O
intraperitoneal	O
)	O
or	O
chronically	O
(	O
via	O
osmotic	O
minipump	O
)	O
to	O
control	O
and	O
norepinephrine	B-geneY
transporter	E-geneY
knockout	O
mice	O
,	O
and	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
or	O
familiar	O
environments	O
was	O
recorded	O
.	O

RESULTS	O
:	O
Acute	O
treatment	O
with	O
most	O
norepinephrine	B-geneY
transporter	E-geneY
-	O
blocking	O
antidepressants	O
decreased	O
spontaneous	O
locomotor	O
activity	O
in	O
a	O
novel	O
environment	O
,	O
whereas	O
chronic	O
treatment	O
decreased	O
spontaneous	O
locomotor	O
activity	O
in	O
both	O
novel	O
and	O
familiar	O
environments	O
.	O

The	O
exception	O
was	O
bupropion	S-chem-C4-1
,	O
a	O
dual	O
norepinephrine	B-geneY-C4-2
transporter	E-geneY-C4-2
/	O
dopamine	B-geneY-C4-2
transporter	E-geneY-C4-2
blocker	O
,	O
which	O
tended	O
to	O
increase	O
spontaneous	O
locomotor	O
activity	O
.	O

Coadministration	O
of	O
reboxetine	S-chem
and	O
the	O
dopamine	B-geneY-C4-2
transporter	E-geneY-C4-2
blocker	O
GBR	B-chem-C4-1
12909	E-chem-C4-1
also	O
increased	O
spontaneous	O
locomotor	O
activity	O
.	O

Norepinephrine	B-geneY
transporter	E-geneY
knockout	O
mice	O
had	O
low	O
basal	O
spontaneous	O
locomotor	O
activity	O
,	O
which	O
was	O
increased	O
by	O
bupropion	S-chem
,	O
whereas	O
reboxetine	S-chem
had	O
no	O
effect	O
in	O
norepinephrine	B-geneY
transporter	E-geneY
knockout	O
mice	O
.	O

CONCLUSIONS	O
:	O
Acute	O
or	O
chronic	O
inactivation	O
of	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
decreases	O
spontaneous	O
locomotor	O
activity	O
in	O
novel	O
and	O
familiar	O
environments	O
unless	O
coupled	O
with	O
dopamine	B-geneY
transporter	E-geneY
blockade	O
.	O

Binding	O
site	O
of	O
amiloride	S-chem
to	O
urokinase	B-geneY
plasminogen	I-geneY
activator	E-geneY
depends	O
on	O
species	O
.	O

A	O
novel	O
drug	O
candidate	O
is	O
checked	O
on	O
its	O
potency	O
on	O
animal	O
models	O
before	O
it	O
can	O
advance	O
to	O
human	O
phase	O
of	O
the	O
research	O
.	O

Usually	O
negative	O
results	O
on	O
animal	O
phase	O
disqualify	O
it	O
.	O

Targeting	O
specific	O
enzymes	O
by	O
small	O
chemicals	O
raises	O
the	O
question	O
about	O
the	O
appropriateness	O
of	O
this	O
approach	O
.	O

As	O
an	O
example	O
,	O
the	O
urokinase	S-geneY
(	O
uPA	S-geneY
)	O
is	O
recognized	O
as	O
an	O
important	O
enzyme	O
responsible	O
for	O
cancer	O
metastasis	O
and	O
angiogenesis	O
.	O

It	O
is	O
therefore	O
important	O
to	O
ask	O
the	O
question	O
if	O
a	O
small	O
chemical	O
will	O
inhibit	O
uPA	S-geneN
of	O
different	O
species	O
with	O
the	O
same	O
or	O
different	O
potency	O
.	O

Using	O
DNA	O
sequence	O
and	O
known	O
structure	O
of	O
uPA	S-geneN
we	O
have	O
modeled	O
3D	O
structures	O
of	O
uPAs	S-geneN
for	O
several	O
different	O
species	O
.	O

By	O
theoretical	O
calculations	O
we	O
have	O
determined	O
most	O
probable	O
structure	O
of	O
amiloride	S-chem
/	O
uPAs	S-geneN
complexes	O
.	O

Catalytic	O
triad	O
(	O
B57	O
,	O
B102	O
,	O
B195	O
)	O
and	O
specificity	O
pocket	O
(	O
B187	O
-	O
B197	O
,	O
B212	O
-	O
B229	O
)	O
are	O
highly	O
conserved	O
in	O
all	O
cases	O
,	O
and	O
are	O
the	O
regions	O
responsible	O
for	O
proteolytic	O
activity	O
and	O
recognition	O
of	O
the	O
substrate	O
.	O

Significant	O
differences	O
were	O
observed	O
in	O
a	O
different	O
region	O
(	O
loop	O
B93	O
-	O
B101	O
)	O
,	O
that	O
we	O
identified	O
as	O
binding	O
site	O
of	O
amiloride	S-chem
to	O
the	O
tissue	B-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
tPA	S-geneY
)	O
.	O

Although	O
tPA	S-geneY
shares	O
the	O
same	O
function	O
of	O
activating	O
plasminogen	O
and	O
it	O
is	O
structurally	O
similar	O
to	O
uPA	S-geneY
.	O

Amiloride	S-chem-C4-1
is	O
a	O
specific	O
inhibitor	O
of	O
uPA	S-geneN-C4-2
but	O
does	O
not	O
inhibit	O
tPA	S-geneY
.	O

Our	O
study	O
shows	O
that	O
predicted	O
position	O
of	O
amiloride	S-chem
depends	O
on	O
species	O
and	O
in	O
some	O
cases	O
was	O
located	O
,	O
as	O
expected	O
,	O
in	O
the	O
specificity	O
pocket	O
,	O
but	O
in	O
the	O
other	O
cases	O
close	O
to	O
the	O
loop	O
B93	O
-	O
B101	O
.	O

This	O
location	O
could	O
weaken	O
affinity	O
of	O
binding	O
or	O
prevent	O
inhibition	O
of	O
uPA	S-geneY
.	O

Therefore	O
,	O
drug	O
screening	O
and	O
elimination	O
process	O
based	O
solely	O
on	O
animal	O
study	O
,	O
without	O
careful	O
structural	O
analysis	O
,	O
could	O
lead	O
to	O
the	O
elimination	O
of	O
potential	O
drugs	O
for	O
humans	O
.	O

Flavopiridol	S-chem
Hoechst	O
AG	O
.	O

Hoechst	O
is	O
developing	O
flavopiridol	S-chem
,	O
a	O
synthetic	O
flavonoid	S-chem
based	O
on	O
an	O
extract	O
from	O
an	O
Indian	O
plant	O
,	O
for	O
the	O
potential	O
treatment	O
of	O
cancer	O
.	O

Flavopiridol	S-chem-C4-1
,	O
a	O
cyclin	B-geneN-C4-2
-	I-geneN-C4-2
dependent	I-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
,	O
arrests	O
cell	O
division	O
and	O
causes	O
apoptosis	O
in	O
non	O
-	O
small	O
lung	O
cancer	O
cells	O
[	O
283660	O
]	O
.	O

A	O
phase	O
II	O
trial	O
,	O
in	O
collaboration	O
with	O
the	O
National	O
Cancer	O
Institute	O
,	O
has	O
commenced	O
at	O
the	O
University	O
of	O
Chicago	O
Medical	O
Center	O
,	O
which	O
involves	O
patients	O
with	O
high	O
or	O
intermediate	O
-	O
grade	O
lymphoma	O
or	O
multiple	O
myeloma	O
[	O
272937	O
]	O
,	O
[	O
277372	O
]	O
.	O

In	O
ex	O
vivo	O
experiments	O
with	O
tumor	O
cells	O
from	O
refractory	O
chronic	O
lymphoblastic	O
leukemia	O
,	O
dose	O
-	O
dependent	O
CDK2	S-geneY-C4-2
inhibition	O
associated	O
with	O
apoptotic	O
changes	O
was	O
seen	O
at	O
concentrations	O
greater	O
than	O
100	O
nM	O
of	O
flavopiridol	S-chem-C4-1
.	O

In	O
vitro	O
pharmacokinetic	O
studies	O
have	O
shown	O
that	O
flavopiridol	S-chem
undergoes	O
hepatic	O
biotransformation	O
to	O
its	O
corresponding	O
glucoronide	S-chem
by	O
uridine	B-chem
diphosphate	E-chem
glucoronosyltransferases	O
[	O
283791	O
]	O
.	O

Flavopiridol	S-chem-C4-1
inhibits	O
CDK	S-geneN-C4-2
with	O
an	O
IC50	O
value	O
of	O
0.4	O
mM	O
[	O
285707	O
]	O
.	O

Preclinical	O
toxicology	O
studies	O
in	O
rats	O
and	O
dogs	O
demonstrated	O
dose	O
-	O
related	O
leukopenia	O
and	O
drug	O
-	O
related	O
lesions	O
in	O
the	O
thymus	O
,	O
spleen	O
and	O
bone	O
marrow	O
.	O

The	O
gastrointestinal	O
and	O
bone	O
marrow	O
toxicity	O
was	O
dose	O
-	O
limiting	O
[	O
178579	O
]	O
.	O

Hoechst	O
Marion	O
Roussel	O
expects	O
to	O
launch	O
flavopiridol	S-chem
in	O
the	O
year	O
2001	O
,	O
with	O
potential	O
sales	O
in	O
excess	O
of	O
DM	O
750	O
million	O
[	O
288651	O
]	O
.	O

Altered	O
vasoreactivity	O
to	O
angiotensin	B-geneY
II	E-geneY
in	O
experimental	O
diabetic	O
neuropathy	O
:	O
role	O
of	O
nitric	B-chem
oxide	E-chem
.	O

We	O
evaluated	O
the	O
effects	O
of	O
angiotensin	B-geneY-C4-2
II	E-geneY-C4-2
and	O
an	O
angiotensin	B-geneY-C4-2
-	I-geneY-C4-2
converting	I-geneY-C4-2
enzyme	E-geneY-C4-2
inhibitor	O
(	O
cilazapril	S-chem-C4-1
)	O
on	O
nerve	O
blood	O
flow	O
(	O
NBF	O
)	O
and	O
electrophysiology	O
in	O
control	O
and	O
diabetic	O
rats	O
.	O

When	O
applied	O
locally	O
to	O
the	O
sciatic	O
nerve	O
,	O
the	O
dose	O
-	O
response	O
curve	O
of	O
angiotensin	B-geneY
II	E-geneY
was	O
more	O
potent	O
in	O
experimental	O
diabetic	O
neuropathy	O
(	O
EDN	O
)	O
than	O
control	O
rats	O
.	O

No	O
difference	O
existed	O
in	O
plasma	O
angiotensin	B-geneY
II	E-geneY
levels	O
between	O
EDN	O
and	O
controls	O
.	O

The	O
rats	O
were	O
given	O
typical	O
rat	O
pellets	O
or	O
pellets	O
treated	O
with	O
10	O
mg	O
/	O
kg	O
per	O
day	O
cilazapril	S-chem
for	O
4	O
weeks	O
.	O

Diabetes	O
caused	O
a	O
significant	O
reduction	O
in	O
NBF	O
,	O
nerve	O
conduction	O
velocity	O
,	O
and	O
compound	O
muscle	O
action	O
potential	O
(	O
CMAP	O
)	O
amplitudes	O
.	O

NBF	O
was	O
significantly	O
increased	O
in	O
diabetic	O
rats	O
supplemented	O
with	O
cilazapril	S-chem
diet	O
,	O
and	O
nerve	O
conduction	O
velocity	O
and	O
amplitudes	O
of	O
the	O
CMAP	O
were	O
also	O
improved	O
after	O
4	O
weeks	O
on	O
this	O
diet	O
.	O

Direct	O
application	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
cilazapril	S-chem
on	O
sciatic	O
nerve	O
did	O
not	O
increase	O
NBF	O
in	O
normal	O
and	O
EDN	O
rats	O
.	O

We	O
topically	O
applied	O
the	O
nitric	B-geneN-C4-2
oxide	I-geneN-C4-2
synthase	E-geneN-C4-2
(	O
NOS	S-geneN-C4-2
)	O
inhibitor	O
,	O
NG	B-chem-C4-1
-	I-chem-C4-1
nitro	I-chem-C4-1
-	I-chem-C4-1
L	I-chem-C4-1
-	I-chem-C4-1
arginine	E-chem-C4-1
,	O
on	O
sciatic	O
nerve	O
and	O
observed	O
reduced	O
inhibition	O
of	O
NBF	O
in	O
EDN	O
,	O
which	O
was	O
correctable	O
with	O
a	O
cilazapril	S-chem
diet	O
.	O

These	O
results	O
suggest	O
that	O
diabetic	O
neuropathy	O
may	O
have	O
an	O
increasing	O
vasopressor	O
action	O
with	O
angiotensin	B-geneY
II	E-geneY
and	O
this	O
is	O
likely	O
to	O
be	O
the	O
mechanism	O
of	O
NOS	S-geneN
inhibition	O
.	O

Angiotensin	B-geneY
II	I-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitors	O
may	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O

The	O
CYP2B6	B-geneY-C9-2
*	I-geneY-C9-2
6	E-geneY-C9-2
Allele	O
Significantly	O
Alters	O
the	O
N	O
-	O
demethylation	O
of	O
Ketamine	S-chem-C9-1
Enantiomers	O
In	O
Vitro	O
.	O

Ketamine	S-chem-C9-1
is	O
primarily	O
metabolized	O
to	O
norketamine	S-chem
by	O
hepatic	O
cytochrome	B-geneY-C9-2
P450	I-geneY-C9-2
(	I-geneY-C9-2
CYP	I-geneY-C9-2
)	I-geneY-C9-2
2B6	E-geneY-C9-2
and	O
CYP3A4	S-geneY-C9-2
-	O
mediated	O
N	O
-	O
demethylation	O
.	O

However	O
,	O
the	O
relative	O
contribution	O
from	O
each	O
enzyme	O
remains	O
controversial	O
.	O

The	O
CYP2B6	B-geneY-C9-2
*	I-geneY-C9-2
6	E-geneY-C9-2
allele	O
is	O
associated	O
with	O
reduced	O
enzyme	O
expression	O
and	O
activity	O
that	O
may	O
lead	O
to	O
interindividual	O
variability	O
in	O
ketamine	S-chem-C9-1
metabolism	O
.	O

We	O
examined	O
the	O
N	O
-	O
demethylation	O
of	O
individual	O
ketamine	S-chem-C9-1
enantiomers	O
using	O
human	O
liver	O
microsomes	O
(	O
HLMs	O
)	O
genotyped	O
for	O
the	O
CYP2B6	B-geneY-C9-2
*	I-geneY-C9-2
6	E-geneY-C9-2
allele	O
,	O
insect	O
cell	O
expressed	O
recombinant	O
CYP2B6	S-geneY
and	O
CYP3A4	S-geneY
enzymes	O
and	O
COS	O
-	O
1	O
cell	O
expressed	O
recombinant	O
CYP2B6.1	S-geneY
and	O
CYP2B6.6	S-geneY
protein	O
variant	O
.	O

Effects	O
of	O
CYP	S-geneN
-	O
selective	O
inhibitors	O
on	O
norketamine	S-chem
formation	O
were	O
also	O
determined	O
in	O
HLMs	O
.	O

The	O
two	O
-	O
enzyme	O
Michaelis	O
-	O
Menten	O
model	O
best	O
fitted	O
the	O
HLM	O
kinetic	O
data	O
.	O

The	O
Km	O
value	O
for	O
the	O
high	O
affinity	O
enzyme	O
and	O
the	O
low	O
affinity	O
enzyme	O
were	O
similar	O
to	O
those	O
for	O
the	O
expressed	O
CYP2B6	S-geneY
and	O
CYP3A4	S-geneY
,	O
respectively	O
.	O

The	O
intrinsic	O
clearance	O
for	O
both	O
ketamine	S-chem-C9-1
enantiomers	O
by	O
the	O
high	O
affinity	O
enzyme	O
in	O
HLMs	O
with	O
CYP2B6	B-geneY-C9-2
*	I-geneY-C9-2
1	E-geneY-C9-2
/	O
*	O
1	O
genotype	O
were	O
at	O
least	O
2	O
-	O
fold	O
and	O
6	O
-	O
fold	O
higher	O
,	O
respectively	O
,	O
than	O
those	O
for	O
CYP2B6	B-geneY
*	I-geneY
1	E-geneY
/	O
*	O
6	O
genotype	O
and	O
CYP2B6	B-geneY
*	I-geneY
6	E-geneY
/	O
*	O
6	O
genotype	O
.	O

The	O
Vmax	O
and	O
Km	O
values	O
for	O
CYP2B6.1	S-geneY
were	O
approximately	O
160	O
%	O
and	O
70	O
%	O
of	O
those	O
for	O
CYP2B6.6	S-geneY
,	O
respectively	O
.	O

ThioTEPA	S-chem-C4-1
(	O
CYP2B6	S-geneY-C4-2
inhibitor	O
,	O
25	O
μM	O
)	O
and	O
the	O
monoclonal	O
antibody	O
against	O
CYP2B6	S-geneY
but	O
not	O
troleandomycin	S-chem-C4-1
(	O
CYP3A4	S-geneY-C4-2
inhibitor	O
,	O
25	O
μM	O
)	O
or	O
the	O
monoclonal	O
antibody	O
against	O
CYP3A4	S-geneY
inhibited	O
ketamine	S-chem
N	O
-	O
demethylation	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

The	O
degree	O
of	O
inhibition	O
was	O
significantly	O
reduced	O
in	O
HLMs	O
with	O
the	O
CYP2B6	B-geneY
*	I-geneY
6	E-geneY
allele	O
(	O
gene	O
-	O
dose	O
P	O
<	O
0.05	O
)	O
.	O

These	O
results	O
indicate	O
a	O
major	O
role	O
of	O
CYP2B6	S-geneY-C9-2
in	O
ketamine	S-chem-C9-1
N	O
-	O
demethylation	O
in	O
vitro	O
and	O
a	O
significant	O
impact	O
of	O
the	O
CYP2B6	B-geneY-C9-2
*	I-geneY-C9-2
6	E-geneY-C9-2
allele	O
on	O
enzyme	O
-	O
ketamine	S-chem-C9-1
binding	O
and	O
catalytic	O
activity	O
.	O

A	O
brief	O
history	O
of	O
oxytocin	S-geneY
and	O
its	O
role	O
in	O
modulating	O
psychostimulant	O
effects	O
.	O

Over	O
the	O
past	O
century	O
,	O
the	O
polypeptide	O
oxytocin	S-geneY
has	O
played	O
an	O
important	O
role	O
in	O
medicine	O
with	O
major	O
highlights	O
including	O
the	O
identification	O
of	O
its	O
involvement	O
in	O
parturition	O
and	O
the	O
milk	O
let	O
-	O
down	O
reflex	O
.	O

Oxytocin	S-geneY
is	O
now	O
implicated	O
in	O
an	O
extensive	O
range	O
of	O
psychological	O
phenomena	O
including	O
reward	O
and	O
memory	O
processes	O
and	O
has	O
been	O
investigated	O
as	O
a	O
treatment	O
for	O
several	O
psychiatric	O
disorders	O
including	O
addiction	O
,	O
anxiety	O
,	O
autism	O
,	O
and	O
schizophrenia	O
.	O

In	O
this	O
review	O
,	O
we	O
first	O
provide	O
an	O
historical	O
overview	O
of	O
oxytocin	S-geneY
and	O
describe	O
key	O
aspects	O
of	O
its	O
physiological	O
activity	O
.	O

We	O
then	O
outline	O
some	O
pharmacological	O
limitations	O
in	O
this	O
field	O
of	O
research	O
before	O
highlighting	O
the	O
role	O
of	O
oxytocin	S-geneY
in	O
a	O
wide	O
range	O
of	O
behavioral	O
and	O
neuronal	O
processes	O
.	O

Finally	O
,	O
we	O
review	O
evidence	O
for	O
a	O
modulatory	O
role	O
of	O
oxytocin	S-geneY
with	O
regard	O
to	O
psychostimulant	O
effects	O
.	O

Key	O
findings	O
suggest	O
that	O
oxytocin	S-geneY
attenuates	O
a	O
broad	O
number	O
of	O
cocaine	S-chem
and	O
methamphetamine	S-chem
induced	O
behaviors	O
and	O
associated	O
neuronal	O
activity	O
in	O
rodents	O
.	O

Evidence	O
also	O
outlines	O
a	O
role	O
for	O
oxytocin	S-geneN
in	O
the	O
prosocial	O
effects	O
of	O
3,4	B-chem
-	I-chem
methylenedioxymethamphetamine	E-chem
(	O
MDMA	S-chem
,	O
Ecstasy	S-chem
)	O
in	O
both	O
rodents	O
and	O
humans	O
.	O

Clinical	O
trials	O
should	O
now	O
investigate	O
the	O
effectiveness	O
of	O
oxytocin	S-geneY
as	O
a	O
novel	O
intervention	O
for	O
psychostimulant	O
addiction	O
and	O
should	O
aim	O
to	O
determine	O
its	O
specific	O
role	O
in	O
the	O
therapeutic	O
properties	O
of	O
MDMA	S-chem
that	O
are	O
currently	O
being	O
investigated	O
.	O

Ras	B-geneY
-	I-geneY
dva	E-geneY
is	O
a	O
novel	O
Pit	B-geneY
-	I-geneY
1	E-geneY
-	O
and	O
glucocorticoid	O
-	O
regulated	O
gene	O
in	O
the	O
embryonic	O
anterior	O
pituitary	O
gland	O
.	O

Glucocorticoids	O
play	O
a	O
role	O
in	O
functional	O
differentiation	O
of	O
pituitary	O
somatotrophs	O
and	O
lactotrophs	O
during	O
embryogenesis	O
.	O

Ras	B-geneY
-	I-geneY
dva	E-geneY
was	O
identified	O
as	O
a	O
gene	O
regulated	O
by	O
anterior	B-geneY
neural	I-geneY
fold	I-geneY
protein	I-geneY
-	I-geneY
1	I-geneY
/	I-geneY
homeobox	E-geneY
expressed	O
in	O
embryonic	O
stem	O
cells	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
known	O
to	O
be	O
critical	O
in	O
pituitary	O
development	O
,	O
and	O
has	O
an	O
expression	O
profile	O
in	O
the	O
chicken	O
embryonic	O
pituitary	O
gland	O
that	O
is	O
consistent	O
with	O
in	O
vivo	O
regulation	O
by	O
glucocorticoids	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
characterize	O
expression	O
and	O
regulation	O
of	O
ras	B-geneY
-	I-geneY
dva	E-geneY
mRNA	O
in	O
the	O
developing	O
chicken	O
anterior	O
pituitary	O
.	O

Pituitary	O
ras	B-geneY
-	I-geneY
dva	E-geneY
mRNA	O
levels	O
increased	O
during	O
embryogenesis	O
to	O
a	O
maximum	O
on	O
embryonic	O
day	O
(	O
e	O
)	O
18	O
and	O
then	O
decreased	O
and	O
remained	O
low	O
or	O
undetectable	O
after	O
hatch	O
.	O

Ras	B-geneY
-	I-geneY
dva	E-geneY
expression	O
was	O
highly	O
enriched	O
in	O
the	O
pituitary	O
gland	O
on	O
e18	O
relative	O
to	O
other	O
tissues	O
examined	O
.	O

Glucocorticoid	O
treatment	O
of	O
pituitary	O
cells	O
from	O
mid	O
-	O
and	O
late	O
-	O
stage	O
embryos	O
rapidly	O
increased	O
ras	B-geneY
-	I-geneY
dva	E-geneY
mRNA	O
,	O
suggesting	O
it	O
may	O
be	O
a	O
direct	O
transcriptional	O
target	O
of	O
glucocorticoids	O
.	O

A	O
reporter	O
construct	O
driven	O
by	O
4	O
kb	O
of	O
the	O
chicken	B-geneY-C3-2
ras	I-geneY-C3-2
-	I-geneY-C3-2
dva	E-geneY-C3-2
5	O
'	O
-	O
flanking	O
region	O
,	O
containing	O
six	O
putative	O
pituitary	B-geneN-C3-2
-	I-geneN-C3-2
specific	I-geneN-C3-2
transcription	I-geneN-C3-2
factor	I-geneN-C3-2
-	I-geneN-C3-2
1	I-geneN-C3-2
(	I-geneN-C3-2
Pit	I-geneN-C3-2
-	I-geneN-C3-2
1	I-geneN-C3-2
)	I-geneN-C3-2
binding	I-geneN-C3-2
sites	E-geneN-C3-2
and	O
two	O
potential	O
glucocorticoid	B-geneN-C3-2
receptor	I-geneN-C3-2
(	I-geneN-C3-2
GR	I-geneN-C3-2
)	I-geneN-C3-2
binding	I-geneN-C3-2
sites	E-geneN-C3-2
,	O
was	O
highly	O
activated	O
in	O
embryonic	O
pituitary	O
cells	O
and	O
up	O
-	O
regulated	O
by	O
corticosterone	S-chem-C3-1
.	O

Mutagenesis	O
of	O
the	O
most	O
proximal	O
Pit	B-geneN
-	I-geneN
1	I-geneN
site	E-geneN
decreased	O
promoter	O
activity	O
in	O
chicken	O
e11	O
pituitary	O
cells	O
,	O
indicating	O
regulation	O
of	O
ras	B-geneY
-	I-geneY
dva	E-geneY
by	O
Pit	B-geneY
-	I-geneY
1	E-geneY
.	O

However	O
,	O
mutating	O
putative	O
GR	B-geneN-C3-2
binding	I-geneN-C3-2
sites	E-geneN-C3-2
did	O
not	O
substantially	O
reduce	O
induction	O
of	O
ras	B-geneN-C3-2
-	I-geneN-C3-2
dva	I-geneN-C3-2
promoter	E-geneN-C3-2
activity	O
by	O
corticosterone	S-chem-C3-1
,	O
suggesting	O
additional	O
DNA	B-geneN
elements	E-geneN
within	O
the	O
5	O
'	O
-	O
flanking	O
region	O
are	O
responsible	O
for	O
glucocorticoid	O
regulation	O
.	O

We	O
have	O
identified	O
ras	B-geneY
-	I-geneY
dva	E-geneY
as	O
a	O
glucocorticoid	O
-	O
regulated	O
gene	O
that	O
is	O
likely	O
expressed	O
in	O
cells	O
of	O
the	O
Pit	B-geneY
-	I-geneY
1	E-geneY
lineage	O
within	O
the	O
developing	O
anterior	O
pituitary	O
gland	O
.	O

Corticotropin	B-geneY
releasing	I-geneY
factor	E-geneY
and	O
catecholamines	S-chem
enhance	O
glutamatergic	O
neurotransmission	O
in	O
the	O
lateral	O
subdivision	O
of	O
the	O
central	O
amygdala	O
.	O

Glutamatergic	O
neurotransmission	O
in	O
the	O
central	O
nucleus	O
of	O
the	O
amygdala	O
(	O
CeA	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
behaviors	O
including	O
anxiety	O
,	O
memory	O
consolidation	O
and	O
cardiovascular	O
responses	O
.	O

While	O
these	O
behaviors	O
can	O
be	O
modulated	O
by	O
corticotropin	B-geneY
releasing	I-geneY
factor	E-geneY
(	O
CRF	S-geneY
)	O
and	O
catecholamine	S-chem
signaling	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
signals	O
modify	O
CeA	O
glutamatergic	O
neurotransmission	O
remains	O
unclear	O
.	O

Utilizing	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
electrophysiology	O
recordings	O
from	O
neurons	O
in	O
the	O
lateral	O
subdivision	O
of	O
the	O
CeA	O
(	O
CeAL	O
)	O
,	O
we	O
show	O
that	O
CRF	S-geneY
,	O
dopamine	B-geneN
(	I-geneN
DA	I-geneN
)	I-geneN
and	I-geneN
the	I-geneN
β	I-geneN
-	I-geneN
adrenergic	I-geneN
receptor	E-geneN
agonist	O
isoproterenol	S-chem
(	O
ISO	S-chem
)	O
all	O
enhance	O
the	O
frequency	O
of	O
spontaneous	O
excitatory	O
postsynaptic	O
currents	O
(	O
sEPSC	O
)	O
without	O
altering	O
sEPSC	O
kinetics	O
,	O
suggesting	O
they	O
increase	O
presynaptic	O
glutamate	S-chem
release	O
.	O

The	O
effect	O
of	O
CRF	S-geneY
on	O
sEPSCs	O
was	O
mediated	O
by	O
a	O
combination	O
of	O
CRFR1	S-geneY
and	O
CRFR2	S-geneY
receptors	O
.	O

While	O
previous	O
work	O
from	O
our	O
lab	O
suggests	O
that	O
CRFRs	S-geneN
mediate	O
the	O
effect	O
of	O
catecholamines	S-chem
on	O
excitatory	O
transmission	O
in	O
other	O
subregions	O
of	O
the	O
extended	O
amygdala	O
,	O
blockade	O
of	O
CRFRs	S-geneN
in	O
the	O
CeAL	O
failed	O
to	O
significantly	O
alter	O
effects	O
of	O
DA	O
and	O
ISO	S-chem
on	O
glutamatergic	O
transmission	O
.	O

These	O
findings	O
suggest	O
that	O
catecholamine	S-chem
and	O
CRF	S-geneY
enhancement	O
of	O
glutamatergic	O
transmission	O
onto	O
CeAL	O
neurons	O
occurs	O
via	O
distinct	O
mechanisms	O
.	O

While	O
CRF	S-geneY
increased	O
spontaneous	O
glutamate	S-chem
release	O
in	O
the	O
CeAL	O
,	O
CRF	S-geneY
caused	O
no	O
significant	O
changes	O
to	O
optogenetically	O
evoked	O
glutamate	S-chem
release	O
in	O
this	O
region	O
.	O

The	O
dissociable	O
effects	O
of	O
CRF	S-geneY
on	O
different	O
types	O
of	O
glutamatergic	O
neurotransmission	O
suggest	O
that	O
CRF	S-geneY
may	O
specifically	O
regulate	O
spontaneous	O
excitatory	O
transmission	O
.	O

An	O
intra	O
-	O
articular	O
salmon	O
calcitonin	O
-	O
based	O
nanocomplex	O
reduces	O
experimental	O
inflammatory	O
arthritis	O
.	O

Prolonged	O
inappropriate	O
inflammatory	O
responses	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
to	O
aspects	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

The	O
orphan	B-geneY
nuclear	I-geneY
receptor	I-geneY
,	I-geneY
NR4A2	E-geneY
,	O
is	O
a	O
key	O
regulator	O
and	O
potential	O
biomarker	O
for	O
inflammation	O
and	O
represents	O
a	O
potentially	O
valuable	O
therapeutic	O
target	O
.	O

Both	O
salmon	O
calcitonin	O
(	O
sCT	O
)	O
and	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
attenuated	O
activated	O
mRNA	O
expression	O
of	O
NR4A1	S-geneY
,	O
NR4A2	S-geneY
,	O
NR4A3	S-geneY
,	O
and	O
matrix	B-geneN
metalloproteinases	I-geneN
(	I-geneN
MMPs	I-geneN
)	I-geneN
1	I-geneN
,	I-geneN
3	I-geneN
and	I-geneN
13	E-geneN
in	O
three	O
human	O
cell	O
lines	O
:	O
SW1353	O
chondrocytes	O
,	O
U937	O
and	O
THP	O
-	O
1	O
monocytes	O
.	O

Ad	O
-	O
mixtures	O
of	O
sCT	O
and	O
HA	O
further	O
down	O
-	O
regulated	O
expression	O
of	O
NR4A2	S-geneY
compared	O
to	O
either	O
agent	O
alone	O
at	O
specific	O
concentrations	O
,	O
hence	O
the	O
rationale	O
for	O
their	O
formulation	O
in	O
nanocomplexes	O
(	O
NPs	O
)	O
using	O
chitosan	O
.	O

The	O
sCT	O
released	O
from	O
NP	O
stimulated	O
cAMP	S-chem
production	O
in	O
human	O
T47D	O
breast	O
cancer	O
cells	O
expressing	O
sCT	B-geneY
receptors	E-geneY
.	O

When	O
NP	O
were	O
injected	O
by	O
the	O
intra	O
-	O
articular	O
(	O
I.A	O
.	O
)	O
route	O
to	O
the	O
mouse	O
knee	O
during	O
on	O
-	O
going	O
inflammatory	O
arthritis	O
of	O
the	O
K	O
/	O
BxN	O
serum	O
transfer	O
model	O
,	O
joint	O
inflammation	O
was	O
reduced	O
together	O
with	O
NR4A2	S-geneY
expression	O
,	O
and	O
local	O
bone	O
architecture	O
was	O
preserved	O
.	O

These	O
data	O
highlight	O
remarkable	O
anti	O
-	O
inflammatory	O
effects	O
of	O
sCT	O
and	O
HA	O
at	O
the	O
level	O
of	O
reducing	O
NR4A2	S-geneY
mRNA	O
expression	O
in	O
vitro	O
.	O

Combining	O
them	O
in	O
NP	O
elicits	O
anti	O
-	O
arthritic	O
effects	O
in	O
vivo	O
following	O
I.A	O
.	O
delivery	O
.	O

Simvastatin	S-chem
regulates	O
non	O
-	O
neuronal	O
cholinergic	O
activity	O
in	O
T	O
lymphocytes	O
via	O
CD11a	S-geneY
-	O
mediated	O
pathways	O
.	O

Lymphocyte	B-geneY
function	I-geneY
associated	I-geneY
antigen	I-geneY
-	I-geneY
1	E-geneY
(	O
LFA	B-geneY
-	I-geneY
1	E-geneY
;	O
CD11a	S-geneY
/	O
CD18	S-geneY
)	O
is	O
an	O
important	O
mediator	O
of	O
leukocyte	O
migration	O
and	O
T	O
cell	O
activation	O
.	O

We	O
previously	O
showed	O
that	O
antithymocyte	B-geneN
globulin	E-geneN
stimulates	O
an	O
independent	O
,	O
non	O
-	O
neuronal	O
cholinergic	O
system	O
in	O
T	O
cells	O
via	O
LFA	B-geneY
-	I-geneY
1	E-geneY
-	O
mediated	O
pathways	O
,	O
as	O
evidenced	O
by	O
increases	O
in	O
acetylcholine	S-chem
(	O
ACh	S-chem
)	O
synthesis	O
and	O
choline	B-geneY
acetyltransferase	E-geneY
(	O
ChAT	S-geneY
)	O
mRNA	O
expression	O
.	O

The	O
cholesterol	S-chem
-	O
lowering	O
drug	O
simvastatin	S-chem-C4-1
inhibits	O
LFA	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
signaling	O
by	O
binding	O
to	O
an	O
allosteric	O
site	O
on	O
CD11a	S-geneY
(	O
LFA	B-geneY
-	I-geneY
1	I-geneY
alpha	I-geneY
chain	E-geneY
)	O
,	O
which	O
leads	O
to	O
immunomodulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
simvastatin	S-chem
modulates	O
lymphocytic	O
cholinergic	O
activity	O
in	O
T	O
cells	O
.	O

We	O
found	O
that	O
anti	O
-	O
CD11a	S-geneN
monoclonal	O
antibody	O
(	O
mAb	O
)	O
increased	O
ChAT	S-geneN
activity	O
,	O
ACh	S-chem
synthesis	O
and	O
release	O
,	O
and	O
expression	O
of	O
ChAT	S-geneY
and	O
M5	B-geneY
muscarinic	I-geneY
ACh	I-geneY
receptor	E-geneY
mRNA	O
in	O
MOLT	O
-	O
3	O
cells	O
,	O
a	O
human	O
leukemic	O
T	O
cell	O
line	O
.	O

Simvastatin	S-chem-C4-1
abolished	O
these	O
anti	O
-	O
CD11a	S-geneY-C4-2
mAb	O
-	O
induced	O
increases	O
in	O
lymphocytic	O
cholinergic	O
activity	O
in	O
a	O
manner	O
independent	O
of	O
its	O
cholesterol	S-chem
-	O
lowering	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
LFA	B-geneY
-	I-geneY
1	E-geneY
contributes	O
to	O
the	O
regulation	O
of	O
lymphocytic	O
cholinergic	O
activity	O
via	O
CD11a	S-geneY
-	O
mediated	O
pathways	O
,	O
and	O
suggest	O
that	O
simvastatin	S-chem
exerts	O
its	O
immunosuppressive	O
effects	O
in	O
part	O
via	O
modification	O
of	O
lymphocytic	O
cholinergic	O
activity	O
.	O

Carbonic	B-geneN
anhydrase	E-geneN
inhibitors	O
.	O
DNA	O
cloning	O
,	O
characterization	O
,	O
and	O
inhibition	O
studies	O
of	O
the	O
human	B-geneY-C4-2
secretory	I-geneY-C4-2
isoform	I-geneY-C4-2
VI	E-geneY-C4-2
,	O
a	O
new	O
target	O
for	O
sulfonamide	S-chem-C4-1
and	O
sulfamate	S-chem-C4-1
inhibitors	O
.	O

The	O
secretory	O
isozyme	O
of	O
human	B-geneN
carbonic	I-geneN
anhydrase	E-geneN
(	O
hCA	S-geneN
,	O
EC	B-geneN
4.2.1.1	E-geneN
)	O
,	O
hCA	B-geneY
VI	E-geneY
,	O
has	O
been	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
in	O
a	O
bacterial	O
expression	O
system	O
.	O

The	O
kinetic	O
parameters	O
for	O
the	O
CO2	S-chem-C9-1
hydration	O
reaction	O
proved	O
hCA	B-geneY-C9-2
VI	E-geneY-C9-2
to	O
possess	O
a	O
kcat	O
of	O
3.4	O
x	O
10	O
(	O
5	O
)	O
s	O
-	O
1	O
and	O
kcat	O
/	O
KM	O
of	O
4.9	O
x	O
10	O
(	O
7	O
)	O
M	O
-	O
1	O
s	O
-	O
1	O
(	O
at	O
pH	O
7.5	O
and	O
20	O
degrees	O
C	O
)	O
.	O
hCA	B-geneY
VI	E-geneY
has	O
a	O
significant	O
catalytic	O
activity	O
for	O
the	O
physiological	O
reaction	O
on	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
the	O
ubiquitous	O
isoform	O
CA	B-geneN
I	E-geneN
or	O
the	O
transmembrane	O
,	O
tumor	O
-	O
associated	O
isozyme	O
CA	B-geneN
IX	E-geneN
.	O

A	O
series	O
of	O
sulfonamides	S-chem
and	O
one	O
sulfamate	S-chem
have	O
been	O
tested	O
for	O
their	O
interaction	O
with	O
this	O
isozyme	O
.	O

Simple	O
benzenesulfonamides	S-chem
were	O
rather	O
ineffective	O
hCA	B-geneY
VI	E-geneY
inhibitors	O
,	O
with	O
inhibition	O
constants	O
in	O
the	O
range	O
of	O
1090	O
-	O
6680	O
nM	O
.	O

Better	O
inhibitors	O
were	O
detected	O
among	O
such	O
derivatives	O
bearing	O
2	B-chem
-	I-chem
or	I-chem
4	I-chem
-	I-chem
amino	E-chem
-	O
,	O
4	B-chem
-	I-chem
aminomethyl	E-chem
-	O
,	O
or	O
4	B-chem
-	I-chem
hydroxymethyl	E-chem
moieties	O
or	O
among	O
halogenated	O
sulfanilamides	S-chem
(	O
KI	O
values	O
of	O
608	O
-	O
955	O
nM	O
)	O
.	O

Some	O
clinically	O
used	O
compounds	O
,	O
such	O
as	O
acetazolamide	S-chem-C4-1
,	O
methazolamide	S-chem-C4-1
,	O
ethoxzolamide	S-chem-C4-1
,	O
dichlorophenamide	S-chem-C4-1
,	O
dorzolamide	S-chem-C4-1
,	O
brinzolamide	S-chem-C4-1
,	O
topiramate	S-chem-C4-1
,	O
sulpiride	S-chem-C4-1
,	O
and	O
indisulam	S-chem-C4-1
,	O
or	O
the	O
orphan	O
drug	O
benzolamide	S-chem-C4-1
,	O
showed	O
effective	O
hCA	B-geneY-C4-2
VI	E-geneY-C4-2
inhibitory	O
activity	O
,	O
with	O
inhibition	O
constants	O
of	O
0.8	O
-	O
79	O
nM	O
.	O

The	O
best	O
inhibitors	O
were	O
brinzolamide	S-chem-C4-1
and	O
sulpiride	S-chem-C4-1
(	O
KI	O
values	O
of	O
0.8	O
-	O
0.9	O
nM	O
)	O
,	O
the	O
latter	O
compound	O
being	O
also	O
a	O
CA	B-geneY-C4-2
VI	E-geneY-C4-2
-	O
selective	O
inhibitor	O
.	O

The	O
metallic	O
taste	O
reported	O
as	O
a	O
side	O
effect	O
after	O
the	O
treatment	O
with	O
systemic	O
sulfonamides	S-chem-C4-1
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
salivary	B-geneY-C4-2
CA	I-geneY-C4-2
VI	E-geneY-C4-2
.	O

Some	O
of	O
the	O
compounds	O
investigated	O
in	O
this	O
study	O
might	O
be	O
used	O
as	O
additives	O
in	O
toothpastes	O
for	O
reducing	O
the	O
acidification	O
produced	O
by	O
the	O
relevant	O
CO2	S-chem-C9-1
hydrase	O
activity	O
of	O
enamel	O
CA	B-geneY-C9-2
VI	E-geneY-C9-2
,	O
which	O
leads	O
to	O
the	O
formation	O
of	O
protons	O
and	O
bicarbonate	S-chem-C9-1
and	O
may	O
have	O
a	O
role	O
in	O
cariogenesis	O
.	O

Dioscin	S-chem
-	O
induced	O
autophagy	O
mitigates	O
cell	O
apoptosis	O
through	O
modulation	O
of	O
PI3K	S-geneN
/	O
Akt	S-geneN
and	O
ERK	S-geneN
and	O
JNK	S-geneN
signaling	O
pathways	O
in	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

Our	O
previous	O
study	O
has	O
revealed	O
that	O
dioscin	S-chem
,	O
a	O
compound	O
with	O
anti	O
-	O
inflammatory	O
,	O
lipid	O
-	O
lowering	O
,	O
anticancer	O
and	O
hepatoprotective	O
effects	O
,	O
may	O
induce	O
autophagy	O
in	O
hepatoma	O
cells	O
.	O

Autophagy	O
is	O
a	O
lysosomal	O
degradation	O
pathway	O
that	O
is	O
essential	O
for	O
cell	O
survival	O
and	O
tissue	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
autophagy	O
and	O
related	O
signaling	O
pathways	O
during	O
dioscin	S-chem
-	O
induced	O
apoptosis	O
in	O
human	O
lung	O
cancer	O
cells	O
was	O
investigated	O
.	O

Results	O
from	O
4	B-chem
'	I-chem
-	I-chem
6	I-chem
-	I-chem
diamidino	I-chem
-	I-chem
2	I-chem
-	I-chem
phenylindole	E-chem
and	O
annexin	O
-	O
V	O
/	O
PI	O
double	O
-	O
staining	O
assay	O
showed	O
that	O
caspase	B-geneY
-	I-geneY
3	E-geneY
-	O
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
-	O
dependent	O
,	O
and	O
dose	O
-	O
dependent	O
apoptoses	O
were	O
detected	O
after	O
a	O
24	O
-	O
h	O
dioscin	S-chem
treatment	O
.	O

Meanwhile	O
,	O
autophagy	O
was	O
detected	O
as	O
early	O
as	O
12	O
h	O
after	O
an	O
exposure	O
to	O
low	O
-	O
dose	O
dioscin	O
,	E-chem-C3-1
as	O
indicated	O
by	O
an	O
up	O
-	O
regulated	O
expression	O
of	O
LC3	O
-	I-geneY-C3-2
II	I-geneY-C3-2
and	O
beclin	O
-	I-geneY-C3-2
1	I-geneY-C3-2
proteins	O
.	O

Blockade	O
of	O
autophagy	O
with	O
bafilomycin	B-chem
A1	E-chem
or	O
3	B-chem
-	I-chem
methyladenine	E-chem
sensitized	O
the	O
A549	O
and	O
H1299	O
cells	O
to	O
apoptosis	O
.	O

Treatment	O
of	O
A549	O
and	O
H1299	O
cells	O
with	O
dioscin	S-chem-MU-1
caused	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
ERK1	B-geneN-C3-2
/	I-geneN-C3-2
2	E-geneN-C3-2
and	O
JNK1	B-geneN-C3-2
/	I-geneN-C3-2
2	E-geneN-C3-2
activity	O
,	O
accompanied	O
with	O
a	O
decreased	O
PI3K	S-geneN-C4-2
expression	O
and	O
decreased	O
phosphorylation	O
of	O
Akt	S-geneN-C4-2
and	O
mTOR	S-geneN-C4-2
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
autophagy	O
occurred	O
earlier	O
than	O
apoptosis	O
during	O
dioscin	S-chem
-	O
induced	O
human	O
lung	O
cancer	O
cell	O
line	O
apoptosis	O
.	O

Dioscin	S-chem
-	O
induced	O
autophagy	O
via	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
JNK1	B-geneN
/	I-geneN
2	E-geneN
pathways	O
may	O
provide	O
a	O
protective	O
mechanism	O
for	O
cell	O
survival	O
against	O
dioscin	S-chem
-	O
induced	O
apoptosis	O
to	O
act	O
as	O
a	O
cytoprotective	O
reaction	O
.	O

Specificity	O
of	O
zebrafish	B-geneY-C9-2
retinol	I-geneY-C9-2
saturase	E-geneY-C9-2
:	O
formation	O
of	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
13,14	I-chem-C9-1
-	I-chem-C9-1
dihydroretinol	E-chem-C9-1
and	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
7,8	I-chem-C9-1
-	I-chem-C9-1
dihydroretinol	E-chem-C9-1
.	O

Metabolism	O
of	O
vitamin	B-chem
A	E-chem
,	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinol	E-chem
,	O
leads	O
to	O
the	O
formation	O
of	O
11	B-chem
-	I-chem
cis	I-chem
-	I-chem
retinaldehyde	E-chem
,	O
the	O
visual	O
chromophore	O
,	O
and	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
,	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
through	O
the	O
retinoic	B-geneN
acid	I-geneN
receptor	E-geneN
.	O

Enzymes	O
and	O
binding	O
proteins	O
involved	O
in	O
retinoid	S-chem
metabolism	O
are	O
highly	O
conserved	O
across	O
species	O
.	O

We	O
previously	O
described	O
a	O
novel	O
mammalian	O
enzyme	O
that	O
saturates	O
the	O
13	O
-	O
14	O
double	O
bond	O
of	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinol	E-chem
to	O
produce	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
13,14	I-chem
-	I-chem
dihydroretinol	E-chem
,	O
which	O
then	O
follows	O
the	O
same	O
metabolic	O
fate	O
as	O
that	O
of	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinol	E-chem
.	O

Specifically	O
,	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
13,14	I-chem-C9-1
-	I-chem-C9-1
dihydroretinol	E-chem-C9-1
is	O
transiently	O
oxidized	O
to	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
13,14	I-chem
-	I-chem
dihydroretinoic	I-chem
acid	E-chem
before	O
being	O
oxidized	O
further	O
by	O
Cyp26	S-geneY-C9-2
enzymes	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
putative	O
RetSat	S-geneY
homologues	O
in	O
zebrafish	O
,	O
one	O
of	O
which	O
,	O
zebrafish	B-geneY
RetSat	I-geneY
A	E-geneY
(	O
zRetSat	B-geneY
A	E-geneY
)	O
,	O
also	O
had	O
retinol	B-geneY
saturase	E-geneY
activity	O
,	O
whereas	O
zebrafish	B-geneY
RetSat	I-geneY
B	E-geneY
(	O
zRetSat	B-geneY
B	E-geneY
)	O
was	O
inactive	O
under	O
similar	O
conditions	O
.	O

Unlike	O
mouse	B-geneY
RetSat	E-geneY
(	O
mRetSat	S-geneY
)	O
,	O
zRetSat	B-geneY-C9-2
A	E-geneY-C9-2
had	O
an	O
altered	O
bond	O
specificity	O
saturating	O
either	O
the	O
13	O
-	O
14	O
or	O
7	O
-	O
8	O
double	O
bonds	O
of	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
retinol	E-chem-C9-1
to	O
produce	O
either	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
13,14	I-chem-C9-1
-	I-chem-C9-1
dihydroretinol	E-chem-C9-1
or	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
7,8	I-chem-C9-1
-	I-chem-C9-1
dihydroretinol	E-chem-C9-1
,	O
respectively	O
.	O
zRetSat	B-geneY-C9-2
A	E-geneY-C9-2
also	O
saturated	O
the	O
13	O
-	O
14	O
or	O
7	O
-	O
8	O
double	O
bonds	O
of	O
all	B-chem-C9-1
-	I-chem-C9-1
trans	I-chem-C9-1
-	I-chem-C9-1
3,4	I-chem-C9-1
-	I-chem-C9-1
didehydroretinol	E-chem-C9-1
(	O
vitamin	B-chem-C9-1
A2	E-chem-C9-1
)	O
,	O
a	O
second	O
endogenous	O
form	O
of	O
vitamin	B-chem
A	E-chem
in	O
zebrafish	O
.	O

The	O
dual	O
enzymatic	O
activity	O
of	O
zRetSat	B-geneY
A	E-geneY
displays	O
a	O
newly	O
acquired	O
specificity	O
for	O
the	O
13	O
-	O
14	O
double	O
bond	O
retained	O
in	O
higher	O
vertebrates	O
and	O
also	O
the	O
evolutionarily	O
preserved	O
activity	O
of	O
bacterial	B-geneN
phytoene	I-geneN
desaturases	E-geneN
and	O
plant	B-geneN
carotenoid	I-geneN
isomerases	E-geneN
.	O

Expression	O
of	O
zRetSat	B-geneY
A	E-geneY
was	O
restricted	O
to	O
the	O
liver	O
and	O
intestine	O
of	O
hatchlings	O
and	O
adult	O
zebrafish	O
,	O
whereas	O
zRetSat	B-geneY
B	E-geneY
was	O
expressed	O
in	O
the	O
same	O
tissues	O
but	O
at	O
earlier	O
developmental	O
stages	O
.	O

Exogenous	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinol	E-chem
,	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
13,14	I-chem
-	I-chem
dihydroretinol	E-chem
,	O
or	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
7,8	I-chem
-	I-chem
dihydroretinol	E-chem
led	O
to	O
the	O
strong	O
induction	O
of	O
the	O
expression	O
of	O
the	O
retinoic	B-chem
acid	E-chem
-	O
metabolizing	O
enzyme	O
,	O
Cyp26A1	S-geneY
,	O
arguing	O
for	O
an	O
active	O
signaling	O
function	O
of	O
dihydroretinoid	S-chem
metabolites	O
in	O
zebrafish	O
.	O

These	O
findings	O
point	O
to	O
a	O
conserved	O
function	O
but	O
altered	O
specificity	O
of	O
RetSat	S-geneY
in	O
vertebrates	O
,	O
leading	O
to	O
the	O
generation	O
of	O
various	O
dihydroretinoid	S-chem
compounds	O
,	O
some	O
of	O
which	O
could	O
have	O
signaling	O
functions	O
.	O

Mechanisms	O
limiting	O
distribution	O
of	O
the	O
threonine	B-geneY-C4-2
-	I-geneY-C4-2
protein	I-geneY-C4-2
kinase	I-geneY-C4-2
B	I-geneY-C4-2
-	I-geneY-C4-2
RaF	E-geneY-C4-2
(	O
V600E	S-geneN-C4-2
)	O
inhibitor	O
dabrafenib	S-chem-C4-1
to	O
the	O
brain	O
:	O
implications	O
for	O
the	O
treatment	O
of	O
melanoma	O
brain	O
metastases	O
.	O

Brain	O
metastases	O
are	O
a	O
common	O
cause	O
of	O
death	O
in	O
stage	O
IV	O
metastatic	O
melanoma	O
.	O

Dabrafenib	O
is	O
a	O
BRAF	S-geneY
(	O
gene	O
encoding	O
serine	B-geneY
/	I-geneY
threonine	I-geneY
-	I-geneY
protein	I-geneY
kinase	I-geneY
B	I-geneY
-	I-geneY
Raf	E-geneY
)	O
inhibitor	O
that	O
has	O
been	O
developed	O
to	O
selectively	O
target	O
the	O
valine	B-geneN
600	I-geneN
to	I-geneN
glutamic	I-geneN
acid	E-geneN
substitution	O
(	O
BRAF	S-geneY
(	O
V600E	S-geneN
)	O
)	O
,	O
which	O
is	O
commonly	O
found	O
in	O
metastatic	O
melanoma	O
.	O

Clinical	O
trials	O
with	O
dabrafenib	S-chem
have	O
shown	O
encouraging	O
results	O
;	O
however	O
,	O
the	O
central	O
nervous	O
system	O
distribution	O
of	O
dabrafenib	S-chem
remains	O
unknown	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
brain	O
distribution	O
of	O
dabrafenib	S-chem
in	O
mice	O
,	O
and	O
to	O
see	O
whether	O
active	O
efflux	O
by	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
and	O
breast	B-geneY
cancer	I-geneY
resistance	I-geneY
protein	E-geneY
(	O
BCRP	S-geneY
)	O
restricts	O
its	O
delivery	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

In	O
vitro	O
accumulation	O
studies	O
conducted	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
II	O
cells	O
indicate	O
that	O
dabrafenib	S-chem-C9-1
is	O
an	O
avid	O
substrate	O
for	O
both	O
P	B-geneN-C9-2
-	I-geneN-C9-2
gp	E-geneN-C9-2
and	O
BCRP	S-geneY-C9-2
.	O

Directional	O
flux	O
studies	O
revealed	O
greater	O
transport	O
in	O
the	O
basolateral	O
to	O
apical	O
direction	O
with	O
corrected	O
efflux	O
ratios	O
greater	O
than	O
2	O
for	O
both	O
P	B-geneN
-	I-geneN
gp	E-geneN
and	O
Bcrp1	S-geneY
transfected	O
cell	O
lines	O
.	O

In	O
vivo	O
,	O
the	O
ratio	O
of	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
(	O
brain	O
)	O
to	O
AUC	O
(	O
plasma	O
)	O
(	O
K	O
(	O
p	O
)	O
)	O
of	O
dabrafenib	S-chem
after	O
an	O
i.v	O
.	O
dose	O
(	O
2.5	O
mg	O
/	O
kg	O
)	O
was	O
0.023	O
,	O
which	O
increased	O
by	O
18	O
-	O
fold	O
in	O
Mdr1	B-geneN
a	I-geneN
/	I-geneN
b	E-geneN
(	O
-	O
/	O
-	O
)	O
Bcrp1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
0.42	O
.	O

Dabrafenib	S-chem
plasma	O
exposure	O
was	O
∼	O
2	O
-	O
fold	O
greater	O
in	O
Mdr1	B-geneN
a	I-geneN
/	I-geneN
b	E-geneN
(	O
-	O
/	O
-	O
)	O
Bcrp1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
as	O
compared	O
with	O
wild	O
-	O
type	O
with	O
an	O
oral	O
dose	O
(	O
25	O
mg	O
/	O
kg	O
)	O
;	O
however	O
,	O
the	O
brain	O
distribution	O
was	O
increased	O
by	O
~	O
10	O
-	O
fold	O
with	O
a	O
resulting	O
K	O
(	O
p	O
)	O
of	O
0.25	O
.	O

Further	O
,	O
compared	O
with	O
vemurafenib	S-chem-C4-1
,	O
another	O
BRAF	S-geneY-C4-2
(	O
V600E	S-geneN-C4-2
)	O
inhibitor	O
,	O
dabrafenib	S-chem
showed	O
greater	O
brain	O
penetration	O
with	O
a	O
similar	O
dose	O
.	O

In	O
conclusion	O
,	O
the	O
dabrafenib	S-chem
brain	O
distribution	O
is	O
limited	O
in	O
an	O
intact	O
BBB	O
model	O
,	O
and	O
the	O
data	O
presented	O
herein	O
may	O
have	O
clinical	O
implications	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
melanoma	O
brain	O
metastases	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
activate	O
carbonic	B-geneN
anhydrase	E-geneN
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

Previous	O
studies	O
by	O
this	O
research	O
team	O
proved	O
that	O
vasodilating	O
prostaglandins	S-chem-C4-1
(	O
PGs	S-chem-C4-1
)	O
E1	O
,	O
E2	O
and	O
I2	O
inhibit	O
carbonic	B-geneN-C4-2
anhydrase	E-geneN-C4-2
(	O
CA	S-geneN-C4-2
)	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
suggested	O
involvement	O
of	O
CA	S-geneN
in	O
gastric	O
acid	O
secretion	O
inhibition	O
and	O
the	O
increase	O
of	O
gastric	O
mucosa	O
blood	O
flow	O
produced	O
by	O
this	O
group	O
of	O
PGs	S-chem
.	O

Relying	O
on	O
these	O
findings	O
,	O
as	O
well	O
as	O
on	O
our	O
clinical	O
observations	O
,	O
we	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
the	O
effects	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
on	O
CA	B-geneY
I	E-geneY
and	O
CA	B-geneY
II	E-geneY
.	O

We	O
also	O
followed	O
in	O
vitro	O
the	O
effects	O
on	O
these	O
isozymes	O
of	O
NSAIDs	O
associated	O
to	O
histamine	S-chem
,	O
Ca	S-chem
,	O
PGE2	O
and	O
acetazolamide	S-chem
.	O

The	O
results	O
show	O
that	O
the	O
NSAIDs	O
used	O
here	O
,	O
which	O
reduce	O
the	O
activity	O
of	O
cyclooxygenase	S-geneN
and	O
PG	S-chem
production	O
,	O
activated	O
CA	B-geneY
I	E-geneY
and	O
CA	B-geneY
II	E-geneY
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
a	O
mechanism	O
of	O
the	O
noncompetitive	O
type	O
.	O

Histamine	S-chem
and	O
Ca	S-chem-C3-1
added	O
to	O
NSAIDs	O
amplified	O
the	O
activating	O
effect	O
of	O
the	O
latter	O
on	O
CA	B-geneY-C3-2
II	E-geneY-C3-2
.	O

Association	O
of	O
PGE2	O
or	O
acetazolamide	S-chem-C4-1
to	O
NSAIDs	O
reduced	O
NSAID	O
-	O
induced	O
activation	O
of	O
CA	B-geneY-C4-2
I	E-geneY-C4-2
and	O
CA	B-geneY-C4-2
II	E-geneY-C4-2
.	O

Indomethacin	S-chem-C3-1
abolished	O
the	O
inhibitory	O
effect	O
of	O
acetazolamide	S-chem-C4-1
on	O
CA	B-geneY-MU-2
I	E-geneY-MU-2
and	O
CA	B-geneY-MU-2
II	E-geneY-MU-2
.	O

Our	O
data	O
imply	O
that	O
between	O
CA	S-geneN
and	O
cyclooxygenase	S-geneN
there	O
is	O
an	O
inverse	O
relationship	O
,	O
CA	S-geneN
activation	O
being	O
accompanied	O
by	O
reduction	O
of	O
cyclooxygenase	S-geneN
activity	O
,	O
a	O
reduction	O
achieved	O
by	O
the	O
pH	O
modifications	O
induced	O
by	O
CA	S-geneN
activation	O
.	O

In	O
this	O
way	O
,	O
cyclooxygenase	S-geneN
,	O
inhibition	O
occurs	O
``	O
via	O
CA	O
,	O
``	O
with	O
the	O
pH	O
variations	O
it	O
brings	O
about	O
.	O

Histamine	S-chem
and	O
asthma	O
:	O
an	O
appraisal	O
based	O
on	O
specific	O
H1	B-geneY
-	I-geneY
receptor	E-geneY
antagonism	O
.	O

H1	B-geneY-C5-2
-	I-geneY-C5-2
receptor	E-geneY-C5-2
antagonists	O
have	O
been	O
utilized	O
,	O
following	O
their	O
initial	O
chemical	O
synthesis	O
in	O
1933	O
,	O
both	O
in	O
the	O
treatment	O
of	O
conditions	O
in	O
which	O
histamine	S-chem-C5-1
is	O
considered	O
to	O
be	O
of	O
pathogenic	O
importance	O
and	O
conversely	O
to	O
help	O
elucidate	O
the	O
role	O
of	O
histamine	S-chem-C5-1
in	O
disease	O
,	O
through	O
an	O
evaluation	O
of	O
their	O
influence	O
on	O
disease	O
expression	O
.	O

While	O
there	O
is	O
considerable	O
indirect	O
evidence	O
to	O
implicate	O
histamine	S-chem-C5-1
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
a	O
critical	O
evaluation	O
of	O
H1	B-geneY-C5-2
-	I-geneY-C5-2
receptor	E-geneY-C5-2
antagonism	O
in	O
this	O
condition	O
has	O
,	O
until	O
recently	O
,	O
proved	O
difficult	O
,	O
as	O
many	O
of	O
the	O
early	O
H1	B-geneY-C5-2
-	I-geneY-C5-2
receptor	E-geneY-C5-2
antagonists	O
possessed	O
additional	O
actions	O
,	O
such	O
as	O
anti	O
-	O
cholinergic	O
,	O
local	O
anaesthetic	O
,	O
alpha	B-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonistic	O
and	O
anti	O
-	O
serotonin	O
activity	O
.	O

In	O
addition	O
,	O
H1	B-geneY
-	I-geneY
receptor	E-geneY
antagonists	O
have	O
been	O
shown	O
to	O
have	O
effects	O
on	O
mast	O
cell	O
function	O
.	O

In	O
low	O
concentrations	O
in	O
vitro	O
,	O
antihistamines	O
have	O
been	O
found	O
to	O
inhibit	O
immunologically	O
stimulated	O
mast	O
cell	O
mediator	O
release	O
,	O
with	O
the	O
IC50	O
in	O
the	O
nanomolar	O
to	O
micromolar	O
range	O
,	O
while	O
at	O
higher	O
concentrations	O
they	O
induce	O
histamine	S-chem
release	O
.	O

The	O
potency	O
of	O
these	O
drugs	O
in	O
producing	O
such	O
effects	O
is	O
unrelated	O
to	O
their	O
H1	B-geneY
-	I-geneY
receptor	E-geneY
blocking	O
activity	O
.	O

Furthermore	O
the	O
sedative	O
effects	O
of	O
these	O
therapeutic	O
agents	O
limit	O
the	O
tolerable	O
administrable	O
dose	O
and	O
thus	O
the	O
degree	O
of	O
H1	B-geneY
-	I-geneY
receptor	E-geneY
blockade	O
achievable	O
within	O
the	O
airways	O
.	O

The	O
recent	O
development	O
of	O
H1	B-geneY-C5-2
-	I-geneY-C5-2
receptor	E-geneY-C5-2
antagonists	O
devoid	O
of	O
clinical	O
sedative	O
effects	O
has	O
enabled	O
the	O
administration	O
of	O
doses	O
of	O
H1	S-geneY
-	O
antihistamines	O
which	O
achieve	O
a	O
greater	O
degree	O
of	O
H1	B-geneY-C5-2
-	I-geneY-C5-2
receptor	E-geneY-C5-2
blockade	O
within	O
the	O
airways	O
,	O
thus	O
permitting	O
a	O
better	O
appraisal	O
of	O
the	O
role	O
of	O
histamine	S-chem-C5-1
in	O
this	O
condition	O
.	O

Furthermore	O
,	O
the	O
receptor	O
specificity	O
of	O
many	O
of	O
these	O
agents	O
has	O
been	O
focused	O
such	O
that	O
terfenadine	S-chem
,	O
astemizole	S-chem
,	O
loratadine	S-chem
and	O
cetirizine	S-chem
are	O
devoid	O
of	O
anticholinergic	O
activity	O
and	O
exhibit	O
little	O
alpha	O
-	O
antagonistic	O
or	O
anti	O
-	O
serotonin	S-chem
activity	O
of	O
clinical	O
relevance	O
.	O

However	O
,	O
of	O
these	O
agents	O
both	O
loratadine	S-chem
and	O
cetirizine	S-chem
possess	O
additional	O
actions	O
likely	O
to	O
be	O
of	O
relevance	O
to	O
asthma	O
.	O

Pretreatment	O
with	O
loratadine	S-chem
has	O
been	O
shown	O
to	O
reduce	O
the	O
recovery	O
of	O
both	O
histamine	S-chem
and	O
prostaglandin	B-chem
D2	E-chem
(	O
PGD2	S-chem
)	O
in	O
nasal	O
lavage	O
fluid	O
following	O
nasal	O
allergen	O
challenge	O
,	O
a	O
finding	O
interpreted	O
as	O
indicative	O
of	O
in	O
vivo	O
mast	O
cell	O
stabilization	O
,	O
and	O
cetirizine	S-chem
has	O
been	O
shown	O
in	O
vivo	O
at	O
therapeutic	O
doses	O
to	O
inhibit	O
allergen	O
-	O
induced	O
eosinophil	O
chemotaxis	O
.	O

Thus	O
while	O
both	O
these	O
agents	O
offer	O
the	O
potential	O
of	O
an	O
oral	O
therapy	O
for	O
asthma	O
based	O
on	O
an	O
H1	B-geneY
-	I-geneY
receptor	E-geneY
antagonist	O
,	O
their	O
additional	O
actions	O
do	O
not	O
make	O
them	O
ideally	O
suited	O
to	O
the	O
exploration	O
of	O
the	O
role	O
of	O
histamine	S-chem
in	O
asthma	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Cardiac	O
effects	O
of	O
the	O
beta	B-geneY-C5-2
3	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
BRL35135	S-chem-C5-1
in	O
man	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
cardiac	O
effects	O
of	O
the	O
beta	B-geneY-C5-2
3	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
BRL35135	S-chem-C5-1
,	O
and	O
determine	O
whether	O
beta	B-geneY
3	I-geneY
-	I-geneY
receptors	E-geneY
are	O
involved	O
in	O
mediating	O
chronotropic	O
or	O
inotropic	O
responses	O
in	O
man	O
.	O

Eight	O
normal	O
males	O
received	O
single	O
oral	O
doses	O
of	O
BRL35135	S-chem
8	O
mg	O
(	O
BRL	S-chem
)	O
or	O
the	O
selective	O
beta	B-geneY-C5-2
2	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
salbutamol	S-chem-C5-1
8	O
mg	O
(	O
SAL	S-chem-C5-1
)	O
,	O
after	O
pretreatment	O
with	O
either	O
placebo	O
(	O
PL	O
)	O
,	O
bisoprolol	S-chem-C6-1
5	O
mg	O
(	O
B5	O
)	O
as	O
a	O
selective	O
beta	B-geneY-C6-2
1	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
,	O
or	O
nadolol	S-chem
20	O
mg	O
(	O
N20	O
)	O
to	O
block	O
beta	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
2	I-geneN
-	I-geneN
but	I-geneN
not	I-geneN
beta	I-geneN
3	I-geneN
-	I-geneN
receptors	E-geneN
.	O

Both	O
BRL	S-chem-C3-1
and	O
SAL	S-chem-C3-1
produced	O
a	O
significant	O
increase	O
in	O
postural	O
finger	O
tremor	O
in	O
keeping	O
with	O
beta	B-geneY-C3-2
2	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptor	E-geneY-C3-2
stimulation	O
,	O
and	O
this	O
response	O
was	O
totally	O
abolished	O
by	O
pretreatment	O
with	O
N20	O
.	O

Significant	O
increases	O
in	O
systolic	O
blood	O
pressure	O
and	O
Doppler	O
stroke	O
distance	O
occurred	O
with	O
BRL	S-chem
and	O
SAL	S-chem
which	O
were	O
unaffected	O
by	O
pretreatment	O
with	O
B5	O
and	O
completely	O
blocked	O
by	O
N20	O
,	O
in	O
keeping	O
with	O
beta	B-geneY
2	E-geneY
-	O
mediated	O
effects	O
.	O

BRL	S-chem
and	O
SAL	S-chem
produced	O
significant	O
chronotropic	O
and	O
minute	O
distance	O
responses	O
which	O
were	O
unaffected	O
by	O
beta	B-geneY
1	I-geneY
-	I-geneY
adrenoceptor	E-geneY
blockade	O
.	O

However	O
,	O
whereas	O
N20	O
blocked	O
these	O
responses	O
to	O
SAL	S-chem
,	O
a	O
small	O
but	O
significant	O
response	O
occurred	O
with	O
BRL	S-chem
in	O
comparison	O
with	O
placebo	O
despite	O
complete	O
blockade	O
of	O
co	O
-	O
existing	O
beta	B-geneY
2	E-geneY
-	O
mediated	O
effects	O
.	O

Compared	O
with	O
PL	O
,	O
the	O
mean	O
responses	O
to	O
N20	O
/	O
BRL	S-chem
,	O
and	O
the	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
differences	O
between	O
the	O
means	O
were	O
7.4	O
beats	O
min	O
-	O
1	O
[	O
3.2	O
to	O
11.6	O
]	O
(	O
P	O
=	O
0.002	O
)	O
for	O
heart	O
rate	O
,	O
and	O
208.8	O
cm	O
[	O
38.3	O
to	O
379.3	O
]	O
(	O
P	O
=	O
0.02	O
)	O
for	O
minute	O
distance	O
responses	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

FCGR2A	S-geneY
and	O
FCGR3A	S-geneY
polymorphisms	O
associated	O
with	O
clinical	O
outcome	O
of	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
expressing	O
metastatic	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
single	O
-	O
agent	O
cetuximab	O
.	O

PURPOSE	O
:	O
Cetuximab	O
,	O
a	O
chimeric	O
immunoglobulin	B-geneY
G	I-geneY
1	E-geneY
(	O
IgG1	S-geneY
)	O
anti	O
-	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
has	O
shown	O
efficacy	O
in	O
10	O
%	O
of	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

Recent	O
studies	O
demonstrate	O
antibody	O
-	O
dependent	O
cell	O
-	O
mediated	O
cytotoxicity	O
(	O
ADCC	O
)	O
is	O
one	O
of	O
the	O
modes	O
of	O
action	O
for	O
rituximab	O
and	O
trastuzumab	O
.	O

Fragment	O
c	O
(	O
Fc	O
)	O
portion	O
of	O
IgG1	S-geneY
mAb	O
has	O
shown	O
to	O
induce	O
ADCC	O
.	O

Fragment	B-geneN
c	I-geneN
gamma	I-geneN
receptors	E-geneN
(	O
FcgammaR	S-geneN
)	O
play	O
an	O
important	O
role	O
in	O
initiating	O
ADCC	O
.	O

Studies	O
have	O
shown	O
that	O
two	O
IgG	S-geneN
FcgammaR	S-geneN
polymorphisms	O
(	O
FCGR2A	S-geneY
-	O
H131R	S-geneN
and	O
FCGR3A	S-geneY
-	O
V158F	S-geneN
)	O
independently	O
predict	O
response	O
to	O
rituximab	O
in	O
patients	O
with	O
follicular	O
lymphoma	O
.	O

We	O
tested	O
the	O
hypothesis	O
of	O
whether	O
these	O
two	O
polymorphisms	O
are	O
associated	O
with	O
clinical	O
outcome	O
in	O
metastatic	O
CRC	O
patients	O
treated	O
with	O
single	O
-	O
agent	O
cetuximab	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Thirty	O
-	O
nine	O
metastatic	O
CRC	O
patients	O
were	O
enrolled	O
onto	O
the	O
ImClone0144	O
trial	O
.	O

Using	O
an	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
based	O
method	O
,	O
gene	O
polymorphisms	O
of	O
FCGA2A	S-geneY
-	O
H131R	S-geneN
and	O
FCGA3A	S-geneY
-	O
V158F	S-geneN
were	O
assessed	O
from	O
genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
samples	O
.	O

RESULTS	O
:	O
FCGR2A	S-geneY
-	O
H131R	S-geneN
and	O
FCGR3A	S-geneY
-	O
V158F	S-geneN
polymorphisms	O
were	O
independently	O
associated	O
with	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
;	O
P	O
=	O
.037	O
and	O
.055	O
,	O
respectively	O
;	O
log	O
-	O
rank	O
test	O
)	O
.	O

Combined	O
analysis	O
of	O
these	O
two	O
polymorphisms	O
showed	O
that	O
patients	O
with	O
the	O
favorable	O
genotypes	O
(	O
FCGR2A	S-geneY
,	O
any	O
histidine	S-chem
allele	O
,	O
and	O
FCGR3A	S-geneY
,	O
any	O
phenylalanine	S-chem
allele	O
)	O
showed	O
a	O
median	O
PFS	O
of	O
3.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
2.4	O
to	O
4.4	O
months	O
)	O
,	O
whereas	O
patients	O
with	O
any	O
two	O
unfavorable	O
genotypes	O
(	O
FCGR2A	S-geneY
arginine	S-chem
/	O
arginine	S-chem
or	O
valine	S-chem
/	O
valine	S-chem
)	O
had	O
a	O
PFS	O
of	O
1.1	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.0	O
to	O
1.4	O
months	O
;	O
P	O
=	O
.004	O
;	O
log	O
-	O
rank	O
test	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
suggest	O
that	O
these	O
two	O
polymorphisms	O
may	O
be	O
useful	O
molecular	O
markers	O
to	O
predict	O
clinical	O
outcome	O
in	O
metastatic	O
CRC	O
patients	O
treated	O
with	O
cetuximab	O
and	O
that	O
they	O
may	O
indicate	O
a	O
role	O
of	O
ADCC	O
of	O
cetuximab	O
.	O

Synthesis	O
and	O
antitumor	O
activity	O
of	O
1,3,4	B-chem-C4-1
-	I-chem-C4-1
oxadiazole	E-chem-C4-1
possessing	O
1,4	B-chem-C4-1
-	I-chem-C4-1
benzodioxan	E-chem-C4-1
moiety	O
as	O
a	O
novel	O
class	O
of	O
potent	O
methionine	B-geneY-C4-2
aminopeptidase	I-geneY-C4-2
type	I-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
.	O

A	O
series	O
of	O
1,3,4	B-chem
-	I-chem
oxadiazole	E-chem
derivatives	O
containing	O
1,4	B-chem
-	I-chem
benzodioxan	E-chem
moiety	O
(	O
7a	O
-	O
7q	O
)	O
have	O
been	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
for	O
their	O
antitumor	O
activity	O
.	O

Most	O
of	O
the	O
synthesized	O
compounds	O
were	O
proved	O
to	O
have	O
potent	O
antitumor	O
activity	O
and	O
low	O
toxicity	O
.	O

Among	O
them	O
,	O
compound	O
7a	O
showed	O
the	O
most	O
potent	O
biological	O
activity	O
against	O
Human	O
Umbilical	O
Vein	O
Endothelial	O
cells	O
,	O
which	O
was	O
comparable	O
to	O
the	O
positive	O
control	O
.	O

The	O
results	O
of	O
apoptosis	O
and	O
flow	O
cytometry	O
(	O
FCM	O
)	O
demonstrated	O
that	O
compound	O
7a	O
induce	O
cell	O
apoptosis	O
by	O
the	O
inhibition	O
of	O
MetAP2	S-geneY
pathway	O
.	O

Molecular	O
docking	O
was	O
performed	O
to	O
position	O
compound	O
7a	O
into	O
MetAP2	S-geneY
binding	O
site	O
in	O
order	O
to	O
explore	O
the	O
potential	O
target	O
.	O

Alteration	O
of	O
α	B-geneY
-	I-geneY
tocopherol	I-geneY
-	I-geneY
associated	I-geneY
protein	E-geneY
(	O
TAP	S-geneY
)	O
expression	O
in	O
human	O
breast	O
epithelial	O
cells	O
during	O
breast	O
cancer	O
development	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
common	O
malignancy	O
among	O
women	O
and	O
has	O
an	O
age	O
-	O
specific	O
incidence	O
profile	O
.	O

Over	O
the	O
last	O
decade	O
,	O
many	O
studies	O
have	O
demonstrated	O
the	O
anticancer	O
activity	O
of	O
α	B-chem
-	I-chem
tocopherol	E-chem
,	O
the	O
main	O
and	O
most	O
active	O
form	O
of	O
natural	O
vitamin	B-chem
E	E-chem
.	O

α	B-geneY
-	I-geneY
Tocopherol	I-geneY
-	I-geneY
associated	I-geneY
protein	E-geneY
(	O
TAP	S-geneY
)	O
was	O
found	O
to	O
be	O
one	O
of	O
the	O
major	O
α	B-geneN
-	I-geneN
tocopherol	I-geneN
binding	I-geneN
proteins	E-geneN
in	O
human	O
serum	O
and	O
in	O
liver	O
,	O
brain	O
,	O
and	O
prostate	O
tissues	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
reduced	O
TAP	S-geneY
expression	O
was	O
significantly	O
correlated	O
with	O
Her2	S-geneY
/	O
neu	S-geneY
receptor	O
expression	O
,	O
breast	O
cancer	O
stage	O
and	O
nodal	O
stage	O
in	O
paired	O
normal	O
and	O
cancerous	O
breast	O
tissue	O
samples	O
from	O
93	O
patients	O
using	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

A	O
cell	O
viability	O
assay	O
showed	O
that	O
α	B-chem
-	I-chem
tocopheryl	I-chem
succinate	E-chem
(	O
α	B-chem
-	I-chem
TOS	E-chem
)	O
,	O
a	O
synthetic	O
derivative	O
of	O
α	B-chem
-	I-chem
tocopherol	E-chem
,	O
enhanced	O
the	O
cells	O
'	O
sensitivity	O
to	O
doxorubicin	S-chem
and	O
resulted	O
in	O
a	O
reduction	O
in	O
cell	O
viability	O
in	O
breast	O
cancers	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
use	O
of	O
vitamin	B-chem
E	E-chem
or	O
its	O
analogue	O
as	O
a	O
dietary	O
supplement	O
may	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
rofecoxib	S-chem-C4-1
(	O
a	O
cyclooxygenase	B-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
)	O
,	O
ibuprofen	S-chem
,	O
and	O
placebo	O
on	O
the	O
gastroduodenal	O
mucosa	O
of	O
patients	O
with	O
osteoarthritis	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O
The	O
Rofecoxib	S-chem
Osteoarthritis	O
Endoscopy	O
Multinational	O
Study	O
Group	O
.	O

OBJECTIVE	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
tested	O
the	O
hypothesis	O
that	O
rofecoxib	S-chem-C4-1
,	O
a	O
drug	O
that	O
specifically	O
inhibits	O
cyclooxygenase	B-geneY-C4-2
2	E-geneY-C4-2
,	O
would	O
cause	O
fewer	O
gastroduodenal	O
ulcers	O
than	O
ibuprofen	S-chem
(	O
in	O
a	O
multicenter	O
trial	O
)	O
,	O
and	O
its	O
side	O
effects	O
would	O
be	O
equivalent	O
to	O
those	O
of	O
placebo	O
(	O
in	O
a	O
prespecified	O
analysis	O
combining	O
the	O
results	O
with	O
another	O
trial	O
of	O
identical	O
design	O
)	O
.	O

METHODS	O
:	O
Seven	O
hundred	O
seventy	O
-	O
five	O
patients	O
with	O
osteoarthritis	O
were	O
randomized	O
to	O
receive	O
rofecoxib	S-chem
at	O
a	O
dosage	O
of	O
25	O
mg	O
or	O
50	O
mg	O
once	O
daily	O
,	O
ibuprofen	O
800	O
mg	O
3	O
times	O
daily	O
,	O
or	O
placebo	O
.	O

Gastroduodenal	O
ulceration	O
was	O
assessed	O
by	O
endoscopy	O
at	O
6	O
,	O
12	O
,	O
and	O
(	O
for	O
active	O
treatment	O
)	O
24	O
weeks	O
.	O

The	O
primary	O
and	O
secondary	O
end	O
points	O
were	O
the	O
incidence	O
of	O
gastroduodenal	O
ulcers	O
at	O
12	O
and	O
24	O
weeks	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Ulcers	O
were	O
significantly	O
less	O
common	O
(	O
P	O
<	O
0.001	O
)	O
following	O
treatment	O
with	O
rofecoxib	S-chem
(	O
25	O
mg	O
or	O
50	O
mg	O
)	O
than	O
with	O
ibuprofen	S-chem
after	O
12	O
weeks	O
(	O
5.3	O
%	O
and	O
8.8	O
%	O
versus	O
29.2	O
%	O
,	O
respectively	O
)	O
or	O
24	O
weeks	O
(	O
9.9	O
%	O
and	O
12.4	O
%	O
versus	O
46.8	O
%	O
,	O
respectively	O
)	O
.	O

In	O
the	O
combined	O
analysis	O
,	O
the	O
12	O
-	O
week	O
ulcer	O
incidence	O
with	O
25	O
mg	O
rofecoxib	S-chem
(	O
4.7	O
%	O
)	O
and	O
with	O
placebo	O
(	O
7.3	O
%	O
)	O
satisfied	O
prespecified	O
criteria	O
for	O
equivalence	O
.	O

CONCLUSION	O
:	O
At	O
2	O
-	O
4	O
times	O
the	O
therapeutically	O
effective	O
dose	O
,	O
rofecoxib	S-chem
caused	O
fewer	O
endoscopically	O
detected	O
ulcers	O
than	O
did	O
ibuprofen	S-chem
.	O

Rofecoxib	O
at	O
a	O
dose	O
of	O
25	O
mg	O
(	O
the	O
highest	O
dose	O
recommended	O
for	O
osteoarthritis	O
)	O
satisfied	O
prespecified	O
criteria	O
for	O
equivalence	O
to	O
placebo	O
.	O

Identification	O
of	O
interaction	O
sites	O
of	O
cyclic	O
nucleotide	S-chem
phosphodiesterase	B-geneY
type	I-geneY
3A	E-geneY
with	O
milrinone	S-chem
and	O
cilostazol	S-chem
using	O
molecular	O
modeling	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

To	O
identify	O
amino	B-chem
acid	E-chem
residues	O
involved	O
in	O
PDE3	S-geneY
-	O
selective	O
inhibitor	O
binding	O
,	O
we	O
selected	O
eight	O
presumed	O
interacting	O
residues	O
in	O
the	O
substrate	O
-	O
binding	O
pocket	O
of	O
PDE3A	S-geneY
using	O
a	O
model	O
created	O
on	O
basis	O
of	O
homology	O
to	O
the	O
PDE4B	S-geneY
crystal	O
structure	O
.	O

We	O
changed	O
the	O
residues	O
to	O
alanine	S-chem
using	O
site	O
-	O
directed	O
mutagenesis	O
technique	O
,	O
expressed	O
the	O
mutants	O
in	O
a	O
baculovirus	O
/	O
Sf9	O
cell	O
system	O
,	O
and	O
analyzed	O
the	O
kinetic	O
characteristics	O
of	O
inhibition	O
of	O
the	O
mutant	O
enzymes	O
by	O
milrinone	S-chem-C4-1
and	O
cilostazol	S-chem-C4-1
,	O
specific	O
inhibitors	O
of	O
PDE3	S-geneY-C4-2
.	O

The	O
mutants	O
displayed	O
differential	O
sensitivity	O
to	O
the	O
inhibitors	O
.	O

Mutants	O
Y751A	S-geneN-C4-2
,	O
D950A	S-geneN-C4-2
,	O
and	O
F1004A	S-geneN-C4-2
had	O
reduced	O
sensitivity	O
to	O
milrinone	S-chem-C4-1
(	O
K	O
(	O
i	O
)	O
changed	O
from	O
0.66	O
microM	O
for	O
the	O
recombinant	O
PDE3A	S-geneY-C4-2
to	O
7.5	O
to	O
156	O
microM	O
for	O
the	O
mutants	O
)	O
,	O
and	O
diminished	O
sensitivity	O
to	O
cilostazol	S-chem-C4-1
(	O
K	O
(	O
i	O
)	O
of	O
the	O
mutants	O
were	O
18	O
-	O
to	O
371	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
recombinant	O
PDE3A	S-geneY-C4-2
)	O
.	O

In	O
contrast	O
,	O
the	O
mutants	O
T844A	S-geneN-C4-2
,	O
F972A	S-geneN-C4-2
and	O
Q975A	S-geneN-C4-2
showed	O
increased	O
K	O
(	O
i	O
)	O
for	O
cilostazol	S-chem-C4-1
but	O
no	O
difference	O
for	O
milrinone	S-chem-C4-1
from	O
the	O
recombinant	O
PDE3A	S-geneY-C4-2
.	O

Molecular	O
models	O
show	O
that	O
the	O
PDE3	S-geneY-C4-2
inhibitors	O
cilostazol	S-chem-C4-1
and	O
milrinone	S-chem-C4-1
share	O
some	O
of	O
common	O
residues	O
but	O
interact	O
with	O
distinct	O
residues	O
at	O
the	O
active	O
site	O
,	O
suggesting	O
that	O
selective	O
inhibitors	O
can	O
be	O
designed	O
with	O
flexible	O
size	O
against	O
PDE3	S-geneY
active	O
site	O
.	O

Our	O
study	O
implies	O
that	O
highly	O
conserved	O
residuals	O
Y751	O
,	O
D950	O
and	O
F1004	O
in	O
the	O
PDE	S-geneY-C4-2
families	O
are	O
key	O
residues	O
for	O
binding	O
of	O
both	O
substrate	O
and	O
inhibitors	O
,	O
and	O
nonconserved	O
T844	O
may	O
be	O
responsible	O
for	O
the	O
cilostazol	S-chem-C4-1
selectivity	O
of	O
PDE3A	S-geneY-C4-2
.	O

Detailed	O
knowledge	O
of	O
the	O
structure	O
of	O
inhibitory	O
sites	O
should	O
contribute	O
to	O
development	O
of	O
more	O
potent	O
and	O
specific	O
inhibitory	O
drugs	O
.	O

Inhibition	O
of	O
human	O
breast	O
cancer	O
cell	O
proliferation	O
in	O
tissue	O
culture	O
by	O
the	O
neuroleptic	O
agents	O
pimozide	S-chem
and	O
thioridazine	S-chem
.	O

Permanent	O
cell	O
culture	O
lines	O
derived	O
from	O
human	O
breast	O
cancer	O
tissue	O
are	O
important	O
experimental	O
models	O
in	O
the	O
study	O
of	O
human	O
breast	O
cancer	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
work	O
,	O
pimozide	S-chem
,	O
thioridazine	S-chem
,	O
W	B-chem
-	I-chem
13	E-chem
,	O
and	O
W	B-chem
-	I-chem
12	E-chem
were	O
shown	O
to	O
inhibit	O
MCF	O
-	O
7	O
human	O
breast	O
cancer	O
cell	O
growth	O
.	O

The	O
50	O
%	O
inhibition	O
concentration	O
values	O
determined	O
in	O
two	O
proliferation	O
assays	O
,	O
[	B-chem
3H	I-chem
]	I-chem
thymidine	E-chem
incorporation	O
and	O
cell	O
number	O
,	O
were	O
in	O
close	O
agreement	O
for	O
each	O
compound	O
tested	O
.	O

The	O
order	O
of	O
potency	O
for	O
growth	O
inhibition	O
in	O
the	O
presence	O
of	O
2	O
%	O
stripped	O
calf	O
serum	O
was	O
pimozide	S-chem
(	O
Ki	O
2	O
microM	O
)	O
greater	O
than	O
thioridazine	S-chem
(	O
Ki	O
5	O
microM	O
)	O
greater	O
than	O
W	B-chem
-	I-chem
13	E-chem
(	O
Ki	O
15	O
microM	O
)	O
greater	O
than	O
W	B-chem
-	I-chem
12	E-chem
(	O
Ki	O
39	O
microM	O
)	O
.	O

Similar	O
concentrations	O
of	O
these	O
compounds	O
blocked	O
estradiol	S-chem
-	O
induced	O
growth	O
of	O
MCF	O
-	O
7	O
cells	O
,	O
but	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
interactions	O
do	O
not	O
seem	O
to	O
be	O
involved	O
.	O

Pimozide	S-chem
and	O
thioridazine	S-chem
had	O
no	O
effect	O
on	O
the	O
estradiol	S-chem
binding	O
properties	O
of	O
the	O
MCF	O
-	O
7	O
ER	S-geneY
,	O
nor	O
did	O
pimozide	S-chem
interfere	O
with	O
the	O
induction	O
of	O
progesterone	B-geneY
receptors	E-geneY
by	O
estradiol	S-chem
.	O

Furthermore	O
,	O
pimozide	S-chem
also	O
inhibited	O
incorporation	O
of	O
[	B-chem
3H	I-chem
]	I-chem
thymidine	E-chem
into	O
MCF	O
-	O
7	O
cells	O
stimulated	O
by	O
polypeptide	B-geneN
hormones	E-geneN
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
Ki	O
for	O
pimozide	S-chem
in	O
serum	O
-	O
free	O
medium	O
alone	O
,	O
0.46	O
microM	O
,	O
was	O
similar	O
to	O
that	O
determined	O
in	O
the	O
presence	O
of	O
insulin	S-geneY
(	O
0.42	O
microM	O
)	O
,	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
I	E-geneY
(	O
0.54	O
microM	O
)	O
,	O
and	O
epidermal	B-geneY
growth	I-geneY
factor	E-geneY
(	O
0.43	O
microM	O
)	O
.	O

The	O
effects	O
of	O
pimozide	S-chem
on	O
breast	O
cancer	O
cell	O
growth	O
were	O
not	O
limited	O
to	O
the	O
MCF	O
-	O
7	O
cell	O
line	O
.	O

Pimozide	S-chem
also	O
blocked	O
cell	O
growth	O
and	O
[	B-chem
3H	I-chem
]	I-chem
thymidine	E-chem
incorporation	O
into	O
the	O
ER	S-geneY
-	O
positive	O
T47D	O
and	O
ZR75	O
-	O
1B	O
human	O
breast	O
cancer	O
cell	O
lines	O
and	O
the	O
ER	S-geneY
-	O
negative	O
human	O
breast	O
cancer	O
cell	O
line	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

Although	O
numerous	O
mechanisms	O
of	O
action	O
of	O
pimozide	S-chem-C6-1
and	O
thioridazine	S-chem-C6-1
have	O
been	O
identified	O
,	O
both	O
drugs	O
are	O
calmodulin	S-geneY-C6-2
antagonists	O
at	O
drug	O
concentrations	O
that	O
inhibit	O
breast	O
cancer	O
cell	O
growth	O
in	O
vitro	O
.	O

Inhibition	O
of	O
MCF	O
-	O
7	O
cell	O
growth	O
by	O
the	O
selective	O
calmodulin	S-geneY-C6-2
antagonists	O
W	B-chem-C6-1
-	I-chem-C6-1
13	E-chem-C6-1
and	O
W	B-chem-C6-1
-	I-chem-C6-1
12	E-chem-C6-1
is	O
consistent	O
with	O
a	O
role	O
for	O
calmodulin	S-geneY-C4-2
antagonism	O
in	O
the	O
broad	O
growth	O
-	O
inhibitory	O
properties	O
of	O
pimozide	S-chem-C4-1
.	O

We	O
conclude	O
that	O
pimozide	S-chem
and	O
thioridazine	S-chem
may	O
be	O
useful	O
in	O
the	O
control	O
of	O
estradiol	S-chem
-	O
and	O
polypeptide	B-geneN
hormone	E-geneN
-	O
induced	O
growth	O
of	O
ER	S-geneY
-	O
positive	O
and	O
ER	S-geneY
-	O
negative	O
human	O
breast	O
tumors	O
.	O

Covalent	O
linkage	O
of	O
apolipoprotein	B-geneY
e	E-geneY
to	O
albumin	S-geneY
nanoparticles	O
strongly	O
enhances	O
drug	O
transport	O
into	O
the	O
brain	O
.	O

Drug	O
delivery	O
to	O
the	O
brain	O
is	O
becoming	O
more	O
and	O
more	O
important	O
but	O
is	O
severely	O
restricted	O
by	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Nanoparticles	O
coated	O
with	O
polysorbates	S-chem
have	O
previously	O
been	O
shown	O
to	O
enable	O
the	O
transport	O
of	O
several	O
drugs	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
which	O
under	O
normal	O
circumstances	O
is	O
impermeable	O
to	O
these	O
compounds	O
.	O

Apolipoprotein	B-geneY
E	E-geneY
was	O
suggested	O
to	O
mediate	O
this	O
drug	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

In	O
the	O
present	O
study	O
,	O
apolipoprotein	B-geneY
E	E-geneY
was	O
coupled	O
by	O
chemical	O
methods	O
to	O
nanoparticles	O
made	O
of	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
HSA	S-geneY
-	O
NP	O
)	O
.	O

Loperamide	S-chem
,	O
which	O
does	O
not	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
but	O
exerts	O
antinociceptive	O
effects	O
after	O
direct	O
injection	O
into	O
the	O
brain	O
,	O
was	O
used	O
as	O
model	O
drug	O
.	O

Apolipoprotein	B-geneY
E	E-geneY
was	O
chemically	O
bound	O
via	O
linkers	O
to	O
loperamide	S-chem
-	O
loaded	O
HSA	S-geneY
-	O
NP	O
.	O

This	O
preparation	O
induced	O
antinociceptive	O
effects	O
in	O
the	O
tail	O
-	O
flick	O
test	O
in	O
ICR	O
mice	O
after	O
i.v	O
.	O
injection	O
.	O

In	O
contrast	O
,	O
nanoparticles	O
linked	O
to	O
apolipoprotein	B-geneY
E	E-geneY
variants	O
that	O
do	O
not	O
recognize	O
lipoprotein	B-geneN
receptors	E-geneN
failed	O
to	O
induce	O
these	O
effects	O
.	O

These	O
results	O
indicate	O
that	O
apolipoprotein	B-geneY
E	E-geneY
attached	O
to	O
the	O
surface	O
of	O
nanoparticles	O
facilitates	O
transport	O
of	O
drugs	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
probably	O
after	O
interaction	O
with	O
lipoprotein	B-geneN
receptors	E-geneN
on	O
the	O
brain	O
capillary	O
endothelial	O
cell	O
membranes	O
.	O

Structural	O
Basis	O
for	O
the	O
ATP	S-chem
-	O
Induced	O
Isomerization	O
of	O
Kinesin	S-geneN
.	O

Kinesin	B-geneN
superfamily	I-geneN
proteins	E-geneN
(	O
KIFs	S-geneN
)	O
are	O
microtubule	B-geneN
-	I-geneN
based	I-geneN
molecular	I-geneN
motors	E-geneN
driven	O
by	O
the	O
energy	O
derived	O
from	O
the	O
hydrolysis	O
of	O
ATP	S-chem
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
the	O
ATP	S-chem
binding	O
step	O
is	O
crucial	O
both	O
for	O
the	O
power	O
stroke	O
to	O
produce	O
motility	O
and	O
for	O
the	O
inter	O
-	O
domain	O
regulation	O
of	O
ATPase	S-geneN
activity	O
to	O
guarantee	O
the	O
processive	O
movement	O
of	O
dimeric	O
KIFs	S-geneN
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
crystal	O
structure	O
of	O
KIF4	S-geneY
complexed	O
with	O
the	O
non	O
-	O
hydrolyzable	O
ATP	S-chem
analog	O
,	O
AMPPNP	S-chem
(	O
adenylyl	B-chem
imidodiphosphate	E-chem
)	O
,	O
at	O
1.7Å	O
resolution	O
.	O

By	O
combining	O
our	O
structure	O
with	O
previously	O
solved	O
KIF1A	S-geneY
structures	O
complexed	O
with	O
two	O
ATP	S-chem
analogs	O
,	O
molecular	O
snapshots	O
during	O
ATP	S-chem
binding	O
reveal	O
that	O
the	O
closure	O
of	O
the	O
nucleotide	S-chem
-	O
binding	O
pocket	O
during	O
ATP	S-chem
binding	O
is	O
achieved	O
by	O
closure	O
of	O
the	O
backdoor	O
.	O

Closure	O
of	O
the	O
backdoor	O
stabilizes	O
two	O
mobile	O
regions	O
,	O
switch	O
I	O
and	O
switch	O
II	O
,	O
to	O
generate	O
the	O
phosphate	S-chem
tube	O
from	O
which	O
hydrolyzed	O
phosphate	S-chem
is	O
released	O
.	O

Through	O
the	O
stabilization	O
of	O
switch	O
II	O
,	O
the	O
local	O
conformational	O
change	O
at	O
the	O
catalytic	O
center	O
is	O
further	O
relayed	O
to	O
the	O
neck	O
-	O
linker	O
element	O
that	O
fully	O
docks	O
to	O
the	O
catalytic	O
core	O
to	O
produce	O
the	O
power	O
stroke	O
.	O

Because	O
the	O
neck	O
linker	O
is	O
a	O
sole	O
element	O
that	O
connects	O
the	O
partner	O
heads	O
in	O
dimeric	O
KIFs	S-geneN
,	O
this	O
tight	O
structural	O
coordination	O
between	O
the	O
catalytic	O
center	O
and	O
neck	O
linker	O
enables	O
inter	O
-	O
domain	O
communication	O
between	O
the	O
partner	O
heads	O
.	O

This	O
study	O
also	O
revealed	O
the	O
putative	O
microtubule	B-geneN
-	I-geneN
binding	I-geneN
site	E-geneN
of	O
KIF4	S-geneY
,	O
thus	O
providing	O
structural	O
insights	O
that	O
describe	O
the	O
specific	O
binding	O
of	O
KIF4	S-geneY
to	O
the	O
microtubule	O
.	O

A	O
novel	O
method	O
for	O
preparing	O
complete	O
antigens	O
of	O
gonyautoxin	B-chem
2,3	E-chem
and	O
their	O
feature	O
of	O
immunogenicity	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
method	O
was	O
proposed	O
to	O
prepare	O
artificial	O
antigens	O
of	O
gonyaulax	O
parlaytic	O
shellfish	O
toxin	O
2	O
and	O
3	O
(	O
GTX2,3	S-chem
)	O
.	O

An	O
intermediate	O
GTX2,3	B-chem
-	I-chem
aldehyde	E-chem
was	O
first	O
synthesized	O
by	O
activating	O
the	O
NH2	S-chem
group	O
of	O
the	O
2nd	O
and	O
8th	O
amino	B-chem
acid	E-chem
residues	O
with	O
three	O
different	O
aldehydes	S-chem
and	O
two	O
artificial	O
complete	O
antigens	O
GTX2,3	B-chem
-	I-chem
aldehyde	E-chem
-	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
BSA	S-geneY
)	O
and	O
GTX2,3	B-chem
-	I-chem
aldehyde	E-chem
-	O
keyhole	B-geneN
limpet	I-geneN
hemocyanin	E-geneN
(	O
KLH	S-geneN
)	O
were	O
then	O
prepared	O
by	O
cross	O
-	O
linking	O
the	O
intermediate	O
with	O
BSA	S-geneY
or	O
KLH	S-geneN
.	O

The	O
successful	O
preparation	O
of	O
the	O
two	O
complete	O
antigens	O
was	O
confirmed	O
by	O
UV	O
spectral	O
scanning	O
,	O
HPLC	O
,	O
production	O
of	O
antibodies	O
with	O
titer	O
of	O
1.28	O
×	O
10	O
(	O
4	O
)	O
from	O
mice	O
immunized	O
with	O
the	O
two	O
complete	O
antigens	O
,	O
indirect	O
ELISA	O
and	O
Western	O
-	O
blot	O
.	O

In	O
conclusion	O
,	O
the	O
synthesized	O
complete	O
antigens	O
have	O
strong	O
immunogenicity	O
,	O
which	O
provides	O
a	O
solid	O
foundation	O
for	O
preparing	O
GTX2,3	S-chem
monoclonal	O
antibody	O
and	O
rapid	O
detection	O
kit	O
.	O

Eprosartan	S-chem
for	O
the	O
treatment	O
of	O
hypertension	O
.	O

Antihypertensive	O
agents	O
are	O
proven	O
to	O
reduce	O
the	O
cardiovascular	O
risk	O
of	O
stroke	O
,	O
coronary	O
heart	O
disease	O
and	O
cardiac	O
failure	O
.	O

The	O
ideal	O
antihypertensive	O
agent	O
should	O
control	O
all	O
grades	O
of	O
hypertension	O
and	O
have	O
a	O
placebo	O
-	O
like	O
side	O
effect	O
profile	O
.	O

Angiotensin	B-geneN
II	I-geneN
(	I-geneN
AII	I-geneN
)	I-geneN
receptor	E-geneN
antagonists	O
are	O
a	O
relatively	O
new	O
class	O
of	O
antihypertensive	O
agent	O
that	O
block	O
AII	B-geneY
Type	I-geneY
1	I-geneY
(	I-geneY
AT	I-geneY
(	I-geneY
1	I-geneY
)	I-geneY
)	I-geneY
receptors	E-geneY
,	O
and	O
reduce	O
the	O
pressor	O
effects	O
of	O
AII	S-geneY
in	O
the	O
vasculature	O
.	O

By	O
this	O
mechanism	O
,	O
they	O
induce	O
similar	O
pharmacological	O
effects	O
compared	O
with	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
(	O
ACE	S-geneY
)	O
inhibitors	O
,	O
resulting	O
in	O
a	O
lowering	O
of	O
blood	O
pressure	O
.	O

However	O
,	O
AII	B-geneN
receptor	E-geneN
blockers	O
differ	O
from	O
ACE	S-geneY
inhibitors	O
with	O
respect	O
to	O
side	O
effects	O
,	O
and	O
induce	O
less	O
cough	O
,	O
a	O
side	O
effect	O
which	O
may	O
be	O
related	O
to	O
bradykinin	S-geneY
or	O
other	O
mediators	O
such	O
as	O
substance	B-chem
P	E-geneY
.	O

Within	O
the	O
class	O
of	O
AII	S-geneY-C4-2
blockers	O
,	O
eprosartan	S-chem-C4-1
differs	O
from	O
other	O
currently	O
available	O
agents	O
in	O
terms	O
of	O
chemical	O
structure	O
,	O
as	O
it	O
is	O
a	O
non	O
-	O
biphenyl	S-chem
,	O
non	O
-	O
tetrazole	S-chem
,	O
non	O
-	O
peptide	O
antagonist	O
with	O
a	O
dual	O
pharmacological	O
mode	O
of	O
action	O
.	O

Eprosartan	S-chem
acts	O
at	O
vascular	O
AT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptors	E-geneY
(	O
postsynaptically	O
)	O
and	O
at	O
presynaptic	O
AT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptors	E-geneY
,	O
where	O
it	O
inhibits	O
sympathetically	O
stimulated	O
noradrenaline	S-chem
release	O
.	O

Its	O
lack	O
of	O
metabolism	O
by	O
cytochrome	B-geneN
P450	E-geneN
enzymes	O
confers	O
a	O
low	O
potential	O
for	O
metabolic	O
drug	O
interactions	O
and	O
may	O
be	O
of	O
importance	O
when	O
treating	O
elderly	O
patients	O
and	O
those	O
on	O
multiple	O
drugs	O
.	O

In	O
clinical	O
trials	O
,	O
eprosartan	S-chem
has	O
been	O
demonstrated	O
to	O
be	O
at	O
least	O
as	O
effective	O
in	O
reducing	O
blood	O
pressure	O
as	O
the	O
ACE	S-geneY-C4-2
inhibitor	O
enalapril	S-chem-C4-1
,	O
and	O
has	O
significantly	O
lower	O
side	O
effects	O
.	O

Eprosartan	S-chem
is	O
safe	O
,	O
effective	O
and	O
well	O
-	O
tolerated	O
in	O
long	O
-	O
term	O
treatment	O
,	O
either	O
as	O
a	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
antihypertensive	O
drugs	O
such	O
as	O
hydrochlorothiazide	S-chem
.	O

Ocular	O
beta	O
-	O
blockers	O
in	O
glaucoma	O
management	O
.	O
Clinical	O
pharmacological	O
aspects	O
.	O

Topical	O
beta	O
-	O
blockers	O
reduce	O
the	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
by	O
blockade	O
of	O
sympathetic	O
nerve	O
endings	O
in	O
the	O
ciliary	O
epithelium	O
causing	O
a	O
fall	O
in	O
aqueous	O
humour	O
production	O
.	O

Two	O
types	O
of	O
topical	O
beta	O
-	O
blockers	O
are	O
available	O
for	O
use	O
in	O
glaucoma	O
:	O
nonselective	O
,	O
which	O
block	O
both	O
beta	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
;	O
and	O
cardioselective	O
,	O
which	O
block	O
only	O
beta	B-geneY
1	I-geneY
-	I-geneY
receptors	E-geneY
.	O

Of	O
the	O
beta	O
-	O
Blockers	O
commercially	O
available	O
,	O
timolol	S-chem
,	O
levobunolol	S-chem
,	O
metipranolol	S-chem
and	O
carteolol	S-chem
are	O
nonselective	O
,	O
and	O
betaxolol	S-chem
is	O
cardioselective	O
.	O

Twice	O
-	O
daily	O
timolol	S-chem
is	O
probably	O
the	O
most	O
effective	O
agent	O
in	O
lowering	O
IOP	O
,	O
although	O
levobunolol	S-chem
is	O
equally	O
effective	O
and	O
can	O
be	O
used	O
once	O
daily	O
with	O
little	O
difference	O
in	O
effect	O
.	O

Carteolol	S-chem
is	O
used	O
twice	O
daily	O
and	O
any	O
theoretical	O
advantage	O
in	O
diminished	O
side	O
effects	O
conferred	O
by	O
its	O
partial	O
beta	O
-	O
agonist	O
activity	O
compared	O
with	O
timolol	S-chem
has	O
not	O
been	O
fully	O
substantiated	O
.	O

Metipranolol	S-chem
is	O
effective	O
twice	O
daily	O
and	O
does	O
not	O
have	O
partial	O
beta	O
-	O
agonist	O
activity	O
.	O

Betaxolol	S-chem
has	O
an	O
effect	O
comparable	O
to	O
timolol	S-chem
in	O
lowering	O
IOP	O
,	O
but	O
is	O
less	O
effective	O
in	O
some	O
patients	O
.	O
beta	O
-	O
Blockers	O
can	O
be	O
used	O
with	O
other	O
antiglaucoma	O
medications	O
,	O
but	O
their	O
combined	O
action	O
with	O
epinephrine	S-chem
(	O
adrenaline	S-chem
)	O
is	O
suspect	O
,	O
particularly	O
in	O
the	O
case	O
of	O
the	O
nonselective	O
beta	O
-	O
blockers	O
,	O
and	O
the	O
effect	O
should	O
be	O
assessed	O
in	O
patients	O
on	O
an	O
individual	O
basis	O
.	O

Local	O
stinging	O
can	O
be	O
a	O
problem	O
in	O
some	O
patients	O
with	O
betaxolol	S-chem
.	O

The	O
most	O
serious	O
side	O
effects	O
of	O
beta	O
-	O
blockers	O
are	O
the	O
exacerbation	O
of	O
chronic	O
obstructive	O
airways	O
disease	O
with	O
nonselective	O
agents	O
and	O
the	O
precipitation	O
of	O
bronchospasm	O
in	O
some	O
patients	O
.	O

Betaxolol	S-chem
seems	O
relatively	O
free	O
of	O
adverse	O
respiratory	O
effects	O
,	O
although	O
this	O
may	O
be	O
dose	O
-	O
related	O
and	O
extreme	O
caution	O
should	O
still	O
be	O
exercised	O
in	O
patients	O
with	O
any	O
history	O
of	O
respiratory	O
illness	O
.	O

Because	O
of	O
the	O
lower	O
risk	O
of	O
precipitating	O
side	O
effects	O
,	O
betaxolol	S-chem
is	O
probably	O
the	O
beta	O
-	O
blocker	O
of	O
first	O
choice	O
for	O
use	O
in	O
glaucoma	O
;	O
timolol	S-chem
or	O
levobunolol	S-chem
are	O
reserved	O
for	O
patients	O
who	O
do	O
not	O
respond	O
satisfactorily	O
to	O
betaxolol	S-chem
and	O
are	O
quite	O
free	O
of	O
respiratory	O
disease	O
.	O

Activity	O
of	O
ponatinib	S-chem
against	O
clinically	O
-	O
relevant	O
AC220	S-chem
-	O
resistant	O
kinase	B-geneN
domain	E-geneN
mutants	O
of	O
FLT3	S-geneY
-	O
ITD	O
.	O

Secondary	O
point	O
mutations	O
in	O
the	O
Fms	B-geneN
-	I-geneN
like	I-geneN
tyrosine	I-geneN
kinase	I-geneN
3	I-geneN
(	I-geneN
FLT3	I-geneN
)	I-geneN
tyrosine	I-geneN
kinase	I-geneN
domain	E-geneN
(	O
KD	S-geneN
)	O
are	O
common	O
causes	O
of	O
acquired	O
clinical	O
resistance	O
to	O
the	O
FLT3	S-geneY-C4-2
inhibitors	O
AC220	S-chem-C4-1
(	O
quizartinib	S-chem-C4-1
)	O
and	O
sorafenib	S-chem-C4-1
.	O

Ponatinib	S-chem-C4-1
(	O
AP24534	S-chem-C4-1
)	O
is	O
a	O
multikinase	S-geneN-C4-2
inhibitor	O
with	O
in	O
vitro	O
and	O
clinical	O
activity	O
in	O
tyrosine	B-geneN
kinase	E-geneN
inhibitor	O
(	O
TKI	O
)	O
-	O
resistant	O
chronic	O
myeloid	O
leukemia	O
,	O
irrespective	O
of	O
BCR	B-geneN
-	I-geneN
ABL	I-geneN
KD	E-geneN
mutation	O
.	O

Ponatinib	S-chem
has	O
demonstrated	O
early	O
clinical	O
efficacy	O
in	O
chemotherapy	O
-	O
resistant	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
patients	O
with	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
mutations	O
in	O
FLT3	S-geneY
.	O

We	O
assessed	O
the	O
in	O
vitro	O
activity	O
of	O
ponatinib	S-chem
against	O
clinically	O
relevant	O
FLT3	S-geneY
-	O
ITD	O
mutant	O
isoforms	O
that	O
confer	O
resistance	O
to	O
AC220	S-chem
or	O
sorafenib	S-chem
.	O

Substitution	O
of	O
the	O
FLT3	S-geneY
``	O
gatekeeper	O
``	B-chem
phenylalanine	O
with	O
leucine	O
(	I-geneN
F691L	O
)	O
conferred	O
mild	O
resistance	O
to	B-chem
ponatinib	O
,	O
but	O
substitutions	O
at	O
the	O
FLT3	I-geneN
activation	I-geneN
loop	O
(	E-geneN
AL	O
)	O
residue	O
D835	O
conferred	O
a	O
high	O
degree	O
of	O
resistance	O
.	O

Saturation	O
mutagenesis	O
of	O
FLT3	S-geneY
-	O
ITD	O
exclusively	O
identified	O
FLT3	S-geneY
AL	O
mutations	O
at	O
positions	O
D835	O
,	O
D839	O
,	O
and	O
Y842	O
.	O

The	O
switch	O
control	O
inhibitor	O
DCC	B-chem
-	I-chem
2036	E-chem
was	O
similarly	O
inactive	O
against	O
FLT3	S-geneY
AL	O
mutations	O
.	O

On	O
the	O
basis	O
of	O
its	O
in	O
vitro	O
activity	O
against	O
FLT3	S-geneY
TKI	O
-	O
resistant	O
F691	O
substitutions	O
,	O
further	O
clinical	O
evaluation	O
of	O
ponatinib	S-chem
in	O
TKI	O
-	O
naive	O
and	O
select	O
TKI	O
-	O
resistant	O
FLT3	S-geneY
-	O
ITD	O
+	O
AML	O
patients	O
is	O
warranted	O
.	O

Alternative	O
strategies	O
will	O
be	O
required	O
for	O
patients	O
with	O
TKI	O
-	O
resistant	O
FLT3	S-geneY
-	O
ITD	O
D835	O
mutations	O
.	O

Glutathione	B-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
polymorphisms	O
,	O
cruciferous	O
vegetable	O
intake	O
and	O
cancer	O
risk	O
in	O
the	O
Central	O
and	O
Eastern	O
European	O
Kidney	O
Cancer	O
Study	O
.	O

High	O
consumption	O
of	O
cruciferous	O
vegetables	O
has	O
been	O
associated	O
with	O
reduced	O
kidney	O
cancer	O
risk	O
in	O
many	O
studies	O
.	O

Isothiocyanates	S-chem
,	O
thought	O
to	O
be	O
responsible	O
for	O
the	O
chemopreventive	O
properties	O
of	O
this	O
food	O
group	O
,	O
are	O
conjugated	O
to	O
glutathione	S-chem
by	O
glutathione	B-geneN
S	I-geneN
-	I-geneN
transferases	E-geneN
(	O
GSTs	S-geneN
)	O
before	O
urinary	O
excretion	O
.	O

Modification	O
of	O
this	O
relationship	O
by	O
host	O
genetic	O
factors	O
is	O
unknown	O
.	O

We	O
investigated	O
cruciferous	O
vegetable	O
intake	O
in	O
1097	O
cases	O
and	O
1555	O
controls	O
enrolled	O
in	O
a	O
multicentric	O
case	O
-	O
control	O
study	O
from	O
the	O
Czech	O
Republic	O
,	O
Poland	O
,	O
Romania	O
and	O
Russia	O
.	O

To	O
assess	O
possible	O
gene	O
-	O
diet	O
interactions	O
,	O
genotyped	O
cases	O
(	O
N	O
=	O
925	O
)	O
and	O
controls	O
(	O
N	O
=	O
1247	O
)	O
for	O
selected	O
functional	O
or	O
non	O
-	O
synonymous	O
polymorphisms	O
including	O
the	O
GSTM1	S-geneY
deletion	O
,	O
GSTM3	S-geneY
3	O
bp	O
deletion	O
(	O
IVS6	O
+	O
22	O
-	O
AGG	O
)	O
and	O
V224I	S-geneN
G	B-geneN
>	I-geneN
A	E-geneN
substitution	O
,	O
GSTT1	S-geneY
deletion	O
and	O
the	O
GSTP1	S-geneY
I105V	S-geneN
A	B-geneN
>	I-geneN
G	E-geneN
substitution	O
.	O

The	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
low	O
(	O
less	O
than	O
once	O
per	O
month	O
)	O
versus	O
high	O
(	O
at	O
least	O
once	O
per	O
week	O
)	O
intake	O
of	O
cruciferous	O
vegetables	O
was	O
1.29	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.02	O
-	O
1.62	O
;	O
P	O
-	O
trend	O
=	O
0.03	O
]	O
.	O

When	O
low	O
intake	O
of	O
cruciferous	O
vegetables	O
(	O
less	O
than	O
once	O
per	O
month	O
)	O
was	O
stratified	O
by	O
GST	S-geneN
genotype	O
,	O
higher	O
kidney	O
cancer	O
risks	O
were	O
observed	O
among	O
individuals	O
with	O
the	O
GSTT1	S-geneY
null	O
(	O
OR	O
=	O
1.86	O
;	O
95	O
%	O
CI	O
:	O
1.07	O
-	O
3.23	O
;	O
P	O
-	O
interaction	O
=	O
0.05	O
)	O
or	O
with	O
both	O
GSTM1	B-geneN
/	I-geneN
T1	E-geneN
null	O
genotypes	O
(	O
OR	O
=	O
2.49	O
;	O
95	O
%	O
CI	O
:	O
1.08	O
-	O
5.77	O
;	O
P	O
-	O
interaction	O
=	O
0.05	O
)	O
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
role	O
of	O
cruciferous	O
vegetables	O
in	O
cancer	O
prevention	O
among	O
individuals	O
with	O
common	O
,	O
functional	O
genetic	O
polymorphisms	O
.	O

Expressions	O
and	O
mechanical	O
functions	O
of	O
alpha1	B-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
in	O
hamster	O
ureter	O
.	O

We	O
characterized	O
the	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
in	O
hamster	O
ureters	O
according	O
to	O
gene	O
and	O
protein	O
expressions	O
and	O
contractile	O
function	O
.	O

Real	O
-	O
time	O
quantitative	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemical	O
analysis	O
were	O
performed	O
to	O
determine	O
mRNA	O
levels	O
and	O
receptor	O
protein	O
expressions	O
respectively	O
,	O
for	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
,	I-geneN
alpha	I-geneN
(	I-geneN
1B	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1D	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
hamster	O
ureteral	O
smooth	O
muscle	O
.	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
Adrenoceptor	E-geneN
antagonists	O
were	O
tested	O
against	O
the	O
phenylephrine	S-chem-C5-1
(	O
alpha	B-geneN-C5-2
(	I-geneN-C5-2
1	I-geneN-C5-2
)	I-geneN-C5-2
-	I-geneN-C5-2
adrenoceptor	E-geneN-C5-2
agonist	O
)	O
-	O
induced	O
contraction	O
in	O
isolated	O
hamster	O
ureteral	O
preparations	O
using	O
a	O
functional	O
experimental	O
approach	O
.	O

In	O
the	O
smooth	O
muscle	O
,	O
relative	O
mRNA	O
expression	O
levels	O
for	O
alpha	B-geneN
(	I-geneN
1a	I-geneN
)	I-geneN
-	I-geneN
,	I-geneN
alpha	I-geneN
(	I-geneN
1b	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1d	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
were	O
10.7	O
%	O
,	O
1.2	O
%	O
and	O
88.1	O
%	O
,	O
respectively	O
,	O
and	O
protein	O
expressions	O
were	O
identified	O
for	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1D	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
immunohistochemically	O
.	O

Noradrenaline	S-chem-C5-1
and	O
phenylephrine	S-chem-C5-1
(	O
alpha	B-geneN-C5-2
(	I-geneN-C5-2
1	I-geneN-C5-2
)	I-geneN-C5-2
-	I-geneN-C5-2
adrenoceptor	E-geneN-C5-2
agonist	O
)	O
each	O
produced	O
a	O
concentration	O
-	O
dependent	O
tonic	O
contraction	O
,	O
their	O
pD	O
(	O
2	O
)	O
values	O
being	O
6.87	O
+	O
/	O
-	O
0.08	O
and	O
6.10	O
+	O
/	O
-	O
0.05	O
,	O
respectively	O
.	O

Prazosin	S-chem-C6-1
(	O
nonselective	O
alpha	B-geneN-MU-2
(	I-geneN-MU-2
1	I-geneN-MU-2
)	I-geneN-MU-2
-	I-geneN-MU-2
adrenoceptor	E-geneN-MU-2
antagonist	O
)	O
,	O
silodosin	S-chem-C6-1
(	O
selective	O
alpha	B-geneN-MU-2
(	I-geneN-MU-2
1A	I-geneN-MU-2
)	I-geneN-MU-2
-	I-geneN-MU-2
adrenoceptor	E-geneN-MU-2
antagonist	O
)	O
and	O
BMY	B-chem-C6-1
-	I-chem-C6-1
7378	E-chem-C6-1
(	O
8	B-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
methoxyphenyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
1	I-chem-C6-1
-	I-chem-C6-1
piperazinyl	I-chem-C6-1
]	I-chem-C6-1
ethyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
8	I-chem-C6-1
-	I-chem-C6-1
azaspiro	I-chem-C6-1
[	I-chem-C6-1
4.5	I-chem-C6-1
]	I-chem-C6-1
decane	I-chem-C6-1
-	I-chem-C6-1
7,9	I-chem-C6-1
-	I-chem-C6-1
dione	I-chem-C6-1
dihydrochloride	E-chem-C6-1
)	O
(	O
selective	O
alpha	B-geneN-MU-2
(	I-geneN-MU-2
1D	I-geneN-MU-2
)	I-geneN-MU-2
-	I-geneN-MU-2
adrenoceptor	E-geneN-MU-2
antagonist	O
)	O
competitively	O
antagonized	O
the	O
phenylephrine	S-chem-C5-1
-	O
induced	O
contraction	O
(	O
pA	O
(	O
2	O
)	O
values	O
,	O
8.60	O
+	O
/	O
-	O
0.07	O
,	O
9.44	O
+	O
/	O
-	O
0.06	O
and	O
5.75	O
+	O
/	O
-	O
0.07	O
,	O
respectively	O
)	O
.	O

Chloroethylclonidine	S-chem
(	O
3x10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
or	O
more	O
)	O
produced	O
a	O
rightward	O
shift	O
in	O
the	O
concentration	O
-	O
response	O
curve	O
for	O
phenylephrine	S-chem
.	O

Thus	O
,	O
in	O
hamster	O
ureters	O
,	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1D	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
were	O
more	O
prevalent	O
than	O
the	O
alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
,	O
with	O
contraction	O
being	O
mediated	O
mainly	O
via	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

If	O
these	O
findings	O
hold	O
true	O
for	O
humans	O
,	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
could	O
become	O
useful	O
medication	O
for	O
stone	O
passage	O
in	O
urolithiasis	O
patients	O
.	O

Effect	O
of	O
enzymatically	O
modified	O
isoquercitrin	S-chem
on	O
preneoplastic	O
liver	O
cell	O
lesions	O
induced	O
by	O
thioacetamide	S-chem
promotion	O
in	O
a	O
two	O
-	O
stage	O
hepatocarcinogenesis	O
model	O
using	O
rats	O
.	O

To	O
investigate	O
the	O
protective	O
effect	O
of	O
enzymatically	O
modified	O
isoquercitrin	S-chem
(	O
EMIQ	O
)	O
on	O
the	O
hepatocarcinogenic	O
process	O
,	O
we	O
used	O
a	O
two	O
-	O
stage	O
hepatocarcinogenesis	O
model	O
in	O
N	B-chem
-	I-chem
diethylnitrosamine	E-chem
-	O
initiated	O
and	O
thioacetamide	S-chem
(	O
TAA	S-chem
)	O
-	O
promoted	O
rats	O
.	O

We	O
examined	O
the	O
modifying	O
effect	O
of	O
co	O
-	O
administration	O
with	O
EMIQ	O
on	O
the	O
liver	O
tissue	O
environment	O
including	O
hepatic	O
macrophages	O
and	O
lymphocytes	O
and	O
on	O
the	O
induction	O
mechanism	O
of	O
preneoplastic	O
cell	O
apoptosis	O
during	O
early	O
stages	O
of	O
hepatocellular	O
tumor	O
promotion	O
.	O

TAA	S-chem-C3-1
increased	O
the	O
number	O
and	O
area	O
of	O
glutathione	B-geneN-C3-2
S	I-geneN-C3-2
-	I-geneN-C3-2
transferase	I-geneN-C3-2
placental	I-geneN-C3-2
form	E-geneN-C3-2
(	O
GST	B-geneN-C3-2
-	I-geneN-C3-2
P	E-geneN-C3-2
)	O
(	O
+	O
)	O
liver	O
cell	O
foci	O
and	O
the	O
numbers	O
of	O
proliferating	O
and	O
apoptotic	O
cells	O
in	O
randomly	O
selected	O
areas	O
in	O
liver	O
sections	O
.	O

Co	O
-	O
administration	O
with	O
EMIQ	O
suppressed	O
these	O
effects	O
.	O

TAA	S-chem-C4-1
also	O
increased	O
the	O
numbers	O
of	O
ED2	O
(	O
+	O
)	O
,	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
+	O
)	O
,	O
and	O
heme	B-geneY-C4-2
oxygenase	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
+	O
)	O
liver	O
cells	O
,	O
as	O
well	O
as	O
the	O
number	O
of	O
CD3	S-geneN-C4-2
(	O
+	O
)	O
lymphocytes	O
.	O

These	O
effects	O
were	O
also	O
suppressed	O
by	O
EMIQ	O
.	O

EMIQ	O
increased	O
liver	O
levels	O
of	O
thiobarbituric	B-chem
acid	E-chem
-	O
reactive	O
substance	O
and	O
8	B-chem
-	I-chem
hydroxydeoxyguanosine	E-chem
,	O
and	O
TUNEL	O
(	O
+	O
)	O
apoptotic	O
cells	O
,	O
death	B-geneY
receptor	I-geneY
5	E-geneY
(	O
DR5	S-geneY
)	O
(	O
+	O
)	O
cells	O
and	O
4	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
2	I-chem
-	I-chem
nonenal	E-chem
(	O
+	O
)	O
cells	O
within	O
GST	B-geneN
-	I-geneN
P	E-geneN
(	O
+	O
)	O
foci	O
.	O

Outside	O
the	O
GST	B-geneN
-	I-geneN
P	E-geneN
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
decreased	O
the	O
numbers	O
of	O
apoptotic	O
cells	O
and	O
DR5	S-geneY
(	O
+	O
)	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
TAA	S-chem
-	O
induced	O
tumor	O
promotion	O
involves	O
activation	O
of	O
hepatic	O
macrophages	O
producing	O
proinflammatory	O
factors	O
.	O

EMIQ	O
may	O
suppress	O
the	O
TAA	S-chem
-	O
induced	O
tumor	O
-	O
promoting	O
activity	O
by	O
an	O
anti	O
-	O
inflammatory	O
mechanism	O
mediated	O
by	O
suppressing	O
the	O
activation	O
of	O
these	O
macrophages	O
.	O

Furthermore	O
,	O
EMIQ	O
may	O
suppress	O
tumor	O
-	O
promoting	O
activity	O
differentially	O
between	O
the	O
inside	O
and	O
outside	O
of	O
GST	B-geneN
-	I-geneN
P	E-geneN
(	O
+	O
)	O
foci	O
.	O

Within	O
GST	B-geneN
-	I-geneN
P	E-geneN
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
facilitates	O
the	O
apoptosis	O
of	O
preneoplastic	O
cells	O
through	O
the	O
upregulation	O
of	O
DR5	S-geneY
.	O

Outside	O
the	O
GST	B-geneN
-	I-geneN
P	E-geneN
(	O
+	O
)	O
foci	O
,	O
EMIQ	O
suppresses	O
apoptosis	O
and	O
the	O
subsequent	O
regeneration	O
of	O
non	O
-	O
transformed	O
liver	O
cells	O
.	O

[	O
A	O
case	O
report	O
of	O
metastatic	O
pancreatic	O
cancer	O
that	O
responded	O
remarkably	O
to	O
the	O
combination	O
of	O
thalidomide	S-chem
,	O
celecoxib	S-chem
and	O
irinotecan	S-chem
]	O
.	O

The	O
prognosis	O
of	O
pancreatic	O
cancer	O
with	O
metastases	O
or	O
recurrence	O
is	O
quite	O
poor	O
.	O

Chemotherapy	O
has	O
not	O
resulted	O
in	O
a	O
significant	O
survival	O
benefit	O
;	O
median	O
survival	O
is	O
3	O
-	O
6	O
months	O
.	O

Various	O
chemotherapeutic	O
agents	O
have	O
been	O
evaluated	O
and	O
the	O
standard	O
chemotherapy	O
of	O
pancreatic	O
cancer	O
is	O
gemcitabine	S-chem
.	O

The	O
response	O
rate	O
,	O
however	O
,	O
is	O
low	O
at	O
13	O
%	O
.	O

Thalidomide	S-chem
and	O
celecoxib	S-chem
have	O
different	O
mechanisms	O
of	O
action	O
and	O
activity	O
in	O
various	O
malignant	O
tumors	O
.	O

Both	O
have	O
been	O
evaluated	O
and	O
shown	O
to	O
demonstrate	O
activity	O
against	O
solid	O
tumors	O
.	O

Thalidomide	S-chem
decreased	O
the	O
stability	O
of	O
TNF	S-geneY
-	O
mRNA	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
mRNA	O
.	O

COX	B-geneY
-	I-geneY
2	E-geneY
is	O
a	O
bifunctional	O
enzyme	O
possessing	O
both	O
cyclooxygenase	S-geneN
and	O
peroxidase	S-geneN
activities	O
.	O

Although	O
celecoxib	S-chem
inhibits	O
PG	O
biosynthesis	O
,	O
most	O
do	O
not	O
affect	O
the	O
peroxidase	S-geneN
activity	O
of	O
COX	S-geneN
,	O
which	O
can	O
generate	O
proximate	O
carcinogens	O
.	O

Because	O
thalidomide	S-chem
does	O
not	O
completely	O
inhibit	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
or	O
PG	O
biosynthesis	O
,	O
a	O
therapeutic	O
strategy	O
combining	O
celecoxib	S-chem
with	O
thalidomide	S-chem
might	O
be	O
more	O
effective	O
than	O
using	O
either	O
agent	O
alone	O
.	O

Differences	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
gemcitabine	S-chem
and	O
irinotecan	S-chem
suggest	O
that	O
a	O
change	O
of	O
gemcitabine	S-chem
to	O
irinotecan	S-chem
could	O
provide	O
clinically	O
efficacious	O
outcomes	O
.	O

In	O
order	O
to	O
accomplish	O
new	O
treatment	O
strategies	O
,	O
we	O
have	O
been	O
using	O
thalidomide	S-chem
,	O
celecoxib	S-chem
and	O
irinotecan	S-chem
in	O
low	O
-	O
doses	O
.	O

We	O
believe	O
this	O
combination	O
represents	O
a	O
viable	O
treatment	O
for	O
patients	O
of	O
pancreatic	O
cancer	O
with	O
recurrence	O
or	O
metastases	O
.	O

Pharmacokinetic	O
,	O
neurochemical	O
,	O
stereological	O
and	O
neuropathological	O
studies	O
on	O
the	O
potential	O
effects	O
of	O
paraquat	S-chem
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
and	O
striatum	O
of	O
male	O
C57BL	O
/	O
6J	O
mice	O
.	O

The	O
pharmacokinetics	O
and	O
neurotoxicity	O
of	O
paraquat	B-chem
dichloride	E-chem
(	O
PQ	O
)	O
were	O
assessed	O
following	O
once	O
weekly	O
administration	O
to	O
C57BL	O
/	O
6J	O
male	O
mice	O
by	O
intraperitoneal	O
injection	O
for	O
1	O
,	O
2	O
or	O
3	O
weeks	O
at	O
doses	O
of	O
10	O
,	O
15	O
or	O
25mg	O
/	O
kg	O
/	O
week	O
.	O

Approximately	O
0.3	O
%	O
of	O
the	O
administered	O
dose	O
was	O
taken	O
up	O
by	O
the	O
brain	O
and	O
was	O
slowly	O
eliminated	O
,	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
3	O
weeks	O
.	O

PQ	O
did	O
not	O
alter	O
the	O
concentration	O
of	O
dopamine	S-chem
(	O
DA	O
)	O
,	O
homovanillic	B-chem
acid	E-chem
(	O
HVA	S-chem
)	O
or	O
3,4	B-chem
-	I-chem
dihydroxyphenylacetic	I-chem
acid	E-chem
(	O
DOPAC	S-chem
)	O
,	O
or	O
increase	O
dopamine	S-chem
turnover	O
in	O
the	O
striatum	O
.	O

There	O
was	O
inconsistent	O
stereological	O
evidence	O
of	O
a	O
loss	O
of	O
DA	O
neurons	O
,	O
as	O
identified	O
by	O
chromogenic	O
or	O
fluorescent	O
-	O
tagged	O
antibodies	O
to	O
tyrosine	B-geneY
hydroxylase	E-geneY
in	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNpc	O
)	O
.	O

There	O
was	O
no	O
evidence	O
that	O
PQ	O
induced	O
neuronal	O
degeneration	O
in	O
the	O
SNpc	O
or	O
degenerating	O
neuronal	O
processes	O
in	O
the	O
striatum	O
,	O
as	O
indicated	O
by	O
the	O
absence	O
of	O
uptake	O
of	O
silver	S-chem
stain	O
or	O
reduced	O
immunolabeling	O
of	O
tyrosine	B-geneY
-	I-geneY
hydroxylase	E-geneY
-	O
positive	O
(	O
TH	S-geneY
(	O
+	O
)	O
)	O
neurons	O
.	O

There	O
was	O
no	O
evidence	O
of	O
apoptotic	O
cell	O
death	O
,	O
which	O
was	O
evaluated	O
using	O
TUNEL	O
or	O
caspase	B-geneY
3	E-geneY
assays	O
.	O

Microglia	O
(	O
IBA	O
-	O
1	O
immunoreactivity	O
)	O
and	O
astrocytes	O
(	O
GFAP	O
immunoreactivity	O
)	O
were	O
not	O
activated	O
in	O
PQ	O
-	O
treated	O
mice	O
4	O
,	O
8	O
,	O
16	O
,	O
24	O
,	O
48	O
,	O
96	O
or	O
168h	O
after	O
1	O
,	O
2	O
or	O
3	O
doses	O
of	O
PQ	O
.	O

In	O
contrast	O
,	O
mice	O
dosed	O
with	O
the	O
positive	O
control	O
substance	O
,	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1,2,3,6	I-chem
-	I-chem
tetrahydropyridine	E-chem
(	O
MPTP	S-chem
;	O
10mg	O
/	O
kg	O
/	O
dose×4	O
doses	O
,	O
2h	O
apart	O
)	O
,	O
displayed	O
significantly	O
reduced	O
DA	O
and	O
DOPAC	S-chem
concentrations	O
and	O
increased	O
DA	O
turnover	O
in	O
the	O
striatum	O
7	O
days	O
after	O
dosing	O
.	O

The	O
number	O
of	O
TH	S-geneY
(	O
+	O
)	O
neurons	O
in	O
the	O
SNpc	O
was	O
reduced	O
,	O
and	O
there	O
were	O
increased	O
numbers	O
of	O
degenerating	O
neurons	O
and	O
neuronal	O
processes	O
in	O
the	O
SNpc	O
and	O
striatum	O
.	O

MPTP	S-chem
-	O
mediated	O
cell	O
death	O
was	O
not	O
attributed	O
to	O
apoptosis	O
.	O

MPTP	S-chem
activated	O
microglia	O
and	O
astrocytes	O
within	O
4h	O
of	O
the	O
last	O
dose	O
,	O
reaching	O
a	O
peak	O
within	O
48h	O
.	O

The	O
microglial	O
response	O
ended	O
by	O
96h	O
in	O
the	O
SNpc	O
,	O
but	O
the	O
astrocytic	O
response	O
continued	O
through	O
168h	O
in	O
the	O
striatum	O
.	O

These	O
results	O
bring	O
into	O
question	O
previous	O
published	O
stereological	O
studies	O
that	O
report	O
loss	O
of	O
TH	S-geneY
(	O
+	O
)	O
neurons	O
in	O
the	O
SNpc	O
of	O
PQ	O
-	O
treated	O
mice	O
.	O

This	O
study	O
also	O
suggests	O
that	O
even	O
if	O
the	O
reduction	O
in	O
TH	S-geneY
(	O
+	O
)	O
neurons	O
reported	O
by	O
others	O
occurs	O
in	O
PQ	O
-	O
treated	O
mice	O
,	O
this	O
apparent	O
phenotypic	O
change	O
is	O
unaccompanied	O
by	O
neuronal	O
cell	O
death	O
or	O
by	O
modification	O
of	O
dopamine	S-chem
levels	O
in	O
the	O
striatum	O
.	O

Snake	B-geneN
venom	I-geneN
metalloproteinases	E-geneN
.	O

Recent	O
proteomic	O
analyses	O
of	O
snake	O
venoms	O
show	O
that	O
metalloproteinases	S-geneN
represent	O
major	O
components	O
in	O
most	O
of	O
the	O
Crotalid	O
and	O
Viperid	O
venoms	O
.	O

In	O
this	O
chapter	O
we	O
discuss	O
the	O
multiple	O
activities	O
of	O
the	O
SVMPs	S-geneN
.	O

In	O
addition	O
to	O
hemorrhagic	O
activity	O
,	O
members	O
of	O
the	O
SVMP	S-geneN
family	O
also	O
have	O
fibrin	O
(	O
ogen	O
)	O
olytic	O
activity	O
,	O
act	O
as	O
prothrombin	S-geneY
activators	O
,	O
activate	O
blood	O
coagulation	B-geneY
factor	I-geneY
X	E-geneY
,	O
possess	O
apoptotic	O
activity	O
,	O
inhibit	O
platelet	O
aggregation	O
,	O
are	O
pro	O
-	O
inflammatory	O
and	O
inactivate	O
blood	O
serine	B-geneN
proteinase	E-geneN
inhibitors	O
.	O

Clearly	O
the	O
SVMPs	S-geneN
have	O
multiple	O
functions	O
in	O
addition	O
to	O
their	O
well	O
-	O
known	O
hemorrhagic	O
activity	O
.	O

The	O
realization	O
that	O
there	O
are	O
structural	O
variations	O
in	O
the	O
SVMPs	S-geneN
and	O
the	O
early	O
studies	O
that	O
led	O
to	O
their	O
classification	O
represents	O
an	O
important	O
event	O
in	O
our	O
understanding	O
of	O
the	O
structural	O
forms	O
of	O
the	O
SVMPs	S-geneN
.	O

The	O
SVMPs	S-geneN
were	O
subdivided	O
into	O
the	O
P	O
-	O
I	O
,	O
P	O
-	O
II	O
and	O
P	O
-	O
III	O
protein	O
classes	O
.	O

The	O
noticeable	O
characteristic	O
that	O
distinguished	O
the	O
different	O
classes	O
was	O
their	O
size	O
(	O
molecular	O
weight	O
)	O
differences	O
and	O
domain	O
structure	O
:	O
Class	O
I	O
(	O
P	O
-	O
I	O
)	O
,	O
the	O
small	O
SVMPs	S-geneN
,	O
have	O
molecular	O
masses	O
of	O
20	O
-	O
30	O
kDa	O
,	O
contain	O
only	O
a	O
pro	O
domain	I-geneN
and	O
the	O
proteinase	O
domain	I-geneN
;	E-geneN
Class	O
II	O
(	O
P	O
-	O
II	O
)	O
,	O
the	O
medium	O
size	O
SVMPs	O
,	E-geneN
molecular	O
masses	O
of	O
30	O
-	O
60	O
kDa	O
,	O
contain	O
the	O
pro	O
domain	I-geneN
,	I-geneN
proteinase	O
domain	I-geneN
and	O
disintegrin	O
domain	I-geneN
;	I-geneN
Class	O
III	O
(	O
P	O
-	O
III	O
)	O
,	O
the	O
large	O
SVMPs	O
,	I-geneN
have	O
molecular	O
masses	O
of	O
60	O
-	O
100	O
kDa	O
,	O
contain	O
pro	O
,	B-geneN
proteinase	O
,	I-geneN
disintegrin	O
-	I-geneN
like	I-geneN
and	E-geneN
cysteine	O
-	I-geneN
rich	I-geneN
domain	I-geneN
structure	O
.	O

Another	O
significant	O
advance	O
in	O
the	O
SVMP	S-geneN
field	O
was	O
the	O
characterization	O
of	O
the	O
crystal	O
structure	O
of	O
the	O
first	O
P	B-geneN
-	I-geneN
I	I-geneN
class	I-geneN
SVMP	E-geneN
.	O

The	O
structures	O
of	O
other	O
P	B-geneN
-	I-geneN
I	I-geneN
SVMPs	E-geneN
soon	O
followed	O
and	O
the	O
structures	O
of	O
P	B-geneN
-	I-geneN
III	I-geneN
SVMPs	E-geneN
have	O
also	O
been	O
determined	O
.	O

The	O
active	O
site	O
of	O
the	O
metalloproteinase	B-geneN
domain	E-geneN
has	O
a	O
consensus	O
HEXXHXXGXXHD	S-geneN
sequence	O
and	O
a	O
Met	S-chem
-	O
turn	O
.	O

The	O
``	O
Met	O
-	O
turn	O
``	O
structure	O
contains	O
a	O
conserved	O
Met	O
residue	O
that	O
forms	O
a	O
hydrophobic	O
basement	O
for	O
the	O
three	O
zinc	O
-	O
binding	O
histidines	O
in	O
the	O
consensus	O
sequence	O
.	O

Mitochondrial	B-geneY-C9-2
arginase	I-geneY-C9-2
II	E-geneY-C9-2
modulates	O
nitric	B-chem-C9-1
-	I-chem-C9-1
oxide	E-chem-C9-1
synthesis	O
through	O
nonfreely	O
exchangeable	O
L	B-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
pools	O
in	O
human	O
endothelial	O
cells	O
.	O

Reduced	O
synthesis	O
of	O
nitric	B-chem-C9-1
oxide	E-chem-C9-1
(	O
NO	S-chem-C9-1
)	O
contributes	O
to	O
the	O
endothelial	O
dysfunction	O
and	O
may	O
be	O
related	O
to	O
limited	O
availability	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
,	O
the	O
common	O
substrate	O
of	O
constitutive	B-geneY-C9-2
nitric	I-geneY-C9-2
-	I-geneY-C9-2
oxide	I-geneY-C9-2
synthase	E-geneY-C9-2
(	O
NOS	S-geneN-C9-2
)	O
and	O
cytosolic	O
arginase	B-geneY-C9-2
I	E-geneY-C9-2
and	O
mitochondrial	B-geneY-C9-2
arginase	I-geneY-C9-2
II	E-geneY-C9-2
.	O

To	O
determine	O
whether	O
arginases	S-geneN-C9-2
modulate	O
the	O
endothelial	O
NO	S-chem-C9-1
synthesis	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
competitive	O
arginase	S-geneN-C4-2
inhibitor	O
N	B-chem-C4-1
(	I-chem-C4-1
omega	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
hydroxy	I-chem-C4-1
-	I-chem-C4-1
nor	I-chem-C4-1
-	I-chem-C4-1
L	I-chem-C4-1
-	I-chem-C4-1
arginine	E-chem-C4-1
(	O
Nor	B-chem-C4-1
-	I-chem-C4-1
NOHA	E-chem-C4-1
)	O
on	O
the	O
activity	O
of	O
NOS	S-geneN
,	O
arginases	S-geneN
,	O
and	O
L	B-geneN
-	I-geneN
arginine	I-geneN
transporter	E-geneN
and	O
on	O
NO	S-chem
release	O
at	O
surface	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

In	O
unstimulated	O
cells	O
,	O
Nor	B-chem-C4-1
-	I-chem-C4-1
NOHA	E-chem-C4-1
dose	O
-	O
dependently	O
reduced	O
the	O
arginase	S-geneN-C4-2
activity	O
with	O
maximal	O
inhibition	O
at	O
20	O
microM	O
.	O

When	O
HUVECs	O
were	O
stimulated	O
by	O
thrombin	S-geneY
without	O
extracellular	O
L	B-chem
-	I-chem
arginine	E-chem
,	O
Nor	B-chem-C3-1
-	I-chem-C3-1
NOHA	E-chem-C3-1
dose	O
-	O
dependently	O
increased	O
the	O
NOS	S-geneN-C3-2
activity	O
and	O
the	O
NO	S-chem
release	O
with	O
maximal	O
effects	O
at	O
20	O
microM	O
.	O

Extracellular	O
L	B-chem-C3-1
-	I-chem-C3-1
arginine	E-chem-C3-1
also	O
dose	O
-	O
dependently	O
increased	O
NO	S-chem
release	O
and	O
arginase	S-geneN-C3-2
activity	O
.	O

When	O
HUVECs	O
were	O
stimulated	O
by	O
thrombin	S-geneY
in	O
the	O
presence	O
of	O
100	O
microM	O
L	B-chem
-	I-chem
arginine	E-chem
,	O
NOS	S-geneN
activity	O
and	O
NO	S-chem
release	O
were	O
similar	O
in	O
untreated	O
and	O
Nor	B-chem
-	I-chem
NOHA	E-chem
-	O
treated	O
cells	O
.	O

However	O
,	O
despite	O
activation	O
of	O
L	B-chem
-	I-chem
arginine	E-chem
uptake	O
,	O
the	O
inhibition	O
of	O
arginase	S-geneN-C4-2
activity	O
by	O
Nor	B-chem-C4-1
-	I-chem-C4-1
NOHA	E-chem-C4-1
was	O
still	O
significant	O
.	O

The	O
depletion	O
of	O
freely	O
exchangeable	O
L	B-chem
-	I-chem
arginine	E-chem
pools	O
with	O
extracellular	O
L	B-chem
-	I-chem
lysine	E-chem
did	O
not	O
prevent	O
Nor	B-chem
-	I-chem
NOHA	E-chem
from	O
increasing	O
the	O
NO	S-chem
release	O
.	O

This	O
indicates	O
the	O
presence	O
of	O
pools	O
,	O
which	O
are	O
accessible	O
to	O
NOS	S-geneN
and	O
arginase	S-geneN
,	O
but	O
not	O
exchangeable	O
.	O

Interestingly	O
,	O
the	O
mitochondrial	B-geneY
arginase	I-geneY
II	E-geneY
was	O
constitutively	O
expressed	O
,	O
whereas	O
the	O
cytosolic	O
arginase	B-geneY
I	E-geneY
was	O
barely	O
detectable	O
in	O
HUVECs	O
.	O

These	O
data	O
suggest	O
that	O
endothelial	O
NO	S-chem-C9-1
synthesis	O
depends	O
on	O
the	O
activity	O
of	O
arginase	B-geneY-C9-2
II	E-geneY-C9-2
in	O
mitochondria	O
and	O
l	B-chem
-	I-chem
arginine	E-chem
carriers	O
in	O
cell	O
membrane	O
.	O

In	O
vitro	O
exploration	O
of	O
potential	O
mechanisms	O
of	O
toxicity	O
of	O
the	O
human	O
hepatotoxic	O
drug	O
fenclozic	B-chem
acid	E-chem
.	O

The	O
carboxylic	B-chem
acid	E-chem
NSAID	O
fenclozic	B-chem
acid	E-chem
exhibited	O
an	O
excellent	O
preclinical	O
safety	O
profile	O
and	O
promising	O
clinical	O
efficacy	O
,	O
yet	O
was	O
withdrawn	O
from	O
clinical	O
development	O
in	O
1971	O
due	O
to	O
hepatotoxicity	O
observed	O
in	O
clinical	O
trials	O
.	O

A	O
variety	O
of	O
modern	O
in	O
vitro	O
approaches	O
have	O
been	O
used	O
to	O
explore	O
potential	O
underlying	O
mechanisms	O
.	O

Covalent	O
binding	O
studies	O
were	O
undertaken	O
with	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
-	I-chem
fenclozic	I-chem
acid	E-chem
to	O
investigate	O
the	O
possible	O
role	O
of	O
reactive	O
metabolites	O
.	O

Time	O
-	O
dependent	O
covalent	O
binding	O
to	O
protein	O
was	O
observed	O
in	O
NADPH	S-chem
-	O
supplemented	O
liver	O
microsomes	O
,	O
although	O
no	O
metabolites	O
were	O
detected	O
in	O
these	O
incubations	O
or	O
in	O
reactive	O
metabolite	O
trapping	O
experiments	O
.	O

In	O
human	O
hepatocytes	O
,	O
covalent	O
binding	O
was	O
observed	O
at	O
lower	O
levels	O
than	O
in	O
microsomes	O
and	O
a	O
minor	O
uncharacterizable	O
metabolite	O
was	O
also	O
observed	O
.	O

In	O
addition	O
,	O
covalent	O
binding	O
was	O
observed	O
in	O
incubations	O
undertaken	O
with	O
dog	O
and	O
rat	O
hepatocytes	O
,	O
where	O
a	O
taurine	S-chem
conjugate	O
of	O
the	O
drug	O
was	O
detected	O
.	O

Although	O
an	O
acyl	B-chem
glucuronide	E-chem
metabolite	O
was	O
detected	O
when	O
liver	O
microsomes	O
from	O
human	O
,	O
rat	O
and	O
dog	O
were	O
supplemented	O
with	O
UDPGA	S-chem
,	O
there	O
was	O
no	O
detectable	O
UDPGA	S-chem
-	O
dependent	O
covalent	O
binding	O
.	O

No	O
effects	O
were	O
observed	O
when	O
fenclozic	B-chem-C4-1
acid	E-chem-C4-1
was	O
assessed	O
for	O
P450	S-geneN
-	O
dependent	O
and	O
P450	S-geneN
-	O
independent	O
cytotoxicity	O
to	O
THLE	O
cell	O
lines	O
,	O
time	O
-	O
dependent	O
inhibition	O
of	O
five	O
major	O
human	B-geneN-C4-2
cytochrome	I-geneN-C4-2
P450	E-geneN-C4-2
enzymes	O
,	O
inhibition	O
of	O
the	O
biliary	O
efflux	B-geneN-C4-2
transporters	E-geneN-C4-2
BSEP	S-geneY-C4-2
and	O
MRP2	S-geneY-C4-2
or	O
mitochondrial	O
toxicity	O
to	O
THLE	O
or	O
HepG2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
Phase	O
1	O
bioactivation	O
plays	O
a	O
role	O
in	O
the	O
hepatotoxicity	O
of	O
fenclozic	B-chem
acid	E-chem
and	O
highlight	O
the	O
unique	O
insight	O
into	O
mechanisms	O
of	O
human	O
drug	O
toxicity	O
that	O
can	O
be	O
provided	O
by	O
investigations	O
of	O
biotransformation	O
and	O
covalent	O
binding	O
to	O
proteins	O
.	O

Decitabine	S-chem
-	O
-	O
bedside	O
to	O
bench	O
.	O

PURPOSE	O
OF	O
THE	O
REVIEW	O
:	O
Epigenetic	O
changes	O
marked	O
by	O
DNA	O
methylation	O
are	O
known	O
to	O
contribute	O
to	O
the	O
malignant	O
transformation	O
of	O
cells	O
by	O
silencing	O
critical	O
genes	O
.	O

Decitabine	S-chem-C4-1
inhibits	O
DNA	B-geneN-C4-2
methyltransferase	E-geneN-C4-2
and	O
has	O
shown	O
therapeutic	O
effects	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
.	O

However	O
,	O
the	O
connection	O
between	O
the	O
clinical	O
activity	O
of	O
decitabine	S-chem
and	O
its	O
demethylating	O
activity	O
is	O
not	O
clear	O
.	O

Herein	O
,	O
we	O
summarize	O
the	O
results	O
of	O
recent	O
clinical	O
trials	O
of	O
decitabine	S-chem
in	O
hematologic	O
malignancies	O
,	O
and	O
review	O
the	O
translational	O
research	O
into	O
decitabine	O
's	O
mechanism	O
of	O
clinical	O
activity	O
.	O

RECENT	O
FINDINGS	O
:	O
Low	O
-	O
dose	O
decitabine	S-chem
has	O
been	O
studied	O
recently	O
in	O
multiple	O
clinical	O
trials	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
treatment	O
of	O
myelodysplastic	O
syndromes	O
.	O

Correlative	O
laboratory	O
studies	O
of	O
clinical	O
trials	O
have	O
shown	O
that	O
decitabine	S-chem
induces	O
global	O
hypomethylation	O
as	O
well	O
as	O
hypomethylation	O
of	O
gene	O
-	O
specific	O
promoters	O
and	O
activation	O
of	O
gene	O
expression	O
.	O

Past	O
a	O
given	O
threshold	O
,	O
induction	O
of	O
higher	O
degrees	O
of	O
hypomethylation	O
is	O
not	O
directly	O
associated	O
with	O
a	O
better	O
clinical	O
outcome	O
.	O

Moreover	O
,	O
studies	O
have	O
suggested	O
that	O
patients	O
with	O
promoter	O
hypermethylation	O
of	O
p15	B-geneY
(	I-geneY
INK4B	I-geneY
)	E-geneY
at	O
baseline	O
have	O
paradoxically	O
a	O
lower	O
chance	O
of	O
achieving	O
response	O
than	O
those	O
without	O
hypermethylation	O
.	O

Furthermore	O
,	O
several	O
other	O
genes	O
activated	O
by	O
decitabine	S-chem
were	O
independent	O
of	O
hypomethylation	O
in	O
the	O
promoter	O
regions	O
.	O

CONCLUSION	O
:	O
While	O
at	O
least	O
part	O
of	O
decitabine	O
's	O
activity	O
is	O
through	O
induction	O
of	O
hypomethylation	O
and	O
reactivation	O
of	O
critical	O
genes	O
,	O
mechanisms	O
independent	O
from	O
hypomethylation	O
are	O
also	O
important	O
for	O
decitabine	O
's	O
antitumor	O
activity	O
.	O

In	O
vitro	O
inhibition	O
of	O
diacylglycerol	B-geneY-C4-2
acyltransferase	E-geneY-C4-2
by	O
prenylflavonoids	S-chem-C4-1
from	O
Sophora	O
flavescens	O
.	O

Four	O
prenylflavonoids	S-chem-C4-1
,	O
kurarinone	S-chem-C4-1
(	O
1	O
)	O
,	O
a	O
chalcone	S-chem-C4-1
of	O
1	O
,	O
kuraridin	S-chem-C4-1
(	O
2	O
)	O
,	O
kurarinol	S-chem-C4-1
(	O
3	O
)	O
,	O
kushenol	B-chem-C4-1
H	E-chem-C4-1
(	O
4	O
)	O
and	O
kushenol	B-chem-C4-1
K	E-chem-C4-1
(	O
5	O
)	O
isolated	O
from	O
the	O
roots	O
of	O
Sophora	O
flavescens	O
were	O
investigated	O
for	O
their	O
inhibitory	O
effects	O
on	O
diacylglycerol	B-geneY-C4-2
acyltransferase	E-geneY-C4-2
(	O
DGAT	S-geneY-C4-2
)	O
.	O

The	O
flavonoids	S-chem-C4-1
inhibited	O
DGAT	S-geneY-C4-2
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
IC50	O
values	O
of	O
10.9	O
microM	O
(	O
1	O
)	O
,	O
9.8	O
microM	O
(	O
2	O
)	O
,	O
8.6	O
microM	O
(	O
3	O
)	O
,	O
142.0	O
microM	O
(	O
4	O
)	O
and	O
250	O
microM	O
(	O
5	O
)	O
.	O

The	O
prenylflavonoids	S-chem
without	O
C3	B-chem
-	I-chem
OH	E-chem
(	O
1	O
,	O
2	O
,	O
3	O
)	O
showed	O
stronger	O
inhibition	O
than	O
those	O
with	O
C3	B-chem
-	I-chem
OH	E-chem
(	O
4	O
,	O
5	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
flavonoids	S-chem
without	O
side	O
chains	O
(	O
hesperetin	S-chem
,	O
naringenin	S-chem
,	O
quercetin	S-chem
and	O
kaempferol	S-chem
)	O
did	O
not	O
inhibit	O
the	O
enzyme	O
activity	O
at	O
a	O
final	O
concentration	O
of	O
800	O
microM	O
.	O

These	O
data	O
suggest	O
that	O
the	O
lavandulyl	S-chem-C4-1
side	O
chain	O
and	O
the	O
position	O
of	O
the	O
hydroxy	S-chem-C4-1
group	O
are	O
important	O
for	O
high	O
DGAT	S-geneY-C4-2
inhibitory	O
activity	O
.	O

Compound	O
1	O
also	O
inhibited	O
de	O
novo	O
synthesis	O
of	O
triacylglycerol	S-chem
(	O
TG	S-chem
)	O
in	O
Raji	O
cells	O
.	O

Telmisartan	S-chem-MU-1
downregulates	O
angiotensin	B-geneY-C4-2
II	I-geneY-C4-2
type	I-geneY-C4-2
1	I-geneY-C4-2
receptor	E-geneY-C4-2
through	O
activation	O
of	O
peroxisome	B-geneY-C3-2
proliferator	I-geneY-C3-2
-	I-geneY-C3-2
activated	I-geneY-C3-2
receptor	I-geneY-C3-2
gamma	E-geneY-C3-2
.	O

OBJECTIVE	O
:	O
Telmisartan	S-chem-MU-1
,	O
an	O
angiotensin	B-geneY-C6-2
II	I-geneY-C6-2
type	I-geneY-C6-2
1	I-geneY-C6-2
receptor	E-geneY-C6-2
(	O
AT1R	S-geneY-C6-2
)	O
antagonist	O
,	O
was	O
found	O
to	O
have	O
a	O
unique	O
property	O
:	O
it	O
is	O
a	O
partial	O
agonist	O
of	O
peroxisome	B-geneY-C5-2
proliferator	I-geneY-C5-2
-	I-geneY-C5-2
activated	I-geneY-C5-2
receptor	I-geneY-C5-2
gamma	E-geneY-C5-2
(	O
PPARgamma	S-geneY-C5-2
)	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
PPARgamma	S-geneY
activators	O
suppressed	O
AT1R	S-geneY
expression	O
,	O
we	O
examined	O
whether	O
telmisartan	S-chem
affects	O
AT1R	S-geneY
expression	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

METHODS	O
:	O
Vascular	O
smooth	O
muscle	O
cells	O
were	O
derived	O
from	O
the	O
thoracic	O
aorta	O
of	O
Wistar	O
-	O
Kyoto	O
rat	O
.	O

Northern	O
and	O
Western	O
blotting	O
analysis	O
were	O
used	O
to	O
examine	O
AT1R	S-geneY
mRNA	O
and	O
protein	O
expression	O
,	O
respectively	O
.	O

The	O
DEAE	O
-	O
dextran	O
method	O
was	O
used	O
for	O
transfection	O
,	O
and	O
the	O
promoter	O
activity	O
of	O
AT1R	S-geneY
was	O
examined	O
by	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Telmisartan	S-chem-C4-1
decreased	O
the	O
expression	O
of	O
AT1R	S-geneY-C4-2
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Decreased	O
AT1R	B-geneN
promoter	E-geneN
activity	O
with	O
unchanged	O
mRNA	O
stability	O
suggested	O
that	O
telmisartan	S-chem-C4-1
suppressed	O
AT1R	S-geneY-C4-2
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
.	O

However	O
,	O
the	O
expression	O
of	O
AT1R	S-geneY
was	O
not	O
suppressed	O
by	O
other	O
AT1R	S-geneY-C6-2
antagonists	O
such	O
as	O
candesartan	S-chem-C6-1
or	O
olmesartan	S-chem-C6-1
.	O

Since	O
the	O
suppression	O
of	O
AT1R	S-geneY-C3-2
expression	O
was	O
prevented	O
by	O
pretreatment	O
with	O
GW9662	S-chem-MU-1
,	O
a	O
PPARgamma	S-geneY-C6-2
antagonist	O
,	O
PPARgamma	S-geneY
should	O
have	O
participated	O
in	O
the	O
process	O
.	O

The	O
deletion	O
and	O
mutation	O
analysis	O
of	O
the	O
AT1R	S-geneY-C4-2
gene	O
promoter	O
indicated	O
that	O
a	O
GC	B-geneN-C4-2
box	E-geneN-C4-2
located	O
in	O
the	O
proximal	O
promoter	O
region	O
is	O
responsible	O
for	O
the	O
telmisartan	S-chem-C4-1
-	O
induced	O
downregulation	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
provides	O
a	O
novel	O
insight	O
into	O
an	O
effect	O
of	O
telmisartan	S-chem
:	O
telmisartan	S-chem-MU-1
inhibits	O
AT1R	S-geneY-C4-2
gene	O
expression	O
through	O
PPARgamma	S-geneY-C3-2
activation	O
.	O

The	O
dual	O
inhibition	O
of	O
angiotensin	B-geneY
II	E-geneY
function	O
by	O
telmisartan	O
-	O
AT1R	S-geneY
blockade	O
and	O
downregulation	O
-	O
would	O
contribute	O
to	O
more	O
complete	O
inhibition	O
of	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
system	O
.	O

Wogonin	S-chem-C4-1
inhibits	O
H2O2	S-chem-C3-1
-	O
induced	O
vascular	O
permeability	O
through	O
suppressing	O
the	O
phosphorylation	O
of	O
caveolin	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
.	O

Wogonin	S-chem
,	O
a	O
naturally	O
occurring	O
monoflavonoid	S-chem
extracted	O
from	O
the	O
root	O
of	O
Scutellaria	O
baicalensis	O
Georgi	O
,	O
has	O
been	O
reported	O
for	O
its	O
anti	O
-	O
oxidant	O
activity	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
wogonin	S-chem
can	O
inhibit	O
oxidant	O
-	O
induced	O
vascular	O
permeability	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
wogonin	S-chem
on	O
H2O2	S-chem
-	O
induced	O
vascular	O
permeability	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

We	O
found	O
that	O
wogonin	S-chem-C4-1
can	O
suppress	O
the	O
H2O2	S-chem-C3-1
-	O
stimulated	O
actin	S-geneN-MU-2
remodeling	O
and	O
albumin	S-geneY-MU-2
uptake	O
of	O
HUVECs	O
,	O
as	O
well	O
as	O
transendothelial	O
cell	O
migration	O
of	O
the	O
human	O
breast	O
carcinoma	O
cell	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

The	O
mechanism	O
revealed	O
that	O
wogonin	S-chem-C4-1
inhibited	O
H2O2	S-chem-C3-1
-	O
induced	O
phosphorylation	O
of	O
caveolin	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
(	O
cav	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
)	O
associating	O
with	O
the	O
suppression	O
of	O
stabilization	O
of	O
VE	B-geneY-C4-2
-	I-geneY-C4-2
cadherin	E-geneY-C4-2
and	O
β	B-geneY-C4-2
-	I-geneY-C4-2
catenin	E-geneY-C4-2
.	O

Moreover	O
,	O
wogonin	S-chem-C4-1
repressed	O
anisomycin	S-chem-C3-1
-	O
induced	O
phosphorylation	O
of	O
p38	S-geneN-MU-2
,	O
cav	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
and	O
vascular	O
permeability	O
.	O

These	O
results	O
suggested	O
that	O
wogonin	S-chem-C4-1
could	O
inhibit	O
H2O2	S-chem-C3-1
-	O
induced	O
vascular	O
permeability	O
by	O
downregulating	O
the	O
phosphorylation	O
of	O
cav	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
,	O
and	O
that	O
it	O
might	O
have	O
a	O
therapeutic	O
potential	O
for	O
the	O
diseases	O
associated	O
with	O
the	O
development	O
of	O
both	O
oxidant	O
and	O
vascular	O
permeability	O
.	O

Fisetin	S-chem
averts	O
oxidative	O
stress	O
in	O
pancreatic	O
tissues	O
of	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
rats	O
.	O

Persistent	O
hyperglycemia	O
is	O
associated	O
with	O
chronic	O
oxidative	O
stress	O
which	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
diabetes	O
-	O
associated	O
complications	O
.	O

The	O
sensitivity	O
of	O
pancreatic	O
β	O
-	O
cells	O
to	O
oxidative	O
stress	O
has	O
been	O
attributed	O
to	O
their	O
low	O
content	O
of	O
antioxidants	O
compared	O
with	O
other	O
tissues	O
.	O

Bioactive	O
compounds	O
with	O
potent	O
antidiabetic	O
properties	O
have	O
been	O
shown	O
to	O
ameliorate	O
hyperglycemia	O
mediated	O
oxidative	O
stress	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
oral	O
administration	O
of	O
fisetin	S-chem
(	O
10	O
mg	O
/	O
Kg	O
b.w	O
.	O
)	O
,	O
a	O
bioflavonoid	O
found	O
to	O
be	O
present	O
in	O
strawberries	O
,	O
persimmon	O
,	O
to	O
STZ	O
-	E-chem
induced	O
experimental	O
diabetic	O
rats	O
significantly	O
improved	O
normoglycemia	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
evaluate	O
the	O
antioxidant	O
potential	O
of	O
fisetin	S-chem
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Diabetes	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
streptozotocin	S-chem
(	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Fisetin	S-chem
was	O
administered	O
orally	O
for	O
30	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
all	O
animals	O
were	O
killed	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
the	O
biochemical	O
estimations	O
.	O

The	O
antioxidant	O
status	O
was	O
evaluated	O
.	O

Histological	O
examinations	O
were	O
performed	O
on	O
pancreatic	O
tissues	O
.	O

Fisetin	S-chem-MU-1
treatment	O
showed	O
a	O
significant	O
decline	O
in	O
the	O
levels	O
of	O
blood	O
glucose	S-chem
,	O
glycosylated	B-geneN-C4-2
hemoglobin	E-geneN-C4-2
(	O
HbA1c	S-geneN-C4-2
)	O
,	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kB	E-geneN-C4-2
p65	S-geneY-C4-2
unit	O
(	O
in	O
pancreas	O
)	O
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
(	O
plasma	O
)	O
,	O
serum	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
with	O
an	O
elevation	O
in	O
plasma	O
insulin	S-geneN-C3-2
.	O

The	O
treatment	O
also	O
improved	O
the	O
antioxidant	O
status	O
in	O
pancreas	O
as	O
well	O
as	O
plasma	O
of	O
diabetic	O
rats	O
indicating	O
the	O
antioxidant	O
potential	O
of	O
fisetin	S-chem
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
DPPH	S-chem
and	O
ABTS	S-chem
assays	O
substantiate	O
the	O
free	O
radical	O
scavenging	O
activity	O
of	O
fisetin	S-chem
.	O

Histological	O
studies	O
of	O
the	O
pancreas	O
also	O
evidenced	O
the	O
tissue	O
protective	O
nature	O
of	O
fisetin	S-chem
.	O

It	O
is	O
concluded	O
that	O
,	O
fisetin	S-chem
possesses	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
property	O
and	O
may	O
be	O
considered	O
as	O
an	O
adjunct	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

Overexpression	O
of	O
beta	B-geneY
1	I-geneY
-	I-geneY
adrenoceptors	E-geneY
in	O
adult	O
rat	O
ventricular	O
myocytes	O
enhances	O
CGP	B-chem
12177A	E-chem
cardiostimulation	O
:	O
implications	O
for	O
'	O
putative	O
'	O
beta	B-geneN
4	I-geneN
-	I-geneN
adrenoceptor	E-geneN
pharmacology	O
.	O

1	O
.	O

CGP	B-chem-C3-1
12177A	E-chem-C3-1
mediates	O
cardiostimulation	O
by	O
activation	O
of	O
the	O
'	O
putative	O
'	O
beta	B-geneN-C3-2
(	I-geneN-C3-2
4	I-geneN-C3-2
)	I-geneN-C3-2
-	I-geneN-C3-2
adrenoceptor	E-geneN-C3-2
;	O
however	O
,	O
it	O
has	O
recently	O
been	O
reported	O
that	O
disruption	O
of	O
the	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
1	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptor	E-geneY-C3-2
gene	O
abolishes	O
this	O
effect	O
.	O

We	O
have	O
adenovirally	O
overexpressed	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
in	O
isolated	O
,	O
cultured	O
adult	O
rat	O
ventricular	O
cardiomyocytes	O
and	O
observed	O
the	O
inotropic	O
potency	O
of	O
isoprenaline	S-chem
and	O
CGP	B-chem
12177A	E-chem
(	O
in	O
the	O
presence	O
of	O
1	O
microm	O
propranolol	S-chem
)	O
.	O

2	O
.	O

Isoprenaline	S-chem
was	O
a	O
full	O
inotropic	O
agonist	O
at	O
rat	O
ventricular	O
myocytes	O
(	O
pD	O
(	O
2	O
)	O
7.69	O
+	O
/	O
-	O
0.12	O
)	O
.	O

CGP	B-chem
12177A	E-chem
was	O
a	O
nonconventional	O
partial	O
agonist	O
(	O
pD	O
(	O
2	O
)	O
6.34	O
+	O
/	O
-	O
0.09	O
)	O
,	O
increasing	O
inotropy	O
and	O
lusitropy	O
,	O
with	O
an	O
intrinsic	O
activity	O
of	O
0.34	O
and	O
antagonised	O
by	O
bupranolol	S-chem
.	O

3.	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
overexpression	O
enhanced	O
the	O
inotropic	O
potency	O
of	O
isoprenaline	S-chem
by	O
11.7	O
-	O
fold	O
(	O
pD	O
(	O
2	O
)	O
8.76	O
+	O
/	O
-	O
0.14	O
)	O
and	O
CGP	O
12177A	O
by	O
5.9	O
-	O
fold	O
(	O
7.11	O
+	O
/	O
-	O
0.10	O
)	O
,	O
respectively	O
.	O

Green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
overexpression	O
did	O
not	O
alter	O
the	O
potency	O
of	O
isoprenaline	S-chem
or	O
CGP	O
12177A	O
(	O
pD	O
(	O
2	O
)	O
7.41	O
+	O
/	O
-	O
0.24	O
and	O
pD	O
(	O
2	O
)	O
6.60	O
+	O
/	O
-	O
0.50	O
,	O
respectively	O
)	O
.	O

4	O
.	O

The	O
cardiostimulant	O
effects	O
of	O
CGP	B-chem
12177A	E-chem
were	O
enhanced	O
by	O
IBMX	O
(	O
phosphodiesterase	S-geneN
inhibitor	O
)	O
and	O
decreased	O
by	O
Rp	B-chem
-	I-chem
cAMPS	E-chem
(	O
cAMP	S-chem
antagonist	O
)	O
.	O

CGP	B-chem
12177A	E-chem
also	O
increased	O
cAMP	S-chem
levels	O
.	O

CGP	B-chem-C3-1
12177A	E-chem-C3-1
but	O
not	O
isoprenaline	S-chem
initiated	O
arrhythmias	O
at	O
lower	O
concentrations	O
following	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
1	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptor	E-geneY-C3-2
overexpression	O
.	O

5	O
.	O

(	B-chem-C3-1
125	I-chem-C3-1
)	I-chem-C3-1
I	I-chem-C3-1
-	I-chem-C3-1
Cyanopindolol	E-chem-C3-1
saturation	O
binding	O
in	O
Adv.beta	O
(	O
1	O
)	O
myocytes	O
demonstrated	O
approximately	O
18	O
-	O
fold	O
increase	O
in	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
1	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptors	E-geneY-C3-2
.	O

(	B-chem-C3-1
3	I-chem-C3-1
)	I-chem-C3-1
H	I-chem-C3-1
-	I-chem-C3-1
CGP	I-chem-C3-1
12177A	E-chem-C3-1
saturation	O
binding	O
,	O
in	O
the	O
presence	O
of	O
propranolol	S-chem-C3-1
,	O
increased	O
approximately	O
5	O
-	O
fold	O
following	O
overexpression	O
of	O
beta	B-geneY-C3-2
(	I-geneY-C3-2
1	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptors	E-geneY-C3-2
.	O

6	O
.	O

This	O
study	O
demonstrates	O
enhanced	O
cardiostimulation	O
by	O
CGP	B-chem
12177A	E-chem
(	O
in	O
the	O
presence	O
of	O
propranolol	S-chem
)	O
in	O
rat	O
ventricular	O
myocytes	O
overexpressing	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
,	O
mediated	O
by	O
a	O
Gs	S-geneN
/	O
cAMP	S-chem
signalling	O
pathway	O
.	O

'	O
Putative	O
'	O
beta	B-geneN
(	I-geneN
4	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
pharmacology	O
appears	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
a	O
novel	O
affinity	O
state	O
of	O
the	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	O
.	O

Peroxisome	B-geneY-C3-2
proliferator	I-geneY-C3-2
-	I-geneY-C3-2
activated	I-geneY-C3-2
receptor	I-geneY-C3-2
alpha	E-geneY-C3-2
(	O
PPARalpha	S-geneY-C3-2
)	O
activators	O
,	O
bezafibrate	S-chem-C3-1
and	O
Wy	B-chem-C3-1
-	I-chem-C3-1
14,643	E-chem-C3-1
,	O
increase	O
uncoupling	B-geneY-C3-2
protein	I-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
mRNA	O
levels	O
without	O
modifying	O
the	O
mitochondrial	O
membrane	O
potential	O
in	O
primary	O
culture	O
of	O
rat	O
preadipocytes	O
.	O

Uncoupling	B-geneN-C9-2
proteins	E-geneN-C9-2
(	O
UCPs	S-geneN-C9-2
)	O
are	O
inner	O
mitochondrial	O
membrane	O
transporters	O
which	O
act	O
as	O
pores	O
for	O
H	B-chem-C9-1
(	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
ions	O
,	O
dissipating	O
the	O
electrochemical	O
gradient	O
that	O
develops	O
during	O
mitochondrial	O
respiration	O
at	O
the	O
expense	O
of	O
ATP	O
synthesis	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
two	O
fibrates	O
,	O
bezafibrate	S-chem
and	O
Wy	B-chem
-	I-chem
14,643	E-chem
,	O
on	O
UCP	B-geneY
-	I-geneY
3	E-geneY
and	O
UCP	B-geneY
-	I-geneY
2	E-geneY
mRNA	O
levels	O
in	O
primary	O
monolayer	O
cultures	O
of	O
rat	O
adipocytes	O
and	O
undifferentiated	O
preadipocytes	O
.	O

Treatment	O
with	O
both	O
PPARalpha	S-geneY
activators	O
for	O
24	O
h	O
up	O
-	O
regulated	O
UCP	B-geneY
-	I-geneY
3	E-geneY
mRNA	O
levels	O
.	O

Thus	O
,	O
bezafibrate	S-chem-C3-1
treatment	O
resulted	O
in	O
an	O
8	O
-	O
fold	O
induction	O
in	O
UCP	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
mRNA	O
levels	O
in	O
preadipocytes	O
compared	O
with	O
the	O
3.5	O
-	O
fold	O
induction	O
observed	O
in	O
adipocytes	O
.	O

Differences	O
in	O
the	O
induction	O
of	O
UCP	B-geneY
-	I-geneY
3	E-geneY
between	O
these	O
cells	O
correlated	O
well	O
with	O
the	O
higher	O
expression	O
of	O
PPARalpha	S-geneY
and	O
RXRalpha	S-geneY
mRNA	O
values	O
in	O
preadipocytes	O
compared	O
to	O
adipocytes	O
.	O

Wy	O
-	O
14,643	O
caused	O
similar	O
effects	O
on	O
UCP	B-geneY
-	I-geneY
3	E-geneY
mRNA	O
expression	O
.	O

In	O
contrast	O
to	O
UCP	B-geneY
-	I-geneY
3	E-geneY
,	O
UCP	B-geneY
-	I-geneY
2	E-geneY
mRNA	O
levels	O
were	O
only	O
slightly	O
modified	O
by	O
bezafibrate	S-chem
in	O
adipocytes	O
.	O

The	O
induction	O
in	O
UCP	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
expression	O
was	O
not	O
accompanied	O
by	O
changes	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
of	O
rat	O
primary	O
preadipocytes	O
after	O
bezafibrate	S-chem-C3-1
or	O
Wy	B-chem-C3-1
-	I-chem-C3-1
14,643	E-chem-C3-1
treatment	O
.	O

Since	O
it	O
has	O
been	O
proposed	O
that	O
UCP	B-geneY
-	I-geneY
3	E-geneY
could	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
use	O
of	O
fatty	O
acids	O
as	O
fuel	O
substrates	O
,	O
the	O
UCP	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
induction	O
achieved	O
after	O
bezafibrate	S-chem-C3-1
and	O
Wy	B-chem-C3-1
-	I-chem-C3-1
14	I-chem-C3-1
,	I-chem-C3-1
643	E-chem-C3-1
treatment	O
may	O
indicate	O
a	O
higher	O
oxidation	O
of	O
fatty	B-chem
acids	E-chem
,	O
limiting	O
their	O
availability	O
to	O
be	O
stored	O
as	O
triglycerides	S-chem
.	O

This	O
change	O
may	O
result	O
in	O
a	O
reduced	O
rate	O
of	O
conversion	O
of	O
preadipocytes	O
to	O
adipocytes	O
,	O
which	O
directly	O
affects	O
fat	O
depots	O
.	O

Copolymerization	O
of	O
2	B-chem
-	I-chem
methylene	I-chem
-	I-chem
1,3	I-chem
-	I-chem
dioxepane	E-chem
and	O
glycidyl	B-chem
methacrylate	E-chem
,	O
a	O
well	O
-	O
defined	O
and	O
efficient	O
process	O
for	O
achieving	O
functionalized	O
polyesters	S-chem
for	O
covalent	O
binding	O
of	O
bioactive	O
molecules	O
.	O

The	O
understanding	O
of	O
cell	O
-	O
material	O
interactions	O
is	O
important	O
for	O
creating	O
personalized	O
implants	O
for	O
tissue	O
engineering	O
.	O

This	O
has	O
resulted	O
in	O
an	O
interest	O
in	O
developing	O
polymers	O
with	O
functional	O
groups	O
with	O
the	O
possibility	O
of	O
controlling	O
the	O
macromolecular	O
surface	O
.	O

We	O
have	O
in	O
a	O
one	O
-	O
pot	O
reaction	O
synthesized	O
a	O
series	O
of	O
amorphous	O
and	O
degradable	O
polyester	S-chem
-	O
based	O
copolymers	O
with	O
active	O
functional	O
groups	O
by	O
copolymerization	O
of	O
2	B-chem
-	I-chem
methylene	I-chem
-	I-chem
1,3	I-chem
-	I-chem
dioxepane	E-chem
and	O
glycidyl	B-chem
methacrylate	E-chem
.	O

The	O
properties	O
of	O
the	O
final	O
polymers	O
were	O
varied	O
by	O
varying	O
the	O
feed	O
ratios	O
of	O
the	O
monomers	O
and	O
it	O
was	O
seen	O
that	O
it	O
was	O
possible	O
to	O
control	O
the	O
amount	O
of	O
active	O
functional	O
groups	O
.	O

The	O
resulting	O
epoxy	B-chem
-	I-chem
functionalized	I-chem
polyester	E-chem
was	O
further	O
modified	O
by	O
covalent	O
immobilization	O
of	O
heparin	O
.	O

The	O
heparinization	O
was	O
done	O
in	O
order	O
,	O
in	O
a	O
future	O
aspect	O
,	O
to	O
enhance	O
the	O
osteogenic	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
.	O

Heparin	O
binds	O
directly	O
with	O
the	O
growth	O
factor	O
bone	B-geneY
morphogenetic	I-geneY
protein	I-geneY
-	I-geneY
2	E-geneY
and	O
helps	O
to	O
retain	O
its	O
activity	O
.	O

The	O
molecular	O
structure	O
of	O
the	O
copolymers	O
was	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
,	O
size	O
exclusion	O
chromatography	O
,	O
and	O
fourier	O
transform	O
infrared	O
spectroscopy	O
.	O

Differential	O
scanning	O
calorimetry	O
and	O
tensile	O
testing	O
showed	O
that	O
the	O
monomer	O
feed	O
ratio	O
had	O
a	O
great	O
influence	O
on	O
the	O
properties	O
of	O
the	O
final	O
polymer	O
and	O
that	O
it	O
thus	O
was	O
possible	O
to	O
control	O
the	O
mechanical	O
properties	O
to	O
suit	O
an	O
intended	O
application	O
.	O

The	O
presence	O
of	O
heparin	O
was	O
verified	O
by	O
toluidine	B-chem
blue	E-chem
staining	O
and	O
all	O
the	O
films	O
tested	O
showed	O
positive	O
signals	O
for	O
heparin	O
.	O

Enhanced	O
beta2	B-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
(	O
beta2AR	S-geneY
)	O
signaling	O
by	O
adeno	O
-	O
associated	O
viral	O
(	O
AAV	O
)	O
-	O
mediated	O
gene	O
transfer	O
.	O

BACKGROUND	O
:	O
Beta2	B-geneY
-	I-geneY
adrenergic	I-geneY
receptors	E-geneY
(	O
beta2AR	S-geneY
)	O
play	O
important	O
regulatory	O
roles	O
in	O
a	O
variety	O
of	O
cells	O
and	O
organ	O
systems	O
and	O
are	O
important	O
therapeutic	O
targets	O
in	O
the	O
treatment	O
of	O
airway	O
and	O
cardiovascular	O
disease	O
.	O

Prolonged	O
use	O
of	O
beta	O
-	O
agonists	O
results	O
in	O
tolerance	O
secondary	O
to	O
receptor	O
down	O
-	O
regulation	O
resulting	O
in	O
reduced	O
therapeutic	O
efficiency	O
.	O

The	O
purpose	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
the	O
signaling	O
capabilities	O
of	O
the	O
beta2AR	S-geneY
expressed	O
by	O
a	O
recombinant	O
adeno	O
-	O
associated	O
viral	O
(	O
AAV	O
)	O
vector	O
that	O
also	O
included	O
an	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
gene	O
(	O
AAV	O
-	O
beta2AR	S-geneY
/	O
EGFP	O
)	O
.	O

RESULTS	O
:	O
By	O
epifluorescence	O
microscopy	O
,	O
approximately	O
40	O
%	O
of	O
infected	O
HEK	O
293	O
cells	O
demonstrated	O
EGFP	O
expression	O
.	O
beta2AR	S-geneY
density	O
measured	O
with	O
[	B-chem
3H	I-chem
]	I-chem
dihydroalprenolol	E-chem
(	O
[	B-chem
3H	I-chem
]	I-chem
DHA	E-chem
)	O
increased	O
either	O
13	O
-	O
or	O
77	O
-	O
fold	O
in	O
infected	O
cells	O
compared	O
to	O
mock	O
infected	O
controls	O
depending	O
on	O
the	O
culture	O
conditions	O
used	O
.	O

The	O
[	B-chem
3H	I-chem
]	I-chem
DHA	E-chem
binding	O
was	O
to	O
a	O
single	O
receptor	O
population	O
with	O
a	O
dissociation	O
constant	O
of	O
0.42	O
nM	O
,	O
as	O
would	O
be	O
expected	O
for	O
wild	O
-	O
type	O
beta2AR	S-geneY
.	O

Agonist	O
competition	O
assays	O
with	O
[	B-chem
3H	I-chem
]	I-chem
DHA	E-chem
showed	O
the	O
following	O
rank	O
order	O
of	O
potency	O
:	O
isoproterenol	S-chem
>	O
epinephrine	S-chem
>	O
norepinephrine	S-chem
,	O
consistent	O
with	O
beta2AR	S-geneY
interaction	O
.	O

Isoproterenol	S-chem
-	O
stimulated	O
cyclic	B-chem
AMP	E-chem
levels	O
were	O
5	O
-	O
fold	O
higher	O
in	O
infected	O
cells	O
compared	O
to	O
controls	O
(	O
314	O
+	O
/	O
-	O
43	O
vs	O
.	O

63.4	O
+	O
/	O
-	O
9.6	O
nmol	O
/	O
dish	O
;	O
n	O
=	O
3	O
)	O
.	O

Receptor	O
trafficking	O
demonstrated	O
surface	O
expression	O
of	O
beta2AR	S-geneY
with	O
vehicle	O
treatment	O
and	O
internalization	O
following	O
isoproterenol	S-chem
treatment	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
HEK	O
293	O
cells	O
infected	O
with	O
AAV	O
-	O
beta2AR	S-geneY
/	O
EGFP	O
effectively	O
express	O
beta2AR	S-geneY
and	O
that	O
increased	O
expression	O
of	O
these	O
receptors	O
results	O
in	O
enhanced	O
beta2AR	S-geneY
signaling	O
.	O

This	O
method	O
of	O
gene	O
transfer	O
may	O
provide	O
an	O
important	O
means	O
to	O
enhance	O
function	O
in	O
in	O
vivo	O
systems	O
.	O

EphB4	S-geneY
enhances	O
the	O
process	O
of	O
endochondral	O
ossification	O
and	O
inhibits	O
remodeling	O
during	O
bone	O
fracture	O
repair	O
.	O

Previous	O
reports	O
have	O
identified	O
a	O
role	O
for	O
the	O
tyrosine	B-geneN
kinase	I-geneN
receptor	E-geneN
EphB4	S-geneY
and	O
its	O
ligand	O
,	O
ephrinB2	S-geneY
,	O
as	O
potential	O
mediators	O
of	O
both	O
bone	O
formation	O
by	O
osteoblasts	O
and	O
bone	O
resorption	O
by	O
osteoclasts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
EphB4	S-geneY
during	O
bone	O
repair	O
after	O
traumatic	O
injury	O
.	O

We	O
performed	O
femoral	O
fractures	O
with	O
internal	O
fixation	O
in	O
transgenic	O
mice	O
that	O
overexpress	O
EphB4	S-geneY
under	O
the	O
collagen	B-geneN
type	I-geneN
1	I-geneN
promoter	E-geneN
(	O
Col1	S-geneN
-	O
EphB4	S-geneY
)	O
and	O
investigated	O
the	O
bone	O
repair	O
process	O
up	O
to	O
12	O
weeks	O
postfracture	O
.	O

The	O
data	O
indicated	O
that	O
Col1	S-geneN
-	O
EphB4	S-geneY
mice	O
exhibited	O
stiffer	O
and	O
stronger	O
bones	O
after	O
fracture	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
fractured	O
bones	O
of	O
Col1	S-geneN
-	O
EphB4	S-geneY
transgenic	O
mice	O
displayed	O
significantly	O
greater	O
tissue	O
and	O
bone	O
volume	O
2	O
weeks	O
postfracture	O
compared	O
with	O
that	O
of	O
wild	O
-	O
type	O
mice	O
.	O

These	O
findings	O
correlated	O
with	O
increased	O
chondrogenesis	O
and	O
mineral	O
formation	O
within	O
the	O
callus	O
site	O
at	O
2	O
weeks	O
postfracture	O
,	O
as	O
demonstrated	O
by	O
increased	O
safranin	B-chem
O	E-chem
and	O
von	O
Kossa	O
staining	O
,	O
respectively	O
.	O

Interestingly	O
,	O
Col1	S-geneN
-	O
EphB4	S-geneY
mice	O
were	O
found	O
to	O
possess	O
significantly	O
greater	O
numbers	O
of	O
clonogenic	O
mesenchymal	O
stromal	O
progenitor	O
cells	O
(	O
CFU	O
-	O
F	O
)	O
,	O
with	O
an	O
increased	O
capacity	O
to	O
form	O
mineralized	O
nodules	O
in	O
vitro	O
under	O
osteogenic	O
conditions	O
,	O
when	O
compared	O
with	O
those	O
of	O
the	O
wild	O
-	O
type	O
control	O
mice	O
.	O

Furthermore	O
,	O
Col1	S-geneN
-	O
EphB4	S-geneY
mice	O
had	O
significantly	O
lower	O
numbers	O
of	O
TRAP	S-geneY
-	O
positive	O
multinucleated	O
osteoclasts	O
within	O
the	O
callus	O
site	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
EphB4	S-geneY
promotes	O
endochondral	O
ossification	O
while	O
inhibiting	O
osteoclast	O
development	O
during	O
callus	O
formation	O
and	O
may	O
represent	O
a	O
novel	O
drug	O
target	O
for	O
the	O
repair	O
of	O
fractured	O
bones	O
.	O

Creatine	S-chem
uptake	O
in	O
brain	O
and	O
skeletal	O
muscle	O
of	O
mice	O
lacking	O
guanidinoacetate	B-geneY
methyltransferase	E-geneY
assessed	O
by	O
magnetic	O
resonance	O
spectroscopy	O
.	O

Creatine	S-chem
(	O
Cr	S-chem
)	O
levels	O
in	O
skeletal	O
muscle	O
and	O
brain	O
of	O
a	O
mouse	O
model	O
of	O
Cr	S-chem
deficiency	O
caused	O
by	O
guanidinoacetate	B-geneY
methyltransferase	E-geneY
absence	O
(	O
GAMT	S-geneY
-	O
/	O
-	O
)	O
were	O
studied	O
after	O
Cr	S-chem
supplementation	O
with	O
2	O
g.kg	O
body	O
wt	O
-	O
1.day	O
-	O
1	O
Cr	S-chem
for	O
35	O
days	O
.	O

Localized	O
1H	S-chem
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
was	O
performed	O
in	O
brain	O
(	O
cerebellum	O
and	O
thalamus	O
/	O
hippocampus	O
)	O
and	O
in	O
hind	O
leg	O
muscle	O
of	O
GAMT	S-geneY
-	O
/	O
-	O
mice	O
before	O
and	O
after	O
Cr	S-chem
supplementation	O
and	O
in	O
control	O
(	O
Con	O
)	O
mice	O
.	O

As	O
expected	O
,	O
a	O
signal	O
for	O
Cr	S-chem
was	O
hardly	O
detectable	O
in	O
MR	O
spectra	O
of	O
GAMT	S-geneY
-	O
/	O
-	O
mice	O
before	O
Cr	S-chem
supplementation	O
.	O

In	O
the	O
thalamus	O
/	O
hippocampus	O
region	O
of	O
these	O
mice	O
,	O
an	O
increase	O
in	O
N	B-chem
-	I-chem
acetylasparate	E-chem
(	O
NAA	S-chem
)	O
was	O
observed	O
.	O

During	O
Cr	S-chem
administration	O
,	O
Cr	S-chem
levels	O
increased	O
faster	O
in	O
skeletal	O
muscle	O
compared	O
with	O
brain	O
,	O
but	O
this	O
occurred	O
only	O
during	O
the	O
first	O
day	O
of	O
supplementation	O
.	O

Thereafter	O
,	O
Cr	S-chem
levels	O
increased	O
by	O
0.8	O
mM	O
/	O
day	O
in	O
all	O
studied	O
locations	O
.	O

After	O
35	O
days	O
of	O
Cr	S-chem
supplementation	O
,	O
Cr	S-chem
levels	O
in	O
all	O
locations	O
were	O
higher	O
compared	O
with	O
Con	O
mice	O
on	O
a	O
Cr	S-chem
-	O
free	O
diet	O
and	O
NAA	S-chem
levels	O
normalized	O
.	O

Only	O
because	O
of	O
the	O
repeated	O
MRS	O
measurements	O
performed	O
in	O
this	O
longitudinal	O
Cr	S-chem
supplementation	O
study	O
on	O
GAMT	S-geneY
-	O
/	O
-	O
mice	O
were	O
we	O
able	O
to	O
discover	O
the	O
initial	O
faster	O
uptake	O
of	O
Cr	S-chem
in	O
skeletal	O
muscle	O
compared	O
with	O
brain	O
,	O
which	O
may	O
represent	O
muscular	O
Cr	S-chem
uptake	O
independent	O
of	O
Cr	S-chem
transporter	O
expression	O
.	O

Our	O
results	O
can	O
provide	O
the	O
basis	O
for	O
additional	O
experiments	O
to	O
optimize	O
Cr	S-chem
supplementation	O
in	O
GAMT	S-geneY
deficiency	O
,	O
as	O
increases	O
in	O
brain	O
Cr	S-chem
are	O
slow	O
in	O
patients	O
after	O
Cr	S-chem
supplementation	O
.	O

Tmem64	S-geneY
modulates	O
calcium	S-chem
signaling	O
during	O
RANKL	S-geneY
-	O
mediated	O
osteoclast	O
differentiation	O
.	O

Osteoclast	O
maturation	O
and	O
function	O
primarily	O
depend	O
on	O
receptor	B-geneY
activator	I-geneY
of	I-geneY
NF	I-geneY
-	I-geneY
κB	I-geneY
ligand	E-geneY
(	O
RANKL	S-geneY
)	O
-	O
mediated	O
induction	O
of	O
nuclear	B-geneY
factor	I-geneY
of	I-geneY
activated	I-geneY
T	I-geneY
cells	I-geneY
c1	I-geneY
(	E-geneY
NFATc1	O
)	E-geneY
,	O
which	O
is	O
further	O
activated	O
via	O
increased	O
intracellular	O
calcium	O
(	E-chem
[	O
Ca	O
(	I-chem
2	I-chem
+	I-chem
)	I-chem
]	E-chem
(	O
i	O
)	O
)	O
oscillation	O
.	O

However	O
,	O
the	O
coordination	O
mechanism	O
that	O
mediates	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
oscillation	O
during	O
osteoclastogenesis	O
remains	O
ill	O
defined	O
.	O

Here	O
,	O
we	O
identified	O
transmembrane	B-geneY
protein	I-geneY
64	E-geneY
(	O
Tmem64	S-geneY
)	O
as	O
a	O
regulator	O
of	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
oscillation	O
during	O
osteoclastogenesis	O
.	O

We	O
found	O
that	O
Tmem64	S-geneY
-	O
deficient	O
mice	O
exhibit	O
increased	O
bone	O
mass	O
due	O
in	O
part	O
to	O
impaired	O
osteoclast	O
formation	O
.	O

Using	O
in	O
vitro	O
osteoclast	O
culture	O
systems	O
,	O
we	O
show	O
here	O
that	O
Tmem64	O
interacts	O
with	O
sarcoplasmic	O
endoplasmic	O
reticulum	O
Ca	O
(	I-chem
2	I-chem
+	I-chem
)	I-chem
ATPase	O
2	O
(	O
SERCA2	O
)	O
and	O
modulates	O
its	O
activity	O
.	O

Consequently	O
,	O
Tmem64	S-geneY
deficiency	O
significantly	O
diminishes	O
RANKL	S-geneY
-	O
induced	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
oscillation	O
,	O
which	O
results	O
in	O
reduced	O
Ca	B-geneY
(	I-geneY
2	I-geneY
+	I-geneY
)	I-geneY
/	I-geneY
calmodulin	I-geneY
-	I-geneY
dependent	I-geneY
protein	I-geneY
kinases	I-geneY
(	I-geneY
CaMK	I-geneY
)	I-geneY
IV	E-geneY
and	O
mitochondrial	O
ROS	O
,	O
both	O
of	O
which	O
contribute	O
to	O
achieving	O
the	O
CREB	S-geneN
activity	O
necessary	O
for	O
osteoclast	O
formation	O
.	O

These	O
data	O
demonstrate	O
that	O
Tmem64	S-geneY
is	O
a	O
positive	O
modulator	O
of	O
osteoclast	O
differentiation	O
via	O
SERCA2	S-geneY
-	O
dependent	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
signaling	O
.	O

Liver	O
choline	B-geneY
dehydrogenase	E-geneY
and	O
kidney	O
betaine	B-geneN
-	I-geneN
homocysteine	I-geneN
methyltransferase	E-geneN
expression	O
are	O
not	O
affected	O
by	O
methionine	S-chem
or	O
choline	S-chem
intake	O
in	O
growing	O
rats	O
.	O

Choline	B-geneY-C9-2
dehydrogenase	E-geneY-C9-2
(	O
CHDH	S-geneY-C9-2
)	O
and	O
betaine	B-geneN-C9-2
-	I-geneN-C9-2
homocysteine	I-geneN-C9-2
methyltransferase	E-geneN-C9-2
(	O
BHMT	S-geneN-C9-2
)	O
are	O
2	O
enzymes	O
involved	O
in	O
choline	S-chem-C9-1
oxidation	O
.	O

BHMT	S-geneN
is	O
expressed	O
at	O
high	O
levels	O
in	O
rat	O
liver	O
and	O
its	O
expression	O
is	O
regulated	O
by	O
dietary	O
Met	S-chem
and	O
choline	S-chem
.	O

BHMT	S-geneN
is	O
also	O
found	O
in	O
rat	O
kidney	O
,	O
albeit	O
in	O
substantially	O
lower	O
amounts	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
kidney	O
BHMT	S-geneN
expression	O
is	O
regulated	O
by	O
dietary	O
Met	S-chem
or	O
choline	S-chem
.	O

Similarly	O
,	O
CHDH	S-geneY
activity	O
is	O
highest	O
in	O
the	O
liver	O
and	O
kidney	O
,	O
but	O
the	O
regulation	O
of	O
its	O
expression	O
by	O
diet	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

Sprague	O
Dawley	O
rats	O
(	O
approximately	O
50	O
g	O
)	O
were	O
fed	O
,	O
for	O
9	O
d	O
in	O
2	O
x	O
3	O
factorial	O
design	O
(	O
n	O
=	O
8	O
)	O
,	O
an	O
l	B-chem
-	I-chem
amino	I-chem
acid	E-chem
-	O
defined	O
diet	O
varying	O
in	O
l	B-chem
-	I-chem
Met	E-chem
(	O
0.125	O
,	O
0.3	O
,	O
or	O
0.8	O
%	O
)	O
and	O
choline	S-chem
(	O
0	O
or	O
25	O
mmol	O
/	O
kg	O
diet	O
)	O
.	O

Liver	O
and	O
kidney	O
BHMT	S-geneN
and	O
CHDH	S-geneY
were	O
assessed	O
using	O
enzymatic	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
PCR	O
analyses	O
.	O

Liver	O
samples	O
were	O
also	O
fixed	O
for	O
histological	O
analysis	O
.	O

Liver	O
BHMT	S-geneN-C3-2
activity	O
was	O
1.3	O
-	O
fold	O
higher	O
in	O
rats	O
fed	O
the	O
Met	S-chem
deficient	O
diet	O
containing	O
choline	S-chem-C3-1
,	O
which	O
was	O
reflected	O
in	O
corresponding	O
increases	O
in	O
mRNA	O
content	O
and	O
immunodetectable	O
protein	O
.	O

Independent	O
of	O
dietary	O
choline	S-chem-C3-1
,	O
supplemental	O
Met	S-chem-C3-1
increased	O
hepatic	O
BHMT	S-geneN-C3-2
activity	O
approximately	O
30	O
%	O
.	O

Kidney	O
BHMT	S-geneN
and	O
liver	O
CHDH	S-geneY
expression	O
were	O
refractory	O
to	O
these	O
diets	O
.	O

Some	O
degree	O
of	O
fatty	O
liver	O
developed	O
in	O
all	O
rats	O
fed	O
a	O
choline	S-chem
-	O
devoid	O
diet	O
,	O
indicating	O
that	O
supplemental	O
Met	S-chem
can	O
not	O
completely	O
compensate	O
for	O
the	O
lack	O
of	O
dietary	O
choline	S-chem
in	O
growing	O
rats	O
.	O

Acid	O
-	O
degradable	O
cationic	O
poly	B-chem
(	I-chem
ketal	I-chem
amidoamine	I-chem
)	E-chem
for	O
enhanced	O
RNA	O
interference	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Efficient	O
delivery	O
of	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
is	O
one	O
of	O
major	O
challenges	O
in	O
the	O
successful	O
applications	O
of	O
siRNA	O
in	O
clinic	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
a	O
new	O
acid	O
-	O
degradable	O
poly	B-chem
(	I-chem
ketal	I-chem
amidoamine	I-chem
)	E-chem
(	O
PKAA	S-chem
)	O
as	O
a	O
siRNA	O
carrier	O
,	O
which	O
has	O
high	O
delivery	O
efficiency	O
and	O
low	O
cytotoxicity	O
.	O

PKAA	S-chem
was	O
designed	O
to	O
have	O
acid	O
-	O
cleavable	O
ketal	O
linkages	O
in	O
the	O
backbone	O
of	O
cationic	O
biodegradable	O
poly	B-chem
(	I-chem
amidoamine	I-chem
)	E-chem
.	O

PKAA	S-chem
efficiently	O
self	O
-	O
assembled	O
with	O
siRNA	O
to	O
form	O
nanocomplexes	O
with	O
a	O
diameter	O
of	O
~	O
200	O
nm	O
and	O
slightly	O
positive	O
charges	O
,	O
which	O
are	O
stable	O
under	O
physiological	O
conditions	O
,	O
but	O
rapidly	O
release	O
siRNA	O
at	O
acidic	O
pH	O
.	O

PKAA	S-chem
exhibited	O
sufficient	O
buffering	O
capability	O
and	O
endosomolytic	O
activity	O
due	O
mainly	O
to	O
the	O
presence	O
of	O
secondary	B-chem
amine	E-chem
groups	O
in	O
its	O
backbone	O
and	O
rapid	O
degradation	O
in	O
acidic	O
endosomes	O
,	O
leading	O
to	O
the	O
enhanced	O
release	O
of	O
siRNA	O
to	O
cytoplasm	O
.	O

Cell	O
culture	O
studies	O
demonstrated	O
that	O
PKAA	S-chem-C4-1
is	O
capable	O
of	O
delivering	O
anti	O
-	O
TNF	S-geneY
(	B-geneY
tumor	I-geneY
necrosis	I-geneY
factor	I-geneY
)	I-geneY
-	I-geneY
α	E-geneY
siRNA	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
macrophages	O
and	O
significantly	O
inhibits	O
the	O
expression	O
of	O
TNF	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
.	O

A	O
mouse	O
model	O
of	O
acetaminophen	S-chem
(	O
APAP	S-chem
)	O
-	O
induced	O
acute	O
liver	O
failure	O
was	O
used	O
to	O
evaluate	O
in	O
vivo	O
siRNA	O
delivery	O
efficacy	O
of	O
PKAA	S-chem
.	O

PKAA	S-chem-C4-1
/	O
anti	O
-	O
TNF	B-geneY
-	I-geneY
α	E-geneY
siRNA	O
nanocomplexes	O
significantly	O
reduced	O
the	O
ALT	S-geneN-C4-2
(	O
alanine	B-geneN-C4-2
transaminase	E-geneN-C4-2
)	O
and	O
the	O
hepatic	O
cellular	O
damages	O
in	O
APAP	S-chem
-	O
intoxicated	O
mice	O
.	O

We	O
anticipate	O
that	O
acid	O
-	O
degradable	O
PKAA	S-chem
has	O
great	O
potential	O
as	O
siRNA	O
carriers	O
based	O
on	O
its	O
excellent	O
biocompatibility	O
,	O
pH	O
sensitivity	O
,	O
potential	O
endosomolytic	O
activity	O
,	O
and	O
high	O
delivery	O
efficiency	O
.	O

Chalcogenopyrylium	S-chem
Dyes	O
as	O
Differential	O
Modulators	O
of	O
Organic	O
Anion	O
Transport	O
by	O
MRP1	S-geneY
,	O
MRP2	S-geneY
and	O
MRP4	S-geneY
.	O

Multidrug	B-geneN
resistance	I-geneN
proteins	E-geneN
(	O
MRPs	S-geneN
)	O
mediate	O
the	O
ATP	S-chem
-	O
dependent	O
efflux	O
of	O
structurally	O
diverse	O
compounds	O
,	O
including	O
anticancer	O
drugs	O
and	O
physiological	O
organic	O
anions	O
.	O

Five	O
classes	O
of	O
chalcogenopyrylium	S-chem
dyes	O
(	O
CGPs	S-chem
)	O
were	O
examined	O
for	O
their	O
ability	O
to	O
modulate	O
transport	O
of	O
[	B-chem-C9-1
(	I-chem-C9-1
3	I-chem-C9-1
)	I-chem-C9-1
H	I-chem-C9-1
]	I-chem-C9-1
estradiol	I-chem-C9-1
glucuronide	E-chem-C9-1
(	O
E217βG	S-chem-C9-1
)	O
(	O
a	O
prototypical	O
MRP	S-geneN-C9-2
substrate	O
)	O
into	O
MRP	S-geneN
-	O
enriched	O
inside	O
-	O
out	O
membrane	O
vesicles	O
.	O

Additionally	O
,	O
some	O
CGPs	S-chem
were	O
tested	O
in	O
intact	O
transfected	O
cells	O
using	O
a	O
calcein	S-chem
efflux	O
assay	O
.	O

Sixteen	O
of	O
34	O
CGPs	S-chem-C4-1
inhibited	O
MRP1	S-geneY-MU-2
-	O
mediated	O
E217βG	S-chem-C9-1
uptake	O
by	O
>	O
50	O
%	O
(	O
IC50	O
's	O
0.7	O
-	O
7.6	O
μM	O
)	O
.	O

Of	O
9	O
CGPs	S-chem
with	O
IC50	O
's	O
≤	O
2	O
μM	O
,	O
two	O
belonged	O
to	O
Class	O
I	O
,	O
two	O
to	O
Class	O
III	O
and	O
five	O
to	O
Class	O
V	O
.	O

When	O
tested	O
in	O
the	O
intact	O
cells	O
,	O
only	O
4	O
of	O
16	O
CGPs	S-chem-C4-1
(	O
at	O
10	O
μM	O
)	O
inhibited	O
MRP1	S-geneY-MU-2
-	O
mediated	O
calcein	S-chem-C9-1
efflux	O
by	O
>	O
50	O
%	O
(	O
III	O
-	O
1	O
,	O
V	O
-	O
3	O
,	O
-	O
4	O
,	O
-	O
6	O
)	O
while	O
a	O
fifth	O
(	O
I	O
-	O
5	O
)	O
inhibited	O
efflux	O
by	O
just	O
23	O
%	O
.	O

These	O
five	O
CGPs	S-chem-C4-1
also	O
inhibited	O
[	B-chem-C9-1
(	I-chem-C9-1
3	I-chem-C9-1
)	I-chem-C9-1
H	I-chem-C9-1
]	I-chem-C9-1
E217βG	E-chem-C9-1
uptake	O
by	O
MRP4	S-geneY-MU-2
.	O

In	O
contrast	O
,	O
their	O
effects	O
on	O
MRP2	S-geneY
varied	O
with	O
two	O
(	O
V	O
-	O
4	O
,	O
V	O
-	O
6	O
)	O
inhibiting	O
E217βG	S-chem
transport	O
(	O
IC50	O
's	O
2.0	O
,	O
9.2	O
μM	O
)	O
,	O
two	O
(	O
V	O
-	O
3	O
,	O
III	O
-	O
1	O
)	O
stimulating	O
transport	O
(	O
>	O
2	O
-	O
fold	O
)	O
,	O
while	O
CGP	S-chem
I	O
-	O
5	O
had	O
no	O
effect	O
.	O

Strikingly	O
,	O
although	O
V	O
-	O
3	O
and	O
V	O
-	O
4	O
had	O
opposite	O
effects	O
on	O
MRP2	S-geneY
activity	O
,	O
they	O
are	O
structurally	O
identical	O
except	O
for	O
their	O
chalcogen	S-chem
atom	O
(	O
Se	S-chem
versus	O
Te	S-chem
)	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
identify	O
Class	O
V	O
CGPs	O
with	O
their	O
distinctive	O
methine	S-chem
or	O
trimethine	S-chem
linkage	O
between	O
two	O
disubstituted	O
pyrylium	S-chem
moieties	O
as	O
a	O
particularly	O
potent	O
class	O
of	O
MRP	S-geneN
modulators	O
and	O
also	O
show	O
that	O
within	O
this	O
core	O
structure	O
,	O
differences	O
in	O
the	O
electronegativity	O
associated	O
with	O
a	O
chalcogen	S-chem
atom	O
can	O
be	O
the	O
sole	O
determinant	O
of	O
whether	O
a	O
compound	O
will	O
stimulate	O
or	O
inhibit	O
MRP2	S-geneY
.	O

In	O
vivo	O
and	O
in	O
vitro	O
characterization	O
of	O
naltrindole	S-chem
-	O
derived	O
ligands	O
at	O
the	O
κ	B-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
.	O

Accumulating	O
evidence	O
supports	O
a	O
role	O
for	O
κ	B-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
antagonists	O
in	O
the	O
treatment	O
of	O
mood	O
disorders	O
.	O

Standard	O
κ	O
-	O
antagonists	O
have	O
an	O
unusual	O
pharmacodynamic	O
action	O
,	O
with	O
a	O
single	O
injection	O
blocking	O
receptor	O
signaling	O
for	O
several	O
weeks	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
κ	O
-	O
selective	O
properties	O
of	O
two	O
ligands	O
,	O
5	B-chem
'	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
aminomethyl	I-chem
)	I-chem
naltrindole	E-chem
(	O
5	B-chem
'	I-chem
-	I-chem
AMN	E-chem
)	O
and	O
N	B-chem
-	I-chem
(	I-chem
(	I-chem
Naltrindol	I-chem
-	I-chem
5	I-chem
-	I-chem
yl	I-chem
)	I-chem
methyl	I-chem
)	I-chem
pentanimidamide	E-chem
(	O
5	B-chem
'	I-chem
-	I-chem
MABN	E-chem
)	O
,	O
to	O
identify	O
whether	O
modifications	O
of	O
the	O
naltrindole	S-chem
side	O
chain	O
produces	O
short	O
-	O
acting	O
κ	O
-	O
antagonists	O
.	O

Opioid	B-geneN
receptor	E-geneN
binding	O
affinity	O
and	O
activity	O
were	O
assessed	O
using	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
diprenorphine	E-chem
binding	O
,	O
guanosine	B-chem
-	I-chem
5	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
[	I-chem
35S	I-chem
]	I-chem
-	I-chem
thio	I-chem
)	I-chem
triphosphate	E-chem
(	O
[	B-chem
(	I-chem
35	I-chem
)	I-chem
S	I-chem
]	I-chem
-	I-chem
GTPγS	E-chem
)	O
binding	O
and	O
isolated	O
guinea	O
-	O
pig	O
ileum	O
.	O

Pharmacodynamic	O
profiles	O
of	O
5	B-chem
'	I-chem
-	I-chem
AMN	E-chem
and	O
5	B-chem
'	I-chem
-	I-chem
MABN	E-chem
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
were	O
investigated	O
using	O
the	O
tail	O
-	O
withdrawal	O
assay	O
and	O
diuresis	O
.	O

Efficacy	O
was	O
also	O
determined	O
in	O
depression	O
-	O
and	O
anxiety	O
-	O
related	O
behavioral	O
paradigms	O
in	O
CD	O
-	O
1	O
mice	O
.	O

Both	O
5	B-chem-C6-1
'	I-chem-C6-1
-	I-chem-C6-1
AMN	E-chem-C6-1
and	O
5	B-chem-C6-1
'	I-chem-C6-1
-	I-chem-C6-1
MABN	E-chem-C6-1
had	O
high	O
affinity	O
for	O
κ	B-geneY
-	I-geneY
receptors	E-geneY
(	O
K	O
(	O
i	O
)	O
1.36	O
±	O
0.98	O
and	O
0.27	O
±	O
0.08	O
,	O
respectively	O
)	O
and	O
were	O
revealed	O
as	O
potent	O
κ	O
-	O
antagonists	O
(	O
pA	O
(	O
2	O
)	O
7.43	O
and	O
8.18	O
,	O
respectively	O
)	O
and	O
μ	B-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
(	O
pA	O
(	O
2	O
)	O
7.62	O
and	O
7.85	O
,	O
respectively	O
)	O
in	O
the	O
ileum	O
.	O

Contrary	O
to	O
our	O
hypothesis	O
,	O
in	O
vivo	O
,	O
5	B-chem
'	I-chem
-	I-chem
AMN	E-chem
and	O
5	B-chem
'	I-chem
-	I-chem
MABN	E-chem
displayed	O
long	O
-	O
lasting	O
antagonist	O
effects	O
in	O
mice	O
,	O
reducing	O
the	O
antinociceptive	O
actions	O
of	O
U50,488	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
at	O
28	O
and	O
21	O
days	O
post	O
-	O
injection	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
5	B-chem
'	I-chem
-	I-chem
AMN	E-chem
and	O
5	B-chem
'	I-chem
-	I-chem
MABN	E-chem
were	O
not	O
κ	O
-	O
selective	O
,	O
both	O
compounds	O
did	O
show	O
significant	O
antidepressant	O
-	O
and	O
anxiolytic	O
-	O
like	O
effects	O
at	O
7	O
-	O
14	O
days	O
post	O
-	O
injection	O
in	O
mice	O
.	O

A	O
multicenter	O
,	O
randomized	O
study	O
of	O
argatroban	S-chem
versus	O
heparin	O
as	O
adjunct	O
to	O
tissue	B-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
TPA	S-geneY
)	O
in	O
acute	O
myocardial	O
infarction	O
:	O
myocardial	O
infarction	O
with	O
novastan	S-chem
and	O
TPA	S-geneY
(	O
MINT	O
)	O
study	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
examined	O
the	O
effect	O
of	O
a	O
small	O
-	O
molecule	O
,	O
direct	O
thrombin	S-geneY-C4-2
inhibitor	O
,	O
argatroban	S-chem-C4-1
,	O
on	O
reperfusion	O
induced	O
by	O
tissue	B-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
TPA	S-geneY
)	O
in	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

BACKGROUND	O
:	O
Thrombin	S-geneY
plays	O
a	O
crucial	O
role	O
in	O
thrombosis	O
and	O
thrombolysis	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
argatroban	S-chem-C4-1
has	O
advantages	O
over	O
heparin	O
for	O
the	O
inhibition	O
of	O
clot	O
-	O
bound	O
thrombin	S-geneY-C4-2
and	O
for	O
the	O
enhancement	O
of	O
thrombolysis	O
with	O
TPA	S-geneY
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	O
with	O
AMI	O
within	O
6	O
h	O
were	O
randomized	O
to	O
heparin	O
,	O
low	O
-	O
dose	O
argatroban	S-chem
or	O
high	O
-	O
dose	O
argatroban	S-chem
in	O
addition	O
to	O
TPA	S-geneY
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
rate	O
of	O
thrombolysis	O
in	O
myocardial	O
infarction	O
(	O
TIMI	O
)	O
grade	O
3	O
flow	O
at	O
90	O
min	O
.	O

RESULTS	O
:	O
TIMI	O
grade	O
3	O
flow	O
was	O
achieved	O
in	O
42.1	O
%	O
of	O
heparin	O
,	O
56.8	O
%	O
of	O
low	O
-	O
dose	O
argatroban	S-chem
(	O
p	O
=	O
0.20	O
vs.	O
heparin	O
)	O
and	O
58.7	O
%	O
of	O
high	O
-	O
dose	O
argatroban	S-chem
patients	O
(	O
p	O
=	O
0.13	O
vs.	O
heparin	O
)	O
.	O

In	O
patients	O
presenting	O
after	O
3	O
h	O
,	O
TIMI	O
grade	O
3	O
flow	O
was	O
significantly	O
more	O
frequent	O
in	O
high	O
-	O
dose	O
argatroban	S-chem
versus	O
heparin	O
patients	O
:	O
57.1	O
%	O
versus	O
20.0	O
%	O
(	O
p	O
=	O
0.03	O
vs.	O
heparin	O
)	O
.	O

Major	O
bleeding	O
was	O
observed	O
in	O
10.0	O
%	O
of	O
heparin	O
,	O
and	O
in	O
2.6	O
%	O
and	O
4.3	O
%	O
of	O
low	O
-	O
dose	O
and	O
high	O
-	O
dose	O
argatroban	S-chem
patients	O
,	O
respectively	O
.	O

The	O
composite	O
of	O
death	O
,	O
recurrent	O
myocardial	O
infarction	O
,	O
cardiogenic	O
shock	O
or	O
congestive	O
heart	O
failure	O
,	O
revascularization	O
and	O
recurrent	O
ischemia	O
at	O
30	O
days	O
occurred	O
in	O
37.5	O
%	O
of	O
heparin	O
,	O
32.0	O
%	O
of	O
low	O
-	O
dose	O
argatroban	S-chem
and	O
25.5	O
%	O
of	O
high	O
-	O
dose	O
argatroban	S-chem
patients	O
(	O
p	O
=	O
0.23	O
)	O
.	O

CONCLUSIONS	O
:	O
Argatroban	S-chem
,	O
as	O
compared	O
with	O
heparin	O
,	O
appears	O
to	O
enhance	O
reperfusion	O
with	O
TPA	S-geneY
in	O
patients	O
with	O
AMI	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
delayed	O
presentation	O
.	O

The	O
incidences	O
of	O
major	O
bleeding	O
and	O
adverse	O
clinical	O
outcome	O
were	O
lower	O
in	O
the	O
patients	O
receiving	O
argatroban	S-chem
.	O

Structure	O
activity	O
relationship	O
studies	O
of	O
tricyclic	B-chem-C4-1
bispyran	I-chem-C4-1
sulfone	E-chem-C4-1
γ	B-geneN-C4-2
-	I-geneN-C4-2
secretase	E-geneN-C4-2
inhibitors	O
.	O

An	O
investigation	O
is	O
detailed	O
of	O
the	O
structure	O
activity	O
relationships	O
(	O
SAR	O
)	O
of	O
two	O
sulfone	S-chem
side	O
chains	O
of	O
compound	O
(	O
-	O
)	O
-	O
1a	O
(	O
SCH	B-chem-C4-1
900229	E-chem-C4-1
)	O
,	O
a	O
potent	O
,	O
PS1	S-geneY-C4-2
-	O
selective	O
γ	B-geneN-C4-2
-	I-geneN-C4-2
secretase	E-geneN-C4-2
inhibitor	O
and	O
clinical	O
candidate	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Specifically	O
,	O
4	B-chem
-	I-chem
CF	I-chem
(	I-chem
3	I-chem
)	E-chem
and	O
4	B-chem
-	I-chem
Br	E-chem
substituted	O
arylsulfone	S-chem
analogs	O
,	O
(	O
-	O
)	O
-	O
1b	O
and	O
(	O
-	O
)	O
-	O
1c	O
,	O
are	O
equipotent	O
to	O
compound	O
(	O
-	O
)	O
-	O
1a	O
.	O

On	O
the	O
right	O
hand	O
side	O
chain	O
,	O
linker	O
size	O
and	O
terminal	O
substituents	O
of	O
the	O
pendant	O
sulfone	S-chem
group	O
are	O
also	O
investigated	O
.	O

Synthesis	O
and	O
in	O
vitro	O
evaluation	O
of	O
N	B-chem-C4-1
-	I-chem-C4-1
Aryl	I-chem-C4-1
pyrido	I-chem-C4-1
-	I-chem-C4-1
quinazolines	E-chem-C4-1
derivatives	O
as	O
potent	O
EGFR	S-geneY-C4-2
inhibitors	O
.	O

A	O
series	O
of	O
pyrido	B-chem-C4-1
-	I-chem-C4-1
quinazolines	E-chem-C4-1
have	O
been	O
synthesised	O
,	O
characterised	O
and	O
tested	O
for	O
their	O
in	O
vitro	O
EGFR	S-geneY-C4-2
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitory	O
activity	O
.	O

The	O
compounds	O
were	O
prepared	O
from	O
Alkylideno	B-chem
/	I-chem
arylideno	I-chem
-	I-chem
bis	I-chem
-	I-chem
ureas	E-chem
.	O

Their	O
final	O
structure	O
of	O
the	O
compounds	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectral	O
studies	O
(	O
IR	O
.	O
,	O
1H	S-chem
NMR	O
,	O
FT	O
-	O
IR	O
and	O
EI	O
-	O
MS	O
)	O
.	O

The	O
cellular	O
EGFR	S-geneY
internalization	O
response	O
of	O
selected	O
compounds	O
was	O
evaluated	O
using	O
HeLa	O
cells	O
.	O

Most	O
of	O
the	O
synthesized	O
compounds	O
displayed	O
potent	O
EGFR	S-geneY
-	O
TK	S-geneN
inhibitory	O
activity	O
and	O
structurally	O
halogenated	O
derivatives	O
had	O
a	O
pronounced	O
effect	O
in	O
inhibiting	O
EGFR	S-geneY
internalization	O
.	O

©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
A	O
/	O
S	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
express	O
mutated	O
NCCT	S-geneY
mRNA	O
in	O
Gitelman	O
's	O
syndrome	O
:	O
evidence	O
for	O
abnormal	O
thiazide	S-chem
-	O
sensitive	O
NaCl	S-chem
cotransport	O
.	O

Genetic	O
analysis	O
has	O
demonstrated	O
complete	O
linkage	O
between	O
the	O
human	B-geneY
thiazide	I-geneY
-	I-geneY
sensitive	I-geneY
sodium	I-geneY
chloride	I-geneY
cotransporter	E-geneY
gene	O
(	O
NCCT	S-geneY
or	O
TSC	S-geneY
)	O
and	O
Gitelman	O
's	O
syndrome	O
(	O
GS	O
)	O
.	O

Several	O
genomic	O
NCCT	S-geneY
mutations	O
have	O
been	O
reported	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
whether	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
express	O
NCCT	S-geneY
mRNA	O
and	O
whether	O
defective	O
PBMC	O
NaCl	S-chem
cotransport	O
could	O
be	O
demonstrated	O
in	O
GS	O
.	O

PBMC	O
were	O
isolated	O
from	O
two	O
brothers	O
with	O
GS	O
,	O
their	O
parents	O
,	O
and	O
healthy	O
control	O
subjects	O
.	O

Northern	O
analysis	O
revealed	O
that	O
NCCT	S-geneY
mRNA	O
is	O
expressed	O
in	O
PBMC	O
.	O

The	O
sequence	O
of	O
full	O
-	O
length	O
NCCT	S-geneY
cDNA	O
amplified	O
from	O
normal	O
PBMC	O
was	O
identical	O
to	O
human	B-geneY
renal	I-geneY
NCCT	E-geneY
cDNA	O
.	O

Two	O
different	O
mutations	O
were	O
detected	O
in	O
the	O
patients	O
'	O
NCCT	S-geneY
cDNA	O
(	O
compound	O
heterozygote	O
)	O
.	O

In	O
cDNA	O
derived	O
from	O
the	O
patient	O
's	O
maternal	O
allele	O
,	O
exon	O
24	O
was	O
deleted	O
,	O
resulting	O
in	O
a	O
premature	O
stop	O
codon	O
(	O
after	O
amino	B-chem
acid	E-chem
920	O
)	O
.	O
cDNA	O
derived	O
from	O
the	O
patient	O
's	O
paternal	O
allele	O
had	O
an	O
additional	O
119	O
-	O
bp	O
insertion	O
between	O
exons	O
3	O
and	O
4	O
,	O
generating	O
a	O
premature	O
stop	O
codon	O
(	O
after	O
amino	B-chem
acid	E-chem
187	O
)	O
.	O

The	O
patient	O
's	O
genomic	O
DNA	O
had	O
a	O
previously	O
described	O
5	O
'	O
splice	O
site	O
mutation	O
in	O
intron	O
24	O
,	O
GGT	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
GTT	E-geneN
(	O
maternal	O
allele	O
)	O
,	O
and	O
a	O
new	O
3	O
'	O
splice	O
site	O
mutation	O
in	O
intron	O
3	O
,	O
CAG	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
CAA	E-geneN
(	O
paternal	O
allele	O
)	O
,	O
which	O
resulted	O
in	O
the	O
activation	O
of	O
a	O
nearby	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
.	O

The	O
latter	O
mutation	O
was	O
not	O
present	O
in	O
300	O
normal	O
chromosomes	O
.	O

To	O
determine	O
the	O
functional	O
significance	O
of	O
these	O
findings	O
,	O
chlorothiazide	S-chem
-	O
inhibitable	O
22Na	S-chem
uptake	O
was	O
measured	O
in	O
PBMC	O
from	O
control	O
subjects	O
,	O
the	O
parents	O
,	O
and	O
the	O
patients	O
with	O
GS	O
in	O
the	O
presence	O
of	O
bumetanide	S-chem
.	O

In	O
control	O
PBMC	O
,	O
chlorothiazide	S-chem
inhibited	O
22Na	S-chem
uptake	O
by	O
approximately	O
9	O
%	O
.	O

PBMC	O
from	O
the	O
two	O
patients	O
with	O
GS	O
failed	O
to	O
respond	O
to	O
chlorothiazide	S-chem
.	O

These	O
results	O
demonstrate	O
that	O
PBMC	O
can	O
be	O
used	O
for	O
mutational	O
analysis	O
of	O
NCCT	S-geneY
mRNA	O
in	O
patients	O
with	O
GS	O
.	O

Furthermore	O
,	O
functional	O
evidence	O
is	O
provided	O
that	O
the	O
underlying	O
cause	O
of	O
GS	O
is	O
defective	O
NCCT	S-geneY
NaCl	S-chem
cotransport	O
.	O

Effectiveness	O
of	O
endopeptidase	S-geneN-C4-2
inhibition	O
(	O
candoxatril	S-chem-C4-1
)	O
in	O
congestive	O
heart	O
failure	O
.	O

Candoxatril	S-chem-C4-1
is	O
a	O
novel	O
,	O
orally	O
active	O
inhibitor	O
of	O
neutral	B-geneY-C4-2
endopeptidase	E-geneY-C4-2
EC	B-geneY-C4-2
3.4.24.11	E-geneY-C4-2
,	O
the	O
enzyme	O
that	O
degrades	O
atrial	B-geneY
natriuretic	I-geneY
peptide	E-geneY
(	O
ANP	S-geneY
)	O
.	O

The	O
acute	O
and	O
chronic	O
(	O
10	O
days	O
treatment	O
)	O
hemodynamic	O
and	O
hormonal	O
effects	O
of	O
candoxatril	S-chem
(	O
150	O
mg	O
twice	O
daily	O
)	O
in	O
12	O
patients	O
with	O
moderately	O
severe	O
congestive	O
heart	O
failure	O
were	O
investigated	O
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

On	O
study	O
day	O
1	O
,	O
candoxatril	S-chem-C3-1
acutely	O
increased	O
plasma	O
ANP	S-geneY-C3-2
levels	O
,	O
suppressed	O
aldosterone	S-chem
and	O
decreased	O
right	O
atrial	O
and	O
pulmonary	O
capillary	O
wedge	O
pressures	O
.	O

After	O
10	O
days	O
of	O
treatment	O
,	O
basal	O
ANP	S-geneY
was	O
increased	O
and	O
basal	O
aldosterone	S-chem
was	O
decreased	O
.	O

Body	O
weight	O
was	O
reduced	O
,	O
most	O
likely	O
reflecting	O
chronic	O
natriuretic	O
or	O
diuretic	O
effects	O
,	O
or	O
both	O
,	O
and	O
there	O
was	O
a	O
trend	O
toward	O
increased	O
cardiac	O
index	O
and	O
reduced	O
preload	O
values	O
.	O

On	O
study	O
day	O
10	O
,	O
the	O
acute	O
effects	O
of	O
candoxatril	S-chem-C3-1
were	O
similar	O
to	O
those	O
on	O
day	O
1	O
(	O
i.e	O
.	O
,	O
ANP	S-geneY-C3-2
was	O
further	O
increased	O
,	O
aldosterone	S-chem
was	O
suppressed	O
,	O
and	O
right	O
and	O
left	O
ventricular	O
filling	O
pressures	O
were	O
decreased	O
)	O
.	O

Thus	O
,	O
candoxatril	S-chem
may	O
offer	O
a	O
new	O
and	O
effective	O
therapeutic	O
approach	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O

Regulation	O
of	O
retinoic	B-geneN
acid	I-geneN
receptors	I-geneN
alpha	I-geneN
,	I-geneN
beta	E-geneN
and	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
alpha	E-geneY
after	O
sciatic	O
nerve	O
injury	O
.	O

Cell	O
culture	O
experiments	O
indicated	O
that	O
activation	O
of	O
the	O
retinoic	B-chem
acid	E-chem
signaling	O
system	O
is	O
involved	O
in	O
axonal	O
regeneration	O
.	O

This	O
hypothesis	O
was	O
tested	O
with	O
sciatic	O
nerve	O
injury	O
in	O
the	O
rat	O
.	O

Since	O
the	O
effect	O
of	O
retinoic	B-chem
acid	E-chem
is	O
mediated	O
via	O
retinoic	B-geneN
acid	I-geneN
receptors	E-geneN
and	O
retinoid	B-geneN
X	I-geneN
receptors	E-geneN
,	O
we	O
investigated	O
mRNA	O
and	O
protein	O
expression	O
of	O
these	O
receptors	O
during	O
injury	O
-	O
induced	O
degeneration	O
and	O
regeneration	O
.	O

Seven	O
days	O
after	O
crush	O
injury	O
,	O
transcript	O
concentrations	O
of	O
all	O
retinoic	B-geneN
acid	I-geneN
receptors	E-geneN
and	O
of	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
alpha	E-geneY
were	O
significantly	O
higher	O
than	O
in	O
non	O
-	O
lesioned	O
nerves	O
.	O

Protein	O
levels	O
of	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
alpha	E-geneY
,	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
beta	E-geneY
and	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
alpha	E-geneY
were	O
upregulated	O
4	O
,	O
7	O
and	O
14	O
days	O
after	O
injury	O
.	O

In	O
degenerating	O
nerves	O
a	O
significant	O
increase	O
of	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
alpha	E-geneY
was	O
detected	O
7	O
and	O
14	O
days	O
,	O
and	O
of	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
beta	E-geneY
14	O
and	O
21	O
days	O
after	O
complete	O
transection	O
.	O

Immunohistochemical	O
staining	O
of	O
retinoid	B-geneN
receptors	E-geneN
revealed	O
their	O
expression	O
in	O
Schwann	O
cells	O
and	O
macrophages	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
alpha	E-geneY
and	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
alpha	E-geneY
appeared	O
in	O
the	O
cell	O
nuclei	O
of	O
macrophages	O
during	O
the	O
lesion	O
-	O
induced	O
inflammatory	O
reaction	O
,	O
and	O
that	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
alpha	E-geneY
-	O
staining	O
co	O
-	O
localized	O
with	O
some	O
regenerating	O
axons	O
.	O

Experiments	O
with	O
Schwann	O
cell	O
primary	O
cultures	O
revealed	O
an	O
effect	O
of	O
retinoic	B-chem
acid	E-chem
on	O
the	O
expression	O
of	O
the	O
neuregulin	B-geneN
receptor	E-geneN
ErbB3	S-geneY
,	O
suggesting	O
that	O
one	O
function	O
of	O
retinoic	B-chem
acid	E-chem
consists	O
in	O
the	O
regulation	O
of	O
neuroglial	O
interactions	O
after	O
peripheral	O
nerve	O
injury	O
.	O

mTOR	S-geneY
Regulates	O
Nox4	S-geneY
-	O
Mediated	O
Podocyte	O
Depletion	O
in	O
Diabetic	O
Renal	O
Injury	O
.	O

Podocyte	O
apoptosis	O
is	O
a	O
critical	O
mechanism	O
for	O
excessive	O
loss	O
of	O
urinary	O
albumin	S-geneY
that	O
eventuates	O
in	O
kidney	O
fibrosis	O
.	O

Pharmacological	O
doses	O
of	O
the	O
mTOR	S-geneY-C4-2
inhibitor	O
rapamycin	S-chem-C4-1
reduce	O
albuminura	O
in	O
diabetes	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
mTOR	S-geneY
mediates	O
podocyte	O
injury	O
in	O
diabetes	O
.	O

High	O
glucose	S-chem-MU-1
(	O
HG	O
)	O
induces	O
apoptosis	O
of	O
podocytes	O
,	O
inhibits	O
AMPK	S-geneN-C4-2
activation	O
,	O
inactivates	O
tuberin	S-geneY-C4-2
and	O
activates	O
mTOR	S-geneY-C3-2
.	O

HG	O
also	O
increases	O
the	O
levels	O
of	O
Nox4	S-geneY
and	O
Nox1	S-geneY
and	O
NADPH	B-geneN
oxidase	E-geneN
activity	O
.	O

Inhibition	O
of	O
mTOR	S-geneY-C4-2
by	O
low	O
dose	O
rapamycin	S-chem-C4-1
decreases	O
HG	O
-	O
induced	O
Nox4	S-geneY-C4-2
and	O
Nox1	S-geneY-C4-2
,	O
NADPH	B-geneN-C4-2
oxidase	E-geneN-C4-2
activity	O
and	O
podocyte	O
apoptosis	O
.	O

Inhibition	O
of	O
mTOR	S-geneY
had	O
no	O
effect	O
on	O
AMPK	S-geneN
or	O
tuberin	S-geneY
phosphorylation	O
indicating	O
that	O
mTOR	S-geneY
is	O
downstream	O
of	O
these	O
signaling	O
molecules	O
.	O

In	O
isolated	O
glomeruli	O
of	O
OVE26	O
mice	O
,	O
there	O
is	O
similar	O
decrease	O
in	O
the	O
activation	O
of	O
AMPK	S-geneN
and	O
tuberin	S-geneY
and	O
activation	O
of	O
mTOR	S-geneY
with	O
increase	O
in	O
Nox4	S-geneY
and	O
NADPH	B-geneN
oxidase	E-geneN
activity	O
.	O

Inhibition	O
of	O
mTOR	S-geneY-C4-2
by	O
small	O
dose	O
of	O
rapamycin	S-chem-C4-1
reduces	O
podocyte	O
apoptosis	O
,	O
attenuates	O
glomerular	O
injury	O
and	O
albuminuria	O
.	O

Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
function	O
of	O
mTOR	S-geneY
in	O
Nox4	S-geneY
-	O
derived	O
ROS	O
generation	O
and	O
podocyte	O
apoptosis	O
that	O
contributes	O
to	O
urinary	O
albumin	S-geneY
excretion	O
in	O
type	O
1	O
diabetes	O
.	O

Thus	O
mTOR	S-geneY
and	O
or	O
NADPH	B-geneN
oxidase	E-geneN
inhibition	O
may	O
represent	O
a	O
therapeutic	O
modality	O
of	O
diabetic	O
kidney	O
disease	O
.	O

Fatal	O
hemorrhage	O
in	O
mice	O
lacking	O
gamma	B-geneY
-	I-geneY
glutamyl	I-geneY
carboxylase	E-geneY
.	O

The	O
carboxylation	O
of	O
glutamic	B-chem-C9-1
acid	E-chem-C9-1
residues	O
to	O
gamma	B-chem-C9-1
-	I-chem-C9-1
carboxyglutamic	I-chem-C9-1
acid	E-chem-C9-1
(	O
Gla	S-chem-C9-1
)	O
by	O
the	O
vitamin	B-geneY-C9-2
K	I-geneY-C9-2
-	I-geneY-C9-2
dependent	I-geneY-C9-2
gamma	I-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
carboxylase	E-geneY-C9-2
(	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
carboxylase	E-geneY-C9-2
)	O
is	O
an	O
essential	O
posttranslational	O
modification	O
required	O
for	O
the	O
biological	O
activity	O
of	O
a	O
number	O
of	O
proteins	O
,	O
including	O
proteins	O
involved	O
in	O
blood	O
coagulation	O
and	O
its	O
regulation	O
.	O

Heterozygous	O
mice	O
carrying	O
a	O
null	O
mutation	O
at	O
the	O
gamma	B-geneY
-	I-geneY
carboxylase	E-geneY
(	O
Ggcx	S-geneY
)	O
gene	O
exhibit	O
normal	O
development	O
and	O
survival	O
with	O
no	O
evidence	O
of	O
hemorrhage	O
and	O
normal	O
functional	O
activity	O
of	O
the	O
vitamin	B-geneN
K	I-geneN
-	I-geneN
dependent	I-geneN
clotting	I-geneN
factors	I-geneN
IX	I-geneN
,	I-geneN
X	E-geneN
,	O
and	O
prothrombin	S-geneY
.	O

Analysis	O
of	O
a	O
Ggcx	S-geneY
(	O
+	O
/	O
-	O
)	O
intercross	O
revealed	O
a	O
partial	O
developmental	O
block	O
with	O
only	O
50	O
%	O
of	O
expected	O
Ggcx	S-geneY
(	O
-	O
/	O
-	O
)	O
offspring	O
surviving	O
to	O
term	O
,	O
with	O
the	O
latter	O
animals	O
dying	O
uniformly	O
at	O
birth	O
of	O
massive	O
intra	O
-	O
abdominal	O
hemorrhage	O
.	O

This	O
phenotype	O
closely	O
resembles	O
the	O
partial	O
midembryonic	O
loss	O
and	O
postnatal	O
hemorrhage	O
previously	O
reported	O
for	O
both	O
prothrombin	S-geneY
-	O
and	O
factor	B-geneY
V	E-geneY
(	O
F5	S-geneY
)	O
-	O
deficient	O
mice	O
.	O

These	O
data	O
exclude	O
the	O
existence	O
of	O
a	O
redundant	O
carboxylase	S-geneN
pathway	O
and	O
suggest	O
that	O
functionally	O
critical	O
substrates	O
for	O
gamma	O
-	O
carboxylation	O
,	O
at	O
least	O
in	O
the	O
developing	O
embryo	O
and	O
neonate	O
,	O
are	O
primarily	O
restricted	O
to	O
components	O
of	O
the	O
blood	O
coagulation	O
cascade	O
.	O

Chemopreventive	O
effects	O
of	O
Ginkgo	O
biloba	O
extract	O
in	O
estrogen	S-chem
-	O
negative	O
human	O
breast	O
cancer	O
cells	O
.	O

Excessive	O
level	O
of	O
estrogen	S-chem
is	O
considered	O
as	O
a	O
main	O
cause	O
of	O
breast	O
cancer	O
,	O
therefore	O
,	O
many	O
studies	O
have	O
focused	O
on	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
-	O
positive	O
breast	O
cancer	O
,	O
even	O
though	O
ER	S-geneY
-	O
negative	O
cancer	O
has	O
a	O
poor	O
prognosis	O
than	O
ER	S-geneY
-	O
positive	O
breast	O
cancer	O
.	O

We	O
evaluated	O
the	O
anti	O
-	O
cancer	O
effects	O
of	O
Ginkgo	O
biloba	O
extract	O
(	O
GBE	O
)	O
in	O
estrogen	S-chem
-	O
independent	O
breast	O
cancer	O
.	O

GBE	O
has	O
been	O
traditionally	O
used	O
as	O
a	O
platelet	O
activating	O
factor	O
,	O
a	O
circulatory	O
stimulant	O
,	O
a	O
tonic	O
,	O
and	O
anti	O
-	O
asthmatic	O
drug	O
,	O
and	O
anti	O
-	O
cancer	O
agent	O
.	O
However	O
,	O
anti	O
-	O
cancer	O
effects	O
of	O
GBE	O
on	O
ER	O
-	E-geneY
negative	O
breast	O
cancer	O
have	O
not	O
been	O
proved	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
chemotherapeutic	O
potential	O
of	O
GBE	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
ER	S-geneY
-	O
negative	O
)	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O
Our	O
results	O
showed	O
that	O
cytotoxicity	O
effects	O
of	O
GBE	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
lead	O
to	O
DNA	O
fragmentation	O
at	O
high	O
concentrations	O
(	O
500	O
and	O
1,000	O
μg	O
/	O
ml	O
)	O
.	O

Caspase	B-geneY
-	I-geneY
3	E-geneY
was	O
significantly	O
activated	O
and	O
mRNA	O
levels	O
of	O
apoptosis	O
-	O
related	O
genes	O
(	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
and	O
Bax	S-geneY
)	O
were	O
altered	O
.	O

These	O
results	O
indicate	O
that	O
GBE	O
induces	O
apoptosis	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

It	O
is	O
presumed	O
that	O
GBE	O
has	O
chemopreventive	O
effects	O
in	O
ER	S-geneY
-	O
independent	O
breast	O
cancer	O
through	O
anti	O
-	O
proliferation	O
and	O
apoptosis	O
-	O
inducing	O
activities	O
.	O

The	O
role	O
of	O
platelet	O
/	O
lymphocyte	O
serotonin	B-geneY
transporter	E-geneY
in	O
depression	O
and	O
beyond	O
.	O

A	O
large	O
amount	O
of	O
the	O
data	O
gathered	O
in	O
the	O
last	O
50	O
years	O
support	O
the	O
hypothesis	O
that	O
alterations	O
of	O
the	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
neurotransmission	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
not	O
only	O
major	O
depression	O
(	O
MD	O
)	O
,	O
but	O
also	O
of	O
different	O
neuropsychiatric	O
disorders	O
.	O

Research	O
in	O
this	O
field	O
has	O
been	O
substantially	O
promoted	O
by	O
the	O
evidence	O
that	O
the	O
reuptake	O
protein	O
(	O
SERT	S-geneY
)	O
,	O
present	O
in	O
presynaptic	O
neurons	O
,	O
is	O
a	O
key	O
element	O
in	O
terminating	O
the	O
activity	O
of	O
the	O
neurotransmitter	O
in	O
the	O
synaptic	O
cleft	O
.	O

For	O
this	O
reason	O
,	O
it	O
was	O
specifically	O
targeted	O
for	O
the	O
development	O
of	O
second	O
-	O
generation	O
antidepressants	O
,	O
in	O
particular	O
of	O
selective	O
5	B-chem
-	I-chem
HT	E-chem
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
with	O
the	O
aim	O
of	O
increasing	O
the	O
intrasynaptic	O
5	B-chem
-	I-chem
HT	E-chem
concentrations	O
.	O

Moreover	O
,	O
since	O
a	O
lot	O
of	O
studies	O
showed	O
that	O
circulating	O
platelets	O
and	O
,	O
more	O
recently	O
,	O
lymphocytes	O
possess	O
functional	O
SERT	S-geneY
proteins	O
,	O
they	O
have	O
been	O
widely	O
used	O
as	O
peripheral	O
mirrors	O
of	O
the	O
same	O
structures	O
located	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
presence	O
of	O
functional	O
SERT	S-geneY
in	O
blood	O
cells	O
suggests	O
strict	O
relationships	O
between	O
the	O
nervous	O
and	O
the	O
immune	O
system	O
that	O
need	O
to	O
be	O
better	O
clarified	O
in	O
MD	O
,	O
as	O
well	O
as	O
the	O
possibility	O
of	O
reciprocal	O
modulation	O
of	O
the	O
two	O
systems	O
by	O
different	O
drugs	O
.	O

This	O
paper	O
aims	O
to	O
review	O
briefly	O
the	O
literature	O
on	O
the	O
5	B-chem
-	I-chem
HT	E-chem
hypothesis	O
of	O
depression	O
with	O
a	O
major	O
focus	O
on	O
the	O
possible	O
role	O
of	O
SERT	S-geneY
in	O
this	O
disorder	O
,	O
while	O
highlighting	O
how	O
recent	O
data	O
are	O
more	O
oriented	O
on	O
dimensional	O
rather	O
than	O
nosological	O
involvement	O
of	O
this	O
structure	O
in	O
different	O
conditions	O
spanning	O
from	O
normality	O
to	O
pathology	O
.	O

Folding	O
pathway	O
of	O
guanidine	S-chem
-	O
denatured	O
disulfide	S-chem
-	O
intact	O
wild	O
-	O
type	O
and	O
mutant	O
bovine	B-geneY
pancreatic	I-geneY
ribonuclease	I-geneY
A	E-geneY
.	O

The	O
refolding	O
kinetics	O
of	O
guanidine	S-chem
-	O
denatured	O
disulfide	S-chem
-	O
intact	O
bovine	B-geneY-C4-2
pancreatic	I-geneY-C4-2
ribonuclease	I-geneY-C4-2
A	E-geneY-C4-2
(	O
RNase	B-geneY-C4-2
A	E-geneY-C4-2
)	O
and	O
its	O
proline	B-geneN-C4-2
-	I-geneN-C4-2
42	I-geneN-C4-2
-	I-geneN-C4-2
to	I-geneN-C4-2
-	I-geneN-C4-2
alanine	E-geneN-C4-2
mutant	O
(	O
Pro42Ala	S-geneN-C4-2
)	O
have	O
been	O
studied	O
by	O
monitoring	O
tyrosine	S-chem
burial	O
and	O
2	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
cytidine	I-chem-C4-1
monophosphate	E-chem-C4-1
(	O
2'CMP	S-chem-C4-1
)	O
inhibitor	O
binding	O
.	O

The	O
folding	O
rate	O
for	O
wild	O
-	O
type	O
RNase	B-geneY-C4-2
A	E-geneY-C4-2
is	O
faster	O
in	O
the	O
presence	O
of	O
the	O
inhibitor	O
2'CMP	S-chem-C4-1
than	O
in	O
its	O
absence	O
,	O
indicating	O
that	O
the	O
transition	O
-	O
state	O
structure	O
in	O
the	O
rate	O
-	O
determining	O
step	O
is	O
stabilized	O
by	O
2'CMP	S-chem
.	O

The	O
folding	O
rate	O
monitored	O
by	O
2'CMP	S-chem
binding	O
to	O
the	O
major	O
slow	O
-	O
folding	O
species	O
of	O
Pro42Ala	S-geneN
RNase	B-geneY
A	E-geneY
is	O
faster	O
than	O
the	O
folding	O
rate	O
monitored	O
by	O
tyrosine	S-chem
burial	O
;	O
however	O
,	O
the	O
folding	O
rate	O
monitored	O
by	O
inhibitor	O
binding	O
to	O
the	O
minor	O
slow	O
-	O
folding	O
species	O
is	O
decreased	O
significantly	O
over	O
the	O
folding	O
rate	O
monitored	O
by	O
tyrosine	S-chem
burial	O
,	O
indicating	O
that	O
the	O
major	O
and	O
minor	O
slow	O
-	O
folding	O
species	O
of	O
Pro42Ala	S-geneN
fold	O
to	O
the	O
native	O
state	O
with	O
different	O
transition	O
-	O
state	O
conformations	O
in	O
the	O
rate	O
-	O
determining	O
step	O
.	O

Dissociation	O
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
-	O
Beclin1	S-geneY
complex	O
by	O
activated	O
AMPK	S-geneY
enhances	O
cardiac	O
autophagy	O
and	O
protects	O
against	O
cardiomyocyte	O
apoptosis	O
in	O
diabetes	O
.	O

Diabetic	O
cardiomyopathy	O
is	O
associated	O
with	O
suppression	O
of	O
cardiac	O
autophagy	O
,	O
and	O
activation	O
of	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	E-geneY
(	O
AMPK	S-geneY
)	O
restores	O
cardiac	O
autophagy	O
and	O
prevents	O
cardiomyopathy	O
in	O
diabetic	O
mice	O
,	O
albeit	O
by	O
an	O
unknown	O
mechanism	O
.	O

We	O
hypothesized	O
that	O
AMPK	S-geneN
-	O
induced	O
autophagy	O
ameliorates	O
diabetic	O
cardiomyopathy	O
by	O
inhibiting	O
cardiomyocyte	O
apoptosis	O
and	O
examined	O
the	O
effects	O
of	O
AMPK	S-geneN
on	O
the	O
interaction	O
between	O
Beclin1	S-geneN
and	O
Bcl	B-geneN
-	I-geneN
2	E-geneN
,	O
a	O
switch	O
between	O
autophagy	O
and	O
apoptosis	O
,	O
in	O
diabetic	O
mice	O
and	O
high	O
glucose	S-chem
-	O
treated	O
H9c2	O
cardiac	O
myoblast	O
cells	O
.	O

Exposure	O
of	O
H9c2	O
cells	O
to	O
high	O
glucose	S-chem-C4-1
reduced	O
AMPK	S-geneY-C4-2
activity	O
,	O
inhibited	O
Jun	B-geneY-C4-2
NH2	I-geneY-C4-2
-	I-geneY-C4-2
terminal	I-geneY-C4-2
kinase	I-geneY-C4-2
1	E-geneY-C4-2
(	O
JNK1	S-geneY-C4-2
)	O
-	O
B	B-geneY-C4-2
-	I-geneY-C4-2
cell	I-geneY-C4-2
lymphoma	I-geneY-C4-2
2	E-geneY-C4-2
(	O
Bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
signaling	O
,	O
and	O
promoted	O
Beclin1	S-geneY
binding	O
to	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
.	O

Conversely	O
,	O
activation	O
of	O
AMPK	S-geneY
by	O
metformin	O
stimulated	O
JNK1	S-geneY
-	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
signaling	O
and	O
disrupted	O
the	O
Beclin1	S-geneY
-	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
complex	O
.	O

Activation	O
of	O
AMPK	S-geneY
,	O
which	O
normalized	O
cardiac	O
autophagy	O
,	O
attenuated	O
high	O
glucose	S-chem
-	O
induced	O
apoptosis	O
in	O
cultured	O
H9c2	O
cells	O
.	O

This	O
effect	O
was	O
attenuated	O
by	O
inhibition	O
of	O
autophagy	O
.	O

Finally	O
,	O
chronic	O
administration	O
of	O
metformin	S-chem-C3-1
in	O
diabetic	O
mice	O
restored	O
cardiac	O
autophagy	O
by	O
activating	O
JNK1	S-geneY-C3-2
-	O
Bcl	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
pathways	O
and	O
dissociating	O
Beclin1	S-geneY
and	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
.	O

The	O
induction	O
of	O
autophagy	O
protected	O
against	O
cardiac	O
apoptosis	O
and	O
improved	O
cardiac	O
structure	O
and	O
function	O
in	O
diabetic	O
mice	O
.	O

We	O
concluded	O
that	O
dissociation	O
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
from	O
Beclin1	S-geneY
may	O
be	O
an	O
important	O
mechanism	O
for	O
preventing	O
diabetic	O
cardiomyopathy	O
via	O
AMPK	S-geneN
activation	O
that	O
restores	O
autophagy	O
and	O
protects	O
against	O
cardiac	O
apoptosis	O
.	O

Depletion	O
of	O
molecular	O
chaperones	O
from	O
the	O
endoplasmic	O
reticulum	O
and	O
fragmentation	O
of	O
the	O
Golgi	O
apparatus	O
associated	O
with	O
pathogenesis	O
in	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
.	O

Missense	O
mutations	O
in	O
the	O
proteolipid	B-geneY
protein	I-geneY
1	E-geneY
(	O
PLP1	S-geneY
)	O
gene	O
cause	O
a	O
wide	O
spectrum	O
of	O
hypomyelinating	O
disorders	O
,	O
from	O
mild	O
spastic	O
paraplegia	O
type	O
2	O
to	O
severe	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
(	O
PMD	O
)	O
.	O

Mutant	O
PLP1	S-geneY
accumulates	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
induces	O
ER	O
stress	O
.	O

However	O
,	O
the	O
link	O
between	O
the	O
clinical	O
severity	O
of	O
PMD	O
and	O
the	O
cellular	O
response	O
induced	O
by	O
mutant	O
PLP1	S-geneY
remains	O
largely	O
unknown	O
.	O

Accumulation	O
of	O
misfolded	O
proteins	O
in	O
the	O
ER	O
generally	O
leads	O
to	O
up	O
-	O
regulation	O
of	O
ER	O
chaperones	O
to	O
alleviate	O
ER	O
stress	O
.	O

Here	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
PLP1	S-geneY
-	O
A243V	S-geneN
mutant	O
,	O
which	O
causes	O
severe	O
disease	O
,	O
depletes	O
some	O
ER	O
chaperones	O
with	O
a	O
KDEL	S-geneN
(	O
Lys	B-geneN
-	I-geneN
Asp	I-geneN
-	I-geneN
Glu	I-geneN
-	I-geneN
Leu	E-geneN
)	O
motif	O
,	O
in	O
HeLa	O
cells	O
,	O
MO3.13	O
oligodendrocytic	O
cells	O
,	O
and	O
primary	O
oligodendrocytes	O
.	O

The	O
same	O
PLP1	S-geneY
mutant	O
also	O
induces	O
fragmentation	O
of	O
the	O
Golgi	O
apparatus	O
(	O
GA	O
)	O
.	O

These	O
organelle	O
changes	O
are	O
less	O
prominent	O
in	O
cells	O
with	O
milder	O
disease	O
-	O
associated	O
PLP1	S-geneY
mutants	O
.	O

Similar	O
changes	O
are	O
also	O
observed	O
in	O
cells	O
expressing	O
another	O
disease	O
-	O
causing	O
gene	O
that	O
triggers	O
ER	O
stress	O
,	O
as	O
well	O
as	O
in	O
cells	O
treated	O
with	O
brefeldin	B-chem
A	E-chem
,	O
which	O
induces	O
ER	O
stress	O
and	O
GA	O
fragmentation	O
by	O
inhibiting	O
GA	O
to	O
ER	O
trafficking	O
.	O

We	O
also	O
found	O
that	O
mutant	O
PLP1	S-geneY
disturbs	O
localization	O
of	O
the	O
KDEL	S-geneN
receptor	O
,	O
which	O
transports	O
the	O
chaperones	O
with	O
the	O
KDEL	B-geneN
motif	E-geneN
from	O
the	O
GA	O
to	O
the	O
ER	O
.	O

These	O
data	O
show	O
that	O
PLP1	S-geneY
mutants	O
inhibit	O
GA	O
to	O
ER	O
trafficking	O
,	O
which	O
reduces	O
the	O
supply	O
of	O
ER	O
chaperones	O
and	O
induces	O
GA	O
fragmentation	O
.	O

We	O
propose	O
that	O
depletion	O
of	O
ER	O
chaperones	O
and	O
GA	O
fragmentation	O
induced	O
by	O
mutant	O
misfolded	O
proteins	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
inherited	O
ER	O
stress	O
-	O
related	O
diseases	O
and	O
affect	O
the	O
disease	O
severity	O
.	O

Anti	O
-	O
asthmatic	O
Effects	O
of	O
Baicalin	S-chem
in	O
a	O
Mouse	O
Model	O
of	O
Allergic	O
Asthma	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
anti	O
-	O
asthmatic	O
effects	O
of	O
baicalin	S-chem
(	O
BA	O
)	O
and	O
the	O
possible	O
mechanisms	O
.	O

Asthma	O
model	O
was	O
established	O
by	O
ovalbumin	S-geneY
(	O
OVA	S-geneY
)	O
intraperitoneal	O
injection	O
.	O

A	O
total	O
of	O
60	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
experimental	O
groups	O
:	O
control	O
,	O
model	O
,	O
dexamethasone	S-chem
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
and	O
BA	O
(	O
10	O
mg	O
/	O
kg	O
,	O
20	O
mg	O
/	O
kg	O
,	O
40	O
mg	O
/	O
kg	O
)	O
.	O

Airway	O
resistance	O
(	O
RI	O
)	O
and	O
lung	O
compliance	O
(	O
Cdyn	O
)	O
were	O
measured	O
,	O
histological	O
studies	O
were	O
evaluated	O
by	O
the	O
hematoxylin	S-chem
and	O
eosin	S-chem
staining	O
,	O
Th1	O
/	O
Th2	O
,	O
OVA	S-geneY
-	O
specific	O
serum	O
,	O
and	O
BALF	O
IgE	S-geneN
levels	O
and	O
Th17	O
cytokines	S-geneN
were	O
evaluated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
Th17	O
cells	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

Our	O
study	O
demonstrated	O
that	O
BA	O
inhibited	O
OVA	S-geneY
-	O
induced	O
increases	O
in	O
RI	O
and	O
eosinophil	O
count	O
;	O
interleukin	O
(	B-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
4	E-geneY
,	O
IL	B-geneY
-	I-geneY
17A	E-geneY
levels	O
,	O
and	O
Cdyn	O
were	O
recovered	O
and	O
increased	O
IFN	B-geneY
-	I-geneY
γ	E-geneY
level	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
BA	O
substantially	O
inhibited	O
OVA	S-geneY
-	O
induced	O
eosinophilia	O
in	O
lung	O
tissue	O
and	O
airway	O
tissue	O
.	O

FCM	O
studies	O
demonstrated	O
that	O
BA	O
substantially	O
inhibited	O
Th17	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
BA	O
may	O
effectively	O
ameliorate	O
the	O
progression	O
of	O
asthma	O
and	O
could	O
be	O
used	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
allergic	O
asthma	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Adenosine	B-geneN
receptor	E-geneN
antagonists	O
intensify	O
the	O
benzodiazepine	S-chem
withdrawal	O
signs	O
in	O
mice	O
.	O

The	O
aim	O
of	O
the	O
present	O
experiment	O
was	O
to	O
assess	O
the	O
involvement	O
of	O
adenosine	B-geneN
receptor	E-geneN
antagonists	O
in	O
benzodiazepine	S-chem
(	O
BDZ	S-chem
)	O
withdrawal	O
signs	O
,	O
observed	O
as	O
the	O
seizure	O
susceptibility	O
in	O
mice	O
.	O

The	O
discontinuation	O
of	O
chronic	O
treatment	O
with	O
temazepam	S-chem
or	O
diazepam	S-chem
decreased	O
seizure	O
threshold	O
(	O
one	O
of	O
BDZ	S-chem
withdrawal	O
signs	O
)	O
.	O

The	O
concomitant	O
application	O
of	O
subconvulsive	O
dose	O
of	O
pentetrazole	S-chem
(	O
55.0	O
mg	O
/	O
kg	O
)	O
with	O
low	O
dose	O
of	O
flumazenil	S-chem-C6-1
(	O
5.0	O
mg	O
/	O
kg	O
)	O
-	O
a	O
BDZ	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
immediately	O
induced	O
BDZ	S-chem
withdrawal	O
signs	O
in	O
these	O
animals	O
.	O

The	O
non	O
-	O
selective	O
adenosine	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
(	O
caffeine	S-chem-C6-1
)	O
,	O
and	O
the	O
selective	O
adenosine	B-geneY-C6-2
A1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
(	O
DPCPX	S-chem-C6-1
)	O
,	O
injected	O
15	O
min	O
before	O
the	O
application	O
of	O
pentetrazole	S-chem
and	O
flumazenil	S-chem
,	O
were	O
able	O
to	O
intensify	O
BDZ	S-chem
withdrawal	O
signs	O
in	O
mice	O
.	O

The	O
most	O
apparent	O
effects	O
were	O
observed	O
after	O
administration	O
of	O
DPCPX	S-chem
,	O
indicating	O
that	O
the	O
adenosine	B-geneY
A1	I-geneY
receptor	E-geneY
may	O
play	O
a	O
more	O
important	O
role	O
in	O
these	O
effects	O
.	O

The	O
obtained	O
data	O
demonstrate	O
that	O
the	O
adenosinergic	O
system	O
is	O
involved	O
in	O
BDZ	S-chem
withdrawal	O
signs	O
in	O
mice	O
,	O
and	O
adenosine	B-geneY
A1	I-geneY
receptor	E-geneY
plays	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Bioactive	O
flavaglines	S-chem
and	O
other	O
constituents	O
isolated	O
from	O
Aglaia	O
perviridis	O
.	O

Eight	O
new	O
compounds	O
,	O
including	O
two	O
cyclopenta	B-chem
[	I-chem
b	I-chem
]	I-chem
benzopyran	E-chem
derivatives	O
(	O
1	O
,	O
2	O
)	O
,	O
two	O
cyclopenta	B-chem
[	I-chem
b	I-chem
]	I-chem
benzofuran	E-chem
derivatives	O
(	O
3	O
,	O
4	O
)	O
,	O
three	O
cycloartane	B-chem
triterpenoids	E-chem
(	O
5	O
-	O
7	O
)	O
,	O
and	O
an	O
apocarotenoid	O
(	O
8	O
)	O
,	O
together	O
with	O
16	O
known	O
compounds	O
,	O
were	O
isolated	O
from	O
the	O
chloroform	S-chem
-	O
soluble	O
partitions	O
of	O
separate	O
methanol	S-chem
extracts	O
of	O
a	O
combination	O
of	O
the	O
fruits	O
,	O
leaves	O
,	O
and	O
twigs	O
and	O
of	O
the	O
roots	O
of	O
Aglaia	O
perviridis	O
collected	O
in	O
Vietnam	O
.	O

Isolation	O
work	O
was	O
monitored	O
using	O
human	O
colon	O
cancer	O
cells	O
(	O
HT	O
-	O
29	O
)	O
and	O
facilitated	O
with	O
an	O
LC	O
/	O
MS	O
dereplication	O
procedure	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
(	O
1	O
-	O
8	O
)	O
were	O
determined	O
on	O
the	O
basis	O
of	O
spectroscopic	O
data	O
interpretation	O
.	O

The	O
Mosher	O
ester	O
method	O
was	O
employed	O
to	O
determine	O
the	O
absolute	O
configurations	O
of	O
5	O
-	O
7	O
,	O
and	O
the	O
absolute	O
configuration	O
of	O
the	O
9,10	O
-	O
diol	S-chem
unit	O
of	O
compound	O
8	O
was	O
established	O
by	O
a	O
dimolybdenum	B-chem
tetraacetate	E-chem
[	O
Mo2	B-chem
(	I-chem
AcO	I-chem
)	I-chem
4	E-chem
]	O
induced	O
circular	O
dichroism	O
procedure	O
.	O

Seven	O
known	O
rocaglate	S-chem
derivatives	O
(	O
9	O
-	O
15	O
)	O
exhibited	O
significant	O
cytotoxicity	O
against	O
the	O
HT	O
-	O
29	O
cell	O
line	O
,	O
with	O
rocaglaol	S-chem
(	O
9	O
)	O
being	O
the	O
most	O
potent	O
(	O
ED50	O
0.0007	O
μM	O
)	O
.	O

The	O
new	O
compounds	O
2	O
-	O
4	O
were	O
also	O
active	O
against	O
this	O
cell	O
line	O
,	O
with	O
ED50	O
values	O
ranging	O
from	O
0.46	O
to	O
4.7	O
μM	O
.	O

The	O
cytotoxic	O
compounds	O
were	O
evaluated	O
against	O
a	O
normal	O
colon	O
cell	O
line	O
,	O
CCD	O
-	O
112CoN	O
.	O

In	O
addition	O
,	O
the	O
new	O
compound	O
perviridicin	B-chem-C4-1
B	E-chem-C4-1
(	O
2	O
)	O
,	O
three	O
known	O
rocaglate	S-chem-C4-1
derivatives	O
(	O
9	O
,	O
11	O
,	O
12	O
)	O
,	O
and	O
a	O
known	O
sesquiterpene	S-chem-C4-1
,	O
2	B-chem-C4-1
-	I-chem-C4-1
oxaisodauc	I-chem-C4-1
-	I-chem-C4-1
5	I-chem-C4-1
-	I-chem-C4-1
en	I-chem-C4-1
-	I-chem-C4-1
12	I-chem-C4-1
-	I-chem-C4-1
al	E-chem-C4-1
(	O
17	O
)	O
,	O
showed	O
significant	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
(	O
p65	S-geneY-C4-2
)	O
inhibitory	O
activity	O
in	O
an	O
ELISA	O
assay	O
.	O

Multidrug	B-geneN-C9-2
resistance	I-geneN-C9-2
-	I-geneN-C9-2
associated	I-geneN-C9-2
proteins	E-geneN-C9-2
are	O
involved	O
in	O
the	O
transport	O
of	O
the	O
glutathione	S-chem-C9-1
conjugates	O
of	O
the	O
ultimate	O
carcinogen	O
of	O
benzo	B-chem
[	I-chem
a	I-chem
]	I-chem
pyrene	E-chem
in	O
human	O
Caco	O
-	O
2	O
cells	O
.	O

A	O
wide	O
variety	O
of	O
contaminants	O
are	O
ingested	O
through	O
food	O
,	O
among	O
them	O
the	O
pro	O
-	O
carcinogenic	O
polycyclic	O
aromatic	O
hydrocarbon	O
benzo	B-chem
[	I-chem
a	I-chem
]	I-chem
pyrene	E-chem
(	O
BP	O
)	O
that	O
is	O
resorbed	O
and	O
partially	O
metabolized	O
in	O
the	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

Previous	O
in	O
vitro	O
studies	O
have	O
revealed	O
that	O
BP	B-chem
phenols	E-chem
are	O
excreted	O
as	O
Phase	O
II	O
metabolites	O
including	O
glucuronides	O
and	O
sulfates	S-chem
.	O

This	O
export	O
is	O
mediated	O
by	O
the	O
breast	B-geneY
cancer	I-geneY
resistance	I-geneY
protein	E-geneY
(	O
ABCG2	S-geneY
)	O
.	O

The	O
ultimate	O
carcinogenic	O
Phase	O
I	O
BP	O
metabolite	O
anti	O
-	O
BP	B-chem
-	I-chem
7,8	I-chem
-	I-chem
dihydrodiol	I-chem
-	I-chem
9,10	I-chem
-	I-chem
epoxide	E-chem
(	O
BPDE	S-chem
)	O
can	O
be	O
detoxified	O
by	O
glutathione	S-chem-C9-1
conjugate	O
formation	O
catalyzed	O
by	O
glutathione	B-geneN-C9-2
S	I-geneN-C9-2
-	I-geneN-C9-2
transferases	E-geneN-C9-2
.	O

In	O
the	O
present	O
study	O
,	O
differentiated	O
human	O
intestinal	O
Caco	O
-	O
2	O
cells	O
were	O
used	O
as	O
a	O
model	O
for	O
the	O
human	O
small	O
intestine	O
to	O
investigate	O
the	O
detoxification	O
of	O
BPDE	S-chem
and	O
excretion	O
of	O
stereoisomeric	O
glutathione	S-chem
conjugates	O
in	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
the	O
glutathione	B-geneN
-	I-geneN
cleaving	I-geneN
enzyme	E-geneN
γ	B-geneN
-	I-geneN
glutamyl	I-geneN
transpeptidase	E-geneN
at	O
the	O
cell	O
surface	O
.	O

The	O
results	O
indicate	O
that	O
the	O
glutathione	S-chem
conjugates	O
of	O
BPDE	S-chem
are	O
formed	O
and	O
excreted	O
mainly	O
to	O
the	O
apical	O
and	O
to	O
a	O
minor	O
extent	O
to	O
the	O
basolateral	O
side	O
of	O
polarized	O
Caco	O
-	O
2	O
monolayers	O
.	O

Inhibition	O
studies	O
revealed	O
that	O
the	O
multidrug	B-geneN-C9-2
resistance	I-geneN-C9-2
-	I-geneN-C9-2
associated	I-geneN-C9-2
proteins	E-geneN-C9-2
(	O
ABCCs	S-geneN-C9-2
)	O
are	O
involved	O
in	O
the	O
transport	O
of	O
BPDE	B-chem-C9-1
glutathione	E-chem-C9-1
conjugates	O
.	O

Stable	O
ABCC1	S-geneY-C9-2
,	O
ABCC2	S-geneY-C9-2
and	O
ABCC3	S-geneY
knockdown	O
cell	O
lines	O
were	O
generated	O
,	O
thus	O
making	O
it	O
possible	O
to	O
demonstrate	O
that	O
ABCC1	S-geneY-C9-2
mediates	O
the	O
basolateral	O
and	O
ABCC2	S-geneY-C9-2
the	O
apical	O
excretion	O
of	O
BPDE	B-chem-C9-1
glutathione	E-chem-C9-1
conjugates	O
.	O

In	O
conclusion	O
,	O
the	O
ultimate	O
carcinogen	O
BPDE	S-chem
is	O
detoxified	O
via	O
glutathione	S-chem
conjugation	O
and	O
subsequently	O
excreted	O
by	O
Caco	O
-	O
2	O
cells	O
in	O
both	O
apical	O
and	O
basolateral	O
directions	O
.	O

This	O
finding	O
is	O
equivalent	O
to	O
a	O
transport	O
into	O
feces	O
as	O
well	O
as	O
blood	O
system	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

Apoptosis	O
initiation	O
of	O
β	B-chem
-	I-chem
ionone	E-chem
in	O
SGC	O
-	O
7901	O
gastric	O
carcinoma	O
cancer	O
cells	O
via	O
a	O
PI3K	S-geneN
-	O
AKT	S-geneN
pathway	O
.	O

β	B-chem
-	I-chem
ionone	E-chem
has	O
been	O
shown	O
to	O
hold	O
potent	O
anti	O
-	O
proliferative	O
and	O
apoptosis	O
induction	O
properties	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
β	B-chem
-	I-chem
ionone	E-chem
on	O
apoptosis	O
initiation	O
and	O
its	O
possible	O
mechanisms	O
of	O
action	O
,	O
we	O
qualified	O
cell	O
apoptosis	O
,	O
proteins	O
related	O
to	O
apoptosis	O
and	O
a	O
phosphatidylinositol	B-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
(	O
PI3K	S-geneN
)	O
-	O
AKT	S-geneN
pathway	O
in	O
human	O
gastric	O
adenocarcinoma	O
cancer	O
SGC	O
-	O
7901	O
cells	O
.	O

The	O
results	O
demonstrated	O
that	O
β	B-chem
-	I-chem
ionone	E-chem
-	O
induced	O
apoptosis	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
SGC	O
-	O
7901	O
cells	O
treated	O
with	O
β	B-chem
-	I-chem
ionone	E-chem
(	O
25	O
,	O
50	O
,	O
100	O
and	O
200	O
μmol	O
/	O
L	O
)	O
for	O
24	O
h	O
.	O

β	B-chem-MU-1
-	I-chem-MU-1
ionone	E-chem-MU-1
was	O
also	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
cleaved	O
-	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
and	O
inhibit	O
bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
expression	O
in	O
SGC	O
-	O
7901	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
significantly	O
decreased	O
levels	O
of	O
p	B-geneN-C4-2
-	I-geneN-C4-2
PI3K	E-geneN-C4-2
and	O
p	B-geneN-C4-2
-	I-geneN-C4-2
AKT	E-geneN-C4-2
expression	O
were	O
observed	O
in	O
SGC	O
-	O
7901	O
cells	O
after	O
β	B-chem-C4-1
-	I-chem-C4-1
ionone	E-chem-C4-1
treatments	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Thus	O
,	O
the	O
apoptosis	O
induction	O
in	O
SGC	O
-	O
7901	O
cells	O
by	O
β	B-chem
-	I-chem
ionone	E-chem
may	O
be	O
regulated	O
through	O
a	O
PI3K	S-geneN
-	O
AKT	S-geneN
pathway	O
.	O

These	O
results	O
demonstrate	O
a	O
potential	O
mechanism	O
by	O
which	O
β	B-chem
-	I-chem
ionone	E-chem
to	O
induce	O
apoptosis	O
initiation	O
in	O
SGC	O
-	O
7901	O
cells	O
.	O

Nuclear	B-geneN
receptor	E-geneN
CAR	S-geneY
specifically	O
activates	O
the	O
two	O
-	O
pore	O
K	B-geneN
+	I-geneN
channel	E-geneN
Kcnk1	S-geneY
gene	O
in	O
male	O
mouse	O
livers	O
,	O
which	O
attenuates	O
phenobarbital	S-chem
-	O
induced	O
hepatic	O
hyperplasia	O
.	O

KCNK1	S-geneY-C3-2
,	O
a	O
member	O
of	O
the	O
family	O
of	O
two	O
-	O
pore	O
K	B-geneN-C3-2
(	I-geneN-C3-2
+	I-geneN-C3-2
)	I-geneN-C3-2
ion	I-geneN-C3-2
channels	E-geneN-C3-2
,	O
is	O
specifically	O
induced	O
in	O
the	O
livers	O
of	O
male	O
mice	O
after	O
phenobarbital	S-chem-C3-1
treatment	O
.	O

Here	O
,	O
we	O
have	O
determined	O
the	O
molecular	O
mechanism	O
of	O
this	O
male	O
-	O
specific	O
activation	O
of	O
the	O
Kcnk1	S-geneY-C3-2
gene	O
and	O
characterized	O
KCNK1	S-geneY-C3-2
as	O
a	O
phenobarbital	S-chem-C3-1
-	O
inducible	O
antihyperplasia	O
factor	O
.	O

Upon	O
activation	O
by	O
phenobarbital	S-chem-C3-1
,	O
nuclear	B-geneN-C3-2
receptor	E-geneN-C3-2
CAR	S-geneY-C3-2
binds	O
the	O
97	O
-	O
bp	O
response	O
element	O
(	O
-	O
2441	O
/	O
-	O
2345	O
)	O
within	O
the	O
Kcnk1	B-geneN
promoter	E-geneN
.	O

This	O
binding	O
is	O
observed	O
in	O
the	O
livers	O
of	O
male	O
mice	O
,	O
but	O
not	O
in	O
the	O
livers	O
of	O
female	O
mice	O
and	O
requires	O
the	O
pituitary	O
gland	O
,	O
because	O
hypophysectomy	O
abrogates	O
it	O
.	O

Hyperplasia	O
further	O
progressed	O
in	O
the	O
livers	O
of	O
Kcnk1	S-geneY
(	O
-	O
/	O
-	O
)	O
male	O
mice	O
compared	O
with	O
those	O
of	O
Kcnk1	S-geneY
(	O
+	O
/	O
+	O
)	O
males	O
after	O
phenobarbital	S-chem
treatment	O
.	O

Thus	O
,	O
KCNK1	S-geneY
suppresses	O
phenobarbital	S-chem
-	O
induced	O
hyperplasia	O
.	O

These	O
results	O
indicate	O
that	O
phenobarbital	S-chem-C3-1
treatment	O
induces	O
KCNK1	S-geneY-C3-2
to	O
elicit	O
a	O
male	O
-	O
specific	O
and	O
growth	O
-	O
suppressing	O
signal	O
.	O

Thus	O
,	O
KCNK1	S-geneY
and	O
Kcnk1	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
provide	O
an	O
experimental	O
tool	O
for	O
further	O
investigation	O
into	O
the	O
molecular	O
mechanism	O
of	O
CAR	S-geneY
-	O
mediated	O
promotion	O
of	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
in	O
mice	O
.	O

Shelf	O
-	O
life	O
of	O
infrared	O
dry	O
-	O
roasted	O
almonds	O
.	O

Infrared	O
heating	O
was	O
recently	O
used	O
to	O
develop	O
a	O
more	O
efficient	O
roasting	O
technology	O
than	O
traditional	O
hot	O
air	O
roasting	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
shelf	O
-	O
life	O
of	O
almonds	O
roasted	O
with	O
three	O
different	O
approaches	O
,	O
namely	O
infrared	O
(	O
IR	O
)	O
,	O
sequential	O
infrared	O
and	O
hot	O
air	O
(	O
SIRHA	O
)	O
and	O
regular	O
hot	O
air	O
(	O
HA	O
)	O
.	O

Nine	O
medium	O
roasted	O
almond	O
samples	O
produced	O
by	O
the	O
aforementioned	O
heating	O
methods	O
were	O
processed	O
at	O
three	O
different	O
temperatures	O
(	O
130	O
,	O
140	O
and	O
150	O
°C	O
)	O
,	O
packed	O
in	O
paper	O
bags	O
and	O
then	O
stored	O
at	O
37	O
°C	O
for	O
three	O
,	O
six	O
or	O
eight	O
months	O
.	O

Shelf	O
-	O
life	O
of	O
the	O
roasted	O
almonds	O
was	O
determined	O
by	O
measuring	O
the	O
changes	O
in	O
colour	O
,	O
peroxide	S-chem
value	O
,	O
moisture	O
content	O
,	O
water	O
activity	O
,	O
volatile	O
components	O
and	O
sensory	O
quality	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
moisture	O
content	O
and	O
water	O
activity	O
among	O
the	O
almond	O
samples	O
processed	O
with	O
different	O
roasting	O
methods	O
and	O
stored	O
under	O
the	O
same	O
conditions	O
.	O

GC	O
/	O
MS	O
analysis	O
showed	O
that	O
aldehydes	S-chem
,	O
alcohols	S-chem
,	O
and	O
pyrazines	S-chem
were	O
the	O
main	O
volatile	O
components	O
of	O
almonds	O
.	O

Aliphatic	B-chem
aldehydes	E-chem
such	O
as	O
hexanal	S-chem
,	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
octenal	E-chem
,	O
and	O
nonanal	S-chem
were	O
produced	O
as	O
off	O
-	O
odours	O
during	O
storage	O
.	O

Although	O
the	O
overall	O
quality	O
of	O
roasted	O
almonds	O
produced	O
with	O
SIRHA	O
and	O
HA	O
heating	O
was	O
similar	O
during	O
the	O
first	O
three	O
months	O
of	O
storage	O
,	O
their	O
peroxide	S-chem
value	O
and	O
concentration	O
of	O
aliphatic	B-chem
aldehydes	E-chem
differed	O
significantly	O
for	O
different	O
roasting	O
methods	O
and	O
increased	O
significantly	O
in	O
all	O
roasted	O
samples	O
during	O
storage	O
.	O

We	O
postulate	O
that	O
hexanal	S-chem
and	O
nonanal	S-chem
might	O
be	O
better	O
indicators	O
of	O
the	O
shelf	O
life	O
of	O
roasted	O
almonds	O
than	O
the	O
current	O
standard	O
,	O
peroxide	S-chem
value	O
.	O

Bisacylimidoselenocarbamates	S-chem
Cause	O
G2	O
/	O
M	O
Arrest	O
Associated	O
with	O
the	O
Modulation	O
of	O
CDK1	S-geneY
and	O
Chk2	S-geneY
in	O
Human	O
Breast	O
Cancer	O
MCF	O
-	O
7	O
Cells	O
.	O

Bisacylimidoselenocarbamate	S-chem
derivatives	O
(	O
BSC	S-chem
)	O
are	O
potent	O
anticancer	O
agents	O
with	O
a	O
strong	O
cytotoxic	O
activity	O
against	O
different	O
types	O
of	O
tumour	O
cells	O
.	O

Based	O
in	O
phosphatidylserine	S-chem
exposure	O
on	O
the	O
cell	O
membranes	O
we	O
show	O
that	O
BSC	S-chem
treatment	O
resulted	O
in	O
enhanced	O
cell	O
death	O
in	O
leukaemia	O
CCRF	O
-	O
CEM	O
cells	O
.	O

DNA	O
fragmentation	O
detection	O
in	O
breast	O
adenocarcinoma	O
MCF	O
-	O
7	O
cells	O
showed	O
that	O
BSC	S-chem
triggered	O
cell	O
death	O
is	O
concentration	O
and	O
time	O
dependent	O
.	O

We	O
also	O
show	O
that	O
two	O
of	O
these	O
compounds	O
,	O
BSC	S-chem
3g	O
and	O
3n	O
,	O
cause	O
cell	O
-	O
cycle	O
arrest	O
in	O
the	O
late	O
G2	O
/	O
M	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Consistent	O
with	O
this	O
,	O
a	O
reduction	O
in	O
CDK1	S-geneY
and	O
CDK2	S-geneY
expression	O
with	O
no	O
change	O
in	O
cyclin	B-geneN
A	I-geneN
an	I-geneN
B1	E-geneN
was	O
observed	O
in	O
this	O
cell	O
line	O
.	O

Activation	O
of	O
caspase	B-geneY
-	I-geneY
2	E-geneY
was	O
also	O
detected	O
.	O

However	O
,	O
the	O
involvement	O
of	O
the	O
caspase	S-geneN
-	O
dependent	O
pathway	O
in	O
the	O
process	O
of	O
cell	O
death	O
induced	O
by	O
either	O
BSC	S-chem
3g	O
or	O
3n	O
is	O
discarded	O
since	O
cell	O
death	O
could	O
not	O
be	O
prevented	O
by	O
pretreatment	O
with	O
the	O
pancaspase	O
inhibitor	O
z	B-chem-C4-1
-	I-chem-C4-1
VAD	I-chem-C4-1
-	I-chem-C4-1
fmk	E-chem-C4-1
.	O

Moreover	O
,	O
since	O
reduced	O
levels	O
of	O
p21CIP1	S-geneY-C4-2
and	O
Chk2	S-geneY-C4-2
proteins	O
but	O
no	O
change	O
in	O
p53	S-geneY
levels	O
could	O
be	O
detected	O
in	O
MCF	O
-	O
7	O
cells	O
after	O
BSC	S-chem-C4-1
3g	O
or	O
3n	O
treatment	O
our	O
results	O
suggest	O
that	O
BSC	S-chem
treated	O
cells	O
die	O
from	O
lethal	O
mitosis	O
.	O

A	O
systematic	O
comparison	O
of	O
the	O
properties	O
of	O
clinically	O
used	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
antagonists	O
.	O

Angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
antagonists	O
(	O
ARBs	O
)	O
have	O
become	O
an	O
important	O
drug	O
class	O
in	O
the	O
treatment	O
of	O
hypertension	O
and	O
heart	O
failure	O
and	O
the	O
protection	O
from	O
diabetic	O
nephropathy	O
.	O

Eight	O
ARBs	O
are	O
clinically	O
available	O
[	O
azilsartan	S-chem
,	O
candesartan	S-chem
,	O
eprosartan	S-chem
,	O
irbesartan	S-chem
,	O
losartan	S-chem
,	O
olmesartan	S-chem
,	O
telmisartan	S-chem
,	O
valsartan	S-chem
]	O
.	O

Azilsartan	S-chem
(	O
in	O
some	O
countries	O
)	O
,	O
candesartan	S-chem
,	O
and	O
olmesartan	S-chem
are	O
orally	O
administered	O
as	O
prodrugs	O
,	O
whereas	O
the	O
blocking	O
action	O
of	O
some	O
is	O
mediated	O
through	O
active	O
metabolites	O
.	O

On	O
the	O
basis	O
of	O
their	O
chemical	O
structures	O
,	O
ARBs	O
use	O
different	O
binding	O
pockets	O
in	O
the	O
receptor	O
,	O
which	O
are	O
associated	O
with	O
differences	O
in	O
dissociation	O
times	O
and	O
,	O
in	O
most	O
cases	O
,	O
apparently	O
insurmountable	O
antagonism	O
.	O

The	O
physicochemical	O
differences	O
between	O
ARBs	O
also	O
manifest	O
in	O
different	O
tissue	O
penetration	O
,	O
including	O
passage	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Differences	O
in	O
binding	O
mode	O
and	O
tissue	O
penetration	O
are	O
also	O
associated	O
with	O
differences	O
in	O
pharmacokinetic	O
profile	O
,	O
particularly	O
duration	O
of	O
action	O
.	O

Although	O
generally	O
highly	O
specific	O
for	O
angiotensin	B-geneY-C6-2
II	I-geneY-C6-2
type	I-geneY-C6-2
1	I-geneY-C6-2
receptors	E-geneY-C6-2
,	O
some	O
ARBs	O
,	O
particularly	O
telmisartan	S-chem-MU-1
,	O
are	O
partial	O
agonists	O
at	O
peroxisome	B-geneY-C5-2
proliferator	I-geneY-C5-2
-	I-geneY-C5-2
activated	I-geneY-C5-2
receptor	I-geneY-C5-2
-	I-geneY-C5-2
γ	E-geneY-C5-2
.	O

All	O
of	O
these	O
properties	O
are	O
comprehensively	O
reviewed	O
in	O
this	O
article	O
.	O

Although	O
there	O
is	O
general	O
consensus	O
that	O
a	O
continuous	O
receptor	O
blockade	O
over	O
a	O
24	O
-	O
hour	O
period	O
is	O
desirable	O
,	O
the	O
clinical	O
relevance	O
of	O
other	O
pharmacological	O
differences	O
between	O
individual	O
ARBs	O
remains	O
to	O
be	O
assessed	O
.	O

Apoptotic	O
cell	O
death	O
in	O
rat	O
epididymis	O
following	O
epichlorohydrin	S-chem
treatment	O
.	O

Epichlorohydrin	S-chem
(	O
ECH	S-chem
)	O
is	O
an	O
antifertility	O
agent	O
that	O
acts	O
both	O
as	O
an	O
epididymal	O
toxicant	O
and	O
an	O
agent	O
capable	O
of	O
directly	O
affecting	O
sperm	O
motility	O
.	O

This	O
study	O
identified	O
the	O
time	O
course	O
of	O
apoptotic	O
cell	O
death	O
in	O
rat	O
epididymides	O
after	O
ECH	O
treatment	O
.	O

Rats	O
were	O
administrated	O
with	O
a	O
single	O
oral	O
dose	O
of	O
ECH	S-chem
(	O
50	O
mg	O
/	O
kg	O
)	O
.	O

ECH	S-chem
-	O
induced	O
apoptotic	O
changes	O
were	O
evaluated	O
by	O
terminal	B-geneY
deoxynucleotidyl	I-geneY
transferase	E-geneY
dUTP	S-chem
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
and	O
its	O
related	O
mechanism	O
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
and	O
colorimetric	O
assay	O
.	O

The	O
TUNEL	O
assay	O
showed	O
that	O
the	O
number	O
of	O
apoptotic	O
cells	O
increased	O
at	O
8	O
h	O
,	O
reached	O
a	O
maximum	O
level	O
at	O
12	O
h	O
,	O
and	O
then	O
decreased	O
progressively	O
.	O

The	O
Western	O
blot	O
analysis	O
demonstrated	O
no	O
significant	O
changes	O
in	O
proapoptotic	O
Bcl	B-geneY
-	I-geneY
2	I-geneY
-	I-geneY
associated	I-geneY
X	E-geneY
(	O
Bax	S-geneY
)	O
and	O
anti	O
-	O
apoptotic	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
expression	O
during	O
the	O
time	O
course	O
of	O
the	O
study	O
.	O

However	O
,	O
phospho	B-geneN
-	I-geneN
p38	E-geneN
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
p	B-geneN
-	I-geneN
p38	E-geneN
MAPK	S-geneN
)	O
and	O
phospho	B-geneN
-	I-geneN
c	I-geneN
-	I-geneN
Jun	I-geneN
amino	I-geneN
-	I-geneN
terminal	I-geneN
kinase	E-geneN
(	O
p	B-geneN
-	I-geneN
JNK	E-geneN
)	O
expression	O
increased	O
at	O
8	O
-	O
24	O
h	O
.	O

Caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
activities	O
also	O
increased	O
at	O
8	O
-	O
48	O
h	O
and	O
12	O
-	O
48	O
h	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
p	O
-	O
p38	B-geneN
MAPK	O
and	O
p	O
-	O
JNK	B-geneN
expression	O
.	O

These	O
results	O
indicate	O
that	O
ECH	O
induced	O
apoptotic	O
changes	O
in	O
rat	O
epididymides	O
and	O
that	O
the	O
apoptotic	O
cell	O
death	O
may	O
be	O
related	O
more	O
to	O
the	O
MAPK	S-geneN
pathway	O
than	O
to	O
the	O
mitochondrial	O
pathway	O
.	O

A	O
genetic	O
program	O
promotes	O
C.	O
elegans	O
longevity	O
at	O
cold	O
temperatures	O
via	O
a	O
thermosensitive	O
TRP	B-geneN
channel	E-geneN
.	O

Both	O
poikilotherms	O
and	O
homeotherms	O
live	O
longer	O
at	O
lower	O
body	O
temperatures	O
,	O
highlighting	O
a	O
general	O
role	O
of	O
temperature	O
reduction	O
in	O
lifespan	O
extension	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

One	O
prominent	O
model	O
is	O
that	O
cold	O
temperatures	O
reduce	O
the	O
rate	O
of	O
chemical	O
reactions	O
,	O
thereby	O
slowing	O
the	O
rate	O
of	O
aging	O
.	O

This	O
view	O
suggests	O
that	O
cold	O
-	O
dependent	O
lifespan	O
extension	O
is	O
simply	O
a	O
passive	O
thermodynamic	O
process	O
.	O

Here	O
,	O
we	O
challenge	O
this	O
view	O
in	O
C.	O
elegans	O
by	O
showing	O
that	O
genetic	O
programs	O
actively	O
promote	O
longevity	O
at	O
cold	O
temperatures	O
.	O

We	O
find	O
that	O
TRPA	B-geneY
-	I-geneY
1	E-geneY
,	O
a	O
cold	O
-	O
sensitive	O
TRP	B-geneN
channel	E-geneN
,	O
detects	O
temperature	O
drop	O
in	O
the	O
environment	O
to	O
extend	O
lifespan	O
.	O

This	O
effect	O
requires	O
cold	O
-	O
induced	O
,	O
TRPA	B-geneY
-	I-geneY
1	E-geneY
-	O
mediated	O
calcium	S-chem
influx	O
and	O
a	O
calcium	S-chem
-	O
sensitive	O
PKC	S-geneN
that	O
signals	O
to	O
the	O
transcription	O
factor	O
DAF	B-geneY
-	I-geneY
16	E-geneY
/	O
FOXO	S-geneY
.	O

Human	B-geneY
TRPA1	E-geneY
can	O
functionally	O
substitute	O
for	O
worm	B-geneN
TRPA	I-geneN
-	I-geneN
1	E-geneN
in	O
promoting	O
longevity	O
.	O

Our	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
function	O
for	O
TRP	B-geneN
channels	E-geneN
,	O
link	O
calcium	S-chem
signaling	O
to	O
longevity	O
,	O
and	O
,	O
importantly	O
,	O
demonstrate	O
that	O
genetic	O
programs	O
contribute	O
to	O
lifespan	O
extension	O
at	O
cold	O
temperatures	O
.	O

Radioprotection	O
by	O
two	O
phenolic	S-chem
compounds	O
:	O
chlorogenic	B-chem
and	I-chem
quinic	I-chem
acid	E-chem
,	O
on	O
X	O
-	O
ray	O
induced	O
DNA	O
damage	O
in	O
human	O
blood	O
lymphocytes	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
the	O
radioprotective	O
effect	O
of	O
two	O
phytochemicals	O
,	O
namely	O
,	O
quinic	B-chem
acid	E-chem
and	O
chlorogenic	B-chem
acid	E-chem
,	O
against	O
X	O
-	O
ray	O
irradiation	O
-	O
induced	O
genomic	O
instability	O
in	O
non	O
-	O
tumorigenic	O
human	O
blood	O
lymphocytes	O
.	O

The	O
protective	O
ability	O
of	O
two	O
phenolic	B-chem
acids	E-chem
against	O
radiation	O
-	O
induced	O
DNA	O
damage	O
was	O
assessed	O
using	O
the	O
alkaline	O
comet	O
assay	O
in	O
human	O
blood	O
lymphocytes	O
isolated	O
from	O
two	O
healthy	O
human	O
donors	O
.	O

A	O
Siemens	O
Mevatron	O
MD2	O
(	O
Siemens	O
AG	O
,	O
USA	O
,	O
1994	O
)	O
linear	O
accelerator	O
was	O
used	O
for	O
irradiation	O
.	O

The	O
results	O
of	O
the	O
alkaline	O
comet	O
assay	O
revealed	O
that	O
quinic	B-chem
acid	E-chem
and	O
chlorogenic	B-chem
acid	E-chem
decreased	O
the	O
DNA	O
damage	O
induced	O
by	O
X	O
-	O
ray	O
irradiation	O
and	O
provided	O
a	O
significant	O
radioprotective	O
effect	O
.	O

Quinic	B-chem
acid	E-chem
decreased	O
the	O
presence	O
of	O
irradiation	O
-	O
induced	O
DNA	O
damage	O
by	O
5.99	O
-	O
53.57	O
%	O
and	O
chlorogenic	B-chem
acid	E-chem
by	O
4.49	O
-	O
48.15	O
%	O
,	O
as	O
determined	O
by	O
the	O
alkaline	O
comet	O
assay	O
.	O

The	O
results	O
show	O
that	O
quinic	B-chem
acid	E-chem
and	O
chlorogenic	B-chem
acid	E-chem
may	O
act	O
as	O
radioprotective	O
compounds	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
determining	O
the	O
mechanism	O
by	O
which	O
these	O
phenolic	B-chem
acids	E-chem
provide	O
radioprotection	O
.	O

Thymidine	B-geneN
kinase	E-geneN
and	O
thymidine	B-geneY
phosphorylase	E-geneY
level	O
as	O
the	O
main	O
predictive	O
parameter	O
for	O
sensitivity	O
to	O
TAS	B-chem
-	I-chem
102	E-chem
in	O
a	O
mouse	O
model	O
.	O

TAS	B-chem
-	I-chem
102	E-chem
is	O
a	O
new	O
oral	O
anti	O
-	O
cancer	O
drug	O
preparation	O
,	O
composed	O
of	O
a	O
1	O
:	O
0.5	O
mixture	O
(	O
on	O
a	O
molar	O
basis	O
)	O
of	O
alpha	B-chem
,	I-chem
alpha	I-chem
,	I-chem
alpha	I-chem
-	I-chem
trifluorothymidine	E-chem
(	O
FTD	S-chem
)	O
and	O
5	B-chem
-	I-chem
chloro	I-chem
-	I-chem
6	I-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
iminopyrrolidinyl	I-chem
)	I-chem
methyl	I-chem
]	I-chem
-	I-chem
2,4	I-chem
(	I-chem
1H,3H	I-chem
)	I-chem
-	I-chem
pyrimidinedione	I-chem
hydrochloride	E-chem
(	O
TPI	S-chem
)	O
.	O

TAS	B-chem-C4-1
-	I-chem-C4-1
102	E-chem-C4-1
currently	O
undergoing	O
clinical	O
trials	O
,	O
has	O
been	O
demonstrated	O
to	O
have	O
at	O
least	O
two	O
mechanisms	O
,	O
inhibition	O
of	O
TS	S-geneY-C4-2
and	O
incorporation	O
into	O
DNA	O
.	O

We	O
hypothesized	O
that	O
the	O
thymidine	S-chem
metabolism	O
enzyme	O
may	O
be	O
a	O
crucial	O
factor	O
that	O
affects	O
the	O
antitumor	O
activity	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
.	O

In	O
the	O
present	O
study	O
,	O
we	O
measured	O
the	O
enzyme	O
activity	O
of	O
thymidine	B-geneN
kinase	E-geneN
(	O
TK	S-geneN
)	O
,	O
thymidine	B-geneY
phosphorylase	E-geneY
(	O
TP	S-geneY
)	O
and	O
thymidilate	B-geneY-C4-2
synthase	E-geneY-C4-2
(	O
TS	S-geneY-C4-2
)	O
in	O
human	O
cancer	O
xenografts	O
to	O
investigate	O
the	O
contribution	O
of	O
these	O
enzymes	O
to	O
the	O
sensitivity	O
of	O
TAS	B-chem-C4-1
-	I-chem-C4-1
102	E-chem-C4-1
.	O

Antitumor	O
activity	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
appears	O
to	O
be	O
associated	O
with	O
TK	S-geneN
,	O
tumor	O
growth	O
and	O
TS	S-geneY
.	O

However	O
,	O
the	O
most	O
related	O
factors	O
in	O
this	O
study	O
were	O
the	O
TK	S-geneN
and	O
TP	S-geneY
ratio	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
(	O
p	O
=	O
0.04	O
)	O
between	O
tumor	O
growth	O
inhibition	O
and	O
this	O
ratio	O
.	O

These	O
results	O
suggested	O
that	O
the	O
activation	O
and	O
degradation	O
pattern	O
of	O
FTD	S-chem
plays	O
an	O
important	O
role	O
in	O
the	O
efficacy	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
and	O
that	O
it	O
is	O
possible	O
to	O
use	O
the	O
TK	S-geneN
/	O
TP	S-geneY
ratio	O
to	O
predict	O
response	O
to	O
TAS	B-chem
-	I-chem
102	E-chem
therapy	O
.	O

We	O
also	O
studied	O
the	O
influence	O
of	O
TPI	S-chem
on	O
the	O
capacity	O
of	O
exogenous	O
dThd	O
to	O
reverse	O
FTD	S-chem
-	O
dependent	O
growth	O
inhibition	O
.	O

Thymidine	S-chem
(	O
dThd	O
)	O
levels	O
rescued	O
the	O
effect	O
of	O
FTD	S-chem
in	O
vitro	O
and	O
significantly	O
increased	O
in	O
serum	O
after	O
administration	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
or	O
TPI	S-chem
alone	O
but	O
not	O
FTD	S-chem
alone	O
.	O

This	O
may	O
suggest	O
the	O
possibility	O
of	O
a	O
decrease	O
in	O
antitumor	O
effect	O
.	O

However	O
,	O
our	O
study	O
indicated	O
that	O
the	O
therapeutic	O
index	O
was	O
clearly	O
increased	O
by	O
FTD	S-chem
combined	O
with	O
TPI	S-chem
,	O
compared	O
with	O
FTD	S-chem
alone	O
,	O
suggesting	O
FTD	S-chem
-	O
induced	O
toxicity	O
to	O
sensitive	O
host	O
tissue	O
can	O
be	O
selectively	O
reversed	O
with	O
dThd	O
.	O

In	O
conclusion	O
,	O
TK	S-geneN
and	O
TPI	S-chem
effects	O
on	O
TP	S-geneY
play	O
important	O
roles	O
in	O
the	O
cytotoxic	O
action	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
,	O
and	O
it	O
is	O
possible	O
to	O
use	O
the	O
TK	S-geneN
/	O
TP	S-geneY
ratio	O
to	O
predict	O
more	O
precisely	O
individual	O
resistance	O
or	O
sensitivity	O
.	O

Interaction	O
with	O
the	O
hERG	S-geneY
channel	O
and	O
cytotoxicity	O
of	O
amiodarone	S-chem
and	O
amiodarone	S-chem
analogues	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Amiodarone	S-chem
(	O
2	B-chem
-	I-chem
n	I-chem
-	I-chem
butyl	I-chem
-	I-chem
3	I-chem
-	I-chem
[	I-chem
3,5	I-chem
diiodo	I-chem
-	I-chem
4	I-chem
-	I-chem
diethylaminoethoxybenzoyl	I-chem
]	I-chem
-	I-chem
benzofuran	E-chem
,	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
diethyl	E-chem
)	O
is	O
an	O
effective	O
class	O
III	O
antiarrhythmic	O
drug	O
demonstrating	O
potentially	O
life	O
-	O
threatening	O
organ	O
toxicity	O
.	O

The	O
principal	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
amiodarone	S-chem-C4-1
analogues	O
that	O
retained	O
human	B-geneY-C4-2
ether	I-geneY-C4-2
-	I-geneY-C4-2
a	I-geneY-C4-2
-	I-geneY-C4-2
go	I-geneY-C4-2
-	I-geneY-C4-2
go	I-geneY-C4-2
-	I-geneY-C4-2
related	I-geneY-C4-2
protein	I-geneY-C4-2
(	I-geneY-C4-2
hERG	I-geneY-C4-2
)	I-geneY-C4-2
channel	E-geneY-C4-2
inhibition	O
but	O
with	O
reduced	O
cytotoxicity	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
We	O
synthesized	O
amiodarone	S-chem
analogues	O
with	O
or	O
without	O
a	O
positively	O
ionizable	O
nitrogen	S-chem
in	O
the	O
phenolic	S-chem
side	O
chain	O
.	O

The	O
cytotoxic	O
properties	O
of	O
the	O
compounds	O
were	O
evaluated	O
using	O
HepG2	O
(	O
a	O
hepatocyte	O
cell	O
line	O
)	O
and	O
A549	O
cells	O
(	O
a	O
pneumocyte	O
line	O
)	O
.	O

Interactions	O
of	O
all	O
compounds	O
with	O
the	O
hERG	S-geneY
channel	O
were	O
measured	O
using	O
pharmacological	O
and	O
in	O
silico	O
methods	O
.	O

KEY	O
RESULTS	O
:	O
Compared	O
with	O
amiodarone	S-chem
,	O
which	O
displayed	O
only	O
a	O
weak	O
cytotoxicity	O
,	O
the	O
mono	O
-	O
and	O
bis	O
-	O
desethylated	O
metabolites	O
,	O
the	O
further	O
degraded	O
alcohol	S-chem
(	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
OH	E-chem
)	O
,	O
the	O
corresponding	O
acid	O
(	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
COOH	E-chem
)	O
and	O
,	O
finally	O
,	O
the	O
newly	O
synthesized	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
pyrrolidine	E-chem
were	O
equally	O
or	O
more	O
toxic	O
.	O

Conversely	O
,	O
structural	O
analogues	O
such	O
as	O
the	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
diisopropyl	E-chem
and	O
the	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
piperidine	E-chem
were	O
significantly	O
less	O
toxic	O
than	O
amiodarone	S-chem
.	O

Cytotoxicity	O
was	O
associated	O
with	O
a	O
drop	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
suggesting	O
mitochondrial	O
involvement	O
.	O

Pharmacological	O
and	O
in	O
silico	O
investigations	O
concerning	O
the	O
interactions	O
of	O
these	O
compounds	O
with	O
the	O
hERG	S-geneY
channel	O
revealed	O
that	O
compounds	O
carrying	O
a	O
basic	O
nitrogen	S-chem
in	O
the	O
side	O
chain	O
display	O
a	O
much	O
higher	O
affinity	O
than	O
those	O
lacking	O
such	O
a	O
group	O
.	O

Specifically	O
,	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
piperidine	E-chem
and	O
B2	B-chem
-	I-chem
O	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
CH	I-chem
(	I-chem
2	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
pyrrolidine	E-chem
revealed	O
a	O
higher	O
affinity	O
towards	O
hERG	S-geneY
channels	O
than	O
amiodarone	S-chem
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Amiodarone	S-chem-C4-1
analogues	O
with	O
better	O
hERG	S-geneY-C4-2
channel	O
inhibition	O
and	O
cytotoxicity	O
profiles	O
than	O
the	O
parent	O
compound	O
have	O
been	O
identified	O
,	O
demonstrating	O
that	O
cytotoxicity	O
and	O
hERG	S-geneY
channel	O
interaction	O
are	O
mechanistically	O
distinct	O
and	O
separable	O
properties	O
of	O
the	O
compounds	O
.	O

Atypical	O
and	O
typical	O
antipsychotic	O
drug	O
interactions	O
with	O
the	O
dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
.	O

A	O
model	O
of	O
the	O
dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
was	O
used	O
to	O
study	O
the	O
receptor	O
interactions	O
of	O
dopamine	S-chem
,	O
the	O
typical	O
antipsychotics	O
haloperidol	S-chem
and	O
loxapine	S-chem
,	O
and	O
the	O
atypical	O
antipsychotics	O
clozapine	S-chem
and	O
melperone	S-chem
.	O

The	O
atypical	O
antipsychotics	O
interacted	O
with	O
the	O
halogen	S-chem
atom	O
of	O
the	O
ring	O
system	O
in	O
the	O
direction	O
of	O
the	O
transmembrane	O
helices	O
(	O
TMHs	O
)	O
2	O
,	O
3	O
and	O
7	O
,	O
while	O
the	O
typical	O
had	O
the	O
corresponding	O
halogen	S-chem
atom	O
in	O
the	O
direction	O
of	O
TMH5	O
.	O

Molecular	O
dynamics	O
simulations	O
indicated	O
that	O
the	O
average	O
helical	O
displacement	O
upon	O
binding	O
increased	O
in	O
the	O
order	O
:	O
typical	O
<	O
atypical	O
<	O
dopamine	S-chem
.	O

Upon	O
binding	O
,	O
the	O
atypical	O
induced	O
larger	O
displacements	O
into	O
TMH5	O
than	O
did	O
the	O
typical	O
.	O

The	O
typical	O
had	O
stronger	O
non	O
-	O
bonded	O
interactions	O
with	O
the	O
receptor	O
than	O
had	O
the	O
atypical	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
experimental	O
observation	O
that	O
the	O
atypical	O
antipsychotic	O
drugs	O
dissociate	O
faster	O
from	O
the	O
receptor	O
than	O
the	O
typical	O
antipsychotic	O
drugs	O
.	O

Ornithine	S-chem
metabolism	O
in	O
male	O
and	O
female	O
rat	O
kidney	O
:	O
mitochondrial	O
expression	O
of	O
ornithine	B-geneY
aminotransferase	E-geneY
and	O
arginase	B-geneY
II	E-geneY
.	O

In	O
the	O
kidney	O
,	O
L	B-chem
-	I-chem
ornithine	E-chem
is	O
reabsorbed	O
along	O
the	O
proximal	O
convoluted	O
tubule	O
(	O
PCT	O
)	O
,	O
transported	O
by	O
basolateral	O
carriers	O
,	O
and	O
produced	O
by	O
arginase	B-geneY
II	E-geneY
(	O
AII	S-geneY
)	O
.	O

Here	O
,	O
the	O
renal	O
metabolic	O
fate	O
of	O
L	B-chem
-	I-chem
ornithine	E-chem
was	O
analyzed	O
in	O
male	O
and	O
female	O
rats	O
.	O

Kidneys	O
and	O
renal	O
zones	O
were	O
dissected	O
and	O
used	O
for	O
Western	O
blot	O
analysis	O
,	O
immunofluorescence	O
,	O
and	O
electron	O
microscopic	O
studies	O
.	O

Ornithine	B-geneY
aminotransferase	E-geneY
(	O
OAT	S-geneY
)	O
and	O
AII	S-geneY
were	O
localized	O
using	O
specific	O
antibodies	O
.	O

Ornithine	S-chem
oxidation	O
was	O
determined	O
by	O
incubating	O
microdissected	O
tubules	O
with	O
L	B-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
14C	I-chem
]	E-chem
or	O
L	B-chem
-	I-chem
[	I-chem
U	I-chem
-	I-chem
14C	I-chem
]	I-chem
ornithine	E-chem
in	O
the	O
presence	O
or	O
absence	O
of	O
energy	O
-	O
providing	O
substrates	O
.	O

Ornithine	B-geneY
decarboxylase	E-geneY
(	O
ODC	S-geneY
)	O
mRNAs	O
were	O
localized	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
48	O
-	O
kDa	O
OAT	S-geneY
protein	O
was	O
detected	O
in	O
male	O
and	O
female	O
kidneys	O
,	O
but	O
its	O
level	O
was	O
fourfold	O
higher	O
in	O
the	O
latter	O
.	O

OAT	S-geneY
relative	O
distribution	O
increased	O
from	O
the	O
superficial	O
cortex	O
toward	O
the	O
outer	O
medulla	O
to	O
reach	O
its	O
highest	O
level	O
.	O

Almost	O
all	O
OAT	S-geneY
protein	O
was	O
localized	O
in	O
cortical	O
and	O
medullary	O
proximal	O
straight	O
tubules	O
(	O
CPST	O
and	O
OSPST	O
,	O
respectively	O
)	O
.	O

In	O
proximal	O
straight	O
tubule	O
(	O
PST	O
)	O
,	O
AII	S-geneY
protein	O
distribution	O
overlapped	O
that	O
of	O
OAT	S-geneY
.	O

No	O
gender	O
difference	O
in	O
AII	S-geneY
protein	O
level	O
was	O
found	O
.	O

OAT	S-geneY
and	O
AII	S-geneY
were	O
colocalized	O
within	O
PST	O
mitochondria	O
.	O

L	B-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
14C	I-chem
]	I-chem
ornithine	E-chem
decarboxylation	O
occurred	O
in	O
all	O
tubules	O
,	O
but	O
predominantly	O
in	O
proximal	O
tubules	O
.	O

L	B-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
14C	I-chem
]	I-chem
ornithine	E-chem
decarboxylation	O
was	O
enhanced	O
when	O
L	B-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
14C	I-chem
]	I-chem
ornithine	E-chem
was	O
given	O
to	O
tubules	O
as	O
the	O
sole	O
substrate	O
.	O

The	O
use	O
of	O
L	B-chem
-	I-chem
[	I-chem
U	I-chem
-	I-chem
14C	I-chem
]	I-chem
ornithine	E-chem
demonstrated	O
the	O
complete	O
oxidation	O
of	O
ornithine	S-chem
.	O

In	O
conclusion	O
,	O
the	O
OAT	S-geneY
gene	O
was	O
expressed	O
more	O
in	O
female	O
rat	O
proximal	O
tubules	O
than	O
in	O
male	O
.	O

Because	O
OAT	S-geneY
and	O
AII	S-geneY
proteins	O
overlapped	O
in	O
PST	O
mitochondria	O
,	O
L	B-chem
-	I-chem
arginine	E-chem
-	O
derived	O
ornithine	S-chem
may	O
be	O
preferentially	O
converted	O
to	O
L	B-chem
-	I-chem
glutamate	E-chem
,	O
as	O
proven	O
by	O
ornithine	S-chem
oxidation	O
.	O

However	O
,	O
the	O
coexpression	O
of	O
ODC	S-geneY
,	O
glutamate	B-geneN
decarboxylase	E-geneN
,	O
and	O
glutamine	B-geneY
synthetase	E-geneY
in	O
PST	O
suggests	O
that	O
L	B-chem
-	I-chem
ornithine	E-chem
can	O
also	O
be	O
metabolized	O
to	O
putrescine	S-chem
,	O
GABA	S-chem
,	O
and	O
L	B-chem
-	I-chem
glutamine	E-chem
.	O

The	O
fate	O
of	O
L	B-chem
-	I-chem
ornithine	E-chem
may	O
depend	O
on	O
the	O
cellular	O
context	O
.	O

Keratinocyte	B-geneY
growth	I-geneY
factor	E-geneY
and	O
acidic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
are	O
mitogens	O
for	O
primary	O
cultures	O
of	O
mammary	O
epithelium	O
.	O

Mammary	O
epithelial	O
cells	O
derived	O
from	O
the	O
entire	O
mammary	O
parenchyma	O
or	O
only	O
end	O
buds	O
were	O
isolated	O
by	O
collagenase	S-geneN
digestion	O
of	O
mammary	O
glands	O
from	O
virgin	O
mice	O
.	O

Cells	O
were	O
cultured	O
within	O
collagen	O
gels	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
insulin	S-geneY
.	O

Keratinocyte	B-geneY
growth	I-geneY
factor	E-geneY
(	O
KGF	S-geneY
or	O
FGF	B-geneY
-	I-geneY
7	E-geneY
)	O
and	O
acidic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
(	O
aFGF	S-geneY
or	O
FGF	B-geneY
-	I-geneY
1	E-geneY
)	O
stimulated	O
multifold	O
proliferation	O
when	O
added	O
alone	O
to	O
this	O
medium	O
.	O

Growth	O
occurred	O
as	O
three	O
-	O
dimensional	O
colonies	O
within	O
the	O
collagen	S-geneN
gel	O
matrix	O
.	O

KGF	S-geneY
stimulated	O
growth	O
was	O
unaffected	O
by	O
adding	O
heparin	O
.	O

Conversely	O
,	O
multifold	O
growth	O
stimulation	O
by	O
acidic	B-geneY
FGF	E-geneY
required	O
heparin	O
.	O

Since	O
end	O
buds	O
are	O
the	O
actively	O
proliferating	O
cell	O
population	O
of	O
ductal	O
glands	O
,	O
organ	O
cultures	O
of	O
these	O
structures	O
were	O
prepared	O
.	O

KGF	S-geneY
stimulated	O
3H	B-chem
-	I-chem
thymidine	E-chem
incorporation	O
in	O
these	O
end	O
buds	O
in	O
the	O
absence	O
and	O
presence	O
of	O
epidermal	B-geneY
growth	I-geneY
factor	E-geneY
.	O

These	O
data	O
suggest	O
that	O
acidic	B-geneY
FGF	E-geneY
and	O
KGF	S-geneY
may	O
represent	O
in	O
vivo	O
stromal	O
factors	O
capable	O
of	O
regulating	O
mammary	O
gland	O
development	O
.	O

Activation	O
-	O
dependent	O
exposure	O
of	O
the	O
inter	B-geneN
-	I-geneN
EGF	I-geneN
sequence	E-geneN
Leu83	B-geneN
-	I-geneN
Leu88	E-geneN
in	O
factor	B-geneY
Xa	E-geneY
mediates	O
ligand	O
binding	O
to	O
effector	B-geneY
cell	I-geneY
protease	I-geneY
receptor	I-geneY
-	I-geneY
1	E-geneY
.	O

Binding	O
of	O
factor	B-geneY
Xa	E-geneY
to	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
is	O
contributed	O
by	O
effector	B-geneY
cell	I-geneY
protease	I-geneY
receptor	I-geneY
-	I-geneY
1	E-geneY
(	O
EPR	B-geneY
-	I-geneY
1	E-geneY
)	O
.	O

The	O
structural	O
requirements	O
of	O
this	O
recognition	O
were	O
investigated	O
.	O

Factor	B-geneY
Xa	E-geneY
or	O
catalytically	O
inactive	O
5	B-chem
-	I-chem
dimethylaminonaphthalene	I-chem
-	I-chem
1sulfonyl	I-chem
(	I-chem
dansyl	I-chem
)	I-chem
Glu	I-chem
-	I-chem
Gly	I-chem
-	I-chem
Arg	I-chem
-	I-chem
(	I-chem
DEGR	I-chem
)	I-chem
-	I-chem
chloromethylketone	E-chem
-	O
factor	B-geneY
Xa	E-geneY
bound	O
indistinguishably	O
to	O
HUVEC	O
and	O
EPR	B-geneY
-	I-geneY
1	E-geneY
transfectants	O
,	O
and	O
inhibited	O
equally	O
well	O
the	O
binding	O
of	O
125I	O
-	O
factor	B-geneY
Xa	E-geneY
to	O
these	O
cells	O
.	O

Similarly	O
,	O
factor	B-geneY
Xa	E-geneY
active	O
site	O
inhibitors	O
TAP	O
or	O
NAP5	O
did	O
not	O
reduce	O
ligand	O
binding	O
to	O
EPR	B-geneY
-	I-geneY
1	E-geneY
.	O

A	O
factor	B-geneY
X	E-geneY
peptide	O
duplicating	O
the	O
inter	B-geneN
-	I-geneN
EGF	I-geneN
sequence	E-geneN
Leu83	B-geneN
-	I-geneN
Phe84	I-geneN
-	I-geneN
Thr85	I-geneN
-	I-geneN
Arg86	I-geneN
-	I-geneN
Lys87	I-geneN
-	I-geneN
Leu88	I-geneN
-	I-geneN
(	I-geneN
Gly	I-geneN
)	E-geneN
inhibited	O
factor	B-geneY
V	I-geneY
/	I-geneY
Va	E-geneY
-	O
independent	O
prothrombin	S-geneY
activation	O
by	O
HUVEC	O
and	O
blocked	O
binding	O
of	O
125I	S-chem
-	O
factor	B-geneY
Xa	E-geneY
to	O
these	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
approximately	O
20	O
-	O
40	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
other	O
factor	B-geneY
X	E-geneY
peptides	O
tested	O
or	O
a	O
control	O
peptide	O
with	O
the	O
inter	B-geneN
-	I-geneN
EGF	I-geneN
sequence	E-geneN
in	O
scrambled	O
order	O
was	O
effective	O
.	O

A	O
recombinant	O
chimeric	O
molecule	O
expressing	O
the	O
factor	B-geneY
X	E-geneY
sequence	O
Leu83	B-geneN
-	I-geneN
Leu88	E-geneN
within	O
a	O
factor	B-geneY
IX	E-geneY
backbone	O
inhibited	O
binding	O
of	O
125I	S-chem
-	O
factor	B-geneY
Xa	E-geneY
to	O
HUVEC	O
and	O
EPR	B-geneY
-	I-geneY
1	E-geneY
transfectants	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
while	O
recombinant	O
factor	B-geneY
IX	E-geneY
or	O
plasma	O
IXa	S-geneY
had	O
no	O
effect	O
.	O

An	O
antibody	O
generated	O
against	O
the	O
factor	B-geneY
X	E-geneY
peptide	O
83	O
-	O
88	O
,	O
and	O
designated	O
JC15	O
,	O
inhibited	O
125I	O
-	O
factor	B-geneY
Xa	E-geneY
binding	O
to	O
HUVEC	O
.	O

The	O
JC15	O
antibody	O
bound	O
to	O
factor	B-geneY
Xa	E-geneY
and	O
the	O
recombinant	O
IX	O
/	O
X83	O
-	O
88	O
chimera	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
while	O
no	O
specific	O
reactivity	O
with	O
factors	B-geneN
X	I-geneN
or	I-geneN
IXa	E-geneN
was	O
observed	O
.	O

Furthermore	O
,	O
binding	O
of	O
125I	S-chem
-	O
factor	B-geneY
Xa	E-geneY
to	O
immobilized	O
JC15	O
was	O
inhibited	O
by	O
molar	O
excess	O
of	O
unlabeled	O
factor	B-geneY
Xa	E-geneY
,	O
but	O
not	O
by	O
comparable	O
concentrations	O
of	O
factors	B-geneN
X	I-geneN
or	I-geneN
IXa	E-geneN
.	O

These	O
findings	O
identify	O
the	O
inter	B-geneN
-	I-geneN
EGF	I-geneN
sequence	E-geneN
Leu83	B-geneN
-	I-geneN
Leu88	E-geneN
in	O
factor	B-geneY
Xa	E-geneY
as	O
a	O
novel	O
recognition	O
site	O
for	O
EPR	B-geneY
-	I-geneY
1	E-geneY
,	O
and	O
suggest	O
its	O
potential	O
role	O
as	O
a	O
protease	O
activation	O
-	O
dependent	O
neo	O
-	O
epitope	O
.	O

This	O
interacting	O
motif	O
may	O
help	O
elucidate	O
the	O
contribution	O
of	O
factor	B-geneY
Xa	E-geneY
to	O
cellular	O
assembly	O
of	O
coagulation	O
and	O
vascular	O
injury	O
.	O

Prosocial	O
effects	O
of	O
oxytocin	S-geneY
in	O
two	O
mouse	O
models	O
of	O
autism	O
spectrum	O
disorders	O
.	O

Clinical	O
evidence	O
suggests	O
that	O
oxytocin	S-geneY
treatment	O
improves	O
social	O
deficits	O
and	O
repetitive	O
behavior	O
in	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

However	O
,	O
the	O
neuropeptide	S-geneN
has	O
a	O
short	O
plasma	O
half	O
-	O
life	O
and	O
poor	O
ability	O
to	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

In	O
order	O
to	O
facilitate	O
the	O
development	O
of	O
more	O
bioavailable	O
oxytocinergic	O
compounds	O
as	O
therapeutics	O
to	O
treat	O
core	O
ASD	O
symptoms	O
,	O
small	O
animal	O
models	O
must	O
be	O
validated	O
for	O
preclinical	O
screens	O
.	O

This	O
study	O
examined	O
the	O
preclinical	O
utility	O
of	O
two	O
inbred	O
mouse	O
strains	O
,	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
,	O
that	O
exhibit	O
phenotypes	O
relevant	O
to	O
core	O
ASD	O
symptoms	O
.	O

Mice	O
from	O
both	O
strains	O
were	O
intraperitoneally	O
administered	O
oxytocin	S-geneY
,	O
using	O
either	O
acute	O
or	O
sub	O
-	O
chronic	O
regimens	O
.	O

Acute	O
oxytocin	S-geneY
did	O
not	O
increase	O
sociability	O
in	O
BALB	O
/	O
cByJ	O
;	O
however	O
,	O
sub	O
-	O
chronic	O
oxytocin	S-geneY
had	O
significant	O
prosocial	O
effects	O
in	O
both	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
.	O

Increased	O
sociability	O
was	O
observed	O
24	O
hours	O
following	O
the	O
final	O
oxytocin	S-geneY
dose	O
in	O
BALB	O
/	O
cByJ	O
,	O
while	O
prosocial	O
effects	O
of	O
oxytocin	S-chem
emerged	O
1	O
-	O
2	O
weeks	O
post	O
-	O
treatment	O
in	O
C58	O
/	O
J	O
.	O

Furthermore	O
,	O
acute	O
oxytocin	S-geneY
decreased	O
motor	O
stereotypy	O
in	O
C58	O
/	O
J	O
and	O
did	O
not	O
induce	O
hypoactivity	O
or	O
anxiolytic	O
-	O
like	O
effects	O
in	O
an	O
open	O
field	O
test	O
.	O

This	O
study	O
demonstrates	O
that	O
oxytocin	S-geneY
administration	O
can	O
attenuate	O
social	O
deficits	O
and	O
repetitive	O
behavior	O
in	O
mouse	O
models	O
of	O
ASD	O
,	O
dependent	O
on	O
dose	O
regimen	O
and	O
genotype	O
.	O

These	O
findings	O
provide	O
validation	O
of	O
the	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
models	O
as	O
useful	O
platforms	O
for	O
screening	O
novel	O
drugs	O
for	O
intervention	O
in	O
ASDs	O
and	O
for	O
elucidating	O
the	O
mechanisms	O
contributing	O
to	O
the	O
prosocial	O
effects	O
of	O
oxytocin	S-geneY
.	O

Discovery	O
of	O
a	O
series	O
of	O
novel	O
5H	B-chem-C4-1
-	I-chem-C4-1
pyrrolo	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyrazine	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
phenyl	I-chem-C4-1
ethers	E-chem-C4-1
,	O
as	O
potent	O
JAK3	S-geneY-C4-2
kinase	S-geneN-C4-2
inhibitors	O
.	O

We	O
report	O
the	O
discovery	O
of	O
a	O
novel	O
series	O
of	O
ATP	S-chem
-	O
competitive	O
Janus	B-geneY-C4-2
kinase	I-geneY-C4-2
3	E-geneY-C4-2
(	O
JAK3	S-geneY-C4-2
)	O
inhibitors	O
based	O
on	O
the	O
5H	B-chem-C4-1
-	I-chem-C4-1
pyrrolo	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyrazine	E-chem-C4-1
scaffold	O
.	O

The	O
initial	O
leads	O
in	O
this	O
series	O
,	O
compounds	O
1a	O
and	O
1h	O
,	O
showed	O
promising	O
potencies	O
,	O
but	O
a	O
lack	O
of	O
selectivity	O
against	O
other	O
isoforms	O
in	O
the	O
JAK	S-geneN
family	O
.	O

Computational	O
and	O
crystallographic	O
analysis	O
suggested	O
that	O
the	O
phenyl	O
ether	O
moiety	O
possessed	O
a	O
favorable	O
vector	O
to	O
achieve	O
selectivity	O
.	O

Exploration	O
of	O
this	O
vector	O
resulted	O
in	O
the	O
identification	O
of	O
12b	O
and	O
12d	O
,	O
as	O
potent	O
JAK3	S-geneY
inhibitors	O
,	O
demonstrating	O
improved	O
JAK	S-geneN
family	O
and	O
kinase	S-geneN
selectivity	O
.	O

Covalent	O
modification	O
of	O
stathmin	S-geneY
by	O
CCNU	O
determined	O
by	O
FTMS	O
analysis	O
of	O
modified	O
proteins	O
and	O
tryptic	O
peptides	O
.	O

Chemical	O
modification	O
of	O
proteins	O
is	O
often	O
carried	O
out	O
to	O
generate	O
protein	O
-	O
small	O
molecule	O
conjugates	O
for	O
various	O
applications	O
.	O

The	O
high	O
resolution	O
and	O
mass	O
accuracy	O
of	O
a	O
Fourier	O
transform	O
mass	O
spectrometer	O
is	O
particularly	O
useful	O
for	O
assessing	O
the	O
extent	O
or	O
sites	O
of	O
covalent	O
modifications	O
.	O

As	O
protein	O
-	O
small	O
molecule	O
reactions	O
often	O
produce	O
products	O
with	O
variable	O
numbers	O
of	O
the	O
compound	O
incorporated	O
at	O
different	O
sites	O
,	O
a	O
direct	O
mass	O
analysis	O
of	O
the	O
reaction	O
products	O
at	O
times	O
yields	O
mass	O
spectra	O
hard	O
to	O
interpret	O
.	O

Chromatographic	O
separation	O
at	O
protein	O
level	O
could	O
reduce	O
the	O
complexity	O
of	O
a	O
sample	O
,	O
thus	O
allowing	O
more	O
accurate	O
mass	O
spectrometric	O
analysis	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
the	O
utility	O
of	O
reversed	O
-	O
phase	O
protein	O
chromatography	O
and	O
FT	O
-	O
ICR	O
mass	O
spectrometry	O
in	O
analyzing	O
CCNU	O
(	O
lomustine	S-chem
,	O
1	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
chloroethyl	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
cyclohexyl	I-chem
-	I-chem
1	I-chem
-	I-chem
nitroso	I-chem
-	I-chem
urea	E-chem
,	O
MW	O
:	O
233.7Da	O
)	O
modification	O
of	O
stathmin	S-geneY
.	O

With	O
this	O
combined	O
approach	O
,	O
we	O
determined	O
the	O
stoichiometry	O
as	O
well	O
as	O
sites	O
of	O
CCNU	O
incorporation	O
into	O
the	O
protein	O
,	O
demonstrating	O
differential	O
reactivity	O
of	O
several	O
lysyl	O
residues	O
to	O
CCNU	O
alkylation	O
.	O

From	O
synaptic	O
spines	O
to	O
nuclear	O
signaling	O
:	O
nuclear	O
and	O
synaptic	O
actions	O
of	O
the	O
amyloid	B-geneY
precursor	I-geneY
protein	E-geneY
.	O

Despite	O
intensive	O
studies	O
of	O
the	O
secretase	S-geneN
-	O
mediated	O
processing	O
of	O
the	O
amyloid	B-geneY
precursor	I-geneY
protein	E-geneY
(	O
APP	S-geneY
)	O
to	O
form	O
the	O
amyloid	B-geneY
β	I-geneY
-	I-geneY
peptide	E-geneY
(	O
Aβ	S-geneY
)	O
,	O
in	O
relation	O
to	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
no	O
new	O
therapeutic	O
agents	O
have	O
reached	O
the	O
clinics	O
based	O
on	O
reducing	O
Aβ	S-geneY
levels	O
through	O
the	O
use	O
of	O
secretase	S-geneN
inhibitors	O
or	O
immunotherapy	O
.	O

Furthermore	O
,	O
the	O
normal	O
neuronal	O
functions	O
of	O
APP	S-geneY
and	O
its	O
various	O
metabolites	O
still	O
remain	O
under	O
-	O
investigated	O
and	O
unclear	O
.	O

Here	O
,	O
we	O
highlight	O
emerging	O
areas	O
of	O
APP	S-geneY
function	O
that	O
may	O
provide	O
new	O
insights	O
into	O
synaptic	O
development	O
,	O
cognition	O
,	O
and	O
gene	O
regulation	O
.	O

By	O
modulating	O
expression	O
levels	O
of	O
endogenous	O
APP	S-geneY
in	O
primary	O
cortical	O
neurons	O
,	O
the	O
frequency	O
and	O
amplitude	O
of	O
calcium	S-chem
oscillations	O
is	O
modified	O
,	O
implying	O
a	O
key	O
role	O
for	O
APP	S-geneY
in	O
maintaining	O
neuronal	O
calcium	S-chem
homeostasis	O
essential	O
for	O
synaptic	O
transmission	O
.	O

Disruption	O
of	O
this	O
homeostatic	O
mechanism	O
predisposes	O
to	O
aging	O
and	O
AD	O
.	O

Synaptic	O
spine	O
loss	O
is	O
a	O
feature	O
of	O
neurogeneration	O
resulting	O
in	O
learning	O
and	O
memory	O
deficits	O
,	O
and	O
emerging	O
evidence	O
indicates	O
a	O
role	O
for	O
APP	S-geneY
,	O
probably	O
mediated	O
via	O
one	O
or	O
more	O
of	O
its	O
metabolites	O
,	O
in	O
spine	O
structure	O
and	O
functions	O
.	O

The	O
intracellular	B-geneN
domain	I-geneN
of	I-geneN
APP	E-geneN
(	O
AICD	S-geneN
)	O
has	O
also	O
emerged	O
as	O
a	O
key	O
epigenetic	O
regulator	O
of	O
gene	O
expression	O
controlling	O
a	O
diverse	O
range	O
of	O
genes	O
,	O
including	O
APP	S-geneY
itself	O
,	O
the	O
amyloid	S-geneY
-	O
degrading	O
enzyme	O
neprilysin	S-geneY
,	O
and	O
aquaporin	B-geneY
-	I-geneY
1	E-geneY
.	O

A	O
fuller	O
understanding	O
of	O
the	O
physiological	O
and	O
pathological	O
actions	O
of	O
APP	S-geneY
and	O
its	O
metabolic	O
network	O
could	O
provide	O
new	O
opportunities	O
for	O
therapeutic	O
intervention	O
in	O
AD	O
.	O

Renal	O
failure	O
associated	O
with	O
the	O
use	O
of	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
.	O

OBJECTIVE	O
:	O
Celecoxib	S-chem-C4-1
and	O
rofecoxib	S-chem-C4-1
are	O
two	O
relatively	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
that	O
selectively	O
inhibit	O
the	O
cyclo	B-geneY-C4-2
-	I-geneY-C4-2
oxygenase	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
isoenzyme	O
at	O
therapeutic	O
concentrations	O
.	O

The	O
nephrotoxic	O
potential	O
of	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
has	O
not	O
been	O
clearly	O
established	O
.	O

This	O
study	O
was	O
conducted	O
in	O
order	O
to	O
understand	O
the	O
association	O
between	O
acute	O
renal	O
failure	O
and	O
the	O
two	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitors	O
celecoxib	S-chem-C4-1
and	O
rofecoxib	S-chem-C4-1
.	O

METHODS	O
:	O
A	O
search	O
was	O
performed	O
in	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
's	O
(	O
FDA	O
)	O
Adverse	O
Event	O
Reporting	O
System	O
(	O
AERS	O
)	O
to	O
identify	O
cases	O
of	O
renal	O
failure	O
submitted	O
to	O
the	O
FDA	O
.	O

A	O
MEDLINE	O
search	O
of	O
the	O
English	O
language	O
literature	O
was	O
also	O
performed	O
to	O
identify	O
published	O
cases	O
of	O
renal	O
failure	O
associated	O
with	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
.	O

RESULTS	O
:	O
One	O
hundred	O
twenty	O
-	O
two	O
and	O
142	O
domestic	O
US	O
cases	O
of	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
-	O
associated	O
renal	O
failure	O
,	O
respectively	O
,	O
were	O
identified	O
in	O
the	O
AERS	O
database	O
.	O

The	O
literature	O
search	O
identified	O
19	O
cases	O
of	O
acute	O
renal	O
impairment	O
in	O
association	O
with	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
.	O

In	O
addition	O
,	O
drug	O
regulatory	O
authorities	O
in	O
the	O
UK	O
,	O
Canada	O
,	O
and	O
Australia	O
have	O
received	O
about	O
50	O
reports	O
of	O
renal	O
failure	O
with	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
.	O

Descriptive	O
statistics	O
of	O
the	O
AERS	O
cases	O
have	O
been	O
summarised	O
in	O
this	O
report	O
.	O

CONCLUSIONS	O
:	O
Data	O
from	O
AERS	O
and	O
published	O
case	O
reports	O
suggest	O
that	O
use	O
of	O
both	O
these	O
drugs	O
is	O
associated	O
with	O
renal	O
effects	O
similar	O
to	O
that	O
of	O
conventional	O
nonselective	O
NSAIDs	O
.	O

Physicians	O
should	O
be	O
aware	O
that	O
serious	O
or	O
life	O
-	O
threatening	O
renal	O
failure	O
has	O
been	O
reported	O
in	O
patients	O
with	O
normal	O
or	O
impaired	O
renal	O
function	O
after	O
short	O
-	O
term	O
therapy	O
with	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
.	O

Patients	O
at	O
greatest	O
risk	O
for	O
renal	O
injury	O
are	O
those	O
with	O
pre	O
-	O
existing	O
renal	O
impairment	O
,	O
heart	O
failure	O
,	O
liver	O
dysfunction	O
,	O
those	O
taking	O
diuretics	O
and	O
/	O
or	O
ACE	S-geneY
inhibitors	O
,	O
and	O
the	O
elderly	O
.	O

Kidney	O
function	O
should	O
be	O
monitored	O
closely	O
for	O
any	O
signs	O
of	O
potential	O
renal	O
injuries	O
soon	O
after	O
initiating	O
treatment	O
with	O
these	O
agents	O
,	O
especially	O
in	O
high	O
-	O
risk	O
populations	O
.	O

In	O
addition	O
,	O
healthcare	O
practitioners	O
should	O
adequately	O
warn	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
renal	O
toxicity	O
,	O
and	O
of	O
the	O
need	O
for	O
them	O
to	O
see	O
their	O
physician	O
promptly	O
if	O
they	O
occur	O
.	O

Celecoxib	S-chem
and	O
rofecoxib	S-chem
are	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
.	O

Serum	O
free	O
fatty	B-chem
acid	E-chem
levels	O
in	O
PCOS	O
patients	O
treated	O
with	O
glucophage	O
,	O
magnesium	B-chem
oxide	E-chem
and	O
spironolactone	S-chem
.	O

Abstract	O
To	O
assess	O
the	O
effect	O
of	O
glucophage	O
,	O
magnesium	B-chem
oxide	E-chem
and	O
spironolactone	S-chem
in	O
altering	O
free	O
fatty	B-chem
acids	E-chem
(	O
FFAs	O
)	O
,	O
36	O
PCOS	O
women	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

Group	O
1	O
(	O
n	O
=	O
14	O
)	O
was	O
treated	O
with	O
500	O
mg	O
glucophage	O
po	O
bid	O
,	O
group	O
2	O
(	O
n	O
=	O
10	O
)	O
was	O
treated	O
with	O
400	O
mg	O
magnesium	O
oxide	I-chem
po	I-chem
bid	I-chem
and	O
group	O
3	O
(	O
n	O
=	O
12	O
)	O
was	O
treated	O
with	O
50	O
mg	O
spironolactone	O
po	I-chem
bid	I-chem
for	I-chem
12	O
weeks	O
.	O

A	O
glucose	S-chem
tolerance	O
test	O
with	O
75	O
g	O
glucose	O
load	O
was	O
performed	O
before	O
and	O
after	O
treatment	O
,	O
collecting	O
blood	O
at	O
0	O
,	O
1	O
and	O
2	O
h	O
for	O
insulin	O
,	I-geneY
glucose	O
,	I-chem
FFA	O
and	O
aldosterone	O
.	I-chem

Amount	O
of	O
FFA	O
before	O
and	O
after	O
treatment	O
were	O
compared	O
by	O
repeated	O
measure	O
ANOVA	O
and	O
represented	O
as	O
area	O
under	O
the	O
curve	O
.	O

FFA	O
levels	O
before	O
treatment	O
were	O
0.83	O
±	O
0.23	O
,	O
0.77	O
±	O
0.15	O
and	O
0.85	O
±	O
0.28	O
and	O
after	O
treatment	O
were	O
0.77	O
±	O
0.48	O
,	O
0.71	O
±	O
0.18	O
and	O
0.66	O
±	O
0.25	O
for	O
glucophage	O
,	O
magnesium	O
oxide	O
and	I-chem
spironolactone	O
-	I-chem
treated	I-chem
patients	O
,	O
respectively	O
.	O

The	O
FFA	O
levels	O
were	O
unchanged	O
in	O
the	O
groups	O
treated	O
with	O
glucophage	O
and	O
magnesium	B-chem
oxide	E-chem
but	O
were	O
significantly	O
(	O
p	O
<	O
0.03	O
)	O
decreased	O
in	O
the	O
group	O
treated	O
with	O
spironolactone	O
.	I-chem

Since	O
FFAs	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
insulin	S-geneY
resistance	O
,	O
these	O
results	O
suggest	O
that	O
spironolactone	S-chem
may	O
be	O
useful	O
for	O
lowering	O
insulin	S-geneY
resistance	O
in	O
PCOS	O
patients	O
.	O

Pharmacology	O
of	O
ramelteon	S-chem-C5-1
,	O
a	O
selective	O
MT1	S-geneY-C5-2
/	O
MT2	S-geneY-C5-2
receptor	O
agonist	O
:	O
a	O
novel	O
therapeutic	O
drug	O
for	O
sleep	O
disorders	O
.	O

An	O
estimated	O
one	O
-	O
third	O
of	O
the	O
general	O
population	O
is	O
affected	O
by	O
insomnia	O
,	O
and	O
this	O
number	O
is	O
increasing	O
due	O
to	O
more	O
stressful	O
working	O
conditions	O
and	O
the	O
progressive	O
aging	O
of	O
society	O
.	O

However	O
,	O
current	O
treatment	O
of	O
insomnia	O
with	O
hypnotics	O
,	O
gamma	B-geneN
-	I-geneN
aminobutyric	I-geneN
acid	I-geneN
A	I-geneN
(	I-geneN
GABA	I-geneN
(	I-geneN
A	I-geneN
)	I-geneN
)	I-geneN
receptor	E-geneN
modulators	O
,	O
induces	O
various	O
side	O
effects	O
,	O
including	O
cognitive	O
impairment	O
,	O
motor	O
disturbance	O
,	O
dependence	O
,	O
tolerance	O
,	O
hangover	O
,	O
and	O
rebound	O
insomnia	O
.	O

Ramelteon	S-chem-C5-1
(	O
Rozerem	S-chem
;	O
Takeda	O
Pharmaceutical	O
Company	O
Limited	O
,	O
Osaka	O
,	O
Japan	O
)	O
is	O
an	O
orally	O
active	O
,	O
highly	O
selective	O
melatonin	S-chem
MT	B-geneY-C5-2
(	I-geneY-C5-2
1	I-geneY-C5-2
)	E-geneY-C5-2
/	O
MT	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	E-geneY-C5-2
receptor	O
agonist	O
.	O

Unlike	O
the	O
sedative	O
hypnotics	O
that	O
target	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
receptor	E-geneN
complexes	O
,	O
ramelteon	S-chem-C5-1
is	O
a	O
chronohypnotic	O
that	O
acts	O
on	O
the	O
melatonin	S-chem
MT	B-geneY-C5-2
(	I-geneY-C5-2
1	I-geneY-C5-2
)	E-geneY-C5-2
and	O
MT	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	E-geneY-C5-2
receptors	O
,	O
which	O
are	O
primarily	O
located	O
in	O
the	O
suprachiasmatic	O
nucleus	O
,	O
the	O
body	O
's	O
``	O
master	O
clock.	O
``	O
As	O
such	O
,	I-chem
ramelteon	O
possesses	O
the	O
first	O
new	O
therapeutic	O
mechanism	O
of	O
action	O
for	O
a	O
prescription	O
insomnia	O
medication	O
in	O
over	O
three	O
decades	O
.	O

Ramelteon	S-chem
has	O
demonstrated	O
sleep	O
-	O
promoting	O
effects	O
in	O
clinical	O
trials	O
,	O
and	O
coupled	O
with	O
its	O
favorable	O
safety	O
profile	O
and	O
lack	O
of	O
abuse	O
potential	O
or	O
dependence	O
,	O
this	O
chronohypnotic	O
provides	O
an	O
important	O
treatment	O
option	O
for	O
insomnia	O
.	O

Molecular	O
mechanisms	O
of	O
fibrosis	O
-	O
associated	O
promotion	O
of	O
liver	O
carcinogenesis	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
mostly	O
develops	O
in	O
patients	O
with	O
advanced	O
fibrosis	O
;	O
however	O
,	O
the	O
mechanisms	O
of	O
interaction	O
between	O
a	O
genotoxic	O
insult	O
and	O
fibrogenesis	O
are	O
not	O
well	O
understood	O
.	O

This	O
study	O
tested	O
a	O
hypothesis	O
that	O
fibrosis	O
promotes	O
HCC	O
via	O
a	O
mechanism	O
that	O
involves	O
activation	O
of	O
liver	O
stem	O
cells	O
.	O

First	O
,	O
B6C3F1	O
mice	O
were	O
administered	O
diethylnitrosamine	S-chem
(	O
DEN	S-chem
;	O
single	O
ip	O
injection	O
of	O
1mg	O
/	O
kg	O
at	O
14	O
days	O
of	O
age	O
)	O
.	O

Second	O
,	O
carbon	B-chem
tetrachloride	E-chem
(	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
;	O
0.2ml	O
/	O
kg	O
,	O
2	O
/	O
week	O
ip	O
starting	O
at	O
8	O
weeks	O
of	O
age	O
)	O
was	O
administered	O
for	O
9	O
or	O
14	O
weeks	O
to	O
develop	O
advanced	O
liver	O
fibrosis	O
.	O

In	O
animals	O
treated	O
with	O
DEN	S-chem
as	O
neonates	O
,	O
presence	O
of	O
liver	O
fibrosis	O
led	O
to	O
more	O
than	O
doubling	O
(	O
to	O
100	O
%	O
)	O
of	O
the	O
liver	O
tumor	O
incidence	O
as	O
early	O
as	O
5	O
months	O
of	O
age	O
.	O

This	O
effect	O
was	O
associated	O
with	O
activation	O
of	O
cells	O
with	O
progenitor	O
features	O
in	O
noncancerous	O
liver	O
tissue	O
,	O
including	O
markers	O
of	O
replicative	O
senescence	O
(	O
p16	S-geneY
)	O
,	O
oncofetal	O
transformation	O
(	O
Afp	S-geneY
,	O
H19	S-geneY
,	O
and	O
Bex1	S-geneY
)	O
,	O
and	O
increased	O
``	O
stemness	O
``	O
(	I-geneY
Prom1	O
and	O
Epcam	O
)	O
.	O

In	O
contrast	O
,	O
the	O
dose	O
of	O
DEN	S-chem
used	O
did	O
not	O
modify	O
the	O
extent	O
of	O
liver	O
inflammation	O
,	O
fibrogenesis	O
,	O
oxidative	O
stress	O
,	O
proliferation	O
,	O
or	O
apoptosis	O
induced	O
by	O
subchronic	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
administration	O
.	O

This	O
study	O
demonstrates	O
the	O
potential	O
role	O
of	O
liver	O
stem	O
-	O
like	O
cells	O
in	O
the	O
mechanisms	O
of	O
chemical	O
-	O
induced	O
,	O
fibrosis	O
-	O
promoted	O
HCC	O
.	O

We	O
posit	O
that	O
the	O
combination	O
of	O
genotoxic	O
and	O
fibrogenic	O
insults	O
is	O
a	O
sensible	O
approach	O
to	O
model	O
liver	O
carcinogenesis	O
in	O
experimental	O
animals	O
.	O

These	O
results	O
may	O
contribute	O
to	O
identification	O
of	O
cirrhotic	O
patients	O
predisposed	O
to	O
HCC	O
by	O
analyzing	O
the	O
expression	O
of	O
hepatic	O
progenitor	O
cell	O
markers	O
in	O
the	O
noncancerous	O
liver	O
tissue	O
.	O

Differentiation	O
of	O
opioid	O
drug	O
effects	O
by	O
hierarchical	O
multi	O
-	O
site	O
phosphorylation	O
.	O

Differences	O
in	O
the	O
ability	O
of	O
opioid	O
drugs	O
to	O
promote	O
regulated	O
endocytosis	O
of	O
μ	B-geneY
-	I-geneY
opioid	I-geneY
receptors	E-geneY
are	O
related	O
to	O
their	O
tendency	O
to	O
produce	O
drug	O
tolerance	O
and	O
dependence	O
.	O

Here	O
we	O
show	O
that	O
drug	O
-	O
specific	O
differences	O
in	O
receptor	O
internalization	O
are	O
determined	O
by	O
a	O
conserved	O
,	O
10	O
-	O
residue	O
sequence	O
in	O
the	O
receptor	O
's	O
carboxyl	B-geneN
-	I-geneN
terminal	I-geneN
cytoplasmic	I-geneN
tail	E-geneN
.	O

Diverse	O
opioids	O
induce	O
receptor	O
phosphorylation	O
at	O
serine	S-chem
(	O
S	O
)	O
375	O
,	O
present	O
in	O
the	O
middle	O
of	O
this	O
sequence	O
,	O
but	O
opioids	O
differ	O
markedly	O
in	O
their	O
ability	O
to	O
drive	O
higher	O
-	O
order	O
phosphorylation	O
on	O
flanking	O
residues	O
[	O
threonine	S-chem
(	O
T	O
)	O
370	O
,	O
T376	O
,	O
and	O
T379	O
]	O
.	O

Multi	O
-	O
phosphorylation	O
is	O
required	O
for	O
the	O
endocytosis	O
-	O
promoting	O
activity	O
of	O
this	O
sequence	O
and	O
occurs	O
both	O
sequentially	O
and	O
hierarchically	O
,	O
with	O
S375	O
representing	O
the	O
initiating	O
site	O
.	O

Higher	O
-	O
order	O
phosphorylation	O
involving	O
T370	O
,	O
T376	O
,	O
and	O
T379	O
specifically	O
requires	O
GRK2	B-geneN
/	I-geneN
3	E-geneN
isoforms	O
,	O
and	O
the	O
same	O
sequence	O
controls	O
opioid	B-geneN
receptor	E-geneN
internalization	O
in	O
neurons	O
.	O

These	O
results	O
reveal	O
a	O
biochemical	O
mechanism	O
differentiating	O
the	O
endocytic	O
activity	O
of	O
opioid	O
drugs	O
.	O

Medical	O
therapy	O
and	O
quality	O
of	O
life	O
.	O

The	O
risk	O
of	O
mortality	O
and	O
long	O
-	O
term	O
morbidity	O
,	O
including	O
loss	O
of	O
sexual	O
function	O
,	O
associated	O
with	O
surgical	O
procedures	O
for	O
symptomatic	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
has	O
prompted	O
research	O
into	O
alternative	O
medical	O
therapies	O
.	O

Phytotherapy	O
involves	O
the	O
use	O
of	O
herbal	O
formulations	O
,	O
where	O
the	O
mechanisms	O
of	O
action	O
are	O
usually	O
obscure	O
and	O
although	O
studies	O
have	O
confirmed	O
their	O
effectiveness	O
in	O
symptom	O
relief	O
and	O
improving	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
,	O
few	O
placebo	O
-	O
controlled	O
trials	O
exist	O
.	O

Both	O
the	O
5	B-geneN-C4-2
alpha	I-geneN-C4-2
-	I-geneN-C4-2
reductase	E-geneN-C4-2
inhibitor	O
finasteride	S-chem-C4-1
and	O
alpha	B-geneN-C6-2
1	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonists	O
(	O
e.g	O
.	O
alfuzosin	S-chem-C6-1
,	O
doxazosin	S-chem-C6-1
,	O
prazosin	S-chem-C6-1
,	O
tamsulosin	S-chem-C6-1
and	O
terazosin	S-chem-C6-1
)	O
have	O
been	O
recommended	O
as	O
appropriate	O
treatment	O
options	O
for	O
patients	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
associated	O
with	O
benign	O
prostatic	O
obstruction	O
(	O
BPO	O
)	O
,	O
and	O
their	O
efficacy	O
has	O
been	O
proven	O
in	O
several	O
placebo	O
-	O
controlled	O
trials	O
.	O

Finasteride	S-chem
reduces	O
the	O
static	O
component	O
of	O
BPO	O
-	O
-	O
by	O
reducing	O
the	O
size	O
of	O
the	O
prostate	O
-	O
-	O
and	O
,	O
as	O
a	O
result	O
,	O
symptom	O
relief	O
is	O
slow	O
(	O
6	O
-	O
12	O
months	O
)	O
and	O
is	O
predominantly	O
restricted	O
to	O
patients	O
with	O
large	O
prostates	O
(	O
>	O
40	O
g	O
)	O
.	O

The	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
,	O
on	O
the	O
other	O
hand	O
,	O
reduce	O
the	O
dynamic	O
component	O
of	O
obstruction	O
-	O
-	O
relaxation	O
of	O
smooth	O
muscle	O
in	O
the	O
prostate	O
,	O
urethra	O
and	O
bladder	O
neck	O
-	O
-	O
and	O
provide	O
rapid	O
symptom	O
relief	O
after	O
only	O
a	O
few	O
doses	O
,	O
relieving	O
LUTS	O
more	O
effectively	O
than	O
finasteride	S-chem
and	O
irrespective	O
of	O
prostate	O
size	O
.	O

All	O
of	O
the	O
various	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
provide	O
effective	O
and	O
comparable	O
relief	O
of	O
LUTS	O
,	O
and	O
an	O
improvement	O
in	O
bothersomeness	O
and	O
symptom	O
-	O
related	O
QOL	O
.	O

However	O
,	O
it	O
is	O
also	O
important	O
that	O
the	O
therapy	O
is	O
fast	O
acting	O
and	O
acceptable	O
to	O
the	O
patient	O
,	O
in	O
that	O
it	O
does	O
not	O
interfere	O
with	O
other	O
medication	O
or	O
produce	O
unpleasant	O
side	O
effects	O
.	O

These	O
documented	O
properties	O
of	O
the	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
antagonists	O
make	O
them	O
an	O
ideal	O
choice	O
for	O
the	O
medical	O
treatment	O
of	O
symptomatic	O
BPH	O
.	O

Synthesis	O
and	O
in	O
Vitro	O
Characterisation	O
of	O
Ifenprodil	S-chem-C6-1
-	O
Based	O
Fluorescein	S-chem-C6-1
Conjugates	O
as	O
GluN1	S-geneY-C6-2
/	O
GluN2B	S-geneY-C6-2
N	B-geneN-C6-2
-	I-geneN-C6-2
Methyl	I-geneN-C6-2
-	I-geneN-C6-2
D	I-geneN-C6-2
-	I-geneN-C6-2
aspartate	I-geneN-C6-2
Receptor	E-geneN-C6-2
Antagonists	O
.	O

GluN2B	S-geneY
-	O
containing	O
NMDA	B-geneN
receptors	E-geneN
are	O
involved	O
in	O
many	O
important	O
physiological	O
functions	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
mediating	O
pain	O
as	O
well	O
as	O
in	O
several	O
neurodegenerative	O
disorders	O
.	O

We	O
aimed	O
to	O
develop	O
fluorescent	O
probes	O
to	O
target	O
the	O
GluN2B	S-geneY
subunit	O
selectively	O
in	O
order	O
to	O
allow	O
better	O
understanding	O
of	O
the	O
relationships	O
between	O
receptor	O
localisation	O
and	O
physiological	O
importance	O
.	O

Ifenprodil	S-chem-C6-1
,	O
known	O
as	O
the	O
GluNR2B	S-geneY-C6-2
antagonist	O
of	O
reference	O
,	O
was	O
chosen	O
as	O
the	O
template	O
for	O
the	O
elaboration	O
of	O
probes	O
.	O

We	O
had	O
previously	O
reported	O
a	O
fluorescein	S-chem
conjugate	O
that	O
was	O
shown	O
(	O
by	O
confocal	O
microscopy	O
imaging	O
of	O
DS	O
-	O
red	O
-	O
labelled	O
cortical	O
neurons	O
)	O
to	O
bind	O
specifically	O
to	O
GluN2B	S-geneY
.	O

To	O
elaborate	O
this	O
probe	O
,	O
we	O
explored	O
the	O
influence	O
of	O
both	O
the	O
nature	O
and	O
the	O
attachment	O
point	O
of	O
the	O
spacer	O
between	O
the	O
fluorophore	O
and	O
the	O
parent	O
compound	O
,	O
ifenprodil	S-chem
.	O

We	O
performed	O
chemical	O
modifications	O
of	O
ifenprodil	S-chem
at	O
the	O
benzylic	S-chem
position	O
and	O
on	O
the	O
phenol	S-chem
ring	O
by	O
introducing	O
secondary	B-chem
amine	I-chem
or	I-chem
amide	E-chem
functions	O
and	O
evaluated	O
alkyl	O
chains	O
from	O
two	O
to	O
20	O
bonds	O
either	O
including	O
or	O
not	O
including	O
secondary	B-chem
amide	E-chem
functions	O
as	O
spacers	O
.	O

The	O
previously	O
developed	O
probe	O
was	O
found	O
to	O
display	O
the	O
greatest	O
activity	O
in	O
the	O
inhibition	O
of	O
NMDA	S-chem
-	O
induced	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
influx	O
by	O
calcium	S-chem
imaging	O
experiments	O
on	O
HEK293	O
cells	O
transfected	O
with	O
the	O
cDNA	O
encoding	O
for	O
GluN1	B-geneY
-	I-geneY
1A	E-geneY
and	O
GluN2B	S-geneY
.	O

Further	O
investigations	O
revealed	O
that	O
this	O
probe	O
had	O
a	O
neuroprotective	O
effect	O
equivalent	O
to	O
that	O
of	O
ifenprodil	S-chem
in	O
a	O
standard	O
test	O
for	O
neurotoxicity	O
.	O

Despite	O
effects	O
of	O
lesser	O
amplitude	O
with	O
these	O
probes	O
relative	O
to	O
ifenprodil	S-chem
,	O
we	O
demonstrated	O
that	O
they	O
displaced	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
ifenprodil	E-chem
in	O
mouse	O
brain	O
slices	O
in	O
a	O
similar	O
manner	O
.	O

Oligomeric	O
procyanidins	S-chem
of	O
lotus	O
seedpod	O
inhibits	O
the	O
formation	O
of	O
advanced	O
glycation	O
end	O
-	O
products	O
by	O
scavenging	O
reactive	O
carbonyls	S-chem
.	O

It	O
has	O
been	O
reported	O
that	O
oligomeric	O
procyanidins	S-chem-C3-1
of	O
lotus	O
seedpod	O
(	O
LSOPC	O
)	O
is	O
effective	O
in	O
the	O
alleviation	O
of	O
Alzheimer	O
's	O
disease	O
and	O
diabetes	O
through	O
its	O
antioxidant	O
and	O
insulin	S-geneY-C3-2
-	O
potentiating	O
activities	O
.	O

This	O
study	O
investigated	O
the	O
anti	O
-	O
glycative	O
activity	O
of	O
LSOPC	O
in	O
a	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
BSA	S-geneY
)	O
-	O
glucose	S-chem
model	O
.	O

The	O
level	O
of	O
glycation	O
and	O
conformational	O
alterations	O
were	O
assessed	O
by	O
specific	O
fluorescence	O
,	O
Congo	O
red	O
binding	O
assay	O
and	O
circular	O
dichroism	O
.	O

The	O
results	O
show	O
that	O
LSOPC	O
has	O
a	O
significant	O
anti	O
-	O
glycative	O
activity	O
in	O
vitro	O
and	O
it	O
can	O
also	O
effectively	O
protect	O
the	O
secondary	O
structure	O
of	O
BSA	S-geneY
during	O
glycation	O
.	O

LSOPC	O
or	O
catechin	S-chem
(	O
a	O
major	O
constituent	O
unit	O
of	O
LSOPC	O
)	O
,	O
were	O
used	O
to	O
react	O
with	O
methylglyoxal	S-chem
.	O

The	O
structures	O
of	O
their	O
carbonyl	S-chem
adducts	O
were	O
tentatively	O
identified	O
using	O
HPLC	O
-	O
MS	O
(	O
2	O
)	O
.	O

Their	O
capacity	O
to	O
scavenge	O
methylglyoxal	S-chem
suggested	O
carbonyl	S-chem
scavenging	O
as	O
a	O
major	O
mechanism	O
of	O
antiglycation	O
.	O

Therefore	O
,	O
LSOPC	O
could	O
be	O
helpful	O
to	O
prevent	O
AGEs	O
-	O
associated	O
diseases	O
,	O
and	O
with	O
the	O
potential	O
to	O
be	O
used	O
as	O
functional	O
food	O
ingredients	O
.	O

Amino	B-chem
acids	E-chem
as	O
co	O
-	O
amorphous	O
stabilizers	O
for	O
poorly	O
water	O
soluble	O
drugs	O
-	O
Part	O
1	O
:	O
Preparation	O
,	O
stability	O
and	O
dissolution	O
enhancement	O
.	O

Poor	O
aqueous	O
solubility	O
of	O
an	O
active	O
pharmaceutical	O
ingredient	O
(	O
API	O
)	O
is	O
one	O
of	O
the	O
most	O
pressing	O
problems	O
in	O
pharmaceutical	O
research	O
and	O
development	O
because	O
up	O
to	O
90	O
%	O
of	O
new	O
API	O
candidates	O
under	O
development	O
are	O
poorly	O
water	O
soluble	O
.	O

These	O
drugs	O
usually	O
have	O
a	O
low	O
and	O
variable	O
oral	O
bioavailability	O
,	O
and	O
therefore	O
an	O
unsatisfactory	O
therapeutic	O
effect	O
.	O

One	O
of	O
the	O
most	O
promising	O
approaches	O
to	O
increase	O
dissolution	O
rate	O
and	O
solubility	O
of	O
these	O
drugs	O
is	O
the	O
conversion	O
of	O
a	O
crystalline	O
form	O
of	O
the	O
drug	O
into	O
its	O
respective	O
amorphous	O
form	O
,	O
usually	O
by	O
incorporation	O
into	O
hydrophilic	O
polymers	O
,	O
forming	O
glass	O
solutions	O
.	O

However	O
,	O
this	O
strategy	O
only	O
led	O
to	O
a	O
small	O
number	O
of	O
marketed	O
products	O
usually	O
because	O
of	O
inadequate	O
physical	O
stability	O
of	O
the	O
drug	O
(	O
crystallization	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
fundamentally	O
different	O
approach	O
to	O
stabilize	O
the	O
amorphous	O
form	O
of	O
drugs	O
,	O
namely	O
the	O
use	O
of	O
amino	B-chem
acids	E-chem
as	O
small	O
molecular	O
weight	O
excipients	O
that	O
form	O
specific	O
molecular	O
interactions	O
with	O
the	O
drug	O
resulting	O
in	O
co	O
-	O
amorphous	O
forms	O
.	O

The	O
two	O
poorly	O
water	O
soluble	O
drugs	O
carbamazepine	S-chem
and	O
indomethacin	S-chem
were	O
combined	O
with	O
amino	B-chem
acids	E-chem
from	O
the	O
binding	O
sites	O
of	O
the	O
biological	O
receptors	O
of	O
these	O
drugs	O
.	O

Mixtures	O
of	O
drug	O
and	O
the	O
amino	B-chem
acids	E-chem
arginine	S-chem
,	O
phenylalanine	S-chem
,	O
tryptophan	S-chem
and	O
tyrosine	S-chem
were	O
prepared	O
by	O
vibrational	O
ball	O
milling	O
.	O

Solid	O
-	O
state	O
characterization	O
with	O
X	O
-	O
ray	O
powder	O
diffraction	O
(	O
XRPD	O
)	O
and	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
revealed	O
that	O
the	O
various	O
blends	O
could	O
be	O
prepared	O
as	O
homogeneous	O
,	O
single	O
phase	O
co	O
-	O
amorphous	O
formulations	O
indicated	O
by	O
the	O
appearance	O
of	O
an	O
amorphous	O
halo	O
in	O
the	O
XRPD	O
diffractograms	O
and	O
a	O
single	O
glass	O
transition	O
temperature	O
(	O
Tg	O
)	O
in	O
the	O
DSC	O
measurements	O
.	O

In	O
addition	O
,	O
the	O
Tgs	O
of	O
the	O
co	O
-	O
amorphous	O
mixtures	O
were	O
significantly	O
increased	O
over	O
those	O
of	O
the	O
individual	O
drugs	O
.	O

The	O
drugs	O
remained	O
chemically	O
stable	O
during	O
the	O
milling	O
process	O
and	O
the	O
co	O
-	O
amorphous	O
formulations	O
were	O
generally	O
physically	O
stable	O
over	O
at	O
least	O
6months	O
at	O
40°C	O
under	O
dry	O
conditions	O
.	O

The	O
dissolution	O
rate	O
of	O
all	O
co	O
-	O
amorphous	O
drug	O
-	O
amino	B-chem
acid	E-chem
mixtures	O
was	O
significantly	O
increased	O
over	O
that	O
of	O
the	O
respective	O
crystalline	O
and	O
amorphous	O
pure	O
drugs	O
.	O

Amino	B-chem
acids	E-chem
thus	O
appear	O
as	O
promising	O
excipients	O
to	O
solve	O
challenges	O
connected	O
with	O
the	O
stability	O
and	O
dissolution	O
of	O
amorphous	O
drugs	O
.	O

Microarray	O
and	O
biochemical	O
analysis	O
of	O
lovastatin	S-chem
-	O
induced	O
apoptosis	O
of	O
squamous	O
cell	O
carcinomas	O
.	O

We	O
recently	O
identified	O
3	B-geneY
-	I-geneY
hydroxy	I-geneY
-	I-geneY
3	I-geneY
-	I-geneY
methylglutaryl	I-geneY
coenzyme	I-geneY
A	I-geneY
(	I-geneY
HMG	I-geneY
-	I-geneY
CoA	I-geneY
)	I-geneY
reductase	E-geneY
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
the	O
mevalonate	O
pathway	O
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
of	O
the	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
(	O
HNSCC	O
)	O
and	O
cervical	O
carcinomas	O
(	O
CC	O
)	O
.	O

The	O
products	O
of	O
this	O
complex	O
biochemical	O
pathway	O
,	O
including	O
de	O
novo	O
cholesterol	S-chem
,	O
are	O
vital	O
for	O
a	O
variety	O
of	O
key	O
cellular	O
functions	O
affecting	O
membrane	O
integrity	O
,	O
cell	O
signaling	O
,	O
protein	O
synthesis	O
,	O
and	O
cell	O
cycle	O
progression	O
.	O

Lovastatin	S-chem-C4-1
,	O
a	O
specific	O
inhibitor	O
of	O
HMG	B-geneY-C4-2
-	I-geneY-C4-2
CoA	I-geneY-C4-2
reductase	E-geneY-C4-2
,	O
induces	O
a	O
pronounced	O
apoptotic	O
response	O
in	O
a	O
specific	O
subset	O
of	O
tumor	O
types	O
,	O
including	O
HNSCC	O
and	O
CC	O
.	O

The	O
mediators	O
of	O
this	O
response	O
are	O
not	O
well	O
established	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
represents	O
a	O
feasible	O
approach	O
to	O
delineate	O
these	O
mediators	O
as	O
lovastatin	S-chem
has	O
the	O
potential	O
to	O
modulate	O
transcription	O
indirectly	O
by	O
perturbing	O
levels	O
of	O
sterols	O
and	O
other	O
mevalonate	S-chem
metabolites	O
.	O

Expression	O
analysis	O
following	O
treatment	O
of	O
the	O
HNSCC	O
cell	O
lines	O
SCC9	O
or	O
SCC25	O
with	O
10	O
microM	O
lovastatin	S-chem
for	O
1	O
day	O
showed	O
that	O
less	O
than	O
2	O
%	O
(	O
9	O
cDNAs	O
)	O
of	O
the	O
588	O
cDNAs	O
on	O
this	O
microarray	O
were	O
affected	O
in	O
both	O
cell	O
lines	O
.	O

These	O
included	O
diazepam	B-geneY
-	I-geneY
binding	I-geneY
inhibitor	E-geneY
/	O
acyl	B-geneY
-	I-geneY
CoA	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
,	E-geneY
the	O
activated	B-geneY
transcription	I-geneY
factor	I-geneY
4	E-geneY
and	O
rhoA	S-geneY
.	O

Because	O
the	O
biosynthesis	O
of	O
mevalonate	S-chem
leads	O
to	O
its	O
incorporation	O
into	O
more	O
than	O
a	O
dozen	O
classes	O
of	O
end	O
products	O
,	O
their	O
role	O
in	O
lovastatin	S-chem
-	O
induced	O
apoptosis	O
was	O
also	O
evaluated	O
.	O

Addition	O
of	O
the	O
metabolites	O
of	O
all	O
the	O
major	O
branches	O
of	O
the	O
mevalonate	S-chem
pathway	O
indicated	O
that	O
only	O
the	O
nonsterol	O
moiety	O
,	O
geranylgeranyl	B-chem
pyrophosphate	E-chem
(	O
GGPP	S-chem
)	O
,	O
significantly	O
inhibited	O
the	O
apoptotic	O
effects	O
of	O
lovastatin	S-chem
in	O
HNSCC	O
and	O
CC	O
cells	O
.	O

Because	O
rhoA	S-geneY
requires	O
GGPP	S-chem
for	O
its	O
function	O
,	O
this	O
links	O
the	O
microarray	O
and	O
biochemical	O
data	O
and	O
identifies	O
rhoA	S-geneY
as	O
a	O
potential	O
mediator	O
of	O
the	O
anticancer	O
properties	O
of	O
lovastatin	S-chem
.	O

Our	O
data	O
suggest	O
that	O
the	O
depletion	O
of	O
nonsterol	O
mevalonate	O
metabolites	O
,	O
particularly	O
GGPP	S-chem
,	O
can	O
be	O
potential	O
mediators	O
of	O
lovastatin	S-chem
-	O
induced	O
apoptosis	O
of	O
HNSCC	O
and	O
CC	O
cells	O
.	O

Assessment	O
of	O
the	O
abuse	O
liability	O
of	O
ABT	B-chem-C6-1
-	I-chem-C6-1
288	E-chem-C6-1
,	O
a	O
novel	O
histamine	B-geneY-C6-2
H3	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
.	O

RATIONALE	O
:	O
Histamine	B-geneY-C6-2
H3	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
,	O
such	O
as	O
ABT	B-chem-C6-1
-	I-chem-C6-1
288	E-chem-C6-1
,	O
have	O
been	O
shown	O
to	O
possess	O
cognitive	O
-	O
enhancing	O
and	O
wakefulness	O
-	O
promoting	O
effects	O
.	O

On	O
the	O
surface	O
,	O
this	O
might	O
suggest	O
that	O
H3	S-geneY
antagonists	O
possess	O
psychomotor	O
stimulant	O
-	O
like	O
effects	O
and	O
,	O
as	O
such	O
,	O
may	O
have	O
the	O
potential	O
for	O
abuse	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
further	O
characterize	O
whether	O
ABT	B-chem
-	I-chem
288	E-chem
possesses	O
stimulant	O
-	O
like	O
properties	O
and	O
whether	O
its	O
pharmacology	O
gives	O
rise	O
to	O
abuse	O
liability	O
.	O

METHODS	O
:	O
The	O
locomotor	O
-	O
stimulant	O
effects	O
of	O
ABT	B-chem
-	I-chem
288	E-chem
were	O
measured	O
in	O
mice	O
and	O
rats	O
,	O
and	O
potential	O
development	O
of	O
sensitization	O
was	O
addressed	O
.	O

Drug	O
discrimination	O
was	O
used	O
to	O
assess	O
amphetamine	S-chem
-	O
like	O
stimulus	O
properties	O
,	O
and	O
drug	O
self	O
-	O
administration	O
was	O
used	O
to	O
evaluate	O
reinforcing	O
effects	O
of	O
ABT	B-chem
-	I-chem
288	E-chem
.	O

The	O
potential	O
development	O
of	O
physical	O
dependence	O
was	O
also	O
studied	O
.	O

RESULTS	O
:	O
ABT	B-chem
-	I-chem
288	E-chem
lacked	O
locomotor	O
-	O
stimulant	O
effects	O
in	O
both	O
rats	O
and	O
mice	O
.	O

Repeated	O
administration	O
of	O
ABT	B-chem
-	I-chem
288	E-chem
did	O
not	O
result	O
in	O
cross	O
-	O
sensitization	O
to	O
the	O
stimulant	O
effects	O
of	O
d	B-chem
-	I-chem
amphetamine	E-chem
in	O
mice	O
,	O
suggesting	O
that	O
there	O
is	O
little	O
overlap	O
in	O
circuitries	O
upon	O
which	O
the	O
two	O
drugs	O
interact	O
for	O
motor	O
activity	O
.	O

ABT	B-chem
-	I-chem
288	E-chem
did	O
not	O
produce	O
amphetamine	S-chem
-	O
like	O
discriminative	O
stimulus	O
effects	O
in	O
drug	O
discrimination	O
studies	O
nor	O
was	O
it	O
self	O
-	O
administered	O
by	O
rats	O
trained	O
to	O
self	O
-	O
administer	O
cocaine	S-chem
.	O

There	O
were	O
no	O
signs	O
of	O
physical	O
dependence	O
upon	O
termination	O
of	O
repeated	O
administration	O
of	O
ABT	B-chem
-	I-chem
288	E-chem
for	O
30	O
days	O
.	O

CONCLUSIONS	O
:	O
The	O
sum	O
of	O
these	O
preclinical	O
data	O
,	O
the	O
first	O
of	O
their	O
kind	O
applied	O
to	O
H3	S-geneY
antagonists	O
,	O
indicates	O
that	O
ABT	B-chem-C6-1
-	I-chem-C6-1
288	E-chem-C6-1
is	O
unlikely	O
to	O
possess	O
a	O
high	O
potential	O
for	O
abuse	O
in	O
the	O
human	O
population	O
and	O
suggests	O
that	O
H3	S-geneY-C6-2
antagonists	O
,	O
as	O
a	O
class	O
,	O
are	O
similar	O
in	O
this	O
regard	O
.	O

The	O
pharmacology	O
of	O
cilostazol	S-chem
.	O

Cilostazol	S-chem
(	B-chem
6	I-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
cyclohexyl	I-chem
-	I-chem
1H	I-chem
-	I-chem
tetrazol	I-chem
-	I-chem
5	I-chem
-	I-chem
yl	I-chem
)	I-chem
butoxy	I-chem
]	I-chem
-	I-chem
3,4	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2	I-chem
(	I-chem
1H	I-chem
)	I-chem
-	I-chem
quinolinone	E-chem
;	O
OPC	B-chem
-	I-chem
13013	E-chem
)	O
is	O
a	O
2	B-chem
-	I-chem
oxo	I-chem
-	I-chem
quinoline	E-chem
derivative	O
with	O
antithrombotic	O
,	O
vasodilator	O
,	O
antimitogenic	O
and	O
cardiotonic	O
properties	O
.	O

The	O
compound	O
is	O
a	O
potent	O
inhibitor	O
of	O
phosphodiesterase	B-geneY
(	I-geneY
PDE	I-geneY
)	I-geneY
3A	E-geneY
,	O
the	O
isoform	O
of	O
PDE	B-geneN
3	E-geneN
in	O
the	O
cardiovascular	O
system	O
(	O
IC50	O
:	O
0.2	O
microM	O
)	O
.	O

In	O
addition	O
,	O
there	O
is	O
inhibition	O
of	O
adenosine	S-chem
uptake	O
,	O
eventually	O
resulting	O
in	O
changes	O
in	O
cAMP	S-chem
levels	O
,	O
dependent	O
on	O
the	O
type	O
of	O
adenosine	B-geneN
receptors	I-geneN
(	I-geneN
A1	I-geneN
or	I-geneN
A2	I-geneN
)	E-geneN
.	O

Cilostazol	S-chem
inhibits	O
platelet	O
aggregation	O
and	O
has	O
considerable	O
antithrombotic	O
effects	O
in	O
vivo	O
.	O

The	O
compound	O
relaxes	O
vascular	O
smooth	O
muscle	O
and	O
inhibits	O
mitogenesis	O
and	O
migration	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

In	O
the	O
heart	O
,	O
cilostazol	S-chem
causes	O
positive	O
inotropic	O
and	O
chronotropic	O
effects	O
.	O

Most	O
,	O
if	O
not	O
all	O
,	O
of	O
these	O
actions	O
are	O
cAMP	S-chem
-	O
mediated	O
,	O
including	O
the	O
modification	O
of	O
cAMP	S-chem
-	O
controlled	O
gene	O
expression	O
.	O

Cilostazol	S-chem-C3-1
decreases	O
levels	O
of	O
serum	O
triglycerides	O
and	O
causes	O
some	O
increase	O
in	O
HDL	S-geneN-C3-2
-	O
cholesterol	S-chem
levels	O
.	O

The	O
compound	O
has	O
a	O
number	O
of	O
additional	O
effects	O
which	O
might	O
contribute	O
to	O
its	O
overall	O
clinical	O
efficacy	O
.	O

Cilostazol	S-chem-C9-1
undergoes	O
intensive	O
and	O
finally	O
complete	O
hepatic	O
metabolism	O
via	O
the	O
cytochrome	B-geneN-C9-2
P450	E-geneN-C9-2
systems	O
.	O

This	O
might	O
result	O
in	O
some	O
drug	O
interaction	O
,	O
i.e	O
.	O
with	O
erythromycin	S-chem
and	O
omeprazole	S-chem
.	O

The	O
half	O
-	O
life	O
is	O
approximately	O
10	O
h	O
,	O
resulting	O
in	O
about	O
2	O
-	O
fold	O
accumulation	O
of	O
the	O
drug	O
during	O
repeated	O
administration	O
.	O

Development	O
and	O
validation	O
of	O
NIR	O
-	O
chemometric	O
methods	O
for	O
chemical	O
and	O
pharmaceutical	O
characterization	O
of	O
meloxicam	S-chem
tablets	O
.	O

Abstract	O
Context	O
:	O
Near	O
-	O
Infrared	O
(	O
NIR	O
)	O
spectroscopy	O
is	O
an	O
important	O
component	O
of	O
a	O
Process	O
Analytical	O
Technology	O
(	O
PAT	O
)	O
toolbox	O
and	O
is	O
a	O
key	O
technology	O
for	O
enabling	O
the	O
rapid	O
analysis	O
of	O
pharmaceutical	O
tablets	O
.	O

Objective	O
:	O
The	O
aim	O
of	O
this	O
research	O
work	O
was	O
to	O
develop	O
and	O
validate	O
NIR	O
-	O
chemometric	O
methods	O
not	O
only	O
for	O
the	O
determination	O
of	O
active	O
pharmaceutical	O
ingredients	O
content	O
but	O
also	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
,	O
disintegration	O
time	O
)	O
of	O
meloxicam	S-chem
tablets	O
.	O

Materials	O
and	O
methods	O
:	O
The	O
development	O
of	O
the	O
method	O
for	O
active	O
content	O
assay	O
was	O
performed	O
on	O
samples	O
corresponding	O
to	O
80	O
%	O
,	O
90	O
%	O
,	O
100	O
%	O
,	O
110	O
%	O
and	O
120	O
%	O
of	O
meloxicam	S-chem
content	O
and	O
the	O
development	O
of	O
the	O
methods	O
for	O
pharmaceutical	O
characterization	O
was	O
performed	O
on	O
samples	O
prepared	O
at	O
seven	O
different	O
compression	O
forces	O
(	O
ranging	O
from	O
7	O
to	O
45	O
kN	O
)	O
using	O
NIR	O
transmission	O
spectra	O
of	O
intact	O
tablets	O
and	O
PLS	O
as	O
a	O
regression	O
method	O
.	O

Results	O
:	O
The	O
results	O
show	O
that	O
the	O
developed	O
methods	O
have	O
good	O
trueness	O
,	O
precision	O
and	O
accuracy	O
and	O
are	O
appropriate	O
for	O
direct	O
active	O
content	O
assay	O
in	O
tablets	O
(	O
ranging	O
from	O
12	O
to	O
18	O
mg	O
/	O
tablet	O
)	O
and	O
also	O
for	O
predicting	O
crushing	O
strength	O
and	O
disintegration	O
time	O
of	O
intact	O
meloxicam	S-chem
tablets	O
.	O

Discussion	O
:	O
The	O
comparative	O
data	O
show	O
that	O
the	O
proposed	O
methods	O
are	O
in	O
good	O
agreement	O
with	O
the	O
reference	O
methods	O
currently	O
used	O
for	O
the	O
characterization	O
of	O
meloxicam	S-chem
tablets	O
(	O
HPLC	O
-	O
UV	O
methods	O
for	O
the	O
assay	O
and	O
European	O
Pharmacopeia	O
methods	O
for	O
determining	O
the	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
.	O

Conclusion	O
:	O
The	O
results	O
show	O
the	O
possibility	O
to	O
predict	O
both	O
chemical	O
properties	O
(	O
active	O
content	O
)	O
and	O
physical	O
/	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
directly	O
,	O
without	O
any	O
sample	O
preparation	O
,	O
from	O
the	O
same	O
NIR	O
transmission	O
spectrum	O
of	O
meloxicam	S-chem
tablets	O
.	O

Changes	O
in	O
morphometry	O
and	O
association	O
between	O
whole	O
-	O
body	O
fatty	B-chem
acids	E-chem
and	O
steroid	S-chem
hormone	O
profiles	O
in	O
relation	O
to	O
bioaccumulation	O
patterns	O
in	O
salmon	O
larvae	O
exposed	O
to	O
perfluorooctane	B-chem
sulfonic	I-chem
or	I-chem
perfluorooctane	I-chem
carboxylic	I-chem
acids	E-chem
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
used	O
salmon	O
embryos	O
whose	O
continuous	O
exposure	O
to	O
waterborne	O
PFOA	S-chem
or	O
PFOS	S-chem
at	O
100	O
μg	O
/	O
L	O
started	O
as	O
freshly	O
fertilized	O
eggs	O
,	O
and	O
lasted	O
for	O
a	O
total	O
of	O
52	O
days	O
.	O

PFOS	S-chem
and	O
PFOA	S-chem
were	O
dissolved	O
in	O
methanol	S-chem
(	O
carrier	O
vehicle	O
)	O
whose	O
concentration	O
never	O
exceeded	O
0.01	O
%	O
of	O
total	O
tank	O
volume	O
.	O

Samples	O
were	O
collected	O
at	O
day	O
21	O
,	O
28	O
,	O
35	O
,	O
52	O
,	O
49	O
and	O
56	O
after	O
the	O
start	O
of	O
the	O
exposure	O
.	O

Note	O
that	O
days	O
49	O
and	O
56	O
represent	O
end	O
of	O
exposure	O
and	O
1	O
week	O
after	O
a	O
recovery	O
period	O
,	O
respectively	O
.	O

Tissue	O
bioaccumulations	O
were	O
determined	O
by	O
HPLC	O
/	O
MS	O
/	O
MS	O
,	O
steroid	S-chem
hormones	O
,	O
fatty	B-chem
acids	E-chem
(	O
FAs	S-chem
)	O
and	O
lipids	O
were	O
determined	O
by	O
GC	O
-	O
MS	O
,	O
while	O
mRNA	O
expression	O
levels	O
of	O
genes	O
were	O
determined	O
by	O
qPCR	O
in	O
whole	O
body	O
homogenate	O
.	O

We	O
observed	O
that	O
PFOS	S-chem
and	O
PFOA	S-chem
showed	O
a	O
steady	O
increase	O
in	O
whole	O
body	O
burden	O
during	O
the	O
exposure	O
period	O
,	O
with	O
a	O
slight	O
decrease	O
after	O
the	O
recovery	O
period	O
.	O

Calculated	O
somatic	O
indexes	O
showed	O
that	O
PFOA	S-chem
produced	O
increases	O
in	O
heart	O
-	O
,	O
thymus	O
-	O
,	O
liver	O
-	O
and	O
kidney	O
somatic	O
indexes	O
(	O
HSI	O
,	O
TSI	O
,	O
LSI	O
and	O
KSI	O
)	O
.	O

PFOA	S-chem
and	O
PFOS	S-chem
exposure	O
produced	O
significant	O
decreases	O
in	O
whole	O
body	O
dehydroepiandrosterone	S-chem
(	O
DHEA	S-chem
)	O
,	O
estrone	O
and	O
testosterone	S-chem
at	O
sampling	O
day	O
21	O
and	O
a	O
strong	O
increase	O
of	O
cortisol	S-chem
and	O
cholesterol	S-chem
at	O
the	O
end	O
of	O
recovery	O
period	O
(	O
day	O
56	O
)	O
.	O

PFOA	S-chem
and	O
PFOS	S-chem
effects	O
differed	O
with	O
DHEA	S-chem
and	O
estrone	S-chem
.	O

While	O
PFOS	S-chem
decreased	O
DHEA	S-chem
levels	O
,	O
PFOA	S-chem
produced	O
an	O
increase	O
at	O
day	O
49	O
,	O
and	O
while	O
PFOS	S-chem
decreased	O
estrone	S-chem
,	O
PFOA	S-chem
produced	O
a	O
slight	O
increase	O
at	O
day	O
56	O
.	O

We	O
observed	O
changes	O
in	O
FA	O
composition	O
that	O
predominantly	O
involved	O
increases	O
in	O
FA	B-chem
methyl	I-chem
esters	E-chem
(	O
FAMEs	S-chem
)	O
,	O
mono	B-chem
-	I-chem
and	I-chem
poly	I-chem
-	I-chem
unsaturated	I-chem
FA	E-chem
(	O
MUFA	S-chem
and	O
PUFA	S-chem
)	O
and	O
a	O
decrease	O
in	O
n	O
-	O
3	O
/	O
n	O
-	O
6	O
PUFA	S-chem
ratio	O
by	O
both	O
PFOA	S-chem
and	O
PFOS	S-chem
.	O

Particularly	O
,	O
an	O
increase	O
in	O
-	O
pentadecenoic	B-chem
MUFA	E-chem
(	O
15	O
:	O
1	O
)	O
,	O
two	O
n	O
-	O
3	O
PUFAs	S-chem
α	B-chem
-	I-chem
linolenic	I-chem
acid	E-chem
[	O
ALA	S-chem
:	O
18	O
:	O
3	O
n3	O
]	O
and	O
eicosapentaenoic	B-chem
acid	E-chem
[	O
EPA	S-chem
:	O
20	O
:	O
5	O
n	O
-	O
3	O
]	O
and	O
n	O
-	O
6	O
PUFA	S-chem
:	O
arachidonic	B-chem
acid	E-chem
[	O
ARA	S-chem
:	O
20	O
:	O
4	O
n6	O
]	O
,	O
docosapentaenoic	B-chem
acid	E-chem
(	O
DPA	S-chem
)	O
by	O
PFOA	S-chem
and	O
PFOS	S-chem
were	O
observed	O
.	O

These	O
effects	O
were	O
associated	O
with	O
changes	O
in	O
mRNA	O
expression	O
of	O
FA	B-geneN
elongase	E-geneN
(	O
FAE	S-geneN
)	O
,	O
Δ	B-geneY
5	I-geneY
-	I-geneY
desaturase	E-geneY
(	O
FAD5	S-geneY
)	O
and	O
Δ	B-geneY
6	I-geneY
-	I-geneY
desaturase	E-geneY
(	O
FAD6	S-geneY
)	O
genes	O
.	O

In	O
summary	O
,	O
the	O
changes	O
in	O
hormonal	O
and	O
FA	O
profiles	O
may	O
represent	O
cellular	O
and	O
/	O
or	O
physiological	O
adaptation	O
to	O
continuous	O
PFOS	S-chem
and	O
PFOA	S-chem
exposure	O
by	O
increasing	O
membrane	O
fluidity	O
,	O
and	O
/	O
or	O
overt	O
developmental	O
effects	O
.	O

The	O
present	O
findings	O
provide	O
some	O
potential	O
insights	O
and	O
basis	O
for	O
a	O
better	O
understanding	O
on	O
the	O
possible	O
mechanisms	O
of	O
PFCs	O
toxicity	O
in	O
fish	O
.	O

TLR4	S-geneY
antagonist	O
reduces	O
early	O
-	O
stage	O
atherosclerosis	O
in	O
diabetic	O
apolipoprotein	B-geneY
E	E-geneY
-	O
deficient	O
mice	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
deficiency	O
of	O
toll	B-geneY
-	I-geneY
like	I-geneY
receptor	I-geneY
4	E-geneY
(	O
TLR4	S-geneY
)	O
is	O
associated	O
with	O
reduced	O
atherosclerosis	O
in	O
atherosclerosis	O
-	O
prone	O
mice	O
and	O
attenuated	O
pro	O
-	O
inflammatory	O
state	O
in	O
diabetic	O
mice	O
,	O
it	O
remains	O
undetermined	O
whether	O
treatment	O
with	O
a	O
TLR4	S-geneY
antagonist	O
reduces	O
atherosclerosis	O
in	O
nondiabetic	O
or	O
diabetic	O
mice	O
that	O
have	O
TLR4	S-geneY
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
Rhodobacter	O
sphaeroides	O
lipopolysaccharide	O
(	O
Rs	O
-	O
LPS	O
)	O
,	O
an	O
established	O
TLR4	S-geneY
antagonist	O
,	O
on	O
early	O
-	O
stage	O
atherosclerosis	O
in	O
nondiabetic	O
and	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
apolipoprotein	B-geneY
E	E-geneY
-	O
deficient	O
(	O
Apoe	S-geneY
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
.	O

Analysis	O
of	O
atherosclerotic	O
lesions	O
of	O
both	O
en	O
face	O
aortas	O
and	O
cross	O
sections	O
of	O
aortic	O
roots	O
showed	O
that	O
administration	O
of	O
Rs	O
-	O
LPS	O
in	O
14	O
-	O
week	O
-	O
old	O
diabetic	O
Apoe	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
for	O
10	O
weeks	O
significantly	O
reduced	O
atherosclerotic	O
lesions	O
.	O

Although	O
atherosclerotic	O
lesions	O
in	O
nondiabetic	O
Apoe	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
appeared	O
to	O
be	O
decreased	O
by	O
Rs	O
-	O
LPS	O
treatment	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Metabolic	O
study	O
showed	O
that	O
Rs	O
-	O
LPS	O
significantly	O
lowered	O
serum	O
levels	O
of	O
cholesterol	S-chem
and	O
triglycerides	S-chem
in	O
nondiabetic	O
mice	O
but	O
not	O
in	O
diabetic	O
mice	O
.	O

Furthermore	O
,	O
immunohistochemistry	O
studies	O
showed	O
that	O
Rs	O
-	O
LPS	O
inhibited	O
the	O
expression	O
of	O
interleukin	B-geneY
6	E-geneY
and	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
and	O
reduced	O
the	O
content	O
of	O
monocytes	O
and	O
macrophages	O
in	O
atherosclerotic	O
plaques	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
TLR4	S-geneY
antagonist	O
inhibited	O
vascular	O
inflammation	O
and	O
atherogenesis	O
in	O
diabetic	O
Apoe	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
lowered	O
serum	O
cholesterol	S-chem
and	O
triglyceride	S-chem
levels	O
in	O
nondiabetic	O
Apoe	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Ribavirin	S-chem-C3-1
-	O
induced	O
intracellular	O
GTP	S-chem
depletion	O
activates	O
transcription	O
elongation	O
in	O
coagulation	B-geneY-C3-2
factor	I-geneY-C3-2
VII	E-geneY-C3-2
gene	O
expression	O
.	O

Coagulation	B-geneY
FVII	E-geneY
(	O
Factor	B-geneY
VII	E-geneY
)	O
is	O
a	O
vitamin	B-chem
K	E-chem
-	O
dependent	O
glycoprotein	O
synthesized	O
in	O
hepatocytes	O
.	O

It	O
was	O
reported	O
previously	O
that	O
FVII	S-geneY-C3-2
gene	O
(	O
F7	S-geneY-C3-2
)	O
expression	O
was	O
up	O
-	O
regulated	O
by	O
ribavirin	S-chem-C3-1
treatment	O
in	O
hepatitis	O
C	O
virus	O
-	O
infected	O
haemophilia	O
patients	O
;	O
however	O
,	O
its	O
precise	O
mechanism	O
is	O
still	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
ribavirin	S-chem-C3-1
-	O
induced	O
up	O
-	O
regulation	O
of	O
F7	S-geneY-C3-2
expression	O
in	O
HepG2	O
(	O
human	O
hepatoma	O
cell	O
line	O
)	O
.	O

We	O
found	O
that	O
intracellular	O
GTP	S-chem
depletion	O
by	O
ribavirin	S-chem
as	O
well	O
as	O
other	O
IMPDH	S-geneN
(	O
inosine	B-geneN
-	I-geneN
5	I-geneN
'	I-geneN
-	I-geneN
monophosphate	I-geneN
dehydrogenase	E-geneN
)	O
inhibitors	O
,	O
such	O
as	O
mycophenolic	B-chem-C3-1
acid	E-chem-C3-1
and	O
6	B-chem-C3-1
-	I-chem-C3-1
mercaptopurine	E-chem-C3-1
,	O
up	O
-	O
regulated	O
F7	S-geneY-C3-2
expression	O
.	O

FVII	S-geneY
mRNA	O
transcription	O
was	O
mainly	O
enhanced	O
by	O
accelerated	O
transcription	O
elongation	O
,	O
which	O
was	O
mediated	O
by	O
the	O
P	B-geneN
-	I-geneN
TEFb	E-geneN
(	O
positive	B-geneN
-	I-geneN
transcription	I-geneN
elongation	I-geneN
factor	I-geneN
b	E-geneN
)	O
complex	O
,	O
rather	O
than	O
by	O
promoter	O
activation	O
.	O

Ribavirin	S-chem-C3-1
unregulated	O
ELL	S-geneY-C3-2
(	O
eleven	B-geneY-C3-2
-	I-geneY-C3-2
nineteen	I-geneY-C3-2
lysine	I-geneY-C3-2
-	I-geneY-C3-2
rich	I-geneY-C3-2
leukaemia	I-geneY-C3-2
)	I-geneY-C3-2
3	E-geneY-C3-2
mRNA	O
expression	O
before	O
F7	S-geneY-C3-2
up	O
-	O
regulation	O
.	O

We	O
observed	O
that	O
ribavirin	S-chem-C3-1
enhanced	O
ELL3	S-geneY-C3-2
recruitment	O
to	O
F7	S-geneY-C3-2
,	O
whereas	O
knockdown	O
of	O
ELL3	S-geneY
diminished	O
ribavirin	S-chem-C3-1
-	O
induced	O
FVII	S-geneY-C3-2
mRNA	O
up	O
-	O
regulation	O
.	O

Ribavirin	S-chem-C3-1
also	O
enhanced	O
recruitment	O
of	O
CDK9	S-geneY-C3-2
(	O
cyclin	B-geneY-C3-2
-	I-geneY-C3-2
dependent	I-geneY-C3-2
kinase	I-geneY-C3-2
9	E-geneY-C3-2
)	O
and	O
AFF4	S-geneY-C3-2
to	O
F7	S-geneY-C3-2
.	O

These	O
data	O
suggest	O
that	O
ribavirin	S-chem-C3-1
-	O
induced	O
intracellular	O
GTP	S-chem
depletion	O
recruits	O
a	O
super	O
elongation	O
complex	O
containing	O
P	B-geneN-C3-2
-	I-geneN-C3-2
TEFb	E-geneN-C3-2
,	O
AFF4	S-geneY-C3-2
and	O
ELL3	S-geneY-C3-2
,	O
to	O
F7	S-geneY-C3-2
,	O
and	O
modulates	O
FVII	S-geneY
mRNA	O
transcription	O
elongation	O
.	O

Collectively	O
,	O
we	O
have	O
elucidated	O
a	O
basal	O
mechanism	O
for	O
ribavirin	S-chem-C3-1
-	O
induced	O
FVII	S-geneY-C3-2
mRNA	O
up	O
-	O
regulation	O
by	O
acceleration	O
of	O
transcription	O
elongation	O
,	O
which	O
may	O
be	O
crucial	O
in	O
understanding	O
its	O
pleiotropic	O
functions	O
in	O
vivo	O
.	O

Degradation	O
of	O
MAC13243	S-chem
and	O
studies	O
of	O
the	O
interaction	O
of	O
resulting	O
thiourea	S-chem
compounds	O
with	O
the	O
lipoprotein	S-geneN
targeting	O
chaperone	S-geneN
LolA	S-geneN
.	O

The	O
discovery	O
of	O
novel	O
small	O
molecules	O
that	O
function	O
as	O
antibacterial	O
agents	O
or	O
cellular	O
probes	O
of	O
biology	O
is	O
hindered	O
by	O
our	O
limited	O
understanding	O
of	O
bacterial	O
physiology	O
and	O
our	O
ability	O
to	O
assign	O
mechanism	O
of	O
action	O
.	O

We	O
previously	O
employed	O
a	O
chemical	O
genomic	O
strategy	O
to	O
identify	O
a	O
novel	O
small	O
molecule	O
,	O
MAC13243	S-chem-C4-1
,	O
as	O
a	O
likely	O
inhibitor	O
of	O
the	O
bacterial	B-geneN-C4-2
lipoprotein	E-geneN-C4-2
targeting	O
chaperone	S-geneN-C4-2
,	O
LolA	S-geneN-C4-2
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
degradation	O
of	O
MAC13243	S-chem
into	O
the	O
active	O
species	O
,	O
S	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chlorobenzyl	I-chem
)	I-chem
isothiourea	E-chem
.	O

Analogs	O
of	O
this	O
compound	O
(	O
e.g	O
.	O
,	O
A22	O
)	O
have	O
previously	O
been	O
characterized	O
as	O
inhibitors	O
of	O
the	O
bacterial	B-geneN
actin	I-geneN
-	I-geneN
like	I-geneN
protein	E-geneN
,	O
MreB	S-geneN
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
antibacterial	O
activity	O
of	O
MAC13243	S-chem
and	O
the	O
thiourea	S-chem
compounds	O
are	O
similar	O
;	O
these	O
activities	O
are	O
suppressed	O
or	O
sensitized	O
in	O
response	O
to	O
increases	O
or	O
decreases	O
of	O
LolA	S-geneN
copy	O
number	O
,	O
respectively	O
.	O

We	O
provide	O
STD	O
NMR	O
data	O
which	O
confirms	O
a	O
physical	O
interaction	O
between	O
LolA	S-geneN
and	O
the	O
thiourea	S-chem
degradation	O
product	O
of	O
MAC13243	S-chem
,	O
with	O
a	O
Kd	O
of	O
~	O
150	O
μM	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
the	O
thiourea	S-chem
series	O
of	O
compounds	O
share	O
a	O
similar	O
cellular	O
mechanism	O
that	O
includes	O
interaction	O
with	O
LolA	S-geneN
in	O
addition	O
to	O
the	O
well	O
-	O
characterized	O
target	O
MreB	S-geneN
.	O

Prolactin	S-geneY
regulates	O
transcription	O
of	O
the	O
ion	O
uptake	O
Na	B-geneY
+	I-geneY
/	I-geneY
Cl	I-geneY
-	I-geneY
cotransporter	E-geneY
(	O
ncc	S-geneY
)	O
gene	O
in	O
zebrafish	O
gill	O
.	O

Prolactin	S-geneY
(	O
PRL	S-geneY
)	O
is	O
a	O
well	O
-	O
known	O
regulator	O
of	O
ion	O
and	O
water	O
transport	O
within	O
osmoregulatory	O
tissues	O
across	O
vertebrate	O
species	O
,	O
yet	O
how	O
PRL	S-geneY
acts	O
on	O
some	O
of	O
its	O
target	O
tissues	O
remains	O
poorly	O
understood	O
.	O

Using	O
zebrafish	O
as	O
a	O
model	O
,	O
we	O
show	O
that	O
ionocytes	O
in	O
the	O
gill	O
directly	O
respond	O
to	O
systemic	O
PRL	S-geneY
to	O
regulate	O
mechanisms	O
of	O
ion	O
uptake	O
.	O

Ion	O
-	O
poor	O
conditions	O
led	O
to	O
increases	O
in	O
the	O
expression	O
of	O
PRL	B-geneN
receptor	E-geneN
(	O
prlra	S-geneY
)	O
,	O
Na	B-geneY
(	I-geneY
+	I-geneY
)	I-geneY
/	I-geneY
Cl	I-geneY
(	I-geneY
-	I-geneY
)	I-geneY
cotransporter	E-geneY
(	O
ncc	S-geneY
;	O
slc12a10.2	S-geneY
)	O
,	O
Na	B-geneY
(	I-geneY
+	I-geneY
)	I-geneY
/	I-geneY
H	I-geneY
(	I-geneY
+	I-geneY
)	I-geneY
exchanger	E-geneY
(	O
nhe3b	S-geneY
;	O
slc9a3.2	S-geneY
)	O
,	O
and	O
epithelial	B-geneY
Ca	I-geneY
(	I-geneY
2	I-geneY
+	I-geneY
)	I-geneY
channel	E-geneY
(	O
ecac	S-geneY
;	O
trpv6	S-geneY
)	O
transcripts	O
within	O
the	O
gill	O
.	O

Intraperitoneal	O
injection	O
of	O
ovine	B-geneY
PRL	E-geneY
(	O
oPRL	S-geneY
)	O
increased	O
ncc	S-geneY
and	O
prlra	S-geneY
transcripts	O
,	O
but	O
did	O
not	O
affect	O
nhe3b	S-geneY
or	O
ecac	S-geneY
.	O

Consistent	O
with	O
direct	O
PRL	S-geneY
action	O
in	O
the	O
gill	O
,	O
addition	O
of	O
oPRL	S-geneY
to	O
cultured	O
gill	O
filaments	O
stimulated	O
ncc	S-geneY
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
blocked	O
by	O
a	O
pure	O
human	B-geneY
PRL	I-geneY
receptor	E-geneY
antagonist	O
(	O
Δ	O
1	O
-	O
9	O
-	O
G129R	S-geneN
-	O
hPRL	S-geneY
)	O
.	O

These	O
results	O
suggest	O
that	O
PRL	S-geneY
signaling	O
through	O
PRL	B-geneN
receptors	E-geneN
in	O
the	O
gill	O
regulates	O
the	O
expression	O
of	O
ncc	S-geneY
,	O
thereby	O
linking	O
this	O
pituitary	B-geneN
hormone	E-geneN
with	O
an	O
effector	O
of	O
Cl	B-chem
(	I-chem
-	I-chem
)	E-chem
uptake	O
in	O
zebrafish	O
for	O
the	O
first	O
time	O
.	O

Treatment	O
of	O
Postmenopausal	O
Breast	O
Cancer	O
with	O
Selective	O
Estrogen	B-geneY
Receptor	E-geneY
Modulators	O
(	O
SERMs	O
)	O
.	O

Endocrine	O
therapy	O
that	O
targets	O
the	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
ER	S-geneY
-	O
positive	O
breast	O
cancer	O
.	O

The	O
selective	O
ER	S-geneY
modulator	O
(	O
SERM	O
)	O
tamoxifen	S-chem
has	O
been	O
in	O
use	O
for	O
the	O
treatment	O
of	O
advanced	O
breast	O
cancer	O
for	O
more	O
than	O
30	O
years	O
and	O
is	O
currently	O
a	O
treatment	O
option	O
for	O
all	O
stages	O
of	O
ER	S-geneY
-	O
positive	O
disease	O
.	O

Tamoxifen	S-chem-MU-1
blocks	O
the	O
action	O
of	O
estrogen	S-chem
by	O
binding	O
to	O
the	O
ER	S-geneY
,	O
and	O
possesses	O
both	O
ER	S-geneY-MU-2
-	O
agonist	O
and	O
antagonist	O
properties	O
.	O

Unfortunately	O
,	O
long	O
-	O
term	O
use	O
of	O
tamoxifen	S-chem
is	O
associated	O
with	O
several	O
important	O
concerns	O
including	O
an	O
increased	O
risk	O
of	O
endometrial	O
cancer	O
and	O
thromboembolic	O
complications	O
.	O

In	O
addition	O
,	O
many	O
patients	O
who	O
initially	O
respond	O
to	O
tamoxifen	S-chem
eventually	O
relapse	O
with	O
resistant	O
disease	O
.	O

New	O
treatment	O
approaches	O
are	O
therefore	O
required	O
.	O

A	O
number	O
of	O
alternative	O
SERMs	O
have	O
been	O
tested	O
as	O
substitutes	O
for	O
tamoxifen	S-chem
.	O

These	O
include	O
;	O
toremifene	S-chem
,	O
droloxifene	S-chem
,	O
idoxifene	S-chem
,	O
and	O
keoxifene	S-chem
.	O

Unfortunately	O
,	O
the	O
SERMs	O
have	O
not	O
proved	O
to	O
be	O
more	O
effective	O
than	O
tamoxifen	S-chem
for	O
the	O
treatment	O
of	O
advanced	O
breast	O
cancer	O
and	O
have	O
shown	O
a	O
high	O
level	O
of	O
cross	O
-	O
resistance	O
with	O
tamoxifen	S-chem
.	O

The	O
subsequent	O
development	O
of	O
the	O
aromatase	S-geneY
inhibitors	O
(	O
AIs	O
)	O
is	O
an	O
important	O
therapeutic	O
advance	O
by	O
creating	O
a	O
``	O
no	O
estrogen	O
``	O
environment	O
.	O

Another	O
approach	O
is	O
the	O
development	O
of	O
pure	O
antiestrogens	O
.	O

Fulvestrant	S-chem-MU-1
is	O
a	O
novel	O
ER	S-geneY-C6-2
antagonist	O
that	O
destroys	O
the	O
ER	S-geneY-C4-2
and	O
its	O
signaling	O
pathway	O
and	O
is	O
not	O
associated	O
with	O
tamoxifen	S-chem
-	O
like	O
agonist	O
effects	O
.	O

It	O
produces	O
high	O
response	O
rates	O
compared	O
with	O
other	O
SERMs	O
and	O
is	O
not	O
cross	O
-	O
resistant	O
to	O
tamoxifen	S-chem
or	O
aromatase	S-geneY
inhibitors	O
and	O
is	O
equally	O
as	O
effective	O
as	O
the	O
AI	O
anastrozole	S-chem
in	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
progressed	O
on	O
prior	O
adjuvant	O
tamoxifen	S-chem
therapy	O
.	O

This	O
review	O
article	O
discusses	O
the	O
significant	O
and	O
continuing	O
value	O
of	O
SERMs	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
ER	S-geneY
-	O
positive	O
breast	O
cancer	O
.	O

Hydrothermal	O
Growth	O
of	O
TiO2	S-chem
Nanorod	O
Arrays	O
and	O
In	O
Situ	O
Conversion	O
to	O
Nanotube	O
Arrays	O
for	O
Highly	O
Efficient	O
Quantum	O
Dot	O
-	O
Sensitized	O
Solar	O
Cells	O
.	O

TiO2	S-chem
nanorod	O
(	O
NR	O
)	O
and	O
nanotube	O
(	O
NT	O
)	O
arrays	O
grown	O
on	O
transparent	O
conductive	O
substrates	O
are	O
attractive	O
electrode	O
for	O
solar	O
cells	O
.	O

In	O
this	O
paper	O
,	O
TiO2	S-chem
NR	O
arrays	O
are	O
hydrothermally	O
grown	O
on	O
FTO	S-chem
substrate	O
,	O
and	O
are	O
in	O
situ	O
converted	O
into	O
NT	O
arrays	O
by	O
hydrothermally	O
etching	O
.	O

The	O
TiO2	S-chem
NR	O
arrays	O
are	O
reported	O
as	O
single	O
crystalline	O
,	O
but	O
the	O
TiO2	S-chem
NR	O
arrays	O
are	O
demonstrated	O
to	O
be	O
polycrystalline	O
with	O
a	O
bundle	O
of	O
2	O
-	O
5	O
nm	O
single	O
crystalline	O
nanocolumns	O
grown	O
along	O
[	O
001	O
]	O
throughout	O
the	O
whole	O
NR	O
from	O
bottom	O
to	O
top	O
.	O

TiO2	S-chem
NRs	O
can	O
be	O
converted	O
to	O
NTs	O
by	O
hydrothermal	O
selective	O
etching	O
of	O
the	O
(	O
001	O
)	O
core	O
and	O
remaining	O
the	O
inert	O
sidewall	O
of	O
(	O
110	O
)	O
face	O
.	O

A	O
growth	O
mechanism	O
of	O
the	O
NR	O
and	O
NT	O
arrays	O
is	O
proposed	O
.	O

Quantum	O
dot	O
-	O
sensitized	O
solar	O
cells	O
(	O
QDSCs	O
)	O
are	O
fabricated	O
by	O
coating	O
CdSe	S-chem
QDs	O
on	O
to	O
the	O
TiO2	S-chem
arrays	O
.	O

After	O
conversion	O
from	O
NRs	O
to	O
NTs	O
,	O
more	O
QDs	O
can	O
be	O
filled	O
in	O
the	O
NTs	O
and	O
the	O
energy	O
conversion	O
efficiency	O
of	O
the	O
QDSCs	O
almost	O
double	O
.	O

New	O
selective	O
inhibitors	O
of	O
MMP	B-geneY
-	I-geneY
13	E-geneY
for	O
inflammatory	O
diseases	O
:	O
a	O
patent	O
evaluation	O
(	O
W02012151158	O
)	O
.	O

A	O
series	O
of	O
compounds	O
incorporating	O
an	O
aromatic	O
scaffold	O
based	O
on	O
isoxazolines	S-chem
were	O
prepared	O
in	O
the	O
patent	O
application	O
(	O
WO2012151158	O
)	O
.	O

The	O
new	O
compounds	O
from	O
the	O
patent	O
are	O
defined	O
to	O
be	O
biologically	O
active	O
metabolites	O
,	O
prodrugs	O
,	O
isomers	O
,	O
stereoisomers	O
,	O
solvates	O
,	O
hydrates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
they	O
are	O
claimed	O
to	O
be	O
useful	O
for	O
treating	O
immunological	O
conditions	O
because	O
of	O
their	O
inhibitory	O
activities	O
on	O
matrix	B-geneN
metalloproteinase	E-geneN
(	O
MMP	B-geneY
-	I-geneY
13	E-geneY
)	O
,	O
although	O
no	O
specific	O
MMP	B-geneY
-	I-geneY
13	E-geneY
inhibition	O
data	O
or	O
other	O
rationale	O
to	O
explain	O
their	O
biological	O
effects	O
is	O
provided	O
.	O

The	O
compounds	O
have	O
a	O
broad	O
potential	O
utility	O
with	O
osteoarthritis	O
,	O
rheumatoid	O
arthritis	O
,	O
juvenile	O
arthritis	O
,	O
psoriatic	O
arthritis	O
,	O
degenerative	O
joint	O
disease	O
or	O
systemic	O
lupus	O
erythematosus	O
among	O
the	O
likely	O
preferred	O
indications	O
.	O

Effects	O
of	O
some	O
mono	B-chem
-	I-chem
and	I-chem
bisquaternary	I-chem
ammonium	E-chem
compounds	O
on	O
the	O
reactivatability	O
of	O
soman	S-chem-C4-1
-	O
inhibited	O
human	B-geneY-C4-2
acetylcholinesterase	E-geneY-C4-2
in	O
vitro	O
.	O

Acetylcholinesterase	S-geneY-MU-2
(	O
AChE	S-geneY-MU-2
)	O
inhibited	O
by	O
the	O
organophosphate	S-chem-C4-1
soman	S-chem-C4-1
(	O
1,2,2	B-chem-C4-1
-	I-chem-C4-1
trimethyl	I-chem-C4-1
-	I-chem-C4-1
propylmethylphosphonofluoridate	E-chem-C4-1
)	O
rapidly	O
becomes	O
resistant	O
to	O
reactivation	O
by	O
oximes	S-chem-C3-1
due	O
to	O
dealkylation	O
of	O
the	O
soman	S-chem
-	O
enzyme	O
complex	O
.	O

This	O
reaction	O
is	O
called	O
aging	O
.	O

The	O
effect	O
of	O
the	O
four	O
mono	B-chem
-	I-chem
and	I-chem
bisquaternary	I-chem
ammonium	E-chem
compounds	O
tetramethylammonium	S-chem
(	O
TMA	S-chem
)	O
,	O
hexamethonium	S-chem
,	O
decamethonium	S-chem
and	O
suxamethonium	S-chem
on	O
the	O
reactivatability	O
of	O
soman	S-chem-C4-1
-	O
inhibited	O
,	O
solubilized	O
AChE	S-geneY-C4-2
from	O
human	O
erythrocytes	O
was	O
investigated	O
in	O
vitro	O
.	O

All	O
compounds	O
were	O
reversible	O
inhibitors	O
of	O
AChE	S-geneY
;	O
the	O
respective	O
dissociation	O
constants	O
and	O
the	O
type	O
of	O
inhibition	O
exhibited	O
considerable	O
differences	O
.	O

The	O
affinities	O
to	O
both	O
the	O
active	O
and	O
the	O
allosteric	O
site	O
were	O
considerably	O
higher	O
for	O
suxamethonium	S-chem
(	O
Kii	O
81.3	O
microM	O
;	O
Ki	O
15.9	O
microM	O
)	O
and	O
decamethonium	S-chem
(	O
Kii	O
15.4	O
microM	O
;	O
Ki	O
4.4	O
microM	O
)	O
than	O
for	O
TMA	S-chem
(	O
Kii	O
1	O
mM	O
;	O
Ki	O
289.6	O
microM	O
)	O
and	O
hexamethonium	S-chem
(	O
Kii	O
4.5	O
mM	O
;	O
Ki	O
331.8	O
microM	O
)	O
.	O

The	O
reactivation	O
experiments	O
were	O
performed	O
in	O
a	O
four	O
-	O
step	O
procedure	O
(	O
soman	S-chem
-	O
inhibition	O
at	O
0	O
degree	O
and	O
pH	O
10	O
,	O
aging	O
at	O
37	O
degrees	O
and	O
pH	O
7.3	O
,	O
reactivation	O
by	O
the	O
oxime	S-chem
HI	O
6	O
at	O
37	O
degrees	O
and	O
pH	O
7.3	O
followed	O
by	O
AChE	S-geneY
assay	O
)	O
.	O

After	O
these	O
four	O
steps	O
(	O
total	O
duration	O
55	O
min	O
)	O
,	O
AChE	S-geneY
was	O
inhibited	O
by	O
soman	O
to	O
95	O
-	O
100	O
%	O
.	O

HI	O
6	O
could	O
reactivate	O
about	O
20	O
%	O
of	O
the	O
inhibited	O
enzyme	O
.	O

All	O
effectors	O
increased	O
the	O
AChE	S-geneY
reactivatability	O
by	O
HI	O
6	O
when	O
added	O
before	O
aging	O
was	O
started	O
.	O

The	O
maximal	O
increase	O
in	O
reactivatability	O
was	O
higher	O
in	O
the	O
presence	O
of	O
1.6	O
mM	O
suxamethonium	S-chem
(	O
+	O
35.8	O
%	O
)	O
and	O
150	O
microM	O
decamethonium	S-chem
(	O
+	O
40	O
%	O
)	O
than	O
of	O
22	O
mM	O
TMA	S-chem
(	O
+	O
22.5	O
%	O
)	O
and	O
8.3	O
mM	O
hexamethonium	S-chem
(	O
+	O
19.2	O
%	O
)	O
.	O

If	O
the	O
effectors	O
were	O
added	O
after	O
5	O
min	O
of	O
aging	O
they	O
increased	O
the	O
activity	O
of	O
soman	S-chem-C4-1
-	O
inhibited	O
AChE	S-geneY-C4-2
,	O
but	O
to	O
a	O
considerably	O
smaller	O
extent	O
than	O
HI	O
6	O
.	O

A	O
good	O
correlation	O
of	O
the	O
respective	O
Kii	O
values	O
and	O
the	O
effective	O
concentrations	O
of	O
these	O
drugs	O
was	O
observed	O
,	O
indicating	O
that	O
an	O
allosteric	O
binding	O
site	O
of	O
AChE	S-geneY
might	O
be	O
involved	O
in	O
the	O
protective	O
effect	O
of	O
these	O
drugs	O
.	O

Characterization	O
of	O
the	O
interaction	O
of	O
ingenol	B-chem
3	I-chem
-	I-chem
angelate	E-chem
with	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
.	O

Ingenol	B-chem
3	I-chem
-	I-chem
angelate	E-chem
(	O
I3A	S-chem
)	O
is	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
Euphorbia	O
peplus	O
,	O
which	O
has	O
been	O
used	O
in	O
traditional	O
medicine	O
.	O

Here	O
,	O
we	O
report	O
the	O
initial	O
characterization	O
of	O
I3A	S-chem
as	O
a	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
(	O
PKC	S-geneN
)	O
ligand	O
.	O

I3A	S-chem
bound	O
to	O
PKC	B-geneY
-	I-geneY
alpha	E-geneY
in	O
the	O
presence	O
of	O
phosphatidylserine	S-chem
with	O
high	O
affinity	O
;	O
however	O
,	O
under	O
these	O
assay	O
conditions	O
,	O
little	O
PKC	S-geneN
isoform	O
selectivity	O
was	O
observed	O
.	O

PKC	S-geneN-C4-2
isoforms	O
did	O
show	O
different	O
sensitivity	O
and	O
selectivity	O
for	O
down	O
-	O
regulation	O
by	O
I3A	S-chem-C4-1
and	O
phorbol	B-chem-C4-1
12	I-chem-C4-1
-	I-chem-C4-1
myristate	I-chem-C4-1
13	I-chem-C4-1
-	I-chem-C4-1
acetate	E-chem-C4-1
(	O
PMA	S-chem-C4-1
)	O
in	O
WEHI	O
-	O
231	O
,	O
HOP	O
-	O
92	O
,	O
and	O
Colo	O
-	O
205	O
cells	O
.	O

In	O
all	O
of	O
the	O
three	O
cell	O
types	O
,	O
I3A	S-chem
inhibited	O
cell	O
proliferation	O
with	O
somewhat	O
lower	O
potency	O
than	O
did	O
PMA	S-chem
.	O

In	O
intact	O
CHO	O
-	O
K1	O
cells	O
,	O
I3A	S-chem
was	O
able	O
to	O
translocate	O
different	O
green	B-geneY
fluorescent	I-geneY
protein	E-geneY
-	O
tagged	O
PKC	S-geneN
isoforms	O
,	O
visualized	O
by	O
confocal	O
microscopy	O
,	O
with	O
equal	O
or	O
higher	O
potency	O
than	O
PMA	S-chem
.	O

PKC	B-geneY
-	I-geneY
delta	E-geneY
in	O
particular	O
showed	O
a	O
different	O
pattern	O
of	O
translocation	O
in	O
response	O
to	O
I3A	S-chem
and	O
PMA	S-chem
.	O

I3A	S-chem-C3-1
induced	O
a	O
higher	O
level	O
of	O
secretion	O
of	O
the	O
inflammatory	O
cytokine	S-geneN-C3-2
interleukin	B-geneY-C3-2
6	E-geneY-C3-2
compared	O
with	O
PMA	S-chem-C3-1
in	O
the	O
WEHI	O
-	O
231	O
cells	O
and	O
displayed	O
a	O
marked	O
biphasic	O
dose	O
-	O
response	O
curve	O
for	O
the	O
induction	O
.	O

I3A	S-chem
was	O
unable	O
to	O
cause	O
the	O
same	O
extent	O
of	O
association	O
of	O
the	O
C1b	B-geneN
domain	E-geneN
of	O
PKC	B-geneY
-	I-geneY
delta	E-geneY
with	O
lipids	O
,	O
compared	O
with	O
PMA	S-chem
or	O
the	O
physiological	O
regulator	O
diacylglycerol	S-chem
,	O
and	O
was	O
able	O
to	O
partially	O
block	O
the	O
association	O
induced	O
by	O
these	O
agents	O
,	O
measured	O
by	O
surface	O
plasmon	O
resonance	O
.	O

The	O
in	O
vitro	O
kinase	O
activity	O
of	O
PKC	B-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
induced	O
by	O
I3A	S-chem-C3-1
was	O
lower	O
than	O
that	O
induced	O
by	O
PMA	S-chem-C3-1
.	O

The	O
novel	O
pattern	O
of	O
behavior	O
of	O
I3A	S-chem
makes	O
it	O
of	O
great	O
interest	O
for	O
further	O
evaluation	O
.	O

2	B-chem
-	I-chem
Hydroxy	I-chem
-	I-chem
3	I-chem
-	I-chem
methylanthraquinone	E-chem
from	O
Hedyotis	O
diffusa	O
Willd	O
induces	O
apoptosis	O
in	O
human	O
leukemic	O
U937	O
cells	O
through	O
modulation	O
of	O
MAPK	S-geneN
pathways	O
.	O

The	O
herb	O
of	O
Hedyotis	O
diffusa	O
Willd	O
(	O
H.	O
diffusa	O
Willd	O
)	O
,	O
an	O
annual	O
herb	O
distributed	O
in	O
northeastern	O
Asia	O
,	O
has	O
been	O
known	O
as	O
a	O
traditional	O
oriental	O
medicine	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Recently	O
,	O
Chinese	O
researchers	O
have	O
discovered	O
that	O
two	O
anthraquinones	S-chem
isolated	O
from	O
a	O
water	O
extract	O
of	O
H.	O
diffusa	O
Willd	O
showed	O
apoptosis	O
-	O
inducing	O
effects	O
against	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
cellular	O
and	O
molecular	O
mechanisms	O
responsible	O
for	O
this	O
phenomenon	O
are	O
poorly	O
understood	O
.	O

The	O
current	O
study	O
determines	O
the	O
role	O
of	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinases	E-geneN
(	O
MAPK	S-geneN
)	O
in	O
human	O
leukemic	O
U937	O
cells	O
apoptosis	O
induced	O
by	O
2	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
3	I-chem
-	I-chem
methylanthraquinone	E-chem
from	O
H.	O
diffusa	O
.	O

Our	O
results	O
showed	O
that	O
2	B-chem-C3-1
-	I-chem-C3-1
hydroxy	I-chem-C3-1
-	I-chem-C3-1
3	I-chem-C3-1
-	I-chem-C3-1
methylanthraquinone	E-chem-C3-1
decreased	O
phosphorylation	O
-	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
(	O
p	B-geneN
-	I-geneN
ERK1	I-geneN
/	I-geneN
2	E-geneN
)	O
,	O
and	O
increased	O
p	B-geneN-C3-2
-	I-geneN-C3-2
p38MAPK	E-geneN-C3-2
,	O
but	O
did	O
not	O
affect	O
expressions	O
of	O
p	B-geneN
-	I-geneN
JNK1	I-geneN
/	I-geneN
2	E-geneN
in	O
U937	O
cells	O
.	O

Moreover	O
,	O
treatment	O
of	O
U937	O
cells	O
with	O
2	B-chem-C3-1
-	I-chem-C3-1
hydroxy	I-chem-C3-1
-	I-chem-C3-1
3	I-chem-C3-1
-	I-chem-C3-1
methylanthraquinone	E-chem-C3-1
resulted	O
in	O
activation	O
of	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
.	O

Furthermore	O
,	O
PD98059	S-chem
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
inhibitor	O
)	O
significantly	O
enhanced	O
2	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
3	I-chem
-	I-chem
methylanthraquinone	E-chem
-	O
induced	O
apoptosis	O
in	O
U937	O
cells	O
,	O
whereas	O
caspase	B-geneY
-	I-geneY
3	E-geneY
inhibitor	O
or	O
SB203580	S-chem-C4-1
(	O
p	B-geneN-C4-2
-	I-geneN-C4-2
p38MAPK	E-geneN-C4-2
inhibitor	O
)	O
,	O
decreased	O
apoptosis	O
in	O
U937	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
study	O
for	O
the	O
first	O
time	O
suggests	O
that	O
2	B-chem-C3-1
-	I-chem-C3-1
hydroxy	I-chem-C3-1
-	I-chem-C3-1
3	I-chem-C3-1
-	I-chem-C3-1
methylanthraquinone	E-chem-C3-1
is	O
able	O
to	O
enhance	O
apoptosis	O
of	O
U937	O
cells	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
activation	O
of	O
p	B-geneN-C3-2
-	I-geneN-C3-2
p38MAPK	E-geneN-C3-2
and	O
downregulation	O
of	O
p	B-geneN
-	I-geneN
ERK1	I-geneN
/	I-geneN
2	E-geneN
.	O

Moreover	O
,	O
the	O
triggering	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activation	O
mediated	O
apoptotic	O
induction	O
.	O

Protective	O
effect	O
of	O
crocin	S-chem
on	O
diazinon	S-chem
induced	O
cardiotoxicity	O
in	O
rats	O
in	O
subchronic	O
exposure	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
crocin	S-chem
,	O
main	O
component	O
of	O
Crocus	O
sativus	O
L	O
.	O

(	O
Saffron	O
)	O
against	O
subchronic	O
diazinon	S-chem
(	O
DZN	S-chem
)	O
induced	O
cardiotoxicity	O
in	O
rats	O
.	O

METHODS	O
:	O
Rats	O
were	O
divided	O
into	O
7	O
groups	O
;	O
control	O
(	O
corn	O
oil	O
,	O
gavage	O
)	O
,	O
DZN	O
(	O
15mg	O
/	O
kg	O
/	O
day	O
,	O
gavage	O
,	O
)	O
,	O
crocin	S-chem
(	O
12.5	O
,	O
25	O
or	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i.p	O
)	O
plus	O
DZN	S-chem
,	O
vitamin	B-chem
E	E-chem
(	O
200IU	O
/	O
kg	O
,	O
i.p	O
,	O
three	O
times	O
per	O
week	O
)	O
plus	O
DZN	S-chem
and	O
crocin	S-chem
(	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i.p	O
)	O
groups	O
.	O

Treatments	O
were	O
continued	O
for	O
4weeks	O
.	O

Creatine	B-geneN
phosphokinase	I-geneN
MB	E-geneN
(	O
CK	B-geneN
-	I-geneN
MB	E-geneN
)	O
,	O
malondealdehyde	S-chem
(	O
MDA	S-chem
)	O
and	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
levels	O
were	O
evaluated	O
in	O
heart	O
tissue	O
at	O
the	O
end	O
of	O
treatments	O
.	O

Levels	O
of	O
apoptotic	O
proteins	O
(	O
Bax	S-geneY
,	O
Bcl2	S-geneY
,	O
caspase	B-geneY
3	E-geneY
)	O
and	O
cytosolic	B-geneY
cytochrome	I-geneY
c	E-geneY
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

Transcript	O
levels	O
of	O
Bax	S-geneY
and	O
Bcl2	S-geneY
were	O
also	O
determined	O
using	O
qRT	O
PCR	O
.	O

RESULTS	O
:	O
DZN	S-chem-C3-1
induced	O
histophatological	O
damages	O
and	O
elevated	O
the	O
level	O
of	O
cardiac	O
marker	O
CK	B-geneN-C3-2
-	I-geneN-C3-2
MB	E-geneN-C3-2
.	O

These	O
effects	O
were	O
associated	O
with	O
increased	O
MDA	S-chem
level	O
,	O
lower	O
level	O
of	O
reduced	O
GSH	S-chem
and	O
induction	O
of	O
apoptosis	O
through	O
elevation	O
of	O
Bax	S-geneY
/	O
Bcl2	S-geneY
ratio	O
(	O
both	O
protein	O
and	O
mRNA	O
levels	O
)	O
,	O
cytochrome	B-geneY
c	E-geneY
release	O
to	O
the	O
cytosol	O
and	O
activation	O
caspase	B-geneY
3	E-geneY
in	O
cardiac	O
tissue	O
.	O

Crocin	S-chem-MU-1
(	O
25	O
and	O
50mg	O
/	O
kg	O
)	O
or	O
vitamin	B-chem-MU-1
E	E-chem-MU-1
improved	O
histopathological	O
damages	O
,	O
decreased	O
MDA	S-chem
and	O
CK	B-geneN-C4-2
-	I-geneN-C4-2
MB	E-geneN-C4-2
,	O
increased	O
GSH	S-chem
content	O
and	O
attenuated	O
the	O
increase	O
of	O
Bax	S-geneY-MU-2
/	O
Bcl2	S-geneY-C4-2
ratio	O
,	O
activation	O
of	O
caspase	B-geneY-C3-2
3	E-geneY-C3-2
and	O
release	O
of	O
cytochrome	B-geneY-MU-2
c	E-geneY-MU-2
to	O
the	O
cytosol	O
induced	O
by	O
DZN	S-chem-MU-1
.	O

In	O
summary	O
,	O
DZN	S-chem
induced	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
in	O
heart	O
tissue	O
of	O
rat	O
following	O
subchronic	O
exposure	O
.	O

Crocin	S-chem
,	O
as	O
an	O
antioxidant	O
,	O
showed	O
protective	O
effects	O
against	O
DZN	S-chem
cardiotoxicity	O
by	O
reducing	O
lipid	O
peroxidation	O
and	O
alleviating	O
apoptosis	O
.	O

The	O
discovery	O
of	O
fused	O
oxadiazepines	S-chem
as	O
gamma	B-geneN
secretase	E-geneN
modulators	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

In	O
an	O
attempt	O
to	O
further	O
improve	O
overall	O
profiles	O
of	O
the	O
oxadiazine	S-chem
series	O
of	O
GSMs	O
,	O
in	O
particular	O
the	O
hERG	S-geneY
activity	O
,	O
conformational	O
modifications	O
of	O
the	O
core	O
structure	O
resulted	O
in	O
the	O
identification	O
of	O
fused	O
oxadiazepines	S-chem-C4-1
such	O
as	O
7i	O
which	O
had	O
an	O
improved	O
hERG	S-geneY-C4-2
inhibition	O
profile	O
and	O
was	O
a	O
highly	O
efficacious	O
GSM	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
rats	O
.	O

These	O
SAR	O
explorations	O
offer	O
opportunities	O
to	O
identify	O
potential	O
drugs	O
to	O
treat	O
Alzheimer	O
's	O
disease	O
.	O

Toxicity	O
and	O
toxicokinetics	O
of	O
binary	O
combinations	O
of	O
petroleum	B-chem
hydrocarbon	E-chem
distillates	O
with	O
the	O
earthworm	O
Eisenia	O
andrei	O
.	O

Petroleum	B-chem
hydrocarbons	E-chem
(	O
PHCs	S-chem
)	O
act	O
via	O
narcosis	O
and	O
are	O
expected	O
to	O
have	O
additive	O
toxicity	O
.	O

However	O
,	O
previous	O
work	O
has	O
demonstrated	O
less	O
-	O
than	O
-	O
additive	O
toxicity	O
with	O
PHC	S-chem
distillates	O
and	O
earthworms	O
.	O

A	O
study	O
was	O
initiated	O
to	O
investigate	O
this	O
through	O
toxicity	O
and	O
toxicokinetic	O
studies	O
with	O
the	O
earthworm	O
Eisenia	O
andrei	O
.	O

Three	O
petroleum	O
distillate	O
fractions	O
,	O
F2	O
(	O
>	O
C10	B-chem
-	I-chem
C16	E-chem
)	O
,	O
F3a	O
(	O
>	O
C16	B-chem
-	I-chem
C23	E-chem
)	O
,	O
and	O
F3b	O
(	O
>	O
C23	B-chem
-	I-chem
C34	E-chem
)	O
,	O
were	O
used	O
in	O
two	O
binary	O
combinations	O
,	O
F2F3a	O
and	O
F3aF3b	O
.	O

In	O
the	O
toxicity	O
study	O
,	O
clean	O
soil	O
was	O
spiked	O
with	O
equitoxic	O
combinations	O
of	O
the	O
two	O
distillates	O
ranging	O
from	O
0.5	O
to	O
2.5	O
toxic	O
units	O
.	O

In	O
the	O
toxicokinetic	O
study	O
,	O
a	O
binary	O
combination	O
consisting	O
of	O
one	O
concentration	O
of	O
each	O
distillate	O
was	O
used	O
.	O

On	O
a	O
soil	O
concentration	O
basis	O
,	O
the	O
toxicity	O
of	O
the	O
binary	O
combinations	O
of	O
distillates	O
was	O
less	O
than	O
additive	O
.	O

Accumulation	O
of	O
the	O
individual	O
distillates	O
,	O
however	O
,	O
was	O
generally	O
reduced	O
when	O
a	O
second	O
distillate	O
was	O
present	O
,	O
resulting	O
in	O
lower	O
body	O
burden	O
.	O

This	O
is	O
thought	O
to	O
be	O
due	O
to	O
the	O
presence	O
of	O
a	O
nonaqueous	O
-	O
phase	O
liquid	O
at	O
the	O
soil	O
concentrations	O
used	O
.	O

On	O
a	O
tissue	O
concentration	O
basis	O
,	O
toxicity	O
was	O
closer	O
to	O
additive	O
.	O

The	O
results	O
demonstrate	O
that	O
tissue	O
concentrations	O
are	O
the	O
preferred	O
metric	O
for	O
toxicity	O
for	O
earthworms	O
.	O

They	O
also	O
demonstrate	O
that	O
the	O
Canada	O
-	O
wide	O
soil	O
standards	O
based	O
on	O
individual	O
distillates	O
are	O
likely	O
protective	O
.	O

Environ	O
.	O

Toxicol	O
.	O

Chem	O
.	O

2013	O
;	O
32	O
:	O
1016	O
-	O
1026	O
.	O

©	O
2013	O
SETAC	O
.	O

The	O
Arg389Gly	S-geneN
beta1	B-geneY
-	I-geneY
adrenoceptor	E-geneY
polymorphism	O
and	O
catecholamine	S-chem
effects	O
on	O
plasma	O
-	O
renin	S-geneY
activity	O
.	O

OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
research	O
was	O
to	O
find	O
out	O
whether	O
,	O
in	O
humans	O
,	O
dobutamine	S-chem
-	O
induced	O
hemodynamic	O
effects	O
and	O
increase	O
in	O
plasma	O
-	O
renin	S-geneY
activity	O
(	O
PRA	O
)	O
might	O
be	O
beta1	B-geneY
-	I-geneY
adrenoceptor	E-geneY
(	O
beta1AR	S-geneY
)	O
genotype	O
-	O
dependent	O
.	O

BACKGROUND	O
:	O
In	O
vitro	O
Arg389Gly	S-geneN
-	O
beta1AR	S-geneY
polymorphism	O
exhibits	O
decreased	O
receptor	O
signaling	O
.	O

METHODS	O
:	O
We	O
studied	O
10	O
male	O
homozygous	O
Arg389	O
-	O
beta1AR	S-geneY
subjects	O
and	O
8	O
male	O
homozygous	O
Gly389beta1AR	O
subjects	O
;	O
to	O
avoid	O
influences	O
of	O
codon	O
49	O
polymorphism	O
,	O
all	O
were	O
homozygous	O
Ser49	O
-	O
beta1AR	S-geneY
.	O

Subjects	O
were	O
infused	O
with	O
dobutamine	S-chem
(	O
1	O
to	O
6	O
microg	O
/	O
kg	O
/	O
min	O
)	O
with	O
or	O
without	O
bisoprolol	S-chem
(	O
10	O
mg	O
orally	O
)	O
pretreatment	O
,	O
and	O
PRA	O
,	O
heart	O
rate	O
,	O
contractility	O
,	O
and	O
blood	O
pressure	O
were	O
assessed	O
.	O

RESULTS	O
:	O
With	O
regard	O
to	O
PRA	O
,	O
dobutamine	S-chem
increased	O
PRA	O
more	O
potently	O
in	O
Arg389	O
-	O
beta1AR	S-geneY
versus	O
Gly389	O
-	O
beta1AR	S-geneY
subjects	O
.	O

Bisoprolol	S-chem
markedly	O
suppressed	O
the	O
dobutamine	S-chem
-	O
induced	O
PRA	O
increase	O
in	O
Arg389	O
-	O
but	O
only	O
marginally	O
in	O
Gly389	O
-	O
beta1AR	S-geneY
subjects	O
.	O

With	O
regard	O
to	O
hemodynamics	O
,	O
dobutamine	S-chem
caused	O
larger	O
heart	O
rate	O
and	O
contractility	O
increases	O
and	O
diastolic	O
blood	O
pressure	O
decreases	O
in	O
Arg389	O
-	O
versus	O
Gly389	O
-	O
beta1AR	S-geneY
subjects	O
.	O

Bisoprolol	S-chem
reduced	O
dobutamine	S-chem
-	O
induced	O
heart	O
rate	O
and	O
contractility	O
increases	O
and	O
diastolic	O
blood	O
pressure	O
decreases	O
more	O
potently	O
in	O
Arg389	O
-	O
versus	O
Gly389	O
-	O
beta1AR	S-geneY
subjects	O
.	O

CONCLUSIONS	O
:	O
Codon	O
389	O
beta1AR	S-geneY
polymorphism	O
is	O
a	O
determinant	O
not	O
only	O
of	O
hemodynamic	O
effects	O
but	O
also	O
of	O
PRA	O
.	O

Thus	O
,	O
beta1AR	S-geneY
polymorphisms	O
may	O
be	O
useful	O
for	O
predicting	O
therapeutic	O
responses	O
to	O
betaAR	S-geneN
-	O
blocker	O
treatment	O
.	O

Changes	O
in	O
submaxillary	O
gland	O
gene	O
expression	O
in	O
F344	O
rats	O
by	O
multiple	O
dosing	O
of	O
theophylline	S-chem
.	O

Multiple	O
exposure	O
to	O
theophylline	S-chem-C4-1
,	O
a	O
phosphodiesterase	S-geneN-C4-2
(	O
PDE	S-geneN-C4-2
)	O
inhibitor	O
,	O
induces	O
acinar	O
hypertrophy	O
in	O
the	O
salivary	O
gland	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
theophylline	S-chem
on	O
the	O
gene	O
expression	O
of	O
secretory	O
proteins	O
and	O
phosphodiesterases	S-geneN
in	O
the	O
submaxillary	O
gland	O
.	O

Male	O
F344	O
rats	O
received	O
saline	O
or	O
theophylline	S-chem
(	O
50	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
4	O
days	O
.	O

The	O
gene	O
expressions	O
for	O
the	O
secretory	O
protein	O
,	O
cystatin	B-geneY
S	E-geneY
(	O
CysS	S-geneY
)	O
,	O
and	O
PDE	B-geneN
subfamilies	I-geneN
3A	I-geneN
and	I-geneN
4D	E-geneN
in	O
the	O
submaxillary	O
gland	O
were	O
quantified	O
using	O
RT	O
-	O
PCR	O
.	O

Theophylline	S-chem-C3-1
exposure	O
resulted	O
in	O
a	O
sustained	O
increase	O
in	O
mRNA	O
expression	O
for	O
CysS	S-geneY-C3-2
and	O
PDE3A	S-geneY-C3-2
,	O
but	O
PDE4D	S-geneY
gene	O
expression	O
was	O
unchanged	O
.	O

Our	O
results	O
suggest	O
that	O
submaxillary	O
hypertrophy	O
is	O
primarily	O
caused	O
by	O
the	O
enhanced	O
transcription	O
of	O
CysS	S-geneY
,	O
and	O
that	O
the	O
transcription	O
of	O
each	O
PDE	S-geneN
subfamily	O
gene	O
is	O
regulated	O
differently	O
.	O

Central	O
5	B-geneY-C3-2
-	I-geneY-C3-2
HT3	E-geneY-C3-2
receptor	O
stimulation	O
by	O
m	B-chem-C3-1
-	I-chem-C3-1
CPBG	E-chem-C3-1
increases	O
blood	O
glucose	S-chem
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
central	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptors	O
on	O
the	O
control	O
of	O
blood	O
glucose	S-chem
in	O
stressed	O
and	O
non	O
-	O
stressed	O
rats	O
in	O
both	O
fasted	O
and	O
fed	O
states	O
.	O

Adult	O
Wistar	O
male	O
rats	O
had	O
each	O
their	O
third	O
ventricle	O
cannulated	O
7	O
days	O
before	O
the	O
experiments	O
.	O

Injections	O
of	O
m	B-chem-C5-1
-	I-chem-C5-1
CPBG	E-chem-C5-1
,	O
a	O
selective	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT3	E-geneY-C5-2
receptor	O
agonist	O
,	O
induced	O
a	O
significant	O
increase	O
in	O
blood	O
glucose	S-chem
in	O
non	O
-	O
stressed	O
rats	O
in	O
both	O
fasted	O
and	O
in	O
fed	O
states	O
.	O

The	O
same	O
procedure	O
was	O
unable	O
to	O
modify	O
stress	O
-	O
induced	O
hyperglycemia	O
.	O

The	O
hyperglycemic	O
effect	O
of	O
m	B-chem-C5-1
-	I-chem-C5-1
CPBG	E-chem-C5-1
central	O
administration	O
was	O
blocked	O
by	O
pretreatment	O
with	O
ondansetron	O
,	O
a	O
specific	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT3	E-geneY-C5-2
receptor	O
antagonist	O
,	O
indicating	O
that	O
the	O
effects	O
here	O
obtained	O
with	O
m	B-chem
-	I-chem
CPBG	E-chem
were	O
a	O
result	O
of	O
its	O
interaction	O
with	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptors	O
.	O

Third	O
ventricle	O
injections	O
of	O
ondansetron	S-chem
alone	O
were	O
not	O
able	O
to	O
modify	O
blood	O
glucose	S-chem
in	O
non	O
-	O
stressed	O
animals	O
and	O
did	O
not	O
change	O
the	O
hyperglycemic	O
responses	O
observed	O
after	O
immobilization	O
stress	O
.	O

We	O
conclude	O
that	O
pharmacological	O
activation	O
of	O
the	O
central	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptor	O
induces	O
a	O
hyperglycemic	O
effect	O
in	O
non	O
-	O
stressed	O
animals	O
.	O

Functional	O
and	O
bioenergetic	O
consequences	O
of	O
AT1	S-geneY-C6-2
antagonist	O
olmesartan	B-chem-C6-1
medoxomil	E-chem-C6-1
in	O
hearts	O
with	O
postinfarction	O
LV	O
remodeling	O
.	O

The	O
structural	O
left	O
ventricular	O
(	O
LV	O
)	O
remodeling	O
and	O
contractile	O
dysfunction	O
of	O
hearts	O
with	O
postinfarction	O
LV	O
remodeling	O
are	O
benefited	O
by	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
(	O
AT1	S-geneY
)	O
blocker	O
.	O

However	O
,	O
the	O
myocardial	O
bioenergetic	O
consequences	O
of	O
AT1	S-geneY
blocker	O
in	O
these	O
hearts	O
are	O
not	O
known	O
.	O

To	O
investigate	O
,	O
we	O
used	O
a	O
porcine	O
model	O
of	O
postinfarction	O
LV	O
remodeling	O
produced	O
by	O
ligation	O
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
.	O

After	O
infarction	O
,	O
7	O
pigs	O
received	O
olmesartan	B-chem
medoxomil	E-chem
(	O
2	O
mg	O
/	O
kg	O
)	O
for	O
comparison	O
against	O
9	O
untreated	O
and	O
10	O
normal	O
pigs	O
.	O

Measurements	O
of	O
hemodynamics	O
,	O
myocardial	O
perfusion	O
,	O
and	O
myocardial	O
bioenergetics	O
were	O
taken	O
7	O
weeks	O
postinfarction	O
.	O

The	O
treated	O
group	O
had	O
an	O
LV	O
-	O
to	O
-	O
body	O
weight	O
ratio	O
significantly	O
lower	O
than	O
the	O
untreated	O
group	O
(	O
2.69	O
+	O
/	O
-	O
0.70	O
,	O
2.96	O
+	O
/	O
-	O
0.51	O
,	O
3.66	O
+	O
/	O
-	O
0.60	O
g	O
/	O
kg	O
for	O
control	O
,	O
treated	O
,	O
and	O
untreated	O
groups	O
,	O
respectively	O
)	O
.	O

The	O
untreated	O
group	O
had	O
a	O
mean	O
aortic	O
pressure	O
significantly	O
higher	O
than	O
the	O
control	O
(	O
73	O
+	O
/	O
-	O
16	O
,	O
86	O
+	O
/	O
-	O
14	O
,	O
and	O
94	O
+	O
/	O
-	O
20	O
mm	O
Hg	O
,	O
respectively	O
)	O
.	O

The	O
subendocardial	O
phosphocreatine	S-chem
-	O
to	O
-	O
ATP	S-chem
ratios	O
of	O
the	O
treated	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
untreated	O
group	O
.	O

The	O
untreated	O
group	O
,	O
but	O
not	O
the	O
treated	O
group	O
,	O
had	O
significant	O
reductions	O
in	O
mitochondrial	O
F0F1	B-geneN
-	I-geneN
ATPase	E-geneN
subunits	O
compared	O
with	O
controls	O
.	O

Congestive	O
heart	O
failure	O
as	O
evidenced	O
by	O
significant	O
ascites	O
(	O
100	O
to	O
2000	O
mL	O
)	O
developed	O
in	O
4	O
of	O
the	O
9	O
untreated	O
animals	O
,	O
but	O
was	O
absent	O
in	O
the	O
treated	O
group	O
.	O

Animals	O
with	O
heart	O
failure	O
demonstrated	O
reductions	O
in	O
both	O
mitochondrial	O
F0F1	B-geneN
-	I-geneN
ATPase	E-geneN
expression	O
and	O
myocardial	O
high	O
-	O
energy	O
phosphate	S-chem
levels	O
.	O

Thus	O
,	O
severe	O
LV	O
dysfunction	O
and	O
accompanying	O
abnormal	O
myocardial	O
bioenergetic	O
phenotype	O
were	O
prevented	O
by	O
the	O
AT1	S-geneY-C6-2
antagonist	O
olmesartan	B-chem-C6-1
medoxomil	E-chem-C6-1
.	O

Allelopathic	O
activity	O
studies	O
of	O
Mikania	O
scandens	O
.	O

Preliminary	O
investigation	O
of	O
a	O
number	O
of	O
plant	O
extracts	O
for	O
allelopathic	O
activity	O
using	O
seed	O
germination	O
inhibition	O
bioassay	O
showed	O
a	O
promising	O
activity	O
of	O
the	O
water	O
extract	O
of	O
the	O
aerial	O
parts	O
of	O
Mikania	O
scandens	O
.	O

Activity	O
-	O
guided	O
fractionation	O
of	O
the	O
M.	O
scandens	O
extract	O
led	O
to	O
the	O
isolation	O
of	O
the	O
highly	O
allelopathic	O
active	O
compound	O
mikanolide	S-chem
,	O
with	O
minimum	O
inhibitory	O
concentration	O
of	O
0.083	O
µM	O
mL	O
(	O
-	O
1	O
)	O
.	O

As	O
M.	O
scandens	O
is	O
a	O
highly	O
abundant	O
invasive	O
plant	O
in	O
Sri	O
Lanka	O
and	O
other	O
South	O
Asian	O
countries	O
,	O
this	O
plant	O
could	O
be	O
developed	O
as	O
an	O
environment	O
friendly	O
natural	O
herbicide	O
,	O
either	O
in	O
crude	O
form	O
as	O
shredded	O
plant	O
material	O
or	O
as	O
pure	O
mikanolide	S-chem
,	O
which	O
is	O
the	O
major	O
constituent	O
(	O
∼	O
0.02	O
%	O
)	O
in	O
the	O
plant	O
.	O

SIRT1	S-geneY
inhibits	O
NADPH	B-geneN
oxidase	E-geneN
activation	O
and	O
protects	O
endothelial	O
function	O
in	O
the	O
rat	O
aorta	O
:	O
Implications	O
for	O
vascular	O
aging	O
.	O

Vascular	O
aging	O
is	O
characterized	O
by	O
up	O
-	O
regulation	O
of	O
NADPH	B-geneN
oxidase	E-geneN
,	O
oxidative	O
stress	O
and	O
endothelial	O
dysfunction	O
.	O

Previous	O
studies	O
demonstrate	O
that	O
the	O
activity	O
of	O
the	O
evolutionarily	O
conserved	O
NAD	B-geneY
(	I-geneY
+	I-geneY
)	I-geneY
-	I-geneY
dependent	I-geneY
deacetylase	I-geneY
SIRT1	E-geneY
declines	O
with	O
age	O
and	O
that	O
pharmacological	O
activators	O
of	O
SIRT1	S-geneY
confer	O
significant	O
anti	O
-	O
aging	O
cardiovascular	O
effects	O
.	O

To	O
determine	O
whether	O
dysregulation	O
of	O
SIRT1	S-geneY
promotes	O
NADPH	B-geneN-C9-2
oxidase	E-geneN-C9-2
-	O
dependent	O
production	O
of	O
reactive	O
oxygen	S-chem-C9-1
species	O
(	O
ROS	O
)	O
and	O
impairs	O
endothelial	O
function	O
we	O
assessed	O
the	O
effects	O
of	O
three	O
structurally	O
different	O
inhibitors	O
of	O
SIRT1	S-geneY-C4-2
(	O
nicotinamide	S-chem-C4-1
,	O
sirtinol	S-chem-C4-1
,	O
EX527	S-chem-C4-1
)	O
in	O
aorta	O
segments	O
isolated	O
from	O
young	O
Wistar	O
rats	O
.	O

Inhibition	O
of	O
SIRT1	S-geneY
induced	O
endothelial	O
dysfunction	O
,	O
as	O
shown	O
by	O
the	O
significantly	O
reduced	O
relaxation	O
to	O
the	O
endothelium	O
-	O
dependent	O
vasodilators	O
acetylcholine	S-chem
and	O
the	O
calcium	S-chem
ionophore	O
A23187	S-chem
.	O

Endothelial	O
dysfunction	O
induced	O
by	O
SIRT1	S-geneY
inhibition	O
was	O
prevented	O
by	O
treatment	O
of	O
the	O
vessels	O
with	O
the	O
NADPH	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitor	O
apocynin	S-chem-C4-1
or	O
superoxide	B-geneN
dismutase	E-geneN
.	O

Inhibition	O
of	O
SIRT1	S-geneY-C9-2
significantly	O
increased	O
vascular	O
superoxide	S-chem-C9-1
production	O
,	O
enhanced	O
NADPH	B-geneN-C4-2
oxidase	E-geneN-C4-2
activity	O
,	O
and	O
mRNA	O
expression	O
of	O
its	O
subunits	O
p22	B-geneY-C4-2
(	I-geneY-C4-2
phox	I-geneY-C4-2
)	E-geneY-C4-2
and	O
NOX4	S-geneY-C4-2
,	O
which	O
were	O
prevented	O
by	O
resveratrol	S-chem-C4-1
.	O

Peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
-	I-geneY
α	E-geneY
(	O
PPARα	S-geneY
)	O
activation	O
mimicked	O
the	O
effects	O
of	O
resveratrol	S-chem-C3-1
while	O
PPARα	S-geneY
inhibition	O
prevented	O
the	O
effects	O
of	O
this	O
SIRT1	S-geneY-C3-2
activator	O
.	O

SIRT1	S-geneY
co	O
-	O
precipitated	O
with	O
PPARα	S-geneY
and	O
nicotinamide	S-chem-C3-1
increased	O
the	O
acetylation	O
of	O
the	O
PPARα	S-geneY
coactivator	O
PGC	B-geneY-MU-2
-	I-geneY-MU-2
1α	E-geneY-MU-2
,	O
which	O
was	O
suppressed	O
by	O
resveratrol	S-chem-C4-1
.	O

In	O
conclusion	O
,	O
impaired	O
activity	O
of	O
SIRT1	S-geneY
induces	O
endothelial	O
dysfunction	O
and	O
up	O
-	O
regulates	O
NADPH	B-geneN
oxidase	E-geneN
-	O
derived	O
ROS	O
production	O
in	O
the	O
vascular	O
wall	O
,	O
mimicking	O
the	O
vascular	O
aging	O
phenotype	O
.	O

Moreover	O
,	O
a	O
new	O
mechanism	O
for	O
controlling	O
endothelial	O
function	O
after	O
SIRT1	S-geneY
activation	O
involves	O
a	O
decreased	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
acetylation	O
and	O
the	O
subsequent	O
PPARα	S-geneY
activation	O
,	O
resulting	O
in	O
both	O
decreased	O
NADPH	B-geneN
oxidase	E-geneN
-	O
driven	O
ROS	O
production	O
and	O
NO	S-chem
inactivation	O
.	O

NAD	B-geneY
(	I-geneY
P	I-geneY
)	I-geneY
H	I-geneY
:	I-geneY
Quinone	I-geneY
Oxidoreductase	I-geneY
1	E-geneY
Inducer	O
Activity	O
of	O
Some	O
Saudi	O
Arabian	O
Medicinal	O
Plants	O
.	O

Medicinal	O
plants	O
are	O
a	O
rich	O
source	O
of	O
biologically	O
-	O
active	O
phytochemicals	O
and	O
have	O
been	O
used	O
in	O
traditional	O
medicine	O
for	O
centuries	O
.	O

Specific	O
phytochemicals	O
and	O
extracts	O
of	O
their	O
plant	O
sources	O
have	O
the	O
ability	O
to	O
reduce	O
the	O
risk	O
for	O
chronic	O
degenerative	O
diseases	O
by	O
induction	O
of	O
enzymes	O
involved	O
in	O
xenobiotic	O
metabolism	O
,	O
many	O
of	O
which	O
also	O
have	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
functions	O
.	O

One	O
such	O
multifunctional	O
cytoprotective	O
enzyme	O
is	O
NAD	B-geneN
(	I-geneN
P	I-geneN
)	I-geneN
H	I-geneN
:	I-geneN
quinone	I-geneN
oxidoreductase	E-geneN
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
extracts	O
of	O
27	O
Saudi	O
Arabian	O
medicinal	O
plants	O
which	O
belong	O
to	O
18	O
different	O
plant	O
families	O
and	O
tested	O
their	O
ability	O
to	O
induce	O
NAD	B-geneN
(	I-geneN
P	I-geneN
)	I-geneN
H	I-geneN
:	I-geneN
quinone	I-geneN
oxidoreductase	E-geneN
in	O
murine	O
hepatoma	O
cells	O
grown	O
in	O
microtiter	O
plate	O
wells	O
.	O

In	O
addition	O
to	O
the	O
Brassicaceae	O
,	O
a	O
known	O
source	O
of	O
NAD	B-geneN
(	I-geneN
P	I-geneN
)	I-geneN
H	I-geneN
:	I-geneN
quinone	I-geneN
oxidoreductase	I-geneN
inducer	I-geneN
activity	E-geneN
,	O
we	O
found	O
substantial	O
inducer	O
activity	O
in	O
extracts	O
from	O
the	O
Apiaceae	O
,	O
Apocynaceae	O
,	O
and	O
the	O
Asteraceae	O
families	O
.	O

Five	O
out	O
of	O
a	O
total	O
of	O
eight	O
active	O
extracts	O
are	O
from	O
plants	O
which	O
belong	O
to	O
the	O
Asteraceae	O
family	O
.	O

We	O
further	O
show	O
that	O
artemisinin	S-chem
,	O
an	O
agent	O
which	O
is	O
used	O
clinically	O
for	O
the	O
treatment	O
of	O
malaria	O
,	O
contributes	O
but	O
does	O
not	O
fully	O
account	O
for	O
the	O
inducer	O
activity	O
of	O
the	O
extract	O
of	O
Artemisia	O
monosperma	O
.	O

In	O
contrast	O
to	O
artemisinin	S-chem
,	O
deoxyartemisinin	S-chem
is	O
inactive	O
in	O
this	O
assay	O
,	O
demonstrating	O
the	O
critical	O
role	O
of	O
the	O
endoperoxide	O
moiety	O
of	O
artemisinin	S-chem
for	O
inducer	O
activity	O
.	O

Thus	O
,	O
the	O
NAD	B-geneN
(	I-geneN
P	I-geneN
)	I-geneN
H	I-geneN
:	I-geneN
quinone	I-geneN
oxidoreductase	E-geneN
inducer	O
activity	O
of	O
extracts	O
of	O
some	O
Saudi	O
Arabian	O
medicinal	O
plants	O
indicates	O
the	O
presence	O
of	O
specific	O
phytochemicals	O
which	O
have	O
the	O
potential	O
to	O
protect	O
against	O
chronic	O
degenerative	O
diseases	O
.	O

Structural	O
,	O
kinetic	O
,	O
and	O
thermodynamic	O
analysis	O
of	O
the	O
binding	O
of	O
the	O
40	O
kDa	O
PEG	S-chem
-	O
interferon	B-geneY
-	I-geneY
alpha2a	E-geneY
and	O
its	O
individual	O
positional	O
isomers	O
to	O
the	O
extracellular	O
domain	O
of	O
the	O
receptor	O
IFNAR2	S-geneY
.	O

Type	B-geneN
-	I-geneN
I	I-geneN
Interferons	E-geneN
exert	O
antiviral	O
and	O
antiproliferative	O
activities	O
through	O
the	O
binding	O
to	O
a	O
common	O
cell	O
surface	O
receptor	O
comprising	O
two	O
subunits	O
,	O
IFNAR1	S-geneY
and	O
IFNAR2	S-geneY
.	O

Human	B-geneY
recombinant	I-geneY
Interferon	I-geneY
-	I-geneY
alpha	I-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
(	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
)	O
is	O
a	O
potent	O
drug	O
(	O
Roferon	O
-	O
A	O
)	O
used	O
to	O
treat	O
various	O
cancers	O
and	O
viral	O
diseases	O
including	O
Hepatitis	O
B	O
/	O
C	O
infections	O
.	O

To	O
significantly	O
improve	O
the	O
pharmacological	O
properties	O
of	O
the	O
drug	O
,	O
a	O
pegylated	O
form	O
of	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
was	O
developed	O
(	O
PEGASYS	O
)	O
.	O

This	O
40	O
kDa	O
PEG	S-chem
-	O
conjugated	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
(	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
)	O
is	O
obtained	O
by	O
the	O
covalent	O
binding	O
of	O
one	O
40	O
kDa	O
branched	O
PEG	O
-	O
polymer	O
to	O
a	O
lysine	S-chem
side	O
-	O
chain	O
of	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
.	O

Here	O
,	O
we	O
report	O
the	O
detailed	O
structural	O
,	O
kinetic	O
,	O
and	O
thermodynamic	O
analysis	O
of	O
the	O
binding	O
to	O
the	O
extracellular	O
domain	O
of	O
the	O
receptor	O
IFNAR2	S-geneY
of	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
and	O
its	O
isolated	O
positional	O
isomers	O
modified	O
at	O
K31	O
,	O
K134	O
,	O
K131	O
,	O
K121	O
,	O
K164	O
,	O
and	O
K70	O
,	O
respectively	O
,	O
in	O
comparison	O
with	O
unmodified	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
.	O

Our	O
binding	O
studies	O
,	O
using	O
the	O
surface	O
plasmon	O
resonance	O
technique	O
,	O
show	O
that	O
the	O
pegylation	O
does	O
not	O
abolish	O
the	O
binding	O
to	O
the	O
receptor	O
,	O
but	O
significantly	O
reduces	O
the	O
affinity	O
mainly	O
due	O
to	O
a	O
change	O
of	O
the	O
association	O
rate	O
.	O

The	O
results	O
are	O
supported	O
by	O
modeling	O
and	O
simulation	O
of	O
the	O
binding	O
,	O
using	O
Self	O
-	O
Avoiding	O
-	O
Walk	O
calculations	O
for	O
the	O
polymer	O
conformations	O
.	O

A	O
correlation	O
between	O
the	O
structural	O
parameters	O
and	O
the	O
kinetic	O
and	O
thermodynamic	O
parameters	O
of	O
the	O
binding	O
of	O
the	O
positional	O
isomers	O
could	O
be	O
established	O
.	O

For	O
the	O
Isomer	O
-	O
K31	O
and	O
-	O
K164	O
,	O
the	O
PEG	O
-	O
polymer	O
attachment	O
point	O
is	O
located	O
in	O
proximity	O
to	O
the	O
binding	O
interface	O
,	O
and	O
the	O
isomers	O
display	O
affinity	O
in	O
the	O
range	O
150	O
-	O
520	O
nM	O
in	O
an	O
enthalpy	O
-	O
driven	O
binding	O
process	O
.	O

In	O
contrast	O
for	O
the	O
Isomer	O
-	O
K134	O
,	O
-	O
K131	O
,	O
-	O
K121	O
,	O
and	O
-	O
K70	O
,	O
the	O
PEG	S-chem
-	O
polymer	O
is	O
attached	O
remotely	O
from	O
the	O
binding	O
interface	O
,	O
and	O
the	O
isomers	O
exhibit	O
a	O
higher	O
affinity	O
(	O
32	O
-	O
76	O
nM	O
)	O
in	O
an	O
entropy	O
-	O
driven	O
binding	O
process	O
.	O

This	O
study	O
constitutes	O
an	O
essential	O
collection	O
of	O
knowledge	O
on	O
which	O
the	O
interaction	O
of	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-geneY
(	I-geneY
2a	I-geneY
)	E-geneY
and	O
its	O
positional	O
isomers	O
with	O
its	O
cellular	O
receptors	O
can	O
be	O
better	O
understood	O
.	O

Silica	S-chem
nanoparticles	O
-	O
induced	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
cultured	O
A431	O
and	O
A549	O
cells	O
.	O

In	O
medicine	O
,	O
the	O
use	O
of	O
silica	S-chem
nanoparticles	O
(	O
SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
)	O
offers	O
new	O
perspectives	O
in	O
biosensor	O
,	O
drug	O
delivery	O
and	O
cancer	O
therapy	O
.	O

However	O
,	O
questions	O
about	O
potential	O
toxic	O
and	O
deleterious	O
effects	O
of	O
SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
have	O
also	O
been	O
raised	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
induction	O
of	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
by	O
SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
(	O
size	O
15	O
nm	O
)	O
in	O
human	O
skin	O
epithelial	O
(	O
A431	O
)	O
and	O
human	O
lung	O
epithelial	O
(	O
A549	O
)	O
cells	O
.	O

SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
(	O
concentration	O
range	O
25	O
-	O
200	O
µg	O
/	O
ml	O
)	O
induced	O
dose	O
-	O
dependent	O
cytotoxicity	O
in	O
both	O
types	O
of	O
cells	O
,	O
which	O
was	O
demonstrated	O
by	O
cell	O
viability	O
(	O
3	O
-	B-chem
(	I-chem
4,5	I-chem
-	I-chem
dimethylthiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
2,5	I-chem
-	I-chem
diphenyltetrazoliumbromide	I-chem
)	E-chem
and	O
lactate	O
dehydrogenase	I-geneN
leakage	O
assays	O
.	O

SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
were	O
also	O
found	O
to	O
induce	O
oxidative	O
stress	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
indicated	O
by	O
depletion	O
of	O
glutathione	S-chem
and	O
induction	O
of	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
generation	O
and	O
lipid	O
peroxidation	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
that	O
following	O
the	O
exposure	O
of	O
cells	O
to	O
SiO	B-chem-C3-1
(	I-chem-C3-1
2	I-chem-C3-1
)	E-chem-C3-1
NPs	O
,	O
the	O
messenger	O
RNA	O
level	O
of	O
apoptotic	O
genes	O
(	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
and	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
9	E-geneY-C3-2
)	O
were	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
activities	O
of	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
and	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
9	E-geneY-C3-2
enzymes	O
were	O
also	O
significantly	O
higher	O
in	O
both	O
kinds	O
of	O
cells	O
exposed	O
to	O
SiO	B-chem-C3-1
(	I-chem-C3-1
2	I-chem-C3-1
)	E-chem-C3-1
NPs	O
.	O

This	O
study	O
suggested	O
that	O
SiO	B-chem
(	I-chem
2	I-chem
)	E-chem
NPs	O
induce	O
cytotoxicity	O
and	O
apoptosis	O
in	O
A431	O
and	O
A549	O
cells	O
,	O
which	O
is	O
likely	O
to	O
be	O
mediated	O
through	O
ROS	O
generation	O
and	O
oxidative	O
stress	O
.	O

Human	B-geneY-C4-2
stearoyl	I-geneY-C4-2
-	I-geneY-C4-2
CoA	I-geneY-C4-2
desaturase	I-geneY-C4-2
1	E-geneY-C4-2
(	O
SCD	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
)	O
gene	O
expression	O
is	O
negatively	O
regulated	O
by	O
thyroid	B-chem-C4-1
hormone	E-chem-C4-1
without	O
direct	O
binding	O
of	O
thyroid	B-geneN
hormone	I-geneN
receptor	E-geneN
to	O
the	O
gene	O
promoter	O
.	O

Stearoyl	B-geneY
-	I-geneY
CoA	I-geneY
desaturase	I-geneY
-	I-geneY
1	E-geneY
(	O
SCD	B-geneY
-	I-geneY
1	E-geneY
)	O
plays	O
a	O
pivotal	O
role	O
in	O
an	O
increase	O
of	O
triglyceride	S-chem
by	O
an	O
excess	O
of	O
dietary	O
carbohydrate	S-chem
intake	O
.	O

Dietary	O
carbohydrates	S-chem-C3-1
increase	O
SCD	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
gene	O
expression	O
in	O
liver	O
by	O
sterol	B-geneY
response	I-geneY
element	I-geneY
binding	I-geneY
protein	I-geneY
(	I-geneY
SREBP	I-geneY
)	I-geneY
-	I-geneY
1c	E-geneY
-	O
dependent	O
and	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
-	O
independent	O
pathways	O
.	O

Previous	O
report	O
demonstrated	O
that	O
thyroid	B-chem-C4-1
hormone	E-chem-C4-1
(	O
TH	O
)	O
negatively	O
regulates	O
mouse	B-geneN-C4-2
SCD	I-geneN-C4-2
-	I-geneN-C4-2
1	I-geneN-C4-2
gene	I-geneN-C4-2
promoter	E-geneN-C4-2
before	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
was	O
revealed	O
.	O

We	O
reported	O
that	O
TH	O
negatively	O
regulates	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
recently	O
.	O

Therefore	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
examined	O
whether	O
and	O
how	O
TH	O
regulates	O
human	B-geneY
SCD	I-geneY
-	I-geneY
1	E-geneY
gene	O
expression	O
and	O
evaluated	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
effect	O
on	O
the	O
negative	O
regulation	O
.	O

Luciferase	O
assays	O
revealed	O
that	O
TH	O
suppresses	O
both	O
mouse	B-geneN
and	I-geneN
human	I-geneN
SCD	I-geneN
-	I-geneN
1	I-geneN
gene	I-geneN
promoter	E-geneN
activity	O
.	O

In	O
SREBP	B-geneY
-	I-geneY
1	E-geneY
knockdown	O
HepG2	O
cells	O
,	O
TH	O
still	O
suppresses	O
SCD	B-geneN
-	I-geneN
1	I-geneN
gene	I-geneN
promoter	E-geneN
activity	O
,	O
and	O
it	O
also	O
exerted	O
the	O
negative	O
regulation	O
under	O
cotransfection	O
of	O
a	O
small	O
amount	O
of	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
.	O

These	O
data	O
indicated	O
that	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
does	O
not	O
play	O
the	O
decisive	O
role	O
for	O
the	O
negative	O
regulation	O
by	O
TH	O
.	O

The	O
responsible	O
region	O
for	O
the	O
negative	O
regulation	O
in	O
human	B-geneN
SCD	I-geneN
-	I-geneN
1	I-geneN
gene	I-geneN
promoter	E-geneN
turned	O
out	O
to	O
be	O
between	O
-	O
124	O
and	O
-	O
92	O
bp	O
,	O
referred	O
to	O
as	O
site	B-geneN
A	E-geneN
.	O

Chromatin	O
immunoprecipitation	O
assays	O
demonstrated	O
that	O
TH	B-geneY
receptor	I-geneY
-	I-geneY
β	E-geneY
is	O
recruited	O
to	O
the	O
region	O
upon	O
T	O
(	O
3	O
)	O
administration	O
,	O
although	O
TR	B-geneY
-	I-geneY
β	E-geneY
does	O
not	O
bind	O
directly	O
to	O
site	B-geneN
A	E-geneN
.	O

In	O
conclusion	O
,	O
TH	O
negatively	O
regulates	O
human	B-geneY
SCD	I-geneY
-	I-geneY
1	E-geneY
gene	O
expression	O
in	O
without	O
direct	O
binding	O
of	O
the	O
TH	B-geneN
receptor	E-geneN
to	O
the	O
SCD	B-geneN
-	I-geneN
1	I-geneN
gene	I-geneN
promoter	E-geneN
.	O

In	O
vitro	O
antiprogestational	O
/	O
antiglucocorticoid	O
activity	O
and	O
progestin	S-geneN
and	O
glucocorticoid	B-geneY
receptor	E-geneY
binding	O
of	O
the	O
putative	O
metabolites	O
and	O
synthetic	O
derivatives	O
of	O
CDB	B-chem
-	I-chem
2914	E-chem
,	O
CDB	B-chem
-	I-chem
4124	E-chem
,	O
and	O
mifepristone	S-chem
.	O

In	O
determining	O
the	O
biological	O
profiles	O
of	O
various	O
antiprogestins	O
,	O
it	O
is	O
important	O
to	O
assess	O
the	O
hormonal	O
and	O
antihormonal	O
activity	O
,	O
selectivity	O
,	O
and	O
potency	O
of	O
their	O
proximal	O
metabolites	O
.	O

The	O
early	O
metabolism	O
of	O
mifepristone	S-chem
is	O
characterized	O
by	O
rapid	O
demethylation	O
and	O
hydroxylation	O
.	O

Similar	O
initial	O
metabolic	O
pathways	O
have	O
been	O
proposed	O
for	O
CDB	B-chem
-	I-chem
2914	E-chem
(	O
CDB	O
:	O
Contraceptive	O
Development	O
Branch	O
of	O
NICHD	O
)	O
and	O
CDB	B-chem
-	I-chem
4124	E-chem
,	O
and	O
their	O
putative	O
metabolites	O
have	O
been	O
synthesized	O
.	O

We	O
have	O
examined	O
the	O
functional	O
activities	O
and	O
potencies	O
,	O
in	O
various	O
cell	O
-	O
based	O
assays	O
,	O
and	O
relative	O
binding	O
affinities	O
(	O
RBAs	O
)	O
for	O
progesterone	B-geneN
receptors	E-geneN
(	O
PR	S-geneN
)	O
and	O
glucocorticoid	B-geneY
receptors	E-geneY
(	O
GR	S-geneY
)	O
of	O
the	O
putative	O
mono	O
-	O
and	O
didemethylated	O
metabolites	O
of	O
CDB	B-chem
-	I-chem
2914	E-chem
,	O
CDB	B-chem
-	I-chem
4124	E-chem
,	O
and	O
mifepristone	S-chem
and	O
of	O
the	O
17alpha	B-chem
-	I-chem
hydroxy	E-chem
and	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
of	O
CDB	B-chem
-	I-chem
2914	E-chem
and	O
CDB	B-chem
-	I-chem
4124	E-chem
.	O

The	O
binding	O
affinities	O
of	O
the	O
monodemethylated	O
metabolites	O
for	O
rabbit	B-geneY
uterine	I-geneY
PR	E-geneY
and	O
human	B-geneY
PR	I-geneY
-	I-geneY
A	E-geneY
and	O
PR	B-geneY
-	I-geneY
B	E-geneY
were	O
similar	O
to	O
those	O
of	O
the	O
parent	O
compounds	O
.	O

Monodemethylated	O
mifepristone	S-chem
bound	O
to	O
rabbit	B-geneY
thymic	I-geneY
GR	E-geneY
with	O
higher	O
affinity	O
than	O
monodemethylated	O
CDB	B-chem
-	I-chem
2914	E-chem
or	O
CDB	B-chem
-	I-chem
4124	E-chem
.	O

T47D	O
-	O
CO	O
cells	O
were	O
used	O
to	O
assess	O
inhibition	O
of	O
R5020	O
-	O
stimulated	O
endogenous	O
alkaline	B-geneN
phosphatase	E-geneN
activity	O
and	O
transactivation	O
of	O
the	O
PRE	B-geneN
(	I-geneN
2	I-geneN
)	E-geneN
-	O
thymidine	B-geneN
kinase	E-geneN
(	O
tk	S-geneN
)	O
-	O
luciferase	O
(	O
LUC	O
)	O
reporter	O
plasmid	O
in	O
transient	O
transfections	O
.	O

The	O
antiprogestational	O
potency	O
was	O
as	O
follows	O
:	O
mifepristone	S-chem
/	O
CDB	B-chem
-	I-chem
2914	E-chem
/	O
CDB	B-chem
-	I-chem
4124	E-chem
/	O
monodemethylated	O
metabolites	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
>	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
>	O
didemethylated	O
/	O
17alpha	B-chem
-	I-chem
hydroxy	E-chem
derivatives	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
.	O

Antiglucocorticoid	O
activity	O
was	O
determined	O
by	O
inhibition	O
of	O
dexamethasone	S-chem
-	O
stimulated	O
transcriptional	O
activity	O
in	O
HepG2	O
cells	O
.	O

The	O
mono	O
-	O
and	O
didemethylated	O
metabolites	O
of	O
CDB	B-chem
-	I-chem
2914	E-chem
and	O
CDB	B-chem
-	I-chem
4124	E-chem
had	O
less	O
antiglucocorticoid	O
activity	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
than	O
monodemethylated	O
mifepristone	S-chem
(	O
IC	O
(	O
50	O
)	O
approximately	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
or	O
the	O
other	O
test	O
compounds	O
.	O

At	O
10	O
(	O
-	O
6	O
)	O
M	O
in	O
transcription	O
assays	O
,	O
none	O
of	O
these	O
compounds	O
showed	O
progestin	S-geneY
agonist	O
activity	O
,	O
whereas	O
mifepristone	S-chem-C5-1
and	O
its	O
monodemethylated	O
metabolite	O
manifested	O
slight	O
glucocorticoid	S-geneY-C5-2
agonist	O
activity	O
.	O

The	O
reduced	O
antiglucocorticoid	O
activity	O
of	O
monodemethylated	O
CDB	B-chem
-	I-chem
2914	E-chem
and	O
CDB	B-chem
-	I-chem
4124	E-chem
was	O
confirmed	O
in	O
vivo	O
by	O
the	O
thymus	O
involution	O
assay	O
in	O
adrenalectomized	O
male	O
rats	O
.	O

The	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
-	O
stimulated	O
transcription	O
of	O
an	O
estrogen	S-chem
-	O
responsive	O
reporter	O
plasmid	O
in	O
MCF	O
-	O
7	O
and	O
T47D	O
-	O
CO	O
human	O
breast	O
cancer	O
cells	O
but	O
were	O
much	O
less	O
potent	O
than	O
estradiol	S-chem
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
proximal	O
metabolites	O
of	O
mifepristone	S-chem
,	O
CDB	B-chem
-	I-chem
2914	E-chem
,	O
and	O
CDB	B-chem
-	I-chem
4124	E-chem
contribute	O
significantly	O
to	O
the	O
antiprogestational	O
activity	O
of	O
the	O
parent	O
compounds	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
reduced	O
antiglucocorticoid	O
activity	O
of	O
CDB	B-chem
-	I-chem
2914	E-chem
and	O
CDB	B-chem
-	I-chem
4124	E-chem
compared	O
to	O
mifepristone	S-chem
in	O
vivo	O
may	O
be	O
due	O
in	O
part	O
to	O
decreased	O
activity	O
of	O
their	O
putative	O
proximal	O
metabolites	O
.	O

Development	O
and	O
validation	O
of	O
a	O
non	O
-	O
radioactive	O
DNA	B-geneN-C4-2
polymerase	E-geneN-C4-2
assay	O
for	O
studying	O
cytomegalovirus	O
resistance	O
to	O
foscarnet	S-chem-C4-1
.	O

Phenotypic	O
characterisation	O
of	O
the	O
human	B-geneY
cytomegalovirus	I-geneY
(	I-geneY
HCMV	I-geneY
)	I-geneY
pUL54	E-geneY
DNA	B-geneN
polymerase	E-geneN
is	O
a	O
useful	O
tool	O
for	O
testing	O
for	O
mutations	O
in	O
the	O
UL54	S-geneY
gene	O
thought	O
to	O
render	O
HCMV	O
resistant	O
to	O
foscarnet	S-chem
.	O

In	O
this	O
study	O
,	O
an	O
in	O
-	O
house	O
non	O
-	O
isotopic	O
method	O
for	O
assessing	O
polymerase	O
enzymatic	O
activity	O
in	O
the	O
presence	O
and	O
absence	O
of	O
foscarnet	S-chem
was	O
developed	O
and	O
its	O
utility	O
for	O
HCMV	B-geneN
polymerase	E-geneN
phenotyping	O
evaluated	O
.	O

Polymerase	S-geneN
activity	O
was	O
assessed	O
by	O
monitoring	O
the	O
incorporation	O
of	O
digoxigenin	S-chem
-	O
labelled	O
nucleotides	O
into	O
the	O
growing	O
DNA	O
chain	O
and	O
foscarnet	S-chem
concentrations	O
inhibiting	O
enzymatic	O
activity	O
by	O
50	O
%	O
were	O
determined	O
.	O

HCMV	B-geneN
DNA	I-geneN
polymerases	E-geneN
were	O
synthesised	O
in	O
vitro	O
by	O
expression	O
of	O
UL54	S-geneY
under	O
the	O
control	O
of	O
the	O
T7	B-geneN
promoter	E-geneN
.	O

Mutations	O
of	O
interest	O
were	O
introduced	O
into	O
the	O
wild	O
-	O
type	O
UL54	S-geneY
gene	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Mutated	O
polymerases	S-geneN
and	O
polymerases	S-geneN
from	O
HCMV	O
reference	O
strains	O
were	O
studied	O
.	O

The	O
activity	O
of	O
polymerases	S-geneN-C4-2
containing	O
mutations	O
known	O
to	O
confer	O
resistance	O
to	O
foscarnet	S-chem
(	O
V715M	S-geneN-C4-2
,	O
T700A	S-geneN-C4-2
and	O
N495K	S-geneN-C4-2
)	O
was	O
inhibited	O
by	O
concentrations	O
of	O
foscarnet	S-chem-C4-1
eight	O
to	O
14	O
times	O
higher	O
than	O
those	O
required	O
to	O
inhibit	O
wild	O
-	O
type	O
polymerases	S-geneN-C4-2
.	O

Our	O
in	O
-	O
house	O
non	O
-	O
radioactive	O
phenotypic	O
assay	O
was	O
sensitive	O
and	O
reproducible	O
.	O

It	O
is	O
also	O
easy	O
to	O
perform	O
and	O
could	O
provide	O
a	O
convenient	O
method	O
for	O
characterising	O
mutations	O
conferring	O
resistance	O
to	O
foscarnet	S-chem
in	O
HCMV	O
.	O

Characterization	O
and	O
partial	O
purification	O
of	O
microsomal	O
NAD	B-geneN
(	I-geneN
P	I-geneN
)	I-geneN
H	I-geneN
:	I-geneN
quinone	I-geneN
oxidoreductases	E-geneN
.	O

Quinone	B-geneN-C9-2
oxidoreductases	E-geneN-C9-2
are	O
flavoproteins	O
that	O
catalyze	O
two	O
-	O
electron	O
reduction	O
and	O
detoxification	O
of	O
quinones	S-chem-C9-1
.	O

This	O
leads	O
to	O
the	O
protection	O
of	O
cells	O
against	O
toxicity	O
,	O
mutagenicity	O
,	O
and	O
cancer	O
due	O
to	O
exposure	O
to	O
environmental	O
and	O
synthetic	O
quinones	S-chem
and	O
its	O
precursors	O
.	O

Two	O
cytosolic	O
forms	O
of	O
quinone	B-geneN
oxidoreductases	E-geneN
[	B-geneY
NAD	I-geneY
(	I-geneY
P	I-geneY
)	I-geneY
H	I-geneY
:	I-geneY
quinone	I-geneY
oxidoreductase	I-geneY
1	E-geneY
(	O
NQO1	S-geneY
)	O
and	O
NRH	B-geneY
:	I-geneY
quinone	I-geneY
oxidoreductase	I-geneY
2	E-geneY
(	O
NQO2	S-geneY
)	O
]	O
were	O
previously	O
identified	O
,	O
purified	O
,	O
and	O
cloned	O
.	O

A	O
role	O
of	O
cytosolic	O
NQO1	S-geneY-C9-2
in	O
protection	O
of	O
cells	O
from	O
oxidative	O
stress	O
,	O
cytotoxicity	O
,	O
and	O
mutagenicity	O
of	O
quinones	S-chem-C9-1
was	O
established	O
.	O

Currently	O
,	O
we	O
have	O
characterized	O
and	O
partially	O
purified	O
the	O
NQO	S-geneN
activity	O
from	O
rat	O
liver	O
microsomes	O
.	O

This	O
activity	O
was	O
designated	O
as	O
microsomal	O
NQO	S-geneN
(	O
mNQO	S-geneN
)	O
.	O

The	O
mNQO	S-geneN-C9-2
activity	O
showed	O
significantly	O
higher	O
affinity	O
for	O
NADH	S-chem
than	O
NADPH	S-chem
as	O
electron	O
donors	O
and	O
catalyzed	O
reduction	O
of	O
2,6	B-chem-C9-1
-	I-chem-C9-1
dichlorophenolindophenol	E-chem-C9-1
and	O
menadione	S-chem-C9-1
.	O

The	O
mNQO	S-geneN
activity	O
was	O
insensitive	O
to	O
dicoumarol	S-chem-C4-1
,	O
a	O
potent	O
inhibitor	O
of	O
cytosolic	O
NQO1	S-geneY-C4-2
.	O

Western	O
analysis	O
of	O
microsomal	O
proteins	O
revealed	O
29	O
-	O
and	O
18	O
-	O
kDa	O
bands	O
that	O
cross	O
-	O
reacted	O
with	O
polyclonal	O
antibodies	O
raised	O
against	O
cytosolic	O
NQO1	S-geneY
.	O

The	O
mNQO	S-geneN
activity	O
was	O
partially	O
purified	O
by	O
solubilization	O
of	O
microsomes	O
with	O
detergent	O
Chaps	O
,	O
ammonium	B-chem
sulfate	E-chem
fractionation	O
,	O
and	O
DEAE	S-chem
-	O
Sephacel	O
column	O
chromatography	O
.	O

The	O
microsomal	O
mNQO	S-geneN
proteins	O
are	O
expected	O
to	O
provide	O
additional	O
protection	O
after	O
cytosolic	O
NQOs	S-geneN
against	O
quinone	S-chem
toxicity	O
and	O
mutagenicity	O
.	O

Cerebrovascular	O
Dilation	O
via	O
Selective	O
Targeting	O
of	O
the	O
Cholane	S-chem
Steroid	S-chem
-	O
Recognition	O
Site	O
in	O
the	O
BK	B-geneY
Channel	I-geneY
β1	I-geneY
-	I-geneY
Subunit	E-geneY
by	O
a	O
Novel	O
Nonsteroidal	O
Agent	O
.	O

The	O
Ca	B-geneY
(	I-geneY
2	I-geneY
+	I-geneY
)	I-geneY
/	I-geneY
voltage	I-geneY
-	I-geneY
gated	I-geneY
K	I-geneY
(	I-geneY
+	I-geneY
)	I-geneY
large	I-geneY
conductance	I-geneY
(	I-geneY
BK	I-geneY
)	I-geneY
channel	I-geneY
β1	E-geneY
subunit	O
is	O
particularly	O
abundant	O
in	O
vascular	O
smooth	O
muscle	O
.	O

By	O
determining	O
their	O
phenotype	O
,	O
BK	B-geneY
β1	E-geneY
allows	O
the	O
BK	B-geneN
channels	E-geneN
to	O
reduce	O
myogenic	O
tone	O
,	O
facilitating	O
vasodilation	O
.	O

The	O
endogenous	O
steroid	S-chem
lithocholic	B-chem
acid	E-chem
(	O
LCA	S-chem
)	O
dilates	O
cerebral	O
arteries	O
via	O
BK	B-geneN
channel	E-geneN
activation	O
,	O
which	O
requires	O
recognition	O
by	O
a	O
BK	B-geneY
β1	E-geneY
site	O
that	O
includes	O
Thr169	S-chem
.	O

Whether	O
exogenous	O
nonsteroidal	O
agents	O
can	O
access	O
this	O
site	O
to	O
selectively	O
activate	O
β1	B-geneY
-	I-geneY
containing	I-geneY
BK	I-geneY
channels	E-geneY
and	O
evoke	O
vasodilation	O
remain	O
unknown	O
.	O

We	O
performed	O
a	O
chemical	O
structure	O
database	O
similarity	O
search	O
using	O
LCA	S-chem
as	O
a	O
template	O
,	O
along	O
with	O
a	O
two	O
-	O
step	O
reaction	O
to	O
generate	O
sodium	B-chem
3	I-chem
-	I-chem
hydroxyolean	I-chem
-	I-chem
12	I-chem
-	I-chem
en	I-chem
-	I-chem
30	I-chem
-	I-chem
oate	E-chem
(	O
HENA	S-chem
)	O
.	O

HENA	S-chem-C3-1
activated	O
the	O
BK	B-geneY-C3-2
(	I-geneY-C3-2
cbv1	I-geneY-C3-2
+	I-geneY-C3-2
β1	I-geneY-C3-2
)	I-geneY-C3-2
channels	E-geneY-C3-2
cloned	O
from	O
rat	O
cerebral	O
artery	O
myocytes	O
with	O
a	O
potency	O
(	O
EC50	O
=	O
53	O
μM	O
)	O
similar	O
to	O
and	O
an	O
efficacy	O
(	O
×2.5	O
potentiation	O
)	O
significantly	O
greater	O
than	O
that	O
of	O
LCA	S-chem-C3-1
.	O

This	O
HENA	S-chem
action	O
was	O
replicated	O
on	O
native	O
channels	O
in	O
rat	O
cerebral	O
artery	O
myocytes	O
.	O

HENA	S-chem-C3-1
failed	O
to	O
activate	O
the	O
channels	O
made	O
of	O
cbv1	O
+	O
β2	O
,	O
β3	O
,	O
β4	O
,	O
or	O
β1T169A	O
,	O
indicating	O
that	O
this	O
drug	O
selectively	O
targets	O
β1	B-geneN-C3-2
-	I-geneN-C3-2
containing	I-geneN-C3-2
BK	I-geneN-C3-2
channels	E-geneN-C3-2
via	O
the	O
BK	B-geneY
β1	E-geneY
steroid	S-chem
-	O
sensing	O
site	O
.	O

HENA	S-chem
(	O
3	O
-	O
45	O
μM	O
)	O
dilated	O
the	O
rat	O
and	O
C57BL	O
/	O
6	O
mouse	O
pressurized	O
cerebral	O
arteries	O
.	O

Consistent	O
with	O
the	O
electrophysiologic	O
results	O
,	O
this	O
effect	O
was	O
larger	O
than	O
that	O
of	O
LCA	S-chem
.	O

HENA	S-chem
failed	O
to	O
dilate	O
the	O
arteries	O
from	O
the	O
KCNMB1	S-geneY
knockout	O
mouse	O
,	O
underscoring	O
BK	B-geneY
β1	E-geneY
's	O
role	O
in	O
HENA	S-chem
action	O
.	O

Finally	O
,	O
carotid	O
artery	O
-	O
infusion	O
of	O
HENA	S-chem
(	O
45	O
μM	O
)	O
dilated	O
the	O
pial	O
cerebral	O
arterioles	O
via	O
selective	O
BK	B-geneN
-	I-geneN
channel	E-geneN
targeting	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
for	O
the	O
first	O
time	O
a	O
nonsteroidal	O
agent	O
that	O
selectively	O
activates	O
β1	B-geneN
-	I-geneN
containing	I-geneN
BK	I-geneN
channels	E-geneN
by	O
targeting	O
the	O
steroid	S-chem
-	O
sensing	O
site	O
in	O
BK	B-geneY
β1	E-geneY
,	O
rendering	O
vasodilation	O
.	O

Cysteinyl	B-chem
leukotriene	E-chem
-	O
dependent	O
interleukin	B-geneY
-	I-geneY
5	E-geneY
production	O
leading	O
to	O
eosinophilia	O
during	O
late	O
asthmatic	O
response	O
in	O
guinea	O
-	O
pigs	O
.	O

BACKGROUND	O
:	O
Allergic	O
airway	O
eosinophilia	O
is	O
suppressed	O
by	O
cysteinyl	B-geneY
leukotriene	I-geneY
(	I-geneY
CysLT	I-geneY
)	I-geneY
receptor	E-geneY
(	O
CysLT1	S-geneY
receptor	O
)	O
antagonists	O
in	O
several	O
species	O
including	O
humans	O
and	O
guinea	O
-	O
pigs	O
,	O
suggesting	O
that	O
CysLTs	S-chem
are	O
directly	O
or	O
indirectly	O
involved	O
in	O
induction	O
of	O
the	O
response	O
.	O

OBJECTIVE	O
:	O
We	O
examined	O
the	O
effect	O
of	O
CysLT	S-chem
antagonists	O
(	O
pranlukast	S-chem
and	O
MCI	B-chem
-	I-chem
826	E-chem
)	O
on	O
antigen	O
inhalation	O
-	O
induced	O
eosinophilia	O
in	O
peripheral	O
blood	O
and	O
lung	O
,	O
and	O
on	O
IL	B-geneY
-	I-geneY
5	E-geneY
activity	O
in	O
serum	O
during	O
late	O
increase	O
of	O
airway	O
resistance	O
(	O
late	O
asthmatic	O
response	O
,	O
LAR	O
)	O
in	O
sensitized	O
guinea	O
-	O
pigs	O
.	O

METHODS	O
:	O
Guinea	O
-	O
pigs	O
inhaled	O
ovalbumin	S-geneY
(	O
OVA	S-geneY
)	O
+	O
Al	B-chem
(	I-chem
OH	I-chem
)	I-chem
3	E-chem
and	O
OVA	S-geneY
mists	O
alternately	O
for	O
sensitization	O
and	O
challenge	O
,	O
respectively	O
,	O
once	O
every	O
2	O
weeks	O
.	O

At	O
the	O
fifth	O
challenge	O
,	O
the	O
effects	O
of	O
CysLT	S-chem
antagonists	O
and	O
an	O
anti	O
-	O
IL	B-geneY
-	I-geneY
5	E-geneY
antibody	O
(	O
TRFK	O
-	O
5	O
)	O
on	O
the	O
occurrence	O
of	O
LAR	O
,	O
and	O
blood	O
and	O
lung	O
eosinophilia	O
,	O
which	O
appeared	O
at	O
5	O
h	O
after	O
challenge	O
,	O
were	O
examined	O
.	O

The	O
time	O
-	O
course	O
of	O
IL	B-geneY
-	I-geneY
5	E-geneY
activity	O
in	O
the	O
serum	O
after	O
the	O
challenge	O
was	O
evaluated	O
by	O
measuring	O
in	O
vitro	O
'	O
eosinophil	O
survival	O
prolongation	O
activity	O
'	O
.	O

The	O
influence	O
of	O
CysLT	S-chem
antagonists	O
on	O
IL	B-geneY
-	I-geneY
5	E-geneY
activity	O
was	O
assessed	O
.	O

RESULTS	O
:	O
CysLT	S-chem
antagonists	O
and	O
TRFK	O
-	O
5	O
completely	O
abolished	O
blood	O
and	O
lung	O
eosinophilia	O
.	O

LAR	O
was	O
suppressed	O
by	O
both	O
MCI	B-chem
-	I-chem
826	E-chem
and	O
TRFK	O
-	O
5	O
by	O
40	O
-	O
50	O
%	O
.	O

Sera	O
obtained	O
from	O
sensitized	O
,	O
challenged	O
animals	O
3	O
h	O
and	O
4	O
h	O
after	O
challenge	O
induced	O
an	O
obvious	O
prolongation	O
of	O
eosinophil	O
survival	O
.	O

The	O
activity	O
of	O
the	O
sera	O
was	O
completely	O
neutralized	O
by	O
prior	O
exposure	O
to	O
TRFK	O
-	O
5	O
,	O
suggesting	O
that	O
it	O
reflected	O
IL	B-geneY
-	I-geneY
5	E-geneY
activity	O
.	O

Increased	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
activity	O
in	O
the	O
serum	O
was	O
inhibited	O
by	O
both	O
pranlukast	S-chem-C4-1
and	O
MCI	B-chem-C4-1
-	I-chem-C4-1
826	E-chem-C4-1
by	O
over	O
90	O
%	O
.	O

CONCLUSIONS	O
:	O
CysLTs	S-chem-C3-1
produced	O
after	O
antigen	O
provocation	O
sequentially	O
induced	O
IL	B-geneY
-	I-geneY
5	E-geneY
production	O
from	O
some	O
immune	O
component	O
cells	O
via	O
CysLT1	S-geneY-C3-2
receptor	O
activation	O
.	O

Thus	O
,	O
it	O
is	O
likely	O
that	O
CysLTs	S-chem
indirectly	O
cause	O
antigen	O
-	O
induced	O
eosinophilia	O
through	O
IL	B-geneY
-	I-geneY
5	E-geneY
production	O
.	O

Identification	O
of	O
a	O
novel	O
benzimidazole	S-chem-C6-1
derivative	O
as	O
a	O
highly	O
potent	O
NPY	B-geneY-C6-2
Y5	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
with	O
an	O
anti	O
-	O
obesity	O
profile	O
.	O

Optimization	O
of	O
HTS	O
hit	O
1	O
for	O
NPY	B-geneY
Y5	I-geneY
receptor	E-geneY
binding	O
affinity	O
,	O
CYP450	S-geneN
inhibition	O
,	O
solubility	O
and	O
metabolic	O
stability	O
led	O
to	O
the	O
identification	O
of	O
some	O
orally	O
available	O
oxygen	S-chem
-	O
linker	O
derivatives	O
for	O
in	O
vivo	O
study	O
.	O

Among	O
them	O
,	O
derivative	O
4i	O
inhibited	O
food	O
intake	O
induced	O
by	O
the	O
NPY	B-geneY
Y5	E-geneY
selective	O
agonist	O
,	O
and	O
chronic	O
oral	O
administration	O
of	O
4i	O
in	O
DIO	O
mice	O
caused	O
a	O
dose	O
-	O
dependent	O
reduction	O
of	O
body	O
weight	O
gain	O
.	O

Treatment	O
of	O
Niemann	O
-	O
Pick	O
disease	O
type	O
C	O
in	O
two	O
children	O
with	O
miglustat	S-chem
:	O
initial	O
responses	O
and	O
maintenance	O
of	O
effects	O
over	O
1	O
year	O
.	O

Niemann	O
-	O
Pick	O
disease	O
type	O
C	O
(	O
NP	O
-	O
C	O
)	O
is	O
a	O
lipid	O
storage	O
disorder	O
characterized	O
by	O
the	O
accumulation	O
of	O
unesterified	O
cholesterol	S-chem
and	O
glycolipids	O
in	O
the	O
lysosomal	O
/	O
late	O
endosomal	O
system	O
of	O
certain	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
visceral	O
organs	O
.	O

Clinical	O
symptoms	O
include	O
progressive	O
neurological	O
deterioration	O
and	O
visceral	O
organomegaly	O
.	O

Miglustat	S-chem-C4-1
,	O
a	O
small	O
iminosugar	O
molecule	O
approved	O
for	O
the	O
treatment	O
of	O
Gaucher	O
disease	O
,	O
reversibly	O
inhibits	O
glucosylceramide	B-geneY-C4-2
synthase	E-geneY-C4-2
,	O
which	O
catalyses	O
the	O
first	O
committed	O
step	O
in	O
glycosphingolipid	O
synthesis	O
.	O

The	O
physicochemical	O
properties	O
of	O
miglustat	O
allow	O
it	O
to	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
suggest	O
possible	O
benefits	O
in	O
lysosomal	O
storage	O
diseases	O
affecting	O
the	O
CNS	O
.	O

Here	O
,	O
we	O
present	O
findings	O
in	O
two	O
children	O
with	O
NP	O
-	O
C	O
,	O
aged	O
14	O
years	O
(	O
patient	O
1	O
)	O
and	O
9	O
years	O
(	O
patient	O
2	O
)	O
,	O
treated	O
with	O
miglustat	S-chem
for	O
1	O
year	O
.	O

Before	O
treatment	O
,	O
patient	O
1	O
presented	O
with	O
severe	O
difficulties	O
in	O
swallowing	O
and	O
walking	O
,	O
and	O
patient	O
2	O
with	O
problems	O
mostly	O
affecting	O
communication	O
and	O
social	O
interaction	O
.	O

Videofluoroscopic	O
studies	O
in	O
patient	O
1	O
demonstrated	O
a	O
substantial	O
improvement	O
in	O
swallowing	O
by	O
month	O
6	O
of	O
treatment	O
,	O
and	O
ambulation	O
index	O
measurements	O
indicated	O
improved	O
walking	O
.	O

Mini	O
Mental	O
-	O
State	O
Examination	O
(	O
MMSE	O
)	O
assessments	O
in	O
patient	O
2	O
showed	O
cognitive	O
improvement	O
by	O
month	O
6	O
,	O
which	O
was	O
sustained	O
up	O
to	O
month	O
12	O
.	O

Liver	O
/	O
spleen	O
volume	O
and	O
plasma	O
chitotriosidase	S-geneY
activities	O
were	O
stabilized	O
in	O
both	O
cases	O
.	O

There	O
was	O
no	O
weight	O
loss	O
during	O
treatment	O
.	O

Patient	O
1	O
experienced	O
severe	O
but	O
self	O
-	O
limiting	O
paresthesia	O
,	O
which	O
was	O
not	O
associated	O
with	O
peripheral	O
neuropathy	O
.	O

We	O
conclude	O
that	O
miglustat	S-chem
can	O
provide	O
therapeutic	O
benefits	O
in	O
CNS	O
symptoms	O
and	O
allows	O
stabilization	O
of	O
systemic	O
disease	O
in	O
childhood	O
-	O
onset	O
NP	O
-	O
C	O
.	O

Further	O
follow	O
-	O
up	O
is	O
crucial	O
to	O
determine	O
the	O
long	O
-	O
term	O
maintenance	O
of	O
these	O
effects	O
.	O

Relationship	O
between	O
serum	B-geneN
thyrotropin	E-geneN
levels	O
and	O
intrarenal	O
hemodynamic	O
parameters	O
in	O
euthyroid	O
subjects	O
.	O

OBJECTIVE	O
:	O
Low	O
thyroid	O
function	O
may	O
be	O
associated	O
with	O
a	O
reduced	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
calculated	O
on	O
the	O
basis	O
of	O
creatinine	S-chem
metabolism	O
.	O

Thyroid	B-chem
hormone	E-chem
directly	O
affects	O
serum	O
creatinine	S-chem
in	O
muscle	O
and	O
low	O
thyroid	O
function	O
might	O
exert	O
a	O
similar	O
direct	O
effect	O
in	O
the	O
kidney	O
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
this	O
possibility	O
by	O
assessment	O
of	O
the	O
inulin	O
-	O
based	O
GFR	O
and	O
to	O
examine	O
the	O
mechanism	O
underlying	O
the	O
reduction	O
of	O
GFR	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Renal	O
and	O
glomerular	O
hemodynamics	O
were	O
assessed	O
by	O
simultaneous	O
measurements	O
of	O
plasma	O
clearance	O
of	O
para	B-chem
-	I-chem
aminohippurate	E-chem
(	O
CPAH	O
)	O
and	O
inulin	O
(	O
Cin	O
)	O
in	O
26	O
patients	O
with	O
serum	O
creatinine	S-chem
<	O
1.00	O
mg	O
/	O
dl	O
and	O
without	O
thyroid	O
disease	O
.	O

All	O
subjects	O
were	O
normotensive	O
with	O
or	O
without	O
antihypertensive	O
treatment	O
and	O
were	O
kept	O
in	O
a	O
sodium	S-chem
-	O
replete	O
state	O
.	O

Renal	O
and	O
glomerular	O
hemodynamics	O
were	O
calculated	O
using	O
Gomez`s	O
formulae	O
.	O

RESULTS	O
:	O
Serum	B-geneN
thyroid	I-geneN
stimulating	I-geneN
hormone	E-geneN
(	O
TSH	S-geneN
)	O
,	O
including	O
within	O
the	O
normal	O
range	O
(	O
0.69	O
-	O
4.30	O
μIU	O
/	O
ml	O
)	O
,	O
was	O
positively	O
correlated	O
with	O
vascular	O
resistance	O
at	O
the	O
afferent	O
arteriole	O
(	O
Ra	O
)	O
(	O
r	O
=	O
0.609	O
,	O
p	O
=	O
0.0010	O
)	O
,	O
but	O
not	O
at	O
the	O
efferent	O
arteriole	O
(	O
Re	O
)	O
.	O

Serum	B-geneN
TSH	E-geneN
was	O
significantly	O
and	O
negatively	O
correlated	O
with	O
renal	O
plasma	O
flow	O
(	O
RPF	O
)	O
,	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
,	O
and	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
(	O
r	O
=	O
-	O
0.456	O
,	O
p	O
=	O
0.0192	O
;	O
r	O
=	O
-	O
0.438	O
,	O
p	O
=	O
0.0252	O
;	O
r	O
=	O
-	O
0.505	O
,	O
p	O
=	O
0.0086	O
,	O
respectively	O
)	O
.	O

In	O
multiple	O
regression	O
analysis	O
,	O
serum	B-geneN
TSH	E-geneN
was	O
significantly	O
positively	O
associated	O
with	O
Ra	O
after	O
adjustment	O
for	O
age	O
and	O
mean	O
blood	O
pressure	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
low	O
thyroid	O
function	O
,	O
even	O
within	O
the	O
normal	O
range	O
,	O
is	O
associated	O
with	O
reduced	O
RPF	O
,	O
RBF	O
and	O
GFR	O
,	O
which	O
might	O
be	O
caused	O
by	O
a	O
preferential	O
increase	O
of	O
Ra	O
.	O

Oxidative	O
and	O
nitrosative	O
stress	O
and	O
apoptosis	O
in	O
oral	O
mucosa	O
cells	O
after	O
ex	O
vivo	O
exposure	O
to	O
lead	O
and	O
benzo	B-chem
[	I-chem
a	I-chem
]	I-chem
pyrene	E-chem
.	O

Exposure	O
of	O
human	O
oral	O
mucosa	O
to	O
lead	O
(	O
Pb	S-chem
)	O
and	O
benzo	B-chem
[	I-chem
a	I-chem
]	I-chem
pyrene	E-chem
(	O
BaP	S-chem
)	O
by	O
inhalation	O
and	O
ingestion	O
can	O
lead	O
to	O
pathological	O
conditions	O
via	O
apoptosis	O
and	O
oxidative	O
and	O
nitrosative	O
stress	O
.	O

However	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
effects	O
of	O
Pb	S-chem
and	O
BaP	S-chem
on	O
oral	O
mucosa	O
cells	O
.	O

Furthermore	O
,	O
previous	O
studies	O
focused	O
on	O
chronic	O
Pb	S-chem
and	O
BaP	S-chem
exposure	O
.	O

Therefore	O
,	O
we	O
evaluated	O
important	O
markers	O
of	O
apoptosis	O
and	O
oxidative	O
and	O
nitrosative	O
stress	O
in	O
oral	O
mucosa	O
cells	O
by	O
incubating	O
the	O
cells	O
with	O
Pb	S-chem
and	O
BaP	S-chem
for	O
5	O
-	O
360	O
min	O
.	O

Ex	O
vivo	O
samples	O
of	O
human	O
oral	O
mucosa	O
were	O
exposed	O
to	O
Pb	S-chem
or	O
BaP	S-chem
,	O
and	O
immunohistochemical	O
staining	O
was	O
performed	O
to	O
evaluate	O
active	O
caspase	B-geneY
-	I-geneY
3	E-geneY
,	O
8	B-chem
-	I-chem
epi	I-chem
-	I-chem
prostaglandin	I-chem
F2	I-chem
alpha	E-chem
(	O
8	B-chem
-	I-chem
epi	I-chem
-	I-chem
PGF2a	E-chem
)	O
,	O
and	O
3	B-chem
-	I-chem
nitrotyrosine	E-chem
(	O
3	B-chem
-	I-chem
NT	E-chem
)	O
.	O

Pb	S-chem-C3-1
and	O
BaP	S-chem-C3-1
treatments	O
significantly	O
increased	O
active	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
levels	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
the	O
treatments	O
induced	O
an	O
early	O
increase	O
in	O
3	B-chem
-	I-chem
NT	E-chem
level	O
,	O
which	O
ceased	O
with	O
longer	O
incubation	O
times	O
.	O

8	B-chem
-	I-chem
Epi	I-chem
-	I-chem
PGF2a	E-chem
level	O
increased	O
only	O
after	O
prolonged	O
incubation	O
with	O
Pb	S-chem
,	O
and	O
this	O
elevation	O
was	O
irrespective	O
of	O
BaP	S-chem
incubation	O
duration	O
.	O

Smokers	O
'	O
samples	O
had	O
significantly	O
lower	O
levels	O
of	O
markers	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
than	O
did	O
nonsmokers	O
'	O
samples	O
.	O

Thus	O
,	O
single	O
,	O
short	O
-	O
term	O
exposure	O
to	O
Pb	S-chem
or	O
BaP	S-chem
increases	O
the	O
levels	O
of	O
apoptosis	O
markers	O
and	O
markers	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
.	O

Physicochemical	O
parameters	O
that	O
influence	O
carotenoids	O
bioaccessibility	O
from	O
a	O
tomato	O
juice	O
.	O

In	O
vitro	O
digestion	O
models	O
have	O
been	O
developed	O
to	O
estimate	O
carotenoid	O
bioavailability	O
but	O
most	O
do	O
not	O
consider	O
that	O
their	O
diffusion	O
from	O
fruit	O
matrix	O
to	O
the	O
lipid	O
phase	O
of	O
the	O
bolus	O
could	O
be	O
a	O
limiting	O
step	O
.	O

Therefore	O
we	O
designed	O
a	O
model	O
in	O
which	O
tomato	O
juice	O
is	O
mixed	O
with	O
oil	O
or	O
oil	O
/	O
water	O
emulsions	O
,	O
and	O
the	O
carotenoids	O
diffusing	O
to	O
oil	O
are	O
measured	O
by	O
spectrometry	O
.	O

Temperature	O
,	O
pH	O
and	O
tomato	O
juice	O
/	O
peanut	O
oil	O
ratio	O
were	O
evaluated	O
for	O
their	O
influence	O
on	O
carotenoid	O
diffusion	O
.	O

When	O
oil	O
/	O
tomato	O
ratio	O
was	O
between	O
0.11	O
and	O
1	O
,	O
extraction	O
of	O
lycopene	S-chem
was	O
limited	O
by	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
.	O

With	O
a	O
large	O
excess	O
of	O
oil	O
,	O
diffusion	O
was	O
also	O
limited	O
,	O
as	O
only	O
31	O
±	O
1	O
%	O
of	O
lycopene	S-chem
could	O
be	O
extracted	O
from	O
the	O
juice	O
.	O

Diffusion	O
did	O
not	O
vary	O
significantly	O
with	O
pH	O
but	O
doubled	O
when	O
temperature	O
rose	O
from	O
10°C	O
to	O
37°C	O
.	O

When	O
the	O
juice	O
was	O
mixed	O
in	O
an	O
emulsion	O
stabilised	O
with	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
or	O
phospholipids	O
the	O
maximum	O
extraction	O
decreased	O
to	O
14.5	O
±	O
0.2	O
%	O
and	O
18.5	O
±	O
1.5	O
%	O
respectively	O
,	O
indicating	O
that	O
in	O
addition	O
to	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
at	O
low	O
oil	O
/	O
tomato	O
ratio	O
and	O
in	O
addition	O
to	O
intrinsic	O
properties	O
of	O
the	O
tomato	O
juice	O
in	O
non	O
-	O
saturating	O
conditions	O
,	O
lycopene	S-chem
diffusion	O
was	O
limited	O
by	O
the	O
structure	O
of	O
the	O
interface	O
in	O
emulsions	O
.	O

Lead	O
-	O
induced	O
ER	O
calcium	S-chem
release	O
and	O
inhibitory	O
effects	O
of	O
methionine	B-chem
choline	E-chem
in	O
cultured	O
rat	O
hippocampal	O
neurons	O
.	O

Lead	O
,	O
a	O
ubiquitous	O
neurotoxicant	O
,	O
can	O
result	O
in	O
learning	O
and	O
memory	O
dysfunction	O
.	O

Long	O
term	O
potentiation	O
in	O
the	O
hippocampus	O
,	O
a	O
potential	O
neural	O
substrate	O
for	O
learning	O
and	O
memory	O
,	O
is	O
thought	O
to	O
be	O
linked	O
to	O
calcium	S-chem
-	O
triggered	O
intracellular	O
events	O
.	O

In	O
this	O
study	O
,	O
laser	O
scanning	O
confocal	O
microscopy	O
was	O
used	O
to	O
examine	O
the	O
effects	O
of	O
Pb	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
on	O
intracellular	O
and	O
endoplasmic	O
reticulum	O
free	O
calcium	S-chem
concentration	O
(	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
and	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
ER	O
)	O
)	O
in	O
cultured	O
neonatal	O
rat	O
hippocampal	O
neurons	O
and	O
their	O
possible	O
antagonism	O
by	O
methionine	B-chem
choline	E-chem
;	O
understanding	O
these	O
effects	O
would	O
help	O
explain	O
the	O
lead	O
-	O
induced	O
cognitive	O
and	O
learning	O
dysfunction	O
and	O
explore	O
efficient	O
safety	O
and	O
relief	O
strategies	O
.	O

The	O
results	O
showed	O
that	O
Pb	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
increased	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
and	O
decreased	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
ER	O
)	O
linearly	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependant	O
manner	O
,	O
and	O
Pb	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
addition	O
after	O
the	O
applying	O
of	O
a	O
ryanodine	B-geneN
receptor	E-geneN
(	O
RyR	S-geneN
)	O
antagonist	O
and	O
an	O
inositol	B-geneN
-	I-geneN
1,4,5	I-geneN
-	I-geneN
triphosphate	I-geneN
receptor	E-geneN
(	O
IP	B-geneN
(	I-geneN
3	I-geneN
)	I-geneN
R	E-geneN
)	O
antagonist	O
did	O
not	O
increase	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
.	O

The	O
addition	O
of	O
10	O
,	O
20	O
,	O
or	O
40	O
mmol	O
/	O
L	O
methionine	B-chem
choline	E-chem
simultaneously	O
with	O
addition	O
of	O
10	O
μmol	O
/	O
L	O
Pb	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
decreased	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
in	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
free	O
culture	O
medium	O
by	O
39.0	O
%	O
,	O
66.0	O
%	O
,	O
and	O
61.6	O
%	O
,	O
respectively	O
,	O
in	O
a	O
concentration	O
-	O
dependant	O
manner	O
in	O
a	O
certain	O
dose	O
range	O
.	O

Our	O
results	O
suggest	O
that	O
Pb	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
induces	O
ER	O
calcium	S-chem
release	O
to	O
increase	O
the	O
resting	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
;	O
and	O
methionine	B-chem
choline	E-chem
inhibit	O
this	O
increase	O
in	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
.	O

Synthesis	O
and	O
cytotoxicity	O
of	O
3	B-chem
-	I-chem
aryl	I-chem
acrylic	I-chem
amide	E-chem
derivatives	O
of	O
the	O
simplified	O
saframycin	S-chem
-	O
ecteinascidin	S-chem
skeleton	O
prepared	O
from	O
l	B-chem
-	I-chem
dopa	E-chem
.	O

Twenty	O
four	O
compounds	O
with	O
diversified	O
3	B-chem
-	I-chem
aryl	I-chem
acrylic	I-chem
amide	E-chem
side	O
chains	O
of	O
the	O
simplified	O
saframycin	S-chem
-	O
ecteinascidin	S-chem
pentacyclic	O
skeleton	O
were	O
synthesized	O
via	O
a	O
14	O
-	O
step	O
stereospecific	O
route	O
starting	O
from	O
l	B-chem
-	I-chem
dopa	E-chem
.	O

The	O
cytotoxicities	O
of	O
these	O
compounds	O
were	O
tested	O
against	O
eight	O
human	O
tumor	O
cell	O
lines	O
including	O
HCT	O
-	O
8	O
,	O
BEL	O
-	O
7402	O
,	O
BGC	O
-	O
803	O
,	O
A549	O
,	O
A2780	O
,	O
MCF	O
-	O
7	O
,	O
MX	O
-	O
1	O
,	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

Most	O
of	O
these	O
compounds	O
exhibited	O
potent	O
antitumor	O
activity	O
,	O
and	O
a	O
preliminary	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
was	O
discussed	O
.	O

Compound	O
28	O
with	O
3	B-chem
-	I-chem
thiophenyl	I-chem
acrylic	I-chem
amide	E-chem
side	O
chain	O
exhibited	O
selective	O
cytotoxicity	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
with	O
the	O
IC50	O
value	O
of	O
50	O
nM	O
.	O

Species	O
-	O
specific	O
differences	O
in	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
transactivation	O
function	O
upon	O
binding	O
with	O
betamethasone	B-chem
-	I-chem
esters	E-chem
.	O

Glucocorticoids	O
(	O
GCs	O
)	O
are	O
the	O
most	O
effective	O
drugs	O
for	O
anti	O
-	O
inflammatory	O
diseases	O
.	O

A	O
number	O
of	O
adverse	O
side	O
effects	O
,	O
however	O
,	O
limit	O
chronic	O
treatment	O
with	O
GCs	O
.	O

To	O
improve	O
their	O
therapeutic	O
usefulness	O
,	O
attempts	O
have	O
been	O
made	O
to	O
dissociate	O
the	O
two	O
main	O
actions	O
of	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
(	O
GR	S-geneY
)	O
,	O
transactivation	O
and	O
transrepression	O
,	O
which	O
are	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
side	O
effects	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
respectively	O
.	O

We	O
report	O
here	O
species	O
-	O
specific	O
differences	O
in	O
the	O
transactivation	O
response	O
mediated	O
by	O
GR	S-geneY
.	O

Dexamethasone	S-chem-C5-1
(	O
DEX	S-chem-C5-1
)	O
,	O
betamethasone	S-chem-C5-1
(	O
BM	S-chem-C5-1
)	O
,	O
and	O
their	O
esterified	O
-	O
derivatives	O
had	O
full	O
transrepression	O
agonistic	O
activity	O
in	O
a	O
reporter	O
assay	O
using	O
CV	O
-	O
1	O
cells	O
transfected	O
with	O
either	O
human	B-geneN-C5-2
or	I-geneN-C5-2
rat	I-geneN-C5-2
GR	E-geneN-C5-2
.	O

These	O
GCs	O
also	O
had	O
full	O
transactivation	O
agonistic	O
activity	O
in	O
CV	O
-	O
1	O
cells	O
transfected	O
with	O
human	B-geneY
GR	E-geneY
.	O

The	O
esterified	O
-	O
BM	S-chem-C5-1
,	O
however	O
,	O
had	O
only	O
partial	O
transactivation	O
agonistic	O
activity	O
in	O
cells	O
transfected	O
with	O
rat	B-geneY-C5-2
GR	E-geneY-C5-2
,	O
whereas	O
BM	S-chem-C5-1
and	O
esterified	O
-	O
DEX	S-chem-C5-1
had	O
full	O
transactivation	O
agonistic	O
activity	O
.	O

Moreover	O
,	O
in	O
rat	O
hepatoma	O
H4	O
-	O
II	O
-	O
E	O
cells	O
,	O
the	O
esterified	O
-	O
BM	S-chem-C5-1
failed	O
to	O
induce	O
tyrosine	B-geneY
aminotransferase	E-geneY
,	O
which	O
is	O
regulated	O
by	O
GR	S-geneY-C5-2
-	O
mediated	O
transactivation	O
activity	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
binding	O
affinity	O
of	O
these	O
GCs	O
to	O
human	B-geneN
and	I-geneN
rat	I-geneN
GR	E-geneN
.	O

Consistent	O
with	O
the	O
weak	O
transactivation	O
activity	O
of	O
esterified	O
-	O
BM	S-chem-C5-1
mediated	O
by	O
rat	B-geneY-C5-2
GR	E-geneY-C5-2
,	O
there	O
were	O
few	O
side	O
effects	O
,	O
evaluated	O
by	O
thymus	O
involution	O
and	O
body	O
weight	O
loss	O
,	O
in	O
an	O
antigen	O
-	O
induced	O
asthmatic	O
model	O
in	O
rats	O
.	O

These	O
results	O
suggest	O
that	O
the	O
potency	O
of	O
esterified	O
-	O
BM	S-chem
to	O
induce	O
transactivation	O
activity	O
is	O
different	O
between	O
species	O
and	O
that	O
this	O
difference	O
is	O
not	O
due	O
to	O
differences	O
in	O
receptor	O
binding	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
models	O
for	O
the	O
therapeutic	O
targeting	O
of	O
Wnt	S-geneN
signaling	O
using	O
a	O
Tet	O
-	O
O	O
Δ	O
N89β	O
-	O
catenin	O
system	O
.	O

Although	O
significant	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
importance	O
of	O
Wnt	S-geneN
signaling	O
in	O
the	O
initiation	O
of	O
colorectal	O
cancer	O
,	O
less	O
is	O
known	O
about	O
responses	O
that	O
accompany	O
the	O
reversal	O
of	O
oncogenic	O
Wnt	S-geneN
signaling	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
in	O
vivo	O
and	O
in	O
vitro	O
responses	O
to	O
an	O
'	O
ideal	O
'	O
Wnt	S-geneN
pathway	O
inhibitor	O
as	O
a	O
model	O
for	O
the	O
therapeutic	O
targeting	O
of	O
the	O
pathway	O
.	O

A	O
tetracycline	S-chem
-	O
inducible	O
transgenic	O
mouse	O
model	O
expressing	O
truncated	O
β	B-geneY
-	I-geneY
catenin	E-geneY
(	O
Δ	O
N89β	O
-	I-geneY
catenin	E-geneY
)	O
that	O
exhibited	O
a	O
strong	O
intestinal	O
hyperplasia	O
was	O
analyzed	O
during	O
the	O
removal	O
of	O
oncogenic	O
β	B-geneY
-	I-geneY
catenin	E-geneY
expression	O
both	O
in	O
3D	O
'	O
crypt	O
culture	O
'	O
and	O
in	O
vivo	O
.	O

Oncogenic	O
Wnt	S-geneN
signaling	O
was	O
rapidly	O
and	O
completely	O
reversed	O
.	O

The	O
strongest	O
inhibition	O
of	O
Wnt	S-geneN
target	O
gene	O
expression	O
occurred	O
within	O
24	O
h	O
of	O
doxycycline	O
removal	O
at	O
which	O
time	O
the	O
target	O
genes	O
Ascl2	O
,	E-geneY
Axin2	O
and	O
C	O
-	B-geneY
myc	I-geneY
were	O
downregulated	O
to	O
levels	O
below	O
that	O
in	O
the	O
control	O
intestine	O
.	O

In	O
vitro	O
,	O
the	O
small	O
molecule	O
Wnt	S-geneN
inhibitor	O
CCT036477	O
induced	O
a	O
response	O
within	O
4	O
h	O
of	O
treatment	O
.	O

By	O
7	O
days	O
following	O
doxycycline	S-chem
withdrawal	O
,	O
gene	O
expression	O
,	O
cell	O
proliferation	O
and	O
tissue	O
morphology	O
were	O
undistinguishable	O
from	O
control	O
animals.In	O
conclusion	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
reversal	O
of	O
Wnt	S-geneN
signaling	O
by	O
inhibitors	O
should	O
ideally	O
be	O
studied	O
within	O
hours	O
of	O
treatment	O
.	O

The	O
reversible	O
system	O
described	O
,	O
involving	O
medium	O
throughput	O
in	O
vitro	O
approaches	O
and	O
rapid	O
in	O
vivo	O
responses	O
,	O
should	O
allow	O
the	O
rapid	O
advance	O
of	O
early	O
stage	O
compounds	O
into	O
efficacy	O
models	O
that	O
are	O
more	O
usually	O
considered	O
later	O
in	O
the	O
drug	O
discovery	O
pipeline	O
.	O

Histamine	B-geneY
H4	I-geneY
receptor	E-geneY
antagonism	O
diminishes	O
existing	O
airway	O
inflammation	O
and	O
dysfunction	O
via	O
modulation	O
of	O
Th2	B-geneN
cytokines	E-geneN
.	O

BACKGROUND	O
:	O
Airway	O
remodeling	O
and	O
dysfunction	O
are	O
characteristic	O
features	O
of	O
asthma	O
thought	O
to	O
be	O
caused	O
by	O
aberrant	O
production	O
of	O
Th2	B-geneN
cytokines	E-geneN
.	O

Histamine	B-geneY
H4	I-geneY
receptor	E-geneY
(	O
H4R	S-geneY
)	O
perturbation	O
has	O
previously	O
been	O
shown	O
to	O
modify	O
acute	O
inflammation	O
and	O
Th2	B-geneN
cytokine	E-geneN
production	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O

We	O
examined	O
the	O
ability	O
of	O
H4R	S-geneY
antagonists	O
to	O
therapeutically	O
modify	O
the	O
effects	O
of	O
Th2	B-geneN
cytokine	E-geneN
production	O
such	O
as	O
goblet	O
cell	O
hyperplasia	O
(	O
GCH	O
)	O
,	O
and	O
collagen	S-geneN
deposition	O
in	O
a	O
sub	O
-	O
chronic	O
model	O
of	O
asthma	O
.	O

In	O
addition	O
,	O
effects	O
on	O
Th2	O
mediated	O
lung	O
dysfunction	O
were	O
also	O
determined	O
.	O

METHODS	O
:	O
Mice	O
were	O
sensitized	O
to	O
ovalbumin	S-geneY
(	O
OVA	S-geneY
)	O
followed	O
by	O
repeated	O
airway	O
challenge	O
with	O
OVA	S-geneY
.	O

After	O
inflammation	O
was	O
established	O
mice	O
were	O
dosed	O
with	O
the	O
H4R	S-geneY-C6-2
antagonist	O
,	O
JNJ	B-chem-C6-1
7777120	E-chem-C6-1
,	O
or	O
anti	O
-	O
IL	B-geneY
-	I-geneY
13	E-geneY
antibody	O
for	O
comparison	O
.	O

Airway	O
hyperreactivity	O
(	O
AHR	O
)	O
was	O
measured	O
,	O
lungs	O
lavaged	O
and	O
tissues	O
collected	O
for	O
analysis	O
.	O

RESULTS	O
:	O
Therapeutic	O
H4R	S-geneY
antagonism	O
inhibited	O
T	O
cell	O
infiltration	O
in	O
to	O
the	O
lung	O
and	O
decreased	O
Th2	B-geneN
cytokines	E-geneN
IL	B-geneY
-	I-geneY
13	E-geneY
and	O
IL	B-geneY
-	I-geneY
5	E-geneY
.	O

IL	B-geneY
-	I-geneY
13	E-geneY
dependent	O
remodeling	O
parameters	O
such	O
as	O
GCH	O
and	O
lung	O
collagen	S-geneN
were	O
reduced	O
.	O

Intervention	O
with	O
H4R	S-geneY
antagonist	O
also	O
improved	O
measures	O
of	O
central	O
and	O
peripheral	O
airway	O
dysfunction	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
that	O
therapeutic	O
H4R	S-geneY
antagonism	O
can	O
significantly	O
ameliorate	O
allergen	O
induced	O
,	O
Th2	B-geneN
cytokine	E-geneN
driven	O
pathologies	O
such	O
as	O
lung	O
remodeling	O
and	O
airway	O
dysfunction	O
.	O

The	O
ability	O
of	O
H4R	S-geneY
antagonists	O
to	O
affect	O
these	O
key	O
manifestations	O
of	O
asthma	O
suggests	O
their	O
potential	O
as	O
novel	O
human	O
therapeutics	O
.	O

Localization	O
of	O
L	B-geneN
-	I-geneN
glutamate	I-geneN
decarboxylase	E-geneN
and	O
GABA	B-geneY
transaminase	E-geneY
immunoreactivity	O
in	O
the	O
sympathetic	O
ganglia	O
of	O
the	O
rat	O
.	O

The	O
location	O
of	O
L	B-geneN
-	I-geneN
glutamate	I-geneN
decarboxylase	E-geneN
and	O
gamma	B-geneY
-	I-geneY
aminobutyrate	I-geneY
(	I-geneY
GABA	I-geneY
)	I-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
in	O
the	O
superior	O
cervical	O
ganglion	O
and	O
in	O
the	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
of	O
the	O
rat	O
was	O
studied	O
by	O
an	O
indirect	O
immunofluorescence	O
method	O
and	O
by	O
immunoelectron	O
microscopy	O
,	O
with	O
specific	O
antisera	O
raised	O
in	O
rabbits	O
against	O
the	O
corresponding	O
enzymes	O
.	O

In	O
light	O
microscopy	O
,	O
several	O
glutamate	B-geneN
decarboxylase	E-geneN
-	O
or	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
-	O
immunoreactive	O
principal	O
nerve	O
cells	O
were	O
detected	O
in	O
the	O
superior	O
cervical	O
ganglion	O
and	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
.	O

In	O
addition	O
,	O
numerous	O
small	O
cells	O
in	O
both	O
the	O
superior	O
cervical	O
ganglion	O
and	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
showed	O
intense	O
immunoreactivity	O
to	O
glutamate	B-geneN
decarboxylase	E-geneN
or	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
.	O

The	O
small	O
cells	O
were	O
10	O
-	O
20	O
micron	O
in	O
diameter	O
and	O
resembled	O
in	O
size	O
and	O
morphology	O
the	O
small	O
intensely	O
fluorescent	O
cells	O
.	O

In	O
consecutive	O
sections	O
,	O
the	O
small	O
glutamate	B-geneN
decarboxylase	E-geneN
-	O
immunoreactive	O
cell	O
clusters	O
also	O
showed	O
immunoreactivity	O
to	O
tyrosine	B-geneY
hydroxylase	E-geneY
,	O
suggesting	O
that	O
these	O
cells	O
contain	O
the	O
enzymes	O
for	O
both	O
GABA	S-chem
and	O
catecholamine	S-chem
synthesis	O
.	O

In	O
the	O
superior	O
cervical	O
ganglion	O
and	O
in	O
the	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
,	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
was	O
also	O
localized	O
in	O
fibre	O
-	O
like	O
processes	O
around	O
and	O
between	O
the	O
principal	O
nerve	O
cells	O
,	O
in	O
nerve	O
trunks	O
traversing	O
the	O
ganglia	O
,	O
and	O
around	O
or	O
in	O
close	O
contact	O
with	O
ganglionic	O
blood	O
vessels	O
.	O

Furthermore	O
,	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
was	O
observed	O
in	O
fibre	O
-	O
like	O
structures	O
close	O
to	O
the	O
capsule	O
of	O
the	O
ganglia	O
.	O

Division	O
of	O
the	O
preganglionic	O
nerve	O
trunk	O
of	O
the	O
superior	O
cervical	O
ganglion	O
caused	O
no	O
detectable	O
change	O
in	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
in	O
the	O
ganglion	O
.	O

In	O
immunoelectron	O
microscopy	O
of	O
the	O
superior	O
cervical	O
ganglion	O
,	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
was	O
localized	O
in	O
nerve	O
fibres	O
in	O
association	O
with	O
neurotubules	O
.	O

A	O
large	O
number	O
of	O
GABA	B-geneY
-	I-geneY
transaminase	E-geneY
labelled	O
principal	O
nerve	O
cells	O
were	O
detected	O
,	O
containing	O
immunoreactivity	O
evenly	O
distributed	O
in	O
their	O
cytoplasm	O
.	O

GABA	B-geneY
-	I-geneY
transaminase	E-geneY
immunoreactivity	O
was	O
also	O
observed	O
in	O
satellite	O
cells	O
and	O
their	O
processes	O
in	O
the	O
superior	O
cervical	O
ganglion	O
.	O

The	O
present	O
immunocytochemical	O
results	O
provide	O
evidence	O
that	O
the	O
rat	O
sympathetic	O
ganglia	O
contain	O
an	O
intrinsic	O
neuronal	O
system	O
showing	O
histochemical	O
markers	O
for	O
GABA	S-chem
synthesis	O
and	O
inactivation	O
,	O
but	O
its	O
functional	O
role	O
in	O
the	O
modulation	O
of	O
ganglionic	O
neurotransmission	O
remains	O
to	O
be	O
established	O
.	O

Alcohol	S-chem
modulates	O
expression	O
of	O
DNA	B-geneN
methyltranferases	E-geneN
and	O
methyl	B-geneN
CpG	I-geneN
-	I-geneN
/	I-geneN
CpG	I-geneN
domain	I-geneN
-	I-geneN
binding	I-geneN
proteins	E-geneN
in	O
murine	O
embryonic	O
fibroblasts	O
.	O

Fetal	O
alcohol	S-chem
syndrome	O
(	O
FAS	O
)	O
,	O
presenting	O
with	O
a	O
constellation	O
of	O
neuro	O
-	O
/	O
psychological	O
,	O
craniofacial	O
and	O
cardiac	O
abnormalities	O
,	O
occurs	O
frequently	O
in	O
offspring	O
of	O
women	O
who	O
consume	O
alcohol	S-chem
during	O
pregnancy	O
,	O
with	O
a	O
prevalence	O
of	O
1	O
-	O
3	O
per	O
1000	O
livebirths	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
alcohol	S-chem
alters	O
global	O
DNA	O
methylation	O
,	O
and	O
modulates	O
expression	O
of	O
the	O
DNA	B-geneN
methyltransferases	E-geneN
(	O
DNMTs	S-geneN
)	O
and	O
various	O
methyl	B-chem
CpG	B-geneN
-	I-geneN
binding	I-geneN
proteins	E-geneN
.	O

Murine	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
,	O
utilized	O
as	O
an	O
in	O
vitro	O
embryonic	O
model	O
system	O
,	O
demonstrated	O
∼	O
5	O
%	O
reduction	O
in	O
global	O
DNA	O
methylation	O
following	O
exposure	O
to	O
200mM	O
ethanol	S-chem
.	O

In	O
addition	O
,	O
ethanol	S-chem-C4-1
induced	O
degradation	O
of	O
DNA	B-geneN-C4-2
methyltransferases	E-geneN-C4-2
(	O
DNMT	B-geneY-C4-2
-	E-geneY-C4-2
1	O
,	O
DNMT	B-geneY-C4-2
-	I-geneY-C4-2
3a	E-geneY-C4-2
,	O
and	O
DNMT	B-geneY-C4-2
-	I-geneY-C4-2
3b	E-geneY-C4-2
)	O
,	O
as	O
well	O
as	O
the	O
methyl	B-geneN-C4-2
CpG	I-geneN-C4-2
-	I-geneN-C4-2
binding	I-geneN-C4-2
proteins	E-geneN-C4-2
(	O
MeCP	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
MBD	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
MBD	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
)	O
,	O
in	O
MEF	O
cells	O
by	O
the	O
proteasomal	O
pathway	O
.	O

Such	O
degradation	O
could	O
be	O
completely	O
rescued	O
by	O
pretreatment	O
of	O
MEF	O
cells	O
with	O
the	O
proteasomal	O
inhibitor	O
,	O
MG	B-chem
-	I-chem
132	E-chem
.	O

These	O
data	O
support	O
a	O
potential	O
epigenetic	O
molecular	O
mechanism	O
underlying	O
the	O
pathogenesis	O
of	O
FAS	O
during	O
mammalian	O
development	O
.	O

Central	O
nervous	O
system	O
damage	O
due	O
to	O
acute	O
paraquat	S-chem
poisoning	O
:	O
an	O
experimental	O
study	O
with	O
rat	O
model	O
.	O

Paraquat	S-chem
(	O
PQ	O
)	O
is	O
a	O
common	O
herbicide	O
and	O
PQ	O
poisoning	O
is	O
a	O
major	O
medical	O
problem	O
in	O
Asia	O
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
acute	O
neurotoxic	O
changes	O
caused	O
by	O
PQ	O
.	O

Here	O
we	O
report	O
the	O
acute	O
neurotoxicological	O
findings	O
of	O
rats	O
treated	O
with	O
lethal	O
dose	O
of	O
PQ	O
.	O

In	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
striatum	O
we	O
found	O
obvious	O
microglia	O
(	O
labeled	O
by	O
Iba	B-geneY
-	I-geneY
1	E-geneY
)	O
activation	O
within	O
one	O
week	O
.	O

In	O
SN	O
and	O
hippocampus	O
,	O
we	O
detected	O
increased	O
oxidative	O
stress	O
in	O
the	O
neurons	O
based	O
on	O
NeuN	O
/	O
8	B-chem
-	I-chem
OHdG	E-chem
immunofluorescence	O
double	O
labeling	O
and	O
laser	O
cofocal	O
microscopy	O
.	O

Moreover	O
,	O
we	O
provided	O
ultrastructural	O
evidences	O
of	O
astrocyte	O
edema	O
and	O
neurons	O
apoptosis	O
in	O
rat	O
brain	O
by	O
electron	O
microscopy	O
.	O

Further	O
studies	O
will	O
be	O
needed	O
with	O
non	O
-	O
lethal	O
dose	O
of	O
PQ	O
to	O
confirm	O
these	O
results	O
and	O
demonstrate	O
the	O
direct	O
CNS	O
toxicity	O
of	O
PQ	O
.	O

Heterogeneity	O
of	O
persistent	O
hyperinsulinaemic	O
hypoglycaemia	O
.	O
A	O
series	O
of	O
175	O
cases	O
.	O

UNLABELLED	O
:	O
Hyperinsulinism	O
is	O
a	O
heterogeneous	O
disorder	O
characterised	O
by	O
severe	O
hypoglycaemia	O
due	O
to	O
an	O
inappropriate	O
oversecretion	O
of	O
insulin	S-geneY
.	O

In	O
a	O
personal	O
series	O
of	O
175	O
patients	O
investigated	O
for	O
hyperinsulinaemic	O
hypoglycaemia	O
over	O
the	O
last	O
20	O
years	O
,	O
we	O
review	O
clinical	O
presentations	O
,	O
molecular	O
studies	O
and	O
therapeutic	O
management	O
of	O
hyperinsulinism	O
.	O

There	O
were	O
98	O
neonatal	O
-	O
onset	O
patients	O
,	O
including	O
86	O
permanent	O
hyperinsulinism	O
and	O
12	O
transient	O
forms	O
,	O
68	O
with	O
infancy	O
-	O
onset	O
and	O
nine	O
with	O
childhood	O
-	O
onset	O
.	O

Hyperammonaemia	O
was	O
found	O
in	O
12	O
out	O
of	O
69	O
patients	O
tested	O
,	O
4	O
neonates	O
and	O
8	O
infants	O
.	O

Neonates	O
were	O
clinically	O
more	O
severely	O
affected	O
than	O
infants	O
.	O

Diagnosis	O
of	O
infancy	O
-	O
onset	O
hyperinsulinism	O
was	O
often	O
delayed	O
because	O
of	O
less	O
profound	O
hypoglycaemia	O
and	O
better	O
tolerance	O
to	O
hypoglycaemia	O
.	O

Neonates	O
required	O
higher	O
rates	O
of	O
i.v	O
.	O
glucose	S-chem
than	O
infants	O
to	O
maintain	O
normal	O
plasma	O
glucose	S-chem
levels	O
(	O
16	O
mg	O
/	O
kg	O
per	O
min	O
versus	O
12	O
mg	O
/	O
kg	O
per	O
min	O
)	O
.	O

Only	O
16	O
%	O
of	O
neonates	O
were	O
diazoxide	S-chem
-	O
sensitive	O
compared	O
to	O
66	O
%	O
of	O
the	O
infants	O
.	O

Neonates	O
with	O
hyperammonaemia	O
or	O
transient	O
hyperinsulinism	O
were	O
diazoxide	S-chem
-	O
sensitive	O
.	O

Most	O
neonates	O
were	O
pancreatectomised	O
whereas	O
65	O
%	O
of	O
the	O
infants	O
were	O
treated	O
medically	O
.	O

Among	O
surgically	O
-	O
treated	O
patients	O
,	O
47	O
%	O
had	O
a	O
focal	O
adenomatous	O
hyperplasia	O
(	O
31	O
neonates	O
and	O
13	O
infants	O
)	O
and	O
53	O
%	O
a	O
diffuse	O
form	O
of	O
hyperinsulinism	O
(	O
39	O
neonates	O
and	O
11	O
infants	O
)	O
.	O

Diazoxide	S-chem
-	O
responsiveness	O
in	O
the	O
focal	O
and	O
diffuse	O
forms	O
did	O
not	O
differ	O
in	O
both	O
neonates	O
and	O
infants	O
;	O
it	O
depended	O
only	O
upon	O
the	O
age	O
of	O
onset	O
of	O
hypoglycaemia	O
.	O

One	O
or	O
two	O
mutations	O
,	O
SUR1	S-geneY
or	O
KIR6.2	S-geneY
,	O
were	O
found	O
in	O
41	O
of	O
73	O
neonates	O
who	O
were	O
investigated	O
and	O
in	O
13	O
/	O
38	O
infants	O
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
of	O
both	O
genes	O
.	O

Almost	O
all	O
patients	O
with	O
SUR1	S-geneY
(	O
38	O
/	O
41	O
)	O
or	O
KIR6.2	S-geneY
(	O
5	O
/	O
7	O
)	O
mutations	O
were	O
resistant	O
to	O
diazoxide	S-chem
.	O

Ten	O
patients	O
with	O
hyperinsulinism	O
-	O
hyperammonaemia	O
syndrome	O
had	O
a	O
mutation	O
in	O
the	O
glutamate	B-geneN
dehydrogenase	E-geneN
gene	O
(	O
three	O
neonates	O
and	O
seven	O
infants	O
)	O
after	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
cDNA	O
.	O

No	O
mutation	O
was	O
found	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
in	O
the	O
glucokinase	S-geneY
gene	O
.	O

Eight	O
of	O
nine	O
patients	O
with	O
childhood	O
onset	O
hyperinsulinism	O
were	O
treated	O
surgically	O
and	O
histological	O
examination	O
confirmed	O
an	O
adenoma	O
in	O
each	O
case	O
.	O

CONCLUSION	O
:	O
the	O
clinical	O
severity	O
of	O
hyperinsulinism	O
varies	O
mainly	O
with	O
age	O
at	O
onset	O
of	O
hypoglycaemia	O
.	O

The	O
heterogeneity	O
of	O
hyperinsulinism	O
has	O
major	O
consequences	O
in	O
terms	O
of	O
therapeutic	O
outcome	O
and	O
genetic	O
counselling	O
.	O

Apple	O
polyphenols	S-chem-C4-1
suppress	O
antigen	O
presentation	O
of	O
ovalbumin	S-geneN-C4-2
by	O
THP	O
-	O
1	O
-	O
derived	O
dendritic	O
cells	O
.	O

Apple	O
polyphenol	S-chem
extract	O
(	O
AP	O
)	O
and	O
procyanidin	S-chem
contained	O
in	O
AP	O
were	O
investigated	O
for	O
their	O
immunomodulatory	O
effects	O
using	O
THP	O
-	O
1	O
-	O
derived	O
human	O
dendritic	O
cells	O
(	O
TDDCs	O
)	O
.	O

The	O
expression	O
levels	O
of	O
HLA	B-geneN
-	I-geneN
DR	E-geneN
(	O
MHC	B-geneN
class	I-geneN
II	E-geneN
)	O
and	O
CD86	S-geneN
(	O
costimulatory	O
molecule	O
)	O
were	O
measured	O
as	O
an	O
indicator	O
of	O
antigen	O
presentation	O
in	O
TDDCs	O
.	O

A	O
significant	O
decrease	O
in	O
HLA	B-geneN-C4-2
-	I-geneN-C4-2
DR	E-geneN-C4-2
expression	O
was	O
observed	O
in	O
the	O
AP	O
and	O
fractionated	O
procyanidin	S-chem-C4-1
-	O
treated	O
cells	O
in	O
the	O
presence	O
of	O
ovalbumin	S-geneN
(	O
OVA	S-geneN
)	O
,	O
but	O
no	O
effect	O
on	O
CD86	S-geneN
expression	O
was	O
observed	O
.	O

The	O
uptake	O
of	O
OVA	S-geneN
was	O
not	O
inhibited	O
by	O
AP	O
treatment	O
,	O
and	O
the	O
gene	O
expression	O
of	O
membrane	O
-	O
associated	O
RING	B-geneN
-	I-geneN
CH	E-geneN
ubiquitin	B-geneN
E3	I-geneN
ligase	E-geneN
,	O
MARCH1	S-geneN
,	O
was	O
up	O
-	O
regulated	O
by	O
AP	O
treatment	O
.	O

It	O
can	O
therefore	O
be	O
presumed	O
that	O
AP	O
suppresses	O
HLA	B-geneN
-	I-geneN
DR	E-geneN
expression	O
via	O
the	O
ubiquitin	S-geneN
-	O
proteasome	S-geneN
pathway	O
.	O

Furthermore	O
,	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-geneN-C3-2
-	I-geneN-C3-2
12	E-geneN-C3-2
and	O
TNF	B-geneN-C3-2
-	I-geneN-C3-2
α	E-geneN-C3-2
was	O
found	O
in	O
the	O
procyanidin	S-chem-C3-1
trimers	O
-	O
treated	O
cells	O
in	O
the	O
presence	O
of	O
OVA	S-geneN
.	O

These	O
results	O
suggest	O
that	O
apple	O
polyphenols	S-chem
would	O
be	O
an	O
effective	O
factor	O
for	O
the	O
development	O
of	O
immunomodulatory	O
agents	O
with	O
suppressive	O
effects	O
of	O
antigen	O
presentation	O
.	O

Novel	O
analgesic	O
/	O
anti	O
-	O
inflammatory	O
agents	O
:	O
1,5	B-chem-C4-1
-	I-chem-C4-1
diarylpyrrole	I-chem-C4-1
nitrooxyalkyl	I-chem-C4-1
ethers	E-chem-C4-1
and	O
related	O
compounds	O
as	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibiting	O
nitric	B-chem-C4-1
oxide	E-chem-C4-1
donors	O
.	O

A	O
series	O
of	O
3	B-chem
-	I-chem
substituted	I-chem
1,5	I-chem
-	I-chem
diarylpyrroles	E-chem
bearing	O
a	O
nitrooxyalkyl	S-chem
side	O
chain	O
linked	O
to	O
different	O
spacers	O
were	O
designed	O
.	O

New	O
classes	O
of	O
pyrrole	S-chem-C4-1
-	O
derived	O
nitrooxyalkyl	S-chem-C4-1
inverse	O
esters	S-chem-C4-1
,	O
carbonates	S-chem-C4-1
,	O
and	O
ethers	S-chem-C4-1
(	O
7	O
-	O
10	O
)	O
as	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
selective	O
inhibitors	O
and	O
NO	S-chem
donors	O
were	O
synthesized	O
and	O
are	O
herein	O
reported	O
.	O

By	O
taking	O
into	O
account	O
the	O
metabolic	O
conversion	O
of	O
nitrooxyalkyl	B-chem
ethers	E-chem
(	O
9	O
,	O
10	O
)	O
into	O
corresponding	O
alcohols	S-chem
,	O
derivatives	O
17	O
and	O
18	O
were	O
also	O
studied	O
.	O

Nitrooxy	S-chem-C4-1
derivatives	O
showed	O
NO	S-chem
-	O
dependent	O
vasorelaxing	O
properties	O
,	O
while	O
most	O
of	O
the	O
compounds	O
proved	O
to	O
be	O
very	O
potent	O
and	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitors	O
in	O
in	O
vitro	O
experimental	O
models	O
.	O

Further	O
in	O
vivo	O
studies	O
on	O
compounds	O
9a	O
,	O
c	O
and	O
17a	O
highlighted	O
good	O
anti	O
-	O
inflammatory	O
and	O
antinociceptive	O
activities	O
.	O

Compound	O
9c	O
was	O
able	O
to	O
inhibit	O
glycosaminoglycan	O
(	O
GAG	O
)	O
release	O
induced	O
by	O
interleukin	B-geneY
-	I-geneY
1β	E-geneY
(	O
IL	B-geneY
-	I-geneY
1β	E-geneY
)	O
,	O
showing	O
cartilage	O
protective	O
properties	O
.	O

Finally	O
,	O
molecular	O
modeling	O
and	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
-	O
and	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
-	O
NMR	O
studies	O
performed	O
on	O
compounds	O
6c	O
,	O
d	O
,	O
9c	O
,	O
and	O
10b	O
allowed	O
the	O
right	O
conformation	O
of	O
nitrooxyalkyl	B-chem
ester	I-chem
and	I-chem
ether	E-chem
side	O
chain	O
of	O
these	O
molecules	O
within	O
the	O
COX	B-geneY
-	I-geneY
2	E-geneY
active	O
site	O
to	O
be	O
assessed	O
.	O

Norepinephrine	B-geneY
transporters	E-geneY
have	O
channel	O
modes	O
of	O
conduction	O
.	O

Neurotransmitter	B-geneN
transporters	E-geneN
couple	O
to	O
existing	O
ion	O
gradients	O
to	O
achieve	O
reuptake	O
of	O
transmitter	O
into	O
presynaptic	O
terminals	O
.	O

For	O
coupled	O
cotransport	O
,	O
substrates	O
and	O
ions	O
cross	O
the	O
membrane	O
in	O
fixed	O
stoichiometry	O
.	O

This	O
is	O
in	O
contrast	O
to	O
ion	B-geneN
channels	E-geneN
,	O
which	O
carry	O
an	O
arbitrary	O
number	O
of	O
ions	O
depending	O
on	O
the	O
channel	O
open	O
time	O
.	O

Members	O
of	O
the	O
gamma	B-geneN
-	I-geneN
aminobutyric	I-geneN
acid	I-geneN
transporter	E-geneN
gene	O
family	O
presumably	O
function	O
with	O
fixed	O
stoichiometry	O
in	O
which	O
a	O
set	O
number	O
of	O
ions	O
cotransport	O
with	O
one	O
transmitter	O
molecule	O
.	O

Here	O
we	O
report	O
channel	O
-	O
like	O
events	O
from	O
a	O
presumably	O
fixed	O
stoichiometry	O
[	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
+	O
,	O
Na	B-chem
+	E-chem
,	O
and	O
Cl	B-chem
-	E-chem
]	O
,	O
human	O
NE	S-chem
(	O
hNET	S-geneY
)	O
in	O
the	O
gamma	B-geneN
-	I-geneN
aminobutyric	I-geneN
acid	I-geneN
transporter	E-geneN
gene	O
family	O
.	O

These	O
events	O
are	O
stimulated	O
by	O
NE	S-chem-C9-1
and	O
by	O
guanethidine	S-chem-C9-1
,	O
an	O
hNET	S-geneY-MU-2
substrate	O
,	O
and	O
they	O
are	O
blocked	O
by	O
cocaine	S-chem-C4-1
and	O
the	O
antidepressant	O
desipramine	S-chem-C4-1
.	O

Voltage	O
-	O
clamp	O
data	O
combined	O
with	O
NE	S-chem-C9-1
uptake	O
data	O
from	O
these	O
same	O
cells	O
indicate	O
that	O
hNETs	S-geneY-C9-2
have	O
two	O
functional	O
modes	O
of	O
conduction	O
:	O
a	O
classical	O
transporter	O
mode	O
(	O
T	O
-	O
mode	O
)	O
and	O
a	O
novel	O
channel	O
mode	O
(	O
C	O
-	O
mode	O
)	O
.	O

Both	O
T	O
-	O
mode	O
and	O
C	O
-	O
mode	O
are	O
gated	O
by	O
the	O
same	O
substrates	O
and	O
antagonized	O
by	O
the	O
same	O
blockers	O
.	O

T	O
-	O
mode	O
is	O
putatively	O
electrogenic	O
because	O
the	O
transmitter	O
and	O
cotransported	O
ions	O
sum	O
to	O
one	O
net	O
charge	O
.	O

However	O
,	O
C	O
-	O
mode	O
carries	O
virtually	O
all	O
of	O
the	O
transmitter	O
-	O
induced	O
current	O
,	O
even	O
though	O
it	O
occurs	O
with	O
low	O
probability	O
.	O

This	O
is	O
because	O
each	O
C	O
-	O
mode	O
opening	O
transports	O
hundreds	O
of	O
charges	O
per	O
event	O
.	O

The	O
existence	O
of	O
a	O
channel	O
mode	O
of	O
conduction	O
in	O
a	O
previously	O
established	O
fixed	O
-	O
stoichiometry	O
transporter	O
suggests	O
the	O
appearance	O
of	O
an	O
aqueous	O
pore	O
through	O
the	O
transporter	O
protein	O
during	O
the	O
transport	O
cycle	O
and	O
may	O
have	O
significance	O
for	O
transporter	O
regulation	O
.	O

Dose	O
-	O
dependent	O
effects	O
of	O
vitamin	B-chem
D	E-chem
on	O
transdifferentiation	O
of	O
skeletal	O
muscle	O
cells	O
to	O
adipose	O
cells	O
.	O

Fat	O
infiltration	O
within	O
muscle	O
is	O
one	O
of	O
a	O
number	O
of	O
features	O
of	O
vitamin	B-chem
D	E-chem
deficiency	O
,	O
which	O
leads	O
to	O
a	O
decline	O
in	O
muscle	O
functionality	O
.	O

The	O
origin	O
of	O
this	O
fat	O
is	O
unclear	O
,	O
but	O
one	O
possibility	O
is	O
that	O
it	O
forms	O
from	O
myogenic	O
precursor	O
cells	O
present	O
in	O
the	O
muscle	O
,	O
which	O
transdifferentiate	O
into	O
mature	O
adipocytes	O
.	O

The	O
current	O
study	O
examined	O
the	O
effect	O
of	O
the	O
active	O
form	O
of	O
vitamin	B-chem
D₃	E-chem
,	O
1,25	B-chem
-	I-chem
dihydroxyvitamin	I-chem
D₃	E-chem
(	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
₂D₃	E-chem
)	O
,	O
on	O
the	O
capacity	O
of	O
the	O
C2C12	O
muscle	O
cell	O
line	O
to	O
differentiate	O
towards	O
the	O
myogenic	O
and	O
adipogenic	O
lineages	O
.	O

Cells	O
were	O
cultured	O
in	O
myogenic	O
or	O
adipogenic	O
differentiation	O
media	O
containing	O
increasing	O
concentrations	O
(	O
0	O
,	O
10⁻¹³	O
,	O
10⁻¹¹	O
,	O
10⁻⁹	O
,	O
10⁻⁷	O
or	O
10⁻⁵	O
M	O
)	O
of	O
1,25	O
(	I-chem
OH	I-chem
)	I-chem
₂D₃	I-chem
for	O
up	O
to	O
6	O
days	O
and	O
markers	O
of	O
muscle	O
and	O
fat	O
development	O
measured	O
.	O

Mature	O
myofibres	O
were	O
formed	O
in	O
both	O
adipogenic	O
and	O
myogenic	O
media	O
,	O
but	O
fat	O
droplets	O
were	O
only	O
observed	O
in	O
adipogenic	O
media	O
.	O

Relative	O
to	O
controls	O
,	O
low	O
physiological	O
concentrations	O
(	O
10⁻¹³	O
and	O
10⁻¹¹	O
M	O
)	O
of	O
1,25	O
(	I-chem
OH	I-chem
)	I-chem
₂D3	I-chem
increased	O
fat	O
droplet	O
accumulation	O
,	O
whereas	O
high	O
physiological	O
(	O
10⁻⁹	O
M	O
)	O
and	O
supraphysiological	O
concentrations	O
(	O
≥	O
10⁻⁷	O
M	O
)	O
inhibited	O
fat	O
accumulation	O
.	O

This	O
increased	O
accumulation	O
of	O
fat	O
with	O
low	O
physiological	O
concentrations	O
(	O
10⁻¹³	O
and	O
10⁻¹¹	O
M	O
)	O
was	O
associated	O
with	O
a	O
sequential	O
up	O
-	O
regulation	O
of	O
PPARγ2	O
(	E-geneY
PPARG	O
)	E-geneY
and	O
FABP4	O
mRNA	O
,	O
indicating	O
formation	O
of	O
adipocytes	O
,	O
whereas	O
higher	O
concentrations	O
(	O
≥	O
10⁻⁹	O
M	O
)	O
reduced	O
all	O
these	O
effects	O
,	O
and	O
the	O
highest	O
concentration	O
(	O
10⁻⁵	O
M	O
)	O
appeared	O
to	O
have	O
toxic	O
effects	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
dose	O
-	O
dependent	O
effects	O
of	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
₂D₃	E-chem
on	O
the	O
transdifferentiation	O
of	O
muscle	O
cells	O
into	O
adipose	O
cells	O
.	O

Low	O
physiological	O
concentrations	O
(	O
possibly	O
mimicking	O
a	O
deficient	O
state	O
)	O
induced	O
adipogenesis	O
,	O
whereas	O
higher	O
(	O
physiological	O
and	O
supraphysiological	O
)	O
concentrations	O
attenuated	O
this	O
effect	O
.	O

Selective	O
antagonism	O
of	O
GluR5	S-geneY-C6-2
kainate	B-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
-	O
mediated	O
synaptic	O
currents	O
by	O
topiramate	S-chem-C6-1
in	O
rat	O
basolateral	O
amygdala	O
neurons	O
.	O

Topiramate	S-chem
is	O
a	O
widely	O
used	O
antiepileptic	O
agent	O
whose	O
mechanism	O
of	O
action	O
is	O
poorly	O
understood	O
.	O

The	O
drug	O
has	O
been	O
reported	O
to	O
interact	O
with	O
various	O
ion	B-geneN
channel	E-geneN
types	O
,	O
including	O
AMPA	B-geneN
/	I-geneN
kainate	I-geneN
receptors	E-geneN
.	O

In	O
whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
recordings	O
from	O
principal	O
neurons	O
of	O
the	O
rat	O
basolateral	O
amygdala	O
,	O
topiramate	S-chem-C4-1
at	O
low	O
concentrations	O
(	O
IC50	O
,	O
approximately	O
0.5	O
microm	O
)	O
selectively	O
inhibited	O
pharmacologically	O
isolated	O
excitatory	O
synaptic	O
currents	O
mediated	O
by	O
kainate	B-geneN-C4-2
receptors	E-geneN-C4-2
containing	O
the	O
GluR5	S-geneY-C4-2
subunit	O
.	O

Topiramate	S-chem-C4-1
also	O
partially	O
depressed	O
predominantly	O
AMPA	B-geneN-C4-2
-	I-geneN-C4-2
receptor	E-geneN-C4-2
-	O
mediated	O
EPSCs	O
,	O
but	O
with	O
lower	O
efficacy	O
.	O

Topiramate	S-chem
did	O
not	O
alter	O
the	O
degree	O
of	O
facilitation	O
in	O
paired	O
-	O
pulse	O
experiments	O
,	O
and	O
it	O
reduced	O
the	O
amplitude	O
of	O
miniature	O
EPSCs	O
without	O
affecting	O
their	O
frequency	O
,	O
demonstrating	O
that	O
the	O
block	O
of	O
synaptic	O
responses	O
occurs	O
postsynaptically	O
.	O

Inhibition	O
of	O
GluR5	S-geneY-C4-2
kainate	B-geneN-C4-2
receptors	E-geneN-C4-2
could	O
represent	O
a	O
key	O
mechanism	O
underlying	O
the	O
anticonvulsant	O
activity	O
of	O
topiramate	S-chem-C4-1
.	O

Moreover	O
,	O
these	O
results	O
support	O
the	O
concept	O
that	O
GluR5	S-geneY
kainate	B-geneN
receptors	E-geneN
represent	O
a	O
novel	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O

Inverted	O
CdSe	S-chem
/	O
CdS	S-chem
/	O
ZnS	S-chem
quantum	O
dot	O
light	O
emitting	O
devices	O
with	O
titanium	B-chem
dioxide	E-chem
as	O
an	O
electron	O
-	O
injection	O
contact	O
.	O

We	O
demonstrated	O
the	O
fabrication	O
of	O
inverted	O
CdSe	S-chem
/	O
CdS	S-chem
/	O
ZnS	S-chem
quantum	O
dot	O
light	O
emitting	O
devices	O
(	O
QD	O
-	O
LEDs	O
)	O
using	O
titanium	B-chem
dioxide	E-chem
(	O
TiO2	S-chem
)	O
as	O
an	O
electron	O
-	O
injection	O
layer	O
and	O
investigated	O
the	O
operating	O
mechanism	O
by	O
utilizing	O
different	O
hole	O
-	O
transport	O
materials	O
,	O
4,4	B-chem
-	I-chem
N	I-chem
,	I-chem
N	I-chem
-	I-chem
dicarbazole	I-chem
-	I-chem
biphenyl	E-chem
(	O
CBP	S-chem
)	O
and	O
4,4',4	B-chem
'	I-chem
'	I-chem
-	I-chem
tris	I-chem
(	I-chem
carbazol	I-chem
-	I-chem
9	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
triphenylamine	E-chem
(	O
TCTA	S-chem
)	O
.	O

A	O
more	O
efficient	O
device	O
with	O
CBP	O
as	O
the	O
hole	O
-	O
transport	O
layer	O
(	O
HTL	O
)	O
was	O
obtained	O
compared	O
with	O
the	O
TCTA	S-chem
based	O
device	O
.	O

The	O
peak	O
efficiency	O
of	O
6.70	O
cd	O
A	O
(	O
-	O
1	O
)	O
for	O
the	O
CBP	O
based	O
device	O
was	O
found	O
to	O
be	O
about	O
74.5	O
%	O
higher	O
than	O
the	O
TCTA	S-chem
based	O
device	O
(	O
3.84	O
cd	O
A	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
studies	O
on	O
the	O
time	O
-	O
resolved	O
photoluminescence	O
spectra	O
of	O
the	O
QD	O
-	O
HTL	O
composite	O
structures	O
showed	O
that	O
the	O
energy	O
transfer	O
(	O
ET	O
)	O
efficiencies	O
from	O
the	O
two	O
HTLs	O
to	O
the	O
QD	O
layer	O
were	O
similar	O
and	O
the	O
charge	O
separation	O
between	O
QDs	O
and	O
HTLs	O
could	O
be	O
neglected	O
.	O

The	O
enhancement	O
in	O
the	O
performance	O
of	O
the	O
CBP	O
based	O
device	O
was	O
attributed	O
to	O
the	O
more	O
efficient	O
hole	O
-	O
injection	O
from	O
CBP	O
to	O
QDs	O
.	O

Lithium	S-chem
modulates	O
desensitization	O
of	O
the	O
glutamate	B-geneN
receptor	E-geneN
subtype	O
gluR3	S-geneY
in	O
Xenopus	O
oocytes	O
.	O

Analysis	O
of	O
splice	O
variants	O
and	O
site	O
-	O
directed	O
mutants	O
of	O
the	O
AMPA	B-geneN
receptor	E-geneN
GluR3	S-geneY
expressed	O
in	O
Xenopus	O
oocytes	O
has	O
shown	O
that	O
lithium	S-chem-C3-1
produces	O
a	O
large	O
potentiation	O
of	O
the	O
GluR3	B-geneY-C3-2
flop	E-geneY-C3-2
splice	O
variant	O
and	O
suggested	O
that	O
lithium	S-chem-C3-1
might	O
inhibit	O
rapid	O
desensitization	O
,	O
which	O
is	O
characteristic	O
of	O
this	O
receptor	O
(	O
Karkanias	O
,	O
N.	O
and	O
Papke	O
,	O
R.	O
,	O
Subtype	O
-	O
specific	O
effects	O
of	O
lithium	S-chem
on	O
glutamate	B-geneN
receptor	E-geneN
function	O
.	O

J	O
.	O

Neurophysiol	O
.	O
,	O
81	O
(	O
1999	O
)	O
1506	O
-	O
1512	O
)	O
.	O

We	O
now	O
show	O
that	O
mutation	O
of	O
the	O
769R	O
/	O
G	O
desensitization	O
site	O
(	O
Lomeli	O
,	O
H.M.J	O
.	O
,	O
Melcher	O
,	O
T.	O
,	O
Hoger	O
,	O
T.	O
,	O
Geiger	O
,	O
J.R.	O
,	O
Kuner	O
,	O
T.	O
,	O
Monyer	O
,	O
H.	O
,	O
Higuchi	O
,	O
M.B.A.	O
and	O
Seeburg	O
,	O
P.H	O
,	O
Control	O
of	O
kinetic	O
properties	O
of	O
AMPA	B-geneN
receptor	E-geneN
channels	O
by	O
nuclear	O
RNA	O
editing	O
.	O

Science	O
,	O
9	O
(	O
266	O
)	O
(	O
1994	O
)	O
1709	O
-	O
1713	O
)	O
greatly	O
attenuates	O
the	O
lithium	S-chem-C3-1
-	O
induced	O
potentiation	O
of	O
GluR3	S-geneY-C3-2
.	O

Additionally	O
,	O
experiments	O
with	O
the	O
non	O
-	O
desensitizing	O
site	O
-	O
directed	O
mutant	O
GluR3	S-geneY
(	O
L507Y	S-geneN
)	O
(	O
Stern	O
-	O
Bach	O
,	O
Y.	O
,	O
Russo	O
,	O
S.	O
,	O
Neuman	O
,	O
M.	O
and	O
Rosenmund	O
,	O
C.	O
,	O
A	O
point	O
mutation	O
in	O
the	O
glutamate	S-chem
binding	O
site	O
blocks	O
desensitization	O
of	O
AMPA	B-geneN
receptors	E-geneN
.	O

Neuron	O
,	O
21	O
(	O
1998	O
)	O
907	O
-	O
918	O
)	O
further	O
confirms	O
that	O
lithium	S-chem-C3-1
enhances	O
GluR3	S-geneY-C3-2
responses	O
by	O
reducing	O
desensitization	O
,	O
since	O
lithium	O
's	O
effects	O
are	O
reversed	O
in	O
this	O
mutant	O
.	O

Lithium	O
's	O
effects	O
on	O
GluR3	S-geneY
desensitization	O
are	O
distinct	O
from	O
the	O
effects	O
of	O
aniracetam	S-chem
on	O
desensitization	O
.	O

Specifically	O
,	O
aniracetam	S-chem-C3-1
,	O
which	O
potentiates	O
wild	O
-	O
type	O
AMPA	B-geneN-C3-2
receptors	E-geneN-C3-2
,	O
is	O
ineffective	O
on	O
the	O
non	O
-	O
desensitizing	O
GluR3	S-geneY-C3-2
(	O
L507Y	S-geneN-C3-2
)	O
mutant	O
,	O
but	O
has	O
synergistic	O
effects	O
with	O
lithium	S-chem-C3-1
on	O
wild	O
-	O
type	O
receptors	O
.	O

Aldose	B-geneY
Reductase	E-geneY
Inhibitory	O
Compounds	O
from	O
Xanthium	O
strumarium	O
.	O

As	O
part	O
of	O
our	O
ongoing	O
search	O
for	O
natural	O
sources	O
of	O
therapeutic	O
and	O
preventive	O
agents	O
for	O
diabetic	O
complications	O
,	O
we	O
evaluated	O
the	O
inhibitory	O
effects	O
of	O
components	O
of	O
the	O
fruit	O
of	O
Xanthium	O
strumarium	O
(	O
X.	O
strumarium	O
)	O
on	O
aldose	B-geneY
reductase	E-geneY
(	O
AR	S-geneY
)	O
and	O
galactitol	S-chem
formation	O
in	O
rat	O
lenses	O
with	O
high	O
levels	O
of	O
glucose	S-chem
.	O

To	O
identify	O
the	O
bioactive	O
components	O
of	O
X.	O
strumarium	O
,	O
7	O
caffeoylquinic	B-chem
acids	E-chem
and	O
3	O
phenolic	S-chem
compounds	O
were	O
isolated	O
and	O
their	O
chemical	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	O
evidence	O
and	O
comparison	O
with	O
published	O
data	O
.	O

The	O
abilities	O
of	O
10	O
X.	O
strumarium	O
-	O
derived	O
components	O
to	O
counteract	O
diabetic	O
complications	O
were	O
investigated	O
by	O
means	O
of	O
inhibitory	O
assays	O
with	O
rat	B-geneY
lens	I-geneY
AR	E-geneY
(	O
rAR	S-geneY
)	O
and	O
recombinant	O
human	B-geneY
AR	E-geneY
(	O
rhAR	S-geneY
)	O
.	O

From	O
the	O
10	O
isolated	O
compounds	O
,	O
methyl	B-chem-C4-1
-	I-chem-C4-1
3,5	I-chem-C4-1
-	I-chem-C4-1
di	I-chem-C4-1
-	I-chem-C4-1
O	I-chem-C4-1
-	I-chem-C4-1
caffeoylquinate	E-chem-C4-1
showed	O
the	O
most	O
potent	O
inhibition	O
,	O
with	O
IC50	O
values	O
of	O
0.30	O
and	O
0.67	O
μM	O
for	O
rAR	O
and	O
rhAR	O
,	E-geneY-C4-2
respectively	O
.	O

In	O
the	O
kinetic	O
analyses	O
using	O
Lineweaver	O
-	O
Burk	O
plots	O
of	O
1	O
/	O
velocity	O
and	O
1	O
/	O
substrate	O
,	O
methyl	B-chem-C4-1
-	I-chem-C4-1
3,5	I-chem-C4-1
-	I-chem-C4-1
di	I-chem-C4-1
-	I-chem-C4-1
O	I-chem-C4-1
-	I-chem-C4-1
caffeoylquinate	E-chem-C4-1
showed	O
competitive	O
inhibition	O
of	O
rhAR	S-geneY-C4-2
.	O

Furthermore	O
,	O
methyl	B-chem
-	I-chem
3,5	I-chem
-	I-chem
di	I-chem
-	I-chem
O	I-chem
-	I-chem
caffeoylquinate	E-chem
inhibited	O
galactitol	S-chem
formation	O
in	O
the	O
rat	O
lens	O
and	O
in	O
erythrocytes	O
incubated	O
with	O
a	O
high	O
concentration	O
of	O
glucose	S-chem
,	O
indicating	O
that	O
this	O
compound	O
may	O
be	O
effective	O
in	O
preventing	O
diabetic	O
complications	O
.	O

Tyrosinase	S-geneY-C9-2
catalyzes	O
an	O
unusual	O
oxidative	O
decarboxylation	O
of	O
3,4	B-chem-C9-1
-	I-chem-C9-1
dihydroxymandelate	E-chem-C9-1
.	O

Tyrosinase	S-geneY-C9-2
usually	O
catalyzes	O
the	O
conversion	O
of	O
monophenols	S-chem-C9-1
to	O
o	O
-	O
diphenols	O
and	O
oxidation	O
of	O
diphenols	S-chem-C9-1
to	O
the	O
corresponding	O
quinones	O
.	O

However	O
,	O
when	O
3,4	B-chem
-	I-chem
dihydroxymandelic	I-chem
acid	E-chem
was	O
provided	O
as	O
the	O
substrate	O
,	O
it	O
catalyzed	O
an	O
unusual	O
oxidative	O
decarboxylation	O
reaction	O
generating	O
3,4	B-chem
-	I-chem
dihydroxybenzaldehyde	E-chem
as	O
the	O
sole	O
product	O
.	O

The	O
identity	O
of	O
the	O
product	O
was	O
confirmed	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
as	O
well	O
as	O
ultraviolet	O
and	O
infrared	O
spectral	O
studies	O
.	O

None	O
of	O
the	O
following	O
enzymes	O
tested	O
catalyzed	O
the	O
new	O
reaction	O
:	O
galactose	B-geneN
oxidase	E-geneN
,	O
ceruloplasmin	S-geneY
,	O
superoxide	B-geneN
dismutase	E-geneN
,	O
ascorbate	B-geneN
oxidase	E-geneN
,	O
dopamine	B-geneY
beta	I-geneY
-	I-geneY
hydroxylase	E-geneY
,	O
and	O
peroxidase	S-geneN
.	O

Phenol	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitors	O
such	O
as	O
phenylthiourea	S-chem-C4-1
,	O
potassium	B-chem-C4-1
cyanide	E-chem-C4-1
,	O
and	O
sodium	B-chem-C4-1
azide	E-chem-C4-1
inhibited	O
the	O
reaction	O
drastically	O
,	O
suggesting	O
the	O
participation	O
of	O
the	O
active	O
site	O
copper	S-chem
of	O
the	O
enzyme	O
in	O
the	O
catalysis	O
.	O

Mimosine	S-chem-C4-1
,	O
a	O
well	O
-	O
known	O
competitive	O
inhibitor	O
of	O
tyrosinase	S-geneY-C4-2
,	O
competitively	O
inhibited	O
the	O
new	O
reaction	O
also	O
.	O

4	B-chem
-	I-chem
Hydroxymandelic	I-chem
acid	E-chem
and	O
3	B-chem
-	I-chem
methoxy	I-chem
-	I-chem
4	I-chem
-	I-chem
hydroxymandelic	I-chem
acid	E-chem
neither	O
served	O
as	O
substrates	O
nor	O
inhibited	O
the	O
reaction	O
.	O

Putative	O
intermediates	O
such	O
as	O
3,4	B-chem
-	I-chem
dihydroxybenzyl	I-chem
alcohol	E-chem
and	O
(	B-chem
3,4	I-chem
-	I-chem
dihydroxybenzoyl	I-chem
)	I-chem
formic	I-chem
acid	E-chem
did	O
not	O
accumulate	O
during	O
the	O
reaction	O
.	O

Oxidation	O
to	O
a	O
quinone	B-chem
methide	E-chem
derivative	O
rather	O
than	O
conventional	O
quinone	S-chem
accounts	O
for	O
this	O
unusual	O
oxidative	O
decarboxylation	O
reaction	O
.	O

Earlier	O
from	O
this	O
laboratory	O
,	O
we	O
reported	O
the	O
conversion	O
of	O
4	B-chem
-	I-chem
alkylcatechols	E-chem
to	O
quinone	B-chem
methides	E-chem
catalyzed	O
by	O
a	O
cuticular	O
phenol	S-chem
oxidase	O
[	O
Sugumaran	O
,	O
M.	O
,	O
&	O
Lipke	O
,	O
H	O
.	O

(	O
1983	O
)	O
FEBS	O
Lett	O
.	O

155	O
,	O
65	O
-	O
68	O
]	O
.	O

Present	O
studies	O
demonstrate	O
that	O
mushroom	B-geneN-C9-2
tyrosinase	E-geneN-C9-2
will	O
also	O
catalyze	O
quinone	B-chem-C9-1
methide	E-chem-C9-1
production	O
with	O
the	O
same	O
active	O
site	O
copper	O
if	O
a	O
suitable	O
substrate	O
such	O
as	O
3,4	B-chem-C9-1
-	I-chem-C9-1
dihydroxymandelic	I-chem-C9-1
acid	E-chem-C9-1
is	O
provided	O
.	O

Genomic	O
variation	O
in	O
the	O
MAP3K5	S-geneY
gene	O
is	O
associated	O
with	O
β	O
-	O
thalassemia	O
disease	O
severity	O
and	O
hydroxyurea	S-chem
treatment	O
efficacy	O
.	O

Aim	O
:	O
In	O
this	O
study	O
we	O
explored	O
the	O
association	O
between	O
genetic	O
variations	O
in	O
MAP3K5	S-geneY
and	O
PDE7B	S-geneY
genes	O
,	O
residing	O
on	O
chromosome	O
6q23	O
,	O
and	O
disease	O
severity	O
in	O
β	O
-	O
hemoglobinopathy	O
patients	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
these	O
variants	O
with	O
response	O
to	O
hydroxyurea	S-chem
(	O
HU	O
)	O
treatment	O
.	O

Furthermore	O
,	O
we	O
examined	O
MAP3K5	S-geneY
expression	O
in	O
the	O
context	O
of	O
high	O
fetal	O
hemoglobin	O
(	O
HbF	O
)	O
and	O
upon	O
HU	O
treatment	O
in	O
erythroid	O
progenitor	O
cells	O
from	O
healthy	O
and	O
KLF1	O
haploinsufficient	O
individuals	O
.	O

Materials	O
&	O
methods	O
:	O
For	O
this	O
purpose	O
,	O
we	O
genotyped	O
β	O
-	O
thalassemia	O
intermedia	O
and	O
major	O
patients	O
and	O
healthy	O
controls	O
,	O
as	O
well	O
as	O
a	O
cohort	O
of	O
compound	O
heterozygous	O
sickle	O
cell	O
disease	O
/	O
β	O
-	O
thalassemia	O
patients	O
receiving	O
HU	O
as	O
HbF	O
augmentation	O
treatment	O
.	O

Furthermore	O
,	O
we	O
examined	O
MAP3K5	S-geneY
expression	O
in	O
the	O
context	O
of	O
high	O
HbF	O
and	O
upon	O
HU	O
treatment	O
in	O
erythroid	O
progenitor	O
cells	O
from	O
healthy	O
and	O
KLF1	O
haploinsufficient	O
individuals	O
.	O

Results	O
:	O
A	O
short	O
tandem	O
repeat	O
in	O
the	O
MAP3K5	B-geneN
promoter	E-geneN
and	O
two	O
intronic	O
MAP3K5	S-geneY
gene	O
variants	O
,	O
as	O
well	O
as	O
a	O
PDE7B	S-geneY
variant	O
,	O
are	O
associated	O
with	O
low	O
HbF	O
levels	O
and	O
a	O
severe	O
disease	O
phenotype	O
.	O

Moreover	O
,	O
MAP3K5	S-geneY
mRNA	O
expression	O
levels	O
are	O
altered	O
in	O
the	O
context	O
of	O
high	O
HbF	O
and	O
are	O
affected	O
by	O
the	O
presence	O
of	O
HU	O
.	O

Lastly	O
,	O
the	O
abovementioned	O
MAP3K5	S-geneY
variants	O
are	O
associated	O
with	O
HU	O
treatment	O
efficacy	O
.	O

Conclusion	O
:	O
Our	O
data	O
suggest	O
that	O
these	O
MAP3K5	S-geneY
variants	O
are	O
indicative	O
of	O
β	O
-	O
thalassemia	O
disease	O
severity	O
and	O
response	O
to	O
HU	O
treatment	O
.	O

Original	O
submitted	O
24	O
September	O
2012	O
;	O
Revision	O
submitted	O
4	O
February	O
2013	O
.	O

Comparison	O
of	O
ophthalmic	O
beta	O
-	O
blocking	O
agents	O
.	O

Glaucoma	O
is	O
described	O
,	O
and	O
the	O
chemistry	O
,	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
adverse	O
effects	O
,	O
and	O
dosage	O
and	O
administration	O
of	O
betaxolol	S-chem
and	O
levobunolol	S-chem
in	O
comparison	O
with	O
timolol	S-chem
are	O
reviewed	O
.	O

Betaxolol	S-chem
and	O
levobunolol	S-chem
are	O
two	O
beta	O
-	O
adrenergic	O
blocking	O
agents	O
being	O
marketed	O
as	O
ophthalmic	O
solutions	O
for	O
treatment	O
of	O
primary	O
open	O
-	O
angle	O
glaucoma	O
(	O
POAG	O
)	O
and	O
ocular	O
hypertension	O
(	O
OHT	O
)	O
.	O

Betaxolol	S-chem
is	O
a	O
relatively	O
cardioselective	O
beta	O
-	O
adrenergic	O
blocker	O
,	O
while	O
levobunolol	S-chem
is	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
.	O

Double	O
-	O
blind	O
comparative	O
trials	O
have	O
suggested	O
that	O
betaxolol	S-chem
has	O
an	O
equal	O
to	O
slightly	O
lower	O
efficacy	O
and	O
levobunolol	S-chem
has	O
equal	O
efficacy	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
compared	O
with	O
timolol	S-chem
,	O
the	O
first	O
ophthalmic	O
beta	O
blocker	O
.	O

A	O
mean	O
reduction	O
in	O
intraocular	O
pressure	O
of	O
15	O
-	O
35	O
%	O
occurs	O
with	O
both	O
betaxolol	S-chem
and	O
levobunolol	S-chem
and	O
is	O
reported	O
to	O
be	O
maintained	O
with	O
prolonged	O
use	O
.	O

Betaxolol	S-chem
is	O
associated	O
with	O
a	O
higher	O
(	O
25	O
%	O
)	O
incidence	O
of	O
local	O
ocular	O
adverse	O
reactions	O
than	O
timolol	S-chem
.	O

However	O
,	O
betaxolol	S-chem-C4-1
produces	O
less	O
systemic	O
beta	O
2	O
-	O
and	O
possibly	O
beta	B-geneY-C4-2
1	I-geneY-C4-2
-	I-geneY-C4-2
adrenergic	I-geneY-C4-2
receptor	E-geneY-C4-2
blockade	O
than	O
either	O
timolol	S-chem-C4-1
or	O
levobunolol	S-chem-C4-1
.	O

Betaxolol	S-chem
may	O
be	O
relatively	O
safer	O
to	O
use	O
in	O
patients	O
with	O
reactive	O
airway	O
disease	O
than	O
either	O
timolol	S-chem
or	O
levobunolol	S-chem
.	O

Levobunolol	S-chem
causes	O
a	O
similar	O
to	O
greater	O
incidence	O
of	O
local	O
ocular	O
adverse	O
reactions	O
and	O
similar	O
systemic	O
beta	O
blockade	O
compared	O
with	O
timolol	S-chem
.	O

Levobunolol	S-chem
may	O
possibly	O
be	O
longer	O
acting	O
than	O
timolol	S-chem
,	O
allowing	O
more	O
patients	O
to	O
be	O
controlled	O
by	O
once	O
-	O
daily	O
dosing	O
.	O

Betaxolol	S-chem
and	O
levobunolol	S-chem
appear	O
to	O
be	O
similar	O
to	O
timolol	S-chem
in	O
controlling	O
IOP	O
in	O
patients	O
with	O
POAG	O
and	O
OHT	O
;	O
additional	O
experience	O
with	O
these	O
agents	O
is	O
needed	O
to	O
assess	O
the	O
advantages	O
and	O
disadvantages	O
of	O
each	O
agent	O
.	O

Fulvestrant	S-chem
:	O
a	O
unique	O
antiendocrine	O
agent	O
for	O
estrogen	S-chem
-	O
sensitive	O
breast	O
cancer	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
The	O
role	O
of	O
estrogen	S-chem
deprivation	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
has	O
been	O
understood	O
since	O
the	O
1800s	O
.	O

Pharmacologic	O
advances	O
in	O
the	O
field	O
in	O
the	O
past	O
decades	O
,	O
including	O
tamoxifen	S-chem
and	O
the	O
aromatase	S-geneY
inhibitors	O
,	O
have	O
contributed	O
significantly	O
to	O
the	O
reduced	O
mortality	O
of	O
estrogen	S-chem
-	O
sensitive	O
breast	O
cancer	O
.	O

However	O
,	O
this	O
subtype	O
of	O
breast	O
cancer	O
still	O
presents	O
with	O
relapses	O
and	O
,	O
once	O
metastatic	O
,	O
progression	O
to	O
hormone	O
-	O
refractory	O
state	O
and	O
loss	O
of	O
disease	O
control	O
remain	O
an	O
expected	O
disease	O
course	O
.	O

Fulvestrant	S-chem-C4-1
,	O
a	O
pure	O
estrogen	B-geneY-C4-2
receptor	E-geneY-C4-2
downregulator	O
,	O
is	O
a	O
new	O
addition	O
to	O
the	O
antiestrogen	O
therapeutic	O
armamentarium	O
since	O
its	O
FDA	O
approval	O
in	O
2002	O
.	O

Its	O
unique	O
mechanism	O
of	O
action	O
offers	O
potential	O
advantages	O
over	O
other	O
estrogen	S-chem
targeted	O
therapies	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
Published	O
scientific	O
literature	O
,	O
including	O
presented	O
abstracts	O
,	O
on	O
fulvestrant	S-chem
from	O
1985	O
to	O
the	O
present	O
were	O
reviewed	O
with	O
selected	O
publications	O
included	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
This	O
review	O
addresses	O
current	O
issues	O
and	O
therapies	O
for	O
estrogen	S-chem
-	O
sensitive	O
breast	O
cancer	O
,	O
highlights	O
the	O
role	O
of	O
fulvestrant	S-chem
in	O
current	O
treatment	O
guidelines	O
and	O
outlines	O
some	O
of	O
the	O
ongoing	O
investigations	O
of	O
this	O
compound	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Fulvestrant	S-chem
is	O
an	O
effective	O
and	O
well	O
-	O
tolerated	O
drug	O
for	O
treatment	O
of	O
metastatic	O
estrogen	S-chem
-	O
sensitive	O
breast	O
cancer	O
.	O

Work	O
is	O
underway	O
to	O
enhance	O
its	O
clinical	O
benefit	O
to	O
patients	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
other	O
therapies	O
.	O

Charge	O
screening	O
between	O
anionic	O
and	O
cationic	O
surfactants	O
in	O
ionic	O
liquids	O
.	O

The	O
aggregation	O
and	O
interfacial	O
behavior	O
of	O
mixtures	O
of	O
anionic	O
(	O
sodium	B-chem
dodecylsulfate	E-chem
,	O
SDS	S-chem
)	O
and	O
cationic	O
(	O
dodecylammonium	B-chem
bromide	E-chem
,	O
DTAB	S-chem
)	O
surfactants	O
were	O
investigated	O
.	O

A	O
room	O
-	O
temperature	O
ionic	O
liquid	O
(	O
IL	O
)	O
was	O
explored	O
as	O
a	O
solvent	O
for	O
the	O
SDS	S-chem
/	O
DTAB	S-chem
system	O
and	O
compared	O
to	O
water	O
.	O

The	O
critical	O
micelle	O
concentration	O
(	O
cmc	O
)	O
and	O
composition	O
in	O
mixed	O
micelles	O
were	O
determined	O
for	O
both	O
solvents	O
.	O

Our	O
experiments	O
showed	O
nearly	O
ideal	O
mixing	O
of	O
SDS	S-chem
/	O
DTAB	S-chem
over	O
the	O
entire	O
composition	O
range	O
and	O
suggest	O
that	O
charge	O
screening	O
is	O
prominent	O
in	O
ILs	O
.	O

This	O
behavior	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
strong	O
electrostatic	O
attraction	O
and	O
a	O
multiphase	O
composition	O
gap	O
in	O
water	O
.	O

Two	O
models	O
by	O
Clint	O
and	O
Rubingh	O
,	O
which	O
describe	O
ideal	O
and	O
nonideal	O
micellar	O
behavior	O
,	O
respectively	O
,	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
our	O
results	O
.	O

According	O
to	O
Rubingh	O
's	O
model	O
,	O
the	O
composition	O
of	O
mixed	O
micelles	O
is	O
gradually	O
changing	O
with	O
the	O
bulk	O
composition	O
in	O
ILs	O
but	O
tends	O
to	O
be	O
a	O
1	O
:	O
1	O
ratio	O
in	O
water	O
.	O

The	O
results	O
here	O
are	O
further	O
support	O
of	O
the	O
strong	O
charge	O
screening	O
in	O
ionic	O
liquids	O
.	O

Quercetin	S-chem
reduces	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
fat	O
accumulation	O
in	O
the	O
liver	O
by	O
regulating	O
lipid	O
metabolism	O
genes	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
influence	O
of	O
quercetin	S-chem
on	O
the	O
physiological	O
effects	O
of	O
hyperlipidemia	O
,	O
we	O
investigated	O
its	O
role	O
in	O
the	O
prevention	O
of	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
obesity	O
and	O
found	O
that	O
it	O
regulated	O
hepatic	O
gene	O
expression	O
related	O
to	O
lipid	O
metabolism	O
.	O

Quercetin	S-chem
supplementation	O
in	O
mice	O
significantly	O
reduced	O
the	O
HFD	O
-	O
induced	O
gains	O
in	O
body	O
weight	O
,	O
liver	O
weight	O
,	O
and	O
white	O
adipose	O
tissue	O
weight	O
compared	O
with	O
the	O
mice	O
fed	O
only	O
with	O
HFD	O
.	O

It	O
also	O
significantly	O
reduced	O
HFD	O
-	O
induced	O
increases	O
in	O
serum	O
lipids	O
,	O
including	O
cholesterol	S-chem
,	O
triglyceride	S-chem
,	O
and	O
thiobarbituric	B-chem
acid	E-chem
-	O
reactive	O
substance	O
(	O
TBARS	O
)	O
.	O

Consistent	O
with	O
the	O
reduced	O
liver	O
weight	O
and	O
white	O
adipose	O
tissue	O
weight	O
,	O
hepatic	O
lipid	O
accumulation	O
and	O
the	O
size	O
of	O
lipid	O
droplets	O
in	O
the	O
epididymal	O
fat	O
pads	O
were	O
also	O
reduced	O
by	O
quercetin	S-chem
supplementation	O
.	O

To	O
further	O
investigate	O
how	O
quercetin	S-chem
may	O
reduce	O
obesity	O
,	O
we	O
analyzed	O
lipid	O
metabolism	O
-	O
related	O
genes	O
in	O
the	O
liver	O
.	O

Quercetin	S-chem
supplementation	O
altered	O
expression	O
profiles	O
of	O
several	O
lipid	O
metabolism	O
-	O
related	O
genes	O
,	O
including	O
Fnta	S-geneY
,	O
Pon1	S-geneY
,	O
Pparg	S-geneY
,	O
Aldh1b1	S-geneY
,	O
Apoa4	S-geneY
,	O
Abcg5	S-geneY
,	O
Gpam	S-geneY
,	O
Acaca	S-geneY
,	O
Cd36	S-geneY
,	O
Fdft1	S-geneY
,	O
and	O
Fasn	S-geneY
,	O
relative	O
to	O
those	O
in	O
HFD	O
control	O
mice	O
.	O

The	O
expression	O
patterns	O
of	O
these	O
genes	O
observed	O
by	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
were	O
confirmed	O
by	O
immunoblot	O
assays	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
quercetin	S-chem
prevents	O
HFD	O
-	O
induced	O
obesity	O
in	O
C57B1	O
/	O
6	O
mice	O
,	O
and	O
its	O
anti	O
-	O
obesity	O
effects	O
may	O
be	O
related	O
to	O
the	O
regulation	O
of	O
lipogenesis	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Identification	O
of	O
the	O
regulatory	O
region	O
of	O
the	O
L	B-geneY
-	I-geneY
type	I-geneY
pyruvate	I-geneY
kinase	E-geneY
gene	O
in	O
mouse	O
liver	O
by	O
hydrodynamics	O
-	O
based	O
gene	O
transfection	O
.	O

Expression	O
of	O
L	B-geneY-C3-2
-	I-geneY-C3-2
type	I-geneY-C3-2
pyruvate	I-geneY-C3-2
kinase	E-geneY-C3-2
(	O
L	B-geneY-C3-2
-	I-geneY-C3-2
PK	E-geneY-C3-2
)	O
is	O
upregulated	O
in	O
the	O
liver	O
by	O
dietary	O
carbohydrate	S-chem-C3-1
.	O

Previously	O
,	O
3	O
carbohydrate	B-geneN
/	I-geneN
insulin	I-geneN
response	I-geneN
elements	E-geneN
were	O
identified	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
L	B-geneY
-	I-geneY
PK	E-geneY
gene	O
up	O
to	O
bp	O
-	O
170	O
.	O

Studies	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
beyond	O
bp	O
-	O
183	O
in	O
transgenic	O
mice	O
suggested	O
that	O
other	O
regulatory	O
elements	O
may	O
be	O
present	O
upstream	O
of	O
bp	O
-	O
183	O
,	O
but	O
the	O
positions	O
of	O
these	O
elements	O
were	O
uncertain	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
existence	O
of	O
regulatory	O
regions	O
of	O
the	O
L	B-geneY
-	I-geneY
PK	E-geneY
gene	O
responding	O
to	O
stimulation	O
by	O
feeding	O
was	O
examined	O
using	O
in	O
vivo	O
hydrodynamics	O
-	O
based	O
gene	O
transfection	O
(	O
HT	O
)	O
in	O
mouse	O
liver	O
.	O

The	O
firefly	O
-	O
luciferase	O
(	O
FL	O
)	O
gene	O
,	O
fused	O
with	O
various	O
lengths	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
L	B-geneY
-	I-geneY
PK	E-geneY
gene	O
,	O
was	O
introduced	O
into	O
mouse	O
liver	O
by	O
HT	O
.	O

The	O
mice	O
had	O
free	O
access	O
to	O
a	O
high	O
-	O
carbohydrate	S-chem
diet	O
.	O

In	O
liver	O
homogenate	O
,	O
luciferase	O
activity	O
of	O
pL	O
-	I-geneY
PK	E-geneY
(	O
-	O
1467	O
)	O
-	O
FL	O
(	O
which	O
included	O
the	O
5	O
'	O
-	O
flanking	O
region	O
from	O
bp	O
-	O
1467	O
to	O
+	O
17	O
)	O
,	O
was	O
markedly	O
stimulated	O
by	O
feeding	O
.	O

5	O
'	O
-	O
Deletion	O
up	O
to	O
bp	O
-	O
1065	O
caused	O
only	O
minor	O
changes	O
in	O
luciferase	O
activity	O
,	O
but	O
further	O
deletion	O
up	O
to	O
bp	O
-	O
690	O
and	O
bp	O
-	O
203	O
caused	O
significant	O
,	O
gradual	O
decreases	O
in	O
activity	O
.	O

Further	O
analyses	O
utilizing	O
5	O
'	O
-	O
deletion	O
mutants	O
indicated	O
the	O
existence	O
of	O
positive	O
regulatory	O
regions	O
that	O
respond	O
to	O
stimulation	O
by	O
feeding	O
between	O
bp	O
-	O
1065	O
and	O
-	O
945	O
,	O
and	O
between	O
-	O
300	O
and	O
-	O
203	O
on	O
the	O
L	B-geneY
-	I-geneY
PK	E-geneY
gene	O
.	O

These	O
results	O
suggest	O
that	O
unidentified	O
cis	B-geneN
-	I-geneN
acting	I-geneN
DNA	I-geneN
elements	E-geneN
exist	O
in	O
the	O
upstream	O
region	O
of	O
the	O
L	B-geneY
-	I-geneY
PK	E-geneY
gene	O
,	O
and	O
that	O
HT	O
is	O
a	O
useful	O
approach	O
for	O
detecting	O
regulatory	O
regions	O
of	O
genes	O
expressed	O
in	O
the	O
liver	O
.	O

Escitalopram	S-chem
.	O

Escitalopram	B-chem
oxalate	E-chem
(	O
S	B-chem
-	I-chem
citalopram	E-chem
,	O
Lexapro	S-chem
)	O
,	O
a	O
selective	O
serotonin	S-chem
re	O
-	O
uptake	O
inhibitor	O
antidepressant	O
which	O
is	O
the	O
S	B-chem
-	I-chem
enantiomer	I-chem
of	I-chem
citalopram	E-chem
,	O
is	O
in	O
clinical	O
development	O
worldwide	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
anxiety	O
disorders	O
.	O

Preclinical	O
studies	O
demonstrate	O
that	O
the	O
therapeutic	O
activity	O
of	O
citalopram	S-chem
resides	O
in	O
the	O
S	O
-	O
isomer	O
and	O
that	O
escitalopram	S-chem
binds	O
with	O
high	O
affinity	O
to	O
the	O
human	B-geneY
serotonin	I-geneY
transporter	E-geneY
.	O

Conversely	O
,	O
R	B-chem
-	I-chem
citalopram	E-chem
is	O
approximately	O
30	O
-	O
fold	O
less	O
potent	O
than	O
escitalopram	S-chem
at	O
this	O
transporter	O
.	O

Escitalopram	S-chem
has	O
linear	O
pharmacokinetics	O
,	O
so	O
that	O
plasma	O
levels	O
increase	O
proportionately	O
and	O
predictably	O
with	O
increased	O
doses	O
and	O
its	O
half	O
-	O
life	O
of	O
27	O
-	O
32	O
h	O
is	O
consistent	O
with	O
once	O
-	O
daily	O
dosing	O
.	O

In	O
addition	O
,	O
escitalopram	S-chem
has	O
negligible	O
effects	O
on	O
cytochrome	B-geneN
P450	E-geneN
drug	O
-	O
metabolising	O
enzymes	O
in	O
vitro	O
,	O
suggesting	O
a	O
low	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
.	O

The	O
efficacy	O
of	O
escitalopram	S-chem
in	O
patients	O
with	O
major	O
depressive	O
disorder	O
has	O
been	O
demonstrated	O
in	O
multiple	O
short	O
-	O
term	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trials	O
,	O
three	O
of	O
which	O
included	O
citalopram	S-chem
as	O
an	O
active	O
control	O
,	O
as	O
well	O
as	O
in	O
a	O
36	O
-	O
week	O
study	O
evaluating	O
efficacy	O
in	O
the	O
prevention	O
of	O
depression	O
relapse	O
.	O

In	O
these	O
studies	O
,	O
escitalopram	S-chem
was	O
shown	O
to	O
have	O
robust	O
efficacy	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
associated	O
symptoms	O
of	O
anxiety	O
relative	O
to	O
placebo	O
.	O

Efficacy	O
has	O
also	O
been	O
shown	O
in	O
treating	O
generalised	O
anxiety	O
disorder	O
,	O
panic	O
disorder	O
and	O
social	O
anxiety	O
disorder	O
.	O

Results	O
also	O
suggest	O
that	O
,	O
at	O
comparable	O
doses	O
,	O
escitalopram	S-chem
demonstrates	O
clinically	O
relevant	O
and	O
statistically	O
significant	O
superiority	O
to	O
placebo	O
treatment	O
earlier	O
than	O
citalopram	S-chem
.	O

Analysis	O
of	O
the	O
safety	O
database	O
shows	O
a	O
low	O
rate	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
,	O
and	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
escitalopram	S-chem
10	O
mg	O
/	O
day	O
and	O
placebo	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
early	O
because	O
of	O
adverse	O
events	O
.	O

The	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
escitalopram	S-chem
which	O
occurred	O
at	O
a	O
rate	O
greater	O
than	O
placebo	O
include	O
nausea	O
,	O
insomnia	O
,	O
ejaculation	O
disorder	O
,	O
diarrhoea	O
,	O
dry	O
mouth	O
and	O
somnolence	O
.	O

Only	O
nausea	O
occurred	O
in	O
>	O
10	O
%	O
of	O
escitalopram	S-chem
-	O
treated	O
patients	O
.	O

Expansion	O
of	O
the	O
Homeostasis	O
Model	O
Assessment	O
of	O
β	O
-	O
Cell	O
Function	O
and	O
Insulin	S-geneY
Resistance	O
to	O
Enable	O
Clinical	O
Trial	O
Outcome	O
Modeling	O
Through	O
the	O
Interactive	O
Adjustment	O
of	O
Physiology	O
and	O
Treatment	O
Effects	O
-	O
-	O
iHOMA2	O
.	O

OBJECTIVETo	O
describe	O
and	O
make	O
available	O
an	O
interactive	O
,	O
24	O
-	O
variable	O
homeostasis	O
model	O
assessment	O
(	O
iHOMA2	O
)	O
that	O
extends	O
the	O
HOMA2	O
model	O
,	O
enabling	O
the	O
modeling	O
of	O
physiology	O
and	O
treatment	O
effects	O
,	O
to	O
present	O
equations	O
of	O
the	O
HOMA2	O
and	O
iHOMA2	O
models	O
,	O
and	O
to	O
exemplify	O
iHOMA2	O
in	O
two	O
widely	O
differing	O
scenarios	O
:	O
changes	O
in	O
insulin	S-geneN
sensitivity	O
with	O
thiazolidinediones	S-chem
and	O
changes	O
in	O
renal	O
threshold	O
with	O
sodium	B-geneN
glucose	I-geneN
transporter	E-geneN
(	O
SGLT2	S-geneY
)	O
inhibition.RESEARCH	O
DESIGN	O
AND	O
METHODSiHOMA2	O
enables	O
a	O
user	O
of	O
the	O
available	O
software	O
to	O
examine	O
and	O
modify	O
the	O
mathematical	O
functions	O
describing	O
the	O
organs	O
and	O
tissues	O
involved	O
in	O
the	O
glucose	S-chem
and	O
hormonal	O
compartments	O
.	O

We	O
exemplify	O
this	O
with	O
SGLT2	S-geneY
inhibition	O
modeling	O
(	O
by	O
changing	O
the	O
renal	O
threshold	O
parameters	O
)	O
using	O
published	O
data	O
of	O
renal	O
effect	O
,	O
showing	O
that	O
the	O
modeled	O
effect	O
is	O
concordant	O
with	O
the	O
effects	O
on	O
fasting	O
glucose	S-chem
from	O
independent	O
data.RESULTSiHOMA2	O
modeling	O
of	O
thiazolidinediones	S-chem
effect	O
suggested	O
that	O
changes	O
in	O
insulin	O
sensitivity	O
in	O
the	O
fasting	O
state	O
are	O
predominantly	O
hepatic	O
.	O

SGLT2	S-geneY
inhibition	O
modeled	O
by	O
iHOMA2	O
resulted	O
in	O
a	O
decrease	O
in	O
mean	O
glucose	S-chem
of	O
1.1	O
mmol	O
/	O
L	O
.	O

Observed	O
data	O
showed	O
a	O
decrease	O
in	O
glucose	S-chem
of	O
0.9	O
mmol	O
/	O
L	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
model	O
and	O
the	O
independent	O
data	O
.	O

Manipulation	O
of	O
iHOMA2s	O
renal	O
excretion	O
threshold	O
variable	O
suggested	O
that	O
a	O
decrease	O
of	O
17	O
%	O
was	O
required	O
to	O
obtain	O
a	O
0.9	O
mmol	O
/	O
L	O
decrease	O
in	O
mean	O
glucose.CONCLUSIONSiHOMA2	S-chem
is	O
an	O
extended	O
mathematical	O
model	O
for	O
the	O
assessment	O
of	O
insulin	S-geneY
resistance	O
and	O
β	O
-	O
cell	O
function	O
.	O

The	O
model	O
can	O
be	O
used	O
to	O
evaluate	O
therapeutic	O
agents	O
and	O
predict	O
effects	O
on	O
fasting	O
glucose	S-chem
and	O
insulin	O
and	O
on	O
β	O
-	O
cell	O
function	O
and	O
insulin	S-geneY
sensitivity	O
.	O

Time	O
-	O
dependent	O
effects	O
of	O
corticosterone	S-chem
on	O
reward	O
-	O
based	O
decision	O
-	O
making	O
in	O
a	O
rodent	O
model	O
of	O
the	O
Iowa	O
Gambling	O
Task	O
.	O

Corticosteroid	O
hormones	O
,	O
released	O
after	O
stress	O
,	O
are	O
known	O
to	O
change	O
neuronal	O
activity	O
in	O
two	O
time	O
-	O
domains	O
:	O
within	O
minutes	O
via	O
non	O
-	O
genomic	O
pathways	O
and	O
with	O
a	O
delay	O
of	O
>	O
1	O
h	O
through	O
pathways	O
involving	O
transcriptional	O
regulation	O
.	O

Recent	O
evidence	O
in	O
rodents	O
and	O
humans	O
indicates	O
that	O
these	O
two	O
modes	O
of	O
corticosteroid	O
action	O
differently	O
affect	O
cognitive	O
tasks	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
reward	O
-	O
based	O
decision	O
-	O
making	O
,	O
in	O
a	O
rat	O
model	O
of	O
the	O
Iowa	O
Gambling	O
Task	O
(	O
rIGT	O
)	O
,	O
is	O
also	O
differently	O
altered	O
by	O
rapid	O
versus	O
delayed	O
actions	O
of	O
corticosterone	S-chem
.	O

We	O
targeted	O
the	O
rapid	O
and	O
delayed	O
time	O
domain	O
by	O
injecting	O
corticosterone	S-chem
(	O
CORT	S-chem
,	O
1	O
mg	O
/	O
kg	O
,	O
s.c.	O
)	O
at	O
30	O
min	O
(	O
rapid	O
)	O
or	O
180	O
min	O
(	O
delayed	O
)	O
respectively	O
prior	O
to	O
behavioural	O
testing	O
,	O
during	O
the	O
final	O
3	O
days	O
of	O
the	O
behavioural	O
paradigm	O
.	O

In	O
saline	O
treated	O
rats	O
,	O
the	O
number	O
of	O
visits	O
to	O
the	O
disadvantageous	O
arm	O
decreased	O
over	O
trial	O
blocks	O
,	O
whilst	O
this	O
was	O
attenuated	O
when	O
CORT	S-chem
was	O
administered	O
30	O
min	O
before	O
testing	O
.	O

This	O
attenuation	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
c	B-geneY
-	I-geneY
Fos	E-geneY
expression	O
in	O
the	O
lateral	O
orbitofrontal	O
cortex	O
and	O
insular	O
cortex	O
,	O
and	O
a	O
trend	O
for	O
an	O
increase	O
in	O
the	O
infralimbic	O
cortex	O
.	O

The	O
rapid	O
corticosteroid	O
effect	O
contrasted	O
with	O
treatment	O
180	O
min	O
before	O
testing	O
,	O
where	O
the	O
number	O
of	O
visits	O
to	O
the	O
disadvantageous	O
arm	O
as	O
well	O
as	O
c	O
-	B-geneY
Fos	I-geneY
labelling	O
was	O
not	O
affected	O
.	O

These	O
findings	O
indicate	O
that	O
rapid	O
corticosteroid	O
actions	O
impair	O
reward	O
-	O
based	O
decision	O
-	O
making	O
.	O

An	O
improved	O
mass	O
spectrometric	O
method	O
for	O
identification	O
and	O
quantification	O
of	O
phenolic	S-chem
compounds	O
in	O
apple	O
fruits	O
.	O

Thirty	O
-	O
nine	O
phenolic	S-chem
compounds	O
were	O
analysed	O
using	O
ultra	O
high	O
performance	O
liquid	O
chromatography	O
(	O
UHPLC	O
)	O
coupled	O
with	O
diode	O
array	O
and	O
accurate	O
mass	O
spectrometry	O
detection	O
using	O
electrospray	O
ionisation	O
(	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
)	O
.	O

Instrumental	O
parameters	O
such	O
as	O
scan	O
speed	O
,	O
resolution	O
,	O
and	O
mass	O
accuracy	O
were	O
optimised	O
to	O
establish	O
accurate	O
mass	O
measurements	O
.	O

The	O
method	O
was	O
fully	O
validated	O
in	O
terms	O
of	O
model	O
deviation	O
(	O
r	O
(	O
2	O
)	O
>	O
0.9990	O
)	O
,	O
range	O
(	O
typically	O
10	O
-	O
3500	O
ngg	O
(	O
-	O
1	O
)	O
)	O
,	O
intra	O
/	O
inter	O
-	O
day	O
precision	O
(	O
<	O
6	O
%	O
and	O
<	O
8	O
%	O
,	O
respectively	O
)	O
and	O
accuracy	O
(	O
typically	O
100	O
±	O
10	O
%	O
)	O
.	O

The	O
mass	O
accuracy	O
of	O
each	O
selected	O
phenolic	S-chem
compound	O
was	O
below	O
1.5	O
ppm	O
.	O

The	O
results	O
confirmed	O
that	O
the	O
UHPLC	O
-	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
method	O
developed	O
here	O
was	O
convenient	O
and	O
reliable	O
for	O
the	O
determination	O
of	O
phenolic	S-chem
compounds	O
in	O
apple	O
extracts	O
.	O

Prohormone	B-geneY
convertase	I-geneY
-	I-geneY
1	E-geneY
will	O
process	O
prorelaxin	S-geneN
,	O
a	O
member	O
of	O
the	O
insulin	S-geneY
family	O
of	O
hormones	O
.	O

Relaxin	S-geneN
is	O
a	O
polypeptide	O
hormone	O
involved	O
in	O
remodeling	O
of	O
the	O
birth	O
canal	O
during	O
parturition	O
.	O

It	O
is	O
synthesized	O
as	O
a	O
preprohormone	O
precursor	O
,	O
which	O
undergoes	O
specific	O
processing	O
to	O
form	O
the	O
mature	O
two	O
-	O
chain	O
disulfide	S-chem
-	O
linked	O
active	O
species	O
that	O
is	O
secreted	O
by	O
the	O
cell	O
.	O

A	O
major	O
part	O
of	O
this	O
processing	O
requires	O
endoproteolytic	O
cleavage	O
at	O
specific	O
pairs	O
of	O
basic	O
amino	B-chem
acid	E-chem
residues	O
,	O
an	O
event	O
necessary	O
for	O
the	O
maturation	O
of	O
a	O
variety	O
of	O
important	O
biologically	O
active	O
proteins	O
,	O
such	O
as	O
insulin	S-geneY
and	O
nerve	B-geneY
growth	I-geneY
factor	E-geneY
.	O

Human	B-geneY
type	I-geneY
2	I-geneY
preprorelaxin	E-geneY
was	O
coexpressed	O
in	O
human	O
kidney	O
293	O
cells	O
with	O
the	O
candidate	O
prohormone	B-geneN
convertase	I-geneN
-	I-geneN
processing	I-geneN
enzymes	E-geneN
mPC1	S-geneY
or	O
mPC2	S-geneY
,	O
both	O
cloned	O
from	O
the	O
mouse	O
pituitary	O
tumor	O
AtT	O
-	O
20	O
cell	O
line	O
,	O
or	O
with	O
the	O
yeast	B-geneY
kex2	E-geneY
alpha	B-geneY
-	I-geneY
mating	I-geneY
factor	I-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
from	O
Saccharomyces	O
cerevisiae	O
.	O

Prorelaxin	S-geneN
expressed	O
alone	O
in	O
293	O
cells	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
unprocessed	O
.	O

Transient	O
coexpression	O
with	O
mPC1	S-geneY
or	O
kex2	S-geneY
,	O
but	O
not	O
with	O
mPC2	S-geneY
,	O
resulted	O
in	O
the	O
secretion	O
of	O
a	O
low	O
mol	O
wt	O
species	O
with	O
an	O
electrophoretic	O
mobility	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
that	O
of	O
authentic	O
mature	O
relaxin	S-geneN
purified	O
from	O
human	O
placenta	O
.	O

This	O
species	O
was	O
precipitable	O
by	O
monoclonal	O
antibodies	O
specific	O
for	O
relaxin	S-geneN
and	O
had	O
a	O
retention	O
time	O
on	O
reverse	O
phase	O
HPLC	O
comparable	O
to	O
that	O
of	O
relaxin	S-geneN
.	O

Its	O
analysis	O
by	O
both	O
electrospray	O
and	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
generated	O
mass	O
data	O
that	O
were	O
consistent	O
only	O
with	O
mature	O
relaxin	S-geneN
.	O

The	O
basic	O
residues	O
required	O
for	O
mPC1	S-geneY
-	O
dependent	O
cleavage	O
of	O
prorelaxin	S-geneN
are	O
defined	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Reticulated	O
platelets	O
and	O
uninhibited	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
decrease	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	S-chem
.	O

BACKGROUND	O
:	O
The	O
mechanisms	O
for	O
the	O
variability	O
in	O
antiplatelet	O
effects	O
of	O
aspirin	S-chem
are	O
unclear	O
.	O

Immature	O
(	O
reticulated	O
)	O
platelets	O
may	O
modulate	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	S-chem
through	O
uninhibited	O
cyclooxygenase	S-geneN
(	B-geneY
COX	I-geneY
)	I-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
reticulated	O
platelets	O
in	O
the	O
antiplatelet	O
effects	O
of	O
aspirin	S-chem
.	O

METHODS	O
:	O
Sixty	O
healthy	O
volunteers	O
had	O
platelet	O
studies	O
performed	O
before	O
and	O
24	O
h	O
after	O
a	O
single	O
325	O
-	O
mg	O
dose	O
of	O
aspirin	S-chem
.	O

Platelet	O
studies	O
included	O
light	O
transmission	O
aggregometry	O
;	O
P	B-geneY
-	I-geneY
selectin	E-geneY
and	O
integrin	B-geneN
alpha	I-geneN
(	I-geneN
IIb	I-geneN
)	I-geneN
beta	I-geneN
(	I-geneN
3	I-geneN
)	E-geneN
expression	O
,	O
and	O
serum	O
thromboxane	B-chem
B	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
TxB	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
levels	O
.	O

Reticulated	O
platelets	O
and	O
platelet	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
were	O
measured	O
using	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
Subjects	O
were	O
divided	O
into	O
tertiles	O
based	O
on	O
the	O
percentage	O
of	O
reticulated	O
platelets	O
in	O
whole	O
blood	O
.	O

Baseline	O
platelet	O
aggregation	O
to	O
1	O
microg	O
mL	O
(	O
-	O
1	O
)	O
collagen	S-geneN
,	O
and	O
postaspirin	O
aggregations	O
to	O
5	O
microm	O
and	O
20	O
microm	O
ADP	S-chem
and	O
collagen	S-geneN
,	O
were	O
greater	O
in	O
the	O
upper	O
than	O
in	O
the	O
lower	O
tertile	O
of	O
reticulated	O
platelets	O
.	O

Stimulated	O
P	B-geneY-C3-2
-	I-geneY-C3-2
selectin	E-geneY-C3-2
and	O
integrin	B-geneN-C3-2
alpha	I-geneN-C3-2
(	I-geneN-C3-2
IIb	I-geneN-C3-2
)	I-geneN-C3-2
beta	I-geneN-C3-2
(	I-geneN-C3-2
3	I-geneN-C3-2
)	E-geneN-C3-2
expression	O
were	O
also	O
higher	O
in	O
the	O
upper	O
tertile	O
both	O
before	O
and	O
after	O
aspirin	S-chem-C3-1
.	O

Platelet	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
was	O
detected	O
in	O
12	O
+	O
/	O
-	O
7	O
%	O
(	O
n	O
=	O
10	O
)	O
of	O
platelets	O
in	O
the	O
upper	O
tertile	O
,	O
and	O
in	O
7	O
+	O
/	O
-	O
3	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
platelets	O
in	O
the	O
lower	O
two	O
tertiles	O
(	O
P	O
=	O
0.03	O
)	O
.	O

Postaspirin	O
serum	O
TxB	O
(	O
2	O
)	O
levels	O
were	O
higher	O
in	O
the	O
upper	O
(	O
5.5	O
+	O
/	O
-	O
4	O
ng	O
mL	O
(	O
-	O
1	O
)	O
)	O
than	O
in	O
the	O
lower	O
tertile	O
(	O
3.2	O
+	O
/	O
-	O
2.5	O
ng	O
mL	O
(	O
-	O
1	O
)	O
,	O
P	O
=	O
0.03	O
)	O
,	O
and	O
decreased	O
even	O
further	O
with	O
ex	O
vivo	O
additional	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
.	O

The	O
incidence	O
of	O
aspirin	O
resistance	O
(	O
>	O
or	O
=	O
70	O
%	O
platelet	O
aggregation	O
to	O
5	O
microm	O
ADP	O
)	O
was	O
significantly	O
higher	O
in	O
the	O
upper	O
tertile	O
(	O
45	O
%	O
)	O
than	O
in	O
the	O
lower	O
tertile	O
(	O
5	O
%	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Reticulated	O
platelets	O
are	O
associated	O
with	O
diminished	O
antiplatelet	O
effects	O
of	O
aspirin	S-chem
and	O
increased	O
aspirin	S-chem
resistance	O
,	O
possibly	O
because	O
of	O
increased	O
reactivity	O
,	O
and	O
uninhibited	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
activity	O
.	O

Neuroprotective	O
effects	O
of	O
oxymatrine	S-chem
against	O
excitotoxicity	O
partially	O
through	O
down	O
-	O
regulation	O
of	O
NR2B	S-geneY
-	O
containing	O
NMDA	B-geneN
receptors	E-geneN
.	O

Oxymatrine	S-chem
(	O
OMT	S-chem
)	O
is	O
a	O
major	O
bioactive	O
component	O
derived	O
from	O
Sophora	O
flavescens	O
Ait	O
(	O
kushen	O
)	O
,	O
which	O
is	O
widely	O
used	O
in	O
Chinese	O
medicine	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
it	O
has	O
neuroprotective	O
effects	O
;	O
however	O
,	O
its	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

We	O
focus	O
on	O
the	O
mechanisms	O
of	O
pharmacologic	O
action	O
in	O
OMT	S-chem
by	O
detecting	O
its	O
pharmacological	O
properties	O
against	O
focal	O
cerebral	O
ischemia	O
in	O
vivo	O
and	O
NMDA	S-chem
-	O
induced	O
neurotoxicity	O
in	O
vitro	O
.	O

OMT	S-chem
prevented	O
cerebral	O
ischemic	O
injury	O
in	O
mice	O
induced	O
via	O
a	O
2	O
h	O
middle	O
cerebral	O
artery	O
occlusion	O
and	O
a	O
24	O
h	O
reperfusion	O
,	O
in	O
vivo	O
.	O

In	O
vitro	O
cultured	O
neurons	O
challenged	O
with	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
D	I-chem
-	I-chem
aspartate	E-chem
(	O
NMDA	S-chem
,	O
200	O
μM	O
)	O
for	O
30	O
min	O
showed	O
significant	O
decrease	O
in	O
the	O
viability	O
of	O
neurons	O
;	O
however	O
,	O
OMT	S-chem
was	O
able	O
to	O
protect	O
neurons	O
against	O
induced	O
neurotoxicity	O
via	O
NMDA	S-chem
exposure	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
OMT	S-chem-C4-1
decreased	O
the	O
expression	O
of	O
Bax	S-geneY-C4-2
and	O
repaired	O
the	O
balance	O
of	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

Furthermore	O
,	O
OMT	S-chem-C4-1
significantly	O
reversed	O
the	O
up	O
-	O
regulation	O
of	O
NR2B	S-geneY-C4-2
and	O
inhibited	O
the	O
calcium	S-chem
overload	O
in	O
the	O
cultured	O
neurons	O
after	O
challenging	O
the	O
NMDA	S-chem
.	O

OMT	S-chem-MU-1
showed	O
partial	O
protection	O
in	O
the	O
cortical	O
neurons	O
via	O
down	O
-	O
regulation	O
of	O
NR2B	S-geneY-C4-2
containing	O
NMDA	B-geneN-C4-2
receptors	E-geneN-C4-2
and	O
up	O
-	O
regulation	O
of	O
Bcl	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
family	O
.	O

Our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
natural	O
therapeutic	O
anti	O
-	O
oxidants	O
against	O
ischemia	O
.	O

Polymorphisms	O
in	O
OCTN1	S-geneY
and	O
OCTN2	S-geneY
transporters	O
genes	O
are	O
associated	O
with	O
prolonged	O
time	O
to	O
progression	O
in	O
unresectable	O
gastrointestinal	O
stromal	O
tumours	O
treated	O
with	O
imatinib	S-chem
therapy	O
.	O

The	O
two	O
basic	O
mainstays	O
of	O
gastrointestinal	O
stromal	O
tumours	O
(	O
GIST	O
)	O
treatment	O
are	O
surgery	O
and	O
imatinib	S-chem-C4-1
,	O
a	O
selective	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
that	O
allows	O
achieving	O
a	O
stable	O
or	O
responding	O
disease	O
in	O
about	O
80	O
%	O
of	O
patients	O
with	O
unresectable	O
/	O
metastatic	O
GIST	O
.	O

Response	O
to	O
imatinib	S-chem
mainly	O
depends	O
from	O
KIT	S-geneY
and	O
PDGFRα	S-geneY
mutational	O
status	O
.	O

Nevertheless	O
,	O
some	O
patients	O
with	O
a	O
potentially	O
responsive	O
genotype	O
do	O
not	O
respond	O
,	O
and	O
others	O
develop	O
a	O
pattern	O
of	O
resistance	O
to	O
imatinib	S-chem
which	O
is	O
not	O
associated	O
with	O
secondary	O
mutations	O
.	O

This	O
emphasizes	O
the	O
presence	O
of	O
mechanisms	O
of	O
resistance	O
other	O
than	O
the	O
receptor	O
-	O
related	O
genotype	O
,	O
and	O
the	O
need	O
of	O
biological	O
predictors	O
to	O
select	O
the	O
optimal	O
therapeutic	O
strategy	O
,	O
particularly	O
now	O
that	O
other	O
potent	O
inhibitors	O
are	O
available	O
.	O

We	O
investigated	O
a	O
panel	O
of	O
31	O
polymorphisms	O
in	O
11	O
genes	O
,	O
potentially	O
associated	O
with	O
the	O
pharmacogenetics	O
of	O
imatinib	S-chem
,	O
in	O
a	O
group	O
of	O
54	O
unresectable	O
/	O
metastatic	O
GISTs	O
treated	O
with	O
imatinib	S-chem
400mg	O
daily	O
as	O
first	O
line	O
therapy	O
.	O

Included	O
in	O
this	O
analysis	O
were	O
polymorphisms	O
in	O
the	O
transporters	O
'	O
family	O
SLC22	S-geneN
,	O
SLCO	S-geneN
,	O
ABC	S-geneN
,	O
and	O
in	O
the	O
metabolizing	O
genes	O
CYP	B-geneN
-	I-geneN
3A4	I-geneN
and	I-geneN
-	I-geneN
3A5	E-geneN
.	O

Time	O
to	O
progression	O
was	O
significantly	O
improved	O
in	O
presence	O
of	O
the	O
C	O
allele	O
in	O
SLC22A4	S-geneY
(	O
OCTN1	S-geneY
rs1050152	O
)	O
,	O
and	O
the	O
two	O
minor	O
alleles	O
(	O
G	O
)	O
in	O
SLC22A5	S-geneY
(	O
OCTN2	S-geneY
rs2631367	O
and	O
rs2631372	O
)	O
.	O

Importantly	O
,	O
multivariate	O
analysis	O
,	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
KIT	S-geneY
/	O
PDGFRα	S-geneY
mutational	O
status	O
,	O
and	O
tumour	O
size	O
,	O
revealed	O
that	O
all	O
the	O
three	O
genotypes	O
maintained	O
independent	O
predictive	O
significance	O
.	O

In	O
conclusion	O
,	O
in	O
this	O
study	O
we	O
showed	O
that	O
SLC22A4	S-geneY
and	O
SLC22A5	S-geneY
genotypes	O
may	O
be	O
an	O
important	O
predictor	O
of	O
time	O
to	O
progression	O
in	O
GIST	O
patients	O
receiving	O
imatinib	S-chem
therapy	O
.	O

Further	O
investigations	O
are	O
required	O
in	O
an	O
attempt	O
to	O
further	O
personalize	O
GIST	O
therapy	O
.	O

Lysine	S-chem
48	O
-	O
linked	O
polyubiquitination	O
of	O
organic	B-geneY
anion	I-geneY
transporter	I-geneY
-	I-geneY
1	E-geneY
is	O
essential	O
for	O
its	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
-	O
regulated	O
endocytosis	O
.	O

Organic	B-geneY
anion	I-geneY
transporter	I-geneY
-	I-geneY
1	E-geneY
(	O
OAT1	S-geneY
)	O
mediates	O
the	O
body	O
's	O
disposition	O
of	O
a	O
diverse	O
array	O
of	O
environmental	O
toxins	O
and	O
clinically	O
important	O
drugs	O
.	O

Therefore	O
,	O
understanding	O
the	O
regulation	O
of	O
this	O
transporter	O
has	O
profound	O
clinical	O
significance	O
.	O

We	O
had	O
previously	O
established	O
that	O
OAT1	S-geneY
undergoes	O
constitutive	O
internalization	O
from	O
and	O
recycling	O
back	O
to	O
the	O
cell	O
surface	O
and	O
that	O
acute	O
activation	O
of	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
(	O
PKC	S-geneN
)	O
inhibits	O
OAT1	S-geneY
activity	O
by	O
reducing	O
OAT1	S-geneY
cell	O
-	O
surface	O
expression	O
through	O
accelerating	O
its	O
internalization	O
from	O
cell	O
surface	O
to	O
intracellular	O
compartments	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
provide	O
novel	O
evidence	O
that	O
acute	O
activation	O
of	O
PKC	S-geneN
significantly	O
enhances	O
OAT1	S-geneY
ubiquitination	O
both	O
in	O
vitro	O
and	O
ex	O
vivo	O
.	O

We	O
further	O
show	O
that	O
ubiquitination	O
of	O
cell	O
-	O
surface	O
OAT1	S-geneY
increases	O
in	O
cells	O
transfected	O
with	O
dominant	O
negative	O
mutant	O
of	O
dynamin	B-geneY
-	I-geneY
2	E-geneY
,	O
a	O
maneuver	O
blocking	O
OAT1	S-geneY
internalization	O
,	O
which	O
suggests	O
that	O
OAT1	S-geneY
ubiquitination	O
proceeds	O
before	O
OAT1	S-geneY
internalization	O
.	O

Mass	O
spectroscopy	O
has	O
revealed	O
that	O
ubiquitination	O
of	O
OAT1	S-geneY
consists	O
of	O
polyubiquitin	O
chains	O
,	O
primarily	O
through	O
lysine	S-chem
48	O
linkage	O
.	O

Transfection	O
of	O
cells	O
with	O
the	O
dominant	O
negative	O
mutant	O
of	O
ubiquitin	O
Ub	O
-	O
K48R	O
,	O
which	O
prevents	O
the	O
formation	O
of	O
Lys48	S-chem
-	O
linked	O
polyubiquitin	O
chains	O
,	O
abolishes	O
PKC	S-geneN
-	O
stimulated	O
OAT1	S-geneY
ubiquitination	O
and	O
internalization	O
.	O

Together	O
,	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Lys48	S-chem
-	O
linked	O
polyubiquitination	O
is	O
essential	O
for	O
PKC	S-geneN
-	O
regulated	O
OAT1	S-geneY
trafficking	O
.	O

Arsenic	S-chem-C3-1
inhibits	O
autophagic	O
flux	O
activating	O
the	O
Nrf2	S-geneY-C3-2
-	O
Keap1	S-geneY-C3-2
pathway	O
in	O
a	O
p62	S-geneY
-	O
dependent	O
manner	O
.	O

The	O
Nrf2	S-geneY
-	O
Keap1	S-geneY
signaling	O
pathway	O
is	O
a	O
protective	O
mechanism	O
promoting	O
cell	O
survival	O
.	O

Activation	O
of	O
the	O
Nrf2	S-geneY
pathway	O
by	O
natural	O
compounds	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
strategy	O
for	O
chemoprevention	O
.	O

Interestingly	O
,	O
a	O
cancer	O
-	O
promoting	O
function	O
of	O
Nrf2	S-geneY
has	O
been	O
recently	O
observed	O
in	O
many	O
types	O
of	O
tumors	O
due	O
to	O
deregulation	O
of	O
the	O
Nrf2	S-geneY
-	O
Keap1	S-geneY
axis	O
,	O
which	O
leads	O
to	O
constitutive	O
activation	O
of	O
Nrf2	S-geneY
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
mechanism	O
of	O
Nrf2	S-geneY
activation	O
by	O
arsenic	O
that	O
is	O
distinct	O
from	O
that	O
of	O
chemopreventive	O
compounds	O
.	O

Arsenic	S-chem-C4-1
deregulates	O
the	O
autophagic	O
pathway	O
through	O
blockage	O
of	O
autophagic	O
flux	O
,	O
resulting	O
in	O
accumulation	O
of	O
autophagosomes	O
and	O
sequestration	O
of	O
p62	S-geneY-C4-2
,	O
Keap1	S-geneY-C4-2
,	O
and	O
LC3	S-geneN-C4-2
.	O

Thus	O
,	O
arsenic	S-chem-C3-1
activates	O
Nrf2	S-geneY-C3-2
through	O
a	O
non	O
-	O
canonical	O
mechanism	O
(	O
p62	S-geneY
-	O
dependent	O
)	O
,	O
leading	O
to	O
a	O
chronic	O
,	O
sustained	O
activation	O
of	O
Nrf2	S-geneY-C3-2
.	O

In	O
contrast	O
,	O
activation	O
of	O
Nrf2	S-geneY-C3-2
by	O
sulforaphane	S-chem-C3-1
and	O
tert	B-chem-C3-1
-	I-chem-C3-1
butylhydroquinone	E-chem-C3-1
depend	O
upon	O
Keap1	S-geneY
-	O
C151	O
and	O
not	O
p62	S-geneY
(	O
the	O
canonical	O
mechanism	O
)	O
.	O

More	O
importantly	O
,	O
SF	O
and	O
tBHQ	S-chem
do	O
not	O
have	O
any	O
effect	O
on	O
autophagy	O
.	O

In	O
fact	O
,	O
SF	O
and	O
tBHQ	S-chem
alleviate	O
arsenic	S-chem
-	O
mediated	O
deregulation	O
of	O
autophagy	O
.	O

Collectively	O
,	O
these	O
findings	O
provide	O
evidence	O
that	O
arsenic	S-chem-C3-1
causes	O
prolonged	O
activation	O
of	O
Nrf2	S-geneY-C3-2
through	O
autophagy	O
dysfunction	O
,	O
possibly	O
providing	O
a	O
similar	O
scenario	O
to	O
constitutive	O
activation	O
of	O
Nrf2	S-geneY-C3-2
found	O
in	O
certain	O
human	O
cancers	O
.	O

This	O
may	O
represent	O
a	O
previously	O
unrecognized	O
mechanism	O
underlying	O
arsenic	S-chem
toxicity	O
and	O
carcinogenicity	O
in	O
humans	O
.	O

Pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
safety	O
of	O
exenatide	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

PURPOSE	O
:	O
The	O
pharmacology	O
and	O
tolerability	O
of	O
exenatide	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
were	O
studied	O
.	O

METHODS	O
:	O
Two	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
studies	O
were	O
conducted	O
.	O

Treatment	O
with	O
oral	O
antidiabetic	O
agents	O
was	O
stopped	O
14	O
days	O
before	O
study	O
initiation	O
.	O

In	O
the	O
first	O
study	O
(	O
study	O
A	O
)	O
,	O
eight	O
subjects	O
received	O
placebo	O
,	O
0.1	O
-	O
,	O
0.2	O
-	O
,	O
0.3	O
-	O
,	O
and	O
either	O
0.4	O
-	O
microg	O
/	O
kg	O
exenatide	O
or	O
placebo	O
five	O
minutes	O
before	O
a	O
meal	O
combined	O
with	O
liquid	O
acetaminophen	S-chem
(	O
to	O
assess	O
the	O
rate	O
of	O
gastric	O
emptying	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
and	O
9	O
.	O

In	O
the	O
second	O
study	O
(	O
study	O
B	O
)	O
,	O
subjects	O
received	O
a	O
single	O
s.c.	O
dose	O
of	O
exenatide	O
or	O
placebo	O
on	O
consecutive	O
days	O
.	O

Part	O
1	O
of	O
study	O
B	O
used	O
exenatide	O
doses	O
of	O
0.01	O
and	O
0.1	O
microg	O
/	O
kg	O
;	O
0.02	O
-	O
,	O
0.05	O
-	O
,	O
and	O
0.1	O
-	O
microg	O
/	O
kg	O
doses	O
were	O
given	O
in	O
part	O
2	O
.	O

After	O
an	O
overnight	O
fast	O
,	O
the	O
study	O
drug	O
was	O
injected	O
15	O
minutes	O
before	O
a	O
meal	O
(	O
part	O
1	O
)	O
and	O
before	O
a	O
meal	O
and	O
acetaminophen	S-chem
(	O
part	O
2	O
)	O
.	O

Parts	O
1	O
and	O
2	O
of	O
study	O
B	O
enrolled	O
six	O
and	O
eight	O
patients	O
,	O
respectively	O
.	O

RESULTS	O
:	O
In	O
both	O
studies	O
,	O
plasma	O
exenatide	O
pharmacokinetic	O
profiles	O
appeared	O
dose	O
proportional	O
.	O

Exenatide	O
doses	O
of	O
0.02	O
-	O
0.2	O
microg	O
/	O
kg	O
dose	O
-	O
dependently	O
lowered	O
postprandial	O
glucose	S-chem
excursions	O
.	O

Exenatide	O
suppressed	O
postprandial	O
plasma	O
glucagon	S-geneY
and	O
slowed	O
gastric	O
emptying	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
events	O
and	O
no	O
patient	O
withdrawals	O
related	O
to	O
treatment	O
.	O

Nausea	O
and	O
vomiting	O
were	O
the	O
most	O
common	O
adverse	O
events	O
and	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
at	O
doses	O
ranging	O
from	O
0.02	O
to	O
0.2	O
microg	O
/	O
kg	O
.	O

CONCLUSION	O
:	O
Administration	O
of	O
preprandial	O
exenatide	O
by	O
s.c.	O
injection	O
resulted	O
in	O
dose	O
-	O
proportional	O
exenatide	O
pharmacokinetics	O
and	O
antidiabetic	O
pharmacodynamic	O
activity	O
.	O

At	O
doses	O
ranging	O
from	O
0.02	O
to	O
0.2	O
microg	O
/	O
kg	O
,	O
exenatide	O
dose	O
-	O
dependently	O
reduced	O
postprandial	O
plasma	O
glucose	S-chem
excursion	O
by	O
insulinotropism	O
,	O
suppression	O
of	O
plasma	O
glucagon	S-geneY
,	O
and	O
slowing	O
of	O
gastric	O
emptying	O
.	O

Pharmacological	O
profile	O
of	O
neuroleptics	S-chem
at	O
human	B-geneN
monoamine	I-geneN
transporters	E-geneN
.	O

Using	O
radioligand	O
binding	O
techniques	O
,	O
we	O
determined	O
the	O
equilibrium	O
dissociation	O
constants	O
(	O
K	O
(	O
D	O
)	O
)	O
for	O
37	O
neuroleptics	S-chem
and	O
one	O
metabolite	O
of	O
a	O
neuroleptic	O
(	O
haloperidol	S-chem
metabolite	O
)	O
for	O
the	O
human	B-geneN
serotonin	I-geneN
,	I-geneN
norepinephrine	I-geneN
,	I-geneN
and	I-geneN
dopamine	I-geneN
transporters	E-geneN
with	O
[	B-chem
3H	I-chem
]	I-chem
imipramine	E-chem
,	O
[	B-chem
3H	I-chem
]	I-chem
nisoxetine	E-chem
,	O
and	O
[	B-chem
3H	I-chem
]	I-chem
WIN35428	E-chem
,	O
respectively	O
.	O

Among	O
neuroleptics	S-chem
,	O
the	O
four	O
most	O
potent	O
compounds	O
at	O
the	O
human	B-geneY
serotonin	I-geneY
transporter	E-geneY
were	O
triflupromazine	S-chem
,	O
fluperlapine	S-chem
,	O
chlorpromazine	S-chem
,	O
and	O
ziprasidone	S-chem
(	O
K	O
(	O
D	O
)	O
24	O
-	O
39	O
nM	O
)	O
;	O
and	O
at	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
,	O
chlorpromazine	S-chem
,	O
zotepine	S-chem
,	O
chlorprothixene	S-chem
,	O
and	O
promazine	S-chem
(	O
K	O
(	O
D	O
)	O
19	O
-	O
25	O
nM	O
)	O
.	O

At	O
the	O
human	B-geneY
dopamine	I-geneY
transporter	E-geneY
,	O
only	O
pimozide	S-chem
(	O
K	O
(	O
D	O
)	O
=	O
69	O
+	O
/	O
-	O
3	O
)	O
ziprasidone	S-chem
(	O
K	O
(	O
D	O
)	O
=	O
76	O
+	O
/	O
-	O
5	O
)	O
had	O
notable	O
potency	O
.	O

These	O
data	O
may	O
be	O
useful	O
in	O
predicting	O
therapeutic	O
and	O
adverse	O
effects	O
,	O
including	O
drug	O
interactions	O
of	O
neuroleptics	S-chem
.	O

Transport	O
Function	O
and	O
Transcriptional	O
Regulation	O
of	O
a	O
Liver	O
-	O
Enriched	O
Human	B-geneY
Organic	I-geneY
Anion	I-geneY
Transporting	I-geneY
Polypeptide	I-geneY
2B1	E-geneY
Transcriptional	O
Start	O
Site	O
Variant	O
.	O

Human	B-geneY
Organic	I-geneY
Anion	I-geneY
Transporting	I-geneY
Polypeptide	I-geneY
2B1	E-geneY
(	O
OATP2B1	S-geneY
)	O
is	O
a	O
membrane	O
transporter	O
that	O
facilitates	O
the	O
cellular	O
uptake	O
of	O
a	O
number	O
of	O
endogenous	O
compounds	O
and	O
drugs	O
.	O

OATP2B1	S-geneY
is	O
widely	O
expressed	O
in	O
tissues	O
including	O
the	O
small	O
intestine	O
,	O
liver	O
,	O
kidney	O
,	O
placenta	O
,	O
heart	O
,	O
skeletal	O
muscle	O
and	O
platelets	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
differential	O
promoter	O
usage	O
in	O
tissues	O
results	O
in	O
expression	O
of	O
five	O
OATP2B1	S-geneY
transcriptional	O
start	O
site	O
variants	O
which	O
utilize	O
distinct	O
first	O
exons	O
but	O
share	O
common	O
subsequent	O
exons	O
.	O

These	O
variants	O
are	O
expected	O
to	O
encode	O
either	O
a	O
full	O
length	O
(	O
OATP2B1	B-geneY
-	I-geneY
FL	E-geneY
)	O
or	O
shortened	O
protein	O
lacking	O
22	O
N	S-chem
-	O
terminus	O
amino	B-chem
acids	E-chem
(	O
OATP2B	B-geneY
-	I-geneY
Short	E-geneY
)	O
.	O

Little	O
is	O
known	O
regarding	O
the	O
transport	O
activity	O
and	O
regulation	O
of	O
OATP2B1	S-geneY
variants	O
with	O
N	S-chem
-	O
terminus	O
truncation	O
.	O

Here	O
,	O
using	O
absolute	O
quantitative	O
polymerase	O
chain	O
reaction	O
we	O
find	O
the	O
full	O
length	O
variant	O
is	O
the	O
major	O
form	O
expressed	O
in	O
duodenum	O
but	O
the	O
short	O
variant	O
predominates	O
in	O
liver	O
.	O

Using	O
a	O
transient	O
heterologous	O
cell	O
expression	O
system	O
,	O
we	O
find	O
that	O
the	O
transport	O
activities	O
of	O
the	O
short	B-geneY-C9-2
OATP2B1	E-geneY-C9-2
variant	O
towards	O
substrates	O
estrone	B-chem-C9-1
sulfate	E-chem-C9-1
and	O
rosuvastatin	S-chem-C9-1
are	O
similar	O
to	O
the	O
well	O
-	O
characterized	O
full	O
length	O
variant	O
.	O

Transcriptional	O
activity	O
screening	O
of	O
the	O
liver	O
enriched	O
OATP2B1	B-geneN
variant	I-geneN
promoter	E-geneN
identified	O
hepatocyte	B-geneY
nuclear	I-geneY
factor	I-geneY
4	I-geneY
alpha	E-geneY
(	O
HNF4α	S-geneY
)	O
as	O
a	O
novel	O
transacting	O
factor	O
.	O

With	O
a	O
combination	O
of	O
in	O
silico	O
screening	O
,	O
promoter	O
mutation	O
in	O
cell	O
-	O
based	O
reporter	O
assays	O
,	O
siRNA	O
knockdown	O
and	O
chromatin	O
immunoprecipitation	O
studies	O
,	O
we	O
identified	O
a	O
functional	O
HNF4α	S-geneY
binding	O
site	O
close	O
to	O
the	O
transcription	O
start	O
site	O
(	O
-	O
17	O
to	O
-	O
4	O
bp	O
)	O
.	O

We	O
conclude	O
that	O
the	O
major	O
OATP2B1	S-geneY
protein	O
form	O
in	O
liver	O
is	O
transport	O
competent	O
and	O
its	O
hepatic	O
expression	O
is	O
regulated	O
by	O
HNF4α	S-geneY
.	O

Cooperative	O
homotropic	O
interaction	O
of	O
L	B-chem
-	I-chem
noradrenaline	E-chem
with	O
the	O
catalytic	O
site	O
of	O
phenylalanine	B-geneY
4	I-geneY
-	I-geneY
monooxygenase	E-geneY
.	O

Catecholamines	S-chem-C4-1
(	O
adrenaline	S-chem-C4-1
,	O
noradrenaline	S-chem-C4-1
and	O
dopamine	S-chem-C4-1
)	O
are	O
potent	O
inhibitors	O
of	O
phenylalanine	B-geneY-C4-2
4	I-geneY-C4-2
-	I-geneY-C4-2
monooxygenase	E-geneY-C4-2
(	O
phenylalanine	B-geneY-C4-2
hydroxylase	E-geneY-C4-2
,	O
EC	B-geneY-C4-2
1.14.16.1	E-geneY-C4-2
)	O
.	O

The	O
amines	O
bind	O
to	O
the	O
enzyme	O
by	O
a	O
direct	O
coordination	O
to	O
the	O
high	O
-	O
spin	O
(	O
S	O
=	O
5	O
/	O
2	O
)	O
Fe	O
(	O
III	O
)	O
at	O
the	O
active	O
site	O
(	O
charge	O
transfer	O
interaction	O
)	O
,	O
as	O
seen	O
by	O
resonance	O
Raman	O
and	O
EPR	O
spectroscopy	O
.	O

Experimental	O
evidence	O
is	O
presented	O
that	O
a	O
group	O
with	O
an	O
apparent	O
pKa	O
value	O
of	O
about	O
5.1	O
(	O
20	O
degrees	O
C	O
)	O
is	O
involved	O
in	O
the	O
interaction	O
between	O
the	O
catecholamine	S-chem
and	O
the	O
enzyme	O
.	O

The	O
high	O
-	O
affinity	O
binding	O
of	O
L	B-chem
-	I-chem
noradrenaline	E-chem
to	O
phenylalanine	B-geneY
hydroxylase	E-geneY
,	O
as	O
studied	O
by	O
equilibrium	O
microdialysis	O
(	O
anaerobically	O
)	O
and	O
ultrafiltration	O
(	O
aerobically	O
)	O
,	O
shows	O
positive	O
cooperativity	O
(	O
h	O
=	O
1.9	O
)	O
;	O
at	O
pH	O
7.2	O
and	O
20	O
degrees	O
C	O
the	O
rat	O
enzyme	O
binds	O
about	O
0.5	O
mol	O
L	B-chem
-	I-chem
noradrenaline	E-chem
/	O
mol	O
subunit	O
with	O
a	O
half	O
-	O
maximal	O
binding	O
(	O
S50	O
)	O
at	O
0.25	O
microM	O
L	B-chem
-	I-chem
noradrenaline	E-chem
.	O

No	O
binding	O
to	O
the	O
ferrous	O
form	O
of	O
the	O
enzyme	O
was	O
observed	O
.	O

The	O
affinity	O
decreases	O
with	O
decreasing	O
pH	O
,	O
by	O
phosphorylation	O
and	O
by	O
preincubation	O
of	O
the	O
enzyme	O
with	O
the	O
substrate	O
L	B-chem
-	I-chem
phenylalanine	E-chem
,	O
while	O
it	O
increases	O
after	O
alkylation	O
of	O
the	O
enzyme	O
with	O
the	O
activator	O
N	B-chem
-	I-chem
ethylmaleimide	E-chem
.	O

Preincubation	O
of	O
the	O
enzyme	O
with	O
L	B-chem
-	I-chem
phenylalanine	E-chem
also	O
leads	O
to	O
a	O
complete	O
loss	O
of	O
the	O
cooperativity	O
of	O
L	B-chem
-	I-chem
noradrenaline	E-chem
binding	O
(	O
h	O
=	O
1.0	O
)	O
.	O

The	O
many	O
similarities	O
in	O
binding	O
properties	O
of	O
the	O
inhibitor	O
L	B-chem
-	I-chem
noradrenaline	E-chem
and	O
the	O
activator	O
/	O
substrate	O
L	B-chem
-	I-chem
phenylalanine	E-chem
makes	O
it	O
likely	O
that	O
the	O
cooperative	O
interactions	O
of	O
these	O
effectors	O
are	O
due	O
to	O
their	O
binding	O
to	O
the	O
same	O
site	O
.	O

The	O
high	O
-	O
affinity	O
of	O
catecholamines	S-chem
to	O
phenylalanine	B-geneY
hydroxylase	E-geneY
is	O
a	O
valuable	O
probe	O
to	O
study	O
the	O
active	O
site	O
of	O
this	O
enzyme	O
and	O
is	O
also	O
relevant	O
for	O
the	O
homologous	O
enzyme	O
tyrosine	B-geneY
hydroxylase	E-geneY
,	O
which	O
is	O
purified	O
as	O
a	O
stable	O
catecholamine	S-chem
-	O
Fe	B-chem
(	I-chem
III	I-chem
)	E-chem
complex	O
.	O

Silencing	O
α1,3	B-geneN
-	I-geneN
fucosyltransferases	E-geneN
in	O
human	O
leukocytes	O
reveals	O
a	O
role	O
for	O
FUT9	S-geneY
enzyme	O
during	O
E	B-geneY
-	I-geneY
selectin	E-geneY
-	O
mediated	O
cell	O
adhesion	O
.	O

Leukocyte	O
adhesion	O
during	O
inflammation	O
is	O
initiated	O
by	O
the	O
binding	O
of	O
sialofucosylated	O
carbohydrates	S-chem
expressed	O
on	O
leukocytes	O
to	O
endothelial	O
E	B-geneN
/	I-geneN
P	I-geneN
-	I-geneN
selectin	E-geneN
.	O

Although	O
the	O
glycosyltransferases	S-geneN
(	O
glycoTs	S-geneN
)	O
constructing	O
selectin	S-geneN
-	O
ligands	O
have	O
largely	O
been	O
identified	O
using	O
knock	O
-	O
out	O
mice	O
,	O
important	O
differences	O
may	O
exist	O
between	O
humans	O
and	O
mice	O
.	O

To	O
address	O
this	O
,	O
we	O
developed	O
a	O
systematic	O
lentivirus	O
-	O
based	O
shRNA	O
delivery	O
workflow	O
to	O
create	O
human	O
leukocytic	O
HL	O
-	O
60	O
cell	O
lines	O
that	O
lack	O
up	O
to	O
three	O
glycoTs	S-geneN
.	O

Using	O
this	O
,	O
the	O
contributions	O
of	O
all	O
three	O
myeloid	O
α1,3	B-geneN
-	I-geneN
fucosyltransferases	E-geneN
(	O
FUT4	S-geneY
,	O
FUT7	S-geneY
,	O
and	O
FUT9	S-geneY
)	O
to	O
selectin	S-geneN
-	O
ligand	O
biosynthesis	O
were	O
evaluated	O
.	O

The	O
cell	O
adhesion	O
properties	O
of	O
these	O
modified	O
cells	O
to	O
L	B-geneN
-	I-geneN
,	I-geneN
E	I-geneN
-	I-geneN
,	I-geneN
and	I-geneN
P	I-geneN
-	I-geneN
selectin	E-geneN
under	O
hydrodynamic	O
shear	O
were	O
compared	O
with	O
bone	O
marrow	O
-	O
derived	O
neutrophils	O
from	O
Fut4	S-geneY
(	O
-	O
/	O
-	O
)	O
Fut7	S-geneY
(	O
-	O
/	O
-	O
)	O
dual	O
knock	O
-	O
out	O
mice	O
.	O

Results	O
demonstrate	O
that	O
predominantly	O
FUT7	S-geneY
,	O
and	O
to	O
a	O
lesser	O
extent	O
FUT4	S-geneY
,	O
forms	O
the	O
selectin	S-geneN
-	O
ligand	O
at	O
the	O
N	S-chem
terminus	O
of	O
leukocyte	O
P	B-geneN
-	I-geneN
selectin	I-geneN
glycoprotein	I-geneN
ligand	I-geneN
-	I-geneN
1	E-geneN
(	O
PSGL	B-geneN
-	I-geneN
1	E-geneN
)	O
in	O
humans	O
and	O
mice	O
.	O

Here	O
,	O
85	O
%	O
reduction	O
in	O
leukocyte	O
interaction	O
was	O
observed	O
in	O
human	B-geneN
FUT4	I-geneN
(	I-geneN
-	I-geneN
)	I-geneN
7	E-geneN
(	O
-	O
)	O
dual	O
knockdowns	O
on	O
P	B-geneN
/	I-geneN
L	I-geneN
-	I-geneN
selectin	E-geneN
substrates	O
.	O

Unlike	O
Fut4	S-geneY
(	O
-	O
/	O
-	O
)	O
Fut7	S-geneY
(	O
-	O
/	O
-	O
)	O
mouse	O
neutrophils	O
,	O
however	O
,	O
human	O
knockdowns	O
lacking	O
FUT4	S-geneY
and	O
FUT7	S-geneY
only	O
exhibited	O
partial	O
reduction	O
in	O
rolling	O
interaction	O
on	O
E	B-geneY
-	I-geneY
selectin	E-geneY
.	O

In	O
this	O
case	O
,	O
the	O
third	O
α1,3	B-geneN
-	I-geneN
fucosyltransferase	E-geneN
FUT9	S-geneY
played	O
an	O
important	O
role	O
because	O
leukocyte	O
adhesion	O
was	O
reduced	O
by	O
50	O
-	O
60	O
%	O
in	O
FUT9	S-geneY
-	O
HL	O
-	O
60	O
,	O
70	O
-	O
80	O
%	O
in	O
dual	O
knockdown	O
FUT7	B-geneN
(	I-geneN
-	I-geneN
)	I-geneN
9	E-geneN
(	O
-	O
)	O
cells	O
,	O
and	O
∼	O
85	O
%	O
in	O
FUT4	B-geneN
(	I-geneN
-	I-geneN
)	I-geneN
7	I-geneN
(	I-geneN
-	I-geneN
)	I-geneN
9	E-geneN
(	O
-	O
)	O
triple	O
knockdowns	O
.	O

Gene	O
silencing	O
results	O
are	O
in	O
agreement	O
with	O
gain	O
-	O
of	O
-	O
function	O
experiments	O
where	O
all	O
three	O
fucosyltransferases	S-geneN
conferred	O
E	B-geneY
-	I-geneY
selectin	E-geneY
-	O
mediated	O
rolling	O
in	O
HEK293T	O
cells	O
.	O

This	O
study	O
advances	O
new	O
tools	O
to	O
study	O
human	B-geneN
glycoT	E-geneN
function	O
.	O

It	O
suggests	O
a	O
species	O
-	O
specific	O
role	O
for	O
FUT9	S-geneY
during	O
the	O
biosynthesis	O
of	O
human	B-geneY
E	I-geneY
-	I-geneY
selectin	E-geneY
ligands	O
.	O

Effect	O
of	O
serum	O
on	O
diesel	O
exhaust	O
particles	O
(	O
DEP	O
)	O
-	O
induced	O
apoptosis	O
of	O
airway	O
epithelial	O
cells	O
in	O
vitro	O
.	O

Patients	O
with	O
chronic	O
airway	O
diseases	O
may	O
be	O
more	O
susceptible	O
to	O
adverse	O
effects	O
of	O
air	O
pollutants	O
including	O
diesel	O
exhaust	O
particles	O
(	O
DEP	O
)	O
.	O

We	O
investigated	O
effects	O
of	O
foetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
DEP	O
-	O
induced	O
changes	O
in	O
airway	O
epithelial	O
cell	O
apoptosis	O
and	O
inflammation	O
.	O

DEP	O
(	O
50	O
-	O
200	O
μg	O
/	O
ml	O
)	O
increased	O
A549	O
cell	O
viability	O
in	O
the	O
absence	O
of	O
FCS	O
.	O

In	O
the	O
presence	O
of	O
3.3	O
%	O
FCS	O
,	O
DEP	O
(	O
50	O
-	O
400	O
μg	O
/	O
ml	O
)	O
decreased	O
A549	O
cell	O
viability	O
.	O

N	B-chem
-	I-chem
acetylcysteine	E-chem
(	O
NAC	S-chem
,	O
33	O
mM	O
)	O
and	O
the	O
c	B-geneN-C4-2
-	I-geneN-C4-2
jun	I-geneN-C4-2
N	I-geneN-C4-2
-	I-geneN-C4-2
terminal	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
JNK	S-geneN-C4-2
)	O
inhibitor	O
(	O
SP600125	S-chem-C4-1
,	O
33	O
μM	O
)	O
further	O
decreased	O
the	O
viability	O
in	O
the	O
presence	O
of	O
DEP	O
(	O
200	O
μg	O
/	O
ml	O
)	O
and	O
3.3	O
%	O
FCS	O
.	O

Under	O
serum	O
-	O
free	O
(	O
SF	O
)	O
condition	O
,	O
DEP	O
(	O
50	O
μg	O
/	O
ml	O
)	O
reduced	O
apoptotic	O
cells	O
;	O
however	O
,	O
when	O
3.3	O
%	O
FCS	O
added	O
to	O
the	O
culture	O
medium	O
,	O
this	O
effect	O
was	O
abolished	O
.	O

DEP	O
(	O
200	O
μg	O
/	O
ml	O
)	O
induced	O
mRNA	O
expression	O
of	O
p21	S-geneY
(	O
CIP1	S-geneY
/	O
WAF1	S-geneY
)	O
both	O
in	O
absence	O
or	O
presence	O
of	O
3.3	O
%	O
FCS	O
and	O
enhanced	O
JNK2	S-geneY
mRNA	O
expression	O
only	O
in	O
the	O
presence	O
of	O
3.3	O
%	O
FCS	O
.	O

Under	O
SF	O
condition	O
,	O
DEP	O
(	O
50	O
μg	O
/	O
ml	O
)	O
induced	O
mRNA	O
expression	O
for	O
p27	S-geneY
and	O
p53	S-geneY
,	O
whereas	O
cyclin	B-geneY
E	E-geneY
mRNA	O
expression	O
was	O
inhibited	O
by	O
DEP	O
(	O
50	O
and	O
200	O
μg	O
/	O
ml	O
)	O
.	O

Furthermore	O
,	O
DEP	O
(	O
200	O
μg	O
/	O
ml	O
)	O
decreased	O
the	O
release	O
of	O
interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
8	E-geneY
in	O
the	O
absence	O
of	O
FCS	O
.	O

In	O
conclusion	O
,	O
FCS	O
modulates	O
effects	O
of	O
DEP	O
on	O
cell	O
death	O
,	O
cell	O
cycle	O
and	O
apoptosis	O
regulating	O
proteins	O
,	O
and	O
IL	B-geneY
-	I-geneY
8	E-geneY
release	O
by	O
activating	O
oxidant	O
stress	O
pathways	O
,	O
JNK	S-geneN
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
.	O

Extravasation	O
of	O
serum	O
,	O
as	O
occurs	O
in	O
the	O
inflamed	O
airways	O
of	O
patients	O
with	O
chronic	O
airway	O
diseases	O
such	O
as	O
asthma	O
and	O
COPD	O
,	O
may	O
render	O
airway	O
epithelial	O
cells	O
more	O
susceptible	O
to	O
the	O
deleterious	O
effects	O
of	O
DEP	O
.	O

Apolipoprotein	B-geneY
E3	E-geneY
(	O
apoE3	S-geneY
)	O
safeguards	O
pig	O
proximal	O
tubular	O
LLC	O
-	O
PK1	O
cells	O
against	O
reduction	O
in	O
SGLT1	S-geneY-C4-2
activity	O
induced	O
by	O
gentamicin	B-chem-C4-1
C	E-chem-C4-1
.	O

Megalin	O
,	O
a	O
family	O
of	O
endocytic	B-geneN-C9-2
receptors	E-geneN-C9-2
related	O
to	O
the	O
low	B-geneN-C9-2
-	I-geneN-C9-2
density	I-geneN-C9-2
lipoprotein	I-geneN-C9-2
(	I-geneN-C9-2
LDL	I-geneN-C9-2
)	I-geneN-C9-2
receptor	E-geneN-C9-2
,	O
is	O
a	O
major	O
pathway	O
for	O
proximal	O
tubular	O
aminoglycoside	S-chem-C9-1
accumulation	O
.	O

We	O
previously	O
reported	O
that	O
aminoglycoside	S-chem-C4-1
antibiotics	O
reduce	O
SGLT1	S-geneY-C4-2
-	O
dependent	O
glucose	S-chem
transport	O
in	O
pig	O
proximal	O
tubular	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
in	O
parallel	O
with	O
the	O
order	O
of	O
their	O
nephrotoxicity	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
model	O
of	O
gentamicin	B-chem-C4-1
C	E-chem-C4-1
(	O
GMC	S-chem-C4-1
)	O
-	O
induced	O
reduction	O
in	O
SGLT1	S-geneY-C4-2
activity	O
,	O
we	O
examined	O
whether	O
ligands	O
for	O
megalin	O
protect	O
LLC	O
-	O
PK1	O
cells	O
from	O
the	O
GMC	S-chem-C4-1
-	O
induced	O
reduction	O
in	O
SGLT1	S-geneY-C4-2
activity	O
.	O

We	O
employed	O
apolipoprotein	B-geneY
E3	E-geneY
(	O
apoE3	S-geneY
)	O
and	O
lactoferrin	S-geneY
as	O
ligands	O
for	O
megalin	O
.	O

Then	O
the	O
cells	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
apoE3	S-geneY
,	O
lactoferrin	S-geneY
and	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
with	O
or	O
without	O
100	O
microg	O
/	O
ml	O
of	O
GMC	S-chem
,	O
and	O
the	O
SGLT1	S-geneY-C9-2
-	O
dependent	O
methyl	B-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
D	I-chem-C9-1
-	I-chem-C9-1
glucopyranoside	E-chem-C9-1
(	O
AMG	S-chem-C9-1
)	O
uptake	O
and	O
levels	O
of	O
SGLT1	S-geneY
expression	O
were	O
determined	O
.	O

As	O
a	O
result	O
,	O
we	O
demonstrated	O
that	O
the	O
apoE3	S-geneY
significantly	O
protects	O
these	O
cells	O
from	O
GMC	S-chem
-	O
induced	O
reduction	O
in	O
AMG	S-chem
uptake	O
,	O
but	O
neither	O
lactoferrin	S-geneY
nor	O
albumin	S-geneY
does	O
.	O

In	O
accord	O
with	O
a	O
rise	O
in	O
AMG	S-chem
uptake	O
activity	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
SGLT1	S-geneY
were	O
apparently	O
up	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
apoE3	S-geneY
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
uptake	O
of	O
[	B-chem
3H	I-chem
]	I-chem
gentamicin	E-chem
is	O
decreased	O
by	O
apoE3	S-geneY
,	O
and	O
that	O
apoE3	S-geneY
showed	O
obvious	O
protection	O
against	O
the	O
GMC	S-chem
-	O
dependent	O
N	B-geneN
-	I-geneN
acetyl	I-geneN
-	I-geneN
beta	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
glucosamidase	E-geneN
(	O
NAG	S-geneN
)	O
release	O
from	O
LLC	O
-	O
PK1	O
cells	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
apoE3	S-geneY
could	O
be	O
a	O
valuable	O
tool	O
for	O
the	O
prevention	O
of	O
aminoglycoside	S-chem
nephrotoxicity	O
.	O

Duloxetine	B-chem
hydrochloride	E-chem
:	O
a	O
new	O
dual	O
-	O
acting	O
medication	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
.	O

BACKGROUND	O
:	O
Duloxetine	B-chem
hydrochloride	E-chem
has	O
recently	O
been	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Duloxetine	S-chem
is	O
a	O
potent	O
inhibitor	O
of	O
serotonin	S-chem
and	O
norepinephrine	S-chem
reuptake	O
,	O
with	O
weak	O
effects	O
on	O
dopamine	S-chem
reuptake	O
.	O

OBJECTIVE	O
:	O
This	O
article	O
reviews	O
the	O
literature	O
on	O
duloxetine	S-chem
with	O
regard	O
to	O
its	O
pharmacodynamics	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
and	O
tolerability	O
.	O

METHODS	O
:	O
A	O
comprehensive	O
search	O
of	O
MEDLINE	O
was	O
performed	O
using	O
the	O
terms	O
duloxetine	S-chem
,	O
Cymbalta	S-chem
,	O
and	O
major	O
depressive	O
disorder	O
,	O
with	O
no	O
restriction	O
on	O
year	O
.	O

The	O
Eli	O
Lilly	O
and	O
Company	O
clinical	O
trial	O
registry	O
,	O
and	O
abstracts	O
and	O
posters	O
from	O
recent	O
American	O
Psychiatric	O
Association	O
meetings	O
were	O
also	O
reviewed	O
.	O

RESULTS	O
:	O
Duloxetine	S-chem
exhibits	O
linear	O
,	O
dose	O
-	O
dependent	O
pharmacokinetics	O
across	O
the	O
approved	O
oral	O
dosage	O
range	O
of	O
40	O
to	O
60	O
mg	O
/	O
d	O
.	O

No	O
dose	O
adjustment	O
appears	O
to	O
be	O
needed	O
based	O
on	O
age	O
.	O

Duloxetine	S-chem
has	O
shown	O
efficacy	O
in	O
reducing	O
depressive	O
symptoms	O
compared	O
with	O
placebo	O
,	O
and	O
duloxetine	O
recipients	O
have	O
shown	O
significant	O
improvements	O
in	O
global	O
functioning	O
compared	O
with	O
placebo	O
(	O
both	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Response	O
and	O
remission	O
rates	O
have	O
been	O
comparable	O
to	O
or	O
greater	O
than	O
those	O
seen	O
with	O
fluoxetine	S-chem
or	O
paroxetine	S-chem
.	O

Duloxetine	S-chem
is	O
generally	O
well	O
tolerated	O
,	O
with	O
nausea	O
,	O
dry	O
mouth	O
,	O
and	O
fatigue	O
being	O
the	O
most	O
common	O
treatment	O
-	O
emergent	O
adverse	O
effects	O
.	O

Cardiovascular	O
adverse	O
effects	O
do	O
not	O
appear	O
to	O
result	O
in	O
sustained	O
blood	O
pressure	O
elevations	O
,	O
QTc	O
-	O
interval	O
prolongation	O
,	O
or	O
other	O
electrocardiographic	O
changes	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
available	O
evidence	O
,	O
duloxetine	S-chem
is	O
a	O
well	O
-	O
tolerated	O
and	O
effective	O
treatment	O
for	O
MDD	O
in	O
adults	O
.	O

Randomized	O
head	O
-	O
to	O
-	O
head	O
comparisons	O
against	O
established	O
antidepressants	O
are	O
needed	O
to	O
determine	O
the	O
relative	O
safety	O
and	O
efficacy	O
of	O
duloxetine	S-chem
.	O

Bupropion	S-chem
inhibits	O
nicotine	S-chem
-	O
evoked	O
[	O
(	B-chem
3	I-chem
)	I-chem
H	E-chem
]	O
overflow	O
from	O
rat	O
striatal	O
slices	O
preloaded	O
with	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
dopamine	E-chem
and	O
from	O
rat	O
hippocampal	O
slices	O
preloaded	O
with	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
norepinephrine	E-chem
.	O

Bupropion	S-chem-C4-1
,	O
an	O
efficacious	O
antidepressant	O
and	O
smoking	O
cessation	O
agent	O
,	O
inhibits	O
dopamine	B-geneN
and	I-geneN
norepinephrine	I-geneN
transporters	E-geneN
(	O
DAT	S-geneY-C4-2
and	O
NET	S-geneY-C4-2
,	O
respectively	O
)	O
.	O

Recently	O
,	O
bupropion	S-chem
has	O
been	O
reported	O
to	O
noncompetitively	O
inhibit	O
alpha3beta2	B-geneN
,	I-geneN
alpha3beta4	I-geneN
,	I-geneN
and	I-geneN
alpha4beta2	I-geneN
nicotinic	I-geneN
acetylcholine	I-geneN
receptors	I-geneN
(	I-geneN
nAChRs	I-geneN
)	E-geneN
expressed	O
in	O
Xenopus	O
oocytes	O
or	O
established	O
cell	O
lines	O
.	O

The	O
present	O
study	O
evaluated	O
bupropion	S-chem
-	O
induced	O
inhibition	O
of	O
native	O
alpha3beta2	B-geneN
*	I-geneN
and	I-geneN
alpha3beta4	I-geneN
*	I-geneN
nAChRs	E-geneN
using	O
functional	O
neurotransmitter	O
release	O
assays	O
,	O
nicotine	S-chem
-	O
evoked	O
[	O
(	B-chem
3	I-chem
)	I-chem
H	E-chem
]	O
overflow	O
from	O
superfused	O
rat	O
striatal	O
slices	O
preloaded	O
with	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
dopamine	E-chem
(	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
DA	E-chem
)	O
,	O
and	O
nicotine	S-chem
-	O
evoked	O
[	O
(	B-chem
3	I-chem
)	I-chem
H	E-chem
]	O
overflow	O
from	O
hippocampal	O
slices	O
preloaded	O
with	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
norepinephrine	E-chem
(	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
NE	E-chem
)	O
.	O

The	O
mechanism	O
of	O
inhibition	O
was	O
evaluated	O
using	O
Schild	O
analysis	O
.	O

To	O
eliminate	O
the	O
interaction	O
of	O
bupropion	S-chem-C4-1
with	O
DAT	S-geneY-C4-2
or	O
NET	S-geneY-C4-2
,	O
nomifensine	S-chem
or	O
desipramine	S-chem
,	O
respectively	O
,	O
was	O
included	O
in	O
the	O
superfusion	O
buffer	O
.	O

A	O
high	O
bupropion	S-chem
concentration	O
(	O
100	O
microM	O
)	O
elicited	O
intrinsic	O
activity	O
in	O
the	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
DA	E-chem
release	O
assay	O
.	O

However	O
,	O
none	O
of	O
the	O
concentrations	O
(	O
1	O
nM	O
-	O
100	O
microM	O
)	O
examined	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
NE	E-chem
overflow	O
and	O
,	O
thus	O
,	O
were	O
without	O
intrinsic	O
activity	O
in	O
this	O
assay	O
.	O

Moreover	O
,	O
bupropion	S-chem
inhibited	O
both	O
nicotine	S-chem
-	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
DA	E-chem
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
1.27	O
microM	O
)	O
and	O
nicotine	S-chem
-	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
NE	E-chem
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
323	O
nM	O
)	O
at	O
bupropion	S-chem
concentrations	O
well	O
below	O
those	O
eliciting	O
intrinsic	O
activity	O
.	O

Results	O
from	O
Schild	O
analyses	O
suggest	O
that	O
bupropion	S-chem
competitively	O
inhibits	O
nicotine	S-chem
-	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
DA	E-chem
overflow	O
,	O
whereas	O
evidence	O
for	O
receptor	O
reserve	O
was	O
obtained	O
upon	O
assessment	O
of	O
bupropion	S-chem
inhibition	O
of	O
nicotine	S-chem
-	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
NE	E-chem
overflow	O
.	O

Thus	O
,	O
bupropion	S-chem-C4-1
acts	O
as	O
an	O
antagonist	O
at	O
alpha3beta2	B-geneN
*	I-geneN
and	I-geneN
alpha3beta4	I-geneN
*	I-geneN
nAChRs	E-geneN
in	O
rat	O
striatum	O
and	O
hippocampus	O
,	O
respectively	O
,	O
across	O
the	O
same	O
concentration	O
range	O
that	O
inhibits	O
DAT	S-geneY-C4-2
and	O
NET	S-geneY-C4-2
function	O
.	O

The	O
combination	O
of	O
nAChR	S-geneN-C4-2
and	O
transporter	O
inhibition	O
produced	O
by	O
bupropion	S-chem-C4-1
may	O
contribute	O
to	O
its	O
clinical	O
efficacy	O
as	O
a	O
smoking	O
cessation	O
agent	O
.	O

Resveratrol	S-chem
attenuates	O
hepatotoxicity	O
of	O
rats	O
exposed	O
to	O
arsenic	B-chem
trioxide	E-chem
.	O

Arsenic	B-chem
trioxide	E-chem
(	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
)	O
is	O
an	O
environmental	O
pollutant	O
and	O
potent	O
toxicant	O
to	O
humans	O
.	O

However	O
,	O
it	O
also	O
shows	O
substantial	O
anti	O
-	O
cancer	O
activity	O
in	O
individuals	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Unfortunately	O
,	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
-	O
treated	O
leukemia	O
patients	O
suffer	O
hepatotoxicity	O
.	O

Resveratrol	S-chem
has	O
been	O
demonstrated	O
to	O
have	O
efficient	O
antioxidant	O
and	O
antineoplastic	O
activities	O
.	O

The	O
study	O
that	O
how	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
in	O
combination	O
with	O
resveratrol	S-chem
affects	O
hepatotoxicity	O
and	O
arsenic	S-chem
accumulation	O
in	O
the	O
liver	O
is	O
lacking	O
,	O
and	O
the	O
present	O
study	O
tackles	O
this	O
question	O
.	O

Wistar	O
rats	O
were	O
injected	O
with	O
3mg	O
/	O
kg	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
on	O
alternate	O
days	O
;	O
resveratrol	S-chem
(	O
8mg	O
/	O
kg	O
)	O
was	O
administered	O
1h	O
before	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
.	O

Rats	O
were	O
killed	O
on	O
the	O
8th	O
day	O
to	O
determine	O
histological	O
liver	O
damage	O
,	O
the	O
antioxidant	O
enzymes	O
in	O
serum	O
,	O
the	O
ratio	O
of	O
reduced	B-chem
glutathione	E-chem
(	O
GSH	S-chem
)	O
to	O
oxidized	B-chem
glutathione	E-chem
(	O
GSSG	S-chem
)	O
,	O
and	O
arsenic	S-chem
accumulation	O
in	O
the	O
liver	O
.	O

In	O
the	O
resveratrol	S-chem
+	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
group	O
,	O
activities	O
of	O
superoxide	B-geneN
dismutase	E-geneN
,	O
catalase	S-geneY
in	O
serum	O
and	O
GSH	S-chem
/	O
GSSG	S-chem
were	O
significantly	O
increased	O
,	O
histopathological	O
effects	O
were	O
reduced	O
,	O
and	O
arsenic	S-chem
accumulation	O
markedly	O
decreased	O
in	O
the	O
liver	O
,	O
compared	O
with	O
the	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
-	O
treated	O
group	O
.	O

Thus	O
,	O
resveratrol	S-chem
attenuated	O
As	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
3	I-chem
)	E-chem
-	O
induced	O
hepatotoxicity	O
by	O
decreasing	O
oxidative	O
stress	O
and	O
arsenic	S-chem
accumulation	O
in	O
the	O
liver	O
.	O

These	O
data	O
suggest	O
that	O
use	O
of	O
resveratrol	S-chem
as	O
post	O
-	O
remission	O
therapy	O
of	O
APL	O
and	O
adjunctive	O
therapy	O
in	O
patients	O
with	O
chronic	O
exposure	O
to	O
arsenic	S-chem
may	O
decrease	O
arsenic	S-chem
hepatotoxicity	O
.	O

Neuroparalysis	O
and	O
oxime	S-chem
efficacy	O
in	O
organophosphate	S-chem
poisoning	O
:	O
a	O
study	O
of	O
butyrylcholinesterase	S-geneY
.	O

The	O
temporal	O
profile	O
of	O
butyrylcholinesterase	S-geneY
(	O
BuChE	S-geneY
)	O
and	O
in	O
vitro	O
pralidoxime	S-chem-C3-1
-	O
reactivated	O
BuChE	S-geneY-C3-2
was	O
studied	O
in	O
a	O
cohort	O
of	O
25	O
organophosphate	S-chem
-	O
poisoned	O
patients	O
to	O
examine	O
their	O
relationship	O
to	O
the	O
development	O
of	O
intermediate	O
syndrome	O
and	O
to	O
understand	O
reasons	O
for	O
lack	O
of	O
efficacy	O
of	O
oxime	S-chem
treatment	O
.	O

The	O
clinical	O
severity	O
of	O
poisoning	O
(	O
assessed	O
by	O
the	O
Namba	O
Scale	O
)	O
correlated	O
significantly	O
with	O
the	O
severity	O
of	O
intermediate	O
syndrome	O
.	O

BuChE	S-geneY
activity	O
increased	O
significantly	O
over	O
time	O
and	O
showed	O
significant	O
relationship	O
to	O
muscle	O
power	O
.	O

The	O
temporal	O
profile	O
of	O
the	O
enzyme	O
was	O
correlated	O
to	O
the	O
clinical	O
severity	O
of	O
poisoning	O
.	O

Reactivation	O
potentials	O
of	O
BuChE	S-geneY-MU-2
(	O
the	O
difference	O
between	O
oxime	S-chem-C3-1
-	O
reactivated	O
and	O
-	O
unreactivated	O
enzyme	O
activity	O
)	O
declined	O
significantly	O
with	O
time	O
after	O
organophosphate	S-chem-C4-1
ingestion	O
.	O

The	O
reactivation	O
potential	O
of	O
the	O
enzyme	O
at	O
admission	O
decreased	O
significantly	O
with	O
increasing	O
severity	O
of	O
poisoning	O
and	O
was	O
lower	O
in	O
patients	O
who	O
developed	O
intermediate	O
syndrome	O
.	O

Patients	O
who	O
received	O
oxime	S-chem-C4-1
prior	O
to	O
hospitalization	O
had	O
a	O
higher	O
rate	O
of	O
intermediate	O
syndrome	O
and	O
lower	O
levels	O
of	O
BuChE	S-geneY-C4-2
at	O
admission	O
than	O
those	O
who	O
had	O
not	O
.	O

The	O
study	O
suggests	O
that	O
(	O
i	O
)	O
BuChE	S-geneY
reflects	O
the	O
clinical	O
course	O
of	O
poisoning	O
,	O
confirming	O
earlier	O
studies	O
;	O
(	O
ii	O
)	O
intermediate	O
syndrome	O
may	O
be	O
associated	O
with	O
a	O
persistent	O
inhibition	O
of	O
BuChE	S-geneY
;	O
and	O
(	O
iii	O
)	O
the	O
lack	O
of	O
oxime	S-chem
efficacy	O
in	O
our	O
patients	O
maybe	O
due	O
to	O
their	O
severity	O
of	O
poisoning	O
and	O
the	O
timing	O
of	O
oxime	S-chem
treatment	O
.	O

Effect	O
of	O
paraoxonase	B-geneY
1	E-geneY
192	B-geneN
Q	I-geneN
/	I-geneN
R	E-geneN
polymorphism	O
on	O
paraoxonase	S-geneY
and	O
acetylcholinesterase	S-geneY
enzyme	O
activities	O
in	O
Turkish	O
population	O
exposed	O
to	O
organophosphate	S-chem
.	O

Organophosphate	S-chem
(	O
OP	O
)	O
compounds	O
are	O
the	O
most	O
commonly	O
used	O
pesticide	O
groups	O
and	O
they	O
are	O
commercially	O
used	O
in	O
the	O
market	O
for	O
local	O
and	O
industrial	O
purposes	O
.	O

Paraoxonase	B-geneY
1	E-geneY
(	O
PON1	S-geneY
)	O
enzyme	O
plays	O
an	O
important	O
role	O
in	O
biotransformation	O
of	O
OP	O
compounds	O
,	O
which	O
shows	O
toxic	O
effects	O
via	O
inhibiting	O
the	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
PON1	S-geneY
gene	O
polymorphism	O
and	O
its	O
effects	O
on	O
PON	S-geneY
and	O
AChE	S-geneY
enzyme	O
activities	O
in	O
individuals	O
who	O
were	O
exposed	O
to	O
organophosphorus	S-chem
insecticides	O
due	O
to	O
occupational	O
reasons	O
,	O
and	O
to	O
profile	O
the	O
probability	O
of	O
susceptibility	O
to	O
organophosphorus	S-chem
compounds	O
.	O

For	O
this	O
purpose	O
,	O
54	O
individuals	O
who	O
were	O
exposed	O
to	O
OPs	O
and	O
54	O
healthy	O
unrelated	O
controls	O
were	O
studied	O
.	O

First	O
,	O
PON1	S-geneY
and	O
AChE	S-geneY
enzyme	O
activities	O
were	O
measured	O
.	O

Second	O
,	O
PON1	S-geneY
192	B-geneN
Q	I-geneN
/	I-geneN
R	E-geneN
polymorphism	O
was	O
determined	O
by	O
standard	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
technique	O
.	O

When	O
the	O
PON1	S-geneY
192	B-geneN
Q	I-geneN
/	I-geneN
R	E-geneN
polymorphism	O
was	O
compared	O
with	O
PON1	S-geneY
enzyme	O
activities	O
,	O
statistically	O
significant	O
association	O
was	O
found	O
in	O
both	O
OP	O
-	O
exposed	O
and	O
control	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

PON1	S-geneY
192	O
R	O
(	O
+	O
)	O
(	O
QR	O
+	O
RR	O
genotypes	O
)	O
genotype	O
carriers	O
had	O
higher	O
PON1	S-geneY
activities	O
than	O
192	O
R	O
(	O
-	O
)	O
(	O
QQ	O
)	O
genotype	O
carriers	O
.	O

On	O
the	O
other	O
hand	O
,	O
results	O
were	O
statistically	O
analyzed	O
in	O
terms	O
of	O
AChE	S-geneY
enzyme	O
activities	O
and	O
there	O
were	O
statistically	O
significant	O
differences	O
only	O
in	O
the	O
OP	O
-	O
exposed	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
mean	O
AChE	S-geneY
concentration	O
in	O
the	O
OP	O
-	O
exposed	O
group	O
was	O
determined	O
as	O
33.79	O
±	O
6.84	O
U	O
/	O
g	O
haemoglobin	S-geneN
(	O
Hb	S-geneN
)	O
for	O
PON1	S-geneY
192	O
R	O
(	O
+	O
)	O
carriers	O
and	O
30.37	O
±	O
7.62	O
U	O
/	O
g	O
Hb	S-geneN
for	O
PON1	S-geneY
192	O
R	O
(	O
+	O
)	O
carriers	O
.	O

As	O
a	O
conclusion	O
,	O
PON1	S-geneY
and	O
AChE	S-geneY
activities	O
were	O
increasing	O
according	O
to	O
the	O
genotypes	O
found	O
in	O
individuals	O
having	O
been	O
exposed	O
to	O
OPs	O
at	O
a	O
chronic	O
level	O
;	O
192	O
R	O
(	O
+	O
)	O
>	O
192	O
R	O
(	O
-	O
)	O
,	O
respectively	O
.	O

Comparison	O
of	O
in	O
vitro	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
screening	O
assays	O
:	O
recommendations	O
for	O
their	O
use	O
in	O
drug	O
discovery	O
.	O

The	O
ATP	B-geneN
-	I-geneN
dependent	I-geneN
drug	I-geneN
efflux	I-geneN
pump	E-geneN
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
affects	O
the	O
absorption	O
and	O
disposition	O
of	O
many	O
compounds	O
.	O

P	B-geneN
-	I-geneN
gp	E-geneN
may	O
also	O
play	O
role	O
in	O
clinically	O
significant	O
drug	O
-	O
drug	O
interactions	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
find	O
potential	O
substrates	O
or	O
inhibitors	O
of	O
P	B-geneN
-	I-geneN
gp	E-geneN
early	O
in	O
the	O
drug	O
discovery	O
process	O
.	O

To	O
identify	O
compounds	O
that	O
interact	O
with	O
this	O
transporter	O
,	O
several	O
P	B-geneN
-	I-geneN
gp	E-geneN
assays	O
were	O
validated	O
and	O
compared	O
by	O
testing	O
a	O
set	O
of	O
28	O
reference	O
compounds	O
,	O
including	O
inhibitors	O
of	O
cytochrome	B-geneY
P450	I-geneY
3A4	E-geneY
(	O
CYP3A4	S-geneY
)	O
.	O

The	O
assays	O
included	O
in	O
silico	S-chem
predictions	O
,	O
inhibition	O
assays	O
(	O
based	O
on	O
cellular	O
uptake	O
of	O
rhodamine	B-chem
-	I-chem
123	E-chem
or	O
calcein	B-chem
AM	E-chem
)	O
,	O
and	O
functional	O
assays	O
(	O
ATPase	S-geneN
activity	O
assay	O
and	O
transcellular	O
transport	O
assay	O
,	O
the	O
latter	O
for	O
a	O
subset	O
of	O
compounds	O
)	O
.	O

In	O
addition	O
,	O
species	O
differences	O
were	O
studied	O
in	O
an	O
indirect	O
fluorescence	O
indicator	O
screening	O
assay	O
and	O
test	O
systems	O
expressing	O
porcine	O
,	O
mouse	O
,	O
or	O
human	O
P	B-geneN
-	I-geneN
gp	E-geneN
.	O

Our	O
results	O
suggest	O
that	O
several	O
P	B-geneN
-	I-geneN
gp	E-geneN
assays	O
should	O
be	O
used	O
in	O
combination	O
to	O
classify	O
compounds	O
as	O
substrates	O
or	O
inhibitors	O
of	O
P	B-geneN
-	I-geneN
gp	E-geneN
.	O

Recommendations	O
are	O
given	O
on	O
screening	O
strategies	O
which	O
can	O
be	O
applied	O
to	O
different	O
phases	O
of	O
the	O
drug	O
discovery	O
and	O
development	O
process	O
.	O

Enhancing	O
Raman	O
Scattering	O
without	O
Plasmons	O
:	O
Unprecedented	O
Sensitivity	O
Achieved	O
by	O
TiO2	S-chem
Shell	O
-	O
Based	O
Resonators	O
.	O

A	O
remarkable	O
enhancement	O
of	O
Raman	O
scattering	O
is	O
achieved	O
by	O
TiO2	S-chem
shell	O
-	O
based	O
spherical	O
resonators	O
in	O
the	O
absence	O
of	O
plasmonic	O
enhancers	O
.	O

This	O
effect	O
is	O
ascribed	O
to	O
the	O
synergistic	O
combination	O
of	O
high	O
refractive	O
index	O
of	O
the	O
shell	O
layer	O
,	O
multiple	O
light	O
scattering	O
through	O
the	O
spheres	O
,	O
and	O
related	O
geometrical	O
factors	O
and	O
can	O
be	O
exploited	O
to	O
fabricate	O
a	O
new	O
generation	O
of	O
self	O
-	O
diagnostic	O
,	O
recyclable	O
SERS	O
-	O
active	O
substrates	O
.	O

Platelet	B-geneY
-	I-geneY
derived	I-geneY
growth	I-geneY
factor	I-geneY
(	I-geneY
PDGF	I-geneY
)	I-geneY
receptor	I-geneY
-	I-geneY
alpha	E-geneY
-	O
activated	O
c	B-geneY
-	I-geneY
Jun	I-geneY
NH2	I-geneY
-	I-geneY
terminal	I-geneY
kinase	I-geneY
-	I-geneY
1	E-geneY
is	O
critical	O
for	O
PDGF	S-geneN
-	O
induced	O
p21WAF1	B-geneN
/	I-geneN
CIP1	I-geneN
promoter	E-geneN
activity	O
independent	O
of	O
p53	S-geneY
.	O

Platelet	B-geneN
-	I-geneN
derived	I-geneN
growth	I-geneN
factor	E-geneN
(	O
PDGF	S-geneN
)	O
is	O
a	O
potent	O
mitogen	O
for	O
mesenchymal	O
cells	O
.	O

PDGF	B-geneY
AA	E-geneY
functions	O
as	O
a	O
``	O
competent	O
factor	O
``	O
that	O
stimulates	O
cell	O
cycle	O
entry	O
but	O
requires	O
additional	O
(	O
progression	O
)	O
factors	O
in	O
serum	O
to	O
transit	O
the	O
cell	O
cycle	O
beyond	O
the	O
G1	O
/	O
S	O
checkpoint	O
.	O

Unlike	O
PDGF	B-geneY
AA	E-geneY
,	O
PDGF	B-geneY
B	E-geneY
-	O
chain	O
(	O
c	O
-	O
sis	O
)	O
homodimer	O
(	O
PDGF	B-geneY
BB	E-geneY
)	O
and	O
its	O
viral	O
counterpart	O
v	O
-	O
sis	O
can	O
serve	O
as	O
both	O
competent	O
and	O
progression	O
factors	O
.	O

PDGF	B-geneY
BB	E-geneY
activates	O
alpha	O
-	O
and	O
beta	O
-	O
receptor	O
subunits	O
(	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
and	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
)	O
and	O
induces	O
phenotypic	O
transformation	O
in	O
NIH	O
3T3	O
cells	O
,	O
whereas	O
PDGF	B-geneY
AA	E-geneY
activates	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
only	O
and	O
fails	O
to	O
induce	O
transformation	O
.	O

We	O
showed	O
previously	O
that	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
antagonizes	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
-	O
mediated	O
transformation	O
through	O
activation	O
of	O
stress	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	I-geneY
-	I-geneY
1	E-geneY
/	O
c	B-geneY
-	I-geneY
Jun	I-geneY
NH2	I-geneY
-	I-geneY
terminal	I-geneY
kinase	I-geneY
-	I-geneY
1	E-geneY
,	O
whereas	O
both	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
and	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
induce	O
mitogenic	O
signals	O
.	O

These	O
studies	O
revealed	O
a	O
striking	O
feature	O
of	O
PDGF	S-geneN
signaling	O
;	O
the	O
specificity	O
and	O
the	O
strength	O
of	O
the	O
PDGF	S-geneN
growth	O
signal	O
is	O
modulated	O
by	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
-	O
mediated	O
simultaneous	O
activation	O
of	O
growth	O
stimulatory	O
and	O
inhibitory	O
signals	O
,	O
whereas	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
mainly	O
induces	O
a	O
growth	O
-	O
promoting	O
signal	O
.	O

Here	O
we	O
demonstrate	O
that	O
PDGF	B-geneY
BB	E-geneY
activation	O
of	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
alone	O
results	O
in	O
more	O
efficient	O
cell	O
cycle	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
than	O
PDGF	B-geneY
BB	E-geneY
activation	O
of	O
both	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
and	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
.	O

PDGF	B-geneY
AA	E-geneY
activation	O
of	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
or	O
PDGF	B-geneY
BB	E-geneY
activation	O
of	O
both	O
alpha	B-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
-	I-geneN
PDGFRs	E-geneN
up	O
-	O
regulates	O
expression	O
of	O
p21WAF1	S-geneY
/	O
CIP1	S-geneY
,	O
an	O
inhibitor	O
of	O
cell	O
cycle	O
-	O
dependent	O
kinases	S-geneN
and	O
a	O
downstream	O
mediator	O
of	O
the	O
tumor	O
suppressor	O
gene	O
product	O
p53	S-geneY
.	O

However	O
,	O
beta	B-geneY
-	I-geneY
PDGFR	E-geneY
activation	O
alone	O
fails	O
to	O
induce	O
p21WAF1	S-geneY
/	O
CIP1	S-geneY
expression	O
.	O

We	O
also	O
demonstrate	O
that	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
-	O
activated	O
JNK	B-geneY
-	I-geneY
1	E-geneY
is	O
a	O
critical	O
signaling	O
component	O
for	O
PDGF	S-geneN
induction	O
of	O
p21WAF1	B-geneN
/	I-geneN
CIP1	E-geneN
promoter	O
activity	O
.	O

The	O
ability	O
of	O
PDGF	S-geneN
/	O
JNK	B-geneY
-	I-geneY
1	E-geneY
to	O
induce	O
p21WAF1	B-geneN
/	I-geneN
CIP1	I-geneN
promoter	E-geneN
activity	O
is	O
independent	O
of	O
p53	S-geneY
,	O
although	O
the	O
overall	O
p21WAF1	B-geneN
/	I-geneN
CIP1	I-geneN
promoter	E-geneN
activities	O
are	O
greatly	O
reduced	O
in	O
the	O
absence	O
of	O
p53	S-geneY
.	O

These	O
results	O
provide	O
a	O
molecular	O
basis	O
for	O
differential	O
regulation	O
of	O
the	O
cell	O
cycle	O
and	O
transformation	O
by	O
alpha	B-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
-	I-geneN
PDGFRs	E-geneN
.	O

Plerixafor	S-chem-C6-1
,	O
a	O
CXCR4	S-geneY-C6-2
antagonist	O
for	O
the	O
mobilization	O
of	O
hematopoietic	O
stem	O
cells	O
.	O

Stem	O
cells	O
harvested	O
from	O
peripheral	O
blood	O
are	O
the	O
most	O
commonly	O
used	O
graft	O
source	O
in	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

While	O
G	B-geneY
-	I-geneY
CSF	E-geneY
is	O
the	O
most	O
frequently	O
used	O
agent	O
for	O
stem	O
cell	O
mobilization	O
,	O
the	O
use	O
of	O
G	B-geneY
-	I-geneY
CSF	E-geneY
alone	O
results	O
in	O
suboptimal	O
stem	O
cell	O
yields	O
in	O
a	O
significant	O
proportion	O
of	O
patients	O
undergoing	O
autologous	O
transplantation	O
.	O

Plerixafor	S-chem-C4-1
(	O
AMD3100	S-chem-C4-1
,	O
Genzyme	O
Corporation	O
)	O
is	O
a	O
bicyclam	S-chem-C4-1
molecule	O
that	O
antagonizes	O
the	O
binding	O
of	O
the	O
chemokine	S-geneN-C4-2
stromal	B-geneY-C4-2
cell	I-geneY-C4-2
-	I-geneY-C4-2
derived	I-geneY-C4-2
factor	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
SDF	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
)	O
to	O
its	O
cognate	O
receptor	O
CXCR4	S-geneY-C4-2
.	O

Plerixafor	S-chem
results	O
in	O
the	O
rapid	O
and	O
reversible	O
mobilization	O
of	O
hematopoietic	O
stem	O
cells	O
into	O
the	O
peripheral	O
circulation	O
and	O
is	O
synergistic	O
when	O
combined	O
with	O
G	B-geneY
-	I-geneY
CSF	E-geneY
.	O

In	O
clinical	O
studies	O
of	O
autologous	O
stem	O
cell	O
transplantation	O
,	O
the	O
combination	O
of	O
plerixafor	S-chem
and	O
G	B-geneY
-	I-geneY
CSF	E-geneY
allows	O
the	O
collection	O
of	O
large	O
numbers	O
of	O
stem	O
cells	O
in	O
fewer	O
apheresis	O
sessions	O
and	O
can	O
salvage	O
those	O
who	O
fail	O
G	B-geneY
-	I-geneY
CSF	E-geneY
mobilization	O
alone	O
.	O

Pharmacological	O
properties	O
of	O
lorglumide	S-chem-C6-1
as	O
a	O
member	O
of	O
a	O
new	O
class	O
of	O
cholecystokinin	S-geneY-C6-2
antagonists	O
.	O

Derivatives	O
of	O
5	B-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
dipentylamino	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
oxo	I-chem-C6-1
-	I-chem-C6-1
pentanoic	I-chem-C6-1
acid	E-chem-C6-1
are	O
a	O
new	O
class	O
of	O
non	O
-	O
peptide	O
cholecystokinin	S-geneY-C6-2
(	O
CCK	S-geneY-C6-2
)	O
antagonists	O
.	O

The	O
most	O
potent	O
compound	O
,	O
D	B-chem-C6-1
,	I-chem-C6-1
L	I-chem-C6-1
-	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
3,4	I-chem-C6-1
-	I-chem-C6-1
dichlorobenzoylamino	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
dipentylamino	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
oxo	I-chem-C6-1
-	I-chem-C6-1
pen	I-chem-C6-1
tanoic	I-chem-C6-1
acid	E-chem-C6-1
(	O
lorglumide	S-chem-C6-1
,	O
CR	B-chem-C6-1
1409	E-chem-C6-1
)	O
,	O
has	O
a	O
great	O
affinity	O
for	O
the	O
pancreatic	O
CCK	B-geneN
receptors	E-geneN
and	O
is	O
a	O
competitive	O
,	O
specific	O
and	O
potent	O
CCK	S-geneY-C6-2
antagonist	O
on	O
the	O
smooth	O
muscles	O
of	O
the	O
gall	O
bladder	O
and	O
ileum	O
of	O
the	O
guinea	O
pig	O
and	O
on	O
the	O
CCK	S-geneY
-	O
induced	O
amylase	S-geneN
secretion	O
of	O
isolated	O
pancreatic	O
acini	O
.	O

In	O
vivo	O
lorglumide	S-chem
antagonizes	O
the	O
contraction	O
of	O
the	O
gall	O
bladder	O
of	O
the	O
guinea	O
pig	O
and	O
of	O
the	O
dog	O
provoked	O
by	O
i.v	O
.	O

CCK	B-geneN
-	I-geneN
8	E-geneN
or	O
ceruletide	S-chem
(	O
caerulein	S-chem
)	O
.	O

It	O
antagonizes	O
the	O
satiety	O
effect	O
of	O
CCK	B-geneY
-	I-geneY
8	E-geneY
in	O
the	O
rat	O
and	O
is	O
protective	O
against	O
ceruletide	S-chem
-	O
,	O
taurocholate	S-chem
-	O
and	O
diet	O
-	O
induced	O
pancreatitis	O
.	O

Lorglumide	S-chem
is	O
therefore	O
a	O
useful	O
pharmacological	O
tool	O
to	O
study	O
the	O
functions	O
of	O
CCK	S-geneY
.	O

For	O
its	O
pharmacological	O
properties	O
,	O
its	O
relatively	O
low	O
toxicity	O
and	O
because	O
it	O
is	O
active	O
also	O
after	O
oral	O
administration	O
,	O
lorglumide	S-chem
is	O
a	O
candidate	O
for	O
diagnostic	O
or	O
therapeutic	O
use	O
in	O
man	O
when	O
an	O
involvement	O
of	O
CCK	S-geneY
is	O
suspected	O
.	O

Murine	O
chromosomal	O
location	O
of	O
the	O
mu	B-geneN
and	I-geneN
kappa	I-geneN
opioid	I-geneN
receptor	E-geneN
genes	O
.	O

Opioid	B-geneN
receptors	E-geneN
are	O
the	O
membrane	O
proteins	O
that	O
mediate	O
the	O
pain	O
-	O
relieving	O
effect	O
of	O
opioid	O
drugs	O
,	O
such	O
as	O
morphine	S-chem
and	O
fentanyl	S-chem
as	O
well	O
as	O
endogenous	B-geneN
opioid	I-geneN
peptides	E-geneN
enkephalins	S-geneY
and	O
endorphins	S-geneN
.	O

Using	O
cDNAs	O
for	O
the	O
mu	B-geneN
and	I-geneN
the	I-geneN
kappa	I-geneN
opioid	I-geneN
receptors	E-geneN
,	O
we	O
mapped	O
the	O
chromosomal	O
locations	O
of	O
their	O
genes	O
in	O
mouse	O
.	O

Multilocus	O
cross	O
analysis	O
located	O
the	O
mu	B-geneY
receptor	E-geneY
gene	O
Oprm	S-geneY
on	O
Chr	O
10	O
and	O
the	O
kappa	B-geneY
receptor	E-geneY
gene	O
Oprk1	S-geneY
on	O
Chr	O
1	O
.	O

Both	O
genes	O
are	O
near	O
centromere	O
,	O
with	O
no	O
markers	O
more	O
centromeric	O
.	O

These	O
data	O
indicate	O
that	O
the	O
two	O
opioid	B-geneN
receptors	E-geneN
are	O
different	O
gene	O
products	O
,	O
ruling	O
out	O
the	O
possibility	O
that	O
they	O
may	O
be	O
differential	O
splicing	O
products	O
from	O
the	O
same	O
gene	O
.	O

Zuclopenthixol	S-chem
facilitates	O
memory	O
retrieval	O
in	O
rats	O
:	O
possible	O
involvement	O
of	O
noradrenergic	O
and	O
serotonergic	O
mechanisms	O
.	O

Although	O
disturbed	O
memory	O
function	O
often	O
coexists	O
with	O
psychosis	O
,	O
the	O
cognitive	O
effects	O
of	O
antipsychotic	O
medications	O
with	O
diverse	O
pharmacodynamic	O
properties	O
are	O
rarely	O
investigated	O
.	O

The	O
neurocognitive	O
profile	O
of	O
zuclopenthixol	S-chem
,	O
a	O
thioxanthene	S-chem
dopaminergic	O
antagonist	O
and	O
a	O
conventional	O
neuroleptic	O
agent	O
,	O
has	O
yet	O
to	O
be	O
investigated	O
despite	O
the	O
effect	O
of	O
the	O
drug	O
on	O
a	O
variety	O
of	O
neurotransmitter	O
systems	O
involved	O
in	O
mediation	O
of	O
learning	O
and	O
memory	O
processes	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
zuclopenthixol	S-chem
was	O
tested	O
on	O
memory	O
retrieval	O
24	O
h	O
after	O
training	O
using	O
an	O
inhibitory	O
avoidance	O
task	O
in	O
rats	O
.	O

Acute	O
administration	O
of	O
zuclopenthixol	S-chem
(	O
0.7	O
and	O
1.4	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
before	O
retrieval	O
testing	O
increased	O
step	O
-	O
through	O
latency	O
during	O
the	O
test	O
session	O
.	O

The	O
same	O
doses	O
of	O
zuclopenthixol	S-chem
did	O
not	O
affect	O
the	O
ambulatory	O
activity	O
of	O
rats	O
in	O
the	O
openfield	O
test	O
and	O
therefore	O
the	O
facilitatory	O
effect	O
of	O
the	O
drug	O
on	O
memory	O
function	O
could	O
not	O
be	O
confounded	O
with	O
any	O
motoric	O
properties	O
.	O

This	O
study	O
also	O
investigated	O
the	O
effect	O
of	O
zuclopenthixol	S-chem
on	O
cortical	O
and	O
hippocampal	O
monoaminergic	O
neurotransmitters	O
'	O
levels	O
together	O
with	O
acetylcholinesterase	S-geneY
enzyme	O
(	O
AChE	S-geneY
)	O
activity	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
important	O
in	O
control	O
of	O
cognitive	O
function	O
.	O

Administration	O
of	O
zuclopenthixol	S-chem
(	O
0.7	O
and	O
1.4	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
neither	O
affected	O
dopamine	S-chem
(	O
DA	S-chem
)	O
level	O
nor	O
AChE	S-geneY
activity	O
in	O
rat	O
cortex	O
and	O
hippocampus	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
lower	O
dose	O
of	O
zuclopenthixol	S-chem
elevated	O
cortical	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
level	O
,	O
while	O
the	O
higher	O
dose	O
elevated	O
both	O
cortical	O
and	O
hippocampal	O
NE	S-chem
level	O
together	O
with	O
hippocampal	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
level	O
.	O

These	O
results	O
may	O
suggest	O
the	O
involvement	O
of	O
adrenergic	O
and	O
serotonergic	O
mechanisms	O
in	O
the	O
facilitatory	O
effect	O
of	O
zuclopenthixol	S-chem
on	O
retrieval	O
memory	O
.	O

Zuclopenthixol	S-chem
may	O
therefore	O
be	O
a	O
better	O
alternative	O
than	O
other	O
commonly	O
used	O
antipsychotic	O
medications	O
reported	O
to	O
impair	O
cognitive	O
function	O
of	O
schizophrenic	O
patients	O
.	O

Affinities	O
of	O
venlafaxine	S-chem
and	O
various	O
reuptake	O
inhibitors	O
for	O
the	O
serotonin	B-geneN
and	I-geneN
norepinephrine	I-geneN
transporters	E-geneN
.	O

In	O
vitro	O
radioligand	O
binding	O
studies	O
were	O
carried	O
out	O
in	O
rat	O
brain	O
membranes	O
to	O
assess	O
the	O
affinity	O
of	O
various	O
reuptake	O
inhibitors	O
for	O
the	O
serotonin	B-geneN
(	I-geneN
5	I-geneN
-	I-geneN
hydroxytryptamine	I-geneN
,	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
and	I-geneN
the	I-geneN
norepinephrine	I-geneN
transporters	E-geneN
using	O
the	O
selective	O
ligands	O
[	B-chem
3H	I-chem
]	I-chem
cyanoimipramine	E-chem
and	O
[	B-chem
3H	I-chem
]	I-chem
nisoxetine	E-chem
,	O
respectively	O
.	O

The	O
selective	O
5	B-chem
-	I-chem
HT	E-chem
reuptake	O
inhibitors	O
paroxetine	S-chem
,	O
indalpine	S-chem
and	O
fluvoxamine	S-chem
displayed	O
a	O
high	O
affinity	O
for	O
the	O
5	B-geneY
-	I-geneY
HT	I-geneY
transporter	E-geneY
,	O
whereas	O
the	O
norepinephrine	S-chem
reuptake	O
inhibitor	O
desipramine	S-chem
had	O
a	O
high	O
affinity	O
for	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
.	O

Duloxetine	S-chem
,	O
a	O
dual	O
5	B-chem
-	I-chem
HT	E-chem
and	O
norepinephrine	S-chem
reuptake	O
inhibitor	O
,	O
displayed	O
a	O
high	O
affinity	O
for	O
both	O
the	O
5	B-geneN
-	I-geneN
HT	I-geneN
and	I-geneN
the	I-geneN
norepinephrine	I-geneN
transporters	E-geneN
.	O

Interestingly	O
,	O
venlafaxine	S-chem
,	O
a	O
dual	O
5	B-chem
-	I-chem
HT	E-chem
and	O
norepinephrine	S-chem
reuptake	O
inhibitor	O
,	O
displayed	O
only	O
a	O
moderate	O
affinity	O
for	O
the	O
5	B-geneY
-	I-geneY
HT	I-geneY
transporter	E-geneY
(	O
Ki	O
=	O
74	O
nM	O
)	O
and	O
a	O
very	O
low	O
affinity	O
for	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
(	O
Ki	O
=	O
1.26	O
microM	O
)	O
.	O

The	O
relatively	O
low	O
affinities	O
of	O
venlafaxine	S-chem
contrast	O
with	O
its	O
potent	O
in	O
vivo	O
5	B-chem
-	I-chem
HT	E-chem
and	O
norepinephrine	S-chem
reuptake	O
blocking	O
properties	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
in	O
vivo	O
effects	O
on	O
the	O
5	B-chem
-	I-chem
HT	E-chem
and	O
norepinephrine	S-chem
reuptake	O
observed	O
with	O
venlafaxine	S-chem
may	O
not	O
be	O
mediated	O
solely	O
by	O
its	O
binding	O
to	O
the	O
[	B-chem
3H	I-chem
]	I-chem
cyanoimipramine	E-chem
and	O
[	B-chem
3H	I-chem
]	I-chem
nisoxetine	E-chem
binding	O
sites	O
.	O

Disodium	B-chem
cromoglycate	E-chem
does	O
not	O
prevent	O
terbutaline	S-chem
-	O
induced	O
desensitization	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
cardiovascular	O
in	O
vivo	O
functions	O
in	O
human	O
volunteers	O
.	O

In	O
humans	O
,	O
prolonged	O
administration	O
of	O
the	O
beta	B-geneY-C5-2
2	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
terbutaline	S-chem-C5-1
leads	O
to	O
a	O
desensitization	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
cardiovascular	O
responses	O
,	O
which	O
can	O
be	O
blunted	O
by	O
concomitant	O
administration	O
of	O
the	O
antianaphylactic	O
drug	O
ketotifen	S-chem
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
disodium	B-chem
cromoglycate	E-chem
,	O
another	O
antiallergic	O
drug	O
,	O
on	O
terbutaline	S-chem
-	O
induced	O
desensitization	O
of	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
-	O
mediated	O
cardiovascular	O
and	O
noncardiovascular	O
responses	O
.	O

In	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
design	O
,	O
nine	O
healthy	O
male	O
volunteers	O
received	O
disodium	B-chem
cromoglycate	E-chem
(	O
4	O
x	O
200	O
mg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
or	O
placebo	O
for	O
3	O
weeks	O
with	O
terbutaline	S-chem
(	O
3	O
x	O
5	O
mg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
administered	O
concomitantly	O
during	O
the	O
last	O
2	O
weeks	O
.	O
beta	B-geneY
2	I-geneY
-	I-geneY
Adrenoceptor	E-geneY
cardiovascular	O
function	O
was	O
assessed	O
by	O
the	O
increase	O
in	O
heart	O
rate	O
and	O
reduction	O
of	O
diastolic	O
blood	O
pressure	O
induced	O
by	O
an	O
incremental	O
intravenous	O
infusion	O
of	O
the	O
unselective	O
beta	B-geneN-C5-2
-	I-geneN-C5-2
adrenoceptor	E-geneN-C5-2
agonist	O
isoprenaline	S-chem-C5-1
;	O
beta	B-geneY
1	I-geneY
-	I-geneY
adrenoceptor	E-geneY
cardiovascular	O
function	O
was	O
assessed	O
by	O
exercise	O
-	O
induced	O
tachycardia	O
.	O

Tremulousness	O
was	O
monitored	O
as	O
a	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
noncardiovascular	O
effect	O
.	O

After	O
2	O
weeks	O
'	O
administration	O
of	O
terbutaline	S-chem
,	O
there	O
was	O
a	O
marked	O
and	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
attenuation	O
of	O
isoprenaline	S-chem
-	O
induced	O
tachycardia	O
(	O
mean	O
percentage	O
attenuation	O
,	O
53.3	O
%	O
)	O
and	O
of	O
the	O
isoprenaline	S-chem
-	O
induced	O
decrease	O
in	O
diastolic	O
blood	O
pressure	O
(	O
mean	O
percentage	O
attenuation	O
,	O
55.6	O
%	O
)	O
.	O

Exercise	O
-	O
induced	O
tachycardia	O
also	O
was	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
blunted	O
,	O
but	O
the	O
magnitude	O
of	O
this	O
attenuation	O
was	O
only	O
very	O
small	O
(	O
mean	O
attenuation	O
,	O
5.6	O
%	O
)	O
.	O

Disodium	B-chem
cromoglycate	E-chem
affected	O
neither	O
the	O
rightward	O
shift	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
responses	O
nor	O
the	O
small	O
rightward	O
shift	O
in	O
beta	B-geneY
1	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
exercise	O
tachycardia	O
after	O
2	O
weeks	O
'	O
administration	O
of	O
terbutaline	S-chem
.	O

Tremulousness	O
observed	O
during	O
the	O
first	O
few	O
days	O
of	O
terbutaline	S-chem
administration	O
disappeared	O
after	O
4	O
to	O
8	O
days	O
,	O
indicating	O
development	O
of	O
desensitization	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
noncardiovascular	O
responses	O
.	O

This	O
was	O
not	O
prevented	O
by	O
disodium	B-chem
cromoglycate	E-chem
.	O

These	O
results	O
confirm	O
that	O
long	O
-	O
term	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonist	O
therapy	O
leads	O
to	O
a	O
desensitization	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
cardiovascular	O
and	O
noncardiovascular	O
effects	O
in	O
humans	O
in	O
vivo	O
.	O

However	O
,	O
unlike	O
ketotifen	S-chem
,	O
cromolyn	B-chem
sodium	E-chem
is	O
not	O
able	O
to	O
attenuate	O
this	O
desensitization	O
.	O

ALL	B-geneY
-	I-geneY
1	E-geneY
gene	O
rearrangements	O
in	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
inhibitor	O
-	O
related	O
leukemia	O
in	O
children	O
.	O

We	O
examined	O
clinical	O
,	O
morphologic	O
,	O
and	O
cytogenetic	O
features	O
and	O
ALL	B-geneY
-	I-geneY
1	E-geneY
(	O
MLL	S-geneY
,	O
Htrxl	S-geneY
,	O
HRX	S-geneY
)	O
gene	O
rearrangements	O
in	O
17	O
cases	O
of	O
secondary	O
leukemia	O
that	O
occurred	O
11	O
months	O
to	O
9	O
years	O
from	O
diagnoses	O
of	O
primary	O
cancers	O
in	O
children	O
who	O
received	O
topoisomerase	B-geneY
II	E-geneY
inhibitors	O
or	O
developed	O
secondary	O
leukemias	O
typical	O
of	O
those	O
associated	O
with	O
this	O
therapy	O
.	O

Primary	O
diagnoses	O
included	O
nine	O
solid	O
tumors	O
and	O
eight	O
leukemias	O
.	O

Ten	O
secondary	O
leukemias	O
were	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
one	O
was	O
of	O
mixed	O
lineage	O
,	O
two	O
were	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
and	O
four	O
presented	O
as	O
myelodysplasia	O
.	O

Of	O
15	O
cases	O
with	O
11q23	O
involvement	O
,	O
11	O
(	O
73	O
%	O
)	O
were	O
cytogenetically	O
identifiable	O
;	O
four	O
cases	O
had	O
molecular	O
rearrangement	O
only	O
.	O

By	O
Southern	O
blot	O
,	O
rearrangements	O
within	O
the	O
ALL	B-geneY
-	I-geneY
1	E-geneY
gene	O
were	O
similar	O
to	O
sporadic	O
cases	O
.	O

The	O
results	O
of	O
this	O
analysis	O
suggest	O
the	O
following	O
:	O
(	O
1	O
)	O
In	O
most	O
pediatric	O
cases	O
of	O
topoisomerase	B-geneY
II	E-geneY
inhibitor	O
-	O
associated	O
leukemia	O
,	O
there	O
is	O
disruption	O
of	O
the	O
breakpoint	O
cluster	O
region	O
of	O
the	O
ALL	B-geneY
-	I-geneY
1	E-geneY
gene	O
at	O
chromosomal	O
band	O
11q23	O
.	O

(	O
2	O
)	O
Exposure	O
histories	O
vary	O
in	O
secondary	O
11q23	O
leukemia	O
,	O
as	O
the	O
only	O
topoisomerase	B-geneY-C4-2
II	E-geneY-C4-2
inhibitor	O
was	O
dactinomycin	S-chem-C4-1
in	O
one	O
case	O
,	O
and	O
,	O
in	O
another	O
case	O
,	O
no	O
topoisomerase	B-geneY
II	E-geneY
inhibitor	O
was	O
administered	O
.	O

(	O
3	O
)	O
There	O
is	O
clinical	O
,	O
morphologic	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
heterogeneity	O
in	O
pediatric	O
secondary	O
11q23	O
leukemia	O
.	O

(	O
4	O
)	O
There	O
are	O
some	O
survivors	O
of	O
pediatric	O
secondary	O
11q23	O
leukemia	O
,	O
but	O
the	O
outcome	O
is	O
most	O
often	O
fatal	O
.	O

Hydrogen	B-chem
sulfide	E-chem
acts	O
as	O
a	O
mediator	O
of	O
inflammation	O
in	O
acute	O
pancreatitis	O
:	O
in	O
vitro	O
studies	O
using	O
isolated	O
mouse	O
pancreatic	O
acinar	O
cells	O
.	O

Hydrogen	B-chem-C9-1
sulphide	E-chem-C9-1
(	O
H	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	I-chem-C9-1
S	E-chem-C9-1
)	O
is	O
synthesized	O
from	O
L	B-chem-C9-1
-	I-chem-C9-1
cysteine	E-chem-C9-1
via	O
the	O
action	O
of	O
cystathionine	B-geneY-C9-2
-	I-geneY-C9-2
gamma	I-geneY-C9-2
-	I-geneY-C9-2
lyase	E-geneY-C9-2
(	O
CSE	S-geneY-C9-2
)	O
and	O
cystathionine	B-geneY-C9-2
-	I-geneY-C9-2
beta	I-geneY-C9-2
-	I-geneY-C9-2
synthase	E-geneY-C9-2
(	O
CBS	S-geneY-C9-2
)	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
acts	O
as	O
a	O
mediator	O
of	O
inflammation	O
.	O

However	O
the	O
mechanism	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
presence	O
of	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
and	O
the	O
expression	O
of	O
H	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	I-chem-C9-1
S	E-chem-C9-1
synthesizing	O
enzymes	O
,	O
CSE	S-geneY-C9-2
and	O
CBS	S-geneY-C9-2
,	O
in	O
isolated	O
mouse	O
pancreatic	O
acini	O
.	O

Pancreatic	O
acinar	O
cells	O
from	O
mice	O
were	O
incubated	O
with	O
or	O
without	O
caerulein	S-chem
(	O
10	O
(	O
-	O
7	O
)	O
M	O
for	O
30	O
and	O
60	O
min	O
)	O
.	O

Caerulein	S-chem-MU-1
increased	O
the	O
levels	O
of	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
and	O
CSE	S-geneY-C3-2
mRNA	O
expression	O
while	O
CBS	S-geneY-C4-2
mRNA	O
expression	O
was	O
decreased	O
.	O

In	O
addition	O
,	O
cells	O
pre	O
-	O
treated	O
with	O
DL	B-chem-C4-1
-	I-chem-C4-1
propargylglycine	E-chem-C4-1
(	O
PAG	S-chem-C4-1
,	O
3	O
mM	O
)	O
,	O
a	O
CSE	S-geneY-C4-2
inhibitor	O
,	O
reduced	O
the	O
formation	O
of	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
in	O
caerulein	S-chem
treated	O
cells	O
,	O
suggesting	O
that	O
CSE	S-geneY-C9-2
may	O
be	O
the	O
main	O
enzyme	O
involved	O
in	O
H	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	I-chem-C9-1
S	E-chem-C9-1
formation	O
in	O
mouse	O
acinar	O
cells	O
.	O

Furthermore	O
,	O
substance	B-geneY-C3-2
P	E-geneY-C3-2
(	O
SP	S-geneY-C3-2
)	O
concentration	O
in	O
the	O
acini	O
and	O
expression	O
of	O
SP	S-geneY-C3-2
gene	O
(	O
preprotachykinin	B-geneY-C3-2
-	I-geneY-C3-2
A	E-geneY-C3-2
,	O
PPT	B-geneY-C3-2
-	I-geneY-C3-2
A	E-geneY-C3-2
)	O
and	O
neurokinin	B-geneY-C3-2
-	I-geneY-C3-2
1	I-geneY-C3-2
receptor	E-geneY-C3-2
(	O
NK	B-geneY-C3-2
-	I-geneY-C3-2
1R	E-geneY-C3-2
)	O
,	O
the	O
primary	O
receptor	O
for	O
SP	S-geneY
,	O
are	O
increased	O
in	O
secretagogue	O
caerulein	S-chem-C3-1
-	O
treated	O
acinar	O
cells	O
.	O

Inhibition	O
of	O
endogenous	O
production	O
of	O
H	B-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
)	I-chem-C4-1
S	E-chem-C4-1
by	O
PAG	S-chem
significantly	O
suppressed	O
SP	S-geneY-C4-2
concentration	O
,	O
PPT	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
expression	O
and	O
NK1	B-geneY-C4-2
-	I-geneY-C4-2
R	E-geneY-C4-2
expression	O
in	O
the	O
acini	O
.	O

To	O
determine	O
whether	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
itself	O
provoked	O
inflammation	O
in	O
acinar	O
cells	O
,	O
the	O
cells	O
were	O
treated	O
with	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
donor	O
drug	O
,	O
sodium	B-chem-C3-1
hydrosulphide	E-chem-C3-1
(	O
NaHS	S-chem-C3-1
)	O
,	O
(	O
10	O
,	O
50	O
and	O
100	O
muM	O
)	O
,	O
that	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
SP	S-geneY-C3-2
concentration	O
and	O
expression	O
of	O
PPT	B-geneY-C3-2
-	I-geneY-C3-2
A	E-geneY-C3-2
and	O
NK1	B-geneY-C3-2
-	I-geneY-C3-2
R	E-geneY-C3-2
in	O
acinar	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
pro	O
-	O
inflammatory	O
effect	O
of	O
H	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	I-chem-C9-1
S	E-chem-C9-1
may	O
be	O
mediated	O
by	O
SP	S-geneY-C9-2
-	O
NK	B-geneY-C9-2
-	I-geneY-C9-2
1R	E-geneY-C9-2
related	O
pathway	O
in	O
mouse	O
pancreatic	O
acinar	O
cells	O
.	O

Optimization	O
of	O
5	B-chem-C4-1
-	I-chem-C4-1
hydroxytryptamines	E-chem-C4-1
as	O
dual	O
function	O
inhibitors	O
targeting	O
phospholipase	B-geneN-C4-2
A2	E-geneN-C4-2
and	O
leukotriene	B-geneY-C4-2
A4	I-geneY-C4-2
hydrolase	E-geneY-C4-2
.	O

Dual	O
function	O
inhibitors	O
targeting	O
phospholipase	B-geneN-C9-2
A	I-geneN-C9-2
(	I-geneN-C9-2
2	I-geneN-C9-2
)	E-geneN-C9-2
(	O
PLA	B-geneN-C9-2
(	I-geneN-C9-2
2	I-geneN-C9-2
)	E-geneN-C9-2
)	O
and	O
leukotriene	B-geneY-C9-2
A	I-geneY-C9-2
(	I-geneY-C9-2
4	I-geneY-C9-2
)	I-geneY-C9-2
hydrolase	E-geneY-C9-2
(	O
LTA	B-geneY-C9-2
(	I-geneY-C9-2
4	I-geneY-C9-2
)	I-geneY-C9-2
H	E-geneY-C9-2
)	O
may	O
balance	O
the	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
(	O
AA	O
)	O
metabolic	O
network	O
and	O
be	O
used	O
as	O
new	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

In	O
previous	O
study	O
,	O
we	O
discovered	O
multi	O
-	O
target	O
drugs	O
towards	O
the	O
AA	O
metabolic	O
network	O
,	O
among	O
which	O
a	O
dual	O
-	O
target	O
inhibitor	O
(	O
JMC08	B-chem-C4-1
-	I-chem-C4-1
4	E-chem-C4-1
)	O
for	O
human	B-geneY-C4-2
nonpancreatic	I-geneY-C4-2
secretory	I-geneY-C4-2
phospholipase	I-geneY-C4-2
A	I-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	E-geneY-C4-2
(	O
hnps	B-geneY-C4-2
-	I-geneY-C4-2
PLA	I-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	E-geneY-C4-2
)	O
and	O
human	B-geneY-C4-2
leukotriene	I-geneY-C4-2
A	I-geneY-C4-2
(	I-geneY-C4-2
4	I-geneY-C4-2
)	I-geneY-C4-2
hydrolase	E-geneY-C4-2
(	O
LTA	B-geneY-C4-2
(	I-geneY-C4-2
4	I-geneY-C4-2
)	I-geneY-C4-2
H	I-geneY-C4-2
-	I-geneY-C4-2
h	E-geneY-C4-2
)	O
was	O
found	O
.	O

Based	O
on	O
the	O
structure	O
of	O
compound	O
JMC08	B-chem
-	I-chem
4	E-chem
,	O
new	O
dual	O
-	O
target	O
inhibitors	O
were	O
designed	O
assisted	O
by	O
molecular	O
docking	O
.	O

In	O
this	O
report	O
,	O
a	O
series	O
of	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
compounds	O
were	O
synthesized	O
;	O
and	O
most	O
of	O
these	O
title	O
compounds	O
showed	O
more	O
potent	O
inhibitory	O
activity	O
than	O
compound	O
JMC08	B-chem
-	I-chem
4	E-chem
in	O
the	O
in	O
vitro	O
bioassay	O
against	O
these	O
two	O
enzymes	O
.	O

The	O
best	O
one	O
inhibited	O
hnps	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
LTA	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
H	I-geneY
-	I-geneY
h	E-geneY
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
9.2	O
±	O
0.5	O
μM	O
and	O
2.4	O
±	O
1.4	O
μM	O
,	O
respectively	O
.	O

Clinical	O
utility	O
of	O
acarbose	S-chem-C4-1
,	O
an	O
alpha	B-geneY-C4-2
-	I-geneY-C4-2
glucosidase	E-geneY-C4-2
inhibitor	O
in	O
cardiometabolic	O
disorders	O
.	O

Diabetes	O
is	O
associated	O
with	O
an	O
increase	O
risk	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Recently	O
,	O
macrovascular	O
complications	O
of	O
diabetes	O
have	O
been	O
shown	O
to	O
start	O
before	O
the	O
development	O
of	O
diabetes	O
.	O

Indeed	O
,	O
several	O
clinical	O
studies	O
have	O
confirmed	O
the	O
increased	O
risk	O
of	O
CVD	O
in	O
patients	O
with	O
impaired	O
glucose	S-chem
tolerance	O
(	O
IGT	O
)	O
.	O

Since	O
postprandial	O
hyperglycemia	O
and	O
insulin	S-geneY
resistance	O
are	O
thought	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
CVD	O
in	O
patients	O
with	O
IGT	O
,	O
amelioration	O
of	O
postprandial	O
hyperglycemia	O
as	O
well	O
as	O
insulin	S-geneY
resistance	O
is	O
a	O
therapeutic	O
target	O
for	O
the	O
prevention	O
of	O
CVD	O
in	O
these	O
high	O
-	O
risk	O
patients	O
.	O

Acarbose	S-chem-C4-1
,	O
an	O
alpha	B-geneY-C4-2
-	I-geneY-C4-2
glucosidase	E-geneY-C4-2
inhibitor	O
,	O
delays	O
the	O
absorption	O
of	O
carbohydrate	S-chem
from	O
the	O
small	O
intestine	O
,	O
thereby	O
reducing	O
postprandial	O
hyperglycemia	O
.	O

Further	O
,	O
recently	O
,	O
acarbose	B-chem
has	I-chem
been	I-chem
shown	I-chem
to	I-chem
improve	I-chem
insulin	S-geneY
resistance	I-chem
in	I-chem
vivo	E-chem
.	O

These	O
findings	O
suggest	O
that	O
acarbose	S-chem
is	O
a	O
promising	O
metabolic	O
modifier	O
that	O
could	O
reduce	O
the	O
risk	O
of	O
CVD	O
in	O
patients	O
with	O
the	O
metabolic	O
syndrome	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
clinical	O
utility	O
of	O
acarbose	S-chem
in	O
various	O
cardiometabolic	O
disorders	O
.	O

Fast	O
protein	O
motions	O
are	O
coupled	O
to	O
enzyme	O
H	S-chem
-	O
transfer	O
reactions	O
.	O

Coupling	O
of	O
fast	O
protein	O
dynamics	O
to	O
enzyme	O
chemistry	O
is	O
controversial	O
and	O
has	O
ignited	O
considerable	O
debate	O
,	O
especially	O
over	O
the	O
past	O
15	O
years	O
in	O
relation	O
to	O
enzyme	O
-	O
catalyzed	O
H	S-chem
-	O
transfer	O
.	O

H	S-chem
-	O
transfer	O
can	O
occur	O
by	O
quantum	O
tunneling	O
,	O
and	O
the	O
temperature	O
dependence	O
of	O
kinetic	O
isotope	O
effects	O
(	O
KIEs	O
)	O
has	O
emerged	O
as	O
the	O
``	O
gold	O
standard	O
``	O
descriptor	O
of	O
these	O
reactions	O
.	O

The	O
anomalous	O
temperature	O
dependence	O
of	O
KIEs	O
is	O
often	O
rationalized	O
by	O
invoking	O
fast	O
motions	O
to	O
facilitate	O
H	S-chem
-	O
transfer	O
,	O
yet	O
crucially	O
,	O
direct	O
evidence	O
for	O
coupled	O
motions	O
is	O
lacking	O
.	O

The	O
fast	O
motions	O
hypothesis	O
underpinning	O
the	O
temperature	O
dependence	O
of	O
KIEs	O
is	O
based	O
on	O
inference	O
.	O

Here	O
,	O
we	O
have	O
perturbed	O
vibrational	O
motions	O
in	O
pentaerythritol	B-geneN
tetranitrate	I-geneN
reductase	E-geneN
(	O
PETNR	S-geneN
)	O
by	O
isotopic	O
substitution	O
where	O
all	O
non	O
-	O
exchangeable	O
atoms	O
were	O
replaced	O
with	O
the	O
corresponding	O
heavy	O
isotope	O
(	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
,	O
(	B-chem
15	I-chem
)	I-chem
N	E-chem
,	O
and	O
(	B-chem
2	I-chem
)	I-chem
H	E-chem
)	O
.	O

The	O
KIE	O
temperature	O
dependence	O
is	O
perturbed	O
by	O
heavy	O
isotope	O
labeling	O
,	O
demonstrating	O
a	O
direct	O
link	O
between	O
(	O
promoting	O
)	O
vibrations	O
in	O
the	O
protein	O
and	O
the	O
observed	O
KIE	O
.	O

Further	O
we	O
show	O
that	O
temperature	O
-	O
independent	O
KIEs	O
do	O
not	O
necessarily	O
rule	O
out	O
a	O
role	O
for	O
fast	O
dynamics	O
coupled	O
to	O
reaction	O
chemistry	O
.	O

We	O
show	O
causality	O
between	O
fast	O
motions	O
and	O
enzyme	O
chemistry	O
and	O
demonstrate	O
how	O
this	O
impacts	O
on	O
experimental	O
KIEs	O
for	O
enzyme	O
reactions	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
novel	O
human	B-geneN-C9-2
phosphodiesterase	E-geneN-C9-2
that	O
hydrolyzes	O
both	O
cAMP	S-chem-C9-1
and	O
cGMP	S-chem-C9-1
(	O
PDE10A	S-geneY-C9-2
)	O
.	O

cDNA	O
encoding	O
a	O
novel	O
phosphodiesterase	S-geneN
(	O
PDE	S-geneN
)	O
was	O
isolated	O
from	O
a	O
human	O
fetal	O
lung	O
cDNA	O
library	O
and	O
designated	O
PDE10A	S-geneY
.	O

The	O
deduced	O
amino	B-chem
acid	E-chem
sequence	O
contains	O
779	O
amino	B-chem
acids	E-chem
,	O
including	O
a	O
putative	O
cGMP	B-geneN
binding	I-geneN
sequence	E-geneN
in	O
the	O
amino	S-chem
-	O
terminal	O
portion	O
of	O
the	O
molecule	O
and	O
a	O
catalytic	O
domain	O
that	O
is	O
16	O
-	O
47	O
%	O
identical	O
in	O
amino	B-chem
acid	E-chem
sequence	O
to	O
those	O
of	O
other	O
PDE	S-geneN
families	O
.	O

Recombinant	O
PDE10A	S-geneY-C9-2
transfected	O
and	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
hydrolyzed	O
cAMP	S-chem-C9-1
and	O
cGMP	S-chem-C9-1
with	O
Km	O
values	O
of	O
0.26	O
and	O
7.2	O
microM	O
,	O
respectively	O
,	O
and	O
Vmax	O
with	O
cGMP	S-chem-C9-1
was	O
almost	O
twice	O
that	O
with	O
cAMP	S-chem-C9-1
.	O

Of	O
the	O
PDE	S-geneN-MU-2
inhibitors	O
tested	O
,	O
dipyridamole	S-chem-C4-1
was	O
most	O
effective	O
,	O
with	O
IC50	O
values	O
of	O
1.2	O
and	O
0.45	O
microM	O
for	O
inhibition	O
of	O
cAMP	S-chem-C9-1
and	O
cGMP	S-chem-C9-1
hydrolysis	O
,	O
respectively	O
.	O
cGMP	S-chem
inhibited	O
hydrolysis	O
of	O
cAMP	S-chem
,	O
and	O
cAMP	S-chem
inhibited	O
cGMP	S-chem
hydrolysis	O
with	O
IC50	O
values	O
of	O
14	O
and	O
0.39	O
microM	O
,	O
respectively	O
.	O

Thus	O
,	O
PDE10A	S-geneY
exhibited	O
properties	O
of	O
a	O
cAMP	B-geneN
PDE	E-geneN
and	O
a	O
cAMP	B-geneN
-	I-geneN
inhibited	I-geneN
cGMP	I-geneN
PDE	E-geneN
.	O

PDE10A	S-geneY
transcripts	O
were	O
particularly	O
abundant	O
in	O
the	O
putamen	O
and	O
caudate	O
nucleus	O
regions	O
of	O
brain	O
and	O
in	O
thyroid	O
and	O
testis	O
,	O
and	O
in	O
much	O
lower	O
amounts	O
in	O
other	O
tissues	O
.	O

The	O
PDE10A	S-geneY
gene	O
was	O
located	O
on	O
chromosome	O
6q26	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
.	O

PDE10A	S-geneY
represents	O
a	O
new	O
member	O
of	O
the	O
PDE	S-geneN
superfamily	O
,	O
exhibiting	O
unique	O
kinetic	O
properties	O
and	O
inhibitor	O
sensitivity	O
.	O

Human	O
and	O
rat	O
bile	B-geneN
acid	I-geneN
-	I-geneN
CoA	I-geneN
:	I-geneN
amino	I-geneN
acid	I-geneN
N	I-geneN
-	I-geneN
acyltransferase	E-geneN
are	O
liver	O
-	O
specific	O
peroxisomal	O
enzymes	O
:	O
implications	O
for	O
intracellular	O
bile	B-chem
salt	E-chem
transport	O
.	O

UNLABELLED	O
:	O
Bile	B-geneY-C9-2
acid	I-geneY-C9-2
-	I-geneY-C9-2
coenzyme	I-geneY-C9-2
A	I-geneY-C9-2
:	I-geneY-C9-2
amino	I-geneY-C9-2
acid	I-geneY-C9-2
N	I-geneY-C9-2
-	I-geneY-C9-2
acyltransferase	E-geneY-C9-2
(	O
BAAT	S-geneY-C9-2
)	O
is	O
the	O
sole	O
enzyme	O
responsible	O
for	O
conjugation	O
of	O
primary	O
and	O
secondary	O
bile	B-chem-C9-1
acids	E-chem-C9-1
to	O
taurine	S-chem-C9-1
and	O
glycine	S-chem-C9-1
.	O

Previous	O
studies	O
indicate	O
a	O
peroxisomal	O
location	O
of	O
BAAT	S-geneY
in	O
peroxisomes	O
with	O
variable	O
amounts	O
up	O
to	O
95	O
%	O
detected	O
in	O
cytosolic	O
fractions	O
.	O

The	O
absence	O
or	O
presence	O
of	O
a	O
cytosolic	O
pool	O
of	O
BAAT	S-geneY-C9-2
has	O
important	O
implications	O
for	O
the	O
intracellular	O
transport	O
of	O
unconjugated	O
/	O
deconjugated	O
bile	B-chem-C9-1
salts	E-chem-C9-1
.	O

We	O
used	O
immunofluorescence	O
microscopy	O
and	O
digitonin	S-chem
permeabilization	O
assays	O
to	O
determine	O
the	O
subcellular	O
location	O
of	O
endogenous	O
BAAT	S-geneN
in	O
primary	O
human	O
and	O
rat	O
hepatocytes	O
.	O

In	O
addition	O
,	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
tagged	O
rat	B-geneY
Baat	E-geneY
(	O
rBaat	S-geneY
)	O
and	O
human	B-geneY
BAAT	E-geneY
(	O
hBAAT	S-geneY
)	O
were	O
transiently	O
expressed	O
in	O
primary	O
rat	O
hepatocytes	O
and	O
human	O
fibroblasts	O
.	O

Catalase	S-geneY
and	O
recombinant	O
GFP	O
-	O
SKL	S-geneN
and	O
DsRed	O
-	O
SKL	S-geneN
were	O
used	O
as	O
peroxisomal	O
markers	O
.	O

Endogenous	O
hBAAT	S-geneY
and	O
rBaat	S-geneY
were	O
found	O
to	O
specifically	O
localize	O
to	O
peroxisomes	O
in	O
human	O
and	O
rat	O
hepatocytes	O
,	O
respectively	O
.	O

No	O
significant	O
cytosolic	O
fraction	O
was	O
detected	O
for	O
either	O
protein	O
.	O

GFP	O
-	O
tagged	O
hBAAT	S-geneY
and	O
rBaat	S-geneY
were	O
efficiently	O
sorted	O
to	O
peroxisomes	O
of	O
primary	O
rat	O
hepatocytes	O
.	O

Significant	O
amounts	O
of	O
GFP	S-geneN
-	O
tagged	O
hBAAT	S-geneY
or	O
rBaat	S-geneY
were	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
coexpressed	O
with	O
DsRed	O
-	O
SKL	S-geneN
,	O
suggesting	O
that	O
hBAAT	S-geneY
/	O
rBaat	S-geneY
and	O
DsRed	O
-	O
SKL	S-geneN
compete	O
for	O
the	O
same	O
peroxisomal	O
import	O
machinery	O
.	O

When	O
expressed	O
in	O
fibroblasts	O
,	O
GFP	O
-	O
tagged	O
hBAAT	S-geneY
localized	O
to	O
the	O
cytosol	O
,	O
confirming	O
earlier	O
observations	O
.	O

CONCLUSION	O
:	O
hBAAT	S-geneY
and	O
rBaat	S-geneY
are	O
peroxisomal	O
enzymes	O
present	O
in	O
undetectable	O
amounts	O
in	O
the	O
cytosol	O
.	O

Unconjugated	O
or	O
deconjugated	O
bile	B-chem
salts	E-chem
returning	O
to	O
the	O
liver	O
need	O
to	O
shuttle	O
through	O
the	O
peroxisome	O
before	O
reentering	O
the	O
enterohepatic	O
circulation	O
.	O

Neurochemical	O
mechanism	O
of	O
action	O
of	O
anorectic	O
drugs	O
.	O

Studies	O
with	O
dexfenfluramine	S-chem
,	O
an	O
anorectic	O
agent	O
which	O
releases	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
from	O
nerve	O
terminals	O
and	O
inhibits	O
its	O
reuptake	O
,	O
have	O
considerably	O
increased	O
our	O
knowledge	O
of	O
the	O
role	O
of	O
5	B-chem
-	I-chem
HT	E-chem
in	O
feeding	O
control	O
.	O

5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
mediate	O
the	O
satiating	O
effect	O
of	O
dexfenfluramine	S-chem
,	O
whereas	O
the	O
mechanism	O
by	O
which	O
5	B-chem
-	I-chem
HT	E-chem
uptake	O
inhibitors	O
such	O
as	O
fluoxetine	S-chem
and	O
sertraline	S-chem
cause	O
anorexia	O
is	O
not	O
clear	O
.	O

Anorexia	O
induced	O
by	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
amphetamine	E-chem
,	O
phentermine	S-chem
,	O
diethylpropion	S-chem
and	O
phenylpropanolamine	S-chem
seems	O
to	O
be	O
the	O
result	O
of	O
their	O
ability	O
to	O
increase	O
the	O
release	O
of	O
noradrenaline	S-chem
and	O
/	O
or	O
dopamine	S-chem
from	O
nerve	O
terminals	O
and	O
inhibit	O
their	O
reuptake	O
or	O
,	O
in	O
the	O
case	O
of	O
phenylpropanolamine	S-chem-C3-1
,	O
to	O
stimulate	O
directly	O
alpha	B-geneN-C3-2
1	I-geneN-C3-2
-	I-geneN-C3-2
adrenoceptors	E-geneN-C3-2
.	O

It	O
has	O
been	O
suggested	O
that	O
beta	B-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
and	O
D1	B-geneY
dopamine	I-geneY
receptors	E-geneY
are	O
involved	O
in	O
their	O
effect	O
on	O
food	O
intake	O
.	O

The	O
difficulties	O
of	O
extrapolation	O
across	O
species	O
limit	O
our	O
knowledge	O
of	O
the	O
mechanism	O
of	O
the	O
anorectic	O
action	O
in	O
humans	O
.	O

Significant	O
advances	O
in	O
the	O
treatment	O
of	O
feeding	O
pathology	O
will	O
be	O
linked	O
to	O
identifying	O
new	O
receptor	O
types	O
and	O
subtypes	O
for	O
neurotransmitters	O
and	O
quantifying	O
and	O
modelling	O
eating	O
disorders	O
such	O
as	O
binge	O
-	O
eating	O
and	O
food	O
craving	O
.	O

Differential	O
effects	O
of	O
organic	O
and	O
inorganic	O
selenium	S-chem
compounds	O
on	O
adenosine	B-geneY
deaminase	E-geneY
activity	O
and	O
scavenger	O
capacity	O
in	O
cerebral	O
cortex	O
slices	O
of	O
young	O
rats	O
.	O

Selenium	S-chem
(	O
Se	S-chem
)	O
has	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
and	O
is	O
necessary	O
for	O
the	O
development	O
and	O
normal	O
function	O
of	O
the	O
central	O
nervous	O
system	O
.	O

This	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
in	O
vitro	O
effects	O
of	O
3	B-chem
-	I-chem
methyl	I-chem
-	I-chem
1	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
phenylseleno	I-chem
)	I-chem
oct	I-chem
-	I-chem
2	I-chem
-	I-chem
en	I-chem
-	I-chem
1	I-chem
-	I-chem
one	E-chem
(	O
C21H2HOSe	S-chem
;	O
organoselenium	S-chem
)	O
and	O
sodium	B-chem
selenate	E-chem
(	O
inorganic	O
Se	S-chem
)	O
on	O
adenosine	B-geneY
deaminase	E-geneY
(	O
ADA	S-geneY
)	O
activity	O
,	O
cell	O
viability	O
,	O
lipid	O
peroxidation	O
,	O
scavenger	O
of	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
and	O
nonprotein	O
thiols	S-chem
(	O
NP	O
-	O
SH	S-chem
)	O
content	O
in	O
the	O
cerebral	O
cortex	O
slices	O
of	O
the	O
young	O
rats	O
.	O

A	O
decrease	O
in	O
ADA	S-geneY-C4-2
activity	O
was	O
observed	O
when	O
the	O
slices	O
were	O
exposed	O
to	O
organoselenium	S-chem-C4-1
at	O
the	O
concentrations	O
of	O
1	O
,	O
10	O
and	O
30	O
µM	O
.	O

The	O
same	O
compound	O
showed	O
higher	O
scavenger	O
capacity	O
of	O
NO	S-chem
than	O
the	O
inorganic	O
compound	O
.	O

Inorganic	O
Se	S-chem
was	O
able	O
to	O
protect	O
against	O
sodium	B-chem
nitroprusside	E-chem
-	O
induced	O
oxidative	O
damage	O
and	O
increased	O
the	O
NP	O
-	O
SH	S-chem
content	O
.	O

Both	O
the	O
compounds	O
displayed	O
distinctive	O
antioxidant	O
capacities	O
and	O
were	O
not	O
cytotoxic	O
for	O
the	O
cerebral	O
cortex	O
slices	O
in	O
the	O
conditions	O
tested	O
.	O

These	O
findings	O
are	O
likely	O
to	O
be	O
related	O
to	O
immunomodulatory	O
and	O
antioxidant	O
properties	O
of	O
this	O
compound	O
.	O

Research	O
on	O
the	O
preparation	O
of	O
antioxidant	O
peptides	O
derived	O
from	O
egg	O
white	O
with	O
assisting	O
of	O
high	O
-	O
intensity	O
pulsed	O
electric	O
field	O
.	O

Egg	O
white	O
protein	O
powder	O
,	O
one	O
of	O
the	O
main	O
egg	O
products	O
,	O
was	O
hydrolysed	O
by	O
Alcalase	S-geneY
,	O
Trypsin	S-geneN
,	O
and	O
Pepsin	S-geneN
respectively	O
to	O
prepare	O
antioxidant	O
peptides	O
.	O

All	O
hydrolysates	O
were	O
assayed	O
by	O
determination	O
of	O
reducing	O
power	O
(	O
RP	O
)	O
ability	O
.	O

Three	O
kinds	O
of	O
hydrolysates	O
were	O
prepared	O
under	O
optimal	O
enzymatic	O
parameters	O
that	O
were	O
obtained	O
from	O
the	O
preliminary	O
one	O
-	O
factor	O
-	O
at	O
-	O
a	O
-	O
time	O
(	O
OFAT	O
)	O
and	O
response	O
surface	O
methodology	O
(	O
RSM	O
)	O
experiments	O
.	O

The	O
results	O
showed	O
that	O
the	O
Alcalase	S-geneY
hydrolysates	O
exerted	O
the	O
best	O
RP	O
ability	O
.	O

Thereafter	O
,	O
the	O
Alcalase	S-geneY
hydrolysates	O
were	O
sequentially	O
fractionated	O
by	O
ultra	O
filtration	O
membranes	O
in	O
cut	O
-	O
off	O
molecular	O
weight	O
(	O
MW	O
)	O
of	O
30	O
,	O
10	O
,	O
and	O
1kDa	O
,	O
and	O
tested	O
their	O
antioxidant	O
activities	O
in	O
terms	O
of	O
RP	O
ability	O
,	O
DPPH	S-chem
radical	O
scavenging	O
ability	O
,	O
ABTS	S-chem
radical	O
scavenging	O
ability	O
,	O
and	O
FRAP	O
assay	O
.	O

Effects	O
of	O
high	O
intensity	O
pulsed	O
electric	O
field	O
treatment	O
were	O
further	O
investigated	O
on	O
antioxidant	O
peptides	O
to	O
improve	O
their	O
activities	O
.	O

The	O
results	O
showed	O
that	O
Alcalase	S-geneY
hydrolysates	O
possessed	O
the	O
strongest	O
antioxidant	O
ability	O
compared	O
with	O
the	O
other	O
two	O
hydrolysates	O
,	O
particularly	O
for	O
the	O
Fraction	O
-	O
3	O
with	O
MW	O
<	O
1kDa	O
.	O

After	O
PEF	O
treatment	O
,	O
this	O
fraction	O
showed	O
a	O
significant	O
improvement	O
of	O
RP	O
ability	O
within	O
5h	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Novel	O
mechanism	O
of	O
action	O
for	O
hydralazine	S-chem-MU-1
:	O
induction	O
of	O
hypoxia	B-geneY-C3-2
-	I-geneY-C3-2
inducible	I-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
1alpha	E-geneY-C3-2
,	O
vascular	B-geneY-C3-2
endothelial	I-geneY-C3-2
growth	I-geneY-C3-2
factor	E-geneY-C3-2
,	O
and	O
angiogenesis	O
by	O
inhibition	O
of	O
prolyl	B-geneN-C4-2
hydroxylases	E-geneN-C4-2
.	O

The	O
vasodilator	O
hydralazine	S-chem
,	O
used	O
clinically	O
in	O
cardiovascular	O
therapy	O
,	O
relaxes	O
arterial	O
smooth	O
muscle	O
by	O
inhibiting	O
accumulation	O
of	O
intracellular	O
free	O
Ca2	B-chem
+	E-chem
via	O
an	O
unidentified	O
primary	O
target	O
.	O

Collagen	B-geneN
prolyl	I-geneN
hydroxylase	E-geneN
is	O
a	O
known	O
target	O
of	O
hydralazine	S-chem
.	O

We	O
therefore	O
investigated	O
whether	O
inhibition	O
of	O
other	O
members	O
of	O
this	O
enzyme	O
family	O
,	O
namely	O
the	O
hypoxia	B-geneN
-	I-geneN
inducible	I-geneN
factor	E-geneN
(	O
HIF	S-geneN
)	O
-	O
regulating	O
O2	S-chem
-	O
dependent	O
prolyl	B-geneN
hydroxylase	I-geneN
domain	E-geneN
(	O
PHD	S-geneN
)	O
enzymes	O
,	O
could	O
represent	O
a	O
novel	O
mechanism	O
of	O
action	O
.	O

Hydralazine	S-chem-C3-1
induced	O
rapid	O
and	O
transient	O
expression	O
of	O
HIF	B-geneY-C3-2
-	I-geneY-C3-2
1alpha	E-geneY-C3-2
and	O
downstream	O
targets	O
of	O
HIF	S-geneN-C3-2
(	O
endothelin	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
,	O
adrenomedullin	S-geneY-C3-2
,	O
haem	B-geneY-C3-2
oxygenase	I-geneY-C3-2
1	E-geneY-C3-2
,	O
and	O
vascular	B-geneY-C3-2
endothelial	I-geneY-C3-2
growth	I-geneY-C3-2
factor	E-geneY-C3-2
[	O
VEGF	S-geneY-C3-2
]	O
)	O
in	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
and	O
induced	O
endothelial	O
cell	O
-	O
specific	O
proliferation	O
.	O

Hydralazine	S-chem-MU-1
dose	O
-	O
dependently	O
inhibited	O
PHD	S-geneN-C4-2
activity	O
and	O
induced	O
nonhydroxylated	O
HIF	B-geneY-C3-2
-	I-geneY-C3-2
1alpha	E-geneY-C3-2
,	O
evidence	O
for	O
HIF	S-geneN
stabilization	O
specifically	O
by	O
inhibition	O
of	O
PHD	S-geneN-C4-2
enzyme	O
activity	O
.	O

In	O
vivo	O
,	O
hydralazine	S-chem-C3-1
induced	O
HIF	B-geneY-C3-2
-	I-geneY-C3-2
1alpha	E-geneY-C3-2
and	O
VEGF	S-geneY-C3-2
protein	O
in	O
tissue	O
extracts	O
and	O
elevated	O
plasma	O
VEGF	S-geneY-C3-2
levels	O
.	O

In	O
sponge	O
angiogenesis	O
assays	O
,	O
hydralazine	S-chem
increased	O
stromal	O
cell	O
infiltration	O
and	O
blood	O
vessel	O
density	O
versus	O
control	O
animals	O
.	O

Thus	O
,	O
hydralazine	S-chem-MU-1
activates	O
the	O
HIF	S-geneN-C3-2
pathway	O
through	O
inhibition	O
of	O
PHD	S-geneN-C4-2
activity	O
and	O
initiates	O
a	O
pro	O
-	O
angiogenic	O
phenotype	O
.	O

This	O
represents	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
hydralazine	S-chem
and	O
presents	O
HIF	S-geneN
as	O
a	O
potential	O
target	O
for	O
treatment	O
of	O
ischemic	O
disease	O
.	O

Activation	O
of	O
alpha	B-geneY-C3-2
2B	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptors	E-geneY-C3-2
mediates	O
the	O
cardiovascular	O
effects	O
of	O
etomidate	S-chem-C3-1
.	O

BACKGROUND	O
:	O
The	O
intravenous	O
anesthetic	O
etomidate	S-chem
exhibits	O
structural	O
similarities	O
to	O
specific	O
alpha2	B-geneN-C5-2
-	I-geneN-C5-2
adrenoceptor	E-geneN-C5-2
agonists	O
of	O
the	O
type	O
such	O
as	O
dexmedetomidine	S-chem-C5-1
.	O

The	O
current	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
possible	O
interaction	O
of	O
etomidate	S-chem
with	O
alpha2	B-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
mice	O
lacking	O
individual	O
alpha2	B-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
(	O
alpha2	O
-	O
KO	O
)	O
.	O

METHODS	O
:	O
Sedative	O
and	O
cardiovascular	O
responses	O
to	O
etomidate	S-chem
and	O
the	O
alpha2	O
-	O
agonist	O
,	O
dexmedetomidine	S-chem-C5-1
,	O
were	O
determined	O
in	O
mice	O
deficient	O
in	O
alpha2	B-geneN-C5-2
-	I-geneN-C5-2
receptor	E-geneN-C5-2
subtypes	O
.	O

Inhibition	O
of	O
binding	O
of	O
the	O
alpha2	B-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
[	B-chem-C6-1
3H	I-chem-C6-1
]	I-chem-C6-1
RX821002	E-chem-C6-1
to	O
recombinant	O
alpha2	B-geneN-C6-2
-	I-geneN-C6-2
receptors	E-geneN-C6-2
by	O
etomidate	S-chem
was	O
tested	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK293	O
)	O
cells	O
in	O
vitro	O
.	O

RESULTS	O
:	O
In	O
vivo	O
,	O
loss	O
and	O
recovery	O
of	O
the	O
righting	O
reflex	O
required	O
similar	O
times	O
after	O
intraperitoneal	O
injection	O
of	O
etomidate	S-chem
in	O
wild	O
-	O
type	O
and	O
in	O
alpha2A	B-geneY
-	I-geneY
receptor	E-geneY
-	O
deficient	O
mice	O
,	O
indicating	O
that	O
the	O
hypnotic	O
effect	O
of	O
etomidate	S-chem
in	O
mice	O
does	O
not	O
require	O
the	O
alpha2A	B-geneY
-	I-geneY
receptor	E-geneY
subtype	O
.	O

Intravenous	O
injection	O
of	O
etomidate	S-chem
resulted	O
in	O
a	O
transient	O
increase	O
(	O
duration	O
2.4	O
+	O
/	O
-	O
0.2	O
min	O
)	O
in	O
arterial	O
blood	O
pressure	O
in	O
wild	O
-	O
type	O
mice	O
(	O
17	O
+	O
/	O
-	O
3	O
mmHg	O
)	O
.	O

Etomidate	S-chem
did	O
not	O
affect	O
blood	O
pressure	O
in	O
alpha2B	O
-	O
KO	O
or	O
alpha2AB	O
-	O
KO	O
mice	O
.	O

In	O
membranes	O
from	O
HEK293	O
cells	O
transfected	O
with	O
alpha2	B-geneN-C6-2
-	I-geneN-C6-2
receptors	E-geneN-C6-2
,	O
etomidate	S-chem
inhibited	O
binding	O
of	O
the	O
alpha2	O
-	O
antagonist	O
,	O
[	B-chem-C6-1
3H	I-chem-C6-1
]	I-chem-C6-1
RX821002	E-chem-C6-1
,	O
with	O
higher	O
potency	O
from	O
alpha2B	B-geneN
-	I-geneN
and	I-geneN
alpha2C	I-geneN
-	I-geneN
receptors	E-geneN
than	O
from	O
alpha2A	B-geneY-C6-2
-	I-geneY-C6-2
receptors	E-geneY-C6-2
(	O
Ki	O
alpha2A	O
208	O
microm	O
,	O
alpha2B	O
26	O
microm	O
,	O
alpha2C	O
56	O
microm	O
)	O
.	O

In	O
alpha2B	B-geneY
-	I-geneY
receptor	E-geneY
-	O
expressing	O
HEK293	O
cells	O
,	O
etomidate	S-chem-C3-1
rapidly	O
increased	O
phosphorylation	O
of	O
the	O
extracellular	B-geneN-C3-2
signal	I-geneN-C3-2
-	I-geneN-C3-2
related	I-geneN-C3-2
kinases	E-geneN-C3-2
ERK1	B-geneN-C3-2
/	I-geneN-C3-2
2	E-geneN-C3-2
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
etomidate	S-chem-C5-1
acts	O
as	O
an	O
agonist	O
at	O
alpha2	B-geneN-C5-2
-	I-geneN-C5-2
adrenoceptors	E-geneN-C5-2
,	O
which	O
appears	O
in	O
vivo	O
primarily	O
as	O
an	O
alpha2B	B-geneY
-	I-geneY
receptor	E-geneY
-	O
mediated	O
increase	O
in	O
blood	O
pressure	O
.	O

This	O
effect	O
of	O
etomidate	S-chem
may	O
contribute	O
to	O
the	O
cardiovascular	O
stability	O
of	O
patients	O
after	O
induction	O
of	O
anesthesia	O
with	O
etomidate	S-chem
.	O

Vapreotide	S-chem
:	O
a	O
somatostatin	S-geneY
analog	O
for	O
the	O
treatment	O
of	O
acute	O
variceal	O
bleeding	O
.	O

BACKGROUND	O
:	O
Portal	O
hypertension	O
is	O
a	O
clinically	O
important	O
consequence	O
of	O
cirrhosis	O
that	O
can	O
lead	O
to	O
morbidities	O
such	O
as	O
variceal	O
bleeding	O
,	O
hepatic	O
encephalopathy	O
and	O
ascites	O
.	O

All	O
of	O
these	O
outcomes	O
carry	O
high	O
mortality	O
rates	O
.	O

There	O
have	O
been	O
several	O
drugs	O
created	O
to	O
assist	O
with	O
endoscopic	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
variceal	O
bleeding	O
.	O

Recently	O
,	O
vapreotide	S-chem
has	O
been	O
studied	O
in	O
patients	O
to	O
evaluate	O
its	O
efficacy	O
as	O
treatment	O
for	O
acute	O
variceal	O
hemorrhage	O
.	O

Although	O
no	O
comparisons	O
have	O
been	O
made	O
between	O
vapreotide	S-chem
and	O
other	O
somatostatin	S-geneY
analogues	O
,	O
this	O
drug	O
has	O
been	O
shown	O
to	O
have	O
efficacy	O
in	O
the	O
control	O
of	O
acute	O
variceal	O
bleeding	O
as	O
well	O
as	O
reducing	O
the	O
risk	O
of	O
recurrent	O
bleeding	O
and	O
death	O
,	O
especially	O
when	O
started	O
prior	O
to	O
endoscopy	O
.	O

OBJECTIVE	O
:	O
This	O
paper	O
reviews	O
the	O
literature	O
regarding	O
the	O
basic	O
science	O
and	O
clinical	O
efficacy	O
of	O
vapreotide	S-chem
in	O
acute	O
variceal	O
bleeding	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
PubMed	O
/	O
Medline	O
search	O
in	O
order	O
to	O
review	O
the	O
literature	O
regarding	O
the	O
drug	O
,	O
vapreotide	S-chem
.	O

RESULTS	O
/	O
CONCLUSIONS	O
:	O
Vapreotide	S-chem
appears	O
to	O
have	O
benefit	O
in	O
the	O
control	O
of	O
acute	O
variceal	O
bleeding	O
.	O

It	O
is	O
easy	O
to	O
administer	O
and	O
has	O
few	O
side	O
effects	O
,	O
which	O
are	O
minor	O
.	O

These	O
findings	O
endorse	O
the	O
need	O
for	O
future	O
trials	O
to	O
evaluate	O
vapreotide	S-chem
and	O
its	O
use	O
in	O
acute	O
variceal	O
hemorrhage	O
,	O
a	O
morbidity	O
among	O
patients	O
with	O
cirrhosis	O
.	O

Transport	O
by	O
OATP1B1	S-geneY-C9-2
and	O
OATP1B3	S-geneY-C9-2
enhances	O
the	O
cytotoxicity	O
of	O
epigallocatechin	B-chem-C9-1
3	I-chem-C9-1
-	I-chem-C9-1
O	I-chem-C9-1
-	I-chem-C9-1
gallate	E-chem-C9-1
and	O
several	O
quercetin	S-chem-C9-1
derivatives	O
.	O

Organic	B-geneN
anion	I-geneN
transporting	I-geneN
polypeptides	I-geneN
(	I-geneN
OATPs	I-geneN
)	I-geneN
1B1	I-geneN
and	I-geneN
1B3	E-geneN
are	O
transporters	O
that	O
are	O
expressed	O
selectively	O
in	O
human	O
hepatocytes	O
under	O
normal	O
conditions	O
.	O

OATP1B3	S-geneY
is	O
also	O
expressed	O
in	O
certain	O
cancers	O
.	O

Flavonoids	S-chem
such	O
as	O
green	O
tea	O
catechins	S-chem
and	O
quercetin	B-chem
glycosides	E-chem
have	O
been	O
shown	O
to	O
modulate	O
the	O
function	O
of	O
some	O
OATPs	S-geneN
.	O

In	O
the	O
present	O
study	O
,	O
the	O
extent	O
to	O
which	O
six	O
substituted	O
quercetin	S-chem
derivatives	O
(	O
1	O
-	O
6	O
)	O
affected	O
the	O
function	O
of	O
OATP1B1	S-geneY
and	O
OATP1B3	S-geneY
was	O
investigated	O
.	O

Uptake	O
of	O
the	O
radiolabeled	O
model	O
substrates	O
estradiol	B-chem-C9-1
17β	I-chem-C9-1
-	I-chem-C9-1
glucuronide	E-chem-C9-1
,	O
estrone	B-chem-C9-1
3	I-chem-C9-1
-	I-chem-C9-1
sulfate	E-chem-C9-1
,	O
and	O
dehydroepiandrosterone	B-chem-C9-1
sulfate	E-chem-C9-1
(	O
DHEAS	S-chem-C9-1
)	O
was	O
determined	O
in	O
the	O
absence	O
and	O
presence	O
of	O
compounds	O
1	O
-	O
6	O
using	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
stably	O
expressing	O
either	O
OATP1B1	S-geneY-C9-2
or	O
OATP1B3	S-geneY-C9-2
.	O

Several	O
of	O
compounds	O
1	O
-	O
6	O
inhibited	O
OATP	S-geneN
-	O
mediated	O
uptake	O
of	O
all	O
three	O
model	O
substrates	O
,	O
suggesting	O
that	O
they	O
could	O
also	O
be	O
potential	O
substrates	O
.	O

Compound	O
6	O
stimulated	O
OATP1B3	S-geneY-C9-2
-	O
mediated	O
estradiol	B-chem-C9-1
17β	I-chem-C9-1
-	I-chem-C9-1
glucuronide	E-chem-C9-1
uptake	O
by	O
increasing	O
the	O
apparent	O
affinity	O
of	O
OATP1B3	S-geneY-C9-2
for	O
its	O
substrate	O
.	O

Cytotoxicity	O
assays	O
demonstrated	O
that	O
epigallocatechin	B-chem-C9-1
3	I-chem-C9-1
-	I-chem-C9-1
O	I-chem-C9-1
-	I-chem-C9-1
gallate	E-chem-C9-1
(	O
EGCG	S-chem-C9-1
)	O
and	O
most	O
of	O
compounds	O
1	O
-	O
6	O
killed	O
preferentially	O
OATP	S-geneN-C9-2
-	O
expressing	O
CHO	O
cells	O
.	O

EGCG	S-chem
,	O
1	O
,	O
and	O
3	O
were	O
the	O
most	O
potent	O
cytotoxic	O
compounds	O
,	O
with	O
EGCG	S-chem-C9-1
and	O
3	O
selectively	O
killing	O
OATP1B3	S-geneY-C9-2
-	O
expressing	O
cells	O
.	O

Given	O
that	O
OATP1B3	S-geneY
is	O
expressed	O
in	O
several	O
cancers	O
,	O
EGCG	S-chem
and	O
some	O
of	O
the	O
quercetin	S-chem
derivatives	O
studied	O
might	O
be	O
promising	O
lead	O
compounds	O
for	O
the	O
development	O
of	O
novel	O
anticancer	O
drugs	O
.	O

Pre	O
-	O
steady	O
-	O
state	O
currents	O
in	O
neutral	B-geneN
amino	I-geneN
acid	I-geneN
transporters	E-geneN
induced	O
by	O
photolysis	O
of	O
a	O
new	O
caged	O
alanine	S-chem
derivative	O
.	O

Na	B-chem
+	E-chem
-	O
Dependent	O
transmembrane	O
transport	O
of	O
small	O
neutral	O
amino	B-chem-C9-1
acids	E-chem-C9-1
,	O
such	O
as	O
glutamine	S-chem-C9-1
and	O
alanine	S-chem-C9-1
,	O
is	O
mediated	O
,	O
among	O
others	O
,	O
by	O
the	O
neutral	B-geneN-C9-2
amino	I-geneN-C9-2
acid	I-geneN-C9-2
transporters	E-geneN-C9-2
of	O
the	O
solute	B-geneN-C9-2
carrier	I-geneN-C9-2
1	E-geneN-C9-2
[	O
SLC1	S-geneN-C9-2
,	O
alanine	B-geneY-C9-2
serine	I-geneY-C9-2
cysteine	I-geneY-C9-2
transporter	I-geneY-C9-2
1	E-geneY-C9-2
(	O
ASCT1	S-geneY-C9-2
)	O
,	O
and	O
ASCT2	S-geneY-C9-2
]	O
and	O
SLC38	S-geneN-C9-2
families	O
[	O
sodium	B-geneY-C9-2
-	I-geneY-C9-2
coupled	I-geneY-C9-2
neutral	I-geneY-C9-2
amino	I-geneY-C9-2
acid	I-geneY-C9-2
transporter	I-geneY-C9-2
1	E-geneY-C9-2
(	O
SNAT1	S-geneY-C9-2
)	O
,	O
SNAT2	S-geneY-C9-2
,	O
and	O
SNAT4	S-geneY-C9-2
]	O
.	O

Many	O
mechanistic	O
aspects	O
of	O
amino	B-chem
acid	E-chem
transport	O
by	O
these	O
systems	O
are	O
not	O
well	O
-	O
understood	O
.	O

Here	O
,	O
we	O
describe	O
a	O
new	O
photolabile	O
alanine	S-chem-C9-1
derivative	O
based	O
on	O
protection	O
of	O
alanine	S-chem-C9-1
with	O
the	O
4	B-chem-C9-1
-	I-chem-C9-1
methoxy	I-chem-C9-1
-	I-chem-C9-1
7	I-chem-C9-1
-	I-chem-C9-1
nitroindolinyl	E-chem-C9-1
(	O
MNI	S-chem-C9-1
)	O
caging	O
group	O
,	O
which	O
we	O
use	O
for	O
pre	O
-	O
steady	O
-	O
state	O
kinetic	O
analysis	O
of	O
alanine	O
transport	O
by	O
ASCT2	S-geneY-C9-2
,	O
SNAT1	S-geneY-C9-2
,	O
and	O
SNAT2	S-geneY-C9-2
.	O

MNI	O
-	O
alanine	S-chem
has	O
favorable	O
photochemical	O
properties	O
and	O
is	O
stable	O
in	O
aqueous	O
solution	O
.	O

It	O
is	O
also	O
inert	O
with	O
respect	O
to	O
the	O
transport	O
systems	O
studied	O
.	O

Photolytic	O
release	O
of	O
free	O
alanine	S-chem
results	O
in	O
the	O
generation	O
of	O
significant	O
transient	O
current	O
components	O
in	O
HEK293	O
cells	O
expressing	O
the	O
ASCT2	S-geneY
,	O
SNAT1	S-geneY
,	O
and	O
SNAT2	S-geneY
proteins	O
.	O

In	O
ASCT2	S-geneY
,	O
these	O
currents	O
show	O
biphasic	O
decay	O
with	O
time	O
constants	O
,	O
tau	O
,	O
in	O
the	O
1	O
-	O
30	O
ms	O
time	O
range	O
.	O

They	O
are	O
fully	O
inhibited	O
in	O
the	O
absence	O
of	O
extracellular	O
Na	B-chem
+	E-chem
,	O
demonstrating	O
that	O
Na	B-chem
+	E-chem
binding	O
to	O
the	O
transporter	O
is	O
necessary	O
for	O
induction	O
of	O
the	O
alanine	S-chem
-	O
mediated	O
current	O
.	O

For	O
SNAT1	S-geneY
,	O
these	O
transient	O
currents	O
differ	O
in	O
their	O
time	O
course	O
(	O
tau	O
=	O
1.6	O
ms	O
)	O
from	O
previously	O
described	O
pre	O
-	O
steady	O
-	O
state	O
currents	O
generated	O
by	O
applying	O
steps	O
in	O
the	O
membrane	O
potential	O
(	O
tau	O
approximately	O
4	O
-	O
5	O
ms	O
)	O
,	O
indicating	O
that	O
they	O
are	O
associated	O
with	O
a	O
fast	O
,	O
previously	O
undetected	O
,	O
electrogenic	O
partial	O
reaction	O
in	O
the	O
SNAT1	S-geneY
transport	O
cycle	O
.	O

The	O
implications	O
of	O
these	O
results	O
for	O
the	O
mechanisms	O
of	O
transmembrane	O
transport	O
of	O
alanine	S-chem
are	O
discussed	O
.	O

The	O
new	O
caged	O
alanine	S-chem
derivative	O
will	O
provide	O
a	O
useful	O
tool	O
for	O
future	O
,	O
more	O
detailed	O
studies	O
of	O
neutral	O
amino	B-chem
acid	E-chem
transport	O
.	O

Anti	O
-	O
inflammatory	O
effects	O
of	O
trans	B-chem
-	I-chem
1,3	I-chem
-	I-chem
diphenyl	I-chem
-	I-chem
2,3	I-chem
-	I-chem
epoxypropane	I-chem
-	I-chem
1	I-chem
-	I-chem
one	E-chem
mediated	O
by	O
suppression	O
of	O
inflammatory	O
mediators	O
in	O
LPS	O
-	O
stimulated	O
RAW	O
264.7	O
macrophages	O
.	O

To	O
assess	O
the	O
potential	O
therapeutic	O
properties	O
of	O
trans	B-chem
-	I-chem
1,3	I-chem
-	I-chem
diphenyl	I-chem
-	I-chem
2,3	I-chem
-	I-chem
epoxypropane	I-chem
-	I-chem
1	I-chem
-	I-chem
one	E-chem
(	O
DPEP	S-chem
)	O
,	O
its	O
anti	O
-	O
inflammatory	O
effects	O
were	O
investigated	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
mouse	O
macrophage	O
(	O
RAW	O
264.7	O
)	O
cells	O
.	O

DPEP	S-chem-C4-1
induced	O
dose	O
-	O
dependent	O
reduction	O
of	O
the	O
protein	O
levels	O
of	O
inducible	B-geneY-C4-2
nitric	I-geneY-C4-2
oxide	I-geneY-C4-2
synthase	E-geneY-C4-2
(	O
iNOS	S-geneY-C4-2
)	O
and	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
and	O
concomitant	O
reduction	O
in	O
the	O
production	O
of	O
NO	S-chem
and	O
prostaglandin	B-chem
E	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
.	O

Additionally	O
,	O
DPEP	S-chem-C4-1
suppressed	O
the	O
production	O
of	O
inflammatory	O
cytokines	S-geneN-C4-2
,	O
including	O
tumor	B-geneY-C4-2
necrosis	I-geneY-C4-2
factor	I-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
(	O
TNF	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
)	O
,	O
interleukin	B-geneY-C4-2
(	I-geneY-C4-2
IL	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
,	O
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
6	E-geneY-C4-2
.	O

We	O
investigated	O
the	O
mechanism	O
by	O
which	O
DPEP	S-chem
inhibits	O
NO	S-chem
and	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
by	O
examining	O
the	O
level	O
of	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
κB	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
activation	O
within	O
the	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
pathway	O
,	O
which	O
is	O
an	O
inflammation	O
-	O
induced	O
signaling	O
pathway	O
in	O
RAW	O
264.7	O
cells	O
.	O

DPEP	S-chem-C4-1
inhibited	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
ERK	S-geneN-C4-2
,	O
JNK	S-geneN-C4-2
,	O
and	O
p38	S-geneN-C4-2
.	O

Furthermore	O
,	O
DPEP	S-chem-C4-1
inhibited	O
the	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
inhibitor	B-geneY-C4-2
κB	I-geneY-C4-2
(	I-geneY-C4-2
IκB	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
and	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
p50	S-geneY-C4-2
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
DPEP	S-chem-C4-1
inhibits	O
LPS	O
-	O
stimulated	O
inflammation	O
by	O
blocking	O
the	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
and	O
MAPK	S-geneN-C4-2
pathways	O
in	O
macrophages	O
.	O

Differential	O
inhibition	O
of	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
and	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
quinuclinidyl	I-chem
benzilate	E-chem
binding	O
to	O
muscarinic	B-geneN
receptors	E-geneN
in	O
rat	O
brain	O
membranes	O
with	O
acetylcholinesterase	S-geneY
inhibitors	O
.	O

The	O
potential	O
interaction	O
of	O
acetylcholinesterase	S-geneY
inhibitors	O
with	O
cholinergic	B-geneN
receptors	E-geneN
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
therapeutic	O
and	O
/	O
or	O
side	O
-	O
effects	O
associated	O
with	O
this	O
class	O
of	O
compound	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
capacity	O
of	O
acetylcholinesterase	S-geneY
inhibitors	O
to	O
interact	O
with	O
muscarinic	B-geneN
receptors	E-geneN
was	O
assessed	O
by	O
their	O
ability	O
to	O
displace	O
both	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
and	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
quinuclinidyl	I-chem
benzilate	E-chem
binding	O
in	O
rat	O
brain	O
membranes	O
.	O

The	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
quinuclinidyl	I-chem
benzilate	E-chem
/	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
affinity	O
ratios	O
permitted	O
predictions	O
to	O
be	O
made	O
of	O
either	O
the	O
antagonist	O
or	O
agonist	O
properties	O
of	O
the	O
different	O
compounds	O
.	O

A	O
series	O
of	O
compounds	O
,	O
representative	O
of	O
the	O
principal	O
classes	O
of	O
acetylcholinesterase	S-geneY
inhibitors	O
,	O
displaced	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
binding	O
with	O
high	O
-	O
to	O
-	O
moderate	O
potency	O
(	O
ambenonium	S-chem
>	O
neostigmine	S-chem
=	O
pyridostigmine	S-chem
=	O
tacrine	S-chem
>	O
physostigmine	S-chem
>	O
edrophonium	S-chem
=	O
galanthamine	S-chem
>	O
desoxypeganine	S-chem
)	O
whereas	O
only	O
ambenonium	S-chem
and	O
tacrine	S-chem
displaced	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
quinuclinidyl	I-chem
benzilate	E-chem
binding	O
.	O

Inhibitors	O
such	O
as	O
desoxypeganine	S-chem
,	O
parathion	O
and	O
gramine	O
demonstrated	O
negligible	O
inhibition	O
of	O
the	O
binding	O
of	O
both	O
radioligands	O
.	O

Scatchard	O
plots	O
constructed	O
from	O
the	O
inhibition	O
of	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
binding	O
in	O
the	O
absence	O
and	O
presence	O
of	O
different	O
inhibitors	O
showed	O
an	O
unaltered	O
Bmax	O
and	O
a	O
reduced	O
affinity	O
constant	O
,	O
indicative	O
of	O
potential	O
competitive	O
or	O
allosteric	O
mechanisms	O
.	O

The	O
capacity	O
of	O
acetylcholinesterase	S-geneY-C4-2
inhibitors	O
,	O
with	O
the	O
exception	O
of	O
tacrine	S-chem-C4-1
and	O
ambenonium	S-chem-C4-1
,	O
to	O
displace	O
bound	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
in	O
preference	O
to	O
[	B-chem
3H	I-chem
]	I-chem
quinuclinidyl	I-chem
benzilate	E-chem
predicts	O
that	O
the	O
former	O
compounds	O
could	O
act	O
as	O
potential	O
agonists	O
at	O
muscarinic	B-geneN
receptors	E-geneN
.	O

Moreover	O
,	O
the	O
rank	O
order	O
for	O
potency	O
in	O
inhibiting	O
acetylcholinesterase	S-geneY-C4-2
(	O
ambenonium	S-chem-C4-1
>	O
neostigmine	S-chem-C4-1
=	O
physostigmine	S-chem-C4-1
=	O
tacrine	S-chem-C4-1
>	O
pyridostigmine	S-chem-C4-1
=	O
edrophonium	S-chem-C4-1
=	O
galanthamine	S-chem-C4-1
>	O
desoxypeganine	S-chem-C4-1
>	O
parathion	S-chem-C4-1
>	O
gramine	S-chem-C4-1
)	O
indicated	O
that	O
the	O
most	O
effective	O
inhibitors	O
of	O
acetylcholinesterase	S-geneY-C4-2
also	O
displaced	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
to	O
the	O
greatest	O
extent	O
.	O

The	O
capacity	O
of	O
these	O
inhibitors	O
to	O
displace	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	E-chem
-	O
M	O
binding	O
preclude	O
their	O
utilisation	O
for	O
the	O
prevention	O
of	O
acetylcholine	S-chem
catabolism	O
in	O
rat	O
brain	O
membranes	O
,	O
the	O
latter	O
being	O
required	O
to	O
estimate	O
the	O
binding	O
of	O
acetylcholine	O
to	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
-	O
labelled	O
muscarinic	B-geneN
receptors	E-geneN
.	O

However	O
,	O
fasciculin	O
-	O
2	O
,	O
a	O
potent	O
peptide	O
inhibitor	O
of	O
acetylcholinesterase	S-geneY
(	O
IC50	O
24	O
nM	O
)	O
,	O
did	O
prevent	O
catabolism	O
of	O
acetylcholine	S-chem
in	O
rat	O
brain	O
membranes	O
with	O
an	O
atypical	O
inhibition	O
isotherm	O
of	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	I-chem
-	I-chem
M	E-chem
binding	O
,	O
thus	O
permitting	O
an	O
estimation	O
of	O
the	O
``	O
global	O
affinity	O
``	O
of	B-chem
acetylcholine	O
(	O
Ki	O
85	O
nM	O
)	O
for	O
[	I-chem
3H	I-chem
]	I-chem
-	I-chem
oxotremorine	E-chem
-	O
M	O
-	O
labelled	O
muscarinic	I-geneN
receptors	O
in	O
rat	O
brain	O
.	O

Membranar	O
effects	O
exerted	O
in	O
vitro	O
by	O
polyphenols	S-chem
-	O
quercetin	S-chem
,	O
epigallocatechin	B-chem
gallate	E-chem
and	O
curcumin	S-chem
-	O
on	O
HUVEC	O
and	O
Jurkat	O
cells	O
,	O
relevant	O
for	O
diabetes	O
mellitus	O
.	O

Polyphenols	S-chem
are	O
largely	O
studied	O
for	O
their	O
beneficial	O
action	O
in	O
various	O
pathologies	O
,	O
but	O
the	O
correlation	O
with	O
their	O
effects	O
on	O
cell	O
membranes	O
is	O
still	O
elusive	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
the	O
effects	O
exerted	O
in	O
vitro	O
by	O
quercetin	S-chem
,	O
epigallocatechin	B-chem
gallate	E-chem
and	O
curcumin	S-chem
on	O
membrane	O
fluidity	O
and	O
transmembrane	O
potential	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
and	O
Jurkat	O
T	O
lymphoblasts	O
,	O
in	O
experimental	O
conditions	O
mimicking	O
diabetes	O
mellitus	O
,	O
i.e	O
.	O
high	O
glucose	S-chem
conditions	O
or	O
increased	O
concentration	O
of	O
advanced	O
glycation	O
end	O
products	O
.	O

Results	O
showed	O
that	O
the	O
investigated	O
polyphenols	S-chem
had	O
beneficial	O
effects	O
on	O
cell	O
membranes	O
altered	O
in	O
diabetic	O
conditions	O
,	O
by	O
restoring	O
transmembrane	O
potential	O
and	O
by	O
membrane	O
``	O
stiffening	O
``	O
.	O

Moreover	O
,	O
they	O
limited	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
factors	O
,	O
like	O
monocyte	B-geneY
chemotactic	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
.	O

These	O
effects	O
were	O
more	O
obvious	O
for	O
cells	O
exposed	O
to	O
advanced	O
glycation	O
end	O
products	O
specific	O
for	O
the	O
late	O
stages	O
of	O
diabetes	O
.	O

Apparently	O
,	O
the	O
inhibitory	O
action	O
of	O
polyphenols	S-chem
on	O
lipid	O
peroxidation	O
was	O
associated	O
with	O
a	O
decrease	O
of	O
membrane	O
fluidity	O
.	O

Concluding	O
,	O
our	O
in	O
vitro	O
study	O
highlighted	O
the	O
potential	O
beneficial	O
action	O
of	O
polyphenols	S-chem
mainly	O
in	O
the	O
late	O
stages	O
of	O
diabetes	O
,	O
exerted	O
at	O
the	O
level	O
of	O
membrane	O
fluidity	O
and	O
transmembrane	O
potential	O
,	O
accompanied	O
by	O
an	O
anti	O
-	O
inflammatory	O
effect	O
on	O
endothelial	O
and	O
immune	O
cells	O
.	O

Metabolic	O
pathways	O
of	O
inhaled	O
glucocorticoids	O
by	O
the	O
CYP3A	S-geneN
enzymes	O
.	O

Asthma	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
diseases	O
in	O
the	O
world	O
,	O
for	O
which	O
the	O
mainstay	O
treatment	O
has	O
been	O
inhaled	O
glucocorticoids	O
(	O
GCs	O
)	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
these	O
drugs	O
,	O
approximately	O
30	O
%	O
of	O
asthma	O
sufferers	O
exhibit	O
some	O
degree	O
of	O
steroid	S-chem
insensitivity	O
or	O
are	O
refractory	O
to	O
inhaled	O
GCs	O
.	O

One	O
hypothesis	O
to	O
explain	O
this	O
phenomenon	O
is	O
interpatient	O
variability	O
in	O
the	O
clearance	O
of	O
these	O
compounds	O
.	O

The	O
objective	O
of	O
this	O
research	O
is	O
to	O
determine	O
how	O
metabolism	O
of	O
GCs	O
by	O
the	O
CYP3A	S-geneN
family	O
of	O
enzymes	O
could	O
affect	O
their	O
effectiveness	O
in	O
asthmatic	O
patients	O
.	O

In	O
this	O
work	O
,	O
the	O
metabolism	O
of	O
four	O
frequently	O
prescribed	O
inhaled	O
GCs	O
,	O
triamcinolone	B-chem-C9-1
acetonide	E-chem-C9-1
,	O
flunisolide	S-chem-C9-1
,	O
budesonide	S-chem-C9-1
,	O
and	O
fluticasone	B-chem-C9-1
propionate	E-chem-C9-1
,	O
by	O
the	O
CYP3A	S-geneN-C9-2
family	O
of	O
enzymes	O
was	O
studied	O
to	O
identify	O
differences	O
in	O
their	O
rates	O
of	O
clearance	O
and	O
to	O
identify	O
their	O
metabolites	O
.	O

Both	O
interenzyme	O
and	O
interdrug	O
variability	O
in	O
rates	O
of	O
metabolism	O
and	O
metabolic	O
fate	O
were	O
observed	O
.	O

CYP3A4	S-geneY
was	O
the	O
most	O
efficient	O
metabolic	O
catalyst	O
for	O
all	O
the	O
compounds	O
,	O
and	O
CYP3A7	S-geneY
had	O
the	O
slowest	O
rates	O
.	O

CYP3A5	S-geneY-C9-2
,	O
which	O
is	O
particularly	O
relevant	O
to	O
GC	O
metabolism	O
in	O
the	O
lungs	O
,	O
was	O
also	O
shown	O
to	O
efficiently	O
metabolize	O
triamcinolone	B-chem-C9-1
acetonide	E-chem-C9-1
,	O
budesonide	S-chem-C9-1
,	O
and	O
fluticasone	B-chem-C9-1
propionate	E-chem-C9-1
.	O

In	O
contrast	O
,	O
flunisolide	S-chem-C9-1
was	O
only	O
metabolized	O
via	O
CYP3A4	S-geneY-C9-2
,	O
with	O
no	O
significant	O
turnover	O
by	O
CYP3A5	S-geneY
or	O
CYP3A7	S-geneY
.	O

Common	O
metabolites	O
included	O
6β	O
-	O
hydroxylation	O
and	O
Δ	O
(	O
6	O
)	O
-	O
dehydrogenation	O
for	O
triamcinolone	B-chem
acetonide	E-chem
,	O
budesonide	S-chem
,	O
and	O
flunisolide	S-chem
.	O

The	O
structure	O
of	O
Δ	B-chem
(	I-chem
6	I-chem
)	I-chem
-	I-chem
flunisolide	E-chem
was	O
unambiguously	O
established	O
by	O
NMR	O
analysis	O
.	O

Metabolism	O
also	O
occurred	O
on	O
the	O
D	O
-	O
ring	O
substituents	O
,	O
including	O
the	O
21	B-chem
-	I-chem
carboxy	E-chem
metabolites	O
for	O
triamcinolone	B-chem
acetonide	E-chem
and	O
flunisolide	S-chem
.	O

The	O
novel	O
metabolite	O
21	B-chem
-	I-chem
nortriamcinolone	I-chem
acetonide	E-chem
was	O
also	O
identified	O
by	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
and	O
NMR	O
analysis	O
.	O

Novel	O
therapeutic	O
targets	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Oncogenic	O
driver	O
mutations	O
frequently	O
occur	O
in	O
lung	O
cancer	O
and	O
play	O
role	O
in	O
carcinogenesis	O
.	O

These	O
mutations	O
are	O
usually	O
associated	O
with	O
distinct	O
clinical	O
and	O
histological	O
features	O
and	O
are	O
attractive	O
targets	O
for	O
anticancer	O
therapy	O
.	O

Recently	O
,	O
several	O
molecularly	O
distinct	O
phenotypes	O
of	O
NSCLC	O
based	O
on	O
specific	O
and	O
mutually	O
exclusive	O
genetic	O
derangements	O
have	O
been	O
described	O
.	O

Few	O
targets	O
like	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
mutations	O
and	O
anaplastic	B-geneY
lymphoma	I-geneY
kinase	E-geneY
(	O
ALK	S-geneY
)	O
gene	O
rearrangements	O
have	O
successfully	O
been	O
targeted	O
with	O
EGFR	S-geneY
tyrosine	B-geneN
kinase	E-geneN
inhibitors	O
(	O
TKIs	O
)	O
and	O
crizotinib	S-chem
,	O
respectively	O
.	O

Many	O
more	O
inhibitors	O
of	O
specific	O
driver	O
mutations	O
involving	O
genes	O
like	O
ROS	S-geneY
,	O
c	B-geneY
-	I-geneY
MET	E-geneY
,	O
FGFR	S-geneN
,	O
mTOR	S-geneY
,	O
IGFR	S-geneY
and	O
RET	S-geneY
are	O
currently	O
under	O
development	O
.	O

However	O
,	O
efforts	O
to	O
target	O
some	O
mutated	O
genes	O
like	O
K	B-geneY
-	I-geneY
RAS	E-geneY
have	O
been	O
unsuccessful	O
.	O

Moreover	O
,	O
the	O
emerging	O
challenge	O
of	O
acquired	O
resistance	O
to	O
initially	O
effective	O
therapy	O
is	O
becoming	O
another	O
major	O
concern	O
.	O

In	O
this	O
review	O
recent	O
data	O
on	O
novel	O
molecular	O
targets	O
and	O
their	O
future	O
prospects	O
are	O
discussed	O
.	O

Analgesic	O
and	O
anti	O
-	O
inflammatory	O
activities	O
of	O
aqueous	O
extract	O
from	O
Glycine	S-chem
tomentella	O
root	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
analgesic	O
effect	O
of	O
the	O
aqueous	O
extract	O
of	O
the	O
root	O
of	O
Glycine	S-chem
tomentella	O
(	O
AGT	O
)	O
using	O
models	O
of	O
acetic	B-chem
acid	E-chem
-	O
induced	O
writhing	O
response	O
and	O
formalin	S-chem
test	O
,	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
AGT	O
using	O
model	O
of	O
lambda	O
-	O
carrageenan	O
-	O
induced	O
paw	O
edema	O
.	O

In	O
order	O
to	O
investigate	O
the	O
anti	O
-	O
inflammatory	O
mechanism	O
of	O
AGT	O
,	O
we	O
have	O
detected	O
the	O
activities	O
of	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GPx	S-geneN
)	O
and	O
glutathione	B-geneY
reductase	E-geneY
(	O
GRx	S-geneY
)	O
in	O
the	O
liver	O
and	O
the	O
levels	O
of	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
and	O
NO	S-chem
in	O
the	O
edema	O
paw	O
.	O

In	O
the	O
analgesic	O
test	O
,	O
AGT	O
(	O
0.5	O
and	O
1.0	O
g	O
/	O
kg	O
)	O
decreased	O
the	O
acetic	B-chem
acid	E-chem
-	O
induced	O
writhing	O
response	O
and	O
the	O
licking	O
time	O
on	O
the	O
late	O
phase	O
in	O
the	O
formalin	S-chem
test	O
.	O

In	O
the	O
anti	O
-	O
inflammatory	O
test	O
,	O
AGT	O
(	O
0.5	O
and	O
1.0	O
g	O
/	O
kg	O
)	O
decreased	O
the	O
paw	O
edema	O
at	O
the	O
third	O
,	O
fourth	O
,	O
fifth	O
and	O
sixth	O
hour	O
after	O
lambda	O
-	O
carrageenan	O
administration	O
,	O
and	O
increased	O
the	O
activities	O
of	O
SOD	S-geneN
,	O
GPx	S-geneN
and	O
GRx	S-geneY
in	O
the	O
liver	O
tissue	O
and	O
decreased	O
the	O
MDA	S-chem
level	O
in	O
the	O
edema	O
paw	O
at	O
the	O
third	O
hour	O
after	O
lambda	O
-	O
carrageenan	O
injection	O
.	O

However	O
,	O
AGT	O
could	O
not	O
affect	O
the	O
NO	S-chem
level	O
which	O
induced	O
by	O
lambda	O
-	O
carrageenan	O
.	O

These	O
results	O
suggested	O
that	O
AGT	O
possessed	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
anti	O
-	O
inflammatory	O
mechanism	O
of	O
AGT	O
might	O
be	O
related	O
to	O
the	O
decrease	O
in	O
the	O
level	O
of	O
MDA	S-chem
in	O
the	O
edema	O
paw	O
via	O
increasing	O
the	O
activities	O
of	O
SOD	S-geneN
,	O
GPx	S-geneN
and	O
GRx	S-geneY
in	O
the	O
liver	O
.	O

Atomoxetine	S-chem
increases	O
extracellular	O
levels	O
of	O
norepinephrine	S-chem
and	O
dopamine	S-chem
in	O
prefrontal	O
cortex	O
of	O
rat	O
:	O
a	O
potential	O
mechanism	O
for	O
efficacy	O
in	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O

The	O
selective	O
norepinephrine	B-geneY-C4-2
(	I-geneY-C4-2
NE	I-geneY-C4-2
)	I-geneY-C4-2
transporter	E-geneY-C4-2
inhibitor	O
atomoxetine	S-chem-C4-1
(	O
formerly	O
called	O
tomoxetine	S-chem-C4-1
or	O
LY139603	S-chem-C4-1
)	O
has	O
been	O
shown	O
to	O
alleviate	O
symptoms	O
in	O
Attention	O
Deficit	O
/	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O

We	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
atomoxetine	S-chem
in	O
ADHD	O
by	O
evaluating	O
the	O
interaction	O
of	O
atomoxetine	S-chem
with	O
monoamine	B-geneN
transporters	E-geneN
,	O
the	O
effects	O
on	O
extracellular	O
levels	O
of	O
monoamines	S-chem
,	O
and	O
the	O
expression	O
of	O
the	O
neuronal	O
activity	O
marker	O
Fos	S-geneY
in	O
brain	O
regions	O
.	O

Atomoxetine	S-chem
inhibited	O
binding	O
of	O
radioligands	O
to	O
clonal	O
cell	O
lines	O
transfected	O
with	O
human	B-geneN
NE	I-geneN
,	I-geneN
serotonin	I-geneN
(	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
and	I-geneN
dopamine	I-geneN
(	I-geneN
DA	I-geneN
)	I-geneN
transporters	E-geneN
with	O
dissociation	O
constants	O
(	O
K	O
(	O
i	O
)	O
)	O
values	O
of	O
5	O
,	O
77	O
and	O
1451	O
nM	O
,	O
respectively	O
,	O
demonstrating	O
selectivity	O
for	O
NE	B-geneY
transporters	E-geneY
.	O

In	O
microdialysis	O
studies	O
,	O
atomoxetine	S-chem
increased	O
extracellular	O
(	O
EX	O
)	O
levels	O
of	O
NE	S-chem
in	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
3	O
-	O
fold	O
,	O
but	O
did	O
not	O
alter	O
5	O
-	O
HT	O
(	O
EX	O
)	O
levels	O
.	O

Atomoxetine	S-chem
also	O
increased	O
DA	O
(	O
EX	O
)	O
concentrations	O
in	O
PFC	O
3	O
-	O
fold	O
,	O
but	O
did	O
not	O
alter	O
DA	O
(	O
EX	O
)	O
in	O
striatum	O
or	O
nucleus	O
accumbens	O
.	O

In	O
contrast	O
,	O
the	O
psychostimulant	O
methylphenidate	S-chem
,	O
which	O
is	O
used	O
in	O
ADHD	O
therapy	O
,	O
increased	O
NE	O
(	O
EX	O
)	O
and	O
DA	O
(	O
EX	O
)	O
equally	O
in	O
PFC	O
,	O
but	O
also	O
increased	O
DA	O
(	O
EX	O
)	O
in	O
the	O
striatum	O
and	O
nucleus	O
accumbens	O
to	O
the	O
same	O
level	O
.	O

The	O
expression	O
of	O
the	O
neuronal	O
activity	O
marker	O
Fos	S-geneY
was	O
increased	O
3.7	O
-	O
fold	O
in	O
PFC	O
by	O
atomoxetine	S-chem
administration	O
,	O
but	O
was	O
not	O
increased	O
in	O
the	O
striatum	O
or	O
nucleus	O
accumbens	O
,	O
consistent	O
with	O
the	O
regional	O
distribution	O
of	O
increased	O
DA	O
(	O
EX	O
)	O
.	O

We	O
hypothesize	O
that	O
the	O
atomoxetine	S-chem
-	O
induced	O
increase	O
of	O
catecholamines	S-chem
in	O
PFC	O
,	O
a	O
region	O
involved	O
in	O
attention	O
and	O
memory	O
,	O
mediates	O
the	O
therapeutic	O
effects	O
of	O
atomoxetine	S-chem
in	O
ADHD	O
.	O

In	O
contrast	O
to	O
methylphenidate	S-chem
,	O
atomoxetine	S-chem
did	O
not	O
increase	O
DA	S-chem
in	O
striatum	O
or	O
nucleus	O
accumbens	O
,	O
suggesting	O
it	O
would	O
not	O
have	O
motoric	O
or	O
drug	O
abuse	O
liabilities	O
.	O

Add	O
-	O
on	O
therapy	O
with	O
the	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
inhibitor	O
sitagliptin	S-chem-C4-1
improves	O
glycemic	O
control	O
in	O
insulin	S-geneY
-	O
treated	O
Japanese	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

The	O
effect	O
of	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	S-chem
on	O
glycemic	O
control	O
was	O
prospectively	O
investigated	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
receiving	O
insulin	S-geneY
alone	O
or	O
insulin	S-geneN
combined	O
with	O
oral	O
antidiabetic	O
drugs	O
.	O

Seventy	O
-	O
one	O
patients	O
were	O
evaluated	O
(	O
38	O
men	O
and	O
33	O
women	O
aged	O
63.9±10.2	O
years	O
)	O
.	O

They	O
were	O
divided	O
into	O
three	O
groups	O
,	O
which	O
were	O
45	O
patients	O
receiving	O
premixed	O
insulin	S-geneY
twice	O
daily	O
,	O
15	O
patients	O
receiving	O
multiple	O
daily	O
insulin	S-geneY
injections	O
,	O
and	O
11	O
patients	O
receiving	O
basal	O
insulin	S-geneY
with	O
oral	O
antidiabetic	O
drugs	O
(	O
basal	O
insulin	S-geneY
therapy	O
)	O
.	O

Concomitant	O
oral	O
drugs	O
included	O
sulfonylureas	S-chem
,	O
α	B-geneN
-	I-geneN
glucosidase	E-geneN
inhibitors	O
and	O
metformin	S-chem
.	O

The	O
hemoglobin	B-geneY-C3-2
A1c	E-geneY-C3-2
(	O
HbA1c	S-geneY-C3-2
)	O
of	O
all	O
patients	O
improved	O
significantly	O
from	O
8.1±1.2	O
%	O
to	O
7.6±1.1	O
%	O
after	O
12	O
weeks	O
of	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	S-chem-C3-1
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
the	O
insulin	S-geneY
dosage	O
was	O
reduced	O
from	O
27.3±15.8	O
U	O
/	O
day	O
to	O
24.5±16.5	O
U	O
/	O
day	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Body	O
weight	O
did	O
not	O
change	O
after	O
the	O
start	O
of	O
concomitant	O
therapy	O
and	O
severe	O
hypoglycemia	O
was	O
not	O
observed	O
.	O

The	O
baseline	O
HbA1c	S-geneY
and	O
glycated	B-geneY
albumin	E-geneY
levels	O
were	O
identified	O
as	O
factors	O
that	O
predicted	O
the	O
response	O
to	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	S-chem
.	O

These	O
findings	O
suggest	O
that	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	S-chem
can	O
be	O
expected	O
to	O
achieve	O
improvement	O
of	O
poor	O
glycemic	O
control	O
irrespective	O
of	O
a	O
patient	O
's	O
demographic	O
profile	O
.	O

Stratified	O
analysis	O
based	O
on	O
the	O
insulin	S-geneY
regimen	O
revealed	O
a	O
stronger	O
antidiabetic	O
effect	O
and	O
a	O
high	O
efficacy	O
of	O
sitagliptin	S-chem
when	O
it	O
was	O
added	O
to	O
basal	O
insulin	S-geneY
therapy	O
.	O

The	O
results	O
of	O
this	O
investigation	O
confirmed	O
that	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	S-chem
to	O
various	O
insulin	S-geneY
regimens	O
could	O
improve	O
glycemic	O
control	O
without	O
severe	O
hypoglycemia	O
and	O
/	O
or	O
weight	O
gain	O
.	O

Molecular	O
mechanism	O
of	O
terbinafine	S-chem
resistance	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Ten	O
mutants	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
resistant	O
to	O
the	O
antimycotic	O
terbinafine	S-chem
were	O
isolated	O
after	O
chemical	O
or	O
UV	O
mutagenesis	O
.	O

Molecular	O
analysis	O
of	O
these	O
mutants	O
revealed	O
single	O
base	O
pair	O
exchanges	O
in	O
the	O
ERG1	S-geneY
gene	O
coding	O
for	O
squalene	B-geneY
epoxidase	E-geneY
,	O
the	O
target	O
of	O
terbinafine	S-chem
.	O

The	O
mutants	O
did	O
not	O
show	O
cross	O
-	O
resistance	O
to	O
any	O
of	O
the	O
substrates	O
of	O
various	O
pleiotropic	O
drug	O
resistance	O
efflux	O
pumps	O
tested	O
.	O

The	O
ERG1	S-geneY
mRNA	O
levels	O
in	O
the	O
mutants	O
did	O
not	O
differ	O
from	O
those	O
in	O
the	O
wild	O
-	O
type	O
parent	O
strains	O
.	O

Terbinafine	S-chem
resistance	O
was	O
transmitted	O
with	O
the	O
mutated	O
alleles	O
in	O
gene	O
replacement	O
experiments	O
,	O
proving	O
that	O
single	O
amino	B-chem
acid	E-chem
substitutions	O
in	O
the	O
Erg1	S-geneY
protein	O
were	O
sufficient	O
to	O
confer	O
the	O
resistance	O
phenotype	O
.	O

The	O
amino	B-chem
acid	E-chem
changes	O
caused	O
by	O
the	O
point	O
mutations	O
were	O
clustered	O
in	O
two	O
regions	O
of	O
the	O
Erg1	S-geneY
protein	O
.	O

Seven	O
mutants	O
carried	O
the	O
amino	B-chem
acid	E-chem
substitutions	O
F402L	S-geneN
(	O
one	O
mutant	O
)	O
,	O
F420L	S-geneN
(	O
one	O
mutant	O
)	O
,	O
and	O
P430S	S-geneN
(	O
five	O
mutants	O
)	O
in	O
the	O
C	S-chem
-	O
terminal	O
part	O
of	O
the	O
protein	O
;	O
and	O
three	O
mutants	O
carried	O
an	O
L251F	S-geneN
exchange	O
in	O
the	O
central	O
part	O
of	O
the	O
protein	O
.	O

Interestingly	O
,	O
all	O
exchanges	O
identified	O
involved	O
amino	B-chem
acids	E-chem
which	O
are	O
conserved	O
in	O
the	O
squalene	B-geneN
epoxidases	E-geneN
of	O
yeasts	O
and	O
mammals	O
.	O

Two	O
mutations	O
that	O
were	O
generated	O
by	O
PCR	O
mutagenesis	O
of	O
the	O
ERG1	S-geneY
gene	O
and	O
that	O
conferred	O
terbinafine	S-chem
resistance	O
mapped	O
in	O
the	O
same	O
regions	O
of	O
the	O
Erg1	S-geneY
protein	O
,	O
with	O
one	O
resulting	O
in	O
an	O
L251F	S-geneN
exchange	O
and	O
the	O
other	O
resulting	O
in	O
an	O
F433S	S-geneN
exchange	O
.	O

The	O
results	O
strongly	O
indicate	O
that	O
these	O
regions	O
are	O
responsible	O
for	O
the	O
interaction	O
of	O
yeast	B-geneY
squalene	I-geneY
epoxidase	E-geneY
with	O
terbinafine	S-chem
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
were	O
investigated	O
with	O
a	O
study	O
of	O
carbon	B-chem
tetrachloride	E-chem
(	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
)	O
-	O
induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
male	O
ICR	O
mice	O
.	O

Oral	O
administration	O
of	O
green	O
tea	O
extract	O
at	O
doses	O
of	O
125	O
,	O
625	O
and	O
1250	O
mg	O
/	O
kg	O
for	O
8	O
weeks	O
significantly	O
reduced	O
(	O
p	O
<	O
0.05	O
)	O
the	O
levels	O
of	O
thiobarbituric	B-chem
acid	E-chem
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
protein	O
carbonyls	S-chem
in	O
the	O
liver	O
by	O
at	O
least	O
28	O
%	O
compared	O
with	O
that	O
was	O
induced	O
by	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
(	O
1	O
mL	O
/	O
kg	O
)	O
in	O
mice	O
.	O

Moreover	O
,	O
green	O
tea	O
extract	O
administration	O
significantly	O
increased	O
(	O
p	O
<	O
0.05	O
)	O
the	O
activities	O
of	O
catalase	S-geneY
,	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GSH	B-geneN
-	I-geneN
Px	E-geneN
)	O
and	O
glutathione	B-geneY
reductase	E-geneY
(	O
GSH	B-geneY
-	I-geneY
Rd	E-geneY
)	O
in	O
the	O
liver	O
.	O

Our	O
study	O
found	O
that	O
oral	O
administration	O
of	O
green	O
tea	O
extract	O
prevented	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
-	O
induced	O
hepatic	O
fibrosis	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
hydroxyproline	S-chem
level	O
in	O
the	O
liver	O
and	O
a	O
reduced	O
incidence	O
of	O
hepatic	O
fibrosis	O
by	O
histological	O
observations	O
.	O

These	O
results	O
indicate	O
that	O
green	O
tea	O
exhibits	O
potent	O
protective	O
effects	O
against	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
-	O
induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
mice	O
by	O
inhibiting	O
oxidative	O
damage	O
and	O
increasing	O
antioxidant	O
enzyme	O
activities	O
.	O

Artificial	O
sweeteners	O
and	O
salts	O
producing	O
a	O
metallic	O
taste	O
sensation	O
activate	O
TRPV1	S-geneY
receptors	O
.	O

Throughout	O
the	O
world	O
many	O
people	O
use	O
artificial	O
sweeteners	O
(	O
AS	O
)	O
for	O
the	O
purpose	O
of	O
reducing	O
caloric	O
intake	O
.	O

The	O
most	O
prominently	O
used	O
of	O
these	O
molecules	O
include	O
saccharin	S-chem
,	O
aspartame	S-chem
(	O
Nutrasweet	S-chem
)	O
,	O
acesulfame	B-chem
-	I-chem
K	E-chem
,	O
and	O
cyclamate	S-chem
.	O

Despite	O
the	O
caloric	O
advantage	O
they	O
provide	O
,	O
one	O
key	O
concern	O
in	O
their	O
use	O
is	O
their	O
aversive	O
aftertaste	O
that	O
has	O
been	O
characterized	O
on	O
a	O
sensory	O
level	O
as	O
bitter	O
and	O
/	O
or	O
metallic	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
activation	O
of	O
particular	O
T2R	S-geneN-C3-2
bitter	O
taste	O
receptors	O
is	O
partially	O
involved	O
with	O
the	O
bitter	O
aftertaste	O
sensation	O
of	O
saccharin	S-chem-C3-1
and	O
acesulfame	B-chem-C3-1
-	I-chem-C3-1
K	E-chem-C3-1
.	O

To	O
more	O
fully	O
understand	O
the	O
biology	O
behind	O
these	O
phenomena	O
we	O
have	O
addressed	O
the	O
question	O
of	O
whether	O
AS	O
could	O
stimulate	O
transient	B-geneY
receptor	I-geneY
potential	I-geneY
vanilloid	I-geneY
-	I-geneY
1	I-geneY
(	I-geneY
TRPV1	I-geneY
)	I-geneY
receptors	E-geneY
,	O
as	O
these	O
receptors	O
are	O
activated	O
by	O
a	O
large	O
range	O
of	O
structurally	O
different	O
chemicals	O
.	O

Moreover	O
,	O
TRPV1	S-geneY
receptors	O
and	O
/	O
or	O
their	O
variants	O
are	O
found	O
in	O
taste	O
receptor	O
cells	O
and	O
in	O
nerve	O
terminals	O
throughout	O
the	O
oral	O
cavity	O
.	O

Hence	O
,	O
TRPV1	S-geneY
activation	O
could	O
be	O
involved	O
in	O
the	O
AS	O
aftertaste	O
or	O
even	O
contribute	O
to	O
the	O
poorly	O
understood	O
metallic	O
taste	O
sensation	O
.	O

Using	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
imaging	O
on	O
TRPV1	S-geneY
receptors	O
heterologously	O
expressed	O
in	O
the	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cells	O
and	O
on	O
dissociated	O
primary	O
sensory	O
neurons	O
,	O
we	O
find	O
that	O
in	O
both	O
systems	O
,	O
AS	O
activate	O
TRPV1	S-geneY
receptors	O
,	O
and	O
,	O
moreover	O
,	O
they	O
sensitize	O
these	O
channels	O
to	O
acid	O
and	O
heat	O
.	O

We	O
also	O
found	O
that	O
TRPV1	S-geneY-C3-2
receptors	O
are	O
activated	O
by	O
CuSO	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
,	O
ZnSO	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
,	O
and	O
FeSO	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
,	O
three	O
salts	O
known	O
to	O
produce	O
a	O
metallic	O
taste	O
sensation	O
.	O

In	O
summary	O
,	O
our	O
results	O
identify	O
a	O
novel	O
group	O
of	O
compounds	O
that	O
activate	O
TRPV1	S-geneY
and	O
,	O
consequently	O
,	O
provide	O
a	O
molecular	O
mechanism	O
that	O
may	O
account	O
for	O
off	O
tastes	O
of	O
sweeteners	O
and	O
metallic	O
tasting	O
salts	O
.	O

Pranlukast	S-chem-MU-1
,	O
a	O
leukotriene	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
inhibits	O
interleukin	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
production	O
via	O
a	O
mechanism	O
distinct	O
from	O
leukotriene	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonism	O
.	O

BACKGROUND	O
:	O
Pranlukast	S-chem-C6-1
,	O
a	O
cysteinyl	B-geneY-C6-2
leukotriene	I-geneY-C6-2
receptor	I-geneY-C6-2
1	E-geneY-C6-2
(	O
CysLTR1	S-geneY-C6-2
)	O
antagonist	O
,	O
inhibits	O
not	O
only	O
airway	O
smooth	O
muscle	O
contraction	O
,	O
but	O
also	O
allergic	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
mechanism	O
of	O
pranlukast	S-chem-C4-1
-	O
induced	O
interleukin	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
(	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
)	O
inhibition	O
in	O
allergic	O
inflammation	O
.	O

METHODS	O
:	O
Surgically	O
resected	O
human	O
lung	O
tissue	O
was	O
passively	O
sensitized	O
in	O
vitro	O
with	O
mite	O
-	O
allergen	O
-	O
sensitized	O
sera	O
,	O
followed	O
by	O
stimulation	O
with	O
mite	O
allergen	O
after	O
pretreatment	O
of	O
the	O
tissue	O
with	O
pranlukast	S-chem
,	O
dexamethasone	S-chem
,	O
or	O
both	O
.	O

The	O
IL	B-geneY
-	I-geneY
5	E-geneY
protein	O
level	O
in	O
the	O
culture	O
medium	O
was	O
measured	O
,	O
and	O
in	O
situ	O
hybridization	O
of	O
IL	B-geneY
-	I-geneY
5	E-geneY
and	O
CysLTR1	S-geneY
mRNA	O
was	O
performed	O
using	O
lung	O
tissues	O
.	O

RESULTS	O
:	O
Pretreatment	O
of	O
lung	O
tissues	O
with	O
pranlukast	S-chem-C4-1
alone	O
significantly	O
decreased	O
the	O
amount	O
of	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
protein	O
in	O
the	O
culture	O
medium	O
by	O
40	O
%	O
.	O

The	O
combination	O
of	O
pranlukast	S-chem
and	O
dexamethasone	S-chem
synergistically	O
enhanced	O
this	O
effect	O
.	O

Quantitative	O
in	O
situ	O
hybridization	O
with	O
image	O
analysis	O
revealed	O
abundant	O
expression	O
of	O
IL	B-geneY
-	I-geneY
5	E-geneY
mRNA	O
in	O
eosinophils	O
,	O
lymphocytes	O
,	O
and	O
mast	O
cells	O
in	O
sensitized	O
and	O
allergen	O
-	O
stimulated	O
lung	O
tissues	O
.	O

CysLTR1	S-geneY
mRNA	O
was	O
detected	O
in	O
macrophages	O
,	O
smooth	O
muscle	O
cells	O
,	O
eosinophils	O
,	O
and	O
mast	O
cells	O
,	O
but	O
was	O
less	O
expressed	O
in	O
lymphocytes	O
.	O

Pranlukast	S-chem-C4-1
-	O
induced	O
inhibition	O
of	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
mRNA	O
expression	O
was	O
noted	O
in	O
various	O
cells	O
,	O
irrespective	O
of	O
their	O
CysLTR1	S-geneY
mRNA	O
expression	O
status	O
.	O

In	O
addition	O
,	O
cysteinyl	B-chem
leukotrienes	E-chem
per	O
se	O
failed	O
to	O
upregulate	O
the	O
IL	B-geneY
-	I-geneY
5	E-geneY
production	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
indicate	O
that	O
pranlukast	S-chem-MU-1
inhibits	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
synthesis	O
via	O
a	O
mechanism	O
distinct	O
from	O
CysLTR1	S-geneY-C6-2
antagonism	O
.	O

Verapamil	S-chem
prevents	O
torsade	O
de	O
pointes	O
by	O
reduction	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
suppression	O
of	O
early	O
afterdepolarizations	O
in	O
an	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

BACKGROUND	O
:	O
In	O
long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
,	O
prolongation	O
of	O
the	O
QT	O
-	O
interval	O
is	O
associated	O
with	O
sudden	O
cardiac	O
death	O
resulting	O
from	O
potentially	O
life	O
-	O
threatening	O
polymorphic	O
tachycardia	O
of	O
the	O
torsade	O
de	O
pointes	O
(	O
TdP	O
)	O
type	O
.	O

Experimental	O
as	O
well	O
as	O
clinical	O
reports	O
support	O
the	O
hypothesis	O
that	O
calcium	B-geneN-C4-2
channel	E-geneN-C4-2
blockers	O
such	O
as	O
verapamil	S-chem-C4-1
may	O
be	O
an	O
appropriate	O
therapeutic	O
approach	O
in	O
LQTS	O
.	O

We	O
investigated	O
the	O
electrophysiologic	O
mechanism	O
by	O
which	O
verapamil	O
suppresses	O
TdP	O
,	O
in	O
a	O
recently	O
developed	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
8	O
Langendorff	O
-	O
perfused	O
rabbit	O
hearts	O
,	O
veratridine	S-chem-C4-1
(	O
0.1	O
microM	O
)	O
,	O
an	O
inhibitor	O
of	O
sodium	B-geneN-C4-2
channel	E-geneN-C4-2
inactivation	O
,	O
led	O
to	O
a	O
marked	O
increase	O
in	O
QT	O
-	O
interval	O
and	O
simultaneously	O
recorded	O
monophasic	O
ventricular	O
action	O
potentials	O
(	O
MAPs	O
)	O
(	O
p	O
<	O
0.05	O
)	O
thereby	O
mimicking	O
LQT3	O
.	O

In	O
bradycardic	O
(	O
AV	O
-	O
blocked	O
)	O
hearts	O
,	O
simultaneous	O
recording	O
of	O
up	O
to	O
eight	O
epi	O
-	O
and	O
endocardial	O
MAPs	O
demonstrated	O
a	O
significant	O
increase	O
in	O
total	O
dispersion	O
of	O
repolarization	O
(	O
56	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
reverse	O
frequency	O
-	O
dependence	O
.	O

After	O
lowering	O
potassium	S-chem
concentration	O
,	O
veratridine	S-chem
reproducibly	O
led	O
to	O
early	O
afterdepolarizations	O
(	O
EADs	O
)	O
and	O
TdP	O
in	O
6	O
of	O
8	O
(	O
75	O
%	O
)	O
hearts	O
.	O

Additional	O
infusion	O
of	O
verapamil	S-chem
(	O
0.75	O
microM	O
)	O
suppressed	O
EADs	O
and	O
consecutively	O
TdP	O
in	O
all	O
hearts	O
.	O

Verapamil	S-chem
significantly	O
shortened	O
endocardial	O
but	O
not	O
epicardial	O
MAPs	O
which	O
resulted	O
in	O
significant	O
reduction	O
of	O
ventricular	O
transmural	O
dispersion	O
of	O
repolarization	O
.	O

CONCLUSIONS	O
:	O
Verapamil	S-chem
is	O
highly	O
effective	O
in	O
preventing	O
TdP	O
via	O
shortening	O
of	O
endocardial	O
MAPs	O
,	O
reduction	O
of	O
left	O
ventricular	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
suppression	O
of	O
EADs	O
in	O
an	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

These	O
data	O
suggest	O
a	O
possible	O
therapeutic	O
role	O
of	O
verapamil	S-chem
in	O
the	O
treatment	O
of	O
LQT3	O
patients	O
.	O

Impaired	O
function	O
of	O
prejunctional	O
adenosine	B-geneY
A1	I-geneY
receptors	E-geneY
expressed	O
by	O
perivascular	O
sympathetic	O
nerves	O
in	O
DOCA	S-chem
-	O
salt	O
hypertensive	O
rats	O
.	O

Increased	O
sympathetic	O
nervous	O
system	O
activity	O
contributes	O
to	O
deoxycorticosterone	B-chem
acetate	E-chem
(	O
DOCA	S-chem
)	O
-	O
salt	O
hypertension	O
in	O
rats	O
.	O

ATP	S-chem
and	O
norepinephrine	S-chem
(	O
NE	O
)	O
are	O
coreleased	O
from	O
perivascular	O
sympathetic	O
nerves	O
.	O

NE	O
acts	O
at	O
prejunctional	O
α2	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
(	O
α2ARs	S-geneN
)	O
to	O
inhibit	O
NE	O
release	O
,	O
and	O
α2AR	S-geneN
function	O
is	O
impaired	O
in	O
DOCA	S-chem
-	O
salt	O
rats	O
.	O

Adenosine	S-chem
,	O
an	O
enzymatic	O
ATP	S-chem
degradation	O
product	O
,	O
acts	O
at	O
prejunctional	O
A1	B-geneY
adenosine	I-geneY
receptors	E-geneY
(	O
A1Rs	S-geneY
)	O
to	O
inhibit	O
NE	O
release	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
prejunctional	O
A1R	S-geneY
function	O
is	O
impaired	O
in	O
sympathetic	O
nerves	O
supplying	O
mesenteric	O
arteries	O
(	O
MAs	O
)	O
and	O
veins	O
(	O
MVs	O
)	O
of	O
DOCA	S-chem
-	O
salt	O
rats	O
.	O

Electrically	O
evoked	O
NE	O
release	O
and	O
constrictions	O
of	O
blood	O
vessels	O
were	O
studied	O
in	O
vitro	O
with	O
use	O
of	O
amperometry	O
to	O
measure	O
NE	O
oxidation	O
currents	O
and	O
video	O
microscopy	O
,	O
respectively	O
.	O

Immunohistochemical	O
methods	O
were	O
used	O
to	O
localize	O
tyrosine	B-geneY
hydroxylase	E-geneY
(	O
TH	S-geneY
)	O
and	O
A1Rs	S-geneY
in	O
perivascular	O
sympathetic	O
nerves	O
.	O

TH	S-geneY
and	O
A1Rs	S-geneY
colocalized	O
to	O
perivascular	O
sympathetic	O
nerves	O
.	O

Adenosine	S-chem-C5-1
and	O
N	B-chem-C5-1
(	I-chem-C5-1
6	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
cyclopentyl	I-chem-C5-1
-	I-chem-C5-1
adenosine	E-chem-C5-1
(	O
CPA	S-chem-C5-1
,	O
A1R	S-geneY-C5-2
agonist	O
)	O
constricted	O
MVs	O
but	O
not	O
MAs	O
.	O

Adenosine	S-chem
and	O
CPA	S-chem
(	O
0.001	O
-	O
10	O
µM	O
)	O
inhibited	O
neurogenic	O
constrictions	O
and	O
NE	O
release	O
in	O
MAs	O
and	O
MVs	O
.	O

DOCA	S-chem
-	O
salt	O
arteries	O
were	O
resistant	O
to	O
adenosine	S-chem
and	O
CPA	S-chem
-	O
mediated	O
inhibition	O
of	O
NE	O
release	O
and	O
constriction	O
.	O

The	O
A2A	B-geneY-C5-2
adenosine	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
CGS21680	S-chem-C5-1
(	O
C23H29N7O6.HCl.xH2O	S-chem-C5-1
)	O
(	O
0.001	O
-	O
0.1	O
μM	O
)	O
did	O
not	O
alter	O
NE	O
oxidation	O
currents	O
.	O

We	O
conclude	O
that	O
there	O
are	O
prejunctional	O
A1Rs	S-geneY
in	O
arteries	O
and	O
both	O
pre	O
-	O
and	O
postjunctional	O
A1Rs	S-geneY
in	O
veins	O
;	O
thus	O
,	O
adenosine	S-chem
selectively	O
constricts	O
the	O
veins	O
.	O

Prejunctional	O
A1R	S-geneY
function	O
is	O
impaired	O
in	O
arteries	O
,	O
but	O
not	O
veins	O
,	O
from	O
DOCA	S-chem
-	O
salt	O
rats	O
.	O

Sympathetic	O
autoreceptor	O
dysfunction	O
is	O
not	O
specific	O
to	O
α2ARs	S-geneN
,	O
but	O
there	O
is	O
a	O
more	O
general	O
disruption	O
of	O
prejunctional	O
mechanisms	O
controlling	O
sympathetic	O
neurotransmitter	O
release	O
in	O
DOCA	S-chem
-	O
salt	O
hypertension	O
.	O

Serotonin	B-geneY
transporter	E-geneY
function	O
in	O
vivo	O
:	O
assessment	O
by	O
chronoamperometry	O
.	O

Local	O
application	O
of	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
,	O
fluvoxamine	S-chem
and	O
citalopram	S-chem
,	O
prolonged	O
the	O
clearance	O
of	O
exogenously	O
administered	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
in	O
both	O
the	O
dentate	O
gyrus	O
and	O
CA3	O
region	O
of	O
the	O
dorsal	O
hippocampus	O
,	O
as	O
measured	O
using	O
in	O
vivo	O
chronoamperometry	O
.	O

These	O
effects	O
were	O
abolished	O
in	O
rats	O
pretreated	O
with	O
5,7	B-chem
-	I-chem
dihydroxytryptamine	E-chem
.	O

The	O
NE	S-chem
uptake	O
inhibitors	O
,	O
desipramine	S-chem
and	O
protriptyline	S-chem
,	O
did	O
not	O
alter	O
the	O
5	B-chem
-	I-chem
HT	E-chem
signal	O
in	O
the	O
CA3	O
region	O
,	O
but	O
prolonged	O
the	O
clearance	O
of	O
5	B-chem
-	I-chem
HT	E-chem
in	O
the	O
dentate	O
gyrus	O
;	O
this	O
effect	O
was	O
absent	O
in	O
rats	O
pretreated	O
with	O
6	B-chem
-	I-chem
hydroxydopamine	E-chem
.	O

From	O
these	O
data	O
,	O
it	O
is	O
inferred	O
that	O
both	O
the	O
SERT	S-geneY-C9-2
and	O
NET	S-geneY-C9-2
contribute	O
to	O
the	O
active	O
clearance	O
of	O
exogenously	O
applied	O
5	B-chem-C9-1
-	I-chem-C9-1
HT	E-chem-C9-1
in	O
the	O
dentate	O
gyrus	O
.	O

In	O
another	O
experiment	O
,	O
cyanopindolol	S-chem-C6-1
,	O
an	O
antagonist	O
of	O
the	O
serotonin	B-geneN-C6-2
terminal	I-geneN-C6-2
autoreceptor	E-geneN-C6-2
,	O
also	O
prolonged	O
the	O
clearance	O
of	O
5	B-chem
-	I-chem
HT	E-chem
from	O
the	O
CA3	O
region	O
.	O

These	O
and	O
other	O
data	O
have	O
generated	O
a	O
working	O
hypothesis	O
that	O
activation	O
of	O
the	O
terminal	O
serotonin	B-geneN-C9-2
autoreceptor	E-geneN-C9-2
enhances	O
the	O
kinetics	O
of	O
5	B-chem-C9-1
-	I-chem-C9-1
HT	E-chem-C9-1
uptake	O
through	O
an	O
effect	O
on	O
the	O
serotonin	B-geneY-C9-2
transporter	E-geneY-C9-2
.	O

Iron	S-chem
overload	O
inhibits	O
osteoblast	O
biological	O
activity	O
through	O
oxidative	O
stress	O
.	O

Iron	S-chem
overload	O
has	O
recently	O
been	O
connected	O
with	O
bone	O
mineral	O
density	O
in	O
osteoporosis	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
effect	O
of	O
iron	S-chem
overload	O
on	O
osteoblasts	O
remains	O
poorly	O
understood	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
osteoblast	O
biological	O
activity	O
under	O
iron	S-chem
overload	O
.	O

The	O
osteoblast	O
cells	O
(	O
hFOB1.19	O
)	O
were	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
different	O
concentrations	O
(	O
50	O
,	O
100	O
,	O
and	O
200	O
μM	O
)	O
of	O
ferric	O
ammonium	I-chem
citrate	I-chem
as	O
a	O
donor	O
of	O
ferric	O
ion	O
.	O

Intracellular	O
iron	S-chem
was	O
measured	O
with	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

Reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
were	O
detected	O
by	O
2,7	B-chem
-	I-chem
dichlorofluorescin	I-chem
diacetate	E-chem
fluorophotometry	O
.	O

Osteoblast	O
biological	O
activities	O
were	O
evaluated	O
by	O
measuring	O
the	O
activity	O
of	O
alkaline	B-geneN
phosphatase	E-geneN
(	O
ALP	S-geneN
)	O
and	O
mineralization	O
function	O
.	O

Results	O
indicated	O
that	O
iron	S-chem
overload	O
could	O
consequently	O
increase	O
intracellular	O
iron	S-chem
concentration	O
and	O
intracellular	O
ROS	O
levels	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Additionally	O
,	O
ALP	S-geneN
activity	O
was	O
suppressed	O
,	O
and	O
a	O
decline	O
in	O
the	O
number	O
of	O
mineralized	O
nodules	O
was	O
observed	O
in	O
in	O
vitro	O
cultured	O
osteoblast	O
cells	O
.	O

According	O
to	O
these	O
results	O
,	O
it	O
seems	O
that	O
iron	S-chem
overload	O
probably	O
inhibits	O
osteoblast	O
function	O
through	O
higher	O
oxidative	O
stress	O
following	O
increased	O
intracellular	O
iron	S-chem
concentrations	O
.	O

A	O
novel	O
tyrosine	B-geneN
kinase	E-geneN
switch	O
is	O
a	O
mechanism	O
of	O
imatinib	S-chem
resistance	O
in	O
gastrointestinal	O
stromal	O
tumors	O
.	O

KIT	S-geneY
or	O
alpha	B-geneY
-	I-geneY
platelet	I-geneY
-	I-geneY
derived	I-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
alpha	B-geneY
-	I-geneY
PDGFR	E-geneY
)	O
activating	O
mutations	O
are	O
the	O
pathogenic	O
mechanisms	O
that	O
characterize	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GIST	O
)	O
.	O

Despite	O
excellent	O
responses	O
to	O
imatinib	B-chem
mesylate	E-chem
(	O
IM	S-chem
)	O
,	O
patients	O
are	O
relapsing	O
.	O

We	O
developed	O
an	O
IM	S-chem
-	O
resistant	O
GIST	O
cell	O
line	O
(	O
GIST	O
-	O
R	O
)	O
from	O
the	O
IM	S-chem
-	O
sensitive	O
GIST882	O
cell	O
line	O
(	O
GIST	O
-	O
S	O
)	O
by	O
growing	O
these	O
cells	O
in	O
IM	S-chem
.	O

Gene	O
expression	O
profiling	O
(	O
GEP	O
)	O
of	O
GIST	O
-	O
S	O
,	O
GIST	O
-	O
R	O
cells	O
and	O
two	O
IM	S-chem-C4-1
resistant	O
GIST	O
patients	O
demonstrated	O
that	O
KIT	S-geneY-C4-2
is	O
downregulated	O
implying	O
a	O
major	O
role	O
in	O
IM	S-chem-C4-1
resistance	O
.	O

Instead	O
,	O
GIST	O
-	O
R	O
cells	O
have	O
acquired	O
IM	S-chem
resistance	O
by	O
overexpressing	O
the	O
oncogenic	B-geneN
receptor	I-geneN
tyrosine	I-geneN
kinase	E-geneN
-	O
AXL	S-geneY
-	O
in	O
a	O
'	O
kinase	S-geneN
switch	O
'	O
.	O

Further	O
,	O
the	O
two	O
IM	S-chem
resistant	O
GIST	O
patients	O
express	O
AXL	S-geneY
and	O
not	O
c	B-geneY
-	I-geneY
Kit	E-geneY
,	O
seen	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Real	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
of	O
the	O
GIST	O
-	O
S	O
and	O
GIST	O
-	O
R	O
cells	O
confirmed	O
the	O
switch	O
from	O
Kit	S-geneY
to	O
AXL	S-geneY
.	O

In	O
GIST	O
-	O
R	O
,	O
AXL	S-geneY
is	O
tyrosine	S-chem
phosphorylated	O
and	O
its	O
ligand	O
growth	B-geneY
-	I-geneY
arrest	I-geneY
-	I-geneY
specific	I-geneY
gene	I-geneY
6	E-geneY
is	O
overexpressed	O
implying	O
autocrine	O
activation	O
.	O

The	O
kinase	S-geneN
switch	O
is	O
associated	O
with	O
a	O
morphological	O
change	O
from	O
spindle	O
to	O
epithelioid	O
.	O

Molecular	O
modeling	O
of	O
the	O
kinase	B-geneN
domain	E-geneN
of	O
mutant	O
c	B-geneY
-	I-geneY
Kit	E-geneY
(	O
V654A	S-geneN
)	O
and	O
AXL	S-geneY
showed	O
no	O
binding	O
to	O
IM	S-chem
but	O
efficient	O
binding	O
to	O
MP470	S-chem-C4-1
,	O
a	O
novel	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Kit	E-geneY-C4-2
/	O
AXL	S-geneY-C4-2
kinase	S-geneN-C4-2
inhibitor	O
.	O

MP470	S-chem
synergizes	O
with	O
docetaxel	S-chem
(	O
taxotere	S-chem
)	O
and	O
is	O
cytotoxic	O
to	O
GIST	O
cells	O
.	O

Discovery	O
and	O
structural	O
characterization	O
of	O
a	O
phospholamban	S-geneY
-	O
binding	O
cyclic	O
peptide	O
and	O
design	O
of	O
novel	O
inhibitors	O
of	O
phospholamban	S-geneY
.	O

The	O
interplay	O
between	O
cardiac	O
sarcoplasmic	O
Ca	B-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
ATPase	E-geneN
and	O
phospholamban	S-geneY
is	O
a	O
key	O
regulating	O
factor	O
of	O
contraction	O
and	O
relaxation	O
in	O
the	O
cardiac	O
muscle	O
.	O

In	O
heart	O
failure	O
,	O
aberrations	O
in	O
the	O
inhibition	O
of	O
sarcoplasmic	O
Ca	B-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
ATPase	E-geneN
by	O
phospholamban	S-geneY
are	O
associated	O
with	O
anomalies	O
in	O
cardiac	O
functions	O
.	O

In	O
experimental	O
heart	O
failure	O
models	O
,	O
modulation	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
has	O
been	O
shown	O
to	O
be	O
a	O
potential	O
therapeutic	O
approach	O
.	O

The	O
aim	O
of	O
our	O
research	O
was	O
to	O
find	O
molecules	O
able	O
to	O
interfere	O
with	O
the	O
inhibitory	O
activity	O
of	O
phospholamban	S-geneY
on	O
sarcoplasmic	O
Ca	B-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
ATPase	E-geneN
.	O

For	O
this	O
purpose	O
,	O
a	O
portion	O
of	O
phospholamban	S-geneY
was	O
synthesized	O
and	O
used	O
as	O
target	O
for	O
a	O
phage	O
-	O
display	O
peptide	O
library	O
screening	O
.	O

The	O
cyclic	O
peptide	O
C	B-geneN
-	I-geneN
Y	I-geneN
-	I-geneN
W	I-geneN
-	I-geneN
E	I-geneN
-	I-geneN
L	I-geneN
-	I-geneN
E	I-geneN
-	I-geneN
W	I-geneN
-	I-geneN
L	I-geneN
-	I-geneN
P	I-geneN
-	I-geneN
C	I-geneN
-	I-geneN
A	E-geneN
was	O
found	O
to	O
bind	O
to	O
phospholamban	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
36	I-geneY
)	E-geneY
with	O
high	O
specificity	O
.	O

Its	O
functional	O
activity	O
was	O
tested	O
in	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
uptake	O
assays	O
utilizing	O
preparations	O
from	O
cardiac	O
sarcoplasmic	O
reticulum	O
.	O

By	O
synthesizing	O
and	O
testing	O
a	O
series	O
of	O
alanine	S-chem
point	O
-	O
mutated	O
cyclic	B-geneN
peptides	E-geneN
,	O
we	O
identified	O
which	O
amino	B-chem
acid	E-chem
was	O
important	O
for	O
the	O
inhibition	O
of	O
the	O
phospholamban	S-geneY
function	O
.	O

The	O
structures	O
of	O
active	O
and	O
inactive	O
alanine	S-chem
-	O
mutated	O
cyclic	B-geneN
peptides	E-geneN
,	O
and	O
of	O
phospholamban	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
36	I-geneY
)	E-geneY
,	O
were	O
determined	O
by	O
NMR	O
.	O

This	O
structure	O
-	O
activity	O
analysis	O
allowed	O
building	O
a	O
model	O
of	O
phospholamban	S-geneY
-	O
cyclic	O
peptide	O
complex	O
.	O

Thereafter	O
,	O
a	O
simple	O
pharmacophore	O
was	O
defined	O
and	O
used	O
for	O
the	O
design	O
of	O
small	O
molecules	O
.	O

Finally	O
,	O
examples	O
of	O
such	O
molecules	O
were	O
synthesized	O
and	O
characterized	O
as	O
phospholamban	S-geneY
inhibitors	O
.	O

Parathyroid	B-geneY
hormone	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
counteracts	O
the	O
suppression	O
of	O
interleukin	B-geneY
-	I-geneY
11	E-geneY
expression	O
by	O
glucocorticoid	O
in	O
murine	O
osteoblasts	O
:	O
a	O
possible	O
mechanism	O
for	O
stimulating	O
osteoblast	O
differentiation	O
against	O
glucocorticoid	O
excess	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
excess	O
causes	O
a	O
rapid	O
loss	O
of	O
bone	O
with	O
a	O
reduction	O
in	O
bone	O
formation	O
.	O

Intermittent	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
administration	O
stimulates	O
bone	O
formation	O
and	O
counteracts	O
the	O
inhibition	O
of	O
bone	O
formation	O
by	O
GC	O
excess	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
mechanical	O
strain	O
enhances	O
interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
11	E-geneY
gene	O
transcription	O
by	O
a	O
rapid	O
induction	O
of	O
Δ	B-geneY
FosB	E-geneY
expression	O
and	O
protein	B-geneY
kinase	I-geneY
C	I-geneY
(	I-geneY
PKC	I-geneY
)	I-geneY
-	I-geneY
δ	E-geneY
-	O
mediated	O
phosphorylation	O
of	O
phosphorylated	O
mothers	O
against	O
decapentaplegic	O
(	O
Smad	O
)	O
-	O
1	O
.	O

Because	O
IL	B-geneY
-	I-geneY
11	E-geneY
suppresses	O
the	O
expression	O
of	O
dickkopf	B-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
and	O
stimulates	O
Wnt	S-geneN
signaling	O
,	O
IL	B-geneY
-	I-geneY
11	E-geneY
appears	O
to	O
mediate	O
at	O
least	O
a	O
part	O
of	O
the	O
effect	O
of	O
mechanical	O
strain	O
on	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
the	O
effect	O
of	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
and	O
GCs	O
on	O
IL	B-geneY
-	I-geneY
11	E-geneY
expression	O
in	O
murine	O
primary	O
osteoblasts	O
(	O
mPOBs	O
)	O
.	O

PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
treatment	O
of	O
mPOBs	O
enhanced	O
IL	B-geneY
-	I-geneY
11	E-geneY
expression	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
also	O
stimulated	O
Δ	B-geneY
FosB	E-geneY
expression	O
and	O
Smad1	S-geneY
phosphorylation	O
,	O
which	O
cooperatively	O
stimulated	O
IL	B-geneY
-	I-geneY
11	E-geneY
gene	O
transcription	O
.	O

PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
-	O
induced	O
Smad1	S-geneY
phosphorylation	O
was	O
mediated	O
via	O
PKC	B-geneY
δ	E-geneY
and	O
was	O
abrogated	O
in	O
mPOBs	O
from	O
PKC	B-geneY
δ	E-geneY
knockout	O
mice	O
.	O

Dexamethasone	S-chem-C4-1
suppressed	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
11	E-geneY-C4-2
gene	O
transcription	O
enhanced	O
by	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
without	O
affecting	O
Δ	B-geneY
FosB	E-geneY
expression	O
or	O
Smad1	O
phosphorylation	O
,	O
and	O
dexamethasone	S-chem
-	O
GC	B-geneY
receptor	E-geneY
complex	O
was	O
bound	O
to	O
JunD	S-geneY
,	O
which	O
forms	O
heterodimers	O
with	O
Δ	B-geneY
FosB	E-geneY
.	O

High	O
doses	O
of	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
counteracted	O
the	O
effect	O
of	O
dexamethasone	S-chem
on	O
apoptosis	O
of	O
mPOBs	O
,	O
which	O
was	O
blunted	O
by	O
neutralizing	O
anti	O
-	O
IL	B-geneY
-	I-geneY
11	E-geneY
antibody	O
or	O
IL	B-geneY
-	I-geneY
11	E-geneY
small	O
interfering	O
RNA	O
.	O

These	O
results	O
demonstrate	O
that	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
and	O
GCs	O
interact	O
to	O
regulate	O
IL	B-geneY
-	I-geneY
11	E-geneY
expression	O
in	O
parallel	O
with	O
osteoblast	O
differentiation	O
and	O
apoptosis	O
and	O
suggest	O
that	O
PTH	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
34	I-geneY
)	E-geneY
and	O
dexamethasone	S-chem
may	O
regulate	O
osteoblast	O
differentiation	O
and	O
apoptosis	O
via	O
their	O
effect	O
on	O
IL	B-geneY
-	I-geneY
11	E-geneY
expression	O
.	O

Quantitative	O
determination	O
of	O
fatty	B-chem
acid	E-chem
chain	O
composition	O
in	O
pork	O
meat	O
products	O
by	O
high	O
resolution	O
1H	S-chem
NMR	O
spectroscopy	O
.	O

High	O
resolution	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
NMR	O
spectroscopy	O
was	O
proposed	O
for	O
the	O
determination	O
of	O
the	O
fatty	B-chem
acid	E-chem
chain	O
profile	O
of	O
lipids	O
in	O
pork	O
meat	O
products	O
during	O
ripening	O
.	O

Two	O
typical	O
Mediterranean	O
PDO	O
salami	O
produced	O
in	O
Calabria	O
,	O
a	O
region	O
in	O
the	O
Southern	O
Italy	O
,	O
were	O
chosen	O
as	O
a	O
case	O
of	O
study	O
.	O

Quantitative	O
NMR	O
analysis	O
provided	O
the	O
fatty	B-chem
acid	E-chem
chain	O
profiles	O
of	O
total	O
lipid	O
extracts	O
.	O

The	O
transesterification	O
of	O
total	O
lipid	O
extracts	O
furnished	O
FAME	S-chem
mixtures	O
that	O
enabled	O
quantitation	O
of	O
fatty	B-chem
acid	I-chem
acyl	E-chem
chains	O
in	O
the	O
acylglycerol	S-chem
and	O
FFA	O
portions	O
.	O

In	O
all	O
cases	O
,	O
oleyl	S-chem
chains	O
were	O
predominant	O
,	O
and	O
high	O
amounts	O
of	O
polyunsaturated	B-chem
fatty	I-chem
acid	E-chem
chains	O
were	O
observed	O
.	O

The	O
proposed	O
spectroscopic	O
method	O
allowed	O
also	O
the	O
estimation	O
of	O
the	O
most	O
important	O
nutritional	O
parameters	O
of	O
dry	O
fermented	O
meat	O
products	O
.	O

Identification	O
of	O
a	O
novel	O
polymorphism	O
in	O
the	O
3'UTR	O
of	O
the	O
L	B-geneN
-	I-geneN
arginine	I-geneN
transporter	E-geneN
gene	O
SLC7A1	S-geneY
:	O
contribution	O
to	O
hypertension	O
and	O
endothelial	O
dysfunction	O
.	O

BACKGROUND	O
:	O
Endothelial	O
dysfunction	O
because	O
of	O
reduced	O
nitric	B-chem
oxide	E-chem
bioavailability	O
is	O
a	O
key	O
feature	O
of	O
essential	O
hypertension	O
.	O

We	O
have	O
found	O
that	O
normotensive	O
siblings	O
of	O
subjects	O
with	O
essential	O
hypertension	O
have	O
impaired	O
endothelial	O
function	O
accompanied	O
by	O
altered	O
arginine	S-chem
metabolism	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
have	O
identified	O
a	O
novel	O
C	O
/	O
T	O
polymorphism	O
in	O
the	O
3'UTR	O
of	O
the	O
principal	O
arginine	B-geneN
transporter	I-geneN
,	I-geneN
solute	I-geneN
carrier	I-geneN
family	I-geneN
7	I-geneN
(	I-geneN
cationic	I-geneN
amino	I-geneN
acid	I-geneN
transporter	I-geneN
,	I-geneN
y	I-geneN
+	I-geneN
system	I-geneN
)	I-geneN
,	I-geneN
member	I-geneN
1	I-geneN
gene	E-geneN
(	O
SLC7A1	S-geneY
)	O
.	O

The	O
minor	O
T	O
allele	O
significantly	O
attenuates	O
reporter	O
gene	O
expression	O
(	O
P	O
<	O
0.01	O
)	O
and	O
is	O
impaired	O
in	O
its	O
capacity	O
to	O
form	O
DNA	O
-	O
protein	O
complexes	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
278	O
hypertensive	O
subjects	O
the	O
frequency	O
of	O
the	O
T	O
allele	O
was	O
13.3	O
%	O
compared	O
with	O
7.6	O
%	O
in	O
498	O
normotensive	O
subjects	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
overall	O
genotype	O
distribution	O
observed	O
in	O
hypertensives	O
differed	O
significantly	O
from	O
that	O
in	O
normotensives	O
(	O
P	O
<	O
0.001	O
)	O
.	O

To	O
complement	O
these	O
studies	O
,	O
we	O
generated	O
an	O
endothelial	O
-	O
specific	O
transgenic	O
mouse	O
overexpressing	O
L	B-geneN
-	I-geneN
arginine	I-geneN
transporter	E-geneN
SLC7A1	S-geneY
.	O

The	O
Slc7A1	S-geneY
transgenic	O
mice	O
exhibited	O
significantly	O
enhanced	O
responses	O
to	O
the	O
endothelium	O
-	O
dependent	O
vasodilator	O
acetylcholine	S-chem
(	O
-	O
log	O
EC50	O
for	O
wild	O
-	O
type	O
versus	O
Slc7A1	S-geneY
transgenic	O
:	O
6.87	O
+	O
/	O
-	O
0.10	O
versus	O
7.56	O
+	O
/	O
-	O
0.13	O
;	O
P	O
<	O
0.001	O
)	O
.	O

This	O
was	O
accompanied	O
by	O
elevated	O
production	O
of	O
nitric	B-chem
oxide	E-chem
by	O
isolated	O
aortic	O
endothelial	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
identifies	O
a	O
key	O
,	O
functionally	O
active	O
polymorphism	O
in	O
the	O
3'UTR	O
of	O
SLC7A1	S-geneY
.	O

As	O
such	O
,	O
this	O
polymorphism	O
may	O
account	O
for	O
the	O
apparent	O
link	O
between	O
altered	O
endothelial	O
function	O
,	O
L	B-chem
-	I-chem
arginine	E-chem
,	O
and	O
nitric	B-chem
oxide	E-chem
metabolism	O
and	O
predisposition	O
to	O
essential	O
hypertension	O
.	O

WNT6	S-geneY
is	O
a	O
novel	O
target	O
gene	O
of	O
caveolin	B-geneY
-	I-geneY
1	E-geneY
promoting	O
chemoresistance	O
to	O
epirubicin	S-chem
in	O
human	O
gastric	O
cancer	O
cells	O
.	O

Resistance	O
to	O
chemotherapy	O
is	O
a	O
major	O
obstacle	O
for	O
curative	O
treatment	O
of	O
human	O
gastric	O
cancer	O
(	O
GC	O
)	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
are	O
largely	O
unknown	O
.	O

Wingless	B-geneN
-	I-geneN
type	I-geneN
MMTV	I-geneN
integration	I-geneN
site	I-geneN
family	I-geneN
members	E-geneN
(	O
WNTs	S-geneN
)	O
are	O
secreted	O
glycoproteins	O
involved	O
in	O
embryogenesis	O
and	O
,	O
on	O
inappropriate	O
expression	O
in	O
the	O
adult	O
,	O
in	O
cancer	O
.	O

Here	O
,	O
we	O
show	O
expression	O
of	O
WNT6	S-geneY
in	O
GC	O
patient	O
specimens	O
,	O
human	O
GC	O
cell	O
lines	O
and	O
in	O
a	O
mouse	O
model	O
of	O
GC	O
.	O

In	O
human	O
GC	O
cells	O
,	O
WNT6	S-geneY
expression	O
was	O
enhanced	O
by	O
caveolin	B-geneY
-	I-geneY
1	E-geneY
(	O
Cav1	S-geneY
)	O
,	O
a	O
scaffold	O
protein	O
of	O
plasma	O
membrane	O
caveolae	O
.	O

WNT6	S-geneY
knock	O
-	O
down	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
WNT6	S-geneY
increased	O
the	O
resistance	O
to	O
apoptotic	O
cell	O
death	O
induced	O
by	O
the	O
anthracycline	S-chem
chemotherapeutics	O
epirubicin	S-chem
(	O
Epi	S-chem
)	O
and	O
doxorubicin	S-chem
(	O
Dox	S-chem
)	O
.	O

Epi	S-chem-C3-1
increased	O
the	O
activity	O
of	O
the	O
human	B-geneN-C3-2
WNT6	I-geneN-C3-2
promoter	E-geneN-C3-2
through	O
Cav1	S-geneY
-	O
dependent	O
binding	O
of	O
β	B-geneY
-	I-geneY
catenin	E-geneY
to	O
the	O
proximal	O
WNT6	B-geneN-C3-2
promoter	E-geneN-C3-2
.	O

Epi	S-chem-C3-1
increased	O
both	O
WNT6	S-geneY-C3-2
/	O
Wnt6	S-geneY-C3-2
and	O
Cav1	S-geneY-C3-2
expression	O
in	O
human	O
GC	O
cells	O
and	O
within	O
the	O
tumor	O
area	O
of	O
a	O
murine	O
model	O
of	O
GC	O
(	O
CEA424	O
-	O
SV40	O
TAg	O
)	O
.	O

In	O
GC	O
patients	O
,	O
WNT6	S-geneY
expression	O
was	O
positively	O
associated	O
with	O
the	O
tumor	O
stage	O
and	O
the	O
nodal	O
status	O
,	O
and	O
inversely	O
correlated	O
with	O
the	O
response	O
to	O
ECF	O
(	O
Epi	S-chem
,	O
cisplatin	S-chem
,	O
5	B-chem
-	I-chem
fluorouracil	E-chem
)	O
chemotherapy	O
.	O

These	O
results	O
showed	O
that	O
WNT6	S-geneY-C3-2
and	O
Cav1	S-geneY-C3-2
are	O
upregulated	O
by	O
chemotherapeutics	O
and	O
enhance	O
the	O
resistance	O
of	O
GC	O
cells	O
to	O
anthracycline	S-chem-C3-1
drugs	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
driving	O
WNT6	S-geneY
/	O
Cav1	S-geneY
-	O
induced	O
drug	O
resistance	O
will	O
provide	O
benefits	O
in	O
developing	O
new	O
therapies	O
for	O
GC	O
.	O

Species	O
-	O
specific	O
pharmacological	O
properties	O
of	O
human	B-geneY
alpha	I-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
.	O

On	O
the	O
basis	O
of	O
data	O
obtained	O
in	O
rabbits	O
,	O
the	O
imidazoline	B-geneN
receptor	E-geneN
ligand	O
rilmenidine	S-chem-C3-1
has	O
been	O
suggested	O
to	O
decrease	O
blood	O
pressure	O
in	O
humans	O
by	O
activating	O
central	O
alpha	B-geneY-C3-2
(	I-geneY-C3-2
2A	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
adrenoceptors	E-geneY-C3-2
.	O

A	O
prerequisite	O
for	O
this	O
hypothesis	O
was	O
the	O
unproved	O
assumption	O
that	O
rabbit	O
and	O
human	O
alpha	B-geneN-C3-2
(	I-geneN-C3-2
2A	I-geneN-C3-2
)	I-geneN-C3-2
-	I-geneN-C3-2
adrenoceptors	E-geneN-C3-2
are	O
equally	O
activated	O
by	O
rilmenidine	S-chem-C3-1
.	O

Because	O
alpha	B-geneN
(	I-geneN
2A	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
the	O
brain	O
and	O
on	O
cardiovascular	O
sympathetic	O
nerve	O
terminals	O
are	O
identical	O
,	O
the	O
latter	O
were	O
used	O
as	O
a	O
model	O
for	O
the	O
former	O
to	O
confirm	O
or	O
disprove	O
this	O
assumption	O
.	O

Human	O
atrial	O
appendages	O
and	O
rabbit	O
pulmonary	O
arteries	O
were	O
used	O
to	O
determine	O
the	O
potencies	O
of	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
in	O
inhibiting	O
the	O
electrically	O
(	O
2	O
Hz	O
)	O
evoked	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
norepinephrine	E-chem
release	O
and	O
of	O
antagonists	O
in	O
counteracting	O
the	O
alpha	B-geneN-C4-2
(	I-geneN-C4-2
2	I-geneN-C4-2
)	I-geneN-C4-2
-	I-geneN-C4-2
adrenoceptor	E-geneN-C4-2
-	O
mediated	O
inhibition	O
induced	O
by	O
moxonidine	S-chem-C4-1
.	O

In	O
the	O
rabbit	O
pulmonary	O
artery	O
,	O
rilmenidine	S-chem-C6-1
and	O
oxymetazoline	S-chem-C6-1
are	O
potent	O
full	O
agonists	O
,	O
whereas	O
in	O
the	O
human	O
atrial	O
appendages	O
they	O
are	O
antagonists	O
at	O
the	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
2	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
autoreceptors	E-geneN-C6-2
,	O
sharing	O
this	O
property	O
with	O
rauwolscine	S-chem-C6-1
,	O
phentolamine	S-chem-C6-1
,	O
and	O
idazoxan	S-chem-C6-1
.	O

In	O
contrast	O
,	O
prazosin	S-chem
is	O
ineffective	O
.	O

In	O
addition	O
,	O
a	O
partial	O
nucleotide	O
and	O
amino	B-chem
acid	E-chem
sequence	O
of	O
the	O
rabbit	B-geneY
alpha	I-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
(	O
a	O
region	O
known	O
to	O
substantially	O
influence	O
the	O
pharmacological	O
characteristics	O
of	O
the	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
)	O
revealed	O
marked	O
differences	O
between	O
the	O
rabbit	O
and	O
the	O
human	O
alpha	B-geneN
(	I-geneN
2A	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
.	O

The	O
sympathetic	O
nerves	O
of	O
both	O
the	O
human	O
atrial	O
appendages	O
and	O
rabbit	O
pulmonary	O
artery	O
are	O
endowed	O
with	O
alpha	B-geneN-MU-2
(	I-geneN-MU-2
2A	I-geneN-MU-2
)	I-geneN-MU-2
-	I-geneN-MU-2
autoreceptors	E-geneN-MU-2
,	O
at	O
which	O
,	O
however	O
,	O
both	O
rilmenidine	S-chem-C6-1
and	O
oxymetazoline	S-chem-C5-1
exhibit	O
different	O
properties	O
(	O
antagonism	O
and	O
agonism	O
,	O
respectively	O
)	O
.	O

The	O
antagonistic	O
property	O
of	O
rilmenidine	S-chem-C6-1
at	O
human	B-geneY-C6-2
alpha	I-geneY-C6-2
(	I-geneY-C6-2
2A	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptors	E-geneY-C6-2
indicates	O
that	O
in	O
contrast	O
to	O
the	O
suggestion	O
based	O
on	O
rabbit	O
data	O
,	O
the	O
hypotensive	O
property	O
of	O
the	O
drug	O
in	O
humans	O
is	O
not	O
due	O
to	O
activation	O
of	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
but	O
other	O
,	O
presumably	O
I	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
imidazoline	I-geneY
receptors	E-geneY
,	O
are	O
probably	O
involved	O
.	O

Monocarboxylate	B-geneN
transporters	E-geneN
in	O
the	O
central	O
nervous	O
system	O
:	O
distribution	O
,	O
regulation	O
and	O
function	O
.	O

Monocarboxylate	B-geneN-C9-2
transporters	E-geneN-C9-2
(	O
MCTs	S-geneN-C9-2
)	O
are	O
proton	O
-	O
linked	O
membrane	O
carriers	O
involved	O
in	O
the	O
transport	O
of	O
monocarboxylates	S-chem-C9-1
such	O
as	O
lactate	S-chem-C9-1
,	O
pyruvate	S-chem-C9-1
,	O
as	O
well	O
as	O
ketone	S-chem-C9-1
bodies	O
.	O

They	O
belong	O
to	O
a	O
larger	O
family	O
of	O
transporters	O
composed	O
of	O
14	O
members	O
in	O
mammals	O
based	O
on	O
sequence	O
homologies	O
.	O

MCTs	S-geneN
are	O
found	O
in	O
various	O
tissues	O
including	O
the	O
brain	O
where	O
three	O
isoforms	O
,	O
MCT1	S-geneY
,	O
MCT2	S-geneY
and	O
MCT4	S-geneY
,	O
have	O
been	O
described	O
.	O

Each	O
of	O
these	O
isoforms	O
exhibits	O
a	O
distinct	O
regional	O
and	O
cellular	O
distribution	O
in	O
rodent	O
brain	O
.	O

At	O
the	O
cellular	O
level	O
,	O
MCT1	S-geneY
is	O
expressed	O
by	O
endothelial	O
cells	O
of	O
microvessels	O
,	O
by	O
ependymocytes	O
as	O
well	O
as	O
by	O
astrocytes	O
.	O

MCT4	S-geneY
expression	O
appears	O
to	O
be	O
specific	O
for	O
astrocytes	O
.	O

By	O
contrast	O
,	O
the	O
predominant	O
neuronal	O
monocarboxylate	B-geneN
transporter	E-geneN
is	O
MCT2	S-geneY
.	O

Interestingly	O
,	O
part	O
of	O
MCT2	S-geneY-C9-2
immunoreactivity	O
is	O
located	O
at	O
postsynaptic	O
sites	O
,	O
suggesting	O
a	O
particular	O
role	O
of	O
monocarboxylates	S-chem-C9-1
and	O
their	O
transporters	O
in	O
synaptic	O
transmission	O
.	O

In	O
addition	O
to	O
variation	O
in	O
expression	O
during	O
development	O
and	O
upon	O
nutritional	O
modifications	O
,	O
new	O
data	O
indicate	O
that	O
MCT	S-geneN
expression	O
is	O
regulated	O
at	O
the	O
translational	O
level	O
by	O
neurotransmitters	O
.	O

Understanding	O
how	O
transport	O
of	O
monocarboxylates	S-chem
is	O
regulated	O
could	O
be	O
of	O
particular	O
importance	O
not	O
only	O
for	O
neuroenergetics	O
but	O
also	O
for	O
areas	O
such	O
as	O
functional	O
brain	O
imaging	O
,	O
regulation	O
of	O
food	O
intake	O
and	O
glucose	S-chem
homeostasis	O
,	O
or	O
for	O
central	O
nervous	O
system	O
disorders	O
such	O
as	O
ischaemia	O
and	O
neurodegenerative	O
diseases	O
.	O

Pharmacokinetic	O
Interactions	O
between	O
Monoamine	B-geneY-C4-2
Oxidase	I-geneY-C4-2
A	E-geneY-C4-2
Inhibitor	O
Harmaline	S-chem-C4-1
and	O
5	B-chem
-	I-chem
Methoxy	I-chem
-	I-chem
N	I-chem
,	I-chem
N	I-chem
-	I-chem
Dimethyltryptamine	E-chem
,	O
and	O
the	O
Impact	O
of	O
CYP2D6	S-geneY
Status	O
.	O

5	B-chem
-	I-chem
Methoxy	I-chem
-	I-chem
N	I-chem
,	I-chem
N	I-chem
-	I-chem
dimethyltryptamine	E-chem
(	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
or	O
street	O
name	O
``	O
5	I-chem
-	I-chem
MEO	O
``	O
)	O
is	O
a	O
newer	O
designer	O
drug	O
belonging	O
to	O
a	O
group	O
of	O
naturally	O
occurring	O
indolealkylamines	O
.	O

Our	O
recent	O
study	O
has	O
demonstrated	O
that	O
coadministration	O
of	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
A	E-geneY-C4-2
(	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
)	O
inhibitor	O
harmaline	S-chem-C4-1
(	O
5	O
mg	O
/	O
kg	O
)	O
increases	O
systemic	O
exposure	O
to	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
(	O
2	O
mg	O
/	O
kg	O
)	O
and	O
active	O
metabolite	O
bufotenine	O
.	O

This	O
study	O
is	O
aimed	O
at	O
delineating	O
harmaline	S-chem
and	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
pharmacokinetic	O
(	O
PK	O
)	O
interactions	O
at	O
multiple	O
dose	O
levels	O
,	O
as	O
well	O
as	O
the	O
impact	O
of	O
CYP2D6	S-geneY
that	O
affects	O
harmaline	S-chem
PK	O
and	O
determines	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
O	S-chem
-	O
demethylation	O
to	O
produce	O
bufotenine	S-chem
.	O

Our	O
data	O
revealed	O
that	O
inhibition	O
of	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
-	O
mediated	O
metabolic	O
elimination	O
by	O
harmaline	S-chem-C4-1
(	O
2	O
,	O
5	O
,	O
and	O
15	O
mg	O
/	O
kg	O
)	O
led	O
to	O
a	O
sharp	O
increase	O
in	O
systemic	O
and	O
cerebral	O
exposure	O
to	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
(	O
2	O
and	O
10	O
mg	O
/	O
kg	O
)	O
at	O
all	O
dose	O
combinations	O
.	O

A	O
more	O
pronounced	O
effect	O
on	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
PK	O
was	O
associated	O
with	O
greater	O
exposure	O
to	O
harmaline	S-chem
in	O
wild	O
-	O
type	O
mice	O
than	O
CYP2D6	S-geneY
-	O
humanized	O
(	O
Tg	O
-	O
CYP2D6	S-geneY
)	O
mice	O
.	O

Harmaline	S-chem
(	O
5	O
mg	O
/	O
kg	O
)	O
also	O
increased	O
blood	O
and	O
brain	O
bufotenine	S-chem
concentrations	O
that	O
were	O
generally	O
higher	O
in	O
Tg	O
-	O
CYP2D6	S-geneY
mice	O
.	O

Surprisingly	O
,	O
greater	O
harmaline	S-chem
dose	O
(	O
15	O
mg	O
/	O
kg	O
)	O
reduced	O
bufotenine	S-chem
levels	O
.	O

The	O
in	O
vivo	O
inhibitory	O
effect	O
of	O
harmaline	S-chem-C4-1
on	O
CYP2D6	S-geneY-MU-2
-	O
catalyzed	O
bufotenine	S-chem-C9-1
formation	O
was	O
confirmed	O
by	O
in	O
vitro	O
study	O
using	O
purified	O
CYP2D6	S-geneY-MU-2
.	O

Given	O
these	O
findings	O
,	O
a	O
unified	O
PK	O
model	O
including	O
the	O
inhibition	O
of	O
MAO	B-geneY-MU-2
-	I-geneY-MU-2
A	E-geneY-MU-2
-	O
and	O
CYP2D6	S-geneY-MU-2
-	O
catalyzed	O
5	B-chem-C9-1
-	I-chem-C9-1
MeO	I-chem-C9-1
-	I-chem-C9-1
DMT	E-chem-C9-1
metabolism	O
by	O
harmaline	S-chem-C4-1
was	O
developed	O
to	O
describe	O
blood	O
harmaline	S-chem-C4-1
,	O
5	B-chem-C9-1
-	I-chem-C9-1
MeO	I-chem-C9-1
-	I-chem-C9-1
DMT	E-chem-C9-1
,	O
and	O
bufotenine	S-chem
PK	O
profiles	O
in	O
both	O
wild	O
-	O
type	O
and	O
Tg	O
-	O
CYP2D6	S-geneY-MU-2
mouse	O
models	O
.	O

This	O
PK	O
model	O
may	O
be	O
further	O
employed	O
to	O
predict	O
harmaline	S-chem
and	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
PK	O
interactions	O
at	O
various	O
doses	O
,	O
define	O
the	O
impact	O
of	O
CYP2D6	S-geneY
status	O
,	O
and	O
drive	O
harmaline	S-chem
-	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
DMT	E-chem
pharmacodynamics	O
.	O

Design	O
and	O
synthesis	O
of	O
highly	O
selective	O
,	O
orally	O
active	O
Polo	B-geneY
-	I-geneY
like	I-geneY
kinase	I-geneY
-	I-geneY
2	E-geneY
(	O
Plk	B-geneY
-	I-geneY
2	E-geneY
)	O
inhibitors	O
.	O

Polo	B-geneY
-	I-geneY
like	I-geneY
kinase	I-geneY
-	I-geneY
2	E-geneY
(	O
Plk	B-geneY
-	I-geneY
2	E-geneY
)	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
Parkinson	O
's	O
disease	O
and	O
this	O
Letter	O
describes	O
the	O
SAR	O
of	O
a	O
series	O
of	O
dihydropteridinone	S-chem-C4-1
based	O
Plk	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitors	O
.	O

By	O
optimizing	O
both	O
the	O
N	O
-	O
8	O
substituent	O
and	O
the	O
biaryl	O
region	O
of	O
the	O
inhibitors	O
we	O
obtained	O
single	O
digit	O
nanomolar	O
compounds	O
such	O
as	O
37	O
with	O
excellent	O
selectivity	O
for	O
Plk	B-geneY
-	I-geneY
2	E-geneY
over	O
Plk	B-geneY
-	I-geneY
1	E-geneY
.	O

When	O
dosed	O
orally	O
in	O
rats	O
,	O
compound	O
37	O
demonstrated	O
a	O
41	O
-	O
45	O
%	O
reduction	O
of	O
pS129	B-geneY
-	I-geneY
α	I-geneY
-	I-geneY
synuclein	E-geneY
levels	O
in	O
the	O
cerebral	O
cortex	O
.	O

Effects	O
of	O
5	B-chem
-	I-chem
aza	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxycytidine	E-chem
on	O
fetal	B-geneN
hemoglobin	E-geneN
levels	O
,	O
red	O
cell	O
adhesion	O
,	O
and	O
hematopoietic	O
differentiation	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

Fetal	B-geneN
hemoglobin	E-geneN
(	O
HbF	S-geneN
)	O
decreases	O
polymerization	O
of	O
sickle	B-geneN
hemoglobin	E-geneN
(	O
HbS	S-geneN
)	O
and	O
improves	O
outcomes	O
in	O
sickle	O
cell	O
disease	O
(	O
SSD	O
)	O
.	O

Therefore	O
,	O
a	O
therapeutic	O
goal	O
in	O
SSD	O
is	O
pharmacologic	O
reactivation	O
of	O
HbF	S-geneN
.	O

Silencing	O
of	O
the	O
gamma	B-geneN
-	I-geneN
globin	E-geneN
(	O
HbF	S-geneN
)	O
gene	O
is	O
associated	O
with	O
DNA	O
methylation	O
.	O

The	O
cytosine	S-chem-C4-1
analog	O
5	B-chem-C4-1
-	I-chem-C4-1
aza	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
deoxycytidine	E-chem-C4-1
(	O
decitabine	S-chem-C4-1
)	O
hypomethylates	O
DNA	O
by	O
inhibiting	O
DNA	B-geneN-C4-2
methyltransferase	E-geneN-C4-2
.	O

We	O
examined	O
if	O
subcutaneous	O
decitabine	S-chem-C3-1
could	O
increase	O
HbF	S-geneN-C3-2
levels	O
and	O
improve	O
SSD	O
pathophysiology	O
without	O
cytotoxicity	O
.	O

Eight	O
symptomatic	O
SSD	O
patients	O
resistant	O
or	O
intolerant	O
of	O
standard	O
treatment	O
with	O
hydroxyurea	S-chem
received	O
decitabine	S-chem
0.2	O
mg	O
/	O
kg	O
subcutaneously	O
1	O
to	O
3	O
times	O
per	O
week	O
in	O
2	O
cycles	O
of	O
6	O
-	O
week	O
duration	O
.	O

Treatment	O
decreased	O
neutrophils	O
and	O
increased	O
mean	O
HbF	S-geneN
(	O
6.5	O
%	O
to	O
20.4	O
%	O
,	O
P	O
<	O
.0001	O
)	O
and	O
mean	O
total	O
hemoglobin	S-geneN
(	O
76	O
to	O
96	O
g	O
/	O
L	O
[	O
7.6	O
to	O
9.6	O
g	O
/	O
dL	O
]	O
,	O
P	O
<	O
.001	O
)	O
.	O

Features	O
of	O
vaso	O
-	O
occlusive	O
crisis	O
pathophysiology	O
such	O
as	O
red	O
cell	O
adhesion	O
,	O
endothelial	O
damage	O
,	O
and	O
coagulation	O
pathway	O
activity	O
significantly	O
improved	O
.	O
gamma	B-geneN
-	I-geneN
Globin	I-geneN
gene	I-geneN
promoter	E-geneN
methylation	O
decreased	O
,	O
and	O
platelets	O
and	O
the	O
proportion	O
of	O
megakaryocytes	O
and	O
erythroid	O
cells	O
in	O
the	O
marrow	O
increased	O
without	O
a	O
decrease	O
in	O
marrow	O
cellularity	O
,	O
consistent	O
with	O
a	O
DNA	O
hypomethylating	O
,	O
noncytotoxic	O
mechanism	O
of	O
action	O
.	O

Weekly	O
subcutaneous	O
decitabine	S-chem-C3-1
produces	O
cumulative	O
increases	O
in	O
HbF	S-geneN-C3-2
and	O
total	O
hemoglobin	S-geneN-C3-2
through	O
a	O
noncytotoxic	O
mechanism	O
of	O
action	O
.	O

Chronic	O
dosing	O
and	O
sustained	O
increases	O
in	O
hemoglobin	B-geneN
F	E-geneN
and	O
total	O
hemoglobin	S-geneN
levels	O
may	O
be	O
possible	O
.	O

Further	O
studies	O
in	O
SSD	O
and	O
thalassemia	O
are	O
indicated	O
.	O

Superparamagnetic	O
Hollow	O
Hybrid	O
Nanogels	O
as	O
a	O
Potential	O
Guidable	O
Vehicle	O
System	O
of	O
Stimuli	O
-	O
Mediated	O
MR	O
Imaging	O
and	O
Multiple	O
Cancer	O
Therapeutics	O
.	O

Hollow	O
hybrid	O
nanogels	O
were	O
prepared	O
first	O
by	O
co	O
-	O
assembly	O
of	O
the	O
citric	B-chem
acid	E-chem
-	O
coated	O
superparamagnetic	O
iron	B-chem
oxide	E-chem
nanoparticles	O
(	O
SPIONs	O
)	O
(	O
44	O
wt	O
%	O
)	O
with	O
the	O
graft	O
copolymer	O
(	O
56	O
wt	O
%	O
)	O
comprising	O
acrylic	B-chem
acid	E-chem
and	O
2	B-chem
-	I-chem
methacryloylethyl	I-chem
acrylate	E-chem
units	O
as	O
the	O
backbone	O
and	O
poly	B-chem
(	I-chem
ethylene	I-chem
glycol	I-chem
)	E-chem
and	O
poly	B-chem
(	I-chem
N	I-chem
-	I-chem
isopropylacrylamide	I-chem
)	E-chem
as	O
the	O
grafts	O
in	O
aqueous	O
phase	O
of	O
pH	O
3.0	O
into	O
the	O
hybrid	O
vesicle	O
structure	O
,	O
followed	O
by	O
in	O
situ	O
covalent	O
stabilization	O
via	O
the	O
photo	O
-	O
initiated	O
polymerization	O
of	O
MEA	S-chem
residues	O
within	O
vesicles	O
.	O

The	O
resultant	O
hollow	O
nanogels	O
,	O
though	O
slightly	O
swollen	O
,	O
satisfactorily	O
retain	O
the	O
structural	O
integrity	O
while	O
the	O
medium	O
pH	O
being	O
adjusted	O
to	O
7.4	O
.	O

Confining	O
SPION	O
clusters	O
to	O
such	O
a	O
high	O
level	O
(	O
44	O
wt	O
%	O
)	O
within	O
the	O
pH	O
-	O
responsive	O
thin	O
gel	O
layer	O
remarkably	O
enhances	O
the	O
transverse	O
relaxivity	O
(	O
r2	O
)	O
and	O
renders	O
the	O
MR	O
imaging	O
highly	O
pH	O
-	O
tunable	O
.	O

For	O
example	O
,	O
with	O
the	O
pH	O
being	O
adjusted	O
from	O
4.0	O
to	O
7.4	O
,	O
the	O
r2	O
value	O
can	O
be	O
dramatically	O
increased	O
from	O
138.5	O
to	O
265.5	O
mM	O
-	O
1	O
s	O
-	O
1	O
.	O

The	O
DOX	O
-	O
loaded	O
hybrid	O
nanogels	O
also	O
exhibit	O
accelerated	O
drug	O
release	O
in	O
response	O
to	O
both	O
pH	O
reduction	O
and	O
temperature	O
increase	O
due	O
to	O
the	O
substantial	O
disruption	O
of	O
the	O
interactions	O
between	O
drug	O
molecules	O
and	O
copolymer	O
components	O
.	O

With	O
magnetic	O
transport	O
guidance	O
toward	O
the	O
target	O
and	O
subsequent	O
exposure	O
to	O
alternating	O
magnetic	O
field	O
,	O
this	O
DOX	O
-	O
loaded	O
nanogel	O
system	O
possessing	O
combined	O
capabilities	O
of	O
hyperthermia	O
and	O
stimuli	O
-	O
triggered	O
drug	O
release	O
showed	O
superior	O
in	O
vitro	O
cytotoxicity	O
against	O
HeLa	O
cells	O
as	O
compared	O
to	O
the	O
case	O
with	O
only	O
free	O
drug	O
or	O
hyperthermia	O
alone	O
.	O

This	O
work	O
demonstrates	O
that	O
the	O
hollow	O
inorganic	O
/	O
organic	O
hybrid	O
nanogels	O
show	O
great	O
potential	O
to	O
serve	O
as	O
a	O
multimodal	O
theranostic	O
vehicle	O
functionalized	O
with	O
such	O
desirable	O
features	O
as	O
guidable	O
delivery	O
of	O
stimuli	O
-	O
mediated	O
diagnostic	O
imaging	O
and	O
hyperthermia	O
/	O
chemotherapies	O
.	O

Dopamine	B-geneY-C5-2
D1	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
and	O
D2	B-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
effects	O
of	O
the	O
natural	O
product	O
(	B-chem-MU-1
-	I-chem-MU-1
)	I-chem-MU-1
-	I-chem-MU-1
stepholidine	E-chem-MU-1
:	O
molecular	O
modeling	O
and	O
dynamics	O
simulations	O
.	O

(	B-chem-MU-1
-	I-chem-MU-1
)	I-chem-MU-1
-	I-chem-MU-1
Stepholidine	E-chem-MU-1
(	O
SPD	S-chem-MU-1
)	O
,	O
an	O
active	O
ingredient	O
of	O
the	O
Chinese	O
herb	O
Stephania	O
,	O
is	O
the	O
first	O
compound	O
found	O
to	O
have	O
dual	O
function	O
as	O
a	O
dopamine	B-geneY-C5-2
receptor	I-geneY-C5-2
D1	E-geneY-C5-2
agonist	O
and	O
D2	S-geneY-C6-2
antagonist	O
.	O

Insights	O
into	O
dynamical	O
behaviors	O
of	O
D1	B-geneN
and	I-geneN
D2	I-geneN
receptors	E-geneN
and	O
their	O
interaction	O
modes	O
with	O
SPD	S-chem
are	O
crucial	O
in	O
understanding	O
the	O
structural	O
and	O
functional	O
characteristics	O
of	O
dopamine	B-geneN
receptors	E-geneN
.	O

In	O
this	O
study	O
a	O
computational	O
approach	O
,	O
integrating	O
protein	O
structure	O
prediction	O
,	O
automated	O
molecular	O
docking	O
,	O
and	O
molecular	O
dynamics	O
simulations	O
were	O
employed	O
to	O
investigate	O
the	O
dual	O
action	O
mechanism	O
of	O
SPD	S-chem
on	O
the	O
D1	B-geneN
and	I-geneN
D2	I-geneN
receptors	E-geneN
,	O
with	O
the	O
eventual	O
aim	O
to	O
develop	O
new	O
drugs	O
for	O
treating	O
diseases	O
affecting	O
the	O
central	O
nervous	O
system	O
such	O
as	O
schizophrenia	O
.	O

The	O
dynamics	O
simulations	O
revealed	O
the	O
surface	O
features	O
of	O
the	O
electrostatic	O
potentials	O
and	O
the	O
conformational	O
``	O
open	O
-	O
closed	O
``	O
process	O
of	O
the	O
binding	O
entrances	O
of	O
two	O
dopamine	I-geneN
receptors	O
.	O

Potential	O
binding	O
conformations	O
of	O
D1	B-geneN
and	I-geneN
D2	I-geneN
receptors	E-geneN
were	O
obtained	O
,	O
and	O
the	O
D1	S-geneY
-	O
SPD	S-chem
and	O
D2	S-geneY
-	O
SPD	S-chem
complexes	O
were	O
generated	O
,	O
which	O
are	O
in	O
good	O
agreement	O
with	O
most	O
of	O
experimental	O
data	O
.	O

The	O
D1	S-geneY
-	O
SPD	S-chem
structure	O
shows	O
that	O
the	O
K	O
-	O
167_EL	O
-	O
2	O
-	O
E	O
-	O
302_EL	O
-	O
3	O
(	O
EL	O
-	O
2	O
:	O
extracellular	O
loop	O
2	O
;	O
EL	O
-	O
3	O
:	O
extracellular	O
loop	O
3	O
)	O
salt	O
bridge	O
plays	O
an	O
important	O
role	O
for	O
both	O
the	O
conformational	O
change	O
of	O
the	O
extracellular	O
domain	O
and	O
the	O
binding	O
of	O
SPD	S-chem
.	O

Based	O
on	O
our	O
modeling	O
and	O
simulations	O
,	O
we	O
proposed	O
a	O
mechanism	O
of	O
the	O
dual	O
action	O
of	O
SPD	S-chem
and	O
a	O
subsequent	O
signal	O
transduction	O
model	O
.	O

Further	O
mutagenesis	O
and	O
biophysical	O
experiments	O
are	O
needed	O
to	O
test	O
and	O
improve	O
our	O
proposed	O
dual	O
action	O
mechanism	O
of	O
SPD	S-chem
and	O
signal	O
transduction	O
model	O
.	O

Pharmacokinetics	O
and	O
metabolism	O
of	O
[	B-chem-C4-1
(	I-chem-C4-1
14	I-chem-C4-1
)	I-chem-C4-1
C	I-chem-C4-1
]	I-chem-C4-1
anagliptin	E-chem-C4-1
,	O
a	O
novel	O
dipeptidyl	B-geneY-C4-2
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
inhibitor	O
,	O
in	O
humans	O
.	O

1	O
.	O
The	O
disposition	O
of	O
anagliptin	O
,	E-chem-C4-1
an	O
orally	O
active	O
,	O
highly	O
selective	O
dipeptidyl	O
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	I-geneY-C4-2
inhibitor	O
,	O
was	O
investigated	O
after	O
a	O
single	O
oral	O
dose	O
of	O
100	O
mg	O
/	O
1.92	O
MBq	O
[	O
(	B-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
anagliptin	I-chem
to	O
six	O
healthy	O
men	O
.	O

Almost	O
all	O
the	O
dose	O
(	O
98.2	O
%	O
)	O
was	O
recovered	O
within	O
168	O
h	O
:	O
73.2	O
%	O
in	O
urine	O
and	O
25.0	O
%	O
in	O
faeces	O
.	O

2	O
.	O
Anagliptin	O
was	O
rapidly	O
absorbed	O
,	O
with	O
peak	O
plasma	O
concentrations	O
of	O
unchanged	O
drug	O
attained	O
at	O
a	O
mean	O
time	O
of	O
1.8	O
-	O
h	O
postdose	O
.	O

Mean	O
fraction	O
of	O
the	O
dose	O
absorbed	O
was	O
>	O
73	O
%	O
.	O

Unchanged	O
drug	O
and	O
a	O
carboxylate	S-chem
metabolite	O
(	O
M1	O
)	O
were	O
the	O
major	O
components	O
in	O
plasma	O
,	O
accounting	O
for	O
66.0	O
and	O
23.4	O
%	O
of	O
total	O
plasma	O
radioactivity	O
area	O
under	O
the	O
curve	O
,	O
respectively	O
.	O

3	O
.	O
Anagliptin	O
was	O
incompletely	O
metabolized	O
,	O
with	O
about	O
50	O
%	O
dose	O
eliminated	O
as	O
unchanged	O
drug	O
(	O
46.6	O
%	O
in	O
urine	O
and	O
4.1	O
%	O
in	O
faeces	O
)	O
.	O

Metabolism	O
to	O
M1	O
accounted	O
for	O
29.2	O
%	O
of	O
the	O
dose	O
.	O

No	O
other	O
metabolite	O
accounted	O
for	O
>	O
1	O
%	O
dose	O
in	O
excreta	O
or	O
yielded	O
measurable	O
systemic	O
exposure	O
.	O

Terminal	O
half	O
-	O
life	O
of	O
anagliptin	S-chem
and	O
M1	O
was	O
4.37	O
and	O
9.88	O
h	O
,	O
respectively	O
.	O

Renal	O
clearance	O
of	O
unbound	O
anagliptin	S-chem
and	O
unbound	O
M1	O
far	O
exceeded	O
glomerular	O
filtration	O
rate	O
,	O
indicating	O
active	O
renal	O
elimination	O
:	O
that	O
might	O
reflect	O
the	O
fact	O
that	O
anagliptin	S-chem-C9-1
may	O
be	O
a	O
substrate	O
of	O
OAT1	S-geneY-C9-2
,	O
OAT3	S-geneY-C9-2
,	O
MDR1	S-geneY-C9-2
and	O
MRP2	S-geneY-C9-2
,	O
and	O
M1	O
a	O
substrate	O
of	O
OAT3	S-geneY
,	O
BCRP	S-geneY
,	O
MRP2	S-geneY
and	O
MRP4	S-geneY
.	O

Kinetic	O
mechanism	O
of	O
quinone	B-geneY-C4-2
oxidoreductase	I-geneY-C4-2
2	E-geneY-C4-2
and	O
its	O
inhibition	O
by	O
the	O
antimalarial	O
quinolines	S-chem-C4-1
.	O

Quinone	B-geneY
oxidoreductase	I-geneY
2	E-geneY
(	O
QR2	S-geneY
)	O
purified	O
from	O
human	O
red	O
blood	O
cells	O
was	O
recently	O
shown	O
to	O
be	O
a	O
potential	O
target	O
of	O
the	O
quinoline	S-chem
antimalarial	O
compounds	O
[	O
Graves	O
et	O
al	O
.	O
,	O
(	O
2002	O
)	O
Mol	O
.	O

Pharmacol	O
.	O

62	O
,	O
1364	O
]	O
.	O

QR2	S-geneY-C9-2
catalyzes	O
the	O
two	O
-	O
electron	O
reduction	O
of	O
menadione	S-chem-C9-1
via	O
the	O
oxidation	O
of	O
N	B-chem-C9-1
-	I-chem-C9-1
alkylated	E-chem-C9-1
or	O
N	B-chem-C9-1
-	I-chem-C9-1
ribosylated	I-chem-C9-1
nicotinamides	E-chem-C9-1
.	O

To	O
investigate	O
the	O
mechanism	O
and	O
consequences	O
of	O
inhibition	O
of	O
QR2	S-geneY-C4-2
by	O
the	O
quinolines	S-chem-C4-1
further	O
,	O
we	O
have	O
used	O
steady	O
-	O
state	O
and	O
transient	O
-	O
state	O
kinetics	O
to	O
define	O
the	O
mechanism	O
of	O
QR2	S-geneY-C4-2
.	O

Importantly	O
,	O
we	O
have	O
shown	O
that	O
QR2	S-geneY
when	O
isolated	O
from	O
an	O
overproducing	O
strain	O
of	O
E.	O
coli	O
is	O
kinetically	O
equivalent	O
to	O
the	O
enzyme	O
from	O
the	O
native	O
human	O
red	O
blood	O
cell	O
source	O
.	O

We	O
observe	O
ping	O
-	O
pong	O
kinetics	O
consistent	O
with	O
one	O
substrate	O
/	O
inhibitor	O
binding	O
site	O
that	O
shows	O
selectivity	O
for	O
the	O
oxidation	O
state	O
of	O
the	O
FAD	O
cofactor	O
,	O
suggesting	O
that	O
selective	O
inhibition	O
of	O
the	O
liver	O
versus	O
red	O
blood	O
cell	O
forms	O
of	O
malaria	O
may	O
be	O
possible	O
.	O

The	O
reductant	O
N	B-chem
-	I-chem
methyldihydronicotinamide	E-chem
and	O
the	O
inhibitor	O
primaquine	S-chem
bind	O
exclusively	O
to	O
the	O
oxidized	O
enzyme	O
.	O

In	O
contrast	O
,	O
the	O
inhibitors	O
quinacrine	S-chem
and	O
chloroquine	S-chem
bind	O
exclusively	O
to	O
the	O
reduced	O
enzyme	O
.	O

The	O
quinone	S-chem
substrate	O
menadione	S-chem
,	O
on	O
the	O
other	O
hand	O
,	O
binds	O
nonspecifically	O
to	O
both	O
forms	O
of	O
the	O
enzyme	O
.	O

Single	O
-	O
turnover	O
kinetics	O
of	O
the	O
reductive	O
half	O
-	O
reaction	O
are	O
chemically	O
and	O
kinetically	O
competent	O
and	O
confirm	O
the	O
inhibitor	O
selectivity	O
seen	O
in	O
the	O
steady	O
-	O
state	O
experiments	O
.	O

Our	O
studies	O
shed	O
light	O
on	O
the	O
possible	O
in	O
vivo	O
potency	O
of	O
the	O
quinolines	S-chem-C4-1
and	O
provide	O
a	O
foundation	O
for	O
future	O
studies	O
aimed	O
at	O
creating	O
more	O
potent	O
QR2	S-geneY-C4-2
inhibitors	O
and	O
at	O
understanding	O
the	O
physiological	O
significance	O
of	O
QR2	S-geneY
.	O

Inhibitory	O
activity	O
of	O
Filipendula	O
ulmaria	O
constituents	O
on	O
recombinant	O
human	B-geneN
histidine	I-geneN
decarboxylase	E-geneN
.	O

Histidine	B-geneY-C9-2
decarboxylase	E-geneY-C9-2
(	O
HDC	S-geneY-C9-2
)	O
catalyses	O
the	O
formation	O
of	O
histamine	S-chem-C9-1
,	O
a	O
bioactive	O
amine	S-chem-C9-1
.	O

Agents	O
that	O
control	O
HDC	S-geneY
activity	O
are	O
beneficial	O
for	O
treating	O
histamine	S-chem
-	O
mediated	O
symptoms	O
,	O
such	O
as	O
allergies	O
and	O
stomach	O
ulceration	O
.	O

We	O
searched	O
for	O
inhibitors	O
of	O
HDC	S-geneY-C4-2
from	O
the	O
ethyl	B-chem-C4-1
acetate	E-chem-C4-1
extract	O
of	O
the	O
petal	O
of	O
Filipendula	O
ulmaria	O
,	O
also	O
called	O
meadowsweet	O
.	O

Rugosin	B-chem
D	E-chem
,	O
rugosin	B-chem
A	E-chem
,	O
rugosin	B-chem
A	I-chem
methyl	I-chem
ester	E-chem
(	O
a	O
novel	O
compound	O
)	O
,	O
and	O
tellimagrandin	B-chem
II	E-chem
were	O
the	O
main	O
components	O
;	O
these	O
4	O
ellagitannins	O
exhibited	O
a	O
non	O
-	O
competitive	O
type	O
of	O
inhibition	O
,	O
with	O
K	O
(	O
i	O
)	O
values	O
of	O
approximately	O
0.35	O
-	O
1	O
μM	O
.	O

These	O
K	O
(	O
i	O
)	O
values	O
are	O
nearly	O
equal	O
to	O
that	O
of	O
histidine	B-chem
methyl	I-chem
ester	E-chem
(	O
K	O
(	O
i	O
)	O
=	O
0.46	O
μM	O
)	O
,	O
an	O
existing	O
substrate	O
analogue	O
inhibitor	O
.	O

Our	O
results	O
show	O
that	O
food	O
products	O
contain	O
potent	O
HDC	S-geneY
inhibitors	O
and	O
that	O
these	O
active	O
food	O
constituents	O
might	O
be	O
useful	O
for	O
designing	O
clinically	O
available	O
HDC	S-geneY
inhibitors	O
.	O

Anti	O
-	O
diabetic	O
Activity	O
of	O
Swertiamarin	S-chem
is	O
due	O
to	O
an	O
Active	O
Metabolite	O
,	O
Gentianine	S-chem-C3-1
,	O
that	O
Upregulates	O
PPAR	B-geneY-C3-2
-	I-geneY-C3-2
γ	E-geneY-C3-2
Gene	O
Expression	O
in	O
3T3	O
-	O
L1	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
the	O
anti	O
-	O
diabetic	O
effects	O
of	O
swertiamarin	S-chem
;	O
however	O
,	O
pharmacokinetic	O
analysis	O
showed	O
that	O
swertiamarin	S-chem
had	O
a	O
plasma	O
half	O
-	O
life	O
of	O
1.3	O
h	O
.	O

Gentianine	S-chem
is	O
an	O
active	O
metabolite	O
of	O
swertiamarin	S-chem
that	O
possesses	O
a	O
pharmacophoric	O
moiety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
possibility	O
whether	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	S-chem
is	O
due	O
to	O
gentianine	S-chem
.	O

Swertiamarin	S-chem-C3-1
treatment	O
had	O
no	O
significant	O
effect	O
on	O
adipogenesis	O
,	O
or	O
the	O
mRNA	O
expression	O
of	O
PPAR	B-geneY
-	I-geneY
γ	E-geneY
and	O
GLUT	B-geneY
-	I-geneY
4	E-geneY
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
adiponectin	S-geneY-C3-2
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
gentianine	S-chem-C3-1
significantly	O
increased	O
adipogenesis	O
,	O
which	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
PPAR	B-geneY-C3-2
-	I-geneY-C3-2
γ	E-geneY-C3-2
,	O
GLUT	B-geneY-C3-2
-	I-geneY-C3-2
4	E-geneY-C3-2
and	O
adiponectin	S-geneY-C3-2
.	O

These	O
findings	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	S-chem
is	O
due	O
to	O
gentianine	S-chem
,	O
an	O
active	O
metabolite	O
of	O
swertiamarin	S-chem
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Pharmacological	O
characterization	O
of	O
glucocorticoid	B-geneN
receptors	E-geneN
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Bronchial	O
epithelial	O
cells	O
play	O
an	O
important	O
role	O
in	O
amplifying	O
and	O
perpetuating	O
airway	O
inflammation	O
and	O
may	O
be	O
a	O
target	O
for	O
inhaled	O
steroids	S-chem
.	O

We	O
have	O
characterized	O
glucocorticoid	B-geneY
receptors	E-geneY
in	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Northern	O
and	O
western	O
blot	O
analyses	O
demonstrated	O
the	O
expression	O
of	O
glucocorticoid	B-geneN
receptor	E-geneN
mRNA	O
and	O
protein	O
,	O
respectively	O
,	O
in	O
primary	O
bronchial	O
epithelial	O
cells	O
.	O

The	O
activity	O
of	O
these	O
receptors	O
was	O
shown	O
using	O
a	O
radioligand	O
binding	O
assay	O
.	O

High	O
-	O
affinity	O
binding	O
with	O
pharmacological	O
specificity	O
was	O
demonstrated	O
for	O
[	B-chem
3H	I-chem
]	I-chem
dexamethasone	E-chem
.	O

The	O
equilibrium	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
density	O
of	O
binding	O
sites	O
(	O
Bmax	O
)	O
for	O
[	B-chem
3H	I-chem
]	I-chem
dexamethasone	E-chem
determined	O
from	O
saturation	O
isotherms	O
were	O
4.4	O
nM	O
x	O
/	O
divided	O
by	O
0.95	O
(	O
SEM	O
)	O
and	O
30.1	O
fmol	O
/	O
mg	O
protein	O
+	O
/	O
-	O
6.4	O
(	O
SEM	O
)	O
.	O

Glucocorticoid	B-geneY-C3-2
receptors	E-geneY-C3-2
were	O
activated	O
by	O
dexamethasone	S-chem-C3-1
as	O
assessed	O
using	O
a	O
glucocorticoid	O
-	O
responsive	O
reporter	O
plasmid	O
,	O
pTAT3	O
-	O
CAT	O
.	O

Transfection	O
of	O
primary	O
human	O
bronchial	O
epithelial	O
cells	O
with	O
this	O
reporter	O
plasmid	O
resulted	O
in	O
35	O
-	O
fold	O
activation	O
of	O
transcription	O
following	O
dexamethasone	S-chem
stimulation	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

The	O
glucocorticoid	B-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
RU	B-chem-C6-1
-	I-chem-C6-1
486	E-chem-C6-1
(	O
mifepristone	S-chem-C6-1
)	O
significantly	O
counteracted	O
the	O
effect	O
of	O
dexamethasone	S-chem
on	O
glucocorticoid	B-geneY
receptor	E-geneY
activation	O
,	O
indicating	O
that	O
the	O
dexamethasone	S-chem
effect	O
is	O
specific	O
and	O
is	O
mediated	O
through	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
.	O

In	O
summary	O
,	O
our	O
study	O
demonstrated	O
that	O
primary	O
cultures	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
possess	O
glucocorticoid	B-geneY
receptors	E-geneY
that	O
function	O
as	O
a	O
ligand	O
-	O
activated	O
transcriptional	O
regulator	O
.	O

The	O
presence	O
of	O
glucocorticoid	B-geneY
receptors	E-geneY
confers	O
their	O
responsiveness	O
to	O
glucocorticoids	O
and	O
indicates	O
that	O
the	O
airway	O
epithelium	O
may	O
be	O
a	O
target	O
for	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
inhaled	O
steroids	S-chem
.	O

Conjugated	O
linoleic	B-chem
acid	E-chem
and	O
calcium	S-chem
co	O
-	O
supplementation	O
improves	O
bone	O
health	O
in	O
ovariectomised	O
mice	O
.	O

Osteoporosis	O
is	O
a	O
significant	O
health	O
concern	O
for	O
the	O
elderly	O
;	O
conjugated	O
linoleic	B-chem
acid	E-chem
(	O
CLA	O
)	O
has	O
been	O
shown	O
to	O
improve	O
overall	O
bone	O
mass	O
when	O
calcium	S-chem
is	O
included	O
as	O
a	O
co	O
-	O
supplement	O
.	O

However	O
,	O
potential	O
effects	O
of	O
CLA	O
and	O
calcium	S-chem
on	O
bone	O
mass	O
during	O
a	O
period	O
of	O
bone	O
loss	O
have	O
not	O
been	O
reported	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
dietary	O
calcium	S-chem
modulates	O
the	O
effects	O
of	O
conjugated	O
linoleic	B-chem
acid	E-chem
(	O
CLA	O
)	O
in	O
preventing	O
bone	O
loss	O
,	O
using	O
an	O
ovariectomised	O
mouse	O
model	O
.	O

CLA	O
supplementation	O
significantly	O
prevented	O
ovariectomy	O
-	O
associated	O
weight	O
and	O
fat	O
mass	O
gain	O
,	O
compared	O
to	O
non	O
-	O
supplemented	O
controls	O
.	O

CLA	O
significantly	O
increased	O
bone	O
markers	O
without	O
major	O
changes	O
in	O
bone	O
mineral	O
composition	O
in	O
the	O
femur	O
compared	O
to	O
respective	O
controls	O
.	O

CLA	O
treatment	O
increased	O
serum	O
parathyroid	B-geneY
hormone	E-geneY
(	O
PTH	S-geneY
)	O
significantly	O
(	O
p	O
=	O
0.0172	O
)	O
,	O
while	O
serum	O
1,25	B-chem
-	I-chem
dihydroxyvitamin	I-chem
D3	E-chem
concentration	O
was	O
not	O
changed	O
by	O
CLA	O
.	O

Meanwhile	O
,	O
CLA	O
significantly	O
reduced	O
femur	O
tartrate	B-geneY
resistant	I-geneY
acid	I-geneY
phosphatase	E-geneY
(	O
TRAP	S-geneY
)	O
activity	O
,	O
suggesting	O
potential	O
reduction	O
of	O
osteoclastogenesis	O
.	O

The	O
data	O
suggest	O
that	O
CLA	O
,	O
along	O
with	O
dietary	O
calcium	S-chem
,	O
has	O
great	O
potential	O
to	O
be	O
used	O
to	O
prevent	O
bone	O
loss	O
and	O
weight	O
gain	O
associated	O
with	O
menopause	O
.	O

Design	O
,	O
synthesis	O
,	O
and	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
tryptanthrins	S-chem
as	O
antitubercular	O
agents	O
.	O

The	O
natural	O
product	O
tryptanthrin	S-chem
(	O
1a	O
)	O
represents	O
a	O
potential	O
lead	O
for	O
new	O
tuberculosis	O
(	O
TB	O
)	O
drugs	O
since	O
tryptanthrin	S-chem
and	O
its	O
synthetic	O
analogues	O
possess	O
potent	O
in	O
vitro	O
activity	O
against	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
)	O
.	O

However	O
,	O
in	O
spite	O
of	O
their	O
in	O
vitro	O
activity	O
,	O
none	O
of	O
these	O
agents	O
have	O
been	O
shown	O
to	O
be	O
efficacious	O
in	O
vivo	O
against	O
animal	O
models	O
of	O
TB	O
.	O

Described	O
herein	O
are	O
syntheses	O
of	O
new	O
tryptanthrin	S-chem
analogues	O
together	O
with	O
a	O
systematic	O
investigation	O
of	O
their	O
in	O
vitro	O
antitubercular	O
activity	O
and	O
ADME	O
properties	O
followed	O
by	O
pharmacokinetic	O
characterization	O
in	O
rodents	O
for	O
the	O
most	O
promising	O
compounds	O
.	O

Those	O
with	O
the	O
best	O
potency	O
and	O
oral	O
bioavailability	O
were	O
progressed	O
to	O
evaluations	O
of	O
efficacy	O
against	O
acute	O
murine	O
TB	O
.	O

The	O
work	O
aimed	O
to	O
prove	O
the	O
concept	O
that	O
this	O
compound	O
class	O
can	O
limit	O
growth	O
of	O
Mtb	O
during	O
infection	O
as	O
well	O
as	O
to	O
establish	O
the	O
SAR	O
for	O
in	O
vitro	O
activity	O
against	O
Mtb	O
and	O
the	O
range	O
of	O
in	O
vitro	O
ADME	O
parameters	O
for	O
this	O
class	O
of	O
natural	O
products	O
.	O

Novel	O
C	O
-	O
11	O
-	O
deoxy	O
(	O
5b	O
)	O
and	O
A	O
-	O
ring	O
-	O
saturated	O
(	O
6	O
)	O
tryptanthrin	S-chem
analogues	O
were	O
discovered	O
that	O
maintained	O
activity	O
against	O
Mtb	O
and	O
showed	O
improved	O
solubility	O
compared	O
to	O
tryptanthrin	S-chem
as	O
well	O
as	O
evidence	O
of	O
oral	O
bioavailability	O
in	O
rodents	O
.	O

However	O
,	O
neither	O
5b	O
nor	O
6	O
demonstrated	O
efficacy	O
against	O
acute	O
murine	O
TB	O
following	O
administration	O
at	O
doses	O
up	O
to	O
400	O
mg	O
/	O
kg	O
daily	O
for	O
4	O
weeks	O
.	O

Although	O
5b	O
and	O
6	O
failed	O
to	O
inhibit	O
replication	O
or	O
kill	O
Mtb	O
in	O
vivo	O
,	O
they	O
illuminate	O
a	O
path	O
to	O
new	O
structural	O
variations	O
of	O
the	O
tryptanthrin	S-chem
scaffold	O
that	O
may	O
maximize	O
the	O
potential	O
of	O
this	O
class	O
of	O
compounds	O
against	O
TB	O
.	O

Design	O
and	O
synthesis	O
of	O
novel	O
2	B-chem-C4-1
-	I-chem-C4-1
methyl	I-chem-C4-1
-	I-chem-C4-1
4,5	I-chem-C4-1
-	I-chem-C4-1
substitutedbenzo	I-chem-C4-1
[	I-chem-C4-1
f	I-chem-C4-1
]	I-chem-C4-1
-	I-chem-C4-1
3,3a,4,5	I-chem-C4-1
-	I-chem-C4-1
tetrahydro	I-chem-C4-1
-	I-chem-C4-1
pyrazolo	I-chem-C4-1
[	I-chem-C4-1
1,5	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
]	I-chem-C4-1
[	I-chem-C4-1
1,4	I-chem-C4-1
]	I-chem-C4-1
oxazepin	I-chem-C4-1
-	I-chem-C4-1
8	I-chem-C4-1
(	I-chem-C4-1
7H	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
one	E-chem-C4-1
derivatives	O
as	O
telomerase	S-geneN-C4-2
inhibitors	O
.	O

Eight	O
novel	O
4,5	B-chem
-	I-chem
tetrahydropyrazolo	I-chem
[	I-chem
1,5	I-chem
-	I-chem
d	I-chem
]	I-chem
[	I-chem
1,4	I-chem
]	I-chem
oxazepine	E-chem
derivatives	O
have	O
been	O
synthesized	O
and	O
purified	O
to	O
be	O
screened	O
for	O
anticancer	O
activity	O
.	O

By	O
a	O
modified	O
TRAP	O
assay	O
,	O
some	O
titled	O
compounds	O
were	O
tested	O
against	O
telomerase	S-geneN
,	O
and	O
compound	O
4a	O
showed	O
the	O
most	O
potent	O
inhibitory	O
activity	O
with	O
IC	O
(	O
50	O
)	O
value	O
at	O
0.78	O
±	O
0.22	O
μM	O
.	O

Western	O
blot	O
assays	O
showed	O
that	O
compounds	O
4a	O
and	O
4b	O
could	O
inhibit	O
expression	O
of	O
Cyclin	B-geneY
D1	E-geneY
,	O
TERT	S-geneY
,	O
phospho	B-geneN
-	I-geneN
AKT	E-geneN
and	O
PI3K	S-geneN
/	O
AKT	S-geneN
pathway	O
.	O

A	O
significant	O
dose	O
-	O
dependent	O
relationship	O
between	O
mercury	S-chem
exposure	O
from	O
dental	O
amalgams	O
and	O
kidney	O
integrity	O
biomarkers	O
:	O
A	O
further	O
assessment	O
of	O
the	O
Casa	O
Pia	O
children	O
's	O
dental	O
amalgam	O
trial	O
.	O

Dental	O
amalgams	O
are	O
a	O
commonly	O
used	O
dental	O
restorative	O
material	O
.	O

Amalgams	O
are	O
about	O
50	O
%	O
mercury	S-chem
(	O
Hg	S-chem
)	O
,	O
and	O
Hg	S-chem
is	O
known	O
to	O
significantly	O
accumulate	O
in	O
the	O
kidney	O
.	O

It	O
was	O
hypothesized	O
that	O
because	O
Hg	S-chem
accumulates	O
in	O
the	O
proximal	O
tubules	O
(	O
PTs	O
)	O
,	O
glutathione	B-geneN
-	I-geneN
S	I-geneN
-	I-geneN
transferases	I-geneN
(	I-geneN
GST	I-geneN
)	I-geneN
-	I-geneN
α	E-geneN
(	O
suggestive	O
of	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
PT	O
)	O
would	O
be	O
expected	O
to	O
be	O
more	O
related	O
to	O
Hg	S-chem
exposure	O
than	O
GST	B-geneY
-	I-geneY
π	E-geneY
(	O
suggestive	O
of	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
the	O
distal	O
tubules	O
)	O
.	O

Urinary	O
biomarkers	O
of	O
kidney	O
integrity	O
were	O
examined	O
in	O
children	O
of	O
8	O
-	O
18	O
years	O
old	O
,	O
with	O
and	O
without	O
dental	O
amalgam	O
fillings	O
,	O
from	O
a	O
completed	O
clinical	O
trial	O
(	O
parent	O
study	O
)	O
.	O

Our	O
study	O
determined	O
whether	O
there	O
was	O
a	O
significant	O
dose	O
-	O
dependent	O
correlation	O
between	O
increasing	O
Hg	S-chem
exposure	O
from	O
dental	O
amalgams	O
and	O
GST	B-geneN
-	I-geneN
α	E-geneN
and	O
GST	B-geneY
-	I-geneY
π	E-geneY
as	O
biomarkers	O
of	O
kidney	O
integrity	O
.	O

Overall	O
,	O
the	O
present	O
study	O
,	O
using	O
a	O
different	O
and	O
more	O
sensitive	O
statistical	O
model	O
than	O
the	O
parent	O
study	O
,	O
revealed	O
a	O
statistically	O
significant	O
dose	O
-	O
dependent	O
correlation	O
between	O
cumulative	O
exposure	O
to	O
Hg	S-chem
from	O
dental	O
amalgams	O
and	O
urinary	O
levels	O
of	O
GST	B-geneN
-	I-geneN
α	E-geneN
,	O
after	O
covariate	O
adjustment	O
;	O
where	O
as	O
,	O
a	O
nonsignificant	O
relationship	O
was	O
observed	O
with	O
urinary	O
levels	O
of	O
GST	B-geneY
-	I-geneY
π	E-geneY
.	O

Furthermore	O
,	O
it	O
was	O
observed	O
that	O
urinary	O
GST	B-geneN
-	I-geneN
α	E-geneN
levels	O
increased	O
by	O
about	O
10	O
%	O
over	O
the	O
8	O
-	O
year	O
course	O
of	O
the	O
study	O
among	O
individuals	O
with	O
an	O
average	O
exposure	O
to	O
amalgams	O
among	O
the	O
study	O
subjects	O
from	O
the	O
amalgam	O
group	O
,	O
in	O
comparison	O
with	O
study	O
subjects	O
with	O
no	O
exposure	O
to	O
dental	O
amalgams	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
dental	O
amalgams	O
contribute	O
to	O
ongoing	O
kidney	O
damage	O
at	O
the	O
level	O
of	O
the	O
PTs	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

EROD	S-geneN-C3-2
activity	O
induction	O
in	O
peripheral	O
blood	O
lymphocytes	O
,	O
liver	O
and	O
brain	O
tissues	O
of	O
rats	O
orally	O
exposed	O
to	O
polycyclic	B-chem-C3-1
aromatic	I-chem-C3-1
hydrocarbons	E-chem-C3-1
.	O

Little	O
is	O
known	O
in	O
terms	O
of	O
multi	O
-	O
matrix	O
cytochrome	B-geneN-C3-2
P450	E-geneN-C3-2
activity	O
induction	O
under	O
repeated	O
oral	O
exposure	O
to	O
planar	O
halogenated	B-chem-C3-1
and	I-chem-C3-1
polycyclic	I-chem-C3-1
aromatic	I-chem-C3-1
hydrocarbons	E-chem-C3-1
(	O
PHH	O
,	O
PAH	S-chem-C3-1
)	O
.	O

In	O
the	O
present	O
study	O
,	O
60	O
rats	O
were	O
daily	O
exposed	O
,	O
during	O
28days	O
,	O
to	O
oral	O
ingestion	O
of	O
a	O
mixture	O
consisting	O
of	O
phenanthrene	S-chem
,	O
pyrene	S-chem
and	O
benzo	B-chem
(	I-chem
a	I-chem
)	I-chem
pyrene	E-chem
at	O
0	O
,	O
6	O
or	O
600μg	O
/	O
day	O
.	O

EROD	S-geneN
activity	O
,	O
reflecting	O
almost	O
exclusively	O
CYP1A1	S-geneY
and	O
CYP1B1	S-geneY
activities	O
,	O
was	O
measured	O
in	O
brain	O
and	O
liver	O
microsomes	O
as	O
well	O
as	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
.	O

All	O
induction	O
kinetics	O
could	O
be	O
appropriately	O
fitted	O
using	O
logistic	O
-	O
like	O
models	O
.	O

After	O
28days	O
of	O
exposure	O
to	O
a	O
6μg	O
/	O
day	O
dose	O
,	O
EROD	S-geneN
activity	O
was	O
found	O
to	O
be	O
91	O
,	O
152	O
and	O
94	O
-	O
fold	O
increased	O
in	O
lymphocytes	O
,	O
liver	O
and	O
brain	O
,	O
respectively	O
,	O
compared	O
to	O
day	O
0	O
.	O

Plateau	O
activities	O
could	O
be	O
appropriately	O
fitted	O
versus	O
ingested	O
doses	O
using	O
Hill	O
or	O
Michaelis	O
-	O
Menten	O
models	O
.	O

Correlations	O
between	O
matrices	O
made	O
it	O
possible	O
to	O
conclude	O
that	O
EROD	S-geneN
activity	O
in	O
PBL	O
should	O
be	O
considered	O
as	O
a	O
sensitive	O
,	O
convenient	O
and	O
non	O
-	O
destructive	O
approach	O
for	O
(	O
i	O
)	O
evaluating	O
EROD	S-geneN
activity	O
in	O
liver	O
,	O
which	O
was	O
found	O
to	O
represent	O
98	O
%	O
of	O
the	O
observed	O
EROD	S-geneN
activities	O
in	O
the	O
three	O
tested	O
matrices	O
and	O
(	O
ii	O
)	O
evaluating	O
oral	O
exposure	O
of	O
homogeneous	O
groups	O
of	O
farm	O
animals	O
(	O
race	O
,	O
diet	O
)	O
to	O
CYP	S-geneN
inducing	O
PAH	O
and	O
PHH	S-chem
.	O

Sterol	B-geneN
transporters	E-geneN
:	O
targets	O
of	O
natural	O
sterols	S-chem
and	O
new	O
lipid	O
lowering	O
drugs	O
.	O

Recent	O
insights	O
in	O
the	O
role	O
of	O
ATP	B-geneN
-	I-geneN
binding	I-geneN
cassette	I-geneN
(	I-geneN
ABC	I-geneN
)	I-geneN
transporters	E-geneN
ABCG5	S-geneY
and	O
ABCG8	S-geneY
,	O
the	O
discovery	O
of	O
ezetimibe	S-chem
,	O
the	O
first	O
approved	O
direct	O
cholesterol	S-chem
absorption	O
inhibitor	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
Niemann	B-geneY
-	I-geneY
Pick	I-geneY
C1	I-geneY
Like	I-geneY
1	E-geneY
(	O
NPC1L1	S-geneY
)	O
protein	O
as	O
sterol	S-chem
transporter	O
in	O
the	O
gut	O
,	O
focused	O
attention	O
on	O
sterol	S-chem
transport	O
processes	O
in	O
the	O
small	O
intestine	O
and	O
the	O
liver	O
.	O

The	O
identification	O
of	O
defective	O
structures	O
in	O
the	O
ABCG5	S-geneY
or	O
ABCG8	S-geneY
transporters	O
in	O
patients	O
with	O
the	O
rare	O
disease	O
of	O
sitosterolemia	O
elucidated	O
their	O
role	O
as	O
sterol	B-geneN
efflux	I-geneN
pumps	E-geneN
regulating	O
at	O
least	O
in	O
parts	O
the	O
intestinal	O
sterol	S-chem
absorption	O
and	O
the	O
hepatic	O
sterol	S-chem
output	O
.	O

ABCG5	S-geneY
and	O
ABCG8	S-geneY
themselves	O
are	O
regulated	O
by	O
cholesterol	S-chem
via	O
liver	B-geneN
X	I-geneN
receptors	E-geneN
(	O
LXRs	S-geneN-C3-2
)	O
,	O
which	O
are	O
also	O
activated	O
by	O
oxysterols	O
and	O
some	O
derivatives	O
of	O
plant	O
sterols	S-chem-C3-1
.	O

NPC1L1	S-geneY-C9-2
could	O
recently	O
be	O
identified	O
as	O
a	O
major	O
sterol	B-geneN-C9-2
transporter	E-geneN-C9-2
for	O
the	O
intestinal	O
uptake	O
of	O
cholesterol	S-chem-C9-1
as	O
well	O
as	O
plant	O
sterols	S-chem-C9-1
.	O

Studies	O
in	O
NPC1L1	S-geneY
knockout	O
mice	O
indicate	O
that	O
this	O
transporter	O
is	O
essential	O
for	O
the	O
intestinal	O
uptake	O
of	O
sterols	S-chem
and	O
that	O
NPC1L1	S-geneY
might	O
also	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
ezetimibe	S-chem
.	O

However	O
,	O
studies	O
with	O
photoreactive	O
cholesterol	S-chem
as	O
well	O
as	O
with	O
photoreactive	O
ezetimibe	S-chem
analogues	O
suggest	O
that	O
other	O
processes	O
might	O
also	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
ezetimibe	S-chem
.	O

VMAT2	S-geneY
:	O
a	O
dynamic	O
regulator	O
of	O
brain	O
monoaminergic	O
neuronal	O
function	O
interacting	O
with	O
drugs	O
of	O
abuse	O
.	O

The	O
monoaminergic	O
neuron	O
,	O
in	O
particular	O
the	O
dopaminergic	O
neuron	O
,	O
is	O
central	O
to	O
mediating	O
the	O
hedonic	O
and	O
addictive	O
properties	O
of	O
drugs	O
of	O
abuse	O
.	O

The	O
effects	O
of	O
amphetamine	S-chem
(	O
AMPH	S-chem
)	O
and	O
cocaine	S-chem
(	O
COC	S-chem
)	O
,	O
for	O
example	O
,	O
depend	O
on	O
the	O
ability	O
to	O
increase	O
dopamine	S-chem
in	O
the	O
synapse	O
,	O
by	O
effects	O
on	O
either	O
the	O
plasma	O
membrane	O
transporter	O
DAT	S-geneY
or	O
the	O
vesicular	O
transporter	O
for	O
monoamine	S-chem
storage	O
,	O
VMAT2	S-geneY
.	O

The	O
potential	O
role	O
of	O
DAT	S-geneY
as	O
a	O
target	O
for	O
AMPH	S-chem
and	O
COC	S-chem
has	O
been	O
reviewed	O
extensively	O
.	O

Here	O
,	O
we	O
present	O
VMAT2	S-geneY
as	O
a	O
target	O
that	O
enables	O
the	O
rewarding	O
and	O
addictive	O
actions	O
of	O
these	O
drugs	O
,	O
based	O
on	O
imaging	O
,	O
neurochemical	O
,	O
biochemical	O
,	O
cell	O
biological	O
,	O
genetic	O
,	O
and	O
immunohistochemical	O
evidence	O
.	O

The	O
presence	O
of	O
VMAT2	S-geneY
in	O
noradrenergic	O
,	O
serotoninergic	O
,	O
histaminergic	O
,	O
and	O
potentially	O
trace	O
aminergic	O
neurons	O
invites	O
consideration	O
of	O
a	O
wider	O
role	O
for	O
aminergic	O
neurotransmission	O
in	O
AMPH	S-chem
and	O
COC	S-chem
abuse	O
and	O
addiction	O
.	O

Phase	O
1	O
and	O
phase	O
2	O
drug	O
metabolism	O
and	O
bile	B-chem
acid	E-chem
production	O
of	O
HepaRG	O
cells	O
in	O
a	O
bioartificial	O
liver	O
in	O
absence	O
of	O
dimethyl	B-chem
sulfoxide	E-chem
.	O

The	O
human	O
liver	O
cell	O
line	O
HepaRG	O
has	O
been	O
recognized	O
as	O
a	O
promising	O
source	O
for	O
in	O
vitro	O
testing	O
of	O
metabolism	O
and	O
toxicity	O
of	O
compounds	O
.	O

However	O
,	O
currently	O
the	O
hepatic	O
differentiation	O
of	O
these	O
cells	O
relies	O
on	O
exposure	O
to	O
dimethylsulfoxide	S-chem
(	O
DMSO	S-chem
)	O
,	O
which	O
,	O
as	O
a	O
side	O
effect	O
,	O
has	O
a	O
cytotoxic	O
effect	O
and	O
represses	O
an	O
all	O
-	O
round	O
hepatic	O
functionality	O
.	O

The	O
AMC	O
-	O
bioartificial	O
liver	O
(	O
AMC	O
-	O
BAL	O
)	O
is	O
a	O
three	O
-	O
dimensional	O
bioreactor	O
that	O
has	O
previously	O
been	O
shown	O
to	O
upregulate	O
various	O
liver	O
functions	O
of	O
cultured	O
cells	O
.	O

We	O
therefore	O
cultured	O
HepaRG	O
cells	O
in	O
the	O
AMC	O
-	O
BAL	O
without	O
DMSO	S-chem
and	O
characterized	O
the	O
drug	O
metabolism	O
.	O

Within	O
14	O
days	O
of	O
culture	O
,	O
the	O
HepaRG	O
-	O
AMC	O
-	O
BALs	O
contained	O
highly	O
polarized	O
viable	O
liver	O
-	O
like	O
tissue	O
with	O
heterogeneous	O
expression	O
of	O
CYP3A4	S-geneY
.	O

We	O
found	O
a	O
substantial	O
metabolism	O
of	O
the	O
tested	O
substrates	O
,	O
ranging	O
from	O
26	O
%	O
(	O
UDP	B-geneY
-	I-geneY
glucuronosyltransferase	I-geneY
1A1	E-geneY
)	O
,	O
47	O
%	O
(	O
CYP3A4	S-geneY
)	O
,	O
to	O
240	O
%	O
(	O
CYP2C9	S-geneY
)	O
of	O
primary	O
human	O
hepatocytes	O
.	O

The	O
CYP3A4	S-geneY-C3-2
activity	O
could	O
be	O
induced	O
2	O
-	O
fold	O
by	O
rifampicin	S-chem-C3-1
,	O
whereas	O
CYP2C9	S-geneY-C3-2
activity	O
remained	O
equally	O
high	O
.	O

The	O
HepaRG	O
-	O
AMC	O
-	O
BAL	O
secreted	O
bile	B-chem
acids	E-chem
at	O
43	O
%	O
the	O
rate	O
of	O
primary	O
human	O
hepatocytes	O
and	O
demonstrated	O
hydroxylation	O
,	O
conjugation	O
,	O
and	O
transport	O
of	O
bile	B-chem
salts	E-chem
.	O

Concluding	O
,	O
culturing	O
HepaRG	O
cells	O
in	O
the	O
AMC	O
-	O
BAL	O
yields	O
substantial	O
phase	O
1	O
and	O
phase	O
2	O
drug	O
metabolism	O
,	O
while	O
maintaining	O
high	O
viability	O
,	O
rendering	O
DMSO	S-chem
addition	O
superfluous	O
for	O
the	O
promotion	O
of	O
drug	O
metabolism	O
.	O

Therefore	O
,	O
AMC	O
-	O
BAL	O
culturing	O
makes	O
the	O
HepaRG	O
cells	O
more	O
suitable	O
for	O
testing	O
metabolism	O
and	O
toxicity	O
of	O
drugs	O
.	O

The	O
pharmacokinetics	O
of	O
fondaparinux	B-chem
sodium	E-chem
in	O
healthy	O
volunteers	O
.	O

OBJECTIVE	O
:	O
Fondaparinux	B-chem-C4-1
sodium	E-chem-C4-1
is	O
the	O
first	O
in	O
a	O
new	O
class	O
of	O
synthetic	O
factor	B-geneY-C4-2
Xa	E-geneY-C4-2
inhibitors	O
that	O
binds	O
reversibly	O
with	O
high	O
affinity	O
to	O
antithrombin	B-geneY
III	E-geneY
.	O

It	O
has	O
been	O
investigated	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
arterial	O
and	O
venous	O
thrombotic	O
disorders	O
and	O
approved	O
for	O
use	O
at	O
a	O
dose	O
of	O
2.5mg	O
once	O
daily	O
in	O
the	O
prevention	O
of	O
venous	O
thromboembolism	O
in	O
major	O
orthopaedic	O
surgery	O
.	O

The	O
pharmacokinetics	O
of	O
fondaparinux	B-chem
sodium	E-chem
were	O
determined	O
in	O
eight	O
studies	O
in	O
young	O
and	O
elderly	O
healthy	O
volunteers	O
.	O

RESULTS	O
:	O
After	O
a	O
2.5mg	O
subcutaneous	O
dose	O
to	O
young	O
volunteers	O
,	O
absolute	O
bioavailability	O
was	O
100	O
%	O
and	O
absorption	O
was	O
rapid	O
and	O
complete	O
[	O
peak	O
plasma	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
0.34	O
mg	O
/	O
L	O
occurred	O
at	O
approximately	O
2	O
hours	O
]	O
.	O

Within	O
-	O
and	O
total	O
-	O
subject	O
variability	O
estimates	O
were	O
small	O
:	O
5.5	O
and	O
11.6	O
%	O
,	O
respectively	O
,	O
for	O
C	O
(	O
max	O
)	O
and	O
4.4	O
and	O
17.5	O
%	O
for	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
.	O

Steady	O
state	O
was	O
obtained	O
after	O
the	O
third	O
or	O
fourth	O
once	O
-	O
daily	O
dose	O
,	O
with	O
a	O
1.3	O
-	O
fold	O
increase	O
in	O
C	O
(	O
max	O
)	O
and	O
AUC	O
.	O

Distribution	O
volume	O
(	O
7	O
to	O
11L	O
)	O
was	O
limited	O
to	O
blood	O
volume	O
.	O

There	O
was	O
no	O
evidence	O
of	O
metabolism	O
.	O

Fondaparinux	B-chem
sodium	E-chem
was	O
almost	O
completely	O
excreted	O
in	O
urine	O
as	O
unchanged	O
compound	O
(	O
64	O
to	O
77	O
%	O
of	O
the	O
dose	O
was	O
recovered	O
at	O
72	O
hours	O
after	O
administration	O
)	O
.	O

Plasma	O
clearance	O
was	O
5.1	O
to	O
7.9	O
ml	O
/	O
min	O
,	O
renal	O
clearance	O
4.0	O
to	O
7.9	O
ml	O
/	O
min	O
,	O
and	O
the	O
terminal	O
half	O
-	O
life	O
was	O
17	O
hours	O
in	O
young	O
volunteers	O
and	O
21	O
hours	O
in	O
elderly	O
volunteers	O
.	O

Pharmacokinetics	O
of	O
fondaparinux	B-chem
sodium	E-chem
were	O
linear	O
in	O
the	O
range	O
2	O
to	O
8mg	O
subcutaneously	O
and	O
2	O
to	O
20mg	O
intravenously	O
.	O

Pharmacokinetics	O
observed	O
in	O
healthy	O
elderly	O
volunteers	O
were	O
consistent	O
with	O
findings	O
in	O
young	O
male	O
volunteers	O
.	O

CONCLUSION	O
:	O
The	O
favourable	O
pharmacokinetic	O
profile	O
of	O
fondaparinux	B-chem
sodium	E-chem
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
major	O
advance	O
that	O
the	O
drug	O
represents	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
thrombotic	O
disorders	O
.	O

Actions	O
of	O
nizatidine	S-chem-C6-1
,	O
a	O
selective	O
histamine	B-geneN-C6-2
H2	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
on	O
gastric	O
acid	O
secretion	O
in	O
dogs	O
,	O
rats	O
and	O
frogs	O
.	O

Nizatidine	S-chem-C6-1
(	O
LY139037	S-chem-C6-1
)	O
,	O
a	O
selective	O
histamine	B-geneN-C6-2
H2	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
gastric	O
acid	O
secretion	O
.	O

It	O
was	O
17.8	O
times	O
as	O
active	O
as	O
cimetidine	S-chem
on	O
histamine	S-chem
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
-	O
induced	O
secretion	O
from	O
the	O
isolated	O
gastric	O
mucosa	O
of	O
the	O
bullfrog	O
.	O

Nizatidine	S-chem
was	O
8.9	O
times	O
as	O
active	O
as	O
cimetidine	S-chem
on	O
basal	O
acid	O
secretion	O
of	O
the	O
chronic	O
gastric	O
fistula	O
rats	O
after	O
s.c.	O
administration	O
.	O

Against	O
acid	O
secretion	O
from	O
the	O
vagally	O
innervated	O
gastric	O
fistula	O
and	O
Heidenhain	O
pouch	O
of	O
dogs	O
stimulated	O
with	O
submaximal	O
doses	O
of	O
histamine	S-chem
,	O
methacholine	S-chem
and	O
gastrin	S-geneY
,	O
nizatidine	S-chem
was	O
,	O
respectively	O
,	O
6.5	O
,	O
5	O
and	O
4.7	O
times	O
as	O
active	O
as	O
cimetidine	S-chem
by	O
i.v	O
.	O
administration	O
.	O

Nizatidine	S-chem
was	O
very	O
well	O
absorbed	O
from	O
the	O
gut	O
and	O
was	O
5	O
to	O
10	O
times	O
as	O
active	O
as	O
cimetidine	S-chem
on	O
gastric	O
acid	O
secretion	O
of	O
dogs	O
induced	O
by	O
submaximal	O
and	O
maximal	O
doses	O
of	O
histamine	S-chem
when	O
given	O
p.o	O
.	O

Equal	O
molar	O
doses	O
of	O
nizatidine	S-chem
showed	O
equal	O
peak	O
effects	O
when	O
given	O
i.v	O
.	O
,	O
s.c.	O
or	O
i.m	O
.	O

Pharmacological	O
data	O
indicate	O
that	O
nizatidine	S-chem
is	O
safe	O
and	O
effective	O
as	O
an	O
agent	O
for	O
the	O
control	O
of	O
excessive	O
gastric	O
acid	O
secretion	O
.	O

Gemcitabine	S-chem
and	O
Pemetrexed	B-chem
disodium	E-chem
in	O
treating	O
breast	O
cancer	O
.	O

Pemetrexed	B-chem-C4-1
disodium	E-chem-C4-1
(	O
Alimta	S-chem-C4-1
,	O
LY231514	S-chem-C4-1
)	O
is	O
a	O
novel	O
,	O
multitargeted	O
antifolate	O
that	O
inhibits	O
thymidylate	B-geneY-C4-2
synthase	E-geneY-C4-2
,	O
dihydrofolate	B-geneY-C4-2
reductase	E-geneY-C4-2
,	O
and	O
glycinamide	B-geneY-C4-2
ribonucleotide	I-geneY-C4-2
formyl	I-geneY-C4-2
transferase	E-geneY-C4-2
.	O

This	O
agent	O
is	O
broadly	O
active	O
in	O
a	O
wide	O
variety	O
of	O
solid	O
tumors	O
,	O
including	O
breast	O
cancer	O
.	O

Pemetrexed	B-chem
disodium	E-chem
has	O
also	O
shown	O
clinically	O
relevant	O
activity	O
in	O
combination	O
with	O
gemcitabine	S-chem
(	O
Gemzar	S-chem
)	O
.	O

This	O
combination	O
is	O
being	O
evaluated	O
for	O
the	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
.	O

Reversal	O
of	O
dopamine	B-geneY
D2	E-geneY
agonist	O
-	O
induced	O
inhibition	O
of	O
ventral	O
tegmental	O
area	O
neurons	O
by	O
Gq	S-geneN
-	O
linked	O
neurotransmitters	O
is	O
dependent	O
on	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
,	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	I-geneN
kinase	E-geneN
,	O
and	O
dynamin	S-geneN
.	O

Dopaminergic	O
neurons	O
of	O
the	O
ventral	O
tegmental	O
area	O
are	O
important	O
components	O
of	O
brain	O
pathways	O
related	O
to	O
addiction	O
.	O

Prolonged	O
exposure	O
of	O
these	O
neurons	O
to	O
moderate	O
concentrations	O
of	O
dopamine	S-chem
(	O
DA	O
)	O
decreases	O
their	O
sensitivity	O
to	O
inhibition	O
by	O
DA	O
,	O
a	O
process	O
called	O
DA	O
-	O
inhibition	O
reversal	O
(	O
DIR	O
)	O
.	O

DIR	O
is	O
mediated	O
by	O
phospholipase	B-geneN
C	E-geneN
and	O
conventional	B-geneN
subtype	I-geneN
of	I-geneN
protein	I-geneN
kinase	I-geneN
C	E-geneN
(	O
cPKC	S-geneN
)	O
through	O
concurrent	O
stimulation	O
of	O
D2	S-geneY
and	O
D1	B-geneN
-	I-geneN
like	I-geneN
DA	I-geneN
receptors	E-geneN
,	O
or	O
by	O
D2	S-geneY
stimulation	O
concurrent	O
with	O
activation	O
of	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
2	I-geneN
)	E-geneN
or	O
neurotensin	B-geneN
receptors	E-geneN
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
this	O
phenomenon	O
by	O
use	O
of	O
extracellular	O
recordings	O
in	O
brain	O
slices	O
to	O
examine	O
whether	O
DIR	O
is	O
linked	O
to	O
G	B-geneY
protein	I-geneY
-	I-geneY
coupled	I-geneY
receptor	I-geneY
kinase	I-geneY
-	I-geneY
2	E-geneY
(	O
GRK2	S-geneY
)	O
or	O
dynamin	S-geneN
by	O
assessing	O
DIR	O
in	O
the	O
presence	O
of	O
antagonists	O
of	O
these	O
enzymes	O
.	O

DIR	O
was	O
blocked	O
by	O
β	O
-	O
ARK1	O
inhibitor	O
,	O
which	O
inhibits	O
GRK2	S-geneY
,	O
and	O
by	O
dynasore	O
,	O
which	O
blocks	O
dynamin	S-geneN
.	O

Reversal	O
of	O
inhibition	O
by	O
D2	S-geneY-MU-2
agonist	O
quinpirole	S-chem-C5-1
was	O
produced	O
by	O
serotonin	S-chem-C3-1
(	O
50	O
µM	O
)	O
and	O
by	O
neurotensin	S-geneY
(	O
5	O
-	O
10	O
nM	O
)	O
.	O

Serotonin	S-chem
-	O
induced	O
or	O
neurotensin	S-geneY
-	O
induced	O
reversal	O
was	O
blocked	O
by	O
β	O
-	O
ARK1	O
inhibitor	O
,	O
dynasore	O
,	O
or	O
cPKC	S-geneN-C6-2
antagonist	O
5,6,7,13	B-chem-C6-1
-	I-chem-C6-1
tetrahydro	I-chem-C6-1
-	I-chem-C6-1
13	I-chem-C6-1
-	I-chem-C6-1
methyl	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
oxo	I-chem-C6-1
-	I-chem-C6-1
12H	I-chem-C6-1
-	I-chem-C6-1
indolo	I-chem-C6-1
[	I-chem-C6-1
2,3	I-chem-C6-1
-	I-chem-C6-1
a	I-chem-C6-1
]	I-chem-C6-1
pyrrolo	I-chem-C6-1
[	I-chem-C6-1
3,4c	I-chem-C6-1
]	I-chem-C6-1
carbazole	I-chem-C6-1
-	I-chem-C6-1
12	I-chem-C6-1
-	I-chem-C6-1
propanenitrile	E-chem-C6-1
(	O
Gö6976	S-chem-C6-1
)	O
.	O

This	O
further	O
characterization	O
of	O
DIR	O
indicates	O
that	O
cPKC	S-geneN
,	O
GRK2	S-geneY
,	O
and	O
dynamin	S-geneN
play	O
important	O
roles	O
in	O
the	O
desensitization	O
of	O
D2	S-geneY
receptors	O
.	O

As	O
drugs	O
of	O
abuse	O
produce	O
persistent	O
increases	O
in	O
DA	O
concentration	O
in	O
the	O
ventral	O
tegmental	O
area	O
,	O
reduction	O
of	O
D2	B-geneY
receptor	E-geneY
sensitivity	O
as	O
a	O
result	O
of	O
drug	O
abuse	O
may	O
be	O
a	O
critical	O
factor	O
in	O
the	O
processes	O
of	O
addiction	O
.	O

Self	O
-	O
cancellation	O
of	O
drug	O
properties	O
as	O
a	O
mode	O
of	O
organ	O
selectivity	O
:	O
the	O
antimuscarinic	O
effects	O
of	O
ambenonium	S-chem
.	O

Ambenonium	S-chem-MU-1
is	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
acetylcholinesterase	S-geneY-C4-2
,	O
and	O
recent	O
data	O
have	O
shown	O
this	O
drug	O
to	O
antagonize	O
muscarinic	B-geneN-C6-2
receptors	E-geneN-C6-2
as	O
well	O
.	O

This	O
latter	O
property	O
was	O
confirmed	O
by	O
Schild	O
analyses	O
of	O
ambenonium	S-chem
-	O
induced	O
blockade	O
of	O
responses	O
to	O
bethanechol	S-chem
in	O
guinea	O
-	O
pig	O
ileal	O
longitudinal	O
smooth	O
muscle	O
,	O
taenia	O
caeci	O
,	O
trachea	O
and	O
rat	O
anococcygeus	O
muscle	O
.	O

Statistical	O
analysis	O
showed	O
ambenonium	S-chem
to	O
be	O
a	O
simple	O
competitive	O
antagonist	O
of	O
responses	O
to	O
bethanechol	S-chem
in	O
these	O
tissues	O
with	O
pKB	O
values	O
in	O
each	O
tissue	O
not	O
significantly	O
different	O
from	O
each	O
other	O
(	O
mean	O
pKB	O
=	O
6.0	O
)	O
.	O

However	O
,	O
considerable	O
variability	O
in	O
pKB	O
estimates	O
was	O
encountered	O
when	O
ambenonium	S-chem
was	O
utilized	O
to	O
block	O
responses	O
to	O
acetylcholine	S-chem
.	O

Ambenonium	S-chem
was	O
a	O
less	O
potent	O
antagonist	O
of	O
tissue	O
responses	O
to	O
acetylcholine	S-chem
,	O
and	O
the	O
underestimation	O
in	O
the	O
pKB	O
(	O
as	O
compared	O
to	O
that	O
obtained	O
with	O
bethanechol	S-chem
)	O
could	O
be	O
eliminated	O
by	O
prior	O
treatment	O
of	O
tissues	O
with	O
the	O
acetylcholinesterase	S-geneY-C4-2
inhibitor	O
neostigmine	S-chem-C4-1
.	O

These	O
data	O
suggested	O
that	O
ambenonium	S-chem-MU-1
had	O
a	O
dual	O
effect	O
on	O
tissue	O
responses	O
to	O
acetylcholine	S-chem-C5-1
-	O
producing	O
potentiation	O
by	O
blockade	O
of	O
acetylcholinesterase	S-geneY-MU-2
and	O
concomitant	O
antagonism	O
by	O
blockade	O
of	O
muscarinic	B-geneN-MU-2
receptors	E-geneN-MU-2
.	O

The	O
Schild	O
regressions	O
obtained	O
for	O
ambenonium	S-chem
antagonism	O
of	O
acetylcholine	S-chem
responses	O
formally	O
satisfied	O
criteria	O
for	O
simple	O
competitive	O
antagonism	O
of	O
a	O
homogenous	O
population	O
of	O
receptors	O
(	O
linear	O
regression	O
,	O
slope	O
equal	O
to	O
unity	O
)	O
.	O

The	O
fact	O
that	O
these	O
regressions	O
yielded	O
erroneous	O
apparent	O
pKB	O
values	O
suggests	O
how	O
two	O
properties	O
of	O
a	O
drug	O
in	O
one	O
molecule	O
could	O
provide	O
misleading	O
information	O
about	O
drug	O
receptors	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

QM	O
/	O
MM	O
simulations	O
of	O
vibrational	O
spectra	O
of	O
bacteriorhodopsin	S-geneN
and	O
channelrhodopsin	B-geneN
-	I-geneN
2	E-geneN
.	O

Channelrhodopsin	B-geneN
-	I-geneN
2	E-geneN
is	O
a	O
light	B-geneN
-	I-geneN
gated	I-geneN
ion	I-geneN
channel	E-geneN
,	O
which	O
has	O
been	O
studied	O
intensively	O
over	O
the	O
last	O
decade	O
.	O

Vibrational	O
spectroscopic	O
experiments	O
started	O
to	O
shed	O
light	O
on	O
the	O
structural	O
changes	O
,	O
that	O
occur	O
during	O
the	O
photocycle	O
,	O
especially	O
in	O
the	O
hydrogen	S-chem
-	O
bonded	O
network	O
surrounding	O
the	O
protonated	O
D156	O
and	O
C128	O
-	O
the	O
DC	O
gate	O
.	O

However	O
,	O
the	O
interpretation	O
of	O
these	O
experiments	O
was	O
only	O
based	O
on	O
homology	O
models	O
.	O

Since	O
then	O
,	O
an	O
X	O
-	O
ray	O
structure	O
and	O
better	O
computational	O
models	O
became	O
available	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
in	O
combination	O
with	O
a	O
recent	O
reparametrization	O
,	O
the	O
approximate	O
DFT	O
method	O
,	O
DFTB	O
,	O
is	O
able	O
to	O
describe	O
the	O
effects	O
of	O
hydrogen	S-chem
bonding	O
on	O
the	O
C	S-chem
[	O
double	O
bond	O
,	O
length	O
as	O
m	O
-	O
dash	O
]	O
O	S-chem
stretch	O
vibration	O
in	O
carboxylic	B-chem
acids	E-chem
reliably	O
and	O
agrees	O
well	O
with	O
full	O
DFT	O
results	O
.	O

We	O
apply	O
DFTB	O
in	O
a	O
QM	O
/	O
MM	O
framework	O
to	O
perform	O
vibrational	O
analysis	O
of	O
buried	O
aspartic	B-chem
acids	E-chem
in	O
bacteriorhodopsin	S-geneN
and	O
channelrhodopsin	B-geneN
-	I-geneN
2	E-geneN
.	O

Using	O
this	O
approach	O
,	O
we	O
can	O
simulate	O
the	O
FTIR	O
spectral	O
difference	O
between	O
D115	O
in	O
the	O
dark	O
-	O
adapted	O
and	O
K	O
states	O
of	O
bacteriorhodopsin	S-geneN
.	O

The	O
FTIR	O
experiments	O
on	O
the	O
DC	O
gate	O
in	O
channelrhodopsin	B-geneN
-	I-geneN
2	E-geneN
are	O
well	O
described	O
using	O
an	O
indirect	O
model	O
,	O
where	O
D156	O
and	O
C128	O
are	O
bridged	O
via	O
a	O
water	O
molecule	O
.	O

Tumor	O
-	O
growth	O
-	O
promoting	O
cyclooxygenase	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
prostaglandin	B-chem-C9-1
E2	E-chem-C9-1
pathway	O
provides	O
medulloblastoma	O
therapeutic	O
targets	O
.	O

Prostaglandin	B-chem
E	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
has	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
several	O
aspects	O
of	O
tumor	O
development	O
and	O
progression	O
.	O

PGE	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
is	O
synthesized	O
from	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
by	O
cyclooxygenases	S-geneN-C9-2
(	O
COX	S-geneN-C9-2
)	O
and	O
prostaglandin	B-geneN-C9-2
E	I-geneN-C9-2
synthases	E-geneN-C9-2
(	O
PGES	S-geneN-C9-2
)	O
and	O
mediates	O
its	O
biological	O
activity	O
through	O
binding	O
to	O
the	O
four	O
prostanoid	B-geneY
receptors	I-geneY
EP	I-geneY
(	I-geneY
1	I-geneY
)	E-geneY
through	O
EP	B-geneY
(	I-geneY
4	I-geneY
)	E-geneY
.	O

In	O
this	O
study	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
medulloblastoma	O
(	O
MB	O
)	O
,	O
the	O
most	O
common	O
malignant	O
childhood	O
brain	O
tumor	O
,	O
expresses	O
high	O
levels	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
,	O
microsomal	B-geneY
prostaglandin	I-geneY
E	I-geneY
synthase	I-geneY
-	I-geneY
1	E-geneY
,	O
and	O
EP	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
through	O
EP	B-geneY
(	I-geneY
4	I-geneY
)	E-geneY
and	O
secretes	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
.	O

PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
and	O
the	O
EP	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
agonist	O
butaprost	O
stimulated	O
MB	O
cell	O
proliferation	O
.	O

Treatment	O
of	O
MB	O
cells	O
with	O
COX	S-geneN
inhibitors	O
suppressed	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
production	O
and	O
induced	O
caspase	S-geneN
-	O
dependent	O
apoptosis	O
.	O

Similarly	O
,	O
specific	O
COX	B-geneY
-	I-geneY
2	E-geneY
silencing	O
by	O
small	O
interfering	O
RNA	O
inhibited	O
MB	O
cell	O
growth	O
.	O

EP	B-geneY-C6-2
(	I-geneY-C6-2
1	I-geneY-C6-2
)	E-geneY-C6-2
and	O
EP	B-geneY-C6-2
(	I-geneY-C6-2
3	I-geneY-C6-2
)	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
ONO	B-chem-C6-1
-	I-chem-C6-1
8713	E-chem-C6-1
and	O
ONO	B-chem-C6-1
-	I-chem-C6-1
AE3	I-chem-C6-1
-	I-chem-C6-1
240	E-chem-C6-1
,	O
but	O
not	O
the	O
EP	B-geneY-C6-2
(	I-geneY-C6-2
4	I-geneY-C6-2
)	E-geneY-C6-2
antagonists	O
ONO	B-chem-C6-1
-	I-chem-C6-1
AE3	I-chem-C6-1
-	I-chem-C6-1
208	E-chem-C6-1
and	O
AH	B-chem-C6-1
23848	E-chem-C6-1
,	O
inhibited	O
tumor	O
cell	O
proliferation	O
,	O
indicating	O
the	O
significance	O
of	O
EP	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
and	O
EP	B-geneY
(	I-geneY
3	I-geneY
)	E-geneY
but	O
not	O
EP	B-geneY
(	I-geneY
4	I-geneY
)	E-geneY
for	O
MB	O
growth	O
.	O

Administration	O
of	O
COX	S-geneN
inhibitors	O
at	O
clinically	O
achievable	O
nontoxic	O
concentrations	O
significantly	O
inhibited	O
growth	O
of	O
established	O
human	O
MB	O
xenografts	O
.	O

Apoptosis	O
was	O
increased	O
,	O
proliferation	O
was	O
reduced	O
,	O
and	O
angiogenesis	O
was	O
inhibited	O
in	O
MBs	O
treated	O
with	O
COX	S-geneN
inhibitors	O
.	O

This	O
study	O
suggests	O
that	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
is	O
important	O
for	O
MB	O
growth	O
and	O
that	O
therapies	O
targeting	O
the	O
prostanoid	O
metabolic	O
pathway	O
are	O
potentially	O
beneficial	O
and	O
should	O
be	O
tested	O
in	O
clinical	O
settings	O
for	O
treatment	O
of	O
children	O
with	O
MB	O
.	O

The	O
inhibitory	O
effect	O
of	O
sodium	B-chem-C4-1
nitroprusside	E-chem-C4-1
on	O
HIF	B-geneN-C4-2
-	I-geneN-C4-2
1	E-geneN-C4-2
activation	O
is	O
not	O
dependent	O
on	O
nitric	B-chem
oxide	E-chem
-	O
soluble	B-geneN
guanylyl	I-geneN
cyclase	E-geneN
pathway	O
.	O

Adaptation	O
to	O
hypoxia	O
and	O
maintenance	O
of	O
O	B-chem
(	I-chem
2	I-chem
)	E-chem
homeostasis	O
involve	O
a	O
wide	O
range	O
of	O
responses	O
that	O
occur	O
at	O
different	O
organizational	O
levels	O
in	O
the	O
body	O
.	O

One	O
of	O
the	O
most	O
important	O
transcription	O
factors	O
that	O
activate	O
the	O
expression	O
of	O
O	B-chem
(	I-chem
2	I-chem
)	E-chem
-	O
regulated	O
genes	O
is	O
hypoxia	B-geneN
-	I-geneN
inducible	I-geneN
factor	I-geneN
1	E-geneN
(	O
HIF	B-geneN
-	I-geneN
1	E-geneN
)	O
.	O

Nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
mediates	O
a	O
variety	O
of	O
biological	O
effects	O
including	O
relaxation	O
of	O
blood	O
vessels	O
and	O
cytotoxicity	O
of	O
activated	O
macrophages	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
clinically	O
used	O
nitrates	O
nitroglycerin	S-chem
(	O
NTG	S-chem
)	O
,	O
isosorbide	B-chem
dinitrate	E-chem
(	O
ISDN	S-chem
)	O
,	O
and	O
sodium	B-chem
nitroprusside	E-chem
(	O
SNP	S-chem
)	O
on	O
HIF	B-geneN
-	I-geneN
1	E-geneN
-	O
mediated	O
transcriptional	O
responses	O
to	O
hypoxia	O
.	O

We	O
demonstrate	O
that	O
among	O
the	O
three	O
nitrates	O
,	O
only	O
SNP	S-chem-C4-1
inhibits	O
HIF	B-geneN-C4-2
-	I-geneN-C4-2
1	E-geneN-C4-2
activation	O
in	O
response	O
to	O
hypoxia	O
.	O

In	O
contrast	O
,	O
NTG	S-chem
or	O
ISDN	S-chem
does	O
not	O
affect	O
HIF	B-geneN
-	I-geneN
1	E-geneN
activity	O
.	O

SNP	S-chem-C4-1
inhibits	O
the	O
accumulation	O
of	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1alpha	E-geneY-C4-2
,	O
the	O
regulatory	O
subunit	O
of	O
HIF	B-geneN-C4-2
-	I-geneN-C4-2
1	E-geneN-C4-2
,	O
and	O
the	O
transcriptional	O
activation	O
of	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1alpha	E-geneY-C4-2
via	O
a	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
either	O
NO	S-chem
or	O
soluble	B-geneN
guanylate	I-geneN
cyclase	E-geneN
.	O

Compound	O
and	O
compositions	O
as	O
TGR5	S-geneY
agonists	O
:	O
WO2012082947	O
.	O

The	O
patent	O
application	O
WO2012082947	O
claims	O
novel	O
compounds	O
as	O
agonists	O
of	O
a	O
plasma	B-geneY
membrane	I-geneY
-	I-geneY
bound	I-geneY
bile	I-geneY
acid	I-geneY
receptor	E-geneY
TGR5	S-geneY
.	O

By	O
activating	O
TGR5	S-geneY
,	O
the	O
agonists	O
improve	O
glycemic	O
control	O
and	O
enhance	O
energy	O
expenditure	O
.	O

The	O
basic	O
generic	O
claim	O
of	O
the	O
patent	O
covers	O
pyrazole	S-chem
derivatives	O
,	O
different	O
permutations	O
on	O
the	O
core	O
pyrazole	S-chem
ring	O
are	O
covered	O
in	O
the	O
subsidiary	O
claims	O
.	O

The	O
claimed	O
compounds	O
are	O
human	B-geneY
TGR5	E-geneY
agonists	O
having	O
potency	O
in	O
the	O
nM	O
range	O
.	O

Bovine	B-geneN
and	I-geneN
ovine	I-geneN
gonadotropin	I-geneN
-	I-geneN
releasing	I-geneN
hormone	I-geneN
(	I-geneN
GnRH	I-geneN
)	I-geneN
-	I-geneN
II	E-geneN
ligand	O
precursors	O
and	O
type	B-geneN
II	I-geneN
GnRH	I-geneN
receptor	E-geneN
genes	O
are	O
functionally	O
inactivated	O
.	O

The	O
decapeptide	O
sequence	O
of	O
GnRH	B-geneN
-	I-geneN
II	E-geneN
is	O
conserved	O
in	O
all	O
jawed	O
vertebrate	O
species	O
studied	O
to	O
date	O
.	O

New	O
data	O
for	O
cattle	O
(	O
Bos	O
taurus	O
)	O
indicates	O
a	O
gene	O
encoding	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
decapeptide	O
possessing	O
arginine	S-chem
(	O
codon	O
:	O
CGG	S-chem
)	O
rather	O
than	O
tryptophan	S-chem
(	O
TGG	S-chem
)	O
at	O
position	O
three	O
in	O
the	O
mature	O
peptide	O
.	O

This	O
substitution	O
is	O
unique	O
.	O

We	O
confirmed	O
the	O
DNA	O
sequence	O
after	O
cloning	O
part	O
of	O
the	O
bovine	B-geneY
prepro	I-geneY
-	I-geneY
GnRH	I-geneY
-	I-geneY
II	E-geneY
gene	O
.	O

Bovine	B-geneY
GnRH	I-geneY
-	I-geneY
II	E-geneY
peptide	O
was	O
synthesized	O
and	O
pharmacologically	O
characterized	O
.	O

It	O
did	O
not	O
bind	O
to	O
mammalian	O
GnRH	B-geneN
receptors	E-geneN
expressed	O
in	O
different	O
types	O
of	O
cell	O
nor	O
did	O
it	O
exhibit	O
agonist	O
or	O
antagonist	O
properties	O
on	O
types	B-geneN
I	I-geneN
or	I-geneN
II	I-geneN
GnRH	I-geneN
receptors	E-geneN
expressed	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Bovine	O
primers	O
facilitated	O
cloning	O
of	O
ovine	B-geneY
GnRH	I-geneY
-	I-geneY
II	E-geneY
DNA	O
.	O

A	O
premature	O
stop	O
codon	O
(	O
TGA	O
)	O
replaces	O
the	O
expected	O
tryptophan	S-chem
codon	O
at	O
position	O
seven	O
of	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
in	O
sheep	O
DNA	O
.	O

Thus	O
,	O
both	O
species	O
possess	O
prepro	B-geneN
-	I-geneN
GnRH	I-geneN
-	I-geneN
II	E-geneN
genes	O
encoding	O
inactive	O
peptides	O
,	O
as	O
previously	O
described	O
for	O
chimpanzee	B-geneY
GnRH	I-geneY
-	I-geneY
II	E-geneY
.	O

The	O
updated	O
bovine	B-geneY
type	I-geneY
II	I-geneY
GnRH	I-geneY
receptor	E-geneY
gene	O
sequence	O
revealed	O
inactivation	O
by	O
frame	O
shifts	O
,	O
premature	O
stop	O
codons	O
,	O
and	O
nucleotide	S-chem
changes	O
specifying	O
nonconservative	O
replacement	O
of	O
amino	B-chem
acid	E-chem
residues	O
,	O
similar	O
to	O
inactivation	O
of	O
sheep	B-geneY
type	I-geneY
II	I-geneY
GnRH	I-geneY
receptor	E-geneY
.	O

Spliced	O
RNA	O
transcripts	O
from	O
the	O
disrupted	O
receptor	O
gene	O
were	O
not	O
detected	O
in	O
bovine	O
pituitary	O
.	O

In	O
contrast	O
,	O
bovine	B-geneY
prepro	I-geneY
-	I-geneY
GnRH	I-geneY
-	I-geneY
I	E-geneY
and	O
type	B-geneY
I	I-geneY
GnRH	I-geneY
receptor	E-geneY
genes	O
are	O
intact	O
,	O
encoding	O
well	O
-	O
conserved	O
protein	O
sequences	O
.	O

These	O
findings	O
,	O
and	O
previous	O
descriptions	O
of	O
inactivation	O
of	O
the	O
human	B-geneY
type	I-geneY
II	I-geneY
GnRH	I-geneY
receptor	E-geneY
and	O
deletions	O
of	O
prepro	B-geneN
-	I-geneN
GnRH	I-geneN
-	I-geneN
II	E-geneN
and	O
type	B-geneN
II	I-geneN
GnRH	I-geneN
receptor	E-geneN
in	O
laboratory	O
rodents	O
,	O
suggest	O
the	O
GnRH	B-geneN
-	I-geneN
II	E-geneN
system	O
has	O
been	O
replaced	O
by	O
the	O
GnRH	B-geneN
-	I-geneN
I	E-geneN
system	O
or	O
is	O
redundant	O
in	O
certain	O
mammals	O
.	O

[	O
Short	O
QT	O
syndrome	O
]	O
.	O

Short	O
QT	O
syndrome	O
is	O
a	O
new	O
genetic	O
disorder	O
associated	O
with	O
familial	O
atrial	O
fibrillation	O
and	O
/	O
or	O
sudden	O
death	O
or	O
syncope	O
.	O

To	O
date	O
,	O
different	O
mutations	O
in	O
genes	O
encoding	O
for	O
cardiac	B-geneN
ion	I-geneN
channels	E-geneN
(	O
KCNH2	S-geneY
,	O
KCNQ1	S-geneY
,	O
and	O
KCNJ2	S-geneY
)	O
have	O
been	O
identified	O
to	O
cause	O
the	O
short	O
QT	O
syndrome	O
.	O

The	O
mutations	O
lead	O
to	O
a	O
gain	O
of	O
function	O
of	O
the	O
affected	O
current	O
(	O
IKr	S-geneY
,	O
IKs	S-geneY
,	O
and	O
IK1	S-geneY
)	O
.	O

The	O
phenotype	O
is	O
characterized	O
by	O
a	O
shortened	O
QT	O
interval	O
<	O
335	O
ms	O
after	O
correction	O
for	O
heart	O
rate	O
at	O
rates	O
<	O
80	O
beats	O
/	O
min	O
.	O

Furthermore	O
,	O
the	O
QT	O
interval	O
poorly	O
adapts	O
to	O
heart	O
rate	O
.	O

Patients	O
exhibit	O
shortened	O
atrial	O
and	O
ventricular	O
effective	O
refractory	O
periods	O
and	O
,	O
in	O
the	O
majority	O
,	O
inducibility	O
of	O
ventricular	O
fibrillation	O
.	O

Death	O
occurs	O
already	O
in	O
newborns	O
.	O

Therapy	O
of	O
choice	O
seems	O
to	O
be	O
the	O
implantable	O
cardioverter	O
defibrillator	O
because	O
of	O
the	O
high	O
incidence	O
of	O
sudden	O
death	O
.	O

Pharmacological	O
treatment	O
has	O
been	O
studied	O
and	O
it	O
could	O
be	O
demonstrated	O
,	O
that	O
some	O
mutant	O
currents	O
may	O
be	O
insufficiently	O
suppressed	O
by	O
drugs	O
targeted	O
to	O
block	O
the	O
specific	O
current	O
such	O
as	O
,	O
e.g	O
.	O
,	O
sotalol	S-chem-C4-1
or	O
ibutilide	S-chem-C4-1
in	O
patients	O
with	O
a	O
mutation	O
in	O
the	O
IKr	S-geneY-C4-2
-	O
coding	O
gene	O
KCNH2	S-geneY-C4-2
(	O
HERG	S-geneY-C4-2
)	O
.	O

Quinidine	S-chem
proved	O
to	O
be	O
efficient	O
in	O
prolonging	O
the	O
QT	O
interval	O
and	O
normalizing	O
the	O
effective	O
refractory	O
periods	O
in	O
some	O
patients	O
.	O

Conformational	O
transitions	O
linked	O
to	O
active	O
site	O
ligation	O
in	O
human	B-geneY
thrombin	E-geneY
:	O
effect	O
on	O
the	O
interaction	O
with	O
fibrinogen	S-geneN
and	O
the	O
cleavable	B-geneN
platelet	I-geneN
receptor	E-geneN
.	O

An	O
experimental	O
strategy	O
based	O
on	O
solution	O
viscosity	O
perturbation	O
allowed	O
us	O
to	O
study	O
the	O
energetics	O
of	O
amide	S-chem
-	O
substrates	O
,	O
p	B-chem
-	I-chem
aminobenzamidine	E-chem
(	O
p	B-chem
-	I-chem
ABZ	E-chem
)	O
and	O
proflavin	S-chem
binding	O
to	O
the	O
catalytic	O
site	O
of	O
two	O
proteolyzed	O
forms	O
of	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
,	O
i.e	O
.	O
zeta	B-geneN
-	I-geneN
and	I-geneN
gamma	I-geneN
T	I-geneN
-	I-geneN
thrombin	E-geneN
.	O

These	O
thrombin	S-geneY
derivatives	O
are	O
cleaved	O
at	O
the	O
Leu144	O
-	O
Gly150	O
loop	O
and	O
at	O
the	O
fibrinogen	B-geneN
recognition	I-geneN
exosite	E-geneN
(	O
FRS	S-geneN
)	O
,	O
respectively	O
.	O

A	O
phenomenological	O
analysis	O
of	O
thermodynamic	O
data	O
showed	O
that	O
the	O
amide	S-chem
substrates	O
and	O
p	B-chem
-	I-chem
ABZ	E-chem
interactions	O
with	O
zeta	B-geneY
-	I-geneY
thrombin	E-geneY
were	O
respectively	O
,	O
associated	O
with	O
a	O
chemical	O
compensation	O
(	O
i.e	O
.	O
the	O
linear	O
relationship	O
between	O
entropy	O
and	O
enthalpy	O
of	O
binding	O
)	O
and	O
a	O
hydrophobic	O
phenomenon	O
(	O
i.e	O
.	O
a	O
change	O
in	O
the	O
standard	O
heat	O
capacity	O
)	O
.	O

The	O
latter	O
was	O
slightly	O
lower	O
than	O
that	O
previously	O
observed	O
for	O
a	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
(	O
0.78	O
+	O
/	O
-	O
0.25	O
versus	O
1.01	O
+	O
/	O
-	O
0.17	O
kcal	O
/	O
mol	O
K	O
)	O
.	O

Both	O
phenomenon	O
were	O
absent	O
in	O
gamma	O
T	O
-	O
thrombin	O
.	O

The	O
interaction	O
of	O
a	O
alpha	B-geneN
-	I-geneN
,	I-geneN
zeta	I-geneN
-	I-geneN
and	I-geneN
gamma	I-geneN
T	I-geneN
-	I-geneN
thrombin	E-geneN
with	O
macromolecular	O
substrates	O
that	O
``	O
bridge	O
-	O
bind	O
``	O
to	O
both	O
the	O
catalytic	O
site	O
(	O
CS	O
)	O
and	O
fibrinogen	I-geneN
recognition	I-geneN
exosite	O
(	I-geneN
FRS	O
)	O
,	O
such	O
as	B-geneN
fibrinogen	O
and	O
the	O
cleavable	I-geneN
platelet	I-geneN
receptor	O
(	I-geneN
CPR	O
)	O
,	O
was	O
also	O
evaluated	O
.	O

These	O
interactions	O
were	O
studied	O
by	O
following	O
fibrinopeptide	B-geneY
A	E-geneY
(	O
FpA	S-geneY
)	O
release	O
and	O
by	O
measuring	O
intraplatelet	O
Ca2	B-chem
+	E-chem
changes	O
induced	O
by	O
thrombin	S-geneY
-	O
CPR	S-geneN
interaction	O
.	O

It	O
was	O
found	O
that	O
the	O
free	O
energy	O
of	O
activation	O
(	O
RT	O
ln	O
Kcat	O
/	O
Km	O
)	O
for	O
both	O
fibrinogen	S-geneN
and	O
CPR	S-geneN
hydrolysis	O
followed	O
the	O
same	O
hierarchy	O
,	O
i.e	O
.	O
alpha	O
>	O
zeta	O
>	O
gamma	O
.	O

Moreover	O
,	O
the	O
values	O
of	O
delta	O
Cp	O
for	O
alpha	B-geneN
-	I-geneN
,	I-geneN
zeta	I-geneN
-	I-geneN
and	I-geneN
gamma	I-geneN
T	I-geneN
-	I-geneN
thrombin	E-geneN
interaction	O
with	O
p	B-chem
-	I-chem
ABZ	E-chem
were	O
found	O
to	O
be	O
linearly	O
correlated	O
to	O
the	O
free	O
energy	O
of	O
activation	O
for	O
both	O
fibrinogen	S-geneN
and	O
CPR	S-geneN
cleavage	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
the	O
Leu144	O
-	O
Gly150	O
loop	O
and	O
the	O
FRS	S-geneN
are	O
both	O
involved	O
in	O
the	O
conformational	O
transition	O
linked	O
to	O
the	O
binding	O
of	O
p	B-chem
-	I-chem
aminobenzamidine	E-chem
to	O
the	O
thrombin	S-geneY
active	O
site	O
;	O
(	O
2	O
)	O
the	O
extent	O
of	O
thrombin	B-geneY
's	E-geneY
capacity	O
to	O
undergo	O
conformational	O
transitions	O
in	O
alpha	O
-	O
,	O
zeta	O
-	O
and	O
gamma	O
T	O
forms	O
is	O
positively	O
correlated	O
to	O
the	O
free	O
energy	O
of	O
activation	O
for	O
hydrolysis	O
of	O
macromolecular	O
substrates	O
interacting	O
with	O
both	O
the	O
catalytic	O
domain	O
and	O
the	O
FRS	S-geneN
.	O

Carbonic	B-geneN
anhydrase	E-geneN
inhibitors	O
.	O
Inhibition	O
of	O
mammalian	B-geneN-C4-2
isoforms	I-geneN-C4-2
I	I-geneN-C4-2
-	I-geneN-C4-2
XIV	E-geneN-C4-2
with	O
a	O
series	O
of	O
natural	O
product	O
polyphenols	S-chem-C4-1
and	O
phenolic	B-chem-C4-1
acids	E-chem-C4-1
.	O

A	O
series	O
of	O
phenolic	B-chem-C4-1
acids	E-chem-C4-1
and	O
phenol	S-chem-C4-1
natural	O
products	O
,	O
such	O
as	O
p	B-chem-C4-1
-	I-chem-C4-1
hydroxybenzoic	I-chem-C4-1
acid	E-chem-C4-1
,	O
p	B-chem-C4-1
-	I-chem-C4-1
coumaric	I-chem-C4-1
acid	E-chem-C4-1
,	O
caffeic	B-chem-C4-1
acid	E-chem-C4-1
,	O
ferulic	B-chem-C4-1
acid	E-chem-C4-1
,	O
gallic	B-chem-C4-1
acid	E-chem-C4-1
,	O
syringic	B-chem-C4-1
acid	E-chem-C4-1
,	O
quercetin	S-chem-C4-1
,	O
and	O
ellagic	B-chem-C4-1
acid	E-chem-C4-1
,	O
were	O
investigated	O
for	O
their	O
inhibitory	O
effects	O
against	O
the	O
metalloenzyme	S-geneN-C4-2
carbonic	B-geneN-C4-2
anhydrase	E-geneN-C4-2
(	O
CA	S-geneN-C4-2
,	O
EC	B-geneY-C4-2
4.2.1.1	E-geneY-C4-2
)	O
.	O

All	O
mammalian	O
isozymes	O
of	O
human	O
(	O
h	O
)	O
or	O
murine	O
(	O
m	O
)	O
origin	O
hCA	B-geneY
I	E-geneY
-	O
hCA	B-geneY
XII	E-geneY
,	O
mCA	B-geneY
XIII	E-geneY
and	O
hCA	B-geneY
XIV	E-geneY
were	O
inhibited	O
in	O
the	O
low	O
micromolar	O
or	O
submicromolar	O
range	O
by	O
these	O
(	O
poly	O
)	O
phenols	O
(	O
K	O
(	O
I	O
)	O
s	O
in	O
the	O
range	O
of	O
0.87	O
-	O
7.79	O
microM	O
)	O
.	O
p	B-chem
-	I-chem
Hydroxybenzoic	I-chem
acid	E-chem
was	O
the	O
best	O
inhibitor	O
of	O
all	O
isozymes	O
(	O
K	O
(	O
I	O
)	O
s	O
of	O
0.87	O
-	O
35.4	O
microM	O
)	O
and	O
the	O
different	O
isozymes	O
showed	O
very	O
variable	O
inhibition	O
profiles	O
with	O
these	O
derivatives	O
.	O

Phenols	S-chem-C4-1
like	O
the	O
ones	O
investigated	O
here	O
possess	O
a	O
CA	S-geneN-C4-2
inhibition	O
mechanism	O
distinct	O
of	O
that	O
of	O
the	O
sulfonamides	S-chem-C4-1
/	O
sulfamates	S-chem-C4-1
used	O
clinically	O
or	O
the	O
coumarins	S-chem-C4-1
.	O

Unlike	O
the	O
sulfonamides	S-chem
,	O
which	O
bind	O
to	O
the	O
catalytic	O
zinc	S-chem
ion	O
,	O
phenols	S-chem
are	O
anchored	O
at	O
the	O
Zn	B-chem
(	I-chem
II	I-chem
)	E-chem
-	O
coordinated	O
water	O
molecule	O
and	O
bind	O
more	O
externally	O
within	O
the	O
active	O
site	O
cavity	O
,	O
making	O
contacts	O
with	O
various	O
amino	B-chem
acid	E-chem
residues	O
.	O

As	O
this	O
is	O
the	O
region	O
with	O
the	O
highest	O
variability	O
between	O
the	O
many	O
CA	S-geneN
isozymes	O
found	O
in	O
mammals	O
,	O
this	O
class	O
of	O
compounds	O
may	O
lead	O
to	O
isoform	O
-	O
selective	O
inhibitors	O
targeting	O
just	O
one	O
or	O
few	O
of	O
the	O
medicinally	O
relevant	O
CAs	S-geneN
.	O

Using	O
a	O
fragment	O
-	O
based	O
approach	O
to	O
target	O
protein	O
-	O
protein	O
interactions	O
.	O

The	O
ability	O
to	O
identify	O
inhibitors	O
of	O
protein	O
-	O
protein	O
interactions	O
represents	O
a	O
major	O
challenge	O
in	O
modern	O
drug	O
discovery	O
and	O
in	O
the	O
development	O
of	O
tools	O
for	O
chemical	O
biology	O
.	O

In	O
recent	O
years	O
,	O
fragment	O
-	O
based	O
approaches	O
have	O
emerged	O
as	O
a	O
new	O
methodology	O
in	O
drug	O
discovery	O
;	O
however	O
,	O
few	O
examples	O
of	O
small	O
molecules	O
that	O
are	O
active	O
against	O
chemotherapeutic	O
targets	O
have	O
been	O
published	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
fragment	O
-	O
based	O
approach	O
of	O
targeting	O
the	O
interaction	O
between	O
the	O
tumour	O
suppressor	O
BRCA2	S-geneY
and	O
the	O
recombination	O
enzyme	O
RAD51	S-geneY
;	O
it	O
makes	O
use	O
of	O
a	O
screening	O
pipeline	O
of	O
biophysical	O
techniques	O
that	O
we	O
expect	O
to	O
be	O
more	O
generally	O
applicable	O
to	O
similar	O
targets	O
.	O

Disruption	O
of	O
this	O
interaction	O
in	O
vivo	O
is	O
hypothesised	O
to	O
give	O
rise	O
to	O
cellular	O
hypersensitivity	O
to	O
radiation	O
and	O
genotoxic	O
drugs	O
.	O

We	O
have	O
used	O
protein	O
engineering	O
to	O
create	O
a	O
monomeric	O
form	O
of	O
RAD51	S-geneY
by	O
humanising	O
a	O
thermostable	O
archaeal	O
orthologue	O
,	O
RadA	S-geneN
,	O
and	O
used	O
this	O
protein	O
for	O
fragment	O
screening	O
.	O

The	O
initial	O
fragment	O
hits	O
were	O
thoroughly	O
validated	O
biophysically	O
by	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
and	O
NMR	O
techniques	O
and	O
observed	O
by	O
X	O
-	O
ray	O
crystallography	O
to	O
bind	O
in	O
a	O
shallow	O
surface	O
pocket	O
that	O
is	O
occupied	O
in	O
the	O
native	O
complex	O
by	O
the	O
side	O
chain	O
of	O
a	O
phenylalanine	S-chem
from	O
the	O
conserved	O
FxxA	B-geneN
interaction	I-geneN
motif	E-geneN
found	O
in	O
BRCA2	S-geneY
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
fragments	O
or	O
any	O
small	O
molecule	O
binding	O
at	O
this	O
protein	O
-	O
protein	O
interaction	O
site	O
.	O

Water	O
extract	O
of	O
licorice	O
had	O
anti	O
-	O
viral	O
activity	O
against	O
human	O
respiratory	O
syncytial	O
virus	O
in	O
human	O
respiratory	O
tract	O
cell	O
lines	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Licorice	O
(	O
Glycyrrhiza	O
uralensis	O
Fisch	O
.	O
,	O
Leguminosae	O
)	O
has	O
been	O
used	O
in	O
herbal	O
medicine	O
and	O
food	O
supplement	O
worldwide	O
for	O
centuries	O
.	O

Licorice	O
is	O
a	O
common	O
ingredient	O
of	O
several	O
prescriptions	O
of	O
traditional	O
Chinese	O
medicine	O
which	O
have	O
been	O
proved	O
to	O
inhibit	O
infection	O
of	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
HRSV	O
)	O
.	O

There	O
are	O
two	O
preparations	O
of	O
licorice	O
,	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
licorice	O
or	O
which	O
preparation	O
of	O
licorice	O
is	O
effective	O
against	O
HRSV	O
,	O
nor	O
is	O
its	O
active	O
constituent	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
Radix	O
Glycyrrhizae	O
can	O
effectively	O
decrease	O
HRSV	O
-	O
induced	O
plaque	O
formation	O
in	O
respiratory	O
mucosal	O
cell	O
lines	O
.	O

We	O
also	O
tried	O
to	O
find	O
out	O
the	O
active	O
constituent	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Anti	O
-	O
HRSV	O
activities	O
of	O
hot	O
water	O
extracts	O
of	O
preparations	O
of	O
licorice	O
,	O
glycyrrhizin	S-chem
and	O
18β	B-chem
-	I-chem
glycyrrhetinic	I-chem
acid	E-chem
(	O
18β	B-chem
-	I-chem
GA	E-chem
)	O
,	O
the	O
active	O
constituents	O
of	O
licorice	O
,	O
were	O
examined	O
by	O
plaque	O
reduction	O
assay	O
in	O
both	O
human	O
upper	O
(	O
HEp	O
-	O
2	O
)	O
and	O
low	O
(	O
A549	O
)	O
respiratory	O
tract	O
cell	O
lines	O
.	O

Abilities	O
of	O
crude	O
licorice	O
to	O
inhibit	O
viral	O
replication	O
and	O
to	O
stimulate	O
IFN	B-geneY
-	I-geneY
β	E-geneY
were	O
evaluated	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
dose	O
-	O
dependently	O
inhibited	O
HRSV	O
-	O
induced	O
plaque	O
formation	O
in	O
both	O
HEp	O
-	O
2	O
and	O
A549	O
cell	O
lines	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
effect	O
of	O
Radix	O
Glycyrrhizae	O
was	O
better	O
than	O
that	O
of	O
Radix	O
Glycyrrhizae	O
Preparata	O
on	O
HEp	O
-	O
2	O
cells	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
of	O
their	O
anti	O
-	O
HRSV	O
effects	O
on	O
A549	O
cells	O
.	O

Besides	O
,	O
glycyrrhizin	S-chem
was	O
ineffective	O
at	O
all	O
.	O

Nevertheless	O
,	O
18β	B-chem
-	I-chem
GA	E-chem
showed	O
a	O
potent	O
anti	O
-	O
HRSV	O
activity	O
.	O

Radix	O
Glycyrrhizae	O
was	O
more	O
effective	O
when	O
given	O
before	O
viral	O
inoculation	O
(	O
p	O
<	O
0.0001	O
)	O
which	O
may	O
be	O
due	O
to	O
its	O
inhibition	O
of	O
viral	O
attachment	O
on	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
penetration	O
(	O
p	O
<	O
0.0001	O
)	O
into	O
the	O
host	O
cells	O
.	O

The	O
anti	O
-	O
HRSV	O
activity	O
of	O
Radix	O
Glycyrrhizae	O
was	O
further	O
confirmed	O
by	O
RT	O
-	O
PCR	O
and	O
qRT	O
-	O
PCR	O
.	O

300μg	O
/	O
ml	O
Radix	O
Glycyrrhizae	O
markedly	O
decreased	O
the	O
viral	O
amounts	O
within	O
the	O
cells	O
and	O
in	O
the	O
suspension	O
.	O

Radix	O
Glycyrrhizae	O
might	O
further	O
stimulate	O
mucosal	O
cells	O
to	O
secrete	O
IFN	B-geneY
-	I-geneY
β	E-geneY
to	O
counteract	O
viral	O
infection	O
.	O

CONCLUSIONS	O
:	O
Both	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
are	O
effective	O
against	O
HRSV	O
infection	O
on	O
airway	O
epithelial	O
cells	O
.	O

Radix	O
Glycyrrhizae	O
inhibited	O
HRSV	O
mainly	O
by	O
preventing	O
viral	O
attachment	O
,	O
internalization	O
,	O
and	O
by	O
stimulating	O
IFN	S-geneN
secretion	O
.	O

18β	B-chem
-	I-chem
GA	E-chem
may	O
be	O
one	O
of	O
its	O
active	O
constituents	O
.	O

The	O
mechanisms	O
responsible	O
for	O
garlic	O
-	O
drug	O
interactions	O
and	O
their	O
in	O
vivo	O
relevance	O
.	O

Garlic	O
phytochemicals	O
and	O
garlic	O
supplements	O
influence	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
behavior	O
of	O
concomitantly	O
ingested	O
drugs	O
.	O

In	O
this	O
paper	O
we	O
have	O
summarized	O
the	O
mechanisms	O
responsible	O
for	O
first	O
-	O
pass	O
intestinal	O
pharmacokinetic	O
interactions	O
by	O
investigating	O
the	O
intestinal	O
permeability	O
of	O
some	O
cardiovascular	O
,	O
antiviral	O
drugs	O
,	O
their	O
transport	O
with	O
hepatic	O
transporters	O
and	O
CYP3A4	S-geneY
metabolism	O
.	O

Transporter	O
-	O
enzyme	O
interplay	O
was	O
studied	O
with	O
several	O
in	O
vitro	O
models	O
of	O
varying	O
complexity	O
:	O
rat	O
small	O
intestine	O
and	O
Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
used	O
in	O
studies	O
of	O
intestinal	O
processes	O
,	O
and	O
hepatic	O
pharmacokinetics	O
was	O
monitored	O
in	O
HepG2	O
cells	O
,	O
isolated	O
rat	O
hepatocytes	O
and	O
rat	O
liver	O
slices	O
.	O

Garlic	O
phytochemicals	O
from	O
aged	O
garlic	O
extract	O
modified	O
the	O
activities	O
of	O
secretory	O
and	O
absorptive	O
transporters	O
in	O
both	O
intestine	O
and	O
liver	O
and	O
competitively	O
inhibited	O
CYP3A4	S-geneY
enzyme	O
.	O

The	O
increased	O
activities	O
of	O
the	O
most	O
important	O
intestinal	O
efflux	O
(	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
-	O
Pgp	S-geneN
,	O
Multidrug	B-geneY
Resistance	I-geneY
Associated	I-geneY
Protein	I-geneY
2	E-geneY
-	O
MRP	B-geneY
-	I-geneY
2	E-geneY
,	O
Breast	B-geneY
Cancer	I-geneY
Resistance	I-geneY
Protein	E-geneY
-	O
BCRP	S-geneY
)	O
and	O
uptake	O
(	O
MonoCarboxylate	B-geneY
Transporter	I-geneY
1	E-geneY
-	O
MCT1	S-geneY
,	O
Organic	B-geneN
Anion	I-geneN
Transporting	I-geneN
Polypeptide	E-geneN
-	O
OATP	S-geneN
,	O
Peptide	B-geneY
transporter	I-geneY
1	E-geneY
-	O
PepT1	S-geneY
)	O
transporters	O
were	O
caused	O
by	O
changes	O
in	O
electrophysiological	O
membrane	O
properties	O
and	O
by	O
allosteric	O
modifications	O
.	O

Because	O
clinical	O
studies	O
investigating	O
interactions	O
between	O
garlic	O
and	O
human	B-geneN-C4-2
immunodeficiency	I-geneN-C4-2
virus	I-geneN-C4-2
protease	E-geneN-C4-2
inhibitors	O
saquinavir	S-chem-C4-1
and	O
ritonavir	S-chem-C4-1
have	O
already	O
been	O
performed	O
,	O
we	O
used	O
these	O
in	O
vivo	O
data	O
to	O
evaluate	O
the	O
in	O
vitro	O
results	O
and	O
the	O
reliability	O
of	O
the	O
models	O
employed	O
as	O
screening	O
tools	O
for	O
forecasting	O
the	O
potential	O
of	O
first	O
-	O
pass	O
intestinal	O
metabolism	O
changes	O
.	O

We	O
also	O
assessed	O
the	O
probability	O
of	O
pharmacokinetic	O
interactions	O
with	O
garlic	O
of	O
the	O
novel	O
drug	O
darunavir	S-chem
and	O
other	O
cardiovascular	O
drugs	O
.	O

Finally	O
,	O
selected	O
garlic	O
phytochemicals	O
were	O
tested	O
for	O
their	O
ability	O
to	O
influence	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
and	O
CYP3A4	S-geneY
activities	O
.	O

Soy	O
protein	O
suppresses	O
gene	O
expression	O
of	O
acetyl	B-geneY
-	I-geneY
coA	I-geneY
carboxylase	I-geneY
alpha	E-geneY
from	O
promoter	B-geneN
PI	E-geneN
in	O
rat	O
liver	O
.	O

Dietary	O
soy	O
protein	O
isolate	O
(	O
SPI	O
)	O
reduces	O
hepatic	O
lipogenesis	O
by	O
suppressing	O
gene	O
expression	O
of	O
lipogenic	O
enzymes	O
,	O
including	O
acetyl	B-geneN
-	I-geneN
CoA	I-geneN
carboxylase	E-geneN
(	O
ACC	S-geneN
)	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
mechanism	O
of	O
this	O
regulation	O
,	O
the	O
effect	O
of	O
dietary	O
SPI	O
on	O
promoter	B-geneN
(	I-geneN
PI	I-geneN
and	I-geneN
PII	I-geneN
)	E-geneN
specific	O
gene	O
expression	O
of	O
ACC	B-geneY
alpha	E-geneY
was	O
investigated	O
.	O

Rats	O
were	O
fed	O
experimental	O
diets	O
containing	O
SPI	O
or	O
casein	S-geneN-C9-2
as	O
a	O
nitrogen	S-chem-C9-1
source	O
.	O

SPI	O
feeding	O
decreased	O
the	O
hepatic	O
contents	O
of	O
total	O
ACC	S-geneN
mRNA	O
as	O
well	O
as	O
triglyceride	S-chem
(	O
TG	S-chem
)	O
content	O
,	O
but	O
dietary	O
SPI	O
affected	O
the	O
amount	O
of	O
sterol	B-geneY
-	I-geneY
regulatory	I-geneY
element	I-geneY
binding	I-geneY
protein	I-geneY
(	I-geneY
SREBP	I-geneY
)	I-geneY
-	I-geneY
1	E-geneY
mRNA	O
and	O
protein	O
very	O
little	O
.	O

The	O
amount	O
of	O
ACC	S-geneN
mRNA	O
transcribed	O
from	O
PII	B-geneN
promoter	E-geneN
containing	O
SRE	S-geneN
was	O
not	O
significantly	O
affected	O
by	O
dietary	O
protein	O
,	O
while	O
a	O
significant	O
decrease	O
in	O
PI	S-geneN
-	O
generated	O
ACC	S-geneN
mRNA	O
content	O
was	O
observed	O
in	O
rats	O
fed	O
the	O
SPI	O
diet	O
.	O

These	O
data	O
suggest	O
that	O
SPI	O
feeding	O
decreased	O
the	O
hepatic	O
contents	O
of	O
ACC	B-geneY
alpha	E-geneY
mRNA	O
mainly	O
by	O
regulating	O
PI	B-geneN
promoter	E-geneN
via	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
other	O
than	O
SREBP	B-geneY
-	I-geneY
1	E-geneY
.	O

Torasemide	S-chem-C4-1
inhibits	O
angiotensin	B-geneY-C4-2
II	E-geneY-C4-2
-	O
induced	O
vasoconstriction	O
and	O
intracellular	O
calcium	S-chem
increase	O
in	O
the	O
aorta	O
of	O
spontaneously	O
hypertensive	O
rats	O
.	O

Torasemide	S-chem
is	O
a	O
loop	O
diuretic	O
that	O
is	O
effective	O
at	O
low	O
once	O
-	O
daily	O
doses	O
in	O
the	O
treatment	O
of	O
arterial	O
hypertension	O
.	O

Because	O
its	O
antihypertensive	O
mechanism	O
of	O
action	O
may	O
not	O
be	O
based	O
entirely	O
on	O
the	O
elimination	O
of	O
salt	O
and	O
water	O
from	O
the	O
body	O
,	O
a	O
vasodilator	O
effect	O
of	O
this	O
drug	O
can	O
be	O
considered	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
ability	O
of	O
different	O
concentrations	O
of	O
torasemide	S-chem
to	O
modify	O
angiotensin	B-geneY
II	E-geneY
(	O
Ang	B-geneY
II	E-geneY
)	O
-	O
induced	O
vascular	O
responses	O
was	O
examined	O
,	O
with	O
the	O
use	O
of	O
an	O
organ	O
bath	O
system	O
,	O
in	O
endothelium	O
-	O
denuded	O
aortic	O
rings	O
from	O
spontaneously	O
hypertensive	O
rats	O
.	O

Ang	B-geneY
II	E-geneY
-	O
induced	O
increases	O
of	O
intracellular	O
free	O
calcium	S-chem
concentration	O
(	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
)	O
were	O
also	O
examined	O
by	O
image	O
analysis	O
in	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
from	O
spontaneously	O
hypertensive	O
rats	O
.	O

A	O
dose	O
-	O
response	O
curve	O
to	O
Ang	B-geneY
II	E-geneY
was	O
plotted	O
for	O
cumulative	O
concentrations	O
(	O
from	O
10	O
(	O
-	O
9	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
)	O
in	O
endothelium	O
-	O
denuded	O
aortic	O
rings	O
(	O
pD	O
(	O
2	O
)	O
=	O
7.5	O
+	O
/	O
-	O
0.3	O
)	O
.	O

Isometric	O
contraction	O
induced	O
by	O
a	O
submaximal	O
concentration	O
of	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
(	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
was	O
reduced	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
by	O
torasemide	S-chem-C4-1
(	O
IC	O
(	O
50	O
)	O
=	O
0.5	O
+	O
/	O
-	O
0.04	O
micromol	O
/	O
L	O
)	O
.	O

Incubation	O
of	O
VSMCs	O
with	O
different	O
concentrations	O
of	O
Ang	B-geneY
II	E-geneY
(	O
from	O
10	O
(	O
-	O
10	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
)	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
rise	O
of	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
(	O
pD	O
(	O
2	O
)	O
=	O
7.5	O
+	O
/	O
-	O
0.3	O
)	O
.	O

The	O
stimulatory	O
effect	O
of	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
induced	O
by	O
a	O
submaximal	O
concentration	O
of	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
(	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
was	O
blocked	O
by	O
torasemide	S-chem-C4-1
(	O
IC	O
(	O
50	O
)	O
=	O
0.5	O
+	O
/	O
-	O
0.3	O
nmol	O
/	O
L	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
torasemide	S-chem-C4-1
blocks	O
the	O
vasoconstrictor	O
action	O
of	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
in	O
vitro	O
.	O

This	O
action	O
can	O
be	O
related	O
to	O
the	O
ability	O
of	O
torasemide	S-chem-C4-1
to	O
block	O
the	O
increase	O
of	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
(	O
i	O
)	O
induced	O
by	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
in	O
VSMCs	O
.	O

It	O
is	O
proposed	O
that	O
these	O
actions	O
might	O
be	O
involved	O
in	O
the	O
antihypertensive	O
effect	O
of	O
torasemide	S-chem
observed	O
in	O
vivo	O
.	O

L	B-chem-C3-1
-	I-chem-C3-1
BMAA	E-chem-C3-1
induced	O
ER	O
stress	O
and	O
enhanced	O
caspase	B-geneY-C3-2
12	E-geneY-C3-2
cleavage	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
at	O
low	O
nonexcitotoxic	O
concentrations	O
.	O

The	O
cyanobacterial	O
β	B-chem
-	I-chem
N	I-chem
-	I-chem
methylamino	I-chem
-	I-chem
L	I-chem
-	I-chem
alanine	E-chem
(	O
L	B-chem
-	I-chem
BMAA	E-chem
)	O
is	O
described	O
as	O
a	O
low	O
-	O
potency	O
excitotoxin	O
,	O
possibly	O
a	O
factor	O
in	O
the	O
increased	O
incidence	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
and	O
Parkinsonism	O
-	O
dementia	O
complex	O
(	O
PDC	O
)	O
in	O
Guam	O
.	O

The	O
latter	O
association	O
is	O
intensively	O
disputed	O
,	O
as	O
L	B-chem
-	I-chem
BMAA	E-chem
concentrations	O
required	O
for	O
toxic	O
effects	O
exceed	O
those	O
assumed	O
to	O
occur	O
via	O
food	O
.	O

The	O
question	O
thus	O
was	O
raised	O
whether	O
L	B-chem
-	I-chem
BMAA	E-chem
leads	O
to	O
neurodegeneration	O
at	O
nonexcitotoxic	O
conditions	O
.	O

Using	O
human	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
,	O
L	B-chem
-	I-chem
BMAA	E-chem
-	O
transport	O
,	O
incorporation	O
into	O
proteins	O
,	O
and	O
subsequent	O
impairment	O
of	O
cellular	O
protein	O
homeostasis	O
were	O
investigated	O
.	O

Binding	O
of	O
L	B-chem
-	I-chem
BMAA	E-chem
to	O
intracellular	O
proteins	O
,	O
but	O
no	O
clear	O
protein	O
incorporation	O
was	O
detected	O
in	O
response	O
to	O
(	B-chem
14	I-chem
)	I-chem
C	E-chem
-	O
L	B-chem
-	I-chem
BMAA	E-chem
exposures	O
.	O

Nevertheless	O
,	O
low	O
L	B-chem-C3-1
-	I-chem-C3-1
BMAA	E-chem-C3-1
concentrations	O
(	O
≥	O
0.1mM	O
,	O
48	O
h	O
)	O
increased	O
protein	O
ubiquitination	O
,	O
20S	B-geneN-C3-2
proteasomal	E-geneN-C3-2
and	O
caspase	B-geneY-C3-2
12	E-geneY-C3-2
activity	O
,	O
expression	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
marker	O
CHOP	S-geneY-C3-2
,	O
and	O
enhanced	O
phosphorylation	O
of	O
elf2α	S-geneY-C3-2
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

In	O
contrast	O
,	O
high	O
L	B-chem
-	I-chem
BMAA	E-chem
concentrations	O
(	O
≥	O
1mM	O
,	O
48	O
h	O
)	O
increased	O
reactive	O
oxygen	S-chem
species	O
and	O
protein	O
oxidization	O
,	O
which	O
were	O
partially	O
ameliorated	O
by	O
coincubation	O
with	O
vitamin	B-chem
E	E-chem
.	O

L	B-chem
-	I-chem
BMAA	E-chem
-	O
mediated	O
cytotoxicity	O
was	O
observable	O
48	O
h	O
following	O
≥	O
2mM	O
L	B-chem
-	I-chem
BMAA	E-chem
treatment	O
.	O

Consequently	O
,	O
the	O
data	O
presented	O
here	O
suggest	O
that	O
low	O
L	B-chem
-	I-chem
BMAA	E-chem
concentrations	O
result	O
in	O
a	O
dysregulation	O
of	O
the	O
cellular	O
protein	O
homeostasis	O
with	O
ensuing	O
ER	O
stress	O
that	O
is	O
independent	O
from	O
high	O
-	O
concentration	O
effects	O
such	O
as	O
excitotoxicity	O
and	O
oxidative	O
stress	O
.	O

Thus	O
,	O
the	O
latter	O
could	O
be	O
a	O
contributing	O
factor	O
in	O
the	O
onset	O
and	O
slow	O
progression	O
of	O
ALS	O
/	O
PDC	O
in	O
Guam	O
.	O

Thalidomide	S-chem-C4-1
inhibits	O
growth	O
of	O
tumors	O
through	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
degradation	O
independent	O
of	O
antiangiogenesis	O
.	O

Thalidomide	S-chem
is	O
an	O
antiangiogenic	O
drug	O
and	O
is	O
clinically	O
useful	O
in	O
a	O
number	O
of	O
cancers	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
by	O
which	O
thalidomide	S-chem
exerts	O
its	O
antitumor	O
effects	O
is	O
poorly	O
understood	O
.	O

This	O
study	O
was	O
designed	O
to	O
clarify	O
the	O
relationship	O
between	O
antiangiogenesis	O
and	O
antitumor	O
effects	O
of	O
thalidomide	S-chem
and	O
to	O
explore	O
the	O
molecular	O
mechanism	O
for	O
its	O
antitumor	O
activity	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
thalidomide	S-chem
on	O
the	O
growth	O
of	O
human	O
tumor	O
cells	O
expressing	O
(	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
)	O
or	O
not	O
expressing	O
(	O
HeLa	O
and	O
K562	O
)	O
COX	B-geneY
-	I-geneY
2	E-geneY
in	O
vitro	O
.	O

We	O
also	O
studied	O
the	O
effects	O
of	O
thalidomide	S-chem
on	O
COX	B-geneY
-	I-geneY
1	E-geneY
,	O
COX	B-geneY
-	I-geneY
2	E-geneY
or	O
bcl	B-geneY
-	I-geneY
2	E-geneY
expression	O
,	O
TNFalpha	S-geneY
,	O
VEGF	S-geneY
,	O
GSH	O
and	O
cytochrome	B-geneY
c	E-geneY
in	O
these	O
cells	O
.	O

Thalidomide	S-chem
could	O
inhibit	O
tumor	O
growth	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
;	O
its	O
IC50s	O
for	O
them	O
were	O
18.36	O
+	O
/	O
-	O
2.34	O
and	O
22.14	O
+	O
/	O
-	O
2.15	O
microM	O
,	O
respectively	O
,	O
while	O
this	O
effect	O
was	O
not	O
observed	O
in	O
HeLa	O
and	O
K562	O
.	O

Thalidomide	S-chem-MU-1
reduced	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
expression	O
accompanied	O
by	O
a	O
decrease	O
of	O
bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
protein	O
,	O
TNFalpha	S-geneY-C4-2
,	O
VEGF	S-geneY-C4-2
,	O
GSH	O
and	O
an	O
increased	O
cytochrome	B-geneY-C3-2
c	E-geneY-C3-2
,	O
but	O
had	O
no	O
effect	O
on	O
that	O
of	O
COX	B-geneY
-	I-geneY
1	E-geneY
,	O
in	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
.	O

Moreover	O
,	O
cells	O
not	O
expressing	O
COX	B-geneY
-	I-geneY
2	E-geneY
were	O
insensitive	O
to	O
the	O
growth	O
-	O
inhibitory	O
and	O
effects	O
on	O
cytokines	S-geneN
of	O
thalidomide	S-chem
.	O

In	O
our	O
mouse	O
xenograft	O
model	O
of	O
OVCAR	O
-	O
3	O
and	O
HCT	O
-	O
8	O
,	O
we	O
found	O
that	O
thalidomide	S-chem
could	O
decrease	O
intratumoral	O
microvessel	O
density	O
in	O
both	O
tumors	O
;	O
it	O
exerted	O
antitumor	O
effects	O
only	O
on	O
OVCAR	O
-	O
3	O
expressing	O
COX	B-geneY
-	I-geneY
2	E-geneY
but	O
did	O
not	O
on	O
HCT	O
-	O
8	O
not	O
expressing	O
COX	B-geneY
-	I-geneY
2	E-geneY
.	O

Effect	O
of	O
thalidomide	S-chem
on	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
in	O
vivo	O
was	O
consistent	O
with	O
that	O
of	O
in	O
vitro	O
.	O

These	O
results	O
demonstrated	O
that	O
thalidomide	S-chem-C4-1
might	O
inhibit	O
growth	O
of	O
tumors	O
through	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
degradation	O
independent	O
of	O
antiangiogenesis	O
.	O

Expression	O
of	O
basic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
correlates	O
with	O
resistance	O
to	O
paclitaxel	S-chem
in	O
human	O
patient	O
tumors	O
.	O

BACKGROUND	O
:	O
Preclinical	O
results	O
indicate	O
acidic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
(	O
aFGF	S-geneY
)	O
and	O
basic	B-geneY
FGF	E-geneY
(	O
bFGF	S-geneY
)	O
present	O
in	O
solid	O
tumors	O
as	O
a	O
cause	O
of	O
broad	O
-	O
spectrum	O
chemoresistance	O
,	O
whereas	O
earlier	O
clinical	O
studies	O
suggest	O
that	O
bFGF	S-geneY
expression	O
is	O
associated	O
with	O
opposing	O
outcomes	O
in	O
patients	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
FGF	S-geneN
expression	O
and	O
paclitaxel	S-chem
activity	O
in	O
tumors	O
from	O
bladder	O
,	O
breast	O
,	O
head	O
and	O
neck	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancer	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Tumors	O
(	O
n	O
=	O
96	O
)	O
were	O
maintained	O
in	O
three	O
-	O
dimensional	O
histocultures	O
,	O
retaining	O
tumor	O
-	O
stromal	O
interaction	O
.	O

Bladder	O
tumors	O
were	O
treated	O
with	O
paclitaxel	S-chem
for	O
2	O
h	O
,	O
and	O
the	O
other	O
tumors	O
for	O
24	O
h	O
.	O

Antiproliferative	O
and	O
proapoptotic	O
effects	O
of	O
paclitaxel	S-chem
were	O
quantified	O
and	O
correlated	O
with	O
expression	O
of	O
aFGF	S-geneY
,	O
bFGF	S-geneY
,	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
Pgp	S-geneN
)	O
,	O
p53	S-geneY
,	O
and	O
bcl	B-geneY
-	I-geneY
2	E-geneY
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
(	O
49	O
/	O
96	O
)	O
and	O
63	O
%	O
(	O
61	O
/	O
96	O
)	O
of	O
tumors	O
showed	O
aFGF	S-geneY
and	O
bFGF	S-geneY
staining	O
,	O
respectively	O
.	O
aFGF	S-geneY
expression	O
was	O
positively	O
correlated	O
with	O
tumor	O
stage	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
bFGF	S-geneY
expression	O
with	O
tumor	O
grade	O
and	O
Pgp	S-geneN
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Paclitaxel	S-chem
inhibited	O
antiproliferation	O
in	O
86	O
%	O
of	O
tumors	O
(	O
83	O
/	O
96	O
)	O
,	O
with	O
an	O
average	O
inhibition	O
of	O
46	O
+	O
/	O
-	O
19	O
%	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
in	O
the	O
responding	O
tumors	O
.	O

Paclitaxel	S-chem
also	O
induced	O
apoptosis	O
in	O
96	O
%	O
of	O
tumors	O
(	O
92	O
/	O
96	O
)	O
,	O
with	O
an	O
average	O
apoptotic	O
index	O
of	O
12	O
+	O
/	O
-	O
7	O
%	O
in	O
the	O
responding	O
tumors	O
.	O
aFGF	S-geneY
expression	O
did	O
not	O
correlate	O
with	O
tumor	O
sensitivity	O
to	O
paclitaxel	S-chem
,	O
whereas	O
bFGF	S-geneY
expression	O
showed	O
an	O
inverse	O
correlation	O
(	O
p	O
<	O
0.01	O
)	O
.	O
bFGF	S-geneY
expression	O
was	O
a	O
stronger	O
predictor	O
of	O
paclitaxel	S-chem
resistance	O
compared	O
to	O
Pgp	S-geneN
,	O
p53	S-geneY
,	O
or	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
.	O

CONCLUSION	O
:	O
These	O
results	O
support	O
a	O
role	O
of	O
bFGF	S-geneY
in	O
paclitaxel	S-chem
resistance	O
in	O
human	O
patient	O
tumors	O
.	O

Reduced	O
plasma	O
oxytocin	S-geneY
levels	O
in	O
female	O
patients	O
with	O
borderline	O
personality	O
disorder	O
.	O

The	O
neuropeptide	O
oxytocin	S-geneY
is	O
involved	O
in	O
social	O
cognition	O
and	O
interaction	O
across	O
species	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
affiliative	O
behaviors	O
.	O

Oxytocin	S-geneY
levels	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
but	O
also	O
in	O
plasma	O
or	O
urine	O
,	O
have	O
been	O
shown	O
to	O
be	O
negatively	O
associated	O
with	O
childhood	O
traumata	O
,	O
aggressive	O
behavior	O
,	O
and	O
suicide	O
attempts	O
.	O

Recently	O
,	O
an	O
altered	O
activity	O
of	O
the	O
oxytocin	S-geneY
system	O
has	O
been	O
discussed	O
to	O
play	O
a	O
prominent	O
role	O
in	O
borderline	O
personality	O
disorder	O
(	O
BPD	O
)	O
,	O
which	O
is	O
thought	O
to	O
be	O
closely	O
related	O
to	O
traumatic	O
experiences	O
in	O
childhood	O
and	O
is	O
characterized	O
by	O
(	O
para	O
)	O
suicidal	O
behaviors	O
as	O
well	O
as	O
aggressive	O
outbursts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
plasma	O
oxytocin	S-geneY
levels	O
of	O
women	O
with	O
and	O
without	O
BPD	O
in	O
the	O
follicular	O
phase	O
and	O
assessed	O
the	O
relationship	O
between	O
oxytocin	S-geneY
concentrations	O
and	O
childhood	O
traumata	O
.	O

Women	O
diagnosed	O
with	O
BPD	O
had	O
significantly	O
reduced	O
oxytocin	S-geneY
concentrations	O
,	O
even	O
after	O
controlling	O
for	O
estrogen	S-chem
,	O
progesterone	S-chem
,	O
and	O
contraceptive	O
intake	O
.	O

In	O
addition	O
,	O
plasma	O
oxytocin	S-geneY
correlated	O
negatively	O
with	O
experiences	O
of	O
childhood	O
traumata	O
,	O
in	O
particular	O
with	O
emotional	O
neglect	O
and	O
abuse	O
.	O

The	O
results	O
of	O
mediation	O
analyses	O
do	O
not	O
support	O
a	O
model	O
of	O
oxytocin	S-geneY
being	O
a	O
prominent	O
mediator	O
in	O
the	O
link	O
between	O
childhood	O
trauma	O
and	O
BPD	O
.	O

Thus	O
,	O
the	O
findings	O
indicate	O
dysregulations	O
in	O
the	O
oxytocin	S-geneY
system	O
of	O
patients	O
diagnosed	O
with	O
BPD	O
with	O
more	O
longitudinal	O
research	O
being	O
necessary	O
to	O
disentangle	O
the	O
relationship	O
between	O
childhood	O
adversities	O
,	O
oxytocin	S-geneY
system	O
,	O
and	O
psychopathology	O
.	O

Cross	O
-	O
inhibition	O
of	O
SR	B-geneY-MU-2
-	I-geneY-MU-2
BI	E-geneY-MU-2
-	O
and	O
ABCA1	S-geneY-MU-2
-	O
mediated	O
cholesterol	S-chem-C9-1
transport	O
by	O
the	O
small	O
molecules	O
BLT	O
-	O
4	O
and	O
glyburide	S-chem-C4-1
.	O

Scavenger	B-geneY
receptor	I-geneY
class	I-geneY
B	I-geneY
type	I-geneY
I	E-geneY
(	O
SR	B-geneY
-	I-geneY
BI	E-geneY
)	O
and	O
ABCA1	S-geneN
are	O
structurally	O
dissimilar	O
cell	O
surface	O
proteins	O
that	O
play	O
key	O
roles	O
in	O
HDL	S-geneN
metabolism	O
.	O

SR	B-geneY-C9-2
-	I-geneY-C9-2
BI	E-geneY-C9-2
is	O
a	O
receptor	O
that	O
binds	O
HDL	S-geneN
with	O
high	O
affinity	O
and	O
mediates	O
both	O
the	O
selective	O
lipid	O
uptake	O
of	O
cholesteryl	B-chem-C9-1
esters	E-chem-C9-1
from	O
lipid	O
-	O
rich	O
HDL	S-geneN
to	O
cells	O
and	O
the	O
efflux	O
of	O
unesterified	O
cholesterol	S-chem-C9-1
from	O
cells	O
to	O
HDL	S-geneN
.	O

ABCA1	S-geneY-C9-2
mediates	O
the	O
efflux	O
of	O
unesterified	O
cholesterol	S-chem-C9-1
and	O
phospholipids	O
from	O
cells	O
to	O
lipid	O
-	O
poor	O
apolipoprotein	B-geneY
A	I-geneY
-	I-geneY
I	E-geneY
(	O
apoA	B-geneY
-	I-geneY
I	E-geneY
)	O
.	O

The	O
activities	O
of	O
ABCA1	S-geneY-C4-2
and	O
other	O
ATP	B-geneN-C4-2
binding	I-geneN-C4-2
cassette	I-geneN-C4-2
superfamily	E-geneN-C4-2
members	O
are	O
inhibited	O
by	O
the	O
drug	O
glyburide	S-chem-C4-1
,	O
and	O
SR	B-geneY
-	I-geneY
BI	E-geneY
-	O
mediated	O
lipid	O
transport	O
is	O
blocked	O
by	O
small	O
molecule	O
inhibitors	O
called	O
BLTs	O
.	O

Here	O
,	O
we	O
show	O
that	O
one	O
BLT	S-chem-C4-1
,	O
[	O
1	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
methoxy	I-chem-C4-1
-	I-chem-C4-1
phenyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
naphthalen	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
-	I-chem-C4-1
urea	E-chem-C4-1
]	O
(	O
BLT	B-chem-C4-1
-	I-chem-C4-1
4	E-chem-C4-1
)	O
,	O
blocked	O
ABCA1	S-geneY-MU-2
-	O
mediated	O
cholesterol	S-chem-C9-1
efflux	O
to	O
lipid	O
-	O
poor	O
apoA	B-geneY
-	I-geneY
I	E-geneY
at	O
a	O
potency	O
similar	O
to	O
that	O
for	O
its	O
inhibition	O
of	O
SR	B-geneY-C4-2
-	I-geneY-C4-2
BI	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
approximately	O
55	O
-	O
60	O
microM	O
)	O
.	O

Reciprocally	O
,	O
glyburide	S-chem-C4-1
blocked	O
SR	B-geneY-C4-2
-	I-geneY-C4-2
BI	E-geneY-C4-2
-	O
mediated	O
selective	O
lipid	O
uptake	O
and	O
efflux	O
at	O
a	O
potency	O
similar	O
to	O
that	O
for	O
its	O
inhibition	O
of	O
ABCA1	S-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
approximately	O
275	O
-	O
300	O
microM	O
)	O
.	O

As	O
is	O
the	O
case	O
with	O
BLTs	O
,	O
glyburide	S-chem
increased	O
the	O
apparent	O
affinity	O
of	O
HDL	S-geneN
binding	O
to	O
SR	B-geneY
-	I-geneY
BI	E-geneY
.	O

The	O
reciprocal	O
inhibition	O
of	O
SR	B-geneY-C4-2
-	I-geneY-C4-2
BI	E-geneY-C4-2
and	O
ABCA1	S-geneY-C4-2
by	O
BLT	O
-	O
4	O
and	O
glyburide	S-chem-C4-1
raises	O
the	O
possibility	O
that	O
these	O
proteins	O
may	O
share	O
similar	O
or	O
common	O
steps	O
in	O
their	O
mechanisms	O
of	O
lipid	O
transport	O
.	O

Underexpression	O
of	O
the	O
Na	B-geneN
+	I-geneN
-	I-geneN
dependent	I-geneN
neutral	I-geneN
amino	I-geneN
acid	I-geneN
transporter	E-geneN
ASCT2	S-geneY
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
kidney	O
.	O

This	O
study	O
examined	O
the	O
inward	O
transport	O
of	O
l	B-chem-C9-1
-	I-chem-C9-1
[	I-chem-C9-1
(	I-chem-C9-1
14	I-chem-C9-1
)	I-chem-C9-1
C	I-chem-C9-1
]	I-chem-C9-1
alanine	E-chem-C9-1
,	O
an	O
ASCT2	S-geneY-C9-2
preferential	O
substrate	O
,	O
in	O
monolayers	O
of	O
immortalized	O
renal	O
proximal	O
tubular	O
epithelial	O
(	O
PTE	O
)	O
cells	O
from	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	O
(	O
SHR	O
)	O
rats	O
.	O

The	O
expression	O
of	O
ASCT2	S-geneY
in	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
and	O
kidney	O
cortices	O
from	O
WKY	O
and	O
SHR	O
was	O
also	O
evaluated	O
.	O
l	B-chem
-	I-chem
[	I-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
alanine	E-chem
uptake	O
was	O
highly	O
dependent	O
on	O
extracellular	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
.	O

Replacement	O
of	O
NaCl	S-chem
by	O
LiCl	S-chem
or	O
choline	B-chem
chloride	E-chem
abolished	O
transport	O
activity	O
in	O
SHR	O
and	O
WKY	O
PTE	O
cells	O
.	O

In	O
the	O
presence	O
of	O
the	O
system	O
L	O
inhibitor	O
BCH	O
,	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
l	B-chem-C9-1
-	I-chem-C9-1
alanine	E-chem-C9-1
uptake	O
in	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
was	O
inhibited	O
by	O
alanine	S-chem-C4-1
,	O
serine	S-chem-C4-1
,	O
and	O
cysteine	S-chem-C4-1
,	O
which	O
is	O
consistent	O
with	O
amino	B-chem-C9-1
acid	E-chem-C9-1
transport	O
through	O
ASCT2	S-geneY-MU-2
.	O

The	O
saturable	O
component	O
of	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
l	B-chem
-	I-chem
alanine	E-chem
transport	O
under	O
V	O
(	O
max	O
)	O
conditions	O
in	O
SHR	O
PTE	O
cells	O
was	O
one	O
-	O
half	O
of	O
that	O
in	O
WKY	O
PTE	O
cells	O
,	O
with	O
similar	O
K	O
(	O
m	O
)	O
values	O
.	O

Differences	O
in	O
magnitude	O
of	O
Na	B-chem-C3-1
(	I-chem-C3-1
+	I-chem-C3-1
)	E-chem-C3-1
-	O
dependent	O
l	B-chem-MU-1
-	I-chem-MU-1
alanine	E-chem-MU-1
uptake	O
through	O
ASCT2	S-geneY-C9-2
between	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
correlated	O
positively	O
with	O
differences	O
in	O
ASCT2	S-geneY-C3-2
protein	O
expression	O
,	O
this	O
being	O
more	O
abundant	O
in	O
WKY	O
PTE	O
cells	O
.	O

Abundance	O
of	O
ASCT2	S-geneY
transcript	O
and	O
protein	O
in	O
kidney	O
cortices	O
of	O
SHR	O
rats	O
was	O
also	O
lower	O
than	O
that	O
in	O
normotensive	O
WKY	O
rats	O
.	O

In	O
conclusion	O
,	O
immortalized	O
SHR	O
and	O
WKY	O
PTE	O
cells	O
take	O
up	O
l	B-chem-C9-1
-	I-chem-C9-1
alanine	E-chem-C9-1
mainly	O
through	O
a	O
high	O
-	O
affinity	O
Na	B-geneN-C9-2
(	I-geneN-C9-2
+	I-geneN-C9-2
)	I-geneN-C9-2
-	I-geneN-C9-2
dependent	I-geneN-C9-2
amino	I-geneN-C9-2
acid	I-geneN-C9-2
transporter	E-geneN-C9-2
,	O
with	O
functional	O
features	O
of	O
ASCT2	S-geneY-C9-2
transport	O
.	O

The	O
activity	O
and	O
expression	O
of	O
the	O
ASCT2	S-geneY
transporter	O
were	O
considerably	O
lower	O
in	O
the	O
SHR	O
cells	O
.	O

SPACRCAN	S-geneN
,	O
a	O
novel	O
human	B-geneN
interphotoreceptor	I-geneN
matrix	I-geneN
hyaluronan	I-geneN
-	I-geneN
binding	I-geneN
proteoglycan	E-geneN
synthesized	O
by	O
photoreceptors	O
and	O
pinealocytes	O
.	O

The	O
interphotoreceptor	O
matrix	O
is	O
a	O
unique	O
extracellular	O
complex	O
occupying	O
the	O
interface	O
between	O
photoreceptors	O
and	O
the	O
retinal	O
pigment	O
epithelium	O
in	O
the	O
fundus	O
of	O
the	O
eye	O
.	O

Because	O
of	O
the	O
putative	O
supportive	O
role	O
in	O
photoreceptor	O
maintenance	O
,	O
it	O
is	O
likely	O
that	O
constituent	O
molecules	O
play	O
key	O
roles	O
in	O
photoreceptor	O
function	O
and	O
may	O
be	O
targets	O
for	O
inherited	O
retinal	S-chem
disease	O
.	O

In	O
this	O
study	O
we	O
identify	O
and	O
characterize	O
SPACRCAN	S-geneN
,	O
a	O
novel	O
chondroitin	O
proteoglycan	O
in	O
this	O
matrix	O
.	O

SPACRCAN	S-geneN
was	O
cloned	O
from	O
a	O
human	O
retinal	S-chem
cDNA	O
library	O
and	O
the	O
gene	O
localized	O
to	O
chromosome	O
3q11.2	O
.	O

Analysis	O
of	O
SPACRCAN	S-geneN
mRNA	O
and	O
protein	O
revealed	O
that	O
SPACRCAN	S-geneN
is	O
expressed	O
exclusively	O
by	O
photoreceptors	O
and	O
pinealocytes	O
.	O

SPACRCAN	S-geneN
synthesized	O
by	O
photoreceptors	O
is	O
localized	O
to	O
the	O
interphotoreceptor	O
matrix	O
where	O
it	O
surrounds	O
both	O
rods	O
and	O
cones	O
.	O

The	O
functional	O
protein	O
contains	O
1160	O
amino	B-chem
acids	E-chem
with	O
a	O
large	O
central	O
mucin	B-geneN
domain	E-geneN
,	O
three	O
consensus	O
sites	O
for	O
glycosaminoglycan	O
attachment	O
,	O
two	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeats	O
,	O
a	O
putative	O
hyaluronan	B-geneN
-	I-geneN
binding	I-geneN
motif	E-geneN
,	O
and	O
a	O
potential	O
transmembrane	O
domain	O
near	O
the	O
C	S-chem
-	O
terminal	O
.	O

Lectin	S-geneN
and	O
Western	O
blotting	O
indicate	O
an	O
M	O
(	O
r	O
)	O
around	O
400,000	O
before	O
and	O
230,000	O
after	O
chondroitinase	B-geneN
ABC	E-geneN
digestion	O
.	O

Removal	O
of	O
N	S-chem
-	O
and	O
O	S-chem
-	O
linked	O
oligosaccharides	O
reduces	O
the	O
M	O
(	O
r	O
)	O
to	O
approximately	O
160,000	O
,	O
suggesting	O
that	O
approximately	O
60	O
%	O
of	O
the	O
mass	O
of	O
SPACRCAN	S-geneN
is	O
carbohydrate	S-chem
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
SPACRCAN	S-geneN
binds	O
hyaluronan	S-geneN
and	O
propose	O
that	O
associations	O
between	O
SPACRCAN	S-geneN
and	O
hyaluronan	S-geneN
may	O
be	O
involved	O
in	O
organization	O
of	O
the	O
insoluble	O
interphotoreceptor	O
matrix	O
,	O
particularly	O
as	O
SPACRCAN	S-geneN
is	O
the	O
major	O
proteoglycan	O
present	O
in	O
this	O
matrix	O
.	O

The	O
role	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
and	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
1B	I-geneN
/	I-geneN
1D	I-geneN
)	I-geneN
receptors	E-geneN
on	O
the	O
modulation	O
of	O
acute	O
fluoxetine	S-chem
-	O
induced	O
changes	O
in	O
extracellular	O
5	B-chem
-	I-chem
HT	E-chem
:	O
the	O
mechanism	O
of	O
action	O
of	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
pindolol	E-chem
.	O

Some	O
clinical	O
evidence	O
has	O
suggested	O
that	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
pindolol	E-chem
can	O
be	O
effective	O
at	O
producing	O
a	O
shortened	O
time	O
to	O
onset	O
of	O
antidepressant	O
activity	O
when	O
co	O
-	O
administered	O
with	O
a	O
serotonin	S-chem
specific	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
the	O
antagonist	O
effects	O
of	O
pindolol	S-chem-C6-1
at	O
the	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
receptor	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
pharmacology	O
of	O
(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
pindolol	E-chem-C6-1
,	O
WAY	B-chem-C6-1
-	I-chem-C6-1
100635	E-chem-C6-1
(	O
a	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
)	O
,	O
GR127935	S-chem
(	O
a	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
1B	I-geneN
/	I-geneN
1D	I-geneN
)	E-geneN
antagonist	O
)	O
,	O
and	O
isamoltane	S-chem-C6-1
(	O
a	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1B	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
)	O
,	O
when	O
given	O
acutely	O
in	O
combination	O
with	O
fluoxetine	S-chem
,	O
using	O
in	O
vivo	O
microdialysis	O
in	O
the	O
frontal	O
cortex	O
of	O
the	O
freely	O
moving	O
rat	O
.	O

We	O
have	O
determined	O
that	O
the	O
acute	O
fluoxetine	S-chem
-	O
induced	O
increases	O
in	O
extracellular	O
5	B-chem
-	I-chem
HT	E-chem
can	O
be	O
augmented	O
by	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
pindolol	E-chem
,	O
WAY100635	S-chem
,	O
GR127935	S-chem
and	O
isamoltane	S-chem
with	O
maximum	O
increases	O
of	O
216	O
+	O
/	O
-	O
32	O
%	O
,	O
235	O
+	O
/	O
-	O
49	O
%	O
,	O
240	O
+	O
/	O
-	O
18	O
%	O
and	O
171	O
+	O
/	O
-	O
47	O
%	O
of	O
preinjection	O
control	O
levels	O
,	O
respectively	O
.	O

Combination	O
of	O
both	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
and	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
1B	I-geneN
/	I-geneN
1D	I-geneN
)	E-geneN
autoreceptor	O
antagonists	O
with	O
fluoxetine	S-chem
produced	O
additive	O
increases	O
in	O
extracellular	O
5	B-chem
-	I-chem
HT	E-chem
(	O
i.e	O
.	O

WAY100635	S-chem
+	O
GR127935	S-chem
+	O
fluoxetine	S-chem
and	O
WAY100635	S-chem
+	O
isamoltane	S-chem
+	O
fluoxetine	S-chem
produced	O
a	O
four	O
-	O
and	O
five	O
-	O
fold	O
potentiation	O
,	O
respectively	O
)	O
,	O
suggesting	O
that	O
this	O
strategy	O
may	O
be	O
useful	O
in	O
further	O
augmenting	O
the	O
action	O
of	O
a	O
SSRI	O
in	O
the	O
treatment	O
of	O
depression	O
.	O

In	O
addition	O
,	O
by	O
comparing	O
the	O
combined	O
administration	O
of	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
pindolol	E-chem
with	O
either	O
WAY100635	S-chem
,	O
GR127935	S-chem
or	O
isamoltane	S-chem
,	O
we	O
have	O
determined	O
that	O
(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
pindolol	E-chem-C6-1
produces	O
much	O
of	O
its	O
acute	O
potentiation	O
of	O
fluoxetine	S-chem
-	O
induced	O
increases	O
in	O
extracellular	O
5	B-chem
-	I-chem
HT	E-chem
via	O
its	O
action	O
at	O
the	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
1B	I-geneN
/	I-geneN
D	I-geneN
)	I-geneN
receptor	E-geneN
in	O
addition	O
to	O
any	O
activity	O
it	O
has	O
at	O
the	O
presynaptic	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
receptor	O
.	O

The	O
antileukemia	O
drug	O
2	B-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyadenosine	E-chem
:	O
an	O
intrinsic	O
transcriptional	O
antagonist	O
.	O

The	O
nucleoside	O
analog	O
2	B-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyadenosine	E-chem
(	O
CldAdo	S-chem
;	O
cladribine	S-chem
)	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hairy	O
cell	O
leukemia	O
and	O
chronic	O
lymphocytic	O
leukemia	O
.	O

CldAdo	S-chem
is	O
phosphorylated	O
and	O
incorporated	O
into	O
cellular	O
DNA	O
but	O
is	O
not	O
an	O
absolute	O
chain	O
terminator	O
.	O

We	O
demonstrated	O
by	O
in	O
vitro	O
gel	O
-	O
shift	O
assays	O
that	O
binding	O
interactions	O
of	O
the	O
human	B-geneY
TATA	I-geneY
box	I-geneY
-	I-geneY
binding	I-geneY
protein	E-geneY
(	O
TBP	S-geneY
)	O
were	O
disrupted	O
on	O
2	B-chem
-	I-chem
chlorodeoxyadenosine	I-chem
monophosphate	E-chem
(	O
CldAMP	S-chem
)	O
-	O
substituted	O
TATA	B-geneN
box	I-geneN
consensus	I-geneN
sequences	E-geneN
.	O

We	O
hypothesized	O
that	O
human	B-geneN
RNA	I-geneN
polymerase	I-geneN
II	E-geneN
(	O
pol	B-geneN
II	E-geneN
)	O
transcriptional	O
processes	O
would	O
therefore	O
be	O
affected	O
by	O
2	B-chem
-	I-chem
chlorodeoxyadenosine	I-chem
triphosphate	E-chem
(	O
CldATP	S-chem
)	O
incorporation	O
into	O
a	O
promoter	O
TATA	B-geneN
element	E-geneN
.	O

Double	O
-	O
stranded	O
DNA	O
templates	O
containing	O
the	O
adenovirus	O
major	O
late	O
promoter	O
and	O
coding	O
sequences	O
were	O
enzymatically	O
synthesized	O
as	O
control	O
or	O
with	O
site	O
-	O
specific	O
CldAMP	S-chem
residues	O
,	O
incubated	O
with	O
HeLa	O
extract	O
,	O
and	O
the	O
synthesis	O
of	O
radiolabeled	O
44	O
-	O
base	O
transcripts	O
was	O
assessed	O
.	O

With	O
increasing	O
amounts	O
of	O
HeLa	O
extract	O
,	O
CldAMP	S-chem
substitution	O
for	O
dAMP	S-chem
within	O
the	O
TATA	B-geneN
box	E-geneN
decreased	O
in	O
vitro	O
pol	B-geneN
II	E-geneN
transcription	O
by	O
approximately	O
35	O
%	O
compared	O
with	O
control	O
substrates	O
.	O

Time	O
-	O
course	O
studies	O
showed	O
that	O
transcript	O
production	O
increased	O
in	O
a	O
linear	O
fashion	O
on	O
control	O
substrates	O
.	O

In	O
contrast	O
,	O
transcription	O
on	O
CldAMP	S-chem
-	O
substituted	O
TATA	B-geneN
sequences	E-geneN
reached	O
a	O
plateau	O
after	O
20	O
min	O
.	O

Furthermore	O
,	O
CldAMP	S-chem
-	O
substituted	O
promoter	O
sequences	O
trapped	O
or	O
sequestered	O
TBP	O
,	O
preventing	O
its	O
dissociation	O
from	O
DNA	O
and	O
subsequent	O
binding	O
to	O
additional	O
TATA	B-geneN
elements	E-geneN
to	O
reinitiate	O
transcription	O
.	O

CldAdo	S-chem
thus	O
represents	O
the	O
first	O
example	O
of	O
a	O
nucleoside	O
analog	O
that	O
acts	O
as	O
a	O
transcriptional	O
antagonist	O
.	O

CldATP	S-chem
incorporation	O
into	O
gene	O
regulatory	O
sequences	O
may	O
provide	O
a	O
novel	O
strategy	O
to	O
modulate	O
specific	O
protein	O
/	O
DNA	O
interactions	O
.	O

Green	O
tea	O
extract	O
alleviates	O
arsenic	S-chem
-	O
induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
in	O
rats	O
.	O

The	O
present	O
work	O
was	O
undertaken	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
an	O
aqueous	O
extract	O
of	O
green	O
tea	O
(	O
GT	O
,	O
Camellia	O
sinensis	O
)	O
leaves	O
against	O
arsenic	S-chem
(	O
NaAsO2	S-chem
)	O
-	O
induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
production	O
in	O
experimental	O
rats	O
.	O

The	O
treatment	O
with	O
arsenic	S-chem-C3-1
exhibited	O
a	O
significant	O
increase	O
in	O
some	O
serum	O
hepatic	O
and	O
renal	O
biochemical	O
parameters	O
(	O
alanine	B-geneN-C3-2
aminotransferase	E-geneN-C3-2
,	O
aspartate	B-geneN-C3-2
aminotransferase	E-geneN-C3-2
,	O
alkaline	B-geneN-C3-2
phosphatase	E-geneN-C3-2
,	O
total	O
protein	O
,	O
albumin	S-geneY-C3-2
,	O
bilirubin	S-chem
,	O
cholesterol	S-chem
,	O
urea	S-chem
and	O
creatinine	S-chem
)	O
.	O

But	O
the	O
co	O
-	O
administration	O
of	O
GT	O
has	O
increased	O
the	O
level	O
of	O
plasmatic	O
concentration	O
of	O
biochemical	O
parameters	O
.	O

Exposure	O
of	O
rats	O
to	O
arsenic	S-chem
caused	O
also	O
a	O
significant	O
increase	O
in	O
liver	O
,	O
kidney	O
and	O
testicular	O
thiobarbituric	B-chem
acid	E-chem
reactive	O
substances	O
compared	O
to	O
control	O
.	O

However	O
,	O
the	O
co	O
-	O
administration	O
of	O
GT	O
was	O
effective	O
in	O
reducing	O
its	O
level	O
.	O

To	O
conclude	O
,	O
our	O
data	O
suggest	O
that	O
arsenic	S-chem
exposure	O
enhanced	O
an	O
oxidative	O
stress	O
by	O
disturbing	O
the	O
tissue	O
antioxidant	O
defense	O
system	O
,	O
but	O
the	O
GT	O
co	O
-	O
administration	O
alleviates	O
the	O
toxicity	O
induced	O
by	O
arsenic	S-chem
exposure	O
.	O

Biosynthesis	O
of	O
iron	S-chem
-	O
sulphur	S-chem
clusters	O
is	O
a	O
complex	O
and	O
highly	O
conserved	O
process	O
.	O

Iron	S-chem
-	O
sulphur	S-chem
(	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
)	O
clusters	O
are	O
simple	O
inorganic	O
prosthetic	O
groups	O
that	O
are	O
contained	O
in	O
a	O
variety	O
of	O
proteins	O
having	O
functions	O
related	O
to	O
electron	O
transfer	O
,	O
gene	O
regulation	O
,	O
environmental	O
sensing	O
and	O
substrate	O
activation	O
.	O

In	O
spite	O
of	O
their	O
simple	O
structures	O
,	O
biological	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
clusters	O
are	O
not	O
formed	O
spontaneously	O
.	O

Rather	O
,	O
a	O
consortium	O
of	O
highly	O
conserved	O
proteins	O
is	O
required	O
for	O
both	O
the	O
formation	O
of	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
clusters	O
and	O
their	O
insertion	O
into	O
various	O
protein	O
partners	O
.	O

Among	O
the	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
cluster	O
biosynthetic	O
proteins	O
are	O
included	O
a	O
pyridoxal	B-chem
phosphate	E-chem
-	O
dependent	O
enzyme	O
(	O
NifS	S-geneY-C9-2
)	O
that	O
is	O
involved	O
in	O
the	O
activation	O
of	O
sulphur	S-chem
from	O
l	B-chem-C9-1
-	I-chem-C9-1
cysteine	E-chem-C9-1
,	O
and	O
a	O
molecular	O
scaffold	O
protein	O
(	O
NifU	S-geneN
)	O
upon	O
which	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
cluster	O
precursors	O
are	O
formed	O
.	O

The	O
formation	O
or	O
transfer	O
of	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
clusters	O
appears	O
to	O
require	O
an	O
electron	O
-	O
transfer	O
step	O
.	O

Another	O
complexity	O
is	O
that	O
molecular	O
chaperones	O
homologous	O
to	O
DnaJ	O
and	O
DnaK	O
are	O
involved	O
in	O
some	O
aspect	O
of	O
the	O
maturation	O
of	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
-	O
cluster	O
-	O
containing	O
proteins	O
.	O

It	O
appears	O
that	O
the	O
basic	O
biochemical	O
features	O
of	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
cluster	O
formation	O
are	O
strongly	O
conserved	O
in	O
Nature	O
,	O
since	O
organisms	O
from	O
all	O
three	O
life	O
Kingdoms	O
contain	O
the	O
same	O
consortium	O
of	O
homologous	O
proteins	O
required	O
for	O
[	O
Fe	B-chem
-	I-chem
S	E-chem
]	O
cluster	O
formation	O
that	O
were	O
discovered	O
in	O
the	O
eubacteria	O
.	O

Differential	O
cell	O
-	O
protective	O
function	O
of	O
two	O
resveratrol	S-chem
(	B-chem
trans	I-chem
-	I-chem
3,5,4	I-chem
'	I-chem
-	I-chem
trihydroxystilbene	I-chem
)	I-chem
glucosides	E-chem
against	O
oxidative	O
stress	O
.	O

Resveratrol	S-chem
(	O
trans	B-chem
-	I-chem
3,5,4	I-chem
'	I-chem
-	I-chem
trihydroxystilbene	E-chem
;	O
RSV	S-chem
)	O
,	O
a	O
natural	O
polyphenol	S-chem
,	O
exerts	O
a	O
beneficial	O
effect	O
on	O
health	O
and	O
diseases	O
.	O

RSV	S-chem-C3-1
targets	O
and	O
activates	O
the	O
NAD	B-geneY-C3-2
(	I-geneY-C3-2
+	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
dependent	I-geneY-C3-2
protein	I-geneY-C3-2
deacetylase	I-geneY-C3-2
SIRT1	E-geneY-C3-2
;	O
in	O
turn	O
,	O
SIRT1	S-geneY-C3-2
induces	O
an	O
intracellular	O
antioxidative	O
mechanism	O
by	O
inducing	O
mitochondrial	B-geneY-C3-2
superoxide	I-geneY-C3-2
dismutase	E-geneY-C3-2
(	O
SOD2	S-geneY-C3-2
)	O
.	O

Most	O
RSV	O
found	O
in	O
plants	O
is	O
glycosylated	O
,	O
and	O
the	O
effect	O
of	O
these	O
glycosylated	O
forms	O
on	O
SIRT1	S-geneY
has	O
not	O
been	O
studied	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effects	O
of	O
RSV	S-chem
and	O
two	O
glycosyl	B-chem
RSVs	E-chem
,	O
resveratrol	B-chem
-	I-chem
3	I-chem
-	I-chem
O	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucoside	E-chem
(	O
3G	B-chem
-	I-chem
RSV	E-chem
;	O
polydatin	S-chem
/	O
piceid	S-chem
)	O
and	O
resveratrol	B-chem
-	I-chem
4	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucoside	E-chem
(	O
4'G	B-chem
-	I-chem
RSV	E-chem
)	O
,	O
at	O
the	O
cellular	O
level	O
.	O

In	O
oxygen	O
radical	O
absorbance	O
capacity	O
and	O
2,2	B-chem
-	I-chem
diphenyl	I-chem
-	I-chem
1	I-chem
-	I-chem
picrylhydrazyl	E-chem
radical	O
scavenging	O
assays	O
,	O
the	O
antioxidant	O
activity	O
of	O
3G	B-chem
-	I-chem
RSV	E-chem
was	O
comparable	O
to	O
that	O
of	O
RSV	S-chem
,	O
whereas	O
the	O
radical	O
-	O
scavenging	O
efficiency	O
of	O
4'G	B-chem
-	I-chem
RSV	E-chem
was	O
less	O
than	O
50	O
%	O
of	O
that	O
of	O
RSV	S-chem
.	O

However	O
,	O
4'G	B-chem-C3-1
-	I-chem-C3-1
RSV	E-chem-C3-1
,	O
but	O
not	O
3G	B-chem
-	I-chem
RSV	E-chem
,	O
induced	O
SIRT1	S-geneY-C3-2
-	O
dependent	O
histone	B-geneN
H3	E-geneN
deacetylation	O
and	O
SOD2	S-geneY-C3-2
expression	O
in	O
mouse	O
C2C12	O
skeletal	O
myoblasts	O
;	O
as	O
with	O
RSV	S-chem
,	O
SIRT1	S-geneY
knockdown	O
blunted	O
these	O
effects	O
.	O

RSV	S-chem
and	O
4'G	B-chem
-	I-chem
RSV	E-chem
,	O
but	O
not	O
3G	B-chem
-	I-chem
RSV	E-chem
,	O
mitigated	O
oxidative	O
stress	O
-	O
induced	O
cell	O
death	O
in	O
C2C12	O
cells	O
and	O
primary	O
neonatal	O
rat	O
cardiomyocytes	O
.	O

RSV	S-chem
and	O
4'G	B-chem
-	I-chem
RSV	E-chem
inhibited	O
C2C12	O
cell	O
proliferation	O
,	O
but	O
3G	B-chem
-	I-chem
RSV	E-chem
did	O
not	O
.	O

RSV	S-chem
was	O
found	O
in	O
both	O
the	O
intracellular	O
and	O
extracellular	O
fractions	O
of	O
C2C12	O
cells	O
that	O
had	O
been	O
incubated	O
with	O
4'G	B-chem
-	I-chem
RSV	E-chem
,	O
indicating	O
that	O
4'G	B-chem
-	I-chem
RSV	E-chem
was	O
extracellularly	O
deglycosylated	O
to	O
RSV	S-chem
,	O
which	O
was	O
then	O
taken	O
up	O
by	O
the	O
cells	O
.	O

C2C12	O
cells	O
did	O
not	O
deglycosylate	O
3G	B-chem
-	I-chem
RSV	E-chem
.	O

Our	O
results	O
point	O
to	O
4'G	B-chem
-	I-chem
RSV	E-chem
as	O
a	O
useful	O
RSV	S-chem
prodrug	O
with	O
high	O
water	O
solubility	O
.	O

These	O
data	O
also	O
show	O
that	O
the	O
in	O
vitro	O
antioxidative	O
activity	O
of	O
these	O
molecules	O
did	O
not	O
correlate	O
with	O
their	O
ability	O
to	O
protect	O
cells	O
from	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
.	O

Nonthrombolytic	O
intervention	O
in	O
acute	O
myocardial	O
infarction	O
.	O

Alternative	O
interventions	O
are	O
available	O
for	O
patients	O
in	O
whom	O
thrombolytic	O
therapy	O
is	O
inappropriate	O
after	O
an	O
acute	O
myocardial	O
infarction	O
.	O

Administration	O
of	O
a	O
beta	O
blocker	O
within	O
the	O
first	O
24	O
hours	O
of	O
the	O
patient	O
's	O
admission	O
to	O
the	O
coronary	O
care	O
unit	O
can	O
reduce	O
overall	O
morbidity	O
and	O
mortality	O
within	O
the	O
first	O
7	O
days	O
by	O
about	O
15	O
%	O
.	O

Maintenance	O
therapy	O
with	O
an	O
oral	O
beta	O
blocker	O
can	O
reduce	O
mortality	O
within	O
the	O
succeeding	O
3	O
years	O
by	O
about	O
25	O
%	O
.	O

Esmolol	S-chem-C4-1
,	O
a	O
unique	O
cardioselective	O
beta	B-geneY-C4-2
1	I-geneY-C4-2
-	I-geneY-C4-2
adrenergic	I-geneY-C4-2
receptor	E-geneY-C4-2
blocker	O
with	O
a	O
half	O
-	O
life	O
of	O
9	O
minutes	O
,	O
can	O
enable	O
some	O
patients	O
with	O
relative	O
contraindications	O
to	O
beta	O
blockers	O
to	O
nevertheless	O
benefit	O
from	O
early	O
beta	O
-	O
blocking	O
therapy	O
.	O

It	O
also	O
is	O
useful	O
in	O
screening	O
patients	O
for	O
subsequent	O
therapy	O
with	O
beta	O
blockers	O
.	O

Those	O
who	O
tolerate	O
the	O
esmolol	S-chem
infusion	O
can	O
be	O
given	O
a	O
long	O
-	O
acting	O
beta	O
blocker	O
.	O

For	O
patients	O
who	O
exhibit	O
intolerance	O
to	O
esmolol	S-chem
,	O
the	O
infusion	O
can	O
be	O
terminated	O
with	O
rapid	O
return	O
to	O
baseline	O
hemodynamics	O
.	O

UCCB01	B-chem
-	I-chem
125	E-chem
,	O
a	O
dimeric	O
inhibitor	O
of	O
PSD	O
-	O
95	O
,	O
reduces	O
inflammatory	O
pain	O
without	O
disrupting	O
cognitive	O
or	O
motor	O
performance	O
:	O
comparison	O
with	O
the	O
NMDA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
MK	B-chem-C6-1
-	I-chem-C6-1
801	E-chem-C6-1
.	O

Excessive	O
N	B-geneN
-	I-geneN
Methyl	I-geneN
-	I-geneN
d	I-geneN
-	I-geneN
aspartate	I-geneN
receptor	E-geneN
(	O
NMDAR	S-geneN
)	O
-	O
dependent	O
production	O
of	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
is	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
chronic	O
pain	O
states	O
,	O
and	O
is	O
mediated	O
by	O
postsynaptic	B-geneY
density	I-geneY
protein	I-geneY
-	I-geneY
95	E-geneY
(	O
PSD	B-geneY
-	I-geneY
95	E-geneY
)	O
.	O

By	O
binding	O
to	O
both	O
the	O
NMDAR	S-geneN
and	O
neuronal	B-geneY
NO	I-geneY
synthase	E-geneY
(	O
nNOS	S-geneY
)	O
,	O
PSD	B-geneY
-	I-geneY
95	E-geneY
mediates	O
a	O
specific	O
coupling	O
between	O
NMDAR	S-geneN
activation	O
and	O
NO	S-chem
production	O
.	O

NMDAR	S-geneN
antagonism	O
shows	O
anti	O
-	O
nociceptive	O
action	O
in	O
humans	O
and	O
animal	O
models	O
of	O
chronic	O
pain	O
but	O
is	O
associated	O
with	O
severe	O
disturbances	O
of	O
cognitive	O
and	O
motor	O
functions	O
.	O

An	O
alternative	O
approach	O
to	O
modulate	O
the	O
NMDAR	S-geneN
-	O
related	O
activity	O
is	O
to	O
perturb	O
the	O
NMDAR	S-geneN
/	O
PSD	B-geneY
-	I-geneY
95	E-geneY
/	O
nNOS	S-geneY
complex	O
by	O
targeting	O
PSD	B-geneN
-	I-geneN
95	E-geneN
,	O
thereby	O
decreasing	O
NO	S-chem
production	O
without	O
interfering	O
with	O
the	O
NMDAR	S-geneN
ion	B-geneN
channel	E-geneN
function	O
.	O

Here	O
,	O
we	O
compared	O
the	O
effects	O
of	O
a	O
dimeric	O
PSD	B-geneY-C4-2
-	I-geneY-C4-2
95	E-geneY-C4-2
inhibitor	O
,	O
UCCB01	B-chem-C4-1
-	I-chem-C4-1
125	E-chem-C4-1
,	O
and	O
the	O
NMDAR	S-geneN-C6-2
antagonist	O
,	O
MK	B-chem-C6-1
-	I-chem-C6-1
801	E-chem-C6-1
,	O
on	O
mechanical	O
hypersensitivity	O
in	O
the	O
complete	O
Freund	O
's	O
adjuvant	O
(	O
CFA	O
)	O
model	O
of	O
inflammatory	O
pain	O
.	O

To	O
examine	O
side	O
-	O
effect	O
profiles	O
we	O
also	O
compared	O
the	O
effects	O
of	O
UCCB01	B-chem
-	I-chem
125	E-chem
and	O
MK	B-chem
-	I-chem
801	E-chem
in	O
tests	O
of	O
attention	O
,	O
long	O
-	O
term	O
memory	O
,	O
and	O
motor	O
performance	O
.	O

When	O
administered	O
concurrently	O
with	O
CFA	O
,	O
both	O
MK	B-chem
-	I-chem
801	E-chem
and	O
UCCB01	B-chem
-	I-chem
125	E-chem
prevented	O
the	O
development	O
of	O
CFA	O
-	O
induced	O
mechanical	O
hypersensitivity	O
1	O
and	O
24	O
h	O
after	O
treatment	O
.	O

Moreover	O
,	O
UCCB01	B-chem
-	I-chem
125	E-chem
was	O
found	O
to	O
reverse	O
CFA	O
-	O
induced	O
hypersensitivity	O
when	O
administered	O
24	O
h	O
after	O
CFA	O
treatment	O
,	O
an	O
effect	O
lasting	O
for	O
at	O
least	O
3	O
days	O
.	O

At	O
the	O
dose	O
reducing	O
hypersensitivity	O
,	O
MK	B-chem
-	I-chem
801	E-chem
disrupted	O
attention	O
,	O
long	O
-	O
term	O
memory	O
,	O
and	O
motor	O
performance	O
.	O

By	O
contrast	O
,	O
even	O
high	O
doses	O
of	O
UCCB01	B-chem
-	I-chem
125	E-chem
were	O
devoid	O
of	O
side	O
-	O
effects	O
in	O
these	O
tests	O
.	O

The	O
data	O
suggest	O
that	O
PSD	B-geneY
-	I-geneY
95	E-geneY
inhibition	O
is	O
a	O
feasible	O
strategy	O
to	O
prevent	O
both	O
development	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
pain	O
,	O
while	O
avoiding	O
NMDAR	S-geneN
antagonism	O
-	O
related	O
side	O
-	O
effects	O
.	O

tert	B-chem-C4-1
-	I-chem-C4-1
Butylcarbamate	E-chem-C4-1
-	O
Containing	O
Histone	B-geneN-C4-2
Deacetylase	E-geneN-C4-2
Inhibitors	O
:	O
Apoptosis	O
Induction	O
,	O
Cytodifferentiation	O
,	O
and	O
Antiproliferative	O
Activities	O
in	O
Cancer	O
Cells	O
.	O

Herein	O
we	O
report	O
novel	O
pyrrole	S-chem-C4-1
-	O
and	O
benzene	S-chem-C4-1
-	O
based	O
hydroxamates	S-chem-C4-1
(	O
8	O
,	O
10	O
)	O
and	O
2	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
aminoanilides	E-chem-C4-1
(	O
9	O
,	O
11	O
)	O
bearing	O
the	O
tert	B-chem-C4-1
-	I-chem-C4-1
butylcarbamate	E-chem-C4-1
group	O
at	O
the	O
CAP	O
moiety	O
as	O
histone	B-geneN-C4-2
deacetylase	E-geneN-C4-2
(	O
HDAC	S-geneN-C4-2
)	O
inhibitors	O
.	O

Compounds	O
8	O
b	O
and	O
10	O
c	O
selectively	O
inhibited	O
HDAC6	O
at	E-geneY
the	O
nanomolar	O
level	O
,	O
whereas	O
the	O
other	O
hydroxamates	O
effected	O
an	O
increase	O
in	O
acetyl	O
-	I-geneN-C3-2
α	I-geneN-C3-2
-	I-geneN-C3-2
tubulin	I-geneN-C3-2
levels	O
in	O
human	O
acute	O
myeloid	O
leukemia	O
U937	O
cells	O
.	O

In	O
the	O
same	O
cell	O
line	O
,	O
compounds	O
8	O
b	O
and	O
10	O
c	O
elicited	O
18.4	O
and	O
21.4	O
%	O
apoptosis	O
,	O
respectively	O
(	O
SAHA	O
:	I-chem
16.9	O
%	O
)	O
,	O
and	O
the	O
pyrrole	O
anilide	I-chem
9	I-chem
c	I-chem
displayed	O
the	O
highest	O
cytodifferentiating	O
effect	O
(	O
90.9	O
%	O
)	O
.	O

In	O
tests	O
against	O
a	O
wide	O
range	O
of	O
various	O
cancer	O
cell	O
lines	O
to	O
determine	O
its	O
antiproliferative	O
effects	O
,	O
compound	O
10	O
c	O
exhibited	O
growth	O
inhibition	O
from	O
sub	O
-	O
micromolar	O
(	O
neuroblastoma	O
LAN	O
-	O
5	O
and	O
SH	O
-	O
SY5Y	O
cells	O
,	O
chronic	O
myeloid	O
leukemia	O
K562	O
cells	O
)	O
to	O
low	O
-	O
micromolar	O
(	O
lung	O
H1299	O
and	O
A549	O
,	O
colon	O
HCT116	O
and	O
HT29	O
cancer	O
cells	O
)	O
concentrations	O
.	O

In	O
HT29	O
cells	O
,	O
10	O
c	O
increased	O
histone	O
H3	I-geneN
acetylation	O
,	O
and	O
decreased	O
the	O
colony	O
-	O
forming	O
potential	O
of	O
the	O
cancer	O
cells	O
by	O
up	O
to	O
60	O
%	O
.	O

Design	O
,	O
synthesis	O
and	O
antiproliferative	O
properties	O
of	O
some	O
new	O
5	B-chem
-	I-chem
substituted	I-chem
-	I-chem
2	I-chem
-	I-chem
iminobenzimidazole	E-chem
derivatives	O
.	O

Some	O
new	O
1,3,5	B-chem
-	I-chem
substituted	I-chem
-	I-chem
2,3	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2	I-chem
-	I-chem
imino	I-chem
-	I-chem
benzimidazoles	E-chem
were	O
synthesized	O
under	O
solid	O
-	O
liquid	O
phase	O
transfer	O
catalysis	O
conditions	O
using	O
5	B-chem
-	I-chem
substituted	I-chem
-	I-chem
2	I-chem
-	I-chem
aminobenzimidazoles	E-chem
as	O
precursors	O
in	O
order	O
to	O
assess	O
their	O
cytotoxicity	O
respectively	O
proliferative	O
activity	O
.	O

The	O
structures	O
of	O
the	O
compounds	O
were	O
confirmed	O
by	O
IR	O
,	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
NMR	O
,	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
NMR	O
and	O
elemental	O
analysis	O
.	O

Compounds	O
9	O
-	O
10	O
,	O
12	O
and	O
16	O
-	O
17	O
were	O
evaluated	O
for	O
their	O
cytotoxical	O
effect	O
on	O
four	O
cancer	O
cell	O
lines	O
:	O
HT	O
-	O
29	O
,	O
breast	O
cancer	O
cells	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
HeLa	O
,	O
HepG2	O
and	O
as	O
well	O
as	O
human	O
diploid	O
cell	O
line	O
Lep	O
-	O
3	O
.	O

Significant	O
cytotoxicity	O
of	O
hydrazone	S-chem
16	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
was	O
established	O
by	O
biologically	O
study	O
,	O
the	O
IC50	O
was	O
6.2	O
nM	O
while	O
the	O
EC50	O
value	O
to	O
Lep	O
3	O
is	O
0.21	O
nM	O
.	O

Relative	O
high	O
antiproliferative	O
effects	O
of	O
the	O
acetate	O
12	E-chem
and	O
compound	O
16	O
against	O
HT	O
-	O
29	O
were	O
ascertained	O
and	O
the	O
calculated	O
IC50	O
values	O
were	O
IC50	O
-	O
0.85	O
nM	O
and	O
IC50	O
-	O
2.83	O
nM	O
respectively	O
.	O

Cytotoxic	O
activity	O
against	O
HeLa	O
and	O
HepG2	O
cells	O
was	O
demonstrated	O
by	O
hydrazone	S-chem
17	O
,	O
IC50	O
was	O
7.2	O
nM	O
and	O
117	O
nM	O
respectively	O
.	O

All	O
tested	O
compounds	O
revealed	O
proliferative	O
activities	O
to	O
human	O
diploid	O
cell	O
line	O
Lep	O
-	O
3	O
.	O

The	O
EC50	O
values	O
were	O
in	O
the	O
range	O
from	O
0.05	O
to	O
16.91	O
nM	O
.	O

The	O
obtained	O
results	O
prove	O
the	O
selective	O
cytotoxicity	O
of	O
the	O
tested	O
compounds	O
and	O
are	O
promising	O
for	O
further	O
evaluation	O
of	O
the	O
investigated	O
compounds	O
in	O
vivo	O
experiments	O
using	O
experimentally	O
induced	O
tumors	O
in	O
laboratory	O
animals	O
.	O

Melanoma	O
targeting	O
property	O
of	O
a	O
Lu	B-chem
-	I-chem
177	E-chem
-	O
labeled	O
lactam	S-chem
bridge	O
-	O
cyclized	O
alpha	B-geneY
-	I-geneY
MSH	E-geneY
peptide	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
melanoma	O
targeting	O
property	O
of	O
(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
in	O
B16	O
/	O
F1	O
melanoma	O
-	O
bearing	O
C57	O
mice	O
.	O

(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
exhibited	O
high	O
receptor	O
-	O
mediated	O
melanoma	O
uptake	O
and	O
fast	O
urinary	O
clearance	O
.	O

The	O
tumor	O
uptake	O
of	O
(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
was	O
20.25	O
±	O
4.59	O
and	O
21.63	O
±	O
6.27	O
%	O
ID	O
/	O
g	O
at	O
0.5	O
and	O
2h	O
post	O
-	O
injection	O
,	O
respectively	O
.	O

Approximately	O
83	O
%	O
of	O
injected	O
dose	O
cleared	O
out	O
the	O
body	O
via	O
urinary	O
system	O
at	O
2h	O
post	O
-	O
injection	O
.	O

(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
showed	O
high	O
tumor	O
to	O
normal	O
organ	O
uptake	O
ratios	O
except	O
for	O
the	O
kidneys	O
.	O

The	O
tumor	O
/	O
kidney	O
uptake	O
ratios	O
of	O
(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
were	O
2.76	O
and	O
1.74	O
at	O
2	O
and	O
24h	O
post	O
-	O
injection	O
.	O

The	O
melanoma	O
lesions	O
were	O
clearly	O
visualized	O
by	O
SPECT	O
/	O
CT	O
using	O
(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
as	O
an	O
imaging	O
probe	O
at	O
2h	O
post	O
-	O
injection	O
.	O

Overall	O
,	O
high	O
melanoma	O
uptake	O
coupled	O
with	O
fast	O
urinary	O
clearance	O
of	O
(	B-chem
177	I-chem
)	I-chem
Lu	I-chem
-	I-chem
DOTA	I-chem
-	I-chem
GGNle	I-chem
-	I-chem
CycMSHhex	E-chem
underscored	O
its	O
potential	O
for	O
melanoma	O
treatment	O
in	O
the	O
future	O
.	O

An	O
Indian	O
butyrylcholinesterase	S-geneY
variant	O
L307P	S-geneN
is	O
not	O
structurally	O
stable	O
:	O
A	O
molecular	O
dynamics	O
simulation	O
study	O
.	O

The	O
human	B-geneY
butyrylcholinesterase	E-geneY
(	O
BChE	S-geneY
)	O
activity	O
is	O
less	O
than	O
1	O
%	O
in	O
the	O
serum	O
of	O
silent	O
variant	O
individuals	O
of	O
Vysya	O
community	O
in	O
India	O
.	O

They	O
are	O
homozygous	O
for	O
a	O
point	O
mutation	O
at	O
codon	O
307	O
(	O
CTT	S-geneN
→	O
CCT	S-geneN
)	O
resulting	O
in	O
the	O
substitution	O
of	O
leucine	B-geneN
307	I-geneN
by	I-geneN
proline	E-geneN
.	O

The	O
reason	O
for	O
the	O
disappearance	O
of	O
the	O
protein	O
in	O
the	O
serum	O
has	O
not	O
been	O
explicated	O
till	O
date	O
.	O

Based	O
on	O
this	O
background	O
,	O
we	O
performed	O
molecular	O
dynamics	O
simulation	O
to	O
probe	O
the	O
structural	O
stability	O
of	O
Indian	O
variant	O
(	O
L307P	S-geneN
)	O
in	O
comparison	O
with	O
wild	O
and	O
other	O
BChE	S-geneY
variants	O
(	O
D70G	S-geneN
,	O
E497V	S-geneN
,	O
V142M	S-geneN
)	O
having	O
differential	O
esterase	S-geneN
activity	O
.	O

The	O
simulation	O
of	O
all	O
the	O
mutants	O
except	O
D70G	S-geneN
showed	O
a	O
much	O
larger	O
Cα	O
root	O
mean	O
square	O
deviation	O
from	O
the	O
wild	O
BChE	S-geneY
crystal	O
structure	O
,	O
showing	O
the	O
overall	O
conformational	O
disturbance	O
.	O

Further	O
analysis	O
revealed	O
that	O
secondary	O
structure	O
of	O
the	O
mutant	O
proteins	O
was	O
not	O
stable	O
.	O

The	O
orientation	O
of	O
the	O
catalytic	O
triad	O
is	O
also	O
distorted	O
in	O
all	O
the	O
mutants	O
.	O

The	O
distance	O
between	O
δ	O
nitrogen	S-chem
of	O
His438	S-chem
to	O
ε	O
oxygen	S-chem
of	O
Glu325	S-chem
and	O
ε	O
nitrogen	S-chem
of	O
His438	S-chem
to	O
γ	O
oxygen	S-chem
of	O
Ser198	S-chem
were	O
highly	O
altered	O
in	O
L307P	S-geneN
mutant	O
than	O
the	O
wild	O
and	O
other	O
three	O
variants	O
throughout	O
the	O
simulation	O
.	O

Such	O
disparity	O
of	O
distances	O
between	O
the	O
catalytic	O
residues	O
may	O
be	O
due	O
to	O
the	O
change	O
in	O
the	O
protein	O
conformation	O
attributing	O
to	O
their	O
differential	O
catalytic	O
activity	O
.	O

Our	O
studies	O
thus	O
prove	O
that	O
the	O
Indian	O
BChE	S-geneY
L307P	S-geneN
mutant	O
with	O
negligible	O
activity	O
is	O
possibly	O
due	O
to	O
its	O
structural	O
instability	O
when	O
compared	O
to	O
other	O
BChE	S-geneY
variants	O
.	O

The	O
Prevalence	O
of	O
Meeting	O
A1C	S-geneY
,	O
Blood	O
Pressure	O
,	O
and	O
LDL	S-geneN
Goals	O
Among	O
People	O
With	O
Diabetes	O
,	O
1988	O
-	O
2010	O
.	O

OBJECTIVETo	O
determine	O
the	O
prevalence	O
of	O
people	O
with	O
diabetes	O
who	O
meet	O
hemoglobin	B-geneY
A	I-geneY
(	I-geneY
1c	I-geneY
)	E-geneY
(	O
A1C	S-geneY
)	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
and	O
LDL	S-geneN
cholesterol	S-chem
(	O
ABC	O
)	O
recommendations	O
,	O
and	O
their	O
current	O
statin	O
use	O
,	O
factors	O
associated	O
with	O
goal	O
achievement	O
,	O
and	O
changes	O
in	O
the	O
proportion	O
achieving	O
goals	O
between	O
1988	O
and	O
2010.RESEARCH	O
AND	O
DESIGN	O
METHODSData	O
were	O
cross	O
-	O
sectional	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Surveys	O
(	O
NHANES	O
)	O
from	O
1988	O
-	O
1994	O
,	O
1999	O
-	O
2002	O
,	O
2003	O
-	O
2006	O
,	O
and	O
2007	O
-	O
2010	O
.	O

Participants	O
were	O
4,926	O
adults	O
aged	O
≥	O
20	O
years	O
who	O
self	O
-	O
reported	O
a	O
previous	O
diagnosis	O
of	O
diabetes	O
and	O
completed	O
the	O
household	O
interview	O
and	O
physical	O
examination	O
(	O
n	O
=	O
1,558	O
for	O
valid	O
LDL	O
levels	O
)	O
.	O

Main	O
outcome	O
measures	O
were	O
A1C	S-geneY
,	O
BP	O
,	O
and	O
LDL	S-geneN
cholesterol	S-chem
,	O
in	O
accordance	O
with	O
the	O
American	O
Diabetes	O
Association	O
recommendations	O
,	O
and	O
current	O
use	O
of	O
statins.RESULTSIn	O
2007	O
-	O
2010	O
,	O
52.5	O
%	O
of	O
people	O
with	O
diabetes	O
achieved	O
A1C	S-geneY
<	O
7.0	O
%	O
(	O
<	O
53	O
mmol	O
/	O
mol	O
)	O
,	O
51.1	O
%	O
achieved	O
BP	O
<	O
130	O
/	O
80	O
mmHg	O
,	O
56.2	O
%	O
achieved	O
LDL	S-geneN
<	O
100	O
mg	O
/	O
dL	O
,	O
and	O
18.8	O
%	O
achieved	O
all	O
three	O
ABCs	O
.	O

These	O
levels	O
of	O
control	O
were	O
significant	O
improvements	O
from	O
1988	O
to	O
1994	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

Statin	O
use	O
significantly	O
increased	O
between	O
1988	O
-	O
1994	O
(	O
4.2	O
%	O
)	O
and	O
2007	O
-	O
2010	O
(	O
51.4	O
%	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Compared	O
with	O
non	O
-	O
Hispanic	O
whites	O
,	O
Mexican	O
Americans	O
were	O
less	O
likely	O
to	O
meet	O
A1C	S-geneY
and	O
LDL	S-geneN
goals	O
(	O
P	O
<	O
0.03	O
)	O
,	O
and	O
non	O
-	O
Hispanic	O
blacks	O
were	O
less	O
likely	O
to	O
meet	O
BP	O
and	O
LDL	S-geneN
goals	O
(	O
P	O
<	O
0.02	O
)	O
.	O

Compared	O
with	O
non	O
-	O
Hispanic	O
blacks	O
,	O
Mexican	O
Americans	O
were	O
less	O
likely	O
to	O
meet	O
A1C	S-geneY
goals	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Younger	O
individuals	O
were	O
less	O
likely	O
to	O
meet	O
A1C	S-geneY
and	O
LDL	S-geneN
goals.CONCLUSIONSDespite	O
significant	O
improvement	O
during	O
the	O
past	O
decade	O
,	O
achieving	O
the	O
ABC	O
goals	O
remains	O
suboptimal	O
among	O
adults	O
with	O
diabetes	O
,	O
particularly	O
in	O
some	O
minority	O
groups	O
.	O

Substantial	O
opportunity	O
exists	O
to	O
further	O
improve	O
diabetes	O
control	O
and	O
,	O
thus	O
,	O
to	O
reduce	O
diabetes	O
-	O
related	O
morbidity	O
and	O
mortality	O
.	O

Characterization	O
of	O
the	O
mouse	O
promoter	O
region	O
of	O
the	O
acyl	B-geneY
-	I-geneY
CoA	I-geneY
synthetase	I-geneY
4	E-geneY
gene	O
:	O
role	O
of	O
Sp1	S-geneY
and	O
CREB	S-geneN
.	O

Acyl	B-geneY
-	I-geneY
CoA	I-geneY
synthetase	I-geneY
4	E-geneY
(	O
Acsl4	S-geneY
)	O
is	O
involved	O
in	O
several	O
cellular	O
functions	O
including	O
steroidogenesis	O
,	O
synaptic	O
development	O
and	O
cancer	O
metastasis	O
.	O

Although	O
the	O
expression	O
of	O
Acsl4	S-geneY
seems	O
to	O
be	O
regulated	O
by	O
tissue	O
-	O
and	O
cell	O
-	O
specific	O
factors	O
as	O
well	O
as	O
pituitary	O
hormones	O
and	O
growth	O
factors	O
,	O
the	O
transcriptional	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O

We	O
demonstrated	O
hCG	S-geneN
and	O
cAMP	S-chem
regulation	O
of	O
Acsl4	S-geneY
mRNA	O
in	O
mouse	O
steroidogenic	O
MA	O
-	O
10	O
Leydig	O
cells	O
.	O

We	O
characterized	O
the	O
transcription	B-geneN
initiation	I-geneN
site	E-geneN
and	O
promoter	O
of	O
the	O
Acsl4	S-geneY
mouse	O
gene	O
and	O
identified	O
three	O
alternative	O
splice	O
variants	O
present	O
in	O
MA	O
-	O
10	O
cells	O
.	O

Sequence	O
analysis	O
of	O
a	O
1.5	O
-	O
kb	O
fragment	O
of	O
the	O
Acsl4	B-geneN
promoter	E-geneN
revealed	O
the	O
absence	O
of	O
a	O
TATA	B-geneN
box	E-geneN
and	O
the	O
presence	O
of	O
many	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
including	O
Sp1	S-geneY
and	O
CREB	S-geneN
.	O

Functional	O
characterization	O
revealed	O
that	O
the	O
specificity	B-geneN
protein	E-geneN
/	O
Krüppel	B-geneN
-	I-geneN
like	I-geneN
factor	E-geneN
Sp1	S-geneY
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
is	O
involved	O
in	O
basal	O
activity	O
and	O
that	O
the	O
cAMP	B-geneN
response	I-geneN
element	E-geneN
-	O
binding	O
site	O
is	O
involved	O
in	O
cAMP	S-chem
stimulation	O
of	O
Acsl4	S-geneY
transcription	O
.	O

The	O
mannose	B-chem
6	I-chem
-	I-chem
phosphate	E-chem
-	O
binding	O
sites	O
of	O
M6P	S-chem
/	O
IGF2R	S-geneY
determine	O
its	O
capacity	O
to	O
suppress	O
matrix	O
invasion	O
by	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

The	O
M6P	S-chem
(	O
mannose	B-chem
6	I-chem
-	I-chem
phosphate	E-chem
)	O
/	O
IGF2R	S-geneY
(	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
II	I-geneY
receptor	E-geneY
)	O
interacts	O
with	O
a	O
variety	O
of	O
factors	O
that	O
impinge	O
on	O
tumour	O
invasion	O
and	O
metastasis	O
.	O

It	O
has	O
been	O
shown	O
that	O
expression	O
of	O
wild	O
-	O
type	O
M6P	S-chem
/	O
IGF2R	S-geneY
reduces	O
the	O
tumorigenic	O
and	O
invasive	O
properties	O
of	O
receptor	O
-	O
deficient	O
SCC	O
-	O
VII	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

We	O
have	O
now	O
used	O
mutant	O
forms	O
of	O
M6P	S-chem
/	O
IGF2R	S-geneY
to	O
assess	O
the	O
relevance	O
of	O
the	O
different	O
ligand	O
-	O
binding	O
sites	O
of	O
the	O
receptor	O
for	O
its	O
biological	O
activities	O
in	O
this	O
cellular	O
system	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
M6P	S-chem
/	O
IGF2R	S-geneY
does	O
not	O
require	O
a	O
functional	O
binding	O
site	O
for	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
II	E-geneY
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
and	O
matrix	O
invasion	O
by	O
SCC	O
-	O
VII	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
simultaneous	O
mutation	O
of	O
both	O
M6P	S-chem
-	O
binding	O
sites	O
is	O
sufficient	O
to	O
impair	O
all	O
cellular	O
functions	O
of	O
the	O
receptor	O
tested	O
.	O

These	O
findings	O
highlight	O
that	O
the	O
interaction	O
between	O
M6P	S-chem
/	O
IGF2R	S-geneY
and	O
M6P	S-chem
-	O
modified	O
ligands	O
is	O
not	O
only	O
important	O
for	O
intracellular	O
accumulation	O
of	O
lysosomal	O
enzymes	O
and	O
formation	O
of	O
dense	O
lysosomes	O
,	O
but	O
is	O
also	O
crucial	O
for	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
suppress	O
SCC	O
-	O
VII	O
growth	O
and	O
invasion	O
.	O

The	O
present	O
study	O
also	O
shows	O
that	O
some	O
of	O
the	O
biological	O
activities	O
of	O
M6P	S-chem
/	O
IGF2R	S-geneY
in	O
SCC	O
-	O
VII	O
cells	O
strongly	O
depend	O
on	O
a	O
functional	O
M6P	S-chem
-	O
binding	O
site	O
within	O
domain	O
3	O
,	O
thus	O
providing	O
further	O
evidence	O
for	O
the	O
non	O
-	O
redundant	O
cellular	O
functions	O
of	O
the	O
individual	O
carbohydrate	S-chem
-	O
binding	O
domains	O
of	O
the	O
receptor	O
.	O

Enzyme	O
expression	O
profiles	O
suggest	O
the	O
novel	O
tumor	O
-	O
activated	O
fluoropyrimidine	B-chem
carbamate	E-chem
capecitabine	S-chem
(	O
Xeloda	S-chem
)	O
might	O
be	O
effective	O
against	O
papillary	O
thyroid	O
cancers	O
of	O
children	O
and	O
young	O
adults	O
.	O

PURPOSE	O
:	O
The	O
fluoropyrimidine	B-chem-C9-1
carbamate	E-chem-C9-1
(	O
capecitabine	S-chem-C9-1
)	O
is	O
converted	O
to	O
5	B-chem-C9-1
-	I-chem-C9-1
fluorouracil	E-chem-C9-1
(	O
5	B-chem-C9-1
-	I-chem-C9-1
FU	E-chem-C9-1
)	O
by	O
thymidine	B-geneY-C9-2
phosphorylase	E-geneY-C9-2
(	O
TP	S-geneY-C9-2
)	O
inside	O
target	O
tissues	O
.	O

5	B-chem-C4-1
-	I-chem-C4-1
FU	E-chem-C4-1
interferes	O
with	O
DNA	O
synthesis	O
by	O
blocking	O
thymidylate	B-geneY-C4-2
synthase	E-geneY-C4-2
(	O
TS	S-geneY-C4-2
)	O
but	O
is	O
inactivated	O
by	O
dihydropyrimidine	B-geneY
dehydrogenase	E-geneY
(	O
DPD	S-geneY
)	O
.	O

Favorable	O
enzyme	O
profiles	O
(	O
high	O
TP	S-geneY-C9-2
and	O
low	O
DPD	S-geneY-C9-2
)	O
generate	O
high	O
intratumor	O
levels	O
of	O
5	B-chem-C9-1
-	I-chem-C9-1
FU	E-chem-C9-1
that	O
are	O
effective	O
against	O
many	O
tumors	O
,	O
especially	O
those	O
with	O
low	O
TS	S-geneY
.	O

Capecitabine	S-chem
has	O
not	O
been	O
tested	O
against	O
thyroid	O
cancers	O
,	O
and	O
it	O
is	O
not	O
known	O
to	O
what	O
extent	O
thyroid	O
cancers	O
express	O
TP	S-geneY
,	O
TS	S-geneY
or	O
DPD	S-geneY
.	O

METHODS	O
:	O
To	O
test	O
this	O
,	O
we	O
determined	O
TP	S-geneY
,	O
TS	S-geneY
and	O
DPD	S-geneY
in	O
19	O
thyroid	O
cancers	O
from	O
young	O
patients	O
(	O
14	O
papillary	O
,	O
4	O
follicular	O
,	O
1	O
medullary	O
)	O
by	O
immunohistochemistry	O
.	O

After	O
approval	O
by	O
the	O
Human	O
Use	O
Committee	O
,	O
the	O
intensity	O
of	O
TP	S-geneY
,	O
TS	S-geneY
,	O
and	O
DPD	S-geneY
staining	O
was	O
determined	O
by	O
two	O
independent	O
examiners	O
and	O
graded	O
(	O
absent	O
=	O
0	O
to	O
intense	O
=	O
3	O
)	O
with	O
>	O
90	O
%	O
concordance	O
.	O

RESULTS	O
:	O
TS	S-geneY
was	O
detected	O
in	O
7	O
/	O
19	O
cancers	O
(	O
37	O
%	O
)	O
,	O
TP	S-geneY
in	O
14	O
/	O
19	O
cancers	O
(	O
74	O
%	O
)	O
and	O
DPD	S-geneY
in	O
14	O
/	O
19	O
cancers	O
(	O
74	O
%	O
)	O
.	O

In	O
six	O
tumors	O
,	O
TP	S-geneY
was	O
more	O
intense	O
that	O
DPD	S-geneY
,	O
suggesting	O
capecitabine	O
sensitivity	O
.	O

Only	O
five	O
tumors	O
failed	O
to	O
express	O
TP	S-geneY
but	O
four	O
of	O
these	O
expressed	O
DPD	S-geneY
,	O
suggesting	O
capecitabine	S-chem
resistance	O
.	O

Overall	O
,	O
6	O
/	O
19	O
tumors	O
(	O
32	O
%	O
of	O
the	O
total	O
)	O
had	O
a	O
favorable	O
expression	O
profile	O
,	O
and	O
all	O
of	O
them	O
were	O
papillary	O
cancers	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
majority	O
of	O
differentiated	O
thyroid	O
cancers	O
(	O
74	O
%	O
)	O
express	O
TP	S-geneY
and	O
low	O
levels	O
of	O
TS	S-geneY
(	O
63	O
%	O
undetectable	O
)	O
.	O

The	O
results	O
support	O
the	O
hypothesis	O
that	O
capecitabine	S-chem
is	O
activated	O
in	O
the	O
majority	O
of	O
differentiated	O
thyroid	O
cancers	O
and	O
that	O
32	O
%	O
have	O
favorable	O
expression	O
of	O
all	O
three	O
enzymes	O
(	O
TP	S-geneY
,	O
TS	S-geneY
,	O
and	O
DPD	S-geneY
)	O
.	O

Effect	O
of	O
N	B-chem
-	I-chem
acetyl	I-chem
cysteine	E-chem
(	O
NAC	S-chem
)	O
,	O
an	O
organosulfur	S-chem
compound	O
from	O
Allium	O
plants	O
,	O
on	O
experimentally	O
induced	O
hepatic	O
prefibrogenic	O
events	O
in	O
wistar	O
rat	O
.	O

Aim	O
of	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
NAC	S-chem
on	O
experimental	O
chronic	O
hepatotoxicity	O
models	O
induced	O
by	O
carbon	B-chem
tetrachloride	E-chem
(	O
CCl4	S-chem
)	O
and	O
thioacetamide	S-chem
(	O
TAA	S-chem
)	O
.	O

CCl4	O
toxicity	O
was	O
induced	O
by	O
administering	O
200μl	O
CCl4	S-chem
(	O
diluted	O
2	O
:	O
3	O
in	O
coconut	O
oil	O
)	O
/	O
100g	O
body	O
weight	O
,	O
p.o	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

TAA	S-chem
toxicity	O
was	O
induced	O
by	O
administering	O
150mg	O
/	O
kg	O
b.	O
wt	O
.	O
of	O
TAA	S-chem
i.p	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

NAC	S-chem
treatment	O
was	O
started	O
along	O
with	O
toxicants	O
(	O
CCl4	S-chem
and	O
TAA	S-chem
)	O
for	O
8	O
weeks	O
and	O
continued	O
for	O
further	O
4	O
weeks	O
.	O

Self	O
reversal	O
group	O
was	O
kept	O
without	O
any	O
treatment	O
for	O
4	O
weeks	O
after	O
completion	O
of	O
toxicant	O
treatments	O
.	O

Alanine	B-geneN
aminotransferase	E-geneN
(	O
ALT	S-geneN
)	O
,	O
Aspartate	B-geneN
aminotransferase	E-geneN
(	O
AST	S-geneN
)	O
,	O
Alkaline	B-geneN
phosphatase	E-geneN
(	O
ALP	S-geneN
)	O
,	O
Bilirubin	S-chem
were	O
measured	O
in	O
serum	O
.	O

Hydroxyproline	S-chem
(	O
HP	O
)	O
,	O
lipid	O
peroxidation	O
(	O
LPO	O
)	O
,	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
,	O
Glutathione	B-geneN
peroxidase	E-geneN
(	O
GPx	S-geneN
)	O
and	O
Glutathione	S-chem
(	O
GSH	S-chem
)	O
were	O
determined	O
in	O
liver	O
samples	O
by	O
colorimetric	O
methods	O
.	O

Cytochrome	B-geneY-C9-2
P450	I-geneY-C9-2
2E1	E-geneY-C9-2
(	O
CYP	B-geneY-C9-2
450	I-geneY-C9-2
2E1	E-geneY-C9-2
)	O
,	O
activity	O
was	O
determined	O
as	O
hydroxylation	O
of	O
aniline	S-chem-C9-1
in	O
liver	O
microsomes	O
.	O

General	O
examination	O
and	O
histological	O
analysis	O
were	O
also	O
performed	O
.	O

Serum	O
markers	O
of	O
liver	O
damage	O
(	O
AST	S-geneN-MU-2
,	O
ALT	S-geneN-MU-2
,	O
ALP	S-geneN-MU-2
and	O
Bilirubin	S-chem
)	O
were	O
increased	O
by	O
CCl4	S-chem-C3-1
and	O
TAA	S-chem-C3-1
intoxication	O
(	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
co	O
-	O
treatment	O
with	O
NAC	S-chem-C4-1
reversed	O
such	O
changes	O
(	O
p	O
<	O
0.001	O
)	O
.	O

HP	O
was	O
enhanced	O
in	O
toxicant	O
groups	O
(	O
p	O
<	O
0.001	O
in	O
CCl4	S-chem
and	O
TAA	S-chem
)	O
,	O
but	O
inhibited	O
by	O
NAC	S-chem
(	O
p	O
<	O
0.001	O
)	O
.	O

LPO	O
was	O
increased	O
while	O
as	O
GSH	S-chem
,	O
CAT	S-geneY-C3-2
and	O
GPx	S-geneN-C3-2
decreased	O
by	O
the	O
administration	O
of	O
CCl4	O
and	O
TAA	O
(	O
p	O
<	O
0.001	O
)	O
;	O
co	O
-	O
administration	O
of	O
NAC	S-chem-C3-1
restored	O
these	O
liver	O
markers	O
to	O
normal	O
levels	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Biochemical	O
determinations	O
were	O
corroborated	O
by	O
general	O
and	O
histological	O
findings	O
.	O

Keeping	O
in	O
view	O
the	O
biochemical	O
and	O
histopathological	O
studies	O
,	O
it	O
was	O
concluded	O
that	O
CCl4	S-chem
and	O
TAA	S-chem
are	O
strong	O
hepatotoxic	O
agents	O
that	O
produce	O
liver	O
fibrosis	O
with	O
close	O
proximity	O
to	O
human	O
etiology	O
(	O
micronodular	O
cirrhosis	O
)	O
and	O
NAC	S-chem
has	O
a	O
significant	O
protective	O
activity	O
against	O
CCl4	S-chem
and	O
TAA	S-chem
.	O

NAC	S-chem
has	O
also	O
been	O
validated	O
as	O
a	O
model	O
against	O
oxidative	O
burden	O
in	O
chronic	O
liver	O
pathology	O
.	O

Immunotherapy	O
for	O
De	O
Novo	O
renal	O
transplantation	O
:	O
what	O
's	O
in	O
the	O
pipeline	O
?	O

Immunosuppressive	O
drugs	O
have	O
been	O
traditionally	O
developed	O
to	O
prevent	O
acute	O
rejection	O
and	O
to	O
improve	O
short	O
-	O
term	O
kidney	O
transplant	O
outcomes	O
.	O

There	O
is	O
still	O
a	O
medical	O
need	O
to	O
improve	O
outcomes	O
among	O
subgroups	O
of	O
patients	O
at	O
higher	O
risk	O
for	O
graft	O
loss	O
and	O
to	O
reduce	O
cardiovascular	O
,	O
infectious	O
and	O
malignancy	O
-	O
associated	O
morbidity	O
and	O
mortality	O
,	O
and	O
improve	O
long	O
-	O
term	O
adherence	O
.	O

Several	O
new	O
immunosuppressive	O
agents	O
and	O
formulations	O
are	O
undergoing	O
clinical	O
investigation	O
and	O
are	O
discussed	O
in	O
this	O
review.A	O
modified	O
release	O
tacrolimus	S-chem
formulation	O
(	O
MR4	O
)	O
for	O
once	O
-	O
daily	O
administration	O
is	O
undergoing	O
phase	O
III	O
trials	O
.	O

It	O
has	O
been	O
developed	O
to	O
be	O
administered	O
de	O
novo	O
or	O
for	O
maintenance	O
using	O
the	O
same	O
therapeutic	O
target	O
tacrolimus	S-chem
trough	O
concentrations	O
as	O
for	O
the	O
original	O
formulation	O
.	O

Belatacept	O
(	O
LEA29Y	O
)	O
,	O
a	O
second	O
generation	O
cytotoxic	B-geneY
-	I-geneY
T	I-geneY
-	I-geneY
lymphocyte	I-geneY
-	I-geneY
associated	I-geneY
antigen	E-geneY
immunoglobulin	S-geneN
(	O
CTLA4	S-geneY
-	O
Ig	S-geneN
)	O
,	O
blocks	O
the	O
interaction	O
between	O
CD80	B-geneN
/	I-geneN
86	E-geneN
and	O
CD28	S-geneY
costimulatory	O
pathways	O
.	O

In	O
phase	O
II	O
trials	O
,	O
belatacept	O
was	O
as	O
effective	O
as	O
ciclosporin	S-chem
(	O
cyclosporine	S-chem
)	O
when	O
administered	O
in	O
combination	O
with	O
basiliximab	O
,	O
mycophenolate	B-chem
mofetil	E-chem
(	O
MMF	S-chem
)	O
and	O
corticosteroids	O
.	O

Currently	O
,	O
belatacept	O
is	O
undergoing	O
phase	O
III	O
trials	O
including	O
one	O
study	O
in	O
recipients	O
of	O
organs	O
from	O
expanded	O
criteria	O
donors	O
.	O

Inhibitors	O
of	O
the	O
Janus	B-geneY
protein	I-geneY
tyrosine	I-geneY
kinase	I-geneY
(	I-geneY
JAK	I-geneY
)	I-geneY
-	I-geneY
3	E-geneY
show	O
some	O
selectivity	O
for	O
cells	O
of	O
the	O
lymphoid	O
lineage	O
and	O
have	O
been	O
shown	O
to	O
be	O
effective	O
in	O
late	O
preclinical	O
transplant	O
models	O
.	O

The	O
most	O
frequent	O
adverse	O
effects	O
have	O
been	O
related	O
to	O
nonspecific	O
binding	O
to	O
JAK2	S-geneY
kinases	S-geneN
.	O

CP	B-chem-C4-1
-	I-chem-C4-1
690550	E-chem-C4-1
,	O
a	O
JAK3	S-geneY-C4-2
inhibitor	O
is	O
currently	O
in	O
phase	O
II	O
clinical	O
trials.FK778	O
,	O
is	O
a	O
synthetic	O
malononitrilamide	S-chem
that	O
targets	O
the	O
critical	O
enzyme	O
of	O
the	O
de	O
novo	O
pyrimidine	S-chem
synthesis	O
,	O
dihydroorotic	B-geneY
acid	I-geneY
dehydrogenase	E-geneY
,	O
and	O
receptor	B-geneN
-	I-geneN
associated	I-geneN
tyrosine	I-geneN
kinases	E-geneN
has	O
completed	O
phase	O
II	O
trials	O
.	O

FK778	S-chem
also	O
shows	O
antiviral	O
activities	O
that	O
have	O
been	O
tested	O
in	O
patients	O
with	O
polyomavirus	O
nephropathy	O
.	O

Fingolimod	S-chem
(	O
FTY720	S-chem
)	O
,	O
a	O
synthetic	O
sphingosine	B-geneN
phosphate	I-geneN
receptor	E-geneN
modulator	O
that	O
reduces	O
the	O
recirculation	O
of	O
lymphocytes	O
to	O
blood	O
and	O
peripheral	O
tissues	O
including	O
inflammatory	O
lesions	O
and	O
graft	O
sites	O
is	O
undergoing	O
phase	O
III	O
trials	O
.	O

Although	O
the	O
efficacy	O
of	O
fingolimod	S-chem
is	O
similar	O
to	O
MMF	S-chem
in	O
patients	O
receiving	O
full	O
doses	O
of	O
ciclosporin	S-chem
,	O
safety	O
issues	O
such	O
as	O
a	O
negative	O
chronotropic	O
effect	O
,	O
macular	O
oedema	O
,	O
pulmonary	O
adverse	O
reactions	O
and	O
graft	O
function	O
resulted	O
in	O
premature	O
discontinuation	O
of	O
the	O
development	O
programme	O
for	O
kidney	O
transplantation	O
.	O

Because	O
there	O
was	O
no	O
clear	O
clinical	O
benefit	O
over	O
treatment	O
options	O
,	O
the	O
clinical	O
development	O
programme	O
of	O
FK778	S-chem
was	O
discontinued.Finally	O
,	O
a	O
new	O
evolving	O
strategy	O
with	O
powerful	O
induction	O
-	O
induced	O
prolonged	O
T	O
-	O
cell	O
depletion	O
followed	O
by	O
low	O
-	O
dose	O
immunosuppressive	O
monotherapy	O
is	O
showing	O
promising	O
results	O
.	O

Success	O
of	O
pyridostigmine	S-chem
,	O
physostigmine	S-chem
,	O
eptastigmine	S-chem
and	O
phosphotriesterase	S-geneN
treatments	O
in	O
acute	O
sarin	S-chem
intoxication	O
.	O

The	O
acute	O
toxicity	O
of	O
organophosphorus	S-chem-C4-1
(	O
OP	O
)	O
compounds	O
in	O
mammals	O
is	O
due	O
to	O
their	O
irreversible	O
inhibition	O
of	O
acetylcholinesterase	S-geneN-MU-2
(	O
AChE	S-geneN-MU-2
)	O
in	O
the	O
nervous	O
system	O
,	O
which	O
leads	O
to	O
increased	O
synaptic	O
acetylcholine	S-chem-C9-1
levels	O
.	O

The	O
protective	O
actions	O
of	O
intravenously	O
(	O
i.v	O
.	O
)	O
administered	O
pyridostigmine	S-chem
,	O
physostigmine	S-chem
,	O
eptastigmine	S-chem
,	O
and	O
an	O
organophosphate	B-geneN
hydrolase	E-geneN
,	O
phosphotriesterase	S-geneN
,	O
in	O
acute	O
sarin	S-chem
intoxication	O
were	O
studied	O
in	O
mice	O
.	O

The	O
acute	O
intragastric	O
(	O
i.g	O
.	O
)	O
toxicity	O
(	O
LD50	O
)	O
of	O
sarin	S-chem
with	O
and	O
without	O
the	O
pretreatments	O
was	O
tested	O
by	O
the	O
up	O
-	O
and	O
-	O
down	O
method	O
.	O

The	O
mice	O
received	O
pyridostigmine	S-chem
(	O
0.06	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
,	O
physostigmine	S-chem
(	O
0.09	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
,	O
the	O
physostigmine	S-chem
derivative	O
eptastigmine	S-chem
(	O
0.90	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
or	O
phosphotriesterase	S-geneN
(	O
104	O
U	O
/	O
g	O
,	O
10.7	O
microg	O
/	O
g	O
body	O
weight	O
)	O
10	O
min	O
prior	O
to	O
the	O
i.g	O
.	O
administration	O
of	O
sarin	S-chem
.	O

Physostigmine	S-chem
was	O
also	O
administered	O
with	O
phosphotriesterase	S-geneN
.	O

Phosphotriesterase	S-geneN
was	O
the	O
most	O
effective	O
antidote	O
in	O
sarin	S-chem
intoxication	O
.	O

The	O
LD50	O
value	O
for	O
sarin	S-chem
increased	O
3.4	O
-	O
fold	O
in	O
mice	O
receiving	O
phosphotriesterase	S-geneN
.	O

Physostigmine	S-chem
was	O
the	O
most	O
effective	O
carbamate	S-chem
in	O
sarin	S-chem
exposure	O
.	O

The	O
protective	O
ratios	O
of	O
physostigmine	S-chem
and	O
pyridostigmine	S-chem
were	O
1.5	O
-	O
and	O
1.2	O
-	O
1.3	O
-	O
fold	O
,	O
respectively	O
.	O

Eptastigmine	S-chem
did	O
not	O
give	O
any	O
protection	O
against	O
sarin	S-chem
toxicity	O
.	O

Both	O
the	O
phosphotriesterase	S-geneN
and	O
physostigmine	S-chem
treatments	O
protected	O
the	O
brain	O
AChE	S-geneY
activities	O
measured	O
24	O
h	O
after	O
sarin	S-chem
exposure	O
.	O

In	O
phosphotriesterase	S-geneN
and	O
physostigmine	S-chem
-	O
treated	O
mice	O
,	O
a	O
4	O
-	O
and	O
2	O
-	O
fold	O
higher	O
sarin	S-chem-C4-1
dose	O
,	O
respectively	O
,	O
was	O
needed	O
to	O
cause	O
a	O
50	O
%	O
inhibition	O
of	O
brain	O
AChE	S-geneY-C4-2
activity	O
.	O

Moreover	O
,	O
the	O
combination	O
of	O
phosphotriesterase	S-geneN
-	O
physostigmine	S-chem
increased	O
the	O
LD50	O
value	O
for	O
sarin	S-chem
4.3	O
-	O
fold	O
.	O

The	O
animals	O
pretreated	O
with	O
phosphotriesterase	S-geneN
-	O
ephysostigmine	S-chem
tolerated	O
four	O
times	O
the	O
lethal	O
dose	O
in	O
control	O
animals	O
,	O
furthermore	O
their	O
survival	O
time	O
was	O
2	O
-	O
3	O
h	O
in	O
comparison	O
to	O
20	O
min	O
in	O
controls	O
.	O

In	O
conclusion	O
,	O
phosphotriesterase	S-geneN
and	O
physostigmine	S-chem
were	O
the	O
most	O
effective	O
treatments	O
against	O
sarin	S-chem
intoxication	O
.	O

However	O
,	O
eptastigmine	S-chem
did	O
not	O
provide	O
any	O
protection	O
against	O
sarin	S-chem
toxicity	O
.	O

Felbamate	S-chem-C4-1
block	O
of	O
recombinant	O
N	B-geneN-C4-2
-	I-geneN-C4-2
methyl	I-geneN-C4-2
-	I-geneN-C4-2
D	I-geneN-C4-2
-	I-geneN-C4-2
aspartate	I-geneN-C4-2
receptors	E-geneN-C4-2
:	O
selectivity	O
for	O
the	O
NR2B	S-geneY-C4-2
subunit	O
.	O

The	O
anticonvulsant	O
felbamate	S-chem-MU-1
blocks	O
N	B-geneN-C4-2
-	I-geneN-C4-2
methyl	I-geneN-C4-2
-	I-geneN-C4-2
D	I-geneN-C4-2
-	I-geneN-C4-2
asparate	I-geneN-C4-2
(	I-geneN-C4-2
NMDA	I-geneN-C4-2
)	I-geneN-C4-2
receptors	E-geneN-C4-2
but	O
fails	O
to	O
exhibit	O
the	O
neurobehavioral	O
toxicity	O
characteristic	O
of	O
other	O
NMDA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonists	O
.	O

To	O
investigate	O
the	O
possibility	O
that	O
felbamate	O
's	O
favorable	O
toxicity	O
profile	O
could	O
be	O
related	O
to	O
NMDA	B-geneN
receptor	E-geneN
subtype	O
selectivity	O
,	O
we	O
examined	O
the	O
specificity	O
of	O
felbamate	S-chem-C4-1
block	O
of	O
recombinant	O
NMDA	B-geneN-C4-2
receptors	E-geneN-C4-2
composed	O
of	O
the	O
NR1a	S-geneY-C4-2
subunit	O
and	O
various	O
NR2	S-geneN-C4-2
subunits	O
.	O

Felbamate	S-chem-C4-1
produced	O
a	O
rapid	O
,	O
concentration	O
-	O
dependent	O
block	O
of	O
currents	O
evoked	O
by	O
50	O
microM	O
NMDA	S-chem
and	O
10	O
microM	O
glycine	S-chem
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
expressing	O
the	O
rat	B-geneY-C4-2
NR1a	E-geneY-C4-2
subunit	O
,	O
and	O
either	O
the	O
NR2A	S-geneY-C4-2
,	O
NR2B	S-geneY-C4-2
or	O
NR2C	S-geneY-C4-2
subunits	O
;	O
the	O
IC50	O
values	O
for	O
block	O
were	O
2.6	O
,	O
0.52	O
and	O
2.4	O
mM	O
,	O
respectively	O
(	O
holding	O
potential	O
,	O
-	O
60	O
mV	O
)	O
.	O

The	O
Hill	O
coefficient	O
values	O
were	O
<	O
1	O
and	O
,	O
in	O
kinetic	O
analyses	O
,	O
onset	O
and	O
recovery	O
from	O
block	O
were	O
well	O
fit	O
by	O
double	O
exponential	O
functions	O
,	O
indicating	O
binding	O
to	O
more	O
than	O
one	O
blocking	O
site	O
on	O
the	O
NMDA	B-geneN
receptor	E-geneN
channel	O
complex	O
.	O

The	O
higher	O
affinity	O
of	O
felbamate	S-chem-C4-1
block	O
of	O
NMDA	B-geneN-C4-2
receptors	E-geneN-C4-2
containing	O
the	O
NR2B	S-geneY-C4-2
subunit	O
could	O
be	O
accounted	O
for	O
by	O
more	O
rapid	O
association	O
and	O
slower	O
dissociation	O
from	O
these	O
sites	O
.	O

We	O
conclude	O
that	O
felbamate	S-chem-C4-1
exhibits	O
modest	O
selectivity	O
for	O
NMDA	B-geneN-C4-2
receptors	E-geneN-C4-2
composed	O
of	O
NR1a	S-geneY-C4-2
/	O
NR2B	S-geneY-C4-2
subunits	O
.	O

This	O
selectivity	O
could	O
,	O
in	O
part	O
,	O
account	O
for	O
the	O
more	O
favorable	O
clinical	O
profile	O
of	O
felbamate	S-chem-C6-1
in	O
comparison	O
with	O
NMDA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonists	O
that	O
do	O
not	O
show	O
subunit	O
selectivity	O
.	O

Effects	O
of	O
serine	B-geneN
/	I-geneN
threonine	I-geneN
protein	I-geneN
phosphatase	E-geneN
inhibitors	O
on	O
morphine	S-chem
-	O
induced	O
antinociception	O
in	O
the	O
tail	O
flick	O
test	O
in	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
serine	B-geneN
/	I-geneN
threonine	I-geneN
protein	I-geneN
phosphatase	E-geneN
(	O
PP	S-geneN
)	O
inhibitors	O
on	O
morphine	S-chem
-	O
induced	O
antinociception	O
in	O
the	O
tail	O
flick	O
test	O
in	O
mice	O
,	O
and	O
on	O
[	B-chem
3H	I-chem
]	I-chem
naloxone	E-chem
binding	O
to	O
the	O
forebrain	O
crude	O
synaptosome	O
fraction	O
.	O

Neither	O
okadaic	B-chem
acid	E-chem
nor	O
cantharidin	S-chem
(	O
1	O
-	O
10000	O
nM	O
)	O
displaced	O
[	B-chem
3H	I-chem
]	I-chem
naloxone	E-chem
from	O
its	O
specific	O
binding	O
sites	O
,	O
which	O
indicates	O
that	O
they	O
do	O
not	O
interact	O
at	O
the	O
opioid	B-geneN
receptor	E-geneN
level	O
.	O

The	O
i.c.v	O
.	O
administration	O
of	O
very	O
low	O
doses	O
of	O
okadaic	B-chem-C4-1
acid	E-chem-C4-1
(	O
0.001	O
-	O
1	O
pg	O
/	O
mouse	O
)	O
and	O
cantharidin	S-chem-C4-1
(	O
0.001	O
-	O
1	O
ng	O
/	O
mouse	O
)	O
,	O
which	O
inhibit	O
PP2A	S-geneN-C4-2
,	O
produced	O
a	O
dose	O
-	O
dependent	O
antagonism	O
of	O
the	O
antinociception	O
induced	O
by	O
morphine	S-chem
(	O
s.c.	O
)	O
.	O

However	O
,	O
L	B-chem
-	I-chem
nor	I-chem
-	I-chem
okadaone	E-chem
(	O
0.001	O
pg	O
/	O
mouse	O
-	O
1	O
ng	O
/	O
mouse	O
,	O
i.c.v	O
.	O
)	O
,	O
an	O
analogue	O
of	O
okadaic	B-chem
acid	E-chem
lacking	O
activity	O
against	O
protein	B-geneN
phosphatases	E-geneN
,	O
did	O
not	O
affect	O
the	O
antinociceptive	O
effect	O
of	O
morphine	S-chem
.	O

On	O
the	O
other	O
hand	O
,	O
high	O
doses	O
of	O
okadaic	B-chem-C4-1
acid	E-chem-C4-1
(	O
10	O
ng	O
/	O
mouse	O
,	O
i.c.v	O
.	O
)	O
and	O
cantharidin	S-chem-C4-1
(	O
1	O
microg	O
/	O
mouse	O
,	O
i.c.v	O
.	O
)	O
,	O
which	O
also	O
block	O
PP1	S-geneN-C4-2
,	O
and	O
calyculin	B-chem-C4-1
-	I-chem-C4-1
A	E-chem-C4-1
(	O
0.1	O
fg	O
/	O
mouse	O
-	O
1	O
ng	O
/	O
mouse	O
,	O
i.c.v	O
.	O
)	O
,	O
which	O
inhibits	O
equally	O
both	O
PP1	S-geneN-C4-2
and	O
PP2A	S-geneN-C4-2
,	O
did	O
not	O
modify	O
the	O
morphine	S-chem
-	O
induced	O
antinociception	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
type	B-geneN
2A	I-geneN
serine	I-geneN
/	I-geneN
threonine	I-geneN
protein	I-geneN
phosphatases	E-geneN
may	O
play	O
a	O
role	O
in	O
the	O
antinociceptive	O
effect	O
of	O
morphine	S-chem
,	O
and	O
that	O
PP1	S-geneN
might	O
counterbalace	O
this	O
activity	O
.	O

Functional	O
characterization	O
of	O
alpha	B-geneN
-	I-geneN
adrenoceptors	E-geneN
mediating	O
pupillary	O
dilation	O
in	O
rats	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
the	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
,	O
but	O
not	O
the	O
alpha	B-geneY
(	I-geneY
1D	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
,	O
mediates	O
pupillary	O
dilation	O
elicited	O
by	O
sympathetic	O
nerve	O
stimulation	O
in	O
rats	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
further	O
characterize	O
the	O
alpha	B-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
mediating	O
pupillary	O
dilation	O
in	O
response	O
to	O
both	O
neural	O
and	O
agonist	O
activation	O
.	O

Pupillary	O
dilator	O
response	O
curves	O
were	O
generated	O
by	O
intravenous	O
injection	O
of	O
norepinephrine	S-chem
in	O
pentobarbital	S-chem
-	O
anesthetized	O
rats	O
.	O

Involvement	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
was	O
established	O
as	O
mydriatic	O
responses	O
were	O
inhibited	O
by	O
systemic	O
administration	O
of	O
nonselective	O
alpha	B-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonists	O
,	O
phentolamine	S-chem-C6-1
(	O
0.3	O
-	O
3	O
mg	O
/	O
kg	O
)	O
and	O
phenoxybenzamine	S-chem-C6-1
(	O
0.03	O
-	O
0.3	O
mg	O
/	O
kg	O
)	O
,	O
as	O
well	O
as	O
by	O
the	O
selective	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
1	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
,	O
prazosin	S-chem-C6-1
(	O
0.3	O
mg	O
/	O
kg	O
)	O
.	O

The	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
2	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
,	O
rauwolscine	S-chem-C6-1
(	O
0.5	O
mg	O
/	O
kg	O
)	O
,	O
was	O
without	O
antagonistic	O
effects	O
.	O
alpha	B-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
Adrenoceptor	E-geneY-C6-2
selective	O
antagonists	O
,	O
2	B-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
[	I-chem-C6-1
2,6	I-chem-C6-1
-	I-chem-C6-1
dimethoxyphenoxyethyl	I-chem-C6-1
]	I-chem-C6-1
aminomethyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
1,4	I-chem-C6-1
-	I-chem-C6-1
benzodioxane	E-chem-C6-1
(	O
WB	B-chem-C6-1
-	I-chem-C6-1
4101	E-chem-C6-1
;	O
0.1	O
-	O
1	O
mg	O
/	O
kg	O
)	O
and	O
5	B-chem-C6-1
-	I-chem-C6-1
methylurapidil	E-chem-C6-1
(	O
0.1	O
-	O
1	O
mg	O
/	O
kg	O
)	O
,	O
the	O
alpha	B-geneY-C6-2
(	I-geneY-C6-2
1B	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
selective	O
antagonist	O
,	O
4	B-chem-C6-1
-	I-chem-C6-1
amino	I-chem-C6-1
-	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
1	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
benzyloxycarbonyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
2	I-chem-C6-1
(	I-chem-C6-1
S	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
[	I-chem-C6-1
(	I-chem-C6-1
1,1	I-chem-C6-1
-	I-chem-C6-1
dimethylethyl	I-chem-C6-1
)	I-chem-C6-1
amino	I-chem-C6-1
]	I-chem-C6-1
carbonyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
piperazinyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
6,7	I-chem-C6-1
-	I-chem-C6-1
dimethoxyquinazoline	E-chem-C6-1
(	O
L	B-chem-C6-1
-	I-chem-C6-1
765314	E-chem-C6-1
;	O
0.3	O
-	O
1	O
mg	O
/	O
kg	O
)	O
,	O
as	O
well	O
as	O
the	O
alpha	B-geneY-C6-2
(	I-geneY-C6-2
1D	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
selective	O
antagonist	O
,	O
8	B-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
methoxyphenyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
1	I-chem-C6-1
-	I-chem-C6-1
piperazinyl	I-chem-C6-1
]	I-chem-C6-1
ethyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
8	I-chem-C6-1
-	I-chem-C6-1
azaspiro	I-chem-C6-1
[	I-chem-C6-1
4.5	I-chem-C6-1
]	I-chem-C6-1
decane	I-chem-C6-1
-	I-chem-C6-1
7,9	I-chem-C6-1
-	I-chem-C6-1
dione	E-chem-C6-1
(	O
BMY	B-chem-C6-1
-	I-chem-C6-1
7378	E-chem-C6-1
;	O
1	O
mg	O
/	O
kg	O
)	O
,	O
were	O
used	O
to	O
delineate	O
the	O
adrenoceptor	S-geneN
subtypes	O
involved	O
.	O

Mydriatic	O
responses	O
to	O
norepinephrine	S-chem
were	O
significantly	O
antagonized	O
by	O
intravenous	O
administration	O
of	O
both	O
WB	B-chem
-	I-chem
4101	E-chem
and	O
5	B-chem
-	I-chem
methylurapidil	E-chem
,	O
but	O
neither	O
by	O
L	B-chem
-	I-chem
765314	E-chem
nor	O
by	O
BMY	B-chem
-	I-chem
7378	E-chem
.	O

L	B-chem
-	I-chem
765314	E-chem
(	O
0.3	O
-	O
3	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
was	O
also	O
ineffective	O
in	O
inhibiting	O
the	O
mydriasis	O
evoked	O
by	O
cervical	O
sympathetic	O
nerve	O
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
do	O
not	O
mediate	O
sympathetic	O
mydriasis	O
in	O
rats	O
,	O
and	O
that	O
the	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
is	O
the	O
exclusive	O
subtype	O
mediating	O
mydriatic	O
responses	O
in	O
this	O
species	O
.	O

Rapid	O
glucocorticoid	B-geneY
receptor	E-geneY
-	O
mediated	O
inhibition	O
of	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
ultradian	O
activity	O
in	O
healthy	O
males	O
.	O

A	O
complex	O
dynamic	O
ultradian	O
rhythm	O
underlies	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
circadian	O
rhythm	O
.	O

We	O
have	O
investigated	O
in	O
normal	O
human	O
male	O
subjects	O
the	O
importance	O
,	O
site	O
of	O
action	O
,	O
and	O
receptor	O
-	O
mediated	O
processes	O
involved	O
in	O
rapid	O
basal	O
corticosteroid	S-chem
feedback	O
and	O
its	O
interaction	O
with	O
corticotrophin	B-geneY
releasing	I-geneY
hormone	E-geneY
(	O
CRH	S-geneY
)	O
drive	O
.	O

Pro	B-geneY
-	I-geneY
opiomelanocortin	E-geneY
(	O
POMC	S-geneY
)	O
,	O
ACTH	O
,	O
and	O
cortisol	O
were	O
measured	O
every	O
10	O
min	O
from	O
healthy	O
males	O
during	O
the	O
awakening	O
period	O
or	O
late	O
afternoon	O
using	O
an	O
automated	O
blood	O
sampling	O
system	O
.	O

Mathematical	O
modeling	O
into	O
discrete	O
pulses	O
of	O
activity	O
revealed	O
that	O
intravenous	O
infusion	O
of	O
the	O
synthetic	O
mixed	O
glucocorticoid	O
/	O
mineralocorticoid	O
agonist	O
prednisolone	S-chem
produced	O
rapid	O
inhibition	O
of	O
ACTH	O
and	O
cortisol	S-chem
pulsatility	O
within	O
30	O
min	O
in	O
the	O
morning	O
and	O
afternoon	O
.	O

Any	O
pulse	O
that	O
had	O
commenced	O
at	O
the	O
time	O
of	O
injection	O
was	O
unaffected	O
,	O
and	O
subsequent	O
pulsatility	O
was	O
inhibited	O
.	O

Prednisolone	S-chem-C4-1
also	O
inhibited	O
ACTH	O
and	O
cortisol	S-chem-C9-1
secretion	O
in	O
response	O
to	O
exogenous	O
CRH	S-geneY-MU-2
stimulation	O
,	O
inferring	O
rapid	O
feedback	O
inhibition	O
at	O
the	O
anterior	O
pituitary	O
.	O

Circulating	O
POMC	S-geneY
peptide	O
concentrations	O
were	O
unaffected	O
,	O
suggesting	O
that	O
the	O
rapid	O
corticosteroid	S-chem
inhibitory	O
effect	O
specifically	O
targeted	O
ACTH	O
secretion	O
from	O
pituitary	O
corticotrophs	O
.	O

Prednisolone	S-chem
fast	O
feedback	O
was	O
only	O
reduced	O
by	O
glucocorticoid	B-geneY
receptor	E-geneY
antagonist	O
pretreatment	O
and	O
not	O
by	O
mineralocorticoid	B-geneY
receptor	E-geneY
antagonism	O
,	O
suggesting	O
a	O
glucocorticoid	B-geneY
receptor	E-geneY
-	O
mediated	O
pathway	O
.	O

The	O
intravenous	O
prednisolone	S-chem
suppression	O
test	O
provides	O
a	O
powerful	O
new	O
tool	O
to	O
investigate	O
HPA	O
abnormalities	O
underlying	O
metabolic	O
and	O
psychiatric	O
disease	O
states	O
.	O

The	O
role	O
of	O
rasagiline	S-chem
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
disorder	O
,	O
affecting	O
1	O
%	O
to	O
2	O
%	O
of	O
people	O
older	O
than	O
60	O
years	O
.	O

Treatment	O
of	O
PD	O
consists	O
of	O
symptomatic	O
therapies	O
while	O
neuroprotective	O
strategies	O
have	O
remained	O
elusive	O
.	O

Rasagiline	S-chem-C4-1
is	O
a	O
novel	O
,	O
potent	O
,	O
and	O
irreversible	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
type	I-geneY-C4-2
B	E-geneY-C4-2
(	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
)	O
inhibitor	O
which	O
has	O
been	O
approved	O
for	O
treatment	O
of	O
PD	O
.	O

Rasagiline	S-chem-C4-1
inhibits	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
more	O
potently	O
than	O
selegiline	O
and	O
has	O
the	O
advantage	O
of	O
once	O
-	O
daily	O
dosing	O
.	O

In	O
several	O
large	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trials	O
,	O
rasagiline	S-chem
has	O
demonstrated	O
efficacy	O
as	O
monotherapy	O
in	O
early	O
PD	O
and	O
as	O
adjunctive	O
therapy	O
in	O
advanced	O
PD	O
.	O

In	O
addition	O
,	O
rasagiline	S-chem
has	O
been	O
shown	O
to	O
have	O
neuroprotective	O
effects	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

The	O
recently	O
completed	O
delayed	O
-	O
start	O
ADAGIO	O
(	O
Attenuation	O
of	O
Disease	O
Progression	O
with	O
Azilect	O
Given	O
Once	O
-	O
daily	O
)	O
trial	O
suggests	O
a	O
potential	O
disease	O
-	O
modifying	O
effect	O
for	O
rasagiline	S-chem
1	O
mg	O
/	O
day	O
,	O
though	O
the	O
clinical	O
import	O
of	O
this	O
finding	O
has	O
yet	O
to	O
be	O
established	O
.	O

Synthesis	O
of	O
novel	O
1,3,4	B-chem
-	I-chem
trisubstituted	I-chem
pyrazoles	E-chem
as	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
agents	O
.	O

Some	O
novel	O
1,3,4	B-chem
-	I-chem
trisubstituted	I-chem
pyrazoles	E-chem
were	O
synthesized	O
and	O
screened	O
for	O
their	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activities	O
as	O
well	O
as	O
their	O
ulcerogenic	O
liability	O
.	O

They	O
showed	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activities	O
with	O
better	O
GIT	O
tolerance	O
than	O
the	O
standard	O
drug	O
phenylbutazone	S-chem
.	O

In	O
addition	O
,	O
IC50	O
values	O
for	O
5e	O
and	O
8e	O
were	O
recorded	O
.	O

Compound	O
5e	O
was	O
found	O
to	O
be	O
the	O
most	O
active	O
one	O
as	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
agent	O
.	O

On	O
the	O
other	O
hand	O
,	O
COX	B-geneY
-	I-geneY
1	E-geneY
/	O
COX	B-geneY
-	I-geneY
2	E-geneY
isozyme	O
selectivity	O
was	O
also	O
done	O
which	O
showed	O
equal	O
inhibition	O
to	O
both	O
isoforms	O
.	O

Upregulation	O
of	O
drug	O
transporter	O
expression	O
by	O
osteopontin	S-geneY
in	O
prostate	O
cancer	O
cells	O
.	O

Multidrug	O
resistance	O
is	O
a	O
major	O
cause	O
of	O
chemotherapy	O
failure	O
.	O

Recent	O
studies	O
indicate	O
that	O
drug	O
resistance	O
can	O
be	O
rapidly	O
induced	O
by	O
some	O
soluble	O
factors	O
,	O
such	O
as	O
cytokines	S-geneN
,	O
chemokines	S-geneN
,	O
growth	O
factors	O
,	O
and	O
cell	B-geneN
adhesion	I-geneN
factors	E-geneN
in	O
the	O
tumor	O
microenvironment	O
.	O

Osteopontin	S-geneY
(	O
OPN	S-geneY
)	O
,	O
an	O
extracellular	O
matrix	O
protein	O
,	O
has	O
a	O
functional	O
arginine	B-geneN
-	I-geneN
glycine	I-geneN
-	I-geneN
aspartic	I-geneN
acid	I-geneN
(	I-geneN
RGD	I-geneN
)	I-geneN
domain	E-geneN
for	O
binding	O
to	O
integrin	S-geneN
.	O

Here	O
we	O
found	O
OPN	S-geneY
expression	O
to	O
be	O
upregulated	O
by	O
hypoxic	O
condition	O
in	O
PC	O
-	O
3	O
prostate	O
tumor	O
cells	O
.	O

OPN	S-geneY
increased	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
p	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
,	O
a	O
subfamily	O
of	O
ATP	B-geneN
-	I-geneN
binding	I-geneN
cassette	I-geneN
transporter	E-geneN
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
increase	O
in	O
P	B-geneN
-	I-geneN
gp	E-geneN
transporter	O
by	O
OPN	S-geneY
was	O
mediated	O
by	O
binding	O
to	O
αvβ3	B-geneN
integrin	E-geneN
.	O

Daunomycin	S-chem
(	O
DUN	S-chem
)	O
,	O
a	O
chemotherapeutic	O
agent	O
with	O
autofluorescence	O
,	O
was	O
used	O
to	O
evaluate	O
the	O
pump	O
activity	O
,	O
and	O
OPN	S-geneY
increased	O
the	O
drug	O
pumping	O
-	O
out	O
activity	O
.	O

OPN	S-geneY
inhibited	O
DUN	S-chem
-	O
induced	O
cell	O
death	O
,	O
which	O
was	O
antagonized	O
by	O
αvβ3	S-geneN
monoclonal	O
antibody	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
DUN	S-chem
further	O
enhanced	O
the	O
expression	O
of	O
OPN	S-geneY
.	O

Knockdown	O
of	O
endogenous	O
OPN	S-geneY
potentiated	O
the	O
DUN	S-chem
-	O
induced	O
apoptosis	O
of	O
PC	O
-	O
3	O
cells	O
.	O

Furthermore	O
,	O
knockdown	O
of	O
OPN	S-geneY
enhanced	O
cell	O
death	O
caused	O
by	O
other	O
drugs	O
,	O
including	O
paclitaxel	S-chem-C9-1
,	O
doxorubicin	S-chem-C9-1
,	O
actinomycin	B-chem-C9-1
-	I-chem-C9-1
D	E-chem-C9-1
,	O
and	O
rapamycin	S-chem-C9-1
,	O
which	O
are	O
also	O
P	B-geneN-C9-2
-	I-geneN-C9-2
gp	E-geneN-C9-2
substrates	O
.	O

The	O
animal	O
studies	O
also	O
showed	O
that	O
OPN	S-geneY
knockdown	O
enhanced	O
the	O
cytotoxic	O
action	O
of	O
DUN	S-chem
.	O

These	O
results	O
indicate	O
that	O
OPN	S-geneY
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
cancer	O
therapy	O
to	O
reduce	O
drug	O
resistance	O
in	O
sensitive	O
tumors	O
.	O

Determination	O
of	O
expression	O
of	O
cyclooxygenase	B-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
isozymes	O
in	O
canine	O
tissues	O
and	O
their	O
differential	O
sensitivity	O
to	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
cyclooxygenase	S-geneN
isozyme	O
distribution	O
in	O
tissues	O
from	O
dogs	O
and	O
determine	O
the	O
differential	O
sensitivity	O
of	O
canine	B-geneN
cyclooxygenase	I-geneN
(	I-geneN
COX	I-geneN
)	I-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
isozymes	O
to	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

SAMPLE	O
POPULATION	O
:	O
Canine	O
tissue	O
samples	O
(	O
stomach	O
,	O
duodenum	O
,	O
ileum	O
,	O
jejunum	O
,	O
colon	O
,	O
spleen	O
,	O
cerebral	O
cortex	O
,	O
lung	O
,	O
ovary	O
,	O
kidney	O
,	O
and	O
liver	O
)	O
were	O
obtained	O
from	O
2	O
dogs	O
for	O
northern	O
and	O
western	O
blot	O
analyses	O
,	O
and	O
blood	O
for	O
whole	O
blood	O
COX	S-geneN
assays	O
was	O
obtained	O
from	O
15	O
dogs	O
.	O

PROCEDURE	O
:	O
11	O
NSAIDs	O
were	O
evaluated	O
to	O
determine	O
their	O
COX	B-geneY
-	I-geneY
2	E-geneY
selectivity	O
in	O
whole	O
blood	O
assays	O
.	O

The	O
concentrations	O
of	O
the	O
drug	O
needed	O
to	O
inhibit	O
50	O
%	O
of	O
enzyme	O
activity	O
(	O
IC50	O
)	O
were	O
then	O
calculated	O
for	O
comparison	O
.	O

Expression	O
and	O
tissue	O
distribution	O
of	O
COX	S-geneN
isozymes	O
were	O
determined	O
by	O
northern	O
and	O
western	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Aspirin	S-chem
,	O
diclofenac	S-chem
,	O
indomethacin	S-chem
,	O
ketoprofen	S-chem
,	O
meclofenamic	B-chem
acid	E-chem
,	O
and	O
piroxicam	S-chem
had	O
little	O
selectivity	O
toward	O
COX	S-geneN
isozymes	O
,	O
whereas	O
NS398	S-chem-C4-1
,	O
carprofen	S-chem-C4-1
,	O
tolfenamic	B-chem-C4-1
acid	E-chem-C4-1
,	O
nimesulide	S-chem-C4-1
,	O
and	O
etodolac	S-chem-C4-1
had	O
more	O
than	O
5	O
times	O
greater	O
preference	O
for	O
inhibiting	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
than	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
.	O

All	O
canine	O
tissues	O
examined	O
,	O
including	O
those	O
from	O
the	O
gastrointestinal	O
tract	O
,	O
coexpressed	O
COX	B-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
mRNA	O
,	O
although	O
protein	O
expression	O
was	O
observed	O
only	O
for	O
COX	B-geneY
-	I-geneY
1	E-geneY
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Canine	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
was	O
selectively	O
inhibited	O
by	O
etodolac	S-chem-C4-1
,	O
nimesulide	S-chem-C4-1
,	O
and	O
NS398	S-chem-C4-1
;	O
tolfenamic	B-chem-C4-1
acid	E-chem-C4-1
and	O
carprofen	S-chem-C4-1
also	O
appeared	O
to	O
be	O
preferential	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitors	O
in	O
dogs	O
.	O

The	O
roles	O
of	O
COX	B-geneY
-	I-geneY
1	E-geneY
as	O
a	O
constitutive	O
housekeeping	O
enzyme	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
as	O
a	O
proinflammatory	O
inducible	O
enzyme	O
(	O
as	O
determined	O
in	O
humans	O
)	O
appear	O
to	O
apply	O
to	O
dogs	O
;	O
therefore	O
,	O
COX	B-geneY
-	I-geneY
2	E-geneY
-	O
selective	O
inhibitors	O
should	O
prove	O
useful	O
in	O
reducing	O
the	O
adverse	O
effects	O
associated	O
with	O
nonselective	O
NSAIDs	O
.	O

Stoichiometry	O
of	O
estramustine	B-chem
phosphate	E-chem
binding	O
to	O
MAP2	S-geneY
measured	O
by	O
the	O
disassembly	O
of	O
chick	B-geneY
brain	I-geneY
MAP2	E-geneY
:	O
tubulin	S-geneN
microtubules	O
.	O

The	O
concentration	O
of	O
estramustine	B-chem-MU-1
phosphate	E-chem-MU-1
required	O
to	O
inhibit	O
the	O
assembly	O
or	O
to	O
induce	O
the	O
disassembly	O
of	O
chick	B-geneY-MU-2
brain	I-geneY-MU-2
MAP2	E-geneY-MU-2
:	O
tubulin	S-geneN-MU-2
microtubules	O
is	O
markedly	O
dependent	O
upon	O
the	O
microtubule	O
protein	O
concentration	O
.	O

Analysis	O
of	O
this	O
relationship	O
shows	O
that	O
estramustine	B-chem
phosphate	E-chem
and	O
tubulin	S-geneN
compete	O
for	O
common	O
MAP2	S-geneY
sites	O
,	O
that	O
MAP2	S-geneY
can	O
bind	O
5	O
-	O
6	O
moles.mole	O
-	O
1	O
estramustine	B-chem
phosphate	E-chem
,	O
and	O
that	O
the	O
Kd	O
of	O
these	O
sites	O
is	O
congruent	O
to	O
20	O
microM	O
estramustine	B-chem
phosphate	E-chem
.	O

It	O
is	O
proposed	O
that	O
two	O
molecules	O
of	O
estramustine	B-chem-C4-1
phosphate	E-chem-C4-1
interact	O
with	O
each	O
of	O
the	O
three	O
tubulin	O
-	O
binding	O
sites	O
of	O
MAP2	S-geneY
and	O
inhibit	O
the	O
MAP2	S-geneY-C4-2
:	O
tubulin	S-geneN-C4-2
interaction	O
by	O
neutralising	O
two	O
highly	O
conserved	O
basic	O
residues	O
.	O

Involvement	O
of	O
EP1	S-geneY
and	O
EP2	B-geneY
receptors	E-geneY
in	O
the	O
regulation	O
of	O
the	O
Na	B-geneN
,	I-geneN
K	I-geneN
-	I-geneN
ATPase	E-geneN
by	O
prostaglandins	S-chem
in	O
MDCK	O
cells	O
.	O

Prostaglandins	S-chem
are	O
key	O
regulators	O
of	O
ion	O
transport	O
in	O
the	O
kidney	O
.	O

In	O
MDCK	O
cells	O
,	O
which	O
model	O
distal	O
tubule	O
cells	O
,	O
the	O
transcription	O
of	O
the	O
Na	B-geneN
,	I-geneN
K	I-geneN
-	I-geneN
ATPase	I-geneN
beta1	E-geneN
subunit	O
is	O
regulated	O
by	O
PGE1	O
and	O
PGE2	O
.	O

To	O
identify	O
the	O
EP	B-geneN
receptors	E-geneN
that	O
mediate	O
transcriptional	O
regulation	O
,	O
transient	O
transfection	O
studies	O
are	O
conducted	O
using	O
the	O
human	O
beta1promoter	O
/	O
luciferase	O
construct	O
,	O
pHbeta1	O
-	O
1141	O
Luc	O
.	O

The	O
involvement	O
of	O
EP1	S-geneY-C5-2
and	O
EP2	B-geneY-C5-2
receptors	E-geneY-C5-2
is	O
indicated	O
by	O
studies	O
with	O
the	O
EP1	S-geneY-C5-2
selective	O
agonist	O
17	B-chem-C5-1
-	I-chem-C5-1
phenyl	I-chem-C5-1
trinor	I-chem-C5-1
PGE2	E-chem-C5-1
,	O
and	O
the	O
EP2	S-geneY-C5-2
selective	O
agonist	O
butaprost	S-chem-C5-1
(	O
which	O
stimulate	O
)	O
,	O
as	O
well	O
as	O
by	O
studies	O
with	O
the	O
antagonists	O
SC	B-chem-C5-1
-	I-chem-C5-1
51089	E-chem-C5-1
(	O
EP1	O
specific	O
)	O
and	O
AH	B-chem-MU-1
6809	E-chem-MU-1
(	O
EP1	S-geneY-MU-2
and	O
EP2	S-geneY-C6-2
specific	O
)	O
.	O

Consistent	O
with	O
the	O
involvement	O
of	O
Gs	S-geneN
coupled	O
EP2	B-geneY
receptors	E-geneY
,	O
is	O
that	O
the	O
PGE1	S-chem
stimulation	O
is	O
inhibited	O
by	O
the	O
PKAI	S-geneN
expression	O
vector	O
(	O
encoding	O
the	O
protein	B-geneN
kinase	I-geneN
A	I-geneN
(	I-geneN
PKA	I-geneN
)	I-geneN
inhibitory	I-geneN
protein	E-geneN
)	O
,	O
as	O
well	O
as	O
by	O
the	O
myristolated	B-geneN
PKA	I-geneN
inhibitory	I-geneN
peptide	E-geneN
PKI	O
.	O

In	O
addition	O
to	O
this	O
evidence	O
(	O
for	O
the	O
involvement	O
of	O
EP2	B-geneY
receptors	E-geneY
)	O
,	O
evidence	O
for	O
the	O
involvement	O
of	O
EP1	B-geneY
receptors	E-geneY
in	O
the	O
PGE1	S-chem-C3-1
mediated	O
stimulation	O
of	O
Na	B-geneN-MU-2
,	I-geneN-MU-2
K	I-geneN-MU-2
-	I-geneN-MU-2
ATPase	I-geneN-MU-2
beta	E-geneN-MU-2
subunit	O
gene	O
transcription	O
includes	O
the	O
stimulatory	O
effect	O
of	O
17	B-chem-C3-1
-	I-chem-C3-1
phenyl	I-chem-C3-1
trinor	I-chem-C3-1
PGE2	E-chem-C3-1
,	O
as	O
well	O
as	O
the	O
inhibitory	O
effects	O
of	O
SC	B-chem-C4-1
-	I-chem-C4-1
51089	E-chem-C4-1
.	O

Also	O
consistent	O
with	O
the	O
involvement	O
of	O
Gq	S-geneN
coupled	O
EP1	B-geneY
receptors	E-geneY
,	O
the	O
PGE1	S-chem
stimulation	O
is	O
inhibited	O
by	O
the	O
PKCI	S-geneN
vector	O
(	O
encoding	O
the	O
PKC	B-geneN
inhibitory	I-geneN
domain	E-geneN
)	O
,	O
the	O
PKC	S-geneN-C4-2
inhibitor	O
Go	B-chem-C4-1
6976	E-chem-C4-1
,	O
thapsigargin	S-chem-C4-1
,	O
as	O
well	O
as	O
the	O
calmodulin	S-geneN-C6-2
antagonists	O
W7	S-chem-C6-1
and	O
W13	S-chem-C6-1
.	O

Cytochrome	B-geneN
P450	I-geneN
4A	E-geneN
,	O
peroxisomal	O
enzymes	O
and	O
nicotinamide	S-chem
cofactors	O
in	O
koala	O
liver	O
.	O

We	O
have	O
examined	O
hepatic	O
levels	O
of	O
microsomal	O
lauric	B-geneN
acid	I-geneN
hydroxylase	E-geneN
activity	O
and	O
cyanide	O
-	O
insensitive	O
palmitoyl	O
coenzyme	O
A	O
oxidative	O
activity	O
in	O
koala	O
(	O
Phascolarctos	O
cinereus	O
)	O
and	O
tammar	O
wallaby	O
(	O
Macropus	O
eugenii	O
)	O
and	O
compared	O
our	O
results	O
to	O
those	O
determined	O
in	O
rat	O
.	O

Microsomal	O
lauric	B-chem
acid	E-chem
hydroxylation	O
was	O
significantly	O
higher	O
in	O
koala	O
than	O
in	O
tammar	O
wallaby	O
or	O
rat	O
.	O

However	O
,	O
cyanide	O
-	O
insensitive	O
palmitoyl	O
-	O
CoA	O
oxidation	O
was	O
absent	O
in	O
the	O
koala	O
.	O

We	O
have	O
also	O
determined	O
the	O
hepatic	O
nicotinamide	S-chem
cofactors	O
in	O
these	O
species	O
.	O

Hepatic	O
nicotinamide	B-chem
-	I-chem
adenine	I-chem
dinucleotide	E-chem
(	O
NAD	S-chem
)	O
and	O
the	O
ratio	O
of	O
NAD	S-chem
/	O
nicotinamide	B-chem
-	I-chem
adenine	I-chem
dinucleotide	I-chem
phosphate	E-chem
(	O
NADP	S-chem
)	O
were	O
higher	O
in	O
koala	O
than	O
in	O
tammar	O
wallaby	O
and	O
rat	O
liver	O
.	O

Reverse	O
transcription	O
of	O
koala	O
liver	O
mRNA	O
,	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
using	O
primers	O
based	O
on	O
highly	O
conserved	O
areas	O
in	O
the	O
CYP4A	S-geneN
family	O
led	O
to	O
the	O
cloning	O
of	O
a	O
partial	O
,	O
near	O
full	O
length	O
,	O
cDNA	O
clone	O
with	O
approximately	O
70	O
%	O
nucleotide	S-chem
and	O
deduced	O
amino	B-chem
acid	E-chem
sequence	O
identity	O
to	O
human	B-geneY
CYP4A11	E-geneY
.	O

The	O
CYP	S-geneN
has	O
been	O
named	O
CYP4A15	S-geneY
.	O

Hypoxia	O
and	O
lactate	S-chem
production	O
in	O
trophoblast	O
cells	O
.	O

The	O
etiology	O
of	O
preeclampsia	O
is	O
unknown	O
but	O
is	O
thought	O
to	O
be	O
related	O
to	O
hypoxia	O
in	O
the	O
placenta	O
.	O

We	O
previously	O
reported	O
that	O
the	O
enzyme	O
lactate	B-geneN
dehydrogenase	E-geneN
(	O
LDH	S-geneN
)	O
has	O
increased	O
activity	O
and	O
gene	O
expression	O
in	O
placentas	O
from	O
preeclamptic	O
pregnancies	O
[	O
Tsoi	O
SCM	O
,	O
Zheng	O
J	O
,	O
Xu	O
F	O
,	O
Kay	O
HH	O
.	O

Differential	O
expression	O
of	O
lactate	B-geneN
dehydrogenase	E-geneN
isozymes	O
(	O
LDH	S-geneN
)	O
in	O
human	O
placenta	O
with	O
high	O
expression	O
of	O
LDH	B-geneY
-	I-geneY
A	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
isozyme	O
in	O
the	O
endothelial	O
cells	O
of	O
pre	O
-	O
eclampsia	O
villi	O
.	O

Placenta	O
2001	O
;	O
22	O
:	O
317	O
-	O
22	O
]	O
.	O

LDH	S-geneN-C9-2
is	O
responsible	O
for	O
pyruvate	S-chem-C9-1
conversion	O
to	O
lactate	S-chem-C9-1
through	O
glycolysis	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
role	O
of	O
hypoxia	O
in	O
primary	O
trophoblast	O
cells	O
and	O
a	O
cultured	O
cell	O
line	O
,	O
JEG3	O
cells	O
,	O
to	O
obtain	O
a	O
better	O
understanding	O
of	O
how	O
it	O
affects	O
the	O
activities	O
of	O
lactate	B-geneN
dehydrogenase	E-geneN
,	O
lactate	S-chem
production	O
and	O
regulatory	O
genes	O
,	O
as	O
a	O
possible	O
model	O
for	O
preeclampsia	O
.	O

Primary	O
trophoblast	O
cells	O
and	O
JEG3	O
cells	O
were	O
cultured	O
under	O
1	O
%	O
oxygen	S-chem
.	O

At	O
6	O
,	O
12	O
and	O
24h	O
,	O
cells	O
were	O
analyzed	O
for	O
LDHA	S-geneY
and	O
LDHB	S-geneY
isozyme	O
activities	O
,	O
mRNA	O
and	O
protein	O
expression	O
compared	O
to	O
standard	O
culture	O
conditions	O
.	O

Lactate	S-chem
was	O
measured	O
from	O
cell	O
medium	O
.	O

The	O
hypoxia	B-geneN
inducible	I-geneN
transcription	I-geneN
factor	E-geneN
(	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
)	O
protein	O
expression	O
was	O
confirmed	O
by	O
western	O
blot	O
.	O

Two	O
lactate	B-geneN
transporters	E-geneN
(	O
MCT1	S-geneY
and	O
MCT4	S-geneY
)	O
mRNA	O
and	O
protein	O
expression	O
were	O
also	O
studied	O
under	O
hypoxia	O
.	O

Finally	O
,	O
lactate	S-chem
was	O
measured	O
in	O
plasma	O
obtained	O
from	O
patients	O
with	O
severe	O
preeclampsia	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
LDHA	S-geneY
mRNA	O
is	O
increased	O
in	O
primary	O
trophoblast	O
cells	O
and	O
JEG3	O
cells	O
.	O

The	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
protein	O
expression	O
is	O
higher	O
in	O
hypoxia	O
-	O
treated	O
JEG3	O
cells	O
than	O
control	O
.	O

LDHA	S-geneY
isozyme	O
activity	O
and	O
its	O
protein	O
expression	O
are	O
increased	O
most	O
significantly	O
at	O
24h	O
of	O
culture	O
under	O
hypoxia	O
.	O

However	O
,	O
LDHB	S-geneY
protein	O
is	O
unchanged	O
while	O
its	O
mRNA	O
is	O
decreased	O
.	O

Lactate	S-chem
secretion	O
from	O
JEG3	O
cells	O
under	O
hypoxia	O
is	O
increased	O
,	O
as	O
is	O
the	O
lactate	S-chem
levels	O
in	O
the	O
plasma	O
from	O
preeclampsia	O
patients	O
.	O

Of	O
the	O
two	O
lactate	S-chem
transporters	O
studied	O
,	O
MCT4	S-geneY
mRNA	O
and	O
protein	O
level	O
are	O
increased	O
under	O
hypoxia	O
.	O

Our	O
findings	O
support	O
the	O
role	O
of	O
hypoxia	O
in	O
inducing	O
HIF	B-geneY
-	I-geneY
1alpha	E-geneY
activity	O
in	O
trophoblasts	O
and	O
increasing	O
LDH	S-geneN
transcription	O
as	O
well	O
as	O
its	O
activity	O
.	O

Higher	O
levels	O
of	O
lactate	S-chem
are	O
produced	O
and	O
secreted	O
which	O
may	O
contribute	O
to	O
the	O
higher	O
lactate	S-chem
levels	O
in	O
plasma	O
of	O
preeclamptic	O
patients	O
.	O

These	O
mechanisms	O
may	O
be	O
important	O
in	O
the	O
pathophysiology	O
of	O
preeclampsia	O
.	O

Alkaloids	O
from	O
Microcos	O
paniculata	O
with	O
cytotoxic	O
and	O
nicotinic	B-geneN
receptor	E-geneN
antagonistic	O
activities	O
.	O

Microcos	O
paniculata	O
is	O
a	O
large	O
shrub	O
or	O
small	O
tree	O
that	O
grows	O
in	O
several	O
countries	O
in	O
South	O
and	O
Southeast	O
Asia	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
new	O
piperidine	B-chem
alkaloids	E-chem
,	O
microgrewiapines	B-chem
A	I-chem
-	I-chem
C	E-chem
(	O
1	O
-	O
3	O
)	O
,	O
as	O
well	O
as	O
three	O
known	O
compounds	O
,	O
inclusive	O
of	O
microcosamine	B-chem
A	E-chem
(	O
4	O
)	O
,	O
7	B-chem
'	I-chem
-	I-chem
(	I-chem
3',4	I-chem
'	I-chem
-	I-chem
dihydroxyphenyl	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
methoxyphenyl	I-chem
)	I-chem
ethyl	I-chem
]	I-chem
propenamide	E-chem
(	O
5	O
)	O
,	O
and	O
liriodenine	S-chem
(	O
6	O
)	O
,	O
were	O
isolated	O
from	O
cytotoxic	O
fractions	O
of	O
the	O
separate	O
chloroform	S-chem
-	O
soluble	O
extracts	O
of	O
the	O
stem	O
bark	O
,	O
branches	O
,	O
and	O
leaves	O
of	O
M.	O
paniculata	O
.	O

Compounds	O
1	O
-	O
6	O
and	O
1a	O
(	O
microgrewiapine	B-chem
A	I-chem
3	I-chem
-	I-chem
acetate	E-chem
)	O
showed	O
a	O
range	O
of	O
cytotoxicity	O
values	O
against	O
the	O
HT	O
-	O
29	O
human	O
colon	O
cancer	O
cell	O
line	O
.	O

When	O
evaluated	O
for	O
their	O
effects	O
on	O
human	B-geneN
α3β4	I-geneN
or	I-geneN
α4β2	I-geneN
nicotinic	I-geneN
acetylcholine	I-geneN
receptors	E-geneN
(	O
nAChRs	S-geneN
)	O
,	O
several	O
of	O
these	O
compounds	O
were	O
shown	O
to	O
be	O
active	O
as	O
nAChR	S-geneN
antagonists	O
.	O

As	O
a	O
result	O
of	O
this	O
study	O
,	O
microgrewiapine	B-chem-C6-1
A	E-chem-C6-1
(	O
1	O
)	O
was	O
found	O
to	O
be	O
a	O
selective	O
cytotoxic	O
agent	O
for	O
colon	O
cancer	O
cells	O
over	O
normal	O
colon	O
cells	O
and	O
to	O
exhibit	O
nicotinic	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonistic	O
activity	O
for	O
both	O
the	O
hα3β4	B-geneN
and	I-geneN
hα4β2	I-geneN
receptor	E-geneN
subtypes	O
.	O

Externalization	O
of	O
phosphatidylserine	S-chem
during	O
apoptosis	O
does	O
not	O
specifically	O
require	O
either	O
isoform	O
of	O
phosphatidylserine	B-geneN
synthase	E-geneN
.	O

Phosphatidylserine	S-chem-C9-1
(	O
PtdSer	S-chem
)	O
is	O
made	O
in	O
mammalian	O
cells	O
by	O
two	O
PtdSer	B-geneN-C9-2
synthases	E-geneN-C9-2
,	O
PSS1	S-geneN-C9-2
and	O
PSS2	S-geneN-C9-2
.	O

In	O
the	O
plasma	O
membrane	O
PtdSer	S-chem
is	O
normally	O
localized	O
on	O
the	O
inner	O
leaflet	O
but	O
undergoes	O
transbilayer	O
movement	O
during	O
apoptosis	O
and	O
becomes	O
exposed	O
on	O
the	O
cell	O
surface	O
.	O

We	O
induced	O
apoptosis	O
with	O
staurosporine	S-chem
in	O
four	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
lines	O
that	O
are	O
deficient	O
in	O
PSS1	S-geneY
and	O
/	O
or	O
PSS2	S-geneY
to	O
determine	O
if	O
PtdSer	S-chem
generated	O
by	O
either	O
of	O
these	O
enzymes	O
is	O
required	O
for	O
externalization	O
on	O
the	O
cell	O
surface	O
during	O
apoptosis	O
.	O

The	O
onset	O
of	O
apoptosis	O
was	O
confirmed	O
by	O
the	O
appearance	O
of	O
morphological	O
changes	O
and	O
DNA	O
fragmentation	O
while	O
the	O
plasma	O
membrane	O
remained	O
largely	O
intact	O
.	O

In	O
all	O
cell	O
lines	O
,	O
regardless	O
of	O
their	O
content	O
of	O
PSS1	S-geneY
and	O
/	O
or	O
PSS2	S-geneY
,	O
apoptosis	O
occurred	O
to	O
approximately	O
the	O
same	O
extent	O
,	O
and	O
within	O
approximately	O
the	O
same	O
time	O
frame	O
,	O
as	O
in	O
parental	O
CHO	O
-	O
K1	O
cells	O
.	O

The	O
exposure	O
of	O
PtdSer	S-chem
on	O
the	O
cell	O
surface	O
was	O
assessed	O
by	O
annexin	O
V	O
labeling	O
and	O
flow	O
cytometry	O
.	O

Cells	O
that	O
were	O
deficient	O
in	O
either	O
PSS1	S-geneY
or	O
PSS2	S-geneY
,	O
as	O
well	O
as	O
cells	O
that	O
were	O
deficient	O
in	O
both	O
PSS1	S-geneY
and	O
PSS2	S-geneY
,	O
externalized	O
normal	O
amounts	O
of	O
PtdSer	S-chem
.	O

Our	O
study	O
demonstrates	O
,	O
that	O
reduction	O
of	O
in	O
vitro	O
serine	S-chem
-	O
exchange	O
activity	O
,	O
even	O
by	O
97	O
%	O
,	O
does	O
not	O
restrict	O
the	O
externalization	O
of	O
PtdSer	S-chem
during	O
apoptosis	O
.	O

Moreover	O
,	O
a	O
normal	O
level	O
of	O
expression	O
of	O
PSS1	S-geneY-C9-2
and	O
/	O
or	O
PSS2	S-geneY-C9-2
is	O
not	O
required	O
for	O
generating	O
the	O
pool	O
of	O
PtdSer	S-chem-C9-1
externalized	O
during	O
apoptosis	O
.	O

Can	O
peripheral	O
blood	O
γ	O
δ	O
T	O
cells	O
predict	O
osteonecrosis	O
of	O
the	O
jaw	O
?	O
An	O
immunological	O
perspective	O
on	O
the	O
adverse	O
drug	O
effects	O
of	O
aminobisphosphonate	S-chem
therapy	O
.	O

Nitrogen	B-chem
-	I-chem
bisphosphonates	E-chem
(	O
n	B-chem
-	I-chem
BP	E-chem
)	O
,	O
often	O
referred	O
to	O
as	O
aminobisphosphonates	S-chem
,	O
are	O
the	O
most	O
commonly	O
prescribed	O
drugs	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
bone	O
fragility	O
.	O

However	O
,	O
long	O
-	O
term	O
continuous	O
treatment	O
predisposes	O
certain	O
individuals	O
to	O
serious	O
rare	O
side	O
effects	O
,	O
such	O
as	O
bisphosphonate	S-chem
-	O
associated	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
BAONJ	O
)	O
.	O
n	B-chem
-	I-chem
BP	E-chem
use	O
is	O
known	O
to	O
unintentionally	O
activate	O
a	O
subset	O
of	O
innate	O
T	O
cells	O
called	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
,	O
but	O
the	O
consequence	O
of	O
this	O
chronic	O
immune	O
stimulation	O
has	O
remained	O
unexplored	O
.	O

The	O
primary	O
objectives	O
of	O
this	O
study	O
were	O
to	O
1	O
)	O
determine	O
the	O
fate	O
of	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
in	O
osteoporotic	O
patients	O
on	O
n	B-chem
-	I-chem
BP	E-chem
therapy	O
as	O
a	O
function	O
of	O
time	O
and	O
type	O
of	O
therapy	O
;	O
2	O
)	O
evaluate	O
the	O
proportion	O
of	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
in	O
patients	O
who	O
had	O
recently	O
experienced	O
n	B-chem
-	I-chem
BP	E-chem
-	O
associated	O
ONJ	O
.	O

We	O
found	O
there	O
is	O
a	O
notable	O
loss	O
of	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
over	O
time	O
in	O
osteoporotic	O
patients	O
on	O
n	B-chem
-	I-chem
BP	E-chem
therapy	O
,	O
particularly	O
those	O
on	O
intravenous	O
(	O
iv	O
)	O
therapy	O
(	O
Spearman	O
r	O
=	O
-	O
0.55	O
,	O
p	O
<	O
0.0001	O
iv	O
;	O
r	O
=	O
-	O
0.3	O
,	O
p	O
<	O
0.03	O
oral	O
)	O
(	O
n	O
=	O
68	O
)	O
;	O
no	O
difference	O
was	O
observed	O
in	O
total	O
T	O
cells	O
,	O
monocytes	O
,	O
or	O
granulocytes	O
.	O

Importantly	O
,	O
the	O
observed	O
negative	O
effect	O
on	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
coincides	O
with	O
the	O
reported	O
route	O
of	O
administration	O
and	O
timing	O
of	O
the	O
rare	O
occurrence	O
of	O
BAONJ	O
.	O

Patients	O
(	O
n	O
=	O
6	O
)	O
who	O
had	O
experienced	O
BAONJ	O
were	O
all	O
found	O
to	O
be	O
significantly	O
deficient	O
in	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
(	O
median	O
=	O
0.07	O
%	O
)	O
in	O
comparison	O
to	O
age	O
-	O
and	O
sex	O
-	O
matched	O
treatment	O
-	O
naïve	O
controls	O
(	O
N	O
=	O
11	O
;	O
median	O
=	O
2.40	O
%	O
)	O
,	O
U	O
=	O
0	O
,	O
p	O
=	O
0.001	O
;	O
this	O
was	O
the	O
only	O
consistent	O
difference	O
in	O
the	O
leukocytes	O
assessed	O
.	O

All	O
BAONJ	O
cases	O
had	O
an	O
underlying	O
condition	O
that	O
further	O
contributed	O
to	O
impaired	O
immunity	O
.	O

We	O
propose	O
Vγ9V	O
δ	O
2	O
T	O
cells	O
show	O
a	O
strong	O
potential	O
to	O
serve	O
as	O
harbingers	O
of	O
possible	O
adverse	O
immune	O
effects	O
of	O
n	B-chem
-	I-chem
BP	E-chem
therapy	O
,	O
particularly	O
in	O
those	O
patients	O
already	O
having	O
a	O
compromised	O
immune	O
system	O
as	O
they	O
may	O
be	O
most	O
vulnerable	O
to	O
the	O
development	O
of	O
conditions	O
such	O
as	O
BAONJ	O
.	O

Conformational	O
landscape	O
of	O
diisopropyl	B-chem
ketone	E-chem
:	O
quantum	O
chemical	O
calculations	O
validated	O
by	O
microwave	O
spectroscopy	O
.	O

We	O
report	O
on	O
the	O
gas	O
-	O
phase	O
structure	O
of	O
the	O
most	O
abundant	O
conformer	O
of	O
diisopropyl	B-chem
ketone	E-chem
,	O
(	B-chem
CH	I-chem
(	I-chem
3	I-chem
)	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
HC	I-chem
-	I-chem
CO	I-chem
-	I-chem
CH	I-chem
(	I-chem
CH	I-chem
(	I-chem
3	I-chem
)	I-chem
)	I-chem
(	I-chem
2	I-chem
)	E-chem
,	O
as	O
observed	O
by	O
molecular	O
beam	O
Fourier	O
transform	O
microwave	O
spectroscopy	O
.	O

The	O
gas	O
-	O
phase	O
structures	O
of	O
five	O
conformers	O
of	O
diisopropyl	B-chem
ketone	E-chem
were	O
optimized	O
using	O
ab	O
initio	O
calculations	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
theory	O
.	O

The	O
natures	O
of	O
the	O
stationary	O
points	O
were	O
verified	O
using	O
harmonic	O
frequency	O
calculations	O
.	O

The	O
only	O
conformer	O
observed	O
in	O
the	O
supersonic	O
jet	O
possesses	O
C	O
(	O
2	O
)	O
symmetry	O
and	O
appears	O
as	O
an	O
enantiomeric	O
pair	O
.	O

From	O
the	O
microwave	O
spectrum	O
,	O
a	O
set	O
of	O
three	O
highly	O
accurate	O
rotational	O
constants	O
,	O
five	O
centrifugal	O
distortion	O
constants	O
,	O
and	O
three	O
sextic	O
centrifugal	O
distortion	O
constants	O
were	O
determined	O
.	O

The	O
structure	O
of	O
the	O
observed	O
conformer	O
was	O
optimized	O
again	O
at	O
different	O
levels	O
of	O
theory	O
using	O
the	O
HF	O
,	O
MP2	O
,	O
and	O
B3LYP	O
methods	O
.	O

The	O
theoretical	O
constants	O
of	O
the	O
C	O
(	O
2	O
)	O
conformer	O
were	O
subsequently	O
validated	O
using	O
the	O
experimental	O
constants	O
.	O

To	O
understand	O
the	O
transitions	O
of	O
one	O
conformer	O
to	O
the	O
others	O
,	O
the	O
isopropyl	S-chem
groups	O
were	O
rotated	O
against	O
each	O
other	O
.	O

The	O
resulting	O
two	O
-	O
dimensional	O
potential	O
energy	O
surface	O
shows	O
nicely	O
the	O
symmetry	O
of	O
the	O
conformational	O
landscape	O
and	O
also	O
indicates	O
the	O
enantiomeric	O
pairs	O
of	O
the	O
conformers	O
.	O

The	O
barriers	O
to	O
internal	O
rotation	O
of	O
the	O
methyl	S-chem
groups	O
were	O
determined	O
to	O
be	O
1052	O
and	O
905	O
cm	O
(	O
-	O
1	O
)	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
and	O
the	O
B3LYP	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
levels	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
the	O
theoretical	O
predictions	O
,	O
no	O
internal	O
rotation	O
patterns	O
could	O
be	O
observed	O
in	O
the	O
microwave	O
spectrum	O
.	O

Association	O
of	O
serum	B-geneY
proprotein	I-geneY
convertase	I-geneY
subtilisin	I-geneY
/	I-geneY
kexin	I-geneY
type	I-geneY
9	E-geneY
with	O
carotid	O
intima	O
media	O
thickness	O
in	O
hypertensive	O
subjects	O
.	O

OBJECTIVE	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
measurement	O
of	O
serum	B-geneY
PCSK9	E-geneY
(	O
proprotein	B-geneY
subtilisin	I-geneY
kexin	I-geneY
type	I-geneY
9	E-geneY
)	O
is	O
not	O
well	O
defined	O
.	O

This	O
study	O
investigated	O
the	O
association	O
between	O
serum	B-geneY
PCSK9	E-geneY
levels	O
and	O
atherosclerosis	O
assessed	O
by	O
carotid	O
intima	O
media	O
thickness	O
(	O
IMT	O
)	O
in	O
hypertensive	O
patients	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
126	O
hypertensive	O
patients	O
over	O
the	O
age	O
of	O
45	O
were	O
enrolled	O
.	O

The	O
maximum	O
carotid	O
IMT	O
(	O
max	O
-	O
IMT	O
)	O
and	O
the	O
mean	O
carotid	O
IMT	O
(	O
mean	O
-	O
IMT	O
)	O
were	O
measured	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Clinical	O
and	O
laboratory	O
parameters	O
including	O
serum	B-geneY
PCSK9	E-geneY
were	O
analyzed	O
.	O

RESULTS	O
:	O
Patients	O
were	O
divided	O
into	O
tertiles	O
based	O
on	O
serum	B-geneY
PCSK9	E-geneY
levels	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
total	O
cholesterol	S-chem
,	O
HDL	S-geneN
-	O
cholesterol	O
and	O
triglyceride	S-chem
,	O
max	O
-	O
IMT	O
was	O
significantly	O
increased	O
in	O
the	O
highest	O
tertile	O
of	O
serum	B-geneY
PCSK9	E-geneY
(	O
0.969±0.033	O
vs	O
0.959±0.033	O
vs	O
1.077±0.033mm	O
,	O
respectively	O
;	O
P	O
=	O
0.026	O
)	O
.	O

Mean	O
-	O
IMT	O
showed	O
a	O
tendency	O
to	O
increase	O
across	O
the	O
tertile	O
groups	O
(	O
0.773±0.025	O
vs	O
0.790±0.026	O
vs	O
0.856±0.025mm	O
,	O
respectively	O
;	O
P	O
=	O
0.059	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
revealed	O
that	O
serum	B-geneY
PCSK9	E-geneY
was	O
independently	O
associated	O
with	O
carotid	O
IMT	O
(	O
max	O
-	O
IMT	O
:	O
β	O
=	O
0.212	O
,	O
P	O
=	O
0.016	O
;	O
mean	O
-	O
IMT	O
:	O
β	O
=	O
0.184	O
,	O
P	O
=	O
0.04	O
)	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
association	O
between	O
serum	B-geneY
PCSK9	E-geneY
levels	O
and	O
carotid	O
IMT	O
in	O
hypertensive	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
serum	B-geneY
PCSK9	E-geneY
may	O
have	O
a	O
certain	O
role	O
in	O
early	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

[	O
Brugada	O
syndrome	O
]	O
.	O

In	O
1992	O
we	O
described	O
a	O
new	O
syndrome	O
consisting	O
of	O
syncopal	O
episodes	O
and	O
/	O
or	O
sudden	O
death	O
in	O
patients	O
with	O
a	O
structurally	O
normal	O
heart	O
and	O
a	O
characteristic	O
electrocardiogram	O
displaying	O
a	O
pattern	O
resembling	O
right	O
bundle	O
branch	O
block	O
with	O
an	O
ST	O
segment	O
elevation	O
in	O
leads	O
V1	O
to	O
V3	O
.	O

In	O
1998	O
it	O
was	O
described	O
that	O
the	O
disease	O
is	O
genetically	O
determined	O
with	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
transmission	O
.	O

Three	O
different	O
mutations	O
have	O
been	O
identified	O
.	O

All	O
three	O
mutations	O
affect	O
the	O
structure	O
and	O
the	O
function	O
of	O
the	O
sodium	B-geneN
channel	E-geneN
SCN5A	S-geneY
.	O

Two	O
mutations	O
result	O
in	O
total	O
loss	O
of	O
function	O
of	O
the	O
sodium	B-geneN
channel	E-geneN
.	O

The	O
other	O
mutation	O
results	O
in	O
acceleration	O
of	O
the	O
recovery	O
of	O
the	O
sodium	B-geneN
channel	E-geneN
from	O
inactivation	O
.	O

The	O
disease	O
causes	O
4	O
to	O
10	O
sudden	O
deaths	O
per	O
10,000	O
inhabitants	O
per	O
year	O
in	O
areas	O
like	O
Thailand	O
and	O
Laos	O
.	O

Up	O
to	O
50	O
%	O
of	O
the	O
yearly	O
sudden	O
deaths	O
in	O
patients	O
with	O
a	O
normal	O
heart	O
might	O
be	O
caused	O
by	O
this	O
syndrome	O
.	O

The	O
diagnosis	O
is	O
easily	O
made	O
by	O
means	O
of	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
.	O

The	O
presence	O
of	O
concealed	O
and	O
intermittent	O
forms	O
,	O
however	O
,	O
makes	O
the	O
diagnosis	O
difficult	O
in	O
some	O
patients	O
.	O

The	O
ECG	O
can	O
be	O
modulated	O
by	O
changes	O
in	O
autonomic	O
balance	O
and	O
the	O
administration	O
of	O
antiarrhythmic	O
drugs	O
.	O

Beta	O
-	O
adrenergic	O
stimulation	O
normalises	O
the	O
ECG	O
,	O
while	O
i.v	O
.	O
ajmaline	S-chem
,	O
flecainide	S-chem
or	O
procainamide	S-chem
accentuate	O
the	O
ST	O
segment	O
elevation	O
and	O
are	O
capable	O
of	O
unmasking	O
concealed	O
and	O
intermittent	O
forms	O
of	O
the	O
disease	O
.	O

The	O
prognosis	O
is	O
poor	O
for	O
patients	O
who	O
do	O
not	O
receive	O
an	O
implantable	O
cardioverter	O
-	O
defibrillator	O
.	O

Antiarrhythmic	O
drugs	O
like	O
amiodarone	S-chem
or	O
beta	O
-	O
blockers	O
do	O
not	O
prevent	O
sudden	O
death	O
in	O
symptomatic	O
or	O
asymptomatic	O
individuals	O
.	O

p38	S-geneN
Mitogen	B-geneN
Activated	I-geneN
Protein	I-geneN
Kinase	E-geneN
Regulates	O
the	O
Nuclear	B-geneN
Receptor	E-geneN
CAR	S-geneY
to	O
Activate	O
the	O
CYP2B6	S-geneY
Gene	O
.	O

The	O
constitutive	B-geneY
active	I-geneY
/	I-geneY
androstane	I-geneY
receptor	E-geneY
(	O
CAR	S-geneY
)	O
regulates	O
hepatic	O
drug	O
metabolism	O
by	O
activating	O
genes	O
such	O
as	O
cytochrome	B-geneN
P450	E-geneN
(	O
CYP	S-geneN
)	O
and	O
certain	O
transferases	S-geneN
.	O
p38	S-geneN
mitogen	B-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
is	O
highly	O
activated	O
in	O
human	O
primary	O
hepatocytes	O
but	O
barely	O
in	O
human	O
hepatoma	O
cell	O
-	O
lines	O
including	O
HepG2	O
cells	O
.	O

Liganded	O
-	O
CAR	S-geneY
induced	O
CYP2B6	S-geneY
mRNA	O
in	O
human	O
primary	O
hepatocytes	O
far	O
more	O
effectively	O
than	O
in	O
HepG2	O
cells	O
ectopically	O
expressing	O
CAR	S-geneY
.	O

Here	O
,	O
we	O
have	O
now	O
found	O
that	O
activation	O
of	O
p38	S-geneN-C3-2
MAPK	S-geneN-C3-2
by	O
anisomycin	S-chem-C3-1
potentiated	O
induction	O
of	O
CYP2B6	S-geneY-C3-2
mRNA	O
by	O
CAR	S-geneY
ligand	O
in	O
HepG2	O
cells	O
to	O
levels	O
observed	O
in	O
ligand	O
-	O
treated	O
human	O
primary	O
hepatocytes	O
.	O
siRNA	O
knockdown	O
of	O
p38	S-geneN
MAPK	S-geneN
abrogated	O
the	O
ability	O
of	O
anisomycin	S-chem-C3-1
to	O
synergistically	O
induce	O
CYP2B6	S-geneY-C3-2
mRNA	O
.	O

In	O
addition	O
to	O
CYP2B6	S-geneY-C3-2
,	O
anisomycin	S-chem-C3-1
co	O
-	O
treatment	O
potentiated	O
an	O
increase	O
in	O
CYP2A7	S-geneY-C3-2
and	O
CYP2C9	S-geneY-C3-2
mRNAs	O
but	O
not	O
CYP3A4	S-geneY
or	O
UDP	B-geneY
-	I-geneY
glucuronosyltransferase	I-geneY
1A1	E-geneY
mRNAs	O
.	O

Thus	O
,	O
activated	O
p38	S-geneN
MAPK	S-geneN
is	O
required	O
for	O
liganded	O
-	O
CAR	S-geneY
to	O
selectively	O
activate	O
a	O
set	O
of	O
genes	O
that	O
encode	O
drug	O
metabolizing	O
enzymes	O
.	O

Our	O
present	O
results	O
suggest	O
that	O
CAR	S-geneY
-	O
mediated	O
induction	O
of	O
these	O
enzymes	O
can	O
not	O
be	O
understood	O
by	O
ligand	O
binding	O
alone	O
because	O
the	O
specificity	O
and	O
magnitude	O
of	O
induction	O
are	O
co	O
-	O
determined	O
by	O
a	O
given	O
cell	O
signaling	O
such	O
as	O
p38	S-geneN
MAPK	S-geneN
;	O
both	O
physiological	O
and	O
pathophysiological	O
states	O
of	O
cell	O
signaling	O
may	O
have	O
a	O
strong	O
impact	O
in	O
hepatic	O
drug	O
metabolizing	O
capability	O
during	O
therapeutic	O
treatments	O
.	O

Synergistic	O
anti	O
-	O
cancer	O
effects	O
of	O
resveratrol	S-chem
and	O
chemotherapeutic	O
agent	O
clofarabine	S-chem
against	O
human	O
malignant	O
mesothelioma	O
MSTO	O
-	O
211H	O
cells	O
.	O

Dietary	O
phytochemicals	O
as	O
adjuvants	O
have	O
been	O
suggested	O
to	O
play	O
important	O
roles	O
in	O
enhancing	O
chemotherapeutic	O
potential	O
owing	O
to	O
multitargeted	O
chemopreventive	O
properties	O
and	O
lack	O
of	O
substantial	O
toxicity	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
efficacy	O
of	O
the	O
combined	O
treatment	O
of	O
various	O
phytochemicals	O
with	O
the	O
anticancer	O
drug	O
clofarabine	S-chem
in	O
malignant	O
mesothelioma	O
MSTO	O
-	O
211H	O
cells	O
and	O
normal	O
mesothelial	O
MeT	O
-	O
5A	O
cells	O
.	O

The	O
combined	O
treatment	O
of	O
resveratrol	S-chem
and	O
clofarabine	S-chem
produced	O
a	O
synergistic	O
antiproliferative	O
effect	O
in	O
MSTO	O
-	O
211H	O
cells	O
,	O
but	O
not	O
in	O
MeT	O
-	O
5A	O
cells	O
.	O

In	O
MSTO	O
-	O
211H	O
cells	O
,	O
the	O
nuclear	O
accumulation	O
of	O
Sp1	S-geneY
and	O
the	O
levels	O
of	O
p	B-geneN
-	I-geneN
Akt	E-geneN
,	O
Sp1	S-geneY
,	O
c	B-geneY
-	I-geneY
Met	E-geneY
,	O
cyclin	B-geneY
D1	E-geneY
,	O
and	O
p21	S-geneY
were	O
effectively	O
decreased	O
by	O
the	O
combined	O
treatment	O
of	O
them	O
.	O

In	O
combination	O
with	O
clofarabine	S-chem-C4-1
,	O
the	O
ability	O
of	O
resveratrol	S-chem-C4-1
to	O
reduce	O
the	O
contents	O
of	O
Sp1	S-geneY-C4-2
and	O
its	O
target	O
gene	O
products	O
was	O
also	O
evident	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
experiment	O
.	O

The	O
inhibition	O
of	O
phosphoinositide	B-geneN-C4-2
3	I-geneN-C4-2
-	I-geneN-C4-2
kinase	E-geneN-C4-2
using	O
Ly294002	S-chem-C4-1
augmented	O
a	O
decrease	O
in	O
the	O
p21	S-geneY-C4-2
level	O
induced	O
by	O
their	O
combination	O
,	O
but	O
it	O
showed	O
no	O
significant	O
effects	O
on	O
expression	O
of	O
Sp1	S-geneY
and	O
cyclin	B-geneY
D1	E-geneY
.	O

Taken	O
together	O
,	O
the	O
data	O
provide	O
evidence	O
that	O
the	O
synergistic	O
antiproliferative	O
effect	O
of	O
resveratrol	S-chem-C4-1
and	O
clofarabine	S-chem-C4-1
is	O
linked	O
to	O
the	O
inhibition	O
of	O
Akt	S-geneN-C4-2
and	O
Sp1	S-geneY-C4-2
activities	O
,	O
and	O
suggest	O
that	O
this	O
combination	O
may	O
have	O
therapeutic	O
value	O
in	O
treatment	O
of	O
malignant	O
mesothelioma	O
.	O

Characterization	O
of	O
insulin	B-geneN
-	I-geneN
like	I-geneN
growth	I-geneN
factor	I-geneN
-	I-geneN
binding	I-geneN
protein	I-geneN
-	I-geneN
related	I-geneN
proteins	I-geneN
(	I-geneN
IGFBP	I-geneN
-	I-geneN
rPs	I-geneN
)	I-geneN
1	I-geneN
,	I-geneN
2	I-geneN
,	I-geneN
and	I-geneN
3	E-geneN
in	O
human	O
prostate	O
epithelial	O
cells	O
:	O
potential	O
roles	O
for	O
IGFBP	B-geneN
-	I-geneN
rP1	I-geneN
and	I-geneN
2	E-geneN
in	O
senescence	O
of	O
the	O
prostatic	O
epithelium	O
.	O

Insulin	B-geneN
-	I-geneN
like	I-geneN
growth	I-geneN
factor	I-geneN
(	I-geneN
IGF	I-geneN
)	I-geneN
-	I-geneN
binding	I-geneN
protein	I-geneN
(	I-geneN
IGFBP	I-geneN
)	I-geneN
-	I-geneN
related	I-geneN
proteins	E-geneN
(	O
IGFBP	B-geneN
-	I-geneN
rPs	E-geneN
)	O
are	O
newly	O
described	O
cysteine	S-chem
-	O
rich	O
proteins	O
that	O
share	O
significant	O
aminoterminal	O
structural	O
similarity	O
with	O
the	O
conventional	O
IGFBPs	S-geneN
and	O
are	O
involved	O
in	O
a	O
diversity	O
of	O
biological	O
functions	O
,	O
including	O
growth	O
regulation	O
.	O

IGFBP	B-geneY
-	I-geneY
rP1	E-geneY
(	O
MAC25	S-geneY
/	O
Angiomodulin	S-geneY
/	O
prostacyclin	B-geneY
-	I-geneY
stimulating	I-geneY
factor	E-geneY
)	O
is	O
a	O
potential	O
tumor	O
-	O
suppressor	O
gene	O
that	O
is	O
differentially	O
expressed	O
in	O
meningiomas	O
,	O
mammary	O
and	O
prostatic	O
cancers	O
,	O
compared	O
with	O
their	O
malignant	O
counterparts	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IGFBP	B-geneY
-	I-geneY
rP1	E-geneY
is	O
preferentially	O
produced	O
by	O
primary	O
cultures	O
of	O
human	O
prostate	O
epithelial	O
cells	O
(	O
HPECs	O
)	O
and	O
by	O
poorly	O
tumorigenic	O
P69SV40T	O
cells	O
,	O
compared	O
with	O
the	O
cancerous	O
prostatic	O
LNCaP	O
,	O
DU145	O
,	O
PC	O
-	O
3	O
,	O
and	O
M12	O
cells	O
.	O

We	O
now	O
show	O
that	O
IGFBP	B-geneY
-	I-geneY
rP1	E-geneY
increases	O
during	O
senescence	O
of	O
HPEC	O
.	O

IGFBP	B-geneY
-	I-geneY
rP2	E-geneY
(	O
also	O
known	O
as	O
connective	B-geneY
tissue	I-geneY
growth	I-geneY
factor	E-geneY
)	O
,	O
a	O
downstream	O
effector	O
of	O
transforming	B-geneN
growth	I-geneN
factor	I-geneN
(	I-geneN
TGF	I-geneN
)	I-geneN
-	I-geneN
beta	E-geneN
and	O
modulator	O
of	O
growth	O
for	O
both	O
fibroblasts	O
and	O
endothelial	O
cells	O
,	O
was	O
detected	O
in	O
most	O
of	O
the	O
normal	O
and	O
malignant	O
prostatic	O
epithelial	O
cells	O
tested	O
,	O
with	O
a	O
marked	O
up	O
-	O
regulation	O
of	O
IGFBP	B-geneY
-	I-geneY
rP2	E-geneY
during	O
senescence	O
of	O
HPEC	O
.	O

Moreover	O
,	O
IGFBP	B-geneY-C3-2
-	I-geneY-C3-2
rP2	E-geneY-C3-2
noticeably	O
increased	O
in	O
response	O
to	O
TGF	B-geneY
-	I-geneY
beta1	E-geneY
and	O
all	B-chem-C3-1
-	I-chem-C3-1
trans	I-chem-C3-1
retinoic	I-chem-C3-1
acid	E-chem-C3-1
(	O
atRA	S-chem-C3-1
)	O
in	O
HPEC	O
and	O
PC	O
-	O
3	O
cells	O
,	O
and	O
it	O
decreased	O
in	O
response	O
to	O
IGF	B-geneY
-	I-geneY
I	E-geneY
in	O
HPEC	O
.	O

IGFBP	B-geneY
-	I-geneY
rP3	E-geneY
[	O
nephroblastoma	B-geneY
overexpressed	E-geneY
(	O
NOV	S-geneY
)	O
]	O
,	O
the	O
protein	O
product	O
of	O
the	O
NOV	S-geneY
protooncogene	O
,	O
was	O
not	O
detected	O
in	O
HPEC	O
but	O
was	O
expressed	O
in	O
the	O
tumorigenic	O
DU145	O
and	O
PC	O
-	O
3	O
cells	O
.	O

It	O
was	O
also	O
synthesized	O
by	O
the	O
SV40	O
-	O
T	O
antigen	O
-	O
transformed	O
P69	O
and	O
malignant	O
M12	O
cells	O
,	O
where	O
it	O
was	O
down	O
-	O
regulated	O
by	O
atRA	S-chem
.	O

These	O
observations	O
suggest	O
biological	O
roles	O
of	O
IGFBP	B-geneN
-	I-geneN
rPs	E-geneN
in	O
the	O
human	O
prostate	O
.	O

IGFBP	B-geneY
-	I-geneY
rP1	E-geneY
and	O
IGFBP	B-geneY
-	I-geneY
rP2	E-geneY
are	O
likely	O
to	O
negatively	O
regulate	O
growth	O
,	O
because	O
they	O
seem	O
to	O
increase	O
during	O
senescence	O
of	O
the	O
prostate	O
epithelium	O
and	O
in	O
response	O
to	O
growth	O
inhibitors	O
(	O
TGF	B-geneY
-	I-geneY
beta1	E-geneY
and	O
atRA	O
)	O
.	O

Although	O
the	O
data	O
collected	O
on	O
IGFBP	B-geneY-C4-2
-	I-geneY-C4-2
rP3	E-geneY-C4-2
in	O
prostate	O
are	O
modest	O
,	O
its	O
role	O
as	O
a	O
growth	O
stimulator	O
and	O
/	O
or	O
protooncogene	O
is	O
supported	O
by	O
its	O
preferential	O
expression	O
in	O
cancerous	O
cells	O
and	O
its	O
down	O
-	O
regulation	O
by	O
atRA	S-chem-C4-1
.	O

Molecular	O
modeling	O
of	O
purinergic	B-geneN
receptor	E-geneN
P2Y12	S-geneY
and	O
interaction	O
with	O
its	O
antagonists	O
.	O

Purinergic	B-geneN
receptors	E-geneN
are	O
a	O
class	O
of	O
cell	O
surface	O
receptors	O
for	O
purines	S-chem
that	O
prefer	O
ATP	S-chem
or	O
ADP	S-chem
over	O
adenosine	S-chem
.	O

The	O
surface	O
receptors	O
for	O
extracellular	O
nucleotides	S-chem
are	O
called	O
P2	B-geneN
receptors	E-geneN
.	O

They	O
are	O
activated	O
by	O
both	O
pyrimidine	B-chem
and	I-chem
purine	I-chem
nucleotides	E-chem
.	O

ADP	S-chem-C3-1
initiates	O
platelet	O
aggregation	O
by	O
'	O
simultaneous	O
activation	O
of	O
two	O
G	B-geneN-C3-2
protein	I-geneN-C3-2
-	I-geneN-C3-2
coupled	I-geneN-C3-2
receptors	E-geneN-C3-2
,	O
P2Y1	S-geneY-C3-2
and	O
P2Y12	S-geneY-C3-2
.	O

P2Y12	S-geneY
has	O
been	O
shown	O
to	O
be	O
the	O
target	O
of	O
the	O
thienopyridine	S-chem
drugs	O
,	O
ticlopidine	S-chem
and	O
clopidogrel	S-chem
.	O

Here	O
,	O
the	O
active	O
sites	O
of	O
P2Y12	S-geneY
for	O
ATP	S-chem
as	O
well	O
as	O
ADP	S-chem
are	O
predicted	O
by	O
bioinformatics	O
and	O
molecular	O
modeling	O
.	O

First	O
,	O
the	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
structure	O
of	O
P2Y12	S-geneY
was	O
constructed	O
by	O
InsightII	O
/	O
Homology	O
module	O
using	O
the	O
corresponding	O
bovine	B-geneY
rhodopsin	E-geneY
(	O
PDB	B-geneY
code	I-geneY
:	I-geneY
1HZX	E-geneY
)	O
as	O
the	O
template	O
.	O

Then	O
the	O
primary	O
structures	O
were	O
optimized	O
by	O
energy	O
minimization	O
that	O
has	O
been	O
successfully	O
accepted	O
by	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	B-geneY
code	I-geneY
:	I-geneY
1VZ1	E-geneY
)	O
.	O

Second	O
,	O
a	O
simple	O
scoring	O
matrix	O
was	O
built	O
up	O
based	O
on	O
the	O
analysis	O
of	O
13	O
known	O
ATP	S-chem
-	O
binding	O
proteins	O
.	O

And	O
the	O
most	O
probable	O
active	O
sites	O
of	O
P2Y12	S-geneY
were	O
predicted	O
using	O
the	O
scoring	O
matrix	O
,	O
which	O
include	O
three	O
distant	O
areas	O
:	O
``	O
head	O
area	O
``	O
(	I-geneN
LGTGPLRTFV	O
,	O
87	O
-	O
96	O
)	O
,	O
``	O
middle	O
area	O
``	I-geneN
(	I-geneN
VGLITNGLAM	O
,	O
38	O
-	O
47	O
,	B-geneN
and	I-geneN
LGAKILSVVI	O
,	O
139	O
-	O
148	O
)	O
,	O
and	O
``	O
bottom	O
area	O
``	I-geneN
(	I-geneN
RTRGVGKVPR	O
,	O
222	O
-	O
231	O
)	O
.	O

Subsequently	O
the	O
structural	O
model	O
of	O
P2Y12	S-geneY
was	O
docked	O
with	O
ATP	S-chem
/	O
ADP	S-chem
in	O
comparison	O
with	O
P2Y1	S-geneY
(	O
PDB	B-geneY
code	I-geneY
1ddd	E-geneY
)	O
.	O

As	O
a	O
comparison	O
,	O
we	O
docked	O
its	O
antagonists	O
,	O
such	O
as	O
ticlopidine	S-chem
and	O
clopidogrel	S-chem
,	O
to	O
the	O
most	O
probable	O
sites	O
and	O
calculated	O
their	O
intermolecular	O
energy	O
.	O

Our	O
results	O
imply	O
that	O
P2Y12	S-geneY-C4-2
has	O
the	O
potential	O
to	O
be	O
inhibited	O
by	O
ADP	S-chem-C4-1
/	O
ATP	S-chem-C4-1
analogs	O
,	O
and	O
it	O
suggests	O
that	O
P2Y12	S-geneY
acts	O
as	O
a	O
target	O
of	O
new	O
drugs	O
that	O
inhibit	O
platelet	O
aggregation	O
.	O

Discovery	O
of	O
a	O
novel	O
series	O
of	O
quinolone	S-chem-C5-1
α7	B-geneY-C5-2
nicotinic	I-geneY-C5-2
acetylcholine	I-geneY-C5-2
receptor	E-geneY-C5-2
agonists	O
.	O

High	O
throughput	O
screening	O
led	O
to	O
the	O
identification	O
of	O
a	O
novel	O
series	O
of	O
quinolone	S-chem-C5-1
α7	B-geneY-C5-2
nicotinic	I-geneY-C5-2
acetylcholine	I-geneY-C5-2
receptor	E-geneY-C5-2
(	O
nAChR	S-geneN-C5-2
)	O
agonists	O
.	O

Optimization	O
of	O
an	O
HTS	O
hit	O
(	O
1	O
)	O
led	O
to	O
4	B-chem
-	I-chem
phenyl	I-chem
-	I-chem
1	I-chem
-	I-chem
(	I-chem
quinuclidin	I-chem
-	I-chem
3	I-chem
-	I-chem
ylmethyl	I-chem
)	I-chem
quinolin	I-chem
-	I-chem
2	I-chem
(	I-chem
1H	I-chem
)	I-chem
-	I-chem
one	E-chem
,	O
which	O
was	O
found	O
to	O
be	O
potent	O
and	O
selective	O
.	O

Poor	O
brain	O
penetrance	O
in	O
this	O
series	O
was	O
attributed	O
to	O
transporter	O
-	O
mediated	O
efflux	O
,	O
which	O
was	O
in	O
turn	O
due	O
to	O
high	O
pKa	O
.	O

A	O
novel	O
4	B-chem
-	I-chem
fluoroquinuclidine	E-chem
significantly	O
lowered	O
the	O
pKa	O
of	O
the	O
quinuclidine	S-chem
moiety	O
,	O
reducing	O
efflux	O
as	O
measured	O
by	O
a	O
Caco	O
-	O
2	O
assay	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
phosphorylated	B-chem-C4-1
flavonoids	E-chem-C4-1
as	O
potent	O
and	O
selective	O
inhibitors	O
of	O
cholesterol	B-geneY-C4-2
esterase	E-geneY-C4-2
.	O

A	O
series	O
of	O
phosphorylated	B-chem-C4-1
flavonoids	E-chem-C4-1
were	O
synthesized	O
and	O
investigated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
pancreatic	O
cholesterol	O
esterase	I-geneY-C4-2
(	E-geneY-C4-2
CEase	O
)	E-geneY-C4-2
and	O
acetylcholinesterase	O
(	E-geneY-C4-2
AChE	O
)	E-geneY-C4-2
.	O

The	O
results	O
showed	O
that	O
most	O
of	O
the	O
synthesized	O
compounds	O
exhibited	O
nanomolar	O
potency	O
against	O
CEase	S-geneY-C4-2
,	O
much	O
better	O
than	O
the	O
parent	O
flavonoids	S-chem-C4-1
.	O

Furthermore	O
,	O
these	O
phosphorylated	B-chem-C4-1
flavonoids	E-chem-C4-1
demonstrated	O
good	O
to	O
high	O
selectivity	O
for	O
CEase	S-geneY-C4-2
over	O
AChE	S-geneY-C4-2
,	O
which	O
only	O
showed	O
micromolar	O
potency	O
inhibition	O
of	O
AChE	S-geneY-C4-2
.	O

The	O
most	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CEase	S-geneY
(	O
3e	O
)	O
had	O
IC50	O
value	O
of	O
0.72	O
nM	O
and	O
11800	O
-	O
fold	O
selectivity	O
for	O
CEase	O
over	O
AChE	O
.	E-geneY

The	O
structure	O
-	O
activity	O
relationships	O
revealed	O
that	O
the	O
free	O
hydroxyl	S-chem-C4-1
group	O
at	O
position	O
5	O
and	O
phosphate	S-chem-C4-1
group	O
at	O
position	O
7	O
of	O
the	O
phosphorylated	B-chem-C4-1
flavonoids	E-chem-C4-1
are	O
favorable	O
to	O
the	O
inhibition	O
of	O
CEase	S-geneY-C4-2
.	O

The	O
inhibition	O
mechanism	O
and	O
kinetic	O
characterization	O
studies	O
indicated	O
that	O
they	O
are	O
irreversible	O
competitive	O
inhibitors	O
of	O
CEase	S-geneY
.	O

(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
tamsulosin	E-chem-C6-1
,	O
an	O
alpha	B-geneY-C6-2
1A	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
,	O
inhibits	O
the	O
positive	O
inotropic	O
effect	O
but	O
not	O
the	O
accumulation	O
of	O
inositol	B-chem
phosphates	E-chem
in	O
rabbit	O
heart	O
.	O

The	O
influence	O
of	O
(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
tamsulosin	E-chem-C6-1
,	O
a	O
selective	O
alpha	B-geneY-C6-2
1A	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
,	O
on	O
the	O
positive	O
inotropic	O
effect	O
and	O
the	O
accumulation	O
of	O
inositol	B-chem
phosphates	E-chem
that	O
are	O
induced	O
via	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
was	O
studied	O
in	O
comparison	O
with	O
that	O
of	O
another	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
ligand	O
oxymetazoline	S-chem
in	O
the	O
rabbit	O
ventricular	O
myocardium	O
.	O

Phenylephrine	S-chem-C5-1
elicited	O
a	O
concentration	O
-	O
dependent	O
positive	O
inotropic	O
effect	O
via	O
alpha	B-geneN-C5-2
1	I-geneN-C5-2
-	I-geneN-C5-2
adrenoceptors	E-geneN-C5-2
in	O
the	O
presence	O
of	O
either	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
bupranolol	E-chem
or	O
S	B-chem
(	I-chem
-	I-chem
)	I-chem
-	I-chem
timolol	E-chem
.	O

The	O
mode	O
of	O
antagonism	O
induced	O
by	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
on	O
the	O
effect	O
of	O
phenylephrine	S-chem
was	O
dependent	O
or	O
the	O
concentration	O
applied	O
:	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
at	O
1	O
and	O
3	O
nM	O
acted	O
in	O
a	O
competitive	O
manner	O
,	O
the	O
slope	O
of	O
the	O
regression	O
line	O
of	O
the	O
Schild	O
plot	O
being	O
unity	O
and	O
the	O
pA2	O
value	O
being	O
9.12	O
;	O
at	O
10	O
nM	O
,	O
it	O
shifted	O
further	O
the	O
concentration	O
-	O
response	O
curve	O
to	O
the	O
right	O
without	O
affecting	O
the	O
maximal	O
response	O
but	O
the	O
slope	O
became	O
less	O
than	O
unity	O
.	O

At	O
100	O
nM	O
and	O
higher	O
,	O
it	O
suppressed	O
the	O
maximal	O
response	O
to	O
phenylephrine	S-chem
.	O

(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
Tamsulosin	E-chem-C6-1
effectively	O
antagonized	O
the	O
positive	O
inotropic	O
effect	O
of	O
phenylephrine	S-chem-C5-1
even	O
after	O
inactivation	O
of	O
alpha	B-geneY-MU-2
1B	I-geneY-MU-2
-	I-geneY-MU-2
adrenoceptors	E-geneY-MU-2
by	O
treatment	O
with	O
chlorethylclonidine	S-chem-C4-1
,	O
which	O
is	O
an	O
indication	O
that	O
the	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
-	O
sensitive	O
subtype	O
belongs	O
to	O
a	O
class	O
resistant	O
to	O
chlorethylclonidine	S-chem
.	O

(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
Tamsulosin	E-chem-C6-1
,	O
over	O
the	O
range	O
of	O
concentrations	O
at	O
which	O
it	O
antagonized	O
the	O
positive	O
inotropic	O
effect	O
mediated	O
by	O
alpha	B-geneN-C6-2
1	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptors	E-geneN-C6-2
,	O
did	O
not	O
affect	O
the	O
accumulation	O
of	O
[	B-chem
3H	I-chem
]	I-chem
inositol	I-chem
phosphates	E-chem
that	O
was	O
induced	O
by	O
10	O
microM	O
phenylephrine	S-chem
.	O

Oxymetazoline	S-chem
antagonized	O
the	O
positive	O
inotropic	O
effect	O
of	O
phenylephrine	S-chem
in	O
a	O
competitive	O
manner	O
without	O
affecting	O
the	O
accumulation	O
of	O
inositol	B-chem
monophosphate	E-chem
induced	O
by	O
phenylephrine	S-chem
.	O

These	O
results	O
indicate	O
that	O
the	O
positive	O
inotropic	O
effect	O
,	O
mediated	O
via	O
(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
tamsulosin	E-chem-C6-1
-	O
and	O
oxymetazoline	S-chem-C5-1
-	O
sensitive	O
subtype	O
of	O
alpha	B-geneN-MU-2
1	I-geneN-MU-2
-	I-geneN-MU-2
adrenoceptors	E-geneN-MU-2
,	O
is	O
exerted	O
by	O
a	O
subcellular	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
accumulation	O
of	O
inositol	B-chem
phosphates	E-chem
.	O

Discovery	O
of	O
novel	O
2	B-chem-C4-1
-	I-chem-C4-1
hydroxydiarylamide	E-chem-C4-1
derivatives	O
as	O
TMPRSS4	S-geneY-C4-2
inhibitors	O
.	O

TMPRSS4	S-geneY
is	O
a	O
novel	O
type	B-geneN
II	I-geneN
transmembrane	I-geneN
serine	I-geneN
protease	E-geneN
that	O
has	O
been	O
implicated	O
in	O
the	O
invasion	O
and	O
metastasis	O
of	O
colon	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
series	O
of	O
2	B-chem-C4-1
-	I-chem-C4-1
hydroxydiarylamide	E-chem-C4-1
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibiting	O
TMPRSS4	S-geneY-C4-2
serine	B-geneN-C4-2
protease	E-geneN-C4-2
activity	O
and	O
suppressing	O
cancer	O
cell	O
invasion	O
.	O

These	O
derivatives	O
demonstrated	O
good	O
inhibitory	O
activity	O
against	O
TMPRSS4	S-geneY
serine	B-geneN
protease	E-geneN
,	O
which	O
correlated	O
with	O
the	O
promising	O
anti	O
-	O
invasive	O
activity	O
of	O
colon	O
cancer	O
cells	O
overexpressing	O
TMPRSS4	S-geneY
.	O

Downregulation	O
of	O
glutaredoxin	S-geneN
but	O
not	O
glutathione	S-chem
loss	O
leads	O
to	O
mitochondrial	O
dysfunction	O
in	O
female	O
mice	O
CNS	O
:	O
implications	O
in	O
excitotoxicity	O
.	O

Oxidative	O
stress	O
,	O
excitotoxicity	O
and	O
mitochondrial	O
dysfunction	O
play	O
synergistic	O
roles	O
in	O
neurodegeneration	O
.	O

Maintenance	O
of	O
thiol	S-chem
homeostasis	O
is	O
important	O
for	O
normal	O
mitochondrial	O
function	O
and	O
dysregulation	O
of	O
protein	O
thiol	S-chem
homeostasis	O
by	O
oxidative	O
stress	O
leads	O
to	O
mitochondrial	O
dysfunction	O
and	O
neurodegeneration	O
.	O

We	O
examined	O
the	O
critical	O
roles	O
played	O
by	O
the	O
antioxidant	O
,	O
non	O
-	O
protein	O
thiol	S-chem
,	O
glutathione	S-chem
and	O
related	O
enzyme	O
,	O
glutaredoxin	S-geneN
in	O
maintaining	O
mitochondrial	O
function	O
during	O
excitotoxicity	O
caused	O
by	O
beta	B-chem
-	I-chem
N	I-chem
-	I-chem
oxalyl	I-chem
amino	I-chem
-	I-chem
L	I-chem
-	I-chem
alanine	E-chem
(	O
L	B-chem
-	I-chem
BOAA	E-chem
)	O
,	O
the	O
causative	O
factor	O
of	O
neurolathyrism	O
,	O
a	O
motor	O
neuron	O
disease	O
involving	O
the	O
pyramidal	O
system	O
.	O

L	B-chem-C4-1
-	I-chem-C4-1
BOAA	E-chem-C4-1
causes	O
loss	O
of	O
GSH	S-chem
and	O
inhibition	O
of	O
mitochondrial	B-geneN-C4-2
complex	I-geneN-C4-2
I	E-geneN-C4-2
in	O
lumbosacral	O
cord	O
of	O
male	O
mice	O
through	O
oxidation	O
of	O
thiol	S-chem
groups	O
,	O
while	O
female	O
mice	O
are	O
resistant	O
.	O

Reducing	O
GSH	S-chem
levels	O
in	O
female	O
mice	O
CNS	O
by	O
pretreatment	O
with	O
diethyl	B-chem
maleate	E-chem
or	O
L	B-chem
-	I-chem
propargyl	I-chem
glycine	E-chem
did	O
not	O
result	O
in	O
inhibition	O
of	O
complex	B-geneN
I	E-geneN
activity	O
,	O
unlike	O
male	O
mice	O
.	O

Further	O
,	O
treatment	O
of	O
female	O
mice	O
depleted	O
of	O
GSH	S-chem
with	O
L	B-chem
-	I-chem
BOAA	E-chem
did	O
not	O
induce	O
inhibition	O
of	O
complex	B-geneN
I	E-geneN
indicating	O
that	O
GSH	S-chem
levels	O
were	O
not	O
critical	O
for	O
maintaining	O
complex	B-geneN
I	E-geneN
activity	O
in	O
female	O
mice	O
unlike	O
their	O
male	O
counterpart	O
.	O

Glutaredoxin	S-geneN
,	O
a	O
thiol	B-geneN
disulfide	I-geneN
oxidoreductase	E-geneN
helps	O
maintain	O
redox	O
status	O
of	O
proteins	O
and	O
downregulation	O
of	O
glutaredoxin	S-geneN
results	O
in	O
loss	O
of	O
mitochondrial	B-geneN
complex	I-geneN
I	E-geneN
activity	O
.	O

Female	O
mice	O
express	O
higher	O
levels	O
of	O
glutaredoxin	S-geneN
in	O
certain	O
CNS	O
regions	O
and	O
downregulation	O
of	O
glutaredoxin	S-geneN
using	O
antisense	O
oligonucleotides	O
sensitizes	O
them	O
to	O
L	B-chem-C4-1
-	I-chem-C4-1
BOAA	E-chem-C4-1
toxicity	O
seen	O
as	O
mitochondrial	B-geneN-C4-2
complex	I-geneN-C4-2
I	E-geneN-C4-2
loss	O
.	O

Ovariectomy	O
downregulates	O
glutaredoxin	S-geneN
and	O
renders	O
female	O
mice	O
vulnerable	O
to	O
L	B-chem-C3-1
-	I-chem-C3-1
BOAA	E-chem-C3-1
toxicity	O
as	O
evidenced	O
by	O
activation	O
of	O
AP1	S-geneY-C3-2
,	O
loss	O
of	O
GSH	S-chem
and	O
complex	B-geneN-C3-2
I	E-geneN-C3-2
activity	O
indicating	O
the	O
important	O
role	O
of	O
glutaredoxin	S-geneN
in	O
neuroprotection	O
.	O

Estrogen	S-chem-C3-1
protects	O
against	O
mitochondrial	O
dysfunction	O
caused	O
by	O
excitotoxicity	O
by	O
maintaining	O
cellular	O
redox	O
status	O
through	O
higher	O
constitutive	O
expression	O
of	O
glutaredoxin	S-geneN-C3-2
in	O
the	O
CNS	O
.	O

Therapeutic	O
interventions	O
designed	O
to	O
upregulate	O
glutaredoxin	S-geneN
may	O
offer	O
neuroprotection	O
against	O
excitotoxicity	O
in	O
motor	O
neurons	O
.	O

Assessment	O
of	O
the	O
role	O
of	O
flavonoids	S-chem
for	O
inducing	O
osteoblast	O
differentiation	O
in	O
isolated	O
mouse	O
bone	O
marrow	O
derived	O
mesenchymal	O
stem	O
cells	O
.	O

Quercetin	S-chem
and	O
rutin	S-chem
are	O
common	O
flavonoids	S-chem
in	O
fruit	O
and	O
vegetables	O
,	O
and	O
have	O
been	O
reported	O
to	O
affect	O
bone	O
development	O
.	O

However	O
,	O
the	O
effect	O
of	O
flavonoids	S-chem
on	O
osteoblast	O
differentiation	O
remains	O
a	O
matter	O
of	O
controversy	O
.	O

In	O
the	O
present	O
study	O
,	O
mouse	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
BMMSCs	O
)	O
were	O
isolated	O
and	O
characterized	O
for	O
their	O
use	O
in	O
osteoblast	O
differentiation	O
using	O
two	O
flavonoids	S-chem
,	O
quercetin	S-chem
and	O
rutin	S-chem
.	O

BMMSCs	O
were	O
cultured	O
in	O
various	O
concentrations	O
of	O
quercetin	S-chem
and	O
rutin	S-chem
during	O
the	O
osteoblast	O
differentiation	O
period	O
of	O
10	O
days	O
.	O

Both	O
quercetin	S-chem
and	O
rutin	S-chem
were	O
found	O
to	O
up	O
regulate	O
the	O
osteoblast	O
differentiation	O
in	O
dose	O
dependent	O
manner	O
,	O
albeit	O
to	O
lesser	O
extent	O
in	O
case	O
of	O
former	O
than	O
that	O
of	O
latter	O
.	O

Quercetin	S-chem-C3-1
and	O
rutin	S-chem-C3-1
also	O
increased	O
alkaline	B-geneN-C3-2
phosphatase	E-geneN-C3-2
activity	O
by	O
about	O
150	O
and	O
240	O
%	O
and	O
demonstrated	O
mineralization	O
up	O
to	O
110	O
and	O
200	O
%	O
respectively	O
as	O
compared	O
to	O
control	O
(	O
which	O
was	O
considered	O
as	O
100	O
%	O
)	O
.	O

Further	O
,	O
both	O
the	O
flavonoids	S-chem-C3-1
were	O
also	O
found	O
to	O
increase	O
the	O
expression	O
of	O
some	O
of	O
the	O
prominent	O
markers	O
for	O
differentiation	O
of	O
osteoblast	O
like	O
osteopontin	S-geneY-C3-2
,	O
osterix	S-geneY-C3-2
,	O
RunX2	S-geneY-C3-2
,	O
osteoprotegerin	S-geneY-C3-2
and	O
osteocalcin	S-geneY-C3-2
.	O

The	O
current	O
data	O
suggests	O
that	O
certain	O
classes	O
of	O
flavonoids	S-chem
like	O
rutin	S-chem
and	O
quercetin	S-chem
can	O
be	O
used	O
in	O
the	O
cure	O
and	O
management	O
of	O
osteodegenerative	O
disorders	O
due	O
to	O
their	O
osteoblast	O
specific	O
differentiation	O
activities	O
.	O

R	B-chem
-	I-chem
modafinil	E-chem
(	O
armodafinil	S-chem
)	O
:	O
a	O
unique	O
dopamine	S-chem
uptake	O
inhibitor	O
and	O
potential	O
medication	O
for	O
psychostimulant	O
abuse	O
.	O

BACKGROUND	O
:	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
Modafinil	E-chem
has	O
piqued	O
interest	O
as	O
a	O
treatment	O
for	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
and	O
stimulant	O
dependence	O
.	O

The	O
R	B-chem
-	I-chem
enantiomer	I-chem
of	I-chem
modafinil	E-chem
might	O
have	O
unique	O
pharmacological	O
properties	O
that	O
should	O
be	O
further	O
investigated	O
.	O

METHODS	O
:	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
Modafinil	E-chem
and	O
its	O
R	O
-	O
(	O
-	O
)	O
-	O
and	O
S	O
-	O
(	O
+	O
)	O
-	O
enantiomers	O
were	O
synthesized	O
and	O
tested	O
for	O
inhibition	O
of	O
[	B-chem-C9-1
(	I-chem-C9-1
3	I-chem-C9-1
)	I-chem-C9-1
H	I-chem-C9-1
]	I-chem-C9-1
dopamine	E-chem-C9-1
(	O
DA	S-chem-C9-1
)	O
uptake	O
and	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
WIN	I-chem
35428	E-chem
binding	O
in	O
human	B-geneY-C9-2
dopamine	I-geneY-C9-2
transporter	E-geneY-C9-2
(	O
DAT	S-geneY-C9-2
)	O
wild	O
-	O
type	O
and	O
mutants	O
with	O
altered	O
conformational	O
equilibria	O
.	O

Data	O
were	O
compared	O
with	O
cocaine	S-chem
and	O
the	O
atypical	O
DA	S-chem
uptake	O
inhibitor	O
,	O
JHW	B-chem
007	E-chem
.	O

R	B-chem
-	I-chem
and	I-chem
S	I-chem
-	I-chem
modafinil	E-chem
were	O
also	O
evaluated	O
in	O
microdialysis	O
studies	O
in	O
the	O
mouse	O
nucleus	O
accumbens	O
shell	O
and	O
in	O
a	O
cocaine	S-chem
discrimination	O
procedure	O
.	O

RESULTS	O
:	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
,	I-chem
R	I-chem
-	I-chem
,	I-chem
and	I-chem
S	I-chem
-	I-chem
modafinil	E-chem
bind	O
to	O
the	O
DAT	S-geneY-C9-2
and	O
inhibit	O
DA	S-chem-C9-1
uptake	O
less	O
potently	O
than	O
cocaine	S-chem
,	O
with	O
R	B-chem
-	I-chem
modafinil	E-chem
having	O
approximately	O
threefold	O
higher	O
affinity	O
than	O
its	O
S	O
-	O
enantiomer	O
.	O

Molecular	O
docking	O
studies	O
revealed	O
subtle	O
differences	O
in	O
binding	O
modes	O
for	O
the	O
enantiomers	O
.	O

R	B-chem
-	I-chem
modafinil	E-chem
was	O
significantly	O
less	O
potent	O
in	O
the	O
DAT	S-geneY
Y156F	S-geneN
mutant	O
compared	O
with	O
wild	O
-	O
type	O
DAT	S-geneY
,	O
whereas	O
S	B-chem
-	I-chem
modafinil	E-chem
was	O
affected	O
less	O
.	O

Studies	O
with	O
the	O
Y335A	S-geneN
DAT	S-geneY
mutant	O
showed	O
that	O
the	O
R	O
-	O
and	O
S	O
-	O
enantiomers	O
tolerated	O
the	O
inward	O
-	O
facing	O
conformation	O
better	O
than	O
cocaine	S-chem
,	O
which	O
was	O
further	O
supported	O
by	O
[	B-chem
2	I-chem
-	I-chem
(	I-chem
trimethylammonium	I-chem
)	I-chem
ethyl	I-chem
]	I-chem
-	I-chem
methanethiosulfonate	E-chem
reactivity	O
on	O
the	O
DAT	S-geneY
E2C	S-geneN
I159C	S-geneN
.	O

Microdialysis	O
studies	O
demonstrated	O
that	O
both	O
R	B-chem
-	I-chem
and	I-chem
S	I-chem
-	I-chem
modafinil	E-chem
produced	O
increases	O
in	O
extracellular	O
DA	S-chem
concentrations	O
in	O
the	O
nucleus	O
accumbens	O
shell	O
less	O
efficaciously	O
than	O
cocaine	S-chem
and	O
with	O
a	O
longer	O
duration	O
of	O
action	O
.	O

Both	O
enantiomers	O
fully	O
substituted	O
in	O
mice	O
trained	O
to	O
discriminate	O
cocaine	S-chem
from	O
saline	O
.	O

CONCLUSIONS	O
:	O
R	B-chem
-	I-chem
modafinil	E-chem
displays	O
an	O
in	O
vitro	O
profile	O
different	O
from	O
cocaine	S-chem
.	O

Future	O
trials	O
with	O
R	B-chem
-	I-chem
modafinil	E-chem
as	O
a	O
substitute	O
therapy	O
with	O
the	O
potential	O
benefit	O
of	O
cognitive	O
enhancement	O
for	O
psychostimulant	O
addiction	O
are	O
warranted	O
.	O

Defective	O
DNA	O
damage	O
response	O
and	O
repair	O
in	O
liver	O
cells	O
expressing	O
hepatitis	B-geneY
B	I-geneY
virus	I-geneY
surface	I-geneY
antigen	E-geneY
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
is	O
implicated	O
in	O
liver	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
out	O
whether	O
HBV	O
or	O
its	O
components	O
[	O
HBV	B-geneY
surface	I-geneY
antigen	E-geneY
(	O
HBsAg	S-geneY
)	O
,	O
HBV	B-geneY
core	I-geneY
protein	E-geneY
(	O
HBc	S-geneY
)	O
,	O
and	O
HBV	B-geneY
X	I-geneY
protein	E-geneY
(	O
HBx	S-geneY
)	O
]	O
could	O
interfere	O
with	O
the	O
host	O
DNA	O
damage	O
response	O
and	O
repair	O
pathway	O
.	O

The	O
full	O
HBV	O
genome	O
or	O
individual	O
HBV	B-geneN
open	I-geneN
-	I-geneN
reading	I-geneN
frame	E-geneN
(	O
ORF	S-geneN
)	O
was	O
introduced	O
into	O
HepG2	O
cells	O
to	O
examine	O
the	O
effect	O
on	O
host	O
genomic	O
stability	O
,	O
DNA	O
repair	O
efficacy	O
in	O
response	O
to	O
double	O
-	O
strand	O
DNA	O
damage	O
,	O
and	O
DNA	O
damage	O
-	O
induced	O
cell	O
death	O
.	O

Responses	O
to	O
apoptosis	O
induction	O
in	O
the	O
HBV	B-geneN
ORF	E-geneN
-	O
transfected	O
HepG2	O
cells	O
were	O
also	O
compared	O
with	O
those	O
in	O
HBV	O
-	O
positive	O
and	O
HBV	O
-	O
negative	O
human	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
.	O

In	O
the	O
absence	O
of	O
HBV	O
replication	O
,	O
accumulation	O
of	O
HBsAg	S-geneY
in	O
liver	O
cells	O
without	O
other	O
HBV	O
proteins	O
enhanced	O
DNA	O
repair	O
protein	O
and	O
tumor	O
suppressor	O
promyelocytic	B-geneY
leukemia	E-geneY
(	O
PML	S-geneY
)	O
degradation	O
,	O
which	O
resulted	O
in	O
resistance	O
to	O
apoptosis	O
induction	O
and	O
deficient	O
double	O
-	O
strand	O
DNA	O
repair	O
.	O

However	O
,	O
HBsAg	S-geneY
-	O
positive	O
cells	O
exhibited	O
increased	O
cell	O
death	O
with	O
exposure	O
to	O
the	O
poly	B-geneN
(	I-geneN
ADP	I-geneN
-	I-geneN
ribose	I-geneN
)	I-geneN
polymerase	E-geneN
inhibitor	O
that	O
blocks	O
single	O
-	O
strand	O
DNA	O
repair	O
.	O

These	O
results	O
indicate	O
that	O
suppression	O
of	O
PML	S-geneY
by	O
HBsAg	S-geneY
disrupts	O
cellular	O
mechanisms	O
that	O
respond	O
to	O
double	O
-	O
strand	O
DNA	O
damage	O
for	O
DNA	O
repair	O
or	O
apoptosis	O
induction	O
,	O
which	O
may	O
facilitate	O
hepatocarcinogenesis	O
and	O
open	O
up	O
a	O
synthetic	O
lethality	O
strategy	O
for	O
HBsAg	S-geneY
-	O
positive	O
HCC	O
treatment	O
.	O
-	O
Chung	O
,	O
Y	O
.	O
-	O
L	O
.	O

Defective	O
DNA	O
damage	O
response	O
and	O
repair	O
in	O
liver	O
cells	O
expressing	O
hepatitis	B-geneY
B	I-geneY
virus	I-geneY
surface	I-geneY
antigen	E-geneY
.	O

Modulation	O
of	O
the	O
JAK	S-geneN
/	O
ERK	S-geneN
/	O
STAT	S-geneN
signaling	O
in	O
melanocortin	S-geneY
-	O
induced	O
inhibition	O
of	O
local	O
and	O
systemic	O
responses	O
to	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

The	O
janus	B-geneN
kinases	E-geneN
(	O
JAK	S-geneN
)	O
,	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinases	E-geneN
(	O
ERK	S-geneN
)	O
and	O
signal	B-geneN
transducers	I-geneN
and	I-geneN
activators	I-geneN
of	I-geneN
transcription	E-geneN
(	O
STAT	S-geneN
)	O
pathways	O
have	O
been	O
shown	O
to	O
play	O
a	O
cardioprotective	O
role	O
.	O

We	O
previously	O
gave	O
evidence	O
that	O
melanocortins	S-geneY
afford	O
cardioprotection	O
in	O
conditions	O
of	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

Here	O
we	O
aimed	O
to	O
investigate	O
the	O
influence	O
of	O
melanocortins	S-geneY
on	O
the	O
JAK	S-geneN
/	O
ERK	S-geneN
/	O
STAT	S-geneN
signaling	O
in	O
cardiac	O
and	O
systemic	O
responses	O
to	O
prolonged	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

Ischemia	O
was	O
produced	O
in	O
rats	O
by	O
ligature	O
of	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
for	O
30min	O
.	O

At	O
the	O
end	O
of	O
the	O
2	O
-	O
h	O
reperfusion	O
,	O
western	O
blot	O
analysis	O
of	O
the	O
cardioprotective	O
transcription	O
factors	O
pJAK2	S-geneY
,	O
pERK1	B-geneN
/	I-geneN
2	E-geneN
,	O
pTyr	B-geneY
-	I-geneY
STAT3	E-geneY
and	O
pSer	B-geneY
-	I-geneY
STAT3	E-geneY
,	O
the	O
inflammatory	O
mediator	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
α	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
the	O
pro	O
-	O
apoptotic	O
factors	O
BAX	S-geneY
and	O
c	B-geneN
-	I-geneN
jun	I-geneN
N	I-geneN
-	I-geneN
terminal	I-geneN
kinases	E-geneN
(	O
pJNK	S-geneN
)	O
,	O
the	O
anti	O
-	O
apoptotic	O
protein	O
Bcl	B-geneY
-	I-geneY
XL	E-geneY
,	O
as	O
well	O
as	O
of	O
the	O
cardioprotective	O
enzyme	O
heme	B-geneY
oxygenase	I-geneY
-	I-geneY
1	E-geneY
(	O
HO	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
was	O
performed	O
in	O
the	O
left	O
ventricle	O
and	O
spleen	O
.	O

Intravenous	O
treatment	O
,	O
during	O
coronary	O
artery	O
occlusion	O
,	O
with	O
the	O
melanocortin	S-geneY
analogs	O
[	O
Nle	S-chem
(	O
4	O
)	O
,	O
D	B-chem
-	I-chem
Phe	E-chem
(	O
7	O
)	O
]	O
α	B-geneY
-	I-geneY
melanocyte	I-geneY
-	I-geneY
stimulating	I-geneY
hormone	E-geneY
(	O
NDP	O
-	O
α	B-geneY
-	I-geneY
MSH	E-geneY
)	O
and	O
adrenocorticotropic	B-geneY
hormone	I-geneY
1	I-geneY
-	I-geneY
24	E-geneY
[	O
ACTH	B-geneY
-	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
24	I-geneY
)	E-geneY
]	O
,	O
induced	O
a	O
left	O
ventricle	O
up	O
-	O
regulation	O
of	O
pJAK2	S-geneY
,	O
pERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
pTyr	B-geneY
-	I-geneY
STAT3	E-geneY
(	O
JAK	S-geneN
-	O
dependent	O
)	O
,	O
and	O
a	O
reduction	O
in	O
pJNK	S-geneN
and	O
TNF	B-geneY
-	I-geneY
α	E-geneY
levels	O
;	O
these	O
effects	O
of	O
NDP	O
-	O
α	B-geneY
-	I-geneY
MSH	E-geneY
and	O
ACTH	B-geneY
-	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
24	I-geneY
)	E-geneY
were	O
associated	O
with	O
over	O
-	O
expression	O
of	O
the	O
pro	O
-	O
survival	O
proteins	O
HO	B-geneY
-	I-geneY
1	E-geneY
and	O
Bcl	B-geneY
-	I-geneY
XL	E-geneY
,	O
and	O
marked	O
decrease	O
of	O
the	O
myocardial	O
infarct	O
size	O
.	O

Melanocortin	S-geneY
treatment	O
did	O
not	O
affect	O
left	O
ventricle	O
pSer	B-geneY
-	I-geneY
STAT3	E-geneY
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
-	O
dependent	O
)	O
and	O
BAX	S-geneY
levels	O
.	O

In	O
the	O
spleen	O
,	O
NDP	O
-	O
α	B-geneY
-	I-geneY
MSH	E-geneY
and	O
ACTH	B-geneY
-	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
24	I-geneY
)	E-geneY
induced	O
similar	O
effects	O
on	O
the	O
expression	O
of	O
the	O
above	O
transcription	O
factors	O
/	O
proteins	O
,	O
except	O
for	O
pERK1	B-geneN
/	I-geneN
2	E-geneN
(	O
down	O
-	O
regulated	O
)	O
and	O
HO	B-geneY
-	I-geneY
1	E-geneY
(	O
unaffected	O
)	O
.	O

Blockade	O
of	O
JAK	S-geneN-C4-2
and	O
ERK	S-geneN-C4-2
pathways	O
with	O
AG490	S-chem-C4-1
and	O
U0126	S-chem-C4-1
,	O
respectively	O
,	O
abrogated	O
the	O
myocardial	O
infarct	O
size	O
reduction	O
by	O
NDP	O
-	O
α	B-geneY
-	I-geneY
MSH	E-geneY
.	O

These	O
results	O
indicate	O
that	O
melanocortins	S-geneY
inhibit	O
local	O
and	O
systemic	O
inflammatory	O
and	O
apoptotic	O
cascades	O
triggered	O
by	O
prolonged	O
myocardial	O
ischemia	O
/	O
reperfusion	O
,	O
with	O
consequent	O
reduction	O
in	O
myocardium	O
infarct	O
size	O
,	O
seemingly	O
via	O
activation	O
of	O
the	O
JAK	S-geneN
/	O
STAT	S-geneN
signaling	O
and	O
with	O
modulation	O
of	O
an	O
ERK	S-geneN
(	O
STAT	S-geneN
unrelated	O
)	O
signaling	O
pathway	O
.	O

Swim	O
training	O
of	O
monosodium	B-chem
L	I-chem
-	I-chem
glutamate	E-chem
-	O
obese	O
mice	O
improves	O
the	O
impaired	O
insulin	B-geneY
receptor	E-geneY
tyrosine	S-chem
phosphorylation	O
in	O
pancreatic	O
islets	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
on	O
glucose	S-chem
homoeostasis	O
and	O
of	O
the	O
insulin	B-geneY
receptor	E-geneY
(	O
IR	S-geneY
)	O
and	O
insulin	B-geneY
receptor	I-geneY
substrate	I-geneY
-	I-geneY
1	E-geneY
(	O
IRS	B-geneY
-	I-geneY
1	E-geneY
)	O
signalling	O
in	O
pancreatic	O
islets	O
from	O
MSG	S-chem
-	O
obese	O
mice	O
submitted	O
to	O
or	O
not	O
submitted	O
to	O
swim	O
training	O
.	O

Swim	O
training	O
of	O
90	O
-	O
day	O
-	O
old	O
MSG	S-chem
mice	O
was	O
used	O
to	O
evaluate	O
whether	O
signalling	O
pathways	O
of	O
the	O
IR	S-geneY
and	O
IRS	B-geneY
-	I-geneY
1	E-geneY
in	O
islets	O
are	O
involved	O
with	O
the	O
insulin	S-geneN
resistance	O
and	O
glucose	S-chem
intolerance	O
observed	O
in	O
this	O
obese	O
animal	O
model	O
.	O

The	O
results	O
showed	O
that	O
IR	S-geneY
tyrosine	S-chem
phosphorylation	O
(	O
pIR	S-geneY-C4-2
)	O
was	O
reduced	O
by	O
42	O
%	O
in	O
MSG	O
-	E-chem-C4-1
obese	O
mice	O
(	O
MSG	O
,	E-chem-C4-1
6.7	O
±	O
0.2	O
arbitrary	O
units	O
(	O
a.u	O
.	O
)	O
;	O
control	O
,	O
11.5	O
±	O
0.4	O
a.u	O
.	O
)	O
;	O
on	O
the	O
other	O
hand	O
,	O
exercise	O
training	O
increased	O
pIR	O
by	O
76	O
%	B-geneY-C4-2
in	E-geneY-C4-2
MSG	O
mice	O
without	O
affecting	O
control	O
mice	O
(	O
MSG	O
,	O
11.8	O
±	B-chem-C4-1
0.3	O
;	O
control	O
,	O
12.8	O
±	O
0.2	O
a.u	O
.	O
)	O
.	O

Although	O
the	O
treatment	O
with	O
MSG	S-chem-C3-1
increased	O
IRS	B-geneY
-	I-geneY
1	E-geneY
tyrosine	S-chem
phosphorylation	O
(	O
pIRS	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
)	O
by	O
96	O
%	O
(	O
MSG	O
,	E-chem-C3-1
17.02	O
±	O
0.6	O
;	O
control	O
,	O
8.7	O
±	O
0.2	O
a.u	O
.	O
)	O
,	O
exercise	O
training	O
also	O
increased	O
it	O
in	O
both	O
groups	O
(	O
control	O
,	O
13.6	O
±	O
0.1	O
;	O
MSG	O
,	O
22.2	O
±	B-chem-C3-1
1.1	O
a.u	O
.	O
)	O
.	O

Current	O
research	O
shows	O
that	O
the	O
practice	O
of	O
swim	O
training	O
increases	O
the	O
tyrosine	S-chem
phosphorylation	O
of	O
IRS	B-geneY
-	I-geneY
1	E-geneY
which	O
can	O
modulate	O
the	O
effect	O
caused	O
by	O
obesity	O
in	O
insulin	B-geneY
receptors	E-geneY
.	O

[	O
Preclinical	O
pharmacology	O
of	O
amoxapine	S-chem
and	O
amitriptyline	S-chem
.	O
Implications	O
of	O
serotoninergic	O
and	O
opiodergic	O
systems	O
in	O
their	O
central	O
effect	O
in	O
rats	O
]	O
.	O

The	O
effects	O
of	O
two	O
antidepressant	O
drugs	O
,	O
amoxapine	S-chem
and	O
amitriptyline	S-chem
,	O
that	O
belong	O
to	O
distinct	O
chemical	O
classes	O
,	O
have	O
been	O
examined	O
on	O
various	O
biochemical	O
parameters	O
related	O
to	O
serotoninergic	O
and	O
opioidergic	O
neurotransmission	O
in	O
the	O
rat	O
brain	O
and	O
spinal	O
cord	O
.	O

In	O
vitro	O
binding	O
studies	O
showed	O
that	O
both	O
amoxapine	S-chem
and	O
amitriptyline	S-chem
interact	O
in	O
the	O
nanomolar	O
range	O
with	O
5	B-geneN
-	I-geneN
HT2	E-geneN
receptors	O
labelled	O
by	O
[	B-chem
3H	I-chem
]	I-chem
ketanserin	E-chem
in	O
cortical	O
membranes	O
.	O

By	O
contrast	O
,	O
neither	O
amoxapine	S-chem
nor	O
amitriptyline	S-chem
can	O
be	O
considered	O
as	O
possible	O
ligands	O
of	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
because	O
their	O
affinities	O
for	O
these	O
sites	O
are	O
in	O
the	O
micromolar	O
range	O
(	O
or	O
even	O
worse	O
)	O
.	O

Interestingly	O
,	O
amoxapine	S-chem
binds	O
with	O
a	O
good	O
affinity	O
(	O
IC50	O
=	O
0.30	O
microM	O
)	O
to	O
5	B-geneN
-	I-geneN
HT3	E-geneN
receptors	O
labelled	O
by	O
[	B-chem
3H	I-chem
]	I-chem
zacopride	E-chem
in	O
cortical	O
membranes	O
.	O

Complementary	O
experiments	O
using	O
the	O
5	B-geneN
-	I-geneN
HT3	E-geneN
-	O
dependent	O
Bezold	O
-	O
Jarisch	O
reflex	O
confirmed	O
that	O
amoxapine	S-chem-C6-1
really	O
acts	O
in	O
vivo	O
as	O
a	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT3	E-geneN-C6-2
antagonist	O
(	O
IC50	O
=	O
50	O
micrograms	O
/	O
kg	O
i.v	O
.	O
)	O
,	O
whereas	O
amitriptyline	S-chem
is	O
essentially	O
inactive	O
on	O
5	B-geneN
-	I-geneN
HT3	E-geneN
receptors	O
.	O

The	O
second	O
part	O
of	O
this	O
study	O
consisted	O
of	O
looking	O
for	O
possible	O
changes	O
in	O
central	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
24	O
h	O
after	O
either	O
a	O
single	O
or	O
a	O
repeated	O
(	O
for	O
14	O
days	O
)	O
treatment	O
with	O
amoxapine	S-chem
(	O
10	O
mg	O
/	O
kg	O
i.p	O
.	O
each	O
day	O
)	O
or	O
amitriptyline	S-chem
(	O
10	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

A	O
marked	O
decrease	O
in	O
the	O
density	O
of	O
5	B-geneN
-	I-geneN
HT2	E-geneN
receptors	O
was	O
found	O
in	O
the	O
cerebral	O
cortex	O
in	O
both	O
treatment	O
groups	O
.	O

By	O
contrast	O
,	O
neither	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
nor	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
were	O
significantly	O
affected	O
in	O
any	O
brain	O
region	O
studied	O
.	O

Finally	O
we	O
explored	O
whether	O
acute	O
and	O
/	O
or	O
chronic	O
administration	O
of	O
amoxapine	S-chem
or	O
amitriptyline	S-chem
affected	O
the	O
levels	O
of	O
opioid	O
peptides	O
and	O
the	O
mu	B-geneN
and	I-geneN
delta	I-geneN
classes	I-geneN
of	I-geneN
opioid	I-geneN
receptors	E-geneN
in	O
various	O
regions	O
of	O
the	O
brain	O
and	O
the	O
spinal	O
cord	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Predictive	O
factors	O
of	O
sensitivity	O
to	O
elisidepsin	S-chem
,	O
a	O
novel	O
kahalalide	B-chem
f	E-chem
-	O
derived	O
marine	O
compound	O
.	O

Elisidepsin	S-chem
(	O
PM02734	S-chem
,	O
Irvalec	S-chem
®	O
)	O
is	O
a	O
synthetic	O
marine	O
-	O
derived	O
cyclic	O
peptide	O
of	O
the	O
Kahalalide	B-chem
F	E-chem
family	O
currently	O
in	O
phase	O
II	O
clinical	O
development	O
.	O

Elisidepsin	S-chem
was	O
shown	O
to	O
induce	O
rapid	O
oncosis	O
in	O
ErbB3	S-geneY
-	O
expressing	O
cells	O
.	O

Other	O
predictive	O
factors	O
of	O
elisidepsin	S-chem
sensitivity	O
remained	O
unknown	O
.	O

A	O
panel	O
of	O
23	O
cancer	O
cell	O
lines	O
of	O
different	O
origin	O
was	O
assessed	O
for	O
elisidepsin	S-chem
cytotoxicity	O
and	O
correlated	O
with	O
mutational	O
state	O
,	O
mRNA	O
and	O
protein	O
expression	O
of	O
selected	O
genes	O
.	O

Elisidepsin	S-chem
showed	O
potent	O
and	O
broad	O
cytotoxic	O
effects	O
in	O
our	O
cancer	O
cell	O
line	O
panel	O
,	O
being	O
active	O
at	O
concentrations	O
ranging	O
from	O
0.4	O
to	O
2	O
μM	O
that	O
may	O
be	O
relevant	O
for	O
clinical	O
settings	O
.	O

We	O
have	O
shown	O
that	O
elisidepsin	S-chem
is	O
more	O
active	O
in	O
cells	O
harboring	O
epithelial	O
phenotype	O
with	O
high	O
E	B-geneY
-	I-geneY
cadherin	E-geneY
and	O
low	O
vimentin	S-geneY
expression	O
.	O

In	O
addition	O
,	O
high	O
ErbB3	S-geneY
and	O
Muc1	S-geneY
expression	O
was	O
correlated	O
with	O
sensitivity	O
to	O
elisidepsin	S-chem
,	O
whereas	O
the	O
presence	O
of	O
KRAS	S-geneY
activating	O
mutations	O
was	O
associated	O
with	O
resistance	O
.	O

In	O
DU	O
-	O
PM	O
cells	O
with	O
acquired	O
resistance	O
to	O
elisidepsin	S-chem-MU-1
,	O
ErbB3	S-geneY-C4-2
expression	O
was	O
decreased	O
,	O
while	O
Bcl2	S-geneY-C3-2
was	O
increased	O
.	O

DU	O
-	O
PM	O
cells	O
displayed	O
higher	O
sensitivity	O
to	O
ErbB1	S-geneY
-	O
inhibitors	O
suggesting	O
possible	O
cross	O
-	O
talk	O
of	O
ErbB1	S-geneY
and	O
ErbB3	S-geneY
signaling	O
pathways	O
.	O

Combinations	O
of	O
elisidepsin	S-chem
with	O
lapatinib	S-chem
and	O
several	O
chemotherapies	O
including	O
5	B-chem
-	I-chem
FU	E-chem
and	O
oxaliplatin	S-chem
resulted	O
in	O
synergistic	O
effects	O
that	O
offer	O
the	O
potential	O
of	O
clinical	O
use	O
of	O
elisidepsin	S-chem
in	O
combination	O
settings	O
.	O

Accurate	O
quantum	O
chemical	O
energies	O
for	O
tetrapeptide	S-chem
conformations	O
:	O
why	O
MP2	O
data	O
with	O
an	O
insufficient	O
basis	O
set	O
should	O
be	O
handled	O
with	O
caution	O
.	O

High	O
-	O
level	O
quantum	O
chemical	O
calculations	O
have	O
been	O
carried	O
out	O
for	O
biologically	O
-	O
relevant	O
conformers	O
of	O
tetrapeptides	S-chem
.	O

Our	O
results	O
indicate	O
potential	O
problems	O
if	O
the	O
widely	O
-	O
applied	O
MP2	O
approach	O
is	O
used	O
in	O
such	O
situations	O
with	O
basis	O
sets	O
of	O
insufficient	O
size	O
.	O

Efficient	O
alternatives	O
are	O
discussed	O
.	O

Sorafenib	S-chem-C4-1
(	O
BAY	B-chem-C4-1
43	I-chem-C4-1
-	I-chem-C4-1
9006	E-chem-C4-1
,	O
Nexavar	S-chem-C4-1
)	O
,	O
a	O
dual	O
-	O
action	O
inhibitor	O
that	O
targets	O
RAF	S-geneN-C4-2
/	O
MEK	S-geneN-C4-2
/	O
ERK	S-geneN-C4-2
pathway	O
in	O
tumor	O
cells	O
and	O
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
VEGFR	S-geneN-C4-2
/	O
PDGFR	S-geneN-C4-2
in	O
tumor	O
vasculature	O
.	O

Activating	O
mutations	O
in	O
Ras	S-geneN
and	O
B	B-geneY
-	I-geneY
RAF	E-geneY
were	O
identified	O
in	O
several	O
human	O
cancers	O
.	O

In	O
addition	O
,	O
several	O
receptor	B-geneN
tyrosine	I-geneN
kinases	E-geneN
,	O
acting	O
upstream	O
of	O
Ras	S-geneN
,	O
were	O
found	O
either	O
mutated	O
or	O
overexpressed	O
in	O
human	O
tumors	O
.	O

Because	O
oncogenic	O
activation	O
of	O
the	O
Ras	S-geneN
/	O
RAF	S-geneN
pathway	O
may	O
lead	O
to	O
a	O
sustained	O
proliferative	O
signal	O
resulting	O
in	O
tumor	O
growth	O
and	O
progression	O
,	O
inhibition	O
of	O
this	O
pathway	O
represents	O
an	O
attractive	O
approach	O
for	O
cancer	O
drug	O
discovery	O
.	O

A	O
novel	O
class	O
of	O
biaryl	B-chem-C4-1
urea	E-chem-C4-1
that	O
inhibits	O
C	B-geneY-C4-2
-	I-geneY-C4-2
RAF	E-geneY-C4-2
kinase	S-geneN-C4-2
was	O
discovered	O
using	O
a	O
combination	O
of	O
medicinal	O
and	O
combinatorial	O
chemistry	O
approaches	O
.	O

This	O
effort	O
culminated	O
in	O
the	O
identification	O
of	O
the	O
clinical	O
candidate	O
BAY	B-chem
43	I-chem
-	I-chem
9006	E-chem
(	O
Sorafenib	S-chem
,	O
Nexavar	S-chem
)	O
,	O
which	O
has	O
recently	O
been	O
approved	O
by	O
the	O
FDA	O
for	O
advanced	O
renal	O
cell	O
carcinoma	O
in	O
phase	O
III	O
clinical	O
trials	O
.	O

Sorafenib	S-chem-C4-1
inhibited	O
the	O
kinase	S-geneN-C4-2
activity	O
of	O
both	O
C	B-geneY-C4-2
-	I-geneY-C4-2
RAF	E-geneY-C4-2
and	O
B	B-geneY-C4-2
-	I-geneY-C4-2
RAF	E-geneY-C4-2
(	O
wild	O
type	O
and	O
V600E	S-geneN-C4-2
mutant	O
)	O
.	O

It	O
inhibited	O
MEK	S-geneN
and	O
ERK	S-geneN
phosphorylation	O
in	O
various	O
cancer	O
cell	O
lines	O
and	O
tumor	O
xenografts	O
and	O
exhibited	O
potent	O
oral	O
antitumor	O
activity	O
in	O
a	O
broad	O
spectrum	O
of	O
human	O
tumor	O
xenograft	O
models	O
.	O

Further	O
characterization	O
of	O
sorafenib	S-chem-C4-1
revealed	O
that	O
this	O
molecule	O
was	O
a	O
multikinase	O
inhibitor	O
that	O
targeted	O
the	O
vascular	B-geneN-C4-2
endothelial	I-geneN-C4-2
growth	I-geneN-C4-2
factor	I-geneN-C4-2
receptor	E-geneN-C4-2
family	O
(	O
VEGFR	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
VEGFR	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
)	O
and	O
platelet	B-geneN-C4-2
-	I-geneN-C4-2
derived	I-geneN-C4-2
growth	I-geneN-C4-2
factor	I-geneN-C4-2
receptor	E-geneN-C4-2
family	O
(	O
PDGFR	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
and	O
Kit	S-geneY-C4-2
)	O
,	O
which	O
play	O
key	O
roles	O
in	O
tumor	O
progression	O
and	O
angiogenesis	O
.	O

Thus	O
,	O
sorafenib	S-chem-C4-1
may	O
inhibit	O
tumor	O
growth	O
by	O
a	O
dual	O
mechanism	O
,	O
acting	O
either	O
directly	O
on	O
the	O
tumor	O
(	O
through	O
inhibition	O
of	O
Raf	S-geneN-C4-2
and	O
Kit	S-geneY-C4-2
signaling	O
)	O
and	O
/	O
or	O
on	O
tumor	O
angiogenesis	O
(	O
through	O
inhibition	O
of	O
VEGFR	S-geneN-C4-2
and	O
PDGFR	S-geneN-C4-2
signaling	O
)	O
.	O

In	O
phase	O
I	O
and	O
phase	O
II	O
clinical	O
trials	O
,	O
sorafenib	S-chem
showed	O
limited	O
side	O
effects	O
and	O
,	O
more	O
importantly	O
,	O
disease	O
stabilization	O
.	O

This	O
agent	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
III	O
clinical	O
trials	O
in	O
renal	O
cell	O
and	O
hepatocellular	O
carcinomas	O
.	O

Tilting	O
the	O
balance	O
between	O
canonical	O
and	O
noncanonical	O
conformations	O
for	O
the	O
H1	B-geneN
hypervariable	I-geneN
loop	E-geneN
of	O
a	O
llama	O
VHH	S-geneN
through	O
point	O
mutations	O
.	O

Nanobodies	O
are	O
single	O
-	O
domain	O
antibodies	O
found	O
in	O
camelids	O
.	O

These	O
are	O
the	O
smallest	O
naturally	O
occurring	O
binding	O
domains	O
and	O
derive	O
functionality	O
via	O
three	O
hypervariable	B-geneN
loops	E-geneN
(	O
H1	S-geneN
-	O
H3	S-geneN
)	O
that	O
form	O
the	O
binding	O
surface	O
.	O

They	O
are	O
excellent	O
candidates	O
for	O
antibody	O
engineering	O
because	O
of	O
their	O
favorable	O
characteristics	O
like	O
small	O
size	O
,	O
high	O
solubility	O
,	O
and	O
stability	O
.	O

To	O
rationally	O
engineer	O
antibodies	O
with	O
affinity	O
for	O
a	O
specific	O
target	O
,	O
the	O
hypervariable	B-geneN
loops	E-geneN
can	O
be	O
tailored	O
to	O
obtain	O
the	O
desired	O
binding	O
surface	O
.	O

As	O
a	O
first	O
step	O
toward	O
such	O
a	O
goal	O
,	O
we	O
consider	O
the	O
design	O
of	O
loops	O
with	O
a	O
desired	O
conformation	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
H1	B-geneN
loop	E-geneN
of	O
the	O
anti	O
-	O
hCG	S-geneN
llama	O
nanobody	O
that	O
exhibits	O
a	O
noncanonical	O
conformation	O
.	O

We	O
aim	O
to	O
``	O
tilt	O
``	O
the	O
stability	O
of	O
the	O
H1	I-geneN
loop	O
structure	O
from	O
a	O
noncanonical	O
conformation	O
to	O
a	O
(	O
humanized	O
)	O
type	O
1	O
canonical	O
conformation	O
by	O
studying	O
the	O
effect	O
of	O
selected	O
mutations	O
to	O
the	O
amino	I-chem
acid	O
sequence	O
of	O
the	O
H1	O
,	E-geneN
H2	O
,	O
and	O
proximal	O
residues	O
.	O

We	O
use	O
all	O
-	O
atomistic	O
,	O
explicit	O
-	O
solvent	O
,	O
biased	O
molecular	O
dynamic	O
simulations	O
to	O
simulate	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
loops	O
in	O
a	O
prefolded	O
framework	O
.	O

We	O
thus	O
find	O
mutants	O
with	O
increasing	O
propensity	O
to	O
form	O
a	O
stable	O
type	O
1	O
canonical	O
conformation	O
of	O
the	O
H1	B-geneN
loop	E-geneN
.	O

Free	O
energy	O
landscapes	O
reveal	O
the	O
existence	O
of	O
conformational	O
isomers	O
of	O
the	O
canonical	O
conformation	O
that	O
may	O
play	O
a	O
role	O
in	O
binding	O
different	O
antigenic	O
surfaces	O
.	O

We	O
also	O
elucidate	O
the	O
approximate	O
mechanism	O
and	O
kinetics	O
of	O
transitions	O
between	O
such	O
conformational	O
isomers	O
by	O
using	O
a	O
Markovian	O
model	O
.	O

We	O
find	O
that	O
a	O
particular	O
three	O
-	O
point	O
mutant	O
has	O
the	O
strongest	O
thermodynamic	O
propensity	O
to	O
form	O
the	O
H1	S-geneN
type	O
1	O
canonical	O
structure	O
but	O
also	O
to	O
exhibit	O
transitions	O
between	O
conformational	O
isomers	O
,	O
while	O
a	O
different	O
,	O
more	O
rigid	O
three	O
-	O
point	O
mutant	O
has	O
the	O
strongest	O
propensity	O
to	O
be	O
kinetically	O
trapped	O
in	O
such	O
a	O
canonical	O
structure	O
.	O

The	O
potential	O
of	O
nicotinic	O
enhancement	O
of	O
cognitive	O
remediation	O
training	O
in	O
schizophrenia	O
.	O

Cognitive	O
deficits	O
in	O
schizophrenia	O
are	O
critically	O
important	O
predictors	O
of	O
long	O
-	O
term	O
psychosocial	O
outcome	O
and	O
are	O
not	O
significantly	O
ameliorated	O
by	O
currently	O
available	O
medications	O
.	O

Cognitive	O
remediation	O
training	O
has	O
shown	O
promise	O
for	O
alleviating	O
cognitive	O
symptoms	O
of	O
schizophrenia	O
,	O
but	O
the	O
clinical	O
significance	O
has	O
often	O
been	O
limited	O
by	O
small	O
effect	O
sizes	O
.	O

Approaches	O
that	O
achieve	O
larger	O
improvement	O
involve	O
time	O
requirements	O
that	O
can	O
be	O
cost	O
-	O
prohibitive	O
within	O
the	O
current	O
clinical	O
care	O
system	O
.	O

This	O
mini	O
-	O
review	O
evaluates	O
the	O
theoretical	O
potential	O
of	O
a	O
pharmacological	O
enhancement	O
strategy	O
of	O
cognitive	O
remediation	O
training	O
with	O
nicotinic	B-geneN
acetylcholine	I-geneN
receptor	E-geneN
(	O
nAChR	S-geneN
)	O
agonists	O
.	O
nAChR	S-geneN
agonists	O
can	O
facilitate	O
sensory	O
processing	O
,	O
alertness	O
,	O
attention	O
,	O
learning	O
and	O
memory	O
.	O

While	O
these	O
effects	O
may	O
be	O
too	O
subtle	O
and	O
short	O
-	O
lasting	O
to	O
be	O
of	O
clinical	O
relevance	O
as	O
a	O
primary	O
treatment	O
of	O
cognitive	O
deficits	O
,	O
they	O
constitute	O
an	O
ideal	O
effects	O
profile	O
for	O
enhancing	O
training	O
benefits	O
.	O

Several	O
mechanisms	O
are	O
described	O
through	O
which	O
repeated	O
coupling	O
of	O
cognitive	O
training	O
challenges	O
with	O
nAChR	S-geneN
stimulation	O
may	O
enhance	O
and	O
accelerate	O
cognitive	O
remediation	O
training	O
effects	O
,	O
advancing	O
such	O
interventions	O
into	O
more	O
effective	O
and	O
practicable	O
treatments	O
of	O
some	O
of	O
the	O
most	O
debilitating	O
symptoms	O
of	O
schizophrenia	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Characterisation	O
of	O
the	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptor	E-geneN
binding	O
profile	O
of	O
eletriptan	S-chem
and	O
kinetics	O
of	O
[	B-chem
3H	I-chem
]	I-chem
eletriptan	E-chem
binding	O
at	O
human	B-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
receptors	O
.	O

The	O
affinity	O
of	O
eletriptan	S-chem
(	O
(	B-chem
R	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
2	I-chem
-	I-chem
pyrrolidinylmethyl	I-chem
)	I-chem
-	I-chem
5	I-chem
-	I-chem
[	I-chem
2	I-chem
-	I-chem
(	I-chem
phenylsulphonyl	I-chem
)	I-chem
ethyl	I-chem
]	I-chem
-	I-chem
1H	I-chem
-	I-chem
indole	E-chem
)	O
for	O
a	O
range	O
of	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
was	O
compared	O
to	O
values	O
obtained	O
for	O
other	O
5	B-geneN
-	I-geneN
HT1B	I-geneN
/	I-geneN
1D	E-geneN
receptor	O
agonists	O
known	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
migraine	O
.	O

Eletriptan	S-chem
,	O
like	O
sumatriptan	S-chem
,	O
zolmitriptan	S-chem
,	O
naratriptan	S-chem
and	O
rizatriptan	S-chem
had	O
highest	O
affinity	O
for	O
the	O
human	B-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
and	O
putative	O
5	B-geneY
-	I-geneY
ht1f	E-geneY
receptor	O
.	O

Kinetic	O
studies	O
comparing	O
the	O
binding	O
of	O
[	B-chem
3H	I-chem
]	I-chem
eletriptan	E-chem
and	O
[	B-chem
3H	I-chem
]	I-chem
sumatriptan	E-chem
to	O
the	O
human	B-geneY
recombinant	I-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
receptors	O
expressed	O
in	O
HeLa	O
cells	O
revealed	O
that	O
both	O
radioligands	O
bound	O
with	O
high	O
specificity	O
(	O
>	O
90	O
%	O
)	O
and	O
reached	O
equilibrium	O
within	O
10	O
-	O
15	O
min	O
.	O

However	O
,	O
[	B-chem
3H	I-chem
]	I-chem
eletriptan	E-chem
had	O
over	O
6	O
-	O
fold	O
higher	O
affinity	O
than	O
[	B-chem
3H	I-chem
]	I-chem
sumatriptan	E-chem
at	O
the	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
receptor	O
(	O
K	O
(	O
D	O
)	O
)	O
:	O
0.92	O
and	O
6.58	O
nM	O
,	O
respectively	O
)	O
and	O
over	O
3	O
-	O
fold	O
higher	O
affinity	O
than	O
[	B-chem
3H	I-chem
]	I-chem
sumatriptan	E-chem
at	O
the	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
(	O
K	O
(	O
D	O
)	O
:	O
3.14	O
and	O
11.07	O
nM	O
,	O
respectively	O
)	O
.	O

Association	O
and	O
dissociation	O
rates	O
for	O
both	O
radioligands	O
could	O
only	O
be	O
accurately	O
determined	O
at	O
the	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
receptor	O
and	O
then	O
only	O
at	O
4	O
degrees	O
C	O
.	O

At	O
this	O
temperature	O
,	O
[	B-chem
3H	I-chem
]	I-chem
eletriptan	E-chem
had	O
a	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
faster	O
association	O
rate	O
(	O
K	O
(	O
on	O
)	O
0.249	O
min	O
(	O
-	O
1	O
)	O
nM	O
(	O
-	O
1	O
)	O
)	O
than	O
[	B-chem
3H	I-chem
]	I-chem
sumatriptan	E-chem
(	O
K	O
(	O
on	O
)	O
0.024	O
min	O
(	O
-	O
1	O
)	O
nM	O
(	O
-	O
1	O
)	O
)	O
and	O
a	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
slower	O
off	O
-	O
rate	O
(	O
K	O
(	O
off	O
)	O
0.027	O
min	O
(	O
-	O
1	O
)	O
compared	O
to	O
0.037	O
min	O
(	O
-	O
1	O
)	O
for	O
[	B-chem
3H	I-chem
]	I-chem
sumatriptan	E-chem
)	O
.	O

These	O
data	O
indicate	O
that	O
eletriptan	O
is	O
a	O
potent	O
ligand	O
at	O
the	O
human	B-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
,	O
and	O
5	B-geneY
-	I-geneY
ht1f	E-geneY
receptors	O
and	O
are	O
consistent	O
with	O
its	O
potent	O
vasoconstrictor	O
activity	O
and	O
use	O
as	O
a	O
drug	O
for	O
the	O
acute	O
treatment	O
of	O
migraine	O
headache	O
.	O

Effects	O
of	O
2	B-chem
-	I-chem
amino	I-chem
-	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
6	I-chem
-	I-chem
phenylimidazo	I-chem
[	I-chem
4	I-chem
,	I-chem
5	I-chem
-	I-chem
b	I-chem
]	I-chem
pyridine	E-chem
(	O
PhIP	S-chem
)	O
on	O
histopathology	O
,	O
oxidative	O
stress	O
,	O
and	O
expression	O
of	O
c	B-geneY
-	I-geneY
fos	E-geneY
,	O
c	B-geneY
-	I-geneY
jun	E-geneY
and	O
p16	S-geneY
in	O
rat	O
stomachs	O
.	O

2	B-chem
-	I-chem
Amino	I-chem
-	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
6	I-chem
-	I-chem
phenylimidazo	I-chem
[	I-chem
4	I-chem
,	I-chem
5	I-chem
-	I-chem
b	I-chem
]	I-chem
pyridine	E-chem
(	O
PhIP	S-chem
)	O
is	O
one	O
of	O
the	O
most	O
abundant	O
heterocyclic	B-chem
amines	E-chem
(	O
HCAs	S-chem
)	O
generated	O
from	O
overcooking	O
meat	O
at	O
high	O
temperatures	O
.	O

To	O
understand	O
the	O
possible	O
mechanism	O
of	O
PhIP	S-chem
-	O
associated	O
stomach	O
cancer	O
,	O
the	O
effects	O
of	O
PhIP	S-chem
on	O
morphology	O
,	O
oxidative	O
stress	O
,	O
gene	O
expression	O
of	O
c	B-geneY
-	I-geneY
fos	E-geneY
,	O
c	B-geneY
-	I-geneY
jun	E-geneY
and	O
p16	S-geneY
in	O
rat	O
stomachs	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
(	O
1	O
)	O
15mg	O
/	O
kg	O
body	O
weight	O
PhIP	S-chem
induced	O
obvious	O
histopathological	O
changes	O
in	O
gastric	O
mucosa	O
;	O
(	O
2	O
)	O
PhIP	S-chem-MU-1
(	O
10	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
superoxide	B-geneN-C4-2
dismutase	E-geneN-C4-2
(	O
SOD	S-geneN-C4-2
)	O
and	O
glutathioneperoxidase	S-geneN-C4-2
(	O
GPx	S-geneN-C4-2
)	O
activities	O
,	O
while	O
increased	O
catalase	S-geneY-C3-2
(	O
CAT	S-geneY-C3-2
)	O
activity	O
compared	O
with	O
the	O
control	O
.	O

With	O
the	O
elevated	O
doses	O
of	O
PhIP	S-chem
,	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
contents	O
,	O
protein	O
carbonyl	S-chem
(	O
PCO	O
)	O
contents	O
and	O
DNA	O
-	O
protein	O
crosslinks	O
(	O
DPC	O
)	O
coefficients	O
were	O
significantly	O
raised	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
(	O
3	O
)	O
PhIP	S-chem-MU-1
at	O
the	O
doses	O
of	O
10mg	O
/	O
kg	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
significantly	O
inhibited	O
p16	S-geneY-C4-2
mRNA	O
and	O
protein	O
expression	O
,	O
whereas	O
enhanced	O
c	B-geneY-C3-2
-	I-geneY-C3-2
fos	E-geneY-C3-2
and	O
c	B-geneY-C3-2
-	I-geneY-C3-2
jun	E-geneY-C3-2
expression	O
relative	O
to	O
control	O
.	O

The	O
data	O
indicated	O
that	O
PhIP	S-chem-MU-1
could	O
cause	O
stomach	O
injury	O
,	O
oxidative	O
stress	O
in	O
rat	O
stomachs	O
as	O
well	O
as	O
the	O
activation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
fos	E-geneY-C3-2
and	O
c	B-geneY-C3-2
-	I-geneY-C3-2
jun	E-geneY-C3-2
and	O
inactivation	O
of	O
p16	S-geneY-C4-2
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
PhIP	S-chem
-	O
associated	O
stomach	O
cancer	O
.	O

Parental	O
exposure	O
to	O
natural	O
mixtures	O
of	O
POPs	O
reduced	O
embryo	O
production	O
and	O
altered	O
gene	O
transcription	O
in	O
zebrafish	O
embryos	O
.	O

Determination	O
of	O
toxicity	O
of	O
complex	O
mixtures	O
has	O
been	O
proposed	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
challenges	O
for	O
modern	O
toxicology	O
.	O

In	O
this	O
study	O
we	O
performed	O
genome	O
wide	O
transcriptome	O
profiling	O
to	O
assess	O
potential	O
toxicant	O
induced	O
changes	O
in	O
gene	O
regulation	O
in	O
zebrafish	O
embryos	O
following	O
parental	O
exposure	O
to	O
two	O
natural	O
mixtures	O
of	O
persistent	O
organic	O
pollutants	O
(	O
POPs	O
)	O
.	O

The	O
mixtures	O
used	O
were	O
extracted	O
from	O
burbot	O
(	O
Lota	O
lota	O
)	O
liver	O
originating	O
from	O
two	O
lakes	O
(	O
Lake	O
Mjøsa	O
and	O
Lake	O
Losna	O
)	O
belonging	O
to	O
the	O
same	O
freshwater	O
system	O
in	O
Norway	O
.	O

The	O
dominating	O
groups	O
of	O
contaminants	O
were	O
polybrominated	B-chem
diphenyl	I-chem
ethers	E-chem
(	O
PBDEs	S-chem
)	O
,	O
polychlorinated	B-chem
biphenyls	E-chem
(	O
PCBs	S-chem
)	O
and	O
dichlorodiphenyltrichloroethane	S-chem
metabolites	O
(	O
DDTs	O
)	O
.	O

Because	O
both	O
mixtures	O
used	O
in	O
the	O
present	O
study	O
induced	O
similar	O
effects	O
,	O
it	O
is	O
likely	O
that	O
the	O
same	O
toxicants	O
are	O
involved	O
.	O

The	O
Mjøsa	O
mixture	O
contains	O
high	O
levels	O
of	O
PBDEs	S-chem
while	O
this	O
group	O
of	O
pollutants	O
is	O
low	O
in	O
the	O
Losna	O
mixture	O
.	O

However	O
,	O
both	O
mixtures	O
contain	O
substantial	O
concentrations	O
of	O
PCB	S-chem
and	O
DDT	S-chem
suggesting	O
these	O
contaminants	O
as	O
the	O
predominant	O
contributors	O
to	O
the	O
toxicity	O
observed	O
.	O

The	O
observed	O
effects	O
included	O
phenotypic	O
traits	O
,	O
like	O
embryo	O
production	O
and	O
survival	O
,	O
and	O
gene	O
transcription	O
changes	O
corresponding	O
with	O
disease	O
and	O
biological	O
functions	O
such	O
as	O
cancer	O
,	O
reproductive	O
system	O
disease	O
,	O
cardiovascular	O
disease	O
,	O
lipid	O
and	O
protein	O
metabolism	O
,	O
small	O
molecule	O
biochemistry	O
and	O
cell	O
cycle	O
.	O

The	O
changes	O
in	O
gene	O
transcription	O
included	O
genes	O
regulated	O
by	O
HNF4A	S-geneY
,	O
insulin	S-geneY
,	O
LH	S-geneN
,	O
FSH	S-geneN
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
which	O
are	O
known	O
to	O
be	O
central	O
regulators	O
of	O
endocrine	O
signaling	O
,	O
metabolism	O
,	O
metabolic	O
homeostasis	O
,	O
immune	O
functions	O
,	O
cancer	O
development	O
and	O
reproduction	O
.	O

The	O
results	O
suggest	O
that	O
relative	O
low	O
concentrations	O
of	O
the	O
natural	O
mixtures	O
of	O
POPs	O
used	O
in	O
the	O
present	O
study	O
might	O
pose	O
a	O
threat	O
to	O
wild	O
freshwater	O
fish	O
living	O
in	O
the	O
lakes	O
from	O
which	O
the	O
POPs	O
mixtures	O
originated	O
.	O

pH	O
-	O
responsive	O
composite	O
microspheres	O
based	O
on	O
magnetic	O
mesoporous	O
silica	S-chem
nanoparticle	O
for	O
drug	O
delivery	O
.	O

pH	O
-	O
responsive	O
composite	O
microspheres	O
,	O
consisting	O
of	O
a	O
core	O
of	O
Fe3O4	S-chem
nanoparticle	O
,	O
a	O
sandwiched	O
layer	O
of	O
mesoporous	O
silica	S-chem
and	O
a	O
shell	O
of	O
crosslinked	O
poly	B-chem
(	I-chem
methacrylic	I-chem
acid	I-chem
)	E-chem
(	O
PMAA	S-chem
)	O
,	O
were	O
successfully	O
synthesized	O
via	O
distillation	O
precipitation	O
polymerization	O
.	O

The	O
pKa	O
of	O
the	O
composite	O
microsphere	O
increased	O
with	O
the	O
increase	O
in	O
the	O
crosslinking	O
density	O
.	O

Doxorubicin	B-chem
hydrochloride	E-chem
(	O
DOX	S-chem
)	O
was	O
applied	O
as	O
a	O
model	O
drug	O
,	O
and	O
the	O
behavior	O
of	O
drug	O
storage	O
/	O
release	O
was	O
investigated	O
.	O

The	O
cumulative	O
release	O
of	O
DOX	S-chem
-	O
loaded	O
composite	O
microsphere	O
in	O
vitro	O
showed	O
that	O
the	O
drug	O
release	O
rate	O
was	O
much	O
faster	O
below	O
its	O
pKa	O
than	O
that	O
of	O
above	O
its	O
pKa	O
.	O

Because	O
pH	O
of	O
most	O
tumor	O
tissues	O
was	O
lower	O
than	O
that	O
of	O
normal	O
tissues	O
,	O
the	O
pH	O
-	O
responsive	O
composite	O
microspheres	O
are	O
promising	O
drug	O
delivery	O
system	O
especially	O
for	O
cancer	O
therapy	O
.	O

Apoptosis	O
induced	O
by	O
oxidized	O
lipids	O
is	O
associated	O
with	O
up	O
-	O
regulation	O
of	O
p66Shc	S-geneY
in	O
intestinal	O
Caco	O
-	O
2	O
cells	O
:	O
protective	O
effects	O
of	O
phenolic	S-chem
compounds	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
alterations	O
of	O
the	O
redox	O
balance	O
induced	O
by	O
the	O
lipid	O
fraction	O
of	O
oxLDL	S-geneN
in	O
Caco	O
-	O
2	O
intestinal	O
cells	O
,	O
and	O
the	O
effects	O
of	O
tyrosol	S-chem
and	O
protocatechuic	B-chem
acid	E-chem
,	O
two	O
dietary	O
phenolic	S-chem
compounds	O
.	O

We	O
found	O
that	O
oxidized	O
lipids	O
extracted	O
from	O
oxLDL	S-geneN
(	O
LipE	S-geneY
)	O
induced	O
oxidative	O
stress	O
by	O
determining	O
,	O
6	O
h	O
after	O
treatment	O
,	O
ROS	O
overproduction	O
(	O
about	O
a	O
100	O
%	O
and	O
a	O
43	O
%	O
increase	O
of	O
O	B-chem
*	I-chem
2	E-chem
and	O
H2O2	S-chem
production	O
,	O
respectively	O
,	O
P	O
<	O
.05	O
:	O
LipE	S-geneY
vs.	O
control	O
)	O
and	O
,	O
12	O
h	O
after	O
treatment	O
,	O
GSH	O
depletion	O
(	O
about	O
a	O
26	O
%	O
decrease	O
,	O
P	O
<	O
.05	O
:	O
LipE	S-geneY
vs.	O
control	O
)	O
,	O
and	O
by	O
impairing	O
the	O
activities	O
of	O
superoxide	B-geneN
dismutase	E-geneN
,	O
catalase	S-geneY
and	O
glutathione	B-geneN
peroxidase	E-geneN
.	O

In	O
response	O
to	O
the	O
induced	O
oxidative	O
stress	O
,	O
we	O
observed	O
significant	O
overexpression	O
of	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
6	O
h	O
after	O
treatment	O
:	O
P	O
<	O
.05	O
)	O
,	O
glutathione	B-geneN
reductase	E-geneN
and	O
gamma	B-geneY
-	I-geneY
glutamylcysteine	I-geneY
synthetase	E-geneY
(	O
12	O
h	O
after	O
treatment	O
:	O
P	O
<	O
.05	O
)	O
.	O

Notably	O
,	O
when	O
GSH	O
depletion	O
occurred	O
,	O
p66Shc	S-geneY
protein	O
expression	O
increased	O
by	O
about	O
300	O
%	O
with	O
respect	O
to	O
control	O
(	O
P	O
<	O
.001	O
;	O
LipE	S-geneY
vs.	O
control	O
)	O
.	O

These	O
effects	O
were	O
fully	O
counteracted	O
by	O
dietary	O
phenolics	S-chem-C4-1
which	O
inhibited	O
ROS	O
overproduction	O
and	O
GSH	O
consumption	O
,	O
rendered	O
the	O
reactive	O
transcription	O
of	O
glutathione	S-chem
-	O
associated	O
enzymes	O
unnecessary	O
and	O
blocked	O
the	O
intracellular	O
signals	O
leading	O
to	O
the	O
overexpression	O
and	O
rearrangement	O
of	O
p66Shc	S-geneY-C4-2
signalling	O
molecule	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
impairment	O
of	O
the	O
antioxidant	O
system	O
hijacks	O
intestinal	O
cells	O
towards	O
an	O
apoptotic	O
-	O
prone	O
phenotype	O
via	O
the	O
activation	O
of	O
p66Shc	S-geneY
molecule	O
.	O

They	O
also	O
propose	O
a	O
reappraisal	O
of	O
dietary	O
polyphenols	S-chem
as	O
intestinal	O
protecting	O
agents	O
,	O
indicating	O
the	O
antiapoptotic	O
effect	O
as	O
a	O
further	O
mechanism	O
of	O
action	O
of	O
these	O
antioxidant	O
compounds	O
.	O

Effect	O
of	O
sinapic	B-chem
acid	E-chem
against	O
dimethylnitrosamine	S-chem
-	O
induced	O
hepatic	O
fibrosis	O
in	O
rats	O
.	O

Sinapic	B-chem
acid	E-chem
is	O
a	O
member	O
of	O
the	O
phenylpropanoid	S-chem
family	O
and	O
is	O
abundant	O
in	O
cereals	O
,	O
nuts	O
,	O
oil	O
seeds	O
,	O
and	O
berries	O
.	O

It	O
exhibits	O
a	O
wide	O
range	O
of	O
pharmacological	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
hepatoprotective	O
and	O
antifibrotic	O
effects	O
of	O
sinapic	B-chem
acid	E-chem
on	O
dimethylnitrosamine	S-chem
(	O
DMN	S-chem
)	O
-	O
induced	O
chronic	O
liver	O
injury	O
in	O
rats	O
.	O

Sinapic	B-chem
acid	E-chem
remarkably	O
prevented	O
DMN	S-chem
-	O
induced	O
loss	O
of	O
body	O
weight	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
levels	O
of	O
serum	O
alanine	B-geneN
transaminase	E-geneN
,	O
aspartate	B-geneY
transaminase	E-geneY
,	O
and	O
liver	O
malondialdehyde	S-chem
content	O
.	O

Furthermore	O
,	O
sinapic	B-chem-C4-1
acid	E-chem-C4-1
reduced	O
hepatic	O
hydroxyproline	S-chem
content	O
,	O
which	O
correlated	O
with	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
type	B-geneN-C4-2
I	I-geneN-C4-2
collagen	E-geneN-C4-2
mRNA	O
and	O
histological	O
analysis	O
of	O
collagen	S-geneN
in	O
liver	O
tissue	O
.	O

Additionally	O
,	O
the	O
expression	O
of	O
hepatic	O
fibrosis	O
-	O
related	O
factors	O
such	O
as	O
α	B-geneY-C4-2
-	I-geneY-C4-2
smooth	I-geneY-C4-2
muscle	I-geneY-C4-2
actin	E-geneY-C4-2
and	O
transforming	B-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
-	I-geneY-C4-2
β1	E-geneY-C4-2
(	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
β1	E-geneY-C4-2
)	O
,	O
were	O
reduced	O
in	O
rats	O
treated	O
with	O
sinapic	B-chem-C4-1
acid	E-chem-C4-1
.	O

Sinapic	B-chem
acid	E-chem
exhibited	O
strong	O
scavenging	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
find	O
that	O
sinapic	B-chem-C4-1
acid	E-chem-C4-1
exhibits	O
hepatoprotective	O
and	O
antifibrotic	O
effects	O
against	O
DMN	S-chem
-	O
induced	O
liver	O
injury	O
,	O
most	O
likely	O
due	O
to	O
its	O
antioxidant	O
activities	O
of	O
scavenging	O
radicals	O
,	O
its	O
capacity	O
to	O
suppress	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
β1	E-geneY-C4-2
and	O
its	O
ability	O
to	O
attenuate	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
.	O

This	O
suggests	O
that	O
sinapic	B-chem
acid	E-chem
is	O
a	O
potentially	O
useful	O
agent	O
for	O
the	O
protection	O
against	O
liver	O
fibrosis	O
and	O
cirrhosis	O
.	O

Manganese	S-chem
-	O
induced	O
oxidative	O
DNA	O
damage	O
in	O
neuronal	O
SH	O
-	O
SY5Y	O
cells	O
:	O
attenuation	O
of	O
thymine	S-chem
base	O
lesions	O
by	O
glutathione	S-chem
and	O
N	B-chem
-	I-chem
acetylcysteine	E-chem
.	O

Manganese	S-chem
(	O
Mn	S-chem
)	O
is	O
an	O
essential	O
trace	O
element	O
required	O
for	O
normal	O
function	O
and	O
development	O
.	O

However	O
,	O
exposure	O
to	O
this	O
metal	O
at	O
elevated	O
levels	O
may	O
cause	O
manganism	O
,	O
a	O
progressive	O
neurodegenerative	O
disorder	O
with	O
neurological	O
symptoms	O
similar	O
to	O
idiopathic	O
Parkinson	O
's	O
disease	O
(	O
IPD	O
)	O
.	O

Elevated	O
body	O
burdens	O
of	O
Mn	S-chem
from	O
exposure	O
to	O
parental	O
nutrition	O
,	O
vapors	O
in	O
mines	O
and	O
smelters	O
and	O
welding	O
fumes	O
have	O
been	O
associated	O
with	O
neurological	O
health	O
concerns	O
.	O

The	O
underlying	O
mechanism	O
of	O
Mn	S-chem
neurotoxicity	O
remains	O
unclear	O
.	O

Accordingly	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
toxic	O
effects	O
of	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
caused	O
a	O
concentration	O
dependent	O
decrease	O
in	O
SH	O
-	O
SY5Y	O
cellular	O
viability	O
compared	O
to	O
controls	O
.	O

The	O
LD50	O
value	O
was	O
12.98	O
μM	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
(	O
p	O
<	O
0.001	O
for	O
control	O
vs	O
.	O

24h	O
Mn	S-chem
treatment	O
)	O
.	O

Both	O
TUNEL	O
and	O
annexin	O
V	O
/	O
propidium	B-chem
iodide	E-chem
(	O
PI	O
)	O
apoptosis	O
assays	O
confirmed	O
the	O
induction	O
of	O
apoptosis	O
in	O
the	O
cells	O
following	O
exposure	O
to	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
(	O
2	O
μM	O
,	O
62	O
μM	O
or	O
125	O
μM	O
)	O
.	O

In	O
addition	O
,	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
induced	O
both	O
the	O
formation	O
and	O
accumulation	O
of	O
DNA	O
single	O
strand	O
breaks	O
(	O
via	O
alkaline	O
comet	O
assay	O
analysis	O
)	O
and	O
oxidatively	O
modified	O
thymine	S-chem
bases	O
(	O
via	O
gas	O
chromatography	O
/	O
mass	O
spectrometry	O
analysis	O
)	O
.	O

Pre	O
-	O
incubation	O
of	O
the	O
cells	O
with	O
characteristic	O
antioxidants	O
,	O
either	O
1mM	O
N	B-chem
-	I-chem
acetylcysteine	E-chem
(	O
NAC	S-chem
)	O
or	O
1mM	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
reduced	O
the	O
level	O
of	O
DNA	O
strand	O
breaks	O
and	O
the	O
formation	O
of	O
thymine	S-chem
base	O
lesions	O
,	O
suggesting	O
protection	O
against	O
oxidative	O
cellular	O
damage	O
.	O

Our	O
findings	O
indicate	O
that	O
(	O
1	O
)	O
exposure	O
of	O
SH	O
-	O
SY5Y	O
cells	O
to	O
Mn	S-chem
promotes	O
both	O
the	O
formation	O
and	O
accumulation	O
of	O
oxidative	O
DNA	O
damage	O
,	O
(	O
2	O
)	O
SH	O
-	O
SY5Y	O
cells	O
with	O
accumulated	O
DNA	O
damage	O
are	O
more	O
likely	O
to	O
die	O
via	O
an	O
apoptotic	O
pathway	O
and	O
(	O
3	O
)	O
the	O
accumulated	O
levels	O
of	O
DNA	O
damage	O
can	O
be	O
abrogated	O
by	O
the	O
addition	O
of	O
exogenous	O
chemical	O
antioxidants	O
.	O

This	O
is	O
the	O
first	O
known	O
report	O
of	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
induction	O
and	O
antioxidant	O
protection	O
of	O
thymine	S-chem
lesions	O
in	O
this	O
SH	O
-	O
SY5Y	O
cell	O
line	O
and	O
contributes	O
new	O
information	O
to	O
the	O
potential	O
use	O
of	O
antioxidants	O
as	O
a	O
therapeutic	O
strategy	O
for	O
protection	O
against	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
induced	O
oxidative	O
DNA	O
damage	O
.	O

The	O
use	O
of	O
escitalopram	S-chem
beyond	O
major	O
depression	O
:	O
pharmacological	O
aspects	O
,	O
efficacy	O
and	O
tolerability	O
in	O
anxiety	O
disorders	O
.	O

Escitalopram	S-chem
,	O
the	O
active	O
(	B-chem
S	I-chem
)	I-chem
-	I-chem
enantiomer	I-chem
of	I-chem
citalopram	E-chem
,	O
has	O
been	O
approved	O
in	O
many	O
countries	O
throughout	O
the	O
world	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
anxiety	O
disorders	O
.	O

It	O
is	O
more	O
potent	O
and	O
selective	O
than	O
citalopram	S-chem
in	O
inhibiting	O
serotonin	S-chem
re	O
-	O
uptake	O
in	O
the	O
CNS	O
,	O
and	O
less	O
potent	O
than	O
various	O
other	O
selective	O
serotonin	S-chem
re	O
-	O
uptake	O
inhibitors	O
in	O
relation	O
to	O
other	O
transporter	O
proteins	O
and	O
receptors	O
:	O
in	O
particular	O
,	O
it	O
is	O
six	O
times	O
less	O
potent	O
than	O
citalopram	S-chem
in	O
binding	O
to	O
the	O
histamine	B-geneY
H1	E-geneY
and	O
muscarinic	B-geneN
receptors	E-geneN
.	O

Escitalopram	S-chem
has	O
favourable	O
pharmacokinetics	O
:	O
it	O
is	O
rapidly	O
absorbed	O
,	O
has	O
a	O
bioavailability	O
of	O
80	O
%	O
and	O
is	O
not	O
affected	O
by	O
food	O
intake	O
.	O

It	O
has	O
little	O
potential	O
for	O
drug	O
interactions	O
:	O
it	O
has	O
low	O
protein	O
binding	O
and	O
,	O
as	O
it	O
is	O
metabolised	O
by	O
three	O
CYP	S-geneN
isozymes	O
,	O
any	O
impairment	O
in	O
the	O
activity	O
of	O
one	O
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
metabolic	O
clearance	O
.	O

Caution	O
is	O
necessary	O
only	O
when	O
it	O
is	O
coadministered	O
with	O
drugs	O
metabolised	O
by	O
CYP2D6	S-geneY-C9-2
,	O
such	O
as	O
metoprolol	S-chem-C9-1
,	O
or	O
administered	O
to	O
the	O
elderly	O
or	O
patients	O
with	O
severe	O
hepatic	O
or	O
renal	O
impairment	O
.	O

The	O
multiple	O
-	O
dose	O
pharmacokinetics	O
of	O
oral	O
escitalopram	S-chem
are	O
proportional	O
at	O
a	O
range	O
of	O
doses	O
including	O
its	O
therapeutic	O
doses	O
.	O

Escitalopram	S-chem
is	O
approved	O
for	O
the	O
treatment	O
of	O
a	O
number	O
of	O
anxiety	O
disorders	O
.	O

It	O
seems	O
to	O
be	O
well	O
tolerated	O
and	O
induces	O
few	O
or	O
no	O
discontinuation	O
symptoms	O
,	O
and	O
may	O
be	O
considered	O
a	O
first	O
-	O
line	O
agent	O
for	O
the	O
pharmacotherapy	O
of	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
generalised	O
anxiety	O
disorder	O
,	O
panic	O
disorder	O
and	O
social	O
phobia	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
define	O
its	O
activity	O
in	O
impulse	O
control	O
disorders	O
.	O

Rapamycin	S-chem
allosterically	O
inhibits	O
the	O
proteasome	S-geneN
.	O

Rapamycin	S-chem
is	O
a	O
canonical	O
allosteric	O
inhibitor	O
of	O
the	O
mTOR	S-geneY
kinase	S-geneN
with	O
immunosuppressive	O
and	O
pro	O
-	O
apoptotic	O
activities	O
.	O

We	O
found	O
that	O
in	O
vitro	O
rapamycin	S-chem
also	O
regulates	O
the	O
proteasome	S-geneN
,	O
an	O
essential	O
intracellular	O
protease	O
of	O
the	O
ubiquitin	S-geneN
-	O
proteasome	S-geneN
pathway	O
.	O

Rapamycin	S-chem-C4-1
inhibits	O
proteinase	S-geneN-C4-2
and	O
selected	O
peptidase	S-geneN-C4-2
activities	O
of	O
the	O
catalytic	O
core	O
proteasome	S-geneN-C4-2
at	O
low	O
micromolar	O
concentrations	O
.	O

Moreover	O
,	O
the	O
drug	O
interferes	O
with	O
binding	O
of	O
the	O
19S	O
cap	O
essential	O
for	O
processing	O
of	O
polyubiquitinylated	O
substrates	O
,	O
and	O
the	O
PA200	S-geneY
activator	O
to	O
the	O
20S	B-geneN
catalytic	I-geneN
core	I-geneN
proteasome	E-geneN
.	O

These	O
protein	O
complexes	O
are	O
known	O
to	O
bind	O
to	O
specific	O
grooves	O
on	O
the	O
α	O
face	O
region	O
of	O
the	O
20S	O
core	O
.	O

A	O
treatment	O
with	O
rapamycin	S-chem
affects	O
conformational	O
dynamics	O
of	O
the	O
proteasomal	O
gate	O
,	O
a	O
centrally	O
positioned	O
within	O
the	O
α	O
face	O
and	O
allosterically	O
regulated	O
element	O
responsible	O
for	O
the	O
intake	O
of	O
substrates	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
rapamycin	S-chem
shares	O
all	O
the	O
proteasome	S-geneN
targeting	O
properties	O
not	O
only	O
with	O
other	O
two	O
-	O
domain	O
,	O
closed	O
-	O
ring	O
analogs	O
(	O
rapalogs	O
)	O
,	O
but	O
also	O
with	O
its	O
single	O
domain	O
mimics	O
,	O
and	O
with	O
seco	B-chem
-	I-chem
rapamycin	E-chem
.	O

The	O
latter	O
is	O
the	O
first	O
in	O
vivo	O
open	O
-	O
ring	O
metabolite	O
of	O
rapamycin	S-chem
that	O
does	O
not	O
affect	O
mTOR	S-geneY
.	O

We	O
hypothesize	O
that	O
the	O
rapamycin	S-chem
and	O
related	O
compounds	O
bind	O
to	O
the	O
α	O
face	O
and	O
allosterically	O
impact	O
the	O
proteasome	S-geneN
function	O
.	O

The	O
implications	O
of	O
our	O
finding	O
for	O
mechanism	O
of	O
in	O
vivo	O
actions	O
of	O
rapamycin	S-chem
and	O
for	O
design	O
of	O
novel	O
allosteric	O
drugs	O
targeting	O
the	O
proteasome	S-geneN
are	O
discussed	O
.	O

A	O
46	O
-	O
amino	B-chem
acid	E-chem
segment	O
in	O
phosphodiesterase	B-geneY
-	I-geneY
5	E-geneY
GAF	B-geneN
-	I-geneN
B	I-geneN
domain	E-geneN
provides	O
for	O
high	O
vardenafil	S-chem
potency	O
over	O
sildenafil	S-chem
and	O
tadalafil	S-chem
and	O
is	O
involved	O
in	O
phosphodiesterase	B-geneY
-	I-geneY
5	E-geneY
dimerization	O
.	O

Phosphodiesterase	B-geneY-C9-2
-	I-geneY-C9-2
5	E-geneY-C9-2
(	O
PDE5	S-geneY-C9-2
)	O
contains	O
a	O
catalytic	O
domain	O
(	O
C	O
domain	O
)	O
that	O
hydrolyzes	O
cGMP	S-chem-C9-1
and	O
a	O
regulatory	O
domain	O
(	O
R	O
domain	O
)	O
that	O
contains	O
two	O
mammalian	B-geneN
cGMP	I-geneN
-	I-geneN
binding	I-geneN
phosphodiesterase	E-geneN
,	O
Anabaena	B-geneY
adenylyl	I-geneY
cyclases	E-geneY
,	O
Escherichia	B-geneY
coli	I-geneY
FhlAs	E-geneY
(	B-geneN
GAFs	I-geneN
)	I-geneN
(	I-geneN
A	I-geneN
and	I-geneN
B	I-geneN
)	E-geneN
and	O
a	O
phosphorylation	O
site	O
for	O
cyclic	B-geneN
nucleotide	I-geneN
-	I-geneN
dependent	I-geneN
protein	I-geneN
kinases	E-geneN
(	O
cNPKs	S-geneN
)	O
.	O

Binding	O
of	O
cGMP	S-chem-C3-1
to	O
GAF	B-geneN
-	I-geneN
A	E-geneN
increases	O
cNPK	S-geneN-C3-2
phosphorylation	O
of	O
PDE5	S-geneY-C3-2
and	O
improves	O
catalytic	O
site	O
affinity	O
for	O
cGMP	S-chem
or	O
inhibitors	O
.	O

GAF	B-geneN
-	I-geneN
B	E-geneN
contributes	O
to	O
dimerization	O
of	O
PDE5	S-geneY
,	O
inhibition	O
of	O
cGMP	S-chem
binding	O
to	O
GAF	B-geneN
-	I-geneN
A	E-geneN
,	O
and	O
sequestration	O
of	O
the	O
phosphorylation	O
site	O
.	O

To	O
probe	O
potential	O
PDE5	B-geneN
R	I-geneN
domain	E-geneN
effects	O
on	O
catalytic	O
site	O
affinity	O
for	O
certain	O
inhibitors	O
,	O
four	O
N	S-chem
-	O
terminal	O
truncation	O
mutants	O
were	O
generated	O
:	O
PDE5Delta1	B-geneY
-	I-geneY
321	E-geneY
contained	O
GAF	B-geneN
-	I-geneN
B	I-geneN
domain	E-geneN
,	O
C	O
domain	O
,	O
and	O
the	O
sequence	O
between	O
GAF	B-geneN
-	I-geneN
A	I-geneN
and	I-geneN
-	I-geneN
B	E-geneN
;	O
PDE5Delta1	B-geneY
-	I-geneY
419	E-geneY
contained	O
GAF	B-geneN
-	I-geneN
B	I-geneN
and	I-geneN
C	I-geneN
domain	E-geneN
;	O
PDE5Delta1	B-geneY
-	I-geneY
465	E-geneY
contained	O
the	O
C	O
domain	O
and	O
the	O
C	S-chem
-	O
terminal	O
portion	O
of	O
GAF	B-geneN
-	I-geneN
B	E-geneN
;	O
and	O
PDE5Delta1	B-geneY
-	I-geneY
534	E-geneY
contained	O
only	O
C	O
domain	O
.	O

Truncated	O
proteins	O
with	O
a	O
complete	O
GAF	B-geneN
-	I-geneN
B	E-geneN
were	O
dimers	O
,	O
but	O
those	O
lacking	O
the	O
N	S-chem
-	O
terminal	O
46	O
amino	B-chem
acids	E-chem
of	O
GAF	B-geneN
-	I-geneN
B	E-geneN
were	O
monomers	O
,	O
indicating	O
that	O
these	O
residues	O
are	O
vital	O
for	O
GAF	B-geneN
-	I-geneN
B	E-geneN
-	O
mediated	O
PDE5	S-geneY
dimerization	O
.	O

K	O
(	O
m	O
)	O
values	O
of	O
the	O
mutants	O
for	O
cGMP	S-chem-C9-1
were	O
similar	O
to	O
that	O
of	O
full	O
-	O
length	O
PDE5	S-geneY-C9-2
.	O

All	O
PDE5	S-geneY
constructs	O
had	O
similar	O
affinities	O
for	O
3	B-chem
-	I-chem
isobutyl	I-chem
-	I-chem
1	I-chem
-	I-chem
methylxanthine	E-chem
,	O
sildenafil	S-chem
,	O
tadalafil	S-chem
,	O
and	O
UK	B-chem
-	I-chem
122764	E-chem
,	O
but	O
mutants	O
containing	O
a	O
complete	O
GAF	B-geneN
-	I-geneN
B	E-geneN
had	O
7	O
-	O
to	O
18	O
-	O
fold	O
higher	O
affinity	O
for	O
vardenafil	S-chem
-	O
based	O
compounds	O
compared	O
with	O
those	O
lacking	O
a	O
complete	O
GAF	B-geneN
-	I-geneN
B	E-geneN
.	O

This	O
indicated	O
that	O
the	O
N	S-chem
-	O
terminal	O
46	O
amino	B-chem
acids	E-chem
in	O
GAF	B-geneN
-	I-geneN
B	E-geneN
are	O
required	O
for	O
high	O
vardenafil	S-chem
potency	O
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
PDE5	B-geneN
R	I-geneN
domain	E-geneN
,	O
and	O
GAF	B-geneN
-	I-geneN
B	E-geneN
in	O
particular	O
,	O
influences	O
affinity	O
and	O
selectivity	O
of	O
the	O
catalytic	O
site	O
for	O
certain	O
classes	O
of	O
inhibitors	O
.	O

Metabolic	O
syndrome	O
:	O
adenosine	B-geneN
monophosphate	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
and	O
malonyl	B-chem
coenzyme	I-chem
A	E-chem
.	O

The	O
metabolic	O
syndrome	O
can	O
be	O
defined	O
as	O
a	O
state	O
of	O
metabolic	O
dysregulation	O
characterized	O
by	O
insulin	S-geneY
resistance	O
,	O
central	O
obesity	O
,	O
and	O
a	O
predisposition	O
to	O
type	O
2	O
diabetes	O
,	O
dyslipidemia	O
,	O
premature	O
atherosclerosis	O
,	O
and	O
other	O
diseases	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
has	O
linked	O
the	O
metabolic	O
syndrome	O
to	O
abnormalities	O
in	O
lipid	O
metabolism	O
that	O
ultimately	O
lead	O
to	O
cellular	O
dysfunction	O
.	O

We	O
review	O
here	O
the	O
hypothesis	O
that	O
,	O
in	O
many	O
instances	O
,	O
the	O
cause	O
of	O
these	O
lipid	O
abnormalities	O
could	O
be	O
a	O
dysregulation	O
of	O
the	O
adenosine	B-geneN
monophosphate	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
AMPK	S-geneN
)	O
/	O
malonyl	B-chem
coenzyme	I-chem
A	E-chem
(	O
CoA	O
)	O
fuel	O
-	O
sensing	O
and	O
signaling	O
mechanism	O
.	O

Such	O
dysregulation	O
could	O
be	O
reflected	O
by	O
isolated	O
increases	O
in	O
malonyl	B-chem
CoA	E-chem
or	O
by	O
concurrent	O
changes	O
in	O
malonyl	B-chem
CoA	E-chem
and	O
AMPK	S-geneN
,	O
both	O
of	O
which	O
would	O
alter	O
intracellular	O
fatty	O
acid	O
partitioning	O
.	O

The	O
possibility	O
is	O
also	O
raised	O
that	O
pharmacological	O
agents	O
and	O
other	O
factors	O
that	O
activate	O
AMPK	S-geneN
and	O
/	O
or	O
decrease	O
malonyl	B-chem
CoA	E-chem
could	O
be	O
therapeutic	O
targets	O
.	O

Chemical	O
cholecystokinin	B-geneN
receptor	E-geneN
activation	O
protects	O
against	O
obesity	O
-	O
diabetes	O
in	O
high	O
fat	O
fed	O
mice	O
and	O
has	O
sustainable	O
beneficial	O
effects	O
in	O
genetic	O
ob	O
/	O
ob	O
mice	O
.	O

The	O
current	O
study	O
has	O
determined	O
the	O
ability	O
of	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
to	O
counter	O
the	O
development	O
of	O
diet	O
-	O
induced	O
obesity	O
-	O
diabetes	O
and	O
examined	O
persistence	O
of	O
beneficial	O
metabolic	O
effects	O
in	O
high	O
fat	O
and	O
ob	O
/	O
ob	O
mice	O
,	O
respectively	O
.	O

Twice	O
daily	O
injection	O
of	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
in	O
normal	O
mice	O
transferred	O
to	O
a	O
high	O
fat	O
diet	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0.001	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0.01	O
)	O
,	O
circulating	O
insulin	S-geneN
and	O
LDL	S-geneN
-	O
cholesterol	S-chem
(	O
p	O
<	O
0.001	O
)	O
and	O
improved	O
insulin	S-geneN
sensitivity	O
(	O
p	O
<	O
0.001	O
)	O
as	O
well	O
as	O
oral	O
and	O
intraperitoneal	O
(	O
p	O
<	O
0.001	O
)	O
glucose	S-chem
tolerance	O
.	O

Energy	O
intake	O
,	O
body	O
weight	O
,	O
circulating	O
insulin	S-geneN
and	O
glucose	S-chem
tolerance	O
of	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
mice	O
were	O
similar	O
to	O
lean	O
controls	O
.	O

In	O
addition	O
,	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
prevented	O
the	O
effect	O
of	O
high	O
fat	O
feeding	O
on	O
triacylglycerol	S-chem
accumulation	O
in	O
liver	O
and	O
muscle	O
.	O

Interestingly	O
,	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
significantly	O
(	O
p	O
<	O
0.001	O
)	O
elevated	O
pancreatic	O
glucagon	S-geneY
content	O
.	O

Histological	O
examination	O
of	O
the	O
pancreata	O
of	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
mice	O
revealed	O
no	O
changes	O
in	O
islet	O
number	O
or	O
size	O
,	O
but	O
there	O
was	O
increased	O
turnover	O
of	O
beta	O
-	O
cells	O
with	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
increased	O
numbers	O
of	O
peripherally	O
located	O
alpha	O
-	O
cells	O
,	O
co	O
-	O
expressing	O
both	O
glucagon	S-geneY
and	O
GLP	B-geneY
-	I-geneY
1	E-geneY
.	O

Beneficial	O
metabolic	O
effects	O
were	O
observed	O
similarly	O
in	O
ob	O
/	O
ob	O
mice	O
treated	O
twice	O
daily	O
with	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
for	O
18	O
days	O
,	O
including	O
significantly	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0.05	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.01	O
)	O
,	O
circulating	O
glucose	S-chem
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.01	O
)	O
and	O
insulin	S-geneN
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
and	O
improved	O
glucose	S-chem
tolerance	O
(	O
p	O
<	O
0.05	O
)	O
and	O
insulin	S-geneN
sensitivity	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Notably	O
,	O
these	O
beneficial	O
effects	O
were	O
still	O
evident	O
18	O
days	O
following	O
cessation	O
of	O
treatment	O
.	O

These	O
studies	O
emphasize	O
the	O
potential	O
of	O
(	B-geneY
pGlu	I-geneY
-	I-geneY
Gln	I-geneY
)	I-geneY
-	I-geneY
CCK	I-geneY
-	I-geneY
8	E-geneY
for	O
the	O
treatment	O
of	O
obesity	O
-	O
diabetes	O
.	O

Impaired	O
local	O
production	O
of	O
pro	O
-	O
resolving	O
lipid	O
mediators	O
in	O
obesity	O
and	O
17	B-chem
-	I-chem
HDHA	E-chem
as	O
a	O
potential	O
treatment	O
for	O
obesity	O
-	O
associated	O
inflammation	O
.	O

Obesity	O
-	O
induced	O
chronic	O
low	O
-	O
grade	O
inflammation	O
originates	O
from	O
adipose	O
tissue	O
and	O
is	O
crucial	O
for	O
obesity	O
-	O
driven	O
metabolic	O
deterioration	O
including	O
insulin	S-geneY
resistance	O
and	O
type	O
2	O
diabetes.Chronic	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
a	O
failure	O
to	O
actively	O
resolve	O
inflammation	O
,	O
and	O
could	O
result	O
from	O
a	O
lack	O
of	O
local	O
specialized	O
pro	O
-	O
resolving	O
lipid	O
mediators	O
(	O
SPM	O
)	O
such	O
as	O
resolvins	S-chem
and	O
protectins	O
,	O
which	O
derive	O
from	O
the	O
n	O
-	O
3	O
polyunsaturated	B-chem
fatty	I-chem
acids	E-chem
eicosapentaenoic	B-chem
acid	E-chem
(	O
EPA	S-chem
)	O
and	O
docosahexaenoic	B-chem
acid	E-chem
(	O
DHA	S-chem
)	O
.	O

We	O
assessed	O
obesity	O
-	O
induced	O
changes	O
of	O
n	O
-	O
3	O
-	O
derived	O
SPM	O
in	O
adipose	O
tissue	O
and	O
effects	O
of	O
dietary	O
EPA	S-chem
/	O
DHA	S-chem
thereon.Moreover	O
,	O
we	O
treated	O
obese	O
mice	O
with	O
SPM	O
precursors	O
and	O
investigated	O
effects	O
on	O
inflammation	O
and	O
metabolic	O
dysregulation	O
.	O

Obesity	O
significantly	O
decreased	O
DHA	S-chem
-	O
derived	O
17	B-chem
-	I-chem
hydroxydocosahexaenoic	I-chem
acid	E-chem
(	O
17	B-chem
-	I-chem
HDHA	E-chem
,	O
resolvin	B-chem
D1	E-chem
precursor	O
)	O
and	O
protectin	B-chem
D1	E-chem
levels	O
in	O
murine	O
adipose	O
tissue	O
.	O

Dietary	O
EPA	S-chem-C3-1
/	O
DHA	S-chem-C3-1
treatment	O
restored	O
endogenous	O
biosynthesis	O
of	O
n	O
-	O
3	O
derived	O
lipid	O
mediators	O
in	O
obesity	O
while	O
attenuating	O
adipose	O
tissue	O
inflammation	O
and	O
improving	O
insulin	S-geneN-C3-2
sensitivity	O
.	O

Notably	O
,	O
17	B-chem-MU-1
-	I-chem-MU-1
HDHA	E-chem-MU-1
treatment	O
reduced	O
adipose	O
tissue	O
expression	O
of	O
inflammatory	O
cytokines	S-geneN-C4-2
,	O
increased	O
adiponectin	S-geneY-C3-2
expression	O
and	O
improved	O
glucose	S-chem
tolerance	O
parallel	O
to	O
insulin	S-geneN-C3-2
sensitivity	O
in	O
obese	O
mice	O
.	O

These	O
findings	O
indicate	O
that	O
impaired	O
biosynthesis	O
of	O
certain	O
SPM	O
and	O
SPM	O
precursors	O
including	O
17	B-chem
-	I-chem
HDHA	E-chem
and	O
protectin	B-chem
D1	E-chem
contributes	O
to	O
adipose	O
tissue	O
inflammation	O
in	O
obesity	O
and	O
suggest	O
17	B-chem
-	I-chem
HDHA	E-chem
as	O
a	O
novel	O
treatment	O
option	O
for	O
obesity	O
-	O
associated	O
complications	O
.	O

Chemoprevention	O
for	O
high	O
-	O
risk	O
women	O
:	O
tamoxifen	S-chem
and	O
beyond	O
.	O

The	O
demonstration	O
by	O
the	O
National	O
Surgical	O
Adjuvant	O
Breast	O
Project	O
(	O
NSABP	O
)	O
that	O
5	O
years	O
of	O
tamoxifen	S-chem
therapy	O
is	O
associated	O
with	O
an	O
approximate	O
50	O
%	O
reduction	O
in	O
breast	O
cancer	O
incidence	O
in	O
high	O
-	O
risk	O
women	O
was	O
a	O
milestone	O
in	O
breast	O
cancer	O
prevention	O
.	O

Because	O
tamoxifen	S-chem
is	O
associated	O
with	O
increased	O
risk	O
of	O
side	O
-	O
effects	O
such	O
as	O
hot	O
flashes	O
,	O
menstrual	O
abnormalities	O
,	O
uterine	O
cancer	O
,	O
and	O
thromboembolic	O
phenomena	O
,	O
its	O
use	O
will	O
not	O
be	O
advisable	O
or	O
acceptable	O
for	O
all	O
high	O
-	O
risk	O
women	O
.	O

Women	O
over	O
50	O
years	O
of	O
age	O
appear	O
to	O
be	O
at	O
highest	O
risk	O
for	O
serious	O
adverse	O
events	O
,	O
such	O
as	O
uterine	O
cancer	O
and	O
thromboembolic	O
phenomena	O
.	O

Individuals	O
in	O
whom	O
tamoxifen	S-chem
-	O
associated	O
breast	O
cancer	O
risk	O
reduction	O
appears	O
to	O
outweigh	O
risk	O
of	O
serious	O
side	O
-	O
effects	O
include	O
women	O
with	O
prior	O
in	O
situ	O
or	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
-	O
positive	O
invasive	O
cancer	O
,	O
atypical	O
hyperplasia	O
,	O
and	O
/	O
or	O
women	O
ages	O
35	O
-	O
49	O
with	O
a	O
calculated	O
Gail	O
5	O
-	O
year	O
risk	O
of	O
>	O
or	O
=	O
1.7	O
%	O
,	O
hysterectomized	O
women	O
aged	O
50	O
and	O
older	O
with	O
a	O
5	O
-	O
year	O
Gail	O
risk	O
of	O
>	O
or	O
=	O
2.5	O
%	O
,	O
and	O
nonhysterectomized	O
women	O
aged	O
50	O
and	O
older	O
with	O
a	O
5	O
-	O
year	O
Gail	O
risk	O
of	O
>	O
5.0	O
%	O
.	O

It	O
is	O
not	O
yet	O
clear	O
whether	O
tamoxifen	S-chem-C4-1
can	O
reduce	O
breast	O
cancer	O
incidence	O
in	O
women	O
with	O
BRCA1	S-geneY
and	O
BRCA2	S-geneY-C4-2
mutations	O
,	O
although	O
preliminary	O
evidence	O
favors	O
benefit	O
for	O
at	O
least	O
those	O
with	O
a	O
BRCA2	S-geneY-C4-2
mutation	O
.	O

Raloxifene	S-chem
is	O
a	O
selective	O
ER	S-geneY
modulator	O
with	O
less	O
uterine	O
estrogen	S-chem
agonist	O
activity	O
than	O
tamoxifen	S-chem
,	O
and	O
it	O
is	O
hoped	O
that	O
it	O
will	O
result	O
in	O
fewer	O
uterine	O
cancers	O
but	O
will	O
be	O
equally	O
efficacious	O
in	O
reducing	O
the	O
risk	O
of	O
breast	O
cancer	O
.	O

The	O
NSABP	O
is	O
currently	O
conducting	O
a	O
randomized	O
study	O
of	O
tamoxifen	S-chem
versus	O
raloxifene	S-chem
in	O
high	O
-	O
risk	O
postmenopausal	O
women	O
.	O

Approximately	O
one	O
third	O
of	O
invasive	O
cancers	O
are	O
ER	S-geneY
negative	O
.	O

Tamoxifen	S-chem
does	O
not	O
reduce	O
the	O
incidence	O
of	O
ER	S-geneY
-	O
negative	O
cancers	O
,	O
nor	O
does	O
it	O
appear	O
to	O
be	O
effective	O
in	O
preventing	O
the	O
appearance	O
of	O
one	O
third	O
of	O
ER	S-geneY
-	O
positive	O
cancers	O
.	O

Priorities	O
in	O
prevention	O
research	O
are	O
to	O
develop	O
(	O
a	O
)	O
biomarkers	O
to	O
refine	O
short	O
-	O
term	O
risk	O
assessments	O
based	O
on	O
epidemiologic	O
models	O
,	O
(	O
b	O
)	O
biomarkers	O
predictive	O
of	O
response	O
to	O
specific	O
classes	O
of	O
preventive	O
agents	O
,	O
(	O
c	O
)	O
drugs	O
with	O
fewer	O
side	O
-	O
effects	O
and	O
/	O
or	O
effective	O
in	O
ER	S-geneY
-	O
negative	O
or	O
ER	S-geneY
-	O
positive	O
tamoxifen	S-chem
-	O
resistant	O
precancerous	O
disease	O
,	O
and	O
(	O
d	O
)	O
efficient	O
clinical	O
trial	O
models	O
to	O
assess	O
new	O
agent	O
efficacy	O
.	O

Breast	O
intraepithelial	O
neoplasia	O
(	O
IEN	O
)	O
may	O
be	O
sampled	O
by	O
minimally	O
invasive	O
techniques	O
and	O
is	O
an	O
attractive	O
short	O
-	O
term	O
risk	O
biomarker	O
.	O

Molecular	O
abnormalities	O
observed	O
in	O
IEN	O
may	O
be	O
used	O
to	O
select	O
potential	O
agents	O
for	O
testing	O
/	O
therapy	O
,	O
and	O
modulation	O
of	O
these	O
abnormalities	O
may	O
be	O
used	O
in	O
phase	O
I	O
trials	O
to	O
select	O
appropriate	O
doses	O
and	O
in	O
phase	O
II	O
trials	O
to	O
assess	O
response	O
.	O

Breast	O
density	O
volume	O
and	O
certain	O
serum	O
markers	O
such	O
as	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
1	E-geneY
are	O
also	O
being	O
studied	O
as	O
potential	O
risk	O
and	O
response	O
biomarkers	O
.	O

Reversal	O
or	O
prevention	O
of	O
advanced	O
IEN	O
as	O
well	O
as	O
modulation	O
of	O
other	O
risk	O
biomarkers	O
in	O
randomized	O
phase	O
II	O
and	O
phase	O
III	O
trials	O
is	O
being	O
evaluated	O
as	O
a	O
means	O
of	O
more	O
efficiently	O
evaluating	O
prevention	O
drugs	O
in	O
the	O
future	O
.	O

A	O
number	O
of	O
agents	O
are	O
being	O
developed	O
that	O
target	O
molecular	O
abnormalities	O
in	O
IEN	O
,	O
have	O
fewer	O
or	O
different	O
side	O
effects	O
than	O
tamoxifen	S-chem
,	O
and	O
may	O
be	O
effective	O
in	O
ER	S-geneY
-	O
negative	O
or	O
tamoxifen	S-chem
-	O
resistant	O
disease	O
.	O

Improved	O
Insulin	S-geneN
Sensitivity	O
despite	O
Increased	O
Visceral	O
Adiposity	O
in	O
Mice	O
Deficient	O
for	O
the	O
Immune	B-geneN
Cell	I-geneN
Transcription	I-geneN
Factor	E-geneN
T	B-geneY
-	I-geneY
bet	E-geneY
.	O

Low	O
-	O
grade	O
inflammation	O
in	O
fat	O
is	O
associated	O
with	O
insulin	S-geneN
resistance	O
,	O
although	O
the	O
mechanisms	O
are	O
unclear	O
.	O

We	O
report	O
that	O
mice	O
deficient	O
in	O
the	O
immune	B-geneN
cell	I-geneN
transcription	I-geneN
factor	E-geneN
T	B-geneY
-	I-geneY
bet	E-geneY
have	O
lower	O
energy	O
expenditure	O
and	O
increased	O
visceral	O
fat	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
,	O
yet	O
paradoxically	O
are	O
more	O
insulin	S-geneN
sensitive	O
.	O

This	O
striking	O
phenotype	O
,	O
present	O
in	O
young	O
T	B-geneY
-	I-geneY
bet	E-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
persisted	O
with	O
high	O
-	O
fat	O
diet	O
and	O
increasing	O
host	O
age	O
and	O
was	O
associated	O
with	O
altered	O
immune	O
cell	O
numbers	O
and	O
cytokine	S-geneN
secretion	O
specifically	O
in	O
visceral	O
adipose	O
tissue	O
.	O

However	O
,	O
the	O
favorable	O
metabolic	O
phenotype	O
observed	O
in	O
T	B-geneY
-	I-geneY
bet	E-geneY
-	O
deficient	O
hosts	O
was	O
lost	O
in	O
T	B-geneY
-	I-geneY
bet	E-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
also	O
lacking	O
adaptive	O
immunity	O
(	O
T	B-geneY
-	I-geneY
bet	E-geneY
(	O
-	O
/	O
-	O
)	O
xRag2	O
(	O
-	O
/	O
-	O
)	O
)	O
,	O
demonstrating	O
that	O
T	B-geneY
-	I-geneY
bet	E-geneY
expression	O
in	O
the	O
adaptive	O
rather	O
than	O
the	O
innate	O
immune	O
system	O
impacts	O
host	O
glucose	S-chem
homeostasis	O
.	O

Indeed	O
,	O
adoptive	O
transfer	O
of	O
T	B-geneY
-	I-geneY
bet	E-geneY
-	O
deficient	O
,	O
but	O
not	O
wild	O
-	O
type	O
,	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
to	O
Rag2	O
(	E-geneY
-	O
/	O
-	O
)	O
mice	O
improved	O
insulin	O
sensitivity	O
.	O

Our	O
results	O
reveal	O
a	O
role	O
for	O
T	B-geneY
-	I-geneY
bet	E-geneY
in	O
metabolic	O
physiology	O
and	O
obesity	O
-	O
associated	O
insulin	S-geneN
resistance	O
.	O

PI3	B-geneN
k	E-geneN
/	O
akt	S-geneN
inhibition	O
induces	O
apoptosis	O
through	O
p38	S-geneN
activation	O
in	O
neurons	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
the	O
PI3K	S-geneN
/	O
AKT	S-geneN
pathway	O
is	O
a	O
pro	O
-	O
survival	O
signalling	O
system	O
in	O
neurons	O
.	O

Therefore	O
,	O
the	O
inhibition	O
of	O
this	O
pathway	O
may	O
be	O
implicated	O
in	O
the	O
degeneration	O
of	O
neurons	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
and	O
other	O
neurological	O
disorders	O
.	O

Here	O
we	O
study	O
the	O
participation	O
of	O
the	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
pathway	O
on	O
apoptosis	O
induced	O
by	O
PI3K	S-geneN
/	O
AKT	S-geneN
inhibition	O
in	O
cultured	O
cerebellar	O
granule	O
cells	O
(	O
CGCs	O
)	O
.	O

LY294002	S-chem-MU-1
,	O
a	O
specific	O
PI3K	S-geneN-C4-2
/	O
AKT	S-geneN-C4-2
inhibitor	O
,	O
selectively	O
activated	O
the	O
p38	S-geneN-C3-2
MAPK	S-geneN-C3-2
kinase	S-geneN-C3-2
pathway	O
and	O
enhanced	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Jun	E-geneY-C3-2
phosphorylation	O
,	O
but	O
did	O
not	O
activate	O
JNK	S-geneN
.	O

The	O
pharmacological	O
inhibitors	O
SB203580	S-chem-C4-1
(	O
p38	S-geneN-C4-2
inhibitor	O
)	O
and	O
SP600125	S-chem-C4-1
(	O
a	O
JNK	S-geneN-C4-2
inhibitor	O
)	O
protected	O
primary	O
cultures	O
of	O
rat	O
CGCs	O
from	O
LY294002	S-chem
-	O
induced	O
apoptosis	O
.	O

Furthermore	O
,	O
both	O
compounds	O
decreased	O
the	O
phosphorylation	O
of	O
c	B-geneY
-	I-geneY
Jun	E-geneY
and	O
lowered	O
mRNA	O
levels	O
of	O
the	O
pro	O
-	O
apoptotic	O
gene	O
dp5	S-geneY
,	O
a	O
direct	O
target	O
of	O
c	B-geneY
-	I-geneY
Jun	E-geneY
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
PI3K	S-geneN
/	O
AKT	S-geneN
inhibition	O
induces	O
neuronal	O
apoptosis	O
,	O
a	O
process	O
that	O
is	O
mediated	O
by	O
the	O
activation	O
of	O
p38	S-geneN
MAPK	S-geneN
/	O
c	B-geneY
-	I-geneY
Jun	E-geneY
/	O
dp5	S-geneY
.	O

Small	O
molecule	O
mediated	O
proliferation	O
of	O
primary	O
retinal	S-chem
pigment	O
epithelial	O
cells	O
.	O

Retinal	S-chem
pigment	O
epithelial	O
(	O
RPE	O
)	O
cells	O
form	O
a	O
monolayer	O
adjacent	O
to	O
the	O
retina	O
and	O
play	O
a	O
critical	O
role	O
in	O
the	O
visual	O
light	O
cycle	O
.	O

Degeneration	O
of	O
this	O
layer	O
results	O
in	O
vision	O
loss	O
,	O
causing	O
retinal	O
disorders	O
such	O
as	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

Cell	O
transplant	O
therapies	O
exist	O
to	O
restore	O
vision	O
loss	O
;	O
however	O
,	O
risks	O
associated	O
with	O
and	O
an	O
inadequate	O
supply	O
of	O
donor	O
cells	O
have	O
limited	O
their	O
therapeutic	O
success	O
.	O

The	O
identification	O
of	O
factors	O
that	O
proliferate	O
RPE	O
cells	O
ex	O
vivo	O
could	O
provide	O
a	O
renewable	O
source	O
of	O
cells	O
for	O
the	O
treatment	O
of	O
such	O
disorders	O
.	O

We	O
show	O
that	O
a	O
small	O
molecule	O
(	O
WS3	O
)	O
can	O
reversibly	O
proliferate	O
primary	O
RPE	O
cells	O
isolated	O
from	O
fetal	O
and	O
adult	O
human	O
donors	O
.	O

Following	O
withdrawal	O
of	O
WS3	O
,	O
RPE	O
cells	O
differentiate	O
into	O
a	O
functional	O
monolayer	O
,	O
as	O
exhibited	O
by	O
their	O
expression	O
of	O
mature	O
RPE	O
genes	O
and	O
phagocytosis	O
of	O
photoreceptor	O
outer	O
segments	O
.	O

Furthermore	O
,	O
chemically	O
expanded	O
RPE	O
cells	O
preserve	O
vision	O
when	O
transplanted	O
into	O
dystrophic	O
Royal	O
College	O
of	O
Surgeons	O
(	O
RCS	O
)	O
rats	O
,	O
a	O
well	O
-	O
established	O
model	O
of	O
retinal	O
degeneration	O
.	O

5	B-geneY
-	I-geneY
Lipoxygenase	E-geneY
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

The	O
unique	O
role	O
of	O
the	O
enzyme	O
5	B-geneY-C9-2
-	I-geneY-C9-2
lipoxygenase	E-geneY-C9-2
(	O
5	B-geneY-C9-2
-	I-geneY-C9-2
LO	E-geneY-C9-2
)	O
in	O
the	O
production	O
of	O
leukotrienes	S-chem-C9-1
(	O
LTs	S-chem-C9-1
)	O
makes	O
it	O
a	O
likely	O
target	O
for	O
biochemical	O
manipulation	O
.	O

The	O
rationale	O
for	O
using	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibitors	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
based	O
on	O
the	O
increased	O
generation	O
of	O
LTs	S-chem
in	O
the	O
inflamed	O
mucosa	O
,	O
LTB4	S-chem
being	O
the	O
most	O
potent	O
chemotactic	O
and	O
chemokinetic	O
metabolite	O
of	O
arachidonic	B-chem
acid	E-chem
.	O

Furthermore	O
,	O
conventional	O
drugs	O
,	O
such	O
as	O
corticosteroids	O
,	O
sulphasalazine	S-chem
,	O
and	O
5	B-chem
-	I-chem
aminosalicylic	I-chem
acid	E-chem
,	O
inhibit	O
LT	S-chem
production	O
and	O
specific	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibition	O
accelerates	O
healing	O
in	O
animal	O
models	O
of	O
acute	O
colitis	O
.	O

The	O
compounds	O
identified	O
as	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibitors	O
can	O
be	O
divided	O
into	O
antioxidants	O
,	O
substrate	O
-	O
analogous	O
,	O
and	O
a	O
large	O
miscellaneous	O
group	O
of	O
inhibitors	O
,	O
where	O
hydroxamic	B-chem-C4-1
acids	E-chem-C4-1
are	O
potent	O
and	O
more	O
selective	O
inhibitors	O
of	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LO	E-geneY-C4-2
.	O

The	O
benzothiophene	B-chem-C4-1
hydroxyurea	E-chem-C4-1
,	O
zileuton	S-chem-C4-1
,	O
is	O
the	O
first	O
selective	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LO	E-geneY-C4-2
inhibitor	O
evaluated	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
IBD	O
.	O

An	O
800	O
-	O
mg	O
oral	O
dose	O
of	O
zileuton	S-chem
was	O
shown	O
to	O
reduce	O
LTB4	S-chem
,	O
but	O
not	O
prostaglandin	B-chem
E2	E-chem
,	O
concentrations	O
by	O
75	O
-	O
85	O
%	O
in	O
rectal	O
dialysates	O
from	O
patients	O
with	O
active	O
ulcerative	O
colitis	O
.	O

The	O
clinical	O
efficacy	O
of	O
zileuton	S-chem
800	O
mg	O
b.i.d	O
.	O
has	O
also	O
been	O
tested	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
similar	O
patients	O
.	O

Zileuton	S-chem
significantly	O
improved	O
the	O
symptom	O
scores	O
and	O
the	O
histology	O
score	O
,	O
but	O
not	O
the	O
sigmoidoscopy	O
score	O
,	O
compared	O
to	O
pretreatment	O
conditions	O
and	O
with	O
response	O
to	O
placebo	O
,	O
the	O
beneficial	O
effects	O
being	O
most	O
pronounced	O
in	O
patients	O
not	O
receiving	O
concomitant	O
sulphasalazine	S-chem
treatment	O
.	O

The	O
mean	O
inhibition	O
of	O
LTB4	S-chem
in	O
the	O
target	O
tissue	O
of	O
inflammation	O
was	O
70	O
%	O
.	O

The	O
proof	O
that	O
any	O
putative	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibitor	O
is	O
blocking	O
LT	S-chem
production	O
is	O
an	O
important	O
stage	O
in	O
assessing	O
any	O
such	O
drug	O
.	O

The	O
main	O
disadvantage	O
of	O
existing	O
new	O
LT	S-chem
inhibitors	O
relates	O
to	O
the	O
high	O
potency	O
of	O
LTs	S-chem
,	O
and	O
unless	O
a	O
higher	O
level	O
of	O
inhibition	O
can	O
be	O
achieved	O
,	O
endogenous	O
LTs	S-chem
may	O
still	O
be	O
present	O
in	O
sufficient	O
amounts	O
to	O
produce	O
their	O
effects	O
.	O

Antitumor	O
activity	O
of	O
sorafenib	S-chem-C4-1
in	O
FLT3	S-geneY-C4-2
-	O
driven	O
leukemic	O
cells	O
.	O

Activating	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
insertions	O
in	O
the	O
juxtamembrane	B-geneN
domain	E-geneN
of	O
the	O
FLT3	S-geneY
tyrosine	B-geneN
kinase	E-geneN
are	O
found	O
in	O
about	O
one	O
fourth	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
and	O
have	O
been	O
shown	O
to	O
be	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
survival	O
.	O

We	O
show	O
that	O
sorafenib	S-chem-C4-1
(	O
BAY	B-chem-C4-1
43	I-chem-C4-1
-	I-chem-C4-1
9006	E-chem-C4-1
,	O
Nexavar	S-chem-C4-1
)	O
potently	O
inhibits	O
FLT3	S-geneY-C4-2
enzymatic	O
and	O
signaling	O
activities	O
.	O

In	O
HEK293	O
cells	O
stably	O
transfected	O
with	O
FLT3	S-geneY
-	O
WT	O
or	O
FLT3	S-geneY
-	O
ITD	O
,	O
sorafenib	S-chem-C4-1
blocked	O
basal	O
and	O
ligand	O
dependent	O
FLT3	S-geneY-C4-2
-	O
mediated	O
tyrosine	S-chem
autophosphorylation	O
as	O
well	O
as	O
extracellular	B-geneN-C4-2
signal	I-geneN-C4-2
-	I-geneN-C4-2
regulated	I-geneN-C4-2
kinase1	I-geneN-C4-2
/	I-geneN-C4-2
2	E-geneN-C4-2
and	O
Stat5	S-geneY-C4-2
phosphorylation	O
.	O

In	O
leukemia	O
cell	O
lines	O
MV4	O
-	O
11	O
and	O
EOL	O
-	O
1	O
,	O
sorafenib	S-chem-C4-1
treatment	O
resulted	O
in	O
decreased	O
cell	O
proliferation	O
and	O
inhibition	O
of	O
FLT3	S-geneY-C4-2
signaling	O
.	O

The	O
growth	O
of	O
the	O
FLT3	S-geneY-C4-2
-	O
independent	O
RS4	O
-	O
11	O
cell	O
line	O
was	O
only	O
weakly	O
inhibited	O
by	O
sorafenib	S-chem-C4-1
.	O

Cell	O
cycle	O
arrest	O
and	O
induction	O
of	O
apoptosis	O
were	O
observed	O
upon	O
treatment	O
with	O
sorafenib	S-chem
in	O
MV4	O
-	O
11	O
and	O
EOL	O
-	O
1	O
cells	O
.	O

The	O
antitumor	O
efficacy	O
of	O
sorafenib	S-chem
was	O
evaluated	O
against	O
the	O
MV4	O
-	O
11	O
leukemia	O
grown	O
subcutaneously	O
in	O
NCr	O
nu	O
/	O
nu	O
mice	O
.	O

Doses	O
of	O
3	O
and	O
10	O
mg	O
/	O
kg	O
administered	O
orally	O
for	O
14	O
days	O
resulted	O
in	O
six	O
and	O
nine	O
out	O
of	O
10	O
animals	O
with	O
complete	O
responses	O
,	O
respectively	O
.	O

The	O
demonstration	O
that	O
sorafenib	S-chem-C4-1
exhibits	O
potent	O
target	O
inhibition	O
and	O
efficacy	O
in	O
FLT3	S-geneY-C4-2
-	O
driven	O
models	O
suggests	O
that	O
this	O
compound	O
may	O
have	O
a	O
therapeutic	O
benefit	O
for	O
patients	O
with	O
FLT3	S-geneY-C4-2
-	O
driven	O
leukemias	O
.	O

Molecular	O
determinants	O
of	O
dofetilide	S-chem-C4-1
block	O
of	O
HERG	S-geneY-C4-2
K	B-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
.	O

The	O
human	B-geneY
ether	I-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
related	I-geneY
gene	E-geneY
(	O
HERG	S-geneY
)	O
encodes	O
a	O
K	B-geneN
+	I-geneN
channel	E-geneN
with	O
biophysical	O
properties	O
nearly	O
identical	O
to	O
the	O
rapid	B-geneN
component	I-geneN
of	I-geneN
the	I-geneN
cardiac	I-geneN
delayed	I-geneN
rectifier	I-geneN
K	I-geneN
+	I-geneN
current	E-geneN
(	O
IKr	S-geneN
)	O
.	O

HERG	S-geneY-C4-2
/	O
IKr	S-geneN-C4-2
channels	O
are	O
a	O
prime	O
target	O
for	O
the	O
pharmacological	O
management	O
of	O
arrhythmias	O
and	O
are	O
selectively	O
blocked	O
by	O
class	O
III	O
antiarrhythmic	O
methanesulfonanilide	S-chem-C4-1
drugs	O
,	O
such	O
as	O
dofetilide	S-chem-C4-1
,	O
E4031	S-chem-C4-1
,	O
and	O
MK	B-chem-C4-1
-	I-chem-C4-1
499	E-chem-C4-1
,	O
at	O
submicromolar	O
concentrations	O
.	O

By	O
contrast	O
,	O
the	O
closely	O
related	O
bovine	B-geneY
ether	I-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	I-geneY
channel	E-geneY
(	O
BEAG	S-geneY
)	O
is	O
100	O
-	O
fold	O
less	O
sensitive	O
to	O
dofetilide	S-chem
.	O

To	O
identify	O
the	O
molecular	O
determinants	O
for	O
dofetilide	S-chem
block	O
,	O
we	O
first	O
engineered	O
chimeras	O
between	O
HERG	S-geneY
and	O
BEAG	S-geneY
and	O
then	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
localize	O
single	O
amino	B-chem
acid	E-chem
residues	O
responsible	O
for	O
block	O
.	O

Using	O
constructs	O
heterologously	O
expressed	O
in	O
Xenopus	O
oocytes	O
,	O
we	O
found	O
that	O
transplantation	O
of	O
the	O
S5	O
-	O
S6	O
linker	O
from	O
BEAG	S-geneY
into	O
HERG	S-geneY
removed	O
high	O
-	O
affinity	O
block	O
by	O
dofetilide	O
.	O

A	O
point	O
mutation	O
in	O
the	O
S5	O
-	O
S6	O
linker	O
region	O
,	O
HERG	S-geneY
S620T	S-geneN
,	O
abolished	O
high	O
-	O
affinity	O
block	O
and	O
interfered	O
with	O
C	O
-	O
type	O
inactivation	O
.	O

Thus	O
,	O
our	O
results	O
indicate	O
that	O
important	O
determinants	O
of	O
dofetilide	S-chem
binding	O
are	O
localized	O
to	O
the	O
pore	O
region	O
of	O
HERG	S-geneY
.	O

Since	O
the	O
loss	O
of	O
high	O
-	O
affinity	O
drug	O
binding	O
was	O
always	O
correlated	O
with	O
a	O
loss	O
of	O
C	O
-	O
type	O
inactivation	O
,	O
it	O
is	O
possible	O
that	O
the	O
changes	O
observed	O
in	O
drug	O
binding	O
are	O
due	O
to	O
indirect	O
allosteric	O
modifications	O
in	O
the	O
structure	O
of	O
the	O
channel	O
protein	O
and	O
not	O
to	O
the	O
direct	O
interaction	O
of	O
dofetilide	S-chem
with	O
the	O
respective	O
mutated	O
site	O
chains	O
.	O

However	O
,	O
the	O
chimeric	O
approach	O
was	O
not	O
able	O
to	O
identify	O
domains	O
outside	O
the	O
S5	O
-	O
S6	O
linker	O
region	O
of	O
the	O
HERG	S-geneY
channel	O
as	O
putative	O
candidates	O
involved	O
in	O
drug	O
binding	O
.	O

Moreover	O
,	O
the	O
reverse	O
mutation	O
BEAG	S-geneY
T432S	S-geneN
increased	O
the	O
affinity	O
of	O
BEAG	S-geneY
K	B-geneN
+	I-geneN
channels	E-geneN
for	O
dofetilide	S-chem
,	O
whereas	O
C	O
-	O
type	O
inactivation	O
could	O
not	O
be	O
recovered	O
.	O

Thus	O
,	O
the	O
serine	S-chem
in	O
position	O
HERG	S-geneY
620	O
may	O
participate	O
directly	O
in	O
dofetilide	S-chem
binding	O
;	O
however	O
,	O
an	O
intact	O
C	O
-	O
type	O
inactivation	O
process	O
seems	O
to	O
be	O
crucial	O
for	O
high	O
-	O
affinity	O
drug	O
binding	O
.	O

Incorporation	O
of	O
trifluoroisoleucine	S-chem
into	O
proteins	O
in	O
vivo	O
.	O

Two	O
fluorinated	O
derivatives	O
of	O
isoleucine	S-chem
:	O
d	B-chem
,	I-chem
l	I-chem
-	I-chem
2	I-chem
-	I-chem
amino	I-chem
-	I-chem
3	I-chem
-	I-chem
trifluoromethyl	I-chem
pentanoic	I-chem
acid	E-chem
(	O
3TFI	S-chem
,	O
2	O
)	O
and	O
d	B-chem
,	I-chem
l	I-chem
-	I-chem
2	I-chem
-	I-chem
amino	I-chem
-	I-chem
5,5,5	I-chem
-	I-chem
trifluoro	I-chem
-	I-chem
3	I-chem
-	I-chem
methyl	I-chem
pentanoic	I-chem
acid	E-chem
(	O
5TFI	S-chem
,	O
3	O
)	O
were	O
prepared	O
.	O

5TFI	S-chem
was	O
incorporated	O
into	O
a	O
model	O
target	O
protein	O
,	O
murine	B-geneY
dihydrofolate	I-geneY
reductase	E-geneY
(	O
mDHFR	S-geneY
)	O
,	O
in	O
an	O
isoleucine	S-chem
auxotrophic	O
Escherichia	O
coli	O
host	O
strain	O
suspended	O
in	O
5TFI	S-chem
-	O
supplemented	O
minimal	O
medium	O
depleted	O
of	O
isoleucine	S-chem
.	O

Incorporation	O
of	O
5TFI	S-chem
was	O
confirmed	O
by	O
tryptic	O
peptide	O
analysis	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
MS	O
)	O
of	O
the	O
protein	O
product	O
.	O

Amino	B-chem
acid	E-chem
analysis	O
showed	O
that	O
more	O
than	O
93	O
%	O
of	O
the	O
encoded	O
isoleucine	S-chem
residues	O
were	O
replaced	O
by	O
5TFI	S-chem
.	O

Measurement	O
of	O
the	O
rate	O
of	O
activation	O
of	O
5TFI	S-chem
by	O
the	O
E.	B-geneY
coli	I-geneY
isoleucyl	I-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
IleRS	S-geneY
)	O
yielded	O
a	O
specificity	O
constant	O
(	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
)	O
134	O
-	O
fold	O
lower	O
than	O
that	O
for	O
isoleucine	S-chem
.	O

5TFI	S-chem
was	O
successfully	O
introduced	O
into	O
the	O
cytokine	S-geneN
murine	B-geneY
interleukin	I-geneY
-	I-geneY
2	E-geneY
(	O
mIL	B-geneY
-	I-geneY
2	E-geneY
)	O
at	O
the	O
encoded	O
isoleucine	S-chem
positions	O
.	O

The	O
concentration	O
of	O
fluorinated	O
protein	O
that	O
elicits	O
50	O
%	O
of	O
the	O
maximal	O
proliferative	O
response	O
is	O
3.87	O
ng	O
/	O
mL	O
,	O
about	O
30	O
%	O
higher	O
than	O
that	O
of	O
wild	O
-	O
type	O
mIL	B-geneY
-	I-geneY
2	E-geneY
(	O
EC	O
(	O
50	O
)	O
=	O
2.70	O
ng	O
/	O
mL	O
)	O
.	O

The	O
maximal	O
responses	O
are	O
equivalent	O
for	O
the	O
fluorinated	O
and	O
wild	O
-	O
type	O
cytokines	S-geneN
,	O
indicating	O
that	O
fluorinated	O
proteins	O
can	O
fold	O
into	O
stable	O
and	O
functional	O
structures	O
.	O

3TFI	S-chem
yielded	O
no	O
evidence	O
for	O
in	O
vivo	O
incorporation	O
into	O
recombinant	O
proteins	O
,	O
and	O
no	O
evidence	O
for	O
activation	O
by	O
IleRS	S-geneY
in	O
vitro	O
.	O

Immunohistochemical	O
characterization	O
of	O
pyrimidine	S-chem-C9-1
synthetic	O
enzymes	O
,	O
thymidine	B-geneY-C9-2
kinase	I-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
and	O
thymidylate	B-geneY-C9-2
synthase	E-geneY-C9-2
,	O
in	O
various	O
types	O
of	O
cancer	O
.	O

Thymidine	B-geneY-C9-2
kinase	I-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
(	O
TK	B-geneY-C9-2
-	I-geneY-C9-2
1	I-geneY-C9-2
)	E-geneY-C9-2
and	O
thymidylate	B-geneY-C9-2
synthase	E-geneY-C9-2
(	O
TS	S-geneY-C9-2
)	O
are	O
key	O
enzymes	O
for	O
salvage	O
and	O
de	O
novo	O
pyrimidine	S-chem-C9-1
synthesis	O
,	O
respectively	O
.	O

Numerous	O
studies	O
have	O
suggested	O
that	O
increased	O
TS	S-geneY
levels	O
are	O
associated	O
closely	O
with	O
resistance	O
to	O
fluoropyrimidine	S-chem
-	O
based	O
chemotherapy	O
.	O

TAS	B-chem-MU-1
-	I-chem-MU-1
102	E-chem-MU-1
is	O
a	O
novel	O
drug	O
containing	O
trifluorothymidine	S-chem-C9-1
,	O
which	O
is	O
phosphorylated	O
by	O
TK	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
to	O
its	O
active	O
monophosphated	O
form	O
,	O
that	O
in	O
turn	O
can	O
inhibit	O
TS	S-geneY-C4-2
.	O

TAS	B-chem
-	I-chem
102	E-chem
has	O
been	O
shown	O
to	O
exhibit	O
antitumor	O
activity	O
in	O
fluoropyrimidine	S-chem
-	O
resistant	O
human	O
cancer	O
cells	O
.	O

TAS	B-chem
-	I-chem
102	E-chem
is	O
currently	O
undergoing	O
clinical	O
trials	O
for	O
use	O
in	O
gastrointestinal	O
cancers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
investigate	O
the	O
expression	O
of	O
TK	B-geneY
-	I-geneY
1	E-geneY
and	O
TS	S-geneY
in	O
various	O
types	O
of	O
cancer	O
.	O

TK	B-geneY
-	I-geneY
1	E-geneY
and	O
TS	S-geneY
expression	O
was	O
markedly	O
different	O
between	O
cancer	O
types	O
.	O

High	O
TK	B-geneY
-	I-geneY
1	E-geneY
expression	O
was	O
detected	O
prominently	O
in	O
gastrointestinal	O
adenocarcinomas	O
and	O
esophageal	O
and	O
uterine	O
squamous	O
cell	O
carcinomas	O
.	O

Gastrointestinal	O
adenocarcinomas	O
and	O
squamous	O
cell	O
uterine	O
carcinomas	O
were	O
often	O
accompanied	O
by	O
high	O
TS	S-geneY-C9-2
expression	O
,	O
indicating	O
activation	O
of	O
pyrimidine	S-chem-C9-1
synthesis	O
through	O
both	O
the	O
salvage	O
and	O
de	O
novo	O
pathways	O
.	O

These	O
results	O
led	O
us	O
to	O
consider	O
that	O
TAS	B-chem
-	I-chem
102	E-chem
may	O
also	O
be	O
effective	O
for	O
esophageal	O
and	O
uterine	O
squamous	O
cell	O
carcinomas	O
,	O
as	O
well	O
as	O
for	O
gastrointestinal	O
adenocarcinomas	O
,	O
even	O
in	O
fluoropyrimidine	S-chem
-	O
resistant	O
cases	O
with	O
high	O
TS	S-geneY
expression	O
.	O

In	O
contrast	O
,	O
thyroid	O
papillary	O
carcinomas	O
,	O
lung	O
adenocarcinomas	O
,	O
hepatocellular	O
carcinomas	O
,	O
pancreatic	O
ductal	O
carcinomas	O
,	O
and	O
renal	O
cell	O
carcinomas	O
,	O
which	O
exhibit	O
low	O
TK	B-geneY
-	I-geneY
1	E-geneY
expression	O
,	O
may	O
be	O
resistant	O
to	O
TAS	B-chem
-	I-chem
102	E-chem
.	O

In	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
,	O
high	O
TK	B-geneY
-	I-geneY
1	E-geneY
expression	O
was	O
demonstrated	O
in	O
squamous	O
cell	O
carcinomas	O
,	O
but	O
not	O
in	O
adenocarcinomas	O
.	O

This	O
result	O
suggests	O
that	O
TAS	B-chem
-	I-chem
102	E-chem
efficacy	O
and	O
the	O
pyrimidine	S-chem
synthetic	O
pathway	O
may	O
differ	O
depending	O
on	O
histological	O
type	O
.	O

Our	O
results	O
indicate	O
that	O
administration	O
of	O
TAS	B-chem
-	I-chem
102	E-chem
could	O
be	O
selected	O
on	O
the	O
basis	O
of	O
the	O
immunohistochemical	O
evaluation	O
of	O
TK	B-geneY
-	I-geneY
1	E-geneY
and	O
TS	S-geneY
.	O

A	O
PET	O
study	O
of	O
dopamine	B-geneN
D2	I-geneN
and	I-geneN
serotonin	I-geneN
5	I-geneN
-	I-geneN
HT2	I-geneN
receptor	E-geneN
occupancy	O
in	O
patients	O
with	O
schizophrenia	O
treated	O
with	O
therapeutic	O
doses	O
of	O
ziprasidone	S-chem
.	O

OBJECTIVE	O
:	O
Ziprasidone	S-chem
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
shows	O
a	O
higher	O
affinity	O
for	O
serotonin	S-chem
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptors	E-geneY
compared	O
with	O
dopamine	B-geneY
D	I-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptors	E-geneY
in	O
vitro	O
.	O

The	O
affinity	O
of	O
ziprasidone	S-chem
for	O
these	O
receptors	O
in	O
vivo	O
in	O
patients	O
was	O
examined	O
in	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
.	O

METHOD	O
:	O
The	O
authors	O
conducted	O
a	O
PET	O
study	O
to	O
evaluate	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
occupancy	O
(	O
using	O
[	B-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
raclopride	E-chem
)	O
and	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
occupancy	O
(	O
using	O
[	B-chem
(	I-chem
18	I-chem
)	I-chem
F	I-chem
]	I-chem
setoperone	E-chem
)	O
in	O
brain	O
regions	O
of	O
interest	O
in	O
16	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
randomly	O
assigned	O
to	O
receive	O
40	O
,	O
80	O
,	O
120	O
,	O
or	O
160	O
mg	O
/	O
day	O
of	O
ziprasidone	S-chem
,	O
which	O
reflected	O
the	O
recommended	O
dose	O
range	O
.	O

PET	O
scanning	O
was	O
done	O
after	O
3	O
weeks	O
of	O
administration	O
and	O
at	O
trough	O
plasma	O
levels	O
,	O
i.e	O
.	O
,	O
12	O
-	O
16	O
hours	O
after	O
the	O
last	O
dose	O
.	O

RESULTS	O
:	O
The	O
mean	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
receptor	O
occupancy	O
was	O
significantly	O
higher	O
than	O
the	O
mean	O
D	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
occupancy	O
(	O
mean	O
=	O
76	O
%	O
,	O
SD	O
=	O
15	O
%	O
,	O
and	O
mean	O
=	O
56	O
%	O
,	O
SD	O
=	O
18	O
%	O
,	O
respectively	O
)	O
.	O

The	O
estimated	O
plasma	O
ziprasidone	S-chem
concentration	O
associated	O
with	O
50	O
%	O
maximal	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
receptor	O
occupancy	O
was	O
almost	O
four	O
times	O
lower	O
than	O
that	O
for	O
D	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
occupancy	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
affirm	O
that	O
ziprasidone	S-chem
is	O
similar	O
to	O
other	O
novel	O
antipsychotics	O
in	O
having	O
greater	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
than	O
D	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
receptor	E-geneN
occupancy	O
at	O
therapeutic	O
doses	O
and	O
suggest	O
that	O
the	O
optimal	O
effective	O
dose	O
of	O
ziprasidone	S-chem
is	O
closer	O
to	O
120	O
mg	O
/	O
day	O
than	O
to	O
the	O
lower	O
doses	O
suggested	O
by	O
previous	O
PET	O
studies	O
.	O

The	O
relatively	O
high	O
D	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
occupancy	O
,	O
even	O
at	O
trough	O
plasma	O
levels	O
,	O
suggests	O
that	O
ziprasidone	S-chem
is	O
more	O
similar	O
to	O
risperidone	S-chem
and	O
olanzapine	O
in	O
receptor	O
occupancy	O
profile	O
than	O
to	O
clozapine	S-chem
and	O
quetiapine	S-chem
.	O

Since	O
ziprasidone	S-chem
plasma	O
levels	O
show	O
significant	O
(	O
more	O
than	O
twofold	O
)	O
variation	O
within	O
a	O
single	O
dose	O
cycle	O
,	O
studies	O
that	O
are	O
aimed	O
at	O
peak	O
plasma	O
levels	O
(	O
6	O
hours	O
after	O
the	O
last	O
dose	O
)	O
and	O
that	O
examine	O
extrastriatal	O
regions	O
are	O
required	O
to	O
fully	O
characterize	O
the	O
in	O
vivo	O
occupancy	O
profile	O
of	O
ziprasidone	S-chem
.	O

Optoelectronic	O
Processes	O
in	O
Squaraine	B-chem
Dye	E-chem
-	O
Doped	O
OLEDs	O
for	O
Emission	O
in	O
the	O
Near	O
-	O
Infrared	O
.	O

A	O
novel	O
all	O
-	O
organic	O
host	O
-	O
guest	O
system	O
for	O
emission	O
in	O
the	O
NIR	O
is	O
introduced	O
and	O
investigated	O
with	O
respect	O
to	O
its	O
opto	O
-	O
electronic	O
processes	O
.	O

The	O
good	O
agreement	O
between	O
theoretical	O
and	O
experimental	O
results	O
highlights	O
the	O
model	O
character	O
of	O
this	O
system	O
and	O
its	O
potential	O
for	O
electroluminescent	O
application	O
.	O

Comparative	O
measurements	O
provide	O
access	O
to	O
the	O
recombination	O
mechanisms	O
on	O
molecular	O
length	O
scale	O
and	O
show	O
that	O
the	O
emission	O
behavior	O
of	O
the	O
device	O
under	O
operation	O
is	O
controlled	O
by	O
charge	O
carrier	O
dynamics	O
.	O

Comparative	O
genomics	O
,	O
molecular	O
evolution	O
and	O
computational	O
modeling	O
of	O
ALDH1B1	S-geneY
and	O
ALDH2	S-geneY
.	O

Vertebrate	B-geneY
ALDH2	E-geneY
genes	O
encode	O
mitochondrial	O
enzymes	O
capable	O
of	O
metabolizing	O
acetaldehyde	S-chem
and	O
other	O
biological	O
aldehydes	S-chem
in	O
the	O
body	O
.	O

Mammalian	B-geneY-C9-2
ALDH1B1	E-geneY-C9-2
,	O
another	O
mitochondrial	O
enzyme	O
sharing	O
72	O
%	O
identity	O
with	O
ALDH2	S-geneY-C9-2
,	O
is	O
also	O
capable	O
of	O
metabolizing	O
acetaldehyde	S-chem-C9-1
but	O
has	O
a	O
tissue	O
distribution	O
and	O
pattern	O
of	O
activity	O
distinct	O
from	O
that	O
of	O
ALDH2	S-geneY
.	O

Bioinformatic	O
analyses	O
of	O
several	O
vertebrate	O
genomes	O
were	O
undertaken	O
using	O
known	O
ALDH2	S-geneY
and	O
ALDH1B1	S-geneY
amino	B-chem
acid	E-chem
sequences	O
.	O

Phylogenetic	O
analysis	O
of	O
many	O
representative	O
vertebrate	O
species	O
(	O
including	O
fish	O
,	O
amphibians	O
,	O
birds	O
and	O
mammals	O
)	O
indicated	O
the	O
presence	O
of	O
ALDH1B1	S-geneY
in	O
many	O
mammalian	O
species	O
and	O
in	O
frogs	O
(	O
Xenopus	O
tropicalis	O
)	O
;	O
no	O
evidence	O
was	O
found	O
for	O
ALDH1B1	S-geneY
in	O
the	O
genomes	O
of	O
birds	O
,	O
reptiles	O
or	O
fish	O
.	O

Predicted	O
vertebrate	B-geneY
ALDH2	E-geneY
and	O
ALDH1B1	S-geneY
subunit	O
sequences	O
and	O
structures	O
were	O
highly	O
conserved	O
,	O
including	O
residues	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
catalysis	O
and	O
coenzyme	O
binding	O
for	O
human	B-geneY
ALDH2	E-geneY
.	O

Studies	O
of	O
ALDH1B1	S-geneY
sequences	O
supported	O
the	O
hypothesis	O
that	O
the	O
ALDH1B1	S-geneN
gene	O
originated	O
in	O
early	O
vertebrates	O
from	O
a	O
retrotransposition	O
of	O
the	O
vertebrate	O
ALDH2	S-geneY
gene	O
.	O

Given	O
the	O
high	O
degree	O
of	O
similarity	O
between	O
ALDH2	S-geneY
and	O
ALDH1B1	S-geneY
,	O
it	O
is	O
surprising	O
that	O
individuals	O
with	O
an	O
inactivating	O
mutation	O
in	O
ALDH2	S-geneY
(	O
ALDH2	S-geneY
*	O
2	O
)	O
do	O
not	O
exhibit	O
a	O
compensatory	O
increase	O
in	O
ALDH1B1	S-geneY
activity	O
.	O

We	O
hypothesized	O
that	O
the	O
similarity	O
between	O
the	O
two	O
ALDHs	S-geneN
would	O
allow	O
for	O
dominant	O
negative	O
heterotetramerization	O
between	O
the	O
inactive	O
ALDH2	S-geneY
mutants	O
and	O
ALDH1B1	S-geneY
.	O

Computational	O
-	O
based	O
molecular	O
modeling	O
studies	O
examining	O
predicted	O
protein	O
-	O
protein	O
interactions	O
indicated	O
that	O
heterotetramerization	O
between	O
ALDH2	S-geneY
and	O
ALDH1B1	S-geneY
subunits	O
was	O
highly	O
probable	O
and	O
may	O
partially	O
explain	O
a	O
lack	O
of	O
compensation	O
by	O
ALDH1B1	S-geneY
in	O
ALDH2	S-geneY
(	O
∗	O
)	O
2	O
individuals	O
.	O

Yeast	B-geneY
epiarginase	E-geneY
regulation	O
,	O
an	O
enzyme	O
-	O
enzyme	O
activity	O
control	O
:	O
identification	O
of	O
residues	O
of	O
ornithine	B-geneY
carbamoyltransferase	E-geneY
and	O
arginase	S-geneY
responsible	O
for	O
enzyme	O
catalytic	O
and	O
regulatory	O
activities	O
.	O

In	O
the	O
presence	O
of	O
ornithine	S-chem
and	O
arginine	S-chem
,	O
ornithine	B-geneY
carbamoyltransferase	E-geneY
(	O
OTCase	S-geneY
)	O
and	O
arginase	S-geneY
form	O
a	O
one	O
-	O
to	O
-	O
one	O
enzyme	O
complex	O
in	O
which	O
the	O
activity	O
of	O
OTCase	S-geneY
is	O
inhibited	O
whereas	O
arginase	S-geneY
remains	O
catalytically	O
active	O
.	O

The	O
mechanism	O
by	O
which	O
these	O
nonallosteric	O
enzymes	O
form	O
a	O
stable	O
complex	O
triggered	O
by	O
the	O
binding	O
of	O
their	O
respective	O
substrates	O
raises	O
the	O
question	O
of	O
how	O
such	O
a	O
cooperative	O
association	O
is	O
induced	O
.	O

Analyses	O
of	O
mutations	O
in	O
both	O
enzymes	O
identify	O
residues	O
that	O
are	O
required	O
for	O
their	O
association	O
,	O
some	O
of	O
them	O
being	O
important	O
for	O
catalysis	O
.	O

In	O
arginase	S-geneY
,	O
two	O
cysteines	S-chem
at	O
the	O
C	S-chem
terminus	O
of	O
the	O
protein	O
are	O
crucial	O
for	O
its	O
epiarginase	S-geneY
function	O
but	O
not	O
for	O
its	O
catalytic	O
activity	O
and	O
trimeric	O
structure	O
.	O

In	O
OTCase	S-geneY
,	O
mutations	O
of	O
putative	O
ornithine	S-chem
binding	O
residues	O
,	O
Asp	S-chem
-	O
182	O
,	O
Asn	S-chem
-	O
184	O
,	O
Asn	S-chem
-	O
185	O
,	O
Cys	S-chem
-	O
289	O
,	O
and	O
Glu	S-chem
-	O
256	O
greatly	O
reduced	O
the	O
affinity	O
for	O
ornithine	S-chem
and	O
impaired	O
the	O
interaction	O
with	O
arginase	S-geneY
.	O

The	O
four	O
lysine	S-chem
residues	O
located	O
in	O
the	O
SMG	O
loop	O
,	O
Lys	S-chem
-	O
260	O
,	O
Lys	S-chem
-	O
263	O
,	O
Lys	S-chem
-	O
265	O
,	O
and	O
Lys	S-chem
-	O
268	O
,	O
also	O
play	O
an	O
important	O
role	O
in	O
mediating	O
the	O
sensitivity	O
of	O
OTCase	S-geneY-C4-2
to	O
ornithine	S-chem-C4-1
and	O
to	O
arginase	S-geneY
and	O
appear	O
to	O
be	O
involved	O
in	O
transducing	O
and	O
enhancing	O
the	O
signal	O
given	O
by	O
ornithine	S-chem
for	O
the	O
closure	O
of	O
the	O
catalytic	O
domain	O
.	O

Amphetamine	S-chem
-	O
type	O
central	O
nervous	O
system	O
stimulants	O
release	O
norepinephrine	S-chem
more	O
potently	O
than	O
they	O
release	O
dopamine	S-chem
and	O
serotonin	S-chem
.	O

A	O
large	O
body	O
of	O
evidence	O
supports	O
the	O
hypothesis	O
that	O
mesolimbic	O
dopamine	S-chem
(	O
DA	S-chem
)	O
mediates	O
,	O
in	O
animal	O
models	O
,	O
the	O
reinforcing	O
effects	O
of	O
central	O
nervous	O
system	O
stimulants	O
such	O
as	O
cocaine	S-chem
and	O
amphetamine	S-chem
.	O

The	O
role	O
DA	S-chem
plays	O
in	O
mediating	O
amphetamine	S-chem
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
remains	O
to	O
be	O
established	O
.	O

Both	O
amphetamine	S-chem
and	O
cocaine	S-chem
increase	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
via	O
stimulation	O
of	O
release	O
and	O
inhibition	O
of	O
reuptake	O
,	O
respectively	O
.	O

If	O
increases	O
in	O
NE	S-chem
mediate	O
amphetamine	S-chem
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
,	O
then	O
one	O
would	O
predict	O
that	O
stimulant	O
medications	O
that	O
produce	O
amphetamine	S-chem
-	O
type	O
subjective	O
effects	O
in	O
humans	O
should	O
share	O
the	O
ability	O
to	O
increase	O
NE	S-chem
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
,	O
using	O
in	O
vitro	O
methods	O
,	O
the	O
neurochemical	O
mechanism	O
of	O
action	O
of	O
amphetamine	S-chem
,	O
3,4	B-chem
-	I-chem
methylenedioxymethamphetamine	E-chem
(	O
MDMA	S-chem
)	O
,	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
methamphetamine	E-chem
,	O
ephedrine	S-chem
,	O
phentermine	S-chem
,	O
and	O
aminorex	S-chem
.	O

As	O
expected	O
,	O
their	O
rank	O
order	O
of	O
potency	O
for	O
DA	S-chem
release	O
was	O
similar	O
to	O
their	O
rank	O
order	O
of	O
potency	O
in	O
published	O
self	O
-	O
administration	O
studies	O
.	O

Interestingly	O
,	O
the	O
results	O
demonstrated	O
that	O
the	O
most	O
potent	O
effect	O
of	O
these	O
stimulants	O
is	O
to	O
release	O
NE	S-chem
.	O

Importantly	O
,	O
the	O
oral	O
dose	O
of	O
these	O
stimulants	O
,	O
which	O
produce	O
amphetamine	S-chem
-	O
type	O
subjective	O
effects	O
in	O
humans	O
,	O
correlated	O
with	O
the	O
their	O
potency	O
in	O
releasing	O
NE	S-chem
,	O
not	O
DA	S-chem
,	O
and	O
did	O
not	O
decrease	O
plasma	O
prolactin	S-geneY
,	O
an	O
effect	O
mediated	O
by	O
DA	S-chem
release	O
.	O

These	O
results	O
suggest	O
that	O
NE	S-chem
may	O
contribute	O
to	O
the	O
amphetamine	S-chem
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
.	O

Rabeprazole	S-chem
:	O
an	O
update	O
of	O
its	O
use	O
in	O
acid	O
-	O
related	O
disorders	O
.	O

UNLABELLED	O
:	O
Rabeprazole	S-chem-C4-1
is	O
an	O
inhibitor	O
of	O
the	O
gastric	B-geneN-C4-2
proton	I-geneN-C4-2
pump	E-geneN-C4-2
.	O

It	O
causes	O
dose	O
-	O
dependent	O
inhibition	O
of	O
acid	O
secretion	O
.	O

In	O
8	O
-	O
week	O
studies	O
,	O
among	O
patients	O
with	O
gastro	O
-	O
oesophageal	O
reflux	O
disease	O
(	O
GORD	O
)	O
,	O
rabeprazole	S-chem
20	O
mg	O
/	O
day	O
or	O
10mg	O
twice	O
daily	O
was	O
as	O
effective	O
as	O
omeprazole	S-chem
and	O
superior	O
to	O
ranitidine	S-chem
in	O
the	O
healing	O
of	O
GORD	O
.	O

Symptom	O
relief	O
with	O
rabeprazole	S-chem
was	O
superior	O
to	O
that	O
provided	O
by	O
placebo	O
and	O
ranitidine	S-chem
and	O
similar	O
to	O
omeprazole	S-chem
.	O

In	O
long	O
-	O
term	O
trials	O
rabeprazole	S-chem
10	O
mg	O
/	O
day	O
was	O
similar	O
to	O
omeprazole	S-chem
20	O
mg	O
/	O
day	O
in	O
a	O
2	O
-	O
year	O
study	O
and	O
superior	O
to	O
placebo	O
in	O
1	O
-	O
year	O
studies	O
,	O
in	O
both	O
the	O
maintenance	O
of	O
healing	O
and	O
prevention	O
of	O
symptoms	O
in	O
patients	O
with	O
healed	O
GORD	O
.	O

In	O
nonerosive	O
GORD	O
,	O
4	O
-	O
week	O
studies	O
have	O
shown	O
rabeprazole	S-chem
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
relieving	O
heartburn	O
and	O
various	O
other	O
gastrointestinal	O
symptoms	O
.	O

Data	O
among	O
patients	O
with	O
Barrett	O
's	O
oesophagus	O
suggest	O
rabeprazole	S-chem
20	O
mg	O
/	O
day	O
may	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
maintaining	O
healing	O
of	O
associated	O
oesophagitis	O
after	O
1	O
year	O
of	O
treatment	O
.	O

One	O
-	O
week	O
triple	O
Helicobacter	O
pylori	O
eradication	O
therapy	O
with	O
rabeprazole	S-chem
plus	O
clarithromycin	S-chem
and	O
amoxicillin	S-chem
achieved	O
eradication	O
rates	O
of	O
>	O
or	O
=	O
85	O
%	O
.	O

Rabeprazole	S-chem
is	O
as	O
effective	O
as	O
omeprazole	S-chem
and	O
lansoprazole	S-chem
when	O
included	O
as	O
part	O
of	O
a	O
triple	O
-	O
therapy	O
regimen	O
for	O
the	O
eradication	O
of	O
H.	O
pylori	O
.	O

Eradication	O
rates	O
of	O
>	O
90	O
%	O
were	O
achieved	O
when	O
rabeprazole	S-chem
20	O
to	O
40	O
mg	O
/	O
day	O
was	O
included	O
as	O
part	O
of	O
a	O
quadruple	O
eradication	O
regimen	O
.	O

As	O
monotherapy	O
for	O
peptic	O
ulcer	O
healing	O
and	O
symptom	O
relief	O
,	O
4	O
-	O
to	O
8	O
-	O
week	O
studies	O
have	O
shown	O
rabeprazole	S-chem
10	O
to	O
40	O
mg	O
/	O
day	O
to	O
be	O
superior	O
to	O
placebo	O
and	O
ranitidine	S-chem
and	O
have	O
similar	O
efficacy	O
to	O
omeprazole	S-chem
.	O

Preliminary	O
1	O
-	O
year	O
data	O
among	O
16	O
patients	O
with	O
Zollinger	O
-	O
Ellison	O
syndrome	O
suggest	O
rabeprazole	S-chem
60	O
to	O
120	O
mg	O
/	O
day	O
can	O
resolve	O
and	O
prevent	O
the	O
recurrence	O
of	O
symptoms	O
and	O
endoscopic	O
lesions	O
associated	O
with	O
this	O
condition	O
.	O

In	O
clinical	O
trials	O
of	O
up	O
to	O
2	O
years	O
'	O
duration	O
the	O
tolerability	O
of	O
rabeprazole	S-chem
is	O
similar	O
to	O
that	O
of	O
placebo	O
,	O
ranitidine	S-chem
and	O
omeprazole	S-chem
.	O

Common	O
adverse	O
events	O
assigned	O
to	O
rabeprazole	S-chem
have	O
been	O
diarrhoea	O
,	O
headache	O
,	O
rhinitis	O
,	O
nausea	O
,	O
pharyngitis	O
and	O
abdominal	O
pain	O
.	O

Histological	O
changes	O
and	O
increases	O
in	O
serum	O
gastrin	S-geneY
levels	O
were	O
unremarkable	O
and	O
typical	O
of	O
proton	B-geneN
pump	E-geneN
inhibitors	O
.	O

No	O
dosage	O
adjustment	O
is	O
necessary	O
in	O
renal	O
and	O
mild	O
to	O
moderate	O
hepatic	O
impairment	O
.	O

CONCLUSION	O
:	O
Rabeprazole	S-chem-C4-1
is	O
a	O
well	O
tolerated	O
proton	B-geneN-C4-2
pump	E-geneN-C4-2
inhibitor	O
.	O

It	O
has	O
proven	O
efficacy	O
in	O
healing	O
,	O
symptom	O
relief	O
and	O
prevention	O
of	O
relapse	O
of	O
peptic	O
ulcers	O
and	O
GORD	O
and	O
can	O
form	O
part	O
of	O
effective	O
H.	O
pylori	O
eradication	O
regimens	O
.	O

It	O
is	O
an	O
important	O
alternative	O
to	O
H	O
(	O
2	O
)	O
antagonists	O
and	O
an	O
additional	O
treatment	O
option	O
to	O
other	O
proton	B-geneN
pump	E-geneN
inhibitors	O
in	O
the	O
management	O
of	O
acid	O
-	O
related	O
disorders	O
.	O

P2Y12	S-geneY
,	O
a	O
new	O
platelet	O
ADP	B-geneN
receptor	E-geneN
,	O
target	O
of	O
clopidogrel	S-chem
.	O

Clopidogrel	S-chem
is	O
a	O
potent	O
antithrombotic	O
drug	O
that	O
inhibits	O
ADP	S-chem
-	O
induced	O
platelet	O
aggregation	O
.	O

The	O
results	O
of	O
large	O
clinical	O
trials	O
have	O
demonstrated	O
an	O
overall	O
benefit	O
of	O
clopidogrel	S-chem
over	O
aspirin	S-chem
in	O
the	O
prevention	O
of	O
vascular	O
ischemic	O
events	O
(	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
vascular	O
death	O
)	O
in	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
atherosclerotic	O
disease	O
.	O

The	O
antiaggregating	O
effect	O
of	O
clopidogrel	S-chem
is	O
attributed	O
to	O
an	O
irreversible	O
inhibition	O
of	O
ADP	S-chem
binding	O
to	O
a	O
purinergic	B-geneN
receptor	E-geneN
present	O
at	O
the	O
platelet	O
surface	O
.	O

Clopidogrel	S-chem
is	O
not	O
active	O
in	O
vitro	O
and	O
can	O
be	O
considered	O
a	O
precursor	O
of	O
an	O
active	O
metabolite	O
formed	O
in	O
the	O
liver	O
.	O

The	O
chemical	O
structure	O
of	O
this	O
active	O
metabolite	O
and	O
its	O
biological	O
activity	O
have	O
been	O
described	O
recently	O
.	O

Several	O
purinergic	B-geneN
receptors	E-geneN
have	O
been	O
described	O
on	O
platelets	O
;	O
P2X	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
,	O
a	O
calcium	B-geneN
channel	E-geneN
,	O
and	O
P2Y1	S-geneY
a	O
Gq	B-geneN
-	I-geneN
coupled	I-geneN
seven	I-geneN
-	I-geneN
transmembrane	I-geneN
domain	I-geneN
receptor	E-geneN
,	O
have	O
been	O
found	O
not	O
to	O
be	O
antagonized	O
by	O
clopidogrel	S-chem
.	O

Another	O
Gi	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
(	O
named	O
P2Y12	S-geneY
)	O
has	O
been	O
recently	O
cloned	O
and	O
stably	O
expressed	O
in	O
CHO	O
cells	O
.	O

These	O
cells	O
displayed	O
a	O
strong	O
affinity	O
for	O
(	B-chem
33	I-chem
)	I-chem
P	I-chem
-	I-chem
2MeS	I-chem
-	I-chem
ADP	E-chem
,	O
a	O
stable	O
analogue	O
of	O
ADP	S-chem
,	O
the	O
binding	O
characteristics	O
of	O
which	O
corresponded	O
in	O
all	O
points	O
to	O
those	O
observed	O
on	O
platelets	O
.	O

The	O
binding	O
of	O
(	B-chem
33	I-chem
)	I-chem
P	I-chem
-	I-chem
2MeS	I-chem
-	I-chem
ADP	E-chem
to	O
these	O
cells	O
was	O
strongly	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
clopidogrel	S-chem
with	O
a	O
potency	O
that	O
was	O
consistent	O
with	O
that	O
observed	O
for	O
this	O
compound	O
on	O
platelets	O
.	O

In	O
these	O
transfected	O
CHO	O
cells	O
,	O
as	O
in	O
platelets	O
,	O
ADP	S-chem
and	O
2MeS	B-chem
-	I-chem
ADP	E-chem
induced	O
adenylyl	S-chem
cyclase	O
downregulation	O
,	O
an	O
effect	O
that	O
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
clopidogrel	S-chem
.	O

These	O
results	O
demonstrate	O
that	O
this	O
receptor	O
corresponds	O
to	O
the	O
previously	O
called	O
``	O
P2t	O
``	B-geneN
platelet	I-geneN
receptor	O
and	O
show	O
that	O
the	O
active	O
metabolite	O
of	B-chem
clopidogrel	O
binds	O
in	O
a	O
covalent	O
manner	O
to	O
this	O
receptor	O
,	O
thus	O
explaining	O
how	O
it	O
blocks	O
the	O
aggregating	O
effect	O
of	B-chem
ADP	O
on	O
platelets	O
.	O

Cucurbitacin	B-chem-C4-1
I	E-chem-C4-1
inhibits	O
rac1	S-geneY-C4-2
activation	O
in	O
breast	O
cancer	O
cells	O
by	O
a	O
reactive	O
oxygen	S-chem
species	O
-	O
mediated	O
mechanism	O
and	O
independently	O
of	O
janus	B-geneY
tyrosine	I-geneY
kinase	I-geneY
2	E-geneY
and	O
p	B-geneY
-	I-geneY
rex1	E-geneY
.	O

The	O
small	O
GTPase	S-geneN
Rac1	S-geneY
has	O
been	O
widely	O
implicated	O
in	O
mammary	O
tumorigenesis	O
and	O
metastasis	O
.	O

Previous	O
studies	O
established	O
that	O
stimulation	O
of	O
ErbB	S-geneY
receptors	O
in	O
breast	O
cancer	O
cells	O
activates	O
Rac1	S-geneY
and	O
enhances	O
motility	O
via	O
the	O
Rac	B-geneN
-	I-geneN
guanine	I-geneN
nucleotide	I-geneN
exchange	I-geneN
factor	E-geneN
P	B-geneY
-	I-geneY
Rex1	E-geneY
.	O

As	O
the	O
Janus	B-geneY
tyrosine	I-geneY
kinase	I-geneY
2	E-geneY
(	O
Jak2	S-geneY
)	O
/	O
signal	B-geneY
transducer	I-geneY
and	I-geneY
activator	I-geneY
of	I-geneY
transcription	I-geneY
3	E-geneY
(	O
Stat3	S-geneY
)	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
functionally	O
associated	O
with	O
ErbB	S-geneY
receptors	O
,	O
we	O
asked	O
if	O
this	O
pathway	O
could	O
mediate	O
P	B-geneY
-	I-geneY
Rex1	E-geneY
/	O
Rac1	S-geneY
activation	O
in	O
response	O
to	O
ErbB	S-geneY
ligands	O
.	O

Here	O
we	O
found	O
that	O
the	O
anticancer	O
agent	O
cucurbitacin	B-chem-C4-1
I	E-chem-C4-1
,	O
a	O
Jak2	S-geneN-C4-2
inhibitor	O
,	O
reduced	O
the	O
activation	O
of	O
Rac1	S-geneY-C4-2
and	O
motility	O
in	O
response	O
to	O
the	O
ErbB3	S-geneY
ligand	O
heregulin	S-geneY
in	O
breast	O
cancer	O
cells	O
.	O

However	O
,	O
Rac1	S-geneY
activation	O
was	O
not	O
affected	O
by	O
Jak2	S-geneY
or	O
Stat3	S-geneY
RNA	O
interference	O
,	O
suggesting	O
that	O
the	O
effect	O
of	O
cucurbitacin	B-chem
I	E-chem
occurs	O
through	O
a	O
Jak2	S-geneN
-	O
independent	O
mechanism	O
.	O

Cucurbitacin	B-chem
I	E-chem
also	O
failed	O
to	O
affect	O
the	O
activation	O
of	O
P	B-geneY
-	I-geneY
Rex1	E-geneY
by	O
heregulin	S-geneY
.	O

Subsequent	O
analysis	O
revealed	O
that	O
cucurbitacin	B-chem-C3-1
I	E-chem-C3-1
strongly	O
activates	O
RhoA	S-geneN-C3-2
and	O
the	O
Rho	S-geneN-C3-2
effector	O
Rho	B-geneN-C3-2
kinase	E-geneN-C3-2
(	O
ROCK	S-geneN-C3-2
)	O
in	O
breast	O
cancer	O
cells	O
and	O
induces	O
the	O
formation	O
of	O
stress	O
fibers	O
.	O

Interestingly	O
,	O
disruption	O
of	O
the	O
RhoA	S-geneN
-	O
ROCK	S-geneN
pathway	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-chem-C4-1
I	E-chem-C4-1
on	O
Rac1	S-geneY-C4-2
activation	O
by	O
heregulin	S-geneY
.	O

Lastly	O
,	O
we	O
found	O
that	O
RhoA	S-geneN-C3-2
activation	O
by	O
cucurbitacin	B-chem-C3-1
I	E-chem-C3-1
is	O
mediated	O
by	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
.	O

The	O
ROS	O
scavenger	O
N	B-chem-C3-1
-	I-chem-C3-1
acetyl	I-chem-C3-1
l	I-chem-C3-1
-	I-chem-C3-1
cysteine	E-chem-C3-1
and	O
the	O
mitochondrial	O
antioxidant	O
Mito	O
-	O
TEMPO	O
rescued	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-chem-C4-1
I	E-chem-C4-1
on	O
Rac1	S-geneY-MU-2
activation	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
indicate	O
that	O
ErbB	S-geneY
-	O
driven	O
Rac1	S-geneY
activation	O
in	O
breast	O
cancer	O
cells	O
proceeds	O
independently	O
of	O
the	O
Jak2	S-geneN
pathway	O
.	O

Moreover	O
,	O
they	O
established	O
that	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-chem-C4-1
I	E-chem-C4-1
on	O
Rac1	S-geneY-C4-2
activity	O
involves	O
the	O
alteration	O
of	O
the	O
balance	O
between	O
Rho	S-geneN
and	O
Rac	S-geneN
.	O

Clock	S-geneY
Gene	O
Expression	O
in	O
the	O
Liver	O
of	O
Streptozotocin	S-chem
-	O
induced	O
and	O
Spontaneous	O
Type	O
1	O
Diabetic	O
Rats	O
.	O

Several	O
investigations	O
have	O
shown	O
a	O
relation	O
between	O
diabetes	O
and	O
alterations	O
of	O
the	O
liver	O
circadian	O
clock	S-geneY
.	O

We	O
investigated	O
the	O
diurnal	O
expression	O
of	O
clock	S-geneY
genes	O
and	O
clock	B-geneN
-	I-geneN
controlled	I-geneN
genes	E-geneN
(	O
CCGs	S-geneN
)	O
in	O
3	O
-	O
hour	O
intervals	O
for	O
a	O
24	O
-	O
h	O
period	O
in	O
the	O
livers	O
of	O
male	O
streptozotocin	S-chem
(	O
STZ	S-chem
)	O
-	O
treated	O
rats	O
,	O
male	O
spontaneous	O
type	O
1	O
diabetic	O
LEW.1AR1	O
-	O
iddm	O
(	O
Iddm	O
)	O
rats	O
,	O
and	O
Iddm	O
rats	O
treated	O
for	O
10	O
days	O
with	O
insulin	S-geneY
.	O

Hepatic	O
mRNA	O
was	O
extracted	O
,	O
and	O
the	O
relative	O
expression	O
of	O
clock	S-geneY
genes	O
(	O
Per1	S-geneY
,	O
Per2	S-geneY
,	O
Bmal1	S-geneY
,	O
Clock	S-geneY
,	O
Cry1	S-geneY
)	O
,	O
as	O
well	O
as	O
CCGs	S-geneN
(	O
Dbp	S-geneY
,	O
E4bp4	S-geneY
,	O
RevErbα	S-geneY
,	O
Rorα	S-geneN
,	O
Pparγ	S-geneY
)	O
,	O
was	O
analyzed	O
by	O
reverse	O
transcription	O
followed	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Diabetic	O
STZ	S-chem
and	O
Iddm	O
rats	O
,	O
as	O
well	O
as	O
insulin	S-geneY
-	O
substituted	O
Iddm	O
rats	O
,	O
exhibited	O
a	O
significant	O
diurnal	O
expression	O
pattern	O
of	O
clock	S-geneY
genes	O
as	O
determined	O
by	O
Cosinor	O
analysis	O
;	O
however	O
,	O
the	O
MESOR	O
(	O
midline	O
estimating	O
statistic	O
of	O
rhythm	O
)	O
of	O
Bmal1	S-geneY
,	O
Per2	S-geneY
,	O
and	O
Clock	S-geneY
transcript	O
expression	O
was	O
altered	O
in	O
Iddm	O
and	O
insulin	S-geneY
-	O
substituted	O
Iddm	O
rats	O
.	O

The	O
hepatic	O
expression	O
of	O
the	O
CCGs	S-geneN
Dbp	S-geneY
and	O
RevErbα	S-geneY
revealed	O
a	O
diurnal	O
rhythm	O
in	O
all	O
investigated	O
groups	O
.	O

Insulin	S-geneY
administration	O
to	O
Iddm	O
rats	O
normalized	O
the	O
enhanced	O
MESOR	O
in	O
the	O
expression	O
of	O
Dbp	S-geneY
,	O
RevErbα	S-geneY
,	O
and	O
E4bp4	S-geneY
to	O
the	O
levels	O
of	O
normoglycemic	O
controls	O
.	O

Cosinor	O
analysis	O
indicated	O
no	O
diurnal	O
rhythm	O
of	O
Pparγ	S-geneY
expression	O
in	O
the	O
livers	O
of	O
diabetic	O
STZ	S-chem
or	O
Iddm	O
rats	O
or	O
in	O
those	O
of	O
insulin	S-geneY
-	O
substituted	O
Iddm	O
rats	O
.	O

Also	O
,	O
insulin	S-geneY
substitution	O
could	O
not	O
reverse	O
the	O
decreased	O
MESOR	O
of	O
Pparγ	S-geneY
expression	O
in	O
Iddm	O
rats	O
.	O

In	O
consequence	O
of	O
the	O
diabetic	O
disease	O
,	O
changes	O
in	O
the	O
expression	O
of	O
clock	S-geneY
genes	O
and	O
CCGs	S-geneN
suggest	O
alterations	O
in	O
the	O
hepatic	O
peripheral	O
clock	S-geneY
mechanism	O
.	O

Therapeutic	O
effectiveness	O
of	O
botulinum	B-geneY
neurotoxin	I-geneY
A	E-geneY
:	O
Potent	O
blockade	O
of	O
autonomic	O
transmission	O
by	O
targeted	O
cleavage	O
of	O
only	O
the	O
pertinent	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
.	O

In	O
search	O
of	O
a	O
basis	O
for	O
the	O
impressive	O
potency	O
of	O
an	O
endoprotease	S-geneN
that	O
cleaves	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
,	O
botulinum	B-geneY
neurotoxin	I-geneY
type	I-geneY
A	E-geneY
(	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
)	O
,	O
in	O
treating	O
numerous	O
diseases	O
due	O
to	O
hyper	O
-	O
active	O
autonomic	O
nerves	O
,	O
truncation	O
of	O
its	O
target	O
and	O
inhibition	O
of	O
neurotransmission	O
were	O
studied	O
in	O
rat	O
sympathetic	O
neurons	O
.	O

Tetrodotoxin	S-chem
-	O
sensitive	O
spontaneous	O
cholinergic	O
neurotransmission	O
was	O
blocked	O
>	O
80	O
%	O
by	O
1	O
pM	O
BoNT	O
/	I-geneY
A	I-geneY
despite	O
cleaving	O
<	O
20	O
%	O
of	O
the	O
SNAP	O
-	I-geneY
25	I-geneY
.	E-geneY

A	O
maximum	O
cleavage	O
of	O
∼	O
60	O
%	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
could	O
be	O
achieved	O
with	O
>	O
1	O
nM	O
BoNT	O
/	I-geneY
A	I-geneY
,	I-geneY
despite	O
an	O
absence	O
of	O
non	O
-	O
cleavable	O
SNAP	O
-	I-geneY
25	I-geneY
in	E-geneY
the	O
detergent	O
-	O
solubilised	O
neurons	O
.	O

In	O
contrast	O
,	O
BoNT	B-geneY
/	I-geneY
E	E-geneY
(	O
100	O
nM	O
)	O
truncated	O
nearly	O
all	O
the	O
SNAP	O
-	I-geneY
25	I-geneY
in	O
the	O
intact	O
cells	O
,	O
but	O
was	O
unable	O
to	O
block	O
neurotransmission	O
at	O
low	O
concentrations	O
like	O
BoNT	O
/	I-geneY
A	I-geneY
.	E-geneY

Chimeras	O
created	O
by	O
inserting	O
the	O
acceptor	O
-	O
binding	O
HC	B-geneN
domain	E-geneN
of	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
into	O
BoNT	B-geneY
/	I-geneY
E	E-geneY
still	O
cleaved	O
all	O
the	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
,	O
indicating	O
ubiquitous	O
expression	O
of	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
acceptors	O
.	O

Accordingly	O
,	O
SV2	S-geneN
and	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
were	O
found	O
to	O
be	O
co	O
-	O
expressed	O
and	O
broadly	O
co	O
-	O
localised	O
in	O
neurons	O
,	O
but	O
absent	O
from	O
non	O
-	O
neuronal	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
partial	O
cleavage	O
by	O
the	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
protease	O
persisted	O
upon	O
replacing	O
its	O
HC	O
with	O
counterparts	O
from	O
BoNT	B-geneY
/	I-geneY
E	E-geneY
or	O
BoNT	B-geneY
/	I-geneY
B	E-geneY
.	O

Moreover	O
,	O
limited	O
cleavage	O
of	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
was	O
conferred	O
onto	O
the	O
protease	S-geneN
from	O
BoNT	B-geneY
/	I-geneY
E	E-geneY
when	O
fused	O
to	O
the	O
N	S-chem
-	O
terminus	O
of	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
.	O

Thus	O
,	O
the	O
BoNT	B-geneY
/	I-geneY
A	E-geneY
protease	S-geneN
is	O
uniquely	O
well	O
-	O
adapted	O
for	O
selectively	O
inactivating	O
the	O
SNAP	B-geneY
-	I-geneY
25	E-geneY
directly	O
involved	O
in	O
neurotransmission	O
;	O
this	O
together	O
with	O
the	O
toxin	O
's	O
acceptor	O
and	O
its	O
target	O
being	O
localised	O
on	O
the	O
peri	O
-	O
somatic	O
boutons	O
likely	O
contribute	O
to	O
its	O
exceptional	O
therapeutic	O
utility	O
in	O
the	O
clinic	O
.	O

Substrate	O
specificity	O
of	O
the	O
human	B-geneN
renal	I-geneN
sodium	I-geneN
dicarboxylate	I-geneN
cotransporter	E-geneN
,	O
hNaDC	B-geneY
-	I-geneY
3	E-geneY
,	O
under	O
voltage	O
-	O
clamp	O
conditions	O
.	O

Proximal	O
tubule	O
cells	O
extract	O
dicarboxylates	O
from	O
filtrate	O
and	O
blood	O
,	O
using	O
cotransporters	O
located	O
in	O
the	O
brush	O
border	O
[	O
sodium	B-geneN
dicarboxylate	I-geneN
cotransporter	E-geneN
(	O
NaDC	B-geneY
-	I-geneY
1	E-geneY
)	O
]	O
and	O
basolateral	O
cell	O
membrane	O
(	O
NaDC	B-geneY
-	I-geneY
3	E-geneY
)	O
.	O

We	O
expressed	O
the	O
human	B-geneY
NaDC	I-geneY
-	I-geneY
3	E-geneY
(	O
hNaDC	B-geneY
-	I-geneY
3	E-geneY
)	O
in	O
Xenopus	O
laevis	O
oocytes	O
and	O
characterized	O
it	O
by	O
the	O
two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
technique	O
.	O

At	O
-	O
60	O
mV	O
,	O
succinate	S-chem
(	O
4	O
carbons	S-chem
)	O
and	O
glutarate	S-chem
(	O
5	O
carbons	S-chem
)	O
generated	O
inward	O
currents	O
due	O
to	O
translocation	O
of	O
three	O
sodium	S-chem
ions	O
and	O
one	O
divalent	O
dicarboxylate	O
,	O
whereas	O
oxalate	S-chem
(	O
2	O
carbons	S-chem
)	O
and	O
malonate	S-chem
(	O
3	O
carbons	S-chem
)	O
did	O
not	O
.	O

The	O
cis	B-chem
-	I-chem
dicarboxylate	I-chem
maleate	E-chem
produced	O
currents	O
smaller	O
in	O
magnitude	O
,	O
whereas	O
the	O
trans	B-chem
-	I-chem
dicarboxylate	I-chem
fumarate	E-chem
generated	O
currents	O
similar	O
to	O
succinate	S-chem
.	O

The	O
substituted	O
succinate	S-chem
derivatives	O
,	O
malate	S-chem
,	O
2,2	B-chem
-	I-chem
and	I-chem
2,3	I-chem
-	I-chem
dimethylsuccinate	E-chem
,	O
and	O
2,3	B-chem
-	I-chem
dimercaptosuccinate	E-chem
elicited	O
inward	O
currents	O
,	O
whereas	O
aspartate	S-chem
and	O
guanidinosuccinate	S-chem
showed	O
hardly	O
detectable	O
currents	O
.	O

The	O
C	B-chem
-	I-chem
5	I-chem
dicarboxylates	I-chem
glutarate	E-chem
and	O
alpha	B-chem
-	I-chem
ketoglutarate	E-chem
produced	O
larger	O
currents	O
than	O
succinate	S-chem
;	O
glutamate	S-chem
and	O
folate	S-chem
failed	O
to	O
cause	O
inward	O
currents	O
.	O

Kinetic	O
analysis	O
revealed	O
,	O
at	O
-	O
60	O
mV	O
,	O
K	O
(	O
0.5	O
)	O
values	O
of	O
25	O
+	O
/	O
-	O
12	O
microM	O
for	O
succinate	S-chem
and	O
45	O
+	O
/	O
-	O
13	O
microM	O
for	O
alpha	B-chem
-	I-chem
ketoglutarate	E-chem
,	O
values	O
close	O
to	O
the	O
plasma	O
concentration	O
of	O
these	O
compounds	O
.	O

For	O
both	O
compounds	O
,	O
the	O
K	O
(	O
0.5	O
)	O
was	O
independent	O
of	O
voltage	O
,	O
whereas	O
the	O
maximal	O
current	O
increased	O
with	O
hyperpolarization	O
.	O

As	O
opposed	O
to	O
the	O
rat	O
and	O
flounder	O
orthologs	O
,	O
hNaDC	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
was	O
hardly	O
inhibited	O
by	O
lithium	S-chem-C4-1
concentrations	O
up	O
to	O
5	O
mM	O
.	O

In	O
the	O
absence	O
of	O
sodium	S-chem
,	O
however	O
,	O
lithium	S-chem
can	O
mediate	O
succinate	S-chem
-	O
dependent	O
currents	O
.	O

The	O
narrow	O
substrate	O
specificity	O
prevents	O
interaction	O
of	O
drugs	O
with	O
dicarboxylate	O
-	O
like	O
structure	O
with	O
hNaDC	B-geneY
-	I-geneY
3	E-geneY
and	O
ensures	O
sufficient	O
support	O
of	O
the	O
proximal	O
tubule	O
cells	O
with	O
alpha	B-chem
-	I-chem
ketoglutarate	E-chem
for	O
anion	O
secretion	O
via	O
organic	B-geneN
anion	I-geneN
transporter	I-geneN
1	I-geneN
or	I-geneN
3	E-geneN
.	O

Synthesis	O
of	O
2	B-chem
-	I-chem
aminomethyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1	I-chem
-	I-chem
azabicyclo	I-chem
[	I-chem
2.2.1	I-chem
]	I-chem
heptanes	E-chem
via	O
LiAlH₄	S-chem
-	O
induced	O
reductive	O
cyclization	O
of	O
2	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
-	I-chem
cyano	I-chem
-	I-chem
2	I-chem
-	I-chem
phenylbutyl	I-chem
)	I-chem
aziridines	E-chem
and	O
evaluation	O
of	O
their	O
antimalarial	O
activity	O
.	O

2	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
Chloro	I-chem
-	I-chem
2	I-chem
-	I-chem
cyano	I-chem
-	I-chem
2	I-chem
-	I-chem
phenylbutyl	I-chem
)	I-chem
aziridines	E-chem
were	O
employed	O
for	O
the	O
one	O
-	O
step	O
stereoselective	O
construction	O
of	O
both	O
endo	B-chem
-	I-chem
and	I-chem
exo	I-chem
-	I-chem
2	I-chem
-	I-chem
aminomethyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1	I-chem
-	I-chem
azabicyclo	I-chem
[	I-chem
2.2.1	I-chem
]	I-chem
heptanes	E-chem
as	O
new	O
azaheterobicyclic	S-chem
scaffolds	O
via	O
a	O
double	O
LiAlH	B-chem
(	I-chem
4	I-chem
)	E-chem
-	O
induced	O
reductive	O
cyclization	O
protocol	O
.	O

Antiplasmodial	O
assessment	O
of	O
these	O
1	B-chem
-	I-chem
azabicyclo	I-chem
[	I-chem
2.2.1	I-chem
]	I-chem
heptanes	E-chem
revealed	O
moderate	O
to	O
good	O
activities	O
in	O
the	O
micromolar	O
range	O
,	O
with	O
the	O
exo	O
-	O
isomers	O
being	O
the	O
most	O
promising	O
structures	O
.	O

Furthermore	O
,	O
the	O
proposed	O
mode	O
of	O
action	O
was	O
supported	O
by	O
ligand	O
docking	O
studies	O
,	O
pointing	O
to	O
a	O
strong	O
binding	O
interaction	O
with	O
the	O
enzyme	O
plasmepsin	B-geneY
II	E-geneY
.	O

Synergy	O
between	O
pairs	O
of	O
competitive	O
antagonists	O
at	O
adult	O
human	B-geneN
muscle	I-geneN
acetylcholine	I-geneN
receptors	E-geneN
.	O

BACKGROUND	O
:	O
Synergistic	O
neuromuscular	O
blocking	O
effects	O
have	O
been	O
observed	O
clinically	O
with	O
certain	O
pairs	O
of	O
nicotinic	B-geneN
acetylcholine	I-geneN
receptor	E-geneN
(	O
nAChR	S-geneN
)	O
competitive	O
antagonists	O
.	O

The	O
mechanism	O
for	O
synergy	O
has	O
not	O
been	O
elucidated	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
synergy	O
arises	O
from	O
a	O
differential	O
selectivity	O
of	O
antagonists	O
for	O
the	O
two	O
ligand	O
binding	O
sites	O
on	O
adult	O
human	B-geneN
nAChR	E-geneN
.	O

METHODS	O
:	O
We	O
expressed	O
nAChR	S-geneN
in	O
BOSC23	O
cells	O
.	O

We	O
applied	O
ACh	O
with	O
or	O
without	O
antagonists	O
to	O
outside	O
-	O
out	O
patches	O
and	O
measured	O
macroscopic	O
currents	O
at	O
room	O
temperature	O
.	O

We	O
determined	O
the	O
IC	O
(	O
90	O
)	O
for	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
tubocurarine	E-chem
,	O
metocurine	S-chem
,	O
pancuronium	S-chem
,	O
vecuronium	S-chem
,	O
cisatracurium	S-chem
,	O
rocuronium	S-chem
,	O
and	O
atracurium	S-chem
.	O

For	O
15	O
combinations	O
of	O
two	O
antagonists	O
,	O
we	O
determined	O
the	O
IC	O
(	O
90	O
)	O
for	O
one	O
antagonist	O
in	O
the	O
presence	O
of	O
the	O
IC	O
(	O
70	O
)	O
of	O
a	O
second	O
antagonist	O
.	O

We	O
constructed	O
isobolograms	O
for	O
90	O
%	O
inhibition	O
.	O

For	O
single	O
antagonists	O
,	O
we	O
measured	O
inhibition	O
of	O
receptors	O
containing	O
mutations	O
in	O
the	O
epsilon	O
-	O
and	O
delta	O
-	O
subunits	O
to	O
determine	O
site	O
selectivity	O
.	O

RESULTS	O
:	O
Two	O
pairs	O
of	O
antagonists	O
,	O
metocurine	S-chem
+	O
cisatracurium	S-chem
and	O
cisatracurium	S-chem
+	O
atracurium	S-chem
exhibited	O
additive	O
inhibition	O
.	O

Ten	O
combinations	O
,	O
including	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
tubocurarine	E-chem
+	O
pancuronium	S-chem
and	O
pancuronium	S-chem
+	O
vecuronium	S-chem
,	O
were	O
highly	O
synergistic	O
such	O
that	O
the	O
combination	O
was	O
two	O
to	O
three	O
times	O
more	O
effective	O
than	O
expected	O
for	O
additivity	O
.	O

Three	O
combinations	O
were	O
1.5	O
-	O
1.6	O
times	O
more	O
effective	O
than	O
expected	O
for	O
additivity	O
.	O

Inhibition	O
by	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
tubocurarine	E-chem
and	O
metocurine	S-chem
was	O
sensitive	O
to	O
mutations	O
in	O
the	O
epsilon	O
-	O
subunit	O
only	O
.	O

Vecuronium	S-chem
was	O
affected	O
by	O
the	O
delta	O
-	O
subunit	O
mutation	O
only	O
.	O

Inhibition	O
by	O
other	O
antagonists	O
was	O
decreased	O
by	O
mutations	O
in	O
either	O
subunit	O
.	O

CONCLUSIONS	O
:	O
Many	O
combinations	O
of	O
antagonists	O
exhibited	O
synergistic	O
effects	O
on	O
adult	O
human	B-geneN
nAChR	E-geneN
.	O

Synergy	O
was	O
observed	O
with	O
structurally	O
similar	O
and	O
dissimilar	O
antagonists	O
.	O

The	O
degree	O
of	O
synergy	O
did	O
not	O
always	O
correlate	O
well	O
with	O
site	O
specificity	O
assayed	O
with	O
mutants	O
.	O

In	O
some	O
,	O
but	O
not	O
all	O
cases	O
,	O
the	O
synergy	O
at	O
the	O
receptor	O
level	O
correlated	O
with	O
clinical	O
determinations	O
of	O
synergy	O
.	O

We	O
conclude	O
that	O
the	O
synergistic	O
actions	O
of	O
muscle	O
relaxants	O
can	O
be	O
partially	O
explained	O
by	O
direct	O
interactions	O
with	O
adult	O
human	B-geneN
nAChR	E-geneN
.	O

Deduced	O
amino	B-chem
acid	E-chem
sequence	O
from	O
the	O
bovine	B-geneY
oxytocin	I-geneY
-	I-geneY
neurophysin	I-geneY
I	I-geneY
precursor	E-geneY
cDNA	O
.	O

The	O
nonapeptide	O
hormone	O
oxytocin	S-geneY
-	O
like	O
arginine	B-geneY
-	I-geneY
vasopressin	E-geneY
(	O
AVP	S-geneY
)	O
is	O
synthesized	O
as	O
part	O
of	O
a	O
larger	O
precursor	O
polypeptide	O
.	O

The	O
precursor	O
also	O
includes	O
the	O
neurophysin	S-geneN
molecule	O
with	O
which	O
the	O
hormone	O
is	O
associated	O
in	O
the	O
neurosecretory	O
granules	O
of	O
the	O
hypothalamo	O
-	O
pituitary	O
tract	O
.	O

A	O
protein	O
of	O
molecular	O
weight	O
(	O
Mr	O
)	O
approximately	O
20,000	O
has	O
been	O
isolated	O
from	O
supraoptic	O
nuclei	O
of	O
rat	O
hypothalami	O
which	O
,	O
after	O
tryptic	O
cleavage	O
,	O
released	O
a	O
neurophysin	S-geneN
-	O
like	O
molecule	O
of	O
Mr	O
approximately	O
10,000	O
and	O
an	O
oligopeptide	O
related	O
to	O
oxytocin	S-geneY
.	O

This	O
result	O
was	O
complemented	O
by	O
in	O
vitro	O
translation	O
of	O
bovine	O
hypothalamic	O
mRNA	O
.	O

Among	O
the	O
primary	O
translation	O
products	O
a	O
single	O
polypeptide	O
of	O
Mr	O
approximately	O
16,500	O
was	O
shown	O
to	O
contain	O
antigenic	O
determinants	O
recognized	O
by	O
specific	O
antisera	O
against	O
bovine	B-geneY
neurophysin	I-geneY
I	E-geneY
and	O
oxytocin	S-geneY
.	O

Here	O
we	O
report	O
the	O
amino	B-chem
acid	E-chem
sequence	O
of	O
the	O
bovine	B-geneY
oxytocin	I-geneY
-	I-geneY
neurophysin	I-geneY
I	I-geneY
(	I-geneY
OT	I-geneY
-	I-geneY
NpI	I-geneY
)	I-geneY
precursor	E-geneY
which	O
was	O
derived	O
from	O
sequence	O
analysis	O
of	O
the	O
cloned	O
cDNA	O
.	O

As	O
is	O
the	O
case	O
for	O
the	O
bovine	B-geneY
arginine	I-geneY
-	I-geneY
vasopressin	I-geneY
-	I-geneY
neurophysin	I-geneY
II	I-geneY
(	I-geneY
AVP	I-geneY
-	I-geneY
NpII	I-geneY
)	I-geneY
precursor	E-geneY
,	O
the	O
signal	O
sequence	O
of	O
the	O
OT	B-geneY
-	I-geneY
NpI	E-geneY
precursor	O
is	O
immediately	O
followed	O
by	O
the	O
nonapeptide	O
hormone	O
which	O
is	O
connected	O
to	O
neurophysin	B-geneY
I	E-geneY
by	O
a	O
Gly	B-geneN
-	I-geneN
Lys	I-geneN
-	I-geneN
Arg	E-geneN
sequence	O
.	O

A	O
striking	O
feature	O
of	O
the	O
nucleic	O
acid	O
sequence	O
is	O
the	O
197	O
-	O
nucleotide	O
long	O
perfect	O
homology	O
with	O
the	O
AVP	B-geneY
-	I-geneY
NpII	I-geneY
precursor	E-geneY
mRNA	O
sequence	O
encoding	O
the	O
conserved	O
middle	O
part	O
of	O
neurophysins	B-geneN
I	I-geneN
and	I-geneN
II	E-geneN
.	O

The	O
glycogen	B-geneY
synthase	I-geneY
kinase	I-geneY
-	I-geneY
3β	E-geneY
/	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
pathway	O
is	O
involved	O
in	O
cinobufagin	S-chem
-	O
induced	O
apoptosis	O
in	O
cultured	O
osteosarcoma	O
cells	O
.	O

Cinobufagin	S-chem
,	O
a	O
major	O
component	O
of	O
cinobufacini	O
(	O
huachansu	O
)	O
,	O
is	O
an	O
important	O
cardenolidal	B-chem
steroid	E-chem
.	O

Several	O
studies	O
have	O
suggested	O
that	O
cinobufagin	S-chem
has	O
potent	O
anti	O
-	O
cancer	O
effects	O
.	O

The	O
present	O
study	O
examines	O
the	O
apoptosis	O
-	O
inducing	O
activity	O
and	O
the	O
underlying	O
mechanism	O
of	O
action	O
of	O
cinobufagin	S-chem
in	O
osteosarcoma	O
(	O
OS	O
)	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
cinobufagin	S-chem
potently	O
inhibited	O
the	O
proliferation	O
of	O
U2OS	O
,	O
MG63	O
and	O
SaOS	O
-	O
2	O
cells	O
.	O

Significant	O
increases	O
in	O
G2	O
/	O
M	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
OS	O
cells	O
were	O
also	O
observed	O
.	O

The	O
expression	O
levels	O
of	O
several	O
apoptotic	O
proteins	O
were	O
assessed	O
after	O
cinobufagin	S-chem
treatment	O
in	O
U2OS	O
cells	O
.	O

Among	O
them	O
,	O
xIAP	S-geneY
,	O
cIAP	B-geneY
-	I-geneY
1	E-geneY
,	O
survivin	S-geneY
and	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
levels	O
decreased	O
remarkably	O
,	O
while	O
the	O
levels	O
of	O
Bax	S-geneY
and	O
cleaved	O
-	O
PARP	S-geneN
increased	O
.	O

Furthermore	O
,	O
we	O
validated	O
the	O
inhibition	O
of	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
/	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
signaling	O
following	O
cinobufagin	S-chem-C4-1
treatment	O
.	O

Western	O
blots	O
showed	O
a	O
decrease	O
in	O
nuclear	O
p65	S-geneY-C4-2
protein	O
expression	O
after	O
exposure	O
to	O
different	O
concentrations	O
of	O
cinobufagin	S-chem-MU-1
,	O
while	O
the	O
phosphorylation	O
of	O
GSK	B-geneY-C3-2
-	I-geneY-C3-2
3β	E-geneY-C3-2
was	O
simultaneously	O
increased	O
.	O

Transduction	O
with	O
constitutively	O
active	O
forms	O
of	O
GSK	B-geneY
-	I-geneY
3β	E-geneY
could	O
protect	O
against	O
the	O
downregulation	O
of	O
p65	S-geneY-C4-2
and	O
upregulation	O
of	O
cleaved	O
-	O
PARP	S-geneN-C3-2
that	O
are	O
induced	O
by	O
cinobufagin	S-chem-MU-1
treatment	O
.	O

However	O
,	O
combined	O
treatment	O
with	O
cinobufagin	S-chem-MU-1
and	O
SB216367	S-chem-MU-1
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
p65	S-geneY-C4-2
and	O
an	O
increase	O
in	O
cleaved	O
-	O
PARP	S-geneN-C3-2
in	O
U2OS	O
cells	O
.	O

Altogether	O
,	O
these	O
results	O
show	O
that	O
cinobufagin	S-chem
is	O
a	O
promising	O
agent	O
for	O
the	O
treatment	O
of	O
OS	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
reveal	O
the	O
involvement	O
of	O
the	O
GSK	B-geneY
-	I-geneY
3β	E-geneY
/	O
NF	B-geneN
-	I-geneN
κB	E-geneN
pathway	O
in	O
cinobufagin	S-chem
-	O
induced	O
apoptosis	O
.	O

Experimental	O
tooth	O
movement	O
-	O
induced	O
osteoclast	O
activation	O
is	O
regulated	O
by	O
sympathetic	O
signaling	O
.	O

Experimental	O
tooth	O
movement	O
(	O
ETM	O
)	O
changes	O
the	O
distribution	O
of	O
sensory	O
nerve	O
fibers	O
in	O
periodontal	O
ligament	O
and	O
the	O
bone	O
architecture	O
through	O
the	O
stimulation	O
of	O
bone	O
remodeling	O
.	O

As	O
the	O
sympathetic	O
nervous	O
system	O
is	O
involved	O
in	O
bone	O
remodeling	O
,	O
we	O
examined	O
whether	O
ETM	O
is	O
controlled	O
by	O
sympathetic	O
signaling	O
or	O
not	O
.	O

In	O
male	O
mice	O
,	O
elastic	O
rubber	O
was	O
inserted	O
between	O
upper	O
left	O
first	O
molar	O
(	O
M1	O
)	O
and	O
second	O
molar	O
(	O
M2	O
)	O
for	O
3	O
or	O
5	O
days	O
.	O

Nerve	O
fibers	O
immunoreactive	O
for	O
not	O
only	O
sensory	O
neuromarkers	O
,	O
such	O
as	O
calcitonin	B-geneN
gene	I-geneN
-	I-geneN
related	I-geneN
peptide	E-geneN
(	O
CGRP	S-geneN
)	O
,	O
but	O
also	O
sympathetic	O
neuromarkers	O
,	O
such	O
as	O
tyrosine	B-geneY
hydroxylase	E-geneY
(	O
TH	S-geneY
)	O
and	O
neuropeptide	B-geneY
Y	E-geneY
(	O
NPY	S-geneY
)	O
were	O
increased	O
in	O
the	O
periodontal	O
ligament	O
during	O
ETM	O
.	O

To	O
elucidate	O
the	O
effect	O
of	O
the	O
sympathetic	O
signal	O
mediated	O
by	O
ETM	O
,	O
mice	O
were	O
intraperitoneally	O
injected	O
with	O
a	O
β	O
-	O
antagonist	O
,	O
propranolol	S-chem
(	O
PRO	S-chem
:	O
20	O
μg	O
/	O
g	O
/	O
day	O
)	O
,	O
or	O
a	O
β	O
-	O
agonist	O
,	O
isoproterenol	S-chem
(	O
ISO	S-chem
:	O
5	O
μg	O
/	O
g	O
/	O
day	O
)	O
from	O
7	O
days	O
before	O
ETM	O
.	O

PRO	S-chem
treatment	O
suppressed	O
the	O
amount	O
of	O
tooth	O
movement	O
by	O
12.9	O
%	O
in	O
3	O
-	O
day	O
ETM	O
and	O
by	O
32.2	O
%	O
in	O
5	O
-	O
day	O
ETM	O
compared	O
with	O
vehicle	O
treatment	O
.	O

On	O
the	O
other	O
hand	O
,	O
ISO	S-chem
treatment	O
increased	O
it	O
.	O

Furthermore	O
,	O
ETM	O
remarkably	O
increased	O
the	O
osteoclast	O
number	O
on	O
the	O
bone	O
surface	O
(	O
alveolar	O
socket	O
)	O
(	O
Oc.N	O
/	O
BS	O
)	O
in	O
all	O
drug	O
treatments	O
.	O

PRO	S-chem
treatment	O
suppressed	O
Oc.N	O
/	O
BS	O
by	O
39.4	O
%	O
in	O
3	O
-	O
day	O
ETM	O
,	O
while	O
ISO	S-chem
treatment	O
increased	O
it	O
by	O
32.1	O
%	O
in	O
3	O
-	O
day	O
ETM	O
compared	O
with	O
vehicle	O
treatment	O
.	O

Chemical	O
sympathectomy	O
using	O
6	B-chem
-	I-chem
hydroxydopamine	E-chem
(	O
6	B-chem
-	I-chem
OHDA	E-chem
:	O
250	O
μg	O
/	O
g	O
)	O
showed	O
results	O
similar	O
to	O
those	O
for	O
PRO	S-chem
treatment	O
in	O
terms	O
of	O
both	O
the	O
amount	O
of	O
tooth	O
movement	O
and	O
osteoclast	O
parameters	O
.	O

Our	O
data	O
showed	O
that	O
blockade	O
of	O
sympathetic	O
signaling	O
inhibited	O
the	O
tooth	O
movement	O
and	O
osteoclast	O
increase	O
induced	O
by	O
ETM	O
,	O
and	O
stimulation	O
of	O
sympathetic	O
signaling	O
accelerated	O
these	O
responses	O
.	O

These	O
data	O
suggest	O
that	O
the	O
mechano	O
-	O
adaptive	O
response	O
induced	O
by	O
ETM	O
is	O
controlled	O
by	O
sympathetic	O
signaling	O
through	O
osteoclast	O
activation	O
.	O

NMDA	B-geneN
Receptor	E-geneN
Activation	O
Down	O
-	O
Regulates	O
Expression	O
of	O
δ	B-geneY
Subunit	I-geneY
-	I-geneY
Containing	I-geneY
GABA	I-geneY
-	I-geneY
A	I-geneY
Receptors	E-geneY
in	O
Cultured	O
Hippocampal	O
Neurons	O
.	O

Neurosteroids	O
are	O
endogenous	O
allosteric	O
modulators	O
of	O
γ	B-geneN
amino	I-geneN
-	I-geneN
butyric	I-geneN
acid	I-geneN
type	I-geneN
A	I-geneN
receptors	E-geneN
(	O
GABARs	S-geneN
)	O
,	O
and	O
enhance	O
GABAR	S-geneN
-	O
mediated	O
inhibition	O
.	O

However	O
,	O
GABARs	S-geneN
expressed	O
on	O
hippocampal	O
dentate	O
granule	O
neurons	O
of	O
epileptic	O
animals	O
are	O
modified	O
such	O
that	O
their	O
neurosteroid	O
sensitivity	O
is	O
reduced	O
and	O
δ	O
subunit	O
expression	O
is	O
diminished	O
.	O

The	O
molecular	O
mechanisms	O
triggering	O
this	O
GABAR	S-geneN
plasticity	O
were	O
explored	O
.	O

In	O
the	O
cultured	O
hippocampal	O
neurons	O
treatment	O
with	O
NMDA	S-chem
(	O
10	O
μM	O
)	O
for	O
48	O
hrs	O
reduced	O
surface	O
expression	O
of	O
δ	O
and	O
α4	O
subunits	O
,	O
but	O
did	O
not	O
increase	O
expression	O
of	O
γ2	O
subunits	O
.	O

The	O
tonic	O
current	O
recorded	O
from	O
neurons	O
in	O
NMDA	S-chem
-	O
treated	O
cultures	O
was	O
reduced	O
,	O
and	O
its	O
neurosteroid	O
modulation	O
was	O
also	O
diminished	O
.	O

In	O
contrast	O
,	O
synaptic	O
inhibition	O
and	O
its	O
modulation	O
by	O
neurosteroids	O
were	O
preserved	O
in	O
these	O
neurons	O
.	O

The	O
time	O
course	O
of	O
NMDA	S-chem
effects	O
on	O
surface	O
and	O
total	O
δ	O
subunit	O
expression	O
were	O
distinct	O
;	O
shorter	O
(	O
6	O
hrs	O
)	O
treatment	O
decreased	O
surface	O
expression	O
,	O
whereas	O
longer	O
treatment	O
reduced	O
both	O
surface	O
and	O
total	O
expression	O
.	O

APV	S-chem
blocked	O
NMDA	S-chem
effects	O
on	O
δ	O
subunit	O
expression	O
.	O

Chelation	O
of	O
calcium	S-chem
ions	O
by	O
BAPTA	B-chem
-	I-chem
AM	E-chem
or	O
blockade	O
of	O
ERK1	B-geneN-C4-2
/	I-geneN-C4-2
2	E-geneN-C4-2
activation	O
by	O
UO126	S-chem-C4-1
also	O
prevented	O
the	O
NMDA	S-chem
effects	O
.	O

Thus	O
prolonged	O
activation	O
of	O
NMDA	B-geneN
receptors	E-geneN
in	O
hippocampal	O
neurons	O
reduced	O
GABAR	B-geneY-C4-2
δ	I-geneY-C4-2
subunit	E-geneY-C4-2
expression	O
through	O
Ca2	B-chem-C4-1
+	E-chem-C4-1
entry	O
and	O
at	O
least	O
in	O
part	O
by	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
activation	O
.	O

Regions	O
on	O
adenylyl	B-geneY
cyclase	I-geneY
VII	E-geneY
required	O
for	O
selective	O
regulation	O
by	O
the	O
G13	S-geneY
pathway	O
.	O

Regulation	O
of	O
multiple	O
adenylyl	B-geneN-C9-2
cyclases	E-geneN-C9-2
(	O
AC	S-geneN-C9-2
)	O
provides	O
unique	O
inputs	O
to	O
mediate	O
the	O
synthesis	O
of	O
cAMP	S-chem-C9-1
,	O
a	O
ubiquitous	O
second	O
messenger	O
that	O
controls	O
many	O
aspects	O
of	O
cellular	O
function	O
.	O

On	O
stimulation	O
by	O
G	B-geneN
(	I-geneN
s	I-geneN
)	E-geneN
,	O
the	O
activities	O
of	O
ACs	S-geneN-C9-2
can	O
be	O
further	O
selectively	O
modulated	O
by	O
other	O
pathways	O
to	O
ensure	O
precise	O
control	O
of	O
intracellular	O
cAMP	S-chem-C9-1
responses	O
to	O
specific	O
stimuli	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
one	O
of	O
the	O
AC	S-geneN
isoforms	O
,	O
AC7	S-geneY
,	O
is	O
uniquely	O
regulated	O
by	O
the	O
G	B-geneY
(	I-geneY
13	I-geneY
)	E-geneY
pathway	O
.	O

To	O
understand	O
more	O
fully	O
the	O
molecular	O
mechanism	O
of	O
this	O
regulation	O
,	O
we	O
compared	O
the	O
regulation	O
of	O
AC7	S-geneY
with	O
that	O
of	O
AC2	S-geneY
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
devoid	O
of	O
AC7	S-geneY
.	O

Although	O
both	O
enzymes	O
could	O
fully	O
restore	O
regulation	O
of	O
cAMP	S-chem
by	O
Gβγ	S-geneN
,	O
activation	O
of	O
the	O
G	B-geneY
(	I-geneY
13	I-geneY
)	E-geneY
pathway	O
preferentially	O
synergized	O
with	O
AC7	S-geneY
.	O

Exchange	O
of	O
domains	O
between	O
the	O
two	O
isoforms	O
indicates	O
that	O
the	O
C1b	B-geneN
domain	E-geneN
and	O
the	O
N	S-chem
-	O
terminus	O
of	O
the	O
C1a	B-geneN
domain	E-geneN
are	O
important	O
for	O
directing	O
selective	O
regulation	O
of	O
AC7	S-geneY
by	O
the	O
G	B-geneY
(	I-geneY
13	I-geneY
)	E-geneY
pathway	O
.	O

A	O
mutagenesis	O
screen	O
identified	O
more	O
specific	O
regions	O
of	O
AC7	S-geneY
that	O
differentially	O
mediate	O
its	O
regulation	O
by	O
distinct	O
pathways	O
.	O

Neuropsychological	O
and	O
conditioned	O
blocking	O
performance	O
in	O
patients	O
with	O
schizophrenia	O
:	O
assessment	O
of	O
the	O
contribution	O
of	O
neuroleptic	O
dose	O
,	O
serum	O
levels	O
and	O
dopamine	B-geneY
D2	I-geneY
-	I-geneY
receptor	E-geneY
occupancy	O
.	O

Patients	O
with	O
schizophrenia	O
show	O
impairments	O
of	O
attention	O
and	O
neuropsychological	O
performance	O
,	O
but	O
the	O
extent	O
to	O
which	O
this	O
is	O
attributable	O
to	O
antipsychotic	O
medication	O
remains	O
largely	O
unexplored	O
.	O

We	O
describe	O
here	O
the	O
putative	O
influence	O
of	O
the	O
dose	O
of	O
antipsychotic	O
medication	O
(	O
chlorpromazine	S-chem
equivalents	O
,	O
CPZ	S-chem
)	O
,	O
the	O
antipsychotic	O
serum	O
concentration	O
of	O
dopamine	B-geneY
(	I-geneY
DA	I-geneY
)	I-geneY
D2	E-geneY
-	O
blocking	O
activity	O
and	O
the	O
approximated	O
central	O
dopamine	S-chem
D2	B-geneY
-	I-geneY
receptor	E-geneY
occupancy	O
(	O
DA	S-chem
D2	S-geneY
-	O
occupancy	O
)	O
,	O
on	O
conditioned	O
blocking	O
(	O
CB	O
)	O
measures	O
of	O
attention	O
and	O
performance	O
on	O
a	O
neuropsychological	O
battery	O
,	O
in	O
108	O
patients	O
with	O
schizophrenia	O
(	O
compared	O
with	O
62	O
healthy	O
controls	O
)	O
.	O

Antipsychotic	O
serum	O
concentration	O
and	O
D2	S-geneY
-	O
occupancy	O
were	O
higher	O
in	O
patients	O
with	O
a	O
paranoid	O
versus	O
non	O
-	O
paranoid	O
diagnosis	O
,	O
and	O
in	O
female	O
versus	O
male	O
patients	O
(	O
independent	O
of	O
symptom	O
severity	O
)	O
.	O

Controlling	O
for	O
D2	S-geneY
-	O
occupancy	O
removed	O
the	O
difference	O
between	O
high	O
CB	O
in	O
paranoid	O
and	O
impaired	O
low	O
CB	O
in	O
non	O
-	O
paranoid	O
patients	O
.	O

Similar	O
partial	O
correlations	O
for	O
antipsychotic	O
drug	O
dose	O
and	O
serum	O
levels	O
of	O
DA	S-chem
D2	S-geneY
-	O
blocking	O
activity	O
with	O
performance	O
of	O
the	O
trail	O
-	O
making	O
and	O
picture	O
completion	O
tests	O
(	O
negative	O
)	O
and	O
the	O
block	O
-	O
design	O
task	O
(	O
positive	O
)	O
showed	O
the	O
functional	O
importance	O
of	O
DA	S-chem
-	O
related	O
activity	O
.	O

High	O
estimates	O
of	O
central	O
DA	S-chem
D2	S-geneY
-	O
occupancy	O
were	O
related	O
to	O
impaired	O
verbal	O
fluency	O
but	O
were	O
associated	O
with	O
improved	O
recall	O
of	O
stories	O
,	O
especially	O
in	O
paranoid	O
patients	O
.	O

This	O
,	O
the	O
first	O
study	O
of	O
its	O
kind	O
,	O
tentatively	O
imputes	O
a	O
role	O
for	O
DA	S-chem
D2	S-geneY
-	O
related	O
activity	O
in	O
left	O
frontal	O
(	O
e.g	O
.	O

CB	O
,	O
verbal	O
fluency	O
)	O
and	O
temporal	O
lobe	O
functions	O
(	O
verbal	O
recall	O
)	O
as	O
well	O
as	O
in	O
some	O
non	O
-	O
verbal	O
abilities	O
mediated	O
more	O
in	O
the	O
right	O
hemisphere	O
in	O
patients	O
with	O
schizophrenia	O
.	O

Furanodiene	S-chem
Presents	O
Synergistic	O
Anti	O
-	O
proliferative	O
Activity	O
With	O
Paclitaxel	S-chem
Via	O
Altering	O
Cell	O
Cycle	O
and	O
Integrin	S-geneN
Signaling	O
in	O
95	O
-	O
D	O
Lung	O
Cancer	O
Cells	O
.	O

Furanodiene	S-chem
(	O
FUR	S-chem
)	O
is	O
a	O
natural	O
terpenoid	S-chem
isolated	O
from	O
Rhizoma	O
Curcumae	O
,	O
a	O
well	O
-	O
known	O
Chinese	O
medicinal	O
herb	O
that	O
presents	O
anti	O
-	O
proliferative	O
activities	O
in	O
several	O
cancer	O
cell	O
lines	O
.	O

Recently	O
,	O
we	O
found	O
that	O
the	O
combined	O
treatment	O
of	O
FUR	S-chem
with	O
paclitaxel	S-chem
(	O
TAX	S-chem
)	O
showed	O
synergetic	O
anti	O
-	O
proliferative	O
activities	O
in	O
95	O
-	O
D	O
lung	O
cancer	O
cells	O
.	O

Herein	O
,	O
we	O
showed	O
that	O
FUR	S-chem
reduced	O
the	O
cell	O
numbers	O
distributed	O
in	O
mitosis	O
phase	O
induced	O
by	O
TAX	S-chem
while	O
increased	O
those	O
in	O
G1	O
phase	O
.	O

The	O
protein	O
levels	O
of	O
cyclin	B-geneY
D1	E-geneY
,	O
cyclin	B-geneY
B1	E-geneY
,	O
CDK6	S-geneY
and	O
c	B-geneY
-	I-geneY
Myc	E-geneY
were	O
all	O
down	O
-	O
regulated	O
in	O
the	O
group	O
of	O
combined	O
treatment	O
.	O

The	O
dramatically	O
down	O
-	O
regulated	O
expression	O
of	O
integrin	B-geneY
β4	E-geneY
,	O
focal	B-geneY
adhesion	I-geneY
kinase	E-geneY
and	O
paxillin	S-geneY
might	O
partially	O
contribute	O
to	O
the	O
synergic	O
effect	O
.	O

Though	O
FUR	S-chem
alone	O
obviously	O
induced	O
endoplasmic	O
reticulum	O
stress	O
,	O
this	O
signaling	O
pathway	O
may	O
not	O
contribute	O
to	O
the	O
synergetic	O
anti	O
-	O
proliferative	O
effect	O
as	O
the	O
protein	O
expression	O
of	O
CHOP	S-geneY
and	O
BIP	S-geneY
was	O
similar	O
in	O
FUR	S-chem
alone	O
and	O
combined	O
treatment	O
group	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Thermodynamic	O
determination	O
of	O
the	O
binding	O
constants	O
of	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitors	O
by	O
a	O
displacement	O
method	O
.	O

Somatic	O
angiotensin	B-geneY
I	I-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
(	O
s	O
-	O
ACE	S-geneY
)	O
plays	O
a	O
central	O
role	O
in	O
blood	O
pressure	O
regulation	O
and	O
has	O
been	O
the	O
target	O
of	O
most	O
antihypertensive	O
drugs	O
.	O

A	O
displacement	O
isothermal	O
titration	O
calorimetry	O
method	O
has	O
been	O
used	O
to	O
accurately	O
determine	O
the	O
binding	O
constant	O
of	O
three	O
strong	O
s	O
-	O
ACE	S-geneY
inhibitors	O
.	O

Under	O
the	O
experimental	O
conditions	O
studied	O
in	O
this	O
work	O
,	O
the	O
relative	O
potency	O
of	O
the	O
inhibitors	O
was	O
determined	O
to	O
be	O
enalaprilat	S-chem
>	O
lisinopril	S-chem
>	O
captopril	S-chem
.	O

We	O
analyze	O
the	O
thermodynamic	O
behaviour	O
of	O
the	O
binding	O
process	O
using	O
the	O
new	O
structural	O
information	O
provided	O
by	O
the	O
ACE	S-geneY
structures	O
,	O
as	O
well	O
as	O
the	O
conformational	O
changes	O
that	O
occur	O
upon	O
binding	O
.	O

Gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	I-geneY
receptor	E-geneY
gene	O
expression	O
during	O
pubertal	O
development	O
of	O
male	O
rats	O
.	O

Appropriate	O
expression	O
of	O
the	O
GnRH	B-geneY
receptor	E-geneY
(	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
)	O
in	O
gonadotropes	O
is	O
critical	O
for	O
GnRH	S-geneY
signaling	O
and	O
hence	O
for	O
gonadotropin	S-geneN
secretion	O
and	O
sexual	O
development	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
the	O
ontogeny	O
of	O
the	O
steady	O
-	O
state	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
mRNA	O
levels	O
in	O
pituitaries	O
of	O
male	O
rats	O
from	O
Day	O
5	O
to	O
Day	O
55	O
,	O
when	O
sexual	O
maturity	O
is	O
attained	O
.	O

Developmental	O
changes	O
of	O
gonadotropin	S-geneN
subunit	O
(	O
alpha	O
,	O
FSHbeta	S-geneY
,	O
and	O
LHbeta	S-geneY
)	O
mRNA	O
levels	O
were	O
also	O
assessed	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
the	O
endogenous	O
GnRH	S-geneY
on	O
the	O
maturational	O
changes	O
of	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
and	O
gonadotropin	S-geneN
subunit	O
gene	O
expression	O
was	O
investigated	O
.	O

Messenger	O
RNA	O
levels	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	O
from	O
anterior	O
pituitaries	O
.	O

Amounts	O
of	O
the	O
most	O
abundant	O
(	O
5.0	O
kb	O
)	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
mRNA	O
increased	O
slowly	O
from	O
Day	O
5	O
through	O
the	O
infantile	O
and	O
the	O
juvenile	O
periods	O
,	O
to	O
peak	O
at	O
Day	O
35	O
(	O
12	O
-	O
fold	O
increase	O
vs	O
.	O

Day	O
5	O
)	O
.	O

Thereafter	O
,	O
the	O
levels	O
of	O
the	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
mRNA	O
decline	O
slightly	O
until	O
Day	O
55	O
(	O
33	O
%	O
decrease	O
vs	O
.	O

Day	O
35	O
)	O
.	O

Parallel	O
changes	O
were	O
observed	O
on	O
the	O
4.5	O
-	O
kb	O
transcript	O
of	O
the	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
gene	O
.	O

Alpha	O
subunit	O
mRNA	O
was	O
easily	O
detected	O
at	O
Day	O
5	O
,	O
and	O
its	O
levels	O
increased	O
progressively	O
through	O
the	O
infantile	O
period	O
(	O
2.5	O
-	O
fold	O
increase	O
)	O
and	O
peaked	O
at	O
Day	O
25	O
(	O
3.3	O
-	O
fold	O
increase	O
vs	O
.	O

Day	O
5	O
)	O
with	O
a	O
smooth	O
nonstatistically	O
significant	O
increment	O
until	O
Day	O
35	O
;	O
then	O
it	O
decreased	O
by	O
41.5	O
%	O
at	O
Day	O
55	O
.	O

FSHbeta	S-geneY
and	O
LHbeta	S-geneY
mRNA	O
levels	O
rose	O
slowly	O
until	O
Day	O
25	O
.	O

A	O
sharp	O
rise	O
occurred	O
thereafter	O
to	O
reach	O
maximum	O
levels	O
at	O
Day	O
35	O
(	O
5.8	O
-	O
fold	O
for	O
FSHbeta	S-geneY
and	O
3.8	O
-	O
fold	O
for	O
LHbeta	S-geneY
vs	O
.	O

Day	O
25	O
)	O
.	O

Thereafter	O
,	O
the	O
levels	O
of	O
both	O
mRNAs	O
fell	O
until	O
Day	O
55	O
(	O
44.1	O
%	O
decrease	O
for	O
FSHbeta	S-geneY
and	O
37.1	O
%	O
decrease	O
for	O
LHbeta	S-geneY
vs	O
.	O

Day	O
35	O
)	O
.	O

To	O
ascertain	O
whether	O
developmental	O
activation	O
of	O
the	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
and	O
gonadotropin	S-geneN
subunit	O
gene	O
expression	O
is	O
GnRH	S-geneY
dependent	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
blocking	O
the	O
endogenous	O
GnRH	S-geneY
action	O
by	O
treating	O
developing	O
male	O
rats	O
with	O
the	O
specific	O
GnRH	S-geneY
antagonist	O
cetrorelix	O
(	O
1.5	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
,	O
s.c.	O
)	O
through	O
the	O
infantile	O
(	O
Days	O
5	O
-	O
20	O
)	O
and	O
the	O
juvenile	O
periods	O
(	O
Days	O
20	O
-	O
35	O
)	O
.	O

Cetrorelix	S-chem-C4-1
completely	O
blocked	O
the	O
rise	O
of	O
levels	O
of	O
the	O
two	O
most	O
abundant	O
species	O
,	O
5.0	O
kb	O
and	O
4.5	O
kb	O
,	O
of	O
the	O
GnRH	B-geneY-C4-2
-	I-geneY-C4-2
R	E-geneY-C4-2
mRNA	O
,	O
during	O
both	O
the	O
infantile	O
and	O
the	O
juvenile	O
periods	O
.	O

Cetrorelix	S-chem-C4-1
also	O
abolished	O
the	O
developmental	O
rise	O
of	O
the	O
gonadotropin	B-geneN-C4-2
beta	E-geneN-C4-2
subunit	O
mRNAs	O
during	O
the	O
two	O
periods	O
of	O
the	O
study	O
.	O

In	O
contrast	O
,	O
the	O
alpha	O
subunit	O
gene	O
expression	O
was	O
not	O
altered	O
by	O
cetrorelix	O
treatment	O
during	O
any	O
of	O
the	O
two	O
periods	O
.	O

These	O
data	O
demonstrate	O
that	O
sexual	O
maturation	O
of	O
male	O
rats	O
is	O
accompanied	O
by	O
a	O
progressive	O
and	O
concerted	O
induction	O
of	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
and	O
gonadotropin	S-geneN
subunit	O
gene	O
expression	O
.	O

Developmental	O
activation	O
of	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
and	O
gonadotropin	B-geneN
beta	E-geneN
subunit	O
genes	O
is	O
GnRH	S-geneY
dependent	O
.	O

The	O
apparent	O
GnRH	S-geneY
-	O
independent	O
regulation	O
of	O
the	O
alpha	B-geneN
-	I-geneN
glycoprotein	E-geneN
subunit	O
mRNA	O
levels	O
may	O
be	O
due	O
to	O
the	O
contribution	O
of	O
thyrotropes	O
and	O
perhaps	O
to	O
the	O
presence	O
of	O
exclusive	O
regulatory	O
signals	O
for	O
this	O
gene	O
.	O

The	O
type	O
2	O
diabetes	O
associated	O
gene	O
Ide	S-geneY
is	O
required	O
for	O
insulin	S-geneN
secretion	O
and	O
suppression	O
of	O
α	B-geneY
-	I-geneY
synuclein	E-geneY
levels	O
in	O
β	O
-	O
cells	O
.	O

Genome	O
wide	O
association	O
studies	O
have	O
identified	O
several	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
risk	O
loci	O
linked	O
to	O
impaired	O
β	O
-	O
cell	O
function	O
.	O

The	O
identity	O
and	O
function	O
of	O
the	O
causal	O
genes	O
in	O
these	O
susceptibility	O
loci	O
remain	O
,	O
however	O
,	O
elusive	O
.	O

The	O
HHEX	S-geneY
/	O
IDE	S-geneY
T2D	O
locus	O
is	O
associated	O
with	O
decreased	O
insulin	S-geneY
secretion	O
in	O
response	O
to	O
oral	O
glucose	S-chem
stimulation	O
in	O
humans	O
.	O

Here	O
we	O
have	O
assessed	O
β	O
-	O
cell	O
function	O
in	O
Ide	S-geneY
knock	O
-	O
out	O
(	O
KO	O
)	O
mice	O
.	O

We	O
find	O
that	O
glucose	S-chem
stimulated	O
insulin	S-geneN
secretion	O
(	O
GSIS	O
)	O
is	O
decreased	O
in	O
Ide	S-geneY
KO	O
mice	O
due	O
to	O
impaired	O
replenishment	O
of	O
the	O
releasable	O
pool	O
of	O
granules	O
and	O
that	O
the	O
Ide	S-geneY
gene	O
is	O
haploinsufficient	O
.	O

We	O
also	O
show	O
that	O
autophagic	O
flux	O
and	O
microtubule	S-geneN
content	O
is	O
reduced	O
in	O
β	O
-	O
cells	O
of	O
Ide	S-geneY
KO	O
mice	O
.	O

One	O
important	O
cellular	O
role	O
for	O
IDE	S-geneY
involves	O
the	O
neutralization	O
of	O
amyloidogenic	O
proteins	O
and	O
we	O
find	O
that	O
α	B-geneY
-	I-geneY
synuclein	E-geneY
and	O
IDE	S-geneY
levels	O
are	O
inversely	O
correlated	O
in	O
β	O
-	O
cells	O
of	O
Ide	S-geneY
KO	O
mice	O
and	O
T2D	O
patients	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
both	O
gain	O
-	O
and	O
loss	O
-	O
of	O
-	O
function	O
of	O
α	B-geneY
-	I-geneY
synuclein	E-geneY
in	O
β	O
-	O
cells	O
in	O
vivo	O
not	O
only	O
impair	O
GSIS	O
but	O
also	O
autophagy	O
.	O

Together	O
,	O
these	O
data	O
identify	O
the	O
Ide	S-geneY
gene	O
as	O
a	O
regulator	O
of	O
GSIS	O
,	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
β	O
-	O
cell	O
degeneration	O
as	O
a	O
consequence	O
of	O
Ide	S-geneY
deficiency	O
,	O
and	O
additionally	O
corroborates	O
and	O
extends	O
a	O
previously	O
established	O
important	O
role	O
for	O
α	B-geneY
-	I-geneY
synuclein	E-geneY
in	O
β	O
-	O
cell	O
function	O
.	O

Neurochemical	O
effects	O
of	O
the	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitor	O
phenelzine	S-chem-C4-1
on	O
brain	O
GABA	S-chem
and	O
alanine	S-chem
:	O
A	O
comparison	O
with	O
vigabatrin	S-chem
.	O

PURPOSE	O
:	O
To	O
compare	O
phenelzine	S-chem-C4-1
(	O
PLZ	S-chem-C4-1
)	O
,	O
an	O
antidepressant	O
drug	O
with	O
anxiolytic	O
properties	O
which	O
inhibits	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
(	O
MAO	S-geneN-C4-2
)	O
but	O
also	O
elevates	O
rat	O
brain	O
levels	O
of	O
the	O
amino	B-chem
acids	E-chem
?	O
-	O
aminobutyric	B-chem
acid	E-chem
(	O
GABA	S-chem
)	O
and	O
alanine	S-chem
(	O
ALA	S-chem
)	O
,	O
with	O
vigabatrin	S-chem-C4-1
(	O
VIG	S-chem-C4-1
)	O
,	O
an	O
anticonvulsant	O
which	O
elevates	O
brain	O
GABA	S-chem
by	O
inhibition	O
of	O
GABA	B-geneY-C4-2
transaminase	E-geneY-C4-2
(	O
GABA	B-geneY-C4-2
-	I-geneY-C4-2
T	E-geneY-C4-2
)	O
,	O
with	O
regard	O
to	O
their	O
actions	O
on	O
brain	O
levels	O
of	O
GABA	S-chem
and	O
ALA	S-chem
and	O
on	O
activities	O
of	O
MAO	S-geneN
,	O
GABA	B-geneY
-	I-geneY
T	E-geneY
and	O
ALA	B-geneN
transaminase	E-geneN
(	O
ALA	B-geneN
-	I-geneN
T	E-geneN
)	O
.	O

METHODS	O
:	O
Male	O
rats	O
were	O
administered	O
PLZ	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
or	O
VIG	S-chem
(	O
1,000	O
mg	O
/	O
kg	O
)	O
i.p	O
.	O
,	O
and	O
the	O
rats	O
were	O
euthanized	O
4	O
hours	O
later	O
and	O
the	O
brains	O
removed	O
for	O
analysis	O
of	O
levels	O
of	O
GABA	S-chem
and	O
ALA	S-chem
(	O
by	O
electron	O
capture	O
gas	O
chromatography	O
after	O
derivatization	O
)	O
and	O
activities	O
of	O
MAO	S-geneN
,	O
GABA	B-geneY
-	I-geneY
T	E-geneY
and	O
ALA	B-geneN
-	I-geneN
T	E-geneN
(	O
radiochemical	O
assays	O
)	O
.	O

RESULTS	O
:	O
Both	O
PLZ	S-chem-C4-1
and	O
VIG	S-chem-C4-1
inhibited	O
GABA	B-geneY-C4-2
-	I-geneY-C4-2
T	E-geneY-C4-2
and	O
elevated	O
GABA	S-chem
levels	O
.	O

Only	O
PLZ	S-chem-C4-1
inhibited	O
MAO	S-geneN-C4-2
and	O
ALA	B-geneN-C4-2
-	I-geneN-C4-2
T	E-geneN-C4-2
and	O
elevated	O
ALA	S-chem
levels	O
.	O

The	O
effects	O
of	O
PLZ	S-chem
on	O
both	O
amino	B-chem
acids	E-chem
and	O
their	O
transaminases	S-geneN-C4-2
were	O
blocked	O
by	O
pre	O
-	O
treatment	O
with	O
the	O
MAO	S-geneN-C4-2
inhibitor	O
tranylcypromine	S-chem-C4-1
.	O

This	O
pretreament	O
had	O
no	O
effect	O
on	O
the	O
inhibition	O
of	O
GABA	B-geneY-C4-2
-	I-geneY-C4-2
T	E-geneY-C4-2
or	O
the	O
elevation	O
of	O
brain	O
GABA	S-chem
levels	O
produced	O
by	O
VIG	S-chem-C4-1
.	O

CONCLUSIONS	O
:	O
At	O
the	O
doses	O
studied	O
,	O
PLZ	S-chem
was	O
as	O
effective	O
as	O
VIG	S-chem
at	O
elevating	O
brain	O
GABA	S-chem
levels	O
,	O
but	O
,	O
unlike	O
VIG	S-chem-C4-1
,	O
also	O
inhibited	O
MAO	S-geneN-C4-2
and	O
ALA	B-geneN-C4-2
-	I-geneN-C4-2
T	E-geneN-C4-2
(	O
and	O
increased	O
brain	O
ALA	S-chem
levels	O
)	O
.	O

Pretreatment	O
of	O
rats	O
with	O
the	O
MAO	S-geneN-C4-2
inhibitor	O
tranylcypromine	S-chem-C4-1
prevented	O
the	O
increase	O
in	O
brain	O
GABA	S-chem
and	O
ALA	S-chem
levels	O
with	O
PLZ	S-chem
,	O
but	O
did	O
not	O
block	O
the	O
effect	O
of	O
VIG	S-chem
on	O
GABA	S-chem
.	O

These	O
observations	O
with	O
tranylcypromine	S-chem
and	O
PLZ	S-chem
support	O
the	O
hypothesis	O
that	O
an	O
active	O
metabolite	O
of	O
PLZ	S-chem
produced	O
by	O
the	O
actions	O
of	O
MAO	S-geneN
on	O
this	O
drug	O
plays	O
a	O
major	O
role	O
in	O
its	O
GABA	S-chem
-	O
and	O
ALA	S-chem
-	O
elevating	O
actions	O
.	O

Preferential	O
and	O
non	O
-	O
selective	O
cyclooxygenase	S-geneN
inhibitors	O
reduce	O
inflammation	O
during	O
lipopolysaccharide	O
-	O
induced	O
synovitis	O
.	O

Synovitis	O
in	O
horses	O
is	O
frequently	O
treated	O
by	O
administration	O
of	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
which	O
inhibit	O
cyclooxygenase	S-geneN
isoforms	O
(	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

Constitutively	O
expressed	O
COX	B-geneY
-	I-geneY
1	E-geneY
is	O
involved	O
in	O
physiologic	O
functions	O
such	O
as	O
maintenance	O
of	O
gastric	O
mucosal	O
integrity	O
,	O
whereas	O
COX	B-geneY
-	I-geneY
2	E-geneY
is	O
up	O
-	O
regulated	O
at	O
sites	O
of	O
inflammation	O
.	O

Thus	O
,	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
reduce	O
inflammation	O
with	O
reduced	O
gastrointestinal	O
side	O
effects	O
as	O
compared	O
to	O
non	O
-	O
selective	O
COX	S-geneY
inhibitors	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
the	O
preferential	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
etodolac	O
with	O
the	O
non	O
-	O
selective	O
COX	S-geneN-C4-2
inhibitor	O
phenylbutazone	S-chem-C4-1
in	O
horses	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
synovitis	O
.	O

Three	O
groups	O
of	O
horses	O
(	O
n	O
=	O
6	O
)	O
received	O
no	O
treatment	O
,	O
phenylbutazone	S-chem
(	O
4.4	O
mg	O
/	O
kg	O
,	O
IV	O
,	O
q12h	O
)	O
,	O
or	O
etodolac	S-chem
(	O
23	O
mg	O
/	O
kg	O
,	O
IV	O
,	O
q12h	O
)	O
,	O
respectively	O
,	O
2	O
-	O
h	O
following	O
injection	O
of	O
LPS	O
into	O
one	O
middle	O
carpal	O
joint	O
.	O

Synovial	O
fluid	O
was	O
analyzed	O
for	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
,	O
and	O
TXB2	S-chem
and	O
PGE2	S-chem
levels	O
.	O

Phenylbutazone	S-chem
and	O
etodolac	S-chem
significantly	O
reduced	O
WBC	O
count	O
6	O
and	O
24	O
-	O
h	O
following	O
injection	O
of	O
LPS	O
compared	O
to	O
untreated	O
horses	O
.	O

In	O
addition	O
,	O
both	O
drugs	O
significantly	O
reduced	O
PGE2	S-chem
levels	O
(	O
P	O
<	O
0.05	O
)	O
6	O
-	O
h	O
following	O
LPS	O
injection	O
,	O
whereas	O
the	O
probable	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
prostanoid	S-chem
TXB2	S-chem
was	O
significantly	O
reduced	O
by	O
phenylbutazone	S-chem-C4-1
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
not	O
etodolac	S-chem
.	O

Etodolac	S-chem
may	O
serve	O
as	O
a	O
more	O
selective	O
anti	O
-	O
inflammatory	O
agent	O
than	O
phenylbutazone	S-chem
for	O
treatment	O
of	O
equine	O
synovitis	O
.	O

Novel	O
5	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
benzyloxy	I-chem-C4-1
)	I-chem-C4-1
pyridin	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
(	I-chem-C4-1
1H	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
one	E-chem-C4-1
derivatives	O
as	O
potent	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Met	E-geneY-C4-2
inhibitors	O
.	O

A	O
series	O
of	O
novel	O
5	B-chem
-	I-chem
(	I-chem
benzyloxy	I-chem
)	I-chem
pyridin	I-chem
-	I-chem
2	I-chem
(	I-chem
1H	I-chem
)	I-chem
-	I-chem
ones	E-chem
were	O
designed	O
,	O
synthesized	O
and	O
biologically	O
evaluated	O
for	O
c	B-geneY
-	I-geneY
Met	E-geneY
inhibition	O
.	O

Various	O
amides	S-chem
and	O
benzoimidazoles	S-chem
at	O
C	O
-	O
3	O
position	O
were	O
investigated	O
.	O

A	O
potent	O
compound	O
12b	O
with	O
a	O
c	B-geneY
-	I-geneY
Met	E-geneY
IC50	O
of	O
12nM	O
was	O
identified	O
.	O

This	O
compound	O
exhibited	O
potent	O
inhibition	O
of	O
EBC	O
-	O
1	O
cell	O
associated	O
with	O
c	B-geneY
-	I-geneY
Met	E-geneY
constitutive	O
activation	O
and	O
showed	O
high	O
selectivity	O
for	O
c	B-geneY
-	I-geneY
Met	E-geneY
than	O
other	O
tested	O
11	O
kinases	S-geneN
.	O

The	O
binding	O
model	O
12b	O
with	O
c	B-geneY
-	I-geneY
Met	E-geneY
was	O
disclosed	O
by	O
docking	O
analysis	O
.	O

A	O
Structural	O
Snapshot	O
of	O
Cytochrome	B-geneY
P450	I-geneY
2B4	E-geneY
in	O
Complex	O
with	O
Paroxetine	S-chem
Provides	O
Insights	O
into	O
Ligand	O
Binding	O
and	O
Clusters	O
of	O
Conformational	O
States	O
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
cytochrome	B-geneY
P450	I-geneY
2B4	E-geneY
in	O
complex	O
with	O
the	O
drug	O
paroxetine	S-chem
was	O
solved	O
at	O
2.14	O
Å	O
resolution	O
.	O

The	O
structure	O
revealed	O
a	O
conformation	O
intermediate	O
to	O
that	O
of	O
the	O
recently	O
solved	O
complex	O
with	O
amlodipine	S-chem
and	O
of	O
the	O
more	O
compact	O
complex	O
with	O
4	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chlorophenyl	I-chem
)	I-chem
imidazole	E-chem
in	O
terms	O
of	O
the	O
placement	O
of	O
the	O
F	O
-	O
G	O
cassette	O
.	O

Moreover	O
,	O
the	O
comparison	O
of	O
the	O
new	O
structure	O
with	O
15	O
previously	O
solved	O
structures	O
of	O
P450	B-geneY
2B4	E-geneY
revealed	O
some	O
new	O
insights	O
into	O
determinants	O
of	O
active	O
site	O
size	O
and	O
shape	O
.	O

The	O
2B4	S-geneY
-	O
paroxetine	S-chem
structure	O
is	O
nearly	O
superimposable	O
on	O
a	O
previously	O
solved	O
closed	O
structure	O
in	O
a	O
ligand	O
free	O
state	O
.	O

Despite	O
the	O
overall	O
conformational	O
similarity	O
among	O
multiple	O
closed	O
structures	O
,	O
the	O
active	O
site	O
cavity	O
volume	O
of	O
the	O
paroxetine	S-chem
complex	O
is	O
enlarged	O
.	O

Further	O
analysis	O
of	O
the	O
accessible	O
space	O
and	O
binding	O
pocket	O
near	O
the	O
heme	O
reveals	O
a	O
new	O
sub	O
-	O
chamber	O
that	O
resulted	O
from	O
the	O
movement	O
of	O
secondary	O
structural	O
elements	O
and	O
rearrangements	O
of	O
active	O
site	O
side	O
chains	O
.	O

Overall	O
,	O
the	O
results	O
from	O
the	O
comparison	O
of	O
all	O
the	O
16	O
structures	O
of	O
P450	B-geneY
2B4	E-geneY
demonstrate	O
a	O
cluster	O
of	O
protein	O
conformations	O
that	O
were	O
observed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
various	O
ligands	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
carbamoylmethylene	S-chem-C4-1
linked	O
prodrugs	O
of	O
BMS	B-chem-C4-1
-	I-chem-C4-1
582949	E-chem-C4-1
,	O
a	O
clinical	O
p38α	S-geneY-C4-2
inhibitor	O
.	O

A	O
series	O
of	O
carbamoylmethylene	S-chem-C4-1
linked	O
prodrugs	O
of	O
1	O
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
582949	E-chem-C4-1
)	O
,	O
a	O
clinical	O
p38α	S-geneY-C4-2
inhibitor	O
,	O
were	O
synthesized	O
and	O
evaluated	O
.	O

Though	O
the	O
phosphoryloxymethylene	B-chem
carbamates	E-chem
(	O
3	O
,	O
4	O
,	O
and	O
5	O
)	O
and	O
α	B-chem
-	I-chem
aminoacyloxymethylene	I-chem
carbamates	E-chem
(	O
22	O
,	O
23	O
,	O
and	O
26	O
)	O
were	O
found	O
unstable	O
at	O
neutral	O
pH	O
values	O
,	O
fumaric	B-chem
acid	E-chem
derived	O
acyloxymethylene	B-chem
carbamates	E-chem
(	O
2	O
,	O
28	O
,	O
and	O
31	O
)	O
were	O
highly	O
stable	O
under	O
both	O
acidic	O
and	O
neutral	O
conditions	O
.	O

Prodrugs	O
2	O
and	O
31	O
were	O
also	O
highly	O
soluble	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
values	O
.	O

At	O
a	O
solution	O
dose	O
of	O
14.2mpk	O
(	O
equivalent	O
to	O
10mpk	O
of	O
1	O
)	O
,	O
2	O
gave	O
essentially	O
the	O
same	O
exposure	O
of	O
1	O
compared	O
to	O
dosing	O
10mpk	O
of	O
1	O
itself	O
.	O

At	O
a	O
suspension	O
dose	O
of	O
142mpk	O
(	O
equivalent	O
to	O
100mpk	O
of	O
1	O
)	O
,	O
2	O
demonstrated	O
that	O
it	O
could	O
overcome	O
the	O
solubility	O
issue	O
associated	O
with	O
1	O
and	O
provide	O
a	O
much	O
higher	O
exposure	O
of	O
1	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
unique	O
type	O
of	O
prodrugs	O
like	O
2	O
,	O
28	O
,	O
and	O
31	O
was	O
not	O
reported	O
in	O
the	O
past	O
and	O
could	O
represent	O
a	O
novel	O
prodrug	O
approach	O
for	O
secondary	B-chem
amides	E-chem
,	O
a	O
class	O
of	O
molecules	O
frequently	O
identified	O
as	O
drug	O
candidates	O
.	O

Mechanisms	O
of	O
Glucose	S-chem
Lowering	O
of	O
Dipeptidyl	B-geneY-C4-2
Peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
Inhibitor	O
Sitagliptin	S-chem-C4-1
When	O
Used	O
Alone	O
or	O
With	O
Metformin	S-chem
in	O
Type	O
2	O
Diabetes	O
:	O
A	O
double	O
-	O
tracer	O
study	O
.	O

OBJECTIVETo	O
assess	O
glucose	S-chem
-	O
lowering	O
mechanisms	O
of	O
sitagliptin	S-chem
(	O
S	O
)	O
,	O
metformin	S-chem
(	O
M	O
)	O
,	O
and	O
the	O
two	O
combined	O
(	O
M	O
+	O
S	O
)	O
.RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
randomized	O
16	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
to	O
four	O
6	O
-	O
week	O
treatments	O
with	O
placebo	O
(	O
P	O
)	O
,	O
M	O
,	O
S	O
,	O
and	O
M	O
+	O
S	O
.	O

After	O
each	O
period	O
,	O
subjects	O
received	O
a	O
6	O
-	O
h	O
meal	O
tolerance	O
test	O
(	O
MTT	S-chem
)	O
with	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
glucose	E-chem
to	O
calculate	O
glucose	S-chem
kinetics	O
.	O

Fasting	O
plasma	O
glucose	S-chem
(	O
FPG	O
)	O
,	O
fasting	O
plasma	O
insulin	S-geneY
,	O
C	B-geneY
-	I-geneY
peptide	E-geneY
(	O
insulin	S-geneY
secretory	O
rate	O
[	O
ISR	O
]	O
)	O
,	O
fasting	O
plasma	O
glucagon	S-geneY
,	O
and	O
bioactive	O
glucagon	B-geneY
-	I-geneY
like	I-geneY
peptide	E-geneY
(	O
GLP	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
gastrointestinal	B-geneY
insulinotropic	I-geneY
peptide	E-geneY
(	O
GIP	S-geneY
)	O
was	O
measured.RESULTSFPG	O
decreased	O
from	O
P	O
,	O
160	O
±	O
4	O
to	O
M	O
,	O
150	O
±	O
4	O
;	O
S	O
,	O
154	O
±	O
4	O
;	O
and	O
M	O
+	O
S	O
,	O
125	O
±	O
3	O
mg	O
/	O
dL	O
.	O

Mean	O
post	O
-	O
MTT	S-chem
PG	O
decreased	O
from	O
P	O
,	O
207	O
±	O
5	O
to	O
M	O
,	O
191	O
±	O
4	O
;	O
S	O
,	O
195	O
±	O
4	O
;	O
and	O
M	O
+	O
S	O
,	O
161	O
±	O
3	O
mg	O
/	O
dL	O
(	O
P	O
<	O
0.01	O
]	O
.	O

The	O
increase	O
in	O
mean	O
post	O
-	O
MTT	S-chem
plasma	O
insulin	S-geneY
and	O
in	O
ISR	O
was	O
similar	O
in	O
P	O
,	O
M	O
,	O
and	O
S	O
and	O
slightly	O
greater	O
in	O
M	O
+	O
S	O
.	O

Fasting	O
plasma	O
glucagon	S-geneY
was	O
equal	O
(	O
∼	O
65	O
-	O
75	O
pg	O
/	O
mL	O
)	O
with	O
all	O
treatments	O
,	O
but	O
there	O
was	O
a	O
significant	O
drop	O
during	O
the	O
initial	O
120	O
min	O
with	O
S	O
24	O
%	O
and	O
M	O
+	O
S	O
34	O
%	O
(	O
both	O
P	O
<	O
0.05	O
)	O
vs	O
.	O

P	O
17	O
%	O
and	O
M	O
16	O
%	O
.	O

Fasting	O
and	O
mean	O
post	O
-	O
MTT	S-chem
plasma	O
bioactive	O
GLP	B-geneY
-	I-geneY
1	E-geneY
were	O
higher	O
(	O
P	O
<	O
0.01	O
)	O
after	O
S	O
and	O
M	O
+	O
S	O
vs	O
.	O

M	O
and	O
P	O
.	O

Basal	O
endogenous	O
glucose	S-chem
production	O
(	O
EGP	O
)	O
fell	O
from	O
P	O
2.0	O
±	O
0.1	O
to	O
S	O
1.8	O
±	O
0.1	O
mg	O
/	O
kg	O
⋅	O
min	O
,	O
M	O
1.8	O
±	O
0.2	O
mg	O
/	O
kg	O
⋅	O
min	O
[	O
both	O
P	O
<	O
0.05	O
vs	O
.	O

P	O
)	O
,	O
and	O
M	O
+	O
S	O
1.5	O
±	O
0.1	O
mg	O
/	O
kg	O
⋅	O
min	O
(	O
P	O
<	O
0.01	O
vs	O
.	O

P	O
)	O
.	O

Although	O
the	O
EGP	O
slope	O
of	O
decline	O
was	O
faster	O
in	O
M	O
and	O
M	O
+	O
S	O
vs	O
.	O

S	O
,	O
all	O
had	O
comparable	O
greater	O
post	O
-	O
MTT	O
EGP	O
inhibition	O
vs	O
.	O

P	O
(	O
P	O
<	O
0.05	O
)	O
.CONCLUSIONSM	O
+	O
S	O
combined	O
produce	O
additive	O
effects	O
to	O
1	O
)	O
reduce	O
FPG	O
and	O
postmeal	O
PG	O
,	O
2	O
)	O
augment	O
GLP	B-geneY
-	I-geneY
1	E-geneY
secretion	O
and	O
β	O
-	O
cell	O
function	O
,	O
3	O
)	O
decrease	O
plasma	O
glucagon	S-geneY
,	O
and	O
4	O
)	O
inhibit	O
fasting	O
and	O
postmeal	O
EGP	O
compared	O
with	O
M	O
or	O
S	O
monotherapy	O
.	O

Hydrogen	B-chem
sulfide	E-chem
as	O
an	O
allosteric	O
modulator	O
of	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
potassium	I-geneN
channels	E-geneN
in	O
colonic	O
inflammation	O
.	O

The	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
potassium	I-geneN
channel	E-geneN
(	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	E-geneN
)	O
in	O
mouse	O
colonic	O
smooth	O
muscle	O
cell	O
is	O
a	O
complex	O
containing	O
a	O
pore	O
-	O
forming	O
subunit	O
(	O
Kir6.1	S-geneY
)	O
and	O
a	O
sulfonylurea	B-geneN
receptor	E-geneN
subunit	O
(	O
SUR2B	S-geneY
)	O
.	O

These	O
channels	O
contribute	O
to	O
the	O
cellular	O
excitability	O
of	O
smooth	O
muscle	O
cells	O
and	O
hence	O
regulate	O
the	O
motility	O
patterns	O
in	O
the	O
colon	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
techniques	O
were	O
used	O
to	O
study	O
the	O
alterations	O
in	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
in	O
smooth	O
muscle	O
cells	O
in	O
experimental	O
colitis	O
.	O

Colonic	O
inflammation	O
was	O
induced	O
in	O
BALB	O
/	O
C	O
mice	O
after	O
intracolonic	O
administration	O
of	O
trinitrobenzene	B-chem
sulfonic	I-chem
acid	E-chem
.	O

K	S-chem
(	O
ATP	S-chem
)	O
currents	O
were	O
measured	O
at	O
a	O
holding	O
potential	O
of	O
-	O
60	O
mV	O
in	O
high	O
K	B-chem
(	I-chem
+	I-chem
)	E-chem
external	O
solution	O
.	O

The	O
concentration	O
response	O
to	O
levcromakalim	S-chem-C3-1
(	O
LEVC	S-chem-C3-1
)	O
,	O
a	O
K	B-geneN-C3-2
(	I-geneN-C3-2
ATP	I-geneN-C3-2
)	I-geneN-C3-2
channel	E-geneN-C3-2
opener	O
,	O
was	O
significantly	O
shifted	O
to	O
the	O
left	O
in	O
the	O
inflamed	O
smooth	O
-	O
muscle	O
cells	O
.	O

Both	O
the	O
potency	O
and	O
maximal	O
currents	O
induced	O
by	O
LEVC	S-chem
were	O
enhanced	O
in	O
inflammation	O
.	O

The	O
EC	O
(	O
50	O
)	O
values	O
in	O
control	O
were	O
6259	O
nM	O
(	O
n	O
=	O
10	O
)	O
and	O
422	O
nM	O
(	O
n	O
=	O
8	O
)	O
in	O
inflamed	O
colon	O
,	O
and	O
the	O
maximal	O
currents	O
were	O
9.9	O
±	O
0.71	O
pA	O
/	O
pF	O
(	O
60	O
μM	O
)	O
in	O
control	O
and	O
39.7	O
±	O
8.8	O
pA	O
/	O
pF	O
(	O
3	O
μM	O
)	O
after	O
inflammation	O
.	O

As	O
was	O
seen	O
with	O
LEVC	S-chem
,	O
the	O
potency	O
and	O
efficacy	O
of	O
sodium	B-chem
hydrogen	I-chem
sulfide	E-chem
(	O
NaHS	S-chem
)	O
(	O
10	O
-	O
1000	O
μM	O
)	O
on	O
K	S-chem
(	O
ATP	S-chem
)	O
currents	O
were	O
significantly	O
greater	O
in	O
inflamed	O
colon	O
compared	O
with	O
controls	O
.	O

In	O
control	O
cells	O
,	O
pretreatment	O
with	O
100	O
µM	O
NaHS	S-chem
shifted	O
the	O
EC	O
(	O
50	O
)	O
for	O
LEV	O
-	O
induced	O
currents	O
from	O
2838	O
(	O
n	O
=	O
6	O
)	O
to	O
154	O
(	O
n	O
=	O
8	O
)	O
nM	O
.	O

Sulfhydration	O
of	O
sulfonylurea	B-geneY-C3-2
receptor	I-geneY-C3-2
2B	E-geneY-C3-2
(	O
SUR2B	S-geneY-C3-2
)	O
was	O
induced	O
by	O
NaHS	S-chem-C3-1
and	O
colonic	O
inflammation	O
.	O

These	O
data	O
suggest	O
that	O
sulfhydration	O
of	O
SUR2B	S-geneY
induces	O
allosteric	O
modulation	O
of	O
K	S-chem
(	O
ATP	S-chem
)	O
currents	O
in	O
colonic	O
inflammation	O
.	O

Suppression	O
of	O
ZIP8	S-geneY
expression	O
is	O
a	O
common	O
feature	O
of	O
cadmium	S-chem
-	O
resistant	O
and	O
manganese	S-chem
-	O
resistant	O
RBL	O
-	O
2H3	O
cells	O
.	O

Rat	O
basophilic	O
leukemia	O
RBL	O
-	O
2H3	O
cells	O
show	O
markedly	O
high	O
sensitivity	O
to	O
both	O
CdCl2	S-chem
and	O
MnCl2	S-chem
compared	O
with	O
other	O
rat	O
cell	O
lines	O
,	O
due	O
to	O
efficient	O
accumulation	O
of	O
cadmium	S-chem
and	O
manganese	S-chem
.	O

To	O
clarify	O
the	O
roles	O
of	O
metal	B-geneN
transporters	E-geneN
in	O
hyperaccumulation	O
of	O
cadmium	S-chem
and	O
manganese	S-chem
in	O
RBL	O
-	O
2H3	O
cells	O
,	O
Cd	S-chem
-	O
resistant	O
and	O
Mn	S-chem
-	O
resistant	O
cells	O
were	O
developed	O
from	O
RBL	O
-	O
2H3	O
cells	O
by	O
continuous	O
exposure	O
to	O
CdCl2	S-chem
and	O
MnCl2	S-chem
,	O
respectively	O
.	O

The	O
established	O
Cd	S-chem
-	O
resistant	O
(	O
RBL	O
-	O
Cdr	O
)	O
and	O
Mn	S-chem
-	O
resistant	O
(	O
RBL	O
-	O
Mnr	O
)	O
cells	O
exhibited	O
about	O
20	O
times	O
higher	O
LC50	O
values	O
of	O
CdCl2	S-chem
and	O
MnCl2	S-chem
,	O
respectively	O
,	O
than	O
parental	O
RBL	O
-	O
2H3	O
cells	O
,	O
and	O
showed	O
cross	O
-	O
resistance	O
to	O
each	O
metal	O
.	O

The	O
resistance	O
to	O
cadmium	S-chem
and	O
manganese	S-chem
was	O
primarily	O
conferred	O
by	O
a	O
marked	O
decrease	O
in	O
the	O
uptake	O
of	O
both	O
metals	O
.	O

RBL	O
-	O
Cdr	O
cells	O
also	O
showed	O
cross	O
-	O
resistance	O
to	O
HgCl2	S-chem
and	O
AgNO3	S-chem
probably	O
due	O
to	O
enhanced	O
expression	O
of	O
metallothionein	S-geneN
.	O

Among	O
the	O
possible	O
transporters	O
involved	O
in	O
the	O
uptake	O
of	O
Cd	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
and	O
Mn	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
,	O
the	O
expression	O
of	O
ZIP8	S-geneY-C9-2
(	O
Zrt	B-geneY-C9-2
-	I-geneY-C9-2
,	I-geneY-C9-2
Irt	I-geneY-C9-2
-	I-geneY-C9-2
related	I-geneY-C9-2
protein	I-geneY-C9-2
8	E-geneY-C9-2
)	O
,	O
encoded	O
by	O
Slc39a8	S-geneY-C9-2
,	O
showed	O
a	O
marked	O
suppression	O
in	O
both	O
RBL	O
-	O
Cdr	O
and	O
RBL	O
-	O
Mnr	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
ZIP8	S-geneY-C9-2
plays	O
a	O
pivotal	O
role	O
in	O
the	O
transport	O
and	O
toxicity	O
of	O
Cd	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
and	O
Mn	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
in	O
RBL	O
-	O
2H3	O
cells	O
.	O

Caffeine	S-chem-C4-1
inhibits	O
the	O
checkpoint	O
kinase	S-geneN-C4-2
ATM	S-geneY-C4-2
.	O

The	O
basis	O
of	O
many	O
anti	O
-	O
cancer	O
therapies	O
is	O
the	O
use	O
of	O
genotoxic	O
agents	O
that	O
damage	O
DNA	O
and	O
thus	O
kill	O
dividing	O
cells	O
.	O

Agents	O
that	O
cause	O
cells	O
to	O
override	O
the	O
DNA	O
-	O
damage	O
checkpoint	O
are	O
predicted	O
to	O
sensitize	O
cells	O
to	O
killing	O
by	O
genotoxic	O
agents	O
.	O

They	O
have	O
therefore	O
been	O
sought	O
as	O
adjuncts	O
in	O
radiation	O
therapy	O
and	O
chemotherapy	O
.	O

One	O
such	O
compound	O
,	O
caffeine	S-chem
,	O
uncouples	O
cell	O
-	O
cycle	O
progression	O
from	O
the	O
replication	O
and	O
repair	O
of	O
DNA	O
[	O
1	O
]	O
[	O
2	O
]	O
.	O

Caffeine	S-chem
therefore	O
servers	O
as	O
a	O
model	O
compound	O
in	O
establishing	O
the	O
principle	O
that	O
agents	O
that	O
override	O
DNA	O
-	O
damage	O
checkpoints	O
can	O
be	O
used	O
to	O
sensitize	O
cells	O
to	O
the	O
killing	O
effects	O
of	O
genotoxic	O
drugs	O
[	O
3	O
]	O
.	O

But	O
despite	O
more	O
than	O
20	O
years	O
of	O
use	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
caffeine	O
affects	O
the	O
cell	O
cycle	O
and	O
checkpoint	O
responses	O
have	O
not	O
been	O
identified	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
caffeine	O
on	O
the	O
G2	O
/	O
M	O
DNA	O
-	O
damage	O
checkpoint	O
in	O
human	O
cells	O
.	O

We	O
report	O
that	O
the	O
radiation	O
-	O
induced	O
activation	O
of	O
the	O
kinase	S-geneN-C4-2
Cds1	S-geneY-C4-2
[	O
4	O
]	O
(	O
also	O
known	O
as	O
Chk2	S-geneY-C4-2
[	O
5	O
]	O
)	O
is	O
inhibited	O
by	O
caffeine	S-chem-C4-1
in	O
vivo	O
and	O
that	O
ATM	S-geneY-C4-2
kinase	S-geneN-C4-2
activity	O
is	O
directly	O
inhibited	O
by	O
caffeine	S-chem-C4-1
in	O
vitro	O
.	O

Inhibition	O
of	O
ATM	S-geneY-C4-2
provides	O
a	O
molecular	O
explanation	O
of	O
the	O
attenuation	O
of	O
DNA	O
-	O
damage	O
checkpoint	O
responses	O
and	O
for	O
the	O
increased	O
radiosensitivity	O
of	O
caffeine	S-chem-C4-1
-	O
treated	O
cells	O
[	O
6	O
]	O
[	O
7	O
]	O
[	O
8	O
]	O
.	O

Influence	O
of	O
developmental	O
lead	O
exposure	O
on	O
expression	O
of	O
DNA	B-geneN
methyltransferases	E-geneN
and	O
methyl	B-geneN
cytosine	I-geneN
-	I-geneN
binding	I-geneN
proteins	E-geneN
in	O
hippocampus	O
.	O

Developmental	O
exposure	O
to	O
lead	O
(	O
Pb	S-chem
)	O
has	O
adverse	O
effects	O
on	O
cognitive	O
functioning	O
and	O
behavior	O
that	O
can	O
persist	O
into	O
adulthood	O
.	O

Exposures	O
that	O
occur	O
during	O
fetal	O
or	O
early	O
life	O
periods	O
may	O
produce	O
changes	O
in	O
brain	O
related	O
to	O
physiological	O
re	O
-	O
programming	O
from	O
an	O
epigenetic	O
influence	O
such	O
as	O
altered	O
DNA	O
methylation	O
status	O
.	O

Since	O
DNA	O
methylation	O
is	O
regulated	O
by	O
DNA	B-geneN
methyltransferases	E-geneN
and	O
methyl	B-geneN
cytosine	I-geneN
-	I-geneN
binding	I-geneN
proteins	E-geneN
,	O
this	O
study	O
assessed	O
the	O
extent	O
to	O
which	O
developmental	O
Pb	S-chem
exposure	O
might	O
affect	O
expression	O
of	O
these	O
proteins	O
in	O
the	O
hippocampus	O
.	O

Long	O
Evans	O
dams	O
were	O
fed	O
chow	O
with	O
or	O
without	O
added	O
Pb	B-chem
acetate	E-chem
(	O
0	O
,	O
150	O
,	O
375	O
,	O
750	O
ppm	O
)	O
prior	O
to	O
breeding	O
and	O
remained	O
on	O
the	O
same	O
diet	O
through	O
weaning	O
(	O
perinatal	O
exposure	O
group	O
)	O
.	O

Other	O
animals	O
were	O
exposed	O
to	O
the	O
same	O
doses	O
of	O
Pb	S-chem
but	O
exposure	O
started	O
on	O
postnatal	O
day	O
1	O
and	O
continued	O
through	O
weaning	O
(	O
early	O
postnatal	O
exposure	O
group	O
)	O
.	O

All	O
animals	O
were	O
euthanized	O
on	O
day	O
55	O
and	O
hippocampi	O
were	O
removed	O
.	O

Western	O
blot	O
analyses	O
showed	O
significant	O
effects	O
of	O
Pb	S-chem
exposure	O
on	O
DNMT1	S-geneY
,	O
DNMT3a	S-geneY
,	O
and	O
MeCP2	S-geneY
expression	O
,	O
with	O
effects	O
often	O
seen	O
at	O
the	O
lowest	O
level	O
of	O
exposure	O
and	O
modified	O
by	O
sex	O
and	O
developmental	O
window	O
of	O
Pb	S-chem
exposure	O
.	O

These	O
data	O
suggest	O
potential	O
epigenetic	O
effects	O
of	O
developmental	O
Pb	S-chem
exposure	O
on	O
DNA	O
methylation	O
mediated	O
at	O
least	O
in	O
part	O
through	O
dysregulation	O
of	O
methyltransferases	S-geneN
.	O

X	B-geneY
-	I-geneY
box	I-geneY
binding	I-geneY
protein	I-geneY
1	E-geneY
is	O
essential	O
for	O
insulin	S-geneY
regulation	O
of	O
pancreatic	O
alpha	O
cell	O
function	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
(	O
T2D	O
)	O
patients	O
often	O
exhibit	O
hyperglucagonemia	O
despite	O
hyperglycemia	O
suggesting	O
defective	O
α	O
-	O
cell	O
function	O
.	O

While	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
has	O
been	O
suggested	O
to	O
underlie	O
β	O
-	O
cell	O
dysfunction	O
in	O
T2D	O
,	O
its	O
role	O
in	O
α	O
-	O
cell	O
biology	O
remains	O
unclear	O
.	O

X	B-geneY
-	I-geneY
box	I-geneY
binding	I-geneY
protein	I-geneY
1	E-geneY
(	O
XBP1	S-geneY
)	O
is	O
a	O
transcription	O
factor	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
and	O
its	O
deficiency	O
in	O
β	O
-	O
cells	O
has	O
been	O
reported	O
to	O
impair	O
insulin	S-geneN
secretion	O
leading	O
to	O
glucose	S-chem
intolerance	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
XBP1	S-geneY
in	O
α	O
-	O
cells	O
,	O
we	O
created	O
complementary	O
in	O
vivo	O
(	O
α	O
-	O
cell	O
specific	O
XBP1	S-geneY
knockout	O
(	O
αXBPKO	O
)	O
mice	O
)	O
and	O
in	O
vitro	O
(	O
stable	O
XBP1	S-geneY
knock	O
down	O
α	O
-	O
cell	O
line	O
,	O
αXBPKD	O
)	O
models	O
.	O

αXBPKO	O
mice	O
exhibited	O
glucose	S-chem
intolerance	O
,	O
mild	O
insulin	S-geneN
resistance	O
and	O
an	O
inability	O
to	O
suppress	O
glucagon	S-geneY
secretion	O
following	O
glucose	S-chem
stimulation	O
.	O

αXBPKD	O
cells	O
exhibited	O
activation	O
of	O
IRE1	S-geneY
,	O
an	O
upstream	O
activator	O
of	O
XBP1	S-geneY
,	O
leading	O
to	O
phosphorylation	O
of	O
JNK	S-geneN
.	O

Interestingly	O
,	O
insulin	S-geneY
treatment	O
of	O
αXBPKD	O
cells	O
reduced	O
tyrosine	S-chem
phosphorylation	O
of	O
IRS	B-geneY
-	I-geneY
1	E-geneY
(	O
pY	O
(	O
896	O
)	O
)	O
,	O
and	O
phosphorylation	O
of	O
Akt	S-geneN
,	O
while	O
enhancing	O
serine	S-chem
phosphorylation	O
(	O
pS	O
(	O
307	O
)	O
)	O
of	O
IRS	B-geneY
-	I-geneY
1	E-geneY
.	O

Consequently	O
the	O
αXBPKD	O
cells	O
exhibited	O
blunted	O
suppression	O
of	O
glucagon	S-geneY
secretion	O
following	O
insulin	S-geneY
treatment	O
in	O
the	O
presence	O
of	O
high	O
glucose	S-chem
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
XBP1	S-geneY
deficiency	O
in	O
pancreatic	O
α	O
-	O
cells	O
induces	O
altered	O
insulin	S-geneY
signaling	O
and	O
dysfunctional	O
glucagon	S-geneY
secretion	O
.	O

Visualization	O
and	O
virtual	O
screening	O
of	O
the	O
chemical	O
universe	O
database	O
GDB	O
-	O
17	O
.	O

The	O
chemical	O
universe	O
database	O
GDB	O
-	O
17	O
contains	O
166.4	O
billion	O
molecules	O
of	O
up	O
to	O
17	O
atoms	O
of	O
C	S-chem
,	O
N	S-chem
,	O
O	S-chem
,	O
S	S-chem
,	O
and	O
halogens	S-chem
obeying	O
rules	O
for	O
chemical	O
stability	O
,	O
synthetic	O
feasibility	O
,	O
and	O
medicinal	O
chemistry	O
.	O

GDB	O
-	O
17	O
was	O
analyzed	O
using	O
42	O
integer	O
value	O
descriptors	O
of	O
molecular	O
structure	O
which	O
we	O
term	O
``	O
Molecular	O
Quantum	O
Numbers	O
``	O
(	O
MQN	O
)	O
.	O

Principal	O
component	O
analysis	O
and	O
representation	O
of	O
the	O
(	O
PC1	O
,	O
PC2	O
)	O
-	O
plane	O
provided	O
a	O
graphical	O
overview	O
of	O
the	O
GDB	O
-	O
17	O
chemical	O
space	O
.	O

Rapid	O
ligand	O
-	O
based	O
virtual	O
screening	O
(	O
LBVS	O
)	O
of	O
GDB	O
-	O
17	O
using	O
the	O
city	O
-	O
block	O
distance	O
CBD	O
(	O
MQN	O
)	O
as	O
a	O
similarity	O
search	O
measure	O
was	O
enabled	O
by	O
a	O
hashed	O
MQN	O
-	O
fingerprint	O
.	O

LBVS	O
of	O
the	O
entire	O
GDB	O
-	O
17	O
and	O
of	O
selected	O
subsets	O
identified	O
shape	O
similar	O
,	O
scaffold	O
hopping	O
analogs	O
(	O
ROCS	O
>	O
1.6	O
and	O
T	O
(	O
SF	O
)	O
<	O
0.5	O
)	O
of	O
15	O
drugs	O
.	O

Over	O
97	O
%	O
of	O
these	O
analogs	O
occurred	O
within	O
CBD	O
(	O
MQN	O
)	O
≤	O
12	O
from	O
each	O
drug	O
,	O
a	O
constraint	O
which	O
might	O
help	O
focus	O
advanced	O
virtual	O
screening	O
.	O

An	O
MQN	O
-	O
searchable	O
50	O
million	O
subset	O
of	O
GDB	O
-	O
17	O
is	O
publicly	O
available	O
at	O
www.gdb.unibe.ch	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
liver	O
and	O
muscle	O
isoforms	O
of	O
ovine	B-geneY
carnitine	I-geneY
palmitoyltransferase	I-geneY
1	E-geneY
:	O
residues	O
within	O
the	O
N	S-chem
-	O
terminus	O
of	O
the	O
muscle	O
isoform	O
influence	O
the	O
kinetic	O
properties	O
of	O
the	O
enzyme	O
.	O

The	O
nucleotide	S-chem
sequence	O
data	O
reported	O
will	O
appear	O
in	O
DDBJ	O
,	O
EMBL	O
,	O
GenBank	O
(	O
R	O
)	O
and	O
GSDB	O
Nucleotide	S-chem
Sequence	O
Databases	O
;	O
the	O
sequences	O
of	O
ovine	B-geneY
CPT1A	E-geneY
and	O
CPT1B	S-geneY
cDNAs	O
have	O
the	O
accession	O
numbers	O
Y18387	S-geneY
and	O
AJ272435	S-geneY
respectively	O
and	O
the	O
partial	O
adipose	O
tissue	O
and	O
liver	O
CPT1A	S-geneY
clones	O
have	O
the	O
accession	O
numbers	O
Y18830	S-geneY
and	O
Y18829	S-geneY
respectively	O
.	O

Fatty	B-chem
acid	E-chem
and	O
ketone	S-chem
body	O
metabolism	O
differ	O
considerably	O
between	O
monogastric	O
and	O
ruminant	O
species	O
.	O

The	O
regulation	O
of	O
the	O
key	O
enzymes	O
involved	O
may	O
differ	O
accordingly	O
.	O

Carnitine	B-geneY
palmitoyltransferase	I-geneY
1	E-geneY
(	O
CPT	B-geneY
1	E-geneY
)	O
is	O
the	O
key	O
locus	O
for	O
the	O
control	O
of	O
long	O
-	O
chain	O
fatty	B-chem
acid	E-chem
beta	O
-	O
oxidation	O
and	O
liver	O
ketogenesis	O
.	O

Previously	O
we	O
showed	O
that	O
CPT	B-geneN
1	E-geneN
kinetics	O
in	O
sheep	O
and	O
rat	O
liver	O
mitochondria	O
differ	O
.	O

We	O
cloned	O
cDNAs	O
for	O
both	O
isoforms	O
[	O
liver	O
-	O
(	O
L	O
-	O
)	O
and	O
muscle	O
-	O
(	O
M	O
-	O
)	O
]	O
of	O
ovine	B-geneY
CPT	I-geneY
1	E-geneY
in	O
order	O
to	O
elucidate	O
the	O
structural	O
features	O
of	O
these	O
proteins	O
and	O
their	O
genes	O
(	O
CPT1A	S-geneY
and	O
CPT1B	S-geneY
)	O
.	O

Their	O
deduced	O
amino	B-chem
acid	E-chem
sequences	O
show	O
a	O
high	O
degree	O
of	O
conservation	O
compared	O
with	O
orthologues	O
from	O
other	O
mammalian	O
species	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
N	S-chem
-	O
terminus	O
of	O
ovine	B-geneY
M	I-geneY
-	I-geneY
CPT	I-geneY
1	E-geneY
.	O

These	O
differences	O
were	O
also	O
present	O
in	O
bovine	B-geneY
M	I-geneY
-	I-geneY
CPT	I-geneY
1	E-geneY
,	O
whose	O
N	S-chem
-	O
terminal	O
sequence	O
we	O
determined	O
.	O

In	O
addition	O
,	O
the	O
5	O
'	O
-	O
end	O
of	O
the	O
sheep	B-geneY
CPT1B	E-geneY
cDNA	O
suggested	O
a	O
different	O
promoter	O
architecture	O
when	O
compared	O
with	O
previously	O
characterized	O
CPT1B	S-geneY
genes	O
.	O

Northern	O
blotting	O
revealed	O
differences	O
in	O
tissue	O
distribution	O
for	O
both	O
CPT1A	S-geneY
and	O
CPT1B	S-geneY
transcripts	O
compared	O
with	O
other	O
species	O
.	O

In	O
particular	O
,	O
ovine	B-geneY
CPT1B	E-geneY
mRNA	O
was	O
less	O
tissue	O
restricted	O
,	O
and	O
the	O
predominant	O
transcript	O
in	O
the	O
pancreas	O
was	O
CPT1B	S-geneY
.	O

Expression	O
in	O
yeast	O
allowed	O
kinetic	O
characterization	O
of	O
the	O
two	O
native	O
enzymes	O
,	O
and	O
of	O
a	O
chimaera	O
in	O
which	O
the	O
distinctive	O
N	S-chem
-	O
terminal	O
segment	O
of	O
ovine	B-geneY
M	I-geneY
-	I-geneY
CPT	I-geneY
1	E-geneY
was	O
replaced	O
with	O
that	O
from	O
rat	B-geneY
M	I-geneY
-	I-geneY
CPT	I-geneY
1	E-geneY
.	O

The	O
ovine	O
N	S-chem
-	O
terminal	O
segment	O
influences	O
the	O
kinetics	O
of	O
the	O
enzyme	O
for	O
both	O
its	O
substrates	O
,	O
such	O
that	O
the	O
K	O
(	O
m	O
)	O
for	O
palmitoyl	B-chem
-	I-chem
CoA	E-chem
is	O
decreased	O
and	O
that	O
for	O
carnitine	S-chem
is	O
increased	O
for	O
the	O
chimaera	O
,	O
relative	O
to	O
the	O
parental	O
ovine	B-geneY
M	I-geneY
-	I-geneY
CPT	I-geneY
1	E-geneY
.	O

Further	O
characterization	O
of	O
5	B-geneN
-	I-geneN
hydroxytryptamine	I-geneN
receptors	E-geneN
(	O
putative	O
5	B-geneY
-	I-geneY
HT2B	E-geneY
)	O
in	O
rat	O
stomach	O
fundus	O
longitudinal	O
muscle	O
.	O

1	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
isolate	O
and	O
characterize	O
pharmacologically	O
homogeneous	O
populations	O
of	O
5	B-geneN
-	I-geneN
hydroxytryptamine	I-geneN
(	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
receptors	E-geneN
from	O
a	O
possible	O
mixed	O
receptor	O
population	O
mediating	O
concentration	O
of	O
the	O
longitudinal	O
muscle	O
of	O
rat	O
stomach	O
fundus	O
.	O

Our	O
aim	O
was	O
to	O
extend	O
the	O
pharmacological	O
characterization	O
of	O
the	O
5	B-geneY
-	I-geneY
HT2B	E-geneY
receptor	O
which	O
is	O
reported	O
to	O
be	O
expressed	O
in	O
this	O
preparation	O
.	O

2	O
.	O

To	O
minimize	O
spontaneous	O
activity	O
and	O
any	O
influence	O
of	O
circular	O
muscle	O
on	O
the	O
contractile	O
response	O
,	O
narrow	O
(	O
1	O
-	O
1.5	O
x	O
20	O
mm	O
)	O
segments	O
of	O
mucosa	O
-	O
denuded	O
longitudinal	O
muscle	O
were	O
used	O
.	O

Under	O
these	O
conditions	O
,	O
blockade	O
of	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
with	O
pargyline	S-chem-C4-1
(	O
100	O
microM	O
for	O
15	O
min	O
)	O
caused	O
a	O
leftward	O
displacement	O
of	O
concentration	O
-	O
effect	O
curves	O
for	O
both	O
5	B-chem
-	I-chem
methoxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
T	E-chem
)	O
and	O
tryptamine	S-chem
.	O

Neither	O
pargyline	S-chem
nor	O
a	O
number	O
of	O
uptake	O
inhibitors	O
affected	O
responses	O
to	O
5	B-chem
-	I-chem
HT	E-chem
.	O

3	O
.	O

In	O
pargyline	S-chem
pretreated	O
preparations	O
,	O
the	O
order	O
of	O
potency	O
of	O
a	O
number	O
of	O
tryptamine	S-chem
analogues	O
was	O
as	O
follows	O
:	O
5	B-chem
-	I-chem
MeO	I-chem
-	I-chem
T	E-chem
>	O
or	O
=	O
alpha	B-chem
-	I-chem
Me	I-chem
-	I-chem
5	I-chem
-	I-chem
HT	E-chem
>	O
or	O
=	O
5	B-chem
-	I-chem
HT	E-chem
>	O
5	B-chem
-	I-chem
carboxamidotryptamine	E-chem
(	O
5	B-chem
-	I-chem
CT	E-chem
)	O
>	O
tryptamine	S-chem
>	O
2	B-chem
-	I-chem
Me	I-chem
-	I-chem
5	I-chem
-	I-chem
HT	E-chem
.	O

In	O
addition	O
several	O
ligands	O
known	O
to	O
act	O
as	O
agonists	O
at	O
either	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT2A	E-geneY-C5-2
or	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT2C	E-geneY-C5-2
receptors	O
including	O
1	B-chem-C5-1
-	I-chem-C5-1
m	I-chem-C5-1
-	I-chem-C5-1
chlorophenylpiperazine	E-chem-C5-1
(	O
m	B-chem-C5-1
-	I-chem-C5-1
CPP	E-chem-C5-1
)	O
,	O
Ru	B-chem-C5-1
24969	E-chem-C5-1
,	O
MK	B-chem-C5-1
212	E-chem-C5-1
and	O
SCH	B-chem-C5-1
23390	E-chem-C5-1
were	O
also	O
agonists	O
in	O
rat	O
fundus	O
whilst	O
sumatriptan	S-chem
,	O
renzapride	S-chem
and	O
8	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
di	I-chem
-	I-chem
n	I-chem
-	I-chem
propylamino	I-chem
)	I-chem
tetralin	E-chem
(	O
8	B-chem
-	I-chem
OH	I-chem
-	I-chem
DPAT	E-chem
)	O
were	O
very	O
weak	O
or	O
inactive	O
.	O

With	O
the	O
exception	O
of	O
2	B-chem
-	I-chem
Me	I-chem
-	I-chem
5	I-chem
-	I-chem
HT	E-chem
and	O
m	B-chem
-	I-chem
CPP	E-chem
,	O
most	O
agonists	O
produced	O
monophasic	O
concentration	O
-	O
effect	O
curves	O
consistent	O
with	O
an	O
interaction	O
at	O
a	O
single	O
site	O
.	O

High	O
concentrations	O
of	O
2	O
-	O
Me	O
-	O
5	O
-	O
HT	O
evoked	O
relaxations	O
which	O
were	O
blocked	O
by	O
phentolamine	O
(	O
1	O
MicroM	O
)	O
suggesting	O
an	O
interaction	O
with	O
alpha	B-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O
m	O
-	O
CPP	O
often	O
evoked	O
biphasic	O
concentration	O
-	O
effect	O
curves	O
with	O
a	O
second	O
contractile	O
phase	O
which	O
was	O
insensitive	O
to	O
yohimbine	S-chem
at	O
concentrations	O
higher	O
than	O
required	O
for	O
antagonism	O
of	O
responses	O
to	O
5	B-chem
-	I-chem
HT.4	O
.	O

LY	B-chem
53857	E-chem
,	O
methiothepin	S-chem
,	O
methysergide	S-chem
,	O
ritanserin	S-chem
and	O
ICI	B-chem
170809	E-chem
were	O
potent	O
but	O
non	O
-	O
surmountable	O
antagonists	O
of	O
5	B-chem
-	I-chem
HT	E-chem
in	O
rat	O
fundus	O
.	O

In	O
contrast	O
,	O
several	O
ligands	O
behaved	O
as	O
surmountable	O
antagonists	O
with	O
the	O
following	O
order	O
of	O
potency	O
:	O
rauwolscine	S-chem
>	O
yohimbine	S-chem
=	O
mesulergine	S-chem
>	O
mianserin	S-chem
=	O
SB	B-chem
204070	E-chem
>	O
WY	B-chem
26703	E-chem
>	O
SB	B-chem
200646	E-chem
>	O
pirenpirone	S-chem
>	O
renzapride	S-chem
.	O

DAU	B-chem
6285	E-chem
,	O
granisetron	S-chem
,	O
spiperone	S-chem
,	O
ketanserin	S-chem
,	O
phentolamine	S-chem
and	O
GR	B-chem
127935	E-chem
did	O
not	O
affect	O
responses	O
to	O
5	B-chem
-	I-chem
HT	E-chem
at	O
concentrations	O
up	O
to	O
1	O
pM	O
.	O

The	O
agonist	O
and	O
concentration	O
independent	O
profile	O
of	O
antagonism	O
supported	O
a	O
single	O
site	O
interaction	O
for	O
both	O
agonists	O
and	O
antagonists.5	O
.	O

We	O
conclude	O
that	O
despite	O
small	O
differences	O
concerning	O
the	O
enantiomeric	O
selectivity	O
and	O
affinity	O
of	O
rauwolscine	S-chem
and	O
yohimbine	S-chem
,	O
the	O
close	O
pharmacological	O
identity	O
of	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
in	O
rat	O
stomach	O
fundus	O
and	O
the	O
recently	O
cloned	O
5	B-geneY
-	I-geneY
HT2B	E-geneY
receptor	O
is	O
maintained	O
.	O

SB	B-chem
200646	E-chem
,	O
which	O
demonstrates	O
some	O
selectivity	O
for	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
in	O
rat	O
stomach	O
fundus	O
,	O
should	O
provide	O
a	O
useful	O
ligand	O
for	O
confirmation	O
of	O
this	O
view	O
and	O
allow	O
discrimination	O
of	O
5	B-geneY
-	I-geneY
HT2B	E-geneY
function	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cell	O
biology	O
of	O
molybdenum	S-chem
.	O

The	O
transition	O
element	O
molybdenum	S-chem
(	O
Mo	S-chem
)	O
is	O
of	O
essential	O
importance	O
for	O
(	O
nearly	O
)	O
all	O
biological	O
systems	O
as	O
it	O
is	O
required	O
by	O
enzymes	O
catalyzing	O
diverse	O
key	O
reactions	O
in	O
the	O
global	O
carbon	S-chem
,	O
sulfur	S-chem
and	O
nitrogen	S-chem
metabolism	O
.	O

The	O
metal	O
itself	O
is	O
biologically	O
inactive	O
unless	O
it	O
is	O
complexed	O
by	O
a	O
special	O
cofactor	O
.	O

With	O
the	O
exception	O
of	O
bacterial	B-geneN
nitrogenase	E-geneN
,	O
where	O
Mo	S-chem
is	O
a	O
constituent	O
of	O
the	O
FeMo	S-chem
-	O
cofactor	O
,	O
Mo	S-chem
is	O
bound	O
to	O
a	O
pterin	S-chem
,	O
thus	O
forming	O
the	O
molybdenum	S-chem
cofactor	O
(	O
Moco	O
)	O
which	O
is	O
the	O
active	O
compound	O
at	O
the	O
catalytic	O
site	O
of	O
all	O
other	O
Mo	S-chem
-	O
enzymes	O
.	O

In	O
eukaryotes	O
,	O
the	O
most	O
prominent	O
Mo	S-chem
-	O
enzymes	O
are	O
(	O
1	O
)	O
sulfite	B-geneY-C9-2
oxidase	E-geneY-C9-2
,	O
which	O
catalyzes	O
the	O
final	O
step	O
in	O
the	O
degradation	O
of	O
sulfur	S-chem-C9-1
-	O
containing	O
amino	B-chem
acids	E-chem
and	O
is	O
involved	O
in	O
detoxifying	O
excess	O
sulfite	S-chem
,	O
(	O
2	O
)	O
xanthine	B-geneY
dehydrogenase	E-geneY
,	O
which	O
is	O
involved	O
in	O
purine	S-chem
catabolism	O
and	O
reactive	O
oxygen	S-chem
production	O
,	O
(	O
3	O
)	O
aldehyde	B-geneY
oxidase	E-geneY
,	O
which	O
oxidizes	O
a	O
variety	O
of	O
aldehydes	S-chem
and	O
is	O
essential	O
for	O
the	O
biosynthesis	O
of	O
the	O
phytohormone	O
abscisic	B-chem
acid	E-chem
,	O
and	O
in	O
autotrophic	O
organisms	O
also	O
(	O
4	O
)	O
nitrate	B-geneN
reductase	E-geneN
,	O
which	O
catalyzes	O
the	O
key	O
step	O
in	O
inorganic	O
nitrogen	S-chem
assimilation	O
.	O

All	O
Mo	S-chem
-	O
enzymes	O
,	O
except	O
plant	B-geneN
sulfite	I-geneN
oxidase	E-geneN
,	O
need	O
at	O
least	O
one	O
more	O
redox	O
active	O
center	O
,	O
many	O
of	O
them	O
involving	O
iron	S-chem
in	O
electron	O
transfer	O
.	O

The	O
biosynthesis	O
of	O
Moco	O
involves	O
the	O
complex	O
interaction	O
of	O
six	O
proteins	O
and	O
is	O
a	O
process	O
of	O
four	O
steps	O
,	O
which	O
also	O
includes	O
iron	O
as	O
well	O
as	O
copper	S-chem
in	O
an	O
indispensable	O
way	O
.	O

Moco	O
as	O
released	O
after	O
synthesis	O
is	O
likely	O
to	O
be	O
distributed	O
to	O
the	O
apoproteins	O
of	O
Mo	S-chem
-	O
enzymes	O
by	O
putative	O
Moco	O
-	O
carrier	O
proteins	O
.	O

Xanthine	B-geneY
dehydrogenase	E-geneY
and	O
aldehyde	B-geneY
oxidase	E-geneY
,	O
but	O
not	O
sulfite	B-geneY
oxidase	E-geneY
and	O
nitrate	B-geneN
reductase	E-geneN
,	O
require	O
the	O
post	O
-	O
translational	O
sulfuration	O
of	O
their	O
Mo	S-chem
-	O
site	O
for	O
becoming	O
active	O
.	O

This	O
final	O
maturation	O
step	O
is	O
catalyzed	O
by	O
a	O
Moco	B-geneY
-	I-geneY
sulfurase	E-geneY
enzyme	O
,	O
which	O
mobilizes	O
sulfur	S-chem
from	O
l	B-chem
-	I-chem
cysteine	E-chem
in	O
a	O
pyridoxal	B-chem
phosphate	E-chem
-	O
dependent	O
manner	O
as	O
typical	O
for	O
cysteine	B-geneN
desulfurases	E-geneN
.	O

A	O
phase	O
-	O
1	O
trial	O
of	O
bexarotene	S-chem
and	O
denileukin	O
diftitox	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
cutaneous	O
T	O
-	O
cell	O
lymphoma	O
.	O

Denileukin	O
diftitox	O
,	O
a	O
genetically	O
engineered	O
fusion	O
protein	O
combining	O
the	O
enzymatically	O
active	O
domains	O
of	O
diphtheria	O
toxin	O
and	O
the	O
full	O
-	O
length	O
sequence	O
for	O
interleukin	B-geneY
-	I-geneY
2	E-geneY
(	O
IL	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
efficiently	O
targets	O
lymphoma	O
cells	O
expressing	O
the	O
high	O
-	O
affinity	O
IL	B-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
(	O
IL	B-geneN
-	I-geneN
2R	E-geneN
)	O
consisting	O
of	O
the	O
alpha	O
/	O
p55	S-geneY
/	O
CD25	S-geneY
,	O
beta	O
/	O
p75	S-geneY
/	O
CD122	S-geneY
,	O
and	O
gamma	O
/	O
p64	S-geneY
/	O
CD132	S-geneY
chains	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
the	O
retinoid	B-geneN
X	I-geneN
receptor	E-geneN
(	O
RXR	S-geneN
)	O
retinoid	O
,	O
bexarotene	S-chem-C3-1
,	O
at	O
biologically	O
relevant	O
concentrations	O
of	O
10	O
(	O
-	O
6	O
)	O
M	O
to	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
upregulated	O
both	O
the	O
p55	S-geneY-C3-2
and	O
p75	S-geneY-C3-2
subunits	O
of	O
the	O
IL	B-geneN-C3-2
-	I-geneN-C3-2
2R	E-geneN-C3-2
and	O
enhanced	O
5	O
-	O
to	O
10	O
-	O
fold	O
the	O
susceptibility	O
of	O
T	O
-	O
cell	O
leukemia	O
cells	O
to	O
denileukin	O
diftitox	O
.	O

To	O
determine	O
whether	O
this	O
biomodulatory	O
effect	O
could	O
be	O
recapitulated	O
in	O
vivo	O
,	O
we	O
treated	O
14	O
patients	O
with	O
relapsed	O
or	O
refractory	O
cutaneous	O
T	O
-	O
cell	O
lymphoma	O
with	O
escalating	O
doses	O
of	O
bexarotene	S-chem
(	O
75	O
mg	O
/	O
day	O
-	O
300	O
mg	O
/	O
day	O
)	O
and	O
denileukin	O
diftitox	O
(	O
18	O
mcg	O
/	O
kg	O
per	O
day	O
x	O
3	O
days	O
every	O
21	O
days	O
)	O
in	O
a	O
phase	O
1	O
trial	O
.	O

Overall	O
response	O
was	O
67	O
%	O
(	O
4	O
complete	O
responses	O
,	O
4	O
partial	O
responses	O
)	O
.	O

Modulation	O
of	O
IL	B-geneN
-	I-geneN
2R	E-geneN
expression	O
was	O
observed	O
at	O
or	O
above	O
a	O
bexarotene	S-chem
dose	O
of	O
150	O
mg	O
/	O
day	O
.	O

Four	O
patients	O
experienced	O
grade	O
2	O
or	O
3	O
leukopenia	O
,	O
and	O
2	O
had	O
grade	O
4	O
lymphopenia	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
combination	O
of	O
denileukin	O
diftitox	O
and	O
bexarotene	S-chem
is	O
well	O
tolerated	O
and	O
that	O
even	O
low	O
doses	O
(	O
150	O
mg	O
/	O
day	O
)	O
of	O
bexarotene	S-chem-C3-1
are	O
capable	O
of	O
in	O
vivo	O
upregulation	O
of	O
CD25	S-geneY-C3-2
expression	O
on	O
circulating	O
leukemia	O
cells	O
.	O

Reelin	S-geneY
down	O
-	O
regulation	O
in	O
mice	O
and	O
psychosis	O
endophenotypes	O
.	O

Reelin	S-geneY
,	O
a	O
large	O
glycoprotein	O
secreted	O
by	O
telencephalic	O
GABAergic	O
neurons	O
,	O
plays	O
an	O
important	O
role	O
in	O
neuronal	O
guidance	O
embryonically	O
and	O
in	O
synaptic	O
plasticity	O
postnatally	O
.	O

The	O
reeler	O
heterozygous	O
mouse	O
(	O
+	O
/	O
rl	O
)	O
appears	O
superficially	O
normal	O
but	O
has	O
been	O
of	O
interest	O
as	O
an	O
animal	O
model	O
for	O
psychosis	O
since	O
the	O
discovery	O
that	O
reelin	S-geneY
is	O
50	O
%	O
down	O
-	O
regulated	O
in	O
postmortem	O
psychotic	O
brain	O
.	O

Brain	O
abnormalities	O
in	O
+	O
/	O
rl	O
are	O
similar	O
to	O
psychotic	O
brain	O
and	O
include	O
a	O
reduction	O
in	O
glutamic	B-geneY
acid	I-geneY
de	I-geneY
carboxylase	I-geneY
67	E-geneY
(	O
GAD67	S-geneY
)	O
,	O
dendritic	O
arbors	O
and	O
spine	O
density	O
in	O
cortex	O
and	O
hippocampus	O
,	O
and	O
abnormalities	O
in	O
synaptic	O
function	O
including	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
.	O

In	O
spite	O
of	O
these	O
abnormalities	O
,	O
behavioral	O
abnormalities	O
in	O
+	O
/	O
rl	O
are	O
subtle	O
and	O
controversial	O
.	O

Recent	O
findings	O
indicate	O
that	O
the	O
reelin	B-geneN
(	I-geneN
RELN	I-geneN
)	I-geneN
and	I-geneN
GAD67	I-geneN
promoters	E-geneN
are	O
hypermethylated	O
in	O
GABAergic	O
neurons	O
of	O
psychotic	O
postmortem	O
brain	O
and	O
that	O
DNA	B-geneY
methyltransferase	I-geneY
1	E-geneY
(	O
DNMT1	S-geneY
)	O
is	O
up	O
-	O
regulated	O
.	O

Hypermethlyation	O
of	O
RELN	B-geneN-C3-2
and	I-geneN-C3-2
GAD67	I-geneN-C3-2
promoters	E-geneN-C3-2
can	O
be	O
induced	O
by	O
treating	O
mice	O
with	O
methionine	S-chem-C3-1
,	O
and	O
these	O
mice	O
display	O
brain	O
and	O
behavioral	O
abnormalities	O
similar	O
to	O
+	O
/	O
rl	O
.	O

Thus	O
,	O
an	O
animal	O
model	O
that	O
combines	O
genetic	O
heterozygocity	O
with	O
epigenesis	O
holds	O
promise	O
for	O
understanding	O
the	O
role	O
of	O
Reelin	S-geneY
down	O
-	O
regulation	O
in	O
psychosis	O
.	O

A	O
DPYD	S-geneY
Variant	O
(	O
Y186C	S-geneN
)	O
in	O
Individuals	O
of	O
African	O
Ancestry	O
Is	O
Associated	O
With	O
Reduced	O
DPD	S-geneY
Enzyme	O
Activity	O
.	O

5	B-chem
-	I-chem
Fluorouracil	E-chem
(	O
5	B-chem
-	I-chem
FU	E-chem
)	O
is	O
used	O
to	O
treat	O
many	O
aggressive	O
cancers	O
,	O
such	O
as	O
those	O
of	O
the	O
colon	O
,	O
breast	O
,	O
and	O
head	O
and	O
neck	O
.	O

The	O
responses	O
to	O
5	B-chem
-	I-chem
FU	E-chem
,	O
with	O
respect	O
to	O
both	O
toxicity	O
and	O
efficacy	O
,	O
vary	O
among	O
racial	O
groups	O
,	O
potentially	O
because	O
of	O
variability	O
in	O
the	O
activity	O
levels	O
of	O
the	O
enzyme	O
dihydropyrimidine	B-geneY
dehydrogenase	E-geneY
(	O
DPD	S-geneY
,	O
encoded	O
by	O
the	O
DPYD	S-geneY
gene	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
genetic	O
associations	O
between	O
DPYD	S-geneY
variations	O
and	O
circulating	O
mononuclear	O
-	O
cell	O
DPD	S-geneY
enzyme	O
activity	O
were	O
evaluated	O
in	O
94	O
African	O
-	O
American	O
and	O
81	O
European	O
-	O
American	O
volunteers	O
.	O

The	O
DPYD	S-geneY
-	O
Y186C	S-geneN
variant	O
was	O
unique	O
to	O
individuals	O
of	O
African	O
ancestry	O
,	O
and	O
DPD	S-geneY
activity	O
was	O
46	O
%	O
lower	O
in	O
carriers	O
as	O
compared	O
with	O
noncarriers	O
(	O
279	O
±	O
35	O
vs	O
.	O

514	O
±	O
168	O
pmol	O
5	O
-	O
FU	B-chem
min	O
(	O
-	O
1	O
)	O
mg	O
(	O
-	O
1	O
)	O
;	O
P	O
=	O
0.00029	O
)	O
.	O

In	O
this	O
study	O
,	O
26	O
%	O
of	O
the	O
African	O
Americans	O
with	O
reduced	O
DPD	S-geneY
activity	O
were	O
carriers	O
of	O
Y186C	S-geneN
.	O

In	O
the	O
African	O
-	O
American	O
cohort	O
,	O
after	O
excluding	O
Y186C	S-geneN
carriers	O
,	O
homozygous	O
carriers	O
of	O
C29R	S-geneN
showed	O
27	O
%	O
higher	O
DPD	S-geneY
activity	O
as	O
compared	O
with	O
noncarriers	O
(	O
609	O
±	O
152	O
and	O
480	O
±	O
152	O
pmol	O
5	O
-	O
FU	O
min	B-chem
(	E-chem
-	O
1	O
)	O
mg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
;	O
P	O
=	O
0.013	O
)	O
.Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
advance	O
online	O
publication	O
1	O
May	O
2013.	O
doi	O
:	O
10.1038	O
/	O
clpt.2013.69	O
.	O

[	O
Inactivated	B-geneY
factor	I-geneY
VII	E-geneY
exercises	O
a	O
powerful	O
antithrombotic	O
activity	O
in	O
an	O
experimental	O
model	O
of	O
recurrent	O
arterial	O
thrombosis	O
]	O
.	O

The	O
extrinsic	O
coagulation	O
pathway	O
is	O
activated	O
when	O
tissue	B-geneY
factor	E-geneY
(	O
TF	S-geneY
)	O
is	O
exposed	O
as	O
a	O
consequence	O
of	O
arterial	O
damage	O
.	O

TF	S-geneY
binds	O
to	O
factor	B-geneY
VII	E-geneY
(	O
FVII	S-geneY
)	O
or	O
activated	B-geneY
FVII	E-geneY
(	O
FVIIa	S-geneY
)	O
,	O
generating	O
a	O
complex	O
that	O
activates	O
both	O
FX	S-geneY
and	O
FIX	S-geneY
,	O
ultimately	O
leading	O
to	O
thrombin	S-geneY
formation	O
.	O

To	O
determine	O
whether	O
inhibition	O
of	O
FVII	S-geneY
binding	O
to	O
TF	S-geneY
would	O
result	O
in	O
antithrombotic	O
effects	O
,	O
active	B-geneY
site	I-geneY
-	I-geneY
blocked	I-geneY
FVIIa	E-geneY
(	O
FVIIai	S-geneY
)	O
was	O
used	O
in	O
a	O
rabbit	O
model	O
of	O
intravascular	O
thrombus	O
formation	O
.	O

In	O
addition	O
,	O
to	O
study	O
the	O
interaction	O
between	O
extrinsic	O
coagulation	O
pathway	O
activation	O
and	O
platelet	O
aggregation	O
,	O
in	O
the	O
same	O
model	O
of	O
intravascular	O
thrombus	O
formation	O
,	O
recombinant	O
human	B-geneY
FVIIa	E-geneY
was	O
administered	O
in	O
antiplatelet	O
-	O
treated	O
rabbits	O
.	O

Cyclic	O
flow	O
variations	O
(	O
CFVs	O
)	O
,	O
due	O
to	O
recurrent	O
thrombus	O
formation	O
,	O
were	O
initiated	O
by	O
placing	O
an	O
external	O
constrictor	O
around	O
the	O
endothelially	O
-	O
injured	O
rabbit	O
carotid	O
arteries	O
(	O
Folt	O
's	O
model	O
)	O
.	O

Carotid	O
blood	O
flow	O
was	O
measured	O
continuously	O
by	O
a	O
Doppler	O
flow	O
probe	O
placed	O
proximally	O
to	O
the	O
constrictor	O
.	O

CFVs	O
were	O
induced	O
in	O
29	O
New	O
Zealand	O
White	O
rabbits	O
.	O

After	O
CFVs	O
were	O
observed	O
for	O
30	O
min	O
,	O
the	O
animals	O
were	O
randomly	O
divided	O
in	O
four	O
groups	O
:	O
5	O
animals	O
received	O
via	O
a	O
small	O
catheter	O
(	O
26G	O
)	O
placed	O
proximally	O
to	O
the	O
stenosis	O
,	O
an	O
intra	O
-	O
arterial	O
infusion	O
of	O
human	B-geneY
recombinant	I-geneY
FVIIai	E-geneY
(	O
0.1	O
mg	O
/	O
kg	O
/	O
min	O
for	O
10	O
min	O
)	O
;	O
9	O
animals	O
received	O
AP	O
-	O
1	O
,	O
a	O
monoclonal	O
antibody	O
against	O
rabbit	B-geneY
TF	E-geneY
(	O
0.1	O
mg	O
/	O
kg	O
i.v	O
.	O
bolus	O
)	O
;	O
7	O
animals	O
received	O
ridogrel	O
,	O
a	O
dual	O
thromboxane	B-geneY
A2	I-geneY
synthetase	E-geneY
inhibitor	O
and	O
thromboxane	B-geneY
A2	I-geneY
receptor	E-geneY
antagonist	O
(	O
10	O
mg	O
/	O
kg	O
i.v	O
.	O
bolus	O
)	O
;	O
finally	O
,	O
8	O
rabbits	O
received	O
aurintrycarboxilic	B-chem-C4-1
acid	E-chem-C4-1
(	O
ATA	S-chem-C4-1
)	O
,	O
an	O
inhibitor	O
of	O
platelet	O
glycoprotein	B-geneN-C4-2
Ib	E-geneN-C4-2
/	O
von	B-geneY-C4-2
Willebrand	I-geneY-C4-2
factor	E-geneY-C4-2
interaction	O
(	O
10	O
mg	O
/	O
kg	O
i.v	O
.	O
bolus	O
)	O
.	O

FVIIai	S-geneY
abolished	O
CFVs	O
in	O
5	O
of	O
5	O
animals	O
(	O
CFV	O
frequency	O
minutes	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0.05	O
;	O
carotid	O
blood	O
flow	O
velocity	O
minutes	O
106	O
+	O
/	O
-	O
9	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
)	O
.	O

AP	O
-	O
1	O
abolished	O
CFVs	O
in	O
7	O
of	O
9	O
animals	O
(	O
CFV	O
frequency	O
minutes	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0.05	O
;	O
carotid	O
blood	O
flow	O
velocity	O
minutes	O
58	O
+	O
/	O
-	O
35	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
)	O
.	O

Finally	O
,	O
in	O
all	O
the	O
animals	O
receiving	O
ridogrel	O
or	O
ATA	S-chem
CFVs	O
were	O
abolished	O
(	O
CFV	O
frequency	O
0	O
cycles	O
/	O
hour	O
;	O
p	O
<	O
0.05	O
in	O
both	O
groups	O
;	O
carotid	O
blood	O
flow	O
velocity	O
,	O
respectively	O
62	O
+	O
/	O
-	O
32	O
and	O
66	O
+	O
/	O
-	O
40	O
%	O
of	O
the	O
baseline	O
values	O
;	O
NS	O
vs	O
baseline	O
in	O
both	O
groups	O
)	O
.	O

Thirty	O
minutes	O
following	O
inhibition	O
of	O
CFVs	O
,	O
in	O
the	O
FVIIai	S-geneY
treated	O
rabbits	O
,	O
human	B-geneY
recombinant	I-geneY
FVIIa	E-geneY
was	O
infused	O
,	O
via	O
the	O
small	O
catheter	O
placed	O
proximally	O
to	O
the	O
stenosis	O
,	O
at	O
the	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
/	O
min	O
for	O
10	O
min	O
.	O

In	O
the	O
other	O
three	O
groups	O
,	O
FVIIa	S-geneY
,	O
at	O
the	O
same	O
dose	O
,	O
was	O
infused	O
i.v	O
.	O

Infusion	O
of	O
FVIIa	S-geneY
restored	O
CFVs	O
in	O
all	O
FVIIai	S-geneY
treated	O
animals	O
and	O
in	O
6	O
of	O
7	O
AP	O
-	O
1	O
treated	O
animals	O
,	O
thus	O
indicating	O
that	O
AP	O
-	O
1	O
and	O
FVIIai	S-geneY
bindings	O
to	O
TF	S-geneY
was	O
competitive	O
and	O
was	O
replaced	O
by	O
FVIIa	S-geneY
.	O

Infusion	O
of	O
FVIIa	S-geneY
failed	O
to	O
restore	O
CFVs	O
in	O
ridogrel	O
e	O
ATA	S-chem
treated	O
rabbits	O
(	O
1	O
of	O
7	O
and	O
0	O
of	O
8	O
rabbits	O
,	O
respectively	O
)	O
,	O
showing	O
that	O
activation	O
of	O
extrinsic	O
coagulation	O
by	O
FVIIa	S-geneY
was	O
overcome	O
by	O
inhibition	O
of	O
platelet	O
function	O
.	O

Activated	O
partial	O
thromboplastin	O
time	O
,	O
and	O
ex	O
vivo	O
platelet	O
aggregation	O
in	O
response	O
to	O
ADP	S-chem
and	O
thrombin	S-geneY
,	O
were	O
not	O
different	O
after	O
FVIIai	S-geneY
infusion	O
,	O
while	O
prothrombin	O
time	O
was	O
slightly	O
but	O
significantly	O
prolonged	O
as	O
compared	O
to	O
baseline	O
values	O
.	O

Thus	O
,	O
FVII	B-geneN
-	I-geneN
VIIa	E-geneN
plays	O
an	O
important	O
role	O
in	O
initiating	O
thrombus	O
formation	O
in	O
vivo	O
.	O

Administration	O
of	O
FVIIai	S-geneY
exerts	O
a	O
potent	O
antithrombotic	O
effects	O
in	O
this	O
model	O
without	O
affecting	O
systemic	O
coagulation	O
.	O

In	O
addition	O
,	O
in	O
this	O
model	O
platelets	O
exert	O
an	O
important	O
role	O
in	O
arterial	O
thrombosis	O
,	O
since	O
in	O
the	O
presence	O
of	O
inhibition	O
of	O
platelet	O
function	O
,	O
activation	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
failed	O
to	O
restore	O
thrombus	O
formation	O
.	O

Neurotoxicity	O
of	O
``	O
ecstasy	O
``	O
and	O
its	O
metabolites	O
in	O
human	O
dopaminergic	O
differentiated	O
SH	O
-	O
SY5Y	O
cells	O
.	O

``	O
Ecstasy	O
``	O
(	I-chem
3,4	I-chem
-	I-chem
methylenedioxymethamphetamine	O
or	B-chem
MDMA	O
)	O
is	O
a	O
widely	O
abused	O
recreational	O
drug	O
,	O
reported	O
to	O
produce	O
neurotoxic	O
effects	O
,	O
both	O
in	O
laboratory	O
animals	O
and	O
in	O
humans	O
.	O

MDMA	S-chem
metabolites	O
can	O
be	O
major	O
contributors	O
for	O
MDMA	S-chem
neurotoxicity	O
.	O

This	O
work	O
studied	O
the	O
neurotoxicity	O
of	O
MDMA	S-chem
and	O
its	O
catechol	S-chem
metabolites	O
,	O
α	B-chem
-	I-chem
methyldopamine	E-chem
(	O
α	B-chem
-	I-chem
MeDA	E-chem
)	O
and	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
α	I-chem
-	I-chem
methyldopamine	E-chem
(	O
N	B-chem
-	I-chem
Me	I-chem
-	I-chem
α	I-chem
-	I-chem
MeDA	E-chem
)	O
in	O
human	O
dopaminergic	O
SH	O
-	O
SY5Y	O
cells	O
differentiated	O
with	O
retinoic	B-chem
acid	E-chem
and	O
12	B-chem
-	I-chem
O	I-chem
-	I-chem
tetradecanoyl	I-chem
-	I-chem
phorbol	I-chem
-	I-chem
13	I-chem
-	I-chem
acetate	E-chem
.	O

Differentiation	O
led	O
to	O
SH	O
-	O
SY5Y	O
neurons	O
with	O
higher	O
ability	O
to	O
accumulate	O
dopamine	S-chem
and	O
higher	O
resistance	O
towards	O
dopamine	S-chem
neurotoxicity	O
.	O

MDMA	S-chem
catechol	S-chem
metabolites	O
were	O
neurotoxic	O
to	O
SH	O
-	O
SY5Y	O
neurons	O
,	O
leading	O
to	O
caspase	B-geneY
3	E-geneY
-	O
independent	O
cell	O
death	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

MDMA	S-chem
did	O
not	O
show	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
death	O
.	O

Pre	O
-	O
treatment	O
with	O
the	O
antioxidant	O
and	O
glutathione	S-chem
precursor	O
,	O
N	B-chem
-	I-chem
acetylcysteine	E-chem
(	O
NAC	S-chem
)	O
,	O
resulted	O
in	O
strong	O
protection	O
against	O
the	O
MDMA	S-chem
metabolites	O
'	O
neurotoxicity	O
.	O

Neither	O
the	O
superoxide	S-chem
radical	O
scavenger	O
,	O
tiron	O
,	O
nor	O
the	O
inhibitor	O
of	O
the	O
dopamine	B-geneY-C4-2
(	I-geneY-C4-2
DA	I-geneY-C4-2
)	I-geneY-C4-2
transporter	E-geneY-C4-2
,	O
GBR	B-chem-C4-1
12909	E-chem-C4-1
,	O
prevented	O
the	O
metabolites	O
'	O
toxicity	O
.	O

Cells	O
exposed	O
to	O
α	B-chem
-	I-chem
MeDA	E-chem
showed	O
an	O
increase	O
in	O
intracellular	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
levels	O
,	O
which	O
,	O
at	O
the	O
48	O
h	O
time	O
-	O
point	O
,	O
was	O
not	O
dependent	O
in	O
the	O
activity	O
increase	O
of	O
γ	B-geneY
-	I-geneY
glutamylcysteine	I-geneY
synthetase	E-geneY
(	O
γ	B-geneY
-	I-geneY
GCS	E-geneY
)	O
,	O
revealing	O
a	O
possible	O
transient	O
effect	O
.	O

Importantly	O
,	O
pre	O
-	O
treatment	O
with	O
buthionine	B-chem-C4-1
sulfoximine	E-chem-C4-1
(	O
BSO	S-chem-C4-1
)	O
,	O
an	O
inhibitor	O
of	O
γ	B-geneY-C4-2
-	I-geneY-C4-2
GCS	E-geneY-C4-2
,	O
prevented	O
α	B-chem
-	I-chem
MeDA	E-chem
induced	O
increase	O
in	O
GSH	S-chem
levels	O
,	O
but	O
did	O
not	O
augment	O
this	O
metabolite	O
cytotoxicity	O
.	O

Even	O
so	O
,	O
BSO	S-chem
pre	O
-	O
treatment	O
abolished	O
NAC	S-chem
protective	O
effects	O
against	O
α	B-chem
-	I-chem
MeDA	E-chem
neurotoxicity	O
,	O
which	O
were	O
,	O
at	O
least	O
partially	O
,	O
due	O
to	O
GSH	S-chem
de	O
novo	O
synthesis	O
.	O

Inversely	O
,	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
BSO	S-chem
augmented	O
N	B-chem
-	I-chem
Me	I-chem
-	I-chem
α	I-chem
-	I-chem
MeDA	E-chem
-	O
induced	O
neurotoxicity	O
,	O
but	O
only	O
slightly	O
affected	O
NAC	S-chem
neuroprotection	O
.	O

In	O
conclusion	O
,	O
MDMA	S-chem
catechol	S-chem
metabolites	O
promote	O
differential	O
toxic	O
effects	O
to	O
differentiated	O
dopaminergic	O
human	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
induce	O
apoptosis	O
in	O
association	O
with	O
activation	O
of	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
in	O
rheumatoid	O
synovial	O
cells	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
have	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
lines	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
NSAIDs	O
on	O
the	O
growth	O
and	O
apoptosis	O
of	O
synovial	O
cells	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
analyzed	O
the	O
activation	O
of	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
PPARgamma	S-geneY
)	O
as	O
a	O
possible	O
mechanism	O
of	O
action	O
of	O
NSAIDs	O
.	O

Cell	O
proliferation	O
and	O
viability	O
were	O
assessed	O
from	O
5	B-chem
-	I-chem
bromo	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyuridine	E-chem
incorporation	O
and	O
by	O
4	B-chem
-	I-chem
[	I-chem
3	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
iodophenyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
nitrophenyl	I-chem
)	I-chem
-	I-chem
2H	I-chem
-	I-chem
5	I-chem
-	I-chem
tetrazolio	I-chem
]	I-chem
-	I-chem
1,3	I-chem
-	I-chem
benzene	I-chem
disulfonate	E-chem
(	O
WST	B-chem
-	I-chem
1	E-chem
)	O
assay	O
,	O
respectively	O
.	O

The	O
apoptosis	O
of	O
synovial	O
cells	O
was	O
identified	O
by	O
DNA	O
fragmentation	O
assay	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
-	O
end	O
labeling	O
assay	O
.	O

Indometacin	S-chem
,	O
diclofenac	S-chem
,	O
oxaprozin	S-chem
,	O
and	O
zaltoprofen	S-chem
reduced	O
cell	O
proliferation	O
and	O
induced	O
apoptotic	O
cell	O
death	O
in	O
synovial	O
cells	O
,	O
whereas	O
ketoprofen	S-chem
and	O
acetaminophen	S-chem
did	O
not	O
.	O

N	B-chem-C4-1
-	I-chem-C4-1
[	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
cyclohexyloxyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
nitrophenyl	I-chem-C4-1
]	I-chem-C4-1
-	I-chem-C4-1
methanesulfonamide	E-chem-C4-1
(	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
)	O
,	O
a	O
selective	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
also	O
inhibited	O
cell	O
proliferation	O
,	O
whereas	O
it	O
did	O
not	O
cause	O
apoptosis	O
.	O

Rheumatoid	O
synovial	O
cells	O
expressed	O
PPARgamma	S-geneY
mRNA	O
,	O
and	O
the	O
PPARgamma	S-geneY
ligands	O
15	B-chem
-	I-chem
deoxy	I-chem
-	I-chem
Delta	I-chem
(	I-chem
12,14	I-chem
)	I-chem
-	I-chem
prostaglandin	I-chem
J	I-chem
(	I-chem
2	I-chem
)	E-chem
and	O
troglitazone	S-chem
reduced	O
the	O
proliferation	O
and	O
induced	O
apoptosis	O
in	O
synovial	O
cells	O
.	O

Luciferase	O
reporter	O
assay	O
demonstrated	O
that	O
not	O
only	O
PPARgamma	S-geneY
ligands	O
but	O
also	O
NSAIDs	O
,	O
which	O
could	O
induce	O
apoptosis	O
,	O
increased	O
the	O
activation	O
of	O
PPARgamma	S-geneY
in	O
synovial	O
cells	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
NSAIDs	O
and	O
PPARgamma	S-geneY
ligands	O
to	O
stimulate	O
the	O
activation	O
of	O
PPARgamma	S-geneY
correlated	O
with	O
their	O
ability	O
to	O
decrease	O
cell	O
viability	O
(	O
r	O
=	O
0.92	O
,	O
p	O
<	O
0.01	O
)	O
and	O
ability	O
to	O
induce	O
DNA	O
fragmentation	O
(	O
r	O
=	O
0.97	O
,	O
p	O
<	O
0.001	O
)	O
in	O
synovial	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PPARgamma	S-geneY
is	O
an	O
attractive	O
target	O
for	O
induction	O
of	O
apoptosis	O
in	O
rheumatoid	O
synovial	O
cells	O
and	O
that	O
the	O
activation	O
of	O
the	O
PPARgamma	S-geneY
pathway	O
is	O
associated	O
with	O
the	O
apoptotic	O
action	O
of	O
NSAIDs	O
.	O

Effect	O
of	O
water	O
extracts	O
from	O
edible	O
myrtaceae	O
plants	O
on	O
uptake	O
of	O
2	B-chem
-	I-chem
(	I-chem
n	I-chem
-	I-chem
(	I-chem
7	I-chem
-	I-chem
nitrobenz	I-chem
-	I-chem
2	I-chem
-	I-chem
oxa	I-chem
-	I-chem
1,3	I-chem
-	I-chem
diazol	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
)	I-chem
amino	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
deoxyglucose	E-chem
in	O
TNF	B-geneY
-	I-geneY
α	E-geneY
-	O
treated	O
FL83B	O
mouse	O
hepatocytes	O
.	O

This	O
study	O
investigated	O
the	O
glucose	S-chem
uptake	O
activity	O
of	O
the	O
water	O
extracts	O
from	O
the	O
leaves	O
and	O
fruit	O
of	O
edible	O
Myrtaceae	O
plants	O
,	O
including	O
guava	O
(	O
Psidium	O
guajava	O
Linn	O
.	O
)	O
,	O
wax	O
apples	O
[	O
Syzygium	O
samarangense	O
(	O
Blume	O
)	O
Merr	O
.	O
and	O
L.M	O
.	O

Perry	O
]	O
,	O
Pu	O
-	O
Tau	O
[	O
Syzygium	O
jambo	O
(	O
L.	O
)	O
Alston	O
]	O
,	O
and	O
Kan	O
-	O
Shi	O
Pu	O
-	O
Tau	O
(	O
Syzygium	O
cumini	O
Linn	O
.	O
)	O
in	O
FL83B	O
mouse	O
hepatocytes	O
.	O

The	O
fluorescent	O
dye	O
2	B-chem
-	I-chem
(	I-chem
n	I-chem
-	I-chem
(	I-chem
7	I-chem
-	I-chem
nitrobenz	I-chem
-	I-chem
2	I-chem
-	I-chem
oxa	I-chem
-	I-chem
1,3	I-chem
-	I-chem
diazol	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
)	I-chem
amino	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
deoxyglucose	E-chem
was	O
used	O
to	O
estimate	O
the	O
uptake	O
ability	O
of	O
the	O
cells	O
.	O

Glucose	S-chem
uptake	O
test	O
showed	O
that	O
pink	O
wax	O
apple	O
fruit	O
extract	O
(	O
PWFE	O
)	O
exhibits	O
the	O
highest	O
glucose	S-chem
uptake	O
activity	O
,	O
at	O
an	O
increment	O
of	O
21	O
%	O
in	O
the	O
insulin	S-geneN
-	O
resistant	O
FL83B	O
mouse	O
hepatocytes	O
as	O
compared	O
with	O
the	O
TNF	B-geneY
-	I-geneY
α	E-geneY
-	O
treated	O
control	O
group	O
.	O

Vescalagin	S-chem
was	O
isolated	O
using	O
column	O
chromatography	O
of	O
PWFE	O
.	O

This	O
compound	O
,	O
at	O
the	O
concentration	O
of	O
6.25	O
µg	O
/	O
mL	O
,	O
exhibits	O
the	O
same	O
glucose	O
uptake	O
improvement	O
in	O
insulin	O
-	E-geneN
resistant	O
cells	O
as	O
PWFE	O
at	O
a	O
100	O
-	O
µg	O
/	O
mL	O
dose	O
.	O

We	O
postulate	O
that	O
vescalagin	S-chem
is	O
an	O
active	O
component	O
in	O
PWFE	O
that	O
may	O
alleviate	O
the	O
insulin	S-geneN
resistance	O
in	O
mouse	O
hepatocytes	O
.	O

Catalytic	O
properties	O
of	O
mouse	B-geneY
carbonic	I-geneY
anhydrase	I-geneY
V	E-geneY
.	O

A	O
cDNA	O
encoding	O
the	O
mouse	B-geneY
carbonic	I-geneY
anhydrase	I-geneY
V	E-geneY
gene	O
was	O
isolated	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
BALB	O
/	O
c	O
mouse	O
liver	O
mRNA	O
.	O

Vectors	O
containing	O
the	O
full	O
coding	O
sequence	O
as	O
well	O
as	O
two	O
different	O
NH2	S-chem
-	O
terminal	O
truncated	O
genes	O
expressed	O
enzymatically	O
active	O
protein	O
in	O
Escherichia	O
coli	O
.	O

The	B-geneY
carbonic	I-geneY
anhydrase	I-geneY
V	E-geneY
produced	O
by	O
a	O
vector	O
containing	O
the	O
full	O
coding	O
sequence	O
,	O
which	O
includes	O
a	O
possible	O
NH2	S-chem
-	O
terminal	O
mitochondrial	O
targeting	O
signal	O
,	O
was	O
proteolytically	O
processed	O
by	O
E.	O
coli	O
and	O
contained	O
several	O
amino	S-chem
-	O
terminal	O
ends	O
.	O

The	O
two	O
NH2	S-chem
-	O
terminal	O
truncated	O
vectors	O
deleted	O
,	O
respectively	O
,	O
1	O
)	O
the	O
29	O
-	O
amino	B-chem
acid	E-chem
putative	O
targeting	O
sequence	O
and	O
2	O
)	O
51	O
amino	B-chem
acids	E-chem
,	O
yielding	O
a	O
protein	O
equivalent	O
to	O
a	O
carbonic	B-geneY
anhydrase	I-geneY
(	I-geneY
CA	I-geneY
)	I-geneY
V	E-geneY
isolated	O
from	O
mouse	O
liver	O
mitochondria	O
;	O
and	O
both	O
vectors	O
produced	O
homogeneous	O
protein	O
fractions	O
.	O

These	O
latter	O
two	O
forms	O
of	O
CA	B-geneY
V	E-geneY
had	O
identical	O
steady	O
-	O
state	O
constants	O
for	O
the	O
hydration	O
of	O
CO2	S-chem
,	O
with	O
maximal	O
values	O
of	O
kcat	O
/	O
Km	O
at	O
3	O
x	O
10	O
(	O
7	O
)	O
M	O
-	O
1	O
s	O
-	O
1	O
and	O
kcat	O
at	O
3	O
x	O
10	O
(	O
5	O
)	O
s	O
-	O
1	O
with	O
an	O
apparent	O
pKa	O
for	O
catalysis	O
of	O
7.4	O
determined	O
from	O
kcat	O
/	O
Km	O
.	O

In	O
catalytic	O
properties	O
,	O
mouse	B-geneY
CA	I-geneY
V	E-geneY
is	O
closest	O
to	O
CA	B-geneY
I	E-geneY
;	O
however	O
,	O
in	O
inhibition	O
by	O
acetazolamide	S-chem-C4-1
,	O
ethoxzolamide	S-chem-C4-1
,	O
and	O
cyanate	S-chem-C4-1
,	O
CA	B-geneY-C4-2
V	E-geneY-C4-2
is	O
very	O
similar	O
to	O
CA	B-geneY-C4-2
II	E-geneY-C4-2
.	O

Mouse	B-geneY
CA	I-geneY
V	E-geneY
has	O
a	O
tyrosine	O
at	O
position	O
64	O
,	O
where	O
the	O
highly	O
active	O
isozyme	O
II	O
has	O
histidine	S-chem
serving	O
as	O
a	O
proton	O
shuttle	O
in	O
the	O
catalytic	O
pathway	O
.	O

Investigation	O
of	O
a	O
site	O
-	O
specific	O
mutant	O
of	O
CA	B-geneY
V	E-geneY
containing	O
the	O
replacement	O
Tyr64	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
His	E-geneN
showed	O
that	O
the	O
unique	O
kinetic	O
properties	O
of	O
CA	B-geneY
V	E-geneY
are	O
not	O
due	O
to	O
the	O
presence	O
of	O
tyrosine	S-chem
at	O
position	O
64	O
.	O

Zymogen	O
factor	B-geneY
IX	E-geneY
potentiates	O
factor	B-geneY
IXa	E-geneY
-	O
catalyzed	O
factor	B-geneY
X	E-geneY
activation	O
.	O

Intrinsic	O
factor	B-geneY
X	E-geneY
activation	O
is	O
accelerated	O
>	O
10	O
(	O
7	O
)	O
-	O
fold	O
by	O
assembly	O
of	O
the	O
entire	O
complex	O
on	O
the	O
activated	O
platelet	O
surface	O
.	O

We	O
have	O
now	O
observed	O
that	O
increasing	O
the	O
concentration	O
of	O
zymogen	O
factor	B-geneY
IX	E-geneY
to	O
physiologic	O
levels	O
(	O
approximately	O
100	O
nM	O
)	O
potentiates	O
factor	B-geneY
IXa	E-geneY
-	O
catalyzed	O
activation	O
of	O
factor	B-geneY
X	E-geneY
on	O
both	O
activated	O
platelets	O
and	O
on	O
negatively	O
charged	O
phospholipid	O
vesicles	O
.	O

In	O
the	O
presence	O
and	O
absence	O
of	O
factor	B-geneY
VIIIa	E-geneY
,	O
factor	B-geneY
IX	E-geneY
(	O
100	O
nM	O
)	O
lowered	O
the	O
K	O
(	O
d	O
,	O
appFIXa	O
)	O
approximately	O
4	O
-	O
fold	O
on	O
platelets	O
and	O
2	O
-	O
10	O
-	O
fold	O
on	O
lipid	O
vesicles	O
.	O

Treatment	O
of	O
two	O
factor	B-geneY
IX	E-geneY
preparations	O
with	O
active	O
-	O
site	O
inhibitors	O
did	O
not	O
affect	O
these	O
observations	O
.	O

Autoradiographs	O
of	O
PAGE	O
-	O
separated	O
reactions	O
containing	O
either	O
(	B-chem
125	I-chem
)	I-chem
I	E-chem
-	O
labeled	O
factor	B-geneY
IX	E-geneY
or	O
(	B-chem
125	I-chem
)	I-chem
I	E-chem
-	O
labeled	O
factor	B-geneY
X	E-geneY
showed	O
that	O
the	O
increased	O
factor	B-geneY
X	E-geneY
activation	O
was	O
not	O
due	O
to	O
factor	B-geneY
Xa	E-geneY
-	O
mediated	O
feedback	O
activation	O
of	O
factor	B-geneY
IX	E-geneY
and	O
that	O
there	O
was	O
increased	O
cleavage	O
of	O
factor	B-geneY
X	I-geneY
heavy	I-geneY
chain	E-geneY
in	O
the	O
presence	O
of	O
factor	B-geneY
IX	E-geneY
in	O
comparison	O
with	O
control	O
reactions	O
but	O
only	O
in	O
the	O
presence	O
of	O
both	O
the	O
enzyme	O
and	O
the	O
surface	O
.	O

Since	O
plasma	O
concentrations	O
of	O
prothrombin	S-geneY
,	O
factor	B-geneY
VII	E-geneY
,	O
protein	B-geneY
C	E-geneY
,	O
or	O
protein	B-geneY
S	E-geneY
did	O
not	O
by	O
themselves	O
potentiate	O
factor	B-geneN
Xa	E-geneN
generation	O
and	O
did	O
not	O
interfere	O
with	O
the	O
potentiation	O
of	O
the	O
reaction	O
of	O
factor	B-geneY
IX	E-geneY
,	O
the	O
effect	O
is	O
specific	O
for	O
factor	B-geneY
IX	E-geneY
and	O
is	O
not	O
attributable	O
to	O
the	O
Gla	B-geneN
domain	E-geneN
of	O
all	O
vitamin	B-chem
K	E-chem
-	O
dependent	O
proteins	O
.	O

These	O
observations	O
indicate	O
that	O
under	O
physiologic	O
conditions	O
,	O
plasma	O
levels	O
of	O
the	O
zymogen	O
factor	B-geneY
IX	E-geneY
specifically	O
increase	O
the	O
affinity	O
of	O
factor	B-geneY
IXa	E-geneY
for	O
the	O
intrinsic	O
factor	B-geneY
X	E-geneY
activation	O
complex	O
.	O

Configuration	O
of	O
a	O
scintillation	O
proximity	O
assay	O
for	O
the	O
activity	O
assessment	O
of	O
recombinant	O
human	B-geneY
adenine	I-geneY
phosphoribosyltransferase	E-geneY
.	O

Adenine	B-geneY-C9-2
phosphoribosyltransferase	E-geneY-C9-2
plays	O
a	O
role	O
in	O
purine	S-chem
salvage	O
by	O
catalyzing	O
the	O
direct	O
conversion	O
of	O
adenine	S-chem-C9-1
to	O
adenosine	B-chem-C9-1
monophosphate	E-chem-C9-1
.	O

The	O
involvement	O
of	O
the	O
purine	S-chem
salvage	O
pathway	O
in	O
tumor	O
proliferation	O
and	O
angiogenesis	O
makes	O
adenine	B-geneY
phosphoribosyltransferase	E-geneY
a	O
potential	O
target	O
for	O
oncology	O
drug	O
discovery	O
.	O

We	O
have	O
expressed	O
and	O
characterized	O
recombinant	O
,	O
N	S-chem
-	O
terminally	O
His	S-chem
-	O
tagged	O
human	B-geneY
adenine	I-geneY
phosphoribosyltransferase	E-geneY
.	O

Two	O
assay	O
formats	O
were	O
assessed	O
for	O
use	O
in	O
a	O
high	O
throughput	O
screen	O
:	O
a	O
spectrophotometric	O
-	O
based	O
enzyme	O
-	O
coupled	O
assay	O
system	O
and	O
a	O
radiometric	O
ionic	O
capture	O
scintillation	O
proximity	O
bead	O
assay	O
format	O
.	O

Ultimately	O
,	O
the	O
scintillation	O
proximity	O
assay	O
format	O
was	O
chosen	O
because	O
of	O
automated	O
screening	O
compatibility	O
limitations	O
of	O
the	O
coupled	O
assay	O
.	O

We	O
describe	O
here	O
the	O
biochemical	O
characterization	O
of	O
adenine	B-geneY
phosphoribosyltransferase	E-geneY
and	O
the	O
development	O
of	O
a	O
robust	O
,	O
homogeneous	O
,	O
384	O
-	O
well	O
assay	O
suitable	O
for	O
high	O
throughput	O
screening	O
.	O

Annexin	B-geneY
A2	E-geneY
regulates	O
β1	B-geneY
integrin	E-geneY
internalization	O
and	O
intestinal	O
epithelial	O
cell	O
migration	O
.	O

The	O
gastrointestinal	O
epithelium	O
functions	O
as	O
an	O
important	O
barrier	O
that	O
separates	O
luminal	S-chem
contents	O
from	O
the	O
underlying	O
tissue	O
compartment	O
and	O
is	O
vital	O
in	O
maintaining	O
mucosal	O
homeostasis	O
.	O

Mucosal	O
wounds	O
in	O
inflammatory	O
disorders	O
compromise	O
the	O
critical	O
epithelial	O
barrier	O
.	O

In	O
response	O
to	O
injury	O
,	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
rapidly	O
migrate	O
to	O
reseal	O
wounds	O
.	O

We	O
have	O
previously	O
observed	O
that	O
a	O
membrane	O
associated	O
,	O
Actin	B-geneN
binding	I-geneN
protein	E-geneN
,	O
Annexin	B-geneN
A2	E-geneN
(	O
AnxA2	S-geneN
)	O
,	O
is	O
up	O
-	O
regulated	O
in	O
migrating	O
IECs	O
and	O
plays	O
an	O
important	O
role	O
in	O
promoting	O
wound	O
closure	O
.	O

To	O
identify	O
the	O
mechanisms	O
by	O
which	O
AnxA2	S-geneY
promotes	O
IEC	O
movement	O
and	O
wound	O
closure	O
we	O
used	O
a	O
loss	O
of	O
function	O
approach	O
.	O

AnxA2	S-geneY
specific	O
shRNA	O
was	O
utilized	O
to	O
generate	O
IECs	O
with	O
stable	O
down	O
-	O
regulation	O
of	O
AnxA2	S-geneY
.	O

Loss	O
of	O
AnxA2	S-geneY
inhibited	O
IEC	O
migration	O
while	O
promoting	O
enhanced	O
cell	O
-	O
matrix	O
adhesion	O
.	O

These	O
functional	O
effects	O
were	O
associated	O
with	O
increased	O
levels	O
of	O
β1	B-geneY
integrin	E-geneY
protein	O
,	O
which	O
is	O
reported	O
to	O
play	O
an	O
important	O
role	O
in	O
mediating	O
the	O
cell	O
-	O
matrix	O
adhesive	O
properties	O
of	O
epithelial	O
cells	O
.	O

Since	O
cell	O
migration	O
requires	O
dynamic	O
turnover	O
of	O
integrin	O
based	O
adhesions	O
,	O
we	O
tested	O
if	O
AnxA2	S-geneY
modulates	O
internalization	O
of	O
cell	O
surface	O
β1	B-geneY
integrin	E-geneY
required	O
for	O
forward	O
cell	O
movement	O
.	O

Indeed	O
,	O
pulse	O
-	O
chase	O
biotinylation	O
experiments	O
in	O
IECs	O
lacking	O
AnxA2	S-geneY
demonstrated	O
a	O
significant	O
increase	O
in	O
cell	O
surface	O
β1	B-geneY
integrin	E-geneY
that	O
was	O
accompanied	O
by	O
decreased	O
β1	B-geneY
integrin	E-geneY
internalization	O
and	O
degradation	O
.	O

These	O
findings	O
support	O
an	O
important	O
role	O
of	O
AnxA2	S-geneY
in	O
controlling	O
dynamics	O
of	O
β1	B-geneY
integrin	E-geneY
at	O
the	O
cell	O
surface	O
that	O
in	O
turn	O
is	O
required	O
for	O
the	O
active	O
turnover	O
of	O
cell	O
-	O
matrix	O
associations	O
,	O
cell	O
migration	O
and	O
wound	O
closure	O
.	O

Chloride	B-geneN
channels	E-geneN
in	O
renal	O
disease	O
.	O

Recent	O
studies	O
of	O
hereditary	O
renal	O
tubular	O
disorders	O
have	O
facilitated	O
the	O
identification	O
and	O
roles	O
of	O
chloride	B-geneN
channels	I-geneN
and	I-geneN
cotransporters	E-geneN
in	O
the	O
regulation	O
of	O
the	O
most	O
abundant	O
anion	O
,	O
Cl	B-chem
-	E-chem
,	O
in	O
the	O
ECF	O
.	O

Thus	O
,	O
mutations	O
that	O
result	O
in	O
a	O
loss	O
of	O
function	O
of	O
the	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
chloride	I-geneN
channel	E-geneN
,	O
CLC	B-geneY
-	I-geneY
5	E-geneY
,	O
are	O
associated	O
with	O
Dent	O
's	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
low	O
-	O
molecular	O
weight	O
proteinuria	O
,	O
hypercalciuria	O
,	O
nephrolithiasis	O
,	O
and	O
renal	O
failure	O
.	O

Mutations	O
of	O
another	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
chloride	I-geneN
channel	E-geneN
,	O
CLC	B-geneY
-	I-geneY
Kb	E-geneY
,	O
are	O
associated	O
with	O
a	O
form	O
of	O
Bartter	O
's	O
syndrome	O
,	O
whereas	O
other	O
forms	O
of	O
Bartter	O
's	O
syndrome	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
bumetanide	B-geneN
-	I-geneN
sensitive	I-geneN
sodium	I-geneN
-	I-geneN
potassium	I-geneN
-	I-geneN
chloride	I-geneN
cotransporter	E-geneN
(	O
NKCC2	S-geneY
)	O
and	O
the	O
potassium	B-geneN
channel	E-geneN
,	O
ROMK	S-geneY
.	O

Finally	O
,	O
mutations	O
of	O
the	O
thiazide	B-geneY
-	I-geneY
sensitive	I-geneY
sodium	I-geneY
-	I-geneY
chloride	I-geneY
cotransporter	E-geneY
(	O
NCCT	S-geneY
)	O
are	O
associated	O
with	O
Gitelman	O
's	O
syndrome	O
.	O

These	O
studies	O
have	O
helped	O
to	O
elucidate	O
some	O
of	O
the	O
renal	O
tubular	O
mechanisms	O
regulating	O
mineral	O
homeostasis	O
and	O
the	O
role	O
of	O
chloride	B-geneN
channels	E-geneN
.	O

Methionine	B-geneY
adenosyltransferase	I-geneY
II	I-geneY
beta	E-geneY
subunit	O
gene	O
expression	O
provides	O
a	O
proliferative	O
advantage	O
in	O
human	O
hepatoma	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Of	O
the	O
2	O
genes	O
(	O
MAT1A	S-geneY-C9-2
,	O
MAT2A	S-geneY-C9-2
)	O
encoding	O
methionine	B-geneN-C9-2
adenosyltransferase	E-geneN-C9-2
,	O
the	O
enzyme	O
that	O
synthesizes	O
S	B-chem-C9-1
-	I-chem-C9-1
adenosylmethionine	E-chem-C9-1
,	O
MAT1A	S-geneY-C9-2
,	O
is	O
expressed	O
in	O
liver	O
,	O
whereas	O
MAT2A	S-geneY
is	O
expressed	O
in	O
extrahepatic	O
tissues	O
.	O

In	O
liver	O
,	O
MAT2A	S-geneY
expression	O
associates	O
with	O
growth	O
,	O
dedifferentiation	O
,	O
and	O
cancer	O
.	O

Here	O
,	O
we	O
identified	O
the	O
beta	O
subunit	O
as	O
a	O
regulator	O
of	O
proliferation	O
in	O
human	O
hepatoma	O
cell	O
lines	O
.	O

The	O
beta	O
subunit	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
lower	O
the	O
K	O
(	O
m	O
)	O
of	O
methionine	B-geneY-MU-2
adenosyltransferase	I-geneY-MU-2
II	I-geneY-MU-2
alpha2	E-geneY-MU-2
(	O
the	O
MAT2A	S-geneY-MU-2
product	O
)	O
for	O
methionine	S-chem-C9-1
and	O
to	O
render	O
the	O
enzyme	O
more	O
susceptible	O
to	O
S	B-chem-C4-1
-	I-chem-C4-1
adenosylmethionine	E-chem-C4-1
inhibition	O
.	O

METHODS	O
:	O
Methionine	B-geneN
adenosyltransferase	I-geneN
II	I-geneN
alpha2	I-geneN
and	I-geneN
beta	E-geneN
subunit	O
expression	O
was	O
analyzed	O
in	O
human	O
and	O
rat	O
liver	O
and	O
hepatoma	O
cell	O
lines	O
and	O
their	O
interaction	O
studied	O
in	O
HuH7	O
cells	O
.	O
beta	O
Subunit	O
expression	O
was	O
up	O
-	O
and	O
down	O
-	O
regulated	O
in	O
human	O
hepatoma	O
cell	O
lines	O
and	O
the	O
effect	O
on	O
DNA	O
synthesis	O
determined	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
beta	O
subunit	O
is	O
expressed	O
in	O
rat	O
extrahepatic	O
tissues	O
but	O
not	O
in	O
normal	O
liver	O
.	O

In	O
human	O
liver	O
,	O
beta	O
subunit	O
expression	O
associates	O
with	O
cirrhosis	O
and	O
hepatoma	O
.	O
beta	O
Subunit	O
is	O
expressed	O
in	O
most	O
(	O
HepG2	O
,	O
PLC	O
,	O
and	O
Hep3B	O
)	O
but	O
not	O
all	O
(	O
HuH7	O
)	O
hepatoma	O
cell	O
lines	O
.	O

Transfection	O
of	O
beta	O
subunit	O
reduced	O
S	B-chem
-	I-chem
adenosylmethionine	E-chem
content	O
and	O
stimulated	O
DNA	O
synthesis	O
in	O
HuH7	O
cells	O
,	O
whereas	O
down	O
-	O
regulation	O
of	O
beta	O
subunit	O
expression	O
diminished	O
DNA	O
synthesis	O
in	O
HepG2	O
.	O

The	O
interaction	O
between	O
methionine	B-geneN
adenosyltransferase	I-geneN
II	I-geneN
alpha2	I-geneN
and	I-geneN
beta	E-geneN
subunit	O
was	O
demonstrated	O
in	O
HuH7	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
indicate	O
that	O
beta	O
subunit	O
associates	O
with	O
cirrhosis	O
and	O
cancer	O
providing	O
a	O
proliferative	O
advantage	O
in	O
hepatoma	O
cells	O
through	O
its	O
interaction	O
with	O
methionine	B-geneY
adenosyltransferase	I-geneY
II	I-geneY
alpha2	E-geneY
and	O
down	O
-	O
regulation	O
of	O
S	B-chem
-	I-chem
adenosylmethionine	E-chem
levels	O
.	O

Interactive	O
and	O
delayed	O
effects	O
of	O
pyridostigmine	S-chem
and	O
physical	O
stress	O
on	O
biochemical	O
and	O
histological	O
changes	O
in	O
peripheral	O
tissues	O
of	O
mice	O
.	O

Gulf	O
War	O
veterans	O
were	O
taking	O
pyridostigmine	S-chem
orally	O
against	O
possible	O
exposure	O
to	O
nerve	O
agents	O
as	O
well	O
as	O
being	O
under	O
physical	O
stress	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
delayed	O
effects	O
of	O
pyridostigmine	S-chem
and	O
treadmill	O
exercise	O
on	O
cholinesterase	S-geneY
activity	O
,	O
lipid	O
peroxidation	O
and	O
histology	O
of	O
peripheral	O
tissues	O
of	O
mice	O
.	O

Male	O
NIH	O
Swiss	O
mice	O
were	O
divided	O
into	O
four	O
groups	O
of	O
15	O
animals	O
each	O
and	O
treated	O
as	O
follows	O
:	O
sedentary	O
control	O
;	O
exercise	O
training	O
for	O
10	O
weeks	O
;	O
pyridostigmine	S-chem
(	O
1.2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
p.o	O
.	O
)	O
for	O
2	O
weeks	O
during	O
weeks	O
5	O
and	O
6	O
;	O
and	O
pyridostigmine	S-chem
plus	O
exercise	O
training	O
.	O

The	O
mice	O
were	O
sacrificed	O
24	O
h	O
after	O
the	O
last	O
exercise	O
,	O
and	O
blood	O
,	O
triceps	O
muscle	O
and	O
sciatic	O
nerve	O
were	O
isolated	O
and	O
analyzed	O
.	O

The	O
group	O
treated	O
with	O
pyridostigmine	S-chem-C4-1
alone	O
showed	O
decreased	O
plasma	O
butyrylcholinesterase	S-geneY-C4-2
(	O
BChE	S-geneY-C4-2
)	O
activity	O
(	O
87	O
%	O
of	O
control	O
)	O
,	O
whereas	O
pyridostigmine	S-chem-C4-1
plus	O
exercise	O
significantly	O
decreased	O
the	O
BChE	S-geneY-C4-2
activity	O
(	O
79	O
%	O
of	O
control	O
)	O
,	O
indicating	O
an	O
interactive	O
effect	O
of	O
the	O
combination	O
.	O

Acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
activity	O
did	O
not	O
alter	O
significantly	O
in	O
red	O
blood	O
cells	O
,	O
platelets	O
or	O
sciatic	O
nerve	O
with	O
either	O
of	O
the	O
treatments	O
.	O

However	O
,	O
AChE	S-geneY-C4-2
activity	O
in	O
triceps	O
muscle	O
decreased	O
significantly	O
(	O
78	O
%	O
of	O
control	O
)	O
in	O
the	O
group	O
treated	O
with	O
pyridostigmine	S-chem-C4-1
plus	O
exercise	O
.	O

Creatine	B-geneN-C3-2
phosphokinase	E-geneN-C3-2
activity	O
in	O
plasma	O
increased	O
slightly	O
(	O
compared	O
to	O
control	O
,	O
pyridostigmine	S-chem-C3-1
or	O
exercise	O
group	O
)	O
in	O
mice	O
treated	O
with	O
pyridostigmine	S-chem-C3-1
plus	O
exercise	O
,	O
which	O
may	O
be	O
indicative	O
of	O
perturbation	O
in	O
the	O
integrity	O
of	O
the	O
skeletal	O
muscle	O
due	O
to	O
combination	O
.	O

However	O
,	O
there	O
were	O
no	O
obvious	O
histological	O
abnormalities	O
in	O
the	O
triceps	O
muscle	O
detected	O
between	O
experimental	O
and	O
control	O
groups	O
.	O

Interaction	O
of	O
pyridostigmine	S-chem
and	O
exercise	O
significantly	O
increased	O
the	O
concentration	O
of	O
the	O
end	O
product	O
of	O
lipid	O
peroxidation	O
(	O
malondialdehyde	S-chem
)	O
(	O
124	O
%	O
of	O
control	O
)	O
in	O
triceps	O
muscle	O
,	O
indicating	O
an	O
oxidative	O
stress	O
response	O
of	O
the	O
combination	O
.	O

These	O
results	O
indicate	O
that	O
physical	O
stress	O
enhanced	O
the	O
delayed	O
toxic	O
effects	O
of	O
a	O
subchronic	O
oral	O
dose	O
of	O
pyridostigmine	S-chem
primarily	O
in	O
the	O
skeletal	O
muscle	O
of	O
mice	O
.	O

Curcumin	S-chem
attenuates	O
allergic	O
airway	O
inflammation	O
by	O
regulation	O
of	O
CD4	O
(	O
+	O
)	O
CD25	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
/	O
Th17	O
balance	O
in	O
ovalbumin	S-geneY
-	O
sensitized	O
mice	O
.	O

The	O
present	O
study	O
aimed	O
to	O
determine	O
the	O
protective	O
effects	O
and	O
the	O
underlying	O
mechanisms	O
of	O
curcumin	S-chem
on	O
ovalbumin	S-geneY
(	O
OVA	S-geneY
)	O
-	O
induced	O
allergic	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
allergic	O
asthma	O
.	O

Asthma	O
mice	O
model	O
was	O
established	O
by	O
ovalbumin	S-geneY
.	O

A	O
total	O
of	O
60	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
experimental	O
groups	O
:	O
control	O
,	O
model	O
,	O
dexamethasone	S-chem
(	O
2mg	O
/	O
kg	O
)	O
,	O
and	O
curcumin	S-chem
(	O
50mg	O
/	O
kg	O
,	O
100mg	O
/	O
kg	O
,	O
200mg	O
/	O
kg	O
)	O
.	O

Airway	O
resistance	O
(	O
Raw	O
)	O
was	O
measured	O
by	O
the	O
forced	O
oscillation	O
technique	O
,	O
differential	O
cell	O
count	O
in	O
BAL	O
fluid	O
(	O
BALF	O
)	O
was	O
measured	O
by	O
Wright	O
-	O
Giemsa	O
staining	O
,	O
histological	O
assessment	O
was	O
measured	O
by	O
hematoxylin	S-chem
and	O
eosin	S-chem
(	O
HE	O
)	O
staining	O
,	O
BALF	O
levels	O
of	O
Treg	O
/	O
Th17	O
cytokines	S-geneN
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
Treg	O
cells	O
and	O
Th17	O
cells	O
were	O
evaluated	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

Our	O
study	O
demonstrated	O
that	O
curcumin	S-chem-MU-1
inhibited	O
OVA	S-geneY-C4-2
-	O
induced	O
increases	O
in	O
eosinophil	O
count	O
;	O
interleukin	B-geneY-C4-2
(	I-geneY-C4-2
IL	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
17A	E-geneY-C4-2
level	O
were	O
recovered	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
increased	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
10	E-geneY-C3-2
level	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
curcumin	S-chem-C4-1
substantially	O
inhibited	O
OVA	S-geneY-C4-2
-	O
induced	O
eosinophilia	O
in	O
lung	O
tissue	O
.	O

Flow	O
cytometry	O
(	O
FCM	O
)	O
studies	O
demonstrated	O
that	O
curcumin	S-chem
remarkably	O
inhibited	O
Th17	O
cells	O
and	O
significantly	O
increased	O
Treg	O
cells	O
.	O

The	O
results	O
in	O
vivo	O
show	O
ovalbumin	S-geneY-C4-2
-	O
induced	O
significantly	O
broke	O
Treg	O
/	O
Th17	O
balance	O
;	O
curcumin	S-chem-C4-1
treatments	O
markedly	O
attenuated	O
the	O
inflammatory	O
in	O
asthma	O
model	O
by	O
regulating	O
Treg	O
/	O
Th17	O
balance	O
.	O

Our	O
findings	O
support	O
the	O
possible	O
use	O
of	O
curcumin	S-chem
as	O
a	O
therapeutic	O
drug	O
for	O
patients	O
with	O
allergic	O
asthma	O
.	O

Effects	O
of	O
nabumetone	S-chem
on	O
prostanoid	S-chem
biosynthesis	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
The	O
active	O
metabolite	O
of	O
the	O
anti	O
-	O
inflammatory	O
drug	O
nabumetone	S-chem-C4-1
has	O
been	O
characterized	O
as	O
a	O
selective	O
inhibitor	O
of	O
the	O
inducible	O
prostaglandin	B-geneN-C4-2
H	I-geneN-C4-2
synthase	E-geneN-C4-2
(	O
PGHS	S-geneN-C4-2
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
rate	O
of	O
eicosanoid	S-chem
biosynthesis	O
after	O
oral	O
dosing	O
with	O
nabumetone	S-chem
in	O
nine	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
We	O
measured	O
the	O
urinary	O
excretion	O
of	O
products	O
of	O
platelet	O
(	O
11	B-chem
-	I-chem
dehydro	I-chem
-	I-chem
thromboxane	I-chem
B2	E-chem
[	O
TXB2	S-chem
]	O
)	O
and	O
renal	O
(	O
prostaglandin	B-chem
IF2	I-chem
alpha	E-chem
[	O
PGF2	B-chem
alpha	E-chem
]	O
)	O
arachidonate	S-chem
metabolism	O
as	O
in	O
vivo	O
indexes	O
of	O
the	O
constitutive	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
pathway	O
.	O

Moreover	O
,	O
the	O
production	O
of	O
TXB2	S-chem-C9-1
during	O
whole	O
blood	O
clotting	O
was	O
assessed	O
as	O
an	O
index	O
of	O
the	O
cyclooxygenase	S-geneN-C9-2
activity	O
of	O
platelet	O
PGHS	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
ex	O
vivo	O
.	O

RESULTS	O
:	O
At	O
steady	O
state	O
,	O
nabumetone	S-chem
(	O
500	O
and	O
1000	O
mg	O
daily	O
for	O
7	O
days	O
)	O
was	O
associated	O
with	O
statistically	O
significant	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
urinary	O
excretion	O
of	O
11	B-chem
-	I-chem
dehydro	I-chem
-	I-chem
TXB2	E-chem
and	O
serum	O
TXB2	S-chem
levels	O
by	O
approximately	O
50	O
%	O
to	O
70	O
%	O
.	O

However	O
,	O
the	O
drug	O
did	O
not	O
significantly	O
affect	O
the	O
urinary	O
excretion	O
of	O
PGF2	B-chem
alpha	E-chem
.	O

After	O
discontinuation	O
of	O
nabumetone	S-chem
,	O
urinary	O
11	B-chem
-	I-chem
dehydro	I-chem
-	I-chem
TXB2	E-chem
excretion	O
and	O
whole	O
blood	O
TXB2	S-chem
production	O
returned	O
to	O
predrug	O
levels	O
with	O
a	O
similar	O
timecourse	O
that	O
was	O
consistent	O
with	O
the	O
elimination	O
half	O
-	O
life	O
of	O
its	O
active	O
metabolite	O
.	O

The	O
daily	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	S-chem-C4-1
(	O
40	O
mg	O
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
platelet	O
PGHS	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
,	O
caused	O
a	O
cumulative	O
inhibition	O
of	O
urinary	O
11	B-chem-C9-1
-	I-chem-C9-1
dehydro	I-chem-C9-1
-	I-chem-C9-1
TXB2	E-chem-C9-1
and	O
whole	O
blood	O
TXB2	S-chem-C9-1
production	O
that	O
recovered	O
with	O
a	O
timecourse	O
consistent	O
with	O
platelet	O
turnover	O
.	O

CONCLUSIONS	O
:	O
Nabumetone	S-chem-C4-1
does	O
dose	O
-	O
dependently	O
inhibit	O
the	O
cyclooxygenase	S-geneN-C4-2
activity	O
of	O
platelet	O
PGHS	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
of	O
healthy	O
subjects	O
both	O
in	O
vivo	O
and	O
ex	O
vivo	O
.	O

Thus	O
it	O
is	O
unlikely	O
that	O
its	O
safety	O
profile	O
in	O
patients	O
may	O
be	O
related	O
to	O
selective	O
inhibition	O
of	O
the	O
inducible	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
.	O

Concurrent	O
Regulation	O
of	O
the	O
Transcription	O
Factors	O
Nrf2	S-geneY
and	O
ATF4	S-geneY
Mediates	O
the	O
Enhancement	O
of	O
Glutathione	S-chem
Levels	O
by	O
the	O
Flavonoid	S-chem
Fisetin	S-chem
.	O

Glutathione	S-chem
(	O
GSH	S-chem
)	O
and	O
GSH	S-chem
-	O
associated	O
metabolism	O
provide	O
the	O
major	O
line	O
of	O
defense	O
for	O
the	O
protection	O
of	O
cells	O
from	O
various	O
forms	O
of	O
toxic	O
stress	O
.	O

GSH	S-chem
also	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
the	O
intracellular	O
redox	O
environment	O
.	O

Thus	O
,	O
maintenance	O
of	O
GSH	S-chem
levels	O
is	O
developing	O
into	O
an	O
important	O
therapeutic	O
objective	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
diseases	O
.	O

Among	O
the	O
transcription	O
factors	O
that	O
play	O
critical	O
roles	O
in	O
GSH	S-chem
metabolism	O
are	O
NF	B-geneY
-	I-geneY
E2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
Nrf2	S-geneY
)	O
and	O
activating	B-geneY
transcription	I-geneY
factor	I-geneY
4	E-geneY
(	O
ATF4	S-geneY
)	O
.	O

Thus	O
,	O
compounds	O
that	O
can	O
upregulate	O
these	O
transcription	O
factors	O
may	O
be	O
particularly	O
useful	O
as	O
treatment	O
options	O
through	O
their	O
effects	O
on	O
GSH	S-chem
metabolism	O
.	O

We	O
previously	O
showed	O
that	O
the	O
flavonoid	S-chem
fisetin	S-chem
not	O
only	O
increases	O
basal	O
levels	O
of	O
GSH	S-chem
but	O
also	O
maintains	O
GSH	S-chem
levels	O
under	O
oxidative	O
stress	O
conditions	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
these	O
effects	O
have	O
remained	O
unknown	O
until	O
now	O
.	O

Here	O
we	O
show	O
that	O
fisetin	S-chem-C3-1
rapidly	O
increases	O
the	O
levels	O
of	O
both	O
Nrf2	S-geneY-C3-2
and	O
ATF4	S-geneY-C3-2
as	O
well	O
as	O
Nrf2	S-geneY-C3-2
-	O
and	O
ATF4	S-geneY-C3-2
-	O
dependent	O
gene	O
transcription	O
via	O
distinct	O
mechanisms	O
.	O

Although	O
fisetin	S-chem-C3-1
greatly	O
increases	O
the	O
stability	O
of	O
both	O
Nrf2	S-geneY-C3-2
and	O
ATF4	S-geneY-C3-2
,	O
only	O
the	O
effect	O
on	O
ATF4	S-geneY
is	O
dependent	O
on	O
protein	B-geneN
kinase	E-geneN
activity	O
.	O

Using	O
siRNA	O
we	O
found	O
that	O
ATF4	S-geneY
,	O
but	O
not	O
Nrf2	S-geneY
,	O
is	O
important	O
for	O
fisetin	S-chem
's	O
ability	O
to	O
increase	O
GSH	S-chem
levels	O
under	O
basal	O
conditions	O
whereas	O
both	O
ATF4	S-geneY
and	O
Nrf2	S-geneY
appear	O
to	O
cooperate	O
to	O
increase	O
GSH	S-chem
levels	O
under	O
oxidative	O
stress	O
conditions	O
.	O

Based	O
upon	O
these	O
results	O
,	O
we	O
hypothesize	O
that	O
compounds	O
able	O
to	O
increase	O
GSH	S-chem
levels	O
via	O
multiple	O
mechanisms	O
,	O
such	O
as	O
fisetin	S-chem
,	O
will	O
be	O
particularly	O
effective	O
for	O
maintaining	O
GSH	S-chem
levels	O
under	O
a	O
variety	O
of	O
different	O
stresses	O
.	O

The	O
human	B-geneY
ribonucleotide	I-geneY
reductase	I-geneY
subunit	I-geneY
hRRM2	E-geneY
complements	O
p53R2	S-geneY
in	O
response	O
to	O
UV	O
-	O
induced	O
DNA	O
repair	O
in	O
cells	O
with	O
mutant	O
p53	S-geneY
.	O

Ribonucleotide	B-geneN-C9-2
reductase	E-geneN-C9-2
(	O
RR	S-geneN-C9-2
)	O
is	O
responsible	O
for	O
the	O
de	O
novo	O
conversion	O
of	O
the	O
ribonucleoside	B-chem-C9-1
diphosphates	E-chem-C9-1
to	O
deoxyribonucleoside	B-chem-C9-1
diphosphates	E-chem-C9-1
,	O
which	O
are	O
essential	O
for	O
DNA	O
synthesis	O
and	O
repair	O
.	O

RR	S-geneN
consists	O
of	O
two	O
subunits	O
,	O
hRRM1	S-geneY
and	O
hRRM2	S-geneY
.	O
p53R2	S-geneY
is	O
a	O
new	O
RR	S-geneN
family	O
member	O
.	O

Because	O
the	O
majority	O
of	O
human	O
tumors	O
possess	O
mutant	O
p53	S-geneY
,	O
it	O
is	O
important	O
to	O
know	O
the	O
molecular	O
mechanism	O
by	O
which	O
mutant	O
p53	S-geneY
regulates	O
RR	S-geneN
and	O
to	O
what	O
extent	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
function	O
of	O
p53R2	S-geneY
and	O
hRRM2	S-geneY
after	O
UV	O
treatment	O
in	O
human	O
prostate	O
cancer	O
PC3	O
cells	O
,	O
which	O
possess	O
mutant	O
p53	S-geneY
with	O
a	O
truncated	O
COOH	S-chem
-	O
terminal	O
,	O
and	O
in	O
human	O
oropharyngeal	O
cancer	O
KB	O
cells	O
,	O
which	O
possess	O
wild	O
-	O
type	O
p53	S-geneY
.	O
p53R2	S-geneY
(	O
analyzed	O
by	O
Western	O
blot	O
and	O
standardized	O
relative	O
to	O
Coomassie	O
Blue	O
-	O
stained	O
band	O
)	O
was	O
down	O
-	O
regulated	O
in	O
PC3	O
cells	O
and	O
up	O
-	O
regulated	O
in	O
KB	O
cells	O
after	O
UV	O
exposure	O
.	O

In	O
contrast	O
,	O
hRRM2	S-geneY
was	O
up	O
-	O
regulated	O
by	O
UV	O
in	O
both	O
PC3	O
cells	O
and	O
KB	O
cells	O
.	O
hRRM2	S-geneY
and	O
p53R2	S-geneY
mRNA	O
levels	O
were	O
assessed	O
by	O
Northern	O
blot	O
,	O
and	O
the	O
results	O
paralleled	O
that	O
of	O
the	O
Western	O
blot	O
.	O

Coimmunoprecipitation	O
assays	O
using	O
agarose	O
-	O
conjugated	O
goat	O
antihuman	O
RRM1	S-geneY
antibody	O
confirmed	O
that	O
the	O
p53R2	S-geneY
binding	O
to	O
hRRM1	S-geneY
decreased	O
in	O
PC3	O
cells	O
but	O
increased	O
in	O
KB	O
cells	O
after	O
UV	O
treatment	O
.	O
hRRM2	S-geneY
binding	O
to	O
hRRM1	S-geneN
increased	O
in	O
both	O
cell	O
lines	O
under	O
the	O
same	O
conditions	O
.	O

These	O
results	O
suggest	O
that	O
PC3	O
cells	O
are	O
deficient	O
in	O
both	O
transcription	O
of	O
p53R2	S-geneY
and	O
binding	O
to	O
hRRM1	S-geneY
in	O
response	O
to	O
UV	O
irradiation	O
.	O

Confocal	O
microscopy	O
further	O
confirmed	O
that	O
these	O
findings	O
were	O
not	O
due	O
to	O
translocation	O
of	O
hRRM2	S-geneY
and	O
p53R2	S-geneY
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

RR	S-geneN
activity	O
was	O
measured	O
following	O
UV	O
treatment	O
and	O
shown	O
to	O
increase	O
in	O
PC3	O
cells	O
.	O

It	O
was	O
unchanged	O
in	O
proportional	O
of	O
KB	O
cells	O
.	O

The	O
RR	S-geneN
activity	O
is	O
consistent	O
with	O
the	O
expression	O
of	O
hRRM2	S-geneN
seen	O
in	O
the	O
Western	O
blots	O
.	O

Thus	O
,	O
we	O
hypothesize	O
that	O
hRRM2	S-geneY
complements	O
p53R2	S-geneY
to	O
form	O
RR	S-geneN
holoenzyme	O
and	O
maintain	O
RR	S-geneN
activity	O
in	O
PC3	O
cells	O
after	O
UV	O
treatment	O
.	O

To	O
further	O
confirm	O
this	O
hypothesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
RRM2	S-geneY
inhibitors	O
on	O
cells	O
exposed	O
to	O
UV	O
.	O

In	O
PC3	O
cells	O
,	O
hydroxyurea	S-chem-C4-1
inhibited	O
hRRM2	S-geneY-C4-2
and	O
resulted	O
in	O
increased	O
sensitivity	O
to	O
UV	O
irradiation	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
UV	O
treatment	O
on	O
the	O
colony	O
-	O
forming	O
ability	O
of	O
cells	O
transfected	O
with	O
hRRM2	S-geneY
as	O
well	O
as	O
p53R2	S-geneY
sense	O
or	O
antisense	O
expression	O
vectors	O
.	O

Expression	O
of	O
antisense	O
hRRM2	S-geneY
in	O
PC3	O
cells	O
led	O
to	O
decreased	O
hRRM2	S-geneY
expression	O
and	O
resulted	O
in	O
greater	O
sensitivity	O
to	O
UV	O
than	O
observed	O
in	O
wild	O
-	O
type	O
PC3	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
UV	O
-	O
induced	O
activation	O
of	O
p53R2	S-geneY
transcription	O
and	O
binding	O
of	O
p53R2	S-geneN
to	O
hRRM1	S-geneY
to	O
form	O
RR	S-geneN
holoenzyme	O
are	O
impaired	O
in	O
the	O
p53	S-geneY
-	O
mutant	O
cell	O
line	O
PC3	O
.	O

The	O
effects	O
of	O
labetalol	S-chem
and	O
dilevalol	S-chem
on	O
isolated	O
cardiovascular	O
preparations	O
of	O
the	O
guinea	O
-	O
pig	O
and	O
rat	O
.	O

Differing	O
effects	O
of	O
labetalol	S-chem
and	O
dilevalol	S-chem
on	O
cardiovascular	O
preparations	O
have	O
been	O
reported	O
.	O

I	O
have	O
studied	O
the	O
effects	O
of	O
labetalol	S-chem
and	O
dilevalol	S-chem
on	O
the	O
contractile	O
responses	O
of	O
the	O
rat	O
and	O
guinea	O
-	O
pig	O
left	O
atria	O
and	O
rat	O
portal	O
vein	O
.	O

On	O
the	O
guinea	O
-	O
pig	O
left	O
atria	O
low	O
concentrations	O
of	O
labetalol	S-chem
(	O
>	O
or	O
=	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
of	O
dilevalol	S-chem
(	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
inhibited	O
to	O
a	O
small	O
extent	O
the	O
responses	O
to	O
electrical	O
cardiac	O
stimulation	O
,	O
which	O
is	O
indicative	O
of	O
membrane	O
stabilizing	O
activity	O
.	O

Labetalol	S-chem-C6-1
(	O
>	O
or	O
=	O
3	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
dilevalol	S-chem-C6-1
(	O
>	O
or	O
=	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
caused	O
surmountable	O
antagonism	O
of	O
the	O
isoprenaline	S-chem-C5-1
responses	O
of	O
the	O
atria	O
and	O
the	O
pA2	O
values	O
were	O
8.60	O
and	O
8.98	O
at	O
the	O
beta	B-geneN-MU-2
1	I-geneN-MU-2
-	I-geneN-MU-2
adrenoceptors	E-geneN-MU-2
of	O
the	O
rat	O
left	O
atria	O
and	O
7.90	O
and	O
8.31	O
,	O
respectively	O
,	O
on	O
the	O
guinea	O
-	O
pig	O
left	O
atria	O
which	O
has	O
functional	O
beta	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

Labetalol	S-chem
and	O
dilevalol	S-chem
(	O
both	O
at	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
attenuated	O
the	O
spontaneous	O
contractile	O
activity	O
of	O
the	O
rat	O
portal	O
vein	O
and	O
the	O
attenuation	O
to	O
labetalol	S-chem
at	O
10	O
(	O
-	O
6	O
)	O
M	O
was	O
abolished	O
by	O
ICI	B-chem
118,551	E-chem
which	O
illustrates	O
that	O
the	O
labetalol	S-chem
-	O
induced	O
attenuation	O
is	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
mediated	O
.	O

The	O
isoprenaline	S-chem
attenuation	O
responses	O
of	O
the	O
portal	O
vein	O
were	O
inhibited	O
by	O
labetalol	S-chem
and	O
dilevalol	S-chem
(	O
both	O
at	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
and	O
the	O
pA2	O
value	O
for	O
the	O
labetalol	S-chem-C6-1
at	O
beta	B-geneN-C6-2
2	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptors	E-geneN-C6-2
was	O
7.59	O
.	O

It	O
is	O
concluded	O
that	O
labetalol	S-chem-C6-1
and	O
dilevalol	S-chem-C6-1
are	O
beta	B-geneN-C6-2
1	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
selective	O
antagonists	O
.	O

Synthesis	O
and	O
NIR	O
optical	O
properties	O
of	O
hollow	O
gold	O
nanospheres	O
with	O
LSPR	O
greater	O
than	O
one	O
micrometer	O
.	O

Optical	O
analysis	O
in	O
the	O
near	O
infrared	O
region	O
is	O
of	O
significant	O
biological	O
importance	O
due	O
to	O
better	O
tissue	O
penetration	O
and	O
reduced	O
autofluorescence	O
.	O

In	O
this	O
work	O
,	O
an	O
improved	O
synthesis	O
of	O
hollow	O
gold	O
nanospheres	O
(	O
HGNs	O
)	O
,	O
which	O
provides	O
a	O
tunable	O
localized	O
surface	O
plasmon	O
resonance	O
(	O
LSPR	O
)	O
from	O
610	O
nm	O
up	O
to	O
1320	O
nm	O
,	O
is	O
demonstrated	O
.	O

The	O
scattering	O
properties	O
of	O
these	O
nanoparticles	O
are	O
shown	O
using	O
surface	O
enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
at	O
1064	O
nm	O
excitation	O
wavelength	O
and	O
are	O
compared	O
to	O
citrate	S-chem
reduced	O
gold	O
and	O
silver	S-chem
nanoparticles	O
of	O
similar	O
physical	O
sizes	O
and	O
surface	O
properties	O
.	O

After	O
the	O
addition	O
of	O
salts	O
,	O
a	O
strong	O
signal	O
was	O
observed	O
from	O
hollow	O
gold	O
with	O
a	O
LSPR	O
of	O
650	O
nm	O
and	O
a	O
weaker	O
,	O
yet	O
observable	O
,	O
signal	O
from	O
HGNs	O
with	O
a	O
LSPR	O
of	O
775	O
nm	O
.	O

However	O
,	O
no	O
obvious	O
signals	O
were	O
observed	O
in	O
the	O
case	O
of	O
standard	O
citrate	S-chem
reduced	O
gold	O
,	O
silver	S-chem
or	O
HGNs	O
with	O
a	O
LSPR	O
of	O
1080	O
nm	O
.	O

The	O
absorption	O
properties	O
of	O
HGNs	O
were	O
investigated	O
by	O
monitoring	O
their	O
photothermal	O
activity	O
.	O

In	O
this	O
case	O
,	O
different	O
nanoparticle	O
suspensions	O
including	O
citrate	S-chem
reduced	O
gold	O
,	O
silver	S-chem
,	O
and	O
HGNs	O
were	O
illuminated	O
by	O
a	O
continuous	O
laser	O
at	O
785	O
nm	O
excitation	O
wavelength	O
and	O
the	O
absorption	O
efficiency	O
of	O
HGNs	O
with	O
a	O
LSPR	O
of	O
775	O
nm	O
was	O
calculated	O
to	O
be	O
0.81	O
%	O
which	O
is	O
more	O
than	O
5	O
times	O
higher	O
than	O
the	O
absorption	O
efficiency	O
of	O
citrate	S-chem
reduced	O
gold	O
nanoparticles	O
under	O
similar	O
conditions	O
.	O

[	O
Retinoid	S-chem
therapy	O
for	O
autoimmune	O
diseases	O
]	O
.	O

Retinoid	S-chem-C3-1
is	O
a	O
collective	O
term	O
for	O
compounds	O
which	O
bind	O
to	O
and	O
activate	O
retinoic	B-geneN-C3-2
acid	I-geneN-C3-2
receptors	E-geneN-C3-2
(	O
RARalpha	B-geneN
,	I-geneN
beta	I-geneN
,	I-geneN
gamma	E-geneN
and	O
RXRalpha	B-geneN
,	I-geneN
beta	I-geneN
,	I-geneN
gamma	E-geneN
)	O
,	O
members	O
of	O
nuclear	B-geneN-C3-2
hormone	I-geneN-C3-2
receptor	E-geneN-C3-2
superfamily	O
.	O

The	O
most	O
important	O
endogeneous	O
retinoid	S-chem
is	O
all	B-chem
-	I-chem
trans	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
(	O
ATRA	S-chem
)	O
which	O
is	O
an	O
RARalpha	B-geneN
,	I-geneN
beta	I-geneN
and	I-geneN
gamma	E-geneN
ligand	O
.	O

ATRA	S-chem
and	O
its	O
mimics	O
have	O
been	O
in	O
clinical	O
use	O
for	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
and	O
some	O
skin	O
diseases	O
.	O

Many	O
synthetic	O
retinoids	O
have	O
been	O
developed	O
and	O
attempts	O
to	O
improve	O
their	O
medicinal	O
properties	O
have	O
been	O
made	O
.	O

Among	O
them	O
,	O
tamibarotene	S-chem
(	O
Am80	S-chem
)	O
is	O
an	O
RARalpha	S-geneY
-	O
and	O
RARbeta	S-geneY
-	O
specific	O
(	O
but	O
RARgamma	S-geneY
-	O
and	O
RXRs	S-geneN
-	O
nonbinding	O
)	O
synthetic	O
retinoid	S-chem
that	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
psoriasis	O
patients	O
and	O
relapsed	O
APL	O
.	O

Experimentally	O
,	O
this	O
compound	O
is	O
also	O
active	O
in	O
animal	O
models	O
of	O
rheumatoid	O
arthritis	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

On	O
this	O
background	O
,	O
possible	O
application	O
of	O
retinoids	S-chem
for	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
was	O
discussed	O
.	O

In	O
particular	O
,	O
Th1	O
dominant	O
autoimmune	O
diseases	O
may	O
be	O
the	O
targets	O
of	O
the	O
retinoids	S-chem
.	O

Human	B-geneY
UGT2B10	E-geneY
in	O
Drug	O
N	O
-	O
glucuronidations	O
:	O
Substrate	O
Screening	O
and	O
Comparison	O
with	O
UGT1A3	S-geneY
and	O
UGT1A4	S-geneY
.	O

Recent	O
observations	O
revealed	O
that	O
human	B-geneY-C9-2
UDP	I-geneY-C9-2
-	I-geneY-C9-2
glucuronosyltransferase	I-geneY-C9-2
(	I-geneY-C9-2
UGT	I-geneY-C9-2
)	I-geneY-C9-2
2B10	E-geneY-C9-2
catalyzes	O
N	O
-	O
glucuronidation	O
of	O
amine	S-chem-C9-1
-	O
containing	O
compounds	O
.	O

Knowledge	O
of	O
the	O
substrate	O
specificity	O
and	O
clinical	O
significance	O
of	O
UGT2B10	S-geneY
is	O
still	O
limited	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
expand	O
the	O
knowledge	O
of	O
UGT2B10	S-geneY
substrates	O
and	O
to	O
evaluate	O
its	O
significance	O
in	O
drug	O
clearance	O
.	O

Using	O
recombinant	O
UGT2B10	S-geneY-C9-2
,	O
we	O
found	O
that	O
it	O
catalyzes	O
the	O
N	O
-	O
glucuronidation	O
of	O
amitriptyline	S-chem-C9-1
,	O
imipramine	S-chem-C9-1
,	O
ketotifen	S-chem-C9-1
,	O
pizotifen	S-chem-C9-1
,	O
olanzapine	S-chem-C9-1
,	O
diphenhydramine	S-chem-C9-1
,	O
tamoxifen	S-chem-C9-1
,	O
ketoconazole	S-chem-C9-1
and	O
midazolam	S-chem-C9-1
.	O

These	O
are	O
drugs	O
that	O
were	O
previously	O
reported	O
to	O
be	O
substrates	O
for	O
UGT1A4	S-geneY
or	O
UGT1A3	S-geneY
and	O
that	O
contain	O
in	O
their	O
structure	O
either	O
tertiary	B-chem
aliphatic	I-chem
amines	E-chem
,	O
cyclic	B-chem
amines	E-chem
,	O
or	O
an	O
imidazole	S-chem
group	O
.	O

UGT2B10	S-geneY
was	O
inactive	O
in	O
the	O
glucuronidation	O
of	O
desipramine	S-chem
,	O
nortriptyline	S-chem
,	O
carbamazepine	S-chem
and	O
afloqualone	S-chem
.	O

This	O
group	O
of	O
drugs	O
contains	O
secondary	B-chem
or	I-chem
primary	I-chem
amines	E-chem
,	O
and	O
these	O
results	O
suggest	O
that	O
UGT2B10	S-geneY-C9-2
preferably	O
conjugates	O
tertiary	B-chem-C9-1
amines	E-chem-C9-1
.	O

This	O
preference	O
is	O
partial	O
because	O
UGT2B10	S-geneY
did	O
not	O
conjugate	O
the	O
tertiary	B-chem
cyclic	I-chem
amine	E-chem
in	O
trifluoperazine	S-chem
.	O

Kinetic	O
analyses	O
revealed	O
that	O
the	O
affinity	O
and	O
clearance	O
of	O
UGT2B10	S-geneY-C9-2
for	O
amitriptyline	S-chem-C9-1
,	O
imipramine	S-chem-C9-1
,	O
and	O
diphenhydramine	S-chem-C9-1
are	O
significantly	O
higher	O
than	O
the	O
corresponding	O
values	O
of	O
UGT1A4	S-geneY-C9-2
and	O
UGT1A3	S-geneY-C9-2
,	O
although	O
the	O
Vmax	O
values	O
of	O
UGT1A4	S-geneY-C9-2
toward	O
these	O
drugs	O
are	O
considerably	O
higher	O
.	O

These	O
findings	O
suggest	O
that	O
UGT2B10	S-geneY
plays	O
a	O
major	O
role	O
in	O
the	O
N	O
-	O
glucuronidation	O
of	O
these	O
drugs	O
at	O
therapeutic	O
concentrations	O
.	O

These	O
results	O
are	O
also	O
supported	O
by	O
inhibition	O
studies	O
with	O
nicotine	S-chem
and	O
hecogenin	S-chem
.	O

In	O
conclusion	O
,	O
this	O
study	O
expands	O
the	O
understanding	O
of	O
the	O
substrate	O
specificity	O
of	O
UGT2B10	S-geneY-C9-2
,	O
highlighting	O
its	O
preference	O
for	O
tertiary	B-chem-C9-1
amines	E-chem-C9-1
with	O
higher	O
affinities	O
and	O
clearance	O
values	O
than	O
those	O
of	O
UGT1A4	S-geneY-C9-2
and	O
UGT1A3	S-geneY-C9-2
.	O

Characterization	O
of	O
four	O
new	O
mouse	B-geneN
cytochrome	I-geneN
P450	E-geneN
enzymes	O
of	O
the	O
CYP2J	S-geneN
subfamily	O
.	O

The	O
cytochrome	B-geneN
P450	E-geneN
superfamily	O
encompasses	O
a	O
diverse	O
group	O
of	O
enzymes	O
that	O
catalyze	O
the	O
oxidation	O
of	O
various	O
substrates	O
.	O

The	O
mouse	O
CYP2J	S-geneN-C9-2
subfamily	O
includes	O
members	O
that	O
have	O
wide	O
tissue	O
distribution	O
and	O
are	O
active	O
in	O
the	O
metabolism	O
of	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
(	O
AA	O
)	O
,	O
linoleic	B-chem-C9-1
acid	E-chem-C9-1
(	O
LA	O
)	O
,	O
and	O
other	O
lipids	O
and	O
xenobiotics	O
.	O

The	O
mouse	B-geneN
Cyp2j	E-geneN
locus	O
contains	O
seven	O
genes	O
and	O
three	O
pseudogenes	O
located	O
in	O
a	O
contiguous	O
0.62	O
megabase	O
cluster	O
on	O
chromosome	O
4	O
.	O

We	O
describe	O
four	O
new	O
mouse	B-geneN
CYP2J	E-geneN
isoforms	O
(	O
designated	O
CYP2J8	S-geneY
,	O
CYP2J11	S-geneY
,	O
CYP2J12	S-geneY
,	O
and	O
CYP2J13	S-geneY
)	O
.	O

The	O
four	O
cDNAs	O
contain	O
open	O
reading	O
frames	O
that	O
encode	O
polypeptides	O
with	O
62	O
-	O
84	O
%	O
identity	O
with	O
the	O
three	O
previously	O
identified	O
mouse	B-geneN
CYP2Js	E-geneN
.	O

All	O
four	O
new	O
CYP2J	S-geneN
proteins	O
were	O
expressed	O
in	O
Sf21	O
insect	O
cells	O
.	O

Each	O
recombinant	O
protein	O
metabolized	O
AA	O
and	O
LA	O
to	O
epoxides	S-chem
and	O
hydroxy	S-chem
derivatives	O
.	O

Specific	O
antibodies	O
,	O
mRNA	O
probes	O
,	O
and	O
polymerase	O
chain	O
reaction	O
primer	O
sets	O
were	O
developed	O
for	O
each	O
mouse	O
CYP2J	S-geneN
to	O
examine	O
their	O
tissue	O
distribution	O
.	O

CYP2J8	S-geneY
transcripts	O
were	O
found	O
in	O
the	O
kidney	O
,	O
liver	O
,	O
and	O
brain	O
,	O
and	O
protein	O
expression	O
was	O
confirmed	O
in	O
the	O
kidney	O
and	O
brain	O
(	O
neuropil	O
)	O
.	O

CYP2J11	S-geneY
transcripts	O
were	O
most	O
abundant	O
in	O
the	O
kidney	O
and	O
heart	O
,	O
with	O
protein	O
detected	O
primarily	O
in	O
the	O
kidney	O
(	O
proximal	O
convoluted	O
tubules	O
)	O
,	O
liver	O
,	O
and	O
heart	O
(	O
cardiomyocytes	O
)	O
.	O

CYP2J12	S-geneY
transcripts	O
were	O
prominently	O
present	O
in	O
the	O
brain	O
,	O
and	O
CYP2J13	S-geneY
transcripts	O
were	O
detected	O
in	O
multiple	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
in	O
the	O
kidney	O
.	O

CYP2J12	S-geneY
and	O
CYP2J13	S-geneY
protein	O
expression	O
could	O
not	O
be	O
determined	O
because	O
the	O
antibodies	O
developed	O
were	O
not	O
immunospecific	O
.	O

We	O
conclude	O
that	O
the	O
four	O
new	O
CYP2J	S-geneN
isoforms	O
might	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
AA	O
and	O
LA	O
to	O
bioactive	O
lipids	O
in	O
mouse	O
hepatic	O
and	O
extrahepatic	O
tissues	O
.	O

Disruption	O
of	O
AtWNK8	S-geneY
Enhances	O
Tolerance	O
of	O
Arabidopsis	O
to	O
Salt	O
and	O
Osmotic	O
Stresses	O
via	O
Modulating	O
Proline	S-chem
Content	O
and	O
Activities	O
of	O
Catalase	S-geneN
and	O
Peroxidase	S-geneN
.	O

With	B-geneN
no	I-geneN
lysine	I-geneN
kinases	E-geneN
(	O
WNKs	S-geneN
)	O
play	O
important	O
roles	O
in	O
plant	O
growth	O
and	O
development	O
.	O

However	O
,	O
its	O
role	O
in	O
salt	O
and	O
osmotic	O
stress	O
tolerance	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
that	O
AtWNK8	S-geneY
is	O
mainly	O
expressed	O
in	O
primary	O
root	O
,	O
hypocotyl	O
,	O
stamen	O
and	O
pistil	O
and	O
is	O
induced	O
by	O
NaCl	S-chem
and	O
sorbitol	S-chem
treatment	O
.	O

Compared	O
to	O
the	O
wild	O
-	O
type	O
,	O
the	O
T	O
-	O
DNA	O
knock	O
-	O
out	O
wnk8	S-geneY
mutant	O
was	O
more	O
tolerant	O
to	O
severe	O
salinity	O
and	O
osmotic	O
stresses	O
,	O
as	O
indicated	O
by	O
27	O
%	O
and	O
198	O
%	O
more	O
fresh	O
weight	O
in	O
the	O
NaCl	S-chem
and	O
sorbitol	S-chem
treatment	O
,	O
respectively	O
.	O

The	O
wnk8	S-geneY
mutant	O
also	O
accumulated	O
1.43	O
-	O
fold	O
more	O
proline	S-chem
than	O
the	O
wild	O
-	O
type	O
in	O
the	O
sorbitol	S-chem
treatment	O
.	O

Under	O
NaCl	S-chem-C3-1
and	O
sorbitol	S-chem-C3-1
stresses	O
,	O
catalase	S-geneN-C3-2
(	O
CAT	S-geneN-C3-2
)	O
activity	O
in	O
wnk8	S-geneY
mutant	O
was	O
1.92	O
-	O
and	O
3.7	O
-	O
times	O
of	O
that	O
in	O
Col	O
-	O
0	O
,	O
respectively	O
.	O

Similarly	O
,	O
under	O
salt	O
and	O
osmotic	O
stress	O
conditions	O
,	O
peroxidase	S-geneN
(	O
POD	S-geneN
)	O
activities	O
in	O
wnk8	S-geneY
mutant	O
were	O
1.81	O
-	O
and	O
1.58	O
-	O
times	O
of	O
that	O
in	O
Col	O
-	O
0	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
we	O
revealed	O
that	O
maintaining	O
higher	O
CAT	S-geneN
and	O
POD	S-geneN
activities	O
might	O
be	O
one	O
of	O
the	O
reasons	O
that	O
the	O
disruption	O
of	O
AtWNK8	S-geneY
enhances	O
the	O
tolerance	O
to	O
salt	O
stress	O
,	O
and	O
accumulating	O
more	O
proline	S-chem
and	O
higher	O
activities	O
of	O
CAT	S-geneN
and	O
POD	S-geneN
might	O
result	O
in	O
the	O
higher	O
tolerance	O
of	O
WNK8	S-geneY
to	O
osmotic	O
stress	O
.	O

Sodium	S-chem
-	O
dependent	O
norepinephrine	S-chem-C3-1
-	O
induced	O
currents	O
in	O
norepinephrine	B-geneY-MU-2
-	I-geneY-MU-2
transporter	E-geneY-MU-2
-	O
transfected	O
HEK	O
-	O
293	O
cells	O
blocked	O
by	O
cocaine	S-chem-C4-1
and	O
antidepressants	O
.	O

Transport	O
of	O
norepinephrine	S-chem
(	O
NE	B-chem
+	E-chem
)	O
by	O
cocaine	S-chem
-	O
and	O
antidepressant	O
-	O
sensitive	O
transporters	O
in	O
presynaptic	O
terminals	O
is	O
predicted	O
to	O
involve	O
the	O
cotransport	O
of	O
Na	B-chem
+	E-chem
and	O
Cl	B-chem
-	E-chem
,	O
resulting	O
in	O
a	O
net	O
movement	O
of	O
charge	O
per	O
transport	O
cycle	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
catecholamine	S-chem
transport	O
and	O
ion	O
permeation	O
through	O
the	O
NE	B-geneY
transporter	E-geneY
,	O
we	O
established	O
a	O
human	B-geneY
norepinephrine	I-geneY
transporter	E-geneY
(	O
hNET	S-geneY
)	O
cell	O
line	O
suitable	O
for	O
biochemical	O
analysis	O
and	O
patch	O
-	O
clamp	O
recording	O
.	O

Stable	O
transfection	O
of	O
hNET	S-geneY
cDNA	O
into	O
HEK	O
-	O
293	O
(	O
human	O
embryonic	O
kidney	O
)	O
cells	O
results	O
in	O
lines	O
exhibiting	O
(	O
1	O
)	O
a	O
high	O
number	O
of	O
transporter	O
copies	O
per	O
cell	O
(	O
10	O
(	O
6	O
)	O
)	O
,	O
as	O
detected	O
by	O
radioligand	O
binding	O
and	O
hNET	S-geneY
-	O
specific	O
antibodies	O
,	O
(	O
2	O
)	O
high	O
-	O
affinity	O
,	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
transport	O
of	O
NE	S-chem
,	O
and	O
(	O
3	O
)	O
inhibitor	O
sensitivities	O
similar	O
to	O
those	O
of	O
native	O
membranes	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
of	O
hNET	S-geneY-MU-2
-	O
293	O
cells	O
reveals	O
NE	S-chem-C3-1
-	O
induced	O
,	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
currents	O
blocked	O
by	O
antidepressants	O
and	O
cocaine	S-chem-C4-1
that	O
are	O
absent	O
in	O
parental	O
cells	O
.	O

In	O
addition	O
to	O
NE	S-chem
-	O
dependent	O
currents	O
,	O
transfected	O
cells	O
posses	O
an	O
NE	S-chem
-	O
independent	O
mode	O
of	O
charge	O
movement	O
mediated	O
by	O
hNET	S-geneY
.	O
hNET	S-geneY
antagonists	O
without	O
effect	O
in	O
non	O
-	O
transfected	O
cells	O
abolish	O
both	O
NE	S-chem
-	O
dependent	O
and	O
NE	S-chem
-	O
independent	O
modes	O
of	O
charge	O
movement	O
in	O
transfected	O
cells	O
.	O

The	O
magnitude	O
of	O
NE	S-chem
-	O
dependent	O
currents	O
in	O
these	O
cells	O
exceeds	O
the	O
expectations	O
of	O
simple	O
carrier	O
models	O
using	O
previous	O
estimates	O
of	O
transport	O
rates	O
.	O

To	O
explain	O
our	O
observations	O
,	O
we	O
propose	O
that	O
hNETs	S-geneY-C9-2
function	O
as	O
ion	B-geneN
-	I-geneN
gated	I-geneN
ligand	I-geneN
channels	E-geneN
with	O
an	O
indefinite	O
stoichiometry	O
relating	O
ion	O
flux	O
to	O
NE	S-chem-C9-1
transport	O
.	O

In	O
this	O
view	O
,	O
external	O
Na	B-chem
+	E-chem
and	O
NE	S-chem
bind	O
to	O
the	O
transporter	O
with	O
finite	O
affinities	O
in	O
a	O
cooperative	O
fashion	O
.	O

However	O
,	O
coupled	O
transport	O
may	O
not	O
predict	O
the	O
magnitude	O
or	O
the	O
kinetics	O
of	O
the	O
total	O
current	O
through	O
the	O
transporter	O
.	O

We	O
propose	O
instead	O
that	O
Na	B-chem
+	E-chem
gates	O
NE	S-chem
transport	O
and	O
also	O
the	O
parallel	O
inward	O
flux	O
of	O
an	O
indeterminate	O
number	O
of	O
ions	O
through	O
a	O
channel	O
-	O
like	O
pore	O
.	O

Induction	O
of	O
cyp1a1	S-geneY
is	O
a	O
nonspecific	O
biomarker	O
of	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
activation	O
:	O
results	O
of	O
large	O
scale	O
screening	O
of	O
pharmaceuticals	O
and	O
toxicants	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Expression	O
of	O
Cyp1a1	S-geneY
and	O
its	O
related	O
enzyme	O
activity	O
have	O
long	O
been	O
used	O
as	O
a	O
biomarker	O
for	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AhR	S-geneY
)	O
activation	O
and	O
a	O
warning	O
of	O
dioxin	S-chem
-	O
like	O
toxicity	O
.	O

As	O
a	O
result	O
,	O
induction	O
of	O
Cyp1a1	S-geneY
by	O
pharmaceutical	O
drug	O
candidates	O
or	O
environmental	O
contaminants	O
raises	O
significant	O
concern	O
in	O
risk	O
assessment	O
.	O

The	O
current	O
study	O
evaluates	O
the	O
specificity	O
of	O
Cyp1a1	S-geneY
induction	O
as	O
a	O
marker	O
for	O
AhR	S-geneY
affinity	O
and	O
activation	O
and	O
provides	O
context	O
to	O
assess	O
the	O
relevancy	O
of	O
AhR	S-geneY
activation	O
to	O
risk	O
assessment	O
.	O

In	O
vivo	O
experiments	O
examined	O
the	O
expression	O
of	O
Cyp1a1	S-geneY
and	O
other	O
AhR	S-geneY
-	O
regulated	O
genes	O
in	O
liver	O
,	O
kidney	O
,	O
and	O
heart	O
in	O
response	O
to	O
596	O
compounds	O
.	O

From	O
this	O
data	O
set	O
,	O
a	O
subset	O
of	O
147	O
compounds	O
was	O
then	O
evaluated	O
for	O
their	O
ability	O
to	O
activate	O
or	O
bind	O
to	O
the	O
AhR	S-geneY
using	O
a	O
combination	O
of	O
gel	O
shift	O
,	O
reporter	O
gene	O
,	O
and	O
competitive	O
receptor	O
binding	O
assays	O
.	O

Whereas	O
in	O
vivo	O
Cyp1a1	S-geneY
mRNA	O
expression	O
is	O
a	O
sensitive	O
marker	O
for	O
AhR	S-geneY
activation	O
,	O
it	O
lacks	O
specificity	O
,	O
because	O
81	O
(	O
59	O
%	O
)	O
of	O
137	O
compounds	O
were	O
found	O
to	O
significantly	O
induce	O
Cyp1a1	S-geneY
in	O
vivo	O
but	O
were	O
not	O
verified	O
to	O
bind	O
or	O
activate	O
the	O
AhR	S-geneY
in	O
vitro	O
.	O

Combining	O
in	O
vivo	O
and	O
in	O
vitro	O
findings	O
,	O
we	O
identified	O
nine	O
AhR	S-geneY
agonists	O
,	O
six	O
of	O
which	O
are	O
marketed	O
therapeutics	O
and	O
have	O
been	O
approved	O
by	O
the	O
U.S	O
.	O

Food	O
and	O
Drug	O
Administration	O
,	O
including	O
leflunomide	S-chem
,	O
flutamide	S-chem
,	O
and	O
nimodipine	S-chem
.	O

These	O
drugs	O
do	O
not	O
produce	O
dioxin	S-chem
-	O
like	O
toxicity	O
in	O
rats	O
or	O
in	O
humans	O
.	O

These	O
data	O
demonstrate	O
that	O
induction	O
of	O
Cyp1a1	S-geneY
is	O
a	O
nonspecific	O
biomarker	O
of	O
direct	O
AhR	S-geneY
affinity	O
and	O
activation	O
and	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
Cyp1a1	S-geneY
induction	O
and	O
/	O
or	O
AhR	S-geneY
activation	O
is	O
not	O
synonymous	O
with	O
dioxin	S-chem
-	O
like	O
toxicity	O
.	O

Effect	O
of	O
ramelteon	S-chem-C5-1
(	O
TAK	B-chem-C5-1
-	I-chem-C5-1
375	E-chem-C5-1
)	O
,	O
a	O
selective	O
MT1	B-geneN-C5-2
/	I-geneN-C5-2
MT2	I-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
,	O
on	O
motor	O
performance	O
in	O
mice	O
.	O

Effect	O
of	O
(	B-chem-C5-1
S	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
N	I-chem-C5-1
-	I-chem-C5-1
[	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
1,6,7,8	I-chem-C5-1
-	I-chem-C5-1
tetrahydro	I-chem-C5-1
-	I-chem-C5-1
2H	I-chem-C5-1
-	I-chem-C5-1
indeno	I-chem-C5-1
-	I-chem-C5-1
[	I-chem-C5-1
5,4	I-chem-C5-1
-	I-chem-C5-1
b	I-chem-C5-1
]	I-chem-C5-1
furan	I-chem-C5-1
-	I-chem-C5-1
8	I-chem-C5-1
-	I-chem-C5-1
yl	I-chem-C5-1
)	I-chem-C5-1
ethyl	I-chem-C5-1
]	I-chem-C5-1
propionamide	E-chem-C5-1
(	O
ramelteon	S-chem-C5-1
,	O
TAK	B-chem-C5-1
-	I-chem-C5-1
375	E-chem-C5-1
)	O
,	O
a	O
selective	O
MT1	B-geneN-C5-2
/	I-geneN-C5-2
MT2	I-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
,	O
on	O
motor	O
coordination	O
was	O
studied	O
using	O
rota	O
-	O
rod	O
performance	O
in	O
mice	O
.	O

Ramelteon	S-chem
did	O
not	O
impair	O
rota	O
-	O
rod	O
performance	O
at	O
doses	O
of	O
3	O
,	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O

Melatonin	S-chem
and	O
N	B-chem
-	I-chem
acetyl	I-chem
-	I-chem
5	I-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
N	B-chem
-	I-chem
acetyl	I-chem
-	I-chem
5	I-chem
-	I-chem
HT	E-chem
)	O
,	O
a	O
ligand	O
of	O
MT3	S-geneN
biding	O
site	O
,	O
also	O
had	O
no	O
impairment	O
on	O
the	O
performance	O
,	O
per	O
se	O
.	O

However	O
,	O
in	O
combination	O
with	O
a	O
low	O
dose	O
of	O
diazepam	S-chem
(	O
3mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
treatment	O
with	O
melatonin	S-chem
and	O
N	B-chem
-	I-chem
acetyl	I-chem
-	I-chem
5	I-chem
-	I-chem
HT	E-chem
exacerbated	O
the	O
impairment	O
by	O
diazepam	S-chem
.	O

Ramelteon	S-chem
had	O
no	O
significant	O
effect	O
on	O
the	O
diazepam	S-chem
-	O
induced	O
impairment	O
of	O
motor	O
coordination	O
.	O

Tunable	O
morphology	O
and	O
mesophase	O
formation	O
by	O
naphthalene	S-chem
-	O
containing	O
poly	B-chem
(	I-chem
aryl	I-chem
ether	I-chem
)	E-chem
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
fluorescent	O
gels	O
.	O

Novel	O
poly	B-chem
(	I-chem
aryl	I-chem
ether	I-chem
)	E-chem
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
organogelaters	O
(	O
LMWG	O
)	O
containing	O
naphthalene	S-chem
units	O
at	O
the	O
core	O
have	O
been	O
synthesized	O
,	O
and	O
the	O
self	O
-	O
assembly	O
of	O
the	O
system	O
has	O
been	O
examined	O
in	O
a	O
variety	O
of	O
solvents	O
and	O
solvent	O
mixtures	O
.	O

The	O
compounds	O
readily	O
form	O
gels	O
with	O
attractive	O
critical	O
gel	O
concentration	O
values	O
associated	O
with	O
gelation	O
-	O
induced	O
enhanced	O
emission	O
(	O
GIEE	O
)	O
.	O

In	O
addition	O
to	O
the	O
remarkable	O
properties	O
of	O
the	O
previously	O
reported	O
anthracene	S-chem
and	O
pyrene	S-chem
analogues	O
(	O
Rajamalli	O
,	O
P.	O
;	O
Prasad	O
,	O
E	O
.	O

Org	O
.	O

Lett.2011	O
,	O
13	O
,	O
3714	O
and	O
Rajamalli	O
,	O
P.	O
;	O
Prasad	O
,	O
E	O
.	O

Soft	O
Matter2012	O
,	O
8	O
,	O
8896	O
)	O
,	O
the	O
self	O
-	O
assembled	O
systems	O
exhibit	O
distinctly	O
different	O
structure	O
-	O
property	O
relationships	O
.	O

Unlike	O
the	O
reported	O
ones	O
,	O
the	O
present	O
system	O
forms	O
sheetlike	O
morphology	O
in	O
nonpolar	O
solvent	O
mixtures	O
,	O
giant	O
vesicles	O
in	O
polar	O
solvent	O
mixtures	O
,	O
and	O
lamellar	O
or	O
hexagonal	O
columnar	O
phases	O
in	O
single	O
solvents	O
.	O

The	O
unique	O
properties	O
of	O
the	O
self	O
-	O
assembled	O
systems	O
,	O
which	O
were	O
analyzed	O
through	O
electron	O
microscopic	O
(	O
SEM	O
,	O
TEM	O
,	O
AFM	O
)	O
and	O
spectroscopic	O
techniques	O
(	O
POM	O
,	O
fluorescence	O
)	O
,	O
are	O
attributed	O
to	O
the	O
replacement	O
of	O
anthracene	S-chem
/	O
pyrene	S-chem
units	O
by	O
naphthalene	S-chem
units	O
.	O

The	O
present	O
work	O
unravels	O
the	O
subtle	O
role	O
of	O
minute	O
structural	O
change	O
in	O
altering	O
the	O
properties	O
of	O
LMWGs	O
based	O
on	O
poly	B-chem
(	I-chem
aryl	I-chem
ether	I-chem
)	E-chem
dendrons	O
.	O

Effect	O
of	O
anabolic	O
-	O
androgenic	O
steroids	S-chem
and	O
glucocorticoids	O
on	O
the	O
kinetics	O
of	O
hAR	S-geneY
and	O
hGR	S-geneY
nucleocytoplasmic	O
translocation	O
.	O

Although	O
the	O
qualitative	O
nucleocytoplasmic	O
transport	O
of	O
nuclear	B-geneN
hormone	I-geneN
receptors	E-geneN
(	O
NHRs	S-geneN
)	O
has	O
been	O
studied	O
,	O
there	O
is	O
little	O
documentation	O
of	O
the	O
cellular	O
kinetics	O
of	O
this	O
transport	O
.	O

Here	O
,	O
translocation	O
studies	O
using	O
the	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
(	O
hAR	S-geneY
)	O
and	O
the	O
human	B-geneY
glucocorticoid	I-geneY
receptor	E-geneY
(	O
hGR	S-geneY
)	O
were	O
performed	O
to	O
aid	O
in	O
identifying	O
the	O
mechanism	O
by	O
which	O
anabolic	O
-	O
androgenic	O
steroids	S-chem-C3-1
(	O
AAS	O
)	O
were	O
activating	O
hAR	S-geneY-C3-2
and	O
potentially	O
interacting	O
with	O
hGR	S-geneY
and	O
how	O
glucocorticoid	O
ligands	O
were	O
interacting	O
with	O
the	O
hGR	S-geneY
and	O
hAR	S-geneY
.	O

The	O
real	O
-	O
time	O
analysis	O
of	O
EGFP	O
-	O
labeled	O
hAR	S-geneY
and	O
hGR	S-geneY
ligand	O
-	O
induced	O
cytoplasm	O
-	O
to	O
-	O
nucleus	O
translocation	O
was	O
performed	O
using	O
fluorescence	O
microscopy	O
to	O
better	O
understand	O
the	O
action	O
of	O
these	O
NHRs	S-geneN
in	O
a	O
physiologically	O
relevant	O
cell	O
-	O
based	O
model	O
.	O

After	O
transient	O
transfection	O
,	O
the	O
hAR	S-geneY
and	O
hGR	S-geneY
individually	O
translocate	O
as	O
expected	O
(	O
i.e	O
.	O
,	O
transport	O
is	O
ligand	O
-	O
induced	O
and	O
dose	O
-	O
dependent	O
)	O
in	O
this	O
model	O
biological	O
system	O
.	O

Testosterone	S-chem
(	O
TEST	S-chem
)	O
had	O
the	O
fastest	O
translocation	O
rate	O
for	O
the	O
hAR	S-geneY
of	O
0.0525	O
min	O
(	O
-	O
1	O
)	O
.	O

The	O
other	O
endogenous	O
steroids	S-chem
,	O
androstenedione	S-chem
(	O
ANE	S-chem
)	O
and	O
dihydrotestosterone	S-chem
(	O
DHT	S-chem
)	O
,	O
had	O
considerably	O
lower	O
hAR	S-geneY
transport	O
rates	O
.	O

The	O
rates	O
of	O
hAR	S-geneY
transport	O
for	O
the	O
exogenous	O
steroids	S-chem
methyltrienelone	S-chem
(	O
MET	S-chem
)	O
,	O
nandrolone	S-chem
(	O
NAN	S-chem
)	O
,	O
and	O
oxandrolone	S-chem
(	O
OXA	S-chem
)	O
are	O
lower	O
than	O
that	O
of	O
testosterone	S-chem
and	O
similar	O
to	O
those	O
of	O
the	O
endogenous	O
steroids	S-chem
ANE	S-chem
and	O
DHT	S-chem
.	O

The	O
hGR	S-geneY
transport	O
rates	O
for	O
cortisol	O
(	O
COR	O
)	O
and	O
dexamethasone	O
(	O
DEX	O
)	O
are	O
also	O
presented	O
.	O

The	O
synthetic	O
GC	O
,	O
DEX	O
,	O
had	O
a	O
more	O
rapid	O
translocation	O
rate	O
(	O
0.1599	O
min	O
(	O
-	O
1	O
)	O
)	O
at	O
the	O
highest	O
dose	O
of	O
100	O
nM	O
compared	O
to	O
the	O
endogenous	O
GC	O
COR	O
(	O
0.0431	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
data	O
obtained	O
agrees	O
with	O
the	O
existing	O
qualitative	O
data	O
and	O
adds	O
an	O
important	O
ligand	O
-	O
dependent	O
kinetic	O
component	O
to	O
hAR	S-geneY
and	O
hGR	S-geneY
transport	O
.	O

These	O
kinetic	O
data	O
can	O
aid	O
our	O
understanding	O
of	O
NHR	S-geneN
action	O
and	O
interaction	O
with	O
other	O
regulatory	O
proteins	O
,	O
and	O
can	O
be	O
useful	O
in	O
the	O
development	O
of	O
new	O
therapies	O
.	O

A	O
novel	O
benzo	B-chem-C4-1
[	I-chem-C4-1
d	I-chem-C4-1
]	I-chem-C4-1
imidazole	E-chem-C4-1
derivate	O
prevents	O
the	O
development	O
of	O
dextran	O
sulfate	O
sodium	S-chem
-	O
induced	O
murine	O
experimental	O
colitis	O
via	O
inhibition	O
of	O
NLRP3	S-geneY-C4-2
inflammasome	O
.	O

NLRP3	S-geneY
inflammasome	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
various	O
kinds	O
of	O
immunological	O
diseases	O
including	O
colitis	O
.	O

However	O
,	O
there	O
are	O
few	O
drug	O
candidates	O
targeting	O
inflammasomes	O
for	O
the	O
treatment	O
of	O
colitis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
at	O
examining	O
the	O
effect	O
of	O
1	B-chem
-	I-chem
ethyl	I-chem
-	I-chem
5	I-chem
-	I-chem
methyl	I-chem
-	I-chem
2	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1H	I-chem
-	I-chem
benzo	I-chem
[	I-chem
d	I-chem
]	I-chem
imidazole	E-chem
,	O
a	O
synthetic	O
small	O
molecular	O
compound	O
also	O
named	O
Fc11a	B-chem
-	I-chem
2	E-chem
,	O
for	O
the	O
treatment	O
of	O
dextran	O
sulfate	S-chem
sodium	S-chem
(	O
DSS	O
)	O
-	O
induced	O
experimental	O
colitis	O
in	O
mice	O
via	O
targeting	O
NLRP3	S-geneY
inflammasome	O
.	O

Treatment	O
with	O
Fc11a	O
-	O
2	O
dose	O
-	O
dependently	O
attenuated	O
the	O
loss	O
of	O
body	O
weight	O
and	O
shortening	O
of	O
colon	O
length	O
induced	O
by	O
DSS	O
.	O

In	O
addition	O
,	O
the	O
disease	O
activity	O
index	O
,	O
histopathologic	O
scores	O
and	O
myeloperoxidase	S-geneN-C4-2
activity	O
were	O
also	O
significantly	O
reduced	O
by	O
Fc11a	B-chem-C4-1
-	I-chem-C4-1
2	E-chem-C4-1
treatment	O
.	O

Moreover	O
,	O
protein	O
and	O
mRNA	O
levels	O
of	O
DSS	O
-	O
induced	O
proinflammatory	O
cytokines	S-geneN-C4-2
in	O
colon	O
,	O
including	O
TNF	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
18	E-geneY-C4-2
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
17A	E-geneY-C4-2
and	O
IFN	B-geneY-C4-2
-	I-geneY-C4-2
γ	E-geneY-C4-2
,	O
were	O
markedly	O
suppressed	O
by	O
Fc11a	B-chem-C4-1
-	I-chem-C4-1
2	E-chem-C4-1
.	O

Furthermore	O
,	O
a	O
decreased	O
CD11c	O
(	O
+	O
)	O
macrophage	O
infiltration	O
in	O
colons	O
and	O
inactivation	O
of	O
caspase	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
in	O
peritoneal	O
macrophages	O
were	O
detected	O
in	O
Fc11a	S-chem-C4-1
-	O
2	O
-	O
treated	O
mice	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
Fc11a	B-chem-C4-1
-	I-chem-C4-1
2	E-chem-C4-1
was	O
related	O
to	O
the	O
inhibition	O
of	O
the	O
cleavage	O
of	O
pro	B-geneY-C4-2
-	I-geneY-C4-2
caspase	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
pro	B-geneY-C4-2
-	I-geneY-C4-2
IL	I-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
and	O
pro	B-geneY-C4-2
-	I-geneY-C4-2
IL	I-geneY-C4-2
-	I-geneY-C4-2
18	E-geneY-C4-2
which	O
in	O
turn	O
suppressed	O
the	O
activation	O
of	O
NLRP3	S-geneY-C4-2
inflammasome	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
ability	O
of	O
Fc11a	B-chem-C4-1
-	I-chem-C4-1
2	E-chem-C4-1
to	O
inhibit	O
NLRP3	S-geneY-C4-2
inflammasome	O
activation	O
and	O
its	O
potential	O
use	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O

Analysis	O
of	O
alpha	B-geneN
1L	I-geneN
-	I-geneN
adrenoceptor	E-geneN
pharmacology	O
in	O
rat	O
small	O
mesenteric	O
artery	O
.	O

1	O
.	O

To	O
illuminate	O
the	O
controversy	O
on	O
alpha	B-geneY
1A	E-geneY
-	O
or	O
alpha	B-geneN
1L	I-geneN
-	I-geneN
adrenoceptor	E-geneN
involvement	O
in	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
small	O
mesenteric	O
artery	O
(	O
SMA	O
)	O
,	O
we	O
have	O
studied	O
the	O
effects	O
of	O
subtype	O
-	O
selective	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
and	O
antagonists	O
under	O
different	O
experimental	O
conditions	O
.	O

2	O
.	O

The	O
agonist	O
potency	O
order	O
in	O
rat	O
SMA	O
was	O
:	O
A61603	S-chem
>	O
>	O
SKF89748	B-chem
-	I-chem
A	E-chem
>	O
cirazoline	S-chem
>	O
noradrenaline	S-chem
>	O
ST	B-chem
-	I-chem
587	E-chem
>	O
methoxamine	S-chem
.	O

Prazosin	S-chem
antagonized	O
all	O
agonists	O
with	O
a	O
low	O
potency	O
(	O
pA2	O
:	O
8.29	O
-	O
8.80	O
)	O
indicating	O
the	O
involvement	O
of	O
alpha	B-geneN
1L	E-geneN
-	O
rather	O
than	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptors	E-geneY
.	O

3	O
.	O

The	O
putative	O
alpha	B-geneN-C6-2
1L	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
JTH	B-chem-C6-1
-	I-chem-C6-1
601	E-chem-C6-1
,	O
but	O
not	O
the	O
alpha	B-geneY-C6-2
1B	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
chloroethylclonidine	S-chem-C6-1
(	O
10	O
microM	O
)	O
antagonized	O
noradrenaline	S-chem
-	O
induced	O
contractions	O
of	O
SMA	O
.	O

The	O
potency	O
of	O
the	O
selective	O
alpha	B-geneY-C6-2
1D	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
BMY	B-chem-C6-1
7378	E-chem-C6-1
against	O
noradrenaline	S-chem
(	O
pA2	O
=	O
6.16	O
+	O
/	O
-	O
0.13	O
)	O
and	O
of	O
the	O
selective	O
alpha	B-geneY-C6-2
1A	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
RS	B-chem-C6-1
-	I-chem-C6-1
17053	E-chem-C6-1
against	O
noradrenaline	S-chem
(	O
pKB	O
=	O
8.35	O
+	O
/	O
-	O
0.10	O
)	O
and	O
against	O
the	O
selective	O
alpha	B-geneY-C5-2
1A	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
A	B-chem-C5-1
-	I-chem-C5-1
61603	E-chem-C5-1
(	O
pKB	O
=	O
8.40	O
+	O
/	O
-	O
0.09	O
)	O
were	O
too	O
low	O
to	O
account	O
for	O
alpha	B-geneY
1D	E-geneY
-	O
and	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
involvement	O
.	O

4	O
.	O

The	O
potency	O
of	O
RS	B-chem
-	I-chem
17053	E-chem
(	O
pKB	O
/	O
pA2	O
's	O
=	O
7.72	O
-	O
8.46	O
)	O
was	O
not	O
affected	O
by	O
lowering	O
temperature	O
,	O
changing	O
experimental	O
protocol	O
or	O
inducing	O
myogenic	O
tone	O
via	O
KCl	S-chem
or	O
U46619	S-chem
.	O

5	O
.	O

Selective	O
protection	O
of	O
a	O
putative	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
population	O
against	O
the	O
irreversible	O
action	O
of	O
phenoxybenzamine	S-chem
also	O
failed	O
to	O
increase	O
the	O
potency	O
of	O
RS	B-chem
-	I-chem
17053	E-chem
(	O
pA2	O
=	O
8.25	O
+	O
/	O
-	O
0.06	O
against	O
A61603	O
)	O
.	O

6	O
.	O

Combined	O
concentration	O
-	O
ratio	O
analysis	O
demonstrated	O
that	O
tamsulosin	S-chem
,	O
which	O
does	O
not	O
discriminate	O
between	O
alpha	B-geneY
1A	E-geneY
-	O
and	O
alpha	B-geneN
1L	I-geneN
-	I-geneN
adrenoceptors	E-geneN
,	O
and	O
RS	B-chem
-	I-chem
17053	E-chem
competed	O
for	O
binding	O
at	O
the	O
same	O
site	O
in	O
the	O
SMA	O
.	O

7	O
.	O

In	O
summary	O
,	O
data	O
obtained	O
in	O
our	O
experiments	O
in	O
rat	O
SMA	O
indicate	O
that	O
the	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
mediating	O
noradrenaline	S-chem
-	O
induced	O
contraction	O
displays	O
a	O
distinct	O
alpha	B-geneN
1L	I-geneN
-	I-geneN
adrenoceptor	E-geneN
pharmacology	O
.	O

This	O
study	O
does	O
not	O
provide	O
evidence	O
for	O
the	O
hypothesis	O
that	O
alpha	B-geneN
1L	I-geneN
-	I-geneN
adrenoceptors	E-geneN
represent	O
an	O
affinity	O
state	O
of	O
the	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
in	O
functional	O
assays	O
.	O

Furthermore	O
,	O
there	O
is	O
no	O
co	O
-	O
existing	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
in	O
the	O
SMA	O
.	O

Chromosomal	O
localization	O
,	O
gene	O
structure	O
,	O
and	O
expression	O
pattern	O
of	O
DDAH1	S-geneY
:	O
comparison	O
with	O
DDAH2	S-geneY
and	O
implications	O
for	O
evolutionary	O
origins	O
.	O

Endogenously	O
produced	O
asymmetrically	O
methylated	O
arginine	S-chem-C4-1
residues	O
are	O
competitive	O
inhibitors	O
of	O
all	O
three	O
isoforms	O
of	O
nitric	B-geneN-C4-2
oxide	I-geneN-C4-2
synthase	E-geneN-C4-2
(	O
NOS	S-geneN-C4-2
)	O
.	O

The	O
enzyme	O
dimethylarginine	B-geneN-C9-2
dimethylaminohydrolase	E-geneN-C9-2
(	O
DDAH	S-geneN-C9-2
)	O
specifically	O
hydrolyzes	O
these	O
asymmetrically	O
methylated	O
arginine	S-chem-C9-1
residues	O
to	O
citrulline	O
and	O
methylamines	O
.	O

Previously	O
we	O
have	O
proposed	O
that	O
regulation	O
of	O
asymmetric	O
methylarginine	S-chem-C9-1
concentration	O
by	O
DDAH	S-geneN-C9-2
may	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
regulation	O
of	O
NOS	S-geneN
activity	O
in	O
vivo	O
.	O

Recently	O
we	O
reported	O
the	O
cloning	O
of	O
human	B-geneN
DDAH	E-geneN
and	O
identified	O
a	O
novel	O
human	B-geneN
DDAH	E-geneN
isoform	O
(	O
DDAH	B-geneY
I	E-geneY
and	O
DDAH	B-geneY
II	E-geneY
,	O
respectively	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
DDAH1	S-geneY
gene	O
maps	O
to	O
chromosome	O
1p22	O
and	O
confirm	O
that	O
DDAH2	S-geneY
maps	O
to	O
the	O
MHC	O
III	O
region	O
of	O
chromosome	O
6p21.3	O
.	O

Extensive	O
analysis	O
of	O
the	O
distribution	O
of	O
DDAH1	S-geneY
and	O
DDAH2	S-geneY
mRNA	O
in	O
50	O
human	O
tissues	O
indicates	O
differential	O
expression	O
of	O
DDAH	S-geneN
isoforms	O
in	O
brain	O
regions	O
,	O
in	O
immune	O
cells	O
,	O
and	O
during	O
development	O
.	O

DDAH2	S-geneY
expression	O
predominates	O
in	O
highly	O
vascularized	O
tissues	O
that	O
express	O
the	O
endothelial	B-geneY
NOS	E-geneY
isoform	O
and	O
in	O
immune	O
tissues	O
that	O
can	O
express	O
iNOS	S-geneY
.	O

Whereas	O
DDAH2	S-geneY
is	O
expressed	O
at	O
relatively	O
high	O
levels	O
in	O
all	O
fetal	O
tissues	O
examined	O
,	O
DDAH1	S-geneY
expression	O
varies	O
little	O
between	O
fetal	O
and	O
adult	O
tissues	O
.	O

The	O
chromosomal	O
localization	O
of	O
the	O
DDAHs	S-geneN
is	O
consistent	O
with	O
gene	O
duplication	O
,	O
and	O
consistent	O
with	O
this	O
,	O
comparison	O
of	O
the	O
gene	O
structures	O
indicates	O
that	O
the	O
intron	O
/	O
exon	O
organization	O
is	O
highly	O
conserved	O
.	O

Phylogenetic	O
analysis	O
of	O
DDAH	S-geneN
sequences	O
from	O
diverse	O
species	O
suggests	O
that	O
DDAH	S-geneN
gene	O
duplication	O
occurred	O
prior	O
to	O
the	O
emergence	O
of	O
bony	O
fish	O
some	O
400	O
million	O
years	O
ago	O
.	O

Overall	O
the	O
data	O
suggest	O
that	O
DDAH2	S-geneY
may	O
be	O
the	O
more	O
ancient	O
of	O
the	O
two	O
genes	O
.	O

Pegylated	B-geneN
recombinant	I-geneN
human	I-geneN
arginase	E-geneN
(	O
rhArg	S-geneN
-	O
peg5,000mw	O
)	O
inhibits	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
proliferation	O
of	O
human	O
hepatocellular	O
carcinoma	O
through	O
arginine	S-chem
depletion	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
believed	O
to	O
be	O
auxotrophic	O
for	O
arginine	S-chem
through	O
the	O
lack	O
of	O
expression	O
of	O
argininosuccinate	B-geneY
synthetase	E-geneY
(	O
ASS	S-geneY
)	O
.	O

The	O
successful	O
use	O
of	O
the	O
arginine	B-geneN
-	I-geneN
depleting	I-geneN
enzyme	E-geneN
arginine	B-geneN
deiminase	E-geneN
(	O
ADI	S-geneN
)	O
to	O
treat	O
ASS	S-geneY
-	O
deficient	O
tumors	O
has	O
opened	O
up	O
new	O
possibilities	O
for	O
effective	O
cancer	O
therapy	O
.	O

Nevertheless	O
,	O
many	O
ASS	S-geneY
-	O
positive	O
HCC	O
cell	O
lines	O
are	O
found	O
to	O
be	O
resistant	O
to	O
ADI	S-geneN
treatment	O
,	O
although	O
most	O
require	O
arginine	S-chem
for	O
proliferation	O
.	O

Thus	O
far	O
,	O
an	O
arginine	B-geneN
-	I-geneN
depleting	I-geneN
enzyme	E-geneN
for	O
killing	O
ASS	S-geneY
-	O
positive	O
tumors	O
has	O
not	O
been	O
reported	O
.	O

Here	O
,	O
we	O
provide	O
direct	O
evidence	O
that	O
recombinant	O
human	B-geneN
arginase	E-geneN
(	O
rhArg	S-geneN
)	O
inhibits	O
ASS	S-geneY
-	O
positive	O
HCCs	O
.	O

All	O
the	O
five	O
human	O
HCC	O
cell	O
lines	O
we	O
used	O
were	O
sensitive	O
to	O
rhArg	S-geneN
but	O
ADI	S-geneN
had	O
virtually	O
no	O
effect	O
on	O
these	O
cells	O
.	O

They	O
all	O
expressed	O
ASS	S-geneY
,	O
but	O
not	O
ornithine	B-geneY-C9-2
transcarbamylase	E-geneY-C9-2
(	O
OTC	S-geneY-C9-2
)	O
,	O
the	O
enzyme	O
that	O
converts	O
ornithine	S-chem-C9-1
,	O
the	O
product	O
of	O
degradation	O
of	O
arginine	S-chem-C9-1
with	O
rhArg	S-geneN-C9-2
,	O
to	O
citrulline	S-chem-C9-1
,	O
which	O
is	O
converted	O
back	O
to	O
arginine	S-chem-C9-1
via	O
ASS	S-geneY-C9-2
.	O

Transfection	O
of	O
HCC	O
cells	O
with	O
OTC	S-geneY
resulted	O
in	O
resistance	O
to	O
rhArg	S-geneN
.	O

Thus	O
,	O
OTC	S-geneY
expression	O
alone	O
may	O
be	O
sufficient	O
to	O
induce	O
rhArg	S-geneN
resistance	O
in	O
ASS	S-geneY
-	O
positive	O
HCC	O
cells	O
.	O

This	O
surprising	O
correlation	O
between	O
the	O
lack	O
of	O
OTC	S-geneY
expression	O
and	O
sensitivity	O
of	O
ASS	S-geneY
-	O
positive	O
HCC	O
cells	O
shows	O
that	O
OTC	S-geneY
-	O
deficient	O
HCCs	O
are	O
sensitive	O
to	O
rhArg	S-geneN-C9-2
-	O
mediated	O
arginine	S-chem-C9-1
depletion	O
.	O

Therefore	O
,	O
pretreatment	O
tumor	O
gene	O
expression	O
profiling	O
of	O
ASS	S-geneY
and	O
OTC	S-geneY
could	O
aid	O
in	O
predicting	O
tumor	O
response	O
to	O
arginine	S-chem-C9-1
depletion	O
with	O
arginine	B-geneN-C9-2
-	I-geneN-C9-2
depleting	I-geneN-C9-2
enzymes	E-geneN-C9-2
.	O

We	O
have	O
also	O
shown	O
that	O
the	O
rhArg	S-geneN
native	O
enzyme	O
and	O
the	O
pegylated	B-geneN
rhArg	E-geneN
(	O
rhArg	S-geneN
-	O
peg	O
(	O
5,000mw	O
)	O
)	O
gave	O
similar	O
anticancer	O
efficacy	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
growth	O
of	O
the	O
OTC	S-geneY
-	O
deficient	O
Hep3B	O
tumor	O
cells	O
(	O
ASS	S-geneY
-	O
positive	O
and	O
ADI	S-geneN
-	O
resistant	O
)	O
in	O
mice	O
was	O
inhibited	O
by	O
treatment	O
with	O
rhArg	S-geneN
-	O
peg	O
(	O
5,000mw	O
)	O
,	O
which	O
is	O
active	O
alone	O
and	O
is	O
synergistic	O
in	O
combination	O
with	O
5	B-chem
-	I-chem
fluorouracil	E-chem
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
rhArg	S-geneN
-	O
peg	O
(	O
5,000mw	O
)	O
is	O
a	O
novel	O
agent	O
for	O
effective	O
cancer	O
therapy	O
.	O

A	O
novel	O
SCN5A	S-geneY
arrhythmia	O
mutation	O
,	O
M1766L	S-geneN
,	O
with	O
expression	O
defect	O
rescued	O
by	O
mexiletine	S-chem
.	O

OBJECTIVE	O
:	O
Mutations	O
in	O
the	O
cardiac	O
sodium	S-chem
channel	O
gene	O
,	O
SCN5A	S-geneY
,	O
cause	O
congenital	O
long	O
QT	O
syndrome	O
(	O
LQT3	O
)	O
,	O
Brugada	O
syndrome	O
,	O
idiopathic	O
ventricular	O
fibrillation	O
,	O
and	O
conduction	O
disease	O
by	O
distinct	O
cellular	O
and	O
clinical	O
electrophysiological	O
phenotypes	O
.	O

METHODS	O
:	O
Postmortem	O
molecular	O
analysis	O
of	O
SCN5A	S-geneY
was	O
conducted	O
on	O
an	O
infant	O
who	O
presented	O
shortly	O
after	O
birth	O
with	O
self	O
-	O
terminating	O
torsades	O
de	O
pointes	O
.	O

The	O
infant	O
was	O
treated	O
with	O
lidocaine	S-chem
,	O
propranolol	S-chem
,	O
and	O
mexiletine	S-chem
and	O
was	O
stable	O
for	O
16	O
months	O
manifesting	O
only	O
a	O
prolonged	O
QT	O
interval	O
.	O

The	O
infant	O
collapsed	O
suddenly	O
following	O
presumed	O
viral	O
gastroenteritis	O
,	O
was	O
found	O
in	O
2	O
:	O
1	O
AV	O
block	O
,	O
and	O
was	O
subsequently	O
declared	O
brain	O
dead	O
.	O

Genomic	O
DNA	O
was	O
subjected	O
to	O
SCN5A	S-geneY
mutational	O
analyses	O
and	O
DNA	O
sequencing	O
revealing	O
a	O
novel	O
,	O
spontaneous	O
germline	O
missense	O
mutation	O
,	O
M1766L	S-geneN
.	O

The	O
M1766L	S-geneN
mutation	O
was	O
engineered	O
into	O
the	O
hH1a	O
clone	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
transfected	O
into	O
embryonic	O
kidney	O
cells	O
(	O
HEK	O
-	O
293	O
)	O
,	O
and	O
studied	O
by	O
voltage	O
clamp	O
.	O

RESULTS	O
:	O
The	O
M1766L	S-geneN
mutation	O
caused	O
a	O
significant	O
decrease	O
in	O
the	O
sodium	S-chem
channel	O
expression	O
.	O

Co	O
-	O
expression	O
with	O
beta1	O
subunit	O
,	O
incubation	O
at	O
low	O
temperature	O
,	O
and	O
most	O
effectively	O
incubation	O
with	O
mexiletine	S-chem
partially	O
'	O
rescued	O
'	O
the	O
defective	O
expression	O
.	O

In	O
addition	O
to	O
this	O
pronounced	O
loss	O
of	O
function	O
,	O
M1766L	S-geneN-C3-2
also	O
showed	O
a	O
10	O
-	O
fold	O
increase	O
in	O
the	O
persistent	O
late	O
sodium	S-chem-C3-1
current	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
M1766L	S-geneN
-	O
SCN5A	S-geneY
channel	O
dysfunction	O
may	O
contribute	O
to	O
the	O
basis	O
of	O
lethal	O
arrhythmias	O
,	O
displays	O
an	O
overlapping	O
electrophysiological	O
phenotype	O
,	O
and	O
represents	O
the	O
first	O
sodium	S-chem
channelopathy	O
rescued	O
by	O
drug	O
.	O

Pelargonidin	S-chem-C3-1
activates	O
the	O
AhR	S-geneY-C3-2
and	O
induces	O
CYP1A1	S-geneY
in	O
primary	O
human	O
hepatocytes	O
and	O
human	O
cancer	O
cell	O
lines	O
HepG2	O
and	O
LS174T	O
.	O

We	O
examined	O
the	O
effects	O
of	O
anthocyanidins	S-chem
(	O
cyanidin	S-chem
,	O
delphinidin	S-chem
,	O
malvidin	S-chem
,	O
peonidin	S-chem
,	O
petunidin	S-chem
,	O
pelargonidin	S-chem
)	O
on	O
the	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AhR	S-geneY
)	O
-	O
CYP1A1	S-geneY
signaling	O
pathway	O
in	O
human	O
hepatocytes	O
,	O
hepatic	O
HepG2	O
and	O
intestinal	O
LS174T	O
cancer	O
cells	O
.	O

AhR	S-geneY-C3-2
-	O
dependent	O
reporter	O
gene	O
expression	O
in	O
transfected	O
HepG2	O
cells	O
was	O
increased	O
by	O
pelargonidin	S-chem-C3-1
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
at	O
24h	O
.	O

Similarly	O
,	O
pelargonidin	S-chem-C3-1
induced	O
the	O
expression	O
of	O
CYP1A1	S-geneY-C3-2
mRNA	O
up	O
to	O
5	O
-	O
fold	O
in	O
HepG2	O
and	O
LS174T	O
cells	O
relative	O
to	O
the	O
induction	O
by	O
5	O
nM	O
2,3,7,8	B-chem-C3-1
-	I-chem-C3-1
tetrachlorodibenzodioxin	E-chem-C3-1
(	O
TCDD	S-chem-C3-1
)	O
,	O
the	O
most	O
potent	O
activator	O
of	O
AhR	S-geneY-C3-2
.	O

CYP1A1	S-geneY-C3-2
and	O
CYP1A2	S-geneY-C3-2
mRNAs	O
were	O
also	O
increased	O
by	O
pelargonidin	S-chem-C3-1
in	O
three	O
primary	O
human	O
hepatocytes	O
cultures	O
(	O
approximately	O
5	O
%	O
of	O
TCDD	S-chem-C3-1
potency	O
)	O
and	O
the	O
increase	O
in	O
CYP1A1	S-geneY-C3-2
protein	O
in	O
HepG2	O
and	O
LS174T	O
cells	O
was	O
comparable	O
to	O
the	O
increase	O
in	O
catalytic	O
activity	O
of	O
CYP1A1	S-geneY-C3-2
enzyme	O
.	O

Ligand	O
binding	O
analysis	O
demonstrated	O
that	O
pelargonidin	S-chem
was	O
a	O
weak	O
ligand	O
of	O
AhR	S-geneY
.	O

Enzyme	O
kinetic	O
analyses	O
using	O
human	O
liver	O
microsomes	O
revealed	O
inhibition	O
of	O
CYP1A1	S-geneY-C4-2
activity	O
by	O
delphinidin	S-chem-C4-1
(	O
IC50	O
78	O
μM	O
)	O
and	O
pelargonidin	S-chem-C4-1
(	O
IC50	O
33	O
μM	O
)	O
.	O

Overall	O
,	O
although	O
most	O
anthocyanidins	S-chem
had	O
no	O
effects	O
on	O
AhR	S-geneY
-	O
CYP1A1	S-geneY
signaling	O
,	O
pelargonidin	S-chem-C3-1
can	O
bind	O
to	O
and	O
activate	O
the	O
AhR	S-geneY-C3-2
and	O
AhR	S-geneY
-	O
dependent	O
gene	O
expression	O
,	O
and	O
pelargonidin	S-chem-C4-1
and	O
delphinidin	S-chem-C4-1
inhibit	O
the	O
CYP1A1	S-geneY-C4-2
catalytic	O
activity	O
.	O

Structural	O
features	O
of	O
the	O
central	O
cannabinoid	S-chem
CB1	S-geneY
receptor	O
involved	O
in	O
the	O
binding	O
of	O
the	O
specific	O
CB1	S-geneY-C6-2
antagonist	O
SR	B-chem-C6-1
141716A	E-chem-C6-1
.	O

The	O
antagonist	O
SR	B-chem
141716A	E-chem
has	O
a	O
high	O
specificity	O
for	O
the	O
central	O
CB1	S-geneY
cannabinoid	B-geneN
receptor	E-geneN
and	O
negligeable	O
affinity	O
for	O
the	O
peripheral	O
CB2	S-geneY
receptor	O
,	O
making	O
it	O
an	O
excellent	O
tool	O
for	O
probing	O
receptor	O
structure	O
-	O
activity	O
relationships	O
.	O

From	O
binding	O
experiments	O
with	O
mutated	O
CB1	S-geneY
and	O
with	O
chimeric	O
CB1	S-geneY
/	O
CB2	S-geneY
receptors	O
we	O
have	O
begun	O
to	O
identify	O
the	O
domains	O
of	O
CB1	S-geneY
implicated	O
in	O
the	O
recognition	O
of	O
SR	B-chem
141716A	E-chem
.	O

Receptors	O
were	O
transiently	O
expressed	O
in	O
COS	O
-	O
3	O
cells	O
,	O
and	O
their	O
binding	O
characteristics	O
were	O
studied	O
with	O
SR	B-chem
141716A	E-chem
and	O
with	O
CP	B-chem
55,940	E-chem
,	O
an	O
agonist	O
recognized	O
equally	O
well	O
by	O
the	O
two	O
receptors	O
.	O

The	O
region	O
delineated	O
by	O
the	O
fourth	O
and	O
fifth	O
transmembrane	O
helices	O
of	O
CB1	S-geneY
proved	O
to	O
be	O
crucial	O
for	O
high	O
affinity	O
binding	O
of	O
SR	B-chem
141716A	E-chem
.	O

The	O
CB1	S-geneY
and	O
CB2	S-geneY
second	O
extracellular	O
loops	O
,	O
e2	O
,	O
were	O
exchanged	O
,	O
modifications	O
that	O
had	O
no	O
effect	O
on	O
SR	B-chem
141716A	E-chem
binding	O
in	O
the	O
CB1	S-geneY
variant	O
but	O
that	O
eliminated	O
CP	B-chem
55,940	E-chem
binding	O
in	O
both	O
mutants	O
.	O

The	O
replacement	O
of	O
the	O
conserved	O
cysteine	S-chem
residues	O
in	O
e2	O
of	O
CB2	S-geneY
by	O
serine	S-chem
also	O
eliminated	O
CP	B-chem
55,940	E-chem
binding	O
,	O
but	O
replacement	O
of	O
those	O
in	O
CB1	S-geneY
resulted	O
in	O
the	O
sequestration	O
of	O
the	O
mutated	O
receptors	O
in	O
the	O
cell	O
cytoplasm	O
.	O

The	O
e2	B-geneN
domain	E-geneN
thus	O
plays	O
some	O
role	O
in	O
CP	B-chem
55,940	E-chem
binding	O
but	O
none	O
in	O
SR	B-chem
141716A	E-chem
recognition	O
,	O
binding	O
of	O
the	O
latter	O
clearly	O
implicating	O
residues	O
in	O
the	O
adjoining	O
transmembrane	O
helices	O
.	O

Antiaggressive	O
activity	O
of	O
central	O
oxytocin	S-geneY
in	O
male	O
rats	O
.	O

RATIONALE	O
:	O
A	O
substantial	O
body	O
of	O
research	O
suggests	O
that	O
the	O
neuropeptide	O
oxytocin	S-geneY
promotes	O
social	O
affiliative	O
behaviors	O
in	O
a	O
wide	O
range	O
of	O
animals	O
including	O
humans	O
.	O

However	O
,	O
its	O
antiaggressive	O
action	O
has	O
not	O
been	O
unequivocally	O
demonstrated	O
in	O
male	O
laboratory	O
rodents	O
.	O

OBJECTIVE	O
:	O
Our	O
primary	O
goal	O
was	O
to	O
examine	O
the	O
putative	O
serenic	O
effect	O
of	O
oxytocin	S-geneY
in	O
a	O
feral	O
strain	O
(	O
wild	O
type	O
Groningen	O
,	O
WTG	O
)	O
of	O
rats	O
that	O
generally	O
show	O
a	O
much	O
broader	O
variation	O
and	O
higher	O
levels	O
of	O
intermale	O
aggression	O
than	O
commonly	O
used	O
laboratory	O
strains	O
of	O
rats	O
.	O

METHODS	O
:	O
Resident	O
animals	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
administered	O
with	O
different	O
doses	O
of	O
synthetic	O
oxytocin	S-geneY
and	O
oxytocin	B-geneY
receptor	E-geneY
antagonist	O
,	O
alone	O
and	O
in	O
combination	O
,	O
in	O
order	O
to	O
manipulate	O
brain	O
oxytocin	S-geneY
functioning	O
and	O
to	O
assess	O
their	O
behavioral	O
response	O
to	O
an	O
intruder	O
.	O

RESULTS	O
:	O
Our	O
data	O
clearly	O
demonstrate	O
that	O
acute	O
icv	O
administered	O
oxytocin	S-geneY
produces	O
dose	O
-	O
dependent	O
and	O
receptor	O
-	O
selective	O
changes	O
in	O
social	O
behavior	O
,	O
reducing	O
aggression	O
and	O
potentiating	O
social	O
exploration	O
.	O

These	O
antiaggressive	O
effects	O
are	O
stronger	O
in	O
the	O
more	O
offensive	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
administration	O
of	O
an	O
oxytocin	B-geneY
receptor	E-geneY
antagonist	O
tends	O
to	O
increase	O
(	O
nonsignificantly	O
)	O
aggression	O
only	O
in	O
low	O
-	O
medium	O
aggressive	O
animals	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
transiently	O
enhancing	O
brain	O
oxytocin	S-geneY
function	O
has	O
potent	O
antiaggressive	O
effects	O
,	O
whereas	O
its	O
attenuation	O
tends	O
to	O
enhance	O
aggressiveness	O
.	O

In	O
addition	O
,	O
a	O
possible	O
inverse	O
relationship	O
between	O
trait	O
aggression	O
and	O
endogenous	O
oxytocinergic	O
signaling	O
is	O
revealed	O
.	O

Overall	O
,	O
this	O
study	O
emphasizes	O
the	O
importance	O
of	O
brain	O
oxytocinergic	O
signaling	O
for	O
regulating	O
intermale	O
offensive	O
aggression	O
.	O

This	O
study	O
supports	O
the	O
suggestion	O
that	O
oxytocin	B-geneY
receptor	E-geneY
agonists	O
could	O
clinically	O
be	O
useful	O
for	O
curbing	O
heightened	O
aggression	O
seen	O
in	O
a	O
range	O
of	O
neuropsychiatric	O
disorders	O
like	O
antisocial	O
personality	O
disorder	O
,	O
autism	O
,	O
and	O
addiction	O
.	O

Carbonic	B-geneN
anhydrase	E-geneN
inhibitors	O
.	O
Benzenesulfonamides	S-chem-C4-1
incorporating	O
cyanoacrylamide	S-chem-C4-1
moieties	O
strongly	O
inhibit	O
Saccharomyces	B-geneY-C4-2
cerevisiae	I-geneY-C4-2
β	I-geneY-C4-2
-	I-geneY-C4-2
carbonic	I-geneY-C4-2
anhydrase	E-geneY-C4-2
.	O

A	O
series	O
of	O
benzenesulfonamides	S-chem-C4-1
incorporating	O
cyanoacrylamide	S-chem-C4-1
moieties	O
(	O
tyrphostine	S-chem-C4-1
analogs	O
)	O
were	O
assayed	O
as	O
inhibitors	O
of	O
the	O
β	B-geneY-C4-2
-	I-geneY-C4-2
carbonic	I-geneY-C4-2
anhydrase	E-geneY-C4-2
(	O
CA	S-geneN-C4-2
,	O
EC	B-geneY-C4-2
4.2.1.1	E-geneY-C4-2
)	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
ScCA	S-geneY-C4-2
.	O

Some	O
of	O
these	O
compounds	O
were	O
low	O
nanomolar	O
or	O
subnanomolar	O
ScCA	S-geneY
inhibitors	O
and	O
showed	O
selectivity	O
ratios	O
in	O
the	O
range	O
of	O
4.91	O
-	O
69.86	O
for	O
inhibiting	O
the	O
yeast	O
enzyme	O
over	O
the	O
offtarget	O
human	O
(	O
h	O
)	O
isoforms	O
hCA	B-geneY
I	E-geneY
and	O
of	O
6.46	O
-	O
13.52	O
for	O
inhibiting	O
ScCA	S-geneY
over	O
hCA	B-geneY
II	E-geneY
.	O

The	O
model	O
organism	O
S.	O
cerevisiae	O
and	O
this	O
particular	O
enzyme	O
may	O
be	O
useful	O
for	O
detecting	O
antifungals	O
with	O
a	O
novel	O
mechanism	O
of	O
action	O
compared	O
to	O
the	O
classical	O
azole	S-chem
drugs	O
to	O
which	O
significant	O
drug	O
resistance	O
emerged	O
.	O

Indeed	O
,	O
some	O
of	O
these	O
sulfonamides	S-chem
inhibited	O
the	O
growth	O
of	O
the	O
yeast	O
with	O
CC50	O
-	O
s	O
in	O
the	O
range	O
of	O
0.73	O
-	O
6.54μM	O
.	O

Polyamine	S-chem
metabolism	O
in	O
a	O
member	O
of	O
the	O
phylum	O
Microspora	O
(	O
Encephalitozoon	O
cuniculi	O
)	O
:	O
effects	O
of	O
polyamine	S-chem
analogues	O
.	O

The	O
uptake	O
,	O
biosynthesis	O
and	O
catabolism	O
of	O
polyamines	S-chem
in	O
the	O
microsporidian	O
parasite	O
Encephalitozoon	O
cuniculi	O
are	O
detailed	O
with	O
reference	O
to	O
the	O
effects	O
of	O
oligoamine	S-chem
and	O
arylamine	S-chem
analogues	O
of	O
polyamines	S-chem
.	O

Enc	O
.	O
cuniculi	O
,	O
an	O
intracellular	O
parasite	O
of	O
mammalian	O
cells	O
,	O
has	O
both	O
biosynthetic	O
and	O
catabolic	O
enzymes	O
of	O
polyamine	S-chem
metabolism	O
,	O
as	O
demonstrated	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
mature	O
spores	O
.	O

The	O
uptake	O
of	O
polyamines	S-chem
was	O
measured	O
in	O
immature	O
,	O
pre	O
-	O
emergent	O
spores	O
isolated	O
from	O
host	O
cells	O
by	O
Percoll	O
gradient	O
.	O

Spermine	O
was	O
rapidly	O
taken	O
up	O
and	O
metabolized	O
to	O
spermidine	O
and	O
an	O
unknown	O
,	O
possibly	O
acetamidopropanal	O
,	O
by	O
spermidine	B-geneN
/	I-geneN
spermine	I-geneN
N	I-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
acetyltransferase	E-geneN
(	O
SSAT	S-geneN
)	O
and	O
polyamine	B-geneN
oxidase	E-geneN
(	O
PAO	S-geneN
)	O
.	O

Most	O
of	O
the	O
spermidine	S-chem
and	O
the	O
unknown	O
product	O
were	O
found	O
in	O
the	O
cell	O
incubation	O
medium	O
,	O
indicating	O
they	O
were	O
released	O
from	O
the	O
cell	O
.	O
bis	B-chem
(	I-chem
Ethyl	I-chem
)	I-chem
oligoamine	E-chem
analogues	O
of	O
polyamines	S-chem
,	O
such	O
as	O
SL	B-chem
-	I-chem
11144	E-chem
and	O
SL	B-chem
-	I-chem
11158	E-chem
,	O
as	O
well	O
as	O
arylamine	S-chem
analogues	O
[	O
BW	B-chem
-	I-chem
1	E-chem
,	O
a	O
bis	B-chem
(	I-chem
phenylbenzyl	I-chem
)	E-chem
3	O
-	O
7	O
-	O
3	O
analogue	O
]	O
blocked	O
uptake	O
and	O
interconversion	O
of	O
spermine	S-chem
at	O
micromolar	O
levels	O
and	O
,	O
in	O
the	O
case	O
of	O
BW	B-chem-C9-1
-	I-chem-C9-1
1	E-chem-C9-1
,	O
acted	O
as	O
substrate	O
for	O
PAO	S-geneN-C9-2
.	O

The	O
Enc	B-geneN
.	I-geneN
cuniculi	I-geneN
PAO	E-geneN
activity	O
differed	O
from	O
that	O
found	O
in	O
mammalian	O
cells	O
with	O
respect	O
to	O
pH	O
optimum	O
,	O
substrate	O
specificity	O
and	O
sensitivity	O
to	O
known	O
PAO	S-geneN
inhibitors	O
.	O

SL	B-chem-C4-1
-	I-chem-C4-1
11158	E-chem-C4-1
inhibited	O
SSAT	S-geneN-C4-2
activity	O
with	O
a	O
mixed	O
type	O
of	O
inhibition	O
in	O
which	O
the	O
analogue	O
had	O
a	O
70	O
-	O
fold	O
higher	O
affinity	O
for	O
the	O
enzyme	O
than	O
the	O
natural	O
substrate	O
,	O
spermine	S-chem
.	O

The	O
interest	O
in	O
Enc	O
.	O
cuniculi	O
polyamine	O
metabolism	O
and	O
the	O
biochemical	O
effects	O
of	O
these	O
polyamine	S-chem
analogues	O
is	O
warranted	O
since	O
they	O
cure	O
model	O
infections	O
of	O
Enc	O
.	O
cuniculi	O
in	O
mice	O
and	O
are	O
potential	O
candidates	O
for	O
human	O
clinical	O
trials	O
.	O

N	B-chem
-	I-chem
carbamylglutamate	E-chem
treatment	O
for	O
acute	O
neonatal	O
hyperammonemia	O
in	O
isovaleric	O
acidemia	O
.	O

Hyperammonemia	O
occurs	O
mainly	O
in	O
patients	O
with	O
branched	O
-	O
chain	O
organic	O
acidemias	O
such	O
as	O
propionic	O
,	O
methylmalonic	O
,	O
and	O
isovaleric	O
acidemias	O
.	O

Its	O
pathophysiological	O
process	O
is	O
mainly	O
via	O
the	O
competitive	O
inhibition	O
of	O
N	B-geneY
-	I-geneY
acetylglutamate	I-geneY
synthetase	E-geneY
.	O

Oral	O
carglumic	B-chem
acid	E-chem
(	O
N	B-chem
-	I-chem
carbamylglutamate	E-chem
)	O
administration	O
can	O
correct	O
hyperammonemia	O
in	O
neonates	O
with	O
propionic	O
and	O
methylmalonic	O
acidemias	O
,	O
thus	O
avoiding	O
dialysis	O
therapy	O
.	O

Isovaleric	O
acidemia	O
is	O
an	O
autosomal	O
recessive	O
disease	O
of	O
leucine	S-chem
metabolism	O
due	O
to	O
deficiency	O
of	O
isovaleryl	B-geneY
-	I-geneY
CoA	I-geneY
dehydrogenase	E-geneY
.	O

For	O
the	O
first	O
time	O
,	O
we	O
report	O
a	O
neonate	O
with	O
isovaleric	O
acidemia	O
,	O
whose	O
plasma	O
ammonia	S-chem
concentration	O
dropped	O
dramatically	O
after	O
one	O
oral	O
load	O
of	O
carglumic	B-chem
acid	E-chem
.	O

This	O
experience	O
suggests	O
that	O
carglumic	B-chem
acid	E-chem
could	O
be	O
considered	O
for	O
acute	O
hyperammonemia	O
resulting	O
from	O
isovaleric	O
acidemia	O
.	O

However	O
,	O
trials	O
with	O
more	O
patients	O
are	O
needed	O
.	O

A	O
Role	O
for	O
Cargo	S-geneN
in	O
the	O
Activation	O
of	O
ADP	B-geneN
-	I-geneN
Ribosylation	I-geneN
Factors	E-geneN
(	O
Arf	S-geneN
)	O
and	O
Adaptor	S-geneN
Recruitment	O
.	O

Membrane	O
traffic	O
requires	O
the	O
specific	O
concentration	O
of	O
protein	B-geneN
cargos	E-geneN
and	O
exclusion	O
of	O
other	O
proteins	O
into	O
nascent	O
carriers	O
.	O

Critical	O
components	O
of	O
this	O
selectivity	O
are	O
the	O
protein	B-geneN
adaptors	E-geneN
that	O
bind	O
to	O
short	O
,	O
linear	O
motifs	O
in	O
the	O
cytoplasmic	O
tails	O
of	O
transmembrane	O
protein	B-geneN
cargos	E-geneN
and	O
sequester	O
them	O
into	O
nascent	O
carriers	O
.	O

The	O
recruitment	O
of	O
the	O
adaptors	O
is	O
mediated	O
by	O
activated	O
Arf	S-geneN
GTPases	S-geneN
and	O
the	O
Arf	S-geneN
-	O
adaptor	S-geneN
complexes	O
mark	O
sites	O
of	O
carrier	O
formation	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
signal	O
(	O
s	O
)	O
that	O
initiate	O
carrier	O
biogenesis	O
remains	O
unknown	O
.	O

We	O
examined	O
the	O
specificity	O
and	O
initial	O
sites	O
of	O
recruitment	O
of	O
Arf	S-geneN
-	O
dependent	O
adaptors	S-geneN
(	O
AP	B-geneN
-	I-geneN
1	E-geneN
and	O
GGAs	S-geneN
)	O
in	O
response	O
to	O
the	O
Golgi	O
or	O
endosomal	O
localization	O
of	O
specific	O
cargo	B-geneN
proteins	E-geneN
(	O
furin	S-geneY
,	O
mannose	B-geneY
-	I-geneY
6	I-geneY
-	I-geneY
phosphate	I-geneY
receptor	E-geneY
(	O
M6PR	S-geneY
)	O
and	O
M6PR	S-geneY
lacking	O
a	O
C	S-chem
-	O
terminal	O
domain	O
M6PR	B-geneY
Δ	I-geneY
C	E-geneY
)	O
.	O

We	O
find	O
that	O
cargo	S-geneN
promotes	O
the	O
recruitment	O
of	O
specific	O
adaptors	S-geneN
,	O
suggesting	O
that	O
it	O
is	O
part	O
of	O
an	O
upstream	O
signaling	O
event	O
.	O

Cargos	S-geneN
do	O
not	O
promote	O
adaptor	S-geneN
recruitment	O
to	O
all	O
compartments	O
in	O
which	O
they	O
reside	O
and	O
thus	O
additional	O
factors	O
regulate	O
the	O
cargo	B-geneN
's	E-geneN
ability	O
to	O
promote	O
Arf	S-geneN
activation	O
and	O
adaptor	S-geneN
recruitment	O
.	O

We	O
document	O
that	O
within	O
a	O
given	O
compartment	O
different	O
cargos	S-geneN
recruit	O
different	O
adaptors	S-geneN
suggesting	O
that	O
there	O
is	O
little	O
or	O
no	O
free	O
,	O
activated	O
Arf	S-geneN
at	O
the	O
membrane	O
and	O
that	O
Arf	S-geneN
activation	O
is	O
spatially	O
and	O
temporally	O
coupled	O
to	O
the	O
cargo	S-geneN
and	O
the	O
adaptor	S-geneN
.	O

Using	O
temperature	O
block	O
,	O
Brefeldin	B-chem
A	E-chem
,	O
and	O
recovery	O
from	O
each	O
,	O
we	O
found	O
that	O
the	O
cytoplasmic	O
tail	O
of	O
M6PR	S-geneY
causes	O
the	O
recruitment	O
of	O
AP	B-geneN
-	I-geneN
1	E-geneN
and	O
GGAs	S-geneN
to	O
recycling	O
endosomes	O
and	O
not	O
at	O
the	O
Golgi	O
,	O
as	O
predicted	O
by	O
steady	O
state	O
staining	O
profiles	O
.	O

These	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
generation	O
of	O
novel	O
models	O
for	O
cargo	S-geneN
-	O
dependent	O
regulation	O
of	O
membrane	O
traffic	O
.	O

Activator	B-geneY
of	I-geneY
G	I-geneY
protein	I-geneY
signaling	I-geneY
3	E-geneY
regulates	O
opiate	O
activation	O
of	O
protein	B-geneN
kinase	I-geneN
A	E-geneN
signaling	O
and	O
relapse	O
of	O
heroin	S-chem
-	O
seeking	O
behavior	O
.	O

The	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
is	O
central	O
to	O
heroin	S-chem
addiction	O
.	O

Activation	O
of	O
opiate	B-geneN
receptors	E-geneN
in	O
the	O
NAc	O
dissociates	O
G	B-geneN
(	I-geneN
i	I-geneN
/	I-geneN
o	I-geneN
)	I-geneN
into	I-geneN
alpha	I-geneN
and	I-geneN
betagamma	E-geneN
subunits	O
.	O

Galpha	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
inhibits	O
cAMP	S-chem
production	O
,	O
but	O
betagamma	O
regulates	O
several	O
molecular	O
pathways	O
,	O
including	O
protein	B-geneN
kinase	I-geneN
A	E-geneN
(	O
PKA	S-geneN
)	O
.	O

We	O
show	O
in	O
NAc	O
/	O
striatal	O
neurons	O
that	O
opiates	O
paradoxically	O
activate	O
PKA	S-geneN
signaling	O
by	O
means	O
of	O
betagamma	O
dimers	O
.	O

Activation	O
requires	O
Galpha	B-geneY
(	I-geneY
i3	I-geneY
)	E-geneY
and	O
an	O
activator	B-geneY
of	I-geneY
G	I-geneY
protein	I-geneY
signaling	I-geneY
3	E-geneY
(	O
AGS3	S-geneY
)	O
.	O

AGS3	S-geneY
competes	O
with	O
betagamma	O
for	O
binding	O
to	O
Galpha	B-geneY
(	I-geneY
i3	I-geneY
)	E-geneY
-	O
GDP	O
and	O
enhances	O
the	O
action	O
of	O
unbound	O
betagamma	O
.	O

AGS3	S-geneY
and	O
Galpha	B-geneY
(	I-geneY
i3	I-geneY
)	E-geneY
knockdown	O
prevents	O
opiate	O
activation	O
of	O
PKA	S-geneN
signaling	O
.	O

In	O
rats	O
self	O
-	O
administering	O
heroin	S-chem
,	O
AGS3	S-geneY
antisense	O
in	O
the	O
NAc	O
core	O
,	O
but	O
not	O
shell	O
,	O
eliminates	O
reinstatement	O
of	O
heroin	S-chem
-	O
seeking	O
behavior	O
,	O
a	O
model	O
of	O
human	O
relapse	O
.	O

Thus	O
,	O
Galpha	B-geneN
(	I-geneN
i3	I-geneN
)	I-geneN
/	I-geneN
betagamma	E-geneN
/	O
AGS3	S-geneY
appears	O
to	O
mediate	O
mu	B-geneY
opiate	I-geneY
receptor	E-geneY
activation	O
of	O
PKA	S-geneN
signaling	O
as	O
well	O
as	O
heroin	S-chem
-	O
seeking	O
behavior	O
.	O

Effect	O
of	O
keratinocyte	B-geneY
growth	I-geneY
factor	E-geneY
on	O
cell	O
viability	O
in	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
.	O

In	O
normal	O
prostate	O
,	O
keratinocyte	B-geneY
growth	I-geneY
factor	E-geneY
(	O
KGF	S-geneY
)	O
,	O
also	O
known	O
as	O
fibroblast	B-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
7	E-geneY
(	O
FGF	B-geneY
-	I-geneY
7	E-geneY
)	O
serves	O
as	O
a	O
paracrine	O
growth	O
factor	O
synthesized	O
in	O
stromal	O
cells	O
that	O
acts	O
on	O
epithelial	O
cells	O
through	O
its	O
receptor	O
,	O
KGFR	S-geneY
.	O

KGF	S-geneY
and	O
KGFR	S-geneY
were	O
found	O
in	O
human	O
cancer	O
epithelial	O
cells	O
as	O
well	O
as	O
stromal	O
cells	O
.	O

Since	O
KGF	S-geneY
expressed	O
in	O
epithelial	O
cells	O
of	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
in	O
prostate	O
cancer	O
,	O
it	O
has	O
been	O
suggested	O
that	O
KGF	S-geneY
might	O
act	O
as	O
an	O
autocrine	O
factor	O
in	O
BPH	O
and	O
prostate	O
cancer	O
.	O

To	O
investigate	O
the	O
roles	O
of	O
KGF	S-geneY
in	O
cancerous	O
stroma	O
,	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
(	O
PCSCs	O
)	O
were	O
isolated	O
and	O
evaluated	O
.	O

These	O
PCSCs	O
possessed	O
estrogen	B-geneY
receptors	E-geneY
and	O
KGFR	S-geneY
,	O
but	O
not	O
androgen	B-geneY
receptor	E-geneY
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
respectively	O
.	O

KGF	S-geneY
exhibited	O
mitogenic	O
and	O
anti	O
-	O
apoptotic	O
effects	O
that	O
correlated	O
with	O
induction	O
of	O
cyclin	B-geneY
-	I-geneY
D1	E-geneY
,	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
,	O
Bcl	B-geneY
-	I-geneY
xL	E-geneY
and	O
phospho	B-geneN
-	I-geneN
Akt	E-geneN
expression	O
in	O
PCSCs	O
,	O
where	O
treatment	O
with	O
KGF	S-geneY
antiserum	O
abolished	O
cell	O
proliferation	O
and	O
anti	O
-	O
apoptotic	O
protein	O
expression	O
.	O

PCSCs	O
exposed	O
to	O
KGF	S-geneY
for	O
various	O
time	O
periods	O
resulted	O
in	O
phosphorylation	O
of	O
Akt	S-geneN
and	O
subsequent	O
up	O
-	O
regulation	O
of	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
.	O

KGF	S-geneY
modulated	O
dynamic	O
protein	O
expression	O
indicated	O
that	O
KGF	S-geneY
triggered	O
cell	O
cycle	O
machinery	O
and	O
then	O
activated	O
anti	O
-	O
apoptotic	O
actions	O
in	O
PCSCs	O
.	O

Cell	O
proliferation	O
analysis	O
indicated	O
that	O
tamoxifen	S-chem
or	O
ICI	B-chem
182,780	E-chem
reduced	O
cell	O
viability	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
however	O
,	O
KGF	S-geneY
prevented	O
this	O
inhibition	O
,	O
which	O
further	O
demonstrated	O
KGF	S-geneY
triggered	O
anti	O
-	O
apoptotic	O
machinery	O
through	O
activating	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
and	O
phospho	B-geneN
-	I-geneN
Akt	E-geneN
expression	O
.	O

In	O
summary	O
,	O
KGF	S-geneY
has	O
an	O
autocrine	O
effect	O
and	O
serves	O
as	O
a	O
survival	O
factor	O
in	O
primary	O
cultured	O
human	O
prostate	O
cancer	O
stromal	O
cells	O
.	O

Structural	O
Investigation	O
and	O
Biological	O
Activity	O
of	O
Sesquiterpene	B-chem
Lactones	E-chem
from	O
the	O
Traditional	O
Chinese	O
Herb	O
Inula	O
racemosa	O
.	O

Five	O
new	O
sesquiterpene	B-chem
lactones	E-chem
,	O
racemosalactones	B-chem
A	I-chem
-	I-chem
E	E-chem
(	O
1	O
-	O
5	O
)	O
,	O
along	O
with	O
19	O
known	O
sesquiterpene	B-chem
latones	E-chem
(	O
6	O
-	O
24	O
)	O
,	O
were	O
isolated	O
from	O
the	O
roots	O
of	O
Inula	O
racemosa	O
.	O

Their	O
structures	O
were	O
elucidated	O
by	O
extensive	O
spectroscopic	O
analysis	O
,	O
and	O
the	O
absolute	O
configuration	O
of	O
2	O
was	O
deduced	O
from	O
X	O
-	O
ray	O
diffraction	O
analysis	O
.	O

Compounds	O
1	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
12	O
,	O
14	O
,	O
and	O
17	O
exhibited	O
antiproliferative	O
activities	O
with	O
IC50	O
values	O
ranging	O
from	O
0.38	O
to	O
4.19	O
μg	O
/	O
mL	O
against	O
human	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
A549	O
,	O
hepatocellular	O
carcinoma	O
HepG2	O
,	O
and	O
human	O
fibrosarcoma	O
HT1080	O
cells	O
.	O

Compounds	O
6	O
and	O
8	O
exhibited	O
antiproliferative	O
activities	O
against	O
endothelial	O
cells	O
with	O
IC50	O
values	O
of	O
2.4	O
and	O
2.5	O
μg	O
/	O
mL	O
,	O
respectively	O
.	O

Furthermore	O
,	O
compounds	O
6	O
and	O
8	O
both	O
inhibited	O
endothelial	O
cell	O
tube	O
formation	O
at	O
1.0	O
μg	O
/	O
mL	O
.	O

A	O
method	O
for	O
the	O
rapid	O
and	O
straightforward	O
preparative	O
-	O
scale	O
isolation	O
of	O
compound	O
6	O
from	O
alantolides	S-chem
is	O
described	O
.	O

Energy	O
depletion	O
of	O
bovine	O
mammary	O
epithelial	O
cells	O
activates	O
AMPK	S-geneN
and	O
suppresses	O
protein	O
synthesis	O
through	O
inhibition	O
of	O
mTORC1	S-geneN
signaling	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
cellular	O
energy	O
status	O
regulates	O
global	O
protein	O
synthesis	O
in	O
mammary	O
epithelial	O
cells	O
have	O
not	O
been	O
characterized	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
AMP	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
AMPK	S-geneN
)	O
activation	O
by	O
2	B-chem
-	I-chem
deoxyglucose	E-chem
on	O
protein	O
synthesis	O
and	O
the	O
mammalian	B-geneN
target	I-geneN
of	I-geneN
rapamycin	I-geneN
complex	I-geneN
1	E-geneN
(	O
mTORC1	S-geneN
)	O
signaling	O
pathway	O
in	O
bovine	O
mammary	O
epithelial	O
cells	O
.	O

Phosphorylation	O
of	O
AMPK	S-geneN-C3-2
at	O
Thr172	S-chem
increased	O
by	O
1.4	O
-	O
fold	O
within	O
5	O
min	O
,	O
and	O
remained	O
elevated	O
throughout	O
a	O
30	O
-	O
min	O
time	O
course	O
,	O
in	O
response	O
to	O
2	B-chem-C3-1
-	I-chem-C3-1
deoxyglucose	E-chem-C3-1
.	O

Global	O
rates	O
of	O
protein	O
synthesis	O
declined	O
by	O
78	O
%	O
of	O
control	O
values	O
.	O

The	O
decline	O
in	O
protein	O
synthesis	O
was	O
associated	O
with	O
repression	O
of	O
mTORC1	S-geneN
signaling	O
,	O
as	O
indicated	O
by	O
reduced	O
phosphorylation	O
of	O
ribosomal	B-geneY
protein	I-geneY
S6	I-geneY
kinase	I-geneY
1	E-geneY
and	O
eIF4E	B-geneY
binding	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
4E	B-geneY
-	I-geneY
BP1	E-geneY
)	O
.	O

Phosphorylation	O
of	O
ER	O
-	O
stress	O
marker	O
eIF2α	S-geneY-C3-2
was	O
also	O
increased	O
but	O
only	O
at	O
30	O
min	O
of	O
2	B-chem-C3-1
-	I-chem-C3-1
deoxyglucose	E-chem-C3-1
exposure	O
.	O

2	B-chem-C3-1
-	I-chem-C3-1
Deoxyglucose	E-chem-C3-1
increased	O
phosphorylation	O
of	O
tuberous	B-geneY-C3-2
sclerosis	I-geneY-C3-2
complex	I-geneY-C3-2
2	E-geneY-C3-2
(	O
TSC2	S-geneY-C3-2
)	O
on	O
AMPK	S-geneN-C3-2
consensus	O
sites	O
but	O
did	O
not	O
change	O
the	O
amount	O
of	O
TSC1	S-geneY
bound	O
to	O
TSC2	S-geneY-C3-2
.	O

Activation	O
of	O
AMPK	S-geneN
did	O
not	O
result	O
in	O
changes	O
in	O
the	O
amount	O
of	O
raptor	O
bound	O
to	O
mTOR	S-geneY
.	O

The	O
inhibitory	O
effects	O
of	O
AMPK	S-geneN
activation	O
on	O
mTORC1	S-geneN
signaling	O
were	O
associated	O
with	O
a	O
marked	O
increase	O
in	O
Ser792	S-chem
phosphorylation	O
on	O
raptor	O
.	O

Collectively	O
,	O
the	O
results	O
suggest	O
that	O
activation	O
of	O
AMPK	S-geneN
represses	O
global	O
protein	O
synthesis	O
in	O
mammary	O
epithelial	O
cells	O
through	O
inhibition	O
of	O
mTORC1	S-geneN
signaling	O
.	O

Effects	O
of	O
an	O
ethanolic	O
salix	O
extract	O
on	O
the	O
release	O
of	O
selected	O
inflammatory	O
mediators	O
in	O
vitro	O
.	O

Salix	O
extracts	O
are	O
in	O
current	O
use	O
for	O
the	O
treatment	O
of	O
pain	O
and	O
inflammation	O
.	O

In	O
order	O
to	O
obtain	O
an	O
insight	O
into	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
the	O
ethanolic	O
Salix	O
extract	O
1520L	O
-	O
-	O
which	O
is	O
essentially	O
similar	O
to	O
an	O
extract	O
for	O
which	O
clinical	O
studies	O
have	O
demonstrated	O
analgesic	O
effectiveness	O
-	O
-	O
its	O
effects	O
were	O
evaluated	O
in	O
an	O
established	O
in	O
vitro	O
assay	O
test	O
system	O
using	O
primary	O
human	O
monocytes	O
.	O

The	O
IC50	O
-	O
values	O
obtained	O
for	O
the	O
inhibition	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
release	O
of	O
prostaglandin	B-chem
E2	E-chem
(	O
PGE2	S-chem
)	O
reflecting	O
cyclooxygenase	B-geneY-C9-2
(	I-geneY-C9-2
COX	I-geneY-C9-2
)	I-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
-	O
mediated	O
PGE2	S-chem-C9-1
release	O
were	O
47	O
microg	O
/	O
ml	O
and	O
0.6	O
microg	O
/	O
ml	O
,	O
for	O
the	O
Salix	O
extract	O
1520L	O
and	O
rofecoxib	S-chem
-	O
like	O
research	O
compound	O
L745337	S-chem
,	O
respectively	O
.	O

There	O
was	O
no	O
effect	O
on	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
activity	O
.	O

The	O
Salix	O
extract	O
inhibited	O
the	O
LPS	O
-	O
induced	O
release	O
of	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
,	O
interleukin	B-geneY
-	I-geneY
1beta	E-geneY
and	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
with	O
IC50	O
-	O
values	O
of	O
180.0	O
,	O
33.0	O
and	O
86.0	O
microg	O
/	O
ml	O
,	O
respectively	O
.	O

Both	O
,	O
salicin	S-chem
and	O
salicylate	S-chem
,	O
had	O
no	O
effect	O
in	O
any	O
of	O
the	O
parameters	O
.	O

Our	O
results	O
indicate	O
that	O
Salix	O
extract	O
1520L	O
inhibits	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
-	O
mediated	O
PGE2	S-chem-C9-1
release	O
through	O
compounds	O
other	O
than	O
salicin	S-chem
or	O
salicylate	S-chem
.	O

Our	O
data	O
further	O
suggest	O
that	O
the	O
proprietary	O
Salix	O
extract	O
is	O
a	O
weak	O
inhibitor	O
of	O
proinflammatory	O
cytokines	S-geneN
.	O

Effects	O
of	O
ORF	B-chem-C6-1
17583	E-chem-C6-1
,	O
other	O
histamine	B-geneN-C6-2
H2	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonists	O
and	O
omeprazole	S-chem
on	O
gastric	O
acid	O
secretory	O
states	O
in	O
rats	O
and	O
dogs	O
.	O

ORF	B-chem-C6-1
17583	E-chem-C6-1
,	O
a	O
histamine	B-geneN-C6-2
H2	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
inhibited	O
gastric	O
acid	O
secretion	O
in	O
pylorus	O
-	O
ligated	O
rats	O
(	O
ED50	O
=	O
4.9	O
mg	O
/	O
kg	O
intraduodenal	O
;	O
3.4	O
mg	O
/	O
kg	O
p.o	O
.	O
;	O
and	O
0.21	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
and	O
in	O
total	O
gastric	O
fistula	O
or	O
Heidenhain	O
pouch	O
dogs	O
stimulated	O
by	O
betazole	S-chem
(	O
ED50	O
=	O
0.12	O
mg	O
/	O
kg	O
p.o	O
.	O
and	O
0.08	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
,	O
histamine	S-chem
,	O
tetragastrin	S-chem
,	O
bethanechol	S-chem
,	O
2	B-chem
-	I-chem
deoxy	I-chem
-	I-chem
D	I-chem
-	I-chem
glucose	E-chem
or	O
a	O
meal	O
(	O
ED50	O
values	O
ranged	O
from	O
0.11	O
-	O
0.26	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
.	O

The	O
nonspecific	O
inhibition	O
of	O
gastric	O
acid	O
by	O
ORF	B-chem
17583	E-chem
supports	O
the	O
existence	O
of	O
interdependence	O
between	O
histamine	B-geneN
and	I-geneN
the	I-geneN
gastrin	I-geneN
and	I-geneN
cholinergic	I-geneN
receptors	E-geneN
on	O
the	O
parietal	O
cell	O
surface	O
.	O

Antisecretory	O
potency	O
of	O
ORF	B-chem
17583	E-chem
after	O
intraduodenal	O
administration	O
in	O
pylorus	O
-	O
ligated	O
rats	O
was	O
6.4	O
times	O
greater	O
than	O
cimetidine	S-chem
,	O
1.8	O
times	O
greater	O
than	O
ranitidine	S-chem
,	O
equal	O
to	O
that	O
of	O
omeprazole	S-chem
and	O
8	O
times	O
less	O
than	O
that	O
of	O
famotidine	S-chem
.	O

Oral	O
antisecretory	O
potency	O
of	O
ORF	B-chem
17583	E-chem
in	O
gastric	O
fistula	O
dogs	O
was	O
31	O
times	O
greater	O
than	O
cimetidine	S-chem
,	O
3.7	O
times	O
greater	O
than	O
ranitidine	S-chem
and	O
equal	O
to	O
that	O
of	O
omeprazole	S-chem
and	O
famotidine	S-chem
.	O

Studies	O
using	O
equieffective	O
antisecretory	O
doses	O
of	O
ORF	B-chem
17583	E-chem
and	O
ranitidine	S-chem
in	O
dogs	O
suggested	O
that	O
ORF	B-chem
17583	E-chem
has	O
a	O
short	O
duration	O
of	O
antisecretory	O
activity	O
similar	O
to	O
that	O
of	O
ranitidine	S-chem
.	O

AT1	S-geneY-C6-2
antagonism	O
by	O
eprosartan	S-chem-C6-1
lowers	O
heart	O
rate	O
variability	O
and	O
baroreflex	O
gain	O
.	O

INTRODUCTION	O
:	O
Blockade	O
of	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
system	O
(	O
RAS	O
)	O
by	O
ACE	S-geneY
inhibitors	O
has	O
been	O
demonstrated	O
to	O
reduce	O
total	O
mortality	O
in	O
cardiovascular	O
diseases	O
.	O

This	O
advantage	O
was	O
attributed	O
in	O
part	O
to	O
changes	O
of	O
autonomic	O
cardiovascular	O
control	O
,	O
exemplified	O
by	O
an	O
increase	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
and	O
baroreflex	O
gain	O
(	O
BRG	O
)	O
.	O

We	O
sought	O
to	O
assess	O
the	O
effects	O
of	O
the	O
angiotensin	B-geneY-C4-2
type	I-geneY-C4-2
1	I-geneY-C4-2
(	I-geneY-C4-2
AT1	I-geneY-C4-2
)	I-geneY-C4-2
receptor	E-geneY-C4-2
blocker	O
eprosartan	S-chem-C4-1
on	O
HRV	O
and	O
BRG	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
randomized	O
cross	O
-	O
over	O
design	O
25	O
young	O
males	O
took	O
eprosartan	S-chem
(	O
600	O
mg	O
/	O
day	O
)	O
and	O
placebo	O
each	O
for	O
a	O
period	O
of	O
7	O
days	O
with	O
a	O
wash	O
-	O
out	O
period	O
of	O
at	O
least	O
4	O
weeks	O
in	O
between	O
.	O

At	O
the	O
end	O
of	O
the	O
intake	O
phases	O
simultaneous	O
recordings	O
of	O
arterial	O
blood	O
pressure	O
(	O
AP	O
;	O
Finapres	O
)	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
were	O
taken	O
.	O

Power	O
spectra	O
of	O
HRV	O
and	O
arterial	O
blood	O
pressure	O
variability	O
(	O
APV	O
)	O
were	O
calculated	O
by	O
fast	O
Fourier	O
transform	O
(	O
FFT	O
)	O
and	O
served	O
to	O
calculate	O
BRG	O
.	O

Ang	B-geneY
-	I-geneY
II	E-geneY
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Eprosartan	S-chem-C3-1
tended	O
to	O
lower	O
mean	O
AP	O
,	O
it	O
slightly	O
increased	O
heart	O
rate	O
(	O
HR	O
)	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
markedly	O
increased	O
circulating	O
Ang	B-geneY-C3-2
-	I-geneY-C3-2
II	E-geneY-C3-2
levels	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Eprosartan	S-chem
diminished	O
the	O
total	O
power	O
of	O
HRV	O
(	O
p	O
<	O
0.05	O
)	O
and	O
the	O
BRG	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
low	O
/	O
high	O
frequency	O
(	O
LF	O
/	O
HF	O
)	O
ratio	O
of	O
HRV	O
and	O
the	O
APV	O
were	O
not	O
altered	O
.	O

CONCLUSIONS	O
:	O
AT1	S-geneY-C6-2
antagonism	O
by	O
eprosartan	S-chem-C6-1
lowers	O
heart	O
rate	O
variability	O
and	O
baroreflex	O
gain	O
.	O

We	O
speculate	O
that	O
these	O
findings	O
are	O
due	O
to	O
the	O
marked	O
increase	O
in	O
circulating	O
angiotensin	B-geneY
II	E-geneY
(	O
Ang	B-geneY
II	E-geneY
)	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
whether	O
angiotensin	B-geneY
type	I-geneY
1	E-geneY
(	O
AT1	S-geneY
)	O
blockers	O
with	O
potential	O
actions	O
inside	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
may	O
have	O
different	O
effects	O
on	O
HRV	O
and	O
BRG	O
.	O

Nutrients	O
and	O
bioactive	O
compounds	O
of	O
Thai	O
indigenous	O
fruits	O
.	O

This	O
study	O
determined	O
the	O
nutritional	O
potential	O
of	O
Thai	O
indigenous	O
fruits	O
in	O
terms	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Three	O
indigenous	O
fruits	O
were	O
collected	O
at	O
two	O
conservation	O
areas	O
in	O
Kanchanaburi	O
province	O
,	O
Thailand	O
.	O

The	O
results	O
showed	O
that	O
Phyllanthus	O
emblica	O
L.	O
exhibited	O
the	O
highest	O
levels	O
of	O
vitamin	B-chem
C	E-chem
(	O
575±452mg	O
/	O
100g	O
)	O
,	O
total	O
phenolics	S-chem
(	O
TP	O
)	O
(	O
3703±1244mGAE	O
/	O
100g	O
)	O
,	O
and	O
antioxidant	O
activities	O
,	O
as	O
measured	O
by	O
DPPH	S-chem
,	O
FRAP	O
and	O
ORAC	O
assays	O
.	O

Compared	O
to	O
the	O
other	O
two	O
fruits	O
,	O
Antidesma	O
velutinosum	O
Blume	O
contained	O
higher	O
levels	O
of	O
most	O
nutrients	O
and	O
dietary	O
fibre	O
(	O
15.6±5.9g	O
/	O
100g	O
)	O
,	O
as	O
well	O
as	O
carotenoids	O
(	O
335±98μg	O
/	O
100g	O
)	O
and	O
phytosterols	S-chem
(	O
22.1±3.9mg	O
/	O
100g	O
)	O
.	O

Spondias	O
pinnata	O
(	O
L.f.	O
)	O
Kurz	O
was	O
high	O
in	O
total	O
phenolics	S-chem
(	O
3178±887mGAE	O
/	O
100g	O
)	O
and	O
antioxidant	O
activity	O
.	O

Moreover	O
,	O
high	O
correlations	O
were	O
found	O
between	O
TP	O
and	O
antioxidant	O
activities	O
(	O
r	O
>	O
0.9	O
)	O
.	O

These	O
Thai	O
indigenous	O
fruits	O
are	O
potentially	O
good	O
sources	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Conservation	O
and	O
utilisation	O
should	O
be	O
promoted	O
for	O
food	O
security	O
and	O
consumption	O
as	O
part	O
of	O
a	O
healthy	O
diet	O
.	O

Protective	O
Role	O
of	O
(	B-chem
RS	I-chem
)	I-chem
-	I-chem
glucoraphanin	E-chem
Bioactivated	O
with	O
Myrosinase	S-geneN
in	O
an	O
Experimental	O
Model	O
of	O
Multiple	O
Sclerosis	O
.	O

AIM	O
:	O
The	O
discovery	O
of	O
new	O
natural	O
compounds	O
with	O
pharmacological	O
properties	O
is	O
a	O
field	O
of	O
interest	O
widely	O
growing	O
.	O

Recent	O
literature	O
shows	O
that	O
Brassica	O
vegetables	O
(	O
Cruciferae	O
)	O
possess	O
therapeutic	O
effects	O
particularly	O
ascribed	O
due	O
to	O
their	O
content	O
in	O
glucosinolates	S-chem-C9-1
,	O
which	O
upon	O
myrosinase	S-geneN-C9-2
hydrolysis	O
release	O
the	O
corresponding	O
isothiocyanates	S-chem-C9-1
.	O

This	O
study	O
examines	O
the	O
potential	O
neuroprotective	O
and	O
immunomodulatory	O
effects	O
of	O
(	B-chem
RS	I-chem
)	I-chem
-	I-chem
glucoraphanin	E-chem
from	O
Tuscan	O
black	O
kale	O
(	O
Brassica	O
oleracea	O
L.	O
var	O
.	O
acephala	O
sabellica	O
)	O
bioactivated	O
with	O
myrosinase	S-geneN
(	O
bioactive	O
RS	B-chem
-	I-chem
GRA	E-chem
)	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
intraperitoneally	O
)	O
,	O
in	O
an	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
a	O
model	O
of	O
multiple	O
sclerosis	O
.	O

METHODS	O
:	O
EAE	O
was	O
induced	O
by	O
immunization	O
with	O
myelin	B-geneY
oligodendroglial	I-geneY
glycoprotein	I-geneY
peptide	E-geneY
(	O
MOG35	B-geneY
-	I-geneY
55	E-geneY
)	O
in	O
mice	O
.	O

After	O
immunization	O
,	O
mice	O
were	O
observed	O
daily	O
for	O
signs	O
of	O
EAE	O
and	O
weight	O
loss	O
.	O

Clinical	O
score	O
was	O
evaluated	O
using	O
a	O
standardized	O
scoring	O
system	O
.	O

RESULTS	O
:	O
By	O
Western	O
blot	O
analysis	O
of	O
spinal	O
cord	O
tissues	O
,	O
we	O
have	O
demonstrated	O
that	O
treatment	O
with	O
bioactive	O
RS	B-chem-C4-1
-	I-chem-C4-1
GRA	E-chem-C4-1
significantly	O
decreased	O
nuclear	B-geneN-C4-2
factor	I-geneN-C4-2
(	I-geneN-C4-2
NF	I-geneN-C4-2
)	I-geneN-C4-2
-	I-geneN-C4-2
kB	E-geneN-C4-2
translocation	O
,	O
pro	O
-	O
inflammatory	O
cytokine	S-geneN-C4-2
production	O
such	O
as	O
interleukin	B-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
(	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
)	O
,	O
and	O
apoptosis	O
(	O
Bax	S-geneY-C4-2
and	O
caspase	B-geneY-C4-2
3	E-geneY-C4-2
expression	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
clearly	O
demonstrate	O
that	O
bioactive	O
RS	B-chem
-	I-chem
GRA	E-chem
treatment	O
may	O
represent	O
a	O
useful	O
therapeutic	O
perspective	O
in	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

Warfarin	S-chem
dose	O
and	O
the	O
pharmacogenomics	O
of	O
CYP2C9	S-geneY
and	O
VKORC1	S-geneY
-	O
rationale	O
and	O
perspectives	O
.	O

Warfarin	S-chem
is	O
the	O
most	O
widely	O
prescribed	O
oral	O
anticoagulant	O
,	O
but	O
there	O
is	O
greater	O
than	O
10	O
-	O
fold	O
interindividual	O
variability	O
in	O
the	O
dose	O
required	O
to	O
attain	O
a	O
therapeutic	O
response	O
.	O

Information	O
from	O
pharmacogenomics	O
,	O
the	O
study	O
of	O
the	O
interaction	O
of	O
an	O
individual	O
's	O
genotype	O
and	O
drug	O
response	O
,	O
can	O
help	O
optimize	O
drug	O
efficacy	O
while	O
minimizing	O
adverse	O
drug	O
reactions	O
.	O

Pharmacogenetic	O
analysis	O
of	O
two	O
genes	O
,	O
the	O
warfarin	S-chem-C9-1
metabolic	O
enzyme	O
CYP2C9	S-geneY-C9-2
and	O
warfarin	S-chem
target	O
enzyme	O
,	O
vitamin	B-geneY
K	I-geneY
epoxide	I-geneY
reductase	I-geneY
complex	I-geneY
1	E-geneY
VKORC1	S-geneY
,	O
confirmed	O
their	O
influence	O
on	O
warfarin	S-chem
maintenance	O
dose	O
.	O

Possession	O
of	O
CYP2C9	S-geneY-C9-2
*	O
2	O
or	O
CYP2C9	S-geneY-C9-2
*	O
3	O
variant	O
alleles	O
,	O
which	O
result	O
in	O
decreased	O
enzyme	O
activity	O
,	O
is	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
mean	O
warfarin	S-chem-C9-1
dose	O
.	O

Several	O
single	O
nucleotide	S-chem
polymorphisms	O
(	O
SNPs	O
)	O
in	O
VKORC1	S-geneY
are	O
associated	O
with	O
warfarin	S-chem
dose	O
across	O
the	O
normal	O
dose	O
range	O
.	O

Haplotypes	O
based	O
on	O
these	O
SNPs	O
explain	O
a	O
large	O
fraction	O
of	O
the	O
interindividual	O
variation	O
in	O
warfarin	S-chem
dose	O
,	O
and	O
VKORC1	S-geneY
has	O
an	O
approximately	O
three	O
-	O
fold	O
greater	O
effect	O
than	O
CYP2C9	S-geneY
.	O

Algorithms	O
incorporating	O
genetic	O
(	O
CYP2C9	S-geneY
and	O
VKORC1	S-geneY
)	O
,	O
demographic	O
,	O
and	O
clinical	O
factors	O
to	O
estimate	O
the	O
warfarin	S-chem
dosage	O
,	O
could	O
potentially	O
minimize	O
the	O
risk	O
of	O
over	O
dose	O
during	O
warfarin	S-chem
induction	O
.	O

Alpha	B-geneY
-	I-geneY
2B	I-geneY
adrenergic	I-geneY
receptor	E-geneY
mediated	O
hemodynamic	O
profile	O
of	O
etomidate	S-chem
.	O

Etomidate	S-chem
has	O
been	O
used	O
since	O
1972	O
as	O
an	O
inductor	O
and	O
in	O
maintaining	O
anesthesia	O
.	O

There	O
are	O
multiple	O
mechanisms	O
that	O
account	O
for	O
the	O
biologic	O
effects	O
of	O
etomidate	S-chem
.	O

One	O
of	O
the	O
most	O
prominent	O
features	O
of	O
this	O
drug	O
is	O
that	O
it	O
provides	O
anesthesia	O
without	O
gross	O
changes	O
in	O
hemodynamic	O
parameters	O
.	O

This	O
feature	O
allows	O
using	O
etomidate	S-chem
in	O
patients	O
with	O
considerable	O
cardiopulmonary	O
compromise	O
avoiding	O
the	O
characteristic	O
hypotension	O
produced	O
by	O
other	O
anesthetics	O
.	O

The	O
mechanism	O
that	O
provides	O
the	O
basis	O
for	O
its	O
cardiovascular	O
stability	O
is	O
the	O
capacity	O
to	O
bind	O
and	O
stimulate	O
peripheral	O
alpha	B-geneY
-	I-geneY
2B	I-geneY
adrenergic	I-geneY
receptors	E-geneY
with	O
a	O
subsequent	O
vasoconstriction	O
.	O

Alterations	O
in	O
the	O
function	O
or	O
number	O
of	O
these	O
receptors	O
may	O
account	O
for	O
abnormal	O
responses	O
during	O
etomidate	S-chem
induction	O
.	O

Pharmacokinetic	O
study	O
of	O
Growth	B-geneY
Hormone	E-geneY
-	I-chem
Releasing	I-chem
Peptide	I-chem
6	E-chem
(	O
GHRP	B-chem
-	I-chem
6	E-chem
)	O
in	O
nine	O
male	O
healthy	O
volunteers	O
.	O

GHRP	B-chem-C3-1
-	I-chem-C3-1
6	E-chem-C3-1
is	O
a	O
growth	B-geneY-C3-2
hormone	E-geneY-C3-2
secretagogue	O
that	O
also	O
enhances	O
tissue	O
viability	O
in	O
different	O
organs	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
studied	O
the	O
pharmacokinetics	O
of	O
this	O
short	O
therapeutic	O
hexapeptide	O
(	O
His	B-chem
-	I-chem
(	I-chem
D	I-chem
-	I-chem
Trp	I-chem
)	I-chem
-	I-chem
Ala	I-chem
-	I-chem
Trp	I-chem
-	I-chem
(	I-chem
D	I-chem
-	I-chem
Phe	I-chem
)	I-chem
-	I-chem
Lys	I-chem
-	I-chem
NH	I-chem
(	I-chem
2	I-chem
,	I-chem
)	E-chem
MW	O
=	O
872.44	O
Da	O
)	O
in	O
nine	O
male	O
healthy	O
volunteers	O
after	O
a	O
single	O
intravenous	O
bolus	O
administration	O
of	O
100	O
,	O
200	O
and	O
400	O
μg	O
/	O
kg	O
of	O
body	O
weight	O
.	O

GHRP	B-chem
-	I-chem
6	E-chem
was	O
quantified	O
in	O
human	O
plasma	O
by	O
a	O
specific	O
LC	O
-	O
MS	O
method	O
,	O
previously	O
developed	O
and	O
validated	O
following	O
FDA	O
guidelines	O
,	O
using	O
(	B-chem
13	I-chem
)	I-chem
C	I-chem
(	I-chem
3	I-chem
)	I-chem
Ala	I-chem
-	I-chem
GHRP	I-chem
-	I-chem
6	E-chem
as	O
internal	O
standard	O
(	O
Gil	O
et	O
al	O
.	O
,	O
2012	O
,	O
J	O
.	O

Pharm	O
.	O

Biomed	O
.	O

Anal	O
.	O

60	O
,	O
19	O
-	O
25	O
)	O
.	O

The	O
Lower	O
Limit	O
of	O
Quantification	O
(	O
5	O
ng	O
/	O
mL	O
)	O
was	O
reached	O
in	O
all	O
subjects	O
at	O
12h	O
post	O
-	O
administration	O
,	O
which	O
was	O
sufficient	O
for	O
modeling	O
a	O
pharmacokinetic	O
profile	O
including	O
over	O
85	O
%	O
of	O
the	O
Area	O
under	O
the	O
Curve	O
(	O
AUC	O
)	O
.	O

Disposition	O
of	O
GHRP	B-chem
-	I-chem
6	E-chem
best	O
fitted	O
a	O
bi	O
-	O
exponential	O
function	O
with	O
R	O
(	O
2	O
)	O
higher	O
than	O
0.99	O
,	O
according	O
to	O
a	O
mathematic	O
modeling	O
and	O
confirmed	O
by	O
an	O
Akaike	O
index	O
(	O
AIC	O
)	O
lower	O
than	O
that	O
of	O
the	O
corresponding	O
one	O
-	O
compartment	O
model	O
for	O
all	O
subjects	O
.	O

Averaging	O
all	O
three	O
dose	O
levels	O
,	O
the	O
distribution	O
and	O
elimination	O
half	O
-	O
life	O
of	O
GHRP	B-chem
-	I-chem
6	E-chem
were	O
7.6	O
±	O
1.9	O
min	O
and	O
2.5	O
±	O
1.1h	O
,	O
respectively	O
.	O

These	O
values	O
are	O
coherent	O
with	O
existing	O
data	O
for	O
other	O
drugs	O
whose	O
disposition	O
also	O
fits	O
this	O
model	O
.	O

Dose	O
dependence	O
analysis	O
revealed	O
a	O
noticeable	O
trend	O
for	O
AUC	O
to	O
increase	O
proportionally	O
with	O
administered	O
dose	O
.	O

Atypical	O
GHRP	B-chem
-	I-chem
6	E-chem
concentration	O
spikes	O
were	O
observed	O
during	O
the	O
elimination	O
phase	O
in	O
four	O
out	O
of	O
the	O
nine	O
subjects	O
studied	O
.	O

Gene	O
silencing	O
of	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
in	O
a	O
murine	O
model	O
of	O
acute	O
colitis	O
using	O
a	O
modified	O
cyclodextrin	O
delivery	O
system	O
.	O

Inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
is	O
a	O
chronic	O
relapsing	O
inflammation	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
cytokine	S-geneN
TNF	B-geneY
-	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
plays	O
a	O
pivotal	O
role	O
in	O
mediating	O
this	O
inflammatory	O
response	O
.	O

RNA	O
interference	O
(	O
RNAi	O
)	O
holds	O
great	O
promise	O
for	O
the	O
specific	O
and	O
selective	O
silencing	O
of	O
aberrantly	O
expressed	O
genes	O
,	O
such	O
as	O
TNF	B-geneY
-	I-geneY
α	E-geneY
in	O
IBD	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
of	O
an	O
amphiphilic	O
cationic	O
cyclodextrin	O
(	O
CD	O
)	O
vector	O
for	O
effective	O
TNF	B-geneY
-	I-geneY
α	E-geneY
siRNA	O
delivery	O
to	O
macrophage	O
cells	O
and	O
to	O
mice	O
with	O
induced	O
acute	O
-	O
colitis	O
.	O

The	O
stability	O
of	O
CD.siRNA	O
was	O
examined	O
by	O
gel	O
electrophoresis	O
in	O
biorelevant	O
media	O
reflecting	O
colonic	O
fluids	O
.	O

RAW264.7	O
cells	O
were	O
transfected	O
with	O
CD.TNF	O
-	I-geneY
α	E-geneY
siRNA	O
,	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
responses	O
were	O
measured	O
by	O
PCR	O
and	O
ELISA	O
.	O

Female	O
C57BL	O
/	O
6	O
mice	O
were	O
exposed	O
to	O
dextran	O
sodium	B-chem
sulphate	E-chem
(	O
DSS	O
)	O
and	O
treated	O
by	O
intrarectal	O
administration	O
with	O
either	O
CD.siRNA	O
TNF	B-geneY
-	I-geneY
α	E-geneY
or	O
a	O
control	O
solution	O
.	O

In	O
vitro	O
,	O
siRNA	O
in	O
CD	O
nanocomplexes	O
remained	O
intact	O
and	O
stable	O
in	O
both	O
fed	O
and	O
fasted	O
simulated	O
colonic	O
fluids	O
.	O

RAW264.7	O
cells	O
transfected	O
with	O
CD.TNF	O
-	I-geneY
α	E-geneY
siRNA	O
and	O
stimulated	O
with	O
LPS	O
displayed	O
a	O
significant	O
reduction	O
in	O
both	O
gene	O
and	O
protein	O
levels	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
.	O

CD.TNF	O
-	I-geneY
α	E-geneY
siRNA	O
-	O
treated	O
mice	O
revealed	O
a	O
mild	O
amelioration	O
in	O
clinical	O
signs	O
of	O
colitis	O
,	O
but	O
significant	O
reductions	O
in	O
total	O
colon	O
weight	O
and	O
colonic	O
mRNA	O
expression	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
compared	O
to	O
DSS	O
-	O
control	O
mice	O
were	O
detected	O
.	O

This	O
data	O
indicates	O
the	O
clinical	O
potential	O
of	O
a	O
local	O
CD	O
-	O
based	O
TNF	B-geneY
-	I-geneY
α	E-geneY
siRNA	O
delivery	O
system	O
for	O
the	O
treatment	O
of	O
IBD	O
.	O

Administration	O
of	O
the	O
optimized	O
β	B-chem
-	I-chem
Lapachone	E-chem
-	O
poloxamer	S-chem
-	O
cyclodextrin	O
ternary	O
system	O
induces	O
apoptosis	O
,	O
DNA	O
damage	O
and	O
reduces	O
tumor	O
growth	O
in	O
a	O
human	O
breast	O
adenocarcinoma	O
xenograft	O
mouse	O
model	O
.	O

β	B-chem
-	I-chem
Lapachone	E-chem
(	O
β	B-chem
-	I-chem
Lap	E-chem
)	O
is	O
a	O
1,2	B-chem
-	I-chem
orthonaphthoquinone	E-chem
that	O
selectively	O
induces	O
cell	O
death	O
in	O
human	O
cancer	O
cells	O
through	O
NAD	B-geneY
(	I-geneY
P	I-geneY
)	I-geneY
H	I-geneY
:	I-geneY
quinone	I-geneY
oxidoreductase	I-geneY
-	I-geneY
1	E-geneY
(	O
NQO1	S-geneY
)	O
.	O

NQO1	S-geneY
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumors	O
,	O
as	O
compared	O
to	O
normal	O
adjacent	O
tissue	O
.	O

However	O
,	O
the	O
low	O
solubility	O
and	O
non	O
-	O
specific	O
distribution	O
of	O
β	B-chem
-	I-chem
Lap	E-chem
limit	O
its	O
suitability	O
for	O
clinical	O
assays	O
.	O

We	O
formulated	O
β	B-chem
-	I-chem
Lap	E-chem
in	O
an	O
optimal	O
random	O
methylated	B-chem
-	I-chem
β	I-chem
-	I-chem
cyclodextrin	E-chem
/	O
poloxamer	B-chem
407	E-chem
mixture	O
(	O
i.e	O
.	O
,	O
β	B-chem
-	I-chem
Lap	E-chem
ternary	O
system	O
)	O
and	O
,	O
using	O
human	O
breast	O
adenocarcinoma	O
MCF	O
-	O
7	O
cells	O
and	O
immunodeficient	O
mice	O
,	O
performed	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
its	O
anti	O
-	O
tumor	O
effects	O
on	O
proliferation	O
,	O
cell	O
cycle	O
,	O
apoptosis	O
,	O
DNA	O
damage	O
,	O
and	O
tumor	O
growth	O
.	O

This	O
ternary	O
system	O
is	O
fluid	O
at	O
room	O
temperature	O
,	O
gels	O
over	O
29°C	O
,	O
and	O
provides	O
a	O
significant	O
amount	O
of	O
drug	O
,	O
thus	O
facilitating	O
intratumoral	O
delivery	O
,	O
in	O
situ	O
gelation	O
,	O
and	O
the	O
formation	O
of	O
a	O
depot	O
for	O
time	O
-	O
release	O
.	O

Administration	O
of	O
β	B-chem
-	I-chem
Lap	E-chem
ternary	O
system	O
to	O
MCF	O
-	O
7	O
cells	O
induces	O
an	O
increase	O
in	O
apoptosis	O
and	O
DNA	O
damage	O
,	O
while	O
producing	O
no	O
changes	O
in	O
cell	O
cycle	O
.	O

Moreover	O
,	O
in	O
a	O
mouse	O
xenograft	O
tumor	O
model	O
,	O
intratumoral	O
injection	O
of	O
the	O
system	O
significantly	O
reduces	O
tumor	O
volume	O
,	O
while	O
increasing	O
apoptosis	O
and	O
DNA	O
damage	O
without	O
visible	O
toxicity	O
to	O
liver	O
or	O
kidney	O
.	O

These	O
anti	O
-	O
tumoral	O
effects	O
and	O
lack	O
of	O
visible	O
toxicity	O
make	O
this	O
system	O
a	O
promising	O
new	O
therapeutic	O
agent	O
for	O
breast	O
cancer	O
treatment	O
.	O

Phorbol	O
esters	O
and	O
norepinephrine	S-chem-C4-1
destabilize	O
alpha	B-geneY-C4-2
1B	I-geneY-C4-2
-	I-geneY-C4-2
adrenergic	I-geneY-C4-2
receptor	E-geneY-C4-2
mRNA	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

The	O
mechanism	O
by	O
which	O
norepinephrine	S-chem-C4-1
(	O
NE	S-chem-C4-1
)	O
down	O
-	O
regulates	O
alpha	B-geneY-C4-2
1B	I-geneY-C4-2
-	I-geneY-C4-2
adrenergic	I-geneY-C4-2
receptor	E-geneY-C4-2
(	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
)	O
mRNA	O
was	O
studied	O
in	O
rabbit	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

NE	S-chem-C4-1
,	O
phorbol	B-chem-C4-1
esters	E-chem-C4-1
,	O
and	O
bradykinin	S-geneY
each	O
decreased	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
mRNA	O
levels	O
by	O
70	O
-	O
80	O
%	O
.	O

The	O
protein	B-geneN-C4-2
kinase	I-geneN-C4-2
C	E-geneN-C4-2
inhibitor	O
(	B-chem-C4-1
+	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
5	I-chem-C4-1
-	I-chem-C4-1
isoquinolinesulfonyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
methylpiperazine	I-chem-C4-1
dihydrochloride	E-chem-C4-1
(	O
H	B-chem-C4-1
-	I-chem-C4-1
7	E-chem-C4-1
)	O
abolished	O
the	O
effects	O
of	O
phorbol	B-chem
esters	E-chem
and	O
NE	S-chem
and	O
decreased	O
basal	O
mRNA	O
levels	O
by	O
52	O
+	O
/	O
-	O
3	O
%	O
.	O

Neither	O
ryanodine	S-chem-C3-1
nor	O
EGTA	S-chem-C3-1
inhibited	O
down	O
-	O
regulation	O
of	O
alpha	B-geneN-MU-2
-	I-geneN-MU-2
AR	E-geneN-MU-2
mRNA	O
by	O
NE	S-chem-C4-1
.	O

Actinomycin	B-chem-C4-1
D	E-chem-C4-1
caused	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
mRNA	O
level	O
to	O
decrease	O
with	O
a	O
half	O
-	O
life	O
of	O
3.2	O
+	O
/	O
-	O
0.4	O
h	O
and	O
blocked	O
the	O
effect	O
of	O
H	B-chem
-	I-chem
7	E-chem
to	O
decrease	O
basal	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
mRNA	O
level	O
.	O

Both	O
NE	S-chem-C4-1
and	O
phorbol	B-chem-C4-1
esters	E-chem-C4-1
increased	O
the	O
rate	O
of	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
mRNA	O
degradation	O
.	O

In	O
NE	S-chem-C4-1
-	O
desensitized	O
cells	O
,	O
phorbol	B-chem-C4-1
esters	E-chem-C4-1
and	O
bradykinin	S-geneY
each	O
caused	O
the	O
expected	O
down	O
-	O
regulation	O
of	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
AR	E-geneN-C4-2
mRNA	O
.	O

The	O
protein	B-geneN-C4-2
phosphatase	E-geneN-C4-2
inhibitor	O
okadaic	B-chem-C4-1
acid	E-chem-C4-1
prolonged	O
the	O
normally	O
transient	O
effect	O
of	O
NE	S-chem
for	O
at	O
least	O
24	O
h	O
.	O

We	O
conclude	O
that	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
exerts	O
two	O
opposing	O
effects	O
on	O
alpha	B-geneN
-	I-geneN
AR	E-geneN
mRNA	O
levels	O
,	O
1	O
)	O
a	O
decrease	O
in	O
the	O
stability	O
of	O
the	O
mRNA	O
that	O
requires	O
the	O
sustained	O
phosphorylation	O
of	O
a	O
protein	B-geneN
kinase	I-geneN
C	E-geneN
substrate	O
and	O
2	O
)	O
a	O
permissive	O
effect	O
on	O
alpha	B-geneN
-	I-geneN
AR	E-geneN
gene	O
transcription	O
.	O

Effects	O
of	O
loperamide	S-chem
on	O
the	O
human	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Loperamide	S-chem-C4-1
,	O
an	O
opiate	O
agonist	O
of	O
high	O
specificity	O
for	O
mu	O
-	O
receptors	O
,	O
was	O
recently	O
reported	O
to	O
suppress	O
ACTH	S-geneY-C4-2
and	O
cortisol	S-chem
levels	O
in	O
normal	O
subjects	O
,	O
but	O
not	O
in	O
patients	O
with	O
proven	O
ACTH	S-geneY
-	O
dependent	O
Cushing	O
's	O
disease	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
on	O
the	O
site	O
of	O
action	O
of	O
loperamide	S-chem
in	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
of	O
man	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
loperamide	S-chem
on	O
pituitary	O
hormone	O
secretion	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
seven	O
normal	O
subjects	O
,	O
basal	O
ACTH	S-geneY-C4-2
plasma	O
levels	O
were	O
significantly	O
suppressed	O
3	O
h	O
after	O
loperamide	S-chem-C4-1
administration	O
(	O
16	O
mg	O
,	O
orally	O
)	O
from	O
5	O
+	O
/	O
-	O
1	O
to	O
2	O
+	O
/	O
-	O
0	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
.	O

After	O
the	O
combined	O
pituitary	O
stimulation	O
test	O
(	O
100	O
micrograms	O
human	B-geneY-C4-2
CRH	E-geneY-C4-2
,	O
100	O
micrograms	O
GnRH	S-geneY-C4-2
,	O
100	O
micrograms	O
GH	B-geneY-C4-2
-	I-geneY-C4-2
releasing	I-geneY-C4-2
hormone	E-geneY-C4-2
,	O
and	O
200	O
micrograms	O
TRH	S-geneN-C4-2
)	O
,	O
the	O
ACTH	S-geneY-C4-2
peak	O
(	O
maximum	O
increase	O
at	O
30	O
min	O
)	O
was	O
significantly	O
blunted	O
by	O
loperamide	S-chem-C4-1
from	O
9	O
+	O
/	O
-	O
1	O
to	O
4	O
+	O
/	O
-	O
1	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
ACTH	S-geneY-C4-2
from	O
0	O
-	O
120	O
min	O
was	O
reduced	O
from	O
35	O
+	O
/	O
-	O
5	O
to	O
23	O
+	O
/	O
-	O
4	O
pmol	O
/	O
L.2	O
h	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
the	O
insulin	S-geneY
-	O
hypoglycemia	O
test	O
(	O
0.15	O
IU	O
/	O
kg	O
BW	O
)	O
,	O
neither	O
the	O
ACTH	S-geneY
peak	O
nor	O
the	O
area	O
under	O
the	O
curve	O
of	O
ACTH	S-geneY
was	O
affected	O
by	O
loperamide	S-chem
.	O

In	O
six	O
patients	O
with	O
Cushing	O
's	O
disease	O
and	O
one	O
patient	O
with	O
secondary	O
adrenal	O
insufficiency	O
due	O
to	O
hypothalamic	O
failure	O
,	O
neither	O
basal	O
ACTH	S-geneY
and	O
cortisol	S-chem
levels	O
nor	O
CRH	S-geneY
-	O
stimulated	O
levels	O
were	O
influenced	O
by	O
loperamide	S-chem
.	O

In	O
four	O
cultured	O
human	O
corticotropic	O
adenomas	O
,	O
loperamide	S-chem
was	O
not	O
able	O
to	O
reduce	O
basal	O
and	O
CRH	S-geneY
-	O
induced	O
ACTH	S-geneY
secretion	O
.	O

In	O
summary	O
,	O
loperamide	S-chem-C4-1
is	O
able	O
to	O
reduce	O
basal	O
and	O
CRH	S-geneY-C4-2
-	O
induced	O
ACTH	S-geneY-C4-2
and	O
cortisol	S-chem
levels	O
in	O
normal	O
subjects	O
,	O
but	O
not	O
in	O
patients	O
with	O
Cushing	O
's	O
disease	O
or	O
secondary	O
adrenal	O
failure	O
of	O
hypothalamic	O
origin	O
.	O

Loperamide	S-chem
has	O
no	O
significant	O
effect	O
on	O
insulin	S-geneY
-	O
hypoglycemia	O
-	O
induced	O
ACTH	S-geneY
and	O
cortisol	S-chem
levels	O
and	O
,	O
therefore	O
,	O
no	O
effect	O
on	O
stress	O
-	O
induced	O
elevation	O
of	O
cortisol	O
levels	O
.	O

Loperamide	S-chem
might	O
act	O
at	O
a	O
suprapituitary	O
site	O
in	O
man	O
in	O
vivo	O
,	O
but	O
,	O
nevertheless	O
,	O
a	O
pituitary	O
site	O
can	O
not	O
be	O
excluded	O
.	O

Inactivation	O
of	O
BAD	S-geneY
by	O
IKK	S-geneN
inhibits	O
TNFα	S-geneY
-	O
induced	O
apoptosis	O
independently	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
.	O

The	O
IκB	B-geneN
kinase	E-geneN
complex	O
(	O
IKK	S-geneN
)	O
is	O
a	O
key	O
regulator	O
of	O
immune	O
responses	O
,	O
inflammation	O
,	O
cell	O
survival	O
,	O
and	O
tumorigenesis	O
.	O

The	O
prosurvival	O
function	O
of	O
IKK	S-geneN
centers	O
on	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B-geneN
-	I-geneN
κB	E-geneN
,	O
whose	O
target	O
gene	O
products	O
inhibit	O
caspases	S-geneN
and	O
prevent	O
prolonged	O
JNK	S-geneN
activation	O
.	O

Here	O
,	O
we	O
report	O
that	O
inactivation	O
of	O
the	O
BH3	S-geneN
-	O
only	O
protein	O
BAD	S-geneY
by	O
IKK	S-geneN
independently	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
suppresses	O
TNFα	S-geneY
-	O
induced	O
apoptosis	O
.	O

TNFα	S-geneY
-	O
treated	O
Ikkβ	S-geneY
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
undergo	O
apoptosis	O
significantly	O
faster	O
than	O
MEFs	O
deficient	O
in	O
both	O
RelA	S-geneY
and	O
cRel	S-geneY
due	O
to	O
lack	O
of	O
inhibition	O
of	O
BAD	S-geneY
by	O
IKK	S-geneN
.	O

IKK	S-geneN
phosphorylates	O
BAD	S-geneY
at	O
serine	S-chem
-	O
26	O
(	O
Ser26	S-chem
)	O
and	O
primes	O
it	O
for	O
inactivation	O
.	O

Elimination	O
of	O
Ser26	S-chem
phosphorylation	O
promotes	O
BAD	S-geneY
proapoptotic	O
activity	O
,	O
thereby	O
accelerating	O
TNFα	S-geneY
-	O
induced	O
apoptosis	O
in	O
cultured	O
cells	O
and	O
increasing	O
mortality	O
in	O
animals	O
.	O

Our	O
results	O
reveal	O
that	O
IKK	S-geneN
inhibits	O
TNFα	S-geneY
-	O
induced	O
apoptosis	O
through	O
two	O
distinct	O
but	O
cooperative	O
mechanisms	O
:	O
activation	O
of	O
the	O
survival	O
factor	O
NF	B-geneN
-	I-geneN
κB	E-geneN
and	O
inactivation	O
of	O
the	O
proapoptotic	O
BH3	S-geneN
-	O
only	O
BAD	S-geneY
protein	O
.	O

Structure	O
and	O
kinetics	O
of	O
monofunctional	O
proline	B-geneY
dehydrogenase	E-geneY
from	O
Thermus	O
thermophilus	O
.	O

Proline	B-geneY-C9-2
dehydrogenase	E-geneY-C9-2
(	O
PRODH	S-geneY-C9-2
)	O
and	O
Delta	B-geneY-C9-2
(	I-geneY-C9-2
1	I-geneY-C9-2
)	I-geneY-C9-2
-	I-geneY-C9-2
pyrroline	I-geneY-C9-2
-	I-geneY-C9-2
5	I-geneY-C9-2
-	I-geneY-C9-2
carboxylate	I-geneY-C9-2
dehydrogenase	E-geneY-C9-2
(	O
P5CDH	S-geneY-C9-2
)	O
catalyze	O
the	O
two	O
-	O
step	O
oxidation	O
of	O
proline	S-chem-C9-1
to	O
glutamate	S-chem-C9-1
.	O

They	O
are	O
distinct	O
monofunctional	O
enzymes	O
in	O
all	O
eukaryotes	O
and	O
some	O
bacteria	O
but	O
are	O
fused	O
into	O
bifunctional	O
enzymes	O
known	O
as	O
proline	B-geneN
utilization	I-geneN
A	E-geneN
(	O
PutA	S-geneN
)	O
in	O
other	O
bacteria	O
.	O

Here	O
we	O
report	O
the	O
first	O
structure	O
and	O
biochemical	O
data	O
for	O
a	O
monofunctional	O
PRODH	S-geneY
.	O

The	O
2.0	O
-	O
A	O
resolution	O
structure	O
of	O
Thermus	B-geneY
thermophilus	I-geneY
PRODH	E-geneY
reveals	O
a	O
distorted	O
(	B-geneN
betaalpha	I-geneN
)	I-geneN
(	I-geneN
8	I-geneN
)	I-geneN
barrel	I-geneN
catalytic	I-geneN
core	I-geneN
domain	E-geneN
and	O
a	O
hydrophobic	B-geneN
alpha	I-geneN
-	I-geneN
helical	I-geneN
domain	E-geneN
located	O
above	O
the	O
carboxyl	S-chem
-	O
terminal	O
ends	O
of	O
the	O
strands	O
of	O
the	O
barrel	O
.	O

Although	O
the	O
catalytic	O
core	O
is	O
similar	O
to	O
that	O
of	O
the	O
PutA	B-geneN
PRODH	I-geneN
domain	E-geneN
,	O
the	O
FAD	O
conformation	O
of	O
T.	B-geneY
thermophilus	I-geneY
PRODH	E-geneY
is	O
remarkably	O
different	O
and	O
likely	O
reflects	O
unique	O
requirements	O
for	O
membrane	O
association	O
and	O
communication	O
with	O
P5CDH	S-geneY
.	O

Also	O
,	O
the	O
FAD	O
of	O
T.	B-geneY
thermophilus	I-geneY
PRODH	E-geneY
is	O
highly	O
solvent	O
-	O
exposed	O
compared	O
with	O
PutA	S-geneN
due	O
to	O
a	O
4	O
-	O
A	O
shift	O
of	O
helix	O
8	O
.	O

Structure	O
-	O
based	O
sequence	O
analysis	O
of	O
the	O
PutA	S-geneN
/	O
PRODH	S-geneY
family	O
led	O
us	O
to	O
identify	O
nine	O
conserved	O
motifs	O
involved	O
in	O
cofactor	O
and	O
substrate	O
recognition	O
.	O

Biochemical	O
studies	O
show	O
that	O
the	O
midpoint	O
potential	O
of	O
the	O
FAD	O
is	O
-	O
75	O
mV	O
and	O
the	O
kinetic	O
parameters	O
for	O
proline	O
are	O
K	O
(	O
m	O
)	O
=	O
27	O
mm	O
and	O
k	O
(	O
cat	O
)	O
=	O
13	O
s	O
(	O
-	O
1	O
)	O
.	O

3,4	B-chem
-	I-chem
Dehydro	I-chem
-	I-chem
l	I-chem
-	I-chem
proline	E-chem
was	O
found	O
to	O
be	O
an	O
efficient	O
substrate	O
,	O
and	O
l	B-chem
-	I-chem
tetrahydro	I-chem
-	I-chem
2	I-chem
-	I-chem
furoic	I-chem
acid	E-chem
is	O
a	O
competitive	O
inhibitor	O
(	O
K	O
(	O
I	O
)	O
=	O
1.0	O
mm	O
)	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
T.	B-geneY-C9-2
thermophilus	I-geneY-C9-2
PRODH	E-geneY-C9-2
reacts	O
with	O
O	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
producing	O
superoxide	S-chem-C9-1
.	O

This	O
is	O
significant	O
because	O
superoxide	S-chem-C9-1
production	O
underlies	O
the	O
role	O
of	O
human	B-geneY-C9-2
PRODH	E-geneY-C9-2
in	O
p53	S-geneY
-	O
mediated	O
apoptosis	O
,	O
implying	O
commonalities	O
between	O
eukaryotic	B-geneN
and	I-geneN
bacterial	I-geneN
monofunctional	I-geneN
PRODHs	E-geneN
.	O

Discovery	O
of	O
novel	O
cannabinoid	B-geneN
receptor	E-geneN
ligands	O
by	O
a	O
virtual	O
screening	O
approach	O
:	O
further	O
development	O
of	O
2,4,6	B-chem-C5-1
-	I-chem-C5-1
trisubstituted	I-chem-C5-1
1,3,5	I-chem-C5-1
-	I-chem-C5-1
triazines	E-chem-C5-1
as	O
CB2	S-geneY-C5-2
agonists	O
.	O

3D	O
ligand	O
-	O
based	O
virtual	O
screening	O
was	O
employed	O
to	O
identify	O
novel	O
scaffolds	O
for	O
cannabinoid	B-geneN
receptor	E-geneN
ligand	O
development	O
.	O

A	O
total	O
of	O
112	O
compounds	O
with	O
diverse	O
structures	O
were	O
purchased	O
from	O
commercial	O
vendors	O
.	O

12	O
CB1	S-geneY
receptor	O
antagonists	O
/	O
inverse	O
agonists	O
and	O
10	O
CB2	S-geneY
receptor	O
agonists	O
were	O
identified	O
in	O
vitro	O
.	O

One	O
of	O
the	O
CB2	S-geneY-C5-2
agonists	O
,	O
N	B-chem-C5-1
-	I-chem-C5-1
cyclopentyl	I-chem-C5-1
-	I-chem-C5-1
4	I-chem-C5-1
-	I-chem-C5-1
ethoxy	I-chem-C5-1
-	I-chem-C5-1
6	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
4	I-chem-C5-1
-	I-chem-C5-1
methylpiperidin	I-chem-C5-1
-	I-chem-C5-1
1	I-chem-C5-1
-	I-chem-C5-1
yl	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
1,3,5	I-chem-C5-1
-	I-chem-C5-1
triazin	I-chem-C5-1
-	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
amine	E-chem-C5-1
(	O
19	O
,	O
-	O
logEC	O
(	O
50	O
)	O
=	O
7.5	O
,	O
E	O
(	O
max	O
)	O
=	O
255	O
%	O
)	O
was	O
selected	O
for	O
further	O
development	O
.	O

As	O
far	O
as	O
we	O
are	O
aware	O
,	O
the	O
compound	O
's	O
1,3,5	B-chem-C5-1
-	I-chem-C5-1
triazine	E-chem-C5-1
scaffold	O
represents	O
a	O
new	O
core	O
structure	O
for	O
CB2	S-geneY-C5-2
agonists	O
.	O

A	O
library	O
of	O
fifty	O
-	O
seven	O
2,4,6	B-chem
-	I-chem
trisubstituted	I-chem
-	I-chem
1,3,5	I-chem
-	I-chem
triazines	E-chem
was	O
created	O
to	O
clarify	O
the	O
structure	O
-	O
activity	O
relationship	O
study	O
of	O
the	O
analogs	O
.	O

Mechanism	O
of	O
the	O
haemostatic	O
effect	O
of	O
ethanolamine	B-chem
oleate	E-chem
in	O
the	O
injection	O
sclerotherapy	O
for	O
oesophageal	O
varices	O
.	O

Changes	O
in	O
coagulation	O
and	O
fibrinolysis	O
were	O
investigated	O
in	O
20	O
patients	O
with	O
oesophageal	O
varices	O
,	O
who	O
underwent	O
endoscopic	O
injection	O
sclerotherapy	O
(	O
EIS	O
)	O
with	O
5	O
per	O
cent	O
ethanolamine	B-chem
oleate	E-chem
(	O
EO	S-chem
)	O
,	O
by	O
means	O
of	O
serial	O
determination	O
of	O
plasma	O
fibrinopeptide	B-geneY
A	E-geneY
(	O
FPA	S-geneY
)	O
and	O
fibrinopeptide	B-geneY
B	I-geneY
beta	I-geneY
15	I-geneY
-	I-geneY
42	E-geneY
(	O
B	B-geneY
beta	I-geneY
15	I-geneY
-	I-geneY
42	E-geneY
)	O
.	O

One	O
hour	O
after	O
the	O
completion	O
of	O
EIS	O
,	O
the	O
value	O
of	O
FPA	S-geneY
was	O
significantly	O
increased	O
to	O
38.1	O
+	O
/	O
-	O
11.1	O
ng	O
/	O
ml	O
(	O
mean	O
+	O
/	O
-	O
s.e.m	O
.	O
)	O
from	O
a	O
pre	O
-	O
EIS	O
value	O
of	O
7.1	O
+	O
/	O
-	O
1.4	O
ng	O
/	O
ml	O
(	O
P	O
less	O
than	O
0.01	O
)	O
and	O
it	O
gradually	O
returned	O
to	O
normal	O
range	O
by	O
48	O
h	O
after	O
EIS	O
.	O

A	O
very	O
similar	O
change	O
was	O
observed	O
in	O
the	O
value	O
of	O
B	B-geneY
beta	I-geneY
15	I-geneY
-	I-geneY
42	E-geneY
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
observations	O
indicated	O
that	O
EIS	O
provokes	O
transient	O
activation	O
of	O
coagulation	O
and	O
fibrinolysis	O
.	O

In	O
vitro	O
studies	O
,	O
however	O
,	O
revealed	O
that	O
EO	S-chem-C4-1
inhibits	O
fibrin	S-geneN-C4-2
clot	O
formation	O
because	O
of	O
the	O
Ca2	B-chem
+	E-chem
-	O
chelating	O
ability	O
of	O
its	O
constituent	O
ethanolamine	S-chem
,	O
although	O
oleate	S-chem
or	O
benzyl	B-chem
alcohol	E-chem
exhibited	O
procoagulant	O
activity	O
in	O
FPA	S-geneY
formation	O
in	O
vitro	O
.	O

Nevertheless	O
,	O
an	O
external	O
application	O
of	O
EO	S-chem
or	O
oleate	S-chem
over	O
decapsulized	O
kidney	O
of	O
rat	O
resulted	O
in	O
a	O
significant	O
accumulation	O
of	O
125I	S-chem
-	O
labelled	O
fibrin	B-geneN
(	I-geneN
ogen	I-geneN
)	E-geneN
.	O

From	O
these	O
results	O
it	O
was	O
suggested	O
that	O
intravascular	O
injection	O
of	O
EO	S-chem
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
coagulation	O
in	O
vitro	O
,	O
activates	O
the	O
local	O
coagulation	O
system	O
.	O

The	O
activation	O
may	O
be	O
accelerated	O
by	O
an	O
acute	O
inflammatory	O
process	O
provoked	O
by	O
oleate	S-chem-C3-1
,	O
which	O
is	O
supported	O
by	O
such	O
clinical	O
manifestations	O
as	O
mild	O
fever	O
,	O
retrosternal	O
pain	O
leukocytosis	O
and	O
an	O
increase	O
in	O
plasma	O
fibrinogen	S-geneN-C3-2
level	O
which	O
was	O
observed	O
in	O
all	O
during	O
the	O
period	O
.	O

Noncanonical	O
control	O
of	O
C.	O
elegans	O
germline	O
apoptosis	O
by	O
the	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
and	O
Ras	S-geneN
/	O
MAPK	S-geneN
signaling	O
pathways	O
.	O

The	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
pathway	O
controls	O
a	O
number	O
of	O
physiological	O
processes	O
in	O
the	O
nematode	O
worm	O
Caenorhabditis	O
elegans	O
,	O
including	O
development	O
,	O
aging	O
and	O
stress	O
response	O
.	O

We	O
previously	O
found	O
that	O
the	O
Akt	S-geneY
/	O
PKB	S-geneY
ortholog	O
AKT	B-geneY
-	I-geneY
1	E-geneY
dampens	O
the	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
in	O
the	O
germline	O
by	O
negatively	O
regulating	O
the	O
p53	B-geneY
-	I-geneY
like	I-geneY
transcription	I-geneY
factor	E-geneY
CEP	B-geneY
-	I-geneY
1	E-geneY
.	O

Here	O
,	O
we	O
report	O
unexpected	O
rearrangements	O
to	O
the	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
pathway	O
,	O
whereby	O
the	O
insulin	B-geneY
-	I-geneY
like	I-geneY
receptor	E-geneY
DAF	B-geneY
-	I-geneY
2	E-geneY
and	O
3	B-geneY
-	I-geneY
phosphoinositide	I-geneY
-	I-geneY
dependent	I-geneY
protein	I-geneY
kinase	I-geneY
PDK	I-geneY
-	I-geneY
1	E-geneY
oppose	O
AKT	B-geneY
-	I-geneY
1	E-geneY
to	O
promote	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

While	O
DNA	O
damage	O
does	O
not	O
affect	O
phosphorylation	O
at	O
the	O
PDK	B-geneY
-	I-geneY
1	E-geneY
site	O
Thr350	B-geneN
/	I-geneN
Thr308	E-geneN
of	O
AKT	B-geneY
-	I-geneY
1	E-geneY
,	O
it	O
increased	O
phosphorylation	O
at	O
Ser517	B-geneN
/	I-geneN
Ser473	E-geneN
.	O

Although	O
ablation	O
of	O
daf	B-geneY
-	I-geneY
2	E-geneY
or	O
pdk	B-geneY
-	I-geneY
1	E-geneY
completely	O
suppressed	O
akt	B-geneY
-	I-geneY
1	E-geneY
-	O
dependent	O
apoptosis	O
,	O
the	O
transcriptional	O
activation	O
of	O
CEP	B-geneY
-	I-geneY
1	E-geneY
was	O
unaffected	O
,	O
suggesting	O
that	O
daf	B-geneY
-	I-geneY
2	E-geneY
and	O
pdk	B-geneY
-	I-geneY
1	E-geneY
act	O
independently	O
or	O
downstream	O
of	O
cep	B-geneY
-	I-geneY
1	E-geneY
and	O
akt	B-geneY
-	I-geneY
1	E-geneY
.	O

Ablation	O
of	O
the	O
akt	B-geneY
-	I-geneY
1	E-geneY
paralog	O
akt	B-geneY
-	I-geneY
2	E-geneY
or	O
the	O
downstream	O
target	O
of	O
the	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
pathway	O
daf	B-geneY
-	I-geneY
16	E-geneY
(	O
a	O
FOXO	S-geneY
transcription	O
factor	O
)	O
restored	O
sensitivity	O
to	O
damage	O
-	O
induced	O
apoptosis	O
in	O
daf	B-geneY
-	I-geneY
2	E-geneY
and	O
pdk	B-geneY
-	I-geneY
1	E-geneY
mutants	O
.	O

In	O
addition	O
,	O
daf	B-geneY
-	I-geneY
2	E-geneY
and	O
pdk	B-geneY
-	I-geneY
1	E-geneY
mutants	O
have	O
reduced	O
levels	O
of	O
phospho	B-geneY
-	I-geneY
MPK	I-geneY
-	I-geneY
1	E-geneY
/	O
ERK	S-geneN
in	O
their	O
germ	O
cells	O
,	O
indicating	O
that	O
the	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
pathway	O
promotes	O
Ras	S-geneN
signaling	O
in	O
the	O
germline	O
.	O

Ablation	O
of	O
the	O
Ras	S-geneN
effector	O
gla	B-geneY
-	I-geneY
3	E-geneY
,	O
a	O
negative	O
regulator	O
of	O
mpk	B-geneY
-	I-geneY
1	E-geneY
,	O
restored	O
sensitivity	O
to	O
apoptosis	O
in	O
daf	B-geneY
-	I-geneY
2	E-geneY
mutants	O
,	O
suggesting	O
that	O
gla	B-geneY
-	I-geneY
3	E-geneY
acts	O
downstream	O
of	O
daf	B-geneY
-	I-geneY
2	E-geneY
.	O

In	O
addition	O
,	O
the	O
hypersensitivity	O
of	O
let	B-geneY
-	I-geneY
60	E-geneY
/	O
Ras	S-geneN
gain	O
-	O
of	O
-	O
function	O
mutants	O
to	O
damage	O
-	O
induced	O
apoptosis	O
was	O
suppressed	O
to	O
wild	O
-	O
type	O
levels	O
by	O
ablation	O
of	O
daf	B-geneY
-	I-geneY
2	E-geneY
.	O

Thus	O
,	O
insulin	S-geneN
/	O
IGF	B-geneN
-	I-geneN
1	E-geneN
signaling	O
selectively	O
engages	O
AKT	B-geneY
-	I-geneY
2	E-geneY
/	O
DAF	B-geneY
-	I-geneY
16	E-geneY
to	O
promote	O
DNA	O
damage	O
-	O
induced	O
germ	O
cell	O
apoptosis	O
downstream	O
of	O
CEP	B-geneY
-	I-geneY
1	E-geneY
through	O
the	O
Ras	S-geneN
pathway	O
.	O

The	O
R740S	S-geneN
mutation	O
in	O
the	O
V	B-geneN
-	I-geneN
ATPase	I-geneN
a3	E-geneN
subunit	O
increases	O
lysosomal	O
pH	O
,	O
impairs	O
NFATc1	S-geneY
translocation	O
,	O
and	O
decreases	O
in	O
vitro	O
osteoclastogenesis	O
.	O

Vacuolar	B-geneN
H	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
ATPase	E-geneN
(	O
V	B-geneN
-	I-geneN
ATPase	E-geneN
)	O
,	O
a	O
multisubunit	O
enzyme	O
located	O
at	O
the	O
ruffled	O
border	O
and	O
in	O
lysosomes	O
of	O
osteoclasts	O
,	O
is	O
necessary	O
for	O
bone	O
resorption	O
.	O

We	O
previously	O
showed	O
that	O
heterozygous	O
mice	O
with	O
an	O
R740S	S-geneN
mutation	O
in	O
the	O
a3	O
subunit	O
of	O
V	B-geneN
-	I-geneN
ATPase	E-geneN
(	O
+	O
/	O
R740S	O
)	O
have	O
mild	O
osteopetrosis	O
resulting	O
from	O
an	O
∼	O
90	O
%	O
reduction	O
in	O
proton	O
translocation	O
across	O
osteoclast	O
membranes	O
.	O

Here	O
we	O
show	O
that	O
lysosomal	O
pH	O
is	O
also	O
higher	O
in	O
+	O
/	O
R740S	S-geneN
compared	O
with	O
wild	O
-	O
type	O
(	O
+	O
/	O
+	O
)	O
osteoclasts	O
.	O

Both	O
osteoclast	O
number	O
and	O
size	O
were	O
decreased	O
in	O
cultures	O
of	O
+	O
/	O
R740S	S-geneN
compared	O
with	O
+	O
/	O
+	O
bone	O
marrow	O
cells	O
,	O
with	O
concomitant	O
decreased	O
expression	O
of	O
key	O
osteoclast	O
markers	O
(	O
TRAP	S-geneN
,	O
cathepsin	B-geneN
K	E-geneN
,	O
OSCAR	S-geneN
,	O
DC	B-geneN
-	I-geneN
STAMP	E-geneN
,	O
and	O
NFATc1	S-geneN
)	O
,	O
suggesting	O
that	O
low	O
lysosomal	O
pH	O
plays	O
an	O
important	O
role	O
in	O
osteoclastogenesis	O
.	O

To	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
,	O
NFATc1	S-geneN
activation	O
was	O
assessed	O
.	O

NFATc1	S-geneN
nuclear	O
translocation	O
was	O
significantly	O
reduced	O
in	O
+	O
/	O
R740S	S-geneN
compared	O
with	O
+	O
/	O
+	O
cells	O
;	O
however	O
,	O
this	O
was	O
not	O
because	O
of	O
impaired	O
enzymatic	O
activity	O
of	O
calcineurin	O
,	O
the	O
phosphatase	O
responsible	O
for	O
NFATc1	S-geneN
dephosphorylation	O
.	O

Protein	O
and	O
RNA	O
expression	O
levels	O
of	O
regulator	O
of	O
calcineurin	B-geneN
1	E-geneN
(	O
RCAN1	S-geneN
)	O
,	O
an	O
endogenous	O
inhibitor	O
of	O
NFATc1	S-geneN
activation	O
and	O
a	O
protein	O
degraded	O
in	O
lysosomes	O
,	O
were	O
not	O
significantly	O
different	O
between	O
+	O
/	O
R740S	S-geneN
and	O
+	O
/	O
+	O
osteoclasts	O
,	O
but	O
the	O
RCAN1	S-geneN
/	O
NFATc1	S-geneN
ratio	O
was	O
significantly	O
higher	O
in	O
+	O
/	O
R740S	S-geneN
versus	O
+	O
/	O
+	O
cells	O
.	O

The	O
lysosomal	O
inhibitor	O
chloroquine	S-chem-C3-1
significantly	O
increased	O
RCAN1	S-geneN-C3-2
accumulation	O
in	O
+	O
/	O
+	O
cells	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
higher	O
lysosomal	O
pH	O
impairs	O
RCAN1	S-geneN
degradation	O
,	O
leading	O
to	O
a	O
higher	O
RCAN1	S-geneN
/	O
NFATc1	S-geneN
ratio	O
and	O
consequently	O
NFATc1	S-geneN
inhibition	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
lysosomal	O
pH	O
in	O
osteoclasts	O
leads	O
to	O
decreased	O
NFATc1	S-geneN
signaling	O
and	O
nuclear	O
translocation	O
,	O
resulting	O
in	O
a	O
cell	O
autonomous	O
impairment	O
of	O
osteoclastogenesis	O
in	O
vitro	O
.	O

Agmatine	S-chem
:	O
an	O
endogenous	O
clonidine	S-chem
-	O
displacing	O
substance	O
in	O
the	O
brain	O
.	O

Clonidine	S-chem
,	O
an	O
antihypertensive	O
drug	O
,	O
binds	O
to	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenergic	I-geneN
and	I-geneN
imidazoline	I-geneN
receptors	E-geneN
.	O

The	O
endogenous	O
ligand	O
for	O
imidazoline	B-geneN
receptors	E-geneN
may	O
be	O
a	O
clonidine	S-chem
-	O
displacing	O
substance	O
,	O
a	O
small	O
molecule	O
isolated	O
from	O
bovine	O
brain	O
.	O

This	O
clonidine	S-chem
-	O
displacing	O
substance	O
was	O
purified	O
and	O
determined	O
by	O
mass	O
spectroscopy	O
to	O
be	O
agmatine	S-chem
(	O
decarboxylated	B-chem
arginine	E-chem
)	O
,	O
heretofore	O
not	O
detected	O
in	O
brain	O
.	O

Agmatine	S-chem
binds	O
to	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenergic	I-geneN
and	I-geneN
imidazoline	I-geneN
receptors	E-geneN
and	O
stimulates	O
release	O
of	O
catecholamines	S-chem
from	O
adrenal	O
chromaffin	O
cells	O
.	O

Its	O
biosynthetic	O
enzyme	O
,	O
arginine	B-geneY
decarboxylase	E-geneY
,	O
is	O
present	O
in	O
brain	O
.	O

Agmatine	S-chem-C5-1
,	O
locally	O
synthesized	O
,	O
is	O
an	O
endogenous	O
agonist	O
at	O
imidazoline	B-geneN-C5-2
receptors	E-geneN-C5-2
,	O
a	O
noncatecholamine	S-chem
ligand	O
at	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
and	O
may	O
act	O
as	O
a	O
neurotransmitter	O
.	O

Modulation	O
of	O
cytochrome	B-geneN
P450	I-geneN
1	E-geneN
(	O
Cyp1	S-geneN
)	O
by	O
vanadium	S-chem
in	O
hepatic	O
tissue	O
and	O
isolated	O
hepatocyte	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
vanadium	S-chem
(	O
V	B-chem
(	I-chem
5	I-chem
+	I-chem
)	E-chem
)	O
on	O
Cyp1	S-geneN
expression	O
and	O
activity	O
in	O
C57BL	O
/	O
6	O
mice	O
liver	O
and	O
isolated	O
hepatocytes	O
.	O

For	O
this	O
purpose	O
,	O
C57BL6	O
mice	O
were	O
injected	O
intraperitoneally	O
with	O
V	B-chem
(	I-chem
5	I-chem
+	I-chem
)	E-chem
(	O
5	O
mg	O
/	O
kg	O
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
2,3,7,8	O
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	I-chem
(	E-chem
TCDD	O
)	E-chem
(	O
15	O
μg	O
/	O
kg	O
)	O
for	O
6	O
and	O
24	O
h	O
.	O

Furthermore	O
,	O
isolated	O
hepatocytes	O
from	O
C57BL6	O
mice	O
were	O
treated	O
with	O
V	B-chem
(	I-chem
5	I-chem
+	I-chem
)	E-chem
(	O
5	O
,	O
10	O
,	O
and	O
20	O
μM	O
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
TCDD	O
(	E-chem
1	O
nM	O
)	O
for	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
.	O

In	O
vivo	O
,	O
V	B-chem
(	I-chem
5	I-chem
+	I-chem
)	E-chem
alone	O
did	O
not	O
significantly	O
alter	O
Cyp1a1	S-geneY
,	O
Cyp1a2	S-geneY
,	O
or	O
Cyp1b1	S-geneY
mRNA	O
,	O
protein	O
,	O
or	O
catalytic	O
activity	O
levels	O
.	O

Upon	O
co	O
-	O
exposure	O
to	O
V	B-chem-C3-1
(	I-chem-C3-1
5	I-chem-C3-1
+	I-chem-C3-1
)	E-chem-C3-1
and	O
TCDD	S-chem-C3-1
,	O
V	B-chem-C3-1
(	I-chem-C3-1
5	I-chem-C3-1
+	I-chem-C3-1
)	E-chem-C3-1
significantly	O
potentiated	O
the	O
TCDD	S-chem-C3-1
-	O
mediated	O
induction	O
of	O
the	O
Cyp1a1	S-geneY-C3-2
,	O
Cyp1a2	S-geneY-C3-2
,	O
and	O
Cyp1b1	S-geneY-C3-2
mRNA	O
,	O
protein	O
,	O
and	O
catalytic	O
activity	O
levels	O
at	O
24	O
h	O
.	O

In	O
vitro	O
,	O
V	B-chem-C4-1
(	I-chem-C4-1
5	I-chem-C4-1
+	I-chem-C4-1
)	E-chem-C4-1
decreased	O
the	O
TCDD	S-chem-C3-1
-	O
mediated	O
induction	O
of	O
Cyp1a1	S-geneY-MU-2
mRNA	O
,	O
protein	O
,	O
and	O
catalytic	O
activity	O
levels	O
.	O

Furthermore	O
,	O
V	B-chem-C4-1
(	I-chem-C4-1
5	I-chem-C4-1
+	I-chem-C4-1
)	E-chem-C4-1
significantly	O
inhibited	O
the	O
TCDD	S-chem-C3-1
-	O
induced	O
AhR	S-geneY-MU-2
-	O
dependent	O
luciferase	O
activity	O
.	O

V	B-chem-C3-1
(	I-chem-C3-1
5	I-chem-C3-1
+	I-chem-C3-1
)	E-chem-C3-1
also	O
increased	O
serum	B-geneN-C3-2
hemoglobin	E-geneN-C3-2
(	O
Hb	S-geneN-C3-2
)	O
levels	O
in	O
animals	O
treated	O
for	O
24	O
h	O
.	O

Upon	O
treatment	O
of	O
isolated	O
hepatocytes	O
with	O
Hb	S-geneN
alone	O
or	O
in	O
the	O
presence	O
of	O
TCDD	S-chem-C3-1
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
AhR	S-geneY-C3-2
-	O
dependent	O
luciferase	O
activity	O
.	O

When	O
isolated	O
hepatocytes	O
were	O
treated	O
for	O
2	O
h	O
with	O
V	O
(	B-chem
5	I-chem
+	I-chem
)	I-chem
in	O
the	O
presence	O
of	O
TCDD	O
,	E-chem
followed	O
by	O
replacement	O
of	O
the	O
medium	O
with	O
new	O
medium	O
containing	O
Hb	O
,	E-geneN
there	O
was	O
further	O
potentiation	O
to	O
the	O
TCDD	O
-	E-chem
mediated	O
effect	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
there	O
is	O
a	O
differential	O
modulation	O
of	O
Cyp1a1	S-geneY
by	O
V	B-chem
(	I-chem
5	I-chem
+	I-chem
)	E-chem
in	O
C57BL	O
/	O
6	O
mice	O
livers	O
and	O
isolated	O
hepatocytes	O
and	O
demonstrates	O
Hb	S-geneN
as	O
an	O
in	O
vivo	O
specific	O
modulator	O
.	O

Resistance	O
to	O
conventional	O
insecticides	O
in	O
Pakistani	O
populations	O
of	O
Musca	O
domestica	O
L.	O
(	O
Diptera	O
:	O
Muscidae	O
)	O
:	O
a	O
potential	O
ectoparasite	O
of	O
dairy	O
animals	O
.	O

The	O
house	O
fly	O
,	O
Musca	O
domestica	O
L.	O
,	O
is	O
an	O
important	O
hygienic	O
pest	O
of	O
humans	O
and	O
dairy	O
animals	O
with	O
the	O
potential	O
to	O
develop	O
resistance	O
to	O
most	O
chemical	O
classes	O
of	O
insecticides	O
.	O

Six	O
adult	O
house	O
fly	O
strains	O
from	O
dairy	O
farms	O
in	O
Punjab	O
,	O
Pakistan	O
were	O
evaluated	O
for	O
resistance	O
to	O
selected	O
insecticides	O
from	O
organochlorine	S-chem
,	O
organophosphate	S-chem
,	O
carbamate	S-chem
and	O
pyrethroid	S-chem
classes	O
.	O

For	O
a	O
chlorocyclodiene	S-chem
and	O
two	O
organophosphates	S-chem
tested	O
,	O
the	O
resistance	O
ratios	O
(	O
RR	O
)	O
at	O
LC50	O
were	O
in	O
the	O
range	O
of	O
5.60	O
-	O
22.02	O
fold	O
for	O
endosulfan	S-chem
,	O
7.66	O
-	O
23.24	O
fold	O
for	O
profenofos	O
and	O
2.47	O
-	O
7.44	O
fold	O
for	O
chlorpyrifos	S-chem
.	O

For	O
two	O
pyrethroids	S-chem
and	O
one	O
carbamate	S-chem
,	O
the	O
RR	O
values	O
at	O
LC50	O
were	O
30.22	O
-	O
70.02	O
for	O
cypermethrin	S-chem
,	O
5.73	O
-	O
18.31	O
for	O
deltamethrin	S-chem
,	O
and	O
4.39	O
-	O
15.50	O
for	O
methomyl	S-chem
.	O

This	O
is	O
the	O
first	O
report	O
of	O
resistance	O
to	O
different	O
classes	O
of	O
insecticides	O
in	O
Pakistani	O
dairy	O
populations	O
of	O
house	O
flies	O
.	O

Regular	O
insecticide	O
resistance	O
monitoring	O
programs	O
on	O
dairy	O
farms	O
are	O
needed	O
to	O
prevent	O
field	O
control	O
failures	O
.	O

Moreover	O
,	O
integrated	O
approaches	O
including	O
the	O
judicious	O
use	O
of	O
insecticides	O
are	O
needed	O
to	O
delay	O
the	O
development	O
of	O
insecticide	O
resistance	O
in	O
house	O
flies	O
.	O

Effects	O
of	O
a	O
serotonin	B-geneY-C6-2
5	I-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
4	I-geneY-C6-2
)	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
SB	B-chem-C6-1
-	I-chem-C6-1
207266	E-chem-C6-1
on	O
gastrointestinal	O
motor	O
and	O
sensory	O
function	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
Serotonin	B-geneY
5	I-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	I-geneY
receptors	E-geneY
are	O
located	O
on	O
enteric	O
cholinergic	O
neurones	O
and	O
may	O
regulate	O
peristalsis	O
.	O

5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptors	O
on	O
primary	O
afferent	O
neurones	O
have	O
been	O
postulated	O
to	O
modulate	O
visceral	O
sensation	O
.	O

While	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
agonists	O
are	O
used	O
as	O
prokinetic	O
agents	O
,	O
the	O
physiological	O
role	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptors	O
in	O
the	O
human	O
gut	O
is	O
unknown	O
.	O

AIMS	O
:	O
Our	O
aim	O
was	O
to	O
characterise	O
the	O
role	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptors	O
in	O
regulating	O
gastrointestinal	O
motor	O
and	O
sensory	O
function	O
in	O
healthy	O
subjects	O
under	O
baseline	O
and	O
stimulated	O
conditions	O
with	O
a	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptor	O
antagonist	O
.	O

METHODS	O
:	O
Part	O
A	O
compared	O
the	O
effects	O
of	O
placebo	O
to	O
four	O
doses	O
of	O
a	O
5	B-geneY-MU-2
-	I-geneY-MU-2
HT	I-geneY-MU-2
(	I-geneY-MU-2
4	I-geneY-MU-2
)	E-geneY-MU-2
receptor	O
antagonist	O
(	O
SB	B-chem-C6-1
-	I-chem-C6-1
207266	E-chem-C6-1
)	O
on	O
the	O
cisapride	S-chem-C5-1
mediated	O
increase	O
in	O
plasma	O
aldosterone	S-chem
(	O
a	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
4	I-geneY-C6-2
)	E-geneY-C6-2
mediated	O
response	O
)	O
and	O
orocaecal	O
transit	O
in	O
18	O
subjects	O
.	O

In	O
part	O
B	O
,	O
52	O
healthy	O
subjects	O
received	O
placebo	O
,	O
or	O
0.05	O
,	O
0.5	O
,	O
or	O
5	O
mg	O
of	O
SB	B-chem
-	I-chem
207266	E-chem
for	O
10	O
-	O
12	O
days	O
;	O
gastric	O
,	O
small	O
bowel	O
,	O
and	O
colonic	O
transit	O
were	O
measured	O
by	O
scintigraphy	O
on	O
days	O
7	O
-	O
9	O
,	O
and	O
fasting	O
and	O
postprandial	O
colonic	O
motor	O
function	O
,	O
compliance	O
,	O
and	O
sensation	O
during	O
distensions	O
were	O
assessed	O
on	O
day	O
12	O
.	O

RESULTS	O
:	O
Part	O
A	O
:	O
0.5	O
,	O
5	O
,	O
and	O
20	O
mg	O
doses	O
of	O
SB	B-chem
-	I-chem
207266	E-chem
had	O
significant	O
and	O
quantitatively	O
similar	O
effects	O
,	O
antagonising	O
the	O
cisapride	O
mediated	O
increase	O
in	O
plasma	O
aldosterone	S-chem
and	O
acceleration	O
of	O
orocaecal	O
transit	O
.	O

Part	O
B	O
:	O
SB	B-chem
-	I-chem
207266	E-chem
tended	O
to	O
delay	O
colonic	O
transit	O
(	O
geometric	O
centre	O
of	O
isotope	O
at	O
24	O
(	O
p	O
=	O
0.06	O
)	O
and	O
48	O
hours	O
(	O
p	O
=	O
0.08	O
)	O
)	O
,	O
but	O
did	O
not	O
have	O
dose	O
related	O
effects	O
on	O
transit	O
,	O
fasting	O
or	O
postprandial	O
colonic	O
motor	O
activity	O
,	O
compliance	O
,	O
or	O
sensation	O
.	O

CONCLUSION	O
:	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptors	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cisapride	S-chem
stimulated	O
orocaecal	O
transit	O
;	O
SB	B-chem
207266	E-chem
tends	O
to	O
modulate	O
colonic	O
transit	O
but	O
not	O
sensory	O
functions	O
or	O
compliance	O
in	O
healthy	O
human	O
subjects	O
.	O

Bone	O
growth	O
retardation	O
in	O
mouse	O
embryos	O
expressing	O
human	B-geneY
collagenase	I-geneY
1	E-geneY
.	O

Cellular	O
growth	O
and	O
differentiation	O
are	O
readouts	O
of	O
multiple	O
signaling	O
pathways	O
from	O
the	O
intercellular	O
and	O
/	O
or	O
extracellular	O
milieu	O
.	O

The	O
extracellular	O
matrix	O
through	O
the	O
activation	O
of	O
cellular	O
receptors	O
transmits	O
these	O
signals	O
.	O

Therefore	O
,	O
extracellular	O
matrix	O
proteolysis	O
could	O
affect	O
cell	O
fate	O
in	O
a	O
variety	O
of	O
biological	O
events	O
.	O

However	O
,	O
the	O
biological	O
consequence	O
of	O
inadequate	O
extracellular	O
matrix	O
degradation	O
in	O
vivo	O
is	O
not	O
clear	O
.	O

We	O
developed	O
a	O
mouse	O
model	O
expressing	O
human	B-geneY
collagenase	E-geneY
(	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
1	E-geneY
,	O
MMP	B-geneY
-	I-geneY
1	E-geneY
)	O
under	O
the	O
control	O
of	O
Col2a1	B-geneN
promoter	E-geneN
.	O

The	O
mice	O
showed	O
significant	O
growth	O
retardation	O
during	O
embryogenesis	O
and	O
a	O
loss	O
of	O
the	O
demarcation	O
of	O
zonal	O
structure	O
and	O
columnar	O
array	O
of	O
the	O
cartilage	O
.	O

Immunological	O
examination	O
revealed	O
increased	O
degradation	O
of	O
type	B-geneN
II	I-geneN
collagen	E-geneN
and	O
upregulation	O
of	O
fibronectin	S-geneY
and	O
alpha	B-geneY
(	I-geneY
5	I-geneY
)	I-geneY
-	I-geneY
integrin	E-geneY
subunit	O
in	O
the	O
transgenic	O
cartilage	O
.	O

The	O
resting	O
zone	O
and	O
proliferating	O
zone	O
of	O
the	O
growth	O
plate	O
cartilage	O
exhibited	O
a	O
simultaneous	O
increase	O
in	O
bromodeoxyuridine	S-chem
(	O
BrdU	S-chem
)	O
-	O
incorporated	O
proliferating	O
cells	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
X	O
-	O
dUTP	O
nick	O
-	O
end	O
labeling	O
-	O
positive	O
apoptotic	O
cells	O
,	O
respectively	O
.	O

Chondrocyte	O
differentiation	O
was	O
not	O
disturbed	O
in	O
the	O
transgenic	O
mice	O
as	O
evidenced	O
by	O
normal	O
expression	O
of	O
the	O
Ihh	O
and	O
type	B-geneN
X	I-geneN
collagen	E-geneN
expression	O
.	O

These	O
data	O
demonstrate	O
that	O
type	B-geneN
II	I-geneN
collagen	E-geneN
proteolysis	O
is	O
an	O
important	O
determinant	O
for	O
the	O
skeletal	O
outgrowth	O
through	O
modulation	O
of	O
chondrocyte	O
survival	O
and	O
cartilagenous	O
growth	O
.	O

Inhibitory	O
effect	O
of	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
on	O
the	O
vesicular	B-geneY
monoamine	I-geneY
transporter	I-geneY
2	E-geneY
.	O

The	O
neuronal	B-geneY
vesicular	I-geneY
monoamine	I-geneY
transporter	E-geneY
(	O
VMAT2	S-geneY
)	O
is	O
the	O
target	O
molecule	O
of	O
action	O
of	O
some	O
psychostimulants	O
,	O
such	O
as	O
methamphetamine	S-chem
and	O
3,4	B-chem
-	I-chem
methylenedioxymethamphetamine	E-chem
(	O
MDMA	S-chem
)	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
antidepressants	O
,	O
such	O
as	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
on	O
VMAT2	S-geneY-C9-2
activity	O
by	O
measuring	O
adenosine	B-chem
triphosphate	E-chem
-	O
dependent	O
[	B-chem-C9-1
(	I-chem-C9-1
3	I-chem-C9-1
)	I-chem-C9-1
H	I-chem-C9-1
]	I-chem-C9-1
dopamine	E-chem-C9-1
uptake	O
into	O
synaptic	O
vesicles	O
prepared	O
from	O
rat	O
striatum	O
.	O

SSRIs	O
,	O
fluoxetine	S-chem
,	O
paroxetine	S-chem
,	O
and	O
fluvoxamine	S-chem
,	O
inhibited	O
vesicular	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
dopamine	E-chem
uptake	O
in	O
vitro	O
.	O

The	O
rank	O
order	O
of	O
potency	O
was	O
reserpine	S-chem
>	O
>	O
fluoxetine	S-chem
,	O
paroxetine	S-chem
>	O
fluvoxamine	S-chem
,	O
methamphetamine	S-chem
>	O
MDMA	S-chem
.	O

Moreover	O
,	O
kinetic	O
analysis	O
revealed	O
that	O
inhibition	O
by	O
reserpine	S-chem-C4-1
,	O
a	O
typical	O
VMAT2	S-geneY-MU-2
inhibitor	O
,	O
was	O
uncompetitive	O
,	O
decreasing	O
maximum	O
velocity	O
and	O
affinity	O
for	O
dopamine	S-chem-C9-1
.	O

Inhibition	O
by	O
fluoxetine	S-chem
was	O
noncompetitive	O
,	O
only	O
decreasing	O
maximum	O
velocity	O
for	O
dopamine	S-chem
.	O

These	O
results	O
suggest	O
that	O
fluoxetine	S-chem-C4-1
inhibited	O
the	O
activity	O
of	O
VMAT2	S-geneY-C4-2
by	O
a	O
mechanism	O
different	O
from	O
that	O
of	O
reserpine	S-chem-C4-1
and	O
did	O
not	O
directly	O
interact	O
with	O
the	O
active	O
site	O
of	O
VMAT2	S-geneY-C4-2
.	O

In	O
vivo	O
genotoxicity	O
of	O
methyleugenol	S-chem
in	O
gpt	S-geneY
delta	O
transgenic	O
rats	O
following	O
medium	O
-	O
term	O
exposure	O
.	O

Methyleugenol	S-chem
(	O
MEG	S-chem
)	O
,	O
which	O
is	O
commonly	O
used	O
as	O
a	O
fragrance	O
and	O
flavoring	O
agent	O
,	O
has	O
been	O
shown	O
to	O
induce	O
hepatocellular	O
tumors	O
in	O
rodents	O
.	O

However	O
,	O
the	O
role	O
of	O
genotoxicity	O
as	O
a	O
possible	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
even	O
though	O
the	O
DNA	O
-	O
reactive	O
metabolite	O
of	O
MEG	S-chem
has	O
been	O
identified	O
.	O

In	O
this	O
study	O
,	O
a	O
gpt	S-geneY
delta	O
transgenic	O
rat	O
model	O
was	O
used	O
to	O
clarify	O
whether	O
genotoxic	O
mechanisms	O
are	O
involved	O
in	O
MEG	S-chem
-	O
induced	O
hepatocarcinogenesis	O
following	O
medium	O
-	O
term	O
exposure	O
.	O

F344	O
gpt	S-geneY
delta	O
rats	O
were	O
subjected	O
to	O
repeated	O
oral	O
administration	O
of	O
MEG	S-chem
at	O
dosages	O
of	O
0	O
,	O
10	O
,	O
30	O
,	O
or	O
100mg	O
/	O
kg	O
(	O
a	O
carcinogenic	O
dose	O
)	O
for	O
13	O
weeks	O
.	O

The	O
relative	O
weight	O
of	O
the	O
liver	O
of	O
the	O
male	O
and	O
female	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	S-chem
and	O
the	O
absolute	O
weight	O
of	O
the	O
liver	O
of	O
the	O
male	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	S-chem
were	O
significantly	O
increased	O
.	O

In	O
addition	O
,	O
the	O
number	O
and	O
area	O
of	O
glutathione	B-geneN-C3-2
S	I-geneN-C3-2
-	I-geneN-C3-2
transferase	I-geneN-C3-2
placental	I-geneN-C3-2
form	E-geneN-C3-2
(	O
GST	B-geneN-C3-2
-	I-geneN-C3-2
P	E-geneN-C3-2
)	O
positive	O
foci	O
and	O
proliferating	B-geneY-C3-2
cell	I-geneY-C3-2
nuclear	I-geneY-C3-2
antigen	E-geneY-C3-2
(	O
PCNA	S-geneY-C3-2
)	O
positive	O
cell	O
ratios	O
in	O
the	O
hepatocytes	O
were	O
significantly	O
increased	O
in	O
the	O
male	O
and	O
female	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	S-chem-C3-1
compared	O
with	O
the	O
control	O
animals	O
.	O

In	O
the	O
in	O
vivo	O
mutation	O
assays	O
,	O
a	O
significant	O
increase	O
in	O
the	O
gpt	S-geneY
and	O
Spi	S-geneN
(	O
-	O
)	O
mutant	O
frequencies	O
was	O
observed	O
in	O
both	O
sexes	O
at	O
the	O
carcinogenic	O
dose	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
participation	O
of	O
genotoxic	O
mechanisms	O
in	O
MEG	S-chem
-	O
induced	O
hepatocarcinogenesis	O
.	O

Glomerular	O
Filtration	O
Rate	O
Equations	O
Overestimate	O
Creatinine	S-chem
Clearance	O
in	O
Older	O
Individuals	O
Enrolled	O
in	O
the	O
Baltimore	O
Longitudinal	O
Study	O
on	O
Aging	O
:	O
Impact	O
on	O
Renal	O
Drug	O
Dosing	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
performance	O
of	O
kidney	O
function	O
estimation	O
equations	O
and	O
to	O
determine	O
the	O
frequency	O
of	O
drug	O
dose	O
discordance	O
in	O
an	O
older	O
population	O
.	O

DESIGN	O
:	O
Cross	O
-	O
sectional	O
analysis	O
of	O
data	O
from	O
community	O
-	O
dwelling	O
volunteers	O
randomly	O
selected	O
from	O
the	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
from	O
January	O
1	O
,	O
2005	O
,	O
to	O
December	O
31	O
,	O
2010	O
.	O

SUBJECTS	O
:	O
A	O
total	O
of	O
269	O
men	O
and	O
women	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
81	O
±	O
6	O
years	O
,	O
mean	O
serum	O
creatinine	O
concentration	O
(	O
Scr	O
)	O
of	O
1.1	O
±	O
0.4	O
mg	O
/	O
dl	O
,	O
and	O
mean	O
24	O
-	O
hour	O
measured	O
creatinine	O
clearance	O
(	O
mClcr	O
)	O
of	O
53	O
±	O
13	O
ml	O
/	O
minute	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Kidney	O
function	O
was	O
estimated	O
by	O
using	O
the	O
following	O
equations	O
:	O
Cockcroft	O
-	O
Gault	O
(	O
CG	O
)	O
,	O
Modification	O
of	O
Diet	O
in	O
Renal	O
Disease	O
(	O
MDRD	O
)	O
,	O
and	O
Chronic	O
Kidney	O
Disease	O
Epidemiology	O
Collaboration	O
(	O
CKD	O
-	O
EPI	O
)	O
.	O

The	O
performance	O
of	O
each	O
equation	O
was	O
assessed	O
by	O
measuring	O
bias	O
and	O
precision	O
relative	O
to	O
mClcr	O
.	O

Dose	O
calculation	O
errors	O
(	O
discordance	O
)	O
were	O
determined	O
for	O
10	O
drugs	O
requiring	O
renal	O
dosage	O
adjustments	O
to	O
avoid	O
toxicity	O
when	O
compared	O
with	O
the	O
dosages	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
.	O

The	O
CG	O
equation	O
was	O
the	O
least	O
biased	O
estimate	O
of	O
mClcr	O
.	O

The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
were	O
significantly	O
positively	O
biased	O
compared	O
with	O
CG	O
(	O
mean	O
±	O
SD	O
34	O
±	O
20	O
%	O
and	O
22	O
±	O
15	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
and	O
mClcr	O
(	O
29	O
±	O
47	O
%	O
and	O
18	O
±	O
40	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Rounding	O
low	O
Scr	O
values	O
(	O
less	O
than	O
1.0	O
mg	O
/	O
dl	O
)	O
up	O
to	O
an	O
arbitrary	O
value	O
of	O
1.0	O
mg	O
/	O
dl	O
resulted	O
in	O
CG	O
values	O
(	O
44	O
±	O
10	O
ml	O
/	O
minute	O
)	O
that	O
were	O
significantly	O
lower	O
than	O
mClcr	O
(	O
56	O
±	O
12	O
ml	O
/	O
minute	O
,	O
p	O
<	O
0.001	O
)	O
and	O
CG	O
(	O
56	O
±	O
15	O
ml	O
/	O
minute	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
had	O
median	O
dose	O
discordance	O
rates	O
of	O
28.6	O
%	O
and	O
22.9	O
%	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
The	O
MDRD	O
and	O
CKD	O
-	O
EPI	O
equations	O
significantly	O
overestimated	O
creatinine	S-chem
clearance	O
(	O
mClcr	O
and	O
CG	O
)	O
in	O
elderly	O
individuals	O
.	O

This	O
leads	O
to	O
dose	O
calculation	O
errors	O
for	O
many	O
drugs	O
,	O
particularly	O
in	O
individuals	O
with	O
severe	O
renal	O
impairment	O
.	O

Thus	O
equations	O
estimating	O
glomerular	O
filtration	O
rate	O
should	O
not	O
be	O
substituted	O
in	O
place	O
of	O
the	O
CG	O
equation	O
in	O
older	O
adults	O
for	O
the	O
purpose	O
of	O
renal	O
dosage	O
adjustments	O
.	O

In	O
addition	O
,	O
the	O
common	O
practice	O
of	O
rounding	O
or	O
replacing	O
low	O
Scr	O
values	O
with	O
an	O
arbitrary	O
value	O
of	O
1.0	O
mg	O
/	O
dl	O
for	O
use	O
in	O
the	O
CG	O
equation	O
should	O
be	O
avoided	O
.	O

Additional	O
studies	O
that	O
evaluate	O
alternative	O
eGFR	O
equations	O
in	O
the	O
older	O
populations	O
that	O
incorporate	O
pharmacokinetic	O
and	O
pharmacodynamic	O
outcomes	O
measures	O
are	O
needed	O
.	O

Effects	O
of	O
17α	B-chem
-	I-chem
ethynylestradiol	E-chem
-	O
induced	O
cholestasis	O
on	O
the	O
pharmacokinetics	O
of	O
doxorubicin	S-chem
in	O
rats	O
:	O
reduced	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
of	O
doxorubicin	S-chem
.	O

Abstract	O
1	O
.	O

Since	O
the	O
prevalent	O
hormonal	O
combination	O
therapy	O
with	O
estrogen	S-chem
analogues	O
in	O
cancer	O
patients	O
has	O
frequency	O
and	O
possibility	O
to	O
induce	O
the	O
cholestasis	O
,	O
the	O
frequent	O
combination	O
therapy	O
with	O
17α	B-chem
-	I-chem
ethynylestradiol	E-chem
(	O
EE	O
,	O
an	O
oral	O
contraceptive	O
)	O
and	O
doxorubicin	S-chem
(	O
an	O
anticancer	O
drug	O
)	O
might	O
be	O
monitored	O
in	O
aspect	O
of	O
efficacy	O
and	O
safety	O
.	O

Doxorubicin	S-chem-C9-1
is	O
mainly	O
excreted	O
into	O
the	O
bile	O
via	O
P	B-geneN-C9-2
-	I-geneN-C9-2
glycoprotein	E-geneN-C9-2
(	O
P	B-geneN-C9-2
-	I-geneN-C9-2
gp	E-geneN-C9-2
)	O
and	O
multidrug	B-geneY-C9-2
resistance	I-geneY-C9-2
-	I-geneY-C9-2
associated	I-geneY-C9-2
protein	I-geneY-C9-2
2	E-geneY-C9-2
(	O
Mrp2	S-geneY-C9-2
)	O
in	O
hepatobiliary	O
route	O
and	O
metabolized	O
via	O
cytochrome	B-geneN-C9-2
P450	I-geneN-C9-2
(	I-geneN-C9-2
CYP	I-geneN-C9-2
)	I-geneN-C9-2
3A	E-geneN-C9-2
subfamily	O
.	O

Also	O
the	O
hepatic	O
Mrp2	S-geneY
(	O
not	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
and	O
CYP3A	S-geneN
subfamily	O
levels	O
were	O
reduced	O
in	O
EE	O
-	O
induced	O
cholestatic	O
(	O
EEC	O
)	O
rats	O
.	O

Thus	O
,	O
we	O
herein	O
report	O
the	O
pharmacokinetic	O
changes	O
of	O
doxorubicin	S-chem
with	O
respect	O
to	O
the	O
changes	O
in	O
its	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
in	O
EEC	O
rats	O
.	O

2	O
.	O

The	O
pharmacokinetic	O
study	O
of	O
doxorubicin	S-chem
after	O
intravenous	O
administration	O
of	O
its	O
hydrochloride	S-chem
was	O
conducted	O
along	O
with	O
the	O
investigation	O
of	O
bile	O
flow	O
rate	O
and	O
hepatobiliary	O
excretion	O
of	O
doxorubicin	S-chem
in	O
control	O
and	O
EEC	O
rats	O
.	O

3	O
.	O

The	O
significantly	O
greater	O
AUC	O
(	O
58.7	O
%	O
increase	O
)	O
of	O
doxorubicin	S-chem
in	O
EEC	O
rats	O
was	O
due	O
to	O
the	O
slower	O
CL	O
(	O
32.9	O
%	O
decrease	O
)	O
.	O

The	O
slower	O
CL	O
was	O
due	O
to	O
the	O
reduction	O
of	O
hepatic	O
biliary	O
excretion	O
(	O
67.0	O
%	O
decrease	O
)	O
and	O
hepatic	O
CYP3A	S-geneN-C9-2
subfamily	O
-	O
mediated	O
metabolism	O
(	O
21.9	O
%	O
decrease	O
)	O
of	O
doxorubicin	S-chem-C9-1
.	O

These	O
results	O
might	O
have	O
broader	O
implications	O
to	O
understand	O
the	O
altered	O
pharmacokinetics	O
and	O
/	O
or	O
pharmacologic	O
effects	O
of	O
doxorubicin	S-chem
via	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
in	O
experimental	O
and	O
clinical	O
estrogen	S-chem
-	O
induced	O
cholestasis	O
.	O

Curcuminoids	S-chem
Modulate	O
Pro	O
-	O
Oxidant	O
-	O
Antioxidant	O
Balance	O
but	O
not	O
the	O
Immune	O
Response	O
to	O
Heat	B-geneY
Shock	I-geneY
Protein	I-geneY
27	E-geneY
and	O
Oxidized	B-geneN
LDL	E-geneN
in	O
Obese	O
Individuals	O
.	O

Curcuminoids	S-chem
have	O
potentially	O
important	O
functional	O
qualities	O
including	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
.	O

In	O
this	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
cross	O
-	O
over	O
trial	O
,	O
the	O
effects	O
of	O
a	O
curcuminoid	S-chem
supplement	O
on	O
serum	O
pro	O
-	O
oxidant	O
-	O
antioxidant	O
balance	O
(	O
PAB	O
)	O
and	O
antibody	O
titres	O
to	O
Hsp27	S-geneY
(	O
anti	O
-	O
Hsp27	S-geneY
)	O
and	O
oxLDL	S-geneN
(	O
anti	O
-	O
oxLDL	S-geneN
)	O
were	O
investigated	O
.	O

Thirty	O
obese	O
individuals	O
were	O
randomized	O
to	O
receive	O
either	O
curcuminoids	S-chem
(	O
1	O
g	O
/	O
day	O
)	O
or	O
placebo	O
for	O
a	O
period	O
of	O
30	O
days	O
.	O

After	O
a	O
wash	O
-	O
out	O
period	O
of	O
2	O
weeks	O
,	O
subjects	O
were	O
crossed	O
over	O
to	O
the	O
alternate	O
regimen	O
for	O
another	O
30	O
days	O
.	O

Serum	O
PAB	O
along	O
with	O
anti	O
-	O
Hsp27	S-geneY
and	O
anti	O
-	O
oxLDL	S-geneN
titres	O
was	O
measured	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
each	O
study	O
period	O
.	O

There	O
was	O
no	O
significant	O
carry	O
-	O
over	O
effect	O
for	O
any	O
of	O
the	O
assessed	O
parameters	O
.	O

Curcuminoid	S-chem
supplementation	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
PAB	O
(	O
p	O
=	O
0.044	O
)	O
.	O

However	O
,	O
no	O
significant	O
change	O
was	O
observed	O
in	O
serum	O
concentrations	O
of	O
anti	O
-	O
Hsp27	S-geneY
or	O
anti	O
-	O
oxLDL	S-geneN
(	O
p	O
>	O
0.05	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
oral	O
curcuminoids	S-chem
supplementation	O
(	O
1g	O
/	O
day	O
)	O
is	O
effective	O
in	O
reducing	O
oxidative	O
stress	O
burden	O
,	O
though	O
this	O
needs	O
to	O
be	O
validated	O
in	O
larger	O
study	O
populations	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

International	O
Union	O
of	O
Pharmacology	O
.	O
LXXXVII	O
.	O
Complement	B-geneN
peptide	I-geneN
C5a	I-geneN
,	I-geneN
C4a	I-geneN
,	I-geneN
and	I-geneN
C3a	I-geneN
receptors	E-geneN
.	O

The	O
activation	O
of	O
the	O
complement	S-geneN
cascade	O
,	O
a	O
cornerstone	O
of	O
the	O
innate	O
immune	O
response	O
,	O
produces	O
a	O
number	O
of	O
small	O
(	O
74	O
-	O
77	O
amino	B-chem
acid	E-chem
)	O
fragments	O
,	O
originally	O
termed	O
anaphylatoxins	S-geneN
,	O
that	O
are	O
potent	O
chemoattractants	O
and	O
secretagogues	O
that	O
act	O
on	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

These	O
fragments	O
,	O
C5a	S-geneY
,	O
C4a	S-geneY
,	O
and	O
C3a	S-geneY
,	O
participate	O
at	O
all	O
levels	O
of	O
the	O
immune	O
response	O
and	O
are	O
also	O
involved	O
in	O
other	O
processes	O
such	O
as	O
neural	O
development	O
and	O
organ	O
regeneration	O
.	O

Their	O
primary	O
function	O
,	O
however	O
,	O
is	O
in	O
inflammation	O
,	O
so	O
they	O
are	O
important	O
targets	O
for	O
the	O
development	O
of	O
antiinflammatory	O
therapies	O
.	O

Only	O
three	O
receptors	O
for	O
complement	O
peptides	O
have	O
been	O
found	O
,	O
but	O
there	O
are	O
no	O
satisfactory	O
antagonists	O
as	O
yet	O
,	O
despite	O
intensive	O
investigation	O
.	O

In	O
humans	O
,	O
there	O
is	O
a	O
single	O
receptor	O
for	O
C3a	S-geneY
(	O
C3a	B-geneY
receptor	E-geneY
)	O
,	O
no	O
known	O
receptor	O
for	O
C4a	S-geneY
,	O
and	O
two	O
receptors	O
for	O
C5a	S-geneY
(	O
C5a₁	B-geneY
receptor	E-geneY
and	O
C5a₂	B-geneY
receptor	E-geneY
)	O
.	O

The	O
most	O
recently	O
characterized	O
receptor	O
,	O
the	O
C5a₂	S-geneY
receptor	O
(	O
previously	O
known	O
as	O
C5L2	S-geneY
or	O
GPR77	S-geneY
)	O
,	O
has	O
been	O
regarded	O
as	O
a	O
passive	O
binding	O
protein	O
,	O
but	O
signaling	O
activities	O
are	O
now	O
ascribed	O
to	O
it	O
,	O
so	O
we	O
propose	O
that	O
it	O
be	O
formally	O
identified	O
as	O
a	O
receptor	O
and	O
be	O
given	O
a	O
name	O
to	O
reflect	O
this	O
.	O

Here	O
,	O
we	O
describe	O
the	O
complex	O
biology	O
of	O
the	O
complement	O
peptides	O
,	O
introduce	O
a	O
new	O
suggested	O
nomenclature	O
,	O
and	O
review	O
our	O
current	O
knowledge	O
of	O
receptor	O
pharmacology	O
.	O

Roles	O
of	O
rifampicin	S-chem
in	O
drug	O
-	O
drug	O
interactions	O
:	O
underlying	O
molecular	O
mechanisms	O
involving	O
the	O
nuclear	B-geneY
pregnane	I-geneY
X	I-geneY
receptor	E-geneY
.	O

Rifampicin	S-chem
,	O
an	O
important	O
drug	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
is	O
used	O
extensively	O
despite	O
its	O
broad	O
effects	O
on	O
drug	O
-	O
drug	O
interactions	O
,	O
creating	O
serious	O
problems	O
.	O

The	O
clinical	O
importance	O
of	O
such	O
interactions	O
includes	O
autoinduction	O
leading	O
to	O
suboptimal	O
or	O
failed	O
treatment	O
.	O

The	O
concomitantly	O
administered	O
effects	O
of	O
rifampicin	S-chem-C9-1
on	O
other	O
drugs	O
can	O
result	O
in	O
their	O
altered	O
metabolism	O
or	O
transportation	O
that	O
are	O
metabolised	O
by	O
cytochromes	B-geneN-C9-2
P450	E-geneN-C9-2
or	O
transported	O
by	O
p	B-geneN-C9-2
-	I-geneN-C9-2
glycoprotein	E-geneN-C9-2
in	O
the	O
gastrointestinal	O
tract	O
and	O
liver	O
.	O

This	O
review	O
paper	O
summarises	O
recent	O
findings	O
with	O
emphases	O
on	O
the	O
molecular	O
mechanisms	O
used	O
to	O
explain	O
these	O
broad	O
drug	O
-	O
drug	O
interactions	O
.	O

In	O
general	O
,	O
rifampicin	S-chem-C5-1
can	O
act	O
on	O
a	O
pattern	O
:	O
rifampicin	S-chem-C3-1
activates	O
the	O
nuclear	B-geneY-MU-2
pregnane	I-geneY-MU-2
X	I-geneY-MU-2
receptor	E-geneY-MU-2
that	O
in	O
turn	O
affects	O
cytochromes	B-geneN
P450	E-geneN
,	O
glucuronosyltransferases	S-geneN
and	O
p	B-geneN
-	I-geneN
glycoprotein	E-geneN
activities	O
.	O

This	O
pattern	O
of	O
action	O
may	O
explain	O
many	O
of	O
the	O
rifampicin	S-chem
inducing	O
drug	O
-	O
drug	O
interactions	O
.	O

However	O
,	O
effects	O
through	O
other	O
mechanisms	O
have	O
also	O
been	O
reported	O
and	O
these	O
make	O
any	O
explanation	O
of	O
such	O
drug	O
-	O
drug	O
interactions	O
more	O
complex	O
.	O

Predicting	O
cardiomyopathic	O
phenotypes	O
by	O
altering	O
Ca2	B-chem
+	E-chem
affinity	O
of	O
cardiac	B-geneY
troponin	I-geneY
C	E-geneY
.	O

Cardiac	O
diseases	O
associated	O
with	O
mutations	O
in	O
troponin	S-geneN
subunits	O
include	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
,	O
dilated	O
cardiomyopathy	O
(	O
DCM	O
)	O
,	O
and	O
restrictive	O
cardiomyopathy	O
(	O
RCM	O
)	O
.	O

Altered	O
calcium	O
handling	O
in	O
these	O
diseases	O
is	O
evidenced	O
by	O
changes	O
in	O
the	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
of	O
contraction	O
.	O

Mutations	O
in	O
the	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensor	O
,	O
troponin	B-geneY
C	E-geneY
(	O
TnC	S-geneY
)	O
,	O
were	O
generated	O
to	O
increase	O
/	O
decrease	O
the	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
of	O
cardiac	O
skinned	O
fibers	O
to	O
create	O
the	O
characteristic	O
effects	O
of	O
DCM	O
,	O
HCM	O
,	O
and	O
RCM	O
.	O

We	O
also	O
used	O
a	O
reconstituted	O
assay	O
to	O
determine	O
the	O
mutation	O
effects	O
on	O
ATPase	S-geneN
activation	O
and	O
inhibition	O
.	O

One	O
mutant	O
(	O
A23Q	S-geneN
)	O
was	O
found	O
with	O
HCM	O
-	O
like	O
properties	O
(	O
increased	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
of	O
force	O
and	O
normal	O
levels	O
of	O
ATPase	S-geneN
inhibition	O
)	O
.	O

Three	O
mutants	O
(	O
S37G	S-geneN
,	O
V44Q	S-geneN
,	O
and	O
L48Q	S-geneN
)	O
were	O
identified	O
with	O
RCM	O
-	O
like	O
properties	O
(	O
a	O
large	O
increase	O
in	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
,	O
partial	O
loss	O
of	O
ATPase	S-geneN
inhibition	O
,	O
and	O
increased	O
basal	O
force	O
)	O
.	O

Two	O
mutations	O
were	O
identified	O
(	O
E40A	S-geneN
and	O
I61Q	S-geneN
)	O
with	O
DCM	O
properties	O
(	O
decreased	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
,	O
maximal	O
force	O
recovery	O
,	O
and	O
activation	O
of	O
the	O
ATPase	S-geneN
at	O
high	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
)	O
.	O

Steady	O
-	O
state	O
fluorescence	O
was	O
utilized	O
to	O
assess	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
affinity	O
in	O
isolated	O
cardiac	B-geneY
(	I-geneY
c	I-geneY
)	I-geneY
TnCs	E-geneY
containing	O
F27W	S-geneN
and	O
did	O
not	O
necessarily	O
mirror	O
the	O
fiber	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
.	O

Circular	O
dichroism	O
of	O
mutant	O
cTnCs	S-geneY
revealed	O
a	O
trend	O
where	O
increased	O
alpha	O
-	O
helical	O
content	O
correlated	O
with	O
increased	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
in	O
skinned	O
fibers	O
and	O
vice	O
versa	O
.	O

The	O
main	O
findings	O
from	O
this	O
study	O
were	O
as	O
follows	O
:	O
1	O
)	O
cTnC	S-geneY
mutants	O
demonstrated	O
distinct	O
functional	O
phenotypes	O
reminiscent	O
of	O
bona	O
fide	O
HCM	O
,	O
RCM	O
,	O
and	O
DCM	O
mutations	O
;	O
2	O
)	O
a	O
region	O
in	O
cTnC	S-geneY
associated	O
with	O
increased	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
in	O
skinned	O
fibers	O
was	O
identified	O
;	O
and	O
3	O
)	O
the	O
F27W	S-geneN
reporter	O
mutation	O
affected	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
sensitivity	O
,	O
maximal	O
force	O
,	O
and	O
ATPase	S-geneN
activation	O
of	O
some	O
mutants	O
.	O

Modification	O
of	O
radiation	O
damage	O
to	O
mitochondrial	O
system	O
in	O
vivo	O
by	O
Podophyllum	O
hexandrum	O
:	O
mechanistic	O
aspects	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
whether	O
RP	O
-	O
1	O
treatment	O
protected	O
mitochondrial	O
system	O
against	O
radiation	O
damage	O
and	O
also	O
to	O
unravel	O
the	O
mechanism	O
associated	O
with	O
this	O
process	O
.	O

Radioprotection	O
of	O
mitochondrial	O
system	O
by	O
Podophyllum	O
hexandrum	O
(	O
RP	O
-	O
1	O
)	O
was	O
investigated	O
to	O
understand	O
its	O
mechanism	O
of	O
action	O
.	O

Levels	O
of	O
superoxide	S-chem
anion	O
(	O
O2	B-chem
-	E-chem
)	O
,	O
reduced	O
or	O
oxidized	O
glutathione	S-chem
(	O
GSH	S-chem
or	O
GSSG	S-chem
)	O
,	O
thiobarbituric	B-chem
acid	E-chem
reactive	O
substance	O
(	O
TBARS	O
)	O
,	O
protein	O
carbonyl	O
(	O
PC	O
)	O
,	O
ATP	S-chem
,	O
NADH	B-geneN
-	I-geneN
ubiquinone	I-geneN
oxidoreductase	E-geneN
(	O
complex	B-geneN
-	I-geneN
I	E-geneN
)	O
,	O
NADH	B-geneN
-	I-geneN
cytochrome	I-geneN
c	I-geneN
oxidoreductase	E-geneN
(	O
complex	B-geneN
I	I-geneN
/	I-geneN
II	E-geneN
)	O
,	O
succinate	B-geneN
-	I-geneN
cytochrome	I-geneN
c	I-geneN
oxidoreductase	E-geneN
(	O
complex	B-geneN
II	I-geneN
/	I-geneN
III	E-geneN
)	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
were	O
studied	O
in	O
mitochondria	O
isolated	O
from	O
liver	O
of	O
mice	O
belonging	O
to	O
various	O
treatment	O
groups	O
.	O

Whole	O
body	O
y	O
-	O
irradiation	O
(	O
10	O
Gy	O
)	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
increased	O
the	O
formation	O
of	O
O2	B-chem
-	E-chem
,	O
PC	O
,	O
and	O
TBARS	O
,	O
upto	O
24	O
h	O
as	O
compared	O
to	O
untreated	O
control	O
.	O

RP	O
-	O
1	O
treatment	O
(	O
200	O
mg	O
/	O
kg	O
b.w	O
.	O
)	O
to	O
mice	O
2	O
h	O
before	O
irradiation	O
reduced	O
the	O
radiation	O
-	O
induced	O
O2	B-chem
-	E-chem
generation	O
within	O
4	O
h	O
and	O
formation	O
of	O
TBARS	O
and	O
PC	O
upto	O
24	O
h	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Singularly	O
irradiation	O
or	O
RP	O
-	O
1	O
treatment	O
significantly	O
(	O
p	O
<	O
0.01	O
)	O
increased	O
the	O
levels	O
of	O
glutathione	S-chem
within	O
an	O
hour	O
,	O
as	O
compared	O
to	O
untreated	O
control	O
.	O

Pre	O
-	O
irradiation	O
administration	O
of	O
RP	O
-	O
1	O
enhanced	O
levels	O
of	O
GSH	S-chem-C3-1
induced	O
increase	O
in	O
complex	B-geneN-C3-2
I	E-geneN-C3-2
(	O
upto	O
16	O
h	O
)	O
,	O
complex	B-geneN-C3-2
I	I-geneN-C3-2
/	I-geneN-C3-2
III	E-geneN-C3-2
(	O
4	O
h	O
)	O
complex	B-geneN-C3-2
II	I-geneN-C3-2
/	I-geneN-C3-2
III	E-geneN-C3-2
activity	O
(	O
upto	O
24	O
h	O
;	O
p	O
<	O
0.01	O
)	O
and	O
inhibited	O
the	O
radiation	O
-	O
induced	O
decrease	O
in	O
MMP	O
significantly	O
(	O
24	O
h	O
;	O
p	O
<	O
0.01	O
)	O
.	O

The	O
present	O
study	O
indicates	O
that	O
RP	O
-	O
1	O
itself	O
modulates	O
several	O
mitichondrial	O
perameters	O
due	O
to	O
its	O
influence	O
on	O
the	O
biochemical	O
milieu	O
within	O
and	O
outside	O
the	O
cells	O
.	O

However	O
,	O
RP	O
-	O
1	O
treatment	O
before	O
irradiation	O
modulates	O
radiation	O
induced	O
perturbations	O
such	O
as	O
the	O
increase	O
in	O
electron	O
transport	O
chain	O
enzyme	O
activity	O
,	O
formation	O
of	O
O2	B-chem
-	E-chem
,	O
TBARS	O
and	O
PC	O
to	O
offer	O
radioprotection	O
.	O

Impaired	O
in	O
vivo	O
binding	O
of	O
MeCP2	S-geneY
to	O
chromatin	O
in	O
the	O
absence	O
of	O
its	O
DNA	B-geneN
methyl	I-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
.	O

MeCP2	S-geneY
is	O
a	O
methyl	B-geneN
-	I-geneN
CpG	I-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
that	O
is	O
a	O
main	O
component	O
of	O
brain	O
chromatin	O
in	O
vertebrates	O
.	O

In	O
vitro	O
studies	O
have	O
determined	O
that	O
in	O
addition	O
to	O
its	O
specific	O
methyl	B-geneN
-	I-geneN
CpG	I-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
(	O
MBD	S-geneN
)	O
MeCP2	S-geneY
also	O
has	O
several	O
chromatin	B-geneN
association	I-geneN
domains	E-geneN
.	O

However	O
,	O
the	O
specific	O
interactions	O
of	O
MeCP2	S-geneY
with	O
methylated	O
or	O
non	O
-	O
methylated	O
chromatin	O
regions	O
and	O
the	O
structural	O
characteristics	O
of	O
the	O
resulting	O
DNA	O
associations	O
in	O
vivo	O
remain	O
poorly	O
understood	O
.	O

We	O
analysed	O
the	O
role	O
of	O
the	O
MBD	S-geneN
in	O
MeCP2	S-geneY
-	O
chromatin	O
associations	O
in	O
vivo	O
using	O
an	O
MeCP2	S-geneY
mutant	O
Rett	O
syndrome	O
mouse	O
model	O
(	O
Mecp2	S-geneY
(	O
tm	O
)	O
(	O
1	O
)	O
(	O
.	O
)	O
(	O
1	O
)	O
(	O
Jae	O
)	O
)	O
in	O
which	O
exon	O
3	O
deletion	O
results	O
in	O
an	O
N	S-chem
-	O
terminal	O
truncation	O
of	O
the	O
protein	O
,	O
including	O
most	O
of	O
the	O
MBD	S-geneN
.	O

Our	O
results	O
show	O
that	O
in	O
mutant	O
mice	O
,	O
the	O
truncated	O
form	O
of	O
MeCP2	S-geneY
(	O
Δ	B-geneY
MeCP2	E-geneY
)	O
is	O
expressed	O
in	O
different	O
regions	O
of	O
the	O
brain	O
and	O
liver	O
,	O
albeit	O
at	O
50	O
%	O
of	O
its	O
wild	O
-	O
type	O
(	O
wt	O
)	O
counterpart	O
.	O

In	O
contrast	O
to	O
the	O
punctate	O
nuclear	O
distribution	O
characteristic	O
of	O
wt	O
MeCP2	S-geneY
,	O
Δ	B-geneY
MeCP2	E-geneY
exhibits	O
both	O
diffuse	O
nuclear	O
localization	O
and	O
a	O
substantial	O
retention	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
a	O
dysfunction	O
of	O
nuclear	O
transport	O
.	O

In	O
mutant	O
brain	O
tissue	O
,	O
neuronal	O
nuclei	O
are	O
smaller	O
,	O
and	O
Δ	B-geneY
MeCP2	E-geneY
chromatin	O
is	O
digested	O
faster	O
by	O
nucleases	S-geneN
,	O
producing	O
a	O
characteristic	O
nuclease	O
-	O
resistant	O
dinucleosome	O
.	O

Although	O
a	O
fraction	O
of	O
Δ	B-geneY
MeCP2	E-geneY
is	O
found	O
associated	O
with	O
nucleosomes	O
,	O
its	O
interaction	O
with	O
chromatin	O
is	O
transient	O
and	O
weak	O
.	O

Thus	O
,	O
our	O
results	O
unequivocally	O
demonstrate	O
that	O
in	O
vivo	O
the	O
MBD	S-geneN
of	O
MeCP2	S-geneY
together	O
with	O
its	O
adjacent	O
region	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
are	O
critical	O
for	O
the	O
proper	O
interaction	O
of	O
the	O
protein	O
with	O
chromatin	O
,	O
which	O
can	O
not	O
be	O
replaced	O
by	O
any	O
other	O
of	O
its	O
protein	O
domains	O
.	O

Characterization	O
of	O
renal	O
ecto	O
-	O
phosphodiesterase	S-geneN
.	O

In	O
kidneys	O
,	O
stimulation	O
of	O
adenylyl	B-geneN
cyclase	E-geneN
causes	O
egress	O
of	O
cAMP	S-chem
,	O
conversion	O
of	O
cAMP	S-chem-C9-1
to	O
AMP	S-chem-C9-1
by	O
ecto	O
-	O
phosphodiesterase	S-geneN-C9-2
,	O
and	O
metabolism	O
of	O
AMP	S-chem-C9-1
to	O
adenosine	S-chem-C9-1
by	O
ecto	B-geneY-C9-2
-	I-geneY-C9-2
5	I-geneY-C9-2
'	I-geneY-C9-2
-	I-geneY-C9-2
nucleotidase	E-geneY-C9-2
.	O

Although	O
much	O
is	O
known	O
about	O
ecto	B-geneY
-	I-geneY
5	I-geneY
'	I-geneY
-	I-geneY
nucleotidase	E-geneY
,	O
the	O
renal	O
ecto	O
-	O
phosphodiesterase	S-geneN
remains	O
uncharacterized	O
.	O

We	O
administered	O
cAMP	S-chem
(	O
10	O
microM	O
in	O
the	O
perfusate	O
)	O
to	O
12	O
different	O
groups	O
of	O
perfused	O
kidneys	O
.	O

AMP	S-chem
was	O
measured	O
in	O
perfusate	O
using	O
ion	O
trap	O
mass	O
spectrometry	O
.	O

In	O
control	O
kidneys	O
(	O
n	O
=	O
19	O
)	O
,	O
basal	O
renal	O
secretion	O
rate	O
of	O
AMP	S-chem
was	O
0.49	O
+	O
/	O
-	O
0.08	O
and	O
increased	O
to	O
3.0	O
+	O
/	O
-	O
0.2	O
nmol	O
AMP	S-chem
/	O
g	O
kidney	O
weight	O
/	O
min	O
during	O
administration	O
of	O
cAMP	S-chem
.	O

A	O
broad	O
-	O
spectrum	O
phosphodiesterase	S-geneN-C4-2
(	O
PDE	S-geneN-C4-2
)	O
inhibitor	O
(	O
1,3	B-chem-C4-1
-	I-chem-C4-1
isobutyl	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
methylxanthine	E-chem-C4-1
,	O
300	O
microM	O
,	O
n	O
=	O
6	O
)	O
and	O
an	O
ecto	O
-	O
phosphodiesterase	O
inhibitor	O
(	O
1,3	B-chem
-	I-chem
dipropyl	I-chem
-	I-chem
8	I-chem
-	I-chem
p	I-chem
-	I-chem
sulfophenylxanthine	E-chem
,	O
1	O
mM	O
,	O
n	O
=	O
6	O
)	O
significantly	O
attenuated	O
cAMP	S-chem
-	O
induced	O
AMP	S-chem
secretion	O
by	O
60	O
and	O
74	O
%	O
,	O
respectively	O
.	O

Blockade	O
of	O
PDE1	S-geneN-C4-2
(	O
8	B-chem-C4-1
-	I-chem-C4-1
methoxymethyl	I-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
isobutyl	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
methylxanthine	E-chem-C4-1
,	O
100	O
microM	O
)	O
,	O
PDE2	S-geneN-C4-2
[	O
erythro	B-chem-C4-1
-	I-chem-C4-1
9	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
hydroxy	I-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
nonyl	I-chem-C4-1
)	I-chem-C4-1
adenine	E-chem-C4-1
,	O
30	O
microM	O
]	O
,	O
PDE3	S-geneN-C4-2
(	O
milrinone	S-chem-C4-1
,	O
10	O
microM	O
;	O
cGMP	O
,	O
10	O
microM	O
)	O
,	O
PDE4	S-geneN-C4-2
(	O
Ro	O
20	O
-	O
1724	O
[	O
4	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
butoxy	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
methoxybenzyl	I-chem-C4-1
)	I-chem-C4-1
imidazolidin	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
one	E-chem-C4-1
]	O
,	O
100	O
microM	O
)	O
,	O
PDE5	S-geneY-C4-2
and	O
PDE6	S-geneN-C4-2
(	O
zaprinast	S-chem-C4-1
,	O
30	O
microM	O
)	O
,	O
and	O
PDE7	S-geneN-C4-2
[	O
BRL	B-chem-C4-1
-	I-chem-C4-1
50481	E-chem-C4-1
(	O
5	B-chem-C4-1
-	I-chem-C4-1
nitro	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
,	I-chem-C4-1
N	I-chem-C4-1
,	I-chem-C4-1
N	I-chem-C4-1
-	I-chem-C4-1
trimethylbenzenesulfonamide	E-chem-C4-1
)	O
,	O
10	O
microM	O
]	O
did	O
not	O
alter	O
renal	O
ecto	O
-	O
phosphodiesterase	S-geneN
activity	O
.	O

Administration	O
of	O
a	O
concentration	O
(	O
100	O
microM	O
)	O
of	O
dipyridamole	S-chem-C4-1
that	O
blocks	O
PDE8	S-geneN-C4-2
inhibited	O
ecto	O
-	O
phosphodiesterase	S-geneN-C4-2
activity	O
(	O
by	O
44	O
%	O
)	O
.	O

However	O
,	O
a	O
lower	O
concentration	O
of	O
dipyridamole	S-chem-C4-1
(	O
3	O
microM	O
)	O
that	O
blocks	O
PDE9	S-geneN-C4-2
,	O
PDE10	S-geneY-C4-2
,	O
and	O
PDE11	S-geneY-C4-2
,	O
but	O
not	O
PDE8	S-geneN
,	O
did	O
not	O
inhibit	O
ecto	O
-	O
phosphodiesterase	S-geneN
activity	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
renal	O
ecto	O
-	O
phosphodiesterase	S-geneN-C4-2
activity	O
is	O
not	O
mediated	O
by	O
PDE1	S-geneN
,	O
PDE2	S-geneN
,	O
PDE3	S-geneN
,	O
PDE4	S-geneN
,	O
PDE5	S-geneY
,	O
PDE6	S-geneN
,	O
PDE7	S-geneN
,	O
PDE9	S-geneN
,	O
PDE10	S-geneY
,	O
or	O
PDE11	S-geneY
and	O
is	O
inhibited	O
by	O
high	O
concentrations	O
of	O
dipyridamole	S-chem-C4-1
.	O

Ecto	O
-	O
phosphodiesterase	S-geneN
has	O
some	O
pharmacological	O
characteristics	O
similar	O
to	O
PDE8	O
.	O

The	O
alpha	B-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
-	I-geneN
adrenoceptor	E-geneN
blocking	O
activities	O
of	O
labetalol	S-chem
and	O
its	O
RR	O
-	O
SR	O
(	O
50	O
:	O
50	O
)	O
stereoisomers	O
.	O

1	O
.	O

We	O
compared	O
the	O
alpha	B-geneN
1	I-geneN
-	I-geneN
,	I-geneN
alpha	I-geneN
2	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
blocking	O
potencies	O
of	O
labetalol	S-chem
with	O
those	O
of	O
its	O
two	O
stereoisomers	O
(	O
RR	O
and	O
SR	O
)	O
in	O
pithed	O
rats	O
and	O
in	O
homogenized	O
rat	O
cerebral	O
cortex	O
and	O
heart	O
.	O

2	O
.	O

In	O
pithed	O
rats	O
,	O
labetalol	S-chem
and	O
the	O
RR	O
-	O
SR	O
combination	O
were	O
given	O
orally	O
either	O
at	O
doses	O
of	O
25	O
and	O
50	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O
or	O
intravenously	O
at	O
doses	O
of	O
1	O
and	O
5	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O

Prazosin	S-chem
4	O
and	O
20	O
micrograms	O
kg	O
-	O
1	O
body	O
wt	O
.	O
and	O
propranolol	S-chem
1	O
and	O
5	O
mg	O
kg	O
-	O
1	O
body	O
wt	O
.	O
,	O
were	O
given	O
intravenously	O
for	O
comparison	O
studies	O
of	O
potency	O
at	O
alpha	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
,	O
respectively	O
.	O

Effects	O
were	O
studied	O
before	O
and	O
after	O
i.v	O
.	O
administration	O
of	O
either	O
phenylephrine	S-chem
(	O
at	O
doses	O
which	O
increased	O
the	O
mean	O
arterial	O
pressure	O
by	O
approximately	O
80	O
mmHg	O
)	O
or	O
isoprenaline	S-chem
(	O
at	O
doses	O
that	O
increased	O
heart	O
rate	O
by	O
approximately	O
100	O
beats	O
min	O
-	O
1	O
)	O
.	O

3	O
.	O

In	O
pithed	O
rats	O
,	O
labetalol	S-chem
and	O
the	O
RR	O
-	O
SR	O
combination	O
antagonized	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
pressor	O
effect	O
of	O
phenylephrine	S-chem
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
the	O
chronotropic	O
effect	O
of	O
isoprenaline	S-chem
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Following	O
both	O
oral	O
and	O
intravenous	O
dosing	O
,	O
the	O
RR	O
-	O
SR	O
combination	O
was	O
twice	O
potent	O
as	O
labetalol	S-chem
in	O
terms	O
of	O
alpha	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonism	O
at	O
equivalent	O
doses	O
.	O

4	O
.	O

Labetalol	S-chem
and	O
the	O
enantiomers	O
lacked	O
affinity	O
at	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
while	O
at	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
the	O
order	O
of	O
potency	O
was	O
prazosin	S-chem
much	O
greater	O
than	O
RR	O
-	O
SR	O
greater	O
than	O
labetalol	S-chem
.	O

At	O
beta	B-geneY
1	I-geneY
-	I-geneY
adrenoceptors	E-geneY
,	O
the	O
affinity	O
of	O
the	O
compound	O
RR	O
-	O
SR	O
was	O
about	O
3	O
times	O
that	O
of	O
labetalol.5	S-chem
.	O

As	O
labetalol	S-chem
is	O
a	O
mixture	O
of	O
active	O
(	O
RR	O
and	O
SR	O
)	O
and	O
inactive	O
(	O
SS	O
and	O
SR	O
)	O
enantiomers	O
(	O
in	O
terms	O
of	O
alpha	B-geneN
and	I-geneN
beta	I-geneN
receptor	E-geneN
actions	O
)	O
,	O
the	O
combination	O
of	O
RR	O
and	O
SR	O
may	O
be	O
a	O
valuable	O
substitute	O
for	O
labetalol	S-chem
in	O
the	O
treatment	O
of	O
systemic	O
hypertension	O
.	O

Although	O
the	O
potential	O
for	O
non	O
-	O
specific	O
side	O
effects	O
(	O
common	O
to	O
all	O
four	O
enantiomers	O
)	O
could	O
be	O
expected	O
to	O
be	O
diminished	O
,	O
recent	O
reports	O
by	O
postmarketing	O
surveillance	O
indicate	O
that	O
the	O
RR	O
isomer	O
(	O
dilevalol	S-chem
)	O
can	O
induce	O
liver	O
toxicity	O
.	O

Interestingly	O
,	O
labetalol	S-chem
is	O
devoid	O
of	O
this	O
effect	O
;	O
whether	O
the	O
combination	O
of	O
RR	O
and	O
SR	O
enantiomers	O
could	O
be	O
of	O
clinical	O
importance	O
warrants	O
further	O
investigation	O
.	O

Transition	O
-	O
state	O
structure	O
of	O
human	B-geneY
5	I-geneY
'	I-geneY
-	I-geneY
methylthioadenosine	I-geneY
phosphorylase	E-geneY
.	O

Kinetic	O
isotope	O
effects	O
(	O
KIEs	O
)	O
and	O
computer	O
modeling	O
using	O
density	O
functional	O
theory	O
were	O
used	O
to	O
approximate	O
the	O
transition	O
state	O
of	O
human	B-geneY
5	I-geneY
'	I-geneY
-	I-geneY
methylthioadenosine	I-geneY
phosphorylase	E-geneY
(	O
MTAP	S-geneY
)	O
.	O

KIEs	O
were	O
measured	O
on	O
the	O
arsenolysis	O
of	O
5	B-chem-C9-1
'	I-chem-C9-1
-	I-chem-C9-1
methylthioadenosine	E-chem-C9-1
(	O
MTA	S-chem-C9-1
)	O
catalyzed	O
by	O
MTAP	S-geneY-C9-2
and	O
were	O
corrected	O
for	O
the	O
forward	O
commitment	O
to	O
catalysis	O
.	O

Intrinsic	O
KIEs	O
were	O
obtained	O
for	O
[	B-chem
1	I-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
,	I-chem
[	I-chem
1	I-chem
'	I-chem
-	I-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
,	I-chem
[	I-chem
2	I-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
,	I-chem
[	I-chem
4	I-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
,	I-chem
[	I-chem
5	I-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
(	I-chem
2	I-chem
)	I-chem
]	I-chem
,	I-chem
[	I-chem
9	I-chem
-	I-chem
(	I-chem
15	I-chem
)	I-chem
N	I-chem
]	I-chem
,	I-chem
and	I-chem
[	I-chem
Me	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
(	I-chem
3	I-chem
)	I-chem
]	I-chem
MTAs	E-chem
.	O

The	O
primary	O
intrinsic	O
KIEs	O
(	O
1	B-chem
'	I-chem
-	I-chem
(	I-chem
14	I-chem
)	I-chem
C	E-chem
and	O
9	B-chem
-	I-chem
(	I-chem
15	I-chem
)	I-chem
N	E-chem
)	O
suggest	O
that	O
MTAP	S-geneY
has	O
a	O
dissociative	O
S	O
(	O
N	O
)	O
1	O
transition	O
state	O
with	O
its	O
cationic	O
center	O
at	O
the	O
anomeric	O
carbon	S-chem
and	O
insignificant	O
bond	O
order	O
to	O
the	O
leaving	O
group	O
.	O

The	O
9	B-chem
-	I-chem
(	I-chem
15	I-chem
)	I-chem
N	E-chem
intrinsic	O
KIE	O
of	O
1.039	O
also	O
establishes	O
an	O
anionic	O
character	O
for	O
the	O
adenine	S-chem
leaving	O
group	O
,	O
whereas	O
the	O
alpha	O
-	O
primary	O
1	B-chem
'	I-chem
-	I-chem
(	I-chem
14	I-chem
)	I-chem
C	E-chem
KIE	O
of	O
1.031	O
indicates	O
significant	O
nucleophilic	O
participation	O
at	O
the	O
transition	O
state	O
.	O

Computational	O
matching	O
of	O
the	O
calculated	O
EIEs	O
to	O
the	O
intrinsic	O
isotope	O
effects	O
places	O
the	O
oxygen	S-chem
nucleophile	O
2.0	O
Angstrom	O
from	O
the	O
anomeric	O
carbon	S-chem
.	O

The	O
4	B-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	E-chem
KIE	O
is	O
sensitive	O
to	O
the	O
polarization	O
of	O
the	O
3	B-chem
'	I-chem
-	I-chem
OH	E-chem
group	O
.	O

Calculations	O
suggest	O
that	O
a	O
4	B-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	E-chem
KIE	O
of	O
1.047	O
is	O
consistent	O
with	O
ionization	O
of	O
the	O
3	B-chem
'	I-chem
-	I-chem
OH	E-chem
group	O
,	O
indicating	O
formation	O
of	O
a	O
zwitterion	O
at	O
the	O
transition	O
state	O
.	O

The	O
transition	O
state	O
has	O
cationic	O
character	O
at	O
the	O
anomeric	O
carbon	S-chem
and	O
is	O
anionic	O
at	O
the	O
3	B-chem
'	I-chem
-	I-chem
OH	E-chem
oxygen	S-chem
,	O
with	O
an	O
anionic	O
leaving	O
group	O
.	O

The	O
isotope	O
effects	O
predicted	O
a	O
3	O
'	O
-	O
endo	O
conformation	O
for	O
the	O
ribosyl	B-chem
zwitterion	E-chem
,	O
corresponding	O
to	O
a	O
H1	B-chem
'	I-chem
-	I-chem
C1	I-chem
'	I-chem
-	I-chem
C2	I-chem
'	I-chem
-	I-chem
H2	I-chem
'	E-chem
torsional	O
angle	O
of	O
33	O
degrees	O
.	O

The	O
[	O
Me	B-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
(	I-chem
3	I-chem
)	E-chem
]	O
and	O
[	O
5	B-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
(	I-chem
2	I-chem
)	E-chem
]	O
KIEs	O
arise	O
predominantly	O
from	O
the	O
negative	O
hyperconjugation	O
of	O
the	O
lone	O
pairs	O
of	O
sulfur	S-chem
with	O
the	O
sigma	O
(	O
C	B-chem
-	I-chem
H	E-chem
)	O
antibonding	O
orbitals	O
.	O

Human	B-geneY
MTAP	E-geneY
is	O
characterized	O
by	O
a	O
late	O
S	O
(	O
N	O
)	O
1	O
transition	O
state	O
with	O
significant	O
participation	O
of	O
the	O
phosphate	S-chem
nucleophile	O
.	O

Does	O
aspirin	S-chem
acetylate	O
multiple	O
cellular	O
proteins	O
?	O
(	O
Review	O
)	O
.	O

Aspirin	S-chem
is	O
a	O
salicylate	S-chem
drug	O
that	O
is	O
extensively	O
used	O
for	O
its	O
anti	O
-	O
inflammatory	O
,	O
antipyretic	O
,	O
analgesic	O
and	O
anti	O
-	O
thrombotic	O
effects	O
.	O

More	O
recently	O
,	O
it	O
has	O
been	O
shown	O
to	O
decrease	O
the	O
incidence	O
of	O
cancers	O
of	O
epithelial	O
origin	O
.	O

In	O
most	O
cases	O
,	O
aspirin	S-chem
is	O
relatively	O
safe	O
.	O

However	O
,	O
it	O
does	O
cause	O
a	O
host	O
of	O
adverse	O
effects	O
and	O
toxicities	O
,	O
including	O
gastrointestinal	O
bleeding	O
,	O
ulcerations	O
,	O
nephrotoxicity	O
and	O
hypersensitivity	O
reactions	O
.	O

Although	O
the	O
inhibition	O
of	O
cyclooxygenases	S-geneN-C4-2
by	O
aspirin	S-chem-C4-1
,	O
which	O
leads	O
to	O
its	O
anti	O
-	O
inflammatory	O
/	O
analgesic	O
properties	O
,	O
has	O
been	O
well	O
studied	O
,	O
the	O
mechanisms	O
involved	O
in	O
its	O
chemopreventive	O
effects	O
as	O
well	O
as	O
some	O
of	O
its	O
adverse	O
effects	O
are	O
as	O
yet	O
ill	O
-	O
defined	O
.	O

Studies	O
over	O
the	O
past	O
decades	O
suggest	O
that	O
,	O
besides	O
cyclooxygenases	S-geneN
,	O
aspirin	S-chem
acetylates	O
other	O
cellular	O
proteins	O
.	O

These	O
studies	O
used	O
radiolabeled	O
3H	S-chem
or	O
14C	S-chem
aspirin	S-chem
,	O
the	O
only	O
approach	O
used	O
to	O
date	O
for	O
the	O
detection	O
of	O
proteins	O
acetylated	O
by	O
aspirin	S-chem
.	O

In	O
a	O
recent	O
study	O
using	O
protein	O
-	O
specific	O
anti	O
-	O
acetyl	O
lysine	S-chem
antibodies	O
and	O
immunological	O
methods	O
,	O
we	O
demonstrated	O
the	O
ability	O
of	O
aspirin	S-chem-C3-1
to	O
acetylate	O
the	O
tumor	B-geneY-C3-2
suppressor	I-geneY-C3-2
protein	I-geneY-C3-2
p53	E-geneY-C3-2
.	O

In	O
this	O
review	O
,	O
we	O
present	O
current	O
research	O
from	O
the	O
literature	O
on	O
the	O
aspirin	S-chem
-	O
induced	O
acetylation	O
of	O
proteins	O
.	O

We	O
also	O
describe	O
an	O
immunological	O
approach	O
to	O
detecting	O
acetylated	O
proteins	O
in	O
aspirin	S-chem
-	O
treated	O
cells	O
,	O
and	O
demonstrate	O
that	O
multiple	O
proteins	O
are	O
acetylated	O
.	O

Since	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
,	O
such	O
as	O
acetylation	O
,	O
may	O
lead	O
to	O
the	O
alteration	O
of	O
their	O
function	O
,	O
it	O
is	O
possible	O
that	O
some	O
of	O
the	O
hitherto	O
unexplained	O
beneficial	O
or	O
adverse	O
effects	O
of	O
aspirin	S-chem
could	O
occur	O
as	O
a	O
result	O
of	O
these	O
modifications	O
.	O

The	O
identification	O
of	O
these	O
novel	O
acetylation	O
targets	O
of	O
aspirin	S-chem
represents	O
a	O
new	O
area	O
for	O
investigation	O
.	O

Correlation	O
between	O
activation	O
of	O
PPARγ	S-geneY-C3-2
and	O
resistin	S-geneY-C4-2
downregulation	O
in	O
a	O
mouse	O
adipocyte	O
cell	O
line	O
by	O
a	O
series	O
of	O
thiazolidinediones	S-chem-MU-1
.	O

The	O
present	O
study	O
shows	O
significant	O
correlations	O
between	O
the	O
EC50	O
for	O
PPARγ	S-geneY
activation	O
in	O
a	O
reporter	O
gene	O
cell	O
line	O
and	O
resistin	S-geneY
downregulation	O
in	O
mouse	O
adipocytes	O
,	O
and	O
between	O
the	O
IC50	O
for	O
resistin	S-geneY
downregulation	O
and	O
the	O
already	O
published	O
minimum	O
effective	O
dose	O
for	O
antihyperglycemic	O
activity	O
in	O
a	O
mouse	O
model	O
.	O

These	O
correlations	O
indicate	O
that	O
PPARγ	S-geneY
mediated	O
downregulation	O
of	O
resistin	O
might	O
promote	O
insulin	S-geneN
sensitivity	O
and	O
that	O
downregulation	O
of	O
resistin	S-geneY
in	O
mouse	O
adipocytes	O
provides	O
an	O
adequate	O
and	O
possibly	O
more	O
direct	O
bioassay	O
for	O
screening	O
of	O
newly	O
developed	O
antihyperglycemic	O
compounds	O
.	O

Because	O
of	O
the	O
higher	O
throughput	O
of	O
the	O
PPARγ	S-geneY
the	O
resistin	S-geneY
downregulation	O
assays	O
seems	O
most	O
suitable	O
to	O
be	O
used	O
as	O
a	O
second	O
tier	O
in	O
a	O
tiered	O
screening	O
strategy	O
.	O

Biosynthetic	O
regulation	O
and	O
intracellular	O
transport	O
of	O
phosphatidylserine	S-chem
in	O
mammalian	O
cells	O
.	O

In	O
mammalian	O
cells	O
,	O
phosphatidylserine	S-chem
(	O
PtdSer	S-chem
)	O
is	O
synthesized	O
through	O
the	O
action	O
of	O
the	O
endoplasmic	O
reticulum	O
enzymes	O
,	O
PtdSer	B-geneN
synthase	I-geneN
1	I-geneN
and	I-geneN
2	E-geneN
,	O
and	O
the	O
decarboxylation	O
of	O
PtdSer	O
accounts	O
for	O
the	O
majority	O
of	O
phosphatidylethanolamine	S-chem
(	O
PtdEtn	S-chem
)	O
synthesis	O
.	O

PtdSer	S-chem
decarboxylation	O
for	O
PtdEtn	S-chem
formation	O
occurs	O
in	O
the	O
mitochondria	O
.	O

In	O
addition	O
,	O
the	O
transport	O
of	O
PtdSer	S-chem
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
mitochondria	O
is	O
probably	O
a	O
rate	O
limiting	O
step	O
for	O
PtdEtn	S-chem
synthesis	O
through	O
the	O
decarboxylation	O
pathway	O
.	O

Therefore	O
,	O
the	O
regulation	O
of	O
PtdSer	S-chem
synthesis	O
and	O
its	O
intracellular	O
transport	O
appear	O
to	O
be	O
essential	O
events	O
for	O
the	O
maintenance	O
of	O
normal	O
cellular	O
PtdSer	S-chem
and	O
PtdEtn	S-chem
levels	O
.	O

Here	O
we	O
describe	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
PtdSer	S-chem
biosynthesis	O
and	O
the	O
transport	O
of	O
PtdSer	S-chem
from	O
the	O
ER	O
to	O
the	O
mitochondria	O
in	O
mammalian	O
cells	O
.	O

Characterization	O
of	O
tyrosinase	S-geneY
inhibitors	O
in	O
the	O
twigs	O
of	O
Cudrania	O
tricuspidata	O
and	O
their	O
structure	O
-	O
activity	O
relationship	O
study	O
.	O

The	O
twigs	O
of	O
Cudrania	O
tricuspidata	O
were	O
found	O
to	O
show	O
strong	O
tyrosinase	S-geneY
inhibitory	O
activity	O
,	O
and	O
further	O
detailed	O
component	O
analysis	O
resulted	O
in	O
the	O
isolation	O
of	O
a	O
new	O
flavanol	B-chem
glucoside	E-chem
,	O
(	B-chem
2S,3S	I-chem
)	I-chem
-	I-chem
2,3	I-chem
-	I-chem
trans	I-chem
-	I-chem
dihydromorin	I-chem
-	I-chem
7	I-chem
-	I-chem
O	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucoside	E-chem
(	O
1	O
)	O
,	O
plus	O
twenty	O
-	O
seven	O
known	O
compounds	O
(	O
2	O
-	O
28	O
)	O
.	O

Their	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
ESI	O
-	O
MS	O
and	O
NMR	O
spectral	O
data	O
.	O

Among	O
the	O
isolated	O
compounds	O
,	O
trans	B-chem-C4-1
-	I-chem-C4-1
dihydromorin	E-chem-C4-1
(	O
8	O
)	O
,	O
oxyresveratrol	S-chem-C4-1
(	O
9	O
)	O
,	O
and	O
steppogenin	S-chem-C4-1
(	O
12	O
)	O
were	O
found	O
to	O
exhibit	O
significant	O
tyrosinase	S-geneY-C4-2
inhibition	O
activities	O
.	O

Moreover	O
,	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
these	O
isolated	O
compounds	O
was	O
also	O
discussed	O
.	O

DNA	O
methylation	O
and	O
histone	S-geneN
modification	O
profiles	O
of	O
mouse	B-geneN
organic	I-geneN
anion	I-geneN
transporting	I-geneN
polypeptides	E-geneN
.	O

Organic	B-geneN
anion	I-geneN
transporting	I-geneN
polypeptides	E-geneN
(	O
rodents	O
,	O
Oatps	S-geneN
;	O
human	O
,	O
OATPs	S-geneN
)	O
are	O
primarily	O
involved	O
in	O
the	O
transmembrane	O
transportation	O
of	O
a	O
wide	O
range	O
of	O
endogenous	O
and	O
exogenous	O
compounds	O
.	O

Multiple	O
mouse	B-geneY
Oatp1	E-geneY
isoforms	O
are	O
closely	O
located	O
on	O
chromosome	O
6	O
,	O
where	O
each	O
isoform	O
shows	O
distinct	O
tissue	O
distribution	O
;	O
Oatp1b2	S-geneY
,	O
Oatp1a6	S-geneN
,	O
and	O
Oatp1c1	S-geneY
are	O
expressed	O
exclusively	O
in	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
cerebrum	O
,	O
respectively	O
;	O
Oatp1a1	S-geneY
in	O
the	O
liver	O
and	O
kidney	O
;	O
and	O
Oatp1a4	S-geneY
in	O
the	O
liver	O
and	O
cerebrum	O
.	O

We	O
have	O
identified	O
tissue	B-geneN
-	I-geneN
dependent	I-geneN
differentially	I-geneN
methylated	I-geneN
region	E-geneN
(	O
T	B-geneN
-	I-geneN
DMR	E-geneN
)	O
around	O
the	O
transcriptional	B-geneN
start	I-geneN
site	E-geneN
(	O
TSS	S-geneN
)	O
of	O
Oatp1b2	S-geneY
,	O
which	O
correlates	O
with	O
its	O
liver	O
-	O
specific	O
expression	O
.	O

Bisulfite	S-chem
sequencing	O
also	O
demonstrated	O
the	O
presence	O
of	O
T	B-geneN
-	I-geneN
DMRs	E-geneN
around	O
the	O
TSS	S-geneN
in	O
other	O
Oatp1	S-geneY
genes	O
:	O
CpG	O
dinucleotides	O
at	O
+	O
149	O
relative	O
to	O
the	O
TSS	S-geneN
for	O
Oatp1c1	S-geneY
;	O
-	O
48	O
,	O
+	O
101	O
,	O
and	O
+	O
356	O
for	O
Oatp1a4	S-geneY
;	O
-	O
572	O
and	O
-	O
550	O
for	O
Oatp1a1	S-geneY
;	O
and	O
-	O
122	O
and	O
+	O
216	O
for	O
Oatp1a6	S-geneN
were	O
differentially	O
methylated	O
among	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
cerebrum	O
.	O

These	O
methylation	O
profiles	O
were	O
largely	O
consistent	O
with	O
the	O
tissue	O
distribution	O
of	O
Oatp1	S-geneY
mRNAs	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O
revealed	O
that	O
the	O
mRNA	O
expression	O
of	O
Oatp1	S-geneY
genes	O
was	O
accompanied	O
by	O
acetylated	O
histone	B-geneN
H3	E-geneN
.	O

Human	B-geneY
OATP1B1	E-geneY
and	O
OATP1B3	S-geneY
are	O
located	O
on	O
chromosome	O
12p12	O
in	O
the	O
OATP1	S-geneY
cluster	O
;	O
both	O
show	O
predominant	O
expression	O
in	O
the	O
liver	O
.	O

These	O
genes	O
also	O
contained	O
T	B-geneN
-	I-geneN
DMRs	E-geneN
that	O
were	O
hypomethylated	O
in	O
the	O
liver	O
,	O
compared	O
with	O
kidney	O
cortex	O
:	O
-	O
511	O
,	O
-	O
411	O
,	O
and	O
+	O
92	O
relative	O
to	O
the	O
TSS	S-geneN
for	O
OATP1B1	S-geneY
and	O
-	O
331	O
,	O
+	O
70	O
,	O
and	O
+	O
73	O
for	O
OATP1B3	S-geneY
.	O

These	O
results	O
suggest	O
that	O
the	O
difference	O
in	O
epigenetic	O
profiles	O
comprising	O
DNA	O
methylation	O
and	O
histone	S-geneN
acetylation	O
determines	O
the	O
distinct	O
tissue	O
distribution	O
of	O
Oatp	S-geneN
/	O
OATP	S-geneN
mRNAs	O
.	O

Use	O
of	O
gene	O
expression	O
data	O
to	O
determine	O
effects	O
on	O
gonad	O
phenotype	O
in	O
japanese	O
medaka	O
after	O
exposure	O
to	O
trenbolone	S-chem
or	O
estradiol	S-chem
.	O

Various	O
aquatic	O
bioassays	O
using	O
one	O
of	O
several	O
fish	O
species	O
have	O
been	O
developed	O
or	O
are	O
in	O
the	O
process	O
of	O
being	O
developed	O
by	O
organizations	O
like	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
and	O
the	O
Office	O
of	O
Economic	O
Cooperation	O
and	O
Development	O
for	O
testing	O
potential	O
endocrine	O
-	O
disrupting	O
chemicals	O
(	O
EDCs	O
)	O
.	O

Often	O
,	O
these	O
involve	O
assessment	O
of	O
the	O
gonad	O
phenotype	O
of	O
individuals	O
as	O
a	O
key	O
endpoint	O
that	O
is	O
inputted	O
into	O
a	O
risk	O
or	O
hazard	O
assessment	O
.	O

Typically	O
,	O
gonad	O
phenotype	O
is	O
determined	O
histologically	O
,	O
which	O
involves	O
specialized	O
and	O
time	O
-	O
consuming	O
techniques	O
.	O

The	O
methods	O
detailed	O
here	O
utilize	O
an	O
entirely	O
different	O
methodology	O
,	O
reverse	O
-	O
transcription	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
to	O
determine	O
the	O
relative	O
expression	O
levels	O
of	O
4	O
genes	O
after	O
exposure	O
to	O
either	O
17β	B-chem
-	I-chem
estradiol	E-chem
or	O
17β	B-chem
-	I-chem
trenbolone	E-chem
and	O
,	O
by	O
extension	O
,	O
the	O
effects	O
of	O
EDCs	O
on	O
the	O
phenotypic	O
status	O
of	O
the	O
gonad	O
.	O

The	O
4	O
genes	O
quantified	O
,	O
Sox9b	S-geneY
,	O
protamine	S-geneY
,	O
Fig1α	S-geneN
,	O
and	O
ZPC1	S-geneN
,	O
are	O
all	O
involved	O
in	O
gonad	O
development	O
and	O
maintenance	O
in	O
Japanese	O
medaka	O
(	O
Oryzias	O
latipes	O
)	O
;	O
these	O
data	O
were	O
then	O
inputted	O
into	O
a	O
permutational	O
multivariate	O
analysis	O
of	O
variance	O
to	O
determine	O
whether	O
significant	O
differences	O
exist	O
between	O
treatment	O
groups	O
.	O

This	O
information	O
in	O
conjunction	O
with	O
the	O
sexual	O
genotype	O
,	O
which	O
can	O
be	O
determined	O
in	O
medaka	O
,	O
can	O
be	O
used	O
to	O
determine	O
adverse	O
effects	O
of	O
exposure	O
to	O
EDCs	O
in	O
a	O
similar	O
fashion	O
to	O
the	O
histologically	O
determined	O
gonad	O
phenotype	O
.	O

Environ	O
Toxicol	O
Chem	O
2013	O
;	O
32	O
:	O
1344	O
-	O
1353	O
.	O

©	O
2013	O
SETAC	O
.	O

Functional	O
and	O
molecular	O
characterization	O
of	O
multiple	O
K	B-geneN
-	I-geneN
Cl	I-geneN
cotransporter	E-geneN
isoforms	O
in	O
corneal	O
epithelial	O
cells	O
.	O

The	O
dependence	O
of	O
regulatory	O
volume	O
decrease	O
(	O
RVD	O
)	O
activity	O
on	O
potassium	B-geneN
-	I-geneN
chloride	I-geneN
cotransporter	E-geneN
(	O
KCC	S-geneN
)	O
isoform	O
expression	O
was	O
characterized	O
in	O
corneal	O
epithelial	O
cells	O
(	O
CEC	O
)	O
.	O

During	O
exposure	O
to	O
a	O
50	O
%	O
hypotonic	O
challenge	O
,	O
the	O
RVD	O
response	O
was	O
larger	O
in	O
SV40	O
-	O
immortalized	O
human	O
CEC	O
(	O
HCEC	O
)	O
than	O
in	O
SV40	O
-	O
immortalized	O
rabbit	O
CEC	O
(	O
RCEC	O
)	O
.	O

A	O
KCC	S-geneN-C4-2
inhibitor	O
-	O
[	B-chem-C4-1
(	I-chem-C4-1
dihydroindenyl	I-chem-C4-1
)	I-chem-C4-1
oxy	I-chem-C4-1
]	I-chem-C4-1
alkanoic	I-chem-C4-1
acid	E-chem-C4-1
(	O
DIOA	S-chem-C4-1
)	O
-	O
blocked	O
RVD	O
more	O
in	O
HCEC	O
than	O
RCEC	O
.	O

Under	O
isotonic	O
conditions	O
,	O
N	B-chem-C3-1
-	I-chem-C3-1
ethylmaleimide	E-chem-C3-1
(	O
NEM	S-chem-C3-1
)	O
produced	O
KCC	S-geneN-C3-2
activation	O
and	O
transient	O
cell	O
shrinkage	O
.	O

Both	O
of	O
these	O
changes	O
were	O
greater	O
in	O
HCEC	O
than	O
in	O
RCEC	O
.	O

Immunoblot	O
analysis	O
of	O
HCEC	O
,	O
RCEC	O
,	O
primary	O
human	O
CEC	O
(	O
pHCEC	O
)	O
,	O
and	O
primary	O
bovine	O
CEC	O
(	O
BCEC	O
)	O
plasma	O
membrane	O
enriched	O
fractions	O
revealed	O
KCC1	S-geneN
,	O
KCC3	S-geneN
,	O
and	O
KCC4	S-geneN
isoform	O
expression	O
,	O
whereas	O
KCC2	S-geneN
was	O
undetectable	O
.	O

During	O
a	O
hypotonic	O
challenge	O
,	O
KCC1	S-geneN
membrane	O
content	O
increased	O
more	O
rapidly	O
in	O
HCEC	O
than	O
in	O
RCEC	O
.	O

Such	O
a	O
challenge	O
induced	O
a	O
larger	O
increase	O
and	O
more	O
transient	O
p44	B-geneN
/	I-geneN
42MAPK	E-geneN
activation	O
in	O
HCEC	O
than	O
RCEC	O
.	O

On	O
the	O
other	O
hand	O
,	O
HCEC	O
and	O
RCEC	O
p38MAPK	S-geneN
phosphorylation	O
reached	O
peak	O
activations	O
at	O
2.5	O
and	O
15	O
min	O
,	O
respectively	O
.	O

Only	O
in	O
HCEC	O
,	O
pharmacological	O
manipulation	O
of	O
KCC	S-geneN
activity	O
modified	O
the	O
hypotonicity	O
-	O
induced	O
activation	O
of	O
p44	B-geneN
/	I-geneN
42MAPK	E-geneN
,	O
whereas	O
p38MAPK	S-geneN
phosphorylation	O
was	O
insensitive	O
to	O
such	O
procedures	O
in	O
both	O
cell	O
lines	O
.	O

Larger	O
increases	O
in	O
HCEC	O
KCC1	S-geneY
membrane	O
protein	O
content	O
correlated	O
with	O
their	O
ability	O
to	O
undergo	O
faster	O
and	O
more	O
complete	O
RVD	O
.	O

Furthermore	O
,	O
pharmacological	O
activation	O
of	O
KCC	S-geneN
increased	O
p44	B-geneN
/	I-geneN
42MAPK	E-geneN
phosphorylation	O
in	O
HCEC	O
but	O
not	O
in	O
RCEC	O
,	O
presumably	O
a	O
reflection	O
of	O
low	O
KCC1	S-geneY
membrane	O
expression	O
in	O
RCEC	O
.	O

These	O
findings	O
suggest	O
that	O
KCC1	S-geneN
plays	O
a	O
role	O
in	O
(	O
i	O
)	O
maintaining	O
isotonic	O
steady	O
-	O
state	O
cell	O
volume	O
homeostasis	O
,	O
(	O
ii	O
)	O
recovery	O
of	O
isotonic	O
cell	O
volume	O
after	O
a	O
hypotonic	O
challenge	O
through	O
RVD	O
,	O
and	O
(	O
iii	O
)	O
regulating	O
hypotonicity	O
-	O
induced	O
activation	O
of	O
the	O
p44	B-geneN
/	I-geneN
42MAPK	E-geneN
signaling	O
pathway	O
required	O
for	O
cell	O
proliferation	O
.	O

Hepatocytes	O
display	O
a	O
compensatory	O
survival	O
response	O
against	O
cadmium	S-chem
toxicity	O
by	O
a	O
mechanism	O
mediated	O
by	O
EGFR	S-geneY
and	O
Src	S-geneY
.	O

Although	O
the	O
liver	O
is	O
a	O
cadmium	S-chem
-	O
target	O
organ	O
,	O
hepatocyte	O
response	O
involved	O
in	O
its	O
toxicity	O
is	O
not	O
yet	O
elucidated	O
.	O

A	O
link	O
between	O
this	O
heavy	O
metal	O
treatment	O
and	O
Stat3	S-geneY
signaling	O
pathways	O
was	O
examined	O
in	O
primary	O
mouse	O
hepatocytes	O
.	O

We	O
provided	O
evidence	O
of	O
a	O
novel	O
link	O
among	O
NADPH	B-geneN
oxidase	E-geneN
and	O
Stat3	S-geneY
signaling	O
,	O
mediated	O
by	O
Src	S-geneY
,	O
EGFR	S-geneY
,	O
and	O
Erk1	B-geneN
/	I-geneN
2	E-geneN
.	O

Cadmium	S-chem-C3-1
activates	O
NADPH	B-geneN-C3-2
oxidase	E-geneN-C3-2
.	O

ROS	O
produced	O
by	O
this	O
oxidase	S-geneN
activates	O
Src	S-geneY
,	O
enable	O
that	O
in	O
turn	O
,	O
transactivates	O
EGFR	S-geneY
that	O
activates	O
Stat3	S-geneY
in	O
tyrosine	S-chem
,	O
allowing	O
its	O
dimerization	O
.	O

Also	O
,	O
ROS	O
from	O
NADPH	B-geneN
oxidase	E-geneN
favors	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
activation	O
that	O
phosphorylates	O
Stat3	S-geneY
in	O
serine	S-chem
,	O
resulting	O
in	O
a	O
compensatory	O
or	O
adaptive	O
survival	O
response	O
such	O
as	O
production	O
of	O
metallothionein	B-geneY
-	I-geneY
II	E-geneY
in	O
short	O
Cd	S-chem
exposure	O
times	O
.	O

However	O
,	O
after	O
12h	O
CdCl2	S-chem-MU-1
treatment	O
,	O
cell	O
viability	O
diminished	O
in	O
50	O
%	O
,	O
accompanied	O
by	O
a	O
drastic	O
decrease	O
of	O
metallothionein	B-geneY-C4-2
-	I-geneY-C4-2
II	E-geneY-C4-2
production	O
,	O
and	O
an	O
increase	O
in	O
p53	S-geneY-C3-2
activation	O
and	O
the	O
pro	O
-	O
apoptotic	O
protein	O
Bax	S-geneY-C3-2
.	O

Molecular	O
characterization	O
of	O
the	O
surface	O
of	O
apoptotic	O
neutrophils	O
:	O
implications	O
for	O
functional	O
downregulation	O
and	O
recognition	O
by	O
phagocytes	O
.	O

We	O
have	O
used	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
and	O
lectins	S-geneN
to	O
examine	O
the	O
profile	O
of	O
surface	O
molecule	O
expression	O
on	O
human	O
neutrophils	O
that	O
have	O
undergone	O
spontaneous	O
apoptosis	O
during	O
in	O
vitro	O
culture	O
.	O

Neutrophil	O
apoptosis	O
was	O
found	O
to	O
be	O
accompanied	O
by	O
down	O
-	O
regulation	O
of	O
the	O
immunoglobulin	S-geneN
superfamily	O
members	O
PECAM	B-geneY
-	I-geneY
1	E-geneY
(	O
CD31	S-geneY
)	O
,	O
ICAM	B-geneY
-	I-geneY
3	E-geneY
(	O
CD50	S-geneY
)	O
,	O
CD66acde	S-geneN
,	O
and	O
CD66b	S-geneY
and	O
the	O
integrin	S-geneN
-	O
associated	O
proteins	O
CD63	S-geneY
and	O
urokinase	B-geneY
plasminogen	I-geneY
activator	I-geneY
receptor	E-geneY
(	O
CD87	S-geneY
)	O
that	O
may	O
alter	O
the	O
potential	O
for	O
adhesive	O
interactions	O
.	O

Cellular	O
interactions	O
may	O
be	O
further	O
influenced	O
by	O
the	O
reduction	O
of	O
the	O
expression	O
of	O
surface	O
carbohydrate	S-chem
moieties	O
,	O
including	O
sialic	B-chem
acid	E-chem
.	O

Reduced	O
expression	O
of	O
FcgammaRII	S-geneN
(	O
CD32	S-geneY
)	O
,	O
complement	B-geneY
receptor	I-geneY
type	I-geneY
1	E-geneY
(	O
CD35	S-geneY
)	O
and	O
receptors	O
for	O
pro	O
-	O
inflammatory	O
mediators	O
C5a	S-geneY
(	O
CD88	S-geneY
)	O
and	O
TNFalpha	S-geneY
(	O
CD120b	S-geneY
)	O
associated	O
with	O
apoptosis	O
might	O
limit	O
neutrophil	O
responsiveness	O
to	O
stimuli	O
that	O
trigger	O
degranulation	O
responses	O
.	O

Although	O
many	O
of	O
the	O
receptors	O
we	O
have	O
examined	O
are	O
expressed	O
at	O
reduced	O
levels	O
on	O
apoptotic	O
neutrophils	O
,	O
we	O
found	O
that	O
there	O
was	O
differential	O
loss	O
of	O
certain	O
receptors	O
(	O
e.g	O
.	O

CD16	S-geneY
,	O
CD15	S-geneY
and	O
CD120b	S-geneY
)	O
and	O
increased	O
expression	O
of	O
aminopeptidase	B-geneY
-	I-geneY
N	E-geneY
(	O
CD13	S-geneY
)	O
.	O

Together	O
with	O
our	O
previous	O
data	O
showing	O
that	O
expression	O
of	O
certain	O
molecules	O
e.g	O
.	O

LFA	B-geneY
-	I-geneY
3	E-geneY
(	O
CD58	S-geneY
)	O
is	O
not	O
altered	O
during	O
neutrophil	O
apoptosis	O
,	O
these	O
data	O
are	O
suggestive	O
of	O
specific	O
changes	O
in	O
receptor	O
mobilisation	O
and	O
shedding	O
associated	O
with	O
apoptosis	O
.	O

Although	O
reduced	O
expression	O
of	O
CD63	S-geneY
(	O
azurophilic	O
granules	O
)	O
and	O
CR1	S-geneY
(	O
specific	O
granules	O
)	O
indicates	O
that	O
granule	O
mobilisation	O
does	O
not	O
accompany	O
apoptosis	O
,	O
a	O
monoclonal	O
antibody	O
(	O
BOB78	O
)	O
,	O
that	O
recognises	O
a	O
90	O
kDa	O
antigen	O
localised	O
in	O
intracellular	O
granules	O
,	O
defines	O
a	O
subpopulation	O
of	O
apoptotic	O
neutrophils	O
that	O
exhibit	O
nuclear	O
degradation	O
yet	O
retain	O
intact	O
plasma	O
membranes	O
.	O

BOB78	O
positive	O
neutrophils	O
were	O
found	O
to	O
bind	O
biotinylated	O
thrombospondin	S-geneY
,	O
suggesting	O
that	O
this	O
mAb	O
defines	O
surface	O
molecular	O
changes	O
associated	O
with	O
exposure	O
of	O
thrombospondin	S-geneY
binding	O
moieties	O
.	O

Distal	O
bowel	O
selectivity	O
in	O
the	O
chemoprevention	O
of	O
experimental	O
colon	O
carcinogenesis	O
by	O
the	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drug	O
nabumetone	S-chem
.	O

Use	O
of	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
for	O
chemoprevention	O
of	O
colon	O
cancer	O
has	O
been	O
hindered	O
by	O
their	O
potential	O
gastro	O
-	O
intestinal	O
toxicity	O
.	O

Nabumetone	S-chem
,	O
which	O
is	O
approximately	O
10	O
to	O
36	O
times	O
safer	O
than	O
conventional	O
NSAIDs	O
,	O
was	O
evaluated	O
in	O
2	O
models	O
of	O
experimental	O
colon	O
carcinogenesis	O
.	O

In	O
azoxymethane	S-chem
(	O
AOM	S-chem
)	O
-	O
treated	O
Fisher	O
344	O
rats	O
,	O
nabumetone	S-chem
caused	O
dose	O
-	O
dependent	O
inhibition	O
of	O
aberrant	O
crypt	O
foci	O
(	O
ACF	O
)	O
,	O
with	O
750	O
and	O
1,500	O
ppm	O
resulting	O
in	O
15	O
%	O
and	O
37	O
%	O
reductions	O
,	O
respectively	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Moreover	O
,	O
complex	O
ACF	O
were	O
reduced	O
by	O
48	O
%	O
in	O
the	O
latter	O
group	O
.	O

MIN	O
mice	O
studies	O
confirmed	O
the	O
chemopreventive	O
efficacy	O
of	O
nabumetone	S-chem
,	O
with	O
900	O
ppm	O
suppressing	O
approximately	O
half	O
of	O
the	O
intestinal	O
tumors	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
intermediate	O
biomarkers	O
in	O
both	O
models	O
was	O
markedly	O
greater	O
in	O
the	O
distal	O
than	O
the	O
proximal	O
bowel	O
.	O

To	O
mechanistically	O
evaluate	O
this	O
regional	O
selectivity	O
,	O
we	O
assessed	O
cyclo	B-geneN-C3-2
-	I-geneN-C3-2
oxygenase	I-geneN-C3-2
-	I-geneN-C3-2
2	E-geneN-C3-2
(	O
COX	B-geneN-C3-2
-	I-geneN-C3-2
2	E-geneN-C3-2
)	O
expression	O
in	O
the	O
uninvolved	O
mucosa	O
and	O
demonstrated	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
excess	O
in	O
the	O
distal	O
relative	O
to	O
the	O
proximal	O
bowel	O
in	O
both	O
MIN	O
mice	O
and	O
AOM	S-chem-C3-1
-	O
treated	O
rats	O
.	O

We	O
then	O
investigated	O
another	O
putative	O
NSAID	O
target	O
,	O
peroxisome	B-geneN
proliferator	I-geneN
-	I-geneN
activated	I-geneN
receptor	I-geneN
-	I-geneN
delta	E-geneN
(	O
PPAR	B-geneN
-	I-geneN
delta	E-geneN
)	O
and	O
demonstrated	O
up	O
-	O
regulation	O
during	O
AOM	O
-	O
induced	O
colonic	O
tumorigenesis	O
.	O

Furthermore	O
,	O
in	O
pre	O
-	O
neoplastic	O
mucosa	O
,	O
there	O
was	O
a	O
3	O
-	O
fold	O
excess	O
of	O
PPAR	B-geneN
-	I-geneN
delta	E-geneN
in	O
the	O
distal	O
colon	O
.	O

We	O
demonstrate	O
that	O
nabumetone	S-chem
is	O
an	O
effective	O
protective	O
agent	O
in	O
both	O
experimental	O
models	O
of	O
colon	O
carcinogenesis	O
.	O

The	O
striking	O
distal	O
predilection	O
of	O
nabumetone	S-chem
may	O
be	O
,	O
at	O
least	O
partially	O
,	O
explained	O
by	O
distal	O
bowel	O
over	O
-	O
expression	O
of	O
COX	B-geneN
-	I-geneN
2	E-geneN
and	O
PPAR	B-geneN
-	I-geneN
delta	E-geneN
.	O

Unraveling	O
a	O
phosphorylation	O
event	O
in	O
a	O
folded	O
protein	O
by	O
NMR	O
spectroscopy	O
:	O
phosphorylation	O
of	O
the	O
Pin1	B-geneN
WW	I-geneN
domain	E-geneN
by	O
PKA	S-geneN
.	O

The	O
Pin1	S-geneY
protein	O
plays	O
a	O
critical	O
role	O
in	O
the	O
functional	O
regulation	O
of	O
the	O
hyperphosphorylated	O
neuronal	O
Tau	B-geneY
protein	E-geneY
in	O
Alzheimer	O
's	O
disease	O
and	O
is	O
by	O
itself	O
regulated	O
by	O
phosphorylation	O
.	O

We	O
have	O
used	O
Nuclear	O
Magnetic	O
Resonance	O
(	O
NMR	O
)	O
spectroscopy	O
to	O
both	O
identify	O
the	O
PKA	S-geneN
phosphorylation	O
site	O
in	O
the	O
Pin1	B-geneN
WW	I-geneN
domain	E-geneN
and	O
investigate	O
the	O
functional	O
consequences	O
of	O
this	O
phosphorylation	O
.	O

Detection	O
and	O
identification	O
of	O
phosphorylation	O
on	O
serine	S-chem
/	O
threonine	S-chem
residues	O
in	O
a	O
globular	O
protein	O
,	O
while	O
mostly	O
occurring	O
in	O
solvent	O
-	O
exposed	O
flexible	O
loops	O
,	O
does	O
not	O
lead	O
to	O
chemical	O
shift	O
changes	O
as	O
obvious	O
as	O
in	O
disordered	O
proteins	O
and	O
hence	O
does	O
not	O
necessarily	O
shift	O
the	O
resonances	O
outside	O
the	O
spectrum	O
of	O
the	O
folded	O
protein	O
.	O

Other	O
complications	O
were	O
encountered	O
to	O
characterize	O
the	O
extent	O
of	O
the	O
phosphorylation	O
,	O
as	O
part	O
of	O
the	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
,	O
(	B-chem
15	I-chem
)	I-chem
N	E-chem
amide	S-chem
resonances	O
around	O
the	O
phosphorylation	O
site	O
are	O
specifically	O
broadened	O
in	O
the	O
unphosphorylated	O
state	O
.	O

Despite	O
these	O
obstacles	O
,	O
NMR	O
spectroscopy	O
was	O
an	O
efficient	O
tool	O
to	O
confirm	O
phosphorylation	O
on	O
S16	O
of	O
the	O
WW	B-geneN
domain	E-geneN
and	O
to	O
quantify	O
the	O
level	O
of	O
phosphorylation	O
.	O

Based	O
on	O
this	O
analytical	O
characterization	O
,	O
we	O
show	O
that	O
WW	S-geneN
phosphorylation	O
on	O
S16	O
abolishes	O
its	O
binding	O
capacity	O
to	O
a	O
phosphorylated	B-geneY
Tau	I-geneY
peptide	E-geneY
.	O

A	O
reduced	O
conformational	O
heterogeneity	O
and	O
flexibility	O
of	O
the	O
phospho	S-chem
-	O
binding	O
loop	O
upon	O
S16	O
phosphorylation	O
could	O
account	O
for	O
part	O
of	O
the	O
decreased	O
affinity	O
for	O
its	O
phosphorylated	O
partner	O
.	O

Additionally	O
,	O
a	O
structural	O
model	O
of	O
the	O
phospho	B-geneN
-	I-geneN
WW	E-geneN
obtained	O
by	O
molecular	O
dynamics	O
simulation	O
and	O
energy	O
minimization	O
suggests	O
that	O
the	O
phosphate	S-chem
moiety	O
of	O
phospho	S-chem
-	O
S16	O
could	O
compete	O
with	O
the	O
phospho	S-chem
-	O
substrate	O
.	O

Differential	O
modulation	O
of	O
retinal	O
ganglion	O
cell	O
light	O
responses	O
by	O
orthosteric	O
and	O
allosteric	O
metabotropic	B-geneY
glutamate	I-geneY
receptor	I-geneY
8	E-geneY
compounds	O
.	O

To	O
investigate	O
the	O
role	O
of	O
mGluR8	S-geneY
in	O
modulating	O
the	O
synaptic	O
responses	O
of	O
retinal	O
ganglion	O
cells	O
,	O
we	O
used	O
a	O
recently	O
identified	O
positive	O
allosteric	O
modulator	O
of	O
mGluR8	S-geneY
,	O
AZ12216052	S-chem
(	O
AZ	O
)	O
and	O
the	O
mGluR8	S-geneY-C5-2
-	O
specific	O
orthosteric	O
agonist	O
(	B-chem-C5-1
S	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
3,4	I-chem-C5-1
-	I-chem-C5-1
dicarboxyphenylglycine	E-chem-C5-1
(	O
DCPG	S-chem-C5-1
)	O
.	O

These	O
agents	O
were	O
applied	O
to	O
whole	O
-	O
cell	O
voltage	O
-	O
clamped	O
ganglion	O
cells	O
from	O
an	O
isolated	O
,	O
superfused	O
mouse	O
retina	O
preparation	O
.	O

DCPG	S-chem
reduced	O
OFF	O
-	O
ganglion	O
cell	O
excitatory	O
currents	O
,	O
whereas	O
AZ	O
enhanced	O
the	O
peak	O
excitatory	O
currents	O
in	O
ON	O
-	O
,	O
OFF	O
-	O
,	O
and	O
ON	O
-	O
OFF	O
-	O
ganglion	O
cells	O
.	O

The	O
effects	O
on	O
ganglion	O
cell	O
inhibitory	O
currents	O
were	O
more	O
varied	O
.	O

The	O
effects	O
of	O
the	O
allosteric	O
modulator	O
were	O
stronger	O
for	O
bright	O
stimuli	O
than	O
for	O
dim	O
stimuli	O
,	O
consistent	O
with	O
receptor	O
stimulation	O
by	O
endogenous	O
glutamate	S-chem
being	O
stronger	O
during	O
bright	O
light	O
stimulation	O
and	O
with	O
mGluR8	S-geneY
receptors	O
mainly	O
being	O
localized	O
away	O
from	O
glutamate	S-chem
release	O
sites	O
,	O
immuno	O
-	O
labeled	O
with	O
VGLUT1	S-geneY
.	O

The	O
differential	O
sensitivity	O
of	O
ganglion	O
cell	O
light	O
responses	O
to	O
DCPG	S-chem
and	O
AZ	O
supports	O
multiple	O
sites	O
where	O
mGluR8	S-geneY
modulates	O
the	O
light	O
responses	O
of	O
ganglion	O
cells	O
.	O

The	O
characteristics	O
of	O
genistin	S-chem
-	O
induced	O
inhibitory	O
effects	O
on	O
intestinal	O
motility	O
.	O

Genistin	S-chem
belongs	O
to	O
isoflavones	S-chem
.	O

Based	O
on	O
the	O
facts	O
that	O
genistin	S-chem
exerts	O
inhibitory	O
effects	O
on	O
the	O
contractility	O
of	O
vascular	O
smooth	O
muscle	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
effects	O
of	O
genistin	S-chem
on	O
intestinal	O
contractility	O
and	O
evaluate	O
its	O
potential	O
clinical	O
implication	O
.	O

Ex	O
vivo	O
[	O
isolated	O
jejunal	O
segment	O
(	O
IJS	O
)	O
of	O
rat	O
]	O
,	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
assays	O
were	O
used	O
in	O
the	O
study	O
.	O

The	O
results	O
indicated	O
that	O
genistin	S-chem
(	O
5	O
-	O
80	O
μmol	O
/	O
L	O
)	O
inhibited	O
the	O
contraction	O
of	O
IJS	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
inhibited	O
the	O
increased	O
-	O
contractility	O
of	O
IJS	O
induced	O
by	O
acetylcholine	S-chem
(	O
ACh	S-chem
)	O
,	O
histamine	S-chem
,	O
high	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
and	O
erythromycin	S-chem
,	O
respectively	O
.	O

The	O
inhibitory	O
effects	O
of	O
genistin	S-chem
were	O
correlated	O
with	O
the	O
stimulation	O
of	O
alpha	B-geneN
adrenergic	I-geneN
and	I-geneN
beta	I-geneN
adrenergic	I-geneN
receptors	E-geneN
since	O
these	O
inhibitory	O
effects	O
were	O
significantly	O
blocked	O
in	O
the	O
presence	O
of	O
phentolamine	S-chem
and	O
propranolol	S-chem
respectively	O
.	O

No	O
further	O
inhibitory	O
effects	O
of	O
genistin	S-chem
were	O
observed	O
in	O
the	O
presence	O
of	O
verapamil	S-chem
or	O
in	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
free	O
condition	O
,	O
indicating	O
genistin	S-chem
-	O
induced	O
inhibitory	O
effects	O
are	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
.	O

Genistin	S-chem-C4-1
decreased	O
myosin	B-geneY-C4-2
light	I-geneY-C4-2
chain	I-geneY-C4-2
kinase	E-geneY-C4-2
(	O
MLCK	S-geneY-C4-2
)	O
protein	O
contents	O
and	O
MLCK	S-geneY-C4-2
mRNA	O
expression	O
in	O
IJS	O
,	O
and	O
inhibited	O
both	O
phosphorylation	O
and	O
Mg	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
ATPase	S-geneN-C4-2
activity	O
of	O
purified	O
myosin	O
,	O
implicating	O
that	O
the	O
decrease	O
of	O
MLCK	S-geneY-C4-2
contents	O
and	O
inhibition	O
of	O
MLCK	S-geneY-C4-2
activity	O
are	O
involved	O
in	O
the	O
genistin	S-chem-C4-1
-	O
induced	O
inhibitory	O
effects	O
.	O

The	O
study	O
suggests	O
the	O
potential	O
clinical	O
implications	O
of	O
genistin	S-chem
in	O
relieving	O
intestinal	O
hypercontractility	O
.	O

A	O
naloxone	B-chem-C6-1
-	I-chem-C6-1
steroid	I-chem-C6-1
hybrid	I-chem-C6-1
azine	E-chem-C6-1
with	O
selective	O
and	O
long	O
-	O
acting	O
opioid	O
antagonism	O
at	O
delta	B-geneY-C6-2
receptors	E-geneY-C6-2
in	O
vitro	O
.	O

The	O
interaction	O
of	O
naloxone	B-chem
estrone	I-chem
azine	E-chem
(	O
N	B-chem
-	I-chem
EH	E-chem
)	O
with	O
various	O
opioid	B-geneN
receptor	E-geneN
types	O
was	O
studied	O
in	O
vitro	O
.	O

Its	O
potency	O
as	O
an	O
antagonist	O
of	O
opioid	O
effects	O
was	O
compared	O
to	O
that	O
of	O
naloxone	S-chem
on	O
the	O
electrically	O
evoked	O
contractions	O
of	O
mouse	O
vas	O
deferens	O
(	O
Mvd	O
)	O
and	O
guinea	O
pig	O
ileum	O
myenteric	O
plexus	O
longitudinal	O
muscle	O
(	O
Gpi	O
)	O
preparations	O
.	O

N	B-chem
-	I-chem
EH	E-chem
was	O
found	O
to	O
be	O
9	O
-	O
fold	O
more	O
potent	O
than	O
naloxone	S-chem
in	O
antagonizing	O
the	O
effects	O
of	O
D	B-chem
-	I-chem
Ala2	I-chem
-	I-chem
Leu5	I-chem
-	I-chem
enkephalin	E-chem
in	O
the	O
Mvd	O
and	O
22	O
-	O
fold	O
less	O
potent	O
in	O
antagonizing	O
normorphine	S-chem
in	O
the	O
Gpi	O
.	O

In	O
the	O
Mvd	O
,	O
the	O
recovery	O
half	O
-	O
time	O
for	O
N	B-chem
-	I-chem
EH	E-chem
was	O
longer	O
than	O
1000	O
min	O
.	O

Neither	O
compound	O
showed	O
agonism	O
.	O

The	O
two	O
compounds	O
were	O
also	O
compared	O
for	O
their	O
capacity	O
to	O
displace	O
the	O
binding	O
of	O
3H	B-chem
-	I-chem
D	I-chem
-	I-chem
Ala2	I-chem
-	I-chem
Leu5	I-chem
-	I-chem
enkephalin	E-chem
,	O
3H	B-chem
-	I-chem
dihydromorphine	E-chem
,	O
and	O
3H	B-chem
-	I-chem
ethylketocyclazocine	E-chem
to	O
rat	O
brain	O
membranes	O
under	O
conditions	O
where	O
delta	O
,	O
mu	O
,	O
and	O
kappa	O
sites	O
were	O
labeled	O
.	O

The	O
relative	O
affinities	O
were	O
0.70	O
,	O
0.16	O
,	O
and	O
0.14	O
for	O
N	B-chem
-	I-chem
EH	E-chem
and	O
0.05	O
,	O
0.87	O
,	O
and	O
0.08	O
for	O
naloxone	S-chem
,	O
respectively	O
.	O

Thus	O
,	O
compared	O
to	O
naloxone	S-chem
,	O
which	O
is	O
mu	O
selective	O
,	O
N	B-chem
-	I-chem
EH	E-chem
is	O
a	O
delta	O
-	O
selective	O
antagonist	O
.	O

Iodine	B-chem
-	I-chem
129	E-chem
microdosing	O
for	O
protein	O
and	O
peptide	O
drug	O
development	O
:	O
erythropoietin	S-geneY
as	O
a	O
case	O
study	O
.	O

BACKGROUND	O
:	O
Microdosing	O
is	O
a	O
technique	O
for	O
studying	O
the	O
behavior	O
of	O
compounds	O
in	O
vivo	O
at	O
1	O
/	O
100th	O
of	O
the	O
dose	O
of	O
a	O
test	O
substance	O
calculated	O
,	O
based	O
on	O
animal	O
data	O
,	O
to	O
yield	O
a	O
pharmacologic	O
effect	O
.	O

In	O
microdosing	O
,	O
use	O
is	O
made	O
of	O
accelerator	O
MS	O
(	O
AMS	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
(	B-chem
129	I-chem
)	I-chem
I	E-chem
-	O
labeling	O
of	O
proteins	O
with	O
subsequent	O
AMS	O
measurements	O
is	O
a	O
suitable	O
method	O
to	O
perform	O
microdose	O
studies	O
with	O
therapeutic	O
proteins	O
.	O

We	O
used	O
erythropoietin	S-geneY
(	O
EPO	S-geneY
)	O
as	O
a	O
case	O
study	O
.	O

RESULTS	O
:	O
In	O
an	O
animal	O
study	O
with	O
(	B-chem
129	I-chem
)	I-chem
I	E-chem
-	O
labeled	O
EPO	S-geneY
in	O
Han	O
-	O
Wistar	O
rats	O
,	O
an	O
increase	O
of	O
(	B-chem
129	I-chem
)	I-chem
I	E-chem
-	O
EPO	S-geneY
is	O
observed	O
after	O
dose	O
administration	O
.	O

The	O
half	O
-	O
life	O
was	O
found	O
to	O
be	O
2	O
and	O
5.5	O
h	O
for	O
two	O
different	O
EPOs	S-geneY
.	O

These	O
results	O
are	O
in	O
accordance	O
with	O
expected	O
values	O
.	O

CoNCLUSION	O
:	O
Although	O
further	O
research	O
is	O
required	O
,	O
(	B-chem
129	I-chem
)	I-chem
I	E-chem
-	O
labeling	O
of	O
proteins	O
seems	O
a	O
feasible	O
method	O
for	O
AMS	O
microdose	O
studies	O
with	O
peptide	O
and	O
protein	O
drugs	O
,	O
such	O
as	O
biosimilars	O
.	O

Antizyme	B-geneN
inhibitor	E-geneN
is	O
rapidly	O
induced	O
in	O
growth	O
-	O
stimulated	O
mouse	O
fibroblasts	O
and	O
releases	O
ornithine	B-geneY
decarboxylase	E-geneY
from	O
antizyme	S-geneN
suppression	O
.	O

Ornithine	B-geneY-C9-2
decarboxylase	E-geneY-C9-2
(	O
ODC	S-geneY-C9-2
)	O
catalyses	O
the	O
first	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
polyamines	O
putrescine	S-chem-C9-1
,	O
spermidine	S-chem-C9-1
and	O
spermine	S-chem-C9-1
.	O

The	O
polyamines	O
are	O
essential	O
for	O
cell	O
growth	O
,	O
but	O
at	O
elevated	O
levels	O
they	O
may	O
be	O
tumorigenic	O
,	O
toxic	O
,	O
or	O
may	O
induce	O
apoptosis	O
.	O

Therefore	O
,	O
ODC	S-geneY
activity	O
is	O
highly	O
regulated	O
.	O

It	O
is	O
induced	O
when	O
cells	O
are	O
stimulated	O
to	O
grow	O
,	O
and	O
it	O
is	O
subjected	O
to	O
feedback	O
inhibition	O
by	O
the	O
polyamines	O
.	O

By	O
causing	O
ribosomal	O
frameshifting	O
,	O
polyamines	O
induce	O
the	O
synthesis	O
of	O
antizyme	S-geneN
,	O
a	O
23	O
-	O
kDa	O
protein	O
,	O
which	O
binds	O
to	O
ODC	S-geneY
,	O
inhibits	O
its	O
activity	O
and	O
promotes	O
its	O
degradation	O
by	O
the	O
26	B-geneN
S	I-geneN
proteasome	E-geneN
.	O

Antizyme	S-geneN
,	O
in	O
turn	O
,	O
is	O
inhibited	O
by	O
antizyme	B-geneN
inhibitor	E-geneN
(	O
AZI	S-geneN
)	O
.	O

We	O
describe	O
the	O
cloning	O
of	O
a	O
mouse	B-geneN
AZI	E-geneN
cDNA	O
,	O
encoding	O
a	O
protein	O
with	O
high	O
homology	O
to	O
mouse	B-geneY
ODC	E-geneY
.	O

Using	O
purified	O
recombinant	O
proteins	O
,	O
we	O
show	O
that	O
AZI	S-geneN
(	O
which	O
has	O
no	O
ODC	S-geneY
activity	O
)	O
can	O
release	O
enzymically	O
active	O
ODC	S-geneY
from	O
antizyme	S-geneN
suppression	O
in	O
vitro	O
.	O

We	O
also	O
show	O
that	O
ODC	S-geneY
reactivation	O
takes	O
place	O
in	O
mouse	O
fibroblasts	O
upon	O
transient	O
transfection	O
with	O
an	O
AZI	S-geneN
-	O
expressing	O
plasmid	O
construct	O
.	O

Finally	O
we	O
demonstrate	O
that	O
the	O
AZI	S-geneN
mRNA	O
content	O
of	O
mouse	O
fibroblasts	O
increases	O
significantly	O
within	O
an	O
hour	O
of	O
growth	O
stimulation	O
,	O
i.e	O
.	O
much	O
earlier	O
than	O
ODC	S-geneY
transcripts	O
.	O

Our	O
results	O
indicate	O
that	O
induction	O
of	O
AZI	S-geneN
synthesis	O
may	O
represent	O
a	O
means	O
of	O
rescuing	O
ODC	S-geneY
molecules	O
that	O
have	O
been	O
inactivated	O
and	O
tagged	O
for	O
degradation	O
by	O
antizyme	S-geneN
,	O
when	O
culture	O
conditions	O
improve	O
and	O
polyamine	O
production	O
is	O
needed	O
for	O
cell	O
growth	O
and	O
proliferation	O
.	O

Pancreatic	O
β	O
-	O
Cell	O
Dysfunction	O
and	O
Risk	O
of	O
New	O
-	O
Onset	O
Diabetes	O
After	O
Kidney	O
Transplantation	O
.	O

OBJECTIVEChronic	O
exposure	O
to	O
calcineurin	S-geneN
inhibitors	O
and	O
corticosteroids	O
poses	O
renal	O
transplant	O
recipients	O
(	O
RTR	O
)	O
at	O
high	O
risk	O
for	O
development	O
of	O
new	O
-	O
onset	O
diabetes	O
after	O
transplantation	O
(	O
NODAT	O
)	O
.	O

Pancreatic	O
β	O
-	O
cell	O
dysfunction	O
may	O
be	O
crucial	O
to	O
the	O
pathophysiology	O
of	O
NODAT	O
and	O
specific	O
markers	O
for	O
β	O
-	O
cell	O
dysfunction	O
may	O
have	O
additive	O
value	O
for	O
predicting	O
NODAT	O
in	O
this	O
population	O
.	O

Therefore	O
,	O
we	O
prospectively	O
investigated	O
whether	O
proinsulin	S-geneY
,	O
as	O
a	O
marker	O
of	O
pancreatic	O
β	O
-	O
cell	O
dysfunction	O
,	O
is	O
associated	O
with	O
future	O
development	O
of	O
NODAT	O
and	O
improves	O
prediction	O
of	O
it.RESEARCH	O
DESIGN	O
AND	O
METHODSAll	O
RTR	O
between	O
2001	O
and	O
2003	O
with	O
a	O
functioning	O
graft	O
for	O
≥	O
1	O
year	O
were	O
considered	O
eligible	O
for	O
inclusion	O
,	O
except	O
for	O
subjects	O
with	O
diabetes	O
at	O
baseline	O
who	O
were	O
excluded	O
.	O

We	O
recorded	O
incidence	O
of	O
NODAT	O
until	O
April	O
2012.RESULTSA	O
total	O
of	O
487	O
RTR	O
(	O
age	O
50	O
±	O
12	O
years	O
,	O
55	O
%	O
men	O
)	O
participated	O
at	O
a	O
median	O
time	O
of	O
6.0	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
,	O
2.6	O
-	O
11.5	O
)	O
years	O
after	O
transplantation	O
.	O

Median	O
fasting	O
proinsulin	S-geneY
levels	O
were	O
16.6	O
(	O
IQR	O
,	O
11.0	O
-	O
24.2	O
)	O
pmol	O
/	O
L	O
.	O

During	O
median	O
follow	O
-	O
up	O
for	O
10.1	O
(	O
IQR	O
,	O
9.1	O
-	O
10.4	O
)	O
years	O
,	O
42	O
(	O
35	O
%	O
)	O
RTR	O
had	O
development	O
of	O
NODAT	O
in	O
the	O
highest	O
quartile	O
of	O
the	O
distribution	O
of	O
proinsulin	S-geneY
versus	O
34	O
(	O
9	O
%	O
)	O
in	O
the	O
lowest	O
three	O
quartiles	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
Cox	O
regression	O
analyses	O
,	O
proinsulin	S-geneY
(	O
hazard	O
ratio	O
,	O
2.29	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.85	O
-	O
2.83	O
;	O
P	O
<	O
0.001	O
)	O
was	O
strongly	O
associated	O
with	O
NODAT	O
development	O
.	O

This	O
was	O
independent	O
of	O
age	O
,	O
sex	O
,	O
calcineurine	S-geneN
inhibitors	O
,	O
prednisolone	S-chem
use	O
,	O
components	O
of	O
the	O
metabolic	O
syndrome	O
,	O
or	O
homeostasis	O
model	O
assessment.CONCLUSIONSIn	O
conclusion	O
,	O
fasting	O
proinsulin	S-geneY
is	O
strongly	O
associated	O
with	O
NODAT	O
development	O
in	O
RTR	O
.	O

Our	O
results	O
highlight	O
the	O
role	O
of	O
β	O
-	O
cell	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
NODAT	O
and	O
indicate	O
the	O
potential	O
value	O
of	O
proinsulin	S-geneY
for	O
identification	O
of	O
RTR	O
at	O
increased	O
risk	O
for	O
NODAT	O
.	O

Caffeic	B-chem-C4-1
Acid	I-chem-C4-1
Phenethyl	I-chem-C4-1
Ester	E-chem-C4-1
Suppresses	O
Proliferation	O
and	O
Survival	O
of	O
TW2.6	O
Human	O
Oral	O
Cancer	O
Cells	O
via	O
Inhibition	O
of	O
Akt	S-geneN-C4-2
Signaling	O
.	O

Caffeic	B-chem
acid	I-chem
phenethyl	I-chem
ester	E-chem
(	O
CAPE	S-chem
)	O
is	O
a	O
bioactive	O
component	O
extracted	O
from	O
honeybee	O
hive	O
propolis	O
.	O

Our	O
observations	O
indicated	O
that	O
CAPE	S-chem
treatment	O
suppressed	O
cell	O
proliferation	O
and	O
colony	O
formation	O
of	O
TW2.6	O
human	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
cells	O
dose	O
-	O
dependently	O
.	O

CAPE	S-chem
treatment	O
decreased	O
G1	O
phase	O
cell	O
population	O
,	O
increased	O
G2	O
/	O
M	O
phase	O
cell	O
population	O
,	O
and	O
induced	O
apoptosis	O
in	O
TW2.6	O
cells	O
.	O

Treatment	O
with	O
CAPE	S-chem-MU-1
decreased	O
protein	O
abundance	O
of	O
Akt	S-geneN-C4-2
,	O
Akt1	S-geneY-C4-2
,	O
Akt2	S-geneY-C4-2
,	O
Akt3	S-geneY-C4-2
,	O
phospho	B-geneN-C4-2
-	I-geneN-C4-2
Akt	E-geneN-C4-2
Ser473	S-chem
,	O
phospho	B-geneN-C4-2
-	I-geneN-C4-2
Akt	E-geneN-C4-2
Thr	O
308	O
,	O
GSK3β	S-geneY-C4-2
,	O
FOXO1	S-geneY-C4-2
,	O
FOXO3a	S-geneY-C4-2
,	O
phospho	B-geneY-C4-2
-	I-geneY-C4-2
FOXO1	E-geneY-C4-2
Thr24	O
,	O
phospho	B-geneY-C4-2
-	I-geneY-C4-2
FoxO3a	E-geneY-C4-2
Thr32	O
,	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
,	O
phospho	B-geneN-C4-2
-	I-geneN-C4-2
NF	I-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
Ser536	O
,	O
Rb	S-geneY-C4-2
,	O
phospho	B-geneY-C4-2
-	I-geneY-C4-2
Rb	E-geneY-C4-2
Ser807	S-chem
/	O
811	O
,	O
Skp2	S-geneY-C4-2
,	O
and	O
cyclin	B-geneY-C4-2
D1	E-geneY-C4-2
,	O
but	O
increased	O
cell	O
cycle	O
inhibitor	O
p27Kip	S-geneY-C3-2
.	O

Overexpression	O
of	O
Akt1	S-geneY
or	O
Akt2	S-geneY
in	O
TW2.6	O
cells	O
rescued	O
growth	O
inhibition	O
caused	O
by	O
CAPE	S-chem
treatment	O
.	O

Co	O
-	O
treating	O
TW2.6	O
cells	O
with	O
CAPE	S-chem
and	O
5	B-chem
-	I-chem
fluorouracil	E-chem
,	O
a	O
commonly	O
used	O
chemotherapeutic	O
drug	O
for	O
oral	O
cancers	O
,	O
exhibited	O
additive	O
cell	O
proliferation	O
inhibition	O
.	O

Our	O
study	O
suggested	O
that	O
administration	O
of	O
CAPE	S-chem
is	O
a	O
potential	O
adjuvant	O
therapy	O
for	O
patients	O
with	O
OSCC	O
oral	O
cancer	O
.	O

Degradation	O
of	O
submandibular	O
gland	O
AQP5	S-geneY-C3-2
by	O
parasympathetic	O
denervation	O
of	O
chorda	O
tympani	O
and	O
its	O
recovery	O
by	O
cevimeline	S-chem-MU-1
,	O
an	O
M3	B-geneY-C5-2
muscarinic	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
.	O

By	O
chorda	O
tympani	O
denervation	O
(	O
CTD	O
,	O
parasympathectomy	O
)	O
,	O
the	O
aquaporin	B-geneY
5	E-geneY
(	O
AQP5	S-geneY
)	O
,	O
but	O
not	O
AQP1	S-geneY
,	O
protein	O
level	O
in	O
the	O
rat	O
submandibular	O
gland	O
(	O
SMG	O
)	O
was	O
significantly	O
decreased	O
,	O
dropping	O
to	O
37	O
%	O
of	O
that	O
of	O
the	O
contralateral	O
gland	O
at	O
4	O
wk	O
.	O

The	O
protein	O
levels	O
of	O
AQP5	S-geneY
and	O
AQP1	S-geneY
were	O
not	O
significantly	O
affected	O
by	O
denervation	O
of	O
the	O
cervical	O
sympathetic	O
trunk	O
(	O
sympathectomy	O
)	O
.	O

Administration	O
of	O
cevimeline	B-chem-MU-1
hydrochloride	E-chem-MU-1
,	O
an	O
M3	B-geneY-C5-2
muscarinic	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
(	O
10	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
but	O
not	O
pilocarpine	S-chem
(	O
0.3	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
recovered	O
the	O
AQP5	S-geneY-C3-2
protein	O
level	O
reduced	O
by	O
CTD	O
and	O
increased	O
the	O
AQP1	S-geneY-C3-2
protein	O
level	O
above	O
the	O
control	O
one	O
.	O

The	O
mRNA	O
level	O
of	O
AQP5	S-geneY
was	O
scarcely	O
affected	O
by	O
CTD	O
and	O
cevimeline	B-chem
hydrochloride	E-chem
administration	O
.	O

Administration	O
of	O
chloroquine	S-chem-C3-1
(	O
50	O
mg	O
/	O
kg	O
for	O
7	O
days	O
po	O
)	O
,	O
a	O
denaturant	O
of	O
lysosomes	O
,	O
increased	O
the	O
AQP5	S-geneY-C3-2
protein	O
level	O
reduced	O
by	O
CTD	O
.	O

An	O
extract	O
obtained	O
from	O
the	O
submandibular	O
lysosomal	O
fraction	O
degraded	O
the	O
AQP5	S-geneY
protein	O
in	O
the	O
total	O
membrane	O
fraction	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
regulation	O
of	O
the	O
AQP5	S-geneY
protein	O
level	O
in	O
the	O
SMG	O
by	O
the	O
parasympathetic	O
nerves	O
/	O
M3	B-geneY
muscarinic	I-geneY
receptor	E-geneY
agonist	O
and	O
imply	O
the	O
involvement	O
of	O
lysosomal	O
enzymes	O
,	O
but	O
not	O
a	O
transcriptional	O
mechanism	O
,	O
in	O
this	O
regulation	O
.	O

Synthesis	O
and	O
dual	O
biological	O
effects	O
of	O
hydroxycinnamoyl	B-chem-C4-1
phenylalanyl	E-chem-C4-1
/	O
prolyl	B-chem-C4-1
hydroxamic	I-chem-C4-1
acid	E-chem-C4-1
derivatives	O
as	O
tyrosinase	S-geneY-C4-2
inhibitor	O
and	O
antioxidant	O
.	O

We	O
previously	O
reported	O
that	O
caffeoyl	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
acidyl	I-chem-C4-1
-	I-chem-C4-1
hydroxamic	I-chem-C4-1
acid	E-chem-C4-1
(	O
CA	B-chem-C4-1
-	I-chem-C4-1
Xaa	I-chem-C4-1
-	I-chem-C4-1
NHOH	E-chem-C4-1
)	O
acted	O
as	O
both	O
a	O
good	O
antioxidant	O
and	O
tyrosinase	S-geneY-C4-2
inhibitor	O
,	O
in	O
particular	O
when	O
caffeic	B-chem
acid	E-chem
was	O
conjugated	O
with	O
proline	S-chem
or	O
amino	B-chem
acids	E-chem
having	O
aromatic	O
ring	O
like	O
phenylalanine	S-chem
.	O

Here	O
,	O
various	O
hydroxycinnamic	B-chem
acid	E-chem
(	O
HCA	S-chem
)	O
derivatives	O
were	O
further	O
conjugated	O
with	O
phenylalanyl	B-chem
hydroxamic	I-chem
acid	E-chem
and	O
prolyl	B-chem
hydroxamic	I-chem
acid	E-chem
(	O
HCA	B-chem
-	I-chem
Phe	I-chem
-	I-chem
NHOH	E-chem
and	O
HCA	B-chem
-	I-chem
Pro	I-chem
-	I-chem
NHOH	E-chem
)	O
to	O
study	O
the	O
structure	O
and	O
activity	O
relationship	O
as	O
both	O
antioxidants	O
and	O
tyrosinase	S-geneY
inhibitors	O
.	O

When	O
their	O
biological	O
activities	O
were	O
evaluated	O
,	O
all	O
HCA	B-chem
-	I-chem
Phe	I-chem
-	I-chem
NHOH	E-chem
and	O
HCA	B-chem
-	I-chem
Pro	I-chem
-	I-chem
NHOH	E-chem
exhibited	O
enhanced	O
antioxidant	O
activity	O
compared	O
to	O
HCA	S-chem
alone	O
.	O

Moreover	O
,	O
derivatives	O
of	O
caffeic	B-chem
acid	E-chem
,	O
ferulic	B-chem
acid	E-chem
,	O
and	O
sinapic	B-chem
acid	E-chem
inhibited	O
lipid	O
peroxidation	O
more	O
efficiently	O
than	O
vitamin	B-chem
E	E-chem
analogue	O
(	O
Trolox	S-chem
)	O
.	O

In	O
addition	O
,	O
derivatives	O
of	O
caffeic	B-chem-C4-1
acid	E-chem-C4-1
and	O
sinapic	B-chem-C4-1
acid	E-chem-C4-1
efficiently	O
inhibited	O
tyrosinase	S-geneY-C4-2
activity	O
and	O
reduced	O
melanin	O
content	O
in	O
melanocytes	O
Mel	O
-	O
Ab	O
cell	O
.	O

Effect	O
of	O
developmental	O
dioxin	S-chem
exposure	O
on	O
methylation	O
and	O
expression	O
of	O
specific	O
imprinted	O
genes	O
in	O
mice	O
.	O

2,3,7,8	B-chem
-	I-chem
Tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
is	O
an	O
endocrine	O
disruptor	O
affecting	O
the	O
reproductive	O
system	O
in	O
humans	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
TCDD	S-chem
administered	O
to	O
pregnant	O
mice	O
at	O
two	O
different	O
doses	O
(	O
2	O
-	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
,	O
on	O
imprinted	O
genes	O
in	O
the	O
male	O
offspring	O
.	O

The	O
degree	O
of	O
methylation	O
and	O
the	O
mRNA	O
expression	O
of	O
Snrpn	S-geneY
,	O
Peg3	S-geneY
and	O
Igf2r	S-geneY
were	O
analyzed	O
in	O
the	O
sperm	O
,	O
skeletal	O
muscle	O
and	O
liver	O
.	O

TCDD	S-chem
administration	O
(	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
decreased	O
the	O
sperm	O
count	O
in	O
the	O
male	O
offspring	O
.	O

It	O
did	O
not	O
affect	O
methylation	O
but	O
increased	O
mRNA	O
expression	O
of	O
Snrpn	S-geneY
,	O
Peg3	S-geneY
,	O
Igf2r	S-geneY
and	O
Air	B-geneY
ncRNA	E-geneY
.	O

In	O
muscle	O
and	O
liver	O
,	O
TCDD	S-chem-C4-1
(	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
induced	O
increases	O
in	O
methylation	O
and	O
decreases	O
in	O
mRNA	O
expression	O
of	O
Igf2r	S-geneY-C4-2
.	O

These	O
results	O
show	O
that	O
the	O
robust	O
effects	O
of	O
TCDD	S-chem
on	O
the	O
mRNA	O
expression	O
of	O
Snrpn	S-geneY
,	O
Peg3	S-geneY
and	O
Igf2r	S-geneY
genes	O
in	O
the	O
sperm	O
and	O
of	O
Igf2r	S-geneY
in	O
the	O
muscle	O
and	O
liver	O
are	O
unrelated	O
to	O
changes	O
in	O
methylation	O
in	O
their	O
respective	O
genes	O
.	O

Occupancy	O
of	O
dopamine	S-chem
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
,	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
serotonin	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
receptors	E-geneY
in	O
schizophrenic	O
patients	O
treated	O
with	O
flupentixol	S-chem
in	O
comparison	O
with	O
risperidone	S-chem
and	O
haloperidol	S-chem
.	O

RATIONALE	O
:	O
Flupentixol	S-chem
(	O
FLX	S-chem
)	O
has	O
been	O
used	O
as	O
a	O
neuroleptic	O
for	O
nearly	O
4	O
decades	O
.	O

In	O
vitro	O
data	O
show	O
comparable	O
affinity	O
to	O
dopamine	B-geneY
D	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
,	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
and	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
receptors	E-geneY
and	O
recently	O
,	O
FLX	S-chem
showed	O
to	O
be	O
not	O
inferior	O
to	O
risperidone	S-chem
in	O
schizophrenic	O
patients	O
with	O
predominant	O
negative	O
symptomatology	O
,	O
which	O
was	O
implicated	O
with	O
flupentixol	O
's	O
interaction	O
with	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
and	O
/	O
or	O
D	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptors	E-geneY
.	O

OBJECTIVES	O
:	O
To	O
assess	O
in	O
vivo	O
receptor	O
occupancy	O
(	O
RO	O
)	O
in	O
patients	O
clinically	O
treated	O
with	O
FLX	O
(	O
n	O
=	O
13	O
,	O
5.7	O
+	O
/	O
-	O
1.4	O
mg	O
/	O
day	O
)	O
in	O
comparison	O
with	O
risperidone	S-chem
(	O
RIS	O
,	O
n	O
=	O
11	O
,	O
3.6	O
+	O
/	O
-	O
1.3	O
mg	O
/	O
day	O
)	O
and	O
haloperidol	S-chem
(	O
HAL	O
,	O
n	O
=	O
11	O
,	O
8.5	O
+	O
/	O
-	O
5.5	O
mg	O
/	O
day	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Each	O
patient	O
underwent	O
two	O
PET	O
scans	O
with	O
3	B-chem
-	I-chem
N	I-chem
-	I-chem
[	I-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
methylspiperone	E-chem
(	O
target	O
:	O
frontal	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
)	O
,	O
[	B-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
SCH23390	E-chem
(	O
striatal	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
)	O
or	O
[	B-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
raclopride	E-chem
(	O
striatal	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
)	O
.	O

RO	O
was	O
calculated	O
as	O
the	O
percentage	O
reduction	O
of	O
specific	O
binding	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
-	O
RO	O
under	O
FLX	O
was	O
between	O
50	O
%	O
and	O
70	O
%	O
,	O
indicating	O
an	O
ED	O
(	O
50	O
)	O
of	O
about	O
0.7	O
ng	O
/	O
ml	O
serum	O
.	O

5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
and	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
-	O
RO	O
was	O
20	O
+	O
/	O
-	O
10	O
%	O
and	O
20	O
+	O
/	O
-	O
5	O
%	O
(	O
mean	O
,	O
SEM	O
)	O
.	O

Under	O
HAL	O
,	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
-	O
RO	O
was	O
14	O
+	O
/	O
-	O
6	O
%	O
and	O
under	O
RIS	O
not	O
significantly	O
different	O
from	O
zero	O
.	O

CONCLUSIONS	O
:	O
We	O
were	O
able	O
to	O
demonstrate	O
a	O
moderate	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
and	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
occupancy	O
under	O
clinically	O
relevant	O
doses	O
of	O
flupentixol	S-chem
,	O
albeit	O
lower	O
than	O
expected	O
from	O
in	O
vitro	O
data	O
and	O
clearly	O
below	O
saturation	O
.	O

Therefore	O
,	O
if	O
flupentixol	O
's	O
efficacy	O
on	O
negative	O
symptoms	O
is	O
based	O
on	O
its	O
interaction	O
with	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
and	O
/	O
or	O
D	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptors	E-geneY
,	O
it	O
should	O
be	O
highly	O
dependent	O
on	O
serum	O
concentration	O
and	O
thus	O
on	O
dosage	O
and	O
metabolism	O
.	O

However	O
,	O
these	O
data	O
suggest	O
that	O
mechanisms	O
other	O
than	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
or	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
antagonism	O
may	O
contribute	O
to	O
flupentixol	O
's	O
efficacy	O
on	O
negative	O
symptoms	O
.	O

Narirutin	S-chem
fraction	O
from	O
citrus	O
peels	O
attenuates	O
alcoholic	O
liver	O
disease	O
in	O
mice	O
.	O

This	O
study	O
aimed	O
to	O
demonstrate	O
protective	O
activities	O
of	O
the	O
narirutin	S-chem
fraction	O
from	O
peels	O
of	O
Citrus	O
unshiu	O
against	O
ethanol	S-chem
-	O
induced	O
hepatic	O
damage	O
through	O
an	O
animal	O
study	O
.	O

Citrus	O
narirutin	S-chem
fraction	O
(	O
CNF	O
)	O
,	O
contained	O
75	O
%	O
of	O
narirutin	S-chem
,	O
was	O
obtained	O
by	O
an	O
ultra	O
-	O
sonicated	O
extraction	O
and	O
further	O
purification	O
.	O

ICR	O
mice	O
were	O
divided	O
into	O
four	O
groups	O
;	O
normaldiet	O
control	O
,	O
ethanol	S-chem
control	O
(	O
6.5g	O
ethanol	S-chem
/	O
kg	O
)	O
,	O
low	O
-	O
CNF	O
(	O
ethanol	S-chem
+	O
150mg	O
CNF	O
/	O
kg	O
)	O
and	O
high	O
-	O
CNF	O
(	O
ethanol	S-chem
+	O
300mg	O
CNF	O
/	O
kg	O
)	O
groups	O
.	O

Consumption	O
of	O
alcohol	S-chem-C3-1
for	O
8weeks	O
induced	O
severe	O
liver	O
damage	O
with	O
increases	O
in	O
prognostic	O
indicators	O
such	O
as	O
aspartate	B-geneN-C3-2
transaminase	E-geneN-C3-2
,	O
alanine	B-geneN-C3-2
transaminase	E-geneN-C3-2
in	O
serum	O
whereas	O
co	O
-	O
administration	O
of	O
CNF	O
suppressed	O
their	O
increases	O
.	O

Excessive	O
accumulations	O
in	O
liver	O
TG	O
and	O
TC	O
in	O
ethanol	S-chem
control	O
group	O
were	O
also	O
suppressed	O
by	O
co	O
-	O
administration	O
of	O
CNF	O
.	O

Co	O
-	O
administration	O
of	O
CNF	O
maintained	O
SOD	S-geneN
activity	O
,	O
GSH	S-chem
and	O
malondialdehyde	S-chem
levels	O
close	O
to	O
those	O
of	O
the	O
normal	O
diet	O
group	O
.	O

Chronic	O
consumption	O
of	O
alcohol	S-chem-C3-1
also	O
stimulated	O
abrupt	O
increases	O
in	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
nuclear	B-geneN-C3-2
factor	I-geneN-C3-2
(	I-geneN-C3-2
NF	I-geneN-C3-2
)	I-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
,	O
tumor	B-geneY-C3-2
necrosis	I-geneY-C3-2
factor	I-geneY-C3-2
(	I-geneY-C3-2
TNF	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
α	E-geneY-C3-2
and	O
interleukin	B-geneY-C3-2
(	I-geneY-C3-2
IL	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
1β	E-geneY-C3-2
in	O
liver	O
otherwise	O
co	O
-	O
administration	O
of	O
CNF	O
effectively	O
suppressed	O
production	O
of	O
these	O
cytokines	S-geneN
dose	O
-	O
dependently	O
.	O

These	O
results	O
indicate	O
that	O
co	O
-	O
administration	O
of	O
CNF	O
with	O
alcohol	S-chem
can	O
alleviate	O
alcohol	S-chem
induced	O
liver	O
damage	O
through	O
preventing	O
lipid	O
formation	O
,	O
protecting	O
antioxidant	O
system	O
and	O
suppressing	O
productions	O
of	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN
.	O

Rescue	O
of	O
platinum	S-chem
-	O
damaged	O
oocytes	O
from	O
programmed	O
cell	O
death	O
through	O
inactivation	O
of	O
the	O
p53	S-geneY
family	O
signaling	O
network	O
.	O

Non	O
-	O
proliferating	O
oocytes	O
within	O
avascular	O
regions	O
of	O
the	O
ovary	O
are	O
exquisitely	O
susceptible	O
to	O
chemotherapy	O
.	O

Early	O
menopause	O
and	O
sterility	O
are	O
unintended	O
consequences	O
of	O
chemotherapy	O
,	O
and	O
efforts	O
to	O
understand	O
the	O
oocyte	O
apoptotic	O
pathway	O
may	O
provide	O
new	O
targets	O
for	O
mitigating	O
this	O
outcome	O
.	O

Recently	O
,	O
the	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Abl	E-geneY-C4-2
kinase	S-geneN-C4-2
inhibitor	O
imatinib	B-chem-C4-1
mesylate	E-chem-C4-1
(	O
imatinib	S-chem-C4-1
)	O
has	O
become	O
the	O
focus	O
of	O
research	O
as	O
a	O
fertoprotective	O
drug	O
against	O
cisplatin	S-chem
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
imatinib	S-chem
protects	O
oocytes	O
is	O
not	O
fully	O
understood	O
,	O
and	O
reports	O
of	O
the	O
drug	O
's	O
efficacy	O
have	O
been	O
contradictory	O
.	O

Using	O
in	O
vitro	O
culture	O
and	O
subrenal	O
grafting	O
of	O
mouse	O
ovaries	O
,	O
we	O
demonstrated	O
that	O
imatinib	S-chem
inhibits	O
the	O
cisplatin	S-chem
-	O
induced	O
apoptosis	O
of	O
oocytes	O
within	O
primordial	O
follicles	O
.	O

We	O
found	O
that	O
,	O
before	O
apoptosis	O
,	O
cisplatin	S-chem-C3-1
induces	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Abl	E-geneY-C3-2
and	O
TAp73	S-geneY-C3-2
expression	O
in	O
the	O
oocyte	O
.	O

Oocytes	O
undergoing	O
apoptosis	O
showed	O
downregulation	O
of	O
TAp63	S-geneY
and	O
upregulation	O
of	O
Bax	S-geneY
.	O

While	O
imatinib	S-chem
was	O
unable	O
to	O
block	O
cisplatin	S-chem-C3-1
-	O
induced	O
DNA	O
damage	O
and	O
damage	O
response	O
,	O
such	O
as	O
the	O
upregulation	O
of	O
p53	S-geneY-C3-2
,	O
imatinib	S-chem-MU-1
inhibited	O
the	O
cisplatin	S-chem-MU-1
-	O
induced	O
nuclear	O
accumulation	O
of	O
c	B-geneY-MU-2
-	I-geneY-MU-2
Abl	E-geneY-MU-2
/	O
TAp73	S-geneY-MU-2
and	O
the	O
subsequent	O
downregulation	O
of	O
TAp63	S-geneY-MU-2
and	O
upregulation	O
of	O
Bax	S-geneY-MU-2
,	O
thereby	O
abrogating	O
oocyte	O
cell	O
death	O
.	O

Surprisingly	O
,	O
the	O
conditional	O
deletion	O
of	O
Trp63	S-geneY
,	O
but	O
not	O
Δ	B-geneY
Np63	E-geneY
,	O
in	O
oocytes	O
inhibited	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
accumulation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Abl	E-geneY-C3-2
and	O
TAp73	S-geneY-C3-2
caused	O
by	O
cisplatin	S-chem-C3-1
.	O

These	O
data	O
suggest	O
that	O
TAp63	S-geneY
is	O
the	O
master	O
regulator	O
of	O
cisplatin	S-chem
-	O
induced	O
oocyte	O
death	O
.	O

The	O
expression	O
kinetics	O
of	O
TAp63	S-geneY
,	O
c	B-geneY
-	I-geneY
Abl	E-geneY
and	O
TAp73	S-geneY
suggest	O
that	O
cisplatin	S-chem-C3-1
activates	O
TAp63	S-geneY-C3-2
-	O
dependent	O
expression	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Abl	E-geneY-C3-2
and	O
TAp73	S-geneY-C3-2
and	O
,	O
in	O
turn	O
,	O
the	O
activation	O
of	O
TAp73	S-geneY-C3-2
by	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Abl	E-geneY-C3-2
-	O
induced	O
BAX	S-geneY-C3-2
expression	O
.	O

Our	O
findings	O
indicate	O
that	O
imatinib	S-chem-MU-1
protects	O
oocytes	O
from	O
cisplatin	S-chem-C3-1
-	O
induced	O
cell	O
death	O
by	O
inhibiting	O
c	B-geneY-MU-2
-	I-geneY-MU-2
Abl	E-geneY-MU-2
kinase	S-geneN-C3-2
,	O
which	O
would	O
otherwise	O
activate	O
TAp73	S-geneY-MU-2
-	O
BAX	S-geneY-MU-2
-	O
mediated	O
apoptosis	O
.	O

Thus	O
,	O
imatinib	S-chem-C4-1
and	O
other	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Abl	E-geneY-C4-2
kinase	S-geneN-C4-2
inhibitors	O
provide	O
an	O
intriguing	O
new	O
way	O
to	O
halt	O
cisplatin	S-chem
-	O
induced	O
oocyte	O
death	O
in	O
early	O
follicles	O
and	O
perhaps	O
conserve	O
the	O
endocrine	O
function	O
of	O
the	O
ovary	O
against	O
chemotherapy.Cell	O
Death	O
and	O
Differentiation	O
advance	O
online	O
publication	O
,	O
19	O
April	O
2013	O
;	O
doi	O
:	O
10.1038	O
/	O
cdd.2013.31	O
.	O

Recent	O
developments	O
in	O
the	O
synthesis	O
of	O
acetylcholinesterase	S-geneY
inhibitors	O
.	O

The	O
acetylcholinesterase	S-geneY-C4-2
(	O
AChE	S-geneY-C4-2
)	O
and	O
butyrylcholinesterase	S-geneY-C4-2
(	O
BuChE	S-geneY-C4-2
)	O
inhibitory	O
activities	O
of	O
a	O
series	O
of	O
pyrano	B-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
quinolines	E-chem-C4-1
(	O
2	O
,	O
3	O
)	O
,	O
[	B-chem-C4-1
1,8	I-chem-C4-1
]	I-chem-C4-1
naphthyridines	E-chem-C4-1
(	O
5	O
,	O
6	O
)	O
,	O
4	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
diaryl	I-chem-C4-1
-	I-chem-C4-1
5,6,7,8	I-chem-C4-1
-	I-chem-C4-1
tetrahydrofuro	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
quinolines	E-chem-C4-1
(	O
11	O
-	O
13	O
)	O
/	O
4	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
6,7,8,9	I-chem-C4-1
-	I-chem-C4-1
tetrahydro	I-chem-C4-1
-	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
diphenyl	I-chem-C4-1
-	I-chem-C4-1
5H	I-chem-C4-1
-	I-chem-C4-1
cyclohepta	I-chem-C4-1
[	I-chem-C4-1
e	I-chem-C4-1
]	I-chem-C4-1
furo	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyridine	E-chem-C4-1
(	O
14	O
)	O
,	O
4	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
5,6,7,8	I-chem-C4-1
-	I-chem-C4-1
tetrahydro	I-chem-C4-1
-	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
diphenylthieno	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
quinoline	E-chem-C4-1
(	O
15	O
)	O
/	O
4	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
6,7,8,9	I-chem-C4-1
-	I-chem-C4-1
tetrahydro	I-chem-C4-1
-	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
diphenyl	I-chem-C4-1
-	I-chem-C4-1
5H	I-chem-C4-1
-	I-chem-C4-1
cyclohepta	I-chem-C4-1
[	I-chem-C4-1
e	I-chem-C4-1
]	I-chem-C4-1
thieno	I-chem-C4-1
[	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyridine	E-chem-C4-1
(	O
16	O
)	O
are	O
described	O
.	O

These	O
compounds	O
are	O
tacrine	S-chem
analogues	O
that	O
have	O
been	O
prepared	O
from	O
readily	O
available	O
polyfunctionalized	O
ethyl	B-chem
[	I-chem
6	I-chem
-	I-chem
amino	I-chem
-	I-chem
5	I-chem
-	I-chem
cyano	I-chem
-	I-chem
4H	I-chem
-	I-chem
pyran	I-chem
]	I-chem
-	I-chem
3	I-chem
-	I-chem
carboxylates	E-chem
(	O
9	O
,	O
10	O
)	O
,	O
ethyl	B-chem
[	I-chem
6	I-chem
-	I-chem
amino	I-chem
-	I-chem
5	I-chem
-	I-chem
cyanopyridine	I-chem
]	I-chem
-	I-chem
3	I-chem
-	I-chem
carboxylates	E-chem
(	O
7	O
,	O
8	O
)	O
,	O
2	B-chem
-	I-chem
amino	I-chem
-	I-chem
3	I-chem
-	I-chem
cyano	I-chem
-	I-chem
4,5	I-chem
-	I-chem
diarylfurans	E-chem
(	O
17	O
-	O
19	O
)	O
and	O
2	B-chem
-	I-chem
amino	I-chem
-	I-chem
3	I-chem
-	I-chem
cyano	I-chem
-	I-chem
4,5	I-chem
-	I-chem
diphenylthiophene	E-chem
(	O
20	O
)	O
via	O
Friedlander	O
condensation	O
with	O
selected	O
ketones	S-chem
.	O

These	O
compounds	O
are	O
competitive	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
non	O
-	O
competitive	O
inhibitors	O
for	O
AChE	S-geneY-C4-2
,	O
the	O
most	O
potent	O
being	O
compound	O
(	O
14	O
)	O
,	O
though	O
three	O
-	O
fold	O
less	O
active	O
than	O
tacrine	S-chem-C4-1
.	O

The	O
BuChE	S-geneY-C4-2
inhibitory	O
activity	O
is	O
only	O
significant	O
in	O
compounds	O
11	O
and	O
14	O
,	O
ten	O
-	O
fold	O
less	O
active	O
than	O
tacrine	S-chem-C4-1
.	O

Furthermore	O
,	O
the	O
products	O
12	O
and	O
13	O
are	O
selective	O
and	O
moderate	O
AChE	S-geneY
inhibitors	O
.	O

Na	B-chem
+	E-chem
/	O
Ca2	B-chem
+	E-chem
exchange	O
inhibitors	O
:	O
a	O
new	O
class	O
of	O
calcium	S-chem
regulators	O
.	O

The	O
Na	B-geneN-C9-2
(	I-geneN-C9-2
+	I-geneN-C9-2
)	I-geneN-C9-2
/	I-geneN-C9-2
Ca	I-geneN-C9-2
(	I-geneN-C9-2
2	I-geneN-C9-2
+	I-geneN-C9-2
)	I-geneN-C9-2
exchanger	E-geneN-C9-2
(	O
NCX	S-geneN
)	O
is	O
a	O
bidirectional	O
transporter	O
that	O
normally	O
extrudes	O
Ca	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
from	O
the	O
cell	O
(	O
forward	O
mode	O
)	O
,	O
but	O
also	O
brings	O
Ca	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
+	I-chem-C9-1
)	E-chem-C9-1
into	O
the	O
cell	O
(	O
reverse	O
mode	O
)	O
under	O
special	O
conditions	O
such	O
as	O
intracellular	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
i	O
)	O
)	O
accumulation	O
or	O
membrane	O
depolarization	O
.	O

There	O
are	O
three	O
mammalian	B-geneN
NCX	E-geneN
isoforms	O
:	O
NCX1	S-geneY
is	O
widely	O
expressed	O
in	O
the	O
heart	O
,	O
kidney	O
,	O
brain	O
,	O
blood	O
vessels	O
,	O
and	O
so	O
on	O
;	O
whereas	O
the	O
expression	O
of	O
NCX2	S-geneY
and	O
NCX3	S-geneY
is	O
limited	O
mainly	O
to	O
the	O
brain	O
and	O
skeletal	O
muscle	O
.	O

The	O
pharmacology	O
of	O
NCX	S-geneN
inhibitors	O
has	O
been	O
studied	O
extensively	O
since	O
the	O
development	O
of	O
KB	B-chem-C4-1
-	I-chem-C4-1
R7943	E-chem-C4-1
,	O
a	O
prototype	O
benzyloxyphenyl	S-chem-C4-1
NCX	S-geneN-C4-2
inhibitor	O
,	O
in	O
1996	O
.	O

Currently	O
,	O
experiments	O
are	O
actively	O
progressing	O
with	O
more	O
selective	O
inhibitors	O
:	O
SEA0400	S-chem
,	O
SN	B-chem
-	I-chem
6	E-chem
,	O
and	O
YM	B-chem
-	I-chem
244769	E-chem
.	O

Intriguingly	O
,	O
the	O
inhibitory	O
potency	O
of	O
benzyloxyphenyl	S-chem-C4-1
NCX	S-geneN-C4-2
inhibitors	O
is	O
directly	O
coupled	O
to	O
the	O
rate	O
of	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
i	O
)	O
-	O
dependent	O
inactivation	O
.	O

Therefore	O
,	O
the	O
benzyloxyphenyl	S-chem
inhibitors	O
are	O
apparently	O
dormant	O
during	O
the	O
forward	O
mode	O
under	O
normal	O
conditions	O
(	O
low	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
i	O
)	O
)	O
,	O
but	O
become	O
effective	O
during	O
the	O
reverse	O
mode	O
under	O
pathological	O
conditions	O
(	O
high	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
i	O
)	O
)	O
.	O

This	O
should	O
be	O
an	O
ideal	O
profile	O
for	O
calcium	S-chem
regulators	O
against	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
(	O
i	O
)	O
-	O
related	O
diseases	O
,	O
such	O
as	O
ischemia	O
/	O
reperfusion	O
injuries	O
,	O
salt	O
-	O
dependent	O
hypertension	O
,	O
and	O
digitalis	O
arrhythmia	O
.	O

Existing	O
ion	B-geneN-C4-2
channel	E-geneN-C4-2
blockers	O
,	O
such	O
as	O
amiodarone	S-chem-C4-1
,	O
dronedarone	S-chem-C4-1
,	O
bepridil	S-chem-C4-1
,	O
aprindine	S-chem-C4-1
,	O
and	O
cibenzoline	S-chem-C4-1
,	O
have	O
been	O
found	O
to	O
have	O
an	O
NCX	S-geneN-C4-2
inhibitory	O
action	O
.	O

It	O
is	O
possible	O
that	O
this	O
property	O
is	O
partly	O
responsible	O
for	O
their	O
antiarrhythmic	O
and	O
cardioprotective	O
effects	O
.	O

This	O
article	O
presents	O
the	O
characteristics	O
of	O
selective	O
and	O
non	O
-	O
selective	O
NCX	S-geneN
inhibitors	O
and	O
their	O
therapeutic	O
potential	O
as	O
a	O
new	O
calcium	S-chem
regulator	O
.	O

Zinc	S-chem
drives	O
a	O
tertiary	O
fold	O
in	O
the	O
prion	B-geneN
protein	E-geneN
with	O
familial	O
disease	O
mutation	O
sites	O
at	O
the	O
interface	O
.	O

The	O
cellular	O
prion	B-geneY
protein	I-geneY
PrP	I-geneY
(	I-geneY
C	I-geneY
)	E-geneY
consists	O
of	O
two	O
domains	O
-	O
-	O
a	O
flexible	O
N	S-chem
-	O
terminal	O
domain	O
,	O
which	O
participates	O
in	O
copper	S-chem
and	O
zinc	S-chem
regulation	O
,	O
and	O
a	O
largely	O
helical	O
C	S-chem
-	O
terminal	O
domain	O
that	O
converts	O
to	O
β	O
sheet	O
in	O
the	O
course	O
of	O
prion	O
disease	O
.	O

These	O
two	O
domains	O
are	O
thought	O
to	O
be	O
fully	O
independent	O
and	O
noninteracting	O
.	O

Compelling	O
cellular	O
and	O
biophysical	O
studies	O
,	O
however	O
,	O
suggest	O
a	O
higher	O
order	O
structure	O
that	O
is	O
relevant	O
to	O
both	O
PrP	B-geneY
(	I-geneY
C	I-geneY
)	E-geneY
function	O
and	O
misfolding	O
in	O
disease	O
.	O

Here	O
,	O
we	O
identify	O
a	O
Zn²	B-chem
⁺	E-chem
-	O
driven	O
N	S-chem
-	O
terminal	O
to	O
C	S-chem
-	O
terminal	O
tertiary	O
interaction	O
in	O
PrP	B-geneY
(	I-geneY
C	I-geneY
)	E-geneY
.	O

The	O
C	S-chem
-	O
terminal	O
surface	O
participating	O
in	O
this	O
interaction	O
carries	O
the	O
majority	O
of	O
the	O
point	O
mutations	O
that	O
confer	O
familial	O
prion	O
disease	O
.	O

Investigation	O
of	O
mutant	O
PrPs	S-geneN
finds	O
a	O
systematic	O
relationship	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
apparent	O
strength	O
of	O
this	O
domain	O
structure	O
.	O

The	O
structural	O
features	O
identified	O
here	O
suggest	O
mechanisms	O
by	O
which	O
physiologic	O
metal	O
ions	O
trigger	O
PrP	B-geneY
(	I-geneY
C	I-geneY
)	E-geneY
trafficking	O
and	O
control	O
prion	O
disease	O
.	O

Biochemical	O
assessments	O
of	O
total	O
antioxidant	O
status	O
in	O
active	O
and	O
nonactive	O
female	O
adults	O
with	O
intellectual	O
disability	O
.	O

Long	O
-	O
term	O
physical	O
activity	O
is	O
known	O
to	O
increase	O
the	O
antioxidant	O
defense	O
(	O
AOD	O
)	O
system	O
,	O
whereas	O
sedentary	O
lifestyle	O
is	O
associated	O
with	O
oxidative	O
stress	O
(	O
OS	O
)	O
.	O

The	O
underlying	O
molecular	O
mechanisms	O
are	O
incompletely	O
understood	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
,	O
nonrandomized	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
the	O
relationship	O
between	O
long	O
-	O
term	O
physical	O
activity	O
and	O
inactivity	O
and	O
plasma	O
antioxidant	O
status	O
in	O
female	O
adults	O
with	O
intellectual	O
disability	O
(	O
ID	O
)	O
that	O
were	O
diagnosed	O
after	O
birth	O
.	O

A	O
total	O
of	O
21	O
adults	O
with	O
ID	O
were	O
examined	O
.	O

The	O
following	O
AOD	O
was	O
examined	O
:	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
,	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GPX	S-geneN
)	O
,	O
vitamin	B-chem
E	E-chem
,	O
and	O
vitamin	B-chem
A	E-chem
.	O

Inactive	O
persons	O
with	O
ID	O
had	O
significantly	O
lower	O
SOD	S-geneN
(	O
p	O
<	O
0.05	O
)	O
,	O
CAT	S-geneY
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
GPX	S-geneN
(	O
p	O
<	O
0.05	O
)	O
.	O

All	O
plasma	O
vitamin	O
levels	O
were	O
significantly	O
higher	O
in	O
physically	O
active	O
subjects	O
(	O
vitamin	B-chem
A	E-chem
:	O
1.42	O
+	O
/	O
-	O
0.05	O
mmol	O
/	O
l	O
,	O
vitamin	B-chem
E	E-chem
:	O
31.32	O
+	O
/	O
-	O
2.62	O
mmol	O
/	O
l	O
)	O
than	O
in	O
sedentary	O
control	O
subjects	O
(	O
vitamin	B-chem
A	E-chem
:	O
1.02	O
+	O
/	O
-	O
0.03	O
mmol	O
/	O
l	O
,	O
vitamin	B-chem
E	E-chem
:	O
18.88	O
+	O
/	O
-	O
2.23	O
mmol	O
/	O
l	O
)	O
p	O
<	O
0.01	O
.	O

These	O
results	O
suggest	O
that	O
regular	O
physical	O
activity	O
is	O
associated	O
with	O
preserved	O
AODs	O
in	O
adults	O
with	O
ID	O
.	O

As	O
opposed	O
to	O
a	O
physically	O
active	O
lifestyle	O
,	O
an	O
inactive	O
results	O
in	O
low	O
levels	O
of	O
antioxidants	O
.	O

Selective	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
does	O
not	O
affect	O
the	O
healing	O
of	O
cutaneous	O
full	O
-	O
thickness	O
incisional	O
wounds	O
in	O
SKH	O
-	O
1	O
mice	O
.	O

BACKGROUND	O
:	O
The	O
inducible	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
enzyme	O
is	O
upregulated	O
in	O
inflammatory	O
diseases	O
,	O
as	O
well	O
as	O
in	O
epithelial	O
cancers	O
,	O
and	O
has	O
an	O
established	O
role	O
in	O
angiogenesis	O
and	O
tissue	O
repair	O
.	O

OBJECTIVE	O
:	O
Because	O
of	O
these	O
physiological	O
effects	O
and	O
the	O
widespread	O
use	O
of	O
the	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
celecoxib	S-chem-C4-1
,	O
we	O
wanted	O
to	O
determine	O
if	O
inhibition	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
would	O
affect	O
incisional	O
skin	O
wound	O
healing	O
.	O

METHODS	O
:	O
Using	O
a	O
cutaneous	O
full	O
-	O
thickness	O
,	O
sutured	O
,	O
incisional	O
wound	O
model	O
in	O
hairless	O
SKH	O
-	O
1	O
mice	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
in	O
the	O
wound	O
healing	O
process	O
by	O
comparing	O
the	O
effects	O
of	O
a	O
nonselective	O
COX	S-geneN-C4-2
inhibitor	O
,	O
diclofenac	S-chem-C4-1
,	O
with	O
a	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
,	O
SC	O
-	O
791	O
.	O

Healing	O
was	O
monitored	O
for	O
up	O
to	O
28	O
days	O
postincision	O
histologically	O
and	O
for	O
recovery	O
of	O
wound	O
strength	O
.	O

RESULTS	O
:	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
was	O
observed	O
over	O
the	O
first	O
week	O
of	O
healing	O
,	O
peaking	O
at	O
day	O
3	O
and	O
was	O
not	O
affected	O
by	O
treatment	O
with	O
the	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
or	O
nonselective	O
COX	S-geneN
inhibitors	O
.	O

Infiltrating	O
macrophages	O
,	O
as	O
well	O
as	O
keratinocytes	O
and	O
dermal	O
fibroblasts	O
at	O
the	O
wound	O
site	O
,	O
expressed	O
COX	B-geneY
-	I-geneY
2	E-geneY
.	O

Neither	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
,	O
nor	O
nonselective	O
COX	S-geneN
inhibition	O
had	O
a	O
significant	O
effect	O
on	O
the	O
macroscopic	O
or	O
microscopic	O
morphology	O
of	O
the	O
wounds	O
,	O
whereas	O
dexamethasone	S-chem
treatment	O
resulted	O
in	O
epidermal	O
and	O
granulation	O
tissue	O
atrophy	O
.	O

In	O
addition	O
,	O
neither	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
,	O
nor	O
nonselective	O
COX	S-geneN
inhibition	O
altered	O
keratinocyte	O
proliferation	O
and	O
differentiation	O
,	O
dermal	O
angiogenesis	O
or	O
the	O
recovery	O
of	O
wound	O
tensile	O
strength	O
,	O
whereas	O
dexamethasone	S-chem
reduced	O
the	O
tensile	O
strength	O
of	O
the	O
wounds	O
by	O
30	O
-	O
38	O
%	O
throughout	O
the	O
healing	O
period	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
does	O
not	O
affect	O
the	O
healing	O
of	O
surgical	O
skin	O
wounds	O
.	O

Anti	O
-	O
inflammatory	O
effects	O
of	O
an	O
aqueous	O
extract	O
of	O
Welsh	O
onion	O
green	O
leaves	O
in	O
mice	O
.	O

The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
an	O
aqueous	O
extract	O
of	O
Welsh	O
onion	O
green	O
leaves	O
(	O
WOE	O
)	O
in	O
mice	O
was	O
investigated	O
.	O

Administration	O
of	O
WOE	O
,	O
in	O
the	O
range	O
of	O
0.25	O
-	O
1g	O
/	O
kg	O
,	O
showed	O
a	O
concentration	O
dependent	O
inhibition	O
on	O
paw	O
edema	O
development	O
after	O
carrageenan	O
treatment	O
in	O
mice	O
.	O

The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
WOE	O
were	O
closely	O
attributed	O
to	O
decreased	O
levels	O
of	O
tissue	O
NO	S-chem
and	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
α	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
.	O

Further	O
evidence	O
for	O
WOE	O
's	O
protection	O
is	O
shown	O
in	O
the	O
reduction	O
of	O
lipid	O
oxidation	O
and	O
the	O
increase	O
of	O
antioxidant	O
enzyme	O
activities	O
,	O
including	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
,	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
and	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GPX	S-geneN
)	O
in	O
vivo	O
.	O

Further	O
,	O
WOE	O
also	O
decreased	O
the	O
number	O
of	O
acetic	B-chem
acid	E-chem
-	O
induced	O
writhing	O
responses	O
and	O
formalin	S-chem
-	O
induced	O
pain	O
in	O
the	O
late	O
phase	O
in	O
mice	O
.	O

Overall	O
,	O
the	O
results	O
showed	O
that	O
WOE	O
might	O
serve	O
as	O
a	O
natural	O
source	O
of	O
anti	O
-	O
inflammatory	O
compounds	O
.	O

Activation	O
of	O
the	O
α7	B-geneY
nicotinic	I-geneY
ACh	I-geneY
receptor	E-geneY
induces	O
anxiogenic	O
effects	O
in	O
rats	O
which	O
is	O
blocked	O
by	O
a	O
5	B-geneY
-	I-geneY
HT1a	E-geneY
receptor	O
antagonist	O
.	O

The	O
α7	B-geneY
nicotinic	I-geneY
acetylcholine	I-geneY
receptor	E-geneY
(	O
nAChR	S-geneN
)	O
is	O
highly	O
expressed	O
in	O
different	O
regions	O
of	O
the	O
brain	O
and	O
is	O
associated	O
with	O
cognitive	O
function	O
as	O
well	O
as	O
anxiety	O
.	O

Agonists	O
and	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
of	O
the	O
α7	B-geneY
subtype	I-geneY
of	I-geneY
nAChRs	E-geneY
have	O
been	O
shown	O
to	O
improve	O
cognition	O
.	O

Previously	O
nicotine	S-chem
,	O
which	O
activates	O
both	O
α7	B-geneN
and	I-geneN
non	I-geneN
-	I-geneN
α7	I-geneN
subtypes	I-geneN
of	I-geneN
nAChRs	E-geneN
,	O
has	O
been	O
shown	O
to	O
have	O
an	O
anxiogenic	O
effect	O
in	O
behavioral	O
tests	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
effects	O
of	O
the	O
α7	O
-	O
selective	O
agonist	O
(	O
PNU	B-chem
-	I-chem
282987	E-chem
)	O
and	O
PAM	O
(	O
PNU	B-chem
-	I-chem
120596	E-chem
)	O
in	O
a	O
variety	O
of	O
behavioral	O
tests	O
in	O
Sprague	O
Dawley	O
rats	O
to	O
look	O
at	O
their	O
effects	O
on	O
learning	O
and	O
memory	O
as	O
well	O
as	O
anxiety	O
.	O

We	O
found	O
that	O
neither	O
PNU	B-chem
-	I-chem
282987	E-chem
nor	O
PNU	B-chem
-	I-chem
120596	E-chem
improved	O
spatial	O
-	O
learning	O
or	O
episodic	O
memory	O
by	O
themselves	O
.	O

However	O
when	O
cognitive	O
impairment	O
was	O
induced	O
in	O
the	O
rats	O
with	O
scopolamine	S-chem
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
both	O
PNU	O
-	I-chem
120596	I-chem
and	O
PNU	O
-	I-chem
282987	I-chem
were	O
able	O
to	O
reverse	O
this	O
memory	O
impairment	O
and	O
restore	O
it	O
back	O
to	O
normal	O
levels	O
.	O

While	O
PNU	B-chem
-	I-chem
120596	E-chem
reversed	O
the	O
scopolamine	O
-	O
induced	O
cognitive	O
impairment	O
,	O
it	O
did	O
not	O
have	O
any	O
adverse	O
effect	O
on	O
anxiety	O
.	O

PNU	B-chem
-	I-chem
282987	E-chem
on	O
the	O
other	O
hand	O
displayed	O
an	O
increase	O
in	O
anxiety	O
-	O
like	O
behavior	O
at	O
a	O
higher	O
dose	O
(	O
10	O
mg	O
/	O
kg	O
)	O
that	O
was	O
significantly	O
reduced	O
by	O
the	O
serotonin	O
5	I-geneY-C6-2
-	I-geneY-C6-2
HT1a	I-geneY-C6-2
receptor	I-geneY-C6-2
antagonist	O
WAY	O
-	I-chem-C6-1
100135	I-chem-C6-1
.	E-chem-C6-1

However	O
the	O
α7	B-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
methyllycaconitine	S-chem-C6-1
was	O
unable	O
to	O
reverse	O
these	O
anxiety	O
-	O
like	O
effects	O
seen	O
with	O
PNU	B-chem
-	I-chem
282987	E-chem
.	O

These	O
results	O
suggest	O
that	O
α7	B-geneY
nAChR	E-geneY
PAMs	O
are	O
pharmacologically	O
advantageous	O
over	O
agonists	O
,	O
and	O
should	O
be	O
considered	O
for	O
further	O
development	O
as	O
therapeutic	O
drugs	O
targeting	O
the	O
α7	B-geneY
receptors	E-geneY
.	O

The	O
use	O
of	O
insulin	S-geneY
analogues	O
in	O
pregnancy	O
.	O

Excellent	O
glycaemic	O
control	O
is	O
essential	O
in	O
pregnancy	O
to	O
optimise	O
maternal	O
and	O
foetal	O
outcomes	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
insulin	S-geneY
analogues	O
in	O
pregnancy	O
.	O

Insulin	S-geneY
lispro	O
and	O
insulin	S-geneY
aspart	O
are	O
safe	O
in	O
pregnancy	O
and	O
may	O
improve	O
post	O
-	O
prandial	O
glycaemic	O
control	O
in	O
women	O
with	O
type	O
1	O
diabetes	O
.	O

However	O
,	O
a	O
lack	O
of	O
data	O
indicating	O
improved	O
foetal	O
outcomes	O
would	O
suggest	O
that	O
there	O
is	O
no	O
imperative	O
to	O
switch	O
to	O
a	O
short	O
-	O
acting	O
analogue	O
where	O
the	O
woman	O
's	O
diabetes	O
is	O
well	O
controlled	O
with	O
human	B-geneY
insulin	E-geneY
.	O

There	O
are	O
no	O
reports	O
of	O
the	O
use	O
of	O
insulin	S-geneY
glulisine	O
in	O
pregnancy	O
and	O
so	O
its	O
use	O
can	O
not	O
be	O
recommended	O
.	O

Most	O
studies	O
of	O
insulin	S-geneY
glargine	O
in	O
pregnancy	O
are	O
small	O
,	O
retrospective	O
and	O
include	O
women	O
with	O
pre	O
-	O
existing	O
diabetes	O
and	O
gestational	O
diabetes	O
.	O

There	O
appear	O
to	O
be	O
no	O
major	O
safety	O
concerns	O
and	O
so	O
it	O
seems	O
reasonable	O
to	O
continue	O
insulin	S-geneY
glargine	O
if	O
required	O
to	O
achieve	O
excellent	O
glycaemic	O
control	O
.	O

A	O
head	O
-	O
to	O
-	O
head	O
comparison	O
between	O
insulin	S-geneY
detemir	O
and	O
NPH	O
insulin	S-geneY
in	O
women	O
with	O
type	O
1	O
diabetes	O
showed	O
that	O
while	O
foetal	O
outcomes	O
did	O
not	O
differ	O
,	O
fasting	O
plasma	O
glucose	S-chem-C3-1
improved	O
with	O
insulin	S-geneY-C3-2
detemir	O
without	O
an	O
increased	O
incidence	O
of	O
hypoglycaemia	O
.	O

The	O
greater	O
evidence	O
base	O
supports	O
the	O
use	O
of	O
insulin	S-geneY
detemir	O
as	O
the	O
first	O
line	O
long	O
-	O
acting	O
analogue	O
in	O
pregnancy	O
but	O
the	O
lack	O
of	O
definitive	O
foetal	O
benefits	O
means	O
that	O
there	O
is	O
no	O
strong	O
need	O
to	O
switch	O
a	O
woman	O
who	O
is	O
well	O
controlled	O
on	O
NPH	O
insulin	S-geneY
.	O

There	O
seems	O
little	O
justification	O
in	O
using	O
long	O
acting	O
insulin	S-geneY
analogues	O
in	O
women	O
with	O
gestational	O
diabetes	O
or	O
type	O
2	O
diabetes	O
where	O
the	O
risk	O
of	O
hypoglycaemia	O
is	O
low	O
.	O

HISTONE	B-geneN
DEACETYLASE	E-geneN
INHIBITION	O
AFFECTS	O
SODIUM	B-geneY
IODIDE	I-geneY
SYMPORTER	E-geneY
(	O
NIS	S-geneY
)	O
EXPRESSION	O
AND	O
INDUCES	O
¹³¹I	S-chem
CYTOTOXICITY	O
IN	O
ANAPLASTIC	O
THYROID	O
CANCER	O
CELLS	O
.	O

Background	O
:	O
Anaplastic	O
thyroid	O
cancers	O
(	O
ATC	O
)	O
represent	O
only	O
1	O
-	O
2	O
%	O
of	O
all	O
thyroid	O
tumors	O
,	O
but	O
they	O
account	O
for	O
up	O
to	O
50	O
%	O
of	O
the	O
mortality	O
.	O

Treatment	O
of	O
differentiated	O
thyroid	O
carcinomas	O
is	O
well	O
standardized	O
and	O
the	O
use	O
of	O
radioiodine	S-chem
represents	O
an	O
essential	O
step	O
;	O
in	O
contrast	O
,	O
there	O
is	O
no	O
standardized	O
therapeutic	O
approach	O
for	O
anaplastic	O
tumors	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

The	O
resistance	O
of	O
anaplastic	O
thyroid	O
cancer	O
to	O
radioiodine	S-chem
treatment	O
is	O
principally	O
due	O
to	O
the	O
absence	O
of	O
expression	O
of	O
the	O
sodium	B-geneY
iodide	I-geneY
symporter	E-geneY
(	O
NIS	S-geneY
)	O
,	O
mainly	O
due	O
to	O
epigenetic	O
silencing	O
.	O

The	O
acetylation	O
status	O
of	O
histones	S-geneN
is	O
involved	O
in	O
the	O
epigenetic	O
control	O
of	O
gene	O
expression	O
and	O
is	O
usually	O
disrupted	O
in	O
advanced	O
thyroid	O
cancer	O
.	O

Histone	B-geneN
deacetylase	E-geneN
inhibitors	O
have	O
been	O
demonstrated	O
as	O
potent	O
anticancer	O
drugs	O
with	O
several	O
different	O
effects	O
on	O
cell	O
viability	O
and	O
differentiation	O
.	O

Methods	O
:	O
Stabilized	O
anaplastic	O
thyroid	O
cancer	O
cell	O
lines	O
(	O
BHT	O
-	O
101	O
and	O
CAL	O
-	O
62	O
)	O
and	O
primary	O
cultures	O
from	O
patients	O
who	O
underwent	O
thyroidectomy	O
for	O
anaplastic	O
thyroid	O
cancer	O
were	O
treated	O
with	O
the	O
histone	B-geneN-C4-2
deacetylase	E-geneN-C4-2
inhibitor	O
LBH589	S-chem-C4-1
.	O

After	O
treatment	O
,	O
we	O
evaluated	O
the	O
expression	O
and	O
function	O
of	O
NIS	S-geneY
.	O

Gene	O
expression	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
;	O
NIS	B-geneN
promoter	E-geneN
activity	O
was	O
determined	O
with	O
a	O
luciferase	O
reporter	O
assay	O
;	O
and	O
protein	O
expression	O
was	O
assessed	O
through	O
immunofluorescence	O
.	O

We	O
tested	O
the	O
protein	O
function	O
by	O
125I	S-chem
uptake	O
and	O
efflux	O
experiments	O
;	O
finally	O
the	O
cytotoxic	O
effect	O
of	O
131I	S-chem
was	O
determined	O
with	O
a	O
clonogenic	O
assay	O
.	O

Results	O
:	O
Our	O
results	O
demonstrate	O
that	O
treatment	O
with	O
LBH589	S-chem-C3-1
leads	O
to	O
NIS	S-geneY-C3-2
RNA	O
expression	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
and	O
luciferase	O
assay	O
,	O
and	O
to	O
protein	O
expression	O
as	O
determined	O
by	O
immunofluorescence	O
in	O
vitro	O
and	O
by	O
immunohistochemistry	O
in	O
xenograft	O
tumors	O
.	O

Moreover	O
,	O
125I	S-chem
uptake	O
and	O
efflux	O
experiments	O
show	O
the	O
correct	O
protein	O
function	O
and	O
iodine	S-chem
retention	O
,	O
that	O
translate	O
into	O
cytotoxicity	O
effects	O
,	O
as	O
demonstrated	O
by	O
a	O
clonogenic	O
assay	O
with	O
131I	S-chem
.	O

Conclusions	O
:	O
This	O
study	O
supplies	O
a	O
new	O
potential	O
strategy	O
for	O
the	O
treatment	O
of	O
ATC	O
by	O
modifying	O
gene	O
expression	O
with	O
the	O
aim	O
of	O
inducing	O
responsiveness	O
towards	O
radioiodine	S-chem
therapy	O
.	O

The	O
transcription	B-geneY
factor	I-geneY
Pitx3	E-geneY
is	O
expressed	O
selectively	O
in	O
midbrain	O
dopaminergic	O
neurons	O
susceptible	O
to	O
neurodegenerative	O
stress	O
.	O

The	O
homeodomain	B-geneY
transcription	I-geneY
factor	I-geneY
Pitx3	E-geneY
is	O
critical	O
for	O
the	O
survival	O
of	O
midbrain	O
dopaminergic	O
(	O
mDA	O
)	O
neurons	O
.	O

Pitx3	S-geneY
-	O
deficient	O
mice	O
exhibit	O
severe	O
but	O
selective	O
developmental	O
loss	O
of	O
mDA	O
neurons	O
,	O
with	O
accompanying	O
locomotor	O
deficits	O
resembling	O
those	O
seen	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
models	O
.	O

Here	O
,	O
we	O
identify	O
specific	O
mDA	O
cell	O
subpopulations	O
that	O
are	O
consistently	O
spared	O
in	O
adult	O
Pitx3	S-geneY
-	O
hypomorphic	O
(	O
aphakia	O
)	O
mice	O
,	O
demonstrating	O
that	O
Pitx3	S-geneY
is	O
not	O
indiscriminately	O
required	O
by	O
all	O
mDA	O
neurons	O
for	O
their	O
survival	O
.	O

In	O
aphakia	O
mice	O
,	O
virtually	O
all	O
surviving	O
mDA	O
neurons	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
the	O
majority	O
of	O
neurons	O
in	O
the	O
adjacent	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
also	O
express	O
calbindin	S-geneY
-	O
D28k	S-geneY
,	O
a	O
calcium	B-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
previously	O
associated	O
with	O
resistance	O
to	O
injury	O
in	O
PD	O
and	O
in	O
animal	O
models	O
.	O

Cell	O
-	O
mapping	O
studies	O
in	O
wild	O
-	O
type	O
mice	O
revealed	O
that	O
Pitx3	S-geneY
is	O
primarily	O
expressed	O
in	O
the	O
ventral	O
SN	O
,	O
a	O
region	O
particularly	O
susceptible	O
to	O
MPTP	S-chem
and	O
other	O
dopaminergic	O
neurotoxins	O
.	O

Furthermore	O
,	O
Pitx3	S-geneY
-	O
expressing	O
SN	O
cells	O
are	O
preferentially	O
lost	O
following	O
MPTP	S-chem
treatment	O
.	O

Finally	O
,	O
SN	O
mDA	O
neurons	O
in	O
Pitx3	S-geneY
hemizygous	O
mice	O
show	O
increased	O
sensitivity	O
when	O
exposed	O
to	O
MPTP	S-chem
.	O

Thus	O
,	O
SN	O
mDA	O
neurons	O
are	O
represented	O
by	O
at	O
least	O
two	O
distinct	O
subpopulations	O
including	O
MPTP	S-chem
-	O
resistant	O
Pitx3	S-geneY
-	O
autonomous	O
,	O
calbindin	S-geneY
-	O
positive	O
neurons	O
,	O
and	O
calbindin	S-geneY
-	O
negative	O
Pitx	B-geneY
-	I-geneY
3	E-geneY
-	O
dependent	O
cells	O
that	O
display	O
elevated	O
vulnerability	O
to	O
toxic	O
injury	O
,	O
and	O
probably	O
correspond	O
to	O
the	O
subpopulation	O
that	O
degenerates	O
in	O
PD	O
.	O

Impairment	O
of	O
Pitx3	S-geneY
-	O
dependent	O
pathways	O
therefore	O
increases	O
vulnerability	O
of	O
mDA	O
neurons	O
to	O
toxic	O
injury	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
a	O
novel	O
link	O
between	O
Pitx3	S-geneY
function	O
and	O
the	O
selective	O
pattern	O
of	O
mDA	O
cell	O
loss	O
observed	O
in	O
PD	O
.	O

Protective	O
effects	O
of	O
protein	O
transduction	O
domain	O
-	O
metallothionein	S-geneN
fusion	O
proteins	O
against	O
hypoxia	O
-	O
and	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
in	O
an	O
ischemia	O
/	O
reperfusion	O
rat	O
model	O
.	O

Ischemic	O
heart	O
diseases	O
caused	O
by	O
insufficient	O
oxygen	S-chem
supply	O
to	O
the	O
cardiac	O
muscle	O
require	O
pharmaceutical	O
agents	O
for	O
the	O
prevention	O
of	O
the	O
progress	O
and	O
recurrence	O
.	O

Metallothionein	S-geneN
(	O
MT	S-geneN
)	O
has	O
a	O
potential	O
as	O
a	O
protein	O
therapeutic	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
due	O
to	O
its	O
anti	O
-	O
oxidative	O
effects	O
under	O
stressful	O
conditions	O
.	O

In	O
spite	O
of	O
its	O
therapeutic	O
potential	O
,	O
efficient	O
delivery	O
systems	O
need	O
to	O
be	O
developed	O
to	O
overcome	O
limitations	O
such	O
as	O
low	O
transduction	O
efficiency	O
,	O
instability	O
and	O
short	O
half	O
-	O
life	O
in	O
the	O
body	O
.	O

To	O
enhance	O
intra	O
-	O
cellular	O
transduction	O
efficiency	O
,	O
Tat	O
sequence	O
as	O
a	O
protein	O
transduction	O
domain	O
(	O
PTD	O
)	O
was	O
fused	O
with	O
MT	S-geneN
in	O
a	O
recombinant	O
method	O
.	O

Anti	O
-	O
apoptotic	O
and	O
anti	O
-	O
oxidative	O
effects	O
of	O
Tat	O
-	O
MT	S-geneN
fusion	O
protein	O
were	O
evaluated	O
under	O
hyperglycemia	O
and	O
hypoxia	O
stress	O
conditions	O
in	O
cultured	O
H9c2	O
cells	O
.	O

Recovery	O
of	O
cardiac	O
functions	O
by	O
anti	O
-	O
apoptotic	O
and	O
anti	O
-	O
fibrotic	O
effects	O
of	O
Tat	O
-	O
MT	S-geneN
was	O
confirmed	O
in	O
an	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
rat	O
myocardial	O
infarction	O
model	O
.	O

Tat	O
-	O
MT	S-geneN
fusion	O
protein	O
effectively	O
protected	O
H9c2	O
cells	O
under	O
stressful	O
conditions	O
by	O
reducing	O
intracellular	O
ROS	O
production	O
and	O
inhibiting	O
caspase	O
-	O
3	O
activation	O
.	O

Tat	O
-	O
MT	S-geneN
fusion	O
protein	O
inhibited	O
apoptosis	O
,	O
reduced	O
fibrosis	O
area	O
and	O
enhanced	O
cardiac	O
functions	O
in	O
I	O
/	O
R	O
.	O

Tat	O
-	O
MT	S-geneN
fusion	O
protein	O
could	O
be	O
a	O
promising	O
therapeutic	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
diseases	O
.	O

Molecular	O
and	O
functional	O
characterization	O
of	O
flavin	B-geneN
-	I-geneN
containing	I-geneN
monooxygenases	E-geneN
in	O
cynomolgus	O
macaque	O
.	O

Flavin	B-geneN
-	I-geneN
containing	I-geneN
monooxygenases	E-geneN
(	O
FMOs	S-geneN
)	O
,	O
drug	O
-	O
metabolizing	O
enzymes	O
essential	O
for	O
the	O
metabolism	O
of	O
endogenous	O
biochemicals	O
and	O
foreign	O
compounds	O
,	O
have	O
been	O
characterized	O
in	O
human	O
(	O
including	O
FMO1	B-geneN
-	I-geneN
5	E-geneN
and	O
FMO6P	S-geneY
)	O
,	O
but	O
remain	O
to	O
be	O
investigated	O
in	O
cynomolgus	O
macaque	O
.	O

In	O
this	O
study	O
,	O
cDNAs	O
of	O
cynomolgus	O
FMO1	B-geneN
-	I-geneN
5	E-geneN
and	O
FMO6	S-geneY
were	O
isolated	O
and	O
characterized	O
.	O

Amino	B-chem
acid	E-chem
sequences	O
of	O
cynomolgus	O
FMO1	B-geneN
-	I-geneN
5	E-geneN
,	O
respectively	O
,	O
shared	O
high	O
sequence	O
identities	O
(	O
94	O
-	O
98	O
%	O
)	O
and	O
were	O
closely	O
clustered	O
in	O
a	O
phylogenetic	O
tree	O
,	O
with	O
human	B-geneN
FMO1	I-geneN
-	I-geneN
5	E-geneN
.	O

Eight	O
different	O
transcripts	O
,	O
due	O
to	O
alternative	O
splicing	O
,	O
were	O
isolated	O
for	O
cynomolgus	B-geneY
FMO6	E-geneY
,	O
which	O
is	O
highly	O
identical	O
(	O
∼	O
96	O
%	O
)	O
to	O
human	B-geneY
FMO6P	E-geneY
.	O

Among	O
the	O
10	O
tissue	O
types	O
analyzed	O
,	O
cynomolgus	O
FMO1	S-geneY
,	O
FMO2	S-geneY
,	O
FMO4	S-geneY
,	O
and	O
FMO6	S-geneY
were	O
most	O
abundantly	O
expressed	O
in	O
kidney	O
,	O
while	O
cynomolgus	B-geneY
FMO3	E-geneY
and	O
FMO5	S-geneY
were	O
most	O
abundantly	O
expressed	O
in	O
liver	O
.	O

In	O
kidney	O
and	O
liver	O
,	O
the	O
most	O
abundantly	O
expressed	O
cynomolgus	B-geneN
FMO	E-geneN
genes	O
were	O
FMO1	S-geneY
and	O
FMO3	S-geneY
respectively	O
.	O

Cynomolgus	B-geneY-C9-2
FMO1	E-geneY-C9-2
,	O
FMO2	S-geneY-C9-2
,	O
FMO3	S-geneY-C9-2
,	O
and	O
FMO5	S-geneY-C9-2
metabolized	O
benzydamine	S-chem-C9-1
,	O
and	O
FMO1	S-geneY-C9-2
/	O
FMO3	S-geneY-C9-2
and	O
FMO3	S-geneY-C9-2
also	O
metabolized	O
methimazole	S-chem-C9-1
and	O
trimethylamine	S-chem-C9-1
,	O
respectively	O
.	O

Rates	O
of	O
benzydamine	S-chem-C9-1
N	S-chem-C9-1
-	O
oxygenation	O
(	O
catalyzed	O
by	O
FMO3	S-geneY-C9-2
)	O
varied	O
(	O
approximately	O
20	O
-	O
fold	O
)	O
among	O
the	O
28	O
cynomolgus	O
livers	O
and	O
were	O
significantly	O
correlated	O
with	O
FMO3	S-geneY
protein	O
expression	O
,	O
indicating	O
that	O
the	O
inter	O
-	O
animal	O
variations	O
in	O
benzydamine	S-chem-C9-1
N	S-chem-C9-1
-	O
oxygenation	O
might	O
be	O
partly	O
accounted	O
for	O
by	O
the	O
variable	O
FMO3	S-geneY-C9-2
expression	O
.	O

Cynomolgus	B-geneY-C9-2
FMO6	E-geneY-C9-2
metabolized	O
benzydamine	S-chem-C9-1
only	O
slightly	O
,	O
but	O
minimal	O
expression	O
of	O
FMO6	S-geneY
in	O
all	O
tissue	O
precludes	O
the	O
importance	O
of	O
FMO6	S-geneY
in	O
drug	O
metabolism	O
,	O
unlike	O
cynomolgus	O
FMO1	S-geneY-C9-2
,	O
FMO2	S-geneY-C9-2
,	O
FMO3	S-geneY-C9-2
,	O
and	O
FMO5	S-geneY-C9-2
which	O
were	O
all	O
functional	O
.	O

Abundant	O
expression	O
of	O
FMO1	S-geneY
and	O
FMO3	S-geneY
in	O
kidney	O
and	O
liver	O
,	O
respectively	O
,	O
suggest	O
their	O
importance	O
in	O
drug	O
metabolism	O
in	O
cynomolgus	O
macaque	O
,	O
similar	O
to	O
human	O
.	O

Effects	O
of	O
labor	O
and	O
delivery	O
on	O
fibrinolysis	O
.	O

Because	O
timing	O
of	O
sampling	O
is	O
crucial	O
in	O
an	O
investigation	O
of	O
the	O
effects	O
of	O
labor	O
and	O
delivery	O
on	O
fibrinolysis	O
we	O
conducted	O
a	O
study	O
of	O
fibrinolytic	O
markers	O
in	O
plasma	O
of	O
10	O
healthy	O
multiparous	O
women	O
in	O
whom	O
labor	O
was	O
induced	O
,	O
which	O
allowed	O
standardization	O
of	O
sampling	O
times	O
in	O
relation	O
to	O
the	O
course	O
of	O
labor	O
and	O
delivery	O
.	O

Blood	O
samples	O
were	O
taken	O
5	O
min	O
before	O
the	O
start	O
of	O
oxytocin	S-geneY
infusion	O
,	O
at	O
full	O
cervical	O
dilatation	O
,	O
and	O
within	O
5	O
min	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O

A	O
sample	O
of	O
mixed	O
free	O
flowing	O
cord	O
blood	O
was	O
obtained	O
after	O
delivery	O
with	O
the	O
placenta	O
in	O
situ	O
.	O

Variables	O
determined	O
were	O
tissue	B-geneY
-	I-geneY
type	I-geneY
plasminogen	I-geneY
-	I-geneY
activator	E-geneY
(	O
t	B-geneY
-	I-geneY
PA	E-geneY
)	O
and	O
the	O
plasminogen	B-geneY
activator	I-geneY
inhibitors	I-geneY
type	I-geneY
1	E-geneY
(	O
PAI	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
type	O
2	O
(	O
PAI	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

The	O
only	O
significant	O
change	O
between	O
the	O
beginning	O
of	O
the	O
induction	O
of	O
labor	O
and	O
the	O
end	O
of	O
the	O
first	O
stage	O
of	O
labor	O
was	O
a	O
rise	O
in	O
t	B-geneY
-	I-geneY
PA	E-geneY
antigen	O
(	O
P	O
=	O
0.01	O
)	O
.	O

All	O
variables	O
,	O
except	O
PAI	B-geneY
-	I-geneY
2	E-geneY
antigen	O
,	O
changed	O
significantly	O
after	O
delivery	O
of	O
the	O
placenta	O
:	O
t	B-geneY
-	I-geneY
PA	E-geneY
antigen	O
and	O
activity	O
showed	O
a	O
rise	O
(	O
P	O
<	O
0.05	O
)	O
,	O
accompanied	O
by	O
a	O
fall	O
in	O
PAI	B-geneY
-	I-geneY
1	E-geneY
antigen	O
and	O
activity	O
(	O
P	O
<	O
0.01	O
)	O
.	O

T	B-geneY
-	I-geneY
PA	E-geneY
activity	O
in	O
cord	O
plasma	O
was	O
higher	O
(	O
P	O
<	O
0.01	O
)	O
in	O
comparison	O
with	O
maternal	O
plasma	O
concentrations	O
at	O
the	O
end	O
of	O
the	O
first	O
stage	O
of	O
labor	O
,	O
t	B-geneY
-	I-geneY
PA	E-geneY
antigen	O
levels	O
were	O
similar	O
,	O
and	O
PAI	B-geneY
-	I-geneY
1	E-geneY
antigen	O
and	O
activity	O
and	O
PAI	B-geneY
-	I-geneY
2	E-geneY
antigen	O
were	O
lower	O
in	O
cord	O
plasma	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Our	O
study	O
shows	O
that	O
activation	O
of	O
the	O
maternal	O
fibrinolytic	O
system	O
can	O
already	O
be	O
detected	O
during	O
labor	O
,	O
with	O
a	O
marked	O
further	O
increase	O
in	O
fibrinolytic	O
potential	O
after	O
placental	O
separation	O
.	O

Differential	O
interactions	O
of	O
heparin	O
and	O
heparan	O
sulfate	O
glycosaminoglycans	O
with	O
the	O
selectins	S-geneN
.	O
Implications	O
for	O
the	O
use	O
of	O
unfractionated	O
and	O
low	O
molecular	O
weight	O
heparins	O
as	O
therapeutic	O
agents	O
.	O

The	O
selectins	S-geneN
are	O
calcium	S-chem
-	O
dependent	O
C	B-geneN
-	I-geneN
type	I-geneN
lectins	E-geneN
that	O
bind	O
certain	O
sialylated	O
,	O
fucosylated	O
,	O
sulfated	O
glycoprotein	O
ligands	O
.	O

L	B-geneY
-	I-geneY
selectin	E-geneY
also	O
recognizes	O
endothelial	O
proteoglycans	O
in	O
a	O
calcium	S-chem
-	O
dependent	O
manner	O
,	O
via	O
heparan	O
sulfate	O
(	O
HS	O
)	O
glycosaminoglycan	O
chains	O
enriched	O
in	O
unsubstituted	O
glucosamine	S-chem
units	O
.	O

We	O
now	O
show	O
that	O
these	O
HS	O
chains	O
can	O
also	O
bind	O
P	B-geneY
-	I-geneY
selectin	E-geneY
,	O
but	O
not	O
E	B-geneY
-	I-geneY
selectin	E-geneY
.	O

However	O
,	O
while	O
L	B-geneY
-	I-geneY
selectin	E-geneY
binding	O
requires	O
micromolar	O
levels	O
of	O
free	O
calcium	O
,	O
P	B-geneY
-	I-geneY
selectin	E-geneY
recognition	O
is	O
largely	O
divalent	O
cation	O
-	O
independent	O
.	O

Despite	O
this	O
,	O
HS	O
chains	O
bound	O
to	O
P	B-geneY
-	I-geneY
selectin	E-geneY
are	O
eluted	O
by	O
ethylenediamine	B-chem
tetraacetic	I-chem
acid	E-chem
(	O
EDTA	S-chem
)	O
,	O
but	O
only	O
at	O
high	O
concentrations	O
.	O

Porcine	O
intestinal	O
mucosal	O
(	O
mast	O
cell	O
-	O
derived	O
)	O
heparin	O
(	O
PIM	O
-	O
heparin	O
)	O
shows	O
similar	O
properties	O
,	O
with	O
no	O
binding	O
to	O
E	B-geneY
-	I-geneY
selectin	E-geneY
,	O
calcium	S-chem
-	O
dependent	O
binding	O
of	O
a	O
subfraction	O
to	O
L	B-geneY
-	I-geneY
selectin	E-geneY
and	O
to	O
P	B-geneY
-	I-geneY
selectin	E-geneY
,	O
and	O
calcium	S-chem
-	O
independent	O
binding	O
of	O
a	O
larger	O
fraction	O
to	O
P	B-geneY
-	I-geneY
selectin	E-geneY
,	O
the	O
latter	O
being	O
disrupted	O
by	O
high	O
EDTA	S-chem
concentrations	O
.	O

Analysis	O
of	O
defined	O
heparin	O
fragment	O
pools	O
shows	O
a	O
size	O
dependence	O
for	O
interaction	O
,	O
with	O
tetradecasaccharides	S-chem
showing	O
easily	O
detectable	O
binding	O
to	O
L	B-geneN
-	I-geneN
and	I-geneN
P	I-geneN
-	I-geneN
selectin	E-geneN
affinity	O
columns	O
.	O

L	B-geneY
-	I-geneY
selectin	E-geneY
binding	O
fragments	O
include	O
more	O
heavily	O
sulfated	O
and	O
epimerized	O
regions	O
and	O
,	O
as	O
with	O
the	O
endothelial	O
HS	O
chains	O
,	O
they	O
are	O
enriched	O
in	O
free	B-chem
amino	E-chem
groups	O
.	O

The	O
P	B-geneY
-	I-geneY
selectin	E-geneY
binding	O
component	O
includes	O
this	O
fraction	O
as	O
well	O
as	O
some	O
less	O
highly	O
modified	O
regions	O
.	O

Thus	O
,	O
endothelium	O
-	O
derived	O
HS	O
chains	O
and	O
mast	O
cell	O
-	O
derived	O
heparins	O
could	O
play	O
a	O
role	O
in	O
modulating	O
the	O
biology	O
of	O
selectins	S-geneN
in	O
vivo	O
.	O

Notably	O
,	O
P	B-geneN
-	I-geneN
and	I-geneN
L	I-geneN
-	I-geneN
selectin	E-geneN
binding	O
to	O
sialyl	O
-	O
Lewisx	O
and	O
to	O
HL	O
-	O
60	O
cells	O
(	O
which	O
are	O
known	O
to	O
carry	O
the	O
native	O
ligand	O
PSGL	B-geneY
-	I-geneY
1	E-geneY
)	O
is	O
inhibited	O
by	O
unfractionated	O
pharmaceutical	O
heparin	O
preparations	O
at	O
concentrations	O
12	O
-	O
50	O
-	O
fold	O
lower	O
than	O
those	O
recommended	O
for	O
effective	O
anticoagulation	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
two	O
low	O
molecular	O
weight	O
heparins	O
currently	O
considered	O
as	O
clinical	O
replacements	O
for	O
unfractionated	O
heparin	O
are	O
much	O
poorer	O
inhibitors	O
.	O

Thus	O
,	O
patients	O
undergoing	O
heparin	O
therapy	O
for	O
other	O
reasons	O
may	O
be	O
experiencing	O
clinically	O
significant	O
inhibition	O
of	O
L	B-geneN
-	I-geneN
and	I-geneN
P	I-geneN
-	I-geneN
selectin	E-geneN
function	O
,	O
and	O
the	O
current	O
switchover	O
to	O
low	O
-	O
molecular	O
weight	O
heparins	O
may	O
come	O
at	O
some	O
loss	O
of	O
this	O
effect	O
.	O

Low	O
-	O
dose	O
unfractionated	O
heparin	O
should	O
be	O
investigated	O
as	O
a	O
treatment	O
option	O
for	O
acute	O
and	O
chronic	O
diseases	O
in	O
which	O
P	B-geneN
-	I-geneN
and	I-geneN
L	I-geneN
-	I-geneN
selectin	E-geneN
play	O
pathological	O
roles	O
.	O

The	O
Effects	O
of	O
Carbohydrate	S-chem
,	O
Unsaturated	O
Fat	O
,	O
and	O
Protein	O
Intake	O
on	O
Measures	O
of	O
Insulin	S-geneY
Sensitivity	O
:	O
Results	O
from	O
the	O
OmniHeart	O
Trial	O
.	O

OBJECTIVE	O
Impaired	O
insulin	S-geneY
sensitivity	O
increases	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

Although	O
calorie	O
restriction	O
and	O
weight	O
loss	O
increase	O
insulin	S-geneY
sensitivity	O
,	O
the	O
effects	O
of	O
modifying	O
macronutrient	O
composition	O
on	O
insulin	S-geneY
sensitivity	O
are	O
uncertain	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
effects	O
on	O
insulin	S-geneY
sensitivity	O
of	O
a	O
carbohydrate	S-chem
-	O
rich	O
diet	O
(	O
CARB	S-chem
;	O
similar	O
to	O
the	O
Dietary	O
Approaches	O
to	O
Stop	O
Hypertension	O
[	O
DASH	O
]	O
diet	O
)	O
,	O
a	O
protein	O
-	O
rich	O
diet	O
(	O
PROT	O
;	O
protein	O
predominantly	O
from	O
plant	O
sources	O
)	O
,	O
and	O
an	O
unsaturated	O
fat	O
-	O
rich	O
diet	O
(	O
UNSAT	O
;	O
predominantly	O
monounsaturated	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
study	O
was	O
a	O
randomized	O
,	O
controlled	O
,	O
three	O
-	O
period	O
,	O
crossover	O
feeding	O
study	O
.	O

The	O
study	O
participants	O
were	O
164	O
individuals	O
with	O
prehypertension	O
or	O
stage	O
1	O
hypertension	O
without	O
diabetes	O
.	O

Diets	O
were	O
administered	O
for	O
6	O
weeks	O
each	O
,	O
with	O
a	O
washout	O
period	O
between	O
diets	O
of	O
2	O
-	O
4	O
weeks	O
.	O

Weight	O
was	O
held	O
constant	O
throughout	O
the	O
study	O
.	O

For	O
our	O
primary	O
outcome	O
,	O
we	O
calculated	O
the	O
quantitative	O
insulin	S-geneY
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
using	O
the	O
end	O
-	O
of	O
-	O
period	O
fasting	O
serum	O
glucose	S-chem
and	O
insulin	S-geneY
.	O

QUICKI	O
is	O
a	O
validated	O
measure	O
of	O
insulin	S-geneY
sensitivity	O
.	O

The	O
primary	O
analyses	O
used	O
generalized	O
estimating	O
equations	O
.	O

RESULTS	O
At	O
baseline	O
,	O
mean	O
(	O
SD	O
)	O
BMI	O
was	O
30.2	O
(	O
6.1	O
)	O
kg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
mean	O
(	O
SD	O
)	O
QUICKI	O
was	O
0.35	O
(	O
0.04	O
)	O
.	O

The	O
UNSAT	O
diet	O
increased	O
QUICKI	O
by	O
0.005	O
,	O
more	O
than	O
the	O
CARB	S-chem
diet	O
(	O
P	O
=	O
0.04	O
)	O
.	O

PROT	O
had	O
no	O
significant	O
effect	O
compared	O
with	O
CARB	S-chem
.	O

CONCLUSIONS	O
A	O
diet	O
that	O
partially	O
replaces	O
carbohydrate	S-chem-C3-1
with	O
unsaturated	O
fat	O
may	O
improve	O
insulin	S-geneY-C3-2
sensitivity	O
in	O
a	O
population	O
at	O
risk	O
for	O
cardiovascular	O
disease	O
.	O

Given	O
the	O
well	O
-	O
recognized	O
challenges	O
of	O
sustaining	O
weight	O
loss	O
,	O
our	O
results	O
suggest	O
an	O
alternative	O
approach	O
for	O
improving	O
insulin	S-geneY
sensitivity	O
.	O

Screening	O
for	O
(	O
anti	O
)	O
androgenic	O
properties	O
using	O
a	O
standard	O
operation	O
protocol	O
based	O
on	O
the	O
human	O
stably	O
transfected	O
androgen	S-chem
sensitive	O
PALM	O
cell	O
line	O
.	O
First	O
steps	O
towards	O
validation	O
.	O

Despite	O
more	O
than	O
a	O
decade	O
of	O
research	O
in	O
the	O
field	O
of	O
endocrine	O
active	O
compounds	O
targeting	O
the	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
,	O
and	O
although	O
suitable	O
cell	O
lines	O
can	O
be	O
obtained	O
,	O
no	O
validated	O
human	O
stably	O
transfected	O
androgen	S-chem
sensitive	O
transactivation	O
assay	O
is	O
available	O
.	O

Bayer	O
Schering	O
Pharma	O
(	O
BSP	O
)	O
and	O
the	O
Flemish	O
Institute	O
for	O
Technological	O
Research	O
(	O
VITO	O
)	O
,	O
partners	O
within	O
the	O
EU	O
-	O
sponsored	O
6th	O
framework	O
project	O
ReProTect	O
,	O
made	O
first	O
steps	O
towards	O
such	O
a	O
validation	O
.	O

A	O
standard	O
operation	O
protocol	O
(	O
SOP	O
)	O
developed	O
at	O
BSP	O
based	O
on	O
the	O
androgen	S-chem
sensitive	O
PALM	O
cell	O
line	O
was	O
transferred	O
to	O
VITO	O
and	O
its	O
performance	O
and	O
transferability	O
were	O
thoroughly	O
studied	O
.	O

The	O
investigation	O
followed	O
a	O
generic	O
protocol	O
prepared	O
for	O
all	O
reporter	O
gene	O
assays	O
evaluated	O
within	O
ReProTect	O
,	O
and	O
in	O
both	O
laboratories	O
at	O
least	O
three	O
independent	O
experiments	O
were	O
performed	O
.	O

The	O
highest	O
concentration	O
to	O
be	O
tested	O
was	O
limited	O
to	O
10	O
microM	O
,	O
if	O
needed	O
.	O

A	O
few	O
compounds	O
,	O
17alpha	B-chem
-	I-chem
methyltestosterone	E-chem
(	O
17alpha	B-chem
-	I-chem
MT	E-chem
)	O
,	O
vinclozolin	S-chem
and	O
linuron	S-chem
,	O
were	O
studied	O
using	O
a	O
real	O
world	O
scenario	O
,	O
i.e	O
.	O
,	O
assuming	O
that	O
their	O
interaction	O
with	O
the	O
AR	S-geneY
was	O
not	O
known	O
:	O
A	O
prescreening	O
for	O
agonism	O
and	O
true	O
,	O
competitive	O
antagonism	O
was	O
used	O
to	O
select	O
conditions	O
such	O
as	O
the	O
appropriate	O
mode	O
of	O
action	O
,	O
and	O
the	O
working	O
range	O
excluding	O
cytotoxicity	O
for	O
the	O
final	O
screening	O
.	O

All	O
other	O
compounds	O
were	O
tested	O
according	O
to	O
the	O
generic	O
protocol	O
:	O
Compounds	O
screened	O
for	O
agonism	O
were	O
the	O
reference	O
androgen	S-chem
17alpha	B-chem
-	I-chem
methyldihydrotestosterone	E-chem
(	O
MDHT	S-chem
)	O
,	O
levonorgestrel	S-chem
,	O
norethynodrel	S-chem
,	O
progesterone	S-chem
,	O
o	B-chem
,	I-chem
p	I-chem
'	I-chem
-	I-chem
DDT	E-chem
,	O
and	O
dibutylphthalate	S-chem
(	O
DBP	S-chem
)	O
,	O
while	O
compounds	O
screened	O
for	O
antagonism	O
were	O
the	O
reference	O
anti	B-chem
-	I-chem
androgen	E-chem
flutamide	S-chem
,	O
prochloraz	S-chem
,	O
o	B-chem
,	I-chem
p	I-chem
'	I-chem
-	I-chem
DDT	E-chem
,	O
progesterone	S-chem
,	O
norethynodrel	S-chem
,	O
and	O
DBP	S-chem
.	O

Cytotoxicity	O
was	O
assessed	O
in	O
parallel	O
as	O
lactate	B-geneN
dehydrogenase	E-geneN
release	O
.	O

The	O
prescreen	O
classified	O
17alpha	B-chem
-	I-chem
MT	E-chem
as	O
androgenic	O
,	O
vinclozolin	S-chem
and	O
linuron	O
as	O
anti	O
-	O
androgenic	O
and	O
compounds	O
were	O
tested	O
accordingly	O
.	O

In	O
the	O
absence	O
of	O
cytotoxicity	O
,	O
appropriate	O
androgenic	O
properties	O
of	O
reference	O
and	O
test	O
compounds	O
were	O
detected	O
by	O
both	O
laboratories	O
,	O
o	B-chem
,	I-chem
p	I-chem
'	I-chem
-	I-chem
DDT	E-chem
and	O
DBP	S-chem
had	O
no	O
androgenic	O
activity	O
.	O

Across	O
the	O
two	O
laboratories	O
EC	O
(	O
50	O
)	O
-	O
values	O
for	O
MDHT	S-chem
,	O
17alpha	B-chem
-	I-chem
MT	E-chem
,	O
and	O
levonorgestrel	S-chem
varied	O
by	O
not	O
more	O
than	O
a	O
factor	O
of	O
3.4	O
,	O
for	O
norethynodrel	S-chem
by	O
a	O
factor	O
of	O
9.7	O
.	O

Progesterone	S-chem
effects	O
could	O
not	O
fully	O
be	O
evaluated	O
,	O
as	O
frequently	O
concentration	O
response	O
curves	O
were	O
incomplete	O
.	O

In	O
the	O
absence	O
of	O
cytotoxicity	O
anti	O
-	O
androgenic	O
properties	O
of	O
reference	O
and	O
test	O
compounds	O
were	O
also	O
detected	O
in	O
both	O
laboratories	O
.	O

DBP	S-chem
,	O
the	O
putative	O
negative	O
reference	O
compound	O
,	O
was	O
inactive	O
,	O
norethynodrel	S-chem
rather	O
showed	O
agonistic	O
properties	O
.	O

Progesterone	S-chem
was	O
an	O
antagonist	O
at	O
low	O
concentrations	O
,	O
but	O
agonistic	O
properties	O
were	O
observed	O
in	O
one	O
laboratory	O
at	O
high	O
concentrations	O
.	O

Since	O
the	O
highest	O
test	O
concentration	O
was	O
limited	O
to	O
10	O
microM	O
,	O
for	O
some	O
compounds	O
no	O
complete	O
concentration	O
response	O
curves	O
were	O
obtained	O
and	O
estimation	O
of	O
EC	O
(	O
50	O
)	O
-	O
values	O
was	O
less	O
robust	O
.	O

Our	O
data	O
demonstrated	O
that	O
the	O
SOP	O
was	O
transferable	O
,	O
and	O
that	O
the	O
assay	O
was	O
able	O
to	O
rank	O
compounds	O
with	O
strong	O
,	O
weak	O
,	O
and	O
without	O
affinity	O
for	O
the	O
AR	S-geneY
and	O
to	O
discriminate	O
agonists	O
and	O
antagonists	O
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
could	O
be	O
improved	O
further	O
,	O
if	O
the	O
limit	O
of	O
solubility	O
or	O
beginning	O
cytotoxicity	O
was	O
chosen	O
as	O
the	O
highest	O
test	O
concentration	O
.	O

The	O
assay	O
avoids	O
the	O
use	O
of	O
tissues	O
from	O
laboratory	O
animals	O
,	O
and	O
thus	O
contributes	O
to	O
the	O
3R	O
concept	O
.	O

Furthermore	O
,	O
it	O
could	O
be	O
adjusted	O
to	O
an	O
intermediate	O
/	O
high	O
throughput	O
format	O
.	O

On	O
the	O
whole	O
,	O
this	O
PALM	O
assay	O
is	O
a	O
promising	O
candidate	O
for	O
further	O
validation	O
.	O

Influence	O
of	O
stimulant	O
-	O
induced	O
hyperactivity	O
on	O
social	O
approach	O
in	O
the	O
BTBR	O
mouse	O
model	O
of	O
autism	O
.	O

Translational	O
research	O
is	O
needed	O
to	O
discover	O
pharmacological	O
targets	O
and	O
treatments	O
for	O
the	O
diagnostic	O
behavioral	O
domains	O
of	O
autism	O
spectrum	O
disorders	O
.	O

Animal	O
models	O
with	O
phenotypic	O
relevance	O
to	O
diagnostic	O
criteria	O
offer	O
clear	O
experimental	O
strategies	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
novel	O
treatments	O
.	O

Antagonists	O
of	O
mGluR5	S-geneY
receptors	O
are	O
in	O
clinical	O
trials	O
for	O
Fragile	O
X	O
syndrome	O
and	O
under	O
investigation	O
for	O
the	O
treatment	O
of	O
autism	O
spectrum	O
disorders	O
.	O

However	O
,	O
in	O
preclinical	O
studies	O
of	O
mGluR5	S-geneY
compounds	O
tested	O
in	O
our	O
laboratory	O
and	O
others	O
,	O
increased	O
locomotion	O
following	O
mGluR5	S-geneY
modulation	O
has	O
been	O
observed	O
.	O

Understanding	O
the	O
influence	O
of	O
general	O
activity	O
on	O
sociability	O
and	O
repetitive	O
behaviors	O
will	O
increase	O
the	O
accuracy	O
of	O
interpretations	O
of	O
positive	O
outcomes	O
measured	O
from	O
pharmacological	O
treatment	O
that	O
produces	O
locomotor	O
activating	O
or	O
sedating	O
effects	O
.	O

In	O
the	O
present	O
studies	O
,	O
dose	O
-	O
response	O
curves	O
for	O
d	B-chem
-	I-chem
amphetamine	E-chem
(	O
AMPH	S-chem
)	O
-	O
induced	O
hyperlocomotion	O
were	O
similar	O
in	O
standard	O
B6	O
mice	O
and	O
in	O
the	O
BTBR	O
mouse	O
model	O
of	O
autism	O
.	O

AMPH	S-chem
produced	O
significant	O
,	O
robust	O
reductions	O
in	O
the	O
high	O
level	O
of	O
repetitive	O
self	O
-	O
grooming	O
that	O
characterizes	O
BTBR	O
,	O
and	O
also	O
reduced	O
the	O
low	O
baseline	O
grooming	O
in	O
B6	O
,	O
indicating	O
that	O
AMPH	S-chem
-	O
induced	O
hyperlocomotion	O
competes	O
with	O
time	O
spent	O
engaged	O
in	O
self	O
-	O
grooming	O
.	O

We	O
then	O
tested	O
AMPH	S-chem
in	O
B6	O
and	O
BTBR	O
on	O
the	O
3	O
-	O
chambered	O
social	O
approach	O
task	O
.	O

One	O
component	O
of	O
sociability	O
,	O
the	O
time	O
spent	O
in	O
the	O
chamber	O
with	O
the	O
novel	O
mouse	O
,	O
in	O
B6	O
mice	O
was	O
reduced	O
,	O
while	O
the	O
sniffing	O
time	O
component	O
of	O
sociability	O
in	O
BTBR	O
mice	O
was	O
enhanced	O
.	O

This	O
finding	O
replicated	O
across	O
multiple	O
cohorts	O
treated	O
with	O
AMPH	S-chem
and	O
saline	O
vehicle	O
.	O

In	O
-	O
depth	O
analysis	O
revealed	O
that	O
AMPH	S-chem
increased	O
the	O
number	O
and	O
decreased	O
the	O
duration	O
of	O
sniffing	O
bouts	O
in	O
BTBR	O
,	O
suggesting	O
BTBR	O
treated	O
with	O
AMPH	S-chem
mostly	O
engaged	O
in	O
brief	O
sniffs	O
rather	O
than	O
true	O
social	O
interactions	O
with	O
the	O
novel	O
mouse	O
during	O
the	O
social	O
approach	O
task	O
.	O

Our	O
data	O
suggest	O
that	O
compounds	O
with	O
stimulant	O
properties	O
may	O
have	O
some	O
direct	O
benefits	O
on	O
reducing	O
repetitive	O
behaviors	O
in	O
autism	O
spectrum	O
disorders	O
,	O
particularly	O
in	O
the	O
subset	O
of	O
autistic	O
individuals	O
with	O
hyperactivity	O
.	O

This	O
article	O
is	O
part	O
of	O
the	O
Special	O
Issue	O
entitled	O
'	O
Neurodevelopmental	O
Disorders	O
'	O
.	O

Nicotinic	B-geneN
acetylcholine	I-geneN
receptor	E-geneN
regulation	O
of	O
spinal	O
norepinephrine	S-chem
release	O
.	O

BACKGROUND	O
:	O
Neuronal	B-geneN
nicotinic	I-geneN
acetylcholine	I-geneN
receptor	E-geneN
(	O
nAChR	S-geneN
)	O
agonists	O
produce	O
antinociception	O
in	O
animals	O
.	O
nAChRs	S-geneN
exist	O
almost	O
exclusively	O
on	O
presynaptic	O
terminals	O
in	O
the	O
central	O
nervous	O
system	O
and	O
stimulate	O
neurotransmitter	O
release	O
.	O

This	O
study	O
tested	O
whether	O
nAChR	S-geneN
agonists	O
stimulate	O
spinal	O
release	O
of	O
the	O
neurotransmitter	O
norepinephrine	S-chem
either	O
by	O
direct	O
actions	O
on	O
noradrenergic	O
terminals	O
or	O
indirectly	O
by	O
stimulating	O
release	O
of	O
other	O
neurotransmitters	O
to	O
induce	O
norepinephrine	S-chem
release	O
.	O

METHODS	O
:	O
Adult	O
male	O
rats	O
were	O
anesthetized	O
and	O
microdialysis	O
probes	O
inserted	O
in	O
the	O
L2	O
-	O
L4	O
dermatomes	O
of	O
the	O
spinal	O
cord	O
.	O

Probes	O
were	O
perfused	O
with	O
artificial	O
cerebrospinal	O
fluid	O
containing	O
nicotine	O
,	O
the	O
specific	O
alpha	B-geneY-C5-2
(	I-geneY-C5-2
4	I-geneY-C5-2
)	I-geneY-C5-2
beta	I-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
*	I-geneY-C5-2
)	I-geneY-C5-2
nAChR	E-geneY-C5-2
agonist	O
metanicotine	S-chem-C5-1
,	O
or	O
nicotine	S-chem-C5-1
plus	O
nAChR	S-geneN
antagonists	O
and	O
norepinephrine	S-chem
measured	O
in	O
the	O
microdialysates	O
.	O

The	O
effects	O
of	O
specific	O
glutamate	B-geneN
receptor	E-geneN
antagonists	O
and	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
inhibitors	O
were	O
also	O
examined	O
.	O

To	O
determine	O
direct	O
effects	O
on	O
noradrenergic	O
terminals	O
,	O
synaptosomes	O
were	O
prepared	O
from	O
spinal	O
cord	O
and	O
incubated	O
with	O
nAChR	S-geneN
agonists	O
and	O
antagonists	O
.	O

RESULTS	O
:	O
Both	O
nicotine	S-chem
and	O
metanicotine	S-chem
induced	O
norepinephrine	S-chem
release	O
in	O
spinal	O
microdialsyates	O
,	O
an	O
effect	O
reduced	O
by	O
nicotinic	O
antagonists	O
but	O
not	O
glutamate	S-chem
antagonists	O
or	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
inhibitors	O
.	O

Both	O
of	O
the	O
nicotinic	O
agonists	O
stimulated	O
norepinephrine	S-chem
release	O
in	O
synaptosomes	O
,	O
and	O
the	O
effect	O
of	O
metanicotine	S-chem
was	O
blocked	O
at	O
lower	O
concentrations	O
of	O
alpha	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
beta	I-geneY
(	I-geneY
2	I-geneY
*	I-geneY
)	E-geneY
-	O
than	O
alpha	B-geneY
(	I-geneY
7	I-geneY
*	I-geneY
)	E-geneY
-	O
preferring	O
nAChR	S-geneN
antagonists	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
one	O
mechanism	O
by	O
which	O
nAChR	S-geneN
agonists	O
act	O
for	O
analgesia	O
is	O
to	O
stimulate	O
spinal	O
norepinephrine	S-chem
release	O
.	O

They	O
do	O
so	O
by	O
actions	O
on	O
alpha	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
beta	I-geneY
(	I-geneY
2	I-geneY
*	I-geneY
)	I-geneY
nAChRs	E-geneY
,	O
and	O
perhaps	O
other	O
subtypes	O
,	O
most	O
likely	O
located	O
on	O
noradrenergic	O
terminals	O
,	O
rather	O
than	O
by	O
indirectly	O
stimulating	O
norepinephrine	S-chem
release	O
through	O
glutamate	S-chem
release	O
or	O
nitric	B-chem
oxide	E-chem
synthesis	O
.	O

Ketoconazole	S-chem
binds	O
to	O
the	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
.	O

Ketoconazole	S-chem
,	O
an	O
imidazole	S-chem
anti	O
-	O
fungal	O
agent	O
,	O
has	O
often	O
produced	O
features	O
of	O
androgen	S-chem
deficiency	O
including	O
decreased	O
libido	O
,	O
gynecomastia	O
,	O
impotence	O
,	O
oligospermia	O
,	O
and	O
decreased	O
testosterone	S-chem
levels	O
,	O
in	O
men	O
being	O
treated	O
for	O
chronic	O
mycotic	O
infections	O
.	O

Based	O
on	O
these	O
potent	O
effects	O
on	O
gonadal	O
function	O
in	O
vivo	O
as	O
well	O
as	O
previous	O
work	O
in	O
vitro	O
demonstrating	O
affinity	O
of	O
ketoconazole	S-chem
for	O
receptor	O
proteins	O
for	O
glucocorticoids	O
and	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
2	I-chem
vitamin	I-chem
D3	E-chem
and	O
for	O
sex	B-geneY
steroid	I-geneY
binding	I-geneY
globulin	E-geneY
(	O
SSBG	S-geneY
)	O
,	O
the	O
binding	O
of	O
ketoconazole	S-chem
to	O
human	B-geneY
androgen	I-geneY
receptors	E-geneY
(	O
AR	S-geneY
)	O
in	O
vitro	O
was	O
also	O
examined	O
.	O

Ketoconazole	S-chem
competition	O
with	O
[	B-chem
3H	I-chem
]	I-chem
methyltrienolone	E-chem
(	O
R1881	S-chem
)	O
for	O
androgen	S-chem
binding	O
sites	O
in	O
dispersed	O
,	O
intact	O
cultured	O
human	O
skin	O
fibroblasts	O
was	O
determined	O
at	O
22	O
degrees	O
C	O
.	O

Fifty	O
percent	O
displacement	O
of	O
[	B-chem
3H	I-chem
]	I-chem
R1881	E-chem
binding	O
to	O
AR	S-geneY
was	O
achieved	O
by	O
6.4	O
+	O
/	O
-	O
1.8	O
(	O
SE	O
)	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
ketoconazole	S-chem
.	O

Additional	O
binding	O
studies	O
performed	O
with	O
ketoconazole	S-chem
in	O
the	O
presence	O
of	O
increasing	O
amounts	O
of	O
[	B-chem
3H	I-chem
]	I-chem
R1881	E-chem
showed	O
that	O
the	O
interaction	O
of	O
ketoconazole	S-chem
with	O
AR	S-geneY
was	O
competitive	O
when	O
the	O
data	O
were	O
analyzed	O
by	O
the	O
Scatchard	O
method	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
the	O
dose	O
of	O
ketoconazole	S-chem
required	O
for	O
50	O
%	O
occupancy	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
is	O
not	O
likely	O
to	O
be	O
achieved	O
in	O
vivo	O
,	O
at	O
least	O
in	O
plasma	O
.	O

Finally	O
,	O
androgen	S-chem
binding	O
studies	O
performed	O
with	O
other	O
imidazoles	S-chem
,	O
such	O
as	O
clotrimazole	S-chem
,	O
miconazole	S-chem
,	O
and	O
fluconozole	S-chem
,	O
revealed	O
that	O
in	O
this	O
class	O
of	O
compounds	O
only	O
ketoconazole	S-chem
appears	O
to	O
interact	O
with	O
the	O
androgen	B-geneY
receptor	E-geneY
.	O

Ketoconazole	S-chem
appears	O
to	O
be	O
the	O
first	O
example	O
of	O
a	O
non	O
-	O
steroidal	S-chem
compound	O
which	O
binds	O
competitively	O
to	O
both	O
SSBG	S-geneY
and	O
multiple	O
steroid	B-geneN
hormone	I-geneN
receptors	E-geneN
,	O
suggesting	O
that	O
the	O
ligand	O
binding	O
sites	O
of	O
these	O
proteins	O
share	O
some	O
features	O
in	O
common	O
.	O

Use	O
of	O
the	O
Combination	O
Index	O
to	O
determine	O
interactions	O
between	O
plant	O
-	O
derived	O
phenolic	B-chem
acids	E-chem
on	O
hepatotoxicity	O
endpoints	O
in	O
human	O
and	O
rat	O
hepatoma	O
cells	O
.	O

The	O
beneficial	O
or	O
adverse	O
effects	O
of	O
isolated	O
phytochemicals	O
are	O
not	O
always	O
concordant	O
with	O
effects	O
of	O
the	O
botanical	O
dietary	O
supplements	O
from	O
which	O
they	O
were	O
derived	O
.	O

This	O
disparity	O
could	O
be	O
due	O
to	O
interactions	O
between	O
the	O
various	O
phytochemicals	O
present	O
in	O
the	O
whole	O
plant	O
.	O

The	O
phenolic	B-chem
acids	E-chem
,	O
rosmarinic	B-chem
acid	E-chem
(	O
RA	O
)	O
,	O
caffeic	B-chem
acid	E-chem
(	O
CA	O
)	O
and	O
ferulic	B-chem
acid	E-chem
(	O
FA	O
)	O
are	O
widely	O
present	O
in	O
foods	O
and	O
dietary	O
supplements	O
,	O
and	O
they	O
are	O
assumed	O
to	O
exert	O
various	O
beneficial	O
biological	O
effects	O
.	O

However	O
,	O
there	O
is	O
little	O
data	O
on	O
the	O
potential	O
biological	O
interactions	O
of	O
these	O
three	O
phenolic	B-chem
acids	E-chem
which	O
commonly	O
occur	O
together	O
and	O
are	O
linked	O
metabolically	O
.	O

In	O
the	O
present	O
study	O
,	O
liver	O
toxicity	O
of	O
the	O
three	O
phenolic	B-chem
acids	E-chem
was	O
assessed	O
on	O
the	O
three	O
compounds	O
singly	O
and	O
in	O
various	O
binary	O
and	O
one	O
ternary	O
combinations	O
.	O

A	O
series	O
of	O
in	O
vitro	O
endpoints	O
relevant	O
to	O
liver	O
toxicity	O
were	O
evaluated	O
in	O
both	O
a	O
human	O
(	O
HepG2	O
/	O
C3A	O
)	O
and	O
rat	O
(	O
MH1C1	O
)	O
hepatocyte	O
cell	O
line	O
.	O

The	O
Combination	O
Index	O
(	O
CI	O
)	O
was	O
calculated	O
for	O
each	O
endpoint	O
from	O
both	O
the	O
concentration	O
responses	O
of	O
the	O
single	O
compounds	O
and	O
the	O
responses	O
of	O
the	O
various	O
binary	O
and	O
ternary	O
mixtures	O
.	O

Both	O
synergistic	O
and	O
antagonistic	O
interactions	O
were	O
observed	O
for	O
some	O
endpoints	O
and	O
some	O
combinations	O
of	O
test	O
agents	O
.	O

Interactions	O
were	O
most	O
prevalent	O
in	O
measures	O
of	O
oxidative	O
stress	O
and	O
cytochrome	B-geneN
P450	E-geneN
activities	O
in	O
both	O
cell	O
types	O
.	O

There	O
was	O
only	O
a	O
53	O
%	O
concordance	O
between	O
the	O
rat	O
and	O
human	O
cells	O
which	O
may	O
be	O
suggestive	O
of	O
species	O
differences	O
.	O

The	O
data	O
suggest	O
an	O
approach	O
for	O
better	O
characterizing	O
the	O
beneficial	O
or	O
adverse	O
effects	O
of	O
complex	O
botanical	O
products	O
through	O
evaluation	O
of	O
interactions	O
between	O
individual	O
phytochemical	O
components	O
.	O

Preclinical	O
pharmacokinetics	O
and	O
in	O
vitro	O
metabolism	O
of	O
dasatinib	S-chem-C4-1
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
354825	E-chem-C4-1
)	O
:	O
a	O
potent	O
oral	O
multi	O
-	O
targeted	O
kinase	S-geneN-C4-2
inhibitor	O
against	O
SRC	S-geneY-C4-2
and	O
BCR	S-geneY-C4-2
-	O
ABL	S-geneY-C4-2
.	O

PURPOSE	O
:	O
Dasatinib	S-chem-C4-1
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
354825	E-chem-C4-1
)	O
,	O
a	O
potent	O
oral	O
multi	O
-	O
targeted	O
kinase	S-geneN-C4-2
inhibitor	O
against	O
SRC	S-geneY-C4-2
and	O
BCR	S-geneY-C4-2
-	O
ABL	S-geneY-C4-2
,	O
has	O
recently	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
in	O
imatinib	S-chem
-	O
acquired	O
resistance	O
and	O
intolerance	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
were	O
conducted	O
to	O
characterize	O
the	O
pharmacokinetics	O
and	O
metabolism	O
of	O
dasatinib	S-chem
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
.	O

Possible	O
mechanisms	O
contributing	O
to	O
the	O
incomplete	O
oral	O
bioavailability	O
of	O
dasatinib	S-chem
in	O
animals	O
were	O
investigated	O
.	O

METHODS	O
:	O
Metabolic	O
stability	O
of	O
dasatinib	S-chem
was	O
measured	O
after	O
incubation	O
with	O
liver	O
microsomes	O
(	O
either	O
NADPH	S-chem
-	O
or	O
UDPGA	S-chem
-	O
fortified	O
)	O
and	O
isolated	O
hepatocytes	O
obtained	O
from	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
monkey	O
,	O
and	O
human	O
.	O

In	O
all	O
cases	O
,	O
substrate	O
depletion	O
over	O
time	O
was	O
measured	O
,	O
and	O
appropriate	O
scaling	O
factors	O
were	O
used	O
to	O
predict	O
in	O
vivo	O
clearance	O
.	O

Pharmacokinetics	O
of	O
dasatinib	S-chem
were	O
determined	O
in	O
mice	O
,	O
rats	O
,	O
dogs	O
,	O
and	O
monkeys	O
after	O
administration	O
of	O
single	O
intravenous	O
or	O
oral	O
doses	O
.	O

In	O
addition	O
,	O
the	O
routes	O
of	O
excretion	O
were	O
investigated	O
after	O
administration	O
of	O
dasatinib	S-chem
to	O
bile	O
duct	O
cannulated	O
(	O
BDC	O
)	O
rats	O
.	O

Absorption	O
and	O
first	O
-	O
pass	O
metabolism	O
were	O
evaluated	O
as	O
possible	O
reasons	O
for	O
the	O
incomplete	O
oral	O
bioavailability	O
using	O
various	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
like	O
Caco	O
-	O
2	O
cells	O
,	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
knockout	O
mice	O
,	O
and	O
intra	O
-	O
portal	O
dosing	O
in	O
rats	O
.	O

RESULTS	O
:	O
In	O
vivo	O
systemic	O
plasma	O
clearance	O
values	O
of	O
dasatinib	S-chem
were	O
62	O
,	O
26	O
,	O
25	O
,	O
and	O
34	O
ml	O
/	O
min	O
/	O
kg	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
,	O
respectively	O
.	O

Scaling	O
of	O
in	O
vitro	O
hepatocyte	O
and	O
liver	O
microsomal	O
data	O
gave	O
reasonably	O
good	O
predictions	O
of	O
in	O
vivo	O
clearances	O
across	O
all	O
species	O
.	O

Percent	O
distribution	O
in	O
blood	O
cells	O
ranged	O
from	O
43	O
%	O
in	O
mouse	O
to	O
57	O
%	O
in	O
dog	O
.	O

Dasatinib	S-chem
showed	O
high	O
volumes	O
of	O
distribution	O
(	O
>	O
3	O
l	O
/	O
kg	O
)	O
and	O
high	O
serum	O
protein	O
binding	O
values	O
(	O
>	O
90	O
%	O
)	O
in	O
all	O
four	O
species	O
tested	O
.	O

Oral	O
bioavailability	O
of	O
dasatinib	S-chem
ranged	O
from	O
14	O
%	O
in	O
the	O
mouse	O
to	O
34	O
%	O
in	O
the	O
dog	O
.	O

In	O
rats	O
,	O
bioavailability	O
after	O
an	O
intraportal	O
dose	O
was	O
comparable	O
to	O
that	O
after	O
intra	O
-	O
arterial	O
administration	O
.	O

In	O
BDC	O
rats	O
,	O
less	O
than	O
15	O
%	O
of	O
an	O
intravenous	O
dose	O
was	O
excreted	O
unchanged	O
in	O
urine	O
,	O
bile	O
,	O
and	O
the	O
gastrointestinal	O
tract	O
,	O
suggesting	O
that	O
dasatinib	S-chem
is	O
cleared	O
primarily	O
via	O
metabolism	O
.	O

Dasatinib	S-chem
has	O
high	O
intrinsic	O
permeability	O
in	O
Caco	O
-	O
2	O
cells	O
,	O
however	O
,	O
the	O
efflux	O
ratio	O
was	O
approximately	O
two	O
-	O
fold	O
indicating	O
that	O
it	O
may	O
be	O
a	O
substrate	O
for	O
an	O
intestinal	O
efflux	O
transporter	O
.	O

However	O
,	O
in	O
vivo	O
studies	O
in	O
P	B-geneN
-	I-geneN
gp	E-geneN
knockout	O
mice	O
versus	O
wild	O
-	O
type	O
mice	O
showed	O
no	O
difference	O
in	O
the	O
amount	O
of	O
dasatinib	S-chem
remaining	O
unabsorbed	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
suggesting	O
that	O
P	B-geneN
-	I-geneN
gp	E-geneN
may	O
not	O
be	O
responsible	O
for	O
the	O
incomplete	O
bioavailability	O
.	O

CONCLUSIONS	O
:	O
Dasatinib	S-chem
shows	O
intermediate	O
clearance	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
,	O
and	O
distributes	O
extensively	O
in	O
those	O
species	O
.	O

Oxidative	O
metabolism	O
appears	O
to	O
be	O
the	O
predominant	O
clearance	O
pathway	O
.	O

The	O
incomplete	O
oral	O
bioavailability	O
may	O
be	O
due	O
to	O
both	O
incomplete	O
absorption	O
and	O
high	O
first	O
-	O
pass	O
metabolism	O
.	O

However	O
,	O
the	O
efflux	B-geneN
transporter	E-geneN
,	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
does	O
not	O
appear	O
to	O
be	O
limiting	O
oral	O
absorption	O
.	O

GALACTOSYLATED	O
MICELLES	O
FOR	O
A	O
RIBAVIRIN	S-chem
PRODRUG	O
TARGETING	O
TO	O
HEPATOCYTES	O
.	O

Polymeric	O
micelles	O
potentially	O
able	O
to	O
carry	O
to	O
hepatocytes	O
a	O
ribavirin	S-chem
(	O
RBV	S-chem
)	O
prodrug	O
,	O
exploiting	O
the	O
presence	O
of	O
carbohydrate	B-geneN
receptors	E-geneN
,	O
i.e	O
.	O
,	O
ASGPR	S-geneN
,	O
were	O
prepared	O
starting	O
from	O
a	O
galactosylated	B-chem
polylactide	I-chem
-	I-chem
polyaminoacid	E-chem
conjugate	O
.	O

This	O
latter	O
was	O
obtained	O
by	O
chemical	O
reaction	O
of	O
alpha	B-chem
,	I-chem
beta	I-chem
-	I-chem
poly	I-chem
(	I-chem
N	I-chem
-	I-chem
2	I-chem
-	I-chem
hydroxyethyl	I-chem
)	I-chem
(	I-chem
2	I-chem
-	I-chem
aminoethylcarbamate	I-chem
)	I-chem
-	I-chem
DL	I-chem
-	I-chem
aspartamide	E-chem
(	O
PHEA	B-chem
-	I-chem
EDA	E-chem
)	O
with	O
polylactic	B-chem
acid	E-chem
(	O
PLA	S-chem
)	O
,	O
and	O
subsequent	O
reaction	O
with	O
lactose	S-chem
,	O
obtaining	O
PHEA	B-chem
-	I-chem
EDA	I-chem
-	I-chem
PLA	I-chem
-	I-chem
GAL	E-chem
copolymer	O
.	O

To	O
enhance	O
the	O
entrapment	O
into	O
obtained	O
nanostructures	O
,	O
a	O
hydrophobic	O
RBV	S-chem
prodrug	O
,	O
i.e	O
.	O

RBV	B-chem
tripalmitate	E-chem
,	O
was	O
synthesized	O
and	O
its	O
capability	O
to	O
release	O
RBV	S-chem
in	O
the	O
presence	O
of	O
an	O
adequate	O
enzymatic	O
activity	O
was	O
demonstrated	O
.	O

Liver	O
-	O
targeted	O
RBV	B-chem
tripalmitate	E-chem
-	O
loaded	O
micelles	O
were	O
obtained	O
in	O
aqueous	O
media	O
at	O
low	O
PHEA	B-chem
-	I-chem
EDA	I-chem
-	I-chem
PLA	I-chem
-	I-chem
GAL	E-chem
copolymer	O
concentration	O
value	O
with	O
nanometric	O
size	O
.	O

By	O
in	O
vitro	O
experiments	O
,	O
the	O
specificity	O
of	O
RBV	B-chem
tripalmitate	E-chem
-	O
loaded	O
PHEA	B-chem
-	I-chem
EDA	I-chem
-	I-chem
PLA	I-chem
-	I-chem
GAL	E-chem
micelles	O
toward	O
HepG2	O
was	O
demonstrated	O
by	O
using	O
a	O
competitive	O
inhibition	O
assay	O
in	O
the	O
presence	O
of	O
free	O
GAL	S-chem
.	O

This	O
finding	O
raises	O
hope	O
in	O
terms	O
of	O
future	O
micelles	O
-	O
based	O
liver	O
-	O
targeted	O
drug	O
delivery	O
strategy	O
for	O
the	O
hepatitis	O
C	O
treatment	O
.	O

Methyl	S-chem
transfer	O
in	O
glycine	B-geneY
N	I-geneY
-	I-geneY
methyltransferase	E-geneY
.	O
A	O
theoretical	O
study	O
.	O

Density	O
functional	O
theory	O
calculations	O
using	O
the	O
hybrid	O
functional	O
B3LYP	O
have	O
been	O
performed	O
to	O
study	O
the	O
methyl	S-chem-C9-1
transfer	O
step	O
in	O
glycine	B-geneY-C9-2
N	I-geneY-C9-2
-	I-geneY-C9-2
methyltransferase	E-geneY-C9-2
(	O
GNMT	S-geneY-C9-2
)	O
.	O

This	O
enzyme	O
catalyzes	O
the	O
S	B-chem
-	I-chem
adenosyl	I-chem
-	I-chem
L	I-chem
-	I-chem
methionine	E-chem
(	O
SAM	S-chem
)	O
-	O
dependent	O
methylation	O
of	O
glycine	S-chem
to	O
form	O
sarcosine	S-chem
.	O

The	O
starting	O
point	O
for	O
the	O
calculations	O
is	O
the	O
recent	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
GNMT	S-geneY-C9-2
complexed	O
with	O
SAM	S-chem-C9-1
and	O
acetate	O
.	O

Several	O
quantum	O
chemical	O
models	O
with	O
different	O
sizes	O
,	O
employing	O
up	O
to	O
98	O
atoms	O
,	O
were	O
used	O
.	O

The	O
calculations	O
demonstrate	O
that	O
the	O
suggested	O
mechanism	O
,	O
where	O
the	O
methyl	O
group	O
is	O
transferred	O
in	O
a	O
single	O
S	O
(	O
N	O
)	O
2	O
step	O
,	O
is	O
thermodynamically	O
plausible	O
.	O

By	O
adding	O
or	O
eliminating	O
various	O
groups	O
at	O
the	O
active	O
site	O
,	O
it	O
was	O
furthermore	O
demonstrated	O
that	O
hydrogen	S-chem
bonds	O
to	O
the	O
amino	S-chem
group	O
of	O
the	O
glycine	S-chem
substrate	O
lower	O
the	O
reaction	O
barrier	O
,	O
while	O
hydrogen	S-chem
bonds	O
to	O
the	O
carboxylate	S-chem
group	O
raise	O
the	O
barrier	O
.	O

Arformoterol	S-chem
:	O
(	B-chem
R	I-chem
,	I-chem
R	I-chem
)	I-chem
-	I-chem
eformoterol	E-chem
,	O
(	B-chem
R	I-chem
,	I-chem
R	I-chem
)	I-chem
-	I-chem
formoterol	E-chem
,	O
arformoterol	B-chem
tartrate	E-chem
,	O
eformoterol	S-chem
-	O
sepracor	O
,	O
formoterol	S-chem
-	O
sepracor	O
,	O
R	B-chem
,	I-chem
R	I-chem
-	I-chem
eformoterol	E-chem
,	O
R	B-chem
,	I-chem
R	I-chem
-	I-chem
formoterol	E-chem
.	O

Sepracor	O
in	O
the	O
US	O
is	O
developing	O
arformoterol	S-chem
[	O
R	B-chem
,	I-chem
R	I-chem
-	I-chem
formoterol	E-chem
]	O
,	O
a	O
single	O
isomer	O
form	O
of	O
the	O
beta	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
formoterol	S-chem-C5-1
[	O
eformoterol	S-chem-C5-1
]	O
.	O

This	O
isomer	O
contains	O
two	O
chiral	O
centres	O
and	O
is	O
being	O
developed	O
as	O
an	O
inhaled	O
preparation	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O

Sepracor	O
believes	O
that	O
arformoterol	S-chem
has	O
the	O
potential	O
to	O
be	O
a	O
once	O
-	O
daily	O
therapy	O
with	O
a	O
rapid	O
onset	O
of	O
action	O
and	O
a	O
duration	O
of	O
effect	O
exceeding	O
12	O
hours	O
.	O

In	O
1995	O
,	O
Sepracor	O
acquired	O
New	O
England	O
Pharmaceuticals	O
,	O
a	O
manufacturer	O
of	O
metered	O
-	O
dose	O
and	O
dry	O
powder	O
inhalers	O
,	O
for	O
the	O
purpose	O
of	O
preparing	O
formulations	O
of	O
levosalbutamol	S-chem
and	O
arformoterol	S-chem
.	O

Phase	O
II	O
dose	O
-	O
ranging	O
clinical	O
studies	O
of	O
arformoterol	S-chem
as	O
a	O
longer	O
-	O
acting	O
,	O
complementary	O
bronchodilator	O
were	O
completed	O
successfully	O
in	O
the	O
fourth	O
quarter	O
of	O
2000	O
.	O

Phase	O
III	O
trials	O
of	O
arformoterol	S-chem
began	O
in	O
September	O
2001	O
.	O

The	O
indications	O
for	O
the	O
drug	O
appeared	O
to	O
be	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

However	O
,	O
an	O
update	O
of	O
the	O
pharmaceutical	O
product	O
information	O
on	O
the	O
Sepracor	O
website	O
in	O
September	O
2003	O
listed	O
COPD	O
maintenance	O
therapy	O
as	O
the	O
only	O
indication	O
for	O
arformoterol	S-chem
.	O

In	O
October	O
2002	O
,	O
Sepracor	O
stated	O
that	O
two	O
pivotal	O
phase	O
III	O
studies	O
were	O
ongoing	O
in	O
1600	O
patients	O
.	O

Sepracor	O
estimates	O
that	O
its	O
NDA	O
submission	O
for	O
arformoterol	S-chem
,	O
which	O
is	O
projected	O
for	O
the	O
first	O
half	O
of	O
2004	O
,	O
will	O
include	O
approximately	O
3000	O
adult	O
subjects	O
.	O

Sepracor	O
stated	O
in	O
July	O
2003	O
that	O
it	O
had	O
completed	O
more	O
than	O
100	O
preclinical	O
studies	O
and	O
initiated	O
or	O
completed	O
15	O
clinical	O
studies	O
for	O
arformoterol	S-chem
inhalation	O
solution	O
for	O
the	O
treatment	O
of	O
bronchospasm	O
in	O
patients	O
with	O
COPD	O
.	O

In	O
addition	O
,	O
Sepracor	O
stated	O
that	O
the	O
two	O
pivotal	O
phase	O
III	O
studies	O
in	O
1600	O
patients	O
were	O
still	O
progressing	O
.	O

In	O
1995	O
,	O
European	O
patents	O
were	O
granted	O
to	O
Sepracor	O
for	O
the	O
use	O
of	O
arformoterol	S-chem
in	O
the	O
treatment	O
of	O
asthma	O
,	O
and	O
the	O
US	O
patent	O
application	O
was	O
pending	O
.	O

Multiple	O
pathways	O
for	O
cationic	O
amino	B-chem
acid	E-chem
transport	O
in	O
rat	O
seminiferous	O
tubule	O
cells	O
.	O

Arginine	S-chem
and	O
ornithine	S-chem
are	O
known	O
to	O
be	O
important	O
for	O
various	O
biological	O
processes	O
in	O
the	O
testis	O
,	O
but	O
the	O
delivery	O
of	O
extracellular	O
cationic	O
amino	B-chem
acids	E-chem
to	O
the	O
seminiferous	O
tubule	O
cells	O
remains	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
activity	O
and	O
expression	O
of	O
cationic	B-geneN
amino	I-geneN
acid	I-geneN
transporters	E-geneN
in	O
isolated	O
rat	O
Sertoli	O
cells	O
,	O
peritubular	O
cells	O
,	O
pachytene	O
spermatocytes	O
,	O
and	O
early	O
spermatids	O
.	O

We	O
assessed	O
the	O
l	B-chem
-	I-chem
arginine	E-chem
uptake	O
kinetics	O
,	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
dependence	O
of	O
transport	O
,	O
profiles	O
of	O
cis	O
inhibition	O
of	O
uptake	O
by	O
cationic	O
and	O
neutral	O
amino	B-chem
acids	E-chem
,	O
and	O
sensitivity	O
to	O
trans	O
stimulation	O
of	O
cationic	B-geneN
amino	I-geneN
acid	I-geneN
transporters	E-geneN
,	O
and	O
studied	O
the	O
expression	O
of	O
the	O
genes	O
encoding	O
them	O
by	O
RT	O
-	O
PCR	O
.	O

Our	O
data	O
suggest	O
that	O
l	B-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
is	O
taken	O
up	O
by	O
Sertoli	O
cells	O
and	O
peritubular	O
cells	O
,	O
principally	O
via	O
system	O
y	O
(	O
+	O
)	O
L	O
(	O
SLC3A2	S-geneY-C9-2
/	O
SLC7A6	S-geneY
)	O
and	O
system	O
y	O
(	O
+	O
)	O
(	O
SLC7A1	S-geneY
and	O
SLC7A2	S-geneY
)	O
,	O
with	O
system	O
B	O
(	O
0	O
+	O
)	O
making	O
a	O
minor	O
contribution	O
.	O

By	O
contrast	O
,	O
system	O
B	O
(	O
0	O
+	O
)	O
,	O
associated	O
with	O
system	O
y	O
(	O
+	O
)	O
L	O
(	O
SLC3A2	S-geneY
/	O
SLC7A7	S-geneY
and	O
SLC7A6	S-geneY
)	O
,	O
made	O
a	O
major	O
contribution	O
to	O
the	O
transport	O
of	O
cationic	O
amino	B-chem
acids	E-chem
in	O
pachytene	O
spermatocytes	O
and	O
early	O
spermatids	O
.	O

Sertoli	O
cells	O
had	O
higher	O
rates	O
of	O
l	B-chem
-	I-chem
arginine	E-chem
transport	O
than	O
the	O
other	O
seminiferous	O
tubule	O
cells	O
.	O

This	O
high	O
efficiency	O
of	O
arginine	S-chem
transport	O
in	O
Sertoli	O
cells	O
and	O
the	O
properties	O
of	O
the	O
y	O
(	O
+	O
)	O
L	O
system	O
predominating	O
in	O
these	O
cells	O
strongly	O
suggest	O
that	O
Sertoli	O
cells	O
play	O
a	O
key	O
role	O
in	O
supplying	O
germ	O
cells	O
with	O
l	B-chem
-	I-chem
arginine	E-chem
and	O
other	O
cationic	O
amino	B-chem
acids	E-chem
.	O

Furthermore	O
,	O
whereas	O
cytokines	S-geneN
induce	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
production	O
in	O
peritubular	O
and	O
Sertoli	O
cells	O
,	O
little	O
or	O
no	O
upregulation	O
of	O
arginine	S-chem
transport	O
by	O
cytokines	S-geneN
was	O
observed	O
in	O
these	O
cells	O
.	O

Thus	O
,	O
NO	S-chem
synthesis	O
does	O
not	O
depend	O
on	O
the	O
stimulation	O
of	O
arginine	S-chem
transport	O
in	O
these	O
somatic	O
tubular	O
cells	O
.	O

Fumarate	B-geneN
reductase	E-geneN
is	O
essential	O
for	O
Helicobacter	O
pylori	O
colonization	O
of	O
the	O
mouse	O
stomach	O
.	O

Fumarate	B-geneN-C9-2
reductase	E-geneN-C9-2
(	O
FRD	S-geneN-C9-2
)	O
is	O
the	O
key	O
enzyme	O
in	O
fumarate	S-chem-C9-1
respiration	O
induced	O
by	O
anaerobic	O
growth	O
of	O
bacteria	O
.	O

In	O
Helicobacter	O
pylori	O
,	O
this	O
enzyme	O
appears	O
to	O
be	O
constitutively	O
expressed	O
under	O
microaerobic	O
conditions	O
and	O
is	O
not	O
essential	O
for	O
its	O
survival	O
in	O
vitro	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
FRD	S-geneN
in	O
the	O
colonization	O
of	O
H.	O
pylori	O
was	O
investigated	O
using	O
a	O
mouse	O
model	O
.	O

The	O
frdA	S-geneY
gene	O
coding	O
for	O
subunit	B-geneY
A	I-geneY
of	I-geneY
FRD	E-geneY
,	O
and	O
two	O
control	O
genes	O
,	O
copA	S-geneY-C9-2
and	O
copP	S-geneY-C9-2
associated	O
with	O
the	O
export	O
of	O
copper	S-chem-C9-1
out	O
of	O
H.	O
pylori	O
,	O
were	O
inactivated	O
by	O
insertion	O
of	O
the	O
chloramphenicol	S-chem
acetyltransferase	O
cassette	O
into	O
these	O
individual	O
genes	O
.	O

The	O
isogenic	O
mutants	O
of	O
H.	O
pylori	O
strain	O
AH244	O
were	O
obtained	O
by	O
natural	O
transformation	O
.	O

Seventy	O
-	O
five	O
ICR	O
mice	O
(	O
15	O
mice	O
/	O
group	O
)	O
were	O
orogastrically	O
dosed	O
with	O
either	O
the	O
wild	O
type	O
H.	O
pylori	O
strain	O
AH244	O
,	O
its	O
isogenic	O
mutants	O
,	O
or	O
Brucella	O
broth	O
(	O
negative	O
control	O
)	O
.	O

Five	O
mice	O
from	O
each	O
group	O
were	O
killed	O
at	O
2	O
,	O
4	O
and	O
8	O
weeks	O
post	O
-	O
inoculation	O
(	O
WPI	O
)	O
,	O
respectively	O
.	O

H.	O
pylori	O
colonization	O
was	O
not	O
detected	O
in	O
mouse	O
gastric	O
mucosa	O
infected	O
with	O
the	O
frdA	S-geneY
mutant	O
at	O
any	O
time	O
point	O
in	O
the	O
study	O
by	O
both	O
quantitative	O
culture	O
and	O
PCR	O
.	O

In	O
contrast	O
,	O
the	O
mice	O
inoculated	O
with	O
either	O
wild	O
type	O
AH244	O
,	O
copA	S-geneY
or	O
copPH	S-geneY
.	O
pylori	O
mutants	O
became	O
readily	O
infected	O
.	O

These	O
data	O
indicate	O
that	O
FRD	S-geneN
plays	O
a	O
crucial	O
role	O
in	O
H.	O
pylori	O
survival	O
in	O
the	O
gastric	O
mucosa	O
of	O
mice	O
.	O

Given	O
that	O
FRD	S-geneN-C4-2
,	O
present	O
in	O
all	O
H.	O
pylori	O
strains	O
,	O
is	O
immunogenic	O
in	O
H.	O
pylori	O
-	O
infected	O
patients	O
and	O
H.	O
pylori	O
growth	O
in	O
vitro	O
can	O
be	O
inhibited	O
by	O
three	O
anthelmintics	O
(	O
morantel	S-chem-C4-1
,	O
oxantel	S-chem-C4-1
and	O
thiabendazole	S-chem-C4-1
)	O
,	O
this	O
enzyme	O
could	O
potentially	O
be	O
used	O
both	O
as	O
a	O
novel	O
drug	O
target	O
as	O
well	O
as	O
in	O
the	O
development	O
of	O
vaccines	O
for	O
H.	O
pylori	O
prevention	O
and	O
eradication	O
.	O

Disposition	O
of	O
a	O
specific	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
valdecoxib	S-chem-C4-1
,	O
in	O
human	O
.	O

Valdecoxib	S-chem-C4-1
is	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
which	O
is	O
used	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
,	O
and	O
the	O
dysmenorrhea	O
pain	O
.	O

Eight	O
male	O
human	O
subjects	O
each	O
received	O
a	O
single	O
50	O
-	O
mg	O
oral	O
dose	O
of	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
valdecoxib	E-chem
.	O

Urine	O
,	O
feces	O
,	O
and	O
blood	O
samples	O
were	O
collected	O
after	O
administration	O
of	O
the	O
radioactive	O
dose	O
.	O

Most	O
of	O
the	O
radioactivity	O
in	O
plasma	O
was	O
associated	O
with	O
valdecoxib	S-chem
and	O
the	O
hydroxylated	O
metabolite	O
of	O
valdecoxib	S-chem
(	O
M1	O
)	O
.	O

The	O
estimated	O
terminal	O
half	O
-	O
life	O
for	O
valdecoxib	S-chem
was	O
about	O
7	O
h	O
.	O

About	O
76.1	O
%	O
of	O
the	O
radioactive	O
dose	O
was	O
recovered	O
in	O
urine	O
and	O
18	O
%	O
of	O
the	O
radioactive	O
dose	O
was	O
recovered	O
in	O
feces	O
.	O

Valdecoxib	S-chem
was	O
extensively	O
metabolized	O
in	O
human	O
,	O
and	O
nine	O
phase	O
I	O
metabolites	O
were	O
identified	O
.	O

The	O
primary	O
oxidative	O
metabolic	O
pathways	O
of	O
valdecoxib	S-chem
involved	O
hydroxylation	O
at	O
either	O
the	O
methyl	S-chem
group	O
to	O
form	O
M1	O
or	O
N	S-chem
-	O
hydroxylation	O
at	O
the	O
sulfonamide	S-chem
moiety	O
to	O
form	O
M2	O
.	O

Further	O
oxidation	O
of	O
M1	O
led	O
to	O
the	O
formation	O
of	O
several	O
other	O
phase	O
I	O
metabolites	O
.	O

Oxidative	O
breakdown	O
of	O
the	O
N	B-chem
-	I-chem
hydroxy	I-chem
sulfonamide	E-chem
function	O
group	O
in	O
M2	O
led	O
to	O
the	O
formation	O
of	O
corresponding	O
sulfinic	B-chem
acid	E-chem
and	O
sulfonic	B-chem
acid	E-chem
metabolites	O
.	O

The	O
O	B-chem
-	I-chem
glucuronide	E-chem
conjugate	O
of	O
M1	O
and	O
N	B-chem
-	I-chem
glucuronide	E-chem
conjugate	O
of	O
valdecoxib	S-chem
were	O
the	O
major	O
urinary	O
metabolites	O
,	O
which	O
accounted	O
for	O
23.3	O
and	O
19.5	O
%	O
of	O
the	O
total	O
administered	O
dose	O
,	O
respectively	O
.	O

The	O
remaining	O
urinary	O
metabolites	O
were	O
glucuronide	O
conjugates	O
of	O
other	O
phase	O
I	O
metabolites	O
.	O

Only	O
3	O
%	O
of	O
the	O
administered	O
dose	O
was	O
recovered	O
in	O
urine	O
as	O
unchanged	O
parent	O
,	O
suggesting	O
that	O
renal	O
clearance	O
is	O
insignificant	O
for	O
valdecoxib	S-chem
.	O

Absorption	O
of	O
valdecoxib	S-chem
was	O
excellent	O
since	O
the	O
recovery	O
of	O
unchanged	O
valdecoxib	S-chem
in	O
feces	O
was	O
<	O
1	O
%	O
of	O
the	O
administered	O
dose	O
.	O

Sequestration	O
of	O
retinyl	B-chem
esters	E-chem
is	O
essential	O
for	O
retinoid	O
signaling	O
in	O
the	O
zebrafish	O
embryo	O
.	O

For	O
vertebrate	O
development	O
,	O
vitamin	B-chem
A	E-chem
(	O
all	B-chem
-	I-chem
trans	I-chem
retinol	E-chem
)	O
is	O
required	O
in	O
quantitative	O
different	O
amounts	O
and	O
spatiotemporal	O
distribution	O
for	O
the	O
production	O
of	O
retinoic	B-chem
acid	E-chem
,	O
a	O
nuclear	O
hormone	O
receptor	O
ligand	O
,	O
and	O
11	B-chem
-	I-chem
cis	I-chem
retinal	E-chem
,	O
the	O
chromophore	O
of	O
visual	O
pigments	O
.	O

We	O
show	O
here	O
for	O
zebrafish	O
that	O
embryonic	O
retinoid	O
homeostasis	O
essentially	O
depends	O
on	O
the	O
activity	O
of	O
a	O
leci	B-geneY
-	I-geneY
thin	I-geneY
:	I-geneY
retinol	I-geneY
acyltransferase	E-geneY
(	O
Lratb	S-geneY
)	O
.	O

During	O
embryogenesis	O
,	O
lratb	S-geneY
is	O
expressed	O
in	O
mostly	O
non	O
-	O
overlapping	O
domains	O
opposite	O
to	O
retinal	B-geneY-C9-2
dehydrogenase	I-geneY-C9-2
2	E-geneY-C9-2
(	O
raldh2	S-geneY-C9-2
)	O
,	O
the	O
key	O
enzyme	O
for	O
retinoic	B-chem-C9-1
acid	E-chem-C9-1
synthesis	O
.	O

Blocking	O
retinyl	B-chem-C9-1
ester	E-chem-C9-1
formation	O
by	O
a	O
targeted	O
knock	O
down	O
of	O
Lratb	S-geneY-C9-2
results	O
in	O
significantly	O
increased	O
retinoic	B-chem
acid	E-chem
levels	O
,	O
which	O
lead	O
to	O
severe	O
embryonic	O
patterning	O
defects	O
.	O

Thus	O
,	O
we	O
provide	O
evidence	O
that	O
a	O
balanced	O
competition	O
between	O
Lratb	S-geneY
and	O
Raldh2	S-geneY
for	O
yolk	O
vitamin	B-chem
A	E-chem
defines	O
embryonic	O
compartments	O
either	O
for	O
retinyl	B-chem
ester	E-chem
or	O
retinoic	B-chem
acid	E-chem
synthesis	O
.	O

This	O
homeostatic	O
mechanism	O
dynamically	O
adjusts	O
embryonic	O
retinoic	B-chem
acid	E-chem
levels	O
for	O
gene	O
regulation	O
,	O
concomitantly	O
sequestering	O
excess	O
yolk	O
vitamin	B-chem
A	E-chem
in	O
the	O
form	O
of	O
retinyl	O
esters	O
for	O
the	O
establishment	O
of	O
larval	O
vision	O
later	O
during	O
development	O
.	O

Nicotine	S-chem
facilitates	O
memory	O
consolidation	O
in	O
perceptual	O
learning	O
.	O

Perceptual	O
learning	O
is	O
a	O
special	O
type	O
of	O
non	O
-	O
declarative	O
learning	O
that	O
involves	O
experience	O
-	O
dependent	O
plasticity	O
in	O
sensory	O
cortices	O
.	O

The	O
cholinergic	O
system	O
is	O
known	O
to	O
modulate	O
declarative	O
learning	O
.	O

In	O
particular	O
,	O
reduced	O
levels	O
or	O
efficacy	O
of	O
the	O
neurotransmitter	O
acetylcholine	S-chem
were	O
found	O
to	O
facilitate	O
declarative	O
memory	O
consolidation	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
the	O
cholinergic	O
system	O
in	O
memory	O
consolidation	O
of	O
non	O
-	O
declarative	O
learning	O
.	O

Here	O
we	O
compared	O
two	O
groups	O
of	O
non	O
-	O
smoking	O
men	O
who	O
learned	O
a	O
visual	O
texture	O
discrimination	O
task	O
(	O
TDT	O
)	O
.	O

One	O
group	O
received	O
chewing	O
tobacco	O
containing	O
nicotine	S-chem
for	O
1	O
h	O
directly	O
following	O
the	O
TDT	O
training	O
.	O

The	O
other	O
group	O
received	O
a	O
similar	O
tasting	O
control	O
substance	O
without	O
nicotine	S-chem
.	O

Electroencephalographic	O
recordings	O
during	O
substance	O
consumption	O
showed	O
reduced	O
alpha	O
activity	O
and	O
P300	S-geneY-C4-2
latencies	O
in	O
the	O
nicotine	S-chem-C4-1
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

When	O
re	O
-	O
tested	O
on	O
the	O
TDT	O
the	O
following	O
day	O
,	O
both	O
groups	O
responded	O
more	O
accurately	O
and	O
more	O
rapidly	O
than	O
during	O
training	O
.	O

These	O
improvements	O
were	O
specific	O
to	O
the	O
retinal	O
location	O
and	O
orientation	O
of	O
the	O
texture	O
elements	O
of	O
the	O
TDT	O
suggesting	O
that	O
learning	O
involved	O
early	O
visual	O
cortex	O
.	O

A	O
group	O
comparison	O
showed	O
that	O
learning	O
effects	O
were	O
more	O
pronounced	O
in	O
the	O
nicotine	S-chem
group	O
than	O
in	O
the	O
control	O
group	O
.	O

These	O
findings	O
suggest	O
that	O
oral	O
consumption	O
of	O
nicotine	S-chem-C3-1
enhances	O
the	O
efficacy	O
of	O
nicotinic	B-geneN-C3-2
acetylcholine	I-geneN-C3-2
receptors	E-geneN-C3-2
.	O

Our	O
findings	O
further	O
suggest	O
that	O
enhanced	O
efficacy	O
of	O
the	O
cholinergic	O
system	O
facilitates	O
memory	O
consolidation	O
in	O
perceptual	O
learning	O
(	O
and	O
possibly	O
other	O
types	O
of	O
non	O
-	O
declarative	O
learning	O
)	O
.	O

In	O
that	O
regard	O
acetylcholine	S-chem
seems	O
to	O
affect	O
consolidation	O
processes	O
in	O
perceptual	O
learning	O
in	O
a	O
different	O
manner	O
than	O
in	O
declarative	O
learning	O
.	O

Alternatively	O
,	O
our	O
findings	O
might	O
reflect	O
dose	O
-	O
dependent	O
cholinergic	O
modulation	O
of	O
memory	O
consolidation	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Increased	O
expression	O
of	O
P450scc	S-geneY
and	O
CYP17	S-geneY
in	O
development	O
of	O
endogenous	O
hyperandrogenism	O
in	O
a	O
rat	O
model	O
of	O
PCOS	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
the	O
effect	O
of	O
insulin	S-geneN
plus	O
hCG	S-geneN
on	O
the	O
expression	O
of	O
steroidogenic	O
enzymes	O
(	O
P450scc	S-geneY
and	O
CYP17	S-geneY
)	O
in	O
polycystic	O
ovaries	O
of	O
rats	O
.	O

Changes	O
in	O
estrous	O
cycle	O
,	O
ovarian	O
morphology	O
,	O
hormonal	O
levels	O
,	O
and	O
protein	O
levels	O
by	O
immunohistochemistry	O
and	O
western	O
-	O
blot	O
were	O
determined	O
.	O

Rats	O
treated	O
with	O
insulin	S-geneN
plus	O
hCG	S-geneN
displayed	O
abnormal	O
estrous	O
cycles	O
with	O
increasing	O
androgen	S-chem
biosynthesis	O
.	O

Meanwhile	O
,	O
insulin	S-geneN
plus	O
hCG	S-geneN
resulted	O
in	O
multiple	O
large	O
cysts	O
with	O
diminished	O
granulosa	O
layers	O
and	O
increased	O
thecal	O
layers	O
and	O
stromal	O
-	O
interstitial	O
tissue	O
.	O

Moreover	O
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
expression	O
of	O
P450scc	S-geneY
and	O
CYP17	S-geneY
in	O
thecal	O
and	O
stromal	O
cells	O
in	O
our	O
PCOS	O
rat	O
model	O
compared	O
with	O
control	O
rats	O
.	O

These	O
results	O
indicate	O
that	O
administration	O
of	O
insulin	S-geneN
with	O
hCG	S-geneN
can	O
synergistically	O
result	O
in	O
endogenous	O
hyperandrogenism	O
which	O
may	O
partially	O
upregulate	O
the	O
expression	O
of	O
steroidogenic	O
enzymes	O
in	O
ovarian	O
tissue	O
.	O

Serine	B-geneN
racemases	E-geneN
from	O
barley	O
,	O
Hordeum	O
vulgare	O
L.	O
,	O
and	O
other	O
plant	O
species	O
represent	O
a	O
distinct	O
eukaryotic	O
group	O
:	O
gene	O
cloning	O
and	O
recombinant	O
protein	O
characterization	O
.	O

Several	O
d	B-chem
-	I-chem
amino	I-chem
acids	E-chem
have	O
been	O
identified	O
in	O
plants	O
.	O

However	O
,	O
the	O
biosynthetic	O
pathway	O
to	O
them	O
is	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
and	O
sequenced	O
a	O
cDNA	O
encoding	O
a	O
serine	B-geneY
racemase	E-geneY
from	O
barley	O
which	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
337	O
amino	B-chem
acid	E-chem
residues	O
.	O

The	O
deduced	O
amino	B-chem
acid	E-chem
sequence	O
showed	O
significant	O
identity	O
to	O
plant	O
and	O
mammalian	O
serine	B-geneN
racemases	E-geneN
and	O
contained	O
conserved	O
pyridoxal	B-chem
5	I-chem
-	I-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
-	O
binding	O
lysine	S-chem
and	O
PLP	S-chem
-	O
interacting	O
amino	B-chem
acid	E-chem
residues	O
.	O

The	O
purified	O
gene	O
product	O
catalyzed	O
not	O
only	O
racemization	O
of	O
serine	S-chem
but	O
also	O
dehydration	O
of	O
serine	S-chem
to	O
pyruvate	S-chem
.	O

The	O
enzyme	O
requires	O
PLP	S-chem
and	O
divalent	O
cations	O
such	O
as	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
Mg	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
or	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
but	O
not	O
ATP	S-chem
,	O
whereas	O
mammalian	O
serine	B-geneN-C3-2
racemase	E-geneN-C3-2
activity	O
is	O
increased	O
by	O
ATP	S-chem-C3-1
.	O

In	O
addition	O
to	O
the	O
results	O
regarding	O
the	O
effect	O
of	O
ATP	S-chem
on	O
enzyme	O
activity	O
and	O
the	O
phylogenetic	O
analysis	O
of	O
eukaryotic	O
serine	B-geneN
racemases	E-geneN
,	O
the	O
antiserum	O
against	O
Arabidopsis	B-geneY
serine	I-geneY
racemase	E-geneY
did	O
not	O
form	O
a	O
precipitate	O
with	O
barley	O
and	O
rice	O
serine	B-geneN
racemases	E-geneN
.	O

This	O
suggests	O
that	O
plant	O
serine	B-geneN
racemases	E-geneN
represent	O
a	O
distinct	O
group	O
in	O
the	O
eukaryotic	O
serine	B-geneN
racemase	E-geneN
family	O
and	O
can	O
be	O
clustered	O
into	O
monocot	O
and	O
dicot	O
types	O
.	O

Schisandrin	B-chem-C3-1
B	E-chem-C3-1
protects	O
against	O
menadione	S-chem
-	O
induced	O
hepatotoxicity	O
by	O
enhancing	O
DT	B-geneY-C3-2
-	I-geneY-C3-2
diaphorase	E-geneY-C3-2
activity	O
.	O

Pretreating	O
mice	O
with	O
schisandrin	B-chem
B	E-chem
(	O
Sch	B-chem
B	E-chem
)	O
,	O
a	O
dibenzocyclooctadiene	O
derivative	O
isolated	O
from	O
the	O
fruit	O
of	O
Schisandra	O
chinensis	O
,	O
at	O
a	O
daily	O
dose	O
of	O
1	O
mmol	O
/	O
kg	O
for	O
3	O
days	O
protected	O
against	O
menadione	S-chem-C4-1
-	O
induced	O
hepatic	O
oxidative	O
damage	O
in	O
mice	O
,	O
as	O
evidenced	O
by	O
decreases	O
in	O
plasma	O
alanine	B-geneN-C4-2
aminotransferase	E-geneN-C4-2
activity	O
(	O
78	O
%	O
)	O
and	O
hepatic	O
malondialdehyde	S-chem
level	O
(	O
70	O
%	O
)	O
,	O
when	O
compared	O
with	O
the	O
menadione	S-chem
intoxicated	O
control	O
.	O

In	O
order	O
to	O
define	O
the	O
biochemical	O
mechanism	O
involved	O
in	O
the	O
hepatoprotection	O
afforded	O
by	O
Sch	B-chem
B	E-chem
pretreatment	O
,	O
we	O
examined	O
the	O
activity	O
of	O
DT	B-geneY
-	I-geneY
diaphorase	E-geneY
(	O
DTD	S-geneY
)	O
in	O
hepatocytes	O
isolated	O
from	O
Sch	B-chem
B	E-chem
pretreated	O
rats	O
.	O

Hepatocytes	O
isolated	O
from	O
Sch	B-chem-C3-1
B	E-chem-C3-1
pretreated	O
(	O
a	O
daily	O
dose	O
of	O
1	O
mmol	O
/	O
kg	O
for	O
3	O
days	O
)	O
rats	O
showed	O
a	O
significant	O
increase	O
(	O
25	O
%	O
)	O
in	O
DTD	S-geneY-C3-2
activity	O
.	O

The	O
increase	O
in	O
DTD	S-geneY
activity	O
was	O
associated	O
with	O
the	O
enhanced	O
rate	O
of	O
menadione	S-chem
elimination	O
in	O
the	O
hepatocyte	O
culture	O
.	O

The	O
ensemble	O
of	O
results	O
suggests	O
that	O
the	O
ability	O
of	O
Sch	B-chem-C3-1
B	E-chem-C3-1
pretreatment	O
to	O
enhance	O
hepatocellular	O
DTD	S-geneY-C3-2
activity	O
may	O
at	O
least	O
in	O
part	O
be	O
attributed	O
to	O
the	O
protection	O
against	O
menadione	S-chem
hepatotoxicity	O
.	O

Autophagy	O
takes	O
place	O
in	O
mutated	O
p53	S-geneY
neuroblastoma	O
cells	O
in	O
response	O
to	O
hypoxia	O
mimetic	O
CoCl	B-chem
(	I-chem
2	I-chem
)	E-chem
.	O

Solid	O
tumors	O
like	O
neuroblastoma	O
exhibit	O
hypoxic	O
areas	O
,	O
which	O
can	O
lead	O
both	O
to	O
cell	O
death	O
or	O
aggressiveness	O
increase	O
.	O

Hypoxia	O
is	O
a	O
known	O
stress	O
able	O
to	O
induce	O
stabilization	O
of	O
p53	S-geneY
,	O
implicated	O
in	O
cell	O
fate	O
regulation	O
.	O

Recently	O
,	O
p53	S-geneY
appeared	O
to	O
be	O
involved	O
in	O
autophagy	O
in	O
an	O
opposite	O
manner	O
,	O
depending	O
on	O
its	O
location	O
:	O
when	O
nuclear	O
,	O
it	O
enhanced	O
transcription	O
of	O
pro	O
-	O
autophagic	O
genes	O
whereas	O
when	O
cytoplasmic	O
,	O
it	O
inhibited	O
the	O
autophagic	O
process	O
.	O

Today	O
,	O
we	O
used	O
cobalt	B-chem-C3-1
chloride	E-chem-C3-1
,	O
a	O
hypoxia	O
mimetic	O
that	O
inhibits	O
proteasomal	O
HIF	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
degradation	O
and	O
generates	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
.	O

We	O
focused	O
on	O
CoCl2	S-chem
-	O
induced	O
cell	O
death	O
in	O
a	O
DNA	O
-	O
binding	O
mutated	O
p53	S-geneY
neuroblastoma	O
cell	O
line	O
(	O
SKNBE	O
(	O
2c	O
)	O
)	O
.	O

An	O
autophagic	O
signaling	O
was	O
evidenced	O
by	O
an	O
increase	O
of	O
Beclin	B-geneY
-	I-geneY
1	E-geneY
,	O
ATG	B-geneN
5	I-geneN
-	I-geneN
12	E-geneN
,	O
and	O
LC3	B-geneY
-	I-geneY
II	E-geneY
expression	O
whereas	O
the	O
p53	S-geneY-C4-2
(	O
mut	O
)	O
presence	O
decreased	O
with	O
CoCl2	S-chem-C4-1
time	O
exposure	O
.	O

Activation	O
of	O
the	O
pathway	O
seemed	O
to	O
protect	O
cells	O
from	O
ROS	O
production	O
and	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
death	O
.	O

The	O
autophagic	O
inhibitors	O
activated	O
the	O
apoptotic	O
signaling	O
and	O
the	O
death	O
was	O
enhanced	O
.	O

To	O
delineate	O
the	O
eventual	O
implication	O
of	O
the	O
p53	S-geneY
(	O
mut	O
)	O
in	O
the	O
autophagic	O
process	O
in	O
response	O
to	O
hypoxia	O
,	O
we	O
monitored	O
signaling	O
in	O
p53	S-geneY
(	O
WT	O
)	O
SHSY5Y	O
cells	O
,	O
after	O
either	O
shRNA	O
-	O
p53	S-geneY
down	O
-	O
regulation	O
or	O
transcriptional	O
activity	O
inhibition	O
by	O
pifithrin	O
alpha	O
.	O

We	O
did	O
not	O
detect	O
autophagy	O
neither	O
with	O
p53	S-geneY
(	O
wt	O
)	O
nor	O
when	O
p53	S-geneY
was	O
lacking	O
whereas	O
such	O
a	O
response	O
was	O
effective	O
with	O
a	O
mutated	O
or	O
inactivated	O
p53	S-geneY
.	O

To	O
conclude	O
,	O
mutated	O
p53	S-geneY
in	O
neuroblastoma	O
cells	O
could	O
be	O
linked	O
with	O
the	O
switch	O
between	O
apoptotic	O
response	O
and	O
cell	O
death	O
by	O
autophagy	O
in	O
response	O
to	O
hypoxic	O
mimetic	O
stress	O
.	O

Influence	O
of	O
the	O
novel	O
histamine	B-geneY
H3	I-geneY
receptor	E-geneY
antagonist	O
ST1283	O
on	O
voluntary	O
alcohol	S-chem
consumption	O
and	O
ethanol	S-chem
-	O
induced	O
place	O
preference	O
in	O
mice	O
.	O

RATIONALE	O
:	O
Growing	O
evidence	O
supports	O
a	O
role	O
for	O
the	O
central	O
histaminergic	O
system	O
to	O
have	O
a	O
modulatory	O
influence	O
on	O
drug	O
addiction	O
in	O
general	O
and	O
alcohol	S-chem
-	O
use	O
disorders	O
in	O
particular	O
through	O
histamine	B-geneY
H3	I-geneY
receptors	E-geneY
(	O
H3R	S-geneY
)	O
.	O

OBJECTIVE	O
:	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
systemic	O
injection	O
of	O
the	O
newly	O
synthesized	O
H3R	S-geneY
antagonist	O
ST1283	O
on	O
ethanol	S-chem
(	O
EtOH	S-chem
)	O
voluntary	O
intake	O
and	O
EtOH	S-chem
-	O
conditioned	O
reward	O
in	O
mice	O
have	O
been	O
investigated	O
.	O

METHODS	O
:	O
Oral	O
EtOH	S-chem
,	O
saccharin	S-chem
,	O
and	O
quinine	S-chem
intake	O
was	O
assessed	O
in	O
a	O
two	O
-	O
bottle	O
choice	O
paradigm	O
using	O
escalating	O
concentrations	O
of	O
alcohol	S-chem
or	O
tastant	O
solutions	O
.	O

EtOH	S-chem
-	O
induced	O
place	O
preference	O
(	O
CPP	O
)	O
,	O
EtOH	S-chem
-	O
induced	O
locomotor	O
activity	O
,	O
and	O
blood	O
ethanol	S-chem
concentration	O
(	O
BEC	O
)	O
were	O
also	O
measured	O
.	O

RESULTS	O
:	O
Following	O
administration	O
of	O
the	O
H3R	S-geneY
antagonist	O
(	O
2.5	O
,	O
5	O
,	O
and	O
10	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
there	O
was	O
a	O
significant	O
dose	O
-	O
dependent	O
decrease	O
in	O
alcohol	O
consumption	O
and	O
preference	O
.	O

Importantly	O
,	O
vehicle	O
-	O
and	O
ST1283	O
(	O
5	O
mg	O
/	O
kg	O
)	O
-	O
treated	O
mice	O
showed	O
similar	O
consumption	O
and	O
preference	O
to	O
increasing	O
concentration	O
of	O
both	O
sweet	O
and	O
bitter	O
tastes	O
.	O

More	O
interestingly	O
,	O
systemic	O
administration	O
of	O
ST1283	O
inhibited	O
EtOH	S-chem
-	O
CPP	O
and	O
EtOH	S-chem
-	O
enhanced	O
locomotion	O
.	O

This	O
inhibition	O
was	O
blocked	O
when	O
mice	O
were	O
pretreated	O
with	O
the	O
selective	O
H3R	S-geneY-C5-2
agonist	O
R	B-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
alpha	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
methyl	I-chem-C5-1
-	I-chem-C5-1
histamine	E-chem-C5-1
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

Finally	O
,	O
vehicle	O
-	O
and	O
ST1283	O
-	O
treated	O
mice	O
had	O
similar	O
BECs	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
ST1283	O
may	O
decrease	O
voluntary	O
EtOH	S-chem
consumption	O
and	O
EtOH	S-chem
-	O
CPP	O
by	O
altering	O
its	O
reinforcing	O
effects	O
,	O
suggesting	O
a	O
novel	O
role	O
for	O
histamine	S-chem
signaling	O
in	O
regulation	O
of	O
alcoholism	O
.	O

Lastly	O
,	O
the	O
results	O
add	O
to	O
the	O
growing	O
literature	O
on	O
H3R	S-geneY
modulation	O
in	O
the	O
pharmacotherapy	O
of	O
EtOH	S-chem
addiction	O
.	O

Effect	O
of	O
the	O
R	B-chem
(	I-chem
-	I-chem
)	I-chem
and	I-chem
S	I-chem
(	I-chem
+	I-chem
)	I-chem
isomers	I-chem
of	I-chem
MDA	E-chem
and	O
MDMA	S-chem
on	O
phosphatidyl	B-chem
inositol	E-chem
turnover	O
in	O
cultured	O
cells	O
expressing	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
or	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
.	O

The	O
effect	O
of	O
the	O
R	B-chem
(	I-chem
-	I-chem
)	I-chem
and	I-chem
S	I-chem
(	I-chem
+	I-chem
)	I-chem
isomers	I-chem
of	I-chem
3,4	I-chem
-	I-chem
methylenedioxyamphetamine	E-chem
(	O
MDA	S-chem
)	O
and	O
its	O
N	B-chem
-	I-chem
methyl	I-chem
analog	I-chem
3,4	I-chem
-	I-chem
methylenedioxymethamphetamine	E-chem
(	O
MDMA	S-chem
)	O
on	O
[	B-chem
3H	I-chem
]	I-chem
inositol	I-chem
monophosphate	E-chem
accumulation	O
was	O
studied	O
in	O
cells	O
expressing	O
either	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
or	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
.	O

The	O
isomers	O
of	O
MDA	S-chem
produced	O
a	O
concentration	O
dependent	O
increase	O
in	O
phosphatidyl	B-chem
inositol	E-chem
(	O
PI	S-chem
)	O
hydrolysis	O
at	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
receptors	O
,	O
with	O
the	O
R	B-chem
(	I-chem
-	I-chem
)	I-chem
isomer	I-chem
of	I-chem
MDA	E-chem
being	O
more	O
potent	O
than	O
the	O
S	O
(	O
+	O
)	O
at	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
receptor	O
.	O

The	O
R	B-chem
(	I-chem
-	I-chem
)	I-chem
and	I-chem
S	I-chem
(	I-chem
+	I-chem
)	I-chem
isomers	I-chem
of	I-chem
MDMA	E-chem
were	O
significantly	O
less	O
efficacious	O
at	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
receptor	O
as	O
compared	O
to	O
MDA	S-chem
;	O
S	B-chem
(	I-chem
+	I-chem
)	I-chem
MDMA	E-chem
had	O
no	O
effect	O
.	O

At	O
the	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
,	O
both	O
R	B-chem
(	I-chem
-	I-chem
)	I-chem
and	I-chem
S	I-chem
(	I-chem
+	I-chem
)	I-chem
MDA	E-chem
were	O
equipotent	O
at	O
stimulating	O
PI	S-chem
hydrolysis	O
,	O
with	O
the	O
S	B-chem
(	I-chem
+	I-chem
)	I-chem
isomer	I-chem
of	I-chem
MDMA	E-chem
being	O
more	O
efficacious	O
at	O
the	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
compared	O
with	O
the	O
R	O
(	O
-	O
)	O
isomer	O
.	O

In	O
all	O
cases	O
at	O
both	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
,	O
the	O
affinities	O
of	O
the	O
isomers	O
of	O
MDMA	S-chem
and	O
MDA	S-chem
were	O
at	O
least	O
2	O
-	O
3	O
orders	O
of	O
magnitude	O
less	O
than	O
5	B-chem
-	I-chem
HT	E-chem
.	O

Despite	O
the	O
weak	O
effect	O
of	O
these	O
compounds	O
at	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
,	O
these	O
substituted	O
amphetamines	S-chem
do	O
possess	O
intrinsic	O
activity	O
which	O
may	O
contribute	O
to	O
their	O
neurotoxic	O
effects	O
when	O
administered	O
at	O
high	O
doses	O
.	O

Metabolism	O
of	O
Beclomethasone	B-chem-C9-1
Dipropionate	E-chem-C9-1
by	O
Cytochrome	B-geneN-C9-2
P450	I-geneN-C9-2
3A	E-geneN-C9-2
Enzymes	O
.	O

Inhaled	O
glucocorticoids	O
,	O
such	O
as	O
beclomethasone	B-chem
dipropionate	E-chem
(	O
BDP	S-chem
)	O
,	O
are	O
the	O
mainstay	O
treatment	O
of	O
asthma	O
.	O

However	O
,	O
∼	O
30	O
%	O
of	O
patients	O
exhibit	O
little	O
to	O
no	O
benefit	O
from	O
treatment	O
.	O

It	O
has	O
been	O
postulated	O
that	O
glucocorticoid	O
resistance	O
,	O
or	O
insensitivity	O
,	O
is	O
attributable	O
to	O
individual	O
differences	O
in	O
glucocorticoid	B-geneY
receptor	E-geneY
-	O
mediated	O
processes	O
.	O

It	O
is	O
possible	O
that	O
variations	O
in	O
cytochrome	B-geneN-C9-2
P450	I-geneN-C9-2
3A	E-geneN-C9-2
enzyme	O
-	O
mediated	O
metabolism	O
of	O
BDP	S-chem-C9-1
may	O
contribute	O
to	O
this	O
phenomenon	O
.	O

This	O
hypothesis	O
was	O
explored	O
by	O
evaluating	O
the	O
contributions	O
of	O
CYP3A4	B-geneN
,	I-geneN
3A5	I-geneN
,	I-geneN
3A7	E-geneN
,	O
and	O
esterase	S-geneN-C9-2
enzymes	O
in	O
the	O
metabolism	O
of	O
BDP	S-chem-C9-1
in	O
vitro	O
and	O
relating	O
metabolism	O
to	O
changes	O
in	O
CYP3A	S-geneN
enzyme	O
mRNA	O
expression	O
via	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
in	O
lung	O
and	O
liver	O
cells	O
.	O

CYP3A4	S-geneY-C9-2
and	O
CYP3A5	S-geneY-C9-2
metabolized	O
BDP	S-chem-C9-1
via	O
hydroxylation	O
(	O
[	O
M4	O
]	O
and	O
[	O
M6	O
]	O
)	O
and	O
dehydrogenation	O
(	O
[	O
M5	O
]	O
)	O
at	O
similar	O
rates	O
;	O
CYP3A7	S-geneY
did	O
not	O
metabolize	O
BDP	S-chem
.	O

A	O
new	O
metabolite	O
[	O
M6	O
]	O
,	O
formed	O
by	O
the	O
combined	O
action	O
of	O
esterases	O
and	O
CYP3A4	S-geneY
hydroxylation	O
,	O
was	O
also	O
characterized	O
.	O

To	O
validate	O
the	O
results	O
observed	O
using	O
microsomes	O
and	O
recombinant	O
enzymes	O
,	O
studies	O
were	O
also	O
conducted	O
using	O
A549	O
lung	O
and	O
DPX2	O
liver	O
cells	O
.	O

Both	O
liver	O
and	O
lung	O
cells	O
produced	O
esterase	O
-	O
dependent	O
metabolites	O
[	O
M1	O
-	O
M3	O
]	O
,	O
with	O
[	O
M1	O
]	O
correlating	O
with	O
CYP3A5	S-geneY
mRNA	O
induction	O
in	O
A549	O
cells	O
.	O

Liver	O
cells	O
produced	O
both	O
hydroxylated	O
and	O
dehydrogenated	O
metabolites	O
[	O
M4	O
,	O
M5	O
,	O
and	O
M6	O
]	O
,	O
but	O
lung	O
cells	O
produced	O
only	O
the	O
dehydrogenated	O
metabolite	O
[	O
M5	O
]	O
.	O

These	O
studies	O
show	O
that	O
CYP3A4	S-geneY-C9-2
and	O
CYP3A5	S-geneY-C9-2
metabolize	O
BDP	S-chem-C9-1
to	O
inactive	O
metabolites	O
and	O
suggest	O
that	O
differences	O
in	O
the	O
expression	O
or	O
function	O
of	O
these	O
enzymes	O
in	O
the	O
lung	O
and	O
/	O
or	O
liver	O
could	O
influence	O
BDP	S-chem
disposition	O
in	O
humans	O
.	O

Minocycline	S-chem
markedly	O
protects	O
the	O
neonatal	O
brain	O
against	O
hypoxic	O
-	O
ischemic	O
injury	O
.	O

Hypoxic	O
-	O
ischemic	O
brain	O
injury	O
in	O
the	O
perinatal	O
period	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Presently	O
,	O
there	O
are	O
no	O
proven	O
effective	O
therapies	O
with	O
which	O
to	O
safeguard	O
the	O
human	O
neonatal	O
brain	O
against	O
this	O
type	O
of	O
injury	O
.	O

Minocycline	S-chem
,	O
a	O
semisynthetic	O
tetracycline	S-chem
,	O
has	O
been	O
shown	O
to	O
be	O
neuroprotective	O
in	O
certain	O
adult	O
ischemic	O
injury	O
/	O
stroke	O
and	O
neurodegenerative	O
disease	O
models	O
.	O

However	O
,	O
minocycline	O
's	O
neuroprotective	O
effects	O
have	O
not	O
been	O
assessed	O
after	O
insults	O
to	O
the	O
neonatal	O
brain	O
.	O

We	O
now	O
report	O
that	O
minocycline	S-chem
administered	O
either	O
immediately	O
before	O
or	O
immediately	O
after	O
a	O
hypoxic	O
-	O
ischemic	O
insult	O
substantially	O
blocks	O
tissue	O
damage	O
in	O
a	O
rodent	O
model	O
of	O
neonatal	O
hypoxic	O
-	O
ischemic	O
brain	O
injury	O
.	O

Minocycline	S-chem-C4-1
treatment	O
prevents	O
the	O
formation	O
of	O
activated	O
caspase	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
,	O
a	O
known	O
effector	O
of	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
calpain	S-geneN
cleaved	O
substrate	O
,	O
a	O
marker	O
of	O
excitotoxic	O
/	O
necrotic	O
cell	O
death	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
systemic	O
treatment	O
that	O
can	O
be	O
administered	O
after	O
a	O
hypoxic	O
-	O
ischemic	O
insult	O
,	O
which	O
provides	O
robust	O
,	O
nearly	O
complete	O
neuroprotection	O
to	O
the	O
developing	O
brain	O
.	O

Our	O
data	O
suggest	O
that	O
minocycline	S-chem
or	O
a	O
related	O
neuroprotective	O
tetracycline	S-chem
may	O
be	O
a	O
candidate	O
to	O
consider	O
in	O
human	O
clinical	O
trials	O
to	O
protect	O
the	O
developing	O
brain	O
against	O
hypoxic	O
-	O
ischemic	O
-	O
induced	O
damage	O
.	O

Time	O
-	O
dependent	O
changes	O
in	O
hepatic	O
and	O
intestinal	O
induction	O
of	O
cytochrome	B-geneN-C3-2
P450	I-geneN-C3-2
3A	E-geneN-C3-2
after	O
administration	O
of	O
dexamethasone	S-chem-C3-1
to	O
rats	O
.	O

Abstract	O
1	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
the	O
dose	O
of	O
and	O
the	O
number	O
of	O
times	O
an	O
inducer	O
was	O
administered	O
and	O
the	O
duration	O
of	O
induction	O
of	O
hepatic	O
and	O
intestinal	O
cytochrome	O
P450	I-geneN-MU-2
3A	I-geneN-MU-2
(	E-geneN-MU-2
CYP3A	O
)	E-geneN-MU-2
in	O
rats	O
using	O
dexamethasone	O
21	I-chem-MU-1
-	I-chem-MU-1
phosphate	I-chem-MU-1
(	E-chem-MU-1
DEX	O
-	I-chem-MU-1
P	I-chem-MU-1
)	E-chem-MU-1
and	O
midazolam	O
(	E-chem-MU-1
MDZ	O
)	E-chem-MU-1
as	O
an	O
inducer	O
and	O
a	O
substrate	O
to	O
CYP3A	O
,	E-geneN-MU-2
respectively	O
.	O

2	O
.	O
The	O
number	O
of	O
times	O
DEX	O
-	I-chem
P	I-chem
was	O
administered	O
was	O
not	O
a	O
significant	O
factor	O
in	O
the	O
induction	O
of	O
either	O
hepatic	O
or	O
intestinal	O
CYP3A	O
;	E-geneN
however	O
,	O
administration	O
of	O
DEX	O
-	I-chem
P	I-chem
multiple	O
times	O
markedly	O
decreased	O
the	O
bioavailability	O
of	O
DEX	O
-	I-chem
P	I-chem
by	O
self	O
-	O
induction	O
of	O
CYP3A	O
.	E-geneN

3	O
.	O
CYP3A	O
induction	O
in	O
the	O
liver	O
increased	O
depending	O
on	O
the	O
dose	O
of	O
DEX	O
-	I-chem-C3-1
P	I-chem-C3-1
,	E-chem-C3-1
whereas	O
that	O
in	O
intestine	O
showed	O
a	O
mild	O
increase	O
,	O
but	O
the	O
induction	O
level	O
was	O
almost	O
constant	O
regardless	O
of	O
the	O
dose	O
of	O
DEX	O
-	I-chem-C3-1
P	I-chem-C3-1
.	E-chem-C3-1

4	O
.	O
Administration	O
of	O
a	O
single	O
dose	O
of	O
DEX	O
-	I-chem-C3-1
P	I-chem-C3-1
showed	O
a	O
temporal	O
increase	O
in	O
CYP3A	O
activity	O
in	O
both	O
tissues	O
and	O
the	O
induction	O
ratios	O
reached	O
maximum	O
values	O
at	O
12	O
h	O
after	O
DEX	O
-	I-chem-C3-1
P	I-chem-C3-1
administration	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
mild	O
increase	O
of	O
CYP3A	S-geneN
activity	O
,	O
which	O
lasted	O
for	O
at	O
least	O
48	O
h	O
,	O
was	O
observed	O
in	O
both	O
tissues	O
after	O
administration	O
of	O
multiple	O
doses	O
.	O

5	O
.	O
Some	O
physiological	O
compounds	O
such	O
as	O
cytokines	O
might	O
be	O
involved	O
in	O
decreasing	O
the	O
CYP3A	O
activity	O
to	O
maintain	O
homeostasis	O
of	O
the	O
body	O
.	O

[	O
Pharmacological	O
effects	O
of	O
a	O
mu	B-geneY-C6-2
-	I-geneY-C6-2
opioid	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
naltrexone	S-chem-C6-1
on	O
alcohol	S-chem
dependence	O
]	O
.	O

Alcohol	S-chem
is	O
one	O
of	O
the	O
most	O
commonly	O
abused	O
substances	O
,	O
and	O
its	O
chronic	O
intake	O
leads	O
to	O
the	O
development	O
of	O
ethanol	S-chem
dependence	O
in	O
both	O
humans	O
and	O
laboratory	O
animals	O
.	O

In	O
many	O
countries	O
,	O
a	O
mu	B-geneY-C6-2
-	I-geneY-C6-2
opioid	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
naltrexone	S-chem-C6-1
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
alcohol	S-chem
dependence	O
.	O

The	O
introduction	O
of	O
naltrexone	S-chem
for	O
the	O
treatment	O
of	O
alcohol	S-chem
dependence	O
has	O
been	O
mainly	O
based	O
on	O
behavioral	O
animal	O
models	O
that	O
provide	O
evidence	O
of	O
the	O
involvement	O
of	O
the	O
endogenous	O
opioid	O
system	O
in	O
alcohol	S-chem
drinking	O
and	O
dependence	O
.	O

It	O
has	O
been	O
well	O
known	O
that	O
alcohol	S-chem
leads	O
to	O
the	O
activation	O
of	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
endogenous	O
opioid	O
agonists	O
,	O
such	O
as	O
beta	B-geneY
-	I-geneY
endorphin	E-geneY
,	O
increase	O
the	O
activity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
through	O
the	O
inhibition	O
of	O
the	O
gamma	B-chem
-	I-chem
aminobutyric	I-chem
acid	E-chem
(	O
GABA	S-chem
)	O
-	O
containing	O
inhibitory	O
interneurons	O
in	O
the	O
ventral	O
tegmental	O
area	O
,	O
resulting	O
in	O
the	O
expression	O
of	O
alcohol	S-chem
reinforcement	O
and	O
/	O
or	O
rewarding	O
effect	O
.	O

Therefore	O
,	O
naltrexone	S-chem
,	O
which	O
is	O
useful	O
for	O
alcohol	S-chem
dependence	O
therapy	O
,	O
may	O
attenuate	O
the	O
rewarding	O
effect	O
of	O
ethanol	S-chem
by	O
interfering	O
with	O
the	O
ethanol	S-chem
-	O
induced	O
stimulation	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
.	O

The	O
following	O
review	O
provides	O
a	O
summary	O
of	O
the	O
interactions	O
between	O
endogenous	O
opioid	O
system	O
and	O
mesolimbic	O
dopaminergic	O
system	O
in	O
alcohol	S-chem
dependence	O
.	O

Vinblastine	S-chem
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
is	O
mediated	O
by	O
Ras	B-geneY
homologous	I-geneY
A	I-geneY
protein	E-geneY
(	O
Rho	B-geneY
A	E-geneY
)	O
via	O
mitochondrial	O
and	O
non	O
-	O
mitochondrial	O
-	O
dependent	O
mechanisms	O
.	O

Despite	O
the	O
availability	O
of	O
melanoma	O
treatment	O
at	O
the	O
primary	O
site	O
,	O
the	O
recurrence	O
of	O
local	O
melanoma	O
can	O
metastasize	O
to	O
any	O
distant	O
organ	O
.	O

Currently	O
,	O
the	O
available	O
therapies	O
for	O
the	O
treatment	O
of	O
metastatic	O
melanoma	O
are	O
of	O
limited	O
benefit	O
.	O

Thus	O
,	O
the	O
functional	O
analysis	O
of	O
conventional	O
therapies	O
may	O
help	O
to	O
improve	O
their	O
efficiency	O
in	O
the	O
treatment	O
of	O
metastatic	O
melanoma	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
exposure	O
of	O
melanoma	O
cells	O
to	O
vinblastine	S-chem
was	O
found	O
to	O
trigger	O
apoptosis	O
as	O
evidenced	O
by	O
the	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
the	O
release	O
of	O
both	O
cytochrome	B-geneY
c	E-geneY
and	O
apoptosis	B-geneY
inducing	I-geneY
factor	E-geneY
,	O
activation	O
of	O
caspase	B-geneN
-	I-geneN
9	I-geneN
and	I-geneN
3	E-geneN
,	O
and	O
cleavage	O
of	O
Poly	B-geneN
(	I-geneN
ADP	I-geneN
-	I-geneN
ribose	I-geneN
)	I-geneN
-	I-geneN
Polymerase	E-geneN
.	O

Also	O
,	O
vinblastine	S-chem-C3-1
enhances	O
the	O
phosphorylation	O
of	O
Ras	B-geneY-C3-2
homologous	I-geneY-C3-2
protein	I-geneY-C3-2
A	E-geneY-C3-2
,	O
the	O
accumulation	O
of	O
reactive	O
oxygen	S-chem
species	O
,	O
the	O
release	O
of	O
intracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
as	O
well	O
as	O
the	O
activation	O
of	O
apoptosis	B-geneY-C3-2
signal	I-geneY-C3-2
-	I-geneY-C3-2
regulating	I-geneY-C3-2
kinase	I-geneY-C3-2
1	E-geneY-C3-2
,	O
c	B-geneN-C3-2
-	I-geneN-C3-2
jun	I-geneN-C3-2
-	I-geneN-C3-2
N	I-geneN-C3-2
-	I-geneN-C3-2
terminal	I-geneN-C3-2
kinase	E-geneN-C3-2
,	O
p38	S-geneN-C3-2
,	O
inhibitor	B-geneY-C3-2
of	I-geneY-C3-2
kappaBα	E-geneY-C3-2
(	O
IκBα	S-geneY-C3-2
)	O
kinase	S-geneN-C3-2
,	O
and	O
inositol	B-geneY-C3-2
requiring	I-geneY-C3-2
enzyme	I-geneY-C3-2
1α	E-geneY-C3-2
.	O

In	O
addition	O
,	O
vinblastine	S-chem-C3-1
induces	O
the	O
DNA	O
-	O
binding	O
activities	O
of	O
the	O
transcription	O
factor	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
,	O
HSF1	S-geneY-C3-2
,	O
AP	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
,	O
and	O
ATF	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
,	O
together	O
with	O
the	O
expression	O
of	O
HSP70	S-geneN-C3-2
and	O
Bax	S-geneY-C3-2
proteins	O
.	O

Moreover	O
,	O
inhibitory	O
experiments	O
addressed	O
a	O
central	O
role	O
for	O
Rho	B-geneY
A	E-geneY
in	O
the	O
regulation	O
of	O
vinblastine	S-chem
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
via	O
mitochondrial	O
and	O
non	O
-	O
mitochondrial	O
-	O
dependent	O
mechanisms	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
addresses	O
for	O
the	O
first	O
time	O
a	O
central	O
role	O
for	O
Rho	B-geneY
A	E-geneY
in	O
the	O
modulation	O
of	O
vinblastine	S-chem
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
and	O
thereby	O
provides	O
an	O
insight	O
into	O
the	O
molecular	O
action	O
of	O
vinblastine	S-chem
in	O
melanoma	O
treatment	O
.	O

Antofine	S-chem
-	O
induced	O
connexin43	S-geneY
gap	O
junction	O
disassembly	O
in	O
rat	O
astrocytes	O
involves	O
protein	B-geneY
kinase	I-geneY
Cβ	E-geneY
.	O

Antofine	S-chem
,	O
a	O
phenanthroindolizidine	B-chem
alkaloid	E-chem
derived	O
from	O
Cryptocaryachinensis	O
and	O
Ficusseptica	O
in	O
the	O
Asclepiadaceae	O
milkweed	O
family	O
,	O
is	O
cytotoxic	O
for	O
various	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
treatment	O
of	O
rat	O
primary	O
astrocytes	O
with	O
antofine	S-chem
induced	O
dose	O
-	O
dependent	O
inhibition	O
of	O
gap	O
junction	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
,	O
as	O
assessed	O
by	O
scrape	O
-	O
loading	O
6	B-chem
-	I-chem
carboxyfluorescein	E-chem
dye	O
transfer	O
.	O

Levels	O
of	O
Cx43	S-geneY-C4-2
protein	O
were	O
also	O
decreased	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
following	O
antofine	S-chem-C4-1
treatment	O
.	O

Double	O
-	O
labeling	O
immunofluorescence	O
microscopy	O
showed	O
that	O
antofine	S-chem
(	O
10ng	O
/	O
ml	O
)	O
induced	O
endocytosis	O
of	O
surface	O
gap	O
junctions	O
into	O
the	O
cytoplasm	O
,	O
where	O
Cx43	S-geneY
was	O
co	O
-	O
localized	O
with	O
the	O
early	O
endosome	O
marker	O
EEA1	S-geneN
.	O

Inhibition	O
of	O
lysosomes	O
or	O
proteasomes	O
by	O
co	O
-	O
treatment	O
with	O
antofine	S-chem
and	O
their	O
respective	O
specific	O
inhibitors	O
,	O
NH4Cl	S-chem
or	O
MG132	S-chem
,	O
partially	O
inhibited	O
the	O
antofine	O
-	O
induced	O
decrease	O
in	O
Cx43	S-geneY
protein	O
levels	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
antofine	O
-	O
induced	O
inhibition	O
of	O
GJIC	O
.	O

After	O
30min	O
of	O
treatment	O
,	O
antofine	O
induced	O
a	O
rapid	O
increase	O
in	O
the	O
intracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
concentration	O
and	O
activation	O
of	O
protein	B-geneN
kinase	I-geneN
C	I-geneN
(	I-geneN
PKC	I-geneN
)	I-geneN
α	I-geneN
/	I-geneN
βII	E-geneN
,	O
which	O
was	O
maintained	O
for	O
at	O
least	O
6h	O
.	O

Co	O
-	O
treatment	O
of	O
astrocytes	O
with	O
antofine	S-chem-C4-1
and	O
the	O
intracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
chelator	O
BAPTA	B-chem-C3-1
-	I-chem-C3-1
AM	E-chem-C3-1
prevented	O
downregulation	O
of	O
Cx43	S-geneY-MU-2
and	O
inhibition	O
of	O
GJIC	O
.	O

Moreover	O
,	O
co	O
-	O
treatment	O
with	O
antofine	S-chem-C4-1
and	O
a	O
specific	O
PKCβ	S-geneY
inhibitor	O
prevented	O
endocytosis	O
of	O
gap	O
junctions	O
,	O
downregulation	O
of	O
Cx43	S-geneY-C4-2
,	O
and	O
inhibition	O
of	O
GJIC	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
antofine	S-chem-C3-1
induces	O
Cx43	S-geneY
gap	O
junction	O
disassembly	O
by	O
the	O
PKCβ	S-geneY-C3-2
signaling	O
pathway	O
.	O

Inhibition	O
of	O
GJIC	O
by	O
antofine	S-chem
may	O
undermine	O
the	O
neuroprotective	O
effect	O
of	O
astrocytes	O
in	O
CNS	O
.	O

Use	O
of	O
nitisinone	S-chem
in	O
patients	O
with	O
alkaptonuria	O
.	O

Alkaptonuria	O
,	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
HGD	S-geneY
gene	O
and	O
deficiency	O
of	O
homogentisate	B-geneY
1,2	I-geneY
dioxygenase	E-geneY
,	O
is	O
characterized	O
by	O
ochronosis	O
,	O
arthritis	O
,	O
and	O
daily	O
excretion	O
of	O
gram	O
quantities	O
of	O
homogentisic	B-chem
acid	E-chem
(	O
HGA	S-chem
)	O
.	O

Nitisinone	O
,	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
4	B-geneY
-	I-geneY
hydroxyphenylpyruvate	I-geneY
dioxygenase	E-geneY
,	O
can	O
drastically	O
reduce	O
urinary	O
excretion	O
of	O
HGA	S-chem
in	O
individuals	O
with	O
alkaptonuria	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
the	O
HGA	S-chem
-	O
depleting	O
efficacy	O
of	O
nitisinone	S-chem
in	O
an	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
study	O
of	O
9	O
alkaptonuria	O
patients	O
(	O
5	O
women	O
,	O
4	O
men	O
;	O
35	O
-	O
69	O
years	O
of	O
age	O
)	O
over	O
the	O
course	O
of	O
3	O
to	O
4	O
months	O
.	O

Each	O
patient	O
received	O
nitisinone	S-chem
in	O
incremental	O
doses	O
,	O
0.35	O
mg	O
bid	O
followed	O
by	O
1.05	O
mg	O
bid	O
,	O
and	O
remained	O
on	O
this	O
dosage	O
and	O
a	O
regular	O
diet	O
for	O
3	O
months	O
.	O

Nitisinone	S-chem
reduced	O
urinary	O
HGA	S-chem
levels	O
from	O
an	O
average	O
of	O
4.0	O
+	O
/	O
-	O
1.8	O
(	O
SD	O
)	O
g	O
/	O
day	O
to	O
0.2	O
+	O
/	O
-	O
0.2	O
g	O
/	O
day	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
average	O
plasma	O
tyrosine	S-chem
concentration	O
,	O
initially	O
68	O
+	O
/	O
-	O
18	O
mmicro	O
mol	O
/	O
L	O
,	O
rose	O
to	O
760	O
+	O
/	O
-	O
181	O
micro	O
mol	O
/	O
L	O
(	O
P	O
<	O
.001	O
)	O
.	O

During	O
the	O
final	O
week	O
of	O
the	O
study	O
,	O
5	O
patients	O
adhered	O
to	O
a	O
protein	O
-	O
restricted	O
diet	O
(	O
40	O
g	O
/	O
day	O
)	O
,	O
and	O
their	O
mean	O
plasma	O
tyrosine	S-chem
level	O
fell	O
from	O
755	O
+	O
/	O
-	O
167	O
to	O
603	O
+	O
/	O
-	O
114	O
mu	O
mol	O
/	O
L	O
.	O

Six	O
of	O
the	O
7	O
patients	O
who	O
received	O
nitisinone	S-chem
for	O
more	O
than	O
1	O
week	O
reported	O
decreased	O
pain	O
in	O
their	O
affected	O
joints	O
.	O

Weekly	O
ophthalmologic	O
examinations	O
showed	O
no	O
signs	O
of	O
corneal	O
toxicity	O
.	O

Adverse	O
events	O
included	O
the	O
passing	O
of	O
kidney	O
stones	O
,	O
the	O
recognition	O
of	O
symptoms	O
related	O
to	O
aortic	O
stenosis	O
,	O
and	O
elevation	O
of	O
liver	O
transaminase	S-geneN
levels	O
.	O

We	O
conclude	O
that	O
low	O
-	O
dose	O
nitisinone	S-chem
effectively	O
reduced	O
urinary	O
HGA	S-chem
levels	O
in	O
patients	O
with	O
alkaptonuria	O
.	O

Future	O
long	O
-	O
term	O
clinical	O
trials	O
are	O
planned	O
to	O
determine	O
the	O
benefits	O
of	O
nitisinone	S-chem
in	O
preventing	O
joint	O
deterioration	O
and	O
providing	O
pain	O
relief	O
,	O
and	O
its	O
long	O
-	O
term	O
side	O
effects	O
.	O

Alternariol	S-chem
induces	O
abnormal	O
nuclear	O
morphology	O
and	O
cell	O
cycle	O
arrest	O
in	O
murine	O
RAW	O
264.7	O
macrophages	O
.	O

The	O
mycotoxin	O
alternariol	S-chem
(	O
AOH	S-chem
)	O
,	O
a	O
frequent	O
contaminant	O
in	O
fruit	O
and	O
cereal	O
products	O
,	O
is	O
known	O
to	O
induce	O
DNA	O
damage	O
with	O
subsequent	O
cell	O
cycle	O
arrest	O
.	O

Here	O
we	O
elucidated	O
the	O
effects	O
of	O
AOH	S-chem
on	O
stages	O
of	O
cell	O
cycle	O
progression	O
using	O
the	O
RAW	O
264.7	O
macrophage	O
model	O
.	O

AOH	S-chem
resulted	O
in	O
an	O
accumulation	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
-	O
phase	O
(	O
4N	O
)	O
.	O

Most	O
cells	O
exhibited	O
a	O
large	O
G2	O
nucleus	O
whereas	O
numbers	O
of	O
true	O
mitotic	O
cells	O
were	O
reduced	O
relative	O
to	O
control	O
.	O

Both	O
cyclin	B-geneY
B1	E-geneY
and	O
p	B-geneY
-	I-geneY
cdc2	E-geneY
levels	O
increased	O
,	O
while	O
cyclin	B-geneY
B1	E-geneY
remained	O
in	O
the	O
cytoplasm	O
;	O
suggesting	O
arrest	O
in	O
the	O
G2	O
/	O
M	O
transition	O
point	O
.	O

Remarkably	O
,	O
after	O
exposure	O
to	O
AOH	S-chem
for	O
24h	O
,	O
most	O
of	O
the	O
cells	O
exhibited	O
abnormally	O
shaped	O
nuclei	O
,	O
as	O
evidenced	O
by	O
partly	O
divided	O
nuclei	O
,	O
nuclear	O
blebs	O
,	O
polyploidy	O
and	O
micronuclei	O
(	O
MN	O
)	O
.	O

AOH	S-chem
treatment	O
also	O
induced	O
abnormal	O
Aurora	B-geneY
B	E-geneY
bridges	O
,	O
suggesting	O
that	O
cytokinesis	O
was	O
interfered	O
within	O
cells	O
undergoing	O
karyokinesis	O
.	O

A	O
minor	O
part	O
of	O
the	O
resultant	O
G1	O
tetraploid	O
(	O
4N	O
)	O
cells	O
re	O
-	O
entered	O
the	O
S	O
-	O
phase	O
and	O
progressed	O
to	O
8N	O
cells	O
.	O

Nutrient	O
signaling	O
in	O
protein	O
homeostasis	O
:	O
an	O
increase	O
in	O
quantity	O
at	O
the	O
expense	O
of	O
quality	O
.	O

The	O
discovery	O
that	O
rapamycin	S-chem
extends	O
the	O
life	O
span	O
of	O
diverse	O
organisms	O
has	O
triggered	O
many	O
studies	O
aimed	O
at	O
identifying	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

Mammalian	B-geneN
target	I-geneN
of	I-geneN
rapamycin	I-geneN
complex	I-geneN
1	E-geneN
(	O
mTORC1	S-geneN
)	O
regulates	O
cell	O
growth	O
and	O
may	O
regulate	O
organismal	O
aging	O
by	O
controlling	O
mRNA	O
translation	O
.	O

However	O
,	O
how	O
inhibiting	O
mTORC1	S-geneN
and	O
decreasing	O
protein	O
synthesis	O
can	O
extend	O
life	O
span	O
remains	O
an	O
unresolved	O
issue	O
.	O

We	O
showed	O
that	O
constitutively	O
active	O
mTORC1	S-geneN
signaling	O
increased	O
general	O
protein	O
synthesis	O
but	O
unexpectedly	O
reduced	O
the	O
quality	O
of	O
newly	O
synthesized	O
polypeptides	O
.	O

We	O
demonstrated	O
that	O
constitutively	O
active	O
mTORC1	S-geneN
decreased	O
translation	O
fidelity	O
by	O
increasing	O
the	O
speed	O
of	O
ribosomal	O
elongation	O
.	O

Conversely	O
,	O
rapamycin	S-chem
treatment	O
restored	O
the	O
quality	O
of	O
newly	O
synthesized	O
polypeptides	O
mainly	O
by	O
slowing	O
the	O
rate	O
of	O
ribosomal	O
elongation	O
.	O

We	O
also	O
found	O
distinct	O
roles	O
for	O
mTORC1	S-geneN
downstream	O
targets	O
in	O
maintaining	O
protein	O
homeostasis	O
.	O

Loss	O
of	O
S6	B-geneN
kinases	E-geneN
,	O
but	O
not	O
4E	B-geneN
-	I-geneN
BP	E-geneN
family	O
proteins	O
,	O
which	O
are	O
both	O
involved	O
in	O
regulation	O
of	O
translation	O
,	O
attenuated	O
the	O
effects	O
of	O
rapamycin	S-chem
on	O
the	O
quality	O
of	O
newly	O
translated	O
proteins	O
.	O

Our	O
results	O
reveal	O
a	O
mechanistic	O
connection	O
between	O
mTORC1	S-geneN
and	O
protein	O
quality	O
,	O
highlighting	O
the	O
central	O
role	O
of	O
nutrient	O
signaling	O
in	O
growth	O
and	O
aging	O
.	O

H3	B-geneY
histamine	I-geneY
receptor	E-geneY
agonist	O
inhibits	O
biliary	O
growth	O
of	O
BDL	O
rats	O
by	O
downregulation	O
of	O
the	O
cAMP	B-geneN
-	I-geneN
dependent	I-geneN
PKA	E-geneN
/	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
/	O
ELK	B-geneY
-	I-geneY
1	E-geneY
pathway	O
.	O

Histamine	S-chem
regulates	O
many	O
functions	O
by	O
binding	O
to	O
four	O
histamine	B-geneN
G	I-geneN
-	I-geneN
coupled	I-geneN
receptor	I-geneN
proteins	E-geneN
(	O
H1R	S-geneY
,	O
H2R	S-geneY
,	O
H3R	S-geneY
and	O
H4R	S-geneY
)	O
.	O

As	O
H3R	S-geneN
exerts	O
their	O
effects	O
by	O
coupling	O
to	O
Galpha	B-geneN
(	I-geneN
i	I-geneN
/	I-geneN
o	I-geneN
)	E-geneN
proteins	O
reducing	O
adenosine	B-chem
3	I-chem
'	I-chem
,	I-chem
5	I-chem
'	I-chem
-	I-chem
monophosphate	E-chem
(	O
cAMP	S-chem
)	O
levels	O
(	O
a	O
key	O
player	O
in	O
the	O
modulation	O
of	O
cholangiocyte	O
hyperplasia	O
/	O
damage	O
)	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
H3R	S-geneY
in	O
the	O
regulation	O
of	O
biliary	O
growth	O
.	O

We	O
posed	O
the	O
following	O
questions	O
:	O
(	O
1	O
)	O
Do	O
cholangiocytes	O
express	O
H3R	S-geneN
?	O
(	O
2	O
)	O
Does	O
in	O
vivo	O
administration	O
of	O
(	B-chem-C5-1
R	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
alpha	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
-	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
methylhistamine	I-chem-C5-1
dihydrobromide	E-chem-C5-1
(	O
RAMH	S-chem-C5-1
)	O
(	O
H3R	S-geneY-C5-2
agonist	O
)	O
,	O
thioperamide	B-chem-C6-1
maleate	E-chem-C6-1
(	O
H3R	S-geneY-C6-2
antagonist	O
)	O
or	O
histamine	S-chem
,	O
in	O
the	O
absence	O
/	O
presence	O
of	O
thioperamide	B-chem
maleate	E-chem
,	O
to	O
bile	O
duct	O
ligated	O
(	O
BDL	O
)	O
rats	O
regulate	O
cholangiocyte	O
proliferation	O
?	O
and	O
(	O
3	O
)	O
Does	O
RAMH	S-chem
inhibit	O
cholangiocyte	O
proliferation	O
by	O
downregulation	O
of	O
cAMP	S-chem
-	O
dependent	O
phosphorylation	O
of	O
protein	B-geneN
kinase	I-geneN
A	E-geneN
(	O
PKA	S-geneN
)	O
/	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
)	O
/	O
ets	B-geneY
-	I-geneY
like	I-geneY
gene	I-geneY
-	I-geneY
1	E-geneY
(	O
Elk	B-geneY
-	I-geneY
1	E-geneY
)	O
?	O
The	O
expression	O
of	O
H3R	S-geneY
was	O
evaluated	O
in	O
liver	O
sections	O
by	O
immunohistochemistry	O
and	O
immunofluorescence	O
,	O
and	O
by	O
real	O
-	O
time	O
PCR	O
in	O
cholangiocyte	O
RNA	O
from	O
normal	O
and	O
BDL	O
rats	O
.	O

BDL	O
rats	O
(	O
immediately	O
after	O
BDL	O
)	O
were	O
treated	O
daily	O
with	O
RAMH	S-chem
,	O
thioperamide	B-chem
maleate	E-chem
or	O
histamine	S-chem
in	O
the	O
absence	O
/	O
presence	O
of	O
thioperamide	B-chem
maleate	E-chem
for	O
1	O
week	O
.	O

Following	O
in	O
vivo	O
treatment	O
of	O
BDL	O
rats	O
with	O
RAMH	S-chem
for	O
1	O
week	O
,	O
and	O
in	O
vitro	O
stimulation	O
of	O
BDL	O
cholangiocytes	O
with	O
RAMH	S-chem
,	O
we	O
evaluated	O
cholangiocyte	O
proliferation	O
,	O
cAMP	S-chem
levels	O
and	O
PKA	S-geneN
,	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
Elk	B-geneY
-	I-geneY
1	E-geneY
phosphorylation	O
.	O

Cholangiocytes	O
from	O
normal	O
and	O
BDL	O
rats	O
express	O
H3R	S-geneY
.	O

The	O
expression	O
of	O
H3R	S-geneY
mRNA	O
increased	O
in	O
BDL	O
compared	O
to	O
normal	O
cholangiocytes	O
.	O

Histamine	S-chem
decreased	O
cholangiocyte	O
growth	O
of	O
BDL	O
rats	O
to	O
a	O
lower	O
extent	O
than	O
that	O
observed	O
in	O
BDL	O
RAMH	S-chem
-	O
treated	O
rats	O
;	O
histamine	S-chem
-	O
induced	O
inhibition	O
of	O
cholangiocyte	O
growth	O
was	O
partly	O
blocked	O
by	O
thioperamide	B-chem
maleate	E-chem
.	O

In	O
BDL	O
rats	O
treated	O
with	O
thioperamide	B-chem
maleate	E-chem
,	O
cholangiocyte	O
hyperplasia	O
was	O
slightly	O
higher	O
than	O
that	O
of	O
BDL	O
rats	O
.	O

In	O
vitro	O
,	O
RAMH	S-chem
inhibited	O
the	O
proliferation	O
of	O
BDL	O
cholangiocytes	O
.	O

RAMH	S-chem-C4-1
inhibition	O
of	O
cholangiocyte	O
growth	O
was	O
associated	O
with	O
decreased	O
cAMP	S-chem
levels	O
and	O
PKA	S-geneN-C4-2
/	O
ERK1	B-geneN-C4-2
/	I-geneN-C4-2
2	E-geneN-C4-2
/	O
Elk	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
phosphorylation	O
.	O

Downregulation	O
of	O
cAMP	S-chem
-	O
dependent	O
PKA	S-geneN
/	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
/	O
Elk	B-geneY
-	I-geneY
1	E-geneY
phosphorylation	O
(	O
by	O
activation	O
of	O
H3R	S-geneY
)	O
is	O
important	O
in	O
the	O
inhibition	O
of	O
cholangiocyte	O
growth	O
in	O
liver	O
diseases	O
.	O

Drug	O
binding	O
interactions	O
in	O
the	O
inner	O
cavity	O
of	O
HERG	S-geneY
channels	O
:	O
molecular	O
insights	O
from	O
structure	O
-	O
activity	O
relationships	O
of	O
clofilium	S-chem
and	O
ibutilide	S-chem
analogs	O
.	O

Block	O
of	O
human	B-geneY
ether	I-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	I-geneY
related	I-geneY
gene	I-geneY
(	I-geneY
hERG	I-geneY
)	I-geneY
K	I-geneY
(	I-geneY
+	I-geneY
)	I-geneY
channels	E-geneY
by	O
otherwise	O
useful	O
drugs	O
is	O
the	O
most	O
common	O
cause	O
of	O
long	O
QT	O
syndrome	O
,	O
a	O
disorder	O
of	O
cardiac	O
repolarization	O
that	O
predisposes	O
patients	O
to	O
potentially	O
fatal	O
arrhythmias	O
.	O

This	O
undesirable	O
long	O
QT	O
side	O
effect	O
has	O
been	O
a	O
major	O
reason	O
for	O
the	O
withdrawal	O
of	O
medications	O
from	O
the	O
pharmaceutical	O
market	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
hERG	S-geneY
block	O
is	O
therefore	O
essential	O
to	O
facilitate	O
the	O
design	O
of	O
safe	O
drugs	O
.	O

Binding	O
sites	O
for	O
hERG	S-geneY
blockers	O
have	O
been	O
mapped	O
within	O
the	O
inner	O
cavity	O
of	O
the	O
channel	O
and	O
include	O
aromatic	O
residues	O
in	O
the	O
S6	O
helix	O
(	O
Tyr	S-chem
-	O
652	O
,	O
Phe	S-chem
-	O
656	O
)	O
and	O
residues	O
in	O
the	O
pore	O
helix	O
(	O
Thr	S-chem
-	O
623	O
,	O
Ser	S-chem
-	O
624	O
,	O
Val	S-chem
-	O
625	O
)	O
.	O

We	O
used	O
mutagenesis	O
of	O
these	O
residues	O
,	O
combined	O
with	O
an	O
investigation	O
of	O
hERG	S-geneY-C4-2
block	O
by	O
close	O
analogs	O
of	O
clofilium	S-chem-C4-1
and	O
ibutilide	S-chem-C4-1
,	O
to	O
assess	O
how	O
specific	O
alterations	O
in	O
drug	O
structure	O
affected	O
potency	O
and	O
binding	O
interactions	O
.	O

Although	O
changing	O
the	O
basic	O
nitrogen	S-chem
from	O
quaternary	O
to	O
tertiary	O
accelerated	O
the	O
onset	O
of	O
block	O
,	O
the	O
IC	O
(	O
50	O
)	O
and	O
kinetics	O
for	O
recovery	O
from	O
block	O
were	O
similar	O
.	O

In	O
contrast	O
,	O
analogs	O
with	O
different	O
para	O
-	O
substituents	O
on	O
the	O
phenyl	S-chem
ring	O
had	O
significantly	O
different	O
potencies	O
for	O
wild	O
-	O
type	O
hERG	S-geneY
block	O
.	O

The	O
highest	O
potency	O
was	O
achieved	O
with	O
polar	O
or	O
electronegative	O
para	O
-	O
substituents	O
,	O
whereas	O
neutral	O
para	O
-	O
substituents	O
had	O
potencies	O
more	O
than	O
100	O
-	O
fold	O
lower	O
.	O

Results	O
from	O
mutagenesis	O
and	O
molecular	O
modeling	O
studies	O
suggest	O
that	O
phenyl	S-chem
ring	O
para	O
-	O
substituents	O
influence	O
drug	O
interactions	O
with	O
Thr	S-chem
-	O
623	O
,	O
Ser	S-chem
-	O
624	O
,	O
and	O
Tyr	S-chem
-	O
652	O
and	O
strongly	O
affect	O
binding	O
affinity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
modifying	O
the	O
para	O
-	O
substituent	O
could	O
be	O
a	O
useful	O
strategy	O
for	O
reducing	O
hERG	O
potency	O
and	O
increasing	O
the	O
safety	O
margin	O
of	O
compounds	O
in	O
development	O
.	O

Dissecting	O
the	O
relative	O
contribution	O
of	O
OATP1B1	S-geneY
-	O
mediated	O
uptake	O
of	O
xenobiotics	O
into	O
human	O
hepatocytes	O
using	O
siRNA	O
.	O

Abstract	O
1	O
.	O

Organic	B-geneY
anion	I-geneY
transporting	I-geneY
polypeptide	I-geneY
1B1	E-geneY
plays	O
a	O
pivotal	O
role	O
in	O
the	O
disposition	O
of	O
many	O
anionic	O
drugs	O
.	O

Significant	O
overlap	O
in	O
substrate	O
specificity	O
between	O
individual	O
OATP	S-geneN
isoforms	O
has	O
hampered	O
the	O
identification	O
of	O
the	O
relative	O
importance	O
of	O
individual	O
isoforms	O
for	O
hepatic	O
uptake	O
of	O
xenobiotics	O
.	O

2	O
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
use	O
of	O
siRNA	O
technology	O
to	O
decrease	O
OATP1B1	S-geneY
selectively	O
in	O
human	O
hepatocytes	O
.	O

Following	O
delivery	O
of	O
siRNA	O
by	O
the	O
novel	O
lipid	O
,	O
AtuFECT01	O
,	O
mRNA	O
expression	O
of	O
OATP1B1	S-geneY
was	O
reduced	O
by	O
94	O
%	O
-	O
98	O
%	O
with	O
no	O
significant	O
toxicity	O
.	O

Off	O
-	O
target	O
effects	O
were	O
also	O
shown	O
to	O
be	O
minimal	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
common	O
drug	O
metabolizing	O
enzymes	O
,	O
transporters	O
,	O
nuclear	O
receptors	O
and	O
associated	O
co	O
-	O
regulators	O
.	O

Uptake	O
of	O
estrone	B-chem-C9-1
-	I-chem-C9-1
3	I-chem-C9-1
-	I-chem-C9-1
sulfate	E-chem-C9-1
(	O
5	O
nM	O
)	O
by	O
OATP1B1	O
was	O
reduced	O
by	O
82	O
%	O
-	O
95	O
%	O
.	O

This	O
methodology	O
was	O
subsequently	O
used	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
OATP1B1	S-geneY-C9-2
uptake	O
in	O
human	O
hepatocytes	O
for	O
olmesartan	S-chem-C9-1
(	O
42	O
%	O
-	O
62	O
%	O
)	O
,	O
valsartan	S-chem-C9-1
(	O
28	O
%	O
-	O
81	O
%	O
)	O
,	O
rosuvastatin	S-chem-C9-1
(	O
64	O
%	O
-	O
72	O
%	O
)	O
,	O
pitavastatin	S-chem-C9-1
(	O
84	O
%	O
-	O
98	O
%	O
)	O
and	O
lopinavir	S-chem-C9-1
(	O
64	O
%	O
-	O
89	O
%	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
previous	O
values	O
obtained	O
using	O
a	O
relative	O
activity	O
factor	O
approach	O
.	O

3	O
.	O

The	O
siRNA	O
approach	O
provides	O
a	O
robust	O
and	O
reproducible	O
method	O
for	O
assessing	O
the	O
relative	O
contribution	O
of	O
OATP1B1	S-geneY
to	O
hepatic	O
uptake	O
of	O
new	O
chemical	O
entities	O
.	O

The	O
technique	O
also	O
has	O
potential	O
utility	O
in	O
facilitating	O
detailed	O
characterization	O
of	O
drug	O
-	O
drug	O
interactions	O
involving	O
hepatic	O
drug	O
transporters	O
.	O

MUC1	B-geneY
-	I-geneY
C	E-geneY
oncoprotein	O
as	O
a	O
target	O
in	O
breast	O
cancer	O
:	O
activation	O
of	O
signaling	O
pathways	O
and	O
therapeutic	O
approaches	O
.	O

Mucin	B-geneY
1	E-geneY
(	O
MUC1	S-geneY
)	O
is	O
a	O
heterodimeric	O
protein	O
formed	O
by	O
two	O
subunits	O
that	O
is	O
aberrantly	O
overexpressed	O
in	O
human	O
breast	O
cancer	O
and	O
other	O
cancers	O
.	O

Historically	O
,	O
much	O
of	O
the	O
early	O
work	O
on	O
MUC1	S-geneY
focused	O
on	O
the	O
shed	O
mucin	S-geneN
subunit	O
.	O

However	O
,	O
more	O
recent	O
studies	O
have	O
been	O
directed	O
at	O
the	O
transmembrane	O
MUC1	B-geneY
-	I-geneY
C	I-geneY
-	I-geneY
terminal	I-geneY
subunit	E-geneY
(	O
MUC1	B-geneY
-	I-geneY
C	E-geneY
)	O
that	O
functions	O
as	O
an	O
oncoprotein	O
.	O

MUC1	B-geneY
-	I-geneY
C	E-geneY
interacts	O
with	O
EGFR	S-geneY
(	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
)	O
,	O
ErbB2	S-geneY
and	O
other	O
receptor	B-geneN
tyrosine	I-geneN
kinases	E-geneN
at	O
the	O
cell	O
membrane	O
and	O
contributes	O
to	O
activation	O
of	O
the	O
PI3KAKT	S-geneN
and	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	I-geneN
kinase	E-geneN
(	O
MEK	S-geneN
)	O
extracellular	O
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
pathways	O
.	O

MUC1	B-geneY
-	I-geneY
C	E-geneY
also	O
localizes	O
to	O
the	O
nucleus	O
where	O
it	O
activates	O
the	O
Wnt	S-geneN
/	O
β	B-geneY
-	I-geneY
catenin	E-geneY
,	O
signal	B-geneN
transducer	I-geneN
and	I-geneN
activator	I-geneN
of	I-geneN
transcription	E-geneN
(	O
STAT	S-geneN
)	O
and	O
NF	S-geneN
(	B-geneN
nuclear	I-geneN
factor	I-geneN
)	I-geneN
-	I-geneN
κB	E-geneN
RelA	S-geneY
pathways	O
.	O

These	O
findings	O
and	O
the	O
demonstration	O
that	O
MUC1	B-geneY
-	I-geneY
C	E-geneY
is	O
a	O
druggable	O
target	O
have	O
provided	O
the	O
experimental	O
basis	O
for	O
designing	O
agents	O
that	O
block	O
MUC1	B-geneY
-	I-geneY
C	E-geneY
function	O
.	O

Notably	O
,	O
inhibitors	O
of	O
the	O
MUC1	B-geneY
-	I-geneY
C	E-geneY
subunit	O
have	O
been	O
developed	O
that	O
directly	O
block	O
its	O
oncogenic	O
function	O
and	O
induce	O
death	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
xenograft	O
models	O
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
a	O
first	O
-	O
in	O
-	O
class	O
MUC1	B-geneY
-	I-geneY
C	E-geneY
inhibitor	O
has	O
entered	O
phase	O
I	O
evaluation	O
as	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
breast	O
cancers	O
who	O
express	O
this	O
oncoprotein	O
.	O

Pharmacological	O
characterization	O
of	O
pannexin	B-geneY
-	I-geneY
1	E-geneY
currents	O
expressed	O
in	O
mammalian	O
cells	O
.	O

Pannexin	B-geneY
(	I-geneY
Panx	I-geneY
)	I-geneY
1	E-geneY
is	O
a	O
widely	O
expressed	O
protein	O
that	O
shares	O
structural	O
,	O
but	O
not	O
amino	B-chem
acid	E-chem
,	O
homology	O
with	O
gap	O
junction	O
proteins	O
,	O
the	O
connexins	S-geneN
.	O

Panx1	S-geneY
does	O
not	O
form	O
gap	O
junctions	O
in	O
mammalian	O
cells	O
,	O
but	O
it	O
may	O
function	O
as	O
a	O
plasma	B-geneN
membrane	I-geneN
hemichannel	E-geneN
.	O

Little	O
is	O
known	O
of	O
the	O
pharmacological	O
properties	O
of	O
panx1	S-geneY
expression	O
in	O
mammalian	O
cells	O
.	O

Here	O
,	O
we	O
identify	O
three	O
variants	O
in	O
the	O
human	B-geneY
PANX1	E-geneY
gene	O
.	O

We	O
expressed	O
these	O
variants	O
and	O
mouse	B-geneY
Panx1	E-geneY
in	O
mammalian	O
cells	O
and	O
compared	O
Panx1	S-geneY
-	O
induced	O
currents	O
.	O

All	O
human	B-geneY
Panx1	E-geneY
variants	O
and	O
the	O
mouse	B-geneY
Panx1	E-geneY
showed	O
identical	O
protein	O
expression	O
levels	O
,	O
localization	O
patterns	O
,	O
and	O
functional	O
properties	O
,	O
although	O
the	O
frequency	O
of	O
functional	O
expression	O
was	O
species	O
-	O
dependent	O
.	O

Panx1	S-geneY
currents	O
were	O
independent	O
of	O
changes	O
in	O
extracellular	O
or	O
intracellular	O
calcium	O
or	O
phospholipase	B-geneN
C	E-geneN
transduction	O
.	O

We	O
found	O
compounds	O
that	O
inhibited	O
Panx1	S-geneY-C4-2
currents	O
with	O
a	O
rank	O
order	O
of	O
potency	O
:	O
carbenoxolone	S-chem-C4-1
>	O
disodium	B-chem-C4-1
4,4	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
diisothiocyanatostilbene	I-chem-C4-1
-	I-chem-C4-1
2,2	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
disulfonate	E-chem-C4-1
(	O
DIDS	S-chem-C4-1
)	O
approximately	O
disodium	B-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
acetamido	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
isothiocyanato	I-chem-C4-1
-	I-chem-C4-1
stilben	I-chem-C4-1
-	I-chem-C4-1
2,2	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
disulfonate	E-chem-C4-1
approximately	O
5	B-chem-C4-1
-	I-chem-C4-1
nitro	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
phenylpropylamino	I-chem-C4-1
)	I-chem-C4-1
benzoic	I-chem-C4-1
acid	E-chem-C4-1
>	O
indanyloxyacetic	B-chem-C4-1
acid	I-chem-C4-1
94	E-chem-C4-1
>	O
>	O
probenecid	S-chem-C4-1
>	O
>	O
flufenamic	B-chem-C4-1
acid	E-chem-C4-1
=	O
niflumic	B-chem-C4-1
acid	E-chem-C4-1
.	O

Triphosphate	B-chem-C4-1
nucleotides	E-chem-C4-1
(	O
ATP	S-chem-C4-1
,	O
GTP	S-chem-C4-1
,	O
and	O
UTP	S-chem-C4-1
)	O
rapidly	O
and	O
reversibly	O
inhibited	O
Panx1	S-geneY-C4-2
currents	O
via	O
mechanism	O
(	O
s	O
)	O
independent	O
of	O
purine	B-geneN
receptors	E-geneN
.	O

When	O
Panx1	S-geneY
was	O
coexpressed	O
with	O
purinergic	B-geneY
P2X	I-geneY
(	I-geneY
7	I-geneY
)	I-geneY
receptor	E-geneY
(	O
P2X	B-geneY
(	I-geneY
7	I-geneY
)	I-geneY
R	E-geneY
)	O
,	O
DIDS	S-chem-C6-1
was	O
found	O
to	O
act	O
as	O
a	O
P2X	B-geneY-C6-2
(	I-geneY-C6-2
7	I-geneY-C6-2
)	I-geneY-C6-2
R	E-geneY-C6-2
antagonist	O
to	O
inhibit	O
ATP	S-chem
-	O
evoked	O
currents	O
,	O
but	O
none	O
of	O
the	O
other	O
compounds	O
inhibited	O
P2X	B-geneY
(	I-geneY
7	I-geneY
)	I-geneY
R	E-geneY
currents	O
.	O

This	O
is	O
the	O
first	O
detailed	O
pharmacological	O
characterization	O
of	O
Panx1	S-geneY
-	O
mediated	O
currents	O
in	O
mammalian	O
cells	O
and	O
sheds	O
new	O
,	O
although	O
contradictory	O
,	O
light	O
on	O
the	O
hypothesis	O
that	O
Panx1	S-geneY
acts	O
as	O
a	O
hemichannel	O
to	O
allow	O
passage	O
of	O
large	O
molecules	O
in	O
response	O
to	O
P2X	B-geneY
(	I-geneY
7	I-geneY
)	I-geneY
R	E-geneY
activation	O
.	O

Conditional	O
activation	O
of	O
Pik3ca	S-geneY
(	O
H1047R	S-geneN
)	O
in	O
a	O
knock	O
-	O
in	O
mouse	O
model	O
promotes	O
mammary	O
tumorigenesis	O
and	O
emergence	O
of	O
mutations	O
.	O

Oncogenic	O
mutations	O
in	O
PIK3CA	S-geneY
,	O
which	O
encodes	O
the	O
phosphoinositide	B-geneY
-	I-geneY
3	I-geneY
-	I-geneY
kinase	I-geneY
(	I-geneY
PI3K	I-geneY
)	I-geneY
catalytic	I-geneY
subunit	I-geneY
p110α	E-geneY
,	O
occur	O
in	O
∼	O
25	O
%	O
of	O
human	O
breast	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
development	O
of	O
a	O
knock	O
-	O
in	O
mouse	O
model	O
for	O
breast	O
cancer	O
where	O
the	O
endogenous	O
Pik3ca	S-geneY
allele	O
was	O
modified	O
to	O
allow	O
tissue	O
-	O
specific	O
conditional	O
expression	O
of	O
a	O
frequently	O
found	O
Pik3ca	S-geneY
(	O
H1047R	S-geneN
)	O
(	O
Pik3ca	S-geneY
(	O
e20H1047R	S-geneN
)	O
)	O
mutant	O
allele	O
.	O

We	O
found	O
that	O
activation	O
of	O
the	O
latent	O
Pik3ca	S-geneY
(	O
H1047R	S-geneN
)	O
allele	O
resulted	O
in	O
breast	O
tumors	O
with	O
multiple	O
histological	O
types	O
.	O

Whole	O
-	O
exome	O
analysis	O
of	O
the	O
Pik3ca	S-geneY
(	O
H1047R	S-geneN
)	O
-	O
driven	O
mammary	O
tumors	O
identified	O
multiple	O
mutations	O
,	O
including	O
Trp53	S-geneY
mutations	O
that	O
appeared	O
spontaneously	O
during	O
the	O
development	O
of	O
adenocarinoma	O
and	O
spindle	O
cell	O
tumors	O
.	O

Further	O
,	O
we	O
used	O
this	O
model	O
to	O
test	O
the	O
efficacy	O
of	O
GDC	B-chem-C4-1
-	I-chem-C4-1
0941	E-chem-C4-1
,	O
a	O
PI3K	S-geneN-C4-2
inhibitor	O
,	O
in	O
clinical	O
development	O
,	O
and	O
showed	O
that	O
the	O
tumors	O
respond	O
to	O
PI3K	S-geneN-C4-2
inhibition	O
.	O

Characterization	O
of	O
rat	B-geneY
brain	I-geneY
aldosterone	I-geneY
receptors	E-geneY
reveals	O
high	O
affinity	O
for	O
corticosterone	S-chem
.	O

The	O
two	O
[	B-chem
3H	I-chem
]	I-chem
aldosterone	E-chem
-	O
binding	O
proteins	O
of	O
rat	O
brain	O
cytosol	O
were	O
characterized	O
by	O
a	O
dextran	O
-	O
coated	O
charcoal	O
method	O
.	O

With	O
molybdate	S-chem
present	O
to	O
stabilize	O
receptors	O
,	O
the	O
affinities	O
of	O
the	O
two	O
sites	O
for	O
[	B-chem
3H	I-chem
]	I-chem
aldosterone	E-chem
in	O
adrenalectomized	O
perfused	O
rat	O
brain	O
cytosols	O
were	O
0.28	O
and	O
18.0	O
nM	O
at	O
4	O
C	O
.	O

High	O
affinity	O
sites	O
comprised	O
15	O
%	O
of	O
the	O
total	O
receptor	O
number	O
.	O

A	O
small	O
contamination	O
of	O
perfused	O
brain	O
cytosol	O
preparations	O
with	O
corticosteroid	B-geneY
-	I-geneY
binding	I-geneY
globulin	E-geneY
(	O
CBG	S-geneY
)	O
was	O
found	O
.	O

However	O
,	O
due	O
to	O
the	O
very	O
high	O
affinity	O
of	O
CBG	S-geneY
for	O
corticosterone	S-chem
at	O
4	O
C	O
,	O
this	O
slight	O
contamination	O
resulted	O
in	O
significant	O
alterations	O
in	O
the	O
apparent	O
affinity	O
of	O
steroids	S-chem
competing	O
for	O
aldosterone	S-chem
-	O
binding	O
sites	O
.	O

Selective	O
precipitation	O
of	O
cytosol	O
receptors	O
with	O
36	O
%	O
(	B-chem-C4-1
NH4	I-chem-C4-1
)	I-chem-C4-1
2SO4	E-chem-C4-1
reduced	O
CBG	S-geneY-C4-2
concentrations	O
to	O
negligible	O
levels	O
.	O

After	O
blockade	O
of	O
low	O
affinity	O
sites	O
with	O
a	O
highly	O
selective	O
glucocorticoid	O
(	O
RU	B-chem
26988	E-chem
)	O
,	O
the	O
order	O
of	O
steroids	S-chem
in	O
competing	O
for	O
the	O
high	O
affinity	O
receptor	O
was	O
desoxycorticosterone	S-chem
greater	O
than	O
fludrocortisone	S-chem
greater	O
than	O
corticosterone	S-chem
greater	O
than	O
aldosterone	S-chem
greater	O
than	O
progesterone	S-chem
greater	O
than	O
dexamethasone	S-chem
.	O

Readdition	O
of	O
a	O
small	O
quantity	O
of	O
dialyzed	O
serum	O
to	O
cytosol	O
preparations	O
yielded	O
a	O
profile	O
of	O
steroid	S-chem
binding	O
similar	O
to	O
that	O
of	O
the	O
kidney	O
mineralocorticoid	B-geneY
receptor	E-geneY
(	O
aldosterone	S-chem
greater	O
than	O
desoxycorticosterone	S-chem
greater	O
than	O
corticosterone	S-chem
)	O
.	O

The	O
distribution	O
of	O
both	O
receptors	O
in	O
brain	O
regions	O
of	O
adrenalectomized	O
rats	O
was	O
determined	O
.	O

Both	O
receptors	O
were	O
at	O
greatest	O
density	O
in	O
the	O
hippocampus	O
and	O
lowest	O
density	O
in	O
the	O
hypothalamus	O
.	O

The	O
high	O
affinity	O
site	O
was	O
at	O
greatest	O
density	O
in	O
limbic	O
regions	O
,	O
whereas	O
the	O
low	O
affinity	O
receptor	O
,	O
apparently	O
identical	O
to	O
the	O
glucocorticoid	B-geneN
type	I-geneN
II	I-geneN
receptor	E-geneN
,	O
was	O
at	O
greatest	O
density	O
in	O
cortex	O
and	O
cerebellum	O
.	O

It	O
is	O
concluded	O
that	O
the	O
high	O
affinity	O
aldosterone	B-geneY
receptor	E-geneY
of	O
rat	O
brain	O
,	O
which	O
had	O
been	O
identified	O
in	O
preliminary	O
studies	O
as	O
a	O
mineralocorticoid	B-geneY
receptor	E-geneY
,	O
may	O
bind	O
either	O
corticosterone	S-chem
or	O
aldosterone	S-chem
in	O
vivo	O
.	O

Distinct	O
roles	O
of	O
methamphetamine	S-chem-C3-1
in	O
modulating	O
spatial	O
memory	O
consolidation	O
,	O
retrieval	O
,	O
reconsolidation	O
and	O
the	O
accompanying	O
changes	O
of	O
ERK	S-geneN-C3-2
and	O
CREB	S-geneN-C3-2
activation	O
in	O
hippocampus	O
and	O
prefrontal	O
cortex	O
.	O

Drugs	O
of	O
abuse	O
modulated	O
learning	O
and	O
memory	O
in	O
humans	O
yet	O
the	O
underlying	O
mechanism	O
remained	O
unclear	O
.	O

The	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
and	O
the	O
transcription	O
factor	O
cAMP	B-geneN
response	I-geneN
element	I-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
(	O
CREB	S-geneN
)	O
were	O
involved	O
in	O
neuroplastic	O
changes	O
associated	O
with	O
learning	O
and	O
memory	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
a	O
Morris	O
water	O
maze	O
to	O
examine	O
the	O
effect	O
of	O
methamphetamine	S-chem
(	O
METH	S-chem
)	O
on	O
different	O
processes	O
of	O
spatial	O
memory	O
in	O
mice	O
.	O

We	O
then	O
investigated	O
the	O
status	O
of	O
ERK	S-geneN
and	O
CREB	S-geneN
in	O
the	O
hippocampus	O
and	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
.	O

We	O
found	O
that	O
1.0	O
mg	O
/	O
kg	O
dose	O
of	O
METH	O
facilitated	O
spatial	O
memory	O
consolidation	O
when	O
it	O
was	O
injected	O
immediately	O
after	O
the	O
last	O
learning	O
trial	O
.	O

In	O
contrast	O
,	O
the	O
same	O
dose	O
of	O
METH	S-chem
had	O
no	O
effect	O
on	O
spatial	O
memory	O
retrieval	O
when	O
it	O
was	O
injected	O
30	O
min	O
before	O
the	O
test	O
.	O

Furthermore	O
,	O
1.0	O
mg	O
/	O
kg	O
dose	O
of	O
METH	O
injected	O
immediately	O
after	O
retrieval	O
had	O
no	O
effect	O
on	O
spatial	O
memory	O
reconsolidation	O
.	O

Activation	O
of	O
both	O
ERK	S-geneN
and	O
CREB	S-geneN
in	O
the	O
hippocampus	O
was	O
found	O
following	O
memory	O
consolidation	O
but	O
not	O
after	O
retrieval	O
or	O
reconsolidation	O
in	O
METH	S-chem
-	O
treated	O
mouse	O
groups	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
both	O
ERK	S-geneN-C3-2
and	O
CREB	S-geneN-C3-2
in	O
the	O
PFC	O
was	O
found	O
following	O
memory	O
retrieval	O
but	O
not	O
other	O
processes	O
in	O
METH	S-chem-C3-1
-	O
treated	O
mouse	O
groups	O
.	O

These	O
results	O
suggested	O
that	O
METH	S-chem
facilitated	O
spatial	O
memory	O
consolidation	O
but	O
not	O
retrieval	O
or	O
reconsolidation	O
.	O

Moreover	O
,	O
activation	O
of	O
the	O
ERK	S-geneN-C3-2
and	O
CREB	S-geneN-C3-2
signaling	O
pathway	O
in	O
the	O
hippocampus	O
might	O
be	O
involved	O
in	O
METH	S-chem-C3-1
-	O
induced	O
spatial	O
memory	O
changes	O
.	O

Bioreducible	O
polymers	O
as	O
a	O
determining	O
factor	O
for	O
polyplex	S-chem
decomplexation	O
rate	O
and	O
transfection	O
.	O

Polyplex	S-chem
formation	O
(	O
complexation	O
)	O
and	O
gene	O
release	O
from	O
the	O
polyplexes	S-chem
(	O
decomplexation	O
)	O
are	O
major	O
events	O
in	O
polymeric	O
gene	O
delivery	O
;	O
however	O
,	O
the	O
effect	O
of	O
the	O
decomplexation	O
rate	O
on	O
transfection	O
has	O
been	O
rarely	O
investigated	O
.	O

This	O
study	O
employed	O
mixed	O
polymers	O
of	O
poly	B-chem
(	I-chem
(	I-chem
L	I-chem
)	I-chem
-	I-chem
lysine	I-chem
)	E-chem
(	O
PLL	S-chem
:	O
MW	O
~	O
7.4	O
kDa	O
)	O
and	O
reducible	O
PLL	S-chem
(	O
RPLL	O
)	O
(	O
MW	O
~	O
6.7	O
kDa	O
)	O
to	O
design	O
decomplexation	O
rate	O
-	O
controllable	O
PLL	S-chem
(	O
100	O
-	O
x	O
)	O
RPLL	O
(	O
x	O
)	O
/	O
pDNA	O
complexes	O
(	O
PRL	O
(	O
x	O
)	O
polyplexes	S-chem
)	O
.	O

The	O
transfection	O
efficiency	O
of	O
a	O
model	O
gene	O
(	O
luciferase	O
)	O
in	O
MCF7	O
and	O
HEK293	O
cell	O
lines	O
increased	O
with	O
increasing	O
x	O
(	O
RPLL	O
content	O
)	O
in	O
the	O
PRL	O
(	O
x	O
)	O
polyplexes	S-chem
until	O
peaking	O
at	O
x	O
=	O
2.5	O
and	O
10	O
,	O
respectively	O
,	O
after	O
which	O
point	O
transfection	O
efficiency	O
declined	O
rapidly	O
.	O

In	O
MCF7	O
cells	O
,	O
PRL	O
(	O
2.5	O
)	O
polyplex	S-chem
produced	O
3	O
or	O
223	O
times	O
higher	O
gene	O
expression	O
than	O
PLL	S-chem
or	O
RPLL	O
polyplexes	S-chem
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
transfection	O
efficiency	O
of	O
PRL	O
(	O
10	O
)	O
polyplex	S-chem
-	O
transfected	O
HEK293	O
cells	O
was	O
3.8	O
or	O
67	O
times	O
higher	O
than	O
that	O
of	O
PLL	S-chem
or	O
RPLL	O
polyplexes	S-chem
,	O
respectively	O
.	O

The	O
transfection	O
results	O
were	O
not	O
apparently	O
related	O
to	O
the	O
particle	O
size	O
,	O
surface	O
charge	O
,	O
complexation	O
/	O
compactness	O
,	O
cellular	O
uptake	O
,	O
or	O
cytotoxicity	O
of	O
the	O
tested	O
polyplexes	S-chem
.	O

However	O
,	O
the	O
decomplexation	O
rate	O
varied	O
by	O
RPLL	O
content	O
in	O
the	O
polyplexes	S-chem
,	O
which	O
in	O
turn	O
influenced	O
the	O
gene	O
transfection	O
.	O

The	O
nuclear	O
localization	O
of	O
pDNA	O
delivered	O
by	O
PRL	O
(	O
x	O
)	O
polyplexes	S-chem
showed	O
a	O
similar	O
trend	O
to	O
their	O
transfection	O
efficiencies	O
.	O

This	O
study	O
suggests	O
that	O
an	O
optimum	O
decomplexation	O
rate	O
may	O
result	O
in	O
high	O
nuclear	O
localization	O
of	O
pDNA	O
and	O
transfection	O
.	O

Understanding	O
in	O
decomplexation	O
and	O
intracellular	O
localization	O
of	O
pDNA	O
may	O
help	O
develop	O
more	O
effective	O
polyplexes	S-chem
.	O

Evaluation	O
of	O
antioxidant	O
activities	O
and	O
chemical	O
characterisation	O
of	O
staghorn	O
sumac	O
fruit	O
(	O
Rhus	O
hirta	O
L.	O
)	O
.	O

Staghorn	O
sumac	O
(	O
Rhus	O
hirta	O
L.	O
)	O
is	O
a	O
native	O
tree	O
in	O
Eastern	O
Canada	O
whose	O
fruit	O
has	O
been	O
used	O
by	O
aboriginal	O
peoples	O
to	O
treat	O
various	O
illnesses	O
,	O
and	O
has	O
recently	O
been	O
found	O
to	O
be	O
a	O
good	O
source	O
of	O
antioxidants	O
.	O

However	O
,	O
the	O
phytochemical	O
composition	O
of	O
R.	O
hirta	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
Four	O
highly	O
accepted	O
assays	O
and	O
confirmed	O
its	O
FRAP	O
,	O
ORAC	O
,	O
β	O
-	O
CLAMS	O
and	O
PCL	O
values	O
to	O
be	O
79.95	O
μmol	O
AAE	O
/	O
g	O
DW	O
,	O
1544	O
μmol	O
TE	O
/	O
g	O
DW	O
,	O
RAA	O
129	O
%	O
and	O
4513	O
μmol	O
TE	O
/	O
g	O
DW	O
,	O
respectively	O
.	O

The	O
antioxidant	O
activities	O
correlated	O
positively	O
to	O
the	O
total	O
polyphenols	S-chem
content	O
,	O
which	O
was	O
higher	O
in	O
the	O
ethanolic	O
extract	O
(	O
81.6	O
mg	O
GAE	O
/	O
g	O
DW	O
)	O
compared	O
to	O
the	O
water	O
extract	O
(	O
46.3mg	O
GAE	O
/	O
g	O
DW	O
)	O
,	O
suggesting	O
polyphenols	S-chem
play	O
an	O
important	O
role	O
.	O

Quantitative	O
data	O
from	O
UHPLC	O
and	O
qualitative	O
studies	O
using	O
HPLC	O
-	O
DAD	O
-	O
MS	O
showed	O
that	O
in	O
addition	O
to	O
commonly	O
found	O
phenolic	B-chem
acids	E-chem
,	O
flavonoids	S-chem
and	O
anthocyanins	S-chem
,	O
R.	O
hirta	O
fruit	O
contained	O
a	O
novel	O
group	O
of	O
unique	O
anthocyanins	S-chem
with	O
aglycones	O
(	O
anthocyanidins	S-chem
)	O
at	O
449	O
,	O
419	O
and	O
433	O
Da	O
.	O

Further	O
studies	O
on	O
the	O
identification	O
and	O
their	O
health	O
beneficial	O
effects	O
are	O
being	O
conducted	O
.	O

Emerging	O
role	O
of	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
inhibition	O
in	O
therapy	O
for	O
advanced	O
malignancy	O
:	O
focus	O
on	O
NSCLC	O
.	O

Combination	O
chemotherapy	O
regimens	O
have	O
emerged	O
as	O
the	O
standard	O
approach	O
in	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O

Meta	O
-	O
analyses	O
have	O
demonstrated	O
a	O
2	O
-	O
month	O
increase	O
in	O
median	O
survival	O
after	O
platinum	S-chem
-	O
based	O
therapy	O
vs.	O
best	O
supportive	O
care	O
,	O
and	O
an	O
absolute	O
10	O
%	O
improvement	O
in	O
the	O
1	O
-	O
year	O
survival	O
rate	O
.	O

Just	O
as	O
importantly	O
,	O
cytotoxic	O
therapy	O
has	O
produced	O
benefits	O
in	O
symptom	O
control	O
and	O
quality	O
of	O
life	O
.	O

Newer	O
agents	O
,	O
including	O
the	O
taxanes	S-chem
,	O
vinorelbine	S-chem
,	O
gemcitabine	S-chem
,	O
and	O
irinotecan	S-chem
,	O
have	O
expanded	O
our	O
therapeutic	O
options	O
in	O
the	O
treatment	O
of	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O

Despite	O
their	O
contributions	O
,	O
we	O
have	O
reached	O
a	O
therapeutic	O
plateau	O
,	O
with	O
response	O
rates	O
seldom	O
exceeding	O
30	O
-	O
40	O
%	O
in	O
cooperative	O
group	O
studies	O
and	O
1	O
-	O
year	O
survival	O
rates	O
stable	O
between	O
30	O
%	O
and	O
40	O
%	O
.	O

It	O
is	O
doubtful	O
that	O
substituting	O
one	O
agent	O
for	O
another	O
in	O
various	O
combinations	O
will	O
lead	O
to	O
any	O
further	O
improvement	O
in	O
these	O
rates	O
.	O

The	O
thrust	O
of	O
current	O
research	O
has	O
focused	O
on	O
targeted	O
therapy	O
,	O
and	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
inhibition	O
is	O
one	O
of	O
the	O
most	O
promising	O
clinical	O
strategies	O
.	O

Epidermal	B-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
receptor	E-geneY-C4-2
inhibitors	O
currently	O
under	O
investigation	O
include	O
the	O
small	O
molecules	O
gefitinib	S-chem-C4-1
(	O
Iressa	S-chem-C4-1
,	O
ZD1839	S-chem-C4-1
)	O
and	O
erlotinib	S-chem-C4-1
(	O
Tarceva	S-chem-C4-1
,	O
OSI	B-chem-C4-1
-	I-chem-C4-1
774	E-chem-C4-1
)	O
,	O
as	O
well	O
as	O
monoclonal	O
antibodies	O
such	O
as	O
cetuximab	S-chem-C4-1
(	O
IMC	B-chem-C4-1
-	I-chem-C4-1
225	E-chem-C4-1
,	O
Erbitux	S-chem-C4-1
)	O
.	O

Agents	O
that	O
have	O
only	O
begun	O
to	O
undergo	O
clinical	O
evaluation	O
include	O
CI	B-chem-C4-1
-	I-chem-C4-1
1033	E-chem-C4-1
,	O
an	O
irreversible	O
pan	O
-	O
erbB	S-geneY-C4-2
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
,	O
and	O
PKI166	S-chem-C4-1
and	O
GW572016	S-chem-C4-1
,	O
both	O
examples	O
of	O
dual	O
kinase	S-geneN-C4-2
inhibitors	O
(	O
inhibiting	O
epidermal	B-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
receptor	E-geneY-C4-2
and	O
Her2	S-geneY-C4-2
)	O
.	O

Preclinical	O
models	O
have	O
demonstrated	O
synergy	O
for	O
all	O
these	O
agents	O
in	O
combination	O
with	O
either	O
chemotherapy	O
or	O
radiotherapy	O
,	O
leading	O
to	O
great	O
enthusiasm	O
regarding	O
their	O
ultimate	O
contribution	O
to	O
lung	O
cancer	O
therapy	O
.	O

However	O
,	O
serious	O
clinical	O
challenges	O
persist	O
.	O

These	O
include	O
the	O
identification	O
of	O
the	O
optimal	O
dose	O
(	O
s	O
)	O
;	O
the	O
proper	O
integration	O
of	O
these	O
agents	O
into	O
popular	O
,	O
established	O
cytotoxic	O
regimens	O
;	O
and	O
the	O
selection	O
of	O
the	O
optimal	O
setting	O
(	O
s	O
)	O
in	O
which	O
to	O
test	O
these	O
compounds	O
.	O

Both	O
gefitinib	S-chem
and	O
erlotinib	S-chem
have	O
shown	O
clinical	O
activity	O
in	O
pretreated	O
,	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
but	O
placebo	O
-	O
controlled	O
randomized	O
Phase	O
III	O
studies	O
evaluating	O
gefitinib	S-chem
in	O
combination	O
with	O
standard	O
cytotoxic	O
therapy	O
,	O
to	O
our	O
chagrin	O
,	O
have	O
failed	O
to	O
demonstrate	O
a	O
survival	O
advantage	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
MEN1	S-geneY
gene	O
in	O
subjects	O
with	O
multiple	O
endocrine	O
neoplasia	O
-	O
1	O
.	O

Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	S-geneY
)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	O
endocrine	O
and	O
pituitary	O
adenomas	O
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	S-geneY
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	S-geneY
with	O
novel	O
mutations	O
in	O
the	O
MEN1	S-geneY
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	O
had	O
primary	O
hyperparathyroidism	O
(	O
PHPT	O
)	O
plus	O
a	O
prolactinoma	O
;	O
three	O
relatives	O
had	O
PHPT	O
only	O
.	O

The	O
index	O
patient	O
in	O
the	O
second	O
family	O
was	O
a	O
46	O
-	O
yr	O
-	O
old	O
woman	O
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	O
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	O
and	O
watery	O
diarrhea	O
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	O
islet	O
cell	O
tumor	O
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	O
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	S-geneY
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	O
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	B-geneN
to	I-geneN
G	I-geneN
transition	I-geneN
at	I-geneN
codon	I-geneN
557	E-geneN
(	O
AAG	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
GAG	E-geneN
)	O
of	O
exon	O
10	O
of	O
MEN1	S-geneY
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	S-chem
by	O
glutamic	B-chem
acid	E-chem
.	O

The	O
Chinese	O
index	O
patient	O
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	O
at	O
codon	O
418	O
of	O
exon	O
9	O
(	O
GAC	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
TAT	E-geneN
)	O
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	B-chem
acid	E-chem
by	O
tyrosine	S-chem
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	S-geneY
gene	O
.	O

[	O
Leflunomide	S-chem
-	O
-	O
a	O
new	O
drug	O
for	O
pharmacological	O
immunomodulation	O
]	O
.	O

The	O
novel	O
immunomodulatory	O
agent	O
leflunomide	S-chem
exhibits	O
a	O
strong	O
anti	O
-	O
inflammatory	O
action	O
.	O

This	O
isoxazole	S-chem
derivative	O
is	O
chemically	O
unrelated	O
to	O
any	O
hitherto	O
applied	O
immunosuppressants	O
.	O

As	O
a	O
prodrug	O
leflunomide	S-chem-C4-1
is	O
completely	O
converted	O
to	O
its	O
active	O
metabolite	O
A	B-chem-C4-1
77	I-chem-C4-1
1726	E-chem-C4-1
(	O
M1	O
)	O
which	O
blocks	O
the	O
dihydroorotate	B-geneY-C4-2
dehydrogenase	E-geneY-C4-2
,	O
a	O
key	O
enzyme	O
of	O
the	O
pyrimidine	S-chem
de	O
novo	O
synthesis	O
.	O

Drug	O
-	O
related	O
adverse	O
effects	O
are	O
mild	O
,	O
dose	O
-	O
related	O
and	O
reversible	O
,	O
characterising	O
leflunomide	S-chem
as	O
a	O
safe	O
immunosuppressant	O
.	O

While	O
up	O
to	O
now	O
leflunomide	S-chem
has	O
just	O
been	O
approved	O
for	O
therapy	O
of	O
rheumatoid	O
arthritis	O
,	O
its	O
mechanism	O
of	O
action	O
affects	O
multiple	O
inflammatory	O
pathways	O
,	O
thereby	O
suggesting	O
it	O
to	O
be	O
a	O
potent	O
therapeutic	O
agent	O
in	O
autoimmune	O
diseases	O
,	O
graft	O
rejection	O
,	O
and	O
tumour	O
therapy	O
.	O

First	O
dermatological	O
experience	O
has	O
been	O
gained	O
in	O
psoriasis	O
and	O
bullous	O
pemphigoid	O
.	O

The	O
role	O
of	O
leflunomide	S-chem
in	O
the	O
dermatologist	O
's	O
therapeutic	O
armamentarium	O
will	O
evolve	O
during	O
the	O
next	O
years	O
.	O

[	O
The	O
effects	O
of	O
nandrolone	B-chem
phenylpropionate	E-chem
on	O
androgen	B-geneY
receptor	E-geneY
of	O
liver	O
and	O
sexual	O
glands	O
in	O
burned	O
rats	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
the	O
effects	O
of	O
nandrolone	B-chem
phenylpropionate	E-chem
(	O
NP	S-chem
)	O
on	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
of	O
liver	O
and	O
sexual	O
glands	O
in	O
burned	O
rats	O
for	O
supporting	O
the	O
clinical	O
application	O
of	O
anabolic	O
steroids	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
Wistar	O
rats	O
with	O
a	O
deep	O
second	O
-	O
degree	O
cutaneous	O
burn	O
of	O
20	O
%	O
total	O
body	O
surface	O
area	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
to	O
receive	O
either	O
5	O
mg	O
/	O
kg	O
NP	S-chem
(	O
NP	S-chem
group	O
)	O
or	O
normal	O
saline	O
as	O
placebo	O
(	O
control	O
group	O
)	O
every	O
other	O
day	O
.	O

The	O
mean	O
integrated	O
optical	O
density	O
(	O
mIOD	O
)	O
of	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
in	O
liver	O
,	O
testis	O
,	O
ovary	O
tissues	O
were	O
measured	O
by	O
immunohistochemistry	O
ENVISION	O
and	O
LSAB	O
respectively	O
on	O
the	O
4th	O
,	O
7th	O
,	O
14th	O
and	O
21st	O
days	O
after	O
scalding	O
.	O

RESULTS	O
:	O
The	O
density	O
of	O
AR	S-geneY-C3-2
in	O
liver	O
tissue	O
in	O
NP	S-chem-C3-1
group	O
was	O
higher	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
density	O
of	O
AR	S-geneY
in	O
testis	O
and	O
ovary	O
tissues	O
showed	O
no	O
significant	O
difference	O
between	O
NP	S-chem
group	O
and	O
control	O
group	O
at	O
every	O
time	O
-	O
point	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
side	O
-	O
effect	O
of	O
NP	S-chem
at	O
this	O
dose	O
level	O
on	O
sexual	O
glands	O
seemed	O
limited	O
.	O

CONCLUSION	O
:	O
Nandrolone	B-chem-C3-1
phenylpropionate	E-chem-C3-1
up	O
-	O
regulated	O
the	O
density	O
of	O
AR	S-geneY-C3-2
in	O
liver	O
tissue	O
,	O
whereas	O
it	O
had	O
no	O
significant	O
effects	O
on	O
the	O
density	O
of	O
AR	S-geneY
in	O
testis	O
and	O
ovary	O
tissues	O
.	O

NP	S-chem
was	O
used	O
with	O
safety	O
at	O
this	O
dose	O
level	O
in	O
rats	O
.	O

Imatinib	B-chem
mesylate	E-chem
(	O
Gleevec	S-chem
)	O
enhances	O
mature	O
osteoclast	O
apoptosis	O
and	O
suppresses	O
osteoclast	O
bone	O
resorbing	O
activity	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
imatinib	B-chem-C4-1
mesylate	E-chem-C4-1
,	O
a	O
kinase	S-geneN-C4-2
inhibitor	O
that	O
targets	O
the	O
intracellular	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
BCR	S-geneY-C4-2
-	O
ABL	S-geneY-C4-2
and	O
the	O
platelet	B-geneN-C4-2
derived	I-geneN-C4-2
growth	I-geneN-C4-2
factor	I-geneN-C4-2
(	I-geneN-C4-2
PDGF	I-geneN-C4-2
)	I-geneN-C4-2
receptor	E-geneN-C4-2
,	O
is	O
an	O
effective	O
inhibitor	O
of	O
the	O
macrophage	B-geneY-C4-2
colony	I-geneY-C4-2
stimulating	I-geneY-C4-2
factor	I-geneY-C4-2
(	I-geneY-C4-2
M	I-geneY-C4-2
-	I-geneY-C4-2
CSF	I-geneY-C4-2
)	I-geneY-C4-2
receptor	E-geneY-C4-2
,	O
c	B-geneY-C4-2
-	I-geneY-C4-2
FMS	E-geneY-C4-2
.	O

Given	O
that	O
M	B-geneY-C4-2
-	I-geneY-C4-2
CSF	E-geneY-C4-2
signalling	O
through	O
c	B-geneY-C4-2
-	I-geneY-C4-2
FMS	E-geneY-C4-2
plays	O
an	O
important	O
role	O
in	O
osteoclast	O
biology	O
,	O
we	O
speculated	O
that	O
blocking	O
such	O
a	O
pathway	O
with	O
imatinib	S-chem-C4-1
may	O
modulate	O
osteoclast	O
activity	O
.	O

Using	O
a	O
cell	O
model	O
of	O
mature	O
rabbit	O
osteoclasts	O
,	O
we	O
thus	O
investigated	O
the	O
effect	O
of	O
imatinib	S-chem
on	O
in	O
vitro	O
osteoclast	O
apoptosis	O
and	O
bone	O
resorbing	O
activity	O
.	O

Our	O
findings	O
demonstrate	O
that	O
imatinib	S-chem
dose	O
-	O
dependently	O
stimulates	O
osteoclast	O
apoptosis	O
,	O
a	O
phenomenon	O
which	O
is	O
blocked	O
by	O
the	O
caspase	B-geneY
I	E-geneY
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
.	O

The	O
ability	O
of	O
imatinib	S-chem
to	O
enhance	O
osteoclast	O
cell	O
death	O
was	O
accompanied	O
by	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
osteoclast	O
bone	O
resorbing	O
activity	O
.	O

Imatinib	S-chem-C4-1
was	O
also	O
found	O
to	O
inhibit	O
M	B-geneY-C4-2
-	I-geneY-C4-2
CSF	E-geneY-C4-2
-	O
induced	O
osteoclast	O
survival	O
as	O
well	O
as	O
M	B-geneY-C4-2
-	I-geneY-C4-2
CSF	E-geneY-C4-2
-	O
induced	O
osteoclast	O
bone	O
resorbing	O
activity	O
,	O
but	O
was	O
without	O
effect	O
on	O
interleukin	B-geneY
1alpha	E-geneY
(	O
IL	B-geneY
-	I-geneY
1alpha	E-geneY
)	O
and	O
receptor	B-geneY
activator	I-geneY
of	I-geneY
nuclear	I-geneY
factor	I-geneY
kappa	I-geneY
B	I-geneY
ligand	E-geneY
(	O
RANKL	S-geneY
)	O
-	O
induced	O
inhibition	O
of	O
osteoclasts	O
apoptosis	O
,	O
further	O
supporting	O
the	O
hypothesis	O
that	O
imatinib	S-chem-C4-1
may	O
affect	O
mature	O
osteoclasts	O
through	O
the	O
inhibition	O
of	O
c	B-geneY-C4-2
-	I-geneY-C4-2
FMS	E-geneY-C4-2
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
imatinib	S-chem
could	O
be	O
of	O
clinical	O
value	O
in	O
treating	O
diseases	O
where	O
bone	O
destruction	O
can	O
occur	O
due	O
to	O
excessive	O
M	B-geneY
-	I-geneY
CSF	E-geneY
production	O
such	O
as	O
osteoporosis	O
,	O
inflammatory	O
-	O
and	O
tumor	O
-	O
induced	O
osteolysis	O
.	O

Effect	O
of	O
bioactive	O
peptide	O
of	O
Carapax	O
Trionycis	O
on	O
TGF	B-geneY
-	I-geneY
β1	E-geneY
-	O
induced	O
intracellular	O
events	O
in	O
hepatic	O
stellate	O
cells	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
In	O
traditional	O
Chinese	O
medicines	O
for	O
hepatic	O
fibrosis	O
therapy	O
,	O
Carapax	O
Trionycis	O
is	O
used	O
usually	O
as	O
an	O
indispensable	O
component	O
and	O
has	O
a	O
long	O
history	O
of	O
medical	O
use	O
in	O
China	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
extracts	O
of	O
Carapax	O
Trionycis	O
were	O
able	O
to	O
protect	O
liver	O
against	O
fibrosis	O
in	O
CCl4	O
animal	O
models	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
verify	O
the	O
inhibitory	O
effect	O
and	O
the	O
underlying	O
mechanisms	O
of	O
Carapax	O
Trionycis	O
extract	O
peptide	O
(	O
CTEP	O
)	O
on	O
activated	O
hepatic	O
stellate	O
cells	O
which	O
play	O
a	O
central	O
role	O
in	O
liver	O
fibrogenesis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Hepatic	O
stellate	O
cells	O
induced	O
by	O
TGF	B-geneY
-	I-geneY
β1	E-geneY
were	O
applied	O
to	O
evaluate	O
the	O
anti	O
-	O
fibrotic	O
effect	O
of	O
CTEP	O
in	O
vitro	O
.	O

MTS	S-chem
assay	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
western	O
blotting	O
were	O
then	O
used	O
to	O
further	O
investigate	O
the	O
molecular	O
mechanisms	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
contents	O
of	O
collagen	B-geneN
I	E-geneN
,	O
collagen	B-geneN
III	E-geneN
and	O
TIMP	B-geneY
-	I-geneY
1	E-geneY
were	O
significantly	O
inhibited	O
and	O
the	O
level	O
of	O
collagen	B-geneN
I	E-geneN
,	O
collagen	B-geneN
III	E-geneN
,	O
p	B-geneY
-	I-geneY
Smad	I-geneY
3	E-geneY
,	O
TIMP	B-geneY
-	I-geneY
1	E-geneY
and	O
α	B-geneY
-	I-geneY
SMA	E-geneY
proteins	O
decreased	O
significantly	O
in	O
a	O
concentration	O
-	O
dependence	O
manner	O
after	O
treatment	O
with	O
CTEP	O
.	O

Interestingly	O
,	O
the	O
level	O
of	O
Smad	B-geneY
3	E-geneY
protein	O
was	O
not	O
different	O
significantly	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
indicate	O
that	O
CTEP	O
efficiently	O
inhibits	O
cultured	O
HSC	O
-	O
T6	O
cell	O
activation	O
and	O
proliferation	O
via	O
the	O
TGF	B-geneY
-	I-geneY
β1	E-geneY
/	O
Smad	S-geneN
pathway	O
as	O
well	O
as	O
by	O
the	O
elimination	O
of	O
the	O
extracellular	O
matrix	O
.	O

Extracellular	B-geneN
loop	I-geneN
3	E-geneN
(	O
EL3	S-geneN
)	O
and	O
EL3	B-geneN
-	I-geneN
proximal	I-geneN
transmembrane	I-geneN
helix	I-geneN
7	E-geneN
of	O
the	O
mammalian	B-geneN
type	I-geneN
I	I-geneN
and	I-geneN
type	I-geneN
II	I-geneN
gonadotropin	I-geneN
-	I-geneN
releasing	I-geneN
hormone	I-geneN
(	I-geneN
GnRH	I-geneN
)	I-geneN
receptors	E-geneN
determine	O
differential	O
ligand	O
selectivity	O
to	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
and	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
.	O

Mammalian	B-geneN
type	I-geneN
I	I-geneN
and	I-geneN
II	I-geneN
gonadotropin	I-geneN
-	I-geneN
releasing	I-geneN
hormone	I-geneN
(	I-geneN
GnRH	I-geneN
)	I-geneN
receptors	E-geneN
(	O
GnRHRs	S-geneN
)	O
show	O
differential	O
ligand	O
preference	O
for	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
and	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
,	O
respectively	O
.	O

Using	O
a	O
variety	O
of	O
chimeric	O
receptors	O
based	O
on	O
green	B-geneY
monkey	I-geneY
GnRHR	I-geneY
-	I-geneY
2	E-geneY
(	O
gmGnRHR	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
a	O
representative	O
type	B-geneY
II	I-geneY
GnRHR	E-geneY
,	O
and	O
rat	B-geneY
GnRHR	E-geneY
,	O
a	O
representative	O
type	B-geneY
I	I-geneY
GnRHR	E-geneY
,	O
this	O
study	O
elucidated	O
specific	O
domains	O
responsible	O
for	O
this	O
ligand	O
selectivity	O
.	O

A	O
chimeric	O
gmGnRHR	B-geneY
-	I-geneY
2	E-geneY
with	O
the	O
extracellular	B-geneN
loop	I-geneN
3	E-geneN
(	O
EL3	S-geneN
)	O
and	O
EL3	B-geneN
-	I-geneN
proximal	I-geneN
transmembrane	I-geneN
helix	I-geneN
7	E-geneN
(	O
TMH7	S-geneN
)	O
of	O
rat	B-geneY
GnRHR	E-geneY
showed	O
a	O
great	O
increase	O
in	O
ligand	O
sensitivity	O
to	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
but	O
not	O
to	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
.	O

Point	O
-	O
mutation	O
studies	O
indicate	O
that	O
four	O
amino	B-chem
acids	E-chem
,	O
Leu	S-chem
/	O
Phe	S-chem
(	O
7.38	O
)	O
,	O
Leu	S-chem
/	O
Phe	S-chem
(	O
7.43	O
)	O
,	O
Ala	S-chem
/	O
Pro	S-chem
(	O
7.46	O
)	O
,	O
and	O
Pro	S-chem
/	O
Cys	S-chem
(	O
7.47	O
)	O
in	O
TMH7	S-geneN
are	O
critical	O
for	O
ligand	O
selectivity	O
as	O
well	O
as	O
receptor	O
conformation	O
.	O

Furthermore	O
,	O
a	O
combinatory	O
mutation	O
(	O
Pro	S-chem
(	O
7.31	O
)	O
-	O
Pro	S-chem
(	O
7.32	O
)	O
-	O
Ser	S-chem
(	O
7.33	O
)	O
motif	O
to	O
Ser	B-chem
-	I-chem
Glu	I-chem
-	I-chem
Pro	E-chem
in	O
EL3	S-geneN
and	O
Leu	S-chem
(	O
7.38	O
)	O
,	O
Leu	S-chem
(	O
7.43	O
)	O
,	O
Ala	S-chem
(	O
7.46	O
)	O
,	O
and	O
Pro	S-chem
(	O
7.47	O
)	O
to	O
those	O
of	O
rat	B-geneY
GnRHR	E-geneY
)	O
in	O
gmGnRH	B-geneY
-	I-geneY
2	E-geneY
exhibited	O
an	O
approximately	O
500	O
-	O
fold	O
increased	O
sensitivity	O
to	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
,	O
indicating	O
that	O
these	O
residues	O
are	O
critical	O
for	O
discriminating	O
GnRH	B-geneY
-	I-geneY
II	E-geneY
from	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
.	O

[	O
Trp	O
(	O
7	O
)	O
]	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
and	O
[	O
Trp	O
(	O
8	O
)	O
]	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
but	O
not	O
[	O
His	O
(	O
5	O
)	O
]	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
exhibit	O
a	O
higher	O
potency	O
in	O
activating	O
wild	O
-	O
type	O
gmGnRHR	B-geneY
-	I-geneY
2	E-geneY
than	O
native	O
GnRH	B-geneY
-	I-geneY
I	E-geneY
,	O
indicating	O
that	O
amino	B-chem
acids	E-chem
at	O
positions	O
7	O
and	O
8	O
of	O
GnRHs	S-geneN
are	O
more	O
important	O
than	O
position	O
5	O
for	O
differential	O
recognition	O
by	O
type	B-geneN
I	I-geneN
and	I-geneN
type	I-geneN
II	I-geneN
GnRHRs	E-geneN
.	O

As	O
a	O
whole	O
,	O
these	O
data	O
suggest	O
a	O
molecular	O
coevolution	O
of	O
ligands	O
and	O
their	O
receptors	O
and	O
facilitate	O
the	O
understanding	O
of	O
the	O
molecular	O
interaction	O
between	O
GnRHs	S-geneN
and	O
their	O
cognate	O
receptors	O
.	O

Lanthanum	B-chem
(	I-chem
III	I-chem
)	E-chem
regulates	O
the	O
nitrogen	S-chem
assimilation	O
in	O
soybean	O
seedlings	O
under	O
ultraviolet	O
-	O
B	O
radiation	O
.	O

Ultraviolet	O
-	O
B	O
(	O
UV	O
-	O
B	O
,	O
280	O
-	O
320	O
nm	O
)	O
radiation	O
has	O
seriously	O
affected	O
the	O
growth	O
of	O
plants	O
.	O

Finding	O
the	O
technology	O
/	O
method	O
to	O
alleviate	O
the	O
damage	O
of	O
UV	O
-	O
B	O
radiation	O
has	O
become	O
a	O
frontal	O
topic	O
in	O
the	O
field	O
of	O
environmental	O
science	O
.	O

The	O
pretreatment	O
with	O
rare	O
earth	O
elements	O
(	O
REEs	O
)	O
is	O
an	O
effective	O
method	O
,	O
but	O
the	O
regulation	O
mechanism	O
of	O
REEs	O
is	O
unknown	O
.	O

Here	O
,	O
the	O
regulation	O
effects	O
of	O
lanthanum	S-chem
(	O
La	B-chem
(	I-chem
III	I-chem
)	E-chem
)	O
on	O
nitrogen	S-chem
assimilation	O
in	O
soybean	O
seedlings	O
(	O
Glycine	O
max	O
L.	O
)	O
under	O
ultraviolet	O
-	O
B	O
radiation	O
were	O
investigated	O
to	O
elucidate	O
the	O
regulation	O
mechanism	O
of	O
REEs	O
on	O
plants	O
under	O
UV	O
-	O
B	O
radiation	O
.	O

UV	O
-	O
B	O
radiation	O
led	O
to	O
the	O
inhibition	O
in	O
the	O
activities	O
of	O
the	O
key	O
enzymes	O
(	O
nitrate	B-geneN
reductase	E-geneN
,	O
glutamine	B-geneN
synthetase	E-geneN
,	O
glutamate	B-geneN
synthase	E-geneN
)	O
in	O
the	O
nitrogen	S-chem
assimilation	O
,	O
the	O
decrease	O
in	O
the	O
contents	O
of	O
nitrate	S-chem
and	O
soluble	O
proteins	O
,	O
as	O
well	O
as	O
the	O
increase	O
in	O
the	O
content	O
of	O
amino	B-chem
acid	E-chem
in	O
soybean	O
seedlings	O
.	O

The	O
change	O
degree	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
high	O
level	O
(	O
0.45	O
W	O
m	O
(	O
-	O
2	O
)	O
)	O
was	O
higher	O
than	O
that	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
low	O
level	O
(	O
0.15	O
W	O
m	O
(	O
-	O
2	O
)	O
)	O
.	O

The	O
pretreatment	O
with	O
20	O
mg	O
L	O
(	O
-	O
1	O
)	O
La	O
(	B-chem-C4-1
III	I-chem-C4-1
)	I-chem-C4-1
could	O
alleviate	O
the	O
effects	O
of	O
UV	O
-	O
B	O
radiation	O
on	O
the	O
activities	O
of	O
nitrate	O
reductase	I-geneN-C4-2
,	I-geneN-C4-2
glutamine	O
synthetase	I-geneN-C4-2
,	I-geneN-C4-2
glutamate	O
synthase	I-geneN-C4-2
,	I-geneN-C4-2
and	O
glutamate	O
dehydrogenase	I-geneN-C4-2
,	I-geneN-C4-2
promoting	O
amino	O
acid	I-chem
conversion	O
and	O
protein	O
synthesis	O
in	O
soybean	O
seedlings	O
.	O

The	O
regulation	O
effect	O
of	O
La	B-chem
(	I-chem
III	I-chem
)	E-chem
under	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
low	O
level	O
was	O
better	O
than	O
that	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
high	O
level	O
.	O

The	O
results	O
indicated	O
that	O
the	O
pretreatment	O
with	O
20	O
mg	O
L	O
(	O
-	O
1	O
)	O
La	O
(	B-chem
III	I-chem
)	I-chem
could	O
alleviate	O
the	O
inhibition	O
of	O
UV	O
-	O
B	O
radiation	O
on	O
nitrogen	O
assimilation	O
in	O
soybean	O
seedlings	O
.	O

Scientific	O
evidence	O
for	O
traditional	O
claim	O
of	O
antiobesity	O
activity	O
of	O
Tecomella	O
undulata	O
bark	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
The	O
bark	O
of	O
Tecomella	O
undulata	O
is	O
traditionally	O
claimed	O
in	O
the	O
treatment	O
of	O
various	O
disease	O
ailments	O
including	O
obesity	O
and	O
cancer	O
.	O

Till	O
now	O
there	O
are	O
no	O
studies	O
about	O
anti	O
obesity	O
activity	O
of	O
Tecomella	O
undulata	O
bark	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
The	O
present	O
study	O
was	O
aimed	O
to	O
establish	O
a	O
scientific	O
evidence	O
for	O
anti	O
obesity	O
efficiency	O
of	O
ethyl	B-chem
acetate	E-chem
extract	O
of	O
Tecomella	O
undulata	O
bark	O
(	O
EATUB	O
)	O
.	O

Further	O
to	O
standardize	O
the	O
active	O
fractions	O
of	O
EATUB	O
using	O
different	O
biomarkers	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
investigated	O
activity	O
of	O
EATUB	O
fractions	O
(	O
F1	O
-	O
F7	O
)	O
using	O
3T3	O
-	O
L1	O
fibroblasts	O
.	O

Further	O
,	O
F1	O
-	O
mediated	O
effects	O
were	O
characterized	O
by	O
determining	O
mRNA	O
and	O
protein	O
levels	O
of	O
SIRT1	S-geneY
,	O
one	O
of	O
the	O
key	O
targets	O
for	O
the	O
treatment	O
of	O
obesity	O
,	O
using	O
semi	O
quantitative	O
RT	O
-	O
PCR	O
(	O
sqRT	O
-	O
PCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O

The	O
consequences	O
of	O
modulation	O
of	O
SIRT1	S-geneY
on	O
mRNA	O
and	O
protein	O
levels	O
of	O
various	O
adipogenesis	O
mediators	O
like	O
PPARγ	S-geneY
,	O
C	B-geneY
/	I-geneY
EBPα	E-geneY
,	O
E2F1	S-geneY
,	O
leptin	S-geneY
,	O
adiponectin	S-geneY
and	O
LPL	S-geneY
were	O
also	O
studied	O
.	O

In	O
-	O
vivo	O
studies	O
were	O
performed	O
using	O
High	O
Fat	O
Diet	O
(	O
HFD	O
)	O
obese	O
mice	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
compared	O
to	O
controls	O
,	O
preadipocytes	O
and	O
adipocytes	O
incubated	O
with	O
F1	O
exhibited	O
a	O
significant	O
decrease	O
in	O
adipogenesis	O
and	O
lipogenesis	O
.	O

In	O
addition	O
,	O
sqRT	O
-	O
PCR	O
and	O
western	O
blot	O
analysis	O
showed	O
significant	O
increase	O
in	O
SIRT1	S-geneY
and	O
adiponectin	S-geneY
levels	O
and	O
decrease	O
in	O
PPARγ	S-geneY
,	O
C	B-geneY
/	I-geneY
EBPα	E-geneY
,	O
E2F1	S-geneY
,	O
leptin	S-geneY
and	O
LPL	S-geneY
levels	O
in	O
preadipocytes	O
and	O
adipocytes	O
.	O

In	O
-	O
vivo	O
studies	O
of	O
F1	O
in	O
HFD	O
induced	O
obese	O
mice	O
showed	O
significant	O
improvement	O
in	O
lipid	O
profile	O
and	O
glucose	S-chem
levels	O
.	O

The	O
bioactive	O
fraction	O
(	O
F1	O
)	O
was	O
determined	O
to	O
possess	O
4.95	O
%	O
of	O
ferulic	B-chem
acid	E-chem
.	O

CONCLUSION	O
:	O
Thus	O
,	O
our	O
findings	O
signified	O
the	O
beneficial	O
effects	O
of	O
Tecomella	O
undulata	O
bark	O
in	O
pharmacologic	O
interventions	O
related	O
to	O
obesity	O
and	O
metabolic	O
disorders	O
.	O

Ferulic	B-chem
acid	E-chem
and	O
rutin	S-chem
are	O
being	O
reported	O
and	O
quantified	O
for	O
the	O
first	O
time	O
from	O
the	O
bark	O
of	O
Tecomella	O
undulata	O
.	O

Kinetic	O
characterization	O
of	O
adenylosuccinate	B-geneY
synthetase	E-geneY
from	O
the	O
thermophilic	O
archaea	O
Methanocaldococcus	O
jannaschii	O
.	O

Adenylosuccinate	B-geneY-C9-2
synthetase	E-geneY-C9-2
(	O
AdSS	S-geneY-C9-2
)	O
catalyzes	O
the	O
Mg2	B-chem-C9-1
+	E-chem-C9-1
dependent	O
condensation	O
of	O
a	O
molecule	O
of	O
IMP	O
with	O
aspartate	S-chem
to	O
form	O
adenylosuccinate	S-chem-C9-1
,	O
in	O
a	O
reaction	O
driven	O
by	O
the	O
hydrolysis	O
of	O
GTP	S-chem
to	O
GDP	S-chem
.	O

AdSS	S-geneY
from	O
the	O
thermophilic	O
archaea	O
,	O
Methanocaldococcus	O
jannaschii	O
(	O
MjAdSS	S-geneY
)	O
is	O
345	O
amino	B-chem
acids	E-chem
long	O
against	O
an	O
average	O
length	O
of	O
430	O
-	O
457	O
amino	B-chem
acids	E-chem
for	O
most	O
mesophilic	O
AdSS	S-geneY
.	O

This	O
short	O
AdSS	S-geneY
has	O
two	O
large	O
deletions	O
that	O
map	O
to	O
the	O
middle	O
and	O
C	S-chem
-	O
terminus	O
of	O
the	O
protein	O
.	O

This	O
article	O
discusses	O
the	O
detailed	O
kinetic	O
characterization	O
of	O
MjAdSS	S-geneY
.	O

Initial	O
velocity	O
and	O
product	O
inhibition	O
studies	O
,	O
carried	O
out	O
at	O
70	O
degrees	O
C	O
,	O
suggest	O
a	O
rapid	O
equilibrium	O
random	O
AB	O
steady	O
-	O
state	O
ordered	O
C	O
kinetic	O
mechanism	O
for	O
the	O
MjAdSS	S-geneY
catalyzed	O
reaction	O
.	O

AdSS	S-geneY
are	O
known	O
to	O
exhibit	O
monomer	O
-	O
dimer	O
equilibrium	O
with	O
the	O
dimer	O
being	O
implicated	O
in	O
catalysis	O
.	O

In	O
contrast	O
,	O
our	O
studies	O
show	O
that	O
MjAdSS	S-geneY
is	O
an	O
equilibrium	O
mixture	O
of	O
dimers	O
and	O
tetramers	O
with	O
the	O
tetramer	O
being	O
the	O
catalytically	O
active	O
form	O
.	O

The	O
tetramer	O
dissociates	O
into	O
dimers	O
with	O
a	O
minor	O
increase	O
in	O
ionic	O
strength	O
of	O
the	O
buffer	O
,	O
while	O
the	O
dimer	O
is	O
extremely	O
stable	O
and	O
does	O
not	O
dissociate	O
even	O
at	O
1.2	O
M	O
NaCl	S-chem
.	O

Phosphate	S-chem-C4-1
,	O
a	O
product	O
of	O
the	O
reaction	O
,	O
was	O
found	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
MjAdSS	S-geneY-C4-2
showing	O
biphasic	O
inhibition	O
of	O
enzyme	O
activity	O
.	O

The	O
inhibition	O
was	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
with	O
GTP	S-chem
.	O

MjAdSS	S-geneY
,	O
like	O
the	O
mouse	B-geneN
acidic	I-geneN
isozyme	E-geneN
,	O
exhibits	O
substrate	O
inhibition	O
,	O
with	O
IMP	O
inhibiting	O
enzyme	O
activity	O
at	O
subsaturating	O
GTP	S-chem
concentrations	O
.	O

Regulation	O
of	O
enzyme	O
activity	O
by	O
the	O
glycolytic	O
intermediate	O
,	O
fructose	S-chem
1,6	B-chem
bisphosphate	E-chem
,	O
was	O
also	O
observed	O
with	O
the	O
inhibition	O
being	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
against	O
GTP	S-chem
.	O

Surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
with	O
enhanced	O
pharmacokinetics	O
and	O
tumor	O
growth	O
inhibition	O
.	O

We	O
characterized	O
in	O
this	O
study	O
the	O
pharmacokinetics	O
and	O
antitumor	O
efficacy	O
of	O
histidine	S-chem
-	O
lysine	S-chem
(	O
HK	O
)	O
:	O
siRNA	O
nanoplexes	O
modified	O
with	O
PEG	S-chem
and	O
a	O
cyclic	O
RGD	S-geneN
(	O
cRGD	S-geneN
)	O
ligand	O
targeting	O
αvβ3	S-geneY
and	O
αvβ5	B-geneY
integrins	E-geneY
.	O

With	O
noninvasive	O
imaging	O
,	O
systemically	O
administered	O
surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
showed	O
nearly	O
4	O
-	O
fold	O
greater	O
blood	O
levels	O
,	O
40	O
%	O
higher	O
accumulation	O
in	O
tumor	O
tissue	O
,	O
and	O
60	O
%	O
lower	O
luciferase	O
activity	O
than	O
unmodified	O
HK	O
:	O
siRNA	O
nanoplexes	O
.	O

We	O
then	O
determined	O
whether	O
the	O
surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplex	O
carrier	O
was	O
more	O
effective	O
in	O
reducing	O
MDA	O
-	O
MB	O
-	O
435	O
tumor	O
growth	O
with	O
an	O
siRNA	O
targeting	O
Raf	B-geneY
-	I-geneY
1	E-geneY
.	O

Repeated	O
systemic	O
administration	O
of	O
the	O
selected	O
surface	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
targeting	O
Raf	B-geneY
-	I-geneY
1	E-geneY
showed	O
35	O
%	O
greater	O
inhibition	O
of	O
tumor	O
growth	O
than	O
unmodified	O
HK	O
:	O
siRNA	O
nanoplexes	O
and	O
60	O
%	O
greater	O
inhibition	O
of	O
tumor	O
growth	O
than	O
untreated	O
mice	O
.	O

The	O
improved	O
blood	O
pharmacokinetic	O
results	O
and	O
tumor	O
localization	O
observed	O
with	O
the	O
integrin	S-geneN
-	O
targeting	O
surface	O
modification	O
of	O
HK	O
:	O
siRNA	O
nanoplexes	O
correlated	O
with	O
greater	O
tumor	O
growth	O
inhibition	O
.	O

This	O
investigation	O
reveals	O
that	O
through	O
control	O
of	O
targeting	O
ligand	O
surface	O
display	O
in	O
association	O
with	O
a	O
steric	O
PEG	S-chem
layer	O
,	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
show	O
promise	O
to	O
advance	O
RNAi	O
therapeutics	O
in	O
oncology	O
and	O
potentially	O
other	O
critical	O
diseases	O
.	O

Bioactivation	O
of	O
the	O
nasal	O
toxicant	O
2,6	B-chem
-	I-chem
dichlorobenzonitrile	E-chem
:	O
an	O
assessment	O
of	O
metabolic	O
activity	O
in	O
human	O
nasal	O
mucosa	O
and	O
identification	O
of	O
indicators	O
of	O
exposure	O
and	O
potential	O
toxicity	O
.	O

The	O
herbicide	O
2,6	B-chem
-	I-chem
dichlorobenzonitrile	E-chem
(	O
DCBN	S-chem
)	O
is	O
a	O
potent	O
nasal	O
toxicant	O
in	O
rodents	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
DCBN	S-chem
causes	O
similar	O
nasal	O
toxicity	O
in	O
humans	O
.	O

The	O
tissue	O
-	O
selective	O
toxicity	O
of	O
DCBN	S-chem
in	O
mouse	O
nasal	O
mucosa	O
is	O
largely	O
dependent	O
on	O
target	O
tissue	O
bioactivation	O
by	O
CYP2A5	S-geneY
.	O

The	O
human	O
orthologues	O
of	O
CYP2A5	S-geneY
,	O
CYP2A6	S-geneY
and	O
CYP2A13	S-geneY
,	O
are	O
both	O
expressed	O
in	O
nasal	O
mucosa	O
and	O
are	O
capable	O
of	O
activating	O
DCBN	S-chem
.	O

In	O
this	O
study	O
,	O
we	O
directly	O
determined	O
the	O
ability	O
of	O
human	O
nasal	O
mucosa	O
to	O
bioactivate	O
DCBN	S-chem
.	O

We	O
also	O
tested	O
the	O
suitability	O
of	O
a	O
glutathione	S-chem
conjugate	O
of	O
DCBN	S-chem
(	O
GS	O
-	O
DCBN	S-chem
)	O
or	O
its	O
derivatives	O
as	O
biomarkers	O
of	O
DCBN	S-chem
exposure	O
and	O
nasal	O
toxicity	O
in	O
mouse	O
models	O
.	O

We	O
found	O
that	O
human	O
fetal	O
nasal	O
mucosa	O
microsomes	O
catalyze	O
the	O
formation	O
of	O
GS	O
-	O
DCBN	S-chem
,	O
with	O
a	O
Km	O
value	O
comparable	O
to	O
that	O
of	O
adult	O
mouse	O
nasal	O
mucosa	O
microsomes	O
.	O

The	O
activity	O
of	O
the	O
human	O
nasal	O
mucosa	O
microsomes	O
was	O
inhibited	O
by	O
8	B-chem-C4-1
-	I-chem-C4-1
methoxypsoralen	E-chem-C4-1
,	O
a	O
known	O
CYP2A	S-geneN-C4-2
inhibitor	O
.	O

GS	O
-	O
DCBN	S-chem
and	O
its	O
metabolites	O
were	O
detected	O
in	O
the	O
nasal	O
mucosa	O
and	O
nasal	O
-	O
wash	O
fluid	O
obtained	O
from	O
DCBN	S-chem
-	O
treated	O
mice	O
,	O
in	O
amounts	O
that	O
increased	O
with	O
escalations	O
in	O
DCBN	S-chem
dose	O
,	O
and	O
they	O
were	O
all	O
still	O
detectable	O
at	O
24	O
h	O
after	O
a	O
DCBN	S-chem
treatment	O
(	O
at	O
10	O
mg	O
/	O
kg	O
)	O
.	O

Further	O
studies	O
in	O
Cyp2a5	S-geneY
-	O
null	O
mice	O
indicated	O
that	O
GS	O
-	O
DCBN	S-chem
and	O
its	O
metabolites	O
in	O
nasal	O
-	O
wash	O
fluid	O
were	O
generated	O
in	O
the	O
nasal	O
mucosa	O
,	O
rather	O
than	O
in	O
other	O
organs	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
the	O
human	O
nasal	O
mucosa	O
is	O
capable	O
of	O
bioactivating	O
DCBN	S-chem
and	O
that	O
GS	O
-	O
DCBN	S-chem
and	O
its	O
metabolites	O
in	O
nasal	O
-	O
wash	O
fluid	O
may	O
collectively	O
serve	O
as	O
indicators	O
of	O
DCBN	S-chem
exposure	O
and	O
potential	O
nasal	O
toxicity	O
in	O
humans	O
.	O

DRF	B-chem
2655	E-chem
:	O
a	O
unique	O
molecule	O
that	O
reduces	O
body	O
weight	O
and	O
ameliorates	O
metabolic	O
abnormalities	O
.	O

OBJECTIVE	O
:	O
Preclinical	O
evaluation	O
of	O
DRF	B-chem-C5-1
2655	E-chem-C5-1
,	O
a	O
peroxisome	B-geneY-C5-2
proliferator	I-geneY-C5-2
-	I-geneY-C5-2
activated	I-geneY-C5-2
receptor	I-geneY-C5-2
alpha	E-geneY-C5-2
(	O
PPARalpha	S-geneY-C5-2
)	O
and	O
PPARgamma	S-geneY-C5-2
agonist	O
,	O
as	O
a	O
body	O
-	O
weight	O
lowering	O
,	O
hypolipidemic	O
and	O
euglycemic	O
agent	O
.	O

RESEARCH	O
METHODS	O
AND	O
PROCEDURES	O
:	O
DRF	B-chem
2655	E-chem
was	O
studied	O
in	O
different	O
genetic	O
,	O
normal	O
,	O
and	O
hyperlipidemic	O
animal	O
models	O
.	O

HEK	O
293	O
cells	O
were	O
used	O
to	O
conduct	O
the	O
reporter	O
-	O
based	O
transactivation	O
of	O
PPARalpha	S-geneY
and	O
PPARgamma	S-geneY
.	O

To	O
understand	O
the	O
biochemical	O
mechanism	O
of	O
lipid	O
-	O
,	O
body	O
-	O
weight	O
-	O
,	O
and	O
glucose	S-chem
-	O
lowering	O
effects	O
,	O
activities	O
of	O
key	O
beta	O
-	O
oxidation	O
and	O
lipid	O
catabolism	O
enzymes	O
and	O
gluconeogenic	O
enzymes	O
were	O
studied	O
in	O
db	O
/	O
db	O
mice	O
treated	O
with	O
DRF	B-chem
2655	E-chem
.	O

3T3L1	O
cells	O
were	O
used	O
for	O
adipogenesis	O
study	O
,	O
and	O
HepG2	O
cells	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
DRF	B-chem
2655	E-chem
on	O
total	O
cholesterol	S-chem
and	O
triglyceride	S-chem
synthesis	O
using	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
acetate	E-chem
and	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
glycerol	E-chem
.	O

RESULTS	O
:	O
DRF	B-chem-C5-1
2655	E-chem-C5-1
showed	O
concentration	O
-	O
dependent	O
transactivation	O
of	O
PPARalpha	S-geneY-C5-2
and	O
PPARgamma	S-geneY-C5-2
.	O

In	O
the	O
3T3L1	O
cell	O
-	O
differentiation	O
study	O
,	O
DRF	B-chem
2655	E-chem
and	O
rosiglitazone	S-chem
showed	O
369	O
%	O
and	O
471	O
%	O
increases	O
,	O
respectively	O
,	O
in	O
triglyceride	S-chem
accumulation	O
.	O

DRF	B-chem
2655	E-chem
showed	O
body	O
-	O
weight	O
lowering	O
and	O
euglycemic	O
and	O
hypolipidemic	O
effects	O
in	O
various	O
animal	O
models	O
.	O
db	O
/	O
db	O
mice	O
treated	O
with	O
DRF	B-chem-MU-1
2655	E-chem-MU-1
showed	O
5	O
-	O
and	O
3.6	O
-	O
fold	O
inhibition	O
in	O
phosphoenolpyruvate	B-geneY-C4-2
carboxykinase	E-geneY-C4-2
and	O
glucose	B-geneY-C4-2
6	I-geneY-C4-2
-	I-geneY-C4-2
phosphatase	E-geneY-C4-2
activity	O
and	O
651	O
%	O
and	O
77	O
%	O
increases	O
in	O
the	O
beta	O
-	O
oxidation	O
enzymes	O
carnitine	B-geneN-C3-2
palmitoyltransferase	E-geneN-C3-2
and	O
carnitine	B-geneY-C3-2
acetyltransferase	E-geneY-C3-2
,	O
respectively	O
.	O

HepG2	O
cells	O
treated	O
with	O
DRF	B-chem
2655	E-chem
showed	O
significant	O
reduction	O
in	O
lipid	O
synthesis	O
.	O

DISCUSSION	O
:	O
DRF	B-chem
2655	E-chem
showed	O
excellent	O
euglycemic	O
and	O
hypolipidemic	O
activities	O
in	O
different	O
animal	O
models	O
.	O

An	O
exciting	O
finding	O
is	O
its	O
body	O
-	O
weight	O
lowering	O
effect	O
in	O
these	O
models	O
,	O
which	O
might	O
be	O
mediated	O
by	O
the	O
induction	O
of	O
target	O
enzymes	O
involved	O
in	O
hepatic	O
lipid	O
catabolism	O
through	O
PPARalpha	S-geneY
activation	O
.	O

Effect	O
of	O
quercetin	S-chem
-	O
rich	O
onion	O
peel	O
extracts	O
on	O
arterial	O
thrombosis	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
oral	O
supplementation	O
of	O
quercetin	S-chem
-	O
rich	O
onion	O
peel	O
extract	O
(	O
OPE	O
)	O
influences	O
blood	O
coagulation	O
and	O
arterial	O
thrombosis	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

24	O
male	O
rats	O
,	O
5weeks	O
old	O
,	O
were	O
divided	O
into	O
three	O
groups	O
with	O
different	O
diets	O
(	O
C	O
:	O
control	O
,	O
2mg	O
OPE	O
:	O
chow	O
diet	O
with	O
2mg	O
OPE	O
supplementation	O
,	O
10mg	O
OPE	O
:	O
chow	O
diet	O
with	O
10mg	O
OPE	O
supplementation	O
)	O
for	O
6weeks	O
.	O

Blood	O
coagulation	O
parameters	O
including	O
prothrombin	S-geneY
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	S-geneY
time	O
(	O
aPTT	O
)	O
and	O
platelet	O
aggregation	O
were	O
examined	O
.	O

The	O
OPE	O
did	O
not	O
affect	O
blood	O
cholesterol	S-chem
levels	O
but	O
significantly	O
decreased	O
blood	O
triglyceride	S-chem
and	O
glucose	S-chem
levels	O
.	O

PT	O
,	O
aPTT	O
and	O
platelet	O
aggregation	O
were	O
not	O
significantly	O
different	O
among	O
all	O
tested	O
groups	O
.	O

However	O
,	O
in	O
vivo	O
arterial	O
thrombosis	O
was	O
significantly	O
delayed	O
in	O
groups	O
that	O
were	O
fed	O
2mg	O
and	O
10mg	O
OPE	O
diets	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
addition	O
,	O
the	O
OPE	O
greatly	O
diminished	O
thrombin	S-geneY
-	O
induced	O
expression	O
of	O
tissue	B-geneY
factor	E-geneY
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
a	O
coagulation	O
initiator	O
.	O

In	O
addition	O
,	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
and	O
c	B-geneY
-	I-geneY
Jun	I-geneY
N	I-geneY
-	I-geneY
terminal	I-geneY
kinase	E-geneY
(	O
JNK	S-geneY
)	O
signaling	O
pathways	O
activated	O
by	O
thrombin	S-geneY
treatment	O
were	O
prevented	O
by	O
the	O
OPE	O
pre	O
-	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
OPE	O
may	O
have	O
anti	O
-	O
thrombotic	O
effects	O
through	O
restricting	O
the	O
induced	O
expression	O
of	O
tissue	B-geneY
factor	E-geneY
via	O
down	O
-	O
regulating	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
activation	O
upon	O
coagulation	O
stimulus	O
,	O
leading	O
to	O
the	O
prolongation	O
of	O
time	O
for	O
arterial	O
thrombosis	O
.	O

Thiazolidinediones	S-chem
(	O
TZDs	S-chem
)	O
affect	O
osteoblast	O
viability	O
and	O
biomarkers	O
independently	O
of	O
the	O
TZD	S-chem
effects	O
on	O
aromatase	S-geneY
.	O

Thiazolidinediones	S-chem
(	O
TZDs	S-chem
)	O
are	O
insulin	S-geneY
sensitizers	O
used	O
for	O
treatment	O
of	O
diabetes	O
.	O

We	O
have	O
previously	O
reported	O
that	O
TZDs	S-chem-C4-1
reduce	O
estrogen	S-chem-C9-1
synthesis	O
by	O
inhibiting	O
aromatase	S-geneY-MU-2
activity	O
in	O
human	O
granulosa	O
cells	O
(	O
HGC	O
)	O
.	O

Multiple	O
clinical	O
trials	O
demonstrated	O
that	O
TZDs	S-chem
increase	O
the	O
risk	O
of	O
fractures	O
in	O
postmenopausal	O
women	O
with	O
type	O
2	O
diabetes	O
.	O

We	O
studied	O
mouse	O
osteoblasts	O
alone	O
or	O
in	O
a	O
co	O
-	O
culture	O
with	O
HGC	O
to	O
determine	O
whether	O
TZD	S-chem-C4-1
inhibition	O
of	O
aromatase	S-geneY-C4-2
plays	O
a	O
role	O
in	O
their	O
effects	O
on	O
bone	O
metabolism	O
.	O

Mouse	O
osteoblasts	O
were	O
cultured	O
with	O
and	O
without	O
HGC	O
,	O
and	O
incubated	O
in	O
a	O
medium	O
with	O
or	O
without	O
testosterone	S-chem
,	O
pioglitazone	S-chem
or	O
rosiglitazone	S-chem
.	O

Cell	O
growth	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	B-geneN
phosphatase	E-geneN
activity	O
,	O
and	O
osteocalcin	S-geneY
production	O
were	O
measured	O
.	O

TZDs	S-chem
inhibited	O
estradiol	S-chem
production	O
by	O
up	O
to	O
84	O
%	O
in	O
HGC	O
/	O
mouse	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZDs	S-chem
induced	O
mouse	O
osteoblast	O
death	O
and	O
increased	O
oleic	B-chem
acid	E-chem
uptake	O
.	O

TZDs	S-chem-C4-1
also	O
inhibited	O
alkaline	B-geneN-C4-2
phosphatase	E-geneN-C4-2
activity	O
(	O
58	O
-	O
75	O
%	O
,	O
p	O
<	O
0.046	O
)	O
and	O
osteocalcin	S-geneY-C4-2
production	O
(	O
52	O
-	O
75	O
%	O
,	O
p	O
<	O
0.031	O
)	O
.	O

For	O
all	O
the	O
parameters	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
osteoblast	O
cultures	O
alone	O
and	O
the	O
HCG	O
/	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZD	S-chem-C4-1
effects	O
on	O
osteoblast	O
viability	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	B-geneN
phosphatase	E-geneN
and	O
osteocalcin	S-geneY
production	O
are	O
independent	O
of	O
their	O
effects	O
on	O
aromatase	S-geneY-C4-2
.	O

Pharmacogenetics	O
of	O
Allopurinol	S-chem
-	O
Making	O
an	O
Old	O
Drug	O
Safer	O
.	O

Allopurinol	S-chem
is	O
a	O
drug	O
that	O
has	O
been	O
used	O
for	O
decades	O
to	O
lower	O
serum	O
urate	O
levels	O
in	O
patients	O
with	O
gout	O
or	O
chronic	O
renal	O
failure	O
and	O
in	O
cancer	O
patients	O
undergoing	O
chemotherapy	O
at	O
risk	O
of	O
tumor	O
lysis	O
syndrome	O
.	O

Patients	O
may	O
develop	O
cutaneous	O
hypersensitivity	O
reactions	O
,	O
ranging	O
from	O
mild	O
rashes	O
to	O
potentially	O
fatal	O
severe	O
cutaneous	O
adverse	O
reactions	O
(	O
SCARs	O
)	O
namely	O
drug	O
hypersensitivity	O
syndrome	O
,	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
,	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
the	O
association	O
between	O
human	B-geneY
leukocyte	I-geneY
antigen	I-geneY
(	I-geneY
HLA	I-geneY
)	I-geneY
B	E-geneY
*	O
58	O
:	O
01	O
allele	O
and	O
allopurinol	S-chem
-	O
induced	O
SCARs	O
,	O
which	O
might	O
explain	O
ethnic	O
differences	O
in	O
their	O
incidences	O
.	O

Genotyping	O
is	O
now	O
required	O
before	O
starting	O
abacavir	S-chem
and	O
carbamazepine	S-chem
so	O
as	O
to	O
identify	O
individuals	O
susceptible	O
to	O
SJS	O
.	O

However	O
,	O
no	O
genetic	O
screening	O
is	O
advocated	O
before	O
commencement	O
of	O
allopurinol	S-chem
.	O

The	O
lack	O
of	O
availability	O
of	O
a	O
rapid	O
and	O
inexpensive	O
screening	O
test	O
for	O
the	O
HLA	B-geneY
-	I-geneY
B	E-geneY
*	O
58	O
:	O
01	O
allele	O
is	O
one	O
of	O
the	O
obstacles	O
to	O
such	O
screening	O
.	O

Development	O
of	O
a	O
test	O
that	O
is	O
quick	O
,	O
accurate	O
,	O
and	O
cost	O
-	O
effective	O
is	O
warranted	O
.	O

Aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
-	O
mediated	O
disruption	O
of	O
contact	O
inhibition	O
is	O
associated	O
with	O
connexin43	S-geneY
downregulation	O
and	O
inhibition	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
.	O

The	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AhR	S-geneY
)	O
contributes	O
to	O
the	O
control	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
,	O
cell	O
adhesion	O
,	O
migration	O
or	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
connexin43	S-geneY
(	O
Cx43	S-geneY
)	O
and	O
Cx43	S-geneY
-	O
mediated	O
gap	O
junctional	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
during	O
the	O
AhR	S-geneY
-	O
dependent	O
disruption	O
of	O
contact	O
inhibition	O
in	O
non	O
-	O
tumorigenic	O
liver	O
epithelial	O
cells	O
.	O

The	O
contact	O
inhibition	O
of	O
cell	O
proliferation	O
is	O
a	O
process	O
restricting	O
the	O
cell	O
division	O
of	O
confluent	O
non	O
-	O
transformed	O
cells	O
,	O
which	O
is	O
frequently	O
abolished	O
in	O
cancer	O
cells	O
;	O
however	O
,	O
the	O
mechanisms	O
contributing	O
to	O
its	O
disruption	O
are	O
still	O
only	O
partially	O
understood	O
.	O

Disruption	O
of	O
contact	O
inhibition	O
,	O
which	O
was	O
induced	O
by	O
toxic	O
AhR	S-geneY
ligands	O
2,3,7,8	B-chem-C4-1
-	I-chem-C4-1
tetrachlorodibenzo	I-chem-C4-1
-	I-chem-C4-1
p	I-chem-C4-1
-	I-chem-C4-1
dioxin	E-chem-C4-1
(	O
TCDD	S-chem-C4-1
)	O
or	O
polycyclic	B-chem-C4-1
aromatic	I-chem-C4-1
hydrocarbons	E-chem-C4-1
in	O
epithelial	O
WB	O
-	O
F344	O
cells	O
,	O
reduced	O
Cx43	S-geneY-C4-2
protein	O
levels	O
,	O
possibly	O
via	O
enhanced	O
proteasomal	O
degradation	O
,	O
significantly	O
decreased	O
the	O
amount	O
of	O
gap	O
junction	O
plaques	O
and	O
downregulated	O
GJIC	O
,	O
in	O
an	O
AhR	S-geneY
-	O
dependent	O
manner	O
.	O

Although	O
both	O
intracellular	O
and	O
membrane	O
Cx43	S-geneY-C4-2
pools	O
were	O
markedly	O
reduced	O
in	O
cells	O
released	O
from	O
contact	O
inhibition	O
by	O
TCDD	S-chem-C4-1
,	O
siRNA	O
-	O
mediated	O
Cx43	S-geneY-C4-2
knock	O
-	O
down	O
was	O
not	O
sufficient	O
to	O
stimulate	O
proliferation	O
in	O
contact	O
-	O
inhibited	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
downregulation	O
of	O
Cx43	S-geneY
/	O
GJIC	O
in	O
non	O
-	O
transformed	O
epithelial	O
cells	O
is	O
an	O
inherent	O
part	O
of	O
disruption	O
of	O
contact	O
inhibition	O
,	O
which	O
occurs	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

This	O
process	O
runs	O
in	O
parallel	O
with	O
alterations	O
of	O
other	O
forms	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
,	O
thus	O
suggesting	O
that	O
toxic	O
AhR	S-geneY
agonists	O
may	O
simultaneously	O
abrogate	O
contact	O
inhibition	O
and	O
reduce	O
GJIC	O
,	O
two	O
essential	O
mechanisms	O
linked	O
to	O
deregulation	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
during	O
tumor	O
promotion	O
and	O
progression	O
.	O

Temperature	O
Effects	O
of	O
Sputtering	O
of	O
Langmuir	O
-	O
Blodgett	O
Multilayers	O
.	O

Time	O
-	O
of	O
-	O
flight	O
secondary	O
ion	O
mass	O
spectrometry	O
(	O
TOF	O
-	O
SIMS	O
)	O
and	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
are	O
employed	O
to	O
characterize	O
a	O
wedge	O
-	O
shaped	O
crater	O
eroded	O
by	O
a	O
40	O
keV	O
C	B-chem
(	I-chem
60	I-chem
)	I-chem
(	I-chem
+	I-chem
)	E-chem
cluster	O
ion	O
beam	O
on	O
an	O
organic	O
thin	O
film	O
of	O
402	O
nm	O
of	O
barium	B-chem
arachidate	E-chem
(	O
AA	O
)	O
multilayers	O
prepared	O
by	O
the	O
Langmuir	O
-	O
Blodgett	O
(	O
LB	O
)	O
technique	O
.	O

Sample	O
cooling	O
to	O
90	O
K	O
was	O
used	O
to	O
help	O
reduce	O
chemical	O
damage	O
,	O
improve	O
depth	O
resolution	O
and	O
maintain	O
constant	O
erosion	O
rate	O
during	O
depth	O
profiling	O
.	O

The	O
film	O
was	O
characterized	O
at	O
90	O
K	O
,	O
135	O
K	O
,	O
165	O
K	O
,	O
205	O
K	O
,	O
265	O
K	O
and	O
300	O
K	O
.	O

It	O
is	O
shown	O
that	O
sample	O
cooling	O
to	O
205	O
K	O
or	O
lower	O
helps	O
to	O
inhibit	O
erosion	O
rate	O
decay	O
,	O
whereas	O
at	O
300	O
K	O
and	O
265	O
K	O
the	O
erosion	O
rate	O
continues	O
to	O
drop	O
after	O
250	O
nm	O
of	O
erosion	O
,	O
reaching	O
about	O
half	O
of	O
the	O
initial	O
value	O
after	O
removal	O
of	O
the	O
entire	O
film	O
.	O

Depth	O
profiles	O
are	O
acquired	O
from	O
the	O
SIMS	O
images	O
of	O
the	O
eroded	O
wedge	O
crater	O
.	O

The	O
results	O
suggest	O
that	O
sample	O
cooling	O
only	O
slightly	O
improves	O
the	O
altered	O
layer	O
thickness	O
,	O
but	O
eliminates	O
the	O
decrease	O
in	O
erosion	O
rate	O
observed	O
above	O
265	O
K	O
.	O

EZETIMIBE	S-chem
INCREASES	O
HEPATIC	O
IRON	S-chem
LEVELS	O
IN	O
MICE	O
FED	O
A	O
HIGH	O
-	O
FAT	O
DIET	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
ezetimibe	S-chem
may	O
be	O
a	O
promising	O
agent	O
for	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
steatohepatitis	O
(	O
NAFLD	O
/	O
NASH	O
)	O
.	O

Phlebotomy	O
and	O
dietary	O
iron	S-chem
restriction	O
reduces	O
serum	B-geneN
transaminase	E-geneN
in	O
NAFLD	O
/	O
NASH	O
patients	O
.	O

Recent	O
studies	O
showed	O
that	O
mutual	O
effects	O
exist	O
between	O
lipid	O
metabolism	O
and	O
iron	S-chem
metabolism	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
ezetimibe	S-chem
on	O
iron	S-chem
metabolism	O
were	O
examined	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
with	O
or	O
without	O
iron	S-chem
.	O

C57BL	O
/	O
6	O
mice	O
were	O
fed	O
the	O
following	O
diets	O
for	O
12	O
weeks	O
.	O

Experiment	O
1	O
:	O
1	O
)	O
a	O
control	O
diet	O
;	O
C	O
2	O
)	O
C	O
plus	O
ezetimibe	S-chem
(	O
0.3mg	O
/	O
day	O
;	O
4	O
weeks	O
)	O
;	O
CE	O
3	O
)	O
a	O
high	O
-	O
fat	O
diet	O
;	O
H	O
4	O
)	O
H	O
plus	O
ezetimibe	S-chem
;	O
HE	O
.	O

Experiment	O
2	O
:	O
1	O
)	O
C	O
containing	O
carbonyl	B-chem
iron	E-chem
(	O
average	O
;	O
22.4mg	O
/	O
day	O
;	O
6	O
weeks	O
)	O
;	O
CI	O
2	O
)	O
CI	O
plus	O
ezetimibe	S-chem
;	O
CIE	O
3	O
)	O
H	O
containing	O
carbonyl	B-chem
iron	E-chem
;	O
HI	O
4	O
)	O
HI	O
plus	O
ezetimibe	S-chem
;	O
HIE	O
.	O

Blood	O
,	O
livers	O
,	O
and	O
duodenum	O
were	O
removed	O
after	O
12	O
weeks	O
.	O

In	O
Experiment	O
1	O
,	O
hepatic	O
iron	S-chem
levels	O
were	O
higher	O
in	O
HE	O
than	O
H	O
,	O
whereas	O
there	O
was	O
no	O
difference	O
between	O
C	O
and	O
CE	O
.	O

Hepatic	O
mRNA	O
expression	O
of	O
transferrin	B-geneN
receptor	I-geneN
1	I-geneN
and	I-geneN
2	E-geneN
,	O
ferritins	S-geneN
,	O
and	O
hepcidin	S-geneY
were	O
increased	O
more	O
in	O
CE	O
than	O
C	O
,	O
and	O
in	O
HE	O
than	O
H	O
.	O

In	O
duodenum	O
,	O
DMT1	S-geneY
,	O
ferritinH	S-geneY
,	O
and	O
hephaestin	S-geneY
mRNA	O
levels	O
were	O
increased	O
in	O
CE	O
compared	O
to	O
C	O
.	O

In	O
Experiment	O
2	O
,	O
hepatic	O
iron	S-chem
concentrations	O
were	O
higher	O
in	O
HIE	O
than	O
HI	O
.	O

Hepatic	O
mRNA	O
expression	O
of	O
ferritinL	S-geneY
and	O
hepcidin	S-geneY
were	O
increased	O
in	O
HIE	O
compared	O
to	O
HI	O
.	O

In	O
duodenum	O
,	O
ferritinL	S-geneY
mRNA	O
was	O
increased	O
in	O
HIE	O
compared	O
to	O
CIE	O
.	O

Ezetimibe	S-chem
induced	O
hepatic	O
iron	S-chem
uptake	O
transporter	O
expression	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
,	O
causing	O
increased	O
hepatic	O
iron	S-chem
concentrations	O
.	O

The	O
therapeutic	O
potential	O
of	O
allosteric	O
ligands	O
for	O
free	O
fatty	B-chem
acid	E-chem
sensitive	O
GPCRs	S-geneN
.	O

G	B-geneN
protein	I-geneN
coupled	I-geneN
receptors	E-geneN
(	O
GPCRs	S-geneN
)	O
are	O
the	O
most	O
historically	O
successful	O
therapeutic	O
targets	O
.	O

Despite	O
this	O
success	O
there	O
are	O
many	O
important	O
aspects	O
of	O
GPCR	S-geneN
pharmacology	O
and	O
function	O
that	O
have	O
yet	O
to	O
be	O
exploited	O
to	O
their	O
full	O
therapeutic	O
potential	O
.	O

One	O
in	O
particular	O
that	O
has	O
been	O
gaining	O
attention	O
in	O
recent	O
times	O
is	O
that	O
of	O
GPCR	S-geneN
ligands	O
that	O
bind	O
to	O
allosteric	O
sites	O
on	O
the	O
receptor	O
distinct	O
from	O
the	O
orthosteric	O
site	O
of	O
the	O
endogenous	O
ligand	O
.	O

As	O
therapeutics	O
,	O
allosteric	O
ligands	O
possess	O
many	O
theoretical	O
advantages	O
over	O
their	O
orthosteric	O
counterparts	O
,	O
including	O
more	O
complex	O
modes	O
of	O
action	O
,	O
improved	O
safety	O
,	O
more	O
physiologically	O
appropriate	O
responses	O
,	O
better	O
target	O
selectivity	O
,	O
and	O
reduced	O
likelihood	O
of	O
desensitisation	O
and	O
tachyphylaxis	O
.	O

Despite	O
these	O
advantages	O
,	O
the	O
development	O
of	O
allosteric	O
ligands	O
is	O
often	O
difficult	O
from	O
a	O
medicinal	O
chemistry	O
standpoint	O
due	O
to	O
the	O
more	O
complex	O
challenge	O
of	O
identifying	O
allosteric	O
leads	O
and	O
their	O
often	O
flat	O
or	O
confusing	O
SAR	O
.	O

The	O
present	O
review	O
will	O
consider	O
the	O
advantages	O
and	O
challenges	O
associated	O
with	O
allosteric	O
GPCR	S-geneN
ligands	O
,	O
and	O
examine	O
how	O
the	O
particular	O
properties	O
of	O
these	O
ligands	O
may	O
be	O
exploited	O
to	O
uncover	O
the	O
therapeutic	O
potential	O
for	O
free	O
fatty	B-chem
acid	E-chem
sensitive	O
GPCRs	S-geneN
.	O

Aromatase	S-geneY
inhibitors	O
for	O
male	O
infertility	O
.	O

PURPOSE	O
:	O
Testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratio	O
levels	O
in	O
infertile	O
men	O
improve	O
during	O
treatment	O
with	O
the	O
aromatase	S-geneY-C4-2
inhibitor	O
,	O
testolactone	S-chem-C4-1
,	O
and	O
resulting	O
changes	O
in	O
semen	O
parameters	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
anastrozole	S-chem-C4-1
,	O
a	O
more	O
selective	O
aromatase	S-geneY-C4-2
inhibitor	O
,	O
on	O
the	O
hormonal	O
and	O
semen	O
profiles	O
of	O
infertile	O
men	O
with	O
abnormal	O
baseline	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
140	O
subfertile	O
men	O
with	O
abnormal	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
were	O
treated	O
with	O
100	O
to	O
200	O
mg.	O
testolactone	S-chem
daily	O
or	O
1	O
mg.	O
anastrozole	S-chem
daily	O
.	O

Changes	O
in	O
testosterone	S-chem
,	O
estradiol	S-chem
,	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
and	O
semen	O
parameters	O
were	O
evaluated	O
during	O
therapy	O
.	O

The	O
effect	O
of	O
obesity	O
,	O
diagnosis	O
of	O
the	O
Klinefelter	O
syndrome	O
,	O
and	O
presence	O
of	O
varicocele	O
and	O
/	O
or	O
history	O
of	O
varicocele	O
repair	O
on	O
treatment	O
results	O
was	O
studied	O
.	O

RESULTS	O
:	O
Men	O
treated	O
with	O
testolactone	S-chem
had	O
an	O
increase	O
in	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
during	O
therapy	O
(	O
mean	O
plus	O
or	O
minus	O
standard	O
error	O
of	O
the	O
mean	O
5.3	O
+	O
/	O
-	O
0.2	O
versus	O
12.4	O
+	O
/	O
-	O
1.1	O
,	O
p	O
<	O
0.001	O
)	O
.	O

This	O
change	O
was	O
confirmed	O
in	O
subgroups	O
of	O
men	O
with	O
the	O
Klinefelter	O
syndrome	O
,	O
a	O
history	O
of	O
varicocele	O
repair	O
and	O
those	O
with	O
varicocele	O
.	O

A	O
total	O
of	O
12	O
oligospermic	O
men	O
had	O
semen	O
analysis	O
before	O
and	O
during	O
testolactone	S-chem
treatment	O
with	O
an	O
increase	O
in	O
sperm	O
concentration	O
(	O
5.5	O
versus	O
11.2	O
million	O
sperm	O
per	O
ml	O
.	O
,	O
p	O
<	O
0.01	O
)	O
,	O
motility	O
(	O
14.7	O
%	O
versus	O
21.0	O
%	O
,	O
p	O
<	O
0.05	O
)	O
,	O
morphology	O
(	O
6.5	O
%	O
versus	O
12.8	O
%	O
,	O
p	O
=	O
0.05	O
)	O
,	O
and	O
motility	O
index	O
(	O
606.3	O
versus	O
1685.2	O
million	O
motile	O
sperm	O
per	O
ejaculate	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
appreciated	O
.	O

During	O
anastrozole	S-chem
treatment	O
,	O
similar	O
changes	O
in	O
the	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
were	O
seen	O
(	O
7.2	O
+	O
/	O
-	O
0.3	O
versus	O
18.1	O
+	O
/	O
-	O
1.0	O
,	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
.	O

This	O
improvement	O
of	O
hormonal	O
parameters	O
was	O
noted	O
for	O
all	O
subgroups	O
except	O
those	O
patients	O
with	O
the	O
Klinefelter	O
syndrome	O
.	O

A	O
total	O
of	O
25	O
oligospermic	O
men	O
with	O
semen	O
analysis	O
before	O
and	O
during	O
anastrozole	S-chem
treatment	O
had	O
an	O
increase	O
in	O
semen	O
volume	O
(	O
2.9	O
versus	O
3.5	O
ml	O
.	O
,	O
p	O
<	O
0.05	O
)	O
,	O
sperm	O
concentration	O
(	O
5.5	O
versus	O
15.6	O
million	O
sperm	O
per	O
ml	O
.	O
,	O
p	O
<	O
0.001	O
)	O
and	O
motility	O
index	O
(	O
832.8	O
versus	O
2930.8	O
million	O
motile	O
sperm	O
per	O
ejaculate	O
,	O
respectively	O
,	O
p	O
<	O
0.005	O
)	O
.	O

These	O
changes	O
were	O
similar	O
to	O
those	O
observed	O
in	O
men	O
treated	O
with	O
testolactone	S-chem
.	O

No	O
significant	O
difference	O
in	O
serum	O
testosterone	S-chem
levels	O
during	O
treatment	O
with	O
testolactone	S-chem
and	O
anastrozole	S-chem
was	O
observed	O
.	O

However	O
,	O
the	O
anastrozole	S-chem
treatment	O
group	O
did	O
have	O
a	O
statistically	O
better	O
improvement	O
of	O
serum	O
estradiol	S-chem
concentration	O
and	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Men	O
who	O
are	O
infertile	O
with	O
a	O
low	O
serum	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratio	O
can	O
be	O
treated	O
with	O
an	O
aromatase	S-geneY
inhibitor	O
.	O

With	O
treatment	O
,	O
an	O
increase	O
in	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratio	O
occurred	O
in	O
association	O
with	O
increased	O
semen	O
parameters	O
.	O

Anastrozole	S-chem
and	O
testolactone	S-chem
have	O
similar	O
effects	O
on	O
hormonal	O
profiles	O
and	O
semen	O
analysis	O
.	O

Anastrazole	S-chem
appears	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
testolactone	S-chem
for	O
treating	O
men	O
with	O
abnormal	O
testosterone	S-chem
-	O
to	O
-	O
estradiol	S-chem
ratios	O
,	O
except	O
for	O
the	O
subset	O
with	O
the	O
Klinefelter	O
syndrome	O
,	O
who	O
appeared	O
to	O
be	O
more	O
effectively	O
treated	O
with	O
testolactone	S-chem
.	O

Methylation	O
damage	O
to	O
RNA	O
induced	O
in	O
vivo	O
in	O
Escherichia	O
coli	O
is	O
repaired	O
by	O
endogenous	O
AlkB	S-geneY
as	O
part	O
of	O
the	O
adaptive	O
response	O
.	O

Cytotoxic	O
1	B-chem
-	I-chem
methyladenine	E-chem
(	O
1	B-chem
-	I-chem
meA	E-chem
)	O
and	O
3	B-chem
-	I-chem
methylcytosine	E-chem
(	O
3	B-chem
-	I-chem
meC	E-chem
)	O
lesions	O
induced	O
in	O
DNA	O
and	O
RNA	O
in	O
vitro	O
and	O
in	O
pre	O
-	O
damaged	O
DNA	O
and	O
RNA	O
bacteriophages	O
in	O
vivo	O
are	O
repaired	O
by	O
the	O
Escherichia	B-geneY
coli	I-geneY
(	I-geneY
E.	I-geneY
coli	I-geneY
)	I-geneY
protein	I-geneY
AlkB	E-geneY
and	O
a	O
human	B-geneY
homolog	I-geneY
,	I-geneY
ALKBH3	E-geneY
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
endogenous	O
RNA	O
is	O
repaired	O
in	O
vivo	O
by	O
repair	O
proteins	O
present	O
at	O
physiological	O
concentrations	O
.	O

The	O
concept	O
of	O
RNA	O
repair	O
as	O
a	O
biologically	O
relevant	O
process	O
has	O
therefore	O
remained	O
elusive	O
.	O

Here	O
,	O
we	O
demonstrate	O
AlkB	S-geneY
-	O
mediated	O
repair	O
of	O
endogenous	O
RNA	O
in	O
vivo	O
by	O
measuring	O
differences	O
in	O
lesion	O
-	O
accumulation	O
in	O
two	O
independent	O
AlkB	S-geneY
-	O
proficient	O
and	O
deficient	O
E.	O
coli	O
strains	O
during	O
exposure	O
to	O
methyl	B-chem
methanesulfonate	E-chem
(	O
MMS	S-chem
)	O
.	O

Repair	O
was	O
observed	O
both	O
in	O
AlkB	S-geneY
-	O
overproducing	O
strains	O
and	O
in	O
the	O
wild	O
-	O
type	O
strains	O
after	O
AlkB	S-geneY
induction	O
.	O

RNA	O
repair	O
appeared	O
to	O
be	O
highest	O
in	O
RNA	O
species	O
below	O
200	O
nucleotides	S-chem
in	O
size	O
,	O
mainly	O
comprising	O
tRNAs	O
.	O

Strikingly	O
,	O
at	O
least	O
10	O
-	O
fold	O
more	O
lesions	O
were	O
repaired	O
in	O
RNA	O
than	O
in	O
DNA	O
.	O

This	O
may	O
be	O
a	O
consequence	O
of	O
some	O
30	O
-	O
fold	O
higher	O
levels	O
of	O
aberrant	O
methylation	O
in	O
RNA	O
than	O
in	O
DNA	O
after	O
exposure	O
to	O
MMS	S-chem
.	O

A	O
high	O
primary	O
kinetic	O
isotope	O
effect	O
(	O
>	O
10	O
)	O
was	O
measured	O
using	O
a	O
deuterated	O
methylated	O
RNA	O
substrate	O
,	O
D3	O
-	O
1me	O
(	O
rA	O
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
catalytic	O
step	O
,	O
and	O
not	O
the	O
search	O
step	O
that	O
is	O
rate	O
-	O
limiting	O
.	O

Our	O
results	O
demonstrate	O
that	O
RNA	O
repair	O
by	O
AlkB	S-geneY
takes	O
place	O
in	O
endogenous	O
RNA	O
as	O
part	O
of	O
an	O
adaptive	O
response	O
in	O
wild	O
-	O
type	O
E.	O
coli	O
cells	O
.	O

Thymidylate	B-geneY
synthase	E-geneY
expression	O
pattern	O
,	O
expression	O
level	O
and	O
single	O
nucleotide	S-chem
polymorphism	O
are	O
predictors	O
for	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
of	O
colorectal	O
cancer	O
treated	O
with	O
5	B-chem
-	I-chem
fluorouracil	E-chem
.	O

Several	O
variables	O
associated	O
to	O
thymidylate	B-geneY
synthase	E-geneY
(	O
TS	S-geneY
)	O
,	O
the	O
biological	O
target	O
of	O
5	B-chem
-	I-chem
fluorouracil	E-chem
(	O
5FU	S-chem
)	O
have	O
been	O
studied	O
for	O
their	O
possible	O
role	O
as	O
predictors	O
of	O
the	O
clinical	O
outcome	O
and	O
response	O
to	O
chemotherapy	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
patients	O
.	O

The	O
level	O
of	O
protein	O
expression	O
and	O
the	O
number	O
of	O
variable	O
tandem	O
-	O
repeats	O
of	O
a	O
28	O
-	O
bp	O
sequence	O
within	O
the	O
gene	O
promoter	O
have	O
been	O
proposed	O
as	O
predictive	O
and	O
/	O
or	O
prognostic	O
factors	O
with	O
variable	O
agreement	O
,	O
while	O
consensus	O
seems	O
to	O
be	O
achieved	O
with	O
respect	O
to	O
the	O
value	O
of	O
a	O
single	O
nucleotide	S-chem
polymorphism	O
(	O
SNP	O
)	O
described	O
within	O
this	O
same	O
region	O
.	O

More	O
recently	O
,	O
an	O
association	O
between	O
TS	O
expression	O
pattern	O
and	O
survival	O
has	O
been	O
disclosed	O
.	O

Paraffin	O
-	O
embedded	O
sections	O
from	O
140	O
CRC	O
patients	O
were	O
analyzed	O
by	O
immuno	O
-	O
histochemistry	O
(	O
Mab	O
TS106	O
)	O
for	O
TS	S-geneY
levels	O
and	O
expression	O
pattern	O
.	O

Also	O
,	O
VNTR	O
and	O
SNP	O
were	O
determined	O
by	O
polymerase	O
-	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
-	O
length	O
-	O
fragment	O
polymorphism	O
(	O
RFLP	O
)	O
in	O
123	O
and	O
112	O
patients	O
,	O
respectively	O
.	O

Cytoplasmic	O
expression	O
pattern	O
tended	O
to	O
be	O
associated	O
to	O
C	O
SNP	O
(	O
p	O
=	O
0.06	O
)	O
.	O

Low	O
TS	S-geneY-C4-2
expression	O
levels	O
,	O
cytoplasmic	O
expression	O
pattern	O
and	O
C	O
SNP	O
arose	O
as	O
variables	O
associated	O
to	O
longer	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
in	O
patients	O
treated	O
with	O
5FU	S-chem-C4-1
.	O

Accordingly	O
,	O
patients	O
having	O
at	O
least	O
two	O
favourable	O
or	O
unfavourable	O
variables	O
were	O
classified	O
respectively	O
as	O
'	O
low	O
risk	O
'	O
and	O
'	O
high	O
risk	O
'	O
,	O
the	O
former	O
showing	O
significantly	O
longer	O
PFS	O
(	O
p	O
=	O
0.0299	O
)	O
.	O

The	O
possibility	O
for	O
designing	O
a	O
selection	O
method	O
for	O
subsequent	O
therapies	O
is	O
suggested	O
on	O
the	O
basis	O
of	O
a	O
probable	O
combined	O
effect	O
of	O
the	O
above	O
mentioned	O
parameters	O
but	O
further	O
studies	O
in	O
larger	O
populations	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
.	O

Salicylate	S-chem
pre	O
-	O
treatment	O
attenuates	O
intensity	O
of	O
bronchial	O
and	O
nasal	O
symptoms	O
precipitated	O
by	O
aspirin	S-chem
in	O
aspirin	S-chem
-	O
intolerant	O
patients	O
.	O

Aspirin	S-chem-C4-1
(	O
ASA	S-chem-C4-1
)	O
and	O
other	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
,	O
which	O
are	O
cyclooxygenase	S-geneN-C4-2
(	O
COX	S-geneN-C4-2
)	O
inhibitors	O
,	O
precipitate	O
asthmatic	O
attacks	O
in	O
ASA	S-chem
-	O
intolerant	O
patients	O
,	O
while	O
sodium	B-chem
salicylate	E-chem
,	O
hardly	O
active	O
on	O
COX	S-geneN
by	O
itself	O
,	O
is	O
well	O
tolerated	O
by	O
these	O
patients	O
.	O

However	O
,	O
salicylate	S-chem
moiety	O
appears	O
to	O
interfere	O
with	O
aspirin	S-chem-C4-1
inhibitory	O
action	O
on	O
platelets	O
and	O
vascular	O
COX	S-geneN-C4-2
.	O

Such	O
interaction	O
,	O
if	O
present	O
at	O
the	O
level	O
of	O
respiratory	O
tract	O
,	O
may	O
be	O
of	O
interest	O
to	O
pathogenesis	O
of	O
ASA	S-chem
-	O
induced	O
asthma	O
.	O

We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
cross	O
-	O
over	O
study	O
on	O
the	O
effect	O
of	O
choline	B-chem
magnesium	I-chem
trisalicylate	E-chem
(	O
CMT	S-chem
,	O
trilisate	S-chem
)	O
pre	O
-	O
treatment	O
on	O
ASA	S-chem
-	O
induced	O
adverse	O
reactions	O
in	O
nine	O
patients	O
.	O

Pulmonary	O
function	O
tests	O
,	O
nasal	O
symptoms	O
score	O
,	O
PNIF	O
and	O
serum	O
salicylate	S-chem
levels	O
were	O
monitored	O
following	O
challenges	O
with	O
threshold	O
doses	O
of	O
ASA	S-chem
.	O

Trilisate	S-chem
administered	O
at	O
a	O
dose	O
of	O
3000	O
mg	O
daily	O
for	O
3	O
days	O
,	O
offered	O
a	O
moderate	O
protection	O
against	O
ASA	S-chem
-	O
induced	O
symptoms	O
;	O
it	O
diminished	O
the	O
severity	O
and	O
/	O
or	O
delayed	O
the	O
appearance	O
of	O
FEV1	O
fall	O
.	O

Maximal	O
decreases	O
in	O
FEV1	O
as	O
well	O
as	O
reaction	O
intensity	O
indexes	O
were	O
significantly	O
lower	O
(	O
P	O
less	O
than	O
0.02	O
and	O
P	O
less	O
than	O
0.002	O
,	O
respectively	O
)	O
after	O
trilisate	S-chem
pre	O
-	O
treatment	O
as	O
compared	O
to	O
placebo	O
.	O

Trilisate	S-chem
also	O
attenuated	O
nasal	O
symptoms	O
in	O
three	O
out	O
of	O
five	O
patients	O
.	O

Although	O
the	O
precise	O
mechanism	O
of	O
the	O
protective	O
action	O
of	O
trilisate	S-chem
is	O
unknown	O
,	O
our	O
data	O
support	O
the	O
possibility	O
of	O
interaction	O
between	O
salicylate	S-chem-C4-1
and	O
ASA	S-chem-C4-1
on	O
cyclo	B-geneN-C4-2
-	I-geneN-C4-2
oxygenase	E-geneN-C4-2
locus	O
in	O
the	O
respiratory	O
tract	O
in	O
ASA	S-chem
-	O
intolerant	O
patients	O
.	O

Mechanism	O
of	O
organophosphates	S-chem
(	O
nerve	O
gases	O
and	O
pesticides	O
)	O
and	O
antidotes	O
:	O
electron	O
transfer	O
and	O
oxidative	O
stress	O
.	O

Evidence	O
indicates	O
that	O
nerve	O
gas	O
toxins	O
operate	O
in	O
ways	O
in	O
addition	O
to	O
inhibition	O
of	O
acetylcholine	B-geneY
esterase	E-geneY
.	O

Alternative	O
bioactivities	O
are	O
discussed	O
with	O
focus	O
on	O
electron	O
transfer	O
.	O

The	O
main	O
class	O
,	O
including	O
pralidoxime	S-chem
(	O
2	B-chem
-	I-chem
PAM	E-chem
)	O
,	O
incorporates	O
conjugated	O
iminium	S-chem
and	O
oxime	S-chem
moieties	O
that	O
are	O
electron	O
affinic	O
.	O

Various	O
physiological	O
properties	O
of	O
iminium	S-chem
and	O
oxime	S-chem
species	O
are	O
reviewed	O
.	O

The	O
organophosphates	S-chem
encompass	O
both	O
nerve	O
gases	O
and	O
insecticides	O
,	O
possessing	O
similar	O
properties	O
,	O
but	O
different	O
activities	O
.	O

Toxic	O
manifestations	O
are	O
apparently	O
due	O
,	O
in	O
part	O
,	O
to	O
oxidative	O
stress	O
.	O

Alkylation	O
of	O
DNA	O
takes	O
place	O
which	O
may	O
lead	O
to	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
.	O

Structure	O
-	O
activity	O
relationships	O
are	O
examined	O
,	O
including	O
reduction	O
potentials	O
and	O
the	O
captodative	O
effect	O
.	O

Synthesis	O
,	O
cytotoxicity	O
and	O
QSAR	O
study	O
of	O
N	B-chem
-	I-chem
tosyl	I-chem
-	I-chem
1,2,3,4	I-chem
-	I-chem
tetrahydroisoquinoline	E-chem
derivatives	O
.	O

1	B-chem
-	I-chem
Substituted	I-chem
-	I-chem
N	I-chem
-	I-chem
tosyl	I-chem
-	I-chem
1,2,3,4	I-chem
-	I-chem
tetrahydroisoquinoline	E-chem
analogs	O
(	O
4a	O
-	O
4l	O
)	O
were	O
synthesized	O
using	O
the	O
modified	O
Pictet	O
-	O
Spengler	O
reaction	O
and	O
evaluated	O
for	O
cytotoxicity	O
.	O

All	O
tetrahydroisoquinolines	S-chem
displayed	O
cytotoxicity	O
against	O
MOLT	O
-	O
3	O
cell	O
lines	O
,	O
except	O
for	O
p	B-chem
-	I-chem
methoxy	E-chem
analog	O
4d	O
.	O

Interestingly	O
,	O
the	O
o	B-chem
-	I-chem
hydroxy	E-chem
derivative	O
4k	O
was	O
shown	O
to	O
be	O
the	O
most	O
potent	O
cytotoxic	O
against	O
HuCCA	O
-	O
1	O
,	O
A	O
-	O
549	O
and	O
MOLT	O
-	O
3	O
cell	O
lines	O
.	O

The	O
lowest	O
IC50	O
value	O
of	O
1.23	O
μM	O
was	O
observed	O
for	O
MOLT	O
-	O
3	O
cells	O
.	O

Trimethoxy	S-chem
analog	O
4f	O
exerted	O
the	O
most	O
potent	O
activity	O
against	O
HepG2	O
with	O
an	O
IC50	O
of	O
22.70	O
μM	O
,	O
which	O
is	O
lower	O
than	O
the	O
reference	O
drug	O
,	O
etoposide	O
.	O

QSAR	O
studies	O
showed	O
that	O
total	O
symmetry	O
index	O
(	O
Gu	O
)	O
,	O
3D	O
-	O
MoRSE	O
(	O
Mor31v	O
and	O
Mor32u	O
)	O
and	O
3D	O
Petitjean	O
index	O
(	O
PJI3	O
)	O
were	O
the	O
most	O
important	O
descriptors	O
accounting	O
for	O
the	O
observed	O
cytotoxicities	O
.	O

The	O
most	O
potent	O
cytotoxic	O
compound	O
(	O
4k	O
)	O
against	O
MOLT	O
-	O
3	O
had	O
the	O
highest	O
Gu	O
value	O
,	O
correspondingly	O
the	O
inactive	O
p	B-chem
-	I-chem
methoxy	E-chem
analog	O
(	O
4d	O
)	O
had	O
the	O
lowest	O
Gu	O
value	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
highest	O
molecular	O
mass	O
compound	O
(	O
4f	O
)	O
was	O
shown	O
to	O
be	O
the	O
most	O
potent	O
cytotoxic	O
against	O
HepG2	O
cells	O
.	O

The	O
studies	O
disclose	O
that	O
tetrahydroisoquinolines	S-chem
4f	O
and	O
4k	O
are	O
potentially	O
interesting	O
lead	O
pharmacophores	O
that	O
should	O
be	O
further	O
explored	O
.	O

The	O
QSAR	O
models	O
provided	O
insights	O
into	O
the	O
physicochemical	O
properties	O
of	O
the	O
investigated	O
compounds	O
.	O

Long	O
-	O
term	O
use	O
of	O
sildenafil	S-chem
.	O

The	O
treatment	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
has	O
been	O
revolutionised	O
by	O
new	O
agents	O
to	O
inhibit	O
the	O
enzyme	O
PDE5	S-geneY
.	O

The	O
scientific	O
basis	O
of	O
this	O
treatment	O
of	O
ED	O
includes	O
relaxation	O
of	O
the	O
corpus	O
cavernosum	O
smooth	O
muscle	O
tissue	O
by	O
inhibition	O
of	O
PDE5	S-geneY-C9-2
that	O
breaks	O
down	O
cGMP	S-chem-C9-1
,	O
the	O
key	O
pathway	O
for	O
the	O
production	O
of	O
erectile	O
function	O
in	O
humans	O
.	O

Many	O
clinical	O
studies	O
,	O
both	O
pre	O
-	O
and	O
post	O
-	O
marketing	O
,	O
have	O
demonstrated	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
sildenafil	S-chem-C4-1
(	O
Viagra	S-chem-C4-1
,	O
Pfizer	O
)	O
-	O
the	O
first	O
approved	O
selective	O
PDE	S-geneN-C4-2
inhibitor	O
for	O
the	O
treatment	O
of	O
ED	O
.	O

Sildenafil	S-chem-C4-1
is	O
inhibitory	O
of	O
PDE5	S-geneY-C4-2
at	O
a	O
rate	O
tenfold	O
higher	O
than	O
for	O
the	O
next	O
PDE	S-geneN-C4-2
(	O
PDE6	S-geneN-C4-2
)	O
,	O
which	O
produces	O
visual	O
changes	O
through	O
the	O
retinal	O
rods	O
.	O

Its	O
clinical	O
effectiveness	O
has	O
been	O
well	O
documented	O
in	O
the	O
majority	O
of	O
men	O
with	O
ED	O
irrespective	O
of	O
aetiology	O
.	O

The	O
aetiology	O
of	O
ED	O
,	O
also	O
,	O
does	O
not	O
appear	O
to	O
effect	O
the	O
function	O
of	O
sildenafil	S-chem
in	O
relaxing	O
corpus	O
cavernosum	O
smooth	O
muscle	O
tissue	O
.	O

Adverse	O
events	O
are	O
usually	O
associated	O
with	O
the	O
vascular	O
changes	O
from	O
PDE5	S-geneY
inhibition	O
.	O

These	O
include	O
headache	O
and	O
flushing	O
.	O

Each	O
of	O
these	O
adverse	O
events	O
,	O
however	O
,	O
declines	O
with	O
medication	O
use	O
.	O

With	O
the	O
use	O
of	O
sildenafil	S-chem-C4-1
,	O
it	O
has	O
been	O
clearly	O
,	O
clinically	O
demonstrated	O
that	O
the	O
selective	O
inhibition	O
of	O
PDE5	S-geneY-C4-2
is	O
an	O
appropriate	O
,	O
effective	O
,	O
safe	O
method	O
for	O
the	O
treatment	O
of	O
ED	O
of	O
all	O
aetiologies	O
and	O
severities	O
.	O

Differential	O
phosphoproteome	O
of	O
the	O
striatum	O
from	O
pleiotrophin	S-geneY
knockout	O
and	O
midkine	S-geneY
knockout	O
mice	O
treated	O
with	O
amphetamine	S-chem
:	O
Correlations	O
with	O
amphetamine	S-chem
-	O
induced	O
neurotoxicity	O
.	O

The	O
neurotrophic	O
factors	O
pleiotrophin	S-geneY
(	O
PTN	S-geneY
)	O
and	O
midkine	S-geneY
(	O
MK	S-geneY
)	O
have	O
been	O
shown	O
to	O
modulate	O
amphetamine	S-chem
-	O
induced	O
neurotoxicity	O
.	O

Accordingly	O
,	O
PTN	S-geneY
-	O
/	O
-	O
and	O
MK	S-geneY
-	O
/	O
-	O
mice	O
show	O
an	O
increased	O
vulnerability	O
to	O
amphetamine	S-chem
-	O
induced	O
neurotoxic	O
effects	O
.	O

In	O
an	O
effort	O
to	O
uncover	O
new	O
pharmacological	O
targets	O
to	O
prevent	O
amphetamine	S-chem
neurotoxic	O
effects	O
,	O
we	O
have	O
now	O
used	O
a	O
proteomic	O
approach	O
to	O
study	O
protein	O
phosphorylation	O
,	O
in	O
which	O
we	O
combined	O
phosphoprotein	O
enrichment	O
,	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
(	O
IMAC	O
)	O
,	O
with	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
,	O
in	O
order	O
to	O
identify	O
the	O
phosphoproteins	O
regulated	O
in	O
the	O
striatum	O
of	O
PTN	S-geneY
-	O
/	O
-	O
,	O
MK	S-geneY
-	O
/	O
-	O
and	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
treated	O
with	O
amphetamine	S-chem
.	O

We	O
identified	O
13	O
differentially	O
expressed	O
phosphoproteins	O
that	O
are	O
judged	O
to	O
be	O
relevant	O
in	O
the	O
neuroprotective	O
roles	O
of	O
PTN	S-geneY
and	O
MK	S-geneY
against	O
amphetamine	S-chem
-	O
induced	O
neurotoxicity	O
.	O

It	O
is	O
very	O
interesting	O
to	O
note	O
that	O
4	O
of	O
these	O
phosphoproteins	O
,	O
annexin	B-geneY
A7	E-geneY
(	O
ANXA7	S-geneY
)	O
,	O
COP9	B-geneY
signalosome	I-geneY
subunit	I-geneY
5	E-geneY
(	O
COPS5	S-geneY
)	O
,	O
aldehyde	B-geneY
dehydrogenase	I-geneY
family	I-geneY
1	I-geneY
member	I-geneY
A1	E-geneY
(	O
ALDH1A1	S-geneY
)	O
and	O
creatine	B-geneY
kinase	I-geneY
U	I-geneY
-	I-geneY
type	E-geneY
(	O
CKMT1	S-geneY
)	O
,	O
are	O
known	O
to	O
be	O
involved	O
in	O
Parkinson	O
's	O
disease	O
,	O
a	O
result	O
of	O
significant	O
importance	O
since	O
PTN	S-geneY
and	O
MK	S-geneY
have	O
been	O
also	O
demonstrated	O
to	O
limit	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
progress	O
and	O
have	O
been	O
suggested	O
to	O
be	O
among	O
the	O
important	O
genetic	O
factors	O
possibly	O
preventing	O
the	O
development	O
of	O
PD	O
in	O
methamphetamine	S-chem
abusers	O
.	O

The	O
data	O
identify	O
phosphoproteins	O
differentially	O
regulated	O
by	O
amphetamine	S-chem
treatment	O
and	O
/	O
or	O
the	O
presence	O
of	O
endogenous	O
PTN	S-geneY
/	O
MK	S-geneY
which	O
may	O
be	O
relevant	O
mediators	O
of	O
PTN	S-geneY
/	O
MK	S-geneY
neuroprotective	O
effects	O
against	O
amphetamine	S-chem
-	O
induced	O
neurotoxicity	O
.	O

The	O
data	O
support	O
further	O
studies	O
to	O
validate	O
the	O
phosphoproteins	O
here	O
identified	O
as	O
possible	O
new	O
pharmacological	O
targets	O
to	O
prevent	O
amphetamine	S-chem
neurotoxic	O
effects	O
.	O

Overexpression	O
of	O
proline	B-geneY-C9-2
oxidase	E-geneY-C9-2
induces	O
proline	S-chem-C9-1
-	O
dependent	O
and	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Proline	B-geneY-C9-2
oxidase	E-geneY-C9-2
(	O
POX	S-geneY-C9-2
)	O
,	O
a	O
mitochondrial	O
inner	O
-	O
membrane	O
protein	O
,	O
catalyzes	O
the	O
rate	O
-	O
limiting	O
oxidation	O
of	O
proline	S-chem-C9-1
to	O
pyrroline	B-chem-C9-1
-	I-chem-C9-1
5	I-chem-C9-1
-	I-chem-C9-1
carboxylate	E-chem-C9-1
(	O
P5C	S-chem-C9-1
)	O
.	O

Previously	O
we	O
showed	O
that	O
overexpression	O
of	O
POX	S-geneY
is	O
associated	O
with	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
and	O
apoptosis	O
in	O
POX	S-geneY
-	O
inducible	O
colorectal	O
cancer	O
cells	O
,	O
DLD	O
-	O
1.POX	O
.	O

We	O
also	O
showed	O
expression	O
of	O
mitochondrial	O
MnSOD	S-geneY
partially	O
blunts	O
POX	S-geneY
-	O
induced	O
ROS	O
generation	O
and	O
apoptosis	O
.	O

To	O
further	O
investigate	O
the	O
molecular	O
basis	O
of	O
POX	S-geneY
-	O
induced	O
apoptosis	O
,	O
we	O
utilized	O
the	O
DLD	O
-	O
1.POX	O
cells	O
to	O
show	O
that	O
cells	O
overproducing	O
POX	S-geneY-C9-2
exhibit	O
an	O
L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
-	O
dependent	O
apoptotic	O
response	O
.	O

The	O
apoptotic	O
effect	O
is	O
specific	O
for	O
L	B-chem
-	I-chem
proline	E-chem
,	O
detectable	O
at	O
0.2	O
mM	O
,	O
maximal	O
at	O
1	O
mM	O
,	O
and	O
occurs	O
during	O
48	O
-	O
72	O
h	O
following	O
the	O
addition	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
to	O
cells	O
with	O
maximally	O
induced	O
POX	S-geneY-C9-2
.	O

The	O
apoptotic	O
response	O
is	O
mitochondria	O
-	O
mediated	O
with	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
,	O
activation	O
of	O
caspase	B-geneY
-	I-geneY
9	E-geneY
,	O
chromatin	O
condensation	O
/	O
DNA	O
fragmentation	O
,	O
and	O
cell	O
shrinkage	O
.	O

We	O
conclude	O
that	O
in	O
the	O
presence	O
of	O
proline	S-chem-C9-1
,	O
high	O
POX	S-geneY-C9-2
activity	O
is	O
sufficient	O
to	O
induce	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Blockade	O
of	O
beta	B-geneY
1	E-geneY
-	O
and	O
desensitization	O
of	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptors	E-geneY
reduce	O
isoprenaline	S-chem
-	O
induced	O
cardiac	O
fibrosis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyse	O
the	O
role	O
of	O
beta	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
the	O
catecholamine	S-chem
-	O
induced	O
myocardial	O
remodeling	O
,	O
especially	O
the	O
interstitial	O
fibrosis	O
.	O

Wistar	O
rats	O
were	O
subjected	O
to	O
a	O
2	O
-	O
week	O
chronic	O
isoprenaline	S-chem
administration	O
(	O
30	O
microg	O
/	O
kg	O
/	O
h	O
)	O
.	O

Rats	O
received	O
a	O
concomitant	O
treatment	O
with	O
the	O
selective	O
beta	B-geneY-C6-2
(	I-geneY-C6-2
1	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonist	O
,	O
bisoprolol	S-chem-C6-1
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
p.o	O
.	O
)	O
or	O
were	O
chronically	O
pretreated	O
with	O
the	O
selective	O
beta	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
agonist	O
salbutamol	S-chem-C5-1
(	O
40	O
microg	O
/	O
kg	O
/	O
h	O
)	O
for	O
1	O
week	O
to	O
induce	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
desensitization	O
.	O

The	O
pretreatment	O
with	O
salbutamol	S-chem-C4-1
induced	O
a	O
59	O
%	O
down	O
-	O
regulation	O
of	O
left	O
ventricular	O
beta	B-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
adrenoceptors	E-geneY-C4-2
compared	O
to	O
control	O
.	O

The	O
extent	O
of	O
the	O
isoprenaline	S-chem
-	O
induced	O
left	O
ventricular	O
fibrosis	O
was	O
significantly	O
reduced	O
in	O
both	O
the	O
bisoprolol	S-chem
and	O
salbutamol	S-chem
groups	O
compared	O
with	O
the	O
control	O
isoprenaline	S-chem
-	O
treated	O
group	O
especially	O
in	O
the	O
apical	O
region	O
(	O
1.7	O
+	O
/	O
-	O
0.6	O
%	O
and	O
1.4	O
+	O
/	O
-	O
0.3	O
%	O
versus	O
6.0	O
+	O
/	O
-	O
1.3	O
%	O
,	O
respectively	O
,	O
P	O
<	O
0.005	O
)	O
.	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
blockade	O
and	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
down	O
-	O
regulation	O
provided	O
similar	O
protection	O
against	O
isoprenaline	S-chem
-	O
induced	O
cardiac	O
interstitial	O
fibrosis	O
suggesting	O
that	O
both	O
beta	B-geneN
-	I-geneN
adrenoceptors	E-geneN
are	O
involved	O
in	O
such	O
cardiac	O
remodeling	O
process	O
.	O

X	O
-	O
ray	O
structure	O
analysis	O
of	O
a	O
solid	O
solution	O
of	O
milbemycins	B-chem
A3	I-chem
and	I-chem
A4	E-chem
.	O

Milbemycins	B-chem
A3	I-chem
and	I-chem
A4	E-chem
are	O
pharmaceutically	O
and	O
agriculturally	O
useful	O
macrolides	O
isolated	O
from	O
Streptomyces	O
species	O
.	O

The	O
molecular	O
structures	O
of	O
the	O
title	O
compounds	O
were	O
unambiguously	O
established	O
by	O
a	O
single	O
crystal	O
X	O
-	O
ray	O
analysis	O
of	O
the	O
solid	O
solution	O
of	O
both	O
compounds	O
.	O

The	O
crystals	O
present	O
trigonal	O
system	O
,	O
space	O
group	O
P32	O
with	O
Z	O
=	O
3	O
,	O
unit	O
cell	O
dimensions	O
:	O
a	O
=	O
12.2211	O
(	O
4	O
)	O
,	O
c	O
=	O
17.5372	O
(	O
7	O
)	O
Å	O
;	O
V	O
=	O
2268.4	O
(	O
1	O
)	O
Å	O
(	O
3	O
)	O
,	O
μ	O
=	O
0.082	O
mm	O
(	O
-	O
1	O
)	O
;	O
d	O
=	O
1.183	O
g	O
cm	O
(	O
-	O
3	O
)	O
.	O

An	O
interesting	O
system	O
of	O
intramolecular	O
hydrogen	S-chem
bonds	O
and	O
weak	O
intermolecular	O
CH	S-chem
…	O
O	S-chem
type	O
hydrogen	S-chem
bond	O
was	O
observed	O
in	O
the	O
solid	O
state	O
.	O

ABCB1	S-geneY
polymorphisms	O
influence	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
and	O
risperidone	S-chem
active	O
moiety	O
.	O

Risperidone	S-chem-C9-1
is	O
metabolized	O
to	O
its	O
active	O
metabolite	O
,	O
9	B-chem-C9-1
-	I-chem-C9-1
hydroxyrisperidone	E-chem-C9-1
,	O
mainly	O
by	O
the	O
cytochrome	B-geneN-C9-2
P450	E-geneN-C9-2
enzymes	O
CYP2D6	B-geneN
and	I-geneN
3A4	E-geneN
.	O

Its	O
antipsychotic	O
effect	O
is	O
assumed	O
to	O
be	O
related	O
to	O
the	O
active	O
moiety	O
,	O
that	O
is	O
,	O
the	O
sum	O
of	O
risperidone	S-chem
and	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
.	O

Both	O
risperidone	S-chem-C9-1
and	O
9	B-chem-C9-1
-	I-chem-C9-1
hydroxyrisperidone	E-chem-C9-1
are	O
substrates	O
of	O
P	B-geneN-C9-2
-	I-geneN-C9-2
glycoprotein	E-geneN-C9-2
(	O
P	B-geneN-C9-2
-	I-geneN-C9-2
gp	E-geneN-C9-2
)	O
,	O
a	O
transport	O
protein	O
involved	O
in	O
drug	O
absorption	O
,	O
distribution	O
,	O
and	O
elimination	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
polymorphisms	O
in	O
genes	O
encoding	O
CYP3A5	S-geneY
and	O
P	B-geneN
-	I-geneN
gp	E-geneN
(	O
ABCB1	S-geneY
)	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
risperidone	S-chem
,	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
,	O
and	O
the	O
active	O
moiety	O
,	O
taking	O
CYP2D6	S-geneY
genotype	O
status	O
into	O
account	O
.	O

Forty	O
-	O
six	O
white	O
patients	O
with	O
schizophrenia	O
treated	O
with	O
risperidone	S-chem
(	O
1	O
-	O
10	O
mg	O
/	O
d	O
)	O
in	O
monotherapy	O
for	O
4	O
-	O
6	O
weeks	O
were	O
genotyped	O
,	O
and	O
their	O
plasma	O
concentrations	O
of	O
risperidone	S-chem
and	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
were	O
measured	O
.	O

Dose	O
-	O
corrected	O
plasma	O
concentrations	O
(	O
C	O
/	O
D	O
)	O
of	O
risperidone	S-chem
,	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
,	O
and	O
active	O
moiety	O
showed	O
up	O
to	O
68	O
-	O
,	O
9	O
-	O
,	O
and	O
10	O
-	O
fold	O
interindividual	O
variation	O
,	O
respectively	O
.	O

Six	O
patients	O
carried	O
1	O
CYP3A5	S-geneY
*	O
1	O
allele	O
and	O
therefore	O
were	O
likely	O
to	O
express	O
the	O
CYP3A5	S-geneY
enzyme	O
.	O

The	O
CYP3A5	S-geneY
genotype	O
did	O
not	O
influence	O
risperidone	S-chem
,	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
,	O
or	O
active	O
moiety	O
C	O
/	O
Ds	O
.	O

The	O
CYP2D6	S-geneY
genotype	O
in	O
these	O
46	O
patients	O
was	O
again	O
associated	O
with	O
risperidone	S-chem
C	O
/	O
D	O
(	O
P	O
=	O
0.001	O
)	O
but	O
not	O
with	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
C	O
/	O
D	O
or	O
active	O
moiety	O
C	O
/	O
D	O
,	O
as	O
previously	O
shown	O
by	O
our	O
group	O
in	O
37	O
of	O
these	O
patients	O
.	O

Patients	O
homozygous	O
for	O
the	O
ABCB1	S-geneY
3435T	O
/	O
2677T	O
/	O
1236T	O
haplotype	O
had	O
significantly	O
lower	O
C	O
/	O
Ds	O
of	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
(	O
P	O
=	O
0.026	O
)	O
and	O
active	O
moiety	O
(	O
P	O
=	O
0.028	O
)	O
than	O
patients	O
carrying	O
other	O
ABCB1	S-geneY
genotypes	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
confirmed	O
the	O
significant	O
effect	O
of	O
CYP2D6	S-geneY
genotype	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
risperidone	S-chem
and	O
showed	O
that	O
ABCB1	S-geneY
polymorphisms	O
have	O
a	O
moderate	O
effect	O
on	O
those	O
of	O
9	B-chem
-	I-chem
hydroxyrisperidone	E-chem
and	O
the	O
active	O
moiety	O
.	O

Metformin	S-chem
and	O
Sulfonylureas	S-chem
in	O
Relation	O
to	O
Cancer	O
Risk	O
in	O
Type	O
II	O
Diabetes	O
Patients	O
:	O
A	O
Meta	O
-	O
analysis	O
using	O
primary	O
data	O
of	O
published	O
studies	O
.	O

INTRODUCTION	O
:	O
Accumulating	O
evidence	O
suggests	O
that	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
hyperinsulinemia	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
malignancies	O
.	O

It	O
remains	O
to	O
be	O
fully	O
elucidated	O
whether	O
use	O
of	O
metformin	S-chem
,	O
an	O
insulin	S-geneY
sensitizer	O
,	O
and	O
/	O
or	O
sulfonylureas	S-chem
,	O
insulin	S-geneY
secretagogues	O
,	O
affect	O
cancer	O
incidence	O
in	O
subjects	O
with	O
T2DM	O
.	O

MATERIAL	O
&	O
METHODS	O
:	O
We	O
performed	O
a	O
meta	O
-	O
analysis	O
using	O
PubMed	O
,	O
of	O
randomized	O
control	O
trials	O
(	O
RCTs	O
)	O
,	O
cohorts	O
,	O
and	O
case	O
-	O
control	O
studies	O
published	O
through	O
July	O
2012	O
that	O
assess	O
effects	O
of	O
metformin	S-chem
and	O
/	O
or	O
sulfonylurea	S-chem
sulfonylureas	S-chem
on	O
cancer	O
risk	O
at	O
any	O
site	O
,	O
in	O
subjects	O
with	O
T2DM	O
.	O

Fixed	O
and	O
random	O
effects	O
meta	O
-	O
analysis	O
models	O
were	O
used	O
,	O
and	O
the	O
effect	O
size	O
was	O
summarized	O
as	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
RCTs	O
/	O
cohorts	O
and	O
as	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
the	O
case	O
-	O
control	O
studies	O
.	O

RESULTS	O
:	O
Analysis	O
of	O
24	O
metformin	S-chem
studies	O
in	O
subjects	O
with	O
T2DM	O
showed	O
that	O
metformin	S-chem
use	O
is	O
associated	O
with	O
reduced	O
risk	O
for	O
the	O
development	O
of	O
cancer	O
,	O
in	O
both	O
cohort	O
(	O
RR	O
=	O
0.70	O
[	O
95	O
%	O
CI	O
=	O
0.67	O
-	O
0.73	O
]	O
)	O
and	O
case	O
-	O
control	O
studies	O
(	O
OR	O
=	O
0.90	O
[	O
95	O
%	O
CI	O
=	O
0.84	O
-	O
0.98	O
]	O
)	O
,	O
but	O
this	O
finding	O
was	O
not	O
supported	O
by	O
RCTs	O
(	O
RR	O
=	O
1.01	O
[	O
95	O
%	O
CI	O
=	O
0.81	O
-	O
1.26	O
]	O
)	O
.	O

Data	O
from	O
18	O
sulfonylurea	S-chem
studies	O
in	O
subjects	O
with	O
T2DM	O
showed	O
that	O
sulfonylurea	S-chem
use	O
is	O
associated	O
with	O
an	O
increase	O
in	O
all	O
-	O
cancer	O
risk	O
,	O
in	O
cohort	O
studies	O
(	O
RR	O
=	O
1.55	O
[	O
95	O
%	O
CI	O
=	O
1.48	O
-	O
1.63	O
]	O
)	O
,	O
though	O
data	O
from	O
RCTs	O
(	O
RR	O
=	O
1.17	O
[	O
95	O
%	O
CI	O
=	O
0.95	O
-	O
1.45	O
]	O
)	O
and	O
case	O
-	O
control	O
studies	O
(	O
OR	O
=	O
1.02	O
[	O
95	O
%	O
CI	O
=	O
0.93	O
-	O
1.13	O
]	O
)	O
failed	O
to	O
demonstrate	O
a	O
statistically	O
significant	O
effect	O
.	O

CONCLUSIONS	O
:	O
This	O
analysis	O
using	O
pooled	O
primary	O
data	O
demonstrates	O
that	O
metformin	S-chem
use	O
reduces	O
,	O
while	O
sulfonylurea	S-chem
use	O
may	O
be	O
associated	O
with	O
an	O
increased	O
cancer	O
risk	O
in	O
subjects	O
with	O
T2DM	O
.	O

These	O
findings	O
need	O
to	O
be	O
confirmed	O
in	O
large	O
-	O
scale	O
RCTs	O
before	O
they	O
are	O
translated	O
into	O
clinical	O
practice	O
.	O

The	O
prostaglandin	B-chem
E	E-chem
series	O
modulates	O
high	B-geneN
-	I-geneN
voltage	I-geneN
-	I-geneN
activated	I-geneN
calcium	I-geneN
channels	E-geneN
probably	O
through	O
the	O
EP3	B-geneY
receptor	E-geneY
in	O
rat	O
paratracheal	O
ganglia	O
.	O

The	O
modulation	O
of	O
high	B-geneN
-	I-geneN
voltage	I-geneN
-	I-geneN
activated	I-geneN
(	I-geneN
HVA	I-geneN
)	I-geneN
Ca2	I-geneN
+	I-geneN
channels	E-geneN
by	O
the	O
prostaglandin	B-chem
E	E-chem
series	O
(	O
PGE1	S-chem
and	O
PGE2	S-chem
)	O
was	O
studied	O
in	O
the	O
paratracheal	O
ganglion	O
cells	O
.	O

Prostaglandin	B-chem
E1	I-chem
,	I-chem
E2	I-chem
,	E-chem
STA2	S-chem-C4-1
(	O
a	O
stable	O
analogue	O
of	O
thromboxane	B-chem-C4-1
A2	E-chem-C4-1
)	O
,	O
17	B-chem-MU-1
-	I-chem-MU-1
phenyl	I-chem-MU-1
-	I-chem-MU-1
trinor	I-chem-MU-1
-	I-chem-MU-1
PGE2	E-chem-MU-1
(	O
an	O
EP1	S-geneY-C5-2
-	O
selective	O
agonist	O
)	O
and	O
sulprostone	S-chem-MU-1
(	O
an	O
EP3	S-geneY-C5-2
-	O
selective	O
agonist	O
)	O
inhibited	O
the	O
HVA	O
Ca2	B-chem
+	E-chem
current	O
(	O
HVA	O
ICa	O
)	O
dose	O
-	O
dependently	O
,	O
and	O
the	O
rank	O
order	O
of	O
potency	O
to	O
inhibit	O
HVA	B-geneN-C4-2
Ca2	I-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
was	O
sulprostone	S-chem-C4-1
>	O
PGE2	S-chem-C4-1
,	O
PGE1	S-chem-C4-1
>	O
STA2	S-chem-C4-1
>	O
>	O
17	B-chem-C4-1
-	I-chem-C4-1
phenyl	I-chem-C4-1
-	I-chem-C4-1
trinor	I-chem-C4-1
-	I-chem-C4-1
PGE2	E-chem-C4-1
.	O

SC	B-chem-C6-1
-	I-chem-C6-1
51089	E-chem-C6-1
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
a	O
selective	O
EP1	B-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
,	O
showed	O
no	O
effect	O
on	O
the	O
PGE1	S-chem
-	O
or	O
PGE2	S-chem
-	O
induced	O
inhibition	O
of	O
the	O
HVA	O
ICa	O
,	O
thereby	O
indicating	O
that	O
PGE1	S-chem-C4-1
-	O
and	O
PGE2	S-chem-C4-1
-	O
induced	O
inhibition	O
of	O
the	O
HVA	B-geneN-C4-2
Ca2	I-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
is	O
possibly	O
mediated	O
by	O
the	O
EP3	B-geneY
receptor	E-geneY
.	O

The	O
PGE1	S-chem
-	O
sensitive	O
component	O
of	O
the	O
current	O
was	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
omega	O
-	O
conotoxin	O
-	O
GVIA	O
(	O
3x10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
but	O
not	O
with	O
nifedipine	S-chem
(	O
3x10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

PGE1	S-chem
and	O
PGE2	S-chem
also	O
inhibited	O
the	O
remaining	O
ICa	O
in	O
a	O
saturating	O
concentration	O
of	O
nifedipine	S-chem
,	O
omega	O
-	O
conotoxin	O
-	O
GVIA	O
and	O
omega	O
-	O
conotoxin	O
-	O
MVIIC	O
,	O
suggesting	O
that	O
R	B-geneN
-	I-geneN
type	I-geneN
Ca2	I-geneN
+	I-geneN
channels	E-geneN
are	O
involved	O
.	O

The	O
inhibitory	O
effect	O
of	O
PGE1	S-chem
or	O
sulprostone	S-chem
was	O
prevented	O
by	O
pretreatment	O
with	O
pertussis	B-geneN
toxin	E-geneN
[	O
islet	B-geneN
activating	I-geneN
protein	E-geneN
(	O
IAP	S-geneN
)	O
]	O
or	O
phorbol	B-chem
-	I-chem
12	I-chem
-	I-chem
myristate	I-chem
-	I-chem
13	I-chem
-	I-chem
acetate	E-chem
(	O
PMA	S-chem
)	O
,	O
and	O
the	O
protein	B-geneN-C4-2
kinase	I-geneN-C4-2
C	E-geneN-C4-2
(	O
PKC	S-geneN-C4-2
)	O
inhibitor	O
chelerythrine	S-chem-C4-1
blocked	O
the	O
action	O
of	O
PMA	S-chem
.	O

It	O
was	O
concluded	O
that	O
PGE1	S-chem-C3-1
selectively	O
reduces	O
both	O
N	O
-	O
and	O
R	O
-	O
type	O
Ca2	B-chem
+	E-chem
currents	O
by	O
activating	O
a	O
G	B-geneN-C3-2
-	I-geneN-C3-2
protein	E-geneN-C3-2
probably	O
through	O
the	O
EP3	B-geneY
receptor	E-geneY
in	O
paratracheal	O
ganglion	O
cells	O
.	O

P2	B-geneN
receptor	E-geneN
mRNA	O
expression	O
profiles	O
in	O
human	O
lymphocytes	O
,	O
monocytes	O
and	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

BACKGROUND	O
:	O
Extracellular	O
nucleotides	S-chem
(	O
ATP	S-chem
,	O
ADP	S-chem
,	O
UTP	S-chem
and	O
UDP	S-chem
)	O
exert	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
in	O
blood	O
cells	O
mediated	O
by	O
multiple	O
ionotropic	O
P2X	S-geneN
receptors	O
and	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
P2Y	I-geneN
receptors	E-geneN
.	O

Although	O
pharmacological	O
experiments	O
have	O
suggested	O
the	O
presence	O
of	O
several	O
P2	B-geneN
receptor	E-geneN
subtypes	O
on	O
monocytes	O
and	O
lymphocytes	O
,	O
some	O
results	O
are	O
contradictory	O
.	O

Few	O
physiological	O
functions	O
have	O
been	O
firmly	O
established	O
to	O
a	O
specific	O
receptor	O
subtype	O
,	O
partly	O
because	O
of	O
a	O
lack	O
of	O
truly	O
selective	O
agonists	O
and	O
antagonists	O
.	O

This	O
stimulated	O
us	O
to	O
investigate	O
the	O
expression	O
of	O
P2X	S-geneN
and	O
P2Y	S-geneN
receptors	O
in	O
human	O
lymphocytes	O
and	O
monocytes	O
with	O
a	O
newly	O
established	O
quantitative	O
mRNA	O
assay	O
for	O
P2	B-geneN
receptors	E-geneN
.	O

In	O
addition	O
,	O
we	O
describe	O
for	O
the	O
first	O
time	O
the	O
expression	O
of	O
P2	B-geneN
receptors	E-geneN
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
implicating	O
a	O
potential	O
role	O
of	O
P2	B-geneN
receptors	E-geneN
in	O
hematopoietic	O
lineage	O
and	O
progenitor	O
/	O
stem	O
cell	O
function	O
.	O

RESULTS	O
:	O
Using	O
a	O
quantitative	O
mRNA	O
assay	O
,	O
we	O
assessed	O
the	O
hypothesis	O
that	O
there	O
are	O
specific	O
P2	B-geneN
receptor	E-geneN
profiles	O
in	O
inflammatory	O
cells	O
.	O

The	O
P2X4	S-geneY
receptor	O
had	O
the	O
highest	O
expression	O
in	O
lymphocytes	O
and	O
monocytes	O
.	O

Among	O
the	O
P2Y	S-geneN
receptors	O
,	O
P2Y12	S-geneY
and	O
P2Y2	S-geneY
had	O
highest	O
expression	O
in	O
lymphocytes	O
,	O
while	O
the	O
P2Y2	S-geneY
and	O
P2Y13	S-geneY
had	O
highest	O
expression	O
in	O
monocytes	O
.	O

Several	O
P2	B-geneN
receptors	E-geneN
were	O
expressed	O
(	O
P2Y2	S-geneY
,	O
P2Y1	S-geneY
,	O
P2Y12	S-geneY
,	O
P2Y13	S-geneY
,	O
P2Y11	S-geneY
,	O
P2X1	S-geneY
,	O
P2X4	S-geneY
)	O
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
most	O
interesting	O
findings	O
were	O
the	O
high	O
mRNA	O
expression	O
of	O
P2Y12	S-geneY
receptors	O
in	O
lymphocytes	O
potentially	O
explaining	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
clopidogrel	S-chem
,	O
P2Y13	S-geneY
receptors	O
in	O
monocytes	O
and	O
a	O
previously	O
unrecognised	O
expression	O
of	O
P2X4	S-geneY
in	O
lymphocytes	O
and	O
monocytes	O
.	O

In	O
addition	O
,	O
for	O
the	O
first	O
time	O
P2	B-geneN
receptor	E-geneN
mRNA	O
expression	O
patterns	O
was	O
studied	O
in	O
CD34	O
+	O
stem	O
and	O
progenitor	O
cells	O
.	O

Several	O
P2	B-geneN
receptors	E-geneN
were	O
expressed	O
(	O
P2Y2	S-geneY
,	O
P2Y1	S-geneY
,	O
P2Y12	S-geneY
,	O
P2Y13	S-geneY
,	O
P2Y11	S-geneY
,	O
P2X1	S-geneY
,	O
P2X4	S-geneY
)	O
,	O
indicating	O
a	O
role	O
in	O
differentiation	O
and	O
proliferation	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
specific	O
antibodies	O
to	O
P2	B-geneN
receptors	E-geneN
could	O
be	O
used	O
to	O
identify	O
progenitors	O
for	O
monocytes	O
,	O
lymphocytes	O
and	O
megakaryocytes	O
.	O

2,3,7,8	B-chem
-	I-chem
Tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
-	O
induced	O
inflammatory	O
activation	O
is	O
mediated	O
by	O
intracellular	O
free	O
calcium	S-chem
in	O
microglial	O
cells	O
.	O

2,3,7,8	B-chem
-	I-chem
Tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
has	O
been	O
known	O
to	O
induce	O
inflammatory	O
signaling	O
in	O
a	O
number	O
of	O
cell	O
types	O
and	O
tissues	O
.	O

However	O
,	O
the	O
adverse	O
effects	O
of	O
TCDD	S-chem
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
have	O
not	O
been	O
entirely	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
using	O
reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
ELISA	O
,	O
we	O
showed	O
that	O
TCDD	S-chem-C3-1
up	O
-	O
regulated	O
the	O
expression	O
and	O
secretion	O
of	O
tumor	B-geneY-C3-2
necrosis	I-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
(	O
TNF	B-geneY-C3-2
-	I-geneY-C3-2
α	E-geneY-C3-2
)	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
in	O
cultured	O
HAPI	O
microglial	O
cells	O
.	O

TCDD	S-chem-C3-1
also	O
caused	O
a	O
fast	O
(	O
within	O
30min	O
as	O
judged	O
by	O
the	O
increase	O
in	O
its	O
mRNA	O
level	O
)	O
activation	O
of	O
cytosolic	B-geneY-C3-2
phospholipase	I-geneY-C3-2
A2	E-geneY-C3-2
(	O
cPLA2	S-geneY-C3-2
)	O
.	O

This	O
initial	O
action	O
was	O
accompanied	O
by	O
up	O
-	O
regulation	O
of	O
cyclooxygenase	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
(	O
COX	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
)	O
,	O
an	O
important	O
inflammation	O
marker	O
within	O
1h	O
after	O
TCDD	S-chem-C3-1
treatment	O
.	O

These	O
pro	O
-	O
inflammatory	O
responses	O
were	O
inhibited	O
by	O
two	O
types	O
of	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
blockers	O
,	O
bis	B-chem
-	I-chem
(	I-chem
o	I-chem
-	I-chem
aminophenoxy	I-chem
)	I-chem
ethane	I-chem
-	I-chem
N	I-chem
,	I-chem
N	I-chem
,	I-chem
N	I-chem
'	I-chem
,	I-chem
N	I-chem
'	I-chem
-	I-chem
tetra	I-chem
-	I-chem
acetic	I-chem
acid	I-chem
acetoxymethyl	I-chem
ester	E-chem
(	O
BAPTA	B-chem
-	I-chem
AM	E-chem
)	O
and	O
nifedipine	S-chem
,	O
thus	O
,	O
indicating	O
that	O
the	O
effects	O
are	O
triggered	O
by	O
initial	O
increase	O
in	O
the	O
intracellular	O
concentration	O
of	O
free	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
(	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
i	O
)	O
.	O

Further	O
,	O
TCDD	S-chem-C3-1
exposure	O
could	O
induce	O
phosphorylation	O
-	O
and	O
ubiquitination	O
-	O
dependent	O
degradation	O
of	O
IкBα	S-geneY-C3-2
,	O
and	O
the	O
translocation	O
of	O
NF	B-geneY
-	I-geneY
κB	I-geneY
p65	E-geneY
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
in	O
this	O
microglial	O
cell	O
line	O
.	O

Thus	O
,	O
the	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
signaling	O
pathway	O
can	O
be	O
activated	O
after	O
TCDD	S-chem-C3-1
treatment	O
.	O

However	O
,	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
blockers	O
also	O
obviously	O
attenuated	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
activation	O
and	O
transnuclear	O
transport	O
induced	O
by	O
TCDD	S-chem-C3-1
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
highlighted	O
that	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokine	S-geneN-C3-2
and	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
activation	O
induced	O
by	O
TCDD	S-chem-C3-1
can	O
be	O
mediated	O
by	O
elevation	O
of	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
i	O
in	O
HAPI	O
microglial	O
cells	O
.	O

The	O
effects	O
of	O
kisspeptin	S-geneN
in	O
human	O
reproductive	O
function	O
-	O
therapeutic	O
implications	O
.	O

Kisspeptin	S-geneN
is	O
a	O
54	O
-	O
amino	B-chem
acid	E-chem
peptide	O
which	O
is	O
encoded	O
by	O
the	O
KiSS	B-geneY
-	I-geneY
1	E-geneY
gene	O
and	O
activates	O
the	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
GPR54	S-geneY
.	O

Evidence	O
suggests	O
that	O
this	O
system	O
is	O
a	O
key	O
regulator	O
of	O
mammalian	O
and	O
human	O
reproduction	O
.	O

Animal	O
studies	O
have	O
shown	O
that	O
GPR54	S-geneY
-	O
deficient	O
mice	O
have	O
abnormal	O
sexual	O
development	O
.	O

Central	O
and	O
peripheral	O
administration	O
of	O
kisspeptin	S-geneN
stimulates	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
(	O
HPG	O
)	O
axis	O
whilst	O
pre	O
-	O
administration	O
of	O
a	O
gonadotrophin	B-geneY
releasing	I-geneY
hormone	E-geneY
(	O
GnRH	S-geneY
)	O
antagonist	O
abolishes	O
this	O
effect	O
.	O

In	O
humans	O
,	O
inactivating	O
GPR54	S-geneY
mutations	O
cause	O
normosmic	O
hypogonadotrophic	O
hypogonadism	O
whilst	O
activation	O
of	O
GPR54	S-geneY
signalling	O
is	O
associated	O
with	O
premature	O
puberty	O
.	O

In	O
healthy	O
human	O
volunteers	O
,	O
the	O
acute	O
intravenous	O
administration	O
of	O
kisspeptin	O
potently	O
increases	O
plasma	O
luteinising	B-geneN
hormone	E-geneN
(	O
LH	S-geneN
)	O
levels	O
and	O
significantly	O
increases	O
plasma	O
follicle	B-geneN
stimulating	I-geneN
hormone	E-geneN
(	O
FSH	S-geneN
)	O
and	O
testosterone	S-chem
without	O
side	O
effects	O
in	O
both	O
males	O
and	O
in	O
females	O
particularly	O
in	O
the	O
preovulatatory	O
phase	O
of	O
the	O
menstrual	O
cycle	O
.	O

In	O
infertility	O
due	O
to	O
hypothalamic	O
amenorrhoea	O
acute	O
administration	O
of	O
kisspeptin	S-geneN
results	O
in	O
stimulation	O
of	O
reproductive	O
hormones	O
.	O

The	O
kisspeptin	S-geneN
/	O
GPR54	S-geneY
system	O
therefore	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
reproduction	O
in	O
humans	O
.	O

Hence	O
kisspeptin	S-geneN
has	O
potential	O
as	O
a	O
novel	O
tool	O
for	O
the	O
manipulation	O
of	O
the	O
HPG	O
axis	O
and	O
treatment	O
of	O
infertility	O
in	O
humans	O
.	O

This	O
review	O
discusses	O
the	O
evidence	O
highlighting	O
kisspeptin	B-geneN
's	E-geneN
key	O
role	O
in	O
human	O
reproduction	O
.	O

Robust	O
autoactivation	O
,	O
chymotrypsin	B-geneY
C	E-geneY
independence	O
and	O
diminished	O
secretion	O
define	O
a	O
subset	O
of	O
hereditary	O
pancreatitis	O
associated	O
cationic	B-geneY
trypsinogen	E-geneY
mutants	O
.	O

Mutations	O
in	O
human	B-geneY
cationic	I-geneY
trypsinogen	E-geneY
cause	O
hereditary	O
pancreatitis	O
by	O
altering	O
its	O
proteolytic	O
regulation	O
of	O
activation	O
and	O
degradation	O
by	O
chymotrypsin	B-geneY
C	E-geneY
(	O
CTRC	S-geneY
)	O
.	O

CTRC	S-geneY
stimulates	O
trypsinogen	O
autoactivation	O
by	O
processing	O
the	O
activation	O
peptide	O
to	O
a	O
shorter	O
form	O
but	O
also	O
promotes	O
degradation	O
by	O
cleaving	O
the	O
calcium	B-geneN
binding	I-geneN
loop	E-geneN
in	O
trypsinogen	O
.	O

Mutations	O
render	O
trypsinogen	O
resistant	O
to	O
CTRC	S-geneY
-	O
mediated	O
degradation	O
and	O
/	O
or	O
increase	O
processing	O
of	O
the	O
activation	O
peptide	O
by	O
CTRC	S-geneN
.	O

Here	O
we	O
demonstrate	O
that	O
activation	O
peptide	O
mutations	O
D19A	S-geneN
,	O
D22G	S-geneN
,	O
K23R	S-geneN
and	O
K23_I24insIDK	S-geneN
robustly	O
increased	O
the	O
rate	O
of	O
trypsinogen	O
autoactivation	O
,	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
CTRC	S-geneY
.	O

Degradation	O
of	O
the	O
mutants	O
by	O
CTRC	S-geneY
was	O
unchanged	O
and	O
processing	O
of	O
the	O
activation	O
peptide	O
was	O
increased	O
only	O
in	O
the	O
D19A	S-geneN
mutant	O
by	O
4	O
-	O
fold	O
.	O

Surprisingly	O
,	O
however	O
,	O
this	O
increased	O
processing	O
had	O
only	O
a	O
minimal	O
effect	O
on	O
autoactivation	O
.	O

The	O
tetra	B-geneN
-	I-geneN
aspartate	I-geneN
motif	E-geneN
in	O
the	O
trypsinogen	O
activation	O
peptide	O
binds	O
calcium	S-chem
(	O
KD	O
~	O
1.6	O
mM	O
)	O
,	O
which	O
stimulates	O
autoactivation	O
.	O

Unexpectedly	O
,	O
calcium	S-chem
binding	O
was	O
not	O
compromised	O
by	O
any	O
of	O
the	O
activation	O
peptide	O
mutations	O
.	O

Despite	O
normal	O
binding	O
,	O
autoactivation	O
of	O
mutants	O
D22G	S-geneN
and	O
K23_I24insIDK	S-geneN
was	O
not	O
stimulated	O
by	O
calcium	S-chem
.	O

Finally	O
,	O
the	O
activation	O
peptide	O
mutants	O
exhibited	O
reduced	O
secretion	O
from	O
transfected	O
cells	O
,	O
and	O
secreted	O
trypsinogen	O
levels	O
were	O
inversely	O
proportional	O
with	O
autoactivation	O
rates	O
.	O

We	O
conclude	O
that	O
D19A	S-geneN
,	O
D22G	S-geneN
,	O
K23R	S-geneN
and	O
K23_I24insIDK	S-geneN
form	O
a	O
mechanistically	O
distinct	O
subset	O
of	O
hereditary	O
pancreatitis	O
associated	O
mutations	O
,	O
which	O
exert	O
their	O
effect	O
primarily	O
through	O
direct	O
stimulation	O
of	O
autoactivation	O
,	O
independently	O
of	O
CTRC	S-geneY
.	O

The	O
potentially	O
severe	O
clinical	O
impact	O
of	O
the	O
markedly	O
increased	O
autoactivation	O
is	O
offset	O
by	O
diminished	O
secretion	O
,	O
resulting	O
in	O
a	O
clinical	O
phenotype	O
indistinguishable	O
from	O
typical	O
hereditary	O
pancreatitis	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Conformationally	O
restricted	O
homotryptamines	S-chem
.	O
Part	O
6	O
:	O
Indole	B-chem
-	I-chem
5	I-chem
-	I-chem
cycloalkyl	I-chem
methylamines	E-chem
as	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
.	O

Racemic	B-chem
5	I-chem
-	I-chem
(	I-chem
trans	I-chem
-	I-chem
2	I-chem
-	I-chem
aminomethylcyclopropyl	I-chem
)	I-chem
indoles	E-chem
,	O
5	B-chem
-	I-chem
(	I-chem
trans	I-chem
-	I-chem
2	I-chem
-	I-chem
aminomethylcyclopentyl	I-chem
)	I-chem
indoles	E-chem
,	O
and	O
5	B-chem
-	I-chem
(	I-chem
cis	I-chem
-	I-chem
2	I-chem
-	I-chem
aminomethylcyclopentyl	I-chem
)	I-chem
indoles	E-chem
were	O
synthesized	O
and	O
evaluated	O
as	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
.	O

These	O
analogs	O
followed	O
SAR	O
trends	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
3	B-chem
-	I-chem
cycloalkyl	I-chem
substituted	I-chem
indoles	E-chem
.	O

The	O
most	O
potent	O
analogs	O
exhibited	O
single	O
digit	O
nanomolar	O
inhibition	O
at	O
the	O
human	B-geneY
serotonin	I-geneY
transporter	E-geneY
but	O
were	O
10	O
-	O
fold	O
less	O
active	O
than	O
the	O
previously	O
reported	O
compounds	O
.	O

(	B-chem
-	I-chem
)	I-chem
Epicatechin	E-chem
attenuates	O
mitochondrial	O
damage	O
by	O
enhancing	O
mitochondrial	O
multi	O
-	O
marker	O
enzymes	O
,	O
adenosine	B-chem
triphosphate	E-chem
and	O
lowering	O
calcium	S-chem
in	O
isoproterenol	S-chem
induced	O
myocardial	O
infarcted	O
rats	O
.	O

Cardiac	O
mitochondrial	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathology	O
of	O
myocardial	O
infarction	O
.	O

The	O
protective	O
effects	O
of	O
(	B-chem
-	I-chem
)	I-chem
epicatechin	E-chem
on	O
cardiac	O
mitochondrial	O
damage	O
in	O
isoproterenol	S-chem
induced	O
myocardial	O
infarction	O
were	O
evaluated	O
in	O
rats	O
.	O

Rats	O
were	O
pretreated	O
with	O
(	B-chem
-	I-chem
)	I-chem
epicatechin	E-chem
(	O
20	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
daily	O
for	O
a	O
period	O
of	O
21	O
days	O
.	O

After	O
the	O
pretreatment	O
period	O
,	O
isoproterenol	S-chem
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
was	O
injected	O
subcutaneously	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
to	O
induce	O
myocardial	O
infarction	O
.	O

Isoproterenol	S-chem-C4-1
induced	O
myocardial	O
infarcted	O
rats	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
cardiac	O
diagnostic	O
markers	O
,	O
heart	O
mitochondrial	O
lipid	O
peroxidation	O
,	O
calcium	S-chem
,	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
activities	O
/	O
levels	O
of	O
heart	O
mitochondrial	O
glutathione	B-geneN-C4-2
peroxidase	E-geneN-C4-2
,	O
glutathione	B-geneY-C4-2
reductase	E-geneY-C4-2
,	O
reduced	B-chem
glutathione	E-chem
,	O
isocitrate	S-chem
,	O
succinate	S-chem
,	O
malate	S-chem
,	O
α	B-chem
-	I-chem
ketoglutarate	E-chem
and	O
NADH	B-geneN-C4-2
-	I-geneN-C4-2
dehydrogenases	E-geneN-C4-2
,	O
cytochrome	B-geneN-C4-2
-	I-geneN-C4-2
C	I-geneN-C4-2
-	I-geneN-C4-2
oxidase	E-geneN-C4-2
and	O
adenosine	B-chem
triphosphate	E-chem
.	O

(	B-chem
-	I-chem
)	I-chem
Epicatechin	E-chem
pretreatment	O
showed	O
significant	O
protective	O
effects	O
on	O
all	O
the	O
biochemical	O
parameters	O
evaluated	O
.	O

The	O
in	O
vitro	O
study	O
revealed	O
the	O
superoxide	S-chem
and	O
hydroxyl	S-chem
radical	O
scavenging	O
activity	O
of	O
(	B-chem
-	I-chem
)	I-chem
epicatechin	E-chem
.	O

The	O
possible	O
mechanisms	O
for	O
the	O
beneficial	O
effects	O
of	O
(	B-chem
-	I-chem
)	I-chem
epicatechin	E-chem
on	O
cardiac	O
mitochondria	O
could	O
be	O
attributed	O
to	O
scavenging	O
of	O
free	O
radicals	O
,	O
decreasing	O
calcium	S-chem
,	O
increasing	O
multi	O
-	O
enzymes	O
(	O
antioxidant	O
,	O
tricarboxylic	B-chem
acid	E-chem
cycle	O
and	O
respiratory	O
chain	O
enzymes	O
)	O
,	O
reduced	O
glutathione	S-chem
and	O
adenosine	B-chem
triphosphate	E-chem
.	O

Thus	O
,	O
(	B-chem
-	I-chem
)	I-chem
epicatechin	E-chem
attenuated	O
mitochondrial	O
damage	O
in	O
isoproterenol	S-chem
induced	O
myocardial	O
infarcted	O
rats	O
.	O

Effects	O
of	O
changeover	O
from	O
voglibose	S-chem
to	O
acarbose	S-chem
on	O
postprandial	O
triglycerides	S-chem
in	O
type	O
2	O
diabetes	O
mellitus	O
patients	O
.	O

INTRODUCTION	O
:	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
alpha	B-geneN-C4-2
-	I-geneN-C4-2
glucosidase	E-geneN-C4-2
inhibitors	O
acarbose	S-chem-C4-1
and	O
voglibose	S-chem-C4-1
on	O
postprandial	O
plasma	O
glucose	S-chem-C4-1
and	O
serum	O
triglyceride	O
levels	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

METHODS	O
:	O
Twenty	O
-	O
one	O
Japanese	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Subjects	O
had	O
been	O
treated	O
with	O
voglibose	S-chem
for	O
at	O
least	O
3	O
months	O
.	O

They	O
underwent	O
a	O
400	O
kcal	O
balanced	O
food	O
meal	O
tolerance	O
test	O
before	O
and	O
8	O
weeks	O
after	O
the	O
changeover	O
from	O
voglibose	S-chem
to	O
acarbose	S-chem
.	O

Subjects	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
first	O
group	O
(	O
low	O
-	O
dose	O
group	O
;	O
n	O
=	O
11	O
)	O
was	O
changed	O
over	O
from	O
0.6	O
mg	O
/	O
day	O
voglibose	S-chem
to	O
150	O
mg	O
/	O
day	O
acarbose	S-chem
,	O
and	O
the	O
other	O
(	O
high	O
-	O
dose	O
group	O
;	O
n	O
=	O
10	O
)	O
from	O
0.9	O
mg	O
/	O
day	O
voglibose	S-chem
to	O
300	O
mg	O
/	O
day	O
acarbose	O
.	O

RESULTS	O
:	O
The	O
increment	O
rate	O
of	O
postprandial	O
plasma	O
glucose	S-chem
(	O
[	O
plasma	O
glucose	S-chem
2	O
hours	O
after	O
test	O
meal	O
-	O
fasting	O
glucose	S-chem
]	O
/	O
fasting	O
glucose	S-chem
)	O
decreased	O
from	O
34.7	O
%	O
+	O
/	O
-	O
23.9	O
%	O
to	O
25.0	O
%	O
+	O
/	O
-	O
24.6	O
%	O
(	O
P	O
=	O
0.13	O
)	O
in	O
the	O
low	O
-	O
dose	O
group	O
,	O
and	O
decreased	O
significantly	O
from	O
56.1	O
%	O
+	O
/	O
-	O
53.1	O
%	O
to	O
31.5	O
%	O
+	O
/	O
-	O
36.0	O
%	O
(	O
P	O
=	O
0.03	O
)	O
in	O
the	O
high	O
-	O
dose	O
group	O
after	O
changeover	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
blood	O
glycated	B-geneY
hemoglobin	E-geneY
(	O
HbA	B-geneY
(	I-geneY
1c	I-geneY
)	E-geneY
)	O
levels	O
before	O
and	O
after	O
changeover	O
in	O
either	O
group	O
.	O

The	O
increment	O
rate	O
of	O
postprandial	O
serum	O
triglyceride	S-chem
(	O
TG	S-chem
)	O
(	O
[	O
serum	O
TG	S-chem
2	O
hours	O
after	O
test	O
meal	O
-	O
fasting	O
TG	S-chem
]	O
/	O
fasting	O
TG	S-chem
)	O
decreased	O
significantly	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
(	O
52.4	O
%	O
+	O
/	O
-	O
60.0	O
%	O
to	O
24.3	O
%	O
+	O
/	O
-	O
16.6	O
%	O
)	O
(	O
P	O
=	O
0.05	O
)	O
.	O

No	O
significant	O
changes	O
in	O
serum	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	S-chem
levels	O
were	O
observed	O
in	O
either	O
group	O
,	O
whereas	O
serum	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
cholesterol	S-chem
levels	O
decreased	O
significantly	O
from	O
3.20	O
+	O
/	O
-	O
0.25	O
to	O
2.65	O
+	O
/	O
-	O
0.18	O
mmol	O
/	O
L	O
(	O
P	O
=	O
0.04	O
)	O
,	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
type	O
2	O
diabetes	O
our	O
findings	O
suggest	O
that	O
acarbose	S-chem
300	O
mg	O
/	O
day	O
is	O
superior	O
to	O
voglibose	S-chem
0.9	O
mg	O
/	O
day	O
in	O
improving	O
postprandial	O
hyperglycemia	O
and	O
hypertriglyceridemia	O
.	O

Novel	O
acylethanolamide	S-chem-MU-1
derivatives	O
that	O
modulate	O
body	O
weight	O
through	O
enhancement	O
of	O
hypothalamic	O
pro	B-geneY-C3-2
-	I-geneY-C3-2
opiomelanocortin	E-geneY-C3-2
(	O
POMC	S-geneY-C3-2
)	O
and	O
/	O
or	O
decreased	O
neuropeptide	B-geneY-C4-2
Y	E-geneY-C4-2
(	O
NPY	S-geneY-C4-2
)	O
.	O

Newly	O
synthesized	O
acylethanolamide	S-chem
derivatives	O
oleoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
(	O
1	O
)	O
,	O
oleoyl	B-chem
-	I-chem
D	I-chem
-	I-chem
valinolamide	E-chem
(	O
2	O
)	O
,	O
elaidoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
(	O
3	O
)	O
,	O
elaidoyl	B-chem
-	I-chem
D	I-chem
-	I-chem
valinolamide	E-chem
(	O
4	O
)	O
stearoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
(	O
5	O
)	O
,	O
and	O
palmitoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
(	O
6	O
)	O
were	O
investigated	O
in	O
mice	O
as	O
antiobesity	O
compounds	O
.	O

Compounds	O
1	O
,	O
2	O
,	O
5	O
,	O
6	O
significantly	O
decreased	O
body	O
weight	O
by	O
6.57	O
%	O
following	O
eight	O
injections	O
of	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
during	O
39	O
days	O
,	O
while	O
3	O
and	O
4	O
showed	O
no	O
such	O
activity	O
.	O

Receptor	O
binding	O
indicated	O
that	O
no	O
compound	O
activated	O
CB1	S-geneY
,	O
CB2	S-geneY
,	O
PPARα	S-geneY
,	O
or	O
TRPV1	S-geneY
receptors	O
.	O

Hypothalamic	O
RT	O
-	O
PCR	O
showed	O
that	O
mRNA	O
expression	O
of	O
the	O
anorexigenic	O
genes	O
POMC	S-geneY
and	O
CART	S-geneY
was	O
up	O
-	O
regulated	O
by	O
1	O
,	O
2	O
,	O
5	O
and	O
1	O
,	O
2	O
,	O
respectively	O
,	O
while	O
that	O
of	O
the	O
orexigenic	O
genes	O
NPY	S-geneY
and	O
CaMKK2	S-geneY
was	O
down	O
-	O
regulated	O
by	O
the	O
respective	O
compounds	O
1	O
,	O
5	O
,	O
6	O
and	O
1	O
,	O
2	O
,	O
5	O
.	O

Oleoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
enhances	O
anorectic	O
pathways	O
and	O
lead	O
to	O
decreased	O
glucose	S-chem
levels	O
,	O
enhanced	O
locomotor	O
activity	O
,	O
and	O
improved	O
cognition	O
.	O

Effects	O
of	O
oleoyl	B-chem
-	I-chem
L	I-chem
-	I-chem
valinolamide	E-chem
on	O
weight	O
were	O
dose	O
-	O
dependent	O
,	O
and	O
it	O
could	O
be	O
given	O
orally	O
.	O

1	O
,	O
2	O
,	O
4	O
,	O
5	O
down	O
-	O
regulated	O
FAAH	S-geneY
mRNA	O
expression	O
.	O

Current	O
understanding	O
of	O
TRPM7	S-geneY
pharmacology	O
and	O
drug	O
development	O
for	O
stroke	O
.	O

The	O
initial	O
excitement	O
and	O
countless	O
efforts	O
to	O
find	O
a	O
pharmacological	O
agent	O
that	O
disrupts	O
the	O
excitotoxic	O
pathway	O
of	O
ischemic	O
neuronal	O
death	O
have	O
only	O
led	O
to	O
disappointing	O
clinical	O
trials	O
.	O

Currently	O
,	O
a	O
thrombolytic	O
agent	O
called	O
recombinant	B-geneY
tissue	I-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
rt	B-geneY
-	I-geneY
PA	E-geneY
)	O
is	O
the	O
only	O
pharmacological	O
treatment	O
available	O
for	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
in	O
most	O
countries	O
.	O

Even	O
though	O
its	O
efficacy	O
has	O
been	O
confirmed	O
repeatedly	O
,	O
rt	B-geneY
-	I-geneY
PA	E-geneY
is	O
considerably	O
underused	O
due	O
to	O
reasons	O
including	O
a	O
short	O
therapeutic	O
window	O
and	O
repeated	O
complications	O
associated	O
with	O
its	O
use	O
.	O

A	O
search	O
for	O
alternative	O
mechanisms	O
that	O
may	O
operate	O
dependently	O
or	O
independently	O
with	O
the	O
well	O
-	O
established	O
excitotoxic	O
mechanism	O
has	O
led	O
researchers	O
to	O
the	O
discovery	O
of	O
newly	O
described	O
non	O
-	O
glutamate	S-chem
mechanisms	O
.	O

Among	O
the	O
latter	O
,	O
transient	B-geneY
receptor	I-geneY
potential	I-geneY
melastatin	I-geneY
7	E-geneY
(	O
TRPM7	S-geneY
)	O
is	O
one	O
of	O
the	O
important	O
nonglutamate	O
mechanisms	O
in	O
stroke	O
,	O
which	O
has	O
been	O
evaluated	O
in	O
both	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
current	O
state	O
of	O
pharmacological	O
treatments	O
of	O
ischemic	O
stroke	O
and	O
provide	O
evidence	O
that	O
TRPM7	S-geneY
is	O
a	O
promising	O
therapeutic	O
target	O
of	O
stroke	O
.	O

Age	O
dependent	O
differences	O
in	O
the	O
regulation	O
of	O
hippocampal	O
steroid	S-chem
hormones	O
and	O
receptor	O
genes	O
:	O
relations	O
to	O
motivation	O
and	O
cognition	O
in	O
male	O
rats	O
.	O

Estrogen	S-chem
and	O
estrogenic	O
functions	O
are	O
age	O
-	O
dependently	O
involved	O
in	O
the	O
modulation	O
of	O
learning	O
,	O
memory	O
and	O
mood	O
in	O
female	O
humans	O
and	O
animals	O
.	O

However	O
,	O
the	O
investigation	O
of	O
estrogenic	O
effects	O
in	O
males	O
has	O
been	O
largely	O
neglected	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
hippocampal	O
gene	O
expression	O
of	O
estrogen	B-geneN
receptors	I-geneN
α	I-geneN
and	I-geneN
β	E-geneN
(	O
ERα	B-geneN
,	I-geneN
β	E-geneN
)	O
in	O
8	O
-	O
week	O
-	O
old	O
,	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
male	O
rats	O
.	O

To	O
control	O
for	O
possible	O
interactions	O
between	O
the	O
expression	O
of	O
the	O
estrogen	B-geneY
receptor	E-geneY
genes	O
and	O
other	O
learning	O
-	O
related	O
steroid	B-geneN
receptors	E-geneN
,	O
androgen	B-geneY
receptors	E-geneY
(	O
AR	S-geneY
)	O
,	O
corticosterone	S-chem
-	O
binding	O
glucocorticoid	B-geneY
receptors	E-geneY
(	O
GR	S-geneY
)	O
and	O
mineralocorticoid	B-geneY
receptors	E-geneY
(	O
MR	S-geneY
)	O
were	O
also	O
measured	O
.	O

Furthermore	O
,	O
the	O
concentrations	O
of	O
the	O
ligands	O
17β	B-chem
-	I-chem
estradiol	E-chem
,	O
testosterone	S-chem
and	O
corticosterone	S-chem
were	O
measured	O
.	O

The	O
spatial	O
training	O
was	O
conducted	O
in	O
a	O
hole	O
-	O
board	O
.	O

The	O
8	O
-	O
week	O
-	O
old	O
rats	O
exhibited	O
higher	O
levels	O
of	O
general	O
activity	O
and	O
exploration	O
during	O
the	O
training	O
and	O
performed	O
best	O
with	O
respect	O
to	O
spatial	O
learning	O
and	O
memory	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
between	O
the	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
trained	O
8	O
-	O
week	O
-	O
old	O
rats	O
exhibited	O
increased	O
gene	O
expression	O
of	O
ERα	S-geneY
compared	O
with	O
the	O
untrained	O
rats	O
in	O
this	O
age	O
group	O
as	O
well	O
as	O
the	O
trained	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
concentrations	O
of	O
estradiol	S-chem
and	O
testosterone	S-chem
,	O
however	O
,	O
were	O
generally	O
higher	O
in	O
the	O
24	O
-	O
week	O
-	O
old	O
rats	O
than	O
in	O
the	O
8	O
-	O
week	O
-	O
old	O
and	O
12	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
ERα	S-geneY
mRNA	O
concentrations	O
correlated	O
positively	O
with	O
behavior	O
that	O
indicate	O
general	O
learning	O
motivation	O
.	O

These	O
results	O
suggest	O
a	O
specific	O
role	O
of	O
ERα	S-geneY
in	O
the	O
age	O
-	O
related	O
differences	O
in	O
motivation	O
and	O
subsequent	O
success	O
in	O
the	O
task	O
.	O

Thus	O
,	O
estrogen	S-chem
and	O
estrogenic	O
functions	O
may	O
play	O
a	O
more	O
prominent	O
role	O
in	O
young	O
male	O
behavior	O
and	O
development	O
than	O
has	O
been	O
previously	O
assumed	O
.	O

NF	B-geneN
-	I-geneN
κB	E-geneN
-	O
associated	O
mechanisms	O
underlying	O
the	O
response	O
of	O
embryonic	O
cells	O
to	O
Doxorubicin	S-chem
.	O

The	O
involvement	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
in	O
the	O
regulation	O
of	O
teratogen	O
-	O
induced	O
apoptosis	O
has	O
not	O
been	O
established	O
yet	O
.	O

Therefore	O
,	O
we	O
tried	O
to	O
assess	O
the	O
involvement	O
of	O
the	O
p65	S-geneY
subunit	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
in	O
the	O
embryonic	O
response	O
to	O
the	O
anti	O
-	O
cancer	O
drug	O
Doxorubicin	S-chem
(	O
DOX	S-chem
)	O
.	O

Thus	O
,	O
exposure	O
of	O
p65	S-geneY
knockout	O
(	O
p65	S-geneY
(	O
-	O
/	O
-	O
)	O
)	O
or	O
wild	O
type	O
(	O
WT	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
to	O
DOX	S-chem
resulted	O
in	O
a	O
decrease	O
in	O
cell	O
survival	O
,	O
culture	O
density	O
and	O
cell	O
proliferation	O
,	O
which	O
was	O
found	O
to	O
be	O
more	O
prominent	O
in	O
p65	S-geneY
(	O
-	O
/	O
-	O
)	O
MEFs	O
.	O

Those	O
phenomena	O
were	O
accompanied	O
by	O
a	O
DOX	S-chem
-	O
induced	O
increase	O
in	O
the	O
proportion	O
of	O
apoptotic	O
cells	O
,	O
which	O
was	O
demonstrated	O
only	O
in	O
p65	S-geneY
(	O
-	O
/	O
-	O
)	O
cells	O
and	O
a	O
G2	O
/	O
M	O
arrest	O
,	O
which	O
was	O
found	O
to	O
be	O
more	O
prominent	O
in	O
WT	O
cells	O
.	O

Furthermore	O
,	O
DOX	S-chem-C4-1
-	O
treated	O
WT	O
and	O
p65	S-geneY
(	O
-	O
/	O
-	O
)	O
MEFs	O
differed	O
in	O
their	O
expression	O
of	O
various	O
apoptosis	O
-	O
associated	O
molecules	O
,	O
when	O
the	O
former	O
demonstrated	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
p65	S-geneY-C4-2
-	O
positive	O
and	O
a	O
more	O
prominent	O
decrease	O
in	O
the	O
percentage	O
of	O
p53	S-geneY
-	O
positive	O
cells	O
,	O
while	O
a	O
decreased	O
percentage	O
of	O
IκBα	S-geneY
-	O
positive	O
and	O
a	O
more	O
prominent	O
decrease	O
in	O
the	O
percentage	O
of	O
bcl	B-geneY
-	I-geneY
2	E-geneY
-	O
positive	O
cells	O
was	O
detected	O
among	O
the	O
latter	O
.	O

The	O
fact	O
that	O
the	O
response	O
of	O
the	O
cells	O
to	O
the	O
teratogen	O
was	O
clearly	O
p65	S-geneY
-	O
dependent	O
implicates	O
this	O
molecule	O
to	O
be	O
involved	O
in	O
the	O
response	O
of	O
the	O
embryonic	O
cells	O
to	O
DOX	S-chem
.	O

Streptococcus	B-geneY
pneumoniae	I-geneY
ClpP	E-geneY
protease	S-geneN
induces	O
apoptosis	O
via	O
caspase	S-geneN
-	O
independent	O
pathway	O
in	O
human	O
neuroblastoma	O
cells	O
:	O
cytoplasmic	O
relocalization	O
of	O
p53	S-geneY
.	O

Streptococcus	O
pneumoniae	O
causes	O
the	O
most	O
severe	O
form	O
of	O
the	O
bacterial	O
meningitis	O
which	O
is	O
the	O
major	O
cause	O
of	O
bacterial	O
meningitis	O
.	O

Virulence	O
factors	O
produced	O
by	O
S.	O
pneumoniae	O
have	O
been	O
known	O
to	O
contribute	O
significantly	O
to	O
the	O
disease	O
process	O
.	O

ClpP	S-geneY
protease	S-geneN
(	O
ClpP	S-geneY
)	O
which	O
is	O
essential	O
for	O
virulence	O
and	O
survival	O
under	O
stress	O
conditions	O
in	O
S.	O
pneumonia	O
was	O
examined	O
for	O
the	O
ability	O
to	O
induce	O
apoptosis	O
and	O
the	O
mechanism	O
of	O
the	O
induction	O
of	O
apoptosis	O
in	O
human	O
neuron	O
-	O
like	O
cells	O
,	O
SK	O
-	O
N	O
-	O
SH	O
neuroblastoma	O
cells	O
.	O

ClpP	S-geneY
inhibited	O
cell	O
growth	O
and	O
induced	O
apoptosis	O
in	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
.	O

Treatment	O
with	O
ClpP	S-geneY
resulted	O
in	O
hypodiploid	O
DNA	O
contents	O
,	O
increased	O
Bax	S-geneY
/	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
ratio	O
and	O
induction	O
of	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
production	O
.	O

The	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
from	O
mitochondria	O
into	O
the	O
cytosol	O
,	O
which	O
is	O
an	O
initiator	O
of	O
the	O
activation	O
of	O
caspase	S-geneN
cascades	O
,	O
was	O
not	O
observed	O
in	O
ClpP	S-geneY
-	O
treated	O
cells	O
.	O

In	O
addition	O
,	O
pretreatment	O
with	O
Z	B-chem-C4-1
-	I-chem-C4-1
Val	I-chem-C4-1
-	I-chem-C4-1
Ala	I-chem-C4-1
-	I-chem-C4-1
Asp	I-chem-C4-1
-	I-chem-C4-1
fluoromethylketone	E-chem-C4-1
(	O
Z	B-chem-C4-1
-	I-chem-C4-1
VAD	I-chem-C4-1
-	I-chem-C4-1
fmk	E-chem-C4-1
)	O
,	O
a	O
broad	O
spectrum	O
of	O
caspase	S-geneN-C4-2
inhibitor	O
,	O
could	O
not	O
rescue	O
apoptotic	O
cells	O
from	O
ClpP	S-geneY
toxicity	O
.	O

Coincidently	O
,	O
caspase	B-geneN
-	I-geneN
3	I-geneN
and	I-geneN
-	I-geneN
8	E-geneN
activation	O
and	O
cleavage	O
of	O
PARP	S-geneN
were	O
not	O
detected	O
.	O

Moreover	O
,	O
caspase	S-geneN
independent	O
apoptosis	B-geneY
-	I-geneY
inducing	I-geneY
factor	E-geneY
(	O
AIF	S-geneY
)	O
was	O
released	O
from	O
mitochondria	O
and	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
ClpP	S-geneY
.	O

We	O
also	O
found	O
that	O
ClpP	S-geneY
treatment	O
resulted	O
in	O
the	O
increase	O
of	O
p53	S-geneY
activity	O
and	O
cytoplasmic	O
p53	S-geneY
levels	O
were	O
increased	O
by	O
ClpP	S-geneY
,	O
suggesting	O
that	O
functional	O
activation	O
of	O
p53	S-geneY
is	O
intact	O
despite	O
increased	O
cytoplasmic	O
accumulation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
ClpP	S-geneY
contributes	O
to	O
neuronal	O
damage	O
in	O
meningitis	O
and	O
provide	O
further	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
action	O
of	O
pneumococcal	O
virulence	O
factors	O
during	O
bacterial	O
pathogenesis	O
.	O

Islet	O
cell	O
antibodies	O
in	O
normal	O
French	O
schoolchildren	O
.	O

Islet	O
-	O
cell	O
antibodies	O
have	O
been	O
reported	O
to	O
be	O
of	O
predictive	O
value	O
for	O
the	O
future	O
development	O
of	O
Type	O
1	O
(	O
insulin	S-geneY
-	O
dependent	O
)	O
diabetes	O
in	O
first	O
degree	O
relatives	O
of	O
diabetic	O
patients	O
with	O
the	O
risk	O
increasing	O
in	O
these	O
subjects	O
with	O
the	O
islet	O
-	O
cell	O
antibodies	O
titre	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
islet	O
-	O
cell	O
antibodies	O
in	O
background	O
populations	O
.	O

Sera	O
(	O
n	O
=	O
8363	O
)	O
from	O
schoolchildren	O
(	O
6	O
-	O
17	O
years	O
)	O
in	O
the	O
French	O
background	O
population	O
were	O
screened	O
for	O
the	O
presence	O
of	O
islet	O
-	O
cell	O
antibodies	O
by	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O

Islet	O
-	O
cell	O
antibodies	O
greater	O
than	O
4.5	O
Juvenile	O
Diabetes	O
Foundation	O
units	O
were	O
found	O
in	O
150	O
sera	O
(	O
prevalence	O
rate	O
1.8	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
1.5	O
-	O
2.1	O
%	O
)	O
.	O

Only	O
17	O
sera	O
demonstrated	O
islet	O
-	O
cell	O
antibody	O
titre	O
greater	O
than	O
or	O
equal	O
to	O
24	O
JDF	O
units	O
.	O

No	O
particular	O
feature	O
was	O
found	O
to	O
be	O
significantly	O
different	O
between	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
and	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
children	O
(	O
age	O
,	O
family	O
history	O
of	O
diabetes	O
,	O
fasting	O
plasma	O
glucose	S-chem
,	O
insulin	O
autoantibodies	O
)	O
.	O

A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
80	O
of	O
150	O
islet	O
-	O
cell	O
antibody	O
positive	O
children	O
after	O
a	O
mean	O
interval	O
of	O
8	O
months	O
.	O

Only	O
11	O
sera	O
became	O
less	O
than	O
4.5	O
JDF	O
units	O
with	O
islet	O
-	O
cell	O
antibody	O
titres	O
being	O
stable	O
in	O
the	O
remaining	O
sera	O
,	O
including	O
the	O
high	O
-	O
titre	O
positive	O
sera	O
(	O
greater	O
than	O
or	O
equal	O
to	O
24	O
JDF	O
units	O
)	O
.	O

HLA	B-geneY
-	I-geneY
DQB	E-geneY
typing	O
was	O
performed	O
by	O
restriction	O
mapping	O
techniques	O
in	O
80	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
,	O
in	O
93	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
and	O
in	O
213	O
Type	O
1	O
diabetic	O
children	O
.	O

The	O
distribution	O
of	O
the	O
susceptibility	O
alleles	O
(	O
DQB1	S-geneY
-	O
Asp57	O
-	O
negative	O
)	O
was	O
not	O
significantly	O
different	O
between	O
islet	O
-	O
cell	O
antibody	O
-	O
positive	O
and	O
islet	O
-	O
cell	O
antibody	O
-	O
negative	O
children	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

ABCA1	S-geneY
single	O
nucleotide	S-chem
polymorphisms	O
on	O
high	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
-	O
cholesterol	S-chem
and	O
overweight	O
:	O
the	O
D.E.S.I.R	O
.	O
study	O
.	O

The	O
adenosine	B-geneY
triphosphate	I-geneY
-	I-geneY
binding	I-geneY
cassette	I-geneY
A1	E-geneY
(	O
ABCA1	S-geneY
)	O
gene	O
plays	O
a	O
key	O
role	O
in	O
reverse	O
cholesterol	S-chem
transport	O
.	O

Some	O
ABCA1	S-geneY
gene	O
polymorphisms	O
have	O
been	O
associated	O
with	O
high	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
-	O
cholesterol	S-chem
(	O
HDL	S-geneN
-	O
C	O
)	O
concentrations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
three	O
polymorphisms	O
,	O
C69T	S-geneN
,	O
G378C	S-geneN
,	O
and	O
G1051A	S-geneN
(	O
R219K	S-geneN
)	O
,	O
on	O
HDL	S-geneN
-	O
C	O
levels	O
and	O
their	O
interaction	O
with	O
BMI	O
in	O
more	O
than	O
5000	O
French	O
whites	O
from	O
the	O
D.E.S.I.R	O
.	O

(	O
Data	O
from	O
an	O
Epidemiological	O
Study	O
on	O
the	O
Insulin	S-geneY
Resistance	O
syndrome	O
)	O
cohort	O
study	O
.	O

The	O
T	O
allele	O
of	O
the	O
C69T	S-geneN
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
was	O
associated	O
with	O
higher	O
HDL	S-geneN
-	O
C	O
levels	O
in	O
normal	O
-	O
weight	O
men	O
(	O
BMI	O
<	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

The	O
C	O
allele	O
of	O
the	O
G378C	S-geneN
SNP	O
was	O
associated	O
with	O
lower	O
HDL	S-geneN
-	O
C	O
in	O
overweight	O
subjects	O
(	O
BMI	O
>	O
or	O
=	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

For	O
the	O
G1051A	S-geneN
SNP	O
,	O
in	O
the	O
normal	O
-	O
weight	O
group	O
,	O
the	O
minor	O
A	O
allele	O
was	O
significantly	O
associated	O
with	O
higher	O
HDL	S-geneN
-	O
C	O
levels	O
.	O

In	O
contrast	O
,	O
in	O
overweight	O
people	O
,	O
the	O
minor	O
allele	O
was	O
associated	O
with	O
lower	O
HDL	S-geneN
-	O
C	O
levels	O
.	O

After	O
accounting	O
for	O
multiple	O
testing	O
,	O
empiric	O
p	O
values	O
remained	O
significant	O
for	O
the	O
associations	O
between	O
G378C	S-geneN
SNP	O
and	O
HDL	S-geneN
-	O
C	O
in	O
the	O
overweight	O
group	O
and	O
between	O
G1051A	S-geneN
SNP	O
and	O
HDL	S-geneN
-	O
C	O
in	O
the	O
normal	O
-	O
weight	O
group	O
.	O

This	O
study	O
suggests	O
that	O
ABCA1	S-geneY
gene	O
polymorphisms	O
modulate	O
HDL	S-geneN
-	O
C	O
concentrations	O
,	O
in	O
interaction	O
with	O
BMI	O
,	O
and	O
,	O
thus	O
,	O
they	O
might	O
influence	O
cardiovascular	O
risk	O
in	O
the	O
general	O
population	O
.	O

The	O
role	O
of	O
de	O
novo	O
catecholamine	S-chem
synthesis	O
in	O
mediating	O
methylmercury	S-chem
-	O
induced	O
vesicular	O
dopamine	S-chem
release	O
from	O
rat	O
pheochromocytoma	O
(	O
PC12	O
)	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
methylmercury	S-chem
(	O
MeHg	S-chem
)	O
-	O
induced	O
dopamine	S-chem
(	O
DA	O
)	O
release	O
from	O
undifferentiated	O
pheochromocytoma	O
(	O
PC12	O
)	O
cells	O
and	O
to	O
examine	O
the	O
potential	O
role	O
for	O
DA	O
synthesis	O
in	O
this	O
process	O
.	O

MeHg	S-chem
caused	O
a	O
significant	O
increase	O
in	O
DA	O
release	O
that	O
was	O
both	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
.	O

DA	O
release	O
was	O
significantly	O
increased	O
by	O
2µM	O
MeHg	S-chem
at	O
60min	O
and	O
by	O
5µM	O
MeHg	S-chem
at	O
30min	O
;	O
1µM	O
MeHg	S-chem
was	O
without	O
effect	O
.	O

Because	O
DA	O
release	O
induced	O
by	O
5µM	O
MeHg	S-chem
was	O
associated	O
with	O
a	O
significant	O
percentage	O
of	O
cell	O
death	O
at	O
60	O
and	O
120min	O
,	O
2µM	O
MeHg	S-chem
was	O
chosen	O
for	O
further	O
characterization	O
of	O
release	O
mechanisms	O
.	O

MeHg	S-chem
-	O
induced	O
DA	O
release	O
was	O
attenuated	O
but	O
not	O
abolished	O
in	O
the	O
absence	O
of	O
extracellular	O
calcium	S-chem
,	O
whereas	O
the	O
vesicular	O
content	O
depleting	O
drug	O
reserpine	O
(	O
50nM	O
)	O
abolished	O
release	O
.	O

Thus	O
,	O
MeHg	S-chem
-	O
induced	O
DA	O
release	O
requires	O
vesicular	O
exocytosis	O
but	O
not	O
extracellular	O
calcium	S-chem
.	O

MeHg	S-chem
also	O
increased	O
intracellular	O
DA	O
and	O
the	O
rate	O
of	O
DA	O
storage	O
utilization	O
,	O
suggesting	O
a	O
role	O
for	O
DA	O
synthesis	O
in	O
MeHg	S-chem
-	O
induced	O
DA	O
release	O
.	O

The	O
tyrosine	B-geneY-C4-2
hydroxylase	E-geneY-C4-2
inhibitor	O
α	B-chem-C4-1
-	I-chem-C4-1
methyltyrosine	E-chem-C4-1
(	O
300µM	O
,	O
24h	O
)	O
completely	O
abolished	O
MeHg	S-chem
-	O
induced	O
DA	O
release	O
.	O

MeHg	S-chem
significantly	O
increased	O
DA	O
precursor	O
accumulation	O
in	O
cells	O
treated	O
with	O
3	B-chem
-	I-chem
hydroxybenzylhydrazine	E-chem
(	O
10µM	O
)	O
,	O
revealing	O
that	O
MeHg	S-chem-C3-1
increases	O
tyrosine	B-geneY-C3-2
hydroxylase	E-geneY-C3-2
activity	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
MeHg	S-chem
facilitates	O
DA	O
synthesis	O
,	O
increases	O
intracellular	O
DA	O
,	O
and	O
augments	O
vesicular	O
exocytosis	O
.	O

Abarelix	S-chem
and	O
other	O
gonadotrophin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
antagonists	O
in	O
prostate	O
cancer	O
.	O

Hormonal	O
therapy	O
is	O
the	O
main	O
recommended	O
treatment	O
for	O
locally	O
advanced	O
and	O
metastatic	O
prostate	O
cancer	O
.	O

Luteinizing	B-geneY-C5-2
hormone	I-geneY-C5-2
-	I-geneY-C5-2
releasing	I-geneY-C5-2
hormone	E-geneY-C5-2
(	O
LHRH	S-geneY-C5-2
)	O
agonists	O
,	O
such	O
as	O
buserelin	S-chem-MU-1
,	O
goserelin	S-chem-MU-1
,	O
leuprorelin	S-chem-MU-1
and	O
triptorelin	S-chem-MU-1
,	O
stimulate	O
the	O
pituitary	O
's	O
gonadotrophin	B-geneY-C3-2
-	I-geneY-C3-2
releasing	I-geneY-C3-2
hormone	I-geneY-C3-2
(	I-geneY-C3-2
GnRH	I-geneY-C3-2
)	I-geneY-C3-2
receptor	E-geneY-C3-2
,	O
ultimately	O
leading	O
to	O
its	O
de	O
-	O
sensitization	O
and	O
subsequent	O
reduction	O
of	O
LH	S-geneN-C4-2
and	O
testosterone	S-chem
levels	O
.	O

However	O
,	O
this	O
reduction	O
is	O
accompanied	O
by	O
a	O
well	O
described	O
increase	O
or	O
'	O
surge	O
'	O
in	O
LH	S-geneN
and	O
testosterone	S-chem
levels	O
,	O
necessitating	O
the	O
concomitant	O
administration	O
of	O
an	O
antiandrogen	O
to	O
combat	O
the	O
potential	O
effects	O
of	O
transient	O
acceleration	O
in	O
cancer	O
activity	O
.	O

Two	O
pure	O
GnRH	S-geneY-C6-2
antagonists	O
have	O
been	O
developed	O
,	O
abarelix	S-chem-C6-1
and	O
degarelix	S-chem-C6-1
,	O
that	O
are	O
devoid	O
of	O
any	O
agonist	O
effect	O
on	O
the	O
GnRH	B-geneY
receptor	E-geneY
and	O
consequently	O
do	O
not	O
result	O
in	O
testosterone	S-chem
flare	O
.	O

Abarelix	S-chem-C6-1
was	O
the	O
first	O
GnRH	S-geneY-C6-2
antagonist	O
to	O
be	O
developed	O
and	O
was	O
approved	O
by	O
the	O
USA	O
Food	O
and	O
Drug	O
Administration	O
in	O
2004	O
for	O
the	O
initiation	O
of	O
hormonal	O
castration	O
in	O
advanced	O
or	O
metastasizing	O
hormone	O
-	O
dependent	O
prostate	O
carcinoma	O
,	O
when	O
rapid	O
androgen	S-chem
suppression	O
is	O
necessary	O
.	O

Clinical	O
data	O
on	O
both	O
abarelix	S-chem
and	O
degarelix	S-chem
show	O
that	O
they	O
can	O
produce	O
rapid	O
and	O
sustained	O
decreases	O
in	O
testosterone	S-chem
to	O
castrate	O
levels	O
without	O
the	O
need	O
for	O
co	O
-	O
administration	O
of	O
an	O
antiandrogen	O
,	O
and	O
with	O
a	O
very	O
low	O
complication	O
rate	O
in	O
the	O
short	O
term	O
.	O

In	O
vivo	O
HIF	S-geneN
-	O
mediated	O
reductive	O
carboxylation	O
is	O
regulated	O
by	O
citrate	S-chem
levels	O
and	O
sensitizes	O
VHL	S-geneY
-	O
deficient	O
cells	O
to	O
glutamine	S-chem
deprivation	O
.	O

Hypoxic	O
and	O
VHL	S-geneY
-	O
deficient	O
cells	O
use	O
glutamine	S-chem
to	O
generate	O
citrate	S-chem
and	O
lipids	O
through	O
reductive	O
carboxylation	O
(	O
RC	O
)	O
of	O
α	B-chem
-	I-chem
ketoglutarate	E-chem
.	O

To	O
gain	O
insights	O
into	O
the	O
role	O
of	O
HIF	S-geneN
and	O
the	O
molecular	O
mechanisms	O
underlying	O
RC	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
disease	O
-	O
associated	O
VHL	S-geneY
mutants	O
and	O
showed	O
that	O
HIF	S-geneN
expression	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
induction	O
of	O
RC	O
in	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
cells	O
.	O

HIF	S-geneN
expression	O
drastically	O
reduced	O
intracellular	O
citrate	S-chem
levels	O
.	O

Feeding	O
VHL	S-geneY
-	O
deficient	O
RCC	O
cells	O
with	O
acetate	S-chem
or	O
citrate	S-chem
or	O
knocking	O
down	O
PDK	B-geneY
-	I-geneY
1	E-geneY
and	O
ACLY	S-geneY
restored	O
citrate	S-chem
levels	O
and	O
suppressed	O
RC	O
.	O

These	O
data	O
suggest	O
that	O
HIF	S-geneN
-	O
induced	O
low	O
intracellular	O
citrate	S-chem
levels	O
promote	O
the	O
reductive	O
flux	O
by	O
mass	O
action	O
to	O
maintain	O
lipogenesis	O
.	O

Using	O
[	B-chem
(	I-chem
1	I-chem
-	I-chem
13	I-chem
)	I-chem
C	I-chem
]	I-chem
glutamine	E-chem
,	O
we	O
demonstrated	O
in	O
vivo	O
RC	O
activity	O
in	O
VHL	S-geneY
-	O
deficient	O
tumors	O
growing	O
as	O
xenografts	O
in	O
mice	O
.	O

Lastly	O
,	O
HIF	S-geneN
rendered	O
VHL	S-geneY
-	O
deficient	O
cells	O
sensitive	O
to	O
glutamine	S-chem
deprivation	O
in	O
vitro	O
,	O
and	O
systemic	O
administration	O
of	O
glutaminase	S-geneN
inhibitors	O
suppressed	O
the	O
growth	O
of	O
RCC	O
cells	O
as	O
mice	O
xenografts	O
.	O

Dynamics	O
of	O
NO	S-chem
rebinding	O
to	O
the	O
heme	B-geneN
domain	I-geneN
of	I-geneN
NO	I-geneN
synthase	I-geneN
-	I-geneN
like	I-geneN
proteins	E-geneN
from	O
bacterial	O
pathogens	O
.	O

Some	O
Gram	O
-	O
positive	O
bacterial	O
pathogens	O
harbor	O
a	O
gene	O
that	O
encodes	O
a	O
protein	O
(	O
HNS	S-geneN
,	O
Heme	B-geneN
domain	I-geneN
of	I-geneN
NO	I-geneN
Synthase	I-geneN
-	I-geneN
like	I-geneN
proteins	E-geneN
)	O
with	O
striking	O
sequence	O
identity	O
to	O
the	O
oxygenase	B-geneN
domain	E-geneN
of	O
mammalian	B-geneN
NO	I-geneN
synthases	E-geneN
(	O
NOS	S-geneN
)	O
.	O

However	O
,	O
they	O
lack	O
the	O
N	B-geneN
-	I-geneN
terminal	I-geneN
and	I-geneN
the	I-geneN
Zn	I-geneN
-	I-geneN
cysteine	I-geneN
motif	E-geneN
participating	O
to	O
the	O
stability	O
of	O
an	O
active	O
dimer	O
in	O
the	O
mammalian	O
isoforms	O
.	O

The	O
unique	O
properties	O
of	O
HNS	S-geneN
make	O
it	O
an	O
excellent	O
model	O
system	O
for	O
probing	O
how	O
the	O
heme	O
environment	O
tunes	O
NO	S-chem
dynamics	O
and	O
for	O
comparing	O
it	O
to	O
the	O
endothelial	B-geneN
NO	I-geneN
synthase	I-geneN
heme	I-geneN
domain	E-geneN
(	O
eNOS	B-geneN
(	I-geneN
HD	I-geneN
)	E-geneN
)	O
using	O
ultrafast	O
transient	O
spectroscopy	O
.	O

NO	S-chem
rebinding	O
in	O
HNS	S-geneN
from	O
Staphylococcus	O
aureus	O
(	O
SA	B-geneN
-	I-geneN
HNS	E-geneN
)	O
is	O
faster	O
than	O
that	O
measured	O
for	O
either	O
Bacillus	O
anthracis	O
(	O
BA	B-geneN
-	I-geneN
HNS	E-geneN
)	O
or	O
for	O
eNOS	B-geneN
(	I-geneN
HD	I-geneN
)	E-geneN
in	O
both	O
oxidized	O
and	O
reduced	O
forms	O
in	O
the	O
presence	O
of	O
arginine	S-chem
.	O

To	O
test	O
whether	O
these	O
distinct	O
rates	O
arise	O
from	O
different	O
energy	O
barriers	O
for	O
NO	S-chem
recombination	O
,	O
we	O
measured	O
rebinding	O
kinetics	O
at	O
several	O
temperatures	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
different	O
barriers	O
for	O
NO	S-chem
recombination	O
in	O
SA	B-geneN
-	I-geneN
HNS	E-geneN
and	O
BA	B-geneN
-	I-geneN
HNS	E-geneN
and	O
the	O
presence	O
of	O
a	O
second	O
NO	S-chem
-	O
binding	O
site	O
.	O

The	O
hypothesis	O
that	O
an	O
additional	O
NO	S-chem
-	O
binding	O
cavity	O
is	O
present	O
in	O
BA	B-geneN
-	I-geneN
HNS	E-geneN
is	O
also	O
consistent	O
with	O
the	O
effect	O
of	O
the	O
NO	S-chem
concentration	O
on	O
its	O
rebinding	O
.	O

The	O
lack	O
of	O
the	O
effect	O
of	O
NO	S-chem
concentration	O
on	O
the	O
geminate	O
rebinding	O
in	O
SA	B-geneN
-	I-geneN
HNS	E-geneN
could	O
be	O
due	O
to	O
an	O
isolated	O
second	O
site	O
.	O

We	O
confirm	O
the	O
existence	O
of	O
a	O
second	O
NO	S-chem
site	O
in	O
the	O
oxygenase	B-geneN
domain	E-geneN
of	O
the	O
reduced	B-geneY
eNOS	E-geneY
as	O
previously	O
hypothesized	O
[	O
A	O
.	O

Slama	O
-	O
Schwok	O
,	O
M	O
.	O

Negrerie	O
,	O
V	O
.	O

Berka	O
,	O
J.C	O
.	O

Lambry	O
,	O
A.L	O
.	O

Tsai	O
,	O
M.H	O
.	O

Vos	O
,	O
J.L	O
.	O

Martin	O
,	O
Nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
traffic	O
in	O
endothelial	B-geneY
NO	I-geneY
synthase	E-geneY
.	O

Evidence	O
for	O
a	O
new	O
NO	S-chem
binding	O
site	O
dependent	O
on	O
tetrahydrobiopterin	S-chem
?	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

277	O
(	O
2002	O
)	O
7581	O
-	O
7586	O
]	O
.	O

This	O
site	O
requires	O
the	O
presence	O
of	O
arginine	S-chem
and	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
;	O
and	O
we	O
propose	O
that	O
NO	S-chem
dynamic	O
and	O
escape	O
from	O
eNOS	S-geneY
is	O
regulated	O
by	O
the	O
active	O
site	O
H	S-chem
-	O
bonding	O
network	O
connecting	O
between	O
the	O
heme	O
,	O
the	O
substrate	O
,	O
and	O
cofactor	O
.	O

Evidence	O
that	O
the	O
granulocyte	B-geneY
colony	I-geneY
-	I-geneY
stimulating	I-geneY
factor	I-geneY
(	I-geneY
G	I-geneY
-	I-geneY
CSF	I-geneY
)	I-geneY
receptor	E-geneY
plays	O
a	O
role	O
in	O
the	O
pharmacokinetics	O
of	O
G	B-geneY
-	I-geneY
CSF	E-geneY
and	O
PegG	O
-	O
CSF	O
using	O
a	O
G	B-geneY
-	I-geneY
CSF	I-geneY
-	I-geneY
R	E-geneY
KO	O
model	O
.	O

The	O
covalent	O
attachment	O
of	O
polyethylene	O
glycol	O
to	O
filgrastim	O
results	O
in	O
a	O
new	O
molecule	O
pegfilgrastim	O
,	O
which	O
has	O
a	O
significantly	O
longer	O
half	O
-	O
life	O
than	O
filgrastim	O
.	O

It	O
is	O
likely	O
that	O
the	O
clearance	O
of	O
both	O
filgrastim	O
and	O
pegfilgrastim	O
involves	O
granulocyte	B-geneY
colony	I-geneY
simulating	I-geneY
factor	I-geneY
(	I-geneY
G	I-geneY
-	I-geneY
CSF	I-geneY
)	I-geneY
receptor	E-geneY
binding	O
,	O
but	O
the	O
pharmacokinetics	O
of	O
these	O
drugs	O
have	O
not	O
been	O
compared	O
in	O
mice	O
with	O
and	O
without	O
a	O
functional	O
G	B-geneY
-	I-geneY
CSF	I-geneY
receptor	E-geneY
.	O

We	O
sought	O
to	O
clarify	O
the	O
role	O
of	O
receptor	O
-	O
mediated	O
clearance	O
of	O
filgrastim	O
and	O
pegfilgrastim	O
using	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
or	O
mice	O
with	O
a	O
non	O
-	O
functional	O
G	B-geneY
-	I-geneY
CSF	I-geneY
-	I-geneY
R	E-geneY
(	O
knockout	O
,	O
KO	O
)	O
.	O

We	O
administered	O
single	O
doses	O
of	O
filgrastim	O
or	O
pegfilgrastim	O
(	O
10	O
or	O
100	O
microg	O
kg	O
(	O
-	O
1	O
)	O
)	O
intravenously	O
to	O
WT	O
and	O
KO	O
mice	O
.	O

Plasma	O
levels	O
of	O
protein	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
at	O
preset	O
time	O
points	O
,	O
and	O
AUC	O
,	O
MRT	O
,	O
CL	O
,	O
V	O
(	O
d	O
)	O
,	O
and	O
T	O
(	O
1	O
/	O
2	O
)	O
were	O
calculated	O
.	O

When	O
compared	O
with	O
WT	O
mice	O
,	O
the	O
G	B-geneY
-	I-geneY
CSF	I-geneY
-	I-geneY
R	E-geneY
KO	O
mice	O
had	O
significantly	O
greater	O
AUC	O
,	O
longer	O
MRT	O
,	O
longer	O
T	O
(	O
1	O
/	O
2	O
)	O
,	O
and	O
lower	O
clearance	O
.	O

This	O
was	O
the	O
case	O
whether	O
animals	O
received	O
10	O
or	O
100	O
microg	O
kg	O
(	O
-	O
1	O
)	O
and	O
whether	O
they	O
received	O
filgrastim	O
or	O
pegfilgrastim	O
.	O

The	O
volume	O
of	O
protein	O
distribution	O
was	O
identical	O
among	O
WT	O
and	O
KO	O
mice	O
.	O

However	O
,	O
the	O
V	O
(	O
d	O
)	O
was	O
larger	O
after	O
pegfilgrastim	O
dosing	O
than	O
after	O
filgrastim	O
dosing	O
.	O

In	O
both	O
WT	O
and	O
KO	O
mice	O
,	O
increasing	O
the	O
dose	O
of	O
figrastim	O
or	O
pegfilgrastim	O
resulted	O
in	O
a	O
proportional	O
increase	O
in	O
the	O
AUC	O
.	O

A	O
functional	O
G	B-geneY
-	I-geneY
CSF	I-geneY
-	I-geneY
R	E-geneY
is	O
an	O
important	O
mechanism	O
in	O
the	O
plasma	O
clearance	O
of	O
both	O
filgrastim	O
and	O
pegfilgrastim	O
.	O

Novel	O
assays	O
for	O
detection	O
of	O
urinary	O
KIM	B-geneY
-	I-geneY
1	E-geneY
in	O
mouse	O
models	O
of	O
kidney	O
injury	O
.	O

Kidney	B-geneY
injury	I-geneY
molecule	I-geneY
-	I-geneY
1	E-geneY
(	O
KIM	B-geneY
-	I-geneY
1	E-geneY
)	O
has	O
been	O
qualified	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicines	O
Agency	O
as	O
a	O
urinary	O
biomarker	O
to	O
monitor	O
preclinical	O
nephrotoxicity	O
in	O
rats	O
and	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
for	O
the	O
translation	O
of	O
potentially	O
nephrotoxic	O
drugs	O
into	O
first	O
-	O
in	O
human	O
studies	O
.	O

Although	O
mouse	O
models	O
are	O
widely	O
employed	O
in	O
preclinical	O
studies	O
,	O
few	O
urinary	O
biomarker	O
studies	O
have	O
been	O
performed	O
in	O
mice	O
due	O
to	O
limited	O
urine	O
availability	O
and	O
lack	O
of	O
sensitive	O
assays	O
.	O

Here	O
,	O
we	O
report	O
the	O
development	O
and	O
validation	O
of	O
two	O
different	O
assays	O
for	O
quantitative	O
assessment	O
of	O
mouse	B-geneY
urinary	I-geneY
KIM	I-geneY
-	I-geneY
1	E-geneY
(	O
uKIM	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
compare	O
the	O
sensitivity	O
of	O
KIM	B-geneY
-	I-geneY
1	E-geneY
relative	O
to	O
other	O
standard	O
markers	O
in	O
ischemia	O
reperfusion	O
and	O
aristolochic	B-chem
acid	E-chem
(	O
AA	O
)	O
-	O
induced	O
kidney	O
injury	O
in	O
mice	O
.	O

A	O
sensitive	O
,	O
reproducible	O
,	O
and	O
quantitative	O
microbead	O
-	O
based	O
KIM	B-geneY
-	I-geneY
1	E-geneY
ELISA	O
was	O
established	O
,	O
which	O
requires	O
only	O
10	O
μl	O
urine	O
for	O
triplicate	O
determination	O
with	O
an	O
assay	O
range	O
of	O
12.21	O
pg	O
/	O
ml	O
to	O
50	O
ng	O
/	O
ml	O
.	O

The	O
second	O
assay	O
is	O
a	O
laminar	O
flow	O
dipstick	O
assay	O
,	O
which	O
has	O
an	O
assay	O
range	O
of	O
195	O
pg	O
/	O
ml	O
to	O
50	O
ng	O
/	O
ml	O
and	O
provides	O
quantitative	O
assessment	O
of	O
KIM	B-geneY
-	I-geneY
1	E-geneY
in	O
15	O
min	O
.	O
uKIM	B-geneY
-	I-geneY
1	E-geneY
levels	O
increased	O
with	O
increasing	O
time	O
of	O
ischemia	O
or	O
time	O
after	O
AA	O
administration	O
.	O

After	O
only	O
10	O
-	O
min	O
ischemia	O
followed	O
by	O
24	O
-	O
h	O
reperfusion	O
,	O
uKIM	B-geneY
-	I-geneY
1	E-geneY
was	O
significantly	O
elevated	O
by	O
13	O
-	O
fold	O
,	O
whereas	O
serum	O
creatinine	S-chem
(	O
sCr	O
)	O
,	O
blood	O
urea	S-chem
nitrogen	S-chem
,	O
N	B-geneY
-	I-geneY
acetyl	I-geneY
-	I-geneY
β	I-geneY
-	I-geneY
glucosaminidase	E-geneY
(	O
NAG	S-geneY
)	O
,	O
and	O
proteinuria	O
levels	O
did	O
not	O
change	O
.	O

After	O
AA	O
administration	O
,	O
uKIM	B-geneY
-	I-geneY
1	E-geneY
levels	O
were	O
significantly	O
upregulated	O
by	O
greater	O
than	O
threefold	O
within	O
12	O
h	O
,	O
whereas	O
sCr	O
and	O
NAG	S-geneY
levels	O
were	O
unchanged	O
.	O

Mouse	B-geneY
KIM	I-geneY
-	I-geneY
1	E-geneY
was	O
stable	O
for	O
multiple	O
freeze	O
-	O
thaw	O
cycles	O
,	O
for	O
up	O
to	O
5	O
days	O
at	O
room	O
temperature	O
and	O
up	O
to	O
at	O
least	O
an	O
year	O
when	O
stored	O
at	O
-	O
80°C	O
.	O

Terbinafine	S-chem-C4-1
:	O
mode	O
of	O
action	O
and	O
properties	O
of	O
the	O
squalene	B-geneY-C4-2
epoxidase	E-geneY-C4-2
inhibition	O
.	O

Terbinafine	S-chem-C4-1
(	O
Lamisil	S-chem-C4-1
)	O
has	O
primarily	O
fungicidal	O
action	O
against	O
many	O
fungi	O
as	O
a	O
result	O
of	O
its	O
specific	O
mechanism	O
of	O
squalene	B-geneY-C4-2
epoxidase	E-geneY-C4-2
inhibition	O
.	O

Treated	O
fungi	O
accumulate	O
squalene	S-chem
while	O
becoming	O
deficient	O
in	O
ergosterol	S-chem
,	O
an	O
essential	O
component	O
of	O
fungal	O
cell	O
membranes	O
.	O

The	O
cidal	O
action	O
is	O
closely	O
associated	O
with	O
the	O
development	O
of	O
high	O
intracellular	O
squalene	S-chem
concentrations	O
,	O
which	O
are	O
believed	O
to	O
interfere	O
with	O
fungal	O
membrane	O
function	O
and	O
cell	O
wall	O
synthesis	O
.	O

In	O
the	O
case	O
of	O
Candida	O
albicans	O
,	O
growth	O
inhibition	O
with	O
terbinafine	S-chem
appears	O
to	O
result	O
from	O
the	O
ergosterol	S-chem
deficiency	O
.	O

The	O
filamentous	O
form	O
of	O
this	O
fungus	O
is	O
more	O
susceptible	O
than	O
the	O
yeast	O
form	O
.	O

Measurement	O
of	O
ergosterol	S-chem
biosynthesis	O
by	O
incorporation	O
of	O
radiolabelled	O
precursors	O
indicates	O
a	O
correlation	O
between	O
inhibition	O
of	O
growth	O
and	O
ergosterol	S-chem
biosynthesis	O
in	O
a	O
range	O
of	O
pathogenic	O
fungi	O
.	O

Terbinafine	S-chem-C4-1
is	O
a	O
potent	O
non	O
-	O
competitive	O
inhibitor	O
of	O
squalene	B-geneY-C4-2
epoxidase	E-geneY-C4-2
from	O
Candida	O
(	O
Ki	O
=	O
30	O
nM	O
)	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
rat	B-geneY-C4-2
liver	I-geneY-C4-2
squalene	I-geneY-C4-2
epoxidase	E-geneY-C4-2
only	O
occurs	O
at	O
higher	O
drug	O
concentrations	O
(	O
Ki	O
=	O
77	O
microM	O
)	O
,	O
and	O
is	O
competitive	O
with	O
squalene	S-chem-C4-1
.	O

Thus	O
,	O
terbinafine	S-chem
has	O
no	O
effect	O
on	O
cholesterol	S-chem
biosynthesis	O
in	O
vivo	O
.	O

Squalene	B-geneY
epoxidase	E-geneY
is	O
not	O
an	O
enzyme	O
of	O
the	O
cytochrome	B-geneN
P	I-geneN
-	I-geneN
450	E-geneN
type	O
,	O
thereby	O
avoiding	O
potential	O
inhibition	O
of	O
this	O
class	O
of	O
enzymes	O
.	O

Polyamine	S-chem
depletion	O
delays	O
apoptosis	O
of	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
polyamines	S-chem
spermidine	S-chem
,	O
spermine	S-chem
,	O
and	O
their	O
precursor	O
putrescine	S-chem
are	O
essential	O
for	O
cell	O
growth	O
and	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O

Recent	O
studies	O
suggest	O
that	O
excessive	O
accumulation	O
of	O
polyamines	S-chem
favors	O
either	O
malignant	O
transformation	O
or	O
apoptosis	O
,	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
stimulus	O
.	O

This	O
study	O
examines	O
the	O
involvement	O
of	O
polyamines	S-chem
in	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
DNA	B-geneY
topoisomerase	I-geneY
I	E-geneY
inhibitor	O
,	O
camptothecin	O
.	O

In	O
IEC	O
-	O
6	O
cells	O
,	O
camptothecin	S-chem
induced	O
apoptosis	O
within	O
6	O
h	O
,	O
accompanied	O
by	O
detachment	O
of	O
cells	O
.	O

Detached	O
cells	O
showed	O
DNA	O
laddering	O
and	O
caspase	B-geneY
3	E-geneY
induction	O
,	O
characteristic	O
features	O
of	O
apoptosis	O
.	O

Depletion	O
of	O
putrescine	S-chem-C9-1
,	O
spermidine	S-chem-C9-1
,	O
and	O
spermine	S-chem-C9-1
by	O
DL	B-chem-C4-1
-	I-chem-C4-1
alpha	I-chem-C4-1
-	I-chem-C4-1
difluoromethylornithine	E-chem-C4-1
(	O
DFMO	S-chem-C4-1
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
ornithine	B-geneY-MU-2
decarboxylase	E-geneY-MU-2
(	O
ODC	S-geneY-MU-2
)	O
that	O
is	O
the	O
first	O
rate	O
-	O
limiting	O
enzyme	O
for	O
polyamine	S-chem
biosynthesis	O
,	O
decreased	O
the	O
apoptotic	O
index	O
.	O

Delayed	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
caspase	B-geneY
3	E-geneY
activity	O
in	O
polyamine	S-chem
-	O
depleted	O
cells	O
.	O

Addition	O
of	O
putrescine	S-chem-C3-1
restored	O
the	O
induction	O
of	O
apoptosis	O
as	O
indicated	O
by	O
an	O
increase	O
in	O
the	O
number	O
of	O
detached	O
cells	O
and	O
caspase	B-geneY-C3-2
3	E-geneY-C3-2
activity	O
.	O

Polyamine	S-chem
depletion	O
did	O
not	O
change	O
the	O
level	O
of	O
caspase	B-geneY
3	E-geneY
protein	O
.	O

Inhibition	O
of	O
S	B-geneY-MU-2
-	I-geneY-MU-2
adenosylmethionine	I-geneY-MU-2
decarboxylase	E-geneY-MU-2
by	O
a	O
specific	O
inhibitor	O
[	O
diethylglyoxal	B-chem-C4-1
bis	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
guanylhydrazone	I-chem-C4-1
)	E-chem-C4-1
;	O
DEGBG	S-chem-C4-1
]	O
led	O
to	O
depletion	O
of	O
spermidine	S-chem-C9-1
and	O
spermine	S-chem-C9-1
with	O
a	O
significant	O
accumulation	O
of	O
putrescine	S-chem
and	O
induction	O
of	O
ODC	S-geneY
.	O

The	O
DEGBG	S-chem
-	O
treated	O
cells	O
showed	O
an	O
increase	O
in	O
apoptosis	O
,	O
suggesting	O
the	O
importance	O
of	O
putrescine	S-chem
in	O
the	O
apoptotic	O
process	O
.	O

Addition	O
of	O
putrescine	S-chem
to	O
DFMO	S-chem
-	O
treated	O
cell	O
extracts	O
did	O
not	O
increase	O
caspase	B-geneY
3	E-geneY
activity	O
.	O

The	O
above	O
results	O
indicate	O
that	O
polyamine	S-chem
depletion	O
delays	O
the	O
onset	O
of	O
apoptosis	O
in	O
IEC	O
-	O
6	O
cells	O
and	O
confers	O
protection	O
against	O
DNA	O
damaging	O
agents	O
,	O
suggesting	O
that	O
polyamines	S-chem-C3-1
might	O
be	O
involved	O
in	O
the	O
caspase	S-geneN-C3-2
activating	O
signal	O
cascade	O
.	O

Neuroprotective	O
Effects	O
of	O
Cilostazol	S-chem
on	O
Retinal	O
Ganglion	O
Cell	O
damage	O
in	O
Diabetic	O
Rats	O
.	O

Neurodegeneration	O
is	O
an	O
important	O
component	O
of	O
diabetic	O
retinopathy	O
with	O
increasing	O
evidence	O
that	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
death	O
occurs	O
early	O
in	O
diabetes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
cilostazol	S-chem
,	O
which	O
has	O
been	O
widely	O
used	O
to	O
manage	O
diabetic	O
complications	O
,	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
diabetic	O
retina	O
.	O

Four	O
-	O
week	O
-	O
old	O
Otsuka	O
Long	O
-	O
Evans	O
Tokushima	O
Fatty	O
(	O
OLETF	O
)	O
rats	O
and	O
Long	O
-	O
Evans	O
Tokushima	O
Otsuka	O
(	O
LETO	O
)	O
rats	O
as	O
matched	O
nondiabetic	O
controls	O
were	O
treated	O
with	O
daily	O
oral	O
cilostazol	S-chem
at	O
30mg	O
/	O
kg	O
or	O
0.9	O
%	O
saline	O
solution	O
.	O

In	O
OLETF	O
rats	O
at	O
the	O
age	O
of	O
40	O
weeks	O
,	O
glial	B-geneY
fibrillary	I-geneY
acidic	I-geneY
protein	E-geneY
(	O
GFAP	S-geneY
)	O
immunofluorescence	O
staining	O
was	O
upregulated	O
in	O
vertical	O
sections	O
and	O
showed	O
a	O
more	O
ramified	O
pattern	O
in	O
whole	O
-	O
mount	O
retinas	O
compared	O
with	O
that	O
in	O
LETO	O
rats	O
.	O

Vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
expression	O
was	O
limited	O
to	O
the	O
ganglion	O
cell	O
layer	O
in	O
LETO	O
rats	O
,	O
but	O
extended	O
into	O
the	O
outer	O
plexiform	O
layer	O
in	O
OLETF	O
rats	O
.	O

Immunofluorescence	O
staining	O
and	O
western	O
blotting	O
demonstrated	O
that	O
cilostazol	S-chem-C4-1
treatment	O
reduced	O
GFAP	S-geneY-C4-2
and	O
VEGF	S-geneY-C4-2
expression	O
in	O
the	O
retinas	O
of	O
OLETF	O
rats	O
.	O

Terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	S-chem
nick	O
-	O
end	O
labeling	O
(	O
TUNLEL	O
)	O
staining	O
revealed	O
an	O
increase	O
in	O
the	O
RGC	O
layer	O
in	O
OLETF	O
compared	O
with	O
LETO	O
rats	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
cilostazol	S-chem
treatment	O
reduced	O
the	O
number	O
of	O
TUNEL	O
-	O
positive	O
cells	O
in	O
OLETF	O
rats	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Relieving	O
retinal	O
ischemia	O
by	O
systemic	O
cilostazol	S-chem
treatment	O
had	O
a	O
noticeable	O
protective	O
effect	O
on	O
RGCs	O
in	O
diabetic	O
rats	O
.	O

Cilostazol	S-chem
treatment	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
diabetic	O
retinal	O
vascular	O
dysfunction	O
and	O
neuronal	O
degeneration	O
.	O

Suppression	O
of	O
Src	S-geneY-C4-2
/	O
ERK	S-geneN-C4-2
and	O
GSK	B-geneN-C4-2
-	I-geneN-C4-2
3	E-geneN-C4-2
/	O
β	B-geneY-C4-2
-	I-geneY-C4-2
catenin	E-geneY-C4-2
signaling	O
by	O
pinosylvin	S-chem-C4-1
inhibits	O
the	O
growth	O
of	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Pinosylvin	S-chem
,	O
a	O
naturally	O
occurring	O
trans	B-chem
-	I-chem
stilbenoid	E-chem
mainly	O
found	O
in	O
Pinus	O
species	O
,	O
has	O
exhibited	O
a	O
potential	O
cancer	O
chemopreventive	O
activity	O
.	O

However	O
,	O
the	O
growth	O
inhibitory	O
activity	O
against	O
cancer	O
cells	O
and	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
the	O
anti	O
-	O
proliferative	O
activity	O
of	O
pinosylvin	S-chem
was	O
investigated	O
in	O
human	O
colorectal	O
HCT	O
116	O
cancer	O
cells	O
.	O

Pinosylvin	S-chem-MU-1
inhibited	O
the	O
proliferation	O
of	O
HCT	O
116	O
cells	O
by	O
arresting	O
transition	O
of	O
cell	O
cycle	O
from	O
G1	O
to	O
S	O
phase	O
along	O
with	O
the	O
downregulation	O
of	O
cyclin	B-geneY-C4-2
D1	E-geneY-C4-2
,	O
cyclin	B-geneY-C4-2
E	E-geneY-C4-2
,	O
cyclin	B-geneY-C4-2
A	E-geneY-C4-2
,	O
cyclin	B-geneY-C4-2
dependent	I-geneY-C4-2
kinase	I-geneY-C4-2
2	E-geneY-C4-2
(	O
CDK2	S-geneY-C4-2
)	O
,	O
CDK4	S-geneY-C4-2
,	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Myc	E-geneY-C4-2
,	O
and	O
retinoblastoma	B-geneY-C4-2
protein	E-geneY-C4-2
(	O
pRb	S-geneY-C4-2
)	O
,	O
and	O
the	O
upregulation	O
of	O
p21	S-geneY-C3-2
(	O
WAF1	S-geneY-C3-2
/	O
CIP1	S-geneY-C3-2
)	O
and	O
p53	S-geneY-C3-2
.	O

Pinosylvin	S-chem-C4-1
was	O
also	O
found	O
to	O
attenuate	O
the	O
activation	O
of	O
proteins	O
involved	O
in	O
focal	O
adhesion	I-geneY-C4-2
kinase	E-geneY-C4-2
(	O
FAK	S-geneY-C4-2
)	O
/	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Src	E-geneY-C4-2
/	O
extracellular	B-geneN-C4-2
signal	I-geneN-C4-2
-	I-geneN-C4-2
regulated	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
ERK	S-geneN-C4-2
)	O
signaling	O
,	O
and	O
phosphoinositide	B-geneN-C4-2
3	I-geneN-C4-2
-	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
PI3K	S-geneN-C4-2
)	O
/	O
Akt	S-geneN-C4-2
/	O
glycogen	B-geneY-C4-2
synthase	I-geneY-C4-2
kinase	I-geneY-C4-2
3β	E-geneY-C4-2
(	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
)	O
signaling	O
pathway	O
.	O

Subsequently	O
,	O
pinosylvin	S-chem-C4-1
suppressed	O
the	O
nuclear	O
translocation	O
of	O
β	B-geneY-C4-2
-	I-geneY-C4-2
catenin	E-geneY-C4-2
,	O
one	O
of	O
downstream	O
molecules	O
of	O
PI3K	S-geneN-C4-2
/	O
Akt	S-geneN-C4-2
/	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
signaling	O
,	O
and	O
these	O
events	O
led	O
to	O
the	O
sequential	O
downregulation	O
of	O
β	B-geneY-C4-2
-	I-geneY-C4-2
catenin	E-geneY-C4-2
-	O
mediated	O
transcription	O
of	O
target	O
genes	O
including	O
BMP4	S-geneY-C4-2
,	O
ID2	S-geneY-C4-2
,	O
survivin	S-geneY-C4-2
,	O
cyclin	B-geneY-C4-2
D1	E-geneY-C4-2
,	O
MMP7	S-geneY-C4-2
,	O
and	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Myc	E-geneY-C4-2
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
anti	O
-	O
proliferative	O
activity	O
of	O
pinosylvin	S-chem
might	O
be	O
associated	O
with	O
the	O
cell	O
cycle	O
arrest	O
and	O
downregulation	O
of	O
cell	O
proliferation	O
regulating	O
signaling	O
pathways	O
in	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Effects	O
of	O
fisetin	S-chem
supplementation	O
on	O
hepatic	O
lipogenesis	O
and	O
glucose	S-chem
metabolism	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
fed	O
on	O
a	O
high	O
fat	O
diet	O
.	O

The	O
modulatory	O
effects	O
of	O
daily	O
fisetin	S-chem
supplementation	O
for	O
8weeks	O
on	O
genes	O
involved	O
in	O
hepatic	O
lipogenesis	O
and	O
gluconeogenesis	O
and	O
hyperglycemia	O
in	O
rats	O
fed	O
a	O
high	O
fat	O
(	O
HF	O
)	O
diet	O
were	O
evaluated	O
.	O

Elevated	O
levels	O
of	O
triglyceride	S-chem
(	O
TG	O
)	O
,	O
along	O
with	O
hepatic	O
TG	O
content	O
and	O
glucose	S-chem
concentrations	O
in	O
a	O
high	O
fat	O
diet	O
group	O
were	O
found	O
to	O
be	O
reduced	O
by	O
fisetin	S-chem
supplementation	O
.	O

The	O
high	O
fat	O
diet	O
significantly	O
increased	O
hepatic	O
mRNA	O
expressions	O
of	O
PPARγ	S-geneY-C4-2
,	O
SREBP1C	S-geneY-C4-2
and	O
SCD	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
genes	O
in	O
comparison	O
to	O
the	O
control	O
diet	O
,	O
which	O
was	O
subsequently	O
reversed	O
by	O
supplementation	O
with	O
fisetin	S-chem-C4-1
.	O

In	O
addition	O
,	O
fisetin	S-chem-C4-1
supplementation	O
significantly	O
reduced	O
hepatic	O
mRNA	O
abundance	O
of	O
FAS	S-geneY-C4-2
,	O
ATPCL	S-geneY-C4-2
and	O
G6Pase	S-geneY-C4-2
compared	O
to	O
the	O
control	O
group	O
.	O

Finally	O
,	O
epididymal	O
mRNA	O
abundance	O
of	O
GLUT4	S-geneY-C3-2
was	O
significantly	O
increased	O
by	O
fisetin	S-chem-C3-1
supplementation	O
,	O
compared	O
to	O
levels	O
in	O
the	O
control	O
and	O
HF	O
groups	O
.	O

Enhancement	O
of	O
GLUT4	S-geneY-C3-2
expression	O
by	O
fisetin	S-chem-C3-1
was	O
further	O
confirmed	O
in	O
differentiated	O
3T3	O
-	O
L1	O
adipocytes	O
.	O

Fisetin	S-chem
supplementation	O
decreases	O
cardiovascular	O
risks	O
by	O
ameliorating	O
hepatic	O
steatosis	O
and	O
lowering	O
circulating	O
glucose	S-chem
concentrations	O
.	O

Molecular	O
determinants	O
for	O
the	O
selective	O
inhibition	O
of	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
by	O
lumiracoxib	S-chem-C4-1
.	O

Lumiracoxib	S-chem-C4-1
is	O
the	O
first	O
example	O
of	O
a	O
marketed	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
of	O
the	O
arylacetic	B-chem-C4-1
acid	E-chem-C4-1
class	O
,	O
and	O
it	O
is	O
reported	O
to	O
be	O
the	O
most	O
selective	O
COXIB	O
in	O
vivo	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
of	O
its	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
has	O
not	O
been	O
completely	O
defined	O
.	O

Using	O
standard	O
assays	O
,	O
lumiracoxib	S-chem-C4-1
was	O
found	O
to	O
be	O
a	O
poor	O
inhibitor	O
of	O
purified	O
ovine	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
and	O
a	O
relatively	O
weak	O
inhibitor	O
of	O
purified	O
human	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
.	O

The	O
extent	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
plateaued	O
at	O
around	O
50	O
%	O
and	O
suggested	O
that	O
the	O
inhibitor	O
may	O
be	O
reversibly	O
bound	O
to	O
the	O
enzyme	O
.	O

Kinetic	O
studies	O
with	O
lumiracoxib	S-chem-C4-1
demonstrated	O
that	O
it	O
was	O
a	O
time	O
-	O
dependent	O
and	O
slowly	O
reversible	O
inhibitor	O
of	O
human	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
that	O
exhibited	O
at	O
least	O
two	O
binding	O
steps	O
during	O
inhibition	O
.	O

Derivatives	O
of	O
lumiracoxib	S-chem
were	O
synthesized	O
with	O
or	O
without	O
the	O
methyl	S-chem
group	O
on	O
the	O
phenylacetic	B-chem
acid	E-chem
ring	O
and	O
with	O
various	O
substitutions	O
on	O
the	O
lower	O
aniline	S-chem
ring	O
.	O

Inhibition	O
studies	O
demonstrated	O
that	O
the	O
methyl	S-chem-C4-1
group	O
on	O
the	O
phenylacetic	B-chem-C4-1
acid	E-chem-C4-1
ring	O
is	O
required	O
for	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
selectivity	O
.	O

The	O
chemical	O
identity	O
and	O
position	O
of	O
the	O
substituents	O
on	O
the	O
lower	O
aniline	S-chem-C4-1
ring	O
were	O
important	O
in	O
determining	O
the	O
potency	O
and	O
extent	O
of	O
COX	S-geneN-C4-2
inhibition	O
as	O
well	O
as	O
COX	B-geneY
-	I-geneY
2	E-geneY
selectivity	O
.	O

Mutation	O
of	O
Ser	B-geneN
-	I-geneN
530	I-geneN
to	I-geneN
Ala	E-geneN
or	O
Val	B-geneN
-	I-geneN
349	I-geneN
to	I-geneN
Ala	I-geneN
or	I-geneN
Leu	E-geneN
abolished	O
the	O
potent	O
inhibition	O
observed	O
with	O
wild	O
-	O
type	O
human	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
key	O
lumiracoxib	S-chem-C4-1
analogs	O
.	O

Interestingly	O
,	O
a	O
Val	B-geneN-C4-2
-	I-geneN-C4-2
349	I-geneN-C4-2
to	I-geneN-C4-2
Ile	E-geneN-C4-2
mutant	O
was	O
inhibited	O
with	O
equal	O
potency	O
to	O
human	B-geneY-C4-2
COX	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
with	O
2,6	B-chem-C4-1
-	I-chem-C4-1
dichloro	E-chem-C4-1
-	O
,	O
2,6	B-chem-C4-1
-	I-chem-C4-1
dimethyl	E-chem-C4-1
-	O
,	O
or	O
2	B-chem-C4-1
-	I-chem-C4-1
chloro	I-chem-C4-1
-	I-chem-C4-1
6	I-chem-C4-1
-	I-chem-C4-1
methyl	E-chem-C4-1
-	O
substituted	O
inhibitors	O
and	O
,	O
in	O
the	O
case	O
of	O
lumiracoxib	S-chem-C4-1
,	O
actually	O
showed	O
an	O
increase	O
in	O
potency	O
.	O

Taken	O
together	O
with	O
a	O
recent	O
crystal	O
structure	O
of	O
a	O
lumiracoxib	S-chem
-	O
COX	B-geneY
-	I-geneY
2	E-geneY
complex	O
,	O
the	O
kinetic	O
analyses	O
presented	O
herein	O
of	O
the	O
inhibition	O
of	O
mutant	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2s	E-geneY-C4-2
by	O
lumiracoxib	S-chem-C4-1
allows	O
the	O
definition	O
of	O
the	O
molecular	O
basis	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibition	O
.	O

Methylation	O
of	O
histone	B-geneN
H3	E-geneN
on	O
lysine	S-chem
4	O
by	O
the	O
lysine	B-geneN
methyltransferase	E-geneN
SET1	S-geneY
protein	O
is	O
needed	O
for	O
normal	O
clock	O
gene	O
expression	O
.	O

The	O
circadian	O
oscillator	O
controls	O
time	O
-	O
of	O
-	O
day	O
gene	O
expression	O
by	O
a	O
network	O
of	O
interconnected	O
feedback	O
loops	O
and	O
is	O
reset	O
by	O
light	O
.	O

The	O
requisite	O
for	O
chromatin	O
regulation	O
in	O
eukaryotic	O
transcription	O
necessitates	O
temporal	O
regulation	O
of	O
histone	O
-	O
modifying	O
and	O
chromatin	O
-	O
remodeling	O
enzymes	O
for	O
proper	O
clock	O
function	O
.	O

CHD1	S-geneN
is	O
known	O
to	O
bind	O
H3K4me3	O
in	O
mammalian	O
cells	O
,	O
and	O
Neurospora	B-geneN
CHD1	E-geneN
is	O
required	O
for	O
proper	O
regulation	O
of	O
the	O
frequency	S-geneY
(	O
frq	S-geneY
)	O
gene	O
.	O

Based	O
on	O
this	O
,	O
we	O
examined	O
a	O
strain	O
lacking	O
SET1	S-geneY
to	O
determine	O
the	O
role	O
of	O
H3K4	O
methylation	O
in	O
clock	O
-	O
and	O
light	O
-	O
mediated	O
frq	S-geneY
regulation	O
.	O

Expression	O
of	O
frq	S-geneY
was	O
altered	O
in	O
strains	O
lacking	O
set1	O
under	O
both	O
circadian	O
-	O
and	O
light	O
-	O
regulated	O
gene	O
expression	O
.	O

There	O
is	O
a	O
delay	O
in	O
the	O
phasing	O
of	O
H3K4me3	O
relative	O
to	O
the	O
peak	O
in	O
frq	S-geneY
expression	O
.	O

White	O
Collar	O
2	O
(	O
WC	O
-	O
2	O
)	O
association	O
with	O
the	O
frq	B-geneN
promoter	E-geneN
persists	O
longer	O
in	O
Δ	B-geneY
set1	E-geneY
,	O
suggesting	O
a	O
more	O
permissible	O
chromatin	O
state	O
.	O

Surprisingly	O
,	O
SET1	S-geneY
is	O
required	O
for	O
DNA	O
methylation	O
in	O
the	O
frq	B-geneN
promoter	E-geneN
,	O
indicating	O
a	O
dependence	O
on	O
H3K4me	O
for	O
DNA	O
methylation	O
.	O

The	O
data	O
support	O
a	O
model	O
where	O
SET1	S-geneY
is	O
needed	O
for	O
proper	O
regulation	O
by	O
modulating	O
chromatin	O
at	O
frq	S-geneY
.	O

New	O
assignments	O
for	O
multitasking	O
signal	O
transduction	O
inhibitors	O
.	O

An	O
article	O
presented	O
in	O
this	O
issue	O
of	O
Molecular	O
Pharmacology	O
(	O
p	O
.	O

1527	O
)	O
provides	O
an	O
intriguing	O
example	O
of	O
how	O
tyrosine	B-geneN
kinase	E-geneN
inhibitors	O
can	O
be	O
put	O
to	O
many	O
uses	O
.	O

In	O
this	O
article	O
,	O
the	O
action	O
of	O
dasatinib	S-chem-C4-1
(	O
BMS	B-chem-C4-1
-	I-chem-C4-1
354825	E-chem-C4-1
)	O
is	O
contrasted	O
with	O
that	O
of	O
imatinib	S-chem-C4-1
,	O
a	O
kinase	S-geneN-C4-2
inhibitor	O
that	O
is	O
currently	O
being	O
used	O
to	O
treat	O
chronic	O
myelogenous	O
leukemia	O
and	O
other	O
disorders	O
.	O

Both	O
pharmacologic	O
inhibitors	O
target	O
several	O
tyrosine	B-geneN
kinases	E-geneN
,	O
including	O
Bcr	S-geneY
-	O
Abl	S-geneY
and	O
the	O
platelet	B-geneN
-	I-geneN
derived	I-geneN
growth	I-geneN
factor	I-geneN
receptor	E-geneN
(	O
PDGFR	S-geneN
)	O
.	O

Up	O
to	O
this	O
point	O
,	O
the	O
PDGFR	S-geneN
has	O
not	O
been	O
a	O
primary	O
therapeutic	O
target	O
for	O
this	O
class	O
of	O
agents	O
.	O

The	O
work	O
of	O
Chen	O
and	O
colleagues	O
shows	O
that	O
dasatinib	S-chem-C4-1
is	O
a	O
particularly	O
potent	O
inhibitor	O
of	O
PDGFR	S-geneN-C4-2
and	O
that	O
the	O
compound	O
also	O
targets	O
Src	B-geneY-C4-2
kinase	E-geneY-C4-2
.	O

The	O
authors	O
suggest	O
that	O
this	O
combination	O
of	O
activities	O
could	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
vascular	O
obstructive	O
diseases	O
.	O

Although	O
a	O
lack	O
of	O
absolute	O
specificity	O
has	O
typically	O
been	O
regarded	O
as	O
a	O
pharmacologic	O
drawback	O
,	O
this	O
study	O
exemplifies	O
how	O
drugs	O
with	O
multiple	O
molecular	O
targets	O
can	O
potentially	O
provide	O
a	O
very	O
beneficial	O
spectrum	O
of	O
therapeutic	O
activities	O
in	O
multiple	O
disease	O
states	O
.	O

The	O
pure	O
antiandrogen	O
RU	B-chem
23908	E-chem
(	O
Anandron	S-chem
)	O
,	O
a	O
candidate	O
of	O
choice	O
for	O
the	O
combined	O
antihormonal	O
treatment	O
of	O
prostatic	O
cancer	O
:	O
a	O
review	O
.	O

The	O
nonsteroidal	O
antiandrogen	O
RU	B-chem
23908	E-chem
(	O
Anandron	S-chem
)	O
weakly	O
interacts	O
with	O
the	O
prostatic	O
cytosolic	O
androgen	B-geneY
receptor	E-geneY
and	O
shows	O
a	O
fast	O
dissociation	O
rate	O
.	O

When	O
administered	O
to	O
immature	O
castrated	O
rats	O
up	O
to	O
the	O
daily	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
,	O
it	O
is	O
devoid	O
of	O
any	O
androgenic	O
activity	O
but	O
efficiently	O
blocks	O
the	O
growth	O
-	O
promoting	O
activity	O
of	O
androgens	S-chem
on	O
ventral	O
prostate	O
and	O
seminal	O
vesicle	O
weight	O
,	O
thus	O
showing	O
the	O
characteristics	O
of	O
a	O
pure	O
antiandrogen	O
.	O

In	O
intact	O
animals	O
,	O
on	O
the	O
other	O
hand	O
,	O
the	O
antiandrogen	O
administered	O
alone	O
exerts	O
only	O
a	O
partial	O
inhibition	O
of	O
prostate	O
and	O
seminal	O
vesicle	O
weight	O
.	O

This	O
is	O
due	O
to	O
the	O
property	O
of	O
the	O
pure	O
antiandrogen	O
to	O
neutralize	O
the	O
inhibitory	O
feedback	O
effect	O
of	O
androgens	S-chem
at	O
the	O
pituitary	O
level	O
on	O
the	O
LH	S-geneN
responsiveness	O
to	O
LHRH	S-geneY
,	O
as	O
illustrated	O
in	O
vitro	O
in	O
rat	O
anterior	O
pituitary	O
cells	O
in	O
culture	O
as	O
well	O
as	O
in	O
vivo	O
in	O
intact	O
and	O
castrated	O
animals	O
.	O

In	O
intact	O
animals	O
,	O
neutralization	O
of	O
the	O
inhibitory	O
feedback	O
action	O
of	O
endogenous	O
androgens	S-chem
leads	O
to	O
an	O
increased	O
LH	S-geneN
and	O
testosterone	S-chem
secretion	O
,	O
which	O
partly	O
overcomes	O
the	O
direct	O
action	O
of	O
the	O
antiandrogen	O
at	O
the	O
level	O
of	O
the	O
prostate	O
and	O
seminal	O
vesicles	O
.	O

In	O
fact	O
,	O
the	O
plasma	O
testosterone	S-chem
concentration	O
is	O
more	O
than	O
doubled	O
6	O
hr	O
after	O
the	O
administration	O
of	O
10	O
mg	O
of	O
RU	B-chem
23908	E-chem
while	O
plasma	O
LH	S-geneN
and	O
testosterone	S-chem
levels	O
are	O
increased	O
by	O
7	O
-	O
and	O
17	O
-	O
fold	O
,	O
respectively	O
,	O
after	O
14	O
days	O
of	O
similar	O
daily	O
treatment	O
.	O

Efficient	O
neutralization	O
of	O
the	O
androgenic	O
action	O
at	O
the	O
prostatic	O
level	O
in	O
intact	O
animals	O
thus	O
requires	O
prevention	O
of	O
this	O
escape	O
phenomenon	O
through	O
inhibition	O
of	O
LH	S-geneN
secretion	O
.	O

Although	O
inhibition	O
of	O
LH	S-geneN-C4-2
release	O
can	O
be	O
achieved	O
by	O
estrogen	S-chem-C4-1
and	O
progestins	S-chem-C4-1
,	O
an	O
optimal	O
inhibitory	O
effect	O
on	O
the	O
prostate	O
is	O
obtained	O
by	O
the	O
combined	O
administration	O
of	O
the	O
antiandrogen	O
with	O
an	O
LHRH	S-geneY
agonist	O
that	O
causes	O
a	O
specific	O
blockage	O
of	O
testicular	O
androgen	S-chem
biosynthesis	O
as	O
well	O
as	O
an	O
inhibition	O
of	O
the	O
LH	S-geneN
responsiveness	O
to	O
LHRH	S-geneY
.	O

Existing	O
and	O
emerging	O
endocrine	O
therapies	O
for	O
breast	O
cancer	O
.	O

Endocrine	O
therapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
patients	O
with	O
estrogen	B-geneY
receptor	E-geneY
-	O
positive	O
or	O
progesterone	B-geneY
receptor	E-geneY
-	O
positive	O
metastatic	O
breast	O
cancer	O
.	O

Commonly	O
used	O
endocrine	O
therapies	O
are	O
tamoxifen	S-chem
,	O
megestrol	B-chem
acetate	E-chem
,	O
and	O
aromatase	S-geneY
inhibitors	O
.	O

Although	O
tamoxifen	S-chem
and	O
megestrol	B-chem
acetate	E-chem
have	O
a	O
favorable	O
therapeutic	O
profile	O
,	O
there	O
are	O
risks	O
associated	O
with	O
these	O
agents	O
.	O

With	O
tamoxifen	S-chem
,	O
the	O
partial	O
agonist	O
property	O
can	O
lead	O
to	O
thromboembolic	O
events	O
.	O

An	O
important	O
adverse	O
event	O
of	O
megestrol	B-chem
acetate	E-chem
is	O
weight	O
gain	O
and	O
fluid	O
retention	O
in	O
some	O
patients	O
.	O

The	O
aromatase	S-geneY
inhibitors	O
are	O
currently	O
used	O
as	O
second	O
-	O
line	O
therapy	O
after	O
tamoxifen	S-chem
failure	O
.	O

A	O
recent	O
study	O
showed	O
that	O
anastrozole	S-chem-C4-1
,	O
an	O
aromatase	S-geneY-C4-2
inhibitor	O
,	O
is	O
as	O
effective	O
or	O
even	O
superior	O
to	O
tamoxifen	S-chem
when	O
used	O
as	O
a	O
first	O
-	O
line	O
therapy	O
.	O

However	O
,	O
not	O
all	O
patients	O
will	O
respond	O
to	O
currently	O
available	O
therapies	O
.	O

A	O
new	O
class	O
of	O
drug	O
,	O
the	O
estrogen	B-geneY
receptor	E-geneY
downregulators	O
,	O
has	O
been	O
developed	O
.	O

Fulvestrant	S-chem-C4-1
,	O
the	O
first	O
agent	O
in	O
this	O
new	O
class	O
,	O
not	O
only	O
induces	O
the	O
degradation	O
of	O
the	O
estrogen	B-geneY-C4-2
receptor	E-geneY-C4-2
but	O
also	O
is	O
an	O
estrogen	S-chem
antagonist	O
;	O
further	O
,	O
its	O
lack	O
of	O
agonist	O
activity	O
provides	O
a	O
better	O
safety	O
profile	O
.	O

Two	O
phase	O
III	O
trials	O
have	O
proven	O
that	O
fulvestrant	S-chem
is	O
at	O
least	O
as	O
effective	O
as	O
anastrozole	S-chem
in	O
postmenopausal	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

Fulvestrant	S-chem
is	O
an	O
effective	O
and	O
safe	O
endocrine	O
therapy	O
for	O
postmenopausal	O
women	O
who	O
have	O
failed	O
prior	O
endocrine	O
therapy	O
.	O

Functional	O
analyses	O
of	O
glycyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
mutations	O
suggest	O
a	O
key	O
role	O
for	O
tRNA	B-geneN
-	I-geneN
charging	I-geneN
enzymes	E-geneN
in	O
peripheral	O
axons	O
.	O

Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
2D	O
(	O
CMT2D	O
)	O
and	O
distal	O
spinal	O
muscular	O
atrophy	O
type	O
V	O
(	O
dSMA	O
-	O
V	O
)	O
are	O
axonal	O
neuropathies	O
characterized	O
by	O
a	O
phenotype	O
that	O
is	O
more	O
severe	O
in	O
the	O
upper	O
extremities	O
.	O

We	O
previously	O
implicated	O
mutations	O
in	O
the	O
gene	O
encoding	O
glycyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
GARS	S-geneY
)	O
as	O
the	O
cause	O
of	O
CMT2D	O
and	O
dSMA	O
-	O
V	O
.	O

GARS	S-geneY
is	O
a	O
member	O
of	O
the	O
family	O
of	O
aminoacyl	B-geneN
-	I-geneN
tRNA	I-geneN
synthetases	E-geneN
responsible	O
for	O
charging	O
tRNA	O
with	O
cognate	O
amino	B-chem
acids	E-chem
;	O
GARS	S-geneY
ligates	O
glycine	S-chem
to	O
tRNA	O
(	O
Gly	O
)	O
.	O

Here	O
,	O
we	O
present	O
functional	O
analyses	O
of	O
disease	O
-	O
associated	O
GARS	S-geneY
mutations	O
and	O
show	O
that	O
there	O
are	O
not	O
any	O
significant	O
mutation	O
-	O
associated	O
changes	O
in	O
GARS	S-geneY
expression	O
levels	O
;	O
that	O
the	O
majority	O
of	O
identified	O
GARS	S-geneY
mutations	O
modeled	O
in	O
yeast	O
severely	O
impair	O
viability	O
;	O
and	O
that	O
,	O
in	O
most	O
cases	O
,	O
mutant	O
GARS	S-geneY
protein	O
mislocalizes	O
in	O
neuronal	O
cells	O
.	O

Indeed	O
,	O
four	O
of	O
the	O
five	O
mutations	O
studied	O
show	O
loss	O
-	O
of	O
-	O
function	O
features	O
in	O
at	O
least	O
one	O
assay	O
,	O
suggesting	O
that	O
tRNA	O
-	O
charging	O
deficits	O
play	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O

Finally	O
,	O
we	O
detected	O
endogenous	O
GARS	S-geneY
-	O
associated	O
granules	O
in	O
the	O
neurite	O
projections	O
of	O
cultured	O
neurons	O
and	O
in	O
the	O
peripheral	O
nerve	O
axons	O
of	O
normal	O
human	O
tissue	O
.	O

These	O
data	O
are	O
particularly	O
important	O
in	O
light	O
of	O
the	O
recent	O
identification	O
of	O
CMT	O
-	O
associated	O
mutations	O
in	O
another	O
tRNA	B-geneN
synthetase	E-geneN
gene	O
[	O
YARS	S-geneY
(	O
tyrosyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
gene	O
)	O
]	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
tRNA	B-geneN
-	I-geneN
charging	I-geneN
enzymes	E-geneN
play	O
a	O
key	O
role	O
in	O
maintaining	O
peripheral	O
axons	O
.	O

Pharmacological	O
characterization	O
of	O
unique	O
prazosin	S-chem
-	O
binding	O
sites	O
in	O
human	O
kidney	O
.	O

In	O
human	O
kidney	O
,	O
we	O
found	O
unique	O
prazosin	S-chem
-	O
binding	O
sites	O
that	O
were	O
insensitive	O
to	O
phentolamine	S-chem
and	O
were	O
thus	O
unlikely	O
to	O
be	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

As	O
the	O
binding	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
prazosin	E-chem
to	O
phentolamine	S-chem
-	O
insensitive	O
sites	O
was	O
prevented	O
by	O
100	O
microM	O
guanabenz	S-chem
,	O
the	O
insensitive	O
sites	O
were	O
evaluated	O
by	O
subtracting	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
prazosin	E-chem
binding	O
in	O
the	O
presence	O
of	O
100	O
microM	O
guanabenz	S-chem
from	O
that	O
in	O
the	O
presence	O
of	O
10	O
microM	O
phentolamine	S-chem
.	O

[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
Prazosin	E-chem
bound	O
to	O
the	O
phentolamine	S-chem
-	O
insensitive	O
sites	O
monophasically	O
with	O
a	O
high	O
affinity	O
(	O
pK	O
(	O
d	O
)	O
;	O
9.1	O
+	O
/	O
-	O
0.08	O
,	O
n	O
=	O
8	O
)	O
,	O
and	O
the	O
B	O
(	O
max	O
)	O
value	O
(	O
814	O
+	O
/	O
-	O
204	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
8	O
)	O
was	O
more	O
than	O
ten	O
times	O
that	O
of	O
the	O
phentolamine	S-chem
-	O
sensitive	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
(	O
pK	O
(	O
d	O
)	O
=	O
9.9	O
+	O
/	O
-	O
0.13	O
,	O
B	O
(	O
max	O
)	O
=	O
66	O
+	O
/	O
-	O
23	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
7	O
)	O
.	O

The	O
phentolamine	S-chem
-	O
insensitive	O
sites	O
in	O
human	O
kidney	O
were	O
highly	O
sensitive	O
to	O
other	O
quinazoline	S-chem
derivatives	O
such	O
as	O
terazosin	S-chem
and	O
doxazosin	S-chem
.	O

However	O
,	O
other	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
1	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonists	O
(	O
tamsulosin	S-chem-C6-1
,	O
WB4101	S-chem-C6-1
and	O
corynanthine	S-chem-C6-1
)	O
did	O
not	O
inhibit	O
the	O
binding	O
at	O
a	O
range	O
of	O
concentrations	O
that	O
generally	O
exhibit	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonism	O
,	O
and	O
noradrenaline	S-chem
,	O
rauwolscine	S-chem
and	O
propranolol	S-chem
were	O
without	O
effect	O
on	O
the	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
prazosin	E-chem
binding	O
.	O

On	O
the	O
other	O
hand	O
,	O
ligands	O
for	O
the	O
renal	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
transporter	E-geneN
(	O
amiloride	S-chem
and	O
triamterene	S-chem
)	O
and	O
for	O
imidazoline	S-chem
recognition	O
sites	O
(	O
guanabenz	S-chem
,	O
guanfacine	S-chem
and	O
agmatine	S-chem
)	O
displaced	O
the	O
binding	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
prazosin	E-chem
to	O
phentolamine	S-chem
-	O
insensitive	O
sites	O
at	O
micromolar	O
concentrations	O
.	O

Photoaffinity	O
labeling	O
with	O
[	B-chem
(	I-chem
125	I-chem
)	I-chem
I	I-chem
]	I-chem
iodoarylazidoprazosin	E-chem
showed	O
phentolamine	S-chem
-	O
insensitive	O
labeling	O
at	O
around	O
100	O
kDa	O
,	O
a	O
molecular	O
size	O
larger	O
than	O
that	O
of	O
human	B-geneN
alpha	I-geneN
(	I-geneN
1a	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1b	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
expressed	O
in	O
293	O
cells	O
(	O
50	O
-	O
60	O
and	O
70	O
-	O
80	O
kDa	O
,	O
respectively	O
)	O
on	O
electrophoresis	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
detectable	O
phentolamine	S-chem
-	O
insensitive	O
binding	O
site	O
but	O
were	O
phentolamine	S-chem
-	O
sensitive	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
human	O
liver	O
(	O
pK	O
(	O
d	O
)	O
=	O
10.0	O
+	O
/	O
-	O
0.06	O
,	O
B	O
(	O
max	O
)	O
=	O
44	O
+	O
/	O
-	O
6	O
fmol	O
mg	O
(	O
-	O
1	O
)	O
protein	O
,	O
n	O
=	O
3	O
)	O
.	O

Phentolamine	S-chem
-	O
insensitive	O
prazosin	S-chem
binding	O
sites	O
were	O
also	O
detected	O
in	O
rabbit	O
kidney	O
(	O
approximately	O
50	O
%	O
of	O
specific	O
binding	O
sites	O
)	O
but	O
were	O
minor	O
in	O
rat	O
kidney	O
(	O
less	O
than	O
20	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
are	O
unique	O
prazosin	S-chem
-	O
binding	O
sites	O
in	O
human	O
kidney	O
,	O
the	O
pharmacological	O
profiles	O
of	O
which	O
were	O
distinct	O
from	O
those	O
of	O
known	O
adrenoceptors	O
.	O

Leishmania	O
donovani	O
singly	O
deficient	O
in	O
HGPRT	S-geneY
,	O
APRT	S-geneY
or	O
XPRT	S-geneY
are	O
viable	O
in	O
vitro	O
and	O
within	O
mammalian	O
macrophages	O
.	O

Leishmania	O
species	O
express	O
three	O
phosphoribosyltransferase	S-geneN
enzymes	O
,	O
hypoxanthine	B-geneY
-	I-geneY
guanine	I-geneY
phosphoribosyltransferase	E-geneY
(	O
HGPRT	S-geneY
)	O
,	O
adenine	B-geneY
phosphoribosyltransferase	E-geneY
(	O
APRT	S-geneY
)	O
,	O
and	O
xanthine	B-geneY
phosphoribosyltransferase	E-geneY
(	O
XPRT	S-geneY
)	O
,	O
which	O
enable	O
this	O
genus	O
to	O
acquire	O
purine	S-chem
nutrients	O
from	O
their	O
hosts	O
.	O

To	O
test	O
whether	O
any	O
of	O
these	O
enzymes	O
is	O
essential	O
for	O
viability	O
,	O
transformation	O
into	O
amastigotes	O
,	O
and	O
infectivity	O
and	O
proliferation	O
within	O
mammalian	O
macrophages	O
,	O
Deltahgprt	O
,	O
Deltaaprt	O
,	O
and	O
Deltaxprt	O
null	O
mutants	O
were	O
created	O
by	O
targeted	O
gene	O
replacement	O
within	O
a	O
virulent	O
background	O
of	O
Leishmania	O
donovani	O
.	O

Each	O
of	O
the	O
three	O
knockout	O
strains	O
was	O
viable	O
as	O
promastigotes	O
and	O
axenic	O
amastigotes	O
and	O
capable	O
of	O
maintaining	O
an	O
infection	O
in	O
bone	O
marrow	O
-	O
derived	O
murine	O
macrophages	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
none	O
of	O
the	O
three	O
phosphoribosyltransferases	S-geneN
is	O
essential	O
for	O
purine	S-chem
salvage	O
or	O
viability	O
by	O
itself	O
and	O
that	O
purine	S-chem
salvage	O
occurs	O
through	O
multiple	O
anabolic	O
routes	O
in	O
both	O
parasite	O
life	O
cycle	O
stages	O
.	O

In	O
addition	O
these	O
studies	O
revealed	O
the	O
presence	O
of	O
an	O
adenine	B-geneY
aminohydrolase	E-geneY
enzyme	O
in	O
L.	O
donovani	O
axenic	O
amastigotes	O
,	O
an	O
activity	O
previously	O
thought	O
to	O
be	O
restricted	O
to	O
promastigotes	O
.	O

Theoretical	O
study	O
of	O
the	O
decomposition	O
of	O
ethyl	B-chem
and	I-chem
ethyl	I-chem
3	I-chem
-	I-chem
phenyl	I-chem
glycidate	E-chem
.	O

The	O
mechanism	O
of	O
the	O
decomposition	O
of	O
ethyl	B-chem
and	I-chem
ethyl	I-chem
3	I-chem
-	I-chem
phenyl	I-chem
glycidate	E-chem
in	O
gas	O
phase	O
was	O
studied	O
by	O
density	O
functional	O
theory	O
(	O
DFT	O
)	O
and	O
MP2	O
methods	O
.	O

A	O
proposed	O
mechanism	O
for	O
the	O
reaction	O
indicates	O
that	O
the	O
ethyl	S-chem
side	O
of	O
the	O
ester	O
is	O
eliminated	O
as	O
ethylene	S-chem
through	O
a	O
concerted	O
six	O
-	O
membered	O
cyclic	O
transition	O
state	O
,	O
and	O
the	O
unstable	O
intermediate	O
glycidic	B-chem
acid	E-chem
decarboxylates	O
rapidly	O
to	O
give	O
the	O
corresponding	O
aldehyde	S-chem
.	O

Two	O
possible	O
pathways	O
for	O
glycidic	B-chem
acid	E-chem
decarboxylation	O
were	O
studied	O
:	O
one	O
via	O
a	O
five	O
-	O
membered	O
cyclic	O
transition	O
state	O
,	O
and	O
the	O
other	O
via	O
a	O
four	O
-	O
membered	O
cyclic	O
transition	O
state	O
.	O

The	O
results	O
of	O
the	O
calculations	O
indicate	O
that	O
the	O
decarboxylation	O
reaction	O
occurs	O
via	O
a	O
mechanism	O
with	O
five	O
-	O
membered	O
cyclic	O
transition	O
state	O
.	O

Bioactive	O
abietane	S-chem
and	O
ent	B-chem
-	I-chem
kaurane	E-chem
diterpenoids	S-chem
from	O
Isodon	O
tenuifolius	O
.	O

Three	O
new	O
abietane	S-chem
diterpenoids	S-chem
,	O
isoabietenins	B-chem
A	I-chem
-	I-chem
C	E-chem
(	O
1	O
-	O
3	O
)	O
,	O
and	O
13	O
new	O
ent	B-chem
-	I-chem
kauranoids	E-chem
,	O
tenuifolins	B-chem
A	I-chem
-	I-chem
M	E-chem
(	O
4	O
-	O
16	O
)	O
,	O
along	O
with	O
four	O
known	O
compounds	O
(	O
17	O
-	O
20	O
)	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Isodon	O
tenuifolius	O
.	O

The	O
structures	O
of	O
the	O
new	O
metabolites	O
were	O
established	O
on	O
the	O
basis	O
of	O
detailed	O
spectroscopic	O
analysis	O
.	O

The	O
absolute	O
configurations	O
of	O
1	O
,	O
15	O
,	O
and	O
16	O
were	O
confirmed	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
diffraction	O
.	O

Selected	O
compounds	O
were	O
evaluated	O
for	O
their	O
cytotoxicity	O
against	O
a	O
small	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
,	O
and	O
some	O
compounds	O
showed	O
inhibitory	O
effects	O
.	O

Furthermore	O
,	O
several	O
isolates	O
exhibited	O
inhibitory	O
activity	O
against	O
nitric	B-chem
oxide	E-chem
production	O
in	O
LPS	O
-	O
activated	O
RAW264.7	O
macrophages	O
.	O

Current	O
perspectives	O
on	O
parathyroid	B-geneY
hormone	E-geneY
(	O
PTH	S-geneY
)	O
and	O
PTH	B-geneY
-	I-geneY
related	I-geneY
protein	E-geneY
(	O
PTHrP	S-geneY
)	O
as	O
bone	O
anabolic	O
therapies	O
.	O

Osteoporosis	O
is	O
characterized	O
by	O
low	O
bone	O
mineral	O
density	O
and	O
/	O
or	O
poor	O
bone	O
microarchitecture	O
leading	O
to	O
an	O
increased	O
risk	O
of	O
fractures	O
.	O

The	O
skeletal	O
alterations	O
in	O
osteoporosis	O
are	O
a	O
consequence	O
of	O
a	O
relative	O
deficit	O
of	O
bone	O
formation	O
compared	O
to	O
bone	O
resorption	O
.	O

Osteoporosis	O
therapies	O
have	O
mostly	O
relied	O
on	O
antiresorptive	O
drugs	O
.	O

An	O
alternative	O
therapeutic	O
approach	O
for	O
osteoporosis	O
is	O
currently	O
available	O
,	O
based	O
on	O
the	O
intermittent	O
administration	O
of	O
parathyroid	B-geneY
hormone	E-geneY
(	O
PTH	S-geneY
)	O
.	O

Bone	O
anabolism	O
caused	O
by	O
PTH	S-geneY
therapy	O
is	O
mainly	O
accounted	O
for	O
by	O
the	O
ability	O
of	O
PTH	S-geneY
to	O
increase	O
osteoblastogenesis	O
and	O
osteoblast	O
survival	O
.	O

PTH	S-geneY
and	O
PTH	B-geneY
-	I-geneY
related	I-geneY
protein	E-geneY
(	O
PTHrP	S-geneY
)	O
-	O
an	O
abundant	O
local	O
factor	O
in	O
bone	O
-	O
interact	O
with	O
the	O
common	O
PTH	B-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
with	O
similar	O
affinities	O
in	O
osteoblasts	O
.	O

Studies	O
mainly	O
in	O
osteoporosis	O
rodent	O
models	O
and	O
limited	O
data	O
in	O
postmenopausal	O
women	O
suggest	O
that	O
N	S-chem
-	O
terminal	O
PTHrP	S-geneY
peptides	O
might	O
be	O
considered	O
a	O
promising	O
bone	O
anabolic	O
therapy	O
.	O

In	O
addition	O
,	O
putative	O
osteogenic	O
actions	O
of	O
PTHrP	S-geneY
might	O
be	O
ascribed	O
not	O
only	O
to	O
its	O
N	S-chem
-	O
terminal	O
domain	O
but	O
also	O
to	O
its	O
PTH	S-geneY
-	O
unrelated	O
C	S-chem
-	O
terminal	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
underlying	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
the	O
anabolic	O
actions	O
of	O
PTH	S-geneY
and	O
the	O
similar	O
potential	O
of	O
PTH	B-geneY
-	I-geneY
related	I-geneY
protein	E-geneY
(	O
PTHrP	S-geneY
)	O
to	O
increase	O
bone	O
mass	O
and	O
improve	O
bone	O
regeneration	O
.	O

Influence	O
of	O
surface	O
groups	O
on	O
poly	B-chem
(	I-chem
propylene	I-chem
imine	I-chem
)	E-chem
dendrimers	O
antiprion	O
activity	O
.	O

Prion	S-geneN
diseases	O
are	O
characterized	O
by	O
the	O
accumulation	O
of	O
PrP	B-geneY
(	I-geneY
Sc	I-geneY
)	E-geneY
,	O
an	O
aberrantly	O
folded	O
isoform	O
of	O
the	O
host	O
protein	O
PrP	B-geneY
(	I-geneY
C	I-geneY
)	E-geneY
.	O

Specific	O
forms	O
of	O
synthetic	O
molecules	O
known	O
as	O
dendrimers	O
are	O
able	O
to	O
eliminate	O
protease	O
-	O
resistant	O
PrP	B-geneY
(	I-geneY
Sc	I-geneY
)	E-geneY
in	O
both	O
an	O
intracellular	O
and	O
in	O
vitro	O
setting	O
.	O

The	O
properties	O
of	O
a	O
dendrimer	O
which	O
govern	O
this	O
ability	O
are	O
unknown	O
.	O

We	O
addressed	O
the	O
issue	O
by	O
comparing	O
the	O
in	O
vitro	O
antiprion	O
ability	O
of	O
numerous	O
modified	O
poly	B-chem
(	I-chem
propylene	I-chem
-	I-chem
imine	I-chem
)	E-chem
dendrimers	O
,	O
which	O
varied	O
in	O
size	O
,	O
structure	O
,	O
charge	O
,	O
and	O
surface	O
group	O
composition	O
.	O

Several	O
of	O
the	O
modified	O
dendrimers	O
,	O
including	O
an	O
anionic	O
glycodendrimer	O
,	O
reduced	O
the	O
level	O
of	O
protease	S-geneN
resistant	O
PrP	B-geneY
(	I-geneY
Sc	I-geneY
)	E-geneY
in	O
a	O
prion	O
strain	O
-	O
dependent	O
manner	O
.	O

This	O
led	O
to	O
the	O
formulation	O
of	O
a	O
new	O
working	O
model	O
for	O
dendrimer	O
/	O
prion	O
interactions	O
which	O
proposes	O
dendrimers	O
eliminate	O
PrP	B-geneY
(	I-geneY
Sc	I-geneY
)	E-geneY
by	O
destabilizing	O
the	O
protein	O
and	O
rendering	O
it	O
susceptible	O
to	O
proteolysis	O
.	O

This	O
ability	O
is	O
not	O
dependent	O
on	O
any	O
particular	O
charge	O
of	O
dendrimer	O
,	O
but	O
does	O
require	O
a	O
high	O
density	O
of	O
reactive	O
surface	O
groups	O
.	O

3D	O
structures	O
and	O
ligand	O
specificities	O
of	O
nuclear	O
xenobiotic	O
receptors	O
CAR	S-geneY
,	O
PXR	S-geneY
and	O
VDR	S-geneY
.	O

The	O
nuclear	B-geneN
receptors	E-geneN
constitutive	B-geneY
androstane	I-geneY
receptor	E-geneY
(	O
CAR	S-geneY
)	O
,	O
pregnane	B-geneY
X	I-geneY
receptor	E-geneY
(	O
PXR	S-geneY
)	O
and	O
vitamin	B-geneY
D	I-geneY
receptor	E-geneY
(	O
VDR	S-geneY
)	O
control	O
a	O
large	O
array	O
of	O
genes	O
that	O
code	O
for	O
important	O
proteins	O
in	O
humans	O
including	O
metabolic	O
enzymes	O
and	O
transporters	O
.	O

3D	O
structures	O
for	O
the	O
ligand	B-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
(	O
LBD	S-geneN
)	O
of	O
these	O
receptors	O
are	O
abundantly	O
available	O
,	O
providing	O
valuable	O
insights	O
into	O
the	O
ligand	O
-	O
binding	O
specificity	O
as	O
well	O
as	O
the	O
activation	O
mechanisms	O
.	O

The	O
ligand	O
-	O
binding	O
site	O
of	O
PXR	S-geneY
is	O
large	O
and	O
flexible	O
,	O
whereas	O
those	O
of	O
CAR	S-geneY
and	O
VDR	S-geneY
are	O
compact	O
and	O
rigid	O
,	O
respectively	O
.	O

In	O
general	O
,	O
the	O
ligand	O
profiles	O
of	O
the	O
receptors	O
are	O
in	O
agreement	O
with	O
the	O
LBD	S-geneN
structures	O
.	O

The	O
crystal	O
structures	O
have	O
greatly	O
helped	O
us	O
to	O
understand	O
the	O
promiscuity	O
and	O
/	O
or	O
specificity	O
of	O
CAR	S-geneY
,	O
PXR	S-geneY
and	O
VDR	S-geneY
.	O

Interacting	O
Glutamate	B-geneN
Receptor	E-geneN
-	O
Like	O
Proteins	O
in	O
Phloem	O
Regulate	O
Lateral	O
Root	O
Initiation	O
in	O
Arabidopsis	O
.	O

Molecular	O
,	O
genetic	O
,	O
and	O
electrophysiological	O
evidence	O
indicates	O
that	O
at	O
least	O
one	O
of	O
the	O
plant	O
Glu	B-geneN
receptor	E-geneN
-	O
like	O
molecules	O
,	O
GLR3.4	S-geneN
,	O
functions	O
as	O
an	O
amino	B-geneN
acid	I-geneN
-	I-geneN
gated	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
at	O
the	O
plasma	O
membrane	O
.	O

The	O
aspect	O
of	O
plant	O
physiology	O
,	O
growth	O
,	O
or	O
development	O
to	O
which	O
GLR3.4	S-geneN
contributes	O
is	O
an	O
open	O
question	O
.	O

Protein	O
localization	O
studies	O
performed	O
here	O
provide	O
important	O
information	O
.	O

In	O
roots	O
,	O
GLR3.4	S-geneN
and	O
the	O
related	O
GLR3.2	S-geneN
protein	O
were	O
present	O
primarily	O
in	O
the	O
phloem	O
,	O
especially	O
in	O
the	O
vicinity	O
of	O
the	O
sieve	O
plates	O
.	O

GLR3.3	S-geneN
was	O
expressed	O
in	O
most	O
cells	O
of	O
the	O
growing	O
primary	O
root	O
but	O
was	O
not	O
enriched	O
in	O
the	O
phloem	O
,	O
including	O
the	O
sieve	O
plate	O
area	O
.	O

GLR3.2	S-geneN
and	O
GLR3.4	S-geneN
physically	O
interacted	O
with	O
each	O
other	O
better	O
than	O
with	O
themselves	O
as	O
evidenced	O
by	O
a	O
biophotonic	O
assay	O
performed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
and	O
Nicotiana	O
benthamiana	O
leaf	O
cells	O
.	O

GLR3.3	S-geneN
interacted	O
poorly	O
with	O
itself	O
or	O
the	O
other	O
two	O
GLRs	S-geneN
.	O

Mutations	O
in	O
GLR3.2	S-geneN
,	O
GLR3.4	S-geneN
,	O
or	O
GLR3.2	S-geneN
and	O
GLR3.4	S-geneN
caused	O
the	O
same	O
and	O
equally	O
severe	O
phenotype	O
,	O
namely	O
,	O
a	O
large	O
overproduction	O
and	O
aberrant	O
placement	O
of	O
lateral	O
root	O
primordia	O
.	O

Loss	O
of	O
GLR3.3	S-geneN
did	O
not	O
affect	O
lateral	O
root	O
primordia	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
apoplastic	O
amino	B-chem
acids	E-chem
acting	O
through	O
heteromeric	O
GLR3.2	S-geneN
/	O
GLR3.4	S-geneN
channels	O
affect	O
lateral	O
root	O
development	O
via	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
signaling	O
in	O
the	O
phloem	O
.	O

Synthesis	O
and	O
in	O
vivo	O
evaluation	O
of	O
novel	O
radiotracers	O
for	O
the	O
in	O
vivo	O
imaging	O
of	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
.	O

The	O
(	B-chem
R	I-chem
,	I-chem
R	I-chem
)	I-chem
and	I-chem
(	I-chem
S	I-chem
,	I-chem
S	I-chem
)	I-chem
enantiomers	I-chem
of	I-chem
2	I-chem
-	I-chem
[	I-chem
(	I-chem
2	I-chem
-	I-chem
methoxyphenoxy	I-chem
)	I-chem
phenylmethyl	I-chem
]	I-chem
morpholine	E-chem
(	O
MeNER	S-chem
)	O
have	O
been	O
radiolabelled	O
with	O
carbon	B-chem
-	I-chem
11	E-chem
in	O
good	O
yield	O
and	O
at	O
high	O
specific	O
activity	O
.	O

These	O
radiotracers	O
are	O
close	O
analogues	O
of	O
reboxetine	S-chem
,	O
a	O
potent	O
and	O
selective	O
ligand	O
for	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
(	O
NET	S-geneY
)	O
.	O

They	O
were	O
examined	O
as	O
potential	O
ligands	O
for	O
imaging	O
NET	S-geneY
in	O
vivo	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

The	O
in	O
vivo	O
brain	O
distribution	O
of	O
both	O
[	O
(	B-chem
11	I-chem
)	I-chem
C	E-chem
]	O
-	O
labeled	O
enantiomers	O
were	O
evaluated	O
in	O
rats	O
.	O

Following	O
tail	O
-	O
vein	O
injection	O
of	O
the	O
(	O
R	O
,	O
R	O
)	O
-	O
enantiomer	O
regional	O
brain	O
uptake	O
and	O
washout	O
of	O
radioactivity	O
was	O
homogeneous	O
at	O
all	O
time	O
points	O
examined	O
(	O
5	O
-	O
60	O
min	O
)	O
.	O

In	O
contrast	O
,	O
administration	O
of	O
the	O
(	O
S	O
,	O
S	O
)	O
-	O
enantiomer	O
produced	O
a	O
heterogeneous	O
distribution	O
of	O
radioactivity	O
in	O
brain	O
with	O
highest	O
uptake	O
in	O
the	O
hypothalamus	O
,	O
a	O
NET	S-geneY
rich	O
region	O
,	O
and	O
lowest	O
uptake	O
in	O
the	O
striatum	O
,	O
a	O
brain	O
region	O
devoid	O
of	O
NET	S-geneY
.	O

Hypothalamus	O
to	O
striatum	O
ratios	O
of	O
2.5	O
to	O
one	O
were	O
achieved	O
at	O
60	O
min	O
post	O
injection	O
of	O
(	B-chem
S	I-chem
,	I-chem
S	I-chem
)	I-chem
-	I-chem
[	I-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
-	I-chem
MeNER	E-chem
.	O

Pre	O
-	O
injection	O
of	O
the	O
norepinephrine	S-chem
reuptake	O
inhibitors	O
,	O
reboxetine	S-chem
or	O
desipramine	S-chem
,	O
reduced	O
hypothalamus	O
to	O
striatum	O
ratios	O
to	O
near	O
unity	O
while	O
reuptake	O
inhibitors	O
of	O
dopamine	S-chem
and	O
serotonin	S-chem
had	O
no	O
significant	O
effect	O
on	O
binding	O
.	O

In	O
vitro	O
autoradiography	O
studies	O
(	O
rat	O
brain	O
slices	O
)	O
with	O
(	B-chem
S	I-chem
,	I-chem
S	I-chem
)	I-chem
-	I-chem
[	I-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
-	I-chem
MeNER	E-chem
produced	O
a	O
regional	O
distribution	O
pattern	O
that	O
was	O
consistent	O
with	O
the	O
reported	O
distribution	O
of	O
NET	S-geneY
.	O

(	B-chem
S	I-chem
,	I-chem
S	I-chem
)	I-chem
-	I-chem
[	I-chem
(	I-chem
11	I-chem
)	I-chem
C	I-chem
]	I-chem
-	I-chem
MeNER	E-chem
has	O
the	O
potential	O
to	O
be	O
the	O
first	O
successful	O
PET	O
ligand	O
to	O
image	O
NET	S-geneY
.	O

Binding	O
between	O
heparin	O
and	O
the	O
integrin	S-geneN
VLA	B-geneY
-	I-geneY
4	E-geneY
.	O

Heparin	O
possesses	O
antimetastatic	O
effects	O
that	O
were	O
related	O
to	O
various	O
molecular	O
mechanisms	O
beyond	O
anticoagulant	O
activities	O
.	O

The	O
ability	O
of	O
heparin	O
to	O
interfere	O
with	O
the	O
function	O
of	O
adhesion	B-geneN
receptors	E-geneN
in	O
the	O
metastatic	O
course	O
appears	O
as	O
a	O
promising	O
therapeutic	O
approach	O
.	O

This	O
refers	O
to	O
numerous	O
findings	O
that	O
heparin	O
attenuates	O
metastasis	O
in	O
a	O
selectin	O
-	O
dependent	O
manner	O
.	O

We	O
recently	O
demonstrated	O
that	O
heparin	O
interferes	O
with	O
the	O
integrin	S-geneN
VLA	B-geneY
-	I-geneY
4	E-geneY
on	O
murine	O
melanoma	O
cells	O
binding	O
to	O
VCAM	B-geneY
-	I-geneY
1	E-geneY
.	O

To	O
confirm	O
this	O
activity	O
and	O
to	O
obtain	O
further	O
insight	O
into	O
molecular	O
recognition	O
of	O
heparin	O
by	O
VLA	B-geneY
-	I-geneY
4	E-geneY
,	O
we	O
investigated	O
the	O
inhibition	O
of	O
VLA	B-geneY
-	I-geneY
4	E-geneY
mediated	O
binding	O
of	O
human	O
melanoma	O
MV3	O
cells	O
to	O
immobilised	O
VCAM	B-geneY
-	I-geneY
1	E-geneY
by	O
different	O
heparins	O
.	O

The	O
size	O
of	O
heparin	O
has	O
an	O
important	O
impact	O
on	O
inhibition	O
.	O

Unfractionated	O
heparin	O
(	O
UFH	O
)	O
and	O
tinzaparin	S-chem
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
(	O
LMWH	O
)	O
representing	O
a	O
mean	O
of	O
about	O
18	O
-	O
20	O
monomers	O
,	O
displayed	O
high	O
inhibitory	O
activity	O
.	O

Fractionating	O
tinzaparin	S-chem
to	O
14	O
-	O
18	O
monomers	O
reduced	O
inhibition	O
slightly	O
,	O
while	O
the	O
pentasaccharide	B-chem
fondaparinux	E-chem
was	O
without	O
effects	O
.	O

To	O
confirm	O
molecular	O
recognition	O
of	O
tinzaparin	S-chem
by	O
VLA	B-geneY
-	I-geneY
4	E-geneY
,	O
a	O
surface	O
acoustic	O
wave	O
-	O
biosensor	O
was	O
applied	O
.	O

A	O
VLA	B-geneY
-	I-geneY
4	E-geneY
containing	O
membrane	O
preparation	O
of	O
MV3	O
cells	O
was	O
immobilised	O
at	O
the	O
sensors	O
to	O
allow	O
for	O
detection	O
of	O
kinetic	O
binding	O
constants	O
of	O
tinzaparin	S-chem
compared	O
to	O
VCAM	B-geneY
-	I-geneY
1	E-geneY
.	O

Tinzaparin	S-chem
binds	O
to	O
VLA	B-geneY
-	I-geneY
4	E-geneY
with	O
affinity	O
in	O
the	O
low	O
micromolar	O
range	O
(	O
4.61	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
which	O
clearly	O
indicates	O
specific	O
molecular	O
recognition	O
.	O

Furthermore	O
,	O
tinzaparin	S-chem
displays	O
a	O
nearly	O
identical	O
k	O
(	O
off	O
)	O
compared	O
to	O
VCAM	B-geneY
-	I-geneY
1	E-geneY
(	O
5.13	O
x	O
10	O
(	O
-	O
3	O
)	O
s	O
(	O
-	O
1	O
)	O
versus	O
3.44	O
x	O
10	O
(	O
-	O
3	O
)	O
s	O
(	O
-	O
1	O
)	O
)	O
which	O
is	O
evident	O
for	O
interference	O
with	O
the	O
ligand	O
binding	O
.	O

The	O
data	O
provide	O
evidence	O
for	O
a	O
direct	O
confirmation	O
of	O
heparin	O
binding	O
to	O
VLA	B-geneY
-	I-geneY
4	E-geneY
and	O
thus	O
,	O
contribute	O
to	O
understand	O
the	O
antimetastatic	O
activity	O
of	O
heparin	O
.	O

Comparisons	O
of	O
beta	O
-	O
adrenergic	O
blocking	O
properties	O
of	O
S	B-chem
-	I-chem
and	I-chem
R	I-chem
-	I-chem
timolol	E-chem
in	O
humans	O
.	O

In	O
animals	O
,	O
the	O
R	B-chem
-	I-chem
enantiomer	I-chem
of	I-chem
timolol	E-chem
causes	O
a	O
significant	O
reduction	O
in	O
intraocular	O
pressure	O
but	O
had	O
only	O
1	O
/	O
80	O
the	O
activity	O
of	O
the	O
S	O
-	O
enantiomer	O
at	O
extraocular	B-geneN
receptors	E-geneN
.	O

The	O
beta	B-geneN
1	I-geneN
-	I-geneN
and	I-geneN
beta	I-geneN
2	I-geneN
-	I-geneN
adrenoceptor	E-geneN
blocking	O
properties	O
of	O
orally	O
administered	O
R	B-chem
-	I-chem
and	I-chem
S	I-chem
-	I-chem
timolol	E-chem
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
controlled	O
trial	O
in	O
two	O
groups	O
of	O
healthy	O
men	O
.	O

Each	O
subject	O
in	O
group	O
A	O
(	O
n	O
=	O
6	O
)	O
received	O
placebo	O
,	O
1	O
and	O
3	O
mg	O
S	B-chem
-	I-chem
timolol	E-chem
and	O
25	O
and	O
75	O
mg	O
R	B-chem
-	I-chem
timolol	E-chem
in	O
random	O
order	O
,	O
group	O
B	O
(	O
n	O
=	O
5	O
)	O
received	O
placebo	O
,	O
0.5	O
,	O
and	O
1	O
mg	O
S	B-chem
-	I-chem
timolol	E-chem
and	O
3	O
and	O
10	O
mg	O
R	B-chem
-	I-chem
timolol	E-chem
.	O

In	O
both	O
groups	O
,	O
R	B-chem
-	I-chem
and	I-chem
S	I-chem
-	I-chem
timolol	E-chem
comparably	O
inhibited	O
isoproterenol	S-chem
-	O
induced	O
increases	O
in	O
heart	O
rate	O
(	O
P	O
<	O
.05	O
)	O
,	O
forearm	O
blood	O
flow	O
(	O
P	O
<	O
.05	O
,	O
except	O
at	O
3	O
micrograms	O
/	O
minute	O
of	O
isoproterenol	S-chem
after	O
the	O
R	O
-	O
doses	O
in	O
group	O
B	O
)	O
,	O
and	O
finger	O
tremor	O
(	O
P	O
<	O
.05	O
)	O
in	O
comparison	O
with	O
placebo	O
.	O

The	O
findings	O
for	O
the	O
R	O
-	O
enantiomer	O
in	O
this	O
study	O
were	O
unexpected	O
based	O
on	O
the	O
animal	O
studies	O
and	O
previous	O
studies	O
that	O
demonstrated	O
marked	O
differences	O
in	O
beta	O
blocking	O
effects	O
of	O
other	O
beta	O
-	O
blockers	O
in	O
which	O
the	O
R	O
-	O
enantiomers	O
were	O
less	O
inhibitory	O
.	O

Synthesis	O
,	O
crystal	O
structure	O
and	O
antidiabetic	O
activity	O
of	O
substituted	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
Benzo	I-chem
[	I-chem
d	I-chem
]	I-chem
thiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
ylamino	I-chem
)	I-chem
phenylprop	I-chem
-	I-chem
2	I-chem
-	I-chem
en	I-chem
-	I-chem
1	I-chem
-	I-chem
one	E-chem
.	O

A	O
novel	O
series	O
of	O
substituted	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
Benzo	I-chem
[	I-chem
d	I-chem
]	I-chem
thiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
ylamino	I-chem
)	I-chem
phenylprop	I-chem
-	I-chem
2	I-chem
-	I-chem
en	I-chem
-	I-chem
1	I-chem
-	I-chem
onewere	O
synthesized	O
starting	O
from	O
2	B-chem
-	I-chem
aminobenzothiazole	E-chem
and	O
1	B-chem
-	I-chem
aryl	I-chem
-	I-chem
3,3	I-chem
-	I-chem
bis	I-chem
-	I-chem
(	I-chem
methylsulfanyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
propen	I-chem
-	I-chem
1	I-chem
-	I-chem
onesin	O
the	O
presence	O
of	O
a	O
catalytic	O
amount	O
of	O
sodium	B-chem
hydride	E-chem
in	O
THF	S-chem
.	O

The	O
synthesised	O
compounds	O
'	O
structures	O
were	O
confirmed	O
by	O
IR	O
,	O
Mass	O
spectrometry	O
,	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
NMR	O
,	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
NMR	O
and	O
HRMS	O
spectral	O
data	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
antidiabetic	O
activity	O
,	O
and	O
most	O
of	O
the	O
derivatives	O
of	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
Benzo	I-chem
[	I-chem
d	I-chem
]	I-chem
thiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
ylamino	I-chem
)	I-chem
phenylprop	I-chem
-	I-chem
2	I-chem
-	I-chem
en	I-chem
-	I-chem
1	I-chem
-	I-chem
one	E-chem
displayed	O
significant	O
antidiabetic	O
activity	O
.	O

A	O
Physiologically	O
-	O
Based	O
Pharmacokinetic	O
Modelling	O
Approach	O
to	O
Predict	O
Disease	O
-	O
Drug	O
Interactions	O
:	O
Suppression	O
of	O
CYP3A	S-geneN
by	O
IL	B-geneY
-	I-geneY
6	E-geneY
.	O

Elevated	O
cytokine	S-geneN
levels	O
can	O
down	O
-	O
regulate	O
expression	O
of	O
cytochrome	B-geneN
P450	E-geneN
enzymes	O
(	O
CYPs	S-geneN
)	O
and	O
suppress	O
their	O
activity	O
.	O

Treatment	O
of	O
inflammation	O
or	O
infection	O
with	O
cytokine	S-geneN
-	O
modulating	O
therapeutic	O
proteins	O
(	O
TP	O
)	O
could	O
reverse	O
suppression	O
manifesting	O
as	O
therapeutic	O
protein	O
-	O
drug	O
drug	O
interactions	O
(	O
TP	O
-	O
DDI	O
)	O
.	O

A	O
physiologically	O
-	O
based	O
pharmacokinetic	O
model	O
was	O
used	O
to	O
quantitatively	O
predict	O
the	O
impact	O
of	O
IL	B-geneY
-	I-geneY
6	E-geneY
on	O
sensitive	O
CYP3A4	S-geneY
substrates	O
.	O

Elevated	O
simvastatin	S-chem
AUC	O
in	O
virtual	O
rheumatoid	O
arthritis	O
patients	O
,	O
following	O
100	O
pg	O
/	O
mL	O
of	O
IL	B-geneY
-	I-geneY
6	E-geneY
was	O
comparable	O
to	O
observed	O
clinical	O
data	O
(	O
59	O
%	O
versus	O
58	O
%	O
)	O
.	O

In	O
virtual	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
patients	O
,	O
500	O
pg	O
/	O
ml	O
of	O
IL	B-geneY
-	I-geneY
6	E-geneY
resulted	O
in	O
increase	O
in	O
cyclosporine	S-chem
AUC	O
that	O
was	O
in	O
good	O
agreement	O
with	O
the	O
observed	O
data	O
(	O
45	O
%	O
versus	O
39	O
%	O
)	O
.	O

In	O
a	O
different	O
group	O
of	O
BMT	O
patients	O
treated	O
with	O
cyclosporine	S-chem
,	O
the	O
magnitude	O
of	O
interaction	O
with	O
IL	B-geneY
-	I-geneY
6	E-geneY
was	O
under	O
predicted	O
~	O
3	O
-	O
fold	O
.	O

The	O
complexity	O
of	O
TP	O
-	O
DDI	O
highlights	O
underlying	O
pathophysiological	O
factors	O
to	O
be	O
considered	O
but	O
these	O
simulations	O
provide	O
valuable	O
first	O
steps	O
towards	O
predictions	O
of	O
TP	O
-	O
DDI	O
risk.Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
accepted	O
article	O
preview	O
online	O
10	O
April	O
2013	O
doi	O
:	O
10.1038	O
/	O
clpt.2013.79	O
.	O

Threshold	O
concentrations	O
of	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
:	O
the	O
effects	O
on	O
contractions	O
induced	O
by	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
in	O
isolated	O
rat	O
cerebral	O
and	O
mesenteric	O
arteries	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
threshold	O
concentrations	O
of	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
in	O
isolated	O
rat	O
basilar	O
arteries	O
with	O
those	O
in	O
mesenteric	O
arterial	O
branches	O
and	O
investigates	O
the	O
mechanisms	O
of	O
inhibitory	O
and	O
potentiating	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
-	O
effects	O
.	O

In	O
basilar	O
arteries	O
,	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
reduces	O
the	O
contractions	O
induced	O
by	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
,	O
by	O
the	O
thromboxane	B-chem
A2	E-chem
agonist	O
U46619	S-chem
,	O
and	O
by	O
vasopressin	S-geneY
.	O

The	O
inhibitory	O
effect	O
of	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
on	O
the	O
contraction	O
induced	O
by	O
5	B-chem
-	I-chem
HT	E-chem
is	O
abolished	O
by	O
deendothelialization	O
,	O
by	O
the	O
endothelin	B-geneY-C6-2
ET	I-geneY-C6-2
(	I-geneY-C6-2
B	I-geneY-C6-2
)	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
RES	B-chem-C6-1
701	I-chem-C6-1
-	I-chem-C6-1
1	E-chem-C6-1
,	O
by	O
indomethacin	S-chem
,	O
or	O
by	O
glibenclamide	S-chem
.	O

In	O
mesenteric	O
arteries	O
,	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
potentiates	O
the	O
contractile	O
effects	O
of	O
5	B-chem
-	I-chem
HT	E-chem
,	O
U46619	S-chem
,	O
and	O
vasopressin	S-geneY
.	O

The	O
potentiation	O
of	O
the	O
contractile	O
effect	O
induced	O
by	O
5	B-chem
-	I-chem
HT	E-chem
is	O
only	O
somewhat	O
modified	O
by	O
deendothelialization	O
,	O
but	O
abolished	O
by	O
the	O
thromboxane	B-geneY-C6-2
A2	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
GR32191	S-chem-C6-1
and	O
ridogrel	S-chem-C6-1
.	O

U46619	S-chem
potentiates	O
the	O
5	B-chem
-	I-chem
HT	E-chem
-	O
effect	O
in	O
mesenteric	O
arteries	O
.	O

Thus	O
,	O
though	O
the	O
contractile	O
endothelin	B-geneN
ET	I-geneN
(	I-geneN
A	I-geneN
)	I-geneN
receptors	E-geneN
were	O
not	O
blocked	O
,	O
threshold	O
concentrations	O
of	O
endothelin	B-geneN
-	I-geneN
1	E-geneN
inhibited	O
contractile	O
effects	O
in	O
the	O
rat	O
basilar	O
artery	O
via	O
activation	O
of	O
endothelial	B-geneY
ET	I-geneY
(	I-geneY
B	I-geneY
)	I-geneY
receptors	E-geneY
.	O

Prostaglandins	S-chem
and	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
K	I-geneN
+	I-geneN
channels	E-geneN
are	O
involved	O
in	O
this	O
inhibitory	O
action	O
.	O

In	O
contrast	O
,	O
endothelin	B-geneN
-	I-geneN
1	E-geneN
potentiates	O
contractile	O
actions	O
in	O
mesenteric	O
arteries	O
via	O
the	O
release	O
of	O
endogeneous	O
thromboxane	B-chem
A2	E-chem
from	O
non	O
-	O
endothelial	O
cells	O
.	O

The	O
study	O
points	O
out	O
the	O
completely	O
different	O
role	O
of	O
the	O
endothelium	O
in	O
combined	O
effects	O
of	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
between	O
cerebral	O
and	O
mesenteric	O
arteries	O
.	O

Cytochrome	B-geneN
P450	E-geneN
-	O
mediated	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
Galgeun	O
-	O
tang	O
.	O

We	O
evaluated	O
the	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
Galgeun	O
-	O
tang	O
(	O
GGT	O
)	O
extracts	O
,	O
mediated	O
by	O
cytochrome	B-geneN
P450	E-geneN
(	O
CYP	S-geneN
)	O
inhibition	O
/	O
induction	O
.	O

Further	O
,	O
the	O
effects	O
of	O
fermentation	O
on	O
the	O
CYP	S-geneN
-	O
mediated	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
GGT	O
extracts	O
were	O
determined	O
.	O

As	O
measured	O
by	O
LC	O
-	O
ESI	O
/	O
MS	O
/	O
MS	O
,	O
GGT	O
extracts	O
(	O
0	O
-	O
300μg	O
/	O
mL	O
)	O
showed	O
no	O
inhibitory	O
activity	O
toward	O
eight	O
CYP	S-geneN
isoforms	O
(	O
1A2	B-geneN
,	I-geneN
2A6	I-geneN
,	I-geneN
2B6	I-geneN
,	I-geneN
2C9	I-geneN
,	I-geneN
2C19	I-geneN
,	I-geneN
2D6	I-geneN
,	I-geneN
2E1	I-geneN
,	I-geneN
and	I-geneN
3A4	E-geneN
)	O
in	O
pooled	O
human	O
liver	O
microsomes	O
,	O
suggesting	O
that	O
GGT	O
may	O
have	O
low	O
potential	O
for	O
herb	O
-	O
drug	O
interactions	O
mediated	O
by	O
CYP	S-geneN
inhibition	O
.	O

Hepatic	O
CYP	S-geneN
expression	O
and	O
activity	O
in	O
rats	O
treated	O
with	O
GGT	O
extracts	O
twice	O
per	O
day	O
for	O
1week	O
was	O
examined	O
.	O

Among	O
the	O
tested	O
CYP	S-geneN
isoforms	O
(	O
1A1	B-geneN
,	I-geneN
1A2	I-geneN
,	I-geneN
1B1	I-geneN
,	I-geneN
2B1	I-geneN
,	I-geneN
2C11	I-geneN
,	I-geneN
2E1	I-geneN
,	I-geneN
3A1	I-geneN
,	I-geneN
3A2	I-geneN
,	I-geneN
and	I-geneN
4A1	E-geneN
)	O
,	O
CYP1B1	B-geneN
and	I-geneN
4A1	E-geneN
were	O
increased	O
by	O
GGT	O
extracts	O
.	O

Hepatic	O
activities	O
of	O
7	B-geneY
-	I-geneY
ethoxyresorufin	I-geneY
-	I-geneY
O	I-geneY
-	I-geneY
deethylase	E-geneY
,	O
7	B-geneY
-	I-geneY
pentoxyresorufin	I-geneY
-	I-geneY
O	I-geneY
-	I-geneY
depentylase	E-geneY
,	O
and	O
chlorzoxazone	B-geneY
6	I-geneY
-	I-geneY
hydroxylase	E-geneY
,	O
but	O
not	O
midazolam	B-geneN
hydroxylase	E-geneN
were	O
also	O
elevated	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
GGT	O
extracts	O
may	O
increase	O
the	O
toxicity	O
of	O
environmental	O
toxicants	O
through	O
the	O
elevating	O
CYP	S-geneN
-	O
dependent	O
metabolic	O
activation	O
.	O

Interestingly	O
,	O
the	O
increases	O
in	O
CYP1B1	S-geneY
and	O
CYP4A1	S-geneY
levels	O
,	O
and	O
7	B-geneY
-	I-geneY
ethoxyresorufin	I-geneY
-	I-geneY
O	I-geneY
-	I-geneY
deethylase	E-geneY
,	O
7	B-geneY
-	I-geneY
pentoxyresorufin	I-geneY
-	I-geneY
O	I-geneY
-	I-geneY
depentylase	E-geneY
,	O
and	O
chlorzoxazone	B-geneY
6	I-geneY
-	I-geneY
hydroxylase	E-geneY
activities	O
were	O
attenuated	O
by	O
fermentation	O
of	O
GGT	O
extract	O
using	O
Lactobacillus	O
plantarum	O
KFRI	O
402	O
,	O
but	O
not	O
144	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
CYP	S-geneN
regulatory	O
component	O
(	O
s	O
)	O
from	O
GGT	O
and	O
determination	O
its	O
metabolism	O
.	O

Studies	O
of	O
the	O
biogenic	B-geneN
amine	I-geneN
transporters	E-geneN
.	O
13	O
.	O
Identification	O
of	O
``	O
agonist	O
``	O
and	O
``	O
antagonist	O
``	O
allosteric	O
modulators	O
of	I-chem
amphetamine	O
-	O
induced	O
dopamine	O
release	O
.	O

Recent	O
studies	O
identified	O
novel	O
allosteric	O
modulators	O
of	O
the	O
dopamine	B-geneY
(	I-geneY
DA	I-geneY
)	I-geneY
transporter	E-geneY
(	O
DAT	S-geneY
)	O
.	O

N	B-chem
-	I-chem
(	I-chem
Diphenylmethyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
4	I-chem
-	I-chem
quinazolinamine	E-chem
(	O
SoRI	B-chem
-	I-chem
9804	E-chem
)	O
,	O
N	B-chem
-	I-chem
(	I-chem
2,2	I-chem
-	I-chem
diphenylethyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
4	I-chem
-	I-chem
quinazolinamine	E-chem
(	O
SoRI	B-chem
-	I-chem
20040	E-chem
)	O
,	O
and	O
N	B-chem
-	I-chem
(	I-chem
3,3	I-chem
-	I-chem
diphenylpropyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
4	I-chem
-	I-chem
quinazolinamine	E-chem
(	O
SoRI	B-chem
-	I-chem
20041	E-chem
)	O
partially	O
inhibited	O
[	B-chem
(	I-chem
125	I-chem
)	I-chem
I	I-chem
]	I-chem
3beta	I-chem
-	I-chem
(	I-chem
4	I-chem
'	I-chem
-	I-chem
iodophenyl	I-chem
)	I-chem
tropan	I-chem
-	I-chem
2beta	I-chem
-	I-chem
carboxylic	I-chem
acid	I-chem
methyl	I-chem
ester	E-chem
(	O
RTI	B-chem
-	I-chem
55	E-chem
)	O
binding	O
,	O
slowed	O
the	O
dissociation	O
rate	O
of	O
[	B-chem
(	I-chem
125	I-chem
)	I-chem
I	I-chem
]	I-chem
RTI	I-chem
-	I-chem
55	E-chem
from	O
the	O
DAT	S-geneY
,	O
and	O
partially	O
inhibited	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
dopamine	E-chem
uptake	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
SoRI	B-chem
-	I-chem
9804	E-chem
and	O
SoRI	B-chem
-	I-chem
20040	E-chem
,	O
at	O
doses	O
that	O
do	O
not	O
alter	O
release	O
,	O
partially	O
inhibited	O
d	B-chem
-	I-chem
amphetamine	E-chem
-	O
induced	O
DAT	S-geneY
-	O
mediated	O
release	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenylpyridinium	E-chem
(	O
MPP	B-chem
(	I-chem
+	I-chem
)	E-chem
)	O
or	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
dopamine	E-chem
from	O
striatal	O
synaptosomes	O
(	O
``	O
DAT	O
-	O
mediated	O
DA	O
release	O
``	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

SoRI	B-chem
-	I-chem
20041	E-chem
,	O
which	O
does	O
not	O
alter	O
DAT	S-geneY
-	O
mediated	O
DA	S-chem
release	O
measured	O
with	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
DA	E-chem
,	O
reversed	O
the	O
effect	O
of	O
SoRI	B-chem
-	I-chem
20040	E-chem
.	O

SoRI	B-chem
-	I-chem
20040	E-chem
and	O
SoRI	B-chem
-	I-chem
9804	E-chem
also	O
partially	O
inhibited	O
DAT	S-geneY
-	O
mediated	O
DA	S-chem
release	O
induced	O
by	O
DA	S-chem
or	O
(	B-chem
+	I-chem
/	I-chem
-	I-chem
)	I-chem
-	I-chem
3,4	I-chem
-	I-chem
methylenedioxyamphetamine	E-chem
,	O
demonstrating	O
that	O
the	O
observed	O
partial	O
inhibition	O
is	O
not	O
specific	O
for	O
a	O
particular	O
DAT	S-geneY
substrate	O
.	O

SoRI	B-chem
-	I-chem
9804	E-chem
and	O
SoRI	B-chem
-	I-chem
20040	E-chem
did	O
not	O
attenuate	O
D	B-chem
-	I-chem
amphetamine	E-chem
-	O
induced	O
release	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
5	I-chem
-	I-chem
hydroxytryptamine	E-chem
from	O
serotonergic	O
,	O
or	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
MPP	I-chem
(	I-chem
+	I-chem
)	E-chem
from	O
noradrenergic	O
,	O
nerve	O
terminals	O
.	O

Kinetic	O
experiments	O
demonstrated	O
that	O
SoRI	B-chem
-	I-chem
9804	E-chem
,	O
in	O
contrast	O
to	O
cocaine	S-chem
,	O
slowed	O
D	B-chem
-	I-chem
amphetamine	E-chem
-	O
induced	O
release	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
MPP	I-chem
(	I-chem
+	I-chem
)	E-chem
from	O
dopaminergic	O
nerve	O
terminals	O
without	O
altering	O
the	O
apparent	O
rate	O
constants	O
.	O

The	O
two	O
major	O
findings	O
of	O
this	O
study	O
are	O
1	O
)	O
the	O
identification	O
of	O
both	O
``	O
agonist	O
``	O
(	I-chem
SoRI	I-chem
-	I-chem
9804	O
and	O
SoRI	I-chem
-	I-chem
20040	O
)	O
and	O
``	O
antagonist	O
``	I-chem
(	I-chem
SoRI	I-chem
-	I-chem
20041	O
)	O
allosteric	O
modulators	O
of	I-chem
D	I-chem
-	I-chem
amphetamine	O
-	O
induced	O
DAT	O
-	O
mediated	O
DA	O
release	O
and	O
2	I-chem
)	I-chem
[	I-chem
(	I-chem
3	I-chem
)	E-chem
H	O
]	O
DA	O
uptake	O
and	I-chem
d	I-chem
-	I-chem
amphetamine	O
-	O
induced	O
DAT	O
-	O
mediated	O
efflux	O
can	O
be	O
separately	O
modulated	O
.	O

Such	O
agents	O
may	O
have	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
stimulant	O
addiction	O
,	O
Parkinson	O
's	O
disease	O
,	O
and	O
other	O
psychiatric	O
disorders	O
.	O

Rosmarinic	B-chem
acid	E-chem
ameliorates	O
acute	O
liver	O
damage	O
and	O
fibrogenesis	O
in	O
carbon	B-chem
tetrachloride	E-chem
-	O
intoxicated	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
rosmarinic	B-chem
acid	E-chem
(	O
RA	O
)	O
,	O
a	O
natural	O
phenolic	O
,	O
in	O
the	O
treatment	O
of	O
acute	O
liver	O
toxicity	O
.	O

RA	O
at	O
10	O
,	O
25	O
and	O
50mg	O
/	O
kg	O
was	O
administered	O
by	O
gavage	O
once	O
daily	O
for	O
2	O
consecutive	O
days	O
,	O
6h	O
after	O
CCl	B-chem
(	I-chem
4	I-chem
)	E-chem
intoxication	O
.	O

CCl	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
intoxication	O
caused	O
hepatic	O
necrosis	O
and	O
increased	O
serum	O
ALT	S-geneN-C3-2
activity	O
.	O

In	O
the	O
livers	O
,	O
oxidative	O
/	O
nitrosative	O
stress	O
was	O
evidenced	O
by	O
increased	O
3	B-chem
-	I-chem
nitrotyrosine	E-chem
(	O
3	B-chem
-	I-chem
NT	E-chem
)	O
and	O
thiobarbituric	B-chem
acid	E-chem
reactive	O
substances	O
(	O
TBARS	O
)	O
formation	O
and	O
a	O
significant	O
decrease	O
in	O
Cu	B-geneY
/	I-geneY
Zn	I-geneY
superoxide	I-geneY
dismutase	E-geneY
(	O
SOD	S-geneN
)	O
activity	O
.	O

CCl	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
administration	O
triggered	O
inflammatory	O
response	O
in	O
mice	O
livers	O
by	O
activating	O
nuclear	B-geneN-C3-2
factor	I-geneN-C3-2
-	I-geneN-C3-2
kappaB	E-geneN-C3-2
(	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
)	O
,	O
which	O
coincided	O
with	O
the	O
induction	O
of	O
tumor	B-geneY-C3-2
necrosis	I-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
(	O
TNF	B-geneY-C3-2
-	I-geneY-C3-2
α	E-geneY-C3-2
)	O
and	O
cyclooxygenase	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
(	O
COX	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
)	O
.	O

RA	O
improved	O
histological	O
and	O
serum	O
markers	O
of	O
liver	O
damage	O
and	O
significantly	O
ameliorated	O
oxidative	O
/	O
nitrosative	O
stress	O
and	O
inflammatory	O
response	O
in	O
liver	O
tissue	O
.	O

Additionally	O
,	O
RA	O
prevented	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
beta1	E-geneY
(	O
TGF	B-geneY
-	I-geneY
β1	E-geneY
)	O
and	O
alpha	B-geneY
-	I-geneY
smooth	I-geneY
muscle	I-geneY
actin	E-geneY
(	O
α	B-geneY
-	I-geneY
SMA	E-geneY
)	O
expression	O
,	O
suggesting	O
suppression	O
of	O
profibrotic	O
response	O
.	O

Furthermore	O
,	O
RA	O
significantly	O
inhibited	O
the	O
CCl	B-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
)	E-chem-C4-1
-	O
induced	O
apoptosis	O
,	O
which	O
was	O
evident	O
from	O
decreased	O
cleavage	O
of	O
caspase	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
.	O

The	O
hepatoprotective	O
activity	O
of	O
RA	O
coincided	O
with	O
enhanced	O
NF	B-geneY
-	I-geneY
E2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
Nrf2	S-geneY
)	O
and	O
heme	B-geneY
oxygenase	I-geneY
-	I-geneY
1	E-geneY
(	O
HO	B-geneY
-	I-geneY
1	E-geneY
)	O
expression	O
.	O

The	O
results	O
of	O
this	O
study	O
indicates	O
that	O
RA	O
possesses	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
,	O
antiapoptotic	O
and	O
antifibrotic	O
activity	O
against	O
acute	O
liver	O
toxicity	O
.	O

Oxidative	O
Stress	O
and	O
DNA	O
Damage	O
in	O
Human	O
Gastric	O
Carcinoma	O
:	O
8	B-chem
-	I-chem
Oxo	I-chem
-	I-chem
7'8	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyguanosine	E-chem
(	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
)	O
as	O
a	O
Possible	O
Tumor	O
Marker	O
.	O

We	O
characterized	O
the	O
oxidative	O
stress	O
(	O
OS	O
)	O
status	O
by	O
the	O
levels	O
of	O
reduced	B-chem
/	I-chem
oxidized	I-chem
glutathione	E-chem
(	O
GSH	S-chem
/	O
GSSG	S-chem
)	O
,	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
and	O
the	O
mutagenic	O
base	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
7'8	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyguanosine	E-chem
(	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
)	O
in	O
human	O
gastric	O
carcinoma	O
(	O
HGC	O
)	O
samples	O
and	O
compared	O
the	O
results	O
with	O
normal	O
tissue	O
from	O
the	O
same	O
patients	O
.	O

We	O
also	O
analyzed	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
in	O
peripheral	O
mononuclear	O
cells	O
(	O
PMNC	O
)	O
and	O
urine	O
from	O
healthy	O
control	O
subjects	O
and	O
in	O
affected	O
patients	O
in	O
the	O
basal	O
state	O
and	O
one	O
,	O
three	O
,	O
six	O
,	O
nine	O
and	O
twelve	O
months	O
after	O
tumor	O
resection	O
.	O

The	O
levels	O
of	O
DNA	O
repair	O
enzyme	O
mRNA	O
expression	O
(	O
hOGG1	S-geneY
,	O
RAD51	S-geneY
,	O
MUYTH	S-geneY
and	O
MTH1	S-geneY
)	O
were	O
determined	O
in	O
tumor	O
specimens	O
and	O
compared	O
with	O
normal	O
mucosa	O
.	O

Tumor	O
specimens	O
exhibited	O
increased	O
levels	O
of	O
MDA	S-chem
and	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
compared	O
with	O
normal	O
gastric	O
tissue	O
.	O

GSH	S-chem
levels	O
were	O
also	O
increased	O
,	O
while	O
GSSG	S-chem
levels	O
remained	O
stable	O
.	O

DNA	O
repair	O
enzyme	O
mRNA	O
expression	O
was	O
induced	O
in	O
the	O
tumor	O
tissues	O
.	O

Levels	O
of	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
were	O
significantly	O
elevated	O
in	O
both	O
urine	O
and	O
PMNC	O
of	O
gastric	O
cancer	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

After	O
gastrectomy	O
,	O
the	O
levels	O
of	O
the	O
damaged	O
base	O
in	O
urine	O
and	O
PMNC	O
decreased	O
progressively	O
to	O
values	O
close	O
to	O
those	O
found	O
in	O
the	O
healthy	O
population	O
.	O

The	O
high	O
levels	O
of	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
dG	E-chem
in	O
urine	O
may	O
be	O
related	O
to	O
the	O
increased	O
induction	O
of	O
DNA	O
repair	O
activity	O
in	O
tumor	O
tissue	O
,	O
and	O
the	O
changes	O
observed	O
after	O
tumor	O
resection	O
support	O
its	O
potential	O
use	O
as	O
a	O
tumor	O
marker	O
.	O

Green	O
approach	O
&	O
#	O
8212	O
;	O
multicomponent	O
production	O
of	O
boron	S-chem
&	O
#	O
8212	O
;	O
containing	O
hantzsch	O
and	O
biginelli	O
esters	O
.	O

Multicomponent	O
reactions	O
are	O
excellent	O
methods	O
that	O
meet	O
the	O
requirements	O
of	O
green	O
chemistry	O
,	O
by	O
reducing	O
the	O
number	O
of	O
steps	O
,	O
and	O
consequently	O
reducing	O
purification	O
requirements	O
.	O

Accordingly	O
,	O
in	O
this	O
work	O
,	O
11	O
novel	O
hybrid	O
-	O
boron	S-chem
-	O
containing	O
molecules	O
,	O
namely	O
eight	O
1,4	B-chem
-	I-chem
dihydropyridines	E-chem
and	O
three	O
3,4	B-chem
-	I-chem
dihydropyrimidinones	E-chem
,	O
derived	O
from	O
formylphenylboronic	B-chem
acids	E-chem
(	O
ortho	O
,	O
meta	O
and	O
para	O
)	O
,	O
were	O
obtained	O
using	O
a	O
green	O
approach	O
,	O
involving	O
H	O
-	O
4CR	O
and	O
B	O
-	O
3CR	O
practices	O
,	O
in	O
the	O
presence	O
of	O
ethanol	S-chem
,	O
which	O
is	O
a	O
green	O
solvent	O
,	O
and	O
using	O
three	O
comparatively	O
different	O
modes	O
of	O
activation	O
(	O
mantle	O
heating	O
,	O
yield	O
3	O
%	O
-	O
7	O
%	O
in	O
24	O
h	O
,	O
Infrared	O
Radiation	O
(	O
IR	O
)	O
irradiation	O
,	O
yield	O
12	O
%	O
-	O
17	O
%	O
in	O
12	O
h	O
,	O
and	O
microwave	O
irradiation	O
,	O
yield	O
18	O
%	O
-	O
80	O
%	O
,	O
requiring	O
very	O
low	O
reaction	O
times	O
of	O
0.25	O
-	O
0.33	O
h	O
)	O
.	O

In	O
addition	O
,	O
as	O
a	O
green	O
-	O
approach	O
is	O
offered	O
,	O
a	O
convenient	O
analysis	O
,	O
of	O
the	O
12	O
green	O
chemistry	O
principles	O
for	O
the	O
overall	O
procedure	O
was	O
performed	O
.	O

Finally	O
,	O
since	O
all	O
the	O
products	O
are	O
new	O
,	O
characterizations	O
were	O
carried	O
out	O
using	O
common	O
analytic	O
procedures	O
(	O
1H	S-chem
,	O
11B	S-chem
,	O
and	O
13C	S-chem
NMR	O
,	O
FAB	O
+	O
MS	O
,	O
HRMS	O
,	O
and	O
IR	O
)	O
.	O

The	O
accurate	O
mass	O
data	O
of	O
unexpected	O
ions	O
related	O
to	O
interactions	O
between	O
thioglycerol	S-chem
and	O
the	O
expected	O
products	O
,	O
in	O
the	O
FAB	O
+	O
-	O
mode	O
,	O
enabled	O
unequivocal	O
characterization	O
of	O
the	O
target	O
molecules	O
.	O

alpha	B-chem
-	I-chem
Linolenic	I-chem
acid	E-chem
,	O
Delta6	B-geneY
-	I-geneY
desaturase	E-geneY
gene	O
polymorphism	O
,	O
and	O
the	O
risk	O
of	O
nonfatal	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Delta	B-geneY
(	I-geneY
6	I-geneY
)	I-geneY
-	I-geneY
Desaturase	E-geneY
(	O
FADS2	S-geneY
)	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
polyunsaturated	B-chem
fatty	I-chem
acid	E-chem
(	O
PUFA	S-chem
)	O
biosynthetic	O
pathway	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
test	O
whether	O
the	O
common	O
deletion	O
[	O
T	O
/	O
-	O
]	O
in	O
the	O
promoter	O
of	O
FADS2	S-geneY-C9-2
affects	O
the	O
PUFA	S-chem-C9-1
biosynthetic	O
pathway	O
and	O
consequently	O
modifies	O
the	O
effect	O
of	O
alpha	B-chem-C9-1
-	I-chem-C9-1
linolenic	I-chem-C9-1
acid	E-chem-C9-1
(	O
ALA	S-chem-C9-1
)	O
on	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

DESIGN	O
:	O
Case	O
subjects	O
(	O
n	O
=	O
1694	O
)	O
with	O
a	O
first	O
nonfatal	O
acute	O
MI	O
were	O
matched	O
by	O
age	O
,	O
sex	O
,	O
and	O
area	O
of	O
residence	O
to	O
1694	O
population	O
-	O
based	O
control	O
subjects	O
in	O
Costa	O
Rica	O
.	O

PUFAs	S-chem
were	O
quantified	O
by	O
gas	O
-	O
liquid	O
chromatography	O
from	O
plasma	O
and	O
adipose	O
tissue	O
samples	O
.	O

Least	O
-	O
squares	O
means	O
from	O
generalized	O
linear	O
models	O
and	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
CIs	O
from	O
multiple	O
conditional	O
logistic	O
regression	O
models	O
were	O
estimated	O
.	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
the	O
variant	O
T	O
/	O
-	O
allele	O
was	O
48	O
%	O
.	O

Eicosapentaenoic	B-chem
acid	E-chem
,	O
gamma	B-chem
-	I-chem
linolenic	I-chem
acid	E-chem
,	O
and	O
arachidonic	B-chem
acid	E-chem
decreased	O
in	O
adipose	O
tissue	O
and	O
plasma	O
with	O
increasing	O
number	O
of	O
copies	O
of	O
the	O
variant	O
allele	O
with	O
a	O
monotonic	O
trend	O
(	O
P	O
<	O
0.05	O
for	O
all	O
)	O
.	O

Fasting	O
plasma	O
triacylglycerols	S-chem
by	O
genotype	O
were	O
2.08	O
mmol	O
/	O
L	O
for	O
TT	O
,	O
2.16	O
mmol	O
/	O
L	O
for	O
T	O
-	O
,	O
and	O
2.26	O
mmol	O
/	O
L	O
for	O
-	O
-	O
[	O
ie	O
,	O
homozygous	O
for	O
the	O
variant	O
(	O
deletion	O
)	O
allele	O
]	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
FADS2	S-geneY
deletion	O
was	O
not	O
associated	O
with	O
MI	O
and	O
did	O
not	O
significantly	O
modify	O
the	O
association	O
between	O
adipose	O
tissue	O
ALA	S-chem
and	O
the	O
risk	O
of	O
MI	O
.	O

CONCLUSIONS	O
:	O
The	O
FADS2	S-geneY
deletion	O
may	O
prevent	O
the	O
conversion	O
of	O
ALA	S-chem
into	O
very	B-chem
-	I-chem
long	I-chem
-	I-chem
chain	I-chem
PUFAs	E-chem
.	O

However	O
,	O
this	O
metabolic	O
effect	O
is	O
not	O
translated	O
into	O
an	O
attenuated	O
risk	O
between	O
ALA	S-chem
and	O
MI	O
among	O
carriers	O
of	O
the	O
variant	O
.	O

It	O
is	O
possible	O
that	O
,	O
at	O
current	O
intakes	O
of	O
ALA	S-chem
,	O
any	O
potential	O
defect	O
in	O
the	O
transcription	O
of	O
the	O
gene	O
is	O
masked	O
by	O
the	O
availability	O
of	O
substrate	O
.	O

Further	O
research	O
in	O
populations	O
deficient	O
in	O
ALA	S-chem
intake	O
is	O
warranted	O
.	O

Management	O
of	O
chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
:	O
focus	O
on	O
newer	O
agents	O
and	O
new	O
uses	O
for	O
older	O
agents	O
.	O

Chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
(	O
CINV	O
)	O
is	O
associated	O
with	O
a	O
significant	O
deterioration	O
in	O
quality	O
of	O
life	O
.	O

The	O
emetogenicity	O
of	O
the	O
chemotherapeutic	O
agents	O
,	O
repeated	O
chemotherapy	O
cycles	O
,	O
and	O
patient	O
risk	O
factors	O
significantly	O
influence	O
CINV	O
.	O

The	O
use	O
of	O
a	O
combination	O
of	O
a	O
serotonin	S-chem
5	B-geneY
-	I-geneY
HT3	E-geneY
receptor	O
antagonist	O
,	O
dexamethasone	S-chem
and	O
a	O
neurokinin	B-geneY
1	I-geneY
(	I-geneY
NK1	I-geneY
)	I-geneY
receptor	E-geneY
antagonist	O
has	O
significantly	O
improved	O
the	O
control	O
of	O
acute	O
and	O
delayed	O
emesis	O
in	O
single	O
-	O
day	O
chemotherapy	O
.	O

Palonosetron	S-chem-C6-1
,	O
a	O
second	O
-	O
generation	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT3	E-geneY-C6-2
receptor	O
antagonist	O
with	O
a	O
different	O
half	O
-	O
life	O
,	O
a	O
different	O
binding	O
capacity	O
and	O
a	O
different	O
mechanism	O
of	O
action	O
than	O
the	O
first	O
-	O
generation	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptor	O
antagonists	O
appears	O
to	O
be	O
the	O
most	O
effective	O
agent	O
in	O
its	O
class	O
.	O

Aprepitant	S-chem-C6-1
,	O
the	O
first	O
and	O
only	O
agent	O
clinically	O
available	O
in	O
the	O
NK1	B-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
drug	O
class	O
has	O
been	O
used	O
effectively	O
as	O
an	O
additive	O
agent	O
to	O
the	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptor	O
antagonists	O
and	O
dexamethasone	S-chem
to	O
control	O
CINV	O
.	O

Rolapitant	S-chem-C6-1
and	O
netupitant	S-chem-C6-1
are	O
other	O
NK1	B-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
that	O
are	O
currently	O
in	O
phase	O
III	O
clinical	O
trials	O
.	O

Despite	O
the	O
control	O
of	O
emesis	O
,	O
nausea	O
has	O
not	O
been	O
well	O
controlled	O
by	O
current	O
agents	O
.	O

Olanzapine	S-chem
,	O
a	O
US	O
-	O
FDA	O
approved	O
antipsychotic	O
,	O
has	O
emerged	O
in	O
recent	O
trials	O
as	O
an	O
effective	O
preventative	O
agent	O
for	O
CINV	O
,	O
as	O
well	O
as	O
a	O
very	O
effective	O
agent	O
for	O
the	O
treatment	O
of	O
breakthrough	O
emesis	O
and	O
nausea	O
.	O

Clinical	O
trials	O
using	O
gabapentin	S-chem
,	O
cannabinoids	O
and	O
ginger	O
have	O
not	O
been	O
definitive	O
regarding	O
their	O
efficacy	O
in	O
the	O
prevention	O
of	O
CINV	O
.	O

Additional	O
studies	O
are	O
necessary	O
for	O
the	O
control	O
of	O
nausea	O
and	O
for	O
the	O
control	O
of	O
CINV	O
in	O
the	O
clinical	O
settings	O
of	O
multiple	O
-	O
day	O
chemotherapy	O
and	O
bone	O
marrow	O
transplantation	O
.	O

3D	O
Organotypic	O
Cultures	O
of	O
Human	O
HepaRG	O
Cells	O
:	O
A	O
Tool	O
for	O
In	O
Vitro	O
Toxicity	O
Studies	O
.	O

Drug	O
-	O
induced	O
human	O
hepatotoxicity	O
is	O
difficult	O
to	O
predict	O
using	O
the	O
current	O
in	O
vitro	O
systems	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
3D	O
organotypic	O
cultures	O
of	O
the	O
human	O
hepatoma	O
HepaRG	O
cell	O
line	O
were	O
prepared	O
using	O
a	O
high	O
-	O
throughput	O
hanging	O
drop	O
method	O
.	O

The	O
organotypic	O
cultures	O
were	O
maintained	O
for	O
3	O
weeks	O
and	O
assessed	O
for	O
(	O
1	O
)	O
liver	O
specific	O
functions	O
,	O
including	O
phase	O
I	O
enzyme	O
and	O
transporter	O
activities	O
,	O
(	O
2	O
)	O
expression	O
of	O
liver	O
-	O
specific	O
proteins	O
,	O
and	O
(	O
3	O
)	O
responses	O
to	O
three	O
drugs	O
(	O
acetaminophen	S-chem
,	O
troglitazone	S-chem
,	O
and	O
rosiglitazone	S-chem
)	O
.	O

Our	O
results	O
show	O
that	O
the	O
organotypic	O
cultures	O
maintain	O
high	O
liver	O
-	O
specific	O
functionality	O
during	O
3	O
weeks	O
of	O
culture	O
.	O

The	O
immunohistochemistry	O
analyses	O
illustrate	O
that	O
the	O
organotypic	O
cultures	O
express	O
liver	O
-	O
specific	O
markers	O
such	O
as	O
albumin	S-geneY
,	O
CYP3A4	S-geneY
,	O
CYP2E1	S-geneY
,	O
and	O
MRP	B-geneY
-	I-geneY
2	E-geneY
throughout	O
the	O
cultivation	O
period	O
.	O

Accordingly	O
,	O
the	O
production	O
rates	O
of	O
albumin	S-geneY
and	O
glucose	S-chem
,	O
as	O
well	O
as	O
CYP2E1	S-geneY
activity	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
3D	O
versus	O
the	O
2D	O
cultures	O
.	O

Toxicity	O
studies	O
show	O
that	O
the	O
organotypic	O
cultures	O
are	O
more	O
sensitive	O
to	O
acetaminophen	S-chem
-	O
and	O
rosiglitazone	S-chem
-	O
induced	O
toxicity	O
but	O
less	O
sensitive	O
to	O
troglitazone	S-chem
-	O
induced	O
toxicity	O
than	O
the	O
2D	O
cultures	O
.	O

Furthermore	O
,	O
the	O
EC50	O
value	O
(	O
2.7mM	O
)	O
for	O
acetaminophen	S-chem
on	O
the	O
3D	O
cultures	O
was	O
similar	O
to	O
in	O
vivo	O
toxicity	O
.	O

In	O
summary	O
,	O
the	O
results	O
from	O
our	O
study	O
suggest	O
that	O
the	O
3D	O
organotypic	O
HepaRG	O
culture	O
is	O
a	O
promising	O
in	O
vitro	O
tool	O
for	O
more	O
accurate	O
assessment	O
of	O
acute	O
and	O
also	O
possibly	O
for	O
chronic	O
drug	O
-	O
induced	O
hepatotoxicity	O
.	O

Effects	O
of	O
minocycline	S-chem
on	O
Fas	S-geneY
-	O
mediated	O
fulminant	O
hepatitis	O
in	O
mice	O
.	O

1	O
.	O

Minocycline	S-chem
has	O
anti	O
-	O
inflammatory	O
and	O
antiapoptotic	O
effects	O
on	O
cartilage	O
,	O
neurons	O
and	O
periodontal	O
tissues	O
,	O
and	O
both	O
properties	O
are	O
central	O
to	O
the	O
pharmaceutical	O
treatment	O
of	O
liver	O
diseases	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
minocycline	S-chem
on	O
fulminant	O
hepatitis	O
in	O
C57BL	O
/	O
6J	O
mice	O
induced	O
by	O
lethal	O
challenge	O
of	O
the	O
activating	O
anti	O
-	O
Fas	S-geneY
antibody	O
,	O
Jo2	O
.	O

2	O
.	O

Intraperitoneal	O
injection	O
of	O
Jo2	O
(	O
0.6	O
microg	O
g	O
(	O
-	O
1	O
)	O
)	O
to	O
mice	O
resulted	O
in	O
fulminant	O
hepatitis	O
,	O
as	O
evidenced	O
by	O
increase	O
of	O
serum	B-geneN
alanine	I-geneN
/	I-geneN
aspartate	I-geneN
transaminase	E-geneN
activities	O
and	O
histopathological	O
alterations	O
in	O
liver	O
sections	O
,	O
as	O
well	O
as	O
animal	O
death	O
.	O

Nevertheless	O
,	O
mice	O
pretreated	O
with	O
three	O
doses	O
of	O
minocycline	S-chem
(	O
5	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
resisted	O
this	O
lethal	O
effect	O
significantly	O
.	O

Minocycline	S-chem
treatment	O
improved	O
the	O
survival	O
kinetics	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
,	O
when	O
mice	O
were	O
challenged	O
simultaneously	O
with	O
Jo2	O
or	O
even	O
treated	O
30	O
min	O
after	O
the	O
lethal	O
challenge	O
.	O

3	O
.	O

Jo2	O
-	O
induced	O
activation	O
of	O
caspase	B-geneN
-	I-geneN
3	I-geneN
or	I-geneN
-	I-geneN
9	E-geneN
in	O
liver	O
tissues	O
was	O
inhibited	O
by	O
minocycline	S-chem
pretreatment	O
,	O
and	O
yet	O
the	O
direct	O
addition	O
of	O
minocycline	S-chem
to	O
liver	O
extracts	O
from	O
Jo2	O
-	O
challenged	O
mice	O
failed	O
to	O
block	O
caspase	S-geneN
activation	O
in	O
vitro	O
.	O

Moreover	O
,	O
minocycline	S-chem-C4-1
efficiently	O
suppressed	O
the	O
release	O
of	O
cytochrome	B-geneY-C4-2
c	E-geneY-C4-2
from	O
mitochondria	O
of	O
the	O
liver	O
tissues	O
from	O
Jo2	O
-	O
challenged	O
mice	O
.	O

In	O
contrast	O
,	O
caspase	B-geneY
-	I-geneY
8	E-geneY
activation	O
and	O
Bid	S-geneY
truncation	O
triggered	O
by	O
Jo2	O
were	O
not	O
diminished	O
by	O
minocycline	S-chem
pretreatment	O
in	O
mouse	O
livers	O
.	O

4	O
.	O

Our	O
results	O
suggest	O
that	O
easing	O
of	O
Fas	S-geneY
-	O
triggered	O
fulminant	O
hepatitis	O
by	O
minocycline	S-chem-C4-1
may	O
involve	O
a	O
mitochondrial	O
apoptotic	O
pathway	O
,	O
probably	O
through	O
preventing	O
cytochrome	B-geneY-C4-2
c	E-geneY-C4-2
release	O
and	O
thereby	O
blocking	O
downstream	O
caspase	S-geneN-C4-2
activation	O
.	O

Albiglutide	O
:	O
a	O
new	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
agonist	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

OBJECTIVE	O
:	O
To	O
review	O
the	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
safety	O
,	O
and	O
efficacy	O
of	O
albiglutide	O
,	O
a	O
glucagon	B-geneY
-	I-geneY
like	I-geneY
peptide	I-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
agonist	O
(	O
GLP	B-geneY
-	I-geneY
1	I-geneY
RA	O
)	O
in	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
.	O

DATA	O
SOURCES	O
:	O
A	O
MEDLINE	O
search	O
(	O
1950	O
-	O
June	O
2014	O
)	O
was	O
conducted	O
using	O
the	O
keyword	O
albiglutide	O
.	O

References	O
were	O
reviewed	O
to	O
identify	O
additional	O
sources	O
.	O

STUDY	O
SELECTION	O
AND	O
DATA	O
EXTRACTION	O
:	O
Articles	O
evaluating	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
safety	O
,	O
or	O
efficacy	O
of	O
albiglutide	O
were	O
included	O
.	O

DATA	O
SYNTHESIS	O
:	O
Albiglutide	O
is	O
a	O
long	O
-	O
acting	O
GLP	B-geneY
-	I-geneY
1	I-geneY
RA	O
that	O
lowers	O
glycosylated	B-geneY
hemoglobin	E-geneY
(	O
A1C	S-geneY
)	O
and	O
reduces	O
weight	O
by	O
stimulating	O
glucose	S-chem
-	O
dependent	O
insulin	S-geneY
secretion	O
,	O
suppressing	O
glucagon	S-geneY
secretion	O
,	O
delaying	O
gastric	O
emptying	O
,	O
and	O
promoting	O
satiety	O
.	O

Albiglutide	O
has	O
a	O
long	O
half	O
-	O
life	O
as	O
a	O
result	O
of	O
resistance	O
to	O
degradation	O
by	O
dipeptidyl	B-geneY
peptidase	I-geneY
-	I-geneY
4	E-geneY
and	O
fusion	O
to	O
albumin	S-geneY
,	O
thus	O
allowing	O
once	O
-	O
weekly	O
dosing	O
.	O

Albiglutide	O
has	O
been	O
studied	O
as	O
monotherapy	O
and	O
add	O
-	O
on	O
therapy	O
to	O
metformin	S-chem
,	O
sulfonylureas	S-chem
,	O
thiazolidinediones	S-chem
,	O
insulin	S-geneY
glargine	O
,	O
and	O
varying	O
combinations	O
of	O
these	O
agents	O
.	O

Clinical	O
studies	O
have	O
shown	O
albiglutide	O
to	O
be	O
superior	O
to	O
placebo	O
,	O
sitagliptin	S-chem
,	O
and	O
glimepiride	S-chem
and	O
noninferior	O
to	O
insulin	S-geneY
glargine	O
and	O
insulin	S-geneY
lispro	O
at	O
reducing	O
A1C	S-geneY
in	O
T2D	O
patients	O
,	O
with	O
A1C	S-geneY
changes	O
from	O
baseline	O
ranging	O
from	O
-	O
0.55	O
%	O
to	O
-	O
0.9	O
%	O
.	O

Noninferiority	O
was	O
not	O
achieved	O
when	O
compared	O
to	O
liraglutide	O
and	O
pioglitazone	S-chem
.	O

Weight	O
changes	O
ranged	O
from	O
+	O
0.28	O
to	O
-	O
1.21	O
kg	O
.	O

The	O
most	O
common	O
side	O
effects	O
are	O
upper	O
-	O
respiratory	O
-	O
tract	O
infections	O
,	O
diarrhea	O
,	O
nausea	O
,	O
and	O
injection	O
-	O
site	O
reactions	O
.	O

CONCLUSION	O
:	O
Albiglutide	O
is	O
the	O
fourth	O
GLP	B-geneY
-	I-geneY
1	I-geneY
RA	O
approved	O
in	O
the	O
United	O
States	O
.	O

Advantages	O
include	O
once	O
-	O
weekly	O
dosing	O
and	O
fewer	O
gastrointestinal	O
side	O
effects	O
compared	O
with	O
liraglutide	O
,	O
but	O
it	O
is	O
less	O
effective	O
at	O
reducing	O
A1C	S-geneY
and	O
weight	O
compared	O
to	O
liraglutide	O
.	O

It	O
has	O
not	O
been	O
compared	O
head	O
to	O
head	O
with	O
other	O
GLP	B-geneY
-	I-geneY
1	I-geneY
RAs	O
.	O

TCDD	S-chem-C4-1
inhibition	O
of	O
canonical	O
wnt	S-geneN-C4-2
signaling	O
disrupts	O
prostatic	O
bud	O
formation	O
in	O
mouse	O
urogenital	O
sinus	O
.	O

In	O
mice	O
,	O
in	O
utero	O
exposure	O
to	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
reduces	O
the	O
number	O
of	O
dorsolateral	O
prostatic	O
buds	O
resulting	O
in	O
a	O
smaller	O
dorsolateral	O
prostate	O
and	O
prevents	O
formation	O
of	O
ventral	O
buds	O
culminating	O
in	O
ventral	O
prostate	O
agenesis	O
.	O

The	O
genes	O
and	O
signaling	O
pathways	O
affected	O
by	O
TCDD	S-chem
that	O
are	O
responsible	O
for	O
disrupting	O
prostate	O
development	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
treatment	O
of	O
urogenital	O
sinus	O
(	O
UGS	O
)	O
organ	O
cultures	O
with	O
known	O
inhibitors	O
of	O
canonical	O
Wnt	S-geneN
signaling	O
also	O
inhibits	O
prostatic	O
bud	O
formation	O
.	O

In	O
support	O
of	O
the	O
hypothesis	O
that	O
TCDD	S-chem-C4-1
decreases	O
canonical	O
Wnt	S-geneN-C4-2
signaling	O
,	O
we	O
identify	O
inhibitory	O
effects	O
of	O
TCDD	S-chem
on	O
multiple	O
components	O
of	O
the	O
canonical	O
Wnt	S-geneN
signaling	O
pathway	O
in	O
the	O
UGS	O
that	O
temporally	O
coincide	O
with	O
the	O
inhibitory	O
effect	O
of	O
TCDD	S-chem-C4-1
on	O
prostatic	O
bud	O
formation	O
:	O
(	O
1	O
)	O
expression	O
of	O
R	B-geneN-C4-2
-	I-geneN-C4-2
spondins	E-geneN-C4-2
(	O
Rspo2	S-geneY-C4-2
and	O
Rspo3	S-geneY-C4-2
)	O
that	O
promote	O
canonical	O
Wnt	S-geneN
signaling	O
is	O
reduced	O
;	O
(	O
2	O
)	O
expression	O
of	O
Lef1	S-geneY-C4-2
,	O
Tcf1	S-geneY-C4-2
,	O
and	O
Wif1	S-geneY-C4-2
,	O
established	O
canonical	O
Wnt	S-geneN
target	O
genes	O
,	O
is	O
decreased	O
;	O
(	O
3	O
)	O
expression	O
of	O
Lgr5	S-geneY-C4-2
,	O
a	O
RSPO	B-geneY-C4-2
receptor	E-geneY-C4-2
that	O
activates	O
canonical	O
Wnt	S-geneN
signaling	O
,	O
is	O
reduced	O
;	O
and	O
(	O
4	O
)	O
expression	O
of	O
Dickkopfs	S-geneN
(	O
Dkks	S-geneN
)	O
,	O
inhibitors	O
of	O
canonical	O
Wnt	S-geneN
signaling	O
,	O
is	O
not	O
increased	O
by	O
TCDD	S-chem
.	O

Thus	O
,	O
the	O
TCDD	S-chem-C4-1
-	O
induced	O
reduction	O
in	O
canonical	O
Wnt	S-geneN-C4-2
signaling	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
activators	O
(	O
Rspo2	S-geneY-C4-2
and	O
Rspo3	S-geneY-C4-2
)	O
rather	O
than	O
an	O
increase	O
in	O
inhibitors	O
(	O
Dkk1	S-geneY-C4-2
and	O
Dkk2	S-geneY-C4-2
)	O
of	O
the	O
pathway	O
.	O

This	O
study	O
focuses	O
on	O
determining	O
whether	O
treatment	O
of	O
TCDD	S-chem
-	O
exposed	O
UGS	O
organ	O
cultures	O
with	O
RSPO2	S-geneY
and	O
/	O
or	O
RSPO3	S-geneY
is	O
capable	O
of	O
rescuing	O
the	O
inhibitory	O
effects	O
of	O
TCDD	S-chem-C4-1
on	O
canonical	O
Wnt	S-geneN-C4-2
signaling	O
and	O
prostatic	O
bud	O
formation	O
.	O

We	O
discovered	O
that	O
each	O
RSPO	S-geneN
alone	O
or	O
in	O
combination	O
partially	O
rescues	O
TCDD	S-chem-C4-1
inhibition	O
of	O
both	O
canonical	O
Wnt	S-geneN-C4-2
signaling	O
and	O
prostatic	O
bud	O
formation	O
.	O

Bimodal	O
occurrence	O
of	O
aspartoacylase	S-geneY
in	O
myelin	O
and	O
cytosol	O
of	O
brain	O
.	O

The	O
growing	O
use	O
of	O
N	B-chem
-	I-chem
acetylaspartate	E-chem
as	O
an	O
indicator	O
of	O
neuronal	O
viability	O
has	O
fostered	O
interest	O
in	O
the	O
biological	O
function	O
(	O
s	O
)	O
of	O
this	O
unusual	O
amino	B-chem
acid	E-chem
derivative	O
.	O

In	O
considering	O
the	O
various	O
physiological	O
roles	O
that	O
have	O
been	O
proposed	O
for	O
this	O
relatively	O
abundant	O
molecule	O
one	O
is	O
obliged	O
to	O
take	O
into	O
account	O
its	O
unusual	O
metabolic	O
compartmentalization	O
,	O
according	O
to	O
which	O
synthesis	O
and	O
storage	O
occur	O
in	O
the	O
neuron	O
and	O
hydrolytic	O
cleavage	O
in	O
the	O
oligodendrocyte	O
.	O

The	O
latter	O
reaction	O
,	O
catalyzed	O
by	O
aspartoacylase	S-geneY-C9-2
(	O
ASPA	S-geneY-C9-2
)	O
,	O
produces	O
acetyl	S-chem-C9-1
groups	O
plus	O
aspartate	S-chem-C9-1
and	O
has	O
been	O
proposed	O
to	O
occur	O
in	O
both	O
soluble	O
and	O
membranous	O
subfractions	O
of	O
white	O
matter	O
.	O

Our	O
study	O
supports	O
such	O
bimodal	O
occurrence	O
and	O
we	O
now	O
present	O
immunoblot	O
,	O
proteomic	O
,	O
and	O
biochemical	O
evidence	O
that	O
the	O
membrane	O
-	O
bound	O
form	O
of	O
ASPA	S-geneY
is	O
intrinsic	O
to	O
purified	O
myelin	O
membranes	O
.	O

This	O
was	O
supported	O
by	O
a	O
novel	O
TLC	O
-	O
based	O
method	O
for	O
the	O
assay	O
of	O
ASPA	S-geneY
.	O

That	O
observation	O
,	O
together	O
with	O
previous	O
demonstrations	O
of	O
numerous	O
lipid	O
-	O
synthesizing	O
enzymes	O
in	O
myelin	O
,	O
suggests	O
utilization	O
of	O
acetyl	S-chem
groups	O
liberated	O
by	O
myelin	O
-	O
localized	O
ASPA	S-geneY
for	O
lipid	O
synthesis	O
within	O
the	O
myelin	O
sheath	O
.	O

Such	O
synthesis	O
might	O
be	O
selective	O
and	O
could	O
explain	O
the	O
deficit	O
of	O
myelin	O
lipids	O
in	O
animals	O
lacking	O
ASPA	S-geneN
.	O

Crystal	O
structure	O
of	O
the	O
IL	B-geneY
-	I-geneY
2	E-geneY
signaling	O
complex	O
:	O
paradigm	O
for	O
a	O
heterotrimeric	O
cytokine	B-geneN
receptor	E-geneN
.	O

IL	B-geneY
-	I-geneY
2	E-geneY
is	O
a	O
cytokine	S-geneN
that	O
functions	O
as	O
a	O
growth	O
factor	O
and	O
central	O
regulator	O
in	O
the	O
immune	O
system	O
and	O
mediates	O
its	O
effects	O
through	O
ligand	O
-	O
induced	O
hetero	O
-	O
trimerization	O
of	O
the	O
receptor	O
subunits	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
,	O
IL	B-geneN
-	I-geneN
2R	I-geneN
beta	I-geneN
,	I-geneN
and	I-geneN
gamma	I-geneN
(	I-geneN
c	I-geneN
)	E-geneN
.	O

Here	O
,	O
we	O
describe	O
the	O
crystal	O
structure	O
of	O
the	O
trimeric	O
assembly	O
of	O
the	O
human	B-geneN
IL	I-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
ectodomains	O
in	O
complex	O
with	O
IL	B-geneY
-	I-geneY
2	E-geneY
at	O
3.0	O
A	O
resolution	O
.	O

The	O
quaternary	O
structure	O
is	O
consistent	O
with	O
a	O
stepwise	O
assembly	O
from	O
IL	B-geneY
-	I-geneY
2	E-geneY
/	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
to	O
IL	B-geneY
-	I-geneY
2	E-geneY
/	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
/	O
IL	B-geneY
-	I-geneY
2R	I-geneY
beta	E-geneY
to	O
IL	B-geneY
-	I-geneY
2	E-geneY
/	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
/	O
IL	B-geneN
-	I-geneN
2R	I-geneN
beta	I-geneN
/	I-geneN
gamma	I-geneN
(	I-geneN
c	I-geneN
)	E-geneN
.	O

The	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
subunit	O
forms	O
the	O
largest	O
of	O
the	O
three	O
IL	B-geneY
-	I-geneY
2	E-geneY
/	O
IL	B-geneN
-	I-geneN
2R	E-geneN
interfaces	O
,	O
which	O
,	O
together	O
with	O
the	O
high	O
abundance	O
of	O
charge	O
-	O
charge	O
interactions	O
,	O
correlates	O
well	O
with	O
the	O
rapid	O
association	O
rate	O
and	O
high	O
-	O
affinity	O
interaction	O
of	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
with	O
IL	B-geneY
-	I-geneY
2	E-geneY
at	O
the	O
cell	O
surface	O
.	O

Surprisingly	O
,	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
makes	O
no	O
contacts	O
with	O
IL	B-geneN
-	I-geneN
2R	I-geneN
beta	I-geneN
or	I-geneN
gamma	I-geneN
(	I-geneN
c	I-geneN
)	E-geneN
,	O
and	O
only	O
minor	O
changes	O
are	O
observed	O
in	O
the	O
IL	B-geneY
-	I-geneY
2	E-geneY
structure	O
in	O
response	O
to	O
receptor	O
binding	O
.	O

These	O
findings	O
support	O
the	O
principal	O
role	O
of	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
to	O
deliver	O
IL	B-geneY
-	I-geneY
2	E-geneY
to	O
the	O
signaling	O
complex	O
and	O
act	O
as	O
regulator	O
of	O
signal	O
transduction	O
.	O

Cooperativity	O
in	O
assembly	O
of	O
the	O
final	O
quaternary	O
complex	O
is	O
easily	O
explained	O
by	O
the	O
extraordinarily	O
extensive	O
set	O
of	O
interfaces	O
found	O
within	O
the	O
fully	O
assembled	O
IL	B-geneY
-	I-geneY
2	E-geneY
signaling	O
complex	O
,	O
which	O
nearly	O
span	O
the	O
entire	O
length	O
of	O
the	O
IL	B-geneN
-	I-geneN
2R	I-geneN
beta	I-geneN
and	I-geneN
gamma	I-geneN
(	I-geneN
c	I-geneN
)	E-geneN
subunits	O
.	O

Helix	O
A	O
of	O
IL	B-geneY
-	I-geneY
2	E-geneY
wedges	O
tightly	O
between	O
IL	B-geneN
-	I-geneN
2R	I-geneN
beta	I-geneN
and	I-geneN
gamma	I-geneN
(	I-geneN
c	I-geneN
)	E-geneN
to	O
form	O
a	O
three	O
-	O
way	O
junction	O
that	O
coalesces	O
into	O
a	O
composite	O
binding	O
site	O
for	O
the	O
final	O
gamma	O
(	O
c	O
)	O
recruitment	O
.	O

The	O
IL	B-geneY
-	I-geneY
2	E-geneY
/	O
gamma	O
(	O
c	O
)	O
interface	O
itself	O
exhibits	O
the	O
smallest	O
buried	O
surface	O
and	O
the	O
fewest	O
hydrogen	S-chem
bonds	O
in	O
the	O
complex	O
,	O
which	O
is	O
consistent	O
with	O
its	O
promiscuous	O
use	O
in	O
other	O
cytokine	B-geneN
receptor	E-geneN
complexes	O
.	O

The	O
impact	O
of	O
thyroid	O
activity	O
variations	O
on	O
some	O
oxidizing	O
-	O
stress	O
parameters	O
in	O
rats	O
.	O

The	O
effect	O
of	O
the	O
thyroid	O
activity	O
on	O
the	O
formation	O
of	O
lipid	O
peroxidation	O
and	O
on	O
liver	O
and	O
heart	O
antioxidant	O
enzyme	O
activities	O
was	O
investigated	O
in	O
Wistar	O
rats	O
.	O

Hypothyroidism	O
and	O
hyperthyroidism	O
conditions	O
were	O
induced	O
for	O
five	O
weeks	O
by	O
the	O
administration	O
of	O
0.05	O
%	O
benzythiouracile	S-chem
(	O
BTU	S-chem
)	O
and	O
L	B-chem
-	I-chem
thyroxine	I-chem
sodium	I-chem
salt	E-chem
(	O
0.0012	O
%	O
)	O
,	O
in	O
drinking	O
water	O
,	O
respectively	O
.	O

No	O
significant	O
effect	O
was	O
observed	O
on	O
the	O
rates	O
of	O
both	O
lipid	O
peroxidation	O
and	O
the	O
vitamin	B-chem
E	E-chem
in	O
hepatic	O
and	O
cardiac	O
tissues	O
of	O
hypothyroidism	O
rats	O
compared	O
to	O
the	O
controls	O
,	O
contrary	O
to	O
the	O
hyperthyroidism	O
rats	O
,	O
which	O
expressed	O
a	O
pronounced	O
increase	O
.	O

The	O
increased	O
glutathione	B-geneN
peroxidase	E-geneN
activity	O
in	O
rats	O
suffering	O
from	O
hyperthyroidism	O
was	O
associated	O
with	O
a	O
fall	O
of	O
the	O
reduced	O
glutathione	S-chem
in	O
the	O
homogenate	O
and	O
a	O
marked	O
increase	O
in	O
the	O
glutathione	B-geneY
reductase	E-geneY
activity	O
.	O

An	O
increase	O
in	O
superoxide	S-chem
dismutase	O
and	O
catalase	O
activities	O
was	O
also	O
recorded	O
in	O
hyperthyroidism	O
.	O

Our	O
results	O
explain	O
the	O
thyroid	O
activity	O
variation	O
in	O
relation	O
to	O
the	O
lipid	O
peroxidation	O
and	O
the	O
tissular	O
contents	O
of	O
the	O
enzymatic	O
and	O
the	O
non	O
-	O
enzymatic	O
antioxidants	O
.	O

To	O
conclude	O
,	O
our	O
results	O
show	O
the	O
occurrence	O
of	O
a	O
state	O
of	O
oxidizing	O
stress	O
in	O
relation	O
to	O
hyperthyroidism	O
.	O

Role	O
of	O
nitric	B-chem
oxide	E-chem
in	O
the	O
chemistry	O
and	O
anticancer	O
activity	O
of	O
etoposide	S-chem
(	O
VP	B-chem
-	I-chem
16,213	E-chem
)	O
.	O

Originally	O
identified	O
as	O
an	O
innate	O
cytotoxin	O
,	O
nitric	B-chem
oxide	E-chem
(	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
)	O
formation	O
in	O
tumors	O
can	O
influence	O
chemotherapy	O
and	O
exacerbate	O
cancer	O
progression	O
.	O

Here	O
,	O
we	O
examined	O
the	O
hypothesis	O
that	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
generation	O
contributes	O
to	O
cancer	O
cell	O
drug	O
resistance	O
toward	O
the	O
widely	O
used	O
anticancer	O
drug	O
Etoposide	S-chem
(	O
VP	B-chem
-	I-chem
16	E-chem
)	O
.	O

The	O
UV	O
-	O
vis	O
spectrum	O
of	O
VP	B-chem
-	I-chem
16	E-chem
was	O
not	O
changed	O
by	O
exposure	O
of	O
VP	B-chem
-	I-chem
16	E-chem
to	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
in	O
aqueous	O
buffer	O
.	O

In	O
contrast	O
,	O
reddish	O
-	O
orange	O
compound	O
(	O
s	O
)	O
characteristic	O
of	O
o	B-chem
-	I-chem
quinone	I-chem
-	I-chem
and	I-chem
nitroso	I-chem
-	I-chem
VP	I-chem
-	I-chem
16	E-chem
were	O
readily	O
generated	O
in	O
a	O
hydrophobic	O
medium	O
(	O
chloroform	S-chem
)	O
in	O
an	O
oxygen	S-chem
-	O
dependent	O
manner	O
.	O

Similar	O
products	O
were	O
also	O
formed	O
when	O
the	O
VP	B-chem
-	I-chem
16	E-chem
radical	O
,	O
generated	O
from	O
VP	B-chem
-	I-chem
16	E-chem
and	O
horseradish	O
peroxidase	O
/	O
H2O2	S-chem
,	O
was	O
exposed	O
directly	O
to	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
in	O
chloroform	S-chem
in	O
the	O
presence	O
of	O
oxygen	S-chem
.	O

Separation	O
and	O
spectral	O
analysis	O
of	O
VP	B-chem
-	I-chem
16	E-chem
reaction	O
extracts	O
by	O
electron	O
spin	O
resonance	O
and	O
UV	O
-	O
vis	O
indicated	O
the	O
generation	O
of	O
the	O
phenoxy	S-chem
radical	O
and	O
the	O
o	B-chem
-	I-chem
quinone	E-chem
of	O
VP	B-chem
-	I-chem
16	E-chem
,	O
as	O
well	O
as	O
putative	O
nitroxide	S-chem
,	O
iminoxyl	S-chem
,	O
and	O
other	O
nitrogen	B-chem
oxide	E-chem
intermediates	O
.	O

Nitric	B-chem
oxide	E-chem
products	O
of	O
VP	B-chem-C4-1
-	I-chem-C4-1
16	E-chem-C4-1
displayed	O
significantly	O
diminished	O
topoisomerase	B-geneY-C4-2
II	E-geneY-C4-2
-	O
dependent	O
cleavage	O
of	O
DNA	O
and	O
cytotoxicity	O
to	O
human	O
HL	O
-	O
60	O
leukemia	O
cells	O
.	O

LPS	O
-	O
mediated	O
induction	O
of	O
nitric	B-geneN
oxide	I-geneN
synthase	E-geneN
in	O
murine	O
macrophages	O
resulted	O
in	O
VP	B-chem
-	I-chem
16	E-chem
resistance	O
compared	O
to	O
Raw	O
cells	O
.	O

Furthermore	O
,	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
products	O
derived	O
from	O
iNOS	S-geneY
rapidly	O
reacted	O
with	O
VP	B-chem
-	I-chem
16	E-chem
leading	O
to	O
decreased	O
DNA	O
damage	O
and	O
cytotoxicity	O
.	O

Together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
formation	O
of	O
(	B-chem
·	I-chem
)	I-chem
NO	E-chem
in	O
tumors	O
(	O
associated	O
macrophages	O
)	O
can	O
contribute	O
to	O
VP	B-chem
-	I-chem
16	E-chem
resistance	O
via	O
the	O
detoxification	O
of	O
VP	B-chem
-	I-chem
16	E-chem
.	O

Quinone	S-chem
compounds	O
regulate	O
the	O
level	O
of	O
ROS	O
production	O
by	O
the	O
NADPH	B-geneN
oxidase	E-geneN
Nox4	S-geneY
.	O

NADPH	B-geneN
oxidase	E-geneN
Nox4	S-geneY
is	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
and	O
plays	O
a	O
role	O
in	O
cellular	O
signaling	O
by	O
providing	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
as	O
intracellular	O
messengers	O
.	O

Nox4	S-geneY-C3-2
oxidase	S-geneN-C3-2
activity	O
is	O
thought	O
to	O
be	O
constitutive	O
and	O
regulated	O
at	O
the	O
transcriptional	O
level	O
;	O
however	O
,	O
we	O
challenge	O
this	O
point	O
of	O
view	O
and	O
suggest	O
that	O
specific	O
quinone	S-chem-C3-1
derivatives	O
could	O
modulate	O
this	O
activity	O
.	O

In	O
fact	O
,	O
we	O
demonstrated	O
a	O
significant	O
stimulation	O
of	O
Nox4	S-geneY-C3-2
activity	O
by	O
4	O
quinone	S-chem-C3-1
derivatives	O
(	O
AA	B-chem-C3-1
-	I-chem-C3-1
861	E-chem-C3-1
,	O
tBuBHQ	S-chem-C3-1
,	O
tBuBQ	S-chem-C3-1
,	O
and	O
duroquinone	S-chem-C3-1
)	O
observed	O
in	O
3	O
different	O
cellular	O
models	O
,	O
HEK293E	O
,	O
T	O
-	O
REx	O
™	O
,	O
and	O
chondrocyte	O
cell	O
lines	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
effect	O
is	O
specific	O
toward	O
Nox4	S-geneY
versus	O
Nox2	S-geneY
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
NAD	B-geneY
(	I-geneY
P	I-geneY
)	I-geneY
H	I-geneY
:	I-geneY
quinone	I-geneY
oxidoreductase	E-geneY
(	O
NQO1	S-geneY
)	O
may	O
participate	O
in	O
this	O
stimulation	O
.	O

Interestingly	O
,	O
Nox4	S-geneY
activity	O
is	O
also	O
stimulated	O
by	O
reducing	O
agents	O
that	O
possibly	O
act	O
by	O
reducing	O
the	O
disulfide	S-chem
bridge	O
(	O
Cys226	S-chem
,	O
Cys270	S-chem
)	O
located	O
in	O
the	O
extracellular	B-geneN
E	I-geneN
-	I-geneN
loop	E-geneN
of	O
Nox4	S-geneY
.	O

Such	O
model	O
of	O
Nox4	S-geneY-C3-2
activity	O
regulation	O
could	O
provide	O
new	O
insight	O
into	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
the	O
electron	O
transfer	O
through	O
the	O
enzyme	O
,	O
i.e	O
.	O
,	O
its	O
potential	O
redox	O
regulation	O
,	O
and	O
could	O
also	O
define	O
new	O
therapeutic	O
targets	O
in	O
diseases	O
in	O
which	O
quinones	S-chem-C3-1
and	O
Nox4	S-geneY
are	O
implicated	O
.	O

Pasireotide	S-chem
:	O
A	O
Review	O
of	O
Its	O
Use	O
in	O
Cushing	O
's	O
Disease	O
.	O

Pasireotide	S-chem-C4-1
(	O
Signifor	S-chem-C4-1
(	O
®	O
)	O
)	O
is	O
a	O
new	O
subcutaneous	O
somatostatin	S-geneY
analogue	O
that	O
acts	O
via	O
somatostatin	B-geneN
receptors	E-geneN
to	O
inhibit	O
the	O
secretion	O
of	O
corticotropin	S-geneY-C4-2
from	O
the	O
pituitary	O
adenoma	O
in	O
patients	O
with	O
Cushing	O
's	O
disease	O
.	O

Pasireotide	S-chem
has	O
a	O
receptor	O
binding	O
profile	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
somatostatin	S-geneY
analogues	O
,	O
binding	O
with	O
high	O
affinity	O
to	O
somatostatin	B-geneY
receptor	I-geneY
subtype	I-geneY
5	E-geneY
,	O
which	O
is	O
strongly	O
over	O
expressed	O
in	O
corticotroph	O
adenoma	O
cells	O
.	O

Pasireotide	S-chem
is	O
the	O
first	O
pituitary	O
-	O
directed	O
agent	O
to	O
be	O
approved	O
for	O
use	O
in	O
Cushing	O
's	O
disease	O
.	O

In	O
a	O
phase	O
III	O
clinical	O
trial	O
in	O
patients	O
with	O
Cushing	O
's	O
disease	O
,	O
twice	O
-	O
daily	O
pasireotide	S-chem
600	O
or	O
900	O
μg	O
for	O
6	O
months	O
led	O
to	O
normalization	O
of	O
urinary	O
free	O
cortisol	O
(	I-chem
UFC	O
)	O
levels	O
in	O
up	O
to	O
a	O
quarter	O
of	O
all	O
patients	O
(	O
primary	O
endpoint	O
)	O
and	O
significantly	O
reduced	O
mean	O
UFC	O
levels	O
.	O

The	O
reduction	O
in	O
UFC	O
levels	O
is	O
rapid	O
(	O
within	O
one	O
to	O
two	O
months	O
)	O
and	O
sustained	O
(	O
up	O
to	O
24	O
months	O
)	O
.	O

Most	O
patients	O
who	O
do	O
not	O
have	O
an	O
early	O
response	O
to	O
pasireotide	S-chem
do	O
not	O
respond	O
at	O
a	O
later	O
time	O
point	O
.	O

Decreases	O
in	O
UFC	O
levels	O
achieved	O
during	O
pasireotide	S-chem
treatment	O
are	O
accompanied	O
by	O
decreases	O
in	O
serum	O
and	O
salivary	O
cortisol	S-chem
levels	O
,	O
as	O
well	O
as	O
improvements	O
in	O
clinical	O
signs	O
and	O
symptoms	O
,	O
including	O
body	O
weight	O
,	O
blood	O
pressure	O
and	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
.	O

Pasireotide	S-chem
has	O
a	O
generally	O
similar	O
tolerability	O
profile	O
to	O
that	O
of	O
other	O
somatostatin	S-geneY
analogues	O
,	O
but	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
incidence	O
of	O
hyperglycaemia	O
,	O
requiring	O
the	O
addition	O
or	O
intensification	O
of	O
glucose	S-chem
-	O
lowering	O
medication	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O

Thus	O
,	O
pasireotide	S-chem
,	O
together	O
with	O
on	O
-	O
going	O
patient	O
monitoring	O
,	O
provides	O
a	O
promising	O
new	O
option	O
for	O
the	O
medical	O
management	O
of	O
Cushing	O
's	O
disease	O
.	O

Cytotoxicity	O
and	O
Modulation	O
of	O
Cancer	O
-	O
Related	O
Signaling	O
by	O
(	B-chem
Z	I-chem
)	I-chem
-	I-chem
and	I-chem
(	I-chem
E	I-chem
)	I-chem
-	I-chem
3,4,3',5	I-chem
'	I-chem
-	I-chem
Tetramethoxystilbene	E-chem
Isolated	O
from	O
Eugenia	O
rigida	O
.	O

Bioassay	O
-	O
guided	O
fractionation	O
of	O
the	O
leaves	O
of	O
Eugenia	O
rigida	O
yielded	O
three	O
stilbenes	S-chem
,	O
(	B-chem
Z	I-chem
)	I-chem
-	I-chem
3,4,3',5	I-chem
'	I-chem
-	I-chem
tetramethoxystilbene	E-chem
(	O
1	O
)	O
,	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
3,4,3',5	I-chem
'	I-chem
-	I-chem
tetramethoxystilbene	E-chem
(	O
2	O
)	O
,	O
and	O
(	B-chem
E	I-chem
)	I-chem
-	I-chem
3,5,4	I-chem
'	I-chem
-	I-chem
trimethoxystilbene	E-chem
(	O
3	O
)	O
.	O

Their	O
structures	O
were	O
determined	O
using	O
1D	O
-	O
and	O
2D	O
-	O
NMR	O
spectroscopy	O
and	O
HRESIMS	O
.	O

The	O
sterically	O
hindered	O
Z	O
-	O
stereoisomer	O
1	O
,	O
a	O
new	O
natural	O
product	O
,	O
was	O
prepared	O
by	O
time	O
-	O
dependent	O
photoisomerization	O
of	O
the	O
E	O
-	O
isomer	O
(	O
2	O
)	O
under	O
UV	O
irradiation	O
at	O
λ254	O
nm	O
,	O
while	O
2,3,5,7	B-chem
-	I-chem
tetramethoxyphenanthrene	E-chem
(	O
5	O
)	O
was	O
identified	O
at	O
λ365	O
nm	O
by	O
UHPLC	O
/	O
APCI	O
-	O
MS	O
and	O
NMR	O
spectroscopy	O
.	O

Compounds	O
1	O
-	O
3	O
were	O
tested	O
against	O
a	O
panel	O
of	O
luciferase	O
reporter	O
gene	O
assays	O
that	O
assess	O
the	O
activity	O
of	O
many	O
cancer	O
-	O
related	O
signaling	O
pathways	O
,	O
and	O
the	O
Z	O
-	O
isomer	O
(	O
1	O
)	O
was	O
found	O
to	O
be	O
more	O
potent	O
than	O
the	O
E	O
-	O
isomer	O
(	O
2	O
)	O
in	O
inhibiting	O
the	O
activation	O
of	O
Stat3	S-geneY
,	O
Smad3	B-geneN
/	I-geneN
4	E-geneN
,	O
myc	S-geneY
,	O
Ets	S-geneN
,	O
Notch	S-geneN
,	O
and	O
Wnt	S-geneN
signaling	O
,	O
with	O
IC50	O
values	O
between	O
40	O
and	O
80	O
μM	O
.	O

However	O
,	O
both	O
compounds	O
showed	O
similar	O
inhibition	O
against	O
Ap	B-geneY
-	I-geneY
1	E-geneY
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
signaling	O
.	O

In	O
addition	O
,	O
1	O
demonstrated	O
cytotoxic	O
activity	O
toward	O
human	O
leukemia	O
cells	O
,	O
solid	O
tumor	O
cells	O
of	O
epidermal	O
,	O
breast	O
,	O
and	O
cervical	O
carcinomas	O
,	O
and	O
skin	O
melanoma	O
,	O
with	O
IC50	O
values	O
between	O
3.6	O
and	O
4.3	O
μM	O
,	O
while	O
2	O
was	O
weakly	O
active	O
against	O
leukemia	O
,	O
cervical	O
carcinoma	O
,	O
and	O
skin	O
melanoma	O
cells	O
.	O

Interestingly	O
,	O
2	O
showed	O
antioxidant	O
activity	O
by	O
inhibition	O
of	O
ROS	O
generation	O
to	O
50	O
%	O
at	O
33.3	O
μM	O
in	O
PMA	S-chem
-	O
induced	O
HL	O
-	O
60	O
cells	O
,	O
while	O
1	O
was	O
inactive	O
at	O
100	O
μM	O
(	O
vs	O
Trolox	S-chem
1.4	O
μM	O
)	O
.	O

Transcriptional	B-geneY
regulatory	I-geneY
factor	I-geneY
X6	E-geneY
(	O
Rfx6	S-geneY
)	O
increases	O
gastric	B-geneY
inhibitory	I-geneY
polypeptide	E-geneY
(	O
GIP	S-geneY
)	O
expression	O
in	O
enteroendocrine	O
K	O
-	O
cells	O
and	O
is	O
involved	O
in	O
GIP	S-geneY
hypersecretion	O
in	O
high	O
fat	O
diet	O
-	O
induced	O
obesity	O
.	O

Gastric	B-geneY
inhibitory	I-geneY
polypeptide	E-geneY
(	O
GIP	S-geneY
)	O
is	O
an	O
incretin	S-geneY
released	O
from	O
enteroendocrine	O
K	O
-	O
cells	O
in	O
response	O
to	O
nutrient	O
ingestion	O
.	O

GIP	S-geneY
potentiates	O
glucose	S-chem-C3-1
-	O
stimulated	O
insulin	S-geneY-C3-2
secretion	O
and	O
induces	O
energy	O
accumulation	O
into	O
adipose	O
tissue	O
,	O
resulting	O
in	O
obesity	O
.	O

Plasma	O
GIP	S-geneY
levels	O
are	O
reported	O
to	O
be	O
increased	O
in	O
the	O
obese	O
state	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
GIP	S-geneY
secretion	O
and	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
GIP	S-geneY
hypersecretion	O
remain	O
unclear	O
,	O
primarily	O
due	O
to	O
difficulties	O
in	O
separating	O
K	O
-	O
cells	O
from	O
other	O
intestinal	O
epithelial	O
cells	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
GIP	S-geneY
-	O
GFP	S-geneN
knock	O
-	O
in	O
mice	O
that	O
enable	O
us	O
to	O
visualize	O
K	O
-	O
cells	O
by	O
enhanced	O
GFP	S-geneY
were	O
established	O
.	O

Microarray	O
analysis	O
of	O
isolated	O
K	O
-	O
cells	O
from	O
these	O
mice	O
revealed	O
that	O
transcriptional	B-geneY
regulatory	I-geneY
factor	I-geneY
X6	E-geneY
(	O
Rfx6	S-geneY
)	O
is	O
expressed	O
exclusively	O
in	O
K	O
-	O
cells	O
.	O

In	O
vitro	O
experiments	O
using	O
the	O
mouse	O
intestinal	O
cell	O
line	O
STC	O
-	O
1	O
showed	O
that	O
knockdown	O
of	O
Rfx6	S-geneY
decreased	O
mRNA	O
expression	O
,	O
cellular	O
content	O
,	O
and	O
secretion	O
of	O
GIP	S-geneY
.	O

Rfx6	S-geneY
bound	O
to	O
the	O
region	O
in	O
the	O
gip	B-geneN
promoter	E-geneN
that	O
regulates	O
gip	B-geneN
promoter	E-geneN
activity	O
,	O
and	O
overexpression	O
of	O
Rfx6	S-geneY
increased	O
GIP	S-geneY
mRNA	O
expression	O
.	O

HFD	O
induced	O
obesity	O
and	O
GIP	S-geneY
hypersecretion	O
in	O
GIP	S-geneY
-	O
GFP	S-geneN
heterozygous	O
mice	O
in	O
vivo	O
.	O

Immunohistochemical	O
and	O
flow	O
cytometry	O
analysis	O
showed	O
no	O
significant	O
difference	O
in	O
K	O
-	O
cell	O
number	O
between	O
control	O
fat	O
diet	O
-	O
fed	O
(	O
CFD	O
)	O
and	O
HFD	O
-	O
fed	O
mice	O
.	O

However	O
,	O
GIP	S-geneY
content	O
in	O
the	O
upper	O
small	O
intestine	O
and	O
GIP	S-geneY
mRNA	O
expression	O
in	O
K	O
-	O
cells	O
were	O
significantly	O
increased	O
in	O
HFD	O
-	O
fed	O
mice	O
compared	O
with	O
those	O
in	O
CFD	O
-	O
fed	O
mice	O
.	O

Furthermore	O
,	O
expression	O
levels	O
of	O
Rfx6	S-geneY
mRNA	O
were	O
increased	O
in	O
K	O
-	O
cells	O
of	O
HFD	O
-	O
fed	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
Rfx6	S-geneY
increases	O
GIP	S-geneY
expression	O
and	O
content	O
in	O
K	O
-	O
cells	O
and	O
is	O
involved	O
in	O
GIP	S-geneY
hypersecretion	O
in	O
HFD	O
-	O
induced	O
obesity	O
.	O

Mechanism	O
of	O
action	O
of	O
leflunomide	S-chem
in	O
rheumatoid	O
arthritis	O
.	O

Leflunomide	S-chem
,	O
a	O
novel	O
drug	O
with	O
proven	O
efficacy	O
in	O
rheumatoid	O
arthritis	O
,	O
is	O
an	O
isoxazol	S-chem
derivative	O
structurally	O
unrelated	O
to	O
other	O
immunomodulatory	O
drugs	O
.	O

Leflunomide	S-chem
is	O
rapidly	O
metabolized	O
to	O
its	O
active	O
form	O
,	O
A77	B-chem
1726	E-chem
.	O

Two	O
mechanisms	O
of	O
action	O
have	O
been	O
identified	O
for	O
A77	B-chem-C4-1
1726	E-chem-C4-1
:	O
inhibition	O
of	O
dihydroorotate	B-geneY-C4-2
dehydrogenase	E-geneY-C4-2
(	O
DHODH	S-geneY-C4-2
)	O
and	O
inhibition	O
of	O
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
.	O

DHODH	S-geneY-C4-2
inhibition	O
occurs	O
at	O
lower	O
concentrations	O
of	O
A77	B-chem-C4-1
1726	E-chem-C4-1
than	O
that	O
of	O
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
and	O
is	O
currently	O
considered	O
the	O
major	O
mode	O
of	O
action	O
.	O

Stimulated	O
lymphocytes	O
must	O
increase	O
ribonucleotide	O
levels	O
from	O
8	O
to	O
16	O
-	O
fold	O
before	O
proceeding	O
from	O
the	O
G1	O
into	O
the	O
S	O
phase	O
.	O

Increased	O
levels	O
of	O
ribonucleotides	O
can	O
only	O
be	O
met	O
by	O
de	O
novo	O
ribonucleotide	O
synthesis	O
.	O

At	O
low	O
levels	O
of	O
ribonucleotides	O
,	O
p53	S-geneY
,	O
a	O
``	O
sensor	O
``	O
molecule	O
,	O
gets	O
activated	O
and	O
prevents	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Therefore	O
,	O
an	O
inhibitor	O
of	O
de	O
novo	O
uridine	B-chem
monophosphate	E-chem
synthesis	O
would	O
predictably	O
arrest	O
stimulated	O
cells	O
at	O
the	O
G1	O
phase	O
.	O

In	O
support	O
of	O
this	O
mechanism	O
of	O
action	O
,	O
in	O
vitro	O
mitogen	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
treated	O
with	O
A77	B-chem
1726	E-chem
undergo	O
arrest	O
at	O
the	O
G1	O
phase	O
;	O
this	O
inhibition	O
is	O
reversed	O
by	O
uridine	S-chem
.	O

Central	O
sympatholysis	O
as	O
a	O
novel	O
countermeasure	O
for	O
cocaine	S-chem
-	O
induced	O
sympathetic	O
activation	O
and	O
vasoconstriction	O
in	O
humans	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
cocaine	O
's	O
sympathomimetic	O
actions	O
can	O
be	O
reversed	O
by	O
a	O
potent	O
centrally	O
acting	O
alpha2	B-geneN-C5-2
adrenergic	I-geneN-C5-2
receptor	E-geneN-C5-2
(	O
AR	S-geneN-C5-2
)	O
agonist	O
(	O
dexmedetomidine	S-chem-C5-1
)	O
.	O

BACKGROUND	O
:	O
We	O
recently	O
showed	O
that	O
cocaine	S-chem
stimulates	O
the	O
human	O
cardiovascular	O
system	O
primarily	O
by	O
acting	O
in	O
the	O
brain	O
to	O
increase	O
sympathetic	O
nerve	O
activity	O
(	O
SNA	O
)	O
,	O
the	O
neural	O
stimulus	O
to	O
norepinephrine	S-chem
release	O
.	O

Thus	O
,	O
SNA	O
constitutes	O
a	O
putative	O
new	O
drug	O
target	O
to	O
block	O
cocaine	O
's	O
adverse	O
cardiovascular	O
effects	O
at	O
their	O
origin	O
.	O

METHODS	O
:	O
In	O
22	O
healthy	O
cocaine	S-chem
-	O
naive	O
humans	O
,	O
we	O
measured	O
skin	O
SNA	O
(	O
microneurography	O
)	O
and	O
skin	O
blood	O
flow	O
(	O
laser	O
Doppler	O
velocimetry	O
)	O
as	O
well	O
as	O
heart	O
rate	O
and	O
blood	O
pressure	O
before	O
and	O
after	O
intranasal	O
cocaine	S-chem
(	O
2	O
mg	O
/	O
kg	O
)	O
alone	O
and	O
in	O
combination	O
with	O
dexmedetomidine	S-chem
or	O
saline	O
.	O

RESULTS	O
:	O
During	O
intranasal	O
cocaine	S-chem
alone	O
,	O
SNA	O
increased	O
by	O
2	O
-	O
fold	O
and	O
skin	O
vascular	O
resistance	O
increased	O
from	O
13.2	O
+	O
/	O
-	O
2.3	O
to	O
20.1	O
+	O
/	O
-	O
2.2	O
resistance	O
units	O
while	O
mean	O
arterial	O
pressure	O
increased	O
by	O
14	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
and	O
heart	O
rate	O
by	O
18	O
+	O
/	O
-	O
3	O
beats	O
/	O
min	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Dexmedetomidine	S-chem
abolished	O
these	O
increases	O
,	O
whereas	O
intravenous	O
saline	O
was	O
without	O
effect	O
.	O

Dexmedetomidine	S-chem
was	O
effective	O
in	O
blocking	O
these	O
sympathomimetic	O
actions	O
of	O
cocaine	S-chem
even	O
in	O
all	O
7	O
subjects	O
who	O
were	O
homozygous	O
for	O
the	O
Del322	O
-	O
325	O
polymorphism	O
in	O
the	O
alpha2C	B-geneY
AR	E-geneY
,	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
that	O
is	O
highly	O
enriched	O
in	O
blacks	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
advance	O
the	O
novel	O
hypothesis	O
that	O
central	O
sympatholysis	O
with	O
dexmedetomidine	S-chem
constitutes	O
a	O
highly	O
effective	O
countermeasure	O
for	O
cocaine	O
's	O
sympathomimetic	O
actions	O
on	O
the	O
human	O
cardiovascular	O
system	O
,	O
even	O
in	O
individuals	O
carrying	O
the	O
alpha2CDel322	S-geneY
-	O
325	O
polymorphism	O
.	O

(	O
Study	O
to	O
Improve	O
Scientific	O
Understanding	O
of	O
the	O
Cardiovascular	O
Actions	O
of	O
Cocaine	S-chem
;	O
http	O
:	O
/	O
/	O
clinicaltrials.gov	O
/	O
ct	O
/	O
show	O
/	O
NCT00338546	O
?	O
order	O
=	O
1	O
;	O
NCT00338546	O
)	O
.	O

Curcumin	S-chem-C4-1
improves	O
TNBS	O
-	O
induced	O
colitis	O
in	O
rats	O
by	O
inhibiting	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
expression	O
via	O
the	O
TLR4	S-geneY-C4-2
/	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
signaling	O
pathway	O
.	O

Curcumin	S-chem
is	O
a	O
widely	O
used	O
spice	O
with	O
anti	O
-	O
inflammatory	O
and	O
anticancer	O
properties	O
.	O

It	O
has	O
been	O
reported	O
to	O
have	O
beneficial	O
effects	O
in	O
experimental	O
colitis	O
.	O

This	O
study	O
explored	O
whether	O
curcumin	S-chem-C4-1
improves	O
colonic	O
inflammation	O
in	O
a	O
rat	O
colitis	O
model	O
through	O
inhibition	O
of	O
the	O
TLR4	S-geneY-C4-2
/	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
signaling	O
pathway	O
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
expression	O
.	O

After	O
induction	O
of	O
colitis	O
with	O
2,4,6	B-chem
-	I-chem
trinitrobenzene	I-chem
sulfonic	I-chem
acid	E-chem
,	O
rats	O
were	O
intragastrically	O
administered	O
with	O
curcumin	S-chem
or	O
sulfasalazine	S-chem
daily	O
for	O
one	O
week	O
.	O

Rat	O
intestinal	O
mucosa	O
was	O
collected	O
for	O
evaluation	O
of	O
the	O
disease	O
activity	O
index	O
,	O
colonic	O
mucosa	O
damage	O
index	O
,	O
and	O
histological	O
score	O
.	O

Myeloperoxidase	S-geneY
activity	O
was	O
detected	O
by	O
immunohistochemistry	O
,	O
and	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
TLR4	S-geneY
,	O
NF	B-geneN
-	I-geneN
κB	E-geneN
,	O
and	O
IL	B-geneY
-	I-geneY
27	E-geneY
in	O
colonic	O
mucosa	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
.	O

Compared	O
with	O
the	O
untreated	O
colitis	O
group	O
,	O
the	O
curcumin	S-chem-C4-1
-	O
treated	O
group	O
showed	O
significant	O
decreases	O
in	O
the	O
disease	O
activity	O
index	O
,	O
colonic	O
mucosa	O
damage	O
index	O
,	O
histological	O
score	O
,	O
myeloperoxidase	S-geneY-C4-2
activity	O
,	O
and	O
expressions	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
mRNA	O
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
mRNA	O
,	O
TLR4	S-geneY-C4-2
protein	O
,	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
p65	S-geneY-C4-2
protein	O
,	O
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
p28	S-geneY-C4-2
protein	O
(	O
p	O
<	O
0.05	O
)	O
.	O

TLR4	S-geneY
mRNA	O
expression	O
did	O
not	O
differ	O
between	O
groups	O
.	O

Disease	O
activity	O
index	O
decreased	O
more	O
rapidly	O
in	O
the	O
curcumin	S-chem
-	O
treated	O
group	O
than	O
in	O
the	O
sulfasalazine	S-chem
-	O
treated	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
TLR4	S-geneY-C4-2
,	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
,	O
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
mRNA	O
and	O
proteins	O
between	O
curcumin	S-chem-C4-1
-	O
treated	O
and	O
sulfasalazine	S-chem-C4-1
-	O
treated	O
groups	O
.	O

Curcumin	S-chem
shows	O
significant	O
therapeutic	O
effects	O
on	O
2,4,6	B-chem
-	I-chem
trinitrobenzene	I-chem
sulfonic	I-chem
acid	E-chem
-	O
induced	O
colitis	O
that	O
are	O
comparable	O
to	O
sulfasalazine	S-chem
.	O

The	O
anti	O
-	O
inflammatory	O
actions	O
of	O
curcumin	S-chem-C4-1
on	O
colitis	O
may	O
involve	O
inhibition	O
of	O
the	O
TLR4	S-geneY-C4-2
/	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
signaling	O
pathway	O
and	O
of	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
27	E-geneY-C4-2
expression	O
.	O

Acyl	B-geneN
-	I-geneN
CoA	I-geneN
synthetase	I-geneN
isoforms	I-geneN
1	I-geneN
,	I-geneN
4	I-geneN
,	I-geneN
and	I-geneN
5	E-geneN
are	O
present	O
in	O
different	O
subcellular	O
membranes	O
in	O
rat	O
liver	O
and	O
can	O
be	O
inhibited	O
independently	O
.	O

Inhibition	O
studies	O
have	O
suggested	O
that	O
acyl	B-geneN
-	I-geneN
CoA	I-geneN
synthetase	E-geneN
(	O
ACS	S-geneN
,	O
EC	O
)	O
isoforms	O
might	O
regulate	O
the	O
use	O
of	O
acyl	B-chem
-	I-chem
CoAs	E-chem
by	O
different	O
metabolic	O
pathways	O
.	O

In	O
order	O
to	O
determine	O
whether	O
the	O
subcellular	O
locations	O
differed	O
for	O
each	O
of	O
the	O
three	O
ACSs	S-geneN
present	O
in	O
liver	O
and	O
whether	O
these	O
isoforms	O
were	O
regulated	O
independently	O
,	O
non	O
-	O
cross	O
-	O
reacting	O
peptide	O
antibodies	O
were	O
raised	O
against	O
ACS1	S-geneY
,	O
ACS4	S-geneY
,	O
and	O
ACS5	S-geneY
.	O

ACS1	S-geneY
was	O
identified	O
in	O
endoplasmic	O
reticulum	O
,	O
mitochondria	O
-	O
associated	O
membrane	O
(	O
MAM	O
)	O
,	O
and	O
cytosol	O
,	O
but	O
not	O
in	O
mitochondria	O
.	O

ACS4	S-geneY
was	O
present	O
primarily	O
in	O
MAM	O
,	O
and	O
the	O
76	O
-	O
kDa	O
ACS5	S-geneY
protein	O
was	O
located	O
in	O
mitochondrial	O
membrane	O
.	O

Consistent	O
with	O
these	O
locations	O
,	O
N	B-chem-C4-1
-	I-chem-C4-1
ethylmaleimide	E-chem-C4-1
,	O
an	O
inhibitor	O
of	O
ACS4	S-geneY-C4-2
,	O
inhibited	O
ACS	S-geneN-C4-2
activity	O
47	O
%	O
in	O
MAM	O
and	O
28	O
%	O
in	O
endoplasmic	O
reticulum	O
.	O

Troglitazone	S-chem-C4-1
,	O
a	O
second	O
ACS4	S-geneY-C4-2
inhibitor	O
,	O
inhibited	O
ACS	S-geneN-C4-2
activity	O
<	O
10	O
%	O
in	O
microsomes	O
and	O
mitochondria	O
and	O
45	O
%	O
in	O
MAM	O
.	O

Triacsin	B-chem-C4-1
C	E-chem-C4-1
,	O
a	O
competitive	O
inhibitor	O
of	O
both	O
ACS1	S-geneY-C4-2
and	O
ACS4	S-geneY-C4-2
,	O
inhibited	O
ACS	S-geneN-C4-2
activity	O
similarly	O
in	O
endoplasmic	O
reticulum	O
,	O
MAM	O
,	O
and	O
mitochondria	O
,	O
suggesting	O
that	O
a	O
hitherto	O
unidentified	O
triacsin	S-chem
-	O
sensitive	O
ACS	S-geneN
is	O
present	O
in	O
mitochondria	O
.	O

ACS1	S-geneY
,	O
ACS4	S-geneY
,	O
and	O
ACS5	S-geneY
were	O
regulated	O
independently	O
by	O
fasting	O
and	O
re	O
-	O
feeding	O
.	O

Fasting	O
rats	O
for	O
48	O
h	O
resulted	O
in	O
a	O
decrease	O
in	O
ACS4	S-geneY
protein	O
,	O
and	O
an	O
increase	O
in	O
ACS5	S-geneY
.	O

Re	O
-	O
feeding	O
normal	O
chow	O
or	O
a	O
high	O
sucrose	S-chem-C3-1
diet	O
for	O
24	O
h	O
after	O
a	O
48	O
-	O
h	O
fast	O
increased	O
both	O
ACS1	S-geneY-C3-2
and	O
ACS4	S-geneY-C3-2
protein	O
expression	O
1.5	O
-	O
2.0	O
-	O
fold	O
,	O
consistent	O
with	O
inhibition	O
studies	O
.	O

These	O
results	O
suggest	O
that	O
ACS1	S-geneY-C9-2
and	O
ACS4	S-geneY-C9-2
may	O
be	O
linked	O
to	O
triacylglycerol	S-chem-C9-1
synthesis	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
acyl	B-chem
-	I-chem
CoAs	E-chem
may	O
be	O
functionally	O
channeled	O
to	O
specific	O
metabolic	O
pathways	O
through	O
different	O
ACS	S-geneN
isoforms	O
in	O
unique	O
subcellular	O
locations	O
.	O

Loperamide	S-chem
,	O
an	O
opiate	O
analog	O
,	O
differently	O
modifies	O
the	O
adrenocorticotropin	S-geneY
responses	O
to	O
corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
and	O
lysine	B-geneY
vasopressin	E-geneY
in	O
patients	O
with	O
Addison	O
's	O
disease	O
.	O

Loperamide	S-chem-C4-1
is	O
a	O
peripheral	O
opiate	O
agonist	O
able	O
to	O
inhibit	O
ACTH	S-geneY-C4-2
secretion	O
.	O

In	O
this	O
work	O
,	O
the	O
interactions	O
between	O
loperamide	S-chem
and	O
two	O
ACTH	S-geneY
secretagogues	O
,	O
lysine	B-geneY
vasopressin	E-geneY
(	O
LVP	S-geneY
)	O
and	O
corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
CRH	S-geneY
)	O
,	O
were	O
investigated	O
in	O
patients	O
with	O
Addison	O
's	O
disease	O
.	O

After	O
loperamide	S-chem
(	O
16	O
mg	O
orally	O
)	O
or	O
placebo	O
administration	O
,	O
5	O
patients	O
received	O
LVP	S-geneY
(	O
0.06	O
IU	O
/	O
kg	O
i.v	O
.	O
over	O
1	O
h	O
)	O
and	O
6	O
patients	O
received	O
oCRH	S-geneY
(	O
1	O
micrograms	O
/	O
kg	O
i.v	O
.	O
as	O
bolus	O
)	O
.	O

In	O
all	O
patients	O
loperamide	S-chem-C4-1
induced	O
a	O
significant	O
fall	O
in	O
plasma	O
ACTH	S-geneY-C4-2
levels	O
.	O

LVP	S-geneY
increased	O
ACTH	S-geneY
levels	O
after	O
both	O
loperamide	S-chem
(	O
from	O
48	O
+	O
/	O
-	O
17.3	O
to	O
a	O
peak	O
of	O
95	O
+	O
/	O
-	O
21	O
pmol	O
/	O
l	O
)	O
and	O
placebo	O
(	O
from	O
231	O
+	O
/	O
-	O
59.5	O
to	O
365	O
+	O
/	O
-	O
86.6	O
pmol	O
/	O
l	O
)	O
:	O
the	O
interaction	O
between	O
treatments	O
and	O
time	O
was	O
not	O
significant	O
.	O

CRH	S-geneY
caused	O
a	O
rise	O
in	O
plasma	O
ACTH	S-geneY
after	O
both	O
loperamide	S-chem
(	O
from	O
30	O
+	O
/	O
-	O
16.6	O
to	O
a	O
peak	O
of	O
108	O
+	O
/	O
-	O
31	O
pmol	O
/	O
l	O
)	O
and	O
placebo	O
(	O
from	O
98.5	O
+	O
/	O
-	O
47	O
to	O
211	O
+	O
/	O
-	O
61.7	O
pmol	O
/	O
l	O
)	O
:	O
the	O
interaction	O
between	O
treatments	O
and	O
time	O
was	O
significant	O
,	O
and	O
the	O
first	O
phase	O
of	O
CRH	S-geneY-C4-2
-	O
induced	O
ACTH	S-geneY-C4-2
secretion	O
was	O
significantly	O
lower	O
after	O
loperamide	S-chem-C4-1
.	O

These	O
data	O
demonstrate	O
that	O
loperamide	S-chem
differently	O
modifies	O
the	O
stimulatory	O
action	O
of	O
LVP	S-geneY
and	O
CRH	S-geneY
on	O
ACTH	S-geneY
secretion	O
:	O
namely	O
,	O
LVP	S-geneY
and	O
loperamide	S-chem
act	O
in	O
an	O
additive	O
manner	O
,	O
while	O
CRH	S-geneY
and	O
loperamide	S-chem
interact	O
in	O
a	O
non	O
additive	O
way	O
.	O

Although	O
these	O
findings	O
might	O
be	O
explained	O
by	O
the	O
involvement	O
of	O
different	O
intracellular	O
ACTH	S-geneY
-	O
secreting	O
mechanisms	O
,	O
an	O
influence	O
of	O
loperamide	S-chem
on	O
some	O
suprapituitary	O
factors	O
modulating	O
the	O
ACTH	S-geneY
response	O
is	O
suggested	O
.	O

Re	O
-	O
evaluation	O
of	O
lisuride	S-chem
pharmacology	O
:	O
5	B-geneY
-	I-geneY
hydroxytryptamine1A	I-geneY
receptor	E-geneY
-	O
mediated	O
behavioral	O
effects	O
overlap	O
its	O
other	O
properties	O
in	O
rats	O
.	O

RATIONALE	O
:	O
There	O
is	O
substantial	O
evidence	O
that	O
lisuride	S-chem
can	O
produce	O
effects	O
linked	O
to	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptor	O
occupancy	O
.	O

Nevertheless	O
,	O
this	O
action	O
has	O
generally	O
been	O
ignored	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
lisuride	S-chem
,	O
in	O
favor	O
of	O
an	O
exclusive	O
role	O
for	O
dopamine	B-geneN
receptors	E-geneN
in	O
considering	O
its	O
antiparkinsonian	O
effects	O
,	O
or	O
an	O
exclusive	O
role	O
of	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
2A	I-geneN
/	I-geneN
2C	I-geneN
)	E-geneN
receptor	O
activation	O
in	O
hallucinogenesis	O
.	O

These	O
conclusions	O
are	O
surprising	O
when	O
one	O
considers	O
that	O
the	O
potent	O
interaction	O
of	O
lisuride	S-chem
with	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptors	O
has	O
been	O
demonstrated	O
in	O
several	O
different	O
laboratories	O
and	O
that	O
activation	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
and	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1B	I-geneY
)	E-geneY
receptors	O
can	O
modulate	O
dopaminergically	O
mediated	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
lack	O
of	O
full	O
substitution	O
of	O
lisuride	S-chem
for	O
lysergic	B-chem
acid	I-chem
diethylamide	E-chem
(	O
LSD	S-chem
)	O
in	O
drug	O
discrimination	O
experiments	O
and	O
induction	O
of	O
a	O
pronounced	O
5	B-chem
-	I-chem
HT	E-chem
syndrome	O
by	O
this	O
compound	O
at	O
relatively	O
low	O
doses	O
convinced	O
us	O
to	O
execute	O
two	O
series	O
of	O
experiments	O
that	O
might	O
explain	O
the	O
primary	O
mechanism	O
responsible	O
for	O
lisuride	S-chem
-	O
mediated	O
biological	O
effects	O
and	O
its	O
paradoxical	O
classification	O
as	O
a	O
dopamine	S-chem
agonist	O
in	O
the	O
literature	O
.	O

RESULTS	O
:	O
In	O
drug	O
discrimination	O
studies	O
,	O
lisuride	S-chem-C5-1
fully	O
mimicked	O
the	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT	I-geneY-C5-2
(	I-geneY-C5-2
1A	I-geneY-C5-2
)	E-geneY-C5-2
agonist	O
LY	B-chem-C5-1
293284	E-chem-C5-1
,	O
only	O
partially	O
substituted	O
for	O
LSD	S-chem
and	O
DOI	S-chem
,	O
and	O
failed	O
to	O
substitute	O
for	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
amphetamine	E-chem
.	O

Lisuride	S-chem
produced	O
a	O
significant	O
dose	O
-	O
related	O
increase	O
in	O
flat	O
body	O
posture	O
,	O
forepaw	O
treading	O
,	O
and	O
lower	O
-	O
lip	O
retraction	O
which	O
reflect	O
a	O
modulation	O
of	O
behavior	O
by	O
action	O
at	O
central	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptors	O
.	O

Only	O
pMPPI	O
[	O
4	B-chem-C6-1
-	I-chem-C6-1
iodo	I-chem-C6-1
-	I-chem-C6-1
N	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
methoxyphenyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
1	I-chem-C6-1
-	I-chem-C6-1
piperazinyl	I-chem-C6-1
]	I-chem-C6-1
ethyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
N	I-chem-C6-1
-	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
pyridynyl	I-chem-C6-1
-	I-chem-C6-1
benzamide	I-chem-C6-1
hydrochloride	E-chem-C6-1
]	O
,	O
a	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
,	O
was	O
effective	O
in	O
inhibiting	O
all	O
5	B-chem
-	I-chem
HT	E-chem
syndrome	O
behaviors	O
produced	O
by	O
lisuride	S-chem
,	O
whereas	O
pMPPI	O
was	O
without	O
effect	O
on	O
any	O
behavior	O
induced	O
by	O
LSD	S-chem
.	O

Lisuride	O
dose	O
dependently	O
decreased	O
body	O
temperature	O
in	O
rats	O
with	O
a	O
potency	O
similar	O
to	O
that	O
of	O
the	O
selective	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT	I-geneY-C5-2
(	I-geneY-C5-2
1A	I-geneY-C5-2
)	E-geneY-C5-2
agonist	O
LY	B-chem-C5-1
293284	E-chem-C5-1
.	O

The	O
hypothermic	O
effect	O
of	O
lisuride	S-chem
was	O
prevented	O
by	O
pre	O
-	O
injection	O
of	O
pMPPI	O
,	O
but	O
not	O
by	O
ketanserin	S-chem
or	O
haloperidol	S-chem
.	O

CONCLUSION	O
:	O
We	O
have	O
demonstrated	O
that	O
the	O
behavioral	O
effects	O
of	O
low	O
doses	O
of	O
lisuride	S-chem
are	O
clearly	O
mediated	O
by	O
stimulation	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptors	O
.	O

Pressor	O
and	O
bradycardic	O
effects	O
of	O
tacrine	S-chem
and	O
other	O
acetylcholinesterase	S-geneY
inhibitors	O
in	O
the	O
rat	O
.	O

The	O
cardiovascular	O
effects	O
of	O
three	O
different	O
acetylcholinesterase	S-geneY-C4-2
inhibitors	O
:	O
physostigmine	S-chem-C4-1
,	O
tacrine	S-chem-C4-1
and	O
rivastigmine	S-chem-C4-1
injected	O
by	O
intravenous	O
(	O
i.v	O
.	O
)	O
route	O
were	O
compared	O
in	O
freely	O
moving	O
Wistar	O
rats	O
.	O

The	O
three	O
drugs	O
significantly	O
increased	O
both	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
decreased	O
heart	O
rate	O
.	O

Compared	O
to	O
physostigmine	S-chem
,	O
a	O
20	O
-	O
fold	O
higher	O
dose	O
of	O
tacrine	S-chem
and	O
a	O
40	O
-	O
fold	O
higher	O
dose	O
of	O
rivastigmine	S-chem
was	O
necessary	O
to	O
induce	O
a	O
comparable	O
pressor	O
effect	O
.	O

Tacrine	S-chem-C4-1
was	O
chosen	O
as	O
a	O
model	O
to	O
study	O
the	O
mechanisms	O
underlying	O
the	O
cardiovascular	O
effects	O
of	O
i.v	O
.	O
cholinesterase	S-geneY-C4-2
inhibitors	O
.	O

Atropine	S-chem
totally	O
abolished	O
while	O
methylatropine	S-chem
did	O
not	O
affect	O
tacrine	S-chem
pressor	O
effects	O
.	O

Conversely	O
,	O
both	O
drugs	O
abolished	O
tacrine	S-chem
-	O
induced	O
bradycardia	O
.	O

The	O
alpha1	B-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
prazosin	S-chem-C6-1
or	O
the	O
vasopressin	B-geneN-C6-2
V1	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
[	B-chem-C6-1
beta	I-chem-C6-1
-	I-chem-C6-1
mercapto	I-chem-C6-1
-	I-chem-C6-1
beta	I-chem-C6-1
,	I-chem-C6-1
beta	I-chem-C6-1
-	I-chem-C6-1
cyclopenta	I-chem-C6-1
-	I-chem-C6-1
methylenepropionyl1	I-chem-C6-1
,	I-chem-C6-1
O	I-chem-C6-1
-	I-chem-C6-1
Me	I-chem-C6-1
-	I-chem-C6-1
Tyr2	I-chem-C6-1
,	I-chem-C6-1
Arg8	I-chem-C6-1
]	I-chem-C6-1
vasopressin	S-geneY-C6-1
partially	O
but	O
significantly	O
reduced	O
tacrine	S-chem
pressor	O
effect	O
and	O
mostly	O
abolished	O
it	O
when	O
administered	O
concomitantly	O
.	O

The	O
tacrine	S-chem
pressor	O
response	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
the	O
i.c.v	O
.	O
administration	O
of	O
the	O
non	O
-	O
selective	O
muscarinic	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
atropine	S-chem-C6-1
(	O
ID50	O
=	O
1.45	O
microg	O
)	O
,	O
the	O
muscarinic	B-geneY-C6-2
M1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
pirenzepine	S-chem-C6-1
(	O
ID50	O
=	O
4.33	O
microg	O
)	O
,	O
the	O
muscarinic	B-geneY-C6-2
M2	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
methoctramine	S-chem-C6-1
(	O
ID50	O
=	O
1.39	O
microg	O
)	O
and	O
the	O
muscarinic	B-geneY-C6-2
M3	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
para	B-chem-C6-1
-	I-chem-C6-1
fluoro	I-chem-C6-1
-	I-chem-C6-1
hexahydro	I-chem-C6-1
-	I-chem-C6-1
sila	I-chem-C6-1
-	I-chem-C6-1
difenidol	E-chem-C6-1
(	O
ID50	O
=	O
31.19	O
microg	O
)	O
.	O

Central	O
injection	O
of	O
such	O
muscarinic	B-geneN
receptor	E-geneN
antagonists	O
did	O
not	O
affect	O
tacrine	S-chem
-	O
induced	O
bradycardia	O
.	O

Our	O
results	O
show	O
that	O
acetylcholinesterase	S-geneY
inhibitors	O
induce	O
significant	O
cardiovascular	O
effects	O
with	O
a	O
pressor	O
response	O
mediated	O
mainly	O
by	O
the	O
stimulation	O
of	O
central	O
muscarinic	B-geneY
M2	I-geneY
receptors	E-geneY
inducing	O
a	O
secondary	O
increase	O
in	O
sympathetic	O
outflow	O
and	O
vasopressin	S-chem
release	O
.	O

Conversely	O
,	O
acetylcholinesterase	S-geneY
inhibitor	O
-	O
induced	O
bradycardia	O
appears	O
to	O
be	O
mediated	O
by	O
peripheral	O
muscarinic	O
mechanisms	O
.	O

Reductive	O
detoxification	O
of	O
arylhydroxylamine	S-chem-C9-1
carcinogens	O
by	O
human	B-geneY-C9-2
NADH	I-geneY-C9-2
cytochrome	I-geneY-C9-2
b5	I-geneY-C9-2
reductase	E-geneY-C9-2
and	O
cytochrome	B-geneY-C9-2
b5	E-geneY-C9-2
.	O

Heterocyclic	B-chem
and	I-chem
aromatic	I-chem
amine	E-chem
carcinogens	O
are	O
thought	O
to	O
lead	O
to	O
tumor	O
initiation	O
via	O
the	O
formation	O
of	O
DNA	O
adducts	O
,	O
and	O
bioactivation	O
to	O
arylhydroxylamine	S-chem
metabolites	O
is	O
necessary	O
for	O
reactivity	O
with	O
DNA	O
.	O

Carcinogenic	O
arylhydroxylamine	S-chem
metabolites	O
are	O
cleared	O
by	O
a	O
microsomal	O
,	O
NADH	S-chem
-	O
dependent	O
,	O
oxygen	S-chem
-	O
insensitive	O
reduction	O
pathway	O
in	O
humans	O
,	O
which	O
may	O
be	O
a	O
source	O
of	O
interindividual	O
variability	O
in	O
response	O
to	O
aromatic	B-chem
amine	E-chem
carcinogens	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
identity	O
of	O
this	O
reduction	O
pathway	O
in	O
human	O
liver	O
.	O

On	O
the	O
basis	O
of	O
our	O
findings	O
with	O
structurally	O
similar	O
arylhydroxylamine	S-chem
metabolites	O
of	O
therapeutic	O
drugs	O
,	O
we	O
hypothesized	O
that	O
the	O
reductive	O
detoxification	O
of	O
arylhydroxylamine	S-chem-C9-1
carcinogens	O
was	O
catalyzed	O
by	O
NADH	B-geneY-C9-2
cytochrome	I-geneY-C9-2
b5	I-geneY-C9-2
reductase	E-geneY-C9-2
(	O
b5R	S-geneY-C9-2
)	O
and	O
cytochrome	B-geneY-C9-2
b5	E-geneY-C9-2
(	O
cyt	B-geneY-C9-2
b5	E-geneY-C9-2
)	O
.	O

We	O
found	O
that	O
reduction	O
of	O
the	O
carcinogenic	O
hydroxylamines	S-chem-C9-1
of	O
the	O
aromatic	B-chem-C9-1
amine	E-chem-C9-1
4	B-chem-C9-1
-	I-chem-C9-1
aminobiphenyl	E-chem-C9-1
(	O
4	B-chem-C9-1
-	I-chem-C9-1
ABP	E-chem-C9-1
;	O
found	O
in	O
cigarette	O
smoke	O
)	O
and	O
the	O
heterocyclic	B-chem-C9-1
amine	E-chem-C9-1
2	B-chem-C9-1
-	I-chem-C9-1
amino	I-chem-C9-1
-	I-chem-C9-1
1	I-chem-C9-1
-	I-chem-C9-1
methyl	I-chem-C9-1
-	I-chem-C9-1
6	I-chem-C9-1
-	I-chem-C9-1
phenylimidazo	I-chem-C9-1
[	I-chem-C9-1
4,5	I-chem-C9-1
-	I-chem-C9-1
b	I-chem-C9-1
]	I-chem-C9-1
pyridine	E-chem-C9-1
(	O
PhIP	S-chem-C9-1
;	O
found	O
in	O
grilled	O
meats	O
)	O
was	O
indeed	O
catalyzed	O
by	O
a	O
purified	O
system	O
containing	O
only	O
human	B-geneY-C9-2
b5R	E-geneY-C9-2
and	O
cyt	B-geneY-C9-2
b5	E-geneY-C9-2
.	O

Specific	O
activities	O
were	O
56	O
-	O
346	O
-	O
fold	O
higher	O
in	O
the	O
purified	O
system	O
as	O
compared	O
to	O
human	O
liver	O
microsomes	O
(	O
HLM	O
)	O
,	O
with	O
similar	O
Michaelis	O
-	O
Menten	O
constants	O
(	O
K	O
(	O
m	O
)	O
values	O
)	O
in	O
both	O
systems	O
.	O

The	O
stoichiometry	O
for	O
b5R	S-geneY
and	O
cyt	B-geneY
b5	E-geneY
that	O
yielded	O
the	O
highest	O
activity	O
in	O
the	O
purified	O
system	O
was	O
also	O
similar	O
to	O
that	O
found	O
in	O
native	O
HLM	O
(	O
approximately	O
1	O
:	O
8	O
to	O
1	O
:	O
10	O
)	O
.	O

Polyclonal	O
antisera	O
to	O
either	O
b5R	S-geneY-C9-2
or	O
cyt	B-geneY-C9-2
b5	E-geneY-C9-2
significantly	O
inhibited	O
N	B-chem-C9-1
-	I-chem-C9-1
hydroxy	I-chem-C9-1
-	I-chem-C9-1
4	I-chem-C9-1
-	I-chem-C9-1
aminobiphenyl	E-chem-C9-1
(	O
NHOH	B-chem-C9-1
-	I-chem-C9-1
4	I-chem-C9-1
-	I-chem-C9-1
ABP	E-chem-C9-1
)	O
reduction	O
by	O
95	O
and	O
89	O
%	O
,	O
respectively	O
,	O
and	O
immunoreactive	O
cyt	O
b5	O
protein	O
content	O
in	O
individual	O
HLM	O
was	O
significantly	O
correlated	O
with	O
individual	O
reduction	O
of	O
both	O
NHOH	B-chem
-	I-chem
4	I-chem
-	I-chem
ABP	E-chem
and	O
N	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
PhIP	E-chem
(	O
NHOH	B-chem
-	I-chem
PhIP	E-chem
)	O
.	O

Finally	O
,	O
titration	O
of	O
HLM	O
into	O
the	O
purified	O
b5R	S-geneY
/	O
cyt	B-geneY
b5	E-geneY
system	O
did	O
not	O
enhance	O
the	O
efficiency	O
of	O
reduction	O
activity	O
.	O

We	O
conclude	O
that	O
b5R	S-geneY
and	O
cyt	B-geneY
b5	E-geneY
are	O
together	O
solely	O
capable	O
of	O
the	O
reduction	O
of	O
arylhydroxylamine	S-chem
carcinogens	O
,	O
and	O
we	O
further	O
hypothesize	O
that	O
this	O
pathway	O
may	O
be	O
a	O
source	O
of	O
individual	O
variability	O
with	O
respect	O
to	O
cancer	O
susceptibility	O
following	O
4	B-chem
-	I-chem
ABP	E-chem
or	O
PhIP	S-chem
exposure	O
.	O

Deficits	O
in	O
male	O
sexual	O
behavior	O
in	O
adulthood	O
after	O
social	O
instability	O
stress	O
in	O
adolescence	O
in	O
rats	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
exposure	O
to	O
stressors	O
in	O
adolescence	O
has	O
long	O
-	O
lasting	O
effects	O
on	O
emotional	O
and	O
cognitive	O
behavior	O
,	O
but	O
little	O
is	O
known	O
as	O
to	O
whether	O
reproductive	O
functions	O
are	O
affected	O
.	O

We	O
investigated	O
appetitive	O
and	O
consummatory	O
aspects	O
of	O
sexual	O
behavior	O
in	O
male	O
rats	O
that	O
were	O
exposed	O
to	O
chronic	O
social	O
instability	O
stress	O
(	O
SS	O
,	O
n	O
=	O
24	O
)	O
for	O
16	O
days	O
in	O
mid	O
-	O
adolescence	O
compared	O
to	O
control	O
rats	O
(	O
CTL	O
,	O
n	O
=	O
24	O
)	O
.	O

Over	O
five	O
sexual	O
behavior	O
test	O
sessions	O
with	O
a	O
receptive	O
female	O
,	O
SS	O
rats	O
made	O
fewer	O
ejaculations	O
(	O
p	O
=	O
0.02	O
)	O
and	O
had	O
longer	O
latencies	O
to	O
ejaculation	O
(	O
p	O
=	O
0.03	O
)	O
.	O

When	O
only	O
data	O
from	O
rats	O
that	O
ejaculated	O
in	O
the	O
fifth	O
session	O
were	O
analyzed	O
,	O
SS	O
rats	O
(	O
n	O
=	O
18	O
)	O
had	O
reduced	O
copulatory	O
efficiency	O
(	O
more	O
mounts	O
and	O
intromissions	O
before	O
ejaculation	O
)	O
compared	O
to	O
CTL	O
rats	O
(	O
n	O
=	O
19	O
)	O
(	O
p	O
=	O
0.004	O
)	O
,	O
and	O
CTL	O
rats	O
were	O
twice	O
as	O
likely	O
as	O
SS	O
rats	O
to	O
make	O
more	O
than	O
one	O
ejaculation	O
in	O
the	O
fifth	O
session	O
(	O
p	O
=	O
0.05	O
)	O
.	O

Further	O
,	O
more	O
CTL	O
(	O
14	O
/	O
24	O
)	O
than	O
SS	O
(	O
5	O
/	O
25	O
)	O
rats	O
ejaculated	O
in	O
four	O
or	O
more	O
sessions	O
(	O
p	O
=	O
0.05	O
)	O
.	O

SS	O
rats	O
had	O
lower	O
plasma	O
testosterone	S-chem
concentrations	O
than	O
CTL	O
rats	O
(	O
p	O
=	O
0.05	O
)	O
,	O
but	O
did	O
not	O
differ	O
in	O
androgen	B-geneY
receptor	E-geneY
,	O
estrogen	B-geneY
receptor	I-geneY
alpha	E-geneY
,	O
or	O
Fos	S-geneY
immunoreactive	O
cell	O
counts	O
in	O
the	O
medial	O
preoptic	O
area	O
.	O

The	O
groups	O
did	O
not	O
differ	O
in	O
a	O
partner	O
preference	O
test	O
administered	O
between	O
the	O
fourth	O
and	O
fifth	O
sexual	O
behavior	O
session	O
.	O

The	O
results	O
suggest	O
that	O
developmental	O
history	O
contributes	O
to	O
individual	O
differences	O
in	O
reproductive	O
behavior	O
,	O
and	O
that	O
stress	O
exposures	O
in	O
adolescence	O
may	O
be	O
a	O
factor	O
in	O
sexual	O
sluggishness	O
.	O

Captopril	S-chem
attenuates	O
matrix	B-geneN
metalloproteinase	I-geneN
-	I-geneN
2	I-geneN
and	I-geneN
-	I-geneN
9	E-geneN
in	O
monocrotaline	S-chem
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
in	O
rats	O
.	O

Little	O
is	O
known	O
about	O
the	O
influence	O
of	O
angiotensin	B-geneY
converting	I-geneY
enzyme	E-geneY
(	O
ACE	S-geneY
)	O
inhibitors	O
on	O
matrix	B-geneN
metalloproteinase	E-geneN
(	O
MMP	S-geneN
)	O
in	O
right	O
ventricular	O
remodeling	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
captopril	S-chem-C4-1
,	O
an	O
ACE	S-geneY-C4-2
inhibitor	O
,	O
on	O
MMP	B-geneY
-	I-geneY
2	E-geneY
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
in	O
monocrotaline	S-chem
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
.	O

Six	O
-	O
week	O
-	O
old	O
male	O
Wistar	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
monocrotaline	S-chem
(	O
60	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
.	O

The	O
rats	O
were	O
administrated	O
captopril	S-chem
(	O
30	O
mg	O
/	O
kg	O
per	O
day	O
)	O
or	O
a	O
vehicle	O
orally	O
for	O
24	O
days	O
from	O
the	O
day	O
of	O
monocrotaline	S-chem
injection	O
.	O

At	O
day	O
25	O
,	O
echocardiography	O
was	O
performed	O
and	O
hearts	O
were	O
excised	O
.	O

Expressions	O
and	O
activities	O
of	O
MMP	B-geneY
-	I-geneY
2	E-geneY
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
were	O
measured	O
by	O
Western	O
blotting	O
and	O
by	O
gelatin	O
zymography	O
,	O
respectively	O
.	O

In	O
monocrotaline	S-chem
-	O
injected	O
rats	O
,	O
right	O
ventricular	O
weight	O
/	O
tail	O
length	O
ratio	O
increased	O
significantly	O
.	O

Histological	O
analysis	O
revealed	O
cardiomyocyte	O
hypertrophy	O
and	O
fibrosis	O
in	O
right	O
ventricular	O
sections	O
.	O

Echocardiography	O
showed	O
right	O
ventricular	O
dysfunction	O
compared	O
with	O
saline	O
-	O
injected	O
rats	O
.	O

The	O
right	O
ventricular	O
hypertrophy	O
,	O
fibrosis	O
,	O
and	O
dysfunction	O
were	O
inhibited	O
by	O
captopril	S-chem
.	O

However	O
,	O
captopril	S-chem
did	O
not	O
attenuate	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
.	O

MMP	B-geneY-MU-2
-	I-geneY-MU-2
2	E-geneY-MU-2
and	O
MMP	B-geneY-MU-2
-	I-geneY-MU-2
9	E-geneY-MU-2
expressions	O
and	O
activities	O
in	O
right	O
ventricles	O
increased	O
significantly	O
in	O
monocrotaline	S-chem-C3-1
-	O
injected	O
rats	O
and	O
captopril	S-chem-C4-1
inhibited	O
them	O
.	O

These	O
findings	O
indicate	O
that	O
captopril	S-chem-C4-1
attenuates	O
the	O
development	O
of	O
monocrotaline	S-chem-C3-1
-	O
induced	O
right	O
ventricular	O
hypertrophy	O
in	O
association	O
with	O
inhibition	O
of	O
MMP	B-geneY-MU-2
-	I-geneY-MU-2
2	E-geneY-MU-2
and	O
MMP	B-geneY-MU-2
-	I-geneY-MU-2
9	E-geneY-MU-2
in	O
rats	O
.	O

Comparison	O
of	O
vaginal	B-geneN
aminopeptidase	E-geneN
enzymatic	O
activities	O
in	O
various	O
animals	O
and	O
in	O
humans	O
.	O

The	O
specific	O
enzymatic	O
activity	O
of	O
four	O
different	O
aminopeptidases	S-geneN
(	O
aminopeptidase	B-geneN
N	E-geneN
,	O
leucine	B-geneN
aminopeptidase	E-geneN
,	O
aminopeptidase	B-geneN
A	E-geneN
and	O
aminopeptidase	B-geneN
B	E-geneN
)	O
in	O
vaginal	O
homogenates	O
from	O
rabbit	O
,	O
rat	O
,	O
guinea	O
-	O
pig	O
,	O
sheep	O
and	O
humans	O
was	O
compared	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
find	O
an	O
appropriate	O
animal	O
model	O
that	O
can	O
be	O
used	O
in	O
degradation	O
studies	O
of	O
protein	O
and	O
peptide	O
drugs	O
.	O

Different	O
substrates	O
were	O
used	O
as	O
the	O
relative	O
specific	O
substrates	O
for	O
the	O
determination	O
of	O
aminopeptidase	S-geneN
enzymatic	O
activity	O
:	O
4	B-chem-C9-1
-	I-chem-C9-1
methoxy	I-chem-C9-1
-	I-chem-C9-1
2	I-chem-C9-1
-	I-chem-C9-1
naphthylamide	E-chem-C9-1
of	O
L	B-chem-C9-1
-	I-chem-C9-1
alanine	E-chem-C9-1
for	O
aminopeptidase	B-geneN-C9-2
N	E-geneN-C9-2
,	O
4	B-chem-C9-1
-	I-chem-C9-1
methoxy	I-chem-C9-1
-	I-chem-C9-1
2	I-chem-C9-1
-	I-chem-C9-1
naphthylamide	E-chem-C9-1
of	O
L	B-chem-C9-1
-	I-chem-C9-1
leucine	E-chem-C9-1
for	O
leucine	B-geneN-C9-2
aminopeptidase	E-geneN-C9-2
,	O
4	B-chem-C9-1
-	I-chem-C9-1
methoxy	I-chem-C9-1
-	I-chem-C9-1
2	I-chem-C9-1
-	I-chem-C9-1
naphthylamide	E-chem-C9-1
of	O
L	B-chem-C9-1
-	I-chem-C9-1
glutamic	I-chem-C9-1
acid	E-chem-C9-1
for	O
aminopeptidase	B-geneN-C9-2
A	E-geneN-C9-2
and	O
4	B-chem-C9-1
-	I-chem-C9-1
methoxy	I-chem-C9-1
-	I-chem-C9-1
2	I-chem-C9-1
-	I-chem-C9-1
naphthylamide	E-chem-C9-1
of	O
L	B-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
for	O
aminopeptidase	B-geneN-C9-2
B	E-geneN-C9-2
.	O

The	O
vaginal	B-geneN
aminopeptidase	E-geneN
enzymatic	O
activity	O
of	O
different	O
species	O
was	O
determined	O
spectrofluorometrically	O
.	O

The	O
inhibition	O
of	O
aminopeptidase	S-geneN-C4-2
activity	O
in	O
the	O
presence	O
of	O
bestatin	S-chem-C4-1
and	O
puromycin	S-chem-C4-1
inhibitors	O
was	O
also	O
investigated	O
.	O

The	O
results	O
showed	O
the	O
presence	O
of	O
aminopeptidase	S-geneN
enzymatic	O
activity	O
in	O
all	O
vaginal	O
homogenates	O
in	O
the	O
order	O
:	O
sheep	O
>	O
guinea	O
-	O
pig	O
>	O
rabbit	O
>	O
or	O
=	O
human	O
>	O
or	O
=	O
rat	O
.	O

Based	O
on	O
the	O
results	O
of	O
the	O
hydrolysis	O
and	O
inhibition	O
of	O
the	O
4	B-chem
-	I-chem
methoxy	I-chem
-	I-chem
2	I-chem
-	I-chem
naphthylamide	E-chem
substrates	O
,	O
it	O
was	O
difficult	O
to	O
have	O
an	O
exact	O
decision	O
on	O
the	O
aminopeptidase	S-geneN
type	O
in	O
the	O
vaginal	O
homogenates	O
from	O
the	O
species	O
studied	O
.	O

It	O
was	O
found	O
that	O
the	O
aminopeptidase	S-geneN
activity	O
in	O
rat	O
,	O
rabbit	O
and	O
humans	O
was	O
not	O
statistically	O
different	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
rats	O
and	O
rabbits	O
could	O
be	O
used	O
as	O
model	O
animals	O
for	O
vaginal	O
enzymatic	O
activity	O
studies	O
and	O
for	O
determination	O
of	O
the	O
degradation	O
of	O
protein	O
and	O
peptide	O
drugs	O
in	O
the	O
vagina	O
.	O

Gene	O
expression	O
signature	O
of	O
parathion	S-chem
-	O
transformed	O
human	O
breast	O
epithelial	O
cells	O
.	O

Environmental	O
substances	O
seem	O
to	O
be	O
involved	O
in	O
the	O
etiology	O
of	O
breast	O
cancers	O
.	O

Many	O
studies	O
have	O
found	O
an	O
association	O
between	O
human	O
cancer	O
and	O
exposure	O
to	O
agricultural	O
pesticides	O
such	O
as	O
the	O
organophosphorous	S-chem
pesticides	O
.	O

Parathion	S-chem-C4-1
is	O
a	O
cholinesterase	S-geneN-C4-2
inhibitor	O
that	O
induces	O
the	O
hydrolysis	O
of	O
body	O
choline	B-chem
esters	E-chem
,	O
including	O
acetylcholine	S-chem
at	O
cholinergic	O
synapses	O
.	O

The	O
primary	O
target	O
of	O
action	O
in	O
insects	O
is	O
the	O
nervous	O
system	O
whereby	O
pesticides	O
inhibit	O
the	O
release	O
of	O
the	O
enzyme	O
acetylcholinesterase	S-geneN
at	O
the	O
synaptic	O
junction	O
.	O

Atropine	O
is	O
a	O
parasympatholytic	O
alkaloid	O
used	O
as	O
an	O
antidote	O
to	O
acetylcholinesterase	S-geneN
inhibitors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
parathion	S-chem
and	O
atropine	S-chem
on	O
cell	O
transformation	O
of	O
human	O
breast	O
epithelial	O
cells	O
in	O
vitro	O
.	O

These	O
studies	O
showed	O
that	O
parathion	S-chem
alone	O
was	O
able	O
to	O
induce	O
malignant	O
transformation	O
of	O
an	O
immortalized	O
human	O
breast	O
epithelial	O
cell	O
line	O
,	O
MCF	O
-	O
10F	O
as	O
indicated	O
by	O
increased	O
cell	O
proliferation	O
,	O
anchorage	O
independency	O
and	O
invasive	O
capabilities	O
.	O

There	O
was	O
also	O
an	O
increase	O
in	O
c	B-geneY-C3-2
-	I-geneY-C3-2
kit	E-geneY-C3-2
,	O
Trio	S-geneY-C3-2
,	O
Rho	B-geneY-C3-2
-	I-geneY-C3-2
A	E-geneY-C3-2
,	O
Rac	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
,	O
EGFR	S-geneY
,	O
Notch	B-geneY-C3-2
-	I-geneY-C3-2
4	E-geneY-C3-2
,	O
Dvl	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
,	O
Ezrin	S-geneY-C3-2
,	O
beta	B-geneY-C3-2
catenin	E-geneY-C3-2
and	O
mutant	O
p53	S-geneY-C3-2
protein	O
expression	O
in	O
the	O
parathion	S-chem-C3-1
-	O
treated	O
cells	O
.	O

However	O
,	O
atropine	S-chem
significantly	O
inhibited	O
this	O
increase	O
.	O

In	O
a	O
human	O
cell	O
cycle	O
array	O
of	O
96	O
genes	O
,	O
13	O
of	O
them	O
were	O
altered	O
by	O
parathion	S-chem
treatment	O
.	O

Among	O
the	O
genes	O
affected	O
were	O
the	O
cyclins	S-geneN
,	O
such	O
as	O
cyclin	B-geneY
D3	E-geneY
,	O
the	O
cyclin	B-geneN
-	I-geneN
dependent	I-geneN
kinases	E-geneN
(	O
CDKs	S-geneN
)	O
such	O
as	O
CDK41	S-geneY
and	O
the	O
minichromosome	B-geneY
maintenance	I-geneY
deficient	I-geneY
(	I-geneY
MCM	I-geneY
)	I-geneY
MCM2	E-geneY
and	O
MCM3	S-geneY
.	O

It	O
is	O
suggested	O
that	O
parathion	S-chem
influences	O
human	O
breast	O
epithelial	O
cell	O
transformation	O
and	O
is	O
an	O
initiator	O
factor	O
in	O
the	O
transformation	O
process	O
in	O
breast	O
cancer	O
.	O

Structure	O
-	O
based	O
design	O
of	O
aliskiren	S-chem-C4-1
,	O
a	O
novel	O
orally	O
effective	O
renin	S-geneY-C4-2
inhibitor	O
.	O

Hypertension	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
such	O
as	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
and	O
heart	O
failure	O
,	O
the	O
leading	O
causes	O
of	O
death	O
in	O
the	O
Western	O
world	O
.	O

Inhibitors	O
of	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
system	O
(	O
RAS	O
)	O
have	O
proven	O
to	O
be	O
successful	O
treatments	O
for	O
hypertension	O
.	O

As	O
renin	S-geneY
specifically	O
catalyses	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
the	O
RAS	O
,	O
it	O
represents	O
the	O
optimal	O
target	O
for	O
RAS	O
inhibition	O
.	O

Several	O
peptide	O
-	O
like	O
renin	S-geneY
inhibitors	O
have	O
been	O
synthesized	O
previously	O
,	O
but	O
poor	O
pharmacokinetic	O
properties	O
meant	O
that	O
these	O
compounds	O
were	O
not	O
clinically	O
useful	O
.	O

We	O
employed	O
a	O
combination	O
of	O
molecular	O
modelling	O
and	O
crystallographic	O
structure	O
analysis	O
to	O
design	O
renin	S-geneY
inhibitors	O
lacking	O
the	O
extended	O
peptide	O
-	O
like	O
backbone	O
of	O
earlier	O
inhibitors	O
,	O
for	O
improved	O
pharmacokinetic	O
properties	O
.	O

This	O
led	O
to	O
the	O
discovery	O
of	O
aliskiren	S-chem-C4-1
,	O
a	O
highly	O
potent	O
and	O
selective	O
inhibitor	O
of	O
human	B-geneY-C4-2
renin	E-geneY-C4-2
in	O
vitro	O
,	O
and	O
in	O
vivo	O
;	O
once	O
-	O
daily	O
oral	O
doses	O
of	O
aliskiren	S-chem-C4-1
inhibit	O
renin	S-geneY-C4-2
and	O
lower	O
blood	O
pressure	O
in	O
sodium	S-chem
-	O
depleted	O
marmosets	O
and	O
hypertensive	O
human	O
patients	O
.	O

Aliskiren	S-chem-C4-1
represents	O
the	O
first	O
in	O
a	O
novel	O
class	O
of	O
renin	S-geneY-C4-2
inhibitors	O
with	O
the	O
potential	O
for	O
treatment	O
of	O
hypertension	O
and	O
related	O
cardiovascular	O
diseases	O
.	O

Oxidative	O
status	O
in	O
ICU	O
patients	O
with	O
septic	O
shock	O
.	O

The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
investigate	O
variability	O
of	O
oxidative	O
stress	O
during	O
sepsis	O
evolution	O
.	O

ICU	O
patients	O
with	O
the	O
diagnosis	O
of	O
septic	O
shock	O
were	O
included	O
.	O

Thiobarbituric	B-chem
-	I-chem
acid	E-chem
reactive	O
substances	O
,	O
total	O
antioxidant	O
capacity	O
,	O
protein	O
carbonyls	S-chem
in	O
plasma	O
,	O
reduced	O
,	O
oxidized	O
glutathione	S-chem
and	O
catalase	O
activity	O
in	O
erythrocyte	O
lysate	O
were	O
assessed	O
in	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
8thday	O
after	O
sepsis	O
appearance	O
.	O

A	O
total	O
of	O
17	O
patients	O
were	O
divided	O
in	O
two	O
groups	O
:	O
survivors	O
(	O
n	O
=	O
7	O
)	O
and	O
non	O
-	O
survivors	O
(	O
n	O
=	O
10	O
)	O
.	O

APACHE	O
II	O
was	O
11.5±5.4	O
and	O
19.9±4.97	O
in	O
survivors	O
and	O
non	O
-	O
survivors	O
respectively	O
(	O
p	O
=	O
0.005	O
)	O
,	O
while	O
mean	O
age	O
and	O
SOFA	O
score	O
at	O
sepsis	O
diagnosis	O
,	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

GSH	S-chem
levels	O
,	O
catalase	O
activity	O
and	O
protein	O
carbonyls	S-chem
presented	O
significant	O
different	O
course	O
in	O
time	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Catalase	S-geneY
activity	O
was	O
significantly	O
higher	O
in	O
survivors	O
(	O
238.8±51.5	O
)	O
than	O
non	O
-	O
survivors	O
(	O
166.4±40.2	O
;	O
p	O
=	O
0.005	O
)	O
,	O
while	O
protein	O
carbonyls	S-chem
levels	O
were	O
significantly	O
lower	O
in	O
survivors	O
(	O
0.32±0.09	O
)	O
than	O
non	O
-	O
survivors	O
(	O
0.48±0.16	O
;	O
p	O
=	O
0.036	O
)	O
on	O
the	O
1stday	O
.	O

Yet	O
,	O
non	O
-	O
survivors	O
exhibited	O
a	O
declining	O
course	O
in	O
GSH	S-chem
levels	O
during	O
time	O
,	O
while	O
GSH	S-chem
levels	O
were	O
maintained	O
in	O
survivors	O
.	O

Conclusively	O
,	O
a	O
longstanding	O
antioxidant	O
deficiency	O
in	O
non	O
-	O
surviving	O
patients	O
was	O
noted	O
.	O

This	O
phenomenon	O
was	O
clearly	O
prominent	O
in	O
patients	O
'	O
erythrocytes	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
a	O
phosphatase	B-geneN
domain	E-geneN
within	O
yeast	O
general	O
transcription	O
factor	O
TFIIIC	S-geneY
.	O

Saccharomyces	B-geneY
cerevisiae	I-geneY
τ55	E-geneY
,	O
a	O
subunit	O
of	O
the	O
RNA	B-geneN
polymerase	I-geneN
III	E-geneN
-	O
specific	O
general	O
transcription	O
factor	O
TFIIIC	S-geneY
,	O
comprises	O
an	O
N	B-geneN
-	I-geneN
terminal	I-geneN
histidine	I-geneN
phosphatase	I-geneN
domain	E-geneN
(	O
τ55	S-geneY
-	O
HPD	S-geneN
)	O
whose	O
catalytic	O
activity	O
and	O
cellular	O
function	O
is	O
poorly	O
understood	O
.	O

We	O
solved	O
the	O
crystal	O
structures	O
of	O
τ55	S-geneY
-	O
HPD	S-geneN
and	O
its	O
closely	O
related	O
paralogue	O
Huf	S-geneN
and	O
used	O
in	O
silico	O
docking	O
methods	O
to	O
identify	O
phospho	B-chem
-	I-chem
serine	E-chem
and	O
phospho	B-chem
-	I-chem
tyrosine	E-chem
containing	O
peptides	O
as	O
possible	O
substrates	O
that	O
were	O
subsequently	O
validated	O
using	O
in	O
vitro	O
phosphatase	S-geneN
assays	O
.	O

A	O
comparative	O
phospho	S-chem
-	O
proteomic	O
study	O
identified	O
additional	O
phosphopeptides	O
as	O
possible	O
targets	O
,	O
which	O
show	O
the	O
involvement	O
of	O
these	O
two	O
phosphatases	S-geneN
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Our	O
results	O
identify	O
τ55	S-geneY
-	O
HPD	S-geneN
and	O
Huf	O
as	O
bona	O
fide	O
protein	B-geneN
phosphatases	E-geneN
,	O
characterize	O
their	O
substrate	O
specificities	O
and	O
provide	O
a	O
small	O
set	O
of	O
regulated	O
phosphosite	O
targets	O
in	O
vivo	O
.	O

Multicenter	O
trial	O
of	O
everolimus	S-chem
in	O
pediatric	O
renal	O
transplant	O
recipients	O
:	O
results	O
at	O
three	O
year	O
.	O

There	O
are	O
few	O
prospective	O
clinical	O
trials	O
of	O
mTOR	S-geneY
inhibitors	O
(	O
or	O
proliferation	O
signal	O
inhibitors	O
)	O
combined	O
with	O
CNI	O
inhibitors	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplantation	O
.	O

Results	O
reported	O
here	O
are	O
from	O
a	O
multicenter	O
,	O
open	O
-	O
label	O
study	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplant	O
patients	O
(	O
<	O
or	O
=	O
16	O
yr	O
)	O
,	O
in	O
which	O
patients	O
received	O
everolimus	O
with	O
cyclosporine	O
and	O
corticosteroids	O
for	O
one	O
yr	O
,	O
then	O
entered	O
an	O
extension	O
study	O
for	O
a	O
further	O
two	O
yr	O
.	O

Nineteen	O
patients	O
completed	O
the	O
one	O
-	O
yr	O
study	O
,	O
of	O
whom	O
three	O
discontinued	O
study	O
medication	O
.	O

Fifteen	O
of	O
the	O
remaining	O
16	O
patients	O
entered	O
the	O
extension	O
study	O
,	O
eight	O
of	O
whom	O
were	O
aged	O
<	O
10	O
yr	O
(	O
Group	O
1	O
)	O
and	O
seven	O
were	O
aged	O
10	O
-	O
16	O
yr	O
(	O
Group	O
2	O
)	O
.	O

Mean	O
daily	O
dose	O
of	O
everolimus	O
during	O
the	O
first	O
36	O
months	O
was	O
1.53	O
mg	O
/	O
m	O
(	O
2	O
)	O
BSA	O
.	O

Biopsy	O
-	O
proven	O
acute	O
rejection	O
occurred	O
in	O
three	O
patients	O
in	O
Group	O
2	O
and	O
in	O
one	O
patient	O
in	O
Group	O
1	O
.	O

Biopsy	O
-	O
proven	O
chronic	O
allograft	O
rejection	O
was	O
reported	O
in	O
four	O
patients	O
(	O
two	O
in	O
each	O
age	O
group	O
)	O
.	O

Graft	O
survival	O
at	O
one	O
yr	O
was	O
100	O
%	O
;	O
one	O
patient	O
in	O
Group	O
2	O
lost	O
their	O
graft	O
subsequently	O
during	O
the	O
extension	O
.	O

For	O
patients	O
entering	O
the	O
extension	O
,	O
patient	O
survival	O
at	O
three	O
yr	O
was	O
100	O
%	O
.	O

There	O
were	O
three	O
cases	O
of	O
viral	O
infection	O
,	O
including	O
one	O
case	O
of	O
cytomegalovirus	O
infection	O
.	O

At	O
three	O
yr	O
,	O
mean	O
total	O
cholesterol	O
was	O
5.5	O
+	O
/	O
-	O
0.8	O
mm	O
/	O
L	O
(	O
213	O
+	O
/	O
-	O
31	O
mg	O
/	O
dL	O
)	O
and	O
four	O
patients	O
received	O
statin	O
therapy	O
.	O

Mean	O
serum	O
creatinine	O
at	O
36	O
months	O
was	O
96	O
+	O
/	O
-	O
36	O
microm	O
/	O
L	O
(	O
1.1	O
+	O
/	O
-	O
0.4	O
mg	O
/	O
dL	O
)	O
.	O

This	O
is	O
the	O
first	O
long	O
-	O
term	O
prospective	O
study	O
to	O
demonstrate	O
that	O
a	O
regimen	O
of	O
everolimus	O
,	O
cyclosporine	O
,	O
and	O
corticosteroids	O
provides	O
good	O
efficacy	O
,	O
tolerability	O
,	O
and	O
safety	O
in	O
de	O
novo	O
pediatric	O
renal	O
transplant	O
patients	O
.	O

Linking	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
receptor	E-geneN
subunits	O
to	O
alcohol	S-chem
-	O
induced	O
conditioned	O
taste	O
aversion	O
and	O
recovery	O
from	O
acute	O
alcohol	S-chem
intoxication	O
.	O

GABA	B-geneN
type	I-geneN
A	I-geneN
receptors	E-geneN
(	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
-	I-geneN
R	E-geneN
)	O
are	O
important	O
for	O
ethanol	S-chem
actions	O
and	O
it	O
is	O
of	O
interest	O
to	O
link	O
individual	O
subunits	O
with	O
specific	O
ethanol	S-chem
behaviors	O
.	O

We	O
studied	O
null	O
mutant	O
mice	O
for	O
six	O
different	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
-	I-geneN
R	I-geneN
subunits	I-geneN
(	I-geneN
α1	I-geneN
,	I-geneN
α2	I-geneN
,	I-geneN
α3	I-geneN
,	I-geneN
α4	I-geneN
,	I-geneN
α5	I-geneN
and	I-geneN
δ	E-geneN
)	O
.	O

Only	O
mice	O
lacking	O
the	O
α2	O
subunit	O
showed	O
reduction	O
of	O
conditioned	O
taste	O
aversion	O
(	O
CTA	O
)	O
to	O
ethanol	S-chem
.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
data	O
from	O
knock	O
-	O
in	O
mice	O
with	O
mutation	O
of	O
the	O
ethanol	S-chem
-	O
sensitive	O
site	O
in	O
the	O
α2	O
-	O
subunit	O
(	O
Blednov	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

All	O
together	O
,	O
they	O
indicate	O
that	O
aversive	O
property	O
of	O
ethanol	S-chem
is	O
dependent	O
on	O
ethanol	S-chem
action	O
on	O
α2	B-geneY
-	I-geneY
containing	I-geneY
GABA	I-geneY
(	I-geneY
A	I-geneY
)	I-geneY
-	I-geneY
R	E-geneY
.	O

Deletion	O
of	O
the	O
α2	O
-	O
subunit	O
led	O
to	O
faster	O
recovery	O
whereas	O
absence	O
of	O
the	O
α3	O
-	O
subunit	O
slowed	O
recovery	O
from	O
ethanol	S-chem
-	O
induced	O
incoordination	O
(	O
rotarod	O
)	O
.	O

Deletion	O
of	O
the	O
other	O
four	O
subunits	O
did	O
not	O
affect	O
this	O
behavior	O
.	O

Similar	O
changes	O
in	O
this	O
behavior	O
for	O
the	O
α2	O
and	O
α3	O
null	O
mutants	O
were	O
found	O
for	O
flurazepam	S-chem
motor	O
incoordination	O
.	O

However	O
,	O
no	O
differences	O
in	O
recovery	O
were	O
found	O
in	O
motor	O
-	O
incoordinating	O
effects	O
of	O
an	O
α1	O
-	O
selective	O
modulator	O
(	O
zolpidem	S-chem
)	O
or	O
an	O
α4	O
-	O
selective	O
agonist	O
(	O
gaboxadol	S-chem
)	O
.	O

Therefore	O
,	O
recovery	O
of	O
rotarod	O
incoordination	O
is	O
under	O
control	O
of	O
two	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
-	I-geneN
R	I-geneN
subunits	I-geneN
:	I-geneN
α2	I-geneN
and	I-geneN
α3	E-geneN
.	O

For	O
motor	O
activity	O
,	O
α3	O
null	O
mice	O
demonstrated	O
higher	O
activation	O
by	O
ethanol	S-chem
(	O
1	O
g	O
/	O
kg	O
)	O
whereas	O
both	O
α2	O
(	O
-	O
/	O
-	O
)	O
and	O
α3	O
(	O
-	O
/	O
Y	O
)	O
knockout	O
mice	O
were	O
less	O
sensitive	O
to	O
ethanol	O
-	E-chem
induced	O
reduction	O
of	O
motor	O
activity	O
(	O
1.5	O
g	O
/	O
kg	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
the	O
effects	O
of	O
ethanol	S-chem
at	O
GABAergic	O
synapses	O
containing	O
α2	O
subunit	O
are	O
important	O
for	O
specific	O
behavioral	O
effects	O
of	O
ethanol	S-chem
which	O
may	O
be	O
relevant	O
to	O
the	O
genetic	O
linkage	O
of	O
the	O
α2	O
subunit	O
with	O
human	O
alcoholism	O
.	O

Effects	O
of	O
a	O
K	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
opener	O
to	O
reduce	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
prevent	O
torsade	O
de	O
pointes	O
in	O
LQT1	O
,	O
LQT2	O
,	O
and	O
LQT3	O
models	O
of	O
the	O
long	O
-	O
QT	O
syndrome	O
.	O

BACKGROUND	O
:	O
This	O
study	O
examines	O
the	O
effects	O
of	O
nicorandil	S-chem-C3-1
,	O
a	O
K	B-geneN-C3-2
(	I-geneN-C3-2
+	I-geneN-C3-2
)	I-geneN-C3-2
channel	E-geneN-C3-2
opener	O
,	O
on	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
and	O
induction	O
of	O
torsade	O
de	O
pointes	O
(	O
TdP	O
)	O
under	O
conditions	O
mimicking	O
the	O
LQT1	O
,	O
LQT2	O
,	O
and	O
LQT3	O
forms	O
of	O
the	O
congenital	O
long	O
-	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transmembrane	O
action	O
potentials	O
of	O
epicardial	O
,	O
M	O
,	O
and	O
endocardial	O
cells	O
were	O
recorded	O
simultaneously	O
from	O
an	O
arterially	O
perfused	O
wedge	O
of	O
canine	O
left	O
ventricle	O
together	O
with	O
a	O
transmural	O
ECG	O
.	O

Chromanol	O
293B	O
(	O
30	O
micromol	O
/	O
L	O
)	O
was	O
used	O
to	O
block	O
I	B-geneN
(	I-geneN
Ks	I-geneN
)	E-geneN
(	O
LQT1	O
model	O
)	O
.	O

Isoproterenol	S-chem-C4-1
(	O
50	O
to	O
100	O
nmol	O
/	O
L	O
)	O
was	O
used	O
to	O
mimic	O
an	O
increase	O
in	O
beta	O
-	O
adrenergic	O
tone	O
,	O
d	B-chem-C4-1
-	I-chem-C4-1
sotalol	E-chem-C4-1
(	O
100	O
micromol	O
/	O
L	O
)	O
to	O
block	O
I	B-geneN-C4-2
(	I-geneN-C4-2
Kr	I-geneN-C4-2
)	E-geneN-C4-2
(	O
LQT2	O
model	O
)	O
,	O
and	O
ATX	B-geneY-C4-2
-	I-geneY-C4-2
II	E-geneY-C4-2
(	O
20	O
nmol	O
/	O
L	O
)	O
to	O
augment	O
late	O
I	O
(	O
Na	S-chem
)	O
(	O
LQT3	O
model	O
)	O
.	O

Isoproterenol	S-chem
+	O
chromanol	B-chem
293B	E-chem
,	O
d	B-chem
-	I-chem
sotalol	E-chem
,	O
and	O
ATX	B-geneY
-	I-geneY
II	E-geneY
produced	O
preferential	O
prolongation	O
of	O
the	O
action	O
potential	O
duration	O
at	O
90	O
%	O
repolarization	O
(	O
APD	O
(	O
90	O
)	O
)	O
of	O
the	O
M	O
cell	O
,	O
an	O
increase	O
of	O
TDR	O
,	O
and	O
spontaneous	O
as	O
well	O
as	O
stimulation	O
-	O
induced	O
TdP	O
(	O
LQT1	O
,	O
3	O
/	O
6	O
;	O
LQT2	O
,	O
3	O
/	O
6	O
;	O
LQT3	O
,	O
5	O
/	O
6	O
)	O
.	O

Nicorandil	S-chem
(	O
2	O
to	O
20	O
micromol	O
/	O
L	O
)	O
abbreviated	O
the	O
QT	O
interval	O
and	O
APD	O
(	O
90	O
)	O
of	O
the	O
3	O
cell	O
types	O
in	O
the	O
3	O
models	O
.	O

High	O
concentrations	O
(	O
10	O
to	O
20	O
micromol	O
/	O
L	O
)	O
completely	O
reversed	O
the	O
effects	O
of	O
293B	O
+	O
/	O
-	O
isoproterenol	S-chem
and	O
those	O
of	O
d	B-chem
-	I-chem
sotalol	E-chem
to	O
increase	O
APD	O
(	O
90	O
)	O
and	O
TDR	O
and	O
to	O
induce	O
TdP	O
in	O
LQT1	O
and	O
LQT2	O
models	O
.	O

Nicorandil	S-chem
20	O
micromol	O
/	O
L	O
reversed	O
only	O
50	O
%	O
of	O
the	O
effect	O
of	O
ATX	B-geneY
-	I-geneY
II	E-geneY
and	O
failed	O
to	O
completely	O
suppress	O
TdP	O
in	O
the	O
LQT3	O
model	O
(	O
5	O
/	O
6	O
to	O
3	O
/	O
6	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
K	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
openers	O
may	O
be	O
capable	O
of	O
abbreviating	O
the	O
long	O
QT	O
interval	O
,	O
reducing	O
TDR	O
,	O
and	O
preventing	O
spontaneous	O
and	O
stimulation	O
-	O
induced	O
TdP	O
when	O
congenital	O
or	O
acquired	O
LQTS	O
is	O
secondary	O
to	O
reduced	O
I	B-geneN
(	I-geneN
Kr	I-geneN
)	E-geneN
or	O
I	B-geneN
(	I-geneN
Ks	I-geneN
)	E-geneN
but	O
less	O
so	O
when	O
it	O
is	O
due	O
to	O
augmented	O
late	O
I	O
(	O
Na	S-chem
)	O
.	O

Norethisterone	S-chem
metabolites	O
modulate	O
the	O
uteroglobin	S-geneY
and	O
progesterone	B-geneY
receptor	E-geneY
gene	O
expression	O
in	O
prepubertal	O
rabbits	O
.	O

Norethisterone	S-chem
(	O
NET	S-chem
)	O
is	O
a	O
synthetic	O
progestin	S-chem
,	O
used	O
as	O
a	O
contraceptive	O
agent	O
,	O
that	O
is	O
biotransformed	O
at	O
target	O
tissues	O
into	O
5	B-chem
alpha	I-chem
-	I-chem
NET	E-chem
and	O
3	B-chem
beta,5	I-chem
alpha	I-chem
-	I-chem
NET	E-chem
,	O
which	O
possess	O
different	O
pharmacological	O
properties	O
.	O

The	O
effects	O
of	O
these	O
metabolites	O
on	O
the	O
expression	O
of	O
uteroglobin	S-geneY
(	O
UG	S-geneY
)	O
and	O
progesterone	B-geneN
receptor	E-geneN
(	O
PR	S-geneN
)	O
genes	O
,	O
both	O
regulated	O
by	O
progesterone	B-chem
(	I-chem
P4	I-chem
)	E-chem
,	O
were	O
evaluated	O
in	O
the	O
uterus	O
of	O
prepubertal	O
female	O
rabbits	O
that	O
were	O
simultaneously	O
treated	O
with	O
P4	O
(	O
1.0	O
mg	O
)	O
for	O
5	O
consecutive	O
days	O
.	O

As	O
determined	O
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
,	O
5	B-chem-C4-1
alpha	I-chem-C4-1
-	I-chem-C4-1
NET	E-chem-C4-1
inhibited	O
the	O
P4	O
-	O
induced	O
UG	S-geneY-C4-2
gene	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
inhibition	O
was	O
observed	O
with	O
the	O
administration	O
of	O
RU	B-chem
-	I-chem
486	E-chem
.	O

The	O
estrogenic	O
agent	O
3	B-chem-C4-1
beta,5	I-chem-C4-1
alpha	I-chem-C4-1
-	I-chem-C4-1
NET	E-chem-C4-1
and	O
estradiol	S-chem-C4-1
at	O
a	O
dose	O
of	O
1.0	O
mg	O
also	O
inhibited	O
the	O
UG	S-geneY-C4-2
gene	O
expression	O
induced	O
by	O
P4	O
.	O

Both	O
5	B-chem-C3-1
alpha	I-chem-C3-1
-	I-chem-C3-1
NET	E-chem-C3-1
and	O
3	B-chem-C3-1
beta,5	I-chem-C3-1
alpha	I-chem-C3-1
-	I-chem-C3-1
NET	E-chem-C3-1
blocked	O
the	O
PR	S-geneY-C3-2
down	O
-	O
regulation	O
induced	O
by	O
P4	O
as	O
assessed	O
by	O
Western	O
and	O
Northern	O
blot	O
methods	O
.	O

The	O
inhibition	O
of	O
UG	S-geneY-C4-2
synthesis	O
and	O
PR	S-geneY-MU-2
down	O
-	O
regulation	O
by	O
5	B-chem-MU-1
alpha	I-chem-MU-1
-	I-chem-MU-1
NET	E-chem-MU-1
and	O
3	B-chem-C4-1
beta,5	I-chem-C4-1
alpha	I-chem-C4-1
-	I-chem-C4-1
NET	E-chem-C4-1
indicates	O
that	O
these	O
NET	S-chem-C4-1
metabolites	O
possess	O
antiprogestational	O
properties	O
.	O

mGluR2	S-geneY
positive	O
allosteric	O
modulators	O
:	O
a	O
patent	O
review	O
(	O
2009	O
-	O
present	O
)	O
.	O

Introduction	O
:	O
The	O
mGlu2	B-geneY
receptor	E-geneY
,	O
which	O
belongs	O
to	O
the	O
group	B-geneY
II	I-geneY
subfamily	I-geneY
of	I-geneY
metabotropic	I-geneY
glutamate	I-geneY
receptors	E-geneY
(	O
mGlu	O
)	O
along	O
with	O
the	O
mGlu3	B-geneY
receptor	E-geneY
,	O
has	O
proven	O
to	O
be	O
of	O
particular	O
importance	O
in	O
neuropharmacology	O
.	O

Preferentially	O
expressed	O
on	O
presynaptic	O
nerve	O
terminals	O
,	O
the	O
mGlu2	B-geneY
receptor	E-geneY
negatively	O
modulates	O
glutamate	S-chem
and	O
GABA	S-chem
release	O
and	O
is	O
widely	O
distributed	O
in	O
the	O
brain	O
.	O

High	O
levels	O
of	O
mGlu2	B-geneY
receptors	E-geneY
are	O
seen	O
in	O
brain	O
areas	O
such	O
as	O
prefrontal	O
cortex	O
,	O
hippocampus	O
and	O
amygdala	O
where	O
glutamate	S-chem
hyperfunction	O
may	O
be	O
implicated	O
in	O
disorders	O
and	O
diseases	O
such	O
as	O
anxiety	O
and	O
schizophrenia	O
.	O

Given	O
the	O
promise	O
offered	O
by	O
mGlu2	B-geneN
/	I-geneN
3	I-geneN
receptor	E-geneN
activation	O
,	O
there	O
is	O
increased	O
interest	O
in	O
identifying	O
small	O
molecules	O
which	O
activate	O
the	O
receptor	O
.	O

A	O
preferred	O
approach	O
is	O
via	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
which	O
bind	O
at	O
an	O
alternative	O
site	O
to	O
agonists	O
.	O

Areas	O
covered	O
:	O
This	O
review	O
covers	O
the	O
patent	O
applications	O
which	O
were	O
published	O
between	O
April	O
2009	O
and	O
December	O
2012	O
on	O
PAMs	O
of	O
the	O
mGlu2	S-geneY
,	O
and	O
it	O
is	O
a	O
continuation	O
of	O
an	O
earlier	O
review	O
published	O
in	O
this	O
journal	O
.	O

Expert	O
opinion	O
:	O
Advances	O
in	O
medicinal	O
chemistry	O
and	O
pharmacology	O
have	O
set	O
the	O
stage	O
in	O
the	O
field	O
of	O
mGlu2	B-geneY
receptor	E-geneY
PAMs	O
.	O

Compounds	O
currently	O
advancing	O
in	O
clinical	O
trials	O
will	O
soon	O
establish	O
the	O
therapeutic	O
potential	O
of	O
this	O
allosteric	O
approach	O
.	O

The	O
tricyclic	S-chem
antidepressant	O
clomipramine	S-chem
increases	O
plasma	O
glucose	S-chem
levels	O
of	O
mice	O
.	O

Effects	O
of	O
the	O
tricyclic	S-chem
antidepressant	O
clomipramine	S-chem
on	O
plasma	O
glucose	S-chem
levels	O
in	O
mice	O
were	O
studied	O
.	O

Clomipramine	S-chem
at	O
doses	O
ranging	O
5	O
-	O
20	O
mg	O
/	O
kg	O
elicited	O
significant	O
hyperglycemia	O
in	O
mice	O
.	O

Hyperglycemia	O
elicited	O
by	O
clomipramine	S-chem
was	O
not	O
reduced	O
by	O
pretreatment	O
with	O
the	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
depleter	O
p	B-chem
-	I-chem
chlorophenylalanine	E-chem
.	O

The	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
1	I-geneN
/	I-geneN
2	I-geneN
/	I-geneN
5	I-geneN
/	I-geneN
7	I-geneN
)	I-geneN
-	I-geneN
receptor	E-geneN
antagonist	O
methysergide	O
and	O
the	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT	I-geneN-C6-2
(	I-geneN-C6-2
2A	I-geneN-C6-2
/	I-geneN-C6-2
2B	I-geneN-C6-2
/	I-geneN-C6-2
2C	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
LY	B-chem-C6-1
53857	E-chem-C6-1
enhanced	O
clomipramine	S-chem
-	O
induced	O
hyperglycemia	O
,	O
while	O
the	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT	I-geneN-C6-2
(	I-geneN-C6-2
1A	I-geneN-C6-2
/	I-geneN-C6-2
1B	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
(	B-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
propranolol	E-chem-C6-1
and	O
the	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT	I-geneN-C6-2
(	I-geneN-C6-2
3	I-geneN-C6-2
/	I-geneN-C6-2
4	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
tropisetron	S-chem-C6-1
did	O
not	O
affect	O
it	O
.	O

The	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT	I-geneN-C6-2
(	I-geneN-C6-2
2B	I-geneN-C6-2
/	I-geneN-C6-2
2C	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
SB	B-chem-C6-1
206553	E-chem-C6-1
facilitated	O
hyperglycemia	O
induced	O
by	O
clomipramine	S-chem
,	O
although	O
the	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
2A	I-geneY-C6-2
)	E-geneY-C6-2
-	O
receptor	O
antagonist	O
ketanserin	S-chem-C6-1
was	O
without	O
effect	O
.	O

Clomipramine	S-chem
-	O
induced	O
hyperglycemia	O
was	O
reduced	O
by	O
prior	O
adrenalectomy	O
.	O

These	O
results	O
suggest	O
that	O
clomipramine	S-chem-C4-1
induces	O
hyperglycemia	O
in	O
mice	O
by	O
blocking	O
the	O
5	B-geneY-C4-2
-	I-geneY-C4-2
HT	I-geneY-C4-2
(	I-geneY-C4-2
2B	I-geneY-C4-2
)	E-geneY-C4-2
and	O
/	O
or	O
5	B-geneY-C4-2
-	I-geneY-C4-2
HT	I-geneY-C4-2
(	I-geneY-C4-2
2C	I-geneY-C4-2
)	E-geneY-C4-2
receptors	O
,	O
which	O
results	O
in	O
facilitation	O
of	O
adrenaline	S-chem
release	O
.	O

DNA	B-geneY
polymerase	I-geneY
POLQ	E-geneY
and	O
cellular	O
defense	O
against	O
DNA	O
damage	O
.	O

In	O
mammalian	O
cells	O
,	O
POLQ	S-geneY
(	O
pol	B-geneY
θ	E-geneY
)	O
is	O
an	O
unusual	O
specialized	O
DNA	B-geneN
polymerase	E-geneN
whose	O
in	O
vivo	O
function	O
is	O
under	O
active	O
investigation	O
.	O

POLQ	S-geneY
has	O
been	O
implicated	O
by	O
different	O
experiments	O
to	O
play	O
a	O
role	O
in	O
resistance	O
to	O
ionizing	O
radiation	O
and	O
defense	O
against	O
genomic	O
instability	O
,	O
in	O
base	O
excision	O
repair	O
,	O
and	O
in	O
immunological	O
diversification	O
.	O

The	O
protein	O
is	O
formed	O
by	O
an	O
N	B-geneN
-	I-geneN
terminal	I-geneN
helicase	I-geneN
-	I-geneN
like	I-geneN
domain	E-geneN
,	O
a	O
C	B-geneN
-	I-geneN
terminal	I-geneN
DNA	I-geneN
polymerase	I-geneN
domain	E-geneN
,	O
and	O
a	O
large	B-geneN
central	I-geneN
domain	E-geneN
that	O
spans	O
between	O
the	O
two	O
.	O

This	O
arrangement	O
is	O
also	O
found	O
in	O
the	O
Drosophila	B-geneY
Mus308	E-geneY
protein	O
,	O
which	O
functions	O
in	O
resistance	O
to	O
DNA	O
interstrand	O
crosslinking	O
agents	O
.	O

Homologs	O
of	O
POLQ	S-geneY
and	O
Mus308	S-geneY
are	O
found	O
in	O
multicellular	O
eukaryotes	O
,	O
including	O
plants	O
,	O
but	O
a	O
comparison	O
of	O
phenotypes	O
suggests	O
that	O
not	O
all	O
of	O
these	O
genes	O
are	O
functional	O
orthologs	O
.	O

Flies	O
defective	O
in	O
Mus308	S-geneY
are	O
sensitive	O
to	O
DNA	O
interstrand	O
crosslinking	O
agents	O
,	O
while	O
mammalian	O
cells	O
defective	O
in	O
POLQ	S-geneY
are	O
primarily	O
sensitive	O
to	O
DNA	O
double	O
-	O
strand	O
breaking	O
agents	O
.	O

Cells	O
from	O
Polq	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
are	O
hypersensitive	O
to	O
radiation	O
and	O
peripheral	O
blood	O
cells	O
display	O
increased	O
spontaneous	O
and	O
ionizing	O
radiation	O
-	O
induced	O
levels	O
of	O
micronuclei	O
(	O
a	O
hallmark	O
of	O
gross	O
chromosomal	O
aberrations	O
)	O
,	O
though	O
mice	O
apparently	O
develop	O
normally	O
.	O

Loss	O
of	O
POLQ	S-geneN
in	O
human	O
and	O
mouse	O
cells	O
causes	O
sensitivity	O
to	O
ionizing	O
radiation	O
and	O
other	O
double	O
strand	O
breaking	O
agents	O
and	O
increased	O
DNA	O
damage	O
signaling	O
.	O

Retrospective	O
studies	O
of	O
clinical	O
samples	O
show	O
that	O
higher	O
levels	O
of	O
POLQ	S-geneY
gene	O
expression	O
in	O
breast	O
and	O
colorectal	O
cancer	O
are	O
correlated	O
with	O
poorer	O
outcomes	O
for	O
patients	O
.	O

A	O
clear	O
understanding	O
of	O
the	O
mechanism	O
of	O
action	O
and	O
physiologic	O
function	O
of	O
POLQ	S-geneY
in	O
the	O
cell	O
is	O
likely	O
to	O
bear	O
clinical	O
relevance	O
.	O

Genetic	O
predictors	O
of	O
the	O
maximum	O
doses	O
patients	O
receive	O
during	O
clinical	O
use	O
of	O
the	O
anti	O
-	O
epileptic	O
drugs	O
carbamazepine	S-chem
and	O
phenytoin	S-chem
.	O

Phenytoin	S-chem
and	O
carbamazepine	S-chem
are	O
effective	O
and	O
inexpensive	O
anti	O
-	O
epileptic	O
drugs	O
(	O
AEDs	O
)	O
.	O

As	O
with	O
many	O
AEDs	O
,	O
a	O
broad	O
range	O
of	O
doses	O
is	O
used	O
,	O
with	O
the	O
final	O
``	O
maintenance	O
``	O
dose	O
normally	O
determined	O
by	O
trial	O
and	O
error	O
.	O

Although	O
many	O
genes	O
could	O
influence	O
response	O
to	O
these	O
medicines	O
,	O
there	O
are	O
obvious	O
candidates	O
.	O

Both	O
drugs	O
target	O
the	O
alpha	B-geneN
-	I-geneN
subunit	I-geneN
of	I-geneN
the	I-geneN
sodium	I-geneN
channel	E-geneN
,	O
encoded	O
by	O
the	O
SCN	S-geneN
family	O
of	O
genes	O
.	O

Phenytoin	S-chem-C9-1
is	O
principally	O
metabolized	O
by	O
CYP2C9	S-geneY-C9-2
,	O
and	O
both	O
are	O
probable	O
substrates	O
of	O
the	O
drug	B-geneN-C9-2
transporter	E-geneN-C9-2
P	B-geneN-C9-2
-	I-geneN-C9-2
glycoprotein	E-geneN-C9-2
.	O

We	O
therefore	O
assessed	O
whether	O
variation	O
in	O
these	O
genes	O
associates	O
with	O
the	O
clinical	O
use	O
of	O
carbamazepine	S-chem
and	O
phenytoin	S-chem
in	O
cohorts	O
of	O
425	O
and	O
281	O
patients	O
,	O
respectively	O
.	O

We	O
report	O
that	O
a	O
known	O
functional	O
polymorphism	O
in	O
CYP2C9	S-geneY
is	O
highly	O
associated	O
with	O
the	O
maximum	O
dose	O
of	O
phenytoin	S-chem
(	O
P	O
=	O
0.0066	O
)	O
.	O

We	O
also	O
show	O
that	O
an	O
intronic	O
polymorphism	O
in	O
the	O
SCN1A	S-geneY
gene	O
shows	O
significant	O
association	O
with	O
maximum	O
doses	O
in	O
regular	O
usage	O
of	O
both	O
carbamazepine	S-chem
and	O
phenytoin	S-chem
(	O
P	O
=	O
0.0051	O
and	O
P	O
=	O
0.014	O
,	O
respectively	O
)	O
.	O

This	O
polymorphism	O
disrupts	O
the	O
consensus	O
sequence	O
of	O
the	O
5	O
'	O
splice	O
donor	O
site	O
of	O
a	O
highly	O
conserved	O
alternative	O
exon	O
(	O
5N	O
)	O
,	O
and	O
it	O
significantly	O
affects	O
the	O
proportions	O
of	O
the	O
alternative	O
transcripts	O
in	O
individuals	O
with	O
a	O
history	O
of	O
epilepsy	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
a	O
drug	O
target	O
polymorphism	O
associated	O
with	O
the	O
clinical	O
use	O
of	O
AEDs	O
and	O
set	O
the	O
stage	O
for	O
a	O
prospective	O
evaluation	O
of	O
how	O
pharmacogenetic	O
diagnostics	O
can	O
be	O
used	O
to	O
improve	O
dosing	O
decisions	O
in	O
the	O
use	O
of	O
phenytoin	S-chem
and	O
carbamazepine	S-chem
.	O

Although	O
the	O
case	O
made	O
here	O
is	O
compelling	O
,	O
our	O
results	O
can	O
not	O
be	O
considered	O
definitive	O
or	O
ready	O
for	O
clinical	O
application	O
until	O
they	O
are	O
confirmed	O
by	O
independent	O
replication	O
.	O

Multipart	O
Copolyelectrolyte	O
Adhesive	O
of	O
the	O
Sandcastle	O
Worm	O
,	O
Phragmatopoma	O
californica	O
(	O
Fewkes	O
)	O
:	O
Catechol	B-geneN
Oxidase	E-geneN
Catalyzed	O
Curing	O
through	O
Peptidyl	O
-	O
DOPA	S-chem
.	O

Tube	O
-	O
building	O
sabellariid	O
polychaetes	O
have	O
major	O
impacts	O
on	O
the	O
geology	O
and	O
ecology	O
of	O
shorelines	O
worldwide	O
.	O

Sandcastle	O
worms	O
,	O
Phragmatopoma	O
californica	O
(	O
Fewkes	O
)	O
,	O
live	O
along	O
the	O
western	O
coast	O
of	O
North	O
America	O
.	O

Individual	O
sabellariid	O
worms	O
build	O
tubular	O
shells	O
by	O
gluing	O
together	O
mineral	O
particles	O
with	O
a	O
multipart	O
polyelectrolytic	O
adhesive	O
.	O

Distinct	O
sets	O
of	O
oppositely	O
charged	O
components	O
are	O
packaged	O
and	O
stored	O
in	O
concentrated	O
granules	O
in	O
separate	O
cell	O
types	O
.	O

Homogeneous	O
granules	O
contain	O
sulfated	O
macromolecules	O
as	O
counter	O
-	O
polyanion	O
to	O
polycationic	O
Pc2	S-geneY
and	O
Pc5	S-geneN
proteins	O
,	O
which	O
become	O
major	O
components	O
of	O
the	O
fully	O
cured	O
glue	O
.	O

Heterogeneous	O
granules	O
contain	O
polyphosphoproteins	O
,	O
Pc3A	B-geneN
/	I-geneN
B	E-geneN
,	O
paired	O
with	O
divalent	O
cations	O
and	O
polycationic	O
Pc1	S-geneY
and	O
Pc4	S-geneN
proteins	O
.	O

Both	O
types	O
of	O
granules	O
contain	O
catechol	B-geneN-C9-2
oxidase	E-geneN-C9-2
that	O
catalyzes	O
oxidative	O
cross	O
-	O
linking	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
DOPA	E-chem-C9-1
.	O

Co	O
-	O
secretion	O
of	O
catechol	B-geneN
oxidase	E-geneN
guarantees	O
rapid	O
and	O
spatially	O
homogeneous	O
curing	O
with	O
limited	O
mixing	O
of	O
the	O
preassembled	O
adhesive	O
packets	O
.	O

Catechol	B-geneN
oxidase	E-geneN
remains	O
active	O
long	O
after	O
the	O
glue	O
is	O
fully	O
cured	O
,	O
perhaps	O
providing	O
an	O
active	O
cue	O
for	O
conspecific	O
larval	O
settlement	O
.	O

Effect	O
of	O
MELANOTAN	S-chem
,	O
[	B-chem
Nle	I-chem
(	I-chem
4	I-chem
)	I-chem
,	I-chem
D	I-chem
-	I-chem
Phe	I-chem
(	I-chem
7	I-chem
)	I-chem
]	I-chem
-	I-chem
alpha	B-geneY
-	I-geneY
MSH	E-geneY
,	O
on	O
melanin	O
synthesis	O
in	O
humans	O
with	O
MC1R	S-geneY
variant	O
alleles	O
.	O

MELANOTAN	S-chem
(	O
NDP	B-chem
-	I-chem
MSH	S-geneY
)	O
binds	O
the	O
MC1	B-geneY
receptor	E-geneY
to	O
significantly	O
increase	O
the	O
eumelanin	O
content	O
of	O
human	O
skin	O
cells	O
.	O

In	O
this	O
study	O
of	O
77	O
Caucasian	O
individuals	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
MELANOTAN	S-chem
in	O
individuals	O
with	O
variant	O
MC1R	S-geneY
genotypes	O
,	O
as	O
it	O
has	O
been	O
suggested	O
through	O
in	O
vitro	O
studies	O
that	O
variant	O
alleles	O
decrease	O
MELANOTAN	S-chem
binding	O
efficacy	O
,	O
which	O
would	O
subsequently	O
affect	O
the	O
synthesis	O
of	O
melanin	O
.	O

Administration	O
of	O
MELANOTAN	S-chem
produced	O
a	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
increase	O
in	O
melanin	O
density	O
in	O
treated	O
,	O
compared	O
to	O
placebo	O
,	O
individuals	O
.	O

Importantly	O
,	O
MELANOTAN	S-chem
increased	O
the	O
melanin	O
density	O
to	O
a	O
greater	O
extent	O
in	O
individuals	O
carrying	O
the	O
variant	O
alleles	O
Val60Leu	O
,	O
Asp84Glu	O
,	O
Val92Met	O
,	O
Arg142His	O
,	O
Arg151Cys	O
,	O
and	O
Arg160Trp	O
than	O
in	O
individuals	O
with	O
no	O
variant	O
alleles	O
.	O

This	O
study	O
demonstrates	O
that	O
MELANOTAN	S-chem
effectively	O
increases	O
the	O
melanin	O
content	O
of	O
skin	O
in	O
those	O
individuals	O
with	O
MC1R	S-geneY
variant	O
alleles	O
and	O
therefore	O
,	O
those	O
most	O
in	O
need	O
of	O
photoprotection	O
.	O

Potentiation	O
of	O
sulfonylurea	S-chem
action	O
by	O
an	O
EPAC	S-geneY
-	O
selective	O
cAMP	S-chem
analog	O
in	O
INS	O
-	O
1	O
cells	O
:	O
comparison	O
of	O
tolbutamide	S-chem
and	O
gliclazide	S-chem
and	O
a	O
potential	O
role	O
for	O
EPAC	S-geneY
activation	O
of	O
a	O
2	O
-	O
APB	O
-	O
sensitive	O
Ca2	O
+	O
influx	O
.	O

Tolbutamide	S-chem-MU-1
and	O
gliclazide	O
block	O
the	O
K	B-geneN-C4-2
(	I-geneN-C4-2
ATP	I-geneN-C4-2
)	I-geneN-C4-2
channel	E-geneN-C4-2
K	B-geneY-C4-2
(	I-geneY-C4-2
ir	I-geneY-C4-2
)	I-geneY-C4-2
6.2	E-geneY-C4-2
/	O
Sur1	S-geneY-C4-2
,	O
causing	O
membrane	O
depolarization	O
and	O
stimulating	O
insulin	S-geneY-C3-2
secretion	O
in	O
pancreatic	O
beta	O
cells	O
.	O

We	O
examined	O
the	O
ability	O
of	O
the	O
EPAC	S-geneY
-	O
selective	O
cAMP	S-chem
analog	O
8	B-chem
-	I-chem
pCPT	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
Me	I-chem
-	I-chem
cAMP	I-chem
-	I-chem
AM	E-chem
to	O
potentiate	O
the	O
action	O
of	O
these	O
drugs	O
and	O
the	O
mechanism	O
that	O
might	O
account	O
for	O
it	O
.	O

Insulin	S-geneN-MU-2
secretion	O
stimulated	O
by	O
both	O
200	O
μM	O
tolbutamide	S-chem-C3-1
and	O
20	O
μM	O
gliclazide	S-chem-C3-1
,	O
concentrations	O
that	O
had	O
equivalent	O
effects	O
on	O
membrane	O
potential	O
,	O
was	O
inhibited	O
by	O
thapsigargin	S-chem-C4-1
(	O
1	O
μM	O
)	O
or	O
the	O
L	B-geneN-C4-2
-	I-geneN-C4-2
type	I-geneN-C4-2
Ca	I-geneN-C4-2
(	I-geneN-C4-2
2	I-geneN-C4-2
+	I-geneN-C4-2
)	I-geneN-C4-2
channel	E-geneN-C4-2
blocker	O
nicardipine	S-chem-C4-1
(	O
2	O
μM	O
)	O
and	O
was	O
potentiated	O
by	O
8	B-chem-C3-1
-	I-chem-C3-1
pCPT	I-chem-C3-1
-	I-chem-C3-1
2	I-chem-C3-1
'	I-chem-C3-1
-	I-chem-C3-1
O	I-chem-C3-1
-	I-chem-C3-1
Me	I-chem-C3-1
-	I-chem-C3-1
cAMP	I-chem-C3-1
-	I-chem-C3-1
AM	E-chem-C3-1
at	O
concentrations	O
≥	O
2	O
μM	O
in	O
INS	O
-	O
1	O
cells	O
.	O

Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
transients	O
stimulated	O
by	O
either	O
tolbutamide	S-chem
or	O
gliclazide	S-chem
were	O
inhibited	O
by	O
thapsigargin	S-chem
or	O
nicardipine	S-chem
and	O
were	O
significantly	O
potentiated	O
by	O
8	O
-	O
pCPT	O
-	O
2	O
'	O
-	O
O	O
-	O
Me	O
-	O
cAMP	O
-	O
AM	O
at	O
5	O
μM	O
but	O
not	O
1	O
μM	O
.	O

Both	O
tolbutamide	S-chem-C3-1
and	O
gliclazide	S-chem-C3-1
stimulated	O
phospholipase	B-geneN-C3-2
C	E-geneN-C3-2
activity	O
;	O
however	O
,	O
only	O
gliclazide	S-chem-C3-1
did	O
so	O
independently	O
of	O
its	O
activity	O
at	O
K	B-geneN-C3-2
(	I-geneN-C3-2
ATP	I-geneN-C3-2
)	I-geneN-C3-2
channels	E-geneN-C3-2
,	O
and	O
this	O
activity	O
was	O
partially	O
inhibited	O
by	O
pertussis	B-geneN
toxin	E-geneN
.	O

8	B-chem
-	I-chem
pCPT	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
Me	I-chem
-	I-chem
cAMP	I-chem
-	I-chem
AM	E-chem
alone	O
(	O
5	O
μM	O
)	O
did	O
not	O
stimulate	O
insulin	S-geneN
secretion	O
,	O
but	O
did	O
increase	O
intracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
concentration	O
significantly	O
,	O
and	O
this	O
activity	O
was	O
inhibited	O
by	O
25	O
μM	O
2	B-chem
-	I-chem
aminoethoxydiphenylborate	E-chem
(	O
2	B-chem
-	I-chem
APB	E-chem
)	O
or	O
the	O
removal	O
of	O
extracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
.	O

8	B-chem-C3-1
-	I-chem-C3-1
pCPT	I-chem-C3-1
-	I-chem-C3-1
2	I-chem-C3-1
'	I-chem-C3-1
-	I-chem-C3-1
O	I-chem-C3-1
-	I-chem-C3-1
Me	I-chem-C3-1
-	I-chem-C3-1
cAMP	I-chem-C3-1
-	I-chem-C3-1
AM	E-chem-C3-1
potentiation	O
of	O
insulin	S-geneN-MU-2
secretion	O
stimulated	O
by	O
tolbutamide	S-chem-C3-1
was	O
markedly	O
inhibited	O
by	O
2	B-chem-C4-1
-	I-chem-C4-1
APB	E-chem-C4-1
(	O
25	O
μM	O
)	O
and	O
enhanced	O
by	O
the	O
PKC	S-geneN-C4-2
inhibitor	O
bisindolylmaleimide	B-chem-MU-1
I	E-chem-MU-1
(	O
1	O
μM	O
)	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
actions	O
of	O
both	O
tolbutamide	S-chem
and	O
gliclazide	S-chem
are	O
strongly	O
potentiated	O
by	O
8	B-chem
-	I-chem
pCPT	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
Me	I-chem
-	I-chem
cAMP	I-chem
-	I-chem
AM	E-chem
,	O
that	O
gliclazide	S-chem-C3-1
can	O
stimulate	O
phospholipase	B-geneN-C3-2
C	E-geneN-C3-2
activity	O
via	O
a	O
partially	O
pertussis	B-geneN
toxin	E-geneN
-	O
sensitive	O
mechanism	O
,	O
and	O
that	O
8	B-chem
-	I-chem
pCPT	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
Me	I-chem
-	I-chem
cAMP	I-chem
-	I-chem
AM	E-chem
potentiation	O
of	O
tolbutamide	O
action	O
may	O
involve	O
activation	O
of	O
a	O
2	B-chem
-	I-chem
APB	E-chem
-	O
sensitive	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
influx	O
.	O

ICA	B-chem-C3-1
-	I-chem-C3-1
105574	E-chem-C3-1
interacts	O
with	O
a	O
common	O
binding	O
site	O
to	O
elicit	O
opposite	O
effects	O
on	O
inactivation	O
gating	O
of	O
EAG	S-geneY-C3-2
and	O
ERG	S-geneY-C3-2
potassium	B-geneN-C3-2
channels	E-geneN-C3-2
.	O

Rapid	O
and	O
voltage	O
-	O
dependent	O
inactivation	O
greatly	O
attenuates	O
outward	O
currents	O
in	O
ether	B-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
related	I-geneY
gene	E-geneY
(	O
ERG	S-geneY
)	O
K	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
.	O

In	O
contrast	O
,	O
inactivation	O
of	O
related	O
ether	B-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	E-geneY
(	O
EAG	S-geneY
)	O
K	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
is	O
very	O
slow	O
and	O
minimally	O
reduces	O
outward	O
currents	O
.	O

ICA	B-chem
-	I-chem
105574	E-chem
(	O
ICA	S-chem
,	O
or	O
3	B-chem
-	I-chem
nitro	I-chem
-	I-chem
N	I-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
phenoxyphenyl	I-chem
]	I-chem
-	I-chem
benzamide	E-chem
)	O
has	O
opposite	O
effects	O
on	O
inactivation	O
of	O
these	O
two	O
channel	O
types	O
.	O

Although	O
ICA	S-chem-MU-1
greatly	O
attenuates	O
ERG	S-geneY-C3-2
inactivation	O
by	O
shifting	O
its	O
voltage	O
dependence	O
to	O
more	O
positive	O
potentials	O
,	O
it	O
enhances	O
the	O
rate	O
and	O
extent	O
of	O
EAG	S-geneY-C4-2
inactivation	O
without	O
altering	O
its	O
voltage	O
dependence	O
.	O

Here	O
,	O
we	O
investigate	O
whether	O
the	O
inverse	O
functional	O
response	O
to	O
ICA	S-chem
in	O
EAG	S-geneY
and	O
ERG	S-geneY
channels	O
is	O
related	O
to	O
differences	O
in	O
ICA	S-chem
binding	O
site	O
or	O
to	O
intrinsic	O
mechanisms	O
of	O
inactivation	O
.	O

Molecular	O
modeling	O
coupled	O
with	O
site	O
-	O
directed	O
mutagenesis	O
suggests	O
that	O
ICA	S-chem
binds	O
in	O
a	O
channel	O
-	O
specific	O
orientation	O
to	O
a	O
hydrophobic	O
pocket	O
bounded	O
by	O
the	O
S5	O
/	O
pore	O
helix	O
/	O
S6	O
of	O
one	O
subunit	O
and	O
S6	O
of	O
an	O
adjacent	O
subunit	O
.	O

ICA	S-chem-C5-1
is	O
a	O
mixed	O
agonist	O
of	O
mutant	O
EAG	S-geneY-C5-2
and	O
EAG	S-geneY-C5-2
/	O
ERG	S-geneY-C5-2
chimera	O
channels	O
that	O
inactivate	O
by	O
a	O
combination	O
of	O
slow	O
and	O
fast	O
mechanisms	O
.	O

With	O
the	O
exception	O
of	O
three	O
residues	O
,	O
the	O
specific	O
amino	B-chem
acids	E-chem
that	O
form	O
the	O
putative	O
binding	O
pocket	O
for	O
ICA	S-chem
in	O
ERG	S-geneY
are	O
conserved	O
in	O
EAG	S-geneY
.	O

Mutations	O
introduced	O
into	O
EAG	S-geneY
to	O
replicate	O
the	O
ICA	S-chem
binding	O
site	O
in	O
ERG	S-geneY
did	O
not	O
alter	O
the	O
functional	O
response	O
to	O
ICA	S-chem
.	O

Together	O
these	O
findings	O
suggest	O
that	O
ICA	S-chem
binds	O
to	O
the	O
same	O
site	O
in	O
EAG	S-geneY
and	O
ERG	S-geneY
channels	O
to	O
elicit	O
opposite	O
functional	O
effects	O
.	O

The	O
resultant	O
agonist	O
or	O
antagonist	O
activity	O
is	O
determined	O
solely	O
by	O
channel	O
-	O
specific	O
differences	O
in	O
the	O
mechanisms	O
of	O
inactivation	O
gating	O
.	O

Nanobody	O
-	O
albumin	S-geneY
nanoparticles	O
(	O
NANAPs	O
)	O
for	O
the	O
delivery	O
of	O
a	O
multikinase	S-geneN-C4-2
inhibitor	O
17864	S-chem-C4-1
to	O
EGFR	S-geneY
overexpressing	O
tumor	O
cells	O
.	O

A	O
novel	O
,	O
EGFR	S-geneY
-	O
targeted	O
nanomedicine	O
has	O
been	O
developed	O
in	O
the	O
current	O
study	O
.	O

Glutaraldehyde	S-chem
crosslinked	O
albumin	S-geneY
nanoparticles	O
with	O
a	O
size	O
of	O
approximately	O
100nm	O
were	O
loaded	O
with	O
the	O
multikinase	S-geneN-C4-2
inhibitor	O
17864	S-chem-C4-1
-	O
L	O
(	O
x	O
)	O
-	O
a	O
platinum	S-chem
-	O
bound	O
sunitinib	S-chem
analogue	O
-	O
which	O
couples	O
the	O
drug	O
to	O
methionine	S-chem
residues	O
of	O
albumin	S-geneY
and	O
is	O
released	O
in	O
a	O
reductive	O
environment	O
.	O

Albumin	S-geneY
nanoparticles	O
were	O
surface	O
-	O
coated	O
with	O
bifunctional	O
polyethylene	B-chem
glycol	E-chem
3500	O
(	O
PEG	S-chem
)	O
and	O
a	O
nanobody	O
-	O
the	O
single	O
variable	O
domain	O
of	O
an	O
antibody	O
-	O
(	O
Ega1	O
)	O
against	O
the	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
.	O

EGa1	O
-	O
PEG	S-chem
functionalized	O
nanoparticles	O
showed	O
a	O
40	O
-	O
fold	O
higher	O
binding	O
to	O
EGFR	S-geneY
-	O
positive	O
14C	S-chem
squamous	O
head	O
and	O
neck	O
cancer	O
cells	O
in	O
comparison	O
to	O
PEGylated	O
nanoparticles	O
.	O

17864	S-chem
-	O
L	O
(	O
x	O
)	O
loaded	O
EGa1	O
-	O
PEG	S-chem
nanoparticles	O
were	O
internalized	O
by	O
clathrin	S-geneN
-	O
mediated	O
endocytosis	O
and	O
ultimately	O
digested	O
in	O
lysosomes	O
.	O

The	O
intracellular	O
routing	O
of	O
EGa1	O
targeted	O
nanoparticles	O
leads	O
to	O
a	O
successful	O
release	O
of	O
the	O
kinase	S-geneN
inhibitor	O
in	O
the	O
cell	O
and	O
inhibition	O
of	O
proliferation	O
whereas	O
the	O
non	O
-	O
targeted	O
formulations	O
had	O
no	O
antiproliferative	O
effects	O
on	O
14C	S-chem
cells	O
.	O

The	O
drug	O
loaded	O
targeted	O
nanoparticles	O
were	O
as	O
effective	O
as	O
the	O
free	O
drug	O
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
multikinase	S-geneN
inhibitor	O
loaded	O
nanoparticles	O
are	O
interesting	O
nanomedicines	O
for	O
the	O
treatment	O
of	O
EGFR	S-geneY
-	O
positive	O
cancers	O
.	O

From	O
in	O
situ	O
to	O
in	O
vivo	O
:	O
an	O
in	O
situ	O
click	O
-	O
chemistry	O
-	O
derived	O
carbonic	O
anhydrase	O
II	O
imaging	O
agent	O
for	O
positron	O
emission	O
tomography	O
.	O

CA	O
II	O
makes	O
a	O
good	O
PET	O
:	O
Discovering	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
probes	O
with	O
high	O
target	O
affinities	O
is	O
challenging	O
.	O

PET	O
probe	O
discovery	O
using	O
in	O
situ	O
click	O
chemistry	O
uses	O
(	O
19	B-chem
)	I-chem
F	I-chem
-	E-chem
bearing	O
fragments	O
as	O
(	O
18	B-chem
)	I-chem
F	I-chem
surrogates	O
.	O

This	O
ensures	O
that	O
the	O
lead	O
hits	O
and	O
PET	O
probes	O
have	O
equivalent	O
chemical	O
or	O
biological	O
characteristics	O
,	O
making	O
PET	O
probe	O
discovery	O
predictable	O
and	O
reliable	O
.	O

Protective	O
effect	O
of	O
butylated	B-chem
hydroxytoluene	E-chem
on	O
ferric	B-chem
nitrilotriacetate	E-chem
induced	O
hepatotoxicity	O
and	O
oxidative	O
stress	O
in	O
mice	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
possible	O
ameliorating	O
effect	O
of	O
butylated	B-chem
hydroxyl	I-chem
toluene	E-chem
(	O
BHT	S-chem
)	O
,	O
associated	O
with	O
ferric	B-chem
nitrilotriacetate	E-chem
(	O
Fe	B-chem
-	I-chem
NTA	E-chem
)	O
-	O
induced	O
oxidative	O
stress	O
and	O
liver	O
injury	O
in	O
mice	O
.	O

The	O
treatment	O
of	O
mice	O
with	O
Fe	B-chem-C3-1
-	I-chem-C3-1
NTA	E-chem-C3-1
alone	O
enhances	O
ornithine	B-geneY-C3-2
decarboxylase	E-geneY-C3-2
activity	O
to	O
4.6	O
folds	O
,	O
protein	O
carbonyl	S-chem
formation	O
increased	O
up	O
to	O
2.9	O
folds	O
and	O
DNA	O
synthesis	O
expressed	O
in	O
terms	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
thymidine	E-chem
incorporation	O
increased	O
to	O
3.2	O
folds	O
,	O
and	O
antioxidants	O
and	O
antioxidant	O
enzymes	O
decreased	O
to	O
1.8	O
-	O
2.5	O
folds	O
,	O
compared	O
with	O
the	O
corresponding	O
saline	O
-	O
treated	O
controls	O
.	O

These	O
changes	O
were	O
reversed	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
in	O
animals	O
receiving	O
a	O
pretreatment	O
of	O
BHT	O
.	I-chem

Our	O
data	O
show	O
that	O
BHT	S-chem
can	O
reciprocate	O
the	O
toxic	O
effects	O
of	O
Fe	B-chem
-	I-chem
NTA	E-chem
and	O
can	O
serve	O
as	O
a	O
potent	O
chemopreventive	O
agent	O
.	O

D1	B-geneN
-	I-geneN
like	I-geneN
receptors	E-geneN
inhibit	O
insulin	S-geneY
-	O
induced	O
vascular	O
smooth	O
muscle	O
cell	O
proliferation	O
via	O
down	O
-	O
regulation	O
of	O
insulin	B-geneY
receptor	E-geneY
expression	O
.	O

OBJECTIVE	O
:	O
Vascular	O
smooth	O
muscle	O
cell	O
(	O
VSMC	O
)	O
proliferation	O
is	O
central	O
to	O
the	O
development	O
of	O
vascular	O
diseases	O
,	O
including	O
hypertension	O
,	O
which	O
is	O
regulated	O
by	O
numerous	O
hormones	O
and	O
humoral	O
factors	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
the	O
stimulatory	O
effect	O
of	O
norepinephrine	S-chem
on	O
VSMC	O
proliferation	O
is	O
inhibited	O
by	O
D1	B-geneN
-	I-geneN
like	I-geneN
receptors	E-geneN
and	O
the	O
D3	B-geneY
dopamine	I-geneY
receptor	E-geneY
,	O
a	O
member	O
of	O
the	O
D2	B-geneN
-	I-geneN
like	I-geneN
receptor	E-geneN
family	O
.	O

Insulin	S-geneY
is	O
a	O
proliferative	O
hormone	O
but	O
it	O
is	O
not	O
known	O
if	O
there	O
is	O
any	O
interaction	O
between	O
insulin	S-geneY
and	O
D1	B-geneN
-	I-geneN
like	I-geneN
receptors	E-geneN
.	O

We	O
hypothesized	O
that	O
Dl	B-geneN
-	I-geneN
like	I-geneN
receptors	E-geneN
may	O
have	O
an	O
inhibitory	O
effect	O
on	O
the	O
insulin	S-geneY
-	O
induced	O
VSMC	O
proliferation	O
;	O
aberrant	O
insulin	S-geneY
and	O
Dl	B-geneN
-	I-geneN
like	I-geneN
receptor	E-geneN
functions	O
could	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
essential	O
hypertension	O
.	O

METHODS	O
:	O
VSMC	O
proliferation	O
was	O
determined	O
by	O
[	B-chem
H	I-chem
]	I-chem
-	I-chem
thymidine	E-chem
incorporation	O
;	O
insulin	B-geneY
receptor	E-geneY
mRNA	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
immunoblotting	O
,	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Insulin	S-geneY
increased	O
VSMC	O
proliferation	O
in	O
immortalized	O
aortic	O
A10	O
cells	O
,	O
determined	O
by	O
[	B-chem
H	I-chem
]	I-chem
-	I-chem
thymidine	E-chem
incorporation	O
.	O

Although	O
the	O
D1	B-geneN
-	I-geneN
like	I-geneN
receptor	E-geneN
,	O
by	O
itself	O
,	O
had	O
no	O
effect	O
on	O
VSMC	O
proliferation	O
,	O
stimulation	O
with	O
fenoldopam	S-chem-MU-1
,	O
a	O
D1	B-geneN-C5-2
-	I-geneN-C5-2
like	I-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
,	O
inhibited	O
the	O
stimulatory	O
effect	O
of	O
insulin	S-geneY-C4-2
.	O

The	O
inhibitory	O
effect	O
of	O
fenoldopam	S-chem-C4-1
on	O
insulin	S-geneY-C4-2
-	O
mediated	O
VSMC	O
proliferation	O
was	O
receptor	O
specific	O
,	O
because	O
its	O
effect	O
could	O
be	O
blocked	O
by	O
SCH23390	S-chem-C6-1
,	O
a	O
D1	B-geneN-C6-2
-	I-geneN-C6-2
like	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
.	O

Fenoldopam	S-chem-C4-1
also	O
inhibited	O
insulin	B-geneY-C4-2
receptor	E-geneY-C4-2
mRNA	O
and	O
protein	O
expression	O
,	O
which	O
was	O
time	O
dependent	O
and	O
concentration	O
dependent	O
.	O

A	O
PKC	S-geneN
or	O
MAP	B-geneN
kinase	E-geneN
inhibitor	O
blocked	O
the	O
inhibitory	O
effect	O
of	O
fenoldopam	S-chem-C4-1
on	O
insulin	B-geneY-C4-2
receptor	E-geneY-C4-2
expression	O
,	O
indicating	O
that	O
PKC	S-geneN
and	O
MAP	B-geneN
kinase	E-geneN
were	O
involved	O
in	O
the	O
signaling	O
pathway	O
.	O

CONCLUSION	O
:	O
The	O
inhibitory	O
effect	O
of	O
D1	B-geneN
-	I-geneN
like	I-geneN
receptors	E-geneN
on	O
insulin	S-geneY
-	O
mediated	O
VSMC	O
proliferation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
blood	O
pressure	O
.	O

Monoacylglycerol	B-geneY
lipase	E-geneY
inhibition	O
-	O
induced	O
changes	O
in	O
plasma	O
corticosterone	S-chem
levels	O
,	O
anxiety	O
and	O
locomotor	O
activity	O
in	O
male	O
CD1	O
mice	O
.	O

The	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
-	O
axis	O
is	O
strongly	O
controlled	O
by	O
the	O
endocannabinoid	O
system	O
.	O

The	O
specific	O
impact	O
of	O
enhanced	O
2	B-chem
-	I-chem
arachidonoylglycerol	E-chem
signaling	O
on	O
corticosterone	S-chem
plasma	O
levels	O
,	O
however	O
,	O
was	O
not	O
investigated	O
so	O
far	O
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
the	O
recently	O
developed	O
monoacylglycerol	B-geneY-C4-2
lipase	E-geneY-C4-2
inhibitor	O
JZL184	S-chem-C4-1
on	O
basal	O
and	O
stress	O
-	O
induced	O
corticosterone	S-chem
levels	O
in	O
male	O
CD1	O
mice	O
,	O
and	O
found	O
that	O
this	O
compound	O
dramatically	O
increased	O
basal	O
levels	O
without	O
affecting	O
stress	O
responses	O
.	O

Since	O
acute	O
changes	O
in	O
corticosterone	S-chem
levels	O
can	O
affect	O
behavior	O
,	O
JZL184	S-chem
was	O
administered	O
concurrently	O
with	O
the	O
corticosterone	S-chem
synthesis	O
inhibitor	O
metyrapone	S-chem
,	O
to	O
investigate	O
whether	O
the	O
previously	O
shown	O
behavioral	O
effects	O
of	O
JZL184	S-chem
are	O
dependent	O
on	O
corticosterone	S-chem
.	O

We	O
found	O
that	O
in	O
the	O
elevated	O
plus	O
-	O
maze	O
,	O
the	O
effects	O
of	O
JZL184	S-chem
on	O
``	O
classical	O
``	O
anxiety	O
-	O
related	O
measures	O
were	O
abolished	O
by	B-chem
corticosterone	O
synthesis	O
blockade	O
.	O

By	O
contrast	O
,	O
effects	O
on	O
the	O
``	O
ethological	O
``	O
measures	O
of	O
anxiety	O
(	O
i.e	O
.	O
risk	O
assessment	O
)	O
were	O
not	O
affected	O
by	B-chem
metyrapone	O
.	O

In	O
the	O
open	O
-	O
field	O
,	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
the	O
compound	O
were	O
not	O
changed	O
either	O
.	O

These	O
findings	O
show	O
that	O
monoacylglycerol	B-geneY
lipase	E-geneY
inhibition	O
dramatically	O
increases	O
basal	O
levels	O
of	O
corticosterone	S-chem
.	O

This	O
endocrine	O
effect	O
partly	O
affects	O
the	O
anxiolytic	O
,	O
but	O
not	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
monoacylglycerol	B-geneY
lipase	E-geneY
blockade	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
nicotinamide	S-chem
derivative	O
as	O
anti	O
-	O
angiogenic	O
agents	O
.	O

Previously	O
,	O
we	O
have	O
found	O
that	O
BRN	B-chem-C4-1
-	I-chem-C4-1
103	E-chem-C4-1
,	O
a	O
nicotinamide	S-chem-C4-1
derivative	O
,	O
inhibits	O
vascular	B-geneY-C4-2
endothelial	I-geneY-C4-2
growth	I-geneY-C4-2
factor	E-geneY-C4-2
(	O
VEGF	S-geneY-C4-2
)	O
-	O
mediated	O
angiogenesis	O
signaling	O
in	O
human	O
endothelial	O
cells	O
.	O

During	O
our	O
continuous	O
efforts	O
to	O
identify	O
more	O
potent	O
anti	O
-	O
angiogenic	O
agents	O
,	O
we	O
synthesized	O
various	O
nicotinamide	S-chem
derivatives	O
and	O
evaluated	O
their	O
anti	O
-	O
angiogenic	O
effects	O
.	O

We	O
found	O
that	O
2	B-chem
-	I-chem
{	I-chem
1	I-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
(	I-chem
6	I-chem
-	I-chem
chloro	I-chem
-	I-chem
5	I-chem
-	I-chem
fluoropyrimidin	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
)	I-chem
ethyl	I-chem
]	I-chem
piperidin	I-chem
-	I-chem
4	I-chem
-	I-chem
ylamino	I-chem
}	I-chem
-	I-chem
N	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
chlorophenyl	I-chem
)	I-chem
pyridine	I-chem
-	I-chem
3	I-chem
-	I-chem
carboxamide	E-chem
(	O
BRN	B-chem
-	I-chem
250	E-chem
)	O
significantly	O
inhibited	O
human	O
umbilical	O
vascular	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
proliferation	O
,	O
migration	O
,	O
tube	O
formation	O
,	O
and	O
microvessel	O
growth	O
in	O
a	O
concentration	O
range	O
of	O
10	O
-	O
100	O
nM	O
.	O

Furthermore	O
,	O
BRN	B-chem-C4-1
-	I-chem-C4-1
250	E-chem-C4-1
inhibited	O
the	O
VEGF	S-geneY-C4-2
-	O
induced	O
phosphorylation	O
and	O
intracellular	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
activity	O
of	O
VEGF	B-geneY-C4-2
receptor	I-geneY-C4-2
2	E-geneY-C4-2
(	O
VEGFR2	S-geneY-C4-2
)	O
and	O
the	O
activation	O
of	O
its	O
downstream	O
AKT	S-geneN-C4-2
pathway	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
BRN	B-chem
-	I-chem
250	E-chem
be	O
considered	O
a	O
potential	O
lead	O
compound	O
for	O
cancer	O
therapy	O
.	O

Anisotropy	O
of	O
chemical	O
bonding	O
in	O
semifluorinated	O
graphite	S-chem
C2F	S-chem
revealed	O
with	O
angle	O
-	O
resolved	O
X	O
-	O
ray	O
absorption	O
spectroscopy	O
.	O

Highly	O
oriented	O
pyrolytic	O
graphite	S-chem
characterized	O
by	O
a	O
low	O
misorientation	O
of	O
crystallites	O
is	O
fluorinated	O
using	O
a	O
gaseous	O
mixture	O
of	O
BrF	B-chem
(	I-chem
3	I-chem
)	E-chem
with	O
Br	B-chem
(	I-chem
2	I-chem
)	E-chem
at	O
room	O
temperature	O
.	O

The	O
golden	O
-	O
colored	O
product	O
,	O
easily	O
delaminating	O
into	O
micrometer	O
-	O
size	O
transparent	O
flakes	O
,	O
is	O
an	O
intercalation	O
compound	O
where	O
Br	B-chem
(	I-chem
2	I-chem
)	E-chem
molecules	O
are	O
hosted	O
between	O
fluorinated	O
graphene	S-chem
layers	O
of	O
approximate	O
C	B-chem
(	I-chem
2	I-chem
)	I-chem
F	E-chem
composition	O
.	O

To	O
unravel	O
the	O
chemical	O
bonding	O
in	O
semifluorinated	O
graphite	S-chem
,	O
we	O
apply	O
angle	O
-	O
resolved	O
near	O
-	O
edge	O
X	O
-	O
ray	O
absorption	O
fine	O
structure	O
(	O
NEXAFS	O
)	O
spectroscopy	O
and	O
quantum	O
-	O
chemical	O
modeling	O
.	O

The	O
strong	O
angular	O
dependence	O
of	O
the	O
CK	O
and	O
FK	O
edge	O
NEXAFS	O
spectra	O
on	O
the	O
incident	O
radiation	O
indicates	O
that	O
room	O
-	O
temperature	O
-	O
produced	O
graphite	B-chem
fluoride	E-chem
is	O
a	O
highly	O
anisotropic	O
material	O
,	O
where	O
half	O
of	O
the	O
carbon	S-chem
atoms	O
are	O
covalently	O
bonded	O
with	O
fluorine	S-chem
,	O
while	O
the	O
rest	O
of	O
the	O
carbon	O
atoms	O
preserve	O
π	O
electrons	O
.	O

Comparison	O
of	O
the	O
experimental	O
CK	O
edge	O
spectrum	O
with	O
theoretical	O
spectra	O
plotted	O
for	O
C	B-chem
(	I-chem
2	I-chem
)	I-chem
F	E-chem
models	O
reveals	O
that	O
fluorine	S-chem
atoms	O
are	O
more	O
likely	O
to	O
form	O
chains	O
.	O

This	O
conclusion	O
agrees	O
with	O
the	O
atomic	O
force	O
microscopy	O
observation	O
of	O
a	O
chain	O
-	O
like	O
pattern	O
on	O
the	O
surface	O
of	O
graphite	B-chem
fluoride	E-chem
layers	O
.	O

Structural	O
optimization	O
of	O
2,5	B-chem-C4-1
-	I-chem-C4-1
thiophene	I-chem-C4-1
amides	E-chem-C4-1
as	O
highly	O
potent	O
and	O
selective	O
17β	B-geneY-C4-2
-	I-geneY-C4-2
hydroxysteroid	I-geneY-C4-2
dehydrogenase	I-geneY-C4-2
type	I-geneY-C4-2
2	E-geneY-C4-2
inhibitors	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Inhibition	O
of	O
17β	B-geneY
-	I-geneY
HSD2	E-geneY
is	O
an	O
attractive	O
mechanism	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

We	O
report	O
here	O
the	O
optimization	O
of	O
human	B-geneY-C4-2
17β	I-geneY-C4-2
-	I-geneY-C4-2
HSD2	E-geneY-C4-2
inhibitors	O
in	O
the	O
2,5	B-chem-C4-1
-	I-chem-C4-1
thiophene	I-chem-C4-1
amide	E-chem-C4-1
class	O
by	O
varying	O
the	O
size	O
of	O
the	O
linker	O
(	O
n	O
equals	O
0	O
and	O
2	O
)	O
between	O
the	O
amide	S-chem
moiety	O
and	O
the	O
phenyl	S-chem
group	O
.	O

While	O
none	O
of	O
the	O
phenethylamides	S-chem
(	O
n	O
=	O
2	O
)	O
were	O
active	O
,	O
most	O
of	O
the	O
anilides	S-chem-C4-1
(	O
n	O
=	O
0	O
)	O
turned	O
out	O
to	O
moderately	O
or	O
strongly	O
inhibit	O
17β	B-geneY-C4-2
-	I-geneY-C4-2
HSD2	E-geneY-C4-2
.	O

The	O
four	O
most	O
active	O
compounds	O
showed	O
an	O
IC₅₀	O
of	O
around	O
60	O
nM	O
and	O
a	O
very	O
good	O
selectivity	O
toward	O
17β	B-geneY
-	I-geneY
HSD1	E-geneY
,	O
17β	B-geneY
-	I-geneY
HSD4	E-geneY
,	O
17β	B-geneY
-	I-geneY
HSD5	E-geneY
,	O
11β	B-geneY
-	I-geneY
HSD1	E-geneY
,	O
11β	B-geneY
-	I-geneY
HSD2	E-geneY
and	O
the	O
estrogen	B-geneN
receptors	I-geneN
α	I-geneN
and	I-geneN
β	E-geneN
.	O

The	O
investigated	O
compounds	O
inhibited	O
monkey	O
17β	B-geneY
-	I-geneY
HSD2	E-geneY
moderately	O
,	O
and	O
one	O
of	O
them	O
showed	O
good	O
inhibitory	O
activity	O
on	O
mouse	B-geneY
17β	I-geneY
-	I-geneY
HSD2	E-geneY
.	O

SAR	O
studies	O
allowed	O
a	O
first	O
characterization	O
of	O
the	O
human	B-geneY
17β	I-geneY
-	I-geneY
HSD2	E-geneY
active	O
site	O
,	O
which	O
is	O
predicted	O
to	O
be	O
considerably	O
larger	O
than	O
that	O
of	O
17β	B-geneY
-	I-geneY
HSD1	E-geneY
.	O

Plasma	O
N	B-geneY
-	I-geneY
terminal	I-geneY
pro	I-geneY
-	I-geneY
brain	I-geneY
natriuretic	I-geneY
peptide	E-geneY
and	O
adrenomedullin	S-geneY
:	O
prognostic	O
utility	O
and	O
prediction	O
of	O
benefit	O
from	O
carvedilol	S-chem
in	O
chronic	O
ischemic	O
left	O
ventricular	O
dysfunction	O
.	O
Australia	O
-	O
New	O
Zealand	O
Heart	O
Failure	O
Group	O
.	O

OBJECTIVES	O
:	O
We	O
sought	O
to	O
assess	O
plasma	O
concentrations	O
of	O
the	O
amino	B-geneY
(	I-geneY
N	I-geneY
)	I-geneY
-	I-geneY
terminal	I-geneY
portion	I-geneY
of	I-geneY
pro	I-geneY
-	I-geneY
brain	I-geneY
natriuretic	I-geneY
peptide	E-geneY
(	O
N	B-geneY
-	I-geneY
BNP	E-geneY
)	O
and	O
adrenomedullin	S-geneY
for	O
prediction	O
of	O
adverse	O
outcomes	O
and	O
responses	O
to	O
treatment	O
in	O
297	O
patients	O
with	O
ischemic	O
left	O
ventricular	O
(	O
LV	O
)	O
dysfunction	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
carvedilol	S-chem
or	O
placebo	O
.	O

BACKGROUND	O
:	O
Although	O
neurohormonal	O
status	O
has	O
known	O
prognostic	O
significance	O
in	O
heart	O
failure	O
,	O
the	O
predictive	O
power	O
of	O
either	O
N	B-geneY
-	I-geneY
BNP	E-geneY
or	O
adrenomedullin	S-geneY
in	O
chronic	O
ischemic	O
LV	O
dysfunction	O
has	O
not	O
been	O
previously	O
reported	O
.	O

METHODS	O
:	O
Plasma	O
N	B-geneY
-	I-geneY
BNP	E-geneY
and	O
adrenomedullin	S-geneY
were	O
measured	O
in	O
297	O
patients	O
with	O
chronic	O
ischemic	O
(	O
LV	O
)	O
dysfunction	O
before	O
randomization	O
to	O
carvedilol	S-chem
or	O
placebo	O
,	O
added	O
to	O
established	O
treatment	O
with	O
a	O
converting	O
enzyme	O
inhibitor	O
and	O
loop	O
diuretic	O
(	O
with	O
or	O
without	O
digoxin	O
)	O
.	O

The	O
patients	O
'	O
clinical	O
outcomes	O
,	O
induding	O
mortality	O
and	O
heart	O
failure	O
events	O
,	O
were	O
recorded	O
for	O
18	O
months	O
.	O

RESULTS	O
:	O
Above	O
-	O
median	O
N	B-geneY
-	I-geneY
BNP	E-geneY
and	O
adrenomedullin	S-geneY
levels	O
conferred	O
increased	O
risks	O
(	O
all	O
p	O
<	O
0.001	O
)	O
of	O
mortality	O
(	O
risk	O
ratios	O
[	O
95	O
%	O
confidence	O
intervals	O
]	O
:	O
4.67	O
[	O
2	O
-	O
10.9	O
]	O
and	O
3.92	O
[	O
1.76	O
-	O
8.7	O
]	O
,	O
respectively	O
)	O
and	O
hospital	O
admission	O
with	O
heart	O
failure	O
(	O
4.7	O
[	O
2.2	O
-	O
10.3	O
]	O
and	O
2.4	O
[	O
1.3	O
-	O
4.5	O
]	O
,	O
respectively	O
)	O
.	O

Both	O
of	O
these	O
predicted	O
death	O
or	O
heart	O
failure	O
independent	O
of	O
age	O
,	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
,	O
LV	O
ejection	O
fraction	O
,	O
previous	O
myocardial	O
infarction	O
or	O
previous	O
admission	O
with	O
heart	O
failure	O
.	O

Carvedilol	S-chem-C4-1
reduced	O
the	O
risk	O
of	O
death	O
or	O
heart	O
failure	O
in	O
patients	O
with	O
above	O
-	O
median	O
levels	O
of	O
N	B-geneY-C4-2
-	I-geneY-C4-2
BNP	E-geneY-C4-2
or	O
adrenomedullin	S-geneY-C4-2
,	O
or	O
both	O
,	O
to	O
rates	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
patients	O
with	O
levels	O
below	O
the	O
median	O
value	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
established	O
ischemic	O
LV	O
dysfunction	O
,	O
plasma	O
N	B-geneY
-	I-geneY
BNP	E-geneY
and	O
adrenomedullin	S-geneY
are	O
independent	O
predictors	O
of	O
mortality	O
and	O
heart	O
failure	O
.	O

Carvedilol	S-chem-C4-1
reduced	O
mortality	O
and	O
heart	O
failure	O
in	O
patients	O
with	O
higher	O
pre	O
-	O
treatment	O
plasma	O
N	B-geneY-C4-2
-	I-geneY-C4-2
BNP	E-geneY-C4-2
and	O
adrenomedullin	S-geneY-C4-2
.	O

Carboxylesterase	B-geneY
-	I-geneY
2	E-geneY
is	O
a	O
highly	O
sensitive	O
target	O
of	O
the	O
antiobesity	O
agent	O
orlistat	S-chem
with	O
profound	O
implications	O
in	O
the	O
activation	O
of	O
anticancer	O
prodrugs	O
.	O

Orlistat	S-chem-C4-1
has	O
been	O
the	O
most	O
used	O
anti	O
-	O
obesity	O
drug	O
and	O
the	O
mechanism	O
of	O
its	O
action	O
is	O
to	O
reduce	O
lipid	O
absorption	O
by	O
inhibiting	O
gastrointestinal	O
lipases	S-geneN-C4-2
.	O

These	O
enzymes	O
,	O
like	O
carboxylesterases	S-geneN
(	O
CESs	S-geneN
)	O
,	O
structurally	O
belong	O
to	O
the	O
α	B-geneN
/	I-geneN
β	I-geneN
hydrolase	E-geneN
fold	O
superfamily	O
.	O

Lipases	S-geneN
and	O
CESs	S-geneN
are	O
functionally	O
related	O
as	O
well	O
.	O

Some	O
CESs	S-geneN
(	O
e.g	O
.	O
,	O
human	B-geneY
CES1	E-geneY
)	O
have	O
been	O
shown	O
to	O
hydrolyze	O
lipids	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
orlistat	S-chem-C4-1
inhibits	O
CESs	S-geneN-C4-2
with	O
higher	O
potency	O
toward	O
CES1	S-geneY-C4-2
than	O
CES2	S-geneY-C4-2
,	O
a	O
carboxylesterase	S-geneN-C4-2
with	O
little	O
lipase	S-geneN-C4-2
activity	O
.	O

Liver	O
microsomes	O
and	O
recombinant	O
CESs	S-geneN
were	O
tested	O
for	O
the	O
inhibition	O
of	O
the	O
hydrolysis	O
of	O
standard	O
substrates	O
and	O
the	O
anticancer	O
prodrugs	O
pentyl	B-chem
carbamate	E-chem
of	O
p	B-chem
-	I-chem
aminobenzyl	I-chem
carbamate	E-chem
of	O
doxazolidine	S-chem
(	O
PPD	S-chem
)	O
and	O
irinotecan	S-chem
.	O

Contrary	O
to	O
the	O
hypothesis	O
,	O
orlistat	O
at	O
1	O
nM	O
inhibited	O
CES2	S-geneY-C4-2
activity	O
by	O
75	O
%	O
but	O
no	O
inhibition	O
on	O
CES1	S-geneY
,	O
placing	O
CES2	S-geneY-C4-2
one	O
of	O
the	O
most	O
sensitive	O
targets	O
of	O
orlistat	S-chem-C4-1
.	O

The	O
inhibition	O
varied	O
among	O
some	O
CES2	S-geneY
polymorphic	O
variants	O
.	O

Pretreatment	O
with	O
orlistat	S-chem
reduced	O
the	O
cell	O
killing	O
activity	O
of	O
PPD	S-chem
.	O

Certain	O
mouse	O
but	O
not	O
rat	B-geneN
CESs	E-geneN
were	O
also	O
highly	O
sensitive	O
.	O

CES2	S-geneY
is	O
responsible	O
for	O
the	O
hydrolysis	O
of	O
many	O
common	O
drugs	O
and	O
abundantly	O
expressed	O
in	O
the	O
gastrointestinal	O
track	O
and	O
liver	O
.	O

Inhibition	O
of	O
this	O
carboxylesterase	S-geneN-C4-2
probably	O
presents	O
a	O
major	O
source	O
for	O
altered	O
therapeutic	O
activity	O
of	O
these	O
medicines	O
if	O
co	O
-	O
administered	O
with	O
orlistat	S-chem-C4-1
.	O

In	O
addition	O
,	O
orlistat	S-chem
has	O
been	O
linked	O
to	O
various	O
types	O
of	O
organ	O
toxicities	O
,	O
and	O
this	O
study	O
provides	O
an	O
alternative	O
target	O
potentially	O
involved	O
in	O
these	O
toxicological	O
responses	O
.	O

Pregnane	B-geneY
X	I-geneY
Receptor	E-geneY
Mediates	O
Dyslipidemia	O
Induced	O
by	O
the	O
HIV	B-geneN-C4-2
Protease	E-geneN-C4-2
Inhibitor	O
Amprenavir	S-chem-C4-1
in	O
Mice	O
.	O

HIV	B-geneY
protease	E-geneY
inhibitors	O
(	O
PIs	O
)	O
have	O
been	O
used	O
successfully	O
in	O
extending	O
the	O
lifespan	O
of	O
people	O
infected	O
with	O
HIV	O
.	O

The	O
use	O
of	O
PIs	O
has	O
also	O
been	O
associated	O
with	O
dyslipidemia	O
and	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
but	O
the	O
underlying	O
mechanisms	O
remain	O
elusive	O
.	O

Several	O
PIs	O
have	O
been	O
implicated	O
to	O
activate	O
the	O
nuclear	O
receptor	O
pregnane	B-geneY
X	I-geneY
receptor	E-geneY
(	O
PXR	S-geneY
)	O
,	O
which	O
acts	O
as	O
a	O
xenobiotic	O
sensor	O
to	O
regulate	O
xenobiotic	O
metabolism	O
in	O
the	O
liver	O
and	O
intestine	O
.	O

Recent	O
studies	O
indicate	O
that	O
PXR	S-geneY
may	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
lipid	O
homeostasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
amprenavir	S-chem-C5-1
,	O
a	O
widely	O
used	O
HIV	O
PI	O
,	O
as	O
a	O
potent	O
PXR	S-geneY-C5-2
-	O
selective	O
agonist	O
.	O

Computational	O
docking	O
studies	O
combined	O
with	O
site	O
-	O
direct	O
mutagenesis	O
identified	O
several	O
key	O
residues	O
within	O
the	O
ligand	O
binding	O
pocket	O
of	O
PXR	S-geneY
that	O
constitute	O
points	O
of	O
interaction	O
with	O
amprenavir	S-chem
.	O

Amprenavir	S-chem-C3-1
efficiently	O
activated	O
PXR	S-geneY-C3-2
and	O
induced	O
PXR	S-geneY-C3-2
target	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Short	O
-	O
term	O
exposure	O
to	O
amprenavir	S-chem
significantly	O
increased	O
plasma	O
total	O
cholesterol	S-chem
and	O
atherogenic	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	S-chem
levels	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
in	O
PXR	S-geneY
-	O
deficient	O
mice	O
.	O

Amprenavir	S-chem-C3-1
-	O
mediated	O
PXR	S-geneY-C3-2
activation	O
stimulated	O
the	O
expression	O
of	O
several	O
key	O
intestinal	O
genes	O
involved	O
in	O
lipid	O
homeostasis	O
.	O

These	O
findings	O
provide	O
critical	O
mechanistic	O
insight	O
for	O
understanding	O
the	O
impact	O
of	O
PIs	O
on	O
cardiovascular	O
disease	O
and	O
demonstrate	O
a	O
potential	O
role	O
of	O
PXR	S-geneY
in	O
mediating	O
adverse	O
effects	O
of	O
HIV	O
PIs	O
in	O
humans	O
.	O

Reduced	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
of	O
siRNA	O
-	O
lipoplexes	O
with	O
addition	O
of	O
polyglutamate	S-chem
.	O

We	O
previously	O
designed	O
a	O
new	O
siRNA	O
vector	O
that	O
efficiently	O
silences	O
genes	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
vector	O
originality	O
is	O
based	O
on	O
the	O
fact	O
that	O
,	O
in	O
addition	O
to	O
the	O
siRNA	O
molecule	O
,	O
it	O
contains	O
two	O
components	O
:	O
1	O
)	O
a	O
cationic	O
liposome	O
that	O
auto	O
-	O
associates	O
with	O
the	O
siRNA	O
to	O
form	O
particles	O
called	O
``	O
lipoplexes	O
``	O
and	O
,	O
2	O
)	O
an	O
anionic	O
polymer	O
which	O
enhances	O
the	O
lipoplex	O
's	O
efficiency	O
.	O

This	O
anionic	O
polymer	O
can	O
be	O
a	O
nucleic	O
acid	O
,	O
a	O
polypeptide	O
or	O
a	O
polysaccharide	O
.	O

We	O
show	O
here	O
how	O
the	O
nature	O
of	O
the	O
added	O
anionic	O
polymer	O
into	O
our	O
siRNA	O
delivery	O
system	O
impacts	O
the	O
toxic	O
effects	O
induced	O
by	O
siRNA	O
lipoplexes	O
.	O

We	O
first	O
observed	O
that	O
:	O
(	O
i	O
)	O
siRNA	O
lipoplexes	O
-	O
induced	O
toxicity	O
was	O
cell	O
line	O
dependent	O
,	O
tumoral	O
cell	O
lines	O
being	O
the	O
more	O
sensitive	O
;	O
and	O
(	O
ii	O
)	O
plasmid	O
DNA	O
-	O
containing	O
siRNA	O
lipoplexes	O
were	O
more	O
toxic	O
than	O
polyglutamate	S-chem
-	O
containing	O
ones	O
or	O
cationic	O
liposomes	O
.	O

We	O
next	O
determined	O
that	O
the	O
toxicity	O
induced	O
by	O
plasmid	O
-	O
containing	O
lipoplexes	O
is	O
a	O
long	O
-	O
lasting	O
effect	O
that	O
decreased	O
cell	O
survival	O
capacity	O
for	O
several	O
generations	O
.	O

We	O
also	O
found	O
that	O
treated	O
cells	O
underwent	O
death	O
following	O
apoptosis	O
pathway	O
.	O

Systemic	O
injection	O
to	O
mice	O
of	O
siRNA	O
lipoplexes	O
,	O
rather	O
than	O
of	O
cationic	O
liposome	O
,	O
triggered	O
a	O
production	O
of	O
several	O
cytokines	S-geneN
in	O
mice	O
and	O
replacement	O
of	O
plasmid	O
by	O
polyglutamate	S-chem-C4-1
reduced	O
the	O
elevation	O
of	O
all	O
assayed	O
cytokines	S-geneN-C4-2
.	O

In	O
order	O
to	O
enhance	O
siRNA	O
lipoplexes	O
efficiency	O
,	O
the	O
addition	O
of	O
polyglutamate	S-chem
as	O
anionic	O
polymer	O
should	O
be	O
preferred	O
to	O
plasmid	O
DNA	O
as	O
far	O
as	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
toxicity	O
is	O
concerned	O
.	O

A	O
novel	O
metabotropic	B-geneY
glutamate	I-geneY
receptor	I-geneY
5	E-geneY
positive	O
allosteric	O
modulator	O
acts	O
at	O
a	O
unique	O
site	O
and	O
confers	O
stimulus	O
bias	O
to	O
mGlu5	S-geneY
signaling	O
.	O

Metabotropic	B-geneY
glutamate	I-geneY
receptor	I-geneY
5	E-geneY
(	O
mGlu5	S-geneY
)	O
is	O
a	O
target	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
,	O
such	O
as	O
schizophrenia	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Furthermore	O
,	O
mGlu5	S-geneY
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
hippocampal	O
synaptic	O
plasticity	O
,	O
specifically	O
in	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
and	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
,	O
which	O
is	O
thought	O
to	O
be	O
involved	O
in	O
cognition	O
.	O

Multiple	O
mGlu5	S-geneY
-	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
have	O
been	O
developed	O
from	O
a	O
variety	O
of	O
different	O
scaffolds	O
.	O

Previous	O
work	O
has	O
extensively	O
characterized	O
a	O
common	O
allosteric	O
site	O
on	O
mGlu5	S-geneY
,	O
termed	O
the	O
MPEP	S-chem
(	O
2	B-chem
-	I-chem
Methyl	I-chem
-	I-chem
6	I-chem
-	I-chem
(	I-chem
phenylethynyl	I-chem
)	I-chem
pyridine	E-chem
)	O
binding	O
site	O
.	O

However	O
,	O
one	O
mGlu5	S-geneY
PAM	O
,	O
CPPHA	S-chem
(	O
N	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
-	I-chem
[	I-chem
(	I-chem
1,3	I-chem
-	I-chem
dioxo	I-chem
-	I-chem
1,3	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2H	I-chem
-	I-chem
isoindol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
methyl	I-chem
]	I-chem
phenyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
hydroxybenzamide	E-chem
)	O
,	O
interacts	O
with	O
a	O
separate	O
allosteric	O
site	O
on	O
mGlu5	S-geneY
.	O

Using	O
cell	O
-	O
based	O
assays	O
and	O
brain	O
slice	O
preparations	O
,	O
we	O
characterized	O
the	O
interaction	O
of	O
a	O
potent	O
and	O
efficacious	O
mGlu5	S-geneY
PAM	O
from	O
the	O
CPPHA	S-chem
series	O
termed	O
NCFP	S-chem
(	O
N	B-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
(	I-chem
4	I-chem
-	I-chem
fluoro	I-chem
-	I-chem
1,3	I-chem
-	I-chem
dioxoisoindolin	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
methyl	I-chem
)	I-chem
phenyl	I-chem
)	I-chem
picolinamide	E-chem
)	O
.	O

NCFP	S-chem-C3-1
binds	O
to	O
the	O
CPPHA	S-chem
site	O
on	O
mGlu5	S-geneY
and	O
potentiates	O
mGlu5	S-geneY-C3-2
-	O
mediated	O
responses	O
in	O
both	O
recombinant	O
and	O
native	O
systems	O
.	O

However	O
,	O
NCFP	S-chem
provides	O
greater	O
mGlu5	S-geneY
subtype	O
selectivity	O
than	O
does	O
CPPHA	S-chem
,	O
making	O
it	O
more	O
suitable	O
for	O
studies	O
of	O
effects	O
on	O
mGlu5	S-geneY
in	O
CNS	O
preparations	O
.	O

Of	O
interest	O
,	O
NCFP	S-chem
does	O
not	O
potentiate	O
responses	O
involved	O
in	O
hippocampal	O
synaptic	O
plasticity	O
(	O
LTD	O
/	O
LTP	O
)	O
,	O
setting	O
it	O
apart	O
from	O
other	O
previously	O
characterized	O
MPEP	S-chem
site	O
PAMs	O
.	O

This	O
suggests	O
that	O
although	O
mGlu5	S-geneY
PAMs	O
may	O
have	O
similar	O
responses	O
in	O
some	O
systems	O
,	O
they	O
can	O
induce	O
differential	O
effects	O
on	O
mGlu5	S-geneY
-	O
mediated	O
physiologic	O
responses	O
in	O
the	O
CNS	O
.	O

Such	O
stimulus	O
bias	O
by	O
mGlu5	S-geneY
PAMs	O
may	O
complicate	O
drug	O
discovery	O
efforts	O
but	O
would	O
also	O
allow	O
for	O
specifically	O
tailored	O
therapies	O
,	O
if	O
pharmacological	O
biases	O
can	O
be	O
attributed	O
to	O
different	O
therapeutic	O
outcomes	O
.	O

Antipsychotic	O
profile	O
of	O
rolipram	S-chem
:	O
efficacy	O
in	O
rats	O
and	O
reduced	O
sensitivity	O
in	O
mice	O
deficient	O
in	O
the	O
phosphodiesterase	B-geneY
-	I-geneY
4B	E-geneY
(	O
PDE4B	S-geneY
)	O
enzyme	O
.	O

RATIONALE	O
:	O
Recent	O
studies	O
provide	O
evidence	O
for	O
reduced	O
phosphodiesterase	B-geneY
-	I-geneY
4B	E-geneY
(	O
PDE4B	S-geneY
)	O
as	O
a	O
genetic	O
susceptibility	O
factor	O
as	O
well	O
as	O
suggesting	O
an	O
association	O
of	O
several	O
single	O
nucleotide	S-chem
polymorphisms	O
(	O
SNPs	O
)	O
in	O
PDE4B	S-geneY
that	O
are	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
schizophrenia	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
activity	O
of	O
rolipram	S-chem-C4-1
,	O
a	O
nonsubtype	O
-	O
selective	O
PDE4	S-geneN-C4-2
inhibitor	O
,	O
in	O
several	O
animal	O
models	O
predictive	O
of	O
antipsychotic	O
-	O
like	O
efficacy	O
and	O
side	O
-	O
effect	O
liability	O
and	O
to	O
use	O
PDE4B	S-geneY
wild	O
-	O
type	O
and	O
knockout	O
mice	O
to	O
begin	O
to	O
understand	O
the	O
subtypes	O
involved	O
in	O
the	O
activity	O
of	O
rolipram	S-chem
.	O

RESULTS	O
:	O
In	O
rats	O
,	O
rolipram	S-chem
antagonized	O
both	O
phencyclidine	B-chem
hydrochloride	E-chem
-	O
and	O
D	B-chem
-	I-chem
amphetamine	E-chem
-	O
induced	O
hyperactivity	O
and	O
inhibited	O
conditioned	O
avoidance	O
responding	O
(	O
CAR	O
)	O
.	O

In	O
PDE4B	S-geneY
wild	O
-	O
type	O
mice	O
,	O
rolipram	S-chem
dose	O
-	O
dependently	O
suppressed	O
CAR	O
(	O
ED	O
(	O
50	O
)	O
=	O
2.4	O
mg	O
/	O
kg	O
)	O
;	O
however	O
,	O
in	O
knockout	O
mice	O
,	O
their	O
sensitivity	O
to	O
rolipram	S-chem
at	O
the	O
higher	O
doses	O
(	O
1.0	O
and	O
3.2	O
mg	O
/	O
kg	O
)	O
was	O
reduced	O
,	O
resulting	O
in	O
a	O
threefold	O
shift	O
in	O
the	O
ED	O
(	O
50	O
)	O
(	O
7.3	O
mg	O
/	O
kg	O
)	O
,	O
suggesting	O
PDE4B	S-geneY
is	O
involved	O
,	O
at	O
least	O
in	O
part	O
,	O
with	O
the	O
activity	O
of	O
rolipram	S-chem
.	O

Only	O
the	O
highest	O
dose	O
of	O
rolipram	S-chem
(	O
3.2	O
mg	O
/	O
kg	O
)	O
produced	O
a	O
modest	O
but	O
significant	O
degree	O
of	O
catalepsy	O
.	O

CONCLUSIONS	O
:	O
Rolipram	S-chem
has	O
a	O
pharmacologic	O
profile	O
similar	O
to	O
that	O
of	O
the	O
atypical	O
antipsychotics	O
and	O
has	O
low	O
extrapyramidal	O
symptom	O
liability	O
.	O

These	O
results	O
suggest	O
that	O
PDE4B	S-geneY
mediates	O
the	O
antipsychotic	O
effects	O
of	O
rolipram	S-chem
in	O
CAR	O
and	O
that	O
the	O
PDE4B	S-geneY-C9-2
-	O
regulated	O
cyclic	B-chem-C9-1
adenosine	I-chem-C9-1
monophosphate	E-chem-C9-1
signaling	O
pathway	O
may	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
and	O
pharmacotherapy	O
of	O
psychosis	O
.	O

Effect	O
of	O
minaprine	S-chem
on	O
cycloheximide	S-chem
-	O
induced	O
amnesia	O
in	O
mice	O
.	O

The	O
effects	O
of	O
minaprine	S-chem
on	O
cycloheximide	S-chem
-	O
induced	O
amnesia	O
were	O
investigated	O
in	O
a	O
step	O
-	O
down	O
passive	O
avoidance	O
task	O
in	O
mice	O
.	O

Minaprine	S-chem
significantly	O
improved	O
cycloheximide	S-chem
-	O
induced	O
amnesia	O
.	O

This	O
effect	O
was	O
inhibited	O
by	O
scopolamine	S-chem
,	O
but	O
was	O
potentiated	O
by	O
physostigmine	S-chem
.	O

The	O
anti	O
-	O
amnesic	O
effect	O
of	O
minaprine	S-chem
on	O
the	O
cycloheximide	S-chem
-	O
induced	O
memory	O
impairment	O
was	O
also	O
antagonized	O
by	O
a	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
releaser	O
,	O
p	B-chem
-	I-chem
chloroamphetamine	E-chem
,	O
and	O
by	O
a	O
5	B-chem
-	I-chem
HT	E-chem
precursor	O
,	O
5	B-chem
-	I-chem
hydroxytryptophan	E-chem
,	O
whereas	O
a	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1A	E-geneY-C5-2
-	O
selective	O
agonist	O
,	O
8	B-chem-C5-1
-	I-chem-C5-1
hydroxy	I-chem-C5-1
-	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
di	I-chem-C5-1
-	I-chem-C5-1
n	I-chem-C5-1
-	I-chem-C5-1
propylamino	I-chem-C5-1
)	I-chem-C5-1
tetralin	E-chem-C5-1
,	O
was	O
inactive	O
.	O

The	O
memory	O
-	O
improving	O
effect	O
of	O
minaprine	S-chem
on	O
cycloheximide	S-chem
-	O
induced	O
amnesia	O
was	O
potentiated	O
by	O
a	O
selective	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT2	E-geneN-C6-2
antagonist	O
,	O
ritanserin	S-chem-C6-1
.	O

These	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
minaprine	S-chem
on	O
cycloheximide	S-chem
-	O
induced	O
amnesia	O
may	O
be	O
related	O
not	O
only	O
to	O
cholinergic	O
but	O
also	O
serotonergic	O
neuronal	O
systems	O
(	O
5	B-geneN
-	I-geneN
HT2	I-geneN
receptors	E-geneN
)	O
.	O

Induction	O
of	O
the	O
metabolic	O
regulator	O
Txnip	S-geneY
in	O
fasting	O
-	O
induced	O
and	O
natural	O
torpor	O
.	O

Torpor	O
is	O
a	O
physiological	O
state	O
characterised	O
by	O
controlled	O
lowering	O
of	O
metabolic	O
rate	O
and	O
core	O
body	O
temperature	O
,	O
allowing	O
substantial	O
energy	O
savings	O
during	O
periods	O
of	O
reduced	O
food	O
availability	O
or	O
harsh	O
environmental	O
conditions	O
.	O

The	O
hypothalamus	O
coordinates	O
energy	O
homeostasis	O
and	O
thermoregulation	O
,	O
and	O
plays	O
a	O
key	O
role	O
in	O
directing	O
torpor	O
.	O

We	O
recently	O
showed	O
that	O
mice	O
lacking	O
the	O
orphan	B-geneN
G	I-geneN
protein	I-geneN
coupled	I-geneN
receptor	E-geneN
Gpr50	S-geneY
readily	O
enter	O
torpor	O
in	O
response	O
to	O
fasting	O
,	O
and	O
have	O
now	O
used	O
these	O
mice	O
to	O
conduct	O
a	O
microarray	O
analysis	O
of	O
hypothalamic	O
gene	O
expression	O
changes	O
related	O
to	O
the	O
torpor	O
state	O
.	O

This	O
revealed	O
a	O
strong	O
induction	O
of	O
thioredoxin	B-geneY
interacting	I-geneY
protein	E-geneY
(	O
Txnip	S-geneY
)	O
in	O
the	O
hypothalamus	O
of	O
torpid	O
mice	O
,	O
which	O
was	O
confirmed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
.	O

In	O
situ	O
hybridisation	O
identified	O
the	O
ependyma	O
lining	O
the	O
third	O
ventricle	O
as	O
the	O
principal	O
site	O
of	O
torpor	O
-	O
related	O
expression	O
of	O
Txnip	S-geneY
.	O

To	O
characterise	O
further	O
the	O
relationship	O
between	O
Txnip	S-geneY
and	O
torpor	O
,	O
we	O
profiled	O
Txnip	S-geneY
expression	O
in	O
mice	O
during	O
prolonged	O
fasting	O
,	O
cold	O
exposure	O
,	O
and	O
2	B-chem
-	I-chem
deoxyglucose	E-chem
-	O
induced	O
hypometabolism	O
,	O
as	O
well	O
as	O
in	O
naturally	O
occurring	O
torpor	O
bouts	O
in	O
the	O
Siberian	O
hamster	O
.	O

Strikingly	O
,	O
pronounced	O
upregulation	O
of	O
Txnip	S-geneY
expression	O
was	O
only	O
observed	O
in	O
WT	O
mice	O
when	O
driven	O
into	O
torpor	O
,	O
and	O
during	O
torpor	O
in	O
the	O
Siberian	O
hamster	O
.	O

Increase	O
of	O
Txnip	S-geneY
was	O
not	O
limited	O
to	O
the	O
hypothalamus	O
,	O
with	O
exaggerated	O
expression	O
in	O
white	O
adipose	O
tissue	O
,	O
brown	O
adipose	O
tissue	O
,	O
and	O
liver	O
also	O
demonstrated	O
in	O
torpid	O
mice	O
.	O

Given	O
the	O
recent	O
identification	O
of	O
Txnip	S-geneY
as	O
a	O
molecular	O
nutrient	O
sensor	O
important	O
in	O
the	O
regulation	O
of	O
energy	O
metabolism	O
,	O
our	O
data	O
suggest	O
that	O
elevated	O
Txnip	S-geneY
expression	O
is	O
critical	O
to	O
regulating	O
energy	O
expenditure	O
and	O
fuel	O
utilisation	O
during	O
the	O
extreme	O
hypometabolic	O
state	O
of	O
torpor	O
.	O

Flt3	B-geneY
receptor	I-geneY
tyrosine	I-geneY
kinase	E-geneY
as	O
a	O
drug	O
target	O
in	O
leukemia	O
.	O

The	O
hematopoietic	B-geneN
class	I-geneN
III	I-geneN
receptor	I-geneN
tyrosine	I-geneN
kinase	I-geneN
(	I-geneN
RTK	I-geneN
)	I-geneN
Flt3	E-geneN
(	O
Flk2	S-geneY
,	O
STK1	S-geneY
)	O
has	O
recently	O
received	O
much	O
attention	O
as	O
a	O
potential	O
drug	O
target	O
.	O

Activation	O
of	O
Flt3	S-geneY
by	O
different	O
types	O
of	O
mutations	O
plays	O
an	O
important	O
role	O
for	O
proliferation	O
,	O
resistance	O
to	O
apoptosis	O
,	O
and	O
prevention	O
of	O
differentiation	O
of	O
leukemic	O
blasts	O
in	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

At	O
least	O
one	O
type	O
of	O
such	O
mutations	O
-	O
an	O
internal	O
tandem	O
duplication	O
in	O
the	O
Flt3	B-geneN
juxtamembrane	I-geneN
domain	E-geneN
(	O
Flt3	B-geneN
-	I-geneN
ITD	E-geneN
)	O
-	O
has	O
been	O
associated	O
with	O
an	O
unfavorable	O
prognosis	O
.	O

Signal	O
transduction	O
of	O
Flt3	S-geneY
involves	O
activation	O
of	O
several	O
conserved	O
pathways	O
,	O
including	O
the	O
RAS	S-geneN
/	O
MAP	B-geneN
-	I-geneN
Kinase	E-geneN
and	O
the	O
phosphoinositide	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
/	O
Akt	S-geneN
signaling	O
cascades	O
.	O

Transforming	O
versions	O
of	O
Flt3	S-geneY
exhibit	O
altered	O
signaling	O
,	O
for	O
example	O
a	O
very	O
pronounced	O
activation	O
of	O
STAT5	S-geneY
,	O
ultimately	O
resulting	O
in	O
alternate	O
profiles	O
of	O
gene	O
expression	O
and	O
cell	O
transformation	O
.	O

Selective	O
inhibitors	O
of	O
Flt3	S-geneY
tyrosine	B-geneN
kinase	E-geneN
activity	O
have	O
the	O
potential	O
to	O
suppress	O
aberrant	O
Flt3	S-geneY
signaling	O
.	O

Although	O
highly	O
homologous	O
to	O
other	O
class	B-geneN
III	I-geneN
RTKs	E-geneN
,	O
Flt3	S-geneY
is	O
resistant	O
to	O
the	O
phenylaminopyrimidine	S-chem-C4-1
STI571	S-chem-C4-1
(	O
Gleevec	S-chem-C4-1
,	O
Imatinib	S-chem-C4-1
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
other	O
RTKs	S-geneN-C4-2
in	O
the	O
family	O
,	O
such	O
as	O
the	O
PDGFbeta	B-geneY-C4-2
-	I-geneY-C4-2
receptor	E-geneY-C4-2
or	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Kit	E-geneY-C4-2
.	O

STI571	S-chem
binding	O
to	O
Flt3	S-geneY
is	O
prevented	O
by	O
the	O
phenylalanine	S-chem
691	O
side	O
-	O
chain	O
in	O
the	O
ATP	S-chem
binding	O
center	O
and	O
mutating	O
this	O
site	O
to	O
threonine	S-chem
renders	O
the	O
corresponding	O
Flt3	S-geneY-C4-2
mutant	O
sensitive	O
to	O
STI571	S-chem-C4-1
.	O

Compounds	O
of	O
several	O
other	O
structural	O
families	O
,	O
including	O
the	O
quinoxaline	S-chem-C4-1
AG1296	S-chem-C4-1
,	O
the	O
bis	B-chem-C4-1
(	I-chem-C4-1
1H	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
indolyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
methanone	E-chem-C4-1
D	B-chem-C4-1
-	I-chem-C4-1
65476	E-chem-C4-1
,	O
the	O
indolinones	S-chem-C4-1
SU5416	S-chem-C4-1
and	O
SU11248	S-chem-C4-1
,	O
the	O
indolocarbazoles	S-chem-C4-1
PKC412	S-chem-C4-1
and	O
CEP	B-chem-C4-1
-	I-chem-C4-1
701	E-chem-C4-1
,	O
and	O
the	O
piperazonyl	B-chem-C4-1
quinazoline	E-chem-C4-1
CT53518	S-chem-C4-1
,	O
are	O
potent	O
inhibitors	O
of	O
Flt3	S-geneY-C4-2
kinase	S-geneN-C4-2
.	O

They	O
exhibit	O
different	O
selectivity	O
profiles	O
,	O
both	O
with	O
respect	O
to	O
other	O
kinases	O
and	O
among	O
wildtype	O
Flt3	S-geneY
and	O
its	O
activated	O
versions	O
.	O

These	O
compounds	O
hold	O
promise	O
as	O
novel	O
drugs	O
against	O
AML	O
and	O
as	O
probes	O
for	O
understanding	O
activation	O
mechanisms	O
and	O
signaling	O
pathways	O
in	O
the	O
class	B-geneN
III	I-geneN
RTK	E-geneN
family	O
.	O

Impairment	O
of	O
novel	O
object	O
recognition	O
in	O
adulthood	O
after	O
neonatal	O
exposure	O
to	O
diazinon	S-chem
.	O

Diazinon	S-chem
is	O
an	O
organophosphate	S-chem
pesticide	O
that	O
is	O
still	O
heavily	O
used	O
in	O
agriculture	O
,	O
home	O
gardening	O
,	O
and	O
indoor	O
pest	O
control	O
in	O
Japan	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
neonatal	O
exposure	O
to	O
diazinon	S-chem
on	O
hippocampus	O
-	O
dependent	O
novel	O
object	O
recognition	O
test	O
performance	O
and	O
the	O
expression	O
of	O
the	O
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
(	I-geneN
NMDA	I-geneN
)	I-geneN
receptor	E-geneN
and	O
its	O
signal	O
transduction	O
pathway	O
-	O
related	O
genes	O
in	O
the	O
hippocampi	O
of	O
young	O
adult	O
and	O
adult	O
mice	O
.	O

Male	O
offspring	O
of	O
C3H	O
/	O
HeN	O
mice	O
were	O
subcutaneously	O
treated	O
with	O
0	O
,	O
0.5	O
,	O
or	O
5	O
mg	O
/	O
kg	O
of	O
diazinon	S-chem
for	O
4	O
consecutive	O
days	O
beginning	O
on	O
postnatal	O
day	O
(	O
PND	O
)	O
8	O
.	O

Beginning	O
on	O
PND	O
46	O
or	O
PND	O
81	O
,	O
a	O
novel	O
object	O
recognition	O
test	O
was	O
performed	O
on	O
4	O
consecutive	O
days	O
.	O

The	O
hippocampi	O
were	O
collected	O
on	O
PND	O
50	O
or	O
PND	O
85	O
after	O
the	O
completion	O
of	O
the	O
novel	O
object	O
recognition	O
test	O
,	O
and	O
the	O
expression	O
levels	O
of	O
neurotrophins	S-geneN
and	O
the	O
NMDA	B-geneN
receptor	E-geneN
and	O
its	O
signal	O
transduction	O
pathway	O
-	O
related	O
genes	O
were	O
examined	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Diazinon	S-chem
-	O
injected	O
mice	O
exhibited	O
a	O
poor	O
ability	O
to	O
discriminate	O
between	O
novel	O
and	O
familiar	O
objects	O
during	O
both	O
the	O
PND	O
49	O
and	O
the	O
PND	O
84	O
tests	O
.	O

The	O
NMDA	B-geneN
receptor	I-geneN
subunits	I-geneN
NR1	I-geneN
and	I-geneN
NR2B	E-geneN
and	O
the	O
related	O
protein	O
kinase	S-geneN
calcium	B-geneY
/	I-geneY
calmodulin	I-geneY
-	I-geneY
dependent	I-geneY
protein	I-geneY
kinase	I-geneY
(	I-geneY
CaMK	I-geneY
)	I-geneY
-	I-geneY
IV	E-geneY
and	O
the	O
transcription	O
factor	O
cyclic	B-geneY
AMP	I-geneY
responsive	I-geneY
element	I-geneY
binding	I-geneY
protein	I-geneY
(	I-geneY
CREB	I-geneY
)	I-geneY
-	I-geneY
1	E-geneY
mRNA	O
levels	O
were	O
reduced	O
in	O
the	O
PND	O
50	O
mice	O
.	O

However	O
,	O
no	O
significant	O
changes	O
in	O
the	O
expressions	O
of	O
the	O
NMDA	S-chem
subunits	O
and	O
their	O
signal	O
transduction	O
molecules	O
were	O
observed	O
in	O
the	O
hippocampi	O
of	O
the	O
PND	O
85	O
mice	O
.	O

The	O
expression	O
level	O
of	O
nerve	B-geneY
growth	I-geneY
factor	E-geneY
mRNA	O
was	O
significantly	O
reduced	O
in	O
the	O
PND	O
50	O
or	O
85	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
neonatal	O
diazinon	S-chem
exposure	O
impaired	O
the	O
hippocampus	O
-	O
dependent	O
novel	O
object	O
recognition	O
ability	O
,	O
accompanied	O
by	O
a	O
modulation	O
in	O
the	O
expressions	O
of	O
the	O
NMDA	B-geneN
receptor	E-geneN
and	O
neurotrophin	O
in	O
young	O
adult	O
and	O
adult	O
mice	O
.	O

Anti	O
-	O
inflammatory	O
effect	O
of	O
essential	O
oil	O
and	O
its	O
constituents	O
from	O
fingered	O
citron	O
(	O
Citrus	O
medica	O
L.	O
var	O
.	O
sarcodactylis	O
)	O
through	O
blocking	O
JNK	S-geneN
,	O
ERK	S-geneN
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
signaling	O
pathways	O
in	O
LPS	O
-	O
activated	O
RAW	O
264.7	O
cells	O
.	O

We	O
investigated	O
the	O
composition	O
of	O
essential	O
oil	O
from	O
fingered	O
citron	O
(	O
Citrus	O
medica	O
L.	O
var	O
.	O
sarcodactylis	O
)	O
(	O
FCEO	O
)	O
peels	O
by	O
GC	O
-	O
MS	O
and	O
its	O
anti	O
-	O
inflammatory	O
effects	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
mouse	O
macrophage	O
(	O
RAW	O
264.7	O
)	O
cells	O
.	O

Fifteen	O
compounds	O
,	O
representing	O
98.97	O
%	O
of	O
the	O
essential	O
oil	O
,	O
were	O
tentatively	O
identified	O
;	O
the	O
main	O
constituents	O
were	O
limonene	S-chem
(	O
52.44	O
%	O
)	O
and	O
γ	B-chem
-	I-chem
terpinene	E-chem
(	O
28.41	O
%	O
)	O
.	O

FCEO	O
significantly	O
inhibited	O
nitric	B-chem-C4-1
oxide	E-chem-C4-1
(	O
NO	S-chem-C4-1
)	O
and	O
prostaglandin	B-chem-C4-1
E2	E-chem-C4-1
(	O
PGE2	S-chem-C4-1
)	O
by	O
suppressing	O
the	O
protein	O
expression	O
of	O
inducible	B-geneY-C4-2
nitric	I-geneY-C4-2
oxide	I-geneY-C4-2
synthase	E-geneY-C4-2
(	O
iNOS	S-geneY-C4-2
)	O
and	O
cyclooxygenase	B-geneY-C4-2
(	I-geneY-C4-2
COX	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
respectively	O
.	O

Additionally	O
,	O
FCEO	O
suppressed	O
the	O
production	O
of	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
α	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
1β	E-geneY
,	O
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
.	O

FCEO	O
attenuated	O
LPS	O
-	O
induced	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
κB	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
activation	O
via	O
inhibition	O
of	O
inhibitor	B-geneY
κB	I-geneY
-	I-geneY
α	E-geneY
phosphorylation	O
.	O

Furthermore	O
,	O
FCEO	O
blocked	O
activation	O
of	O
c	B-geneN
-	I-geneN
Jun	I-geneN
N	I-geneN
-	I-geneN
terminal	I-geneN
kinase	E-geneN
(	O
JNK	S-geneN
)	O
and	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
but	O
not	O
that	O
of	O
p38	B-geneN
mitogen	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
.	O

These	O
results	O
indicate	O
that	O
FCEO	O
inhibits	O
LPS	O
-	O
stimulated	O
inflammation	O
by	O
blocking	O
the	O
NF	B-geneN
-	I-geneN
κB	E-geneN
,	O
JNK	S-geneN
,	O
and	O
ERK	S-geneN
pathways	O
in	O
macrophages	O
,	O
and	O
demonstrate	O
that	O
FCEO	O
possesses	O
anti	O
-	O
inflammatory	O
properties	O
.	O

A	O
novel	O
variant	O
L263F	S-geneN
in	O
human	B-geneY
inosine	I-geneY
5	I-geneY
'	I-geneY
-	I-geneY
monophosphate	I-geneY
dehydrogenase	I-geneY
2	E-geneY
is	O
associated	O
with	O
diminished	O
enzyme	O
activity	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Inosine	B-geneY
5	I-geneY
'	I-geneY
-	I-geneY
monophosphate	I-geneY
dehydrogenase	I-geneY
2	E-geneY
is	O
required	O
for	O
purine	O
synthesis	O
in	O
activated	O
lymphocytes	O
.	O

Variants	O
in	O
the	O
IMPDH2	S-geneY
gene	O
may	O
account	O
for	O
the	O
large	O
inter	O
-	O
individual	O
variability	O
in	O
baseline	O
enzyme	O
activity	O
,	O
immunosuppressive	O
efficacy	O
and	O
side	O
effects	O
in	O
transplant	O
recipients	O
receiving	O
mycophenolic	B-chem
acid	E-chem
.	O

Therefore	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
and	O
functionally	O
characterize	O
IMPDH2	S-geneY
variants	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
152	O
solid	O
organ	O
transplant	O
patients	O
were	O
screened	O
at	O
exons	O
and	O
exon	O
/	O
intron	O
junctions	O
of	O
the	O
IMPDH2	S-geneY
genes	O
by	O
PCR	O
amplification	O
followed	O
by	O
bidirectional	O
direct	O
DNA	O
sequencing	O
.	O

Genetic	O
variant	O
was	O
constructed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
transformed	O
to	O
an	O
inosine	B-geneY
5	I-geneY
'	I-geneY
-	I-geneY
monophosphate	I-geneY
dehydrogenase	E-geneY
-	O
deficient	O
strain	O
of	O
Escherichia	O
coli	O
h712	O
.	O

Proteins	O
were	O
purified	O
to	O
homogeneity	O
and	O
the	O
enzymatic	O
activity	O
was	O
measured	O
by	O
reduced	O
nicotinamide	B-chem
adenine	I-chem
dinucleotide	E-chem
production	O
.	O

RESULTS	O
:	O
Nine	O
genetic	O
variants	O
were	O
identified	O
in	O
the	O
IMPDH2	S-geneY
gene	O
,	O
with	O
frequencies	O
of	O
the	O
rarer	O
alleles	O
ranging	O
from	O
0.5	O
to	O
10.2	O
%	O
.	O

A	O
novel	O
nonsynonymous	O
variant	O
L263F	S-geneN
was	O
identified	O
,	O
and	O
the	O
kinetic	O
assay	O
demonstrated	O
that	O
the	O
inosine	B-geneN
5	I-geneN
'	I-geneN
-	I-geneN
monophosphate	I-geneN
dehydrogenase	E-geneN
activity	O
of	O
L263F	S-geneN
variant	O
was	O
decreased	O
to	O
10	O
%	O
of	O
the	O
wild	O
-	O
type	O
.	O

The	O
Ki	O
for	O
mycophenolic	B-chem-C4-1
acid	E-chem-C4-1
inhibition	O
of	O
the	O
L263F	S-geneN-C4-2
variant	O
was	O
comparable	O
with	O
the	O
wild	O
-	O
type	O
,	O
and	O
the	O
variant	O
Km	O
for	O
inosine	B-chem
5	I-chem
'	I-chem
-	I-chem
monophosphate	E-chem
and	O
nicotinamide	B-chem
adenine	I-chem
dinucleotide	E-chem
did	O
not	O
change	O
significantly	O
.	O

CONCLUSIONS	O
:	O
IMPDH2	S-geneY
has	O
low	O
genetic	O
diversity	O
,	O
but	O
the	O
nonsynonymous	O
variant	O
L263F	S-geneN
has	O
a	O
significant	O
impact	O
on	O
inosine	B-geneN
5	I-geneN
'	I-geneN
-	I-geneN
monophosphate	I-geneN
dehydrogenase	E-geneN
activity	O
.	O

This	O
novel	O
functional	O
variant	O
may	O
be	O
one	O
of	O
the	O
factors	O
contributing	O
to	O
the	O
inter	O
-	O
individual	O
difference	O
of	O
baseline	O
inosine	B-geneN
5	I-geneN
'	I-geneN
-	I-geneN
monophosphate	I-geneN
dehydrogenase	E-geneN
activity	O
as	O
well	O
as	O
drug	O
efficacy	O
and	O
adverse	O
events	O
in	O
transplant	O
patients	O
.	O

Optimization	O
of	O
frozen	O
sour	O
cherries	O
vacuum	O
drying	O
process	O
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
optimize	O
the	O
vacuum	O
-	O
drying	O
of	O
frozen	O
sour	O
cherries	O
in	O
order	O
to	O
preserve	O
health	O
-	O
beneficial	O
phytochemicals	O
,	O
as	O
well	O
as	O
textural	O
characteristics	O
.	O

Investigated	O
range	O
of	O
temperature	O
was	O
46	O
-	O
74°C	O
and	O
,	O
of	O
pressure	O
,	O
17	O
-	O
583mbar	O
,	O
in	O
a	O
new	O
design	O
of	O
vacuum	O
-	O
dryer	O
equipment	O
.	O

The	O
total	O
solids	O
,	O
a	O
(	O
w	O
)	O
value	O
,	O
total	O
phenolics	S-chem
,	O
vitamin	B-chem
C	E-chem
,	O
antioxidant	O
activity	O
,	O
anthocyanin	S-chem
content	O
,	O
total	O
colour	O
change	O
and	O
firmness	O
were	O
used	O
as	O
quality	O
indicators	O
of	O
dried	O
sour	O
cherry	O
.	O

Within	O
the	O
experimental	O
range	O
of	O
studied	O
variables	O
,	O
the	O
optimum	O
conditions	O
of	O
54.03°C	O
and	O
148.16mbar	O
were	O
established	O
for	O
vacuum	O
drying	O
of	O
sour	O
cherry	O
.	O

Separate	O
validation	O
experiments	O
were	O
conducted	O
,	O
under	O
optimum	O
conditions	O
,	O
to	O
verify	O
predictions	O
and	O
adequacy	O
of	O
the	O
second	O
-	O
order	O
polynomial	O
models	O
.	O

Under	O
these	O
optimal	O
conditions	O
,	O
the	O
predicted	O
amount	O
of	O
total	O
phenolics	S-chem
was	O
744mg	O
CAE	O
/	O
100	O
dw	O
,	O
vitamin	B-chem
C	E-chem
1.44mg	O
/	O
100g	O
per	O
dry	O
weight	O
(	O
g	O
dw	O
)	O
,	O
anthocyanin	S-chem
content	O
125mg	O
/	O
100g	O
dw	O
,	O
IC	O
(	O
50	O
)	O
3.23mg	O
/	O
ml	O
,	O
total	O
solids	O
70.72	O
%	O
,	O
a	O
(	O
w	O
)	O
value	O
0.646	O
,	O
total	O
colour	O
change	O
52.61	O
and	O
firmness	O
3395.4g	O
.	O

The	O
investigated	O
parameters	O
had	O
a	O
significant	O
effect	O
on	O
the	O
quality	O
of	O
the	O
dried	O
sour	O
cherries	O
.	O

Support	O
for	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
functional	O
selectivity	O
in	O
vivo	O
utilizing	O
structurally	O
diverse	O
,	O
selective	O
5	O
-	B-geneY
HT2C	I-geneY
receptor	O
ligands	O
and	O
the	O
2,5	O
-	I-chem
dimethoxy	I-chem
-	I-chem
4	I-chem
-	I-chem
iodoamphetamine	I-chem
elicited	O
head	O
-	O
twitch	O
response	O
model	O
.	O

There	O
are	O
seemingly	O
conflicting	O
data	O
in	O
the	O
literature	O
regarding	O
the	O
role	O
of	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
in	O
the	O
mouse	O
head	O
-	O
twitch	O
response	O
(	O
HTR	O
)	O
elicited	O
by	O
the	O
hallucinogenic	O
5	B-geneN
-	I-geneN
HT2A	I-geneN
/	I-geneN
2B	I-geneN
/	I-geneN
2C	I-geneN
receptor	E-geneN
agonist	O
2,5	B-chem
-	I-chem
dimethoxy	I-chem
-	I-chem
4	I-chem
-	I-chem
iodoamphetamine	E-chem
(	O
DOI	S-chem
)	O
.	O

Namely	O
,	O
both	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
agonists	O
and	O
antagonists	O
,	O
regarding	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
-	O
mediated	O
Gq	S-geneN
-	O
phospholipase	B-geneN
C	E-geneN
(	O
PLC	S-geneN
)	O
signaling	O
,	O
reportedly	O
attenuate	O
the	O
HTR	O
response	O
.	O

The	O
present	O
experiments	O
tested	O
the	O
hypothesis	O
that	O
both	O
classes	O
of	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
compounds	O
could	O
attenuate	O
the	O
DOI	S-chem
-	O
elicited	O
-	O
HTR	O
in	O
a	O
single	O
strain	O
of	O
mice	O
,	O
C57Bl	O
/	O
6J	O
.	O

The	O
expected	O
results	O
were	O
considered	O
in	O
accordance	O
with	O
ligand	O
functional	O
selectivity	O
.	O

Commercially	O
-	O
available	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT2C	E-geneY-C5-2
agonists	O
(	O
CP	B-chem-C5-1
809101	E-chem-C5-1
,	O
Ro	B-chem-C5-1
60	I-chem-C5-1
-	I-chem-C5-1
0175	E-chem-C5-1
,	O
WAY	B-chem-C5-1
161503	E-chem-C5-1
,	O
mCPP	S-chem-C5-1
,	O
and	O
1	B-chem-C5-1
-	I-chem-C5-1
methylpsilocin	E-chem-C5-1
)	O
,	O
novel	O
4	O
-	B-chem-C5-1
phenyl	I-chem-C5-1
-	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
N	I-chem-C5-1
,	I-chem-C5-1
N	I-chem-C5-1
-	I-chem-C5-1
dimethyl	I-chem-C5-1
-	I-chem-C5-1
aminotetralin	I-chem-C5-1
(	E-chem-C5-1
PAT	O
)	E-chem-C5-1
-	O
type	O
5	O
-	B-geneY-C5-2
HT2C	I-geneY-C5-2
agonists	O
(	O
with	O
5	O
-	B-geneN
HT2A	I-geneN
/	I-geneN
2B	I-geneN
antagonist	O
activity	O
)	O
,	O
and	O
antagonists	O
selective	O
for	O
5	O
-	B-geneY-C6-2
HT2A	I-geneY-C6-2
(	E-geneY-C6-2
M100907	O
)	E-chem-C6-1
,	O
5	O
-	B-geneY-C6-2
HT2C	I-geneY-C6-2
(	E-geneY-C6-2
SB	O
-	I-chem-C6-1
242084	I-chem-C6-1
)	E-chem-C6-1
,	O
and	O
5	O
-	B-geneN
HT2B	I-geneN
/	I-geneN
2C	I-geneN
(	E-geneN
SB	O
-	I-chem
206553	I-chem
)	E-chem
receptors	O
attenuated	O
the	O
DOI	O
-	E-chem
elicited	O
-	O
HTR	O
.	O

In	O
contrast	O
,	O
there	O
were	O
differential	O
effects	O
on	O
locomotion	O
across	O
classes	O
of	O
compounds	O
.	O

The	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
agonists	O
and	O
M100907	S-chem
decreased	O
locomotion	O
,	O
SB	B-chem
-	I-chem
242084	E-chem
increased	O
locomotion	O
,	O
SB	B-chem
-	I-chem
206553	E-chem
resulted	O
in	O
dose	O
-	O
dependent	O
biphasic	O
effects	O
on	O
locomotion	O
,	O
and	O
the	O
PATs	O
did	O
not	O
alter	O
locomotion	O
.	O

In	O
vitro	O
molecular	O
pharmacology	O
studies	O
showed	O
that	O
5	O
-	B-geneY
HT2C	I-geneY
agonists	O
potent	O
for	O
attenuating	O
the	O
DOI	O
-	E-chem
elicited	O
-	O
HTR	O
also	O
reduced	O
the	O
efficacy	O
of	O
DOI	O
to	O
activate	O
mouse	O
5	I-geneY-C3-2
-	I-geneY-C3-2
HT2C	I-geneY-C3-2
receptor	O
-	O
mediated	O
PLC	O
signaling	O
in	O
HEK	O
cells	O
.	O

Although	O
there	O
were	O
differences	O
in	O
affinities	O
of	O
a	O
few	O
compounds	O
at	O
mouse	O
compared	O
to	O
human	B-geneY
5	I-geneY
-	I-geneY
HT2A	E-geneY
or	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
,	O
all	O
compounds	O
tested	O
retained	O
their	O
selectivity	O
for	O
either	O
receptor	O
,	O
regardless	O
of	O
receptor	O
species	O
.	O

Results	O
indicate	O
that	O
5	B-geneN
-	I-geneN
HT2C	E-geneN
receptor	O
agonists	O
and	O
antagonists	O
attenuate	O
the	O
DOI	S-chem
-	O
elicited	O
-	O
HTR	O
in	O
C57Bl	O
/	O
6J	O
mice	O
,	O
and	O
suggest	O
that	O
structurally	O
diverse	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
ligands	O
result	O
in	O
different	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
signaling	O
outcomes	O
compared	O
to	O
DOI	S-chem
.	O

Further	O
insights	O
into	O
the	O
effect	O
of	O
quinidine	S-chem
in	O
short	O
QT	O
syndrome	O
caused	O
by	O
a	O
mutation	O
in	O
HERG	S-geneY
.	O

INTRODUCTION	O
:	O
The	O
principal	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
quinidine	S-chem-C4-1
in	O
suppressing	O
IKr	S-geneN-C4-2
in	O
vitro	O
and	O
in	O
modulating	O
the	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
in	O
the	O
``	O
SQT1	O
``	O
form	O
of	O
the	O
short	O
QT	O
syndrome	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Graded	O
-	O
intensity	O
bicycle	O
exercise	O
testing	O
was	O
performed	O
off	O
drug	O
in	O
three	O
patients	O
and	O
during	O
oral	O
quinidine	S-chem
in	O
two	O
patients	O
with	O
short	O
QT	O
syndrome	O
and	O
compared	O
to	O
a	O
control	O
group	O
of	O
healthy	O
normal	O
subjects	O
.	O

The	O
in	O
vitro	O
effects	O
of	O
quinidine	S-chem
on	O
currents	O
in	O
patch	O
clamp	O
technique	O
were	O
investigated	O
.	O

Off	O
drugs	O
QTpV3	O
/	O
heart	O
rate	O
correlation	O
is	O
much	O
weaker	O
in	O
patients	O
with	O
short	O
QT	O
syndrome	O
,	O
and	O
QTpV3	O
shortens	O
less	O
with	O
heart	O
rate	O
increase	O
compared	O
to	O
normal	O
subjects	O
.	O

In	O
addition	O
to	O
prolonging	O
the	O
QT	O
interval	O
into	O
the	O
normal	O
range	O
,	O
quinidine	S-chem
restored	O
the	O
heart	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
toward	O
a	O
range	O
of	O
adaptation	O
reported	O
for	O
normal	O
subjects	O
.	O

Data	O
from	O
heterologous	O
expression	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
HERG	S-geneY
genes	O
indicate	O
the	O
mutation	O
causes	O
a	O
20	O
-	O
fold	O
increase	O
in	O
IC50	O
of	O
d	O
-	O
sotalol	O
but	O
only	O
a	O
5.8	O
-	O
fold	O
increase	O
in	O
IC50	O
of	O
quinidine	S-chem
.	O

CONCLUSION	O
:	O
Oral	O
quinidine	S-chem-C4-1
is	O
effective	O
in	O
suppressing	O
the	O
gain	O
of	O
function	O
in	O
IKr	S-geneN-C4-2
responsible	O
for	O
some	O
cases	O
of	O
short	O
QT	O
syndrome	O
with	O
a	O
mutation	O
in	O
HERG	S-geneY
and	O
thus	O
restoring	O
normal	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
and	O
rendering	O
ventricular	O
tachycardia	O
/	O
ventricular	O
fibrillation	O
noninducible	O
.	O

Selective	O
costimulation	O
modulators	O
:	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

T	O
cells	O
have	O
a	O
central	O
role	O
in	O
the	O
orchestration	O
of	O
the	O
immune	O
pathways	O
that	O
contribute	O
to	O
the	O
inflammation	O
and	O
joint	O
destruction	O
characteristic	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

The	O
requirement	O
for	O
a	O
dual	O
signal	O
for	O
T	O
-	O
cell	O
activation	O
and	O
the	O
construction	O
of	O
a	O
fusion	O
protein	O
that	O
prevents	O
engagement	O
of	O
the	O
costimulatory	O
molecules	O
required	O
for	O
this	O
activation	O
has	O
led	O
to	O
a	O
new	O
approach	O
to	O
RA	O
therapy	O
.	O

This	O
approach	O
is	O
mechanistically	O
distinct	O
from	O
other	O
currently	O
used	O
therapies	O
;	O
it	O
targets	O
events	O
early	O
rather	O
than	O
late	O
in	O
the	O
immune	O
cascade	O
,	O
and	O
it	O
results	O
in	O
immunomodulation	O
rather	O
than	O
complete	O
immunosuppression	O
.	O

The	O
fusion	O
protein	O
abatacept	O
is	O
a	O
selective	O
costimulation	O
modulator	O
that	O
avidly	O
binds	O
to	O
the	O
CD80	S-geneY
/	O
CD86	S-geneY
ligands	O
on	O
an	O
antigen	O
-	O
presenting	O
cell	O
,	O
resulting	O
in	O
the	O
inability	O
of	O
these	O
ligands	O
to	O
engage	O
the	O
CD28	B-geneN
receptor	E-geneN
on	O
the	O
T	O
cell	O
.	O

Abatacept	O
dose	O
-	O
dependently	O
reduces	O
T	O
-	O
cell	O
proliferation	O
,	O
serum	O
concentrations	O
of	O
acute	O
-	O
phase	O
reactants	O
,	O
and	O
other	O
markers	O
of	O
inflammation	O
,	O
including	O
the	O
production	O
of	O
rheumatoid	O
factor	O
by	O
B	O
cells	O
.	O

Recent	O
studies	O
have	O
provided	O
consistent	O
evidence	O
that	O
treatment	O
with	O
abatacept	O
results	O
in	O
a	O
rapid	O
onset	O
of	O
efficacy	O
that	O
is	O
maintained	O
over	O
the	O
course	O
of	O
treatment	O
in	O
patients	O
with	O
inadequate	O
response	O
to	O
methotrexate	S-chem
and	O
anti	O
-	O
tumor	B-geneN
necrosis	I-geneN
factor	E-geneN
therapies	O
.	O

This	O
efficacy	O
includes	O
patient	O
-	O
centered	O
outcomes	O
and	O
radiographic	O
measurement	O
of	O
disease	O
progression	O
.	O

Abatacept	O
has	O
also	O
demonstrated	O
a	O
very	O
favorable	O
safety	O
profile	O
to	O
date	O
.	O

This	O
article	O
reviews	O
the	O
rationale	O
for	O
this	O
therapeutic	O
approach	O
and	O
highlights	O
some	O
of	O
the	O
recent	O
studies	O
that	O
demonstrate	O
the	O
benefits	O
obtained	O
by	O
using	O
abatacept	O
.	O

This	O
clinical	O
experience	O
indicates	O
that	O
abatacept	O
is	O
a	O
significant	O
addition	O
to	O
the	O
therapeutic	O
armamentarium	O
for	O
the	O
management	O
of	O
patients	O
with	O
RA	O
.	O

Interleukin	B-geneY
2	E-geneY
toxin	O
:	O
a	O
step	O
toward	O
selective	O
immunomodulation	O
.	O

We	O
have	O
used	O
protein	O
engineering	O
and	O
recombinant	O
DNA	O
methodologies	O
to	O
genetically	O
replace	O
the	O
eukaryotic	B-geneN
cell	I-geneN
receptor	I-geneN
binding	I-geneN
domain	E-geneN
of	O
diphtheria	O
toxin	O
with	O
interleukin	B-geneY
2	E-geneY
(	O
IL	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

The	O
toxin	O
-	O
related	O
T	B-geneN
cell	I-geneN
growth	I-geneN
factor	E-geneN
fusion	O
gene	O
has	O
been	O
cloned	O
in	O
Escherichia	O
coli	O
K12	O
.	O

Recombinant	O
strains	O
of	O
E	O
coli	O
produce	O
a	O
68,086	O
K	O
hybrid	O
toxin	O
,	O
IL	B-geneY
-	I-geneY
2	E-geneY
toxin	O
that	O
retains	O
immunologic	O
properties	O
intrinsic	O
to	O
both	O
its	O
diphtheria	O
toxin	O
and	O
IL	B-geneY
-	I-geneY
2	E-geneY
components	O
.	O

IL	B-geneN
-	I-geneN
2	E-geneN
toxin	O
has	O
been	O
found	O
to	O
selectively	O
inhibit	O
protein	O
synthesis	O
in	O
both	O
human	O
and	O
murine	O
T	O
cell	O
lines	O
that	O
bear	O
high	O
affinity	O
IL	B-geneN
-	I-geneN
2	I-geneN
receptors	E-geneN
,	O
whereas	O
the	O
hybrid	O
toxin	O
is	O
not	O
active	O
against	O
cells	O
that	O
do	O
not	O
bear	O
this	O
receptor	O
.	O

The	O
cytotoxic	O
action	O
of	O
IL	B-geneY
-	I-geneY
2	E-geneY
toxin	O
is	O
specifically	O
blocked	O
by	O
free	O
IL	B-geneY
-	I-geneY
2	E-geneY
and	O
monoclonal	O
antibodies	O
that	O
bind	O
to	O
the	O
p55	S-geneY
(	O
Tac	S-geneN
antigen	O
)	O
subunit	O
of	O
the	O
high	O
affinity	O
IL	B-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
.	O

In	O
addition	O
,	O
IL	B-geneY
-	I-geneY
2	E-geneY
toxin	O
,	O
like	O
diphtheria	O
toxin	O
itself	O
,	O
must	O
pass	O
through	O
an	O
acidic	O
compartment	O
in	O
order	O
to	O
deliver	O
its	O
adenosine	B-geneN
diphosphate	I-geneN
ribosyl	I-geneN
transferase	E-geneN
activity	O
to	O
the	O
cytosol	O
of	O
target	O
T	O
cells	O
.	O

In	O
a	O
murine	O
delayed	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
model	O
system	O
,	O
we	O
have	O
shown	O
that	O
IL	B-geneY
-	I-geneY
2	E-geneY
toxin	O
treatment	O
induces	O
a	O
marked	O
immunosuppression	O
.	O

Reversible	O
inhibition	O
of	O
human	B-geneN-C4-2
carboxylesterases	E-geneN-C4-2
by	O
acyl	B-chem-C4-1
glucuronides	E-chem-C4-1
.	O

Carboxylesterases	S-geneN-C9-2
hydrolyze	O
esters	S-chem-C9-1
,	O
amides	S-chem-C9-1
,	O
and	O
thioesters	S-chem-C9-1
to	O
produce	O
carboxylic	B-chem-C9-1
acids	E-chem-C9-1
and	O
resulting	O
alcohols	S-chem-C9-1
,	O
amines	S-chem-C9-1
,	O
and	O
thiols	S-chem-C9-1
,	O
respectively	O
.	O

Uridine	B-geneN-C9-2
5	I-geneN-C9-2
'	I-geneN-C9-2
-	I-geneN-C9-2
diphosphate	I-geneN-C9-2
-	I-geneN-C9-2
glucuronosyltransferases	E-geneN-C9-2
are	O
colocalized	O
with	O
carboxylesterases	S-geneN-C9-2
and	O
have	O
the	O
potential	O
to	O
further	O
metabolize	O
carboxylic	B-chem-C9-1
acids	E-chem-C9-1
to	O
acyl	B-chem-C9-1
glucuronides	E-chem-C9-1
,	O
but	O
it	O
is	O
currently	O
unknown	O
if	O
acyl	B-chem-C9-1
glucuronides	E-chem-C9-1
,	O
being	O
esters	S-chem
,	O
also	O
interact	O
with	O
carboxylesterases	S-geneN
.	O

Objective	O
:	O
This	O
study	O
explores	O
the	O
ability	O
of	O
acyl	B-chem-MU-1
glucuronides	E-chem-MU-1
to	O
act	O
as	O
substrates	O
or	O
inhibitors	O
of	O
human	B-geneY-MU-2
carboxylesterases	I-geneY-MU-2
1	E-geneY-MU-2
(	O
hCES1	S-geneY-MU-2
)	O
and	O
2	O
(	O
hCES2	S-geneY-MU-2
)	O
.	O

Methods	O
:	O
The	O
stability	O
of	O
six	O
acyl	B-chem-C9-1
glucuronides	E-chem-C9-1
in	O
the	O
presence	O
of	O
hCES1	S-geneY-C9-2
,	O
hCES2	S-geneY-C9-2
,	O
and	O
buffer	O
alone	O
(	O
100	O
mM	O
potassium	B-chem
phosphate	E-chem
,	O
pH	O
7.4	O
,	O
37°C	O
)	O
were	O
investigated	O
.	O

Reversible	O
inhibition	O
of	O
4	B-chem
-	I-chem
nitrophenyl	I-chem
acetate	E-chem
hydrolysis	O
by	O
the	O
acyl	B-chem
glucuronides	E-chem
was	O
also	O
studied	O
.	O

Diclofenac	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
was	O
used	O
to	O
explore	O
potential	O
time	O
-	O
dependent	O
inactivation	O
.	O

Results	O
:	O
The	O
chemical	O
stability	O
half	O
-	O
life	O
values	O
for	O
CGP	B-chem
47292	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
,	O
diclofenac	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
,	O
(	B-chem
R	I-chem
)	I-chem
-	I-chem
naproxen	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
,	O
(	B-chem
S	I-chem
)	I-chem
-	I-chem
naproxen	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
,	O
ibuprofen	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	I-chem
(	I-chem
racemic	I-chem
)	E-chem
,	O
clopidogrel	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
,	O
and	O
valproate	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
were	O
found	O
to	O
be	O
0.252	O
,	O
0.537	O
,	O
0.996	O
,	O
1.77	O
,	O
3.67	O
,	O
5.02	O
,	O
and	O
15.2	O
hours	O
,	O
respectively	O
.	O

Diclofenac	B-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
-	I-chem-C4-1
glucuronide	E-chem-C4-1
,	O
clopidogrel	B-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
-	I-chem-C4-1
glucuronide	E-chem-C4-1
,	O
ibuprofen	B-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
-	I-chem-C4-1
glucuronide	E-chem-C4-1
,	O
(	B-chem-C4-1
R	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
naproxen	I-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
-	I-chem-C4-1
glucuronide	E-chem-C4-1
,	O
and	O
(	B-chem-C4-1
S	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
naproxen	I-chem-C4-1
-	I-chem-C4-1
β	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
-	I-chem-C4-1
glucuronide	E-chem-C4-1
selectively	O
inhibited	O
hCES1	S-geneY-C4-2
,	O
with	O
Ki	O
values	O
of	O
4.32	O
±	O
0.47	O
,	O
24.8	O
±	O
4.2	O
,	O
355	O
±	O
38	O
,	O
468	O
±	O
21	O
,	O
707	O
±	O
64	O
µM	O
,	O
respectively	O
,	O
but	O
did	O
not	O
significantly	O
inhibit	O
hCES2	S-geneY
.	O

Valproate	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
and	O
CGP	B-chem
47292	I-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
did	O
not	O
inhibit	O
either	O
hCES	S-geneN
.	O

Time	O
-	O
dependent	O
inactivation	O
of	O
hCES1	S-geneY
by	O
diclofenac	B-chem
-	I-chem
β	I-chem
-	I-chem
d	I-chem
-	I-chem
glucuronide	E-chem
was	O
not	O
observed	O
.	O

Lastly	O
,	O
both	O
hCES1	S-geneY
and	O
hCES2	S-geneY
were	O
shown	O
not	O
to	O
catalyze	O
the	O
hydrolysis	O
of	O
the	O
acyl	B-chem
glucuronides	E-chem
studied	O
.	O

Conclusion	O
:	O
Drug	O
-	O
drug	O
interaction	O
studies	O
may	O
be	O
warranted	O
for	O
drugs	O
that	O
metabolize	O
to	O
acyl	B-chem-C4-1
glucuronides	E-chem-C4-1
due	O
to	O
the	O
potential	O
inhibition	O
of	O
hCESs	S-geneN-C4-2
.	O

Comparative	O
gene	O
expression	O
profiling	O
of	O
in	O
vitro	O
differentiated	O
megakaryocytes	O
and	O
erythroblasts	O
identifies	O
novel	O
activatory	O
and	O
inhibitory	O
platelet	O
membrane	O
proteins	O
.	O

To	O
identify	O
previously	O
unknown	O
platelet	B-geneN
receptors	E-geneN
we	O
compared	O
the	O
transcriptomes	O
of	O
in	O
vitro	O
differentiated	O
megakaryocytes	O
(	O
MKs	O
)	O
and	O
erythroblasts	O
(	O
EBs	O
)	O
.	O

RNA	O
was	O
obtained	O
from	O
purified	O
,	O
biologically	O
paired	O
MK	O
and	O
EB	O
cultures	O
and	O
compared	O
using	O
cDNA	O
microarrays	O
.	O

Bioinformatical	O
analysis	O
of	O
MK	O
-	O
up	O
-	O
regulated	O
genes	O
identified	O
151	O
transcripts	O
encoding	O
transmembrane	O
domain	O
-	O
containing	O
proteins	O
.	O

Although	O
many	O
of	O
these	O
were	O
known	O
platelet	O
genes	O
,	O
a	O
number	O
of	O
previously	O
unidentified	O
or	O
poorly	O
characterized	O
transcripts	O
were	O
also	O
detected	O
.	O

Many	O
of	O
these	O
transcripts	O
,	O
including	O
G6b	S-geneY
,	O
G6f	S-geneY
,	O
LRRC32	S-geneY
,	O
LAT2	S-geneY
,	O
and	O
the	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
SUCNR1	S-geneY
,	O
encode	O
proteins	O
with	O
structural	O
features	O
or	O
functions	O
that	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
the	O
modulation	O
of	O
platelet	O
function	O
.	O

Immunoblotting	O
on	O
platelets	O
confirmed	O
the	O
presence	O
of	O
the	O
encoded	O
proteins	O
,	O
and	O
flow	O
cytometric	O
analysis	O
confirmed	O
the	O
expression	O
of	O
G6b	S-geneY
,	O
G6f	S-geneY
,	O
and	O
LRRC32	S-geneY
on	O
the	O
surface	O
of	O
platelets	O
.	O

Through	O
comparative	O
analysis	O
of	O
expression	O
in	O
platelets	O
and	O
other	O
blood	O
cells	O
we	O
demonstrated	O
that	O
G6b	S-geneY
,	O
G6f	S-geneY
,	O
and	O
LRRC32	S-geneY
are	O
restricted	O
to	O
the	O
platelet	O
lineage	O
,	O
whereas	O
LAT2	S-geneY
and	O
SUCNR1	S-geneY
were	O
also	O
detected	O
in	O
other	O
blood	O
cells	O
.	O

The	O
identification	O
of	O
the	O
succinate	B-geneN-C5-2
receptor	E-geneN-C5-2
SUCNR1	S-geneY-C5-2
in	O
platelets	O
is	O
of	O
particular	O
interest	O
,	O
because	O
physiologically	O
relevant	O
concentrations	O
of	O
succinate	S-chem-C5-1
were	O
shown	O
to	O
potentiate	O
the	O
effect	O
of	O
low	O
doses	O
of	O
a	O
variety	O
of	O
platelet	O
agonists	O
.	O

Inhibition	O
of	O
platelet	O
aggregation	O
by	O
AZD6140	S-chem-C6-1
,	O
a	O
reversible	O
oral	O
P2Y12	S-geneY-C6-2
receptor	O
antagonist	O
,	O
compared	O
with	O
clopidogrel	S-chem-C6-1
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
.	O

OBJECTIVES	O
:	O
In	O
a	O
substudy	O
of	O
DISPERSE	O
(	O
Dose	O
confIrmation	O
Study	O
assessing	O
anti	O
-	O
Platelet	O
Effects	O
of	O
AZD6140	S-chem
vs.	O
clopidogRel	O
in	O
non	O
-	O
ST	O
-	O
segment	O
Elevation	O
myocardial	O
infarction	O
)	O
-	O
2	O
,	O
we	O
compared	O
the	O
antiplatelet	O
effects	O
of	O
AZD6140	S-chem
and	O
clopidogrel	S-chem
and	O
assessed	O
the	O
effects	O
of	O
AZD6140	S-chem
in	O
clopidogrel	S-chem
-	O
pretreated	O
patients	O
.	O

BACKGROUND	O
:	O
Clopidogrel	S-chem
,	O
in	O
combination	O
with	O
aspirin	O
,	O
reduces	O
cardiovascular	O
events	O
in	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
(	O
ACS	O
)	O
.	O

However	O
,	O
patients	O
with	O
poor	O
inhibition	O
of	O
platelet	O
aggregation	O
with	O
clopidogrel	S-chem
may	O
be	O
less	O
well	O
protected	O
.	O

AZD6140	S-chem-C6-1
is	O
a	O
reversible	O
oral	O
P2Y	B-geneY-C6-2
(	I-geneY-C6-2
12	I-geneY-C6-2
)	E-geneY-C6-2
receptor	O
antagonist	O
that	O
has	O
been	O
studied	O
in	O
ACS	O
patients	O
in	O
comparison	O
with	O
clopidogrel	S-chem-C6-1
(	O
DISPERSE	O
-	O
2	O
study	O
)	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
to	O
receive	O
either	O
AZD6140	S-chem
90	O
mg	O
twice	O
a	O
day	O
,	O
AZD6140	S-chem
180	O
mg	O
twice	O
a	O
day	O
,	O
or	O
clopidogrel	S-chem
75	O
mg	O
once	O
a	O
day	O
for	O
up	O
to	O
12	O
weeks	O
in	O
a	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
design	O
.	O

One	O
-	O
half	O
the	O
patients	O
allocated	O
AZD6140	S-chem
received	O
a	O
270	O
-	O
mg	O
loading	O
dose	O
.	O

Patients	O
randomized	O
to	O
receive	O
clopidogrel	S-chem
were	O
given	O
a	O
300	O
-	O
mg	O
loading	O
dose	O
unless	O
they	O
had	O
already	O
been	O
treated	O
with	O
clopidogrel	S-chem
.	O

Adenosine	B-chem
diphosphate	E-chem
-	O
induced	O
platelet	O
aggregation	O
was	O
assessed	O
by	O
optical	O
aggregometry	O
on	O
day	O
1	O
and	O
at	O
4	O
-	O
week	O
intervals	O
.	O

RESULTS	O
:	O
AZD6140	S-chem
inhibited	O
platelet	O
aggregation	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
both	O
doses	O
achieved	O
greater	O
levels	O
of	O
inhibition	O
than	O
clopidogrel	S-chem
(	O
e.g	O
.	O
,	O
4	O
weeks	O
,	O
4	O
-	O
h	O
postdose	O
[	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
]	O
:	O
clopidogrel	S-chem
64	O
%	O
[	O
+	O
/	O
-	O
22	O
%	O
]	O
,	O
AZD6140	S-chem
90	O
mg	O
79	O
%	O
[	O
+	O
/	O
-	O
22	O
%	O
]	O
,	O
AZD6140	S-chem
180	O
mg	O
95	O
%	O
[	O
+	O
/	O
-	O
8	O
%	O
]	O
.	O

AZD6140	S-chem
also	O
produced	O
further	O
suppression	O
of	O
platelet	O
aggregation	O
in	O
patients	O
previously	O
treated	O
with	O
clopidogrel	S-chem
.	O

CONCLUSIONS	O
:	O
AZD6140	S-chem
exhibited	O
greater	O
mean	O
inhibition	O
of	O
platelet	O
aggregation	O
than	O
a	O
standard	O
regimen	O
of	O
clopidogrel	S-chem
in	O
ACS	O
patients	O
.	O

In	O
addition	O
,	O
AZD6140	S-chem
further	O
suppressed	O
platelet	O
aggregation	O
in	O
clopidogrel	O
pretreated	O
patients	O
.	O

Neuropeptide	B-geneY
Y	I-geneY
Y1	I-geneY
receptor	E-geneY
knockdown	O
can	O
modify	O
glutathione	B-geneN
peroxidase	E-geneN
and	O
c	B-geneN
-	I-geneN
AMP	I-geneN
response	I-geneN
element	I-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
in	O
phenylpropanolamine	S-chem
-	O
treated	O
rats	O
.	O

It	O
has	O
been	O
reported	O
that	O
antioxidative	O
enzymes	O
,	O
neuropeptide	B-geneY
Y	E-geneY
(	O
NPY	S-geneY
)	O
,	O
and	O
c	B-geneN
-	I-geneN
AMP	I-geneN
response	I-geneN
element	I-geneN
-	I-geneN
binding	I-geneN
protein	E-geneN
(	O
CREB	S-geneN
)	O
are	O
involved	O
in	O
regulating	O
phenylpropanolamine	S-chem
(	O
PPA	S-chem
)	O
-	O
mediated	O
appetite	O
suppression	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
Y1	B-geneY
receptor	E-geneY
(	O
Y1R	S-geneY
)	O
might	O
be	O
involved	O
in	O
this	O
regulation	O
.	O

Rats	O
were	O
daily	O
treated	O
with	O
PPA	S-chem
for	O
4	O
days	O
.	O

Changes	O
in	O
the	O
contents	O
of	O
NPY	S-geneY
,	O
Y1R	S-geneY
,	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GP	S-geneN
)	O
,	O
and	O
CREB	S-geneN
were	O
assessed	O
and	O
compared	O
.	O

Results	O
showed	O
that	O
Y1R	S-geneY
,	O
GP	S-geneN
,	O
and	O
CREB	S-geneN
increased	O
,	O
with	O
a	O
maximal	O
increase	O
about	O
100	O
,	O
200	O
,	O
and	O
150	O
%	O
,	O
respectively	O
,	O
on	O
Day	O
2	O
.	O

By	O
contrast	O
,	O
NPY	S-geneY
decreased	O
with	O
a	O
biggest	O
reduction	O
about	O
48	O
%	O
on	O
Day	O
2	O
and	O
the	O
pattern	O
of	O
expression	O
during	O
PPA	O
treatment	O
was	O
opposite	O
to	O
those	O
of	O
Y1R	O
,	E-geneY
GP	O
,	E-geneN
and	O
CREB	O
.	E-geneN

Central	O
knockdown	O
(	O
using	O
antisense	O
)	O
or	O
inhibition	O
(	O
using	O
antagonist	O
)	O
of	O
Y1R	S-geneY
expression	O
modulated	O
the	O
anorectic	O
response	O
of	O
PPA	S-chem
and	O
the	O
reciprocal	O
regulation	O
between	O
NPY	S-geneY
and	O
GP	S-geneN
(	O
or	O
CREB	S-geneN
)	O
,	O
revealing	O
an	O
essential	O
role	O
of	O
Y1R	S-geneY
in	O
regulating	O
NPY	S-geneY
,	O
GP	S-geneN
,	O
and	O
CREB	S-geneN
.	O

These	O
results	O
suggest	O
that	O
Y1R	S-geneY
participates	O
in	O
the	O
reciprocal	O
regulation	O
of	O
NPY	S-geneY
,	O
GP	S-geneN
,	O
and	O
CREB	S-geneN
in	O
the	O
hypothalamus	O
during	O
PPA	S-chem
treatment	O
in	O
conscious	O
rats	O
.	O

The	O
present	O
results	O
may	O
aid	O
the	O
therapeutic	O
research	O
of	O
PPA	S-chem
and	O
related	O
antiobesity	O
drugs	O
.	O

A	O
water	O
-	O
alcohol	S-chem
extract	O
of	O
Citrus	O
grandis	O
whole	O
fruits	O
has	O
beneficial	O
metabolic	O
effects	O
in	O
the	O
obese	O
Zucker	O
rats	O
fed	O
with	O
high	O
fat	O
/	O
high	O
cholesterol	S-chem
diet	O
.	O

Epidemiological	O
studies	O
suggest	O
that	O
citrus	O
fruits	O
and	O
compounds	O
such	O
as	O
flavonoids	S-chem
,	O
limonoids	O
and	O
pectins	O
have	O
health	O
promoting	O
effects	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
effects	O
of	O
Citrus	O
grandis	O
(	O
L.	O
)	O
Osbeck	O
var	O
.	O
tomentosa	O
hort	O
.	O
fruit	O
extract	O
on	O
the	O
energy	O
metabolism	O
.	O

A	O
whole	O
fruit	O
powder	O
from	O
dry	O
water	O
and	O
alcohol	S-chem
extracts	O
of	O
C.	O
grandis	O
containing	O
19	O
%	O
naringin	S-chem
flavonoid	O
was	O
prepared	O
.	O

The	O
effects	O
of	O
the	O
citrus	O
extract	O
were	O
followed	O
in	O
the	O
obese	O
Zucker	O
rats	O
fed	O
with	O
the	O
HFD	O
.	O

The	O
circulatory	O
levels	O
of	O
GLP	B-geneY
-	I-geneY
1	E-geneY
decreased	O
significantly	O
by	O
the	O
extract	O
in	O
comparison	O
to	O
the	O
HFD	O
group	O
,	O
whereas	O
the	O
decreased	O
ghrelin	S-geneY
levels	O
were	O
reversed	O
.	O

The	O
levels	O
of	O
PYY	S-geneY
were	O
decreased	O
in	O
all	O
HFD	O
groups	O
.	O

The	O
leptin	S-geneY
amounts	O
decreased	O
but	O
not	O
significantly	O
whereas	O
insulin	S-geneN
and	O
amylin	S-geneY
were	O
unchanged	O
.	O

The	O
cholesterol	S-chem
and	O
glucose	S-chem
levels	O
were	O
somewhat	O
but	O
not	O
systematically	O
improved	O
in	O
the	O
HFD	O
fed	O
rats	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
active	O
compounds	O
and	O
their	O
mechanisms	O
.	O

Development	O
of	O
new	O
cyclic	O
plasmin	S-geneY
inhibitors	O
with	O
excellent	O
potency	O
and	O
selectivity	O
.	O

The	O
trypsin	S-geneN
-	O
like	O
serine	B-geneN
protease	E-geneN
plasmin	S-geneY
is	O
a	O
target	O
for	O
the	O
development	O
of	O
antifibrinolytic	O
drugs	O
for	O
use	O
in	O
cardiac	O
surgery	O
with	O
cardiopulmonary	O
bypass	O
or	O
organ	O
transplantations	O
to	O
reduce	O
excessive	O
blood	O
loss	O
.	O

The	O
optimization	O
of	O
our	O
recently	O
described	O
substrate	O
-	O
analogue	O
plasmin	S-geneY
inhibitors	O
,	O
which	O
were	O
cyclized	O
between	O
their	O
P3	O
and	O
P2	O
side	O
chains	O
,	O
provided	O
a	O
new	O
series	O
with	O
improved	O
efficacy	O
and	O
excellent	O
selectivity	O
.	O

The	O
most	O
potent	O
inhibitor	O
8	O
binds	O
to	O
plasmin	S-geneY
with	O
an	O
inhibition	O
constant	O
of	O
0.2	O
nM	O
,	O
whereas	O
K	O
(	O
i	O
)	O
values	O
>	O
1	O
μM	O
were	O
determined	O
for	O
nearly	O
all	O
other	O
tested	O
trypsin	B-geneN
-	I-geneN
like	I-geneN
serine	I-geneN
proteases	E-geneN
,	O
with	O
the	O
exception	O
of	O
trypsin	S-geneN
,	O
which	O
is	O
also	O
inhibited	O
in	O
the	O
nanomolar	O
range	O
.	O

Docking	O
studies	O
revealed	O
a	O
potential	O
binding	O
mode	O
in	O
the	O
widely	O
open	O
active	O
site	O
of	O
plasmin	S-geneY
that	O
explains	O
the	O
strong	O
potency	O
and	O
selectivity	O
profile	O
of	O
these	O
inhibitors	O
.	O

The	O
dialkylated	O
piperazine	S-chem
-	O
linker	O
segment	O
contributes	O
to	O
an	O
excellent	O
solubility	O
of	O
all	O
analogues	O
.	O

Based	O
on	O
their	O
overall	O
profile	O
the	O
presented	O
inhibitors	O
are	O
well	O
suited	O
for	O
further	O
development	O
as	O
injectable	O
antifibrinolytic	O
drugs	O
.	O

Expression	O
and	O
selective	O
inhibition	O
of	O
the	O
constitutive	B-geneN
and	I-geneN
inducible	I-geneN
forms	I-geneN
of	I-geneN
human	I-geneN
cyclo	I-geneN
-	I-geneN
oxygenase	E-geneN
.	O

The	O
enzyme	O
cyclo	B-geneN-C9-2
-	I-geneN-C9-2
oxygenase	E-geneN-C9-2
catalyses	O
the	O
oxygenation	O
of	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
,	O
leading	O
to	O
the	O
formation	O
of	O
prostaglandins	S-chem-C9-1
.	O

Recently	O
two	O
forms	O
of	O
cyclo	B-geneN
-	I-geneN
oxygenase	E-geneN
have	O
been	O
described	O
:	O
a	O
constitutive	O
(	O
COX	B-geneY
-	I-geneY
1	E-geneY
)	O
enzyme	O
present	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
and	O
an	O
inducible	O
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
isoenzyme	O
observed	O
in	O
many	O
cells	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN
.	O

Constitutive	B-geneN
and	I-geneN
inducible	I-geneN
forms	I-geneN
of	I-geneN
human	I-geneN
cyclo	I-geneN
-	I-geneN
oxygenase	E-geneN
(	O
hCOX	B-geneY
-	I-geneY
1	E-geneY
and	O
hCOX	B-geneY
-	I-geneY
2	E-geneY
)	O
were	O
cloned	O
and	O
expressed	O
in	O
insect	O
cells	O
,	O
utilizing	O
a	O
baculovirus	O
expression	O
system	O
.	O
hCOX	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
had	O
a	O
specific	O
activity	O
of	O
18.8	O
mumol	O
of	O
O2	S-chem
/	O
mg	O
with	O
a	O
Km	O
of	O
13.8	O
microM	O
for	O
arachidonate	S-chem-C9-1
and	O
Vmax	O
.	O
of	O
1500	O
nmol	O
of	O
O2	O
/	O
nmol	O
of	O
enzyme	O
,	O
whereas	O
hCOX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
had	O
a	O
specific	O
activity	O
of	O
12.2	O
mumol	O
of	O
O2	S-chem
/	O
mg	O
with	O
a	O
Km	O
of	O
8.7	O
microM	O
for	O
arachidonate	S-chem-C9-1
and	O
a	O
Vmax	O
.	O
of	O
1090	O
nmol	O
of	O
O2	S-chem
/	O
nmol	O
of	O
enzyme	O
.	O

Indomethacin	S-chem-C4-1
inhibited	O
both	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
and	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
whereas	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
and	O
Dup	B-chem-C4-1
-	I-chem-C4-1
697	E-chem-C4-1
selectively	O
inhibited	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
.	O

Both	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
and	O
Dup	B-chem-C4-1
-	I-chem-C4-1
697	E-chem-C4-1
exhibited	O
time	O
-	O
dependent	O
inactivation	O
of	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
as	O
did	O
indomethacin	S-chem-C4-1
on	O
both	O
enzymes	O
.	O

The	O
competitive	O
inhibitor	O
of	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
mefenamic	B-chem-C4-1
acid	E-chem-C4-1
,	O
also	O
displayed	O
competitive	O
inhibition	O
of	O
hCOX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
.	O

These	O
results	O
demonstrate	O
the	O
ability	O
to	O
generate	O
selective	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
which	O
could	O
provide	O
useful	O
improvement	O
therapeutically	O
in	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
disease	O
.	O

L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
accumulation	O
and	O
freeze	O
tolerance	O
of	O
Saccharomyces	O
cerevisiae	O
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
PRO1	S-geneY
gene	O
encoding	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
kinase	E-geneY-C9-2
.	O

We	O
previously	O
isolated	O
a	O
mutant	O
which	O
showed	O
a	O
high	O
tolerance	O
to	O
freezing	O
that	O
correlated	O
with	O
higher	O
levels	O
of	O
intracellular	O
L	B-chem
-	I-chem
proline	E-chem
derived	O
from	O
L	B-chem
-	I-chem
proline	E-chem
analogue	O
-	O
resistant	O
mutants	O
.	O

The	O
mutation	O
responsible	O
for	O
the	O
analogue	O
resistance	O
and	O
L	B-chem
-	I-chem
proline	E-chem
accumulation	O
was	O
a	O
single	O
nuclear	O
dominant	O
mutation	O
.	O

By	O
introducing	O
the	O
mutant	O
-	O
derived	O
genomic	O
library	O
into	O
a	O
non	O
-	O
L	B-chem
-	I-chem
proline	E-chem
-	O
utilizing	O
strain	O
,	O
the	O
mutant	O
was	O
found	O
to	O
carry	O
an	O
allele	O
of	O
the	O
wild	O
-	O
type	O
PRO1	S-geneY
gene	O
encoding	O
gamma	B-geneY
-	I-geneY
glutamyl	I-geneY
kinase	E-geneY
,	O
which	O
resulted	O
in	O
a	O
single	O
amino	B-chem
acid	E-chem
replacement	O
;	O
Asp	S-chem
(	O
GAC	S-geneN
)	O
at	O
position	O
154	O
was	O
replaced	O
by	O
Asn	S-chem
(	O
AAC	S-geneN
)	O
.	O

Interestingly	O
,	O
the	O
allele	O
of	O
PRO1	S-geneY
was	O
shown	O
to	O
enhance	O
the	O
activities	O
of	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
kinase	E-geneY-C9-2
and	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
phosphate	I-geneY-C9-2
reductase	E-geneY-C9-2
,	O
both	O
of	O
which	O
catalyze	O
the	O
first	O
two	O
steps	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
synthesis	O
from	O
L	B-chem-C9-1
-	I-chem-C9-1
glutamate	E-chem-C9-1
and	O
which	O
together	O
may	O
form	O
a	O
complex	O
in	O
vivo	O
.	O

When	O
cultured	O
in	O
liquid	O
minimal	O
medium	O
,	O
yeast	O
cells	O
expressing	O
the	O
mutated	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
kinase	E-geneY-C9-2
were	O
found	O
to	O
accumulate	O
intracellular	O
L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
and	O
showed	O
a	O
prominent	O
increase	O
in	O
cell	O
viability	O
after	O
freezing	O
at	O
-	O
20	O
degrees	O
C	O
compared	O
to	O
the	O
viability	O
of	O
cells	O
harboring	O
the	O
wild	O
-	O
type	O
PRO1	S-geneY
gene	O
.	O

These	O
results	O
suggest	O
that	O
the	O
altered	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
kinase	E-geneY-C9-2
results	O
in	O
stabilization	O
of	O
the	O
complex	O
or	O
has	O
an	O
indirect	O
effect	O
on	O
gamma	B-geneY-C9-2
-	I-geneY-C9-2
glutamyl	I-geneY-C9-2
phosphate	I-geneY-C9-2
reductase	E-geneY-C9-2
activity	O
,	O
which	O
leads	O
to	O
an	O
increase	O
in	O
L	B-chem-C9-1
-	I-chem-C9-1
proline	E-chem-C9-1
production	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
approach	O
described	O
in	O
this	O
paper	O
could	O
be	O
a	O
practical	O
method	O
for	O
breeding	O
novel	O
freeze	O
-	O
tolerant	O
yeast	O
strains	O
.	O

Atypical	O
antipsychotic	O
drugs	O
,	O
quetiapine	S-chem
,	O
iloperidone	S-chem
,	O
and	O
melperone	S-chem
,	O
preferentially	O
increase	O
dopamine	S-chem
and	O
acetylcholine	S-chem
release	O
in	O
rat	O
medial	O
prefrontal	O
cortex	O
:	O
role	O
of	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
receptor	O
agonism	O
.	O

Preferential	O
increases	O
in	O
both	O
cortical	O
dopamine	S-chem
(	O
DA	S-chem
)	O
and	O
acetylcholine	S-chem
(	O
ACh	S-chem
)	O
release	O
have	O
been	O
proposed	O
to	O
distinguish	O
the	O
atypical	O
antipsychotic	O
drugs	O
(	O
APDs	O
)	O
clozapine	S-chem
,	O
olanzapine	S-chem
,	O
risperidone	S-chem
and	O
ziprasidone	S-chem
from	O
typical	O
APDs	O
such	O
as	O
haloperidol	S-chem
.	O

Although	O
only	O
clozapine	S-chem-MU-1
and	O
ziprasidone	S-chem-MU-1
are	O
directly	O
acting	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT	I-geneY-C5-2
(	I-geneY-C5-2
1A	I-geneY-C5-2
)	E-geneY-C5-2
agonists	O
,	O
WAY100635	S-chem-MU-1
,	O
a	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
,	O
partially	O
attenuates	O
these	O
atypical	O
APD	O
-	O
induced	O
increases	O
in	O
cortical	O
DA	S-chem
release	O
that	O
may	O
be	O
due	O
to	O
combined	O
5	B-geneY-C4-2
-	I-geneY-C4-2
HT	I-geneY-C4-2
(	I-geneY-C4-2
2A	I-geneY-C4-2
)	E-geneY-C4-2
and	O
D	B-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	E-geneY-C4-2
blockade	O
.	O

However	O
,	O
WAY100635	S-chem
does	O
not	O
attenuate	O
clozapine	S-chem
-	O
induced	O
cortical	O
ACh	S-chem
release	O
.	O

The	O
present	O
study	O
determined	O
whether	O
quetiapine	S-chem
,	O
iloperidone	S-chem
and	O
melperone	S-chem
,	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
/	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
antagonist	O
atypical	O
APDs	O
,	O
also	O
increase	O
cortical	O
DA	S-chem
and	O
ACh	S-chem
release	O
,	O
and	O
whether	O
these	O
effects	O
are	O
related	O
to	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
agonism	O
.	O

Quetiapine	S-chem
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
iloperidone	S-chem
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
,	O
and	O
melperone	S-chem
(	O
3	O
-	O
10	O
mg	O
/	O
kg	O
)	O
increased	O
DA	S-chem
and	O
ACh	S-chem
release	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
.	O

Iloperidone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
melperone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
but	O
not	O
quetiapine	S-chem
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
produced	O
an	O
equivalent	O
or	O
a	O
smaller	O
increase	O
in	O
DA	S-chem
release	O
in	O
the	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
mPFC	O
,	O
whereas	O
none	O
of	O
them	O
increased	O
ACh	S-chem
release	O
in	O
the	O
NAC	O
.	O

WAY100635	S-chem
(	O
0.2	O
mg	O
/	O
kg	O
)	O
,	O
which	O
alone	O
did	O
not	O
affect	O
DA	S-chem
or	O
ACh	S-chem
release	O
,	O
partially	O
attenuated	O
quetiapine	S-chem
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
,	O
iloperidone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
-	O
and	O
melperone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
DA	S-chem
release	O
in	O
the	O
mPFC	O
.	O

WAY100635	S-chem
also	O
partially	O
attenuated	O
quetiapine	S-chem
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
ACh	S-chem
release	O
in	O
the	O
mPFC	O
,	O
but	O
not	O
that	O
induced	O
by	O
iloperidone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
or	O
melperone	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
indicate	O
that	O
quetiapine	S-chem
,	O
iloperidone	S-chem
and	O
melperone	S-chem
preferentially	O
increase	O
DA	S-chem
release	O
in	O
the	O
mPFC	O
,	O
compared	O
to	O
the	O
NAC	O
via	O
a	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
-	O
related	O
mechanism	O
.	O

However	O
,	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT	I-geneY-C5-2
(	I-geneY-C5-2
1A	I-geneY-C5-2
)	E-geneY-C5-2
agonism	O
may	O
be	O
important	O
only	O
for	O
quetiapine	S-chem-C5-1
-	O
induced	O
ACh	S-chem
release	O
.	O

Robust	O
array	O
-	O
based	O
coregulator	O
binding	O
assay	O
predicting	O
ERα	S-geneY
-	O
agonist	O
potency	O
and	O
generating	O
binding	O
profiles	O
reflecting	O
ligand	O
structure	O
.	O

Testing	O
chemicals	O
for	O
their	O
endocrine	O
-	O
disrupting	O
potential	O
,	O
including	O
interference	O
with	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
signaling	O
,	O
is	O
an	O
important	O
aspect	O
of	O
chemical	O
safety	O
testing	O
.	O

Because	O
of	O
the	O
practical	O
drawbacks	O
of	O
animal	O
testing	O
,	O
the	O
development	O
of	O
in	O
vitro	O
alternatives	O
for	O
the	O
uterotrophic	O
assay	O
and	O
other	O
in	O
vivo	O
(	O
anti	O
)	O
estrogenicity	O
tests	O
has	O
high	O
priority	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
an	O
in	O
vitro	O
assay	O
that	O
profiles	O
ligand	O
-	O
induced	O
binding	O
of	O
ERα	S-geneY
to	O
a	O
microarray	O
of	O
coregulator	O
-	O
derived	O
peptides	O
might	O
be	O
a	O
valuable	O
candidate	O
for	O
a	O
panel	O
of	O
in	O
vitro	O
assays	O
aiming	O
at	O
an	O
ultimate	O
replacement	O
of	O
the	O
uterotrophic	O
assay	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
reproducibility	O
and	O
robustness	O
of	O
this	O
coregulator	O
binding	O
assay	O
was	O
determined	O
by	O
measuring	O
the	O
binding	O
profiles	O
of	O
14	O
model	O
compounds	O
that	O
are	O
recommended	O
by	O
the	O
Office	O
of	O
Prevention	O
,	O
Pesticides	O
and	O
Toxic	O
Substances	O
for	O
testing	O
laboratory	O
proficiency	O
in	O
estrogen	B-geneY
receptor	E-geneY
transactivation	O
assays	O
.	O

With	O
a	O
median	O
coefficient	O
of	O
variation	O
of	O
5.0	O
%	O
and	O
excellent	O
correlation	O
(	O
R	O
(	O
2	O
)	O
=	O
0.993	O
)	O
between	O
duplicate	O
measurements	O
,	O
the	O
reproducibility	O
of	O
the	O
ERα	S-geneY
-	O
coregulator	O
binding	O
assay	O
was	O
better	O
than	O
the	O
reproducibility	O
of	O
other	O
commonly	O
used	O
in	O
vitro	O
ER	S-geneY
functional	O
assays	O
.	O

In	O
addition	O
,	O
the	O
coregulator	O
binding	O
assay	O
is	O
correctly	O
predicting	O
the	O
estrogenicity	O
for	O
13	O
out	O
of	O
14	O
compounds	O
tested	O
.	O

When	O
the	O
potency	O
of	O
the	O
ER	S-geneY
-	O
agonists	O
to	O
induce	O
ERα	S-geneY
-	O
coregulator	O
binding	O
was	O
compared	O
to	O
their	O
ER	S-geneY
binding	O
affinity	O
,	O
their	O
ranking	O
was	O
similar	O
,	O
and	O
the	O
correlation	O
between	O
the	O
EC50	O
values	O
was	O
excellent	O
(	O
R	O
(	O
2	O
)	O
=	O
0.96	O
)	O
,	O
as	O
was	O
the	O
correlation	O
with	O
their	O
potency	O
in	O
a	O
transactivation	O
assay	O
(	O
R	O
(	O
2	O
)	O
=	O
0.94	O
)	O
.	O

Moreover	O
,	O
when	O
the	O
ERα	S-geneY
-	O
coregulator	O
binding	O
profiles	O
were	O
hierarchically	O
clustered	O
using	O
Euclidian	O
cluster	O
distance	O
,	O
the	O
structurally	O
related	O
compounds	O
were	O
found	O
to	O
cluster	O
together	O
,	O
whereas	O
the	O
steroid	S-chem
test	O
compounds	O
having	O
an	O
aromatic	O
A	O
-	O
ring	O
were	O
separated	O
from	O
those	O
with	O
a	O
cyclohexene	S-chem
A	O
-	O
ring	O
.	O

We	O
concluded	O
that	O
this	O
assay	O
is	O
capable	O
of	O
distinguishing	O
ERα	S-geneY
agonists	O
and	O
antagonists	O
and	O
that	O
it	O
even	O
reflects	O
the	O
structural	O
similarity	O
of	O
ERα	S-geneY
agonists	O
,	O
indicating	O
a	O
potential	O
to	O
achieve	O
identification	O
and	O
classification	O
of	O
ERα	S-geneY
endocrine	O
disruptors	O
with	O
high	O
fidelity	O
.	O

Wogonoside	S-chem
induces	O
autophagy	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
by	O
regulating	O
MAPK	S-geneN
-	O
mTOR	S-geneY
pathway	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
wogonoside	S-chem
,	O
a	O
bioactive	O
flavonoid	S-chem
extracted	O
from	O
the	O
root	O
of	O
Scutellaria	O
baicalensis	O
Gerogi	O
,	O
has	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
angiogenic	O
activities	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
wogonoside	S-chem
-	O
induced	O
autophagy	O
on	O
human	O
breast	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

We	O
report	O
that	O
wogonoside	S-chem
triggered	O
the	O
formation	O
of	O
microtubule	B-geneN
-	I-geneN
associated	I-geneN
protein	I-geneN
-	I-geneN
light	I-geneN
chain	I-geneN
3	E-geneN
(	O
MAP	B-geneN
-	I-geneN
LC3	E-geneN
)	O
positive	O
autophagosomes	O
and	O
the	O
accumulation	O
of	O
acidic	O
vesicular	O
and	O
autolysosomes	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

In	O
addition	O
,	O
cells	O
treated	O
by	O
wogonoside	S-chem
developed	O
autophagosome	O
-	O
like	O
characteristics	O
,	O
including	O
single	O
and	O
double	O
membrane	O
vacuoles	O
containing	O
intact	O
and	O
degraded	O
cellular	O
debris	O
.	O

The	O
results	O
showed	O
that	O
wogonoside	S-chem-C3-1
promotes	O
the	O
expression	O
of	O
LC3	B-geneY-C3-2
-	I-geneY-C3-2
II	E-geneY-C3-2
and	O
Beclin	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
.	O

Furthermore	O
,	O
wogonoside	S-chem
inhibited	O
cell	O
growth	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
which	O
was	O
associated	O
with	O
wogonoside	S-chem
-	O
induced	O
autophagy	O
.	O

Wogonoside	S-chem-C4-1
also	O
suppressed	O
the	O
activation	O
of	O
mammalian	B-geneY-C4-2
target	I-geneY-C4-2
of	I-geneY-C4-2
rapamycin	E-geneY-C4-2
(	O
mTOR	S-geneY-C4-2
)	O
and	O
p70	B-geneN-C4-2
-	I-geneN-C4-2
S6	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
p70S6K	B-geneN-C4-2
)	E-geneN-C4-2
by	O
regulating	O
the	O
expression	O
of	O
the	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
)	O
and	O
p38	S-geneN
involved	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
wogonoside	S-chem
partially	O
inhibits	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
growth	O
by	O
inducing	O
autophagy	O
through	O
the	O
MAPK	S-geneN
-	O
mTOR	S-geneY
pathway	O
and	O
may	O
be	O
a	O
promising	O
anti	O
-	O
tumor	O
agent	O
.	O

Nucleotide	S-chem
sequence	O
of	O
the	O
gene	O
for	O
human	B-geneY
factor	I-geneY
IX	E-geneY
(	O
antihemophilic	B-geneY
factor	I-geneY
B	E-geneY
)	O
.	O

Two	O
different	O
human	O
genomic	O
DNA	O
libraries	O
were	O
screened	O
for	O
the	O
gene	O
for	O
blood	O
coagulation	B-geneY
factor	I-geneY
IX	E-geneY
by	O
employing	O
a	O
cDNA	O
for	O
the	O
human	O
protein	O
as	O
a	O
hybridization	O
probe	O
.	O

Five	O
overlapping	O
lambda	O
phages	O
were	O
identified	O
that	O
contained	O
the	O
gene	O
for	O
factor	B-geneY
IX	E-geneY
.	O

The	O
complete	O
DNA	O
sequence	O
of	O
about	O
38	O
kilobases	O
for	O
the	O
gene	O
and	O
the	O
adjacent	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
was	O
established	O
by	O
the	O
dideoxy	O
chain	O
termination	O
and	O
chemical	O
degradation	O
methods	O
.	O

The	O
gene	O
contained	O
about	O
33.5	O
kilobases	O
of	O
DNA	O
,	O
including	O
seven	O
introns	O
and	O
eight	O
exons	O
within	O
the	O
coding	O
and	O
3	O
'	O
noncoding	O
regions	O
of	O
the	O
gene	O
.	O

The	O
eight	O
exons	O
code	O
for	O
a	O
prepro	O
leader	O
sequence	O
and	O
415	O
amino	B-chem
acids	E-chem
that	O
make	O
up	O
the	O
mature	O
protein	O
circulating	O
in	O
plasma	O
.	O

The	O
intervening	O
sequences	O
range	O
in	O
size	O
from	O
188	O
to	O
9473	O
nucleotides	S-chem
and	O
contain	O
four	O
Alu	O
repetitive	O
sequences	O
,	O
including	O
one	O
in	O
intron	O
A	O
and	O
three	O
in	O
intron	O
F	O
.	O

A	O
fifth	O
Alu	O
repetitive	O
sequence	O
was	O
found	O
immediately	O
flanking	O
the	O
3	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
50	O
base	O
pair	O
insert	O
in	O
intron	O
A	O
was	O
found	O
in	O
a	O
clone	O
from	O
one	O
of	O
the	O
genomic	O
libraries	O
but	O
was	O
absent	O
in	O
clones	O
from	O
the	O
other	O
library	O
.	O

Intron	O
A	O
as	O
well	O
as	O
the	O
3	O
'	O
noncoding	O
region	O
of	O
the	O
gene	O
also	O
contained	O
alternating	O
purine	S-chem
-	O
pyrimidine	S-chem
sequences	O
that	O
provide	O
potential	O
left	O
-	O
handed	O
helical	O
DNA	O
or	O
Z	O
-	O
DNA	O
structures	O
for	O
the	O
gene	O
.	O

KpnI	B-geneN
repetitive	I-geneN
sequences	E-geneN
were	O
identified	O
in	O
intron	O
D	O
and	O
the	O
region	O
flanking	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

The	O
5	O
'	O
flanking	O
region	O
also	O
contained	O
a	O
1.9	O
-	O
kb	O
HindIII	O
subfamily	O
repeat	O
.	O

The	O
seven	O
introns	O
in	O
the	O
gene	O
for	O
factor	B-geneY
IX	E-geneY
were	O
located	O
in	O
essentially	O
the	O
same	O
position	O
as	O
the	O
seven	O
introns	O
in	O
the	O
gene	O
for	O
human	O
protein	O
C	O
,	O
while	O
the	O
first	O
three	O
were	O
found	O
in	O
positions	O
identical	O
with	O
those	O
in	O
the	O
gene	O
for	O
human	O
prothrombin	O
.	O

Mutations	O
within	O
the	O
human	B-geneY
GLYT2	E-geneY
(	O
SLC6A5	S-geneY
)	O
gene	O
associated	O
with	O
hyperekplexia	O
.	O

Hereditary	O
hyperekplexia	O
is	O
a	O
neuromotor	O
disorder	O
characterized	O
by	O
exaggerated	O
startle	O
reflexes	O
and	O
muscle	O
stiffness	O
in	O
the	O
neonate	O
.	O

The	O
disease	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
glycine	B-geneN
receptor	E-geneN
subunit	O
genes	O
GLRA1	S-geneY
and	O
GLRB	S-geneY
.	O

Here	O
,	O
we	O
describe	O
mutations	O
within	O
the	O
neuronal	O
glycine	B-geneY
transporter	I-geneY
2	E-geneY
gene	O
(	O
GLYT2	S-geneY
,	O
or	O
SLC6A5	S-geneY
,	O
)	O
of	O
hyperekplexia	O
patients	O
,	O
whose	O
symptoms	O
can	O
not	O
be	O
attributed	O
to	O
glycine	B-geneN
receptor	E-geneN
mutations	O
.	O

One	O
of	O
the	O
GLYT2	S-geneY
mutations	O
identified	O
causes	O
truncation	O
of	O
the	O
transporter	B-geneN
protein	E-geneN
and	O
a	O
complete	O
loss	O
of	O
transport	O
function	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
GLYT2	S-geneY
being	O
a	O
disease	O
gene	O
in	O
human	O
hyperekplexia	O
.	O

Structural	O
features	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
heparins	O
affecting	O
their	O
affinity	O
to	O
antithrombin	O
.	O

As	O
part	O
of	O
a	O
more	O
extensive	O
investigation	O
on	O
structural	O
features	O
of	O
different	O
low	O
-	O
molecular	O
-	O
weight	O
heparins	O
(	O
LMWHs	O
)	O
that	O
can	O
affect	O
their	O
biological	O
activities	O
,	O
Enoxaparin	O
,	O
Tinzaparin	O
and	O
Dalteparin	O
were	O
characterised	O
with	O
regards	O
to	O
the	O
distribution	O
of	O
different	O
chain	O
length	O
oligosaccharides	O
as	O
determined	O
by	O
size	O
-	O
exclusion	O
(	O
SE	O
)	O
chromatography	O
,	O
as	O
well	O
as	O
their	O
structure	O
as	O
defined	O
by	O
2D	O
-	O
NMR	O
spectra	O
(	O
HSQC	O
)	O
.	O

The	O
three	O
LMWHs	O
were	O
also	O
fractionated	O
into	O
high	O
affinity	O
(	O
HA	O
)	O
and	O
no	O
affinity	O
(	O
NA	O
)	O
pools	O
with	O
regards	O
to	O
their	O
ability	O
to	O
bind	O
antithrombin	O
(	O
AT	O
)	O
.	O

The	O
HA	O
fractions	O
were	O
further	O
subfractionated	O
and	O
characterised	O
.	O

For	O
the	O
parent	O
LMWHs	O
and	O
selected	O
fractions	O
,	O
molecular	O
weight	O
parameters	O
were	O
measured	O
using	O
a	O
SE	O
chromatographic	O
system	O
with	O
a	O
triple	O
detector	O
(	O
TDA	O
)	O
to	O
obtain	O
absolute	O
molecular	O
weights	O
.	O

The	O
SE	O
chromatograms	O
clearly	O
indicate	O
that	O
Enoxaparin	O
is	O
consistently	O
richer	O
in	O
shorter	O
oligosaccharides	O
than	O
Tinzaparin	O
and	O
Dalteparin	O
.	O

Besides	O
providing	O
the	O
content	O
of	O
terminal	O
groups	O
and	O
individual	O
glucosamine	S-chem
and	O
uronic	B-chem
acid	E-chem
residues	O
with	O
different	O
sulfate	S-chem
substituents	O
,	O
the	O
HSQC	O
-	O
NMR	O
spectra	O
permitted	O
us	O
to	O
evaluate	O
and	O
correlate	O
the	O
content	O
of	O
the	O
pentasaccharide	S-chem
,	O
AT	O
-	O
binding	O
sequence	O
A	B-geneN
-	I-geneN
G	I-geneN
-	I-geneN
A	I-geneN
*	I-geneN
-	I-geneN
I	I-geneN
-	I-geneN
A	E-geneN
(	O
AT	O
-	O
bs	O
)	O
through	O
quantification	O
of	O
signals	O
of	O
the	O
disaccharide	S-chem
sequence	O
G	O
-	O
A	O
*	O
.	O

Whereas	O
the	O
percent	O
content	O
of	O
HA	O
species	O
is	O
approximately	O
the	O
same	O
for	O
the	O
three	O
LMWHs	O
,	O
substantial	O
differences	O
were	O
observed	O
for	O
the	O
chain	O
distribution	O
of	O
AT	O
-	O
bs	O
as	O
a	O
function	O
of	O
length	O
,	O
with	O
the	O
AT	O
-	O
bs	O
being	O
preferentially	O
contained	O
in	O
the	O
longest	O
chains	O
of	O
each	O
LMWH	O
.	O

The	O
above	O
information	O
will	O
be	O
useful	O
in	O
establishing	O
structure	O
-	O
activity	O
relationships	O
currently	O
under	O
way	O
.	O

This	O
study	O
is	O
therefore	O
critical	O
for	O
establishing	O
correlations	O
between	O
structural	O
features	O
of	O
LMWHs	O
and	O
their	O
AT	O
-	O
mediated	O
anticoagulant	O
activity	O
.	O

Bioactive	O
phenolics	S-chem
from	O
Seriphidium	O
stenocephalum	O
.	O

Chromatographic	O
separation	O
of	O
the	O
ethyl	B-chem
acetate	E-chem
soluble	O
part	O
of	O
the	O
methanolic	O
extract	O
from	O
Seriphidium	O
stenocephalum	O
yielded	O
three	O
new	O
compounds	O
:	O
stenocepflavone	S-chem
(	O
1	O
)	O
,	O
stenocepflavan	S-chem
(	O
2	O
)	O
,	O
and	O
stenocephol	S-chem
(	O
3	O
)	O
,	O
together	O
with	O
cirsimaritin	S-chem
(	O
4	O
)	O
,	O
5,7,5	B-chem
'	I-chem
-	I-chem
trihydroxy	I-chem
-	I-chem
3',4',6	I-chem
-	I-chem
trimethoxyflavone	E-chem
(	O
5	O
)	O
,	O
5,6,7,5	B-chem
'	I-chem
-	I-chem
tetrahydroxy	I-chem
-	I-chem
4	I-chem
'	I-chem
-	I-chem
methoxyflavone	E-chem
(	O
6	O
)	O
,	O
and	O
axillaroside	S-chem
(	O
7	O
)	O
.	O

All	O
isolates	O
were	O
characterized	O
with	O
the	O
help	O
of	O
spectroscopic	O
data	O
including	O
1D	O
,	O
2D	O
NMR	O
,	O
and	O
high	O
resolution	O
mass	O
spectrometry	O
and	O
/	O
or	O
in	O
comparison	O
with	O
the	O
related	O
compounds	O
in	O
literature	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
in	O
vitro	O
enzyme	O
inhibitory	O
activities	O
against	O
acetylcholinesterase	S-geneY
,	O
butyrylcholinesterase	S-geneY
,	O
and	O
lipoxygenase	S-geneN
.	O

Compounds	O
1	O
and	O
4	O
-	O
7	O
exhibited	O
significant	O
activity	O
against	O
all	O
the	O
tested	O
enzymes	O
,	O
whereas	O
compounds	O
2	O
and	O
3	O
were	O
found	O
inactive	O
.	O

alpha7	B-geneN
nicotinic	I-geneN
receptor	I-geneN
gene	I-geneN
promoter	E-geneN
polymorphisms	O
in	O
inbred	O
mice	O
affect	O
expression	O
in	O
a	O
cell	O
type	O
-	O
specific	O
fashion	O
.	O

Inbred	O
mouse	O
strains	O
display	O
significant	O
differences	O
in	O
their	O
levels	O
of	O
brain	O
alpha7	B-geneY
nicotinic	I-geneY
acetylcholine	I-geneY
receptor	E-geneY
(	O
alpha7	B-geneY
nAChR	E-geneY
)	O
expression	O
,	O
as	O
measured	O
by	O
binding	O
of	O
the	O
alpha7	O
-	O
selective	O
antagonist	O
alpha	O
-	O
bungarotoxin	O
.	O

Variations	O
in	O
alpha	B-geneY
-	I-geneY
bungarotoxin	E-geneY
binding	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
an	O
animal	O
's	O
sensitivity	O
to	O
nicotine	S-chem
-	O
induced	O
seizures	O
and	O
sensory	O
gating	O
.	O

In	O
two	O
inbred	O
mouse	O
strains	O
,	O
C3H	O
/	O
2Ibg	O
(	O
C3H	O
)	O
and	O
DBA	O
/	O
2Ibg	O
(	O
DBA	O
/	O
2	O
)	O
,	O
the	O
inter	O
-	O
strain	O
binding	O
differences	O
are	O
linked	O
to	O
a	O
restriction	O
length	O
polymorphism	O
in	O
the	O
alpha7	B-geneY
nAChR	E-geneY
gene	O
,	O
Chrna7	S-geneY
.	O

Despite	O
this	O
finding	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
through	O
which	O
genetic	O
variability	O
in	O
Chrna7	S-geneY
may	O
contribute	O
to	O
alpha7	B-geneY
nAChR	E-geneY
expression	O
differences	O
remains	O
unknown	O
.	O

However	O
,	O
studies	O
of	O
the	O
human	B-geneY
alpha7	I-geneY
nAChR	E-geneY
gene	O
(	O
CHRNA7	S-geneY
)	O
previously	O
have	O
demonstrated	O
that	O
CHRNA7	B-geneN
promoter	E-geneN
polymorphisms	O
are	O
associated	O
with	O
differences	O
in	O
promoter	O
activity	O
as	O
well	O
as	O
differences	O
in	O
sensory	O
processing	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
947	O
-	O
base	O
pair	O
region	O
of	O
the	O
Chrna7	B-geneN
promoter	E-geneN
was	O
cloned	O
from	O
both	O
the	O
C3H	O
and	O
DBA	O
/	O
2	O
inbred	O
mouse	O
strains	O
in	O
an	O
attempt	O
to	O
identify	O
polymorphisms	O
that	O
may	O
underlie	O
alpha7	B-geneY
nAChR	E-geneY
differential	O
expression	O
.	O

Sequence	O
analysis	O
of	O
these	O
fragments	O
identified	O
14	O
single	O
nucleotide	S-chem
polymorphisms	O
(	O
SNPs	O
)	O
.	O

A	O
combination	O
of	O
two	O
of	O
these	O
SNPs	O
affects	O
promoter	O
activity	O
in	O
an	O
in	O
vitro	O
luciferase	O
reporter	O
assay	O
.	O

These	O
results	O
suggest	O
a	O
mechanism	O
through	O
which	O
the	O
Chrna7	B-geneN
promoter	E-geneN
genotype	O
may	O
influence	O
interstrain	O
variations	O
in	O
alpha7	B-geneY
nAChR	E-geneY
expression	O
.	O

Effects	O
of	O
venlafaxine	S-chem
on	O
extracellular	O
concentrations	O
of	O
5	B-chem
-	I-chem
HT	E-chem
and	O
noradrenaline	S-chem
in	O
the	O
rat	O
frontal	O
cortex	O
:	O
augmentation	O
via	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
receptor	O
antagonism	O
.	O

Venlafaxine	S-chem
is	O
a	O
novel	O
serotonin	S-chem
/	O
noradrenaline	S-chem
reuptake	O
inhibitor	O
(	O
SNRI	O
)	O
which	O
has	O
been	O
shown	O
clinically	O
to	O
be	O
an	O
effective	O
antidepressant	O
(	O
AD	O
)	O
with	O
a	O
faster	O
onset	O
of	O
action	O
than	O
serotonin	S-chem
specific	O
reuptake	O
inhibitors	O
(	O
SSRI	O
)	O
.	O

Preclinically	O
,	O
venlafaxine	S-chem
has	O
been	O
shown	O
to	O
potently	O
inhibit	O
dorsal	O
raphe	O
neuronal	O
(	O
DRN	O
)	O
firing	O
through	O
a	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
mediated	O
mechanism	O
,	O
in	O
a	O
similar	O
manner	O
to	O
SSRIs	O
.	O

Here	O
we	O
demonstrate	O
the	O
acute	O
neurochemical	O
effects	O
of	O
venlafaxine	S-chem
on	O
extracellular	O
concentrations	O
of	O
5	B-chem
-	I-chem
HT	E-chem
and	O
noradrenaline	S-chem
(	O
NA	S-chem
)	O
from	O
the	O
rat	O
frontal	O
cortex	O
using	O
in	O
vivo	O
microdialysis	O
.	O

Administration	O
of	O
venlafaxine	S-chem
(	O
3	O
-	O
50	O
mg	O
/	O
kg	O
s.c.	O
)	O
resulted	O
in	O
a	O
significant	O
dose	O
-	O
dependent	O
increase	O
in	O
extracellular	O
NA	S-chem
,	O
but	O
produced	O
no	O
significant	O
increase	O
in	O
5	B-chem
-	I-chem
HT	E-chem
concentrations	O
.	O

Combination	O
treatment	O
with	O
the	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1A	E-geneY-C6-2
antagonist	O
WAY100635	S-chem-C6-1
produced	O
a	O
dose	O
-	O
dependent	O
augmentation	O
of	O
venlafaxine	S-chem
-	O
induced	O
(	O
3	O
-	O
30	O
mg	O
/	O
kg	O
s.c	O
)	O
extracellular	O
5	B-chem
-	I-chem
HT	E-chem
concentrations	O
,	O
but	O
had	O
no	O
further	O
effect	O
on	O
NA	S-chem
above	O
that	O
produced	O
by	O
venlafaxine	S-chem
alone	O
.	O

WAY100635	S-chem
,	O
at	O
doses	O
as	O
low	O
as	O
0.03	O
mg	O
/	O
kg	O
s.c.	O
,	O
maintained	O
this	O
potentiation	O
effect	O
.	O

The	O
beta	O
-	O
adrenergic	O
/	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1A	E-geneY-C6-2
receptor	O
antagonist	O
(	B-chem-C6-1
+	I-chem-C6-1
/	I-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
pindolol	E-chem-C6-1
and	O
the	O
selective	O
5	B-geneN
-	I-geneN
HT1B	I-geneN
/	I-geneN
D	E-geneN
antagonist	O
GR127935	S-chem
produced	O
no	O
significant	O
augmentation	O
of	O
venlafaxine	S-chem
-	O
induced	O
changes	O
in	O
either	O
5	B-chem
-	I-chem
HT	E-chem
or	O
NA	S-chem
.	O

Using	O
the	O
alpha1	B-geneN
and	I-geneN
alpha2	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
,	O
prazosin	S-chem
and	O
idazoxane	S-chem
,	O
we	O
also	O
demonstrate	O
the	O
role	O
of	O
the	O
alpha	B-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
the	O
augmentation	O
of	O
venlafaxine	S-chem
-	O
induced	O
changes	O
.	O

The	O
possible	O
mechanisms	O
underlying	O
venlafaxines	S-chem
improved	O
clinical	O
AD	O
action	O
and	O
the	O
potential	O
for	O
further	O
enhancement	O
of	O
this	O
SNRIs	O
clinical	O
effects	O
are	O
discussed	O
.	O

Testosterone	S-chem
versus	O
testosterone	S-chem
and	O
testolactone	S-chem
in	O
treating	O
reproductive	O
and	O
sexual	O
dysfunction	O
in	O
men	O
with	O
epilepsy	O
and	O
hypogonadism	O
.	O

Antiepileptic	O
drug	O
-	O
induced	O
reductions	O
in	O
serum	O
levels	O
of	O
biologically	O
active	O
testosterone	S-chem
and	O
elevations	O
in	O
serum	O
estradiol	S-chem
(	O
E2	S-chem
)	O
may	O
contribute	O
to	O
sexual	O
dysfunction	O
among	O
men	O
with	O
epilepsy	O
.	O

Treatment	O
using	O
a	O
combination	O
of	O
testosterone	S-chem
and	O
the	O
aromatase	S-geneY-C4-2
inhibitor	O
testolactone	S-chem-C4-1
may	O
have	O
significantly	O
better	O
effects	O
on	O
sexual	O
function	O
and	O
also	O
seizure	O
frequency	O
than	O
testosterone	S-chem
alone	O
.	O

Spectrum	O
of	O
mutations	O
in	O
mut	S-geneY
methylmalonic	O
acidemia	O
and	O
identification	O
of	O
a	O
common	O
Hispanic	O
mutation	O
and	O
haplotype	O
.	O

Cobalamin	S-chem
nonresponsive	O
methylmalonic	O
acidemia	O
(	O
MMA	O
,	O
mut	O
complementation	O
class	O
)	O
results	O
from	O
mutations	O
in	O
the	O
nuclear	O
gene	O
MUT	S-geneY
,	O
which	O
codes	O
for	O
the	O
mitochondrial	O
enzyme	O
methylmalonyl	B-geneY
CoA	I-geneY
mutase	E-geneY
(	O
MCM	S-geneY
)	O
.	O

To	O
better	O
elucidate	O
the	O
spectrum	O
of	O
mutations	O
that	O
cause	O
MMA	O
,	O
the	O
MUT	S-geneY
gene	O
was	O
sequenced	O
in	O
160	O
patients	O
with	O
mut	S-geneY
MMA	O
.	O

Sequence	O
analysis	O
identified	O
mutations	O
in	O
96	O
%	O
of	O
disease	O
alleles	O
.	O

Mutations	O
were	O
found	O
in	O
all	O
coding	O
exons	O
,	O
but	O
predominantly	O
in	O
exons	O
2	O
,	O
3	O
,	O
6	O
,	O
and	O
11	O
.	O

A	O
total	O
of	O
116	O
different	O
mutations	O
,	O
68	O
of	O
which	O
were	O
novel	O
,	O
were	O
identified	O
.	O

Of	O
the	O
116	O
different	O
mutations	O
,	O
53	O
%	O
were	O
missense	O
mutations	O
,	O
22	O
%	O
were	O
deletions	O
,	O
duplications	O
or	O
insertions	O
,	O
16	O
%	O
were	O
nonsense	O
mutations	O
,	O
and	O
9	O
%	O
were	O
splice	O
-	O
site	O
mutations	O
.	O

Sixty	O
-	O
one	O
of	O
the	O
mutations	O
have	O
only	O
been	O
identified	O
in	O
one	O
family	O
.	O

A	O
novel	O
mutation	O
in	O
exon	O
2	O
,	O
c.322C	O
>	I-geneN
T	E-geneN
(	O
p.R108C	O
)	O
,	O
was	O
identified	O
in	O
16	O
of	O
27	O
Hispanic	O
patients	O
.	O

SNP	O
genotyping	O
data	O
demonstrated	O
that	O
Hispanic	O
patients	O
with	O
this	O
mutation	O
share	O
a	O
common	O
haplotype	O
.	O

Three	O
other	O
mutations	O
were	O
seen	O
exclusively	O
in	O
Hispanic	O
patients	O
:	O
c.280G	O
>	I-geneN
A	E-geneN
(	O
p.G94R	O
)	O
,	O
c.1022dupA	O
,	O
and	O
c.970G	O
>	I-geneN
A	E-geneN
(	O
p.A324T	O
)	O
.	O

Seven	O
mutations	O
were	O
seen	O
almost	O
exclusively	O
in	O
black	O
patients	O
,	O
including	O
the	O
previously	O
reported	O
c.2150G	O
>	I-geneN
T	E-geneN
(	O
p.G717V	O
)	O
mutation	O
,	O
which	O
was	O
identified	O
in	O
12	O
of	O
29	O
black	O
patients	O
.	O

Two	O
mutations	O
were	O
seen	O
only	O
in	O
Asian	O
patients	O
.	O

Some	O
frequently	O
identified	O
mutations	O
were	O
not	O
population	O
-	O
specific	O
and	O
were	O
identified	O
in	O
patients	O
of	O
various	O
ethnic	O
backgrounds	O
.	O

Some	O
of	O
these	O
mutations	O
were	O
found	O
in	O
mutation	O
clusters	O
in	O
exons	O
2	O
,	O
3	O
,	O
6	O
,	O
and	O
11	O
,	O
suggesting	O
a	O
recurrent	O
mutation	O
.	O

Effect	O
of	O
ifenprodil	S-chem
on	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
receptor	E-geneN
gating	O
.	O

Ifenprodil	S-chem
is	O
an	O
allosteric	O
inhibitor	O
of	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
receptors	E-geneN
.	O

Despite	O
its	O
widespread	O
use	O
as	O
a	O
prototype	O
for	O
drug	O
development	O
and	O
a	O
subtype	O
-	O
selective	O
tool	O
for	O
physiologic	O
experiments	O
,	O
its	O
precise	O
effect	O
on	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
gating	O
is	O
yet	O
to	O
be	O
fully	O
understood	O
.	O

Interestingly	O
,	O
recent	O
crystallographic	O
evidence	O
identified	O
that	O
ifenprodil	B-chem
,	E-chem
unlike	O
zinc	S-chem
,	O
binds	O
at	O
the	O
interface	O
of	O
the	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
amino	S-chem
terminal	O
domain	O
dimer	O
by	O
an	O
induced	O
-	O
fit	O
mechanism	O
.	O

To	O
delineate	O
the	O
effect	O
of	O
this	O
unique	O
binding	O
on	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
receptor	O
gating	O
,	O
we	O
recorded	O
steady	O
-	O
state	O
currents	O
from	O
cell	O
-	O
attached	O
and	O
outside	O
-	O
out	O
patches	O
.	O

At	O
pH	O
7.9	O
in	O
cell	O
-	O
attached	O
patches	O
,	O
ifenprodil	S-chem
increased	O
the	O
occupancy	O
of	O
the	O
long	O
-	O
lived	O
shut	O
conformations	O
,	O
thereby	O
reducing	O
the	O
open	O
probability	O
of	O
the	O
receptor	O
with	O
no	O
change	O
in	O
the	O
mean	O
open	O
time	O
.	O

In	O
addition	O
,	O
ifenprodil	S-chem
selectively	O
affected	O
the	O
area	O
of	O
shut	O
time	O
constants	O
,	O
but	O
not	O
the	O
time	O
constants	O
themselves	O
.	O

Kinetic	O
analyses	O
suggested	O
that	O
ifenprodil	S-chem
prevents	O
the	O
transition	O
of	O
the	O
receptor	O
to	O
an	O
open	O
state	O
and	O
increases	O
its	O
dwell	O
time	O
in	O
an	O
intrinsically	O
occurring	O
closed	O
conformation	O
or	O
desensitized	O
state	O
.	O

We	O
found	O
distinct	O
differences	O
in	O
the	O
action	O
of	O
ifenprodil	S-chem
at	O
GluN1	S-geneY
/	O
GluN2B	S-geneY
in	O
comparison	O
with	O
previous	O
studies	O
on	O
the	O
effect	O
of	O
zinc	S-chem
on	O
GluN1	S-geneY
/	O
GluN2A	S-geneY
gating	O
,	O
which	O
may	O
arise	O
due	O
to	O
their	O
unique	O
binding	O
sites	O
.	O

Our	O
data	O
also	O
uncover	O
the	O
potential	O
pH	O
-	O
dependent	O
action	O
of	O
ifenprodil	S-chem
on	O
gating	O
.	O

At	O
a	O
low	O
pH	O
(	O
pH	O
7.4	O
)	O
,	O
but	O
not	O
pH	O
7.9	O
,	O
ifenprodil	S-chem-C4-1
reduces	O
the	O
mean	O
open	O
time	O
of	O
GluN1	S-geneY-C4-2
/	O
GluN2B	S-geneY-C4-2
receptors	O
,	O
which	O
may	O
be	O
responsible	O
for	O
its	O
usefulness	O
as	O
a	O
context	O
-	O
dependent	O
inhibitor	O
in	O
conditions	O
like	O
ischemia	O
and	O
stroke	O
,	O
when	O
the	O
pH	O
of	O
the	O
extracellular	O
milieu	O
becomes	O
acidic	O
.	O

Refining	O
the	O
UGT1A	S-geneN
haplotype	O
associated	O
with	O
irinotecan	S-chem
-	O
induced	O
hematological	O
toxicity	O
in	O
metastatic	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
5	B-chem
-	I-chem
fluorouracil	E-chem
/	O
irinotecan	S-chem
-	O
based	O
regimens	O
.	O

Despite	O
the	O
importance	O
of	O
UDP	B-geneY
-	I-geneY
glucuronosyltransferase	I-geneY
(	I-geneY
UGT	I-geneY
)	I-geneY
1A1	E-geneY
*	O
28	O
in	O
irinotecan	S-chem
pharmacogenetics	O
,	O
our	O
capability	O
to	O
predict	O
drug	O
-	O
induced	O
severe	O
toxicity	O
remains	O
limited	O
.	O

We	O
aimed	O
at	O
identifying	O
novel	O
genetic	O
markers	O
that	O
would	O
improve	O
prediction	O
of	O
irinotecan	S-chem
toxicity	O
and	O
response	O
in	O
advanced	O
colorectal	O
cancer	O
patients	O
treated	O
with	O
folic	B-chem
acid	E-chem
(	O
leucovorin	S-chem
)	O
,	O
fluorouracil	S-chem
(	O
5	B-chem
-	I-chem
FU	E-chem
)	O
,	O
and	O
irinotecan	S-chem
(	O
camptosar	S-chem
)	O
-	O
based	O
regimens	O
.	O

The	O
relationships	O
between	O
UGT1A	S-geneN
candidate	O
markers	O
across	O
the	O
gene	O
(	O
n	O
=	O
21	O
)	O
and	O
toxicity	O
were	O
prospectively	O
evaluated	O
in	O
167	O
patients	O
.	O

We	O
included	O
variants	O
in	O
the	O
3'untranscribed	O
region	O
(	O
3'UTR	O
)	O
of	O
the	O
UGT1A	S-geneN
locus	O
,	O
not	O
studied	O
in	O
this	O
context	O
yet	O
.	O

These	O
genetic	O
markers	O
were	O
further	O
investigated	O
in	O
250	O
Italian	O
FOLFIRI	S-chem
-	O
treated	O
patients	O
.	O

Several	O
functional	O
UGT1A	S-geneN
variants	O
,	O
including	O
UGT1A1	S-geneY
*	O
28	O
,	O
significantly	O
influenced	O
risk	O
of	O
severe	O
hematologic	O
toxicity	O
.	O

As	O
previously	O
reported	O
in	O
the	O
Italian	O
cohort	O
,	O
a	O
5	O
-	O
marker	O
risk	O
haplotype	O
[	O
haplotype	O
II	O
(	O
HII	O
)	O
;	O
UGTs	S-geneN
1A9	O
/	O
1A7	O
/	O
1A1	O
]	O
was	O
associated	O
with	O
severe	O
neutropenia	O
in	O
our	O
cohort	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
2.43	O
;	O
P	O
=	O
0.004	O
]	O
.	O

The	O
inclusion	O
of	O
a	O
3'UTR	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
permitted	O
refinement	O
of	O
the	O
previously	O
defined	O
HI	O
,	O
in	O
which	O
HIa	O
was	O
associated	O
with	O
the	O
absence	O
of	O
severe	O
neutropenia	O
in	O
combined	O
cohorts	O
(	O
OR	O
=	O
0.55	O
;	O
P	O
=	O
0.038	O
)	O
.	O

Among	O
all	O
tested	O
UGT1A	S-geneN
variations	O
and	O
upon	O
multivariate	O
analyses	O
,	O
no	O
UGT1A1	S-geneY
SNPs	O
remained	O
significant	O
,	O
whereas	O
three	O
SNPs	O
located	O
in	O
the	O
central	O
region	O
of	O
UGT1A	S-geneN
were	O
linked	O
to	O
neutropenia	O
grade	O
3	O
-	O
4	O
.	O

Haplotype	O
analyses	O
of	O
these	O
markers	O
with	O
the	O
3'UTR	O
SNP	O
allowed	O
the	O
identification	O
of	O
a	O
protective	O
HI	O
(	O
OR	O
=	O
0.50	O
;	O
P	O
=	O
0.048	O
)	O
and	O
two	O
risk	O
haplotypes	O
,	O
HII	O
and	O
HIII	O
,	O
characterized	O
by	O
2	O
and	O
3	O
unfavorable	O
alleles	O
,	O
respectively	O
,	O
revealing	O
a	O
dosage	O
effect	O
(	O
ORs	O
of	O
2.15	O
and	O
5.28	O
;	O
P	O
≤	O
0.030	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
specific	O
SNPs	O
in	O
UGT1A	S-geneN
,	O
other	O
than	O
UGT1A1	S-geneY
*	O
28	O
,	O
may	O
influence	O
irinotecan	S-chem
toxicity	O
and	O
should	O
be	O
considered	O
to	O
refine	O
pharmacogenetic	O
testing	O
.	O

Melatonin	S-chem
and	O
ethanol	S-chem
intake	O
exert	O
opposite	O
effects	O
on	O
circulating	O
estradiol	S-chem
and	O
progesterone	S-chem
and	O
differentially	O
regulate	O
sex	B-geneN
steroid	I-geneN
receptors	E-geneN
in	O
the	O
ovaries	O
,	O
oviducts	O
,	O
and	O
uteri	O
of	O
adult	O
rats	O
.	O

Chronic	O
ethanol	S-chem
intake	O
is	O
associated	O
with	O
sex	O
hormone	O
disturbances	O
,	O
and	O
it	O
is	O
well	O
known	O
that	O
melatonin	S-chem
plays	O
a	O
key	O
role	O
in	O
regulating	O
several	O
reproductive	O
processes	O
.	O

We	O
report	O
the	O
effects	O
of	O
ethanol	S-chem
intake	O
and	O
melatonin	S-chem
treatment	O
(	O
at	O
doses	O
of	O
100μg	O
/	O
100gBW	O
/	O
day	O
)	O
on	O
sex	O
hormones	O
and	O
steroid	B-geneN
receptors	E-geneN
in	O
the	O
ovaries	O
,	O
oviducts	O
and	O
uteri	O
of	O
ethanol	S-chem
-	O
preferring	O
rats	O
.	O

After	O
150	O
days	O
of	O
treatment	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
tissue	O
samples	O
were	O
harvested	O
to	O
evaluate	O
androgen	B-geneN
,	I-geneN
estrogen	I-geneN
,	I-geneN
progesterone	I-geneN
and	I-geneN
melatonin	I-geneN
receptor	E-geneN
subunits	O
(	O
AR	S-geneY
,	O
ER	B-geneY
-	I-geneY
α	E-geneY
and	O
ER	B-geneY
-	I-geneY
β	E-geneY
,	O
PRA	S-geneY
,	O
PRB	S-geneY
and	O
MT1R	S-geneY
,	O
respectively	O
)	O
.	O

Melatonin	S-chem
decreased	O
estradiol	S-chem
(	O
E2	O
)	O
and	O
increased	O
progesterone	S-chem
(	O
P4	O
)	O
and	O
6	B-chem
-	I-chem
sulfatoxymelatonin	E-chem
(	O
6	B-chem
-	I-chem
STM	E-chem
)	O
,	O
while	O
an	O
ethanol	S-chem
-	O
melatonin	S-chem
combination	O
reduced	O
both	O
P4	O
and	O
E2	O
.	O

Ovarian	O
AR	S-geneY
was	O
not	O
influenced	O
by	O
either	O
treatment	O
,	O
and	O
oviduct	O
AR	S-geneY-C4-2
was	O
reduced	O
after	O
ethanol	S-chem-C4-1
-	O
melatonin	S-chem-C4-1
combination	O
.	O

Oviduct	O
ER	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
,	O
ER	B-geneY-C4-2
-	I-geneY-C4-2
β	E-geneY-C4-2
and	O
uterine	O
ER	B-geneY-C4-2
-	I-geneY-C4-2
β	E-geneY-C4-2
were	O
down	O
-	O
regulated	O
by	O
either	O
ethanol	S-chem-C4-1
or	O
melatonin	S-chem-C4-1
.	O

Conversely	O
,	O
ovarian	O
PRA	S-geneY
and	O
PRB	S-geneY
were	O
positively	O
regulated	O
by	O
ethanol	S-chem
and	O
ethanol	S-chem
-	O
melatonin	S-chem
combination	O
,	O
whereas	O
PRA	S-geneY-C4-2
was	O
down	O
-	O
regulated	O
in	O
the	O
uterus	O
and	O
oviduct	O
after	O
ethanol	S-chem-C4-1
consumption	O
.	O

MT1R	S-geneY-C3-2
was	O
increased	O
in	O
ovaries	O
and	O
uteri	O
of	O
melatonin	S-chem-C3-1
-	O
treated	O
rats	O
.	O

Ethanol	S-chem
and	O
melatonin	S-chem
exert	O
opposite	O
effects	O
on	O
E2	O
and	O
P4	O
,	O
and	O
they	O
differentially	O
regulate	O
the	O
expression	O
of	O
sex	B-geneN
steroid	I-geneN
receptors	E-geneN
in	O
female	O
reproductive	O
tissues	O
.	O

Carbonic	B-geneN
anhydrase	E-geneN
inhibitors	O
.	O
Comparison	O
of	O
chlorthalidone	S-chem
,	O
indapamide	S-chem
,	O
trichloromethiazide	S-chem
,	O
and	O
furosemide	S-chem
X	O
-	O
ray	O
crystal	O
structures	O
in	O
adducts	O
with	O
isozyme	O
II	O
,	O
when	O
several	O
water	O
molecules	O
make	O
the	O
difference	O
.	O

Thiazide	S-chem-C4-1
and	O
high	O
ceiling	O
diuretics	O
were	O
recently	O
shown	O
to	O
inhibit	O
all	O
mammalian	O
isoforms	O
of	O
carbonic	B-geneN-C4-2
anhydrase	E-geneN-C4-2
(	O
CA	S-geneN-C4-2
,	O
EC	B-geneY-C4-2
4.2.1.1	E-geneY-C4-2
)	O
with	O
a	O
very	O
different	O
profile	O
as	O
compared	O
to	O
classical	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	S-chem-C4-1
,	O
methazolamide	S-chem-C4-1
,	O
and	O
ethoxzolamide	S-chem-C4-1
.	O

Some	O
of	O
these	O
structurally	O
related	O
compounds	O
have	O
a	O
very	O
different	O
behavior	O
against	O
the	O
widespread	O
isozyme	O
CA	B-geneY
II	E-geneY
,	O
with	O
chlorthalidone	S-chem-C4-1
,	O
trichloromethiazide	S-chem-C4-1
,	O
and	O
furosemide	S-chem-C4-1
being	O
efficient	O
inhibitors	O
against	O
CA	B-geneY-C4-2
II	E-geneY-C4-2
(	O
K	O
(	O
I	O
)	O
s	O
of	O
65	O
-	O
138	O
nM	O
)	O
,	O
whereas	O
indapamide	S-chem-C4-1
is	O
a	O
much	O
weaker	O
one	O
(	O
K	O
(	O
I	O
)	O
of	O
2520	O
nM	O
)	O
.	O

Furthermore	O
,	O
some	O
of	O
these	O
diuretics	O
are	O
quite	O
efficient	O
(	O
low	O
nanomolar	O
)	O
inhibitors	O
of	O
other	O
isoforms	O
,	O
for	O
example	O
,	O
chlorthalidone	S-chem
against	O
hCA	B-geneN
VB	I-geneN
,	I-geneN
VII	I-geneN
,	I-geneN
IX	I-geneN
,	I-geneN
and	I-geneN
XIII	E-geneN
;	O
indapamide	S-chem
against	O
CA	B-geneN
VII	I-geneN
,	I-geneN
IX	I-geneN
,	I-geneN
XII	I-geneN
,	I-geneN
and	I-geneN
XIII	E-geneN
,	O
trichloromethiazide	S-chem
against	O
CA	B-geneN
VII	I-geneN
and	I-geneN
IX	E-geneN
,	O
and	O
furosemide	S-chem
against	O
CA	B-geneN
I	I-geneN
and	I-geneN
XIV	E-geneN
.	O

Examining	O
the	O
four	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
their	O
CA	B-geneY
II	E-geneY
adducts	O
,	O
we	O
observed	O
several	O
(	O
2	O
-	O
3	O
)	O
active	O
site	O
water	O
molecules	O
interacting	O
with	O
the	O
chlorthalidone	S-chem
,	O
trichloromethiazide	S-chem
,	O
and	O
furosemide	S-chem
scaffolds	O
which	O
may	O
be	O
responsible	O
for	O
this	O
important	O
difference	O
of	O
activity	O
.	O

Indeed	O
,	O
indapamide	S-chem
bound	O
to	O
CA	B-geneY
II	E-geneY
has	O
no	O
interactions	O
with	O
active	O
site	O
water	O
molecules	O
.	O

Chlorthalidone	S-chem
bound	O
within	O
the	O
CA	B-geneY
II	E-geneY
active	O
site	O
is	O
in	O
an	O
enolic	O
(	O
lactimic	O
)	O
tautomeric	O
form	O
,	O
with	O
the	O
enolic	O
OH	S-chem
also	O
participating	O
in	O
two	O
strong	O
hydrogen	S-chem
bonds	O
with	O
Asn67	O
and	O
a	O
water	O
molecule	O
.	O

The	O
newly	O
evidenced	O
binding	O
modes	O
of	O
these	O
diuretics	O
may	O
be	O
exploited	O
for	O
designing	O
better	O
CA	B-geneY
II	E-geneY
inhibitors	O
as	O
well	O
as	O
compounds	O
with	O
selectivity	O
/	O
affinity	O
for	O
various	O
isoforms	O
with	O
medicinal	O
chemistry	O
applications	O
.	O

Bioinspired	O
Water	O
-	O
Enhanced	O
Mechanical	O
Gradient	O
Nanocomposite	O
Films	O
That	O
Mimic	O
the	O
Architecture	O
and	O
Properties	O
of	O
the	O
Squid	O
Beak	O
.	O

Inspired	O
by	O
the	O
water	O
-	O
enhanced	O
mechanical	O
gradient	O
character	O
of	O
the	O
squid	O
beak	O
,	O
we	O
herein	O
report	O
a	O
nanocomposite	O
that	O
mimics	O
both	O
the	O
architecture	O
and	O
properties	O
of	O
this	O
interesting	O
natural	O
material	O
.	O

Similar	O
to	O
the	O
squid	O
beak	O
,	O
we	O
have	O
developed	O
nanocomposites	O
where	O
the	O
degree	O
of	O
cross	O
-	O
linking	O
is	O
controlled	O
along	O
the	O
length	O
of	O
the	O
film	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
tunicate	O
cellulose	O
nanocrystals	O
as	O
the	O
nanofiller	O
that	O
are	O
functionalized	O
with	O
allyl	S-chem
moieties	O
.	O

Using	O
photoinduced	O
thiol	S-chem
-	O
ene	O
chemistry	O
,	O
we	O
have	O
been	O
able	O
to	O
cross	O
-	O
link	O
the	O
CNC	O
nanofiller	O
.	O

In	O
the	O
dry	O
state	O
where	O
strong	O
CNC	O
interactions	O
can	O
occur	O
,	O
only	O
a	O
small	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
cross	O
-	O
linked	O
and	O
uncross	O
-	O
linked	O
samples	O
.	O

However	O
,	O
when	O
the	O
films	O
are	O
exposed	O
to	O
water	O
,	O
which	O
``	O
switches	O
off	O
``	O
the	O
noncovalent	O
CNC	O
interactions	O
,	O
a	O
significant	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
same	O
films	O
.	O

For	O
example	O
,	O
at	O
20	O
wt	O
%	O
CNC	O
(	O
in	O
the	O
dry	O
film	O
)	O
,	O
an	O
increase	O
in	O
wet	O
modulus	O
from	O
60	O
to	O
300	O
MPa	O
(	O
∼	O
500	O
%	O
increase	O
)	O
is	O
observed	O
after	O
photoirradiation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
wet	O
modulus	O
can	O
be	O
controlled	O
by	O
altering	O
the	O
UV	O
exposure	O
time	O
which	O
allows	O
access	O
to	O
mechanical	O
gradient	O
films	O
.	O

Increased	O
urinary	O
excretion	O
of	O
albumin	S-geneN-C3-2
,	O
hemopexin	S-geneY-C3-2
,	O
transferrin	S-geneY-C3-2
and	O
VDBP	S-geneY-C3-2
correlates	O
with	O
chronic	O
sensitization	O
to	O
gentamicin	S-chem-C3-1
nephrotoxicity	O
in	O
rats	O
.	O

Drug	O
nephrotoxicity	O
is	O
a	O
serious	O
health	O
and	O
economic	O
problem	O
worldwide	O
.	O

Rats	O
can	O
be	O
acutely	O
sensitized	O
to	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
by	O
subnephrotoxic	O
treatments	O
with	O
potentially	O
nephrotoxic	O
drugs	O
.	O

Acquired	O
sensitization	O
to	O
AKI	O
poses	O
a	O
silent	O
risk	O
impossible	O
to	O
diagnose	O
pre	O
-	O
emptively	O
with	O
the	O
technology	O
available	O
at	O
the	O
clinical	O
level	O
.	O

Herein	O
,	O
we	O
hypothesized	O
whether	O
a	O
chronic	O
,	O
subnephrotoxic	O
insult	O
to	O
the	O
kidneys	O
might	O
result	O
in	O
chronically	O
acquired	O
sensitization	O
to	O
AKI	O
,	O
and	O
whether	O
chronic	O
sensitization	O
might	O
be	O
detected	O
through	O
specific	O
urinary	O
markers	O
.	O

To	O
this	O
end	O
,	O
rats	O
were	O
treated	O
with	O
a	O
subtoxic	O
dosage	O
of	O
the	O
experimental	O
nephrotoxin	O
uranyl	O
nitrate	S-chem
(	O
UN	O
)	O
in	O
the	O
drinking	O
water	O
for	O
21	O
weeks	O
,	O
or	O
plain	O
water	O
(	O
as	O
control	O
)	O
,	O
and	O
then	O
with	O
low	O
-	O
dose	O
gentamicin	S-chem
for	O
7	O
days	O
.	O

Renal	O
function	O
and	O
renal	O
tissue	O
damage	O
were	O
evaluated	O
through	O
the	O
experiment	O
.	O

The	O
mild	O
renal	O
damage	O
caused	O
by	O
gentamicin	S-chem
was	O
markedly	O
magnified	O
in	O
rats	O
having	O
received	O
UN	O
chronically	O
,	O
which	O
was	O
evident	O
both	O
at	O
the	O
functional	O
and	O
histological	O
level	O
.	O

Four	O
proteins	O
,	O
namely	O
albumin	S-geneN
,	O
hemopexin	S-geneY
,	O
transferrin	S-geneY
and	O
vitamin	B-geneY
D	I-geneY
binding	I-geneY
protein	E-geneY
were	O
increased	O
in	O
the	O
urine	O
in	O
temporal	O
association	O
with	O
the	O
appearance	O
of	O
chronic	O
predisposition	O
.	O

Although	O
further	O
studies	O
are	O
necessary	O
,	O
our	O
results	O
suggest	O
that	O
these	O
proteins	O
might	O
be	O
potentially	O
used	O
as	O
markers	O
of	O
hidden	O
,	O
chronic	O
predisposition	O
to	O
gentamicin	S-chem
nephrotoxicity	O
,	O
in	O
order	O
to	O
appropriately	O
and	O
pre	O
-	O
emptively	O
stratify	O
and	O
handle	O
individuals	O
according	O
to	O
their	O
specific	O
risk	O
in	O
the	O
long	O
term	O
,	O
and	O
to	O
conveniently	O
optimize	O
their	O
life	O
conditions	O
or	O
additional	O
clinical	O
procedures	O
or	O
treatments	O
that	O
might	O
trigger	O
the	O
disease	O
.	O

This	O
might	O
reduce	O
AKI	O
incidence	O
and	O
severity	O
and	O
the	O
associated	O
costs	O
.	O

In	O
vivo	O
effects	O
of	O
amtolmetin	B-chem
guacyl	E-chem
on	O
lipid	O
peroxidation	O
and	O
antioxidant	O
defence	O
systems	O
.	O
Comparison	O
with	O
non	O
-	O
selective	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
selective	O
NSAIDs	O
.	O

1	O
.	O

The	O
in	O
vivo	O
effects	O
of	O
the	O
non	O
-	O
steroid	S-chem
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
amtolmetin	B-chem
guacyl	E-chem
,	O
a	O
pro	O
-	O
drug	O
of	O
the	O
NSAID	O
tolmetin	S-chem
,	O
on	O
lipid	O
peroxidation	O
,	O
glutathione	S-chem
levels	O
and	O
activity	O
of	O
antioxidant	O
enzymes	O
(	O
superoxide	B-geneN
dismutase	E-geneN
,	O
catalase	S-geneY
,	O
glutathione	B-geneN
peroxidase	E-geneN
and	O
glutathione	B-geneN
reductase	E-geneN
)	O
in	O
rat	O
gastric	O
mucosa	O
,	O
colon	O
mucosa	O
and	O
liver	O
,	O
were	O
compared	O
with	O
the	O
effects	O
of	O
non	O
-	O
selective	O
(	O
indomethacin	S-chem
,	O
diclofenac	S-chem
)	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
selective	O
(	O
celecoxib	S-chem
)	O
NSAIDs	O
.	O

2	O
.	O

Indomethacin	S-chem-MU-1
treatment	O
led	O
to	O
an	O
increase	O
in	O
lipid	O
peroxidation	O
,	O
glutathione	B-geneN-C3-2
peroxidase	E-geneN-C3-2
and	O
glucose	B-geneY-C3-2
-	I-geneY-C3-2
6	I-geneY-C3-2
-	I-geneY-C3-2
phosphate	I-geneY-C3-2
dehydrogenase	E-geneY-C3-2
activities	O
and	O
to	O
a	O
decrease	O
in	O
catalase	S-geneY-C4-2
activity	O
and	O
glutathione	S-chem
levels	O
in	O
gastric	O
mucosa	O
.	O

In	O
contrast	O
,	O
amtolmetin	B-chem
guacyl	E-chem
treatment	O
was	O
without	O
effects	O
in	O
gastric	O
and	O
colon	O
mucosa	O
,	O
or	O
liver	O
from	O
control	O
animals	O
.	O

Like	O
amtolmetin	B-chem
guacyl	E-chem
,	O
celecoxib	S-chem
had	O
no	O
effect	O
on	O
the	O
lipid	O
peroxidation	O
,	O
or	O
on	O
enzyme	O
and	O
non	O
-	O
enzyme	O
antioxidant	O
defence	O
systems	O
in	O
gastric	O
mucosa	O
.	O

3	O
.	O

It	O
is	O
suggested	O
that	O
the	O
lack	O
of	O
pro	O
-	O
oxidant	O
effects	O
in	O
vivo	O
associated	O
with	O
amtolmetin	B-chem
guacyl	E-chem
treatment	O
contribute	O
improved	O
gastric	O
tolerability	O
.	O

Effects	O
of	O
nedocromil	B-chem
sodium	E-chem
and	O
WEB	B-chem
2086	E-chem
on	O
chemoattractant	O
-	O
stimulated	O
neutrophil	O
migration	O
through	O
cellular	O
and	O
noncellular	O
barriers	O
.	O

Nedocromil	B-chem
sodium	E-chem
(	O
Tilade	S-chem
)	O
is	O
an	O
effective	O
therapeutic	O
agent	O
against	O
asthma	O
and	O
has	O
been	O
shown	O
to	O
exhibit	O
antiinflammatory	O
activity	O
in	O
vitro	O
;	O
however	O
,	O
its	O
mode	O
of	O
action	O
is	O
yet	O
to	O
be	O
described	O
fully	O
.	O

Using	O
an	O
in	O
vitro	O
assay	O
designed	O
to	O
mimic	O
the	O
extravasation	O
of	O
neutrophils	O
from	O
the	O
peripheral	O
circulation	O
through	O
cellular	O
barriers	O
to	O
sites	O
of	O
inflammation	O
,	O
the	O
effect	O
of	O
nedocromil	B-chem
sodium	E-chem
on	O
chemoattractant	O
-	O
stimulated	O
neutrophil	O
migration	O
was	O
examined	O
.	O

We	O
also	O
examined	O
the	O
effects	O
of	O
WEB	B-chem-C6-1
2086	E-chem-C6-1
,	O
a	O
platelet	B-geneY-C6-2
-	I-geneY-C6-2
activating	I-geneY-C6-2
factor	I-geneY-C6-2
(	I-geneY-C6-2
PAF	I-geneY-C6-2
)	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
,	O
in	O
parallel	O
.	O

Neutrophils	O
and	O
the	O
cellular	O
barrier	O
were	O
pretreated	O
and	O
/	O
or	O
co	O
-	O
incubated	O
with	O
nedocromil	O
or	O
WEB	B-chem
2086	E-chem
and	O
the	O
effects	O
on	O
neutrophil	O
chemotaxis	O
measured	O
.	O

In	O
all	O
treatments	O
,	O
nedocromil	S-chem
did	O
not	O
significantly	O
affect	O
chemotaxis	O
through	O
cellular	O
or	O
noncellular	O
barriers	O
to	O
N	B-chem
-	I-chem
formyl	I-chem
-	I-chem
methionyl	I-chem
-	I-chem
leucyl	I-chem
-	I-chem
phenylalanine	E-chem
(	O
FMLP	S-chem
)	O
,	O
leukotriene	B-chem
B4	E-chem
(	O
LTB4	S-chem
)	O
,	O
or	O
PAF	S-chem
.	O

In	O
contrast	O
,	O
WEB	B-chem
2086	E-chem
inhibited	O
PAF	S-chem
-	O
induced	O
neutrophil	O
migration	O
through	O
both	O
naked	O
filters	O
and	O
endothelial	O
and	O
epithelial	O
monolayers	O
cultured	O
on	O
these	O
filters	O
.	O

We	O
conclude	O
that	O
while	O
nedocromil	S-chem
has	O
been	O
shown	O
to	O
have	O
inhibitory	O
effects	O
on	O
neutrophils	O
and	O
is	O
an	O
effective	O
therapeutic	O
agent	O
for	O
asthma	O
and	O
inflammatory	O
conditions	O
,	O
its	O
activity	O
is	O
not	O
primarily	O
mediated	O
by	O
inhibition	O
of	O
neutrophil	O
chemotaxis	O
.	O

Platelet	B-geneY
-	I-geneY
activating	I-geneY
factor	E-geneY
antagonists	O
may	O
partially	O
be	O
effective	O
in	O
asthma	O
through	O
inhibitory	O
effects	O
on	O
neutrophil	O
chemotaxis	O
.	O

Cis	O
-	O
silencing	O
of	O
PIP5K1B	S-geneY
evidenced	O
in	O
Friedreich	O
's	O
ataxia	O
patient	O
cells	O
results	O
in	O
cytoskeleton	O
anomalies	O
.	O

Friedreich	O
's	O
ataxia	O
(	O
FRDA	O
)	O
is	O
a	O
progressive	O
neurodegenerative	O
disease	O
characterized	O
by	O
ataxia	O
,	O
variously	O
associating	O
heart	O
disease	O
,	O
diabetes	O
mellitus	O
and	O
/	O
or	O
glucose	S-chem
intolerance	O
.	O

It	O
results	O
from	O
intronic	O
expansion	O
of	O
GAA	B-geneN
triplet	I-geneN
repeats	E-geneN
at	O
the	O
FXN	S-geneY
locus	O
.	O

Homozygous	O
expansions	O
cause	O
silencing	O
of	O
the	O
FXN	S-geneY
gene	O
and	O
subsequent	O
decreased	O
expression	O
of	O
the	O
encoded	O
mitochondrial	O
frataxin	S-geneY
.	O

Detailed	O
analyses	O
in	O
fibroblasts	O
and	O
neuronal	O
tissues	O
from	O
FRDA	O
patients	O
have	O
revealed	O
profound	O
cytoskeleton	O
anomalies	O
.	O

So	O
far	O
,	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
these	O
cytoskeleton	O
defects	O
remains	O
unknown	O
.	O

We	O
show	O
here	O
that	O
gene	O
silencing	O
spreads	O
in	O
cis	O
over	O
the	O
PIP5K1B	S-geneY
gene	O
in	O
cells	O
from	O
FRDA	O
patients	O
(	O
circulating	O
lymphocytes	O
and	O
primary	O
fibroblasts	O
)	O
,	O
correlating	O
with	O
expanded	O
GAA	O
repeat	O
size	O
.	O

PIP5K1B	S-geneY-C9-2
encodes	O
phosphatidylinositol	B-geneY-C9-2
4	I-geneY-C9-2
-	I-geneY-C9-2
phosphate	I-geneY-C9-2
5	I-geneY-C9-2
-	I-geneY-C9-2
kinase	I-geneY-C9-2
β	I-geneY-C9-2
type	I-geneY-C9-2
I	E-geneY-C9-2
(	O
pip5k1β	S-geneY-C9-2
)	O
,	O
an	O
enzyme	O
functionally	O
linked	O
to	O
actin	S-geneN
cytoskeleton	O
dynamics	O
that	O
phosphorylates	O
phosphatidylinositol	B-chem-C9-1
4	I-chem-C9-1
-	I-chem-C9-1
phosphate	E-chem-C9-1
[	O
PI	B-chem-C9-1
(	I-chem-C9-1
4	I-chem-C9-1
)	I-chem-C9-1
P	E-chem-C9-1
]	O
to	O
generate	O
phosphatidylinositol	B-chem-C9-1
-	I-chem-C9-1
4,5	I-chem-C9-1
-	I-chem-C9-1
bisphosphate	E-chem-C9-1
[	O
PI	B-chem-C9-1
(	I-chem-C9-1
4,5	I-chem-C9-1
)	I-chem-C9-1
P2	E-chem-C9-1
]	O
.	O

Accordingly	O
,	O
loss	O
of	O
pip5k1β	S-geneY-C9-2
function	O
in	O
FRDA	O
cells	O
was	O
accompanied	O
by	O
decreased	O
PI	B-chem-C9-1
(	I-chem-C9-1
4,5	I-chem-C9-1
)	I-chem-C9-1
P2	E-chem-C9-1
levels	O
and	O
was	O
shown	O
instrumental	O
for	O
destabilization	O
of	O
the	O
actin	O
network	O
and	O
delayed	O
cell	O
spreading	O
.	O

Knockdown	O
of	O
PIP5K1B	S-geneY
in	O
control	O
fibroblasts	O
using	O
shRNA	O
reproduced	O
abnormal	O
actin	S-geneN
cytoskeleton	O
remodeling	O
,	O
whereas	O
over	O
-	O
expression	O
of	O
PIP5K1B	S-geneY
,	O
but	O
not	O
FXN	S-geneY
,	O
suppressed	O
this	O
phenotype	O
in	O
FRDA	O
cells	O
.	O

In	O
addition	O
to	O
provide	O
new	O
insights	O
into	O
the	O
consequences	O
of	O
the	O
FXN	S-geneY
gene	O
expansion	O
,	O
these	O
findings	O
raise	O
the	O
question	O
whether	O
PIP5K1B	S-geneY
silencing	O
may	O
contribute	O
to	O
the	O
variable	O
manifestation	O
of	O
this	O
complex	O
disease	O
.	O

Mouse	B-geneY-C9-2
brain	I-geneY-C9-2
serine	I-geneY-C9-2
racemase	E-geneY-C9-2
catalyzes	O
specific	O
elimination	O
of	O
L	B-chem-C9-1
-	I-chem-C9-1
serine	E-chem-C9-1
to	O
pyruvate	S-chem-C9-1
.	O

D	B-chem-C5-1
-	I-chem-C5-1
Serine	E-chem-C5-1
was	O
previously	O
identified	O
in	O
mammalian	O
brain	O
and	O
was	O
shown	O
to	O
be	O
a	O
co	O
-	O
agonist	O
at	O
the	O
'	O
glycine	S-chem
'	O
site	O
of	O
the	O
N	B-geneN-C5-2
-	I-geneN-C5-2
methyl	I-geneN-C5-2
-	I-geneN-C5-2
D	I-geneN-C5-2
-	I-geneN-C5-2
aspartate	I-geneN-C5-2
(	I-geneN-C5-2
NMDA	I-geneN-C5-2
)	I-geneN-C5-2
-	I-geneN-C5-2
type	I-geneN-C5-2
receptors	E-geneN-C5-2
.	O

Racemization	O
of	O
serine	S-chem-C9-1
is	O
catalyzed	O
by	O
serine	B-geneY-C9-2
racemase	E-geneY-C9-2
,	O
a	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
-	O
dependent	O
enzyme	O
expressed	O
mainly	O
in	O
brain	O
and	O
liver	O
.	O

NMDA	B-geneN
receptor	E-geneN
overactivation	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
pathological	O
conditions	O
and	O
inhibitors	O
of	O
serine	B-geneY
racemase	E-geneY
are	O
thus	O
potentially	O
interesting	O
targets	O
for	O
therapy	O
.	O

We	O
expressed	O
recombinant	O
mouse	B-geneY
serine	I-geneY
racemase	E-geneY
in	O
insect	O
cells	O
and	O
purified	O
it	O
to	O
near	O
homogeneity	O
.	O

The	O
enzyme	O
is	O
a	O
non	O
-	O
covalent	O
homodimer	O
in	O
solution	O
and	O
requires	O
divalent	O
cations	O
Mg	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
or	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
for	O
activity	O
but	O
not	O
for	O
dimerization	O
.	O

In	O
addition	O
to	O
the	O
racemization	O
it	O
also	O
catalyzes	O
specific	O
elimination	O
of	O
L	B-chem
-	I-chem
Ser	E-chem
to	O
pyruvate	S-chem
.	O

D	B-chem
-	I-chem
Serine	E-chem
is	O
eliminated	O
much	O
less	O
efficiently	O
.	O

Both	O
L	B-chem
-	I-chem
serine	E-chem
racemization	O
and	O
elimination	O
activities	O
of	O
serine	S-chem
racemase	O
are	O
of	O
comparable	O
magnitude	O
,	O
display	O
alkaline	S-chem
pH	O
optimum	O
and	O
are	O
negligible	O
below	O
pH	O
6.5	O
.	O

Glutathione	B-geneN
S	I-geneN
-	I-geneN
transferase	I-geneN
M1	I-geneN
and	I-geneN
P1	E-geneN
polymorphisms	O
and	O
risk	O
of	O
breast	O
cancer	O
and	O
fibrocystic	O
breast	O
conditions	O
in	O
Chinese	O
women	O
.	O

Enzymes	O
encoded	O
by	O
the	O
glutathione	B-geneY
S	I-geneY
-	I-geneY
tranferase	I-geneY
mu	I-geneY
1	E-geneY
(	O
GSTM1	S-geneY
)	O
and	O
pi	B-geneY
1	E-geneY
(	O
GSTP1	S-geneY
)	O
genes	O
,	O
which	O
are	O
expressed	O
in	O
breast	O
tissue	O
,	O
catalyze	O
the	O
detoxification	O
of	O
endogenous	O
and	O
exogenous	O
electrophiles	O
.	O

Reduced	O
enzyme	O
activity	O
,	O
due	O
to	O
carriage	O
of	O
the	O
GSTM1	S-geneY
deletion	O
or	O
the	O
GSTP1	S-geneY
Ile105Val	O
Val	O
allele	O
,	O
may	O
therefore	O
affect	O
susceptibility	O
to	O
breast	O
cancer	O
and	O
related	O
conditions	O
.	O

In	O
a	O
case	O
-	O
control	O
study	O
of	O
Chinese	O
women	O
,	O
we	O
examined	O
whether	O
these	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
breast	O
cancer	O
and	O
fibrocystic	O
breast	O
conditions	O
.	O

Women	O
diagnosed	O
with	O
breast	O
cancer	O
(	O
n	O
=	O
615	O
)	O
or	O
fibrocystic	O
breast	O
conditions	O
(	O
n	O
=	O
467	O
)	O
were	O
compared	O
to	O
women	O
without	O
clinical	O
breast	O
disease	O
(	O
n	O
=	O
878	O
)	O
.	O

We	O
also	O
examined	O
whether	O
these	O
associations	O
differed	O
by	O
menopausal	O
status	O
or	O
by	O
presence	O
of	O
proliferation	O
in	O
the	O
extra	O
-	O
tumoral	O
epithelium	O
among	O
women	O
with	O
breast	O
cancer	O
and	O
in	O
lesions	O
among	O
women	O
with	O
fibrocystic	O
conditions	O
.	O

No	O
overall	O
association	O
of	O
either	O
GST	S-geneN
polymorphism	O
with	O
risk	O
of	O
breast	O
cancer	O
or	O
fibrocystic	O
breast	O
conditions	O
was	O
observed	O
.	O

There	O
was	O
some	O
evidence	O
of	O
slightly	O
elevated	O
cancer	O
risk	O
associated	O
with	O
carriage	O
of	O
the	O
GSTM1	S-geneY
null	O
genotype	O
and	O
at	O
least	O
one	O
GSTP1	S-geneY
105	O
-	O
Val	O
allele	O
(	O
OR	O
=	O
1.33	O
,	O
95	O
%	O
CI	O
,	O
0.99	O
-	O
1.80	O
)	O
,	O
compared	O
to	O
carriage	O
of	O
the	O
GSTM1	S-geneY
non	O
-	O
null	O
and	O
GSTP1	S-geneY
Ile	O
/	O
Ile	O
genotypes	O
.	O

This	O
relationship	O
was	O
stronger	O
in	O
women	O
who	O
had	O
breast	O
cancer	O
with	O
extra	O
-	O
tumoral	O
tissue	O
proliferation	O
(	O
OR	O
=	O
1.77	O
,	O
95	O
%	O
CI	O
,	O
1.03	O
-	O
3.04	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
GSTM1	S-geneY
and	O
GSTP1	S-geneY
genotypes	O
do	O
not	O
individually	O
influence	O
susceptibility	O
to	O
breast	O
cancer	O
or	O
fibrocystic	O
breast	O
conditions	O
.	O

The	O
observed	O
increased	O
risk	O
of	O
breast	O
cancer	O
associated	O
with	O
joint	O
carriage	O
of	O
the	O
GSTM1	S-geneY
null	O
genotype	O
and	O
GSTP1	S-geneY
105	O
-	O
Val	O
allele	O
needs	O
confirmation	O
in	O
other	O
studies	O
.	O

Longer	O
HSD11B2	S-geneY
CA	B-geneN
-	I-geneN
repeat	E-geneN
in	O
impaired	O
glucose	S-chem
tolerance	O
and	O
type	O
2	O
diabetes	O
.	O

Type	B-geneY-C9-2
2	I-geneY-C9-2
11β	I-geneY-C9-2
-	I-geneY-C9-2
hydroxysteroid	I-geneY-C9-2
dehydrogenase	E-geneY-C9-2
encoded	O
by	O
the	O
HSD11B2	S-geneY-C9-2
gene	O
converts	O
cortisol	S-chem-C9-1
to	O
inactive	O
cortisone	S-chem-C9-1
,	O
and	O
alteration	O
in	O
this	O
enzymatic	O
activity	O
might	O
affect	O
glucose	S-chem
homeostasis	O
by	O
affecting	O
circulating	O
levels	O
or	O
tissue	O
availability	O
of	O
glucocorticoids	O
.	O

We	O
investigated	O
the	O
association	O
of	O
HSD11B2	S-geneY
variant	O
with	O
glucose	S-chem
homeostasis	O
.	O

Subjects	O
with	O
normal	O
glucose	S-chem
tolerance	O
(	O
n	O
=	O
585	O
)	O
,	O
impaired	O
glucose	S-chem
tolerance	O
(	O
n	O
=	O
202	O
)	O
and	O
type	O
2	O
diabetes	O
(	O
n	O
=	O
355	O
)	O
were	O
genotyped	O
for	O
a	O
highly	O
polymorphic	O
CA	B-geneN
-	I-geneN
repeat	E-geneN
polymorphism	O
in	O
the	O
first	O
intron	O
of	O
HSD11B2	S-geneY
.	O

Allele	O
and	O
genotype	O
frequencies	O
differed	O
between	O
normal	O
and	O
impaired	O
glucose	S-chem
tolerance	O
(	O
P	O
=	O
0.0014	O
and	O
0.0407	O
,	O
respectively	O
;	O
4DF	O
)	O
or	O
type	O
2	O
diabetes	O
(	O
P	O
=	O
0.0053	O
and	O
0.0078	O
)	O
,	O
with	O
significant	O
linear	O
trends	O
between	O
the	O
repeat	O
length	O
and	O
the	O
phenotype	O
fraction	O
.	O

In	O
normal	O
subjects	O
,	O
total	O
CA	B-geneN
-	I-geneN
repeat	E-geneN
length	O
was	O
negatively	O
correlated	O
with	O
fasting	O
insulin	S-geneY
and	O
HOMA	O
-	O
β	O
.	O

Thus	O
,	O
subjects	O
having	O
more	O
CA	B-geneN
repeats	E-geneN
are	O
susceptible	O
to	O
developing	O
abnormal	O
glucose	S-chem
tolerance	O
,	O
whereas	O
normal	O
subjects	O
carrying	O
more	O
CA	B-geneN
repeats	E-geneN
appeared	O
to	O
have	O
frugal	O
characteristics	O
in	O
insulin	S-geneY
secretion	O
.	O

Efficacy	O
of	O
the	O
GluK1	S-geneY-C6-2
/	O
AMPA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
LY293558	S-chem-C6-1
against	O
seizures	O
and	O
neuropathology	O
in	O
a	O
soman	O
-	O
exposure	O
model	O
without	O
pretreatment	O
and	O
its	O
pharmacokinetics	O
after	O
intramuscular	O
administration	O
.	O

Control	O
of	O
brain	O
seizures	O
after	O
exposure	O
to	O
nerve	O
agents	O
is	O
imperative	O
for	O
the	O
prevention	O
of	O
brain	O
damage	O
and	O
death	O
.	O

Animal	O
models	O
of	O
nerve	O
agent	O
exposure	O
make	O
use	O
of	O
pretreatments	O
,	O
or	O
medication	O
administered	O
within	O
1	O
minute	O
after	O
exposure	O
,	O
in	O
order	O
to	O
prevent	O
rapid	O
death	O
from	O
peripheral	O
toxic	O
effects	O
and	O
respiratory	O
failure	O
,	O
which	O
then	O
allows	O
the	O
testing	O
of	O
anticonvulsant	O
compounds	O
.	O

However	O
,	O
in	O
a	O
real	O
-	O
case	O
scenario	O
of	O
an	O
unexpected	O
attack	O
with	O
nerve	O
agents	O
,	O
pretreatment	O
would	O
not	O
be	O
possible	O
,	O
and	O
medical	O
assistance	O
may	O
not	O
be	O
available	O
immediately	O
.	O

To	O
determine	O
if	O
control	O
of	O
seizures	O
and	O
survival	O
are	O
still	O
possible	O
without	O
pretreatment	O
or	O
immediate	O
pharmacologic	O
intervention	O
,	O
we	O
studied	O
the	O
anticonvulsant	O
efficacy	O
of	O
the	O
GluK1	S-geneY-C6-2
(	O
GluR5	S-geneY-C6-2
)	O
/	O
α	B-geneN-C6-2
-	I-geneN-C6-2
amino	I-geneN-C6-2
-	I-geneN-C6-2
3	I-geneN-C6-2
-	I-geneN-C6-2
hydroxy	I-geneN-C6-2
-	I-geneN-C6-2
5	I-geneN-C6-2
-	I-geneN-C6-2
methyl	I-geneN-C6-2
-	I-geneN-C6-2
4	I-geneN-C6-2
-	I-geneN-C6-2
isoxazolepropionic	I-geneN-C6-2
acid	I-geneN-C6-2
(	I-geneN-C6-2
AMPA	I-geneN-C6-2
)	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
(	B-chem-C6-1
3S,4aR,6R,8aR	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
6	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
1	I-chem-C6-1
(	I-chem-C6-1
2	I-chem-C6-1
)	I-chem-C6-1
H	I-chem-C6-1
-	I-chem-C6-1
tetrazole	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
yl	I-chem-C6-1
)	I-chem-C6-1
ethyl	I-chem-C6-1
]	I-chem-C6-1
decahydroisoquinoline	I-chem-C6-1
-	I-chem-C6-1
3	I-chem-C6-1
-	I-chem-C6-1
carboxylic	I-chem-C6-1
acid	E-chem-C6-1
(	O
LY293558	S-chem-C6-1
)	O
in	O
rats	O
that	O
did	O
not	O
receive	O
any	O
treatment	O
until	O
20	O
minutes	O
after	O
exposure	O
to	O
the	O
nerve	O
agent	O
soman	O
.	O

We	O
injected	O
LY293558	S-chem
intramuscularly	O
,	O
as	O
this	O
would	O
be	O
the	O
most	O
likely	O
route	O
of	O
administration	O
to	O
humans	O
.	O

LY293558	S-chem
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
injected	O
along	O
with	O
atropine	O
and	O
the	O
oxime	S-chem
HI	B-chem
-	I-chem
6	E-chem
at	O
20	O
minutes	O
after	O
soman	O
exposure	O
,	O
stopped	O
seizures	O
and	O
increased	O
survival	O
rate	O
from	O
64	O
%	O
to	O
100	O
%	O
.	O

LY293558	S-chem
also	O
prevented	O
neuronal	O
loss	O
in	O
the	O
amygdala	O
and	O
hippocampus	O
,	O
and	O
reduced	O
neurodegeneration	O
in	O
a	O
number	O
of	O
brain	O
regions	O
studied	O
7	O
days	O
after	O
soman	O
exposure	O
.	O

Analysis	O
of	O
the	O
LY293558	S-chem
pharmacokinetics	O
after	O
intramuscular	O
administration	O
showed	O
that	O
this	O
compound	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

There	O
was	O
good	O
correspondence	O
between	O
the	O
time	O
course	O
of	O
seizure	O
suppression	O
by	O
LY293558	S-chem
and	O
the	O
brain	O
levels	O
of	O
the	O
compound	O
.	O

Pharmacokinetic	O
and	O
pharmacodynamic	O
modeling	O
of	O
hedgehog	S-geneN-C4-2
inhibitor	O
TAK	B-chem-C4-1
-	I-chem-C4-1
441	E-chem-C4-1
for	O
the	O
inhibition	O
of	O
Gli1	S-geneY-C4-2
messenger	O
RNA	O
expression	O
and	O
antitumor	O
efficacy	O
in	O
xenografted	O
tumor	O
model	O
mice	O
.	O

6	B-chem
-	I-chem
Ethyl	I-chem
-	I-chem
N	I-chem
-	I-chem
[	I-chem
1	I-chem
-	I-chem
(	I-chem
hydroxyacetyl	I-chem
)	I-chem
piperidin	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
]	I-chem
-	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
oxo	I-chem
-	I-chem
5	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
oxo	I-chem
-	I-chem
2	I-chem
-	I-chem
phenylethyl	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
2,2,2	I-chem
-	I-chem
trifluoroethoxy	I-chem
)	I-chem
-	I-chem
4,5	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
1H	I-chem
-	I-chem
pyrrolo	I-chem
[	I-chem
3,2	I-chem
-	I-chem
c	I-chem
]	I-chem
pyridine	I-chem
-	I-chem
2	I-chem
-	I-chem
carboxamide	E-chem
(	O
TAK	B-chem-C4-1
-	I-chem-C4-1
441	E-chem-C4-1
)	O
is	O
a	O
potent	O
,	O
selective	O
hedgehog	S-geneN-C4-2
signaling	O
pathway	O
inhibitor	O
that	O
binds	O
to	O
Smo	S-geneY
and	O
is	O
being	O
developed	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

The	O
objectives	O
of	O
these	O
studies	O
were	O
to	O
explore	O
the	O
possibility	O
of	O
establishing	O
of	O
a	O
link	O
between	O
the	O
pharmacokinetics	O
of	O
TAK	B-chem
-	I-chem
441	E-chem
and	O
the	O
responses	O
of	O
Gli1	S-geneY
mRNA	O
in	O
tumor	O
-	O
associated	O
stromal	O
or	O
skin	O
cells	O
and	O
the	O
antitumor	O
effect	O
of	O
hedgehog	S-geneN
inhibition	O
.	O

To	O
this	O
end	O
,	O
we	O
built	O
pharmacokinetic	O
and	O
pharmacodynamic	O
models	O
that	O
describe	O
the	O
relationship	O
of	O
the	O
concentrations	O
of	O
TAK	B-chem
-	I-chem
441	E-chem
plasma	O
to	O
the	O
responses	O
of	O
Gli1	S-geneY
mRNA	O
in	O
the	O
tumor	O
(	O
target	O
)	O
and	O
skin	O
(	O
surrogate	O
)	O
and	O
to	O
tumor	O
growth	O
inhibition	O
in	O
mice	O
bearing	O
xenografts	O
of	O
human	O
pancreatic	O
tumors	O
(	O
PAN	O
-	O
04	O
)	O
.	O

The	O
responses	O
of	O
Gli1	S-geneY
mRNA	O
and	O
tumor	O
growth	O
were	O
described	O
by	O
an	O
indirect	O
response	O
model	O
and	O
an	O
exponential	O
tumor	O
growth	O
model	O
,	O
respectively	O
.	O

The	O
IC50	O
values	O
for	O
Gli1	S-geneY-C4-2
mRNA	O
inhibition	O
in	O
the	O
tumor	O
and	O
skin	O
by	O
TAK	B-chem-C4-1
-	I-chem-C4-1
441	E-chem-C4-1
were	O
estimated	O
to	O
be	O
0.0457	O
and	O
0.113	O
μg	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
IC90	O
value	O
for	O
tumor	O
growth	O
inhibition	O
was	O
estimated	O
to	O
be	O
0.68	O
μg	O
/	O
ml	O
.	O

These	O
results	O
suggest	O
that	O
a	O
>	O
83	O
%	O
inhibition	O
of	O
Gli1	S-geneY
mRNA	O
expression	O
in	O
the	O
skin	O
or	O
a	O
>	O
94	O
%	O
inhibition	O
of	O
Gli1	S-geneY
mRNA	O
expression	O
in	O
the	O
tumor	O
would	O
be	O
required	O
to	O
sufficiently	O
inhibit	O
(	O
>	O
90	O
%	O
)	O
hedgehog	S-geneN
-	O
related	O
tumor	O
growth	O
in	O
the	O
xenografted	O
model	O
mice	O
.	O

We	O
conclude	O
that	O
Gli1	S-geneY
mRNA	O
expression	O
in	O
the	O
tumor	O
and	O
skin	O
could	O
be	O
a	O
useful	O
biomarker	O
for	O
predicting	O
the	O
antitumor	O
effect	O
of	O
hedgehog	S-geneN
inhibitors	O
.	O

Rasagiline	S-chem
protects	O
against	O
alpha	B-geneY
-	I-geneY
synuclein	E-geneY
induced	O
sensitivity	O
to	O
oxidative	O
stress	O
in	O
dopaminergic	O
cells	O
.	O

Rasagiline	S-chem-C4-1
is	O
a	O
propargylamine	S-chem-C4-1
and	O
irreversible	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
(	I-geneY-C4-2
MAO	I-geneY-C4-2
)	I-geneY-C4-2
B	E-geneY-C4-2
inhibitor	O
used	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

It	O
has	O
demonstrated	O
neuroprotective	O
properties	O
in	O
laboratory	O
studies	O
.	O

Current	O
concepts	O
of	O
PD	O
aetiopathogenesis	O
include	O
the	O
role	O
of	O
alpha	B-geneY
-	I-geneY
synuclein	E-geneY
,	O
protein	O
aggregation	O
,	O
free	O
radical	O
metabolism	O
and	O
mitochondrial	O
dysfunction	O
in	O
contributing	O
to	O
cell	O
death	O
.	O

We	O
have	O
used	O
a	O
combination	O
of	O
alpha	B-geneY
-	I-geneY
synuclein	E-geneY
and	O
free	O
radical	O
mediated	O
toxicity	O
in	O
a	O
dopaminergic	O
cell	O
line	O
to	O
provide	O
a	O
model	O
of	O
nigral	O
toxicity	O
in	O
order	O
to	O
investigate	O
the	O
potential	O
molecular	O
mechanisms	O
that	O
mediate	O
rasagiline	S-chem
protection	O
.	O

We	O
demonstrate	O
that	O
rasagiline	S-chem
protects	O
against	O
cell	O
death	O
induced	O
by	O
the	O
combination	O
of	O
free	O
radicals	O
generated	O
by	O
paraquat	S-chem
and	O
either	O
wild	O
-	O
type	O
or	O
A53T	S-geneN
mutant	O
alpha	B-geneY
-	I-geneY
synuclein	E-geneY
over	O
-	O
expression	O
.	O

This	O
protection	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
caspase	B-geneY
3	E-geneY
activation	O
,	O
a	O
reduction	O
in	O
superoxide	S-chem
generation	O
and	O
a	O
trend	O
to	O
ameliorate	O
the	O
fall	O
in	O
mitochondrial	O
membrane	O
potential	O
.	O

Rasagiline	S-chem
induced	O
an	O
increase	O
in	O
cellular	O
glutathione	S-chem
levels	O
.	O

The	O
results	O
support	O
a	O
role	O
for	O
rasagiline	S-chem
in	O
protecting	O
dopaminergic	O
cells	O
against	O
free	O
radical	O
mediated	O
damage	O
and	O
apoptosis	O
in	O
the	O
presence	O
of	O
alpha	B-geneY
-	I-geneY
synuclein	E-geneY
over	O
-	O
expression	O
.	O

The	O
data	O
are	O
of	O
relevance	O
to	O
the	O
interpretation	O
of	O
the	O
potential	O
mechanisms	O
of	O
action	O
of	O
rasagiline	S-chem
in	O
explaining	O
the	O
results	O
of	O
disease	O
modification	O
trials	O
in	O
PD	O
.	O

Effects	O
of	O
chronic	O
social	O
defeat	O
stress	O
on	O
behavior	O
and	O
choline	B-geneY
acetyltransferase	E-geneY
,	O
78	B-geneY
-	I-geneY
kDa	I-geneY
glucose	I-geneY
-	I-geneY
regulated	I-geneY
protein	E-geneY
,	O
and	O
CCAAT	B-geneY
/	I-geneY
enhancer	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
(	I-geneY
C	I-geneY
/	I-geneY
EBP	I-geneY
)	I-geneY
homologous	I-geneY
protein	E-geneY
in	O
adult	O
mice	O
.	O

RATIONALE	O
:	O
Social	O
defeat	O
stress	O
induces	O
physiological	O
and	O
behavioral	O
symptoms	O
,	O
including	O
anxiety	O
,	O
anhedonia	O
,	O
immune	O
deficits	O
,	O
and	O
altered	O
expression	O
of	O
key	O
brain	O
genes	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
social	O
defeat	O
stress	O
on	O
the	O
behaviors	O
and	O
expressions	O
of	O
Chat	S-geneY
,	O
Grp78	S-geneY
,	O
and	O
chop	S-geneY
in	O
the	O
brains	O
of	O
adult	O
mice	O
.	O

METHODS	O
:	O
Adult	O
mice	O
were	O
divided	O
into	O
susceptible	O
and	O
unsusceptible	O
groups	O
after	O
10	O
days	O
of	O
social	O
defeat	O
stress	O
.	O

In	O
experiment	O
1	O
,	O
behavioral	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
27	O
after	O
stress	O
.	O

In	O
experiment	O
2	O
,	O
social	O
avoidance	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
12	O
after	O
stress	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
decreased	O
and	O
increased	O
locomotion	O
and	O
anxiety	O
behavior	O
in	O
all	O
defeated	O
mice	O
.	O

Decrease	O
in	O
social	O
interaction	O
,	O
increased	O
immobility	O
,	O
and	O
impaired	O
memory	O
performance	O
were	O
only	O
observed	O
in	O
susceptible	O
mice	O
.	O

A	O
decrease	O
in	O
the	O
Chat	O
level	O
at	O
days	O
12	O
and	O
27	O
was	O
noted	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
amygdala	O
(	O
Amyg	O
)	O
,	O
and	O
dorsal	O
hippocampus	O
(	O
HIP	O
)	O
in	O
defeated	O
mice	O
.	O

The	O
expression	O
levels	O
of	O
Grp78	S-geneY
and	O
chop	S-geneY
measured	O
on	O
days	O
12	O
and	O
27	O
were	O
significantly	O
greater	O
in	O
the	O
Amyg	O
of	O
susceptible	O
mice	O
.	O

In	O
the	O
PFC	O
and	O
HIP	O
,	O
defeated	O
mice	O
displayed	O
different	O
patterns	O
in	O
the	O
levels	O
of	O
Grp78	S-geneY
and	O
chop	S-geneY
expressions	O
measured	O
on	O
days	O
12	O
and	O
27	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrated	O
that	O
chronic	O
social	O
defeat	O
stress	O
in	O
mice	O
produces	O
stress	O
-	O
related	O
behaviors	O
.	O

Different	O
response	O
patterns	O
were	O
noted	O
for	O
Grp78	S-geneY
and	O
chop	S-geneY
expression	O
among	O
the	O
groups	O
in	O
terms	O
of	O
brain	O
regions	O
and	O
time	O
-	O
course	O
effects	O
.	O

2	B-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
Aminoethyl	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
quinoline	E-chem-C5-1
(	O
D	B-chem-C5-1
-	I-chem-C5-1
1997	E-chem-C5-1
)	O
:	O
a	O
novel	O
agonist	O
at	O
5	B-geneN-C5-2
-	I-geneN-C5-2
hydroxytryptamine1	I-geneN-C5-2
-	I-geneN-C5-2
like	I-geneN-C5-2
receptors	E-geneN-C5-2
in	O
the	O
canine	O
basilar	O
artery	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
mechanisms	O
involved	O
in	O
the	O
contractile	O
effects	O
produced	O
by	O
the	O
novel	O
quinoline	S-chem
derivative	O
,	O
2	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
aminoethyl	I-chem
)	I-chem
-	I-chem
quinoline	E-chem
(	O
D	B-chem
-	I-chem
1997	E-chem
)	O
,	O
in	O
the	O
canine	O
isolated	O
basilar	O
artery	O
.	O

For	O
comparison	O
,	O
the	O
effects	O
of	O
D	B-chem
-	I-chem
1997	E-chem
were	O
also	O
evaluated	O
on	O
rat	O
aorta	O
.	O

Canine	O
basilar	O
artery	O
and	O
rat	O
aortic	O
rings	O
were	O
prepared	O
and	O
mounted	O
in	O
organ	O
baths	O
to	O
record	O
isometric	O
tension	O
changes	O
.	O

The	O
contractile	O
effects	O
of	O
D	B-chem
-	I-chem
1997	E-chem
in	O
the	O
basilar	O
artery	O
were	O
compared	O
with	O
those	O
produced	O
by	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
and	O
the	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptor	E-geneN
agonist	O
quipazine	S-chem
.	O

Thus	O
,	O
4	B-chem
-	I-chem
HT	E-chem
(	O
10	O
(	O
-	O
10	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
D	B-chem
-	I-chem
1997	E-chem
(	O
3.1	O
x	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
)	O
and	O
quipazine	S-chem
(	O
3.1	O
x	O
10	O
(	O
-	O
7	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
)	O
each	O
caused	O
concentration	O
-	O
dependent	O
contractions	O
of	O
the	O
canine	O
basilar	O
artery	O
with	O
a	O
rank	O
order	O
of	O
agonist	O
potency	O
of	O
5	B-chem
-	I-chem
HT	E-chem
>	O
D	B-chem
-	I-chem
1997	E-chem
>	O
quipazine	S-chem
.	O

5	B-chem
-	I-chem
HT	E-chem
and	O
D	B-chem
-	I-chem
1997	E-chem
exhibited	O
similar	O
maximum	O
effects	O
which	O
were	O
higher	O
than	O
that	O
of	O
quipazine	S-chem
.	O

Similar	O
concentrations	O
of	O
D	B-chem
-	I-chem
1997	E-chem
failed	O
to	O
produce	O
contraction	O
in	O
rat	O
aorta	O
.	O

The	O
effects	O
of	O
D	B-chem
-	I-chem
1997	E-chem
in	O
the	O
basilar	O
artery	O
were	O
not	O
modified	O
by	O
incubation	O
with	O
either	O
the	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT2	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
ketanserin	S-chem-C6-1
(	O
0.01	O
-	O
1	O
microM	O
)	O
,	O
the	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT3	E-geneN-C6-2
and	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT4	E-geneY-C6-2
receptor	O
antagonist	O
ICS205930	O
(	O
tropisetron	S-chem-C6-1
;	O
0.1	O
-	O
10	O
microM	O
)	O
,	O
the	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1A	E-geneY-C6-2
receptor	O
antagonist	O
spiroxatrine	S-chem-C6-1
(	O
0.01	O
-	O
1	O
microM	O
)	O
,	O
the	O
beta	B-geneN-C4-2
-	I-geneN-C4-2
adrenoceptor	E-geneN-C4-2
blocker	O
with	O
high	O
affinity	O
for	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
binding	O
sites	O
(	B-chem-C4-1
+	I-chem-C4-1
/	I-chem-C4-1
-	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
pindolol	E-chem-C4-1
(	O
0.01	O
-	O
1	O
microM	O
)	O
,	O
or	O
the	O
alpha	B-geneN-C6-2
1	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
prazosin	S-chem-C6-1
(	O
0.01	O
-	O
1	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
the	O
D	B-chem-C5-1
-	I-chem-C5-1
1997	E-chem-C5-1
-	O
induced	O
responses	O
were	O
potently	O
and	O
concentration	O
-	O
dependently	O
antagonized	O
by	O
the	O
mixed	O
5	B-geneN-MU-2
-	I-geneN-MU-2
HT1	I-geneN-MU-2
-	I-geneN-MU-2
like	E-geneN-MU-2
and	O
5	B-geneN-MU-2
-	I-geneN-MU-2
HT2	I-geneN-MU-2
receptor	E-geneN-MU-2
antagonist	O
methiothepin	S-chem-C6-1
(	O
0.01	O
-	O
1	O
microM	O
)	O
.	O

It	O
is	O
concluded	O
that	O
D	B-chem-C3-1
-	I-chem-C3-1
1997	E-chem-C3-1
contracts	O
the	O
canine	O
basilar	O
artery	O
by	O
stimulating	O
5	B-geneN-C3-2
-	I-geneN-C3-2
HT1	I-geneN-C3-2
-	I-geneN-C3-2
like	I-geneN-C3-2
receptors	E-geneN-C3-2
unrelated	O
to	O
either	O
the	O
5	B-geneY-C3-2
-	I-geneY-C3-2
HT1A	E-geneY-C3-2
or	O
5	B-geneY-C3-2
-	I-geneY-C3-2
HT1B	E-geneY-C3-2
receptor	O
subtypes	O
.	O

The	O
compound	O
seems	O
to	O
be	O
devoid	O
of	O
5	B-geneN
-	I-geneN
HT2	I-geneN
receptor	E-geneN
agonist	O
properties	O
in	O
rat	O
aorta	O
.	O

Searching	O
for	O
preventive	O
measures	O
of	O
cardiovascular	O
events	O
in	O
aged	O
Japanese	O
taxi	O
drivers	O
-	O
-	O
the	O
daily	O
rhythm	O
of	O
cardiovascular	O
risk	O
factors	O
during	O
a	O
night	O
duty	O
day	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
Japanese	O
taxi	O
drivers	O
are	O
exposed	O
to	O
more	O
risk	O
factors	O
and	O
have	O
a	O
higher	O
mortality	O
rate	O
due	O
to	O
cardiovascular	O
disease	O
than	O
other	O
occupational	O
groups	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
night	O
taxi	O
driving	O
with	O
a	O
view	O
to	O
preventing	O
acute	O
events	O
of	O
cardiovascular	O
disease	O
among	O
aged	O
taxi	O
drivers	O
.	O

Twenty	O
-	O
nine	O
taxi	O
drivers	O
(	O
41	O
-	O
67	O
years	O
old	O
)	O
were	O
examined	O
for	O
urine	O
normetanephrine	S-chem
/	O
creatinine	S-chem
,	O
von	B-geneY
Willebrand	I-geneY
factor	E-geneY
,	O
anti	B-geneY
-	I-geneY
thrombin	I-geneY
III	E-geneY
,	O
t	B-geneY
-	I-geneY
plasminogen	I-geneY
activator	E-geneY
-	O
plasminogen	B-geneY
activator	I-geneY
inhibitor	I-geneY
1	E-geneY
-	O
complex	O
,	O
hematocrit	O
,	O
blood	O
glucose	S-chem
and	O
blood	O
pressure	O
in	O
the	O
morning	O
and	O
at	O
midnight	O
during	O
a	O
duty	O
day	O
and	O
in	O
the	O
following	O
morning	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
blood	O
pressure	O
and	O
blood	O
glucose	S-chem
of	O
46	O
taxi	O
drivers	O
(	O
43	O
-	O
67	O
years	O
old	O
)	O
in	O
the	O
morning	O
after	O
a	O
night	O
duty	O
with	O
little	O
sleep	O
and	O
in	O
the	O
morning	O
after	O
daytime	O
work	O
and	O
subsequent	O
night	O
sleep	O
were	O
compared	O
.	O

The	O
results	O
obtained	O
indicate	O
that	O
the	O
aggravation	O
of	O
sympathetic	O
nervous	O
system	O
functions	O
with	O
disturbed	O
circadian	O
rhythms	O
,	O
increased	O
blood	O
coagulation	O
and	O
blood	O
concentration	O
,	O
endothelial	O
injury	O
and	O
the	O
elevation	O
of	O
blood	O
glucose	O
at	O
midnight	O
or	O
the	O
next	O
morning	O
were	O
induced	O
by	O
their	O
night	O
work	O
.	O

These	O
conditions	O
are	O
supposed	O
to	O
favour	O
acute	O
vascular	O
events	O
in	O
aged	O
taxi	O
drivers	O
.	O

Preventive	O
measures	O
considered	O
include	O
social	O
support	O
for	O
anticoagulant	O
food	O
and	O
water	O
intake	O
,	O
short	O
exercise	O
and	O
walking	O
as	O
well	O
as	O
taking	O
a	O
rest	O
and	O
a	O
nap	O
during	O
night	O
work	O
.	O

Protective	O
effect	O
of	O
vitamin	B-chem
E	E-chem
and	O
epicatechin	S-chem
against	O
nicotine	S-chem
-	O
induced	O
oxidative	O
stress	O
in	O
rats	O
.	O

Nicotine	S-chem
is	O
a	O
major	O
pharmacologically	O
active	O
and	O
addictive	O
component	O
of	O
tobacco	O
smoke	O
,	O
which	O
is	O
regarded	O
to	O
be	O
a	O
primary	O
risk	O
factor	O
in	O
the	O
development	O
of	O
cardiovascular	O
and	O
pulmonary	O
diseases	O
.	O

Epicatechin	S-chem
is	O
one	O
of	O
the	O
most	O
potent	O
antioxidants	O
present	O
in	O
the	O
human	O
diet	O
.	O

Particularly	O
high	O
levels	O
of	O
this	O
compound	O
are	O
found	O
in	O
tea	O
,	O
apples	O
and	O
chocolate	O
.	O

It	O
has	O
been	O
reported	O
that	O
tea	O
extracts	O
and	O
/	O
or	O
its	O
constituents	O
have	O
antibacterial	O
,	O
antiviral	O
,	O
antioxidative	O
,	O
antitumor	O
and	O
antimutagenic	O
activities	O
.	O

Vitamin	B-chem
E	E-chem
is	O
a	O
major	O
lipid	O
-	O
soluble	O
antioxidant	O
vitamin	O
and	O
free	O
radical	O
scavenger	O
,	O
presents	O
as	O
an	O
integral	O
component	O
of	O
cellular	O
membranes	O
and	O
has	O
important	O
biological	O
functions	O
.	O

The	O
primary	O
mechanism	O
by	O
which	O
vitamin	B-chem
E	E-chem
is	O
proposed	O
to	O
prevent	O
cancer	O
is	O
through	O
their	O
antioxidant	O
properties	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effect	O
of	O
epicatechin	S-chem
alone	O
or	O
combined	O
with	O
vitamin	B-chem
E	E-chem
in	O
inhibiting	O
the	O
oxidative	O
stress	O
induced	O
by	O
nicotine	S-chem
in	O
rats	O
.	O

Results	O
obtained	O
indicated	O
that	O
there	O
was	O
a	O
significant	O
elevation	O
in	O
the	O
levels	O
of	O
malondialdhyde	S-chem
(	O
MDA	S-chem
)	O
in	O
nicotine	S-chem
injected	O
rats	O
.	O

The	O
combined	O
treatment	O
(	O
epicatechin	S-chem
+	O
Vit	B-chem
E	E-chem
)	O
group	O
showed	O
a	O
potential	O
reduction	O
of	O
these	O
parameters	O
more	O
than	O
individual	O
treatment	O
.	O

The	O
activities	O
of	O
superoxide	B-geneN
dismutase	E-geneN
,	O
catalase	S-geneY
and	O
glutathione	B-geneN
peroxidase	E-geneN
were	O
found	O
significantly	O
higher	O
in	O
combined	O
treated	O
than	O
untreated	O
rats	O
.	O

In	O
nicotine	S-chem
group	O
,	O
a	O
negative	O
significant	O
correlation	O
between	O
reduced	O
glutathione	S-chem
and	O
MDA	S-chem
(	O
r	O
=	O
-	O
0.92	O
)	O
was	O
observed	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggested	O
that	O
the	O
supplementation	O
of	O
diet	O
with	O
epicatechin	S-chem
and	O
vitamin	B-chem
E	E-chem
provided	O
antioxidant	O
defense	O
with	O
strong	O
chemopreventive	O
activity	O
against	O
nicotine	S-chem
-	O
induced	O
carcinogenesis	O
.	O

Phenserine	S-chem
.	O

Phenserine	S-chem-C4-1
,	O
a	O
derivative	O
of	O
physostigmine	S-chem-C4-1
,	O
was	O
first	O
described	O
as	O
an	O
inhibitor	O
of	O
acetylcholinesterase	S-geneN-C4-2
(	O
AChE	S-geneN-C4-2
)	O
and	O
was	O
shown	O
to	O
improve	O
cognition	O
in	O
various	O
experimental	O
paradigms	O
in	O
rodents	O
and	O
dogs	O
.	O

It	O
was	O
clinically	O
tested	O
for	O
Alzheimer	O
's	O
disease	O
,	O
with	O
moderate	O
success	O
in	O
initial	O
Phase	O
II	O
studies	O
.	O

Phenserine	S-chem-C4-1
deserves	O
attention	O
for	O
an	O
additional	O
quality	O
of	O
action	O
:	O
in	O
addition	O
to	O
inhibiting	O
AChE	S-geneY-C4-2
,	O
it	O
modulates	O
the	O
amount	O
of	O
beta	B-geneY
-	I-geneY
amyloid	I-geneY
precursor	I-geneY
protein	E-geneY
(	O
APP	S-geneY
)	O
in	O
neuronal	O
cell	O
culture	O
by	O
reducing	O
APP	S-geneY-C4-2
translation	O
.	O

This	O
effect	O
probably	O
involves	O
interaction	O
of	O
phenserine	S-chem
with	O
a	O
regulatory	O
element	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
APP	S-geneY
gene	O
that	O
controls	O
APP	S-geneY
expression	O
.	O

Phenserine	S-chem-C4-1
apparently	O
reduces	O
translational	O
efficiency	O
of	O
APP	S-geneY-C4-2
mRNA	O
into	O
protein	O
,	O
a	O
process	O
that	O
may	O
involve	O
an	O
interaction	O
with	O
iron	S-chem
and	O
/	O
or	O
an	O
iron	S-chem
-	O
responsive	O
element	O
.	O

As	O
a	O
consequence	O
,	O
phenserine	S-chem-C4-1
reduces	O
beta	B-geneY-C4-2
-	I-geneY-C4-2
amyloid	E-geneY-C4-2
peptide	O
(	O
Abeta	S-geneY-C4-2
)	O
formation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Phenserine	S-chem
is	O
also	O
unique	O
because	O
of	O
differing	O
actions	O
of	O
its	O
enantiomers	O
:	O
(	B-chem-C4-1
-	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
phenserine	E-chem-C4-1
is	O
the	O
active	O
enantiomer	O
for	O
inhibition	O
of	O
AChE	S-geneY-C4-2
,	O
whereas	O
(	B-chem-C4-1
+	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
phenserine	E-chem-C4-1
(	O
'	O
posiphen	S-chem-C4-1
'	O
)	O
has	O
weak	O
activity	O
as	O
an	O
AChE	S-geneY-C4-2
inhibitor	O
and	O
can	O
be	O
dosed	O
much	O
higher	O
.	O

Both	O
enantiomers	O
are	O
equipotent	O
in	O
downregulating	O
APP	S-geneY
expression	O
.	O

(	B-chem
+	I-chem
)	I-chem
-	I-chem
Posiphen	E-chem
may	O
be	O
a	O
promising	O
drug	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
phenserine	E-chem
,	O
to	O
attenuate	O
the	O
progression	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Arsenic	S-chem-C3-1
upregulates	O
the	O
expression	O
of	O
angiotensin	B-geneN-C3-2
II	I-geneN-C3-2
Type	I-geneN-C3-2
I	I-geneN-C3-2
receptor	E-geneN-C3-2
in	O
mouse	O
aortic	O
endothelial	O
cells	O
.	O

Although	O
chronic	O
arsenic	S-chem
exposure	O
is	O
a	O
well	O
-	O
known	O
risk	O
for	O
cardiovascular	O
disease	O
and	O
has	O
a	O
strong	O
correlation	O
with	O
hypertension	O
,	O
the	O
molecular	O
pathogenesis	O
underlying	O
arsenic	S-chem
exposure	O
-	O
induced	O
hypertension	O
remains	O
poorly	O
understood	O
.	O

To	O
delineate	O
the	O
pathogenesis	O
,	O
we	O
examined	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
2	O
angiotensin	B-geneN
II	I-geneN
Type	I-geneN
I	I-geneN
receptor	E-geneN
(	O
AT1R	S-geneN
)	O
subtypes	O
,	O
AT1AR	S-geneY
and	O
AT1BR	S-geneY
,	O
in	O
a	O
mouse	O
aortic	O
endothelial	O
cell	O
line	O
,	O
END	O
-	O
D	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
revealed	O
significant	O
increases	O
in	O
the	O
mRNA	O
levels	O
of	O
2	O
AT1R	S-geneN-C3-2
subtypes	O
,	O
AT1AR	S-geneY-C3-2
and	O
AT1BR	S-geneY-C3-2
following	O
sodium	B-chem-C3-1
arsenite	E-chem-C3-1
(	O
SA	O
)	O
treatment	O
.	O

Flow	O
cytometry	O
analysis	O
revealed	O
that	O
SA	O
increases	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
western	O
blot	O
analysis	O
revealed	O
that	O
SA	O
enhances	O
the	O
phosphorylations	O
of	O
c	B-geneN
-	I-geneN
Jun	I-geneN
N	I-geneN
-	I-geneN
terminal	I-geneN
kinases	E-geneN
(	O
JNK	S-geneN
)	O
and	O
activated	B-geneY
protein	I-geneY
1	E-geneY
(	O
AP	B-geneY
-	I-geneY
1	E-geneY
)	O
.	O

These	O
phosphorylations	O
were	O
inhibited	O
by	O
N	B-chem
-	I-chem
acetylcysteine	E-chem
(	O
NAC	S-chem
)	O
,	O
an	O
anti	O
-	O
oxidant	O
.	O

Finally	O
,	O
SA	O
-	O
induced	O
AT1R	S-geneN-C4-2
expression	O
was	O
found	O
to	O
be	O
prevented	O
both	O
by	O
NAC	O
and	O
specific	O
JNK	S-geneN-C4-2
inhibitor	O
,	O
SP6001325	S-chem-C4-1
,	O
strongly	O
indicating	O
that	O
AT1R	S-geneN
upregulation	O
is	O
a	O
result	O
of	O
the	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
JNK	S-geneN
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
arsenic	S-chem-C3-1
indeed	O
upregulates	O
the	O
AT1R	S-geneN-C3-2
expression	O
,	O
thus	O
highlighting	O
a	O
role	O
of	O
arsenic	S-chem-C3-1
-	O
induced	O
aberrant	O
AT1R	S-geneN-C3-2
signaling	O
in	O
the	O
pathogenesis	O
of	O
hypertension	O
.	O

Effects	O
of	O
carvedilol	S-chem
on	O
plasma	B-geneY
B	I-geneY
-	I-geneY
type	I-geneY
natriuretic	I-geneY
peptide	E-geneY
concentration	O
and	O
symptoms	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
preserved	O
ejection	O
fraction	O
.	O

Although	O
the	O
benefits	O
of	O
carvedilol	S-chem
in	O
patients	O
with	O
heart	O
failure	O
and	O
depressed	O
ejection	O
fraction	O
(	O
EF	O
)	O
have	O
been	O
elucidated	O
,	O
those	O
in	O
patients	O
with	O
preserved	O
EF	O
are	O
not	O
understood	O
.	O

We	O
enrolled	O
40	O
patients	O
with	O
mild	O
or	O
moderate	O
heart	O
failure	O
and	O
EF	O
>	O
/	O
=	O
45	O
%	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
carvedilol	S-chem
(	O
n	O
=	O
19	O
)	O
or	O
conventional	O
therapy	O
(	O
n	O
=	O
21	O
)	O
.	O

After	O
12	O
months	O
of	O
treatment	O
,	O
carvedilol	S-chem-C4-1
significantly	O
improved	O
all	O
end	O
points	O
(	O
plasma	O
concentration	O
of	O
B	B-geneY-C4-2
-	I-geneY-C4-2
type	I-geneY-C4-2
natriuretic	I-geneY-C4-2
peptide	E-geneY-C4-2
[	O
BNP	S-geneY-C4-2
]	O
from	O
175	O
(	O
35	O
to	O
209	O
)	O
to	O
106	O
(	O
52	O
to	O
160	O
)	O
pg	O
/	O
ml	O
,	O
mean	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
p	O
<	O
0.01	O
;	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
from	O
2.37	O
(	O
2.13	O
to	O
2.61	O
)	O
to	O
1.56	O
(	O
1.21	O
to	O
1.91	O
)	O
,	O
p	O
<	O
0.01	O
;	O
exercise	O
capacity	O
estimated	O
with	O
the	O
Specific	O
Activity	O
Scale	O
from	O
4.75	O
(	O
4.50	O
to	O
5.00	O
)	O
to	O
5.68	O
(	O
5.22	O
to	O
6.14	O
)	O
METs	O
,	O
p	O
<	O
0.02	O
)	O
,	O
whereas	O
conventional	O
therapy	O
did	O
not	O
(	O
plasma	B-geneY
BNP	E-geneY
concentration	O
from	O
150	O
(	O
114	O
to	O
186	O
)	O
to	O
174	O
(	O
100	O
to	O
248	O
)	O
pg	O
/	O
ml	O
;	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
from	O
2.29	O
(	O
2.08	O
to	O
2.50	O
)	O
to	O
2.11	O
(	O
1.73	O
to	O
2.49	O
)	O
;	O
exercise	O
capacity	O
from	O
4.57	O
(	O
4.34	O
to	O
4.80	O
)	O
to	O
4.72	O
(	O
4.41	O
to	O
5.03	O
)	O
METs	O
)	O
.	O

Univariate	O
regression	O
analyses	O
showed	O
that	O
only	O
the	O
use	O
of	O
carvedilol	S-chem-C4-1
was	O
correlated	O
with	O
the	O
decrease	O
in	O
plasma	B-geneY-C4-2
BNP	E-geneY-C4-2
concentration	O
(	O
p	O
<	O
0.03	O
)	O
.	O

Multivariate	O
analyses	O
demonstrated	O
that	O
an	O
ischemic	O
cause	O
of	O
heart	O
failure	O
(	O
p	O
<	O
0.02	O
)	O
,	O
high	O
plasma	O
concentration	O
of	O
BNP	S-geneY
(	O
p	O
<	O
0.02	O
)	O
,	O
left	O
ventricular	O
dilation	O
(	O
p	O
<	O
0.03	O
)	O
,	O
and	O
use	O
of	O
carvedilol	S-chem
(	O
p	O
<	O
0.04	O
)	O
at	O
baseline	O
were	O
predictive	O
of	O
a	O
decrease	O
in	O
plasma	O
concentration	O
of	O
BNP	S-geneY
.	O

In	O
conclusion	O
,	O
carvedilol	S-chem
potentially	O
decreased	O
neurohumoral	O
activation	O
,	O
decreased	O
symptoms	O
,	O
and	O
increased	O
exercise	O
capacity	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
preserved	O
EF	O
.	O

Exogenous	O
C2	B-chem-C3-1
-	I-chem-C3-1
ceramide	E-chem-C3-1
activates	O
c	B-geneN-C3-2
-	I-geneN-C3-2
fos	I-geneN-C3-2
serum	I-geneN-C3-2
response	I-geneN-C3-2
element	E-geneN-C3-2
via	O
Rac	S-geneN
-	O
dependent	O
signalling	O
pathway	O
.	O

Ceramide	S-chem
is	O
an	O
important	O
regulatory	O
molecule	O
implicated	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
in	O
response	O
to	O
stress	O
and	O
cytokines	S-geneN
.	O

To	O
understand	O
the	O
signal	O
transduction	O
pathway	O
of	O
ceramide	S-chem
to	O
the	O
nucleus	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
C2	B-chem
-	I-chem
ceramide	E-chem
,	O
a	O
cell	O
permeable	O
ceramide	S-chem
,	O
activates	O
c	B-geneN
-	I-geneN
fos	I-geneN
serum	I-geneN
response	I-geneN
element	E-geneN
(	O
SRE	S-geneN
)	O
.	O

Treatment	O
of	O
Rat	O
-	O
2	O
fibroblast	O
cells	O
with	O
C2	B-chem-C3-1
-	I-chem-C3-1
ceramide	E-chem-C3-1
caused	O
the	O
stimulation	O
of	O
c	B-geneN-C3-2
-	I-geneN-C3-2
fos	I-geneN-C3-2
SRE	E-geneN-C3-2
-	O
dependent	O
reporter	O
gene	O
activity	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
by	O
transient	O
transfection	O
analysis	O
.	O

Next	O
,	O
we	O
examined	O
the	O
role	O
of	O
Rho	S-geneN
family	O
GTPases	S-geneN
in	O
the	O
ceramide	S-chem-C3-1
-	O
induced	O
signalling	O
to	O
SRE	S-geneN-C3-2
activation	O
.	O

By	O
reporter	O
gene	O
analysis	O
following	O
transient	O
transfections	O
with	O
various	O
plasmids	O
expressing	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
Cdc42	S-geneY
,	O
Rac1	S-geneY
or	O
RhoA	S-geneY
,	O
C2	B-chem-C3-1
-	I-chem-C3-1
ceramide	E-chem-C3-1
-	O
induced	O
SRE	S-geneN-C3-2
activation	O
was	O
shown	O
to	O
be	O
selectively	O
repressed	O
by	O
pEXV	O
-	O
RacN17	O
encoding	O
a	O
dominant	O
negative	O
mutant	O
of	O
Rac1	S-geneY
,	O
suggesting	O
that	O
Rac	S-geneN
activity	O
is	O
essential	O
for	O
the	O
signalling	O
cascade	O
of	O
ceramide	S-chem
to	O
the	O
nucleus	O
.	O

In	O
a	O
further	O
study	O
to	O
analyse	O
the	O
downstream	O
mediator	O
of	O
Rac	S-geneN
in	O
the	O
ceramide	S-chem
-	O
signalling	O
pathway	O
,	O
we	O
observed	O
that	O
either	O
pretreatment	O
with	O
mepacrine	S-chem
,	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
phospholipase	O
A2	O
,	O
or	O
co	O
-	O
transfection	O
with	O
antisense	O
cytosolic	B-geneY
phospholipase	I-geneY
A2	E-geneY
(	O
cPLA2	S-geneY
)	O
oligonucleotide	O
repressed	O
the	O
C2	B-chem-C3-1
-	I-chem-C3-1
ceramide	E-chem-C3-1
-	O
induced	O
SRE	S-geneN-C3-2
activation	O
selectively	O
,	O
implying	O
a	O
critical	O
role	O
of	O
cPLA2	S-geneY
in	O
C2	B-chem
-	I-chem
ceramide	E-chem
-	O
induced	O
signalling	O
to	O
nucleus	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
translocation	O
of	O
cPLA2	S-geneY
protein	O
as	O
well	O
as	O
the	O
release	O
of	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
,	O
a	O
principal	O
product	O
of	O
phospholipase	B-geneY-C9-2
A2	E-geneY-C9-2
,	O
was	O
rapidly	O
induced	O
by	O
the	O
addition	O
of	O
C2	B-chem
-	I-chem
ceramide	E-chem
in	O
a	O
Rac	S-geneN
-	O
dependent	O
manner	O
.	O

Together	O
,	O
our	O
findings	O
suggest	O
the	O
critical	O
role	O
of	O
'	O
Rac	S-geneN
and	O
subsequent	O
activation	O
of	O
phospholipase	B-geneY-C3-2
A2	E-geneY-C3-2
'	O
in	O
ceramide	S-chem-C3-1
-	O
signalling	O
to	O
nucleus	O
.	O

The	O
effect	O
of	O
inorganic	O
arsenic	S-chem
on	O
endothelium	O
-	O
dependent	O
relaxation	O
:	O
Role	O
of	O
NADPH	B-geneN
oxidase	E-geneN
and	O
hydrogen	B-chem
peroxide	E-chem
.	O

Chronic	O
arsenic	S-chem
ingestion	O
predisposes	O
to	O
vascular	O
disease	O
,	O
but	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
effects	O
of	O
short	O
-	O
term	O
arsenite	S-chem
exposure	O
on	O
vascular	O
function	O
and	O
endothelium	O
-	O
dependent	O
relaxation	O
.	O

Endothelium	O
-	O
dependent	O
relaxations	O
,	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
and	O
endothelium	O
derived	O
hyperpolarizing	O
factor	O
(	O
EDHF	O
)	O
-	O
type	O
,	O
were	O
studied	O
in	O
rabbit	O
iliac	O
artery	O
and	O
aortic	O
rings	O
using	O
the	O
G	B-geneN-C5-2
protein	I-geneN-C5-2
-	I-geneN-C5-2
coupled	I-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
acetylcholine	S-chem-C5-1
(	O
ACh	S-chem-C5-1
)	O
and	O
by	O
cyclopiazonic	B-chem-C4-1
acid	E-chem-C4-1
(	O
CPA	S-chem-C4-1
)	O
,	O
which	O
promotes	O
store	O
-	O
operated	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
entry	O
by	O
inhibiting	O
the	O
endothelial	O
SERCA	S-geneN-C4-2
pump	O
.	O

Production	O
of	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
in	O
the	O
endothelium	O
of	O
rabbit	O
aortic	O
valve	O
leaflets	O
and	O
endothelium	O
-	O
denuded	O
RIA	O
and	O
aortic	O
rings	O
was	O
assessed	O
by	O
imaging	O
of	O
dihydroethidium	S-chem
.	O

In	O
the	O
iliac	O
artery	O
,	O
exposure	O
to	O
100μM	O
arsenite	S-chem
for	O
30min	O
potentiated	O
EDHF	O
-	O
type	O
relaxations	O
evoked	O
by	O
both	O
CPA	S-chem
and	O
ACh	S-chem
.	O

Potentiation	O
was	O
prevented	O
by	O
catalase	S-geneY
,	O
the	O
catalase	S-geneY
/	O
superoxide	B-geneN
dismutase	E-geneN
mimetic	O
manganese	B-chem
porphyrin	E-chem
and	O
the	O
NADPH	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitor	O
apocynin	S-chem-C4-1
.	O

By	O
contrast	O
in	O
aortic	O
rings	O
,	O
that	O
exhibited	O
negligible	O
EDHF	O
-	O
type	O
responses	O
,	O
endothelium	O
-	O
dependent	O
NO	S-chem
-	O
mediated	O
relaxations	O
evoked	O
by	O
CPA	S-chem
and	O
ACh	S-chem
were	O
unaffected	O
by	O
arsenite	S-chem
.	O

Arsenite	S-chem
induced	O
apocynin	S-chem
-	O
sensitive	O
increases	O
in	O
ROS	O
production	O
in	O
the	O
aortic	O
valve	O
endothelium	O
,	O
but	O
not	O
in	O
the	O
media	O
and	O
adventitia	O
of	O
the	O
iliac	O
artery	O
and	O
aorta	O
.	O

Our	O
results	O
suggest	O
that	O
arsenite	S-chem
can	O
potentiate	O
EDHF	O
-	O
type	O
relaxations	O
via	O
a	O
mechanism	O
that	O
is	O
dependent	O
on	O
hydrogen	B-chem
peroxide	E-chem
,	O
thus	O
demonstrating	O
that	O
dismutation	O
of	O
the	O
superoxide	S-chem-C9-1
anion	O
generated	O
by	O
NADPH	B-geneN-C9-2
oxidase	E-geneN-C9-2
can	O
potentially	O
offset	O
loss	O
of	O
NO	S-chem
bioavailability	O
under	O
conditions	O
of	O
reduced	O
eNOS	S-geneY
activity	O
.	O

By	O
contrast	O
,	O
selective	O
increases	O
in	O
endothelial	O
ROS	O
production	O
following	O
exposure	O
to	O
arsenite	S-chem
failed	O
to	O
modify	O
relaxations	O
mediated	O
by	O
endogenous	O
NO	S-chem
.	O

In	O
vitro	O
investigation	O
of	O
efficacy	O
of	O
new	O
reactivators	O
on	O
OPC	O
inhibited	O
rat	B-geneY
brain	I-geneY
acetylcholinesterase	E-geneY
.	O

Organophosphorus	S-chem
compounds	O
(	O
OPC	O
)	O
were	O
developed	O
as	O
warfare	O
nerve	O
agents	O
.	O

They	O
are	O
also	O
widely	O
used	O
as	O
pesticides	O
.	O

The	O
drug	O
therapy	O
of	O
intoxication	O
with	O
OPC	O
includes	O
mainly	O
combination	O
of	O
cholinesterase	S-geneY
(	O
ChE	S-geneY
)	O
reactivators	O
and	O
cholinolytics	O
.	O

There	O
is	O
no	O
single	O
ChE	S-geneY
reactivator	O
having	O
an	O
ability	O
to	O
reactivate	O
sufficiently	O
the	O
inhibited	O
enzyme	O
due	O
to	O
the	O
high	O
variability	O
of	O
chemical	O
structure	O
of	O
the	O
inhibitors	O
.	O

The	O
difficulties	O
in	O
reactivation	O
of	O
ChE	S-geneY
activity	O
and	O
slight	O
antidote	O
effect	O
regarding	O
intoxication	O
with	O
some	O
OPC	O
are	O
some	O
of	O
the	O
reasons	O
for	O
continuous	O
efforts	O
to	O
obtain	O
new	O
reactivators	O
of	O
ChE	S-geneY
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
some	O
ChE	S-geneY
reactivators	O
against	O
OPC	O
intoxication	O
(	O
tabun	S-chem
,	O
paraoxon	S-chem
and	O
dichlorvos	S-chem
)	O
in	O
in	O
vitro	O
experiments	O
and	O
to	O
compare	O
their	O
activity	O
to	O
that	O
known	O
for	O
some	O
currently	O
used	O
oximes	S-chem
(	O
obidoxime	S-chem
,	O
HI	B-chem
-	I-chem
6	E-chem
,	O
2	B-chem
-	I-chem
PAM	E-chem
)	O
.	O

Experiments	O
were	O
carried	O
out	O
using	O
rat	B-geneY
brain	I-geneY
acetylcholinesterase	E-geneY
(	O
AChE	S-geneY
)	O
.	O

Reactivators	O
showed	O
different	O
activity	O
in	O
the	O
reactivation	O
of	O
rat	B-geneY-C4-2
brain	I-geneY-C4-2
AChE	E-geneY-C4-2
after	O
dichlorvos	S-chem-C4-1
,	O
paraoxon	S-chem-C4-1
and	O
tabun	S-chem-C4-1
inhibition	O
.	O

AChE	S-geneY-C3-2
was	O
easier	O
reactivated	O
after	O
paraoxon	S-chem-C3-1
treatment	O
.	O

The	O
best	O
effect	O
showed	O
BT	B-chem
-	I-chem
07	I-chem
-	I-chem
4M	E-chem
,	O
obidoxime	S-chem
,	O
TMB	B-chem
-	I-chem
4	E-chem
and	O
BT	B-chem
-	I-chem
08	E-chem
from	O
the	O
group	O
of	O
symmetric	O
oximes	S-chem
,	O
and	O
Toxidin	S-chem
,	O
BT	B-chem
-	I-chem
05	E-chem
and	O
BT	B-chem
-	I-chem
03	E-chem
from	O
asymmetric	O
compounds	O
.	O

The	O
reactivation	O
of	O
brain	O
AChE	S-geneY-C3-2
inhibited	O
with	O
tabun	O
demonstrated	O
better	O
activity	O
of	O
new	O
compound	O
BT	B-chem-C3-1
-	I-chem-C3-1
07	I-chem-C3-1
-	I-chem-C3-1
4M	E-chem-C3-1
,	O
TMB	B-chem-C3-1
-	I-chem-C3-1
4	E-chem-C3-1
and	O
obidoxime	S-chem-C3-1
from	O
symmetric	O
oximes	S-chem-C3-1
,	O
and	O
BT	B-chem-C3-1
-	I-chem-C3-1
05	E-chem-C3-1
and	O
BT	B-chem-C3-1
-	I-chem-C3-1
03	E-chem-C3-1
possessing	O
asymmetric	O
structure	O
.	O

All	O
compounds	O
showed	O
low	O
activity	O
toward	O
inhibition	O
of	O
AChE	S-geneY-C4-2
caused	O
by	O
dichlorvos	S-chem-C4-1
.	O

Comparison	O
of	O
two	O
main	O
structure	O
types	O
(	O
symmetric	O
/	O
asymmetric	O
)	O
showed	O
that	O
the	O
symmetric	O
compounds	O
reactivated	O
better	O
AChE	S-geneY
,	O
inhibited	O
with	O
this	O
OPC	O
,	O
than	O
asymmetric	O
ones	O
.	O

Na	B-chem-C3-1
+	E-chem-C3-1
/	O
Cl	B-chem-C3-1
-	E-chem-C3-1
dipole	O
couples	O
agonist	O
binding	O
to	O
kainate	B-geneN-C3-2
receptor	E-geneN-C3-2
activation	O
.	O

Kainate	B-geneN-C3-2
-	I-geneN-C3-2
selective	I-geneN-C3-2
ionotropic	I-geneN-C3-2
glutamate	I-geneN-C3-2
receptors	E-geneN-C3-2
(	O
GluRs	S-geneN-C3-2
)	O
require	O
external	O
Na	B-chem-C3-1
+	E-chem-C3-1
and	O
Cl	B-chem-C3-1
-	E-chem-C3-1
as	O
well	O
as	O
the	O
neurotransmitter	O
L	B-chem-C3-1
-	I-chem-C3-1
glutamate	E-chem-C3-1
for	O
activation	O
.	O

Although	O
,	O
external	O
anions	O
and	O
cations	O
apparently	O
coactivate	O
kainate	B-geneN
receptors	E-geneN
(	O
KARs	S-geneN
)	O
in	O
an	O
identical	O
manner	O
,	O
it	O
has	O
yet	O
to	O
be	O
established	O
how	O
ions	O
of	O
opposite	O
charge	O
achieve	O
this	O
.	O

An	O
additional	O
complication	O
is	O
that	O
KARs	S-geneN
are	O
subject	O
to	O
other	O
forms	O
of	O
cation	O
modulation	O
via	O
extracellular	O
acidification	O
(	O
i.e	O
.	O
,	O
protons	O
)	O
and	O
divalent	O
ions	O
.	O

Consequently	O
,	O
other	O
cation	O
species	O
may	O
compete	O
with	O
Na	B-chem
+	E-chem
to	O
regulate	O
the	O
time	O
KARs	S-geneN
remain	O
in	O
the	O
open	O
state	O
.	O

Here	O
we	O
designed	O
experiments	O
to	O
unravel	O
how	O
external	O
ions	O
regulate	O
GluR6	S-geneN
KARs	S-geneN
.	O

We	O
show	O
that	O
GluR6	S-geneY
kinetics	O
are	O
unaffected	O
by	O
alterations	O
in	O
physiological	O
pH	O
but	O
that	O
divalent	O
and	O
alkali	O
metal	O
ions	O
compete	O
to	O
determine	O
the	O
time	O
course	O
of	O
KAR	B-geneN
channel	E-geneN
activity	O
.	O

Additionally	O
,	O
Na	B-chem-C3-1
+	E-chem-C3-1
and	O
Cl	B-chem-C3-1
-	E-chem-C3-1
ions	O
coactivate	O
GluR6	S-geneY-C3-2
receptors	O
by	O
establishing	O
a	O
dipole	O
,	O
accounting	O
for	O
their	O
common	O
effect	O
on	O
KARs	S-geneN
.	O

Using	O
charged	O
amino	B-chem
acids	E-chem
as	O
tethered	O
ions	O
,	O
we	O
further	O
demonstrate	O
that	O
the	O
docking	O
order	O
is	O
fixed	O
with	O
cations	O
binding	O
first	O
,	O
followed	O
by	O
anions	O
.	O

Together	O
,	O
our	O
findings	O
identify	O
the	O
dipole	O
as	O
a	O
novel	O
gating	O
feature	O
that	O
couples	O
neurotransmitter	O
binding	O
to	O
KAR	S-geneN
activation	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
1,3,4	B-chem-C4-1
-	I-chem-C4-1
thiadiazole	E-chem-C4-1
analogues	O
as	O
novel	O
AChE	S-geneY-C4-2
and	O
BuChE	S-geneY-C4-2
inhibitors	O
.	O

In	O
this	O
paper	O
a	O
series	O
of	O
new	O
1,3,4	B-chem-C4-1
-	I-chem-C4-1
thiadiazole	E-chem-C4-1
derivatives	O
has	O
been	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
as	O
the	O
acetyl	B-geneN-C4-2
-	I-geneN-C4-2
and	I-geneN-C4-2
butyrylcholinesterase	E-geneN-C4-2
inhibitors	O
.	O

Some	O
analogues	O
showed	O
promising	O
inhibition	O
of	O
both	O
enzymes	O
in	O
vitro	O
in	O
the	O
nM	O
range	O
.	O

Generally	O
,	O
inhibitory	O
potency	O
of	O
compounds	O
was	O
stronger	O
against	O
AChE	S-geneY
than	O
BuChE	S-geneY
,	O
and	O
one	O
of	O
them	O
was	O
1154	O
-	O
fold	O
more	O
active	O
inhibiting	O
AChE	S-geneY
(	O
IC50	O
=	O
0.17	O
μM	O
)	O
than	O
BuChE	O
.	I-geneY

The	O
kinetic	O
studies	O
showed	O
that	O
one	O
of	O
the	O
most	O
active	O
analogues	O
8	O
(	O
IC50	O
=	O
0.09	O
μM	O
,	O
AChE	O
)	I-geneY
acted	O
as	O
a	O
non	O
-	O
competitive	O
AChE	O
inhibitor	O
and	O
was	O
characterized	O
by	O
the	O
high	O
selectivity	O
index	O
(	O
300	O
)	O
.	O

The	O
other	O
derivative	O
(	O
1	O
)	O
exhibited	O
a	O
mixed	O
-	O
type	O
of	O
AChE	S-geneY
inhibition	O
.	O

Docking	O
simulations	O
enabled	O
the	O
detection	O
of	O
key	O
binding	O
interactions	O
of	O
the	O
compounds	O
with	O
AChE	S-geneY
and	O
revealed	O
that	O
they	O
occupied	O
mainly	O
the	O
catalytic	O
active	O
site	O
.	O

The	O
scoring	O
function	O
for	O
the	O
novel	O
compounds	O
was	O
similar	O
or	O
higher	O
than	O
for	O
the	O
reference	O
inhibitor	O
.	O

Additionally	O
,	O
based	O
on	O
Lipinski	O
and	O
other	O
filters	O
,	O
the	O
drug	O
-	O
likeness	O
of	O
compounds	O
was	O
assessed	O
.	O

They	O
revealed	O
that	O
the	O
compounds	O
possess	O
properties	O
which	O
can	O
suggest	O
the	O
favourable	O
pharmacokinetics	O
in	O
the	O
human	O
body	O
after	O
oral	O
admission	O
.	O

Inhibition	O
by	O
troglitazone	S-chem
of	O
the	O
antigen	O
-	O
induced	O
production	O
of	O
leukotrienes	S-chem
in	O
immunoglobulin	B-geneN
E	E-geneN
-	O
sensitized	O
RBL	O
-	O
2H3	O
cells	O
.	O

1	O
.	O

The	O
effect	O
of	O
troglitazone	S-chem
,	O
an	O
anti	O
-	O
diabetic	O
drug	O
with	O
insulin	S-geneN
-	O
sensitizing	O
action	O
,	O
on	O
antigen	O
-	O
induced	O
production	O
of	O
leukotriene	B-chem
(	I-chem
LT	I-chem
)	I-chem
B	I-chem
(	I-chem
4	I-chem
)	I-chem
,	I-chem
C	I-chem
(	I-chem
4	I-chem
)	I-chem
and	I-chem
E	I-chem
(	I-chem
4	I-chem
)	E-chem
and	O
prostaglandin	B-chem
D	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
PGD	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
was	O
examined	O
in	O
dinitrophenol	S-chem
(	O
DNP	S-chem
)	O
-	O
specific	O
immunoglobulin	B-geneN
E	E-geneN
(	O
IgE	S-geneN
)	O
-	O
sensitized	O
RBL	O
-	O
2H3	O
mast	O
cells	O
following	O
stimulation	O
by	O
the	O
antigen	O
,	O
DNP	S-chem
-	O
conjugated	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
.	O

Levels	O
of	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
,	O
C	O
(	O
4	O
)	O
and	O
E	O
(	O
4	O
)	O
and	O
PGD	B-chem
(	I-chem
2	I-chem
)	E-chem
in	O
the	O
conditioned	O
medium	O
were	O
enzyme	O
-	O
immunoassayed	O
.	O

2	O
.	O

Troglitazone	S-chem
inhibited	O
the	O
antigen	O
-	O
induced	O
production	O
of	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
,	O
C	O
(	O
4	O
)	O
and	O
E	O
(	O
4	O
)	O
and	O
the	O
potency	O
of	O
the	O
inhibition	O
was	O
comparable	O
to	O
that	O
of	O
zileuton	S-chem-C4-1
,	O
a	O
specific	O
inhibitor	O
of	O
5	B-geneY-C4-2
-	I-geneY-C4-2
lipoxygenase	E-geneY-C4-2
(	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
)	O
and	O
a	O
clinically	O
used	O
anti	O
-	O
asthmatic	O
drug	O
.	O

Neither	O
troglitazone	S-chem
nor	O
zileuton	S-chem
affected	O
antigen	O
-	O
induced	O
production	O
of	O
PGD	B-chem
(	I-chem
2	I-chem
)	E-chem
,	O
arachidonic	B-chem
acid	E-chem
release	O
from	O
membrane	O
phospholipids	O
and	O
degranulation	O
.	O

3	O
.	O

Troglitazone	S-chem
inhibited	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
production	O
by	O
the	O
supernatant	O
fraction	O
of	O
RBL	O
-	O
2H3	O
cell	O
lysate	O
with	O
similar	O
potency	O
to	O
zileuton	S-chem-C4-1
,	O
suggesting	O
that	O
troglitazone	S-chem-C4-1
inhibits	O
LT	O
production	O
by	O
direct	O
inhibition	O
of	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
activity	O
.	O

4	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
troglitazone	S-chem
as	O
well	O
as	O
zileuton	S-chem
inhibited	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
production	O
in	O
A23187	S-chem
-	O
stimulated	O
rat	O
peritoneal	O
neutrophils	O
.	O

5	O
.	O

These	O
findings	O
suggest	O
that	O
troglitazone	S-chem-C4-1
inhibits	O
antigen	O
-	O
induced	O
LT	O
production	O
in	O
the	O
IgE	S-geneN
-	O
sensitized	O
RBL	O
-	O
2H3	O
cells	O
and	O
A23187	S-chem
-	O
stimulated	O
rat	O
peritoneal	O
neutrophils	O
by	O
direct	O
inhibition	O
of	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
activity	O
.	O

Rapid	O
and	O
specific	O
purification	O
of	O
Argonaute	S-geneN
-	O
small	O
RNA	O
complexes	O
from	O
crude	O
cell	O
lysates	O
.	O

Small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
direct	O
Argonaute	S-geneN
proteins	O
,	O
the	O
core	O
components	O
of	O
the	O
RNA	B-geneN
-	I-geneN
induced	I-geneN
silencing	I-geneN
complex	E-geneN
(	O
RISC	S-geneN
)	O
,	O
to	O
cleave	O
complementary	O
target	O
RNAs	O
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
to	O
purify	O
active	O
RISC	S-geneN
containing	O
a	O
single	O
,	O
unique	O
small	O
RNA	O
guide	O
sequence	O
.	O

We	O
begin	O
by	O
capturing	O
RISC	S-geneN
using	O
a	O
complementary	O
2	B-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
methyl	E-chem
oligonucleotide	O
tethered	O
to	O
beads	O
.	O

Unlike	O
other	O
methods	O
that	O
capture	O
RISC	S-geneN
but	O
do	O
not	O
allow	O
its	O
recovery	O
,	O
our	O
strategy	O
purifies	O
active	O
,	O
soluble	O
RISC	S-geneN
in	O
good	O
yield	O
.	O

The	O
method	O
takes	O
advantage	O
of	O
the	O
finding	O
that	O
RISC	O
partially	O
paired	O
to	O
a	O
target	O
through	O
its	O
siRNA	O
guide	O
dissociates	O
more	O
than	O
300	O
times	O
faster	O
than	O
a	O
fully	O
paired	O
siRNA	O
in	O
RISC	S-geneN
.	O

We	O
use	O
this	O
strategy	O
to	O
purify	O
fly	B-geneY
Ago1	E-geneY
-	O
and	O
Ago2	B-geneY
-	I-geneY
RISC	E-geneY
,	O
as	O
well	O
as	O
mouse	B-geneY
AGO2	I-geneY
-	I-geneY
RISC	E-geneY
.	O

The	O
method	O
can	O
discriminate	O
among	O
RISCs	S-geneN
programmed	O
with	O
different	O
guide	O
strands	O
,	O
making	O
it	O
possible	O
to	O
deplete	O
and	O
recover	O
specific	O
RISC	S-geneN
populations	O
.	O

Endogenous	O
microRNA	O
:	O
Argonaute	S-geneN
complexes	O
can	O
also	O
be	O
purified	O
from	O
cell	O
lysates	O
.	O

Our	O
method	O
scales	O
readily	O
and	O
takes	O
less	O
than	O
a	O
day	O
to	O
complete	O
.	O

S	S-chem
-	O
nitrosation	O
of	O
glutathione	B-geneY
transferase	I-geneY
P1	I-geneY
-	I-geneY
1	E-geneY
is	O
controlled	O
by	O
the	O
conformation	O
of	O
a	O
dynamic	O
active	O
-	O
site	O
helix	O
.	O

S	S-chem
-	O
nitrosation	O
is	O
a	O
post	O
-	O
translational	O
modification	O
of	O
protein	O
cysteine	S-chem
residues	O
which	O
occurs	O
in	O
response	O
to	O
cellular	O
oxidative	O
stress	O
.	O

Although	O
it	O
is	O
increasingly	O
being	O
linked	O
to	O
physiologically	O
important	O
processes	O
,	O
the	O
molecular	O
basis	O
for	O
protein	O
regulation	O
by	O
this	O
modification	O
remains	O
poorly	O
understood	O
.	O

We	O
used	O
transient	O
kinetic	O
methods	O
to	O
determine	O
a	O
minimal	O
mechanism	O
for	O
spontaneous	O
GSNO	O
-	O
mediated	O
transnitrosation	O
of	O
human	B-geneY
glutathione	I-geneY
transferase	I-geneY
(	I-geneY
GST	I-geneY
)	I-geneY
P1	I-geneY
-	I-geneY
1	E-geneY
,	O
a	O
major	O
detoxification	O
enzyme	O
and	O
key	O
regulator	O
of	O
cell	O
proliferation	O
.	O

C47	O
of	O
GSTP1	B-geneY
-	I-geneY
1	E-geneY
is	O
S	S-chem
-	O
nitrosated	O
in	O
two	O
steps	O
,	O
with	O
the	O
chemical	O
step	O
limited	O
by	O
a	O
pre	O
-	O
equilibrium	O
between	O
the	O
open	O
and	O
closed	O
conformations	O
of	O
helix	O
α2	O
at	O
the	O
active	O
site	O
.	O

C101	O
,	O
in	O
contrast	O
,	O
is	O
S	S-chem
-	O
nitrosated	O
in	O
a	O
single	O
step	O
but	O
is	O
subject	O
to	O
negative	O
cooperativity	O
due	O
to	O
steric	O
hindrance	O
at	O
the	O
dimer	O
interface	O
.	O

Despite	O
the	O
presence	O
of	O
a	O
GSNO	B-geneN
binding	I-geneN
site	E-geneN
at	O
the	O
active	O
site	O
of	O
GSTP1	B-geneY
-	I-geneY
1	E-geneY
,	O
isothermal	O
titration	O
calorimetry	O
as	O
well	O
as	O
nitrosation	O
experiments	O
using	O
CysNO	S-chem
demonstrate	O
that	O
GSNO	O
binding	O
does	O
not	O
precede	O
S	S-chem
-	O
nitrosation	O
of	O
GSTP1	B-geneY
-	I-geneY
1	E-geneY
.	O

Kinetics	O
experiments	O
using	O
the	O
cellular	O
reductant	O
GSH	S-chem
show	O
that	O
C101	O
-	O
NO	S-chem
is	O
substantially	O
more	O
resistant	O
to	O
denitrosation	O
than	O
C47	O
-	O
NO	S-chem
,	O
suggesting	O
a	O
potential	O
role	O
for	O
C101	O
-	O
NO	S-chem
in	O
long	O
term	O
nitric	B-chem
oxide	E-chem
storage	O
or	O
transfer	O
.	O

These	O
results	O
constitute	O
the	O
first	O
report	O
of	O
the	O
molecular	O
mechanism	O
of	O
spontaneous	O
protein	O
transnitrosation	O
,	O
providing	O
insight	O
into	O
the	O
post	O
-	O
translational	O
control	O
of	O
GSTP1	B-geneY
-	I-geneY
1	E-geneY
as	O
well	O
as	O
the	O
process	O
of	O
protein	O
transnitrosation	O
in	O
general	O
.	O

Purification	O
and	O
multimeric	O
structure	O
of	O
bovine	O
N	B-geneY
-	I-geneY
acetylglucosamine	I-geneY
-	I-geneY
1	I-geneY
-	I-geneY
phosphodiester	I-geneY
alpha	I-geneY
-	I-geneY
N	I-geneY
-	I-geneY
acetylglucosaminidase	E-geneY
.	O

N	B-geneY-C9-2
-	I-geneY-C9-2
Acetylglucosamine	I-geneY-C9-2
-	I-geneY-C9-2
1	I-geneY-C9-2
-	I-geneY-C9-2
phosphodiester	I-geneY-C9-2
alpha	I-geneY-C9-2
-	I-geneY-C9-2
N	I-geneY-C9-2
-	I-geneY-C9-2
Acetylglucosaminidase	E-geneY-C9-2
(	O
EC	B-geneY-C9-2
3.1.4.45	E-geneY-C9-2
;	O
phosphodiester	B-geneY-C9-2
alpha	I-geneY-C9-2
-	I-geneY-C9-2
GlcNAcase	E-geneY-C9-2
)	O
catalyzes	O
the	O
second	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
mannose	B-chem-C9-1
6	I-chem-C9-1
-	I-chem-C9-1
phosphate	E-chem-C9-1
determinant	O
required	O
for	O
efficient	O
intracellular	O
targeting	O
of	O
newly	O
synthesized	O
lysosomal	O
hydrolases	O
to	O
the	O
lysosome	O
.	O

A	O
partially	O
purified	O
preparation	O
of	O
phosphodiester	B-geneY
alpha	I-geneY
-	I-geneY
GlcNAcase	E-geneY
from	O
bovine	O
pancreas	O
was	O
used	O
to	O
generate	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
.	O

The	O
anti	O
-	O
phosphodiester	B-geneY
alpha	I-geneY
-	I-geneY
GlcNAcase	E-geneY
monoclonal	O
antibody	O
UC1	O
was	O
coupled	O
to	O
a	O
solid	O
support	O
and	O
used	O
to	O
immunopurify	O
the	O
bovine	O
liver	O
enzyme	O
670,000	O
-	O
fold	O
in	O
two	O
steps	O
to	O
apparent	O
homogeneity	O
with	O
an	O
overall	O
yield	O
of	O
14	O
%	O
.	O

The	O
purified	O
phosphodiester	B-geneY-C9-2
alpha	I-geneY-C9-2
-	I-geneY-C9-2
GlcNAcase	E-geneY-C9-2
has	O
a	O
specific	O
activity	O
of	O
498	O
micromol	O
of	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
GlcNAc	I-chem-C9-1
-	I-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
phosphomannose	I-chem-C9-1
-	I-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
methyl	E-chem-C9-1
cleaved	O
per	O
h	O
per	O
mg	O
of	O
protein	O
using	O
0.5	O
mM	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
GlcNAc	I-chem-C9-1
-	I-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
phosphomannose	I-chem-C9-1
-	I-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
methyl	E-chem-C9-1
as	O
substrate	O
.	O

The	O
subunit	O
structure	O
of	O
the	O
enzyme	O
was	O
determined	O
using	O
a	O
combination	O
of	O
analytical	O
gel	O
filtration	O
chromatography	O
,	O
SDS	S-chem
-	O
polyacrylamide	S-chem
gel	O
electrophoresis	O
,	O
and	O
amino	O
-	O
terminal	O
sequencing	O
.	O

The	O
data	O
indicate	O
that	O
bovine	O
phosphodiester	B-geneY
alpha	I-geneY
-	I-geneY
GlcNAcase	E-geneY
is	O
a	O
272,000	O
-	O
Da	O
complex	O
of	O
four	O
identical	O
68,000	O
-	O
Da	O
glycoprotein	O
subunits	O
arranged	O
as	O
two	O
disulfide	S-chem
-	O
linked	O
homodimers	O
.	O

A	O
soluble	O
form	O
of	O
the	O
enzyme	O
,	O
isolated	O
from	O
fetal	O
bovine	O
serum	O
,	O
showed	O
the	O
same	O
subunit	O
structure	O
.	O

Both	O
forms	O
of	O
the	O
enzyme	O
reacted	O
with	O
a	O
rabbit	O
antibody	O
raised	O
to	O
the	O
amino	S-chem
-	O
terminal	O
peptide	O
of	O
the	O
liver	O
enzyme	O
,	O
suggesting	O
that	O
phosphodiester	B-geneY
alpha	I-geneY
-	I-geneY
GlcNAcase	E-geneY
is	O
a	O
type	B-geneN
I	I-geneN
membrane	I-geneN
-	I-geneN
spanning	I-geneN
glycoprotein	E-geneN
with	O
its	O
amino	S-chem
terminus	O
in	O
the	O
lumen	O
of	O
the	O
Golgi	O
apparatus	O
.	O

Fisetin	S-chem
regulates	O
obesity	O
by	O
targeting	O
mTORC1	S-geneN
signaling	O
.	O

Fisetin	S-chem
,	O
a	O
flavonol	S-chem
present	O
in	O
vegetables	O
and	O
fruits	O
,	O
possesses	O
antioxidative	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
fisetin	S-chem
prevents	O
diet	O
-	O
induced	O
obesity	O
through	O
regulation	O
of	O
the	O
signaling	O
of	O
mammalian	B-geneN
target	I-geneN
of	I-geneN
rapamycin	I-geneN
complex	I-geneN
1	E-geneN
(	O
mTORC1	S-geneN
)	O
,	O
a	O
central	O
mediator	O
of	O
cellular	O
growth	O
,	O
cellular	O
proliferation	O
and	O
lipid	O
biosynthesis	O
.	O

To	O
evaluate	O
whether	O
fisetin	S-chem
regulates	O
mTORC1	S-geneN
signaling	O
,	O
we	O
investigated	O
the	O
phosphorylation	O
and	O
kinase	S-geneN
activity	O
of	O
the	O
70	B-geneY
-	I-geneY
kDa	I-geneY
ribosomal	I-geneY
protein	I-geneY
S6	I-geneY
kinase	I-geneY
1	E-geneY
(	O
S6K1	S-geneY
)	O
and	O
mTORC1	S-geneN
in	O
3T3	O
-	O
L1	O
preadipocytes	O
.	O

Fisetin	S-chem-C4-1
treatment	O
of	O
preadipocytes	O
reduced	O
the	O
phosphorylation	O
of	O
S6K1	S-geneY-C4-2
and	O
mTORC1	S-geneN-C4-2
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

To	O
further	O
our	O
understanding	O
of	O
how	O
fisetin	S-chem-C4-1
negatively	O
regulates	O
mTORC1	S-geneN-C4-2
signaling	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
of	O
S6K1	S-geneY
,	O
mTOR	S-geneY
and	O
Akt	S-geneN
in	O
fisetin	S-chem
-	O
treated	O
TSC2	S-geneY
-	O
knockdown	O
cells	O
.	O

The	O
results	O
suggested	O
that	O
fisetin	S-chem-C4-1
treatment	O
inhibits	O
mTORC1	S-geneN-C4-2
activity	O
in	O
an	O
Akt	S-geneN-C4-2
-	O
dependent	O
manner	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
adipocyte	O
differentiation	O
is	O
dependent	O
on	O
mTORC1	S-geneN
activity	O
.	O

Fisetin	S-chem
treatment	O
inhibited	O
adipocyte	O
differentiation	O
,	O
consistent	O
with	O
the	O
negative	O
effect	O
of	O
fisetin	S-chem-C4-1
on	O
mTOR	S-geneY-C4-2
.	O

The	O
inhibitory	O
effect	O
of	O
fisetin	S-chem
on	O
adipogenesis	O
is	O
dependent	O
of	O
mTOR	S-geneY
activity	O
,	O
suggesting	O
that	O
fisetin	S-chem
inhibits	O
adipogenesis	O
and	O
the	O
accumulation	O
of	O
intracellular	O
triglycerides	S-chem
during	O
adipocyte	O
differentiation	O
by	O
targeting	O
mTORC1	S-geneN
signaling	O
.	O

Fisetin	S-chem
supplementation	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
significantly	O
attenuated	O
HFD	O
-	O
induced	O
increases	O
in	O
body	O
weight	O
and	O
white	O
adipose	O
tissue	O
.	O

We	O
also	O
observed	O
that	O
fisetin	S-chem-C4-1
efficiently	O
suppressed	O
the	O
phosphorylation	O
of	O
Akt	S-geneN-C4-2
,	O
S6K1	S-geneY-C4-2
and	O
mTORC1	S-geneN-C4-2
in	O
adipose	O
tissue	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
mTORC1	S-geneN-C4-2
signaling	O
by	O
fisetin	S-chem-C4-1
prevents	O
adipocyte	O
differentiation	O
of	O
3T3	O
-	O
L1	O
preadipocytes	O
and	O
obesity	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O

Therefore	O
,	O
fisetin	S-chem
may	O
be	O
a	O
useful	O
phytochemical	O
agent	O
for	O
attenuating	O
diet	O
-	O
induced	O
obesity	O
.	O

Characterization	O
of	O
the	O
mouse	B-geneN
cold	I-geneN
-	I-geneN
menthol	I-geneN
receptor	E-geneN
TRPM8	S-geneY
and	O
vanilloid	B-geneY
receptor	I-geneY
type	I-geneY
-	I-geneY
1	E-geneY
VR1	S-geneY
using	O
a	O
fluorometric	O
imaging	O
plate	O
reader	O
(	O
FLIPR	O
)	O
assay	O
.	O

1	O
.	O

TRPM8	S-geneY-C3-2
(	O
CMR1	S-geneY-C3-2
)	O
is	O
a	O
Ca	B-geneN-C3-2
(	I-geneN-C3-2
2	I-geneN-C3-2
+	I-geneN-C3-2
)	I-geneN-C3-2
-	I-geneN-C3-2
permeable	I-geneN-C3-2
channel	E-geneN-C3-2
,	O
which	O
can	O
be	O
activated	O
by	O
low	O
temperatures	O
,	O
menthol	S-chem-C3-1
,	O
eucalyptol	S-chem-C3-1
and	O
icilin	S-chem-C3-1
.	O

It	O
belongs	O
to	O
the	O
transient	B-geneN
receptor	I-geneN
potential	I-geneN
(	I-geneN
TRP	I-geneN
)	I-geneN
family	E-geneN
,	O
and	O
therefore	O
is	O
related	O
to	O
vanilloid	B-geneY
receptor	I-geneY
type	I-geneY
-	I-geneY
1	E-geneY
(	O
VR1	S-geneY
,	O
TRPV1	S-geneY
)	O
.	O

We	O
tested	O
whether	O
substances	O
which	O
are	O
structurally	O
related	O
to	O
menthol	S-chem
,	O
or	O
which	O
produce	O
a	O
cooling	O
sensation	O
,	O
could	O
activate	O
TRPM8	S-geneY
,	O
and	O
compared	O
the	O
responses	O
of	O
TRPM8	S-geneY
and	O
VR1	S-geneY
to	O
these	O
ligands	O
.	O

2	O
.	O

The	O
effects	O
of	O
70	O
odorants	O
and	O
menthol	S-chem
-	O
related	O
substances	O
on	O
recombinant	O
mouse	B-geneY
TRPM8	E-geneY
(	O
mTRPM8	S-geneY
)	O
,	O
expressed	O
in	O
HEK293	O
cells	O
,	O
were	O
examined	O
using	O
a	O
FLIPR	O
assay	O
.	O

In	O
all	O
,	O
10	O
substances	O
(	O
linalool	S-chem
,	O
geraniol	S-chem
,	O
hydroxycitronellal	S-chem
,	O
WS	B-chem
-	I-chem
3	E-chem
,	O
WS	B-chem
-	I-chem
23	E-chem
,	O
FrescolatMGA	S-chem
,	O
FrescolatML	S-chem
,	O
PMD38	S-chem
,	O
CoolactP	S-chem
and	O
Cooling	B-chem
Agent	I-chem
10	E-chem
)	O
were	O
found	O
to	O
be	O
agonists	O
.	O

3	O
.	O

The	O
EC	O
(	O
50	O
)	O
values	O
of	O
the	O
agonists	O
defined	O
their	O
relative	O
potencies	O
:	O
icilin	S-chem
(	O
0.2	O
+	O
/	O
-	O
0.1	O
microM	O
)	O
>	O
FrescolatML	S-chem
(	O
3.3	O
+	O
/	O
-	O
1.5	O
microM	O
)	O
>	O
WS	B-chem
-	I-chem
3	E-chem
(	O
3.7	O
+	O
/	O
-	O
1.7	O
microM	O
)	O
>	O
(	B-chem
-	I-chem
)	I-chem
menthol	E-chem
(	O
4.1	O
+	O
/	O
-	O
1.3	O
microM	O
)	O
>	O
frescolatMAG	S-chem
(	O
4.8	O
+	O
/	O
-	O
1.1	O
microM	O
)	O
>	O
cooling	B-chem
agent	I-chem
10	E-chem
(	O
6	O
+	O
/	O
-	O
2.2	O
microM	O
)	O
>	O
(	B-chem
+	I-chem
)	I-chem
menthol	E-chem
(	O
14.4	O
+	O
/	O
-	O
1.3	O
microM	O
)	O
>	O
PMD38	S-chem
(	O
31	O
+	O
/	O
-	O
1.1	O
microM	O
)	O
>	O
WS	B-chem
-	I-chem
23	E-chem
(	O
44	O
+	O
/	O
-	O
7.3	O
microM	O
)	O
>	O
Coolact	B-chem
P	E-chem
(	O
66	O
+	O
/	O
-	O
20	O
microM	O
)	O
>	O
geraniol	S-chem
(	O
5.9	O
+	O
/	O
-	O
1.6	O
mM	O
)	O
>	O
linalool	S-chem
(	O
6.7	O
+	O
/	O
-	O
2.0	O
mM	O
)	O
>	O
eucalyptol	S-chem
(	O
7.7	O
+	O
/	O
-	O
2.0	O
mM	O
)	O
>	O
hydroxycitronellal	S-chem
(	O
19.6	O
+	O
/	O
-	O
2.2	O
mM	O
)	O
.	O

4	O
.	O

Known	O
VR1	S-geneY-C6-2
antagonists	O
(	O
BCTC	S-chem-MU-1
,	O
thio	B-chem-MU-1
-	I-chem-MU-1
BCTC	E-chem-MU-1
and	O
capsazepine	S-chem-MU-1
)	O
were	O
also	O
able	O
to	O
block	O
the	O
response	O
of	O
TRPM8	S-geneY-MU-2
to	O
menthol	S-chem-C3-1
(	O
IC	O
(	O
50	O
)	O
:	O
0.8	O
+	O
/	O
-	O
1.0	O
,	O
3.5	O
+	O
/	O
-	O
1.1	O
and	O
18	O
+	O
/	O
-	O
1.1	O
microM	O
,	O
respectively	O
)	O
.	O

5	O
.	O

The	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
response	O
of	O
hVR1	S-geneY-C3-2
-	O
transfected	O
HEK293	O
cells	O
to	O
the	O
endogenous	O
VR1	S-geneY-C5-2
agonist	O
N	B-chem-MU-1
-	I-chem-MU-1
arachidonoyl	I-chem-MU-1
-	I-chem-MU-1
dopamine	E-chem-MU-1
was	O
potentiated	O
by	O
low	O
pH	O
.	O

In	O
contrast	O
,	O
menthol	S-chem-C3-1
-	O
and	O
icilin	S-chem-C3-1
-	O
activated	O
TRPM8	S-geneY-C3-2
currents	O
were	O
suppressed	O
by	O
low	O
pH	O
.	O

6	O
.	O

In	O
conclusion	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
identified	O
10	O
new	O
agonists	O
and	O
three	O
antagonists	O
of	O
TRPM8	S-geneY
.	O

We	O
found	O
that	O
,	O
in	O
contrast	O
to	O
VR1	S-geneY
,	O
TRPM8	S-geneY
is	O
inhibited	O
rather	O
than	O
potentiated	O
by	O
protons	O
.	O

Tryptophan	B-geneY
hydroxylase	E-geneY
mRNA	O
levels	O
are	O
elevated	O
by	O
repeated	O
immobilization	O
stress	O
in	O
rat	O
raphe	O
nuclei	O
but	O
not	O
in	O
pineal	O
gland	O
.	O

Repeated	O
stress	O
triggers	O
a	O
wide	O
range	O
of	O
adaptive	O
changes	O
in	O
the	O
central	O
nervous	O
system	O
including	O
the	O
elevation	O
of	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
metabolism	O
and	O
an	O
increased	O
susceptibility	O
to	O
affective	O
disorders	O
.	O

To	O
begin	O
to	O
examine	O
whether	O
these	O
changes	O
are	O
mediated	O
by	O
alterations	O
in	O
gene	O
expression	O
for	O
tryptophan	B-geneY-C9-2
hydroxylase	E-geneY-C9-2
(	O
TPH	S-geneY-C9-2
)	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
5	B-chem-C9-1
-	I-chem-C9-1
HT	E-chem-C9-1
biosynthesis	O
,	O
we	O
quantitated	O
its	O
mRNA	O
levels	O
by	O
competitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Repeated	O
immobilization	O
stress	O
(	O
2	O
h	O
,	O
7	O
days	O
)	O
elicited	O
a	O
six	O
-	O
or	O
ten	O
-	O
fold	O
rise	O
in	O
TPH	S-geneY
mRNA	O
in	O
median	O
raphe	O
nucleus	O
(	O
MRN	O
)	O
and	O
dorsal	O
raphe	O
nucleus	O
(	O
DRN	O
)	O
,	O
respectively	O
,	O
without	O
significantly	O
altering	O
TPH	S-geneY
mRNA	O
levels	O
in	O
the	O
pineal	O
gland	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
change	O
in	O
mRNA	O
levels	O
for	O
GTP	B-geneY-C9-2
cyclohydrolase	I-geneY-C9-2
I	E-geneY-C9-2
(	O
GTPCH	S-geneY-C9-2
)	O
,	O
the	O
rate	O
limiting	O
enzyme	O
in	O
synthesis	O
of	O
the	O
tetrahydrobiopterin	S-chem-C9-1
(	O
BH4	S-chem-C9-1
)	O
,	O
the	O
obligate	O
cofactor	O
for	O
TPH	S-geneY
.	O

This	O
is	O
the	O
first	O
study	O
to	O
reveal	O
stress	O
-	O
elicited	O
activation	O
of	O
TPH	S-geneY
gene	O
expression	O
.	O

Safety	O
of	O
selegiline	S-chem
(	O
deprenyl	S-chem
)	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

Selegiline	S-chem-C4-1
(	O
deprenyl	S-chem-C4-1
)	O
,	O
a	O
selective	O
,	O
irreversible	O
inhibitor	O
of	O
monoamine	B-geneY-C4-2
oxidase	I-geneY-C4-2
type	I-geneY-C4-2
B	E-geneY-C4-2
(	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
)	O
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

As	O
the	O
first	O
MAO	B-geneY
-	I-geneY
B	E-geneY
inhibitor	O
approved	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
,	O
concerns	O
were	O
raised	O
about	O
the	O
safety	O
of	O
the	O
drug	O
based	O
on	O
the	O
adverse	O
effect	O
profiles	O
of	O
older	O
,	O
nonselective	O
MAO	S-geneN
inhibitors	O
.	O

Unlike	O
the	O
nonselective	O
MAO	S-geneN-C4-2
inhibitors	O
,	O
selegiline	S-chem-C4-1
does	O
not	O
significantly	O
potentiate	O
tyramine	S-chem
-	O
induced	O
hypertension	O
(	O
the	O
'	O
cheese	O
effect	O
'	O
)	O
at	O
the	O
dosages	O
(	O
5	O
to	O
10	O
mg	O
daily	O
)	O
used	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

Selegiline	S-chem
has	O
been	O
well	O
tolerated	O
when	O
given	O
alone	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
seen	O
during	O
monotherapy	O
have	O
been	O
insomnia	O
,	O
nausea	O
,	O
benign	O
cardiac	O
arrhythmias	O
,	O
dizziness	O
and	O
headache	O
.	O

When	O
combined	O
with	O
levodopa	S-chem
,	O
selegiline	S-chem
can	O
potentiate	O
the	O
typical	O
adverse	O
effects	O
of	O
levodopa	S-chem
,	O
if	O
the	O
dose	O
of	O
levodopa	S-chem
is	O
not	O
reduced	O
sufficiently	O
.	O

Thus	O
,	O
the	O
most	O
common	O
adverse	O
effects	O
associated	O
with	O
this	O
combination	O
are	O
nausea	O
,	O
dizziness	O
,	O
fatigue	O
,	O
constipation	O
and	O
insomnia	O
.	O

At	O
the	O
later	O
stages	O
of	O
Parkinson	O
's	O
disease	O
when	O
fluctuations	O
in	O
disability	O
occur	O
,	O
peak	O
dose	O
dyskinesias	O
,	O
psychiatric	O
complications	O
like	O
hallucinations	O
and	O
insomnia	O
,	O
and	O
orthostatic	O
hypotension	O
are	O
further	O
potentiated	O
by	O
selegiline	S-chem
.	O

Mortality	O
was	O
recently	O
reported	O
to	O
be	O
increased	O
when	O
selegiline	S-chem
and	O
levodopa	S-chem
were	O
given	O
together	O
in	O
comparison	O
with	O
treatment	O
with	O
levodopa	S-chem
alone	O
,	O
but	O
a	O
large	O
meta	O
-	O
analysis	O
of	O
5	O
long	O
term	O
studies	O
and	O
4	O
separate	O
studies	O
did	O
not	O
support	O
this	O
conclusion	O
.	O

Selegiline	S-chem
seems	O
to	O
be	O
generally	O
well	O
tolerated	O
in	O
combination	O
with	O
other	O
drugs	O
.	O

However	O
,	O
when	O
pethidine	S-chem
(	O
meperidine	S-chem
)	O
has	O
been	O
given	O
to	O
patients	O
who	O
are	O
receiving	O
selegiline	S-chem
therapy	O
,	O
severe	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O

Thus	O
,	O
the	O
concomitant	O
use	O
of	O
these	O
drugs	O
is	O
not	O
recommended	O
.	O

A	O
low	O
tyramine	S-chem
diet	O
is	O
recommended	O
if	O
selegiline	S-chem-C4-1
is	O
used	O
together	O
with	O
nonselective	O
MAO	S-geneN-C4-2
inhibitors	O
or	O
the	O
selective	O
,	O
reversible	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
inhibitor	O
,	O
moclobemide	S-chem-C4-1
.	O

Several	O
adverse	O
effects	O
have	O
been	O
reported	O
when	O
fluoxetine	S-chem
and	O
selegiline	S-chem
have	O
been	O
used	O
together	O
.	O

A	O
recent	O
survey	O
revealed	O
that	O
the	O
incidence	O
of	O
a	O
true	O
serotonin	S-chem
syndrome	O
is	O
,	O
however	O
,	O
very	O
low	O
with	O
this	O
combination	O
.	O

Concomitant	O
use	O
of	O
selegiline	S-chem
and	O
other	O
selective	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
;	O
5	B-chem
-	I-chem
HT	E-chem
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
like	O
citalopram	S-chem
,	O
which	O
have	O
generally	O
less	O
interactions	O
than	O
fluoxetine	S-chem
,	O
seems	O
to	O
be	O
well	O
tolerated	O
.	O

Nevertheless	O
,	O
caution	O
is	O
advised	O
when	O
combining	O
a	O
SSRI	O
or	O
a	O
tricyclic	S-chem
antidepressant	O
and	O
selegiline	S-chem
.	O

Mechanisms	O
of	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
human	B-geneY
kappa	I-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
:	O
internalization	O
is	O
required	O
for	O
down	O
-	O
regulation	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
human	B-geneY-C4-2
kappa	I-geneY-C4-2
-	I-geneY-C4-2
opioid	I-geneY-C4-2
receptor	E-geneY-C4-2
(	O
hkor	S-geneY-C4-2
)	O
stably	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
underwent	O
down	O
-	O
regulation	O
after	O
prolonged	O
U50,488H	S-chem-C4-1
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
mechanisms	O
underlying	O
this	O
process	O
.	O

U50	B-chem-C4-1
,	I-chem-C4-1
488H	E-chem-C4-1
caused	O
a	O
significant	O
down	O
-	O
regulation	O
of	O
the	O
hkor	S-geneY-C4-2
,	O
although	O
etorphine	S-chem
did	O
not	O
.	O

Neither	O
U50,488H	S-chem
nor	O
etorphine	S-chem
caused	O
down	O
-	O
regulation	O
of	O
the	O
rat	B-geneY
kappa	I-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
.	O

Thus	O
,	O
similar	O
to	O
internalization	O
,	O
there	O
are	O
agonist	O
and	O
species	O
differences	O
in	O
down	O
-	O
regulation	O
of	O
kappa	B-geneY
-	I-geneY
opioid	I-geneY
receptors	E-geneY
.	O

Expression	O
of	O
the	O
dominant	O
negative	O
mutants	O
arrestin	B-geneY
-	I-geneY
2	E-geneY
(	O
319	O
-	O
418	O
)	O
or	O
dynamin	B-geneY
I	E-geneY
-	O
K44A	S-geneN
significantly	O
reduced	O
U50,488H	S-chem-C4-1
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
hkor	S-geneY-C4-2
.	O

Coexpression	O
of	O
GRK2	S-geneY
or	O
GRK2	S-geneY
and	O
arrestin	B-geneY
-	I-geneY
2	E-geneY
permitted	O
etorphine	S-chem-C4-1
to	O
induce	O
down	O
-	O
regulation	O
of	O
the	O
hkor	S-geneY-C4-2
,	O
although	O
expression	O
of	O
arrestin	B-geneY
-	I-geneY
2	E-geneY
or	O
dynamin	B-geneY
I	E-geneY
alone	O
did	O
not	O
.	O

Expression	O
of	O
the	O
dominant	O
negative	O
mutants	O
rab5A	S-geneY-C4-2
-	O
N133I	S-geneN-C4-2
or	O
rab7	S-geneN-C4-2
-	O
N125I	S-geneN-C4-2
blunted	O
U50,488H	S-chem-C4-1
-	O
induced	O
down	O
-	O
regulation	O
.	O

Pretreatment	O
with	O
lysosomal	O
enzyme	O
inhibitors	O
[	B-chem
(	I-chem
2S	I-chem
,	I-chem
3S	I-chem
)	I-chem
trans	I-chem
-	I-chem
epoxysuccinyl	I-chem
-	I-chem
L	I-chem
-	I-chem
leucylamido	I-chem
-	I-chem
3	I-chem
-	I-chem
methylbutane	I-chem
ethyl	I-chem
ester	I-chem
or	I-chem
chloroquine	I-chem
]	E-chem
or	O
proteasome	S-geneN
inhibitors	O
(	O
proteasome	S-geneN-C4-2
inhibitor	O
I	O
,	O
MG	B-chem-C4-1
-	I-chem-C4-1
132	E-chem-C4-1
,	O
or	O
lactacystin	S-chem-C4-1
)	O
decreased	O
the	O
extent	O
of	O
U50,488H	S-chem
-	O
induced	O
down	O
-	O
regulation	O
.	O

A	O
combination	O
of	O
chloroquine	S-chem
and	O
proteasome	S-geneN
inhibitor	O
I	O
abolished	O
U50,488H	S-chem
-	O
induced	O
down	O
-	O
regulation	O
.	O

These	O
results	O
indicate	O
that	O
U50,488H	S-chem-C4-1
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
hkor	S-geneY-C4-2
involves	O
GRK	S-geneN
-	O
,	O
arrestin	B-geneY
-	I-geneY
2	E-geneY
-	O
,	O
dynamin	S-geneN
-	O
,	O
rab5	S-geneN
-	O
,	O
and	O
rab7	S-geneN
-	O
dependent	O
mechanisms	O
and	O
receptors	O
seem	O
to	O
be	O
trafficked	O
to	O
lysosomes	O
and	O
proteasomes	S-geneN
for	O
degradation	O
.	O

Thus	O
,	O
U50,488H	S-chem-C4-1
-	O
induced	O
internalization	O
and	O
down	O
-	O
regulation	O
of	O
the	O
hkor	S-geneY-C4-2
share	O
initial	O
common	O
mechanisms	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
these	O
results	O
represent	O
the	O
first	O
report	O
on	O
the	O
involvement	O
of	O
both	O
rab5	S-geneN
and	O
rab7	S-geneN
in	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
a	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
.	O

In	O
addition	O
,	O
this	O
study	O
is	O
among	O
the	O
first	O
to	O
show	O
the	O
involvement	O
of	O
proteasomes	S-geneN
in	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
a	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
.	O

Chronic	O
effect	O
of	O
[	B-chem
D	I-chem
-	I-chem
Pen2	I-chem
,	I-chem
D	I-chem
-	I-chem
Pen5	I-chem
]	I-chem
enkephalin	E-chem
on	O
rat	B-geneN
brain	I-geneN
opioid	I-geneN
receptors	E-geneN
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
demonstrated	O
that	O
chronic	O
etorphine	S-chem
or	O
[	B-chem
D	I-chem
-	I-chem
Ala2	I-chem
,	I-chem
D	I-chem
-	I-chem
Leu5	I-chem
]	I-chem
enkephalin	E-chem
(	O
DADLE	S-chem
)	O
treatment	O
of	O
rats	O
results	O
in	O
the	O
reduction	O
of	O
mu	B-geneN
-	I-geneN
and	I-geneN
delta	I-geneN
-	I-geneN
opioid	I-geneN
receptor	E-geneN
binding	O
activities	O
as	O
tolerance	O
develops	O
.	O

As	O
both	O
etorphine	S-chem
and	O
DADLE	S-chem
are	O
relatively	O
non	O
-	O
specific	O
opioid	O
ligands	O
,	O
interacting	O
with	O
both	O
mu	B-geneN
-	I-geneN
and	I-geneN
delta	I-geneN
-	I-geneN
receptors	E-geneN
,	O
these	O
studies	O
could	O
not	O
determine	O
whether	O
down	O
-	O
regulation	O
of	O
a	O
specific	O
receptor	O
type	O
occurs	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
studies	O
,	O
animals	O
were	O
rendered	O
tolerant	O
to	O
the	O
delta	B-geneY-C5-2
-	I-geneY-C5-2
opioid	I-geneY-C5-2
receptor	E-geneY-C5-2
-	O
selective	O
agonist	O
[	B-chem-C5-1
D	I-chem-C5-1
-	I-chem-C5-1
Pen2	I-chem-C5-1
,	I-chem-C5-1
D	I-chem-C5-1
-	I-chem-C5-1
Pen5	I-chem-C5-1
]	I-chem-C5-1
enkephalin	E-chem-C5-1
(	O
DPDPE	S-chem-C5-1
)	O
,	O
and	O
receptor	O
binding	O
activities	O
were	O
measured	O
.	O

Treating	O
Sprague	O
-	O
Dawley	O
rats	O
with	O
increasing	O
doses	O
of	O
DPDPE	S-chem
(	O
80	O
-	O
160	O
-	O
240	O
-	O
320	O
micrograms	O
/	O
kg	O
)	O
i.c.v	O
.	O
for	O
1	O
to	O
4	O
days	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
the	O
AD50	O
of	O
DPDPE	S-chem
to	O
elicit	O
an	O
antinociceptive	O
response	O
.	O

When	O
delta	B-geneY
-	I-geneY
receptor	E-geneY
binding	O
was	O
determined	O
by	O
using	O
[	B-chem
3H	I-chem
]	I-chem
DPDPE	E-chem
,	O
a	O
40	O
-	O
50	O
%	O
decrease	O
in	O
binding	O
in	O
the	O
midbrain	O
and	O
cortex	O
,	O
and	O
25	O
-	O
35	O
%	O
decrease	O
in	O
binding	O
in	O
the	O
striatum	O
were	O
observed	O
after	O
3	O
or	O
4	O
days	O
of	O
DPDPE	S-chem
treatment	O
.	O

Scatchard	O
analysis	O
of	O
the	O
[	B-chem
3H	I-chem
]	I-chem
DPDPE	E-chem
saturation	O
binding	O
data	O
revealed	O
a	O
decrease	O
in	O
Bmax	O
values	O
and	O
no	O
significant	O
change	O
in	O
Kd	O
values	O
.	O

To	O
our	O
surprise	O
,	O
when	O
mu	B-geneY
-	I-geneY
receptor	E-geneY
binding	O
was	O
determined	O
by	O
using	O
[	B-chem
3H	I-chem
]	I-chem
Tyr	I-chem
-	I-chem
D	I-chem
-	I-chem
Ala	I-chem
-	I-chem
Gly	I-chem
-	I-chem
MePhe	I-chem
-	I-chem
Gly	I-chem
-	I-chem
ol	E-chem
(	O
DAMGO	S-chem
)	O
,	O
a	O
10	O
-	O
15	O
%	O
decrease	O
in	O
binding	O
was	O
also	O
observed	O
in	O
the	O
midbrain	O
and	O
cortex	O
after	O
4	O
days	O
of	O
DPDPE	S-chem
treatment	O
.	O

Our	O
conclusion	O
is	O
that	O
chronic	O
DPDPE	S-chem-C4-1
treatment	O
preferentially	O
reduces	O
delta	B-geneY-C4-2
-	I-geneY-C4-2
opioid	I-geneY-C4-2
receptor	E-geneY-C4-2
binding	O
activity	O
.	O

Its	O
minor	O
effect	O
on	O
the	O
mu	B-geneY
-	I-geneY
opioid	I-geneY
receptor	E-geneY
maybe	O
due	O
to	O
an	O
interaction	O
between	O
delta	B-geneY
cx	E-geneY
and	O
mu	B-geneY
cx	E-geneY
binding	O
sites	O
.	O

Activation	O
of	O
group	B-geneN
I	I-geneN
metabotropic	I-geneN
glutamate	I-geneN
receptors	E-geneN
potentiates	O
heteromeric	O
kainate	B-geneN
receptors	E-geneN
.	O

Kainate	B-geneN
receptors	E-geneN
(	O
KARs	S-geneN
)	O
,	O
a	O
family	O
of	O
ionotropic	B-geneN
glutamate	I-geneN
receptors	E-geneN
,	O
are	O
widely	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
are	O
critically	O
involved	O
in	O
synaptic	O
transmission	O
.	O

KAR	S-geneN
activation	O
is	O
influenced	O
by	O
metabotropic	B-geneN
glutamate	I-geneN
receptor	E-geneN
(	O
mGlu	S-geneN
)	O
signaling	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
not	O
understood	O
.	O

We	O
undertook	O
studies	O
to	O
examine	O
how	O
mGlu	S-geneN
modulation	O
affects	O
activation	O
of	O
KARs	S-geneN
.	O

Confocal	O
immunohistochemistry	O
of	O
rat	O
hippocampus	O
and	O
cultured	O
rat	O
cortex	O
revealed	O
colocalization	O
of	O
the	O
high	O
-	O
affinity	O
KAR	S-geneN
subunits	O
with	O
group	B-geneN
I	I-geneN
mGlu	I-geneN
receptors	E-geneN
.	O

In	O
hippocampal	O
and	O
cortical	O
cultures	O
,	O
the	O
calcium	S-chem
signal	O
caused	O
by	O
activation	O
of	O
native	O
KARs	S-geneN
was	O
potentiated	O
by	O
activation	O
of	O
group	B-geneN
I	I-geneN
mGlu	I-geneN
receptors	E-geneN
.	O

In	O
Xenopus	O
laevis	O
oocytes	O
,	O
activation	O
of	O
group	B-geneN
I	I-geneN
mGlu	I-geneN
receptors	E-geneN
potentiated	O
heteromeric	O
but	O
not	O
homomeric	O
KAR	S-geneN
-	O
mediated	O
currents	O
,	O
with	O
no	O
change	O
in	O
agonist	O
potency	O
.	O

The	O
potentiation	O
of	O
heteromeric	O
KARs	S-geneN-C4-2
by	O
mGlu1	S-geneY-C4-2
activation	O
was	O
attenuated	O
by	O
GDPβS	O
,	O
blocked	O
by	O
an	O
inhibitor	O
of	O
phospholipase	B-geneN
C	E-geneN
or	O
the	O
calcium	S-chem
chelator	O
1,2	B-chem-C4-1
-	I-chem-C4-1
bis	I-chem-C4-1
(	I-chem-C4-1
o	I-chem-C4-1
-	I-chem-C4-1
aminophenoxy	I-chem-C4-1
)	I-chem-C4-1
ethane	I-chem-C4-1
-	I-chem-C4-1
N	I-chem-C4-1
,	I-chem-C4-1
N	I-chem-C4-1
,	I-chem-C4-1
N	I-chem-C4-1
'	I-chem-C4-1
,	I-chem-C4-1
N	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
tetraacetic	I-chem-C4-1
acid	E-chem-C4-1
(	O
BAPTA	S-chem-C4-1
)	O
,	O
prolonged	O
by	O
the	O
phosphatase	S-geneN-C4-2
inhibitor	O
okadaic	B-chem-C4-1
acid	E-chem-C4-1
,	O
but	O
unaffected	O
by	O
the	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
lavendustin	B-chem-C4-1
A	E-chem-C4-1
.	O

Protein	B-geneN
kinase	I-geneN
C	E-geneN
(	O
PKC	S-geneN
)	O
inhibition	O
reduced	O
the	O
potentiation	O
by	O
mGlu1	S-geneY
of	O
GluK2	S-geneY
/	O
GluK5	S-geneY
,	O
and	O
conversely	O
,	O
direct	O
activation	O
of	O
PKC	S-geneN-C3-2
by	O
phorbol	B-chem-C3-1
12	I-chem-C3-1
-	I-chem-C3-1
myristate,13	I-chem-C3-1
-	I-chem-C3-1
acetate	E-chem-C3-1
potentiated	O
GluK2	S-geneY-C3-2
/	O
GluK5	S-geneY-C3-2
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
identified	O
three	O
serines	S-chem
(	O
Ser833	S-chem
,	O
Ser836	S-chem
,	O
and	O
Ser840	S-chem
)	O
within	O
the	O
membrane	O
proximal	O
region	O
of	O
the	O
GluK5	S-geneY
C	S-chem
-	O
terminal	O
domain	O
that	O
,	O
in	O
combination	O
,	O
are	O
required	O
for	O
mGlu1	S-geneY
-	O
mediated	O
potentiation	O
of	O
KARs	S-geneN
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
phosphorylation	O
of	O
key	O
residues	O
in	O
the	O
C	S-chem
-	O
terminal	O
domain	O
changes	O
the	O
overall	O
charge	O
of	O
this	O
domain	O
,	O
resulting	O
in	O
potentiated	O
agonist	O
responses	O
.	O

The	O
food	O
contaminant	O
deoxynivalenol	S-chem-C3-1
activates	O
the	O
mitogen	B-geneN-C3-2
activated	I-geneN-C3-2
protein	I-geneN-C3-2
kinases	E-geneN-C3-2
in	O
the	O
intestine	O
:	O
interest	O
of	O
ex	O
vivo	O
models	O
as	O
an	O
alternative	O
to	O
in	O
vivo	O
experiments	O
.	O

Trichothecenes	S-chem
induce	O
changes	O
in	O
the	O
intestinal	O
barrier	O
function	O
through	O
decreased	O
expression	O
of	O
cell	O
junction	O
proteins	O
and	O
apoptosis	O
of	O
enterocytes	O
.	O

The	O
mitogen	B-geneN
activated	I-geneN
protein	I-geneN
kinases	E-geneN
(	O
MAPK	S-geneN
)	O
play	O
an	O
important	O
role	O
in	O
the	O
signaling	O
pathways	O
of	O
cell	O
turnover	O
and	O
differentiation	O
.	O

Using	O
ex	O
vivo	O
and	O
in	O
vivo	O
approaches	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
ability	O
of	O
low	O
doses	O
of	O
DON	S-chem
to	O
induce	O
histological	O
changes	O
in	O
the	O
intestine	O
and	O
to	O
activate	O
the	O
MAPK	S-geneN
ERK	B-geneN
1	I-geneN
/	I-geneN
2	E-geneN
,	O
p38	S-geneN
and	O
JNK	S-geneN
.	O

Twelve	O
weaning	O
piglets	O
received	O
during	O
four	O
weeks	O
a	O
control	O
diet	O
or	O
a	O
DON	S-chem
-	O
contaminated	O
diet	O
(	O
2.3	O
mg	O
DON	S-chem
/	O
kg	O
feed	O
)	O
.	O

Six	O
weaning	O
piglets	O
were	O
used	O
to	O
prepare	O
jejunal	O
explants	O
(	O
ex	O
vivo	O
model	O
)	O
.	O

Explants	O
were	O
exposed	O
during	O
4	O
h	O
to	O
vehicle	O
,	O
5	O
or	O
10	O
μM	O
DON	S-chem
.	O

Intestinal	O
changes	O
were	O
graded	O
using	O
a	O
histological	O
score	O
.	O

Pigs	O
fed	O
a	O
DON	S-chem
-	O
diet	O
and	O
explants	O
exposed	O
to	O
DON	S-chem
showed	O
a	O
significant	O
decrease	O
in	O
the	O
jejunal	O
score	O
.	O

In	O
both	O
models	O
,	O
the	O
toxin	O
significantly	O
enhanced	O
phosphorylation	O
of	O
ERK	B-geneN
1	I-geneN
/	I-geneN
2	E-geneN
and	O
p38	S-geneN
,	O
whereas	O
the	O
increased	O
phosphorylation	O
of	O
JNK	S-geneN
was	O
non	O
significant	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
in	O
vivo	O
or	O
ex	O
vivo	O
exposure	O
of	O
intestinal	O
tissue	O
to	O
DON	S-chem-C3-1
lead	O
to	O
similar	O
intestinal	O
lesions	O
and	O
activation	O
of	O
MAPK	S-geneN-C3-2
.	O

These	O
effects	O
could	O
impair	O
the	O
homeostasis	O
of	O
intestinal	O
tissue	O
in	O
the	O
aspects	O
of	O
barrier	O
function	O
and	O
immune	O
protection	O
.	O

The	O
similarity	O
of	O
the	O
in	O
vivo	O
and	O
ex	O
vivo	O
results	O
provides	O
also	O
strong	O
evidence	O
that	O
the	O
jejunal	O
explant	O
model	O
is	O
a	O
good	O
alternative	O
for	O
toxicological	O
studies	O
in	O
intestinal	O
tissue	O
.	O

Co	B-chem
-	I-chem
C	E-chem
bond	O
activation	O
in	O
methylmalonyl	B-geneY
-	I-geneY
CoA	I-geneY
mutase	E-geneY
by	O
stabilization	O
of	O
the	O
post	O
-	O
homolysis	O
product	O
Co2	B-chem
+	E-chem
cobalamin	S-chem
.	O

Despite	O
decades	O
of	O
research	O
,	O
the	O
mechanism	O
by	O
which	O
coenzyme	B-chem
B12	E-chem
(	O
adenosylcobalamin	S-chem
,	O
AdoCbl	S-chem
)	O
-	O
dependent	O
enzymes	O
promote	O
homolytic	O
cleavage	O
of	O
the	O
cofactor	O
's	O
Co	B-chem
-	I-chem
C	E-chem
bond	O
to	O
initiate	O
catalysis	O
has	O
continued	O
to	O
elude	O
researchers	O
.	O

In	O
this	O
work	O
,	O
we	O
utilized	O
magnetic	O
circular	O
dichroism	O
spectroscopy	O
to	O
explore	O
how	O
the	O
electronic	O
structure	O
of	O
the	O
reduced	O
B12	O
cofactor	O
(	O
i.e	O
.	O
,	O
the	O
post	O
-	O
homolysis	O
product	O
Co2	B-chem
+	I-chem
Cbl	E-chem
)	O
is	O
modulated	O
by	O
the	O
enzyme	O
methylmalonyl	B-geneY
-	I-geneY
CoA	I-geneY
mutase	E-geneY
.	O

Our	O
data	O
reveal	O
a	O
fairly	O
uniform	O
stabilization	O
of	O
the	O
Co	O
3d	O
orbitals	O
relative	O
to	O
the	O
corrin	O
pi	O
/	O
pi	O
*	O
-	O
based	O
molecular	O
orbitals	O
when	O
Co2	B-chem
+	I-chem
Cbl	E-chem
is	O
bound	O
to	O
the	O
enzyme	O
active	O
site	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
substrate	O
.	O

Contrastingly	O
,	O
our	O
previous	O
studies	O
(	O
Brooks	O
,	O
A	O
.	O

J.	O
;	O
Vlasie	O
,	O
M.	O
;	O
Banerjee	O
,	O
R.	O
;	O
Brunold	O
,	O
T	O
.	O

C	O
.	O

J	O
.	O

Am	O
.	O

Chem	O
.	O

Soc	O
.	O

2004	O
,	O
126	O
,	O
8167	O
-	O
8180	O
.	O
)	O
showed	O
that	O
when	O
AdoCbl	S-chem
is	O
bound	O
to	O
the	O
MMCM	S-geneY
active	O
site	O
,	O
no	O
enzymatic	O
perturbation	O
of	O
the	O
Co3	B-chem
+	I-chem
Cbl	E-chem
electronic	O
structure	O
occurs	O
,	O
even	O
in	O
the	O
presence	O
of	O
substrate	O
(	O
analogues	O
)	O
.	O

Collectively	O
,	O
these	O
observations	O
provide	O
direct	O
evidence	O
that	O
enzymatic	O
Co	B-chem
-	I-chem
C	E-chem
bond	O
activation	O
involves	O
stabilization	O
of	O
the	O
post	O
-	O
homolysis	O
product	O
,	O
Co2	B-chem
+	I-chem
Cbl	E-chem
,	O
rather	O
than	O
destabilization	O
of	O
the	O
Co3	B-chem
+	I-chem
Cbl	E-chem
``	O
ground	O
``	O
state	O
.	O

A	O
New	O
Proposed	O
Rodent	O
Model	O
of	O
Chemically	O
Induced	O
Prostate	O
Carcinogenesis	O
:	O
Distinct	O
Time	O
-	O
Course	O
Prostate	O
Cancer	O
Progression	O
in	O
the	O
Dorsolateral	O
and	O
Ventral	O
Lobes	O
.	O

BACKGROUND	O
:	O
Characterization	O
of	O
novel	O
rodent	O
models	O
for	O
prostate	O
cancer	O
studies	O
requires	O
evaluation	O
of	O
either	O
spontaneous	O
and	O
carcinogen	O
-	O
induced	O
tumors	O
as	O
well	O
as	O
tumor	O
incidence	O
in	O
different	O
prostatic	O
lobes	O
.	O

We	O
propose	O
a	O
new	O
short	O
-	O
term	O
rodent	O
model	O
of	O
chemically	O
induced	O
prostate	O
carcinogenesis	O
in	O
which	O
prostate	O
cancer	O
progression	O
occurs	O
differentially	O
in	O
the	O
dorsolateral	O
and	O
ventral	O
lobes	O
.	O

METHODS	O
:	O
Adult	O
gerbils	O
were	O
treated	O
with	O
MNU	S-chem
alone	O
or	O
associated	O
with	O
testosterone	S-chem
for	O
3	O
or	O
6	O
months	O
of	O
treatment	O
.	O

Tumor	O
incidence	O
,	O
latency	O
,	O
localization	O
,	O
and	O
immunohistochemistry	O
(	O
AR	S-geneN
,	O
PCNA	S-geneN
,	O
smooth	B-geneN
muscle	I-geneN
α	I-geneN
-	I-geneN
actin	E-geneN
,	O
p63	S-geneN
,	O
MGMT	S-geneN
,	O
and	O
E	B-geneY
-	I-geneY
cadherin	E-geneY
)	O
were	O
studied	O
in	O
both	O
lobes	O
.	O

RESULTS	O
:	O
Comparisons	O
between	O
both	O
lobes	O
revealed	O
that	O
lesions	O
developed	O
first	O
in	O
the	O
DL	O
while	O
the	O
VL	O
presented	O
longer	O
tumor	O
latency	O
.	O

However	O
,	O
after	O
6	O
months	O
,	O
there	O
was	O
a	O
dramatic	O
increase	O
in	O
tumor	O
multiplicity	O
in	O
the	O
VL	O
,	O
mainly	O
in	O
MNU	S-chem
-	O
treated	O
groups	O
.	O

Lesions	O
clearly	O
progressed	O
from	O
a	O
premalignant	O
to	O
a	O
malignant	O
phenotype	O
over	O
time	O
and	O
tumor	O
latency	O
was	O
decreased	O
by	O
MNU	S-chem
+	O
testosterone	O
administration	O
.	O

Three	O
-	O
dimensional	O
reconstruction	O
of	O
the	O
prostatic	O
complex	O
showed	O
that	O
the	O
DL	O
developed	O
tumors	O
exclusively	O
in	O
the	O
periurethral	O
area	O
and	O
showed	O
intense	O
AR	S-geneN
,	O
PCNA	S-geneN
,	O
and	O
MGMT	S-geneN
immunostaining	O
.	O

Moreover	O
,	O
VL	O
lesions	O
emerged	O
throughout	O
the	O
entire	O
lobe	O
.	O

MNU	S-chem-MU-1
-	O
induced	O
lesions	O
presented	O
markers	O
indicative	O
of	O
an	O
aggressive	O
phenotype	O
:	O
lack	O
of	O
basal	O
cells	O
,	O
rupture	O
of	O
the	O
smooth	O
muscle	O
cell	O
layer	O
,	O
loss	O
of	O
E	B-geneY-C4-2
-	I-geneY-C4-2
cadherin	E-geneY-C4-2
,	O
and	O
high	O
MGMT	S-geneN-C3-2
staining	O
.	O

CONCLUSIONS	O
:	O
There	O
are	O
distinct	O
pathways	O
involved	O
in	O
tumor	O
progression	O
in	O
gerbil	O
prostate	O
lobes	O
.	O

This	O
animal	O
provides	O
a	O
good	O
model	O
for	O
prostate	O
cancer	O
since	O
it	O
allows	O
the	O
investigation	O
of	O
advanced	O
steps	O
of	O
carcinogenesis	O
with	O
shorter	O
latency	O
periods	O
in	O
both	O
lobes	O
.	O

Prostate	O
©	O
2013	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Mechanistic	O
differences	O
of	O
various	O
AT1	S-geneY
-	O
receptor	O
blockers	O
in	O
isolated	O
vessels	O
of	O
different	O
origin	O
.	O

The	O
functional	O
inhibitory	O
characteristics	O
of	O
the	O
angiotensin	B-geneN-C4-2
II	I-geneN-C4-2
type	I-geneN-C4-2
1	I-geneN-C4-2
receptor	E-geneN-C4-2
blockers	O
(	O
ARB	O
)	O
candesartan	S-chem-C4-1
;	O
irbesartan	S-chem-C4-1
;	O
and	O
losartan	S-chem-C4-1
and	O
its	O
active	O
metabolite	O
EXP	B-chem-C4-1
3174	E-chem-C4-1
(	O
EXP	S-chem-C4-1
)	O
were	O
studied	O
in	O
rabbit	O
aortic	O
strips	O
and	O
rat	O
portal	O
vein	O
preparations	O
in	O
vitro	O
.	O

Moreover	O
,	O
plasma	O
-	O
protein	O
binding	O
was	O
determined	O
,	O
and	O
the	O
binding	O
was	O
high	O
(	O
>	O
98	O
.	O

5	O
%	O
)	O
for	O
all	O
ARBs	O
.	O

These	O
values	O
were	O
needed	O
to	O
relate	O
the	O
concentrations	O
of	O
the	O
ARBs	O
used	O
in	O
vitro	O
to	O
the	O
nonprotein	O
bound	O
concentrations	O
in	O
clinical	O
use	O
.	O

In	O
both	O
vascular	O
preparations	O
,	O
candesartan	S-chem-C4-1
caused	O
a	O
marked	O
decrease	O
in	O
the	O
maximal	O
contractile	O
response	O
of	O
the	O
angiotensin	B-geneN-C4-2
II	E-geneN-C4-2
(	O
Ang	B-geneN-C4-2
II	E-geneN-C4-2
)	O
concentration	O
-	O
response	O
curve	O
.	O

Losartan	S-chem
,	O
EXP	S-chem
,	O
and	O
irbesartan	S-chem
caused	O
a	O
rightward	O
parallel	O
shift	O
without	O
any	O
major	O
effects	O
on	O
the	O
maximal	O
response	O
to	O
Ang	B-geneN
II	E-geneN
.	O

The	O
inhibitory	O
effect	O
of	O
candesartan	S-chem
developed	O
slowly	O
(	O
maximal	O
effect	O
after	O
>	O
30	O
minutes	O
)	O
and	O
lasted	O
>	O
2	O
hours	O
despite	O
repeated	O
washing	O
of	O
the	O
vessels	O
.	O

The	O
effect	O
of	O
losartan	S-chem
,	O
irbesartan	S-chem
,	O
and	O
EXP	S-chem
had	O
a	O
faster	O
onset	O
,	O
and	O
most	O
of	O
the	O
inhibitory	O
effect	O
disappeared	O
after	O
washing	O
.	O

The	O
duration	O
of	O
the	O
inhibitory	O
effects	O
of	O
the	O
ARBs	O
were	O
not	O
related	O
to	O
lipophilicity	O
of	O
the	O
compounds	O
.	O

Cooling	O
of	O
the	O
rat	O
portal	O
vein	O
preparations	O
to	O
4	O
degrees	O
C	O
before	O
administration	O
of	O
candesartan	S-chem
prevented	O
the	O
persistent	O
inhibition	O
of	O
Ang	B-geneY
II	E-geneY
response	O
seen	O
at	O
37	O
degrees	O
C	O
.	O

For	O
the	O
other	O
ARBs	O
studied	O
,	O
the	O
magnitude	O
of	O
inhibition	O
and	O
the	O
speed	O
of	O
recovery	O
of	O
the	O
Ang	B-geneN
II	E-geneN
response	O
were	O
independent	O
of	O
the	O
incubation	O
temperature	O
before	O
washing	O
.	O

In	O
addition	O
,	O
when	O
candesartan	S-chem-C4-1
was	O
given	O
to	O
conscious	O
rats	O
,	O
the	O
inhibitory	O
effect	O
on	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
-	O
induced	O
blood	O
pressure	O
responses	O
persisted	O
during	O
the	O
24	O
-	O
hour	O
period	O
despite	O
nondetectable	O
plasma	O
concentrations	O
of	O
candesartan	S-chem
at	O
24	O
hours	O
.	O

It	O
is	O
concluded	O
that	O
functional	O
inhibitory	O
characteristics	O
of	O
candesartan	S-chem
differ	O
from	O
those	O
of	O
the	O
other	O
ARBs	O
tested	O
.	O

At	O
clinically	O
relevant	O
concentrations	O
,	O
candesartan	S-chem-C4-1
is	O
an	O
insurmountable	O
and	O
long	O
-	O
lasting	O
antagonist	O
of	O
the	O
vascular	O
contractile	O
responses	O
to	O
Ang	B-geneN-C4-2
II	E-geneN-C4-2
.	O

Topoisomerase	B-geneY
IIβ	E-geneY
deficiency	O
enhances	O
camptothecin	S-chem
-	O
induced	O
apoptosis	O
.	O

Camptothecin	S-chem
(	O
CPT	S-chem
)	O
,	O
a	O
topoisomerase	B-geneY
(	I-geneY
Top	I-geneY
)	I-geneY
I	E-geneY
-	O
targeting	O
drug	O
that	O
stabilizes	O
Top1	S-geneY
-	O
DNA	O
covalent	O
adducts	O
,	O
can	O
induce	O
S	O
-	O
phase	O
-	O
specific	O
cytotoxicity	O
due	O
to	O
the	O
arrest	O
of	O
progressing	O
replication	O
forks	O
.	O

However	O
,	O
CPT	S-chem
-	O
induced	O
non	O
-	O
S	O
-	O
phase	O
cytotoxicity	O
is	O
less	O
well	O
characterized	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
topoisomerase	B-geneY
IIβ	E-geneY
(	O
Top2β	S-geneY
)	O
as	O
a	O
specific	O
determinant	O
for	O
CPT	S-chem
sensitivity	O
,	O
but	O
not	O
for	O
many	O
other	O
cytotoxic	O
agents	O
,	O
in	O
non	O
-	O
S	O
-	O
phase	O
cells	O
.	O

First	O
,	O
quiescent	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
lacking	O
Top2β	S-geneY
were	O
shown	O
to	O
be	O
hypersensitive	O
to	O
CPT	S-chem
with	O
prominent	O
induction	O
of	O
apoptosis	O
.	O

Second	O
,	O
ICRF	B-chem-C4-1
-	I-chem-C4-1
187	E-chem-C4-1
,	O
a	O
Top2	S-geneY-C4-2
catalytic	O
inhibitor	O
known	O
to	O
deplete	O
Top2β	S-geneY-C4-2
,	O
specifically	O
sensitized	O
MEFs	O
to	O
CPT	S-chem
.	O

To	O
explore	O
the	O
molecular	O
basis	O
for	O
CPT	S-chem
hypersensitivity	O
in	O
Top2β	S-geneY
-	O
deficient	O
cells	O
,	O
we	O
found	O
that	O
upon	O
CPT	S-chem-C4-1
exposure	O
,	O
the	O
RNA	B-geneN-C4-2
polymerase	I-geneN-C4-2
II	I-geneN-C4-2
large	I-geneN-C4-2
subunit	E-geneN-C4-2
(	O
RNAP	B-geneN-C4-2
LS	E-geneN-C4-2
)	O
became	O
progressively	O
depleted	O
,	O
followed	O
by	O
recovery	O
to	O
nearly	O
the	O
original	O
level	O
in	O
wild	O
-	O
type	O
MEFs	O
,	O
whereas	O
RNAP	B-geneN-C4-2
LS	E-geneN-C4-2
remained	O
depleted	O
without	O
recovery	O
in	O
Top2β	S-geneY
-	O
deficient	O
cells	O
.	O

Concomitant	O
with	O
the	O
reduction	O
of	O
the	O
RNAP	B-geneN
LS	E-geneN
level	O
,	O
the	O
p53	S-geneY
protein	O
level	O
was	O
greatly	O
induced	O
.	O

Interestingly	O
,	O
RNAP	B-geneN
LS	E-geneN
depletion	O
has	O
been	O
well	O
documented	O
to	O
lead	O
to	O
p53	S-geneY
-	O
dependent	O
apoptosis	O
.	O

Altogether	O
,	O
our	O
findings	O
support	O
a	O
model	O
in	O
which	O
Top2β	S-geneY
deficiency	O
promotes	O
CPT	S-chem-MU-1
-	O
induced	O
apoptosis	O
in	O
quiescent	O
non	O
-	O
S	O
-	O
phase	O
cells	O
,	O
possibly	O
due	O
to	O
RNAP	B-geneN-C4-2
LS	E-geneN-C4-2
depletion	O
and	O
p53	S-geneY-C3-2
accumulation	O
.	O

Effectors	O
of	O
the	O
activation	O
of	O
human	B-geneY
[	I-geneY
Glu1	I-geneY
]	I-geneY
plasminogen	E-geneY
by	O
human	B-geneY
tissue	I-geneY
plasminogen	I-geneY
activator	E-geneY
.	O

The	O
activation	O
of	O
human	B-geneY-MU-2
[	I-geneY-MU-2
Glu1	I-geneY-MU-2
]	I-geneY-MU-2
plasminogen	E-geneY-MU-2
[	O
(	B-geneY-MU-2
Glu1	I-geneY-MU-2
]	I-geneY-MU-2
Pg	E-geneY-MU-2
)	O
by	O
human	O
recombinant	O
(	O
rec	O
)	O
two	O
-	O
chain	O
tissue	B-geneY-MU-2
plasminogen	I-geneY-MU-2
activator	E-geneY-MU-2
(	O
t	B-geneY-MU-2
-	I-geneY-MU-2
PA	E-geneY-MU-2
)	O
is	O
inhibited	O
by	O
Cl	B-chem-C4-1
-	E-chem-C4-1
,	O
at	O
physiological	O
concentrations	O
,	O
and	O
stimulated	O
by	O
epsilon	B-chem-C3-1
-	I-chem-C3-1
aminocaproic	I-chem-C3-1
acid	E-chem-C3-1
(	O
EACA	S-chem-C3-1
)	O
,	O
as	O
well	O
as	O
fibrin	O
(	O
ogen	O
)	O
.	O

Chloride	S-chem
functions	O
as	O
a	O
result	O
of	O
its	O
binding	O
to	O
[	B-geneY
Glu1	I-geneY
]	I-geneY
Pg	E-geneY
,	O
with	O
a	O
Ki	O
of	O
approximately	O
9.0	O
mM	O
,	O
thereby	O
rendering	O
[	B-geneY
Glu1	I-geneY
]	I-geneY
Pg	E-geneY
a	O
less	O
effective	O
substrate	O
for	O
two	O
-	O
chain	O
rec	O
-	O
t	B-geneY
-	I-geneY
PA	E-geneY
.	O

EACA	S-chem
stimulates	O
the	O
activation	O
in	O
Cl	B-chem
-	I-chem
(	I-chem
-	I-chem
)	E-chem
containing	O
solutions	O
,	O
with	O
a	O
Ka	O
of	O
approximately	O
4.0	O
mM	O
,	O
primarily	O
by	O
reversal	O
of	O
the	O
Cl	B-chem
-	I-chem
(	I-chem
-	I-chem
)	E-chem
inhibitory	O
effect	O
.	O

Fibrinogen	S-geneN
appears	O
to	O
exert	O
its	O
stimulatory	O
properties	O
mainly	O
through	O
effects	O
on	O
the	O
enzyme	O
,	O
two	O
-	O
chain	O
rec	O
-	O
t	B-geneY
-	I-geneY
PA	E-geneY
,	O
with	O
a	O
Ka	O
of	O
approximately	O
3.7	O
microM	O
in	O
activation	O
systems	O
containing	O
physiological	O
levels	O
of	O
Cl	B-chem
-	E-chem
.	O

Analysis	O
of	O
the	O
results	O
of	O
this	O
paper	O
reveals	O
that	O
normal	O
plasma	O
components	O
,	O
Cl	B-chem
-	E-chem
and	O
fibrinogen	S-geneN
,	O
exert	O
major	O
regulatory	O
roles	O
on	O
the	O
ability	O
of	O
[	B-geneY
Glu1	I-geneY
]	I-geneY
Pg	E-geneY
to	O
be	O
activated	O
by	O
two	O
-	O
chain	O
rec	O
-	O
t	B-geneY
-	I-geneY
PA	E-geneY
,	O
in	O
in	O
vitro	O
systems	O
.	O

The	O
presence	O
of	O
Cl	B-chem-C4-1
-	E-chem-C4-1
inhibits	O
the	O
stimulation	O
of	O
[	B-geneY-C4-2
Glu1	I-geneY-C4-2
]	I-geneY-C4-2
Pg	E-geneY-C4-2
activation	O
that	O
would	O
normally	O
occur	O
in	O
the	O
presence	O
of	O
fibrinogen	S-geneN
,	O
a	O
result	O
of	O
possible	O
importance	O
to	O
the	O
observation	O
that	O
some	O
degree	O
of	O
systemic	O
fibrinogenolysis	O
accompanies	O
therapeutic	O
use	O
of	O
tissue	B-geneY
plasminogen	I-geneY
activator	E-geneY
.	O

Endogenous	O
opioid	O
systems	O
and	O
alcohol	S-chem
addiction	O
.	O

Alcohol	S-chem
exerts	O
numerous	O
pharmacological	O
effects	O
through	O
its	O
interaction	O
with	O
various	O
neurotransmitters	O
and	O
neuromodulators	O
.	O

Among	O
the	O
latter	O
,	O
the	O
endogenous	O
opioids	O
play	O
a	O
key	O
role	O
in	O
the	O
rewarding	O
(	O
addictive	O
)	O
properties	O
of	O
ethanol	S-chem
.	O

Three	O
types	O
of	O
opioid	B-geneN
receptors	I-geneN
(	I-geneN
mu	I-geneN
,	I-geneN
delta	I-geneN
and	I-geneN
kappa	I-geneN
)	E-geneN
represent	O
the	O
respective	O
targets	O
of	O
the	O
major	O
opioid	B-geneN
peptides	E-geneN
(	O
beta	B-geneY
-	I-geneY
endorphin	E-geneY
,	O
enkephalins	S-geneN
and	O
dynorphins	S-geneY
,	O
respectively	O
)	O
.	O

The	O
rewarding	O
(	O
reinforcing	O
)	O
properties	O
of	O
mu	B-geneN
-	I-geneN
and	I-geneN
delta	I-geneN
-	I-geneN
receptor	E-geneN
ligands	O
are	O
brought	O
by	O
activation	O
of	O
the	O
mesolimbic	O
dopamine	O
system	O
which	O
ascends	O
from	O
the	O
ventral	O
tegmentum	O
of	O
the	O
midbrain	O
(	O
VTA	O
)	O
to	O
rostral	O
structures	O
;	O
of	O
these	O
,	O
the	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
is	O
of	O
particular	O
importance	O
in	O
drug	O
addiction	O
.	O

In	O
contrast	O
,	O
dysphoria	O
results	O
from	O
activation	O
of	O
kappa	B-geneN
-	I-geneN
receptors	E-geneN
.	O

The	O
neurochemical	O
manifestations	O
of	O
these	O
opposing	O
effects	O
are	O
,	O
respectively	O
,	O
increases	O
and	O
decreases	O
in	O
dopamine	S-chem
release	O
in	O
the	O
NAC	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
alcohol	S-chem
interferes	O
with	O
endogenous	O
opioid	O
mechanisms	O
which	O
are	O
closely	O
linked	O
with	O
dopamine	S-chem
transmission	O
in	O
the	O
mesolimbic	O
pathway	O
.	O

The	O
view	O
that	O
condensation	O
products	O
of	O
dopamine	S-chem
and	O
alcohol	S-chem
-	O
derived	O
aldehyde	S-chem
(	O
tetrahydroisoquinolines	S-chem
)	O
play	O
a	O
role	O
remains	O
controversial	O
.	O

There	O
is	O
,	O
however	O
,	O
much	O
information	O
on	O
the	O
direct	O
(	O
acute	O
and	O
chronic	O
)	O
effects	O
of	O
alcohol	S-chem-C3-1
on	O
the	O
binding	O
properties	O
of	O
opioid	B-geneN
receptors	E-geneN
,	O
as	O
well	O
as	O
modulation	O
of	O
opioid	B-geneN
peptide	E-geneN
synthesis	O
and	O
secretion	O
(	O
e.g	O
.	O
a	O
suggested	O
increase	O
in	O
beta	B-geneY-C3-2
-	I-geneY-C3-2
endorphin	E-geneY-C3-2
release	O
)	O
.	O

In	O
view	O
of	O
the	O
reinforcing	O
properties	O
of	O
alcohol	S-chem
,	O
it	O
is	O
relevant	O
to	O
consider	O
behavioural	O
studies	O
involving	O
alcohol	S-chem
self	O
-	O
administration	O
in	O
rodents	O
and	O
primates	O
.	O

Low	O
doses	O
of	O
morphine	O
have	O
been	O
found	O
to	O
increase	O
,	O
and	O
higher	O
doses	O
of	O
the	O
opiate	O
to	O
decrease	O
,	O
alcohol	S-chem
consumption	O
.	O

Conversely	O
,	O
opioid	O
antagonists	O
such	O
as	O
naloxone	S-chem-C6-1
and	O
naltrexone	S-chem-C3-1
(	O
which	O
bind	O
to	O
non	O
-	O
selectively	O
opioid	B-geneN-MU-2
receptors	E-geneN-MU-2
)	O
have	O
been	O
shown	O
to	O
decrease	O
alcohol	S-chem
consumption	O
under	O
various	O
experimental	O
conditions	O
.	O

Similar	O
results	O
have	O
been	O
reported	O
when	O
selective	O
mu	B-geneN
-	I-geneN
or	I-geneN
delta	I-geneN
-	I-geneN
receptor	E-geneN
antagonists	O
are	O
administered	O
.	O

Results	O
obtained	O
in	O
genetic	O
models	O
of	O
high	O
preference	O
for	O
alcohol	S-chem
also	O
support	O
the	O
view	O
that	O
alcohol	O
intake	O
depends	O
on	O
the	O
activity	O
of	O
the	O
endogenous	O
opioid	O
reward	O
system	O
and	O
that	O
alcohol	S-chem
consumption	O
may	O
serve	O
to	O
compensate	O
for	O
inherent	O
deficits	O
in	O
this	O
system	O
.	O

One	O
hypothetical	O
model	O
proposes	O
that	O
reward	O
results	O
from	O
activation	O
of	O
mu	B-geneY
-	I-geneY
opioid	I-geneY
receptors	E-geneY
in	O
the	O
VTA	O
and	O
/	O
or	O
delta	B-geneY
-	I-geneY
receptor	E-geneY
in	O
the	O
NAC	O
;	O
both	O
these	O
nuclei	O
are	O
targets	O
of	O
endogenous	O
beta	B-geneY
-	I-geneY
endorphin	E-geneY
.	O

It	O
is	O
suggested	O
that	O
alcohol	S-chem
interferes	O
with	O
this	O
reward	O
pathway	O
either	O
directly	O
or	O
indirectly	O
.	O

The	O
available	O
experimental	O
data	O
accord	O
well	O
with	O
those	O
obtained	O
from	O
clinical	O
studies	O
which	O
opioid	O
antagonists	O
have	O
been	O
used	O
to	O
prevent	O
relapse	O
in	O
alcoholics	O
.	O

Conceptual	O
considerations	O
concerning	O
communalities	O
between	O
various	O
forms	O
of	O
addictions	O
are	O
also	O
discussed	O
in	O
this	O
review	O
.	O

Display	O
of	O
amino	S-chem
groups	O
on	O
substrate	O
surfaces	O
by	O
simple	O
dip	O
-	O
coating	O
of	O
methacrylate	S-chem
-	O
based	O
polymers	O
and	O
its	O
application	O
to	O
DNA	O
immobilization	O
.	O

The	O
implementation	O
of	O
a	O
reactive	O
functional	O
group	O
onto	O
a	O
material	O
surface	O
is	O
of	O
great	O
importance	O
.	O

Reactive	O
functional	O
groups	O
(	O
e.g	O
.	O
,	O
an	O
amino	S-chem
group	O
and	O
a	O
hydroxyl	S-chem
group	O
)	O
are	O
usually	O
hydrophilic	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
display	O
them	O
on	O
a	O
dry	O
polymer	O
surface	O
.	O

We	O
here	O
propose	O
a	O
novel	O
method	O
for	O
displaying	O
amino	S-chem
groups	O
on	O
the	O
surfaces	O
of	O
polymeric	O
substrates	O
through	O
dip	O
-	O
coating	O
of	O
a	O
methacrylate	S-chem
-	O
based	O
copolymer	O
.	O

We	O
synthesized	O
copolymers	O
composed	O
of	O
methyl	B-chem
methacrylate	E-chem
and	O
2	B-chem
-	I-chem
aminoethyl	I-chem
methacrylate	E-chem
with	O
different	O
protecting	O
groups	O
or	O
ion	O
-	O
complexes	O
on	O
their	O
amino	S-chem
groups	O
,	O
then	O
dip	O
-	O
coated	O
the	O
copolymers	O
onto	O
a	O
poly	B-chem
(	I-chem
methyl	I-chem
methacrylate	I-chem
)	E-chem
(	O
PMMA	S-chem
)	O
substrate	O
.	O

Evaluation	O
using	O
a	O
cleavable	O
fluorescent	O
compound	O
,	O
which	O
was	O
synthesized	O
in	O
the	O
present	O
study	O
to	O
quantify	O
a	O
small	O
amount	O
(	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
of	O
amino	S-chem
groups	O
on	O
a	O
solid	O
surface	O
,	O
revealed	O
that	O
the	O
protection	O
of	O
amino	S-chem
groups	O
affected	O
their	O
surface	O
segregation	O
in	O
the	O
copolymer	O
coating	O
.	O
p	B-chem
-	I-chem
Toluenesulfonate	E-chem
ion	O
-	O
complex	O
and	O
tert	B-chem
-	I-chem
butoxycarbonyl	E-chem
(	O
Boc	S-chem
)	O
protection	O
of	O
amino	S-chem
groups	O
were	O
found	O
to	O
effectively	O
display	O
amino	S-chem
groups	O
on	O
the	O
surface	O
(	O
more	O
than	O
70	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
.	O

The	O
density	O
of	O
amino	S-chem
groups	O
displayed	O
on	O
a	O
surface	O
can	O
be	O
easily	O
controlled	O
by	O
mixing	O
the	O
copolymer	O
and	O
PMMA	S-chem
before	O
dip	O
-	O
coating	O
.	O

Dip	O
-	O
coating	O
of	O
the	O
copolymer	O
with	O
Boc	S-chem
protection	O
on	O
various	O
polymeric	O
substrates	O
also	O
successfully	O
displayed	O
amino	S-chem
groups	O
on	O
their	O
surfaces	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
amino	S-chem
groups	O
displayed	O
can	O
be	O
utilized	O
for	O
the	O
immobilization	O
of	O
a	O
DNA	O
oligonucleotide	O
on	O
a	O
substrate	O
surface	O
.	O

No	O
mutations	O
in	O
the	O
serotonin	S-chem
related	O
TPH1	S-geneY
and	O
HTR1B	S-geneY
genes	O
in	O
patients	O
with	O
monogenic	O
sclerosing	O
bone	O
disorders	O
.	O

Since	O
the	O
identification	O
of	O
LRP5	S-geneY
as	O
the	O
causative	O
gene	O
for	O
the	O
osteoporosis	O
pseudoglioma	O
syndrome	O
(	O
OPPG	O
)	O
as	O
well	O
as	O
the	O
high	O
bone	O
mass	O
(	O
HBM	O
)	O
phenotype	O
,	O
LRP5	S-geneY
and	O
the	O
Wnt	S-geneN
/	O
β	B-geneY
-	I-geneY
catenin	E-geneY
signaling	O
have	O
been	O
extensively	O
studied	O
for	O
their	O
role	O
in	O
the	O
differentiation	O
and	O
proliferation	O
of	O
osteoblasts	O
,	O
in	O
the	O
apoptosis	O
of	O
osteoblasts	O
and	O
osteocytes	O
and	O
in	O
the	O
response	O
of	O
bone	O
to	O
mechanical	O
loading	O
.	O

However	O
,	O
more	O
recently	O
the	O
direct	O
effect	O
of	O
LRP5	S-geneY
on	O
osteoblasts	O
and	O
bone	O
formation	O
has	O
been	O
questioned	O
.	O

Gene	O
expression	O
studies	O
showed	O
that	O
mice	O
lacking	O
lrp5	S-geneY
have	O
increased	O
expression	O
of	O
tph1	S-geneY
,	O
the	O
rate	O
limiting	O
enzyme	O
for	O
the	O
production	O
of	O
serotonin	S-chem
in	O
the	O
gut	O
.	O

Furthermore	O
mice	O
lacking	O
either	O
tph1	S-geneY
or	O
htr1B	S-geneY
,	O
the	O
receptor	O
for	O
serotonin	S-chem
on	O
the	O
osteoblasts	O
,	O
were	O
reported	O
to	O
have	O
an	O
increased	O
bone	O
mass	O
due	O
to	O
increased	O
bone	O
formation	O
.	O

This	O
led	O
to	O
the	O
still	O
controversial	O
hypothesis	O
that	O
LRP5	S-geneY
influences	O
bone	O
formation	O
indirectly	O
by	O
regulating	O
the	O
expression	O
of	O
thp1	S-geneY
and	O
as	O
a	O
consequence	O
influencing	O
the	O
production	O
of	O
serotonin	S-chem
in	O
the	O
gut	O
.	O

Based	O
on	O
these	O
data	O
we	O
decided	O
to	O
evaluate	O
the	O
role	O
of	O
TPH1	S-geneY
and	O
HTR1B	S-geneY
in	O
the	O
development	O
of	O
craniotubular	O
hyperostoses	O
,	O
a	O
group	O
of	O
monogenic	O
sclerosing	O
bone	O
dysplasias	O
.	O

We	O
screened	O
the	O
coding	O
regions	O
of	O
both	O
genes	O
in	O
53	O
patients	O
lacking	O
a	O
mutation	O
in	O
the	O
known	O
causative	O
genes	O
LRP5	S-geneY
,	O
LRP4	S-geneY
and	O
SOST	S-geneY
.	O

We	O
could	O
not	O
find	O
disease	O
-	O
causing	O
coding	O
variants	O
in	O
neither	O
of	O
the	O
tested	O
genes	O
and	O
therefore	O
,	O
we	O
can	O
not	O
provide	O
support	O
for	O
an	O
important	O
function	O
of	O
TPH1	S-geneY
and	O
HTR1B	S-geneY
in	O
the	O
pathogenesis	O
of	O
sclerosing	O
bone	O
dysplasias	O
in	O
our	O
tested	O
patient	O
cohort	O
.	O

Vandetanib	S-chem
:	O
opening	O
a	O
new	O
treatment	O
practice	O
in	O
advanced	O
medullary	O
thyroid	O
carcinoma	O
.	O

Medullary	O
thyroid	O
cancer	O
(	O
MTC	O
)	O
is	O
frequently	O
diagnosed	O
in	O
a	O
locally	O
advanced	O
or	O
metastatic	O
stage	O
,	O
and	O
10	O
-	O
year	O
survival	O
rates	O
in	O
these	O
cases	O
are	O
below	O
20	O
%	O
.	O

Cytotoxic	O
chemotherapy	O
has	O
no	O
significant	O
impact	O
on	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
.	O

Vandetanib	S-chem-C4-1
(	O
Caprelsa	S-chem-C4-1
(	O
®	O
)	O
,	O
AstraZeneca	O
)	O
is	O
a	O
once	O
-	O
daily	O
oral	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
that	O
selectively	O
inhibits	O
signalling	O
mediated	O
by	O
growth	B-geneN-C4-2
-	I-geneN-C4-2
factor	I-geneN-C4-2
receptor	I-geneN-C4-2
tyrosine	I-geneN-C4-2
kinase	E-geneN-C4-2
RET	S-geneY-C4-2
(	O
constitutively	O
activated	O
in	O
roughly	O
60	O
%	O
of	O
all	O
MTCs	O
)	O
,	O
vascular	O
endothelial	I-geneN
growth	I-geneN
-	I-geneN
factor	I-geneN
receptors	I-geneN
2	I-geneN
and	I-geneN
3	I-geneN
,	E-geneN
and	O
epidermal	O
growth	I-geneY-C4-2
-	I-geneY-C4-2
factor	I-geneY-C4-2
receptors	I-geneY-C4-2
.	E-geneY-C4-2

It	O
is	O
the	O
first	O
systemic	O
drug	O
with	O
demonstrated	O
anti	O
-	O
tumor	O
benefits	O
in	O
advanced	O
MTC	O
,	O
and	O
it	O
has	O
recently	O
been	O
approved	O
for	O
locally	O
advanced	O
or	O
metastatic	O
MTC	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
(	O
April	O
2011	O
)	O
and	O
the	O
European	O
Medicines	O
Agency	O
(	O
February	O
2012	O
)	O
.	O

This	O
review	O
,	O
starting	O
from	O
the	O
phases	O
II	O
and	O
III	O
efficacy	O
and	O
safety	O
data	O
that	O
led	O
to	O
these	O
approvals	O
,	O
explores	O
important	O
issues	O
related	O
to	O
dosing	O
,	O
patient	O
selection	O
,	O
and	O
strategies	O
for	O
managing	O
the	O
substantial	O
risk	O
of	O
toxicity	O
associated	O
with	O
the	O
drug	O
(	O
including	O
life	O
-	O
threatening	O
cardiac	O
events	O
that	O
are	O
the	O
subject	O
of	O
a	O
black	O
-	O
box	O
warning	O
in	O
the	O
United	O
States	O
)	O
.	O

All	O
these	O
issues	O
still	O
remain	O
to	O
be	O
defined	O
.	O

Vandetanib	S-chem
is	O
becoming	O
a	O
standard	O
of	O
care	O
for	O
symptomatic	O
,	O
progressive	O
,	O
metastatic	O
MTCs	O
,	O
to	O
be	O
used	O
selectively	O
in	O
those	O
patients	O
who	O
are	O
likely	O
to	O
benefit	O
from	O
it	O
.	O

Cefepime	S-chem
:	O
overview	O
of	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cefepime	S-chem
is	O
a	O
novel	O
methoxyimino	B-chem
-	I-chem
aminothiazolyl	I-chem
cephalosporin	E-chem
with	O
a	O
quaternized	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
pyrrolidine	E-chem
moiety	O
at	O
the	O
3	O
'	O
position	O
conferring	O
zwitterionic	O
properties	O
.	O

Because	O
of	O
this	O
the	O
molecule	O
penetrates	O
the	O
outer	O
cell	O
membrane	O
of	O
Gram	O
-	O
negative	O
bacteria	O
rapidly	O
.	O

In	O
addition	O
it	O
is	O
resistant	O
to	O
degradation	O
by	O
several	O
plasmid	O
and	O
chromosomally	O
-	O
mediated	O
beta	B-geneN
-	I-geneN
lactamases	E-geneN
,	O
for	O
which	O
it	O
also	O
shows	O
very	O
low	O
affinity	O
and	O
no	O
inducing	O
capacity	O
.	O

It	O
has	O
good	O
affinity	O
for	O
PBPs	B-geneN
2	I-geneN
and	I-geneN
3	E-geneN
of	O
Escherichia	O
coli	O
and	O
for	O
PBP	B-geneY
3	E-geneY
of	O
Pseudomonas	O
aeruginosa	O
.	O

Its	O
broad	O
-	O
spectrum	O
of	O
activity	O
includes	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
pathogens	O
.	O

It	O
is	O
more	O
active	O
than	O
cefotaxime	S-chem
or	O
ceftazidime	S-chem
,	O
against	O
Enterobacteriaceae	O
.	O

The	O
MIC90	O
for	O
P.	O
aeruginosa	O
is	O
higher	O
than	O
that	O
of	O
ceftazidime	S-chem
,	O
but	O
lower	O
than	O
those	O
of	O
cefpirome	S-chem
,	O
cefoperazone	S-chem
and	O
latamoxef	S-chem
.	O

Other	O
Gram	O
-	O
negative	O
organisms	O
,	O
Haemophilus	O
influenzae	O
,	O
Neiserria	O
meningitidis	O
,	O
Neiserria	O
gonorrhoeae	O
,	O
Moraxella	O
catarrhalis	O
are	O
highly	O
susceptible	O
to	O
cefepime	S-chem
.	O

Among	O
Gram	O
-	O
positive	O
species	O
methicillin	O
-	O
susceptible	O
Staphylococcus	O
aureus	O
and	O
coagulase	S-geneN
-	O
negative	O
staphylococci	O
,	O
whether	O
beta	B-geneN
-	I-geneN
lactamase	E-geneN
producers	O
or	O
not	O
,	O
Streptococcus	O
pneumoniae	O
and	O
Streptococcus	O
pyogenes	O
are	O
susceptible	O
.	O

Cefepime	S-chem
is	O
active	O
against	O
cefotaxime	S-chem
-	O
and	O
/	O
or	O
ceftazidime	S-chem
-	O
resistant	O
Enterobacteriaceae	O
.	O

Only	O
strains	O
of	O
P.	O
aeruginosa	O
producing	O
large	O
amounts	O
of	O
beta	B-geneN
-	I-geneN
lactamase	E-geneN
may	O
be	O
resistant	O
to	O
both	O
ceftazidime	S-chem
and	O
cefepime	S-chem
.	O

In	O
experimental	O
infections	O
such	O
as	O
meningitis	O
,	O
induced	O
with	O
various	O
bacterial	O
species	O
in	O
neonatal	O
rats	O
and	O
chronic	O
staphylococcal	O
osteomyelitis	O
in	O
rabbits	O
,	O
cefepime	S-chem
has	O
shown	O
good	O
efficacy	O
.	O

Significance	O
of	O
the	O
transient	B-geneY
receptor	I-geneY
potential	I-geneY
canonical	I-geneY
2	E-geneY
(	O
TRPC2	S-geneY
)	O
channel	O
in	O
the	O
regulation	O
of	O
rat	O
thyroid	O
FRTL	O
-	O
5	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
and	O
invasion	O
.	O

Mammalian	B-geneN
transient	I-geneN
receptor	I-geneN
potential	I-geneN
(	I-geneN
TRP	I-geneN
)	I-geneN
channels	E-geneN
are	O
involved	O
in	O
many	O
physiologically	O
important	O
processes	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
significance	O
of	O
the	O
TRPC2	S-geneY
channel	O
in	O
the	O
regulation	O
of	O
rat	O
thyroid	O
FRTL	O
-	O
5	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
and	O
invasion	O
,	O
using	O
stable	O
TRPC2	S-geneY
(	O
shTRPC2	O
)	O
knock	O
-	O
down	O
cells	O
.	O

In	O
the	O
shTRPC2	O
cells	O
,	O
proliferation	O
was	O
decreased	O
due	O
to	O
a	O
prolonged	O
G1	O
/	O
S	O
cell	O
cycle	O
phase	O
.	O

The	O
tumor	B-geneY
suppressor	I-geneY
p53	E-geneY
and	O
the	O
cyclin	B-geneY
-	I-geneY
dependant	I-geneY
kinase	I-geneY
inhibitors	I-geneY
p27	E-geneY
and	O
p21	S-geneY
were	O
upregulated	O
.	O

Cell	O
invasion	O
,	O
adhesion	O
and	O
migration	O
were	O
also	O
attenuated	O
in	O
shTRPC2	O
cells	O
,	O
probably	O
due	O
to	O
decreased	O
activity	O
of	O
both	O
Rac	S-geneN
and	O
calpain	S-geneN
,	O
and	O
a	O
decreased	O
secretion	O
and	O
activity	O
of	O
matrix	B-geneY
metalloproteinase	I-geneY
2	E-geneY
.	O

The	O
attenuated	O
proliferation	O
,	O
migration	O
,	O
invasion	O
and	O
ATP	S-chem
-	O
evoked	O
calcium	S-chem
entry	O
was	O
mimicked	O
by	O
overexpressing	O
a	O
non	O
-	O
conducting	O
,	O
truncated	O
TRPC2	S-geneY
(	O
TRPC2	S-geneY
-	O
DN	O
)	O
in	O
wild	O
type	O
cells	O
,	O
and	O
was	O
reversed	O
by	O
overexpression	O
of	O
TRPC2	S-geneY
-	O
GFP	O
in	O
shTRPC2	O
cells	O
.	O

In	O
conclusion	O
,	O
TRPC2	S-geneY
is	O
an	O
important	O
regulator	O
of	O
rat	O
thyroid	O
cell	O
function	O
.	O

Conivaptan	S-chem-C6-1
:	O
a	O
dual	O
vasopressin	B-geneN-C6-2
receptor	I-geneN-C6-2
v1a	I-geneN-C6-2
/	I-geneN-C6-2
v2	E-geneN-C6-2
antagonist	O
[	O
corrected	O
]	O
.	O

Several	O
fluid	O
retentive	O
states	O
such	O
as	O
heart	O
failure	O
,	O
cirrhosis	O
of	O
the	O
liver	O
,	O
and	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
secretion	O
are	O
associated	O
with	O
inappropriate	O
elevation	O
in	O
plasma	O
levels	O
of	O
arginine	B-geneY
vasopressin	E-geneY
(	O
AVP	S-geneY
)	O
,	O
a	O
neuropeptide	O
that	O
is	O
secreted	O
by	O
the	O
hypothalamus	O
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
serum	O
osmolality	O
and	O
in	O
circulatory	O
homeostasis	O
.	O

The	O
actions	O
of	O
AVP	S-geneY
are	O
mediated	O
by	O
three	O
receptor	O
subtypes	O
V1a	O
,	O
V2	O
,	O
and	O
V1b	O
.	O

The	O
V1a	B-geneY
receptor	E-geneY
regulates	O
vasodilation	O
and	O
cellular	O
hypertrophy	O
while	O
the	O
V2	B-geneY
receptor	E-geneY
regulates	O
free	O
water	O
excretion	O
.	O

The	O
V1b	B-geneY
receptor	E-geneY
regulates	O
adrenocorticotropin	B-geneY
hormone	E-geneY
release	O
.	O

Conivaptan	S-chem-C6-1
is	O
a	O
nonpeptide	O
dual	O
V1a	B-geneN-C6-2
/	I-geneN-C6-2
V2	I-geneN-C6-2
AVP	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
.	O

It	O
binds	O
with	O
high	O
affinity	O
,	O
competitively	O
,	O
and	O
reversibly	O
to	O
the	O
V1a	B-geneN
/	I-geneN
V2	I-geneN
receptor	E-geneN
subtypes	O
;	O
its	O
antagonistic	O
effect	O
is	O
concentration	O
dependent	O
.	O

It	O
inhibits	O
CYP3A4	S-geneY
liver	O
enzyme	O
and	O
elevates	O
plasma	O
levels	O
of	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
.	O

It	O
is	O
approved	O
only	O
for	O
short	O
-	O
term	O
intravenous	O
use	O
.	O

Infusion	O
site	O
reaction	O
is	O
the	O
most	O
common	O
reason	O
for	O
discontinuation	O
of	O
the	O
drug	O
.	O

In	O
animals	O
conivaptan	O
increased	O
urine	O
volume	O
and	O
free	O
water	O
clearance	O
.	O

In	O
heart	O
failure	O
models	O
it	O
improved	O
hemodynamic	O
parameters	O
and	O
free	O
water	O
excretion	O
.	O

Conivaptan	S-chem
has	O
been	O
shown	O
to	O
correct	O
hyponatremia	O
in	O
euvolemic	O
or	O
hypervolemic	O
patients	O
.	O

Its	O
efficacy	O
and	O
safety	O
for	O
short	O
-	O
term	O
use	O
have	O
led	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approval	O
of	O
its	O
intravenous	O
form	O
for	O
the	O
correction	O
of	O
hyponatremia	O
in	O
euvolemic	O
and	O
hypervolemic	O
states	O
.	O

Despite	O
its	O
ability	O
to	O
block	O
the	O
action	O
of	O
AVP	S-geneY
on	O
V1a	B-geneY
receptors	E-geneY
,	O
no	O
demonstrable	O
benefit	O
from	O
this	O
action	O
was	O
noted	O
in	O
patients	O
with	O
chronic	O
compensated	O
heart	O
failure	O
and	O
it	O
is	O
not	O
approved	O
for	O
this	O
indication	O
.	O

Consideration	O
should	O
be	O
given	O
to	O
further	O
evaluation	O
of	O
its	O
potential	O
benefits	O
in	O
patients	O
with	O
acute	O
decompensated	O
heart	O
failure	O
.	O

Effect	O
of	O
pitavastatin	S-chem
on	O
apolipoprotein	B-geneY
A	I-geneY
-	I-geneY
I	E-geneY
production	O
in	O
HepG2	O
cell	O
.	O

There	O
are	O
few	O
reports	O
describing	O
the	O
mechanism	O
of	O
HDL	S-geneN
-	O
elevating	O
action	O
of	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibitors	O
(	O
statins	O
)	O
.	O

As	O
it	O
is	O
considered	O
that	O
the	O
key	O
step	O
of	O
HDL	S-geneN
production	O
is	O
the	O
secretion	O
of	O
apolipoprotein	B-geneY
A	I-geneY
-	I-geneY
I	E-geneY
(	O
apoA	B-geneY
-	I-geneY
I	E-geneY
)	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
statins	O
on	O
apoA	B-geneY
-	I-geneY
I	E-geneY
synthesis	O
and	O
secretion	O
by	O
HepG2	O
cell	O
to	O
elucidate	O
the	O
mechanism	O
of	O
the	O
action	O
.	O

Each	O
statin	O
induced	O
apoA	B-geneY
-	I-geneY
I	E-geneY
expression	O
(	O
mRNA	O
and	O
protein	O
)	O
dose	O
-	O
dependently	O
:	O
the	O
rank	O
order	O
of	O
the	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
induction	O
pitavastatin	S-chem-C3-1
(	O
3	O
microM	O
)	O
>	O
simvastatin	S-chem-C3-1
(	O
10	O
microM	O
)	O
>	O
atorvastatin	S-chem-C3-1
(	O
30	O
microM	O
)	O
.	O

The	O
induction	O
of	O
apoA	B-geneY-C4-2
-	I-geneY-C4-2
I	E-geneY-C4-2
by	O
statins	O
disappeared	O
with	O
addition	O
of	O
mevalonate	S-chem-C4-1
,	O
which	O
indicates	O
that	O
the	O
effect	O
is	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibition	O
-	O
dependent	O
.	O

Based	O
on	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibition	O
,	O
pitavastatin	S-chem-C3-1
-	O
induced	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
more	O
efficiently	O
than	O
simvastatin	S-chem-C3-1
and	O
atorvastatin	S-chem-C3-1
.	O

Further	O
study	O
revealed	O
that	O
pitavastatin	S-chem-C3-1
increased	O
ABCA1	S-geneY-C3-2
mRNA	O
in	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
-	O
dependent	O
manner	O
and	O
that	O
Rho	S-geneN-C4-2
and	O
Rho	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
(	O
C3T	O
and	O
Y27632	S-chem-MU-1
)	O
increased	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
production	O
in	O
the	O
HepG2	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
pitavastatin	S-chem-MU-1
efficiently	O
increases	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
in	O
the	O
culture	O
medium	O
of	O
HepG2	O
cells	O
by	O
promoting	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
production	O
through	O
inhibition	O
of	O
HMG	B-geneY-C4-2
-	I-geneY-C4-2
CoA	I-geneY-C4-2
reductase	E-geneY-C4-2
and	O
suppression	O
of	O
Rho	S-geneN-C4-2
activity	O
and	O
by	O
protecting	O
apoA	B-geneY
-	I-geneY
I	E-geneY
from	O
catabolism	O
through	O
ABCA1	S-geneY-C3-2
induction	O
and	O
lipidation	O
of	O
apoA	B-geneY-C3-2
-	I-geneY-C3-2
I	E-geneY-C3-2
.	O

In	O
Vitro	O
Reconstitution	O
of	O
Complexes	O
between	O
proMatrix	B-geneY
Metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
and	O
the	O
Proteoglycans	O
Serglycin	O
and	O
Versican	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
a	O
fraction	O
of	O
the	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
(	O
MMP	B-geneY
-	I-geneY
9	E-geneY
)	O
synthesized	O
by	O
the	O
macrophage	O
cell	O
line	O
THP	O
-	O
1	O
was	O
bound	O
to	O
a	O
chondroitin	B-geneN
sulphate	I-geneN
proteoglycan	I-geneN
(	I-geneN
CSPG	I-geneN
)	I-geneN
core	I-geneN
protein	E-geneN
as	O
a	O
reduction	O
sensitive	O
heteromer	O
.	O

It	O
was	O
also	O
shown	O
that	O
the	O
hemopexin	B-geneN
-	I-geneN
like	I-geneN
(	I-geneN
PEX	I-geneN
)	I-geneN
domain	E-geneN
and	O
the	O
fibronectin	B-geneN
-	I-geneN
like	I-geneN
(	I-geneN
FnII	I-geneN
)	I-geneN
module	E-geneN
in	O
the	O
enzyme	O
are	O
involved	O
in	O
the	O
heteromer	O
formation	O
.	O

In	O
the	O
present	O
work	O
we	O
show	O
that	O
reduction	O
sensitive	O
and	O
SDS	S-chem
-	O
stable	O
heteromers	O
can	O
be	O
reconstituted	O
in	O
vitro	O
by	O
mixing	O
proMMP	B-geneY
-	I-geneY
9	E-geneY
with	O
either	O
serglycin	O
,	O
versican	O
or	O
CSPGs	S-geneN
isolated	O
from	O
various	O
monocytic	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
a	O
strong	O
but	O
SDS	S-chem
-	O
soluble	O
proMMP	B-geneY
-	I-geneY
9	E-geneY
·	O
CSPG	S-geneN
heteromer	O
was	O
formed	O
.	O

The	O
two	O
macromolecules	O
in	O
the	O
SDS	S-chem
-	O
stable	O
reduction	O
sensitive	O
heteromers	O
were	O
not	O
linked	O
together	O
by	O
disulphide	S-chem
bonds	O
.	O

As	O
for	O
the	O
heteromer	O
isolated	O
from	O
THP	O
-	O
1	O
cells	O
,	O
the	O
in	O
vitro	O
reconstituted	O
SDS	S-chem
-	O
stable	O
and	O
SDS	S-chem
-	O
soluble	O
heteromers	O
had	O
a	O
weaker	O
binding	O
to	O
gelatin	O
than	O
the	O
proMMP	B-geneY
-	I-geneY
9	E-geneY
monomer	O
.	O

Furthermore	O
,	O
gelatin	O
inhibited	O
the	O
in	O
vitro	O
reconstitution	O
of	O
the	O
heteromers	O
,	O
showing	O
that	O
the	O
FnII	B-geneN
module	E-geneN
is	O
involved	O
in	O
the	O
complex	O
formation	O
.	O

TIMP	B-geneY
-	I-geneY
1	E-geneY
could	O
not	O
be	O
detected	O
in	O
the	O
formed	O
proMMP	B-geneY
-	I-geneY
9	E-geneY
·	O
CSPG	S-geneN
complexes	O
.	O

However	O
,	O
the	O
presence	O
of	O
TIMP	B-geneY
-	I-geneY
1	E-geneY
inhibited	O
the	O
formation	O
of	O
the	O
SDS	S-chem
-	O
soluble	O
heteromer	O
,	O
but	O
not	O
the	O
SDS	S-chem
-	O
stable	O
reduction	O
sensitive	O
heteromer	O
.	O

This	O
indicates	O
that	O
different	O
regions	O
in	O
the	O
PEX	B-geneN
domain	E-geneN
are	O
involved	O
the	O
formation	O
of	O
these	O
heteromers	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Estramustine	B-geneN
binding	I-geneN
protein	E-geneN
in	O
primary	O
tumours	O
and	O
metastases	O
of	O
malignant	O
melanoma	O
.	O

The	O
presence	O
of	O
estramustine	B-geneN
binding	I-geneN
protein	E-geneN
(	O
EMBP	S-geneN
)	O
,	O
a	O
54	O
kD	O
cytosolic	O
glycoprotein	O
,	O
which	O
is	O
distinct	O
from	O
the	O
estrogen	B-geneY
receptor	E-geneY
,	O
was	O
investigated	O
in	O
a	O
pilot	O
study	O
of	O
primary	O
malignant	O
melanomas	O
and	O
their	O
metastases	O
.	O

In	O
11	O
primary	O
melanomas	O
EMBP	S-geneN
was	O
demonstrated	O
by	O
immunohistochemistry	O
.	O

The	O
percentage	O
of	O
positive	O
melanoma	O
cells	O
ranged	O
between	O
11	O
-	O
91	O
%	O
with	O
a	O
mean	O
of	O
57	O
%	O
.	O

Radioimmunoassay	O
on	O
metastatic	O
tissue	O
revealed	O
significant	O
amounts	O
of	O
EMBP	S-geneN
,	O
with	O
values	O
ranging	O
between	O
0.6	O
-	O
4.2	O
with	O
a	O
mean	O
of	O
1.6	O
ng	O
/	O
mg	O
protein	O
.	O

A	O
high	O
number	O
of	O
cells	O
with	O
a	O
positive	O
stain	O
for	O
EMBP	S-geneN
in	O
the	O
primary	O
tumours	O
was	O
significantly	O
correlated	O
to	O
a	O
short	O
interval	O
between	O
diagnosis	O
and	O
the	O
occurrence	O
of	O
metastases	O
.	O

Presence	O
of	O
EMBP	S-geneN
in	O
malignant	O
melanoma	O
may	O
have	O
prognostic	O
significance	O
and	O
the	O
role	O
of	O
hormone	O
-	O
linked	O
cytostatic	O
drugs	O
in	O
the	O
treatment	O
of	O
this	O
disease	O
needs	O
further	O
investigation	O
.	O

Donepezil	B-chem
hydrochloride	E-chem
:	O
a	O
treatment	O
drug	O
for	O
Alzheimer	O
's	O
disease	O
.	O

The	O
role	O
of	O
the	O
cholinergic	O
system	O
with	O
respect	O
to	O
cognitive	O
deficits	O
characteristic	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
has	O
led	O
to	O
a	O
number	O
of	O
studies	O
focusing	O
on	O
the	O
development	O
of	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
inhibitors	O
as	O
a	O
drug	O
for	O
treating	O
this	O
disease	O
.	O

The	O
earliest	O
known	O
AChE	S-geneY-C4-2
inhibitors	O
,	O
namely	O
,	O
physostigmine	S-chem-C4-1
and	O
tacrine	S-chem-C4-1
,	O
performed	O
poorly	O
in	O
clinical	O
trials	O
(	O
e.g	O
.	O
,	O
poor	O
oral	O
activity	O
,	O
brain	O
penetration	O
,	O
and	O
hepatotoxic	O
liability	O
)	O
.	O

Studies	O
were	O
then	O
focused	O
on	O
finding	O
a	O
new	O
type	O
of	O
acetylcholinesterase	O
inhibitor	O
that	O
would	O
overcome	O
the	O
disadvantages	O
of	O
these	O
two	O
compounds	O
.	O

Donepezil	B-chem-C4-1
hydrochloride	E-chem-C4-1
inaugurates	O
a	O
new	O
class	O
of	O
AChE	S-geneY-C4-2
inhibitors	O
with	O
longer	O
and	O
more	O
selective	O
action	O
and	O
with	O
manageable	O
adverse	O
effects	O
.	O

Inhibition	O
of	O
platelet	B-geneN
receptors	E-geneN
involved	O
in	O
neutrophil	O
-	O
platelet	O
interaction	O
in	O
model	O
cardiopulmonary	O
bypass	O
.	O

We	O
investigated	O
the	O
interactions	O
between	O
neutrophils	O
,	O
platelets	O
,	O
and	O
artificial	O
surfaces	O
,	O
and	O
whether	O
blocking	O
of	O
relevant	O
receptors	O
on	O
platelets	O
reduced	O
unwanted	O
activation	O
responses	O
in	O
model	O
cardiopulmonary	O
bypass	O
.	O

Isolated	O
neutrophils	O
and	O
platelets	O
resuspended	O
in	O
heparin	O
-	O
anticoagulated	O
plasma	O
were	O
recirculated	O
with	O
and	O
without	O
blocking	O
antibodies	O
to	O
CD62P	S-geneY
,	O
CD42b	S-geneY
,	O
or	O
junctional	B-geneY
adhesion	I-geneY
molecule	I-geneY
C	E-geneY
(	O
JAM	B-geneY
-	I-geneY
C	E-geneY
)	O
in	O
polyvinyl	B-chem
chloride	E-chem
tubing	O
using	O
a	O
roller	O
pump	O
.	O

Platelet	O
adhesion	O
to	O
the	O
tubing	O
was	O
inhibited	O
by	O
anti	O
-	O
CD42b	S-geneY
and	O
anti	O
-	O
CD62P	S-geneY
,	O
and	O
adhesion	O
of	O
neutrophils	O
by	O
anti	O
-	O
JAM	B-geneY
-	I-geneY
C	E-geneY
.	O

Formation	O
of	O
platelet	O
-	O
neutrophil	O
and	O
platelet	O
aggregates	O
was	O
reduced	O
by	O
anti	O
-	O
CD62P	S-geneY
.	O

Anti	O
-	O
JAM	B-geneY
-	I-geneY
C	E-geneY
decreased	O
platelet	O
-	O
neutrophil	O
aggregation	O
at	O
low	O
concentrations	O
and	O
platelet	O
macroaggregates	O
at	O
high	O
concentrations	O
.	O

Anti	O
-	O
CD62P	S-geneY
increased	O
neutrophil	O
CD11b	S-geneY
expression	O
but	O
not	O
degranulation	O
.	O

Anti	O
-	O
JAM	B-geneY
-	I-geneY
C	E-geneY
substantially	O
increased	O
neutrophil	O
degranulation	O
and	O
slightly	O
increased	O
CD11b	S-geneY
expression	O
.	O

Platelet	O
activation	O
increased	O
when	O
CD62P	S-geneY
was	O
blocked	O
and	O
decreased	O
with	O
anti	O
-	O
CD42b	S-geneY
antibody	O
.	O

High	O
-	O
dose	O
anti	O
-	O
JAM	B-geneY
-	I-geneY
C	E-geneY
reduced	O
platelet	O
activation	O
.	O

In	O
conclusion	O
,	O
inhibiting	O
platelet	O
and	O
neutrophil	O
-	O
platelet	O
interactions	O
had	O
useful	O
effects	O
but	O
no	O
single	O
blocking	O
antibody	O
seemed	O
capable	O
of	O
inducing	O
only	O
beneficial	O
effects	O
.	O

Characterization	O
of	O
steroidogenic	O
enzyme	O
expression	O
in	O
aldosterone	S-chem
-	O
producing	O
adenoma	O
:	O
a	O
comparison	O
with	O
various	O
human	O
adrenal	O
tumors	O
.	O

We	O
analyzed	O
the	O
expression	O
profiles	O
of	O
several	O
steroidogenic	O
enzymes	O
in	O
normal	O
adrenals	O
,	O
aldosterone	S-chem
-	O
producing	O
adenomas	O
(	O
APA	O
)	O
,	O
cortisol	S-chem
-	O
producing	O
adenomas	O
combined	O
with	O
Cushing	O
's	O
syndrome	O
(	O
CPA	O
)	O
or	O
with	O
subclinical	O
Cushing	O
's	O
syndrome	O
(	O
SCPA	O
)	O
,	O
and	O
nonfunctioning	O
adrenal	O
adenomas	O
(	O
NFA	O
)	O
to	O
clarify	O
the	O
nature	O
and	O
characteristics	O
of	O
steroidogenesis	O
in	O
APA	O
.	O

Clinical	O
data	O
were	O
collected	O
for	O
all	O
subjects	O
.	O

In	O
resected	O
adrenal	O
glands	O
(	O
normal	O
adrenals	O
,	O
APA	O
,	O
CPA	O
,	O
SCPA	O
,	O
and	O
NFA	O
)	O
,	O
the	O
mRNA	O
expression	O
levels	O
of	O
the	O
CYP17	S-geneY
,	O
HSD3B2	S-geneY
,	O
CYP11B1	S-geneY
,	O
and	O
CYP11B2	S-geneY
genes	O
were	O
studied	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
and	O
immunohistochemistry	O
.	O

The	O
CYP11B2	S-geneY
mRNA	O
level	O
in	O
APA	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
groups	O
.	O

The	O
CYP17	S-geneY
/	O
HSD3B2	S-geneY
ratio	O
for	O
mRNA	O
in	O
APA	O
was	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
other	O
groups	O
.	O

Low	O
ratio	O
of	O
CYP17	S-geneY
/	O
HSD3B2	S-geneY
with	O
high	O
expression	O
of	O
CYP11B2	S-geneY
seems	O
to	O
explain	O
steroidogenic	O
characteristics	O
of	O
APA	O
.	O

Thyroid	B-geneN
hormone	I-geneN
receptor	E-geneN
expression	O
in	O
the	O
obligatory	O
paedomorphic	O
salamander	O
Necturus	O
maculosus	O
.	O

Amphibian	O
metamorphosis	O
is	O
under	O
the	O
strict	O
control	O
of	O
thyroid	B-chem
hormones	E-chem
(	O
TH	S-chem
)	O
.	O

These	O
hormones	O
induce	O
metamorphosis	O
by	O
controlling	O
gene	O
expression	O
through	O
binding	O
to	O
thyroid	B-geneN
hormone	I-geneN
receptors	E-geneN
(	O
TRs	S-geneN
)	O
.	O

Necturus	O
maculosus	O
is	O
considered	O
to	O
be	O
an	O
obligatory	O
paedomorphic	O
Amphibian	O
since	O
metamorphosis	O
never	O
occurs	O
spontaneously	O
and	O
can	O
not	O
be	O
induced	O
by	O
pharmacological	O
means	O
.	O

Since	O
metamorphosis	O
depends	O
on	O
the	O
acquisition	O
of	O
response	O
of	O
tadpole	O
tissues	O
to	O
thyroid	B-chem
hormone	E-chem
,	O
we	O
aimed	O
to	O
determine	O
TR	S-geneN
gene	O
expression	O
patterns	O
in	O
Necturus	O
maculosus	O
as	O
well	O
as	O
the	O
expression	O
of	O
two	O
TH	S-chem
-	O
related	O
genes	O
:	O
Cytosolic	B-geneN
Thyroid	I-geneN
Hormone	I-geneN
-	I-geneN
Binding	I-geneN
Protein	E-geneN
(	O
CTHBP	S-geneN
)	O
-	O
M2	B-geneN
-	I-geneN
pyruvate	I-geneN
kinase	E-geneN
,	O
a	O
gene	O
encoding	O
a	O
cytosolic	B-geneN
TH	I-geneN
binding	I-geneN
protein	E-geneN
and	O
stromelysin	B-geneY
3	E-geneY
,	O
a	O
direct	O
TH	O
target	O
gene	O
in	O
Xenopus	O
laevis	O
.	O

Tissue	O
samples	O
were	O
obtained	O
from	O
specimens	O
of	O
Necturus	O
maculosus	O
.	O

We	O
performed	O
in	O
situ	O
hybridization	O
using	O
non	O
-	O
cross	O
-	O
hybridizing	O
RNA	O
probes	O
obtained	O
from	O
the	O
cloned	O
Necturus	B-geneY
TRalpha	E-geneY
and	O
TRbeta	S-geneY
genes	O
.	O

We	O
found	O
clear	O
expression	O
of	O
Necturus	B-geneY
TRalpha	E-geneY
gene	O
in	O
several	O
tissues	O
including	O
the	O
central	O
nervous	O
system	O
,	O
epithelial	O
cells	O
of	O
digestive	O
and	O
urinary	O
organs	O
,	O
as	O
well	O
as	O
myocardium	O
and	O
skeletal	O
muscle	O
.	O

TRbeta	S-geneY
was	O
also	O
expressed	O
in	O
the	O
brain	O
.	O

In	O
other	O
tissues	O
,	O
hybridization	O
signals	O
were	O
too	O
low	O
to	O
draw	O
reliable	O
conclusions	O
about	O
their	O
precise	O
distribution	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
expression	O
of	O
CTHBP	S-geneN
and	O
ST3	S-geneY
is	O
largely	O
distinct	O
from	O
that	O
of	O
TRs	O
.	O

The	O
fact	O
that	O
we	O
observed	O
a	O
clear	O
expression	O
of	O
TRalpha	S-geneY
and	O
TRbeta	S-geneY
which	O
are	O
evolutionary	O
conserved	O
,	O
suggests	O
that	O
Necturus	O
tissues	O
express	O
TRs	S-geneN
.	O

Our	O
results	O
thus	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
previously	O
held	O
hypotheses	O
,	O
Necturus	O
tissues	O
are	O
TH	S-chem
responsive	O
.	O

Total	O
saponins	S-chem
of	O
Panax	O
notoginseng	O
enhance	O
VEGF	O
and	O
relative	O
receptors	O
signals	O
and	O
promote	O
angiogenesis	O
derived	O
from	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Total	O
saponins	O
of	O
Panax	O
notoginseng	O
(	O
tPNS	O
)	O
,	O
main	O
constituents	O
extracted	O
from	O
Panax	O
Notoginseng	O
,	O
a	O
highly	O
valued	O
traditional	O
Chinese	O
medicine	O
,	O
has	O
been	O
shown	O
to	O
increase	O
protein	O
expression	O
and	O
the	O
secretion	O
of	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

AIMS	O
OF	O
THE	O
STUDY	O
:	O
The	O
effects	O
of	O
tPNS	O
on	O
angiogenesis	O
were	O
studied	O
in	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
(	O
rBMSCs	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
rBMSCs	O
were	O
stimulated	O
by	O
tPNS	O
of	O
48h	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
VEGF	B-geneY
-	I-geneY
A	E-geneY
,	O
Flt	B-geneY
-	I-geneY
1	E-geneY
and	O
Kdr	S-geneY
in	O
rBMSCs	O
were	O
determined	O
by	O
quantitative	O
real	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O
rBMSCs	O
were	O
induced	O
to	O
differentiate	O
into	O
endothelial	O
-	O
like	O
cells	O
and	O
the	O
effects	O
of	O
tPNS	O
on	O
the	O
angiogenesis	O
ability	O
of	O
rBMSCs	O
and	O
rBMSCs	O
after	O
endothelial	O
differentiation	O
were	O
assayed	O
by	O
a	O
Matrigel	O
model	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

RESULTS	O
:	O
tPNS	O
(	O
100μg	O
/	O
ml	O
)	O
significantly	O
enhanced	O
the	O
mRNA	O
expression	O
level	O
of	O
VEGF	B-geneY
-	I-geneY
A	E-geneY
and	O
Kdr	S-geneY
compared	O
to	O
the	O
control	O
group	O
,	O
while	O
they	O
had	O
no	O
obvious	O
effect	O
on	O
the	O
expression	O
of	O
Flt	B-geneY
-	I-geneY
1.	O
tPNS	O
(	O
1μg	O
/	O
ml	O
and	O
100μg	O
/	O
ml	O
)	O
significantly	O
increased	O
capillary	O
network	O
forming	O
of	O
rBMSCs	O
after	O
endothelial	O
differentiation	O
in	O
Matrigel	O
in	O
vitro	O
.	O
tPNS	O
(	O
50μg	O
/	O
kg	O
,	O
100μg	O
/	O
kg	O
and	O
150μg	O
/	O
kg	O
)	O
also	O
significantly	O
increased	O
angiogenesis	O
induced	O
by	O
the	O
combination	O
with	O
implantation	O
of	O
rBMSCs	O
and	O
Matrigel	O
in	O
vivo	O
.	O

CONCLUSION	O
:	O
tPNS	O
up	O
-	O
regulate	O
VEGF	B-geneY
-	I-geneY
A	E-geneY
and	O
Kdr	S-geneY
expression	O
,	O
and	O
promote	O
angiogenesis	O
in	O
rat	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

Mechanism	O
of	O
the	O
irreversible	O
inactivation	O
of	O
mouse	B-geneY-C4-2
ornithine	I-geneY-C4-2
decarboxylase	E-geneY-C4-2
by	O
alpha	B-chem-C4-1
-	I-chem-C4-1
difluoromethylornithine	E-chem-C4-1
.	O
Characterization	O
of	O
sequences	O
at	O
the	O
inhibitor	O
and	O
coenzyme	O
binding	O
sites	O
.	O

Mouse	B-geneY-C4-2
ornithine	I-geneY-C4-2
decarboxylase	E-geneY-C4-2
(	O
ODC	S-geneY-C4-2
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
the	O
purified	O
recombinant	O
enzyme	O
used	O
for	O
determination	O
of	O
the	O
binding	O
site	O
for	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
and	O
of	O
the	O
residues	O
modified	O
in	O
the	O
inactivation	O
of	O
the	O
enzyme	O
by	O
the	O
enzyme	O
-	O
activated	O
irreversible	O
inhibitor	O
,	O
alpha	B-chem-C4-1
-	I-chem-C4-1
difluoromethylornithine	E-chem-C4-1
(	O
DFMO	S-chem-C4-1
)	O
.	O

The	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
binding	O
lysine	S-chem
in	O
mouse	B-geneY
ODC	E-geneY
was	O
identified	O
as	O
lysine	S-chem
69	O
of	O
the	O
mouse	O
sequence	O
by	O
reduction	O
of	O
the	O
purified	O
holoenzyme	O
form	O
with	O
NaB	B-chem
[	I-chem
3H	I-chem
]	I-chem
4	E-chem
followed	O
by	O
digestion	O
of	O
the	O
carboxymethylated	O
protein	O
with	O
endoproteinase	B-geneY
Lys	I-geneY
-	I-geneY
C	E-geneY
,	O
radioactive	O
peptide	O
mapping	O
using	O
reversed	O
-	O
phase	O
high	O
pressure	O
liquid	O
chromatography	O
and	O
gas	O
-	O
phase	O
peptide	O
sequencing	O
.	O

This	O
lysine	S-chem
is	O
contained	O
in	O
the	O
sequence	O
PFYAVKC	S-geneN
,	O
which	O
is	O
found	O
in	O
all	O
known	O
ODCs	S-geneN
from	O
eukaryotes	O
.	O

The	O
preceding	O
amino	B-chem
acids	E-chem
do	O
not	O
conform	O
to	O
the	O
consensus	O
sequence	O
of	O
SXHK	S-geneN
,	O
which	O
contains	O
the	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
binding	O
lysine	S-chem
in	O
a	O
number	O
of	O
other	O
decarboxylases	S-geneN
including	O
ODCs	S-geneN
from	O
E.	O
coli	O
.	O

Using	O
a	O
similar	O
procedure	O
to	O
analyze	O
ODC	S-geneY
labeled	O
by	O
reaction	O
with	O
[	B-chem
5	I-chem
-	I-chem
14C	I-chem
]	I-chem
DFMO	E-chem
,	O
it	O
was	O
found	O
that	O
lysine	S-chem
69	O
and	O
cysteine	S-chem
360	O
formed	O
covalent	O
adducts	O
with	O
the	O
inhibitor	O
.	O

Cysteine	S-chem
360	O
,	O
which	O
was	O
the	O
major	O
adduct	O
accounting	O
for	O
about	O
90	O
%	O
of	O
the	O
total	O
labeling	O
,	O
is	O
contained	O
within	O
the	O
sequence	O
-	O
WGPTCDGL	B-geneN
(	I-geneN
I	I-geneN
)	I-geneN
D	E-geneN
-	O
,	O
which	O
is	O
present	O
in	O
all	O
known	O
eukaryote	B-geneN
ODCs	E-geneN
.	O

These	O
results	O
provide	O
strong	O
evidence	O
that	O
these	O
two	O
peptides	O
form	O
essential	O
parts	O
of	O
the	O
catalytic	O
site	O
of	O
ODC	S-geneY
.	O

Analysis	O
by	O
fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometry	O
of	O
tryptic	O
peptides	O
containing	O
the	O
DFMO	S-chem
-	O
cysteine	S-chem
adduct	O
indicated	O
that	O
the	O
adduct	O
formed	O
in	O
the	O
enzyme	O
was	O
probably	O
the	O
cyclic	B-chem
imine	E-chem
S	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
pyrroline	I-chem
)	I-chem
methyl	I-chem
)	I-chem
cysteine	E-chem
.	O

This	O
is	O
readily	O
oxidized	O
to	O
S	B-chem
-	I-chem
(	I-chem
(	I-chem
2	I-chem
-	I-chem
pyrrole	I-chem
)	I-chem
methyl	I-chem
)	I-chem
cysteine	E-chem
or	O
converted	O
to	O
S	B-chem
-	I-chem
(	I-chem
(	I-chem
2	I-chem
-	I-chem
pyrrolidine	I-chem
)	I-chem
methyl	I-chem
)	I-chem
cysteine	E-chem
by	O
NaBH4	S-chem
reduction	O
.	O

This	O
adduct	O
is	O
consistent	O
with	O
spectral	O
evidence	O
showing	O
that	O
inactivation	O
of	O
the	O
enzyme	O
with	O
DFMO	S-chem
does	O
not	O
entail	O
the	O
formation	O
of	O
a	O
stable	O
adduct	O
between	O
the	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
,	O
the	O
enzyme	O
,	O
and	O
the	O
inhibitor	O
.	O

Parnaparin	O
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
,	O
prevents	O
P	B-geneY
-	I-geneY
selectin	E-geneY
-	O
dependent	O
formation	O
of	O
platelet	O
-	O
leukocyte	O
aggregates	O
in	O
human	O
whole	O
blood	O
.	O

Parnaparin	O
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
(	O
LMWH	O
)	O
,	O
prevents	O
platelet	O
activation	O
and	O
interaction	O
with	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
in	O
a	O
washed	O
cell	O
system	O
.	O

The	O
in	O
-	O
vitro	O
effect	O
of	O
parnaparin	O
was	O
studied	O
here	O
on	O
platelet	O
-	O
PMN	O
aggregates	O
formed	O
with	O
more	O
physiologic	O
approaches	O
in	O
whole	O
blood	O
,	O
in	O
parallel	O
with	O
unfractionated	O
heparin	O
and	O
enoxaparin	O
,	O
another	O
LMWH	O
.	O

Citrated	O
blood	O
from	O
healthy	O
subjects	O
was	O
stimulated	O
:	O
i	O
)	O
from	O
passage	O
through	O
the	O
``	O
Platelet	O
Function	O
Analyzer	O
``	O
(	O
PFA	O
-	O
100	O
)	O
,	O
a	O
device	O
that	O
exposes	O
blood	O
to	O
standardized	O
high	O
shear	O
flow	O
through	O
collagen	O
/	I-chem
ADP	O
cartridges	O
;	O
ii	O
)	O
by	O
collagen	O
and	O
ADP	O
(	O
2	O
and	O
50	O
mug	O
/	O
ml	O
,	O
respectively	O
)	O
added	O
in	O
combination	O
under	O
stirring	O
in	O
an	O
aggregometer	O
cuvette	O
;	O
iii	O
)	O
with	O
recombinant	O
Tissue	I-geneY
Factor	O
,	O
to	O
generate	O
thrombin	O
concentrations	O
able	O
to	O
activate	O
platelets	O
without	O
inducing	O
blood	O
clotting	O
,	O
or	O
iv	O
)	O
the	O
Thrombin	O
Receptor	O
Activating	O
Peptide	O
-	O
6	O
(	O
TRAP	O
-	O
6	O
)	O
.	O

Platelet	B-geneY
P	I-geneY
-	I-geneY
selectin	E-geneY
and	O
platelet	O
-	O
PMN	O
aggregates	O
were	O
measured	O
by	O
flow	O
cytometry	O
upon	O
stimulation	O
of	O
blood	O
.	O

Fibrinogen	S-geneN
binding	O
to	O
platelets	O
and	O
markers	O
of	O
PMN	O
activation	O
were	O
also	O
detected	O
.	O

Platelet	B-geneY
P	I-geneY
-	I-geneY
selectin	E-geneY
expression	O
and	O
platelet	O
-	O
PMN	O
aggregate	O
formation	O
were	O
induced	O
in	O
all	O
four	O
activation	O
conditions	O
tested	O
.	O

Parnaparin	O
prevented	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
0.3	O
-	O
0.8	O
IUaXa	O
/	O
ml	O
)	O
the	O
expression	O
of	O
P	B-geneY
-	I-geneY
selectin	E-geneY
and	O
the	O
formation	O
of	O
mixed	O
aggregates	O
,	O
while	O
the	O
two	O
reference	O
heparin	O
preparations	O
had	O
a	O
much	O
weaker	O
effect	O
.	O

Platelet	B-geneN
fibrinogen	E-geneN
binding	O
and	O
PMN	O
activation	O
markers	O
(	O
fibrinogen	S-geneN
binding	O
,	O
CD11b	S-geneY
and	O
CD40	S-geneY
)	O
were	O
also	O
prevented	O
by	O
parnaparin	O
.	O

These	O
data	O
extend	O
in	O
more	O
physiological	O
systems	O
of	O
platelet	O
activation	O
,	O
the	O
anti	O
-	O
inflammatory	O
profile	O
of	O
parnaparin	O
,	O
previously	O
reported	O
in	O
washed	O
cells	O
.	O

The	O
greater	O
effect	O
of	O
parnaparin	O
,	O
as	O
compared	O
to	O
the	O
reference	O
heparins	O
,	O
could	O
be	O
due	O
to	O
chemico	O
-	O
physical	O
differences	O
possibly	O
unrelated	O
to	O
their	O
anticoagulant	O
effect	O
.	O

Indomethacin	S-chem-C3-1
activates	O
carbonic	B-geneN-MU-2
anhydrase	E-geneN-MU-2
and	O
antagonizes	O
the	O
effect	O
of	O
the	O
specific	O
carbonic	B-geneN-MU-2
anhydrase	E-geneN-MU-2
inhibitor	O
acetazolamide	S-chem-C4-1
,	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
paper	O
we	O
investigated	O
the	O
effect	O
of	O
indomethacin	S-chem
,	O
acetazolamide	S-chem
and	O
their	O
combination	O
in	O
vitro	O
and	O
in	O
vivo	O
on	O
carbonic	B-geneN
anhydrase	E-geneN
(	O
CA	S-geneN
)	O
isozymes	O
.	O

METHOD	O
:	O
In	O
vitro	O
experiments	O
followed	O
the	O
effect	O
of	O
the	O
two	O
substances	O
at	O
concentrations	O
between	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
on	O
purified	O
human	B-geneN
red	I-geneN
cell	I-geneN
CA	I-geneN
I	I-geneN
and	I-geneN
II	E-geneN
as	O
well	O
as	O
on	O
human	B-geneY
gastric	I-geneY
mucosa	I-geneY
CA	I-geneY
IV	E-geneY
using	O
dose	O
-	O
response	O
relationships	O
.	O

Kinetic	O
studies	O
were	O
also	O
performed	O
.	O

The	O
effects	O
of	O
single	O
and	O
combined	O
administration	O
of	O
indomethacin	S-chem
and	O
acetazolamide	S-chem
on	O
red	O
cell	O
CA	S-geneN
and	O
on	O
gastric	O
acid	O
secretion	O
were	O
studied	O
in	O
vivo	O
.	O

RESULTS	O
:	O
Indomethacin	S-chem-C3-1
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
induces	O
an	O
increase	O
in	O
erythorcyte	O
CA	B-geneY-C3-2
I	E-geneY-C3-2
and	O
CA	B-geneY-C3-2
II	E-geneY-C3-2
activity	O
.	O

Acetazolamide	S-chem-C4-1
,	O
a	O
specific	O
inhibitor	O
of	O
CA	S-geneN-C4-2
,	O
reduces	O
the	O
activity	O
of	O
CA	B-geneY-C4-2
I	E-geneY-C4-2
and	O
CA	B-geneY-C4-2
II	E-geneY-C4-2
from	O
red	O
cells	O
.	O

Indomethacin	S-chem-C3-1
completely	O
antagonizes	O
CA	S-geneN-MU-2
activity	O
,	O
i.e	O
.	O
abolishes	O
the	O
inhibitory	O
effect	O
of	O
acetazolamide	S-chem-C4-1
on	O
CA	S-geneN-MU-2
.	O

In	O
humans	O
,	O
an	O
increase	O
or	O
decrease	O
in	O
erythrocyte	O
CA	B-geneY
II	E-geneY
activity	O
is	O
correlated	O
with	O
an	O
increase	O
or	O
decrease	O
in	O
gastric	O
acid	O
secretion	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
show	O
that	O
indomethacin	S-chem-MU-1
,	O
a	O
known	O
cyclooxygenase	S-geneN-C4-2
(	O
COX	S-geneN-C4-2
)	O
inhibitor	O
,	O
is	O
also	O
an	O
activator	O
of	O
CA	S-geneN-C3-2
.	O

Our	O
data	O
also	O
prove	O
that	O
indomethacin	S-chem-C3-1
is	O
not	O
only	O
an	O
activator	O
of	O
CA	S-geneN-MU-2
but	O
also	O
antagonizes	O
the	O
effect	O
of	O
acetazolamide	S-chem-C4-1
,	O
a	O
specific	O
inhibitor	O
of	O
this	O
enzyme	O
.	O

In	O
view	O
of	O
the	O
role	O
of	O
CA	S-geneN
in	O
acid	O
-	O
base	O
balance	O
as	O
well	O
as	O
the	O
fact	O
that	O
an	O
increase	O
or	O
decrease	O
in	O
its	O
activity	O
is	O
accompanied	O
by	O
an	O
increase	O
or	O
decrease	O
in	O
intra	O
-	O
and	O
extracellular	O
pH	O
,	O
our	O
results	O
suggest	O
that	O
:	O
firstly	O
,	O
CA	S-geneN-C3-2
activation	O
induced	O
by	O
indomethacin	S-chem-C3-1
might	O
cause	O
changes	O
in	O
COX	S-geneN
activity	O
;	O
secondly	O
,	O
PGs	O
are	O
synthetized	O
as	O
a	O
consequence	O
of	O
the	O
changes	O
in	O
COX	S-geneN
activity	O
,	O
a	O
hypothesis	O
that	O
requires	O
further	O
study	O
.	O

Progesterone	B-geneY
receptor	E-geneY
induces	O
bcl	B-geneY
-	I-geneY
x	E-geneY
expression	O
through	O
intragenic	B-geneN
binding	I-geneN
sites	E-geneN
favoring	O
RNA	B-geneN
polymerase	I-geneN
II	E-geneN
elongation	O
.	O

Steroid	B-geneN
receptors	E-geneN
were	O
classically	O
described	O
for	O
regulating	O
transcription	O
by	O
binding	O
to	O
target	O
gene	O
promoters	O
.	O

However	O
,	O
genome	O
-	O
wide	O
studies	O
reveal	O
that	O
steroid	B-geneN
receptors	I-geneN
-	I-geneN
binding	I-geneN
sites	E-geneN
are	O
mainly	O
located	O
at	O
intragenic	O
regions	O
.	O

To	O
determine	O
the	O
role	O
of	O
these	O
sites	O
,	O
we	O
examined	O
the	O
effect	O
of	O
progestins	O
on	O
the	O
transcription	O
of	O
the	O
bcl	B-geneY
-	I-geneY
x	E-geneY
gene	O
,	O
where	O
only	O
intragenic	B-geneN
progesterone	I-geneN
receptor	I-geneN
-	I-geneN
binding	I-geneN
sites	E-geneN
(	O
PRbs	S-geneN
)	O
were	O
identified	O
.	O

We	O
found	O
that	O
in	O
response	O
to	O
hormone	O
treatment	O
,	O
the	O
PR	S-geneY
is	O
recruited	O
to	O
these	O
sites	O
along	O
with	O
two	O
histone	B-geneN
acetyltransferases	E-geneN
CREB	B-geneY
-	I-geneY
binding	I-geneY
protein	E-geneY
(	O
CBP	S-geneY
)	O
and	O
GCN5	S-geneY
,	O
leading	O
to	O
an	O
increase	O
in	O
histone	B-geneN
H3	E-geneN
and	O
H4	S-geneN
acetylation	O
and	O
to	O
the	O
binding	O
of	O
the	O
SWI	B-geneN
/	I-geneN
SNF	I-geneN
complex	E-geneN
.	O

Concomitant	O
,	O
a	O
more	O
relaxed	O
chromatin	O
was	O
detected	O
along	O
bcl	B-geneY
-	I-geneY
x	E-geneY
gene	O
mainly	O
in	O
the	O
regions	O
surrounding	O
the	O
intragenic	O
PRbs	S-geneN
.	O

PR	S-geneY
also	O
mediated	O
the	O
recruitment	O
of	O
the	O
positive	B-geneN
elongation	I-geneN
factor	E-geneN
pTEFb	S-geneN
,	O
favoring	O
RNA	B-geneN
polymerase	I-geneN
II	E-geneN
(	O
Pol	B-geneN
II	E-geneN
)	O
elongation	O
activity	O
.	O

Together	O
these	O
events	O
promoted	O
the	O
re	O
-	O
distribution	O
of	O
the	O
active	O
Pol	B-geneN
II	E-geneN
toward	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
gene	O
and	O
a	O
decrease	O
in	O
the	O
ratio	O
between	O
proximal	O
and	O
distal	O
transcription	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
PR	S-geneY
regulates	O
gene	O
expression	O
by	O
facilitating	O
the	O
proper	O
passage	O
of	O
the	O
polymerase	S-geneN
along	O
hormone	O
-	O
dependent	O
genes	O
.	O

Quantitation	O
of	O
UGT1A1	S-geneY
in	O
human	O
liver	O
microsomes	O
using	O
stable	O
isotope	O
-	O
labelled	O
peptides	O
and	O
mass	O
spectrometry	O
based	O
proteomic	O
approaches	O
.	O

1	O
.	O
UDP	O
-	I-geneN
glucuronosyltransferases	I-geneN
(	E-geneN
UGTs	O
)	E-geneN
are	O
a	O
group	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
that	O
catalyse	O
the	O
conjugation	O
of	O
endogeonous	O
compounds	O
and	O
xenobiotics	O
to	O
yield	O
hydrophilic	O
glucuronides	O
which	O
subsequently	O
undergo	O
excretion	O
.	O

This	O
report	O
describes	O
an	O
approach	O
for	O
the	O
identification	O
and	O
accurate	O
quantitation	O
of	O
human	B-geneY
UGT1A1	E-geneY
in	O
complex	O
biological	O
matrices	O
using	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
/	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
analysis	O
of	O
protein	O
digests	O
.	O

2	O
.	O
A	O
stable	O
isotope	O
-	O
labelled	O
(	O
SIL	O
)	O
peptide	O
of	O
a	O
unique	O
peptide	O
spanning	O
residues	O
54	O
-	O
69	O
in	O
exon	O
1	O
of	O
the	O
human	O
UGT1A1	I-geneY
protein	O
with	O
the	O
sequence	O
RIYLSADPALVVIEHG	O
was	O
synthesized	O
.	O

The	O
peptide	O
sequence	O
synthesized	O
was	O
in	O
the	O
reverse	O
order	O
of	O
the	O
human	O
peptide	O
with	O
the	O
stable	O
isotope	O
-	O
labels	O
in	O
the	O
amino	B-chem
acid	E-chem
arginine	S-chem
(	O
(	B-chem
13	I-chem
)	I-chem
C6	I-chem
(	I-chem
15	I-chem
)	I-chem
N4	E-chem
)	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
mass	O
of	O
the	O
SIL	O
peptide	O
of	O
10	O
amu	O
,	O
from	O
1753	O
to	O
1763	O
.	O

The	O
SIL	O
peptide	O
was	O
quantitated	O
by	O
injecting	O
increasing	O
concentrations	O
of	O
the	O
peptide	O
into	O
the	O
LC	O
-	O
MS	O
to	O
obtain	O
a	O
standard	O
curve	O
.	O

3	O
.	O
The	O
labelled	O
peptide	O
along	O
with	O
precursor	O
ion	O
monitoring	O
was	O
used	O
to	O
quantify	O
the	O
levels	O
of	O
UGT1A1	O
in	O
commercial	O
recombinant	O
preparations	O
(	O
supersomes	O
)	O
and	O
individual	O
human	O
liver	O
microsomal	O
samples	O
and	O
pooled	O
human	O
liver	O
micrsomes	O
obtained	O
from	O
BD	O
Biosciences	O
.	O

4	O
.	O
Glucuronidation	O
activity	O
studies	O
were	O
performed	O
,	O
which	O
demonstrated	O
a	O
positive	O
correlation	O
between	O
enzyme	O
activity	O
levels	O
and	O
the	O
UGT1A1	O
content	O
in	O
the	O
liver	O
microsomes	O
obtained	O
from	O
individual	O
human	O
donors	O
.	O

Pharmacological	O
properties	O
of	O
the	O
anti	O
-	O
Parkinson	O
drug	O
rasagiline	S-chem
;	O
modification	O
of	O
endogenous	O
brain	O
amines	S-chem
,	O
reserpine	S-chem
reversal	O
,	O
serotonergic	O
and	O
dopaminergic	O
behaviours	O
.	O

Rasagiline	S-chem-C4-1
[	O
N	B-chem-C4-1
-	I-chem-C4-1
propargyl	I-chem-C4-1
-	I-chem-C4-1
1R	I-chem-C4-1
(	I-chem-C4-1
+	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
aminoindan	E-chem-C4-1
;	O
TVP1012	S-chem-C4-1
]	O
is	O
a	O
potent	O
irreversible	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
(	O
MAO	S-geneN-C4-2
)	O
inhibitor	O
with	O
selectivity	O
for	O
type	O
B	O
of	O
the	O
enzyme	O
,	O
which	O
is	O
being	O
developed	O
for	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

In	O
this	O
study	O
we	O
examined	O
effects	O
of	O
rasagiline	S-chem
on	O
CNS	O
monoamine	S-chem
levels	O
,	O
modification	O
of	O
behavioural	O
response	O
to	O
L	B-chem
-	I-chem
tryptophan	E-chem
,	O
fluoxetine	S-chem
and	O
L	B-chem
-	I-chem
DOPA	E-chem
,	O
and	O
reversal	O
of	O
reserpine	S-chem
syndrome	O
.	O

Reserpine	S-chem
-	O
induced	O
ptosis	O
was	O
reversed	O
by	O
rasagiline	S-chem-C4-1
at	O
doses	O
above	O
2	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i.p	O
.	O
,	O
which	O
inhibit	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
as	O
well	O
as	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
,	O
but	O
not	O
at	O
MAO	B-geneY
-	I-geneY
B	E-geneY
-	O
selective	O
doses	O
.	O

However	O
,	O
combination	O
of	O
rasagiline	S-chem
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i.p	O
.	O
)	O
with	O
L	B-chem
-	I-chem
DOPA	E-chem
or	O
L	B-chem
-	I-chem
tryptophan	E-chem
(	O
50	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i.p	O
.	O
)	O
,	O
or	O
rasagiline	S-chem
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
p.o	O
.	O
)	O
with	O
fluoxetine	S-chem
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
p.o	O
.	O
)	O
,	O
did	O
not	O
induce	O
the	O
behavioural	O
hyperactivity	O
syndrome	O
which	O
is	O
seen	O
following	O
inhibition	O
of	O
both	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
and	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
by	O
tranylcypromine	S-chem-C4-1
together	O
with	O
the	O
monoamine	S-chem-C4-1
precursors	O
.	O

Following	O
oral	O
administration	O
,	O
levels	O
of	O
noradrenaline	S-chem
(	O
NA	S-chem
)	O
,	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
and	O
dopamine	S-chem
(	O
DA	S-chem
)	O
were	O
unaffected	O
in	O
hippocampus	O
and	O
striatum	O
after	O
single	O
doses	O
of	O
rasagiline	S-chem
up	O
to	O
2	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
.	O

Following	O
chronic	O
oral	O
administration	O
(	O
21	O
days	O
,	O
one	O
dose	O
daily	O
)	O
,	O
levels	O
of	O
NA	S-chem
,	O
5	B-chem
-	I-chem
HT	E-chem
and	O
DA	S-chem
in	O
hippocampus	O
and	O
striatum	O
were	O
unaffected	O
by	O
rasagiline	S-chem
at	O
doses	O
up	O
to	O
1	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
.	O

Rasagiline	S-chem-C4-1
does	O
not	O
modify	O
CNS	O
monoamine	S-chem
tissue	O
levels	O
or	O
monoamine	S-chem
-	O
induced	O
behavioural	O
syndromes	O
at	O
doses	O
which	O
selectively	O
inhibit	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
B	E-geneY-C4-2
but	O
not	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
.	O

Anthocyanin	S-chem
,	O
antioxidant	O
activity	O
and	O
stress	O
-	O
induced	O
gene	O
expression	O
in	O
high	O
CO2	S-chem
-	O
treated	O
table	O
grapes	O
stored	O
at	O
low	O
temperature	O
.	O

A	O
pretreatment	O
with	O
20kPa	O
CO2	S-chem
+	O
20	O
kPa	O
O2	O
+	O
60	O
kPa	O
N2	S-chem
for	O
3	O
days	O
proved	O
effective	O
in	O
maintaining	O
the	O
fruit	O
quality	O
and	O
controlling	O
decay	O
in	O
table	O
grapes	O
(	O
Vitis	O
vinifera	O
cv	O
.	O

Cardinal	O
)	O
stored	O
at	O
0	O
degrees	O
C	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
analyzed	O
whether	O
total	O
anthocyanin	S-chem
content	O
,	O
the	O
molecular	O
mechanism	O
implicated	O
in	O
their	O
biosynthesis	O
and	O
antioxidant	O
activity	O
is	O
related	O
to	O
the	O
beneficial	O
effect	O
of	O
this	O
gaseous	O
treatment	O
.	O

We	O
isolated	O
partial	O
cDNAs	O
that	O
codified	O
for	O
enzymes	O
implicated	O
in	O
the	O
anthocyanin	S-chem-C9-1
biosynthesis	O
such	O
as	O
l	B-geneY-C9-2
-	I-geneY-C9-2
phenylalanine	I-geneY-C9-2
ammonia	I-geneY-C9-2
-	I-geneY-C9-2
lyase	E-geneY-C9-2
(	O
PAL	S-geneY-C9-2
)	O
and	O
chalcone	B-geneY-C9-2
synthase	E-geneY-C9-2
(	O
CHS	S-geneY-C9-2
)	O
,	O
and	O
an	O
antioxidant	O
enzyme	O
such	O
as	O
ascorbate	B-geneY-C9-2
peroxidase	E-geneY-C9-2
(	O
APX	S-geneY-C9-2
)	O
.	O

Low	O
temperatures	O
induced	O
an	O
accumulation	O
of	O
total	O
anthocyanin	S-chem
content	O
in	O
the	O
skin	O
of	O
both	O
treated	O
and	O
non	O
-	O
treated	O
grapes	O
,	O
although	O
levels	O
were	O
lower	O
in	O
CO2	S-chem
-	O
treated	O
fruit	O
.	O

By	O
contrast	O
,	O
antioxidant	O
activity	O
decreased	O
during	O
storage	O
at	O
0	O
degrees	O
C	O
in	O
non	O
-	O
treated	O
grapes	O
but	O
did	O
not	O
change	O
in	O
CO2	S-chem
-	O
treated	O
grapes	O
.	O

The	O
up	O
-	O
regulation	O
of	O
anthocyanin	S-chem
biosynthesis	O
gene	O
expression	O
and	O
VcAPX	S-geneY
mRNA	O
observed	O
in	O
non	O
-	O
treated	O
grape	O
is	O
not	O
enhanced	O
in	O
CO2	S-chem
-	O
treated	O
grapes	O
,	O
which	O
presented	O
low	O
total	O
decay	O
.	O

These	O
results	O
point	O
out	O
the	O
ability	O
of	O
CO2	S-chem
-	O
treated	O
grapes	O
to	O
prevent	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
rather	O
than	O
their	O
inactivation	O
by	O
means	O
of	O
induction	O
of	O
studied	O
defense	O
systems	O
.	O

Nanoparticle	O
toxicity	O
in	O
Daphnia	O
magna	O
reproduction	O
studies	O
:	O
the	O
importance	O
of	O
test	O
design	O
.	O

The	O
increasing	O
use	O
of	O
titanium	B-chem
dioxide	E-chem
nanoparticles	O
(	O
nTiO	O
(	I-chem
2	I-chem
)	E-chem
)	O
inevitably	O
results	O
in	O
their	O
release	O
into	O
the	O
environment	O
,	O
raising	O
concerns	O
about	O
potential	O
adverse	O
effects	O
in	O
wildlife	O
.	O

By	O
following	O
standard	O
test	O
protocols	O
,	O
several	O
studies	O
investigated	O
the	O
ecotoxicity	O
of	O
nTiO	O
(	I-chem
2	I-chem
)	E-chem
among	O
others	O
to	O
Daphnia	O
magna	O
.	O

These	O
studies	O
indicated	O
a	O
large	O
variability	O
-	O
several	O
orders	O
of	O
magnitude	O
-	O
in	O
the	O
response	O
variables	O
.	O

However	O
,	O
other	O
factors	O
,	O
like	O
nanoparticle	O
characteristics	O
and	O
test	O
design	O
,	O
potentially	O
triggering	O
these	O
differences	O
,	O
were	O
largely	O
ignored	O
.	O

Therefore	O
,	O
the	O
present	O
study	O
assessed	O
the	O
chronic	O
ecotoxicity	O
of	O
two	O
nTiO	O
(	I-chem
2	I-chem
)	E-chem
products	O
with	O
varying	O
crystalline	O
structure	O
(	O
A	O
-	O
100	O
;	O
P25	O
)	O
to	O
D.	O
magna	O
.	O

A	O
semi	O
-	O
static	O
and	O
a	O
flow	O
-	O
through	O
exposure	O
scenario	O
were	O
compared	O
,	O
ensuring	O
that	O
both	O
contained	O
environmentally	O
relevant	O
concentrations	O
of	O
dissolved	O
organic	O
carbon	S-chem
.	O

Utilizing	O
the	O
semi	O
-	O
static	O
test	O
design	O
,	O
a	O
concentration	O
as	O
low	O
as	O
0.06	O
mg	O
/	O
L	O
A	O
-	O
100	O
(	O
∼	O
330	O
nm	O
)	O
significantly	O
reduced	O
the	O
reproduction	O
of	O
daphnia	O
indicating	O
environmental	O
risk	O
.	O

In	O
contrast	O
,	O
no	O
implication	O
in	O
the	O
number	O
of	O
released	O
offspring	O
was	O
observed	O
during	O
the	O
flow	O
-	O
through	O
experiment	O
with	O
A	O
-	O
100	O
(	O
∼	O
140	O
nm	O
)	O
.	O

Likewise	O
,	O
P25	O
(	O
∼	O
130	O
nm	O
)	O
did	O
not	O
adversely	O
affect	O
reproduction	O
irrespective	O
of	O
the	O
test	O
design	O
utilized	O
.	O

Given	O
the	O
present	O
study	O
's	O
results	O
,	O
the	O
particle	O
size	O
,	O
the	O
product	O
composition	O
,	O
i.e	O
.	O
the	O
crystalline	O
structure	O
,	O
and	O
the	O
accumulation	O
of	O
nTiO	O
(	I-chem
2	I-chem
)	E-chem
at	O
the	O
bottom	O
of	O
the	O
test	O
vessel	O
-	O
the	O
latter	O
is	O
relevant	O
for	O
a	O
semi	O
-	O
static	O
test	O
design	O
-	O
may	O
be	O
suggested	O
as	O
factors	O
potentially	O
triggering	O
differences	O
in	O
nTiO	O
(	I-chem
2	I-chem
)	E-chem
toxicity	O
to	O
D.	O
magna	O
.	O

Hence	O
,	O
these	O
factors	O
should	O
be	O
considered	O
to	O
improve	O
environmental	O
risk	O
assessment	O
of	O
nanoparticles	O
.	O

The	O
decrease	O
of	O
catalase	S-geneY
or	O
esterase	B-geneY
D	E-geneY
activity	O
in	O
patients	O
with	O
microdeletions	O
of	O
11p	O
or	O
13q	O
does	O
not	O
increase	O
their	O
radiosensitivity	O
.	O

Lymphocyte	O
cultures	O
from	O
patients	O
affected	O
by	O
retinoblastoma	O
(	O
Rb	O
)	O
,	O
with	O
or	O
without	O
a	O
microdeletion	O
of	O
chromosome	O
13	O
,	O
and	O
Wilms	O
tumor	O
(	O
WT	O
)	O
,	O
with	O
a	O
microdeletion	O
of	O
chromosome	O
11p	O
where	O
exposed	O
to	O
gamma	O
-	O
ray	O
radiation	O
during	O
S	O
and	O
G2	O
phases	O
.	O

Chromatid	O
and	O
chromosome	O
lesions	O
were	O
scored	O
and	O
compared	O
to	O
those	O
observed	O
in	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
detected	O
,	O
neither	O
between	O
patients	O
and	O
controls	O
,	O
nor	O
between	O
patients	O
carrying	O
or	O
not	O
a	O
microdeletion	O
.	O

This	O
lack	O
of	O
difference	O
was	O
unexpected	O
since	O
the	O
genes	O
for	O
catalase	S-geneY
and	O
esterase	B-geneY
D	E-geneY
,	O
also	O
called	O
S	B-geneY
-	I-geneY
formyl	I-geneY
glutathione	I-geneY
hydrolase	E-geneY
,	O
which	O
are	O
two	O
detoxication	O
enzymes	O
,	O
are	O
deleted	O
in	O
case	O
of	O
microdeletion	O
of	O
11p	O
and	O
13q	O
,	O
respectively	O
.	O

Enzymatic	O
catalysis	O
in	O
crystals	O
of	O
Escherichia	B-geneY
coli	I-geneY
maltodextrin	I-geneY
phosphorylase	E-geneY
.	O

The	O
bacterial	O
enzyme	O
maltodextrin	B-geneN-C9-2
phosphorylase	E-geneN-C9-2
(	O
MalP	S-geneN-C9-2
)	O
catalyses	O
the	O
phosphorolysis	O
of	O
an	O
alpha	O
-	O
1,4	O
-	O
glycosidic	O
bond	O
in	O
maltodextrins	O
,	O
removing	O
the	O
non	O
-	O
reducing	O
glucosyl	S-chem
residues	O
of	O
linear	O
oligosaccharides	O
as	O
glucose	B-chem-C9-1
-	I-chem-C9-1
1	I-chem-C9-1
-	I-chem-C9-1
phosphate	E-chem-C9-1
(	O
Glc1P	S-chem-C9-1
)	O
.	O

In	O
contrast	O
to	O
the	O
well	O
-	O
studied	O
muscle	O
glycogen	B-geneY
phosphorylase	E-geneY
(	O
GP	S-geneY
)	O
,	O
MalP	S-geneY
exhibits	O
no	O
allosteric	O
properties	O
and	O
has	O
a	O
higher	O
affinity	O
for	O
linear	O
oligosaccharides	O
than	O
GP	S-geneY
.	O

We	O
have	O
used	O
MalP	S-geneY
as	O
a	O
model	O
system	O
to	O
study	O
catalysis	O
in	O
the	O
crystal	O
in	O
the	O
direction	O
of	O
maltodextrin	O
synthesis	O
.	O

The	O
2.0A	O
crystal	O
structure	O
of	O
the	O
MalP	S-geneY
/	O
Glc1P	S-chem
binary	O
complex	O
shows	O
that	O
the	O
Glc1P	S-chem
substrate	O
adopts	O
a	O
conformation	O
seen	O
previously	O
with	O
both	O
inactive	O
and	O
active	O
forms	O
of	O
mammalian	B-geneN
GP	E-geneN
,	O
with	O
the	O
phosphate	S-chem
group	O
not	O
in	O
close	O
contact	O
with	O
the	O
5	B-chem
'	I-chem
-	I-chem
phosphate	E-chem
group	O
of	O
the	O
essential	O
pyridoxal	B-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
cofactor	O
.	O

In	O
the	O
active	O
MalP	S-geneY
enzyme	O
,	O
the	O
residue	O
Arg569	O
stabilizes	O
the	O
negative	O
-	O
charged	O
Glc1P	S-chem
,	O
whereas	O
in	O
the	O
inactive	O
form	O
of	O
GP	S-geneY
this	O
key	O
residue	O
is	O
held	O
away	O
from	O
the	O
catalytic	O
site	O
by	O
loop	O
280s	O
and	O
an	O
allosteric	O
transition	O
of	O
the	O
mammalian	O
enzyme	O
is	O
required	O
for	O
activation	O
.	O

The	O
comparison	O
between	O
MalP	S-geneY
structures	O
shows	O
that	O
His377	O
,	O
through	O
a	O
hydrogen	O
bond	O
with	O
the	O
6	B-chem
-	I-chem
hydroxyl	E-chem
group	O
of	O
Glc1P	S-chem
substrate	O
,	O
triggers	O
a	O
conformational	O
change	O
of	O
the	O
380s	O
loop	O
.	O

This	O
mobile	O
region	O
folds	O
over	O
the	O
catalytic	O
site	O
and	O
contributes	O
to	O
the	O
specific	O
recognition	O
of	O
the	O
oligosaccharide	O
and	O
to	O
the	O
synergism	O
between	O
substrates	O
in	O
promoting	O
the	O
formation	O
of	O
the	O
MalP	S-geneY
ternary	O
complex	O
.	O

The	O
structures	O
solved	O
after	O
the	O
diffusion	O
of	O
oligosaccharides	O
(	O
either	O
maltotetraose	S-chem
,	O
G4	O
or	O
maltopentaose	S-chem
,	O
G5	O
)	O
into	O
MalP	S-geneY
/	O
Glc1P	S-chem
crystals	O
show	O
the	O
formation	O
of	O
phosphate	S-chem
and	O
elongation	O
of	O
the	O
oligosaccharide	O
chain	O
.	O

These	O
structures	O
,	O
refined	O
at	O
1.8A	O
and	O
at	O
2.2A	O
,	O
confirm	O
that	O
only	O
when	O
an	O
oligosaccharide	O
is	O
bound	O
to	O
the	O
catalytic	O
site	O
will	O
Glc1P	S-chem
bend	O
its	O
phosphate	S-chem
group	O
down	O
so	O
it	O
can	O
contact	O
the	O
PLP	S-chem
5	B-chem
'	I-chem
phosphate	E-chem
group	O
and	O
promote	O
catalysis	O
.	O

The	O
relatively	O
large	O
oligosaccharide	O
substrates	O
can	O
diffuse	O
quickly	O
into	O
the	O
MalP	S-geneY
/	O
Glc1P	S-chem
crystals	O
and	O
the	O
enzymatic	O
reaction	O
can	O
occur	O
without	O
significant	O
crystal	O
damage	O
.	O

These	O
structures	O
obtained	O
before	O
and	O
after	O
catalysis	O
have	O
been	O
used	O
as	O
frames	O
of	O
a	O
molecular	O
movie	O
.	O

This	O
movie	O
reveals	O
the	O
relative	O
positions	O
of	O
substrates	O
in	O
the	O
catalytic	O
channel	O
and	O
shows	O
a	O
minimal	O
movement	O
of	O
the	O
protein	O
,	O
involving	O
mainly	O
Arg569	O
,	O
which	O
tracks	O
the	O
substrate	O
phosphate	S-chem
group	O
.	O

PF	B-chem-C4-1
-	I-chem-C4-1
04859989	E-chem-C4-1
as	O
a	O
template	O
for	O
structure	O
-	O
based	O
drug	O
design	O
:	O
identification	O
of	O
new	O
pyrazole	S-chem-C4-1
series	O
of	O
irreversible	O
KAT	B-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
with	O
improved	O
lipophilic	O
efficiency	O
.	O

The	O
structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
new	O
pyrazole	S-chem-C4-1
series	O
of	O
irreversible	O
KAT	B-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
are	O
described	O
herein	O
.	O

The	O
modification	O
of	O
the	O
inhibitor	O
scaffold	O
of	O
1	O
and	O
2	O
from	O
a	O
dihydroquinolinone	S-chem-C4-1
core	O
to	O
a	O
tetrahydropyrazolopyridinone	S-chem-C4-1
core	O
led	O
to	O
discovery	O
of	O
a	O
new	O
series	O
of	O
potent	O
KAT	B-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
with	O
excellent	O
physicochemical	O
properties	O
.	O

Compound	O
20	O
is	O
the	O
most	O
potent	O
and	O
lipophilically	O
efficient	O
of	O
these	O
new	O
pyrazole	S-chem
analogs	O
,	O
with	O
a	O
k	O
(	O
inact	O
)	O
/	O
K	O
(	O
i	O
)	O
value	O
of	O
112,000	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
and	O
lipophilic	O
efficiency	O
(	O
LipE	O
)	O
of	O
8.53	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
20	O
with	O
KAT	B-geneY
II	E-geneY
demonstrates	O
key	O
features	O
that	O
contribute	O
to	O
this	O
remarkable	O
potency	O
and	O
binding	O
efficiency	O
.	O

Effect	O
of	O
gene	O
disruptions	O
of	O
the	O
TCA	S-chem
cycle	O
on	O
production	O
of	O
succinic	B-chem
acid	E-chem
in	O
Saccharomyces	O
cerevisiae	O
.	O

Succinate	S-chem
is	O
the	O
main	O
taste	O
component	O
produced	O
by	O
yeasts	O
during	O
sake	O
(	O
Japanese	O
rice	O
wine	O
)	O
fermentation	O
.	O

The	O
pathway	O
leading	O
to	O
accumulation	O
of	O
succinate	S-chem
was	O
examined	O
in	O
liquid	O
culture	O
in	O
the	O
presence	O
of	O
a	O
high	O
concentration	O
(	O
15	O
%	O
)	O
of	O
glucose	S-chem
under	O
aerobic	O
and	O
anaerobic	O
conditions	O
using	O
a	O
series	O
of	O
Saccharomyces	O
cerevisiae	O
strains	O
in	O
which	O
various	O
genes	O
that	O
encode	O
the	O
expression	O
of	O
enzymes	O
required	O
in	O
TCA	S-chem
cycle	O
were	O
disrupted	O
.	O

When	O
cultured	O
in	O
YPD	O
medium	O
containing	O
15	O
%	O
glucose	S-chem
under	O
aerobic	O
conditions	O
,	O
the	O
KGD1	S-geneY-C9-2
(	O
alpha	B-geneY-C9-2
-	I-geneY-C9-2
ketoglutarate	I-geneY-C9-2
dehydrogenase	E-geneY-C9-2
)	O
gene	O
disrupted	O
mutant	O
produced	O
a	O
lower	O
level	O
of	O
succinate	S-chem-C9-1
than	O
the	O
wild	O
-	O
type	O
strain	O
,	O
while	O
the	O
SDH1	S-geneY-C9-2
(	O
succinate	B-geneY-C9-2
dehydrogenase	E-geneY-C9-2
)	O
gene	O
-	O
disrupted	O
mutant	O
produced	O
an	O
increased	O
level	O
of	O
succinate	S-chem-C9-1
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
FUM1	S-geneY-C9-2
(	O
fumarase	S-geneY-C9-2
)	O
gene	O
disrupted	O
mutant	O
produced	O
significantly	O
higher	O
levels	O
of	O
fumarate	S-chem-C9-1
but	O
did	O
not	O
form	O
malate	S-chem
at	O
all	O
.	O

These	O
results	O
indicate	O
that	O
succinate	S-chem
,	O
fumarate	S-chem
and	O
malate	S-chem
are	O
mainly	O
synthesized	O
through	O
the	O
TCA	S-chem
cycle	O
(	O
oxidative	O
direction	O
)	O
even	O
in	O
the	O
presence	O
of	O
glucose	S-chem
at	O
a	O
concentration	O
as	O
high	O
as	O
15	O
%	O
.	O

When	O
the	O
growth	O
condition	O
was	O
shifted	O
from	O
aerobic	O
to	O
anaerobic	O
,	O
the	O
increased	O
level	O
of	O
succinate	S-chem-C9-1
in	O
SDH1	S-geneY-C9-2
disruptants	O
was	O
no	O
longer	O
observed	O
,	O
whereas	O
the	O
decreased	O
level	O
of	O
succinate	S-chem-C9-1
in	O
the	O
KGD1	S-geneY-C9-2
diruptant	O
was	O
still	O
observed	O
.	O

A	O
double	O
mutant	O
of	O
the	O
two	O
fumarate	B-geneN-C9-2
reductase	E-geneN-C9-2
isozyme	O
genes	O
(	O
OSM1	S-geneY-C9-2
and	O
FRDS	S-geneY-C9-2
)	O
showed	O
a	O
succinate	S-chem-C9-1
productivity	O
of	O
50	O
%	O
as	O
compared	O
to	O
the	O
parent	O
when	O
cells	O
were	O
incubated	O
in	O
glucose	S-chem
-	O
buffered	O
solution	O
.	O

These	O
results	O
indicate	O
that	O
succinate	S-chem
could	O
be	O
synthesized	O
through	O
two	O
pathways	O
,	O
namely	O
,	O
alpha	B-chem
-	I-chem
ketoglutarate	E-chem
oxidation	O
via	O
the	O
TCA	S-chem
cycle	O
and	O
fumarate	S-chem
reduction	O
under	O
anaerobic	O
conditions	O
.	O

Peyer	O
's	O
patch	O
-	O
mediated	O
intestinal	O
immune	O
system	O
modulating	O
activity	O
of	O
pectic	O
-	O
type	O
polysaccharide	O
from	O
peel	O
of	O
Citrus	O
unshiu	O
.	O

An	O
intestinal	O
immune	O
system	O
modulating	O
polysaccharide	O
(	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
,	O
18kDa	O
)	O
was	O
purified	O
from	O
Citrus	O
unshiu	O
peel	O
.	O

CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
mainly	O
comprised	O
GalA	S-chem
,	O
GlcA	S-chem
,	O
Ara	S-chem
,	O
Gal	S-chem
and	O
Rha	S-chem
,	O
and	O
it	O
consisted	O
of	O
4	O
-	O
linked	O
GalA	S-chem
,	O
terminal	O
Araf	S-chem
,	O
4	O
-	O
or	O
5	O
-	O
linked	O
/	O
3,4	O
-	O
or	O
3,5	O
-	O
branched	O
Ara	S-chem
,	O
terminal	O
Gal	S-chem
,	O
and	O
2	O
-	O
linked	O
/	O
2,4	O
-	O
branched	O
Rha	S-chem
.	O

After	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
digestion	O
by	O
endo	O
-	O
α	O
-	O
d	O
-	O
(	O
1	O
→	O
4	O
)	O
-	O
polygalacturonase	S-geneN
,	O
its	O
hydrolysate	O
was	O
fractionated	O
into	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
.	O

Methylation	O
analyses	O
of	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
using	O
base	O
-	O
catalysed	O
β	O
-	O
elimination	O
suggested	O
that	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
be	O
assumed	O
as	O
pectic	O
-	O
type	O
polysaccharide	O
.	O

Since	O
the	O
activities	O
of	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
were	O
potently	O
decreased	O
,	O
the	O
whole	O
polysaccharide	O
structure	O
of	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
would	O
be	O
essential	O
to	O
maintain	O
the	O
activity	O
.	O

Meanwhile	O
,	O
when	O
CUI	O
-	O
3IIb	O
was	O
orally	O
administered	O
in	O
mice	O
,	O
bone	O
marrow	O
cell	O
proliferation	O
and	O
GM	O
-	O
CSF	O
/	O
IL	B-geneY
-	I-geneY
6	E-geneY
production	O
from	O
Peyer	O
's	O
patch	O
cell	O
were	O
significantly	O
higher	O
(	O
1.76	O
-	O
and	O
2.03	O
/	O
2.51	O
-	O
fold	O
,	O
respectively	O
)	O
than	O
a	O
saline	O
.	O

Therefore	O
,	O
a	O
pectic	O
-	O
type	O
polysaccharide	O
from	O
citrus	O
peel	O
could	O
stimulate	O
Peyer	O
's	O
patches	O
and	O
produce	O
hematopoietic	O
growth	O
factors	O
resulted	O
in	O
bone	O
marrow	O
cell	O
proliferation	O
.	O

Potent	O
fibrinolysis	O
inhibitor	O
discovered	O
by	O
shape	O
and	O
electrostatic	O
complementarity	O
to	O
the	O
drug	O
tranexamic	B-chem
Acid	E-chem
.	O

Protein	O
-	O
protein	O
interfaces	O
provide	O
an	O
important	O
class	O
of	O
drug	O
targets	O
currently	O
receiving	O
increased	O
attention	O
.	O

The	O
typical	O
design	O
strategy	O
to	O
inhibit	O
protein	O
-	O
protein	O
interactions	O
usually	O
involves	O
large	O
molecules	O
such	O
as	O
peptides	O
and	O
macrocycles	O
.	O

One	O
exception	O
is	O
tranexamic	B-chem-C4-1
acid	E-chem-C4-1
(	O
TXA	S-chem-C4-1
)	O
,	O
which	O
,	O
as	O
a	O
lysine	S-chem-C4-1
mimetic	O
,	O
inhibits	O
binding	O
of	O
plasminogen	S-geneY-C4-2
to	O
fibrin	S-geneN-C4-2
.	O

However	O
,	O
the	O
daily	O
dose	O
of	O
TXA	S-chem
is	O
high	O
due	O
to	O
its	O
modest	O
potency	O
and	O
pharmacokinetic	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
computational	O
approach	O
,	O
where	O
the	O
focus	O
was	O
on	O
finding	O
electrostatic	O
potential	O
similarities	O
to	O
TXA	S-chem
.	O

Coupling	O
this	O
computational	O
technique	O
with	O
a	O
high	O
-	O
quality	O
low	O
-	O
throughput	O
screen	O
identified	O
5	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
piperidyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
isoxazolol	E-chem-C4-1
(	O
4	B-chem-C4-1
-	I-chem-C4-1
PIOL	E-chem-C4-1
)	O
as	O
a	O
potent	O
plasminogen	S-geneY-C4-2
binding	O
inhibitor	O
with	O
the	O
potential	O
for	O
the	O
treatment	O
of	O
various	O
bleeding	O
disorders	O
.	O

Remarkably	O
,	O
4	B-chem
-	I-chem
PIOL	E-chem
was	O
found	O
to	O
be	O
more	O
than	O
four	O
times	O
as	O
potent	O
as	O
the	O
drug	O
TXA	S-chem
.	O

Withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	S-chem-C3-1
consumption	O
results	O
in	O
increased	O
packing	O
density	O
of	O
glutamine	B-geneY-C3-2
synthetase	E-geneY-C3-2
-	O
immunoreactive	O
astrocytes	O
in	O
the	O
prelimbic	O
cortex	O
of	O
alcohol	S-chem
-	O
preferring	O
rats	O
.	O

Excess	O
activation	O
of	O
glutamatergic	O
neurotransmission	O
in	O
the	O
cerebral	O
cortex	O
following	O
ethanol	S-chem
withdrawal	O
is	O
considered	O
to	O
contribute	O
to	O
significant	O
behavioural	O
disturbances	O
,	O
and	O
to	O
alcohol	S-chem
craving	O
.	O

Astrocytes	O
may	O
play	O
a	O
role	O
in	O
these	O
manifestations	O
because	O
astrocytes	O
are	O
essential	O
in	O
the	O
regulation	O
of	O
released	O
glutamate	S-chem-C9-1
and	O
its	O
conversion	O
to	O
glutamine	S-chem-C9-1
through	O
the	O
enzyme	O
glutamine	B-geneY-C9-2
synthetase	E-geneY-C9-2
(	O
GS	S-geneY-C9-2
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
if	O
withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	S-chem
drinking	O
causes	O
changes	O
in	O
the	O
numbers	O
of	O
astrocytes	O
expressing	O
GS	S-geneY
or	O
the	O
cytoskeletal	O
protein	O
of	O
astrocytes	O
glial	B-geneY
fibrillary	I-geneY
acidic	I-geneY
protein	E-geneY
(	O
GFAP	S-geneY
)	O
.	O

Alcohol	S-chem
-	O
preferring	O
(	O
P	O
)	O
rats	O
exposed	O
to	O
free	O
-	O
choice	O
ethanol	S-chem
drinking	O
were	O
either	O
maintained	O
without	O
forced	O
interruption	O
of	O
ethanol	S-chem
drinking	O
,	O
subjected	O
to	O
a	O
3	O
-	O
day	O
withdrawal	O
period	O
at	O
the	O
end	O
of	O
2	O
months	O
,	O
or	O
subjected	O
to	O
three	O
3	O
-	O
day	O
withdrawal	O
periods	O
along	O
6	O
months	O
.	O

At	O
2	O
months	O
,	O
P	O
rats	O
were	O
also	O
compared	O
with	O
alcohol	S-chem
-	O
naive	O
alcohol	S-chem
non	O
-	O
preferring	O
rats	O
(	O
NP	O
)	O
rats	O
.	O

Packing	O
density	O
of	O
GS	S-geneY
and	O
GFAP	S-geneY
-	O
immunoreactive	O
(	O
IR	O
)	O
astrocytes	O
was	O
measured	O
in	O
sections	O
from	O
the	O
prelimbic	O
cortex	O
(	O
PLC	O
)	O
using	O
the	O
optical	O
disector	O
probe	O
.	O

An	O
alcohol	S-chem
deprivation	O
effect	O
was	O
observed	O
in	O
P	O
rats	O
with	O
withdrawals	O
during	O
a	O
6	O
-	O
month	O
ethanol	O
drinking	O
period	O
.	O

Ethanol	S-chem
withdrawal	O
significantly	O
increased	O
the	O
packing	O
density	O
of	O
GS	S-geneY
-	O
and	O
GFAP	S-geneY
-	O
IR	O
astrocytes	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
as	O
compared	O
with	O
P	O
rats	O
with	O
continuous	O
access	O
to	O
ethanol	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
pre	O
-	O
withdrawal	O
ethanol	S-chem
consumption	O
and	O
the	O
packing	O
density	O
of	O
GS	S-geneY
-	O
IR	O
astrocytes	O
.	O

The	O
present	O
results	O
suggest	O
the	O
involvement	O
of	O
astrocytes	O
in	O
the	O
regulation	O
of	O
the	O
glutamatergic	O
activation	O
associated	O
with	O
withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	S-chem
consumption	O
and	O
point	O
to	O
differential	O
adaptations	O
of	O
GS	S-geneY
and	O
GFAP	S-geneY
to	O
prolonged	O
alcohol	S-chem
drinking	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
.	O

Relative	O
myotoxic	O
and	O
haemodynamic	O
effects	O
of	O
the	O
beta	O
-	O
agonists	O
fenoterol	S-chem
and	O
clenbuterol	S-chem
measured	O
in	O
conscious	O
unrestrained	O
rats	O
.	O

The	O
beta	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
(	O
beta	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	I-geneY-C5-2
-	I-geneY-C5-2
AR	E-geneY-C5-2
)	O
agonists	O
clenbuterol	S-chem-C5-1
and	O
fenoterol	S-chem-C5-1
have	O
similar	O
beneficial	O
effects	O
in	O
animal	O
models	O
of	O
heart	O
failure	O
.	O

However	O
,	O
large	O
doses	O
of	O
clenbuterol	S-chem
can	O
induce	O
cardiomyocyte	O
death	O
,	O
and	O
it	O
is	O
not	O
known	O
which	O
of	O
these	O
agents	O
has	O
the	O
most	O
favourable	O
therapeutic	O
profile	O
.	O

We	O
have	O
investigated	O
the	O
cardiotoxicity	O
of	O
clenbuterol	S-chem
and	O
fenoterol	S-chem
alongside	O
that	O
of	O
isoprenaline	S-chem
,	O
and	O
compared	O
their	O
haemodynamic	O
effects	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
6	O
per	O
group	O
)	O
were	O
subcutaneously	O
injected	O
with	O
each	O
beta	O
-	O
agonist	O
(	O
0.003	O
-	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
)	O
or	O
saline	O
,	O
and	O
cardiomyocyte	O
apoptosis	O
was	O
detected	O
by	O
caspase	B-geneY
3	E-geneY
immunohistochemistry	O
.	O

In	O
a	O
separate	O
experiment	O
,	O
rats	O
(	O
n	O
=	O
4	O
)	O
were	O
given	O
equivalent	O
doses	O
to	O
those	O
used	O
in	O
the	O
myotoxicity	O
studies	O
,	O
in	O
a	O
randomized	O
cross	O
-	O
over	O
design	O
,	O
and	O
their	O
blood	O
pressure	O
recorded	O
via	O
radiotelemetry	O
.	O

Injection	O
of	O
0.3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
fenoterol	S-chem
or	O
isoprenaline	S-chem
,	O
but	O
not	O
clenbuterol	S-chem
,	O
induced	O
significant	O
cardiomyocyte	O
apoptosis	O
(	O
0.4	O
+	O
/	O
-	O
0.05	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O

At	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
,	O
all	O
agonists	O
induced	O
apoptosis	O
(	O
fenoterol	S-chem
,	O
1.1	O
+	O
/	O
-	O
0.1	O
%	O
;	O
isoprenaline	S-chem
,	O
0.9	O
+	O
/	O
-	O
0.8	O
%	O
;	O
and	O
clenbuterol	S-chem
,	O
0.4	O
+	O
/	O
-	O
0.07	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O
beta	B-geneY-C6-2
(	I-geneY-C6-2
1	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
Adrenoceptor	E-geneY-C6-2
antagonism	O
(	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
bisoprolol	S-chem-C6-1
)	O
prevented	O
92	O
%	O
(	O
P	O
<	O
0.05	O
)	O
of	O
apoptosis	O
induced	O
by	O
all	O
three	O
agonists	O
,	O
but	O
clenbuterol	S-chem
-	O
induced	O
apoptosis	O
could	O
also	O
be	O
prevented	O
by	O
96	O
%	O
(	O
P	O
<	O
0.05	O
)	O
by	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
AR	E-geneY
antagonism	O
(	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
ICI	O
118	O
551	O
)	O
.	O

Clenbuterol	S-chem
decreased	O
diastolic	O
(	O
1.3	O
-	O
to	O
1.6	O
-	O
fold	O
;	O
P	O
<	O
0.05	O
)	O
and	O
systolic	O
blood	O
pressure	O
(	O
1.3	O
-	O
fold	O
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
doses	O
>	O
0.3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
increased	O
heart	O
rate	O
(	O
1.4	O
-	O
fold	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Fenoterol	S-chem
increased	O
heart	O
rate	O
(	O
1.2	O
-	O
to	O
1.4	O
-	O
fold	O
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
doses	O
>	O
0.3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
decreased	O
diastolic	O
blood	O
pressure	O
(	O
1.3	O
-	O
fold	O
;	O
P	O
<	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
cardiotoxicity	O
of	O
fenoterol	S-chem
was	O
similar	O
to	O
isoprenaline	S-chem
and	O
greater	O
than	O
clenbuterol	S-chem
,	O
and	O
fenoterol	S-chem
had	O
less	O
desirable	O
haemodynamic	O
effects	O
.	O

Smoothened	S-geneY
is	O
a	O
fully	O
competent	O
activator	O
of	O
the	O
heterotrimeric	O
G	B-geneN
protein	E-geneN
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
.	O

Smoothened	S-geneY
(	O
Smo	S-geneY
)	O
is	O
a	O
7	O
-	O
transmembrane	O
protein	O
essential	O
to	O
the	O
activation	O
of	O
Gli	S-geneY
transcription	O
factors	O
(	O
Gli	S-geneY
)	O
by	O
hedgehog	O
morphogens	O
.	O

The	O
structure	O
of	O
Smo	S-geneY
implies	O
interactions	O
with	O
heterotrimeric	O
G	B-geneN
proteins	E-geneN
,	O
but	O
the	O
degree	O
to	O
which	O
G	B-geneN
proteins	E-geneN
participate	O
in	O
the	O
actions	O
of	O
hedgehogs	O
remains	O
controversial	O
.	O

We	O
posit	O
that	O
the	O
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
family	O
of	O
G	B-geneN
proteins	E-geneN
provides	O
to	O
hedgehogs	O
the	O
ability	O
to	O
expand	O
well	O
beyond	O
the	O
bounds	O
of	O
Gli	S-geneY
.	O

In	O
this	O
regard	O
,	O
we	O
evaluate	O
here	O
the	O
efficacy	O
of	O
Smo	S-geneY
as	O
it	O
relates	O
to	O
the	O
activation	O
of	O
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
,	O
by	O
comparing	O
Smo	S-geneY
with	O
the	O
5	B-geneY
-	I-geneY
hydroxytryptamine	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
(	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
)	O
receptor	O
,	O
a	O
quintessential	O
G	B-geneN
(	I-geneN
i	I-geneN
)	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
.	O

We	O
find	O
that	O
with	O
use	O
of	O
[	B-chem
(	I-chem
35	I-chem
)	I-chem
S	I-chem
]	I-chem
guanosine	I-chem
5	I-chem
'	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
O	I-chem
-	I-chem
thio	I-chem
)	I-chem
triphosphate	E-chem
,	O
first	O
,	O
with	O
forms	O
of	O
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
endogenous	O
to	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
-	O
293	O
cells	O
made	O
to	O
express	O
epitope	O
-	O
tagged	O
receptors	O
and	O
,	O
second	O
,	O
with	O
individual	O
forms	O
of	O
Gα	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
fused	O
to	O
the	O
C	O
terminus	O
of	O
each	O
receptor	O
,	O
Smo	S-geneY
is	O
equivalent	O
to	O
the	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptor	O
in	O
the	O
assay	O
as	O
it	O
relates	O
to	O
capacity	O
to	O
activate	O
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
.	O

This	O
finding	O
is	O
true	O
regardless	O
of	O
subtype	O
of	O
G	B-geneN
(	I-geneN
i	I-geneN
)	E-geneN
(	O
e.g	O
.	O
,	O
G	B-geneY
(	I-geneY
i2	I-geneY
)	E-geneY
,	O
G	B-geneY
(	I-geneY
o	I-geneY
)	E-geneY
,	O
and	O
G	B-geneY
(	I-geneY
z	I-geneY
)	E-geneY
)	O
tested	O
.	O

We	O
also	O
find	O
that	O
Smo	S-geneY
endogenous	O
to	O
HEK	O
-	O
293	O
cells	O
,	O
ostensibly	O
through	O
inhibition	O
of	O
adenylyl	B-geneN
cyclase	E-geneN
,	O
decreases	O
intracellular	O
levels	O
of	O
cAMP	S-chem
.	O

The	O
results	O
indicate	O
that	O
Smo	S-geneY
is	O
a	O
receptor	O
that	O
can	O
engage	O
not	O
only	O
Gli	S-geneY
but	O
also	O
other	O
more	O
immediate	O
effectors	O
.	O

ABT	B-chem-C4-1
-	I-chem-C4-1
199	E-chem-C4-1
,	O
a	O
potent	O
and	O
selective	O
BCL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
achieves	O
antitumor	O
activity	O
while	O
sparing	O
platelets	O
.	O

Proteins	O
in	O
the	O
B	B-geneY
cell	I-geneY
CLL	I-geneY
/	I-geneY
lymphoma	I-geneY
2	E-geneY
(	O
BCL	B-geneY
-	I-geneY
2	E-geneY
)	O
family	O
are	O
key	O
regulators	O
of	O
the	O
apoptotic	O
process	O
.	O

This	O
family	O
comprises	O
proapoptotic	O
and	O
prosurvival	O
proteins	O
,	O
and	O
shifting	O
the	O
balance	O
toward	O
the	O
latter	O
is	O
an	O
established	O
mechanism	O
whereby	O
cancer	O
cells	O
evade	O
apoptosis	O
.	O

The	O
therapeutic	O
potential	O
of	O
directly	O
inhibiting	O
prosurvival	O
proteins	O
was	O
unveiled	O
with	O
the	O
development	O
of	O
navitoclax	S-chem-C4-1
,	O
a	O
selective	O
inhibitor	O
of	O
both	O
BCL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
BCL	B-geneY-C4-2
-	I-geneY-C4-2
2	I-geneY-C4-2
-	I-geneY-C4-2
like	I-geneY-C4-2
1	E-geneY-C4-2
(	O
BCL	B-geneY-C4-2
-	I-geneY-C4-2
X	I-geneY-C4-2
(	I-geneY-C4-2
L	I-geneY-C4-2
)	E-geneY-C4-2
)	O
,	O
which	O
has	O
shown	O
clinical	O
efficacy	O
in	O
some	O
BCL	B-geneY
-	I-geneY
2	E-geneY
-	O
dependent	O
hematological	O
cancers	O
.	O

However	O
,	O
concomitant	O
on	O
-	O
target	O
thrombocytopenia	O
caused	O
by	O
BCL	B-geneY
-	I-geneY
X	I-geneY
(	I-geneY
L	I-geneY
)	E-geneY
inhibition	O
limits	O
the	O
efficacy	O
achievable	O
with	O
this	O
agent	O
.	O

Here	O
we	O
report	O
the	O
re	O
-	O
engineering	O
of	O
navitoclax	S-chem-C4-1
to	O
create	O
a	O
highly	O
potent	O
,	O
orally	O
bioavailable	O
and	O
BCL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
-	O
selective	O
inhibitor	O
,	O
ABT	B-chem-C4-1
-	I-chem-C4-1
199	E-chem-C4-1
.	O

This	O
compound	O
inhibits	O
the	O
growth	O
of	O
BCL	B-geneY
-	I-geneY
2	E-geneY
-	O
dependent	O
tumors	O
in	O
vivo	O
and	O
spares	O
human	O
platelets	O
.	O

A	O
single	O
dose	O
of	O
ABT	B-chem
-	I-chem
199	E-chem
in	O
three	O
patients	O
with	O
refractory	O
chronic	O
lymphocytic	O
leukemia	O
resulted	O
in	O
tumor	O
lysis	O
within	O
24	O
h	O
.	O

These	O
data	O
indicate	O
that	O
selective	O
pharmacological	O
inhibition	O
of	O
BCL	B-geneY
-	I-geneY
2	E-geneY
shows	O
promise	O
for	O
the	O
treatment	O
of	O
BCL	B-geneY
-	I-geneY
2	E-geneY
-	O
dependent	O
hematological	O
cancers	O
.	O

Combining	O
QSAR	O
classification	O
models	O
for	O
predictive	O
modeling	O
of	O
human	B-geneN
monoamine	I-geneN
oxidase	E-geneN
inhibitors	O
.	O

Due	O
to	O
their	O
role	O
in	O
the	O
metabolism	O
of	O
monoamine	O
neurotransmitters	O
,	O
MAO	B-geneY
-	I-geneY
A	E-geneY
and	O
MAO	B-geneY
-	I-geneY
B	E-geneY
present	O
a	O
significant	O
pharmacological	O
interest	O
.	O

For	O
instance	O
the	O
inhibitors	O
of	O
human	B-geneY
MAO	I-geneY
-	I-geneY
B	E-geneY
are	O
considered	O
useful	O
tools	O
for	O
the	O
treatment	O
of	O
Parkinson	O
Disease	O
.	O

Therefore	O
,	O
the	O
rational	O
design	O
and	O
synthesis	O
of	O
new	O
MAOs	S-geneN
inhibitors	O
is	O
considered	O
of	O
great	O
importance	O
for	O
the	O
development	O
of	O
new	O
and	O
more	O
effective	O
treatments	O
of	O
Parkinson	O
Disease	O
.	O

In	O
this	O
work	O
,	O
Quantitative	O
Structure	O
Activity	O
Relationships	O
(	O
QSAR	O
)	O
has	O
been	O
developed	O
to	O
predict	O
the	O
human	B-geneN
MAO	E-geneN
inhibitory	O
activity	O
and	O
selectivity	O
.	O

The	O
first	O
step	O
was	O
the	O
selection	O
of	O
a	O
suitable	O
dataset	O
of	O
heterocyclic	O
compounds	O
that	O
include	O
chromones	S-chem
,	O
coumarins	S-chem
,	O
chalcones	S-chem
,	O
thiazolylhydrazones	S-chem
,	O
etc	O
.	O

These	O
compounds	O
were	O
previously	O
synthesized	O
in	O
one	O
of	O
our	O
laboratories	O
,	O
or	O
elsewhere	O
,	O
and	O
their	O
activities	O
measured	O
by	O
the	O
same	O
assays	O
and	O
for	O
the	O
same	O
laboratory	O
staff	O
.	O

Applying	O
linear	O
discriminant	O
analysis	O
to	O
data	O
derived	O
from	O
a	O
variety	O
of	O
molecular	O
representations	O
and	O
feature	O
selection	O
algorithms	O
,	O
reliable	O
QSAR	O
models	O
were	O
built	O
which	O
could	O
be	O
used	O
to	O
predict	O
for	O
test	O
compounds	O
the	O
inhibitory	O
activity	O
and	O
selectivity	O
toward	O
human	B-geneN
MAO	E-geneN
.	O

This	O
work	O
also	O
showed	O
how	O
several	O
QSAR	O
models	O
can	O
be	O
combined	O
to	O
make	O
better	O
predictions	O
.	O

The	O
final	O
models	O
exhibit	O
significant	O
statistics	O
,	O
interpretability	O
,	O
as	O
well	O
as	O
displaying	O
predictive	O
power	O
on	O
an	O
external	O
validation	O
set	O
made	O
up	O
of	O
chromone	O
derivatives	O
with	O
unknown	O
activity	O
(	O
that	O
are	O
being	O
reported	O
here	O
for	O
first	O
time	O
)	O
synthesized	O
by	O
our	O
group	O
,	O
and	O
coumarins	S-chem
recently	O
reported	O
in	O
the	O
literature	O
.	O

Conformation	O
Guides	O
Molecular	O
Efficacy	O
in	O
Docking	O
Screens	O
of	O
Activated	O
β	B-geneY
-	I-geneY
2	I-geneY
Adrenergic	I-geneY
G	I-geneY
Protein	I-geneY
Coupled	I-geneY
Receptor	E-geneY
.	O

A	O
prospective	O
,	O
large	O
library	O
virtual	O
screen	O
against	O
an	O
activated	O
β2	B-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
(	O
β2AR	S-geneY
)	O
structure	O
returned	O
potent	O
agonists	O
to	O
the	O
exclusion	O
of	O
inverse	O
-	O
agonists	O
,	O
providing	O
the	O
first	O
complement	O
to	O
the	O
previous	O
virtual	O
screening	O
campaigns	O
against	O
inverse	O
-	O
agonist	O
-	O
bound	O
G	B-geneN
protein	I-geneN
coupled	I-geneN
receptor	E-geneN
(	O
GPCR	S-geneN
)	O
structures	O
,	O
which	O
predicted	O
only	O
inverse	O
-	O
agonists	O
.	O

In	O
addition	O
,	O
two	O
hits	O
recapitulated	O
the	O
signaling	O
profile	O
of	O
the	O
co	O
-	O
crystal	O
ligand	O
with	O
respect	O
to	O
the	O
G	B-geneN
protein	E-geneN
and	O
arrestin	S-geneN
mediated	O
signaling	O
.	O

This	O
functional	O
fidelity	O
has	O
important	O
implications	O
in	O
drug	O
design	O
,	O
as	O
the	O
ability	O
to	O
predict	O
ligands	O
with	O
predefined	O
signaling	O
properties	O
is	O
highly	O
desirable	O
.	O

However	O
,	O
the	O
agonist	O
-	O
bound	O
state	O
provides	O
an	O
uncertain	O
template	O
for	O
modeling	O
the	O
activated	O
conformation	O
of	O
other	O
GPCRs	S-geneN
,	O
as	O
a	O
dopamine	B-geneN
D2	I-geneN
receptor	E-geneN
(	O
DRD2	S-geneY
)	O
activated	O
model	O
templated	O
on	O
the	O
activated	O
β2AR	S-geneY
structure	O
returned	O
few	O
hits	O
of	O
only	O
marginal	O
potency	O
.	O

A	O
positron	O
emission	O
tomography	O
study	O
of	O
quetiapine	S-chem
in	O
schizophrenia	O
:	O
a	O
preliminary	O
finding	O
of	O
an	O
antipsychotic	O
effect	O
with	O
only	O
transiently	O
high	O
dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
occupancy	O
.	O

BACKGROUND	O
:	O
Quetiapine	S-chem
is	O
a	O
new	O
atypical	O
antipsychotic	O
medication	O
.	O

As	O
such	O
,	O
relatively	O
little	O
has	O
been	O
published	O
regarding	O
its	O
in	O
vivo	O
effects	O
at	O
the	O
dopamine	B-geneY
type	I-geneY
2	E-geneY
(	O
D2	S-geneY
)	O
and	O
serotonin	B-geneY
type	I-geneY
2a	I-geneY
(	I-geneY
5	I-geneY
-	I-geneY
HT2a	I-geneY
)	I-geneY
receptor	E-geneY
systems	O
.	O

The	O
following	O
study	O
was	O
undertaken	O
to	O
explore	O
these	O
effects	O
across	O
the	O
clinical	O
dose	O
range	O
and	O
relate	O
this	O
information	O
to	O
its	O
clinical	O
profile	O
.	O

METHODS	O
:	O
Twelve	O
patients	O
with	O
schizophrenia	O
were	O
randomly	O
assigned	O
to	O
doses	O
of	O
150	O
to	O
600	O
mg	O
/	O
d	O
(	O
n	O
=	O
3	O
,	O
at	O
150	O
,	O
300	O
,	O
450	O
,	O
and	O
600	O
mg	O
/	O
d	O
)	O
of	O
quetiapine	S-chem
.	O

After	O
3	O
weeks	O
of	O
treatment	O
,	O
D2	S-geneY
and	O
5	B-geneY
-	I-geneY
HT2a	E-geneY
occupancy	O
were	O
measured	O
using	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
,	O
12	O
to	O
14	O
hours	O
after	O
the	O
last	O
dose	O
.	O

Clinical	O
efficacy	O
and	O
adverse	O
effect	O
ratings	O
were	O
obtained	O
at	O
baseline	O
,	O
at	O
the	O
time	O
of	O
PET	O
scanning	O
,	O
and	O
at	O
12	O
weeks	O
.	O

Two	O
additional	O
patients	O
were	O
included	O
to	O
examine	O
the	O
effects	O
of	O
the	O
drug	O
2	O
to	O
3	O
hours	O
after	O
last	O
dose	O
.	O

RESULTS	O
:	O
Quetiapine	S-chem-C3-1
was	O
an	O
effective	O
antipsychotic	O
and	O
improved	O
the	O
extrapyramidal	O
symptoms	O
and	O
prolactin	S-geneY-C3-2
level	O
elevation	O
noted	O
at	O
baseline	O
.	O

It	O
achieved	O
these	O
results	O
with	O
minimal	O
(	O
0	O
%	O
-	O
27	O
%	O
)	O
D2	S-geneY
occupancy	O
12	O
hours	O
after	O
the	O
last	O
dose	O
.	O

Study	O
of	O
the	O
additional	O
subjects	O
revealed	O
that	O
quetiapine	S-chem
does	O
give	O
rise	O
to	O
transiently	O
high	O
(	O
58	O
%	O
-	O
64	O
%	O
)	O
D2	S-geneY
occupancy	O
2	O
to	O
3	O
hours	O
after	O
a	O
single	O
dose	O
that	O
then	O
decreases	O
to	O
minimal	O
levels	O
in	O
12	O
hours	O
.	O

CONCLUSIONS	O
:	O
Quetiapine	S-chem
shows	O
a	O
transiently	O
high	O
D2	S-geneY
occupancy	O
,	O
which	O
decreases	O
to	O
very	O
low	O
levels	O
by	O
the	O
end	O
of	O
the	O
dosing	O
interval	O
.	O

Quetiapine	O
's	O
low	O
D2	S-geneY
occupancy	O
can	O
explain	O
its	O
freedom	O
from	O
extrapyramidal	O
symptoms	O
and	O
prolactin	O
level	O
elevation	O
.	O

The	O
data	O
suggest	O
that	O
transient	O
D2	S-geneY
occupancy	O
may	O
be	O
sufficient	O
for	O
its	O
antipsychotic	O
effect	O
.	O

Future	O
studies	O
controlling	O
for	O
nonpharmacological	O
effects	O
as	O
well	O
as	O
activities	O
on	O
other	O
receptors	O
will	O
be	O
necessary	O
to	O
confirm	O
this	O
suggestion	O
.	O

Regulation	O
of	O
retinal	O
dehydrogenases	O
and	O
retinoic	B-chem
acid	E-chem
synthesis	O
by	O
cholesterol	S-chem
metabolites	O
.	O

Retinoic	B-chem
acid	E-chem
(	O
RA	S-chem
)	O
constitutes	O
the	O
major	O
active	O
ingredient	O
of	O
vitamin	B-chem
A	E-chem
and	O
is	O
required	O
for	O
various	O
biological	O
processes	O
.	O

The	O
tissue	O
RA	S-chem
level	O
is	O
maintained	O
through	O
a	O
cascade	O
of	O
metabolic	O
reactions	O
where	O
retinal	B-geneN-C9-2
dehydrogenases	E-geneN-C9-2
(	O
RALDHs	S-geneN-C9-2
)	O
catalyze	O
the	O
terminal	O
reaction	O
of	O
RA	S-chem-C9-1
biosynthesis	O
from	O
retinal	S-chem-C9-1
,	O
a	O
rate	O
-	O
limiting	O
step	O
.	O

We	O
showed	O
that	O
dietary	O
supplement	O
of	O
cholesterol	S-chem
enhanced	O
the	O
expression	O
of	O
RALDH1	B-geneN
and	I-geneN
2	E-geneN
genes	O
and	O
the	O
cellular	O
RA	S-chem
content	O
in	O
vital	O
organs	O
such	O
as	O
brain	O
,	O
kidney	O
,	O
liver	O
and	O
heart	O
.	O

Consistently	O
,	O
the	O
cholesterol	S-chem
-	O
lowering	O
agent	O
(	O
pravastatin	B-chem
sodium	E-chem
)	O
downregulated	O
the	O
expression	O
of	O
RALDH1	B-geneN
and	I-geneN
2	E-geneN
genes	O
in	O
several	O
organs	O
especially	O
the	O
liver	O
and	O
in	O
cultured	O
liver	O
cells	O
.	O

Further	O
,	O
cholesterol	S-chem-C3-1
metabolites	O
,	O
predominantly	O
the	O
oxysterols	S-chem-C3-1
,	O
the	O
natural	O
ligands	O
for	O
liver	B-geneN
X	I-geneN
receptor	E-geneN
(	O
LXR	S-geneN
)	O
,	O
induced	O
these	O
genes	O
via	O
upregulation	O
of	O
sterol	B-geneY-C3-2
regulatory	I-geneY-C3-2
element	I-geneY-C3-2
binding	I-geneY-C3-2
protein	I-geneY-C3-2
-	I-geneY-C3-2
1c	E-geneY-C3-2
(	O
SREBP	B-geneY-C3-2
-	I-geneY-C3-2
1c	E-geneY-C3-2
)	O
that	O
bound	O
to	O
the	O
regulatory	O
regions	O
of	O
these	O
genes	O
.	O

Knockdown	O
of	O
LXRalpha	B-geneN
/	I-geneN
beta	E-geneN
or	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
downregulated	O
the	O
expression	O
of	O
RALDH	S-geneN
genes	O
,	O
which	O
could	O
be	O
rescued	O
by	O
re	O
-	O
expressing	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
,	O
suggesting	O
SREBP	B-geneY
-	I-geneY
1c	E-geneY
as	O
a	O
direct	O
positive	O
regulator	O
for	O
these	O
genes	O
.	O

This	O
study	O
uncovered	O
a	O
novel	O
crosstalk	O
between	O
cholesterol	S-chem
and	O
RA	S-chem
biosynthesis	O
.	O

In	O
vitro	O
study	O
of	O
intestinal	O
transport	O
of	O
fluoride	S-chem
using	O
the	O
Caco	O
-	O
2	O
cell	O
line	O
.	O

Water	O
and	O
food	O
are	O
the	O
main	O
sources	O
of	O
fluoride	S-chem
exposure	O
and	O
therefore	O
it	O
is	O
necessary	O
to	O
study	O
intestinal	O
absorption	O
in	O
order	O
to	O
make	O
a	O
correct	O
evaluation	O
of	O
the	O
risk	O
/	O
benefit	O
associated	O
with	O
exposure	O
to	O
fluoride	S-chem
.	O

The	O
present	O
study	O
characterizes	O
intestinal	O
transport	O
of	O
fluoride	S-chem
,	O
using	O
the	O
Caco	O
-	O
2	O
cell	O
line	O
as	O
a	O
model	O
of	O
the	O
intestinal	O
epithelium	O
,	O
and	O
evaluates	O
the	O
coefficients	O
of	O
apparent	O
permeability	O
and	O
intracellular	O
accumulation	O
in	O
various	O
conditions	O
(	O
pH	O
,	O
temperature	O
,	O
opening	O
of	O
cell	O
junctions	O
,	O
presence	O
of	O
anions	O
)	O
.	O

The	O
results	O
indicate	O
that	O
fluoride	S-chem
is	O
an	O
element	O
with	O
moderate	O
absorption	O
(	O
<	O
70	O
%	O
)	O
in	O
both	O
directions	O
(	O
absorptive	O
and	O
secretory	O
)	O
.	O

Both	O
in	O
absorption	O
(	O
apical	O
-	O
basolateral	O
)	O
and	O
in	O
secretion	O
(	O
basolateral	O
-	O
apical	O
)	O
there	O
is	O
transport	O
by	O
the	O
paracellular	O
pathway	O
,	O
which	O
may	O
be	O
considered	O
predominant	O
.	O

Absorption	O
and	O
secretion	O
of	O
fluoride	S-chem-C9-1
increase	O
at	O
acid	O
pH	O
levels	O
,	O
possibly	O
because	O
of	O
its	O
non	O
-	O
ionized	O
state	O
at	O
these	O
pHs	O
and	O
/	O
or	O
because	O
of	O
participation	O
of	O
a	O
F	B-geneN-C9-2
(	I-geneN-C9-2
-	I-geneN-C9-2
)	I-geneN-C9-2
/	I-geneN-C9-2
H	I-geneN-C9-2
(	I-geneN-C9-2
+	I-geneN-C9-2
)	I-geneN-C9-2
cotransporter	E-geneN-C9-2
or	O
a	O
F	B-geneN-C9-2
(	I-geneN-C9-2
-	I-geneN-C9-2
)	I-geneN-C9-2
/	I-geneN-C9-2
OH	I-geneN-C9-2
(	I-geneN-C9-2
-	I-geneN-C9-2
)	I-geneN-C9-2
antiporter	E-geneN-C9-2
.	O

The	O
results	O
also	O
suggest	O
transcellular	O
participation	O
of	O
mechanisms	O
involved	O
in	O
transport	O
of	O
Cl	B-chem
(	I-chem
-	I-chem
)	E-chem
and	O
of	O
an	O
active	O
transport	O
in	O
the	O
secretory	O
direction	O
.	O

The	O
present	O
study	O
extend	O
the	O
knowledge	O
on	O
the	O
cellular	O
transport	O
of	O
fluoride	S-chem
and	O
provide	O
the	O
basis	O
for	O
future	O
studies	O
aimed	O
at	O
identifying	O
potential	O
transporters	O
involved	O
in	O
human	O
fluoride	S-chem
absorption	O
.	O

Can	O
the	O
chemical	O
reactivity	O
of	O
an	O
ultimate	O
carcinogen	O
be	O
related	O
to	O
its	O
carcinogenicity	O
?	O
An	O
application	O
to	O
propylene	B-chem
oxide	E-chem
.	O

In	O
this	O
article	O
we	O
report	O
calculations	O
of	O
the	O
activation	O
free	O
energy	O
for	O
a	O
chemical	O
reaction	O
between	O
propylene	B-chem
oxide	E-chem
and	O
DNA	O
,	O
in	O
particular	O
with	O
the	O
guanine	S-chem
at	O
the	O
N7	O
position	O
.	O

Calculations	O
were	O
performed	O
using	O
Hartree	O
-	O
Fock	O
and	O
MP2	O
methods	O
in	O
conjunction	O
with	O
flexible	O
basis	O
sets	O
.	O

The	O
effects	O
of	O
solvation	O
were	O
considered	O
using	O
the	O
Langevin	O
dipoles	O
and	O
solvent	O
reaction	O
field	O
methods	O
.	O

The	O
calculated	O
activation	O
free	O
energies	O
are	O
in	O
good	O
agreement	O
with	O
the	O
experimental	O
value	O
of	O
25.36	O
kcal	O
/	O
mol	O
.	O

Moreover	O
,	O
the	O
reactivities	O
of	O
a	O
series	O
of	O
ultimate	O
carcinogens	O
of	O
the	O
epoxy	S-chem
type	O
toward	O
DNA	O
are	O
shown	O
to	O
be	O
related	O
to	O
their	O
carcinogenicities	O
.	O

Higher	O
reactivity	O
is	O
generally	O
associated	O
with	O
higher	O
carcinogenicity	O
,	O
although	O
transport	O
properties	O
,	O
reactions	O
with	O
ultimate	O
carcinogen	O
scavengers	O
,	O
and	O
the	O
DNA	O
correction	O
mechanism	O
are	O
also	O
very	O
important	O
.	O

It	O
is	O
very	O
likely	O
that	O
the	O
window	O
of	O
reactivity	O
rather	O
than	O
a	O
high	O
reactivity	O
value	O
is	O
the	O
relevant	O
measure	O
of	O
carcinogenicity	O
,	O
since	O
highly	O
reactive	O
ultimate	O
carcinogens	O
interact	O
with	O
water	O
and	O
proteins	O
before	O
they	O
reach	O
DNA	O
.	O

Involvement	O
of	O
regucalcin	S-geneY
in	O
lipid	O
metabolism	O
and	O
diabetes	O
.	O

Regucalcin	S-geneY
(	O
RGN	S-geneY
/	O
SMP30	S-geneY
)	O
was	O
originally	O
discovered	O
in	O
1978	O
as	O
a	O
unique	O
calcium	S-chem
-	O
binding	O
protein	O
that	O
does	O
not	O
contain	O
the	O
EF	B-geneN
-	I-geneN
hand	I-geneN
motif	E-geneN
of	O
calcium	B-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
.	O

The	O
regucalcin	S-geneY
gene	O
(	O
rgn	S-geneY
)	O
is	O
localized	O
on	O
the	O
X	O
chromosome	O
and	O
is	O
identified	O
in	O
over	O
15	O
species	O
consisting	O
the	O
regucalcin	S-geneY
family	O
.	O

Regucalcin	S-geneY
has	O
been	O
shown	O
to	O
play	O
a	O
multifunctional	O
role	O
in	O
cell	O
regulation	O
;	O
maintaining	O
of	O
intracellular	O
calcium	S-chem
homeostasis	O
and	O
suppressing	O
of	O
signal	O
transduction	O
,	O
translational	O
protein	O
synthesis	O
,	O
nuclear	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
and	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
synthesis	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

Moreover	O
,	O
regucalcin	S-geneY
may	O
play	O
a	O
pathophysiological	O
role	O
in	O
metabolic	O
disorder	O
.	O

The	O
expression	O
of	O
regucalcin	S-geneY-C4-2
is	O
stimulated	O
through	O
the	O
action	O
of	O
insulin	S-geneY
in	O
liver	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
it	O
is	O
decreased	O
in	O
the	O
liver	O
of	O
rats	O
with	O
type	O
I	O
diabetes	O
induced	O
by	O
streptozotocin	S-chem-C4-1
administration	O
in	O
vivo	O
.	O

Overexpression	O
of	O
endogenous	O
regucalcin	S-geneY
stimulates	O
glucose	S-chem
utilization	O
and	O
lipid	O
production	O
in	O
liver	O
cells	O
with	O
glucose	S-chem
supplementation	O
in	O
vitro	O
.	O

Regucalcin	S-geneY
reveals	O
insulin	S-geneY
resistance	O
in	O
liver	O
cells	O
.	O

Deficiency	O
of	O
regucalcin	S-geneY
induces	O
an	O
impairment	O
of	O
glucose	S-chem
tolerance	O
and	O
lipid	O
accumulation	O
in	O
the	O
liver	O
of	O
mice	O
in	O
vivo	O
.	O

Overexpression	O
of	O
endogenous	O
regucalcin	S-geneY
has	O
been	O
shown	O
to	O
decrease	O
triglyceride	S-chem
,	O
total	O
cholesterol	S-chem
and	O
glycogen	O
contents	O
in	O
the	O
liver	O
of	O
rats	O
,	O
inducing	O
hyperlipidemia	O
.	O

Leptin	S-geneY
and	O
adiponectin	S-geneY
mRNA	O
expressions	O
in	O
the	O
liver	O
tissues	O
are	O
decreased	O
in	O
regucalcin	S-geneY
transgenic	O
rats	O
.	O

Decrease	O
in	O
hepatic	O
regucalcin	S-geneY
is	O
associated	O
with	O
the	O
development	O
and	O
progression	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
and	O
fibrosis	O
in	O
human	O
patients	O
.	O

Regucalcin	O
may	O
be	O
a	O
key	O
molecule	O
in	O
lipid	O
metabolic	O
disorder	O
and	O
diabetes	O
.	O

Regulation	O
of	O
norepinephrine	B-geneY
transporter	E-geneY
abundance	O
by	O
catecholamines	S-chem
and	O
desipramine	S-chem
in	O
vivo	O
.	O

The	O
norepinephrine	B-geneY
transporter	E-geneY
(	O
NET	S-geneY
)	O
regulates	O
adrenoreceptor	S-geneN
signaling	O
by	O
controlling	O
the	O
availability	O
of	O
synaptic	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
,	O
and	O
it	O
is	O
a	O
direct	O
target	O
for	O
some	O
classes	O
of	O
antidepressant	O
drugs	O
.	O

NET	S-geneY
levels	O
are	O
normal	O
in	O
dopamine	B-geneY
beta	I-geneY
-	I-geneY
hydroxylase	E-geneY
knockout	O
(	O
Dbh	S-geneY
-	O
/	O
-	O
)	O
mice	O
that	O
lack	O
NE	S-chem
,	O
demonstrating	O
that	O
the	O
NET	S-geneY
does	O
not	O
require	O
endogenous	O
NE	S-chem
for	O
appropriate	O
regulation	O
under	O
physiological	O
conditions	O
.	O

In	O
contrast	O
,	O
tyrosine	B-geneY
hydroxylase	E-geneY
knockout	O
(	O
Th	S-geneY
-	O
/	O
-	O
)	O
mice	O
that	O
lack	O
both	O
NE	S-chem
and	O
dopamine	S-chem
(	O
DA	S-chem
)	O
have	O
reduced	O
levels	O
of	O
NET	S-geneY
,	O
suggesting	O
that	O
it	O
is	O
down	O
-	O
regulated	O
by	O
a	O
complete	O
absence	O
of	O
catecholamines	S-chem
and	O
not	O
NE	S-chem
per	O
se	O
.	O

Chronic	O
treatment	O
with	O
the	O
NET	S-geneY-C4-2
inhibitor	O
,	O
desipramine	S-chem-C4-1
(	O
DMI	O
)	O
,	O
reduced	O
NET	S-geneY-C4-2
levels	O
in	O
both	O
control	O
and	O
Dbh	S-geneY
-	O
/	O
-	O
mice	O
,	O
demonstrating	O
that	O
NE	S-chem
is	O
not	O
required	O
for	O
the	O
regulation	O
of	O
NET	S-geneY
by	O
antidepressant	O
drugs	O
.	O

There	O
are	O
some	O
qualitative	O
and	O
quantitative	O
differences	O
in	O
the	O
down	O
-	O
regulation	O
of	O
the	O
NET	S-geneY
by	O
catecholamine	O
depletion	O
and	O
DMI	O
treatment	O
,	O
suggesting	O
that	O
different	O
mechanisms	O
may	O
be	O
involved	O
.	O

Atypical	O
neuroleptics	O
have	O
low	O
affinity	O
for	O
dopamine	B-geneY
D2	I-geneY
receptors	E-geneY
or	O
are	O
selective	O
for	O
D4	B-geneY
receptors	E-geneY
.	O

This	O
review	O
examines	O
the	O
possible	O
receptor	O
basis	O
of	O
the	O
atypical	O
action	O
of	O
those	O
atypical	O
antipsychotic	O
drugs	O
that	O
elicit	O
low	O
levels	O
of	O
Parkinsonism	O
.	O

Such	O
an	O
examination	O
requires	O
consistent	O
and	O
accurate	O
dissociation	O
constants	O
for	O
the	O
antipsychotic	O
drugs	O
at	O
the	O
relevant	O
dopamine	B-geneN
and	I-geneN
serotonin	I-geneN
receptors	E-geneN
.	O

It	O
has	O
long	O
been	O
known	O
,	O
however	O
,	O
that	O
the	O
dissociation	O
constant	O
of	O
a	O
given	O
antipsychotic	O
drug	O
at	O
the	O
dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
varies	O
between	O
laboratories	O
.	O

Although	O
such	O
variation	O
depends	O
on	O
several	O
factors	O
,	O
it	O
has	O
recently	O
been	O
recognized	O
that	O
the	O
radioligand	O
used	O
to	O
measure	O
the	O
competition	O
between	O
the	O
antipsychotic	O
drug	O
and	O
the	O
radioligand	O
is	O
an	O
important	O
variable	O
.	O

The	O
present	O
review	O
summarizes	O
information	O
on	O
this	O
radioligand	O
dependence	O
.	O

In	O
general	O
,	O
a	O
radioligand	O
of	O
low	O
solubility	O
in	O
the	O
membrane	O
(	O
i.e	O
.	O
,	O
low	O
tissue	O
:	O
buffer	O
partition	O
)	O
results	O
in	O
a	O
low	O
value	O
for	O
the	O
antipsychotic	O
dissociation	O
constant	O
when	O
the	O
drug	O
competes	O
with	O
the	O
radioligand	O
.	O

Hence	O
,	O
by	O
first	O
obtaining	O
the	O
antipsychotic	O
dissociation	O
constants	O
using	O
different	O
radioligands	O
of	O
different	O
solubility	O
in	O
the	O
membrane	O
,	O
one	O
can	O
then	O
extrapolate	O
the	O
data	O
to	O
low	O
or	O
``	O
zero	O
``	O
ligand	O
solubility	O
.	O

The	O
extrapolated	O
value	O
represents	O
the	O
radioligand	O
-	O
independent	O
dissociation	O
constant	O
of	O
the	O
antipsychotic	O
.	O

These	O
values	O
are	O
here	O
given	O
for	O
dopamine	B-geneN
D2	I-geneN
and	I-geneN
D4	I-geneN
receptors	E-geneN
,	O
as	O
well	O
as	O
for	O
serotonin	B-geneY
5	I-geneY
-	I-geneY
HT2A	I-geneY
receptors	E-geneY
.	O

These	O
values	O
,	O
moreover	O
,	O
agree	O
with	O
the	O
dissociation	O
constant	O
directly	O
obtained	O
with	O
the	O
radioactive	O
antipsychotic	O
itself	O
.	O

For	O
example	O
,	O
clozapine	S-chem
revealed	O
a	O
radioligand	O
-	O
independent	O
value	O
of	O
1.6	O
nM	O
at	O
the	O
dopamine	B-geneY
D4	I-geneY
receptor	E-geneY
,	O
agreeing	O
with	O
the	O
value	O
directly	O
measured	O
with	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
clozapine	E-chem
at	O
D4	S-geneY
.	O

However	O
,	O
because	O
clozapine	S-chem
competes	O
with	O
endogenous	O
dopamine	S-chem
,	O
the	O
in	O
vivo	O
concentration	O
of	O
clozapine	S-chem
(	O
to	O
occupy	O
dopamine	B-geneY
D4	I-geneY
receptors	E-geneY
)	O
can	O
be	O
derived	O
to	O
be	O
about	O
13	O
nM	O
,	O
agreeing	O
with	O
the	O
value	O
of	O
12	O
to	O
20	O
nM	O
in	O
the	O
plasma	O
water	O
or	O
spinal	O
fluid	O
observed	O
in	O
treated	O
patients	O
.	O

The	O
atypical	O
neuroleptics	O
remoxipride	S-chem
,	O
clozapine	S-chem
,	O
perlapine	S-chem
,	O
seroquel	S-chem
,	O
and	O
melperone	S-chem
had	O
low	O
affinity	O
for	O
the	O
dopamine	S-chem
D2	B-geneY
receptor	E-geneY
(	O
radioligand	O
-	O
independent	O
dissociation	O
constants	O
of	O
30	O
to	O
90	O
nM	O
)	O
.	O

Such	O
low	O
affinity	O
makes	O
these	O
latter	O
five	O
drugs	O
readily	O
displaceable	O
by	O
high	O
levels	O
of	O
endogenous	O
dopamine	S-chem
in	O
the	O
caudate	O
or	O
putamen	O
.	O

Most	O
typical	O
neuroleptics	O
have	O
radioligand	O
-	O
independent	O
values	O
of	O
0.3	O
to	O
5	O
nM	O
at	O
dopamine	B-geneY
D2	I-geneY
receptors	E-geneY
,	O
making	O
them	O
more	O
resistant	O
to	O
displacement	O
by	O
endogenous	O
dopamine	S-chem
.	O

Finally	O
,	O
a	O
relation	O
was	O
found	O
between	O
the	O
neuroleptic	O
doses	O
for	O
rat	O
catalepsy	O
and	O
the	O
D2	S-geneY
:	O
D4	S-geneY
ratio	O
of	O
the	O
radioligand	O
-	O
independent	O
K	O
values	O
for	O
these	O
two	O
receptors	O
.	O

Thus	O
,	O
the	O
atypical	O
neuroleptics	O
appear	O
to	O
fall	O
into	O
two	O
groups	O
,	O
those	O
that	O
have	O
a	O
low	O
affinity	O
for	O
dopamine	B-geneY
D2	I-geneY
receptors	E-geneY
and	O
those	O
that	O
are	O
selective	O
for	O
dopamine	B-geneY
D4	I-geneY
receptors	E-geneY
.	O

Antigenotoxic	O
potencies	O
of	O
a	O
lichen	O
species	O
,	O
Evernia	O
prunastri	O
.	O

In	O
this	O
article	O
,	O
the	O
genotoxic	O
and	O
antigenotoxic	O
effects	O
of	O
methanol	S-chem
extract	O
of	O
Evernia	O
prunastri	O
(	O
Huds	O
.	O
)	O
Willd	O
.	O

(	O
MEP	O
)	O
were	O
studied	O
using	O
WP2	O
,	O
Ames	O
(	O
TA1535	O
and	O
TA1537	O
)	O
and	O
sister	O
chromatid	O
exchange	O
(	O
SCE	O
)	O
test	O
systems	O
.	O

The	O
results	O
obtained	O
from	O
bacterial	O
test	O
systems	O
demonstrated	O
that	O
MEP	O
has	O
strong	O
antimutagenic	O
potencies	O
on	O
TA1537	O
and	O
WP2	O
strains	O
.	O

The	O
highest	O
inhibition	O
rates	O
for	O
MEP	O
on	O
TA1537	O
and	O
WP2	O
strains	O
were	O
37.70	O
%	O
and	O
69.70	O
%	O
,	O
respectively	O
.	O

According	O
to	O
the	O
SCE	O
test	O
system	O
,	O
MEP	O
reduced	O
the	O
genotoxic	O
effects	O
of	O
aflatoxin	S-chem
.	O

In	O
order	O
to	O
clarify	O
the	O
mechanism	O
underlying	O
the	O
antigenotoxic	O
effects	O
of	O
MEP	O
,	O
the	O
antioxidants	O
were	O
determined	O
.	O

Cotreatments	O
of	O
5	O
,	O
10	O
and	O
20	O
µg	O
/	O
mL	O
concentrations	O
of	O
MEP	O
with	O
aflatoxin	B-chem-C3-1
B	I-chem-C3-1
(	I-chem-C3-1
1	I-chem-C3-1
)	E-chem-C3-1
decreased	O
the	O
frequencies	O
of	O
SCE	O
and	O
the	O
malondialdehyde	S-chem
level	O
and	O
increased	O
amount	O
of	O
superoxide	B-geneN-C3-2
dismutase	E-geneN-C3-2
,	O
glutathione	S-chem
and	O
glutathione	B-geneN-C4-2
peroxidase	E-geneN-C4-2
which	O
were	O
decreased	O
by	O
aflatoxin	S-chem-C4-1
.	O

The	O
data	O
obtained	O
from	O
this	O
work	O
have	O
clearly	O
shown	O
that	O
MEP	O
has	O
significant	O
antigenotoxic	O
effects	O
which	O
are	O
thought	O
to	O
be	O
partly	O
due	O
to	O
the	O
antioxidant	O
activities	O
and	O
antioxidant	O
inducing	O
capability	O
of	O
MEP	O
.	O

This	O
is	O
the	O
first	O
report	O
indicating	O
the	O
antigenotoxic	O
activities	O
of	O
MEP	O
against	O
several	O
mutagen	O
agents	O
such	O
as	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
N	I-chem
'	I-chem
-	I-chem
nitro	I-chem
-	I-chem
N	I-chem
-	I-chem
nitrosoguanidine	E-chem
,	O
acridin	S-chem
and	O
aflatoxin	S-chem
.	O

Oral	O
administration	O
of	O
tetrahydrobiopterin	S-chem
prevents	O
endothelial	O
dysfunction	O
and	O
vascular	O
oxidative	O
stress	O
in	O
the	O
aortas	O
of	O
insulin	S-geneN
-	O
resistant	O
rats	O
.	O

We	O
have	O
reported	O
that	O
a	O
deficiency	O
of	O
tetrahydrobiopterin	S-chem
(	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
)	O
,	O
an	O
active	O
cofactor	O
of	O
endothelial	B-geneY
NO	I-geneY
synthase	E-geneY
(	O
eNOS	S-geneY
)	O
,	O
contributes	O
to	O
the	O
endothelial	O
dysfunction	O
through	O
reduced	O
eNOS	S-geneY
activity	O
and	O
increased	O
superoxide	B-chem
anion	E-chem
(	O
O	B-chem
(	I-chem
2	I-chem
)	I-chem
(	I-chem
-	I-chem
)	E-chem
)	O
generation	O
in	O
the	O
insulin	S-geneN
-	O
resistant	O
state	O
.	O

To	O
further	O
confirm	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
dietary	O
treatment	O
with	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
on	O
endothelium	O
-	O
dependent	O
arterial	O
relaxation	O
and	O
vascular	O
oxidative	O
stress	O
in	O
the	O
aortas	O
of	O
insulin	S-geneN
-	O
resistant	O
rats	O
.	O

Oral	O
supplementation	O
of	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
(	O
10	O
mg.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
)	O
for	O
8	O
weeks	O
significantly	O
increased	O
the	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
content	O
in	O
cardiovascular	O
tissues	O
of	O
rats	O
fed	O
high	O
levels	O
of	O
fructose	S-chem
(	O
fructose	S-chem
-	O
fed	O
rats	O
)	O
.	O

Impairment	O
of	O
endothelium	O
-	O
dependent	O
arterial	O
relaxation	O
in	O
the	O
aortic	O
strips	O
of	O
the	O
fructose	S-chem
-	O
fed	O
rats	O
was	O
reversed	O
with	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
treatment	O
.	O

The	O
BH	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
treatment	O
was	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
eNOS	S-geneY-C3-2
activity	O
as	O
well	O
as	O
a	O
70	O
%	O
reduction	O
in	O
endothelial	O
O	B-chem
(	I-chem
2	I-chem
)	I-chem
(	I-chem
-	I-chem
)	E-chem
production	O
compared	O
with	O
those	O
in	O
fructose	S-chem
-	O
fed	O
rats	O
.	O

The	O
BH	B-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
)	E-chem-C3-1
treatment	O
also	O
partially	O
improved	O
the	O
insulin	S-geneN-C3-2
sensitivity	O
and	O
blood	O
pressure	O
,	O
as	O
well	O
as	O
the	O
serum	O
triglyceride	S-chem
concentration	O
,	O
in	O
the	O
fructose	S-chem
-	O
fed	O
rats	O
.	O

Moreover	O
,	O
BH	B-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
)	E-chem-C4-1
treatment	O
of	O
the	O
fructose	S-chem-C3-1
-	O
fed	O
rats	O
markedly	O
reduced	O
the	O
lipid	O
peroxide	S-chem
content	O
of	O
both	O
aortic	O
and	O
cardiac	O
tissues	O
and	O
inhibited	O
the	O
activation	O
of	O
2	O
redox	O
-	O
sensitive	O
transcription	O
factors	O
,	O
nuclear	B-geneN-MU-2
factor	I-geneN-MU-2
-	I-geneN-MU-2
kappaB	E-geneN-MU-2
and	O
activating	B-geneY-MU-2
protein	I-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
,	O
which	O
were	O
increased	O
in	O
fructose	S-chem-C3-1
-	O
fed	O
rats	O
.	O

The	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
treatment	O
of	O
control	O
rats	O
did	O
not	O
have	O
any	O
significant	O
effects	O
on	O
these	O
parameters	O
.	O

These	O
results	O
indicate	O
that	O
BH	B-chem
(	I-chem
4	I-chem
)	E-chem
augmentation	O
is	O
essential	O
for	O
the	O
restoration	O
of	O
eNOS	S-geneY
function	O
and	O
the	O
reduction	O
of	O
vascular	O
oxidative	O
stress	O
in	O
insulin	S-geneN
-	O
resistant	O
rats	O
.	O

In	O
situ	O
forming	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
for	O
facile	O
loading	O
and	O
triggered	O
intracellular	O
release	O
of	O
proteins	O
.	O

In	O
situ	O
forming	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
were	O
designed	O
and	O
developed	O
based	O
on	O
poly	B-chem
(	I-chem
ethylene	I-chem
glycol	I-chem
)	I-chem
-	I-chem
b	I-chem
-	I-chem
poly	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
hydroxyethyl	I-chem
)	I-chem
methacrylate	I-chem
-	I-chem
co	I-chem
-	I-chem
acryloyl	I-chem
carbonate	I-chem
)	E-chem
(	O
PEG	B-chem
-	I-chem
P	I-chem
(	I-chem
HEMA	I-chem
-	I-chem
co	I-chem
-	I-chem
AC	I-chem
)	E-chem
)	O
block	O
copolymers	O
for	O
efficient	O
loading	O
as	O
well	O
as	O
triggered	O
intracellular	O
release	O
of	O
proteins	O
.	O

PEG	B-chem
-	I-chem
P	I-chem
(	I-chem
HEMA	I-chem
-	I-chem
co	I-chem
-	I-chem
AC	I-chem
)	E-chem
copolymers	O
were	O
prepared	O
with	O
controlled	O
Mn	O
of	O
9.1	O
,	O
9.5	O
,	O
and	O
9.9	O
kg	O
/	O
mol	O
and	O
varying	O
numbers	O
of	O
AC	O
units	O
per	O
molecule	O
of	O
7	O
,	O
9	O
and	O
11	O
,	O
respectively	O
(	O
denoted	O
as	O
copolymer	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
by	O
reversible	O
addition	O
-	O
fragmentation	O
chain	O
transfer	O
copolymerization	O
.	O

These	O
copolymers	O
were	O
freely	O
soluble	O
in	O
phosphate	S-chem
buffer	O
but	O
formed	O
disulfide	S-chem
-	O
cross	O
-	O
linked	O
nanogels	O
with	O
defined	O
sizes	O
ranging	O
from	O
72.5	O
to	O
124.1	O
nm	O
in	O
the	O
presence	O
of	O
cystamine	S-chem
via	O
ring	O
-	O
opening	O
reaction	O
with	O
cyclic	B-chem
carbonate	E-chem
groups	O
.	O

The	O
sizes	O
of	O
nanogels	O
decreased	O
with	O
increasing	O
AC	O
units	O
as	O
a	O
result	O
of	O
increased	O
cross	O
-	O
linking	O
density	O
.	O

Dynamic	O
light	O
scattering	O
studies	O
showed	O
that	O
these	O
nanogels	O
though	O
stable	O
at	O
physiological	O
conditions	O
were	O
rapidly	O
dissociated	O
in	O
response	O
to	O
10	O
mM	O
dithiothreitol	S-chem
(	O
DTT	S-chem
)	O
.	O

Interestingly	O
,	O
FITC	S-chem
-	O
labeled	O
cytochrome	B-geneY
C	E-geneY
(	O
FITC	S-chem
-	O
CC	S-geneY
)	O
could	O
be	O
readily	O
loaded	O
into	O
nanogels	O
with	O
remarkable	O
loading	O
efficiencies	O
(	O
up	O
to	O
98.2	O
%	O
)	O
and	O
loading	O
contents	O
(	O
up	O
to	O
48.2	O
wt	O
.	O
%	O
)	O
.	O

The	O
in	O
vitro	O
release	O
studies	O
showed	O
that	O
release	O
of	O
FITC	S-chem
-	O
CC	S-geneY
was	O
minimal	O
under	O
physiological	O
conditions	O
but	O
significantly	O
enhanced	O
under	O
reductive	O
conditions	O
in	O
the	O
presence	O
of	O
10	O
mM	O
DTT	S-chem
with	O
about	O
96.8	O
%	O
of	O
FITC	S-chem
-	O
CC	S-geneY
released	O
in	O
22	O
h	O
from	O
nanogel	O
1	O
.	O

In	O
contrast	O
,	O
protein	O
release	O
from	O
1,4	B-chem
-	I-chem
butanediamine	E-chem
cross	O
-	O
linked	O
nanogels	O
(	O
reduction	O
-	O
insensitive	O
control	O
)	O
remained	O
low	O
under	O
otherwise	O
the	O
same	O
conditions	O
.	O

MTT	S-chem
assays	O
showed	O
that	O
these	O
nanogels	O
were	O
nontoxic	O
to	O
HeLa	O
cells	O
up	O
to	O
a	O
tested	O
concentration	O
of	O
2	O
mg	O
/	O
mL	O
.	O

Confocal	O
microscopy	O
results	O
showed	O
that	O
nanogel	O
1	O
delivered	O
and	O
released	O
FITC	S-chem
-	O
CC	S-geneY
into	O
the	O
perinuclei	O
region	O
of	O
HeLa	O
cells	O
following	O
8	O
h	O
incubation	O
.	O

CC	S-geneY
-	O
loaded	O
reductively	O
degradable	O
nanogels	O
demonstrated	O
apparently	O
better	O
apoptotic	O
activity	O
than	O
free	O
CC	S-geneY
as	O
well	O
as	O
reduction	O
-	O
insensitive	O
controls	O
.	O

These	O
in	O
situ	O
forming	O
,	O
surfactant	O
and	O
oil	O
-	O
free	O
,	O
and	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
are	O
highly	O
promising	O
for	O
targeted	O
protein	O
therapy	O
.	O

Cyclopentenone	B-chem-C4-1
prostaglandins	E-chem-C4-1
suppress	O
activation	O
of	O
microglia	O
:	O
down	O
-	O
regulation	O
of	O
inducible	B-geneY-C4-2
nitric	I-geneY-C4-2
-	I-geneY-C4-2
oxide	I-geneY-C4-2
synthase	E-geneY-C4-2
by	O
15	B-chem-C4-1
-	I-chem-C4-1
deoxy	I-chem-C4-1
-	I-chem-C4-1
Delta12,14	I-chem-C4-1
-	I-chem-C4-1
prostaglandin	I-chem-C4-1
J2	E-chem-C4-1
.	O

Mechanisms	O
leading	O
to	O
down	O
-	O
regulation	O
of	O
activated	O
microglia	O
and	O
astrocytes	O
are	O
poorly	O
understood	O
,	O
in	O
spite	O
of	O
the	O
potentially	O
detrimental	O
role	O
of	O
activated	O
glia	O
in	O
neurodegeneration	O
.	O

Prostaglandins	S-chem
,	O
produced	O
both	O
by	O
neurons	O
and	O
glia	O
,	O
may	O
serve	O
as	O
mediators	O
of	O
glial	O
and	O
neuronal	O
functions	O
.	O

We	O
examined	O
the	O
influence	O
of	O
cyclopentenone	B-chem
prostaglandins	E-chem
and	O
their	O
precursors	O
on	O
activated	O
glia	O
.	O

As	O
models	O
of	O
glial	O
activation	O
,	O
production	O
of	O
inducible	B-geneY
nitric	I-geneY
-	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
was	O
studied	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
rat	O
microglia	O
,	O
a	O
murine	O
microglial	O
cell	O
line	O
BV	O
-	O
2	O
,	O
and	O
IL	B-geneY
-	I-geneY
1beta	E-geneY
-	O
stimulated	O
rat	O
astrocytes	O
.	O

Cyclopentenone	B-chem-C4-1
prostaglandins	E-chem-C4-1
were	O
potent	O
inhibitors	O
of	O
iNOS	S-geneY-C4-2
induction	O
and	O
were	O
more	O
effective	O
than	O
their	O
precursors	O
,	O
prostaglandins	B-chem-C4-1
E2	I-chem-C4-1
and	I-chem-C4-1
D2	E-chem-C4-1
.	O

15	B-chem
-	I-chem
Deoxy	I-chem
-	I-chem
Delta12,14	I-chem
-	I-chem
prostaglandin	I-chem
J2	E-chem
(	O
15d	B-chem
-	I-chem
PGJ2	E-chem
)	O
was	O
the	O
most	O
potent	O
prostaglandin	S-chem
among	O
those	O
tested	O
.	O

In	O
activated	O
microglia	O
,	O
15d	B-chem-C4-1
-	I-chem-C4-1
PGJ2	E-chem-C4-1
suppressed	O
iNOS	B-geneN-C4-2
promoter	E-geneN-C4-2
activity	O
,	O
iNOS	S-geneY-C4-2
mRNA	O
,	O
and	O
protein	O
levels	O
.	O

The	O
action	O
of	O
15d	B-chem
-	I-chem
PGJ2	E-chem
does	O
not	O
appear	O
to	O
involve	O
its	O
nuclear	O
receptor	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
PPARgamma	S-geneY
)	O
because	O
troglitazone	S-chem
,	O
a	O
specific	O
ligand	O
of	O
PPARgamma	S-geneY
,	O
was	O
unable	O
to	O
inhibit	O
iNOS	S-geneY
induction	O
,	O
and	O
neither	O
troglitazone	S-chem
nor	O
15d	B-chem
-	I-chem
PGJ2	E-chem
could	O
stimulate	O
the	O
activity	O
of	O
a	O
PPAR	S-geneN
-	O
dependent	O
promoter	O
in	O
the	O
absence	O
of	O
cotransfected	O
PPARgamma	S-geneY
.	O

15d	B-chem-C4-1
-	I-chem-C4-1
PGJ2	E-chem-C4-1
did	O
not	O
block	O
nuclear	O
translocation	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NFkappaB	S-geneN
,	O
but	O
it	O
did	O
inhibit	O
the	O
activity	O
of	O
an	O
NFkappaB	S-geneN-C4-2
reporter	O
construct	O
,	O
suggesting	O
that	O
the	O
mechanism	O
of	O
suppression	O
of	O
microglial	O
iNOS	S-geneY-C4-2
by	O
15d	B-chem-C4-1
-	I-chem-C4-1
PGJ2	E-chem-C4-1
may	O
involve	O
interference	O
with	O
NFkappaB	S-geneN
transcriptional	O
activity	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
pathway	O
mediated	O
by	O
cyclopentenone	B-chem
prostaglandins	E-chem
,	O
which	O
may	O
represent	O
part	O
of	O
a	O
feedback	O
mechanism	O
leading	O
to	O
the	O
cessation	O
of	O
inflammatory	O
glial	O
responses	O
in	O
the	O
brain	O
.	O

Nonadrenergic	O
imidazoline	S-chem
binding	O
sites	O
on	O
human	O
platelets	O
.	O

Human	O
platelets	O
are	O
shown	O
to	O
possess	O
at	O
least	O
two	O
high	O
-	O
affinity	O
,	O
imidazol	B-chem
(	I-chem
in	I-chem
)	I-chem
e	E-chem
-	O
preferring	O
binding	O
sites	O
that	O
are	O
pharmacologically	O
distinct	O
from	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptors	E-geneN
.	O

These	O
nonadrenergic	O
sites	O
were	O
radiolabeled	O
even	O
in	O
the	O
presence	O
of	O
a	O
10	O
microM	O
norepinephrine	S-chem
mask	O
of	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptors	E-geneN
.	O

Heterogeneity	O
at	O
the	O
nonadrenergic	O
sites	O
was	O
demonstrated	O
by	O
comparing	O
[	B-chem
3H	I-chem
]	I-chem
idazoxan	E-chem
(	O
IDX	S-chem
)	O
binding	O
vs	O
.	O

[	B-chem
125I	I-chem
]	I-chem
p	I-chem
-	I-chem
iodoclonidine	E-chem
(	O
PIC	S-chem
)	O
binding	O
.	O

Nonadrenergic	O
[	B-chem
125I	I-chem
]	I-chem
PIC	E-chem
-	O
labeled	O
sites	O
were	O
enriched	O
in	O
platelet	O
plasma	O
membranes	O
,	O
whereas	O
the	O
nonadrenergic	O
sites	O
labeled	O
by	O
[	B-chem
3H	I-chem
]	I-chem
IDX	E-chem
were	O
codistributed	O
between	O
plasma	O
and	O
internal	O
membranes	O
(	O
nonadrenergic	O
[	B-chem
125I	I-chem
]	I-chem
PIC	E-chem
-	O
labeled	O
sites	O
had	O
Bmax	O
=	O
62	O
fmol	O
/	O
mg	O
in	O
plasma	O
membranes	O
and	O
20	O
fmol	O
/	O
mg	O
in	O
internal	O
membranes	O
vs.	O
the	O
[	B-chem
3H	I-chem
]	I-chem
IDX	E-chem
-	O
labeled	O
sites	O
had	O
Bmax	O
=	O
141	O
fmol	O
/	O
mg	O
in	O
plasma	O
membranes	O
and	O
192	O
fmol	O
/	O
mg	O
in	O
internal	O
membranes	O
)	O
.	O

Furthermore	O
,	O
competition	O
binding	O
studies	O
in	O
the	O
presence	O
of	O
a	O
10	O
microM	O
norepinephrine	S-chem
mask	O
revealed	O
major	O
(	O
approximately	O
75	O
%	O
)	O
and	O
minor	O
(	O
approximately	O
25	O
%	O
)	O
binding	O
components	O
on	O
plasma	O
membranes	O
for	O
[	B-chem
125I	I-chem
]	I-chem
PIC	E-chem
.	O

Affinities	O
for	O
the	O
major	O
nonadrenergic	O
[	B-chem
125I	I-chem
]	I-chem
PIC	E-chem
binding	O
site	O
were	O
highly	O
comparable	O
to	O
human	B-geneY
subtype	I-geneY
-	I-geneY
I1	I-geneY
imidazol	I-geneY
(	I-geneY
in	I-geneY
)	I-geneY
e	I-geneY
receptor	E-geneY
sites	O
in	O
the	O
brain	O
stem	O
(	O
rank	O
order	O
:	O
moxonidine	S-chem
>	O
clonidine	S-chem
>	O
cirazoline	S-chem
>	O
IDX	S-chem
>	O
amiloride	S-chem
)	O
.	O

However	O
,	O
the	O
minor	O
component	O
of	O
[	B-chem
125I	I-chem
]	I-chem
PIC	E-chem
binding	O
was	O
similar	O
to	O
a	O
site	O
reported	O
in	O
kidney	O
,	O
having	O
low	O
affinities	O
for	O
all	O
compounds	O
tested	O
,	O
except	O
guanabenz	S-chem
.	O

Finally	O
,	O
a	O
third	O
nonadrenergic	O
internal	O
membrane	O
site	O
,	O
labeled	O
by	O
[	B-chem
3H	I-chem
]	I-chem
IDX	E-chem
,	O
was	O
consistent	O
with	O
a	O
subtype	B-geneN
-	I-geneN
I2	I-geneN
imidazol	I-geneN
(	I-geneN
in	I-geneN
)	I-geneN
e	I-geneN
receptor	E-geneN
site	O
(	O
rank	O
order	O
:	O
cirazoline	S-chem
>	O
IDX	O
>	O
>	O
amiloride	S-chem
>	O
moxonidine	S-chem
>	O
clonidine	S-chem
)	O
.	O

Thus	O
,	O
based	O
on	O
differential	O
subcellular	O
distributions	O
and	O
affinity	O
constants	O
,	O
human	O
platelets	O
appear	O
to	O
possess	O
imidazoline	B-geneN
receptors	E-geneN
(	O
subtype	B-geneY
-	I-geneY
I1	I-geneY
imidazol	I-geneY
(	I-geneY
in	I-geneY
)	I-geneY
e	I-geneY
receptor	E-geneY
and	O
subtype	B-geneN
-	I-geneN
I2	I-geneN
imidazol	I-geneN
(	I-geneN
in	I-geneN
)	I-geneN
e	I-geneN
receptor	E-geneN
)	O
,	O
plus	O
a	O
novel	O
guanabenz	S-chem
-	O
sensitive	O
site	O
,	O
as	O
well	O
as	O
an	O
alpha	B-geneY
-	I-geneY
2A	I-geneY
adrenoceptor	E-geneY
.	O

These	O
nonadrenoceptor	O
binding	O
sites	O
may	O
explain	O
certain	O
novel	O
platelet	O
aggregatory	O
properties	O
previously	O
ascribed	O
to	O
clonidine	S-chem-C3-1
and	O
endogenous	O
clonidine	S-chem
-	O
displacing	O
substance	O
(	O
s	O
)	O
,	O
and	O
may	O
serve	O
as	O
markers	O
of	O
imidazoline	B-geneN-C3-2
receptors	E-geneN-C3-2
in	O
humans	O
.	O

Synthesis	O
,	O
characterization	O
and	O
targeting	O
potential	O
of	O
zidovudine	S-chem
loaded	O
sialic	B-chem
acid	E-chem
conjugated	O
-	O
mannosylated	B-chem
poly	I-chem
(	I-chem
propyleneimine	I-chem
)	E-chem
dendrimers	O
.	O

The	O
present	O
investigation	O
was	O
aimed	O
at	O
exploring	O
dual	O
targeting	O
of	O
anti	O
-	O
HIV	O
drug	O
,	O
zidovudine	S-chem
(	O
ZDV	S-chem
)	O
via	O
sialic	B-chem
acid	E-chem
conjugated	O
-	O
mannosylated	B-chem
poly	I-chem
(	I-chem
propyleneimine	I-chem
)	E-chem
(	O
PPI	S-chem
)	O
dendritic	O
nano	O
-	O
constructs	O
.	O

Fourth	O
generation	O
PPI	S-chem
dendrimers	O
,	O
sialic	B-chem
acid	E-chem
conjugated	O
PPI	S-chem
dendrimers	O
(	O
SPPI	O
)	O
,	O
mannose	S-chem
conjugated	O
PPI	S-chem
dendrimers	O
(	O
MPPI	O
)	O
and	O
dual	O
ligand	O
system	O
i.e	O
.	O
sialic	B-chem
acid	E-chem
conjugated	O
-	O
mannosylated	B-chem
PPI	E-chem
dendrimers	O
(	O
SMPPI	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
FT	O
-	O
IR	O
and	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
NMR	O
spectroscopies	O
and	O
were	O
further	O
confirmed	O
by	O
size	O
exclusion	O
chromatography	O
and	O
differential	O
scanning	O
calorimetry	O
.	O

Various	O
parameters	O
like	O
drug	O
loading	O
,	O
pH	O
dependent	O
in	O
vitro	O
release	O
,	O
hemolytic	O
toxicity	O
,	O
macrophage	O
uptake	O
and	O
cytotoxicity	O
concerning	O
PPI	S-chem
,	O
SPPI	O
,	O
MPPI	O
and	O
SMPPI	O
dendrimers	O
were	O
evaluated	O
.	O

ZDV	S-chem
loaded	O
SMPPI	O
,	O
SPPI	O
and	O
MPPI	O
have	O
shown	O
reduced	O
hemolytic	O
toxicity	O
,	O
cytotoxicity	O
and	O
in	O
vitro	O
drug	O
release	O
at	O
pH	O
7.4	O
.	O

Extremely	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
increase	O
in	O
cellular	O
uptake	O
of	O
ZDV	S-chem
by	O
macrophage	O
cells	O
was	O
observed	O
in	O
case	O
of	O
SMPPI	O
as	O
compared	O
to	O
PPI	S-chem
and	O
free	O
drug	O
.	O

The	O
in	O
vivo	O
blood	O
level	O
and	O
tissue	O
distribution	O
studies	O
in	O
albino	O
rats	O
also	O
demonstrated	O
potential	O
of	O
dual	O
targeted	O
system	O
towards	O
sialoadhesin	S-geneY
and	O
carbohydrate	B-geneN
receptors	E-geneN
.	O

The	O
drug	O
concentration	O
in	O
lymph	O
nodes	O
was	O
increased	O
to	O
about	O
28	O
times	O
in	O
case	O
of	O
SMPPI	O
(	O
1335	O
±	O
17.6	O
ng	O
/	O
g	O
)	O
as	O
compared	O
to	O
free	O
drug	O
(	O
48	O
±	O
5.8	O
ng	O
/	O
g	O
)	O
at	O
6th	O
hr	O
.	O

The	O
results	O
suggested	O
that	O
such	O
dual	O
ligand	O
dendritic	O
system	O
(	O
SMPPI	O
)	O
hold	O
potential	O
to	O
enhance	O
biocompatibility	O
and	O
site	O
specific	O
delivery	O
of	O
antiretroviral	O
drug	O
,	O
ZDV	S-chem
.	O

The	O
preparation	O
and	O
human	B-geneN
muscarinic	I-geneN
receptor	E-geneN
profiling	O
of	O
oxybutynin	S-chem
and	O
N	B-chem
-	I-chem
desethyloxybutynin	E-chem
enantiomers	O
.	O

Oxybutynin	S-chem-C6-1
(	O
1	O
)	O
is	O
a	O
non	O
-	O
selective	O
muscarinic	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
that	O
is	O
used	O
clinically	O
for	O
the	O
treatment	O
of	O
urinary	O
incontinence	O
.	O

The	O
major	O
metabolite	O
of	O
oxybutynin	S-chem
in	O
humans	O
is	O
desethyloxybutynin	S-chem
(	O
2	O
)	O
.	O

We	O
have	O
prepared	O
the	O
enantiomers	O
of	O
1	O
and	O
2	O
and	O
evaluated	O
their	O
ability	O
to	O
displace	O
N	B-chem
-	I-chem
CT	I-chem
(	I-chem
3	I-chem
)	I-chem
-	I-chem
scopolamine	I-chem
chloride	E-chem
(	O
(	B-chem
3	I-chem
)	I-chem
H	I-chem
-	I-chem
NMS	E-chem
)	O
binding	O
on	O
human	B-geneN
cloned	I-geneN
muscarinic	I-geneN
m1	I-geneN
-	I-geneN
5	I-geneN
receptors	E-geneN
.	O

Compounds	O
1	O
and	O
2	O
potently	O
displaced	O
(	B-chem
3	I-chem
)	I-chem
H	I-chem
-	I-chem
NMS	E-chem
binding	O
at	O
m1	B-geneN
,	I-geneN
m3	I-geneN
and	I-geneN
m4	I-geneN
receptors	E-geneN
,	O
but	O
were	O
less	O
potent	O
at	O
the	O
m2	S-geneY
and	O
m5	S-geneY
subtypes	O
.	O

However	O
,	O
metabolite	O
2	O
was	O
more	O
potent	O
than	O
the	O
parent	O
compound	O
1	O
in	O
the	O
binding	O
assay	O
.	O

In	O
general	O
the	O
R	O
enantiomers	O
were	O
more	O
potent	O
than	O
their	O
respective	O
S	O
enantiomers	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
the	O
cholinergic	O
side	O
effects	O
associated	O
with	O
2	O
may	O
be	O
due	O
to	O
its	O
greater	O
apparent	O
potency	O
with	O
m1	B-geneN
and	I-geneN
m3	I-geneN
receptors	E-geneN
,	O
especially	O
of	O
its	O
R	O
-	O
enantiomer	O
,	O
when	O
compared	O
with	O
parent	O
drug	O
1	O
.	O

Effect	O
of	O
bosentan	S-chem-C6-1
(	O
ETA	S-geneY-C6-2
/	O
ETB	S-geneY-C6-2
receptor	O
antagonist	O
)	O
on	O
metabolic	O
changes	O
during	O
stress	O
and	O
diabetes	O
.	O

Elevated	O
plasma	O
ET	B-geneY
-	I-geneY
1	E-geneY
levels	O
have	O
been	O
reported	O
in	O
several	O
conditions	O
such	O
as	O
stress	O
and	O
diabetes	O
.	O

ET	B-geneY
-	I-geneY
1	E-geneY
is	O
found	O
to	O
cause	O
insulin	S-geneY
resistance	O
and	O
to	O
stimulate	O
liver	O
glycogenolysis	O
.	O

The	O
question	O
arises	O
whether	O
ET	B-geneY
-	I-geneY
1	E-geneY
has	O
a	O
role	O
in	O
the	O
metabolic	O
changes	O
occurring	O
in	O
such	O
conditions	O
.	O

To	O
test	O
this	O
,	O
we	O
studied	O
the	O
possible	O
effect	O
of	O
the	O
endothelin	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
bosentan	S-chem-C6-1
(	O
50	O
and	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
on	O
serum	O
glucose	S-chem
and	O
insulin	S-geneN
levels	O
as	O
well	O
as	O
on	O
liver	O
glycogen	O
contents	O
in	O
normoglycemic	O
stressed	O
animals	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
bosentan	S-chem
on	O
serum	O
glucose	S-chem
and	O
insulin	S-geneN
levels	O
in	O
both	O
mild	O
and	O
severely	O
diabetic	O
rats	O
and	O
its	O
effect	O
on	O
insulin	S-geneN
-	O
induced	O
hypoglycemia	O
were	O
also	O
determined	O
.	O

Restraining	O
water	O
immersion	O
stress	O
was	O
used	O
as	O
a	O
model	O
for	O
severe	O
stress	O
reported	O
to	O
elevate	O
plasma	O
ET	B-geneY
-	I-geneY
1	E-geneY
level	O
.	O

Mild	O
diabetes	O
was	O
induced	O
in	O
rats	O
by	O
intraperitoneal	O
injection	O
of	O
a	O
low	O
dose	O
of	O
streptozotocin	S-chem
(	O
38	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
while	O
severe	O
diabetes	O
was	O
induced	O
by	O
intraperitoneal	O
injection	O
of	O
a	O
higher	O
dose	O
of	O
streptozotocin	S-chem
(	O
45	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

Bosentan	S-chem
partially	O
prevented	O
stress	O
-	O
induced	O
both	O
hyperglycemia	O
and	O
decrease	O
in	O
glycogen	O
content	O
while	O
it	O
completely	O
blocked	O
the	O
stress	O
-	O
induced	O
decrease	O
in	O
insulin	S-geneN
level	O
in	O
normoglycemic	O
stressed	O
rats	O
.	O

Bosentan	S-chem
also	O
decreased	O
serum	O
glucose	S-chem
level	O
without	O
any	O
effect	O
on	O
insulin	S-geneN
secretion	O
in	O
mild	O
diabetic	O
rats	O
and	O
potentiated	O
the	O
hypoglycemic	O
action	O
of	O
insulin	S-geneN
.	O

DICO	S-chem
,	O
a	O
novel	O
nonaromatic	O
B	O
-	O
ring	O
flavonoid	S-chem
,	O
induces	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
human	O
hepatoma	O
cells	O
.	O

DICO	S-chem
was	O
a	O
novel	O
nonaromatic	O
B	O
-	O
ring	O
flavonoid	S-chem
obtained	O
from	O
Macrothelypteris	O
torresiana	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
antitumor	O
activity	O
and	O
the	O
antineoplastic	O
mechanism	O
of	O
DICO	S-chem
.	O

Our	O
study	O
showed	O
that	O
DICO	S-chem
inhibited	O
the	O
growth	O
of	O
HepG2	O
cells	O
in	O
dose	O
and	O
time	O
-	O
dependent	O
manners	O
.	O

As	O
well	O
as	O
DICO	S-chem
induced	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
via	O
a	O
ROS	O
-	O
mediated	O
mitochondrial	O
pathway	O
.	O

Western	O
blot	O
assay	O
demonstrated	O
that	O
DICO	S-chem-MU-1
decreased	O
Bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
level	O
and	O
induced	O
Bax	S-geneY-C3-2
translocation	O
to	O
cause	O
cytochrome	B-geneY-C3-2
c	E-geneY-C3-2
release	O
.	O

Subsequently	O
,	O
caspase	B-geneY
-	I-geneY
9	E-geneY
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
were	O
activated	O
.	O

Meanwhile	O
,	O
the	O
alterations	O
of	O
cyclin	B-geneN
A	I-geneN
and	I-geneN
B1	E-geneN
,	O
p	B-geneY
-	I-geneY
CDK1	E-geneY
and	O
p	B-geneY
-	I-geneY
cdc25c	E-geneY
levels	O
were	O
also	O
observed	O
in	O
response	O
to	O
DICO	S-chem
treatment	O
.	O

Taken	O
together	O
,	O
DICO	S-chem
displayed	O
a	O
significant	O
antitumor	O
effect	O
through	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
induction	O
,	O
which	O
suggested	O
DICO	S-chem
might	O
have	O
therapeutic	O
potential	O
against	O
tumors	O
.	O

Pseudoephedrine	S-chem-C4-1
inhibits	O
T	O
-	O
cell	O
activation	O
by	O
targeting	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
,	O
NFAT	S-geneN-C4-2
and	O
AP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
signaling	O
pathways	O
.	O

Pseudoephedrine	S-chem
(	O
PSE	S-chem
)	O
is	O
a	O
stereoisomer	O
of	O
ephedrine	S-chem
that	O
is	O
commonly	O
used	O
as	O
a	O
nasal	O
decongestant	O
in	O
combination	O
with	O
other	O
anti	O
-	O
inflammatory	O
drugs	O
for	O
the	O
symptomatic	O
treatment	O
of	O
some	O
common	O
pathologies	O
such	O
as	O
common	O
cold	O
.	O

Herein	O
,	O
we	O
describe	O
for	O
the	O
first	O
time	O
the	O
effects	O
of	O
PSE	S-chem
on	O
T	O
-	O
cell	O
activation	O
events	O
.	O

We	O
found	O
that	O
PSE	S-chem-MU-1
inhibits	O
interleukin	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
and	O
tumor	B-geneY-C3-2
necrosis	I-geneY-C3-2
factor	I-geneY-C3-2
(	I-geneY-C3-2
TNF	I-geneY-C3-2
)	I-geneY-C3-2
alpha	E-geneY-C3-2
-	O
gene	O
transcription	O
in	O
stimulated	O
Jurkat	O
cells	O
,	O
a	O
human	O
T	O
-	O
cell	O
leukemia	O
cell	O
line	O
.	O

To	O
further	O
characterize	O
the	O
inhibitory	O
mechanisms	O
of	O
PSE	S-chem
at	O
the	O
transcriptional	O
level	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
nuclear	B-geneN
factor	I-geneN
kappa	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
)	O
,	O
nuclear	B-geneN
factor	I-geneN
of	I-geneN
activated	I-geneN
T	I-geneN
cells	E-geneN
(	O
NFAT	S-geneN
)	O
,	O
and	O
activator	B-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
AP	B-geneY
-	I-geneY
1	E-geneY
)	O
transcription	O
factors	O
and	O
found	O
that	O
PSE	S-chem-C4-1
inhibited	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
-	O
dependent	O
transcriptional	O
activity	O
without	O
affecting	O
either	O
the	O
phosphorylation	O
,	O
the	O
degradation	O
of	O
the	O
cytoplasmic	O
NF	B-geneY
-	I-geneY
kappaB	I-geneY
inhibitory	I-geneY
protein	E-geneY
,	O
IkappaBalpha	S-geneY
or	O
the	O
DNA	O
-	O
binding	O
activity	O
.	O

However	O
,	O
phosphorylation	O
of	O
the	O
p65	S-geneY-C4-2
/	O
RelA	S-geneY-C4-2
subunit	O
was	O
clearly	O
inhibited	O
by	O
PSE	S-chem-C4-1
in	O
stimulated	O
cells	O
.	O

In	O
addition	O
,	O
PSE	S-chem-C4-1
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NFAT	S-geneN-C4-2
without	O
interfering	O
with	O
the	O
calcium	S-chem-C3-1
-	O
induced	O
NFAT	S-geneN-C3-2
dephosphorylation	O
event	O
,	O
which	O
represents	O
the	O
major	O
signaling	O
pathway	O
for	O
its	O
activation	O
.	O

NFAT	S-geneN
cooperates	O
with	O
c	B-geneY
-	I-geneY
Jun	E-geneY
,	O
a	O
compound	O
of	O
the	O
AP	B-geneY
-	I-geneY
1	E-geneY
complex	O
,	O
to	O
activate	O
target	O
genes	O
,	O
and	O
we	O
also	O
found	O
that	O
PSE	S-chem-C4-1
inhibited	O
both	O
JNK	S-geneN-C4-2
activation	O
and	O
AP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
transcriptional	O
activity	O
.	O

These	O
findings	O
provide	O
new	O
mechanistic	O
insights	O
into	O
the	O
potential	O
immunomodulatory	O
activities	O
of	O
PSE	S-chem
and	O
highlight	O
their	O
potential	O
in	O
designing	O
novel	O
therapeutic	O
strategies	O
to	O
manage	O
inflammatory	O
diseases	O
.	O

Corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
reduces	O
pressure	O
pain	O
sensitivity	O
in	O
humans	O
without	O
involvement	O
of	O
beta	B-geneY
-	I-geneY
endorphin	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
,	O
but	O
does	O
not	O
reduce	O
heat	O
pain	O
sensitivity	O
.	O

In	O
the	O
present	O
study	O
the	O
effects	O
of	O
intravenously	O
administered	O
corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
CRH	S-geneY
)	O
on	O
the	O
release	O
of	O
proopiomelanocortin	S-geneY
(	O
POMC	S-geneY
)	O
derivatives	O
such	O
as	O
adrenocorticotropic	B-geneY
hormone	E-geneY
(	O
ACTH	S-geneY
)	O
,	O
beta	B-geneY
-	I-geneY
lipotropin	E-geneY
(	O
beta	B-geneY
-	I-geneY
LPH	E-geneY
)	O
and	O
beta	B-geneY
-	I-geneY
endorphin	E-geneY
(	O
beta	B-geneY
-	I-geneY
END	E-geneY
)	O
as	O
well	O
as	O
direct	O
effects	O
of	O
CRH	S-geneY
on	O
pain	O
sensitivity	O
were	O
examined	O
.	O

In	O
16	O
healthy	O
volunteers	O
we	O
studied	O
the	O
effects	O
of	O
100	O
microg	O
intravenously	O
administered	O
CRH	S-geneY
in	O
absence	O
or	O
presence	O
of	O
12	O
mg	O
naloxone	S-chem
on	O
heat	O
or	O
pressure	O
pain	O
sensitivity	O
,	O
using	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
and	O
placebo	O
-	O
controlled	O
design	O
.	O

To	O
evaluate	O
analgesic	O
effects	O
of	O
CRH	S-geneY
via	O
release	O
of	O
POMC	S-geneY
derivatives	O
,	O
we	O
determined	O
plasma	O
concentrations	O
of	O
beta	B-geneY
-	I-geneY
END	E-geneY
-	O
immunoreactive	O
material	O
(	O
IRM	O
)	O
,	O
authentic	O
beta	B-geneY
-	I-geneY
END	E-geneY
(	O
beta	B-geneY
-	I-geneY
END	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
)	O
and	O
beta	B-geneY
-	I-geneY
LPH	E-geneY
IRM	O
,	O
in	O
parallel	O
with	O
heat	O
and	O
pressure	O
pain	O
tolerance	O
thresholds	O
before	O
and	O
15	O
and	O
30	O
min	O
after	O
treatment	O
with	O
CRH	S-geneY
(	O
or	O
placebo	O
)	O
,	O
and	O
5	O
min	O
after	O
naloxone	S-chem
(	O
or	O
placebo	O
)	O
administration	O
which	O
was	O
administered	O
40	O
min	O
after	O
CRH	S-geneY
(	O
or	O
placebo	O
)	O
injection	O
.	O

CRH	S-geneY
increased	O
levels	O
of	O
beta	B-geneY
-	I-geneY
END	E-geneY
IRM	O
,	O
beta	B-geneY
-	I-geneY
END	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
and	O
beta	B-geneY
-	I-geneY
LPH	E-geneY
IRM	O
.	O

As	O
compared	O
to	O
beta	B-geneY
-	I-geneY
END	E-geneY
IRM	O
levels	O
measured	O
by	O
a	O
commercial	O
RIA	O
kit	O
,	O
the	O
beta	B-geneY
-	I-geneY
END	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
levels	O
determined	O
by	O
a	O
highly	O
specific	O
two	O
-	O
site	O
RIA	O
,	O
proved	O
to	O
be	O
remarkably	O
small	O
.	O

Furthermore	O
,	O
CRH	S-geneY
did	O
not	O
induce	O
increases	O
of	O
heat	O
pain	O
tolerance	O
thresholds	O
,	O
but	O
of	O
pressure	O
pain	O
tolerance	O
thresholds	O
,	O
which	O
,	O
however	O
,	O
were	O
not	O
reversible	O
by	O
naloxone	S-chem
.	O

Neither	O
beta	B-geneY
-	I-geneY
END	E-geneY
nor	O
beta	B-geneY
-	I-geneY
LPH	E-geneY
IRM	O
nor	O
beta	B-geneY
-	I-geneY
END	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
levels	O
correlated	O
with	O
heat	O
or	O
pressure	O
pain	O
tolerance	O
thresholds	O
.	O

We	O
conclude	O
that	O
CRH	S-geneN
does	O
not	O
modulate	O
heat	O
,	O
but	O
pressure	O
pain	O
;	O
POMC	S-geneY
derivatives	O
like	O
beta	B-geneY
-	I-geneY
END	E-geneY
IRM	O
,	O
beta	B-geneY
-	I-geneY
END	I-geneY
(	I-geneY
1	I-geneY
-	I-geneY
31	I-geneY
)	E-geneY
or	O
beta	B-geneY
-	I-geneY
LPH	E-geneY
do	O
not	O
mediate	O
this	O
effect	O
.	O

The	O
effects	O
of	O
adulthood	O
olanzapine	S-chem
treatment	O
on	O
cognitive	O
performance	O
and	O
neurotrophic	B-geneN
factor	E-geneN
content	O
in	O
male	O
and	O
female	O
rats	O
neonatally	O
treated	O
with	O
quinpirole	S-chem
.	O

Male	O
and	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
administered	O
quinpirole	S-chem
(	O
1	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
or	O
saline	O
once	O
daily	O
from	O
postnatal	O
day	O
(	O
P	O
)	O
1	O
to	O
P21	O
.	O

This	O
drug	O
treatment	O
has	O
been	O
shown	O
to	O
produce	O
long	O
-	O
term	O
priming	O
of	O
the	O
D2	B-geneY
receptor	E-geneY
.	O

Beginning	O
on	O
P62	O
,	O
rats	O
were	O
administered	O
the	O
atypical	O
antipsychotic	O
olanzapine	S-chem
(	O
2.5	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
twice	O
daily	O
(	O
i.p	O
.	O
)	O
for	O
28	O
days	O
.	O

One	O
day	O
after	O
olanzapine	S-chem
treatment	O
ceased	O
,	O
rats	O
were	O
tested	O
on	O
the	O
place	O
and	O
match	O
-	O
to	O
-	O
place	O
versions	O
of	O
the	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
for	O
seven	O
consecutive	O
days	O
.	O

Dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
priming	O
was	O
verified	O
through	O
a	O
yawning	O
behavioural	O
test	O
,	O
a	O
D2	B-geneY
receptor	E-geneY
-	O
mediated	O
event	O
,	O
before	O
olanzapine	S-chem
was	O
administered	O
as	O
well	O
as	O
after	O
olanzapine	S-chem
treatment	O
and	O
behavioural	O
testing	O
were	O
complete	O
.	O

Results	O
showed	O
that	O
neonatal	O
quinpirole	S-chem-C3-1
treatment	O
induced	O
D2	S-geneY-MU-2
priming	O
that	O
was	O
eliminated	O
by	O
olanzapine	S-chem-C4-1
treatment	O
.	O

On	O
the	O
MWM	O
place	O
version	O
,	O
D2	S-geneY
-	O
primed	O
rats	O
demonstrated	O
a	O
significant	O
impairment	O
that	O
was	O
eliminated	O
by	O
olanzapine	S-chem
treatment	O
,	O
but	O
olanzapine	S-chem
treatment	O
to	O
animals	O
neonatally	O
treated	O
with	O
saline	O
produced	O
a	O
significant	O
deficit	O
on	O
the	O
place	O
version	O
of	O
the	O
MWM	O
.	O

There	O
were	O
no	O
significant	O
deficits	O
on	O
the	O
match	O
-	O
to	O
-	O
place	O
version	O
.	O

Brain	O
tissue	O
analyses	O
revealed	O
that	O
neonatal	O
quinpirole	S-chem-C4-1
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
hippocampal	O
NGF	S-geneY-MU-2
,	O
BDNF	S-geneY-MU-2
and	O
ChAT	S-geneY-MU-2
that	O
was	O
eliminated	O
by	O
olanzapine	S-chem-C3-1
treatment	O
.	O

Neonatal	O
quinpirole	S-chem-C4-1
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
BDNF	S-geneY-C4-2
and	O
ChAT	S-geneY-C4-2
in	O
the	O
frontal	O
cortex	O
that	O
was	O
unaffected	O
by	O
olanzapine	S-chem
treatment	O
.	O

These	O
results	O
show	O
that	O
olanzapine	S-chem-C4-1
eliminates	O
D2	B-geneY-C4-2
receptor	E-geneY-C4-2
priming	O
and	O
cognitive	O
impairment	O
and	O
also	O
alleviates	O
decreases	O
in	O
neurotrophins	O
and	O
acetylcholinergic	O
markers	O
produced	O
by	O
D2	S-geneY
priming	O
in	O
the	O
hippocampus	O
.	O

In	O
vivo	O
comparison	O
of	O
the	O
reinforcing	O
and	O
dopamine	B-geneY
transporter	E-geneY
effects	O
of	O
local	O
anesthetics	O
in	O
rhesus	O
monkeys	O
.	O

Dopaminergic	O
mechanisms	O
are	O
thought	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
reinforcing	O
effects	O
of	O
cocaine	S-chem
.	O

Similar	O
to	O
cocaine	S-chem
,	O
other	O
local	O
anesthetics	O
bind	O
to	O
the	O
dopamine	B-geneN
transporter	E-geneN
(	O
DAT	S-geneN
)	O
and	O
inhibit	O
DA	S-chem
uptake	O
in	O
rodent	O
and	O
monkey	O
brain	O
.	O

Additionally	O
,	O
local	O
anesthetics	O
are	O
self	O
-	O
administered	O
in	O
rhesus	O
monkeys	O
,	O
indicative	O
of	O
abuse	O
liability	O
.	O

The	O
present	O
study	O
examined	O
the	O
reinforcing	O
and	O
DAT	S-geneY
effects	O
of	O
the	O
local	O
anesthetics	O
dimethocaine	S-chem
,	O
procaine	S-chem
and	O
cocaine	S-chem
using	O
in	O
vivo	O
techniques	O
.	O

Monkeys	O
were	O
trained	O
to	O
respond	O
under	O
a	O
second	O
-	O
order	O
schedule	O
for	O
i.v	O
.	O
cocaine	S-chem
administration	O
(	O
0.10	O
or	O
0.30	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
.	O

When	O
responding	O
was	O
stable	O
,	O
dimethocaine	S-chem
(	O
0.030	O
-	O
1.7	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
or	O
procaine	S-chem
(	O
0.10	O
-	O
10	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
was	O
substituted	O
for	O
the	O
cocaine	S-chem
training	O
dose	O
.	O

Dimethocaine	S-chem
administration	O
produced	O
higher	O
response	O
rates	O
compared	O
with	O
that	O
of	O
procaine	S-chem
,	O
and	O
was	O
a	O
more	O
potent	O
reinforcer	O
.	O

Drug	O
effects	O
on	O
behavior	O
were	O
related	O
to	O
DAT	S-geneY
occupancy	O
in	O
monkey	O
striatum	O
during	O
neuroimaging	O
with	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

DAT	S-geneY
occupancy	O
was	O
determined	O
by	O
displacement	O
of	O
8	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
[	I-chem
(	I-chem
18	I-chem
)	I-chem
F	I-chem
]	I-chem
fluroethyl	I-chem
)	I-chem
2beta	I-chem
-	I-chem
carbomethoxy	I-chem
-	I-chem
3beta	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chlorophenyl	I-chem
)	I-chem
nortropane	E-chem
(	O
FECNT	S-chem
)	O
.	O

DAT	S-geneY
occupancy	O
was	O
between	O
66	O
and	O
82	O
%	O
and	O
<	O
10	O
-	O
41	O
%	O
for	O
doses	O
of	O
dimethocaine	S-chem
and	O
procaine	S-chem
that	O
maintained	O
maximum	O
response	O
rates	O
,	O
respectively	O
.	O

Finally	O
,	O
in	O
vivo	O
microdialysis	O
in	O
awake	O
subjects	O
determined	O
drug	O
-	O
induced	O
changes	O
in	O
extracellular	O
DA	S-chem
in	O
the	O
caudate	O
nucleus	O
.	O

There	O
was	O
close	O
correspondence	O
between	O
peak	O
increases	O
in	O
DA	S-chem
and	O
DAT	S-geneY
occupancy	O
.	O

Overall	O
,	O
reinforcing	O
effects	O
were	O
consistent	O
with	O
DAT	S-geneY
effects	O
determined	O
with	O
in	O
vivo	O
techniques	O
.	O

The	O
results	O
further	O
support	O
a	O
role	O
for	O
the	O
DAT	S-geneY
in	O
the	O
abuse	O
liability	O
of	O
local	O
anesthetics	O
.	O

Effects	O
of	O
lactational	O
and	O
/	O
or	O
in	O
utero	O
exposure	O
to	O
environmental	O
contaminants	O
on	O
the	O
glucocorticoid	O
stress	O
-	O
response	O
and	O
DNA	O
methylation	O
of	O
the	O
glucocorticoid	B-geneN
receptor	I-geneN
promoter	E-geneN
in	O
male	O
rats	O
.	O

Perinatal	O
events	O
can	O
reprogram	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
for	O
the	O
entire	O
lifespan	O
leading	O
to	O
abnormal	O
glucocorticoid	O
stress	O
-	O
response	O
(	O
GSR	O
)	O
in	O
adulthood	O
:	O
a	O
phenomenon	O
reported	O
to	O
be	O
mediated	O
by	O
changes	O
in	O
DNA	O
methylation	O
of	O
the	O
glucocorticoid	B-geneN
receptor	I-geneN
(	I-geneN
GR	I-geneN
)	I-geneN
gene	I-geneN
promoter	E-geneN
.	O

We	O
examined	O
whether	O
in	O
utero	O
and	O
/	O
or	O
lactational	O
exposure	O
to	O
mixtures	O
of	O
environmental	O
contaminants	O
can	O
also	O
induce	O
abnormal	O
GSR	O
during	O
adulthood	O
.	O

The	O
experiment	O
included	O
nine	O
treatment	O
groups	O
.	O

From	O
gestation	O
day	O
(	O
GD	O
)	O
0	O
until	O
postnatal	O
day	O
(	O
PND	O
)	O
20	O
,	O
dams	O
were	O
fed	O
daily	O
with	O
a	O
cookie	O
laced	O
with	O
corn	O
oil	O
(	O
control	O
)	O
or	O
a	O
chemical	O
mixture	O
(	O
M	O
)	O
[	O
polychlorinated	B-chem
biphenyls	E-chem
(	O
PCBs	S-chem
)	O
,	O
organochlorine	S-chem
pesticides	O
,	O
and	O
methylmercury	S-chem
]	O
at	O
0.5	O
or	O
1.0mg	O
/	O
kg	O
/	O
day	O
(	O
0.5M	O
,	O
and	O
M	O
)	O
.	O

At	O
birth	O
,	O
some	O
control	O
(	O
C	O
)	O
and	O
M	O
litters	O
were	O
cross	O
-	O
fostered	O
to	O
create	O
four	O
groups	O
with	O
the	O
following	O
in	O
utero	O
/	O
postnatal	O
exposure	O
:	O
C	O
/	O
C	O
,	O
M	O
/	O
C	O
,	O
C	O
/	O
M	O
,	O
M	O
/	O
M	O
.	O

Other	O
dams	O
received	O
1.8ng	O
/	O
kg	O
/	O
day	O
of	O
a	O
mixture	O
of	O
aryl	B-geneY-C5-2
hydrocarbon	I-geneY-C5-2
receptor	E-geneY-C5-2
(	O
AhR	S-geneY
)	O
agonists	O
(	O
non	B-chem-C5-1
-	I-chem-C5-1
ortho	I-chem-C5-1
PCBs	O
,	O
PC	B-chem-C5-1
-	I-chem-C5-1
dibenzodioxins	E-chem-C5-1
and	O
PC	B-chem-C5-1
-	I-chem-C5-1
dibenzofurans	E-chem-C5-1
)	O
without	O
or	O
with	O
0.5M	O
(	O
0.5MAhR	O
)	O
.	O

In	O
adult	O
male	O
offspring	O
the	O
abundance	O
of	O
GR	S-geneY
in	O
treated	O
groups	O
was	O
not	O
different	O
from	O
the	O
control	O
,	O
but	O
the	O
AhR	S-geneY
and	O
M	O
groups	O
were	O
significantly	O
different	O
from	O
each	O
other	O
with	O
opposite	O
effects	O
in	O
the	O
hippocampus	O
and	O
liver	O
.	O

There	O
was	O
no	O
change	O
in	O
DNA	O
methylation	O
of	O
the	O
GR	B-geneN
promoter	E-geneN
(	O
exon	O
-	O
17	O
and	O
-	O
110	O
)	O
.	O

Abnormal	O
GSRs	O
were	O
detected	O
in	O
the	O
AhR	S-geneY
,	O
0.5MAhR	O
,	O
CM	O
,	O
and	O
MM	O
groups	O
.	O

The	O
literature	O
associates	O
abnormal	O
GSR	O
with	O
metabolic	O
and	O
mental	O
health	O
impairments	O
,	O
thus	O
these	O
results	O
support	O
further	O
investigation	O
of	O
the	O
influence	O
of	O
developmental	O
exposure	O
to	O
environmental	O
contaminants	O
and	O
predisposition	O
to	O
stress	O
-	O
induced	O
diseases	O
.	O

Optimization	O
of	O
a	O
1,5	B-chem-C4-1
-	I-chem-C4-1
dihydrobenzo	I-chem-C4-1
[	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
[	I-chem-C4-1
1,4	I-chem-C4-1
]	I-chem-C4-1
diazepine	I-chem-C4-1
-	I-chem-C4-1
2,4	I-chem-C4-1
-	I-chem-C4-1
dione	E-chem-C4-1
series	O
of	O
HIV	B-geneN-C4-2
capsid	E-geneN-C4-2
assembly	O
inhibitors	O
2	O
:	O
Structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
of	O
the	O
C3	O
-	O
phenyl	S-chem-C4-1
moiety	O
.	O

Detailed	O
structure	O
-	O
activity	O
relationships	O
of	O
the	O
C3	O
-	O
phenyl	S-chem
moiety	O
that	O
allow	O
for	O
the	O
optimization	O
of	O
antiviral	O
potency	O
of	O
a	O
series	O
of	O
1,5	B-chem-C4-1
-	I-chem-C4-1
dihydrobenzo	I-chem-C4-1
[	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
[	I-chem-C4-1
1,4	I-chem-C4-1
]	I-chem-C4-1
diazepine	I-chem-C4-1
-	I-chem-C4-1
2,4	I-chem-C4-1
-	I-chem-C4-1
dione	E-chem-C4-1
inhibitors	O
of	O
HIV	B-geneN-C4-2
capsid	E-geneN-C4-2
(	O
CA	S-geneN-C4-2
)	O
assembly	O
are	O
described	O
.	O

Combination	O
of	O
favorable	O
substitutions	O
gave	O
additive	O
SAR	O
and	O
allowed	O
for	O
the	O
identification	O
of	O
the	O
most	O
potent	O
compound	O
in	O
the	O
series	O
,	O
analog	O
27	O
.	O

Productive	O
SAR	O
also	O
transferred	O
to	O
the	O
benzotriazepine	S-chem
and	O
spirobenzodiazepine	S-chem
scaffolds	O
,	O
providing	O
a	O
solution	O
to	O
the	O
labile	O
stereocenter	O
at	O
the	O
C3	O
position	O
.	O

The	O
molecular	O
basis	O
of	O
how	O
compound	O
27	O
inhibits	O
mature	O
CA	S-geneN
assembly	O
is	O
rationalized	O
using	O
high	O
-	O
resolution	O
structural	O
information	O
.	O

Our	O
understanding	O
of	O
how	O
compound	O
27	O
may	O
inhibit	O
immature	O
Gag	S-geneN
assembly	O
is	O
also	O
discussed	O
.	O

Vitamin	B-chem
K2	E-chem
covalently	O
binds	O
to	O
Bak	S-geneY
and	O
induces	O
Bak	S-geneY
-	O
mediated	O
apoptosis	O
.	O

Vitamin	B-chem
K2	E-chem
(	O
VK2	S-chem
,	O
menaquinone	S-chem
)	O
is	O
known	O
to	O
have	O
anticancer	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Although	O
its	O
effect	O
is	O
thought	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
identified	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
antagonist	O
killer	O
1	O
(	O
Bak	S-geneY
)	O
as	O
a	O
molecular	O
target	O
of	O
VK2	S-chem
-	O
induced	O
apoptosis	O
.	O

VK2	S-chem
directly	O
interacts	O
with	O
Bak	S-geneY
and	O
induces	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
.	O

Although	O
Bak	S-geneY
and	O
Bcl	B-geneY
-	I-geneY
2	I-geneY
-	I-geneY
associated	I-geneY
X	I-geneY
protein	E-geneY
(	O
Bax	S-geneY
)	O
,	O
another	O
member	O
of	O
the	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
family	O
,	O
are	O
generally	O
thought	O
to	O
be	O
functionally	O
redundant	O
,	O
only	O
Bak	S-geneY
is	O
necessary	O
and	O
sufficient	O
for	O
VK2	S-chem-C3-1
-	O
induced	O
cytochrome	B-geneY-C3-2
c	E-geneY-C3-2
(	O
cyt	B-geneY-C3-2
c	E-geneY-C3-2
)	O
release	O
and	O
cell	O
death	O
.	O

Moreover	O
,	O
VK2	B-chem
-	I-chem
2,3	I-chem
epoxide	E-chem
,	O
an	O
intracellular	O
metabolite	O
of	O
VK2	S-chem
,	O
was	O
shown	O
to	O
covalently	O
bind	O
to	O
the	O
cysteine	S-chem
-	O
166	O
residue	O
of	O
Bak	S-geneY
.	O

Several	O
lines	O
of	O
evidence	O
suggested	O
that	O
the	O
covalent	O
attachment	O
of	O
VK2	S-chem
is	O
critical	O
for	O
apoptosis	O
induction	O
.	O

Thus	O
this	O
study	O
reveals	O
a	O
specific	O
role	O
for	O
Bak	S-geneY
in	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

This	O
study	O
also	O
provides	O
insight	O
into	O
the	O
anticancer	O
effects	O
of	O
VK2	S-chem
and	O
suggests	O
that	O
Bak	S-geneY
may	O
be	O
a	O
potential	O
target	O
of	O
cancer	O
therapy	O
.	O

Anti	O
-	O
inflammatory	O
effect	O
of	O
prunetin	S-chem-C4-1
via	O
the	O
suppression	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
pathway	O
.	O

Prunetin	S-chem
is	O
an	O
O	B-chem
-	I-chem
methylated	I-chem
isoflavone	E-chem
,	O
which	O
is	O
found	O
in	O
Prunus	O
yedoensis	O
.	O

To	O
date	O
no	O
report	O
has	O
been	O
published	O
on	O
anti	O
-	O
inflammatory	O
activities	O
of	O
prunetin	S-chem
.	O

In	O
the	O
present	O
study	O
,	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
prunetin	S-chem
on	O
LPS	O
-	O
stimulated	O
RAW	O
264.7	O
macrophage	O
and	O
LPS	O
-	O
induced	O
septic	O
shock	O
model	O
were	O
investigated	O
.	O

Inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
,	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
α	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
(	O
IL	B-geneY
-	I-geneY
6	E-geneY
)	O
,	O
and	O
interleukin	B-geneY
-	I-geneY
1β	E-geneY
(	O
IL	B-geneY
-	I-geneY
1β	E-geneY
)	O
expressions	O
were	O
determined	O
by	O
western	O
blot	O
and	O
or	O
realtime	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

To	O
elucidate	O
its	O
underlying	O
mechanism	O
,	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
κb	E-geneN
)	O
activation	O
and	O
its	O
downstream	O
pathways	O
were	O
investigated	O
by	O
NF	B-geneN
-	I-geneN
κB	E-geneN
transcription	O
factor	O
assay	O
,	O
reporter	O
gene	O
expression	O
,	O
and	O
western	O
blot	O
.	O

In	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
prunetin	S-chem
were	O
evaluated	O
in	O
LPS	O
-	O
induced	O
endotoxemia	O
.	O

Promoter	O
assay	O
revealed	O
that	O
prunetin	S-chem-C4-1
inhibits	O
LPS	O
-	O
induced	O
nitric	B-chem
oxide	E-chem
and	O
prostaglandin	B-chem
E2	E-chem
production	O
through	O
the	O
suppression	O
of	O
iNOS	S-geneY-C4-2
and	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
at	O
the	O
transcriptional	O
level	O
.	O

In	O
addition	O
,	O
prunetin	S-chem-C4-1
inhibits	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
-	O
dependent	O
inflammatory	O
responses	O
by	O
modulating	O
IκB	B-geneN
kinase	E-geneN
(	O
IKK	S-geneN
)	O
-	O
inhibitor	B-geneY
κBα	E-geneY
(	O
IκBα	S-geneY
)	O
-	O
NF	B-geneN
-	I-geneN
κB	E-geneN
signaling	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
prunetin	S-chem-C4-1
significantly	O
reduced	O
serum	O
levels	O
of	O
inflammatory	O
cytokines	S-geneN-C4-2
and	O
mortality	O
in	O
mice	O
challenged	O
with	O
lipopolysaccharide	O
.	O

These	O
findings	O
offer	O
a	O
potential	O
mechanism	O
for	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
prunetin	S-chem
.	O

Supra	O
-	O
normal	O
stimulation	O
of	O
dopamine	B-geneY
D1	I-geneY
receptors	E-geneY
in	O
the	O
prelimbic	O
cortex	O
blocks	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
through	O
a	O
cyclic	B-chem
-	I-chem
AMP	E-chem
-	O
dependent	O
signaling	O
pathway	O
.	O

Dopamine	B-geneN
(	I-geneN
DA	I-geneN
)	I-geneN
receptor	E-geneN
transmission	O
through	O
either	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
or	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
-	O
like	O
subtypes	O
is	O
involved	O
critically	O
in	O
the	O
processing	O
of	O
emotional	O
information	O
within	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
.	O

However	O
the	O
functional	O
role	O
of	O
specific	O
DA	B-geneY
D	I-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
like	I-geneY
receptor	E-geneY
transmission	O
in	O
the	O
expression	O
of	O
emotionally	O
salient	O
associative	O
memories	O
(	O
either	O
aversive	O
or	O
rewarding	O
)	O
is	O
not	O
currently	O
understood	O
.	O

Here	O
we	O
demonstrate	O
that	O
specific	O
activation	O
of	O
DA	B-geneY
D	I-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptors	E-geneY
in	O
the	O
prelimbic	O
(	O
PLC	O
)	O
division	O
of	O
the	O
mPFC	O
causes	O
a	O
transient	O
block	O
in	O
the	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
.	O

We	O
report	O
that	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
selective	O
D	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptor	E-geneY
agonist	O
block	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
olfactory	O
fear	O
memory	O
,	O
without	O
altering	O
the	O
stability	O
of	O
the	O
original	O
memory	O
trace	O
.	O

Furthermore	O
,	O
using	O
an	O
unbiased	O
place	O
conditioning	O
procedure	O
(	O
CPP	O
)	O
,	O
intra	O
-	O
PLC	O
D	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
receptor	E-geneY
activation	O
blocks	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
morphine	S-chem
(	O
5	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
)	O
reward	O
memory	O
,	O
while	O
leaving	O
morphine	O
-	E-chem
primed	O
memory	O
expression	O
intact	O
.	O

Interestingly	O
,	O
both	O
intra	O
-	O
PLC	O
D	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
receptor	E-geneY
mediated	O
block	O
of	O
either	O
fear	O
-	O
related	O
or	O
reward	O
-	O
related	O
associative	O
memories	O
were	O
dependent	O
upon	O
downstream	O
cyclic	B-chem
-	I-chem
AMP	E-chem
(	O
cAMP	S-chem
)	O
signaling	O
as	O
both	O
effects	O
were	O
rescued	O
by	O
co	O
-	O
administration	O
of	O
a	O
cAMP	S-chem
signaling	O
inhibitor	O
.	O

The	O
blockade	O
of	O
both	O
rewarding	O
and	O
aversive	O
associative	O
memories	O
is	O
mediated	O
through	O
a	O
D	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
-	O
specific	O
signaling	O
pathway	O
,	O
as	O
neither	O
forms	O
of	O
spontaneous	O
memory	O
expression	O
were	O
blocked	O
by	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
D	O
(	B-geneY
2	I-geneY
)	I-geneY
-	I-geneY
like	I-geneY
receptor	I-geneY
agonist	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
spontaneous	O
expression	O
of	O
either	O
rewarding	O
or	O
aversive	O
emotionally	O
salient	O
memories	O
shares	O
a	O
common	O
,	O
D	O
(	B-geneY
1	I-geneY
)	I-geneY
-	I-geneY
receptor	I-geneY
mediated	O
substrate	O
within	O
the	O
mPFC	O
.	O

Ethanol	S-chem
extract	O
of	O
Adiantum	O
capillus	O
-	O
veneris	O
L.	O
suppresses	O
the	O
production	O
of	O
inflammatory	O
mediators	O
by	O
inhibiting	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Adiantum	O
capillus	O
-	O
veneris	O
L.	O
is	O
a	O
wildly	O
distributed	O
plant	O
species	O
and	O
has	O
been	O
extensively	O
used	O
in	O
south	O
of	O
China	O
as	O
traditional	O
folk	O
medicine	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
To	O
investigate	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
ethanolic	O
extracts	O
of	O
Adiantum	O
capillus	O
-	O
veneris	O
L.	O
and	O
the	O
involvement	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
signaling	O
in	O
the	O
regulation	O
of	O
inflammation	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
plant	O
ethanolic	O
extracts	O
were	O
initially	O
tested	O
against	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
prostaglandin	B-chem
E2	E-chem
(	O
PGE2	S-chem
)	O
production	O
in	O
RAW264.7	O
mouse	O
macrophages	O
,	O
and	O
interleukin	B-geneY
6	E-geneY
(	O
IL	B-geneY
-	I-geneY
6	E-geneY
)	O
and	O
tumor	B-geneY
necrosis	I-geneY
factor	E-geneY
(	O
TNF	S-geneY
)	O
production	O
in	O
human	O
U937	O
monocytes	O
.	O

The	O
effect	O
of	O
the	O
plant	O
extracts	O
on	O
the	O
transcription	O
factor	O
nuclear	B-geneN
factor	I-geneN
kappa	I-geneN
B	E-geneN
(	B-geneN
NF	I-geneN
-	I-geneN
κB	E-geneN
)	O
pathway	O
was	O
evaluated	O
in	O
TNF	B-geneY
-	I-geneY
α	E-geneY
stimulated	O
HepG2	O
cells	O
by	O
luciferase	O
gene	O
reporter	O
assay	O
and	O
Western	O
blotting	O
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
.	O

Subsequently	O
,	O
the	O
inhibition	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
downstream	O
gene	O
expression	O
(	O
IL	B-geneY
-	I-geneY
8	E-geneY
and	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
)	O
by	O
the	O
plant	O
extracts	O
was	O
assessed	O
via	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O

Lastly	O
,	O
the	O
anti	O
-	O
inflammatory	O
activities	O
of	O
the	O
plant	O
extracts	O
in	O
vivo	O
were	O
evaluated	O
by	O
testing	O
spleen	O
index	O
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
related	O
protein	O
expression	O
in	O
LPS	O
-	O
stimulated	O
CD1	O
mice	O
.	O

RESULTS	O
:	O
The	O
plant	O
ethanolic	O
extracts	O
effectively	O
suppressed	O
PGE2	S-chem
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
and	O
TNF	S-geneY
release	O
with	O
an	O
IC50	O
less	O
than	O
50μg	O
/	O
ml	O
.	O

Moreover	O
,	O
luciferase	O
expression	O
could	O
be	O
specifically	O
blocked	O
in	O
HepG2	O
cells	O
,	O
not	O
in	O
HEK293	O
cells	O
,	O
showing	O
that	O
the	O
plant	O
extracts	O
displayed	O
a	O
cell	O
-	O
specific	O
pattern	O
on	O
NF	B-geneN
-	I-geneN
κB	E-geneN
gene	O
transcription	O
.	O

The	O
assayed	O
biological	O
activity	O
also	O
depended	O
on	O
the	O
order	O
of	O
adding	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
the	O
plant	O
extracts	O
because	O
the	O
plant	O
extracts	O
could	O
only	O
block	O
the	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
if	O
added	O
earlier	O
but	O
were	O
unable	O
to	O
stop	O
the	O
signal	O
when	O
added	O
after	O
TNF	B-geneY
-	I-geneY
α	E-geneY
.	O

However	O
,	O
the	O
plant	O
extracts	O
did	O
not	O
exert	O
any	O
effect	O
on	O
ubiquitination	O
which	O
regulates	O
several	O
steps	O
in	O
the	O
NF	B-geneN
-	I-geneN
κB	E-geneN
pathway	O
.	O

Additionally	O
,	O
the	O
plant	O
extracts	O
down	O
-	O
regulated	O
phosphorylation	O
of	O
IKKα	B-geneN
/	I-geneN
β	E-geneN
at	O
S176	O
/	O
180	O
,	O
p38	S-geneN
at	O
T180	O
/	O
Y182	O
and	O
p65	S-geneY
at	O
S536	O
,	O
but	O
not	O
p65	S-geneY
at	O
S276	O
.	O

This	O
was	O
confirmed	O
by	O
their	O
ability	O
to	O
selectively	O
abrogate	O
the	O
induction	O
of	O
IL	B-geneY
-	I-geneY
8	E-geneY
transcription	O
,	O
whereas	O
the	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
gene	O
,	O
which	O
is	O
not	O
transcribed	O
selectively	O
by	O
an	O
NF	B-geneN
-	I-geneN
κB	E-geneN
complex	O
containing	O
a	O
form	O
of	O
p65	S-geneY
phosphorylated	O
on	O
Ser536	S-chem
,	O
did	O
not	O
change	O
.	O

Finally	O
,	O
the	O
plant	O
extracts	O
at	O
200μg	O
/	O
mg	O
could	O
normalize	O
the	O
LPS	O
-	O
induced	O
elevation	O
of	O
spleen	O
index	O
as	O
well	O
as	O
NF	B-geneN
-	I-geneN
κB	E-geneN
and	O
p38	S-geneN
activations	O
in	O
CD1	O
mice	O
.	O

CONCLUSION	O
:	O
The	O
present	O
studies	O
presents	O
the	O
potential	O
utilization	O
of	O
this	O
plant	O
extracts	O
,	O
as	O
a	O
natural	O
resources	O
for	O
the	O
development	O
of	O
an	O
anti	O
-	O
inflammatory	O
medicine	O
.	O

Involvement	O
of	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
and	O
up	O
-	O
regulated	O
prostaglandin	B-geneY-C9-2
E	I-geneY-C9-2
synthases	E-geneY-C9-2
in	O
phosphatidylserine	S-chem
liposome	O
-	O
induced	O
prostaglandin	B-chem-C9-1
E2	E-chem-C9-1
production	O
by	O
microglia	O
.	O

After	O
engulfment	O
of	O
apoptotic	O
cells	O
through	O
phosphatidylserine	S-chem
(	O
PS	O
)	O
-	O
mediated	O
recognition	O
,	O
microglia	O
secrete	O
prostaglandin	B-chem
E2	E-chem
(	O
PGE2	S-chem
)	O
,	O
a	O
potent	O
anti	O
-	O
inflammatory	O
molecule	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Despite	O
the	O
clinical	O
significance	O
,	O
the	O
mechanism	O
underlying	O
PGE2	S-chem
production	O
by	O
phagocytosis	O
of	O
apoptotic	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
PS	O
liposomes	O
to	O
elucidate	O
the	O
phagocytic	O
pathway	O
for	O
PGE2	S-chem
production	O
in	O
microglia	O
,	O
because	O
PS	O
liposomes	O
mimic	O
the	O
effects	O
of	O
apoptotic	O
cells	O
on	O
microglia	O
/	O
macrophages	O
.	O

The	O
level	O
of	O
PGE2	S-chem
in	O
the	O
culture	O
medium	O
of	O
primary	O
cultured	O
rat	O
microglia	O
was	O
significantly	O
increased	O
by	O
PS	O
liposomes	O
treatment	O
but	O
not	O
by	O
phosphatidylcholine	S-chem
liposomes	O
treatment	O
.	O

The	O
specific	O
ligand	O
for	O
class	B-geneN
B	I-geneN
scavenger	I-geneN
receptor	E-geneN
(	O
SR	B-geneN
-	I-geneN
B	E-geneN
)	O
,	O
high	B-geneN
density	I-geneN
lipoprotein	E-geneN
,	O
significantly	O
suppressed	O
PS	O
liposome	O
-	O
induced	O
PGE2	S-chem
production	O
.	O

PS	O
liposomes	O
were	O
immediately	O
phagocytosed	O
by	O
microglia	O
and	O
sorted	O
to	O
endosomes	O
/	O
lysosomes	O
.	O

Cyclooxygenase	S-geneN
(	B-geneY
COX	I-geneY
)	I-geneY
-	I-geneY
2	E-geneY
and	O
membrane	O
-	O
bound	O
prostaglandin	B-geneY
E	I-geneY
synthase	I-geneY
-	I-geneY
1	E-geneY
(	O
mPGES	B-geneY
-	I-geneY
1	E-geneY
)	O
were	O
induced	O
by	O
treatment	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
but	O
not	O
with	O
PS	O
liposomes	O
.	O

On	O
the	O
other	O
hand	O
,	O
mPGES	B-geneY
-	I-geneY
2	E-geneY
and	O
cytosolic	B-geneY
PGES	E-geneY
(	O
cPGES	S-geneY
)	O
that	O
are	O
functionally	O
coupled	O
with	O
COX	B-geneY
-	I-geneY
1	E-geneY
were	O
upregulated	O
after	O
treatment	O
with	O
PS	O
liposomes	O
or	O
LPS	O
.	O

Furthermore	O
,	O
PS	O
liposome	O
-	O
induced	O
PGE2	S-chem
production	O
was	O
significantly	O
suppressed	O
by	O
indomethacin	S-chem-C4-1
,	O
a	O
preferential	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibitor	O
,	O
but	O
not	O
by	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
,	O
a	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
.	O

PS	O
liposomes	O
induced	O
activation	O
of	O
p44	S-geneY
/	O
p42	S-geneY
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
but	O
not	O
p38	S-geneN
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
in	O
SR	B-geneY
-	I-geneY
BI	E-geneY
independent	O
manner	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
up	O
-	O
regulation	O
of	O
terminal	O
PGESs	S-geneY-C9-2
that	O
are	O
preferentially	O
coupled	O
with	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
,	O
especially	O
mPGES	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
,	O
plays	O
the	O
pivotal	O
role	O
in	O
PS	O
liposome	O
-	O
induced	O
PGE2	S-chem-C9-1
production	O
by	O
microglia	O
.	O

Although	O
SR	B-geneY
-	I-geneY
BI	E-geneY
plays	O
an	O
essential	O
role	O
in	O
PS	O
liposome	O
-	O
induced	O
PGE2	S-chem
production	O
,	O
other	O
PS	B-geneN
-	I-geneN
recognizing	I-geneN
receptors	E-geneN
,	O
possibly	O
PS	B-geneN
-	I-geneN
specific	I-geneN
receptor	E-geneN
,	O
could	O
also	O
promote	O
PGE2	S-chem
production	O
by	O
transducing	O
intracellular	O
signals	O
including	O
p44	S-geneY
/	O
p42	S-geneY
ERK	S-geneN
after	O
PS	O
liposomes	O
treatment	O
.	O

Review	O
article	O
:	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
agonists	O
and	O
antagonists	O
in	O
the	O
modulation	O
of	O
gastrointestinal	O
motility	O
and	O
sensation	O
:	O
clinical	O
implications	O
.	O

Serotonin	S-chem
(	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
;	O
5	B-chem
-	I-chem
HT	E-chem
)	O
is	O
found	O
in	O
the	O
enteric	O
nervous	O
system	O
where	O
it	O
has	O
been	O
implicated	O
in	O
controlling	O
gastrointestinal	O
motor	O
function	O
.	O

A	O
number	O
of	O
receptor	O
or	O
recognition	O
sites	O
have	O
been	O
identified	O
in	O
the	O
gut	O
,	O
but	O
recently	O
most	O
attention	O
has	O
focused	O
on	O
the	O
5	B-geneY
-	I-geneY
HT3	E-geneY
and	O
5	B-geneY
-	I-geneY
HT4	E-geneY
receptors	O
.	O

The	O
functional	O
role	O
of	O
the	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptor	O
remains	O
incompletely	O
understood	O
,	O
but	O
it	O
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
colonic	O
motility	O
and	O
visceral	O
pain	O
in	O
the	O
gut	O
.	O

A	O
number	O
of	O
selective	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT3	E-geneY-C6-2
antagonists	O
have	O
been	O
developed	O
including	O
ondansetron	S-chem-C6-1
,	O
granisetron	S-chem-C6-1
,	O
tropisetron	S-chem-C6-1
renzapride	S-chem-C6-1
and	O
zacopride	S-chem-C6-1
.	O

While	O
the	O
substituted	O
benzamide	S-chem-MU-1
prokinetics	O
(	O
for	O
example	O
,	O
metoclopramide	S-chem-MU-1
,	O
cisapride	S-chem-MU-1
)	O
also	O
block	O
5	B-geneY-C4-2
-	I-geneY-C4-2
HT3	E-geneY-C4-2
receptors	O
in	O
high	O
concentrations	O
,	O
their	O
prokinetic	O
action	O
is	O
believed	O
to	O
be	O
on	O
the	O
basis	O
of	O
their	O
agonist	O
effects	O
on	O
the	O
putative	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT4	E-geneY-C5-2
receptor	O
.	O

Some	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT3	E-geneY-C6-2
antagonists	O
have	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT4	E-geneY-C5-2
agonist	O
activity	O
(	O
for	O
example	O
,	O
renzapride	S-chem-MU-1
,	O
zacopride	S-chem-MU-1
)	O
and	O
others	O
do	O
not	O
(	O
for	O
example	O
,	O
ondansetron	S-chem
,	O
granisetron	S-chem
)	O
,	O
while	O
tropisetron	S-chem-C6-1
in	O
high	O
concentrations	O
is	O
a	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT4	E-geneY-C6-2
antagonist	O
.	O

Based	O
on	O
the	O
pharmacological	O
data	O
,	O
it	O
has	O
been	O
suggested	O
that	O
specific	O
5	B-chem
-	I-chem
HT	E-chem
antagonists	O
and	O
agonists	O
may	O
prove	O
to	O
be	O
beneficial	O
in	O
a	O
number	O
of	O
gastrointestinal	O
disorders	O
including	O
the	O
irritable	O
bowel	O
syndrome	O
,	O
functional	O
dyspepsia	O
,	O
non	O
-	O
cardiac	O
chest	O
pain	O
,	O
gastrooesophageal	O
reflux	O
and	O
refractory	O
nausea	O
.	O

In	O
this	O
review	O
,	O
the	O
rationale	O
for	O
the	O
use	O
of	O
these	O
compounds	O
is	O
discussed	O
,	O
and	O
the	O
available	O
experimental	O
evidence	O
is	O
summarized	O
.	O

Synthesis	O
,	O
receptor	O
binding	O
and	O
functional	O
studies	O
of	O
mesoridazine	S-chem
stereoisomers	O
.	O

The	O
four	O
stereoisomers	O
of	O
mesoridazine	S-chem
were	O
synthesized	O
and	O
evaluated	O
in	O
D2	S-geneY
,	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
,	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
,	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
,	O
D1	S-geneY
,	O
and	O
D3	B-geneY
receptor	E-geneY
binding	O
and	O
functional	O
assays	O
.	O

Two	O
isomers	O
demonstrated	O
potent	O
D2	O
receptor	O
binding	O
(	O
Ki	O
<	O
3	O
nM	O
)	O
and	O
functional	O
antagonism	O
(	O
IC50	O
<	O
or	O
=	O
10	O
nM	O
)	O
activities	O
.	O

These	O
two	O
isomers	O
also	O
showed	O
moderate	O
affinity	O
for	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
and	O
D3	B-geneY
receptors	E-geneY
.	O

A	O
third	O
isomer	O
was	O
devoid	O
of	O
significant	O
D2	B-geneY
receptor	E-geneY
binding	O
,	O
but	O
did	O
have	O
moderate	O
affinity	O
for	O
the	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
and	O
D3	B-geneY
receptors	E-geneY
.	O

The	O
fourth	O
isomer	O
demonstrated	O
poor	O
affinity	O
for	O
all	O
the	O
receptors	O
tested	O
.	O

Most	O
significantly	O
,	O
the	O
stereochemistry	O
of	O
the	O
sulfoxide	S-chem
moiety	O
played	O
a	O
dominant	O
role	O
in	O
the	O
observed	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
.	O

Histochemical	O
staining	O
and	O
quantification	O
of	O
dihydrolipoamide	B-geneY
dehydrogenase	E-geneY
diaphorase	S-geneN
activity	O
using	O
blue	O
native	O
PAGE	O
.	O

Mammalian	B-geneY
mitochondrial	I-geneY
dihydrolipoamide	I-geneY
dehydrogenase	E-geneY
(	O
DLDH	S-geneY
,	O
EC	B-geneY
1.8.1.4	E-geneY
)	O
catalyzes	O
NAD	B-chem
(	I-chem
+	I-chem
)	E-chem
-	O
dependent	O
oxidation	O
of	O
dihydrolipoamide	S-chem
in	O
vivo	O
and	O
can	O
also	O
act	O
as	O
a	O
diaphorase	S-geneN
catalyzing	O
in	O
vitro	O
nicotinamide	B-chem
adenine	I-chem
dinucleotide	I-chem
(	I-chem
reduced	I-chem
form	I-chem
)	E-chem
(	O
NADH	S-chem
)	O
-	O
dependent	O
reduction	O
of	O
electron	O
-	O
accepting	O
molecules	O
such	O
as	O
ubiquinone	O
and	O
nitroblue	B-chem
tetrazolium	E-chem
(	O
NBT	S-chem
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
gel	O
-	O
based	O
method	O
for	O
histochemical	O
staining	O
and	O
quantification	O
of	O
DLDH	S-geneY
diaphorase	S-geneN
activity	O
using	O
blue	O
native	O
PAGE	O
(	O
BN	O
-	O
PAGE	O
)	O
.	O

Rat	O
brain	O
mitochondrial	O
extracts	O
,	O
used	O
as	O
the	O
source	O
of	O
DLDH	S-geneY
,	O
were	O
resolved	O
by	O
nongradient	O
BN	O
-	O
PAGE	O
(	O
9	O
%	O
)	O
,	O
which	O
was	O
followed	O
by	O
diaphorase	S-geneN
activity	O
staining	O
using	O
NADH	S-chem
as	O
the	O
electron	O
donor	O
and	O
NBT	S-chem
as	O
the	O
electron	O
acceptor	O
.	O

It	O
was	O
shown	O
that	O
activity	O
staining	O
of	O
DLDH	S-geneY
diaphorase	S-geneN
was	O
both	O
protein	O
amount	O
-	O
and	O
time	O
-	O
dependent	O
.	O

Moreover	O
,	O
this	O
in	O
-	O
gel	O
activity	O
-	O
staining	O
method	O
was	O
demonstrated	O
to	O
be	O
in	O
good	O
agreement	O
with	O
the	O
conventional	O
spectrophotometric	O
method	O
that	O
measures	O
DLDH	S-geneY
dehydrogenase	S-geneN
activity	O
using	O
dihydrolipoamide	S-chem
as	O
the	O
substrate	O
.	O

The	O
method	O
was	O
applied	O
to	O
determine	O
levels	O
of	O
DLDH	S-geneY
diaphorase	S-geneN
activity	O
in	O
several	O
rat	O
tissues	O
other	O
than	O
the	O
brain	O
,	O
and	O
the	O
results	O
indicated	O
a	O
similar	O
level	O
of	O
DLDH	S-geneY
diaphorase	S-geneN
activity	O
for	O
all	O
the	O
tissues	O
examined	O
.	O

Finally	O
,	O
the	O
effects	O
of	O
thiol	S-chem
-	O
reactive	O
reagents	O
such	O
as	O
N	B-chem
-	I-chem
ethylmaleimide	E-chem
(	O
NEM	S-chem
)	O
and	O
nitric	B-chem
oxide	E-chem
donors	O
on	O
DLDH	S-geneY
diaphorase	S-geneN
activity	O
were	O
evaluated	O
,	O
demonstrating	O
that	O
,	O
with	O
this	O
method	O
,	O
DLDH	S-geneY
diaphorase	S-geneN
activity	O
can	O
be	O
determined	O
without	O
having	O
to	O
remove	O
these	O
thiol	S-chem
-	O
reactive	O
reagents	O
that	O
may	O
otherwise	O
interfere	O
with	O
spectrophotometric	O
measurement	O
of	O
DLDH	S-geneY
dehydrogenase	S-geneN
activity	O
.	O

The	O
gel	O
-	O
based	O
method	O
can	O
also	O
be	O
used	O
as	O
a	O
means	O
to	O
isolate	O
mitochondrial	O
DLDH	S-geneY
that	O
is	O
to	O
be	O
analyzed	O
by	O
mass	O
spectral	O
techniques	O
in	O
studying	O
DLDH	S-geneY
post	O
-	O
translational	O
modifications	O
.	O

The	O
Protective	O
Effects	O
of	O
α	B-chem
-	I-chem
Lipoic	I-chem
Acid	E-chem
on	O
Kidneys	O
in	O
Type	O
2	O
Diabetic	O
Goto	O
-	O
Kakisaki	O
Rats	O
via	O
Reducing	O
Oxidative	O
Stress	O
.	O

To	O
evaluate	O
the	O
protective	O
effects	O
of	O
α	B-chem
-	I-chem
lipoic	I-chem
acid	E-chem
on	O
the	O
kidneys	O
of	O
Goto	O
-	O
Kakisaki	O
(	O
GK	O
)	O
diabetic	O
rats	O
,	O
ten	O
GK	O
diabetic	O
rats	O
were	O
randomly	O
divided	O
into	O
a	O
diabetic	O
control	O
group	O
and	O
a	O
lipoic	B-chem
acid	E-chem
-	O
treated	O
diabetic	O
group	O
with	O
α	B-chem
-	I-chem
lipoic	I-chem
acid	E-chem
35	O
mg	O
·	O
Kg	O
-	O
1	O
intraperitoneal	O
injections	O
.	O

Four	O
healthy	O
Wistar	O
rats	O
served	O
as	O
normal	O
controls	O
.	O

Malonaldehyde	S-chem
(	O
MDA	S-chem
)	O
,	O
ascorbic	B-chem
acid	E-chem
(	O
vitamin	B-chem
C	E-chem
)	O
,	O
vitamin	B-chem
E	E-chem
,	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
and	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
levels	O
in	O
renal	O
homogenate	O
,	O
and	O
urine	O
protein	O
excretion	O
were	O
measured	O
.	O

The	O
expression	O
of	O
mRNA	O
for	O
NF	B-geneN
-	I-geneN
κB	E-geneN
,	O
NADPH	B-geneN
oxidase	E-geneN
subunits	O
p22phox	S-geneY
and	O
p47phox	S-geneY
in	O
renal	O
tissue	O
was	O
examined	O
by	O
realtime	O
PCR	O
.	O

Pathological	O
changes	O
in	O
renal	O
tissue	O
were	O
evaluated	O
by	O
light	O
and	O
electron	O
microscopy	O
.	O

There	O
were	O
significant	O
increases	O
in	O
urine	O
protein	O
excretion	O
,	O
MDA	S-chem
levels	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
,	O
p22phox	S-geneY
and	O
p47phox	S-geneY
,	O
and	O
significant	O
decreases	O
in	O
GSH	S-chem
,	O
SOD	S-geneN
,	O
vitamin	B-chem
C	E-chem
and	O
vitamin	B-chem
E	E-chem
levels	O
in	O
the	O
diabetic	O
control	O
group	O
compared	O
with	O
the	O
normal	O
control	O
group	O
.	O

Pathological	O
changes	O
of	O
renal	O
tissue	O
were	O
more	O
progressive	O
in	O
the	O
diabetic	O
control	O
group	O
than	O
in	O
the	O
normal	O
control	O
group	O
.	O

All	O
the	O
parameters	O
above	O
were	O
improved	O
in	O
the	O
α	B-chem
-	I-chem
lipoic	I-chem
acid	E-chem
-	O
treated	O
diabetic	O
group	O
.	O

Oxidative	O
stress	O
is	O
increased	O
in	O
the	O
kidney	O
of	O
type	O
2	O
diabetic	O
GK	O
rats	O
.	O

It	O
is	O
associated	O
with	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

α	B-chem
-	I-chem
lipoic	I-chem
acid	E-chem
can	O
protect	O
renal	O
function	O
in	O
diabetic	O
rats	O
via	O
its	O
antioxidant	O
activity	O
.	O

chi	O
-	O
Conopeptide	O
MrIA	O
partially	O
overlaps	O
desipramine	B-geneN
and	I-geneN
cocaine	I-geneN
binding	I-geneN
sites	E-geneN
on	O
the	O
human	B-geneY
norepinephrine	I-geneY
transporter	E-geneY
.	O

The	O
interactions	O
of	O
chi	O
-	O
conopeptide	O
MrIA	O
with	O
the	O
human	B-geneY
norepinephrine	I-geneY
transporter	E-geneY
(	O
hNET	S-geneY
)	O
were	O
investigated	O
by	O
determining	O
the	O
effects	O
of	O
hNET	S-geneY
point	O
mutations	O
on	O
the	O
inhibitory	O
potency	O
of	O
MrIA	O
.	O

The	O
mutants	O
were	O
produced	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
.	O

The	O
potency	O
of	O
MrIA	O
was	O
greater	O
for	O
inhibition	O
of	O
uptake	O
by	O
hNET	S-geneY-C9-2
of	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
norepinephrine	E-chem-C9-1
(	O
Ki	O
1.89	O
microM	O
)	O
than	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
dopamine	E-chem-C9-1
(	O
Ki	O
4.33	O
microM	O
)	O
,	O
and	O
the	O
human	B-geneY
dopamine	I-geneY
transporter	E-geneY
and	O
serotonin	B-geneY
transporter	E-geneY
were	O
not	O
inhibited	O
by	O
MrIA	O
(	O
to	O
7	O
microM	O
)	O
.	O

Of	O
18	O
mutations	O
where	O
hNET	S-geneY
amino	B-chem
acid	E-chem
residues	O
were	O
exchanged	O
with	O
those	O
of	O
the	O
human	B-geneY
dopamine	I-geneY
transporter	E-geneY
,	O
MrIA	O
had	O
increased	O
potency	O
for	O
inhibition	O
of	O
[	B-chem
3H	I-chem
]	I-chem
norepinephrine	E-chem
uptake	O
for	O
three	O
mutations	O
(	O
in	O
predicted	O
extracellular	O
loops	O
3	O
and	O
4	O
and	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
8	O
)	O
and	O
decreased	O
potency	O
for	O
one	O
mutation	O
(	O
in	O
TMD6	O
and	O
intracellular	O
loop	O
(	O
IL	O
)	O
3	O
)	O
.	O

Of	O
the	O
12	O
additional	O
mutations	O
in	O
TMDs	O
2	O
,	O
4	O
,	O
5	O
,	O
and	O
11	O
and	O
IL1	O
,	O
three	O
mutations	O
(	O
in	O
TMD2	O
and	O
IL1	O
)	O
had	O
reduced	O
MrIA	O
inhibitory	O
potency	O
.	O

All	O
of	O
the	O
other	O
mutations	O
tested	O
had	O
no	O
influence	O
on	O
MrIA	O
potency	O
.	O

A	O
comparison	O
of	O
the	O
results	O
with	O
previous	O
data	O
for	O
desipramine	S-chem
and	O
cocaine	O
inhibition	O
of	O
norepinephrine	S-chem-C9-1
uptake	O
by	O
the	O
mutant	O
hNETs	S-geneY-C9-2
reveals	O
that	O
MrIA	O
binding	O
to	O
hNET	S-geneY
occurs	O
at	O
a	O
site	O
that	O
is	O
distinct	O
from	O
but	O
overlaps	O
with	O
the	O
binding	O
sites	O
for	O
tricyclic	S-chem
antidepressants	O
and	O
cocaine	S-chem
.	O

Drosophila	B-geneN
GABA	I-geneN
-	I-geneN
gated	I-geneN
chloride	I-geneN
channel	E-geneN
:	O
modified	O
[	B-chem
3H	I-chem
]	I-chem
EBOB	E-chem
binding	O
site	O
associated	O
with	O
Ala	S-chem
-	O
-	O
>	O
Ser	S-chem
or	O
Gly	S-chem
mutants	O
of	O
Rdl	S-geneY
subunit	O
.	O

The	O
non	O
-	O
competitive	O
blocker	O
site	O
of	O
the	O
GABA	B-geneN
-	I-geneN
gated	I-geneN
chloride	I-geneN
ion	I-geneN
channel	E-geneN
in	O
normal	O
susceptible	O
strains	O
of	O
Drosophila	O
melanogaster	O
and	O
simulans	O
binds	O
4	B-chem
-	I-chem
n	I-chem
-	I-chem
[	I-chem
3H	I-chem
]	I-chem
propyl	I-chem
-	I-chem
4	I-chem
'	I-chem
-	I-chem
ethynylbicycloorthobenzoate	E-chem
(	O
[	B-chem
3H	I-chem
]	I-chem
EBOB	E-chem
)	O
at	O
specific	O
sites	O
with	O
KdS	O
of	O
1.6	O
-	O
1.9	O
nM	O
and	O
BmaxS	O
of	O
171	O
-	O
181	O
fmol	O
/	O
mg	O
protein	O
.	O

This	O
specific	O
binding	O
of	O
[	B-chem
3H	I-chem
]	I-chem
EBOB	E-chem
is	O
strongly	O
inhibited	O
by	O
:	O
a	O
large	O
number	O
and	O
variety	O
of	O
insecticidal	O
channel	O
blockers	O
at	O
20	O
nM	O
(	O
lindane	S-chem
,	O
alpha	B-chem
-	I-chem
endosulfan	E-chem
,	O
dieldrin	S-chem
,	O
12	B-chem
-	I-chem
ketoendrin	E-chem
,	O
fipronil	S-chem
,	O
and	O
a	O
representative	O
bicycloorthobenzoate	S-chem
and	O
dithiane	S-chem
)	O
or	O
200	O
nM	O
(	O
picrotoxinin	S-chem
)	O
;	O
the	O
insecticidal	O
channel	O
activators	O
avermectin	S-chem
and	O
moxidectin	S-chem
at	O
20	O
nM	O
;	O
muscimol	S-chem
at	O
30	O
microM	O
and	O
GABA	S-chem
at	O
300	O
microM	O
.	O

Cyclodiene	S-chem
resistance	O
in	O
D.	O
melanogaster	O
has	O
been	O
attributed	O
to	O
a	O
mutation	O
resulting	O
in	O
an	O
Ala302	B-geneN
-	I-geneN
-	I-geneN
>	I-geneN
Ser	E-geneN
replacement	O
in	O
the	O
Rdl	B-geneY
GABA	I-geneY
receptor	E-geneY
subunit	O
and	O
in	O
D.	O
simulans	O
to	O
an	O
homologous	O
Ala	S-chem
-	O
-	O
>	O
Ser	S-chem
or	O
Gly	S-chem
replacement	O
.	O

These	O
mutations	O
are	O
shown	O
here	O
to	O
greatly	O
reduce	O
[	B-chem
3H	I-chem
]	I-chem
EBOB	E-chem
binding	O
,	O
i.e	O
.	O
lower	O
affinity	O
and	O
apparent	O
number	O
of	O
binding	O
sites	O
.	O

The	O
Ala	S-chem
-	O
-	O
>	O
Ser	S-chem
replacement	O
with	O
both	O
melanogaster	O
and	O
simulans	O
almost	O
always	O
reduces	O
the	O
potency	O
in	O
inhibiting	O
[	B-chem
3H	I-chem
]	I-chem
EBOB	E-chem
binding	O
of	O
each	O
of	O
eight	O
channel	O
blockers	O
and	O
of	O
muscimol	S-chem
and	O
GABA	S-chem
.	O

The	O
Ala	S-chem
-	O
-	O
>	O
Gly	S-chem
replacement	O
in	O
D.	O
simulans	O
is	O
generally	O
less	O
effective	O
than	O
the	O
Ala	S-chem
-	O
-	O
>	O
Ser	S-chem
modification	O
in	O
reducing	O
sensitivity	O
to	O
the	O
channel	O
blockers	O
and	O
to	O
muscimol	S-chem
and	O
GABA	S-chem
.	O

The	O
channel	O
activators	O
avermectin	S-chem-C4-1
and	O
moxidectin	S-chem-C4-1
usually	O
retain	O
their	O
inhibitory	O
potency	O
in	O
the	O
Rdl	S-geneY-C4-2
subunit	O
mutants	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
replacement	O
of	O
Ala	S-chem
by	O
Ser	S-chem
generally	O
modifies	O
the	O
non	O
-	O
competitive	O
blocker	O
site	O
and	O
its	O
coupling	O
to	O
the	O
GABA	S-chem
-	O
recognition	O
site	O
with	O
less	O
effect	O
on	O
the	O
channel	O
activator	O
site	O
.	O

In	O
contrast	O
,	O
the	O
Ala	S-chem
-	O
-	O
>	O
Gly	S-chem
replacement	O
has	O
less	O
impact	O
in	O
protecting	O
the	O
chloride	B-geneN
channel	E-geneN
from	O
the	O
action	O
of	O
insecticidal	O
blockers	O
.	O

Each	O
of	O
the	O
resistant	O
strains	O
has	O
the	O
same	O
level	O
of	O
resistance	O
to	O
the	O
lethal	O
action	O
of	O
the	O
five	O
channel	O
blockers	O
examined	O
but	O
none	O
to	O
avermectins	S-chem
and	O
muscimol	S-chem
.	O

Catalpol	S-chem
suppresses	O
advanced	O
glycation	O
end	O
-	O
products	O
-	O
induced	O
inflammatory	O
responses	O
through	O
inhibition	O
of	O
reactive	O
oxygen	S-chem
species	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Advanced	O
glycation	O
end	O
-	O
products	O
(	O
AGEs	O
)	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
diabetic	O
complications	O
by	O
inducing	O
inflammation	O
.	O

We	O
previously	O
reported	O
that	O
the	O
fresh	O
roots	O
of	O
Rehmannia	O
glutinosa	O
Libosch	O
.	O
,	O
which	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
in	O
traditional	O
Korean	O
medicine	O
,	O
also	O
have	O
the	O
potential	O
to	O
suppress	O
AGE	O
-	O
mediated	O
inflammatory	O
response	O
in	O
THP	O
-	O
1	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
isolated	O
catalpol	S-chem
from	O
R.	O
glutinosa	O
,	O
and	O
examined	O
whether	O
it	O
has	O
anti	O
-	O
inflammatory	O
effects	O
on	O
AGE	O
-	O
stimulated	O
THP	O
-	O
1	O
cells	O
.	O

Catalpol	S-chem-C4-1
reduced	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediates	O
,	O
such	O
as	O
monocyte	B-geneY-C4-2
chemotactic	I-geneY-C4-2
protein	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
MCP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
)	O
,	O
tumor	B-geneY-C4-2
necrosis	I-geneY-C4-2
factor	I-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
(	O
TNF	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
)	O
,	O
inducible	B-geneY-C4-2
NO	I-geneY-C4-2
synthase	E-geneY-C4-2
(	O
iNOS	S-geneY-C4-2
)	O
,	O
and	O
receptor	B-geneY-C4-2
for	I-geneY-C4-2
AGE	E-geneY-C4-2
(	O
RAGE	S-geneY-C4-2
)	O
.	O

Promoter	O
and	O
electromobility	O
shift	O
assays	O
showed	O
that	O
transcriptional	O
activation	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
was	O
significantly	O
reduced	O
by	O
catalpol	S-chem-C4-1
treatment	O
,	O
while	O
AP	B-geneY
-	I-geneY
1	E-geneY
was	O
not	O
.	O

Catalpol	S-chem-C4-1
also	O
suppressed	O
AGE	O
-	O
induced	O
phosphorylation	O
of	O
mitogen	B-geneN-C4-2
activated	I-geneN-C4-2
protein	I-geneN-C4-2
(	I-geneN-C4-2
MAP	I-geneN-C4-2
)	I-geneN-C4-2
kinases	E-geneN-C4-2
,	O
degradation	O
of	O
IκBα	S-geneY-C4-2
and	O
the	O
nuclear	O
localization	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
.	O

Moreover	O
,	O
the	O
production	O
of	O
intracellular	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
elicited	O
by	O
AGE	O
was	O
also	O
suppressed	O
by	O
catalpol	S-chem-C4-1
treatment	O
,	O
through	O
dual	O
action	O
of	O
reducing	O
ROS	O
itself	O
and	O
inhibiting	O
NADPH	B-geneN-C4-2
oxidase	E-geneN-C4-2
activity	O
.	O

Our	O
findings	O
indicate	O
that	O
catalpol	S-chem-C4-1
suppresses	O
AGE	O
-	O
mediated	O
inflammation	O
by	O
inhibiting	O
ROS	O
production	O
and	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
activity	O
.	O

We	O
suggest	O
that	O
catalpol	S-chem
,	O
a	O
major	O
constituent	O
of	O
the	O
fresh	O
roots	O
of	O
R.	O
glutinosa	O
,	O
contributes	O
to	O
the	O
prevention	O
of	O
AGE	O
-	O
mediated	O
diabetic	O
complications	O
.	O

DNA	B-geneN
polymerase	I-geneN
minor	I-geneN
groove	E-geneN
interactions	O
modulate	O
mutagenic	O
bypass	O
of	O
a	O
templating	O
8	B-chem
-	I-chem
oxoguanine	E-chem
lesion	O
.	O

A	O
major	O
base	O
lesion	O
resulting	O
from	O
oxidative	O
stress	O
is	O
8	B-chem
-	I-chem
oxo	I-chem
-	I-chem
7,8	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxyguanosine	E-chem
(	O
8	B-chem
-	I-chem
oxoG	E-chem
)	O
that	O
has	O
ambiguous	O
coding	O
potential	O
.	O

Error	O
-	O
free	O
DNA	O
synthesis	O
involves	O
8	B-chem
-	I-chem
oxoG	E-chem
adopting	O
an	O
anti	O
-	O
conformation	O
to	O
base	O
pair	O
with	O
cytosine	S-chem
whereas	O
mutagenic	O
bypass	O
involves	O
8	B-chem
-	I-chem
oxoG	E-chem
adopting	O
a	O
syn	O
-	O
conformation	O
to	O
base	O
pair	O
with	O
adenine	S-chem
.	O

Left	O
unrepaired	O
the	O
syn	B-chem
-	I-chem
8	I-chem
-	I-chem
oxoG	E-chem
/	O
dAMP	S-chem
base	O
pair	O
results	O
in	O
a	O
G	O
-	O
C	O
to	O
T	O
-	O
A	O
transversion	O
.	O

During	O
base	O
excision	O
repair	O
of	O
this	O
mispair	O
,	O
DNA	B-geneY
polymerase	I-geneY
(	I-geneY
pol	I-geneY
)	I-geneY
β	E-geneY
is	O
confronted	O
with	O
gap	O
filling	O
opposite	O
8	B-chem
-	I-chem
oxoG	E-chem
.	O

To	O
determine	O
how	O
pol	B-geneY
β	E-geneY
discriminates	O
between	O
anti	B-chem
-	I-chem
and	I-chem
syn	I-chem
-	I-chem
8	I-chem
-	I-chem
oxoG	E-chem
,	O
we	O
introduced	O
a	O
point	O
mutation	O
(	O
R283K	S-geneN
)	O
to	O
alter	O
insertion	O
specificity	O
.	O

Kinetic	O
studies	O
demonstrate	O
that	O
this	O
substitution	O
results	O
in	O
an	O
increased	O
fidelity	O
opposite	O
8	B-chem
-	I-chem
oxoG	E-chem
.	O

Structural	O
studies	O
with	O
R283K	S-geneN
pol	B-geneY
β	E-geneY
show	O
that	O
the	O
binary	O
DNA	O
complex	O
has	O
8	B-chem
-	I-chem
oxoG	E-chem
in	O
equilibrium	O
between	O
anti	O
-	O
and	O
syn	O
-	O
forms	O
.	O

Ternary	O
complexes	O
with	O
incoming	O
dCTP	S-chem
resemble	O
the	O
wild	O
-	O
type	O
enzyme	O
,	O
with	O
templating	O
anti	B-chem
-	I-chem
8	I-chem
-	I-chem
oxoG	E-chem
base	O
pairing	O
with	O
incoming	O
cytosine	S-chem
.	O

In	O
contrast	O
to	O
wild	O
-	O
type	O
pol	B-geneY
β	E-geneY
,	O
the	O
ternary	O
complex	O
of	O
the	O
R283K	S-geneN
mutant	O
with	O
an	O
incoming	O
dATP	S-chem
-	O
analogue	O
and	O
templating	O
8	B-chem
-	I-chem
oxoG	E-chem
resembles	O
a	O
G	O
-	O
A	O
mismatched	O
structure	O
with	O
8	B-chem
-	I-chem
oxoG	E-chem
adopting	O
an	O
anti	O
-	O
conformation	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
incoming	O
nucleotide	S-chem
is	O
unable	O
to	O
induce	O
a	O
syn	B-chem
-	I-chem
8	I-chem
-	I-chem
oxoG	E-chem
conformation	O
without	O
minor	B-geneN
groove	E-geneN
DNA	B-geneN
polymerase	E-geneN
interactions	O
that	O
influence	O
templating	O
(	O
anti	O
-	O
/	O
syn	O
-	O
equilibrium	O
)	O
of	O
8	B-chem
-	I-chem
oxoG	E-chem
while	O
modulating	O
fidelity	O
.	O

5	B-chem-MU-1
-	I-chem-MU-1
Hydroxy	I-chem-MU-1
-	I-chem-MU-1
3,6,7,8,3'4	I-chem-MU-1
'	I-chem-MU-1
-	I-chem-MU-1
hexamethoxyflavone	E-chem-MU-1
inhibits	O
nitric	B-chem
oxide	E-chem
production	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
BV2	O
microglia	O
via	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
suppression	O
and	O
Nrf	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
-	O
dependent	O
heme	B-geneY-C3-2
oxygenase	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
induction	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
5	B-chem-C4-1
-	I-chem-C4-1
hydroxy	I-chem-C4-1
-	I-chem-C4-1
3,6,7,8,3'4	I-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
hexamethoxyflavone	E-chem-C4-1
(	O
5HHMF	S-chem-C4-1
)	O
from	O
Hizikia	O
fusiforme	O
considerably	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
NO	S-chem
production	O
by	O
suppressing	O
the	O
expression	O
of	O
inducible	B-geneY-C4-2
NO	I-geneY-C4-2
synthase	E-geneY-C4-2
(	O
iNOS	S-geneY-C4-2
)	O
in	O
BV2	O
microglia	O
.	O

In	O
addition	O
,	O
5HHMF	S-chem-C4-1
blocked	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
IκB	S-geneN-C4-2
,	O
resulting	O
in	O
suppression	O
of	O
the	O
nuclear	O
translocation	O
of	O
nuclear	B-geneN-C4-2
factor	I-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
(	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
)	O
subunits	O
,	O
namely	O
p65	S-geneY-C4-2
and	O
p50	S-geneY-C4-2
,	O
which	O
are	O
important	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
iNOS	S-geneY
expression	O
.	O

Pyrrolidine	B-chem-C4-1
dithiocarbamate	E-chem-C4-1
(	O
PDTC	S-chem-C4-1
)	O
,	O
a	O
specific	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
inhibitor	O
,	O
along	O
with	O
20S	B-geneN
proteasome	E-geneN
inhibitor	O
(	O
PSI	O
)	O
significantly	O
inhibited	O
LPS	O
-	O
induced	O
iNOS	S-geneY-C4-2
expression	O
,	O
which	O
indirectly	O
suggested	O
that	O
5HHMF	S-chem-C4-1
downregulated	O
iNOS	S-geneY-C4-2
expression	O
by	O
suppressing	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
activity	O
.	O

Thus	O
,	O
we	O
found	O
that	O
5HHMF	S-chem-C3-1
enhances	O
heme	B-geneY-C3-2
oxygenase	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
(	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
)	O
expression	O
via	O
nuclear	B-geneY-C3-2
factor	I-geneY-C3-2
-	I-geneY-C3-2
erythroid	I-geneY-C3-2
2	I-geneY-C3-2
-	I-geneY-C3-2
related	I-geneY-C3-2
factor	I-geneY-C3-2
2	E-geneY-C3-2
(	O
Nrf2	S-geneY-C3-2
)	O
activation	O
.	O

In	O
addition	O
,	O
cobalt	B-chem-C3-1
protoporphyrin	E-chem-C3-1
(	O
CoPP	S-chem-C3-1
)	O
,	O
a	O
specific	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
inducer	O
,	O
predominantly	O
suppressed	O
LPS	O
-	O
induced	O
NO	S-chem
production	O
.	O

In	O
contrast	O
,	O
zinc	B-chem-C4-1
protoporphyrin	E-chem-C4-1
(	O
ZnPP	S-chem-C4-1
)	O
,	O
a	O
specific	O
HO	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibitor	O
,	O
showed	O
a	O
partial	O
suppressive	O
effect	O
of	O
5HHMF	S-chem
on	O
LPS	O
-	O
induced	O
NO	S-chem
production	O
.	O

Further	O
,	O
5HHMF	S-chem-C3-1
increased	O
specific	O
DNA	O
-	O
binding	O
activity	O
of	O
Nrf2	S-geneY-C3-2
,	O
and	O
transient	O
knockdown	O
with	O
Nrf2	S-geneY-C3-2
siRNA	O
subsequently	O
reversed	O
5HHMF	S-chem-MU-1
-	O
induced	O
NO	S-chem-C4-1
inhibition	O
,	O
which	O
was	O
followed	O
by	O
suppression	O
of	O
HO	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
5HHMF	S-chem-MU-1
suppresses	O
NO	S-chem-C4-1
production	O
through	O
modulation	O
of	O
iNOS	S-geneY
,	O
consequently	O
suppressing	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
activity	O
and	O
induction	O
of	O
Nrf2	S-geneY-MU-2
-	O
dependent	O
HO	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
activity	O
.	O

Brain	O
but	O
not	O
spinal	O
NR2B	S-geneY-C6-2
receptor	O
is	O
responsible	O
for	O
the	O
anti	O
-	O
allodynic	O
effect	O
of	O
an	O
NR2B	S-geneY-C6-2
subunit	O
-	O
selective	O
antagonist	O
CP	B-chem-C6-1
-	I-chem-C6-1
101,606	E-chem-C6-1
in	O
a	O
rat	O
chronic	O
constriction	O
injury	O
model	O
.	O

In	O
order	O
to	O
examine	O
the	O
site	O
of	O
action	O
of	O
an	O
NR2B	S-geneY-C6-2
subtype	O
-	O
selective	O
NMDA	S-geneN-C6-2
antagonist	O
CP	B-chem-C6-1
-	I-chem-C6-1
101,606	E-chem-C6-1
,	O
we	O
investigated	O
its	O
analgesic	O
effect	O
in	O
a	O
rat	O
model	O
of	O
neuropathic	O
pain	O
at	O
various	O
routes	O
of	O
administration	O
.	O

Mechanical	O
allodynia	O
was	O
induced	O
by	O
chronic	O
constriction	O
injury	O
(	O
CCI	O
)	O
of	O
the	O
sciatic	O
nerve	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Subcutaneous	O
treatment	O
of	O
the	O
animals	O
with	O
CP	B-chem
-	I-chem
101,606	E-chem
at	O
10	O
mg	O
/	O
kg	O
significantly	O
inhibited	O
CCI	O
-	O
induced	O
mechanical	O
allodynia	O
.	O

Intracerebroventricular	O
injection	O
of	O
CP	B-chem
-	I-chem
101,606	E-chem
at	O
10	O
,	O
30	O
and	O
100	O
nmol	O
also	O
inhibited	O
the	O
mechanical	O
allodynia	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
statistically	O
significant	O
effect	O
being	O
achieved	O
at	O
the	O
highest	O
dose	O
tested	O
(	O
100	O
nmol	O
)	O
without	O
producing	O
any	O
behavioral	O
abnormalities	O
.	O

However	O
,	O
intrathecal	O
injection	O
of	O
CP	B-chem
-	I-chem
101,606	E-chem
at	O
a	O
dose	O
of	O
300	O
nmol	O
failed	O
to	O
inhibit	O
CCI	O
-	O
induced	O
allodynia	O
.	O

A	O
receptor	O
binding	O
assay	O
using	O
rat	O
forebrain	O
and	O
spinal	O
cord	O
membrane	O
preparations	O
demonstrated	O
that	O
[	B-chem
3H	I-chem
]	I-chem
CP	I-chem
-	I-chem
101,606	E-chem
bound	O
to	O
the	O
brain	O
NR2B	S-geneY
receptor	O
with	O
a	O
greater	O
extent	O
compared	O
to	O
the	O
spinal	O
cord	O
one	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
anti	O
-	O
allodynia	O
effect	O
of	O
CP	B-chem-C4-1
-	I-chem-C4-1
101,606	E-chem-C4-1
is	O
ascribable	O
to	O
blockade	O
of	O
NR2B	S-geneY-C4-2
receptors	O
at	O
the	O
brain	O
,	O
but	O
not	O
at	O
the	O
spinal	O
cord	O
.	O

In	O
contrast	O
,	O
intrathecal	O
injection	O
of	O
a	O
non	O
-	O
selective	O
NMDA	S-geneN-C6-2
antagonist	O
,	O
memantine	S-chem-C6-1
,	O
significantly	O
inhibited	O
CCI	O
-	O
induced	O
mechanical	O
allodynia	O
at	O
a	O
dose	O
of	O
300	O
nmol	O
,	O
indicating	O
the	O
difference	O
in	O
the	O
site	O
of	O
action	O
between	O
the	O
non	O
-	O
selective	O
NMDA	S-geneN
antagonist	O
and	O
the	O
NR2B	S-geneY
-	O
specific	O
NMDA	S-geneN
antagonist	O
.	O

Anti	O
-	O
Ulcerative	O
Colitis	O
Activity	O
of	O
Compounds	O
from	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
anti	O
-	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
activity	O
of	O
the	O
total	O
alcohol	S-chem
extracts	O
of	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

(	O
Euphorpiaceae	O
)	O
,	O
isolate	O
and	O
identify	O
the	O
active	O
compounds	O
that	O
could	O
be	O
responsible	O
for	O
the	O
activity	O
,	O
in	O
addition	O
to	O
determination	O
of	O
the	O
possible	O
mechanism	O
of	O
action	O
.	O

Six	O
compounds	O
were	O
isolated	O
and	O
identified	O
from	O
this	O
plant	O
:	O
three	O
phenolic	S-chem
compounds	O
(	O
kampferol	S-chem
,	O
kampferol	B-chem
-	I-chem
3	I-chem
-	I-chem
glucoside	E-chem
and	O
kampferol	B-chem
-	I-chem
3	I-chem
-	I-chem
galactoside	E-chem
)	O
in	O
addition	O
to	O
three	O
steroidal	O
compounds	O
(	O
1	B-chem
-	I-chem
ethoxypentacosane	E-chem
,	O
heptacosan	B-chem
-	I-chem
1	I-chem
-	I-chem
ol	E-chem
and	O
β	B-chem
-	I-chem
sitosterol	E-chem
)	O
.	O

Three	O
compounds	O
(	O
heptacosan	B-chem
-	I-chem
1	I-chem
-	I-chem
ol	E-chem
,	O
β	B-chem
-	I-chem
sitosterol	E-chem
and	O
kampferol	B-chem
-	I-chem
3	I-chem
-	I-chem
galactoside	E-chem
)	O
were	O
found	O
to	O
be	O
responsible	O
for	O
the	O
anti	O
-	O
UC	O
activity	O
of	O
E.	O
granuleta	O
extract	O
.	O

The	O
anti	O
-	O
UC	O
activity	O
of	O
these	O
compounds	O
may	O
be	O
explained	O
by	O
reducing	O
the	O
pro	O
-	O
inflammatory	O
cytokine	S-geneN
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
in	O
addition	O
to	O
reduction	O
of	O
colonic	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
contents	O
.	O

No	O
side	O
effects	O
were	O
reported	O
on	O
liver	O
and	O
kidney	O
functions	O
.	O

The	O
active	O
compounds	O
reduced	O
both	O
serum	O
TNF	B-geneY
-	I-geneY
α	E-geneY
and	O
mucosal	O
MDA	S-chem
levels	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Preclinical	O
properties	O
of	O
18F	B-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
:	O
a	O
PET	O
agent	O
for	O
Abeta	S-geneY
plaques	O
in	O
the	O
brain	O
.	O

UNLABELLED	O
:	O
beta	B-geneY
-	I-geneY
amyloid	E-geneY
plaques	O
(	O
Abeta	S-geneY
plaques	O
)	O
in	O
the	O
brain	O
,	O
containing	O
predominantly	O
fibrillary	O
Abeta	S-geneY
peptide	O
aggregates	O
,	O
represent	O
a	O
defining	O
pathologic	O
feature	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Imaging	O
agents	O
targeting	O
the	O
Abeta	S-geneY
plaques	O
in	O
the	O
living	O
human	O
brain	O
are	O
potentially	O
valuable	O
as	O
biomarkers	O
of	O
pathogenesis	O
processes	O
in	O
AD	O
.	O

(	B-chem
E	I-chem
)	I-chem
-	I-chem
4	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
6	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
(	I-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
fluoroethoxy	I-chem
)	I-chem
ethoxy	I-chem
)	I-chem
ethoxy	I-chem
)	I-chem
pyridin	I-chem
-	I-chem
3	I-chem
-	I-chem
yl	I-chem
)	I-chem
vinyl	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
methy	I-chem
l	I-chem
benzenamine	E-chem
(	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
)	O
is	O
such	O
as	O
an	O
agent	O
currently	O
in	O
phase	O
III	O
clinical	O
studies	O
for	O
PET	O
of	O
Abeta	S-geneY
plaques	O
in	O
the	O
brain	O
.	O

METHODS	O
:	O
In	O
vitro	O
binding	O
of	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
to	O
Abeta	S-geneY
plaques	O
in	O
the	O
postmortem	O
AD	O
brain	O
tissue	O
was	O
evaluated	O
by	O
in	O
vitro	O
binding	O
assay	O
and	O
autoradiography	O
.	O

In	O
vivo	O
biodistribution	O
of	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
in	O
mice	O
and	O
ex	O
vivo	O
autoradiography	O
of	O
AD	O
transgenic	O
mice	O
(	O
APPswe	S-geneY
/	O
PSEN1	S-geneY
)	O
with	O
Abeta	S-geneY
aggregates	O
in	O
the	O
brain	O
were	O
performed	O
.	O

Small	O
-	O
animal	O
PET	O
of	O
a	O
monkey	O
brain	O
after	O
an	O
intravenous	O
injection	O
of	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
was	O
evaluated	O
.	O

RESULTS	O
:	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
displayed	O
a	O
high	O
binding	O
affinity	O
and	O
specificity	O
to	O
Abeta	S-geneY
plaques	O
(	O
K	O
(	O
d	O
)	O
,	O
3.72	O
+	O
/	O
-	O
0.30	O
nM	O
)	O
.	O

In	O
vitro	O
autoradiography	O
of	O
postmortem	O
human	O
brain	O
sections	O
showed	O
substantial	O
plaque	O
labeling	O
in	O
AD	O
brains	O
and	O
not	O
in	O
the	O
control	O
brains	O
.	O

Initial	O
high	O
brain	O
uptake	O
and	O
rapid	O
washout	O
from	O
the	O
brain	O
of	O
healthy	O
mice	O
and	O
monkey	O
were	O
observed	O
.	O

Metabolites	O
produced	O
in	O
the	O
blood	O
of	O
healthy	O
mice	O
after	O
an	O
intravenous	O
injection	O
were	O
identified	O
.	O

(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
displayed	O
excellent	O
binding	O
affinity	O
to	O
Abeta	S-geneY
plaques	O
in	O
the	O
AD	O
brain	O
by	O
ex	O
vivo	O
autoradiography	O
in	O
transgenic	O
AD	O
model	O
mice	O
.	O

The	O
results	O
lend	O
support	O
that	O
(	B-chem
18	I-chem
)	I-chem
F	I-chem
-	I-chem
AV	I-chem
-	I-chem
45	E-chem
may	O
be	O
a	O
useful	O
PET	O
agent	O
for	O
detecting	O
Abeta	S-geneY
plaques	O
in	O
the	O
living	O
human	O
brain	O
.	O

Characterization	O
of	O
the	O
regulation	O
of	O
renal	B-geneN
Na	I-geneN
+	I-geneN
/	I-geneN
H	I-geneN
+	I-geneN
exchanger	E-geneN
NHE3	S-geneY
by	O
insulin	S-geneY
.	O

Insulin	B-geneY
receptors	E-geneY
are	O
widely	O
distributed	O
in	O
the	O
kidney	O
and	O
affect	O
multiple	O
aspects	O
of	O
renal	O
function	O
.	O

In	O
the	O
proximal	O
tubule	O
,	O
insulin	S-geneY
regulates	O
volume	O
and	O
acid	O
-	O
base	O
regulation	O
through	O
stimulation	O
of	O
the	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
/	I-geneN
H	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
exchanger	E-geneN
NHE3	S-geneY
.	O

This	O
paper	O
characterizes	O
the	O
signaling	O
pathway	O
by	O
which	O
insulin	S-geneY
stimulates	O
NHE3	S-geneY
in	O
a	O
cell	O
culture	O
model	O
[	O
opossum	O
kidney	O
(	O
OK	O
)	O
cell	O
]	O
.	O

Insulin	S-geneY
has	O
two	O
distinct	O
phases	O
of	O
action	O
on	O
NHE3	S-geneY
.	O

Chronic	O
insulin	S-geneY
(	O
24	O
h	O
)	O
activates	O
NHE3	S-geneY
through	O
the	O
classic	O
phosphatidylinositol	B-geneN-C4-2
3	I-geneN-C4-2
-	I-geneN-C4-2
kinase	E-geneN-C4-2
-	O
serum	B-geneN
-	I-geneN
and	I-geneN
glucocorticoid	I-geneN
-	I-geneN
dependent	I-geneN
kinase	I-geneN
1	E-geneN
(	O
PI3K	S-geneN-C4-2
-	O
SGK1	S-geneN
)	O
pathway	O
as	O
insulin	S-geneY
stimulates	O
SGK1	S-geneN
phosphorylation	O
and	O
the	O
insulin	S-geneY
effect	O
can	O
be	O
blocked	O
by	O
the	O
PI3K	S-geneN-C4-2
inhibitor	O
wortmannin	S-chem-C4-1
or	O
a	O
dominant	O
-	O
negative	O
SGK1	S-geneN
.	O

We	O
showed	O
that	O
SGK1	S-geneN
transcript	O
and	O
protein	O
are	O
expressed	O
in	O
rat	O
proximal	O
tubule	O
and	O
OK	O
cells	O
.	O

We	O
previously	O
showed	O
that	O
glucocorticoids	O
augment	O
the	O
effect	O
of	O
insulin	S-geneY
on	O
NHE3	S-geneY
(	O
Klisic	O
J	O
,	O
Hu	O
MC	O
,	O
Nief	O
V	O
,	O
Reyes	O
L	O
,	O
Fuster	O
D	O
,	O
Moe	O
OW	O
,	O
Ambuhl	O
PM	O
.	O

Am	O
J	O
Physiol	O
Renal	O
Physiol	O
283	O
:	O
F532	O
-	O
F539	O
,	O
2002	O
)	O
.	O

Part	O
of	O
this	O
can	O
be	O
mediated	O
via	O
induction	O
of	O
SGK1	S-geneY
by	O
glucocorticoids	O
,	O
and	O
indeed	O
the	O
insulin	S-geneY
effect	O
on	O
NHE3	S-geneY
can	O
also	O
be	O
amplified	O
by	O
overexpression	O
of	O
SGK1	S-geneY
.	O

We	O
next	O
addressed	O
the	O
acute	O
effect	O
of	O
insulin	S-geneY
(	O
1	O
-	O
2	O
h	O
)	O
on	O
NHE3	S-geneY
by	O
systematically	O
examining	O
the	O
candidate	O
signaling	O
cascades	O
and	O
activation	O
mechanisms	O
of	O
NHE3	S-geneY
.	O

We	O
ruled	O
out	O
the	O
PI3K	S-geneN
-	O
SGK1	S-geneN
-	O
Akt	S-geneN
and	O
TC10	S-geneN
pathways	O
,	O
increased	O
surface	O
NHE3	S-geneY
,	O
NHE3	S-geneY
phosphorylation	O
,	O
NHE3	S-geneY
association	O
with	O
calcineurin	B-geneN
homologous	I-geneN
protein	I-geneN
1	E-geneN
or	O
megalin	S-geneY
as	O
mechanisms	O
of	O
acute	O
activation	O
of	O
NHE3	S-geneY
by	O
insulin	S-geneY
.	O

In	O
summary	O
,	O
insulin	S-geneY
stimulates	O
NHE3	S-geneY
acutely	O
via	O
yet	O
undefined	O
pathways	O
and	O
mechanisms	O
.	O

The	O
chronic	O
effect	O
of	O
insulin	S-geneY
is	O
mediated	O
by	O
the	O
classic	O
PI3K	S-geneN
-	O
SGK1	S-geneN
route	O
.	O

Novel	O
non	O
-	O
canonical	O
TGF	B-geneN
-	I-geneN
β	E-geneN
signaling	O
networks	O
:	O
emerging	O
roles	O
in	O
airway	O
smooth	O
muscle	O
phenotype	O
and	O
function	O
.	O

The	O
airway	O
smooth	O
muscle	O
(	O
ASM	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

ASM	O
cells	O
express	O
a	O
wide	O
range	O
of	O
receptors	O
involved	O
in	O
contraction	O
,	O
growth	O
,	O
matrix	O
protein	O
production	O
and	O
the	O
secretion	O
of	O
cytokines	S-geneN
and	O
chemokines	S-geneN
.	O

Transforming	B-geneN
growth	I-geneN
factor	I-geneN
beta	E-geneN
(	O
TGF	B-geneN
-	I-geneN
β	E-geneN
)	O
is	O
one	O
of	O
the	O
major	O
players	O
in	O
determining	O
the	O
structural	O
and	O
functional	O
abnormalities	O
of	O
the	O
ASM	O
in	O
asthma	O
and	O
COPD	O
.	O

It	O
is	O
increasingly	O
evident	O
that	O
TGF	B-geneN
-	I-geneN
β	E-geneN
functions	O
as	O
a	O
master	O
switch	O
,	O
controlling	O
a	O
network	O
of	O
intracellular	O
and	O
autocrine	O
signaling	O
loops	O
that	O
effect	O
ASM	O
phenotype	O
and	O
function	O
.	O

In	O
this	O
review	O
,	O
the	O
various	O
elements	O
that	O
participate	O
in	O
non	O
-	O
canonical	O
TGF	B-geneN
-	I-geneN
β	E-geneN
signaling	O
,	O
including	O
MAPK	S-geneN
,	O
PI3K	S-geneN
,	O
WNT	S-geneN
/	O
β	B-geneY
-	I-geneY
catenin	E-geneY
,	O
and	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
,	O
are	O
discussed	O
,	O
focusing	O
on	O
their	O
effect	O
on	O
ASM	O
phenotype	O
and	O
function	O
.	O

In	O
addition	O
,	O
new	O
aspects	O
of	O
ASM	O
biology	O
and	O
their	O
possible	O
association	O
with	O
non	O
-	O
canonical	O
TGF	B-geneN
-	I-geneN
β	E-geneN
signaling	O
will	O
be	O
discussed	O
.	O

Effect	O
of	O
bisphenol	B-chem
-	I-chem
A	E-chem
on	O
insulin	S-geneN
signal	O
transduction	O
and	O
glucose	S-chem
oxidation	O
in	O
skeletal	O
muscle	O
of	O
adult	O
male	O
albino	O
rat	O
.	O

The	O
estrogenic	O
monomer	O
bisphenol	B-chem
-	I-chem
A	E-chem
(	O
BPA	S-chem
)	O
is	O
an	O
endocrine	O
-	O
disrupting	O
chemical	O
used	O
in	O
the	O
production	O
of	O
epoxy	S-chem
resins	O
,	O
plastic	O
food	O
and	O
beverage	O
containers	O
,	O
leading	O
to	O
ubiquitous	O
human	O
exposure	O
.	O

Environmentally	O
relevant	O
doses	O
of	O
BPA	S-chem
have	O
profound	O
effects	O
on	O
mice	O
endocrine	O
pancreas	O
.	O

It	O
increases	O
pancreatic	O
insulin	S-geneN
content	O
and	O
favors	O
postprandial	O
hyperinsulinemia	O
and	O
insulin	S-geneN
resistance	O
in	O
male	O
mice	O
.	O

Skeletal	O
muscle	O
plays	O
a	O
crucial	O
role	O
in	O
maintaining	O
systemic	O
glucose	S-chem
metabolism	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
effects	O
of	O
BPA	S-chem
on	O
insulin	S-geneN
-	O
signaling	O
molecules	O
and	O
glucose	S-chem
oxidation	O
in	O
skeletal	O
muscle	O
of	O
male	O
rat	O
.	O

Adult	O
male	O
Wistar	O
albino	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
.	O

Group	O
I	O
:	O
control	O
(	O
vehicle	O
treated	O
)	O
and	O
groups	O
II	O
and	O
III	O
were	O
administered	O
with	O
BPA	S-chem
orally	O
(	O
20	O
and	O
200	O
mg	O
/	O
kg	O
bw	O
/	O
day	O
,	O
respectively	O
)	O
.	O

Although	O
there	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
insulin	B-geneY
receptor	E-geneY
(	O
IR	S-geneY
)	O
,	O
Akt	S-geneN
(	O
protein	B-geneN
kinase	I-geneN
B	E-geneN
)	O
and	O
glucose	B-geneY
transporter	I-geneY
-	I-geneY
4	E-geneY
(	O
GLUT4	S-geneY
)	O
messenger	O
RNA	O
,	O
BPA	S-chem-C4-1
significantly	O
decreased	O
the	O
IR	S-geneY-C4-2
,	O
Akt	S-geneN-C4-2
and	O
GLUT4	S-geneY-C4-2
protein	O
levels	O
(	O
both	O
plasma	O
membrane	O
and	O
cytosolic	O
fraction	O
)	O
of	O
the	O
gastrocnemius	O
muscle	O
.	O

There	O
was	O
an	O
increase	O
in	O
serum	O
insulin	S-geneN
and	O
decrease	O
in	O
serum	O
testosterone	S-chem
levels	O
but	O
fasting	O
blood	O
glucose	S-chem
level	O
remained	O
unaltered	O
.	O

In	O
conclusion	O
,	O
BPA	S-chem-C4-1
has	O
adverse	O
effects	O
on	O
phosphorylation	O
of	O
Akt	S-geneN-C4-2
,	O
GLUT4	S-geneY-C4-2
translocation	O
and	O
(	B-chem
14	I-chem
)	I-chem
C	I-chem
-	I-chem
glucose	E-chem
oxidation	O
.	O

Rufinamide	S-chem
attenuates	O
mechanical	O
allodynia	O
in	O
a	O
model	O
of	O
neuropathic	O
pain	O
in	O
the	O
mouse	O
and	O
stabilizes	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
channel	E-geneN
inactivated	O
state	O
.	O

BACKGROUND	O
:	O
Voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
channels	E-geneN
dysregulation	O
is	O
important	O
for	O
hyperexcitability	O
leading	O
to	O
pain	O
persistence	O
.	O

Sodium	B-geneN
channel	E-geneN
blockers	O
currently	O
used	O
to	O
treat	O
neuropathic	O
pain	O
are	O
poorly	O
tolerated	O
.	O

Getting	O
new	O
molecules	O
to	O
clinical	O
use	O
is	O
laborious	O
.	O

We	O
here	O
propose	O
a	O
drug	O
already	O
marketed	O
as	O
anticonvulsant	O
,	O
rufinamide	S-chem
.	O

METHODS	O
:	O
We	O
compared	O
the	O
behavioral	O
effect	O
of	O
rufinamide	S-chem
to	O
amitriptyline	S-chem
using	O
the	O
Spared	O
Nerve	O
Injury	O
neuropathic	O
pain	O
model	O
in	O
mice	O
.	O

We	O
compared	O
the	O
effect	O
of	O
rufinamide	S-chem
on	O
sodium	S-chem
currents	O
using	O
in	O
vitro	O
patch	O
clamp	O
in	O
cells	O
expressing	O
the	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
channel	E-geneN
Nav1.7	S-geneY
isoform	O
and	O
on	O
dissociated	O
dorsal	O
root	O
ganglion	O
neurons	O
to	O
amitriptyline	S-chem
and	O
mexiletine	S-chem
.	O

RESULTS	O
:	O
In	O
naive	O
mice	O
,	O
amitriptyline	S-chem
(	O
20	O
mg	O
/	O
kg	O
)	O
increased	O
withdrawal	O
threshold	O
to	O
mechanical	O
stimulation	O
from	O
1.3	O
(	O
0.6	O
-	O
1.9	O
)	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
)	O
to	O
2.3	O
g	O
(	O
2.2	O
-	O
2.5	O
)	O
and	O
latency	O
of	O
withdrawal	O
to	O
heat	O
stimulation	O
from	O
13.1	O
(	O
10.4	O
-	O
15.5	O
)	O
to	O
30.0	O
s	O
(	O
21.8	O
-	O
31.9	O
)	O
,	O
whereas	O
rufinamide	S-chem
had	O
no	O
effect	O
.	O

Rufinamide	S-chem
and	O
amitriptyline	S-chem
alleviated	O
injury	O
-	O
induced	O
mechanical	O
allodynia	O
for	O
4	O
h	O
(	O
maximal	O
effect	O
:	O
0.10	O
+	O
/	O
-	O
0.03	O
g	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
1.99	O
+	O
/	O
-	O
0.26	O
g	O
for	O
rufinamide	S-chem
and	O
0.25	O
+	O
/	O
-	O
0.22	O
g	O
to	O
1.92	O
+	O
/	O
-	O
0.85	O
g	O
for	O
amitriptyline	S-chem
)	O
.	O

All	O
drugs	O
reduced	O
peak	O
current	O
and	O
stabilized	O
the	O
inactivated	O
state	O
of	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
channel	E-geneN
Nav1.7	S-geneY
,	O
with	O
similar	O
effects	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

CONCLUSIONS	O
:	O
At	O
doses	O
alleviating	O
neuropathic	O
pain	O
,	O
amitriptyline	S-chem
showed	O
alteration	O
of	O
behavioral	O
response	O
possibly	O
related	O
to	O
either	O
alteration	O
of	O
basal	O
pain	O
sensitivity	O
or	O
sedative	O
effect	O
or	O
both	O
.	O

Side	O
-	O
effects	O
and	O
drug	O
tolerance	O
/	O
compliance	O
are	O
major	O
problems	O
with	O
drugs	O
such	O
as	O
amitriptyline	S-chem
.	O

Rufinamide	S-chem
seems	O
to	O
have	O
a	O
better	O
tolerability	O
profile	O
and	O
could	O
be	O
a	O
new	O
alternative	O
to	O
explore	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O

Enzyme	O
-	O
responsive	O
surface	O
erosion	O
of	O
poly	B-chem
(	I-chem
ethylene	I-chem
carbonate	I-chem
)	E-chem
for	O
controlled	O
drug	O
release	O
.	O

Cholesterol	B-geneY-C9-2
esterase	E-geneY-C9-2
(	O
CE	S-geneY-C9-2
)	O
induced	O
surface	O
erosion	O
of	O
poly	B-chem-C9-1
(	I-chem-C9-1
ethylene	I-chem-C9-1
carbonate	I-chem-C9-1
)	E-chem-C9-1
(	O
PEC	S-chem-C9-1
)	O
and	O
drug	O
release	O
from	O
PEC	S-chem
under	O
mild	O
physiological	O
environment	O
was	O
investigated	O
.	O

The	O
degradation	O
process	O
was	O
monitored	O
by	O
changes	O
of	O
mass	O
and	O
molecular	O
weight	O
(	O
MW	O
)	O
and	O
surface	O
morphology	O
of	O
polymer	O
films	O
.	O

During	O
the	O
whole	O
period	O
of	O
degradation	O
,	O
MW	O
of	O
PEC	S-chem
was	O
unchanged	O
.	O

Water	O
uptake	O
of	O
the	O
polymer	O
was	O
only	O
2.8	O
and	O
0.2	O
%	O
for	O
PEC	S-chem
with	O
the	O
MW	O
of	O
200	O
kDa	O
(	O
PEC200	S-chem
)	O
and	O
PEC	S-chem
with	O
the	O
MW	O
of	O
41	O
kDa	O
(	O
PEC41	S-chem
)	O
,	O
respectively	O
.	O

Degradation	O
of	O
less	O
hydrophilic	O
PEC41	S-chem
with	O
higher	O
density	O
was	O
slower	O
than	O
that	O
of	O
PEC200	S-chem
.	O

By	O
this	O
mechanism	O
,	O
CE	S-geneY
-	O
responsive	O
drug	O
in	O
vitro	O
release	O
from	O
PEC	S-chem
in	O
situ	O
forming	O
depots	O
(	O
ISFD	O
)	O
was	O
conducted	O
successfully	O
.	O

As	O
expected	O
,	O
less	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
BSA	S-geneY
)	O
was	O
released	O
from	O
PEC41	S-chem
compared	O
with	O
that	O
of	O
PEC200	S-chem
in	O
the	O
same	O
time	O
period	O
.	O

In	O
conclusion	O
,	O
this	O
work	O
enabled	O
the	O
in	O
vitro	O
drug	O
release	O
evaluation	O
of	O
existing	O
PEC	S-chem
devices	O
and	O
implied	O
a	O
new	O
candidate	O
for	O
the	O
development	O
of	O
enzyme	O
-	O
responsive	O
systems	O
.	O

The	O
exposure	O
of	O
highly	O
toxic	O
aconitine	S-chem
does	O
not	O
significantly	O
impact	O
the	O
activity	O
and	O
expression	O
of	O
cytochrome	B-geneN
P450	I-geneN
3A	E-geneN
in	O
rats	O
determined	O
by	O
a	O
novel	O
ultra	O
performance	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometric	O
method	O
of	O
a	O
specific	O
probe	O
buspirone	S-chem
.	O

Aconitum	O
species	O
are	O
widely	O
used	O
to	O
treat	O
rheumatism	O
,	O
cardiovascular	O
diseases	O
,	O
and	O
tumors	O
in	O
China	O
and	O
other	O
Asian	O
countries	O
.	O

The	O
herbs	O
are	O
always	O
used	O
with	O
drugs	O
such	O
as	O
paclitaxel	S-chem
.	O

Aconitine	S-chem
(	O
AC	O
)	O
is	O
one	O
of	O
the	O
main	O
bioactive	O
/	O
high	O
-	O
toxic	O
alkaloids	O
of	O
Aconitum	O
roots	O
.	O

AC	O
is	O
metabolized	O
by	O
cytochrome	B-geneN
P450	I-geneN
(	I-geneN
CYP	I-geneN
)	I-geneN
3A	E-geneN
.	O

However	O
,	O
whether	O
AC	O
inhibits	O
/	O
induces	O
CYP3A	S-geneN
,	O
which	O
causes	O
drug	O
-	O
drug	O
interaction	O
(	O
DDI	O
)	O
is	O
unclear	O
.	O

Our	O
study	O
aims	O
to	O
explore	O
the	O
potent	O
effects	O
of	O
AC	O
,	O
as	O
a	O
marker	O
component	O
of	O
Aconitum	O
,	O
on	O
CYP3A	S-geneN
using	O
the	O
probe	O
buspirone	S-chem
in	O
rats	O
.	O

The	O
effects	O
of	O
oral	O
AC	O
on	O
pharmacokinetics	O
of	O
buspirone	S-chem
were	O
evaluated	O
.	O

CYP3A	S-geneN
activity	O
and	O
protein	O
levels	O
in	O
rat	O
liver	O
microsomes	O
pretreated	O
with	O
oral	O
AC	O
were	O
also	O
measured	O
using	O
in	O
vitro	O
buspirone	S-chem
metabolism	O
and	O
Western	O
blot	O
.	O

Buspirone	S-chem
and	O
its	O
major	O
metabolites	O
1	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
pyrimidinyl	I-chem
)	I-chem
piperazine	E-chem
and	O
6	B-chem
'	I-chem
-	I-chem
hydroxybuspirone	E-chem
were	O
determined	O
using	O
a	O
newly	O
validated	O
UPLC	O
-	O
MS	O
/	O
MS	O
method	O
.	O

Single	O
dose	O
and	O
7	O
-	O
day	O
AC	O
administration	O
at	O
0.125mg	O
/	O
kg	O
had	O
no	O
effect	O
on	O
CYP3A	S-geneN
activity	O
since	O
no	O
change	O
in	O
the	O
formation	O
of	O
1	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
pyrimidinyl	I-chem
)	I-chem
piperazine	E-chem
and	O
6	B-chem
'	I-chem
-	I-chem
hydroxybuspirone	E-chem
.	O

CYP3A	S-geneN
activity	O
and	O
protein	O
levels	O
in	O
liver	O
microsomes	O
were	O
also	O
not	O
affected	O
by	O
7	O
-	O
day	O
AC	O
pretreatment	O
at	O
0.125mg	O
/	O
kg	O
.	O

Therefore	O
,	O
AC	O
neither	O
inhibits	O
nor	O
induces	O
CYP3A	S-geneN
in	O
rats	O
,	O
indicating	O
AC	O
does	O
not	O
cause	O
CYP3A	S-geneN
-	O
related	O
DDI	O
in	O
the	O
liver	O
.	O

Beta	B-geneY
1	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
polymorphisms	O
and	O
antihypertensive	O
response	O
to	O
metoprolol	S-chem
.	O

OBJECTIVES	O
:	O
Marked	O
interpatient	O
variability	O
exists	O
in	O
blood	O
pressure	O
response	O
to	O
beta	O
-	O
blocker	O
monotherapy	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
2	O
common	O
polymorphisms	O
in	O
the	O
gene	O
for	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
are	O
associated	O
with	O
antihypertensive	O
response	O
to	O
metoprolol	S-chem
in	O
patients	O
with	O
uncomplicated	O
hypertension	O
.	O

METHODS	O
:	O
Forty	O
hypertensive	O
men	O
and	O
women	O
aged	O
35	O
to	O
65	O
years	O
were	O
studied	O
.	O

Baseline	O
studies	O
included	O
24	O
-	O
hour	O
ambulatory	O
blood	O
pressure	O
monitoring	O
.	O

Patients	O
took	O
50	O
mg	O
metoprolol	S-chem
twice	O
daily	O
with	O
weekly	O
titration	O
to	O
response	O
or	O
200	O
mg	O
twice	O
daily	O
.	O

After	O
a	O
minimum	O
of	O
4	O
weeks	O
at	O
stable	O
dose	O
,	O
treatment	O
phase	O
24	O
-	O
hour	O
ambulatory	O
blood	O
pressure	O
monitoring	O
was	O
repeated	O
.	O

The	O
codon	O
49	O
and	O
389	O
genotypes	O
for	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Multilinear	O
regression	O
was	O
performed	O
to	O
determine	O
the	O
impact	O
of	O
genotype	O
and	O
other	O
variables	O
on	O
blood	O
pressure	O
response	O
to	O
metoprolol	S-chem
.	O

RESULTS	O
:	O
Patients	O
homozygous	O
for	O
Arg	S-chem
at	O
codon	O
389	O
had	O
a	O
nearly	O
3	O
-	O
fold	O
greater	O
reduction	O
in	O
daytime	O
diastolic	O
blood	O
pressure	O
(	O
-	O
13.3	O
%	O
+	O
/	O
-	O
8.4	O
%	O
versus	O
-	O
4.5	O
%	O
+	O
/	O
-	O
8.2	O
%	O
,	O
P	O
=	O
.0018	O
)	O
compared	O
with	O
those	O
who	O
carried	O
the	O
variant	O
allele	O
.	O

The	O
haplotype	O
pair	O
(	O
diplotype	O
)	O
for	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
was	O
also	O
a	O
significant	O
predictor	O
of	O
response	O
,	O
with	O
patients	O
having	O
the	O
Ser49Arg389	S-geneN
/	O
Ser49Arg389	S-geneN
diplotype	O
demonstrating	O
a	O
decline	O
in	O
blood	O
pressure	O
of	O
14.7	O
mm	O
Hg	O
versus	O
0.5	O
mm	O
Hg	O
in	O
patients	O
with	O
the	O
Gly49Arg389	S-geneN
/	O
Ser49Gly389	S-geneN
diplotype	O
.	O

In	O
multiregression	O
analysis	O
,	O
baseline	O
daytime	O
diastolic	O
blood	O
pressure	O
,	O
codon	O
389	O
genotype	O
,	O
and	O
codon	O
49	O
genotype	O
were	O
significant	O
predictors	O
of	O
blood	O
pressure	O
after	O
treatment	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
polymorphisms	O
are	O
important	O
determinants	O
of	O
antihypertensive	O
response	O
to	O
metoprolol	S-chem
.	O

In	O
the	O
future	O
,	O
codon	O
49	O
and	O
389	O
genotypes	O
or	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
haplotypes	O
might	O
be	O
used	O
to	O
predict	O
the	O
diastolic	O
blood	O
pressure	O
response	O
to	O
metoprolol	S-chem
in	O
patients	O
with	O
hypertension	O
.	O

Predictive	O
modeling	O
of	O
insulin	S-geneY
release	O
profile	O
from	O
cross	O
-	O
linked	O
chitosan	O
microspheres	O
.	O

Insulin	S-geneY
-	O
loaded	O
microspheres	O
composed	O
of	O
chitosan	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
,	O
and	O
loading	O
120	O
IU	O
insulin	S-geneY
were	O
produced	O
by	O
emulsion	O
cross	O
-	O
linking	O
method	O
.	O

Cross	O
-	O
linking	O
time	O
was	O
5	O
h	O
and	O
glutaraldehyde	S-chem
3.5	O
%	O
(	O
v	O
/	O
v	O
)	O
was	O
used	O
as	O
cross	O
-	O
linker	O
.	O

Swelling	O
ratio	O
studies	O
were	O
evaluated	O
to	O
predict	O
release	O
of	O
insulin	S-geneY
from	O
chitosan	O
microspheres	O
.	O

Bacitracin	S-chem
and	O
sodium	B-chem
taurocholate	E-chem
were	O
incorporated	O
in	O
the	O
formulations	O
as	O
proteolytic	O
enzyme	O
inhibitor	O
and	O
absorption	O
enhancer	O
,	O
respectively	O
.	O

In	O
vitro	O
insulin	S-geneY
release	O
studies	O
were	O
performed	O
in	O
phosphate	S-chem
buffer	O
pH	O
7.4	O
and	O
also	O
in	O
HCl	S-chem
pH	O
2	O
with	O
and	O
without	O
trypsin	S-geneN
.	O

Activity	O
of	O
bacitracin	S-chem
was	O
also	O
evaluated	O
.	O

In	O
vitro	O
release	O
showed	O
a	O
controlled	O
profile	O
up	O
to	O
12	O
h	O
and	O
the	O
formulation	O
containing	O
0.15	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
bacitracin	S-chem
revealed	O
a	O
maximum	O
biological	O
activity	O
of	O
about	O
49.1	O
±	O
4.1	O
%	O
.	O

Mathematical	O
modeling	O
using	O
Higuchi	O
and	O
Korsmeyer	O
-	O
Peppas	O
suggested	O
a	O
non	O
-	O
Fickian	O
diffusion	O
as	O
the	O
mechanism	O
of	O
insulin	S-geneY
release	O
.	O

Insulin	S-geneY
-	O
loaded	O
chitosan	O
microspheres	O
for	O
oral	O
delivery	O
showed	O
to	O
be	O
an	O
innovative	O
and	O
reliable	O
delivery	O
system	O
to	O
overcome	O
conventional	O
insulin	S-geneY
therapy	O
.	O

Common	O
and	O
specific	O
determinants	O
for	O
fibroblast	B-geneN
growth	I-geneN
factors	E-geneN
in	O
the	O
ectodomain	O
of	O
the	O
receptor	B-geneN
kinase	E-geneN
complex	O
.	O

The	O
assembly	O
and	O
activation	O
of	O
oligomeric	O
complexes	O
of	O
FGF	S-geneN
,	O
the	O
transmembrane	B-geneN
receptor	I-geneN
kinase	E-geneN
(	O
FGFR	S-geneN
)	O
,	O
and	O
heparan	O
sulfate	S-chem
transmit	O
intracellular	O
signals	O
regulating	O
growth	O
and	O
function	O
of	O
cells	O
.	O

An	O
understanding	O
of	O
the	O
structural	O
relationships	O
between	O
the	O
three	O
subunits	O
and	O
their	O
redundancy	O
and	O
specificity	O
is	O
essential	O
for	O
understanding	O
the	O
ubiquitous	O
FGF	S-geneN
signaling	O
system	O
in	O
health	O
and	O
disease	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
a	O
primary	O
heparin	O
or	O
heparan	O
sulfate	S-chem
binding	O
site	O
resides	O
in	O
a	O
distinct	O
sequence	O
in	O
immunoglobulin	B-geneN
(	I-geneN
Ig	I-geneN
)	I-geneN
-	I-geneN
like	I-geneN
module	I-geneN
II	E-geneN
of	O
the	O
three	O
modules	O
of	O
FGFR	S-geneN
.	O

Here	O
we	O
report	O
that	O
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
,	O
isolated	O
Ig	B-geneN
module	I-geneN
II	E-geneN
of	O
FGFR1	S-geneY
supports	O
the	O
binding	O
of	O
FGF	B-geneY
-	I-geneY
1	E-geneY
,	O
FGF	B-geneY
-	I-geneY
2	E-geneY
,	O
and	O
FGF	B-geneY
-	I-geneY
7	E-geneY
in	O
respective	O
order	O
of	O
affinity	O
.	O

None	O
of	O
the	O
three	O
FGFs	S-geneN
detectably	O
bind	O
Ig	B-geneN
module	I-geneN
I	I-geneN
or	I-geneN
the	I-geneN
IIIb	I-geneN
and	I-geneN
IIIc	E-geneN
splice	O
variants	O
of	O
Ig	B-geneN
module	I-geneN
III	E-geneN
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
.	O

Ig	B-geneN
module	I-geneN
I	E-geneN
and	O
the	O
C	S-chem
-	O
terminus	O
of	O
Ig	B-geneN
module	I-geneN
III	E-geneN
are	O
dispensable	O
for	O
high	O
-	O
affinity	O
binding	O
of	O
FGF	B-geneY
-	I-geneY
1	E-geneY
,	O
FGF	B-geneY
-	I-geneY
2	E-geneY
,	O
and	O
FGF	B-geneY
-	I-geneY
7	E-geneY
.	O

Alterations	O
in	O
highly	O
conserved	O
Ig	B-geneN
module	I-geneN
II	E-geneN
in	O
the	O
heparin	O
binding	O
domain	O
and	O
substitution	O
of	O
individual	O
sequence	O
domains	O
spanning	O
the	O
entire	O
sequence	O
of	O
Ig	B-geneN
module	I-geneN
II	E-geneN
with	O
those	O
from	O
Ig	B-geneN
module	I-geneN
I	E-geneN
obliterated	O
FGF	S-geneN
binding	O
.	O

Addition	O
of	O
a	O
specific	O
number	O
of	O
FGFR	S-geneN
sequences	O
to	O
the	O
C	S-chem
-	O
terminus	O
of	O
Ig	B-geneN
module	I-geneN
II	E-geneN
resulted	O
in	O
a	O
gain	O
in	O
affinity	O
for	O
FGF	B-geneY
-	I-geneY
7	E-geneY
.	O

Several	O
site	O
-	O
specific	O
alterations	O
in	O
the	O
C	S-chem
-	O
terminus	O
of	O
full	O
-	O
length	O
FGFR1IIIc	S-geneN
,	O
an	O
isoform	O
that	O
otherwise	O
absolutely	O
rejects	O
FGF	B-geneY
-	I-geneY
7	E-geneY
,	O
resulted	O
in	O
gain	O
of	O
FGF	B-geneY
-	I-geneY
7	E-geneY
binding	O
.	O

These	O
results	O
suggest	O
that	O
a	O
complex	O
of	O
Ig	B-geneN
module	I-geneN
II	E-geneN
and	O
heparan	O
sulfate	S-chem
is	O
the	O
base	O
common	O
active	O
core	O
of	O
the	O
FGFR	B-geneN
ectodomain	E-geneN
and	O
that	O
flanking	O
structural	O
domains	O
modify	O
FGF	S-geneN
affinity	O
and	O
determine	O
specificity	O
.	O

Optimization	O
of	O
taxane	S-chem
binding	O
to	O
microtubules	S-geneN
:	O
binding	O
affinity	O
dissection	O
and	O
incremental	O
construction	O
of	O
a	O
high	O
-	O
affinity	O
analog	O
of	O
paclitaxel	S-chem
.	O

The	O
microtubule	S-geneN
binding	O
affinities	O
of	O
a	O
series	O
of	O
synthetic	O
taxanes	S-chem
have	O
been	O
measured	O
with	O
the	O
aims	O
of	O
dissecting	O
individual	O
group	O
contributions	O
and	O
obtaining	O
a	O
rationale	O
for	O
the	O
design	O
of	O
novel	O
compounds	O
with	O
the	O
ability	O
to	O
overcome	O
drug	O
resistance	O
.	O

As	O
previously	O
observed	O
for	O
epothilones	S-chem
,	O
the	O
positive	O
and	O
negative	O
contributions	O
of	O
the	O
different	O
substituents	O
to	O
the	O
binding	O
free	O
energies	O
are	O
cumulative	O
.	O

By	O
combining	O
the	O
most	O
favorable	O
substitutions	O
we	O
increased	O
the	O
binding	O
affinity	O
of	O
paclitaxel	S-chem
500	O
-	O
fold	O
.	O

Insight	O
into	O
the	O
structural	O
basis	O
for	O
this	O
improvement	O
was	O
gained	O
with	O
molecular	O
modeling	O
and	O
NMR	O
data	O
obtained	O
for	O
microtubule	S-geneN
-	O
bound	O
docetaxel	S-chem
.	O

Taxanes	S-chem
with	O
affinities	O
for	O
microtubules	S-geneN
well	O
above	O
their	O
affinities	O
for	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
are	O
shown	O
not	O
to	O
be	O
affected	O
by	O
multidrug	O
resistance	O
.	O

This	O
finding	O
strongly	O
indicates	O
that	O
optimization	O
of	O
the	O
ligand	O
-	O
target	O
interaction	O
is	O
a	O
good	O
strategy	O
to	O
overcome	O
multidrug	O
resistance	O
mediated	O
by	O
efflux	B-geneN
pumps	E-geneN
.	O

Involvement	O
of	O
pertussis	B-geneN
toxin	E-geneN
-	O
sensitive	O
G	B-geneN
-	I-geneN
proteins	E-geneN
in	O
the	O
hormonal	O
inhibition	O
of	O
dihydropyridine	S-chem
-	O
sensitive	O
Ca2	B-chem
+	E-chem
currents	O
in	O
an	O
insulin	S-geneY
-	O
secreting	O
cell	O
line	O
(	O
RINm5F	O
)	O
.	O

Adrenaline	S-chem-C4-1
inhibits	O
insulin	S-geneY-C4-2
secretion	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
mechanisms	O
.	O

Since	O
voltage	O
-	O
dependent	O
Ca2	B-chem
+	E-chem
currents	O
play	O
a	O
key	O
role	O
in	O
insulin	S-geneY
secretion	O
,	O
we	O
examined	O
whether	O
adrenaline	S-chem
modulates	O
voltage	O
-	O
dependent	O
Ca2	B-chem
+	E-chem
currents	O
of	O
the	O
rat	O
insulinoma	O
cell	O
line	O
,	O
RINm5F	O
.	O

In	O
the	O
whole	O
-	O
cell	O
configuration	O
of	O
the	O
patch	O
-	O
clamp	O
technique	O
,	O
dihydropyridine	S-chem
-	O
but	O
not	O
omega	O
-	O
conotoxin	O
-	O
sensitive	O
Ca2	B-chem
+	E-chem
currents	O
were	O
identified	O
.	O

Adrenaline	S-chem
via	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
inhibited	O
the	O
Ca2	B-chem
+	E-chem
currents	O
by	O
about	O
50	O
%	O
.	O

Somatostatin	S-geneY
which	O
also	O
inhibits	O
insulin	S-geneY
secretion	O
was	O
less	O
efficient	O
(	O
inhibition	O
by	O
20	O
%	O
)	O
.	O

The	O
hormonal	O
inhibition	O
of	O
Ca2	B-chem
+	E-chem
currents	O
was	O
not	O
affected	O
by	O
intracellularly	O
applied	O
cAMP	S-chem
but	O
blocked	O
by	O
the	O
intracellularly	O
applied	O
GDP	S-chem
analog	O
guanosine	B-chem
5	I-chem
'	I-chem
-	I-chem
O	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
thiodiphosphate	I-chem
)	E-chem
and	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B-geneN
toxin	E-geneN
.	O

In	O
contrast	O
to	O
adrenaline	S-chem-C4-1
and	O
somatostatin	S-geneY
,	O
galanin	S-geneY
,	O
another	O
inhibitor	O
of	O
insulin	S-geneY-C4-2
secretion	O
,	O
reduced	O
Ca2	B-chem
+	E-chem
currents	O
by	O
about	O
40	O
%	O
in	O
a	O
pertussis	B-geneN
toxin	E-geneN
-	O
insensitive	O
manner	O
.	O

Immunoblot	O
experiments	O
performed	O
with	O
antibodies	O
generated	O
against	O
synthetic	O
peptides	O
revealed	O
that	O
membranes	O
of	O
RINm5F	O
cells	O
possess	O
four	O
pertussis	B-geneN
toxin	E-geneN
-	O
sensitive	O
G	B-geneN
-	I-geneN
proteins	E-geneN
including	O
Gi1	S-geneY
,	O
Gi2	S-geneY
,	O
Go2	S-geneY
,	O
and	O
another	O
Go	S-geneN
subtype	O
,	O
most	O
likely	O
representing	O
Go1	S-geneY
.	O

In	O
membranes	O
of	O
control	O
but	O
not	O
of	O
pertussis	B-geneN
toxin	E-geneN
-	O
treated	O
cells	O
,	O
adrenaline	S-chem
via	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
stimulated	O
incorporation	O
of	O
the	O
photo	O
-	O
reactive	O
GTP	S-chem
analog	O
[	B-chem
alpha	I-chem
-	I-chem
32P	I-chem
]	I-chem
GTP	I-chem
azidoanilide	E-chem
into	O
pertussis	O
toxin	O
substrates	O
comigrating	O
with	O
the	O
alpha	O
-	O
subunits	O
of	O
Gi2	S-geneY
,	O
Go2	S-geneY
,	O
and	O
the	O
not	O
further	O
identified	O
Go	S-geneN
subtype	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
activated	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptors	E-geneN
of	O
RINm5F	O
cells	O
interact	O
with	O
multiple	O
G	B-geneN
-	I-geneN
proteins	E-geneN
,	O
i.e	O
.	O
two	O
forms	O
of	O
Go	S-geneN
and	O
with	O
Gi2	S-geneY
.	O

These	O
G	B-geneN
-	I-geneN
proteins	E-geneN
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
adrenaline	S-chem
-	O
induced	O
inhibition	O
of	O
dihydropyridine	S-chem
-	O
sensitive	O
Ca2	B-chem
+	E-chem
currents	O
and	O
in	O
other	O
signal	O
transduction	O
pathways	O
contributing	O
to	O
the	O
adrenaline	S-chem-C4-1
-	O
induced	O
inhibition	O
of	O
insulin	S-geneY-C4-2
secretion	O
.	O

Cyclooxygenase	S-geneN
and	O
5	B-geneY
-	I-geneY
lipoxygenase	E-geneY
inhibitors	O
protect	O
against	O
mononuclear	O
phagocyte	O
neurotoxicity	O
.	O

Neuroinflammation	O
and	O
oxidative	O
stress	O
are	O
believed	O
to	O
be	O
contributing	O
factors	O
to	O
neurodegeneration	O
in	O
normal	O
aging	O
,	O
as	O
well	O
as	O
in	O
age	O
-	O
related	O
neurological	O
disorders	O
.	O

Reactive	O
microglia	O
are	O
found	O
in	O
increased	O
numbers	O
in	O
aging	O
brain	O
and	O
are	O
prominently	O
associated	O
with	O
lesions	O
in	O
such	O
age	O
-	O
related	O
degenerative	O
conditions	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
.	O

In	O
vitro	O
,	O
stimulated	O
microglia	O
or	O
microglial	O
-	O
like	O
cells	O
secrete	O
neurotoxic	O
materials	O
and	O
are	O
generators	O
of	O
free	O
radicals	O
through	O
their	O
respiratory	O
burst	O
system	O
.	O

Agents	O
that	O
suppress	O
microglial	O
activation	O
are	O
therefore	O
candidates	O
for	O
neuroprotection	O
.	O

We	O
have	O
developed	O
quantitative	O
in	O
vitro	O
assays	O
for	O
measuring	O
neurotoxicity	O
of	O
microglia	O
or	O
other	O
mononuclear	O
phagocytes	O
.	O

Neuronal	O
like	O
SH	O
-	O
SY5Y	O
cells	O
are	O
cultured	O
in	O
supernatants	O
from	O
activated	O
cells	O
of	O
the	O
human	O
monocytic	O
THP	O
-	O
1	O
line	O
and	O
their	O
survival	O
is	O
followed	O
.	O

Respiratory	O
burst	O
is	O
directly	O
measured	O
on	O
the	O
activated	O
cells	O
.	O

We	O
tested	O
inhibitors	O
of	O
the	O
cyclooxygenase	S-geneN
(	O
COX	S-geneN
)	O
or	O
the	O
5	B-geneY
-	I-geneY
lipoxygenase	E-geneY
(	O
5	B-geneY
-	I-geneY
LOX	E-geneY
)	O
pathways	O
as	O
possible	O
neuroprotective	O
agents	O
.	O

The	O
COX	S-geneN-C9-2
pathway	O
generates	O
inflammatory	O
prostaglandins	S-chem-C9-1
,	O
while	O
the	O
5	B-geneY-C9-2
-	I-geneY-C9-2
LOX	E-geneY-C9-2
pathway	O
generates	O
inflammatory	O
leukotrienes	S-chem-C9-1
.	O

We	O
found	O
that	O
inhibitors	O
of	O
both	O
these	O
pathways	O
suppressed	O
neurotoxicity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

They	O
included	O
the	O
COX	B-geneY
-	I-geneY
1	E-geneY
inhibitor	O
indomethacin	O
;	O
the	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
;	O
the	O
mixed	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
/	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
ibuprofen	S-chem-C4-1
;	O
the	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
derivatives	O
of	O
indomethacin	S-chem
,	O
ibuprofen	S-chem
and	O
flurbiprofen	S-chem
;	O
the	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
inhibitor	O
REV	B-chem-C4-1
5901	E-chem-C4-1
;	O
and	O
the	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	I-geneY-C4-2
activating	I-geneY-C4-2
protein	E-geneY-C4-2
(	O
FLAP	S-geneY-C4-2
)	O
inhibitor	O
MK	B-chem-C4-1
-	I-chem-C4-1
886	E-chem-C4-1
.	O

The	O
FLAP	S-geneY
inhibitor	O
also	O
reduced	O
respiratory	O
burst	O
activity	O
in	O
a	O
more	O
potent	O
manner	O
than	O
indomethacin	O
.	O

Combinations	O
of	O
COX	S-geneN
and	O
5	B-geneY
-	I-geneY
LOX	E-geneY
inhibitors	O
were	O
more	O
effective	O
than	O
single	O
inhibitors	O
.	O

The	O
data	O
suggest	O
that	O
both	O
COX	S-geneN
inhibitors	O
and	O
5	B-geneY
-	I-geneY
LOX	E-geneY
inhibitors	O
may	O
be	O
neuroprotective	O
in	O
vivo	O
by	O
suppressing	O
toxic	O
actions	O
of	O
microglia	O
/	O
macrophages	O
,	O
and	O
that	O
combinations	O
of	O
the	O
two	O
might	O
have	O
greater	O
therapeutic	O
potential	O
than	O
single	O
inhibitors	O
of	O
either	O
class	O
.	O

Tissue	O
expression	O
and	O
translational	O
control	O
of	O
rat	B-geneY
kynurenine	I-geneY
aminotransferase	O
/	O
glutamine	B-geneY
transaminase	I-geneY
K	E-geneY
mRNAs	O
.	O

Kynurenic	B-chem-C6-1
acid	E-chem-C6-1
(	O
KA	S-chem-C6-1
)	O
is	O
an	O
endogenous	O
glutamate	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
at	O
the	O
level	O
of	O
the	O
different	O
ionotropic	B-geneN-C6-2
glutamate	I-geneN-C6-2
receptors	E-geneN-C6-2
.	O

One	O
of	O
the	O
enzymes	O
responsible	O
for	O
the	O
production	O
of	O
KA	S-chem-C9-1
,	O
kynurenine	B-geneY-C9-2
aminotransferase	I-geneY-C9-2
I	E-geneY-C9-2
(	O
KATI	S-geneY-C9-2
)	O
,	O
also	O
catalyses	O
the	O
reversible	O
transamination	O
of	O
glutamine	S-chem-C9-1
to	O
oxoglutaramic	B-chem-C9-1
acid	E-chem-C9-1
(	O
GTK	S-geneY-C9-2
,	O
EC	B-geneY-C9-2
2.6.1.15	E-geneY-C9-2
)	O
.	O

The	O
enzyme	O
exists	O
in	O
a	O
cytosolic	O
and	O
in	O
a	O
mitochondrial	O
form	O
because	O
of	O
the	O
presence	O
of	O
two	O
different	O
KATI	S-geneY
mRNAs	O
coding	O
for	O
a	O
protein	O
respectively	O
with	O
and	O
without	O
leader	B-geneN
sequence	E-geneN
targeting	O
the	O
protein	O
into	O
mitochondria	O
.	O

We	O
have	O
cloned	O
from	O
a	O
phage	O
library	O
of	O
rat	O
kidney	O
cDNA	O
four	O
new	O
KATI	S-geneY
cDNAs	O
containing	O
different	O
5	B-geneN
'	I-geneN
untranslated	I-geneN
regions	E-geneN
(	O
UTRs	S-geneN
)	O
.	O

One	O
of	O
the	O
transcripts	O
(	O
+	O
14KATI	O
cDNA	O
)	O
contains	O
an	O
alternative	O
site	O
of	O
initiation	O
of	O
translation	O
.	O

The	O
tissue	O
distribution	O
of	O
the	O
different	O
transcripts	O
was	O
studied	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
study	O
demonstrated	O
that	O
several	O
KATI	S-geneY
mRNAs	O
are	O
constitutively	O
expressed	O
in	O
ubiquitous	O
manner	O
,	O
while	O
+	O
14KATI	O
mRNA	O
is	O
present	O
only	O
in	O
kidney	O
.	O

The	O
translational	O
efficiency	O
of	O
the	O
different	O
transcripts	O
was	O
studied	O
in	O
vitro	O
and	O
enzymatic	O
activities	O
were	O
measured	O
in	O
transiently	O
transfected	O
Cos	O
-	O
1	O
cells	O
.	O

Each	O
KATI	S-geneY
mRNA	O
exhibits	O
a	O
different	O
in	O
vitro	O
translational	O
efficiency	O
,	O
which	O
corresponds	O
to	O
different	O
levels	O
of	O
KAT	S-geneY
enzymatic	O
activity	O
in	O
transfected	O
cells	O
.	O

Both	O
findings	O
correlate	O
with	O
the	O
predicted	O
accessibility	O
of	O
the	O
ribosomal	O
binding	O
sites	O
of	O
the	O
different	O
mRNAs	O
.	O

The	O
structure	O
of	O
the	O
rat	B-geneY
KATI	E-geneY
/	O
GTK	S-geneY
gene	O
was	O
also	O
studied	O
.	O

The	O
expression	O
of	O
several	O
KATI	S-geneY
mRNAs	O
with	O
different	O
5'UTRs	S-geneN
represents	O
an	O
interesting	O
example	O
of	O
transcriptional	O
/	O
translational	O
control	O
on	O
the	O
expression	O
of	O
pyridoxal	B-geneN
phosphate	I-geneN
(	I-geneN
PLP	I-geneN
)	I-geneN
-	I-geneN
dependent	I-geneN
aminotransferases	E-geneN
.	O

Vitamin	B-chem
B12	E-chem
responsive	O
homocystinuria	O
and	O
megaloblastic	O
anemia	O
:	O
heterogeneity	O
in	O
methylcobalamin	S-chem
deficiency	O
.	O

A	O
male	O
infant	O
with	O
methyl	B-chem
-	I-chem
B12	E-chem
deficiency	O
(	O
cblE	O
)	O
presented	O
at	O
age	O
6	O
weeks	O
with	O
lethargy	O
,	O
staring	O
spells	O
,	O
and	O
vomiting	O
.	O

He	O
later	O
became	O
hypotonic	O
and	O
unresponsive	O
to	O
stimuli	O
and	O
required	O
intubation	O
and	O
ventilation	O
.	O

He	O
had	O
homocystinuria	O
and	O
hypomethioninemia	O
with	O
megaloblastic	O
anemia	O
but	O
normal	O
serum	O
folate	S-chem
and	O
vitamin	B-chem
B12	E-chem
concentrations	O
.	O

No	O
methylmalonic	B-chem
aciduria	E-chem
was	O
detected	O
.	O

Fibroblasts	O
,	O
cultured	O
from	O
the	O
patient	O
,	O
were	O
unable	O
to	O
grow	O
in	O
medium	O
in	O
which	O
homocysteine	S-chem
replaced	O
methionine	S-chem
and	O
incorporated	O
abnormally	O
small	O
amounts	O
of	O
[	B-chem
14C	I-chem
]	I-chem
-	I-chem
methyl	I-chem
-	I-chem
tetrahydrofolate	E-chem
but	O
normal	O
amounts	O
of	O
[	B-chem
14C	I-chem
]	I-chem
-	I-chem
propionate	E-chem
into	O
protein	O
.	O

Methyl	B-chem
-	I-chem
B12	E-chem
content	O
of	O
fibroblasts	O
was	O
low	O
,	O
while	O
the	O
adenosyl	B-chem
-	I-chem
B12	E-chem
content	O
was	O
normal	O
.	O

Methionine	B-geneY
synthase	E-geneY
activity	O
was	O
decreased	O
when	O
the	O
assay	O
was	O
performed	O
under	O
both	O
optimal	O
and	O
suboptimal	O
reducing	O
conditions	O
,	O
suggesting	O
heterogeneity	O
in	O
the	O
cblE	O
disease	O
.	O

The	O
patient	O
responded	O
dramatically	O
to	O
hydroxocobalamin	S-chem
treatment	O
.	O

Homocystinuria	O
disappeared	O
after	O
10	O
days	O
of	O
therapy	O
,	O
and	O
methionine	S-chem
was	O
normalized	O
after	O
3	O
weeks	O
.	O

Psychometric	O
testing	O
at	O
age	O
15	O
months	O
showed	O
a	O
developmental	O
age	O
of	O
9	O
months	O
.	O

Alpha1	B-geneN
-	I-geneN
adrenoceptors	E-geneN
are	O
required	O
for	O
normal	O
male	O
sexual	O
function	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
are	O
extensively	O
used	O
in	O
the	O
treatment	O
of	O
hypertension	O
and	O
lower	O
urinary	O
tract	O
symptoms	O
associated	O
with	O
benign	O
prostatic	O
hyperplasia	O
.	O

Among	O
the	O
side	O
effects	O
,	O
ejaculatory	O
dysfunction	O
occurs	O
more	O
frequently	O
with	O
drugs	O
that	O
are	O
relatively	O
selective	O
for	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
compared	O
with	O
other	O
drugs	O
of	O
this	O
class	O
.	O

This	O
suggests	O
that	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
may	O
contribute	O
to	O
ejaculation	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
studied	O
at	O
the	O
molecular	O
level	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
The	O
physiological	O
contribution	O
of	O
each	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtype	O
was	O
characterized	O
using	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtype	O
-	O
selective	O
knockout	O
(	O
KO	O
)	O
mice	O
(	O
alpha	B-geneN
(	I-geneN
1A	I-geneN
)	I-geneN
-	I-geneN
,	I-geneN
alpha	I-geneN
(	I-geneN
1B	I-geneN
)	I-geneN
-	I-geneN
and	I-geneN
alpha	I-geneN
(	I-geneN
1D	I-geneN
)	I-geneN
-	I-geneN
AR	E-geneN
KO	O
mice	O
)	O
since	O
the	O
subtype	O
-	O
specific	O
drugs	O
available	O
are	O
only	O
moderately	O
selective	O
.	O

We	O
analysed	O
the	O
role	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
the	O
blood	O
pressure	O
and	O
vascular	O
response	O
as	O
well	O
as	O
ejaculation	O
by	O
determining	O
these	O
variables	O
in	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtype	O
-	O
selective	O
KO	O
mice	O
and	O
in	O
mice	O
with	O
all	O
their	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
deleted	O
(	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
AR	E-geneN
triple	O
-	O
KO	O
mice	O
)	O
.	O

KEY	O
RESULTS	O
:	O
The	O
pregnancy	O
rate	O
was	O
reduced	O
by	O
50	O
%	O
in	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
KO	O
mice	O
,	O
and	O
this	O
reduction	O
was	O
dramatically	O
enhanced	O
in	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
triple	O
-	O
KO	O
mice	O
.	O

Contractile	O
tension	O
of	O
the	O
vas	O
deferens	O
in	O
response	O
to	O
noradrenaline	S-chem
was	O
markedly	O
decreased	O
in	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
KO	O
mice	O
,	O
and	O
this	O
contraction	O
was	O
completely	O
abolished	O
in	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
triple	O
-	O
KO	O
mice	O
.	O

This	O
attenuation	O
of	O
contractility	O
was	O
also	O
observed	O
in	O
the	O
electrically	O
stimulated	O
vas	O
deferens	O
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
,	O
particularly	O
alpha	B-geneY
(	I-geneY
1A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
,	O
are	O
required	O
for	O
normal	O
contractility	O
of	O
the	O
vas	O
deferens	O
and	O
consequent	O
sperm	O
ejaculation	O
as	O
well	O
as	O
having	O
a	O
function	O
in	O
fertility	O
.	O

TSG	B-geneY
-	I-geneY
6	E-geneY
,	O
an	O
arthritis	O
-	O
associated	O
hyaluronan	B-geneN
binding	I-geneN
protein	E-geneN
,	O
forms	O
a	O
stable	O
complex	O
with	O
the	O
serum	B-geneN
protein	I-geneN
inter	I-geneN
-	I-geneN
alpha	I-geneN
-	I-geneN
inhibitor	E-geneN
.	O

TSG	B-geneY
-	I-geneY
6	E-geneY
is	O
a	O
secreted	O
35	B-geneN
-	I-geneN
kDa	I-geneN
glycoprotein	E-geneN
,	O
inducible	O
by	O
TNF	S-geneY
and	O
IL	B-geneN
-	I-geneN
1	E-geneN
.	O

The	O
N	S-chem
-	O
terminal	O
portion	O
of	O
TSG	B-geneY
-	I-geneY
6	E-geneY
shows	O
sequence	O
homology	O
to	O
members	O
of	O
the	O
cartilage	O
link	O
protein	O
family	O
of	O
hyaluronan	B-geneN
binding	I-geneN
proteins	E-geneN
.	O

The	O
C	S-chem
-	O
terminal	O
half	O
of	O
TSG	B-geneY
-	I-geneY
6	E-geneY
contains	O
a	O
so	O
-	O
called	O
CUB	B-geneN
domain	E-geneN
,	O
characteristic	O
for	O
developmentally	O
regulated	O
proteins	O
.	O

High	O
levels	O
of	O
TSG	B-geneY
-	I-geneY
6	E-geneY
protein	O
are	O
found	O
in	O
the	O
synovial	O
fluid	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
some	O
other	O
arthritic	O
diseases	O
.	O

Here	O
we	O
show	O
that	O
TSG	B-geneN
-	I-geneN
6	E-geneN
readily	O
formed	O
a	O
complex	O
with	O
a	O
protein	O
present	O
in	O
human	O
,	O
bovine	O
,	O
rabbit	O
,	O
and	O
mouse	O
serum	O
.	O

This	O
complex	O
was	O
stable	O
during	O
SDS	O
-	O
PAGE	O
under	O
reducing	O
conditions	O
,	O
and	O
in	O
the	O
presence	O
of	O
8	O
M	O
urea	S-chem
.	O

The	O
protein	O
that	O
binds	O
TSG	B-geneY
-	I-geneY
6	E-geneY
was	O
purified	O
from	O
human	O
serum	O
and	O
identified	O
as	O
inter	B-geneN
-	I-geneN
alpha	I-geneN
-	I-geneN
inhibitor	E-geneN
(	O
I	B-geneN
alpha	I-geneN
I	E-geneN
)	O
by	O
N	S-chem
-	O
terminal	O
microsequencing	O
.	O

Microsequencing	O
of	O
the	O
complex	O
itself	O
revealed	O
the	O
presence	O
of	O
TSG	B-geneY
-	I-geneY
6	E-geneY
and	O
two	O
of	O
the	O
three	O
polypeptide	O
chains	O
of	O
I	B-geneN
alpha	I-geneN
I	E-geneN
(	O
bikunin	S-geneY
and	O
HC2	S-geneY
)	O
.	O

Experiments	O
with	O
recombinant	O
TSG	B-geneY
-	I-geneY
6	E-geneY
and	O
I	B-geneN
alpha	I-geneN
I	E-geneN
purified	O
from	O
human	O
serum	O
showed	O
that	O
the	O
TSG	B-geneY
-	I-geneY
6	E-geneY
/	O
I	B-geneN
alpha	I-geneN
I	E-geneN
complex	O
is	O
rapidly	O
formed	O
even	O
in	O
the	O
apparent	O
absence	O
of	O
other	O
proteins	O
at	O
37	O
degrees	O
C	O
,	O
but	O
not	O
at	O
4	O
degrees	O
C	O
.	O

The	O
TSG	B-geneY
-	I-geneY
6	E-geneY
/	O
I	B-geneN
alpha	I-geneN
I	E-geneN
complex	O
was	O
cleaved	O
by	O
chondroitin	B-geneN
sulfate	I-geneN
ABC	I-geneN
lyase	E-geneN
,	O
suggesting	O
that	O
cross	O
-	O
linking	O
by	O
chondroitin	O
sulfate	S-chem
is	O
required	O
for	O
the	O
stability	O
of	O
the	O
complex	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phenothiazines	S-chem-C4-1
inhibit	O
S100A4	S-geneY-C4-2
function	O
by	O
inducing	O
protein	O
oligomerization	O
.	O

S100A4	S-geneY
,	O
a	O
member	O
of	O
the	O
S100	S-geneN
family	O
of	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
binding	O
proteins	O
,	O
regulates	O
carcinoma	O
cell	O
motility	O
via	O
interactions	O
with	O
myosin	B-geneY
-	I-geneY
IIA	E-geneY
.	O

Numerous	O
studies	O
indicate	O
that	O
S100A4	S-geneY
is	O
not	O
simply	O
a	O
marker	O
for	O
metastatic	O
disease	O
,	O
but	O
rather	O
has	O
a	O
direct	O
role	O
in	O
metastatic	O
progression	O
.	O

These	O
observations	O
suggest	O
that	O
S100A4	S-geneY
is	O
an	O
excellent	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Using	O
a	O
unique	O
biosensor	O
-	O
based	O
assay	O
,	O
trifluoperazine	S-chem-C4-1
(	O
TFP	S-chem-C4-1
)	O
was	O
identified	O
as	O
an	O
inhibitor	O
that	O
disrupts	O
the	O
S100A4	S-geneY-C4-2
/	O
myosin	B-geneY-C4-2
-	I-geneY-C4-2
IIA	E-geneY-C4-2
interaction	O
.	O

To	O
examine	O
the	O
interaction	O
of	O
S100A4	S-geneY
with	O
TFP	S-chem
,	O
we	O
determined	O
the	O
2.3	O
A	O
crystal	O
structure	O
of	O
human	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
S100A4	S-geneY
bound	O
to	O
TFP	S-chem
.	O

Two	O
TFP	S-chem
molecules	O
bind	O
within	O
the	O
hydrophobic	O
target	O
binding	O
pocket	O
of	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
S100A4	S-geneY
with	O
no	O
significant	O
conformational	O
changes	O
observed	O
in	O
the	O
protein	O
upon	O
complex	O
formation	O
.	O

NMR	O
chemical	O
shift	O
perturbations	O
are	O
consistent	O
with	O
the	O
crystal	O
structure	O
and	O
demonstrate	O
that	O
TFP	S-chem
binds	O
to	O
the	O
target	O
binding	O
cleft	O
of	O
S100A4	S-geneY
in	O
solution	O
.	O

Remarkably	O
,	O
TFP	S-chem
binding	O
results	O
in	O
the	O
assembly	O
of	O
five	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
S100A4	S-geneY
/	O
TFP	O
dimers	O
into	O
a	O
tightly	O
packed	O
pentameric	O
ring	O
.	O

Within	O
each	O
pentamer	O
most	O
of	O
the	O
contacts	O
between	O
S100A4	S-geneY
dimers	O
occurs	O
through	O
the	O
TFP	S-chem
moieties	O
.	O

The	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
S100A4	S-geneY
/	O
prochlorperazine	S-chem
(	O
PCP	S-chem
)	O
complex	O
exhibits	O
a	O
similar	O
pentameric	O
assembly	O
.	O

Equilibrium	O
sedimentation	O
and	O
cross	O
-	O
linking	O
studies	O
demonstrate	O
the	O
cooperative	O
formation	O
of	O
a	O
similarly	O
sized	O
S100A4	S-geneY
/	O
TFP	S-chem
oligomer	O
in	O
solution	O
.	O

Assays	O
examining	O
the	O
ability	O
of	O
TFP	S-chem-C4-1
to	O
block	O
S100A4	S-geneY-C4-2
-	O
mediated	O
disassembly	O
of	O
myosin	B-geneY-C4-2
-	I-geneY-C4-2
IIA	E-geneY-C4-2
filaments	O
demonstrate	O
that	O
significant	O
inhibition	O
of	O
S100A4	S-geneY-C4-2
function	O
occurs	O
only	O
at	O
TFP	S-chem-MU-1
concentrations	O
that	O
promote	O
S100A4	S-geneY-C3-2
oligomerization	O
.	O

Together	O
these	O
studies	O
support	O
a	O
unique	O
mode	O
of	O
inhibition	O
in	O
which	O
phenothiazines	S-chem-C4-1
disrupt	O
the	O
S100A4	S-geneY-C4-2
/	O
myosin	B-geneY-C4-2
-	I-geneY-C4-2
IIA	E-geneY-C4-2
interaction	O
by	O
sequestering	O
S100A4	S-geneY
via	O
small	O
molecule	O
-	O
induced	O
oligomerization	O
.	O

High	O
-	O
glucose	S-chem-C3-1
environment	O
enhanced	O
oxidative	O
stress	O
and	O
increased	O
interleukin	B-geneY-C3-2
-	I-geneY-C3-2
8	E-geneY-C3-2
secretion	O
from	O
keratinocytes	O
:	O
New	O
insights	O
on	O
impaired	O
diabetic	O
wound	O
healing	O
.	O

Impaired	O
wound	O
healing	O
frequently	O
occurs	O
in	O
patients	O
with	O
diabetes	O
.	O

Interluekin	B-geneY
-	I-geneY
8	E-geneY
(	O
IL	B-geneY
-	I-geneY
8	E-geneY
)	O
production	O
by	O
keratinocyte	O
is	O
responsible	O
for	O
recruiting	O
neutrophils	O
during	O
healing	O
.	O

Intense	O
inflammation	O
is	O
associated	O
with	O
diabetic	O
wounds	O
while	O
reduction	O
of	O
neutrophil	O
infiltration	O
is	O
associated	O
with	O
enhanced	O
healing	O
.	O

We	O
hypothesized	O
that	O
increased	O
neutrophil	O
recruitment	O
by	O
keratinocytes	O
may	O
contribute	O
to	O
the	O
delayed	O
healing	O
of	O
diabetic	O
wound	O
.	O

Using	O
cultured	O
human	O
keratinocytes	O
and	O
diabetic	O
rat	O
model	O
,	O
the	O
current	O
study	O
showed	O
that	O
high	O
-	O
glucose	S-chem-C3-1
environment	O
enhanced	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
8	E-geneY-C3-2
production	O
via	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
-	O
extracelluar	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
pathway	O
in	O
a	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
-	O
dependent	O
manner	O
in	O
keratinocytes	O
.	O

In	O
addition	O
,	O
diabetic	O
rat	O
skin	O
showed	O
enhanced	O
EGFR	S-geneY
,	O
ERK	S-geneN
and	O
IL	B-geneN
-	I-geneN
8	E-geneN
expression	O
as	O
compared	O
to	O
control	O
rats	O
.	O

The	O
dermal	O
neutrophil	O
infiltration	O
of	O
the	O
wound	O
,	O
as	O
represented	O
by	O
expression	O
of	O
myeloperoxidase	S-geneY
level	O
,	O
was	O
also	O
significantly	O
higher	O
in	O
diabetic	O
rats	O
.	O

Treating	O
diabetic	O
rats	O
with	O
dapsone	S-chem
,	O
an	O
agent	O
known	O
to	O
inhibit	O
neutrophil	O
function	O
,	O
was	O
associated	O
with	O
improved	O
healing	O
.	O

In	O
conclusion	O
,	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
8	E-geneY-C3-2
production	O
and	O
neutrophil	O
infiltration	O
are	O
increased	O
in	O
high	O
-	O
glucose	S-chem-C3-1
environment	O
due	O
to	O
elevated	O
ROS	O
level	O
and	O
contributed	O
to	O
impaired	O
wound	O
healing	O
in	O
diabetic	O
skin	O
.	O

Targeting	O
these	O
dysfunctions	O
may	O
present	O
novel	O
therapeutic	O
approaches	O
.	O

Alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptor	E-geneN
subtype	O
causing	O
nitric	B-chem
oxide	E-chem
-	O
mediated	O
vascular	O
relaxation	O
in	O
rats	O
.	O

The	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptor	E-geneN
subtype	O
and	O
its	O
signal	O
transduction	O
pathway	O
mediating	O
vascular	O
relaxation	O
in	O
rats	O
were	O
studied	O
in	O
vitro	O
using	O
rings	O
of	O
superior	O
mesenteric	O
arteries	O
.	O

Removal	O
of	O
endothelium	O
or	O
incubation	O
with	O
NG	B-chem
-	I-chem
nitro	I-chem
-	I-chem
L	I-chem
-	I-chem
arginine	E-chem
completely	O
blocked	O
relaxant	O
responses	O
to	O
UK14,304	S-chem
,	O
suggesting	O
endothelium	O
-	O
derived	O
nitric	B-chem
oxide	E-chem
mediates	O
relaxation	O
.	O

The	O
order	O
of	O
potency	O
for	O
full	O
(	O
F	O
)	O
or	O
partial	O
(	O
P	O
)	O
agonists	O
causing	O
relaxation	O
was	O
guanabenz	S-chem
(	O
P	O
)	O
>	O
UK14,304	S-chem
(	O
F	O
)	O
>	O
clonidine	S-chem
(	O
P	O
)	O
>	O
epinephrine	S-chem
(	O
F	O
)	O
>	O
norepinephrine	S-chem
(	O
F	O
)	O
.	O

Affinities	O
(	O
Ka	O
)	O
of	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptor	E-geneN
subtype	O
-	O
selective	O
drugs	O
for	O
blocking	O
relaxation	O
were	O
obtained	O
in	O
side	O
-	O
by	O
-	O
side	O
experiments	O
comparing	O
rat	O
mesenteric	O
arteries	O
with	O
pig	O
coronary	O
arteries	O
.	O

Relaxation	O
of	O
pig	O
coronary	O
arteries	O
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
alpha	B-geneY
-	I-geneY
2A	I-geneY
adrenoceptor	E-geneY
subtype	O
.	O

Ka	O
values	O
in	O
nM	O
for	O
rauwolscine	S-chem
(	O
19	O
)	O
,	O
WB	B-chem
-	I-chem
4101	E-chem
(	O
265	O
)	O
,	O
SKF	B-chem
-	I-chem
104078	E-chem
(	O
197	O
)	O
,	O
spiroxatrine	S-chem
(	O
128	O
)	O
,	O
and	O
prazosin	S-chem
(	O
1531	O
)	O
for	O
blocking	O
relaxation	O
in	O
rat	O
arteries	O
were	O
consistent	O
with	O
their	O
affinities	O
for	O
binding	O
at	O
the	O
alpha	B-geneY
-	I-geneY
2D	I-geneY
adrenoceptor	E-geneY
subtype	O
.	O

Ka	O
values	O
for	O
rauwolscine	S-chem
and	O
WB	B-chem
-	I-chem
4101	E-chem
,	O
drugs	O
distinguishing	O
the	O
alpha	O
-	O
2D	O
from	O
the	O
alpha	B-geneY
-	I-geneY
2A	I-geneY
adrenoceptor	E-geneY
subtype	O
,	O
were	O
significantly	O
higher	O
in	O
blocking	O
relaxation	O
of	O
rat	O
arteries	O
compared	O
with	O
pig	O
arteries	O
,	O
suggesting	O
the	O
alpha	B-geneY
-	I-geneY
2D	I-geneY
adrenoceptor	E-geneY
subtype	O
mediates	O
NO	S-chem
-	O
induced	O
relaxation	O
in	O
rat	O
arteries	O
.	O

We	O
used	O
forskolin	S-chem
to	O
oppose	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptor	E-geneN
-	O
mediated	O
inhibition	O
of	O
cAMP	S-chem
formation	O
by	O
directly	O
stimulating	O
cAMP	S-chem
formation	O
in	O
endothelium	O
.	O

Forskolin	S-chem
did	O
not	O
affect	O
the	O
relaxant	O
response	O
to	O
UK14,304	S-chem
,	O
suggesting	O
that	O
cAMP	S-chem
is	O
not	O
involved	O
in	O
the	O
coupling	O
of	O
alpha	B-geneN
-	I-geneN
2	I-geneN
adrenoceptors	E-geneN
to	O
nitric	B-chem
oxide	E-chem
-	O
induced	O
vascular	O
relaxation	O
.	O

Acetaminophen	S-chem-C4-1
(	O
paracetamol	S-chem-C4-1
)	O
is	O
a	O
selective	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
in	O
man	O
.	O

For	O
more	O
than	O
three	O
decades	O
,	O
acetaminophen	S-chem
(	O
INN	S-chem
,	O
paracetamol	S-chem
)	O
has	O
been	O
claimed	O
to	O
be	O
devoid	O
of	O
significant	O
inhibition	O
of	O
peripheral	O
prostanoids	S-chem
.	O

Meanwhile	O
,	O
attempts	O
to	O
explain	O
its	O
action	O
by	O
inhibition	O
of	O
a	O
central	O
cyclooxygenase	B-geneN
(	I-geneN
COX	I-geneN
)	I-geneN
-	I-geneN
3	E-geneN
have	O
been	O
rejected	O
.	O

The	O
fact	O
that	O
acetaminophen	S-chem-C4-1
acts	O
functionally	O
as	O
a	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
led	O
us	O
to	O
investigate	O
the	O
hypothesis	O
of	O
whether	O
it	O
works	O
via	O
preferential	O
COX	B-geneY
-	I-geneY
2	E-geneY
blockade	O
.	O

Ex	O
vivo	O
COX	S-geneN-C4-2
inhibition	O
and	O
pharmacokinetics	O
of	O
acetaminophen	S-chem-C4-1
were	O
assessed	O
in	O
5	O
volunteers	O
receiving	O
single	O
1000	O
mg	O
doses	O
orally	O
.	O

Coagulation	O
-	O
induced	O
thromboxane	B-chem-C9-1
B	I-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
and	O
lipopolysaccharide	O
-	O
induced	O
prostaglandin	B-chem-C9-1
E	I-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
were	O
measured	O
ex	O
vivo	O
and	O
in	O
vitro	O
in	O
human	O
whole	O
blood	O
as	O
indices	O
of	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
and	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
activity	O
.	O

In	O
vitro	O
,	O
acetaminophen	S-chem-C4-1
elicited	O
a	O
4.4	O
-	O
fold	O
selectivity	O
toward	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibition	O
(	O
IC	O
(	O
50	O
)	O
=	O
113.7	O
micromol	O
/	O
L	O
for	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
;	O
IC	O
(	O
50	O
)	O
=	O
25.8	O
micromol	O
/	O
L	O
for	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
.	O

Following	O
oral	O
administration	O
of	O
the	O
drug	O
,	O
maximal	O
ex	O
vivo	O
inhibitions	O
were	O
56	O
%	O
(	O
COX	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
83	O
%	O
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

Acetaminophen	S-chem-C4-1
plasma	O
concentrations	O
remained	O
above	O
the	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
for	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
for	O
at	O
least	O
5	O
h	O
postadministration	O
.	O

Ex	O
vivo	O
IC	O
(	O
50	O
)	O
values	O
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
:	O
105.2	O
micromol	O
/	O
L	O
;	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
:	O
26.3	O
micromol	O
/	O
L	O
)	O
of	O
acetaminophen	S-chem-C4-1
compared	O
favorably	O
with	O
its	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
.	O

In	O
contrast	O
to	O
previous	O
concepts	O
,	O
acetaminophen	S-chem-C4-1
inhibited	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
by	O
more	O
than	O
80	O
%	O
,	O
i.e	O
.	O
,	O
to	O
a	O
degree	O
comparable	O
to	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
.	O

However	O
,	O
a	O
>	O
95	O
%	O
COX	B-geneY
-	I-geneY
1	E-geneY
blockade	O
relevant	O
for	O
suppression	O
of	O
platelet	O
function	O
was	O
not	O
achieved	O
.	O

Our	O
data	O
may	O
explain	O
acetaminophen	O
's	O
analgesic	O
and	O
antiinflammatory	O
action	O
as	O
well	O
as	O
its	O
superior	O
overall	O
gastrointestinal	O
safety	O
profile	O
compared	O
with	O
NSAIDs	O
.	O

In	O
view	O
of	O
its	O
substantial	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibition	O
,	O
recently	O
defined	O
cardiovascular	O
warnings	O
for	O
use	O
of	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
should	O
also	O
be	O
considered	O
for	O
acetaminophen	S-chem-C4-1
.	O

Toxicity	O
profile	O
of	O
small	O
-	O
molecule	O
IAP	S-geneN-C6-2
antagonist	O
GDC	B-chem-C6-1
-	I-chem-C6-1
0152	E-chem-C6-1
is	O
linked	O
to	O
TNF	B-geneY
-	I-geneY
α	E-geneY
pharmacology	O
.	O

Inhibitor	B-geneN
-	I-geneN
of	I-geneN
-	I-geneN
apoptosis	E-geneN
(	O
IAP	S-geneN
)	O
proteins	O
suppress	O
apoptosis	O
and	O
are	O
overexpressed	O
in	O
a	O
variety	O
of	O
cancers	O
.	O

Small	O
-	O
molecule	O
IAP	S-geneN
antagonists	O
are	O
currently	O
being	O
tested	O
in	O
clinical	O
trials	O
as	O
novel	O
cancer	O
therapeutics	O
.	O

GDC	B-chem-C6-1
-	I-chem-C6-1
0152	E-chem-C6-1
is	O
a	O
small	O
-	O
molecule	O
drug	O
that	O
triggers	O
tumor	O
cell	O
apoptosis	O
by	O
selectively	O
antagonizing	O
IAPs	S-geneN-C6-2
.	O

GDC	B-chem-C3-1
-	I-chem-C3-1
0152	E-chem-C3-1
induces	O
NF	B-geneN-C3-2
-	I-geneN-C3-2
κB	E-geneN-C3-2
transcriptional	O
activity	O
leading	O
to	O
expression	O
of	O
several	O
chemokines	S-geneN
and	O
cytokines	S-geneN
,	O
of	O
which	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
is	O
the	O
most	O
important	O
for	O
single	O
-	O
agent	O
tumor	O
activity	O
.	O

TNF	B-geneY
-	I-geneY
α	E-geneY
is	O
a	O
pleiotropic	O
cytokine	S-geneN
that	O
drives	O
a	O
variety	O
of	O
cellular	O
responses	O
,	O
comprising	O
inflammation	O
,	O
proliferation	O
,	O
and	O
cell	O
survival	O
or	O
death	O
depending	O
on	O
the	O
cellular	O
context	O
.	O

As	O
malignant	O
and	O
normal	O
cells	O
produce	O
TNF	B-geneY
-	I-geneY
α	E-geneY
upon	O
IAP	S-geneN
antagonism	O
,	O
increased	O
TNF	B-geneY
-	I-geneY
α	E-geneY
could	O
drive	O
both	O
efficacy	O
and	O
toxicity	O
.	O

The	O
toxicity	O
profile	O
of	O
GDC	B-chem
-	I-chem
0152	E-chem
in	O
dogs	O
and	O
rats	O
was	O
characterized	O
after	O
iv	O
dose	O
administration	O
once	O
every	O
2	O
weeks	O
for	O
four	O
doses	O
.	O

Findings	O
in	O
both	O
species	O
consisted	O
of	O
a	O
dose	O
-	O
related	O
,	O
acute	O
,	O
systemic	O
inflammatory	O
response	O
,	O
and	O
hepatic	O
injury	O
.	O

Laboratory	O
findings	O
included	O
elevated	O
plasma	O
cytokines	S-geneN
,	O
an	O
inflammatory	O
leukogram	O
,	O
and	O
increased	O
liver	B-geneN
transaminases	E-geneN
with	O
histopathological	O
findings	O
of	O
inflammatory	O
infiltrates	O
and	O
apoptosis	O
/	O
necrosis	O
in	O
multiple	O
tissues	O
;	O
a	O
toxicology	O
profile	O
consistent	O
with	O
TNF	B-geneY
-	I-geneY
α	E-geneY
-	O
mediated	O
toxicity	O
.	O

Dogs	O
exhibited	O
more	O
severe	O
findings	O
than	O
rats	O
,	O
and	O
humans	O
did	O
not	O
exhibit	O
these	O
findings	O
,	O
at	O
comparable	O
exposures	O
across	O
species	O
.	O

Furthermore	O
,	O
elevations	O
in	O
blood	O
neutrophil	O
count	O
,	O
serum	O
monocyte	B-geneY
chemoattractant	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
,	O
and	O
other	O
markers	O
of	O
inflammation	O
corresponded	O
to	O
GDC	B-chem
-	I-chem
0152	E-chem
exposure	O
and	O
toxicity	O
and	O
thus	O
may	O
have	O
utility	O
as	O
safety	O
biomarkers	O
.	O

Levels	O
of	O
2	B-chem
-	I-chem
thiothiazolidine	I-chem
-	I-chem
4	I-chem
-	I-chem
carboxylic	I-chem
acid	E-chem
(	O
TTCA	S-chem
)	O
and	O
effect	O
modification	O
of	O
polymorphisms	O
of	O
glutathione	S-chem
-	O
related	O
genes	O
in	O
vulcanization	O
workers	O
in	O
the	O
southern	O
Sweden	O
rubber	O
industries	O
.	O

OBJECTIVES	O
:	O
Workers	O
in	O
the	O
rubber	O
industry	O
are	O
exposed	O
to	O
a	O
complex	O
mixture	O
of	O
hazardous	O
substances	O
and	O
have	O
increased	O
risk	O
of	O
developing	O
several	O
diseases	O
.	O

However	O
,	O
there	O
is	O
no	O
up	O
to	O
date	O
survey	O
examining	O
the	O
exposure	O
in	O
the	O
Swedish	O
rubber	O
industry	O
.	O

One	O
of	O
the	O
toxic	O
compounds	O
in	O
the	O
industry	O
is	O
carbon	O
disulfide	O
(	O
CS	O
(	O
2	O
)	O
)	O
,	O
which	O
is	O
biotransformed	O
to	O
2	B-chem
-	I-chem
thiothiazolidine	I-chem
-	I-chem
4	I-chem
-	I-chem
carboxylic	I-chem
acid	E-chem
(	O
TTCA	S-chem
)	O
.	O

TTCA	S-chem
is	O
used	O
as	O
a	O
biomarker	O
of	O
CS	O
(	O
2	O
)	O
exposure	O
,	O
but	O
there	O
seem	O
to	O
exist	O
inter	O
-	O
and	O
intraindividual	O
variability	O
;	O
which	O
could	O
partly	O
be	O
due	O
to	O
genetic	O
variation	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
TTCA	S-chem
levels	O
and	O
the	O
modifying	O
effects	O
of	O
glutathione	S-chem
-	O
related	O
genes	O
in	O
a	O
group	O
of	O
Swedish	O
rubber	O
workers	O
.	O

METHODS	O
:	O
Urine	O
was	O
collected	O
from	O
both	O
exposed	O
workers	O
and	O
controls	O
during	O
the	O
last	O
4	O
h	O
of	O
the	O
work	O
shift	O
.	O

The	O
level	O
of	O
TTCA	S-chem
in	O
urine	O
was	O
analyzed	O
by	O
liquid	O
chromatograpy	O
tandem	O
mass	O
spectrometry	O
.	O

Genotyping	O
of	O
the	O
single	O
nucleotide	S-chem
polymorphisms	O
GCLC	S-geneY
-	O
129	O
,	O
GCLM	S-geneY
-	O
588	O
,	O
GSTA1	S-geneY
-	O
52	O
,	O
GSTP1	S-geneY
-	O
105	O
and	O
GSTP1	S-geneY
-	O
114	O
and	O
deletions	O
of	O
GSTM1	S-geneY
and	O
GSTT1	S-geneY
were	O
performed	O
with	O
real	O
-	O
time	O
PCR	O
or	O
ordinary	O
PCR	O
and	O
subsequent	O
agarose	O
electrophoresis	O
.	O

RESULTS	O
:	O
The	O
highest	O
levels	O
of	O
TTCA	S-chem
were	O
found	O
among	O
workers	O
curing	O
with	O
salt	O
bath	O
,	O
hot	O
air	O
,	O
microwaves	O
or	O
fluid	O
-	O
bed	O
,	O
and	O
lower	O
levels	O
were	O
found	O
among	O
workers	O
curing	O
with	O
injection	O
and	O
compression	O
molding	O
.	O

Furthermore	O
,	O
with	O
respect	O
to	O
GSTM1	S-geneY
and	O
GSTT1	S-geneY
there	O
were	O
statistically	O
significant	O
differences	O
in	O
TTCA	S-chem
-	O
levels	O
between	O
genotypes	O
among	O
exposed	O
workers	O
but	O
not	O
among	O
controls	O
.	O

The	O
other	O
five	O
polymorphisms	O
had	O
no	O
impact	O
on	O
the	O
TTCA	S-chem
levels	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
relatively	O
high	O
levels	O
of	O
TTCA	S-chem
in	O
urine	O
from	O
Swedish	O
rubber	O
workers	O
.	O

Polymorphisms	O
in	O
GSTM1	S-geneY
and	O
GSTT1	S-geneY
modify	O
the	O
levels	O
.	O

Testosterone	S-chem
deficiency	O
induces	O
markedly	O
decreased	O
serum	O
triglycerides	S-chem
,	O
increased	O
small	O
dense	O
LDL	S-geneN
,	O
and	O
hepatic	O
steatosis	O
mediated	O
by	O
dysregulation	O
of	O
lipid	O
assembly	O
and	O
secretion	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
.	O

OBJECTIVE	O
:	O
Although	O
low	O
serum	O
testosterone	S-chem
(	O
T	O
)	O
is	O
associated	O
with	O
metabolic	O
disorders	O
,	O
the	O
mechanism	O
of	O
this	O
association	O
is	O
unclear	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
T	O
deficiency	O
and	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
on	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
.	O

MATERIALS	O
/	O
METHODS	O
:	O
Orchiectomized	O
(	O
ORX	O
)	O
mice	O
and	O
sham	O
-	O
operated	O
(	O
SHAM	O
)	O
mice	O
were	O
randomly	O
divided	O
into	O
five	O
groups	O
:	O
SHAM	O
mice	O
fed	O
a	O
standard	O
diet	O
(	O
SD	O
)	O
,	O
SHAM	O
mice	O
fed	O
HFD	O
,	O
ORX	O
mice	O
fed	O
SD	O
,	O
ORX	O
mice	O
fed	O
HFD	O
,	O
and	O
ORX	O
mice	O
fed	O
HFD	O
with	O
T	O
supplementation	O
.	O

After	O
4weeks	O
of	O
treatment	O
,	O
we	O
investigated	O
the	O
synthesis	O
and	O
secretion	O
of	O
lipids	O
in	O
the	O
liver	O
and	O
detailed	O
serum	O
lipoprotein	O
profiles	O
in	O
each	O
group	O
.	O

RESULTS	O
:	O
ORX	O
mice	O
fed	O
HFD	O
showed	O
increased	O
hepatic	O
steatosis	O
,	O
markedly	O
decreased	O
serum	O
triglyceride	S-chem
(	O
TG	O
)	O
and	O
TG	O
-	O
VLDL	S-geneN
content	O
,	O
and	O
increased	O
serum	O
very	O
small	O
-	O
LDL	S-geneN
content	O
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
ORX	O
mice	O
fed	O
HFD	O
showed	O
significantly	O
decreased	O
expression	O
of	O
microsomal	B-geneY
triglyceride	I-geneY
transfer	I-geneY
protein	E-geneY
,	O
lipin	B-geneY
-	I-geneY
1	E-geneY
,	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
(	I-geneY
PPAR	I-geneY
)	I-geneY
-	I-geneY
α	E-geneY
and	O
PPAR	B-geneY
-	I-geneY
γ	I-geneY
coactivator	I-geneY
1	I-geneY
-	I-geneY
α	E-geneY
,	O
and	O
significantly	O
increased	O
sterol	B-geneY
regulatory	I-geneY
element	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
,	O
diacylglycerol	B-geneY
acyltransferase	I-geneY
-	I-geneY
2	E-geneY
and	O
fatty	B-geneY
acid	I-geneY
synthase	E-geneY
.	O

Reduction	O
of	O
hepatic	O
AMPK	S-geneN
phosphorylation	O
was	O
observed	O
in	O
ORX	O
mice	O
fed	O
HFD	O
.	O

These	O
perturbations	O
in	O
ORX	O
mice	O
fed	O
HFD	O
were	O
normalized	O
to	O
the	O
levels	O
of	O
SHAM	O
mice	O
fed	O
HFD	O
by	O
T	O
supplementation	O
.	O

CONCLUSION	O
:	O
T	O
deficiency	O
is	O
associated	O
with	O
failure	O
of	O
lipid	O
homeostasis	O
mediated	O
by	O
altered	O
expression	O
of	O
genes	O
involved	O
in	O
hepatic	O
assembly	O
and	O
secretion	O
of	O
lipids	O
.	O

Protective	O
Effects	O
of	O
a	O
Purified	O
Saponin	S-chem
Mixture	O
from	O
Astragalus	O
corniculatus	O
Bieb	O
.	O
,	O
in	O
vivo	O
Hepatotoxicity	O
Models	O
.	O

In	O
this	O
study	O
,	O
the	O
in	O
vivo	O
effects	O
of	O
a	O
purified	O
saponin	S-chem
mixture	O
(	O
PSM	O
)	O
,	O
obtained	O
from	O
Astragalus	O
corniculatus	O
Bieb	O
.	O
,	O
were	O
investigated	O
using	O
two	O
in	O
vivo	O
hepatotoxicity	O
models	O
based	O
on	O
liver	O
damage	O
caused	O
by	O
paracetamol	S-chem
(	O
PC	O
)	O
and	O
carbon	B-chem
tetrachloride	E-chem
(	O
CCl4	S-chem
)	O
.	O

The	O
effects	O
of	O
PSM	O
were	O
compared	O
with	O
silymarin	S-chem
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
orally	O
with	O
20	O
%	O
CCl4	S-chem
or	O
PC	O
(	O
2	O
g	O
/	O
kg	O
)	O
four	O
days	O
after	O
being	O
pre	O
-	O
treated	O
with	O
PSM	O
(	O
100	O
mg	O
/	O
kg	O
)	O
or	O
silymarin	S-chem
(	O
200	O
mg	O
/	O
kg	O
)	O
.	O

A	O
significant	O
decrease	O
of	O
aspartate	B-geneY-C4-2
aminotransferase	E-geneY-C4-2
,	O
alanine	B-geneN-C4-2
aminotransferase	E-geneN-C4-2
,	O
lactate	B-geneN-C4-2
dehydrogenase	E-geneN-C4-2
(	O
LDH	S-geneN-C4-2
)	O
activities	O
and	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
levels	O
and	O
an	O
increase	O
of	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
quantity	O
was	O
observed	O
after	O
CCl4	S-chem-C4-1
and	O
PC	O
administration	O
alone	O
.	O

PSM	O
pre	O
-	O
treatment	O
decreased	O
serum	B-geneN
transaminases	E-geneN
and	O
LDH	S-geneN
activities	O
and	O
MDA	S-chem
levels	O
and	O
increased	O
the	O
levels	O
of	O
cell	O
protector	O
GSH	S-chem
.	O

Biotransformation	O
phase	O
I	O
enzymes	O
were	O
also	O
assessed	O
in	O
both	O
models	O
.	O

In	O
the	O
CCl4	S-chem
hepatotoxicity	O
model	O
,	O
pre	O
-	O
treatment	O
with	O
PSM	O
or	O
silymarin	S-chem-C3-1
resulted	O
in	O
significantly	O
increased	O
activities	O
of	O
ethylmorphine	B-geneN-C3-2
-	I-geneN-C3-2
N	I-geneN-C3-2
-	I-geneN-C3-2
demethylase	E-geneN-C3-2
and	O
aniline	B-geneN-C3-2
4	I-geneN-C3-2
-	I-geneN-C3-2
hydroxylase	E-geneN-C3-2
activity	O
and	O
cytochrome	B-geneN-C3-2
P450	E-geneN-C3-2
,	O
compared	O
to	O
the	O
CCl4	S-chem-C3-1
only	O
group	O
.	O

Neither	O
silymarin	S-chem
nor	O
PSM	O
influenced	O
PC	O
biotransformation	O
.	O

Our	O
results	O
suggest	O
that	O
PSM	O
,	O
obtained	O
from	O
A.	O
corniculatus	O
,	O
Bieb	O
.	O
showed	O
in	O
vivo	O
hepatoprotective	O
and	O
antioxidant	O
activities	O
against	O
CCl4	S-chem
and	O
PC	O
-	O
induced	O
liver	O
damage	O
comparable	O
to	O
that	O
of	O
silymarin	S-chem
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Mechanisms	O
of	O
lipid	O
-	O
lowering	O
agents	O
.	O

Lipid	O
-	O
lowering	O
agents	O
are	O
used	O
with	O
the	O
purpose	O
of	O
ameliorating	O
hyperlipoproteinemias	O
,	O
in	O
order	O
to	O
prevent	O
arterial	O
disease	O
.	O

Lipid	O
-	O
lowering	O
drugs	O
can	O
be	O
classified	O
into	O
absorbable	O
agents	O
and	O
into	O
nonabsorbable	O
compounds	O
,	O
acting	O
within	O
the	O
gastrointestinal	O
lumen	O
.	O

Absorbable	O
drugs	O
(	O
fibric	B-chem-C4-1
acids	E-chem-C4-1
,	O
nicotinic	B-chem-C4-1
acid	E-chem-C4-1
,	O
probucol	S-chem-C4-1
,	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibitors	O
)	O
reduce	O
plasma	B-geneN-C4-2
very	I-geneN-C4-2
-	I-geneN-C4-2
low	I-geneN-C4-2
-	I-geneN-C4-2
density	I-geneN-C4-2
lipoproteins	E-geneN-C4-2
(	O
VLDL	S-geneN-C4-2
)	O
and	O
/	O
or	O
low	B-geneN-C4-2
-	I-geneN-C4-2
density	I-geneN-C4-2
lipoproteins	E-geneN-C4-2
(	O
LDL	S-geneN-C4-2
)	O
by	O
a	O
variety	O
of	O
mechanisms	O
.	O

Fibric	B-chem-C4-1
acids	E-chem-C4-1
,	O
in	O
particular	O
,	O
act	O
by	O
stimulating	O
the	O
catabolism	O
of	O
VLDL	S-geneN-C4-2
and	O
also	O
,	O
as	O
a	O
consequence	O
,	O
improving	O
LDL	S-geneN
delipidation	O
,	O
thus	O
favoring	O
receptor	O
uptake	O
.	O

Nicotinic	B-chem
acid	E-chem
and	O
acipimox	O
interfere	O
with	O
the	O
biosynthesis	O
of	O
LDL	S-geneN
and	O
can	O
also	O
improve	O
the	O
clearance	O
of	O
VLDL	S-geneN
/	O
LDL	S-geneN
.	O

Probucol	S-chem
acts	O
by	O
a	O
newly	O
described	O
mechanism	O
,	O
i.e	O
.	O
accelerating	O
reverse	O
transport	O
of	O
cholesteryl	B-chem-C9-1
esters	E-chem-C9-1
from	O
high	B-geneN-C9-2
-	I-geneN-C9-2
density	I-geneN-C9-2
lipoproteins	E-geneN-C9-2
to	O
lower	B-geneN-C9-2
-	I-geneN-C9-2
density	I-geneN-C9-2
lipoproteins	E-geneN-C9-2
.	O

Finally	O
,	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibitors	O
,	O
interfering	O
with	O
the	O
biosynthesis	O
of	O
cholesterol	S-chem
,	O
can	O
induce	O
an	O
increased	O
expression	O
of	O
liver	O
high	O
-	O
affinity	O
lipoprotein	B-geneN
receptors	E-geneN
.	O

Nonabsorbable	O
agents	O
(	O
anion	O
-	O
exchange	O
resins	O
,	O
neomycin	S-chem
,	O
beta	B-chem
-	I-chem
sitosterol	E-chem
)	O
interrupt	O
the	O
recirculation	O
of	O
bile	B-chem
acids	E-chem
and	O
/	O
or	O
reduce	O
the	O
absorption	O
of	O
cholesterol	S-chem
with	O
the	O
gut	O
.	O

They	O
display	O
a	O
selective	O
activity	O
on	O
hypercholesterolemia	O
,	O
again	O
by	O
increasing	O
LDL	B-geneN
receptor	E-geneN
expression	O
.	O

The	O
choice	O
of	O
one	O
or	O
more	O
lipid	O
-	O
lowering	O
agents	O
will	O
depend	O
upon	O
the	O
patient	O
's	O
phenotype	O
,	O
determining	O
responsiveness	O
to	O
the	O
pharmacological	O
treatment	O
.	O

Inhibition	O
of	O
NF	B-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
by	O
sodium	O
salicylate	O
and	O
aspirin	O
.	O

The	O
transcription	O
factor	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin	B-geneN
-	I-geneN
1	E-geneN
(	O
IL	B-geneN
-	I-geneN
1	E-geneN
)	O
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
,	O
and	O
adhesion	O
molecules	O
.	O

The	O
anti	O
-	O
inflammatory	O
drugs	O
sodium	B-chem-C4-1
salicylate	E-chem-C4-1
and	O
aspirin	S-chem-C4-1
inhibited	O
the	O
activation	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappa	I-geneN-C4-2
B	E-geneN-C4-2
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF	B-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
inhibitor	O
,	O
I	B-geneN
kappa	I-geneN
B	E-geneN
,	O
and	O
therefore	O
NF	B-geneN
-	I-geneN
kappa	I-geneN
B	E-geneN
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	B-chem-C4-1
salicylate	E-chem-C4-1
and	O
aspirin	S-chem-C4-1
also	O
inhibited	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappa	I-geneN-C4-2
B	E-geneN-C4-2
-	O
dependent	O
transcription	O
from	O
the	O
Ig	B-geneY-C4-2
kappa	E-geneY-C4-2
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O

Bioinspired	O
and	O
highly	O
oriented	O
clay	O
nanocomposites	O
with	O
a	O
xyloglucan	O
biopolymer	O
matrix	O
:	O
extending	O
the	O
range	O
of	O
mechanical	O
and	O
barrier	O
properties	O
.	O

The	O
development	O
of	O
clay	O
bionanocomposites	O
requires	O
processing	O
routes	O
with	O
nanostructural	O
control	O
.	O

Moreover	O
,	O
moisture	O
durability	O
is	O
a	O
concern	O
with	O
water	O
-	O
soluble	O
biopolymers	O
.	O

Here	O
,	O
oriented	O
bionanocomposite	O
coatings	O
with	O
strong	O
in	O
-	O
plane	O
orientation	O
of	O
clay	O
platelets	O
are	O
for	O
the	O
first	O
time	O
prepared	O
by	O
continuous	O
water	O
-	O
based	O
processing	O
.	O

Montmorillonite	S-chem
(	O
MTM	S-chem
)	O
and	O
a	O
``	O
new	O
``	O
unmodified	O
biological	O
polymer	O
(	O
xyloglucan	O
(	O
XG	O
)	O
)	O
are	O
combined	O
.	O

The	O
resulting	O
nanocomposites	O
are	O
characterized	O
by	O
FE	O
-	O
SEM	O
,	O
TEM	O
,	O
and	O
XRD	O
.	O

XG	O
adsorption	O
on	O
MTM	S-chem
is	O
measured	O
by	O
quartz	S-chem
crystal	O
microbalance	O
analysis	O
.	O

Mechanical	O
and	O
gas	O
barrier	O
properties	O
are	O
measured	O
,	O
also	O
at	O
high	O
relative	O
humidity	O
.	O

The	O
reinforcement	O
effects	O
are	O
modeled	O
.	O

XG	O
dimensions	O
in	O
composites	O
are	O
estimated	O
using	O
atomistic	O
simulations	O
.	O

The	O
nanostructure	O
shows	O
highly	O
oriented	O
and	O
intercalated	O
clay	O
platelets	O
.	O

The	O
reinforcement	O
efficiency	O
and	O
effects	O
on	O
barrier	O
properties	O
are	O
remarkable	O
and	O
are	O
likely	O
to	O
be	O
due	O
to	O
highly	O
oriented	O
and	O
well	O
-	O
dispersed	O
MTM	S-chem
and	O
strong	O
XG	O
-	O
MTM	S-chem
interactions	O
.	O

Properties	O
are	O
well	O
preserved	O
in	O
humid	O
conditions	O
and	O
the	O
reasons	O
for	O
this	O
are	O
discussed	O
.	O

Secretion	O
of	O
L	B-chem
-	I-chem
glutamate	E-chem
from	O
osteoclasts	O
through	O
transcytosis	O
.	O

Osteoclasts	O
are	O
involved	O
in	O
the	O
catabolism	O
of	O
the	O
bone	O
matrix	O
and	O
eliminate	O
the	O
resulting	O
degradation	O
products	O
through	O
transcytosis	O
,	O
but	O
the	O
molecular	O
mechanism	O
and	O
regulation	O
of	O
transcytosis	O
remain	O
poorly	O
understood	O
.	O

Upon	O
differentiation	O
,	O
osteoclasts	O
express	O
vesicular	B-geneY-C9-2
glutamate	I-geneY-C9-2
transporter	I-geneY-C9-2
1	E-geneY-C9-2
(	O
VGLUT1	S-geneY-C9-2
)	O
,	O
which	O
is	O
essential	O
for	O
vesicular	O
storage	O
and	O
subsequent	O
exocytosis	O
of	O
glutamate	S-chem-C9-1
in	O
neurons	O
.	O

VGLUT1	S-geneY-C9-2
is	O
localized	O
in	O
transcytotic	O
vesicles	O
and	O
accumulates	O
L	B-chem-C9-1
-	I-chem-C9-1
glutamate	E-chem-C9-1
.	O

Osteoclasts	O
secrete	O
L	B-chem
-	I-chem
glutamate	E-chem
and	O
the	O
bone	O
degradation	O
products	O
upon	O
stimulation	O
with	O
KCl	S-chem
or	O
ATP	S-chem
in	O
a	O
Ca2	B-chem
+	E-chem
-	O
dependent	O
manner	O
.	O

KCl	S-chem
-	O
and	O
ATP	S-chem
-	O
dependent	O
secretion	O
of	O
L	B-chem
-	I-chem
glutamate	E-chem
was	O
absent	O
in	O
osteoclasts	O
prepared	O
from	O
VGLUT1	S-geneY
-	O
/	O
-	O
knockout	O
mice	O
.	O

Osteoclasts	O
express	O
mGluR8	S-geneY
,	O
a	O
class	B-geneN
III	I-geneN
metabotropic	I-geneN
glutamate	I-geneN
receptor	E-geneN
.	O

Its	O
stimulation	O
by	O
a	O
specific	O
agonist	O
inhibits	O
secretion	O
of	O
L	B-chem
-	I-chem
glutamate	E-chem
and	O
bone	O
degradation	O
products	O
,	O
whereas	O
its	O
suppression	O
by	O
a	O
specific	O
antagonist	O
stimulates	O
bone	O
resorption	O
.	O

Finally	O
,	O
it	O
was	O
found	O
that	O
VGLUT1	S-geneY
-	O
/	O
-	O
mice	O
develop	O
osteoporosis	O
.	O

Thus	O
,	O
in	O
bone	O
-	O
resorbing	O
osteoclasts	O
,	O
L	B-chem
-	I-chem
glutamate	E-chem
and	O
bone	O
degradation	O
products	O
are	O
secreted	O
through	O
transcytosis	O
and	O
the	O
released	O
L	B-chem
-	I-chem
glutamate	E-chem
is	O
involved	O
in	O
autoregulation	O
of	O
transcytosis	O
.	O

Glutamate	S-chem
signaling	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
bone	O
homeostasis	O
.	O

Minocycline	S-chem
reduces	O
cell	O
death	O
and	O
improves	O
functional	O
recovery	O
after	O
traumatic	O
spinal	O
cord	O
injury	O
in	O
the	O
rat	O
.	O

We	O
examined	O
the	O
effects	O
of	O
minocycline	S-chem
,	O
an	O
anti	O
-	O
inflammatory	O
drug	O
,	O
on	O
functional	O
recovery	O
following	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
.	O

Rats	O
received	O
a	O
mild	O
,	O
weight	O
-	O
drop	O
contusion	O
injury	O
to	O
the	O
spinal	O
cord	O
and	O
were	O
treated	O
with	O
the	O
vehicle	O
or	O
minocycline	S-chem
at	O
a	O
dose	O
of	O
90	O
mg	O
/	O
kg	O
immediately	O
after	O
SCI	O
and	O
then	O
twice	O
at	O
a	O
dose	O
of	O
45	O
mg	O
/	O
kg	O
every	O
12	O
h	O
.	O

Injecting	O
minocycline	S-chem
after	O
SCI	O
improved	O
hind	O
limb	O
motor	O
function	O
as	O
determined	O
by	O
the	O
Basso	O
-	O
Beattie	O
-	O
Bresnahan	O
(	O
BBB	O
)	O
locomotor	O
open	O
field	O
behavioral	O
rating	O
test	O
.	O

Twenty	O
four	O
to	O
38	O
days	O
after	O
SCI	O
,	O
BBB	O
scores	O
were	O
significantly	O
higher	O
in	O
minocycline	S-chem
-	O
treated	O
rats	O
as	O
compared	O
with	O
those	O
in	O
vehicle	O
-	O
treated	O
rats	O
.	O

Morphological	O
analysis	O
showed	O
that	O
lesion	O
size	O
increased	O
progressively	O
in	O
both	O
vehicle	O
-	O
treated	O
and	O
minocycline	S-chem
-	O
treated	O
spinal	O
cords	O
.	O

However	O
,	O
in	O
response	O
to	O
treatment	O
with	O
minocycline	S-chem
,	O
the	O
lesion	O
size	O
was	O
significantly	O
reduced	O
at	O
21	O
-	O
38	O
days	O
after	O
SCI	O
when	O
compared	O
to	O
the	O
vehicle	O
control	O
.	O

Minocycline	S-chem
treatment	O
significantly	O
reduced	O
the	O
number	O
of	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
-	O
mediated	O
deoxyuridine	B-chem
triphosphate	I-chem
-	I-chem
biotin	E-chem
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
-	O
positive	O
cells	O
24	O
h	O
after	O
SCI	O
as	O
compared	O
to	O
that	O
of	O
the	O
vehicle	O
control	O
.	O

DNA	O
gel	O
electrophoresis	O
also	O
revealed	O
a	O
marked	O
decrease	O
in	O
DNA	O
laddering	O
in	O
response	O
to	O
treatment	O
with	O
minocycline	S-chem
.	O

In	O
addition	O
,	O
minocycline	S-chem-C4-1
treatment	O
significantly	O
reduced	O
the	O
specific	O
caspase	B-geneY-C4-2
-	I-geneY-C4-2
3	E-geneY-C4-2
activity	O
after	O
SCI	O
as	O
compared	O
to	O
that	O
of	O
vehicle	O
control	O
.	O

Furthermore	O
,	O
RT	O
-	O
PCR	O
analyses	O
revealed	O
that	O
minocycline	S-chem-MU-1
treatment	O
increased	O
expression	O
of	O
interleukin	B-geneY-C3-2
-	I-geneY-C3-2
10	E-geneY-C3-2
mRNA	O
but	O
decreased	O
tumor	B-geneY-C4-2
necrosis	I-geneY-C4-2
factor	I-geneY-C4-2
-	I-geneY-C4-2
alpha	E-geneY-C4-2
expression	O
.	O

These	O
data	O
suggest	O
that	O
,	O
after	O
SCI	O
,	O
minocycline	S-chem
treatment	O
modulated	O
expression	O
of	O
cytokines	S-geneN
,	O
attenuated	O
cell	O
death	O
and	O
the	O
size	O
of	O
lesions	O
,	O
and	O
improved	O
functional	O
recovery	O
in	O
the	O
injured	O
rat	O
.	O

This	O
approach	O
may	O
provide	O
a	O
therapeutic	O
intervention	O
enabling	O
us	O
to	O
reduce	O
cell	O
death	O
and	O
improve	O
functional	O
recovery	O
after	O
SCI	O
.	O

Pretreatment	O
renal	O
vascular	O
tone	O
predicts	O
the	O
effect	O
of	O
specific	O
renin	S-geneY
inhibition	O
on	O
natriuresis	O
in	O
essential	O
hypertension	O
.	O

BACKGROUND	O
:	O
In	O
essential	O
hypertension	O
an	O
elevated	O
renal	O
vascular	O
resistance	O
(	O
RVR	O
)	O
may	O
be	O
a	O
marker	O
of	O
renin	S-geneY
-	O
angiotensin	S-geneY
-	O
aldosterone	S-chem
system	O
-	O
mediated	O
impairment	O
of	O
renal	O
sodium	S-chem
excretion	O
.	O

This	O
hypothesis	O
was	O
tested	O
by	O
investigating	O
whether	O
,	O
in	O
subjects	O
with	O
essential	O
hypertension	O
,	O
the	O
natriuretic	O
response	O
to	O
specific	O
renin	S-geneY-C4-2
-	O
angiotensin	S-geneY-C4-2
-	O
aldosterone	S-chem
system	O
(	O
RAAS	O
)	O
blockade	O
by	O
renin	S-geneY-C4-2
-	O
inhibitor	O
remikiren	S-chem-C4-1
could	O
be	O
predicted	O
from	O
pretreatment	O
renal	O
vascular	O
tone	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Renal	O
hemodynamics	O
,	O
and	O
the	O
effects	O
of	O
single	O
(	O
n	O
=	O
17	O
)	O
and	O
multiple	O
doses	O
(	O
n	O
=	O
8	O
,	O
8	O
days	O
)	O
of	O
remikiren	S-chem
(	O
600	O
mg	O
day	O
-	O
1	O
)	O
on	O
sodium	S-chem
excretion	O
were	O
studied	O
under	O
conditions	O
of	O
carefully	O
controlled	O
sodium	S-chem
balance	O
.	O

RESULTS	O
:	O
Pretreatment	O
renal	O
vascular	O
tone	O
showed	O
considerable	O
individual	O
differences	O
:	O
filtration	O
fraction	O
(	O
FF	O
)	O
ranged	O
from	O
21.2	O
to	O
30.3	O
%	O
and	O
RVR	O
from	O
18.8	O
to	O
33.5	O
10	O
-	O
2	O
mmHg	O
min	O
mL	O
-	O
1	O
in	O
the	O
single	O
dose	O
study	O
,	O
and	O
FF	O
from	O
20.8	O
to	O
24.9	O
%	O
and	O
RVR	O
from	O
14.8	O
to	O
28.8	O
10	O
-	O
2	O
mmHg	O
min	O
mL	O
-	O
1	O
in	O
the	O
multiple	O
dose	O
study	O
.	O

Remikiren	S-chem
induced	O
a	O
fall	O
in	O
blood	O
pressure	O
,	O
FF	O
and	O
RVR	O
,	O
with	O
considerable	O
interindividual	O
variability	O
in	O
natriuretic	O
response	O
.	O

During	O
single	O
dose	O
,	O
cumulative	O
sodium	S-chem
loss	O
was	O
5.1	O
mmol	O
per	O
5	O
h	O
(	O
-	O
8.8	O
to	O
+	O
24.6	O
)	O
,	O
whereas	O
after	O
8	O
days	O
treatment	O
cumulative	O
sodium	S-chem
loss	O
was	O
72	O
+	O
/	O
-	O
30	O
mmol	O
(	O
-	O
46	O
to	O
+	O
187	O
)	O
.	O

The	O
natriuretic	O
response	O
to	O
remikiren	S-chem
during	O
single	O
as	O
well	O
as	O
multiple	O
dose	O
significantly	O
correlated	O
with	O
pretreatment	O
renal	O
vascular	O
tone	O
(	O
estimated	O
from	O
FF	O
and	O
RVR	O
)	O
but	O
not	O
with	O
remikiren	S-chem
-	O
induced	O
changes	O
in	O
renal	O
hemodynamics	O
or	O
in	O
hormonal	O
parameters	O
.	O

Cumulative	O
sodium	S-chem
loss	O
was	O
largest	O
in	O
patients	O
with	O
a	O
higher	O
pretreatment	O
FF	O
and	O
RVR	O
(	O
r	O
=	O
0.74	O
,	O
P	O
<	O
0.001	O
and	O
r	O
=	O
0.52	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
,	O
single	O
dose	O
;	O
and	O
r	O
=	O
0.75	O
,	O
P	O
<	O
0.05	O
and	O
r	O
=	O
0.73	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
,	O
multiple	O
dose	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
in	O
essential	O
hypertension	O
an	O
elevated	O
renal	O
vascular	O
tone	O
is	O
a	O
marker	O
of	O
RAAS	O
-	O
mediated	O
impairment	O
of	O
sodium	S-chem
excretion	O
.	O

The	O
effects	O
of	O
jaspamide	S-chem
on	O
human	O
cardiomyocyte	O
function	O
and	O
cardiac	B-geneN
ion	I-geneN
channel	E-geneN
activity	O
.	O

Jaspamide	S-chem
(	O
jasplakinolide	S-chem
;	O
NSC	B-chem
-	I-chem
613009	E-chem
)	O
is	O
a	O
cyclodepsipeptide	S-chem
that	O
has	O
antitumor	O
activity	O
.	O

A	O
narrow	O
margin	O
of	O
safety	O
was	O
observed	O
between	O
doses	O
required	O
for	O
efficacy	O
in	O
mouse	O
tumor	O
models	O
and	O
doses	O
that	O
caused	O
severe	O
acute	O
toxicity	O
in	O
rats	O
and	O
dogs	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
the	O
observed	O
toxicity	O
was	O
due	O
to	O
cardiotoxicity	O
.	O

Jaspamide	S-chem
was	O
tested	O
in	O
a	O
patch	O
clamp	O
assay	O
to	O
determine	O
its	O
effect	O
on	O
selected	O
cardiac	B-geneN
ion	I-geneN
channels	E-geneN
.	O

Jaspamide	S-chem
(	O
10	O
μM	O
)	O
inhibited	O
Kv1.5	O
activity	O
by	O
98.5	O
%	O
.	O

Jaspamide	S-chem-C4-1
also	O
inhibited	O
other	O
channels	O
including	O
Cav1.2	S-geneN-C4-2
,	O
Cav3.2	S-geneN-C4-2
,	O
and	O
HCN2	S-geneN-C4-2
;	O
however	O
,	O
the	O
Kv11.1	S-geneY
(	O
hERG	S-geneY
)	O
channel	O
was	O
minimally	O
affected	O
.	O

Using	O
spontaneously	O
contracting	O
human	O
cardiomyocytes	O
derived	O
from	O
induced	O
pluripotent	O
stem	O
cells	O
,	O
effects	O
on	O
cardiomyocyte	O
contraction	O
and	O
viability	O
were	O
also	O
examined	O
.	O

Jaspamide	S-chem
(	O
30	O
nM	O
to	O
30	O
μM	O
)	O
decreased	O
cardiomyocyte	O
cell	O
indices	O
and	O
beat	O
amplitude	O
,	O
putative	O
measurements	O
of	O
cell	O
viability	O
and	O
cardiac	O
contractility	O
,	O
respectively	O
.	O

Concentration	O
-	O
dependent	O
increases	O
in	O
rhythmic	O
beating	O
rate	O
were	O
noted	O
at	O
≤	O
6	O
h	O
of	O
treatment	O
,	O
followed	O
by	O
dose	O
-	O
dependent	O
decreases	O
after	O
6	O
and	O
72	O
h	O
exposure	O
.	O

The	O
toxic	O
effects	O
of	O
jaspamide	S-chem
were	O
compared	O
with	O
that	O
of	O
the	O
known	O
cardiotoxicant	O
mitoxantrone	S-chem
,	O
and	O
confirmed	O
by	O
multiparameter	O
fluorescence	O
imaging	O
analysis	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
toxicity	O
observed	O
in	O
rats	O
and	O
dogs	O
is	O
due	O
to	O
toxic	O
effects	O
of	O
jaspamide	S-chem
on	O
cardiomyocytes	O
.	O

Store	O
-	O
operated	O
Ca2	B-chem
+	E-chem
Entry	O
(	O
SOCE	O
)	O
Induced	O
by	O
Protease	B-geneY
-	I-geneY
activated	I-geneY
Receptor	I-geneY
-	I-geneY
1	E-geneY
mediates	O
STIM1	S-geneY
Phosphorylation	O
to	O
inhibit	O
SOCE	O
in	O
Endothelial	O
Cells	O
through	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
Protein	I-geneY
Kinase	E-geneY
and	O
p38beta	S-geneY
Mitogen	B-geneN
-	I-geneN
activated	I-geneN
Protein	I-geneN
Kinase	E-geneN
.	O

The	O
Ca2	B-chem
+	E-chem
sensor	O
STIM1	S-geneY
is	O
crucial	O
for	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	B-chem
+	E-chem
entry	O
(	O
SOCE	O
)	O
through	O
TRPC	S-geneN
and	O
Orai	B-geneN
channels	E-geneN
.	O

STIM1	S-geneY
phosphorylation	O
serves	O
as	O
an	O
off	O
-	O
switch	O
for	O
SOCE	O
.	O

However	O
,	O
the	O
signaling	O
pathway	O
for	O
STIM1	S-geneY
phosphorylation	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
SOCE	O
activates	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	E-geneY
(	O
AMPK	S-geneY
)	O
;	O
its	O
effector	O
p38β	S-geneY
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
p38β	S-geneY
MAPK	S-geneN
)	O
phosphorylates	O
STIM1	S-geneY
,	O
thus	O
inhibiting	O
SOCE	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Activation	O
of	O
AMPK	S-geneY-C3-2
using	O
AICAR	S-chem-MU-1
resulted	O
in	O
STIM1	S-geneY-C3-2
phosphorylation	O
on	O
serine	S-chem
residues	O
and	O
prevented	O
PAR	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
-	O
induced	O
Ca2	B-chem
+	E-chem
entry	O
.	O

Further	O
,	O
AICAR	S-chem-C4-1
pretreatment	O
blocked	O
PAR	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
-	O
induced	O
increase	O
in	O
permeability	O
of	O
mouse	O
-	O
lung	O
microvessels	O
.	O

Activation	O
of	O
SOCE	O
with	O
thrombin	S-geneY
caused	O
phosphorylation	O
of	O
isoform	O
α1	O
,	O
but	O
not	O
α2	O
of	O
the	O
AMPK	S-geneY
catalytic	O
subunit	O
.	O

Moreover	O
,	O
knockdown	O
of	O
AMPKα1	S-geneY
augmented	O
SOCE	O
induced	O
by	O
thrombin	S-geneY
.	O

Interestingly	O
,	O
SB203580	S-chem-C4-1
,	O
a	O
selective	O
inhibitor	O
of	O
p38	S-geneN-C4-2
MAPK	S-geneN-C4-2
,	O
blocked	O
STIM1	S-geneY-C4-2
phosphorylation	O
and	O
led	O
to	O
sustained	O
STIM1	S-geneY
-	O
puncta	O
formation	O
and	O
Ca2	B-chem
+	E-chem
entry	O
.	O

Of	O
the	O
three	O
p38	S-geneN
MAPK	S-geneN
isoforms	O
expressed	O
in	O
ECs	O
,	O
p38β	S-geneY
knockdown	O
prevented	O
PAR	B-geneY
-	I-geneY
1	E-geneY
-	O
mediated	O
STIM1	S-geneY
phosphorylation	O
and	O
potentiated	O
SOCE	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
the	O
SOCE	O
downstream	O
target	O
CaMKKβ	S-geneY
or	O
knockdown	O
of	O
AMPKα1	S-geneY
suppressed	O
PAR	B-geneY
-	I-geneY
1	E-geneY
-	O
mediated	O
phosphorylation	O
of	O
p38β	S-geneY
and	O
hence	O
STIM1	S-geneY
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
SOCE	O
activates	O
CaMKKβ	S-geneY
-	O
AMPKα1	S-geneY
-	O
p38β	S-geneY
MAPK	S-geneN
signaling	O
to	O
phosphorylate	O
STIM1	S-geneY
,	O
thereby	O
suppressing	O
endothelial	O
SOCE	O
and	O
permeability	O
responses	O
.	O

Changes	O
of	O
phosphorylation	O
of	O
cAMP	B-geneN
response	I-geneN
element	I-geneN
binding	I-geneN
protein	E-geneN
in	O
rat	O
nucleus	O
accumbens	O
after	O
chronic	O
ethanol	S-chem
intake	O
:	O
naloxone	S-chem
reversal	O
.	O

AIM	O
:	O
To	O
study	O
the	O
changes	O
in	O
the	O
expression	O
and	O
phosphorylation	O
of	O
cAMP	B-geneN
response	I-geneN
element	I-geneN
binding	I-geneN
protein	E-geneN
(	O
CREB	S-geneN
)	O
in	O
the	O
rat	O
nucleus	O
accumbens	O
after	O
chronic	O
ethanol	S-chem
intake	O
and	O
its	O
withdrawal	O
.	O

METHODS	O
:	O
Ethanol	S-chem
was	O
given	O
in	O
drinking	O
water	O
at	O
the	O
concentration	O
of	O
6	O
%	O
(	O
v	O
/	O
v	O
)	O
,	O
for	O
one	O
month	O
.	O

Changes	O
in	O
the	O
levels	O
of	O
CREB	S-geneN
and	O
phospho	B-geneN
-	I-geneN
CREB	E-geneN
(	O
p	B-geneN
-	I-geneN
CREB	E-geneN
)	O
protein	O
in	O
the	O
nucleus	O
accumbens	O
were	O
measured	O
by	O
immunohistochemistry	O
methods	O
.	O

RESULTS	O
:	O
Ethanol	S-chem-C4-1
given	O
to	O
rats	O
in	O
drinking	O
water	O
decreased	O
the	O
level	O
of	O
p	B-geneN-C4-2
-	I-geneN-C4-2
CREB	E-geneN-C4-2
protein	O
in	O
the	O
nucleus	O
accumbens	O
(	O
-	O
75	O
%	O
)	O
at	O
the	O
time	O
of	O
exposure	O
to	O
ethanol	S-chem
.	O

The	O
decrement	O
of	O
p	B-geneN-C4-2
-	I-geneN-C4-2
CREB	E-geneN-C4-2
protein	O
in	O
the	O
nucleus	O
accumbens	O
remained	O
at	O
24	O
h	O
(	O
-	O
35	O
%	O
)	O
and	O
72	O
h	O
(	O
-	O
28	O
%	O
)	O
of	O
ethanol	S-chem-C4-1
withdrawal	O
,	O
which	O
recovered	O
toward	O
control	O
level	O
after	O
7	O
d	O
of	O
ethanol	S-chem-C4-1
withdrawal	O
.	O

However	O
,	O
chronic	O
ethanol	S-chem
,	O
as	O
well	O
as	O
ethanol	S-chem
withdrawal	O
failed	O
to	O
produce	O
any	O
significant	O
alteration	O
in	O
the	O
level	O
of	O
CREB	S-geneN
protein	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Naloxone	S-chem
(	O
alone	O
)	O
treatment	O
of	O
rats	O
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
CREB	S-geneN
and	O
p	B-geneN
-	I-geneN
CREB	E-geneN
protein	O
in	O
the	O
nucleus	O
accumbens	O
.	O

However	O
,	O
when	O
naloxone	O
was	O
administered	O
concurrently	O
with	O
ethanol	S-chem-C4-1
treatment	O
,	O
it	O
antagonized	O
the	O
down	O
-	O
regulation	O
of	O
p	B-geneN-C4-2
-	I-geneN-C4-2
CREB	E-geneN-C4-2
protein	O
in	O
the	O
nucleus	O
accumbens	O
(	O
142	O
%	O
)	O
of	O
rats	O
exposed	O
to	O
ethanol	S-chem-C4-1
.	O

CONCLUSION	O
:	O
A	O
long	O
-	O
term	O
intake	O
of	O
ethanol	S-chem-C4-1
solution	O
down	O
-	O
regulates	O
the	O
phosphorylation	O
of	O
CREB	S-geneN-MU-2
in	O
the	O
nucleus	O
accumbens	O
,	O
and	O
those	O
changes	O
can	O
be	O
reversed	O
by	O
naloxone	S-chem-C3-1
,	O
which	O
may	O
be	O
one	O
kind	O
of	O
the	O
molecular	O
mechanisms	O
associated	O
with	O
ethanol	S-chem
dependence	O
.	O

Serotonin	B-geneY
transporter	E-geneY
production	O
and	O
degradation	O
rates	O
:	O
studies	O
with	O
RTI	B-chem
-	I-chem
76	E-chem
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
turnover	O
of	O
the	O
serotonin	B-geneY
transporter	E-geneY
(	O
SERT	S-geneY
)	O
by	O
determining	O
its	O
production	O
rate	O
(	O
r	O
)	O
,	O
degradation	O
rate	O
constant	O
(	O
k	O
)	O
and	O
half	O
-	O
life	O
of	O
recovery	O
(	O
t1	O
/	O
2	O
)	O
.	O

The	O
turnover	O
of	O
SERT	S-geneY-C4-2
was	O
determined	O
from	O
the	O
rate	O
of	O
recovery	O
of	O
binding	O
after	O
administration	O
of	O
RTI	B-chem-C4-1
-	I-chem-C4-1
76	E-chem-C4-1
,	O
an	O
irreversible	O
inhibitor	O
of	O
ligand	O
binding	O
.	O

In	O
preliminary	O
studies	O
,	O
in	O
vitro	O
incubation	O
of	O
rat	O
cerebral	O
cortex	O
with	O
RTI	B-chem-C4-1
-	I-chem-C4-1
76	E-chem-C4-1
produced	O
a	O
wash	O
and	O
temperature	O
resistant	O
inhibition	O
of	O
SERT	S-geneY-C4-2
binding	O
densities	O
(	O
Bmax	O
)	O
.	O

Citalopram	S-chem
protected	O
against	O
the	O
RTI	B-chem-C4-1
-	I-chem-C4-1
76	E-chem-C4-1
-	O
induced	O
inhibition	O
of	O
SERT	S-geneY-C4-2
binding	O
.	O

Following	O
6	O
h	O
of	O
in	O
vivo	O
intracerebroventricular	O
injections	O
of	O
100	O
nmol	O
of	O
RTI	B-chem
-	I-chem
76	E-chem
,	O
there	O
was	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
reduction	O
(	O
-	O
60	O
%	O
)	O
of	O
SERT	S-geneY
binding	O
in	O
hippocampus	O
and	O
striatum	O
,	O
without	O
a	O
change	O
in	O
the	O
Kd	O
.	O

SERT	S-geneY
binding	O
densities	O
recovered	O
over	O
several	O
days	O
,	O
reaching	O
control	O
levels	O
by	O
day	O
14	O
.	O

The	O
recovery	O
curve	O
fit	O
the	O
standard	O
model	O
of	O
protein	O
synthesis	O
and	O
degradation	O
.	O

The	O
turnover	O
parameters	O
of	O
SERT	S-geneY
were	O
determined	O
in	O
hippocampus	O
and	O
striatum	O
,	O
regions	O
that	O
receive	O
serotonergic	O
innervation	O
from	O
the	O
dorsal	O
and	O
median	O
midbrain	O
raphe	O
nuclei	O
,	O
respectively	O
.	O

In	O
the	O
hippocampus	O
,	O
the	O
production	O
rate	O
constant	O
was	O
2.36	O
fmol	O
mg	O
protein	O
(	O
-	O
1	O
)	O
h	O
(	O
-	O
1	O
)	O
;	O
the	O
degradation	O
rate	O
constant	O
was	O
0.0077	O
h	O
(	O
-	O
1	O
)	O
;	O
and	O
the	O
half	O
-	O
life	O
of	O
the	O
SERT	S-geneY
recovery	O
was	O
3.4	O
days	O
.	O

The	O
values	O
in	O
the	O
striatum	O
were	O
similar	O
.	O

The	O
decrease	O
and	O
recovery	O
of	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
-	I-chem-C9-1
5	I-chem-C9-1
-	I-chem-C9-1
HT	E-chem-C9-1
uptake	O
correlated	O
highly	O
(	O
r	O
=	O
0.93	O
)	O
with	O
the	O
recovery	O
of	O
SERT	S-geneY-C9-2
binding	O
.	O

[	O
Effects	O
of	O
Panax	O
notoginseng	O
saponins	S-chem
on	O
mRNA	O
expressions	O
of	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
,	O
its	O
correlative	O
factors	O
and	O
cysteinyl	B-geneN
-	I-geneN
aspartate	I-geneN
specific	I-geneN
protease	E-geneN
after	O
cerebral	O
ischemia	O
-	O
reperfusion	O
in	O
rats	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
Panax	O
notoginseng	O
saponins	S-chem
(	O
PNS	O
)	O
on	O
mRNA	O
expressions	O
of	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
(	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
receptor	I-geneY
type	I-geneY
I	E-geneY
(	O
IL	B-geneY
-	I-geneY
1RI	E-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
receptor	I-geneY
antagonist	E-geneY
(	O
IL	B-geneY
-	I-geneY
1ra	E-geneY
)	O
,	O
intercellular	B-geneY
adhesion	I-geneY
molecule	I-geneY
-	I-geneY
1	E-geneY
(	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
cysteinyl	B-geneY
-	I-geneY
aspartate	I-geneY
specific	I-geneY
protease	I-geneY
-	I-geneY
1	E-geneY
(	O
caspase	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
after	O
cerebral	O
ischemia	O
-	O
reperfusion	O
in	O
rats	O
.	O

METHODS	O
:	O
Focal	O
cerebral	O
ischemia	O
reperfusion	O
in	O
rats	O
was	O
induced	O
by	O
the	O
method	O
of	O
nylon	O
monofilament	O
via	O
the	O
internal	O
carotid	O
artery	O
.	O

PNS	O
was	O
administered	O
intraperitoneally	O
respectively	O
five	O
minutes	O
before	O
cerebral	O
ischemia	O
and	O
twelve	O
hours	O
after	O
cerebral	O
ischemia	O
.	O

After	O
cerebral	O
ischemia	O
for	O
two	O
hours	O
followed	O
by	O
reperfusion	O
for	O
twenty	O
two	O
hours	O
,	O
the	O
mRNA	O
expressions	O
of	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
,	O
IL	B-geneY
-	I-geneY
1RI	E-geneY
,	O
IL	B-geneY
-	I-geneY
1ra	E-geneY
,	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
in	O
brain	O
tissue	O
were	O
determined	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

RESULTS	O
:	O
After	O
cerebral	O
ischemia	O
for	O
two	O
hours	O
followed	O
by	O
reperfusion	O
for	O
twenty	O
two	O
hours	O
,	O
the	O
mRNA	O
expression	O
levels	O
of	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
,	O
IL	B-geneY
-	I-geneY
1RI	E-geneY
,	O
IL	B-geneY
-	I-geneY
1ra	E-geneY
,	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
in	O
brain	O
tissue	O
in	O
the	O
untreated	O
group	O
were	O
obviously	O
elevated	O
as	O
compared	O
to	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
(	O
P	O
<	O
0.05	O
or	O
P	O
<	O
0.01	O
)	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
,	O
IL	B-geneY
-	I-geneY
1RI	E-geneY
,	O
IL	B-geneY
-	I-geneY
1ra	E-geneY
in	O
brain	O
tissue	O
in	O
the	O
PNS	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
untreated	O
group	O
,	O
but	O
higher	O
than	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
,	O
and	O
without	O
statistical	O
differences	O
as	O
compared	O
to	O
those	O
in	O
the	O
sham	O
-	O
operation	O
group	O
and	O
in	O
the	O
untreated	O
group	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
mRNA	O
expression	O
level	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
in	O
brain	O
tissue	O
in	O
the	O
PNS	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
untreated	O
group	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
PNS	O
had	O
no	O
effect	O
on	O
the	O
mRNA	O
expression	O
levels	O
of	O
ICAM	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
1	E-geneY
and	O
caspase	B-geneY
-	I-geneY
8	E-geneY
in	O
brain	O
tissue	O
.	O

CONCLUSION	O
:	O
PNS	O
can	O
inhibit	O
the	O
mRNA	O
expression	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
,	O
slightly	O
inhibit	O
the	O
mRNA	O
expressions	O
of	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
and	O
its	O
correlative	O
inflammatory	O
factors	O
in	O
brain	O
tissue	O
.	O

The	O
protective	O
effects	O
of	O
PNS	O
on	O
cerebral	O
injury	O
induced	O
by	O
ischemia	O
-	O
reperfusion	O
may	O
be	O
related	O
to	O
inhibiting	O
the	O
mRNA	O
expressions	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
,	O
IL	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
and	O
its	O
correlative	O
inflammatory	O
factors	O
in	O
brain	O
tissue	O
.	O

Apomorphine	S-chem
is	O
a	O
bimodal	O
modulator	O
of	O
TRPA1	S-geneY
channels	O
.	O

Apomorphine	S-chem
is	O
a	O
non	O
-	O
narcotic	O
derivative	O
of	O
morphine	S-chem
,	O
which	O
acts	O
as	O
a	O
dopamine	S-chem
agonist	O
and	O
is	O
clinically	O
used	O
to	O
treat	O
``	O
off	O
-	O
states	O
``	O
in	O
patients	O
suffering	O
from	O
Parkinson	O
's	O
disease	O
.	O

Adverse	O
effects	O
of	O
apomorphine	S-chem
treatment	O
include	O
severe	O
emesis	O
and	O
nausea	O
,	O
and	O
ulceration	O
and	O
pain	O
at	O
the	O
injection	O
site	O
.	O

We	O
wanted	O
to	O
test	O
whether	O
sensory	O
transient	B-geneN
receptor	I-geneN
potential	I-geneN
(	I-geneN
TRP	I-geneN
)	I-geneN
channels	E-geneN
are	O
a	O
molecular	O
target	O
for	O
apomorphine	S-chem
.	O

Here	O
,	O
we	O
show	O
that	O
rTRPV1	S-geneY
,	O
rTRPV2	S-geneY
,	O
rTRPV3	S-geneY
,	O
and	O
mTRPV4	S-geneY
,	O
as	O
well	O
as	O
hTRPM8	S-geneY
,	O
and	O
rTRPM3	S-geneY
,	O
which	O
are	O
expressed	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
,	O
are	O
insensitive	O
toward	O
apomorphine	S-chem
treatment	O
.	O

This	O
also	O
applied	O
to	O
the	O
cellular	O
redox	O
sensor	O
hTRPM2	S-geneY
.	O

On	O
the	O
contrary	O
,	O
human	B-geneY
TRPA1	E-geneY
could	O
be	O
concentration	O
-	O
dependently	O
modulated	O
by	O
apomorphine	S-chem
.	O

Whereas	O
the	O
addition	O
of	O
apomorphine	S-chem-C4-1
in	O
the	O
low	O
micromolar	O
range	O
produced	O
an	O
irreversible	O
activation	O
of	O
the	O
channel	O
,	O
application	O
of	O
higher	O
concentrations	O
caused	O
a	O
reversible	O
voltage	O
-	O
dependent	O
inhibition	O
of	O
heterologously	O
expressed	O
TRPA1	S-geneY-C4-2
channels	O
,	O
resulting	O
from	O
a	O
reduction	O
of	O
single	O
-	O
channel	O
open	O
times	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
that	O
apomorphine	S-chem-C3-1
also	O
acts	O
on	O
endogenous	O
TRPA1	S-geneN
in	O
cultured	O
dorsal	O
root	O
ganglion	O
neurons	O
from	O
rats	O
and	O
in	O
the	O
enterochromaffin	O
model	O
cell	O
line	O
QGP	O
-	O
1	O
,	O
from	O
which	O
serotonin	S-chem
is	O
released	O
upon	O
activation	O
of	O
TRPA1	S-geneY-C3-2
.	O

Our	O
study	O
shows	O
that	O
human	B-geneY
TRPA1	E-geneY
is	O
a	O
target	O
for	O
apomorphine	S-chem-C3-1
,	O
suggesting	O
that	O
an	O
activation	O
of	O
TRPA1	S-geneY-C3-2
might	O
contribute	O
to	O
adverse	O
side	O
effects	O
such	O
as	O
nausea	O
and	O
painful	O
injections	O
,	O
which	O
can	O
occur	O
during	O
treatment	O
with	O
apomorphine	S-chem-C3-1
.	O

Activating	O
glucocorticoid	B-geneY-C3-2
receptor	E-geneY-C3-2
-	O
ERK	S-geneN-C3-2
signaling	O
pathway	O
contributes	O
to	O
ginsenoside	B-chem-MU-1
Rg1	E-chem-MU-1
protection	O
against	O
β	B-geneY-C4-2
-	I-geneY-C4-2
amyloid	I-geneY-C4-2
peptide	E-geneY-C4-2
-	O
induced	O
human	O
endothelial	O
cells	O
apoptosis	O
.	O

The	O
deposition	O
of	O
β	B-geneY
-	I-geneY
amyloid	E-geneY
(	O
Aβ	S-geneY
)	O
in	O
neurons	O
and	O
vascular	O
cells	O
of	O
the	O
brain	O
has	O
been	O
characterized	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Ginsenoside	B-chem
Rg1	E-chem
(	O
Rg1	S-chem
)	O
is	O
an	O
active	O
components	O
in	O
Panax	O
ginseng	O
,	O
a	O
famous	O
traditional	O
Chinese	O
medicines	O
recorded	O
in	O
Compendium	O
of	O
Materia	O
Medica	O
.	O

Present	O
study	O
attempted	O
to	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
Aβ	S-geneY
-	O
mediated	O
insult	O
and	O
the	O
protective	O
effects	O
of	O
Rg1	S-chem
on	O
human	O
endothelial	O
cells	O
.	O

Rg1	S-chem-C4-1
attenuated	O
the	O
Aβ25	B-geneY-C4-2
-	I-geneY-C4-2
35	E-geneY-C4-2
-	O
associated	O
mitochondrial	O
apoptotic	O
events	O
,	O
accompanied	O
by	O
inhibiting	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1α	E-geneY-C4-2
expression	O
followed	O
by	O
intracellular	O
reactive	O
nitrogen	S-chem
species	O
generation	O
,	O
and	O
protein	O
nitrotyrosination	O
.	O

These	O
protective	O
effects	O
were	O
abolished	O
by	O
glucocorticoid	B-geneY-C6-2
receptor	E-geneY-C6-2
(	O
GR	S-geneY-C6-2
)	O
antagonist	O
RU486	S-chem-C6-1
or	O
p	B-geneN-C4-2
-	I-geneN-C4-2
ERK	E-geneN-C4-2
inhibitor	O
U0126	S-chem-C4-1
rather	O
than	O
estrogen	B-geneY-C6-2
receptor	I-geneY-C6-2
α	E-geneY-C6-2
antagonist	O
ICI	B-chem-C6-1
82,780	E-chem-C6-1
.	O

Taken	O
together	O
,	O
our	O
results	O
suggested	O
that	O
Rg1	S-chem-MU-1
protected	O
against	O
Aβ25	B-geneY-C4-2
-	I-geneY-C4-2
35	E-geneY-C4-2
-	O
induced	O
apoptosis	O
at	O
least	O
in	O
part	O
by	O
two	O
complementary	O
GR	S-geneY
-	O
dependent	O
ERK	S-geneN-C3-2
phosphorylation	O
pathways	O
:	O
(	O
1	O
)	O
down	O
-	O
regulating	O
HIF	B-geneY-C4-2
-	I-geneY-C4-2
1α	E-geneY-C4-2
initiated	O
protein	O
nitrotyrosination	O
,	O
and	O
(	O
2	O
)	O
inhibiting	O
mitochondrial	O
apoptotic	O
cascades	O
.	O

These	O
data	O
provided	O
a	O
novel	O
insight	O
to	O
the	O
mechanisms	O
of	O
Rg1protective	S-chem
effects	O
on	O
Aβ25	B-geneY-C4-2
-	I-geneY-C4-2
35	E-geneY-C4-2
-	O
induced	O
endothelial	O
cells	O
apoptosis	O
,	O
suggesting	O
that	O
GR	S-geneY
-	O
ERK	S-geneN
signaling	O
pathway	O
might	O
play	O
an	O
important	O
role	O
in	O
it	O
.	O

Ankyrin	S-geneN
repeat	O
and	O
suppressors	O
of	O
cytokine	B-geneN
signaling	I-geneN
box	I-geneN
protein	E-geneN
asb	B-geneY
-	I-geneY
9	E-geneY
targets	O
creatine	B-geneY
kinase	I-geneY
B	E-geneY
for	O
degradation	O
.	O

The	O
suppressors	B-geneN
of	I-geneN
cytokine	I-geneN
signaling	I-geneN
(	I-geneN
SOCS	I-geneN
)	I-geneN
proteins	E-geneN
inhibit	O
cytokine	S-geneN
action	O
by	O
direct	O
interaction	O
with	O
Janus	B-geneN
kinases	E-geneN
or	O
activated	O
cytokine	B-geneN
receptors	E-geneN
.	O

In	O
addition	O
to	O
the	O
N	S-chem
-	O
terminal	O
and	O
Src	B-geneN
homology	I-geneN
2	I-geneN
domains	E-geneN
that	O
mediate	O
these	O
interactions	O
,	O
SOCS	S-geneN
proteins	O
contain	O
a	O
C	S-chem
-	O
terminal	O
SOCS	B-geneN
box	E-geneN
.	O

DNA	O
data	O
base	O
searches	O
have	O
identified	O
a	O
number	O
of	O
other	O
protein	O
families	O
that	O
possess	O
a	O
SOCS	B-geneN
box	E-geneN
,	O
of	O
which	O
the	O
ankyrin	S-geneN
repeat	O
and	O
SOCS	B-geneN
box	E-geneN
-	O
containing	O
(	O
Asb	S-geneN
)	O
proteins	O
constitute	O
the	O
largest	O
.	O

Although	O
it	O
is	O
known	O
that	O
the	O
SOCS	S-geneN
proteins	O
are	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
cytokine	S-geneN
signaling	O
,	O
the	O
biological	O
and	O
biochemical	O
functions	O
of	O
the	O
Asbs	S-geneN
are	O
largely	O
undefined	O
.	O

Using	O
a	O
proteomics	O
approach	O
,	O
we	O
demonstrate	O
that	O
creatine	B-geneY
kinase	I-geneY
B	E-geneY
(	O
CKB	S-geneY
)	O
interacts	O
with	O
Asb	B-geneY
-	I-geneY
9	E-geneY
in	O
a	O
specific	O
,	O
SOCS	B-geneN
box	E-geneN
-	O
independent	O
manner	O
.	O

This	O
interaction	O
increases	O
the	O
polyubiquitylation	O
of	O
CKB	S-geneY
and	O
decreases	O
total	O
CKB	S-geneY
levels	O
within	O
the	O
cell	O
.	O

The	O
targeting	O
of	O
CKB	S-geneY
for	O
degradation	O
by	O
Asb	B-geneY
-	I-geneY
9	E-geneY
was	O
primarily	O
SOCS	B-geneN
box	E-geneN
-	O
dependent	O
and	O
suggests	O
that	O
Asb	B-geneY
-	I-geneY
9	E-geneY
acts	O
as	O
a	O
specific	O
ubiquitin	B-geneN
ligase	E-geneN
regulating	O
levels	O
of	O
this	O
evolutionarily	O
conserved	O
enzyme	O
.	O

The	O
transporters	O
GlyT2	S-geneY
and	O
VIAAT	S-geneY
cooperate	O
to	O
determine	O
the	O
vesicular	O
glycinergic	O
phenotype	O
.	O

The	O
mechanisms	O
that	O
specify	O
the	O
vesicular	O
phenotype	O
of	O
inhibitory	O
interneurons	O
in	O
vertebrates	O
are	O
poorly	O
understood	O
because	O
the	O
two	O
main	O
inhibitory	O
transmitters	O
,	O
glycine	S-chem-C9-1
and	O
GABA	S-chem-C9-1
,	O
share	O
the	O
same	O
vesicular	B-geneY-C9-2
inhibitory	I-geneY-C9-2
amino	I-geneY-C9-2
acid	I-geneY-C9-2
transporter	E-geneY-C9-2
(	O
VIAAT	S-geneY-C9-2
)	O
and	O
are	O
both	O
present	O
in	O
neurons	O
during	O
postnatal	O
development	O
.	O

We	O
have	O
expressed	O
VIAAT	S-geneY-C9-2
and	O
the	O
plasmalemmal	B-geneN-C9-2
transporters	E-geneN-C9-2
for	O
glycine	S-chem-C9-1
and	O
GABA	S-chem-C9-1
in	O
a	O
neuroendocrine	O
cell	O
line	O
and	O
measured	O
the	O
quantal	O
release	O
of	O
glycine	S-chem
and	O
GABA	S-chem
using	O
a	O
novel	O
double	O
-	O
sniffer	O
patch	O
-	O
clamp	O
technique	O
.	O

We	O
found	O
that	O
glycine	S-chem-C9-1
is	O
released	O
from	O
vesicles	O
when	O
VIAAT	S-geneY-C9-2
is	O
coexpressed	O
with	O
either	O
the	O
neuronal	B-geneN
transporter	E-geneN
GlyT2	S-geneY
or	O
the	O
glial	B-geneN
transporter	E-geneN
GlyT1	S-geneY
.	O

However	O
,	O
GlyT2	S-geneY
was	O
more	O
effective	O
than	O
GlyT1	S-geneY
,	O
probably	O
because	O
GlyT2	S-geneY
is	O
unable	O
to	O
operate	O
in	O
the	O
reverse	O
mode	O
,	O
which	O
gives	O
it	O
an	O
advantage	O
in	O
maintaining	O
the	O
high	O
cytosolic	O
glycine	S-chem-C9-1
concentration	O
required	O
for	O
efficient	O
vesicular	O
loading	O
by	O
VIAAT	S-geneY-C9-2
.	O

The	O
vesicular	O
inhibitory	O
phenotype	O
was	O
gradually	O
altered	O
from	O
glycinergic	O
to	O
GABAergic	O
through	O
mixed	O
events	O
when	O
GABA	S-chem-C9-1
is	O
introduced	O
into	O
the	O
secretory	O
cell	O
and	O
competes	O
for	O
uptake	O
by	O
VIAAT	S-geneY-C9-2
.	O

Interestingly	O
,	O
the	O
VIAAT	S-geneN
ortholog	O
from	O
Caenorhabditis	O
elegans	O
(	O
UNC	O
-	O
47	O
)	O
,	O
a	O
species	O
lacking	O
glycine	S-chem
transmission	O
,	O
also	O
supports	O
glycine	S-chem-C9-1
exocytosis	O
in	O
the	O
presence	O
of	O
GlyT2	S-geneN-C9-2
,	O
and	O
a	O
point	O
mutation	O
of	O
UNC	O
-	O
47	O
that	O
abolishes	O
GABA	S-chem
transmission	O
in	O
the	O
worm	O
confers	O
glycine	O
specificity	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
an	O
increased	O
cytosolic	O
availability	O
of	O
glycine	S-chem-C9-1
in	O
VIAAT	S-geneY-C9-2
-	O
containing	O
terminals	O
was	O
crucial	O
for	O
the	O
emergence	O
of	O
glycinergic	O
transmission	O
in	O
vertebrates	O
.	O

Lifelong	O
exposure	O
to	O
bisphenol	B-chem
a	E-chem
alters	O
cardiac	O
structure	O
/	O
function	O
,	O
protein	O
expression	O
,	O
and	O
DNA	O
methylation	O
in	O
adult	O
mice	O
.	O

Bisphenol	B-chem
A	E-chem
(	O
BPA	S-chem
)	O
is	O
an	O
estrogenizing	O
endocrine	O
disruptor	O
compound	O
of	O
concern	O
.	O

Our	O
objective	O
was	O
to	O
test	O
whether	O
lifelong	O
BPA	S-chem
would	O
impact	O
cardiac	O
structure	O
/	O
function	O
,	O
calcium	S-chem
homeostasis	O
protein	O
expression	O
,	O
and	O
the	O
DNA	O
methylation	O
of	O
cardiac	O
genes	O
.	O

We	O
delivered	O
0.5	O
and	O
5.0	O
µg	O
/	O
kg	O
/	O
day	O
BPA	S-chem
lifelong	O
from	O
gestation	O
day	O
11	O
or	O
200	O
µg	O
/	O
kg	O
/	O
day	O
from	O
gestation	O
day	O
11	O
to	O
postnatal	O
day	O
21	O
via	O
the	O
drinking	O
water	O
to	O
C57bl	O
/	O
6n	O
mice	O
.	O

BPA	S-chem
5.0	O
males	O
and	O
females	O
had	O
increased	O
body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
surface	O
area	O
,	O
and	O
adiposity	O
.	O

Echocardiography	O
identified	O
concentric	O
remodeling	O
in	O
all	O
BPA	S-chem
-	O
treated	O
males	O
.	O

Systolic	O
and	O
diastolic	O
cardiac	O
functions	O
were	O
essentially	O
similar	O
,	O
but	O
lifelong	O
BPA	S-chem
enhanced	O
male	O
and	O
reduced	O
female	O
sex	O
-	O
specific	O
differences	O
in	O
velocity	O
of	O
circumferential	O
shortening	O
and	O
ascending	O
aorta	O
velocity	O
time	O
integral	O
.	O

Diastolic	O
blood	O
pressure	O
was	O
increased	O
in	O
all	O
BPA	S-chem
females	O
.	O

The	O
calcium	S-chem-C9-1
homeostasis	O
proteins	O
sarcoendoplasmic	B-geneY-C9-2
reticulum	I-geneY-C9-2
ATPase	I-geneY-C9-2
2a	E-geneY-C9-2
(	O
SERCA2a	S-geneY-C9-2
)	O
,	O
sodium	B-geneY-C9-2
calcium	I-geneY-C9-2
exchanger	I-geneY-C9-2
-	I-geneY-C9-2
1	E-geneY-C9-2
,	O
phospholamban	S-geneY-C9-2
(	O
PLB	S-geneY-C9-2
)	O
,	O
phospho	B-geneY-C9-2
-	I-geneY-C9-2
PLB	E-geneY-C9-2
,	O
and	O
calsequestrin	B-geneY-C9-2
2	E-geneY-C9-2
are	O
important	O
for	O
contraction	O
and	O
relaxation	O
.	O

Changes	O
in	O
their	O
expression	O
suggest	O
increased	O
calcium	S-chem
mobility	O
in	O
males	O
and	O
reduced	O
calcium	S-chem
mobility	O
in	O
females	O
supporting	O
the	O
cardiac	O
function	O
changes	O
.	O

DNA	B-geneY-MU-2
methyltransferase	I-geneY-MU-2
3a	E-geneY-MU-2
expression	O
was	O
increased	O
in	O
all	O
BPA	S-chem-C3-1
males	O
and	O
BPA	S-chem-C3-1
0.5	O
females	O
and	O
reduced	O
in	O
BPA	S-chem-C4-1
200	O
females	O
.	O

Global	O
DNA	O
methylation	O
was	O
increased	O
in	O
BPA	S-chem
0.5	O
males	O
and	O
reduced	O
in	O
BPA	S-chem
0.5	O
females	O
.	O

BPA	S-chem
induced	O
sex	O
-	O
specific	O
altered	O
DNA	O
methylation	O
in	O
specific	O
CpG	S-chem
pairs	O
in	O
the	O
calsequestrin	B-geneY
2	E-geneY
CpG	O
island	O
.	O

These	O
results	O
suggest	O
that	O
continual	O
exposure	O
to	O
BPA	S-chem
impacts	O
cardiac	O
structure	O
/	O
function	O
,	O
protein	O
expression	O
,	O
and	O
epigenetic	O
DNA	O
methylation	O
marks	O
in	O
males	O
and	O
females	O
.	O

Identification	O
of	O
binding	O
sites	O
for	O
bepridil	S-chem
and	O
trifluoperazine	S-chem
on	O
cardiac	B-geneY
troponin	I-geneY
C	E-geneY
.	O

The	O
solution	O
structure	O
of	O
cardiac	B-geneY
troponin	I-geneY
C	E-geneY
(	O
cTnC	S-geneY
)	O
(	O
Sia	O
,	O
S.	O
,	O
Li	O
,	O
M	O
.	O

X.	O
,	O
Spyracopoulos	O
,	O
L.	O
,	O
Gagne	O
,	O
S	O
.	O

M.	O
,	O
Liu	O
,	O
W.	O
,	O
Putkey	O
,	O
J	O
.	O

A	O
.	O

&	O
Sykes	O
,	O
B	O
.	O

D	O
.	O

(	O
1997	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

272	O
,	O
18216	O
-	O
18221	O
)	O
challenges	O
existing	O
structure	O
/	O
function	O
models	O
for	O
this	O
critical	O
regulatory	O
protein	O
.	O

For	O
example	O
,	O
it	O
is	O
clear	O
that	O
the	O
closed	O
conformation	O
of	O
the	O
regulatory	O
N	S-chem
-	O
terminal	O
domain	O
in	O
Ca2	B-chem
+	E-chem
-	O
bound	O
cardiac	B-geneY
troponin	I-geneY
C	E-geneY
(	O
cTnC	S-geneY
)	O
presents	O
a	O
much	O
different	O
binding	O
surface	O
for	O
Ca2	B-chem
+	E-chem
-	O
sensitizing	O
compounds	O
than	O
previously	O
thought	O
.	O

We	O
report	O
here	O
the	O
use	O
of	O
Met	O
methyl	O
groups	O
as	O
site	O
-	O
specific	O
structural	O
markers	O
to	O
identify	O
drug	O
binding	O
sites	O
for	O
trifluoperazine	S-chem
and	O
bepridil	S-chem
on	O
cTnC	S-geneY
.	O

Drug	O
dependent	O
changes	O
in	O
the	O
NMR	O
heteronuclear	O
single	O
-	O
quantum	O
coherence	O
spectra	O
of	O
[	O
methyl	B-chem
-	I-chem
13C	E-chem
]	O
Met	O
-	O
labeled	O
cTnC	S-geneY
indicate	O
that	O
bepridil	S-chem
and	O
trifluoperazine	S-chem
bind	O
to	O
similar	O
sites	O
but	O
only	O
in	O
the	O
presence	O
of	O
Ca2	B-chem
+	E-chem
.	O

There	O
are	O
3	O
-	O
4	O
drug	O
binding	O
sites	O
in	O
the	O
N	S-chem
-	O
and	O
C	S-chem
-	O
terminal	O
domains	O
of	O
intact	O
cTnC	S-geneY
that	O
exhibit	O
fast	O
exchange	O
on	O
the	O
NMR	O
time	O
scale	O
.	O

Use	O
of	O
a	O
novel	O
spin	O
-	O
labeled	O
phenothiazine	S-chem
and	O
detection	O
of	O
isotope	O
-	O
filtered	O
nuclear	O
Overhauser	O
effects	O
allowed	O
identification	O
of	O
drug	O
binding	O
sites	O
in	O
the	O
shallow	O
hydrophobic	O
cup	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
and	O
on	O
two	O
hydrophobic	O
surfaces	O
on	O
the	O
N	S-chem
-	O
terminal	O
regulatory	O
domain	O
.	O

The	O
data	O
presented	O
here	O
,	O
coupled	O
with	O
our	O
previous	O
study	O
using	O
covalent	O
blocking	O
groups	O
,	O
support	O
a	O
model	O
in	O
which	O
the	O
Ca2	B-chem
+	E-chem
-	O
sensitizing	O
binding	O
site	O
includes	O
Met	O
-	O
45	O
in	O
helix	O
B	O
of	O
site	O
I	O
,	O
and	O
Met	O
-	O
60	O
and	O
-	O
80	O
in	O
helices	O
B	O
and	O
C	O
of	O
the	O
regulatory	O
site	O
II	O
.	O

This	O
subregion	O
in	O
cTnC	S-geneY
makes	O
a	O
likely	O
target	O
against	O
which	O
to	O
design	O
new	O
and	O
selective	O
Ca2	B-chem
+	E-chem
-	O
sensitizing	O
compounds	O
.	O

Mechanisms	O
of	O
inhibition	O
of	O
calmodulin	B-geneN
-	I-geneN
stimulated	I-geneN
cyclic	I-geneN
nucleotide	I-geneN
phosphodiesterase	E-geneN
by	O
dihydropyridine	O
calcium	O
antagonists	O
.	O

Calmodulin	B-geneN
-	I-geneN
dependent	I-geneN
cyclic	I-geneN
nucleotide	I-geneN
phosphodiesterase	E-geneN
(	O
CaMPDE	S-geneN
)	O
is	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
complex	O
interaction	O
between	O
the	O
cyclic	O
nucleotide	S-chem
and	O
Ca2	B-chem
+	E-chem
second	O
-	O
messenger	O
systems	O
.	O

CaMPDE	S-geneN
exists	O
as	O
tissue	O
-	O
specific	O
isozymes	O
,	O
and	O
initially	O
these	O
isozymes	O
were	O
designated	O
according	O
to	O
their	O
respective	O
subunit	O
molecular	O
mass	O
.	O

A	O
variety	O
of	O
pharmacological	O
agents	O
have	O
been	O
used	O
to	O
inhibit	O
CaMPDE	S-geneN
,	O
and	O
this	O
inhibition	O
occurs	O
mostly	O
via	O
Ca2	B-chem
+	E-chem
-	O
dependent	O
association	O
with	O
the	O
proteins	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
dihydropyridine	S-chem-C4-1
Ca2	B-geneN-C4-2
+	I-geneN-C4-2
-	I-geneN-C4-2
channel	E-geneN-C4-2
blockers	O
felodipine	S-chem-C4-1
and	O
nicardipine	S-chem-C4-1
on	O
CaMPDE	S-geneN
.	O

The	O
results	O
suggest	O
that	O
the	O
63	O
-	O
kDa	O
(	O
PDE	B-geneY-C4-2
1B1	E-geneY-C4-2
)	O
and	O
60	O
-	O
kDa	O
(	O
PDE	B-geneY-C4-2
1A2	E-geneY-C4-2
)	O
CaMPDE	S-geneN-C4-2
isozymes	O
are	O
inhibited	O
by	O
felodipine	S-chem-C4-1
and	O
nicardipine	S-chem-C4-1
by	O
partial	O
competitive	O
inhibition	O
and	O
that	O
these	O
two	O
Ca2	B-chem
+	E-chem
antagonists	O
appear	O
to	O
counteract	O
each	O
other	O
.	O

This	O
study	O
further	O
demonstrates	O
the	O
existence	O
of	O
a	O
specific	O
site	O
,	O
distinct	O
from	O
the	O
active	O
site	O
on	O
CaMPDE	S-geneN
,	O
that	O
exhibits	O
high	O
-	O
affinity	O
binding	O
of	O
these	O
drugs	O
.	O

Felodipine	S-chem
and	O
nicardipine	S-chem
have	O
similar	O
affinities	O
for	O
60	O
-	O
kDa	O
CaMPDE	S-geneN-C4-2
isozymes	O
but	O
bring	O
about	O
different	O
levels	O
of	O
enzyme	O
inhibition	O
,	O
suggesting	O
the	O
possibility	O
of	O
designing	O
specific	O
drugs	O
that	O
can	O
protect	O
the	O
enzyme	O
from	O
inhibition	O
by	O
dihydropyridine	S-chem-C4-1
Ca2	B-geneN-C4-2
+	I-geneN-C4-2
-	I-geneN-C4-2
channel	E-geneN-C4-2
blockers	O
.	O

Phenolic	S-chem
compounds	O
present	O
in	O
Sardinian	O
wine	O
extracts	O
protect	O
against	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
induced	O
by	O
oxysterols	S-chem
in	O
CaCo	O
-	O
2	O
human	O
enterocyte	O
-	O
like	O
cells	O
.	O

Cholesterol	S-chem
auto	O
-	O
oxidation	O
products	O
,	O
namely	O
oxysterols	S-chem
,	O
are	O
widely	O
present	O
in	O
cholesterol	S-chem
-	O
rich	O
foods	O
.	O

They	O
are	O
thought	O
to	O
potentially	O
interfere	O
with	O
homeostasis	O
of	O
the	O
human	O
digestive	O
tract	O
,	O
playing	O
a	O
role	O
in	O
intestinal	O
mucosal	O
damage	O
.	O

This	O
report	O
concerns	O
the	O
marked	O
up	O
-	O
regulation	O
in	O
differentiated	O
CaCo	O
-	O
2	O
colonic	O
epithelial	O
cells	O
of	O
two	O
key	O
inflammatory	O
interleukins	S-geneN-C3-2
,	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
6	E-geneY-C3-2
and	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
8	E-geneY-C3-2
,	O
caused	O
by	O
a	O
mixture	O
of	O
oxysterols	S-chem-C3-1
representative	O
of	O
a	O
high	O
cholesterol	S-chem-C3-1
diet	O
.	O

This	O
strong	O
pro	O
-	O
inflammatory	O
effect	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
net	O
imbalance	O
of	O
red	O
-	O
ox	O
equilibrium	O
with	O
the	O
production	O
of	O
excessive	O
levels	O
of	O
reactive	O
oxygen	S-chem
species	O
through	O
the	O
colonic	O
NADPH	B-geneN
-	I-geneN
oxidase	E-geneN
NOX1	S-geneY
activation	O
.	O

Induction	O
of	O
NOX1	S-geneY
was	O
markedly	O
while	O
not	O
fully	O
inhibited	O
by	O
CaCo	O
-	O
2	O
cell	O
pre	O
-	O
incubation	O
with	O
phenolic	O
extracts	O
obtained	O
from	O
well	O
-	O
selected	O
wines	O
from	O
typical	O
grape	O
varieties	O
grown	O
in	O
Sardinia	O
.	O

Oxysterol	S-chem-C3-1
-	O
dependent	O
NOX1	S-geneY-MU-2
activation	O
,	O
as	O
well	O
as	O
interleukin	S-geneN-MU-2
synthesis	O
,	O
were	O
completely	O
prevented	O
by	O
Cannonau	O
red	O
wine	O
extract	O
that	O
contains	O
an	O
abundant	O
phenolic	O
fraction	O
,	O
in	O
particular	O
phenolic	B-chem-C4-1
acids	E-chem-C4-1
and	O
flavonoids	S-chem-C4-1
.	O

Conversely	O
,	O
cell	O
pre	O
-	O
treatment	O
with	O
Vermentino	O
white	O
wine	O
extract	O
with	O
smaller	O
phenolic	O
fraction	O
showed	O
only	O
a	O
partial	O
NOX1	S-geneY-C3-2
down	O
-	O
regulation	O
and	O
was	O
ineffective	O
in	O
interleukin	S-geneN-C3-2
synthesis	O
induced	O
by	O
dietary	O
oxysterols	S-chem-C3-1
.	O

It	O
is	O
thus	O
likely	O
that	O
the	O
effects	O
of	O
Sardinian	O
wine	O
extracts	O
against	O
intestinal	O
inflammation	O
induced	O
by	O
dietary	O
oxysterols	S-chem
are	O
mainly	O
due	O
to	O
their	O
high	O
phenolic	O
content	O
:	O
low	O
doses	O
of	O
phenolics	S-chem
would	O
be	O
responsible	O
only	O
for	O
direct	O
scavenging	O
oxysterol	S-chem
-	O
dependent	O
ROS	O
production	O
.	O

Besides	O
this	O
direct	O
activity	O
,	O
an	O
excess	O
of	O
phenolic	S-chem-C4-1
compounds	O
detectable	O
in	O
red	O
wine	O
,	O
may	O
exert	O
an	O
additional	O
indirect	O
action	O
by	O
blocking	O
oxysterol	S-chem-C3-1
-	O
related	O
NOX1	S-geneY-MU-2
induction	O
,	O
thus	O
totally	O
preventing	O
the	O
pro	O
-	O
oxidant	O
and	O
pro	O
-	O
inflammatory	O
events	O
triggered	O
by	O
dietary	O
oxysterols	S-chem
.	O

Evidence	O
for	O
a	O
new	O
mechanism	O
behind	O
HIFU	O
-	O
triggered	O
release	O
from	O
liposomes	O
.	O

A	O
promising	O
approach	O
for	O
local	O
drug	O
delivery	O
is	O
high	O
-	O
intensity	O
focused	O
ultrasound	O
(	O
HIFU	O
)	O
-	O
triggered	O
release	O
of	O
drugs	O
from	O
stimuli	O
-	O
responsive	O
nanoparticles	O
such	O
as	O
liposomes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
another	O
release	O
mechanism	O
is	O
involved	O
with	O
HIFU	O
-	O
triggered	O
release	O
from	O
liposomes	O
beside	O
cavitation	O
and	O
temperature	O
.	O

Furthermore	O
,	O
it	O
was	O
studied	O
whether	O
this	O
new	O
release	O
mechanism	O
allows	O
the	O
release	O
of	O
lipophilic	O
compounds	O
.	O

Therefore	O
,	O
both	O
a	O
lipophilic	O
(	O
Nile	B-chem
red	E-chem
)	O
and	O
a	O
hydrophilic	O
(	O
fluorescein	S-chem
)	O
compound	O
were	O
loaded	O
into	O
thermosensitive	O
(	O
TSL	O
)	O
or	O
non	O
-	O
thermosensitive	O
liposomes	O
(	O
NTSL	O
)	O
and	O
the	O
liposomes	O
were	O
subjected	O
both	O
to	O
continuous	O
wave	O
-	O
(	O
CW	O
)	O
and	O
pulsed	O
wave	O
(	O
PW	O
)	O
-	O
HIFU	O
.	O

The	O
mean	O
liposome	O
size	O
varied	O
from	O
97	O
to	O
139nm	O
with	O
a	O
polydispersity	O
index	O
(	O
PDI	O
)	O
≤	O
0.06	O
for	O
the	O
different	O
formulations	O
.	O

The	O
Tm	O
of	O
the	O
phospholipid	O
bilayer	O
of	O
the	O
TSL	O
was	O
around	O
42°C	O
.	O

Approximately	O
80	O
%	O
of	O
fluorescein	S-chem
was	O
released	O
within	O
15min	O
from	O
TSL	O
at	O
temperatures	O
≥	O
42°C	O
.	O

In	O
contrast	O
,	O
no	O
fluorescein	S-chem
release	O
from	O
NTSL	O
and	O
NR	O
release	O
from	O
both	O
TSL	O
and	O
NTSL	O
was	O
observed	O
at	O
temperatures	O
up	O
to	O
60°C	O
.	O

CW	O
-	O
HIFU	O
exposure	O
of	O
TSL	O
resulted	O
in	O
rapid	O
temperature	O
elevation	O
up	O
to	O
52°C	O
and	O
subsequently	O
almost	O
quantitative	O
fluorescein	S-chem
release	O
.	O

Fluorescein	S-chem
release	O
from	O
NTSL	O
was	O
also	O
substantial	O
(	O
~	O
64	O
%	O
after	O
16min	O
at	O
20W	O
)	O
.	O

Surprisingly	O
,	O
CW	O
-	O
HIFU	O
exposure	O
(	O
20W	O
for	O
16min	O
)	O
resulted	O
in	O
the	O
release	O
of	O
NR	O
from	O
TSL	O
(	O
~	O
66	O
%	O
of	O
the	O
loaded	O
amount	O
)	O
,	O
and	O
this	O
was	O
even	O
higher	O
from	O
NTSL	O
(	O
~	O
78	O
%	O
)	O
.	O

PW	O
-	O
HIFU	O
exposure	O
did	O
not	O
result	O
in	O
temperatures	O
above	O
the	O
Tm	O
of	O
TSL	O
.	O

However	O
,	O
nearly	O
85	O
%	O
of	O
fluorescein	S-chem
was	O
released	O
from	O
TSL	O
after	O
32min	O
at	O
20W	O
of	O
PW	O
-	O
HIFU	O
exposure	O
,	O
whereas	O
the	O
release	O
from	O
NTSL	O
was	O
around	O
27	O
%	O
.	O

Interestingly	O
,	O
NR	O
release	O
from	O
NTSL	O
was	O
~	O
30	O
%	O
after	O
2min	O
PW	O
-	O
HIFU	O
exposure	O
and	O
increased	O
to	O
~	O
70	O
%	O
after	O
32min	O
.	O

Furthermore	O
,	O
addition	O
of	O
microbubbles	O
to	O
the	O
liposomes	O
prior	O
to	O
PW	O
-	O
HIFU	O
exposure	O
did	O
not	O
result	O
in	O
more	O
release	O
,	O
which	O
suggests	O
that	O
cavitation	O
can	O
be	O
excluded	O
as	O
the	O
main	O
mechanism	O
responsible	O
for	O
the	O
triggered	O
release	O
of	O
both	O
a	O
hydrophilic	O
and	O
a	O
lipophilic	O
model	O
compound	O
from	O
liposomes	O
.	O

Dynamic	O
light	O
scattering	O
analysis	O
showed	O
that	O
the	O
mean	O
size	O
and	O
PDI	O
of	O
the	O
liposomes	O
did	O
not	O
significantly	O
change	O
after	O
CW	O
-	O
and	O
PW	O
-	O
HIFU	O
exposure	O
.	O

Taken	O
together	O
,	O
it	O
is	O
therefore	O
concluded	O
that	O
neither	O
temperature	O
elevation	O
nor	O
inertial	O
cavitation	O
is	O
essential	O
for	O
the	O
release	O
of	O
both	O
hydrophilic	O
and	O
lipophilic	O
compounds	O
from	O
liposomes	O
.	O

It	O
is	O
assumed	O
that	O
the	O
release	O
originates	O
from	O
radiation	O
force	O
-	O
induced	O
acoustic	O
streaming	O
,	O
causing	O
the	O
liposomes	O
to	O
collide	O
at	O
the	O
walls	O
of	O
the	O
exposure	O
chamber	O
leading	O
to	O
shear	O
forces	O
which	O
in	O
turn	O
results	O
in	O
reversible	O
liposome	O
destabilization	O
and	O
release	O
of	O
both	O
hydrophilic	O
and	O
lipophilic	O
compounds	O
.	O

Copy	O
number	O
variations	O
of	O
the	O
human	B-geneY
histamine	I-geneY
H4	I-geneY
receptor	E-geneY
gene	O
are	O
associated	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
:	O
Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
a	O
complex	O
genetic	O
disease	O
;	O
the	O
histamine	B-geneY
H4	I-geneY
receptor	E-geneY
(	O
HRH4	S-geneY
)	O
has	O
been	O
shown	O
to	O
be	O
related	O
to	O
different	O
kinds	O
of	O
autoimmune	O
disorders	O
;	O
and	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
various	O
types	O
of	O
diseases	O
.	O

OBJECTIVES	O
:	O
To	O
explore	O
a	O
possible	O
association	O
between	O
HRH4	S-geneY
(	O
formerly	O
H4R	S-geneY
)	O
CNVs	O
and	O
the	O
risk	O
of	O
SLE	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
and	O
RNA	O
from	O
340	O
patients	O
with	O
SLE	O
and	O
392	O
healthy	O
controls	O
were	O
extracted	O
,	O
and	O
CNVs	O
and	O
mRNA	O
levels	O
of	O
HRH4	S-geneY
were	O
examined	O
.	O

RESULTS	O
:	O
The	O
expression	O
of	O
HRH4	S-geneY
mRNA	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
SLE	O
compared	O
with	O
controls	O
.	O

Amplification	O
of	O
HRH4	S-geneY
copy	O
numbers	O
significantly	O
increased	O
the	O
risk	O
of	O
SLE	O
[	O
P	O
<	O
0.001	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
2.26	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.50	O
-	O
3.40	O
]	O
.	O

HRH4	S-geneY
amplifications	O
also	O
positively	O
correlated	O
with	O
the	O
incidence	O
of	O
arthritis	O
(	O
P	O
=	O
0.019	O
,	O
OR	O
1.96	O
,	O
95	O
%	O
CI	O
1.11	O
-	O
3.47	O
)	O
,	O
and	O
proteinuria	O
(	O
P	O
<	O
0.001	O
,	O
OR	O
2.95	O
,	O
95	O
%	O
CI	O
1.73	O
-	O
5.00	O
)	O
and	O
antinuclear	O
antibody	O
abnormalities	O
(	O
P	O
<	O
0.001	O
,	O
OR	O
2.97	O
,	O
95	O
%	O
CI	O
1.66	O
-	O
5.33	O
)	O
.	O

Deletions	O
of	O
HRH4	S-geneY
copy	O
numbers	O
were	O
protective	O
against	O
proteinuria	O
(	O
P	O
=	O
0.03	O
,	O
OR	O
0.50	O
,	O
95	O
%	O
CI	O
0.26	O
-	O
0.94	O
)	O
.	O

CONCLUSION	O
:	O
CNVs	O
of	O
the	O
HRH4	S-geneY
gene	O
are	O
associated	O
with	O
SLE	O
.	O

Balancing	O
societal	O
needs	O
and	O
regulatory	O
certainty	O
:	O
the	O
case	O
study	O
of	O
peramivir	S-chem
in	O
Japan	O
.	O

Regulators	O
must	O
balance	O
societal	O
and	O
medical	O
requirements	O
against	O
the	O
need	O
for	O
certainty	O
about	O
benefit	O
and	O
risk	O
for	O
new	O
medicines	O
.	O

This	O
is	O
described	O
in	O
a	O
case	O
study	O
of	O
the	O
expedited	O
review	O
and	O
approval	O
of	O
peramivir	S-chem-C4-1
,	O
a	O
novel	O
neuraminidase	S-geneN-C4-2
inhibitor	O
,	O
in	O
Japan	O
in	O
the	O
context	O
of	O
the	O
emergence	O
of	O
new	O
strain	O
of	O
influenza	O
in	O
2009	O
.	O

The	O
case	O
illustrates	O
the	O
importance	O
of	O
regulatory	O
science	O
and	O
transparency	O
in	O
supporting	O
such	O
decision	O
making	O
.	O

Role	O
of	O
hydrogen	B-chem
sulfide	E-chem
in	O
acute	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
.	O

Hydrogen	B-chem
sulfide	E-chem
(	O
H2S	S-chem
)	O
is	O
a	O
naturally	O
occurring	O
gas	O
with	O
potent	O
vasodilator	O
activity	O
.	O

Cystathionine	B-geneY-C9-2
-	I-geneY-C9-2
gamma	I-geneY-C9-2
-	I-geneY-C9-2
lyase	E-geneY-C9-2
(	O
CSE	S-geneY-C9-2
)	O
and	O
cystathionine	B-geneY-C9-2
-	I-geneY-C9-2
beta	I-geneY-C9-2
-	I-geneY-C9-2
synthase	E-geneY-C9-2
(	O
CBS	S-geneY-C9-2
)	O
utilize	O
L	B-chem-C9-1
-	I-chem-C9-1
cysteine	E-chem-C9-1
as	O
substrate	O
to	O
form	O
H2S	S-chem-C9-1
.	O

Of	O
these	O
two	O
enzymes	O
,	O
cystathionine	B-geneY-C9-2
-	I-geneY-C9-2
gamma	I-geneY-C9-2
-	I-geneY-C9-2
lyase	E-geneY-C9-2
(	O
CSE	S-geneY-C9-2
)	O
is	O
believed	O
to	O
be	O
the	O
key	O
enzyme	O
that	O
forms	O
H2S	S-chem-C9-1
in	O
the	O
cardiovascular	O
system	O
.	O

Whilst	O
H2S	S-chem
has	O
been	O
reported	O
to	O
relax	O
precontracted	O
rat	O
arteries	O
in	O
vitro	O
and	O
to	O
lower	O
blood	O
pressure	O
in	O
the	O
rat	O
,	O
its	O
effect	O
in	O
an	O
inflammatory	O
condition	O
such	O
as	O
acute	O
pancreatitis	O
has	O
not	O
previously	O
been	O
reported	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
presence	O
of	O
H2S	S-chem
synthesizing	O
enzyme	O
activity	O
and	O
CSE	S-geneY
(	O
as	O
determined	O
by	O
mRNA	O
signal	O
)	O
in	O
the	O
pancreas	O
.	O

Also	O
,	O
prophylactic	O
,	O
as	O
well	O
as	O
therapeutic	O
,	O
treatment	O
with	O
the	O
CSE	S-geneY-C4-2
inhibitor	O
,	O
DL	B-chem-C4-1
-	I-chem-C4-1
propargylglycine	E-chem-C4-1
(	O
PAG	S-chem-C4-1
)	O
,	O
significantly	O
reduced	O
the	O
severity	O
of	O
caerulein	S-chem
-	O
induced	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
,	O
as	O
determined	O
by	O
1	O
)	O
hyperamylasemia	O
[	O
plasma	O
amylase	S-geneN
(	O
U	O
/	O
L	O
)	O
(	O
control	O
,	O
1204	O
+	O
/	O
-	O
59	O
)	O
;	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
10635	O
+	O
/	O
-	O
305	O
;	O
PAG	S-chem
,	O
7904	O
+	O
/	O
-	O
495	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
10427	O
+	O
/	O
-	O
470	O
;	O
PAG	S-chem
,	O
7811	O
+	O
/	O
-	O
428	O
;	O
P	O
<	O
0.05	O
PAG	S-chem
c.f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
]	O
;	O
2	O
)	O
neutrophil	O
sequestration	O
in	O
the	O
pancreas	O
[	O
pancreatic	O
myeloperoxidase	B-geneY-C3-2
oxidase	E-geneY-C3-2
(	O
MPO	S-geneY-C3-2
)	O
activity	O
(	O
fold	O
increase	O
over	O
control	O
)	O
(	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
5.78	O
+	O
/	O
-	O
0.63	O
;	O
PAG	S-chem-C3-1
,	O
2.97	O
+	O
/	O
-	O
0.39	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
5.48	O
+	O
/	O
-	O
0.52	O
;	O
PAG	S-chem
,	O
3.03	O
+	O
/	O
-	O
0.47	O
;	O
P	O
<	O
0.05	O
PAG	S-chem
c.f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
)	O
]	O
;	O
3	O
)	O
pancreatic	O
acinar	O
cell	O
injury	O
/	O
necrosis	O
;	O
4	O
)	O
lung	O
MPO	O
activity	O
(	O
fold	O
increase	O
over	O
control	O
)	O
[	O
prophylactic	O
treatment	O
:	O
placebo	O
,	O
1.99	O
+	O
/	O
-	O
0.16	O
;	O
PAG	S-chem
,	O
1.34	O
+	O
/	O
-	O
0.14	O
;	O
therapeutic	O
treatment	O
:	O
placebo	O
,	O
2.03	O
+	O
/	O
-	O
0.12	O
;	O
PAG	S-chem
,	O
1.41	O
+	O
/	O
-	O
0.97	O
;	O
P	O
<	O
0.05	O
PAG	S-chem
c.f	O
.	O
placebo	O
;	O
n	O
=	O
24	O
animals	O
in	O
each	O
group	O
]	O
;	O
and	O
5	O
)	O
histological	O
evidence	O
of	O
lung	O
injury	O
.	O

These	O
effects	O
of	O
CSE	S-geneY
blockade	O
suggest	O
an	O
important	O
proinflammatory	O
role	O
of	O
H2S	S-chem
in	O
regulating	O
the	O
severity	O
of	O
pancreatitis	O
and	O
associated	O
lung	O
injury	O
and	O
raise	O
the	O
possibility	O
that	O
H2S	S-chem
may	O
exert	O
similar	O
activity	O
in	O
other	O
forms	O
of	O
inflammation	O
.	O

Loss	O
of	O
Kruppel	B-geneY
-	I-geneY
like	I-geneY
Factor	I-geneY
3	E-geneY
(	O
KLF3	S-geneY
/	O
BKLF	S-geneY
)	O
leads	O
to	O
upregulation	O
of	O
the	O
insulin	B-geneY
-	I-geneY
sensitizing	I-geneY
factor	I-geneY
adipolin	E-geneY
(	O
FAM132A	S-geneY
/	O
CTRP12	S-geneY
/	O
C1qdc2	S-geneY
)	O
.	O

Krüppel	B-geneY
-	I-geneY
like	I-geneY
Factor	I-geneY
3	E-geneY
(	O
KLF3	S-geneY
)	O
is	O
a	O
transcriptional	O
regulator	O
that	O
we	O
have	O
shown	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
adipogenesis	O
in	O
vitro	O
.	O

Here	O
we	O
report	O
that	O
KLF3	S-geneY
null	O
mice	O
are	O
lean	O
and	O
protected	O
from	O
diet	O
-	O
induced	O
obesity	O
and	O
glucose	S-chem
intolerance	O
.	O

On	O
a	O
chow	O
diet	O
,	O
plasma	O
levels	O
of	O
leptin	S-geneY
are	O
decreased	O
,	O
and	O
adiponectin	S-geneY
is	O
increased	O
.	O

Despite	O
significant	O
reductions	O
in	O
body	O
weight	O
and	O
adiposity	O
,	O
wildtype	O
and	O
knockout	O
animals	O
show	O
equivalent	O
energy	O
intake	O
,	O
expenditure	O
and	O
excretion	O
.	O

To	O
investigate	O
the	O
molecular	O
events	O
underlying	O
these	O
observations	O
,	O
we	O
used	O
microarray	O
analysis	O
to	O
compare	O
gene	O
expression	O
in	O
Klf3	S-geneY
(	O
+	O
/	O
+	O
)	O
and	O
Klf3	S-geneY
(	O
-	O
/	O
-	O
)	O
tissues	O
.	O

We	O
found	O
that	O
mRNA	O
expression	O
of	O
Fam132a	S-geneY
,	O
which	O
encodes	O
a	O
newly	O
identified	O
insulin	S-geneN
-	O
sensitizing	O
adipokine	S-geneN
,	O
adipolin	S-geneY
,	O
is	O
significantly	O
upregulated	O
in	O
the	O
absence	O
of	O
KLF3	S-geneY
.	O

We	O
confirmed	O
that	O
KLF3	S-geneY
binds	O
the	O
Fam132a	B-geneN
promoter	E-geneN
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
this	O
leads	O
to	O
repression	O
of	O
promoter	O
activity	O
.	O

Further	O
,	O
plasma	O
adipolin	S-geneY
levels	O
were	O
significantly	O
increased	O
in	O
Klf3	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Boosting	O
levels	O
of	O
adipolin	S-geneY
via	O
targeting	O
of	O
KLF3	S-geneY
offers	O
a	O
novel	O
potential	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
insulin	S-geneN
resistance	O
.	O

Minocycline	S-chem-C4-1
inhibits	O
cytochrome	B-geneY-C4-2
c	E-geneY-C4-2
release	O
and	O
delays	O
progression	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
in	O
mice	O
.	O

Minocycline	S-chem
mediates	O
neuroprotection	O
in	O
experimental	O
models	O
of	O
neurodegeneration	O
.	O

It	O
inhibits	O
the	O
activity	O
of	O
caspase	B-geneY
-	I-geneY
1	E-geneY
,	O
caspase	B-geneY
-	I-geneY
3	E-geneY
,	O
inducible	B-geneY
form	I-geneY
of	I-geneY
nitric	I-geneY
oxide	I-geneY
synthetase	E-geneY
(	O
iNOS	S-geneY
)	O
and	O
p38	S-geneN
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
.	O

Although	O
minocycline	S-chem
does	O
not	O
directly	O
inhibit	O
these	O
enzymes	O
,	O
the	O
effects	O
may	O
result	O
from	O
interference	O
with	O
upstream	O
mechanisms	O
resulting	O
in	O
their	O
secondary	O
activation	O
.	O

Because	O
the	O
above	O
-	O
mentioned	O
factors	O
are	O
important	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
we	O
tested	O
minocycline	S-chem
in	O
mice	O
with	O
ALS	O
.	O

Here	O
we	O
report	O
that	O
minocycline	S-chem
delays	O
disease	O
onset	O
and	O
extends	O
survival	O
in	O
ALS	O
mice	O
.	O

Given	O
the	O
broad	O
efficacy	O
of	O
minocycline	S-chem
,	O
understanding	O
its	O
mechanisms	O
of	O
action	O
is	O
of	O
great	O
importance	O
.	O

We	O
find	O
that	O
minocycline	S-chem-C4-1
inhibits	O
mitochondrial	O
permeability	O
-	O
transition	O
-	O
mediated	O
cytochrome	B-geneY-C4-2
c	E-geneY-C4-2
release	O
.	O

Minocycline	S-chem-C4-1
-	O
mediated	O
inhibition	O
of	O
cytochrome	B-geneY-C4-2
c	E-geneY-C4-2
release	O
is	O
demonstrated	O
in	O
vivo	O
,	O
in	O
cells	O
,	O
and	O
in	O
isolated	O
mitochondria	O
.	O

Understanding	O
the	O
mechanism	O
of	O
action	O
of	O
minocycline	S-chem
will	O
assist	O
in	O
the	O
development	O
and	O
testing	O
of	O
more	O
powerful	O
and	O
effective	O
analogues	O
.	O

Because	O
of	O
the	O
safety	O
record	O
of	O
minocycline	S-chem
,	O
and	O
its	O
ability	O
to	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
this	O
drug	O
may	O
be	O
a	O
novel	O
therapy	O
for	O
ALS	O
.	O

The	O
effects	O
of	O
the	O
adenosine	B-geneY-C5-2
A3	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
IB	B-chem-C5-1
-	I-chem-C5-1
MECA	E-chem-C5-1
on	O
sodium	B-chem
taurocholate	E-chem
-	O
induced	O
experimental	O
acute	O
pancreatitis	O
.	O

The	O
role	O
of	O
adenosine	B-geneY
A3	I-geneY
receptors	E-geneY
and	O
their	O
distribution	O
in	O
the	O
gastrointestinal	O
tract	O
have	O
been	O
widely	O
investigated	O
.	O

Most	O
of	O
the	O
reports	O
discuss	O
their	O
role	O
in	O
intestinal	O
inflammations	O
.	O

However	O
,	O
the	O
role	O
of	O
adenosine	B-geneY
A3	I-geneY
receptor	E-geneY
agonist	O
in	O
pancreatitis	O
has	O
not	O
been	O
well	O
established	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
(	O
Ed	O
note	O
:	O
Purpose	O
statements	O
should	O
be	O
in	O
present	O
tense	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
the	O
adenosine	B-geneY
A3	I-geneY
receptor	E-geneY
agonist	O
on	O
the	O
course	O
of	O
sodium	B-chem
taurocholate	E-chem
-	O
induced	O
experimental	O
acute	O
pancreatitis	O
(	O
EAP	O
)	O
.	O

The	O
experiments	O
were	O
performed	O
on	O
80	O
male	O
Wistar	O
rats	O
,	O
58	O
of	O
which	O
survived	O
,	O
subdivided	O
into	O
3	O
groups	O
:	O
C	O
-	O
control	O
rats	O
,	O
I	O
-	O
EAP	O
group	O
,	O
and	O
II	O
-	O
EAP	O
group	O
treated	O
with	O
the	O
adenosine	B-geneY-C5-2
A3	I-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
IB	B-chem-C5-1
-	I-chem-C5-1
MECA	E-chem-C5-1
(	B-chem-C5-1
1	I-chem-C5-1
-	I-chem-C5-1
deoxy	I-chem-C5-1
-	I-chem-C5-1
1	I-chem-C5-1
-	I-chem-C5-1
6	I-chem-C5-1
[	I-chem-C5-1
[	I-chem-C5-1
(	I-chem-C5-1
3	I-chem-C5-1
-	I-chem-C5-1
iodophenyl	I-chem-C5-1
)	I-chem-C5-1
methyl	I-chem-C5-1
]	I-chem-C5-1
amino	I-chem-C5-1
]	I-chem-C5-1
-	I-chem-C5-1
9H	I-chem-C5-1
-	I-chem-C5-1
purin	I-chem-C5-1
-	I-chem-C5-1
9	I-chem-C5-1
-	I-chem-C5-1
yl	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
N	I-chem-C5-1
-	I-chem-C5-1
methyl	I-chem-C5-1
-	I-chem-C5-1
B	I-chem-C5-1
-	I-chem-C5-1
D	I-chem-C5-1
-	I-chem-C5-1
ribofuronamide	E-chem-C5-1
at	O
a	O
dose	O
of	O
0.75	O
mg	O
/	O
kg	O
b.w	O
.	O
i.p	O
.	O
at	O
48	O
,	O
24	O
,	O
12	O
and	O
1	O
h	O
before	O
and	O
1	O
h	O
after	O
the	O
injection	O
of	O
5	O
%	O
sodium	O
taurocholate	I-chem
solution	O
into	O
the	O
biliary	O
-	O
pancreatic	O
duct	O
.	O

Serum	O
for	O
α	B-geneN
-	I-geneN
amylase	E-geneN
and	O
lipase	S-geneN
determinations	O
and	O
tissue	O
samples	O
for	O
morphological	O
examinations	O
were	O
collected	O
at	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
of	O
the	O
experiment	O
.	O

In	O
the	O
IB	B-chem-C4-1
-	I-chem-C4-1
MECA	E-chem-C4-1
group	O
,	O
α	B-geneN-C4-2
-	I-geneN-C4-2
amylase	E-geneN-C4-2
activity	O
was	O
decreased	O
with	O
statistically	O
high	O
significance	O
compared	O
to	O
group	O
I	O
.	O

The	O
activity	O
of	O
lipase	S-geneN
was	O
not	O
significantly	O
different	O
among	O
the	O
experimental	O
groups	O
but	O
higher	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
administration	O
of	O
IB	B-chem
-	I-chem
MECA	E-chem
attenuated	O
the	O
histological	O
parameters	O
of	O
inflammation	O
as	O
compared	O
to	O
untreated	O
animals	O
.	O

The	O
use	O
of	O
A3	B-geneY-C5-2
receptor	E-geneY-C5-2
agonist	O
IB	B-chem-C5-1
-	I-chem-C5-1
MECA	E-chem-C5-1
attenuates	O
EAP	O
.	O

Our	O
findings	O
suggest	O
that	O
stimulation	O
of	O
adenosine	B-geneY
A3	I-geneY
receptors	E-geneY
plays	O
a	O
positive	O
role	O
in	O
the	O
sodium	B-chem
taurocholate	E-chem
-	O
induced	O
EAP	O
in	O
rats	O
.	O

Structures	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
human	B-geneY
spermidine	I-geneY
/	I-geneY
spermine	I-geneY
N1	I-geneY
-	I-geneY
acetyltransferase	E-geneY
,	O
a	O
potential	O
therapeutic	O
drug	O
target	O
.	O

Spermidine	B-geneY-C9-2
/	I-geneY-C9-2
spermine	I-geneY-C9-2
N1	I-geneY-C9-2
-	I-geneY-C9-2
acetyltransferase	E-geneY-C9-2
(	O
SSAT	S-geneY
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
control	O
of	O
polyamine	S-chem-C9-1
levels	O
in	O
human	O
cells	O
,	O
as	O
acetylation	O
of	O
spermidine	S-chem-C9-1
and	O
spermine	S-chem-C9-1
triggers	O
export	O
or	O
degradation	O
.	O

Increased	O
intracellular	O
polyamine	S-chem
levels	O
accompany	O
several	O
types	O
of	O
cancers	O
as	O
well	O
as	O
other	O
human	O
diseases	O
,	O
and	O
compounds	O
that	O
affect	O
the	O
expression	O
,	O
activity	O
,	O
or	O
stability	O
of	O
SSAT	S-geneY
are	O
being	O
explored	O
as	O
potential	O
therapeutic	O
drugs	O
.	O

We	O
have	O
expressed	O
human	B-geneY
SSAT	E-geneY
from	O
the	O
cloned	O
cDNA	O
in	O
Escherichia	O
coli	O
and	O
have	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
SSAT	S-geneY
,	O
as	O
the	O
free	O
dimer	O
and	O
in	O
binary	O
and	O
ternary	O
complexes	O
with	O
CoA	S-chem
,	O
acetyl	B-chem
-	I-chem
CoA	E-chem
(	O
AcCoA	S-chem
)	O
,	O
spermine	S-chem
,	O
and	O
the	O
inhibitor	O
N1	B-chem
,	I-chem
N11bis	I-chem
-	I-chem
(	I-chem
ethyl	I-chem
)	I-chem
-	I-chem
norspermine	E-chem
(	O
BE	O
-	O
3	O
-	O
3	O
-	O
3	O
)	O
.	O

These	O
structures	O
show	O
details	O
of	O
binding	O
sites	O
for	O
cofactor	O
,	O
substrates	O
,	O
and	O
inhibitor	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
enzymatic	O
activity	O
,	O
mutations	O
,	O
and	O
the	O
action	O
of	O
potential	O
drugs	O
.	O

Two	O
dimer	O
conformations	O
were	O
observed	O
:	O
a	O
symmetric	O
form	O
with	O
two	O
open	O
surface	O
channels	O
capable	O
of	O
binding	O
substrate	O
or	O
cofactor	O
,	O
and	O
an	O
asymmetric	O
form	O
in	O
which	O
only	O
one	O
of	O
the	O
surface	O
channels	O
appears	O
capable	O
of	O
binding	O
and	O
acetylating	O
polyamines	S-chem
.	O

SSAT	S-geneY
was	O
found	O
to	O
self	O
-	O
acetylate	S-chem
lysine	S-chem
-	O
26	O
in	O
the	O
presence	O
of	O
AcCoA	S-chem
and	O
absence	O
of	O
substrate	O
,	O
a	O
reaction	O
apparently	O
catalzyed	O
by	O
AcCoA	S-chem
bound	O
in	O
the	O
second	O
channel	O
of	O
the	O
asymmetric	O
dimer	O
.	O

These	O
unexpected	O
and	O
intriguing	O
complexities	O
seem	O
likely	O
to	O
have	O
some	O
as	O
yet	O
undefined	O
role	O
in	O
regulating	O
SSAT	S-geneY-C9-2
activity	O
or	O
stability	O
as	O
a	O
part	O
of	O
polyamine	S-chem-C9-1
homeostasis	O
.	O

Sequence	O
signatures	O
group	O
SSAT	S-geneY
with	O
proteins	O
that	O
appear	O
to	O
have	O
thialysine	B-geneY
Nepsilon	I-geneY
-	I-geneY
acetyltransferase	E-geneY
activity	O
.	O

Methylenedioxymethamphetamine	S-chem
decreases	O
plasmalemmal	O
and	O
vesicular	O
dopamine	S-chem
transport	O
:	O
mechanisms	O
and	O
implications	O
for	O
neurotoxicity	O
.	O

Administration	O
of	O
a	O
high	O
-	O
dose	O
regimen	O
of	O
methamphetamine	S-chem
(	O
METH	S-chem
)	O
rapidly	O
and	O
profoundly	O
decreases	O
plasmalemmal	O
and	O
vesicular	O
dopamine	S-chem
(	O
DA	S-chem
)	O
transport	O
in	O
the	O
striatum	O
,	O
as	O
assessed	O
in	O
synaptosomes	O
and	O
purified	O
vesicles	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
these	O
responses	O
were	O
common	O
to	O
other	O
amphetamines	S-chem
of	O
abuse	O
,	O
effects	O
of	O
methylenedioxymethamphetamine	S-chem
(	O
MDMA	S-chem
)	O
on	O
the	O
plasmalemmal	O
DA	B-geneY
transporter	E-geneY
(	O
DAT	S-geneY
)	O
and	O
vesicular	B-geneY
monoamine	I-geneY
transporter	I-geneY
-	I-geneY
2	E-geneY
(	O
VMAT	B-geneY
-	I-geneY
2	E-geneY
)	O
were	O
assessed	O
.	O

Similar	O
to	O
effects	O
of	O
METH	S-chem
reported	O
previously	O
,	O
multiple	O
high	O
-	O
dose	O
MDMA	S-chem
administrations	O
rapidly	O
(	O
within	O
1	O
h	O
)	O
decreased	O
plasmalemmal	O
DA	S-chem
uptake	O
,	O
as	O
assessed	O
ex	O
vivo	O
in	O
synaptosomes	O
prepared	O
from	O
treated	O
rats	O
.	O

Unlike	O
effects	O
of	O
multiple	O
METH	S-chem
injections	O
,	O
this	O
deficit	O
was	O
reversed	O
completely	O
24	O
h	O
after	O
drug	O
treatment	O
.	O

Also	O
in	O
contrast	O
to	O
effects	O
of	O
multiple	O
METH	S-chem-C4-1
injections	O
,	O
1	O
)	O
MDMA	S-chem
caused	O
little	O
or	O
no	O
decrease	O
in	O
binding	O
of	O
the	O
DAT	S-geneY-MU-2
ligand	O
WIN35428	S-chem
,	O
and	O
2	O
)	O
neither	O
prevention	O
of	O
hyperthermia	O
nor	O
prior	O
depletion	O
of	O
DA	S-chem-C9-1
prevented	O
the	O
MDMA	S-chem-C4-1
-	O
induced	O
reduction	O
in	O
plasmalemmal	O
DA	S-chem-C9-1
transport	O
.	O

However	O
,	O
a	O
role	O
for	O
phosphorylation	O
was	O
suggested	O
because	O
pretreatment	O
with	O
protein	B-geneY
kinase	I-geneY
C	E-geneY
inhibitors	O
attenuated	O
the	O
deficit	O
caused	O
by	O
MDMA	S-chem
in	O
an	O
in	O
vitro	O
model	O
system	O
.	O

In	O
addition	O
to	O
affecting	O
DAT	S-geneY-C9-2
function	O
,	O
MDMA	S-chem
rapidly	O
decreased	O
vesicular	O
DA	S-chem-C9-1
transport	O
as	O
assessed	O
in	O
striatal	O
vesicles	O
prepared	O
from	O
treated	O
rats	O
.	O

Unlike	O
effects	O
of	O
multiple	O
METH	S-chem
injections	O
reported	O
previously	O
,	O
this	O
decrease	O
partially	O
recovered	O
by	O
24	O
h	O
after	O
drug	O
treatment	O
.	O

Taken	O
together	O
,	O
these	O
results	O
reveal	O
several	O
differences	O
between	O
effects	O
of	O
MDMA	S-chem
and	O
previously	O
reported	O
METH	S-chem
on	O
DAT	S-geneY
and	O
VMAT	B-geneY
-	I-geneY
2	E-geneY
;	O
differences	O
that	O
may	O
underlie	O
the	O
dissimilar	O
neurotoxic	O
profile	O
of	O
these	O
agents	O
.	O

Dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
occupancy	O
by	O
risperidone	S-chem
:	O
implications	O
for	O
the	O
timing	O
and	O
magnitude	O
of	O
clinical	O
response	O
.	O

The	O
objective	O
of	O
the	O
study	O
is	O
to	O
investigate	O
whether	O
dopamine	B-geneY
D2	I-geneY
receptor	E-geneY
occupancy	O
by	O
risperidone	S-chem
and	O
plasma	O
levels	O
over	O
time	O
can	O
account	O
for	O
therapeutic	O
efficacy	O
and	O
the	O
latency	O
period	O
to	O
response	O
.	O

Thirty	O
-	O
eight	O
examinations	O
with	O
(	B-chem
123	I-chem
)	I-chem
I	I-chem
-	I-chem
IBZM	E-chem
single	O
photon	O
emission	O
computed	O
tomography	O
were	O
performed	O
on	O
22	O
patients	O
with	O
schizophrenia	O
,	O
at	O
diagnosis	O
,	O
48	O
h	O
after	O
starting	O
risperidone	S-chem
treatment	O
and	O
at	O
a	O
stable	O
dose	O
.	O

Risperidone	S-chem
plasma	O
levels	O
were	O
determined	O
and	O
psychopathologic	O
evaluations	O
(	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
,	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
)	O
were	O
carried	O
out	O
.	O

No	O
differences	O
in	O
the	O
striatal	O
/	O
occipital	O
(	O
S	O
/	O
O	O
)	O
ratio	O
or	O
plasma	O
levels	O
were	O
found	O
between	O
examinations	O
at	O
the	O
48	O
-	O
h	O
time	O
point	O
and	O
when	O
a	O
stable	O
dose	O
level	O
had	O
been	O
established	O
,	O
so	O
these	O
parameters	O
could	O
not	O
account	O
for	O
the	O
latency	O
period	O
required	O
for	O
clinical	O
response	O
.	O

D2	B-geneY
receptor	E-geneY
occupancy	O
at	O
48	O
h	O
correlated	O
positively	O
with	O
clinical	O
improvement	O
after	O
2	O
weeks	O
of	O
treatment	O
.	O

Therefore	O
,	O
if	O
these	O
results	O
are	O
confirmed	O
,	O
D2	B-geneY
receptor	E-geneY
occupancy	O
at	O
the	O
beginning	O
of	O
treatment	O
with	O
risperidone	S-chem
may	O
be	O
a	O
predictor	O
of	O
subsequent	O
clinical	O
response	O
.	O

TCDD	S-chem-C3-1
induces	O
the	O
expression	O
of	O
insulin	B-geneY-C3-2
-	I-geneY-C3-2
like	I-geneY-C3-2
growth	I-geneY-C3-2
factor	I-geneY-C3-2
binding	I-geneY-C3-2
protein	I-geneY-C3-2
4	E-geneY-C3-2
in	O
5L	O
rat	O
hepatoma	O
cells	O
:	O
a	O
cautionary	O
tale	O
of	O
the	O
use	O
of	O
this	O
cell	O
line	O
in	O
studies	O
on	O
dioxin	S-chem
toxicity	O
.	O

Previous	O
quantitative	O
proteomic	O
studies	O
on	O
the	O
actions	O
of	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
in	O
5L	O
rat	O
hepatoma	O
cells	O
,	O
a	O
cell	O
model	O
frequently	O
used	O
for	O
investigating	O
the	O
mechanisms	O
of	O
TCDD	S-chem
toxicity	O
,	O
had	O
indicated	O
that	O
dioxin	S-chem
exposure	O
reduced	O
the	O
abundance	O
of	O
numerous	O
proteins	O
which	O
are	O
regulated	O
at	O
the	O
level	O
of	O
protein	O
synthesis	O
initiation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
analysed	O
the	O
mechanism	O
mediating	O
this	O
inhibition	O
.	O

TCDD	S-chem
treatment	O
of	O
the	O
cells	O
largely	O
prevented	O
the	O
activation	O
of	O
eukaryotic	B-geneY
translation	I-geneY
initiation	I-geneY
factor	I-geneY
4E	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
1	E-geneY
,	O
a	O
regulator	O
of	O
translation	O
initiation	O
and	O
substrate	O
of	O
the	O
mammalian	B-geneY
target	I-geneY
of	I-geneY
rapamycin	E-geneY
(	O
mTOR	S-geneY
)	O
.	O

By	O
``	O
working	O
upwards	O
``	O
from	O
mTOR	O
,	O
we	O
observed	O
that	O
TCDD	O
inhibited	O
endogenous	O
and	O
IGF	E-geneY-C4-2
-	O
I	O
-	O
induced	O
AKT	O
and	O
ERK	O
activation	O
by	O
interfering	O
with	O
tyrosine	O
phosphorylation	O
of	B-geneY
insulin	I-geneY
receptor	I-geneY
substrate	O
1	O
.	O

This	O
inhibition	O
was	O
mediated	O
by	O
a	O
TCDD	S-chem-C3-1
-	O
induced	O
secreted	O
factor	O
which	O
was	O
identified	O
as	O
insulin	B-geneY-C3-2
-	I-geneY-C3-2
like	I-geneY-C3-2
growth	I-geneY-C3-2
factor	I-geneY-C3-2
binding	I-geneY-C3-2
protein	I-geneY-C3-2
4	E-geneY-C3-2
(	O
IGFBP	B-geneY-C3-2
-	I-geneY-C3-2
4	E-geneY-C3-2
)	O
.	O

The	O
induction	O
of	O
IGFBP	B-geneY
-	I-geneY
4	E-geneY
protein	O
was	O
dependent	O
on	O
a	O
functional	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
and	O
was	O
preceded	O
by	O
a	O
rapid	O
increase	O
in	O
the	O
level	O
of	O
IGFBP	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
mRNA	O
indicating	O
that	O
IGFBP	B-geneY
-	I-geneY
4	E-geneY
is	O
a	O
previously	O
unknown	O
transcriptional	O
target	O
of	O
TCDD	S-chem-C4-1
in	O
5L	O
cells	O
.	O

IGFBP	B-geneY
-	I-geneY
4	E-geneY
was	O
not	O
induced	O
by	O
TCDD	S-chem
in	O
the	O
parental	O
cell	O
line	O
of	O
5L	O
cells	O
,	O
Fao	O
,	O
and	O
in	O
various	O
closely	O
related	O
rat	O
hepatoma	O
cell	O
lines	O
as	O
well	O
as	O
in	O
other	O
unrelated	O
cell	O
types	O
.	O

Analysis	O
of	O
5L	O
cell	O
chromosomes	O
by	O
multicolour	O
spectral	O
karyotyping	O
(	O
SKY	O
)	O
revealed	O
that	O
the	O
cells	O
carry	O
several	O
hitherto	O
uncharacterised	O
chromosomal	O
translocations	O
.	O

The	O
observations	O
suggest	O
that	O
in	O
5L	O
cells	O
the	O
Igfbp	B-geneY
-	I-geneY
4	E-geneY
gene	O
may	O
have	O
got	O
under	O
the	O
control	O
of	O
a	O
promoter	O
containing	O
dioxin	B-geneN
responsive	I-geneN
element	I-geneN
(	I-geneN
s	I-geneN
)	E-geneN
leading	O
to	O
the	O
induction	O
of	O
IGFBP	B-geneY-C3-2
-	I-geneY-C3-2
4	E-geneY-C3-2
by	O
TCDD	S-chem-C3-1
.	O

These	O
findings	O
emphasise	O
a	O
particular	O
caution	O
when	O
interpreting	O
and	O
extrapolating	O
results	O
on	O
the	O
action	O
mechanisms	O
of	O
TCDD	S-chem
obtained	O
in	O
studies	O
using	O
5L	O
cells	O
as	O
a	O
model	O
system	O
.	O

Formation	O
of	O
Mallory	O
body	O
-	O
like	O
inclusions	O
and	O
cell	O
death	O
induced	O
by	O
deregulated	O
expression	O
of	O
keratin	B-geneY
18	E-geneY
.	O

Mallory	O
bodies	O
(	O
MBs	O
)	O
are	O
cytoplasmic	O
inclusions	O
that	O
contain	O
keratin	B-geneY
8	E-geneY
(	O
K8	S-geneY
)	O
and	O
K18	S-geneY
and	O
are	O
present	O
in	O
hepatocytes	O
of	O
individuals	O
with	O
alcoholic	S-chem
liver	O
disease	O
,	O
nonalcoholic	S-chem
steatohepatitis	O
,	O
or	O
benign	O
or	O
malignant	O
hepatocellular	O
neoplasia	O
.	O

Mice	O
fed	O
long	O
term	O
with	O
griseofulvin	S-chem
are	O
an	O
animal	O
model	O
of	O
MB	O
formation	O
.	O

However	O
,	O
the	O
lack	O
of	O
a	O
cellular	O
model	O
has	O
impeded	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
this	O
process	O
.	O

Culture	O
of	O
HepG2	O
cells	O
with	O
griseofulvin	S-chem-C3-1
has	O
now	O
been	O
shown	O
to	O
induce	O
both	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
containing	O
K18	S-geneY-C3-2
as	O
well	O
as	O
an	O
increase	O
in	O
the	O
abundance	O
of	O
K18	S-geneY-C3-2
mRNA	O
.	O

Overexpression	O
of	O
K18	S-geneY
in	O
HepG2	O
,	O
HeLa	O
,	O
or	O
COS	O
-	O
7	O
cells	O
also	O
induced	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
that	O
stained	O
with	O
antibodies	O
to	O
ubiquitin	S-geneN
and	O
with	O
rhodamine	B-chem
B	E-chem
(	O
characteristics	O
of	O
MBs	O
formed	O
in	O
vivo	O
)	O
,	O
eventually	O
leading	O
to	O
cell	O
death	O
.	O

The	O
MB	O
-	O
like	O
aggregates	O
were	O
deposited	O
around	O
centrosomes	O
and	O
disrupted	O
the	O
microtubular	O
array	O
.	O

Coexpression	O
of	O
K8	S-geneY
with	O
K18	S-geneY
restored	O
the	O
normal	O
fibrous	O
pattern	O
of	O
keratin	S-geneN
distribution	O
and	O
reduced	O
the	O
toxicity	O
of	O
K18	S-geneY
.	O

In	O
contrast	O
,	O
an	O
NH	B-chem
(	I-chem
2	I-chem
)	E-chem
-	O
terminal	O
deletion	O
mutant	O
of	O
K8	S-geneY
promoted	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
even	O
in	O
the	O
absence	O
of	O
K18	S-geneY
overexpression	O
.	O

Deregulated	O
expression	O
of	O
K18	S-geneY
,	O
or	O
an	O
imbalance	O
between	O
K8	S-geneY
and	O
K18	S-geneY
,	O
may	O
thus	O
be	O
an	O
important	O
determinant	O
of	O
MB	O
formation	O
,	O
which	O
compromises	O
the	O
function	O
of	O
centrosomes	O
and	O
the	O
microtubule	O
network	O
and	O
leads	O
to	O
cell	O
death	O
.	O

Tolvaptan	S-chem
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
hyponatremia	O
.	O

Tolvaptan	S-chem-C4-1
is	O
a	O
selective	O
arginine	B-geneY-C4-2
vasopressin	I-geneY-C4-2
(	I-geneY-C4-2
AVP	I-geneY-C4-2
)	I-geneY-C4-2
V	I-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	I-geneY-C4-2
receptor	E-geneY-C4-2
blocker	O
used	O
to	O
induce	O
free	O
water	O
diuresis	O
in	O
the	O
treatment	O
of	O
euvolemic	O
or	O
hypervolemic	O
hyponatremia	O
.	O

Currently	O
the	O
orally	O
active	O
medication	O
is	O
in	O
the	O
final	O
stages	O
prior	O
to	O
approval	O
by	O
the	O
FDA	O
for	O
outpatient	O
therapy	O
.	O

It	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
at	O
promoting	O
aquaresis	O
and	O
raising	O
serum	O
sodium	S-chem
levels	O
in	O
both	O
short	O
-	O
and	O
long	O
-	O
term	O
studies	O
.	O

Tolvaptan	S-chem
is	O
also	O
effective	O
for	O
treatment	O
of	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
exacerbation	O
,	O
but	O
whether	O
there	O
are	O
long	O
standing	O
beneficial	O
effects	O
on	O
CHF	O
is	O
still	O
controversial	O
.	O

Prolonged	O
use	O
of	O
tolvaptan	S-chem-C3-1
leads	O
to	O
increased	O
endogenous	O
levels	O
of	O
AVP	S-geneY-C3-2
and	O
perhaps	O
over	O
-	O
stimulation	O
of	O
V	B-geneY-C3-2
(	I-geneY-C3-2
1A	I-geneY-C3-2
)	I-geneY-C3-2
receptors	E-geneY-C3-2
.	O

Theoretically	O
this	O
activation	O
could	O
lead	O
to	O
increased	O
afterload	O
and	O
cardiac	O
myocyte	O
fibrosis	O
,	O
causing	O
progression	O
of	O
CHF	O
.	O

However	O
,	O
after	O
52	O
weeks	O
of	O
tolvaptan	S-chem
therapy	O
there	O
was	O
no	O
worsening	O
of	O
left	O
ventricular	O
dilatation	O
.	O

In	O
addition	O
,	O
tolvaptan	S-chem-C9-1
is	O
metabolized	O
by	O
the	O
CYP3A4	S-geneY-C9-2
system	O
;	O
thus	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
increased	O
interactions	O
with	O
other	O
medications	O
.	O

Tolvaptan	S-chem
is	O
a	O
breakthrough	O
in	O
the	O
therapy	O
of	O
hyponatremia	O
as	O
it	O
directly	O
combats	O
elevated	O
AVP	S-geneY
levels	O
associated	O
with	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	B-geneY
hormone	E-geneY
,	O
congestive	O
heart	O
failure	O
,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Effects	O
of	O
ozone	S-chem
and	O
fine	O
particulate	O
matter	O
(	O
PM	O
(	O
2.5	O
)	O
)	O
on	O
rat	O
system	O
inflammation	O
and	O
cardiac	O
function	O
.	O

In	O
order	O
to	O
understand	O
the	O
toxic	O
mechanisms	O
of	O
cardiovascular	O
system	O
injuries	O
induced	O
by	O
ambient	O
PM	O
(	O
2.5	O
)	O
and	O
/	O
or	O
ozone	S-chem
,	O
a	O
subacute	O
toxicological	O
animal	O
experiment	O
was	O
designed	O
with	O
exposure	O
twice	O
a	O
week	O
for	O
3	O
continuous	O
weeks	O
.	O

Wistar	O
rats	O
were	O
randomly	O
categorized	O
into	O
8	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
1	O
control	O
group	O
,	O
3	O
groups	O
exposed	O
to	O
fine	O
particulate	O
matters	O
(	O
PM	O
(	O
2.5	O
)	O
)	O
alone	O
at	O
3	O
doses	O
(	O
0.2	O
,	O
0.8	O
,	O
or	O
3.2	O
mg	O
/	O
rat	O
)	O
,	O
1	O
group	O
to	O
ozone	S-chem
(	O
0.81	O
ppm	O
)	O
alone	O
and	O
3	O
groups	O
to	O
ozone	S-chem
plus	O
PM	O
(	O
2.5	O
)	O
at	O
3	O
doses	O
(	O
0.2	O
,	O
0.8	O
,	O
or	O
3.2	O
mg	O
/	O
rat	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
at	O
approximately	O
24	O
-	O
h	O
both	O
after	O
the	O
3rd	O
exposure	O
and	O
the	O
last	O
(	O
6th	O
)	O
exposure	O
,	O
and	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
monitored	O
at	O
approximately	O
24	O
-	O
h	O
after	O
the	O
6th	O
exposure	O
.	O

Biomarkers	O
of	O
systemic	O
inflammation	O
and	O
injuries	O
(	O
CRP	S-geneY
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
,	O
LDH	S-geneN
,	O
CK	S-geneN
)	O
,	O
heart	O
oxidative	O
stress	O
(	O
MDA	S-chem
,	O
SOD	S-geneN
)	O
and	O
endothelial	O
function	O
(	O
ET	B-geneY
-	I-geneY
1	E-geneY
,	O
VEGF	S-geneY
)	O
were	O
analyzed	O
after	O
the	O
6th	O
exposure	O
.	O

Additionally	O
,	O
myocardial	O
ultrastructural	O
alterations	O
were	O
observed	O
under	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
for	O
histopathological	O
analyses	O
.	O

Results	O
showed	O
that	O
PM	O
(	O
2.5	O
)	O
alone	O
exposure	O
could	O
trigger	O
the	O
significant	O
increase	O
of	O
CRP	S-geneY
,	O
MDA	S-chem
,	O
CK	S-geneN
,	O
ET	B-geneY
-	I-geneY
1	E-geneY
and	O
SBP	O
and	O
decrease	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
a	O
marker	O
of	O
cardiac	O
autonomic	O
nervous	O
system	O
(	O
ANS	O
)	O
function	O
.	O

Ozone	S-chem
alone	O
exposure	O
in	O
rats	O
did	O
not	O
show	O
significant	O
alterations	O
in	O
any	O
indicators	O
.	O

Ozone	S-chem-MU-1
plus	O
PM	O
(	O
2.5	O
)	O
exposure	O
,	O
however	O
,	O
induced	O
CRP	S-geneY-C3-2
,	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
6	E-geneY-C3-2
,	O
CK	S-geneN-C3-2
,	O
LDH	S-geneN-C3-2
and	O
MDA	S-chem
increase	O
,	O
SOD	S-geneN-C4-2
and	O
HRV	O
decrease	O
significantly	O
in	O
a	O
dose	O
-	O
response	O
way	O
.	O

Meanwhile	O
,	O
abnormal	O
ECG	O
types	O
were	O
monitored	O
in	O
rats	O
exposed	O
to	O
PM	O
(	O
2.5	O
)	O
with	O
and	O
without	O
ozone	S-chem
and	O
obvious	O
myocardial	O
ultrastructural	O
changes	O
were	O
observed	O
by	O
TEM	O
.	O

In	O
conclusion	O
,	O
PM	O
(	O
2.5	O
)	O
alone	O
exposure	O
could	O
cause	O
inflammation	O
,	O
endothelial	O
function	O
and	O
ANS	O
injuries	O
,	O
and	O
ozone	S-chem
potentiated	O
these	O
effects	O
induced	O
by	O
PM	O
(	O
2.5	O
)	O
.	O

Peptide	O
and	O
non	O
-	O
peptide	O
agonists	O
and	O
antagonists	O
for	O
the	O
vasopressin	S-geneY
and	O
oxytocin	S-geneY
V1a	S-geneY
,	O
V1b	S-geneY
,	O
V2	S-geneY
and	O
OT	B-geneY
receptors	E-geneY
:	O
research	O
tools	O
and	O
potential	O
therapeutic	O
agents	O
.	O

Oxytocin	S-geneY
(	O
OT	S-geneY
)	O
and	O
vasopressin	S-geneY
(	O
AVP	S-geneY
)	O
mediate	O
their	O
biological	O
actions	O
by	O
acting	O
on	O
four	O
known	O
receptors	O
:	O
The	O
OT	S-geneY
(	O
uterine	O
)	O
and	O
the	O
AVP	S-geneY
V	B-geneY
(	I-geneY
1a	I-geneY
)	E-geneY
(	O
vasopressor	O
)	O
,	O
V	B-geneY
(	I-geneY
1b	I-geneY
)	E-geneY
(	O
pituitary	O
)	O
,	O
V	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
(	O
renal	O
)	O
receptors	O
and	O
a	O
fifth	O
putative	O
AVP	S-geneY
V	B-geneN
(	I-geneN
1c	I-geneN
)	E-geneN
?	O
(	O
vasodilating	O
)	O
receptor	O
.	O

This	O
presentation	O
will	O
summarize	O
some	O
highlights	O
of	O
the	O
recent	O
progress	O
,	O
in	O
the	O
design	O
and	O
synthesis	O
of	O
selective	O
peptide	O
agonists	O
,	O
antagonists	O
,	O
radioiodinated	O
ligands	O
,	O
fluorescent	O
ligands	O
and	O
bivalent	O
ligands	O
for	O
these	O
receptors	O
.	O

Here	O
we	O
present	O
published	O
and	O
unpublished	O
pharmacological	O
data	O
on	O
the	O
most	O
widely	O
used	O
agonists	O
,	O
antagonists	O
and	O
labelled	O
ligands	O
.	O

The	O
pharmacological	O
properties	O
of	O
promising	O
new	O
selective	O
OT	S-geneY
antagonists	O
and	O
V	B-geneY
(	I-geneY
1b	I-geneY
)	E-geneY
agonists	O
are	O
also	O
presented	O
.	O

This	O
review	O
should	O
serve	O
as	O
a	O
useful	O
guide	O
for	O
the	O
selection	O
of	O
the	O
most	O
appropriate	O
ligand	O
for	O
a	O
given	O
study	O
.	O

The	O
current	O
status	O
of	O
non	O
-	O
peptide	O
OT	S-geneY
and	O
AVP	S-geneY
antagonists	O
and	O
agonists	O
is	O
also	O
summarized	O
.	O

The	O
relative	O
merits	O
of	O
peptide	O
and	O
non	O
-	O
peptide	O
AVP	S-geneY
and	O
OT	S-geneY
agonists	O
and	O
antagonists	O
as	O
:	O
(	O
1	O
)	O
research	O
tools	O
and	O
(	O
2	O
)	O
therapeutic	O
agents	O
will	O
be	O
evaluated	O
.	O

Many	O
of	O
the	O
receptor	O
selective	O
peptide	O
agonists	O
and	O
antagonists	O
from	O
this	O
and	O
other	O
laboratories	O
are	O
far	O
more	O
widely	O
used	O
as	O
pharmacological	O
tools	O
for	O
studies	O
on	O
the	O
peripheral	O
and	O
central	O
effects	O
of	O
OT	S-geneY
and	O
AVP	S-geneY
than	O
their	O
non	O
-	O
peptide	O
counterparts	O
.	O

In	O
addition	O
to	O
OT	S-geneY
and	O
to	O
a	O
lesser	O
extent	O
AVP	S-geneY
(	O
pitressin	O
)	O
,	O
a	O
number	O
of	O
OT	S-geneY
and	O
AVP	S-geneY
analogues	O
;	O
such	O
as	O
carbetocin	S-chem-C5-1
(	O
OT	S-geneY-C5-2
agonist	O
)	O
dDAVP	O
(	O
desmopressin	S-chem-C5-1
,	O
V	B-geneY-C5-2
(	I-geneY-C5-2
2	I-geneY-C5-2
)	E-geneY-C5-2
agonist	O
)	O
,	O
terlipressin	S-chem-C5-1
(	O
V	B-geneY-C5-2
(	I-geneY-C5-2
1a	I-geneY-C5-2
)	E-geneY-C5-2
agonist	O
)	O
,	O
felypressin	S-chem-C5-1
(	O
V	B-geneY-C5-2
(	I-geneY-C5-2
1a	I-geneY-C5-2
)	E-geneY-C5-2
agonist	O
)	O
and	O
atosiban	S-chem-C6-1
(	O
Tractocile	S-chem-C6-1
OT	S-geneY-C6-2
antagonist	O
)	O
are	O
also	O
in	O
clinical	O
use	O
.	O

Despite	O
much	O
early	O
promise	O
,	O
no	O
non	O
-	O
peptide	O
V	B-geneY
(	I-geneY
1a	I-geneY
)	E-geneY
or	O
OT	S-geneY
antagonists	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

While	O
a	O
number	O
of	O
orally	O
active	O
non	O
-	O
peptide	O
V	B-geneY-C6-2
(	I-geneY-C6-2
2	I-geneY-C6-2
)	E-geneY-C6-2
antagonists	O
(	O
Vaptans	O
)	O
;	O
notably	O
,	O
Tolvaptan	S-chem-C6-1
,	O
Lixivaptan	S-chem-C6-1
and	O
Satavaptan	S-chem-C6-1
,	O
are	O
currently	O
in	O
Phase	O
III	O
clinical	O
trials	O
;	O
to	O
date	O
,	O
only	O
the	O
mixed	O
V	B-geneY-C6-2
(	I-geneY-C6-2
2	I-geneY-C6-2
)	E-geneY-C6-2
/	O
V	B-geneY-C6-2
(	I-geneY-C6-2
1a	I-geneY-C6-2
)	E-geneY-C6-2
,	O
antagonist	O
Conivaptan	S-chem-C6-1
(	O
Vaprisol	S-chem-C6-1
)	O
,	O
has	O
been	O
approved	O
by	O
the	O
US	O
FDA	O
for	O
clinical	O
use	O
(	O
by	O
i.v	O
.	O
administration	O
)	O
,	O
for	O
the	O
treatment	O
of	O
euvolemic	O
and	O
hypervolemic	O
hyponatremia	O
in	O
hospitalized	O
patients	O
.	O

Promising	O
new	O
non	O
-	O
peptide	O
V	B-geneY
(	I-geneY
1b	I-geneY
)	E-geneY
and	O
OT	S-geneY
antagonists	O
,	O
as	O
well	O
as	O
non	O
-	O
peptide	O
V	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
OT	S-geneY
agonists	O
are	O
now	O
in	O
pre	O
-	O
clinical	O
development	O
.	O

Functional	O
consequences	O
of	O
the	O
arrhythmogenic	O
G306R	S-geneN
KvLQT1	S-geneY
K	B-geneN
+	I-geneN
channel	E-geneN
mutant	O
probed	O
by	O
viral	O
gene	O
transfer	O
in	O
cardiomyocytes	O
.	O

IKs	O
,	O
the	O
slow	O
component	O
of	O
the	O
delayed	O
rectifier	O
potassium	S-chem
current	O
,	O
figures	O
prominently	O
in	O
the	O
repolarization	O
of	O
heart	O
cells	O
.	O

The	O
K	B-geneN
+	I-geneN
channel	E-geneN
gene	O
KvLQT1	S-geneY
is	O
mutated	O
in	O
the	O
heritable	O
long	O
QT	O
(	O
LQT	O
)	O
syndrome	O
.	O

Heterologous	O
coexpression	O
of	O
KvLQT1	S-geneY
and	O
the	O
accessory	O
protein	O
minK	S-geneY
yields	O
an	O
IKs	O
-	O
like	O
current	O
.	O

Nevertheless	O
,	O
the	O
links	O
between	O
KvLQT1	S-geneY
and	O
cardiac	O
IKs	O
are	O
largely	O
inferential	O
.	O

Since	O
the	O
LQT	O
syndrome	O
mutant	O
KvLQT1	S-geneY
-	O
G306R	S-geneN
suppresses	O
channel	O
activity	O
when	O
coexpressed	O
with	O
wild	O
-	O
type	O
KvLQT1	S-geneY
in	O
a	O
heterologous	O
system	O
,	O
overexpression	O
of	O
this	O
mutant	O
in	O
cardiomyocytes	O
should	O
reduce	O
or	O
eliminate	O
native	O
IKs	O
if	O
KvLQT1	S-geneY
is	O
indeed	O
the	O
major	O
molecular	O
component	O
of	O
this	O
current	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
created	O
the	O
adenovirus	O
AdRMGI	O
-	O
KvLQT1	S-geneY
-	O
G306R	S-geneN
,	O
which	O
overexpresses	O
KvLQT1	S-geneY
-	O
G306R	S-geneN
channels	O
.	O

In	O
>	O
60	O
%	O
of	O
neonatal	O
mouse	O
myocytes	O
,	O
a	O
sizable	O
IKs	O
could	O
be	O
measured	O
using	O
perforated	O
-	O
patch	O
recordings	O
(	O
8.0	O
+	O
/	O
-	O
1.6	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
13	O
)	O
.	O

IKs	O
was	O
increased	O
by	O
forskolin	S-chem
and	O
blocked	O
by	O
clofilium	S-chem
or	O
indapamide	S-chem
but	O
not	O
by	O
E	B-chem
-	I-chem
4031	E-chem
.	O

While	O
cells	O
infected	O
with	O
a	O
reporter	O
virus	O
expressing	O
only	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
displayed	O
IKs	O
similar	O
to	O
that	O
in	O
uninfected	O
cells	O
,	O
AdRMGI	O
-	O
KvLQT1	S-geneY
-	O
G306R	S-geneN
-	O
infected	O
cells	O
showed	O
a	O
significantly	O
reduced	O
IKs	O
(	O
2.4	O
+	O
/	O
-	O
1.1	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
when	O
measured	O
60	O
-	O
72	O
h	O
after	O
infection	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
adult	O
guinea	O
-	O
pig	O
myocytes	O
(	O
5.9	O
+	O
/	O
-	O
1.2	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
9	O
,	O
for	O
control	O
vs	O
.	O

0.1	O
+	O
/	O
-	O
0.1	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
5	O
,	O
for	O
AdRMGI	O
-	O
KvLQT1	S-geneY
-	O
G306R	S-geneN
-	O
infected	O
cells	O
)	O
.	O

We	O
conclude	O
that	O
KvLQT1	S-geneY
is	O
the	O
major	O
molecular	O
component	O
of	O
IKs	O
.	O

Our	O
results	O
further	O
establish	O
a	O
dominant	O
-	O
negative	O
mechanism	O
for	O
the	O
G306R	S-geneN
LQT	O
syndrome	O
mutation	O
.	O

Compared	O
pharmacological	O
characteristics	O
in	O
humans	O
of	O
racemic	O
cetirizine	S-chem-C6-1
and	O
levocetirizine	S-chem-C6-1
,	O
two	O
histamine	B-geneY-C6-2
H1	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonists	O
.	O

The	O
potent	O
histamine	B-geneY-C6-2
H	I-geneY-C6-2
(	I-geneY-C6-2
1	I-geneY-C6-2
)	I-geneY-C6-2
-	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
cetirizine	S-chem-C6-1
(	O
Zyrtec	S-chem-C6-1
)	O
is	O
a	O
racemic	O
mixture	O
of	O
levocetirizine	S-chem-C6-1
(	O
now	O
available	O
under	O
the	O
trademark	O
Xyzal	S-chem-C6-1
and	O
dextrocetirizine	S-chem-C6-1
.	O

In	O
this	O
Commentary	O
,	O
we	O
examine	O
some	O
biological	O
properties	O
of	O
cetirizine	S-chem
and	O
levocetirizine	S-chem
,	O
namely	O
enantioselectivity	O
in	O
pharmacological	O
activity	O
and	O
pharmacokinetic	O
properties	O
,	O
with	O
emphasis	O
on	O
the	O
possibility	O
of	O
racemization	O
,	O
the	O
compared	O
behavior	O
of	O
the	O
two	O
enantiomers	O
,	O
and	O
the	O
potential	O
for	O
interactions	O
with	O
other	O
drugs	O
.	O

Recent	O
data	O
demonstrate	O
that	O
the	O
antihistaminergic	O
activity	O
of	O
the	O
racemate	O
is	O
primarily	O
due	O
to	O
levocetirizine	S-chem
.	O

Levocetirizine	S-chem
is	O
rapidly	O
and	O
extensively	O
absorbed	O
,	O
poorly	O
metabolized	O
,	O
and	O
not	O
subject	O
to	O
racemization	O
.	O

Its	O
pharmacokinetic	O
characteristics	O
are	O
comparable	O
after	O
administration	O
alone	O
or	O
in	O
the	O
racemate	O
.	O

Its	O
apparent	O
volume	O
of	O
distribution	O
is	O
smaller	O
than	O
that	O
of	O
dextrocetirizine	S-chem
(	O
0.41	O
L	O
kg	O
(	O
-	O
1	O
)	O
vs	O
.	O

0.60	O
L	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

Moreover	O
,	O
the	O
non	O
-	O
renal	O
(	O
mostly	O
hepatic	O
)	O
clearance	O
of	O
levocetirizine	S-chem
is	O
also	O
significantly	O
lower	O
than	O
that	O
of	O
dextrocetirizine	S-chem
(	O
11.8	O
mL	O
min	O
(	O
-	O
1	O
)	O
vs	O
.	O

29.2	O
mL	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

Our	O
conclusion	O
is	O
that	O
levocetirizine	S-chem
is	O
indeed	O
the	O
eutomer	O
of	O
cetirizine	S-chem
.	O

The	O
evidence	O
reviewed	O
here	O
confirms	O
preclinical	O
findings	O
and	O
offers	O
a	O
rationale	O
for	O
the	O
chiral	O
switch	O
from	O
the	O
racemate	O
to	O
levocetirizine	S-chem
.	O

An	O
overview	O
on	O
the	O
marine	O
neurotoxin	O
,	O
saxitoxin	S-chem
:	O
genetics	O
,	O
molecular	O
targets	O
,	O
methods	O
of	O
detection	O
and	O
ecological	O
functions	O
.	O

Marine	O
neurotoxins	O
are	O
natural	O
products	O
produced	O
by	O
phytoplankton	O
and	O
select	O
species	O
of	O
invertebrates	O
and	O
fish	O
.	O

These	O
compounds	O
interact	O
with	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
,	I-geneN
potassium	I-geneN
and	I-geneN
calcium	I-geneN
channels	E-geneN
and	O
modulate	O
the	O
flux	O
of	O
these	O
ions	O
into	O
various	O
cell	O
types	O
.	O

This	O
review	O
provides	O
a	O
summary	O
of	O
marine	O
neurotoxins	O
,	O
including	O
their	O
structures	O
,	O
molecular	O
targets	O
and	O
pharmacologies	O
.	O

Saxitoxin	S-chem
and	O
its	O
derivatives	O
,	O
collectively	O
referred	O
to	O
as	O
paralytic	O
shellfish	O
toxins	O
(	O
PSTs	O
)	O
,	O
are	O
unique	O
among	O
neurotoxins	O
in	O
that	O
they	O
are	O
found	O
in	O
both	O
marine	O
and	O
freshwater	O
environments	O
by	O
organisms	O
inhabiting	O
two	O
kingdoms	O
of	O
life	O
.	O

Prokaryotic	O
cyanobacteria	O
are	O
responsible	O
for	O
PST	O
production	O
in	O
freshwater	O
systems	O
,	O
while	O
eukaryotic	O
dinoflagellates	O
are	O
the	O
main	O
producers	O
in	O
marine	O
waters	O
.	O

Bioaccumulation	O
by	O
filter	O
-	O
feeding	O
bivalves	O
and	O
fish	O
and	O
subsequent	O
transfer	O
through	O
the	O
food	O
web	O
results	O
in	O
the	O
potentially	O
fatal	O
human	O
illnesses	O
,	O
paralytic	O
shellfish	O
poisoning	O
and	O
saxitoxin	S-chem
pufferfish	O
poisoning	O
.	O

These	O
illnesses	O
are	O
a	O
result	O
of	O
saxitoxin	S-chem
's	O
ability	O
to	O
bind	O
to	O
the	O
voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
channel	E-geneN
,	O
blocking	O
the	O
passage	O
of	O
nerve	O
impulses	O
and	O
leading	O
to	O
death	O
via	O
respiratory	O
paralysis	O
.	O

Recent	O
advances	O
in	O
saxitoxin	S-chem
research	O
are	O
discussed	O
,	O
including	O
the	O
molecular	O
biology	O
of	O
toxin	O
synthesis	O
,	O
new	O
protein	O
targets	O
,	O
association	O
with	O
metal	B-geneN
-	I-geneN
binding	I-geneN
motifs	E-geneN
and	O
methods	O
of	O
detection	O
.	O

The	O
eco	O
-	O
evolutionary	O
role	O
(	O
s	O
)	O
PSTs	O
may	O
serve	O
for	O
phytoplankton	O
species	O
that	O
produce	O
them	O
are	O
also	O
discussed	O
.	O

State	O
-	O
dependent	O
mibefradil	S-chem-C4-1
block	O
of	O
Na	B-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
.	O

Mibefradil	S-chem-C6-1
is	O
a	O
T	B-geneN-C6-2
-	I-geneN-C6-2
type	I-geneN-C6-2
Ca2	I-geneN-C6-2
+	I-geneN-C6-2
channel	E-geneN-C6-2
antagonist	O
with	O
reported	O
cross	O
-	O
reactivity	O
with	O
other	O
classes	O
of	O
ion	O
channels	O
,	O
including	O
K	B-geneN
+	I-geneN
,	I-geneN
Cl	I-geneN
-	I-geneN
,	I-geneN
and	I-geneN
Na	I-geneN
+	I-geneN
channels	E-geneN
.	O

Using	O
whole	O
-	O
cell	O
voltage	O
clamp	O
,	O
we	O
examined	O
mibefradil	S-chem-C4-1
block	O
of	O
four	O
Na	B-geneN-C4-2
+	I-geneN-C4-2
channel	E-geneN-C4-2
isoforms	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
:	O
Nav1.5	S-geneY-C4-2
(	O
cardiac	O
)	O
,	O
Nav1.4	S-geneY-C4-2
(	O
skeletal	O
muscle	O
)	O
,	O
Nav1.2	S-geneY-C4-2
(	O
brain	O
)	O
,	O
and	O
Nav1.7	S-geneY-C4-2
(	O
peripheral	O
nerve	O
)	O
.	O

Mibefradil	S-chem-C4-1
blocked	O
Nav1.5	S-geneY-C4-2
in	O
a	O
use	O
/	O
frequency	O
-	O
dependent	O
manner	O
,	O
indicating	O
preferential	O
binding	O
to	O
states	O
visited	O
during	O
depolarization	O
.	O

Mibefradil	S-chem-C4-1
blocked	O
currents	O
of	O
all	O
Na	B-geneN-C4-2
+	I-geneN-C4-2
channel	E-geneN-C4-2
isoforms	O
with	O
similar	O
affinity	O
and	O
a	O
dependence	O
on	O
holding	O
potential	O
,	O
and	O
drug	O
off	O
-	O
rate	O
was	O
slowed	O
at	O
depolarized	O
potentials	O
(	O
k	O
(	O
off	O
)	O
was	O
0.024	O
/	O
s	O
at	O
-	O
130	O
mV	O
and	O
0.007	O
/	O
s	O
at	O
-	O
100	O
mV	O
for	O
Nav1.5	S-geneY-C4-2
)	O
.	O

We	O
further	O
probed	O
the	O
interaction	O
of	O
mibefradil	S-chem
with	O
inactivated	O
Nav1.5	S-geneY
channels	O
.	O

Neither	O
the	O
degree	O
nor	O
the	O
time	O
course	O
of	O
block	O
was	O
dependent	O
on	O
the	O
stimulus	O
duration	O
,	O
which	O
dramatically	O
changed	O
the	O
residency	O
time	O
of	O
channels	O
in	O
the	O
fast	O
-	O
inactivated	O
state	O
.	O

In	O
addition	O
,	O
inhibiting	O
the	O
binding	O
of	O
the	O
fast	O
inactivation	O
lid	O
(	O
Nav1.5	S-geneY-C4-2
ICM	O
+	O
MTSET	O
)	O
did	O
not	O
alter	O
mibefradil	S-chem-C4-1
block	O
,	O
confirming	O
that	O
the	O
drug	O
does	O
not	O
preferentially	O
interact	O
with	O
the	O
fast	O
-	O
inactivated	O
state	O
.	O

We	O
also	O
tested	O
whether	O
mibefradil	S-chem
interacted	O
with	O
slow	O
-	O
inactivated	O
state	O
(	O
s	O
)	O
.	O

When	O
selectively	O
applied	O
to	O
channels	O
after	O
inducing	O
slow	O
inactivation	O
with	O
a	O
60	O
-	O
s	O
pulse	O
to	O
-	O
10	O
mV	O
,	O
mibefradil	S-chem-C4-1
(	O
1	O
microM	O
)	O
produced	O
45	O
%	O
fractional	O
block	O
in	O
Nav1.5	S-geneY-C4-2
and	O
greater	O
block	O
(	O
88	O
%	O
)	O
in	O
an	O
isoform	O
(	O
Nav1.4	S-geneY-C4-2
)	O
that	O
slow	O
-	O
inactivates	O
more	O
completely	O
.	O

Our	O
results	O
suggest	O
that	O
mibefradil	S-chem-C4-1
blocks	O
Na	B-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
in	O
a	O
state	O
-	O
dependent	O
manner	O
that	O
does	O
not	O
depend	O
on	O
fast	O
inactivation	O
but	O
probably	O
involves	O
interaction	O
with	O
one	O
or	O
more	O
slow	O
-	O
inactivated	O
state	O
(	O
s	O
)	O
.	O

Reboxetine	S-chem
versus	O
fluvoxamine	S-chem
in	O
the	O
treatment	O
of	O
motor	O
vehicle	O
accident	O
-	O
related	O
posttraumatic	O
stress	O
disorder	O
:	O
a	O
double	O
-	O
blind	O
,	O
fixed	O
-	O
dosage	O
,	O
controlled	O
trial	O
.	O

BACKGROUND	O
:	O
Motor	O
vehicle	O
accidents	O
(	O
MVAs	O
)	O
are	O
a	O
leading	O
cause	O
of	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
in	O
the	O
general	O
population	O
.	O

Alterations	O
in	O
norepinephrine	S-chem
and	O
serotonin	S-chem
systems	O
have	O
been	O
proposed	O
as	O
mechanisms	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
condition	O
,	O
with	O
treatment	O
directed	O
at	O
these	O
neurotransmitter	O
systems	O
.	O

Reboxetine	S-chem-C4-1
,	O
a	O
selective	O
norepinephrine	S-chem
reuptake	O
inhibitor	O
,	O
exhibits	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
human	B-geneY-C4-2
norepinephrine	I-geneY-C4-2
transporter	E-geneY-C4-2
.	O

Inasmuch	O
as	O
PTSD	O
may	O
be	O
associated	O
with	O
dysregulation	O
of	O
noradrenergic	O
activity	O
,	O
the	O
present	O
double	O
-	O
blind	O
randomized	O
clinical	O
trial	O
intended	O
to	O
evaluate	O
reboxetine	O
's	O
efficacy	O
in	O
the	O
management	O
of	O
MVA	O
-	O
related	O
PTSD	O
and	O
to	O
compare	O
its	O
efficacy	O
with	O
a	O
medication	O
commonly	O
used	O
in	O
PTSD	O
,	O
the	O
selective	O
serotonin	S-chem
reuptake	O
inhibitor	O
fluvoxamine	S-chem
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
MVA	O
-	O
related	O
PTSD	O
attending	O
a	O
local	O
community	O
mental	O
health	O
outpatient	O
clinic	O
were	O
randomized	O
to	O
receive	O
a	O
fixed	O
dose	O
of	O
either	O
reboxetine	S-chem
(	O
8	O
mg	O
/	O
d	O
)	O
or	O
fluvoxamine	S-chem
(	O
150	O
mg	O
/	O
d	O
)	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
for	O
a	O
period	O
of	O
8	O
weeks	O
.	O

RESULTS	O
:	O
At	O
baseline	O
and	O
at	O
study	O
end	O
point	O
,	O
the	O
2	O
subgroups	O
demonstrated	O
no	O
statistical	O
differences	O
in	O
scores	O
on	O
PTSD	O
,	O
depression	O
,	O
and	O
anxiety	O
rating	O
scales	O
.	O

Both	O
medications	O
led	O
to	O
significant	O
improvements	O
in	O
all	O
clinical	O
scales	O
measured	O
.	O

Nine	O
patients	O
receiving	O
reboxetine	S-chem
and	O
3	O
receiving	O
fluvoxamine	S-chem
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
Study	O
observations	O
indicate	O
comparable	O
efficacy	O
of	O
reboxetine	S-chem
and	O
fluvoxamine	S-chem
in	O
the	O
management	O
of	O
MVA	O
-	O
related	O
PTSD	O
despite	O
reboxetine	O
's	O
selective	O
noradrenergic	O
activity	O
.	O

Reboxetine	S-chem
appears	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
fluvoxamine	S-chem
and	O
may	O
offer	O
an	O
alternative	O
management	O
option	O
in	O
this	O
often	O
difficult	O
-	O
to	O
-	O
treat	O
and	O
disabling	O
condition	O
.	O

A	O
lower	O
and	O
flexible	O
reboxetine	S-chem
dosing	O
schedule	O
will	O
be	O
recommended	O
for	O
future	O
research	O
to	O
improve	O
its	O
tolerability	O
in	O
PTSD	O
patients	O
.	O

Substrates	O
of	O
IAP	S-geneN
ubiquitin	B-geneN
ligases	E-geneN
identified	O
with	O
a	O
designed	O
orthogonal	O
E3	B-geneN
ligase	E-geneN
,	O
the	O
NEDDylator	O
.	O

Inhibitors	B-geneN
of	I-geneN
Apoptosis	I-geneN
Protein	E-geneN
(	O
IAPs	S-geneN
)	O
are	O
guardian	O
ubiquitin	B-geneN
ligases	E-geneN
that	O
keep	O
classic	O
proapoptotic	O
proteins	O
in	O
check	O
.	O

Systematic	O
identification	O
of	O
additional	O
IAP	O
substrates	O
is	O
challenged	O
by	O
the	O
heterogeneity	O
and	O
sheer	O
number	O
of	O
ubiquitinated	O
proteins	O
(	O
>	O
5,000	O
)	O
.	O

Here	O
we	O
report	O
a	O
powerful	O
catalytic	O
tagging	O
tool	O
,	O
the	O
NEDDylator	O
,	O
which	O
fuses	O
a	O
NEDD8	S-geneY
E2	B-geneN
-	I-geneN
conjugating	I-geneN
enzyme	E-geneN
,	O
Ubc12	S-geneY
,	O
to	O
the	O
ubiquitin	B-geneN
ligase	E-geneN
,	O
XIAP	S-geneY
or	O
cIAP1	S-geneY
.	O

This	O
permits	O
transfer	O
of	O
the	O
rare	O
ubiquitin	S-geneN
homolog	O
NEDD8	S-geneY
to	O
the	O
ubiquitin	B-geneN
E3	E-geneN
substrates	O
,	O
allowing	O
them	O
to	O
be	O
efficiently	O
purified	O
for	O
LC	O
-	O
MS	O
/	O
MS	O
identification	O
.	O

We	O
have	O
identified	O
>	O
50	O
potential	O
IAP	S-geneN
substrates	O
of	O
both	O
cytosolic	O
and	O
mitochondrial	O
origin	O
that	O
bear	O
hallmark	O
N	S-chem
-	O
terminal	O
IAP	S-geneN
binding	O
motifs	O
.	O

These	O
substrates	O
include	O
the	O
recently	O
discovered	O
protein	B-geneN
phosphatase	E-geneN
PGAM5	S-geneY
,	O
which	O
we	O
show	O
is	O
proteolytically	O
processed	O
,	O
accumulates	O
in	O
cytosol	O
during	O
apoptosis	O
,	O
and	O
sensitizes	O
cells	O
to	O
death	O
.	O

These	O
studies	O
reveal	O
mechanisms	O
and	O
antagonistic	O
partners	O
for	O
specific	O
IAPs	S-geneN
,	O
and	O
provide	O
a	O
powerful	O
technology	O
for	O
labeling	O
binding	O
partners	O
in	O
transient	O
protein	O
-	O
protein	O
complexes	O
.	O

PXR	S-geneY
antagonists	O
and	O
implication	O
in	O
drug	O
metabolism	O
.	O

Adopted	O
orphan	B-geneN
nuclear	I-geneN
receptor	E-geneN
(	O
NR	S-geneN
)	O
,	O
pregnane	B-geneY
X	I-geneY
receptor	E-geneY
(	O
PXR	S-geneY
)	O
,	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
xeno	O
-	O
and	O
endobiotic	O
metabolism	O
.	O

Since	O
the	O
discovery	O
of	O
the	O
functional	O
role	O
of	O
PXR	S-geneY
in	O
1998	O
,	O
there	O
is	O
evolving	O
evidence	O
for	O
the	O
role	O
of	O
PXR	S-geneY
agonists	O
in	O
abrogating	O
metabolic	O
pathophysiology	O
(	O
e.g	O
.	O
,	O
cholestasis	O
,	O
hypercholesterolemia	O
,	O
and	O
inflammation	O
)	O
.	O

However	O
,	O
more	O
recently	O
,	O
it	O
is	O
clear	O
that	O
PXR	S-geneY
is	O
also	O
an	O
important	O
mediator	O
of	O
adverse	O
xeno	O
-	O
(	O
e.g	O
.	O
,	O
enhances	O
acetaminophen	S-chem
toxicity	O
)	O
and	O
endobiotic	O
(	O
e.g	O
.	O
,	O
hepatic	O
steatosis	O
)	O
metabolic	O
phenotypes	O
.	O

Moreover	O
,	O
in	O
cancer	O
therapeutics	O
,	O
PXR	S-geneY
activation	O
can	O
induce	O
drug	O
resistance	O
,	O
and	O
there	O
is	O
growing	O
evidence	O
for	O
tissue	O
-	O
specific	O
enhancement	O
of	O
the	O
malignant	O
phenotype	O
.	O

Thus	O
,	O
in	O
these	O
instances	O
,	O
there	O
may	O
be	O
a	O
role	O
for	O
PXR	S-geneY
antagonists	O
.	O

However	O
,	O
as	O
opposed	O
to	O
the	O
discovery	O
efforts	O
for	O
PXR	S-geneY
agonists	O
,	O
there	O
are	O
only	O
a	O
few	O
antagonists	O
described	O
.	O

The	O
mode	O
of	O
action	O
of	O
these	O
antagonists	O
(	O
e.g	O
.	O
,	O
sulforaphane	S-chem
)	O
remains	O
less	O
clear	O
.	O

Our	O
laboratory	O
efforts	O
have	O
focused	O
on	O
this	O
question	O
.	O

Since	O
the	O
original	O
discovery	O
of	O
azoles	S-chem-C6-1
analogs	O
as	O
PXR	S-geneY-C6-2
antagonists	O
,	O
we	O
have	O
preliminarily	O
defined	O
an	O
important	O
PXR	S-geneY-C6-2
antagonist	O
pharmacophore	O
and	O
developed	O
less	O
-	O
toxic	O
PXR	S-geneY-C6-2
antagonists	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
our	O
published	O
and	O
unpublished	O
findings	O
on	O
recent	O
structure	O
-	O
function	O
studies	O
involving	O
the	O
azole	S-chem
chemical	O
scaffold	O
.	O

Further	O
work	O
in	O
the	O
future	O
is	O
needed	O
to	O
fully	O
define	O
potent	O
,	O
more	O
-	O
selective	O
PXR	S-geneY
antagonists	O
that	O
may	O
be	O
useful	O
in	O
clinical	O
application	O
.	O

The	O
evolution	O
of	O
progesterone	B-geneY
receptor	E-geneY
ligands	O
.	O

Progesterone	S-chem
is	O
one	O
of	O
the	O
first	O
nuclear	B-geneN
receptor	E-geneN
hormones	O
to	O
be	O
described	O
functionally	O
and	O
subsequently	O
approached	O
as	O
a	O
drug	O
target	O
.	O

Because	O
progesterone	S-chem
(	O
1	O
)	O
affects	O
both	O
menstruation	O
and	O
gestation	O
via	O
the	O
progesterone	B-geneY
receptor	E-geneY
(	O
PR	S-geneY
)	O
,	O
research	O
aimed	O
at	O
modulating	O
its	O
activity	O
is	O
usually	O
surrounded	O
by	O
controversy	O
.	O

However	O
,	O
ligands	O
for	O
PR	S-geneY
were	O
developed	O
into	O
drugs	O
,	O
and	O
their	O
evolution	O
can	O
be	O
crudely	O
divided	O
into	O
three	O
periods	O
:	O
(	O
1	O
)	O
drug	O
-	O
like	O
steroids	S-chem
that	O
mimic	O
the	O
gestational	O
properties	O
of	O
progesterone	S-chem
;	O
(	O
2	O
)	O
drug	O
-	O
like	O
steroids	S-chem
with	O
different	O
properties	O
from	O
progesterone	S-chem
and	O
expanded	O
therapeutic	O
applications	O
;	O
and	O
(	O
3	O
)	O
non	O
-	O
steroidal	S-chem
PR	S-geneY
ligands	O
with	O
improved	O
selectivity	O
and	O
modulator	O
properties	O
and	O
further	O
expanded	O
therapeutic	O
applications	O
.	O

Although	O
the	O
latter	O
have	O
yet	O
to	O
see	O
widespread	O
clinical	O
applications	O
,	O
their	O
development	O
is	O
founded	O
on	O
a	O
half	O
century	O
of	O
research	O
,	O
and	O
they	O
represent	O
the	O
future	O
for	O
this	O
drug	O
target	O
.	O

Alpha1	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
and	O
their	O
inhibitors	O
in	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
benign	O
prostatic	O
hyperplasia	O
.	O

PURPOSE	O
:	O
We	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
role	O
of	O
alpha1	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	O
(	O
alpha1ARs	S-geneN
)	O
as	O
critical	O
mediators	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
and	O
pathophysiology	O
in	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
and	O
we	O
review	O
the	O
pharmacological	O
antagonists	O
of	O
alpha1ARs	S-geneN
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
review	O
was	O
performed	O
of	O
pertinent	O
studies	O
in	O
the	O
literature	O
relating	O
to	O
the	O
pathophysiology	O
of	O
LUTS	O
and	O
BPH	O
,	O
focusing	O
on	O
the	O
role	O
of	O
alpha1ARs	S-geneN
,	O
and	O
of	O
clinical	O
trial	O
and	O
practice	O
data	O
evaluating	O
the	O
different	O
agents	O
that	O
inhibit	O
these	O
receptors	O
.	O

RESULTS	O
:	O
Further	O
characterization	O
of	O
the	O
alpha1AR	S-geneN
gene	O
family	O
indicates	O
that	O
3	O
receptor	O
subtypes	O
exist	O
in	O
humans	O
.	O

Their	O
different	O
distribution	O
between	O
urinary	O
tract	O
and	O
cardiovascular	O
tissues	O
has	O
provided	O
a	O
strategy	O
for	O
the	O
development	O
of	O
improved	O
therapeutic	O
agents	O
.	O

Since	O
excessive	O
activity	O
of	O
the	O
alpha1aAR	S-geneY
and	O
alpha1dAR	S-geneY
subtypes	O
appears	O
to	O
be	O
a	O
common	O
feature	O
in	O
symptomatic	O
BPH	O
and	O
alpha1aARs	S-geneY
are	O
enriched	O
in	O
prostatic	O
tissue	O
,	O
drugs	O
that	O
demonstrate	O
high	O
alpha1aAR	S-geneY
selectivity	O
have	O
attracted	O
attention	O
.	O

Tamsulosin	S-chem
,	O
which	O
has	O
high	O
affinity	O
for	O
alpha1aAR	S-geneY
and	O
alpha1dAR	S-geneY
subtypes	O
but	O
not	O
for	O
alpha1bAR	S-geneY
,	O
shows	O
efficacy	O
similar	O
to	O
the	O
nonsubtype	O
selective	O
agents	O
terazosin	S-chem
and	O
doxazosin	S-chem
.	O

It	O
is	O
associated	O
with	O
fewer	O
cardiovascular	O
side	O
effects	O
,	O
although	O
it	O
has	O
some	O
ejaculatory	O
side	O
effects	O
.	O

The	O
nonsubtype	O
selective	O
agent	O
alfuzosin	S-chem
also	O
demonstrates	O
efficacy	O
and	O
offers	O
an	O
enhanced	O
side	O
effect	O
profile	O
,	O
particularly	O
minimizing	O
hypotension	O
.	O

Other	O
agents	O
with	O
super	O
selective	O
specificity	O
for	O
the	O
alpha1aAR	S-geneY
subtype	O
are	O
under	O
investigation	O
.	O

CONCLUSIONS	O
:	O
Further	O
advances	O
in	O
the	O
treatment	O
of	O
LUTS	O
associated	O
with	O
BPH	O
may	O
depend	O
not	O
only	O
on	O
receptor	O
subtype	O
selectivity	O
,	O
but	O
also	O
on	O
other	O
pharmacokinetic	O
and	O
pharmacodynamic	O
factors	O
.	O

3D	O
-	O
QSAR	O
-	O
assisted	O
drug	O
design	O
:	O
identification	O
of	O
a	O
potent	O
quinazoline	S-chem-C4-1
-	O
based	O
Aurora	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
.	O

We	O
describe	O
the	O
3D	O
-	O
QSAR	O
-	O
assisted	O
design	O
of	O
an	O
Aurora	B-geneY
kinase	I-geneY
A	I-geneY
inhibitor	O
with	O
improved	O
physicochemical	O
properties	O
,	O
in	O
vitro	O
activity	O
,	O
and	O
in	O
vivo	O
pharmacokinetic	O
profiles	O
over	O
those	O
of	O
the	O
initial	O
lead	O
.	O

Three	O
different	O
3D	O
-	O
QSAR	O
models	O
were	O
built	O
and	O
validated	O
by	O
using	O
a	O
set	O
of	O
66	O
pyrazole	S-chem-C4-1
(	O
Model	O
I	O
)	O
and	O
furanopyrimidine	O
(	E-chem-C4-1
Model	O
II	O
)	O
compounds	O
with	O
IC	O
(	O
50	O
)	O
values	O
toward	O
Aurora	O
kinase	I-geneY-C4-2
A	I-geneY-C4-2
ranging	O
from	O
33	O
nM	O
to	O
10.5	O
μM	O
.	O

The	O
best	O
3D	O
-	O
QSAR	O
model	O
,	O
Model	O
III	O
,	O
constructed	O
with	O
24	O
training	O
set	O
compounds	O
from	O
both	O
series	O
,	O
showed	O
robustness	O
(	O
r	O
(	O
2	O
)	O
(	O
CV	O
)	O
=	O
0.54	O
and	O
0.52	O
for	O
CoMFA	O
and	O
CoMSIA	O
,	O
respectively	O
)	O
and	O
superior	O
predictive	O
capacity	O
for	O
42	O
test	O
set	O
compounds	O
(	O
R	O
(	O
2	O
)	O
(	O
pred	O
)	O
=	O
0.52	O
and	O
0.67	O
,	O
CoMFA	O
and	O
CoMSIA	O
)	O
.	O

Superimposition	O
of	O
CoMFA	O
and	O
CoMSIA	O
Model	O
III	O
over	O
the	O
crystal	O
structure	O
of	O
Aurora	O
kinase	I-geneY
A	I-geneY
suggests	O
the	O
potential	O
to	O
improve	O
the	O
activity	O
of	O
the	O
ligands	O
by	O
decreasing	O
the	O
steric	O
clash	O
with	O
Val147	O
and	O
Leu139	O
and	O
by	O
increasing	O
hydrophobic	O
contact	O
with	O
Leu139	O
and	O
Gly216	O
residues	O
in	O
the	O
solvent	O
-	O
exposed	O
region	O
of	O
the	O
enzyme	O
.	O

Based	O
on	O
these	O
suggestions	O
,	O
the	O
rational	O
redesign	O
of	O
furanopyrimidine	S-chem-C4-1
24	O
(	O
clog	O
P	O
=	O
7.41	O
;	O
Aurora	O
A	I-geneY-C4-2
IC	E-geneY-C4-2
(	O
50	O
)	O
=	O
43	O
nM	O
;	O
HCT	O
-	O
116	O
IC	O
(	O
50	O
)	O
=	O
400	O
nM	O
)	O
led	O
to	O
the	O
identification	O
of	O
quinazoline	O
67	I-chem-C4-1
(	I-chem-C4-1
clog	O
P	O
=	O
5.28	O
;	O
Aurora	O
A	I-geneY-C4-2
IC	I-geneY-C4-2
(	I-geneY-C4-2
50	I-geneY-C4-2
)	E-geneY-C4-2
=	O
25	O
nM	O
;	O
HCT	O
-	O
116	O
IC	O
(	O
50	O
)	O
=	O
23	O
nM	O
)	O
.	O

Rat	O
in	O
vivo	O
pharmacokinetic	O
studies	O
showed	O
that	O
67	O
has	O
better	O
systemic	O
exposure	O
after	O
i.v	O
.	O
administration	O
than	O
24	O
,	O
and	O
holds	O
potential	O
for	O
further	O
development	O
.	O

Resveratrol	S-chem
improves	O
cardiomyopathy	O
in	O
dystrophin	S-geneY
-	O
deficient	O
mice	O
through	O
SIRT1	S-geneY
protein	O
-	O
mediated	O
modulation	O
of	O
p300	S-geneY
protein	O
.	O

Cardiomyopathy	O
is	O
the	O
main	O
cause	O
of	O
death	O
in	O
Duchenne	O
muscular	O
dystrophy	O
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
administration	O
of	O
resveratrol	S-chem-C3-1
,	O
which	O
leads	O
to	O
activation	O
of	O
an	O
NAD	B-geneY-C3-2
(	I-geneY-C3-2
+	I-geneY-C3-2
)	I-geneY-C3-2
-	I-geneY-C3-2
dependent	I-geneY-C3-2
protein	I-geneY-C3-2
deacetylase	I-geneY-C3-2
SIRT1	E-geneY-C3-2
,	O
suppresses	O
cardiac	O
hypertrophy	O
and	O
fibrosis	O
and	O
restores	O
cardiac	O
diastolic	O
function	O
in	O
dystrophin	S-geneY
-	O
deficient	O
mdx	O
mice	O
.	O

The	O
pro	O
-	O
hypertrophic	O
co	O
-	O
activator	O
p300	S-geneY
protein	O
but	O
not	O
p300	S-geneY
mRNA	O
was	O
up	O
-	O
regulated	O
in	O
the	O
mdx	O
heart	O
,	O
and	O
resveratrol	S-chem-C4-1
administration	O
down	O
-	O
regulated	O
the	O
p300	S-geneY-C4-2
protein	O
level	O
.	O

In	O
cultured	O
cardiomyocytes	O
,	O
cardiomyocyte	O
hypertrophy	O
induced	O
by	O
the	O
α	O
(	O
1	O
)	O
-	O
agonist	O
phenylephrine	S-chem
was	O
inhibited	O
by	O
the	O
overexpression	O
of	O
SIRT1	S-geneY
as	O
well	O
as	O
resveratrol	S-chem-C4-1
,	O
both	O
of	O
which	O
down	O
-	O
regulated	O
p300	S-geneY-C4-2
protein	O
levels	O
but	O
not	O
p300	S-geneY
mRNA	O
levels	O
.	O

In	O
addition	O
,	O
activation	O
of	O
atrial	B-geneN
natriuretic	I-geneN
peptide	I-geneN
promoter	E-geneN
by	O
p300	S-geneY
was	O
inhibited	O
by	O
SIRT1	S-geneY
.	O

We	O
found	O
that	O
SIRT1	S-geneY
induced	O
p300	S-geneY
down	O
-	O
regulation	O
via	O
the	O
ubiquitin	S-geneN
-	O
proteasome	S-geneN
pathway	O
by	O
deacetylation	O
of	O
lysine	S-chem
residues	O
for	O
ubiquitination	O
.	O

These	O
findings	O
indicate	O
the	O
pathological	O
significance	O
of	O
p300	S-geneY
up	O
-	O
regulation	O
in	O
the	O
dystrophic	O
heart	O
and	O
indicate	O
that	O
SIRT1	S-geneY
activation	O
has	O
therapeutic	O
potential	O
for	O
dystrophic	O
cardiomyopathy	O
.	O

Psychopharmacology	O
of	O
anticonvulsants	O
:	O
levetiracetam	S-chem
as	O
a	O
synaptic	B-geneN
vesicle	I-geneN
protein	E-geneN
modulator	O
.	O

ISSUE	O
:	O
A	O
novel	O
mechanism	O
of	O
action	O
has	O
recently	O
been	O
described	O
for	O
levetiracetam	S-chem
,	O
a	O
member	O
of	O
a	O
new	O
class	O
of	O
anticonvulsants	O
.	O

Levetiracetam	S-chem
binds	O
selectively	O
and	O
with	O
high	O
affinity	O
to	O
a	O
synaptic	B-geneN
vesicle	I-geneN
protein	E-geneN
known	O
as	O
SV2A	S-geneY
,	O
thought	O
to	O
be	O
involved	O
with	O
synaptic	O
vesicle	O
exocytosis	O
and	O
presynaptic	O
neurotransmitter	O
release	O
.	O

Aberrant	O
transcription	O
of	O
the	O
LHCGR	S-geneY
gene	O
caused	O
by	O
a	O
mutation	O
in	O
exon	O
6A	O
leads	O
to	O
Leydig	O
cell	O
hypoplasia	O
type	O
II	O
.	O

The	O
luteinizing	B-geneY
hormone	I-geneY
/	I-geneY
chorionic	I-geneY
gonadotropin	I-geneY
receptor	E-geneY
(	O
LHCGR	S-geneY
)	O
is	O
essential	O
for	O
normal	O
male	O
sex	O
differentiation	O
.	O

Recently	O
,	O
the	O
additional	O
primate	O
-	O
specific	O
exon	O
6A	O
of	O
the	O
LHCGR	S-geneY
was	O
discovered	O
and	O
it	O
was	O
shown	O
to	O
act	O
as	O
regulatory	O
element	O
at	O
the	O
transcriptional	O
level	O
.	O

Compound	O
heterozygous	O
mutations	O
in	O
exon	O
6A	O
(	O
c.580	B-geneN
A	I-geneN
>	I-geneN
G	E-geneN
)	O
and	O
exon	O
11	O
(	O
c.1244T	B-geneN
>	I-geneN
C	E-geneN
)	O
were	O
identified	O
in	O
the	O
LHCGR	S-geneY
of	O
a	O
male	O
46	O
,	O
XY	O
patient	O
with	O
genital	O
malformation	O
.	O

Analysis	O
revealed	O
that	O
mutation	O
c.580A	B-geneN
>	I-geneN
G	E-geneN
in	O
exon	O
6A	O
affects	O
the	O
splicing	O
pattern	O
resulting	O
in	O
an	O
increase	O
of	O
transcripts	O
containing	O
the	O
internal	O
variants	O
of	O
exon	O
6A	O
prone	O
to	O
nonsense	O
-	O
mediated	O
decay	O
.	O

In	O
contrast	O
,	O
mutation	O
c.1244T	B-geneN
>	I-geneN
C	E-geneN
results	O
in	O
an	O
amino	B-chem
acid	E-chem
substitution	O
(	O
Ile415Thr	S-geneN
)	O
,	O
which	O
abolishes	O
signal	O
transduction	O
due	O
to	O
structural	O
changes	O
.	O

When	O
inherited	O
in	O
a	O
compound	O
heterozygous	O
fashion	O
these	O
mutations	O
result	O
in	O
Leydig	O
cell	O
hypoplasia	O
(	O
LCH	O
)	O
type	O
II	O
.	O

Thus	O
this	O
study	O
provides	O
proof	O
that	O
mutations	O
causing	O
aberrant	O
transcription	O
can	O
impair	O
receptor	O
function	O
and	O
thereby	O
be	O
causative	O
of	O
LCH	O
.	O

Structural	O
basis	O
for	O
the	O
altered	O
drug	O
sensitivities	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
-	O
associated	O
mutants	O
of	O
human	B-geneY
epidermal	I-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
.	O

The	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
has	O
an	O
essential	O
role	O
in	O
multiple	O
signaling	O
pathways	O
,	O
including	O
cell	O
proliferation	O
and	O
migration	O
,	O
through	O
extracellular	O
ligand	O
binding	O
and	O
subsequent	O
activation	O
of	O
its	O
intracellular	O
tyrosine	B-geneN
kinase	I-geneN
(	I-geneN
TK	I-geneN
)	I-geneN
domain	E-geneN
.	O

The	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
-	O
associated	O
EGFR	S-geneY
mutants	O
,	O
L858R	S-geneN
and	O
G719S	S-geneN
,	O
are	O
constitutively	O
active	O
and	O
oncogenic	O
.	O

They	O
display	O
sensitivity	O
to	O
TK	S-geneN-C4-2
inhibitors	O
,	O
including	O
gefitinib	S-chem-C4-1
and	O
erlotinib	S-chem-C4-1
.	O

In	O
contrast	O
,	O
the	O
secondary	O
mutation	O
of	O
the	O
gatekeeper	O
residue	O
,	O
T790M	S-geneN
,	O
reportedly	O
confers	O
inhibitor	O
resistance	O
on	O
the	O
oncogenic	O
EGFR	S-geneY
mutants	O
.	O

In	O
this	O
study	O
,	O
our	O
biochemical	O
analyses	O
revealed	O
that	O
the	O
introduction	O
of	O
the	O
T790M	S-geneN
mutation	O
confers	O
gefitinib	S-chem
resistance	O
on	O
the	O
G719S	S-geneN
mutant	O
.	O

The	O
G719S	S-geneN
/	O
T790M	S-geneN
double	O
mutant	O
has	O
enhanced	O
activity	O
and	O
retains	O
high	O
gefitinib	S-chem
-	O
binding	O
affinity	O
.	O

The	O
T790M	S-geneN
mutation	O
increases	O
the	O
ATP	S-chem
affinity	O
of	O
the	O
G719S	S-geneN
mutant	O
,	O
explaining	O
the	O
acquired	O
drug	O
resistance	O
of	O
the	O
double	O
mutant	O
.	O

Structural	O
analyses	O
of	O
the	O
G719S	S-geneN
/	O
T790M	S-geneN
double	O
mutant	O
,	O
as	O
well	O
as	O
the	O
wild	O
type	O
and	O
the	O
G719S	S-geneN
and	O
L858R	S-geneN
mutants	O
,	O
revealed	O
that	O
the	O
T790M	S-geneN
mutation	O
stabilizes	O
the	O
hydrophobic	O
spine	O
of	O
the	O
active	O
EGFR	S-geneY
-	O
TK	S-geneN
conformation	O
.	O

The	O
Met790	S-chem
side	O
chain	O
of	O
the	O
G719S	S-geneN
/	O
T790M	S-geneN
double	O
mutant	O
,	O
in	O
the	O
apo	O
form	O
and	O
gefitinib	S-chem
-	O
and	O
AMPPNP	O
-	O
bound	O
forms	O
,	O
adopts	O
different	O
conformations	O
that	O
explain	O
the	O
accommodation	O
of	O
these	O
ligands	O
.	O

In	O
the	O
L858R	S-geneN
mutant	O
structure	O
,	O
the	O
active	O
-	O
site	O
cleft	O
is	O
expanded	O
by	O
the	O
repositioning	O
of	O
Phe723	S-chem
within	O
the	O
P	O
-	O
loop	O
.	O

Notably	O
,	O
the	O
introduction	O
of	O
the	O
F723A	S-geneN
mutation	O
greatly	O
enhanced	O
the	O
gefitinib	S-chem
sensitivity	O
of	O
the	O
wild	O
-	O
type	O
EGFR	S-geneY
in	O
vivo	O
,	O
supporting	O
our	O
hypothesis	O
that	O
the	O
expansion	O
of	O
the	O
active	O
-	O
site	O
cleft	O
results	O
in	O
enhanced	O
gefitinib	S-chem
sensitivity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
altered	O
drug	O
sensitivities	O
caused	O
by	O
distinct	O
NSCLC	O
-	O
associated	O
EGFR	S-geneY
mutations	O
.	O

Deep	O
brain	O
stimulation	O
,	O
histone	B-geneN
deacetylase	E-geneN
inhibitors	O
and	O
glutamatergic	O
drugs	O
rescue	O
resistance	O
to	O
fear	O
extinction	O
in	O
a	O
genetic	O
mouse	O
model	O
.	O

Anxiety	O
disorders	O
are	O
characterized	O
by	O
persistent	O
,	O
excessive	O
fear	O
.	O

Therapeutic	O
interventions	O
that	O
reverse	O
deficits	O
in	O
fear	O
extinction	O
represent	O
a	O
tractable	O
approach	O
to	O
treating	O
these	O
disorders	O
.	O

We	O
previously	O
reported	O
that	O
129S1	O
/	O
SvImJ	O
(	O
S1	O
)	O
mice	O
show	O
no	O
extinction	O
learning	O
following	O
normal	O
fear	O
conditioning	O
.	O

We	O
now	O
demonstrate	O
that	O
weak	O
fear	O
conditioning	O
does	O
permit	O
fear	O
reduction	O
during	O
massed	O
extinction	O
training	O
in	O
S1	O
mice	O
,	O
but	O
reveals	O
specific	O
deficiency	O
in	O
extinction	O
memory	O
consolidation	O
/	O
retrieval	O
.	O

Rescue	O
of	O
this	O
impaired	O
extinction	O
consolidation	O
/	O
retrieval	O
was	O
achieved	O
with	O
d	B-chem
-	I-chem
cycloserine	E-chem
(	O
N	B-chem
-	I-chem
methly	I-chem
-	I-chem
d	I-chem
-	I-chem
aspartate	E-chem
partial	O
agonist	O
)	O
or	O
MS	B-chem-C4-1
-	I-chem-C4-1
275	E-chem-C4-1
(	O
histone	B-geneN-C4-2
deacetylase	E-geneN-C4-2
(	O
HDAC	S-geneN-C4-2
)	O
inhibitor	O
)	O
,	O
applied	O
after	O
extinction	O
training	O
.	O

We	O
next	O
examined	O
the	O
ability	O
of	O
different	O
drugs	O
and	O
non	O
-	O
pharmacological	O
manipulations	O
to	O
rescue	O
the	O
extreme	O
fear	O
extinction	O
deficit	O
in	O
S1	O
following	O
normal	O
fear	O
conditioning	O
with	O
the	O
ultimate	O
aim	O
to	O
produce	O
low	O
fear	O
levels	O
in	O
extinction	O
retrieval	O
tests	O
.	O

Results	O
showed	O
that	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
by	O
applying	O
high	O
frequency	O
stimulation	O
to	O
the	O
nucleus	O
accumbens	O
(	O
ventral	O
striatum	O
)	O
during	O
extinction	O
training	O
,	O
indeed	O
significantly	O
reduced	O
fear	O
during	O
extinction	O
retrieval	O
compared	O
to	O
sham	O
stimulation	O
controls	O
.	O

Rescue	O
of	O
both	O
impaired	O
extinction	O
acquisition	O
and	O
deficient	O
extinction	O
consolidation	O
/	O
retrieval	O
was	O
achieved	O
with	O
prior	O
extinction	O
training	O
administration	O
of	O
valproic	B-chem-C4-1
acid	E-chem-C4-1
(	O
a	O
GABAergic	O
enhancer	O
and	O
HDAC	S-geneN-C4-2
inhibitor	O
)	O
or	O
AMN082	S-chem-C5-1
[	O
metabotropic	B-geneY-C5-2
glutamate	I-geneY-C5-2
receptor	I-geneY-C5-2
7	E-geneY-C5-2
(	O
mGlu7	S-geneY-C5-2
)	O
agonist	O
]	O
,	O
while	O
MS	B-chem-C3-1
-	I-chem-C3-1
275	E-chem-C3-1
or	O
PEPA	S-chem-C3-1
(	O
AMPA	B-geneN-C3-2
receptor	E-geneN-C3-2
potentiator	O
)	O
failed	O
to	O
affect	O
extinction	O
acquisition	O
in	O
S1	O
mice	O
.	O

Collectively	O
,	O
these	O
data	O
identify	O
potential	O
beneficial	O
effects	O
of	O
DBS	O
and	O
various	O
drug	O
treatments	O
,	O
including	O
those	O
with	O
HDAC	S-geneN
inhibiting	O
or	O
mGlu7	S-geneY
agonism	O
properties	O
,	O
as	O
adjuncts	O
to	O
overcome	O
treatment	O
resistance	O
in	O
exposure	O
-	O
based	O
therapies	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Synthesis	O
and	O
selected	O
immunological	O
properties	O
of	O
substituted	O
quino	B-chem
[	I-chem
3,2	I-chem
-	I-chem
b	I-chem
]	I-chem
benzo	I-chem
[	I-chem
1,4	I-chem
]	I-chem
thiazines	E-chem
.	O

A	O
new	O
type	O
of	O
azaphenothiazines	S-chem
-	O
tetracyclic	B-chem
quino	I-chem
[	I-chem
3,2	I-chem
-	I-chem
b	I-chem
]	I-chem
benzo	I-chem
[	I-chem
1,4	I-chem
]	I-chem
thiazines	E-chem
,	O
possessing	O
common	O
substituents	O
(	O
H	S-chem
,	O
CH3	S-chem
,	O
Cl	S-chem
,	O
Br	S-chem
,	O
F	S-chem
,	O
CF3	S-chem
,	O
SCH3	S-chem
)	O
in	O
positions	O
8	O
-	O
10	O
and	O
pharmacophoric	O
aminoalkyl	S-chem
substituents	O
in	O
position	O
6	O
,	O
were	O
obtained	O
from	O
diquinodithiin	S-chem
and	O
2,2	B-chem
'	I-chem
-	I-chem
dichloro	I-chem
-	I-chem
3,3	I-chem
'	I-chem
-	I-chem
diquinolinyl	I-chem
disulfide	E-chem
in	O
several	O
-	O
step	O
syntheses	O
.	O

Sixty	O
one	O
compounds	O
,	O
grouped	O
as	O
the	O
6H	O
,	O
6	B-chem
-	I-chem
dialkylaminoalkyl	E-chem
,	O
6	B-chem
-	I-chem
acylaminoalkyl	E-chem
and	O
sulfonylaminoalkyl	S-chem
derivatives	O
,	O
were	O
tested	O
for	O
cytotoxicity	O
,	O
their	O
effects	O
on	O
phytohemagglutin	B-geneN
A	E-geneN
(	O
PHA	S-geneN
)	O
-	O
induced	O
proliferative	O
response	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
production	O
by	O
these	O
cells	O
.	O

The	O
compounds	O
exhibited	O
differential	O
inhibitory	O
activities	O
in	O
these	O
tests	O
and	O
significantly	O
varied	O
in	O
terms	O
of	O
cytotoxicity	O
.	O

The	O
most	O
promising	O
compounds	O
were	O
tested	O
for	O
growth	O
inhibition	O
of	O
leukemia	O
L	O
-	O
1210	O
cells	O
,	O
colon	O
cancer	O
SV	O
-	O
948	O
cells	O
and	O
epidermal	O
carcinoma	O
A	O
-	O
341	O
cells	O
.	O

The	O
most	O
active	O
compounds	O
exhibited	O
anticancer	O
activity	O
against	O
these	O
cell	O
lines	O
comparable	O
to	O
that	O
of	O
cisplatin	S-chem
.	O

The	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
compounds	O
were	O
discussed	O
.	O

Complexities	O
of	O
androgen	S-chem
action	O
.	O

Androgens	S-chem
mediate	O
a	O
wide	O
range	O
of	O
processes	O
during	O
embryogenesis	O
and	O
in	O
the	O
adult	O
.	O

In	O
mammals	O
,	O
the	O
principal	O
androgens	S-chem
are	O
testosterone	S-chem
and	O
its	O
5alpha	O
-	O
reduced	O
metabolite	O
,	O
5alpha	B-chem
-	I-chem
dihydrotestosterone	E-chem
(	O
DHT	S-chem
)	O
.	O

Although	O
these	O
androgenic	O
hormones	O
are	O
diverse	O
in	O
character	O
,	O
it	O
is	O
believed	O
that	O
their	O
effects	O
are	O
mediated	O
via	O
the	O
protein	O
products	O
of	O
a	O
single	O
androgen	B-geneY
receptor	E-geneY
gene	O
encoded	O
on	O
the	O
X	O
-	O
chromosome	O
.	O

A	O
great	O
deal	O
of	O
information	O
has	O
now	O
accumulated	O
pertaining	O
to	O
the	O
mechanisms	O
by	O
which	O
nuclear	B-geneN
receptors	E-geneN
,	O
such	O
as	O
the	O
androgen	B-geneY
receptor	E-geneY
,	O
modulate	O
the	O
activity	O
of	O
responsive	O
genes	O
.	O

The	O
studies	O
have	O
demonstrated	O
the	O
participation	O
of	O
a	O
number	O
of	O
ancillary	O
proteins	O
in	O
modulating	O
activation	O
or	O
repression	O
by	O
nuclear	B-geneN
receptors	E-geneN
.	O

In	O
addition	O
to	O
studies	O
focused	O
on	O
the	O
mechanisms	O
of	O
nuclear	B-geneN
receptor	E-geneN
function	O
,	O
additional	O
work	O
has	O
illuminated	O
the	O
mechanism	O
by	O
which	O
androgens	S-chem
are	O
metabolized	O
in	O
selected	O
tissues	O
.	O

This	O
information	O
provides	O
a	O
perspective	O
on	O
the	O
number	O
of	O
levels	O
of	O
complexity	O
by	O
which	O
differential	O
gene	O
regulation	O
by	O
androgens	S-chem
may	O
occur	O
in	O
different	O
tissues	O
and	O
in	O
different	O
cell	O
types	O
.	O

Phenolics	S-chem
content	O
and	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
of	O
legume	O
fractions	O
.	O

Two	O
faba	O
bean	O
(	O
Vicia	O
faba	O
L.	O
)	O
subspecies	O
major	O
and	O
minor	O
and	O
lentil	O
seeds	O
grown	O
in	O
Algeria	O
were	O
separated	O
into	O
cotyledons	O
and	O
hulls	O
.	O

These	O
fractions	O
,	O
together	O
with	O
their	O
corresponding	O
whole	O
seeds	O
,	O
were	O
extracted	O
with	O
two	O
solvents	O
,	O
aqueous	O
(	O
70	O
%	O
)	O
acetone	S-chem
and	O
(	O
80	O
%	O
)	O
ethanol	S-chem
,	O
and	O
evaluated	O
for	O
antioxidant	O
activity	O
in	O
relation	O
to	O
their	O
phenolic	S-chem
contents	O
.	O

Acetone	S-chem
selectively	O
extracted	O
tannins	S-chem
from	O
faba	O
beans	O
.	O

The	O
hulls	O
always	O
exhibited	O
high	O
antioxidant	O
activity	O
,	O
measured	O
using	O
the	O
reducing	O
power	O
(	O
RP	O
)	O
,	O
antiradical	O
activity	O
(	O
DPPH	S-chem
)	O
or	O
oxygen	S-chem
radical	O
absorbance	O
capacity	O
(	O
ORAC	O
)	O
assays	O
.	O

Aqueous	O
ethanol	S-chem-C4-1
(	O
80	O
%	O
)	O
extract	O
of	O
lentil	O
hulls	O
exhibited	O
high	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
preferentially	O
inhibiting	O
15	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
,	O
55	O
μg	O
/	O
ml	O
)	O
,	O
with	O
moderate	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
,	O
66	O
μg	O
/	O
ml	O
)	O
and	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
IC	O
(	O
50	O
)	O
,	O
119	O
μg	O
/	O
ml	O
)	O
inhibitory	O
effects	O
on	O
the	O
COX	S-geneN-C4-2
pathway	O
,	O
whereas	O
faba	O
bean	O
hull	O
extracts	O
exerted	O
relatively	O
mild	O
LOX	S-geneN-C4-2
inhibitory	O
activity	O
.	O

Characterization	O
of	O
substituted	O
phenylpropylamides	S-chem-C5-1
as	O
highly	O
selective	O
agonists	O
at	O
the	O
melatonin	B-geneY-C5-2
MT2	I-geneY-C5-2
receptor	E-geneY-C5-2
.	O

Melatonin	S-chem
is	O
a	O
widely	O
distributed	O
hormone	O
that	O
regulates	O
several	O
major	O
physiological	O
processes	O
,	O
including	O
the	O
circadian	O
rhythm	O
and	O
seasonal	O
adaptation	O
.	O

The	O
two	O
subtypes	O
of	O
mammalian	B-geneN
G	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
melatonin	I-geneN
receptors	E-geneN
are	O
primarily	O
responsible	O
for	O
mediating	O
the	O
actions	O
of	O
melatonin	S-chem
.	O

Because	O
synthetic	O
melatonin	S-geneN
agonists	O
have	O
considerable	O
therapeutic	O
potentials	O
in	O
modulating	O
insomnia	O
and	O
circadian	O
-	O
related	O
sleep	O
disorders	O
,	O
it	O
is	O
highly	O
desirable	O
to	O
develop	O
subtype	O
-	O
selective	O
melatoninergic	O
compounds	O
.	O

The	O
pharmacological	O
potencies	O
of	O
a	O
series	O
of	O
substituted	O
N	B-chem
-	I-chem
[	I-chem
3	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
methoxyphenyl	I-chem
)	I-chem
propyl	I-chem
]	I-chem
amides	E-chem
towards	O
human	B-geneY
melatonin	I-geneY
MT	I-geneY
(	I-geneY
1	I-geneY
)	E-geneY
and	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptors	E-geneY
were	O
evaluated	O
by	O
the	O
FLIPR	O
high	O
-	O
throughput	O
screening	O
assay	O
,	O
whilst	O
their	O
subtype	O
-	O
selectivity	O
was	O
subsequently	O
verified	O
with	O
ERK	S-geneN
phosphorylation	O
and	O
cAMP	S-chem
assays	O
.	O

Structure	O
-	O
activity	O
relationship	O
analysis	O
of	O
highly	O
potent	O
subtype	O
-	O
selective	O
ligands	O
(	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
EC	O
(	O
50	O
)	O
10	O
-	O
90	O
pM	O
)	O
revealed	O
that	O
a	O
benzyloxyl	S-chem
substituent	O
incorporated	O
at	O
C6	O
position	O
of	O
the	O
3	B-chem
-	I-chem
methoxyphenyl	E-chem
ring	O
dramatically	O
enhanced	O
the	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
potency	O
and	O
at	O
the	O
same	O
time	O
decreased	O
MT	B-geneY
(	I-geneY
1	I-geneY
)	E-geneY
potency	O
.	O

Incorporation	O
of	O
structural	O
moieties	O
conferring	O
the	O
subtype	O
selectivity	O
produced	O
several	O
extremely	O
potent	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
-	O
selective	O
ligands	O
.	O

The	O
most	O
potent	O
subtype	O
-	O
selective	O
ligand	O
,	O
2q	O
had	O
a	O
substantially	O
higher	O
potency	O
for	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
than	O
melatonin	S-chem
for	O
elevation	O
of	O
[	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
]	O
i	O
and	O
inhibition	O
of	O
forskolin	O
-	O
elevated	O
cAMP	O
.	O

Representative	O
MT	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
-	O
selective	O
ligands	O
also	O
induced	O
ERK	S-geneN
phosphorylation	O
in	O
both	O
recombinant	O
and	O
native	O
cell	O
lines	O
,	O
and	O
no	O
cross	O
-	O
reactivity	O
to	O
17	O
other	O
GPCRs	S-geneN
could	O
be	O
detected	O
.	O

These	O
ligands	O
represent	O
invaluable	O
tools	O
for	O
delineating	O
the	O
functional	O
roles	O
of	O
distinct	O
melatonin	B-geneN
receptor	E-geneN
subtypes	O
and	O
are	O
viable	O
candidates	O
for	O
drug	O
development	O
.	O

The	O
Ras	S-geneN
-	O
GTPase	S-geneN
activity	O
of	O
neurofibromin	S-geneY
restrains	O
ERK	S-geneN
-	O
dependent	O
FGFR	S-geneN
signaling	O
during	O
endochondral	O
bone	O
formation	O
.	O

The	O
severe	O
defects	O
in	O
growth	O
plate	O
development	O
caused	O
by	O
chondrocyte	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
protein	I-geneN
kinases	I-geneN
1	I-geneN
and	I-geneN
2	E-geneN
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
)	O
gain	O
or	O
loss	O
-	O
of	O
-	O
function	O
suggest	O
that	O
tight	O
spatial	O
and	O
temporal	O
regulation	O
of	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
signaling	O
is	O
necessary	O
to	O
achieve	O
harmonious	O
growth	O
plate	O
elongation	O
and	O
structure	O
.	O

We	O
provide	O
here	O
evidence	O
that	O
neurofibromin	S-geneY
,	O
via	O
its	O
Ras	S-geneN
guanosine	B-geneN
triphosphatase	E-geneN
-	O
activating	O
activity	O
,	O
controls	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
-	O
dependent	O
fibroblast	B-geneN
growth	I-geneN
factor	I-geneN
receptor	E-geneN
(	O
FGFR	S-geneN
)	O
signaling	O
in	O
chondrocytes	O
.	O

We	O
show	O
first	O
that	O
neurofibromin	S-geneY
is	O
expressed	O
in	O
FGFR	S-geneN
-	O
positive	O
prehypertrophic	O
and	O
hypertrophic	O
chondrocytes	O
during	O
growth	O
plate	O
endochondral	O
ossification	O
.	O

Using	O
mice	O
lacking	O
neurofibromin	B-geneY
1	E-geneY
(	O
Nf1	S-geneY
)	O
in	O
type	B-geneN
II	I-geneN
collagen	E-geneN
-	O
expressing	O
cells	O
,	O
(	O
Nf1col2	S-geneY
(	O
-	O
/	O
-	O
)	O
mutant	O
mice	O
)	O
,	O
we	O
then	O
show	O
that	O
lack	O
of	O
neurofibromin	S-geneY
in	O
post	O
-	O
mitotic	O
chondrocytes	O
triggers	O
a	O
number	O
of	O
phenotypes	O
reminiscent	O
of	O
the	O
ones	O
observed	O
in	O
mice	O
characterized	O
by	O
FGFR	S-geneN
gain	O
-	O
of	O
-	O
function	O
mutations	O
.	O

Those	O
include	O
dwarfism	O
,	O
constitutive	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
activation	O
,	O
strongly	O
reduced	O
Ihh	S-geneY
expression	O
and	O
decreased	O
chondrocyte	O
proliferation	O
and	O
maturation	O
,	O
increased	O
chondrocytic	O
expression	O
of	O
Rankl	S-geneY
,	O
matrix	B-geneY
metalloproteinase	I-geneY
9	E-geneY
(	O
Mmp9	S-geneY
)	O
and	O
Mmp13	S-geneY
and	O
enhanced	O
growth	O
plate	O
osteoclastogenesis	O
,	O
as	O
well	O
as	O
increased	O
sensitivity	O
to	O
caspase	B-geneY
-	I-geneY
9	E-geneY
mediated	O
apoptosis	O
.	O

Using	O
wildtype	O
(	O
WT	O
)	O
and	O
Nf1	S-geneY
(	O
-	O
/	O
-	O
)	O
chondrocyte	O
cultures	O
in	O
vitro	O
,	O
we	O
show	O
that	O
FGF2	S-geneY
pulse	O
-	O
stimulation	O
triggers	O
rapid	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
in	O
both	O
genotypes	O
,	O
but	O
that	O
return	O
to	O
the	O
basal	O
level	O
is	O
delayed	O
in	O
Nf1	S-geneY
(	O
-	O
/	O
-	O
)	O
chondrocytes	O
.	O

Importantly	O
,	O
in	O
vivo	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
inhibition	O
by	O
daily	O
injection	O
of	O
a	O
recombinant	O
form	O
of	O
C	B-geneY
-	I-geneY
type	I-geneY
natriuretic	I-geneY
peptide	E-geneY
to	O
post	O
-	O
natal	O
pups	O
for	O
18	O
days	O
was	O
able	O
to	O
correct	O
the	O
short	O
stature	O
of	O
Nf1col2	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Together	O
,	O
these	O
results	O
underscore	O
the	O
requirement	O
of	O
neurofibromin	O
and	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
for	O
normal	O
endochondral	O
bone	O
formation	O
and	O
support	O
the	O
notion	O
that	O
neurofibromin	O
,	O
by	O
restraining	O
RAS	S-geneN
-	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
signaling	O
,	O
is	O
a	O
negative	O
regulator	O
of	O
FGFR	S-geneN
signaling	O
in	O
differentiating	O
chondrocytes	O
.	O

A	O
case	O
of	O
therapy	O
-	O
related	O
acute	O
myeloblastic	O
leukemia	O
with	O
t	O
(	O
16	O
;	O
21	O
)	O
(	O
q24	O
;	O
q22	O
)	O
after	O
chemotherapy	O
with	O
DNA	B-geneY-C4-2
-	I-geneY-C4-2
topoisomerase	I-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
,	O
etoposide	S-chem-C4-1
and	O
mitoxantrone	S-chem-C4-1
,	O
and	O
the	O
alkylating	O
agent	O
,	O
cyclophosphamide	S-chem
.	O

A	O
59	O
-	O
year	O
-	O
old	O
female	O
suffering	O
from	O
malignant	O
lymphoma	O
developed	O
therapy	O
-	O
related	O
acute	O
myeloblastic	O
leukemia	O
(	O
t	O
-	O
AML	O
)	O
after	O
chemotherapy	O
consisting	O
of	O
treatment	O
with	O
DNA	B-geneY-C4-2
-	I-geneY-C4-2
topoisomerase	I-geneY-C4-2
II	E-geneY-C4-2
inhibitors	O
,	O
etoposide	S-chem-C4-1
and	O
mitoxantrone	S-chem-C4-1
,	O
and	O
an	O
alkylating	O
agent	O
,	O
cyclophosphamide	S-chem
.	O

The	O
cumulative	O
dose	O
of	O
etoposide	S-chem
administration	O
was	O
5500	O
mg	O
;	O
1500	O
mg	O
given	O
intravenously	O
and	O
4000	O
mg	O
orally	O
.	O

One	O
year	O
later	O
,	O
she	O
suddenly	O
developed	O
AML	O
of	O
FAB	O
M2	O
.	O

Cytogenetic	O
analysis	O
of	O
bone	O
marrow	O
cells	O
revealed	O
deletion	O
of	O
7q	O
and	O
a	O
rare	O
translocation	O
,	O
t	O
(	O
16	O
;	O
21	O
)	O
(	O
q24	O
;	O
q22	O
)	O
.	O

Southern	O
blot	O
analysis	O
of	O
bone	O
marrow	O
cells	O
did	O
not	O
detect	O
rearrangement	O
of	O
the	O
AML1	S-geneY
gene	O
,	O
however	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
of	O
bone	O
marrow	O
cells	O
at	O
interphase	O
and	O
metaphase	O
revealed	O
a	O
translocational	O
splitting	O
between	O
chromosome	O
21	O
involving	O
AML1	S-geneY
gene	O
and	O
chromosome	O
16	O
.	O

These	O
results	O
suggest	O
that	O
the	O
breakpoint	O
is	O
not	O
located	O
in	O
the	O
breakpoint	B-geneN
cluster	I-geneN
region	E-geneN
for	O
t	O
(	O
8	O
;	O
21	O
)	O
.	O

The	O
patient	O
was	O
treated	O
with	O
chemotherapy	O
and	O
entered	O
complete	O
remission	O
.	O

Androgen	B-geneY
Receptor	E-geneY
mRNA	O
Measured	O
by	O
Quantitative	O
Real	O
Time	O
PCR	O
is	O
Decreased	O
in	O
the	O
Urethral	O
Mucosa	O
of	O
Patients	O
with	O
Middle	O
Idiopathic	O
Hypospadias	O
.	O

Androgen	S-chem
action	O
is	O
exerted	O
through	O
the	O
androgen	B-geneY
receptor	E-geneY
.	O

The	O
normal	O
46	O
,	O
XY	O
genital	O
virilization	O
depends	O
on	O
androgen	B-geneY
receptor	E-geneY
gene	O
expression	O
,	O
which	O
is	O
tissue	O
specific	O
,	O
and	O
requires	O
normal	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
levels	O
in	O
androgen	S-chem
sensitive	O
tissues	O
.	O

Hypospadias	O
is	O
a	O
frequent	O
male	O
genital	O
abnormality	O
,	O
potentially	O
related	O
to	O
reduced	O
androgen	S-chem
sensitivity	O
in	O
genital	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
,	O
by	O
quantitative	O
real	O
time	O
PCR	O
,	O
the	O
amount	O
of	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
in	O
cells	O
obtained	O
from	O
the	O
urethral	O
mucosa	O
of	O
patients	O
with	O
middle	O
idiopathic	O
hypospadias	O
with	O
the	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
levels	O
observed	O
in	O
control	O
phimosis	O
subjects	O
with	O
eutopic	O
urethral	O
opening	O
.	O

Prepubertal	O
individuals	O
were	O
studied	O
,	O
including	O
41	O
controls	O
and	O
17	O
hypospadias	O
patients	O
with	O
mean	O
(	O
SD	O
)	O
ages	O
of	O
4.7	O
(	O
2.1	O
)	O
years	O
and	O
4.0	O
(	O
3.0	O
)	O
years	O
,	O
respectively	O
.	O

We	O
observed	O
significantly	O
less	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
in	O
the	O
urethral	O
mucosa	O
of	O
patients	O
with	O
hypospadias	O
than	O
in	O
the	O
controls	O
(	O
p	O
=	O
0.002	O
)	O
.	O

The	O
correlation	O
between	O
the	O
level	O
of	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
expression	O
and	O
the	O
penile	O
size	O
was	O
almost	O
statistically	O
significant	O
only	O
in	O
hypospadias	O
patients	O
(	O
r	O
=	O
0.47	O
;	O
p	O
=	O
0.053	O
)	O
.	O

We	O
also	O
established	O
the	O
number	O
of	O
CAG	B-geneN
repeats	E-geneN
in	O
exon	O
1	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
gene	O
by	O
GeneScan	O
analysis	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
number	O
of	O
CAG	B-geneN
repeats	E-geneN
when	O
patients	O
and	O
controls	O
were	O
compared	O
.	O

A	O
negative	O
correlation	O
between	O
the	O
CAG	B-geneN
repeats	E-geneN
and	O
penile	O
size	O
was	O
detected	O
in	O
patients	O
with	O
hypospadias	O
,	O
but	O
not	O
in	O
controls	O
.	O

Our	O
data	O
suggest	O
that	O
a	O
critical	O
lower	O
level	O
of	O
androgen	B-geneY
receptor	E-geneY
mRNA	O
expression	O
could	O
be	O
a	O
determining	O
factor	O
in	O
the	O
development	O
of	O
middle	O
hypospadias	O
.	O

Supervillin	S-geneY
-	O
mediated	O
suppression	O
of	O
p53	S-geneY
protein	O
enhances	O
cell	O
survival	O
.	O

Integrin	S-geneN
-	O
based	O
adhesions	O
promote	O
cell	O
survival	O
as	O
well	O
as	O
cell	O
motility	O
and	O
invasion	O
.	O

We	O
show	O
here	O
that	O
the	O
adhesion	B-geneN
regulatory	I-geneN
protein	E-geneN
supervillin	S-geneY
increases	O
cell	O
survival	O
by	O
decreasing	O
levels	O
of	O
the	O
tumor	B-geneN
suppressor	I-geneN
protein	E-geneN
p53	S-geneY
and	O
downstream	O
target	O
genes	O
.	O

RNAi	O
-	O
mediated	O
knockdown	O
of	O
a	O
new	O
splice	O
form	O
of	O
supervillin	B-geneN
(	I-geneN
isoform	I-geneN
4	I-geneN
)	I-geneN
or	I-geneN
both	I-geneN
isoforms	I-geneN
1	I-geneN
and	I-geneN
4	E-geneN
increases	O
the	O
amount	O
of	O
p53	S-geneY
and	O
cell	O
death	O
,	O
whereas	O
p53	S-geneY
levels	O
decrease	O
after	O
overexpression	O
of	O
either	O
supervillin	S-geneY
isoform	O
.	O

Cellular	O
responses	O
to	O
DNA	O
damage	O
induced	O
by	O
etoposide	S-chem-MU-1
or	O
doxorubicin	S-chem-MU-1
include	O
down	O
-	O
regulation	O
of	O
endogenous	O
supervillin	S-geneY-C4-2
coincident	O
with	O
increases	O
in	O
p53	S-geneY-C3-2
.	O

In	O
DNA	O
-	O
damaged	O
supervillin	S-geneY
knockdown	O
cells	O
,	O
p53	S-geneY
knockdown	O
or	O
inhibition	O
partially	O
rescues	O
the	O
loss	O
of	O
cell	O
metabolic	O
activity	O
,	O
a	O
measure	O
of	O
cell	O
proliferation	O
.	O

Knockdown	O
of	O
the	O
p53	S-geneY
deubiquitinating	O
enzyme	O
USP7	S-geneY
/	O
HAUSP	S-geneY
also	O
reverses	O
the	O
supervillin	S-geneY
phenotype	O
,	O
blocking	O
the	O
increase	O
in	O
p53	S-geneY
levels	O
seen	O
after	O
supervillin	S-geneY
knockdown	O
and	O
accentuating	O
the	O
decrease	O
in	O
p53	S-geneY
levels	O
triggered	O
by	O
supervillin	S-geneY
overexpression	O
.	O

Conversely	O
,	O
supervillin	S-geneY
overexpression	O
decreases	O
the	O
association	O
of	O
USP7	S-geneY
and	O
p53	S-geneY
and	O
attenuates	O
USP7	S-geneN
-	O
mediated	O
p53	S-geneY
deubiquitination	O
.	O

USP7	S-geneN
binds	O
directly	O
to	O
the	O
supervillin	S-geneY
N	S-chem
terminus	O
and	O
can	O
deubiquitinate	O
and	O
stabilize	O
supervillin	S-geneY
.	O

Supervillin	S-geneN
also	O
is	O
stabilized	O
by	O
derivatization	O
with	O
the	O
ubiquitin	S-geneN
-	O
like	O
protein	O
SUMO1	S-geneY
.	O

These	O
results	O
show	O
that	O
supervillin	S-geneY
regulates	O
cell	O
survival	O
through	O
control	O
of	O
p53	S-geneY
levels	O
and	O
suggest	O
that	O
supervillin	S-geneY
and	O
its	O
interaction	O
partners	O
at	O
sites	O
of	O
cell	O
-	O
substrate	O
adhesion	O
constitute	O
a	O
locus	O
for	O
cross	O
-	O
talk	O
between	O
survival	O
signaling	O
and	O
cell	O
motility	O
pathways	O
.	O

Anti	O
-	O
aging	O
molecule	O
,	O
Sirt1	S-geneY
:	O
a	O
novel	O
therapeutic	O
target	O
for	O
diabetic	O
nephropathy	O
.	O

Caloric	O
restriction	O
prolongs	O
the	O
lifespan	O
of	O
many	O
species	O
.	O

Therefore	O
,	O
investigators	O
have	O
researched	O
the	O
usefulness	O
of	O
caloric	O
restriction	O
for	O
healthy	O
lifespan	O
extension	O
.	O

Sirt1	S-geneY
,	O
an	O
NAD	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
dependent	I-geneN
deacetylase	E-geneN
,	O
was	O
identified	O
as	O
a	O
molecule	O
necessary	O
for	O
caloric	O
restriction	O
-	O
related	O
anti	O
-	O
aging	O
strategies	O
.	O

Sirt1	S-geneY
functions	O
as	O
an	O
intracellular	O
energy	O
sensor	O
to	O
detect	O
the	O
concentration	O
of	O
NAD	B-chem
(	I-chem
+	I-chem
)	E-chem
,	O
and	O
controls	O
in	O
vivo	O
metabolic	O
changes	O
under	O
caloric	O
restriction	O
and	O
starvation	O
through	O
its	O
deacetylase	S-geneN
activity	O
to	O
many	O
targets	O
including	O
histones	S-geneN
,	O
nuclear	O
transcriptional	O
factors	O
,	O
and	O
enzymes	O
.	O

During	O
the	O
past	O
decade	O
,	O
investigators	O
have	O
reported	O
the	O
relationship	O
between	O
disturbance	O
of	O
Sirt1	S-geneY
activation	O
and	O
the	O
onset	O
of	O
aging	O
-	O
and	O
obesity	O
-	O
associated	O
diseases	O
such	O
as	O
diabetes	O
,	O
cardiovascular	O
disease	O
and	O
neurodegenerative	O
disorders	O
.	O

Consequently	O
,	O
a	O
calorie	O
restriction	O
-	O
mimetic	O
action	O
of	O
Sirt1	S-geneY
is	O
now	O
expected	O
as	O
a	O
new	O
therapy	O
for	O
these	O
diseases	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
gradually	O
clarified	O
the	O
role	O
of	O
Sirt1	S-geneY
in	O
the	O
onset	O
of	O
kidney	O
disease	O
.	O

Its	O
activation	O
may	O
also	O
become	O
a	O
new	O
target	O
of	O
treatment	O
in	O
the	O
patients	O
with	O
chronic	O
kidney	O
disease	O
including	O
diabetic	O
nephropathy	O
.	O

In	O
this	O
article	O
,	O
we	O
would	O
like	O
to	O
review	O
the	O
role	O
of	O
Sirt1	S-geneY
in	O
the	O
onset	O
of	O
kidney	O
disease	O
based	O
on	O
previous	O
studies	O
,	O
and	O
discuss	O
its	O
possibility	O
as	O
the	O
target	O
of	O
treatment	O
in	O
diabetic	O
nephropathy	O
.	O

The	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
ZD1839	S-chem-C4-1
(	O
``	O
Iressa	O
``	O
)	O
inhibits	O
HER2	O
-	O
driven	O
signaling	O
and	O
suppresses	O
the	O
growth	O
of	B-geneY-C4-2
HER2	O
-	O
overexpressing	O
tumor	O
cells	O
.	O

The	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
is	O
commonly	O
overexpressed	O
in	O
many	O
human	O
tumors	O
and	O
provides	O
a	O
new	O
target	O
for	O
anticancer	O
drug	O
development	O
.	O

ZD1839	S-chem-C4-1
(	O
``	O
Iressa	O
``	O
)	O
,	B-chem
a	I-chem
quinazoline	I-chem
tyrosine	I-geneN-C4-2
kinase	O
inhibitor	O
selective	O
for	O
the	O
EGFR	O
,	O
has	O
shown	O
good	O
activity	O
in	O
preclinical	O
studies	O
and	O
in	O
the	O
early	O
phase	O
of	O
clinical	O
trials	O
.	O

However	O
,	O
because	O
it	O
remains	O
unclear	O
which	O
tumor	O
types	O
are	O
the	O
best	O
targets	O
for	O
treatment	O
with	O
this	O
agent	O
,	O
the	O
molecular	O
characteristics	O
that	O
correlate	O
with	O
tumor	O
sensitivity	O
to	O
ZD1839	S-chem
have	O
been	O
studied	O
.	O

In	O
a	O
panel	O
of	O
human	O
breast	O
cancer	O
and	O
other	O
epithelial	O
tumor	O
cell	O
lines	O
,	O
HER2	S-geneY
-	O
overexpressing	O
tumors	O
were	O
particularly	O
sensitive	O
to	O
ZD1839	S-chem
.	O

Growth	O
inhibition	O
of	O
these	O
tumor	O
cell	O
lines	O
was	O
associated	O
with	O
the	O
dephosphorylation	O
of	O
EGFR	S-geneY
,	O
HER2	S-geneY
,	O
and	O
HER3	S-geneY
,	O
accompanied	O
by	O
the	O
loss	O
of	O
association	O
of	O
HER3	O
with	O
phosphatidylinositol	B-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
,	O
and	O
down	O
-	O
regulation	O
of	O
Akt	S-geneN
activity	O
.	O

These	O
studies	O
suggest	O
that	O
HER2	S-geneY
-	O
overexpressing	O
tumors	O
are	O
particularly	O
susceptible	O
to	O
the	O
inhibition	O
of	O
HER	S-geneN
family	O
tyrosine	B-geneN
kinase	E-geneN
signaling	O
and	O
suggest	O
novel	O
strategies	O
to	O
treat	O
these	O
particularly	O
aggressive	O
tumors	O
.	O

5	B-geneY
-	I-geneY
Lipoxygenase	E-geneY
inhibitors	O
:	O
a	O
review	O
of	O
recent	O
patents	O
(	O
2010	O
-	O
2012	O
)	O
.	O

Introduction	O
:	O
5	B-geneY-C9-2
-	I-geneY-C9-2
Lipoxygenase	E-geneY-C9-2
(	O
5	B-geneY-C9-2
-	I-geneY-C9-2
LO	E-geneY-C9-2
)	O
is	O
a	O
crucial	O
enzyme	O
of	O
the	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
(	O
AA	O
)	O
cascade	O
and	O
catalyzes	O
the	O
formation	O
of	O
bioactive	O
leukotrienes	O
(	O
LTs	O
)	O
with	O
the	O
help	O
of	O
FLAP	S-geneY
,	O
the	O
5	B-geneY
-	I-geneY
LO	I-geneY
-	I-geneY
activating	I-geneY
protein	E-geneY
.	O

LTs	O
are	O
inflammatory	O
mediators	O
playing	O
a	O
pathophysiological	O
role	O
in	O
different	O
diseases	O
like	O
asthma	O
,	O
allergic	O
rhinitis	O
as	O
well	O
as	O
cardiovascular	O
diseases	O
and	O
certain	O
types	O
of	O
cancer	O
.	O

With	O
the	O
rising	O
number	O
of	O
indications	O
for	O
anti	O
-	O
LT	O
therapy	O
,	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibitor	O
drug	O
development	O
becomes	O
increasingly	O
important	O
.	O

Areas	O
covered	O
:	O
Here	O
,	O
both	O
recent	O
findings	O
regarding	O
the	O
pathophysiological	O
role	O
of	O
5	B-geneY
-	I-geneY
LO	E-geneY
and	O
the	O
patents	O
claimed	O
for	O
5	B-geneY
-	I-geneY
LO	E-geneY
inhibitors	O
are	O
discussed	O
.	O

Focusing	O
on	O
direct	O
inhibitors	O
,	O
several	O
patents	O
disclosing	O
FLAP	S-geneY
antagonists	O
are	O
also	O
subject	O
of	O
this	O
review	O
.	O

Novel	O
compounds	O
include	O
1,5	B-chem
-	I-chem
diarylpyrazoles	E-chem
,	O
indolizines	S-chem
and	O
indoles	S-chem
and	O
several	O
natural	O
product	O
extracts	O
.	O

Expert	O
opinion	O
:	O
Evaluation	O
of	O
the	O
patent	O
activities	O
revealed	O
only	O
quite	O
moderate	O
action	O
.	O

Nevertheless	O
,	O
several	O
auspicious	O
drug	O
-	O
like	O
molecules	O
were	O
disclosed	O
.	O

It	O
seems	O
that	O
in	O
the	O
near	O
future	O
,	O
FLAP	S-geneY
inhibitors	O
can	O
be	O
expected	O
to	O
enter	O
the	O
market	O
for	O
the	O
treatment	O
of	O
asthma	O
.	O

With	O
the	O
resolved	O
structure	O
of	O
5	B-geneY
-	I-geneY
LO	E-geneY
,	O
structure	O
-	O
based	O
drug	O
design	O
is	O
now	O
applicable	O
.	O

Together	O
with	O
the	O
identification	O
of	O
downstream	O
enzyme	O
inhibitors	O
and	O
dual	O
-	O
targeting	O
drugs	O
within	O
the	O
AA	O
cascade	O
,	O
several	O
tools	O
are	O
at	O
hand	O
to	O
cope	O
with	O
5	B-geneY
-	I-geneY
LOs	E-geneY
increasing	O
pathophysiological	O
roles	O
.	O

Palonosetron	S-chem
:	O
in	O
the	O
prevention	O
of	O
nausea	O
and	O
vomiting	O
.	O

Palonosetron	S-chem-C6-1
is	O
a	O
second	O
-	O
generation	O
serotonin	B-geneN-C6-2
5	I-geneN-C6-2
-	I-geneN-C6-2
HT3	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
with	O
a	O
distinct	O
pharmacological	O
profile	O
that	O
differs	O
from	O
first	O
-	O
generation	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT3	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonists	O
.	O

Intravenous	O
palonosetron	S-chem
is	O
widely	O
indicated	O
for	O
the	O
prevention	O
of	O
chemotherapy	O
-	O
induced	O
nausea	O
and	O
vomiting	O
(	O
CINV	O
)	O
in	O
the	O
acute	O
and	O
delayed	O
phases	O
following	O
moderately	O
emetogenic	O
chemotherapy	O
(	O
MEC	O
)	O
and	O
the	O
prevention	O
of	O
CINV	O
in	O
the	O
acute	O
phase	O
following	O
highly	O
emetogenic	O
chemotherapy	O
(	O
HEC	O
)	O
.	O

In	O
the	O
US	O
,	O
oral	O
palonosetron	S-chem
is	O
approved	O
for	O
the	O
prevention	O
of	O
CINV	O
in	O
the	O
acute	O
phase	O
following	O
MEC	O
(	O
although	O
this	O
formulation	O
is	O
not	O
currently	O
available	O
)	O
,	O
and	O
intravenous	O
palonosetron	S-chem
is	O
indicated	O
for	O
the	O
prevention	O
of	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
in	O
the	O
first	O
24	O
hours	O
following	O
surgery	O
.	O

All	O
indications	O
are	O
currently	O
limited	O
to	O
adult	O
patients	O
.	O

Intravenous	O
palonosetron	S-chem
was	O
noninferior	O
to	O
intravenous	O
ondansetron	S-chem
(	O
with	O
statistically	O
greater	O
efficacy	O
than	O
ondansetron	S-chem
)	O
or	O
dolasetron	S-chem
in	O
preventing	O
CINV	O
following	O
MEC	O
,	O
or	O
to	O
intravenous	O
ondansetron	S-chem
or	O
granisetron	S-chem
in	O
preventing	O
CINV	O
following	O
HEC	O
,	O
in	O
the	O
acute	O
phase	O
.	O

Statistically	O
greater	O
efficacy	O
was	O
seen	O
with	O
intravenous	O
palonosetron	S-chem
than	O
ondansetron	S-chem
or	O
dolasetron	S-chem
in	O
preventing	O
CINV	O
following	O
MEC	O
in	O
the	O
delayed	O
phase	O
.	O

Oral	O
palonosetron	S-chem
was	O
noninferior	O
to	O
intravenous	O
palonosetron	S-chem
in	O
preventing	O
CINV	O
in	O
the	O
acute	O
phase	O
in	O
patients	O
receiving	O
MEC	O
.	O

Intravenous	O
palonosetron	S-chem
was	O
superior	O
to	O
placebo	O
in	O
preventing	O
PONV	O
in	O
the	O
first	O
24	O
hours	O
following	O
surgery	O
.	O

Palonosetron	S-chem
was	O
generally	O
well	O
tolerated	O
in	O
clinical	O
trials	O
.	O

Intravenous	O
palonosetron	S-chem
is	O
a	O
valuable	O
option	O
in	O
the	O
prevention	O
of	O
acute	O
-	O
and	O
delayed	O
-	O
phase	O
CINV	O
in	O
adult	O
patients	O
receiving	O
MEC	O
,	O
and	O
of	O
acute	O
-	O
phase	O
CINV	O
in	O
patients	O
receiving	O
HEC	O
.	O

Oral	O
palonosetron	S-chem-C6-1
is	O
likely	O
to	O
be	O
a	O
useful	O
addition	O
to	O
oral	O
formulations	O
of	O
other	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT3	I-geneN-C6-2
receptor	O
antagonists	O
in	O
preventing	O
CINV	O
in	O
patients	O
receiving	O
MEC	O
.	O

Intravenous	O
palonosetron	S-chem
is	O
a	O
useful	O
alternative	O
to	O
currently	O
recommended	O
agents	O
in	O
PONV	O
prevention	O
.	O

Conformational	O
variations	O
of	O
both	O
phosphodiesterase	B-geneY-C4-2
-	I-geneY-C4-2
5	E-geneY-C4-2
and	O
inhibitors	O
provide	O
the	O
structural	O
basis	O
for	O
the	O
physiological	O
effects	O
of	O
vardenafil	S-chem
and	O
sildenafil	S-chem-C4-1
.	O

Vardenafil	S-chem
has	O
higher	O
affinity	O
to	O
phosphodiesterase	B-geneY
-	I-geneY
5	E-geneY
(	O
PDE5	S-geneY
)	O
than	O
sildenafil	S-chem
and	O
lower	O
administered	O
dosage	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
these	O
differences	O
is	O
puzzling	O
because	O
two	O
drugs	O
have	O
similar	O
chemical	O
structures	O
.	O

Reported	O
here	O
is	O
a	O
crystal	O
structure	O
of	O
the	O
fully	O
active	O
and	O
nonmutated	O
PDE5A1	B-geneN
catalytic	I-geneN
domain	E-geneN
in	O
complex	O
with	O
vardenafil	S-chem
.	O

The	O
structure	O
shows	O
that	O
the	O
conformation	O
of	O
the	O
H	O
-	O
loop	O
in	O
the	O
PDE5A1	S-geneY
-	O
vardenafil	S-chem
complex	O
is	O
different	O
from	O
those	O
of	O
any	O
known	O
structures	O
of	O
the	O
unliganded	O
PDE5	S-geneY
and	O
its	O
complexes	O
with	O
the	O
inhibitors	O
.	O

In	O
addition	O
,	O
the	O
molecular	O
configuration	O
of	O
vardenafil	S-chem
differs	O
from	O
that	O
of	O
sildenafil	S-chem
when	O
bound	O
to	O
PDE5	S-geneY
.	O

It	O
is	O
noteworthy	O
that	O
the	O
binding	O
of	O
vardenafil	S-chem
causes	O
loss	O
of	O
the	O
divalent	O
metal	O
ions	O
that	O
have	O
been	O
observed	O
in	O
all	O
the	O
previously	O
published	O
PDE	S-geneN
structures	O
.	O

The	O
conformational	O
variation	O
of	O
both	O
PDE5	S-geneY
and	O
the	O
inhibitors	O
provides	O
structural	O
insight	O
into	O
the	O
different	O
potencies	O
of	O
the	O
drugs	O
.	O

Diethylcarbamazine	S-chem
activity	O
against	O
Brugia	O
malayi	O
microfilariae	O
is	O
dependent	O
on	O
inducible	B-geneY
nitric	I-geneY
-	I-geneY
oxide	I-geneY
synthase	E-geneY
and	O
the	O
cyclooxygenase	S-geneN
pathway	O
.	O

BACKGROUND	O
:	O
Diethylcarbamazine	S-chem
(	O
DEC	S-chem
)	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
the	O
treatment	O
of	O
human	O
lymphatic	O
filariasis	O
.	O

Its	O
mode	O
of	O
action	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
known	O
to	O
interact	O
with	O
the	O
arachidonic	B-chem
acid	E-chem
pathway	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
contribution	O
of	O
the	O
nitric	B-chem
oxide	E-chem
and	O
cyclooxygenase	S-geneN
(	O
COX	S-geneN
)	O
pathways	O
to	O
the	O
activity	O
of	O
DEC	S-chem
against	O
B.	O
malayi	O
microfilariae	O
in	O
mice	O
.	O

METHODS	O
:	O
B.	O
malayi	O
microfilariae	O
were	O
injected	O
intravenously	O
into	O
mice	O
and	O
parasitaemia	O
was	O
measured	O
24	O
hours	O
later	O
.	O

DEC	S-chem
was	O
then	O
administered	O
to	O
BALB	O
/	O
c	O
mice	O
with	O
and	O
without	O
pre	O
-	O
treatment	O
with	O
indomethacin	S-chem
or	O
dexamethasone	S-chem
and	O
the	O
parasitaemia	O
monitored	O
.	O

To	O
investigate	O
a	O
role	O
for	O
inducible	O
nitric	B-chem
oxide	E-chem
in	O
DEC	O
's	O
activity	O
,	O
DEC	S-chem
and	O
ivermectin	S-chem
were	O
administered	O
to	O
microfilaraemic	O
iNOS	S-geneY
-	O
/	O
-	O
mice	O
and	O
their	O
background	O
strain	O
(	O
129	O
/	O
SV	O
)	O
.	O

Western	O
blot	O
analysis	O
was	O
used	O
to	O
determine	O
any	O
effect	O
of	O
DEC	S-chem
on	O
the	O
production	O
of	O
COX	S-geneN
and	O
inducible	O
nitric	B-geneY
-	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
proteins	O
.	O

RESULTS	O
:	O
DEC	O
administered	O
alone	O
to	O
BALB	O
/	O
c	O
mice	O
resulted	O
in	O
a	O
rapid	O
and	O
profound	O
reduction	O
in	O
circulating	O
microfilariae	O
within	O
five	O
minutes	O
of	O
treatment	O
.	O

Microfilarial	O
levels	O
began	O
to	O
recover	O
after	O
24	O
hours	O
and	O
returned	O
to	O
near	O
pre	O
-	O
treatment	O
levels	O
two	O
weeks	O
later	O
,	O
suggesting	O
that	O
the	O
sequestration	O
of	O
microfilariae	O
occurs	O
independently	O
of	O
parasite	O
killing	O
.	O

Pre	O
-	O
treatment	O
of	O
animals	O
with	O
dexamethasone	S-chem
or	O
indomethacin	S-chem
reduced	O
DEC	O
's	O
efficacy	O
by	O
almost	O
90	O
%	O
or	O
56	O
%	O
,	O
respectively	O
,	O
supporting	O
a	O
role	O
for	O
the	O
arachidonic	B-chem
acid	E-chem
and	O
cyclooxygenase	S-geneN
pathways	O
in	O
vivo	O
.	O

Furthermore	O
,	O
experiments	O
showed	O
that	O
treatment	O
with	O
DEC	S-chem-C4-1
results	O
in	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
protein	O
in	O
peritoneal	O
exudate	O
cells	O
.	O

Additionally	O
,	O
in	O
iNOS	S-geneY
-	O
/	O
-	O
mice	O
infected	O
with	O
B.	O
malayi	O
microfilariae	O
,	O
DEC	S-chem
showed	O
no	O
activity	O
,	O
whereas	O
the	O
efficacy	O
of	O
another	O
antifilarial	O
drug	O
,	O
ivermectin	S-chem
,	O
was	O
unaffected	O
.	O

CONCLUSION	O
:	O
These	O
results	O
confirm	O
the	O
important	O
role	O
of	O
the	O
arachidonic	B-chem
acid	E-chem
metabolic	O
pathway	O
in	O
DEC	O
's	O
mechanism	O
of	O
action	O
in	O
vivo	O
and	O
show	O
that	O
in	O
addition	O
to	O
its	O
effects	O
on	O
the	O
5	B-geneY
-	I-geneY
lipoxygenase	E-geneY
pathway	O
,	O
it	O
targets	O
the	O
cyclooxygenase	S-geneN
pathway	O
and	O
COX	B-geneY
-	I-geneY
1	E-geneY
.	O

Moreover	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
inducible	O
nitric	B-chem
oxide	E-chem
is	O
essential	O
for	O
the	O
rapid	O
sequestration	O
of	O
microfilariae	O
by	O
DEC	S-chem
.	O

Serotonin	B-geneY
5	I-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2B	I-geneY
)	I-geneY
receptor	E-geneY
loss	O
of	O
function	O
mutation	O
in	O
a	O
patient	O
with	O
fenfluramine	S-chem
-	O
associated	O
primary	O
pulmonary	O
hypertension	O
.	O

OBJECTIVE	O
:	O
Appetite	O
-	O
suppressant	O
drug	O
fenfluramine	O
is	O
implicated	O
in	O
primary	O
pulmonary	O
hypertension	O
(	O
PPH	O
)	O
but	O
the	O
molecular	O
pathways	O
that	O
mediate	O
this	O
effect	O
are	O
unknown	O
.	O

A	O
mouse	O
model	O
incriminates	O
the	O
serotonin	B-geneY
5	I-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2B	I-geneY
)	I-geneY
receptor	E-geneY
but	O
contrasts	O
with	O
other	O
models	O
where	O
this	O
receptor	O
has	O
been	O
shown	O
to	O
mediate	O
pulmonary	O
arterial	O
relaxation	O
via	O
nitric	B-chem
oxide	E-chem
production	O
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
human	B-geneY
5	I-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2B	I-geneY
)	E-geneY
gene	O
in	O
10	O
patients	O
with	O
appetite	O
-	O
suppressant	O
drug	O
-	O
associated	O
PPH	O
.	O

RESULTS	O
:	O
A	O
mutation	O
causing	O
premature	O
truncation	O
of	O
the	O
protein	O
product	O
was	O
found	O
in	O
one	O
patient	O
.	O

The	O
mutation	O
was	O
not	O
found	O
in	O
80	O
control	O
subjects	O
and	O
no	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2B	I-geneY
)	E-geneY
mutation	O
was	O
found	O
in	O
18	O
PPH	O
patients	O
not	O
associated	O
with	O
appetite	O
-	O
suppressants	O
.	O

Functional	O
analysis	O
of	O
the	O
transfected	O
receptor	O
expressed	O
either	O
transiently	O
in	O
COS	O
cells	O
or	O
stably	O
in	O
CHO	S-chem
cells	O
demonstrated	O
that	O
the	O
mutated	O
receptor	O
fails	O
to	O
activate	O
the	O
second	O
messenger	O
inositol	B-chem
-	I-chem
phosphates	E-chem
cascade	O
and	O
subsequent	O
intracellular	O
calcium	S-chem
release	O
,	O
in	O
spite	O
of	O
normal	O
expression	O
at	O
the	O
cell	O
membrane	O
.	O

The	O
mutated	O
receptor	O
had	O
no	O
constitutive	O
activity	O
,	O
and	O
produced	O
no	O
dominant	O
negative	O
effect	O
on	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

CONCLUSION	O
:	O
Loss	O
of	O
serotonin	S-chem
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2B	I-geneY
)	I-geneY
receptor	E-geneY
function	O
may	O
predispose	O
to	O
fenfluramine	S-chem
-	O
associated	O
PPH	O
in	O
man	O
.	O

Amylin	S-geneY
receptors	O
:	O
molecular	O
composition	O
and	O
pharmacology	O
.	O

Several	O
receptors	O
which	O
bind	O
the	O
hormone	O
AMY	S-geneY
(	O
amylin	S-geneY
)	O
with	O
high	O
affinity	O
have	O
now	O
been	O
identified	O
.	O

The	O
minimum	O
binding	O
unit	O
is	O
composed	O
of	O
the	O
CT	B-geneY
(	I-geneY
calcitonin	I-geneY
)	I-geneY
receptor	E-geneY
at	O
its	O
core	O
,	O
plus	O
a	O
RAMP	S-geneN
(	O
receptor	B-geneN
activity	I-geneN
modifying	I-geneN
protein	E-geneN
)	O
.	O

The	O
receptors	O
have	O
been	O
named	O
AMY	B-geneN
(	I-geneN
1	I-geneN
(	I-geneN
a	I-geneN
)	I-geneN
)	E-geneN
,	O
AMY	B-geneN
(	I-geneN
2	I-geneN
(	I-geneN
a	I-geneN
)	I-geneN
)	E-geneN
and	O
AMY	B-geneN
(	I-geneN
3	I-geneN
(	I-geneN
a	I-geneN
)	I-geneN
)	E-geneN
in	O
accordance	O
with	O
the	O
association	O
of	O
the	O
CT	B-geneY
receptor	E-geneY
(	B-geneY
CT	I-geneY
(	I-geneY
(	I-geneY
a	I-geneY
)	I-geneY
)	I-geneY
)	E-geneY
with	O
RAMP1	S-geneY
,	O
RAMP2	S-geneY
and	O
RAMP3	S-geneY
respectively	O
.	O

The	O
challenge	O
is	O
now	O
to	O
determine	O
the	O
localization	O
and	O
pharmacological	O
nature	O
of	O
each	O
of	O
these	O
receptors	O
.	O

Recent	O
attempts	O
to	O
achieve	O
these	O
aims	O
will	O
be	O
briefly	O
discussed	O
.	O

5	B-chem-C3-1
-	I-chem-C3-1
hydroxytryptamine	E-chem-C3-1
evokes	O
endothelial	B-geneY-C3-2
nitric	I-geneY-C3-2
oxide	I-geneY-C3-2
synthase	E-geneY-C3-2
activation	O
in	O
bovine	O
aortic	O
endothelial	O
cell	O
cultures	O
.	O

Activation	O
of	O
endothelial	B-geneY-C9-2
nitric	I-geneY-C9-2
oxide	I-geneY-C9-2
synthase	E-geneY-C9-2
(	O
eNOS	S-geneY-C9-2
)	O
results	O
in	O
the	O
production	O
of	O
nitric	B-chem-C9-1
oxide	E-chem-C9-1
(	O
NO	S-chem-C9-1
)	O
that	O
mediates	O
the	O
vasorelaxing	O
properties	O
of	O
endothelial	O
cells	O
.	O

The	O
goal	O
of	O
this	O
project	O
was	O
to	O
address	O
the	O
possibility	O
that	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
(	O
5	B-chem
-	I-chem
HT	E-chem
)	O
stimulates	O
eNOS	S-geneY
activity	O
in	O
bovine	O
aortic	O
endothelial	O
cell	O
(	O
BAEC	O
)	O
cultures	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
mediate	O
eNOS	S-geneY-C9-2
activation	O
by	O
measuring	O
agonist	O
-	O
stimulated	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
L	I-chem-C9-1
-	I-chem-C9-1
citrulline	E-chem-C9-1
(	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
L	I-chem-C9-1
-	I-chem-C9-1
Cit	E-chem-C9-1
)	O
formation	O
in	O
BAEC	O
cultures	O
.	O

We	O
found	O
that	O
5	B-chem-C3-1
-	I-chem-C3-1
HT	E-chem-C3-1
stimulated	O
the	O
conversion	O
of	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
L	I-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
(	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
L	I-chem-C9-1
-	I-chem-C9-1
Arg	E-chem-C9-1
)	O
to	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
L	I-chem-C9-1
-	I-chem-C9-1
Cit	E-chem-C9-1
,	O
indicating	O
eNOS	S-geneY-MU-2
activation	O
.	O

The	O
high	O
affinity	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1B	E-geneY-C5-2
receptor	O
agonist	O
,	O
5	B-chem-C5-1
-	I-chem-C5-1
nonyloxytryptamine	E-chem-C5-1
(	O
5	O
-	O
NOT	O
)	O
-	O
stimulated	O
[	B-chem
3H	I-chem
]	I-chem
L	I-chem
-	I-chem
Cit	E-chem
turnover	O
responses	O
were	O
concentration	O
-	O
(	O
0.01	O
nM	O
to	O
100	O
microM	O
)	O
and	O
time	O
-	O
dependent	O
.	O

Maximal	O
responses	O
were	O
observed	O
within	O
10	O
min	O
following	O
agonist	O
exposures	O
.	O

These	O
responses	O
were	O
effectively	O
blocked	O
by	O
the	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
antagonist	O
,	O
isamoltane	O
,	O
the	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1B	E-geneY-C6-2
/	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT2	I-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
methiothepin	S-chem-C6-1
,	O
and	O
the	O
eNOS	S-geneY-C6-2
selective	O
antagonists	O
(	O
0.01	O
-	O
10	O
microM	O
)	O
:	O
L	B-chem-C6-1
-	I-chem-C6-1
Nomega	I-chem-C6-1
-	I-chem-C6-1
monomethyl	I-chem-C6-1
-	I-chem-C6-1
L	I-chem-C6-1
-	I-chem-C6-1
arginine	E-chem-C6-1
(	O
L	B-chem-C6-1
-	I-chem-C6-1
NMMA	E-chem-C6-1
)	O
and	O
L	B-chem-C6-1
-	I-chem-C6-1
N	I-chem-C6-1
omega	I-chem-C6-1
-	I-chem-C6-1
iminoethyl	I-chem-C6-1
-	I-chem-C6-1
L	I-chem-C6-1
-	I-chem-C6-1
ornithine	E-chem-C6-1
(	O
L	B-chem-C6-1
-	I-chem-C6-1
NIO	E-chem-C6-1
)	O
.	O

Pretreatment	O
of	O
BAEC	O
cultures	O
with	O
pertussis	B-geneN
toxin	E-geneN
(	O
PTX	S-geneN
;	O
1	O
-	O
100	O
ng	O
/	O
ml	O
)	O
for	O
16	O
hr	O
resulted	O
in	O
significant	O
inhibition	O
of	O
the	O
agonist	O
-	O
stimulated	O
eNOS	S-geneY
activity	O
,	O
indicating	O
the	O
involvement	O
of	O
Gi	B-geneN
proteins	E-geneN
.	O

These	O
findings	O
lend	O
evidence	O
of	O
a	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
/	O
eNOS	S-geneY
pathway	O
,	O
accounting	O
in	O
part	O
for	O
the	O
activation	O
of	O
eNOS	S-geneY-C3-2
by	O
5	B-chem-C3-1
-	I-chem-C3-1
HT	E-chem-C3-1
.	O

Further	O
investigation	O
is	O
needed	O
to	O
determine	O
the	O
role	O
of	O
other	O
vascular	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptors	E-geneN
in	O
the	O
stimulation	O
of	O
eNOS	S-geneY
activity	O
.	O

Epinastine	S-chem
(	O
WAL	B-chem
801CL	E-chem
)	O
modulates	O
the	O
noncholinergic	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
in	O
vitro	O
by	O
a	O
prejunctional	O
5	B-geneN
-	I-geneN
HT1	I-geneN
-	I-geneN
like	I-geneN
receptor	E-geneN
.	O

Electrical	O
field	O
stimulation	O
(	O
EFS	O
)	O
of	O
guinea	O
-	O
pig	O
airways	O
,	O
in	O
vitro	O
,	O
evokes	O
an	O
excitatory	O
nonadrenergic	O
noncholinergic	O
(	O
eNANC	O
)	O
contraction	O
mediated	O
by	O
release	O
of	O
tachykinins	O
from	O
sensory	O
nerve	O
endings	O
.	O

Epinastine	S-chem
(	O
WAL	B-chem
801CL	E-chem
)	O
is	O
an	O
antihistaminic	O
drug	O
with	O
binding	O
affinity	O
at	O
certain	O
other	O
receptors	O
,	O
including	O
alpha	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
and	O
various	O
serotonin	B-geneN
(	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
receptor	E-geneN
subtypes	O
.	O

It	O
is	O
used	O
in	O
asthma	O
treatment	O
;	O
however	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
fully	O
defined	O
.	O

We	O
have	O
investigated	O
whether	O
epinastine	S-chem
could	O
modulate	O
the	O
eNANC	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
in	O
vitro	O
,	O
and	O
have	O
tried	O
to	O
elucidate	O
its	O
receptor	O
mechanism	O
.	O

Epinastine	S-chem
(	O
0.1	O
-	O
100	O
microM	O
)	O
produced	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
the	O
noncholinergic	O
contraction	O
,	O
with	O
a	O
maximum	O
inhibition	O
of	O
91	O
+	O
/	O
-	O
7	O
%	O
at	O
100	O
microM	O
.	O

Pretreatment	O
of	O
the	O
tissues	O
with	O
combined	O
5	B-geneN-MU-2
-	I-geneN-MU-2
HT1	E-geneN-MU-2
/	O
5	B-geneN-MU-2
-	I-geneN-MU-2
HT2	E-geneN-MU-2
antagonists	O
,	O
methysergide	S-chem-C6-1
(	O
1	O
microM	O
)	O
or	O
methiothepin	S-chem-C6-1
(	O
0.1	O
microM	O
)	O
,	O
significantly	O
attenuated	O
the	O
inhibitory	O
effect	O
of	O
epinastine	S-chem-C5-1
on	O
the	O
noncholinergic	O
contraction	O
.	O

Pretreatment	O
with	O
tropisetron	S-chem-C6-1
(	O
1	O
microM	O
)	O
,	O
a	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT3	E-geneN-C6-2
antagonist	O
,	O
ketanserin	S-chem-C6-1
(	O
10	O
microM	O
)	O
,	O
a	O
5	B-geneN-C6-2
-	I-geneN-C6-2
HT2	E-geneN-C6-2
antagonist	O
,	O
thioperamide	S-chem-C6-1
(	O
10	O
microM	O
)	O
,	O
a	O
histamine	B-geneY-C6-2
H3	E-geneY-C6-2
antagonist	O
,	O
or	O
phentolamine	S-chem
(	O
10	O
microM	O
)	O
,	O
an	O
alpha	O
-	O
adrenergic	O
antagonist	O
,	O
however	O
,	O
had	O
no	O
effect	O
.	O

Chlorpheniramine	S-chem-C6-1
(	O
10	O
microM	O
)	O
,	O
another	O
histamine	B-geneY-C6-2
H1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
without	O
significant	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptor	E-geneN
binding	O
affinity	O
,	O
did	O
not	O
produce	O
any	O
inhibition	O
of	O
the	O
eNANC	O
contraction	O
.	O

Epinastine	S-chem
(	O
100	O
microM	O
)	O
did	O
not	O
displace	O
the	O
dose	O
-	O
response	O
curve	O
to	O
exogenously	O
applied	O
substance	B-geneY
P	E-geneY
(	O
0.01	O
-	O
10	O
microM	O
)	O
.	O

These	O
results	O
suggest	O
that	O
epinastine	S-chem-MU-1
,	O
although	O
identified	O
as	O
a	O
5	B-chem
-	I-chem
HT	E-chem
antagonist	O
,	O
acts	O
as	O
a	O
5	B-geneN-C5-2
-	I-geneN-C5-2
HT1	E-geneN-C5-2
agonist	O
and	O
that	O
it	O
inhibits	O
the	O
noncholinergic	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
through	O
stimulation	O
of	O
a	O
prejunctional	O
5	B-geneN-C3-2
-	I-geneN-C3-2
HT1	I-geneN-C3-2
-	I-geneN-C3-2
like	I-geneN-C3-2
receptor	E-geneN-C3-2
,	O
located	O
to	O
sensory	O
nerves	O
.	O

The	O
glutamate	B-geneN-C9-2
-	I-geneN-C9-2
aspartate	I-geneN-C9-2
transporter	E-geneN-C9-2
GLAST	S-geneN-C9-2
mediates	O
glutamate	S-chem-C9-1
uptake	O
at	O
inner	O
hair	O
cell	O
afferent	O
synapses	O
in	O
the	O
mammalian	O
cochlea	O
.	O

Ribbon	O
synapses	O
formed	O
between	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
and	O
afferent	O
dendrites	O
in	O
the	O
mammalian	O
cochlea	O
can	O
sustain	O
high	O
rates	O
of	O
release	O
,	O
placing	O
strong	O
demands	O
on	O
glutamate	S-chem
clearance	O
mechanisms	O
.	O

To	O
investigate	O
the	O
role	O
of	O
transporters	O
in	O
glutamate	S-chem
removal	O
at	O
these	O
synapses	O
,	O
we	O
made	O
whole	O
-	O
cell	O
recordings	O
from	O
IHCs	O
,	O
afferent	O
dendrites	O
,	O
and	O
glial	O
cells	O
adjacent	O
to	O
IHCs	O
[	O
inner	O
phalangeal	O
cells	O
(	O
IPCs	O
)	O
]	O
in	O
whole	O
-	O
mount	O
preparations	O
of	O
rat	O
organ	O
of	O
Corti	O
.	O

Focal	O
application	O
of	O
the	O
transporter	O
substrate	O
D	B-chem
-	I-chem
aspartate	E-chem
elicited	O
inward	O
currents	O
in	O
IPCs	O
,	O
which	O
were	O
larger	O
in	O
the	O
presence	O
of	O
anions	O
that	O
permeate	O
the	O
transporter	O
-	O
associated	O
anion	B-geneN-C6-2
channel	E-geneN-C6-2
and	O
blocked	O
by	O
the	O
transporter	O
antagonist	O
D	B-chem-C6-1
,	I-chem-C6-1
L	I-chem-C6-1
-	I-chem-C6-1
threo	I-chem-C6-1
-	I-chem-C6-1
beta	I-chem-C6-1
-	I-chem-C6-1
benzyloxyaspartate	E-chem-C6-1
.	O

These	O
currents	O
were	O
produced	O
by	O
glutamate	B-geneY-C4-2
-	I-geneY-C4-2
aspartate	I-geneY-C4-2
transporters	E-geneY-C4-2
(	O
GLAST	S-geneY-C4-2
)	O
(	O
excitatory	B-geneY-C4-2
amino	I-geneY-C4-2
acid	I-geneY-C4-2
transporter	I-geneY-C4-2
1	E-geneY-C4-2
)	O
because	O
they	O
were	O
weakly	O
inhibited	O
by	O
dihydrokainate	S-chem-MU-1
,	O
an	O
antagonist	O
of	O
glutamate	B-geneY-C6-2
transporter	I-geneY-C6-2
-	I-geneY-C6-2
1	E-geneY-C6-2
(	O
excitatory	B-geneY-C6-2
amino	I-geneY-C6-2
acid	I-geneY-C6-2
transporter	I-geneY-C6-2
2	E-geneY-C6-2
)	O
and	O
were	O
absent	O
from	O
IPCs	O
in	O
GLAST	S-geneY
-	O
/	O
-	O
cochleas	O
.	O

Furthermore	O
,	O
D	B-chem
-	I-chem
aspartate	E-chem
-	O
induced	O
currents	O
in	O
outside	O
-	O
out	O
patches	O
from	O
IPCs	O
exhibited	O
larger	O
steady	O
-	O
state	O
currents	O
than	O
responses	O
elicited	O
by	O
L	B-chem-C9-1
-	I-chem-C9-1
glutamate	E-chem-C9-1
,	O
a	O
prominent	O
feature	O
of	O
GLAST	S-geneY-C9-2
,	O
and	O
examination	O
of	O
cochlea	O
from	O
GLAST	S-geneY
-	O
Discosoma	O
red	O
(	O
DsRed	O
)	O
promoter	O
reporter	O
mice	O
revealed	O
that	O
DsRed	O
expression	O
was	O
restricted	O
to	O
IPCs	O
and	O
other	O
supporting	O
cells	O
surrounding	O
IHCs	O
.	O

Saturation	O
of	O
transporters	O
by	O
photolysis	O
of	O
caged	O
D	B-chem
-	I-chem
aspartate	E-chem
failed	O
to	O
elicit	O
transporter	O
currents	O
in	O
IHCs	O
,	O
as	O
did	O
local	O
application	O
of	O
D	B-chem
-	I-chem
aspartate	E-chem
to	O
afferent	O
terminals	O
,	O
indicating	O
that	O
neither	O
presynaptic	O
nor	O
postsynaptic	O
membranes	O
are	O
major	O
sites	O
for	O
glutamate	S-chem
removal	O
.	O

These	O
data	O
indicate	O
that	O
GLAST	S-geneY
in	O
supporting	O
cells	O
is	O
responsible	O
for	O
transmitter	O
uptake	O
at	O
IHC	O
afferent	O
synapses	O
.	O

Synthesis	O
and	O
cancer	O
stem	O
cell	O
-	O
based	O
activity	O
of	O
substituted	O
5	B-chem-C4-1
-	I-chem-C4-1
morpholino	I-chem-C4-1
-	I-chem-C4-1
7H	I-chem-C4-1
-	I-chem-C4-1
thieno	I-chem-C4-1
[	I-chem-C4-1
3,2	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyran	I-chem-C4-1
-	I-chem-C4-1
7	I-chem-C4-1
-	I-chem-C4-1
ones	E-chem-C4-1
designed	O
as	O
next	O
generation	O
PI3K	S-geneN-C4-2
inhibitors	O
.	O

Dysregulation	O
of	O
the	O
phosphatidylinositol	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
(	O
PI3K	S-geneN
)	O
pathway	O
in	O
a	O
wide	O
range	O
of	O
tumors	O
has	O
made	O
PI3K	S-geneN
a	O
consensus	O
target	O
to	O
inhibit	O
as	O
illustrated	O
by	O
more	O
than	O
15	O
inhibitors	O
now	O
in	O
clinical	O
trials	O
.	O

Our	O
previous	O
work	O
,	O
built	O
on	O
the	O
early	O
pioneering	O
multikinase	O
inhibitor	O
LY294002	S-chem-C4-1
,	O
resulted	O
in	O
the	O
only	O
PI3K	S-geneN-C4-2
vascular	O
-	O
targeted	O
PI3K	S-geneN-C4-2
inhibitor	O
prodrug	O
,	O
SF1126	S-chem-C4-1
,	O
which	O
has	O
now	O
completed	O
Phase	O
I	O
clinical	O
trials	O
.	O

This	O
inhibitor	O
has	O
properties	O
that	O
impart	O
more	O
in	O
vivo	O
activity	O
than	O
should	O
be	O
warranted	O
by	O
its	O
enzymatic	O
potency	O
,	O
which	O
in	O
general	O
is	O
much	O
lower	O
than	O
other	O
clinical	O
stage	O
PI3K	S-geneN
inhibitors	O
.	O

We	O
embarked	O
on	O
the	O
exploration	O
of	O
scaffolds	O
that	O
retained	O
such	O
properties	O
while	O
simultaneously	O
exhibiting	O
an	O
increased	O
potency	O
toward	O
PI3K	S-geneN
.	O

This	O
work	O
resulted	O
in	O
the	O
discovery	O
of	O
the	O
5	B-chem-C4-1
-	I-chem-C4-1
morpholino	I-chem-C4-1
-	I-chem-C4-1
7H	I-chem-C4-1
-	I-chem-C4-1
thieno	I-chem-C4-1
[	I-chem-C4-1
3,2	I-chem-C4-1
-	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
pyran	I-chem-C4-1
-	I-chem-C4-1
7	I-chem-C4-1
-	I-chem-C4-1
one	E-chem-C4-1
system	O
as	O
the	O
foundation	O
of	O
a	O
new	O
compound	O
class	O
of	O
potential	O
PI3K	S-geneN-C4-2
inhibitors	O
having	O
improved	O
potency	O
toward	O
PI3K	S-geneN-C4-2
.	O

The	O
synthesis	O
and	O
cancer	O
stem	O
cell	O
-	O
based	O
activity	O
of	O
these	O
compounds	O
are	O
reported	O
herein	O
.	O

Everolimus	S-chem
:	O
the	O
first	O
approved	O
product	O
for	O
patients	O
with	O
advanced	O
renal	O
cell	O
cancer	O
after	O
sunitinib	S-chem
and	O
/	O
or	O
sorafenib	S-chem
.	O

Everolimus	S-chem-C4-1
(	O
RAD001	S-chem-C4-1
,	O
Afinitor	B-chem-C4-1
(	I-chem-C4-1
(	I-chem-C4-1
R	I-chem-C4-1
)	I-chem-C4-1
)	I-chem-C4-1
Novartis	E-chem-C4-1
)	O
is	O
the	O
first	O
oral	O
inhibitor	O
of	O
mTOR	S-geneY-C4-2
(	O
mammalian	B-geneY-C4-2
target	I-geneY-C4-2
of	I-geneY-C4-2
rapamycin	E-geneY-C4-2
)	O
to	O
reach	O
the	O
oncology	O
clinic	O
.	O

Everolimus	S-chem
10	O
mg	O
daily	O
achieves	O
complete	O
inhibition	O
of	O
its	O
target	O
at	O
below	O
the	O
maximum	O
tolerable	O
dose	O
for	O
most	O
patients	O
.	O

A	O
phase	O
III	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
has	O
examined	O
the	O
impact	O
of	O
everolimus	S-chem
in	O
patients	O
with	O
clear	O
cell	O
renal	O
cancers	O
and	O
progressive	O
disease	O
on	O
or	O
within	O
6	O
months	O
of	O
the	O
VEGFR	S-geneN-C4-2
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitors	O
sunitinib	S-chem-C4-1
and	O
/	O
or	O
sorafenib	S-chem-C4-1
.	O

The	O
primary	O
endpoint	O
of	O
progression	O
-	O
free	O
survival	O
was	O
increased	O
from	O
median	O
1.9	O
to	O
4.9	O
months	O
(	O
hazard	O
ratio	O
0.33	O
,	O
P	O
<	O
0.001	O
)	O
and	O
25	O
%	O
were	O
still	O
progression	O
-	O
free	O
after	O
10	O
months	O
of	O
everolimus	S-chem
therapy	O
.	O

There	O
was	O
a	O
delay	O
in	O
time	O
to	O
decline	O
of	O
performance	O
status	O
and	O
trends	O
to	O
improvement	O
in	O
quality	O
of	O
life	O
,	O
disease	O
-	O
related	O
symptoms	O
,	O
and	O
overall	O
survival	O
despite	O
crossover	O
of	O
the	O
majority	O
of	O
patients	O
assigned	O
to	O
placebo	O
.	O

In	O
2009	O
,	O
everolimus	S-chem
was	O
approved	O
in	O
the	O
US	O
and	O
Europe	O
as	O
the	O
only	O
validated	O
option	O
for	O
this	O
indication	O
.	O

Toxicities	O
are	O
usually	O
mild	O
to	O
moderate	O
and	O
can	O
be	O
managed	O
with	O
dose	O
reduction	O
or	O
interruption	O
if	O
necessary	O
.	O

Opportunistic	O
infections	O
and	O
non	O
-	O
infectious	O
pneumonitis	O
are	O
seen	O
as	O
a	O
class	O
effect	O
.	O

Management	O
of	O
common	O
practical	O
management	O
issues	O
are	O
discussed	O
.	O

Clinical	O
trials	O
are	O
in	O
progress	O
to	O
examine	O
additional	O
roles	O
for	O
everolimus	S-chem
in	O
renal	O
cancer	O
,	O
alone	O
and	O
in	O
combination	O
with	O
other	O
agents	O
.	O

TCF7L2	S-geneY
Variation	O
and	O
Proliferative	O
Diabetic	O
Retinopathy	O
.	O

Proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
is	O
the	O
most	O
severe	O
vision	O
-	O
threatening	O
complication	O
of	O
diabetes	O
.	O

To	O
investigated	O
genetic	O
association	O
between	O
TCF7L2	S-geneY
and	O
PDR	O
in	O
Caucasian	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
its	O
functional	O
consequences	O
,	O
383	O
T2DM	O
patients	O
with	O
PDR	O
(	O
T2DM	O
-	O
PDR	O
)	O
and	O
756	O
T2DM	O
patients	O
without	O
diabetic	O
retinopathy	O
(	O
T2DM	O
-	O
no	O
DR	O
)	O
were	O
genotyped	O
with	O
rs7903146	O
in	O
TCF7L2	S-geneY
.	O

We	O
found	O
that	O
risk	O
allele	O
(	O
T	O
)	O
frequency	O
of	O
rs7903146	O
was	O
significantly	O
higher	O
in	O
T2DM	O
-	O
PDR	O
patients	O
(	O
allelic	O
P	O
=	O
2.52E	O
-	O
04	O
)	O
.	O

In	O
lymphoblastoid	O
cells	O
induced	O
to	O
undergo	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
by	O
treatment	O
of	O
tunicamycin	S-chem
,	O
higher	O
fold	O
change	O
of	O
TCF7L2	S-geneY
and	O
VEGFA	S-geneY
mRNA	O
levels	O
were	O
observed	O
in	O
rs7903146	O
-	O
TT	O
cells	O
than	O
that	O
in	O
rs7903146	O
-	O
CC	O
cells	O
(	O
P	O
=	O
0.02	O
for	O
TCF7L2	S-geneY
;	O
P	O
=	O
0.004	O
for	O
VEGFA	S-geneY
)	O
,	O
suggesting	O
ER	O
stress	O
plays	O
a	O
role	O
in	O
PDR	O
pathogenesis	O
.	O

Silencing	O
TCF7L2	S-geneY
resulted	O
in	O
decreased	O
mRNA	O
levels	O
of	O
both	O
TCF7L2	S-geneY
and	O
VEGFA	S-geneY
(	O
P	O
<	O
0.001	O
)	O
.	O

Retinas	O
of	O
oxygen	S-chem
-	O
induced	O
retinopathy	O
(	O
OIR	O
)	O
mice	O
(	O
a	O
model	O
for	O
PDR	O
)	O
had	O
higher	O
TCF7L2	S-geneY
and	O
VEGFA	S-geneY
mRNA	O
levels	O
than	O
controls	O
(	O
P	O
=	O
2.9E	O
-	O
04	O
for	O
TCF7L2	S-geneY
;	O
P	O
=	O
1.9E	O
-	O
07	O
for	O
VEGFA	S-geneY
)	O
.	O

Together	O
,	O
our	O
study	O
showed	O
that	O
TCF7L2	S-geneY
-	O
rs7903146	O
is	O
associated	O
with	O
PDR	O
in	O
Caucasian	O
T2DM	O
and	O
suggested	O
TCF7L2	S-geneY
promoted	O
pathological	O
retinal	O
neovascularization	O
via	O
ER	O
stress	O
-	O
dependent	O
upregulation	O
of	O
VEGFA	S-geneY
.	O

Synthesis	O
of	O
a	O
DOTA	S-chem-C4-1
(	O
Gd	B-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
+	I-chem-C4-1
)	E-chem-C4-1
)	O
-	O
conjugate	O
of	O
proton	B-geneN-C4-2
-	I-geneN-C4-2
pump	E-geneN-C4-2
inhibitor	O
pantoprazole	S-chem-C4-1
for	O
gastric	O
wall	O
imaging	O
studies	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
is	O
used	O
to	O
evaluate	O
gastrointestinal	O
(	O
GI	O
)	O
structure	O
and	O
functions	O
in	O
humans	O
.	O

Despite	O
filling	O
the	O
viscus	O
lumen	O
with	O
a	O
contrast	O
agent	O
,	O
visualization	O
of	O
the	O
viscus	O
wall	O
is	O
limited	O
.	O

To	O
overcome	O
this	O
limitation	O
,	O
we	O
de	O
novo	O
synthesized	O
a	O
conjugate	O
that	O
covalently	O
combines	O
a	O
Gd	S-chem-C4-1
-	O
based	O
MRI	O
contrast	O
agent	O
,	O
encaged	O
with	O
a	O
chelating	O
agent	O
(	O
DOTA	S-chem-C4-1
)	O
,	O
with	O
pantoprazole	S-chem-C4-1
,	O
which	O
is	O
a	O
widely	O
used	O
proton	B-geneN-C4-2
pump	E-geneN-C4-2
inhibitor	O
that	O
binds	O
to	O
proton	B-geneN
pumps	E-geneN
in	O
the	O
stomach	O
and	O
colon	O
.	O

The	O
DOTA	S-chem
linkage	O
was	O
installed	O
at	O
a	O
mechanism	O
-	O
based	O
strategic	O
location	O
in	O
the	O
pantoprazole	S-chem
molecule	O
to	O
minimize	O
a	O
possible	O
negative	O
effect	O
of	O
the	O
structural	O
modification	O
on	O
the	O
drug	O
.	O

It	O
is	O
anticipated	O
that	O
by	O
defining	O
the	O
wall	O
of	O
the	O
stomach	O
and	O
colon	O
,	O
this	O
compound	O
will	O
facilitate	O
functional	O
MRI	O
of	O
the	O
GI	O
tract	O
in	O
humans	O
.	O

Gender	O
and	O
strain	O
contributions	O
to	O
the	O
variability	O
of	O
buprenorphine	S-chem
-	O
related	O
respiratory	O
toxicity	O
in	O
mice	O
.	O

While	O
most	O
deaths	O
from	O
asphyxia	O
related	O
to	O
buprenorphine	S-chem
(	O
BUP	S-chem
)	O
overdose	O
have	O
been	O
reported	O
in	O
males	O
,	O
higher	O
plasma	O
concentrations	O
of	O
BUP	S-chem
and	O
its	O
toxic	O
metabolite	O
norbuprenorphine	S-chem
(	O
NBUP	S-chem
)	O
have	O
been	O
observed	O
in	O
females	O
.	O

We	O
previously	O
demonstrated	O
that	O
P	B-geneN
-	I-geneN
glycoprotein	E-geneN
(	O
P	B-geneN
-	I-geneN
gp	E-geneN
)	O
modulation	O
at	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
contributes	O
highly	O
to	O
BUP	S-chem
-	O
related	O
respiratory	O
toxicity	O
,	O
by	O
limiting	O
NBUP	S-chem
entrance	O
into	O
the	O
brain	O
.	O

In	O
this	O
work	O
,	O
we	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
P	B-geneN
-	I-geneN
gp	E-geneN
-	O
mediated	O
transport	O
at	O
the	O
BBB	O
in	O
gender	O
and	O
strain	O
-	O
related	O
variability	O
of	O
BUP	S-chem
and	O
NBUP	S-chem
-	O
induced	O
respiratory	O
effects	O
in	O
mice	O
.	O

Ventilation	O
was	O
studied	O
using	O
plethysmography	O
,	O
P	B-geneN
-	I-geneN
gp	E-geneN
expression	O
using	O
western	O
blot	O
,	O
and	O
transport	O
at	O
the	O
BBB	O
using	O
in	O
situ	O
cerebral	O
perfusion	O
.	O

In	O
male	O
Fvb	O
and	O
Swiss	O
mice	O
,	O
BUP	S-chem
was	O
responsible	O
for	O
ceiling	O
respiratory	O
effects	O
.	O

NBUP	S-chem
-	O
related	O
reduction	O
in	O
minute	O
volume	O
was	O
dose	O
-	O
dependent	O
but	O
more	O
marked	O
in	O
Fvb	O
(	O
p	O
<	O
0.01	O
at	O
1mg	O
/	O
kg	O
NBUP	S-chem
and	O
p	O
<	O
0.001	O
at	O
3	O
and	O
9mg	O
/	O
kg	O
NBUP	S-chem
)	O
than	O
in	O
Swiss	O
mice	O
(	O
p	O
<	O
0.001	O
at	O
9mg	O
/	O
kg	O
NBUP	S-chem
)	O
.	O

Female	O
Fvb	O
mice	O
were	O
more	O
susceptible	O
to	O
BUP	S-chem
than	O
males	O
with	O
significantly	O
increased	O
inspiratory	O
time	O
(	O
p	O
<	O
0.05	O
)	O
and	O
to	O
NBUP	S-chem
with	O
significantly	O
increased	O
expiratory	O
time	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Following	O
BUP	S-chem
administration	O
,	O
plasma	O
BUP	S-chem
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0.01	O
)	O
and	O
plasma	O
NBUP	S-chem
concentrations	O
significantly	O
lower	O
(	O
p	O
<	O
0.001	O
)	O
in	O
Fvb	O
mice	O
compared	O
to	O
Swiss	O
mice	O
.	O

Plasma	O
BUP	S-chem
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
and	O
plasma	O
NBUP	S-chem
concentrations	O
significantly	O
lower	O
(	O
p	O
<	O
0.01	O
)	O
in	O
male	O
compared	O
to	O
female	O
Fvb	O
mice	O
.	O

In	O
contrast	O
,	O
following	O
NBUP	S-chem
administration	O
,	O
comparable	O
plasma	O
NBUP	S-chem
concentrations	O
were	O
observed	O
in	O
both	O
genders	O
and	O
strains	O
.	O

No	O
differences	O
in	O
P	B-geneN
-	I-geneN
gp	E-geneN
expression	O
or	O
BUP	S-chem
and	O
NBUP	S-chem
transport	O
across	O
the	O
BBB	O
were	O
observed	O
between	O
male	O
and	O
female	O
Fvb	O
mice	O
as	O
well	O
as	O
between	O
Swiss	O
and	O
Fvb	O
mice	O
.	O

Our	O
results	O
suggest	O
that	O
P	B-geneN
-	I-geneN
gp	E-geneN
-	O
mediated	O
transport	O
across	O
the	O
BBB	O
does	O
not	O
play	O
a	O
key	O
-	O
role	O
in	O
gender	O
and	O
strain	O
-	O
related	O
variability	O
in	O
BUP	S-chem
and	O
NBUP	S-chem
-	O
induced	O
respiratory	O
toxicity	O
in	O
mice	O
.	O

Both	O
gender	O
-	O
and	O
strain	O
-	O
related	O
differences	O
in	O
respiratory	O
effects	O
of	O
BUP	S-chem
could	O
be	O
attributed	O
to	O
BUP	S-chem
itself	O
rather	O
than	O
to	O
its	O
metabolite	O
,	O
NBUP	S-chem
.	O

Influence	O
of	O
extraction	O
procedures	O
on	O
phenolic	O
content	O
and	O
antioxidant	O
activity	O
of	O
Cretan	O
barberry	O
herb	O
.	O

The	O
main	O
goal	O
of	O
present	O
study	O
was	O
the	O
development	O
,	O
optimization	O
and	O
application	O
of	O
different	O
extraction	O
protocols	O
,	O
especially	O
those	O
employing	O
green	O
technologies	O
,	O
in	O
order	O
to	O
obtain	O
from	O
Berberis	O
cretica	O
extracts	O
with	O
high	O
antioxidant	O
capacity	O
.	O

For	O
this	O
purpose	O
,	O
the	O
applied	O
methods	O
:	O
maceration	O
,	O
ASE	O
and	O
SFE	O
coupled	O
with	O
ASE	O
were	O
incorporated	O
.	O

The	O
antioxidant	O
assessment	O
was	O
carried	O
out	O
using	O
DPPH	S-chem
and	O
total	O
phenolic	O
content	O
(	O
Folin	O
-	O
Ciocalteu	O
)	O
assays	O
.	O

Major	O
constituents	O
were	O
elucidated	O
using	O
HPLC	O
-	O
DAD	O
and	O
UHPLC	O
-	O
HRMS	O
/	O
MS	O
(	O
hybrid	O
IT	O
-	O
Orbital	O
trap	O
spectrometer	O
)	O
equipped	O
with	O
an	O
ESI	O
probe	O
.	O

The	O
chromatographic	O
and	O
spectral	O
data	O
revealed	O
the	O
presence	O
of	O
several	O
simple	O
phenolic	B-chem
acids	E-chem
,	O
derivatives	O
of	O
both	O
caffeic	B-chem
and	I-chem
benzoic	I-chem
acids	E-chem
,	O
and	O
flavonoids	S-chem
in	O
the	O
produced	O
extracts	O
.	O

It	O
was	O
clearly	O
evidenced	O
that	O
the	O
extraction	O
method	O
and	O
solvents	O
used	O
affected	O
both	O
the	O
activity	O
and	O
the	O
chemical	O
content	O
of	O
the	O
results	O
,	O
significantly	O
.	O

The	O
most	O
beneficial	O
conditions	O
were	O
calculated	O
for	O
methanol	S-chem
and	O
water	O
:	O
ethanol	S-chem
(	O
50	O
:	O
50	O
)	O
extracts	O
derived	O
from	O
the	O
combination	O
of	O
SFE	O
and	O
ASE	O
methodologies	O
.	O

Obtained	O
results	O
classify	O
Cretan	O
barberry	O
as	O
a	O
strong	O
antioxidant	O
agent	O
.	O

Alefacept	S-geneY
,	O
an	O
immunomodulatory	O
recombinant	O
LFA	B-geneY
-	I-geneY
3	E-geneY
/	O
IgG1	S-geneY
fusion	O
protein	O
,	O
induces	O
CD16	S-geneN
signaling	O
and	O
CD2	S-geneY
/	O
CD16	S-geneN
-	O
dependent	O
apoptosis	O
of	O
CD2	O
(	O
+	O
)	O
cells	O
.	O

Alefacept	S-geneY
,	O
an	O
immunomodulatory	O
recombinant	O
fusion	O
protein	O
composed	O
of	O
the	O
first	O
extracellular	O
domain	O
of	O
LFA	B-geneY
-	I-geneY
3	E-geneY
fused	O
to	O
the	O
human	B-geneN
IgG1	I-geneN
hinge	I-geneN
,	I-geneN
C	I-geneN
(	I-geneN
H	I-geneN
)	I-geneN
2	I-geneN
,	I-geneN
and	I-geneN
C	I-geneN
(	I-geneN
H	I-geneN
)	I-geneN
3	I-geneN
domains	E-geneN
,	O
has	O
recently	O
been	O
shown	O
in	O
phase	O
II	O
and	O
III	O
clinical	O
trials	O
to	O
safely	O
reduce	O
disease	O
expression	O
in	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
.	O

Alefacept	S-geneY
modulates	O
the	O
function	O
of	O
and	O
selectively	O
induces	O
apoptosis	O
of	O
CD2	O
(	O
+	O
)	O
human	O
memory	O
-	O
effector	O
T	O
cells	O
in	O
vivo	O
.	O

We	O
have	O
sought	O
to	O
gain	O
further	O
understanding	O
of	O
the	O
mechanisms	O
of	O
action	O
that	O
influence	O
the	O
biological	O
activity	O
of	O
alefacept	S-geneY
and	O
may	O
contribute	O
to	O
its	O
efficacy	O
and	O
patient	O
responsiveness	O
.	O

Specifically	O
evaluated	O
is	O
the	O
ability	O
of	O
alefacept	S-geneY
to	O
activate	O
intracellular	O
signals	O
mediated	O
via	O
CD2	S-geneY
and	O
/	O
or	O
Fc	B-geneN
gamma	I-geneN
RIII	E-geneN
(	O
CD16	S-geneN
)	O
.	O

Experimentation	O
using	O
isoforms	O
of	O
alefacept	S-geneY
engineered	O
to	O
have	O
amino	B-chem
acid	E-chem
substitutions	O
in	O
the	O
IgG1	B-geneN
C	I-geneN
(	I-geneN
H	I-geneN
)	I-geneN
2	I-geneN
domain	E-geneN
that	O
impact	O
Fc	B-geneN
gamma	I-geneN
R	E-geneN
binding	O
indicate	O
that	O
alefacept	S-geneY
mediates	O
cognate	O
interactions	O
between	O
cells	O
expressing	O
human	B-geneY
CD2	E-geneY
and	O
CD16	S-geneN
to	O
activate	O
cells	O
,	O
e.g	O
.	O
,	O
increase	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
phosphorylation	O
,	O
up	O
-	O
regulate	O
cell	O
surface	O
expression	O
of	O
the	O
activation	O
marker	O
CD25	S-geneY
,	O
and	O
induce	O
release	O
of	O
granzyme	B-geneY
B	E-geneY
.	O

In	O
the	O
systems	O
used	O
,	O
this	O
signaling	O
is	O
shown	O
to	O
require	O
binding	O
to	O
CD2	S-geneY
and	O
CD16	S-geneN
and	O
be	O
mediated	O
through	O
CD16	S-geneN
,	O
but	O
not	O
CD2	S-geneY
.	O

Experimentation	O
using	O
human	B-geneY
CD2	E-geneY
-	O
transgenic	O
mice	O
and	O
isoforms	O
of	O
alefacept	S-geneY
confirmed	O
the	O
requirement	O
for	O
Fc	B-geneN
gamma	I-geneN
R	E-geneN
binding	O
for	O
detection	O
of	O
the	O
pharmacological	O
effects	O
of	O
alefacept	O
in	O
vivo	O
.	O

Thus	O
alefacept	S-geneY
acts	O
as	O
an	O
effector	O
molecule	O
,	O
mediating	O
cognate	O
interactions	O
to	O
activate	O
Fc	O
gamma	O
R	O
(	O
+	O
)	O
cells	O
(	O
e.g	O
.	O
,	O
NK	O
cells	O
)	O
to	O
induce	O
apoptosis	O
of	O
sensitive	O
CD2	O
(	O
+	O
)	O
target	O
cells	O
.	O

Controlled	O
Assembly	O
of	O
Gold	O
Nanoparticles	O
through	O
Antibody	O
Recognition	O
:	O
Study	O
and	O
Utilizing	O
the	O
Effect	O
of	O
Particle	O
Size	O
on	O
Interparticle	O
Distance	O
.	O

An	O
assembly	O
of	O
gold	O
nanoparticle	O
through	O
the	O
recognition	O
of	O
unmodified	O
antibody	O
was	O
developed	O
.	O

The	O
use	O
of	O
peptide	O
(	O
Cys	B-geneN
-	I-geneN
Ala	I-geneN
-	I-geneN
Leu	I-geneN
-	I-geneN
Asn	I-geneN
-	I-geneN
Asn	E-geneN
)	O
as	O
ligands	O
to	O
stabilize	O
and	O
functionalize	O
gold	O
nanoparticles	O
provides	O
technical	O
and	O
operational	O
convenience	O
.	O

These	O
peptide	O
-	O
capped	O
particles	O
in	O
different	O
sizes	O
are	O
recognized	O
by	O
antibody	O
and	O
assembly	O
to	O
form	O
dimers	O
and	O
expanded	O
hybrid	O
material	O
by	O
controlling	O
the	O
conditions	O
.	O

The	O
interparticle	O
spacing	O
of	O
these	O
assemblies	O
was	O
well	O
studied	O
with	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
measurements	O
,	O
and	O
it	O
was	O
found	O
that	O
the	O
interparticle	O
spacing	O
is	O
inversely	O
dependent	O
on	O
the	O
particle	O
size	O
.	O

This	O
relationship	O
of	O
interparticle	O
spacing	O
and	O
particle	O
size	O
is	O
closely	O
related	O
to	O
the	O
structure	O
of	O
antibody	O
linker	O
.	O

Therefore	O
,	O
analyzing	O
the	O
interparticle	O
spacing	O
of	O
assemblies	O
can	O
reveal	O
the	O
equilibrium	O
configuration	O
of	O
IgG	S-geneN
.	O

Based	O
on	O
the	O
investigation	O
,	O
the	O
Fab	O
-	O
Fab	O
angle	O
of	O
IgG	S-geneN
is	O
obtained	O
to	O
be	O
≈	O
102°	O
and	O
the	O
Fab	O
arms	O
are	O
≈	O
7.8	O
nm	O
.	O

These	O
results	O
provide	O
new	O
experimental	O
data	O
on	O
the	O
structure	O
of	O
flexible	O
IgG	S-geneN
.	O

Phenelzine	S-chem-C4-1
causes	O
an	O
increase	O
in	O
brain	O
ornithine	O
that	O
is	O
prevented	O
by	O
prior	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibition	O
.	O

Phenelzine	S-chem-C4-1
(	O
PLZ	S-chem-C4-1
)	O
,	O
a	O
nonselective	O
irreversible	O
inhibitor	O
of	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
(	O
MAO	S-geneN-C4-2
)	O
,	O
also	O
inhibits	O
GABA	B-geneY-C4-2
-	I-geneY-C4-2
transaminase	E-geneY-C4-2
(	O
GABA	B-geneY-C4-2
-	I-geneY-C4-2
T	E-geneY-C4-2
)	O
,	O
markedly	O
increasing	O
brain	O
GABA	S-chem
levels	O
.	O

PLZ	S-chem-C9-1
is	O
also	O
a	O
substrate	O
for	O
MAO	S-geneN-C9-2
,	O
and	O
studies	O
suggest	O
that	O
a	O
metabolite	O
formed	O
by	O
the	O
action	O
of	O
this	O
enzyme	O
on	O
PLZ	S-chem
may	O
be	O
responsible	O
for	O
the	O
increase	O
in	O
GABA	S-chem
observed	O
.	O

We	O
have	O
recently	O
found	O
that	O
PLZ	S-chem
also	O
elevates	O
brain	O
ornithine	S-chem
(	O
ORN	S-chem
)	O
,	O
an	O
amino	B-chem
acid	E-chem
precursor	O
to	O
both	O
glutamate	S-chem
(	O
and	O
GABA	S-chem
)	O
and	O
the	O
polyamines	S-chem
,	O
and	O
have	O
conducted	O
dose	O
-	O
and	O
time	O
-	O
response	O
studies	O
on	O
this	O
effect	O
.	O

Rats	O
were	O
treated	O
with	O
vehicle	O
or	O
PLZ	S-chem
doses	O
(	O
7.5	O
,	O
15	O
or	O
30	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
and	O
brains	O
were	O
collected	O
3	O
h	O
later	O
.	O

In	O
the	O
time	O
-	O
response	O
study	O
,	O
animals	O
were	O
treated	O
with	O
vehicle	O
or	O
PLZ	S-chem
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
and	O
brains	O
were	O
collected	O
1	O
-	O
24	O
h	O
later	O
.	O

To	O
determine	O
whether	O
a	O
metabolite	O
formed	O
by	O
the	O
action	O
of	O
MAO	S-geneN
on	O
PLZ	S-chem
may	O
be	O
responsible	O
for	O
the	O
elevation	O
in	O
brain	O
ORN	S-chem
observed	O
,	O
animals	O
were	O
pretreated	O
with	O
vehicle	O
or	O
the	O
MAO	S-geneN-C4-2
inhibitor	O
tranylcypromine	S-chem-C4-1
(	O
TCP	S-chem-C4-1
)	O
before	O
vehicle	O
or	O
PLZ	S-chem
(	O
15	O
mg	O
/	O
kg	O
)	O
,	O
and	O
brains	O
collected	O
3	O
h	O
later	O
.	O

ORN	S-chem
levels	O
(	O
measured	O
by	O
an	O
HPLC	O
procedure	O
)	O
were	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
increased	O
in	O
PLZ	S-chem
-	O
treated	O
animals	O
,	O
with	O
levels	O
reaching	O
approximately	O
650	O
%	O
of	O
control	O
at	O
6	O
and	O
12	O
h	O
.	O

Pretreatment	O
with	O
TCP	S-chem
completely	O
abolished	O
the	O
PLZ	S-chem
-	O
induced	O
increase	O
in	O
brain	O
ORN	S-chem
,	O
suggesting	O
,	O
as	O
with	O
GABA	S-chem
,	O
that	O
a	O
metabolite	O
of	O
PLZ	S-chem-C9-1
formed	O
by	O
the	O
action	O
of	O
MAO	S-geneN-C9-2
is	O
responsible	O
for	O
the	O
elevation	O
of	O
brain	O
ORN	S-chem
observed	O
.	O

The	O
possible	O
contribution	O
of	O
increased	O
ORN	S-chem
to	O
therapeutic	O
and	O
/	O
or	O
neuroprotective	O
properties	O
of	O
PLZ	S-chem
is	O
discussed	O
.	O

Activation	O
of	O
ALDH2	S-geneY-C3-2
with	O
ethanol	S-chem-C3-1
attenuates	O
diabetes	O
induced	O
myocardial	O
injury	O
in	O
rats	O
.	O

This	O
study	O
assessed	O
changes	O
in	O
myocardial	O
ALDH2	S-geneY
expression	O
in	O
the	O
diabetic	O
rat	O
,	O
in	O
particular	O
the	O
diabetic	O
rat	O
pretreated	O
with	O
ALDH2	S-geneY-C3-2
activator	O
ethanol	S-chem-C3-1
(	O
EtOH	S-chem-C3-1
)	O
.	O

The	O
rats	O
were	O
divided	O
into	O
six	O
groups	O
:	O
control	O
,	O
EtOH	S-chem
control	O
,	O
diabetic	O
rat	O
at	O
4th	O
week	O
(	O
DM4W	O
)	O
,	O
8th	O
week	O
(	O
DM8W	O
)	O
,	O
12th	O
week	O
(	O
DM12W	O
)	O
and	O
EtOH	S-chem
+	O
DM8W	O
groups	O
.	O

Compared	O
with	O
control	O
group	O
,	O
fasting	O
blood	O
glucose	S-chem
(	O
FBG	O
)	O
and	O
glycosylated	B-geneN
hemoglobin	E-geneN
(	O
HbA1c	S-geneN
)	O
levels	O
were	O
increased	O
in	O
DM	O
groups	O
.	O

HbA1c	S-geneN
level	O
in	O
DM12W	O
group	O
was	O
higher	O
than	O
in	O
DM4W	O
group	O
,	O
HbA1c	S-geneN-C4-2
level	O
in	O
EtOH	S-chem-C4-1
+	O
DM8W	O
group	O
was	O
lower	O
than	O
in	O
DM8W	O
group	O
.	O

Compared	O
with	O
control	O
group	O
,	O
there	O
were	O
no	O
changes	O
of	O
LVDP	O
,	O
HR	O
and	O
±dp	O
/	O
dtmax	O
in	O
DM4W	O
group	O
,	O
but	O
there	O
were	O
decreased	O
in	O
DM8W	O
and	O
DM12W	O
groups	O
,	O
and	O
increased	O
in	O
the	O
EtOH	S-chem
+	O
DM8W	O
group	O
.	O

In	O
DM	O
groups	O
,	O
SOD	S-geneN
activity	O
,	O
ALDH2	S-geneY
mRNA	O
and	O
protein	O
levels	O
were	O
reduced	O
,	O
MDA	S-chem
content	O
was	O
increased	O
compared	O
with	O
control	O
group	O
;	O
which	O
decreased	O
further	O
as	O
diabetes	O
progressed	O
.	O

Compared	O
with	O
DM8W	O
group	O
,	O
SOD	S-geneN-C3-2
and	O
ALDH2	S-geneY-C3-2
in	O
EtOH	S-chem-C3-1
+	O
DM8W	O
group	O
was	O
increased	O
,	O
MDA	S-chem
was	O
decreased	O
.	O

Our	O
results	O
indicated	O
with	O
the	O
development	O
of	O
diabetes	O
,	O
myocardial	O
ALDH2	S-geneY
expression	O
was	O
further	O
decreased	O
accompanying	O
decreased	O
ventricular	O
function	O
.	O

However	O
,	O
activation	O
of	O
ALDH2	S-geneY
can	O
decrease	O
diabetes	O
induced	O
myocardial	O
injury	O
.	O

ALDH2	S-geneY
may	O
be	O
one	O
key	O
endogenous	O
cardiac	O
protective	O
factor	O
in	O
diabetic	O
individuals	O
.	O

Structures	O
and	O
cytotoxic	O
evaluation	O
of	O
new	O
and	O
known	O
acyclic	O
Ene	O
-	O
Ynes	O
from	O
an	O
American	O
Samoa	O
Petrosia	O
sp	O
.	O
Sponge	O
.	O

Four	O
new	O
compounds	O
,	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
petrosynoic	I-chem
acids	I-chem
A	I-chem
-	I-chem
D	E-chem
(	O
1	O
-	O
4	O
)	O
,	O
and	O
five	O
known	O
congeners	O
,	O
pellynols	B-chem
A	I-chem
(	I-chem
5	I-chem
)	I-chem
,	I-chem
C	I-chem
(	I-chem
6	I-chem
)	I-chem
,	I-chem
D	I-chem
(	I-chem
7	I-chem
)	I-chem
,	I-chem
F	I-chem
(	I-chem
8	I-chem
)	I-chem
,	I-chem
and	I-chem
I	E-chem
(	O
9	O
)	O
,	O
were	O
isolated	O
from	O
a	O
Petrosia	O
sp	O
.	O
marine	O
sponge	O
collected	O
in	O
American	O
Samoa	O
.	O

Isolation	O
work	O
was	O
guided	O
by	O
cytotoxicity	O
against	O
human	O
lung	O
cancer	O
cells	O
(	O
H460	O
)	O
.	O

The	O
structures	O
of	O
the	O
C31	B-chem
-	I-chem
C33	I-chem
polyacetylenes	E-chem
(	O
1	O
-	O
9	O
)	O
were	O
determined	O
on	O
the	O
basis	O
of	O
1D	O
-	O
and	O
2D	O
-	O
NMR	O
analysis	O
,	O
mass	O
spectrometry	O
,	O
and	O
comparison	O
of	O
specific	O
rotation	O
values	O
.	O

Compounds	O
1	O
-	O
9	O
were	O
found	O
to	O
be	O
broadly	O
cytotoxic	O
with	O
limited	O
selectivity	O
for	O
cancer	O
cells	O
,	O
as	O
they	O
were	O
all	O
moderately	O
active	O
against	O
the	O
A2058	O
(	O
melanoma	O
)	O
,	O
H522	O
-	O
T1	O
(	O
lung	O
)	O
,	O
and	O
H460	O
(	O
lung	O
)	O
human	O
cancer	O
cell	O
lines	O
as	O
well	O
as	O
IMR	O
-	O
90	O
quiescent	O
human	O
fibroblast	O
cells	O
.	O

Crystal	O
structure	O
of	O
prostate	B-geneY
-	I-geneY
specific	I-geneY
membrane	I-geneY
antigen	E-geneY
,	O
a	O
tumor	O
marker	O
and	O
peptidase	S-geneN
.	O

Prostate	B-geneY
-	I-geneY
specific	I-geneY
membrane	I-geneY
antigen	E-geneY
(	O
PSMA	S-geneY
)	O
is	O
highly	O
expressed	O
in	O
prostate	O
cancer	O
cells	O
and	O
nonprostatic	O
solid	O
tumor	O
neovasculature	O
and	O
is	O
a	O
target	O
for	O
anticancer	O
imaging	O
and	O
therapeutic	O
agents	O
.	O

PSMA	S-geneY-C9-2
acts	O
as	O
a	O
glutamate	B-geneN-C9-2
carboxypeptidase	E-geneN-C9-2
(	O
GCPII	S-geneY-C9-2
)	O
on	O
small	O
molecule	O
substrates	O
,	O
including	O
folate	S-chem-C9-1
,	O
the	O
anticancer	O
drug	O
methotrexate	S-chem-C9-1
,	O
and	O
the	O
neuropeptide	O
N	B-chem-C9-1
-	I-chem-C9-1
acetyl	I-chem-C9-1
-	I-chem-C9-1
l	I-chem-C9-1
-	I-chem-C9-1
aspartyl	I-chem-C9-1
-	I-chem-C9-1
l	I-chem-C9-1
-	I-chem-C9-1
glutamate	E-chem-C9-1
.	O

Here	O
we	O
present	O
the	O
3.5	O
-	O
A	O
crystal	O
structure	O
of	O
the	O
PSMA	B-geneN
ectodomain	E-geneN
,	O
which	O
reveals	O
a	O
homodimer	O
with	O
structural	O
similarity	O
to	O
transferrin	B-geneN
receptor	E-geneN
,	O
a	O
receptor	O
for	O
iron	S-chem
-	O
loaded	O
transferrin	S-geneY
that	O
lacks	O
protease	S-geneN
activity	O
.	O

Unlike	O
transferrin	B-geneN
receptor	E-geneN
,	O
the	O
protease	B-geneN
domain	E-geneN
of	O
PSMA	S-geneY
contains	O
a	O
binuclear	O
zinc	S-chem
site	O
,	O
catalytic	O
residues	O
,	O
and	O
a	O
proposed	O
substrate	O
-	O
binding	O
arginine	S-chem
patch	O
.	O

Elucidation	O
of	O
the	O
PSMA	S-geneY-C9-2
structure	O
combined	O
with	O
docking	O
studies	O
and	O
a	O
proposed	O
catalytic	O
mechanism	O
provides	O
insight	O
into	O
the	O
recognition	O
of	O
inhibitors	O
and	O
the	O
natural	O
substrate	O
N	B-chem-C9-1
-	I-chem-C9-1
acetyl	I-chem-C9-1
-	I-chem-C9-1
l	I-chem-C9-1
-	I-chem-C9-1
aspartyl	I-chem-C9-1
-	I-chem-C9-1
l	I-chem-C9-1
-	I-chem-C9-1
glutamate	E-chem-C9-1
.	O

The	O
PSMA	S-geneY
structure	O
will	O
facilitate	O
development	O
of	O
chemotherapeutics	O
,	O
cancer	O
-	O
imaging	O
agents	O
,	O
and	O
agents	O
for	O
treatment	O
of	O
neurological	O
disorders	O
.	O

ATR	S-geneY
regulates	O
a	O
G2	O
-	O
phase	O
cell	O
-	O
cycle	O
checkpoint	O
in	O
Arabidopsis	O
thaliana	O
.	O

Ataxia	B-geneY
telangiectasia	I-geneY
-	I-geneY
mutated	I-geneY
and	I-geneY
Rad3	I-geneY
-	I-geneY
related	E-geneY
(	O
ATR	S-geneY
)	O
plays	O
a	O
central	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
,	O
transmitting	O
DNA	O
damage	O
signals	O
to	O
downstream	O
effectors	O
of	O
cell	O
-	O
cycle	O
progression	O
.	O

In	O
animals	O
,	O
ATR	S-geneY
is	O
an	O
essential	O
gene	O
.	O

Here	O
,	O
we	O
find	O
that	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
atr	S-geneY
-	O
/	O
-	O
mutants	O
were	O
viable	O
,	O
fertile	O
,	O
and	O
phenotypically	O
wild	O
-	O
type	O
in	O
the	O
absence	O
of	O
exogenous	O
DNA	O
damaging	O
agents	O
but	O
exhibit	O
altered	O
expression	O
of	O
AtRNR1	S-geneY
(	O
ribonucleotide	B-geneY
reductase	I-geneY
large	I-geneY
subunit	E-geneY
)	O
and	O
alteration	O
of	O
some	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
.	O
atr	S-geneY
mutants	O
were	O
hypersensitive	O
to	O
hydroxyurea	S-chem
(	O
HU	S-chem
)	O
,	O
aphidicolin	S-chem
,	O
and	O
UV	O
-	O
B	O
light	O
but	O
only	O
mildly	O
sensitive	O
to	O
gamma	O
-	O
radiation	O
.	O

G2	O
arrest	O
was	O
observed	O
in	O
response	O
to	O
gamma	O
-	O
irradiation	O
in	O
both	O
wild	O
-	O
type	O
and	O
atr	S-geneY
plants	O
,	O
albeit	O
with	O
slightly	O
different	O
kinetics	O
,	O
suggesting	O
that	O
ATR	S-geneY
plays	O
a	O
secondary	O
role	O
in	O
response	O
to	O
double	O
-	O
strand	O
breaks	O
.	O

G2	O
arrest	O
also	O
was	O
observed	O
in	O
wild	O
-	O
type	O
plants	O
in	O
response	O
to	O
aphidicolin	S-chem
but	O
was	O
defective	O
in	O
atr	S-geneY
mutants	O
,	O
resulting	O
in	O
compaction	O
of	O
nuclei	O
and	O
subsequent	O
cell	O
death	O
.	O

By	O
contrast	O
,	O
HU	O
-	O
treated	O
wild	O
-	O
type	O
and	O
atr	S-geneY
plants	O
arrested	O
in	O
G1	O
and	O
showed	O
no	O
obvious	O
signs	O
of	O
cell	O
death	O
.	O

We	O
propose	O
that	O
,	O
in	O
plants	O
,	O
HU	O
invokes	O
a	O
novel	O
checkpoint	O
responsive	O
to	O
low	O
levels	O
of	O
deoxynucleotide	B-chem
triphosphates	E-chem
.	O

These	O
results	O
demonstrate	O
the	O
important	O
role	O
of	O
cell	O
-	O
cycle	O
checkpoints	O
in	O
the	O
ability	O
of	O
plant	O
cells	O
to	O
sense	O
and	O
cope	O
with	O
problems	O
associated	O
with	O
DNA	O
replication	O
.	O

Neural	O
tube	O
defects	O
and	O
folate	S-chem
pathway	O
genes	O
:	O
family	O
-	O
based	O
association	O
tests	O
of	O
gene	O
-	O
gene	O
and	O
gene	O
-	O
environment	O
interactions	O
.	O

BACKGROUND	O
:	O
Folate	S-chem
metabolism	O
pathway	O
genes	O
have	O
been	O
examined	O
for	O
association	O
with	O
neural	O
tube	O
defects	O
(	O
NTDs	O
)	O
because	O
folic	B-chem
acid	E-chem
supplementation	O
reduces	O
the	O
risk	O
of	O
this	O
debilitating	O
birth	O
defect	O
.	O

Most	O
studies	O
addressed	O
these	O
genes	O
individually	O
,	O
often	O
with	O
different	O
populations	O
providing	O
conflicting	O
results	O
.	O

OBJECTIVES	O
:	O
Our	O
study	O
evaluates	O
several	O
folate	S-chem
pathway	O
genes	O
for	O
association	O
with	O
human	O
NTDs	O
,	O
incorporating	O
an	O
environmental	O
cofactor	O
:	O
maternal	O
folate	S-chem
supplementation	O
.	O

METHODS	O
:	O
In	O
304	O
Caucasian	O
American	O
NTD	O
families	O
with	O
myelomeningocele	O
or	O
anencephaly	O
,	O
we	O
examined	O
28	O
polymorphisms	O
in	O
11	O
genes	O
:	O
folate	B-geneY
receptor	I-geneY
1	E-geneY
,	O
folate	B-geneY
receptor	I-geneY
2	E-geneY
,	O
solute	B-geneY
carrier	I-geneY
family	I-geneY
19	I-geneY
member	I-geneY
1	E-geneY
,	O
transcobalamin	B-geneY
II	E-geneY
,	O
methylenetetrahydrofolate	B-geneY
dehydrogenase	I-geneY
1	E-geneY
,	O
serine	B-geneY
hydroxymethyl	I-geneY
-	I-geneY
transferase	I-geneY
1	E-geneY
,	I-chem
5,10	B-geneY
-	I-geneY
methylenetetrahydrofolate	I-geneY
reductase	E-geneY
(	O
MTHFR	S-geneY
)	O
,	O
5	B-geneY
-	I-geneY
methyltetrahydrofolate	I-geneY
-	I-geneY
homo	I-geneY
-	I-geneY
cysteine	I-geneY
methyltransferase	E-geneY
,	O
5	B-geneY
-	I-geneY
methyltetrahydrofolate	I-geneY
-	I-geneY
homocysteine	I-geneY
methyltransferase	I-geneY
reductase	E-geneY
,	O
betaine	B-geneY
-	I-geneY
homocysteine	I-geneY
methyltransferase	E-geneY
(	O
BHMT	S-geneY
)	O
,	O
and	O
cystathionine	B-geneY
-	I-geneY
beta	I-geneY
-	I-geneY
synthase	E-geneY
.	O

RESULTS	O
:	O
Only	O
single	O
nucleotide	S-chem
polymorphisms	O
(	O
SNPs	O
)	O
in	O
BHMT	S-geneY
were	O
significantly	O
associated	O
in	O
the	O
overall	O
data	O
set	O
;	O
this	O
significance	O
was	O
strongest	O
when	O
mothers	O
took	O
folate	S-chem
-	O
containing	O
nutritional	O
supplements	O
before	O
conception	O
.	O

The	O
BHMT	S-geneY
SNP	O
rs3733890	O
was	O
more	O
significant	O
when	O
the	O
data	O
were	O
stratified	O
by	O
preferential	O
transmission	O
of	O
the	O
MTHFR	S-geneY
rs1801133	O
thermolabile	O
T	O
allele	O
from	O
parent	O
to	O
offspring	O
.	O

Other	O
SNPs	O
in	O
folate	S-chem
pathway	O
genes	O
were	O
marginally	O
significant	O
in	O
some	O
analyses	O
when	O
stratified	O
by	O
maternal	O
supplementation	O
,	O
MTHFR	S-geneY
,	O
or	O
BHMT	S-geneY
allele	O
transmission	O
.	O

CONCLUSIONS	O
:	O
BHMT	S-geneY
rs3733890	O
is	O
significantly	O
associated	O
in	O
our	O
data	O
set	O
,	O
whereas	O
MTHFR	S-geneY
rs1801133	O
is	O
not	O
a	O
major	O
risk	O
factor	O
.	O

Further	O
investigation	O
of	O
folate	S-chem
and	O
methionine	S-chem
cycle	O
genes	O
will	O
require	O
extensive	O
SNP	O
genotyping	O
and	O
/	O
or	O
resequencing	O
to	O
identify	O
novel	O
variants	O
,	O
inclusion	O
of	O
environmental	O
factors	O
,	O
and	O
investigation	O
of	O
gene	O
-	O
gene	O
interactions	O
in	O
large	O
data	O
sets	O
.	O

5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
,	O
alpha2A	O
/	O
2C	O
-	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
alpha1	B-geneN
-	I-geneN
adrenoceptors	E-geneN
mediate	O
the	O
external	O
carotid	O
vasoconstriction	O
to	O
ergotamine	S-chem
in	O
vagosympathectomised	O
dogs	O
.	O

It	O
has	O
previously	O
been	O
suggested	O
that	O
ergotamine	S-chem
produces	O
external	O
carotid	O
vasoconstriction	O
in	O
vagosympathectomised	O
dogs	O
via	O
5	B-geneN
-	I-geneN
HT1B	I-geneN
/	I-geneN
1D	E-geneN
receptors	O
and	O
alpha2	B-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

The	O
present	O
study	O
has	O
reanalysed	O
this	O
suggestion	O
by	O
using	O
more	O
selective	O
antagonists	O
alone	O
and	O
in	O
combination	O
.	O

Fifty	O
-	O
two	O
anaesthetised	O
dogs	O
were	O
prepared	O
for	O
ultrasonic	O
measurements	O
of	O
external	O
carotid	O
blood	O
flow	O
.	O

The	O
animals	O
were	O
divided	O
into	O
thirteen	O
groups	O
(	O
n	O
=	O
4	O
each	O
)	O
receiving	O
an	O
i.v	O
.	O
bolus	O
injection	O
of	O
,	O
either	O
physiological	O
saline	O
(	O
0.3	O
ml	O
/	O
kg	O
;	O
control	O
)	O
,	O
or	O
the	O
antagonists	O
SB224289	S-chem-C6-1
(	O
300	O
microg	O
/	O
kg	O
;	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1B	E-geneY-C6-2
)	O
,	O
BRL15572	S-chem-C6-1
(	O
300	O
microg	O
/	O
kg	O
;	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT1D	E-geneY-C6-2
)	O
,	O
rauwolscine	S-chem
(	O
300	O
microg	O
/	O
kg	O
;	O
alpha2	O
)	O
,	O
SB224289	S-chem
+	O
BRL15572	S-chem
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
SB224289	S-chem
+	O
rauwolscine	S-chem
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
BRL15572	S-chem
+	O
rauwolscine	S-chem
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
rauwolscine	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
;	O
alpha1	O
)	O
,	O
SB224289	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
)	O
,	O
SB224289	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
rauwolscine	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
)	O
,	O
SB224289	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
BRL44408	S-chem
(	O
1,000	O
microg	O
/	O
kg	O
;	O
alpha2A	O
)	O
,	O
SB224289	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
imiloxan	S-chem
(	O
1,000	O
microg	O
/	O
kg	O
;	O
alpha2B	O
)	O
,	O
or	O
SB224289	S-chem
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	S-chem
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
MK912	S-chem
(	O
300	O
microg	O
/	O
kg	O
;	O
alpha2C	O
)	O
.	O

Each	O
group	O
received	O
consecutive	O
1	O
-	O
min	O
intracarotid	O
infusions	O
of	O
ergotamine	S-chem
(	O
0.56	O
,	O
1	O
,	O
1.8	O
,	O
3.1	O
,	O
5.6	O
,	O
10	O
and	O
18	O
microg	O
/	O
min	O
)	O
,	O
following	O
a	O
cumulative	O
schedule	O
.	O

In	O
saline	O
-	O
pretreated	O
animals	O
,	O
ergotamine	S-chem
induced	O
dose	O
-	O
dependent	O
decreases	O
in	O
external	O
carotid	O
blood	O
flow	O
without	O
affecting	O
arterial	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

These	O
control	O
responses	O
were	O
:	O
unaffected	O
by	O
SB224289	S-chem
,	O
BRL15572	S-chem
,	O
rauwolscine	S-chem
or	O
the	O
combinations	O
of	O
SB224289	S-chem
+	O
BRL15572	S-chem
,	O
BRL15572	S-chem
+	O
rauwolscine	S-chem
,	O
rauwolscine	S-chem
+	O
prazosin	S-chem
,	O
SB224289	S-chem
+	O
prazosin	S-chem
,	O
or	O
SB224289	S-chem
+	O
prazosin	S-chem
+	O
imiloxan	S-chem
;	O
slightly	O
blocked	O
by	O
SB224289	S-chem
+	O
rauwolscine	S-chem
;	O
and	O
markedly	O
blocked	O
by	O
SB224289	S-chem
+	O
rauwolscine	S-chem
+	O
prazosin	S-chem
,	O
SB224289	S-chem
+	O
prazosin	S-chem
+	O
BRL44408	S-chem
or	O
SB224289	S-chem
+	O
prazosin	S-chem
+	O
MK912	S-chem
.	O

Thus	O
,	O
the	O
cranio	O
-	O
selective	O
vasoconstriction	O
elicited	O
by	O
ergotamine	S-chem
in	O
dogs	O
is	O
predominantly	O
mediated	O
by	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
as	O
well	O
as	O
alpha2A	B-geneN
/	I-geneN
2C	I-geneN
-	I-geneN
adrenoceptor	E-geneN
subtypes	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
alpha1	B-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

Pulmonary	O
delivery	O
of	O
an	O
aerosolized	O
recombinant	O
human	B-geneY
butyrylcholinesterase	E-geneY
pretreatment	O
protects	O
against	O
aerosolized	O
paraoxon	S-chem
in	O
macaques	O
.	O

Butyrylcholinesterase	S-geneY
(	O
BChE	S-geneY
)	O
is	O
the	O
leading	O
pretreatment	O
candidate	O
against	O
exposure	O
to	O
organophosphates	S-chem
(	O
OPs	O
)	O
,	O
which	O
pose	O
an	O
ever	O
increasing	O
public	O
and	O
military	O
health	O
.	O

Since	O
respiratory	O
failure	O
is	O
the	O
primary	O
cause	O
of	O
death	O
following	O
acute	O
OP	O
poisoning	O
,	O
an	O
inhaled	O
BChE	S-geneY
therapeutic	O
could	O
prove	O
highly	O
efficacious	O
in	O
preventing	O
acute	O
toxicity	O
as	O
well	O
as	O
the	O
associated	O
delayed	O
neuropathy	O
.	O

To	O
address	O
this	O
,	O
studies	O
have	O
been	O
performed	O
in	O
mice	O
and	O
macaques	O
using	O
Chinese	O
Hamster	O
Ovary	O
cells	O
(	O
CHO	O
)	O
-	O
derived	O
recombinant	O
(	O
r	O
)	O
BChE	S-geneY
delivered	O
by	O
the	O
pulmonary	O
route	O
,	O
to	O
examine	O
whether	O
the	O
deposition	O
of	O
both	O
macaque	O
(	O
Ma	O
)	O
and	O
human	O
(	O
Hu	O
)	O
rBChE	S-geneY
administered	O
as	O
aerosols	O
(	O
aer	O
)	O
favored	O
the	O
creation	O
and	O
retention	O
of	O
an	O
efficient	O
protective	O
``	O
pulmonary	O
bioshield	O
``	O
that	O
could	O
scavenge	O
incoming	O
(	O
inhaled	O
)	O
OPs	O
in	O
situ	O
thereby	O
preventing	O
entry	O
into	O
the	O
circulation	O
and	O
inhibition	O
of	O
plasma	O
BChE	O
and	O
AChE	O
on	O
red	O
blood	O
cells	O
(	O
RBC	O
-	I-geneY
AChE	O
)	O
and	O
in	O
cholinergic	O
synapses	O
.	O

In	O
contrast	O
to	O
parenteral	O
delivery	O
of	O
rBChE	S-geneY
,	O
which	O
currently	O
requires	O
posttranslational	O
modification	O
for	O
good	O
plasma	O
stability	O
,	O
an	O
unmodified	O
aer	O
-	O
rBChE	S-geneY
pretreatment	O
given	O
1	O
-	O
40h	O
prior	O
to	O
>	O
1	O
LD50	O
of	O
aer	O
-	O
paraoxon	S-chem-C3-1
(	O
Px	O
)	O
was	O
able	O
to	O
prevent	O
inhibition	O
of	O
circulating	O
cholinesterase	S-geneY-C3-2
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
show	O
protection	O
by	O
rBChE	S-geneY
against	O
a	O
pesticide	O
such	O
as	O
paraoxon	S-chem
when	O
delivered	O
directly	O
into	O
the	O
lung	O
and	O
bode	O
well	O
for	O
the	O
use	O
of	O
a	O
non	O
-	O
invasive	O
and	O
consumer	O
friendly	O
method	O
of	O
rHuBChE	S-geneY
delivery	O
as	O
a	O
human	O
treatment	O
to	O
counteract	O
OP	O
toxicity	O
.	O

[	O
Screening	O
of	O
short	O
peptides	O
binding	O
to	O
cell	O
surface	O
interleukin	B-geneY
-	I-geneY
2	I-geneY
receptor	I-geneY
alpha	I-geneY
chain	E-geneY
]	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
and	O
characterize	O
the	O
short	O
peptides	O
which	O
bind	O
specifically	O
to	O
interleukin	B-geneY
-	I-geneY
2	I-geneY
(	I-geneY
IL	I-geneY
-	I-geneY
2	I-geneY
)	I-geneY
receptor	I-geneY
alpha	I-geneY
chain	E-geneY
(	O
IL	B-geneY
-	I-geneY
2Ralpha	E-geneY
)	O
for	O
acquisition	O
of	O
small	O
antagonists	O
for	O
blocking	O
the	O
binding	O
of	O
IL	B-geneY
-	I-geneY
2	E-geneY
with	O
IL	B-geneY
-	I-geneY
2Ralpha	E-geneY
.	O

METHODS	O
:	O
12	O
-	O
mer	O
phage	O
displayed	O
peptide	O
library	O
was	O
screened	O
with	O
the	O
target	O
cells	O
of	O
MT	O
-	O
2	O
cells	O
which	O
expressed	O
IL	B-geneY
-	I-geneY
2Ralpha	E-geneY
at	O
high	O
levels	O
.	O

The	O
binding	O
phage	O
clones	O
were	O
eluted	O
by	O
anti	O
-	O
IL	B-geneY
-	I-geneY
2Ralpha	E-geneY
monoclonal	O
antibody	O
.	O

After	O
3	O
rounds	O
of	O
screening	O
,	O
the	O
positive	O
phage	O
clones	O
were	O
identified	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
immunohistochemistry	O
,	O
and	O
the	O
amino	B-chem
acid	E-chem
sequences	O
of	O
the	O
positive	O
clones	O
were	O
deduced	O
from	O
the	O
DNA	O
sequences	O
.	O

RESULTS	O
:	O
Seven	O
positive	O
clones	O
were	O
screened	O
out	O
of	O
the	O
17	O
phage	O
clones	O
bound	O
to	O
MT	O
-	O
2	O
cells	O
.	O

The	O
positive	O
clone	O
M15	O
could	O
bind	O
specifically	O
to	O
MT	O
-	O
2	O
cell	O
and	O
PHA	O
-	O
activated	O
peripheral	O
blood	O
monouclear	O
cells	O
.	O

Amino	B-chem
acid	E-chem
sequence	O
analysis	O
identified	O
6	O
sequences	O
,	O
all	O
of	O
which	O
contained	O
hydrophilic	O
residues	O
,	O
and	O
5	O
of	O
these	O
6	O
sequences	O
included	O
Tyr	S-chem
,	O
Phe	S-chem
and	O
Leu	S-chem
conservative	O
residues	O
.	O

CONCLUSION	O
:	O
The	O
peptide	O
sequences	O
containing	O
Tyr	S-chem
,	O
Phe	S-chem
conservative	O
residues	O
identified	O
in	O
this	O
study	O
can	O
bind	O
to	O
cell	O
surface	O
IL	B-geneY
-	I-geneY
2Ralpha	E-geneY
.	O

Cloning	O
,	O
functional	O
expression	O
and	O
brain	O
localization	O
of	O
a	O
novel	O
unconventional	O
outward	B-geneN
rectifier	I-geneN
K	I-geneN
+	I-geneN
channel	E-geneN
.	O

Human	B-geneY
TWIK	I-geneY
-	I-geneY
1	E-geneY
,	O
which	O
has	O
been	O
cloned	O
recently	O
,	O
is	O
a	O
new	O
structural	O
type	O
of	O
weak	O
inward	B-geneN
rectifier	I-geneN
K	I-geneN
+	I-geneN
channel	E-geneN
.	O

Here	O
we	O
report	O
the	O
structural	O
and	O
functional	O
properties	O
of	O
TREK	B-geneY
-	I-geneY
1	E-geneY
,	O
a	O
mammalian	B-geneY
TWIK	I-geneY
-	I-geneY
1	I-geneY
-	I-geneY
related	I-geneY
K	I-geneY
+	I-geneY
channel	E-geneY
.	O

Despite	O
a	O
low	O
amino	B-chem
acid	E-chem
identity	O
between	O
TWIK	B-geneY
-	I-geneY
1	E-geneY
and	O
TREK	B-geneY
-	I-geneY
1	E-geneY
(	O
approximately	O
28	O
%	O
)	O
,	O
both	O
channel	O
proteins	O
share	O
the	O
same	O
overall	O
structural	O
arrangement	O
consisting	O
of	O
two	O
pore	B-geneN
-	I-geneN
forming	I-geneN
domains	E-geneN
and	O
four	O
transmembrane	O
segments	O
(	O
TMS	O
)	O
.	O

This	O
structural	O
similarity	O
does	O
not	O
give	O
rise	O
to	O
a	O
functional	O
analogy	O
.	O

K	B-chem
+	E-chem
currents	O
generated	O
by	O
TWIK	B-geneY
-	I-geneY
1	E-geneY
are	O
inwardly	O
rectifying	O
while	O
K	B-chem
+	E-chem
currents	O
generated	O
by	O
TREK	B-geneY
-	I-geneY
1	E-geneY
are	O
outwardly	O
rectifying	O
.	O

These	O
channels	O
have	O
a	O
conductance	O
of	O
14	O
pS	O
.	O

TREK	B-geneY
-	I-geneY
1	E-geneY
currents	O
are	O
insensitive	O
to	O
pharmacological	O
agents	O
that	O
block	O
TWIK	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
activity	O
such	O
as	O
quinine	S-chem-C4-1
and	O
quinidine	S-chem-C4-1
.	O

Extensive	O
inhibitions	O
of	O
TREK	B-geneY
-	I-geneY
1	E-geneY
activity	O
are	O
observed	O
after	O
activation	O
of	O
protein	B-geneN
kinases	I-geneN
A	I-geneN
and	I-geneN
C	E-geneN
.	O

TREK	B-geneY
-	I-geneY
1	E-geneY
currents	O
are	O
sensitive	O
to	O
extracellular	O
K	B-chem
+	E-chem
and	O
Na	B-chem
+	E-chem
.	O

TREK	B-geneY
-	I-geneY
1	E-geneY
mRNA	O
is	O
expressed	O
in	O
most	O
tissues	O
and	O
is	O
particularly	O
abundant	O
in	O
the	O
lung	O
and	O
in	O
the	O
brain	O
.	O

Its	O
localization	O
in	O
this	O
latter	O
tissue	O
has	O
been	O
studied	O
by	O
in	O
situ	O
hybridization	O
.	O

TREK	B-geneY
-	I-geneY
1	E-geneY
expression	O
is	O
high	O
in	O
the	O
olfactory	O
bulb	O
,	O
hippocampus	O
and	O
cerebellum	O
.	O

These	O
results	O
provide	O
the	O
first	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
K	B-geneN
+	I-geneN
channel	E-geneN
family	O
with	O
four	O
TMS	O
and	O
two	O
pore	B-geneN
domains	E-geneN
in	O
the	O
nervous	O
system	O
of	O
mammals	O
.	O

They	O
also	O
show	O
that	O
different	O
members	O
in	O
this	O
structural	O
family	O
can	O
have	O
totally	O
different	O
functional	O
properties	O
.	O

Indoxyl	B-chem-C3-1
3	I-chem-C3-1
-	I-chem-C3-1
sulfate	E-chem-C3-1
stimulates	O
Th17	O
differentiation	O
enhancing	O
phosphorylation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Src	E-geneY-C3-2
and	O
STAT3	S-geneY-C3-2
to	O
worsen	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Although	O
AhR	S-geneY
activation	O
regulates	O
CD4T	O
cell	O
differentiation	O
,	O
how	O
it	O
works	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
in	O
vitro	O
Th17	O
differentiation	O
model	O
,	O
we	O
examined	O
effects	O
of	O
AhR	S-geneY-C3-2
activation	O
by	O
indoxyl	B-chem-C3-1
3	I-chem-C3-1
-	I-chem-C3-1
sulfate	E-chem-C3-1
(	O
I3S	S-chem-C3-1
)	O
,	O
a	O
uremic	O
toxin	O
,	O
on	O
Th17	O
differentiation	O
and	O
investigated	O
underlying	O
mechanisms	O
.	O

I3S	S-chem-C3-1
increased	O
expression	O
of	O
RORγt	S-geneY-C3-2
,	O
the	O
master	O
transcription	O
factor	O
for	O
Th17	O
differentiation	O
,	O
and	O
stimulated	O
Th17	O
differentiation	O
,	O
in	O
a	O
comparative	O
manner	O
as	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
,	O
a	O
prototypical	O
AhR	S-geneY
ligand	O
.	O

Activation	O
of	O
STAT3	S-geneY-C3-2
,	O
which	O
is	O
phosphorylated	O
by	O
the	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
6	E-geneY-C3-2
signaling	O
pathways	O
and	O
thus	O
is	O
necessary	O
for	O
Th17	O
differentiation	O
,	O
was	O
strongly	O
stimulated	O
by	O
I3S	S-chem-C3-1
and	O
TCDD	S-chem-C3-1
.	O

Phosphorylation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Src	E-geneY-C3-2
,	O
which	O
was	O
shown	O
to	O
be	O
activated	O
by	O
AhR	S-geneY
ligands	O
,	O
was	O
also	O
increased	O
by	O
I3S	S-chem-C3-1
and	O
TCDD	S-chem-C3-1
,	O
and	O
blocking	O
of	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Src	E-geneY-C4-2
activity	O
by	O
4	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
5	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
chlorophenyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
7	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
t	I-chem-C4-1
-	I-chem-C4-1
butyl	I-chem-C4-1
)	I-chem-C4-1
pyrazolo	I-chem-C4-1
[	I-chem-C4-1
3,4	I-chem-C4-1
-	I-chem-C4-1
d	I-chem-C4-1
]	I-chem-C4-1
pyrimidine	E-chem-C4-1
(	O
PP2	O
)	O
inhibited	O
phosphorylation	O
of	O
both	O
c	B-geneY-C4-2
-	I-geneY-C4-2
Src	E-geneY-C4-2
and	O
STAT3	S-geneY-C4-2
,	O
raising	O
a	O
possibility	O
that	O
stimulatory	O
activities	O
of	O
I3S	S-chem-C3-1
and	O
TCDD	S-chem-C3-1
on	O
Th17	O
differentiation	O
could	O
be	O
exerted	O
via	O
increased	O
phosphorylation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Src	E-geneY-C3-2
,	O
which	O
in	O
turn	O
stimulates	O
STAT3	S-geneY-C3-2
activation	O
.	O

Finally	O
,	O
we	O
found	O
that	O
I3S	S-chem-C3-1
worsened	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
which	O
is	O
primarily	O
mediated	O
by	O
Th17	O
cells	O
,	O
enhancing	O
the	O
frequency	O
of	O
IL	B-geneY-C3-2
-	I-geneY-C3-2
17	E-geneY-C3-2
-	O
producing	O
cells	O
in	O
draining	O
lymph	O
nodes	O
.	O

Genetic	O
polymorphisms	O
predisposing	O
to	O
hyperhomocysteinemia	O
in	O
cardiac	O
transplant	O
patients	O
.	O

Genetic	O
determinants	O
for	O
high	O
homocysteine	S-chem
(	O
Hcy	S-chem
)	O
levels	O
are	O
now	O
well	O
known	O
.	O

We	O
studied	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
Hcy	S-chem
-	O
regulating	O
genes	O
[	O
methylenetetrahydrofolate	B-geneY
reductase	E-geneY
(	O
MTHFR	S-geneY
)	O
C677T	S-geneN
and	O
A1298C	S-geneN
;	O
methionine	B-geneY
synthase	E-geneY
(	O
MS	S-geneY
)	O
A2756G	S-geneN
;	O
methionine	B-geneY
synthase	I-geneY
reductase	E-geneY
(	O
MTRR	S-geneY
)	O
A66G	S-geneN
]	O
in	O
relation	O
to	O
total	O
plasma	O
Hcy	S-chem
levels	O
,	O
transplant	O
coronary	O
artery	O
disease	O
and	O
thromboembolic	O
episodes	O
in	O
84	O
heart	O
transplant	O
patients	O
,	O
and	O
we	O
compared	O
the	O
incidence	O
of	O
these	O
polymorphisms	O
with	O
those	O
in	O
a	O
healthy	O
adult	O
controls	O
.	O

At	O
least	O
one	O
copy	O
of	O
the	O
G	O
allele	O
of	O
the	O
MTRR	S-geneY
A66G	S-geneN
SNP	O
was	O
found	O
in	O
a	O
significantly	O
greater	O
proportion	O
of	O
cardiac	O
transplant	O
(	O
CTX	O
)	O
recipients	O
compared	O
with	O
controls	O
(	O
94.0	O
%	O
vs	O
.	O

79.9	O
%	O
respectively	O
)	O
.	O

None	O
of	O
the	O
SNP	O
analyzed	O
were	O
correlated	O
with	O
total	O
Hcy	S-chem
plasma	O
levels	O
or	O
the	O
presence	O
of	O
transplant	O
coronary	O
artery	O
disease	O
.	O

However	O
,	O
MS	S-geneY
A2756G	S-geneN
was	O
significantly	O
associated	O
with	O
cobalamin	S-chem
levels	O
(	O
AA	O
genotype	O
:	O
290	O
+	O
/	O
-	O
122	O
pmol	O
/	O
l	O
;	O
AG	O
:	O
381	O
+	O
/	O
-	O
151	O
pmol	O
/	O
l	O
and	O
GG	O
:	O
415	O
+	O
/	O
-	O
100	O
pmol	O
/	O
l	O
)	O
,	O
as	O
was	O
MTRR	S-geneY
A66G	S-geneN
(	O
AA	O
:	O
478	O
+	O
/	O
-	O
219	O
pmol	O
/	O
l	O
,	O
AG	O
:	O
306	O
+	O
/	O
-	O
124	O
pmol	O
/	O
l	O
and	O
GG	O
:	O
306	O
+	O
/	O
-	O
123	O
pmol	O
/	O
l	O
)	O
.	O

MTRR	S-geneY
A66G	S-geneN
was	O
also	O
correlated	O
with	O
serum	O
folate	O
.	O

No	O
association	O
was	O
found	O
with	O
thromboembolic	O
events	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
the	O
G	O
allele	O
genotype	O
of	O
the	O
MTRR	S-geneY
A66G	S-geneN
in	O
CTX	O
patients	O
versus	O
controls	O
.	O

Differences	O
in	O
cobalamin	S-chem
and	O
folate	O
levels	O
with	O
the	O
MTRR	S-geneY
A66G	S-geneN
and	O
MS	S-geneY
A2756G	S-geneN
polymorphisms	O
were	O
noted	O
.	O

Thus	O
,	O
SNP	O
in	O
Hcy	S-chem
-	O
regulating	O
genes	O
may	O
be	O
important	O
determinants	O
of	O
vitamin	O
metabolism	O
in	O
CTX	O
,	O
raising	O
the	O
question	O
of	O
increased	O
vitamin	O
requirements	O
to	O
minimize	O
increased	O
plasma	O
Hcy	S-chem
in	O
this	O
high	O
-	O
risk	O
group	O
.	O

Tub	S-geneY
has	O
a	O
key	O
role	O
in	O
insulin	S-geneN
and	O
leptin	S-geneY
signaling	O
and	O
action	O
in	O
vivo	O
in	O
hypothalamic	O
nuclei	O
.	O

Mutation	O
of	O
tub	S-geneY
gene	O
in	O
mice	O
induces	O
obesity	O
,	O
suggesting	O
that	O
tub	S-geneY
could	O
be	O
an	O
important	O
regulator	O
of	O
energy	O
balance	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
insulin	S-geneN
,	O
leptin	S-geneY
,	O
and	O
obesity	O
can	O
modulate	O
Tub	S-geneY
in	O
vivo	O
in	O
hypothalamic	O
nuclei	O
,	O
and	O
we	O
investigated	O
possible	O
consequences	O
on	O
energy	O
balance	O
,	O
neuropeptide	O
expression	O
,	O
and	O
hepatic	O
glucose	S-chem
metabolism	O
.	O

Food	O
intake	O
,	O
metabolic	O
characteristics	O
,	O
signaling	O
proteins	O
,	O
and	O
neuropeptide	O
expression	O
were	O
measured	O
in	O
response	O
to	O
fasting	O
and	O
refeeding	O
,	O
intracerebroventricular	O
insulin	S-geneN
and	O
leptin	S-geneY
,	O
and	O
Tub	S-geneY
antisense	O
oligonucleotide	O
(	O
ASO	O
)	O
.	O

Tub	S-geneY
tyrosine	S-chem
phosphorylation	O
(	O
Tub	O
-	O
p	O
-	O
tyr	S-chem
)	O
is	O
modulated	O
by	O
nutritional	O
status	O
.	O

Tub	S-geneY
is	O
a	O
substrate	O
of	O
insulin	B-geneY
receptor	I-geneY
tyrosine	I-geneY
kinase	E-geneY
(	O
IRTK	S-geneY
)	O
and	O
leptin	B-geneY
receptor	E-geneY
(	O
LEPR	S-geneY
)	O
-	O
Janus	B-geneY
kinase	I-geneY
2	E-geneY
(	O
JAK2	S-geneY
)	O
in	O
hypothalamic	O
nuclei	O
.	O

After	O
leptin	S-geneY
or	O
insulin	S-geneN
stimulation	O
,	O
Tub	S-geneY
translocates	O
to	O
the	O
nucleus	O
.	O

Inhibition	O
of	O
Tub	S-geneY
expression	O
in	O
hypothalamus	O
by	O
ASO	O
increased	O
food	O
intake	O
,	O
fasting	O
blood	O
glucose	S-chem
,	O
and	O
hepatic	O
glucose	S-chem
output	O
,	O
decreased	O
O	B-chem
(	I-chem
2	I-chem
)	E-chem
consumption	O
,	O
and	O
blunted	O
the	O
effect	O
of	O
insulin	S-geneN
or	O
leptin	S-geneY
on	O
proopiomelanocortin	S-geneY
,	O
thyroid	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
,	O
melanin	B-geneY
-	I-geneY
concentrating	I-geneY
hormone	E-geneY
,	O
and	O
orexin	S-geneY
expression	O
.	O

In	O
hypothalamus	O
of	O
mice	O
administered	O
a	O
high	O
-	O
fat	O
diet	O
,	O
there	O
is	O
a	O
reduction	O
in	O
leptin	S-geneY
and	O
insulin	S-geneN
-	O
induced	O
Tub	S-geneY
-	O
p	O
-	O
tyr	S-chem
and	O
nuclear	O
translocation	O
,	O
which	O
is	O
reversed	O
by	O
reducing	O
protein	B-geneY
tyrosine	I-geneY
phosphatase	I-geneY
1B	E-geneY
expression	O
.	O

These	O
results	O
indicate	O
that	O
Tub	S-geneY
has	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
insulin	S-geneN
and	O
leptin	S-geneY
effects	O
on	O
food	O
intake	O
,	O
and	O
the	O
modulation	O
of	O
Tub	S-geneY
may	O
contribute	O
to	O
insulin	S-geneN
and	O
leptin	S-geneY
resistance	O
in	O
DIO	O
mice	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
potent	O
activator	O
of	O
p53	S-geneY
-	O
independent	O
cellular	O
senescence	O
via	O
a	O
small	O
-	O
molecule	O
screen	O
for	O
modifiers	O
of	O
the	O
integrated	O
stress	O
response	O
.	O

The	O
Integrated	O
Stress	O
Response	O
(	O
ISR	O
)	O
is	O
a	O
signaling	O
program	O
that	O
enables	O
cellular	O
adaptation	O
to	O
stressful	O
conditions	O
like	O
hypoxia	O
and	O
nutrient	O
deprivation	O
in	O
the	O
tumor	O
microenvironment	O
.	O

An	O
important	O
effector	O
of	O
the	O
ISR	O
is	O
activating	B-geneY
transcription	I-geneY
factor	I-geneY
4	E-geneY
(	O
ATF4	S-geneY
)	O
,	O
a	O
transcription	O
factor	O
that	O
regulates	O
genes	O
involved	O
in	O
redox	O
homeostasis	O
and	O
amino	B-chem
acid	E-chem
metabolism	O
and	O
transport	O
.	O

Because	O
both	O
inhibition	O
and	O
overactivation	O
of	O
the	O
ISR	O
can	O
induce	O
tumor	O
cell	O
death	O
,	O
modulators	O
of	O
ATF4	S-geneY
expression	O
could	O
prove	O
to	O
be	O
clinically	O
useful	O
.	O

In	O
this	O
study	O
,	O
chemical	O
libraries	O
were	O
screened	O
for	O
modulators	O
of	O
ATF4	S-geneY
expression	O
.	O

We	O
identified	O
one	O
compound	O
,	O
E235	S-chem-C3-1
(	B-chem-C3-1
N	I-chem-C3-1
-	I-chem-C3-1
(	I-chem-C3-1
1	I-chem-C3-1
-	I-chem-C3-1
benzyl	I-chem-C3-1
-	I-chem-C3-1
piperidin	I-chem-C3-1
-	I-chem-C3-1
4	I-chem-C3-1
-	I-chem-C3-1
yl	I-chem-C3-1
)	I-chem-C3-1
-	I-chem-C3-1
2	I-chem-C3-1
-	I-chem-C3-1
(	I-chem-C3-1
4	I-chem-C3-1
-	I-chem-C3-1
fluoro	I-chem-C3-1
-	I-chem-C3-1
phenyl	I-chem-C3-1
)	I-chem-C3-1
-	I-chem-C3-1
benzo	I-chem-C3-1
[	I-chem-C3-1
d	I-chem-C3-1
]	I-chem-C3-1
imidazo	I-chem-C3-1
[	I-chem-C3-1
2,1	I-chem-C3-1
-	I-chem-C3-1
b	I-chem-C3-1
]	I-chem-C3-1
thiazole	I-chem-C3-1
-	I-chem-C3-1
7	I-chem-C3-1
-	I-chem-C3-1
carboxamide	I-chem-C3-1
)	E-chem-C3-1
,	O
that	O
activated	O
the	O
ISR	O
and	O
dose	O
-	O
dependently	O
increased	O
levels	O
of	O
ATF4	S-geneY-C3-2
in	O
transformed	O
cells	O
.	O

A	O
dose	O
-	O
dependent	O
decrease	O
in	O
viability	O
was	O
observed	O
in	O
several	O
mouse	O
and	O
human	O
tumor	O
cell	O
lines	O
,	O
and	O
knockdown	O
of	O
ATF4	S-geneY
significantly	O
increased	O
the	O
antiproliferative	O
effects	O
of	O
E235	S-chem
.	O

Interestingly	O
,	O
low	O
μM	O
doses	O
of	O
E235	S-chem
induced	O
senescence	O
in	O
many	O
cell	O
types	O
,	O
including	O
HT1080	O
human	O
fibrosarcoma	O
and	O
B16F10	O
mouse	O
melanoma	O
cells	O
.	O

E235	S-chem
-	O
mediated	O
induction	O
of	O
senescence	O
was	O
not	O
dependent	O
on	O
p21	S-geneY
or	O
p53	S-geneY
;	O
however	O
,	O
p21	S-geneY
conferred	O
protection	O
against	O
the	O
growth	O
inhibitory	O
effects	O
of	O
E235	S-chem
.	O

Treatment	O
with	O
E235	S-chem
resulted	O
in	O
an	O
increase	O
in	O
cells	O
arrested	O
at	O
the	O
G2	O
/	O
M	O
phase	O
with	O
a	O
concurrent	O
decrease	O
in	O
S	O
-	O
phase	O
cells	O
.	O

E235	S-chem-C3-1
also	O
activated	O
DNA	O
damage	O
response	O
signaling	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
Ser15	S-chem
-	O
phosphorylated	B-geneY-C3-2
p53	E-geneY-C3-2
,	O
γ	B-geneY-C3-2
-	I-geneY-C3-2
H2AX	E-geneY-C3-2
,	O
and	O
phosphorylated	B-geneY-C3-2
checkpoint	I-geneY-C3-2
kinase	I-geneY-C3-2
2	E-geneY-C3-2
(	O
Chk2	S-geneY-C3-2
)	O
,	O
although	O
E235	S-chem
does	O
not	O
appear	O
to	O
cause	O
physical	O
DNA	O
damage	O
.	O

Induction	O
of	O
γ	B-geneY
-	I-geneY
H2AX	E-geneY
was	O
abrogated	O
in	O
ATF4	S-geneY
knockdown	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
modulation	O
of	O
the	O
ISR	O
pathway	O
with	O
the	O
small	O
molecule	O
E235	S-chem
could	O
be	O
a	O
promising	O
antitumor	O
strategy	O
.	O

Osteochondral	O
tissue	O
regeneration	O
using	O
a	O
bilayered	O
composite	O
hydrogel	O
with	O
modulating	O
dual	O
growth	O
factor	O
release	O
kinetics	O
in	O
a	O
rabbit	O
model	O
.	O

Biodegradable	O
oligo	B-chem
(	I-chem
poly	I-chem
(	I-chem
ethylene	I-chem
glycol	I-chem
)	I-chem
fumarate	I-chem
)	E-chem
(	O
OPF	S-chem
)	O
composite	O
hydrogels	O
have	O
been	O
investigated	O
for	O
the	O
delivery	O
of	O
growth	O
factors	O
(	O
GFs	O
)	O
with	O
the	O
aid	O
of	O
gelatin	O
microparticles	O
(	O
GMPs	O
)	O
and	O
stem	O
cell	O
populations	O
for	O
osteochondral	O
tissue	O
regeneration	O
.	O

In	O
this	O
study	O
,	O
a	O
bilayered	O
OPF	S-chem
composite	O
hydrogel	O
that	O
mimics	O
the	O
distinctive	O
hierarchical	O
structure	O
of	O
native	O
osteochondral	O
tissue	O
was	O
utilized	O
to	O
investigate	O
the	O
effect	O
of	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
β3	E-geneY
(	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
)	O
with	O
varying	O
release	O
kinetics	O
and	O
/	O
or	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
1	E-geneY
(	O
IGF	B-geneY
-	I-geneY
1	E-geneY
)	O
on	O
osteochondral	O
tissue	O
regeneration	O
in	O
a	O
rabbit	O
full	O
-	O
thickness	O
osteochondral	O
defect	O
model	O
.	O

The	O
four	O
groups	O
investigated	O
included	O
(	O
i	O
)	O
a	O
blank	O
control	O
(	O
no	O
GFs	O
)	O
,	O
(	O
ii	O
)	O
GMP	O
-	O
loaded	O
IGF	B-geneY
-	I-geneY
1	E-geneY
alone	O
,	O
(	O
iii	O
)	O
GMP	O
-	O
loaded	O
IGF	B-geneY
-	I-geneY
1	E-geneY
and	O
gel	O
-	O
loaded	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
,	O
and	O
(	O
iv	O
)	O
GMP	O
-	O
loaded	O
IGF	B-geneY
-	I-geneY
1	E-geneY
and	O
GMP	O
-	O
loaded	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
in	O
OPF	S-chem
composite	O
hydrogels	O
.	O

The	O
results	O
of	O
an	O
in	O
vitro	O
release	O
study	O
demonstrated	O
that	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
release	O
kinetics	O
could	O
be	O
modulated	O
by	O
the	O
GF	O
incorporation	O
method	O
.	O

At	O
12weeks	O
post	O
-	O
implantation	O
,	O
the	O
quality	O
of	O
tissue	O
repair	O
in	O
both	O
chondral	O
and	O
subchondral	O
layers	O
was	O
analyzed	O
based	O
on	O
quantitative	O
histological	O
scoring	O
.	O

All	O
groups	O
incorporating	O
GFs	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
cartilage	O
morphology	O
compared	O
to	O
the	O
control	O
.	O

Single	O
delivery	O
of	O
IGF	B-geneY
-	I-geneY
1	E-geneY
showed	O
higher	O
scores	O
in	O
subchondral	O
bone	O
morphology	O
as	O
well	O
as	O
chondrocyte	O
and	O
glycosaminoglycan	O
amount	O
in	O
adjacent	O
cartilage	O
tissue	O
when	O
compared	O
to	O
a	O
dual	O
delivery	O
of	O
IGF	B-geneY
-	I-geneY
1	E-geneY
and	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
,	O
independent	O
of	O
the	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
release	O
kinetics	O
.	O

The	O
results	O
suggest	O
that	O
although	O
the	O
dual	O
delivery	O
of	O
TGF	B-geneY
-	I-geneY
β3	E-geneY
and	O
IGF	B-geneY
-	I-geneY
1	E-geneY
may	O
not	O
synergistically	O
enhance	O
the	O
quality	O
of	O
engineered	O
tissue	O
,	O
the	O
delivery	O
of	O
IGF	B-geneY
-	I-geneY
1	E-geneY
alone	O
from	O
bilayered	O
composite	O
hydrogels	O
positively	O
affects	O
osteochondral	O
tissue	O
repair	O
and	O
holds	O
promise	O
for	O
osteochondral	O
tissue	O
engineering	O
applications	O
.	O

Synthesis	O
and	O
Structure	O
-	O
Activity	O
Relationship	O
Studies	O
of	O
Derivatives	O
of	O
the	O
Dual	O
Aromatase	S-geneY-C4-2
-	O
Sulfatase	S-geneY-C4-2
Inhibitor	O
4	B-chem-C4-1
-	I-chem-C4-1
{	I-chem-C4-1
[	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
Cyanophenyl	I-chem-C4-1
)	I-chem-C4-1
(	I-chem-C4-1
4H	I-chem-C4-1
-	I-chem-C4-1
1,2,4	I-chem-C4-1
-	I-chem-C4-1
triazol	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
)	I-chem-C4-1
amino	I-chem-C4-1
]	I-chem-C4-1
methyl	I-chem-C4-1
}	I-chem-C4-1
phenyl	I-chem-C4-1
sulfamate	E-chem-C4-1
.	O

4	B-chem-C4-1
-	I-chem-C4-1
{	I-chem-C4-1
[	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
Cyanophenyl	I-chem-C4-1
)	I-chem-C4-1
(	I-chem-C4-1
4H	I-chem-C4-1
-	I-chem-C4-1
1,2,4	I-chem-C4-1
-	I-chem-C4-1
triazol	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
)	I-chem-C4-1
amino	I-chem-C4-1
]	I-chem-C4-1
methyl	I-chem-C4-1
}	I-chem-C4-1
phenyl	I-chem-C4-1
sulfamate	E-chem-C4-1
and	O
its	O
ortho	O
-	O
halogenated	O
(	O
F	S-chem-C4-1
,	O
Cl	S-chem-C4-1
,	O
Br	S-chem-C4-1
)	O
derivatives	O
are	O
first	O
-	O
generation	O
dual	O
aromatase	S-geneY-C4-2
and	O
sulfatase	S-geneY-C4-2
inhibitors	O
(	O
DASIs	O
)	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
were	O
performed	O
on	O
these	O
compounds	O
,	O
and	O
various	O
modifications	O
were	O
made	O
to	O
their	O
structures	O
involving	O
relocation	O
of	O
the	O
halogen	S-chem
atom	O
,	O
introduction	O
of	O
more	O
halogen	S-chem
atoms	O
,	O
replacement	O
of	O
the	O
halogen	S-chem
with	O
another	O
group	O
,	O
replacement	O
of	O
the	O
methylene	S-chem
linker	O
with	O
a	O
difluoromethylene	S-chem
linker	O
,	O
replacement	O
of	O
the	O
para	B-chem
-	I-chem
cyanophenyl	E-chem
ring	O
with	O
other	O
ring	O
structures	O
,	O
and	O
replacement	O
of	O
the	O
triazolyl	S-chem
group	O
with	O
an	O
imidazolyl	S-chem
group	O
.	O

The	O
most	O
potent	O
in	O
vitro	O
DASI	O
discovered	O
is	O
an	O
imidazole	O
derivative	O
with	O
IC50	O
values	O
against	O
aromatase	O
and	O
steroid	O
sulfatase	I-geneY-C4-2
in	O
a	O
JEG	O
-	O
3	O
cell	O
preparation	O
of	O
0.2	O
and	O
2.5	O
nM	O
,	O
respectively	O
.	O

The	O
parent	O
phenol	S-chem-C4-1
of	O
this	O
compound	O
inhibits	O
aromatase	S-geneY-C4-2
with	O
an	O
IC50	O
value	O
of	O
0.028	O
nM	O
in	O
the	O
same	O
assay	O
.	O

In	O
ovo	O
effects	O
of	O
two	O
organophosphate	S-chem
flame	O
retardants	O
,	O
TCPP	S-chem
and	O
TDCPP	S-chem
,	O
on	O
pipping	O
success	O
,	O
development	O
,	O
mRNA	O
expression	O
and	O
thyroid	O
hormone	O
levels	O
in	O
chicken	O
embryos	O
.	O

Tris	B-chem
(	I-chem
1	I-chem
-	I-chem
chloro	I-chem
-	I-chem
2	I-chem
-	I-chem
propyl	I-chem
)	I-chem
phosphate	E-chem
(	O
TCPP	S-chem
)	O
and	O
tris	B-chem
(	I-chem
1,3	I-chem
-	I-chem
dichloro	I-chem
-	I-chem
2	I-chem
-	I-chem
propyl	I-chem
)	I-chem
phosphate	E-chem
(	O
TDCPP	S-chem
)	O
are	O
organic	O
flame	O
retardants	O
detected	O
in	O
the	O
environment	O
and	O
biota	O
for	O
which	O
toxicological	O
data	O
for	O
avian	O
species	O
are	O
limited	O
.	O

In	O
this	O
study	O
,	O
domestic	O
chicken	O
eggs	O
were	O
injected	O
with	O
TCPP	S-chem
or	O
TDCPP	S-chem
(	O
maximum	O
dose	O
=	O
51600	O
and	O
45000	O
ng	O
/	O
g	O
egg	O
,	O
respectively	O
)	O
to	O
determine	O
dose	O
-	O
dependent	O
effects	O
on	O
pipping	O
success	O
,	O
development	O
,	O
hepatic	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
xenobiotic	O
metabolism	O
and	O
the	O
thyroid	O
hormone	O
(	O
TH	O
)	O
pathway	O
,	O
and	O
TH	O
levels	O
following	O
20	O
-	O
22	O
days	O
of	O
incubation	O
.	O

Neither	O
compound	O
reduced	O
pipping	O
success	O
;	O
however	O
,	O
TCPP	S-chem
significantly	O
delayed	O
pipping	O
at	O
9240	O
and	O
51600	O
ng	O
/	O
g	O
and	O
reduced	O
tarsus	O
length	O
at	O
51600	O
ng	O
/	O
g	O
.	O

TDCPP	S-chem
exposure	O
resulted	O
in	O
significant	O
decreases	O
in	O
head	O
plus	O
bill	O
length	O
,	O
embryo	O
mass	O
and	O
gallbladder	O
size	O
at	O
45000	O
ng	O
/	O
g	O
and	O
reduced	O
plasma	O
free	O
T4	O
levels	O
at	O
7640	O
ng	O
/	O
g	O
.	O

Type	B-geneY-C3-2
I	I-geneY-C3-2
deiodinase	E-geneY-C3-2
,	O
liver	B-geneY-C3-2
fatty	I-geneY-C3-2
-	I-geneY-C3-2
acid	I-geneY-C3-2
binding	I-geneY-C3-2
protein	E-geneY-C3-2
and	O
cytochrome	B-geneY-C3-2
P450	I-geneY-C3-2
(	I-geneY-C3-2
CYP	I-geneY-C3-2
)	I-geneY-C3-2
3A37	E-geneY-C3-2
mRNA	O
levels	O
were	O
significantly	O
induced	O
by	O
TCPP	S-chem-C3-1
,	O
while	O
TDCPP	S-chem-C3-1
induced	O
CYP3A37	S-geneY-C3-2
and	O
CYP2H1	S-geneY-C3-2
.	O

Chemical	O
analysis	O
of	O
egg	O
contents	O
at	O
incubation	O
days	O
0	O
,	O
5	O
,	O
11	O
,	O
18	O
,	O
and	O
19	O
revealed	O
that	O
>	O
92	O
%	O
of	O
the	O
injected	O
TCPP	S-chem
or	O
TDCPP	S-chem
concentration	O
was	O
detectable	O
up	O
to	O
day	O
5	O
;	O
however	O
,	O
<	O
1	O
%	O
was	O
detected	O
by	O
day	O
19	O
.	O

The	O
observed	O
phenotypic	O
responses	O
to	O
TCPP	S-chem
and	O
TDCPP	S-chem
exposure	O
may	O
be	O
associated	O
with	O
disruption	O
of	O
the	O
TH	O
-	O
axis	O
,	O
which	O
is	O
critical	O
for	O
normal	O
growth	O
and	O
development	O
in	O
birds	O
.	O

The	O
effects	O
of	O
TDCPP	S-chem
on	O
the	O
gallbladder	O
indicate	O
that	O
the	O
disturbance	O
of	O
lipid	O
metabolism	O
is	O
a	O
likely	O
target	O
in	O
its	O
mechanism	O
of	O
toxicity	O
.	O

Sitagliptin	S-chem
.	O

Sitagliptin	S-chem-MU-1
,	O
an	O
oral	O
dipeptidyl	B-geneY-C4-2
peptidase	I-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
(	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
)	O
inhibitor	O
,	O
improves	O
glycaemic	O
control	O
by	O
inhibiting	O
DPP	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
inactivation	O
of	O
the	O
incretin	B-geneN-C3-2
hormones	E-geneN-C3-2
glucagon	B-geneY-C3-2
-	I-geneY-C3-2
like	I-geneY-C3-2
peptide	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
and	O
glucose	B-geneY-C3-2
-	I-geneY-C3-2
dependent	I-geneY-C3-2
insulinotropic	I-geneY-C3-2
polypeptide	E-geneY-C3-2
.	O

This	O
increases	O
active	O
incretin	S-geneN
and	O
insulin	S-geneY
levels	O
,	O
and	O
decreases	O
glucagon	S-geneY
levels	O
and	O
post	O
-	O
glucose	S-chem
-	O
load	O
glucose	S-chem
excursion	O
.	O

In	O
large	O
,	O
well	O
designed	O
phase	O
III	O
trials	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
,	O
sitagliptin	S-chem
100	O
or	O
200mg	O
once	O
daily	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antihyperglycaemics	O
was	O
associated	O
with	O
significant	O
improvements	O
relative	O
to	O
placebo	O
in	O
overall	O
glycaemic	O
control	O
and	O
indices	O
for	O
insulin	S-geneY
response	O
and	O
beta	O
-	O
cell	O
function	O
.	O

Improvements	O
from	O
baseline	O
in	O
mean	O
glycosylated	B-geneY-C3-2
haemoglobin	E-geneY-C3-2
(	O
HbA	B-geneY-C3-2
(	I-geneY-C3-2
1c	I-geneY-C3-2
)	E-geneY-C3-2
)	O
were	O
significantly	O
greater	O
with	O
sitagliptin	S-chem-C3-1
monotherapy	O
than	O
with	O
placebo	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

As	O
add	O
-	O
on	O
therapy	O
in	O
patients	O
with	O
suboptimal	O
glycaemic	O
control	O
despite	O
oral	O
antihyperglycaemic	O
treatment	O
,	O
sitagliptin	S-chem-C3-1
improved	O
HbA	B-geneY-MU-2
(	I-geneY-MU-2
1c	I-geneY-MU-2
)	E-geneY-MU-2
to	O
a	O
significantly	O
greater	O
extent	O
than	O
placebo	O
when	O
added	O
to	O
metformin	S-chem-C3-1
or	O
pioglitazone	S-chem-C3-1
and	O
was	O
noninferior	O
to	O
glipizide	S-chem
when	O
added	O
to	O
metformin	S-chem-C4-1
.	O

Sitagliptin	S-chem
was	O
well	O
tolerated	O
when	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antihyperglycaemics	O
,	O
with	O
an	O
adverse	O
event	O
profile	O
similar	O
to	O
that	O
shown	O
with	O
placebo	O
.	O

The	O
incidence	O
of	O
hypoglycaemia	O
with	O
sitagliptin	S-chem
was	O
similar	O
to	O
that	O
with	O
placebo	O
and	O
,	O
in	O
combination	O
with	O
metformin	S-chem
,	O
lower	O
than	O
that	O
with	O
glipizide	S-chem
.	O

Sitagliptin	S-chem
had	O
a	O
generally	O
neutral	O
effect	O
on	O
bodyweight	O
.	O

Niacin	S-chem
mediates	O
lipolysis	O
in	O
adipose	O
tissue	O
through	O
its	O
G	B-geneY
-	I-geneY
protein	I-geneY
coupled	I-geneY
receptor	I-geneY
HM74A	E-geneY
.	O

A	O
G	B-geneN
-	I-geneN
protein	I-geneN
coupled	I-geneN
receptor	E-geneN
to	O
niacin	S-chem
(	O
nicotinic	B-chem
acid	E-chem
)	O
was	O
identified	O
recently	O
but	O
the	O
physiological	O
/	O
pharmacological	O
role	O
of	O
the	O
receptor	O
remains	O
poorly	O
defined	O
.	O

We	O
present	O
our	O
studies	O
to	O
demonstrate	O
that	O
HM74A	S-geneN
,	O
but	O
not	O
HM74	S-geneN
,	O
binds	O
niacin	S-chem-C3-1
at	O
high	O
affinities	O
and	O
effectively	O
mediates	O
Gi	S-geneN-C3-2
signaling	O
events	O
in	O
human	O
embryonic	O
kidney	O
HEK293	O
cells	O
as	O
well	O
as	O
in	O
3T3L1	O
adipocytes	O
expressing	O
HM74A	S-geneN
.	O

Furthermore	O
,	O
HM74A	S-geneY
,	O
but	O
not	O
HM74	S-geneY
,	O
expressed	O
in	O
differentiated	O
3T3L1	O
adipocytes	O
effectively	O
mediated	O
inhibition	O
of	O
lipolysis	O
by	O
niacin	S-chem
.	O

Our	O
results	O
provided	O
direct	O
evidence	O
indicating	O
that	O
HM74A	S-geneY
,	O
but	O
not	O
HM74	S-geneY
,	O
was	O
sufficient	O
to	O
mediate	O
anti	O
-	O
lipolytic	O
effect	O
of	O
niacin	S-chem
in	O
adipose	O
tissue	O
.	O

A	O
genetically	O
encoded	O
and	O
gate	O
for	O
cell	O
-	O
targeted	O
metabolic	O
labeling	O
of	O
proteins	O
.	O

We	O
describe	O
a	O
genetic	O
AND	O
gate	O
for	O
cell	O
-	O
targeted	O
metabolic	O
labeling	O
and	O
proteomic	O
analysis	O
in	O
complex	O
cellular	O
systems	O
.	O

The	O
centerpiece	O
of	O
the	O
AND	O
gate	O
is	O
a	O
bisected	O
methionyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
MetRS	S-geneY
)	O
that	O
charges	O
the	O
Met	S-chem
surrogate	O
azidonorleucine	S-chem
(	O
Anl	S-chem
)	O
to	O
tRNA	O
(	O
Met	S-chem
)	O
.	O

Cellular	O
protein	O
labeling	O
occurs	O
only	O
upon	O
activation	O
of	O
two	O
different	O
promoters	O
that	O
drive	O
expression	O
of	O
the	O
N	S-chem
-	O
and	O
C	S-chem
-	O
terminal	O
fragments	O
of	O
the	O
bisected	O
MetRS	S-geneY
.	O

Anl	S-chem
-	O
labeled	O
proteins	O
can	O
be	O
tagged	O
with	O
fluorescent	O
dyes	O
or	O
affinity	O
reagents	O
via	O
either	O
copper	S-chem
-	O
catalyzed	O
or	O
strain	O
-	O
promoted	O
azide	O
-	O
alkyne	O
cycloaddition	O
.	O

Protein	O
labeling	O
is	O
apparent	O
within	O
5	O
min	O
after	O
addition	O
of	O
Anl	S-chem
to	O
bacterial	O
cells	O
in	O
which	O
the	O
AND	O
gate	O
has	O
been	O
activated	O
.	O

This	O
method	O
allows	O
spatial	O
and	O
temporal	O
control	O
of	O
proteomic	O
labeling	O
and	O
identification	O
of	O
proteins	O
made	O
in	O
specific	O
cellular	O
subpopulations	O
.	O

The	O
approach	O
is	O
demonstrated	O
by	O
selective	O
labeling	O
of	O
proteins	O
in	O
bacterial	O
cells	O
immobilized	O
in	O
the	O
center	O
of	O
a	O
laminar	O
-	O
flow	O
microfluidic	O
channel	O
,	O
where	O
they	O
are	O
exposed	O
to	O
overlapping	O
,	O
opposed	O
gradients	O
of	O
inducers	O
of	O
the	O
N	S-chem
-	O
and	O
C	S-chem
-	O
terminal	O
MetRS	S-geneY
fragments	O
.	O

The	O
observed	O
labeling	O
profile	O
is	O
predicted	O
accurately	O
from	O
the	O
strengths	O
of	O
the	O
individual	O
input	O
signals	O
.	O

Atp	O
-	O
bound	O
topoisomerase	B-geneY
ii	E-geneY
as	O
a	O
target	O
for	O
antitumor	O
drugs	O
.	O

Topoisomerase	B-geneY
II	E-geneY
(	O
TOP2	S-geneY
)	O
poisons	O
interfere	O
with	O
the	O
breakage	O
/	O
reunion	O
reaction	O
of	O
TOP2	S-geneY
resulting	O
in	O
DNA	O
cleavage	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
show	O
that	O
two	O
different	O
classes	O
(	O
ATP	S-chem
-	O
sensitive	O
and	O
-	O
insensitive	O
)	O
of	O
TOP2	S-geneY
poisons	O
can	O
be	O
identified	O
based	O
on	O
their	O
differential	O
sensitivity	O
to	O
the	O
ATP	S-chem
-	O
bound	O
conformation	O
of	O
TOP2	S-geneY
.	O

First	O
,	O
in	O
the	O
presence	O
of	O
1	O
mm	O
ATP	S-chem
or	O
the	O
nonhydrolyzable	O
analog	O
adenosine	B-chem
5	I-chem
'	I-chem
-	I-chem
(	I-chem
beta	I-chem
,	I-chem
gamma	I-chem
-	I-chem
imino	I-chem
)	I-chem
triphosphate	E-chem
,	O
TOP2	S-geneY-C4-2
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	S-chem
-	O
sensitive	O
TOP2	S-geneY-C4-2
poisons	O
(	O
e.g	O
.	O
doxorubicin	S-chem-C4-1
,	O
etoposide	S-chem-C4-1
,	O
mitoxantrone	S-chem-C4-1
,	O
and	O
4	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
9	I-chem-C4-1
-	I-chem-C4-1
acridinylamino	I-chem-C4-1
)	I-chem-C4-1
methanesulfon	I-chem-C4-1
-	I-chem-C4-1
m	I-chem-C4-1
-	I-chem-C4-1
anisidide	E-chem-C4-1
)	O
was	O
30	O
-	O
100	O
-	O
fold	O
stimulated	O
,	O
whereas	O
DNA	O
cleavage	O
induced	O
by	O
ATP	S-chem
-	O
insensitive	O
TOP2	S-geneY-C4-2
poisons	O
(	O
e.g	O
.	O
amonafide	S-chem-C4-1
,	O
batracylin	S-chem-C4-1
,	O
and	O
menadione	S-chem-C4-1
)	O
was	O
only	O
slightly	O
(	O
less	O
than	O
3	O
-	O
fold	O
)	O
affected	O
.	O

In	O
addition	O
,	O
ADP	S-chem
was	O
shown	O
to	O
strongly	O
antagonize	O
TOP2	S-geneY-C3-2
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	S-chem-C3-1
-	O
sensitive	O
but	O
not	O
ATP	S-chem
-	O
insensitive	O
TOP2	S-geneY
poisons	O
.	O

Second	O
,	O
C427A	S-geneN
mutant	O
human	B-geneY
TOP2alpha	E-geneY
,	O
which	O
exhibits	O
reduced	O
ATPase	S-geneN-C4-2
activity	O
,	O
was	O
shown	O
to	O
exhibit	O
cross	O
-	O
resistance	O
to	O
all	O
ATP	S-chem
-	O
sensitive	O
but	O
not	O
ATP	S-chem-C4-1
-	O
insensitive	O
TOP2	S-geneY
poisons	O
.	O

Third	O
,	O
using	O
ciprofloxacin	S-chem
competition	O
assay	O
,	O
TOP2	S-geneY
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	S-chem
-	O
sensitive	O
but	O
not	O
ATP	S-chem
-	O
insensitive	O
poisons	O
was	O
shown	O
to	O
be	O
antagonized	O
by	O
ciprofloxacin	S-chem
.	O

These	O
results	O
suggest	O
that	O
ATP	S-chem
-	O
bound	O
TOP2	S-geneY
may	O
be	O
the	O
specific	O
target	O
of	O
ATP	S-chem
-	O
sensitive	O
TOP2	S-geneY
poisons	O
.	O

Using	O
Lac	B-geneN
repressor	I-geneN
-	I-geneN
operator	I-geneN
complexes	E-geneN
as	O
roadblocks	O
,	O
we	O
show	O
that	O
ATP	S-chem
-	O
bound	O
TOP2	S-geneY
acts	O
as	O
a	O
circular	O
clamp	O
capable	O
of	O
entering	O
DNA	O
ends	O
and	O
sliding	O
on	O
unobstructed	O
duplex	O
DNA	O
.	O

Comparison	O
of	O
antidepressant	O
activity	O
in	O
4	O
-	O
and	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
in	O
the	O
forced	O
swimming	O
test	O
:	O
involvement	O
of	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
in	O
old	O
mice	O
.	O

RATIONALE	O
:	O
A	O
recent	O
study	O
suggested	O
that	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
were	O
inactive	O
in	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
,	O
possibly	O
because	O
of	O
alteration	O
of	O
5	B-geneN
-	I-geneN
HT1	E-geneN
receptors	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
action	O
of	O
various	O
antidepressant	O
drugs	O
in	O
4	O
-	O
and	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
using	O
the	O
mouse	O
forced	O
swimming	O
test	O
and	O
determining	O
the	O
involvement	O
of	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
mediating	O
the	O
effects	O
.	O

METHODS	O
:	O
Different	O
classes	O
of	O
antidepressants	O
[	O
imipramine	S-chem
(	O
tricyclic	S-chem
)	O
,	O
maprotiline	S-chem
(	O
noradrenline	S-chem
reuptake	O
inhibitor	O
)	O
,	O
venlafaxine	S-chem
(	O
mixed	O
serotonin	S-chem
and	O
noradrenaline	S-chem
reuptake	O
inhibitors	O
)	O
,	O
fluvoxamine	S-chem
and	O
sertraline	S-chem
(	O
selective	O
serotonin	S-chem
reuptake	O
inhibitor	O
)	O
]	O
were	O
tested	O
in	O
the	O
same	O
randomised	O
experimental	O
session	O
,	O
alone	O
and	O
in	O
combination	O
with	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
agonists	O
[	O
buspirone	S-chem-C5-1
(	O
partial	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1A	E-geneY-C5-2
agonist	O
)	O
,	O
anpirtoline	S-chem-C5-1
(	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1B	E-geneY-C5-2
agonist	O
)	O
]	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
.	O

RESULTS	O
:	O
All	O
antidepressants	O
were	O
found	O
to	O
be	O
active	O
in	O
the	O
mouse	O
forced	O
swimming	O
test	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
and	O
40	O
-	O
week	O
-	O
old	O
mice	O
,	O
with	O
the	O
exception	O
of	O
fluvoxamine	S-chem
in	O
the	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

The	O
anti	O
-	O
immobility	O
effect	O
after	O
antidepressant	O
administration	O
was	O
higher	O
in	O
4	O
-	O
week	O
-	O
old	O
male	O
mice	O
than	O
in	O
40	O
-	O
week	O
-	O
old	O
male	O
mice	O
.	O

Venlafaxine	S-chem
is	O
the	O
most	O
active	O
antidepressant	O
drug	O
in	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Prior	O
administration	O
of	O
buspirone	S-chem
(	O
0.06	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
or	O
anpirtoline	S-chem
(	O
1	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
enhanced	O
the	O
antidepressant	O
-	O
like	O
effects	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
(	O
except	O
in	O
the	O
case	O
of	O
sertraline	S-chem
,	O
8	O
mg	O
/	O
kg	O
)	O
.	O

In	O
elderly	O
mice	O
,	O
only	O
prior	O
administration	O
of	O
buspirone	S-chem
enhanced	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
fluvoxamine	S-chem
.	O

A	O
neurochemical	O
study	O
showed	O
that	O
significantly	O
higher	O
serotonin	S-chem
and	O
dopamine	S-chem
concentrations	O
were	O
found	O
in	O
40	O
-	O
week	O
-	O
old	O
control	O
mice	O
brains	O
than	O
4	O
-	O
week	O
-	O
old	O
control	O
mice	O
brains	O
but	O
that	O
the	O
noradrenaline	S-chem
concentration	O
is	O
higher	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
.	O

CONCLUSION	O
:	O
Tricyclic	S-chem
,	O
noradrenaline	S-chem
reuptake	O
inhibitors	O
and	O
serotonin	S-chem
reuptake	O
inhibitors	O
are	O
more	O
active	O
in	O
4	O
-	O
week	O
-	O
old	O
mice	O
than	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Our	O
results	O
suggested	O
that	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
may	O
be	O
more	O
altered	O
than	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
receptors	O
in	O
40	O
-	O
week	O
-	O
old	O
mice	O
.	O

Cannabis	O
and	O
cannabinoids	O
:	O
pharmacology	O
and	O
rationale	O
for	O
clinical	O
use	O
.	O

It	O
is	O
now	O
known	O
that	O
there	O
are	O
at	O
least	O
two	O
types	O
of	O
cannabinoid	B-geneN
receptors	E-geneN
.	O

These	O
are	O
CB1	S-geneY
receptors	O
,	O
present	O
mainly	O
on	O
central	O
and	O
peripheral	O
neurones	O
,	O
and	O
CB2	S-geneY
receptors	O
,	O
present	O
mainly	O
on	O
immune	O
cells	O
.	O

Endogenous	O
cannabinoid	B-geneN
receptor	E-geneN
agonists	O
(	O
'	O
endocannabinoids	O
'	O
)	O
have	O
also	O
been	O
identified	O
.	O

The	O
discovery	O
of	O
this	O
'	O
endogenous	O
cannabinoid	O
system	O
'	O
has	O
led	O
to	O
the	O
development	O
of	O
selective	O
CB1	S-geneY
and	O
CB2	S-geneY
receptor	O
ligands	O
and	O
fueled	O
renewed	O
interest	O
in	O
the	O
clinical	O
potential	O
of	O
cannabinoids	O
.	O

Two	O
cannabinoid	O
CB1	S-geneY
receptor	O
agonists	O
are	O
already	O
used	O
clinically	O
,	O
as	O
antiemetics	O
or	O
as	O
appetite	O
stimulants	O
.	O

These	O
are	O
D	B-chem
9	I-chem
-	I-chem
tetrahydrocannabinol	E-chem
(	O
THC	S-chem
)	O
and	O
nabilone	S-chem
.	O

Other	O
possible	O
uses	O
for	O
CB1	S-geneY
receptor	O
agonists	O
include	O
the	O
suppression	O
of	O
muscle	O
spasm	O
/	O
spasticity	O
associated	O
with	O
multiple	O
sclerosis	O
or	O
spinal	O
cord	O
injury	O
,	O
the	O
relief	O
of	O
chronic	O
pain	O
and	O
the	O
management	O
of	O
glaucoma	O
and	O
bronchial	O
asthma	O
.	O

CB1	S-geneY
receptor	O
antagonists	O
may	O
also	O
have	O
clinical	O
applications	O
,	O
e.	O
g.	O
as	O
appetite	O
suppressants	O
and	O
in	O
the	O
management	O
of	O
schizophrenia	O
or	O
disorders	O
of	O
cognition	O
and	O
memory	O
.	O

So	O
too	O
may	O
CB2	S-geneY
receptor	O
ligands	O
and	O
drugs	O
that	O
activate	O
cannabinoid	B-geneN
receptors	E-geneN
indirectly	O
by	O
augmenting	O
endocannabinoid	O
levels	O
at	O
cannabinoid	B-geneN
receptors	E-geneN
.	O

When	O
taken	O
orally	O
,	O
THC	S-chem
seems	O
to	O
undergo	O
variable	O
absorption	O
and	O
to	O
have	O
a	O
narrow	O
'	O
therapeutic	O
window	O
'	O
(	O
dose	O
range	O
in	O
which	O
it	O
is	O
effective	O
without	O
producing	O
significant	O
unwanted	O
effects	O
)	O
.	O

This	O
makes	O
it	O
difficult	O
to	O
predict	O
an	O
oral	O
dose	O
that	O
will	O
be	O
both	O
effective	O
and	O
tolerable	O
to	O
a	O
patient	O
and	O
indicates	O
a	O
need	O
for	O
better	O
cannabinoid	O
formulations	O
and	O
modes	O
of	O
administration	O
.	O

For	O
the	O
therapeutic	O
potential	O
of	O
cannabis	O
or	O
CB1	S-geneY
receptor	O
agonists	O
to	O
be	O
fully	O
exploited	O
,	O
it	O
will	O
be	O
important	O
to	O
establish	O
objectively	O
and	O
conclusively	O
(	O
a	O
)	O
whether	O
these	O
agents	O
have	O
efficacy	O
against	O
selected	O
symptoms	O
that	O
is	O
of	O
clinical	O
significance	O
and	O
,	O
if	O
so	O
,	O
whether	O
the	O
benefits	O
outweigh	O
the	O
risks	O
,	O
(	O
b	O
)	O
whether	O
cannabis	O
has	O
therapeutic	O
advantages	O
over	O
individual	O
cannabinoids	O
,	O
(	O
c	O
)	O
whether	O
there	O
is	O
a	O
need	O
for	O
additional	O
drug	O
treatments	O
to	O
manage	O
any	O
of	O
the	O
disorders	O
against	O
which	O
cannabinoids	O
are	O
effective	O
,	O
and	O
(	O
d	O
)	O
whether	O
it	O
will	O
be	O
possible	O
to	O
develop	O
drugs	O
that	O
have	O
reduced	O
psychotropic	O
activity	O
and	O
yet	O
retain	O
the	O
ability	O
to	O
act	O
through	O
CB1	S-geneY
receptors	O
to	O
produce	O
their	O
sought	O
-	O
after	O
effects	O
.	O

Resistin	S-geneY
knockout	O
mice	O
exhibit	O
impaired	O
adipocyte	O
glucose	B-geneY
-	I-geneY
dependent	I-geneY
insulinotropic	I-geneY
polypeptide	I-geneY
receptor	E-geneY
(	O
GIPR	S-geneY
)	O
expression	O
.	O

Glucose	B-geneY
-	I-geneY
dependent	I-geneY
insulinotropic	I-geneY
polypeptide	E-geneY
(	O
GIP	S-geneY
)	O
is	O
an	O
incretin	B-geneN
hormone	E-geneN
that	O
also	O
plays	O
a	O
regulatory	O
role	O
in	O
fat	O
metabolism	O
.	O

In	O
3T3	O
-	O
L1	O
cells	O
,	O
resistin	S-geneY
was	O
demonstrated	O
to	O
be	O
a	O
key	O
mediator	O
of	O
GIP	S-geneY
stimulation	O
of	O
lipoprotein	B-geneY
lipase	E-geneY
(	O
LPL	S-geneY
)	O
activity	O
,	O
involving	O
activation	O
of	O
protein	B-geneY
kinase	I-geneY
B	E-geneY
(	O
PKB	S-geneY
)	O
and	O
reduced	O
phosphorylation	O
of	O
liver	B-geneY
kinase	I-geneY
B1	E-geneY
(	O
LKB1	S-geneY
)	O
and	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	E-geneY
(	O
AMPK	S-geneY
)	O
.	O

The	O
current	O
study	O
was	O
initiated	O
to	O
determine	O
whether	O
resistin	S-geneY
has	O
additional	O
roles	O
in	O
GIP	S-geneY
-	O
regulated	O
adipocyte	O
functions	O
.	O

Analysis	O
of	O
primary	O
adipocytes	O
isolated	O
from	O
Retn	S-geneY
(	O
-	O
/	O
-	O
)	O
,	O
Retn	S-geneY
(	O
+	O
/	O
-	O
)	O
,	O
and	O
Retn	S-geneY
(	O
+	O
/	O
+	O
)	O
mice	O
found	O
that	O
GIP	S-geneY
stimulated	O
the	O
PKB	S-geneY
/	O
LKB1	S-geneY
/	O
AMPK	S-geneY
/	O
LPL	S-geneY
pathway	O
and	O
fatty	B-chem
acid	E-chem
uptake	O
only	O
in	O
Retn	S-geneY
(	O
+	O
/	O
+	O
)	O
adipocytes	O
,	O
suggesting	O
that	O
GIP	S-geneY
signaling	O
and	O
/	O
or	O
GIP	S-geneY
responsiveness	O
were	O
compromised	O
in	O
Retn	S-geneY
(	O
+	O
/	O
-	O
)	O
and	O
Retn	S-geneY
(	O
-	O
/	O
-	O
)	O
adipocytes	O
.	O

GIP	B-geneY
receptor	E-geneY
(	O
GIPR	S-geneY
)	O
protein	O
and	O
mRNA	O
were	O
decreased	O
in	O
Retn	S-geneY
(	O
+	O
/	O
-	O
)	O
and	O
Retn	S-geneY
(	O
-	O
/	O
-	O
)	O
adipocytes	O
,	O
but	O
resistin	S-geneY
treatment	O
rescued	O
LPL	O
responsiveness	O
to	O
GIP	S-geneY
.	O

In	O
addition	O
,	O
genes	O
encoding	O
tumor	B-geneY
necrosis	I-geneY
factor	E-geneY
(	O
TNF	S-geneY
)	O
,	O
TNF	B-geneY
receptor	I-geneY
2	E-geneY
(	O
TNFR2	S-geneY
)	O
,	O
and	O
the	O
signaling	O
proteins	O
stress	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
SAPK	S-geneN
)	O
/	O
Jun	B-geneN
NH	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
terminal	I-geneN
kinase	E-geneN
(	O
JNK	S-geneN
)	O
,	O
were	O
downregulated	O
,	O
and	O
phosphorylated	O
levels	O
of	O
SAPK	S-geneN
/	O
JNK	S-geneN
/	O
c	B-geneY
-	I-geneY
Jun	E-geneY
were	O
decreased	O
in	O
Retn	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
were	O
used	O
to	O
identify	O
a	O
12	B-geneN
-	I-geneN
O	I-geneN
-	I-geneN
tetradecanoylphorbol	I-geneN
-	I-geneN
13	I-geneN
-	I-geneN
acetate	I-geneN
(	I-geneN
TPA	I-geneN
)	I-geneN
-	I-geneN
response	I-geneN
element	E-geneN
(	O
TRE	B-geneN
-	I-geneN
III	E-geneN
)	O
responsible	O
for	O
c	B-geneY
-	I-geneY
Jun	E-geneY
-	O
mediated	O
transcriptional	O
activation	O
of	O
Gipr	S-geneY
.	O

Blunted	O
GIP	S-geneY
responsiveness	O
in	O
Retn	S-geneY
(	O
+	O
/	O
-	O
)	O
and	O
Retn	S-geneY
(	O
-	O
/	O
-	O
)	O
adipocytes	O
was	O
therefore	O
largely	O
due	O
to	O
the	O
greatly	O
reduced	O
GIPR	S-geneY
expression	O
associated	O
with	O
decreased	O
c	B-geneN
-	I-geneN
Jun	E-geneN
-	O
mediated	O
transcriptional	O
activation	O
of	O
Gipr	S-geneY
.	O

A	O
new	O
series	O
of	O
N2	B-chem-C4-1
-	I-chem-C4-1
substituted	I-chem-C4-1
-	I-chem-C4-1
5	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
p	I-chem-C4-1
-	I-chem-C4-1
toluenesulfonylamino	I-chem-C4-1
)	I-chem-C4-1
phthalimide	E-chem-C4-1
analogues	O
as	O
α	B-geneN-C4-2
-	I-geneN-C4-2
glucosidase	E-geneN-C4-2
inhibitors	O
.	O

Several	O
members	O
of	O
a	O
new	O
family	O
of	O
non	O
-	O
sugar	S-chem
-	O
type	O
α	B-geneN-C4-2
-	I-geneN-C4-2
glycosidase	E-geneN-C4-2
inhibitors	O
,	O
bearing	O
a	O
5	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
p	I-chem-C4-1
-	I-chem-C4-1
toluenesulfonylamino	I-chem-C4-1
)	I-chem-C4-1
phthalimide	E-chem-C4-1
moiety	O
and	O
various	O
substituent	O
at	O
the	O
N2	O
position	O
,	O
were	O
synthesized	O
and	O
their	O
activities	O
were	O
investigated	O
.	O

The	O
newly	O
synthesized	O
compounds	O
displayed	O
different	O
inhibition	O
profile	O
towards	O
yeast	B-geneY
α	I-geneY
-	I-geneY
glycosidase	E-geneY
and	O
rat	B-geneN
intestinal	I-geneN
α	I-geneN
-	I-geneN
glycosidase	E-geneN
.	O

Almost	O
all	O
the	O
compounds	O
had	O
strong	O
inhibitory	O
activities	O
against	O
yeast	B-geneY
α	I-geneY
-	I-geneY
glycosidase	E-geneY
.	O

Regarding	O
rat	B-geneN
intestinal	I-geneN
α	I-geneN
-	I-geneN
glycosidase	E-geneN
,	O
only	O
analogs	O
with	O
N2	O
-	O
aromatic	O
substituents	O
displayed	O
varying	O
degrees	O
of	O
inhibitory	O
activities	O
on	O
rat	B-geneN
intestinal	I-geneN
maltase	E-geneN
and	O
lactase	S-geneN
and	O
nearly	O
all	O
compounds	O
showed	O
no	O
inhibition	O
against	O
rat	B-geneN
intestinal	I-geneN
α	I-geneN
-	I-geneN
amylase	E-geneN
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
indicated	O
that	O
5	B-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
p	I-chem-C4-1
-	I-chem-C4-1
toluenesulfonylamino	I-chem-C4-1
)	I-chem-C4-1
phthalimide	E-chem-C4-1
moiety	O
is	O
a	O
favorable	O
scaffold	O
to	O
exert	O
the	O
α	B-geneN-C4-2
-	I-geneN-C4-2
glucosidase	E-geneN-C4-2
inhibitory	O
activity	O
and	O
substituents	O
at	O
the	O
N2	O
position	O
have	O
considerable	O
influence	O
on	O
the	O
efficacy	O
of	O
the	O
inhibition	O
activities	O
.	O

The	O
serotonin	B-geneY
transporter	E-geneY
polymorphism	O
,	O
5HTTLPR	S-geneY
,	O
is	O
associated	O
with	O
a	O
faster	O
response	O
time	O
to	O
sertraline	S-chem
in	O
an	O
elderly	O
population	O
with	O
major	O
depressive	O
disorder	O
.	O

RATIONALE	O
:	O
A	O
common	O
polymorphism	O
(	O
5HTTLPR	S-geneY
)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
serotonin	B-geneY
transporter	E-geneY
gene	O
(	O
LSC6A4	S-geneY
)	O
has	O
been	O
shown	O
to	O
influence	O
response	O
time	O
as	O
well	O
as	O
overall	O
response	O
to	O
selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
in	O
subjects	O
with	O
major	O
depressive	O
disorder	O
.	O

We	O
hypothesized	O
that	O
a	O
similar	O
effect	O
in	O
response	O
time	O
to	O
sertraline	S-chem
would	O
be	O
observed	O
and	O
that	O
no	O
effect	O
on	O
response	O
time	O
would	O
be	O
seen	O
in	O
a	O
placebo	O
arm	O
.	O

OBJECTIVES	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
at	O
the	O
5HTTLPR	S-geneY
polymorphism	O
would	O
respond	O
more	O
rapidly	O
to	O
sertraline	S-chem
than	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
.	O

METHODS	O
:	O
HAM	O
-	O
D	O
and	O
CGI	O
-	O
I	O
responses	O
to	O
sertraline	S-chem
and	O
placebo	O
were	O
measured	O
weekly	O
in	O
the	O
context	O
of	O
an	O
8	O
-	O
week	O
,	O
placebo	O
-	O
controlled	O
study	O
in	O
elderly	O
depressed	O
subjects	O
.	O

Genotyping	O
of	O
the	O
5HTTLPR	S-geneY
polymorphism	O
was	O
performed	O
to	O
test	O
for	O
correlations	O
with	O
response	O
at	O
each	O
week	O
in	O
the	O
sertraline	S-chem
and	O
placebo	O
groups	O
(	O
n	O
=	O
206	O
)	O
.	O

RESULTS	O
:	O
Subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
of	O
5HTTLPR	S-geneY
showed	O
a	O
significant	O
increase	O
in	O
response	O
at	O
week	O
1	O
and	O
week	O
2	O
,	O
as	O
assessed	O
by	O
the	O
CGI	O
-	O
I	O
scale	O
compared	O
with	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
(	O
P	O
=	O
0.01	O
at	O
both	O
weeks	O
)	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
genetic	O
variation	O
in	O
the	O
serotonin	B-geneY
transporter	E-geneY
gene	O
effects	O
the	O
response	O
time	O
to	O
sertraline	S-chem
and	O
provides	O
complementing	O
evidence	O
to	O
previous	O
reports	O
that	O
this	O
polymorphism	O
affects	O
response	O
time	O
to	O
other	O
SSRIs	O
.	O

Efficacy	O
of	O
asiatic	B-chem
acid	E-chem
,	O
a	O
pentacyclic	B-chem
triterpene	E-chem
on	O
attenuating	O
the	O
key	O
enzymes	O
activities	O
of	O
carbohydrate	S-chem
metabolism	O
in	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
rats	O
.	O

Asiatic	B-chem
acid	E-chem
(	O
AA	O
)	O
,	O
a	O
triterpenoid	S-chem
derivative	O
of	O
Centella	O
asiatica	O
,	O
has	O
shown	O
significant	O
biological	O
effects	O
of	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Aim	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
the	O
antihyperglycemic	O
effect	O
of	O
AA	O
on	O
the	O
activities	O
of	O
hepatic	O
enzymes	O
of	O
carbohydrate	S-chem
metabolism	O
in	O
streptozotocin	S-chem
(	O
STZ	S-chem
)	O
-	O
induced	O
diabetic	O
rats	O
.	O

To	O
induce	O
diabetes	O
mellitus	O
,	O
rats	O
were	O
injected	O
with	O
streptozotocin	S-chem
intraperitoneally	O
at	O
a	O
single	O
dose	O
of	O
40	O
mg	O
/	O
kg	O
b.w	O
.	O

Diabetic	O
rats	O
showed	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
increased	O
in	O
plasma	O
glucose	S-chem
,	O
glycosylated	B-geneN
hemoglobin	E-geneN
and	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decreased	O
in	O
circulating	O
insulin	S-geneN
and	O
hemoglobin	S-geneN
.	O

The	O
altered	O
activities	O
of	O
key	O
enzymes	O
such	O
as	O
glucose	B-geneY-C9-2
-	I-geneY-C9-2
6	I-geneY-C9-2
-	I-geneY-C9-2
phosphatase	E-geneY-C9-2
and	O
fructose	B-geneY-C9-2
-	I-geneY-C9-2
1,6	I-geneY-C9-2
-	I-geneY-C9-2
bisphosphatase	E-geneY-C9-2
of	O
carbohydrate	S-chem-C9-1
metabolism	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
increased	O
whereas	O
hexokinase	S-geneN
,	O
pyruvate	B-geneN
kinase	E-geneN
,	O
glucose	B-geneY
-	I-geneY
6	I-geneY
-	I-geneY
phosphate	I-geneY
dehydrogenase	E-geneY
and	O
glycogen	O
content	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
decreased	O
in	O
the	O
liver	O
of	O
diabetic	O
rats	O
and	O
also	O
increased	O
activities	O
of	O
aspartate	B-geneN
transaminase	E-geneN
(	O
AST	S-geneN
)	O
,	O
alanine	B-geneN
transaminase	E-geneN
(	O
ALT	S-geneN
)	O
and	O
alkaline	B-geneN
phosphatase	E-geneN
(	O
ALP	S-geneN
)	O
.	O

Oral	O
administration	O
of	O
AA	O
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
b.w	O
.	O
)	O
and	O
glibenclamide	S-chem
(	O
600	O
μg	O
/	O
kg	O
b.w	O
.	O
)	O
to	O
diabetic	O
rats	O
for	O
45	O
days	O
prevented	O
the	O
above	O
alteration	O
and	O
reverted	O
to	O
near	O
normalcy	O
.	O

Protection	O
of	O
body	O
weight	O
loss	O
of	O
diabetic	O
rats	O
by	O
AA	O
was	O
also	O
observed	O
.	O

No	O
significant	O
effect	O
was	O
observed	O
in	O
normal	O
rats	O
treated	O
with	O
AA	O
(	O
20	O
mg	O
/	O
kg	O
b.w	O
.	O
)	O
.	O

In	O
this	O
search	O
,	O
AA	O
found	O
to	O
be	O
potential	O
bioactive	O
compound	O
to	O
regulate	O
the	O
carbohydrate	S-chem
metabolism	O
by	O
modulating	O
the	O
key	O
regulatory	O
enzymes	O
in	O
diabetic	O
rats	O
.	O

These	O
findings	O
merit	O
further	O
research	O
in	O
this	O
field	O
.	O

How	O
may	O
anticancer	O
chemotherapy	O
with	O
fluorouracil	S-chem
be	O
individualised	O
?	O

Fluorouracil	S-chem
is	O
used	O
clinically	O
against	O
various	O
solid	O
tumours	O
.	O

Both	O
fluorouracil	S-chem
toxicity	O
and	O
pharmacokinetics	O
vary	O
highly	O
within	O
and	O
between	O
individuals	O
.	O

The	O
reasons	O
why	O
doses	O
are	O
not	O
individualised	O
routinely	O
are	O
difficulties	O
in	O
defining	O
,	O
predicting	O
and	O
achieving	O
an	O
optimal	O
fluorouracil	S-chem
exposure	O
or	O
dose	O
because	O
of	O
a	O
narrow	O
therapeutic	O
index	O
,	O
nonlinear	O
pharmacokinetics	O
,	O
variabilities	O
in	O
administration	O
rates	O
and	O
metabolism	O
,	O
and	O
in	O
targets	O
like	O
thymidylate	B-geneY
synthase	E-geneY
.	O

To	O
individualise	O
fluorouracil	S-chem
administration	O
before	O
the	O
first	O
dose	O
,	O
assessment	O
of	O
the	O
individual	O
dihydropyrimidine	B-geneY
dehydrogenase	E-geneY
(	O
DPD	S-geneY
)	O
activity	O
may	O
be	O
useful	O
,	O
because	O
this	O
genetically	O
highly	O
polymorphic	O
enzyme	O
controls	O
approximately	O
80	O
%	O
of	O
fluorouracil	S-chem
elimination	O
.	O

A	O
complete	O
or	O
partial	O
loss	O
of	O
DPD	S-geneY
activity	O
in	O
0.1	O
and	O
3	O
-	O
5	O
%	O
of	O
Caucasians	O
,	O
respectively	O
,	O
leads	O
to	O
increased	O
fluorouracil	S-chem
exposure	O
and	O
toxicity	O
.	O

Several	O
methods	O
to	O
assess	O
DPD	S-geneY
activity	O
in	O
patients	O
have	O
been	O
proposed	O
(	O
genotyping	O
,	O
various	O
phenotyping	O
methods	O
)	O
,	O
but	O
each	O
of	O
them	O
has	O
limitations	O
,	O
as	O
has	O
the	O
fluorouracil	S-chem
test	O
dose	O
approach	O
.	O

To	O
adapt	O
exposure	O
towards	O
fluorouracil	S-chem
a	O
priori	O
,	O
a	O
combination	O
of	O
genotyping	O
and	O
phenotyping	O
may	O
yield	O
better	O
prediction	O
of	O
toxicity	O
than	O
one	O
method	O
alone	O
.	O

A	O
prerequisite	O
for	O
dose	O
adaptation	O
is	O
the	O
definition	O
of	O
fluorouracil	S-chem
exposure	O
ranges	O
with	O
sufficient	O
therapeutic	O
activity	O
,	O
but	O
without	O
serious	O
toxicity	O
.	O

While	O
an	O
increased	O
risk	O
of	O
leukopenia	O
,	O
diarrhoea	O
,	O
stomatitis	O
,	O
and	O
hand	O
-	O
foot	O
syndrome	O
during	O
continuous	O
5	O
-	O
day	O
infusions	O
was	O
related	O
to	O
fluorouracil	S-chem
exposures	O
above	O
an	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
threshold	O
of	O
25	O
-	O
30	O
mg.h	O
/	O
L	O
,	O
tumour	O
response	O
was	O
higher	O
when	O
an	O
AUC	O
of	O
approximately	O
30	O
mg.h	O
/	O
L	O
was	O
achieved	O
,	O
illustrating	O
the	O
extremely	O
narrow	O
therapeutic	O
window	O
of	O
fluorouracil	S-chem
.	O

Pharmacokinetic	O
target	O
values	O
are	O
less	O
clear	O
for	O
other	O
regimens	O
,	O
including	O
chronomodulated	O
regimens	O
,	O
which	O
yielded	O
a	O
superior	O
clinically	O
efficacy	O
and	O
tolerability	O
in	O
several	O
trials	O
.	O

However	O
,	O
the	O
monitoring	O
of	O
fluorouracil	S-chem
plasma	O
concentrations	O
seems	O
principally	O
useful	O
for	O
individual	O
a	O
posteriori	O
dose	O
adjustment	O
.	O

Whether	O
an	O
adaptation	O
of	O
the	O
fluorouracil	S-chem
starting	O
dose	O
to	O
the	O
results	O
of	O
two	O
DPD	S-geneY
activity	O
tests	O
before	O
fluorouracil	S-chem
administration	O
a	O
priori	O
,	O
and	O
the	O
adaptation	O
of	O
doses	O
to	O
fluorouracil	S-chem
exposure	O
a	O
posteriori	O
is	O
a	O
reasonable	O
approach	O
to	O
better	O
prevent	O
toxicity	O
and	O
increase	O
efficacy	O
,	O
remains	O
to	O
be	O
evaluated	O
in	O
randomised	O
clinical	O
studies	O
comparing	O
these	O
strategies	O
to	O
routine	O
clinical	O
safety	O
monitoring	O
.	O

Dopamine	B-geneY
D	I-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
-	O
induced	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
-	O
mediated	O
production	O
of	O
prostaglandin	B-chem-C9-1
E	I-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
in	O
D	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
-	O
transfected	O
Chinese	O
hamster	O
ovary	O
cells	O
without	O
simultaneous	O
administration	O
of	O
a	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
mobilizing	O
agent	O
.	O

We	O
have	O
earlier	O
demonstrated	O
that	O
dopamine	O
stimulates	O
the	O
liberation	O
of	O
the	O
prostaglandin	B-chem
E	I-chem
(	I-chem
2	I-chem
)	E-chem
(	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
)	O
precursor	O
,	O
arachidonic	B-chem
acid	E-chem
,	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
transfected	O
with	O
the	O
rat	B-geneY
dopamine	I-geneY
D	I-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	I-geneY
(	I-geneY
long	I-geneY
isoform	I-geneY
)	E-geneY
,	O
also	O
without	O
concomitant	O
administration	O
of	O
a	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
releasing	O
agent	O
[	O
Nilsson	O
et	O
al	O
.	O
,	O
Br	O
J	O
Pharmacol	O
1998	O
;	O
124	O
:	O
1651	O
-	O
8	O
]	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
dopamine	S-chem
,	O
under	O
the	O
same	O
conditions	O
,	O
also	O
induces	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
the	O
production	O
of	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
,	O
with	O
a	O
maximal	O
effect	O
of	O
235	O
%	O
at	O
approximately	O
100	O
microM	O
,	O
and	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
794	O
nM	O
.	O

The	O
effect	O
was	O
counteracted	O
by	O
the	O
D	B-geneY-C6-2
(	I-geneY-C6-2
2	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
eticlopride	S-chem-C6-1
,	O
pertussis	B-geneN
toxin	E-geneN
,	O
the	O
inhibitor	O
of	O
intracellular	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
release	O
TMB	O
-	O
8	O
,	O
incubation	O
in	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
free	O
experimental	O
medium	O
,	O
and	O
PKC	S-geneN
desensitization	O
obtained	O
by	O
chronic	O
pretreatment	O
with	O
the	O
phorbol	O
ester	O
TPA	O
.	O

It	O
was	O
also	O
antagonized	O
by	O
the	O
non	O
-	O
specific	O
cyclooxygenase	S-geneN-C4-2
(	O
COX	S-geneN-C4-2
)	O
inhibitor	O
,	O
indomethacin	S-chem-C4-1
,	O
and	O
by	O
the	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
NS	B-chem-C4-1
-	I-chem-C4-1
398	E-chem-C4-1
,	O
but	O
not	O
by	O
the	O
specific	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibitor	O
,	O
valeryl	B-chem-C4-1
salicylate	E-chem-C4-1
.	O

Both	O
the	O
non	O
-	O
specific	O
phospholipase	B-geneY-C4-2
A	I-geneY-C4-2
(	I-geneY-C4-2
2	I-geneY-C4-2
)	E-geneY-C4-2
inhibitor	O
,	O
quinacrine	S-chem-C4-1
,	O
and	O
an	O
inhibitor	O
of	O
cPLA	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
iPLA	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
,	O
AACOF3	O
,	O
counteracted	O
the	O
effect	O
;	O
in	O
contrast	O
,	O
a	O
selective	O
iPLA	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
inhibitor	O
,	O
BEL	O
,	O
and	O
a	O
selective	O
sPLA	B-geneN
(	I-geneN
2	I-geneN
)	E-geneN
inhibitor	O
,	O
TAPC	O
,	O
were	O
ineffective	O
.	O

No	O
effects	O
of	O
dopamine	S-chem
were	O
obtained	O
in	O
control	O
cells	O
mock	O
-	O
transfected	O
with	O
the	O
p3C	O
vector	O
only	O
.	O

The	O
results	O
reinforce	O
previous	O
assumptions	O
that	O
dopamine	S-chem-C3-1
may	O
interact	O
with	O
eicosanoid	S-chem
metabolism	O
by	O
means	O
of	O
D	B-geneY-C3-2
(	I-geneY-C3-2
2	I-geneY-C3-2
)	I-geneY-C3-2
receptor	E-geneY-C3-2
activation	O
,	O
and	O
implicate	O
an	O
involvement	O
of	O
cPLA	B-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
in	O
this	O
effect	O
.	O

It	O
is	O
suggested	O
that	O
measurement	O
of	O
dopamine	S-chem
-	O
induced	O
PGE	O
(	O
2	O
)	O
production	O
may	O
serve	O
as	O
a	O
convenient	O
way	O
to	O
study	O
D	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
function	O
in	O
vitro	O
.	O

Licofelone	S-chem-C4-1
,	O
a	O
balanced	O
inhibitor	O
of	O
cyclooxygenase	S-geneN-C4-2
and	O
5	B-geneY-C4-2
-	I-geneY-C4-2
lipoxygenase	E-geneY-C4-2
,	O
reduces	O
inflammation	O
in	O
a	O
rabbit	O
model	O
of	O
atherosclerosis	O
.	O

Licofelone	S-chem-C4-1
,	O
a	O
dual	O
anti	O
-	O
inflammatory	O
drug	O
that	O
inhibits	O
5	B-geneY-C4-2
-	I-geneY-C4-2
lipoxygenase	E-geneY-C4-2
(	O
LOX	S-geneN-C4-2
)	O
and	O
cyclooxygenase	S-geneN-C4-2
(	O
COX	S-geneN-C4-2
)	O
enzymes	O
,	O
may	O
have	O
a	O
better	O
cardiovascular	O
profile	O
that	O
cycloxygenase	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
due	O
to	O
cycloxygenase	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
blockade	O
-	O
mediated	O
antithrombotic	O
effect	O
and	O
a	O
better	O
gastrointestinal	O
tolerability	O
.	O

We	O
examined	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
licofelone	S-chem
on	O
atherosclerotic	O
lesions	O
as	O
well	O
as	O
in	O
isolated	O
neutrophils	O
from	O
whole	O
blood	O
of	O
rabbits	O
compared	O
with	O
a	O
selective	O
inhibitor	O
of	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
rofecoxib	S-chem-C4-1
.	O

We	O
also	O
assessed	O
the	O
antithrombotic	O
effect	O
of	O
licofelone	S-chem
in	O
rabbit	O
platelet	O
-	O
rich	O
plasma	O
.	O

For	O
this	O
purpose	O
,	O
30	O
rabbits	O
underwent	O
injury	O
of	O
femoral	O
arteries	O
,	O
and	O
they	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
/	O
kg	O
/	O
day	O
licofelone	S-chem
or	O
5	O
mg	O
/	O
kg	O
/	O
day	O
rofecoxib	S-chem
or	O
no	O
treatment	O
during	O
4	O
weeks	O
with	O
atherogenic	O
diet	O
in	O
all	O
cases	O
.	O

Ten	O
healthy	O
rabbits	O
were	O
used	O
as	O
controls	O
.	O

Neutrophils	O
and	O
platelets	O
were	O
isolated	O
from	O
peripheral	O
blood	O
of	O
rabbits	O
for	O
ex	O
vivo	O
studies	O
.	O

Licofelone	S-chem-C4-1
reduced	O
intima	O
/	O
media	O
ratio	O
in	O
injured	O
arteries	O
,	O
the	O
macrophages	O
infiltration	O
in	O
the	O
neointimal	O
area	O
,	O
monocyte	B-geneY-C4-2
chemoattractant	I-geneY-C4-2
protein	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
(	O
MCP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
)	O
gene	O
expression	O
,	O
and	O
the	O
activation	O
of	O
nuclear	B-geneN-C4-2
factor	I-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
in	O
rabbit	O
atheroma	O
.	O

Moreover	O
,	O
licofelone	S-chem-C4-1
inhibited	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
5	B-geneY-C4-2
-	I-geneY-C4-2
LOX	E-geneY-C4-2
protein	O
expression	O
in	O
vascular	O
lesions	O
.	O

Rofecoxib	S-chem-C4-1
only	O
diminished	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
protein	O
expression	O
and	O
MCP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
gene	O
expression	O
in	O
vascular	O
atheroma	O
.	O

Prostaglandin	B-chem
E	I-chem
(	I-chem
2	I-chem
)	E-chem
in	O
rabbit	O
plasma	O
was	O
attenuated	O
by	O
both	O
drugs	O
.	O

Licofelone	S-chem-C4-1
almost	O
abolished	O
5	B-geneY-MU-2
-	I-geneY-MU-2
LOX	E-geneY-MU-2
activity	O
by	O
inhibiting	O
leukotriene	B-chem-C9-1
B4	E-chem-C9-1
generation	O
in	O
rabbit	O
neutrophils	O
and	O
prevented	O
platelet	O
thromboxane	B-chem-C9-1
B2	E-chem-C9-1
production	O
from	O
whole	O
blood	O
.	O

Licofelone	S-chem
reduces	O
neointimal	O
formation	O
and	O
inflammation	O
in	O
an	O
atherosclerotic	O
rabbit	O
model	O
more	O
markedly	O
than	O
rofecoxib	S-chem
.	O

This	O
effect	O
,	O
together	O
with	O
the	O
antiplatelet	O
activity	O
of	O
licofelone	S-chem
,	O
suggests	O
that	O
this	O
drug	O
may	O
have	O
a	O
favorable	O
cardiovascular	O
profile	O
.	O

FXR	S-geneY
-	O
dependent	O
and	O
-	O
independent	O
interaction	O
of	O
glucocorticoids	O
with	O
the	O
regulatory	O
pathways	O
involved	O
in	O
the	O
control	O
of	O
bile	B-chem
acid	E-chem
handling	O
by	O
the	O
liver	O
.	O

Treatment	O
with	O
glucocorticoids	O
(	O
GCs	O
)	O
may	O
cause	O
adverse	O
effects	O
,	O
including	O
cholestasis	O
.	O

The	O
ability	O
of	O
dexamethasone	S-chem
,	O
prednisolone	S-chem
and	O
budesonide	S-chem
to	O
affect	O
the	O
liver	O
handling	O
of	O
bile	B-chem
acids	E-chem
(	O
BAs	O
)	O
has	O
been	O
investigated	O
.	O

In	O
rats	O
treated	O
with	O
GCs	O
for	O
4	O
days	O
,	O
altered	O
serum	O
and	O
bile	O
BA	O
levels	O
,	O
changed	O
conjugation	O
pattern	O
,	O
and	O
delayed	O
and	O
decreased	O
ability	O
to	O
conjugate	O
/	O
secrete	O
exogenously	O
administered	O
deoxycholate	S-chem
,	O
were	O
found	O
using	O
HPLC	O
-	O
MS	O
/	O
MS	O
.	O

RT	O
-	O
QPCR	O
analyses	O
revealed	O
that	O
GC	O
treatment	O
also	O
induced	O
a	O
down	O
-	O
regulation	O
of	O
liver	B-geneN
nuclear	I-geneN
receptors	E-geneN
(	O
Fxr	S-geneY
,	O
Gr	S-geneY
and	O
Shp	S-geneY
)	O
,	O
transporters	O
(	O
Ntcp	S-geneY
,	O
Mrp4	S-geneY
and	O
Bcrp	S-geneY
)	O
and	O
enzymes	O
(	O
Cyp7a1	S-geneY
and	O
Baat	S-geneY
)	O
,	O
whereas	O
Bsep	S-geneY
,	O
Mrp2	S-geneY
and	O
Cyp27a1	S-geneY
were	O
up	O
-	O
regulated	O
.	O

Human	O
HepG2	O
and	O
Alexander	O
cell	O
lines	O
were	O
used	O
as	O
in	O
vitro	O
models	O
of	O
liver	O
cells	O
with	O
and	O
without	O
constitutive	O
FXR	S-geneY
expression	O
,	O
respectively	O
.	O

In	O
HepG2	O
cells	O
,	O
GCs	O
induced	O
a	O
decreased	O
expression	O
of	O
FXR	S-geneY
and	O
SHP	S-geneY
,	O
and	O
inhibited	O
the	O
regulatory	O
effect	O
of	O
GW4064	S-chem
on	O
FXR	S-geneY
-	O
target	O
genes	O
.	O

In	O
Alexander	O
cells	O
,	O
only	O
when	O
they	O
were	O
transfected	O
with	O
FXR	S-geneY
+	O
RXR	S-geneN
,	O
GW4064	S-chem-MU-1
caused	O
up	O
-	O
regulation	O
of	O
SHP	S-geneY-C3-2
and	O
OSTβ	S-geneY-C3-2
,	O
and	O
a	O
down	O
-	O
regulation	O
of	O
CYP27A1	S-geneY-C4-2
.	O

GCs	O
had	O
the	O
opposite	O
effect	O
on	O
these	O
genes	O
,	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
FXR	S-geneY
expression	O
.	O

Co	O
-	O
transfection	O
of	O
Alexander	O
cells	O
with	O
IR	O
-	O
1	O
-	O
Luc	O
and	O
FXR	S-geneY
+	O
RXR	S-geneN
revealed	O
that	O
GCs	O
did	O
not	O
inhibit	O
but	O
moderately	O
enhanced	O
FXR	S-geneY
activity	O
.	O

Moreover	O
,	O
GCs	O
have	O
a	O
synergistic	O
effect	O
on	O
GW4064	S-chem-C3-1
-	O
induced	O
FXR	S-geneY-C3-2
activation	O
,	O
whereas	O
chenodeoxycholate	S-chem
and	O
GW4064	S-chem
have	O
an	O
additive	O
effect	O
.	O

In	O
conclusion	O
,	O
GCs	O
are	O
able	O
to	O
directly	O
or	O
indirectly	O
activate	O
FXR	S-geneY
but	O
they	O
also	O
antagonize	O
,	O
through	O
FXR	S-geneY
-	O
independent	O
mechanisms	O
,	O
the	O
expression	O
of	O
FXR	S-geneY
and	O
FXR	S-geneY
target	O
genes	O
involved	O
in	O
the	O
hepatic	O
handling	O
of	O
BAs	O
.	O

Glutathione	B-geneN
peroxidases	E-geneN
and	O
redox	O
-	O
regulated	O
transcription	O
factors	O
.	O

Analysis	O
of	O
the	O
selenoproteome	O
identified	O
five	O
glutathione	B-geneN
peroxidases	E-geneN
(	O
GPxs	S-geneN
)	O
in	O
mammals	O
:	O
cytosolic	B-geneN
GPx	E-geneN
(	O
cGPx	S-geneN
,	O
GPx1	S-geneN
)	O
,	O
phospholipid	B-geneN
hydroperoxide	I-geneN
GPx	E-geneN
(	O
PHGPX	S-geneN
,	O
GPx4	S-geneN
)	O
,	O
plasma	B-geneN
GPx	E-geneN
(	O
pGPX	S-geneN
,	O
GPx3	S-geneN
)	O
,	O
gastrointestinal	B-geneN
GPx	E-geneN
(	O
GI	B-geneN
-	I-geneN
GPx	E-geneN
,	O
GPx2	S-geneN
)	O
and	O
,	O
in	O
humans	B-geneY
,	I-geneY
GPx6	E-geneY
,	O
which	O
is	O
restricted	O
to	O
the	O
olfactory	O
system	O
.	O

GPxs	S-geneN-C9-2
reduce	O
hydroperoxides	O
to	O
the	O
corresponding	O
alcohols	S-chem-C9-1
by	O
means	O
of	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
.	O

They	O
have	O
long	O
been	O
considered	O
to	O
only	O
act	O
as	O
antioxidant	O
enzymes	O
.	O

Increasing	O
evidence	O
,	O
however	O
,	O
suggests	O
that	O
nature	O
has	O
not	O
created	O
redundant	O
GPxs	S-geneN
just	O
to	O
detoxify	O
hydroperoxides	O
.	O
cGPx	S-geneY
clearly	O
acts	O
as	O
an	O
antioxidant	O
,	O
as	O
convincingly	O
demonstrated	O
in	O
GPx1	S-geneY
-	O
knockout	O
mice	O
.	O

PHGPx	S-geneN
specifically	O
interferes	O
with	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
activation	O
by	O
interleukin	B-geneN
-	I-geneN
1	E-geneN
,	O
reduces	O
leukotriene	S-chem
and	O
prostanoid	S-chem
biosynthesis	O
,	O
prevents	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
,	O
and	O
is	O
indispensable	O
for	O
sperm	O
maturation	O
and	O
embryogenesis	O
.	O

GI	B-geneN
-	I-geneN
GPx	E-geneN
,	O
which	O
is	O
not	O
exclusively	O
expressed	O
in	O
the	O
gastrointestinal	O
system	O
,	O
is	O
upregulated	O
in	O
colon	O
and	O
skin	O
cancers	O
and	O
in	O
certain	O
cultured	O
cancer	O
cells	O
.	O

GI	B-geneN
-	I-geneN
GPx	E-geneN
is	O
a	O
target	O
for	O
Nrf2	S-geneY
,	O
and	O
thus	O
is	O
part	O
of	O
the	O
adaptive	O
response	O
by	O
itself	O
,	O
while	O
PHGPx	S-geneN
might	O
prevent	O
cancer	O
by	O
interfering	O
with	O
inflammatory	O
pathways	O
.	O

In	O
conclusion	O
,	O
cGPx	S-geneY
,	O
PHGPx	S-geneN
and	O
GI	B-geneN
-	I-geneN
GPx	E-geneN
have	O
distinct	O
roles	O
,	O
particularly	O
in	O
cellular	O
defence	O
mechanisms	O
.	O

Redox	O
sensing	O
and	O
redox	O
regulation	O
of	O
metabolic	O
events	O
have	O
become	O
attractive	O
paradigms	O
to	O
unravel	O
the	O
specific	O
and	O
in	O
part	O
still	O
enigmatic	O
roles	O
of	O
GPxs	S-geneN
.	O

Absence	O
of	O
correlation	O
between	O
oxysterol	S-chem
accumulation	O
in	O
lipid	B-geneN
raft	I-geneN
microdomains	E-geneN
,	O
calcium	S-chem
increase	O
,	O
and	O
apoptosis	O
induction	O
on	O
158N	O
murine	O
oligodendrocytes	O
.	O

There	O
is	O
some	O
evidence	O
that	O
oxidized	O
derivatives	O
of	O
cholesterol	S-chem
,	O
7	B-chem
-	I-chem
ketocholesterol	E-chem
(	O
7KC	S-chem
)	O
and	O
7β	B-chem
-	I-chem
hydroxycholesterol	E-chem
(	O
7βOHC	S-chem
)	O
,	O
are	O
increased	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
neurodegenerative	O
diseases	O
associated	O
with	O
demyelinization	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

It	O
was	O
therefore	O
of	O
interest	O
to	O
investigate	O
the	O
effects	O
of	O
these	O
oxysterols	S-chem
on	O
oligodendrocytes	O
,	O
the	O
myelin	O
-	O
forming	O
cells	O
in	O
the	O
CNS	O
.	O

To	O
this	O
end	O
,	O
158N	O
murine	O
oligodendrocytes	O
were	O
treated	O
with	O
7KC	S-chem-C3-1
or	O
7βOHC	S-chem-C3-1
inducing	O
an	O
apoptotic	O
mode	O
of	O
cell	O
death	O
characterized	O
by	O
condensation	O
/	O
fragmentation	O
of	O
the	O
nuclei	O
,	O
dephosphorylation	O
of	O
Akt	S-geneY
and	O
GSK3	S-geneN
,	O
mitochondrial	O
depolarization	O
involving	O
Mcl	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
,	O
and	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
activation	O
.	O

In	O
contrast	O
,	O
under	O
treatment	O
with	O
27	B-chem
-	I-chem
hydroxycholesterol	E-chem
(	O
27OHC	O
)	O
,	O
no	O
cell	O
death	O
was	O
observed	O
.	O

When	O
the	O
cells	O
were	O
stained	O
with	O
Fura	B-chem
-	I-chem
2	E-chem
,	O
no	O
significant	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
rise	O
was	O
found	O
with	O
the	O
different	O
oxysterols	S-chem
,	O
whereas	O
strong	O
signals	O
were	O
detected	O
with	O
ionomycin	S-chem
used	O
as	O
positive	O
control	O
.	O

At	O
concentrations	O
which	O
induced	O
apoptosis	O
,	O
7KC	S-chem
but	O
not	O
7βOHC	S-chem
accumulated	O
in	O
lipid	O
rafts	O
.	O

Although	O
not	O
cytotoxic	O
,	O
27OHC	S-chem
was	O
mainly	O
detected	O
in	O
lipid	O
rafts	O
.	O

It	O
is	O
noteworthy	O
that	O
α	B-chem
-	I-chem
tocopherol	E-chem
(	O
but	O
not	O
ellagic	B-chem
acid	E-chem
and	O
resveratrol	S-chem
)	O
was	O
able	O
to	O
counteract	O
7KC	S-chem
-	O
and	O
7βOHC	S-chem
-	O
induced	O
apoptosis	O
and	O
to	O
decrease	O
the	O
accumulation	O
of	O
7KC	S-chem
and	O
27OHC	S-chem
in	O
lipid	O
rafts	O
.	O

Thus	O
,	O
in	O
158N	O
cells	O
,	O
the	O
ability	O
of	O
oxysterols	S-chem-C3-1
to	O
trigger	O
a	O
mode	O
of	O
cell	O
death	O
by	O
apoptosis	O
involving	O
GSK	B-geneN-C3-2
-	I-geneN-C3-2
3	E-geneN-C3-2
and	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
activation	O
is	O
independent	O
of	O
the	O
increase	O
in	O
the	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
level	O
and	O
of	O
their	O
accumulation	O
in	O
lipid	O
raft	O
microdomains	O
.	O

Differential	O
IL	B-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
expression	O
in	O
renal	O
allograft	O
recipients	O
treated	O
with	O
an	O
anti	O
-	O
IL	B-geneN
-	I-geneN
2	I-geneN
-	I-geneN
receptor	E-geneN
antibody	O
.	O

Patients	O
were	O
entered	O
into	O
a	O
randomized	O
trial	O
of	O
prophylaxis	O
for	O
renal	O
allograft	O
rejection	O
by	O
the	O
administration	O
of	O
an	O
anti	O
-	O
human	B-geneN
IL	I-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
antibody	O
,	O
anti	O
-	O
Tac	O
,	O
during	O
the	O
first	O
ten	O
days	O
posttransplant	O
.	O

Interleukin	B-geneN
-	I-geneN
2	I-geneN
receptor	E-geneN
(	O
IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
)	O
expression	O
was	O
measured	O
using	O
two	O
anti	O
-	O
IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
monoclonal	O
antibodies	O
(	O
moAbs	O
)	O
,	O
anti	O
-	O
Tac	O
and	O
1HT4	O
-	O
4H3	O
.	O

These	O
two	O
antibodies	O
recognize	O
closely	O
spaced	O
epitopes	O
on	O
the	O
55	O
kD	O
chain	O
of	O
the	O
IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
.	O

IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
expression	O
was	O
examined	O
on	O
peripheral	O
blood	O
small	O
lymphocytes	O
in	O
three	O
groups	O
of	O
patients	O
who	O
received	O
:	O
(	B-chem
A	I-chem
)	I-chem
cyclosporine	E-chem
CsA	S-chem
and	O
prednisone	S-chem
for	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
9	O
)	O
;	O
(	O
B	O
)	O
anti	O
-	O
Tac	O
with	O
CsA	S-chem
and	O
prednisone	S-chem
as	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
12	O
)	O
;	O
and	O
(	O
C	O
)	O
anti	O
-	O
Tac	O
with	O
azathioprine	S-chem
and	O
prednisone	S-chem
as	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
5	O
)	O
.	O

We	O
found	O
that	O
large	O
numbers	O
of	O
T	O
cells	O
express	O
IL	B-geneN
-	I-geneN
2	I-geneN
receptors	E-geneN
despite	O
the	O
presence	O
of	O
anti	O
-	O
Tac	O
(	O
average	O
of	O
IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
-	O
positive	O
cells	O
at	O
day	O
of	O
peak	O
IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
expression	O
56.0	O
+	O
/	O
-	O
20.8	O
%	O
in	O
group	O
A	O
,	O
65.2	O
+	O
/	O
-	O
26.6	O
%	O
in	O
group	O
B	O
,	O
21.0	O
+	O
/	O
-	O
7.4	O
%	O
in	O
group	O
C	O
)	O
.	O

IL	B-geneN
-	I-geneN
2	I-geneN
R	E-geneN
expression	O
did	O
not	O
correlate	O
with	O
clinical	O
activity	O
,	O
and	O
the	O
presence	O
or	O
accessibility	O
of	O
epitopes	O
on	O
the	O
same	O
55	O
kD	O
chain	O
varied	O
dramatically	O
from	O
patient	O
to	O
patient	O
.	O

Effect	O
of	O
thiazinotrienomycin	B-chem
B	E-chem
,	O
an	O
ansamycin	S-chem
antibiotic	O
,	O
on	O
the	O
function	O
of	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
in	O
human	O
stomach	O
tumor	O
cells	O
.	O

Thiazinotrienomycin	B-chem
B	E-chem
(	O
TT	B-chem
-	I-chem
B	E-chem
)	O
,	O
an	O
ansamycin	S-chem
isolated	O
from	O
fermentation	O
broths	O
of	O
Streptomyces	O
sp	O
.	O

MJ672	O
-	O
m3	O
,	O
inhibited	O
the	O
growth	O
in	O
vitro	O
of	O
human	O
stomach	O
tumor	O
SC	O
-	O
6	O
cells	O
over	O
10	O
times	O
more	O
strongly	O
than	O
the	O
growth	O
of	O
other	O
human	O
tumor	O
cells	O
,	O
such	O
as	O
HeLa	O
(	O
cervix	O
)	O
,	O
T24	O
(	O
bladder	O
)	O
and	O
LX	O
-	O
1	O
(	O
lung	O
)	O
.	O

The	O
extent	O
of	O
growth	O
inhibition	O
by	O
TT	O
-	O
B	O
of	O
SC	O
-	O
6	O
,	O
but	O
not	O
of	O
LX	O
-	O
1	O
nor	O
T24	O
,	O
was	O
lowered	O
in	O
a	O
competitive	O
manner	O
by	O
raising	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

TT	B-chem
-	I-chem
B	E-chem
inhibited	O
the	O
cell	O
cycle	O
progression	O
of	O
SC	O
-	O
6	O
at	O
an	O
early	O
stage	O
of	O
the	O
progression	O
from	O
G0	O
/	O
G1	O
to	O
S	O
.	O

The	O
inhibition	O
was	O
again	O
competitive	O
with	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

No	O
direct	O
inhibition	O
of	O
DNA	O
synthesis	O
was	O
observed	O
at	O
the	O
concentration	O
range	O
which	O
caused	O
the	O
cell	O
cycle	O
arrest	O
.	O

TT	B-chem
-	I-chem
B	E-chem
and	O
anti	O
-	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
anti	O
-	O
EGFR	S-geneY
)	O
were	O
antagonistic	O
to	O
each	O
other	O
in	O
inhibiting	O
the	O
cell	O
cycle	O
progression	O
of	O
SC	O
-	O
6	O
from	O
G0	O
/	O
G1	O
to	O
S	O
,	O
suggesting	O
that	O
the	O
two	O
compounds	O
share	O
the	O
same	O
target	O
,	O
EGFR	S-geneY
.	O

The	O
kinase	S-geneN-C4-2
activity	O
of	O
EGFR	S-geneY-C4-2
was	O
little	O
inhibited	O
by	O
TT	B-chem-C4-1
-	I-chem-C4-1
B	E-chem-C4-1
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

Amsacrine	S-chem
and	O
etoposide	S-chem
hypersensitivity	O
of	O
yeast	O
cells	O
overexpressing	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
.	O

Increasing	O
the	O
cellular	O
concentration	O
of	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
in	O
yeast	O
by	O
expressing	O
constitutively	O
a	O
plasmid	O
-	O
borne	O
TOP2	S-geneY
gene	O
encoding	O
the	O
enzyme	O
greatly	O
increases	O
the	O
sensitivity	O
of	O
the	O
cells	O
to	O
amsacrine	S-chem
and	O
etoposide	S-chem
(	O
VP	B-chem
-	I-chem
16	E-chem
)	O
.	O

This	O
increased	O
drug	O
sensitivity	O
at	O
a	O
higher	O
intracellular	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
level	O
is	O
observed	O
in	O
both	O
RAD52	S-geneY
+	O
repair	O
-	O
proficient	O
strains	O
and	O
rad52	S-geneY
mutants	O
that	O
are	O
defective	O
in	O
the	O
repair	O
of	O
double	O
-	O
stranded	O
breaks	O
.	O

These	O
results	O
provide	O
strong	O
support	O
of	O
the	O
hypothesis	O
that	O
the	O
cellular	O
target	O
of	O
these	O
drugs	O
is	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
,	O
and	O
that	O
these	O
drugs	O
kill	O
cells	O
by	O
converting	O
DNA	B-geneY
topoisomerase	I-geneY
II	E-geneY
into	O
a	O
DNA	O
damaging	O
agent	O
.	O

Inhibition	O
of	O
neurite	O
outgrowth	O
and	O
alteration	O
of	O
cytoskeletal	O
gene	O
expression	O
by	O
sodium	B-chem
arsenite	E-chem
.	O

Arsenic	S-chem
compounds	O
that	O
are	O
often	O
found	O
in	O
drinking	O
water	O
increase	O
the	O
risk	O
of	O
developmental	O
brain	O
disorders	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
live	O
imaging	O
analyses	O
of	O
Neuro	O
-	O
2a	O
cells	O
expressing	O
SCAT3	O
,	O
a	O
caspase	B-geneY
-	I-geneY
3	E-geneY
cleavage	O
peptide	O
sequence	O
linking	O
two	O
fluorescent	O
proteins	O
;	O
enhanced	O
cyan	O
fluorescence	O
protein	O
(	O
ECFP	O
)	O
and	O
Venus	O
,	O
to	O
determine	O
whether	O
sodium	B-chem
arsenite	E-chem
(	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
;	O
0	O
,	O
1	O
,	O
5	O
,	O
or	O
10	O
μM	O
)	O
affects	O
both	O
neurite	O
outgrowth	O
and	O
/	O
or	O
induces	O
apoptosis	O
with	O
the	O
same	O
doses	O
and	O
in	O
the	O
same	O
cell	O
cultures	O
.	O

We	O
observed	O
that	O
the	O
area	O
ratio	O
of	O
neurite	O
to	O
cell	O
body	O
in	O
SCAT3	O
-	O
expressing	O
cells	O
was	O
significantly	O
reduced	O
by	O
5	O
and	O
10	O
μM	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
,	O
but	O
not	O
by	O
1	O
μM	O
,	O
although	O
the	O
emission	O
ratio	O
of	O
ECFP	O
to	O
Venus	O
,	O
an	O
endpoint	O
of	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
,	O
was	O
not	O
changed	O
.	O

However	O
,	O
cytological	O
assay	O
using	O
apoptotic	O
and	O
necrotic	O
markers	O
resulted	O
in	O
that	O
apoptosis	O
,	O
but	O
not	O
necrosis	O
,	O
was	O
significantly	O
induced	O
in	O
Neuro	O
-	O
2a	O
cells	O
when	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
exposure	O
continued	O
after	O
the	O
significant	O
effects	O
of	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
on	O
neurite	O
outgrowth	O
were	O
found	O
by	O
live	O
imaging	O
.	O

These	O
results	O
suggested	O
that	O
neurite	O
outgrowth	O
was	O
suppressed	O
by	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
prior	O
to	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
-	O
induced	O
apoptosis	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
on	O
cytoskeletal	O
gene	O
expression	O
in	O
Neuro	O
-	O
2a	O
cells	O
.	O

NaAsO	B-chem-MU-1
(	I-chem-MU-1
2	I-chem-MU-1
)	E-chem-MU-1
increased	O
the	O
mRNA	O
levels	O
of	O
the	O
light	B-geneN-C3-2
and	I-geneN-C3-2
medium	I-geneN-C3-2
subunits	I-geneN-C3-2
of	I-geneN-C3-2
neurofilament	E-geneN-C3-2
and	O
decreased	O
the	O
mRNA	O
levels	O
of	O
tau	S-geneY-C4-2
and	O
tubulin	S-geneN-C4-2
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
no	O
significant	O
effect	O
was	O
found	O
in	O
the	O
mRNA	O
levels	O
of	O
the	O
heavy	B-geneY
subunit	I-geneY
of	I-geneY
neurofilament	E-geneY
,	O
microtubule	B-geneY
-	I-geneY
associated	I-geneY
protein	I-geneY
2	E-geneY
,	O
or	O
actin	S-geneN
.	O

The	O
changes	O
in	O
cytoskeletal	O
gene	O
expression	O
are	O
likely	O
responsible	O
for	O
the	O
inhibitory	O
effects	O
of	O
NaAsO	B-chem
(	I-chem
2	I-chem
)	E-chem
on	O
neurite	O
outgrowth	O
.	O

Tetrahydrofolate	S-chem
biosynthesis	O
in	O
plants	O
:	O
molecular	O
and	O
functional	O
characterization	O
of	O
dihydrofolate	B-geneY
synthetase	E-geneY
and	O
three	O
isoforms	O
of	O
folylpolyglutamate	B-geneN
synthetase	E-geneN
in	O
Arabidopsis	O
thaliana	O
.	O

Tetrahydrofolate	S-chem
coenzymes	O
involved	O
in	O
one	O
-	O
carbon	S-chem
(	O
C1	S-chem
)	O
metabolism	O
are	O
polyglutamylated	O
.	O

In	O
organisms	O
that	O
synthesize	O
tetrahydrofolate	S-chem
de	O
novo	O
,	O
dihydrofolate	B-geneY
synthetase	E-geneY
(	O
DHFS	S-geneY
)	O
and	O
folylpolyglutamate	B-geneN
synthetase	E-geneN
(	O
FPGS	S-geneN
)	O
catalyze	O
the	O
attachment	O
of	O
glutamate	S-chem
residues	O
to	O
the	O
folate	S-chem
molecule	O
.	O

In	O
this	O
study	O
we	O
isolated	O
cDNAs	O
coding	O
a	O
DHFS	S-geneY
and	O
three	O
isoforms	O
of	O
FPGS	S-geneN
from	O
Arabidopsis	O
thaliana	O
.	O

The	O
function	O
of	O
each	O
enzyme	O
was	O
demonstrated	O
by	O
complementation	O
of	O
yeast	O
mutants	O
deficient	O
in	O
DHFS	S-geneY
or	O
FPGS	S-geneY
activity	O
,	O
and	O
by	O
measuring	O
in	O
vitro	O
glutamate	S-chem
incorporation	O
into	O
dihydrofolate	S-chem
or	O
tetrahydrofolate	S-chem
.	O

DHFS	S-geneY-C9-2
is	O
present	O
exclusively	O
in	O
the	O
mitochondria	O
,	O
making	O
this	O
compartment	O
the	O
sole	O
site	O
of	O
synthesis	O
of	O
dihydrofolate	S-chem-C9-1
in	O
the	O
plant	O
cell	O
.	O

In	O
contrast	O
,	O
FPGS	S-geneN
is	O
present	O
as	O
distinct	O
isoforms	O
in	O
the	O
mitochondria	O
,	O
the	O
cytosol	O
,	O
and	O
the	O
chloroplast	O
.	O

Each	O
isoform	O
is	O
encoded	O
by	O
a	O
separate	O
gene	O
,	O
a	O
situation	O
that	O
is	O
unique	O
among	O
eukaryotes	O
.	O

The	O
compartmentation	O
of	O
FPGS	S-geneN
isoforms	O
is	O
in	O
agreement	O
with	O
the	O
predominance	O
of	O
gamma	B-chem
-	I-chem
glutamyl	I-chem
-	I-chem
conjugated	I-chem
tetrahydrofolate	E-chem
derivatives	O
and	O
the	O
presence	O
of	O
serine	B-geneN
hydroxymethyltransferase	E-geneN
and	O
C1	B-geneN
-	I-geneN
tetrahydrofolate	I-geneN
interconverting	I-geneN
enzymes	E-geneN
in	O
the	O
cytosol	O
,	O
the	O
mitochondria	O
,	O
and	O
the	O
plastids	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
FPGS	S-geneN
with	O
these	O
folate	S-chem
-	O
mediated	O
reactions	O
can	O
supply	O
each	O
compartment	O
with	O
the	O
polyglutamylated	O
folate	S-chem
coenzymes	O
required	O
for	O
the	O
reactions	O
of	O
C1	S-chem
metabolism	O
.	O

Also	O
,	O
the	O
multicompartmentation	O
of	O
FPGS	S-geneN
in	O
the	O
plant	O
cell	O
suggests	O
that	O
the	O
transported	O
forms	O
of	O
folate	S-chem
are	O
unconjugated	O
.	O

Wired	O
Enzyme	O
Electrodes	O
-	O
A	O
Retroperspective	O
Story	O
about	O
an	O
Exciting	O
Time	O
at	O
University	O
of	O
Texas	O
at	O
Austin	O
and	O
Its	O
Impact	O
on	O
My	O
Scientific	O
Career	O
.	O

The	O
present	O
paper	O
features	O
an	O
exciting	O
time	O
in	O
the	O
late	O
1980s	O
when	O
I	O
,	O
as	O
a	O
visiting	O
scientist	O
,	O
had	O
the	O
privilege	O
to	O
participate	O
in	O
the	O
early	O
and	O
very	O
exciting	O
development	O
of	O
the	O
in	O
vivo	O
redox	O
-	O
polymer	O
-	O
wired	O
glucose	S-chem
sensor	O
in	O
Professor	O
Adam	O
Heller	O
's	O
laboratory	O
at	O
the	O
Department	O
of	O
Chemical	O
Engineering	O
at	O
University	O
of	O
Texas	O
at	O
Austin	O
.	O

This	O
story	O
is	O
followed	O
by	O
an	O
overview	O
of	O
the	O
research	O
my	O
visit	O
initiated	O
at	O
Uppsala	O
University	O
.	O

In	O
collaboration	O
with	O
Swedish	O
colleagues	O
,	O
we	O
explored	O
a	O
few	O
of	O
the	O
many	O
possibilities	O
to	O
form	O
new	O
biosensors	O
by	O
utilizing	O
Prof	O
.	O

Heller	O
's	O
concept	O
of	O
cross	O
-	O
linked	O
redox	O
-	O
polymer	O
/	O
redox	O
-	O
enzyme	O
electrodes	O
.	O

MAPKAPK2	B-geneN
/	I-geneN
3	E-geneN
Regulate	O
SERCA2a	S-geneY
Expression	O
and	O
Fiber	O
Type	O
Composition	O
to	O
Modulate	O
Skeletal	O
Muscle	O
and	O
Cardiomyocyte	O
Function	O
.	O

The	O
MAPK	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinases	I-geneN
2	I-geneN
and	I-geneN
3	E-geneN
(	O
MAPKAPK2	B-geneN
/	I-geneN
3	E-geneN
,	O
MK2	B-geneN
/	I-geneN
3	E-geneN
)	O
represent	O
protein	B-geneN
kinases	E-geneN
downstream	O
of	O
the	O
p38	S-geneN
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
.	O

Using	O
MK2	B-geneN
/	I-geneN
3	E-geneN
double	O
knockout	O
mice	O
(	O
MK2	B-geneN
/	I-geneN
3	E-geneN
(	O
-	O
/	O
-	O
)	O
)	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
MK2	B-geneN
/	I-geneN
3	E-geneN
in	O
cross	O
-	O
striated	O
muscle	O
by	O
transcriptome	O
and	O
proteome	O
analyses	O
,	O
and	O
by	O
histology	O
.	O

We	O
demonstrated	O
enhanced	O
expression	O
of	O
the	O
slow	O
oxidative	O
skeletal	O
muscle	O
myofiber	O
gene	O
program	O
,	O
including	O
the	O
PPARγ	B-geneY
coactivator	I-geneY
1α	E-geneY
(	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
)	O
.	O

Using	O
reporter	O
gene	O
and	O
electrophoretic	O
gel	O
mobility	O
shift	O
assays	O
we	O
demonstrated	O
that	O
MK2	S-geneY
catalytic	O
activity	O
directly	O
regulated	O
the	O
promoters	O
of	O
the	O
fast	O
fiber	O
-	O
specific	O
myosin	B-geneN
heavy	I-geneN
chain	I-geneN
IId	I-geneN
/	I-geneN
x	E-geneN
and	O
the	O
slow	O
fiber	O
-	O
specific	O
sarco	B-geneY
/	I-geneY
endoplasmic	I-geneY
reticulum	I-geneY
Ca	I-geneY
(	I-geneY
2	I-geneY
+	I-geneY
)	I-geneY
-	I-geneY
ATPase	I-geneY
(	I-geneY
SERCA	I-geneY
)	I-geneY
2	E-geneY
gene	O
.	O

Elevated	O
SERCA2a	S-geneY
gene	O
expression	O
caused	O
by	O
a	O
decreased	O
transcription	O
factor	O
Egr	B-geneY
-	I-geneY
1	E-geneY
to	O
Sp1	S-geneY
ratio	O
was	O
associated	O
with	O
accelerated	O
relaxation	O
and	O
enhanced	O
contractility	O
in	O
MK2	B-geneN
/	I-geneN
3	E-geneN
(	O
-	O
/	O
-	O
)	O
cardiomyocytes	O
,	O
concomitant	O
with	O
improved	O
force	O
parameters	O
in	O
MK2	B-geneN
/	I-geneN
3	E-geneN
(	O
-	O
/	O
-	O
)	O
soleus	O
muscle	O
.	O

These	O
results	O
link	O
MK2	B-geneN
/	I-geneN
3	E-geneN
to	O
the	O
regulation	O
of	O
calcium	S-chem
dynamics	O
and	O
identify	O
enzymatic	O
activity	O
of	O
MK2	B-geneN
/	I-geneN
3	E-geneN
as	O
a	O
critical	O
factor	O
for	O
modulating	O
cross	O
-	O
striated	O
muscle	O
function	O
by	O
generating	O
a	O
unique	O
muscle	O
phenotype	O
exhibiting	O
both	O
,	O
reduced	O
fatigability	O
and	O
enhanced	O
force	O
in	O
MK2	B-geneN
/	I-geneN
3	E-geneN
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Hence	O
,	O
the	O
p38	S-geneN
-	O
MK2	B-geneN
/	I-geneN
3	E-geneN
axis	O
may	O
represent	O
a	O
novel	O
target	O
for	O
the	O
design	O
of	O
therapeutic	O
strategies	O
for	O
diseases	O
related	O
to	O
fiber	O
type	O
changes	O
or	O
impaired	O
SERCA2	S-geneY
function	O
.	O

Effect	O
of	O
apocalmodulin	S-geneY
on	O
recombinant	O
human	B-geneY
brain	I-geneY
glutamic	I-geneY
acid	I-geneY
decarboxylase	E-geneY
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
the	O
recombinant	O
glutathione	B-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
(	O
GST	S-geneN
)	O
-	O
human	B-geneY
L	I-geneY
-	I-geneY
glutamic	I-geneY
acid	I-geneY
decarboxylase	E-geneY
(	O
HGAD	S-geneY
)	O
isoforms	O
,	O
65	B-geneY
-	I-geneY
kDa	I-geneY
L	I-geneY
-	I-geneY
glutamic	I-geneY
acid	I-geneY
decarboxylase	E-geneY
(	O
GAD	S-geneY
)	O
(	O
GST	S-geneN
-	O
HGAD65	S-geneY
)	O
fusion	O
protein	O
or	O
free	O
truncated	O
HGAD65	S-geneY
,	O
were	O
activated	O
by	O
apocalmodulin	S-geneY
(	O
ApoCaM	S-geneY
)	O
to	O
an	O
extent	O
of	O
60	O
%	O
.	O

Both	O
truncated	O
forms	O
of	O
GAD67	S-geneY
(	O
tGAD67	S-geneY
)	O
,	O
HGAD67	B-geneY
(	I-geneY
Delta1	I-geneY
-	I-geneY
70	I-geneY
)	E-geneY
and	O
HGAD67	B-geneY
(	I-geneY
Delta1	I-geneY
-	I-geneY
90	I-geneY
)	E-geneY
,	O
were	O
markedly	O
activated	O
by	O
ApoCaM	S-geneY
to	O
an	O
extent	O
of	O
141	O
and	O
85	O
%	O
,	O
respectively	O
,	O
while	O
GST	S-geneN
-	O
HGAD67	S-geneY
was	O
not	O
significantly	O
affected	O
.	O

The	O
activation	O
appears	O
to	O
be	O
due	O
to	O
an	O
increase	O
of	O
GAD	S-geneY
affinity	O
for	O
its	O
cofactor	O
,	O
pyridoxal	B-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
.	O

This	O
conclusion	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

Firstly	O
,	O
the	O
V	O
(	O
max	O
)	O
of	O
GAD	S-geneY-C9-2
was	O
increased	O
when	O
ApoCaM	S-geneY
was	O
present	O
whereas	O
the	O
affinity	O
for	O
the	O
substrate	O
,	O
glutamate	S-chem-C9-1
,	O
was	O
not	O
affected	O
.	O

Secondly	O
,	O
the	O
affinity	O
of	O
GAD	S-geneY
for	O
PLP	S-chem
was	O
increased	O
in	O
the	O
presence	O
of	O
ApoCaM	S-geneY
.	O

Thirdly	O
,	O
results	O
from	O
calmodulin	S-geneY
-	O
agarose	O
affinity	O
column	O
chromatography	O
studies	O
indicated	O
a	O
direct	O
interaction	O
or	O
binding	O
between	O
ApoCaM	S-geneY
and	O
GAD	S-geneY
.	O

Fourthly	O
,	O
ApoCaM	S-geneY
was	O
found	O
to	O
be	O
copurified	O
with	O
GAD65	S-geneY
/	O
GAD67	S-geneY
by	O
anti	O
-	O
GAD65	B-geneN
/	I-geneN
67	E-geneN
immunoaffinity	O
column	O
using	O
rat	O
brain	O
extract	O
.	O

Hence	O
,	O
it	O
is	O
proposed	O
that	O
a	O
conformational	O
change	O
is	O
induced	O
when	O
ApoCaM	S-geneY
interacts	O
with	O
GAD65	S-geneY
or	O
tGAD67	S-geneY
,	O
resulting	O
in	O
an	O
increase	O
of	O
GAD	S-geneY
affinity	O
for	O
PLP	S-chem
and	O
the	O
activation	O
of	O
GAD	S-geneY
.	O

The	O
physiological	O
significance	O
of	O
the	O
interaction	O
between	O
GAD	S-geneY
and	O
ApoCaM	S-geneY
is	O
discussed	O
.	O

Treatment	O
-	O
related	O
osteoporosis	O
in	O
men	O
with	O
prostate	O
cancer	O
.	O

The	O
intended	O
therapeutic	O
effect	O
of	O
gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
GnRH	S-geneY
)	O
agonists	O
is	O
hypogonadism	O
,	O
a	O
major	O
cause	O
of	O
acquired	O
osteoporosis	O
in	O
men	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
GnRH	S-geneY
agonists	O
increase	O
bone	O
turnover	O
and	O
decrease	O
bone	O
mineral	O
density	O
,	O
a	O
surrogate	O
for	O
fracture	O
risk	O
.	O

Large	O
claims	O
-	O
based	O
analyses	O
and	O
other	O
retrospective	O
studies	O
provide	O
compelling	O
evidence	O
that	O
GnRH	S-geneY
agonists	O
increase	O
risk	O
of	O
clinical	O
fractures	O
.	O

Estrogens	S-chem
play	O
a	O
central	O
role	O
in	O
homeostasis	O
of	O
the	O
normal	O
male	O
skeleton	O
,	O
and	O
estrogen	S-chem
deficiency	O
rather	O
than	O
testosterone	S-chem
deficiency	O
seems	O
to	O
be	O
primarily	O
responsible	O
for	O
the	O
adverse	O
skeletal	O
effects	O
of	O
GnRH	S-geneY
agonists	O
.	O

In	O
randomized	O
controlled	O
trials	O
,	O
bisphosphonates	S-chem
(	O
pamidronate	S-chem
and	O
zoledronic	B-chem
acid	E-chem
)	O
and	O
selective	O
estrogen	B-geneY
receptor	E-geneY
modulators	O
(	O
raloxifene	S-chem
and	O
toremifene	S-chem
)	O
increased	O
bone	O
mineral	O
density	O
in	O
GnRH	S-geneY
agonist	O
-	O
treated	O
men	O
.	O

Two	O
ongoing	O
large	O
randomized	O
placebo	O
-	O
controlled	O
studies	O
will	O
prospectively	O
define	O
fracture	O
outcomes	O
in	O
men	O
with	O
prostate	O
cancer	O
and	O
assess	O
the	O
efficacy	O
of	O
novel	O
pharmacologic	O
interventions	O
(	O
AMG162	O
,	O
toremifene	S-chem
)	O
during	O
GnRH	S-geneY
agonist	O
treatment	O
.	O

In	O
functional	O
experiments	O
,	O
risperidone	S-chem
is	O
selective	O
,	O
not	O
for	O
the	O
B	O
,	O
but	O
for	O
the	O
A	O
subtype	O
of	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
.	O

The	O
potency	O
of	O
the	O
antipsychotic	O
drug	O
,	O
risperidone	S-chem-C6-1
,	O
to	O
antagonize	O
alpha	B-geneY-C6-2
1A	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
-	O
mediated	O
contraction	O
in	O
rat	O
vas	O
deferens	O
and	O
vasoconstriction	O
in	O
rat	O
perfused	O
kidney	O
,	O
and	O
alpha	B-geneY-C6-2
1B	I-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
-	O
mediated	O
contractions	O
in	O
spleen	O
from	O
guinea	O
-	O
pig	O
and	O
mouse	O
was	O
evaluated	O
and	O
compared	O
to	O
that	O
of	O
alpha	B-geneN-C6-2
1	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
subtype	O
-	O
discriminating	O
antagonists	O
.	O

Prazosin	S-chem
was	O
found	O
to	O
be	O
unselective	O
;	O
2	B-chem
-	I-chem
(	I-chem
2,6	I-chem
-	I-chem
dimethoxyphenoxyethyl	I-chem
)	I-chem
aminomethyl	I-chem
-	I-chem
1,4	I-chem
-	I-chem
benzodioxane	E-chem
(	O
WB	B-chem
4101	E-chem
)	O
,	O
5	B-chem
-	I-chem
methyl	I-chem
-	I-chem
urapidil	E-chem
,	O
indoramin	S-chem
and	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
niguldipine	E-chem
were	O
confirmed	O
as	O
selective	O
for	O
the	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptor	E-geneY
,	O
whereas	O
spiperone	S-chem
was	O
weakly	O
alpha	O
1B	O
-	O
selective	O
.	O

Risperidone	S-chem
was	O
equipotent	O
to	O
prazosin	S-chem
at	O
alpha	B-geneY
1A	I-geneY
-	I-geneY
adrenoceptors	E-geneY
in	O
rat	O
vas	O
deferens	O
and	O
kidney	O
.	O

However	O
,	O
at	O
guinea	B-geneN
-	I-geneN
pig	I-geneN
and	I-geneN
mouse	I-geneN
splenic	I-geneN
alpha	I-geneN
1B	I-geneN
-	I-geneN
adrenoceptors	E-geneN
,	O
the	O
affinity	O
values	O
of	O
risperidone	S-chem
were	O
10	O
-	O
fold	O
lower	O
than	O
those	O
of	O
prazosin	S-chem
.	O

Thus	O
,	O
in	O
functional	O
experiments	O
the	O
presumed	O
high	O
selectivity	O
of	O
risperidone	S-chem
for	O
the	O
B	O
subtype	O
of	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptors	E-geneN
could	O
not	O
be	O
confirmed	O
,	O
the	O
drug	O
instead	O
appears	O
to	O
be	O
moderately	O
selective	O
(	O
10	O
-	O
fold	O
)	O
for	O
the	O
A	O
subtype	O
.	O

Screening	O
of	O
acetylcholinesterase	S-geneY
inhibitors	O
by	O
CE	O
after	O
enzymatic	O
reaction	O
at	O
capillary	O
inlet	O
.	O

In	O
this	O
study	O
the	O
development	O
of	O
a	O
procedure	O
based	O
on	O
capillary	O
electrophoresis	O
after	O
enzymatic	O
reaction	O
at	O
capillary	O
inlet	O
methodology	O
for	O
the	O
screening	O
and	O
in	O
vitro	O
evaluation	O
of	O
the	O
biological	O
activity	O
of	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
inhibitors	O
is	O
presented	O
.	O

The	O
progress	O
of	O
the	O
enzymatic	O
reaction	O
of	O
the	O
hydrolysis	O
of	O
acetylthiocholine	S-chem-C9-1
at	O
pH	O
8	O
in	O
the	O
presence	O
of	O
AChE	S-geneY-C9-2
and	O
the	O
inhibitor	O
studied	O
is	O
determined	O
by	O
measuring	O
at	O
230	O
nm	O
the	O
peak	O
area	O
of	O
the	O
reaction	O
product	O
thiocholine	S-chem
(	O
TCh	O
)	O
.	O

In	O
the	O
method	O
employed	O
the	O
capillary	O
was	O
first	O
filled	O
with	O
30	O
mM	O
borate	S-chem
-	O
phosphate	S-chem
buffer	O
(	O
pH	O
8.0	O
)	O
and	O
subsequently	O
,	O
plugs	O
of	O
:	O
(	O
i	O
)	O
water	O
,	O
(	O
ii	O
)	O
AChE	S-geneY
solution	O
,	O
(	O
iii	O
)	O
substrate	O
solution	O
with	O
or	O
without	O
inhibitor	O
,	O
(	O
iv	O
)	O
AChE	S-geneY
solution	O
,	O
and	O
(	O
v	O
)	O
water	O
,	O
were	O
hydrodynamically	O
injected	O
into	O
the	O
capillary	O
,	O
and	O
were	O
allowed	O
to	O
stand	O
(	O
and	O
react	O
)	O
during	O
a	O
waiting	O
period	O
of	O
2	O
min	O
.	O

The	O
applicability	O
of	O
the	O
proposed	O
methodology	O
to	O
estimate	O
different	O
kinetic	O
parameters	O
of	O
interest	O
such	O
as	O
inhibition	O
constants	O
K	O
(	O
i	O
)	O
,	O
identification	O
of	O
inhibitory	O
action	O
mechanism	O
and	O
IC	O
(	O
50	O
)	O
,	O
is	O
evaluated	O
using	O
compounds	O
with	O
known	O
activity	O
,	O
tacrine	S-chem
edrophonium	S-chem
,	O
and	O
neostigmine	S-chem
.	O

The	O
results	O
obtained	O
are	O
compared	O
with	O
bibliographic	O
values	O
and	O
confirm	O
the	O
effectiveness	O
of	O
the	O
methodology	O
proposed	O
.	O

Finally	O
a	O
method	O
for	O
AChE	S-geneY
Inhibitor	O
screening	O
is	O
proposed	O
.	O

[	O
Study	O
on	O
the	O
effect	O
of	O
cysteinyl	B-chem
leukotriene	E-chem
antagonist	O
,	O
pranlukast	B-chem
hydrate	E-chem
,	O
on	O
adhesive	O
interaction	O
between	O
eosinophils	O
and	O
pulmonary	O
endothelial	O
cells	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
cysteinyl	B-chem
leukotriene	E-chem
(	O
CysLT	S-chem
)	O
antagonists	O
reduce	O
the	O
accumulation	O
of	O
eosinophils	O
in	O
the	O
asthmatic	O
airway	O
.	O

However	O
,	O
the	O
exact	O
mechanism	O
of	O
this	O
action	O
remains	O
to	O
be	O
established	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
a	O
CysLT	S-chem
antagonist	O
modifies	O
the	O
adhesive	O
interaction	O
between	O
blood	O
eosinophils	O
and	O
endothelial	O
cells	O
.	O

Pranlukast	B-chem
hydrate	E-chem
,	O
a	O
CysLT	S-chem
antagonist	O
,	O
blocked	O
the	O
chemotactic	O
response	O
and	O
adhesion	O
of	O
eosinophils	O
induced	O
by	O
LTD4	S-chem
.	O

On	O
the	O
other	O
hand	O
,	O
pranlukast	S-chem
did	O
not	O
modify	O
the	O
eosinophil	O
spontaneous	O
adhesion	O
to	O
the	O
resting	O
or	O
IL	B-geneY
-	I-geneY
4	E-geneY
plus	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
-	O
stimulated	O
pulmonary	O
endothelial	O
cells	O
.	O

Similarly	O
,	O
pranlukast	S-chem
did	O
not	O
modulate	O
IL	B-geneY
-	I-geneY
5	E-geneY
-	O
or	O
FMLP	O
-	O
activated	O
eosinophil	O
adhesion	O
to	O
the	O
resting	O
endothelial	O
cells	O
.	O

Finally	O
,	O
pranlukast	S-chem
did	O
not	O
modify	O
the	O
expression	O
of	O
adhesion	O
molecules	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
endothelial	O
activating	O
cytokines	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibitory	O
action	O
of	O
CysLT	S-chem
antagonist	O
on	O
eosinophil	O
accumulation	O
in	O
the	O
asthmatic	O
airways	O
involves	O
mechanisms	O
other	O
than	O
the	O
adhesive	O
interaction	O
between	O
eosinophils	O
and	O
endothelial	O
cells	O
.	O

Serotonin	S-chem
-	O
glutamate	S-chem
and	O
serotonin	S-chem
-	O
dopamine	S-chem
reciprocal	O
interactions	O
as	O
putative	O
molecular	O
targets	O
for	O
novel	O
antipsychotic	O
treatments	O
:	O
from	O
receptor	O
heterodimers	O
to	O
postsynaptic	O
scaffolding	O
and	O
effector	O
proteins	O
.	O

The	O
physical	O
and	O
functional	O
interactions	O
between	O
serotonin	S-chem
-	O
glutamate	S-chem
and	O
serotonin	S-chem
-	O
dopamine	S-chem
signaling	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
psychosis	O
pathophysiology	O
and	O
are	O
supposed	O
to	O
be	O
relevant	O
for	O
antipsychotic	O
treatment	O
.	O

Type	B-geneY
II	I-geneY
metabotropic	I-geneY
glutamate	I-geneY
receptors	E-geneY
(	O
mGluRs	S-geneN
)	O
and	O
serotonin	S-chem
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
receptors	O
have	O
been	O
reported	O
to	O
form	O
heterodimers	O
that	O
modulate	O
G	B-geneN
-	I-geneN
protein	E-geneN
-	O
mediated	O
intracellular	O
signaling	O
differentially	O
compared	O
to	O
mGluR2	S-geneY
and	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
homomers	O
.	O

Additionally	O
,	O
direct	O
evidence	O
has	O
been	O
provided	O
that	O
D	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
and	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
2A	I-geneN
)	I-geneN
receptors	E-geneN
form	O
physical	O
heterocomplexes	O
which	O
exert	O
a	O
functional	O
cross	O
-	O
talk	O
,	O
as	O
demonstrated	O
by	O
studies	O
on	O
hallucinogen	O
-	O
induced	O
signaling	O
.	O

Moving	O
from	O
receptors	O
to	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
scenario	O
,	O
the	O
scaffolding	O
protein	O
PSD	O
-	O
95	O
is	O
known	O
to	O
interact	O
with	O
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
(	I-geneN
NMDA	I-geneN
)	I-geneN
,	I-geneN
D	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
and	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
receptors	E-geneN
,	O
regulating	O
their	O
activation	O
state	O
.	O

Homer1a	O
,	O
the	O
inducible	O
member	O
of	O
the	O
Homer	S-geneN
family	O
of	O
PSD	O
proteins	O
that	O
is	O
implicated	O
in	O
glutamatergic	O
signal	O
transduction	O
,	O
is	O
induced	O
in	O
striatum	O
by	O
antipsychotics	O
with	O
high	O
dopamine	S-chem
receptor	O
affinity	O
and	O
in	O
the	O
cortex	O
by	O
antipsychotics	O
with	O
mixed	O
serotonergic	O
/	O
dopaminergic	O
profile	O
.	O

Signaling	O
molecules	O
,	O
such	O
as	O
Akt	S-geneN
and	O
glycogen	B-geneN
-	I-geneN
synthase	I-geneN
-	I-geneN
kinase	I-geneN
-	I-geneN
3	E-geneN
(	O
GSK	B-geneN
-	I-geneN
3	E-geneN
)	O
,	O
could	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
antipsychotics	O
,	O
targeting	O
dopamine	S-chem
,	O
serotonin	S-chem
,	O
and	O
glutamate	S-chem
neurotransmission	O
.	O

Altogether	O
,	O
these	O
proteins	O
stand	O
at	O
the	O
crossroad	O
of	O
glutamate	S-chem
-	O
dopamine	S-chem
-	O
serotonin	S-chem
signaling	O
pathways	O
and	O
may	O
be	O
considered	O
as	O
valuable	O
molecular	O
targets	O
for	O
current	O
and	O
new	O
antipsychotics	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
critical	O
appraisal	O
on	O
serotonin	S-chem
-	O
glutamate	S-chem
and	O
serotonin	S-chem
-	O
dopamine	S-chem
interplay	O
to	O
support	O
the	O
idea	O
that	O
next	O
generation	O
schizophrenia	O
pharmacotherapy	O
should	O
not	O
exclusively	O
rely	O
on	O
receptor	O
targeting	O
strategies	O
.	O

Purification	O
and	O
characterization	O
of	O
calcitonin	B-geneN
receptors	E-geneN
in	O
rat	O
kidney	O
membranes	O
by	O
covalent	O
cross	O
-	O
linking	O
techniques	O
.	O

We	O
have	O
characterized	O
the	O
binding	O
parameters	O
of	O
renal	B-geneN
receptors	E-geneN
(	O
Scatchard	O
analysis	O
revealed	O
the	O
presence	O
of	O
two	O
binding	O
sites	O
:	O
site	O
I	O
,	O
Ka1	O
=	O
1.29	O
X	O
10	O
(	O
9	O
)	O
M	O
-	O
1	O
,	O
number	O
of	O
binding	O
sites	O
=	O
9.9	O
X	O
10	O
(	O
6	O
)	O
/	O
micrograms	O
protein	O
;	O
site	O
II	O
,	O
Ka2	O
=	O
0.93	O
X	O
10	O
(	O
8	O
)	O
M	O
-	O
1	O
,	O
number	O
of	O
binding	O
sites	O
=	O
4.27	O
X	O
10	O
(	O
8	O
)	O
/	O
micrograms	O
protein	O
)	O
and	O
studied	O
the	O
effect	O
of	O
solubilization	O
.	O

The	O
high	O
-	O
affinity	O
sites	O
are	O
preserved	O
during	O
affinity	O
chromatography	O
and	O
the	O
process	O
results	O
in	O
a	O
6080	O
-	O
fold	O
purification	O
of	O
those	O
sites	O
.	O

The	O
lower	O
-	O
affinity	O
sites	O
are	O
also	O
preserved	O
but	O
the	O
overall	O
purification	O
factor	O
is	O
about	O
40	O
%	O
lower	O
than	O
that	O
obtained	O
using	O
molecular	O
sieving	O
.	O

The	O
purification	O
of	O
the	O
renal	O
calcitonin	B-geneN
receptor	E-geneN
by	O
molecular	O
sieving	O
(	O
Sephacryl	O
S	O
-	O
200	O
)	O
is	O
accompanied	O
by	O
total	O
loss	O
of	O
the	O
high	O
-	O
affinity	O
site	O
;	O
however	O
,	O
the	O
low	O
-	O
affinity	O
site	O
is	O
enriched	O
over	O
1642	O
-	O
fold	O
.	O

Binding	O
parameters	O
were	O
obtained	O
for	O
the	O
purified	O
fractions	O
.	O

Synthetic	O
salmon	O
calcitonin	O
was	O
also	O
bound	O
to	O
renal	O
membranes	O
using	O
the	O
bifunctional	O
reagent	O
disuccinimidyl	B-chem
suberate	E-chem
and	O
photo	O
-	O
affinity	O
cross	O
-	O
linking	O
using	O
hydroxysuccinimidyl	B-chem
azidobenzonate	E-chem
reagent	O
.	O

Cross	O
-	O
linked	O
receptor	O
eluted	O
in	O
the	O
same	O
volume	O
as	O
solubilized	O
membranes	O
specifically	O
binding	O
salmon	O
calcitonin	O
(	O
S	O
-	O
200	O
chromatography	O
)	O
.	O

Sodium	B-chem
dodecyl	I-chem
sulfate	E-chem
polyacrylamide	S-chem
gel	O
electrophoresis	O
analysis	O
of	O
purified	O
fractions	O
showed	O
several	O
protein	O
bands	O
with	O
apparent	O
molecular	O
masses	O
ranging	O
from	O
18	O
000	O
Da	O
to	O
100	O
000	O
Da	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
reducing	O
agent	O
(	O
2	B-chem
-	I-chem
mercaptoethanol	E-chem
)	O
.	O

Autoradiography	O
of	O
polyacrylamide	S-chem
gels	O
of	O
cross	O
-	O
linked	O
calcitonin	B-geneN
receptor	E-geneN
showed	O
only	O
three	O
protein	O
bands	O
specifically	O
binding	O
salmon	O
calcitonin	O
.	O

Their	O
molecular	O
masses	O
were	O
70	O
000	O
Da	O
,	O
40	O
000	O
Da	O
and	O
33	O
000	O
Da	O
respectively	O
.	O

The	O
40	O
000	O
-	O
Da	O
molecule	O
represents	O
a	O
major	O
band	O
(	O
47	O
%	O
total	O
binding	O
species	O
)	O
.	O

This	O
suggests	O
that	O
these	O
three	O
proteins	O
are	O
the	O
principal	O
components	O
of	O
the	O
calcitonin	O
receptor	O
and	O
that	O
S	B-chem
-	I-chem
S	E-chem
bonds	O
are	O
not	O
involved	O
in	O
the	O
assembly	O
of	O
the	O
receptor	O
subunits	O
.	O

Intestinal	O
and	O
hepatic	O
first	O
-	O
pass	O
extraction	O
of	O
the	O
11β	B-geneY-C4-2
-	I-geneY-C4-2
HSD1	E-geneY-C4-2
inhibitor	O
AMG	B-chem-C4-1
221	E-chem-C4-1
in	O
rats	O
with	O
chronic	O
vascular	O
catheters	O
.	O

Abstract	O
1	O
.	O

A	O
catheterized	O
rat	O
model	O
was	O
used	O
to	O
define	O
the	O
intestinal	O
and	O
hepatic	O
components	O
of	O
oral	O
bioavailability	O
for	O
an	O
11β	B-geneY-C4-2
-	I-geneY-C4-2
HSD1	E-geneY-C4-2
inhibitor	O
,	O
AMG	B-chem-C4-1
221	E-chem-C4-1
.	O

These	O
data	O
were	O
integrated	O
with	O
standard	O
in	O
vivo	O
metabolism	O
studies	O
to	O
elucidate	O
the	O
components	O
contributing	O
to	O
the	O
oral	O
disposition	O
of	O
a	O
novel	O
drug	O
candidate	O
.	O

2	O
.	O

Intestinal	O
and	O
hepatic	O
extraction	O
ratios	O
of	O
AMG	B-chem
221	E-chem
obtained	O
using	O
a	O
five	O
-	O
catheter	O
rat	O
model	O
were	O
0.56	O
and	O
0.32	O
,	O
respectively	O
.	O

Therefore	O
,	O
both	O
intestinal	O
and	O
hepatic	O
extraction	O
contributed	O
to	O
the	O
first	O
-	O
pass	O
component	O
of	O
oral	O
bioavailability	O
.	O

There	O
was	O
no	O
evidence	O
for	O
significant	O
gut	O
extraction	O
of	O
systemically	O
administered	O
drug	O
.	O

3	O
.	O

Mass	O
balance	O
data	O
and	O
in	O
vivo	O
metabolite	O
characterization	O
obtained	O
after	O
administration	O
of	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
AMG	I-chem
221	E-chem
to	O
rat	O
showed	O
that	O
AMG	B-chem
221	E-chem
was	O
completely	O
absorbed	O
from	O
the	O
gut	O
lumen	O
following	O
an	O
oral	O
dose	O
,	O
primarily	O
excreted	O
in	O
urine	O
and	O
was	O
almost	O
completely	O
metabolized	O
prior	O
to	O
excretion	O
.	O

4	O
.	O

Hepatic	O
bioavailability	O
(	O
FH	O
)	O
,	O
measured	O
in	O
two	O
animals	O
at	O
various	O
time	O
points	O
after	O
oral	O
dose	O
administration	O
was	O
somewhat	O
variable	O
but	O
generally	O
characterized	O
by	O
an	O
initial	O
reduction	O
during	O
the	O
absorption	O
phase	O
followed	O
by	O
an	O
increase	O
during	O
the	O
elimination	O
phase	O
,	O
consistent	O
with	O
hepatic	O
distribution	O
of	O
AMG	B-chem
221	E-chem
.	O

5	O
.	O

The	O
five	O
-	O
catheter	O
rat	O
model	O
afforded	O
estimates	O
of	O
hepatic	O
and	O
intestinal	O
contribution	O
to	O
oral	O
bioavailability	O
that	O
were	O
used	O
with	O
other	O
data	O
to	O
define	O
the	O
preclinical	O
ADME	O
characteristics	O
of	O
a	O
drug	O
candidate	O
.	O

Pirfenidone	S-chem-C4-1
inhibits	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
expression	O
in	O
malignant	O
glioma	O
cells	O
.	O

Due	O
to	O
its	O
immunosuppressive	O
properties	O
,	O
the	O
cytokine	S-geneN
transforming	B-geneY
growth	I-geneY
factor	I-geneY
(	I-geneY
TGF	I-geneY
)	I-geneY
-	I-geneY
beta	E-geneY
has	O
become	O
a	O
promising	O
target	O
in	O
the	O
experimental	O
treatment	O
of	O
human	O
malignant	O
gliomas	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
antifibrotic	O
drug	O
5	B-chem-C4-1
-	I-chem-C4-1
methyl	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
phenyl	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
1H	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
pyridone	E-chem-C4-1
(	O
pirfenidone	S-chem-C4-1
,	O
PFD	S-chem-C4-1
)	O
elicits	O
growth	O
-	O
inhibitory	O
effects	O
and	O
reduces	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta2	E-geneY-C4-2
protein	O
levels	O
in	O
human	O
glioma	O
cell	O
lines	O
.	O

This	O
reduction	O
in	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta2	E-geneY-C4-2
is	O
biologically	O
relevant	O
since	O
PFD	S-chem-C4-1
treatment	O
reduces	O
the	O
growth	O
inhibition	O
of	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
-	O
sensitive	O
CCL	O
-	O
64	O
cells	O
mediated	O
by	O
conditioned	O
media	O
of	O
glioma	O
cells	O
.	O

The	O
downregulation	O
of	O
TGF	B-geneY
-	I-geneY
beta	E-geneY
is	O
mediated	O
at	O
multiple	O
levels	O
.	O

PFD	S-chem-C4-1
leads	O
to	O
a	O
reduction	O
of	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta2	E-geneY-C4-2
mRNA	O
levels	O
and	O
of	O
the	O
mature	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta2	E-geneY-C4-2
protein	O
due	O
to	O
decreased	O
expression	O
and	O
direct	O
inhibition	O
of	O
the	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
pro	B-geneN-C4-2
-	I-geneN-C4-2
protein	I-geneN-C4-2
convertase	E-geneN-C4-2
furin	S-geneY-C4-2
.	O

In	O
addition	O
,	O
PFD	S-chem-C4-1
reduces	O
the	O
protein	O
levels	O
of	O
the	O
matrix	B-geneY-C4-2
metalloproteinase	I-geneY-C4-2
(	I-geneY-C4-2
MMP	I-geneY-C4-2
)	I-geneY-C4-2
-	I-geneY-C4-2
11	E-geneY-C4-2
,	O
a	O
TGF	B-geneY-C4-2
-	I-geneY-C4-2
beta	E-geneY-C4-2
target	O
gene	O
and	O
furin	S-geneY
substrate	O
involved	O
in	O
carcinogenesis	O
.	O

These	O
data	O
define	O
PFD	S-chem
or	O
PFD	S-chem
-	O
related	O
agents	O
as	O
promising	O
agents	O
for	O
human	O
cancers	O
associated	O
with	O
enhanced	O
TGF	B-geneY
-	I-geneY
beta	E-geneY
activity	O
.	O

Inhibitory	O
effects	O
of	O
the	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitor	O
tranylcypromine	S-chem-C4-1
on	O
the	O
cytochrome	B-geneN
P450	E-geneN
enzymes	O
CYP2C19	S-geneY
,	O
CYP2C9	S-geneY
,	O
and	O
CYP2D6	S-geneY
.	O

1	O
.	O

The	O
inhibitory	O
effects	O
of	O
tranylcypromine	S-chem-C4-1
,	O
a	O
nonselective	O
irreversible	O
inhibitor	O
of	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
(	O
MAO	S-geneN-C4-2
)	O
,	O
on	O
three	O
cytochrome	B-geneN
P450	E-geneN
(	O
CYP	S-geneN
)	O
enzymes	O
,	O
namely	O
CYP2C9	S-geneY
,	O
CYP2C19	S-geneY
,	O
and	O
CYP2D6	S-geneY
,	O
have	O
been	O
evaluated	O
in	O
vitro	O
.	O

2	O
.	O

The	O
studies	O
were	O
conducted	O
using	O
cDNA	O
-	O
expressed	O
human	B-geneN
CYP	E-geneN
enzymes	O
and	O
probe	O
substrates	O
.	O

3	O
.	O

A	O
range	O
of	O
substrate	O
concentrations	O
was	O
coincubated	O
with	O
a	O
range	O
of	O
tranylcypromine	S-chem
concentrations	O
in	O
the	O
presence	O
of	O
each	O
of	O
the	O
CYP	S-geneN
enzymes	O
at	O
37	O
degrees	O
C	O
for	O
a	O
predetermined	O
period	O
of	O
time	O
.	O

Product	O
concentrations	O
were	O
quantified	O
by	O
HPLC	O
with	O
UV	O
detection	O
.	O

4	O
.	O

The	O
results	O
demonstrated	O
that	O
tranylcypromine	S-chem-C4-1
is	O
a	O
competitive	O
inhibitor	O
of	O
CYP2C19	S-geneY-C4-2
(	O
Ki	O
=	O
32	O
microM	O
)	O
and	O
CYP2D6	S-geneY-C4-2
(	O
Ki	O
=	O
367	O
microM	O
)	O
and	O
a	O
noncompetitive	O
inhibitor	O
of	O
CYP2C9	S-geneY-C4-2
(	O
Ki	O
=	O
56	O
microM	O
)	O
.	O

5	O
.	O

None	O
of	O
these	O
inhibitory	O
effects	O
are	O
considered	O
clinically	O
significant	O
at	O
usual	O
therapeutic	O
doses	O
.	O

However	O
,	O
in	O
certain	O
situations	O
such	O
as	O
high	O
dose	O
tranylcypromine	S-chem
therapy	O
,	O
or	O
in	O
poor	O
metabolizers	O
of	O
CYP2C19	S-geneY
substrates	O
,	O
clinically	O
significant	O
interactions	O
might	O
occur	O
,	O
particularly	O
when	O
tranylcypromine	S-chem
is	O
coadministered	O
with	O
drugs	O
with	O
a	O
narrow	O
therapeutic	O
index	O
.	O

Anticancer	O
activity	O
of	O
novel	O
hybrid	O
molecules	O
containing	O
5	B-chem
-	I-chem
benzylidene	I-chem
thiazolidine	I-chem
-	I-chem
2,4	I-chem
-	I-chem
dione	E-chem
.	O

Hybridization	O
of	O
two	O
different	O
bioactive	O
molecules	O
with	O
different	O
mechanism	O
of	O
action	O
is	O
one	O
of	O
the	O
methods	O
that	O
are	O
being	O
adopted	O
to	O
treat	O
cancer	O
.	O

Molecules	O
bearing	O
a	O
thiazolidine	B-chem
-	I-chem
2,4	I-chem
-	I-chem
dione	E-chem
scaffold	O
have	O
been	O
recognized	O
as	O
antineoplastic	O
agents	O
with	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
many	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
described	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
two	O
series	O
of	O
N	B-chem
-	I-chem
3	I-chem
-	I-chem
substituted	I-chem
-	I-chem
5	I-chem
-	I-chem
arylidene	I-chem
thiazolidine	I-chem
-	I-chem
2,4	I-chem
-	I-chem
diones	E-chem
,	O
bearing	O
the	O
α	B-chem
-	I-chem
bromoacryloylamido	E-chem
moiety	O
at	O
the	O
para	O
-	O
or	O
meta	O
-	O
position	O
on	O
the	O
phenyl	S-chem
of	O
the	O
arylidene	S-chem
portion	O
.	O

We	O
have	O
observed	O
that	O
selected	O
compounds	O
5a	O
,	O
5c	O
and	O
5g	O
suppress	O
proliferation	O
of	O
human	O
myeloid	O
leukaemia	O
HL	O
-	O
60	O
and	O
U937	O
cells	O
by	O
triggering	O
morphological	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
which	O
are	O
well	O
-	O
known	O
features	O
of	O
apoptosis	O
.	O

Finally	O
,	O
our	O
results	O
indicated	O
that	O
the	O
investigated	O
compounds	O
induced	O
apoptotic	O
cell	O
death	O
through	O
a	O
mechanism	O
that	O
involved	O
activation	O
of	O
multiple	O
caspases	S-geneN
and	O
was	O
also	O
associated	O
with	O
the	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
from	O
the	O
mitochondria	O
.	O

Toxicity	O
of	O
beta	B-geneY
-	I-geneY
amyloid	E-geneY
in	O
HEK293	O
cells	O
expressing	O
NR1	S-geneY
/	O
NR2A	S-geneY
or	O
NR1	S-geneY
/	O
NR2B	S-geneY
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
receptor	E-geneN
subunits	O
.	O

Neurotoxicity	O
induced	O
by	O
beta	B-geneY
-	I-geneY
amyloid	I-geneY
peptide	E-geneY
(	O
Abeta	S-geneY
)	O
involves	O
glutamate	S-chem
toxicity	O
,	O
resulting	O
from	O
overactivation	O
of	O
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
(	I-geneN
NMDA	I-geneN
)	I-geneN
receptors	E-geneN
and	O
elevation	O
of	O
intracellular	O
calcium	S-chem
.	O

However	O
,	O
the	O
heterogeneity	O
of	O
the	O
NMDA	B-geneN
receptors	E-geneN
,	O
frequently	O
composed	O
of	O
NR1	S-geneY
and	O
NR2A	B-geneN
-	I-geneN
D	E-geneN
subunits	O
,	O
has	O
been	O
less	O
studied	O
.	O

Thus	O
,	O
we	O
determined	O
the	O
contribution	O
of	O
NMDA	B-geneN
receptor	E-geneN
subtypes	O
on	O
Abeta	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
40	I-geneY
)	E-geneY
toxicity	O
in	O
HEK293	O
cells	O
transiently	O
expressing	O
NR1	S-geneY
/	O
NR2A	S-geneY
or	O
NR1	S-geneY
/	O
NR2B	S-geneY
subunits	O
.	O

Analysis	O
of	O
lactate	B-geneN
dehydrogenase	E-geneN
(	O
LDH	S-geneN
)	O
release	O
and	O
trypan	B-chem
blue	E-chem
exclusion	O
revealed	O
an	O
increase	O
in	O
Abeta	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
40	I-geneY
)	E-geneY
toxicity	O
upon	O
NR1	S-geneY
/	O
NR2A	S-geneY
expression	O
,	O
compared	O
to	O
NR1	S-geneY
/	O
NR2B	S-geneY
,	O
indicating	O
loss	O
of	O
plasma	O
membrane	O
integrity	O
.	O

Furthermore	O
,	O
Abeta	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
40	I-geneY
)	E-geneY
decreased	O
intracellular	O
ATP	S-chem
in	O
cells	O
expressing	O
NR1	S-geneY
/	O
NR2A	S-geneY
.	O

MK	B-chem-C6-1
-	I-chem-C6-1
801	E-chem-C6-1
(	O
(	B-chem-C6-1
+	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
5	I-chem-C6-1
-	I-chem-C6-1
methyl	I-chem-C6-1
-	I-chem-C6-1
10,11	I-chem-C6-1
-	I-chem-C6-1
dihydro	I-chem-C6-1
-	I-chem-C6-1
5H	I-chem-C6-1
-	I-chem-C6-1
dibenzo	I-chem-C6-1
[	I-chem-C6-1
a	I-chem-C6-1
,	I-chem-C6-1
d	I-chem-C6-1
]	I-chem-C6-1
cyclohepten	I-chem-C6-1
-	I-chem-C6-1
5,10	I-chem-C6-1
-	I-chem-C6-1
imine	I-chem-C6-1
maleate	E-chem-C6-1
)	O
,	O
a	O
noncompetitive	O
NMDA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
partially	O
prevented	O
the	O
decrease	O
in	O
cell	O
viability	O
and	O
the	O
energy	O
impairment	O
.	O

These	O
differences	O
were	O
not	O
accounted	O
for	O
by	O
the	O
activation	O
of	O
caspases	B-geneN
2	I-geneN
,	I-geneN
3	I-geneN
,	I-geneN
8	I-geneN
and	I-geneN
9	E-geneN
or	O
calpains	O
or	O
by	O
DNA	O
fragmentation	O
,	O
excluding	O
the	O
hypothesis	O
of	O
apoptosis	O
.	O

Functional	O
NR1	S-geneY
/	O
NR2A	S-geneY
and	O
NR1	S-geneY
/	O
NR2B	S-geneY
receptor	O
subtypes	O
were	O
further	O
evidenced	O
by	O
single	O
-	O
cell	O
calcium	S-chem
imaging	O
.	O

Stimulation	O
of	O
NR1	S-geneY
/	O
NR2A	S-geneY
receptors	O
with	O
NMDA	S-chem
/	O
glycine	S-chem
revealed	O
an	O
increase	O
in	O
intracellular	O
calcium	S-chem
in	O
cells	O
pre	O
-	O
exposed	O
to	O
Abeta	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
40	I-geneY
)	E-geneY
.	O

Opposite	O
effects	O
were	O
observed	O
upon	O
activation	O
of	O
NR1	S-geneY
/	O
NR2B	S-geneY
receptors	O
.	O

These	O
results	O
suggest	O
that	O
NR1	S-geneY
/	O
NR2A	S-geneY
-	O
composed	O
NMDA	B-geneN
receptors	E-geneN
mediate	O
necrotic	O
cell	O
death	O
in	O
HEK293	O
cells	O
exposed	O
to	O
Abeta	B-geneY
(	I-geneY
1	I-geneY
-	I-geneY
40	I-geneY
)	E-geneY
through	O
changes	O
in	O
calcium	S-chem
homeostasis	O
.	O

Ruxolitinib	S-chem
:	O
a	O
new	O
treatment	O
option	O
for	O
myelofibrosis	O
.	O

Myelofibrosis	O
is	O
a	O
myeloproliferative	O
neoplasm	O
characterized	O
by	O
bone	O
marrow	O
fibrosis	O
and	O
extramedullary	O
hematopoiesis	O
.	O

Evolution	O
of	O
myelofibrosis	O
can	O
lead	O
to	O
life	O
-	O
threatening	O
complications	O
,	O
including	O
transformation	O
to	O
leukemia	O
,	O
thrombotic	O
events	O
,	O
and	O
hemorrhagic	O
episodes	O
.	O

The	O
only	O
curative	O
therapy	O
for	O
myelofibrosis	O
is	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Because	O
this	O
disease	O
manifests	O
primarily	O
in	O
the	O
older	O
population	O
,	O
many	O
patients	O
diagnosed	O
with	O
myelofibrosis	O
are	O
not	O
considered	O
medically	O
fit	O
for	O
such	O
aggressive	O
therapy	O
.	O

Other	O
available	O
medical	O
therapies	O
do	O
not	O
halt	O
disease	O
progression	O
;	O
instead	O
,	O
current	O
treatment	O
strategies	O
have	O
focused	O
on	O
targeting	O
specific	O
symptomology	O
,	O
although	O
with	O
limited	O
efficacy	O
.	O

The	O
lack	O
of	O
effective	O
treatment	O
options	O
for	O
patients	O
with	O
myelofibrosis	O
has	O
rendered	O
this	O
orphan	O
disease	O
state	O
an	O
unmet	O
medical	O
need	O
,	O
and	O
novel	O
approaches	O
to	O
improve	O
outcomes	O
are	O
necessary	O
.	O

Emerging	O
research	O
has	O
identified	O
numerous	O
molecular	O
mutations	O
in	O
patients	O
with	O
myelofibrosis	O
,	O
making	O
this	O
disease	O
a	O
potential	O
candidate	O
for	O
molecularly	O
targeted	O
therapy	O
.	O

The	O
most	O
prevalent	O
mutation	O
identified	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
Janus	B-geneN
kinase	E-geneN
(	O
JAK	S-geneN
)	O
family	O
,	O
JAK2	S-geneY
V617F	S-geneN
,	O
which	O
has	O
been	O
identified	O
in	O
more	O
than	O
half	O
of	O
patients	O
with	O
myelofibrosis	O
.	O

This	O
mutation	O
results	O
in	O
a	O
constitutively	O
active	O
JAK	S-geneN
-	O
signal	B-geneN
transducer	I-geneN
and	I-geneN
activator	I-geneN
of	I-geneN
transcription	E-geneN
pathway	O
resulting	O
in	O
dysregulated	O
cellular	O
proliferation	O
and	O
hematopoiesis	O
.	O

Ruxolitinib	S-chem-C4-1
is	O
a	O
small	O
-	O
molecule	O
inhibitor	O
of	O
JAK1	O
and	O
JAK2	O
and	O
recently	O
became	O
the	O
first	O
drug	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
symptomatic	O
intermediate	O
-	O
or	O
high	O
-	O
risk	O
myelofibrosis	O
.	O

In	O
clinical	O
trials	O
,	O
ruxolitinib	S-chem
demonstrated	O
promising	O
efficacy	O
in	O
reducing	O
splenomegaly	O
and	O
myelofibrosis	O
-	O
related	O
symptoms	O
.	O

However	O
,	O
ruxolitinib	S-chem
did	O
not	O
demonstrate	O
disease	O
-	O
modifying	O
potential	O
and	O
is	O
not	O
considered	O
a	O
curative	O
therapeutic	O
option	O
.	O

Adverse	O
events	O
associated	O
with	O
ruxolitinib	O
are	O
primarily	O
hematologic	O
,	O
with	O
thrombocytopenia	O
and	O
anemia	O
being	O
the	O
most	O
common	O
toxicologic	O
events	O
identified	O
.	O

Future	O
research	O
will	O
shed	O
light	O
on	O
whether	O
ruxolitinib	S-chem
in	O
combination	O
with	O
other	O
treatments	O
will	O
further	O
enhance	O
outcomes	O
in	O
myelofibrosis	O
.	O

Salsolinol	S-chem
induced	O
apoptotic	O
changes	O
in	O
neural	O
stem	O
cells	O
:	O
amelioration	O
by	O
neurotrophin	S-geneN
support	O
.	O

Salsolinol	S-chem
(	O
SAL	S-chem
)	O
,	O
a	O
catechol	B-chem
isoquinoline	E-chem
has	O
invited	O
considerable	O
attention	O
due	O
to	O
its	O
structural	O
similarity	O
with	O
dopaminergic	O
neurotoxin	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1,2,3,6	I-chem
-	I-chem
tetrahydropyridine	E-chem
(	O
MPTP	S-chem
)	O
.	O

Its	O
high	O
endogenous	O
presence	O
in	O
Parkinsonian	O
brain	O
implicated	O
its	O
possible	O
association	O
with	O
the	O
disease	O
process	O
.	O

SAL	S-chem
is	O
also	O
present	O
in	O
alcohol	O
beverages	O
and	O
certain	O
food	O
materials	O
and	O
can	O
get	O
access	O
to	O
brain	O
especially	O
in	O
conditions	O
of	O
immature	O
or	O
impaired	O
BBB	O
.	O

Besides	O
this	O
,	O
the	O
effect	O
of	O
SAL	S-chem
on	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
which	O
are	O
potential	O
candidates	O
for	O
adult	O
neurogenesis	O
and	O
transplantation	O
mediated	O
rejuvenating	O
attempts	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
brain	O
has	O
not	O
been	O
known	O
so	O
far	O
.	O

NSCs	O
in	O
both	O
the	O
cases	O
have	O
to	O
overcome	O
suppressive	O
cues	O
of	O
diseased	O
brain	O
for	O
their	O
survival	O
and	O
function	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
toxicity	O
of	O
SAL	S-chem
toward	O
NSCs	O
focusing	O
on	O
apoptosis	O
and	O
status	O
of	O
PI3K	S-geneN
survival	O
signaling	O
.	O

NSCs	O
cultured	O
from	O
embryonic	O
day	O
11	O
rat	O
fetal	O
brain	O
including	O
those	O
differentiated	O
to	O
TH	O
(	O
+	O
ve	O
)	O
colonies	O
,	O
when	O
challenged	O
with	O
SAL	S-chem
(	O
1	O
-	O
100μM	O
)	O
,	O
elicited	O
a	O
concentration	O
and	O
time	O
dependent	O
cell	O
death	O
/	O
loss	O
of	O
mitochondrial	O
viability	O
.	O

10μM	O
SAL	S-chem
on	O
which	O
significant	O
mitochondrial	O
impairment	O
initiated	O
was	O
further	O
used	O
to	O
study	O
mechanism	O
of	O
toxicity	O
.	O

Morphological	O
impairment	O
,	O
enhanced	O
TUNEL	O
positivity	O
,	O
cleaved	O
caspase	B-geneY
-	I-geneY
3	E-geneY
and	O
decreased	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
:	O
Bax	S-geneY
suggested	O
apoptosis	O
.	O

Sal	S-chem-C4-1
toxicity	O
coincided	O
with	O
reduced	O
pAkt	S-geneN-C4-2
level	O
and	O
its	O
downstream	O
effectors	O
:	O
pCREB	S-geneN-C4-2
,	O
pGSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
,	O
Bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
and	O
neurotrophins	S-geneN-C4-2
GDNF	S-geneY-C4-2
,	O
BDNF	S-geneY-C4-2
suggesting	O
repressed	O
PI3K	S-geneN-C4-2
/	O
Akt	S-geneN-C4-2
signaling	O
.	O

Multiple	O
neurotrophic	O
factor	O
support	O
in	O
the	O
form	O
of	O
Olfactory	O
Ensheathing	O
Cell	O
's	O
Conditioned	O
Media	O
(	O
OEC	O
CM	O
)	O
potentially	O
protected	O
NSCs	O
against	O
SAL	S-chem
through	O
activating	O
PI3K	S-geneN
/	O
Akt	S-geneN
pathway	O
.	O

This	O
was	O
confirmed	O
on	O
adding	O
LY294002	S-chem-C4-1
the	O
PI3K	S-geneN-C4-2
inhibitor	O
which	O
abolished	O
the	O
protection	O
.	O

We	O
inferred	O
that	O
SAL	S-chem
exerts	O
substantial	O
toxicity	O
toward	O
NSCs	O
.	O

These	O
findings	O
will	O
lead	O
to	O
better	O
understanding	O
of	O
endogenous	O
threats	O
that	O
might	O
affect	O
the	O
fate	O
of	O
transplanted	O
NSCs	O
and	O
their	O
probable	O
antidotes	O
.	O

Crystal	O
structure	O
of	O
a	O
human	O
membrane	O
protein	O
involved	O
in	O
cysteinyl	B-chem
leukotriene	E-chem
biosynthesis	O
.	O

The	O
cysteinyl	B-chem
leukotrienes	E-chem
,	O
namely	O
leukotriene	B-chem
(	I-chem
LT	I-chem
)	I-chem
C4	E-chem
and	O
its	O
metabolites	O
LTD4	S-chem
and	O
LTE4	S-chem
,	O
the	O
components	O
of	O
slow	O
-	O
reacting	O
substance	O
of	O
anaphylaxis	O
,	O
are	O
lipid	O
mediators	O
of	O
smooth	O
muscle	O
constriction	O
and	O
inflammation	O
,	O
particularly	O
implicated	O
in	O
bronchial	O
asthma	O
.	O

LTC4	B-geneY-C9-2
synthase	E-geneY-C9-2
(	O
LTC4S	S-geneY-C9-2
)	O
,	O
the	O
pivotal	O
enzyme	O
for	O
the	O
biosynthesis	O
of	O
LTC4	S-chem-C9-1
(	O
ref	O
.	O

10	O
)	O
,	O
is	O
an	O
18	O
-	O
kDa	O
integral	O
nuclear	O
membrane	O
protein	O
that	O
belongs	O
to	O
a	O
superfamily	O
of	O
membrane	O
-	O
associated	O
proteins	O
in	O
eicosanoid	S-chem-C9-1
and	O
glutathione	S-chem-C9-1
metabolism	O
that	O
includes	O
5	B-geneY
-	I-geneY
lipoxygenase	I-geneY
-	I-geneY
activating	I-geneY
protein	E-geneY
,	O
microsomal	B-geneN-C9-2
glutathione	I-geneN-C9-2
S	I-geneN-C9-2
-	I-geneN-C9-2
transferases	E-geneN-C9-2
(	O
MGSTs	S-geneN-C9-2
)	O
,	O
and	O
microsomal	B-geneY-C9-2
prostaglandin	I-geneY-C9-2
E	I-geneY-C9-2
synthase	I-geneY-C9-2
1	E-geneY-C9-2
(	O
ref	O
.	O

13	O
)	O
.	O

LTC4S	S-geneY
conjugates	O
glutathione	S-chem
to	O
LTA4	S-chem
,	O
the	O
endogenous	O
substrate	O
derived	O
from	O
arachidonic	B-chem
acid	E-chem
through	O
the	O
5	B-geneY
-	I-geneY
lipoxygenase	E-geneY
pathway	O
.	O

In	O
contrast	O
with	O
MGST2	S-geneY
and	O
MGST3	S-geneY
(	O
refs	O
15	O
,	O
16	O
)	O
,	O
LTC4S	S-geneY
does	O
not	O
conjugate	O
glutathione	S-chem
to	O
xenobiotics	O
.	O

Here	O
we	O
show	O
the	O
atomic	O
structure	O
of	O
human	B-geneY
LTC4S	E-geneY
in	O
a	O
complex	O
with	O
glutathione	S-chem
at	O
3.3	O
A	O
resolution	O
by	O
X	O
-	O
ray	O
crystallography	O
and	O
provide	O
insights	O
into	O
the	O
high	O
substrate	O
specificity	O
for	O
glutathione	S-chem
and	O
LTA4	S-chem
that	O
distinguishes	O
LTC4S	S-geneY
from	O
other	O
MGSTs	S-geneN
.	O

The	O
LTC4S	S-geneY
monomer	O
has	O
four	O
transmembrane	O
alpha	O
-	O
helices	O
and	O
forms	O
a	O
threefold	O
symmetric	O
trimer	O
as	O
a	O
unit	O
with	O
functional	O
domains	O
across	O
each	O
interface	O
.	O

Glutathione	S-chem
resides	O
in	O
a	O
U	O
-	O
shaped	O
conformation	O
within	O
an	O
interface	O
between	O
adjacent	O
monomers	O
,	O
and	O
this	O
binding	O
is	O
stabilized	O
by	O
a	O
loop	O
structure	O
at	O
the	O
top	O
of	O
the	O
interface	O
.	O

LTA4	S-chem
would	O
fit	O
into	O
the	O
interface	O
so	O
that	O
Arg	S-chem
104	O
of	O
one	O
monomer	O
activates	O
glutathione	S-chem
to	O
provide	O
the	O
thiolate	S-chem
anion	O
that	O
attacks	O
C6	S-chem
of	O
LTA4	S-chem
to	O
form	O
a	O
thioether	S-chem
bond	O
,	O
and	O
Arg	S-chem
31	O
in	O
the	O
neighbouring	O
monomer	O
donates	O
a	O
proton	O
to	O
form	O
a	O
hydroxyl	S-chem
group	O
at	O
C5	O
,	O
resulting	O
in	O
5	B-chem
(	I-chem
S	I-chem
)	I-chem
-	I-chem
hydroxy	I-chem
-	I-chem
6	I-chem
(	I-chem
R	I-chem
)	I-chem
-	I-chem
S	I-chem
-	I-chem
glutathionyl	I-chem
-	I-chem
7,9	I-chem
-	I-chem
trans	I-chem
-	I-chem
11,14	I-chem
-	I-chem
cis	I-chem
-	I-chem
eicosatetraenoic	I-chem
acid	E-chem
(	O
LTC4	S-chem
)	O
.	O

These	O
findings	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
development	O
of	O
LTC4S	S-geneY
inhibitors	O
for	O
a	O
proinflammatory	O
pathway	O
mediated	O
by	O
three	O
cysteinyl	B-chem
leukotriene	E-chem
ligands	O
whose	O
stability	O
and	O
potency	O
are	O
different	O
and	O
by	O
multiple	O
cysteinyl	B-geneN
leukotriene	I-geneN
receptors	E-geneN
whose	O
functions	O
may	O
be	O
non	O
-	O
redundant	O
.	O

Altered	O
gene	O
expression	O
in	O
murine	O
branchial	O
arches	O
following	O
in	O
utero	O
exposure	O
to	O
retinoic	B-chem
acid	E-chem
.	O

Retinoic	B-chem
acid	E-chem
(	O
RA	S-chem
)	O
in	O
the	O
form	O
of	O
isotretinoin	S-chem
(	O
Accutane	S-chem
)	O
and	O
tretinoin	S-chem
(	O
Retin	B-chem
-	I-chem
A	E-chem
)	O
is	O
a	O
clinically	O
important	O
compound	O
in	O
the	O
treatment	O
of	O
dermatologic	O
disorders	O
.	O

However	O
,	O
it	O
is	O
also	O
a	O
potent	O
teratogen	O
associated	O
with	O
a	O
number	O
of	O
serious	O
congenital	O
malformations	O
.	O

Generally	O
,	O
these	O
malformations	O
involve	O
the	O
craniofacial	O
structures	O
derived	O
from	O
the	O
first	O
and	O
second	O
branchial	O
arches	O
.	O

To	O
determine	O
how	O
altered	O
gene	O
expression	O
may	O
contribute	O
to	O
the	O
observed	O
RA	S-chem
-	O
induced	O
defects	O
,	O
pregnant	O
LM	O
/	O
Bc	O
mice	O
were	O
administered	O
(	O
5	O
mg	O
/	O
kg	O
)	O
all	B-chem
-	I-chem
trans	I-chem
RA	E-chem
on	O
gestational	O
day	O
(	O
GD	O
)	O
8	O
:	O
12	O
.	O

First	O
and	O
second	O
branchial	O
arches	O
were	O
removed	O
from	O
control	O
and	O
teratogen	O
-	O
treated	O
embryos	O
on	O
GD	O
10	O
:	O
00	O
10	O
:	O
12	O
,	O
or	O
12	O
:	O
00	O
,	O
processed	O
by	O
in	O
situ	O
transcription	O
/	O
aRNA	O
techniques	O
,	O
and	O
analyzed	O
for	O
alterations	O
in	O
gene	O
expression	O
.	O

In	O
these	O
studies	O
,	O
a	O
panel	O
of	O
40	O
candidate	O
genes	O
that	O
are	O
known	O
to	O
be	O
important	O
in	O
mammalian	O
craniofacial	O
development	O
were	O
examined	O
.	O

This	O
analysis	O
revealed	O
significant	O
differences	O
in	O
the	O
expression	O
level	O
of	O
the	O
nicotinic	B-geneY
acetylcholine	I-geneY
receptor	I-geneY
subunit	I-geneY
alpha	E-geneY
(	O
NAChR	S-geneY
)	O
,	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
beta	I-geneY
2	E-geneY
(	O
TGF	B-geneY
beta	I-geneY
2	E-geneY
)	O
,	O
type	B-geneY
1	I-geneY
cellular	I-geneY
retinoid	I-geneY
binding	I-geneY
protein	E-geneY
(	O
CRBP	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
retinoic	B-geneY
acid	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
RAR	B-geneY
gamma	E-geneY
)	O
,	O
and	O
cAMP	B-geneN
response	I-geneN
element	I-geneN
binding	I-geneN
protein	E-geneN
(	O
CREB	S-geneN
)	O
.	O

The	O
alterations	O
observed	O
in	O
the	O
expression	O
of	O
these	O
genes	O
following	O
RA	S-chem
exposure	O
may	O
prohibit	O
normal	O
morphogenetic	O
processes	O
within	O
the	O
second	O
branchial	O
arch	O
and	O
lead	O
to	O
the	O
observed	O
malformations	O
.	O

Pre	O
-	O
clinical	O
pharmacology	O
of	O
zolmitriptan	S-chem-C5-1
(	O
Zomig	S-chem-C5-1
;	O
formerly	S-chem
311C90	S-chem-C5-1
)	O
,	O
a	O
centrally	O
and	O
peripherally	O
acting	O
5HT1B	B-geneN-C5-2
/	I-geneN-C5-2
1D	E-geneN-C5-2
agonist	O
for	O
migraine	O
.	O

Zolmitriptan	S-chem-C5-1
(	O
Zomig	S-chem-C5-1
;	O
formerly	S-chem
311C90	S-chem-C5-1
)	O
is	O
a	O
novel	O
5	B-geneN-C5-2
-	I-geneN-C5-2
hydroxytryptamine	I-geneN-C5-2
(	I-geneN-C5-2
5HT	I-geneN-C5-2
)	I-geneN-C5-2
1B	I-geneN-C5-2
/	I-geneN-C5-2
1D	E-geneN-C5-2
receptor	O
agonist	O
with	O
proven	O
efficacy	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	O
with	O
or	O
without	O
preceding	O
aura	O
.	O

The	O
drug	O
differs	O
from	O
presently	O
available	O
members	O
of	O
this	O
drug	O
class	O
in	O
that	O
it	O
combines	O
5HT1B	B-geneN
/	I-geneN
1D	E-geneN
receptor	O
partial	O
agonist	O
activity	O
with	O
robust	O
oral	O
pharmacokinetics	O
and	O
an	O
ability	O
to	O
inhibit	O
trigeminovascular	O
activation	O
centrally	O
as	O
well	O
as	O
peripherally	O
in	O
preclinical	O
studies	O
.	O

Consistent	O
with	O
its	O
selectivity	O
for	O
5HT1B	B-geneN
/	I-geneN
1D	E-geneN
receptors	O
,	O
zolmitriptan	S-chem
produces	O
constriction	O
of	O
various	O
isolated	O
blood	O
vessels	O
,	O
most	O
notably	O
cranial	O
arteries	O
.	O

In	O
anaesthetized	O
animals	O
,	O
these	O
vascular	O
effects	O
manifest	O
as	O
a	O
selective	O
constriction	O
of	O
cranial	O
arterio	O
-	O
venous	O
anastomoses	O
resulting	O
in	O
a	O
redistribution	O
of	O
carotid	O
arterial	O
blood	O
flow	O
.	O

This	O
effect	O
is	O
produced	O
without	O
significant	O
effects	O
on	O
heart	O
rate	O
,	O
blood	O
pressure	O
or	O
blood	O
flow	O
to	O
the	O
brain	O
,	O
heart	O
or	O
lungs	O
.	O

Zolmitriptan	S-chem
also	O
inhibits	O
trigeminal	O
-	O
evoked	O
increases	O
in	O
cerebral	O
blood	O
flow	O
in	O
anaesthetized	O
cats	O
and	O
blocks	O
trigeminal	O
-	O
evoked	O
plasma	O
protein	O
extravasation	O
in	O
the	O
dura	O
of	O
guinea	O
-	O
pigs	O
.	O

These	O
actions	O
are	O
consistent	O
with	O
a	O
pre	O
-	O
junctional	O
inhibition	O
of	O
neuropeptide	O
release	O
from	O
perivascular	O
afferents	O
of	O
the	O
trigeminal	O
nerve	O
,	O
as	O
confirmed	O
by	O
independent	O
studies	O
showing	O
that	O
zolmitriptan	S-chem-C4-1
blocks	O
elevations	O
of	O
calcitonin	B-geneN-C4-2
-	I-geneN-C4-2
gene	I-geneN-C4-2
-	I-geneN-C4-2
related	I-geneN-C4-2
peptide	E-geneN-C4-2
in	O
jugular	O
venous	O
blood	O
during	O
electrical	O
stimulation	O
of	O
the	O
trigeminal	O
ganglion	O
.	O

In	O
all	O
of	O
these	O
effects	O
,	O
zolmitriptan	S-chem
is	O
three	O
to	O
four	O
times	O
more	O
potent	O
than	O
sumatriptan	S-chem
,	O
but	O
produces	O
the	O
same	O
maximum	O
response	O
.	O

Zolmitriptan	S-chem
crosses	O
the	O
intact	O
blood	O
-	O
brain	O
barrier	O
to	O
inhibit	O
trigeminovascular	O
activation	O
in	O
the	O
brainstem	O
.	O

This	O
was	O
shown	O
initially	O
by	O
the	O
ability	O
of	O
the	O
drug	O
to	O
block	O
a	O
brainstem	O
reflex	O
provoking	O
vasoactive	O
intestinal	O
peptide	O
release	O
from	O
the	O
VIIth	O
cranial	O
(	O
facial	O
)	O
nerve	O
during	O
trigeminal	O
stimulation	O
.	O

Subsequent	O
ex	O
vivo	O
autoradiography	O
confirmed	O
that	O
intravenously	O
injected	O
[	B-chem
3H	I-chem
]	I-chem
zolmitriptan	E-chem
labels	O
a	O
discrete	O
population	O
of	O
cells	O
in	O
the	O
trigeminal	O
nucleus	O
caudalis	O
(	O
TNC	O
)	O
and	O
nucleus	O
tractus	O
solitarius	O
.	O

Direct	O
evidence	O
for	O
a	O
central	O
neuromodulatory	O
effect	O
of	O
zolmitriptan	S-chem
was	O
provided	O
by	O
electrophysiological	O
experiments	O
which	O
clearly	O
demonstrated	O
that	O
the	O
drug	O
inhibits	O
the	O
excitability	O
of	O
cells	O
in	O
the	O
TNC	O
after	O
systemic	O
administration	O
.	O

This	O
novel	O
pre	O
-	O
clinical	O
profile	O
not	O
only	O
distinguishes	O
zolmitriptan	S-chem
from	O
sumatriptan	S-chem
,	O
but	O
raises	O
intriguing	O
questions	O
about	O
the	O
clinical	O
relevance	O
of	O
a	O
dual	O
action	O
.	O

Studies	O
to	O
date	O
show	O
that	O
zolmitriptan	S-chem
indeed	O
modulates	O
cranial	O
sensory	O
processing	O
in	O
humans	O
,	O
yet	O
central	O
side	O
-	O
effects	O
are	O
no	O
different	O
from	O
sumatriptan	S-chem
.	O

This	O
property	O
may	O
account	O
for	O
the	O
remarkable	O
consistency	O
in	O
clinical	O
efficacy	O
observed	O
in	O
clinical	O
trials	O
.	O

Dimerized	O
Glycosaminoglycan	O
Chains	O
Increase	O
FGF	S-geneN
Signaling	O
during	O
Zebrafish	O
Development	O
.	O

Proteoglycans	O
(	O
PGs	O
)	O
modulate	O
numerous	O
signaling	O
pathways	O
during	O
development	O
through	O
binding	O
of	O
their	O
glycosaminoglycan	O
(	O
GAG	O
)	O
side	O
chains	O
to	O
various	O
signaling	O
molecules	O
,	O
including	O
fibroblast	B-geneN
growth	I-geneN
factors	E-geneN
(	O
FGFs	S-geneN
)	O
.	O

A	O
majority	O
of	O
PGs	O
possess	O
two	O
or	O
more	O
GAG	O
side	O
chains	O
,	O
suggesting	O
that	O
GAG	O
multivalency	O
is	O
imperative	O
for	O
biological	O
functions	O
in	O
vivo	O
.	O

However	O
,	O
only	O
a	O
few	O
studies	O
have	O
examined	O
the	O
biological	O
significance	O
of	O
GAG	O
multivalency	O
.	O

In	O
this	O
report	O
,	O
we	O
utilized	O
a	O
library	O
of	O
bis	B-chem
-	I-chem
and	I-chem
tris	I-chem
-	I-chem
xylosides	E-chem
that	O
produce	O
two	O
and	O
three	O
GAG	O
chains	O
on	O
the	O
same	O
scaffold	O
,	O
respectively	O
,	O
thus	O
mimicking	O
PGs	O
,	O
to	O
examine	O
the	O
importance	O
of	O
GAG	O
valency	O
and	O
chain	O
type	O
in	O
regulating	O
FGF	S-geneN
/	O
FGFR	S-geneN
interactions	O
in	O
vivo	O
in	O
zebrafish	O
.	O

A	O
number	O
of	O
bis	B-chem
-	I-chem
and	I-chem
tris	I-chem
-	I-chem
xylosides	E-chem
,	O
but	O
not	O
mono	B-chem
-	I-chem
xylosides	E-chem
,	O
caused	O
an	O
elongation	O
phenotype	O
upon	O
their	O
injection	O
into	O
embryos	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
elongated	O
embryos	O
have	O
elevated	O
expression	O
of	O
the	O
FGF	S-geneN
target	O
gene	O
mkp3	S-geneY
but	O
unchanged	O
expression	O
of	O
reporters	O
for	O
other	O
pathways	O
,	O
indicating	O
that	O
FGF	S-geneN
/	O
FGFR	S-geneN
signaling	O
was	O
specifically	O
hyperactivated	O
.	O

In	O
support	O
of	O
this	O
observation	O
,	O
elongation	O
can	O
be	O
reversed	O
by	O
the	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
SU5402	S-chem-C4-1
,	O
mRNA	O
for	O
the	O
FGFR	S-geneN
antagonist	O
sprouty4	S-geneY
,	O
or	O
FGF8	S-geneY
morpholino	O
.	O

Endogenous	O
GAGs	O
seem	O
to	O
be	O
unaffected	O
after	O
xyloside	S-chem
treatment	O
,	O
suggesting	O
that	O
this	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Furthermore	O
,	O
expression	O
of	O
a	O
multivalent	O
but	O
not	O
a	O
monovalent	O
GAG	O
containing	O
syndecan	B-geneN
-	I-geneN
1	E-geneN
proteoglycan	O
recapitulates	O
the	O
elongation	O
phenotype	O
observed	O
with	O
the	O
bivalent	O
xylosides	S-chem
.	O

On	O
the	O
basis	O
of	O
these	O
in	O
vivo	O
findings	O
,	O
we	O
propose	O
a	O
new	O
model	O
for	O
GAG	O
/	O
FGF	S-geneN
/	O
FGFR	S-geneN
interactions	O
in	O
which	O
dimerized	O
GAG	O
chains	O
can	O
activate	O
FGF	S-geneN
-	O
mediated	O
signal	O
transduction	O
pathways	O
.	O

New	O
aspects	O
in	O
the	O
management	O
of	O
obesity	O
:	O
operation	O
and	O
the	O
impact	O
of	O
lipase	S-geneN
inhibitors	O
.	O

Obesity	O
is	O
an	O
increasing	O
health	O
problem	O
in	O
most	O
developed	O
countries	O
and	O
its	O
prevalence	O
is	O
also	O
increasing	O
in	O
developing	O
countries	O
.	O

There	O
has	O
been	O
no	O
great	O
success	O
with	O
dietary	O
means	O
and	O
life	O
style	O
modification	O
for	O
permanent	O
weight	O
loss	O
.	O

Various	O
surgical	O
treatment	O
methods	O
for	O
obesity	O
are	O
now	O
available	O
.	O

They	O
are	O
aimed	O
at	O
limiting	O
oral	O
energy	O
intake	O
with	O
or	O
without	O
causing	O
dumping	O
or	O
inducing	O
selective	O
maldigestion	O
and	O
malabsorption	O
.	O

Based	O
on	O
current	O
literature	O
,	O
up	O
to	O
75	O
%	O
of	O
excess	O
weight	O
is	O
lost	O
by	O
surgical	O
treatment	O
with	O
concomitant	O
disappearance	O
of	O
hyperlipidaemias	O
,	O
type	O
2	O
diabetes	O
,	O
hypertension	O
or	O
sleep	O
apnoea	O
.	O

The	O
main	O
indication	O
for	O
operative	O
treatment	O
is	O
morbid	O
obesity	O
(	O
body	O
mass	O
index	O
greater	O
than	O
40	O
kg	O
/	O
m2	O
)	O
or	O
severe	O
obesity	O
(	O
body	O
mass	O
index	O
>	O
35	O
kg	O
/	O
m2	O
)	O
with	O
comorbidities	O
of	O
obesity	O
.	O

Orlistat	S-chem-C4-1
is	O
a	O
new	O
inhibitor	O
of	O
pancreatic	B-geneY-C4-2
lipase	E-geneY-C4-2
enzyme	O
.	O

At	O
doses	O
of	O
120	O
mg	O
three	O
times	O
per	O
day	O
with	O
meals	O
it	O
results	O
in	O
a	O
30	O
%	O
reduction	O
in	O
dietary	O
fat	O
absorption	O
,	O
which	O
equals	O
approximately	O
200	O
kcal	O
daily	O
energy	O
deficit	O
.	O

In	O
the	O
long	O
term	O
,	O
orlistat	S-chem-C4-1
has	O
been	O
shown	O
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
body	O
weight	O
and	O
serum	O
total	O
and	O
low	B-geneN-C4-2
-	I-geneN-C4-2
density	I-geneN-C4-2
lipoprotein	E-geneN-C4-2
cholesterol	S-chem
levels	O
.	O

Orlistat	S-chem
has	O
a	O
lowering	O
effect	O
on	O
serum	O
cholesterol	S-chem
independent	O
of	O
weight	O
loss	O
.	O

Along	O
with	O
weight	O
loss	O
,	O
orlistat	S-chem
also	O
favourably	O
affects	O
blood	O
pressure	O
and	O
glucose	S-chem
and	O
insulin	S-geneY
levels	O
in	O
obese	O
individuals	O
and	O
in	O
obese	O
type	O
2	O
diabetic	O
patients	O
.	O

Structural	O
basis	O
for	O
LFA	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibition	O
upon	O
lovastatin	S-chem-C4-1
binding	O
to	O
the	O
CD11a	B-geneN
I	I-geneN
-	I-geneN
domain	E-geneN
.	O

The	O
lymphocyte	B-geneY
function	I-geneY
-	I-geneY
associated	I-geneY
antigen	E-geneY
(	O
LFA	B-geneY
-	I-geneY
1	E-geneY
)	O
belongs	O
to	O
the	O
family	O
of	O
beta2	B-geneY
-	I-geneY
integrins	E-geneY
and	O
plays	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
activation	O
and	O
leukocyte	O
migration	O
to	O
sites	O
of	O
inflammation	O
.	O

We	O
report	O
here	O
that	O
lovastatin	S-chem-C4-1
,	O
a	O
drug	O
clinically	O
used	O
for	O
lowering	O
cholesterol	S-chem
levels	O
,	O
inhibits	O
the	O
interaction	O
of	O
human	B-geneY-C4-2
LFA	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
with	O
its	O
counter	O
-	O
receptor	O
intercellular	B-geneY-C4-2
adhesion	I-geneY-C4-2
molecule	I-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
.	O

Using	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
and	O
X	O
-	O
ray	O
crystallography	O
we	O
show	O
that	O
the	O
inhibitor	O
binds	O
to	O
a	O
highly	O
conserved	O
domain	O
of	O
the	O
LFA	B-geneY
-	I-geneY
1	I-geneY
alpha	I-geneY
-	I-geneY
chain	E-geneY
called	O
the	O
I	B-geneN
-	I-geneN
domain	E-geneN
.	O

The	O
first	O
three	O
-	O
dimensional	O
structure	O
of	O
an	O
integrin	S-geneN
inhibitor	O
bound	O
to	O
its	O
receptor	O
reveals	O
atomic	O
details	O
for	O
a	O
hitherto	O
unknown	O
mode	O
of	O
LFA	B-geneY
-	I-geneY
1	E-geneY
inhibition	O
.	O

It	O
also	O
sheds	O
light	O
into	O
possible	O
mechanisms	O
of	O
LFA	B-geneY
-	I-geneY
1	E-geneY
mediated	O
signalling	O
and	O
will	O
support	O
the	O
design	O
of	O
novel	O
anti	O
-	O
adhesive	O
and	O
immunosuppressive	O
drugs	O
.	O

Investigating	O
the	O
regulation	O
of	O
one	O
-	O
carbon	S-chem
metabolism	O
in	O
Arabidopsis	O
thaliana	O
.	O

Serine	S-chem
(	O
Ser	S-chem
)	O
biosynthesis	O
in	O
C	O
(	O
3	O
)	O
plants	O
can	O
occur	O
via	O
several	O
pathways	O
.	O

One	O
major	O
route	O
involves	O
the	O
tetrahydrofolate	S-chem
(	O
THF	S-chem
)	O
-	O
dependent	O
activities	O
of	O
the	O
glycine	B-geneN-C9-2
decarboxylase	I-geneN-C9-2
complex	E-geneN-C9-2
(	O
GDC	S-geneN-C9-2
,	O
EC	B-geneY-C9-2
2.1.1.10	E-geneY-C9-2
)	O
and	O
serine	B-geneN-C9-2
hydroxymethyltransferase	E-geneN-C9-2
(	O
SHMT	S-geneN-C9-2
,	O
EC	B-geneY-C9-2
2.1.2.1	E-geneY-C9-2
)	O
with	O
glycine	S-chem-C9-1
(	O
Gly	S-chem-C9-1
)	O
as	O
one	O
-	O
carbon	S-chem
(	O
1	B-chem
-	I-chem
C	E-chem
)	O
source	O
.	O

An	O
alternative	O
THF	S-chem
-	O
dependent	O
pathway	O
involves	O
the	O
C1	B-geneY-C9-2
-	I-geneY-C9-2
THF	I-geneY-C9-2
synthase	E-geneY-C9-2
/	O
SHMT	S-geneN-C9-2
activities	O
with	O
formate	S-chem-C9-1
as	O
1	B-chem
-	I-chem
C	E-chem
source	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
aspects	O
of	O
the	O
regulation	O
of	O
these	O
two	O
folate	O
-	O
mediated	O
pathways	O
in	O
Arabidopsis	O
thaliana	O
(	O
L.	O
)	O
Heynh	O
.	O

Columbia	O
using	O
two	O
approaches	O
.	O

Firstly	O
,	O
transgenic	O
plants	O
overexpressing	O
formate	B-geneY-C9-2
dehydrogenase	E-geneY-C9-2
(	O
FDH	S-geneY-C9-2
,	O
EC	B-geneY-C9-2
1.2.1.2	E-geneY-C9-2
)	O
were	O
used	O
to	O
continue	O
our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
FDH	S-geneY-C9-2
in	O
formate	S-chem-C9-1
metabolism	O
.	O

The	O
formate	S-chem
pool	O
size	O
was	O
approximately	O
73	O
nmol	O
(	O
g	O
FW	O
)	O
(	O
-	O
1	O
)	O
in	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	O
plants	O
;	O
three	O
independent	O
transgenic	O
lines	O
had	O
similar	O
-	O
sized	O
pools	O
of	O
formate	S-chem
.	O

Transgenic	O
plants	O
produced	O
more	O
(	B-chem
13	I-chem
)	I-chem
CO	I-chem
(	I-chem
2	I-chem
)	E-chem
from	O
supplied	O
[	B-chem
(	I-chem
13	I-chem
)	I-chem
C	I-chem
]	I-chem
formate	E-chem
than	O
did	O
WT	O
plants	O
but	O
were	O
not	O
significantly	O
different	O
from	O
WT	O
plants	O
in	O
their	O
synthesis	O
of	O
Ser	S-chem
.	O

We	O
concluded	O
that	O
FDH	S-geneY
has	O
no	O
direct	O
role	O
in	O
the	O
regulation	O
of	O
the	O
above	O
two	O
pathways	O
of	O
Ser	S-chem
synthesis	O
;	O
the	O
breakdown	O
of	O
formate	S-chem-C9-1
to	O
CO	B-chem-C9-1
(	I-chem-C9-1
2	I-chem-C9-1
)	E-chem-C9-1
by	O
the	O
FDH	S-geneY-C9-2
reaction	O
is	O
the	O
primary	O
and	O
preferred	O
fate	O
of	O
the	O
organic	O
acid	O
in	O
Arabidopsis	O
.	O

The	O
ratio	O
between	O
the	O
GDC	S-geneN-C9-2
/	O
SHMT	S-geneN-C9-2
and	O
C1	B-geneY-C9-2
-	I-geneY-C9-2
THF	I-geneY-C9-2
synthase	E-geneY-C9-2
/	O
SHMT	S-geneN-C9-2
pathways	O
of	O
Ser	S-chem-C9-1
synthesis	O
from	O
[	B-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
(	I-chem-C9-1
13	I-chem-C9-1
)	I-chem-C9-1
C	I-chem-C9-1
]	I-chem-C9-1
Gly	E-chem-C9-1
and	O
[	B-chem-C9-1
(	I-chem-C9-1
13	I-chem-C9-1
)	I-chem-C9-1
C	I-chem-C9-1
]	I-chem-C9-1
formate	E-chem-C9-1
,	O
respectively	O
,	O
in	O
Arabidopsis	O
shoots	O
was	O
21	O
:	O
1	O
;	O
in	O
roots	O
,	O
9	O
:	O
1	O
.	O

In	O
shoots	O
,	O
therefore	O
,	O
the	O
pathway	O
from	O
formate	S-chem
plays	O
only	O
a	O
small	O
role	O
in	O
Ser	S-chem
synthesis	O
;	O
in	O
the	O
case	O
of	O
roots	O
,	O
results	O
indicated	O
that	O
the	O
9	O
:	O
1	O
ratio	O
was	O
as	O
a	O
result	O
of	O
greater	O
fluxes	O
of	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
through	O
both	O
pathways	O
together	O
with	O
a	O
relatively	O
higher	O
contribution	O
from	O
the	O
C1	B-geneY
-	I-geneY
THF	I-geneY
synthase	E-geneY
/	O
SHMT	S-geneN
route	O
than	O
in	O
shoots	O
.	O

We	O
also	O
examined	O
the	O
synthesis	O
of	O
Ser	S-chem
in	O
a	O
GDC	S-geneN
-	O
deficient	O
mutant	O
of	O
Arabidopsis	O
(	O
glyD	S-chem
)	O
where	O
the	O
GDC	S-geneN
/	O
SHMT	S-geneN
pathway	O
was	O
impaired	O
.	O

Compared	O
with	O
WT	O
,	O
glyD	S-chem
plants	O
accumulated	O
5	O
-	O
fold	O
more	O
Gly	S-chem
than	O
WT	O
after	O
supplying	O
[	B-chem
alpha	I-chem
-	I-chem
(	I-chem
13	I-chem
)	I-chem
C	I-chem
]	I-chem
Gly	E-chem
for	O
24	O
h	O
;	O
the	O
accumulation	O
of	O
Ser	S-chem
from	O
[	B-chem
alpha	I-chem
-	I-chem
(	I-chem
13	I-chem
)	I-chem
C	I-chem
]	I-chem
Gly	E-chem
was	O
reduced	O
by	O
25	O
%	O
in	O
the	O
same	O
time	O
period	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
accumulation	O
of	O
Ser	S-chem-C9-1
through	O
the	O
C1	B-geneY
-	I-geneY
THF	I-geneY
synthase	E-geneY
/	O
SHMT	S-geneN-C9-2
pathway	O
in	O
glyD	S-chem
plants	O
was	O
2.5	O
-	O
fold	O
greater	O
than	O
that	O
in	O
WT	O
plants	O
.	O

Our	O
experiments	O
confirmed	O
that	O
the	O
GDC	S-geneN
/	O
SHMT	S-geneN
and	O
C1	B-geneY
-	I-geneY
THF	I-geneY
synthase	E-geneY
/	O
SHMT	S-geneN
pathways	O
normally	O
operate	O
independently	O
in	O
Arabidopsis	O
plants	O
but	O
that	O
when	O
the	O
primary	O
GDC	S-geneN
/	O
SHMT	S-geneN
pathway	O
is	O
impaired	O
the	O
alternative	O
C1	B-geneY
-	I-geneY
THF	I-geneY
synthase	E-geneY
/	O
SHMT	S-geneN
pathway	O
can	O
partially	O
compensate	O
for	O
deficiencies	O
in	O
the	O
synthesis	O
of	O
Ser	S-chem
.	O

Genetic	O
risk	O
factors	O
for	O
infection	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

We	O
analyzed	O
clinical	O
and	O
genetic	O
factors	O
contributing	O
to	O
infections	O
in	O
457	O
subjects	O
with	O
early	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
enrolled	O
in	O
a	O
prospective	O
,	O
1	O
-	O
year	O
clinical	O
trial	O
of	O
methotrexate	S-chem
and	O
the	O
TNF	S-geneY
inhibitor	O
etanercept	O
.	O

Subjects	O
were	O
genotyped	O
for	O
the	O
following	O
single	O
nucleotide	S-chem
polymorphisms	O
(	O
SNPs	O
)	O
:	O
(	O
TNF	S-geneY
-	O
308	O
,	O
-	O
238	O
,	O
and	O
+	O
488	O
)	O
;	O
lymphotoxin	B-geneY
-	I-geneY
alpha	E-geneY
(	O
LTA	S-geneY
)	O
(	O
LTA	S-geneY
+	O
249	O
,	O
+	O
365	O
,	O
and	O
+	O
720	O
)	O
;	O
and	O
Fc	B-geneN
gamma	I-geneN
receptors	E-geneN
FCGR2A	S-geneY
131	O
H	O
/	O
R	O
;	O
FCGR3A	S-geneY
176	O
F	O
/	O
V	O
;	O
and	O
FCGR3B	S-geneY
NA	O
1	O
/	O
2	O
and	O
genotypes	O
were	O
correlated	O
with	O
infections	O
.	O

At	O
least	O
one	O
URI	O
was	O
noted	O
in	O
52	O
%	O
of	O
subjects	O
(	O
99	O
/	O
191	O
)	O
with	O
the	O
NA2	O
/	O
NA2	O
genotype	O
of	O
the	O
neutrophil	O
-	O
specific	O
FCGR3B	S-geneY
gene	O
,	O
compared	O
to	O
42	O
%	O
(	O
77	O
/	O
181	O
)	O
of	O
those	O
with	O
the	O
NA1	O
/	O
NA2	O
genotype	O
and	O
39	O
%	O
(	O
23	O
/	O
59	O
)	O
of	O
those	O
with	O
the	O
NA1	O
/	O
NA1	O
genotype	O
(	O
P	O
=	O
0.038	O
)	O
.	O

Urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
was	O
associated	O
with	O
the	O
TNF	S-geneY
-	O
238	O
A	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2.56	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.05	O
-	O
6.25	O
)	O
and	O
LTA	S-geneY
+	O
365	O
C	O
(	O
OR	O
1.73	O
,	O
95	O
%	O
CI	O
1.07	O
-	O
2.79	O
)	O
alleles	O
,	O
and	O
marginally	O
with	O
the	O
FCGR3A	S-geneY
F	O
allele	O
(	O
OR	O
1.72	O
,	O
95	O
%	O
CI	O
0.99	O
-	O
3.00	O
)	O
.	O

There	O
was	O
a	O
striking	O
linear	O
correlation	O
between	O
UTI	O
and	O
the	O
number	O
of	O
risk	O
alleles	O
defined	O
by	O
these	O
three	O
SNPs	O
(	O
P	O
<	O
0.001	O
)	O
,	O
suggesting	O
an	O
additive	O
effect	O
on	O
susceptibility	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
role	O
of	O
genetics	O
in	O
susceptibility	O
to	O
bacterial	O
and	O
viral	O
infections	O
.	O

REMNANT	O
UPTAKE	O
AS	O
A	O
POSTOPERATIVE	O
ONCOLOGIC	O
QUALITY	O
INDICATOR	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
utility	O
of	O
remnant	O
uptake	O
on	O
postoperative	O
radioiodine	S-chem
scans	O
as	O
an	O
oncologic	O
indicator	O
after	O
thyroidectomy	O
for	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
patients	O
undergoing	O
total	O
thyroidectomy	O
for	O
DTC	O
and	O
subsequent	O
radioactive	O
iodine	S-chem
(	O
RAI	O
)	O
treatment	O
.	O

Of	O
the	O
eight	O
surgeons	O
included	O
,	O
three	O
were	O
considered	O
high	O
volume	O
,	O
performing	O
at	O
least	O
20	O
thyroidectomies	O
per	O
year	O
.	O

Patients	O
with	O
distant	O
metastases	O
at	O
diagnosis	O
or	O
poorly	O
differentiated	O
variants	O
were	O
excluded	O
.	O

To	O
control	O
for	O
the	O
effect	O
of	O
varying	O
RAI	O
doses	O
,	O
the	O
remnant	O
uptake	O
was	O
analyzed	O
as	O
a	O
ratio	O
of	O
the	O
percentage	O
uptake	O
to	O
the	O
dose	O
received	O
(	O
uptake	O
to	O
dose	O
ratio	O
,	O
UDR	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
determine	O
the	O
influence	O
of	O
UDR	O
on	O
recurrence	O
.	O

RESULTS	O
:	O
Of	O
the	O
223	O
patients	O
who	O
met	O
inclusion	O
criteria	O
,	O
21	O
patients	O
(	O
9.42	O
%	O
)	O
experienced	O
a	O
recurrence	O
.	O

Those	O
who	O
recurred	O
had	O
a	O
ten	O
-	O
fold	O
higher	O
UDR	O
compared	O
to	O
those	O
who	O
did	O
not	O
recur	O
(	O
0.030	O
vs	O
.	O

0.003	O
,	O
p	O
=	O
0.001	O
)	O
.	O

Similarly	O
,	O
patients	O
with	O
increasing	O
postoperative	O
thyroglobulin	S-geneY
measurements	O
(	O
0.339	O
vs	O
.	O

0.003	O
,	O
p	O
<	O
0.001	O
)	O
also	O
had	O
significantly	O
greater	O
UDRs	O
compared	O
to	O
those	O
with	O
stable	O
thyroglobulin	S-geneY
.	O

The	O
UDRs	O
of	O
high	O
volume	O
surgeons	O
were	O
significantly	O
smaller	O
than	O
low	O
volume	O
surgeons	O
(	O
0.003	O
vs	O
.	O

0.025	O
,	O
p	O
=	O
0.002	O
)	O
.	O

When	O
combined	O
with	O
other	O
known	O
predictors	O
for	O
recurrence	O
,	O
UDR	O
(	O
OR	O
3.71	O
,	O
C.I	O
1.05	O
-	O
13.10	O
,	O
p	O
=	O
0.041	O
)	O
was	O
significantly	O
associated	O
with	O
recurrence	O
.	O

High	O
volume	O
surgeons	O
maintained	O
a	O
low	O
level	O
of	O
permanent	O
complications	O
across	O
all	O
UDRs	O
whereas	O
low	O
volume	O
surgeons	O
had	O
greater	O
permanent	O
complications	O
associated	O
with	O
higher	O
uptake	O
.	O

Short	O
-	O
term	O
heating	O
reduces	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
fresh	O
raw	O
garlic	O
extracts	O
on	O
the	O
LPS	O
-	O
induced	O
production	O
of	O
NO	S-chem
and	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN
by	O
downregulating	O
allicin	S-chem
activity	O
in	O
RAW	O
264.7	O
macrophages	O
.	O

Garlic	O
has	O
a	O
variety	O
of	O
biologic	O
activities	O
,	O
including	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Although	O
garlic	O
has	O
several	O
biologic	O
activities	O
,	O
some	O
people	O
dislike	O
eating	O
fresh	O
raw	O
garlic	O
because	O
of	O
its	O
strong	O
taste	O
and	O
smell	O
.	O

Therefore	O
,	O
garlic	O
formulations	O
involving	O
heating	O
procedures	O
have	O
been	O
developed	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
short	O
-	O
term	O
heating	O
affects	O
the	O
anti	O
-	O
inflammatory	O
properties	O
of	O
garlic	O
.	O

Fresh	O
and	O
heated	O
raw	O
garlic	O
extracts	O
(	O
FRGE	O
and	O
HRGE	O
)	O
were	O
prepared	O
with	O
incubation	O
at	O
25°C	O
and	O
95°C	O
,	O
respectively	O
,	O
for	O
2h	O
.	O

Treatment	O
with	O
FRGE	O
and	O
HRGE	O
significantly	O
reduced	O
the	O
LPS	O
-	O
induced	O
increase	O
in	O
the	O
pro	O
-	O
inflammatory	O
cytokine	S-geneN
concentration	O
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IL	B-geneY
-	I-geneY
1β	E-geneY
,	O
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
)	O
and	O
NO	S-chem
through	O
HO	B-geneY
-	I-geneY
1	E-geneY
upregulation	O
in	O
RAW	O
264.7	O
macrophages	O
.	O

The	O
anti	O
-	O
inflammatory	O
effect	O
was	O
greater	O
in	O
FRGE	O
than	O
in	O
HRGE	O
.	O

The	O
allicin	S-chem
concentration	O
was	O
higher	O
in	O
FRGE	O
than	O
in	O
HRGE	O
.	O

Allicin	S-chem-MU-1
treatment	O
showed	O
reduced	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN-C4-2
and	O
NO	S-chem
and	O
increased	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
activity	O
.	O

The	O
results	O
show	O
that	O
the	O
decrease	O
in	O
LPS	O
-	O
induced	O
NO	S-chem
and	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN
in	O
RAW	O
264.7	O
macrophages	O
through	O
HO	B-geneY
-	I-geneY
1	E-geneY
induction	O
was	O
greater	O
for	O
FRGE	O
compared	O
with	O
HRGE	O
.	O

Additionally	O
,	O
the	O
results	O
indicate	O
that	O
allicin	S-chem
is	O
responsible	O
for	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
FRGE	O
.	O

Our	O
results	O
suggest	O
a	O
potential	O
therapeutic	O
use	O
of	O
allicin	S-chem
in	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
disease	O
.	O

2	B-chem
-	I-chem
aminothiazoles	E-chem
with	O
improved	O
pharmacotherapeutic	O
properties	O
for	O
treatment	O
of	O
prion	O
disease	O
.	O

Recently	O
,	O
we	O
described	O
the	O
aminothiazole	S-chem
lead	O
(	B-chem
4	I-chem
-	I-chem
biphenyl	I-chem
-	I-chem
4	I-chem
-	I-chem
ylthiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
(	I-chem
6	I-chem
-	I-chem
methylpyridin	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
amine	E-chem
(	O
1	O
)	O
,	O
which	O
exhibits	O
many	O
desirable	O
properties	O
,	O
including	O
excellent	O
stability	O
in	O
liver	O
microsomes	O
,	O
oral	O
bioavailability	O
of	O
∼	O
40	O
%	O
,	O
and	O
high	O
exposure	O
in	O
the	O
brains	O
of	O
mice	O
.	O

Despite	O
its	O
good	O
pharmacokinetic	O
properties	O
,	O
compound	O
1	O
exhibited	O
only	O
modest	O
potency	O
in	O
mouse	O
neuroblastoma	O
cells	O
overexpressing	O
the	O
disease	O
-	O
causing	O
prion	B-geneY
protein	I-geneY
PrP	I-geneY
(	I-geneY
Sc	I-geneY
)	E-geneY
.	O

Accordingly	O
,	O
we	O
sought	O
to	O
identify	O
analogues	O
of	O
1	O
with	O
improved	O
antiprion	O
potency	O
in	O
ScN2a	O
-	O
cl3	O
cells	O
while	O
retaining	O
similar	O
or	O
superior	O
properties	O
.	O

Herein	O
we	O
report	O
the	O
discovery	O
of	O
improved	O
lead	O
compounds	O
such	O
as	O
(	B-chem
6	I-chem
-	I-chem
methylpyridin	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
pyridin	I-chem
-	I-chem
3	I-chem
-	I-chem
yl	I-chem
-	I-chem
phenyl	I-chem
)	I-chem
thiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
]	I-chem
amine	E-chem
and	O
cyclopropanecarboxylic	B-chem
acid	I-chem
(	I-chem
4	I-chem
-	I-chem
biphenylthiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
amide	E-chem
,	O
which	O
exhibit	O
brain	O
exposure	O
/	O
EC50	O
ratios	O
at	O
least	O
tenfold	O
greater	O
than	O
that	O
of	O
compound	O
1	O
.	O

Inhibition	O
of	O
the	O
uterotropic	O
activity	O
of	O
estrogens	O
and	O
antiestrogens	O
by	O
the	O
short	O
acting	O
antiestrogen	O
LY117018	S-chem
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
the	O
dihydroxylated	O
antiestrogen	O
LY117018	S-chem
,	O
with	O
a	O
high	O
affinity	O
for	O
the	O
estrogen	B-geneY
receptor	E-geneY
and	O
low	O
intrinsic	O
estrogenic	O
activity	O
,	O
could	O
inhibit	O
the	O
uterotropic	O
actions	O
of	O
steroidal	O
[	O
estradiol	B-chem
-	I-chem
17	I-chem
beta	E-chem
(	O
E2	S-chem
)	O
]	O
and	O
nonsteroidal	O
[	O
ICI	O
3188	O
and	O
trianisylchloroethylene	S-chem
(	O
TACE	S-chem
)	O
]	O
estrogens	O
in	O
immature	O
rats	O
and	O
also	O
the	O
uterotropic	O
actions	O
of	O
tamoxifen	S-chem
and	O
monohydroxytamoxifen	S-chem
in	O
the	O
ovariectomized	O
mouse	O
and	O
immature	O
rat	O
.	O

In	O
the	O
first	O
series	O
of	O
experiments	O
,	O
LY117018	S-chem
was	O
compared	O
with	O
monohydroxytamoxifen	S-chem
.	O

Both	O
antiestrogens	O
inhibited	O
the	O
uterotropic	O
actions	O
of	O
E2	S-chem
(	O
0.32	O
micrograms	O
daily	O
)	O
,	O
ICI	O
3188	O
(	O
5	O
micrograms	O
daily	O
)	O
,	O
and	O
TACE	O
(	O
40	O
and	O
160	O
micrograms	O
daily	O
)	O
in	O
a	O
dose	O
-	O
related	O
manner	O
(	O
0.32	O
-	O
82	O
micrograms	O
daily	O
)	O
.	O

The	O
potency	O
of	O
the	O
antiestrogens	O
against	O
E2	O
and	O
ICI	O
3188	O
was	O
similar	O
,	O
however	O
,	O
at	O
higher	O
doses	O
(	O
20.48	O
and	O
82	O
micrograms	O
daily	O
)	O
LY117018	S-chem
reduced	O
uterine	O
weights	O
to	O
below	O
the	O
lowest	O
level	O
achieved	O
by	O
monohydroxytamoxifen	S-chem
.	O

In	O
contrast	O
,	O
LY117018	S-chem
was	O
less	O
effective	O
against	O
the	O
long	O
acting	O
estrogen	O
TACE	O
.	O

The	O
competitive	O
interaction	O
of	O
LY117018	S-chem
with	O
tamoxifen	S-chem
and	O
monohydroxytamoxifen	S-chem
was	O
compared	O
in	O
3	O
-	O
day	O
ovariectomized	O
mouse	O
and	O
immature	O
rat	O
uterine	O
weight	O
tests	O
.	O

Tamoxifen	S-chem
and	O
monohydroxytamoxifen	S-chem
were	O
fully	O
estrogenic	O
in	O
the	O
mouse	O
(	O
5	O
micrograms	O
daily	O
)	O
and	O
partially	O
estrogenic	O
in	O
the	O
rat	O
(	O
1.5	O
-	O
20	O
micrograms	O
daily	O
)	O
.	O

LY117018	S-chem
was	O
a	O
partial	O
estrogen	O
in	O
the	O
mouse	O
and	O
a	O
weekly	O
active	O
partial	O
estrogen	O
in	O
the	O
rat	O
(	O
2.5	O
-	O
120	O
micrograms	O
daily	O
)	O
.	O

LY117018	S-chem
produced	O
dose	O
-	O
related	O
decreases	O
in	O
the	O
uterine	O
weight	O
increases	O
induced	O
by	O
tamoxifen	S-chem
and	O
monohydroxytamoxifen	S-chem
in	O
both	O
species	O
.	O

However	O
,	O
in	O
the	O
rat	O
,	O
LY117018	S-chem
was	O
more	O
effective	O
against	O
the	O
less	O
potent	O
compound	O
tamoxifen	S-chem
,	O
at	O
a	O
6	O
:	O
1	O
dosage	O
ratio	O
compared	O
with	O
a	O
24	O
:	O
1	O
dosage	O
ratio	O
required	O
for	O
the	O
potent	O
compound	O
monohydroxytamoxifen	S-chem
.	O

LY117018	S-chem
had	O
a	O
short	O
duration	O
of	O
action	O
as	O
an	O
antiestrogen	O
when	O
compared	O
with	O
monohydroxytamoxifen	S-chem
.	O

LY117018	S-chem
(	O
120	O
micrograms	O
)	O
was	O
only	O
completely	O
effective	O
as	O
an	O
antiestrogen	O
if	O
administered	O
repeatedly	O
with	O
E2	S-chem
whereas	O
a	O
single	O
injection	O
of	O
monohydroxytamoxifen	S-chem
(	O
120	O
micrograms	O
)	O
was	O
sufficient	O
to	O
inhibit	O
fully	O
E2	S-chem
action	O
in	O
the	O
uterus	O
for	O
up	O
to	O
4	O
days	O
.	O

Because	O
LY117018	S-chem
has	O
a	O
shorter	O
duration	O
of	O
action	O
than	O
monohydroxytamoxifen	S-chem
,	O
a	O
high	O
dosage	O
ratio	O
of	O
LY117018	S-chem
over	O
monohydroxytamoxifen	S-chem
is	O
required	O
to	O
maintain	O
effective	O
competitive	O
antagonism	O
in	O
the	O
uterus	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
monohydroxytamoxifen	S-chem
and	O
LY117018	S-chem
probably	O
act	O
through	O
the	O
same	O
mechanism	O
of	O
action	O
via	O
the	O
estrogen	B-geneY
receptor	E-geneY
.	O

Evidence	O
for	O
a	O
new	O
binding	O
mode	O
to	O
GSK	B-geneN
-	I-geneN
3	E-geneN
:	O
allosteric	O
regulation	O
by	O
the	O
marine	O
compound	O
palinurin	S-chem
.	O

Glycogen	B-geneY
synthase	I-geneY
kinase	I-geneY
3β	E-geneY
(	O
GSK	B-geneY
-	I-geneY
3β	E-geneY
)	O
is	O
widely	O
recognised	O
as	O
a	O
relevant	O
player	O
in	O
the	O
pathogenesis	O
of	O
several	O
highly	O
prevalent	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
mood	O
disorders	O
,	O
diabetes	O
and	O
cancer	O
.	O

Therefore	O
,	O
this	O
enzyme	O
constitutes	O
a	O
highly	O
attractive	O
therapeutic	O
target	O
for	O
the	O
development	O
of	O
selective	O
inhibitors	O
as	O
new	O
promising	O
drugs	O
for	O
the	O
treatment	O
of	O
these	O
pathologies	O
.	O

We	O
describe	O
here	O
the	O
isolation	O
and	O
biochemical	O
characterization	O
of	O
the	O
marine	O
natural	O
sesquiterpene	S-chem-C4-1
palinurin	S-chem-C4-1
as	O
a	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
inhibitor	O
.	O

Experimental	O
studies	O
performed	O
for	O
characterizing	O
the	O
inhibitory	O
mechanism	O
indicate	O
that	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
inhibition	O
by	O
palinurin	S-chem-C4-1
can	O
not	O
be	O
competed	O
out	O
by	O
ATP	S-chem
nor	O
peptide	O
substrate	O
.	O

Molecular	O
modelling	O
techniques	O
have	O
enabled	O
us	O
to	O
propose	O
an	O
unconventional	O
binding	O
mode	O
to	O
GSK	B-geneY
-	I-geneY
3β	E-geneY
.	O

Moreover	O
,	O
molecular	O
dynamics	O
simulations	O
have	O
identified	O
an	O
allosteric	O
mechanism	O
by	O
which	O
binding	O
of	O
palinurin	S-chem-C4-1
leads	O
to	O
GSK	B-geneY-C4-2
-	I-geneY-C4-2
3β	E-geneY-C4-2
inhibition	O
.	O

The	O
inhibitory	O
activities	O
determined	O
for	O
a	O
series	O
of	O
structurally	O
related	O
analogues	O
support	O
the	O
proposed	O
binding	O
mode	O
of	O
palinurin	S-chem
,	O
which	O
is	O
the	O
first	O
compound	O
described	O
to	O
target	O
this	O
allosteric	O
site	O
.	O

The	O
results	O
offer	O
new	O
opportunities	O
for	O
designing	O
and	O
developing	O
selective	O
inhibitors	O
with	O
novel	O
mechanisms	O
of	O
action	O
.	O

Methylphenidate	S-chem
administration	O
to	O
juvenile	O
rats	O
alters	O
brain	O
areas	O
involved	O
in	O
cognition	O
,	O
motivated	O
behaviors	O
,	O
appetite	O
,	O
and	O
stress	O
.	O

Thousands	O
of	O
children	O
receive	O
methylphenidate	S-chem
(	O
MPH	S-chem
;	O
Ritalin	S-chem
)	O
for	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
yet	O
the	O
long	O
-	O
term	O
neurochemical	O
consequences	O
of	O
MPH	S-chem
treatment	O
are	O
unknown	O
.	O

To	O
mimic	O
clinical	O
Ritalin	S-chem
treatment	O
in	O
children	O
,	O
male	O
rats	O
were	O
injected	O
with	O
MPH	S-chem
(	O
5	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
twice	O
daily	O
from	O
postnatal	O
day	O
7	O
(	O
PND7	O
)	O
-	O
PND35	O
.	O

At	O
the	O
end	O
of	O
administration	O
(	O
PND35	O
)	O
or	O
in	O
adulthood	O
(	O
PND135	O
)	O
,	O
brain	O
sections	O
from	O
littermate	O
pairs	O
were	O
immunocytochemically	O
labeled	O
for	O
neurotransmitters	O
and	O
cytological	O
markers	O
in	O
16	O
regions	O
implicated	O
in	O
MPH	S-chem
effects	O
and	O
/	O
or	O
ADHD	O
etiology	O
.	O

At	O
PND35	O
,	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
of	O
rats	O
given	O
MPH	S-chem-MU-1
showed	O
55	O
%	O
greater	O
immunoreactivity	O
(	O
-	O
ir	O
)	O
for	O
the	O
catecholamine	S-chem
marker	O
tyrosine	B-geneY-C3-2
hydroxylase	E-geneY-C3-2
(	O
TH	S-geneY-C3-2
)	O
,	O
60	O
%	O
more	O
Nissl	O
-	O
stained	O
cells	O
,	O
and	O
40	O
%	O
less	O
norepinephrine	B-geneY-C4-2
transporter	E-geneY-C4-2
(	O
NET	S-geneY-C4-2
)	O
-	O
ir	O
density	O
.	O

In	O
hippocampal	O
dentate	O
gyrus	O
,	O
MPH	S-chem-MU-1
-	O
receiving	O
rats	O
showed	O
a	O
51	O
%	O
decrease	O
in	O
NET	S-geneY-C4-2
-	O
ir	O
density	O
and	O
a	O
61	O
%	O
expanded	O
distribution	O
of	O
the	O
new	O
-	O
cell	O
marker	O
PSA	O
-	O
NCAM	S-geneY-C3-2
(	O
polysialylated	O
form	O
of	O
neural	B-geneY-C3-2
cell	I-geneY-C3-2
adhesion	I-geneY-C3-2
molecule	E-geneY-C3-2
)	O
.	O

In	O
medial	O
striatum	O
,	O
TH	S-geneY-C4-2
-	O
ir	O
decreased	O
by	O
21	O
%	O
,	O
and	O
in	O
hypothalamus	O
neuropeptide	B-geneY-C3-2
Y	E-geneY-C3-2
-	O
ir	O
increased	O
by	O
10	O
%	O
in	O
MPH	S-chem-MU-1
-	O
exposed	O
rats	O
.	O

At	O
PND135	O
,	O
MPH	O
-	O
exposed	O
rats	O
exhibited	O
decreased	O
anxiety	O
in	O
the	O
elevated	O
plus	O
-	O
maze	O
and	O
a	O
trend	O
for	O
decreased	O
TH	S-geneY
-	O
ir	O
in	O
the	O
mPFC	O
.	O

Neither	O
PND35	O
nor	O
PND135	O
rats	O
showed	O
major	O
structural	O
differences	O
with	O
MPH	S-chem
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
developmental	O
exposure	O
to	O
high	O
therapeutic	O
doses	O
of	O
MPH	S-chem
has	O
short	O
-	O
term	O
effects	O
on	O
select	O
neurotransmitters	O
in	O
brain	O
regions	O
involved	O
in	O
motivated	O
behaviors	O
,	O
cognition	O
,	O
appetite	O
,	O
and	O
stress	O
.	O

Although	O
the	O
observed	O
neuroanatomical	O
changes	O
largely	O
resolve	O
with	O
time	O
,	O
chronic	O
modulation	O
of	O
young	O
brains	O
with	O
MPH	S-chem
may	O
exert	O
effects	O
on	O
brain	O
neurochemistry	O
that	O
modify	O
some	O
behaviors	O
even	O
in	O
adulthood	O
.	O

Valproic	B-chem-C4-1
acid	E-chem-C4-1
selectively	O
inhibits	O
conversion	O
of	O
arachidonic	B-chem-C9-1
acid	E-chem-C9-1
to	O
arachidonoyl	B-chem-C9-1
-	I-chem-C9-1
CoA	E-chem-C9-1
by	O
brain	B-geneN-MU-2
microsomal	I-geneN-MU-2
long	I-geneN-MU-2
-	I-geneN-MU-2
chain	I-geneN-MU-2
fatty	I-geneN-MU-2
acyl	I-geneN-MU-2
-	I-geneN-MU-2
CoA	I-geneN-MU-2
synthetases	E-geneN-MU-2
:	O
relevance	O
to	O
bipolar	O
disorder	O
.	O

RATIONALE	O
:	O
Several	O
drugs	O
used	O
to	O
treat	O
bipolar	O
disorder	O
(	O
lithium	S-chem-C4-1
and	O
carbamazepine	S-chem-C4-1
)	O
,	O
when	O
administered	O
chronically	O
to	O
rats	O
,	O
reduce	O
the	O
turnover	O
of	O
arachidonic	B-chem
acid	E-chem
,	O
but	O
not	O
docosahexaenoic	B-chem
acid	E-chem
,	O
in	O
brain	O
phospholipids	O
by	O
decreasing	O
the	O
activity	O
of	O
an	O
arachidonic	B-chem
acid	E-chem
-	O
selective	O
phospholipase	B-geneN-C4-2
A	I-geneN-C4-2
(	I-geneN-C4-2
2	I-geneN-C4-2
)	E-geneN-C4-2
.	O

Although	O
chronic	O
valproic	B-chem
acid	E-chem
produces	O
similar	O
effects	O
on	O
brain	O
arachidonic	B-chem
acid	E-chem
and	O
docosahexaenoic	B-chem
acid	E-chem
turnover	O
,	O
it	O
does	O
not	O
alter	O
phospholipase	B-geneN
A	I-geneN
(	I-geneN
2	I-geneN
)	E-geneN
activity	O
,	O
suggesting	O
that	O
it	O
targets	O
a	O
different	O
enzyme	O
in	O
the	O
turnover	O
pathway	O
.	O

MATERIALS	O
AND	O
METHODS	O
/	O
RESULTS	O
:	O
By	O
isolating	O
rat	B-geneN
brain	I-geneN
microsomal	I-geneN
long	I-geneN
-	I-geneN
chain	I-geneN
fatty	I-geneN
acyl	I-geneN
-	I-geneN
CoA	I-geneN
synthetases	E-geneN
(	O
Acsl	S-geneN
)	O
,	O
we	O
show	O
in	O
vitro	O
that	O
valproic	B-chem-C4-1
acid	E-chem-C4-1
is	O
a	O
non	O
-	O
competitive	O
inhibitor	O
of	O
Acsl	S-geneN-C4-2
,	O
as	O
it	O
reduces	O
the	O
maximal	O
velocity	O
of	O
the	O
reaction	O
without	O
changing	O
the	O
affinity	O
of	O
the	O
substrate	O
for	O
the	O
enzyme	O
.	O

While	O
valproic	B-chem
acid	E-chem
inhibited	O
the	O
synthesis	O
of	O
arachidonoyl	B-chem
-	I-chem
CoA	E-chem
,	O
palmitoyl	B-chem
-	I-chem
CoA	E-chem
,	O
and	O
docosahexaenoyl	B-chem
-	I-chem
CoA	E-chem
,	O
the	O
K	O
(	O
i	O
)	O
for	O
inhibition	O
of	O
arachidonoyl	B-chem
-	I-chem
CoA	E-chem
synthesis	O
(	O
14.1	O
mM	O
)	O
was	O
approximately	O
one	O
fifth	O
the	O
K	O
(	O
i	O
)	O
for	O
inhibiting	O
palmitoyl	B-chem
-	I-chem
CoA	E-chem
(	O
85.4	O
mM	O
)	O
and	O
docosahexaenoyl	B-chem
-	I-chem
CoA	E-chem
(	O
78.2	O
mM	O
)	O
synthesis	O
.	O

As	O
chronic	O
administration	O
of	O
valproic	B-chem
acid	E-chem
in	O
bipolar	O
disorder	O
achieves	O
whole	O
-	O
brain	O
levels	O
of	O
1.0	O
to	O
1.5	O
mM	O
,	O
inhibition	O
of	O
arachidonoyl	B-chem
-	I-chem
CoA	E-chem
formation	O
can	O
occur	O
at	O
brain	O
concentrations	O
that	O
are	O
therapeutically	O
relevant	O
to	O
this	O
disease	O
.	O

Furthermore	O
,	O
brain	B-geneN
microsomal	I-geneN
Acsl	E-geneN
did	O
not	O
produce	O
valproyl	B-chem
-	I-chem
CoA	E-chem
.	O

CONCLUSIONS	O
:	O
This	O
study	O
shows	O
that	O
valproic	B-chem-C4-1
acid	E-chem-C4-1
acts	O
as	O
a	O
non	O
-	O
competitive	O
inhibitor	O
of	O
brain	B-geneN-C4-2
microsomal	I-geneN-C4-2
Acsl	E-geneN-C4-2
,	O
and	O
that	O
inhibition	O
is	O
substrate	O
-	O
selective	O
.	O

The	O
study	O
supports	O
the	O
hypothesis	O
that	O
valproic	B-chem
acid	E-chem
acts	O
in	O
bipolar	O
disorder	O
by	O
reducing	O
the	O
brain	O
arachidonic	B-chem
acid	E-chem
cascade	O
,	O
by	O
inhibiting	O
arachidonoyl	B-chem
-	I-chem
CoA	E-chem
formation	O
.	O

More	O
than	O
cool	O
:	O
promiscuous	O
relationships	O
of	O
menthol	S-chem
and	O
other	O
sensory	O
compounds	O
.	O

Several	O
temperature	B-geneN
-	I-geneN
activated	I-geneN
transient	I-geneN
receptor	I-geneN
potential	I-geneN
(	I-geneN
thermoTRP	I-geneN
)	I-geneN
ion	I-geneN
channels	E-geneN
are	O
the	O
molecular	O
receptors	O
of	O
natural	O
compounds	O
that	O
evoke	O
thermal	O
and	O
pain	O
sensations	O
.	O

Menthol	S-chem-C3-1
,	O
popularly	O
known	O
for	O
its	O
cooling	O
effect	O
,	O
activates	O
TRPM8	S-geneY-C3-2
-	O
-	O
a	O
cold	O
-	O
activated	O
thermoTRP	B-geneN-C3-2
ion	I-geneN-C3-2
channel	E-geneN-C3-2
.	O

However	O
,	O
human	O
physiological	O
studies	O
demonstrate	O
a	O
paradoxical	O
role	O
of	O
menthol	S-chem
in	O
modulation	O
of	O
warm	O
sensation	O
,	O
and	O
here	O
,	O
we	O
show	O
that	O
menthol	S-chem-C3-1
also	O
activates	O
heat	O
-	O
activated	O
TRPV3	S-geneY-C3-2
.	O

We	O
further	O
show	O
that	O
menthol	S-chem-C4-1
inhibits	O
TRPA1	S-geneY-C4-2
,	O
potentially	O
explaining	O
the	O
use	O
of	O
menthol	S-chem
as	O
an	O
analgesic	O
.	O

Similar	O
to	O
menthol	S-chem-C3-1
,	O
both	O
camphor	S-chem-C3-1
and	O
cinnamaldehyde	S-chem-C3-1
(	O
initially	O
reported	O
to	O
be	O
specific	O
activators	O
of	O
TRPV3	S-geneY-C3-2
and	O
TRPA1	S-geneY-C3-2
,	O
respectively	O
)	O
also	O
modulate	O
other	O
thermoTRPs	S-geneN
.	O

Therefore	O
,	O
we	O
find	O
that	O
many	O
``	O
sensory	O
compounds	O
``	O
presumed	O
to	O
be	O
specific	O
have	O
a	O
promiscuous	O
relationship	O
with	O
thermoTRPs	O
.	O

Involvement	O
of	O
serotonin	S-chem
5	B-geneY
-	I-geneY
HT3	E-geneY
receptors	O
in	O
the	O
modulation	O
of	O
noradrenergic	O
transmission	O
by	O
serotonin	S-chem
reuptake	O
inhibitors	O
:	O
a	O
microdialysis	O
study	O
in	O
rat	O
brain	O
.	O

RATIONALE	O
:	O
Selective	O
serotonin	S-chem
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
in	O
addition	O
to	O
being	O
able	O
to	O
enhance	O
serotonergic	O
neurotransmission	O
,	O
are	O
able	O
to	O
modulate	O
other	O
brain	O
systems	O
involved	O
in	O
depression	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
evaluates	O
the	O
neurochemical	O
effect	O
of	O
the	O
SSRI	O
citalopram	O
on	O
brain	O
noradrenergic	O
activity	O
and	O
the	O
serotonin	B-geneN
receptor	E-geneN
involved	O
in	O
this	O
effect	O
.	O

METHODS	O
:	O
Dual	O
-	O
probe	O
microdialysis	O
in	O
the	O
locus	O
coeruleus	O
(	O
LC	O
)	O
and	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
was	O
performed	O
in	O
freely	O
awake	O
rats	O
.	O

RESULTS	O
:	O
Systemic	O
citalopram	S-chem
(	O
10	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
increased	O
noradrenaline	O
(	E-chem
NA	O
)	O
in	O
the	O
LC	O
(	O
E	O
max	O
=	O
141	O
±	O
13	O
%	O
)	O
and	O
simultaneously	O
decreased	O
NA	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
-	O
46	O
±	O
7	O
%	O
)	O
.	O

In	O
the	O
local	O
presence	O
into	O
the	O
LC	O
of	O
the	O
α2	B-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
RS79948	S-chem-C6-1
(	O
1	O
μM	O
)	O
,	O
systemic	O
citalopram	O
increased	O
NA	O
in	O
the	O
LC	O
(	O
Emax	O
=	O
157	O
±	O
25	O
%	O
)	O
and	O
PFC	O
(	O
Emax	O
=	O
175	O
±	O
24	O
%	O
)	O
.	O

Local	O
citalopram	S-chem
(	O
0.1	O
-	O
100	O
μM	O
)	O
into	O
the	O
LC	O
induced	O
NA	O
increase	O
in	O
the	O
LC	O
(	O
Emax	O
=	O
210	O
±	O
25	O
%	O
)	O
and	O
decrease	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
-	O
38	O
±	O
9	O
%	O
)	O
.	O

Local	O
LC	O
citalopram	S-chem
effect	O
was	O
abolished	O
by	O
LC	O
presence	O
of	O
the	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT3	E-geneY-C6-2
receptor	O
antagonist	O
MDL72222	S-chem-C6-1
(	O
1	O
μM	O
)	O
but	O
not	O
the	O
5	O
-	B-geneN-C6-2
HT1	I-geneN-C6-2
/	I-geneN-C6-2
2	I-geneN-C6-2
receptor	O
antagonist	O
methiothepin	O
(	E-chem-C6-1
1	O
μM	O
)	O
.	O

Systemic	O
citalopram	S-chem
in	O
the	O
LC	O
presence	O
of	O
MDL72222	S-chem
did	O
not	O
modify	O
NA	O
in	O
the	O
LC	O
but	O
increased	O
NA	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
158	O
±	O
26	O
%	O
)	O
.	O

Local	O
citalopram	S-chem
into	O
the	O
PFC	O
enhanced	O
NA	O
(	O
Emax	O
=	O
376	O
±	O
18	O
%	O
)	O
in	O
the	O
area	O
,	O
which	O
was	O
prevented	O
by	O
MDL72222	O
.	I-chem

CONCLUSIONS	O
:	O
The	O
SSRI	O
citalopram	S-chem
modulates	O
central	O
noradrenergic	O
neurotransmission	O
by	O
activation	O
,	O
through	O
endogenous	O
serotonin	S-chem
,	O
of	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptors	O
expressed	O
in	O
the	O
somatodendritic	O
(	O
LC	O
)	O
and	O
terminal	O
(	O
PFC	O
)	O
areas	O
,	O
which	O
subsequently	O
promote	O
an	O
enhancement	O
of	O
local	O
NA	O
.	O

Therefore	O
,	O
5	B-geneY
-	I-geneY
HT3	E-geneY
receptors	O
and	O
somatodendritic	O
α2	B-geneN
-	I-geneN
adrenoceptors	E-geneN
in	O
the	O
LC	O
play	O
an	O
important	O
role	O
in	O
the	O
global	O
effect	O
of	O
SSRIs	O
.	O

Cerebral	O
and	O
extracerebral	O
cholesterol	S-chem
metabolism	O
and	O
CSF	O
markers	O
of	O
Alzheimer	O
's	O
disease	O
.	O

The	O
disturbances	O
of	O
the	O
cholesterol	S-chem
synthesis	O
and	O
metabolism	O
described	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
may	O
be	O
both	O
a	O
consequence	O
of	O
the	O
neurodegenerative	O
process	O
and	O
a	O
contributor	O
to	O
the	O
pathogenesis	O
.	O

These	O
putative	O
relationships	O
and	O
their	O
underlying	O
mechanisms	O
are	O
not	O
well	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
the	O
cerebral	O
and	O
extracerebral	O
cholesterol	S-chem
synthesis	O
and	O
metabolism	O
,	O
and	O
the	O
AD	O
pathology	O
as	O
reflected	O
by	O
CSF	O
markers	O
in	O
humans	O
.	O

We	O
evaluated	O
the	O
relationships	O
between	O
the	O
plasma	O
and	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
of	O
cholesterol	S-chem
,	O
the	O
cholesterol	S-chem
precursors	O
lanosterol	S-chem
,	O
lathosterol	S-chem
and	O
desmosterol	S-chem
,	O
and	O
the	O
cholesterol	S-chem
elimination	O
products	O
24S	B-chem
-	I-chem
hydroxycholesterol	E-chem
and	O
27	B-chem
-	I-chem
hydroxycholesterol	E-chem
,	O
and	O
the	O
CSF	O
markers	O
for	O
AD	O
pathology	O
Aβ1	B-geneY
-	I-geneY
42	E-geneY
and	O
p	B-geneY
-	I-geneY
tau181	E-geneY
in	O
86	O
subjects	O
with	O
normal	O
cognition	O
and	O
in	O
107	O
AD	O
patients	O
.	O

CSF	O
desmosterol	S-chem
,	O
cholesterol	S-chem
and	O
24S	B-chem
-	I-chem
hydroxycholesterol	E-chem
in	O
the	O
AD	O
group	O
,	O
and	O
CSF	O
24S	B-chem
-	I-chem
hydroxycholesterol	E-chem
in	O
the	O
control	O
group	O
correlated	O
with	O
the	O
p	B-geneY
-	I-geneY
tau181	E-geneY
levels	O
.	O

Neither	O
CSF	O
nor	O
plasma	O
concentrations	O
of	O
the	O
included	O
compounds	O
correlated	O
with	O
the	O
CSF	O
Aβ1	B-geneY
-	I-geneY
42	E-geneY
levels	O
.	O

In	O
multivariate	O
regression	O
tests	O
including	O
age	O
,	O
gender	O
,	O
albumin	O
ratio	O
,	O
number	O
of	O
the	O
APOEɛ4	S-geneY
alleles	O
,	O
and	O
diagnosis	O
,	O
p	B-geneY
-	I-geneY
tau181	E-geneY
levels	O
independently	O
predicted	O
the	O
CSF	O
desmosterol	S-chem
,	O
cholesterol	S-chem
and	O
24S	B-chem
-	I-chem
hydroxycholesterol	E-chem
concentrations	O
.	O

The	O
associations	O
remained	O
significant	O
for	O
CSF	O
cholesterol	S-chem
and	O
24S	B-chem
-	I-chem
hydroxycholesterol	E-chem
when	O
analyses	O
were	O
separately	O
performed	O
in	O
the	O
AD	O
group	O
.	O

The	O
results	O
suggest	O
that	O
alterations	O
of	O
CNS	O
cholesterol	S-chem
de	O
novo	O
genesis	O
and	O
metabolism	O
are	O
related	O
to	O
neurodegeneration	O
and	O
in	O
particular	O
to	O
the	O
cerebral	O
accumulation	O
of	O
phosphorylated	B-geneY
tau	E-geneY
.	O

Cell	O
cycle	O
regulation	O
by	O
glucosamine	S-chem
in	O
human	O
pulmonary	O
epithelial	O
cells	O
.	O

Airway	O
epithelial	O
cells	O
play	O
an	O
important	O
role	O
against	O
intruding	O
pathogens	O
.	O

Glucosamine	S-chem
,	O
a	O
commonly	O
used	O
supplemental	O
compound	O
,	O
has	O
recently	O
begun	O
to	O
be	O
regarded	O
as	O
a	O
potential	O
anti	O
-	O
inflammatory	O
molecule	O
.	O

This	O
study	O
aimed	O
to	O
uncover	O
how	O
glucosamine	S-chem
impacts	O
on	O
cellular	O
proliferation	O
in	O
human	O
alveolar	O
epithelial	O
cells	O
(	O
A549	O
)	O
and	O
bronchial	O
epithelial	O
cells	O
(	O
HBECs	O
)	O
.	O

With	O
trypan	B-chem
blue	E-chem
-	O
exclusion	O
assay	O
,	O
we	O
observed	O
that	O
glucosamine	S-chem
(	O
10	O
,	O
20	O
,	O
50	O
mM	O
)	O
caused	O
a	O
decrease	O
in	O
cell	O
number	O
at	O
24	O
and	O
48	O
h	O
;	O
with	O
a	O
flow	O
cytometric	O
analysis	O
,	O
we	O
also	O
noted	O
an	O
enhanced	O
cell	O
accumulation	O
within	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
at	O
24	O
h	O
and	O
induction	O
of	O
late	O
apoptosis	O
at	O
24	O
and	O
48	O
h	O
by	O
glucosamine	O
(	I-chem
10	I-chem
,	E-chem
20	O
,	O
50	O
mM	O
)	O
in	O
A549	O
cells	O
and	O
HBECs	O
.	O

Examination	O
of	O
phosphorylation	O
in	O
retinoblastoma	B-geneY-C4-2
(	I-geneY-C4-2
Rb	I-geneY-C4-2
)	I-geneY-C4-2
protein	E-geneY-C4-2
,	O
we	O
found	O
an	O
inhibitory	O
effect	O
by	O
glucosamine	S-chem-C4-1
at	O
20	O
and	O
50	O
mM	O
.	O

Glucosamine	S-chem-MU-1
at	O
50	O
mM	O
was	O
demonstrated	O
to	O
elevate	O
both	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
p53	O
and	O
heme	O
oxygenase	I-geneY-C3-2
-	I-geneY-C3-2
1	I-geneY-C3-2
(	E-geneY-C3-2
HO	O
-	I-geneY
1	I-geneY
)	E-geneY
,	O
but	O
also	O
caused	O
a	O
reduction	O
in	O
p21	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
glucosamine	S-chem-MU-1
attenuated	O
p21	S-geneY-C4-2
protein	O
stability	O
via	O
the	O
proteasomal	O
proteolytic	O
pathway	O
,	O
as	O
well	O
as	O
inducing	O
p21	S-geneY-C3-2
nuclear	O
accumulation	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
a	O
high	O
dose	O
of	O
glucosamine	S-chem-MU-1
may	O
inhibit	O
cell	O
proliferation	O
through	O
apoptosis	O
and	O
disturb	O
cell	O
cycle	O
progression	O
with	O
a	O
halt	O
at	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
,	O
and	O
that	O
this	O
occurs	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
reduction	O
in	O
Rb	S-geneY-C4-2
phosphorylation	O
together	O
with	O
modulation	O
of	O
p21	S-geneY
,	O
p53	S-geneN
and	O
HO	B-geneY
-	I-geneY
1	E-geneY
expression	O
,	O
and	O
nuclear	O
p21	S-geneY-C3-2
accumulation	O
.	O

Discovery	O
and	O
optimization	O
of	O
anthranilic	B-chem-C4-1
acid	I-chem-C4-1
sulfonamides	E-chem-C4-1
as	O
inhibitors	O
of	O
methionine	B-geneY
aminopeptidase	I-geneY
-	I-geneY
2	E-geneY
:	O
a	O
structural	O
basis	O
for	O
the	O
reduction	O
of	O
albumin	S-geneY-C4-2
binding	O
.	O

Methionine	B-geneY
aminopeptidase	I-geneY
-	I-geneY
2	E-geneY
(	O
MetAP2	S-geneY
)	O
is	O
a	O
novel	O
target	O
for	O
cancer	O
therapy	O
.	O

As	O
part	O
of	O
an	O
effort	O
to	O
discover	O
orally	O
active	O
reversible	O
inhibitors	O
of	O
MetAP2	S-geneY
,	O
a	O
series	O
of	O
anthranilic	B-chem
acid	I-chem
sulfonamides	E-chem
with	O
micromolar	O
affinities	O
for	O
human	B-geneY
MetAP2	E-geneY
were	O
identified	O
using	O
affinity	O
selection	O
by	O
mass	O
spectrometry	O
(	O
ASMS	O
)	O
screening	O
.	O

These	O
micromolar	O
hits	O
were	O
rapidly	O
improved	O
to	O
nanomolar	O
leads	O
on	O
the	O
basis	O
of	O
insights	O
from	O
protein	O
crystallography	O
;	O
however	O
,	O
the	O
compounds	O
displayed	O
extensive	O
binding	O
to	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
and	O
had	O
limited	O
activity	O
in	O
cellular	O
assays	O
.	O

Modifications	O
based	O
on	O
structural	O
information	O
on	O
the	O
binding	O
of	O
lead	O
compounds	O
to	O
both	O
MetAP2	S-geneY
and	O
domain	B-geneN
III	I-geneN
of	I-geneN
albumin	E-geneN
allowed	O
the	O
identification	O
of	O
compounds	O
with	O
significant	O
improvements	O
in	O
both	O
parameters	O
,	O
which	O
showed	O
good	O
cellular	O
activity	O
in	O
both	O
proliferation	O
and	O
methionine	S-chem
processing	O
assays	O
.	O

Prostacyclin	S-chem-C4-1
analogues	O
inhibit	O
tissue	B-geneY-C4-2
factor	E-geneY-C4-2
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
via	O
a	O
cyclic	B-chem
AMP	E-chem
-	O
dependent	O
mechanism	O
.	O

Increased	O
expression	O
of	O
tissue	B-geneY
factor	E-geneY
procoagulant	O
by	O
peripheral	O
blood	O
monocytes	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
thrombotic	O
disorders	O
.	O

The	O
present	O
studies	O
were	O
undertaken	O
to	O
determine	O
whether	O
stable	O
analogues	O
of	O
prostacyclin	S-chem-C4-1
,	O
a	O
potent	O
endothelium	O
-	O
derived	O
platelet	O
inhibitor	O
and	O
vasodilator	O
,	O
could	O
inhibit	O
tissue	B-geneY-C4-2
factor	E-geneY-C4-2
expression	O
by	O
human	O
monocytic	O
cells	O
.	O

Exposure	O
of	O
monocytic	O
tumor	O
THP	O
-	O
1	O
cells	O
to	O
100	O
ng	O
/	O
ml	O
endotoxin	O
,	O
2	O
units	O
/	O
ml	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
,	O
or	O
5	O
ng	O
/	O
ml	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
for	O
4	O
hours	O
led	O
to	O
increased	O
tissue	B-geneY
factor	E-geneY
procoagulant	O
activity	O
.	O

Preincubation	O
for	O
30	O
minutes	O
with	O
iloprost	S-chem-C4-1
,	O
ciprostene	S-chem-C4-1
,	O
and	O
carbacyclin	S-chem-C4-1
led	O
to	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
tissue	B-geneY-C4-2
factor	E-geneY-C4-2
expression	O
induced	O
by	O
all	O
three	O
challenging	O
agents	O
.	O

Iloprost	S-chem
was	O
the	O
most	O
potent	O
:	O
50	O
%	O
inhibition	O
occurred	O
at	O
5	O
nM	O
,	O
a	O
concentration	O
close	O
to	O
the	O
reported	O
dissociation	O
constant	O
for	O
iloprost	S-chem
binding	O
to	O
the	O
platelet	O
prostacyclin	B-geneY
receptor	E-geneY
.	O

An	O
orally	O
active	O
analogue	O
,	O
cicaprost	S-chem
,	O
was	O
equally	O
effective	O
against	O
endotoxin	O
-	O
induced	O
tissue	B-geneY
factor	E-geneY
expression	O
.	O

Carbacyclin	S-chem
and	O
ciprostene	S-chem
were	O
100	O
times	O
less	O
potent	O
.	O

Iloprost	O
prevented	O
the	O
endotoxin	O
-	O
induced	O
expression	O
of	O
tissue	B-geneY
factor	E-geneY
antigen	O
on	O
the	O
surface	O
of	O
THP	O
-	O
1	O
cells	O
,	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Iloprost	S-chem
(	O
500	O
pM	O
-	O
50	O
nM	O
)	O
increased	O
intracellular	O
levels	O
of	O
cyclic	B-chem
AMP	E-chem
.	O

This	O
effect	O
was	O
potentiated	O
by	O
isobutylmethylxanthine	S-chem-C4-1
,	O
an	O
inhibitor	O
of	O
phosphodiesterase	S-geneN-C4-2
.	O

The	O
inhibitory	O
effects	O
of	O
iloprost	O
on	O
tissue	B-geneY-C4-2
factor	E-geneY-C4-2
expression	O
were	O
also	O
potentiated	O
by	O
isobutylmethylxanthine	S-chem-C4-1
and	O
mimicked	O
by	O
forskolin	S-chem-C4-1
and	O
dibutyryl	O
cyclic	I-chem-C4-1
AMP	E-chem-C4-1
but	O
not	O
dibutyryl	B-chem
cyclic	I-chem
GMP	E-chem
.	O

These	O
results	O
suggest	O
that	O
prostacyclin	S-chem-C4-1
may	O
play	O
a	O
role	O
in	O
downregulating	O
tissue	B-geneY-C4-2
factor	E-geneY-C4-2
expression	O
in	O
monocytes	O
,	O
at	O
least	O
in	O
part	O
via	O
elevation	O
of	O
intracellular	O
levels	O
of	O
cyclic	B-chem-C4-1
AMP	E-chem-C4-1
.	O

Inhibitory	O
effect	O
of	O
synthetic	O
progestins	S-chem-C4-1
,	O
4	B-chem-C4-1
-	I-chem-C4-1
MA	E-chem-C4-1
and	O
cyanoketone	S-chem-C4-1
on	O
human	B-geneN-C4-2
placental	I-geneN-C4-2
3	I-geneN-C4-2
beta	I-geneN-C4-2
-	I-geneN-C4-2
hydroxysteroid	I-geneN-C4-2
dehydrogenase	I-geneN-C4-2
/	I-geneN-C4-2
5	I-geneN-C4-2
-	I-geneN-C4-2
-	I-geneN-C4-2
-	I-geneN-C4-2
-	I-geneN-C4-2
4	I-geneN-C4-2
-	I-geneN-C4-2
ene	I-geneN-C4-2
-	I-geneN-C4-2
isomerase	E-geneN-C4-2
activity	O
.	O

Human	B-geneN-C9-2
placental	I-geneN-C9-2
3	I-geneN-C9-2
beta	I-geneN-C9-2
-	I-geneN-C9-2
hydroxysteroid	I-geneN-C9-2
dehydrogenase	I-geneN-C9-2
/	I-geneN-C9-2
5	I-geneN-C9-2
-	I-geneN-C9-2
-	I-geneN-C9-2
-	I-geneN-C9-2
-	I-geneN-C9-2
4	I-geneN-C9-2
-	I-geneN-C9-2
ene	I-geneN-C9-2
isomerase	E-geneN-C9-2
(	O
3	B-geneN-C9-2
beta	I-geneN-C9-2
-	I-geneN-C9-2
HSD	E-geneN-C9-2
)	O
purified	O
from	O
human	O
placenta	O
transforms	O
C	O
-	O
21	O
(	O
pregnenolone	S-chem-C9-1
and	O
17	B-chem-C9-1
alpha	I-chem-C9-1
-	I-chem-C9-1
hydroxy	I-chem-C9-1
pregnenolone	E-chem-C9-1
)	O
as	O
well	O
as	O
C	O
-	O
19	O
(	O
dehydroepiandrosterone	S-chem-C9-1
and	O
androst	B-chem-C9-1
-	I-chem-C9-1
5	I-chem-C9-1
-	I-chem-C9-1
ene	I-chem-C9-1
-	I-chem-C9-1
3	I-chem-C9-1
beta	I-chem-C9-1
,	I-chem-C9-1
17	I-chem-C9-1
beta	I-chem-C9-1
-	I-chem-C9-1
diol	E-chem-C9-1
)	O
steroids	O
into	O
the	O
corresponding	O
3	B-chem-C9-1
-	I-chem-C9-1
keto	I-chem-C9-1
-	I-chem-C9-1
4	I-chem-C9-1
-	I-chem-C9-1
ene	I-chem-C9-1
-	I-chem-C9-1
steroids	E-chem-C9-1
and	O
is	O
thus	O
involved	O
in	O
the	O
biosynthesis	O
of	O
all	O
classes	O
of	O
hormonal	O
steroids	O
.	O

Trilostane	S-chem-C4-1
,	O
epostane	S-chem-C4-1
and	O
cyanoketone	S-chem-C4-1
are	O
potent	O
inhibitors	O
of	O
3	B-geneN-C4-2
beta	I-geneN-C4-2
-	I-geneN-C4-2
HSD	E-geneN-C4-2
with	O
Ki	O
values	O
of	O
approximately	O
50	O
nM	O
.	O

4	B-chem-C4-1
-	I-chem-C4-1
MA	E-chem-C4-1
,	O
a	O
well	O
known	O
5	B-geneN-C4-2
alpha	I-geneN-C4-2
-	I-geneN-C4-2
reductase	E-geneN-C4-2
inhibitor	O
,	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
3	B-geneN-C4-2
beta	I-geneN-C4-2
-	I-geneN-C4-2
HSD	E-geneN-C4-2
with	O
a	O
Ki	O
value	O
of	O
56	O
nM	O
.	O

Synthetic	O
progestin	S-chem
compounds	O
such	O
as	O
promegestone	S-chem
and	O
RU2323	S-chem
show	O
relatively	O
strong	O
inhibitory	O
effects	O
with	O
Ki	O
values	O
of	O
110	O
and	O
190	O
nM	O
,	O
respectively	O
.	O

Cyproterone	B-chem-C4-1
acetate	E-chem-C4-1
,	O
a	O
progestin	S-chem-C4-1
used	O
in	O
the	O
treatment	O
of	O
hirsutism	O
,	O
acne	O
and	O
prostate	O
cancer	O
as	O
well	O
as	O
norgestrel	S-chem-C4-1
and	O
norethindrone	S-chem-C4-1
that	O
are	O
widely	O
used	O
as	O
oral	O
contraceptives	O
also	O
inhibit	O
3	B-geneN-C4-2
beta	I-geneN-C4-2
-	I-geneN-C4-2
HSD	E-geneN-C4-2
activity	O
at	O
Ki	O
values	O
of	O
1.5	O
,	O
1.7	O
and	O
2.5	O
microM	O
,	O
respectively	O
.	O

Tyrosine	B-geneY
hydroxylase	E-geneY
binds	O
tetrahydrobiopterin	S-chem
cofactor	O
with	O
negative	O
cooperativity	O
,	O
as	O
shown	O
by	O
kinetic	O
analyses	O
and	O
surface	O
plasmon	O
resonance	O
detection	O
.	O

Kinetic	O
studies	O
of	O
tetrameric	O
recombinant	O
human	B-geneY
tyrosine	I-geneY
hydroxylase	I-geneY
isoform	I-geneY
1	E-geneY
(	O
hTH1	S-geneY
)	O
have	O
revealed	O
properties	O
so	O
far	O
not	O
reported	O
for	O
this	O
enzyme	O
.	O

Firstly	O
,	O
with	O
the	O
natural	O
cofactor	O
(	B-chem
6R	I-chem
)	I-chem
-	I-chem
Lerythro	I-chem
-	I-chem
5,6,7	I-chem
,	I-chem
8	I-chem
-	I-chem
tetrahydrobiopterin	E-chem
(	O
H4biopterin	S-chem
)	O
a	O
time	O
-	O
dependent	O
change	O
(	O
burst	O
)	O
in	O
enzyme	O
activity	O
was	O
observed	O
,	O
with	O
a	O
half	O
-	O
time	O
of	O
about	O
20	O
s	O
for	O
the	O
kinetic	O
transient	O
.	O

Secondly	O
,	O
nonhyperbolic	O
saturation	O
behaviour	O
was	O
found	O
for	O
H4biopterin	S-chem
with	O
a	O
pronounced	O
negative	O
cooperativity	O
(	O
0.39	O
<	O
h	O
<	O
0.58	O
;	O
[	O
S	O
]	O
0.5	O
=	O
24	O
+	O
/	O
-	O
4	O
microM	O
)	O
.	O

On	O
phosphorylation	O
of	O
Ser40	S-chem-C9-1
by	O
protein	B-geneN-C9-2
kinase	I-geneN-C9-2
A	E-geneN-C9-2
,	O
the	O
affinity	O
for	O
H4biopterin	S-chem
increased	O
(	O
[	O
S	O
]	O
0.5	O
=	O
11	O
+	O
/	O
-	O
2	O
microM	O
)	O
and	O
the	O
negative	O
cooperativity	O
was	O
amplified	O
(	O
h	O
=	O
0.27	O
+	O
/	O
-	O
0.03	O
)	O
.	O

The	O
dimeric	O
C	S-chem
-	O
terminal	O
deletion	O
mutant	O
(	O
Delta473	O
-	O
528	O
)	O
of	O
hTH1	S-geneY
also	O
showed	O
negative	O
cooperativity	O
of	O
H4biopterin	S-chem
binding	O
(	O
h	O
=	O
0.4	O
)	O
.	O

Cooperativity	O
was	O
not	O
observed	O
with	O
the	O
cofactor	O
analogues	O
6	B-chem
-	I-chem
methyl	I-chem
-	I-chem
5,6,7,8	I-chem
-	I-chem
tetrahydropterin	E-chem
(	O
h	O
=	O
0.9	O
+	O
/	O
-	O
0.1	O
;	O
Km	O
=	O
62.7	O
+	O
/	O
-	O
5.7	O
microM	O
)	O
and	O
3	B-chem
-	I-chem
methyl	I-chem
-	I-chem
5,6,7	I-chem
,	I-chem
8	I-chem
-	I-chem
tetrahydropterin	E-chem
(	O
H43	B-chem
-	I-chem
methyl	I-chem
-	I-chem
pterin	E-chem
)	O
(	O
h	O
=	O
1.0	O
+	O
/	O
-	O
0.1	O
;	O
Km	O
=	O
687	O
+	O
/	O
-	O
50	O
microM	O
)	O
.	O

In	O
the	O
presence	O
of	O
1	O
mM	O
H43	B-chem
-	I-chem
methyl	I-chem
-	I-chem
pterin	E-chem
,	O
used	O
as	O
a	O
competitive	O
cofactor	O
analogue	O
to	O
BH4	O
,	O
hyperbolic	O
saturation	O
curves	O
were	O
also	O
found	O
for	O
H4biopterin	S-chem
(	O
h	O
=	O
1.0	O
)	O
,	O
thus	O
confirming	O
the	O
genuine	O
nature	O
of	O
the	O
kinetic	O
negative	O
cooperativity	O
.	O

This	O
cooperativity	O
was	O
confirmed	O
by	O
real	O
-	O
time	O
biospecific	O
interaction	O
analysis	O
by	O
surface	O
plasmon	O
resonance	O
detection	O
.	O

The	O
equilibrium	O
binding	O
of	O
H4biopterin	S-chem
to	O
the	O
immobilized	O
iron	O
-	O
free	O
apoenzyme	O
results	O
in	O
a	O
saturable	O
positive	O
resonance	O
unit	O
(	O
DeltaRU	O
)	O
response	O
with	O
negative	O
cooperativity	O
(	O
h	O
=	O
0.52	O
-	O
0.56	O
)	O
.	O

Infrared	O
spectroscopic	O
studies	O
revealed	O
a	O
reduced	O
thermal	O
stability	O
both	O
of	O
the	O
apo	O
-	O
and	O
the	O
holo	O
-	O
hTH1	S-geneY
on	O
binding	O
of	O
H4biopterin	S-chem
and	O
Lerythro	B-chem
-	I-chem
dihydrobiopterin	E-chem
(	O
H2biopterin	S-chem
)	O
.	O

Moreover	O
,	O
the	O
ligand	O
-	O
bound	O
forms	O
of	O
the	O
enzyme	O
also	O
showed	O
a	O
decreased	O
resistance	O
to	O
limited	O
tryptic	O
proteolysis	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
binding	O
of	O
H4biopterin	S-chem
at	O
the	O
active	O
site	O
induces	O
a	O
destabilizing	O
conformational	O
change	O
in	O
the	O
enzyme	O
which	O
could	O
be	O
related	O
to	O
the	O
observed	O
negative	O
cooperativity	O
.	O

Thus	O
,	O
our	O
studies	O
provide	O
new	O
insight	O
into	O
the	O
regulation	O
of	O
TH	S-geneY
by	O
the	O
concentration	O
of	O
H4biopterin	S-chem
which	O
may	O
have	O
significant	O
implications	O
for	O
the	O
physiological	O
regulation	O
of	O
catecholamine	S-chem
biosynthesis	O
in	O
neuroendocrine	O
cells	O
.	O

Steroidal	B-chem
glycosides	E-chem
from	O
the	O
bulbs	O
of	O
Easter	O
lily	O
(	O
Lilium	O
longiflorum	O
Thunb	O
.	O
)	O
promote	O
dermal	O
fibroblast	O
migration	O
in	O
vitro	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Preparations	O
derived	O
from	O
bulbs	O
of	O
various	O
Lilium	O
species	O
have	O
been	O
used	O
to	O
promote	O
the	O
healing	O
of	O
skin	O
abrasions	O
,	O
sores	O
and	O
burns	O
and	O
to	O
aid	O
in	O
healing	O
wounds	O
in	O
Traditional	O
Chinese	O
and	O
Greco	O
-	O
Roman	O
Medicine	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
To	O
evaluate	O
fractionated	O
Easter	O
lily	O
bulb	O
extracts	O
and	O
their	O
steroidal	B-chem
glycosides	E-chem
(	O
1	O
-	O
5	O
)	O
for	O
the	O
promotion	O
of	O
dermal	O
fibroblast	O
migration	O
in	O
vitro	O
,	O
as	O
a	O
model	O
for	O
the	O
early	O
events	O
in	O
wound	O
healing	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
An	O
activity	O
-	O
guided	O
screening	O
approach	O
was	O
used	O
by	O
coupling	O
sequential	O
solvent	O
extraction	O
,	O
gel	O
permeation	O
chromatography	O
(	O
GPC	O
)	O
,	O
and	O
semi	O
-	O
preparative	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
RP	O
-	O
HPLC	O
)	O
with	O
an	O
in	O
vitro	O
dermal	O
fibroblast	O
migration	O
assay	O
.	O

Cytotoxicity	O
was	O
evaluated	O
with	O
methyl	B-chem
thiazole	I-chem
tetrazolium	E-chem
(	O
MTT	S-chem
)	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mode	O
of	O
action	O
of	O
the	O
steroidal	B-chem
glycosides	E-chem
,	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
production	O
,	O
and	O
expression	O
of	O
genes	O
for	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
beta	I-geneY
-	I-geneY
1	E-geneY
(	O
TGF	B-geneY
-	I-geneY
β	E-geneY
)	O
and	O
its	O
receptors	O
were	O
evaluated	O
.	O

RESULTS	O
:	O
Fractionated	O
bulb	O
extracts	O
and	O
the	O
two	O
isolated	O
steroidal	B-chem-C3-1
glycoalkaloids	E-chem-C3-1
(	O
1	O
)	O
and	O
(	O
2	O
)	O
induced	O
NO	S-chem
production	O
and	O
TGF	B-geneY-C3-2
-	I-geneY-C3-2
β	I-geneY-C3-2
receptor	I-geneY-C3-2
I	E-geneY-C3-2
mRNA	O
expression	O
in	O
fibroblast	O
cell	O
culture	O
.	O

In	O
a	O
cytotoxicity	O
assay	O
,	O
steroidal	B-chem
glycosides	E-chem
(	O
1	O
)	O
and	O
(	O
3	O
)	O
had	O
IC50	O
values	O
of	O
8.2	O
and	O
8.7µM	O
,	O
but	O
the	O
natural	O
acetylation	O
of	O
the	O
C	O
-	O
6″	O
'	O
hydroxy	S-chem
of	O
the	O
terminal	O
glucose	S-chem
unit	O
in	O
(	O
2	O
)	O
resulted	O
in	O
a	O
3	O
-	O
fold	O
decrease	O
in	O
cell	O
cytotoxicity	O
when	O
compared	O
with	O
(	O
1	O
)	O
.	O

Results	O
from	O
the	O
dermal	O
fibroblast	O
migration	O
assay	O
revealed	O
that	O
the	O
steroidal	B-chem
glycoalkaloids	E-chem
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
and	O
the	O
furostanol	B-chem
saponin	E-chem
(	O
3	O
)	O
promoted	O
fibroblast	O
migration	O
from	O
the	O
range	O
of	O
23.7±5.7	O
to	O
37.7±5.1	O
%	O
,	O
as	O
compared	O
with	O
the	O
control	O
.	O

CONCLUSION	O
:	O
Collectively	O
,	O
our	O
data	O
demonstrate	O
that	O
the	O
steroidal	B-chem
glycosides	E-chem
present	O
in	O
Easter	O
lily	O
bulbs	O
induce	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
observed	O
dermal	O
fibroblast	O
migration	O
activity	O
of	O
the	O
bulb	O
extracts	O
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
steroidal	B-chem
glycosides	E-chem
from	O
L.	O
longiflorum	O
may	O
potentially	O
play	O
a	O
role	O
in	O
the	O
wound	O
healing	O
process	O
and	O
may	O
provide	O
a	O
scientific	O
basis	O
for	O
the	O
historical	O
use	O
of	O
lily	O
bulbs	O
for	O
this	O
purpose	O
.	O

Contribution	O
of	O
single	B-geneY
-	I-geneY
minded	I-geneY
2	E-geneY
to	O
hyperglycaemia	O
-	O
induced	O
neurotoxicity	O
.	O

Diabetes	O
mellitus	O
is	O
associated	O
to	O
central	O
nervous	O
system	O
damage	O
,	O
which	O
results	O
in	O
impairment	O
of	O
brain	O
functions	O
and	O
cognitive	O
deficits	O
and	O
decline	O
in	O
memory	O
.	O

However	O
,	O
the	O
mechanisms	O
mediating	O
the	O
actions	O
of	O
glucose	S-chem
on	O
the	O
neurons	O
remained	O
elusive	O
.	O

Single	B-geneY
-	I-geneY
minded	I-geneY
2	E-geneY
(	O
Sim2	S-geneY
)	O
,	O
a	O
basic	B-geneN
helix	I-geneN
-	I-geneN
loop	I-geneN
-	I-geneN
helix	E-geneN
(	O
bHLH	S-geneN
)	O
-	O
PAS	S-geneN
transcriptional	O
repressor	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
some	O
symptoms	O
of	O
Down	O
syndrome	O
.	O

We	O
hypothesized	O
that	O
Sim2	S-geneY
mediated	O
hyperglycaemia	O
-	O
induced	O
neuronal	O
injury	O
and	O
impairment	O
of	O
learning	O
and	O
memory	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
Sim2	S-geneY-C3-2
protein	O
in	O
cortical	O
neurons	O
was	O
increased	O
in	O
streptozotocin	S-chem-C3-1
-	O
induced	O
diabetes	O
mellitus	O
rat	O
model	O
.	O

Drebrin	S-geneY
,	O
down	O
-	O
regulated	O
by	O
Sim2	S-geneY
,	O
was	O
subsequently	O
decreased	O
as	O
detected	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
Western	O
blot	O
analysis	O
.	O

The	O
expression	O
pattern	O
of	O
Sim2	S-geneY
and	O
Drebrin	S-geneY
correspond	O
to	O
50mmol	O
/	O
L	O
glucose	S-chem
(	O
hyperglycaemia	O
)	O
was	O
also	O
found	O
in	O
primary	O
cultured	O
neurons	O
.	O

Curcumin	S-chem
,	O
one	O
neuroprotective	O
agent	O
,	O
inhibited	O
hyperglycaemia	O
-	O
induced	O
neurotoxicity	O
.	O

Moreover	O
,	O
curcumin	S-chem-C3-1
alleviated	O
Sim2	S-geneY-C3-2
expression	O
,	O
and	O
reversely	O
raised	O
Drebrin	S-geneY-C3-2
expression	O
in	O
neurons	O
treated	O
with	O
hyperglycaemia	O
.	O

Finally	O
,	O
we	O
found	O
that	O
silencing	O
Sim2	S-geneY
expression	O
decreased	O
hyperglycaemia	O
-	O
induced	O
neuronal	O
injury	O
.	O

In	O
conclusion	O
,	O
Sim2	S-geneY
may	O
mediate	O
neurotoxicity	O
during	O
hyperglycaemia	O
and	O
thereby	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
hyperglycaemia	O
-	O
induced	O
cognitive	O
deficits	O
.	O

Structure	O
-	O
based	O
design	O
of	O
novel	O
dihydroisoquinoline	S-chem-C4-1
BACE	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibitors	O
that	O
do	O
not	O
engage	O
the	O
catalytic	O
aspartates	S-chem
.	O

The	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
series	O
of	O
dihydroisoquinoline	S-chem-C4-1
BACE	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
inhibitors	O
is	O
described	O
.	O

Application	O
of	O
structure	O
-	O
based	O
design	O
to	O
screening	O
hit	O
1	O
yielded	O
sub	O
-	O
micromolar	O
inhibitors	O
.	O

Replacement	O
of	O
the	O
carboxylic	B-chem
acid	E-chem
of	O
1	O
was	O
guided	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
which	O
allowed	O
the	O
replacement	O
of	O
a	O
key	O
water	O
-	O
mediated	O
hydrogen	S-chem
bond	O
.	O

This	O
work	O
culminated	O
in	O
compounds	O
such	O
as	O
31	O
,	O
which	O
possess	O
good	O
BACE	B-geneY
-	I-geneY
1	E-geneY
potency	O
,	O
excellent	O
permeability	O
and	O
a	O
low	O
P	B-geneN
-	I-geneN
gp	E-geneN
efflux	O
ratio	O
.	O

Pharmacological	O
Inhibition	O
of	O
Platelet	O
-	O
tumor	O
Cell	O
Cross	O
-	O
talk	O
Prevents	O
Platelet	O
-	O
induced	O
Overexpression	O
of	O
Cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
in	O
HT29	O
Human	O
Colon	O
Carcinoma	O
Cells	O
.	O

Cyclooxygenase	B-geneY-C9-2
(	I-geneY-C9-2
COX	I-geneY-C9-2
)	I-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
-	O
derived	O
prostanoids	S-chem-C9-1
can	O
influence	O
several	O
processes	O
that	O
are	O
linked	O
to	O
carcinogenesis	O
.	O

We	O
aimed	O
to	O
address	O
the	O
hypothesis	O
that	O
platelets	O
contribute	O
to	O
aberrant	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
in	O
HT29	O
colon	O
carcinoma	O
cells	O
and	O
to	O
reveal	O
the	O
role	O
of	O
platelet	O
-	O
induced	O
COX	B-geneY
-	I-geneY
2	E-geneY
on	O
the	O
expression	O
of	O
proteins	O
involved	O
in	O
malignancy	O
and	O
marker	O
genes	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Human	O
platelets	O
co	O
-	O
cultured	O
with	O
HT29	O
cells	O
rapidly	O
adhered	O
to	O
cancer	O
cells	O
and	O
induced	O
COX	B-geneY
-	I-geneY
2	E-geneY
mRNA	O
expression	O
,	O
but	O
not	O
protein	O
synthesis	O
which	O
required	O
the	O
late	O
release	O
of	O
platelet	O
PDGF	S-geneN
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
mRNA	O
stabilization	O
.	O

Platelet	O
-	O
induced	O
COX	B-geneY-C9-2
-	I-geneY-C9-2
2	E-geneY-C9-2
-	O
dependent	O
PGE2	S-chem-C9-1
synthesis	O
in	O
HT29	O
cells	O
was	O
involved	O
in	O
downregulation	O
of	O
p21	S-geneY-C3-2
(	O
WAF1	S-geneY-C3-2
/	O
CIP1	S-geneY-C3-2
)	O
and	O
upregulation	O
of	O
cyclinB1	S-geneY-C4-2
,	O
since	O
these	O
effects	O
were	O
prevented	O
by	O
rofecoxib	S-chem-MU-1
(	O
a	O
selective	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
)	O
and	O
rescued	O
by	O
exogenous	O
PGE2	S-chem
.	O

Galectin	B-geneY
-	I-geneY
3	E-geneY
,	O
highly	O
expressed	O
in	O
HT29	O
cells	O
,	O
is	O
unique	O
among	O
galectins	O
because	O
it	O
contains	O
a	O
collagen	B-geneN
-	I-geneN
like	I-geneN
domain	E-geneN
.	O

Thus	O
,	O
we	O
studied	O
the	O
role	O
of	O
galectin	B-geneY
-	I-geneY
3	E-geneY
and	O
platelet	B-geneY
collagen	I-geneY
receptors	E-geneY
in	O
platelet	O
-	O
induced	O
COX	B-geneY
-	I-geneY
2	E-geneY
overexpression	O
.	O

Inhibitors	O
of	O
galectin	B-geneY
-	I-geneY
3	E-geneY
function	O
(	O
β	B-chem
-	I-chem
lactose	E-chem
,	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
galectin	B-geneY
-	I-geneY
3	E-geneY
,	O
Gal	B-geneY
-	I-geneY
3C	E-geneY
,	O
and	O
anti	O
-	O
galectin	B-geneY
-	I-geneY
3	E-geneY
antibody	O
M3	O
/	O
38	O
)	O
or	O
collagen	B-geneY
receptor	E-geneY
-	O
mediated	O
platelet	O
adhesion	O
(	O
revacept	O
,	O
a	O
dimeric	O
collagen	B-geneY
receptor	E-geneY
GPVI	S-geneY
-	O
Fc	S-geneN
)	O
prevented	O
aberrant	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
.	O

Inhibition	O
of	O
platelet	O
-	O
cancer	O
cell	O
interaction	O
by	O
revacept	O
was	O
more	O
effective	O
than	O
rofecoxib	S-chem
in	O
preventing	O
platelet	O
-	O
induced	O
mRNA	O
changes	O
of	O
EMT	O
markers	O
suggesting	O
that	O
direct	O
cell	O
-	O
cell	O
contact	O
and	O
aberrant	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
synergistically	O
induced	O
gene	O
expression	O
modifications	O
associated	O
with	O
EMT	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
provide	O
the	O
rationale	O
for	O
testing	O
blockers	O
of	O
collagen	B-geneN
binding	I-geneN
sites	E-geneN
,	O
such	O
as	O
revacept	O
,	O
and	O
galectin	B-geneY
-	I-geneY
3	E-geneY
inhibitors	O
in	O
the	O
prevention	O
of	O
colon	O
cancer	O
metastasis	O
in	O
animal	O
models	O
followed	O
by	O
studies	O
in	O
patients	O
.	O

A	O
Re	O
-	O
evaluation	O
of	O
the	O
Role	O
of	O
hCTR1	S-geneY
,	O
the	O
Human	B-geneN
High	I-geneN
Affinity	I-geneN
Cu	I-geneN
Transporter	E-geneN
in	O
Pt	S-chem
-	O
Drug	O
Entry	O
into	O
Human	O
Cells	O
.	O

Cisplatin	S-chem
(	O
cDDP	S-chem
)	O
is	O
an	O
anti	O
-	O
cancer	O
drug	O
used	O
in	O
a	O
number	O
of	O
malignancies	O
including	O
testicular	O
,	O
ovarian	O
,	O
cervical	O
,	O
bladder	O
,	O
lung	O
,	O
head	O
,	O
and	O
neck	O
cancers	O
.	O

Its	O
use	O
is	O
limited	O
by	O
the	O
development	O
of	O
resistance	O
,	O
often	O
rationalized	O
via	O
effects	O
on	O
cellular	O
uptake	O
.	O

It	O
has	O
been	O
claimed	O
that	O
hCTR1	S-geneY-C9-2
,	O
the	O
human	B-geneN-C9-2
high	I-geneN-C9-2
affinity	I-geneN-C9-2
copper	I-geneN-C9-2
transporter	E-geneN-C9-2
,	O
is	O
the	O
major	O
entry	O
pathway	O
for	O
cDDP	S-chem-C9-1
and	O
related	O
drugs	O
via	O
a	O
mechanism	O
that	O
mimics	O
copper	O
.	O

This	O
is	O
an	O
unexpected	O
property	O
of	O
hCTR1	S-geneY
,	O
a	O
highly	O
selective	O
copper	B-geneN
(	I-geneN
I	I-geneN
)	I-geneN
transporter	E-geneN
.	O

We	O
compared	O
the	O
uptake	O
rates	O
of	O
copper	O
with	O
cDDP	O
(	O
and	O
several	O
analogs	O
)	O
into	O
HEK293	O
cells	O
over	O
-	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
hCTR1	S-geneY
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
mefs	O
)	O
that	O
do	O
or	O
do	O
not	O
express	O
CTR1	S-geneY
,	O
and	O
human	O
ovarian	O
tumor	O
cells	O
,	O
sensitive	O
or	O
resistant	O
to	O
cDDP	S-chem
.	O

We	O
have	O
also	O
compared	O
the	O
effects	O
of	O
extracellular	O
copper	S-chem
,	O
which	O
causes	O
regulatory	O
endocytosis	O
of	O
hCTR1	S-geneY
,	O
to	O
those	O
of	O
cDDP	S-chem
.	O

We	O
confirm	O
the	O
correlation	O
between	O
higher	O
hCTR1	S-geneY-C9-2
levels	O
and	O
higher	O
Pt	S-chem-C9-1
-	O
drug	O
uptake	O
in	O
tumor	O
cells	O
sensitive	O
to	O
the	O
drug	O
.	O

However	O
,	O
we	O
show	O
that	O
hCTR1	S-geneY
is	O
not	O
the	O
major	O
entry	O
route	O
of	O
platinum	S-chem
-	O
drugs	O
and	O
that	O
the	O
copper	S-chem
transporter	O
is	O
not	O
internalized	O
in	O
response	O
to	O
extracellular	O
drug	O
.	O

Our	O
data	O
suggest	O
the	O
major	O
entry	O
pathway	O
for	O
platinum	S-chem
-	O
drugs	O
is	O
not	O
saturable	O
at	O
relevant	O
concentrations	O
and	O
not	O
protein	O
-	O
mediated	O
.	O

Clinical	O
trials	O
have	O
been	O
initiated	O
that	O
depend	O
upon	O
regulating	O
membrane	O
levels	O
of	O
hCTR1	S-geneY
.	O

If	O
reduced	O
drug	O
uptake	O
is	O
a	O
major	O
factor	O
in	O
resistance	O
,	O
hCTR1	S-geneY
is	O
unlikely	O
to	O
be	O
a	O
productive	O
target	O
in	O
attempts	O
to	O
enhance	O
efficacy	O
,	O
although	O
the	O
proteins	O
involved	O
in	O
copper	S-chem
homeostasis	O
may	O
play	O
a	O
role	O
.	O

CASK	S-geneY
is	O
a	O
new	O
intracellular	O
modulator	O
of	O
P2X3	B-geneY
receptors	E-geneY
.	O

ATP	B-geneY
-	I-geneY
gated	I-geneY
P2X3	I-geneY
receptors	E-geneY
of	O
sensory	O
ganglion	O
neurons	O
are	O
important	O
transducers	O
of	O
painful	O
stimuli	O
and	O
are	O
modulated	O
by	O
extracellular	O
algogenic	O
substances	O
,	O
via	O
changes	O
in	O
the	O
receptor	O
phosphorylation	O
state	O
.	O

The	O
present	O
study	O
investigated	O
the	O
role	O
of	O
calcium	B-geneY
/	I-geneY
calmodulin	I-geneY
-	I-geneY
dependent	I-geneY
serine	I-geneY
protein	I-geneY
kinase	E-geneY
CASK	S-geneY
in	O
interacting	O
and	O
controlling	O
P2X3	B-geneY
receptor	E-geneY
expression	O
and	O
function	O
in	O
mouse	O
trigeminal	O
ganglia	O
.	O

Most	O
ganglion	O
neurons	O
in	O
situ	O
or	O
in	O
culture	O
co	O
-	O
expressed	O
P2X3	S-geneY
and	O
CASK	S-geneY
.	O

CASK	S-geneY
was	O
immunoprecipitated	O
with	O
P2X3	S-geneY
receptors	O
from	O
trigeminal	O
ganglia	O
and	O
from	O
P2X3	S-geneY
/	O
CASK	S-geneY
-	O
cotransfected	O
HEK	O
cells	O
.	O

Recombinant	O
P2X3	S-geneY
/	O
CASK	S-geneY
expression	O
in	O
HEK	O
cells	O
increased	O
serine	S-chem
phosphorylation	O
of	O
P2X3	S-geneY
receptors	O
,	O
typically	O
associated	O
with	O
receptor	O
upregulation	O
.	O

CASK	S-geneY
deletion	O
mutants	O
also	O
enhanced	O
P2X3	S-geneY
subunit	O
expression	O
.	O

After	O
silencing	O
CASK	S-geneY
,	O
cell	O
surface	O
P2X3	S-geneY
receptor	O
expression	O
was	O
decreased	O
,	O
which	O
is	O
consistent	O
with	O
depressed	O
P2X3	S-geneY
currents	O
.	O

The	O
reduction	O
of	O
P2X3	S-geneY-C3-2
expression	O
levels	O
was	O
reversed	O
by	O
the	O
proteasomal	O
inhibitor	O
MG	B-chem-C3-1
-	I-chem-C3-1
132	E-chem-C3-1
.	O

Moreover	O
,	O
neuronal	O
CASK	S-geneY
/	O
P2X3	S-geneY
interaction	O
was	O
upregulated	O
by	O
NGF	S-geneY
signaling	O
and	O
downregulated	O
by	O
P2X3	S-geneY
agonist	O
-	O
induced	O
desensitization	O
.	O

These	O
data	O
suggest	O
a	O
novel	O
interaction	O
between	O
CASK	S-geneY
and	O
P2X3	S-geneY
receptors	O
with	O
positive	O
outcome	O
for	O
receptor	O
stability	O
and	O
function	O
.	O

As	O
CASK	S-geneY
-	O
mediated	O
control	O
of	O
P2X3	S-geneY
receptors	O
was	O
dependent	O
on	O
the	O
receptor	O
activation	O
state	O
,	O
CASK	S-geneY
represents	O
an	O
intracellular	O
gateway	O
to	O
regulate	O
purinergic	O
nociceptive	O
signaling	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Conformational	O
epitopes	O
on	O
the	O
diabetes	O
autoantigen	O
GAD65	S-geneY
identified	O
by	O
peptide	O
phage	O
display	O
and	O
molecular	O
modeling	O
.	O

The	O
major	B-geneN
diabetes	I-geneN
autoantigen	E-geneN
,	O
glutamic	B-geneN
acid	I-geneN
decarboxylase	E-geneN
(	O
GAD65	S-geneY
)	O
,	O
contains	O
a	O
region	O
of	O
sequence	O
similarity	O
,	O
including	O
six	O
identical	O
residues	O
PEVKEK	S-geneN
,	O
to	O
the	O
P2C	B-geneY
protein	E-geneY
of	O
coxsackie	O
B	O
virus	O
,	O
suggesting	O
that	O
cross	O
-	O
reactivity	O
between	O
coxsackie	O
B	O
virus	O
and	O
GAD65	S-geneY
can	O
initiate	O
autoimmune	O
diabetes	O
.	O

We	O
used	O
the	O
human	O
islet	O
cell	O
mAbs	O
MICA3	O
and	O
MICA4	O
to	O
identify	O
the	O
Ab	O
epitopes	O
of	O
GAD65	S-geneY
by	O
screening	O
phage	O
-	O
displayed	O
random	O
peptide	O
libraries	O
.	O

The	O
identified	O
peptide	O
sequences	O
could	O
be	O
mapped	O
to	O
a	O
homology	O
model	O
of	O
the	O
pyridoxal	B-geneN
phosphate	I-geneN
(	I-geneN
PLP	I-geneN
)	I-geneN
binding	I-geneN
domain	E-geneN
of	O
GAD65	S-geneY
.	O

For	O
MICA3	O
,	O
a	O
surface	O
loop	O
containing	O
the	O
sequence	O
PEVKEK	S-geneN
and	O
two	O
adjacent	O
exposed	O
helixes	O
were	O
identified	O
in	O
the	O
PLP	B-geneN
binding	I-geneN
domain	E-geneN
as	O
well	O
as	O
a	O
region	O
of	O
the	O
C	S-chem
terminus	O
of	O
GAD65	S-geneY
that	O
has	O
previously	O
been	O
identified	O
as	O
critical	O
for	O
MICA3	O
binding	O
.	O

To	O
confirm	O
that	O
the	O
loop	O
containing	O
the	O
PEVKEK	S-geneN
sequence	O
contributes	O
to	O
the	O
MICA3	O
epitope	O
,	O
this	O
loop	O
was	O
deleted	O
by	O
mutagenesis	O
.	O

This	O
reduced	O
binding	O
of	O
MICA3	O
by	O
70	O
%	O
.	O

Peptide	O
sequences	O
selected	O
using	O
MICA4	O
were	O
rich	O
in	O
basic	O
or	O
hydroxyl	S-chem
-	O
containing	O
amino	B-chem
acids	E-chem
,	O
and	O
the	O
surface	O
of	O
the	O
GAD65	B-geneN
PLP	I-geneN
-	I-geneN
binding	I-geneN
domain	E-geneN
surrounding	O
Lys358	O
,	O
which	O
is	O
known	O
to	O
be	O
critical	O
for	O
MICA4	O
binding	O
,	O
was	O
likewise	O
rich	O
in	O
these	O
amino	B-chem
acids	E-chem
.	O

Also	O
,	O
the	O
two	O
phage	O
most	O
reactive	O
with	O
MICA4	O
encoded	O
the	O
motif	O
VALxG	S-geneN
,	O
and	O
the	O
reverse	O
of	O
this	O
sequence	O
,	O
LAV	S-geneN
,	O
was	O
located	O
in	O
this	O
same	O
region	O
.	O

Thus	O
,	O
we	O
have	O
defined	O
the	O
MICA3	O
and	O
MICA4	O
epitopes	O
on	O
GAD65	S-geneY
using	O
the	O
combination	O
of	O
phage	O
display	O
,	O
molecular	O
modeling	O
,	O
and	O
mutagenesis	O
and	O
have	O
provided	O
compelling	O
evidence	O
for	O
the	O
involvement	O
of	O
the	O
PEVKEK	S-geneN
loop	O
in	O
the	O
MICA3	O
epitope	O
.	O

State	O
-	O
dependent	O
cocaine	S-chem-C4-1
block	O
of	O
sodium	B-geneN-C4-2
channel	E-geneN-C4-2
isoforms	O
,	O
chimeras	O
,	O
and	O
channels	O
coexpressed	O
with	O
the	O
beta1	O
subunit	O
.	O

Cocaine	S-chem-C4-1
block	O
of	O
human	B-geneY-C4-2
cardiac	I-geneY-C4-2
(	I-geneY-C4-2
hH1	I-geneY-C4-2
)	E-geneY-C4-2
and	O
rat	B-geneY-C4-2
skeletal	I-geneY-C4-2
(	I-geneY-C4-2
mu1	I-geneY-C4-2
)	I-geneY-C4-2
muscle	I-geneY-C4-2
sodium	I-geneY-C4-2
channels	E-geneY-C4-2
was	O
examined	O
under	O
whole	O
-	O
cell	O
voltage	O
clamp	O
in	O
transiently	O
transfected	O
HEK293t	O
cells	O
.	O

Low	O
affinity	O
block	O
of	O
resting	O
mu1	S-geneY
and	O
hH1	B-geneY
channels	E-geneY
at	O
-	O
180	O
mV	O
was	O
the	O
same	O
,	O
and	O
high	O
affinity	O
block	O
of	O
inactivated	O
channels	O
at	O
-	O
70	O
mV	O
was	O
the	O
same	O
.	O

Cocaine	S-chem-C4-1
block	O
of	O
hH1	B-geneY-C4-2
channels	E-geneY-C4-2
was	O
greater	O
than	O
block	O
of	O
mu1	B-geneY-C4-2
channels	E-geneY-C4-2
at	O
voltages	O
between	O
-	O
120	O
mV	O
and	O
-	O
90	O
mV	O
,	O
suggesting	O
that	O
greater	O
steady	O
-	O
state	O
inactivation	O
of	O
hH1	B-geneY-C4-2
channels	E-geneY-C4-2
in	O
this	O
voltage	O
range	O
makes	O
them	O
more	O
susceptible	O
to	O
cocaine	S-chem-C4-1
block	O
.	O

We	O
induced	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
at	O
mu1	S-geneY
and	O
hH1	B-geneY
channels	E-geneY
by	O
constructing	O
mu1	S-geneY
/	O
hH1	B-geneY
channel	E-geneY
chimeras	O
or	O
by	O
coexpressing	O
the	O
wild	O
-	O
type	O
channels	O
with	O
the	O
rat	O
brain	O
beta1	O
subunit	O
.	O

In	O
contrast	O
to	O
several	O
previous	O
reports	O
,	O
coexpression	O
of	O
the	O
rat	O
brain	O
beta1	O
subunit	O
with	O
mu1	S-geneY
or	O
hH1	S-geneY
produced	O
large	O
positive	O
shifts	O
in	O
steady	O
-	O
state	O
inactivation	O
.	O

Shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
steady	O
-	O
state	O
inactivation	O
elicited	O
linear	O
shifts	O
in	O
steady	O
-	O
state	O
cocaine	S-chem
block	O
,	O
yet	O
these	O
manipulations	O
did	O
not	O
affect	O
the	O
cocaine	S-chem
affinity	O
of	O
resting	O
or	O
inactivated	O
channels	O
.	O

These	O
data	O
,	O
as	O
well	O
as	O
simulations	O
used	O
to	O
predict	O
block	O
,	O
indicate	O
that	O
state	O
-	O
dependent	O
cocaine	S-chem
block	O
depends	O
on	O
both	O
steady	O
-	O
state	O
inactivation	O
and	O
channel	O
activation	O
,	O
although	O
inactivation	O
appears	O
to	O
have	O
the	O
predominant	O
role	O
.	O

A	O
multitargeted	O
,	O
metronomic	O
,	O
and	O
maximum	O
-	O
tolerated	O
dose	O
``	O
chemo	O
-	O
switch	O
``	O
regimen	O
is	O
antiangiogenic	O
,	O
producing	O
objective	O
responses	O
and	O
survival	O
benefit	O
in	O
a	O
mouse	O
model	O
of	O
cancer	O
.	O

PURPOSE	O
:	O
A	O
transgenic	O
mouse	O
model	O
has	O
revealed	O
parameters	O
of	O
the	O
angiogenic	O
switch	O
during	O
multistep	O
tumorigenesis	O
of	O
pancreatic	O
islets	O
,	O
and	O
demonstrated	O
efficacy	O
of	O
antiangiogenic	O
therapies	O
.	O

Pericytes	O
have	O
been	O
revealed	O
as	O
functionally	O
important	O
for	O
tumor	O
neovasculature	O
,	O
using	O
kinase	O
inhibitors	O
targeting	O
their	O
platelet	B-geneY
-	I-geneY
derived	I-geneY
growth	I-geneY
factor	I-geneY
receptors	E-geneY
(	O
PDGFRs	S-geneY
)	O
.	O

Additionally	O
,	O
vascular	B-geneN
endothelial	I-geneN
growth	I-geneN
factor	I-geneN
receptor	E-geneN
(	O
VEGFR	S-geneN
)	O
inhibitors	O
and	O
metronomic	O
chemotherapy	O
show	O
modest	O
benefit	O
against	O
early	O
-	O
but	O
not	O
late	O
-	O
stage	O
disease	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Seeking	O
to	O
improve	O
efficacy	O
against	O
otherwise	O
intractable	O
end	O
-	O
stage	O
pancreatic	O
islet	O
tumors	O
,	O
two	O
receptor	B-geneN-C4-2
tyrosine	I-geneN-C4-2
kinase	E-geneN-C4-2
inhibitors	O
,	O
imatinib	S-chem-C4-1
and	O
SU11248	S-chem-C4-1
,	O
were	O
used	O
to	O
disrupt	O
PDGFR	S-geneY-C4-2
-	O
mediated	O
pericyte	O
support	O
of	O
tumor	O
endothelial	O
cells	O
in	O
concert	O
with	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
or	O
metronomic	O
chemotherapy	O
and	O
/	O
or	O
VEGFR	S-geneN-C4-2
inhibition	O
.	O

RESULTS	O
:	O
Imatinib	S-chem-C4-1
,	O
despite	O
equivocal	O
efficacy	O
as	O
monotherapy	O
,	O
reduced	O
pericyte	O
coverage	O
of	O
tumor	O
vessels	O
and	O
enhanced	O
efficacy	O
in	O
combination	O
with	O
metronomic	O
chemotherapy	O
or	O
VEGFR	S-geneN-C4-2
inhibition	O
.	O

A	O
regimen	O
involving	O
all	O
three	O
was	O
even	O
better	O
.	O

MTD	O
using	O
cyclophosphamide	S-chem
caused	O
transitory	O
regression	O
,	O
but	O
then	O
rapid	O
regrowth	O
,	O
in	O
contrast	O
to	O
metronomic	O
cyclophosphamide	S-chem
plus	O
imatinib	S-chem
,	O
which	O
produced	O
stable	O
disease	O
.	O

The	O
MTD	O
regimen	O
elicited	O
apoptosis	O
of	O
tumor	O
cells	O
but	O
not	O
endothelial	O
cells	O
,	O
whereas	O
the	O
other	O
regimens	O
increased	O
endothelial	O
cell	O
apoptosis	O
concordant	O
with	O
efficacy	O
.	O

A	O
``	O
chemo	O
-	O
switch	O
``	O
protocol	O
,	O
involving	O
sequential	O
MTD	O
and	O
then	O
metronomic	O
chemotherapy	O
,	O
overlaid	O
with	O
multitargeted	O
inhibition	O
of	B-geneY
PDGFR	O
and	O
VEGFR	O
,	O
gave	O
complete	O
responses	O
and	O
unprecedented	O
survival	O
advantage	O
in	O
this	O
model	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
a	O
potentially	O
tractable	O
clinical	O
strategy	O
in	O
a	O
stringent	O
preclinical	O
model	O
,	O
wherein	O
standard	O
-	O
of	O
-	O
care	O
chemotherapy	O
is	O
followed	O
by	O
a	O
novel	O
maintenance	O
regimen	O
:	O
PDFGR	S-geneY
is	O
targeted	O
to	O
disrupt	O
pericyte	O
support	O
,	O
while	O
metronomic	O
chemotherapy	O
and	O
/	O
or	O
VEGFR	S-geneN
inhibitors	O
target	O
consequently	O
sensitized	O
endothelial	O
cells	O
,	O
collectively	O
destabilizing	O
pre	O
-	O
existing	O
tumor	O
vasculature	O
and	O
inhibiting	O
ongoing	O
angiogenesis	O
.	O

Amezinium	S-chem-MU-1
and	O
debrisoquine	S-chem-MU-1
are	O
substrates	O
of	O
uptake1	S-geneN-C9-2
and	O
potent	O
inhibitors	O
of	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
in	O
perfused	O
lungs	O
of	O
rats	O
.	O

Previous	O
studies	O
have	O
resulted	O
in	O
the	O
classification	O
of	O
amezinium	S-chem-C4-1
as	O
a	O
selective	O
inhibitor	O
of	O
neuronal	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
(	O
MAO	S-geneN-C4-2
)	O
,	O
because	O
it	O
is	O
a	O
much	O
more	O
potent	O
MAO	S-geneN-C4-2
inhibitor	O
in	O
intact	O
tissues	O
,	O
in	O
which	O
it	O
is	O
accumulated	O
in	O
noradrenergic	O
neurones	O
by	O
uptake1	O
,	O
than	O
in	O
tissue	O
homogenates	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
amezinium	S-chem
on	O
the	O
deamination	O
of	O
noradrenaline	S-chem
were	O
investigated	O
in	O
intact	O
lungs	O
of	O
rats	O
,	O
since	O
the	O
pulmonary	O
endothelial	O
cells	O
are	O
a	O
site	O
where	O
the	O
catecholamine	S-chem
transporter	O
is	O
non	O
-	O
neuronal	O
uptake1	S-geneN
.	O

In	O
addition	O
,	O
another	O
drug	O
that	O
is	O
both	O
a	O
substrate	O
of	O
uptake1	S-geneN-C9-2
and	O
a	O
MAO	S-geneN-C4-2
inhibitor	O
,	O
debrisoquine	S-chem-MU-1
,	O
was	O
investigated	O
in	O
the	O
study	O
.	O

The	O
first	O
aim	O
of	O
the	O
study	O
was	O
to	O
show	O
whether	O
amezinium	S-chem
and	O
debrisoquine	S-chem
are	O
substrates	O
of	O
uptake1	S-geneN
in	O
rat	O
lungs	O
.	O

After	O
loading	O
of	O
isolated	O
perfused	O
lungs	O
with	O
3H	B-chem
-	I-chem
noradrenaline	E-chem
(	O
MAO	S-geneN
and	O
catechol	B-geneY
-	I-geneY
O	I-geneY
-	I-geneY
methyltransferase	E-geneY
(	O
COMT	S-geneY
)	O
inhibited	O
)	O
,	O
the	O
efflux	O
of	O
3H	B-chem
-	I-chem
noradrenaline	E-chem
was	O
measured	O
for	O
30	O
min	O
.	O

When	O
1	O
mumol	O
/	O
l	O
amezinium	S-chem
or	O
15	O
mumol	O
/	O
l	O
debrisoquine	S-chem
was	O
added	O
for	O
the	O
last	O
15	O
min	O
of	O
efflux	O
,	O
there	O
was	O
a	O
rapid	O
and	O
marked	O
increase	O
in	O
the	O
fractional	O
rate	O
of	O
loss	O
of	O
3H	B-chem
-	I-chem
noradrenaline	E-chem
,	O
which	O
was	O
reduced	O
by	O
about	O
70	O
%	O
when	O
1	O
mumol	O
/	O
l	O
desipramine	S-chem
was	O
present	O
throughout	O
the	O
efflux	O
period	O
.	O

These	O
results	O
showed	O
that	O
both	O
drugs	O
were	O
substrates	O
for	O
uptake1	S-geneN
in	O
rat	O
lungs	O
.	O

In	O
lungs	O
perfused	O
with	O
1	O
nmol	O
/	O
l	O
3H	B-chem
-	I-chem
noradrenaline	E-chem
(	O
COMT	S-geneY
inhibited	O
)	O
,	O
10	O
,	O
30	O
and	O
300	O
nmol	O
/	O
l	O
amezinium	S-chem
caused	O
58	O
%	O
,	O
76	O
%	O
and	O
74	O
%	O
inhibition	O
of	O
noradrenaline	S-chem
deamination	O
,	O
respectively	O
,	O
and	O
30	O
,	O
300	O
and	O
3000	O
nmol	O
/	O
l	O
debrisoquine	S-chem
caused	O
56	O
%	O
,	O
89	O
%	O
and	O
96	O
%	O
inhibition	O
of	O
noradrenaline	S-chem
deamination	O
,	O
respectively	O
.	O

When	O
MAO	B-geneY
-	I-geneY
B	E-geneY
was	O
also	O
inhibited	O
,	O
10	O
nmol	O
/	O
l	O
amezinium	S-chem-C4-1
caused	O
84	O
%	O
inhibition	O
of	O
the	O
deamination	O
of	O
noradrenaline	S-chem
by	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
in	O
the	O
lungs	O
.	O

In	O
contrast	O
,	O
in	O
hearts	O
perfused	O
with	O
10	O
nmol	O
/	O
l	O
3H	B-chem
-	I-chem
noradrenaline	E-chem
under	O
conditions	O
where	O
the	O
amine	O
was	O
accumulated	O
by	O
uptake2	S-geneN
(	O
COMT	S-geneY
,	O
uptake1	S-geneN
and	O
vesicular	O
transport	O
inhibited	O
)	O
,	O
10	O
nmol	O
/	O
l	O
amezinium	S-chem
had	O
no	O
effect	O
and	O
300	O
nmol	O
/	O
l	O
amezinium	S-chem
caused	O
only	O
36	O
%	O
inhibition	O
of	O
deamination	O
of	O
noradrenaline	S-chem
.	O

The	O
results	O
when	O
considered	O
with	O
previous	O
reports	O
in	O
the	O
literature	O
show	O
that	O
amezinium	S-chem-MU-1
is	O
about	O
1000	O
times	O
more	O
potent	O
and	O
debrisoquine	S-chem-MU-1
is	O
about	O
20	O
times	O
more	O
potent	O
for	O
MAO	S-geneN-C4-2
inhibition	O
in	O
rat	O
lungs	O
than	O
in	O
tissue	O
homogenates	O
,	O
and	O
the	O
reason	O
for	O
their	O
high	O
potencies	O
in	O
the	O
intact	O
lungs	O
is	O
transport	O
and	O
accumulation	O
of	O
the	O
drugs	O
in	O
the	O
pulmonary	O
endothelial	O
cells	O
by	O
uptake1	S-geneN-C9-2
.	O

Amezinium	S-chem-MU-1
is	O
much	O
less	O
potent	O
as	O
a	O
MAO	S-geneN-C4-2
inhibitor	O
in	O
cells	O
with	O
the	O
uptake2	B-geneN-C9-2
transporter	E-geneN-C9-2
,	O
such	O
as	O
the	O
myocardial	O
cells	O
of	O
the	O
heart	O
.	O

The	O
results	O
also	O
confirmed	O
previous	O
reports	O
that	O
amezinium	S-chem-C4-1
is	O
highly	O
selective	O
for	O
MAO	B-geneY-C4-2
-	I-geneY-C4-2
A	E-geneY-C4-2
.	O

Effect	O
of	O
tetrabrombisphenol	B-chem
A	E-chem
on	O
induction	O
of	O
apoptosis	O
in	O
the	O
testes	O
and	O
changes	O
in	O
expression	O
of	O
selected	O
testicular	O
genes	O
in	O
CD1	O
mice	O
.	O

Tetrabromobisphenol	B-chem
A	E-chem
(	O
TBBPA	S-chem
)	O
is	O
a	O
substance	O
widely	O
used	O
in	O
industry	O
as	O
a	O
flame	O
retardant	O
.	O

TBBPA	S-chem
was	O
found	O
in	O
the	O
environment	O
and	O
was	O
detected	O
even	O
in	O
the	O
human	O
body	O
.	O

The	O
effect	O
of	O
this	O
chemical	O
was	O
observed	O
in	O
different	O
cell	O
lines	O
in	O
vitro	O
and	O
it	O
is	O
supposed	O
that	O
TBBPA	S-chem
may	O
affect	O
various	O
hormonal	O
systems	O
in	O
vivo	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
effect	O
of	O
TBBPA	S-chem
on	O
the	O
reproductive	O
parameters	O
of	O
two	O
generations	O
of	O
outbred	O
mice	O
in	O
vivo	O
.	O

Experimental	O
and	O
control	O
animals	O
of	O
F1	O
generation	O
were	O
bred	O
in	O
various	O
conditions	O
to	O
enable	O
evaluation	O
of	O
the	O
possible	O
trans	O
-	O
generational	O
effect	O
.	O

An	O
increased	O
incidence	O
of	O
apoptosis	O
in	O
the	O
testes	O
and	O
changes	O
in	O
the	O
morphometry	O
of	O
seminiferous	O
tubules	O
was	O
detected	O
in	O
the	O
experimental	O
animals	O
.	O

In	O
addition	O
,	O
changes	O
in	O
the	O
expression	O
pattern	O
of	O
selected	O
genes	O
encoding	O
proteins	O
that	O
play	O
an	O
important	O
role	O
during	O
spermatogenesis	O
were	O
observed	O
.	O

In	O
contrast	O
,	O
sperm	O
quality	O
and	O
reproduction	O
were	O
not	O
affected	O
by	O
TBBPA	S-chem
.	O

Application	O
of	O
the	O
bradford	O
hill	O
criteria	O
to	O
assess	O
the	O
causality	O
of	O
cisapride	S-chem
-	O
induced	O
arrhythmia	O
:	O
a	O
model	O
for	O
assessing	O
causal	O
association	O
in	O
pharmacovigilance	O
.	O

INTRODUCTION	O
:	O
The	O
Bradford	O
Hill	O
criteria	O
are	O
a	O
widely	O
used	O
,	O
useful	O
tool	O
for	O
the	O
assessment	O
of	O
biomedical	O
causation	O
.	O

We	O
have	O
examined	O
their	O
application	O
to	O
pharmacovigilance	O
using	O
the	O
example	O
of	O
cisapride	S-chem
-	O
induced	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
.	O

METHODS	O
:	O
A	O
literature	O
search	O
was	O
conducted	O
using	O
MEDLINE	O
,	O
EMBASE	O
,	O
Reactions	O
Weekly	O
and	O
regulatory	O
websites	O
to	O
identify	O
evidence	O
for	O
the	O
association	O
between	O
cisapride	S-chem
and	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
that	O
had	O
been	O
published	O
in	O
the	O
English	O
language	O
.	O

Two	O
hundred	O
and	O
five	O
publications	O
were	O
identified	O
as	O
being	O
potentially	O
suitable	O
for	O
the	O
study	O
.	O

After	O
excluding	O
irrelevant	O
articles	O
,	O
studies	O
on	O
high	O
-	O
risk	O
populations	O
and	O
review	O
articles	O
,	O
70	O
publications	O
were	O
assessed	O
using	O
the	O
Bradford	O
Hill	O
criteria	O
.	O

These	O
included	O
24	O
case	O
reports	O
,	O
case	O
series	O
or	O
spontaneous	O
report	O
summaries	O
;	O
eight	O
epidemiological	O
studies	O
;	O
22	O
clinical	O
studies	O
;	O
and	O
16	O
experimental	O
(	O
in	O
vivo	O
and	O
in	O
vitro	O
)	O
publications	O
.	O

RESULTS	O
:	O
The	O
most	O
compelling	O
evidence	O
for	O
an	O
association	O
between	O
cisapride	S-chem
use	O
and	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
came	O
from	O
case	O
/	O
spontaneous	O
reports	O
and	O
biological	O
plausibility	O
.	O

Considering	O
the	O
rare	O
incidence	O
of	O
serious	O
cardiac	O
events	O
,	O
these	O
criteria	O
formed	O
the	O
basis	O
for	O
the	O
strength	O
of	O
the	O
association	O
.	O

The	O
number	O
of	O
reports	O
from	O
different	O
populations	O
showed	O
consistency	O
.	O

Specificity	O
was	O
supported	O
by	O
clinical	O
and	O
cardiographic	O
characterisation	O
of	O
the	O
events	O
.	O

There	O
were	O
temporal	O
relationships	O
between	O
the	O
events	O
and	O
the	O
initiation	O
of	O
cisapride	S-chem
treatment	O
,	O
increases	O
in	O
the	O
dosage	O
and	O
the	O
receipt	O
of	O
interacting	O
medications	O
.	O

The	O
relationships	O
between	O
the	O
adverse	O
events	O
and	O
the	O
latter	O
two	O
factors	O
exhibited	O
biological	O
gradients	O
.	O

Experimental	O
evidence	O
could	O
be	O
found	O
from	O
biological	O
models	O
,	O
as	O
well	O
as	O
reports	O
of	O
positive	O
dechallenge	O
and	O
/	O
or	O
rechallenge	O
found	O
in	O
individual	O
patients	O
.	O

Cisapride	S-chem
was	O
found	O
to	O
bind	O
the	O
human	B-geneY
ether	I-geneY
-	I-geneY
a	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
go	I-geneY
-	I-geneY
related	I-geneY
gene	I-geneY
(	I-geneY
HERG	I-geneY
)	I-geneY
potassium	I-geneY
channel	E-geneY
,	O
which	O
provides	O
a	O
plausible	O
mechanism	O
for	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
.	O

Other	O
QTc	O
interval	O
-	O
prolonging	O
/	O
arrhythmic	O
drugs	O
that	O
also	O
bind	O
to	O
HERG	S-geneY
provided	O
an	O
analogy	O
for	O
cisapride	S-chem
causing	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
via	O
this	O
mechanism	O
.	O

The	O
evidence	O
provided	O
by	O
clinical	O
studies	O
was	O
inconsistent	O
,	O
and	O
epidemiological	O
studies	O
failed	O
to	O
demonstrate	O
an	O
association	O
.	O

Nevertheless	O
,	O
this	O
did	O
not	O
prevent	O
the	O
assessment	O
of	O
causation	O
.	O

DISCUSSION	O
:	O
This	O
study	O
showed	O
how	O
different	O
types	O
of	O
evidence	O
found	O
in	O
pharmacovigilance	O
can	O
be	O
evaluated	O
using	O
the	O
Bradford	O
Hill	O
criteria	O
.	O

Further	O
work	O
is	O
required	O
to	O
examine	O
how	O
the	O
criteria	O
can	O
be	O
applied	O
to	O
different	O
types	O
of	O
adverse	O
events	O
and	O
how	O
they	O
may	O
be	O
applied	O
to	O
pharmacovigilance	O
.	O

Lutein	O
and	O
eicosapentaenoic	B-chem
acid	E-chem
interact	O
to	O
modify	O
iNOS	S-geneY
mRNA	O
levels	O
through	O
the	O
PPARgamma	S-geneY
/	O
RXR	S-geneN
pathway	O
in	O
chickens	O
and	O
HD11	O
cell	O
lines	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
lutein	O
and	O
fat	O
or	O
eicosapentaenoic	B-chem
acid	E-chem
(	O
EPA	S-chem
)	O
interaction	O
on	O
inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
,	O
PPARs	B-geneN
alpha	I-geneN
,	I-geneN
beta	I-geneN
,	I-geneN
and	I-geneN
gamma	E-geneN
,	O
and	O
retinoic	B-geneN
acid	I-geneN
X	I-geneN
receptor	I-geneN
(	I-geneN
RXR	I-geneN
)	I-geneN
alpha	I-geneN
and	I-geneN
gamma	E-geneN
mRNA	O
levels	O
.	O

In	O
Expt	O
.	O

1	O
,	O
macrophages	O
were	O
collected	O
from	O
broiler	O
chicks	O
fed	O
3	O
or	O
6	O
%	O
dietary	O
fat	O
(	O
g	O
/	O
100	O
g	O
)	O
with	O
0	O
,	O
25	O
,	O
and	O
50	O
mg	O
lutein	O
/	O
kg	O
feed	O
for	O
23	O
d	O
.	O

In	O
Expt	O
.	O

2	O
,	O
using	O
a	O
3	O
x	O
3	O
factorial	O
,	O
eicosapentaenoic	B-chem
acid	E-chem
(	O
EPA	S-chem
)	O
at	O
0	O
,	O
15	O
and	O
50	O
micromol	O
/	O
L	O
and	O
lutein	O
at	O
0	O
,	O
10	O
and	O
100	O
micromol	O
/	O
L	O
were	O
applied	O
to	O
HD11	O
cell	O
culture	O
for	O
24	O
h	O
.	O

In	O
both	O
experiments	O
,	O
cells	O
were	O
stimulated	O
with	O
lipopolysaccharide	O
before	O
RNA	O
isolation	O
.	O

Lutein	O
interacted	O
with	O
fat	O
in	O
Expt	O
.	O

1	O
and	O
with	O
EPA	O
in	O
Expt	O
.	O

2	O
to	O
affect	O
mRNA	O
levels	O
of	O
iNOS	S-geneY
,	O
PPARgamma	S-geneY
,	O
and	O
RXRalpha	S-geneY
in	O
chicken	O
macrophages	O
and	O
HD11	O
cells	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O

At	O
3	O
%	O
dietary	O
fat	O
or	O
up	O
to	O
15	O
micromol	O
/	O
L	O
EPA	O
in	O
the	O
medium	O
,	O
increasing	O
lutein	O
increased	O
the	O
iNOS	S-geneY
mRNA	O
.	O

However	O
,	O
at	O
6	O
%	O
dietary	O
fat	O
or	O
50	O
micromol	O
/	O
L	O
EPA	O
,	O
lutein	O
did	O
not	O
cause	O
a	O
rise	O
in	O
iNOS	S-geneY
mRNA	O
.	O

Increasing	O
lutein	O
in	O
the	O
medium	O
from	O
0	O
to	O
100	O
micromol	O
/	O
L	O
decreased	O
iNOS	S-geneY
mRNA	O
.	O

Increasing	O
lutein	O
with	O
high	O
fat	O
(	O
6	O
%	O
)	O
or	O
EPA	O
(	O
15	O
micromol	O
/	O
L	O
EPA	O
)	O
increased	O
PPARgamma	S-geneY
and	O
RXRalpha	S-geneY
mRNA	O
levels	O
.	O

Lutein	O
increased	O
PPARalpha	S-geneY
mRNA	O
levels	O
in	O
both	O
macrophages	O
(	O
P	O
<	O
0.01	O
)	O
and	O
HD11	O
(	O
P	O
=	O
0.01	O
)	O
cells	O
and	O
RXRgamma	S-geneY
(	O
P	O
<	O
0.01	O
)	O
mRNA	O
levels	O
in	O
macrophages	O
.	O

GW9662	S-chem-MU-1
,	O
a	O
PPARgamma	S-geneY-C6-2
antagonist	O
,	O
prevented	O
(	O
P	O
<	O
0.01	O
)	O
the	O
lutein	O
-	O
induced	O
iNOS	S-geneY-C3-2
mRNA	O
downregulation	O
in	O
HD11	O
cells	O
.	O

LG101208	O
,	O
a	O
RXR	S-geneN
antagonist	O
,	O
prevented	O
(	O
P	O
<	O
0.01	O
)	O
iNOS	S-geneY
upregulation	O
induced	O
by	O
10	O
micromol	O
/	O
L	O
lutein	O
and	O
iNOS	S-geneY
mRNA	O
downregulation	O
induced	O
by	O
100	O
micromol	O
/	O
L	O
lutein	O
.	O

We	O
conclude	O
that	O
lutein	O
and	O
EPA	S-chem
interact	O
through	O
the	O
PPARgamma	S-geneY
and	O
RXR	S-geneN
pathways	O
to	O
modulate	O
iNOS	S-geneY
mRNA	O
.	O

Neurochemical	O
control	O
of	O
rapid	O
stress	O
-	O
induced	O
changes	O
in	O
brain	O
aromatase	S-geneY
activity	O
.	O

In	O
the	O
male	O
brain	O
,	O
the	O
medial	O
preoptic	O
nucleus	O
(	O
POM	O
)	O
is	O
known	O
to	O
be	O
a	O
critical	O
relay	O
for	O
the	O
activation	O
of	O
sexual	O
behaviour	O
,	O
with	O
the	O
aromatisation	O
of	O
testosterone	S-chem
into	O
17β	B-chem
-	I-chem
oestradiol	E-chem
(	O
E2	O
)	O
playing	O
a	O
key	O
role	O
.	O

Acute	O
stress	O
has	O
been	O
shown	O
to	O
differentially	O
modulate	O
the	O
aromatase	S-geneY
enzyme	O
in	O
this	O
and	O
other	O
brain	O
nuclei	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
.	O

In	O
POM	O
specifically	O
,	O
stress	O
induces	O
increases	O
in	O
aromatase	S-geneY
activity	O
(	O
AA	O
)	O
that	O
are	O
both	O
rapid	O
and	O
reversible	O
.	O

How	O
the	O
physiological	O
processes	O
initiated	O
during	O
an	O
acute	O
stress	O
response	O
mediate	O
sex	O
-	O
and	O
nuclei	O
-	O
specific	O
changes	O
in	O
AA	O
and	O
which	O
stress	O
response	O
hormones	O
are	O
involved	O
remains	O
to	O
be	O
determined	O
.	O

By	O
examining	O
the	O
relative	O
effects	O
of	O
corticosterone	S-chem
(	O
CORT	S-chem
)	O
,	O
arginine	B-geneN
vasotocin	E-geneN
(	O
AVT	S-geneN
,	O
the	O
avian	O
homologue	O
to	O
arginine	B-geneY
vasopressin	E-geneY
)	O
and	O
corticotrophin	B-geneY
-	I-geneY
releasing	I-geneY
factor	E-geneY
(	O
CRF	S-geneY
)	O
,	O
the	O
present	O
study	O
aimed	O
to	O
define	O
the	O
hormone	O
profile	O
regulating	O
stress	O
-	O
induced	O
increases	O
in	O
AA	O
in	O
the	O
POM	O
.	O

We	O
found	O
that	O
CORT	S-chem
,	O
AVT	S-geneN
and	O
CRF	S-geneY
all	O
appear	O
to	O
play	O
some	O
role	O
in	O
these	O
changes	O
in	O
the	O
male	O
brain	O
.	O

In	O
addition	O
,	O
these	O
effects	O
occur	O
in	O
a	O
targeted	O
manner	O
,	O
such	O
that	O
modulation	O
of	O
the	O
enzyme	O
by	O
these	O
hormones	O
only	O
occurs	O
in	O
the	O
POM	O
rather	O
than	O
in	O
all	O
aromatase	S-geneY
-	O
expressing	O
nuclei	O
.	O

Similarly	O
,	O
in	O
the	O
female	O
brain	O
,	O
the	O
experimental	O
effects	O
were	O
restricted	O
to	O
the	O
POM	O
but	O
only	O
CRF	S-geneY
was	O
capable	O
of	O
inducing	O
the	O
stress	O
-	O
like	O
increases	O
in	O
AA	O
.	O

These	O
data	O
further	O
demonstrate	O
the	O
high	O
degree	O
of	O
specificity	O
(	O
nuclei	O
-	O
,	O
sex	O
-	O
and	O
hormone	O
-	O
specific	O
effects	O
)	O
in	O
this	O
system	O
,	O
highlighting	O
the	O
complexity	O
of	O
the	O
stress	O
-	O
aromatase	S-geneY
link	O
and	O
suggesting	O
modes	O
through	O
which	O
the	O
nongenomic	O
modulation	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
targeted	O
,	O
rapid	O
changes	O
in	O
local	O
oestrogen	S-chem
concentrations	O
.	O

Influence	O
of	O
the	O
dopamine	B-geneN
D2	I-geneN
receptor	I-geneN
(	I-geneN
DRD2	I-geneN
)	I-geneN
exon	I-geneN
8	E-geneN
genotype	O
on	O
efficacy	O
of	O
tiapride	S-chem
and	O
clinical	O
outcome	O
of	O
alcohol	S-chem
withdrawal	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
allelic	O
variants	O
of	O
the	O
human	B-geneN
dopamine	I-geneN
D2	I-geneN
receptor	I-geneN
E8	E-geneN
genotype	O
are	O
associated	O
with	O
(	O
i	O
)	O
dopamine	B-geneY
D2	E-geneY
antagonist	O
tiapride	O
dose	O
in	O
treatment	O
of	O
alcohol	S-chem
withdrawal	O
(	O
n	O
=	O
50	O
)	O
and	O
(	O
ii	O
)	O
with	O
anxiety	O
and	O
depression	O
in	O
patients	O
during	O
alcoholism	O
detoxification	O
therapy	O
(	O
admission	O
n	O
=	O
87	O
;	O
discharge	O
n	O
=	O
50	O
)	O
.	O

DRD2	B-geneN
E8	E-geneN
A	O
/	O
A	O
genotype	O
was	O
associated	O
with	O
increased	O
dose	O
of	O
tiapride	S-chem
during	O
a	O
9	O
-	O
day	O
detoxification	O
therapy	O
and	O
with	O
increased	O
anxiety	O
and	O
depression	O
scores	O
on	O
admission	O
and	O
2	O
weeks	O
later	O
.	O

The	O
findings	O
suggest	O
a	O
pharmacogenetic	O
influence	O
of	O
DRD2	B-geneN
E8	E-geneN
genotype	O
on	O
tiapride	O
efficacy	O
in	O
alcohol	O
withdrawal	O
.	O

In	O
an	O
earlier	O
report	O
,	O
DRD2	S-geneY
E8	O
A	O
/	O
A	O
genotype	O
was	O
associated	O
with	O
reduced	O
responsiveness	O
to	O
the	O
dopamine	B-geneY-C5-2
D2	E-geneY-C5-2
agonist	O
apomorphine	S-chem-C5-1
;	O
however	O
,	O
it	O
is	O
not	O
clear	O
whether	O
both	O
findings	O
share	O
the	O
same	O
biological	O
basis	O
.	O

Earlier	O
findings	O
concerning	O
association	O
of	O
DRD2	B-geneN
E8	E-geneN
A	O
/	O
A	O
with	O
increased	O
anxiety	O
and	O
depression	O
are	O
replicated	O
for	O
the	O
first	O
time	O
.	O

Effects	O
of	O
inhibition	O
of	O
urokinase	B-geneY-C4-2
-	I-geneY-C4-2
type	I-geneY-C4-2
plasminogen	I-geneY-C4-2
activator	E-geneY-C4-2
(	O
u	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
)	O
by	O
amiloride	S-chem-C4-1
in	O
the	O
cornea	O
and	O
tear	O
fluid	O
of	O
eyes	O
irradiated	O
with	O
UVB	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
our	O
hypothesis	O
that	O
amiloride	S-chem-C4-1
,	O
a	O
specific	O
u	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
inhibitor	O
,	O
effectively	O
decreases	O
u	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
activity	O
in	O
cornea	O
as	O
well	O
as	O
in	O
tear	O
fluid	O
and	O
favourably	O
affects	O
corneal	O
healing	O
.	O

Therefore	O
,	O
comparative	O
histochemical	O
and	O
biochemical	O
studies	O
of	O
u	B-geneY-C9-2
-	I-geneY-C9-2
PA	E-geneY-C9-2
and	O
the	O
effects	O
of	O
amiloride	S-chem
were	O
performed	O
on	O
rabbit	O
corneas	O
and	O
tear	O
fluid	O
using	O
the	O
sensitive	O
fluorogenic	O
substrate	O
Z	B-chem-C9-1
-	I-chem-C9-1
Gly	I-chem-C9-1
-	I-chem-C9-1
Gly	I-chem-C9-1
-	I-chem-C9-1
Arg	I-chem-C9-1
-	I-chem-C9-1
7	I-chem-C9-1
-	I-chem-C9-1
amino	I-chem-C9-1
-	I-chem-C9-1
4	I-chem-C9-1
-	I-chem-C9-1
trifluoromethylcoumarin	E-chem-C9-1
.	O

Rabbit	O
eyes	O
were	O
repeatedly	O
irradiated	O
with	O
UVB	O
for	O
9	O
days	O
and	O
during	O
the	O
irradiation	O
topically	O
treated	O
with	O
amiloride	S-chem
(	O
1	O
mg	O
/	O
ml	O
saline	O
)	O
or	O
placebo	O
(	O
saline	O
)	O
(	O
dropwise	O
,	O
5	O
times	O
daily	O
)	O
.	O

Results	O
show	O
that	O
in	O
placebo	O
-	O
treated	O
eyes	O
,	O
UVB	O
evoked	O
the	O
appearance	O
of	O
u	B-geneY
-	I-geneY
PA	E-geneY
activity	O
in	O
cornea	O
and	O
tear	O
fluid	O
in	O
early	O
stages	O
of	O
irradiation	O
,	O
and	O
u	B-geneY
-	I-geneY
PA	E-geneY
levels	O
increased	O
during	O
irradiation	O
.	O

Corneal	O
epithelium	O
was	O
gradually	O
lost	O
and	O
remnants	O
of	O
the	O
epithelium	O
as	O
well	O
as	O
keratocytes	O
in	O
the	O
upper	O
part	O
of	O
corneal	O
stroma	O
showed	O
high	O
u	B-geneY
-	I-geneY
PA	E-geneY
activity	O
.	O

Finally	O
,	O
corneas	O
lost	O
their	O
epithelium	O
completely	O
.	O

In	O
corneal	O
stroma	O
,	O
numerous	O
u	B-geneY
-	I-geneY
PA	E-geneY
-	O
containing	O
inflammatory	O
cells	O
were	O
present	O
.	O

Corneas	O
were	O
vascularized	O
.	O

When	O
amiloride	S-chem-C4-1
was	O
dropped	O
on	O
the	O
eye	O
surface	O
on	O
the	O
first	O
day	O
of	O
irradiation	O
and	O
subsequently	O
daily	O
until	O
the	O
end	O
of	O
the	O
experiment	O
,	O
u	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
activity	O
in	O
both	O
cornea	O
and	O
tear	O
fluid	O
was	O
strongly	O
inhibited	O
.	O

Corneas	O
were	O
covered	O
with	O
a	O
continuous	O
epithelium	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

The	O
number	O
of	O
inflammatory	O
cells	O
was	O
significantly	O
decreased	O
.	O

Corneal	O
vascularization	O
was	O
reduced	O
by	O
50	O
%	O
.	O

In	O
conclusion	O
,	O
early	O
application	O
of	O
amiloride	S-chem-C4-1
inhibited	O
u	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
activity	O
in	O
UVB	O
-	O
irradiated	O
corneas	O
as	O
well	O
as	O
in	O
tear	O
fluid	O
and	O
diminished	O
the	O
development	O
of	O
corneal	O
pathology	O
.	O

Hepatocyte	B-geneY
growth	I-geneY
factor	I-geneY
activator	I-geneY
inhibitor	I-geneY
type	I-geneY
2	E-geneY
(	O
HAI	B-geneY
-	I-geneY
2	E-geneY
)	O
modulates	O
hepcidin	S-geneY
expression	O
by	O
inhibiting	O
the	O
cell	O
surface	O
protease	S-geneN
matriptase	B-geneY
-	I-geneY
2	E-geneY
.	O

Matriptase	B-geneY
-	I-geneY
2	E-geneY
,	O
a	O
recently	O
identified	O
cell	O
surface	O
protease	S-geneN
,	O
is	O
the	O
key	O
enzyme	O
of	O
iron	S-chem
homoeostasis	O
modulating	O
the	O
expression	O
of	O
the	O
liver	O
peptide	O
hormone	O
hepcidin	S-geneY
.	O

HAI	S-geneN
(	B-geneN
hepatocyte	I-geneN
growth	I-geneN
factor	I-geneN
activator	I-geneN
inhibitor	I-geneN
)	I-geneN
types	I-geneN
1	I-geneN
and	I-geneN
2	E-geneN
(	O
HAI	B-geneY
-	I-geneY
1	E-geneY
and	O
HAI	B-geneY
-	I-geneY
2	E-geneY
respectively	O
)	O
have	O
been	O
shown	O
to	O
inhibit	O
the	O
close	O
homologue	O
,	O
i.e	O
.	O
matriptase	S-geneN
.	O

By	O
co	O
-	O
expressing	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
and	O
the	O
inhibitor	O
HAI	B-geneY
-	I-geneY
2	E-geneY
we	O
have	O
identified	O
HAI	B-geneY
-	I-geneY
2	E-geneY
displaying	O
high	O
inhibitory	O
potential	O
against	O
matriptase	B-geneN
-	I-geneN
2	E-geneN
at	O
the	O
cell	O
surface	O
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O

Accordingly	O
,	O
complex	O
formation	O
between	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
and	O
HAI	B-geneY
-	I-geneY
2	E-geneY
was	O
demonstrated	O
by	O
isolation	O
of	O
the	O
complex	O
via	O
immobilizing	O
either	O
HAI	B-geneY
-	I-geneY
2	E-geneY
or	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
from	O
lysates	O
and	O
conditioned	O
medium	O
of	O
co	O
-	O
expressing	O
cells	O
.	O

Furthermore	O
,	O
HAI	B-geneY
-	I-geneY
2	E-geneY
indirectly	O
influences	O
the	O
expression	O
of	O
the	O
hepcidin	S-geneY
-	O
encoding	O
gene	O
HAMP	S-geneY
.	O

The	O
inhibitor	O
abrogates	O
the	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
-	O
mediated	O
suppression	O
of	O
HAMP	S-geneY
expression	O
,	O
presumably	O
by	O
inhibiting	O
the	O
supposed	O
potential	O
of	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
to	O
cleave	O
membrane	O
-	O
bound	O
HJV	O
(	O
haemojuvelin	O
)	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
have	O
characterized	O
HAI	B-geneY
-	I-geneY
2	E-geneY
as	O
an	O
inhibitor	O
of	O
matriptase	B-geneY
-	I-geneY
2	E-geneY
that	O
modulates	O
the	O
synthesis	O
of	O
hepcidin	S-geneY
and	O
provides	O
new	O
insights	O
into	O
the	O
regulatory	O
mechanism	O
of	O
iron	S-chem
homoeostasis	O
,	O
with	O
clinical	O
importance	O
for	O
a	O
treatment	O
of	O
iron	S-chem
overload	O
diseases	O
.	O

Impaired	O
cliff	O
avoidance	O
reaction	O
in	O
dopamine	B-geneY
transporter	E-geneY
knockout	O
mice	O
.	O

RATIONALE	O
:	O
Impulsivity	O
is	O
a	O
key	O
feature	O
of	O
disorders	O
that	O
include	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

The	O
cliff	O
avoidance	O
reaction	O
(	O
CAR	O
)	O
assesses	O
maladaptive	O
impulsive	O
rodent	O
behavior	O
.	O

Dopamine	B-geneY
transporter	E-geneY
knockout	O
(	O
DAT	S-geneY
-	O
KO	O
)	O
mice	O
display	O
features	O
of	O
ADHD	O
and	O
are	O
candidates	O
in	O
which	O
to	O
test	O
other	O
impulsive	O
phenotypes	O
.	O

OBJECTIVES	O
:	O
Impulsivity	O
of	O
DAT	S-geneY
-	O
KO	O
mice	O
was	O
assessed	O
in	O
the	O
CAR	O
paradigm	O
.	O

For	O
comparison	O
,	O
attentional	O
deficits	O
were	O
also	O
assessed	O
in	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
which	O
DAT	S-geneY
-	O
KO	O
mice	O
have	O
been	O
shown	O
to	O
exhibit	O
impaired	O
sensorimotor	O
gating	O
.	O

RESULTS	O
:	O
DAT	S-geneY
-	O
KO	O
mice	O
exhibited	O
a	O
profound	O
CAR	O
impairment	O
compared	O
to	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

As	O
expected	O
,	O
DAT	S-geneY
-	O
KO	O
mice	O
showed	O
PPI	O
deficits	O
compared	O
to	O
WT	O
mice	O
.	O

Furthermore	O
,	O
the	O
DAT	S-geneY
-	O
KO	O
mice	O
with	O
the	O
most	O
impaired	O
CAR	O
exhibited	O
the	O
most	O
severe	O
PPI	O
deficits	O
.	O

Treatment	O
with	O
methylphenidate	S-chem
or	O
nisoxetine	S-chem
ameliorated	O
CAR	O
impairments	O
in	O
DAT	S-geneY
-	O
KO	O
mice	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
DAT	S-geneY
-	O
KO	O
mice	O
exhibit	O
impulsive	O
CAR	O
behavior	O
that	O
correlates	O
with	O
their	O
PPI	O
deficits	O
.	O

Blockade	O
of	O
monoamine	B-geneN
transporters	E-geneN
,	O
especially	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
(	O
NET	S-geneY
)	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
may	O
contribute	O
to	O
pharmacological	O
improvement	O
of	O
impulsivity	O
in	O
these	O
mice	O
.	O

[	B-chem-C6-1
6	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
gingerol	E-chem-C6-1
:	O
a	O
novel	O
AT₁	S-geneY-C6-2
antagonist	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disease	O
.	O

Considering	O
the	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
public	O
health	O
and	O
the	O
limited	O
validated	O
therapeutic	O
options	O
,	O
this	O
study	O
aimed	O
to	O
find	O
novel	O
compounds	O
targeting	O
the	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
,	O
accepted	O
as	O
a	O
therapeutic	O
target	O
in	O
cardiovascular	O
disease	O
.	O

A	O
small	O
library	O
consisting	O
of	O
89	O
compounds	O
from	O
39	O
Chinese	O
herbs	O
was	O
profiled	O
using	O
a	O
cell	O
-	O
based	O
calcium	O
mobilization	O
assay	O
which	O
was	O
developed	O
and	O
characterized	O
for	O
high	O
-	O
throughput	O
screening	O
.	O

[	B-chem-C6-1
6	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
Gingerol	E-chem-C6-1
derived	O
from	O
Zingiber	O
officinale	O
Roscoe	O
(	O
ginger	O
)	O
was	O
identified	O
as	O
a	O
novel	O
angiotensin	B-geneY-C6-2
II	I-geneY-C6-2
type	I-geneY-C6-2
1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
,	O
with	O
an	O
IC50	O
value	O
of	O
8.173	O
µM	O
.	O

The	O
hit	O
was	O
further	O
tested	O
by	O
a	O
specificity	O
assay	O
indicating	O
that	O
it	O
had	O
no	O
antagonistic	O
effects	O
on	O
other	O
evaluated	O
GPCRs	S-geneN
,	O
such	O
as	O
endothelin	B-geneN
receptors	E-geneN
.	O

The	O
major	O
ingredient	O
of	O
ginger	O
,	O
[	B-chem-C4-1
6	I-chem-C4-1
]	I-chem-C4-1
-	I-chem-C4-1
gingerol	E-chem-C4-1
,	O
could	O
inhibit	O
angiotensin	B-geneY-C4-2
II	I-geneY-C4-2
type	I-geneY-C4-2
1	I-geneY-C4-2
receptor	E-geneY-C4-2
activation	O
,	O
which	O
partially	O
clarified	O
the	O
mechanism	O
of	O
ginger	O
regulating	O
blood	O
pressure	O
and	O
strengthening	O
heart	O
in	O
the	O
cardiovascular	O
system	O
.	O

Molecular	O
pharmacology	O
of	O
human	B-geneY
Cav3.2	E-geneY
T	B-geneN
-	I-geneN
type	I-geneN
Ca2	I-geneN
+	I-geneN
channels	E-geneN
:	O
block	O
by	O
antihypertensives	O
,	O
antiarrhythmics	O
,	O
and	O
their	O
analogs	O
.	O

Antihypertensive	O
drugs	O
of	O
the	O
``	O
calcium	I-geneN
channel	O
blocker	O
``	O
or	O
``	I-chem
calcium	O
antagonist	O
``	O
class	O
have	O
been	O
used	O
to	O
establish	O
the	O
physiological	O
role	O
of	I-geneN
L	I-geneN
-	I-geneN
type	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channels	O
in	O
vascular	O
smooth	O
muscle	O
.	O

In	O
contrast	O
,	O
there	O
has	O
been	O
limited	O
progress	O
on	O
the	O
pharmacology	O
T	B-geneN
-	I-geneN
type	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
.	O

T	B-geneN
-	I-geneN
type	I-geneN
channels	E-geneN
play	O
a	O
role	O
in	O
cardiac	O
pacemaking	O
,	O
aldosterone	S-chem
secretion	O
,	O
and	O
renal	O
hemodynamics	O
,	O
leading	O
to	O
the	O
hypothesis	O
that	O
mixed	O
T	O
-	O
and	O
L	O
-	O
type	O
blockers	O
may	O
have	O
therapeutic	O
advantages	O
over	O
selective	O
L	O
-	O
type	O
blockers	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
identify	O
compounds	O
that	O
block	O
the	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
3.2	E-geneY
T	B-geneN
-	I-geneN
type	I-geneN
channel	E-geneN
with	O
high	O
affinity	O
,	O
focusing	O
on	O
two	O
classes	O
of	O
compounds	O
:	O
phenylalkylamines	S-chem
(	O
e.g	O
.	O
,	O
mibefradil	S-chem
)	O
and	O
dihydropyridines	S-chem
(	O
e.g	O
.	O
,	O
efonidipine	S-chem
)	O
.	O

Compounds	O
were	O
tested	O
using	O
a	O
validated	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
influx	O
assay	O
into	O
a	O
cell	O
line	O
expressing	O
recombinant	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
3.2	E-geneY
channels	O
.	O

This	O
study	O
identified	O
four	O
clinically	O
approved	O
antihypertensive	O
drugs	O
(	O
efonidipine	S-chem-C4-1
,	O
felodipine	S-chem-C4-1
,	O
isradipine	S-chem-C4-1
,	O
and	O
nitrendipine	S-chem-C4-1
)	O
as	O
potent	O
T	B-geneN-C4-2
-	I-geneN-C4-2
channel	E-geneN-C4-2
blockers	O
(	O
IC	O
(	O
50	O
)	O
<	O
3	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
other	O
widely	O
prescribed	O
dihydropyridines	S-chem
,	O
such	O
as	O
amlodipine	S-chem
and	O
nifedipine	S-chem
,	O
were	O
10	O
-	O
fold	O
less	O
potent	O
,	O
making	O
them	O
a	O
more	O
appropriate	O
choice	O
in	O
research	O
studies	O
on	O
the	O
role	O
of	O
L	O
-	O
type	O
currents	O
.	O

In	O
summary	O
,	O
the	O
present	O
results	O
support	O
the	O
notion	O
that	O
many	O
available	O
antihypertensive	O
drugs	O
block	O
a	O
substantial	O
fraction	O
of	O
T	O
-	O
current	O
at	O
therapeutically	O
relevant	O
concentrations	O
,	O
contributing	O
to	O
their	O
mechanism	O
of	O
action	O
.	O

Interferon	B-geneY
-	I-geneY
gamma	E-geneY
is	O
causatively	O
involved	O
in	O
experimental	O
inflammatory	O
bowel	O
disease	O
in	O
mice	O
.	O

Cytokines	S-geneN
may	O
be	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
,	O
but	O
it	O
remains	O
controversial	O
whether	O
interferon	B-geneY
(	I-geneY
IFN	I-geneY
)	I-geneY
-	I-geneY
gamma	E-geneY
,	O
a	O
typical	O
proinflammatory	O
cytokine	S-geneN
,	O
is	O
an	O
essential	O
mediator	O
to	O
cause	O
the	O
disorders	O
.	O

In	O
the	O
present	O
study	O
,	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
C57BL	O
/	O
6	O
mice	O
were	O
fed	O
2.5	O
%	O
dextran	O
sodium	O
sulphate	O
(	O
DSS	O
)	O
in	O
drinking	O
water	O
for	O
7	O
days	O
,	O
in	O
order	O
to	O
investigate	O
DSS	O
-	O
induced	O
intestinal	O
inflammation	O
.	O

The	O
DSS	O
-	O
treated	O
WT	O
mice	O
exhibited	O
a	O
robust	O
production	O
of	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
in	O
the	O
gut	O
,	O
a	O
remarkable	O
loss	O
of	O
body	O
weight	O
,	O
as	O
well	O
as	O
high	O
rate	O
of	O
mortality	O
(	O
60	O
%	O
)	O
.	O

In	O
striking	O
contrast	O
,	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
deficient	O
mice	O
did	O
not	O
develop	O
DSS	O
-	O
induced	O
colitis	O
,	O
as	O
indicated	O
by	O
the	O
maintenance	O
of	O
body	O
weight	O
and	O
survival	O
rate	O
of	O
100	O
%	O
.	O

Severe	O
intestinal	O
inflammation	O
was	O
demonstrated	O
exclusively	O
in	O
WT	O
animals	O
in	O
terms	O
of	O
the	O
shortening	O
of	O
the	O
bowel	O
as	O
well	O
as	O
the	O
elevation	O
of	O
the	O
disease	O
activity	O
index	O
,	O
myeloperoxidase	S-geneY
(	O
MPO	S-geneY
)	O
activity	O
and	O
serum	B-geneY
haptoglobin	E-geneY
level	O
.	O

Histological	O
study	O
of	O
DSS	O
-	O
treated	O
WT	O
intestine	O
revealed	O
disruption	O
of	O
mucosal	O
epithelium	O
and	O
massive	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
while	O
the	O
organ	O
from	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
remained	O
virtually	O
normal	O
in	O
appearance	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
analyses	O
indicated	O
abundant	O
production	O
of	O
three	O
chemokines	S-geneN
,	O
i.e	O
.	O
monokine	B-geneY
induced	I-geneY
by	I-geneY
interferon	I-geneY
-	I-geneY
gamma	E-geneY
(	O
MIG	S-geneY
)	O
,	O
interferon	B-geneY
-	I-geneY
inducible	I-geneY
protein	I-geneY
10	E-geneY
(	O
IP	B-geneY
-	I-geneY
10	E-geneY
)	O
and	O
monocyte	B-geneY
chemoattractant	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
MCP	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
in	O
the	O
DSS	O
-	O
irritated	O
intestine	O
of	O
WT	O
but	O
not	O
of	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

The	O
present	O
results	O
demonstrate	O
clearly	O
that	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
plays	O
indispensable	O
roles	O
in	O
the	O
initiation	O
of	O
DSS	O
colitis	O
,	O
and	O
some	O
chemokines	S-geneN
are	O
produced	O
in	O
an	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
-	O
dependent	O
fashion	O
.	O

A	O
novel	O
function	O
of	O
differentiation	O
revealed	O
by	O
cDNA	O
microarray	O
profiling	O
of	O
p75NTR	S-geneY
-	O
regulated	O
gene	O
expression	O
.	O

The	O
expression	O
of	O
the	O
p75	B-geneY
neurotrophin	I-geneY
receptor	E-geneY
(	O
p75NTR	S-geneY
)	O
is	O
diminished	O
in	O
epithelial	O
cells	O
during	O
progression	O
of	O
prostate	O
cancer	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
a	O
role	O
for	O
p75NTR	S-geneY
as	O
a	O
tumor	O
suppressor	O
in	O
prostate	O
growth	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanism	O
of	O
p75	B-geneY
(	I-geneY
NTR	I-geneY
)	E-geneY
on	O
tumor	O
suppression	O
,	O
we	O
utilized	O
a	O
complementary	O
deoxyribonucleic	B-chem
acid	E-chem
microarray	O
composed	O
of	O
approximately	O
6,000	O
human	O
cancer	O
-	O
related	O
genes	O
to	O
determine	O
the	O
gene	O
expression	O
pattern	O
altered	O
by	O
re	O
-	O
introduction	O
of	O
p75NTR	S-geneY
into	O
PC	O
-	O
3	O
prostate	O
tumor	O
cells	O
.	O

Comparison	O
of	O
the	O
transcripts	O
in	O
the	O
neo	O
and	O
p75NTR	S-geneY
-	O
transfected	O
cells	O
revealed	O
52	O
differentially	O
expressed	O
genes	O
,	O
of	O
which	O
21	O
were	O
up	O
-	O
regulated	O
and	O
31	O
were	O
down	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
p75NTR	S-geneY
.	O

Based	O
on	O
the	O
known	O
biological	O
functions	O
of	O
the	O
p75NTR	S-geneY
-	O
regulated	O
genes	O
,	O
we	O
observed	O
that	O
p75NTR	S-geneY
modulated	O
the	O
expression	O
of	O
genes	O
that	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
differentiation	O
as	O
well	O
as	O
cell	O
adhesion	O
,	O
signal	O
transduction	O
,	O
apoptosis	O
,	O
tumor	O
cell	O
invasion	O
,	O
and	O
metastasis	O
.	O

Several	O
differentially	O
expressed	O
genes	O
identified	O
by	O
microarray	O
were	O
selected	O
for	O
confirmation	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Immunoblot	O
analysis	O
further	O
confirmed	O
increased	O
cellular	B-geneY
retinoic	I-geneY
acid	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
I	E-geneY
(	O
CRABPI	S-geneY
)	O
and	O
IGFBP5	S-geneY
protein	O
levels	O
and	O
decreased	O
level	O
of	O
PLAUR	S-geneY
protein	O
with	O
increasing	O
p75NTR	S-geneY
protein	O
expression	O
.	O

As	O
CRABPI	S-geneY
was	O
elevated	O
far	O
more	O
than	O
any	O
other	O
genes	O
,	O
we	O
observed	O
that	O
the	O
retinoids	S-chem
,	O
all	B-chem
-	I-chem
trans	I-chem
retinoic	I-chem
acid	E-chem
and	O
9	B-chem
-	I-chem
cis	I-chem
retinoic	I-chem
acid	E-chem
,	O
that	O
bind	O
CRABPI	S-geneY
,	O
promoted	O
nitroblue	B-chem
tetrazolium	E-chem
-	O
associated	O
functional	O
cell	O
differentiation	O
in	O
p75NTR	S-geneY
PC	O
-	O
3	O
cells	O
,	O
but	O
not	O
in	O
neo	O
control	O
PC	O
-	O
3	O
cells	O
.	O

Subsequent	O
examination	O
of	O
the	O
retinoic	B-geneN
acid	I-geneN
receptors	E-geneN
(	B-geneN
RARs	E-geneN
)	O
expression	O
levels	O
demonstrated	O
an	O
absence	O
of	O
RAR	B-geneY
-	I-geneY
beta	E-geneY
in	O
the	O
neo	O
control	O
cells	O
and	O
re	O
-	O
expression	O
in	O
the	O
p75NTR	S-geneY
expressing	O
cells	O
,	O
consistent	O
with	O
previous	O
findings	O
where	O
RAR	B-geneY
-	I-geneY
beta	E-geneY
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
as	O
a	O
tumor	O
suppressor	O
gene	O
that	O
is	O
lost	O
during	O
de	O
-	O
differentiation	O
of	O
prostate	O
epithelial	O
cells	O
.	O

Whereas	O
the	O
RAR	B-geneN
-	I-geneN
alpha	I-geneN
and	I-geneN
-	I-geneN
gamma	E-geneN
protein	O
levels	O
remained	O
unchanged	O
,	O
retinoid	B-geneN
X	I-geneN
receptor	I-geneN
(	I-geneN
RXR	I-geneN
)	I-geneN
-	I-geneN
alpha	I-geneN
and	I-geneN
-	I-geneN
beta	E-geneN
also	O
exhibited	O
increasing	O
protein	O
levels	O
with	O
re	O
-	O
expression	O
of	O
the	O
p75NTR	S-geneY
protein	O
.	O

Moreover	O
,	O
the	O
ability	O
of	O
p75NTR	S-geneY
siRNA	O
to	O
knockdown	O
levels	O
of	O
RAR	B-geneY
-	I-geneY
beta	E-geneY
,	O
RXR	B-geneY
-	I-geneY
alpha	E-geneY
,	O
and	O
RXR	B-geneY
-	I-geneY
beta	E-geneY
supports	O
the	O
specificity	O
of	O
the	O
functional	O
involvement	O
of	O
p75NTR	S-geneY
in	O
differentiation	O
.	O

Hence	O
,	O
re	O
-	O
expression	O
of	O
the	O
p75NTR	S-geneY
appears	O
to	O
partially	O
reverse	O
de	O
-	O
differentiation	O
of	O
prostate	O
cancer	O
cells	O
by	O
up	O
-	O
regulating	O
the	O
expression	O
of	O
CRABPI	S-geneY-C3-2
for	O
localized	O
sequestration	O
of	O
retinoids	S-chem-C3-1
that	O
are	O
available	O
to	O
newly	O
up	O
-	O
regulated	O
RAR	B-geneY
-	I-geneY
beta	E-geneY
,	O
RXR	B-geneY
-	I-geneY
alpha	E-geneY
,	O
and	O
RXR	B-geneY
-	I-geneY
beta	E-geneY
.	O

Contribution	O
of	O
the	O
m1	O
transmembrane	O
helix	O
and	O
pre	O
-	O
m1	O
region	O
to	O
positive	O
allosteric	O
modulation	O
and	O
gating	O
of	O
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
d	I-geneN
-	I-geneN
aspartate	I-geneN
receptors	E-geneN
.	O

N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
d	I-geneN
-	I-geneN
aspartate	I-geneN
(	I-geneN
NMDA	I-geneN
)	I-geneN
receptors	E-geneN
are	O
glutamate	B-geneN
-	I-geneN
gated	I-geneN
ion	I-geneN
channels	E-geneN
whose	O
function	O
is	O
critical	O
for	O
normal	O
excitatory	O
synaptic	O
transmission	O
in	O
the	O
brain	O
and	O
whose	O
dysfunction	O
has	O
been	O
implicated	O
in	O
several	O
neurologic	O
conditions	O
.	O

NMDA	B-geneN
receptor	E-geneN
function	O
is	O
subject	O
to	O
extensive	O
allosteric	O
regulation	O
both	O
by	O
endogenous	O
compounds	O
and	O
by	O
exogenous	O
small	O
molecules	O
.	O

Elucidating	O
the	O
structural	O
determinants	O
and	O
mechanism	O
of	O
action	O
by	O
which	O
allosteric	O
regulators	O
control	O
gating	O
will	O
enhance	O
our	O
understanding	O
of	O
NMDA	B-geneN
receptor	E-geneN
activation	O
and	O
facilitate	O
the	O
development	O
of	O
novel	O
therapeutics	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
structural	O
determinants	O
for	O
(	B-chem
3	I-chem
-	I-chem
chlorophenyl	I-chem
)	I-chem
(	I-chem
6,7	I-chem
-	I-chem
dimethoxy	I-chem
-	I-chem
1	I-chem
-	I-chem
(	I-chem
(	I-chem
4	I-chem
-	I-chem
methoxyphenoxy	I-chem
)	I-chem
methyl	I-chem
)	I-chem
-	I-chem
3,4	I-chem
-	I-chem
dihydroisoquinolin	I-chem
-	I-chem
2	I-chem
(	I-chem
1H	I-chem
)	I-chem
-	I-chem
yl	I-chem
)	I-chem
methanone	E-chem
(	O
CIQ	S-chem
)	O
,	O
a	O
GluN2C	O
/	O
2D	O
-	O
selective	O
positive	O
allosteric	O
modulator	O
.	O

We	O
show	O
that	O
CIQ	S-chem
does	O
not	O
bind	O
to	O
the	O
amino	S-chem
-	O
terminal	O
domain	O
of	O
the	O
NMDA	B-geneN
receptor	E-geneN
and	O
does	O
not	O
share	O
structural	O
determinants	O
with	O
modulators	O
acting	O
at	O
the	O
agonist	O
-	O
binding	O
domain	O
dimer	O
interface	O
or	O
ion	B-geneN
channel	E-geneN
pore	O
.	O

Rather	O
,	O
we	O
identified	O
critical	O
determinants	O
of	O
CIQ	S-chem
modulation	O
in	O
the	O
region	O
near	O
the	O
first	O
transmembrane	O
helix	O
of	O
GluN2D	O
,	O
including	O
in	O
a	O
putative	O
pre	O
-	O
M1	O
cuff	O
helix	O
that	O
may	O
influence	O
channel	O
gating	O
.	O

We	O
also	O
show	O
that	O
mutations	O
within	O
the	O
GluN2D	O
pre	O
-	O
M1	O
region	O
alter	O
open	O
probability	O
of	O
the	O
NMDA	B-geneN
receptor	E-geneN
.	O

These	O
results	O
suggest	O
a	O
novel	O
site	O
of	O
action	O
for	O
potentiation	O
of	O
NMDA	B-geneN
receptors	E-geneN
by	O
small	O
molecules	O
and	O
implicate	O
the	O
pre	O
-	O
M1	O
region	O
in	O
NMDA	B-geneN
receptor	E-geneN
gating	O
.	O

Hydroxysafflor	B-chem
yellow	I-chem
a	E-chem
inhibits	O
lipopolysaccharide	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

Hydroxysafflor	B-chem
yellow	I-chem
A	E-chem
(	O
HSYA	S-chem
)	O
is	O
an	O
active	O
ingredient	O
obtained	O
from	O
the	O
flower	O
of	O
Carthamus	O
tinctorius	O
L	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
HSYA	S-chem
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

A549	O
cells	O
stimulated	O
with	O
LPS	O
were	O
incubated	O
with	O
three	O
doses	O
of	O
HSYA	S-chem
(	O
1	O
,	O
4	O
and	O
16μmol	O
/	O
L	O
)	O
.	O

HSYA	S-chem-C4-1
suppressed	O
the	O
expression	O
of	O
TLR	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
,	O
Myd88	S-geneY-C4-2
,	O
ICAM	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
TNFα	S-geneY-C4-2
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
1β	E-geneY-C4-2
and	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
6	E-geneY-C4-2
at	O
the	O
mRNA	O
and	O
protein	O
level	O
,	O
and	O
inhibited	O
the	O
adhesion	O
of	O
leukocytes	O
to	O
A549	O
cells	O
.	O

HSYA	S-chem-C4-1
treatment	O
also	O
decreased	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
κB	E-geneN-C4-2
p65	S-geneY-C4-2
nuclear	O
translocation	O
and	O
inhibited	O
the	O
phosphorylation	O
of	O
p38	S-geneN-C4-2
mitogen	B-geneN-C4-2
-	I-geneN-C4-2
activated	I-geneN-C4-2
protein	I-geneN-C4-2
kinase	E-geneN-C4-2
(	O
p38	S-geneN-C4-2
MAPK	S-geneN-C4-2
)	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	S-chem
effectively	O
inhibits	O
LPS	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
A549	O
cells	O
.	O

A	O
one	O
-	O
pot	O
domino	O
synthesis	O
and	O
discovery	O
of	O
highly	O
functionalized	O
dihydrobenzo	B-chem-C4-1
[	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
thiophenes	E-chem-C4-1
as	O
AChE	S-geneY-C4-2
inhibitors	O
.	O

A	O
library	O
of	O
novel	O
5	B-chem
-	I-chem
amino	I-chem
-	I-chem
2,7	I-chem
-	I-chem
diaryl	I-chem
-	I-chem
2,3	I-chem
-	I-chem
dihydrobenzo	I-chem
[	I-chem
b	I-chem
]	I-chem
thiophene	I-chem
-	I-chem
4,6	I-chem
-	I-chem
dicarbonitriles	E-chem
have	O
been	O
synthesized	O
regioselectively	O
in	O
good	O
yields	O
through	O
the	O
one	O
-	O
pot	O
domino	O
reactions	O
of	O
5	B-chem
-	I-chem
aryldihydro	I-chem
-	I-chem
3	I-chem
(	I-chem
2H	I-chem
)	I-chem
-	I-chem
thiophenones	E-chem
,	O
malononitrile	S-chem
and	O
aromatic	B-chem
aldehydes	E-chem
in	O
the	O
presence	O
of	O
morpholine	S-chem
.	O

This	O
transformation	O
presumably	O
involves	O
Knoevenagel	O
condensation	O
-	O
Michael	O
addition	O
-	O
intramolecular	O
Thorpe	O
-	O
Ziegler	O
cyclization	O
-	O
Tautomerization	O
-	O
Elimination	O
sequence	O
of	O
reactions	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
inhibitory	O
activity	O
and	O
5	B-chem-C4-1
-	I-chem-C4-1
amino	I-chem-C4-1
-	I-chem-C4-1
2,7	I-chem-C4-1
-	I-chem-C4-1
bis	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
methoxyphenyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
2,3	I-chem-C4-1
-	I-chem-C4-1
dihydrobenzo	I-chem-C4-1
[	I-chem-C4-1
b	I-chem-C4-1
]	I-chem-C4-1
thiophene	I-chem-C4-1
-	I-chem-C4-1
4,6	I-chem-C4-1
-	I-chem-C4-1
dicarbonitrile	E-chem-C4-1
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
against	O
AChE	S-geneY-C4-2
with	O
IC50	O
4.16	O
μmol	O
/	O
L	O
.	O

Update	O
on	O
the	O
use	O
of	O
aromatase	S-geneY
inhibitors	O
in	O
breast	O
cancer	O
.	O

Estrogens	S-chem-C9-1
are	O
biosynthesised	O
from	O
androgens	S-chem-C9-1
by	O
the	O
CYP450	S-geneN-C9-2
enzyme	O
complex	O
called	O
aromatase	S-geneY-C9-2
.	O

Aromatase	S-geneY
is	O
expressed	O
in	O
the	O
ovary	O
,	O
placenta	O
,	O
brain	O
,	O
bone	O
,	O
adipose	O
tissue	O
and	O
breast	O
tissue	O
.	O

In	O
breast	O
cancer	O
,	O
intratumoural	O
aromatase	S-geneY-C9-2
is	O
the	O
source	O
for	O
local	O
estrogen	S-chem-C9-1
production	O
in	O
the	O
tissue	O
.	O

Inhibition	O
of	O
aromatase	S-geneY
is	O
an	O
important	O
approach	O
for	O
reducing	O
growth	O
stimulatory	O
effects	O
of	O
estrogens	S-chem
in	O
estrogen	S-chem
-	O
dependent	O
breast	O
cancer	O
.	O

The	O
potent	O
and	O
selective	O
third	O
-	O
generation	O
aromatase	S-geneY-C4-2
inhibitors	O
anastrozole	S-chem-C4-1
,	O
letrozole	S-chem-C4-1
and	O
exemestane	O
were	O
introduced	O
to	O
the	O
market	O
as	O
endocrine	O
therapy	O
in	O
postmenopausal	O
patients	O
failing	O
anti	O
-	O
estrogen	S-chem
therapy	O
alone	O
,	O
or	O
multiple	O
hormonal	O
therapies	O
.	O

Anastrozole	S-chem-C4-1
and	O
letrozole	S-chem-C4-1
are	O
both	O
non	O
-	O
steroidal	S-chem
aromatase	S-geneY-C4-2
inhibitors	O
that	O
compete	O
with	O
the	O
substrate	O
for	O
binding	O
to	O
the	O
enzyme	O
active	O
site	O
.	O

Exemestane	O
is	O
a	O
mechanism	O
-	O
based	O
steroidal	S-chem
inhibitor	O
that	O
mimics	O
the	O
substrate	O
,	O
is	O
converted	O
by	O
the	O
enzyme	O
to	O
a	O
reactive	O
intermediate	O
,	O
and	O
results	O
in	O
inactivation	O
of	O
aromatase	S-geneY
.	O

These	O
third	O
-	O
generation	O
aromatase	S-geneY
inhibitors	O
are	O
currently	O
approved	O
as	O
first	O
-	O
line	O
therapy	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
metastatic	O
estrogen	S-chem
-	O
dependent	O
breast	O
cancer	O
.	O

The	O
use	O
of	O
an	O
aromatase	S-geneY
inhibitor	O
as	O
initial	O
therapy	O
,	O
or	O
after	O
treatment	O
with	O
tamoxifen	S-chem
,	O
is	O
now	O
recommended	O
as	O
adjuvant	O
hormonal	O
therapy	O
for	O
postmenopausal	O
women	O
with	O
hormone	O
-	O
dependent	O
breast	O
cancer	O
.	O

Several	O
clinical	O
studies	O
of	O
aromatase	S-geneY
inhibitors	O
focus	O
on	O
the	O
use	O
of	O
these	O
agents	O
in	O
the	O
adjuvant	O
setting	O
,	O
for	O
the	O
treatment	O
of	O
early	O
breast	O
cancer	O
.	O

Recently	O
published	O
results	O
show	O
improved	O
responses	O
with	O
these	O
agents	O
compared	O
with	O
tamoxifen	S-chem
.	O

ZEB2	S-geneY
zinc	B-geneN
-	I-geneN
finger	E-geneN
missense	O
mutations	O
lead	O
to	O
hypomorphic	O
alleles	O
and	O
a	O
mild	O
Mowat	O
-	O
Wilson	O
syndrome	O
.	O

Mowat	O
-	O
Wilson	O
syndrome	O
(	O
MWS	O
)	O
is	O
a	O
severe	O
intellectual	O
disability	O
(	O
ID	O
)	O
-	O
distinctive	O
facial	O
gestalt	O
-	O
multiple	O
congenital	O
anomaly	O
syndrome	O
,	O
commonly	O
associating	O
microcephaly	O
,	O
epilepsy	O
,	O
corpus	O
callosum	O
agenesis	O
,	O
conotruncal	O
heart	O
defects	O
,	O
urogenital	O
malformations	O
and	O
Hirschsprung	O
disease	O
(	O
HSCR	O
)	O
.	O

MWS	O
is	O
caused	O
by	O
de	O
novo	O
heterozygous	O
mutations	O
in	O
the	O
ZEB2	S-geneY
gene	O
.	O

The	O
majority	O
of	O
mutations	O
lead	O
to	O
haplo	O
-	O
insufficiency	O
through	O
premature	O
stop	O
codons	O
or	O
large	O
gene	O
deletions	O
.	O

Only	O
three	O
missense	O
mutations	O
have	O
been	O
reported	O
so	O
far	O
;	O
none	O
of	O
which	O
resides	O
in	O
a	O
known	O
functional	O
domain	O
of	O
ZEB2	S-geneY
.	O

In	O
this	O
study	O
,	O
we	O
report	O
and	O
analyze	O
the	O
functional	O
consequences	O
of	O
three	O
novel	O
missense	O
mutations	O
,	O
p.Tyr1055Cys	S-geneN
,	O
p.Ser1071Pro	S-geneN
and	O
p.His1045Arg	S-geneN
,	O
identified	O
in	O
the	O
highly	O
conserved	O
C	B-geneN
-	I-geneN
zinc	I-geneN
-	I-geneN
finger	I-geneN
(	I-geneN
C	I-geneN
-	I-geneN
ZF	I-geneN
)	I-geneN
domain	E-geneN
of	O
ZEB2	S-geneY
.	O

Patients	O
'	O
phenotype	O
included	O
the	O
facial	O
gestalt	O
of	O
MWS	O
and	O
moderate	O
ID	O
,	O
but	O
no	O
microcephaly	O
,	O
heart	O
defects	O
or	O
HSCR	O
.	O

In	O
vitro	O
studies	O
showed	O
that	O
all	O
the	O
three	O
mutations	O
prevented	O
binding	O
and	O
repression	O
of	O
the	O
E	B-geneN
-	I-geneN
cadherin	I-geneN
promoter	E-geneN
,	O
a	O
characterized	O
ZEB2	S-geneY
target	O
gene	O
.	O

Taking	O
advantage	O
of	O
the	O
zebrafish	O
morphant	O
technology	O
,	O
we	O
performed	O
rescue	O
experiments	O
using	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
mutant	O
human	B-geneY
ZEB2	E-geneY
mRNAs	O
.	O

Variable	O
,	O
mutation	O
-	O
dependent	O
,	O
embryo	O
rescue	O
,	O
correlating	O
with	O
the	O
severity	O
of	O
patients	O
'	O
phenotype	O
,	O
was	O
observed	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
these	O
missense	O
mutations	O
cause	O
a	O
partial	O
loss	O
of	O
function	O
of	O
ZEB2	S-geneY
,	O
suggesting	O
that	O
its	O
role	O
is	O
not	O
restricted	O
to	O
repression	O
of	O
E	B-geneY
-	I-geneY
cadherin	E-geneY
.	O

Functional	O
domains	O
other	O
than	O
C	B-geneN
-	I-geneN
ZF	E-geneN
may	O
play	O
a	O
role	O
in	O
early	O
embryonic	O
development	O
.	O

Finally	O
,	O
these	O
findings	O
broaden	O
the	O
clinical	O
spectrum	O
of	O
ZEB2	S-geneY
mutations	O
,	O
indicating	O
that	O
MWS	O
ought	O
to	O
be	O
considered	O
in	O
patients	O
with	O
lesser	O
degrees	O
of	O
ID	O
and	O
a	O
suggestive	O
facial	O
gestalt	O
,	O
even	O
in	O
the	O
absence	O
of	O
congenital	O
malformation	O
.	O

Hormonal	O
therapy	O
of	O
prostate	O
cancer	O
.	O

Of	O
all	O
cancers	O
,	O
prostate	O
cancer	O
is	O
the	O
most	O
sensitive	O
to	O
hormones	O
:	O
it	O
is	O
thus	O
very	O
important	O
to	O
take	O
advantage	O
of	O
this	O
unique	O
property	O
and	O
to	O
always	O
use	O
optimal	O
androgen	S-chem
blockade	O
when	O
hormone	O
therapy	O
is	O
the	O
appropriate	O
treatment	O
.	O

A	O
fundamental	O
observation	O
is	O
that	O
the	O
serum	O
testosterone	S-chem
concentration	O
only	O
reflects	O
the	O
amount	O
of	O
testosterone	S-chem
of	O
testicular	O
origin	O
which	O
is	O
released	O
in	O
the	O
blood	O
from	O
which	O
it	O
reaches	O
all	O
tissues	O
.	O

Recent	O
data	O
show	O
,	O
however	O
,	O
that	O
an	O
approximately	O
equal	O
amount	O
of	O
testosterone	S-chem
is	O
made	O
from	O
dehydroepiandrosterone	S-chem
(	O
DHEA	S-chem
)	O
directly	O
in	O
the	O
peripheral	O
tissues	O
,	O
including	O
the	O
prostate	O
,	O
and	O
does	O
not	O
appear	O
in	O
the	O
blood	O
.	O

Consequently	O
,	O
after	O
castration	O
,	O
the	O
95	O
-	O
97	O
%	O
fall	O
in	O
serum	O
testosterone	S-chem
does	O
not	O
reflect	O
the	O
40	O
-	O
50	O
%	O
testosterone	S-chem
(	O
testo	S-chem
)	O
and	O
dihydrotestosterone	S-chem
(	O
DHT	S-chem
)	O
made	O
locally	O
in	O
the	O
prostate	O
from	O
DHEA	S-chem
of	O
adrenal	O
origin	O
.	O

In	O
fact	O
,	O
while	O
elimination	O
of	O
testicular	O
androgens	S-chem
by	O
castration	O
alone	O
has	O
never	O
been	O
shown	O
to	O
prolong	O
life	O
in	O
metastatic	O
prostate	O
cancer	O
,	O
combination	O
of	O
castration	O
(	O
surgical	O
or	O
medical	O
with	O
a	O
gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
GnRH	S-geneY
)	O
agonist	O
)	O
with	O
a	O
pure	O
anti	O
-	O
androgen	S-chem
has	O
been	O
the	O
first	O
treatment	O
shown	O
to	O
prolong	O
life	O
.	O

Most	O
importantly	O
,	O
when	O
applied	O
at	O
the	O
localized	O
stage	O
,	O
the	O
same	O
combined	O
androgen	S-chem
blockade	O
(	O
CAB	O
)	O
can	O
provide	O
long	O
-	O
term	O
control	O
or	O
cure	O
of	O
the	O
disease	O
in	O
more	O
than	O
90	O
%	O
of	O
cases	O
.	O

Obviously	O
,	O
since	O
prostate	O
cancer	O
usually	O
grows	O
and	O
metastasizes	O
without	O
signs	O
or	O
symptoms	O
,	O
screening	O
with	O
prostate	B-geneY
-	I-geneY
specific	I-geneY
antigen	E-geneY
(	O
PSA	S-geneY
)	O
is	O
absolutely	O
needed	O
to	O
diagnose	O
prostate	O
cancer	O
at	O
an	O
'	O
early	O
'	O
stage	O
before	O
metastasis	O
occurs	O
and	O
the	O
cancer	O
becomes	O
non	O
-	O
curable	O
.	O

While	O
the	O
role	O
of	O
androgens	S-chem
was	O
believed	O
to	O
have	O
become	O
non	O
-	O
significant	O
in	O
cancer	O
progressing	O
under	O
any	O
form	O
of	O
androgen	S-chem
blockade	O
,	O
recent	O
data	O
have	O
shown	O
increased	O
expression	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
in	O
treatment	O
-	O
resistant	O
disease	O
with	O
a	O
benefit	O
of	O
further	O
androgen	S-chem
blockade	O
.	O

Since	O
the	O
available	O
anti	O
-	O
androgens	S-chem
have	O
low	O
affinity	O
for	O
AR	S-geneY
and	O
can	O
not	O
block	O
androgen	S-chem
action	O
completely	O
,	O
especially	O
in	O
the	O
presence	O
of	O
increased	O
AR	S-geneY
levels	O
,	O
it	O
becomes	O
important	O
to	O
discover	O
more	O
potent	O
and	O
purely	O
antagonistic	O
blockers	O
of	O
AR	S-geneY
.	O

The	O
data	O
obtained	O
with	O
compounds	O
under	O
development	O
are	O
promising	O
.	O

While	O
waiting	O
for	O
this	O
(	O
these	O
)	O
new	O
anti	O
-	O
androgen	B-chem
(	I-chem
s	I-chem
)	E-chem
,	O
combined	O
treatment	O
with	O
castration	O
and	O
a	O
pure	O
anti	O
-	O
androgen	S-chem
(	O
bicalutamide	S-chem
,	O
flutamide	S-chem
or	O
nilutamide	S-chem
)	O
is	O
the	O
only	O
available	O
and	O
the	O
best	O
scientifically	O
based	O
means	O
of	O
treating	O
prostate	O
cancer	O
by	O
hormone	O
therapy	O
at	O
any	O
stage	O
of	O
the	O
disease	O
with	O
the	O
optimal	O
chance	O
of	O
success	O
and	O
even	O
cure	O
in	O
localized	O
disease	O
.	O

Involvement	O
of	O
p	B-geneN
-	I-geneN
CREB	E-geneN
and	O
phase	B-geneN
II	I-geneN
detoxifying	I-geneN
enzyme	E-geneN
system	O
in	O
neuroprotection	O
mediated	O
by	O
the	O
flavonoid	O
calycopterin	S-chem
isolated	O
from	O
Dracocephalum	O
kotschyi	O
.	O

PURPOSE	O
:	O
There	O
is	O
an	O
increasing	O
amount	O
of	O
experimental	O
evidence	O
that	O
oxidative	O
stress	O
has	O
a	O
central	O
role	O
in	O
the	O
neuropathology	O
of	O
neurodegenerative	O
diseases	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
loss	O
of	O
cell	O
function	O
results	O
from	O
the	O
increased	O
oxidative	O
damage	O
to	O
proteins	O
and	O
DNA	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
a	O
natural	O
neuroprotective	O
flavonoid	O
,	O
calycopterin	S-chem
,	O
on	O
H2O2	S-chem-C4-1
-	O
induced	O
disruption	O
of	O
phase	B-geneN-C4-2
II	I-geneN-C4-2
detoxifying	I-geneN-C4-2
enzyme	E-geneN-C4-2
system	O
and	O
cAMP	B-geneN-C4-2
response	I-geneN-C4-2
element	I-geneN-C4-2
binding	I-geneN-C4-2
protein	E-geneN-C4-2
(	O
CREB	S-geneN-C4-2
)	O
phosphorylation	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
25	O
,	O
50	O
and	O
100μM	O
of	O
calycopterin	S-chem
for	O
3h	O
,	O
followed	O
by	O
adding	O
H2O2	S-chem
(	O
150μM	O
)	O
for	O
24h	O
.	O

The	O
extent	O
of	O
apoptosis	O
was	O
assessed	O
by	O
comet	O
assay	O
.	O

The	O
level	O
of	O
phosphorylated	B-geneN
CREB	E-geneN
,	O
nuclear	B-geneY
factor	I-geneY
erythroid	I-geneY
2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
Nrf2	S-geneY
)	O
,	O
glutamylcysteine	B-geneY
synthetase	E-geneY
(	O
γ	B-geneY
-	I-geneY
GCS	E-geneY
)	O
and	O
heme	B-geneY
oxygenase	I-geneY
1	E-geneY
(	O
HO	B-geneY
-	I-geneY
1	E-geneY
)	O
were	O
measured	O
by	O
western	O
blot	O
method	O
.	O

The	O
concentration	O
of	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
was	O
determined	O
in	O
whole	O
cell	O
lysate	O
using	O
dithionitrobenzoic	O
acid	O
method	O
.	O

Superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
activity	O
was	O
measured	O
by	O
colorimetric	O
assay	O
.	O

RESULT	O
:	O
Morphological	O
analysis	O
of	O
protection	O
induced	O
by	O
calycopterin	S-chem
,	O
determined	O
by	O
comet	O
assay	O
,	O
showed	O
that	O
calycopterin	S-chem
reduced	O
DNA	O
in	O
tail	O
.	O

We	O
found	O
that	O
H2O2	S-chem
decreased	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
,	O
while	O
,	O
calycopterin	S-chem
prevented	O
this	O
decrease	O
in	O
MMP	O
in	O
presence	O
of	O
H2O2	S-chem
.	O

In	O
H2O2	S-chem
-	O
treated	O
cells	O
,	O
calycopterin	S-chem-C4-1
also	O
suppressed	O
cytochrome	B-geneY-C4-2
C	E-geneY-C4-2
release	O
to	O
cytosol	O
that	O
is	O
necessary	O
for	O
maintaining	O
mitochondrial	O
homeostasis	O
in	O
survived	O
cells	O
.	O

Moreover	O
,	O
calycopterin	S-chem-C3-1
,	O
in	O
presence	O
of	O
H2O2	S-chem
inhibited	O
the	O
decrease	O
caused	O
by	O
oxidative	O
stress	O
in	O
stress	O
-	O
sensing	O
transcription	O
factors	O
,	O
CREB	S-geneN-C3-2
and	O
Nrf2	S-geneY-C3-2
,	O
which	O
play	O
an	O
important	O
role	O
in	O
antioxidant	O
capacity	O
of	O
the	O
cell	O
.	O

There	O
was	O
also	O
an	O
increase	O
in	O
γ	B-geneY-C3-2
-	I-geneY-C3-2
GCS	E-geneY-C3-2
and	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
levels	O
in	O
calycopterin	S-chem-C3-1
pretreated	O
cells	O
.	O

In	O
the	O
presence	O
of	O
H2O2	S-chem
,	O
calycopterin	S-chem-C3-1
inhibited	O
decrease	O
in	O
GSH	S-chem
level	O
and	O
SOD	S-geneN-C3-2
activity	O
.	O

CONCLUSION	O
:	O
We	O
provided	O
documentation	O
of	O
neuroprotective	O
effect	O
of	O
a	O
natural	O
flavone	O
,	O
calycopterin	S-chem
,	O
against	O
H2O2	S-chem
-	O
induced	O
oxidative	O
stress	O
in	O
differentiated	O
PC12	O
cells	O
by	O
modulating	O
the	O
level	O
of	O
CREB	S-geneN
phosphorylation	O
and	O
Nrf2	S-geneY
pathway	O
.	O

Regulation	O
of	O
the	O
expression	O
of	O
peptidylarginine	B-geneY
deiminase	I-geneY
type	I-geneY
II	E-geneY
gene	O
(	O
PADI2	S-geneY
)	O
in	O
human	O
keratinocytes	O
involves	O
Sp1	S-geneY
and	O
Sp3	S-geneY
transcription	O
factors	O
.	O

Peptidylarginine	B-geneN
deiminases	E-geneN
(	O
PAD	S-geneN
)	O
convert	O
protein	O
-	O
bound	O
arginine	S-chem
residues	O
into	O
citrulline	S-chem
residues	O
in	O
a	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
ion	O
-	O
dependent	O
manner	O
.	O

Among	O
the	O
five	O
isoforms	O
(	O
PAD1	B-geneN
,	I-geneN
2	I-geneN
,	I-geneN
3	I-geneN
,	I-geneN
4	I-geneN
,	I-geneN
and	I-geneN
6	E-geneN
)	O
existing	O
in	O
rodents	O
and	O
humans	O
,	O
PAD2	S-geneY
is	O
the	O
most	O
widely	O
expressed	O
in	O
both	O
species	O
,	O
tissues	O
,	O
and	O
organs	O
.	O

In	O
order	O
to	O
study	O
the	O
mechanisms	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-geneY
PAD2	E-geneY
gene	O
,	O
PADI2	S-geneY
,	O
we	O
characterized	O
its	O
promoter	O
region	O
using	O
transfected	O
human	O
keratinocytes	O
.	O

A	O
series	O
of	O
reporter	O
gene	O
constructions	O
derived	O
from	O
the	O
2	O
kb	O
region	O
upstream	O
of	O
the	O
transcription	B-geneN
initiation	I-geneN
site	E-geneN
defined	O
a	O
minimal	O
promoter	O
sequence	O
from	O
nucleotides	O
-	O
132	O
to	O
-	O
41	O
.	O

This	O
PADI2	S-geneY
region	O
is	O
GC	O
-	O
rich	O
and	O
lacks	O
canonical	O
TATA	S-geneN
and	O
CAAT	B-geneN
boxes	E-geneN
.	O

Investigation	O
of	O
cis	B-geneN
-	I-geneN
acting	I-geneN
elements	E-geneN
in	O
the	O
region	O
,	O
further	O
deletion	O
analyses	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
specific	O
antibodies	O
revealed	O
four	O
Sp1	B-geneN
-	I-geneN
binding	I-geneN
sites	E-geneN
and	O
identified	O
Sp1	S-geneY
and	O
Sp3	S-geneY
as	O
binding	O
factors	O
important	O
for	O
the	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
Sp1	S-geneY
/	O
Sp3	S-geneY
cooperation	O
may	O
provide	O
a	O
mechanism	O
to	O
control	O
the	O
transcription	O
of	O
PADI2	S-geneY
.	O

SUR	S-geneY
-	O
dependent	O
modulation	O
of	O
KATP	B-geneN
channels	E-geneN
by	O
an	O
N	S-chem
-	O
terminal	O
KIR6.2	S-geneY
peptide	O
.	O
Defining	O
intersubunit	O
gating	O
interactions	O
.	O

Ntp	O
and	O
Ctp	O
,	O
synthetic	O
peptides	O
based	O
on	O
the	O
N	S-chem
-	O
and	O
C	S-chem
-	O
terminal	O
sequences	O
of	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.0	E-geneY
,	O
respectively	O
,	O
were	O
used	O
to	O
probe	O
gating	O
of	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.0	E-geneY
/	O
SUR	S-geneY
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
.	O

Micromolar	O
Ntp	O
dose	O
-	O
dependently	O
increased	O
the	O
mean	O
open	O
channel	O
probability	O
in	O
ligand	O
-	O
free	O
solution	O
(	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
)	O
and	O
attenuated	O
the	O
ATP	S-chem-C4-1
inhibition	O
of	O
K	B-geneY-C4-2
(	I-geneY-C4-2
IR	I-geneY-C4-2
)	I-geneY-C4-2
6.2	E-geneY-C4-2
/	O
SUR1	S-geneY-C4-2
,	O
but	O
had	O
no	O
effect	O
on	O
homomeric	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.2	E-geneY
channels	O
.	O

Ntp	O
(	O
up	O
to	O
approximately	O
10	O
(	O
-	O
4	O
)	O
m	O
)	O
did	O
not	O
affect	O
significantly	O
the	O
mean	O
open	O
or	O
``	O
fast	O
,	O
``	B-chem
K	I-chem
(	E-chem
+	O
)	O
driving	O
force	O
-	O
dependent	O
,	O
intraburst	O
closed	O
times	O
,	O
verifying	O
that	O
Ntp	O
selectively	O
modulates	O
the	O
ratio	O
of	O
mean	O
burst	O
to	O
interburst	O
times	O
.	O

Ctp	O
and	O
Rnp	O
,	O
a	O
randomized	O
Ntp	O
,	O
had	O
no	O
effect	O
,	O
indicating	O
that	O
the	O
effects	O
of	O
Ntp	O
are	O
structure	O
specific	O
.	O

Ntp	O
opened	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.1	E-geneY
/	O
SUR1	S-geneY
channels	O
normally	O
silent	O
in	O
the	O
absence	O
of	O
stimulatory	O
Mg	O
(	O
-	O
)	O
nucleotide	B-chem
(	I-chem
s	I-chem
)	E-chem
and	O
attenuated	O
the	O
coupling	O
of	O
high	O
-	O
affinity	O
sulfonylurea	S-chem
binding	O
with	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	E-geneN
pore	O
closure	O
.	O

These	O
effects	O
resemble	O
those	O
seen	O
with	O
N	S-chem
-	O
terminal	O
deletions	O
(	O
DeltaN	O
)	O
of	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.0	E-geneY
,	O
and	O
application	O
of	O
Ntp	O
to	O
DeltaNK	B-geneN-C4-2
(	I-geneN-C4-2
ATP	I-geneN-C4-2
)	I-geneN-C4-2
channels	E-geneN-C4-2
decreased	O
their	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
and	O
apparent	O
IC	O
(	O
50	O
)	O
for	O
ATP	S-chem-C4-1
in	O
the	O
absence	O
of	O
Mg	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
.	O

The	O
results	O
are	O
consistent	O
with	O
a	O
competition	O
between	O
Ntp	O
and	O
the	O
endogenous	O
N	S-chem
terminus	O
for	O
a	O
site	O
of	O
interaction	O
on	O
the	O
cytoplasmic	O
face	O
of	O
the	O
channel	O
or	O
with	O
partial	O
replacement	O
of	O
the	O
deleted	O
N	S-chem
terminus	O
by	O
Ntp	O
,	O
respectively	O
.	O

The	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	E-geneY
N	S-chem
terminus	O
and	O
the	O
TMD0	O
-	O
L0	O
segment	O
of	O
SUR1	S-geneY
are	O
known	O
to	O
control	O
the	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
.	O

The	O
L0	O
linker	O
has	O
been	O
reported	O
to	O
be	O
required	O
for	O
glibenclamide	S-chem
binding	O
,	O
and	O
DeltaNK	B-geneY
(	I-geneY
IR	I-geneY
)	I-geneY
6.2	E-geneY
/	O
SUR1	S-geneY
channels	O
exhibit	O
reduced	O
labeling	O
of	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	E-geneY
with	O
(	B-chem
125	I-chem
)	I-chem
I	I-chem
-	I-chem
azidoglibenclamide	E-chem
,	O
implying	O
that	O
the	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	E-geneY
N	S-chem
terminus	O
and	O
L0	O
of	O
SUR1	S-geneY
are	O
in	O
proximity	O
.	O

We	O
hypothesize	O
that	O
L0	O
interacts	O
with	O
the	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	E-geneY
N	S-chem
terminus	O
in	O
ligand	O
-	O
inhibited	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
and	O
put	O
forward	O
a	O
model	O
,	O
based	O
on	O
the	O
architecture	O
of	O
BtuCD	S-geneN
,	O
MsbA	S-geneN
,	O
and	O
the	O
KcsA	S-geneN
channel	O
,	O
in	O
which	O
TMD0	O
-	O
L0	O
links	O
the	O
MDR	S-geneN
-	O
like	O
core	O
of	O
SUR	S-geneY
with	O
the	O
K	B-geneY
(	I-geneY
IR	I-geneY
)	E-geneY
pore	O
.	O

Interaction	O
of	O
rofecoxib	S-chem
and	O
celecoxib	S-chem
with	O
warfarin	S-chem
.	O

The	O
interaction	O
of	O
celecoxib	S-chem
and	O
rofecoxib	S-chem
with	O
warfarin	S-chem
was	O
studied	O
.	O

Patients	O
stable	O
on	O
warfarin	S-chem
therapy	O
and	O
concurrently	O
taking	O
a	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
inhibitor	O
comparator	O
(	O
traditional	O
nonsteroidal	O
antiinflammatory	O
medications	O
,	O
salsalate	S-chem-C4-1
,	O
or	O
acetaminophen	S-chem-C4-1
)	O
randomly	O
received	O
celecoxib	S-chem-C4-1
200	O
mg	O
/	O
day	O
or	O
rofecoxib	S-chem-C4-1
25	O
mg	O
/	O
day	O
for	O
three	O
weeks	O
.	O

After	O
a	O
one	O
-	O
week	O
washout	O
period	O
,	O
the	O
patients	O
were	O
crossed	O
over	O
to	O
treatment	O
with	O
the	O
opposite	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
for	O
three	O
more	O
weeks	O
.	O

The	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
was	O
measured	O
at	O
baseline	O
and	O
at	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
of	O
therapy	O
with	O
each	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
by	O
testing	O
blood	O
samples	O
obtained	O
by	O
finger	O
stick	O
.	O

Data	O
for	O
16	O
patients	O
were	O
analyzed	O
.	O

The	O
INR	O
increased	O
by	O
13	O
%	O
,	O
6	O
%	O
,	O
and	O
5	O
%	O
on	O
average	O
in	O
patients	O
taking	O
celecoxib	S-chem
at	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
,	O
and	O
by	O
5	O
%	O
,	O
9	O
%	O
,	O
and	O
5	O
%	O
in	O
patients	O
taking	O
rofecoxib	S-chem
.	O

Changes	O
in	O
the	O
INR	O
were	O
statistically	O
significant	O
at	O
week	O
1	O
for	O
celecoxib	S-chem
and	O
at	O
week	O
2	O
for	O
rofecoxib	S-chem
.	O

Of	O
the	O
12	O
subjects	O
who	O
had	O
a	O
clinically	O
significant	O
>	O
or	O
=	O
15	O
%	O
change	O
in	O
the	O
INR	O
while	O
receiving	O
either	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
,	O
4	O
showed	O
this	O
change	O
for	O
both	O
agents	O
.	O

Adverse	O
drug	O
reactions	O
were	O
similar	O
for	O
each	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
,	O
but	O
the	O
rate	O
of	O
edema	O
requiring	O
medical	O
intervention	O
was	O
higher	O
in	O
the	O
rofecoxib	S-chem
group	O
.	O

Significant	O
increases	O
in	O
the	O
INR	O
were	O
observed	O
in	O
patients	O
who	O
were	O
stable	O
on	O
warfarin	S-chem
therapy	O
after	O
the	O
addition	O
of	O
therapy	O
with	O
rofecoxib	S-chem
or	O
celecoxib	S-chem
.	O

Thalidomide	S-chem
in	O
multiple	O
myeloma	O
.	O

Thalidomide	S-chem-C4-1
-	O
-	O
removed	O
from	O
widespread	O
clinical	O
use	O
by	O
1962	O
because	O
of	O
severe	O
teratogenicity	O
-	O
-	O
has	O
anti	O
-	O
angiogenic	O
and	O
immunomodulatory	O
effects	O
,	O
including	O
the	O
inhibition	O
of	O
TNF	B-geneY-C4-2
alpha	E-geneY-C4-2
.	O

It	O
has	O
returned	O
to	O
practice	O
as	O
an	O
effective	O
oral	O
agent	O
in	O
the	O
management	O
of	O
various	O
disease	O
states	O
including	O
erythema	O
nodosum	O
leprosum	O
,	O
for	O
which	O
it	O
was	O
FDA	O
-	O
approved	O
in	O
1998	O
,	O
and	O
more	O
recently	O
certain	O
malignancies	O
,	O
including	O
multiple	O
myeloma	O
.	O

Whilst	O
the	O
mechanism	O
of	O
action	O
of	O
thalidomide	S-chem
remains	O
incompletely	O
understood	O
,	O
considerable	O
insight	O
has	O
been	O
generated	O
by	O
extensive	O
preclinical	O
studies	O
in	O
multiple	O
myeloma	O
.	O

Moreover	O
,	O
clinical	O
trials	O
both	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
have	O
confirmed	O
benefit	O
in	O
relapsed	O
and	O
refractory	O
disease	O
.	O

Thalidomide	O
's	O
role	O
in	O
treating	O
newly	O
diagnosed	O
patients	O
is	O
currently	O
under	O
study	O
and	O
it	O
is	O
now	O
established	O
as	O
an	O
important	O
therapeutic	O
option	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O

Prenatal	O
exposure	O
to	O
bisphenol	B-chem
A	E-chem
impacts	O
midbrain	O
dopamine	S-chem
neurons	O
and	O
hippocampal	O
spine	O
synapses	O
in	O
non	O
-	O
human	O
primates	O
.	O

Prevalent	O
use	O
of	O
bisphenol	B-chem
-	I-chem
A	E-chem
(	O
BPA	S-chem
)	O
in	O
the	O
manufacture	O
of	O
resins	O
,	O
plastics	O
and	O
paper	O
products	O
has	O
led	O
to	O
frequent	O
exposure	O
of	O
most	O
people	O
to	O
this	O
endocrine	O
disruptor	O
.	O

Some	O
rodent	O
studies	O
have	O
suggested	O
that	O
BPA	S-chem
can	O
exert	O
detrimental	O
effects	O
on	O
brain	O
development	O
.	O

However	O
as	O
rodent	O
models	O
can	O
not	O
be	O
relied	O
on	O
to	O
predict	O
consequences	O
of	O
human	O
exposure	O
to	O
BPA	S-chem
during	O
development	O
,	O
it	O
is	O
important	O
to	O
investigate	O
the	O
effects	O
of	O
BPA	S-chem
on	O
non	O
-	O
human	O
primate	O
brain	O
development	O
.	O

Previous	O
research	O
suggests	O
that	O
BPA	S-chem
preferentially	O
targets	O
dopamine	S-chem
neurons	O
in	O
ventral	O
mesencephalon	O
and	O
glutamatergic	O
neurons	O
in	O
hippocampus	O
,	O
so	O
the	O
present	O
work	O
examined	O
the	O
susceptibility	O
of	O
these	O
systems	O
to	O
low	O
dose	O
BPA	S-chem
exposure	O
at	O
the	O
fetal	O
and	O
juvenile	O
stages	O
of	O
development	O
in	O
non	O
-	O
human	O
primates	O
.	O

Exposure	O
of	O
pregnant	O
rhesus	O
monkeys	O
to	O
relatively	O
low	O
levels	O
of	O
BPA	S-chem
during	O
the	O
final	O
2	O
months	O
of	O
gestation	O
,	O
induced	O
abnormalities	O
in	O
fetal	O
ventral	O
mesencephalon	O
and	O
hippocampus	O
.	O

Specifically	O
,	O
light	O
microscopy	O
revealed	O
a	O
decrease	O
in	O
tyrosine	B-geneN
hydroxylase	E-geneN
-	O
expressing	O
(	O
dopamine	S-chem
)	O
neurons	O
in	O
the	O
midbrain	O
of	O
BPA	S-chem
-	O
exposed	O
fetuses	O
and	O
electron	O
microscopy	O
identified	O
a	O
reduction	O
in	O
spine	O
synapses	O
in	O
the	O
CA1	O
region	O
of	O
hippocampus	O
.	O

In	O
contrast	O
,	O
administration	O
of	O
BPA	S-chem
to	O
juvenile	O
vervet	O
monkeys	O
(	O
14	O
-	O
18	O
months	O
of	O
age	O
)	O
was	O
without	O
effect	O
on	O
these	O
indices	O
,	O
or	O
on	O
dopamine	S-chem
and	O
serotonin	S-chem
concentrations	O
in	O
striatum	O
and	O
prefrontal	O
cortex	O
,	O
or	O
on	O
performance	O
of	O
a	O
cognitive	O
task	O
that	O
tests	O
working	O
memory	O
capacity	O
.	O

These	O
data	O
indicate	O
that	O
BPA	S-chem
exerts	O
an	O
age	O
-	O
dependent	O
detrimental	O
impact	O
on	O
primate	O
brain	O
development	O
,	O
at	O
blood	O
levels	O
within	O
the	O
range	O
measured	O
in	O
humans	O
having	O
only	O
environmental	O
contact	O
with	O
BPA	S-chem
.	O

Hyperphagia	O
alters	O
expression	O
of	O
hypothalamic	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
genes	O
and	O
plasma	O
des	B-geneY
-	I-geneY
acyl	I-geneY
ghrelin	E-geneY
levels	O
in	O
Ay	O
mice	O
.	O

The	O
central	O
melanocortin	S-geneY
(	O
MC	S-geneY
)	O
pathway	O
is	O
suggested	O
to	O
mediate	O
satiety	O
signaling	O
downstream	O
of	O
serotonin	B-geneY
(	I-geneY
5	I-geneY
-	I-geneY
HT	I-geneY
)	I-geneY
2C	I-geneY
receptors	E-geneY
.	O

5	B-geneY
-	I-geneY
HT2C	E-geneY
receptor	O
mutant	O
mice	O
consume	O
more	O
food	O
,	O
which	O
leads	O
to	O
late	O
-	O
onset	O
obesity	O
and	O
impaired	O
glucose	S-chem
tolerance	O
.	O

Ay	O
mice	O
with	O
ectopic	O
expression	O
of	O
the	O
agouti	B-geneY
peptide	E-geneY
,	O
which	O
leads	O
to	O
a	O
perturbation	O
of	O
the	O
central	O
MC	S-geneY
pathway	O
,	O
develop	O
obesity	O
and	O
diabetes	O
,	O
associated	O
with	O
low	O
levels	O
of	O
plasma	O
total	O
ghrelin	S-geneY
.	O

Here	O
,	O
we	O
report	O
that	O
5	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
consumed	O
more	O
food	O
in	O
association	O
with	O
decreases	O
in	O
levels	O
of	O
plasma	O
des	B-geneY
-	I-geneY
acyl	I-geneY
ghrelin	E-geneY
,	O
but	O
not	O
active	O
ghrelin	S-geneY
,	O
and	O
increases	O
in	O
hypothalamic	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
gene	O
expression	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
matched	O
for	O
age	O
and	O
body	O
weight	O
.	O

These	O
alterations	O
were	O
also	O
observed	O
in	O
8	O
-	O
wk	O
-	O
old	O
obese	O
Ay	O
mice	O
.	O

Restricted	O
feeding	O
significantly	O
decreased	O
hypothalamic	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
gene	O
expression	O
in	O
association	O
with	O
a	O
reversal	O
of	O
the	O
decreases	O
in	O
plasma	O
des	B-geneY
-	I-geneY
acyl	I-geneY
ghrelin	E-geneY
levels	O
in	O
5	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
.	O

Moreover	O
,	O
restricted	O
feeding	O
reduced	O
body	O
weight	O
,	O
hyperinsulinemia	O
,	O
and	O
hyperglycemia	O
in	O
association	O
with	O
increases	O
in	O
plasma	O
des	B-geneY
-	I-geneY
acyl	I-geneY
ghrelin	E-geneY
levels	O
in	O
8	O
-	O
wk	O
-	O
old	O
obese	O
Ay	O
mice	O
.	O

Administration	O
of	O
m	B-chem
-	I-chem
chlorophenylpiperazine	E-chem
and	O
fenfluramine	S-chem
,	O
both	O
of	O
which	O
induce	O
anorexic	O
effects	O
via	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
receptors	O
and	O
/	O
or	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
,	O
suppressed	O
food	O
intake	O
in	O
5	O
-	O
and	O
8	O
-	O
wk	O
-	O
old	O
Ay	O
mice	O
,	O
whereas	O
the	O
anorexic	O
effects	O
were	O
attenuated	O
in	O
food	O
-	O
restricted	O
Ay	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
agouti	B-geneY
peptide	E-geneY
down	O
-	O
regulates	O
hypothalamic	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptor	O
gene	O
expression	O
under	O
restricted	O
feeding	O
conditions	O
,	O
whereas	O
chronic	O
hyperphagia	O
increases	O
the	O
expression	O
of	O
these	O
genes	O
and	O
decreases	O
plasma	O
des	B-geneY
-	I-geneY
acyl	I-geneY
ghrelin	E-geneY
levels	O
in	O
Ay	O
mice	O
.	O

Functional	O
imaging	O
of	O
legumain	S-geneY
in	O
cancer	O
using	O
a	O
new	O
quenched	O
activity	O
-	O
based	O
probe	O
.	O

Legumain	S-geneY
is	O
a	O
lysosomal	O
cysteine	B-geneN
protease	E-geneN
whose	O
biological	O
function	O
remains	O
poorly	O
defined	O
.	O

Legumain	S-geneY
activity	O
is	O
up	O
-	O
regulated	O
in	O
most	O
human	O
cancers	O
and	O
inflammatory	O
diseases	O
most	O
likely	O
as	O
the	O
result	O
of	O
high	O
expression	O
in	O
populations	O
of	O
activated	O
macrophages	O
.	O

Within	O
the	O
tumor	O
microenvironment	O
,	O
legumain	S-geneY
activity	O
is	O
thought	O
to	O
promote	O
tumorigenesis	O
.	O

To	O
obtain	O
a	O
greater	O
understanding	O
of	O
the	O
role	O
of	O
legumain	S-geneY
activity	O
during	O
cancer	O
progression	O
and	O
inflammation	O
,	O
we	O
developed	O
an	O
activity	O
-	O
based	O
probe	O
that	O
becomes	O
fluorescent	O
only	O
upon	O
binding	O
active	O
legumain	S-geneY
.	O

This	O
probe	O
is	O
highly	O
selective	O
for	O
legumain	S-geneY
,	O
even	O
in	O
the	O
context	O
of	O
whole	O
cells	O
and	O
tissues	O
,	O
and	O
is	O
also	O
a	O
more	O
effective	O
label	O
of	O
legumain	O
than	O
previously	O
reported	O
probes	O
.	O

Here	O
we	O
present	O
the	O
synthesis	O
and	O
application	O
of	O
our	O
probe	O
to	O
the	O
analysis	O
of	O
legumain	S-geneY
activity	O
in	O
primary	O
macrophages	O
and	O
in	O
two	O
mouse	O
models	O
of	O
cancer	O
.	O

We	O
find	O
that	O
legumain	S-geneY
activity	O
is	O
highly	O
correlated	O
with	O
macrophage	O
activation	O
and	O
furthermore	O
that	O
it	O
is	O
an	O
ideal	O
marker	O
for	O
primary	O
tumor	O
inflammation	O
and	O
early	O
stage	O
metastatic	O
lesions	O
.	O

Lessons	O
from	O
the	O
dissection	O
of	O
the	O
activation	B-geneN
functions	E-geneN
(	O
AF	B-geneN
-	I-geneN
1	E-geneN
and	O
AF	B-geneN
-	I-geneN
2	E-geneN
)	O
of	O
the	O
estrogen	B-geneY
receptor	I-geneY
alpha	E-geneY
in	O
vivo	O
.	O

Estrogens	S-chem
influence	O
most	O
of	O
the	O
physiological	O
processes	O
in	O
mammals	O
,	O
including	O
but	O
not	O
limited	O
to	O
reproduction	O
,	O
cognition	O
,	O
behavior	O
,	O
vascular	O
system	O
,	O
metabolism	O
and	O
bone	O
integrity	O
.	O

Given	O
this	O
widespread	O
role	O
for	O
estrogen	S-chem
in	O
human	O
physiology	O
,	O
it	O
is	O
not	O
surprising	O
that	O
estrogen	S-chem
influence	O
the	O
pathophysiology	O
of	O
numerous	O
diseases	O
,	O
including	O
cancer	O
(	O
of	O
the	O
reproductive	O
tract	O
as	O
breast	O
,	O
endometrial	O
but	O
also	O
colorectal	O
,	O
prostate	O
,	O
…	O
)	O
,	O
as	O
well	O
as	O
neurodegenerative	O
,	O
inflammatory	O
-	O
immune	O
,	O
cardiovascular	O
and	O
metabolic	O
diseases	O
,	O
and	O
osteoporosis	O
.	O

These	O
actions	O
are	O
mediated	O
by	O
the	O
activation	O
of	O
estrogen	B-geneN
receptors	I-geneN
(	I-geneN
ER	I-geneN
)	I-geneN
alpha	I-geneN
(	I-geneN
ERα	I-geneN
)	I-geneN
and	I-geneN
beta	E-geneN
(	O
ERβ	S-geneY
)	O
,	O
which	O
regulate	O
target	O
gene	O
transcription	O
(	O
genomic	O
action	O
)	O
through	O
two	O
independent	O
activation	B-geneN
functions	E-geneN
(	B-geneN
AF	I-geneN
)	I-geneN
-	I-geneN
1	E-geneN
and	O
AF	B-geneN
-	I-geneN
2	E-geneN
,	O
but	O
can	O
also	O
elicit	O
rapid	O
membrane	O
initiated	O
steroid	S-chem
signals	O
(	O
MISS	O
)	O
.	O

Targeted	O
ER	S-geneY
gene	O
inactivation	O
has	O
shown	O
that	O
although	O
ERβ	S-geneY
plays	O
an	O
important	O
role	O
in	O
the	O
central	O
nervous	O
system	O
and	O
in	O
the	O
heart	O
,	O
ERα	S-geneY
appears	O
to	O
play	O
a	O
prominent	O
role	O
in	O
most	O
of	O
the	O
other	O
tissues	O
.	O

Pharmacological	O
activation	O
or	O
inhibition	O
of	O
ERα	S-geneY
and	O
/	O
or	O
ERβ	S-geneY
provides	O
already	O
the	O
basis	O
for	O
many	O
therapeutic	O
interventions	O
,	O
from	O
hormone	O
replacement	O
at	O
menopause	O
to	O
prevention	O
of	O
the	O
recurrence	O
of	O
breast	O
cancer	O
.	O

However	O
,	O
the	O
use	O
of	O
these	O
estrogens	S-chem
or	O
selective	O
estrogen	B-geneY
receptors	E-geneY
modulators	O
(	O
SERMs	O
)	O
have	O
also	O
induced	O
undesired	O
effects	O
.	O

Thus	O
,	O
an	O
important	O
challenge	O
consists	O
now	O
to	O
uncouple	O
the	O
beneficial	O
actions	O
from	O
other	O
deleterious	O
ones	O
.	O

The	O
in	O
vivo	O
molecular	O
``	O
dissection	O
``	O
of	B-geneY
ERα	O
represents	O
both	O
a	O
molecular	O
and	O
integrated	O
approach	O
that	O
already	O
allowed	O
to	O
delineate	O
in	O
mouse	O
the	O
role	O
of	O
the	O
main	O
``	O
subfunctions	O
``	O
of	O
the	O
receptor	O
and	O
that	O
could	O
pave	O
the	O
way	O
to	O
an	O
optimization	O
of	O
the	O
ER	O
modulation	O
.	O

The	O
impact	O
of	O
oxytocin	S-geneY
administration	O
and	O
maternal	O
love	O
withdrawal	O
on	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
responses	O
to	O
emotional	O
faces	O
with	O
performance	O
feedback	O
.	O

This	O
is	O
the	O
first	O
experimental	O
study	O
on	O
the	O
effect	O
of	O
oxytocin	S-geneY
administration	O
on	O
the	O
neural	O
processing	O
of	O
facial	O
stimuli	O
conducted	O
with	O
female	O
participants	O
that	O
uses	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O

Using	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
within	O
-	O
subjects	O
design	O
,	O
we	O
studied	O
the	O
effects	O
of	O
16	O
IU	O
of	O
intranasal	O
oxytocin	S-geneY
on	O
ERPs	O
to	O
pictures	O
combining	O
performance	O
feedback	O
with	O
emotional	O
facial	O
expressions	O
in	O
48	O
female	O
undergraduate	O
students	O
.	O

Participants	O
also	O
reported	O
on	O
the	O
amount	O
of	O
love	O
withdrawal	O
they	O
experienced	O
from	O
their	O
mothers	O
.	O

Vertex	O
positive	O
potential	O
(	O
VPP	O
)	O
and	O
late	O
positive	O
potential	O
(	O
LPP	O
)	O
amplitudes	O
were	O
more	O
positive	O
after	O
oxytocin	S-geneY
compared	O
to	O
placebo	O
administration	O
.	O

This	O
suggests	O
that	O
oxytocin	S-geneY
increased	O
attention	O
to	O
the	O
feedback	O
stimuli	O
(	O
LPP	O
)	O
and	O
enhanced	O
the	O
processing	O
of	O
emotional	O
faces	O
(	O
VPP	O
)	O
.	O

Oxytocin	S-geneY
heightened	O
processing	O
of	O
the	O
happy	O
and	O
disgusted	O
faces	O
primarily	O
for	O
those	O
reporting	O
less	O
love	O
withdrawal	O
.	O

Significant	O
associations	O
with	O
LPP	O
amplitude	O
suggest	O
that	O
more	O
maternal	O
love	O
withdrawal	O
relates	O
to	O
the	O
allocation	O
of	O
attention	O
toward	O
the	O
motivationally	O
relevant	O
combination	O
of	O
negative	O
feedback	O
with	O
a	O
disgusted	O
face	O
.	O

In	O
vitro	O
inhibitory	O
effects	O
of	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
on	O
4	B-chem
-	I-chem
methylumbelliferone	E-chem
glucuronidation	O
in	O
recombinant	O
human	B-geneY-C4-2
UDP	I-geneY-C4-2
-	I-geneY-C4-2
glucuronosyltransferase	I-geneY-C4-2
1A9	E-geneY-C4-2
-	O
-	O
potent	O
inhibition	O
by	O
niflumic	B-chem-C4-1
acid	E-chem-C4-1
.	O

The	O
inhibitory	O
potencies	O
of	O
non	O
-	O
steroidal	S-chem
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
on	O
UDP	B-geneY
-	I-geneY
glucuronosyltransferase	I-geneY
(	I-geneY
UGT	I-geneY
)	I-geneY
1A9	E-geneY
activity	O
were	O
investigated	O
in	O
recombinant	O
human	B-geneY
UGT1A9	E-geneY
using	O
4	B-chem
-	I-chem
methylumbelliferone	E-chem
(	O
4	B-chem
-	I-chem
MU	E-chem
)	O
as	O
a	O
substrate	O
for	O
glucuronidation	O
.	O

4	B-chem
-	I-chem
MU	E-chem
glucuronidation	O
(	O
4	O
-	O
MUG	O
)	O
showed	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
a	O
Km	O
value	O
of	O
6.7	O
microM	O
.	O

The	O
inhibitory	O
effects	O
of	O
the	O
following	O
seven	O
NSAIDs	O
were	O
investigated	O
:	O
acetaminophen	S-chem
,	O
diclofenac	S-chem
,	O
diflunisal	S-chem
,	O
indomethacin	S-chem
,	O
ketoprofen	S-chem
,	O
naproxen	S-chem
and	O
niflumic	B-chem
acid	E-chem
.	O

Niflumic	B-chem
acid	E-chem
had	O
the	O
most	O
potent	O
inhibitory	O
effect	O
on	O
4	O
-	O
MUG	O
with	O
an	O
IC50	O
value	O
of	O
0.0341	O
microM	O
.	O

The	O
IC50	O
values	O
of	O
diflunisal	S-chem
,	O
diclofenac	S-chem
and	O
indomethacin	S-chem
were	O
1.31	O
,	O
24.2	O
,	O
and	O
34.1	O
microM	O
,	O
respectively	O
,	O
while	O
acetaminophen	S-chem
,	O
ketoprofen	S-chem
and	O
naproxen	S-chem
showed	O
less	O
potent	O
inhibition	O
.	O

Niflumic	B-chem
acid	E-chem
,	O
diflunisal	S-chem
,	O
diclofenac	S-chem
and	O
indomethacin	S-chem
inhibited	O
4	O
-	O
MUG	O
competitively	O
with	O
Ki	O
values	O
of	O
0.0275	O
,	O
0.710	O
,	O
53.3	O
and	O
69.9	O
microM	O
,	O
respectively	O
,	O
being	O
similar	O
to	O
each	O
IC50	O
value	O
.	O

In	O
conclusion	O
,	O
of	O
the	O
seven	O
NSAIDs	O
investigated	O
,	O
niflumic	B-chem-C4-1
acid	E-chem-C4-1
was	O
the	O
most	O
potent	O
inhibitor	O
of	O
recombinant	O
UGT1A9	S-geneY-C4-2
via	O
4	O
-	O
MUG	O
in	O
a	O
competitive	O
manner	O
.	O

An	O
engineered	O
human	B-geneY
follistatin	E-geneY
variant	O
:	O
insights	O
into	O
the	O
pharmacokinetic	O
and	O
pharmocodynamic	O
relationships	O
of	O
a	O
novel	O
molecule	O
with	O
broad	O
therapeutic	O
potential	O
.	O

Human	B-geneY
follistatin	E-geneY
is	O
a	O
regulatory	O
glycoprotein	O
with	O
widespread	O
biologic	O
functions	O
,	O
including	O
antiinflammatory	O
activities	O
,	O
wound	O
-	O
healing	O
properties	O
,	O
and	O
muscle	O
-	O
stimulating	O
effects	O
.	O

The	O
role	O
of	O
follistatin	S-geneY
in	O
a	O
wide	O
range	O
of	O
biologic	O
activities	O
shows	O
promise	O
for	O
potential	O
clinical	O
application	O
,	O
which	O
has	O
prompted	O
considerable	O
interest	O
in	O
the	O
investigation	O
of	O
the	O
protein	O
as	O
a	O
potential	O
disease	O
-	O
modifying	O
agent	O
.	O

In	O
spite	O
of	O
this	O
potential	O
,	O
the	O
development	O
of	O
follistatin	S-geneY
as	O
a	O
broad	O
use	O
biotherapeutic	O
has	O
been	O
severely	O
hindered	O
by	O
a	O
poor	O
understanding	O
and	O
characterization	O
of	O
its	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK	O
/	O
PD	O
)	O
relationships	O
.	O

Therefore	O
,	O
to	O
better	O
define	O
these	O
relationships	O
,	O
we	O
performed	O
in	O
-	O
depth	O
analyses	O
of	O
the	O
PK	O
/	O
PD	O
relationships	O
of	O
native	O
follistatin	B-geneY
-	I-geneY
315	E-geneY
(	O
FST315	S-geneY
)	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
intrinsic	O
PK	O
/	O
PD	O
properties	O
of	O
native	O
FST315	S-geneY
are	O
poorly	O
suited	O
for	O
acting	O
as	O
a	O
parentally	O
administered	O
biotherapeutic	O
with	O
broad	O
systemic	O
effects	O
.	O

Here	O
,	O
we	O
leveraged	O
protein	O
engineering	O
to	O
modify	O
the	O
PK	O
characteristics	O
of	O
the	O
native	O
molecule	O
by	O
fusing	O
FST315	S-geneY
to	O
a	O
murine	B-geneN
IgG	I-geneN
(	I-geneN
1	I-geneN
)	I-geneN
Fc	E-geneN
and	O
removing	O
the	O
intrinsic	O
heparan	O
sulfate	S-chem
-	O
binding	O
activity	O
of	O
follistatin	S-geneY
.	O

The	O
engineered	O
variant	O
molecule	O
had	O
~	O
100	O
-	O
and	O
~	O
1600	O
-	O
fold	O
improvements	O
in	O
terminal	O
half	O
-	O
life	O
and	O
exposure	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
the	O
native	O
FST315	S-geneY
,	O
the	O
variant	O
showed	O
a	O
robust	O
,	O
dose	O
-	O
dependent	O
pharmacological	O
effect	O
when	O
administered	O
subcutaneously	O
on	O
a	O
weekly	O
basis	O
in	O
mouse	O
models	O
of	O
muscle	O
atrophy	O
and	O
degeneration	O
.	O

These	O
studies	O
highlight	O
the	O
underappreciated	O
and	O
critical	O
relationship	O
between	O
optimizing	O
multiple	O
physical	O
and	O
chemical	O
properties	O
of	O
follistatin	S-geneY
on	O
its	O
overall	O
PK	O
/	O
PD	O
profile	O
.	O

Moreover	O
,	O
our	O
findings	O
provide	O
the	O
first	O
documented	O
strategy	O
toward	O
the	O
development	O
of	O
a	O
follistatin	S-geneY
therapeutic	O
with	O
potential	O
use	O
in	O
patients	O
affected	O
with	O
skeletal	O
muscle	O
diseases	O
.	O

Phospholipase	B-geneY-MU-2
A2	E-geneY-MU-2
inhibitors	O
p	B-chem-MU-1
-	I-chem-MU-1
bromophenacyl	I-chem-MU-1
bromide	E-chem-MU-1
and	O
arachidonyl	B-chem-C4-1
trifluoromethyl	I-chem-C4-1
ketone	E-chem-C4-1
suppressed	O
interleukin	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
)	O
expression	O
in	O
murine	O
primary	O
splenocytes	O
.	O

Phospholipase	B-geneY
A2	E-geneY
(	O
PLA2	S-geneY
)	O
has	O
been	O
postulated	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cytokine	S-geneN
expression	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
PLA2	S-geneY-C4-2
inhibitors	O
p	B-chem-C4-1
-	I-chem-C4-1
bromophenacyl	I-chem-C4-1
bromide	E-chem-C4-1
(	O
BPB	S-chem-C4-1
)	O
and	O
arachidonyl	B-chem-C4-1
trifluoromethyl	I-chem-C4-1
ketone	E-chem-C4-1
(	O
AACOCF3	S-chem-C4-1
)	O
on	O
interleukin	B-geneY
-	I-geneY
2	E-geneY
(	O
IL	B-geneY
-	I-geneY
2	E-geneY
)	O
expression	O
in	O
murine	O
primary	O
splenocytes	O
.	O

Pretreatment	O
of	O
the	O
splenocytes	O
with	O
both	O
BPB	S-chem-C4-1
and	O
AACOCF3	S-chem-C4-1
suppressed	O
phorbol	B-chem-C3-1
12	I-chem-C3-1
-	I-chem-C3-1
myristate	I-chem-C3-1
13	I-chem-C3-1
-	I-chem-C3-1
acetate	E-chem-C3-1
plus	O
ionomycin	O
-	O
induced	O
IL	B-geneY-MU-2
-	I-geneY-MU-2
2	E-geneY-MU-2
secretion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
>	O
90	O
%	O
of	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
secretion	O
was	O
observed	O
at	O
1	O
microM	O
BPB	S-chem-C4-1
and	O
10	O
microM	O
AACOCF3	S-chem-C4-1
compared	O
to	O
the	O
respective	O
vehicle	O
control	O
.	O

Likewise	O
,	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
steady	O
-	O
state	O
mRNA	O
expression	O
was	O
inhibited	O
by	O
both	O
PLA2	S-geneY-C4-2
inhibitors	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
with	O
>	O
90	O
%	O
inhibition	O
at	O
1	O
microM	O
BPB	S-chem-C4-1
and	O
20	O
microM	O
AACOCF3	S-chem-C4-1
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
PLA2	S-geneY-C4-2
inhibitors	O
BPB	S-chem-C4-1
and	O
AACOCF3	S-chem-C4-1
are	O
robust	O
inhibitors	O
of	O
IL	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
murine	O
splenocytes	O
.	O

Moreover	O
,	O
these	O
findings	O
suggest	O
that	O
drugs	O
and	O
chemicals	O
which	O
inhibit	O
PLA2	S-geneY
may	O
have	O
marked	O
effects	O
on	O
T	O
-	O
cell	O
function	O
.	O

Matrix	B-geneN-C4-2
Metalloproteinase	E-geneN-C4-2
Inhibitors	O
Based	O
on	O
the	O
3	B-chem-C4-1
-	I-chem-C4-1
Mercaptopyrrolidine	E-chem-C4-1
Core	O
.	O

New	O
series	O
of	O
pyrrolidine	B-chem-C4-1
mercaptosulfide	E-chem-C4-1
,	O
2	B-chem-C4-1
-	I-chem-C4-1
mercaptocyclopentane	I-chem-C4-1
arylsulfonamide	E-chem-C4-1
,	O
and	O
3	B-chem-C4-1
-	I-chem-C4-1
mercapto	I-chem-C4-1
-	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
arylsulfonamido	I-chem-C4-1
pyrrolidine	E-chem-C4-1
matrix	B-geneN-C4-2
metalloproteinase	E-geneN-C4-2
inhibitors	O
(	O
MMPIs	O
)	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
.	O

Exhibiting	O
unique	O
properties	O
over	O
other	O
MMPIs	O
(	O
e.g	O
.	O
,	O
hydroxamates	S-chem-C4-1
)	O
,	O
these	O
newly	O
reported	O
compounds	O
are	O
capable	O
of	O
modulating	O
activities	O
of	O
several	O
MMPs	S-geneN-C4-2
in	O
the	O
low	O
nanomolar	O
range	O
,	O
including	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
(	O
~	O
2	O
to	O
50	O
nM	O
)	O
,	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
13	E-geneY-C4-2
(	O
~	O
2	O
to	O
50	O
nM	O
)	O
,	O
and	O
MMP	B-geneY-C4-2
-	I-geneY-C4-2
14	E-geneY-C4-2
(	O
~	O
4	O
to	O
60	O
nM	O
)	O
.	O

Additionally	O
these	O
compounds	O
are	O
selective	O
to	O
intermediate	O
-	O
and	O
deep	O
-	O
pocket	O
MMPs	S-geneN
but	O
not	O
shallow	O
-	O
pocketed	O
MMPs	S-geneN
(	O
e.g	O
.	O
,	O
MMP	B-geneY
-	I-geneY
1	E-geneY
,	O
~	O
850	O
to	O
>	O
50,000	O
nM	O
;	O
MMP	B-geneY
-	I-geneY
7	E-geneY
,	O
~	O
4,000	O
to	O
>	O
25,000	O
nM	O
)	O
.	O

Our	O
previous	O
work	O
with	O
the	O
mercaptosulfide	S-chem
functionality	O
attached	O
to	O
both	O
cyclopentane	S-chem
and	O
pyrrolidine	S-chem
frameworks	O
demonstrated	O
that	O
the	O
cis	O
-	O
(	O
3S,4R	O
)	O
-	O
stereochemistry	O
was	O
optimal	O
for	O
all	O
of	O
the	O
MMPs	S-geneN
tested	O
.	O

However	O
,	O
in	O
our	O
newest	O
compounds	O
an	O
interesting	O
shift	O
of	O
preference	O
to	O
the	O
trans	O
-	O
form	O
of	O
the	O
mercaptosulfonamides	S-chem
was	O
observed	O
with	O
increased	O
oxidative	O
stability	O
and	O
biological	O
compatibility	O
.	O

We	O
also	O
report	O
several	O
kinetic	O
and	O
biological	O
characteristics	O
showing	O
that	O
these	O
compounds	O
may	O
be	O
used	O
to	O
probe	O
the	O
mechanistic	O
activities	O
of	O
MMPs	S-geneN
in	O
disease	O
.	O

Conversion	O
of	O
5	B-geneN
-	I-geneN
aminolevulinate	I-geneN
synthase	E-geneN
into	O
a	O
more	O
active	O
enzyme	O
by	O
linking	O
the	O
two	O
subunits	O
:	O
spectroscopic	O
and	O
kinetic	O
properties	O
.	O

The	O
two	O
active	O
sites	O
of	O
dimeric	O
5	B-geneN
-	I-geneN
aminolevulinate	I-geneN
synthase	E-geneN
(	O
ALAS	S-geneN
)	O
,	O
a	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
-	O
dependent	O
enzyme	O
,	O
are	O
located	O
on	O
the	O
subunit	O
interface	O
with	O
contribution	O
of	O
essential	O
amino	B-chem
acids	E-chem
from	O
each	O
subunit	O
.	O

Linking	O
the	O
two	O
subunits	O
into	O
a	O
single	O
polypeptide	O
chain	O
dimer	O
(	O
2XALAS	S-geneN
)	O
yielded	O
an	O
enzyme	O
with	O
an	O
approximate	O
sevenfold	O
greater	O
turnover	O
number	O
than	O
that	O
of	O
wild	O
-	O
type	O
ALAS	S-geneN
.	O

Spectroscopic	O
and	O
kinetic	O
properties	O
of	O
2XALAS	S-geneN
were	O
investigated	O
to	O
explore	O
the	O
differences	O
in	O
the	O
coenzyme	O
structure	O
and	O
kinetic	O
mechanism	O
relative	O
to	O
those	O
of	O
wild	O
-	O
type	O
ALAS	S-geneN
that	O
confer	O
a	O
more	O
active	O
enzyme	O
.	O

The	O
absorption	O
spectra	O
of	O
both	O
ALAS	S-geneN
and	O
2XALAS	S-geneN
had	O
maxima	O
at	O
410	O
and	O
330	O
nm	O
,	O
with	O
a	O
greater	O
A	O
(	O
410	O
)	O
/	O
A	O
(	O
330	O
)	O
ratio	O
at	O
pH	O
approximately	O
7.5	O
for	O
2XALAS	S-geneN
.	O

The	O
330	O
nm	O
absorption	O
band	O
showed	O
an	O
intense	O
fluorescence	O
at	O
385	O
nm	O
but	O
not	O
at	O
510	O
nm	O
,	O
indicating	O
that	O
the	O
330	O
nm	O
absorption	O
species	O
is	O
the	O
substituted	O
aldamine	S-chem
rather	O
than	O
the	O
enolimine	S-chem
form	O
of	O
the	O
Schiff	B-chem
base	E-chem
.	O

The	O
385	O
nm	O
emission	O
intensity	O
increased	O
with	O
increasing	O
pH	O
with	O
a	O
single	O
pK	O
of	O
approximately	O
8.5	O
for	O
both	O
enzymes	O
,	O
and	O
thus	O
the	O
410	O
and	O
330	O
nm	O
absorption	O
species	O
were	O
attributed	O
to	O
the	O
ketoenamine	S-chem
and	O
substituted	O
aldamine	S-chem
,	O
respectively	O
.	O

Transient	O
kinetic	O
analysis	O
of	O
the	O
formation	O
and	O
decay	O
of	O
the	O
quinonoid	S-chem
intermediate	O
EQ	O
(	O
2	O
)	O
indicated	O
that	O
,	O
although	O
their	O
rates	O
were	O
similar	O
in	O
ALAS	S-geneN
and	O
2XALAS	S-geneN
,	O
accumulation	O
of	O
this	O
intermediate	O
was	O
greater	O
in	O
the	O
2XALAS	S-geneN
-	O
catalyzed	O
reaction	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
ketoenamine	S-chem
is	O
the	O
active	O
form	O
of	O
the	O
coenzyme	O
and	O
forms	O
a	O
more	O
prominent	O
coenzyme	O
structure	O
in	O
2XALAS	S-geneN
than	O
in	O
ALAS	S-geneN
at	O
pH	O
approximately	O
7.5	O
.	O

Antioxidant	O
activity	O
of	O
phytosteryl	B-chem
phenolates	E-chem
in	O
different	O
model	O
systems	O
.	O

As	O
part	O
of	O
a	O
comprehensive	O
study	O
of	O
the	O
physiochemical	O
and	O
biological	O
properties	O
of	O
phytosteryl	B-chem
phenolates	E-chem
,	O
successfully	O
synthesized	O
chemoenzymatically	O
in	O
our	O
lab	O
,	O
their	O
antioxidant	O
activity	O
was	O
evaluated	O
using	O
three	O
different	O
in	O
vitro	O
model	O
systems	O
,	O
namely	O
bulk	O
oil	O
model	O
system	O
,	O
β	B-chem
-	I-chem
carotene	E-chem
-	O
linoleate	S-chem
model	O
system	O
and	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
cholesterol	S-chem
(	O
LDL	S-geneN
-	O
C	O
)	O
oxidation	O
assay	O
.	O

In	O
the	O
bulk	O
oil	O
system	O
,	O
phytosteryl	B-chem
phenolates	E-chem
showed	O
similar	O
or	O
lower	O
antioxidant	O
activity	O
compared	O
with	O
those	O
of	O
phenolic	B-chem
acids	E-chem
.	O

However	O
,	O
in	O
β	B-chem
-	I-chem
carotene	E-chem
-	O
linoleate	S-chem
assay	O
,	O
an	O
emulsion	O
model	O
system	O
,	O
phytosteryl	B-chem
phenolates	E-chem
showed	O
enhanced	O
antioxidant	O
activity	O
except	O
phytosteryl	B-chem
ferulates	E-chem
.	O

Moderate	O
inhibitory	O
effect	O
of	O
LDL	S-geneN-C4-2
-	O
C	O
oxidation	O
by	O
phytosteryl	B-chem-C4-1
phenolates	E-chem-C4-1
was	O
observed	O
.	O

These	O
findings	O
demonstrate	O
that	O
use	O
of	O
multidimensional	O
antioxidant	O
activity	O
determinations	O
with	O
differing	O
reaction	O
mechanisms	O
is	O
necessary	O
to	O
provide	O
an	O
overall	O
understanding	O
of	O
the	O
mechanisms	O
of	O
antioxidant	O
action	O
of	O
phytosteryl	B-chem
phenolates	E-chem
.	O

Effect	O
of	O
antidepressant	O
drugs	O
in	O
mice	O
lacking	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
.	O

One	O
of	O
the	O
main	O
theories	O
concerning	O
the	O
mechanism	O
of	O
action	O
of	O
antidepressant	O
drugs	O
(	O
ADs	O
)	O
is	O
based	O
on	O
the	O
notion	O
that	O
the	O
neurochemical	O
background	O
of	O
depression	O
involves	O
an	O
impairment	O
of	O
central	O
noradrenergic	O
transmission	O
with	O
a	O
concomitant	O
decrease	O
of	O
the	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
in	O
the	O
synaptic	O
gap	O
.	O

Many	O
ADs	O
increase	O
synaptic	O
NE	S-chem
availability	O
by	O
inhibition	O
of	O
the	O
reuptake	O
of	O
NE	S-chem
.	O

Using	O
mice	O
lacking	O
NE	B-geneY
transporter	E-geneY
(	O
NET	S-geneY
-	O
/	O
-	O
)	O
we	O
examined	O
their	O
baseline	O
phenotype	O
as	O
well	O
as	O
the	O
response	O
in	O
the	O
forced	O
swim	O
test	O
(	O
FST	O
)	O
and	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
upon	O
treatment	O
with	O
ADs	O
that	O
display	O
different	O
pharmacological	O
profiles	O
.	O

In	O
both	O
tests	O
,	O
the	O
NET	S-geneY
-	O
/	O
-	O
mice	O
behaved	O
like	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
acutely	O
treated	O
with	O
ADs	O
.	O

Autoradiographic	O
studies	O
showed	O
decreased	O
binding	O
of	O
the	O
beta	O
-	O
adrenergic	O
ligand	O
[	B-chem
3H	I-chem
]	I-chem
CGP12177	E-chem
in	O
the	O
cerebral	O
cortex	O
of	O
NET	S-geneY
-	O
/	O
-	O
mice	O
,	O
indicating	O
the	O
changes	O
at	O
the	O
level	O
of	O
beta	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
similar	O
to	O
those	O
obtained	O
with	O
ADs	O
treatment	O
.	O

The	O
binding	O
of	O
[	B-chem
3H	I-chem
]	I-chem
prazosin	E-chem
to	O
alpha1	B-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
in	O
the	O
cerebral	O
cortex	O
of	O
NET	S-geneY
-	O
/	O
-	O
mice	O
was	O
also	O
decreased	O
,	O
most	O
probably	O
as	O
an	O
adaptive	O
response	O
to	O
the	O
sustained	O
elevation	O
of	O
extracellular	O
NE	S-chem
levels	O
observed	O
in	O
these	O
mice	O
.	O

A	O
pronounced	O
NET	S-geneY
knockout	O
-	O
induced	O
shortening	O
of	O
the	O
immobility	O
time	O
in	O
the	O
TST	O
(	O
by	O
ca	O
50	O
%	O
)	O
compared	O
to	O
WT	O
mice	O
was	O
not	O
reduced	O
any	O
further	O
by	O
NET	S-geneY-C4-2
-	O
inhibiting	O
ADs	O
such	O
as	O
reboxetine	S-chem-C4-1
,	O
desipramine	S-chem-C4-1
,	O
and	O
imipramine	S-chem-C4-1
.	O

Citalopram	S-chem
,	O
which	O
is	O
devoid	O
of	O
affinity	O
for	O
the	O
NET	S-geneY
,	O
exerted	O
a	O
significant	O
reduction	O
of	O
immobility	O
time	O
in	O
the	O
NET	S-geneY
-	O
/	O
-	O
mice	O
.	O

In	O
the	O
FST	O
,	O
reboxetine	S-chem
,	O
desipramine	S-chem
,	O
imipramine	S-chem
,	O
and	O
citalopram	S-chem
administered	O
acutely	O
did	O
not	O
reduce	O
any	O
further	O
the	O
immobility	O
time	O
shortened	O
by	O
NET	S-geneY
knockout	O
itself	O
(	O
ca	O
25	O
%	O
)	O
;	O
however	O
,	O
antidepressant	O
-	O
like	O
action	O
of	O
repeatedly	O
(	O
7	O
days	O
)	O
administered	O
desipramine	S-chem
was	O
observed	O
in	O
NET	S-geneY
-	O
/	O
-	O
mice	O
,	O
indicating	O
that	O
the	O
chronic	O
presence	O
of	O
this	O
drug	O
may	O
also	O
affect	O
other	O
neurochemical	O
targets	O
involved	O
in	O
the	O
behavioral	O
reactions	O
monitored	O
by	O
this	O
test	O
.	O

From	O
the	O
present	O
study	O
,	O
it	O
may	O
be	O
concluded	O
that	O
mice	O
lacking	O
the	O
NET	S-geneY
may	O
represent	O
a	O
good	O
model	O
of	O
some	O
aspects	O
of	O
depression	O
-	O
resistant	O
behavior	O
,	O
paralleled	O
with	O
alterations	O
in	O
the	O
expression	O
of	O
adrenergic	B-geneN
receptors	E-geneN
,	O
which	O
result	O
as	O
an	O
adaptation	O
to	O
elevated	O
levels	O
of	O
extracellular	O
NE	S-chem
.	O

Protective	O
effect	O
of	O
ethyl	B-chem
acetate	E-chem
fraction	O
of	O
Acacia	O
ferruginea	O
DC	O
.	O
against	O
ethanol	S-chem
-	O
induced	O
gastric	O
ulcer	O
in	O
rats	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
In	O
traditional	O
systems	O
of	O
medicine	O
,	O
stem	O
bark	O
of	O
Acacia	O
ferruginea	O
DC	O
.	O
is	O
used	O
for	O
the	O
treatment	O
of	O
itching	O
,	O
leucoderma	O
,	O
ulcers	O
,	O
stomatitis	O
and	O
diseases	O
of	O
the	O
blood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
antioxidant	O
and	O
anti	O
-	O
ulcerogenic	O
activities	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Acetone	S-chem
extract	O
and	O
its	O
sub	O
-	O
fractions	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
were	O
subjected	O
to	O
assess	O
their	O
antioxidant	O
potential	O
using	O
various	O
in	O
vitro	O
systems	O
such	O
as	O
DPPH	B-chem
(	I-chem
•	I-chem
)	E-chem
,	O
ABTS	B-chem
(	I-chem
•	I-chem
+	I-chem
)	E-chem
scavenging	O
,	O
FRAP	O
and	O
phosphomolybdenum	S-chem
reduction	O
activities	O
.	O

Based	O
on	O
the	O
antioxidant	O
potential	O
,	O
the	O
ethyl	O
acetate	O
fraction	O
was	O
used	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
ethanol	S-chem
-	O
induced	O
gastric	O
damage	O
in	O
rat	O
model	O
.	O

Enzyme	O
activities	O
such	O
as	O
superoxide	B-geneN
dismutase	E-geneN
,	O
glutathione	S-chem
,	O
catalase	S-geneY
and	O
lipid	O
peroxidation	O
were	O
also	O
determined	O
in	O
the	O
stomach	O
tissues	O
.	O

RESULTS	O
:	O
Ethyl	B-chem
acetate	E-chem
fraction	O
(	O
AFE	O
)	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
registered	O
higher	O
antioxidant	O
and	O
free	O
radical	O
scavenging	O
activities	O
than	O
the	O
crude	O
acetone	S-chem
extract	O
and	O
other	O
fractions	O
.	O

In	O
addition	O
,	O
AFE	O
exhibited	O
that	O
the	O
IC50	O
values	O
of	O
DPPH	S-chem
(	O
2.5µg	O
/	O
ml	O
)	O
and	O
ABTS	S-chem
(	O
1.8µg	O
/	O
ml	O
)	O
were	O
lower	O
when	O
compared	O
to	O
the	O
standard	O
quercetin	S-chem
(	O
12.4µg	O
/	O
ml	O
and	O
4.7µg	O
/	O
ml	O
,	O
respectively	O
)	O
.	O

In	O
ethanol	S-chem
induced	O
gastric	O
ulcer	O
,	O
administration	O
of	O
AFE	O
at	O
doses	O
of	O
10mg	O
/	O
kg	O
,	O
50mg	O
/	O
kg	O
and	O
100mg	O
/	O
kg	O
body	O
weight	O
prior	O
to	O
ethanol	S-chem
ingestion	O
significantly	O
protected	O
the	O
stomach	O
ulceration	O
.	O

Consequently	O
significant	O
changes	O
were	O
observed	O
in	O
enzyme	O
activities	O
such	O
as	O
SOD	S-geneN
,	O
CAT	S-geneY
,	O
GSH	S-chem
and	O
LPO	O
in	O
the	O
stomach	O
tissues	O
when	O
compared	O
with	O
ethanol	S-chem
control	O
group	O
.	O

CONCLUSION	O
:	O
It	O
is	O
concluded	O
that	O
the	O
ethyl	B-chem
acetate	E-chem
fraction	O
of	O
Acacia	O
ferruginea	O
stem	O
bark	O
possessed	O
higher	O
antioxidant	O
and	O
anti	O
-	O
ulcerogenic	O
activities	O
.	O

Based	O
on	O
the	O
results	O
we	O
suggest	O
that	O
Acacia	O
ferruginea	O
stem	O
bark	O
has	O
potential	O
to	O
provide	O
a	O
therapeutic	O
approach	O
to	O
ethanol	S-chem
mediated	O
ulcer	O
as	O
an	O
effective	O
anti	O
-	O
ulcer	O
agent	O
.	O

High	B-geneN
density	I-geneN
lipoprotein	E-geneN
as	O
a	O
source	O
of	O
cholesterol	S-chem
for	O
adrenal	O
steroidogenesis	O
:	O
a	O
study	O
in	O
individuals	O
with	O
low	O
plasma	O
HDL	S-geneN
-	O
C	O
.	O

Few	O
studies	O
have	O
addressed	O
the	O
delivery	O
of	O
lipoprotein	S-geneN
-	O
derived	O
cholesterol	S-chem
to	O
the	O
adrenals	O
for	O
steroid	S-chem
production	O
in	O
humans	O
.	O

While	O
there	O
is	O
evidence	O
against	O
a	O
role	O
for	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
(	O
LDL	S-geneN
)	O
,	O
it	O
is	O
unresolved	O
whether	O
high	B-geneN
density	I-geneN
lipoprotein	E-geneN
(	O
HDL	S-geneN
)	O
contributes	O
to	O
adrenal	O
steroidogenesis	O
.	O

To	O
study	O
this	O
,	O
steroid	B-chem
hormone	E-chem
profiles	O
in	O
urine	O
were	O
assessed	O
in	O
male	O
subjects	O
suffering	O
from	O
functional	O
mutations	O
in	O
ATP	B-geneY
binding	I-geneY
cassette	I-geneY
transporter	I-geneY
A1	E-geneY
(	O
ABCA1	S-geneY
)	O
(	O
n	O
=	O
24	O
)	O
,	O
lecithin	B-geneY
:	I-geneY
cholesterol	I-geneY
acyltransferase	E-geneY
(	O
LCAT	S-geneY
)	O
(	O
n	O
=	O
40	O
)	O
,	O
as	O
well	O
as	O
in	O
11	O
subjects	O
with	O
low	O
HDL	S-geneN
cholesterol	S-chem
(	O
HDL	S-geneN
-	O
C	O
)	O
without	O
ABCA1	S-geneY
/	O
LCAT	S-geneY
mutations	O
.	O

HDL	S-geneN
-	O
C	O
levels	O
were	O
39	O
%	O
lower	O
in	O
the	O
ABCA1	S-geneY
,	O
LCAT	S-geneY
,	O
and	O
low	O
HDL	S-geneN
-	O
C	O
groups	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O

In	O
all	O
groups	O
with	O
low	O
HDL	S-geneN
-	O
C	O
levels	O
,	O
urinary	O
excretion	O
of	O
17	B-chem
-	I-chem
ketogenic	I-chem
steroids	E-chem
was	O
reduced	O
by	O
33	O
%	O
,	O
27	O
%	O
,	O
and	O
32	O
%	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0.04	O
)	O
.	O

In	O
seven	O
carriers	O
of	O
either	O
type	O
of	O
mutation	O
,	O
adrenocorticotropic	B-geneY
hormone	E-geneY
(	O
ACTH	S-geneY
)	O
stimulation	O
did	O
not	O
reveal	O
differences	O
from	O
normolipidemic	O
controls	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
basal	O
but	O
not	O
stimulated	O
corticosteroid	O
metabolism	O
is	O
attenuated	O
in	O
subjects	O
with	O
low	O
HDL	S-geneN
-	O
C	O
,	O
irrespective	O
of	O
its	O
molecular	O
origin	O
.	O

These	O
findings	O
lend	O
support	O
to	O
a	O
role	O
for	O
HDL	S-geneN
as	O
a	O
cholesterol	S-chem
donor	O
for	O
basal	O
adrenal	O
steroidogenesis	O
in	O
humans	O
.	O

[	O
Psychopharmacological	O
profile	O
of	O
venlafaxine	S-chem
]	O
.	O

Venlafaxine	S-chem
is	O
an	O
antidepressant	O
which	O
blocks	O
reuptake	O
of	O
noradrenaline	S-chem
and	O
serotonin	S-chem
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
dopamine	S-chem
.	O

These	O
data	O
have	O
been	O
confirmed	O
by	O
behavioral	O
tests	O
.	O

It	O
has	O
been	O
shown	O
that	O
by	O
decreasing	O
the	O
overall	O
cerebral	O
quantity	O
of	O
5	B-chem
-	I-chem
HT	E-chem
and	O
NA	S-chem
,	O
venlafaxine	S-chem
continued	O
to	O
have	O
an	O
antidepressant	O
action	O
in	O
animal	O
models	O
.	O

In	O
addition	O
,	O
the	O
drug	O
has	O
been	O
shown	O
to	O
act	O
preferentially	O
on	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
.	O

Discriminative	O
stimulus	O
effects	O
of	O
esteratic	O
local	O
anesthetics	O
in	O
squirrel	O
monkeys	O
.	O

A	O
number	O
of	O
esteratic	O
local	O
anesthetics	O
serve	O
as	O
positive	O
reinforcers	O
and	O
produce	O
cocaine	S-chem
-	O
like	O
discriminative	O
stimulus	O
effects	O
in	O
animals	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
affinity	O
of	O
these	O
compounds	O
for	O
a	O
site	O
on	O
the	O
dopamine	B-geneY
transporter	E-geneY
,	O
and	O
not	O
their	O
local	O
anesthetic	O
actions	O
,	O
is	O
responsible	O
for	O
these	O
abuse	O
-	O
related	O
behavioral	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
local	O
anesthetics	O
previously	O
shown	O
to	O
be	O
self	O
-	O
administered	O
in	O
animals	O
were	O
examined	O
in	O
squirrel	O
monkeys	O
trained	O
to	O
discriminate	O
cocaine	S-chem
(	O
0.3	O
mg	O
/	O
kg	O
)	O
from	O
saline	O
in	O
a	O
two	O
-	O
lever	O
,	O
food	O
-	O
reinforced	O
procedure	O
.	O

Dimethocaine	S-chem
(	O
0.1	O
-	O
3.0	O
mg	O
/	O
kg	O
)	O
fully	O
and	O
dose	O
-	O
dependently	O
substituted	O
for	O
cocaine	S-chem
.	O

Doses	O
of	O
dimethocaine	S-chem
(	O
1.7	O
mg	O
/	O
kg	O
)	O
and	O
cocaine	S-chem
(	O
0.3	O
mg	O
/	O
kg	O
)	O
which	O
produced	O
full	O
(	O
>	O
80	O
%	O
)	O
substitution	O
for	O
cocaine	S-chem
were	O
administered	O
in	O
combination	O
with	O
the	O
dopamine	B-geneY-C6-2
D1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
SCH	B-chem-C6-1
39166	E-chem-C6-1
(	O
(	B-chem-C6-1
-	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
trans	I-chem-C6-1
-	I-chem-C6-1
6,7,7a,8,9,13b	I-chem-C6-1
-	I-chem-C6-1
hexahydro	I-chem-C6-1
-	I-chem-C6-1
3	I-chem-C6-1
-	I-chem-C6-1
chloro	I-chem-C6-1
-	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
hydroxy	I-chem-C6-1
-	I-chem-C6-1
N	I-chem-C6-1
-	I-chem-C6-1
methyl	I-chem-C6-1
-	I-chem-C6-1
5H	I-chem-C6-1
-	I-chem-C6-1
benzo	I-chem-C6-1
[	I-chem-C6-1
d	I-chem-C6-1
]	I-chem-C6-1
naphtho	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
2,1	I-chem-C6-1
-	I-chem-C6-1
b	I-chem-C6-1
)	I-chem-C6-1
azepine	E-chem-C6-1
)	O
and	O
the	O
dopamine	B-geneY-C6-2
D2	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
raclopride	S-chem-C6-1
(	O
both	O
at	O
0.003	O
-	O
0.03	O
mg	O
/	O
kg	O
)	O
.	O

SCH	B-chem
39166	E-chem
fully	O
blocked	O
the	O
cocaine	S-chem
-	O
like	O
discriminative	O
stimulus	O
effects	O
of	O
dimethocaine	S-chem
and	O
cocaine	S-chem
,	O
but	O
raclopride	S-chem
produced	O
only	O
partial	O
antagonism	O
of	O
cocaine	S-chem
-	O
lever	O
selection	O
.	O

In	O
addition	O
,	O
there	O
was	O
some	O
evidence	O
that	O
raclopride	S-chem
blocked	O
cocaine	S-chem
-	O
lever	O
responding	O
produced	O
by	O
a	O
lower	O
dose	O
of	O
dimethocaine	S-chem
.	O

In	O
substitution	O
studies	O
,	O
neither	O
procaine	S-chem
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
nor	O
chloroprocaine	S-chem
(	O
1	O
-	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
cocaine	S-chem
-	O
like	O
effects	O
.	O

These	O
results	O
support	O
a	O
role	O
for	O
dopamine	S-chem
in	O
the	O
behavioral	O
effects	O
of	O
some	O
local	O
anesthetics	O
.	O

Mechanism	O
of	O
action	O
of	O
dopaminergic	O
agents	O
in	O
Parkinson	O
's	O
disease	O
.	O

As	O
the	O
substantia	O
nigra	O
degenerates	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
the	O
nigrostriatal	O
pathway	O
is	O
disrupted	O
,	O
reducing	O
striatal	O
dopamine	S-chem
and	O
producing	O
PD	O
symptoms	O
.	O

Although	O
dopamine	S-chem
does	O
not	O
readily	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
its	O
precursor	O
,	O
levodopa	S-chem
,	O
does	O
.	O

Levodopa	S-chem-C9-1
is	O
absorbed	O
in	O
the	O
small	O
bowel	O
and	O
is	O
rapidly	O
catabolized	O
by	O
aromatic	B-geneY-C9-2
-	I-geneY-C9-2
L	I-geneY-C9-2
-	I-geneY-C9-2
amino	I-geneY-C9-2
-	I-geneY-C9-2
acid	I-geneY-C9-2
decarboxylase	E-geneY-C9-2
(	O
AADC	S-geneY-C9-2
)	O
and	O
catechol	B-geneY-C9-2
-	I-geneY-C9-2
O	I-geneY-C9-2
-	I-geneY-C9-2
methyltransferase	E-geneY-C9-2
(	O
COMT	S-geneY-C9-2
)	O
.	O

Because	O
gastric	O
AADC	S-geneY-C9-2
and	O
COMT	S-geneY-C9-2
degrade	O
levodopa	S-chem-C9-1
,	O
the	O
drug	O
is	O
given	O
with	O
inhibitors	O
of	O
AADC	S-geneY-C4-2
(	O
carbidopa	S-chem-C4-1
or	O
benserazide	S-chem-C4-1
)	O
,	O
and	O
inhibitors	O
of	O
COMT	S-geneY
will	O
also	O
enter	O
clinical	O
use	O
.	O

Although	O
the	O
exact	O
site	O
of	O
decarboxylation	O
of	O
exogenous	O
levodopa	S-chem
to	O
dopamine	S-chem
in	O
the	O
brain	O
is	O
unknown	O
,	O
most	O
striatal	O
AADC	S-geneY
is	O
located	O
in	O
nigrostriatal	O
dopaminergic	O
nerve	O
terminals	O
.	O

Newly	O
synthesized	O
dopamine	O
is	O
stored	O
in	O
the	O
terminals	O
and	O
then	O
released	O
,	O
stimulating	O
postsynaptic	O
dopamine	B-geneN
receptors	E-geneN
and	O
mediating	O
the	O
antiparkinsonian	O
action	O
of	O
levodopa	S-chem
.	O

Dopamine	S-chem
agonists	O
act	O
directly	O
on	O
postsynaptic	O
dopamine	B-geneN
receptors	E-geneN
,	O
thus	O
obviating	O
the	O
need	O
for	O
metabolic	O
conversion	O
,	O
storage	O
,	O
and	O
release	O
.	O

How	O
the	O
actions	O
of	O
dopaminergic	O
drugs	O
produce	O
side	O
effects	O
and	O
how	O
these	O
side	O
effects	O
should	O
be	O
managed	O
are	O
discussed	O
.	O

Transforming	B-geneY
growth	I-geneY
factor	I-geneY
β	E-geneY
integrates	O
Smad	B-geneY
3	E-geneY
to	O
mechanistic	B-geneY
target	I-geneY
of	I-geneY
rapamycin	E-geneY
complexes	O
to	O
arrest	O
deptor	S-geneY
abundance	O
for	O
glomerular	O
mesangial	O
cell	O
hypertrophy	O
.	O

In	O
many	O
renal	O
diseases	O
,	O
transforming	B-geneY
growth	I-geneY
factor	I-geneY
β	E-geneY
(	O
TGFβ	S-geneY
)	O
-	O
stimulated	O
canonical	O
Smad	B-geneY
3	E-geneY
and	O
noncanonical	O
mechanistic	B-geneY
target	I-geneY
of	I-geneY
rapamycin	E-geneY
(	O
mTOR	S-geneY
)	O
promote	O
increased	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
.	O

The	O
cellular	O
underpinnings	O
involving	O
these	O
signaling	O
molecules	O
to	O
regulate	O
mesangial	O
cell	O
hypertrophy	O
are	O
not	O
fully	O
understood	O
.	O

Deptor	S-geneY
has	O
recently	O
been	O
identified	O
as	O
an	O
mTOR	S-geneY
interacting	O
protein	O
and	O
functions	O
as	O
an	O
endogenous	O
inhibitor	O
of	O
the	O
kinase	S-geneN
activity	O
for	O
both	O
TORC1	S-geneY
and	O
TORC2	S-geneY
.	O

Prolonged	O
incubation	O
of	O
mesangial	O
cells	O
with	O
TGFβ	S-geneY
reduced	O
the	O
levels	O
of	O
deptor	S-geneY
concomitant	O
with	O
an	O
increase	O
in	O
TORC1	S-geneY
and	O
TORC2	S-geneY
activity	O
.	O

Sustained	O
TGFβ	S-geneY
activation	O
was	O
required	O
to	O
inhibit	O
association	O
of	O
deptor	S-geneY
with	O
mTOR	S-geneN
,	O
whereas	O
rapid	O
activation	O
had	O
no	O
effect	O
.	O

Using	O
the	O
mTOR	S-geneY-C4-2
inhibitor	O
PP242	B-chem-C4-1
,	E-chem-C4-1
we	O
found	O
that	O
TGFβ	S-geneY
-	O
induced	O
both	O
early	O
and	O
sustained	O
activation	O
of	O
TORC1	S-geneY
and	O
TORC2	S-geneY
was	O
necessary	O
for	O
deptor	S-geneY
suppression	O
.	O

PP242	S-chem-C3-1
-	O
induced	O
reversal	O
of	O
deptor	S-geneY-C3-2
suppression	O
by	O
TGFβ	S-geneY
was	O
associated	O
with	O
a	O
significant	O
inhibition	O
of	O
TGFβ	S-geneY
-	O
stimulated	O
protein	O
synthesis	O
and	O
hypertrophy	O
.	O

Interestingly	O
,	O
expression	O
of	O
siRNA	O
against	O
Smad	B-geneY
3	E-geneY
or	O
Smad	B-geneY
7	E-geneY
,	O
which	O
blocks	O
TGFβ	B-geneN
receptor	E-geneN
-	O
specific	O
Smad	B-geneY
3	E-geneY
signaling	O
,	O
prevented	O
TGFβ	S-geneY
-	O
induced	O
suppression	O
of	O
deptor	S-geneY
abundance	O
and	O
TORC1	B-geneN
/	I-geneN
2	E-geneN
activities	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
Smad	B-geneY
3	E-geneY
decreased	O
deptor	S-geneY
expression	O
similar	O
to	O
TGFβ	S-geneY
stimulation	O
concomitant	O
with	O
increased	O
TORC1	S-geneY
and	O
TORC2	S-geneY
activities	O
.	O

Finally	O
,	O
knockdown	O
of	O
deptor	S-geneY
reversed	O
Smad	B-geneY
7	E-geneY
-	O
mediated	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
induced	O
by	O
TGFβ	S-geneY
.	O

These	O
data	O
reveal	O
the	O
requirement	O
of	O
both	O
early	O
and	O
late	O
activation	O
of	O
mTOR	S-geneY
for	O
TGFβ	S-geneY
-	O
induced	O
protein	O
synthesis	O
.	O

Our	O
results	O
support	O
that	O
TGFβ	S-geneY
-	O
stimulated	O
Smad	B-geneY
3	E-geneY
acts	O
as	O
a	O
key	O
node	O
to	O
instill	O
a	O
feedback	O
loop	O
between	O
deptor	S-geneY
down	O
-	O
regulation	O
and	O
TORC1	B-geneN
/	I-geneN
2	E-geneN
activation	O
in	O
driving	O
mesangial	O
cell	O
hypertrophy	O
.	O

Functional	O
divergence	O
of	O
a	O
unique	O
C	S-chem
-	O
terminal	O
domain	O
of	O
leucyl	B-geneN
-	I-geneN
tRNA	I-geneN
synthetase	E-geneN
to	O
accommodate	O
its	O
splicing	O
and	O
aminoacylation	O
roles	O
.	O

Leucyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
LeuRS	S-geneY
)	O
performs	O
dual	O
essential	O
roles	O
in	O
group	O
I	O
intron	O
RNA	O
splicing	O
as	O
well	O
as	O
protein	O
synthesis	O
within	O
the	O
yeast	O
mitochondria	O
.	O

Deletions	O
of	O
the	O
C	S-chem
terminus	O
differentially	O
impact	O
the	O
two	O
functions	O
of	O
the	O
enzyme	O
in	O
splicing	O
and	O
aminoacylation	O
in	O
vivo	O
.	O

Herein	O
,	O
we	O
determined	O
that	O
a	O
fiveamino	B-chem
acid	E-chem
C	S-chem
-	O
terminal	O
deletion	O
of	O
LeuRS	S-geneY
,	O
which	O
does	O
not	O
complement	O
a	O
null	O
strain	O
,	O
can	O
form	O
a	O
ternary	O
complex	O
with	O
the	O
bI4	O
intron	O
and	O
its	O
maturase	O
splicing	O
partner	O
.	O

However	O
,	O
the	O
complex	O
fails	O
to	O
stimulate	O
splicing	O
activity	O
.	O

The	O
x	O
-	O
ray	O
co	O
-	O
crystal	O
structure	O
of	O
LeuRS	S-geneY
showed	O
that	O
a	O
C	S-chem
-	O
terminal	O
extension	O
of	O
about	O
60	O
amino	B-chem
acids	E-chem
forms	O
a	O
discrete	O
domain	O
,	O
which	O
is	O
unique	O
among	O
the	O
LeuRSs	S-geneY
and	O
interacts	O
with	O
the	O
corner	O
of	O
the	O
L	O
-	O
shaped	O
tRNALeu	O
.	O

Interestingly	O
,	O
deletion	O
of	O
the	O
entire	O
yeast	B-geneY
mitochondrial	I-geneY
LeuRS	E-geneY
C	S-chem
-	O
terminal	O
domain	O
enhanced	O
its	O
aminoacylation	O
and	O
amino	B-chem
acid	E-chem
editing	O
activities	O
.	O

In	O
striking	O
contrast	O
,	O
deletion	O
of	O
the	O
corresponding	O
C	S-chem
-	O
terminal	O
domain	O
of	O
Escherichia	B-geneY
coli	I-geneY
LeuRS	E-geneY
abolished	O
aminoacylation	O
of	O
tRNALeu	O
and	O
also	O
amino	B-chem
acid	E-chem
editing	O
of	O
mischarged	O
tRNA	O
molecules	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
the	O
leucine	S-chem
-	O
specific	O
C	S-chem
-	O
terminal	O
domain	O
in	O
tRNA	O
recognition	O
for	O
aminoacylation	O
and	O
amino	B-chem
acid	E-chem
editing	O
has	O
adapted	O
differentially	O
and	O
with	O
surprisingly	O
opposite	O
effects	O
.	O

We	O
propose	O
that	O
the	O
secondary	O
role	O
of	O
yeast	B-geneY
mitochondrial	I-geneY
LeuRS	E-geneY
in	O
RNA	O
splicing	O
has	O
impacted	O
the	O
functional	O
evolution	O
of	O
this	O
critical	O
C	S-chem
-	O
terminal	O
domain	O
.	O

Characterization	O
of	O
human	O
recombinant	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
expressed	O
in	O
Chinese	O
hamster	O
lung	O
cells	O
using	O
extracellular	O
acidification	O
rate	O
changes	O
.	O

1	O
.	O

Human	B-geneY
alpha	I-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
heterologously	O
expressed	O
in	O
Chinese	O
hamster	O
lung	O
(	O
CHL	O
)	O
fibroblasts	O
have	O
been	O
characterized	O
pharmacologically	O
using	O
a	O
cytosensor	O
microphysiometer	O
to	O
measure	O
ligand	O
-	O
induced	O
extracellular	O
acidification	O
rate	O
changes	O
.	O

2	O
.	O

In	O
untransfected	O
CHL	O
cells	O
,	O
noradrenaline	S-chem
had	O
no	O
effect	O
at	O
concentrations	O
up	O
to	O
100	O
microM	O
.	O

In	O
alpha	B-geneY-C5-2
(	I-geneY-C5-2
2A	I-geneY-C5-2
)	I-geneY-C5-2
-	I-geneY-C5-2
adrenoceptor	E-geneY-C5-2
transfected	O
cells	O
the	O
rank	O
order	O
of	O
agonist	O
potency	O
was	O
A	B-chem-C5-1
-	I-chem-C5-1
54741	E-chem-C5-1
(	O
mean	O
pEC	O
(	O
50	O
)	O
=	O
8.96	O
)	O
>	O
dexmedetomidine	S-chem-C5-1
(	O
8.88	O
)	O
>	O
UK	B-chem-C5-1
-	I-chem-C5-1
14304	E-chem-C5-1
(	O
8.42	O
)	O
>	O
B	B-chem-C5-1
-	I-chem-C5-1
HT	I-chem-C5-1
920	E-chem-C5-1
(	O
7.05	O
)	O
>	O
noradrenaline	S-chem-C5-1
(	O
6.92	O
)	O
.	O

A	B-chem
-	I-chem
54741	E-chem
,	O
UK	B-chem
-	I-chem
14304	E-chem
and	O
noradrenaline	S-chem
had	O
the	O
same	O
maximum	O
response	O
while	O
dexmedetomidine	S-chem
and	O
B	B-chem
-	I-chem
HT	I-chem
920	E-chem
behaved	O
as	O
partial	O
agonists	O
.	O

3	O
.	O

The	O
selective	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
ligand	O
rauwolscine	S-chem
antagonized	O
acidification	O
rate	O
changes	O
with	O
an	O
affinity	O
independent	O
of	O
the	O
agonist	O
used	O
;	O
the	O
affinity	O
(	O
mean	O
pK	O
(	O
B	O
)	O
)	O
against	O
noradrenaline	S-chem
was	O
8.43	O
.	O

4	O
.	O

The	O
selective	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
ligands	O
prazosin	S-chem
and	O
doxazosin	S-chem
(	O
each	O
3	O
microM	O
)	O
had	O
no	O
effect	O
on	O
noradrenaline	S-chem
responses	O
.	O

5	O
.	O

Acidification	O
rate	O
changes	O
induced	O
by	O
each	O
agonist	O
were	O
abolished	O
by	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
pertussis	B-geneN
toxin	E-geneN
.	O

6	O
.	O

These	O
data	O
suggest	O
that	O
agonist	O
-	O
induced	O
acidification	O
rate	O
responses	O
in	O
CHL	O
cells	O
transfected	O
with	O
the	O
human	B-geneY
alpha	I-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
are	O
mediated	O
exclusively	O
by	O
the	O
recombinant	O
protein	O
,	O
via	O
pertussis	B-geneN
toxin	E-geneN
sensitive	O
G	B-geneN
(	I-geneN
i	I-geneN
/	I-geneN
o	I-geneN
)	I-geneN
proteins	E-geneN
.	O

Influence	O
of	O
chain	O
length	O
and	O
double	O
bond	O
on	O
the	O
aqueous	O
behavior	O
of	O
choline	B-chem
carboxylate	E-chem
soaps	O
.	O

In	O
preceding	O
studies	O
,	O
we	O
demonstrated	O
that	O
choline	B-chem
carboxylates	E-chem
ChC	B-chem
(	I-chem
m	I-chem
)	E-chem
with	O
alkyl	S-chem
chain	O
lengths	O
of	O
m	O
=	O
12	O
-	O
18	O
are	O
highly	O
water	O
-	O
soluble	O
(	O
for	O
m	O
=	O
12	O
,	O
soluble	O
up	O
to	O
93	O
wt	O
%	O
soap	O
and	O
0	O
°C	O
)	O
.	O

In	O
addition	O
,	O
choline	S-chem
soaps	O
are	O
featured	O
by	O
an	O
extraordinary	O
lyotropic	O
phase	O
behavior	O
.	O

With	O
decreasing	O
water	O
concentration	O
,	O
the	O
following	O
phases	O
were	O
found	O
:	O
micellar	O
phase	O
(	O
L	O
(	O
1	O
)	O
)	O
,	O
discontinuous	O
cubic	O
phase	O
(	O
I	O
(	O
1	O
)	O
'	O
and	O
I	O
(	O
1	O
)	O
``	O
)	O
,	O
hexagonal	O
phase	O
(	O
H	O
(	O
1	O
)	O
)	O
,	O
bicontinuous	O
cubic	O
phase	O
(	O
V	O
(	O
1	O
)	O
)	O
,	O
and	O
lamellar	O
phase	O
(	O
L	O
(	O
α	O
)	O
)	O
.	O

The	O
present	O
work	O
is	O
also	O
focused	O
on	O
the	O
lyotropic	O
phase	O
behavior	O
of	O
choline	S-chem
soaps	O
but	O
with	O
shorter	O
alkyl	S-chem
chains	O
or	O
different	O
alkyl	S-chem
chain	O
properties	O
.	O

We	O
have	O
investigated	O
the	O
aqueous	O
phase	O
behavior	O
of	O
choline	S-chem
soaps	O
with	O
C	B-chem
(	I-chem
8	I-chem
)	E-chem
and	O
C	B-chem
(	I-chem
10	I-chem
)	E-chem
chain	O
-	O
lengths	O
(	O
choline	B-chem
octanoate	E-chem
and	O
choline	B-chem
decanoate	E-chem
)	O
and	O
with	O
a	O
C	B-chem
(	I-chem
18	I-chem
)	E-chem
chain	O
-	O
length	O
with	O
a	O
cis	O
-	O
double	O
bond	O
(	O
choline	B-chem
oleate	E-chem
)	O
.	O

We	O
found	O
that	O
choline	B-chem
decanoate	E-chem
follows	O
the	O
lyotropic	O
phase	O
behavior	O
of	O
the	O
longer	O
-	O
chain	O
homologues	O
mentioned	O
above	O
.	O

Choline	B-chem
octanoate	E-chem
in	O
water	O
shows	O
no	O
discontinuous	O
cubic	O
phases	O
,	O
but	O
an	O
extended	O
,	O
isotropic	O
micellar	O
solution	O
phase	O
.	O

In	O
addition	O
,	O
choline	B-chem
octanoate	E-chem
is	O
at	O
the	O
limit	O
between	O
a	O
surfactant	O
and	O
a	O
hydrotrope	O
.	O

The	O
double	O
bond	O
in	O
choline	B-chem
oleate	E-chem
leads	O
also	O
to	O
a	O
better	O
solubility	O
in	O
water	O
and	O
a	O
decrease	O
of	O
the	O
solubilization	O
temperature	O
.	O

It	O
also	O
influences	O
the	O
Gaussian	O
curvature	O
of	O
the	O
aggregates	O
which	O
results	O
in	O
a	O
loss	O
of	O
discontinuous	O
cubic	O
phases	O
in	O
the	O
binary	O
phase	O
diagram	O
.	O

The	O
different	O
lyotropic	O
mesophases	O
were	O
identified	O
by	O
the	O
penetration	O
scan	O
technique	O
with	O
polarizing	O
light	O
microscope	O
and	O
visual	O
observations	O
.	O

To	O
clarify	O
the	O
structural	O
behavior	O
small	O
(	O
SAXS	O
)	O
and	O
wide	O
(	O
WAXS	O
)	O
angle	O
X	O
-	O
ray	O
scattering	O
were	O
performed	O
.	O

To	O
further	O
characterize	O
the	O
extended	O
,	O
isotropic	O
micellar	O
solution	O
phase	O
in	O
the	O
binary	O
phase	O
diagram	O
of	O
choline	B-chem
octanoate	E-chem
viscosity	O
and	O
conductivity	O
measurements	O
were	O
also	O
carried	O
out	O
.	O

Gemfibrozil	S-chem-C4-1
,	O
a	O
lipid	O
-	O
lowering	O
drug	O
,	O
inhibits	O
the	O
induction	O
of	O
nitric	B-geneN-C4-2
-	I-geneN-C4-2
oxide	I-geneN-C4-2
synthase	E-geneN-C4-2
in	O
human	O
astrocytes	O
.	O

Gemfibrozil	S-chem-C4-1
,	O
a	O
lipid	O
-	O
lowering	O
drug	O
,	O
inhibited	O
cytokine	S-geneN-C4-2
-	O
induced	O
production	O
of	O
NO	S-chem-C9-1
and	O
the	O
expression	O
of	O
inducible	B-geneY-MU-2
nitric	I-geneY-MU-2
-	I-geneY-MU-2
oxide	I-geneY-MU-2
synthase	E-geneY-MU-2
(	O
iNOS	S-geneY-MU-2
)	O
in	O
human	O
U373MG	O
astroglial	O
cells	O
and	O
primary	O
astrocytes	O
.	O

Similar	O
to	O
gemfibrozil	S-chem-C4-1
,	O
clofibrate	S-chem-C4-1
,	O
another	O
fibrate	S-chem-C4-1
drug	O
,	O
also	O
inhibited	O
the	O
expression	O
of	O
iNOS	S-geneY-C4-2
.	O

Inhibition	O
of	O
human	B-geneN-C4-2
iNOS	I-geneN-C4-2
promoter	E-geneN-C4-2
-	O
driven	O
luciferase	O
activity	O
by	O
gemfibrozil	S-chem-C4-1
in	O
cytokine	S-geneN
-	O
stimulated	O
U373MG	O
astroglial	O
cells	O
suggests	O
that	O
this	O
compound	O
inhibits	O
the	O
transcription	O
of	O
iNOS	S-geneY-C4-2
.	O

Since	O
gemfibrozil	S-chem-C3-1
is	O
known	O
to	O
activate	O
peroxisome	B-geneY-C3-2
proliferator	I-geneY-C3-2
-	I-geneY-C3-2
activated	I-geneY-C3-2
receptor	I-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
(	O
PPAR	B-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
)	O
,	O
we	O
investigated	O
the	O
role	O
of	O
PPAR	B-geneY-C3-2
-	I-geneY-C3-2
alpha	E-geneY-C3-2
in	O
gemfibrozil	S-chem-MU-1
-	O
mediated	O
inhibition	O
of	O
iNOS	S-geneY-C4-2
.	O

Gemfibrozil	S-chem-C3-1
induced	O
peroxisome	B-geneN-C3-2
proliferator	I-geneN-C3-2
-	I-geneN-C3-2
responsive	I-geneN-C3-2
element	E-geneN-C3-2
(	O
PPRE	S-geneN-C3-2
)	O
-	O
dependent	O
luciferase	O
activity	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
expression	O
of	O
DeltahPPAR	B-geneY
-	I-geneY
alpha	E-geneY
,	O
the	O
dominant	O
-	O
negative	O
mutant	O
of	O
human	B-geneY
PPAR	I-geneY
-	I-geneY
alpha	E-geneY
.	O

However	O
,	O
DeltahPPAR	B-geneY
-	I-geneY
alpha	E-geneY
was	O
unable	O
to	O
abrogate	O
gemfibrozil	S-chem-C4-1
-	O
mediated	O
inhibition	O
of	O
iNOS	S-geneY-C4-2
suggesting	O
that	O
gemfibrozil	S-chem-C4-1
inhibits	O
iNOS	S-geneY-C4-2
independent	O
of	O
PPAR	B-geneY
-	I-geneY
alpha	E-geneY
.	O

The	O
human	B-geneN
iNOS	I-geneN
promoter	E-geneN
contains	O
consensus	O
sequences	O
for	O
the	O
binding	O
of	O
transcription	O
factors	O
,	O
including	O
interferon	B-geneY
-	I-geneY
gamma	I-geneY
(	I-geneY
IFN	I-geneY
-	I-geneY
gamma	I-geneY
)	I-geneY
regulatory	I-geneY
factor	I-geneY
-	I-geneY
1	E-geneY
(	O
IRF	B-geneY
-	I-geneY
1	E-geneY
)	O
binding	O
to	O
interferon	B-geneN
-	I-geneN
stimulated	I-geneN
responsive	I-geneN
element	E-geneN
(	O
ISRE	S-geneN
)	O
,	O
signal	B-geneN
transducer	I-geneN
and	I-geneN
activator	I-geneN
of	I-geneN
transcription	E-geneN
(	O
STAT	S-geneN
)	O
binding	O
to	O
gamma	O
-	O
activation	O
site	O
(	O
GAS	O
)	O
,	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
kappaB	E-geneN
(	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
)	O
,	O
activator	B-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
AP	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
and	O
CCAAT	B-geneY
/	I-geneY
enhancer	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
beta	E-geneY
(	O
C	B-geneY
/	I-geneY
EBPbeta	E-geneY
)	O
;	O
therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
gemfibrozil	S-chem
on	O
the	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

The	O
combination	O
of	O
interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
1beta	E-geneY
and	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
induced	O
the	O
activation	O
of	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
,	O
AP	B-geneY
-	I-geneY
1	E-geneY
,	O
C	B-geneY
/	I-geneY
EBPbeta	E-geneY
,	O
and	O
GAS	O
but	O
not	O
that	O
of	O
ISRE	S-geneN
,	O
suggesting	O
that	O
IRF	B-geneY
-	I-geneY
1	E-geneY
may	O
not	O
be	O
involved	O
in	O
cytokine	S-geneN
-	O
induced	O
expression	O
of	O
iNOS	S-geneY
in	O
human	O
astrocytes	O
.	O

Interestingly	O
,	O
gemfibrozil	S-chem-C4-1
strongly	O
inhibited	O
the	O
activation	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
,	O
AP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
and	O
C	B-geneY-C4-2
/	I-geneY-C4-2
EBPbeta	E-geneY-C4-2
but	O
not	O
that	O
of	O
GAS	O
in	O
cytokine	S-geneN
-	O
stimulated	O
astroglial	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
gemfibrozil	S-chem-C4-1
inhibits	O
the	O
induction	O
of	O
iNOS	S-geneY-C4-2
probably	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	B-geneN-C4-2
-	I-geneN-C4-2
kappaB	E-geneN-C4-2
,	O
AP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
and	O
C	B-geneY-C4-2
/	I-geneY-C4-2
EBPbeta	E-geneY-C4-2
and	O
that	O
gemfibrozil	S-chem
,	O
a	O
prescribed	O
drug	O
for	O
humans	O
,	O
may	O
further	O
find	O
its	O
therapeutic	O
use	O
in	O
neuroinflammatory	O
diseases	O
.	O

Toxicological	O
profiles	O
of	O
selected	O
synthetic	O
cannabinoids	S-chem
showing	O
high	O
binding	O
affinities	O
to	O
the	O
cannabinoid	B-geneY
receptor	I-geneY
subtype	I-geneY
CB1	E-geneY
.	O

Products	O
containing	O
synthetic	O
cannabinoids	S-chem
are	O
consumed	O
as	O
a	O
surrogate	O
for	O
marihuana	O
due	O
to	O
their	O
non	O
-	O
detectability	O
with	O
commonly	O
used	O
drug	O
tests	O
and	O
their	O
strong	O
cannabimimetic	O
effects	O
.	O

Because	O
data	O
concerning	O
their	O
toxicological	O
properties	O
are	O
scarce	O
,	O
the	O
cytotoxic	O
,	O
genotoxic	O
,	O
immunomodulatory	O
,	O
and	O
hormonal	O
activities	O
of	O
four	O
naphthoylindole	S-chem
compounds	O
(	O
JWH	B-chem
-	I-chem
018	E-chem
,	O
JWH	B-chem
-	I-chem
073	E-chem
,	O
JWH	B-chem
-	I-chem
122	E-chem
and	O
JWH	B-chem
-	I-chem
210	E-chem
)	O
and	O
of	O
one	O
benzoylindole	S-chem
(	O
AM	B-chem
-	I-chem
694	E-chem
)	O
were	O
studied	O
in	O
human	O
cell	O
lines	O
and	O
primary	O
cells	O
;	O
tetrahydrocannabinol	S-chem
was	O
included	O
as	O
the	O
classical	O
non	O
-	O
endogenous	O
cannabinoid	B-geneN
receptor	E-geneN
ligand	O
.	O

All	O
compounds	O
induced	O
damage	O
to	O
the	O
cell	O
membranes	O
of	O
buccal	O
(	O
TR146	O
)	O
and	O
breast	O
(	O
MCF	O
-	O
7	O
)	O
derived	O
cells	O
at	O
concentrations	O
of	O
≥	O
75	O
-	O
100	O
μM	O
.	O

No	O
cytotoxic	O
responses	O
were	O
seen	O
in	O
other	O
assays	O
which	O
reflect	O
mitochondrial	O
damage	O
,	O
protein	O
synthesis	O
,	O
and	O
lysosomal	O
activities	O
.	O

JWH	B-chem
-	I-chem
073	E-chem
and	O
JWH	B-chem
-	I-chem
122	E-chem
induced	O
DNA	O
migration	O
in	O
buccal	O
and	O
liver	O
cells	O
(	O
HepG2	O
)	O
in	O
single	O
cell	O
gel	O
electrophoresis	O
assays	O
,	O
while	O
JWH	B-chem
-	I-chem
210	E-chem
was	O
only	O
in	O
the	O
latter	O
cell	O
line	O
active	O
.	O

No	O
estrogenic	O
activities	O
were	O
detected	O
in	O
bone	O
marrow	O
cells	O
(	O
U2	O
-	O
OS	O
)	O
,	O
but	O
all	O
compounds	O
caused	O
anti	O
-	O
estrogenic	O
effects	O
at	O
levels	O
between	O
2.1	O
and	O
23.0	O
μM	O
.	O

Furthermore	O
,	O
no	O
impact	O
on	O
cytokine	S-geneN
release	O
(	O
i.e	O
.	O
,	O
on	O
IL	B-geneY
-	I-geneY
10	E-geneY
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
,	O
IL	B-geneN
-	I-geneN
12	E-geneN
/	O
23p40	S-geneY
and	O
TNFα	S-geneY
levels	O
)	O
was	O
seen	O
in	O
LPS	O
-	O
stimulated	O
human	O
PBMCs	O
,	O
except	O
with	O
JWH	B-chem-C4-1
-	I-chem-C4-1
210	E-chem-C4-1
and	O
JWH	B-chem-C4-1
-	I-chem-C4-1
122	E-chem-C4-1
which	O
caused	O
a	O
decrease	O
of	O
TNFα	S-geneY-C4-2
and	O
IL	B-geneN-C4-2
-	I-geneN-C4-2
12	E-geneN-C4-2
/	O
23p40	S-geneY-C4-2
.	O

All	O
toxic	O
effects	O
were	O
observed	O
with	O
concentrations	O
higher	O
than	O
those	O
expected	O
in	O
body	O
fluids	O
of	O
users	O
.	O

Since	O
genotoxic	O
effects	O
are	O
in	O
general	O
linear	O
over	O
a	O
wide	O
concentration	O
range	O
and	O
the	O
exposure	O
levels	O
may	O
be	O
higher	O
in	O
epithelial	O
cells	O
or	O
in	O
serum	O
,	O
further	O
experimental	O
work	O
is	O
required	O
to	O
find	O
out	O
if	O
DNA	O
damage	O
takes	O
place	O
in	O
drug	O
users	O
.	O

Hydroxy	S-chem
-	O
terminated	O
conjugated	O
polymer	O
nanoparticles	O
have	O
near	O
-	O
unity	O
bright	O
fraction	O
and	O
reveal	O
cholesterol	S-chem
-	O
dependence	O
of	O
IGF1R	B-geneN
nanodomains	E-geneN
.	O

Fluorescent	O
nanoparticles	O
have	O
enabled	O
many	O
discoveries	O
regarding	O
how	O
molecular	O
machines	O
function	O
.	O

Quantum	O
dots	O
have	O
been	O
the	O
dominant	O
class	O
of	O
fluorescent	O
nanoparticles	O
but	O
suffer	O
from	O
blinking	O
and	O
from	O
a	O
substantial	O
dark	O
fraction	O
-	O
-	O
particles	O
where	O
the	O
fluorescence	O
is	O
never	O
seen	O
-	O
-	O
complicating	O
any	O
analysis	O
of	O
biological	O
function	O
.	O

Nanoparticles	O
composed	O
of	O
conjugated	O
fluorescent	O
polymers	O
(	O
Pdots	O
)	O
have	O
recently	O
been	O
shown	O
to	O
have	O
high	O
brightness	O
and	O
no	O
blinking	O
.	O

Here	O
we	O
develop	O
a	O
robust	O
and	O
efficient	O
means	O
to	O
measure	O
the	O
dark	O
fraction	O
of	O
Pdots	O
,	O
conjugating	O
Atto	O
dyes	O
to	O
the	O
nanoparticles	O
and	O
testing	O
fluorescence	O
colocalization	O
of	O
dye	O
and	O
Pdot	O
puncta	O
.	O

This	O
established	O
that	O
the	O
Pdots	O
we	O
generated	O
had	O
minimal	O
dark	O
fraction	O
:	O
∼	O
3	O
%	O
.	O

The	O
application	O
of	O
nanoparticles	O
in	O
biological	O
environments	O
is	O
highly	O
sensitive	O
to	O
surface	O
functionalization	O
.	O

For	O
Pdots	O
we	O
found	O
that	O
passivation	O
with	O
uncharged	O
hydroxy	S-chem
-	O
terminated	O
polyethylene	B-chem
glycol	E-chem
caused	O
a	O
dramatic	O
reduction	O
in	O
nonspecific	O
cell	O
binding	O
and	O
aggregation	O
compared	O
to	O
a	O
charged	O
coating	O
.	O

Using	O
carbonyl	B-chem
di	I-chem
-	I-chem
imidazole	E-chem
the	O
hydroxy	S-chem
-	O
Pdots	O
were	O
functionalized	O
efficiently	O
with	O
streptavidin	O
for	O
high	O
stability	O
targeting	O
,	O
allowing	O
specific	O
labeling	O
of	O
mammalian	O
cells	O
.	O

Type	B-geneY
I	I-geneY
insulin	I-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
IGF1R	S-geneY
)	O
regulates	O
cell	O
survival	O
and	O
development	O
,	O
with	O
roles	O
in	O
aging	O
,	O
heart	O
disease	O
,	O
and	O
cancer	O
.	O

We	O
used	O
hydroxy	S-chem
-	O
Pdots	O
to	O
track	O
the	O
dynamics	O
of	O
IGF1R	S-geneY
on	O
a	O
breast	O
cancer	O
cell	O
-	O
line	O
,	O
determining	O
the	O
diffusion	O
characteristics	O
and	O
showing	O
cholesterol	S-chem
-	O
containing	O
membrane	O
nanodomains	O
were	O
important	O
for	O
receptor	O
mobility	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
near	O
-	O
unity	O
bright	O
fraction	O
and	O
low	O
nonspecific	O
binding	O
of	O
hydroxy	S-chem
-	O
Pdots	O
,	O
combined	O
with	O
Pdot	O
photostability	O
and	O
lack	O
of	O
blinking	O
,	O
provides	O
many	O
advantages	O
for	O
investigations	O
at	O
the	O
single	O
molecule	O
level	O
.	O

Contributions	O
of	O
rat	B-geneY-C9-2
Ctr1	E-geneY-C9-2
to	O
the	O
uptake	O
and	O
toxicity	O
of	O
copper	S-chem-C9-1
and	O
platinum	S-chem-C9-1
anticancer	O
drugs	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

Dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
neurons	O
are	O
affected	O
by	O
platinum	S-chem
-	O
induced	O
neurotoxicity	O
and	O
neurodegenerative	O
processes	O
associated	O
with	O
disturbed	O
copper	S-chem
homeostasis	O
and	O
transport	O
.	O

This	O
study	O
aimed	O
to	O
understand	O
the	O
role	O
of	O
copper	B-geneY
transporter	I-geneY
1	E-geneY
(	O
Ctr1	S-geneY
)	O
in	O
the	O
uptake	O
and	O
toxicity	O
of	O
copper	S-chem
and	O
platinum	S-chem
drugs	O
in	O
cultured	O
rat	O
DRG	O
neurons	O
,	O
and	O
the	O
functional	O
activities	O
of	O
rat	B-geneY
Ctr1	E-geneY
(	O
rCtr1	S-geneY
)	O
as	O
a	O
membrane	O
transporter	O
of	O
copper	S-chem
and	O
platinum	S-chem
drugs	O
.	O

Heterologous	O
expression	O
of	O
rCtr1	S-geneY-C9-2
in	O
HEK293	O
cells	O
(	O
HEK	O
/	O
rCtr1	S-geneY-C9-2
cells	O
)	O
increased	O
the	O
uptake	O
and	O
cytotoxicity	O
of	O
copper	S-chem-C9-1
,	O
oxaliplatin	S-chem-C9-1
,	O
cisplatin	S-chem-C9-1
and	O
carboplatin	S-chem-C9-1
,	O
in	O
comparison	O
to	O
isogenic	O
vector	O
-	O
transfected	O
control	O
cells	O
.	O

Cultured	O
rat	O
DRG	O
neurons	O
endogenously	O
expressed	O
rCtr1	S-geneY-C9-2
protein	O
on	O
their	O
neuronal	O
cell	O
body	O
plasma	O
membranes	O
and	O
cytoplasm	O
,	O
and	O
displayed	O
substantial	O
capacity	O
for	O
taking	O
up	O
copper	S-chem-C9-1
,	O
but	O
were	O
resistant	O
to	O
copper	S-chem
toxicity	O
.	O

The	O
uptake	O
of	O
copper	S-chem-C9-1
by	O
both	O
cultured	O
rat	O
DRG	O
neurons	O
and	O
HEK	O
/	O
rCtr1	S-geneY-C9-2
cells	O
was	O
saturable	O
and	O
inhibited	O
by	O
cold	O
temperature	O
,	O
silver	S-chem
and	O
zinc	S-chem
,	O
consistent	O
with	O
it	O
being	O
mediated	O
by	O
rCtr1	S-geneY
.	O

Cultured	O
rat	O
DRG	O
neurons	O
accumulated	O
platinum	S-chem
during	O
their	O
exposure	O
to	O
oxaliplatin	S-chem
and	O
were	O
sensitive	O
to	O
oxaliplatin	S-chem
cytotoxicity	O
.	O

The	O
accumulation	O
of	O
platinum	S-chem
by	O
both	O
cultured	O
rat	O
DRG	O
neurons	O
and	O
HEK	O
/	O
rCtr1	S-geneY
cells	O
,	O
during	O
oxaliplatin	S-chem
exposure	O
,	O
was	O
saturable	O
and	O
temperature	O
dependent	O
,	O
but	O
was	O
inhibited	O
by	O
copper	S-chem
only	O
in	O
HEK	O
/	O
rCtr1	S-geneY
cells	O
.	O

In	O
conclusion	O
,	O
rCtr1	S-geneY-C9-2
can	O
transport	O
copper	S-chem-C9-1
and	O
platinum	S-chem-C9-1
drugs	O
,	O
and	O
sensitizes	O
cells	O
to	O
their	O
cytotoxicities	O
.	O

DRG	O
neurons	O
display	O
substantial	O
capacity	O
for	O
accumulating	O
copper	S-chem-C9-1
via	O
a	O
transport	O
process	O
mediated	O
by	O
rCtr1	S-geneY-C9-2
,	O
but	O
appear	O
able	O
to	O
resist	O
copper	S-chem
toxicity	O
and	O
use	O
alternative	O
mechanisms	O
to	O
take	O
up	O
oxaliplatin	S-chem-C9-1
.	O

Abnormally	O
high	O
plasma	O
levels	O
of	O
vitamin	B-chem
B6	E-chem
in	O
children	O
with	O
autism	O
not	O
taking	O
supplements	O
compared	O
to	O
controls	O
not	O
taking	O
supplements	O
.	O

BACKGROUND	O
:	O
There	O
have	O
been	O
many	O
studies	O
of	O
the	O
effect	O
of	O
high	O
-	O
dose	O
supplementation	O
of	O
vitamin	B-chem
B6	E-chem
on	O
children	O
and	O
adults	O
with	O
autism	O
,	O
with	O
all	O
but	O
one	O
reporting	O
benefits	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
biochemical	O
basis	O
for	O
vitamin	B-chem
B6	E-chem
therapy	O
by	O
measuring	O
the	O
level	O
of	O
total	O
vitamin	B-chem
B6	E-chem
in	O
the	O
plasma	O
of	O
unsupplemented	O
children	O
with	O
autism	O
spectrum	O
disorder	O
compared	O
to	O
unsupplemented	O
control	O
subjects	O
.	O

PARTICIPANTS	O
:	O
Children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
n	O
=	O
35	O
,	O
age	O
3	O
-	O
9	O
years	O
)	O
and	O
unrelated	O
typical	O
children	O
(	O
n	O
=	O
11	O
,	O
age	O
6	O
-	O
9	O
years	O
)	O
,	O
all	O
from	O
Arizona	O
,	O
were	O
studied	O
.	O

(	O
This	O
includes	O
the	O
data	O
from	O
24	O
children	O
with	O
autism	O
from	O
our	O
previous	O
study	O
.	O
)	O
METHODOLOGY	O
:	O
A	O
microbiologic	O
assay	O
was	O
used	O
to	O
measure	O
the	O
level	O
of	O
total	O
vitamin	B-chem
B6	E-chem
(	O
including	O
phosphorylated	O
and	O
unphosphorylated	O
forms	O
)	O
,	O
in	O
a	O
blinded	O
fashion	O
.	O

RESULTS	O
:	O
Children	O
with	O
autism	O
had	O
a	O
75	O
%	O
higher	O
level	O
of	O
total	O
vitamin	B-chem
B6	E-chem
than	O
the	O
controls	O
(	O
medians	O
of	O
56	O
versus	O
32	O
ng	O
/	O
mL	O
,	O
respectively	O
,	O
p	O
=	O
0.00002	O
)	O
.	O

Most	O
of	O
the	O
autistic	O
children	O
(	O
77	O
%	O
)	O
had	O
levels	O
that	O
were	O
more	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
median	O
value	O
of	O
the	O
controls	O
.	O

The	O
autistic	O
girls	O
(	O
n	O
=	O
5	O
)	O
also	O
had	O
elevated	O
levels	O
(	O
mean	O
of	O
54.6	O
ng	O
/	O
mL	O
,	O
median	O
of	O
60	O
ng	O
/	O
mL	O
)	O
.	O

DISCUSSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
previous	O
studies	O
that	O
found	O
that	O
:	O
(	O
1	O
)	O
pyridoxal	B-geneY
kinase	E-geneY
had	O
a	O
very	O
low	O
activity	O
in	O
children	O
with	O
autism	O
and	O
(	O
2	O
)	O
pyridoxal	B-chem
5	I-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
levels	O
are	O
unusually	O
low	O
in	O
children	O
with	O
autism	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
low	O
conversion	O
of	O
pyridoxal	S-chem
and	O
pyridoxine	S-chem
to	O
PLP	S-chem
results	O
in	O
low	O
levels	O
of	O
PLP	S-chem
,	O
which	O
is	O
the	O
active	O
cofactor	O
for	O
113	O
known	O
enzymatic	O
reactions	O
,	O
including	O
the	O
formation	O
of	O
many	O
key	O
neurotransmitters	O
.	O

CONCLUSIONS	O
:	O
Total	O
vitamin	B-chem
B6	E-chem
is	O
abnormally	O
high	O
in	O
autism	O
,	O
consistent	O
with	O
previous	O
reports	O
of	O
an	O
impaired	O
pyridoxal	B-geneY-C9-2
kinase	E-geneY-C9-2
for	O
the	O
conversion	O
of	O
pyridoxine	S-chem-C9-1
and	O
pyridoxal	S-chem-C9-1
to	O
PLP	S-chem-C9-1
.	O

This	O
may	O
explain	O
the	O
many	O
published	O
studies	O
of	O
benefits	O
of	O
high	O
-	O
dose	O
vitamin	B-chem
B6	E-chem
supplementation	O
in	O
some	O
children	O
and	O
adults	O
with	O
autism	O
.	O

Comparative	O
antioxidant	O
effects	O
of	O
lycopene	O
,	O
apo	B-chem
-	I-chem
10	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
and	O
apo	B-chem
-	I-chem
14	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
in	O
human	O
macrophages	O
exposed	O
to	O
H2O2	S-chem
and	O
cigarette	O
smoke	O
extract	O
.	O

Much	O
of	O
the	O
beneficial	O
effects	O
of	O
tomato	O
lycopene	S-chem
in	O
the	O
prevention	O
of	O
chronic	O
diseases	O
has	O
been	O
attributed	O
to	O
its	O
antioxidant	O
properties	O
,	O
which	O
could	O
be	O
mediated	O
by	O
its	O
metabolites	O
and	O
/	O
or	O
oxidation	O
products	O
.	O

However	O
,	O
the	O
biological	O
functions	O
of	O
these	O
lycopene	S-chem
derivatives	O
remain	O
still	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
and	O
compared	O
the	O
antioxidant	O
efficacy	O
of	O
the	O
lycopene	S-chem
eccentric	O
cleavage	O
products	O
apo	B-chem
-	I-chem
10	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
and	O
apo	B-chem
-	I-chem
14	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
in	O
counteracting	O
the	O
oxidative	O
effects	O
of	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
2	I-chem
)	E-chem
and	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
in	O
THP	O
-	O
1	O
macrophages	O
.	O

Both	O
apo	B-chem
-	I-chem
10	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
and	O
apo	B-chem
-	I-chem
14	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
were	O
able	O
to	O
inhibit	O
spontaneous	O
and	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
2	I-chem
)	E-chem
-	O
induced	O
ROS	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Such	O
an	O
effect	O
was	O
accompanied	O
by	O
an	O
inhibition	O
of	O
MAPK	S-geneN
phosphorylation	O
,	O
by	O
NF	B-geneN
-	I-geneN
κB	E-geneN
inactivation	O
,	O
and	O
by	O
inhibition	O
of	O
hsp	B-geneN
-	I-geneN
70	E-geneN
and	O
hsp	B-geneN
-	I-geneN
90	E-geneN
expressions	O
.	O

Both	O
apo	B-chem-C4-1
-	I-chem-C4-1
lycopenoic	I-chem-C4-1
acids	E-chem-C4-1
also	O
decreased	O
CSE	O
-	O
induced	O
ROS	O
production	O
,	O
8	B-chem
-	I-chem
OHdG	E-chem
formation	O
and	O
reduced	O
the	O
increase	O
in	O
NOX	B-geneY-C4-2
-	I-geneY-C4-2
4	E-geneY-C4-2
and	O
COX	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
expressions	O
caused	O
by	O
CSE	O
.	O

However	O
,	O
in	O
both	O
the	O
models	O
of	O
oxidative	O
stress	O
,	O
apo	B-chem
-	I-chem
14	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
was	O
much	O
more	O
potent	O
as	O
an	O
antioxidant	O
than	O
apo	B-chem
-	I-chem
10	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
,	O
showing	O
antioxidant	O
properties	O
similar	O
to	O
lycopene	S-chem
.	O

These	O
data	O
strongly	O
suggest	O
that	O
apo	B-chem
-	I-chem
lycopenoic	I-chem
acids	E-chem
,	O
and	O
particularly	O
apo	B-chem
-	I-chem
14	I-chem
'	I-chem
-	I-chem
lycopenoic	I-chem
acid	E-chem
,	O
may	O
mediate	O
some	O
of	O
the	O
antioxidant	O
functions	O
of	O
lycopene	O
in	O
cells	O
.	O

In	O
silico	O
identification	O
of	O
poly	B-geneY
(	I-geneY
ADP	I-geneY
-	I-geneY
ribose	I-geneY
)	I-geneY
polymerase	I-geneY
-	I-geneY
1	E-geneY
inhibitors	O
and	O
their	O
chemosensitizing	O
effects	O
against	O
cisplatin	S-chem
-	O
resistant	O
human	O
gastric	O
cancer	O
cells	O
.	O

Poly	B-geneY
(	I-geneY
ADP	I-geneY
-	I-geneY
ribose	I-geneY
)	I-geneY
polymerase	I-geneY
-	I-geneY
1	E-geneY
(	O
PARP	B-geneY
-	I-geneY
1	E-geneY
)	O
enzyme	O
is	O
involved	O
in	O
the	O
repair	O
of	O
DNA	O
damages	O
made	O
by	O
certain	O
anticancer	O
agents	O
.	O

It	O
is	O
suggested	O
that	O
PARP	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
potentiate	O
the	O
cytotoxic	O
effects	O
and	O
circumvent	O
the	O
resistance	O
of	O
DNA	O
-	O
modifying	O
anticancer	O
agents	O
such	O
as	O
cisplatin	S-chem
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
virtual	O
screening	O
of	O
Korea	O
Chemical	O
Bank	O
database	O
targeting	O
PARP	B-geneY
-	I-geneY
1	E-geneY
and	O
identified	O
several	O
potent	O
PARP	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
with	O
submicromolar	O
IC50	O
values	O
(	O
77	O
-	O
79nM	O
)	O
.	O

We	O
then	O
examined	O
the	O
chemosensitization	O
of	O
cisplatin	S-chem
by	O
pre	O
-	O
treatment	O
of	O
PARP	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
in	O
cisplatin	S-chem
-	O
resistant	O
human	O
gastric	O
cancer	O
cells	O
.	O

Our	O
results	O
show	O
that	O
PARP	B-geneY
-	I-geneY
1	E-geneY
inhibitors	O
suppress	O
the	O
formation	O
of	O
poly	B-chem
(	I-chem
ADP	I-chem
-	I-chem
ribose	I-chem
)	E-chem
and	O
enhance	O
the	O
cytotoxicity	O
of	O
cisplatin	S-chem
.	O

Silibinin	S-chem
triggers	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
of	O
SGC7901	O
cells	O
.	O

Silibinin	S-chem
,	O
a	O
flavonoid	S-chem
compound	O
,	O
has	O
shown	O
to	O
be	O
of	O
chemopreventive	O
potential	O
against	O
many	O
cancers	O
.	O

However	O
,	O
its	O
efficacy	O
against	O
gastric	O
cancer	O
has	O
not	O
been	O
well	O
elucidated	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
activity	O
of	O
Silibinin	S-chem
on	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
in	O
human	O
gastric	O
cells	O
culture	O
system	O
using	O
SGC	O
-	O
7901	O
as	O
the	O
model	O
.	O

Silibinin	S-chem
treatment	O
could	O
inhibit	O
the	O
cell	O
growth	O
and	O
cause	O
a	O
prominent	O
G2	O
phase	O
arrest	O
and	O
apoptosis	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
mechanistic	O
studies	O
,	O
Silibinin	S-chem-C4-1
decreased	O
the	O
protein	O
level	O
of	O
p34cdc2	S-geneY-C4-2
,	O
which	O
might	O
be	O
the	O
possible	O
molecular	O
mechanism	O
of	O
Silibinin	S-chem
efficacy	O
on	O
the	O
growth	O
inhibition	O
in	O
SGC	O
-	O
7901	O
cells	O
.	O

In	O
addition	O
,	O
Silibinin	S-chem-C3-1
caused	O
an	O
increase	O
in	O
p53	S-geneY-C3-2
and	O
p21	S-geneY-C3-2
protein	O
level	O
as	O
well	O
as	O
mRNA	O
levels	O
.	O

Interestingly	O
,	O
Silibinin	S-chem
-	O
induced	O
apoptosis	O
in	O
SGC	O
-	O
7901	O
cells	O
was	O
independent	O
of	O
caspases	O
activation	O
.	O

These	O
results	O
indicated	O
that	O
Silibinin	S-chem
is	O
a	O
cell	O
-	O
cycle	O
regulator	O
and	O
apoptosis	O
inducer	O
in	O
human	O
gastric	O
carcinoma	O
SGC	O
-	O
7901	O
cells	O
and	O
might	O
be	O
used	O
as	O
a	O
candidate	O
chemopreventive	O
agent	O
for	O
gastric	O
carcinoma	O
prevention	O
and	O
intervention	O
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

The	O
Atrial	B-geneY
Natriuretic	I-geneY
Peptide	E-geneY
Genetic	O
Variant	O
Rs5068	S-geneY
Is	O
Associated	O
With	O
a	O
Favorable	O
Cardiometabolic	O
Phenotype	O
in	O
a	O
Mediterranean	O
Population	O
.	O

OBJECTIVEWe	O
hypothesized	O
that	O
the	O
minor	O
allele	O
of	O
the	O
atrial	B-geneY
natriuretic	I-geneY
peptide	E-geneY
(	O
ANP	S-geneY
)	O
genetic	O
variant	O
rs5068	S-geneY
is	O
associated	O
with	O
a	O
favorable	O
cardiometabolic	O
phenotype	O
in	O
a	O
general	O
Mediterranean	O
population.RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
genotyped	O
a	O
random	O
sample	O
of	O
the	O
residents	O
of	O
Ventimiglia	O
di	O
Sicilia	O
,	O
Sicily	O
,	O
for	O
rs5068.RESULTSGenotype	S-geneY
frequencies	O
of	O
rs5068	S-geneY
are	O
AA	O
,	O
93.5	O
%	O
;	O
AG	O
,	O
6.4	O
%	O
;	O
and	O
GG	O
,	O
0.1	O
%	O
.	O

All	O
subsequent	O
analyses	O
are	O
AA	O
versus	O
AG	O
+	O
GG	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
the	O
minor	O
G	O
allele	O
is	O
associated	O
with	O
lower	O
BMI	O
(	O
estimate	O
[	O
SE	O
]	O
:	O
-	O
1.7	O
kg	O
/	O
m	O
(	O
2	O
)	O
[	O
0.8	O
]	O
,	O
P	O
=	O
0.04	O
)	O
.	O

In	O
the	O
AG	O
+	O
GG	O
group	O
,	O
males	O
with	O
HDL	S-geneN
cholesterol	S-chem
levels	O
<	O
40	O
mg	O
/	O
dL	O
are	O
less	O
frequent	O
(	O
P	O
=	O
0.05	O
)	O
and	O
obesity	O
tends	O
to	O
be	O
less	O
prevalent	O
(	O
P	O
=	O
0.07	O
)	O
.	O

Importantly	O
,	O
the	O
G	O
allele	O
is	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
metabolic	O
syndrome	O
(	O
P	O
=	O
0.02	O
)	O
.	O

After	O
adjusting	O
for	O
BMI	O
,	O
the	O
above	O
associations	O
were	O
attenuated	O
.	O

Independently	O
of	O
age	O
,	O
sex	O
,	O
and	O
BMI	O
,	O
the	O
minor	O
allele	O
is	O
also	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
-	O
6.0	O
mmHg	O
[	O
2.5	O
]	O
,	O
P	O
=	O
0.02	O
)	O
and	O
lower	O
prevalence	O
of	O
hypertension	O
(	O
odds	O
ratio	O
0.41	O
[	O
95	O
%	O
CI	O
0.20	O
-	O
0.83	O
]	O
,	O
P	O
=	O
0.01	O
)	O
.CONCLUSIONSThe	O
association	O
between	O
the	O
minor	O
allele	O
of	O
rs5068	S-geneY
and	O
a	O
favorable	O
cardiometabolic	O
phenotype	O
that	O
we	O
previously	O
reported	O
in	O
a	O
U.S.	O
population	O
is	O
now	O
replicated	O
in	O
a	O
Mediterranean	O
population	O
in	O
which	O
the	O
G	O
allele	O
of	O
rs5068	S-geneY
is	O
associated	O
with	O
lower	O
blood	O
pressure	O
,	O
BMI	O
,	O
and	O
prevalence	O
of	O
hypertension	O
and	O
metabolic	O
syndrome	O
.	O

These	O
findings	O
may	O
lead	O
to	O
a	O
diagnostic	O
strategy	O
to	O
assess	O
cardiometabolic	O
risk	O
and	O
lay	O
the	O
foundation	O
for	O
the	O
future	O
development	O
of	O
an	O
ANP	S-geneY
or	O
ANP	S-geneY
-	O
like	O
therapy	O
for	O
metabolic	O
syndrome	O
.	O

Hinokitiol	S-chem
inhibits	O
platelet	O
activation	O
ex	O
vivo	O
and	O
thrombus	O
formation	O
in	O
vivo	O
.	O

Hinokitiol	S-chem
is	O
a	O
tropolone	O
-	O
related	O
bioactive	O
compound	O
that	O
has	O
been	O
used	O
in	O
hair	O
tonics	O
,	O
cosmetics	O
,	O
and	O
food	O
as	O
an	O
antimicrobial	O
agent	O
.	O

Recently	O
,	O
hinokitiol	S-chem
has	O
attracted	O
considerable	O
interest	O
because	O
of	O
its	O
anticancer	O
activities	O
.	O

Platelet	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
atherothrombotic	O
processes	O
.	O

We	O
examined	O
the	O
effects	O
of	O
hinokitiol	S-chem
treatment	O
on	O
platelet	O
activation	O
using	O
human	O
platelets	O
.	O

In	O
the	O
present	O
study	O
,	O
hinokitiol	S-chem-C4-1
(	O
1	O
and	O
2μM	O
)	O
inhibited	O
the	O
collagen	S-geneN-C4-2
-	O
induced	O
aggregation	O
of	O
human	O
platelets	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
activation	O
of	O
platelets	O
by	O
other	O
agonists	O
,	O
including	O
thrombin	S-geneY
,	O
arachidonic	B-chem
acid	E-chem
,	O
and	O
ADP	S-chem
.	O

Hinokitiol	S-chem-C4-1
inhibited	O
the	O
phosphorylation	O
of	O
phospholipase	B-geneY-C4-2
C	I-geneY-C4-2
(	I-geneY-C4-2
PLC	I-geneY-C4-2
)	I-geneY-C4-2
γ2	E-geneY-C4-2
,	O
protein	B-geneN-C4-2
kinase	I-geneN-C4-2
C	E-geneN-C4-2
(	O
PKC	S-geneN-C4-2
)	O
,	O
mitogen	B-geneN-C4-2
-	I-geneN-C4-2
activated	I-geneN-C4-2
protein	I-geneN-C4-2
kinases	E-geneN-C4-2
(	O
MAPKs	S-geneN-C4-2
)	O
,	O
and	O
Akt	S-geneN-C4-2
in	O
collagen	S-geneN-C4-2
-	O
activated	O
human	O
platelets	O
,	O
and	O
significantly	O
reduced	O
intracellular	O
calcium	S-chem
mobilization	O
and	O
hydroxyl	S-chem
radical	O
(	O
OH	S-chem
)	O
formation	O
.	O

Hinokitiol	S-chem-C4-1
also	O
reduced	O
the	O
PKC	S-geneN-C4-2
activation	O
and	O
platelet	O
aggregation	O
stimulated	O
by	O
PDBu	O
.	O

In	O
addition	O
,	O
hinokitiol	S-chem
significantly	O
prolonged	O
thrombogenesis	O
in	O
mice	O
.	O

Hinokitiol	S-chem
did	O
not	O
influence	O
the	O
binding	O
of	O
a	O
fluorescent	O
triflavin	O
probe	O
to	O
the	O
αIIbβ3	B-geneY
integrin	E-geneY
on	O
platelet	O
membrane	O
,	O
and	O
neither	O
ODQ	S-chem
nor	O
SQ22536	S-chem
significantly	O
reversed	O
the	O
hinokitiol	S-chem
-	O
mediated	O
inhibition	O
of	O
platelet	O
aggregation	O
.	O

In	O
conclusion	O
,	O
hinokitiol	S-chem-C4-1
may	O
inhibit	O
platelet	O
activation	O
by	O
inhibiting	O
the	O
PLCγ2	S-geneY-C4-2
-	O
PKC	S-geneN-C4-2
cascade	O
and	O
hydroxyl	S-chem
radical	O
formation	O
,	O
followed	O
by	O
suppressing	O
the	O
activation	O
of	O
MAPKs	S-geneN-C4-2
and	O
Akt	S-geneN-C4-2
.	O

Our	O
study	O
suggests	O
that	O
hinokitiol	S-chem
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
thromboembolic	O
disorders	O
.	O

Molecular	O
cloning	O
and	O
radioligand	O
binding	O
characterization	O
of	O
the	O
chemokine	B-geneN
receptor	I-geneN
CCR5	E-geneN
from	O
rhesus	O
macaque	O
and	O
human	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
macaque	O
represents	O
a	O
suitable	O
species	O
for	O
the	O
pre	O
-	O
clinical	O
evaluation	O
of	O
novel	O
CCR5	S-geneY-C6-2
antagonists	O
,	O
such	O
as	O
maraviroc	S-chem-C6-1
(	O
UK	B-chem-C6-1
-	I-chem-C6-1
427,857	E-chem-C6-1
)	O
.	O

To	O
do	O
this	O
we	O
cloned	O
and	O
expressed	O
CCR5	S-geneY
from	O
rhesus	O
macaque	O
and	O
compared	O
the	O
binding	O
properties	O
of	O
[	O
125I	S-chem
]	O
-	O
MIP	O
-	O
1beta	O
and	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
maraviroc	E-chem
with	O
human	B-geneY
recombinant	I-geneY
CCR5	E-geneY
.	O

[	O
125I	S-chem
]	O
-	O
MIP	O
-	O
1beta	O
bound	O
with	O
similar	O
high	O
affinity	O
to	O
CCR5	S-geneN
from	O
macaque	O
(	O
K	O
(	O
d	O
)	O
=	O
0.24	O
+	O
/	O
-	O
0.05	O
nM	O
)	O
and	O
human	O
(	O
K	O
(	O
d	O
)	O
=	O
0.23	O
+	O
/	O
-	O
0.05	O
nM	O
)	O
and	O
with	O
similar	O
kinetic	O
properties	O
.	O

In	O
competition	O
binding	O
studies	O
the	O
affinity	O
of	O
a	O
range	O
of	O
human	O
chemokines	O
for	O
macaque	B-geneY
CCR5	E-geneY
was	O
also	O
similar	O
to	O
human	B-geneY
CCR5	E-geneY
.	O

Maraviroc	S-chem-C6-1
inhibited	O
binding	O
of	O
[	O
125I	S-chem
]	O
-	O
MIP	O
-	O
1beta	O
to	O
CCR5	S-geneN
from	O
macaque	O
and	O
human	O
with	O
similar	O
potency	O
(	O
IC50	O
=	O
17.50	O
+	O
/	O
-	O
1.24	O
nM	O
and	O
7.18	O
+	O
/	O
-	O
0.93	O
nM	O
,	O
respectively	O
)	O
and	O
antagonised	O
MIP	O
-	O
1beta	O
induced	O
intracellular	O
calcium	S-chem
release	O
mediated	O
through	O
CCR5	S-geneN-C6-2
from	O
macaque	O
and	O
human	O
with	O
similar	O
potency	O
(	O
IC50	O
=	O
17.50	O
+	O
/	O
-	O
3.30	O
nM	O
and	O
12.07	O
+	O
/	O
-	O
1.89	O
,	O
respectively	O
)	O
.	O

[	B-chem
3H	I-chem
]	I-chem
-	I-chem
maraviroc	E-chem
bound	O
with	O
high	O
affinity	O
to	O
CCR5	S-geneN
from	O
macaque	O
(	O
K	O
(	O
d	O
)	O
=	O
1.36	O
+	O
/	O
-	O
0.07	O
nM	O
)	O
and	O
human	O
(	O
K	O
(	O
d	O
)	O
=	O
0.86	O
+	O
/	O
-	O
0.08	O
nM	O
)	O
,	O
but	O
was	O
found	O
to	O
dissociate	O
approximately	O
10	O
-	O
fold	O
more	O
quickly	O
from	O
macaque	B-geneY
CCR5	E-geneY
.	O

However	O
,	O
as	O
with	O
the	O
human	O
receptor	O
,	O
maraviroc	S-chem-C6-1
was	O
shown	O
to	O
be	O
a	O
high	O
affinity	O
,	O
potent	O
functional	O
antagonist	O
of	O
macaque	B-geneY-C6-2
CCR5	E-geneY-C6-2
thereby	O
indicating	O
that	O
the	O
macaque	O
should	O
be	O
a	O
suitable	O
species	O
in	O
which	O
to	O
evaluate	O
the	O
pharmacology	O
,	O
safety	O
and	O
potential	O
mechanism	O
-	O
related	O
toxicology	O
of	O
novel	O
CCR5	S-geneY-C6-2
antagonists	O
.	O

Inhibitory	O
effects	O
of	O
a	O
bazedoxifene	S-chem
/	O
conjugated	O
equine	O
estrogen	S-chem
combination	O
on	O
human	O
breast	O
cancer	O
cells	O
in	O
vitro	O
.	O

Breast	O
cancer	O
incidence	O
is	O
increased	O
in	O
women	O
receiving	O
menopausal	O
hormone	O
therapy	O
with	O
estrogen	S-chem
plus	O
progestin	O
but	O
not	O
with	O
estrogen	S-chem
alone	O
.	O

The	O
use	O
of	O
a	O
tissue	O
-	O
selective	O
estrogen	S-chem
complex	O
(	O
TSEC	O
)	O
has	O
been	O
proposed	O
as	O
a	O
novel	O
menopausal	O
hormone	O
therapy	O
strategy	O
to	O
eliminate	O
the	O
requirement	O
for	O
a	O
progestogen	S-chem
.	O

Combination	O
of	O
bazedoxifene	S-chem
(	O
BZA	S-chem
)	O
with	O
conjugated	O
estrogens	S-chem
(	O
CEs	O
)	O
,	O
the	O
first	O
TSEC	O
,	O
has	O
shown	O
beneficial	O
effects	O
.	O

Whether	O
it	O
would	O
exert	O
antiestrogenic	O
effects	O
on	O
breast	O
cancer	O
is	O
not	O
clear	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
compared	O
estradiol	S-chem
(	O
E	O
(	O
2	O
)	O
)	O
and	O
CE	O
alone	O
on	O
proliferation	O
and	O
apoptosis	O
in	O
MCF	O
-	O
7	O
breast	O
cancer	O
cells	O
.	O

CE	O
stimulated	O
growth	O
of	O
MCF	O
-	O
7	O
cells	O
at	O
a	O
peak	O
concentration	O
10	O
-	O
fold	O
higher	O
than	O
required	O
for	O
E	O
(	O
2	O
)	O
.	O

Both	O
CE	O
and	O
E	O
(	O
2	O
)	O
alone	O
increased	O
DNA	O
synthesis	O
and	O
reduced	O
apoptosis	O
with	O
activation	O
of	O
MAPK	S-geneN-C4-2
,	O
Akt	S-geneN-C4-2
,	O
and	O
p70S6K	S-geneN-C4-2
and	O
up	O
-	O
regulation	O
of	O
antiapoptotic	O
factors	O
survivin	S-geneY-C4-2
,	O
Bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
and	O
X	B-geneY-C4-2
-	I-geneY-C4-2
linked	I-geneY-C4-2
inhibitor	I-geneY-C4-2
of	I-geneY-C4-2
apoptosis	I-geneY-C4-2
protein	E-geneY-C4-2
,	O
These	O
effects	O
could	O
be	O
completely	O
blocked	O
by	O
BZA	S-chem-C4-1
.	O

Gene	O
expression	O
studies	O
demonstrated	O
that	O
CE	O
and	O
E	O
(	O
2	O
)	O
were	O
equally	O
potent	O
on	O
expression	O
of	O
cMyc	S-geneY
,	O
pS2	S-geneY
,	O
and	O
WNT1	B-geneY
inducible	I-geneY
signaling	I-geneY
pathway	I-geneY
protein	I-geneY
2	E-geneY
,	O
whereas	O
the	O
stimulatory	O
effects	O
of	O
CE	O
on	O
progesterone	B-geneY
receptor	E-geneY
and	O
amphiregulin	S-geneY
expression	O
were	O
weaker	O
than	O
E	O
(	O
2	O
)	O
.	O

BZA	S-chem
effectively	O
blocked	O
each	O
of	O
these	O
effects	O
and	O
showed	O
no	O
estrogen	S-chem
agonistic	O
effects	O
when	O
used	O
alone	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stimulatory	O
effects	O
of	O
E	O
(	O
2	O
)	O
or	O
CE	O
on	O
breast	O
cancer	O
cells	O
could	O
be	O
completely	O
abrogated	O
by	O
BZA	S-chem
.	O

These	O
studies	O
imply	O
that	O
the	O
CE	O
/	O
BZA	S-chem
,	O
TSEC	O
,	O
exerts	O
antiestrogenic	O
effects	O
on	O
breast	O
cancer	O
cells	O
and	O
might	O
block	O
the	O
growth	O
of	O
occult	O
breast	O
neoplasms	O
in	O
postmenopausal	O
women	O
,	O
resulting	O
in	O
an	O
overall	O
reduction	O
in	O
tumor	O
incidence	O
.	O

Sodium	B-chem
fluoride	E-chem
induces	O
apoptosis	O
in	O
odontoblasts	O
via	O
a	O
JNK	S-geneN
-	O
dependent	O
mechanism	O
.	O

Sodium	B-chem
fluoride	E-chem
(	O
NaF	S-chem
)	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
dental	O
caries	O
and	O
dentin	O
hypersensitivity	O
.	O

However	O
,	O
its	O
pro	O
-	O
apoptotic	O
effect	O
on	O
odontoblasts	O
may	O
lead	O
to	O
harmful	O
side	O
-	O
effects	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
pro	O
-	O
apoptotic	O
effects	O
of	O
NaF	S-chem
in	O
odontoblasts	O
and	O
elucidate	O
the	O
possible	O
underlying	O
molecular	O
mechanisms	O
.	O

NaF	S-chem
generated	O
cytotoxic	O
effects	O
in	O
odontoblast	O
-	O
lineage	O
cell	O
(	O
OLC	O
)	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Exposure	O
of	O
cells	O
to	O
4mM	O
NaF	S-chem-C3-1
for	O
24h	O
induced	O
caspase	B-geneY-C3-2
-	I-geneY-C3-2
3	E-geneY-C3-2
activation	O
,	O
ultrastructural	O
alterations	O
,	O
and	O
resulted	O
in	O
the	O
translocation	O
of	O
Bax	S-geneY
to	O
the	O
mitochondria	O
and	O
the	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
from	O
the	O
mitochondrial	O
inter	O
-	O
membrane	O
space	O
into	O
the	O
cytosol	O
,	O
indicating	O
that	O
fluoride	S-chem
-	O
mediated	O
apoptosis	O
is	O
mitochondria	O
-	O
dependent	O
.	O

Fluoride	S-chem-C3-1
treatment	O
also	O
increased	O
phosphorylation	O
of	O
JNK	S-geneN-C3-2
and	O
ERK	S-geneN-C3-2
,	O
but	O
not	O
p38	S-geneN
,	O
and	O
apoptosis	O
induced	O
by	O
fluoride	S-chem
was	O
notably	O
or	O
partly	O
suppressed	O
by	O
treatment	O
with	O
JNK	S-geneN
or	O
ERK	S-geneN
inhibitors	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
NaF	S-chem
induces	O
apoptosis	O
in	O
OLC	O
odontoblasts	O
through	O
a	O
JNK	S-geneN
-	O
dependent	O
mitochondrial	O
pathway	O
.	O

Targeting	O
protein	O
-	O
protein	O
interactions	O
within	O
the	O
cyclic	B-chem
AMP	E-chem
signaling	O
system	O
as	O
a	O
therapeutic	O
strategy	O
for	O
cardiovascular	O
disease	O
.	O

The	O
cAMP	S-chem
signaling	O
system	O
can	O
trigger	O
precise	O
physiological	O
cellular	O
responses	O
that	O
depend	O
on	O
the	O
fidelity	O
of	O
many	O
protein	O
-	O
protein	O
interactions	O
,	O
which	O
act	O
to	O
bring	O
together	O
signaling	O
intermediates	O
at	O
defined	O
locations	O
within	O
cells	O
.	O

In	O
the	O
heart	O
,	O
cAMP	S-chem
participates	O
in	O
the	O
fine	O
control	O
of	O
excitation	O
-	O
contraction	O
coupling	O
,	O
hence	O
,	O
any	O
disregulation	O
of	O
this	O
signaling	O
cascade	O
can	O
lead	O
to	O
cardiac	O
disease	O
.	O

Due	O
to	O
the	O
ubiquitous	O
nature	O
of	O
the	O
cAMP	S-chem
pathway	O
,	O
general	O
inhibitors	O
of	O
cAMP	S-chem
signaling	O
proteins	O
such	O
as	O
PKA	S-geneN
,	O
EPAC	S-geneY
and	O
PDEs	S-geneN
would	O
act	O
non	O
-	O
specifically	O
and	O
universally	O
,	O
increasing	O
the	O
likelihood	O
of	O
serious	O
'	O
off	O
target	O
'	O
effects	O
.	O

Recent	O
advances	O
in	O
the	O
discovery	O
of	O
peptides	O
and	O
small	O
molecules	O
that	O
disrupt	O
the	O
protein	O
-	O
protein	O
interactions	O
that	O
underpin	O
cellular	O
targeting	O
of	O
cAMP	S-chem
signaling	O
proteins	O
are	O
described	O
and	O
discussed	O
.	O

The	O
PARP	S-geneN-C4-2
inhibitor	O
PJ34	S-chem-C4-1
modifies	O
proliferation	O
,	O
NIS	S-geneY
expression	O
and	O
epigenetic	O
marks	O
in	O
thyroid	O
cancer	O
cell	O
lines	O
.	O

Since	O
PARP	B-geneY
-	I-geneY
1	E-geneY
is	O
supposed	O
to	O
be	O
part	O
of	O
a	O
multimeric	O
repressor	O
of	O
sodium	B-geneY
iodide	I-geneY
symporter	E-geneY
(	O
NIS	S-geneY
)	O
expression	O
,	O
in	O
this	O
study	O
the	O
effect	O
of	O
the	O
PARP	S-geneN-C4-2
inhibitor	O
PJ34	S-chem-C4-1
on	O
several	O
properties	O
of	O
thyroid	O
cancer	O
cell	O
lines	O
was	O
investigated	O
.	O

In	O
TPC1	O
,	O
BCPAP	O
,	O
FRO	O
,	O
WRO	O
cell	O
lines	O
PJ34	S-chem-C3-1
induced	O
a	O
strong	O
increase	O
in	O
NIS	S-geneY-C3-2
mRNA	O
levels	O
.	O

In	O
BCPAP	O
and	O
TPC1	O
cells	O
also	O
significant	O
increase	O
of	O
radio	B-chem
-	I-chem
iodine	E-chem
uptake	O
was	O
induced	O
.	O

Accordingly	O
,	O
in	O
transfection	O
experiments	O
performed	O
in	O
TPC1	O
cells	O
,	O
treatment	O
with	O
PJ34	S-chem-C3-1
increased	O
NIS	B-geneN-C3-2
promoter	E-geneN-C3-2
activity	O
without	O
affecting	O
PARP	B-geneY
-	I-geneY
1	E-geneY
binding	O
to	O
the	O
promoter	O
sequence	O
.	O

We	O
also	O
investigated	O
the	O
epigenetic	O
status	O
of	O
NIS	B-geneN
promoter	E-geneN
after	O
PJ34	S-chem-C3-1
treatment	O
in	O
TPC1	O
cell	O
line	O
:	O
in	O
addition	O
to	O
an	O
increase	O
of	O
histone	B-geneN-C3-2
modification	I-geneN-C3-2
activation	I-geneN-C3-2
marks	E-geneN-C3-2
(	O
H3K9K14ac	S-geneN-C3-2
,	O
H3K4me3	S-geneN-C3-2
)	O
,	O
surprisingly	O
we	O
observed	O
also	O
an	O
increase	O
of	O
H3K27me3	O
,	O
a	O
classical	O
repressive	O
mark	O
.	O

Our	O
data	O
demonstrate	O
that	O
in	O
various	O
thyroid	O
cancer	O
cell	O
lines	O
PARP	S-geneN
inhibition	O
increases	O
NIS	S-geneY
gene	O
expression	O
through	O
a	O
particular	O
modulation	O
of	O
transcriptional	O
regulatory	O
mechanisms	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
PARP	S-geneN
inhibitors	O
may	O
deserve	O
future	O
investigations	O
as	O
tools	O
for	O
medical	O
treatment	O
of	O
thyroid	O
cancer	O
.	O

Androgen	S-chem
deprivation	O
from	O
pre	O
-	O
puberty	O
to	O
peripuberty	O
interferes	O
in	O
proteins	O
expression	O
in	O
pubertal	O
and	O
adult	O
rat	O
epididymis	O
.	O

Few	O
studies	O
have	O
focused	O
on	O
experimental	O
testosterone	S-chem
deprivation	O
in	O
immature	O
animals	O
.	O

Therefore	O
,	O
this	O
study	O
used	O
sexually	O
immature	O
rats	O
aiming	O
to	O
evaluate	O
the	O
testes	O
and	O
epididymis	O
histology	O
and	O
proteins	O
expression	O
in	O
these	O
organs	O
on	O
PND50	O
and	O
75	O
,	O
after	O
premature	O
antiandrogen	O
exposure	O
,	O
from	O
PND21	O
to	O
44	O
.	O

Although	O
the	O
androgen	S-chem
deprivation	O
from	O
pre	O
-	O
puberty	O
up	O
to	O
peripuberty	O
did	O
not	O
alter	O
the	O
histological	O
organization	O
of	O
the	O
testes	O
and	O
epididymis	O
either	O
at	O
puberty	O
or	O
at	O
adulthood	O
,	O
the	O
treatment	O
impaired	O
the	O
expression	O
of	O
specific	O
proteins	O
in	O
epididymal	O
tissue	O
at	O
puberty	O
and	O
adulthood	O
(	O
androgen	B-geneY
receptor	E-geneY
,	O
calmodulin	S-geneN
,	O
Rab11A	S-geneY
)	O
.	O

These	O
changes	O
may	O
be	O
related	O
to	O
impaired	O
epididymal	O
function	O
,	O
sperm	O
quality	O
and	O
fertility	O
capacity	O
as	O
observed	O
in	O
a	O
previous	O
study	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
better	O
investigate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
impairment	O
on	O
reproductive	O
competence	O
of	O
male	O
rats	O
after	O
precocious	O
hormonal	O
injury	O
.	O

Plasma	O
S	O
/	O
R	O
ratio	O
of	O
warfarin	S-chem
co	O
-	O
varies	O
with	O
VKORC1	S-geneY
haplotype	O
.	O

We	O
recently	O
reported	O
that	O
the	O
low	O
-	O
dose	O
VKORC1	S-geneY
*	O
2	O
haplotype	O
is	O
an	O
important	O
genetic	O
determinant	O
for	O
warfarin	S-chem
dose	O
requirement	O
and	O
is	O
associated	O
with	O
difficulties	O
to	O
attain	O
stable	O
therapeutic	O
prothrombin	S-geneY
time	O
-	O
-	O
International	O
Normalized	O
Ratio	O
in	O
patients	O
undergoing	O
anticoagulation	O
therapy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
patients	O
with	O
VKORC1	S-geneY
*	O
2	O
compared	O
with	O
patients	O
carrying	O
high	O
-	O
dose	O
haplotypes	O
VKORC1	S-geneY
*	O
3	O
or	O
VKORC1	S-geneY
*	O
4	O
had	O
different	O
warfarin	B-chem
S	I-chem
/	I-chem
R	E-chem
ratios	O
in	O
their	O
plasma	O
,	O
and	O
whether	O
that	O
was	O
related	O
to	O
CYP2C9	S-geneY
variants	O
CYP2C9	S-geneY
*	O
2	O
and	O
CYP2C9	S-geneY
*	O
3	O
or	O
other	O
factors	O
.	O

Samples	O
from	O
patients	O
previously	O
haplotyped	O
for	O
VKORC1	S-geneY
and	O
measured	O
for	O
plasma	O
warfarin	S-chem
concentration	O
were	O
genotyped	O
for	O
the	O
CYP2C9	S-geneY
variants	O
CYP2C9	S-geneY
*	O
2	O
and	O
CYP2C9	S-geneY
*	O
3	O
.	O

Nonparametric	O
statistical	O
analysis	O
was	O
performed	O
to	O
elucidate	O
whether	O
there	O
was	O
any	O
significant	O
difference	O
in	O
the	O
warfarin	B-chem
S	I-chem
/	I-chem
R	E-chem
ratio	O
between	O
the	O
two	O
patient	O
groups	O
.	O

Our	O
result	O
shows	O
that	O
there	O
is	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0.01	O
)	O
in	O
warfarin	B-chem
S	I-chem
/	I-chem
R	E-chem
ratios	O
between	O
VKORC1	S-geneY
*	O
2	O
and	O
VKORC1	S-geneY
*	O
3	O
or	O
VKORC1	S-geneY
*	O
4	O
patients	O
.	O

This	O
difference	O
did	O
not	O
originate	O
from	O
CYP2C9	S-geneY
variants	O
CYP2C9	S-geneY
*	O
2	O
and	O
CYP2C9	S-geneY
*	O
3	O
.	O

We	O
speculate	O
that	O
VKORC1	S-geneY
haplotypes	O
possibly	O
are	O
linked	O
to	O
some	O
unidentified	O
factors	O
involved	O
in	O
the	O
metabolic	O
clearance	O
of	O
warfarin	S-chem
enantiomers	O
.	O

Dose	O
-	O
dependent	O
variations	O
in	O
(	B-chem
S	I-chem
)	I-chem
-	I-chem
warfarin	E-chem
and	O
(	B-chem
R	I-chem
)	I-chem
-	I-chem
warfarin	E-chem
clearance	O
in	O
these	O
patients	O
can	O
also	O
be	O
a	O
probable	O
explanation	O
for	O
the	O
difference	O
in	O
warfarin	B-chem
S	I-chem
/	I-chem
R	E-chem
ratios	O
.	O

p300	S-geneY
-	O
mediated	O
acetylation	O
of	O
TRF2	S-geneY
is	O
required	O
for	O
maintaining	O
functional	O
telomeres	O
.	O

The	O
human	B-geneY
telomeric	I-geneY
protein	I-geneY
TRF2	E-geneY
is	O
required	O
to	O
protect	O
chromosome	O
ends	O
by	O
facilitating	O
their	O
organization	O
into	O
the	O
protective	O
capping	O
structure	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
TRF2	S-geneY
such	O
as	O
phosphorylation	O
,	O
ubiquitination	O
,	O
SUMOylation	O
,	O
methylation	O
and	O
poly	O
(	O
ADP	S-chem
-	O
ribosyl	O
)	O
ation	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
telomere	O
function	O
.	O

Here	O
we	O
show	O
that	O
TRF2	S-geneY
specifically	O
interacts	O
with	O
the	O
histone	B-geneY
acetyltransferase	I-geneY
p300	E-geneY
,	O
and	O
that	O
p300	S-geneY
acetylates	O
the	O
lysine	S-chem
residue	O
at	O
position	O
293	O
of	O
TRF2	S-geneY
.	O

We	O
also	O
report	O
that	O
p300	S-geneY
-	O
mediated	O
acetylation	O
stabilizes	O
the	O
TRF2	S-geneY
protein	O
by	O
inhibiting	O
its	O
ubiquitin	S-geneN
-	O
dependent	O
proteolysis	O
and	O
is	O
required	O
for	O
efficient	O
telomere	O
binding	O
of	O
TRF2	S-geneY
.	O

Furthermore	O
,	O
overexpression	O
of	O
the	O
acetylation	O
-	O
deficient	O
mutant	O
,	O
K293R	S-geneN
,	O
induces	O
DNA	O
-	O
damage	O
response	O
foci	O
at	O
telomeres	O
,	O
thereby	O
leading	O
to	O
induction	O
of	O
impaired	O
cell	O
growth	O
,	O
cellular	O
senescence	O
and	O
altered	O
cell	O
cycle	O
distribution	O
.	O

A	O
small	O
but	O
significant	O
number	O
of	O
metaphase	O
chromosomes	O
show	O
no	O
telomeric	O
signals	O
at	O
chromatid	O
ends	O
,	O
suggesting	O
an	O
aberrant	O
telomere	O
structure	O
.	O

These	O
findings	O
demonstrate	O
that	O
acetylation	O
of	O
TRF2	S-geneY
by	O
p300	S-geneY
plays	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
of	O
functional	O
telomeres	O
as	O
well	O
as	O
in	O
the	O
regulation	O
of	O
the	O
telomere	O
-	O
associated	O
DNA	O
-	O
damage	O
response	O
,	O
thus	O
providing	O
a	O
new	O
route	O
for	O
modulating	O
telomere	O
protection	O
function	O
.	O

Determination	O
of	O
paralytic	O
shellfish	O
poisoning	O
toxins	O
by	O
HILIC	O
-	O
MS	O
/	O
MS	O
coupled	O
with	O
dispersive	O
solid	O
phase	O
extraction	O
.	O

This	O
paper	O
describes	O
the	O
use	O
of	O
QuEChERS	O
(	O
Quick	O
,	O
Easy	O
,	O
Cheap	O
,	O
Effective	O
,	O
Rugged	O
and	O
Safe	O
)	O
for	O
the	O
extraction	O
,	O
cleanup	O
and	O
detection	O
of	O
10	O
paralytic	O
shellfish	O
toxins	O
(	O
PSP	O
)	O
in	O
sea	O
food	O
by	O
HILIC	O
-	O
MS	O
/	O
MS	O
with	O
positive	O
ESI	O
.	O

Matrix	O
matched	O
calibration	O
standards	O
were	O
used	O
to	O
compensate	O
for	O
matrix	O
effects	O
.	O

The	O
toxins	O
were	O
extracted	O
with	O
acetonitrile	S-chem
/	O
water	O
(	O
90	O
:	O
10	O
,	O
v	O
/	O
v	O
)	O
containing	O
0.1	O
%	O
formic	B-chem
acid	E-chem
and	O
cleaned	O
by	O
HLB	O
and	O
GCB	S-chem
sorbents	O
.	O

Qualitative	O
and	O
quantitative	O
detection	O
for	O
the	O
analytes	O
were	O
carried	O
out	O
under	O
the	O
multiple	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
in	O
positive	O
ionization	O
mode	O
after	O
chromatography	O
separation	O
on	O
a	O
TSK	O
-	O
gel	O
Amide	S-chem
-	O
80	O
®	O
column	O
(	O
150	O
mm×2.0	O
mm×3	O
μm	O
)	O
.	O

Studies	O
at	O
three	O
fortification	O
levels	O
for	O
the	O
toxins	O
in	O
the	O
range	O
of	O
8.1	O
-	O
225.5	O
μg	O
/	O
kg	O
gave	O
mean	O
recoveries	O
from	O
71.3	O
%	O
to	O
104.6	O
%	O
with	O
relative	O
standard	O
deviation	O
(	O
RSD	O
)	O
≤	O
15.8	O
%	O
.	O

The	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
was	O
below	O
the	O
recommended	O
regulatory	O
limit	O
of	O
170	O
μgSTX	O
(	O
equ	O
.	O
)	O
/	O
kg	O
and	O
the	O
proposed	O
method	O
fully	O
meets	O
the	O
needs	O
of	O
daily	O
monitoring	O
.	O

Mammalian	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
,	O
a	O
highly	O
divergent	O
myosin	S-geneN
.	O

The	O
Mus	B-geneY
musculus	I-geneY
myosin	I-geneY
-	I-geneY
18A	E-geneY
gene	O
is	O
expressed	O
as	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
α	O
and	O
β	O
,	O
with	O
reported	O
roles	O
in	O
Golgi	O
localization	O
,	O
in	O
maintenance	O
of	O
cytoskeleton	O
,	O
and	O
as	O
receptors	O
for	O
immunological	O
surfactant	O
proteins	O
.	O

Both	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
isoforms	O
feature	O
a	O
myosin	B-geneN
motor	I-geneN
domain	E-geneN
,	O
a	O
single	O
predicted	O
IQ	B-geneN
motif	E-geneN
,	O
and	O
a	O
long	O
coiled	O
-	O
coil	O
reminiscent	O
of	O
myosin	B-geneY
-	I-geneY
2	E-geneY
.	O

The	O
myosin	B-geneY
-	I-geneY
18Aα	E-geneY
isoform	O
,	O
additionally	O
,	O
has	O
an	O
N	S-chem
-	O
terminal	O
PDZ	B-geneN
domain	E-geneN
.	O

Recombinant	O
heavy	O
meromyosin	O
-	O
and	O
subfragment	O
-	O
1	O
(	O
S1	O
)	O
-	O
like	O
constructs	O
for	O
both	O
myosin	B-geneN
-	I-geneN
18Aα	I-geneN
and	I-geneN
-	I-geneN
18β	E-geneN
species	O
were	O
purified	O
from	O
the	O
baculovirus	O
/	O
Sf9	O
cell	O
expression	O
system	O
.	O

These	O
constructs	O
bound	O
both	O
essential	O
and	O
regulatory	O
light	O
chains	O
,	O
indicating	O
an	O
additional	O
noncanonical	O
light	O
chain	O
binding	O
site	O
in	O
the	O
neck	O
.	O

Myosin	B-geneN
-	I-geneN
18Aα	I-geneN
-	I-geneN
S1	I-geneN
and	I-geneN
-	I-geneN
18Aβ	I-geneN
-	I-geneN
S1	E-geneN
molecules	O
bound	O
actin	O
weakly	O
with	O
Kd	O
values	O
of	O
4.9	O
and	O
54	O
μm	O
,	O
respectively	O
.	O

The	O
actin	O
binding	O
data	O
could	O
be	O
modeled	O
by	O
assuming	O
an	O
equilibrium	O
between	O
two	O
myosin	O
conformations	O
,	O
a	O
competent	O
and	O
an	O
incompetent	O
form	O
to	O
bind	O
actin	O
.	O

Actin	S-geneN
binding	O
was	O
unchanged	O
by	O
presence	O
of	O
nucleotide	S-chem
.	O

Both	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
isoforms	O
bound	O
N	B-chem
-	I-chem
methylanthraniloyl	I-chem
-	I-chem
nucleotides	E-chem
,	O
but	O
the	O
rate	O
of	O
ATP	S-chem
hydrolysis	O
was	O
very	O
slow	O
(	O
<	O
0.002	O
s	O
(	O
-	O
1	O
)	O
)	O
and	O
not	O
significantly	O
enhanced	O
by	O
actin	S-geneN
.	O

Phosphorylation	O
of	O
the	O
regulatory	O
light	O
chain	O
had	O
no	O
effect	O
on	O
ATP	S-chem
hydrolysis	O
,	O
and	O
neither	O
did	O
the	O
addition	O
of	O
tropomyosin	O
or	O
of	O
GOLPH3	O
,	O
a	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
binding	O
partner	O
.	O

Electron	O
microscopy	O
of	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
-	O
S1	O
showed	O
that	O
the	O
lever	O
is	O
strongly	O
angled	O
with	O
respect	O
to	O
the	O
long	O
axis	O
of	O
the	O
motor	O
domain	O
,	O
suggesting	O
a	O
pre	O
-	O
power	O
stroke	O
conformation	O
regardless	O
of	O
the	O
presence	O
of	O
ATP	S-chem
.	O

These	O
data	O
lead	O
us	O
to	O
conclude	O
that	O
myosin	B-geneY
-	I-geneY
18A	E-geneY
does	O
not	O
operate	O
as	O
a	O
traditional	O
molecular	O
motor	O
in	O
cells	O
.	O

Acute	O
effects	O
of	O
brexpiprazole	S-chem
on	O
serotonin	S-chem
,	O
dopamine	S-chem
,	O
and	O
norepinephrine	S-chem
systems	O
:	O
an	O
in	O
vivo	O
electrophysiologic	O
characterization	O
.	O

Brexpiprazole	S-chem
,	O
a	O
compound	O
sharing	O
structural	O
molecular	O
characteristics	O
with	O
aripiprazole	S-chem
,	O
is	O
currently	O
under	O
investigation	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
and	O
depression	O
.	O

Using	O
electrophysiologic	O
techniques	O
,	O
the	O
present	O
study	O
assessed	O
the	O
in	O
vivo	O
action	O
of	O
brexpiprazole	S-chem
on	O
serotonin	B-geneN
(	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
receptor	E-geneN
subtypes	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
,	O
and	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
;	O
dopamine	B-geneY
(	I-geneY
DA	I-geneY
)	I-geneY
D2	I-geneY
autoreceptors	E-geneY
,	O
and	O
alpha1	B-geneN
-	I-geneN
and	I-geneN
alpha2	I-geneN
-	I-geneN
adrenergic	I-geneN
receptors	E-geneN
.	O

In	O
addition	O
,	O
the	O
effects	O
on	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
autoreceptors	O
in	O
the	O
dorsal	O
raphe	O
nucleus	O
(	O
DRN	O
)	O
and	O
D2	B-geneY
autoreceptors	E-geneY
in	O
the	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
were	O
compared	O
with	O
those	O
of	O
aripiprazole	S-chem
,	O
an	O
agent	O
in	O
wide	O
clinical	O
use	O
.	O

In	O
the	O
DRN	O
,	O
brexpiprazole	S-chem-C5-1
completely	O
inhibited	O
the	O
firing	O
of	O
5	B-chem
-	I-chem
HT	E-chem
neurons	O
via	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1A	E-geneY-C5-2
agonism	O
and	O
was	O
more	O
potent	O
than	O
aripiprazole	S-chem-C5-1
(	O
ED50	O
=	O
230	O
and	O
700	O
mug	O
/	O
kg	O
,	O
respectively	O
)	O
.	O

In	O
the	O
locus	O
coeruleus	O
,	O
brexpiprazole	S-chem
reversed	O
the	O
inhibitory	O
effect	O
of	O
the	O
preferential	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT2A	E-geneY-C5-2
receptor	O
agonist	O
DOI	S-chem-C5-1
(	O
2,5	B-chem-C5-1
-	I-chem-C5-1
dimethoxy	I-chem-C5-1
-	I-chem-C5-1
4	I-chem-C5-1
-	I-chem-C5-1
iodoamphetamine	E-chem-C5-1
)	O
on	O
norepinephrine	S-chem
neuronal	O
firing	O
(	O
ED50	O
=	O
110	O
mug	O
/	O
kg	O
)	O
,	O
demonstrating	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
antagonistic	O
action	O
.	O

Brexpiprazole	S-chem
reversed	O
the	O
inhibitory	O
effect	O
of	O
the	O
DA	S-chem
agonist	O
apomorphine	S-chem-C5-1
on	O
VTA	O
DA	O
neurons	O
(	O
ED50	O
=	O
61	O
mug	O
/	O
kg	O
)	O
,	O
whereas	O
it	O
was	O
ineffective	O
when	O
administered	O
alone	O
,	O
indicating	O
partial	O
agonistic	O
action	O
on	O
D2	B-geneY-C5-2
receptors	E-geneY-C5-2
.	O

Compared	O
with	O
aripiprazole	S-chem
,	O
which	O
significantly	O
inhibited	O
the	O
firing	O
activity	O
of	O
VTA	O
DA	S-chem
neurons	O
,	O
brexpiprazole	S-chem-C4-1
displayed	O
less	O
efficacy	O
at	O
D2	B-geneY-C4-2
receptors	E-geneY-C4-2
.	O

In	O
the	O
hippocampus	O
,	O
brexpiprazole	S-chem-C5-1
acted	O
as	O
a	O
full	O
agonist	O
at	O
5	B-geneY-C5-2
-	I-geneY-C5-2
HT1A	E-geneY-C5-2
receptors	O
on	O
pyramidal	O
neurons	O
.	O

Furthermore	O
,	O
it	O
increased	O
5	B-chem
-	I-chem
HT	E-chem
release	O
by	O
terminal	O
alpha2	B-geneN
-	I-geneN
adrenergic	I-geneN
heteroceptor	E-geneN
but	O
not	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
autoreceptor	O
antagonism	O
.	O

In	O
the	O
lateral	O
geniculate	O
nucleus	O
,	O
brexpiprazole	S-chem-C6-1
displayed	O
alpha1B	B-geneY-C6-2
-	I-geneY-C6-2
adrenoceptor	E-geneY-C6-2
antagonistic	O
action	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
insight	O
into	O
the	O
in	O
vivo	O
action	O
of	O
brexpiprazole	S-chem
on	O
monoamine	S-chem
targets	O
relevant	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
schizophrenia	O
.	O

Magnetic	O
nanoclusters	O
exhibiting	O
protein	O
-	O
activated	O
near	O
-	O
infrared	O
fluorescence	O
.	O

Composite	O
nanoclusters	O
with	O
chemical	O
,	O
magnetic	O
,	O
and	O
biofunctionality	O
offer	O
broad	O
opportunities	O
for	O
targeted	O
cellular	O
imaging	O
.	O

A	O
key	O
challenge	O
is	O
to	O
load	O
a	O
high	O
degree	O
of	O
targeting	O
,	O
imaging	O
,	O
and	O
therapeutic	O
functionality	O
onto	O
stable	O
metal	B-chem
-	I-chem
oxide	E-chem
nanoparticles	O
.	O

Here	O
we	O
report	O
a	O
route	O
for	O
producing	O
magnetic	O
nanoclusters	O
(	O
MNCs	O
)	O
with	O
alkyne	S-chem
surface	O
functionality	O
that	O
can	O
be	O
utilized	O
as	O
multimodal	O
imaging	O
probes	O
.	O

We	O
form	O
MNCs	O
composed	O
of	O
magnetic	O
Fe	O
(	O
3	O
)	O
O	O
(	O
4	O
)	O
nanoparticles	O
and	O
poly	O
(	O
acrylic	O
acid	O
-	O
co	O
-	O
propargyl	O
acrylate	O
)	O
by	O
the	O
co	O
-	O
precipitation	O
of	O
iron	O
salts	O
in	O
the	O
presence	O
of	O
copolymer	O
stabilizers	O
.	O

The	O
MNCs	O
were	O
surface	O
-	O
modified	O
with	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
emitting	O
fluorophore	O
used	O
in	O
photodynamic	O
therapy	O
,	O
an	O
azide	S-chem
-	O
modified	O
indocyanine	B-chem
green	E-chem
.	O

The	O
fluorophores	O
engaged	O
and	O
complexed	O
with	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
,	O
forming	O
an	O
extended	O
coverage	O
of	O
serum	O
proteins	O
on	O
the	O
MNCs	O
.	O

These	O
proteins	O
isolated	O
indocyanine	B-chem
green	E-chem
fluorophores	O
from	O
the	O
aqueous	O
environment	O
and	O
induced	O
an	O
effective	O
``	O
turn	O
-	O
on	O
``	O
of	O
NIR	O
emission	O
.	O

A	O
population	O
-	O
based	O
study	O
of	O
dosing	O
and	O
persistence	O
with	O
anti	O
-	O
dementia	O
medications	O
.	O

PURPOSE	O
:	O
Cholinesterase	S-geneY
inhibitors	O
and	O
memantine	S-chem
are	O
the	O
mainstay	O
of	O
pharmacological	O
intervention	O
for	O
the	O
cognitive	O
symptoms	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

This	O
study	O
assessed	O
the	O
adequacy	O
of	O
dosing	O
and	O
persistence	O
with	O
AD	O
medications	O
and	O
the	O
predictors	O
of	O
these	O
variables	O
in	O
the	O
'	O
real	O
world	O
'	O
(	O
outside	O
the	O
clinical	O
trial	O
setting	O
)	O
.	O

METHODS	O
:	O
The	O
Health	O
Service	O
Executive	O
-	O
Primary	O
Care	O
Reimbursement	O
Services	O
prescription	O
claims	O
database	O
in	O
the	O
Republic	O
of	O
Ireland	O
contains	O
prescription	O
information	O
for	O
1.6	O
million	O
people	O
.	O

Patients	O
aged	O
>	O
70	O
years	O
who	O
received	O
at	O
least	O
two	O
prescriptions	O
for	O
donepezil	O
,	E-chem
rivastigmine	O
,	E-chem
galantamine	O
and	O
memantine	O
between	O
January	O
2006	O
and	O
December	O
2010	O
were	O
included	O
in	O
the	O
study	O
.	O

Rates	O
of	O
dose	O
-	O
maximisation	O
were	O
recorded	O
by	O
examining	O
the	O
initiation	O
dose	O
of	O
each	O
AD	O
drug	O
commenced	O
during	O
the	O
study	O
period	O
and	O
any	O
subsequent	O
dose	O
titrations	O
.	O

Non	O
-	O
persistence	O
was	O
defined	O
by	O
a	O
gap	O
in	O
prescribing	O
of	O
more	O
than	O
63	O
consecutive	O
days	O
.	O

Predictors	O
of	O
dose	O
-	O
maximisation	O
and	O
non	O
-	O
persistence	O
were	O
also	O
analysed	O
.	O

RESULTS	O
:	O
Between	O
January	O
2006	O
and	O
December	O
2010	O
,	O
20,729	O
patients	O
aged	O
>	O
70	O
years	O
received	O
a	O
prescription	O
for	O
an	O
AD	O
medication	O
.	O

Despite	O
most	O
patients	O
on	O
donepezil	S-chem
and	O
memantine	S-chem
receiving	O
a	O
prescription	O
for	O
the	O
maximum	O
drug	O
dose	O
,	O
this	O
dose	O
was	O
maintained	O
for	O
2	O
consecutive	O
months	O
in	O
only	O
two	O
-	O
thirds	O
of	O
patients	O
.	O

Patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
their	O
doses	O
of	O
donepezil	S-chem
and	O
memantine	S-chem
maximised	O
if	O
prescribed	O
in	O
more	O
recent	O
years	O
(	O
2010	O
vs	O
.	O

2007	O
)	O
.	O

Rates	O
of	O
non	O
-	O
persistence	O
were	O
30.1	O
%	O
at	O
6	O
months	O
and	O
43.8	O
%	O
at	O
12	O
months	O
.	O

Older	O
age	O
[	O
75	O
+	O
vs	O
.	O

<	O
75	O
years	O
;	O
hazards	O
ratio	O
(	O
HR	O
)	O
1.16	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.06	O
-	O
1.27	O
]	O
and	O
drug	O
type	O
(	O
rivastigmine	O
vs.	E-chem
donepezil	O
;	I-chem
HR	E-chem
1.15	O
,	O
95	O
%	O
CI	O
1.03	O
-	O
1.27	O
)	O
increased	O
the	O
risk	O
of	O
non	O
-	O
persistence	O
.	O

Non	O
-	O
persistence	O
was	O
lower	O
for	O
those	O
commencing	O
therapy	O
in	O
more	O
recent	O
years	O
(	O
2010	O
vs	O
.	O

2007	O
;	O
HR	O
0.81	O
,	O
95	O
%	O
CI	O
0.73	O
-	O
0.89	O
,	O
p	O
<	O
0.001	O
)	O
and	O
for	O
those	O
on	O
multiple	O
anti	O
-	O
dementia	O
medications	O
(	O
HR	O
0.59	O
,	O
95	O
%	O
CI	O
0.54	O
-	O
0.65	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Persistence	O
was	O
significantly	O
higher	O
when	O
memantine	S-chem
was	O
co	O
-	O
prescribed	O
with	O
donepezil	S-chem
(	O
p	O
<	O
0.0001	O
)	O
.	O

CONCLUSION	O
:	O
Future	O
studies	O
should	O
explore	O
the	O
reasons	O
underlying	O
non	O
-	O
persistence	O
and	O
failure	O
to	O
maintain	O
dose	O
-	O
maximisation	O
in	O
patients	O
on	O
AD	O
medications	O
.	O

There	O
may	O
be	O
scope	O
to	O
improve	O
the	O
dosing	O
and	O
persistence	O
with	O
these	O
medications	O
in	O
the	O
community	O
.	O

Cellular	O
effects	O
of	O
imatinib	S-chem
on	O
medullary	O
thyroid	O
cancer	O
cells	O
harboring	O
multiple	O
endocrine	O
neoplasia	O
Type	O
2A	O
and	O
2B	O
associated	O
RET	S-geneY
mutations	O
.	O

BACKGROUND	O
:	O
Activating	O
mutations	O
in	O
the	O
RET	S-geneY
gene	O
,	O
which	O
encodes	O
a	O
tyrosine	B-geneN
kinase	I-geneN
receptor	E-geneN
,	O
often	O
cause	O
medullary	O
thyroid	O
carcinoma	O
(	O
MTC	O
)	O
.	O

Surgical	O
resection	O
is	O
the	O
only	O
curative	O
treatment	O
;	O
no	O
effective	O
systemic	O
treatment	O
is	O
available	O
.	O

We	O
evaluated	O
imatinib	S-chem-C4-1
,	O
a	O
tyrosine	B-geneN-C4-2
kinase	E-geneN-C4-2
inhibitor	O
currently	O
used	O
to	O
treat	O
chronic	O
myelogenous	O
leukemia	O
and	O
gastrointestinal	O
stromal	O
tumors	O
,	O
as	O
a	O
potential	O
drug	O
for	O
systemic	O
treatment	O
of	O
MTC	O
,	O
in	O
2	O
MTC	O
-	O
derived	O
cell	O
lines	O
expressing	O
multiple	O
endocrine	O
neoplasia	O
-	O
associated	O
mutant	O
RET	B-geneN
receptors	E-geneN
.	O

METHODS	O
:	O
We	O
determined	O
RET	S-geneY
expression	O
and	O
Y1062	S-geneN
phosphorylation	O
using	O
Western	O
blot	O
analysis	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

We	O
determined	O
the	O
effects	O
on	O
cell	O
proliferation	O
by	O
a	O
3	B-chem
-	I-chem
[	I-chem
4,5	I-chem
-	I-chem
dimethylthiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
]	I-chem
-	I-chem
2,5	I-chem
-	I-chem
diphenyltetrazolium	I-chem
bromide	E-chem
assay	O
,	O
and	O
we	O
used	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
with	O
annexin	O
V	O
/	O
propidium	B-chem
iodide	E-chem
staining	O
to	O
study	O
imatinib	S-chem
-	O
induced	O
cell	O
-	O
cycle	O
arrest	O
,	O
apoptosis	O
,	O
and	O
cell	O
death	O
.	O

RESULTS	O
:	O
Imatinib	S-chem-C4-1
inhibited	O
RET	S-geneY-C4-2
Y1062	S-geneN-C4-2
phosphorylation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
after	O
1.5	O
hours	O
of	O
exposure	O
.	O

After	O
16	O
hours	O
both	O
RET	S-geneY
Y1062	S-geneN
phosphorylation	O
and	O
protein	O
expression	O
levels	O
were	O
affected	O
.	O

Dose	O
-	O
dependent	O
decreases	O
in	O
cell	O
proliferation	O
of	O
both	O
cell	O
lines	O
after	O
exposure	O
to	O
imatinib	S-chem
with	O
inhibitory	O
concentration	O
of	O
50	O
%	O
levels	O
of	O
23	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
and	O
25	O
+	O
/	O
-	O
4	O
micromol	O
/	O
L	O
were	O
seen	O
.	O

These	O
values	O
are	O
high	O
,	O
compared	O
with	O
those	O
for	O
chronic	O
myelogenous	O
leukemia	O
and	O
gastrointestinal	O
stromal	O
tumors	O
.	O

We	O
further	O
could	O
show	O
that	O
imatinib	S-chem
induced	O
cell	O
-	O
cycle	O
arrest	O
,	O
and	O
apoptotic	O
and	O
nonapoptotic	O
cell	O
death	O
.	O

CONCLUSIONS	O
:	O
Imatinib	S-chem-C4-1
inhibits	O
RET	S-geneY-C4-2
-	O
mediated	O
MTC	O
cell	O
growth	O
affecting	O
RET	S-geneY-C4-2
protein	O
levels	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
concentration	O
of	O
imatinib	S-chem-C4-1
necessary	O
to	O
inhibit	O
RET	S-geneY-C4-2
in	O
vitro	O
,	O
however	O
,	O
makes	O
it	O
impossible	O
to	O
conclude	O
that	O
imatinib	S-chem
monotherapy	O
will	O
be	O
a	O
good	O
option	O
for	O
systemic	O
therapy	O
of	O
MTC	O
.	O

Clinical	O
pharmacology	O
of	O
enalkiren	S-chem-C4-1
,	O
a	O
novel	O
,	O
dipeptide	S-chem-C4-1
renin	S-geneY-C4-2
inhibitor	O
.	O

Enalkiren	S-chem-C4-1
(	O
A	B-chem-C4-1
-	I-chem-C4-1
64662	E-chem-C4-1
)	O
,	O
a	O
potent	O
,	O
dipeptide	S-chem-C4-1
renin	S-geneY-C4-2
inhibitor	O
,	O
mimics	O
the	O
transition	O
state	O
of	O
the	O
human	B-geneY-C4-2
renin	E-geneY-C4-2
substrate	O
,	O
angiotensinogen	S-geneY
.	O

Enalkiren	S-chem-C4-1
has	O
been	O
shown	O
to	O
produce	O
dose	O
-	O
related	O
suppression	O
of	O
plasma	O
renin	S-geneY-C4-2
activity	O
(	O
PRA	O
)	O
and	O
angiotensin	B-geneY-C4-2
II	E-geneY-C4-2
when	O
administered	O
intravenously	O
.	O

Doses	O
of	O
enalkiren	S-chem
of	O
less	O
than	O
0.1	O
mg	O
/	O
kg	O
induced	O
little	O
hemodynamic	O
response	O
in	O
normotensive	O
and	O
hypertensive	O
volunteers	O
despite	O
marked	O
suppression	O
of	O
PRA	O
.	O

However	O
,	O
at	O
doses	O
of	O
0.3	O
and	O
1.2	O
mg	O
/	O
kg	O
,	O
enalkiren	S-chem
produced	O
significant	O
,	O
dose	O
-	O
related	O
decreases	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
hypertensive	O
patients	O
,	O
and	O
the	O
BP	O
response	O
was	O
enhanced	O
by	O
pretreatment	O
with	O
hydrochlorothiazide	S-chem
.	O

The	O
effects	O
of	O
enalkiren	S-chem
on	O
PRA	O
and	O
BP	O
are	O
prolonged	O
despite	O
its	O
relatively	O
short	O
elimination	O
phase	O
plasma	O
half	O
-	O
life	O
(	O
1.6	O
h	O
)	O
.	O

Persistent	O
pharmacologic	O
activity	O
without	O
evidence	O
of	O
tachyphylaxis	O
was	O
demonstrated	O
during	O
1	O
week	O
of	O
treatment	O
in	O
hypertensive	O
patients	O
.	O

The	O
observed	O
dissociation	O
between	O
suppression	O
of	O
PRA	O
and	O
BP	O
response	O
and	O
the	O
recruitment	O
of	O
dose	O
-	O
related	O
BP	O
decrements	O
,	O
despite	O
complete	O
suppression	O
of	O
PRA	O
,	O
are	O
unexplained	O
phenomena	O
.	O

The	O
results	O
of	O
clinical	O
trials	O
with	O
enalkiren	S-chem-C4-1
are	O
encouraging	O
,	O
and	O
suggest	O
that	O
renin	S-geneY-C4-2
inhibitors	O
may	O
be	O
safe	O
,	O
useful	O
therapeutic	O
agents	O
in	O
the	O
management	O
of	O
hypertension	O
.	O

Inhibition	O
of	O
recombinant	O
L	B-geneN
-	I-geneN
type	I-geneN
voltage	I-geneN
-	I-geneN
gated	I-geneN
calcium	I-geneN
channels	E-geneN
by	O
positive	O
allosteric	O
modulators	O
of	O
GABAA	B-geneN
receptors	E-geneN
.	O

Benzodiazepines	S-chem
(	O
BDZs	S-chem
)	O
depress	O
neuronal	O
excitability	O
via	O
positive	O
allosteric	O
modulation	O
of	O
inhibitory	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
receptors	E-geneN
(	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
R	E-geneN
)	O
.	O

BDZs	S-chem-C4-1
and	O
other	O
positive	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
R	E-geneN
modulators	O
,	O
including	O
barbiturates	S-chem-C4-1
,	O
ethanol	S-chem-C4-1
,	O
and	O
neurosteroids	S-chem-C4-1
,	O
can	O
also	O
inhibit	O
L	B-geneN-C4-2
-	I-geneN-C4-2
type	I-geneN-C4-2
voltage	I-geneN-C4-2
-	I-geneN-C4-2
gated	I-geneN-C4-2
calcium	I-geneN-C4-2
channels	E-geneN-C4-2
(	O
L	B-geneN-C4-2
-	I-geneN-C4-2
VGCCs	E-geneN-C4-2
)	O
,	O
which	O
could	O
contribute	O
to	O
reduced	O
neuronal	O
excitability	O
.	O

Because	O
neuronal	O
L	B-geneN
-	I-geneN
VGCC	E-geneN
function	O
is	O
up	O
-	O
regulated	O
after	O
long	O
-	O
term	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
R	E-geneN
modulator	O
exposure	O
,	O
an	O
interaction	O
with	O
L	B-geneN
-	I-geneN
VGCCs	E-geneN
may	O
also	O
play	O
a	O
role	O
in	O
physical	O
dependence	O
.	O

The	O
current	O
studies	O
assessed	O
the	O
effects	O
of	O
BDZs	S-chem
(	O
diazepam	S-chem
,	O
flurazepam	S-chem
,	O
and	O
desalkylflurazepam	S-chem
)	O
,	O
allopregnanolone	S-chem
,	O
pentobarbital	S-chem
,	O
and	O
ethanol	S-chem
on	O
whole	O
-	O
cell	O
Ba	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
currents	O
through	O
recombinant	O
neuronal	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
1.2	E-geneY
and	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
1.3	E-geneY
L	B-geneN
-	I-geneN
VGCCs	E-geneN
expressed	O
with	O
beta	O
(	O
3	O
)	O
and	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
in	O
HEK293T	O
cells	O
.	O

Allopregnanolone	S-chem
was	O
the	O
most	O
potent	O
inhibitor	O
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
10	O
muM	O
)	O
,	O
followed	O
by	O
BDZs	S-chem
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
50	O
muM	O
)	O
,	O
pentobarbital	S-chem
(	O
IC	O
(	O
50	O
)	O
,	O
0.3	O
-	O
1	O
mM	O
)	O
,	O
and	O
ethanol	S-chem
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
300	O
mM	O
)	O
.	O

Ca	B-geneY-C4-2
(	I-geneY-C4-2
v	I-geneY-C4-2
)	I-geneY-C4-2
1.3	E-geneY-C4-2
channels	O
were	O
less	O
sensitive	O
to	O
pentobarbital	S-chem-C4-1
inhibition	O
than	O
Ca	B-geneY-C4-2
(	I-geneY-C4-2
v	I-geneY-C4-2
)	I-geneY-C4-2
1.2	E-geneY-C4-2
channels	O
,	O
similar	O
to	O
dihydropyridine	S-chem-MU-1
(	O
DHP	S-chem-MU-1
)	O
L	B-geneN-C6-2
-	I-geneN-C6-2
VGCC	E-geneN-C6-2
antagonists	O
.	O

All	O
GABA	B-geneN
(	I-geneN
A	I-geneN
)	I-geneN
R	E-geneN
modulators	O
induced	O
a	O
negative	O
shift	O
in	O
the	O
steady	O
-	O
state	O
inactivation	O
curve	O
of	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
1.3	E-geneY
channels	O
,	O
but	O
only	O
BDZs	S-chem-C4-1
and	O
pentobarbital	S-chem-C4-1
induced	O
a	O
negative	O
shift	O
in	O
Ca	B-geneY-C4-2
(	I-geneY-C4-2
v	I-geneY-C4-2
)	I-geneY-C4-2
1.2	E-geneY-C4-2
channel	O
inactivation	O
.	O

Mutation	O
of	O
the	O
high	B-geneN
-	I-geneN
affinity	I-geneN
DHP	I-geneN
binding	I-geneN
site	E-geneN
(	O
T1039Y	S-geneN
and	O
Q1043M	S-geneN
)	O
in	O
Ca	B-geneY
(	I-geneY
v	I-geneY
)	I-geneY
1.2	E-geneY
channels	O
reduced	O
pentobarbital	S-chem
potency	O
.	O

Despite	O
the	O
structural	O
similarity	O
between	O
benzothiazepines	S-chem
and	O
BDZs	S-chem
,	O
mutation	O
of	O
an	O
amino	B-chem
acid	E-chem
important	O
for	O
diltiazem	S-chem
potency	O
(	O
I1150A	S-geneN-C4-2
)	O
did	O
not	O
affect	O
diazepam	S-chem-C4-1
potency	O
.	O

Although	O
L	B-geneN-C4-2
-	I-geneN-C4-2
VGCC	E-geneN-C4-2
inhibition	O
by	O
BDZs	S-chem-C4-1
occurred	O
at	O
concentrations	O
that	O
are	O
possibly	O
too	O
high	O
to	O
be	O
clinically	O
relevant	O
and	O
is	O
not	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
up	O
-	O
regulation	O
of	O
L	B-geneN
-	I-geneN
VGCCs	E-geneN
during	O
long	O
-	O
term	O
treatment	O
,	O
pentobarbital	S-chem-C4-1
and	O
ethanol	O
inhibited	O
L	B-geneN-C4-2
-	I-geneN-C4-2
VGCCs	E-geneN-C4-2
at	O
clinically	O
relevant	O
concentrations	O
.	O

A	O
Nanogram	O
Dose	O
of	O
the	O
CYP3A	S-geneN-C9-2
Probe	O
Substrate	O
Midazolam	S-chem-C9-1
to	O
Evaluate	O
Drug	O
Interactions	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
establish	O
an	O
in	O
vivo	O
method	O
for	O
assessing	O
cytochrome	B-geneN
P450	I-geneN
3A	E-geneN
(	O
CYP3A	S-geneN
)	O
activity	O
using	O
therapeutically	O
inert	O
nanogram	O
doses	O
of	O
midazolam	S-chem
.	O

We	O
administered	O
four	O
escalating	O
single	O
doses	O
of	O
oral	O
midazolam	S-chem
(	O
0.0001	O
-	O
3	O
mg	O
)	O
to	O
12	O
healthy	O
participants	O
,	O
stratified	O
according	O
to	O
CYP3A5	O
carrier	O
status	O
,	O
to	O
assess	O
pharmacokinetics	O
linearity	O
.	O

We	O
then	O
evaluated	O
the	O
interactions	O
with	O
the	O
CYP3A	S-geneN-C4-2
inhibitor	O
ketoconazole	S-chem-C4-1
(	O
400	O
mg	O
q.d	O
.	O
)	O
after	O
nanogram	O
and	O
regular	O
doses	O
of	O
midazolam	O
.	E-chem

Area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
and	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
were	O
linear	O
over	O
the	O
entire	O
range	O
of	O
doses	O
.	O

Ketoconazole	S-chem
reduced	O
midazolam	S-chem
oral	O
clearance	O
by	O
92.8	O
%	O
.	O

AUC	O
and	O
Cmax	O
increased	O
by	O
1,540	O
and	O
363	O
%	O
,	O
respectively	O
.	O

CYP3A5	S-geneY-MU-2
carrier	O
status	O
had	O
no	O
influence	O
on	O
midazolam	S-chem-C9-1
oral	O
clearance	O
or	O
its	O
inhibition	O
by	O
ketoconazole	S-chem-C4-1
.	O

This	O
is	O
the	O
first	O
study	O
showing	O
that	O
midazolam	S-chem
pharmacokinetics	O
is	O
linear	O
in	O
a	O
30,000	O
-	O
fold	O
concentration	O
range	O
,	O
and	O
therefore	O
that	O
nano	O
-	O
and	O
microgram	O
doses	O
of	O
midazolam	S-chem
can	O
reliably	O
predict	O
the	O
pharmacokinetics	O
of	O
midazolam	S-chem
in	O
therapeutic	O
doses	O
and	O
can	O
be	O
used	O
to	O
assess	O
CYP3A	S-geneY
activity	O
even	O
in	O
the	O
presence	O
of	O
strong	O
CYP3A	S-geneY
inhibitors.Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
advance	O
online	O
publication	O
20	O
March	O
2013.	O
doi	O
:	O
10.1038	O
/	O
clpt.2013.27	O
.	O

Vasoconstrictive	O
drugs	O
increase	O
carbonic	B-geneY
anhydrase	I-geneY
I	E-geneY
in	O
vascular	O
smooth	O
muscle	O
while	O
vasodilating	O
drugs	O
reduce	O
the	O
activity	O
of	O
this	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

Carbonic	B-geneN-C9-2
anhydrase	E-geneN-C9-2
(	O
CA	S-geneN-C9-2
)	O
is	O
a	O
zinc	S-chem
enzyme	O
that	O
catalyses	O
the	O
reversible	O
hydration	O
reaction	O
of	O
CO2	S-chem-C9-1
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
acid	O
-	O
base	O
balance	O
.	O

We	O
have	O
previously	O
shown	O
that	O
certain	O
vasoconstrictive	O
therapeutic	O
agents	O
increase	O
CA	B-geneY
I	E-geneY
activity	O
whereas	O
vasodilating	O
drugs	O
reduce	O
the	O
activity	O
of	O
this	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

In	O
this	O
paper	O
we	O
studied	O
the	O
effect	O
of	O
other	O
vasoconstrictive	O
and	O
vasodilating	O
agents	O
on	O
CA	B-geneY
I	E-geneY
activity	O
in	O
order	O
to	O
elucidate	O
the	O
involvement	O
of	O
vascular	O
smooth	O
muscle	O
CA	B-geneY
I	E-geneY
in	O
vasoconstrictive	O
and	O
vasodilating	O
processes	O
.	O

We	O
studied	O
the	O
in	O
vitro	O
effects	O
of	O
noradrenaline	S-chem
,	O
prostaglandin	B-chem
F2	I-chem
alpha	E-chem
,	O
thromboxane	B-chem
A2	E-chem
,	O
leukotriene	B-chem
B4	E-chem
,	O
angiotensin	B-geneY
II	E-geneY
,	O
vasopressin	S-geneY
,	O
indomethacin	S-chem
,	O
prazosin	S-chem
,	O
hydralazine	S-chem
,	O
clonidine	S-chem
,	O
reserpine	S-chem
,	O
prostaglandin	B-chem
I2	E-chem
,	O
indapamide	S-chem
,	O
furosemide	S-chem
,	O
amlodipine	S-chem
,	O
verapamil	S-chem
and	O
irbesartan	S-chem
on	O
purified	O
human	B-geneY
red	I-geneY
blood	I-geneY
cell	I-geneY
CA	I-geneY
I	E-geneY
and	O
vascular	O
smooth	O
muscle	O
CA	B-geneY
I	E-geneY
isolated	O
from	O
rabbits	O
.	O

In	O
vivo	O
,	O
we	O
selected	O
six	O
groups	O
of	O
five	O
rabbits	O
each	O
,	O
which	O
were	O
administered	O
the	O
following	O
substances	O
in	O
acute	O
experiments	O
:	O
orciprenaline	S-chem
(	O
group	O
1	O
)	O
,	O
desmopressin	S-chem
(	O
group	O
2	O
)	O
,	O
verapamil	S-chem
(	O
group	O
3	O
)	O
,	O
irbesartan	S-chem
(	O
group	O
4	O
)	O
,	O
acetazolamide	S-chem
(	O
group	O
5	O
)	O
and	O
placebo	O
(	O
control	O
group	O
)	O
.	O

Vascular	O
smooth	O
muscle	O
CA	B-geneY
I	E-geneY
activity	O
and	O
systolic	O
blood	O
pressure	O
were	O
determined	O
and	O
compared	O
with	O
those	O
of	O
the	O
control	O
group	O
.	O

In	O
vitro	O
results	O
showed	O
that	O
all	O
the	O
vasoconstrictive	O
agents	O
studied	O
increased	O
purified	O
and	O
human	B-geneY
erythrocyte	I-geneY
CA	I-geneY
I	E-geneY
activity	O
as	O
well	O
as	O
vascular	O
smooth	O
muscle	O
CA	B-geneY
I	E-geneY
,	O
while	O
vasodilating	O
substances	O
reduced	O
the	O
activity	O
of	O
isozyme	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

The	O
same	O
results	O
obtained	O
in	O
vivo	O
showed	O
that	O
activation	O
of	O
vascular	O
smooth	O
muscle	O
CA	B-geneY
I	E-geneY
increased	O
blood	O
pressure	O
while	O
its	O
inhibition	O
reduced	O
blood	O
pressure	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
pHi	O
changes	O
,	O
induced	O
by	O
activating	O
or	O
inhibiting	O
CA	B-geneY
I	E-geneY
in	O
vascular	O
smooth	O
muscle	O
,	O
might	O
be	O
responsible	O
for	O
changes	O
in	O
vascular	O
tonus	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
aliphatic	B-chem
amido	I-chem
-	I-chem
quaternary	I-chem
ammonium	I-chem
salts	E-chem
for	O
anticancer	O
chemotherapy	O
:	O
Part	O
II	O
.	O

A	O
series	O
of	O
novel	O
aliphatic	B-chem
amido	I-chem
-	I-chem
quaternary	I-chem
ammonium	I-chem
salts	E-chem
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anticancer	O
effects	O
involving	O
induction	O
of	O
RhoB	S-geneY
.	O

Most	O
of	O
these	O
compounds	O
,	O
featuring	O
open	O
-	O
ring	O
forms	O
of	O
aliphatic	B-chem
amido	I-chem
-	I-chem
quaternary	I-chem
ammonium	I-chem
salts	E-chem
,	O
exhibited	O
potent	O
anti	O
-	O
proliferative	O
activities	O
in	O
human	O
cancer	O
cell	O
lines	O
,	O
including	O
PC	O
-	O
3	O
,	O
NUGC	O
-	O
3	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
ACHN	O
,	O
HCT	O
-	O
15	O
,	O
and	O
NCI	O
-	O
H23	O
.	O

In	O
further	O
evaluation	O
,	O
the	O
representative	O
compound	O
N	B-chem-C3-1
,	I-chem-C3-1
N	I-chem-C3-1
-	I-chem-C3-1
diethyl	I-chem-C3-1
-	I-chem-C3-1
N	I-chem-C3-1
-	I-chem-C3-1
(	I-chem-C3-1
2	I-chem-C3-1
-	I-chem-C3-1
(	I-chem-C3-1
N	I-chem-C3-1
-	I-chem-C3-1
methyltetradecanamido	I-chem-C3-1
)	I-chem-C3-1
ethyl	I-chem-C3-1
)	I-chem-C3-1
prop	I-chem-C3-1
-	I-chem-C3-1
2	I-chem-C3-1
-	I-chem-C3-1
en	I-chem-C3-1
-	I-chem-C3-1
1	I-chem-C3-1
-	I-chem-C3-1
aminium	I-chem-C3-1
bromide	E-chem-C3-1
(	O
3b	O
)	O
exhibited	O
potent	O
pro	O
-	O
apoptotic	O
activity	O
,	O
through	O
RhoB	S-geneY-C3-2
activation	O
,	O
in	O
HeLa	O
cells	O
.	O

Truncated	O
ErbB2	S-geneY
receptor	O
(	O
p95ErbB2	S-geneY
)	O
is	O
regulated	O
by	O
heregulin	S-geneY
through	O
heterodimer	O
formation	O
with	O
ErbB3	S-geneY
yet	O
remains	O
sensitive	O
to	O
the	O
dual	O
EGFR	S-geneY
/	O
ErbB2	S-geneY-C4-2
kinase	O
inhibitor	O
GW572016	S-chem-C4-1
.	O

The	O
expression	O
of	O
the	O
NH2	S-chem
terminally	O
truncated	O
ErbB2	S-geneY
receptor	O
(	O
p95ErbB2	S-geneY
)	O
in	O
breast	O
cancer	O
correlates	O
with	O
metastatic	O
disease	O
progression	O
compared	O
with	O
the	O
expression	O
of	O
full	O
-	O
length	O
p185ErbB2	S-geneY
.	O

We	O
now	O
show	O
that	O
heregulin	S-geneY
(	O
HRG	S-geneY
)	O
,	O
but	O
not	O
EGF	S-geneY
,	O
stimulates	O
p95ErbB2	S-geneY
phosphorylation	O
in	O
BT474	O
breast	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
phospho	B-geneY
-	I-geneY
p95ErbB2	E-geneY
forms	O
heterodimers	O
with	O
ErbB3	S-geneY
,	O
but	O
not	O
EGFR	S-geneY
,	O
while	O
p185ErbB2	S-geneY
heterodimerizes	O
with	O
both	O
EGFR	S-geneY
and	O
ErbB3	S-geneY
.	O

The	O
predilection	O
of	O
p95ErbB2	S-geneY
to	O
heterodimerize	O
with	O
ErbB3	S-geneY
provides	O
an	O
explanation	O
for	O
its	O
regulation	O
by	O
HRG	S-geneY
,	O
an	O
ErbB3	S-geneY
ligand	O
.	O

GW572016	S-chem-C4-1
,	O
a	O
reversible	O
small	O
molecule	O
inhibitor	O
of	O
EGFR	S-geneY-C4-2
and	O
ErbB2	S-geneY-C4-2
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
,	O
inhibits	O
baseline	O
p95ErbB2	S-geneY-C4-2
phosphorylation	O
in	O
BT474	O
cells	O
and	O
tumor	O
xenografts	O
.	O

Inhibition	O
of	O
p95ErbB2	S-geneY-C4-2
,	O
p185ErbB2	S-geneY-C4-2
,	O
and	O
EGFR	S-geneY-C4-2
phosphorylation	O
by	O
GW572016	S-chem-C4-1
resulted	O
in	O
the	O
inhibition	O
of	O
downstream	O
phospho	O
-	O
Erk1	B-geneN-C4-2
/	I-geneN-C4-2
2	E-geneN-C4-2
,	O
phospho	O
-	O
AKT	S-geneN-C4-2
,	O
and	O
cyclin	B-geneN-C4-2
D	E-geneN-C4-2
steady	O
-	O
state	O
protein	O
levels	O
.	O

Increased	O
phosphorylation	O
of	O
p95ErbB2	S-geneY-C4-2
and	O
AKT	S-geneN-C4-2
in	O
response	O
to	O
HRG	S-geneN
was	O
abrogated	O
to	O
varying	O
degrees	O
by	O
GW572016	S-chem-C4-1
.	O

In	O
contrast	O
,	O
trastuzumab	O
did	O
not	O
inhibit	O
p95ErbB2	S-geneY
phosphorylation	O
or	O
the	O
expression	O
of	O
downstream	O
phospho	O
-	O
Erk1	B-geneN
/	I-geneN
2	E-geneN
,	O
phospho	B-geneN
-	I-geneN
AKT	E-geneN
,	O
or	O
cyclin	B-geneN
D	E-geneN
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
trastuzumab	O
resistance	O
may	O
be	O
mediated	O
in	O
part	O
by	O
the	O
selection	O
of	O
p95ErbB2	S-geneY
-	O
expressing	O
breast	O
cancer	O
cells	O
capable	O
of	O
exerting	O
potent	O
growth	O
and	O
prosurvival	O
signals	O
through	O
p95ErbB2	S-geneY
-	O
ErbB3	S-geneY
heterodimers	O
.	O

Thus	O
,	O
p95ErbB2	S-geneY
represents	O
a	O
target	O
for	O
therapeutic	O
intervention	O
,	O
and	O
one	O
that	O
is	O
sensitive	O
to	O
GW572016	S-chem
therapy	O
.	O

2,3,7,8	B-chem
-	I-chem
Tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
-	O
mediated	O
production	O
of	O
reactive	O
oxygen	S-chem
species	O
is	O
an	O
essential	O
step	O
in	O
the	O
mechanism	O
of	O
action	O
to	O
accelerate	O
human	O
keratinocyte	O
differentiation	O
.	O

Chloracne	O
is	O
commonly	O
observed	O
in	O
humans	O
exposed	O
to	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
;	O
yet	O
,	O
the	O
mechanism	O
of	O
toxicity	O
is	O
not	O
well	O
understood	O
.	O

Using	O
normal	O
human	O
epidermal	O
keratinocytes	O
,	O
we	O
investigated	O
the	O
mechanism	O
of	O
TCDD	S-chem
-	O
mediated	O
enhancement	O
of	O
epidermal	O
differentiation	O
by	O
integrating	O
functional	O
genomic	O
,	O
metabolomic	O
,	O
and	O
biochemical	O
analyses	O
.	O

TCDD	S-chem
increased	O
the	O
expression	O
of	O
40	O
%	O
of	O
the	O
genes	O
of	O
the	O
epidermal	O
differentiation	O
complex	O
found	O
on	O
chromosome	O
1q21	O
and	O
75	O
%	O
of	O
the	O
genes	O
required	O
for	O
de	O
novo	O
ceramide	S-chem
biosynthesis	O
.	O

Lipid	O
analysis	O
demonstrated	O
that	O
eight	O
of	O
the	O
nine	O
classes	O
of	O
ceramides	S-chem
were	O
increased	O
by	O
TCDD	S-chem
,	O
altering	O
the	O
ratio	O
of	O
ceramides	S-chem
to	O
free	O
fatty	B-chem
acids	E-chem
.	O

TCDD	S-chem-C4-1
decreased	O
the	O
expression	O
of	O
the	O
glucose	B-geneN-C4-2
transporter	E-geneN-C4-2
,	O
SLC2A1	S-geneY-C4-2
,	O
and	O
most	O
of	O
the	O
glycolytic	O
transcripts	O
,	O
followed	O
by	O
decreases	O
in	O
glycolytic	O
intermediates	O
,	O
including	O
pyruvate	S-chem
.	O

NADH	S-chem
and	O
Krebs	O
cycle	O
intermediates	O
were	O
decreased	O
,	O
whereas	O
NAD	B-chem
(	I-chem
+	I-chem
)	E-chem
was	O
increased	O
.	O

Mitochondrial	O
glutathione	B-geneN-C4-2
(	I-geneN-C4-2
GSH	I-geneN-C4-2
)	I-geneN-C4-2
reductase	E-geneN-C4-2
activity	O
and	O
the	O
GSH	S-chem
/	O
glutathione	B-chem
disulfide	E-chem
ratio	O
were	O
decreased	O
by	O
TCDD	S-chem-C4-1
,	O
ultimately	O
leading	O
to	O
mitochondrial	O
dysfunction	O
,	O
characterized	O
by	O
decreased	O
inner	O
mitochondrial	O
membrane	O
potential	O
and	O
ATP	S-chem
production	O
,	O
and	O
increased	O
production	O
of	O
the	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
,	O
hydrogen	B-chem
peroxide	E-chem
.	O

Aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AHR	S-geneY
)	O
antagonists	O
blocked	O
the	O
response	O
of	O
many	O
transcripts	O
to	O
TCDD	S-chem
,	O
and	O
the	O
endpoints	O
of	O
decreased	O
ATP	S-chem
production	O
and	O
differentiation	O
,	O
suggesting	O
regulation	O
by	O
the	O
AHR	S-geneY
.	O

Cotreatment	O
of	O
cells	O
with	O
chemical	O
antioxidants	O
or	O
the	O
enzyme	O
catalase	S-geneY
blocked	O
the	O
TCDD	S-chem
-	O
mediated	O
acceleration	O
of	O
keratinocyte	O
cornified	O
envelope	O
formation	O
,	O
an	O
endpoint	O
of	O
terminal	O
differentiation	O
.	O

Thus	O
,	O
TCDD	S-chem
-	O
mediated	O
ROS	O
production	O
is	O
a	O
critical	O
step	O
in	O
the	O
mechanism	O
of	O
this	O
chemical	O
to	O
accelerate	O
keratinocyte	O
differentiation	O
.	O

Synthesis	O
and	O
in	O
vitro	O
pharmacology	O
at	O
AMPA	S-chem
and	O
kainate	S-chem
preferring	O
glutamate	B-geneN
receptors	E-geneN
of	O
4	B-chem
-	I-chem
heteroarylmethylidene	I-chem
glutamate	E-chem
analogues	O
.	O

2	B-chem-C5-1
-	I-chem-C5-1
Amino	I-chem-C5-1
-	I-chem-C5-1
3	I-chem-C5-1
-	I-chem-C5-1
[	I-chem-C5-1
3	I-chem-C5-1
-	I-chem-C5-1
hydroxy	I-chem-C5-1
-	I-chem-C5-1
5	I-chem-C5-1
-	I-chem-C5-1
(	I-chem-C5-1
2	I-chem-C5-1
-	I-chem-C5-1
thiazolyl	I-chem-C5-1
)	I-chem-C5-1
-	I-chem-C5-1
4	I-chem-C5-1
-	I-chem-C5-1
isoxazolyl	I-chem-C5-1
]	I-chem-C5-1
propionic	I-chem-C5-1
acid	E-chem-C5-1
(	O
1	O
)	O
is	O
a	O
potent	O
AMPA	B-geneN-C5-2
receptor	E-geneN-C5-2
agonist	O
with	O
moderate	O
affinity	O
for	O
native	O
kainic	B-geneN
acid	I-geneN
(	I-geneN
KA	I-geneN
)	I-geneN
receptors	E-geneN
,	O
whereas	O
(	B-chem
S	I-chem
)	I-chem
-	I-chem
E	I-chem
-	I-chem
4	I-chem
-	I-chem
(	I-chem
2,2	I-chem
-	I-chem
dimethylpropylidene	I-chem
)	I-chem
glutamic	I-chem
acid	E-chem
(	O
3	O
)	O
show	O
high	O
affinity	O
for	O
the	O
GluR5	S-geneY
subtype	O
of	O
KA	B-geneN
receptors	E-geneN
and	O
much	O
lower	O
affinity	O
for	O
the	O
GluR2	S-geneY
subtype	O
of	O
AMPA	B-geneN
receptors	E-geneN
.	O

As	O
an	O
attempt	O
to	O
develop	O
new	O
pharmacological	O
tools	O
for	O
studies	O
of	O
GluR5	S-geneY
receptors	O
,	O
(	B-chem
S	I-chem
)	I-chem
-	I-chem
E	I-chem
-	I-chem
4	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
thiazolylmethylene	I-chem
)	I-chem
glutamic	I-chem
acid	E-chem
(	O
4a	O
)	O
was	O
designed	O
as	O
a	O
structural	O
hybrid	O
between	O
1	O
and	O
3	O
.	O

4a	O
was	O
shown	O
to	O
be	O
a	O
potent	O
GluR5	S-geneY
agonist	O
and	O
a	O
high	O
affinity	O
ligand	O
and	O
to	O
indiscriminately	O
bind	O
to	O
the	O
AMPA	B-geneN
receptor	E-geneN
subtypes	O
GluR1	B-geneN
-	I-geneN
4	E-geneN
with	O
lower	O
affinities	O
.	O

Compounds	O
4b	O
-	O
h	O
,	O
in	O
which	O
the	O
2	B-chem
-	I-chem
thiazolyl	E-chem
substituent	O
of	O
4a	O
was	O
replaced	O
by	O
other	O
heterocyclic	S-chem
rings	O
,	O
which	O
have	O
previously	O
been	O
incorporated	O
as	O
5	O
-	O
substituents	O
in	O
AMPA	S-chem
analogues	O
,	O
as	O
exemplified	O
by	O
1	O
were	O
also	O
synthesized	O
.	O

Compounds	O
4b	O
-	O
h	O
were	O
either	O
inactive	O
(	O
4e	O
,	O
f	O
)	O
or	O
weaker	O
than	O
4a	O
as	O
affinity	O
ligands	O
for	O
GluR1	B-geneN
-	I-geneN
4	E-geneN
and	O
GluR5	S-geneY
with	O
relative	O
potencies	O
comparable	O
with	O
those	O
of	O
the	O
corresponding	O
AMPA	S-chem
analogues	O
as	O
AMPA	B-geneN
receptor	E-geneN
agonists	O
.	O

Compounds	O
4a	O
-	O
h	O
may	O
be	O
useful	O
tools	O
for	O
the	O
progressing	O
pharmacophore	O
mapping	O
of	O
the	O
GluR5	S-geneY
agonist	O
binding	O
site	O
.	O

Human	B-geneY
serum	I-geneY
albumin	E-geneY
-	O
based	O
design	O
of	O
a	O
diflunisal	S-chem
prodrug	O
.	O

The	O
cyclooxygenase	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
inhibitor	O
,	O
diflunisal	S-chem-C4-1
,	O
is	O
used	O
in	O
the	O
clinic	O
for	O
its	O
anti	O
-	O
inflammatory	O
activity	O
.	O

About	O
99	O
%	O
of	O
a	O
dose	O
of	O
diflunisal	S-chem
is	O
unavailable	O
for	O
reaction	O
with	O
the	O
target	O
enzyme	O
,	O
because	O
diflunisal	S-chem
strongly	O
binds	O
to	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
HSA	S-geneY
)	O
.	O

To	O
reduce	O
the	O
binding	O
affinity	O
of	O
diflunisal	S-chem
to	O
albumin	S-geneY
,	O
we	O
designed	O
and	O
synthesized	O
the	O
prodrug	O
acetyldiflunisal	S-chem
.	O

The	O
crystal	O
structure	O
of	O
HSA	S-geneY
complexed	O
with	O
fatty	B-chem
acid	E-chem
and	O
acetyldiflunisal	S-chem
revealed	O
that	O
acetyldiflunisal	S-chem
binds	O
to	O
the	O
IIA	B-geneN
subdomain	E-geneN
and	O
that	O
upon	O
binding	O
,	O
it	O
acetylates	O
lysine	S-chem
199	O
.	O

Mass	O
spectrometry	O
confirmed	O
that	O
acetyldiflunisal	S-chem
acetylates	O
Lys199	S-chem
.	O

The	O
acetylated	B-geneY
albumin	E-geneY
had	O
twofold	O
weaker	O
binding	O
affinity	O
for	O
diflunisal	S-chem
as	O
demonstrated	O
by	O
fluorescence	O
quenching	O
.	O

Reduced	O
binding	O
affinity	O
means	O
that	O
diflunisal	S-chem
is	O
more	O
easily	O
released	O
from	O
acetylated	B-geneY
albumin	E-geneY
into	O
the	O
circulation	O
.	O

Therefore	O
,	O
lower	O
doses	O
of	O
acetyldiflunisal	S-chem
compared	O
to	O
diflunisal	S-chem
will	O
be	O
required	O
.	O

Taken	O
together	O
,	O
our	O
results	O
not	O
only	O
provide	O
a	O
template	O
for	O
design	O
of	O
HSA	S-geneY
-	O
based	O
prodrugs	O
,	O
but	O
also	O
pave	O
the	O
way	O
toward	O
more	O
effective	O
use	O
of	O
diflunisal	S-chem
in	O
the	O
clinic	O
.	O

Efficacy	O
and	O
safety	O
of	O
tamsulosin	S-chem
in	O
the	O
treatment	O
of	O
urological	O
diseases	O
.	O

The	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
1	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptor	E-geneN-C6-2
antagonist	O
,	O
tamsulosin	S-chem-C6-1
,	O
is	O
selective	O
for	O
alpha	B-geneN-C6-2
(	I-geneN-C6-2
1A	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
and	I-geneN-C6-2
alpha	I-geneN-C6-2
(	I-geneN-C6-2
1D	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
over	I-geneN-C6-2
alpha	I-geneN-C6-2
(	I-geneN-C6-2
1B	I-geneN-C6-2
)	I-geneN-C6-2
-	I-geneN-C6-2
adrenoceptors	E-geneN-C6-2
.	O

Both	O
placebo	O
-	O
controlled	O
and	O
comparative	O
studies	O
with	O
other	O
agents	O
have	O
demonstrated	O
tamsulosin	S-chem
to	O
be	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
lower	O
urinary	O
symptoms	O
suggestive	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

Its	O
effectiveness	O
appears	O
to	O
be	O
maintained	O
over	O
many	O
years	O
.	O

Tamsulosin	S-chem
may	O
also	O
effectively	O
reduce	O
lower	O
urinary	O
tract	O
symptoms	O
in	O
other	O
urological	O
diseases	O
.	O

A	O
dose	O
of	O
tamsulosin	S-chem
0.4	O
mg	O
/	O
day	O
has	O
a	O
tolerability	O
close	O
to	O
that	O
of	O
placebo	O
and	O
has	O
little	O
,	O
if	O
any	O
,	O
blood	O
pressure	O
lowering	O
effects	O
.	O

Tolerability	O
and	O
lack	O
of	O
blood	O
pressure	O
lowering	O
are	O
maintained	O
even	O
in	O
high	O
-	O
risk	O
patients	O
such	O
as	O
those	O
with	O
cardiovascular	O
comorbidity	O
and	O
/	O
or	O
comedication	O
.	O

Apart	O
from	O
adrenoceptor	S-geneN
subtype	O
-	O
selectivity	O
,	O
a	O
smooth	O
pharmacokinetic	O
profile	O
of	O
its	O
modified	O
-	O
release	O
formulation	O
and	O
a	O
selective	O
accumulation	O
in	O
target	O
tissues	O
may	O
contribute	O
to	O
an	O
excellent	O
efficacy	O
:	O
tolerability	O
ratio	O
.	O

alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
adrenergic	I-geneY
receptors	E-geneY
in	O
gonadotrophin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
neurones	O
:	O
relation	O
to	O
Transport	O
-	O
P	O
.	O

1	O
.	O

Peptidergic	O
neurones	O
accumulate	O
amines	S-chem
via	O
an	O
unusual	O
uptake	O
process	O
,	O
designated	O
Transport	O
-	O
P	O
.	O

[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
binds	O
to	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
adrenoceptors	E-geneN
on	O
these	O
cells	O
and	O
is	O
displaceable	O
by	O
unlabelled	O
prazosin	S-chem
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
7	O
)	O
M	O
.	O

However	O
,	O
at	O
greater	O
concentrations	O
of	O
prazosin	S-chem
,	O
there	O
is	O
a	O
paradoxical	O
accumulation	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
which	O
we	O
have	O
attributed	O
to	O
Transport	O
-	O
P	O
.	O

Uptake	O
of	O
prazosin	S-chem
via	O
Transport	O
-	O
P	O
is	O
detectable	O
at	O
10	O
(	O
-	O
10	O
)	O
M	O
prazosin	S-chem
concentration	O
,	O
is	O
linear	O
up	O
to	O
10	O
(	O
-	O
7	O
)	O
M	O
and	O
at	O
greater	O
concentrations	O
becomes	O
non	O
-	O
linear	O
.	O

In	O
contrast	O
,	O
in	O
noradrenergic	O
neurones	O
,	O
noradrenaline	S-chem
uptake	O
is	O
linear	O
and	O
saturates	O
above	O
10	O
(	O
-	O
7	O
)	O
M	O
.	O

In	O
noradrenergic	O
neurones	O
and	O
in	O
non	O
-	O
neuronal	O
cells	O
,	O
there	O
is	O
no	O
uptake	O
of	O
prazosin	S-chem
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
suggesting	O
that	O
Transport	O
-	O
P	O
is	O
a	O
specialised	O
function	O
of	O
peptidergic	O
neurones	O
.	O

2	O
.	O

Using	O
a	O
mouse	O
peptidergic	O
(	O
gonadotrophin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
,	O
GnRH	S-geneY
)	O
neuronal	O
cell	O
line	O
which	O
possesses	O
Transport	O
-	O
P	O
,	O
we	O
have	O
studied	O
the	O
interaction	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
adrenoceptors	E-geneN
with	O
Transport	O
-	O
P	O
.	O

Polymerase	O
chain	O
reactions	O
and	O
DNA	O
sequencing	O
of	O
the	O
products	O
demonstrated	O
that	O
only	O
the	O
alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
sub	I-geneY
-	I-geneY
type	I-geneY
of	I-geneY
adrenoceptors	E-geneY
is	O
present	O
in	O
GnRH	S-geneY
cells	O
.	O

3	O
.	O

In	O
COS	O
cells	O
transfected	O
with	O
alpha	B-geneY
(	I-geneY
1b	I-geneY
)	I-geneY
adrenoceptor	E-geneY
cDNA	O
and	O
in	O
DDT	O
(	O
1	O
)	O
MF	O
-	O
2	O
cells	O
which	O
express	O
native	O
alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
adrenoceptors	E-geneY
,	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
was	O
displaced	O
by	O
unlabelled	O
prazosin	S-chem
in	O
a	O
normal	O
equilibrium	O
process	O
,	O
with	O
no	O
prazosin	S-chem
paradox	O
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

In	O
DDT	O
(	O
1	O
)	O
MF	O
-	O
2	O
cells	O
,	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
was	O
displaced	O
likewise	O
by	O
a	O
series	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	E-geneN
adrenergic	O
agonists	O
,	O
none	O
of	O
which	O
increased	O
the	O
binding	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
.	O

Hence	O
,	O
the	O
prazosin	S-chem
paradox	O
is	O
not	O
due	O
to	O
some	O
function	O
of	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
adrenoceptors	E-geneN
,	O
such	O
as	O
internalization	O
of	O
ligand	O
-	O
receptor	O
complexes	O
.	O

4	O
.	O

In	O
neurones	O
which	O
possess	O
Transport	O
-	O
P	O
,	O
transfection	O
with	O
alpha	B-geneY
(	I-geneY
1b	I-geneY
)	I-geneY
adrenoceptor	E-geneY
cDNA	O
resulted	O
in	O
over	O
-	O
expression	O
of	O
alpha	B-geneY
(	I-geneY
1B	I-geneY
)	I-geneY
adrenoceptors	E-geneY
,	O
but	O
the	O
prazosin	S-chem
paradox	O
was	O
unaltered	O
.	O

Thus	O
,	O
alpha	B-geneN
(	I-geneN
1	I-geneN
)	I-geneN
adrenoceptors	E-geneN
and	O
Transport	O
-	O
P	O
mediate	O
distinct	O
functions	O
in	O
peptidergic	O
neurones	O
.	O

Temporal	O
profile	O
of	O
brain	O
and	O
pituitary	O
GnRHs	S-geneN
,	O
GnRH	B-geneY
-	I-geneY
R	E-geneY
and	O
gonadotropin	S-geneN
mRNA	O
expression	O
and	O
content	O
during	O
early	O
development	O
in	O
European	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
L.	O
)	O
.	O

A	O
likely	O
endocrine	O
control	O
mechanism	O
for	O
sexual	O
differentiation	O
in	O
size	O
-	O
graded	O
populations	O
of	O
European	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
)	O
is	O
proposed	O
by	O
evaluating	O
the	O
brain	O
expression	O
and	O
pituitary	O
content	O
of	O
two	O
forms	O
of	O
gonadotropin	B-geneN
-	I-geneN
releasing	I-geneN
hormone	E-geneN
(	O
GnRH	S-geneN
)	O
,	O
namely	O
sea	O
bream	O
(	O
sbGnRH	S-geneN
)	O
and	O
salmon	O
(	O
sGnRH	S-geneN
)	O
,	O
the	O
pituitary	O
expression	O
of	O
one	O
subtype	O
of	O
GnRH	B-geneY
receptor	E-geneY
(	O
dlGnRH	B-geneN
-	I-geneN
R	I-geneN
-	I-geneN
2A	E-geneN
)	O
and	O
the	O
three	O
gonadotropin	S-geneN
(	O
GtH	S-geneN
)	O
subunits	O
,	O
namely	O
glycoprotein	B-geneN
alpha	E-geneN
(	O
GPalpha	S-geneN
)	O
,	O
follicle	B-geneN
-	I-geneN
stimulating	I-geneN
hormone	I-geneN
beta	E-geneN
(	O
FSHbeta	S-geneN
)	O
and	O
luteinizing	B-geneN
hormone	I-geneN
beta	E-geneN
(	O
LHbeta	S-geneN
)	O
,	O
as	O
well	O
as	O
the	O
pituitary	O
and	O
plasma	O
LH	S-geneN
levels	O
between	O
50	O
and	O
300	O
days	O
post	O
-	O
hatching	O
(	O
dph	O
)	O
.	O

Four	O
gradings	O
were	O
conducted	O
between	O
2	O
and	O
8	O
months	O
after	O
hatching	O
,	O
resulting	O
in	O
a	O
population	O
of	O
large	O
and	O
small	O
individuals	O
,	O
having	O
96.5	O
%	O
females	O
(	O
female	O
-	O
dominant	O
population	O
)	O
and	O
69.2	O
%	O
males	O
(	O
male	O
-	O
dominant	O
population	O
)	O
,	O
respectively	O
,	O
after	O
the	O
last	O
grading	O
.	O

The	O
onset	O
of	O
gonadal	O
differentiation	O
was	O
different	O
in	O
the	O
two	O
sexes	O
,	O
and	O
coincided	O
with	O
a	O
peak	O
of	O
expression	O
of	O
sbGnRH	S-geneN
or	O
sGnRH	S-geneN
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
these	O
GnRHs	S-geneN
was	O
correlated	O
with	O
the	O
expression	O
of	O
dlGnRH	B-geneN
-	I-geneN
R	I-geneN
-	I-geneN
2A	E-geneN
.	O

Sex	O
-	O
related	O
differences	O
in	O
the	O
brain	O
and	O
pituitary	O
content	O
of	O
sbGnRH	S-geneN
were	O
also	O
found	O
at	O
the	O
time	O
of	O
sexual	O
differentiation	O
.	O

Moreover	O
,	O
the	O
observed	O
sexual	O
dimorphism	O
at	O
the	O
transcriptional	O
or	O
synthesis	O
level	O
of	O
these	O
GnRH	S-geneN
forms	O
suggests	O
that	O
a	O
different	O
neuro	O
-	O
hormonal	O
regulation	O
is	O
operating	O
according	O
to	O
sex	O
.	O

At	O
the	O
onset	O
of	O
sex	O
differentiation	O
,	O
FSHbeta	S-geneN
transcriptional	O
activity	O
reached	O
maximal	O
values	O
,	O
which	O
were	O
maintained	O
until	O
the	O
completion	O
of	O
the	O
process	O
.	O

The	O
present	O
study	O
suggests	O
a	O
role	O
for	O
sbGnRH	S-geneN
,	O
sGnRH	S-geneN
and	O
the	O
dlGnRH	B-geneN
-	I-geneN
R	I-geneN
-	I-geneN
2A	E-geneN
during	O
gonadal	O
differentiation	O
,	O
possibly	O
through	O
enhancement	O
of	O
FSHbeta	S-geneN
gene	O
expression	O
.	O

In	O
males	O
,	O
a	O
different	O
endocrine	O
regulation	O
seems	O
to	O
exist	O
also	O
during	O
spermiogenesis	O
and	O
spermiation	O
,	O
when	O
gene	O
transcription	O
,	O
peptide	O
synthesis	O
and	O
release	O
of	O
LH	S-geneN
are	O
of	O
greater	O
importance	O
.	O

Inhibitory	O
effect	O
of	O
1α,25	B-chem
-	I-chem
dihydroxyvitamin	I-chem
D₃	E-chem
on	O
excretion	O
of	O
JBP485	S-chem
via	O
organic	B-geneN
anion	I-geneN
transporters	E-geneN
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
pharmacokinetic	O
mechanism	O
of	O
interaction	O
between	O
JBP485	S-chem
and	O
1α,25	B-chem
-	I-chem
dihydroxyvitamin	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
[	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
]	O
.	O

Rats	O
were	O
injected	O
intraperitoneally	O
with	O
0.64	O
nmol	O
/	O
kg	O
/	O
day	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
in	O
1	O
ml	O
/	O
kg	O
corn	O
oil	O
for	O
5	O
days	O
.	O

The	O
plasma	O
and	O
urine	O
concentrations	O
of	O
JBP485	S-chem
after	O
intravenous	O
administration	O
and	O
the	O
uptake	O
of	O
JBP485	S-chem
in	O
kidney	O
slices	O
in	O
vitro	O
were	O
determined	O
by	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
.	O

Quantitative	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blotting	O
,	O
immunohistochemical	O
analysis	O
and	O
immunofluorescence	O
were	O
used	O
to	O
determine	O
the	O
changes	O
in	O
the	O
expression	O
of	O
organic	B-geneN
anion	I-geneN
transporter	E-geneN
(	B-geneY
Oat	I-geneY
)	I-geneY
1	E-geneY
and	O
Oat3	S-geneY
in	O
rat	O
kidney	O
in	O
response	O
to	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
treatment	O
.	O

The	O
plasma	O
concentrations	O
and	O
AUCs	O
of	O
JBP485	S-chem
were	O
significantly	O
increased	O
,	O
while	O
the	O
renal	O
clearance	O
of	O
JBP485	S-chem
and	O
uptake	O
of	O
JBP485	S-chem
in	O
kidney	O
slices	O
were	O
significantly	O
decreased	O
after	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
treatment	O
.	O

These	O
results	O
confirmed	O
that	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
inhibited	O
renal	O
excretion	O
of	O
JBP485	S-chem
.	O

Moreover	O
,	O
1,25	B-chem-C4-1
(	I-chem-C4-1
OH	I-chem-C4-1
)	I-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
)	I-chem-C4-1
D	I-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
)	E-chem-C4-1
decreased	O
expression	O
of	O
Oat1	S-geneY-C4-2
and	O
Oat3	S-geneY-C4-2
in	O
rat	O
kidney	O
.	O

Our	O
results	O
are	O
novel	O
in	O
demonstrating	O
an	O
interaction	O
between	O
JBP485	S-chem
and	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
when	O
they	O
are	O
co	O
-	O
administered	O
.	O

The	O
mechanism	O
of	O
interaction	O
between	O
JBP485	S-chem
and	O
1,25	B-chem
(	I-chem
OH	I-chem
)	I-chem
(	I-chem
2	I-chem
)	I-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
could	O
be	O
explained	O
at	O
least	O
in	O
part	O
by	O
inhibitory	O
effect	O
of	O
1,25	B-chem-C4-1
(	I-chem-C4-1
OH	I-chem-C4-1
)	I-chem-C4-1
(	I-chem-C4-1
2	I-chem-C4-1
)	I-chem-C4-1
D	I-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
)	E-chem-C4-1
on	O
expression	O
of	O
Oats	S-geneN-C4-2
in	O
rat	O
kidney	O
.	O

Effects	O
of	O
bidentate	O
coordination	O
on	O
the	O
molecular	O
properties	O
rapta	B-chem
-	I-chem
C	E-chem
based	O
complex	O
using	O
theoretical	O
approach	O
.	O

In	O
this	O
work	O
several	O
quantum	O
properties	O
including	O
the	O
NEDA	O
and	O
QTAIM	O
are	O
computed	O
on	O
three	O
models	O
of	O
rapta	B-chem
-	I-chem
C	E-chem
complexes	O
using	O
DFT	O
with	O
hybrid	O
functional	O
and	O
basis	O
set	O
with	O
ECP	O
and	O
without	O
ECP	O
.	O

Several	O
interesting	O
correlations	O
within	O
the	O
observed	O
properties	O
and	O
also	O
with	O
the	O
reported	O
experimental	O
behaviors	O
of	O
these	O
complexes	O
including	O
their	O
biological	O
activities	O
are	O
presented	O
.	O

The	O
study	O
shows	O
that	O
the	O
stability	O
of	O
the	O
two	O
complexes	O
with	O
bidentate	O
ligands	O
is	O
associated	O
with	O
their	O
high	O
hydrogen	S-chem
bonding	O
stability	O
and	O
existence	O
of	O
stronger	O
non	O
-	O
covalent	O
metal	O
-	O
ligand	O
bonds	O
.	O

The	O
energy	O
decomposition	O
analysis	O
indicated	O
that	O
inter	O
-	O
atomic	O
interactions	O
in	O
the	O
three	O
forms	O
of	O
rapta	B-chem
-	I-chem
C	E-chem
complexes	O
and	O
their	O
stability	O
are	O
governed	O
by	O
the	O
charge	O
transfer	O
term	O
with	O
significant	O
contributions	O
from	O
polarization	O
and	O
electrostatic	O
terms	O
.	O

The	O
higher	O
stability	O
of	O
complex	O
1	O
and	O
2	O
over	O
3	O
comes	O
from	O
the	O
lower	O
exchange	O
repulsion	O
and	O
higher	O
polarization	O
contributions	O
to	O
their	O
stability	O
which	O
agrees	O
perfectly	O
with	O
the	O
experimental	O
observation	O
.	O

Our	O
results	O
provide	O
insight	O
into	O
the	O
nature	O
of	O
intramolecular	O
forces	O
that	O
influence	O
the	O
structural	O
stability	O
of	O
the	O
three	O
complexes	O
.	O

Changes	O
in	O
A1C	S-geneY
Levels	O
Are	O
Significantly	O
Associated	O
With	O
Changes	O
in	O
Levels	O
of	O
the	O
Cardiovascular	O
Risk	O
Biomarker	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
:	O
Results	O
from	O
SteP	O
Study	O
.	O

OBJECTIVEThe	O
effect	O
of	O
therapeutic	O
strategies	O
on	O
cardiovascular	O
(	O
CV	O
)	O
disease	O
can	O
be	O
evaluated	O
by	O
monitoring	O
changes	O
in	O
CV	O
risk	O
biomarkers	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
a	O
structured	O
self	O
-	O
monitoring	O
of	O
blood	O
glucose	S-chem
(	O
SMBG	O
)	O
protocol	O
and	O
the	O
resulting	O
improvements	O
in	O
glycemic	O
control	O
on	O
changes	O
in	O
high	O
-	O
sensitivity	O
C	B-geneY
-	I-geneY
reactive	I-geneY
protein	E-geneY
(	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
)	O
in	O
insulin	S-geneY
-	O
naïve	O
patients	O
with	O
type	O
2	O
diabetes.RESEARCH	O
DESIGN	O
AND	O
METHODSThe	O
Structured	O
Testing	O
Program	O
(	O
STeP	O
)	O
study	O
was	O
a	O
prospective	O
,	O
cluster	O
-	O
randomized	O
,	O
multicenter	O
trial	O
in	O
which	O
483	O
poorly	O
controlled	O
,	O
insulin	S-geneY
-	O
naïve	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
randomized	O
to	O
active	O
control	O
(	O
ACG	O
)	O
or	O
structured	O
testing	O
(	O
STG	O
)	O
that	O
included	O
quarterly	O
structured	O
SMBG	O
.	O

Changes	O
in	O
A1C	S-geneY
,	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
,	O
and	O
glycemic	O
variability	O
(	O
STG	O
subjects	O
only	O
)	O
were	O
measured	O
at	O
baseline	O
and	O
quarterly.RESULTSReductions	O
in	O
geometric	O
mean	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
values	O
were	O
significantly	O
greater	O
in	O
the	O
STG	O
group	O
at	O
months	O
3	O
(	O
P	O
=	O
0.005	O
)	O
,	O
6	O
(	O
P	O
=	O
0.0003	O
)	O
,	O
and	O
12	O
(	O
P	O
=	O
0.04	O
)	O
than	O
in	O
the	O
ACG	O
group	O
.	O

STG	O
patients	O
at	O
high	O
CV	O
risk	O
(	O
>	O
3	O
mg	O
/	O
L	O
)	O
showed	O
significantly	O
greater	O
reductions	O
in	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
levels	O
than	O
ACG	O
patients	O
at	O
high	O
CV	O
risk	O
:	O
-	O
3.64	O
mg	O
/	O
dL	O
(	O
95	O
%	O
CI	O
-	O
4.21	O
to	O
-	O
3.06	O
)	O
versus	O
-	O
2.18	O
mg	O
/	O
dL	O
(	O
-	O
2.93	O
to	O
-	O
1.43	O
)	O
,	O
respectively	O
(	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
reductions	O
in	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
and	O
A1C	S-geneY
in	O
both	O
groups	O
:	O
standardized	O
coefficient	O
(	O
β	O
)	O
was	O
0.25	O
for	O
the	O
entire	O
cohort	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
0.31	O
for	O
STG	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
0.16	O
for	O
ACG	O
(	O
P	O
=	O
0.02	O
)	O
.CONCLUSIONSReductions	O
in	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
level	O
are	O
associated	O
with	O
reductions	O
in	O
A1C	S-geneY
but	O
not	O
reductions	O
in	O
lipids	O
or	O
glycemic	O
variability	O
.	O

Comprehensive	O
structured	O
SMBG	O
-	O
based	O
interventions	O
that	O
lower	O
A1C	S-geneY
may	O
translate	O
into	O
improvements	O
in	O
CV	O
risk	O
,	O
as	O
evidenced	O
by	O
levels	O
of	O
the	O
biomarker	O
hs	B-geneY
-	I-geneY
CRP	E-geneY
.	O

Gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
antagonist	O
in	O
the	O
management	O
of	O
prostate	O
cancer	O
.	O

Luteinizing	B-geneY
hormone	I-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
LHRH	S-geneY
)	O
agonist	O
therapy	O
to	O
induce	O
medical	O
castration	O
has	O
become	O
the	O
most	O
common	O
form	O
of	O
hormonal	O
therapy	O
for	O
advanced	O
and	O
metastatic	O
prostate	O
cancer	O
.	O

When	O
treatment	O
is	O
started	O
,	O
LHRH	S-geneY
agonists	O
initially	O
stimulate	O
the	O
release	O
of	O
LH	S-geneN
,	O
causing	O
a	O
surge	O
in	O
serum	O
testosterone	S-chem
that	O
can	O
precipitate	O
a	O
``	O
flare	O
``	O
phenomenon	O
or	O
worsening	O
of	O
disease	O
,	O
particularly	O
in	O
patients	O
with	O
bone	O
metastatic	O
disease	O
.	O

Gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	I-geneY
(	I-geneY
GnRH	I-geneY
)	I-geneY
receptor	E-geneY
antagonism	O
represents	O
a	O
newer	O
approach	O
to	O
medical	O
castration	O
.	O

Abarelix	O
is	O
a	O
pure	O
GnRH	B-geneY
receptor	E-geneY
antagonist	O
that	O
is	O
devoid	O
of	O
any	O
LHRH	S-geneY
agonist	O
activity	O
.	O

Results	O
from	O
1	O
phase	O
II	O
and	O
3	O
phase	O
III	O
clinical	O
trials	O
demonstrate	O
that	O
abarelix	O
produces	O
medical	O
castration	O
more	O
quickly	O
and	O
without	O
causing	O
testosterone	S-chem
surge	O
,	O
as	O
compared	O
with	O
LHRH	S-geneY
agonists	O
with	O
or	O
without	O
a	O
nonsteroidal	O
antagonist	O
.	O

The	O
safety	O
profile	O
in	O
terms	O
of	O
adverse	O
events	O
is	O
comparable	O
between	O
the	O
2	O
types	O
of	O
treatment	O
,	O
but	O
the	O
lack	O
of	O
testosterone	S-chem
surge	O
with	O
abarelix	O
might	O
confer	O
a	O
safety	O
advantage	O
by	O
abolishing	O
the	O
risk	O
of	O
a	O
disease	O
flare	O
.	O

Desvenlafaxine	B-chem
succinate	E-chem
:	O
A	O
new	O
serotonin	S-chem
and	O
norepinephrine	S-chem
reuptake	O
inhibitor	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
a	O
new	O
chemical	O
entity	O
,	O
desvenlafaxine	B-chem
succinate	E-chem
(	O
DVS	S-chem
)	O
.	O

DVS	S-chem
is	O
a	O
novel	O
salt	O
form	O
of	O
the	O
isolated	O
major	O
active	O
metabolite	O
of	O
venlafaxine	S-chem
.	O

Competitive	O
radioligand	O
binding	O
assays	O
were	O
performed	O
using	O
cells	O
expressing	O
either	O
the	O
human	B-geneY-C4-2
serotonin	I-geneY-C4-2
(	I-geneY-C4-2
5	I-geneY-C4-2
-	I-geneY-C4-2
HT	I-geneY-C4-2
)	I-geneY-C4-2
transporter	E-geneY-C4-2
(	O
hSERT	S-geneY-C4-2
)	O
or	O
norepinephrine	B-geneY-C4-2
(	I-geneY-C4-2
NE	I-geneY-C4-2
)	I-geneY-C4-2
transporter	E-geneY-C4-2
(	O
hNET	S-geneY-C4-2
)	O
with	O
K	O
(	O
i	O
)	O
values	O
for	O
DVS	S-chem-C4-1
of	O
40.2	O
+	O
/	O
-	O
1.6	O
and	O
558.4	O
+	O
/	O
-	O
121.6	O
nM	O
,	O
respectively	O
.	O

DVS	S-chem
showed	O
weak	O
binding	O
affinity	O
(	O
62	O
%	O
inhibition	O
at	O
100	O
microM	O
)	O
at	O
the	O
human	B-geneY
dopamine	I-geneY
(	I-geneY
DA	I-geneY
)	I-geneY
transporter	E-geneY
.	O

Inhibition	O
of	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
5	I-chem-C9-1
-	I-chem-C9-1
HT	E-chem-C9-1
or	O
[	B-chem-C9-1
3H	I-chem-C9-1
]	I-chem-C9-1
NE	E-chem-C9-1
uptake	O
by	O
DVS	S-chem
for	O
the	O
hSERT	S-geneY-C9-2
or	O
hNET	S-geneY-C9-2
produced	O
IC50	O
values	O
of	O
47.3	O
+	O
/	O
-	O
19.4	O
and	O
531.3	O
+	O
/	O
-	O
113.0	O
nM	O
,	O
respectively	O
.	O

DVS	S-chem
(	O
10	O
microM	O
)	O
,	O
examined	O
at	O
a	O
large	O
number	O
of	O
nontransporter	O
targets	O
,	O
showed	O
no	O
significant	O
activity	O
.	O

DVS	S-chem
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
rapidly	O
penetrated	O
the	O
male	O
rat	O
brain	O
and	O
hypothalamus	O
.	O

DVS	S-chem
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
significantly	O
increased	O
extracellular	O
NE	S-chem
levels	O
compared	O
with	O
baseline	O
in	O
the	O
male	O
rat	O
hypothalamus	O
but	O
had	O
no	O
effect	O
on	O
DA	S-chem
levels	O
using	O
microdialysis	O
.	O

To	O
mimic	O
chronic	O
selective	O
serotonin	S-chem
reuptake	O
inhibitor	O
treatment	O
and	O
to	O
block	O
the	O
inhibitory	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
autoreceptors	O
,	O
a	O
5	B-geneY-C6-2
-	I-geneY-C6-2
HT	I-geneY-C6-2
(	I-geneY-C6-2
1A	I-geneY-C6-2
)	E-geneY-C6-2
antagonist	O
,	O
N	B-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
[	I-chem-C6-1
4	I-chem-C6-1
-	I-chem-C6-1
(	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
methoxyphenyl	I-chem-C6-1
)	I-chem-C6-1
-	I-chem-C6-1
1	I-chem-C6-1
-	I-chem-C6-1
piperazinyl	I-chem-C6-1
]	I-chem-C6-1
ethyl	I-chem-C6-1
]	I-chem-C6-1
-	I-chem-C6-1
N	I-chem-C6-1
-	I-chem-C6-1
2	I-chem-C6-1
-	I-chem-C6-1
pyridinylcyclo	I-chem-C6-1
hexanecarboxamide	I-chem-C6-1
maleate	I-chem-C6-1
salt	E-chem-C6-1
(	O
WAY	B-chem-C6-1
-	I-chem-C6-1
100635	E-chem-C6-1
)	O
(	O
0.3	O
mg	O
/	O
kg	O
s.c.	O
)	O
,	O
was	O
administered	O
with	O
DVS	S-chem
(	O
30	O
mg	O
/	O
kg	O
orally	O
)	O
.	O

5	B-chem
-	I-chem
HT	E-chem
increased	O
78	O
%	O
compared	O
with	O
baseline	O
with	O
no	O
additional	O
increase	O
in	O
NE	S-chem
or	O
DA	S-chem
levels	O
.	O

In	O
conclusion	O
,	O
DVS	S-chem
is	O
a	O
new	O
5	B-chem
-	I-chem
HT	E-chem
and	O
NE	S-chem
reuptake	O
inhibitor	O
in	O
vitro	O
and	O
in	O
vivo	O
that	O
demonstrates	O
good	O
brain	O
-	O
to	O
-	O
plasma	O
ratios	O
,	O
suggesting	O
utility	O
in	O
a	O
variety	O
of	O
central	O
nervous	O
system	O
-	O
related	O
disorders	O
.	O

Interactions	O
between	O
CYP2E1	S-geneY
and	O
CYP2B4	S-geneY
:	O
effects	O
on	O
affinity	O
for	O
NADPH	B-geneY
-	I-geneY
cytochrome	I-geneY
P450	I-geneY
reductase	E-geneY
and	O
substrate	O
metabolism	O
.	O

Studies	O
in	O
microsomal	O
and	O
reconstituted	O
systems	O
have	O
shown	O
that	O
the	O
presence	O
of	O
one	O
cytochrome	B-geneN
P450	E-geneN
isoform	O
can	O
significantly	O
influence	O
the	O
catalytic	O
activity	O
of	O
another	O
isoform	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
whether	O
CYP2E1	S-geneY
could	O
influence	O
the	O
catalytic	O
activity	O
of	O
CYP2B4	S-geneY
under	O
steady	O
-	O
state	O
turnover	O
conditions	O
.	O

The	O
results	O
show	O
that	O
CYP2E1	S-geneY
inhibits	O
CYP2B4	S-geneY-C9-2
-	O
mediated	O
metabolism	O
of	O
benzphetamine	S-chem-C9-1
(	O
BNZ	S-chem-C9-1
)	O
with	O
a	O
K	O
(	O
i	O
)	O
of	O
0.04	O
µM	O
.	O

However	O
,	O
CYP2B4	S-geneY
is	O
not	O
an	O
inhibitor	O
of	O
CYP2E1	S-geneY-C9-2
-	O
mediated	O
p	B-chem-C9-1
-	I-chem-C9-1
nitrophenol	E-chem-C9-1
hydroxylation	O
.	O

When	O
these	O
inhibition	O
studies	O
were	O
performed	O
with	O
the	O
artificial	O
oxidant	O
tert	B-chem
-	I-chem
butyl	I-chem
hydroperoxide	E-chem
,	O
CYP2E1	S-geneY
did	O
not	O
significantly	O
inhibit	O
CYP2B4	S-geneY
activity	O
.	O

Determinations	O
of	O
the	O
apparent	O
K	O
(	O
M	O
)	O
and	O
k	O
(	O
cat	O
)	O
of	O
CYP2B4	S-geneY
for	O
CPR	S-geneY
in	O
the	O
presence	O
of	O
increasing	O
concentrations	O
of	O
CYP2E1	S-geneY
revealed	O
a	O
mixed	O
inhibition	O
of	O
CYP2B4	S-geneY
by	O
CYP2E1	S-geneY
.	O

At	O
low	O
concentrations	O
of	O
CYP2E1	S-geneY
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	S-geneY
for	O
CPR	S-geneY
increased	O
up	O
to	O
23	O
-	O
fold	O
with	O
virtually	O
no	O
change	O
in	O
the	O
k	O
(	O
cat	O
)	O
for	O
the	O
reaction	O
,	O
however	O
,	O
at	O
higher	O
concentrations	O
of	O
CYP2E1	S-geneY
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	S-geneY
for	O
CPR	S-geneY
decreased	O
to	O
levels	O
similar	O
to	O
those	O
observed	O
in	O
the	O
absence	O
of	O
CYP2E1	S-geneY
and	O
the	O
k	O
(	O
cat	O
)	O
also	O
decreased	O
by	O
11	O
-	O
fold	O
.	O

Additionally	O
,	O
CYP2E1	S-geneY
increased	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	S-geneY
for	O
BNZ	S-chem
by	O
8	O
-	O
fold	O
and	O
the	O
apparent	O
K	O
(	O
M	O
)	O
did	O
not	O
decrease	O
to	O
its	O
original	O
value	O
when	O
saturating	O
concentrations	O
of	O
CPR	S-geneY
were	O
used	O
.	O

While	O
the	O
individual	O
apparent	O
K	O
(	O
M	O
)	O
values	O
of	O
CYP2B4	S-geneY
and	O
CYP2E1	S-geneY
for	O
CPR	S-geneY
are	O
similar	O
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2E1	S-geneY
for	O
CPR	S-geneY
in	O
the	O
presence	O
of	O
CYP2B4	S-geneN
decreased	O
significantly	O
,	O
thus	O
suggesting	O
that	O
CYP2B4	S-geneY
enhances	O
the	O
affinity	O
of	O
CYP2E1	S-geneY
for	O
CPR	S-geneY
and	O
this	O
may	O
allow	O
CYP2E1	S-geneY
to	O
out	O
-	O
compete	O
CYP2B4	S-geneY
for	O
CPR	S-geneY
.	O

AMPK	S-geneN
is	O
a	O
negative	O
regulator	O
of	O
the	O
Warburg	O
effect	O
and	O
suppresses	O
tumor	O
growth	O
in	O
vivo	O
.	O

AMPK	S-geneN
is	O
a	O
metabolic	O
sensor	O
that	O
helps	O
maintain	O
cellular	O
energy	O
homeostasis	O
.	O

Despite	O
evidence	O
linking	O
AMPK	S-geneN
with	O
tumor	O
suppressor	O
functions	O
,	O
the	O
role	O
of	O
AMPK	S-geneN
in	O
tumorigenesis	O
and	O
tumor	O
metabolism	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
AMPK	S-geneN
negatively	O
regulates	O
aerobic	O
glycolysis	O
(	O
the	O
Warburg	O
effect	O
)	O
in	O
cancer	O
cells	O
and	O
suppresses	O
tumor	O
growth	O
in	O
vivo	O
.	O

Genetic	O
ablation	O
of	O
the	O
α1	B-geneY
catalytic	I-geneY
subunit	I-geneY
of	I-geneY
AMPK	E-geneY
accelerates	O
Myc	S-geneY
-	O
induced	O
lymphomagenesis	O
.	O

Inactivation	O
of	O
AMPKα	S-geneN
in	O
both	O
transformed	O
and	O
nontransformed	O
cells	O
promotes	O
a	O
metabolic	O
shift	O
to	O
aerobic	O
glycolysis	O
,	O
increased	O
allocation	O
of	O
glucose	S-chem
carbon	S-chem
into	O
lipids	O
,	O
and	O
biomass	O
accumulation	O
.	O

These	O
metabolic	O
effects	O
require	O
normoxic	O
stabilization	O
of	O
the	O
hypoxia	B-geneY
-	I-geneY
inducible	I-geneY
factor	I-geneY
-	I-geneY
1α	E-geneY
(	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
)	O
,	O
as	O
silencing	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
reverses	O
the	O
shift	O
to	O
aerobic	O
glycolysis	O
and	O
the	O
biosynthetic	O
and	O
proliferative	O
advantages	O
conferred	O
by	O
reduced	O
AMPKα	S-geneN
signaling	O
.	O

Together	O
our	O
findings	O
suggest	O
that	O
AMPK	S-geneN
activity	O
opposes	O
tumor	O
development	O
and	O
that	O
its	O
loss	O
fosters	O
tumor	O
progression	O
in	O
part	O
by	O
regulating	O
cellular	O
metabolic	O
pathways	O
that	O
support	O
cell	O
growth	O
and	O
proliferation	O
.	O

Comparative	O
phosphoproteomic	O
analysis	O
of	O
checkpoint	O
recovery	O
identifies	O
new	O
regulators	O
of	O
the	O
DNA	O
damage	O
response	O
.	O

How	O
cells	O
recover	O
from	O
a	O
DNA	O
damage	O
-	O
induced	O
arrest	O
is	O
currently	O
poorly	O
understood	O
.	O

We	O
performed	O
large	O
-	O
scale	O
quantitative	O
phosphoproteomics	O
to	O
identify	O
changes	O
in	O
protein	O
phosphorylation	O
that	O
occurred	O
during	O
recovery	O
from	O
arrest	O
in	O
the	O
G2	O
phase	O
of	O
the	O
cell	O
cycle	O
caused	O
by	O
DNA	O
damage	O
.	O

We	O
identified	O
154	O
proteins	O
that	O
were	O
differentially	O
phosphorylated	O
,	O
and	O
systematic	O
depletion	O
of	O
each	O
of	O
these	O
differentially	O
phosphorylated	O
proteins	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
identified	O
at	O
least	O
10	O
potential	O
regulators	O
of	O
recovery	O
.	O

Astrin	S-geneY
,	O
a	O
protein	O
associated	O
with	O
the	O
mitotic	O
spindle	O
,	O
was	O
among	O
the	O
potential	O
regulators	O
of	O
recovery	O
.	O

We	O
found	O
that	O
astrin	S-geneY
controlled	O
the	O
abundance	O
of	O
the	O
cell	O
cycle	O
regulator	O
p53	S-geneY
during	O
DNA	O
damage	O
-	O
induced	O
arrest	O
.	O

Cells	O
in	O
which	O
astrin	S-geneY
was	O
depleted	O
had	O
decreased	O
murine	B-geneY
double	I-geneY
minute	I-geneY
2	E-geneY
(	O
MDM2	S-geneY
)	O
abundance	O
and	O
increased	O
p53	S-geneY
at	O
the	O
later	O
stages	O
of	O
the	O
DNA	O
damage	O
response	O
.	O

Astrin	S-geneY
was	O
required	O
for	O
continued	O
expression	O
of	O
genes	O
encoding	O
proteins	O
that	O
promote	O
cell	O
cycle	O
progression	O
in	O
arrested	O
cells	O
.	O

Thus	O
,	O
by	O
controlling	O
p53	S-geneY
abundance	O
in	O
cells	O
recovering	O
from	O
DNA	O
damage	O
,	O
astrin	S-geneY
maintains	O
the	O
cells	O
in	O
a	O
state	O
competent	O
to	O
resume	O
the	O
cell	O
cycle	O
.	O

Transfection	O
of	O
HepG2	O
cells	O
with	O
hGSTA4	S-geneY
provides	O
protection	O
against	O
4	B-chem
-	I-chem
hydroxynonenal	E-chem
-	O
mediated	O
oxidative	O
injury	O
.	O

4	B-chem-C9-1
-	I-chem-C9-1
Hydroxynonenal	E-chem-C9-1
(	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
)	O
is	O
a	O
mutagenic	O
alpha	B-chem-C9-1
,	I-chem-C9-1
beta	I-chem-C9-1
-	I-chem-C9-1
unsaturated	I-chem-C9-1
aldehyde	E-chem-C9-1
produced	O
during	O
oxidative	O
injury	O
that	O
is	O
conjugated	O
by	O
several	O
glutathione	B-geneN-C9-2
S	I-geneN-C9-2
-	I-geneN-C9-2
transferase	E-geneN-C9-2
(	O
GST	S-geneN-C9-2
)	O
isoforms	O
.	O

The	O
alpha	O
class	O
human	B-geneY-C9-2
GSTA4	I-geneY-C9-2
-	I-geneY-C9-2
4	E-geneY-C9-2
enzyme	O
(	O
hGSTA4	B-geneY-C9-2
-	I-geneY-C9-2
4	E-geneY-C9-2
)	O
has	O
a	O
particularly	O
high	O
catalytic	O
efficiency	O
toward	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
conjugation	O
.	O

However	O
,	O
hGST4	B-geneY
-	I-geneY
4	E-geneY
expression	O
is	O
low	O
in	O
most	O
human	O
cells	O
and	O
there	O
are	O
other	O
aldehyde	S-chem
metabolizing	O
enzymes	O
that	O
detoxify	O
4	B-chem
-	I-chem
HNE	E-chem
.	O

In	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
over	O
-	O
expression	O
of	O
hGSTA4	S-geneY
mRNA	O
on	O
the	O
sensitivity	O
of	O
HepG2	O
cells	O
to	O
4	B-chem
-	I-chem
HNE	E-chem
injury	O
.	O

HepG2	O
cells	O
transfected	O
with	O
an	O
hGSTA4	S-geneY
vector	O
construct	O
exhibited	O
high	O
steady	O
-	O
state	O
hGSTA4	S-geneY
mRNA	O
,	O
high	O
GST	B-geneY
-	I-geneY
4	E-geneY
-	I-chem
HNE	E-chem
catalytic	O
activities	O
,	O
but	O
lower	O
basal	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
concentrations	O
relative	O
to	O
insert	O
-	O
free	O
vector	O
(	O
control	O
)	O
cells	O
.	O

Exposure	O
to	O
4	B-chem
-	I-chem
HNE	E-chem
elicited	O
an	O
increase	O
in	O
GSH	S-chem
concentrations	O
in	O
the	O
control	O
and	O
hGSTA4	S-geneY
cells	O
,	O
although	O
the	O
dose	O
-	O
response	O
of	O
GSH	S-chem
induction	O
differed	O
among	O
the	O
two	O
cell	O
types	O
.	O

Specifically	O
,	O
hGSTA4	S-geneY-C9-2
cells	O
had	O
significantly	O
higher	O
GSH	S-chem
concentrations	O
when	O
exposed	O
to	O
5	O
-	O
15	O
microM	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
,	O
but	O
not	O
at	O
20	O
microM	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
,	O
suggesting	O
extensive	O
GSH	S-chem
utilization	O
at	O
high	O
concentrations	O
of	O
4	B-chem
-	I-chem
HNE	E-chem
.	O

The	O
hGSTA4	S-geneY
cells	O
exhibited	O
a	O
significant	O
growth	O
advantage	O
relative	O
to	O
control	O
cells	O
in	O
the	O
absence	O
of	O
4	B-chem
-	I-chem
HNE	E-chem
,	O
and	O
a	O
trend	O
towards	O
increased	O
growth	O
at	O
low	O
dose	O
exposures	O
to	O
4	B-chem
-	I-chem
HNE	E-chem
.	O

However	O
,	O
the	O
hGSTA4	S-geneY
cells	O
did	O
not	O
exhibit	O
a	O
growth	O
advantage	O
relative	O
to	O
control	O
cells	O
at	O
higher	O
4	B-chem
-	I-chem
HNE	E-chem
exposures	O
associated	O
with	O
increased	O
GSH	S-chem
utilization	O
.	O

As	O
expected	O
,	O
the	O
hGSTA4	S-geneY
cells	O
showed	O
resistance	O
to	O
4	B-chem
-	I-chem
HNE	E-chem
stimulated	O
lipid	O
peroxidation	O
at	O
all	O
4	B-chem
-	I-chem
HNE	E-chem
doses	O
.	O

In	O
summary	O
,	O
our	O
data	O
indicates	O
that	O
over	O
-	O
expression	O
of	O
hGSTA4	S-geneY
at	O
levels	O
conferring	O
high	O
GST	S-geneN-C9-2
-	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
conjugating	O
activity	O
confers	O
a	O
partial	O
growth	O
advantage	O
to	O
HepG2	O
cells	O
and	O
protects	O
against	O
4	B-chem
-	I-chem
HNE	E-chem
oxidative	O
injury	O
.	O

However	O
,	O
the	O
loss	O
of	O
proliferative	O
capacity	O
of	O
hGSTA4	S-geneY-C9-2
cells	O
challenged	O
with	O
levels	O
of	O
4	B-chem-C9-1
-	I-chem-C9-1
HNE	E-chem-C9-1
associated	O
with	O
severe	O
oxidative	O
stress	O
indicates	O
a	O
role	O
of	O
other	O
aldehyde	S-chem
metabolizing	O
enzymes	O
,	O
and	O
/	O
or	O
GSH	S-chem
-	O
electrophile	O
transporter	O
proteins	O
,	O
in	O
providing	O
full	O
cellular	O
protection	O
against	O
4	B-chem
-	I-chem
HNE	E-chem
toxicity	O
.	O

Identification	O
of	O
aldo	B-geneN
-	I-geneN
keto	I-geneN
reductases	E-geneN
as	O
NRF2	S-geneY
-	O
target	O
marker	O
genes	O
in	O
human	O
cells	O
.	O

Transcription	O
factor	O
NF	B-geneY
-	I-geneY
E2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
NRF2	S-geneY
)	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
cellular	O
defense	O
against	O
oxidative	O
/	O
electrophilic	O
stress	O
by	O
up	O
-	O
regulating	O
multiple	O
antioxidant	O
genes	O
.	O

Numerous	O
studies	O
with	O
genetically	O
modified	O
animals	O
have	O
demonstrated	O
that	O
Nrf2	S-geneY
is	O
a	O
sensitivity	O
determining	O
factor	O
upon	O
the	O
exposure	O
to	O
environmental	O
chemicals	O
including	O
carcinogens	O
.	O

Moreover	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
polymorphism	O
in	O
the	O
human	B-geneN
NRF2	I-geneN
promoter	E-geneN
is	O
associated	O
with	O
higher	O
risks	O
for	O
developing	O
acute	O
lung	O
injury	O
,	O
gastric	O
mucosal	O
inflammation	O
,	O
and	O
nephritis	O
.	O

Therefore	O
,	O
the	O
identification	O
of	O
reliable	O
and	O
effective	O
human	O
target	O
genes	O
of	O
NRF2	S-geneY
may	O
allow	O
the	O
monitoring	O
of	O
NRF2	S-geneY
activity	O
and	O
to	O
predict	O
individual	O
sensitivity	O
to	O
environmental	O
stress	O
-	O
induced	O
damage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
investigated	O
genes	O
that	O
are	O
tightly	O
controlled	O
by	O
NRF2	S-geneY
to	O
establish	O
markers	O
for	O
NRF2	S-geneY
activity	O
in	O
human	O
cells	O
.	O

Firstly	O
,	O
in	O
the	O
normal	O
human	O
renal	O
epithelial	O
HK	O
-	O
2	O
cells	O
,	O
the	O
measurement	O
of	O
the	O
expression	O
of	O
30	O
previously	O
reported	O
NRF2	S-geneY-C3-2
target	O
genes	O
in	O
response	O
to	O
NRF2	S-geneY-C3-2
inducers	O
(	O
sulforaphane	S-chem-C3-1
,	O
tert	B-chem-C3-1
-	I-chem-C3-1
butylhydroquinone	E-chem-C3-1
,	O
cinnamic	B-chem-C3-1
aldehyde	E-chem-C3-1
,	O
and	O
hydrogen	B-chem-C3-1
peroxide	E-chem-C3-1
)	O
showed	O
that	O
the	O
aldo	B-geneY-C3-2
-	I-geneY-C3-2
keto	I-geneY-C3-2
reductase	I-geneY-C3-2
(	I-geneY-C3-2
AKR	I-geneY-C3-2
)	I-geneY-C3-2
1C1	E-geneY-C3-2
is	O
highly	O
inducible	O
by	O
all	O
treatments	O
.	O

Accordantly	O
,	O
the	O
basal	O
and	O
inducible	O
expressions	O
of	O
AKRs	S-geneN
were	O
significantly	O
attenuated	O
in	O
NRF2	S-geneY
-	O
silenced	O
HK	O
-	O
2	O
cells	O
.	O

Whereas	O
,	O
cells	O
with	O
stable	O
KEAP1	S-geneY
knockdown	O
,	O
which	O
causes	O
a	O
modest	O
NRF2	S-geneY
activation	O
,	O
demonstrated	O
substantially	O
increased	O
levels	O
of	O
AKR1A1	B-geneN
,	I-geneN
1B1	I-geneN
,	I-geneN
1B10	I-geneN
,	I-geneN
1C1	I-geneN
,	I-geneN
1C2	I-geneN
,	I-geneN
and	I-geneN
1C3	E-geneN
.	O

Secondly	O
,	O
the	O
linkage	O
between	O
NRF2	S-geneY
and	O
the	O
AKRs	S-geneN
was	O
confirmed	O
in	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
U937	O
,	O
which	O
can	O
be	O
a	O
model	O
of	O
peripherally	O
available	O
blood	O
cells	O
.	O

The	O
treatment	O
of	O
U937	O
cells	O
with	O
NRF2	S-geneY-C3-2
inducers	O
including	O
sulforaphane	S-chem-C3-1
effectively	O
elevated	O
the	O
expression	O
of	O
AKR1B1	B-geneN-C3-2
,	I-geneN-C3-2
1B10	I-geneN-C3-2
,	I-geneN-C3-2
1C1	I-geneN-C3-2
,	I-geneN-C3-2
1C2	I-geneN-C3-2
,	I-geneN-C3-2
and	I-geneN-C3-2
1C3	E-geneN-C3-2
.	O

Whereas	O
,	O
the	O
levels	O
of	O
both	O
the	O
basal	O
and	O
sulforaphane	S-chem-C3-1
-	O
inducible	O
expression	O
of	O
AKR1C1	S-geneY-C3-2
were	O
significantly	O
reduced	O
in	O
NRF2	S-geneY
-	O
silenced	O
stable	O
U937	O
cells	O
compared	O
to	O
the	O
control	O
cells	O
.	O

Similarly	O
,	O
the	O
inducible	O
expression	O
of	O
AKR1C1	S-geneY
was	O
observed	O
in	O
another	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
as	O
well	O
as	O
in	O
human	O
primary	O
blood	O
CD14	O
(	O
+	O
)	O
monocytes	O
.	O

In	O
conclusion	O
,	O
together	O
with	O
the	O
high	O
inducibility	O
and	O
NRF2	S-geneY
dependency	O
shown	O
in	O
renal	O
epithelial	O
cells	O
as	O
well	O
as	O
in	O
peripherally	O
available	O
blood	O
cells	O
,	O
current	O
findings	O
suggest	O
that	O
AKRs	S-geneN
can	O
be	O
utilized	O
as	O
a	O
marker	O
of	O
NRF2	S-geneY
activity	O
in	O
human	O
cells	O
.	O

Synthesis	O
,	O
molecular	O
modeling	O
and	O
evaluation	O
of	O
novel	O
N	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
benzylpiperidin	I-chem-C4-1
-	I-chem-C4-1
/	I-chem-C4-1
piperazin	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
)	I-chem-C4-1
acylhydrazone	E-chem-C4-1
derivatives	O
as	O
dual	O
inhibitors	O
for	O
cholinesterases	S-geneY-C4-2
and	O
Aβ	S-geneY-C4-2
aggregation	O
.	O

To	O
develop	O
new	O
drugs	O
for	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
,	O
a	O
group	O
of	O
N	B-chem-C4-1
'	I-chem-C4-1
-	I-chem-C4-1
2	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
4	I-chem-C4-1
-	I-chem-C4-1
Benzylpiperidin	I-chem-C4-1
-	I-chem-C4-1
/	I-chem-C4-1
piperazin	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
yl	I-chem-C4-1
)	I-chem-C4-1
acylhydrazones	E-chem-C4-1
was	O
designed	O
,	O
synthesized	O
and	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
acetylcholinesterase	S-geneY-C4-2
,	O
butyrylcholinesterase	S-geneY-C4-2
and	O
aggregation	O
of	O
amyloid	B-geneN
beta	I-geneN
peptides	I-geneN
(	I-geneN
1	I-geneN
-	I-geneN
40	I-geneN
,	I-geneN
1	I-geneN
-	I-geneN
42	I-geneN
and	I-geneN
1	I-geneN
-	I-geneN
40_1	I-geneN
-	I-geneN
42	I-geneN
)	E-geneN
.	O

The	O
enzyme	O
inhibition	O
assay	O
results	O
indicated	O
that	O
compounds	O
moderately	O
inhibit	O
both	O
acetylcholinesterase	S-geneY
and	O
butyrylcholinesterase	S-geneY
.	O

β	B-geneY
-	I-geneY
Amyloid	E-geneY
aggregation	O
results	O
showed	O
that	O
all	O
compounds	O
exhibited	O
remarkable	O
Aβ	S-geneY-C4-2
fibril	O
aggregation	O
inhibition	O
activity	O
with	O
a	O
nearly	O
similar	O
potential	O
as	O
the	O
reference	O
compound	O
rifampicin	S-chem-C4-1
,	O
which	O
makes	O
them	O
promising	O
anti	O
-	O
Alzheimer	O
drug	O
candidates	O
.	O

Docking	O
experiments	O
were	O
carried	O
out	O
with	O
the	O
aim	O
to	O
understand	O
the	O
interactions	O
of	O
the	O
most	O
active	O
compounds	O
with	O
the	O
active	O
site	O
of	O
the	O
cholinesterase	S-geneY
enzymes	O
.	O

Xanthurenic	O
aciduria	O
due	O
to	O
a	O
mutation	O
in	O
KYNU	S-geneY
encoding	O
kynureninase	S-geneY
.	O

Massive	O
urinary	O
excretion	O
of	O
xanthurenic	B-chem
acid	E-chem
,	O
3	B-chem
-	I-chem
hydroxykynurenine	E-chem
and	O
kynurenine	S-chem
,	O
known	O
as	O
xanthurenic	O
aciduria	O
or	O
hydroxykynureninuria	O
,	O
in	O
a	O
young	O
Somali	O
boy	O
suggested	O
kynureninase	S-geneY
deficiency	O
.	O

Mutation	O
analysis	O
of	O
KYNU	S-geneY
encoding	O
kynureninase	S-geneY
of	O
the	O
index	O
case	O
revealed	O
homozygosity	O
for	O
a	O
c.593	O
A	B-geneN
>	I-geneN
G	E-geneN
substitution	O
leading	O
to	O
a	O
threonine	B-geneN
-	I-geneN
to	I-geneN
-	I-geneN
alanine	E-geneN
(	O
T198A	S-geneN
)	O
shift	O
.	O

A	O
younger	O
brother	O
was	O
found	O
to	O
have	O
a	O
similar	O
excretion	O
pattern	O
and	O
the	O
same	O
genotype	O
.	O

At	O
present	O
,	O
neither	O
of	O
the	O
two	O
boys	O
has	O
symptoms	O
of	O
niacin	O
deficiency	O
.	O

This	O
is	O
the	O
first	O
report	O
linking	O
xanthurenic	O
aciduria	O
to	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
kynureninase	S-geneY
.	O

Diet	O
,	O
physical	O
exercise	O
and	O
Orlistat	S-chem-C3-1
administration	O
increase	O
serum	O
Anti	B-geneY-C3-2
-	I-geneY-C3-2
Müllerian	I-geneY-C3-2
Hormone	E-geneY-C3-2
(	O
AMH	S-geneY-C3-2
)	O
levels	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

The	O
present	O
study	O
investigates	O
the	O
combined	O
effect	O
of	O
diet	O
,	O
physical	O
exercise	O
and	O
Orlistat	S-chem
for	O
24	O
weeks	O
,	O
on	O
serum	O
Anti	B-geneY
-	I-geneY
Müllerian	I-geneY
Hormone	O
(	O
AMH	S-geneY
)	O
levels	O
in	O
overweight	O
and	O
obese	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
and	O
in	O
overweight	O
and	O
obese	O
controls	O
.	O

Sixty	O
-	O
one	O
(	O
61	O
)	O
selected	O
women	O
with	O
PCOS	O
and	O
20	O
overweight	O
and	O
obese	O
controls	O
followed	O
an	O
energy	O
-	O
restricted	O
diet	O
,	O
physical	O
exercise	O
plus	O
Orlistat	S-chem
administration	O
(	O
120	O
mg	O
,	O
3	O
times	O
per	O
day	O
)	O
for	O
24	O
weeks	O
.	O

At	O
baseline	O
,	O
week	O
12	O
and	O
week	O
24	O
,	O
serum	O
levels	O
of	O
AMH	S-geneY
,	O
FSH	S-geneN
,	O
LH	S-geneN
,	O
PRL	S-geneY
,	O
androgens	S-chem
,	O
sex	B-geneY
hormone	I-geneY
-	I-geneY
binding	I-geneY
globulin	E-geneY
(	O
SHBG	S-geneY
)	O
,	O
glucose	S-chem
,	O
and	O
insulin	S-geneY
were	O
measured	O
and	O
Free	O
Androgen	S-chem
Index	O
(	O
FAI	O
)	O
and	O
Insulin	S-geneY
Resistance	O
(	O
IR	O
)	O
indices	O
were	O
calculated	O
.	O

In	O
PCOS	O
women	O
,	O
serum	O
AMH	S-geneY
levels	O
increased	O
after	O
12	O
and	O
24	O
weeks	O
of	O
treatment	O
.	O

After	O
12	O
weeks	O
LH	S-geneN
and	O
SHBG	S-geneY
were	O
increased	O
,	O
while	O
Testosterone	S-chem
decreased	O
.	O

After	O
12	O
and	O
24	O
weeks	O
,	O
FAI	O
was	O
decreased	O
and	O
all	O
indices	O
of	O
IR	O
were	O
significantly	O
improved	O
.	O

We	O
concluded	O
that	O
in	O
overweight	O
and	O
obese	O
women	O
with	O
PCOS	O
Orlistat	S-chem-C3-1
administration	O
,	O
combined	O
with	O
diet	O
and	O
physical	O
exercise	O
,	O
for	O
24	O
weeks	O
,	O
resulted	O
in	O
significant	O
weight	O
loss	O
,	O
improvement	O
of	O
hyperandrogenism	O
and	O
insulin	S-geneY
sensitivity	O
,	O
and	O
increased	O
serum	O
AMH	S-geneY-C3-2
levels	O
.	O

Sucralfate	S-chem
:	O
the	O
Bangkok	O
review	O
.	O

Sucralfate	S-chem
is	O
a	O
site	O
-	O
protective	O
ulcer	O
healing	O
drug	O
with	O
a	O
remarkable	O
range	O
of	O
mechanisms	O
of	O
action	O
.	O

Recent	O
studies	O
highlight	O
the	O
capacity	O
of	O
sucralfate	S-chem
to	O
bind	O
basic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
(	O
bFGF	S-geneY
)	O
and	O
deliver	O
it	O
in	O
high	O
concentration	O
to	O
the	O
ulcer	O
.	O

Basic	B-geneY
fibroblast	I-geneY
growth	I-geneY
factor	E-geneY
stimulates	O
the	O
production	O
of	O
granulation	O
tissue	O
,	O
angiogenesis	O
and	O
re	O
-	O
epithelization	O
,	O
thus	O
improving	O
the	O
quality	O
of	O
ulcer	O
healing	O
.	O

The	O
effect	O
of	O
sucralfate	S-chem
in	O
reducing	O
parietal	O
cell	O
sensitivity	O
may	O
be	O
another	O
factor	O
important	O
in	O
the	O
lower	O
relapse	O
rate	O
demonstrated	O
after	O
duodenal	O
ulcer	O
healing	O
.	O

Sucralfate	S-chem
has	O
been	O
demonstrated	O
to	O
be	O
efficacious	O
in	O
healing	O
both	O
duodenal	O
and	O
gastric	O
ulcers	O
together	O
with	O
mild	O
oesophagitis	O
,	O
and	O
it	O
is	O
safe	O
for	O
both	O
short	O
-	O
term	O
use	O
and	O
maintenance	O
.	O

In	O
stress	O
ulcer	O
prophylaxis	O
it	O
is	O
as	O
effective	O
as	O
acid	O
suppression	O
or	O
neutralization	O
and	O
has	O
the	O
advantage	O
of	O
lesser	O
rates	O
of	O
nosocomial	O
pneumonia	O
than	O
are	O
demonstrated	O
with	O
antacids	O
or	O
H2	O
antagonists	O
.	O

The	O
potential	O
advantages	O
of	O
sucralfate	S-chem
lie	O
in	O
the	O
better	O
quality	O
of	O
ulcer	O
healing	O
associated	O
with	O
longer	O
duration	O
of	O
remission	O
.	O

Tissue	B-geneY
-	I-geneY
type	I-geneY
plasminogen	I-geneY
activator	E-geneY
acts	O
as	O
a	O
cytokine	S-geneN
that	O
triggers	O
intracellular	O
signal	O
transduction	O
and	O
induces	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
gene	O
expression	O
.	O

Tissue	B-geneY
-	I-geneY
type	I-geneY
plasminogen	I-geneY
activator	E-geneY
(	O
tPA	S-geneY
)	O
,	O
a	O
serine	B-geneN
protease	E-geneN
well	O
known	O
for	O
generating	O
plasmin	S-geneY
,	O
has	O
been	O
demonstrated	O
to	O
induce	O
matrix	B-geneY
metalloproteinase	I-geneY
-	I-geneY
9	E-geneY
(	O
MMP	B-geneY
-	I-geneY
9	E-geneY
)	O
gene	O
expression	O
and	O
protein	O
secretion	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O

However	O
,	O
exactly	O
how	O
tPA	S-geneY
transduces	O
its	O
signal	O
into	O
the	O
nucleus	O
to	O
control	O
gene	O
expression	O
is	O
unknown	O
.	O

This	O
study	O
investigated	O
the	O
mechanism	O
by	O
which	O
tPA	S-geneY
induces	O
MMP	B-geneY
-	I-geneY
9	E-geneY
gene	O
expression	O
.	O

Both	O
wild	O
-	O
type	O
and	O
non	O
-	O
enzymatic	O
mutant	O
tPA	S-geneY
were	O
found	O
to	O
induce	O
MMP	B-geneY
-	I-geneY
9	E-geneY
expression	O
in	O
rat	O
kidney	O
interstitial	O
fibroblasts	O
(	O
NRK	O
-	O
49F	O
)	O
,	O
indicating	O
that	O
the	O
actions	O
of	O
tPA	S-geneY
are	O
independent	O
of	O
its	O
proteolytic	O
activity	O
.	O
tPA	S-geneY
bound	O
to	O
the	O
low	B-geneY
density	I-geneY
lipoprotein	I-geneY
receptor	I-geneY
-	I-geneY
related	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
LRP	B-geneY
-	I-geneY
1	E-geneY
)	O
in	O
NRK	O
-	O
49F	O
cells	O
,	O
and	O
this	O
binding	O
was	O
competitively	O
abrogated	O
by	O
the	O
LRP	B-geneY
-	I-geneY
1	E-geneY
antagonist	O
,	O
the	O
receptor	O
-	O
associated	O
protein	O
.	O

In	O
mouse	O
embryonic	O
fibroblasts	O
(	O
PEA	O
-	O
13	O
)	O
lacking	O
LRP	B-geneY
-	I-geneY
1	E-geneY
,	O
tPA	S-geneY
failed	O
to	O
induce	O
MMP	B-geneY
-	I-geneY
9	E-geneY
expression	O
.	O

Furthermore	O
,	O
tPA	S-geneY
induced	O
rapid	O
tyrosine	S-chem-C3-1
phosphorylation	O
on	O
the	O
beta	O
subunit	O
of	O
LRP	B-geneY
-	I-geneY
1	E-geneY
,	O
which	O
was	O
followed	O
by	O
the	O
activation	O
of	O
Mek1	S-geneY-C3-2
and	O
its	O
downstream	O
Erk	B-geneN-C3-2
-	I-geneN-C3-2
1	I-geneN-C3-2
and	I-geneN-C3-2
-	I-geneN-C3-2
2	E-geneN-C3-2
.	O

Blockade	O
of	O
Erk	B-geneN
-	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
activation	O
by	O
the	O
Mek1	S-geneY
inhibitor	O
abolished	O
MMP	B-geneY
-	I-geneY
9	E-geneY
induction	O
by	O
tPA	S-geneY
in	O
NRK	O
-	O
49F	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
constitutively	B-geneY
activated	I-geneY
Mek1	E-geneY
induced	O
Erk	B-geneN
-	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
expression	O
.	O

In	O
mouse	O
obstructed	O
kidney	O
,	O
tPA	S-geneY
,	O
LRP	B-geneY
-	I-geneY
1	E-geneY
,	O
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
were	O
concomitantly	O
induced	O
in	O
the	O
renal	O
interstitium	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
besides	O
its	O
classical	O
proteolytic	O
activity	O
,	O
tPA	S-geneY
acts	O
as	O
a	O
cytokine	S-geneN
that	O
binds	O
to	O
the	O
cell	O
membrane	O
receptor	O
LRP	B-geneY
-	I-geneY
1	E-geneY
,	O
induces	O
its	O
tyrosine	S-chem
phosphorylation	O
,	O
and	O
triggers	O
intracellular	O
signal	O
transduction	O
,	O
thereby	O
inducing	O
specific	O
gene	O
expression	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O

Thioredoxin	S-geneY
-	O
mimetic	O
peptides	O
(	O
TXM	O
)	O
reverse	O
auranofin	S-chem
induced	O
apoptosis	O
and	O
restore	O
insulin	S-geneN
secretion	O
in	O
insulinoma	O
cells	O
.	O

The	O
thioredoxin	B-geneN
reductase	E-geneN
/	O
thioredoxin	S-geneY
system	O
(	O
TrxR	S-geneN
/	O
Trx1	S-geneY
)	O
plays	O
a	O
major	O
role	O
in	O
protecting	O
cells	O
from	O
oxidative	O
stress	O
.	O

Disruption	O
of	O
the	O
TrxR	S-geneN
-	O
Trx1	S-geneY
system	O
keeps	O
Trx1	S-geneY
in	O
the	O
oxidized	O
state	O
leading	O
to	O
cell	O
death	O
through	O
activation	O
of	O
the	O
ASK1	S-geneY
-	O
Trx1	S-geneY
apoptotic	O
pathway	O
.	O

The	O
potential	O
mechanism	O
and	O
ability	O
of	O
tri	O
-	O
and	O
tetra	O
-	O
oligopeptides	O
derived	O
from	O
the	O
canonical	O
-	O
CxxC	B-geneN
-	I-geneN
motif	E-geneN
of	O
the	O
Trx1	S-geneY
-	O
active	O
site	O
to	O
mimic	O
and	O
enhance	O
Trx1	S-geneY
cellular	O
activity	O
was	O
examined	O
.	O

The	O
Trx	S-geneY
mimetics	O
peptides	O
(	O
TXM	O
)	O
protected	O
insulinoma	O
INS	O
832	O
/	O
13	O
cells	O
from	O
oxidative	O
stress	O
induced	O
by	O
selectively	O
inhibiting	O
TrxR	S-geneN-C4-2
with	O
auranofin	S-chem-C4-1
(	O
AuF	S-chem-C4-1
)	O
.	O

TXM	O
reversed	O
the	O
AuF	S-chem
-	O
effects	O
preventing	O
apoptosis	O
,	O
and	O
increasing	O
cell	O
-	O
viability	O
.	O

The	O
TXM	O
peptides	O
were	O
effective	O
in	O
inhibiting	O
AuF	S-chem-C3-1
-	O
induced	O
MAPK	S-geneN-C3-2
,	O
JNK	S-geneN-C3-2
and	O
p38	S-geneN-C3-2
(	O
MAPK	S-geneN-C3-2
)	O
phosphorylation	O
,	O
in	O
correlation	O
with	O
preventing	O
caspase	B-geneY
-	I-geneY
3	E-geneY
cleavage	O
and	O
thereby	O
PARP	B-geneY
-	I-geneY
1	E-geneY
dissociation	O
.	O

The	O
ability	O
to	O
form	O
a	O
disulfide	S-chem
-	O
bridge	O
-	O
like	O
conformation	O
was	O
estimated	O
from	O
molecular	O
dynamics	O
simulations	O
.	O

The	O
TXM	O
peptides	O
restored	O
insulin	S-geneN
secretion	O
and	O
displayed	O
Trx1	S-geneY
denitrosylase	S-geneN
activity	O
.	O

Their	O
potency	O
was	O
10	O
-	O
100	O
-	O
fold	O
higher	O
than	O
redox	O
reagents	O
like	O
NAC	S-chem
,	O
AD4	S-chem
,	O
or	O
ascorbic	B-chem
acid	E-chem
.	O

Unable	O
to	O
reverse	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
,	O
TXM	O
-	O
CB3	O
(	O
NAc	B-chem
-	I-chem
Cys	I-chem
-	I-chem
Pro	I-chem
-	I-chem
Cys	I-chem
amide	E-chem
)	O
appeared	O
to	O
function	O
in	O
part	O
,	O
through	O
inhibiting	O
ASK1	S-geneY
-	O
Trx	S-geneY
dissociation	O
.	O

These	O
highly	O
effective	O
anti	O
-	O
apoptotic	O
effects	O
of	O
Trx1	S-geneY
mimetic	O
peptides	O
exhibited	O
in	O
INS	O
832	O
/	O
13	O
cells	O
could	O
become	O
valuable	O
in	O
treating	O
adverse	O
oxidative	O
-	O
stress	O
related	O
disorders	O
such	O
as	O
diabetes	O
.	O

Ibuprofen	S-chem-C4-1
inhibits	O
cystic	B-geneY-C4-2
fibrosis	I-geneY-C4-2
transmembrane	I-geneY-C4-2
conductance	I-geneY-C4-2
regulator	E-geneY-C4-2
-	O
mediated	O
Cl	O
-	O
secretion	O
.	O

We	O
evaluated	O
the	O
acute	O
effects	O
of	O
ibuprofen	S-chem
and	O
salicylic	B-chem
acid	E-chem
on	O
cAMP	S-chem
-	O
mediated	O
Cl	O
-	O
secretion	O
(	O
Isc	O
)	O
in	O
both	O
colonic	O
and	O
airway	O
epithelia	O
.	O

In	O
T84	O
cells	O
,	O
ibuprofen	S-chem
inhibited	O
the	O
forskolin	S-chem
-	O
dependent	O
Isc	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
having	O
an	O
apparent	O
Ki	O
of	O
142	O
microM	O
.	O

Salicylic	B-chem
acid	E-chem
inhibited	O
Isc	O
with	O
an	O
apparent	O
Ki	O
of	O
646	O
microM	O
.	O

We	O
determined	O
whether	O
ibuprofen	S-chem
would	O
also	O
inhibit	O
the	O
forskolin	S-chem
-	O
stimulated	O
Isc	O
in	O
primary	O
cultures	O
of	O
mouse	O
trachea	O
epithelia	O
(	O
MTE	O
)	O
and	O
human	O
bronchial	O
epithelia	O
(	O
HBE	O
)	O
.	O

Similar	O
to	O
our	O
results	O
in	O
T84	O
cells	O
,	O
ibuprofen	S-chem
(	O
500	O
microM	O
)	O
inhibited	O
the	O
forskolin	S-chem
-	O
induced	O
Isc	O
in	O
MTEs	O
and	O
HBEs	O
by	O
59	O
+	O
/	O
-	O
4	O
%	O
(	O
n	O
=	O
11	O
)	O
and	O
39	O
+	O
/	O
-	O
6	O
%	O
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O

Nystatin	S-chem
was	O
employed	O
to	O
selectively	O
permeabilize	O
the	O
basolateral	O
or	O
apical	O
membrane	O
to	O
determine	O
the	O
effect	O
of	O
ibuprofen	S-chem
on	O
apical	O
Cl	O
-	O
(	O
ICl	O
)	O
and	O
basolateral	O
K	B-chem
+	E-chem
(	O
IK	O
)	O
currents	O
after	O
stimulation	O
by	O
forskolin	S-chem
.	O

After	O
forskolin	S-chem
stimulation	O
,	O
ibuprofen	S-chem
(	O
500	O
microM	O
)	O
reduced	O
both	O
the	O
ICl	O
and	O
IK	O
;	O
reducing	O
ICl	O
and	O
IK	O
by	O
60	O
and	O
15	O
%	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
this	O
inhibition	O
of	O
ICl	O
was	O
due	O
to	O
the	O
inhibition	O
of	O
CFTR	S-geneY
,	O
the	O
effects	O
of	O
ibuprofen	S-chem
and	O
salicylic	B-chem
acid	E-chem
on	O
CFTR	S-geneY
Cl	B-geneN
-	I-geneN
channels	E-geneN
in	O
excised	O
,	O
inside	O
-	O
out	O
patches	O
from	O
L	O
-	O
cells	O
were	O
evaluated	O
.	O

Ibuprofen	S-chem-C4-1
(	O
300	O
microM	O
)	O
reduced	O
CFTR	S-geneY-C4-2
Cl	O
-	O
current	O
by	O
60	O
+	O
/	O
-	O
16	O
%	O
and	O
this	O
was	O
explained	O
by	O
a	O
short	O
-	O
lived	O
block	O
(	O
approximately	O
1.2	O
ms	O
)	O
which	O
causes	O
an	O
apparent	O
reduction	O
in	O
single	O
channel	O
amplitude	O
from	O
1.07	O
+	O
/	O
-	O
0.04	O
pA	O
to	O
0.59	O
+	O
/	O
-	O
0.04	O
pA	O
(	O
n	O
=	O
3	O
)	O
.	O

Similarly	O
,	O
salicylic	B-chem-C4-1
acid	E-chem-C4-1
(	O
3	O
mM	O
)	O
reduced	O
CFTR	S-geneY-C4-2
Cl	O
-	O
current	O
by	O
50	O
+	O
/	O
-	O
8	O
%	O
with	O
an	O
apparent	O
reduction	O
in	O
single	O
channel	O
amplitude	O
from	O
1.08	O
+	O
/	O
-	O
0.03	O
pA	O
to	O
0.48	O
+	O
/	O
-	O
0.06	O
pA	O
(	O
n	O
=	O
4	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
conclude	O
that	O
the	O
NSAIDs	O
ibuprofen	S-chem-C4-1
and	O
salicylic	B-chem-C4-1
acid	E-chem-C4-1
inhibit	O
cAMP	S-chem
-	O
mediated	O
Cl	O
-	O
secretion	O
in	O
human	O
colonic	O
and	O
airway	O
epithelia	O
via	O
a	O
direct	O
inhibition	O
of	O
CFTR	S-geneY-C4-2
Cl	B-geneN-C4-2
-	I-geneN-C4-2
channels	E-geneN-C4-2
as	O
well	O
as	O
basolateral	O
membrane	O
K	B-geneN-C4-2
+	I-geneN-C4-2
channels	E-geneN-C4-2
.	O

This	O
may	O
reduce	O
their	O
efficacy	O
in	O
conjunction	O
with	O
other	O
therapeutic	O
strategies	O
designed	O
to	O
increase	O
CFTR	S-geneY
expression	O
and	O
/	O
or	O
function	O
in	O
secretory	O
epithelia	O
.	O

Evaluation	O
of	O
animal	O
models	O
for	O
intestinal	O
first	O
-	O
pass	O
metabolism	O
of	O
drug	O
candidates	O
to	O
be	O
metabolized	O
by	O
CYP3A	S-geneY
enzymes	O
via	O
in	O
vivo	O
and	O
in	O
vitro	O
oxidation	O
of	O
midazolam	S-chem
and	O
triazolam	S-chem
.	O

Abstract	O
1	O
.	O

To	O
search	O
an	O
appropriate	O
evaluation	O
methodology	O
for	O
the	O
intestinal	O
first	O
-	O
pass	O
metabolism	O
of	O
new	O
drug	O
candidates	O
,	O
grapefruit	O
juice	O
(	O
GFJ	O
)	O
-	O
and	O
vehicle	O
(	O
tap	O
water	O
)	O
-	O
pretreated	O
mice	O
or	O
rats	O
were	O
orally	O
administered	O
midazolam	S-chem
(	O
MDZ	S-chem
)	O
or	O
triazolam	S-chem
(	O
TRZ	S-chem
)	O
,	O
and	O
blood	O
levels	O
of	O
the	O
parent	O
compounds	O
and	O
their	O
metabolites	O
were	O
measured	O
by	O
liquid	O
chromatography	O
/	O
MS	O
/	O
MS	O
.	O

A	O
significant	O
effect	O
of	O
GFJ	O
to	O
elevate	O
the	O
blood	O
levels	O
was	O
observed	O
only	O
for	O
TRZ	S-chem
in	O
mice	O
.	O

2	O
.	O

In	O
vitro	O
experiments	O
using	O
mouse	O
,	O
rat	O
and	O
human	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
demonstrated	O
that	O
GFJ	O
suppressed	O
the	O
intestinal	O
microsomal	O
oxidation	O
of	O
MDZ	S-chem
and	O
especially	O
TRZ	S-chem
.	O

Substrate	O
inhibition	O
by	O
MDZ	S-chem
caused	O
reduction	O
in	O
1	O
'	O
-	O
hydroxylation	O
but	O
not	O
4	O
-	O
hydroxylation	O
in	O
both	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
.	O

The	O
kinetic	O
profiles	O
of	O
MDZ	S-chem
oxidation	O
and	O
the	O
substrate	O
inhibition	O
in	O
mouse	O
intestinal	O
and	O
hepatic	O
microsomal	O
fractions	O
were	O
very	O
similar	O
to	O
those	O
in	O
human	O
microsomes	O
but	O
were	O
different	O
from	O
those	O
in	O
rat	O
microsomes	O
.	O

Furthermore	O
,	O
MDZ	S-chem-C4-1
caused	O
mechanism	O
-	O
based	O
inactivation	O
of	O
cytochrome	B-geneN-MU-2
P450	I-geneN-MU-2
3A	E-geneN-MU-2
-	O
dependent	O
TRZ	S-chem-C9-1
1	O
'	O
-	O
hydroxylation	O
in	O
mouse	O
,	O
rat	O
and	O
human	O
intestinal	O
microsomes	O
with	O
similar	O
potencies	O
.	O

3	O
.	O

These	O
results	O
are	O
useful	O
information	O
in	O
the	O
analysis	O
of	O
data	O
obtained	O
in	O
mouse	O
and	O
rat	O
for	O
the	O
evaluation	O
of	O
first	O
-	O
pass	O
effects	O
of	O
drug	O
candidates	O
to	O
be	O
metabolized	O
by	O
CYP3A	S-geneN
enzymes	O
.	O

Cortisol	S-chem
and	O
interferon	O
tau	O
regulation	O
of	O
endometrial	O
function	O
and	O
conceptus	O
development	O
in	O
female	O
sheep	O
.	O

During	O
early	O
pregnancy	O
in	O
sheep	O
,	O
the	O
elongating	O
conceptus	O
secretes	O
interferon	B-geneN
-	I-geneN
τ	E-geneN
(	O
IFNT	S-geneN
)	O
and	O
the	O
conceptus	O
as	O
well	O
as	O
endometrial	O
epithelia	O
produce	O
prostaglandins	S-chem-C9-1
(	O
PG	O
)	O
via	O
PG	B-geneY-C9-2
synthase	I-geneY-C9-2
2	E-geneY-C9-2
(	O
PTGS2	S-geneY-C9-2
)	O
and	O
cortisol	S-chem-C9-1
via	O
hydroxysteroid	B-geneY-C9-2
(	I-geneY-C9-2
11	I-geneY-C9-2
-	I-geneY-C9-2
β	I-geneY-C9-2
)	I-geneY-C9-2
dehydrogenase	I-geneY-C9-2
1	E-geneY-C9-2
(	O
HSD11B1	S-geneY-C9-2
)	O
.	O

Ovarian	O
progesterone	S-chem
induces	O
and	O
PG	O
and	O
IFNT	S-geneN
stimulates	O
endometrial	O
HSD11B1	S-geneY
expression	O
and	O
keto	B-geneN
-	I-geneN
reductase	E-geneN
activity	O
as	O
well	O
as	O
many	O
epithelial	O
genes	O
that	O
govern	O
trophectoderm	O
proliferation	O
,	O
migration	O
,	O
and	O
attachment	O
during	O
elongation	O
.	O

The	O
primary	O
aim	O
of	O
these	O
studies	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
HSD11B1	S-geneY-C9-2
-	O
derived	O
cortisol	S-chem-C9-1
has	O
a	O
biological	O
role	O
in	O
endometrial	O
function	O
and	O
conceptus	O
development	O
during	O
early	O
pregnancy	O
in	O
sheep	O
.	O

In	O
study	O
1	O
,	O
cyclic	O
ewes	O
received	O
vehicle	O
,	O
cortisol	S-chem
,	O
PF	B-chem-C4-1
915275	E-chem-C4-1
(	O
PF	O
;	O
a	O
selective	O
inhibitor	O
of	O
HSD11B1	S-geneY-C4-2
)	O
,	O
cortisol	S-chem
and	O
PF	O
,	O
meloxicam	S-chem-C4-1
(	O
a	O
selective	O
inhibitor	O
of	O
PTGS2	S-geneY-C4-2
)	O
,	O
cortisol	S-chem
and	O
meloxicam	S-chem
,	O
recombinant	O
ovine	B-geneN
IFNT	E-geneN
,	O
or	O
IFNT	S-geneN
and	O
PF	O
into	O
the	O
uterus	O
from	O
day	O
10	O
to	O
day14	O
after	O
estrus	O
.	O

Cortisol	S-chem-C3-1
and	O
IFNT	S-geneN
stimulated	O
endometrial	O
HSD11B1	S-geneY-C3-2
expression	O
and	O
activity	O
,	O
increased	O
endometrial	O
PTGS2	S-geneY-C3-2
activity	O
and	O
the	O
amount	O
of	O
PG	O
in	O
the	O
uterine	O
lumen	O
,	O
and	O
up	O
-	O
regulated	O
many	O
conceptus	O
elongation	O
-	O
related	O
genes	O
in	O
the	O
endometrium	O
.	O

Some	O
effects	O
of	O
cortisol	S-chem
and	O
IFNT	S-geneN
were	O
mediated	O
by	O
PTGS2	S-geneY
-	O
derived	O
PG	O
.	O

In	O
study	O
2	O
,	O
bred	O
ewes	O
received	O
PF	B-chem
915275	E-chem
or	O
recombinant	O
ovine	B-geneN
IFNT	E-geneN
and	O
into	O
the	O
uterus	O
from	O
day	O
10	O
to	O
day	O
14	O
after	O
mating	O
.	O

Inhibition	O
of	O
HSD11B1	S-geneY
activity	O
in	O
utero	O
prevented	O
conceptus	O
elongation	O
,	O
whereas	O
IFNT	S-geneN
rescued	O
conceptus	O
elongation	O
in	O
PF	O
-	O
infused	O
ewes	O
.	O

These	O
results	O
suggest	O
that	O
HSD11B1	S-geneY-C9-2
-	O
derived	O
cortisol	S-chem-C9-1
mediates	O
,	O
in	O
part	O
,	O
actions	O
of	O
ovarian	O
progesterone	S-chem
and	O
the	O
conceptus	O
on	O
endometrial	O
function	O
and	O
support	O
the	O
hypothesis	O
that	O
IFNT	S-geneN
,	O
PG	O
,	O
and	O
cortisol	S-chem
coordinately	O
regulate	O
endometrial	O
functions	O
important	O
for	O
conceptus	O
elongation	O
and	O
implantation	O
during	O
early	O
pregnancy	O
in	O
sheep	O
.	O

Endothelial	O
nitric	B-chem
oxide	E-chem
production	O
is	O
tightly	O
coupled	O
to	O
the	O
citrulline	B-chem
-	I-chem
NO	E-chem
cycle	O
.	O

Nitric	B-chem-C9-1
oxide	E-chem-C9-1
(	O
NO	S-chem-C9-1
)	O
is	O
an	O
important	O
vasorelaxant	O
produced	O
along	O
with	O
L	B-chem-C9-1
-	I-chem-C9-1
citrulline	E-chem-C9-1
from	O
L	B-chem-C9-1
-	I-chem-C9-1
arginine	E-chem-C9-1
in	O
a	O
reaction	O
catalyzed	O
by	O
endothelial	B-geneY-C9-2
nitric	I-geneY-C9-2
oxide	I-geneY-C9-2
synthase	E-geneY-C9-2
(	O
eNOS	S-geneY-C9-2
)	O
.	O

Previous	O
studies	O
suggested	O
that	O
the	O
recycling	O
of	O
L	B-chem
-	I-chem
citrulline	E-chem
to	O
L	B-chem
-	I-chem
arginine	E-chem
is	O
essential	O
for	O
NO	S-chem
production	O
in	O
endothelial	O
cells	O
.	O

However	O
,	O
there	O
is	O
no	O
direct	O
evidence	O
demonstrating	O
the	O
degree	O
to	O
which	O
the	O
recycling	O
of	O
L	B-chem
-	I-chem
citrulline	E-chem
to	O
L	B-chem
-	I-chem
arginine	E-chem
is	O
coupled	O
to	O
NO	S-chem
production	O
.	O

We	O
hypothesized	O
that	O
the	O
amount	O
of	O
NO	S-chem
formed	O
would	O
be	O
significantly	O
higher	O
than	O
the	O
amount	O
of	O
L	B-chem
-	I-chem
citrulline	E-chem
formed	O
due	O
to	O
the	O
efficiency	O
of	O
L	B-chem
-	I-chem
citrulline	E-chem
recycling	O
via	O
the	O
citrulline	S-chem
-	O
NO	S-chem
cycle	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
endothelial	O
cells	O
were	O
incubated	O
with	O
[	B-chem
14C	I-chem
]	I-chem
-	I-chem
L	I-chem
-	I-chem
arginine	E-chem
and	O
stimulated	O
by	O
various	O
agents	O
to	O
produce	O
NO	S-chem
.	O

The	O
extent	O
of	O
NO	S-chem
and	O
[	B-chem
14C	I-chem
]	I-chem
-	I-chem
L	I-chem
-	I-chem
citrulline	E-chem
formation	O
were	O
simultaneously	O
determined	O
.	O

NO	S-chem
production	O
exceeded	O
apparent	O
L	B-chem
-	I-chem
citrulline	E-chem
formation	O
of	O
the	O
order	O
of	O
8	O
to	O
1	O
,	O
under	O
both	O
basal	O
and	O
stimulated	O
conditions	O
.	O

As	O
further	O
support	O
,	O
alpha	B-chem-C4-1
-	I-chem-C4-1
methyl	I-chem-C4-1
-	I-chem-C4-1
DL	I-chem-C4-1
-	I-chem-C4-1
aspartate	E-chem-C4-1
,	O
an	O
inhibitor	O
of	O
argininosuccinate	B-geneY-C4-2
synthase	E-geneY-C4-2
(	O
AS	S-geneY-C4-2
)	O
,	O
a	O
component	O
of	O
the	O
citrulline	S-chem
-	O
NO	S-chem
cycle	O
,	O
inhibited	O
NO	S-chem
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
evidence	O
for	O
the	O
essential	O
and	O
efficient	O
coupling	O
of	O
L	B-chem
-	I-chem
citrulline	E-chem
recycling	O
,	O
via	O
the	O
citrulline	S-chem
-	O
NO	S-chem
cycle	O
,	O
to	O
endothelial	O
NO	S-chem
production	O
.	O

Mutations	O
in	O
the	O
follicle	B-geneN
-	I-geneN
stimulating	I-geneN
hormone	I-geneN
-	I-geneN
beta	E-geneN
(	O
FSH	B-geneN
beta	E-geneN
)	O
and	O
FSH	B-geneN
receptor	E-geneN
genes	O
in	O
mice	O
and	O
humans	O
.	O

Follicle	B-geneN-C9-2
-	I-geneN-C9-2
stimulating	I-geneN-C9-2
hormone	E-geneN-C9-2
(	O
FSH	S-geneN-C9-2
)	O
,	O
a	O
dimeric	O
glycoprotein	O
synthesized	O
in	O
the	O
anterior	O
pituitary	O
gland	O
,	O
is	O
important	O
for	O
the	O
production	O
of	O
sex	O
steroids	S-chem-C9-1
and	O
gametes	O
.	O

FSH	B-geneY
-	I-geneY
beta	E-geneY
(	O
FSH	B-geneY
beta	E-geneY
)	O
and	O
FSH	B-geneY
receptor	E-geneY
(	O
FSHR	S-geneY
)	O
knockout	O
mice	O
display	O
impaired	O
ovarian	O
follicular	O
development	O
and	O
infertility	O
in	O
females	O
and	O
small	O
testes	O
,	O
oligospermia	O
,	O
and	O
fertility	O
in	O
males	O
.	O

Humans	O
with	O
FSH	B-geneY-C9-2
beta	E-geneY-C9-2
gene	O
mutations	O
tend	O
to	O
have	O
a	O
more	O
severe	O
phenotype	O
than	O
those	O
with	O
FSHR	S-geneY
gene	O
mutations	O
,	O
although	O
infertility	O
and	O
varying	O
degrees	O
of	O
impaired	O
sex	O
steroid	S-chem-C9-1
production	O
occur	O
in	O
both	O
types	O
of	O
mutations	O
.	O

Data	O
from	O
human	O
and	O
mouse	O
mutations	O
in	O
the	O
FSH	B-geneN
beta	E-geneN
and	O
FSHR	S-geneN
genes	O
suggest	O
that	O
FSH	S-geneN
is	O
necessary	O
for	O
normal	O
pubertal	O
development	O
and	O
fertility	O
in	O
males	O
and	O
females	O
.	O

Tetrahydrobiopterin	S-chem
in	O
nitric	B-chem
oxide	E-chem
synthesis	O
:	O
a	O
novel	O
biological	O
role	O
for	O
pteridines	S-chem
.	O

Ever	O
since	O
the	O
discovery	O
that	O
(	B-chem
6R	I-chem
)	I-chem
-	I-chem
5,6,7,8	I-chem
-	I-chem
tetrahydro	I-chem
-	I-chem
L	I-chem
-	I-chem
biopterin	E-chem
(	O
BH4	S-chem
)	O
is	O
a	O
cofactor	O
of	O
NOS	S-geneN
,	O
its	O
function	O
has	O
been	O
the	O
object	O
of	O
intense	O
research	O
and	O
occasional	O
controversy	O
.	O

Only	O
in	O
the	O
last	O
couple	O
of	O
years	O
a	O
consensus	O
has	O
been	O
reached	O
on	O
what	O
constitutes	O
the	O
main	O
role	O
of	O
BH4	S-chem
in	O
NO	S-chem
synthesis	O
.	O

In	O
this	O
review	O
we	O
aim	O
to	O
provide	O
an	O
outline	O
of	O
the	O
various	O
ways	O
in	O
which	O
BH4	S-chem
affects	O
NOS	S-geneN
catalysis	O
.	O

First	O
we	O
give	O
a	O
brief	O
general	O
description	O
of	O
the	O
structure	O
and	O
catalytic	O
mechanism	O
of	O
NOS	S-geneN
,	O
with	O
special	O
emphasis	O
on	O
those	O
aspects	O
of	O
catalysis	O
that	O
are	O
actively	O
debated	O
,	O
and	O
that	O
directly	O
or	O
indirectly	O
involve	O
BH4	S-chem
.	O

Foremost	O
among	O
those	O
issues	O
is	O
uncoupled	O
catalysis	O
,	O
i.e	O
.	O
the	O
NOS	S-geneN
-	O
catalyzed	O
oxidation	O
of	O
NADPH	S-chem
in	O
the	O
absence	O
of	O
substrate	O
or	O
pterin	O
that	O
does	O
not	O
result	O
in	O
NO	S-chem
production	O
.	O

We	O
also	O
shortly	O
discuss	O
the	O
ongoing	O
debate	O
on	O
whether	O
NO	S-chem-C9-1
is	O
the	O
actual	O
reaction	O
product	O
of	O
NOS	S-geneN-C9-2
catalysis	O
,	O
as	O
well	O
as	O
the	O
phenomenon	O
of	O
NO	S-chem
-	O
mediated	O
autoinhibition	O
.	O

We	O
describe	O
the	O
function	O
of	O
BH4	S-chem
in	O
aromatic	B-chem
amino	I-chem
acid	E-chem
hydroxylation	O
,	O
and	O
discuss	O
the	O
allosteric	O
and	O
structural	O
effects	O
that	O
BH4	S-chem
exerts	O
on	O
NOS	S-geneN
.	O

Next	O
we	O
turn	O
our	O
attention	O
to	O
what	O
is	O
now	O
becoming	O
accepted	O
as	O
the	O
central	O
function	O
of	O
BH4	S-chem
:	O
its	O
capacity	O
to	O
act	O
as	O
a	O
1	O
-	O
electron	O
donor	O
during	O
reductive	O
activation	O
of	O
the	O
oxyferrous	S-chem
complex	O
of	O
the	O
heme	O
.	O

Finally	O
,	O
we	O
illustrate	O
how	O
BH4	S-chem
might	O
transform	O
the	O
NOS	S-geneN
dimer	O
into	O
an	O
efficient	O
S	B-geneN
-	I-geneN
nitrosoglutathione	I-geneN
synthase	E-geneN
,	O
and	O
briefly	O
touch	O
on	O
some	O
more	O
speculative	O
aspects	O
of	O
the	O
role	O
of	O
BH4	S-chem
in	O
NO	S-chem
synthesis	O
.	O

Lapatinib	S-chem-C4-1
:	O
a	O
dual	O
inhibitor	O
of	O
human	B-geneY-C4-2
epidermal	I-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
receptor	E-geneY-C4-2
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
.	O

BACKGROUND	O
:	O
Lapatinib	S-chem-C4-1
,	O
the	O
first	O
dual	O
inhibitor	O
of	O
epidermal	B-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
receptor	E-geneY-C4-2
(	O
EGFR	S-geneY-C4-2
)	O
and	O
human	B-geneY-C4-2
epidermal	I-geneY-C4-2
growth	I-geneY-C4-2
factor	I-geneY-C4-2
receptor	I-geneY-C4-2
2	E-geneY-C4-2
(	O
HER2	S-geneY-C4-2
)	O
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
,	O
was	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
in	O
2007	O
.	O

It	O
is	O
indicated	O
for	O
use	O
in	O
combination	O
with	O
capecitabine	S-chem
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
breast	O
cancer	O
or	O
metastatic	O
breast	O
cancer	O
(	O
MBC	O
)	O
whose	O
tumors	O
overexpress	O
HER2	S-geneY
(	O
ErbB2	S-geneY
)	O
and	O
who	O
have	O
received	O
previous	O
treatment	O
that	O
included	O
an	O
anthracycline	S-chem
,	O
a	O
taxane	S-chem
,	O
and	O
trastuzumab	O
.	O

OBJECTIVE	O
:	O
This	O
review	O
summarizes	O
the	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
and	O
safety	O
profile	O
of	O
lapatinib	S-chem
,	O
and	O
its	O
current	O
and	O
potential	O
role	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
and	O
other	O
malignancies	O
.	O

METHODS	O
:	O
Relevant	O
English	O
-	O
language	O
publications	O
were	O
identified	O
through	O
searches	O
of	O
MEDLINE	O
(	O
1966	O
-	O
May	O
2008	O
)	O
,	O
the	O
American	O
Society	O
of	O
Clinical	O
Oncology	O
abstracts	O
database	O
(	O
2000	O
-	O
2007	O
)	O
,	O
abstracts	O
from	O
the	O
San	O
Antonio	O
Breast	O
Cancer	O
Symposium	O
(	O
2005	O
-	O
2007	O
)	O
,	O
and	O
the	O
FDA	O
Web	O
site	O
(	O
January	O
2008	O
)	O
.	O

Search	O
terms	O
included	O
lapatinib	S-chem
,	O
GW572016	S-chem
,	O
HER2	S-geneY
,	O
EGFR	S-geneY
,	O
receptor	B-geneN
tyrosine	I-geneN
kinase	E-geneN
,	O
dual	O
-	O
receptor	O
blockade	O
,	O
adverse	O
events	O
,	O
and	O
clinical	O
trials	O
.	O

RESULTS	O
:	O
The	O
T	O
(	O
max	O
)	O
of	O
lapatinib	S-chem
after	O
oral	O
administration	O
is	O
3	O
to	O
4	O
hours	O
.	O

Dividing	O
the	O
dose	O
or	O
administering	O
it	O
with	O
food	O
,	O
particularly	O
a	O
high	O
-	O
fat	O
meal	O
,	O
increases	O
the	O
AUC	O
>	O
2	O
-	O
fold	O
.	O

Lapatinib	S-chem-C9-1
is	O
metabolized	O
primarily	O
by	O
the	O
cytochrome	B-geneY-C9-2
P450	I-geneY-C9-2
3A4	E-geneY-C9-2
isozyme	O
,	O
with	O
1	O
metabolite	O
remaining	O
active	O
against	O
EGFR	S-geneY
but	O
not	O
HER2	S-geneY
.	O

Due	O
to	O
drug	O
accumulation	O
,	O
the	O
t	O
(	O
1	O
/	O
2	O
)	O
of	O
lapatinib	S-chem
is	O
24	O
hours	O
with	O
continuous	O
dosing	O
.	O

In	O
a	O
Phase	O
III	O
trial	O
comparing	O
lapatinib	S-chem
and	O
capecitabine	S-chem
with	O
capecitabine	S-chem
alone	O
in	O
women	O
with	O
HER2	S-geneY
-	O
positive	O
,	O
locally	O
advanced	O
breast	O
cancer	O
or	O
MBC	O
that	O
had	O
progressed	O
after	O
treatment	O
with	O
an	O
anthracycline	S-chem
,	O
a	O
taxane	S-chem
,	O
and	O
trastuzumab	O
,	O
the	O
combination	O
of	O
lapatinib	S-chem
and	O
capecitabine	S-chem
was	O
associated	O
with	O
a	O
numeric	O
improvement	O
in	O
response	O
rate	O
compared	O
with	O
capecitabine	S-chem
alone	O
(	O
22	O
%	O
vs	O
14	O
%	O
,	O
respectively	O
;	O
P	O
=	O
NS	O
)	O
and	O
a	O
significant	O
increase	O
in	O
time	O
to	O
progression	O
(	O
6.2	O
vs	O
4.3	O
months	O
;	O
hazard	O
ratio	O
=	O
0.57	O
;	O
95	O
%	O
CI	O
,	O
0.43	O
-	O
0.77	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Lapatinib	S-chem
has	O
been	O
reported	O
to	O
have	O
antitumor	O
activity	O
in	O
Phase	O
II	O
trials	O
when	O
used	O
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	O
,	O
in	O
patients	O
with	O
inflammatory	O
breast	O
cancer	O
,	O
and	O
in	O
patients	O
with	O
central	O
nervous	O
system	O
metastases	O
.	O

Phase	O
II	O
trials	O
in	O
other	O
solid	O
tumor	O
types	O
found	O
modest	O
activity	O
.	O

The	O
approved	O
dosing	O
of	O
lapatinib	S-chem
is	O
1,250	O
mg	O
PO	O
QD	O
given	O
continuously	O
in	O
combination	O
with	O
capecitabine	S-chem
2,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
daily	O
administered	O
in	O
2	O
divided	O
doses	O
on	O
days	O
1	O
to	O
14	O
of	O
a	O
21	O
-	O
day	O
cycle	O
.	O

The	O
most	O
common	O
clinical	O
toxicities	O
of	O
all	O
grades	O
associated	O
with	O
lapatinib	S-chem
used	O
in	O
combination	O
with	O
capecitabine	S-chem
in	O
the	O
pivotal	O
clinical	O
trial	O
were	O
diarrhea	O
(	O
65	O
%	O
)	O
,	O
hand	O
-	O
foot	O
syndrome	O
(	O
53	O
%	O
)	O
,	O
nausea	O
(	O
44	O
%	O
)	O
,	O
rash	O
(	O
29	O
%	O
)	O
,	O
and	O
fatigue	O
(	O
24	O
%	O
)	O
.	O

Cardiac	O
toxicity	O
appears	O
to	O
be	O
less	O
frequent	O
with	O
lapatinib	S-chem
than	O
with	O
trastuzumab	O
.	O

CONCLUSIONS	O
:	O
Lapatinib	S-chem-C4-1
is	O
a	O
dual	O
inhibitor	O
of	O
the	O
EGFR	S-geneY-C4-2
and	O
HER2	S-geneY-C4-2
tyrosine	B-geneN-C4-2
kinases	E-geneN-C4-2
.	O

It	O
is	O
approved	O
by	O
the	O
FDA	O
for	O
use	O
in	O
combination	O
with	O
capecitabine	S-chem
for	O
the	O
treatment	O
of	O
HER2	S-geneY
-	O
positive	O
MBC	O
that	O
has	O
progressed	O
with	O
standard	O
treatment	O
.	O

In	O
clinical	O
trials	O
,	O
this	O
combination	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
the	O
time	O
to	O
progression	O
in	O
patients	O
with	O
MBC	O
.	O

Lapatinib	O
's	O
efficacy	O
in	O
other	O
malignancies	O
that	O
overexpress	O
EGFR	S-geneY
and	O
/	O
or	O
HER2	S-geneY
is	O
under	O
evaluation	O
.	O

Disposition	O
and	O
Metabolism	O
of	O
GSK2251052	S-chem
in	O
Humans	O
:	O
A	O
Novel	O
Boron	S-chem
-	O
Containing	O
Antibiotic	O
.	O

(	B-chem-C4-1
S	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
Aminomethyl	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
7	I-chem-C4-1
-	I-chem-C4-1
(	I-chem-C4-1
3	I-chem-C4-1
-	I-chem-C4-1
hydroxypropoxy	I-chem-C4-1
)	I-chem-C4-1
-	I-chem-C4-1
1	I-chem-C4-1
-	I-chem-C4-1
hydroxy	I-chem-C4-1
-	I-chem-C4-1
1,3	I-chem-C4-1
-	I-chem-C4-1
dihydro	I-chem-C4-1
-	I-chem-C4-1
2,1	I-chem-C4-1
-	I-chem-C4-1
benzoxaborole	E-chem-C4-1
(	O
GSK2251052	S-chem-C4-1
)	O
is	O
a	O
novel	O
boron	S-chem
-	O
containing	O
antibiotic	O
that	O
inhibits	O
bacterial	B-geneN-C4-2
leucyl	I-geneN-C4-2
tRNA	I-geneN-C4-2
synthetase	E-geneN-C4-2
,	O
and	O
that	O
has	O
been	O
in	O
development	O
for	O
the	O
treatment	O
of	O
serious	O
Gram	O
-	O
negative	O
infections	O
.	O

In	O
this	O
study	O
,	O
six	O
healthy	O
adult	O
male	O
subjects	O
received	O
a	O
single	O
i.v	O
.	O
dose	O
of	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
GSK2251052	E-chem
,	O
1500	O
mg	O
infused	O
over	O
1	O
hour	O
.	O

Blood	O
,	O
urine	O
,	O
and	O
feces	O
were	O
collected	O
over	O
an	O
extended	O
period	O
of	O
14	O
days	O
,	O
and	O
accelerator	O
mass	O
spectrometry	O
was	O
used	O
to	O
quantify	O
low	O
levels	O
of	O
radioactivity	O
in	O
plasma	O
at	O
later	O
time	O
points	O
to	O
supplement	O
the	O
less	O
-	O
sensitive	O
liquid	O
scintillation	O
counting	O
technique	O
.	O

An	O
excellent	O
mass	O
balance	O
recovery	O
was	O
achieved	O
representing	O
a	O
mean	O
total	O
of	O
98.2	O
%	O
of	O
the	O
dose	O
,	O
including	O
90.5	O
%	O
recovered	O
in	O
the	O
urine	O
.	O

Pharmacokinetic	O
analysis	O
demonstrated	O
that	O
radioactivity	O
was	O
moderately	O
associated	O
with	O
the	O
blood	O
cellular	O
components	O
,	O
and	O
together	O
with	O
GSK2251052	S-chem
,	O
both	O
were	O
highly	O
distributed	O
into	O
tissues	O
.	O

The	O
parent	O
compound	O
had	O
a	O
much	O
shorter	O
half	O
-	O
life	O
than	O
total	O
radioactivity	O
in	O
plasma	O
,	O
approximately	O
11.6	O
hours	O
compared	O
with	O
96	O
hours	O
.	O

GSK2251052	S-chem
and	O
its	O
major	O
metabolite	O
M3	O
,	O
which	O
resulted	O
from	O
oxidation	O
of	O
the	O
propanol	S-chem
side	O
chain	O
to	O
the	O
corresponding	O
carboxylic	B-chem
acid	E-chem
,	O
comprised	O
the	O
majority	O
of	O
the	O
plasma	O
radioactivity	O
,	O
37	O
and	O
53	O
%	O
of	O
the	O
area	O
under	O
the	O
plasma	O
versus	O
time	O
concentration	O
curve	O
from	O
time	O
zero	O
to	O
infinity	O
,	O
respectively	O
.	O

Additionally	O
,	O
M3	O
was	O
eliminated	O
renally	O
,	O
and	O
was	O
demonstrated	O
to	O
be	O
responsible	O
for	O
the	O
long	O
plasma	O
radioactivity	O
elimination	O
half	O
-	O
life	O
.	O

A	O
combination	O
of	O
in	O
vitro	O
metabolism	O
experiments	O
and	O
a	O
pharmacokinetic	O
study	O
in	O
monkeys	O
with	O
the	O
inhibitor	O
4	B-chem-C4-1
-	I-chem-C4-1
methylpyrazole	E-chem-C4-1
provided	O
strong	O
evidence	O
that	O
alcohol	B-geneN-C4-2
dehydrogenase	E-geneN-C4-2
,	O
potentially	O
in	O
association	O
with	O
aldehyde	B-geneN
dehydrogenase	E-geneN
,	O
is	O
the	O
primary	O
enzyme	O
involved	O
in	O
the	O
formation	O
of	O
the	O
M3	O
metabolite	O
.	O

Combination	O
lopinavir	S-chem
and	O
ritonavir	S-chem
alter	O
exogenous	O
and	O
endogenous	O
bile	B-chem
acid	E-chem
disposition	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
.	O

Inhibition	O
of	O
the	O
bile	B-geneY
salt	I-geneY
export	I-geneY
pump	E-geneY
(	O
BSEP	S-geneY
)	O
can	O
cause	O
intracellular	O
accumulation	O
of	O
bile	B-chem
acids	E-chem
and	O
is	O
a	O
risk	O
factor	O
for	O
drug	O
-	O
induced	O
liver	O
injury	O
in	O
humans	O
.	O

Antiretroviral	O
protease	S-geneN-C4-2
inhibitors	O
lopinavir	S-chem-C4-1
(	O
LPV	S-chem-C4-1
)	O
and	O
ritonavir	S-chem-C4-1
(	O
RTV	S-chem-C4-1
)	O
are	O
reported	O
BSEP	S-geneY-C4-2
inhibitors	O
.	O

However	O
,	O
the	O
consequences	O
of	O
LPV	S-chem
and	O
RTV	S-chem
,	O
alone	O
and	O
combined	O
(	O
LPV	S-chem
/	O
r	O
)	O
,	O
on	O
hepatocyte	O
viability	O
,	O
bile	B-chem
acid	E-chem
transport	O
,	O
and	O
endogenous	O
bile	B-chem
acid	E-chem
disposition	O
in	O
rat	O
hepatocytes	O
have	O
not	O
been	O
examined	O
.	O

The	O
effect	O
of	O
LPV	S-chem
,	O
RTV	S-chem
,	O
and	O
LPV	S-chem
/	O
r	O
on	O
cellular	O
viability	O
and	O
the	O
disposition	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
taurocholic	I-chem
acid	E-chem
(	O
TCA	S-chem
)	O
and	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
chenodeoxycholic	I-chem
acid	E-chem
(	O
CDCA	S-chem
)	O
was	O
determined	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
(	O
SCRH	O
)	O
and	O
suspended	O
rat	O
hepatocytes	O
.	O

Lactate	S-chem
dehydrogenase	O
and	O
ATP	S-chem
assays	O
revealed	O
a	O
concentration	O
-	O
dependent	O
effect	O
of	O
LPV	S-chem
and	O
RTV	S-chem
on	O
cellular	O
viability	O
.	O

LPV	S-chem
(	O
5	O
µM	O
)	O
,	O
alone	O
and	O
combined	O
with	O
5	O
µM	O
RTV	S-chem
,	O
significantly	O
decreased	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
TCA	E-chem
accumulation	O
in	O
cells	O
+	O
bile	O
of	O
SCRHs	O
compared	O
with	O
control	O
.	O

LPV	S-chem
/	O
r	O
significantly	O
increased	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
TCA	E-chem
cellular	O
accumulation	O
(	O
7.7	O
±	O
0.1	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
compared	O
with	O
vehicle	O
and	O
5	O
µM	O
LPV	S-chem
alone	O
(	O
5.1	O
±	O
0.7	O
and	O
5.0	O
±	O
0.5	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

The	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
TCA	E-chem
biliary	O
clearance	O
was	O
reduced	O
significantly	O
by	O
LPV	S-chem
and	O
RTV	S-chem
and	O
further	O
reduced	O
by	O
LPV	S-chem
/	O
r	O
.	O

LPV	S-chem
and	O
RTV	S-chem
did	O
not	O
affect	O
the	O
initial	O
uptake	O
rates	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
TCA	E-chem
or	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
CDCA	E-chem
in	O
suspended	O
rat	O
hepatocytes	O
.	O

LPV	S-chem
(	O
50	O
µM	O
)	O
,	O
RTV	S-chem
(	O
5	O
µM	O
)	O
,	O
and	O
LPV	S-chem
/	O
r	O
(	O
5	O
and	O
50	O
µM	O
/	O
5	O
µM	O
)	O
significantly	O
decreased	O
the	O
accumulation	O
of	O
total	O
measured	O
endogenous	O
bile	B-chem
acids	E-chem
(	O
TCA	S-chem
,	O
glycocholic	B-chem
acid	E-chem
,	O
taurochenodeoxycholic	B-chem
acid	E-chem
,	O
glycochenodeoxycholic	B-chem
acid	E-chem
,	O
and	O
α	B-chem
/	I-chem
β	I-chem
-	I-chem
tauromuricholic	I-chem
acid	E-chem
)	O
in	O
SCRH	O
.	O

Quantification	O
of	O
endogenous	O
bile	B-chem
acids	E-chem
in	O
SCRH	O
may	O
reveal	O
important	O
adaptive	O
responses	O
associated	O
with	O
exposure	O
to	O
known	O
BSEP	S-geneY
inhibitors	O
.	O

Effects	O
of	O
felodipine	S-chem-C4-1
(	O
a	O
dihydropyridine	S-chem-C4-1
calcium	B-geneN-C4-2
channel	E-geneN-C4-2
blocker	O
)	O
and	O
analogues	O
on	O
calmodulin	B-geneN
-	I-geneN
dependent	I-geneN
enzymes	E-geneN
.	O

We	O
have	O
examined	O
the	O
effects	O
on	O
the	O
activities	O
of	O
three	O
calmodulin	B-geneN
-	I-geneN
dependent	I-geneN
enzymes	E-geneN
(	O
cAMP	B-geneN
phosphodiesterase	E-geneN
,	O
caldesmon	B-geneN
kinase	E-geneN
and	O
myosin	B-geneY
light	I-geneY
chain	I-geneY
kinase	E-geneY
)	O
of	O
the	O
dihydropyridine	S-chem
Ca2	B-geneN-C4-2
+	I-geneN-C4-2
channel	E-geneN-C4-2
blocker	O
felodipine	S-chem-C4-1
and	O
three	O
analogues	O
(	O
p	B-chem
-	I-chem
chloro	E-chem
,	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
)	O
exhibiting	O
different	O
pharmacological	O
potencies	O
.	O

The	O
cAMP	B-geneN-C4-2
phosphodiesterase	E-geneN-C4-2
was	O
inhibited	O
completely	O
by	O
felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
with	O
IC50	O
values	O
of	O
3.7	O
and	O
1.5	O
microM	O
respectively	O
.	O

The	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
analogues	O
were	O
relatively	O
ineffective	O
in	O
inhibiting	O
cAMP	B-geneN
phosphodiesterase	E-geneN
.	O

Felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
inhibited	O
the	O
basal	O
(	O
Ca2	B-chem
+	E-chem
/	O
calmodulin	O
-	O
independent	O
)	O
activity	O
of	O
cAMP	B-geneN-C4-2
phosphodiesterase	E-geneN-C4-2
as	O
well	O
as	O
the	O
calmodulin	S-geneY-C4-2
-	O
stimulated	O
activity	O
.	O

Calmodulin	S-geneY
was	O
relatively	O
ineffective	O
in	O
preventing	O
inhibition	O
of	O
cAMP	B-geneN-C4-2
phosphodiesterase	E-geneN-C4-2
by	O
felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
.	O

These	O
observations	O
suggest	O
that	O
felodipine	S-chem
may	O
act	O
directly	O
on	O
the	O
phosphodiesterase	S-geneN
as	O
well	O
as	O
through	O
calmodulin	S-geneY
.	O

Felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
inhibited	O
Ca2	B-chem
+	E-chem
/	O
calmodulin	S-geneY
-	O
dependent	O
caldesmon	B-geneN-C4-2
kinase	E-geneN-C4-2
with	O
similar	O
potencies	O
(	O
IC50	O
=	O
17.4	O
microM	O
)	O
,	O
whereas	O
the	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
analogues	O
caused	O
no	O
inhibition	O
.	O

Similarly	O
,	O
felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
inhibited	O
myosin	B-geneY-C4-2
light	I-geneY-C4-2
chain	I-geneY-C4-2
kinase	E-geneY-C4-2
activity	O
whether	O
the	O
isolated	O
20	O
kD	O
light	O
chain	O
(	O
IC50	O
=	O
12.6	O
microM	O
)	O
or	O
intact	O
myosin	S-geneN
(	O
IC50	O
=	O
11.0	O
microM	O
)	O
was	O
used	O
as	O
substrate	O
.	O

Inhibition	O
in	O
each	O
case	O
was	O
prevented	O
by	O
excess	O
calmodulin	S-geneY
.	O

The	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
derivatives	O
caused	O
little	O
or	O
no	O
inhibition	O
.	O

Finally	O
,	O
the	O
effects	O
of	O
felodipine	S-chem
and	O
the	O
three	O
analogues	O
on	O
two	O
processes	O
which	O
are	O
dependent	O
on	O
myosin	S-geneN
phosphorylation	O
were	O
examined	O
,	O
namely	O
the	O
actin	S-geneN
-	O
activated	O
Mg2	B-geneN
+	I-geneN
-	I-geneN
ATPase	E-geneN
activity	O
of	O
myosin	S-geneN
and	O
the	O
assembly	O
of	O
myosin	S-geneN
filaments	O
.	O

Felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
inhibited	O
the	O
actin	S-geneN
-	O
activated	O
Mg2	B-geneN-C4-2
+	I-geneN-C4-2
-	I-geneN-C4-2
ATPase	E-geneN-C4-2
activity	O
of	O
smooth	O
muscle	O
myosin	S-geneN-C4-2
(	O
IC50	O
=	O
25.1	O
microM	O
)	O
.	O

The	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
analogues	O
exhibited	O
no	O
inhibition	O
.	O

Similarly	O
,	O
felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
blocked	O
myosin	S-geneN-C4-2
filament	O
assembly	O
induced	O
by	O
low	O
concentrations	O
of	O
calmodulin	S-geneY
,	O
whereas	O
the	O
oxidized	O
and	O
t	B-chem
-	I-chem
butyl	E-chem
analogues	O
did	O
not	O
.	O

Again	O
,	O
inhibition	O
of	O
the	O
actin	S-geneN
-	O
activated	O
myosin	S-geneN-C4-2
Mg2	B-geneN-C4-2
+	I-geneN-C4-2
-	I-geneN-C4-2
ATPase	E-geneN-C4-2
and	O
myosin	S-geneN-C4-2
filament	O
assembly	O
by	O
felodipine	S-chem-C4-1
and	O
the	O
p	B-chem-C4-1
-	I-chem-C4-1
chloro	E-chem-C4-1
analogue	O
could	O
be	O
reversed	O
by	O
raising	O
the	O
calmodulin	S-geneY
concentration	O
.	O

These	O
observations	O
suggest	O
that	O
some	O
of	O
the	O
pharmacological	O
actions	O
of	O
felodipine	S-chem-C4-1
on	O
smooth	O
muscle	O
may	O
involve	O
inhibition	O
of	O
calmodulin	B-geneN-C4-2
-	I-geneN-C4-2
dependent	I-geneN-C4-2
enzymes	E-geneN-C4-2
which	O
are	O
functionally	O
involved	O
in	O
the	O
regulation	O
of	O
smooth	O
muscle	O
contraction	O
.	O

Amantadine	S-chem-C3-1
induces	O
c	B-geneY-C3-2
-	I-geneY-C3-2
fos	E-geneY-C3-2
in	O
rat	O
striatum	O
:	O
reversal	O
with	O
dopamine	B-geneY
D1	E-geneY
and	O
NMDA	B-geneN
receptor	E-geneN
antagonists	O
.	O

Amantadine	S-chem-C3-1
(	O
1	B-chem-C3-1
-	I-chem-C3-1
aminoadamantane	E-chem-C3-1
)	O
induced	O
Fos	S-geneY-C3-2
expression	O
in	O
the	O
central	O
,	O
dorsal	O
-	O
medial	O
and	O
ventral	O
-	O
medial	O
part	O
of	O
the	O
striatum	O
.	O

The	O
distribution	O
pattern	O
of	O
Fos	S-geneY-C3-2
induced	O
by	O
amantadine	S-chem-C3-1
was	O
more	O
similar	O
to	O
those	O
seen	O
with	O
dopaminomimetics	O
than	O
with	O
N	B-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
(	I-geneN
NMDA	I-geneN
)	I-geneN
receptor	E-geneN
antagonists	O
.	O

Pretreatment	O
with	O
the	O
dopamine	B-geneY-C6-2
D1	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
,	O
SCH23390	S-chem-MU-1
,	O
and	O
the	O
NMDA	B-geneN-C6-2
receptor	E-geneN-C6-2
antagonist	O
,	O
MK	B-chem-MU-1
-	I-chem-MU-1
801	E-chem-MU-1
,	O
blocked	O
amantadine	S-chem-C3-1
induction	O
of	O
Fos	S-geneY-MU-2
in	O
the	O
striatum	O
.	O

However	O
,	O
amantadine	S-chem-C3-1
induction	O
of	O
Fos	S-geneY-C3-2
in	O
the	O
striatum	O
was	O
unaffected	O
by	O
the	O
dopamine	B-geneY-C6-2
D2	I-geneY-C6-2
receptor	E-geneY-C6-2
antagonist	O
,	O
sulpiride	S-chem-C6-1
.	O

These	O
results	O
suggest	O
that	O
amantadine	S-chem-C3-1
induction	O
of	O
Fos	S-geneY-C3-2
in	O
the	O
rat	O
striatum	O
is	O
related	O
to	O
dopamine	B-geneY
D1	E-geneY
and	O
NMDA	B-geneN
receptors	E-geneN
.	O

Long	O
acting	O
beta	O
-	O
agonists	O
versus	O
theophylline	S-chem
for	O
maintenance	O
treatment	O
of	O
asthma	O
.	O

BACKGROUND	O
:	O
Theophylline	S-chem
and	O
long	O
acting	O
beta2	O
-	O
agonists	O
are	O
bronchodilators	O
used	O
for	O
the	O
management	O
of	O
persistent	O
asthma	O
symptoms	O
,	O
especially	O
nocturnal	O
asthma	O
.	O

They	O
represent	O
different	O
classes	O
of	O
drug	O
with	O
differing	O
side	O
-	O
effect	O
profiles	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
comparative	O
efficacy	O
,	O
safety	O
and	O
side	O
-	O
effects	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
and	O
theophylline	S-chem
in	O
the	O
maintenance	O
treatment	O
of	O
asthma	O
.	O

SEARCH	O
STRATEGY	O
:	O
Randomised	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
were	O
identified	O
using	O
the	O
Cochrane	O
Airways	O
Group	O
register	O
.	O

The	O
register	O
was	O
searched	O
using	O
the	O
following	O
terms	O
:	O
asthma	O
and	O
theophylline	S-chem
and	O
long	O
acting	O
beta	O
-	O
agonist	O
or	O
formoterol	S-chem
or	O
foradile	S-chem
or	O
eformoterol	S-chem
or	O
salmeterol	S-chem
or	O
bambuterol	S-chem
or	O
bitolterol	S-chem
.	O

Titles	O
and	O
abstracts	O
were	O
then	O
screened	O
to	O
identify	O
potentially	O
relevant	O
studies	O
.	O

The	O
bibliography	O
of	O
each	O
RCT	O
was	O
searched	O
for	O
additional	O
RCTs	O
.	O

Authors	O
of	O
identified	O
RCTs	O
were	O
contacted	O
for	O
other	O
relevant	O
published	O
and	O
unpublished	O
studies	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
included	O
studies	O
were	O
RCTs	O
involving	O
adults	O
and	O
children	O
with	O
clinical	O
evidence	O
of	O
asthma	O
.	O

These	O
studies	O
must	O
have	O
compared	O
oral	O
sustained	O
release	O
and	O
/	O
or	O
dose	O
adjusted	O
theophylline	S-chem
with	O
an	O
inhaled	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Potentially	O
relevant	O
trials	O
,	O
identified	O
by	O
screening	O
titles	O
and	O
/	O
or	O
abstracts	O
,	O
were	O
obtained	O
.	O

Two	O
reviewers	O
independently	O
assessed	O
full	O
text	O
versions	O
of	O
these	O
trials	O
to	O
decided	O
whether	O
the	O
trial	O
should	O
be	O
included	O
in	O
the	O
review	O
,	O
and	O
assessed	O
its	O
methodological	O
quality	O
.	O

Where	O
there	O
was	O
disagreement	O
between	O
reviewers	O
,	O
this	O
was	O
resolved	O
by	O
consensus	O
,	O
or	O
reference	O
to	O
a	O
third	O
party	O
.	O

Data	O
were	O
extracted	O
by	O
two	O
independent	O
reviewers	O
.	O

Inter	O
-	O
rater	O
reliability	O
was	O
assessed	O
by	O
simple	O
agreement	O
.	O

Study	O
authors	O
were	O
contacted	O
to	O
clarify	O
randomisation	O
methods	O
,	O
provide	O
missing	O
data	O
,	O
verify	O
the	O
data	O
extracted	O
and	O
identify	O
unpublished	O
studies	O
.	O

Relevant	O
pharmaceutical	O
manufacturers	O
were	O
also	O
contacted	O
.	O

MAIN	O
RESULTS	O
:	O
Six	O
trials	O
met	O
the	O
inclusion	O
criteria	O
.	O

Five	O
used	O
salmeterol	S-chem
and	O
one	O
,	O
biltoterol	S-chem
.	O

They	O
were	O
of	O
varying	O
quality	O
.	O

There	O
was	O
a	O
trend	O
for	O
salmeterol	S-chem
to	O
improve	O
FEV1	O
more	O
than	O
theophylline	S-chem
in	O
three	O
studies	O
and	O
salmeterol	S-chem
use	O
was	O
associated	O
with	O
more	O
symptom	O
free	O
nights	O
.	O

Bitolterol	S-chem
,	O
used	O
in	O
only	O
one	O
study	O
,	O
was	O
reported	O
to	O
be	O
less	O
effective	O
than	O
theophylline	S-chem
.	O

Subjects	O
taking	O
salmeterol	S-chem
experienced	O
fewer	O
adverse	O
events	O
than	O
those	O
using	O
theophylline	S-chem
(	O
Relative	O
Risk	O
0.38	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0.25	O
,	O
0.57	O
)	O
.	O

Significant	O
reductions	O
were	O
reported	O
for	O
central	O
nervous	O
system	O
adverse	O
events	O
(	O
Relative	O
Risk	O
0.51	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0.30	O
,	O
0.88	O
)	O
and	O
gastrointestinal	O
adverse	O
events	O
(	O
Relative	O
Risk	O
0.32	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0.17	O
,	O
0.59	O
)	O
.	O

REVIEWER	O
'S	O
CONCLUSIONS	O
:	O
Salmeterol	S-chem
may	O
be	O
more	O
effective	O
than	O
theophylline	S-chem
in	O
reducing	O
asthma	O
symptoms	O
including	O
night	O
waking	O
and	O
improving	O
lung	O
function	O
.	O

More	O
adverse	O
events	O
occurred	O
in	O
subjects	O
using	O
theophylline	S-chem
when	O
compared	O
to	O
salmeterol	S-chem
.	O

Different	O
neuroleptics	O
show	O
common	O
dose	O
and	O
time	O
dependent	O
effects	O
in	O
quantitative	O
field	O
potential	O
analysis	O
in	O
freely	O
moving	O
rats	O
.	O

Under	O
the	O
assumption	O
that	O
field	O
potentials	O
recorded	O
from	O
particular	O
brain	O
areas	O
reflect	O
the	O
net	O
balance	O
of	O
neurotransmitter	O
activities	O
,	O
the	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
responses	O
induced	O
by	O
intraperitoneal	O
application	O
of	O
different	O
neuroleptic	O
drugs	O
are	O
quantified	O
by	O
spectral	O
analysis	O
of	O
the	O
electroencephalogram	O
recorded	O
from	O
frontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
reticular	O
formation	O
.	O

The	O
actions	O
of	O
haloperidol	S-chem
,	O
chlorpromazine	S-chem
,	O
clozapine	S-chem
,	O
prothipendyl	S-chem
and	O
thioridazine	S-chem
in	O
general	O
were	O
characterized	O
by	O
increases	O
of	O
the	O
spectral	O
power	O
in	O
the	O
alpha	O
1	O
and	O
beta	O
range	O
,	O
at	O
higher	O
dosages	O
also	O
in	O
the	O
theta	O
range	O
.	O

This	O
observed	O
pattern	O
of	O
changes	O
is	O
in	O
line	O
with	O
the	O
neuroleptic	O
induced	O
spectral	O
changes	O
reported	O
in	O
the	O
literature	O
for	O
other	O
animals	O
and	O
man	O
.	O

In	O
the	O
light	O
of	O
the	O
already	O
known	O
effects	O
of	O
other	O
psychoactive	O
drugs	O
on	O
the	O
frequency	O
content	O
of	O
field	O
potentials	O
in	O
the	O
rat	O
,	O
it	O
should	O
now	O
be	O
possible	O
to	O
classify	O
different	O
drugs	O
in	O
terms	O
of	O
their	O
clinical	O
indication	O
.	O

With	O
respect	O
to	O
the	O
type	O
of	O
neurotransmitter	O
control	O
underlying	O
the	O
changes	O
produced	O
by	O
various	O
neuroleptics	O
,	O
it	O
is	O
quite	O
obvious	O
from	O
the	O
comparisons	O
with	O
the	O
respective	O
drug	O
effects	O
that	O
dopamine	B-geneY
-	I-geneY
D1	I-geneY
-	I-geneY
receptor	E-geneY
controlled	O
transmission	O
is	O
not	O
responsible	O
for	O
this	O
action	O
.	O

On	O
the	O
basis	O
of	O
earlier	O
findings	O
a	O
possible	O
interaction	O
between	O
dopamine	B-geneY
-	I-geneY
D2	I-geneY
receptor	E-geneY
or	O
glutamatergic	O
transmitter	O
control	O
is	O
discussed	O
.	O

CYP2J2	S-geneY
overexpression	O
increases	O
EETs	S-chem
and	O
protects	O
against	O
angiotensin	B-geneY
II	E-geneY
-	O
induced	O
abdominal	O
aortic	O
aneurysm	O
in	O
mice	O
.	O

Cytochrome	B-geneY-C9-2
P450	I-geneY-C9-2
epoxygenase	I-geneY-C9-2
2J2	E-geneY-C9-2
(	O
CYP2J2	S-geneY-C9-2
)	O
metabolizes	O
arachidonic	B-chem-C9-1
acids	E-chem-C9-1
to	O
form	O
epoxyeicosatrienoic	B-chem-C9-1
acids	E-chem-C9-1
(	O
EETs	S-chem-C9-1
)	O
,	O
which	O
possess	O
various	O
beneficial	O
effects	O
on	O
the	O
cardiovascular	O
system	O
.	O

However	O
,	O
whether	O
increasing	O
EETs	S-chem-C9-1
production	O
by	O
CYP2J2	S-geneY-C9-2
overexpression	O
in	O
vivo	O
could	O
prevent	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
remains	O
unknown	O
.	O

Here	O
we	O
investigated	O
the	O
effects	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
rAAV	O
)	O
-	O
mediated	O
CYP2J2	S-geneY
overexpression	O
on	O
angiotensin	B-geneY
(	I-geneY
Ang	I-geneY
)	I-geneY
II	E-geneY
-	O
induced	O
AAA	O
in	O
apoE	O
-	O
deficient	O
mice	O
.	O
rAAV	O
-	O
CYP2J2	S-geneY
delivery	O
led	O
to	O
an	O
abundant	O
aortic	O
CYP2J2	S-geneY
expression	O
and	O
increased	O
EETs	S-chem
generation	O
.	O

It	O
was	O
shown	O
that	O
CYP2J2	S-geneY
overexpression	O
attenuated	O
matrix	B-geneN
metalloproteinase	E-geneN
expression	O
and	O
activity	O
,	O
elastin	S-geneY
degradation	O
,	O
and	O
AAA	O
formation	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
aortic	O
inflammation	O
and	O
macrophage	O
infiltration	O
.	O

In	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
,	O
rAAV	O
-	O
mediated	O
CYP2J2	S-geneY
overexpression	O
and	O
EETs	S-chem-C4-1
markedly	O
suppressed	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
-	O
induced	O
inflammatory	O
cytokine	S-geneN-C4-2
expression	O
.	O

Moreover	O
,	O
overexpressed	O
CYP2J2	S-geneY
and	O
EETs	S-chem-C4-1
inhibited	O
Ang	B-geneY-C4-2
II	E-geneY-C4-2
-	O
induced	O
macrophage	O
migration	O
in	O
a	O
VSMC	O
-	O
macrophage	O
coculture	O
system	O
.	O

We	O
further	O
indicated	O
that	O
these	O
protective	O
effects	O
were	O
mediated	O
by	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
(	I-geneY
PPAR	I-geneY
)	I-geneY
γ	E-geneY
activation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
rAAV	O
-	O
mediated	O
CYP2J2	S-geneY
overexpression	O
prevents	O
AAA	O
development	O
which	O
is	O
likely	O
via	O
PPARγ	S-geneY
activation	O
and	O
anti	O
-	O
inflammatory	O
action	O
,	O
suggesting	O
that	O
increasing	O
EETs	S-chem
levels	O
could	O
be	O
considered	O
as	O
a	O
potential	O
strategy	O
to	O
prevent	O
and	O
treat	O
AAA	O
.	O

Concentration	O
-	O
dependent	O
inhibitory	O
effects	O
of	O
baicalin	S-chem-C4-1
on	O
the	O
metabolism	O
of	O
dextromethorphan	S-chem-C9-1
,	O
a	O
dual	O
probe	O
of	O
CYP2D	S-geneN-MU-2
and	O
CYP3A	S-geneN-MU-2
,	O
in	O
rats	O
.	O

Baicalin	S-chem
has	O
been	O
shown	O
to	O
possess	O
many	O
pharmacological	O
effects	O
,	O
including	O
antiviral	O
,	O
antioxidant	O
,	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
reveal	O
the	O
inhibitory	O
effects	O
of	O
baicalin	S-chem-C4-1
on	O
the	O
metabolism	O
of	O
dextromethorphan	S-chem-C9-1
(	O
DXM	S-chem-C9-1
)	O
,	O
a	O
dual	O
probe	O
substrate	O
of	O
CYP2D	S-geneN-MU-2
and	O
CYP3A	S-geneN-MU-2
,	O
in	O
rats	O
.	O

Lineweaver	O
-	O
Burk	O
plots	O
demonstrated	O
that	O
baicalin	S-chem-C4-1
inhibited	O
the	O
activities	O
of	O
CYP2D	S-geneN-C4-2
and	O
CYP3A	S-geneN-C4-2
in	O
a	O
non	O
-	O
competitive	O
manner	O
in	O
rat	O
liver	O
microsomes	O
(	O
RLMs	O
)	O
.	O

Concomitant	O
administration	O
of	O
baicalin	S-chem
(	O
0.90g	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
and	O
DXM	S-chem
(	O
10mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
increased	O
the	O
maximum	O
drug	O
concentration	O
(	O
Cmax	O
)	O
(	O
37	O
%	O
)	O
and	O
the	O
area	O
under	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
(	O
42	O
%	O
)	O
and	O
decreased	O
the	O
clearance	O
(	O
CL	O
)	O
(	O
27	O
%	O
)	O
of	O
DXM	S-chem
in	O
a	O
randomised	O
,	O
crossover	O
study	O
in	O
rats	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
change	O
in	O
the	O
AUC	O
of	O
DXM	S-chem
was	O
significantly	O
correlated	O
with	O
the	O
Cmax	O
and	O
AUC	O
of	O
baicalin	S-chem
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
inhibitory	O
effects	O
of	O
multiple	O
doses	O
of	O
baicalin	S-chem
(	O
0.90g	O
/	O
kg	O
,	O
i.v	O
.	O
,	O
12days	O
)	O
on	O
the	O
metabolism	O
of	O
DXM	S-chem
were	O
similar	O
to	O
those	O
observed	O
following	O
a	O
single	O
dose	O
in	O
rats	O
.	O

The	O
activity	O
of	O
CYP3A	S-geneN-C4-2
in	O
excised	O
liver	O
samples	O
from	O
rats	O
following	O
multiple	O
baicalin	S-chem-C4-1
treatment	O
was	O
significantly	O
decreased	O
compared	O
to	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
multiple	O
doses	O
of	O
baicalin	S-chem
had	O
no	O
obvious	O
effect	O
on	O
the	O
activity	O
of	O
CYP2D	S-geneN
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
baicalin	S-chem-C4-1
inhibits	O
the	O
metabolism	O
of	O
DXM	S-chem-C9-1
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
rats	O
,	O
possibly	O
through	O
inhibiting	O
hepatic	O
CYP2D	S-geneN-MU-2
and	O
CYP3A	S-geneN-MU-2
activities	O
.	O

Neuroprotective	O
role	O
of	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
potassium	I-geneN
channels	E-geneN
in	O
cerebral	O
ischemia	O
.	O

ATP	B-geneN
-	I-geneN
sensitive	I-geneN
potassium	I-geneN
(	I-geneN
K	I-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
)	I-geneN
channels	E-geneN
are	O
weak	O
,	O
inward	O
rectifiers	O
that	O
couple	O
metabolic	O
status	O
to	O
cell	O
membrane	O
electrical	O
activity	O
,	O
thus	O
modulating	O
many	O
cellular	O
functions	O
.	O

An	O
increase	O
in	O
the	O
ADP	S-chem-C3-1
/	O
ATP	S-chem-C3-1
ratio	O
opens	O
K	B-geneN-C3-2
(	I-geneN-C3-2
ATP	I-geneN-C3-2
)	I-geneN-C3-2
channels	E-geneN-C3-2
,	O
leading	O
to	O
membrane	O
hyperpolarization	O
.	O

K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
are	O
ubiquitously	O
expressed	O
in	O
neurons	O
located	O
in	O
different	O
regions	O
of	O
the	O
brain	O
,	O
including	O
the	O
hippocampus	O
and	O
cortex	O
.	O

Brief	O
hypoxia	O
triggers	O
membrane	O
hyperpolarization	O
in	O
these	O
central	O
neurons	O
.	O

In	O
vivo	O
animal	O
studies	O
confirmed	O
that	O
knocking	O
out	O
the	O
Kir6.2	S-geneN
subunit	O
of	O
the	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
increases	O
ischemic	O
infarction	O
,	O
and	O
overexpression	O
of	O
the	O
Kir6.2	S-geneN
subunit	O
reduces	O
neuronal	O
injury	O
from	O
ischemic	O
insults	O
.	O

These	O
findings	O
provide	O
the	O
basis	O
for	O
a	O
practical	O
strategy	O
whereby	O
activation	O
of	O
endogenous	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
reduces	O
cellular	O
damage	O
resulting	O
from	O
cerebral	O
ischemic	O
stroke	O
.	O

K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channel	E-geneN
modulators	O
may	O
prove	O
to	O
be	O
clinically	O
useful	O
as	O
part	O
of	O
a	O
combination	O
therapy	O
for	O
stroke	O
management	O
in	O
the	O
future	O
.	O

eIF4F	S-geneY
suppression	O
in	O
breast	O
cancer	O
affects	O
maintenance	O
and	O
progression	O
.	O

Levels	O
of	O
eukaryotic	B-geneY
initiation	I-geneY
factor	I-geneY
4E	E-geneY
(	O
eIF4E	S-geneY
)	O
are	O
frequently	O
elevated	O
in	O
human	O
cancers	O
and	O
in	O
some	O
instances	O
have	O
been	O
associated	O
with	O
poor	O
prognosis	O
and	O
outcome	O
.	O

Here	O
we	O
utilize	O
transgenic	O
and	O
allograft	O
breast	O
cancer	O
models	O
to	O
demonstrate	O
that	O
increased	O
mammalian	B-geneY
target	I-geneY
of	I-geneY
rapamycin	E-geneY
(	O
mTOR	S-geneY
)	O
signalling	O
can	O
be	O
a	O
significant	O
contributor	O
to	O
breast	O
cancer	O
progression	O
in	O
vivo	O
.	O

Suppressing	O
mTOR	S-geneY
activity	O
,	O
as	O
well	O
as	O
levels	O
and	O
activity	O
of	O
the	O
downstream	O
translation	O
regulators	O
,	O
eIF4E	S-geneY
and	O
eIF4A	S-geneY
,	O
delayed	O
breast	O
cancer	O
progression	O
,	O
onset	O
of	O
associated	O
pulmonary	O
metastasis	O
in	O
vivo	O
and	O
breast	O
cancer	O
cell	O
invasion	O
and	O
migration	O
in	O
vitro	O
.	O

Translation	O
of	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
,	O
matrix	B-geneY
metallopeptidase	I-geneY
9	E-geneY
(	O
MMP9	S-geneY
)	O
and	O
cyclin	B-geneY
D1	E-geneY
mRNAs	O
,	O
which	O
encode	O
products	O
associated	O
with	O
the	O
metastatic	O
phenotype	O
,	O
is	O
inhibited	O
upon	O
eIF4E	S-geneY
suppression	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
mTOR	S-geneY
/	O
eIF4F	S-geneY
axis	O
is	O
an	O
important	O
contributor	O
to	O
tumor	O
maintenance	O
and	O
progression	O
programs	O
in	O
breast	O
cancer	O
.	O

Targeting	O
this	O
pathway	O
may	O
be	O
of	O
therapeutic	O
benefit	O
.	O

The	O
unexpected	O
side	O
effects	O
of	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Conventional	O
nonselective	O
NSAIDs	O
are	O
classically	O
associated	O
with	O
a	O
risk	O
of	O
gastrointestinal	O
disorders	O
.	O

These	O
drugs	O
have	O
a	O
broad	O
range	O
of	O
relative	O
selectivity	O
towards	O
the	O
COX	S-geneN
family	O
,	O
mainly	O
towards	O
two	O
isoforms	O
of	O
these	O
enzymes	O
:	O
COX	B-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
.	O

As	O
examples	O
,	O
ketorolac	S-chem
,	O
flurbiprofen	S-chem
,	O
ketoprofen	S-chem
and	O
indomethacin	S-chem
have	O
increased	O
COX	B-geneY
-	I-geneY
1	E-geneY
selectivity	O
when	O
compared	O
with	O
naproxen	S-chem
and	O
ibuprofen	S-chem
.	O

Paeoniflorin	S-chem-C3-1
protects	O
human	O
EA.hy926	O
endothelial	O
cells	O
against	O
gamma	O
-	O
radiation	O
induced	O
oxidative	O
injury	O
by	O
activating	O
the	O
NF	B-geneY-C3-2
-	I-geneY-C3-2
E2	I-geneY-C3-2
-	I-geneY-C3-2
related	I-geneY-C3-2
factor	I-geneY-C3-2
2	E-geneY-C3-2
/	O
heme	B-geneY-C3-2
oxygenase	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
pathway	O
.	O

Pulmonary	O
endothelial	O
cells	O
have	O
been	O
demonstrated	O
to	O
have	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
radiation	O
-	O
induced	O
lung	O
injury	O
.	O

Our	O
preliminary	O
experiments	O
indicated	O
that	O
Paeoniflorin	S-chem
protected	O
human	O
EA.hy926	O
endothelial	O
cells	O
from	O
radiation	O
-	O
induced	O
oxidative	O
injury	O
.	O

This	O
study	O
was	O
designed	O
to	O
confirm	O
the	O
protective	O
effect	O
of	O
Paeoniflorin	S-chem
against	O
radiation	O
-	O
induced	O
endothelial	O
cellular	O
damage	O
and	O
to	O
elucidate	O
the	O
underlying	O
mechanisms	O
.	O

Preincubation	O
of	O
EA.hy926	O
cells	O
with	O
Paeoniflorin	S-chem
before	O
γ	O
-	O
radiation	O
resulted	O
in	O
significant	O
inhibition	O
of	O
apoptosis	O
,	O
a	O
decrease	O
in	O
mitochondrial	O
membrane	O
potential	O
and	O
enhanced	O
cell	O
viability	O
.	O

In	O
particular	O
,	O
we	O
showed	O
that	O
Paeoniflorin	S-chem-MU-1
significantly	O
reduced	O
the	O
formation	O
of	O
intracellular	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
,	O
the	O
level	O
of	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
and	O
lactate	B-geneN-C4-2
dehydrogenase	E-geneN-C4-2
(	O
LDH	S-geneN-C4-2
)	O
leakage	O
,	O
and	O
enhanced	O
production	O
of	O
the	O
endogenous	O
antioxidants	O
,	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
and	O
superoxide	B-geneN-C3-2
dismutase	E-geneN-C3-2
(	O
SOD	S-geneN-C3-2
)	O
in	O
EA.hy926	O
cells	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
Paeoniflorin	S-chem-C3-1
significantly	O
induced	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
expression	O
.	O

Moreover	O
,	O
Paeoniflorin	S-chem
promoted	O
the	O
nuclear	O
translocation	O
of	O
nuclear	B-geneY
factor	I-geneY
erythroid	I-geneY
2	I-geneY
related	I-geneY
factor	I-geneY
-	I-geneY
2	E-geneY
(	O
Nrf	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

The	O
Paeoniflorin	S-chem-C3-1
-	O
induced	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
expression	O
was	O
abrogated	O
by	O
Nrf2	S-geneY
siRNA	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
HO	B-geneY-MU-2
-	I-geneY-MU-2
1	E-geneY-MU-2
with	O
zinc	B-chem-C4-1
protoporphyrin	I-chem-C4-1
IX	E-chem-C4-1
(	O
ZNPP	S-chem-C4-1
)	O
significantly	O
reversed	O
the	O
protective	O
effect	O
of	O
Paeoniflorin	S-chem-C3-1
against	O
radiation	O
-	O
induced	O
damage	O
in	O
EA.hy926	O
cells	O
.	O

Our	O
findings	O
confirmed	O
that	O
Paeoniflorin	S-chem-C3-1
protected	O
EA.hy926	O
cells	O
against	O
radiation	O
-	O
induced	O
injury	O
through	O
the	O
Nrf2	S-geneY-C3-2
/	O
HO	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
pathway	O
.	O

Methionine	B-geneY
synthase	I-geneY
reductase	E-geneY
polymorphisms	O
are	O
associated	O
with	O
serum	O
osteocalcin	S-geneY
levels	O
in	O
postmenopausal	O
women	O
.	O

Homocysteine	S-chem
(	O
Hcy	S-chem
)	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
osteoporosis	O
and	O
fracture	O
.	O

Methionine	B-geneY-C9-2
synthase	I-geneY-C9-2
reductase	E-geneY-C9-2
(	O
MTRR	S-geneY-C9-2
)	O
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conversion	O
of	O
Hcy	S-chem-C9-1
to	O
methionine	S-chem-C9-1
.	O

We	O
hypothesized	O
that	O
certain	O
genetic	O
polymorphisms	O
of	O
MTRR	S-geneY
leading	O
to	O
reduced	O
enzyme	O
activity	O
may	O
cause	O
hyperhomocysteinemia	O
and	O
affect	O
bone	O
metabolism	O
.	O

We	O
therefore	O
examined	O
the	O
associations	O
of	O
the	O
A66G	S-geneN
and	O
C524T	S-geneN
polymorphisms	O
of	O
the	O
MTRR	S-geneY
gene	O
with	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
and	O
serum	O
osteocalcin	S-geneY
levels	O
in	O
postmenopausal	O
women	O
.	O

Although	O
we	O
did	O
not	O
detect	O
any	O
significant	O
associations	O
between	O
MTRR	S-geneY
polymorphisms	O
and	O
BMD	O
or	O
serum	O
osteocalcin	S-geneY
levels	O
,	O
we	O
found	O
that	O
the	O
66G	O
/	O
524C	O
haplotype	O
,	O
which	O
has	O
reduced	O
enzyme	O
activity	O
,	O
was	O
significantly	O
associated	O
with	O
serum	O
osteocalcin	S-geneY
levels	O
in	O
a	O
gene	O
-	O
dose	O
dependent	O
manner	O
(	O
P	O
=	O
0.002	O
)	O
.	O

That	O
is	O
,	O
the	O
highest	O
osteocalcin	S-geneY
levels	O
(	O
34.5	O
+	O
/	O
-	O
16.8	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
two	O
copies	O
,	O
intermediate	O
osteocalcin	S-geneY
levels	O
(	O
32.6	O
+	O
/	O
-	O
14.4	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
one	O
copy	O
,	O
and	O
the	O
lowest	O
levels	O
of	O
osteocalcin	S-geneY
(	O
28.8	O
+	O
/	O
-	O
10.9	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
no	O
copies	O
.	O

These	O
results	O
suggest	O
that	O
the	O
66G	O
/	O
524C	O
haplotype	O
of	O
the	O
MTRR	S-geneY
gene	O
affect	O
bone	O
turn	O
over	O
rate	O
.	O

The	O
role	O
of	O
late	O
I	O
and	O
antiarrhythmic	O
drugs	O
in	O
EAD	O
formation	O
and	O
termination	O
in	O
Purkinje	O
fibers	O
.	O

Multiple	O
components	O
of	O
cardiac	O
Na	S-chem
current	O
play	O
a	O
role	O
in	O
determining	O
electrical	O
excitation	O
in	O
the	O
heart	O
.	O

Recently	O
,	O
the	O
role	O
of	O
nonequilibrium	O
components	O
in	O
controlling	O
cardiac	O
action	O
potential	O
plateau	O
duration	O
,	O
and	O
their	O
importance	O
in	O
regulating	O
the	O
occurrence	O
of	O
afterdepolarizations	O
and	O
arrhythmias	O
have	O
garnered	O
more	O
attention	O
.	O

In	O
particular	O
,	O
late	O
Na	S-chem
current	O
(	O
late	O
I	O
(	O
Na	S-chem
)	O
)	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
LQT2	O
and	O
LQT3	O
arrhythmias	O
.	O

Class	O
III	O
agents	O
like	O
dofetilide	S-chem
,	O
clofilium	S-chem
,	O
and	O
sotalol	S-chem
,	O
which	O
can	O
all	O
cause	O
a	O
drug	O
-	O
induced	O
form	O
of	O
LQT2	O
,	O
significantly	O
lengthen	O
action	O
potential	O
duration	O
at	O
50	O
%	O
and	O
90	O
%	O
repolarization	O
in	O
isolated	O
rabbit	O
Purkinje	O
fibers	O
,	O
and	O
can	O
initiate	O
the	O
formation	O
of	O
early	O
afterdepolarizations	O
,	O
and	O
extra	O
beats	O
.	O

These	O
actions	O
can	O
lead	O
to	O
the	O
development	O
of	O
a	O
serious	O
ventricular	O
tachycardia	O
,	O
torsades	O
de	O
pointes	O
,	O
in	O
animal	O
models	O
and	O
patients	O
.	O

However	O
,	O
pretreatment	O
with	O
agents	O
that	O
block	O
late	O
I	O
(	O
Na	S-chem
)	O
,	O
like	O
lidocaine	S-chem
,	O
mexiletine	S-chem
,	O
and	O
RSD1235	S-chem-C4-1
,	O
a	O
novel	O
mixed	O
ion	B-geneN-C4-2
channel	E-geneN-C4-2
blocker	O
for	O
the	O
rapid	O
pharmacologic	O
conversion	O
of	O
atrial	O
fibrillation	O
,	O
significantly	O
attenuates	O
the	O
prolonging	O
effects	O
of	O
Class	O
III	O
agents	O
or	O
those	O
induced	O
by	O
ATX	O
-	O
II	O
,	O
a	O
specific	O
toxin	O
that	O
delays	O
Na	B-geneN
channel	E-geneN
inactivation	O
and	O
amplifies	O
late	O
I	O
(	O
Na	S-chem
)	O
greatly	O
,	O
mimicking	O
LQT3	O
.	O

The	O
Na	B-geneN-C4-2
channel	E-geneN-C4-2
block	O
caused	O
by	O
lidocaine	S-chem-C4-1
and	O
RSD1235	S-chem-C4-1
can	O
be	O
through	O
the	O
open	O
or	O
inactivated	O
states	O
of	O
the	O
channel	O
,	O
but	O
both	O
equivalently	O
inhibit	O
a	O
late	O
component	O
of	O
Na	S-chem
current	O
(	O
I	O
(	O
Na	S-chem
)	O
)	O
,	O
recorded	O
at	O
22	O
degrees	O
C	O
using	O
whole	O
-	O
cell	O
patch	O
clamp	O
of	O
Nav	B-geneY
1.5	E-geneY
expressed	O
in	O
HEK	O
cells	O
.	O

These	O
protective	O
actions	O
of	O
lidocaine	S-chem
,	O
mexiletine	S-chem
,	O
and	O
RSD1235	S-chem
may	O
result	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
their	O
ability	O
to	O
inhibit	O
late	O
I	O
(	O
Na	S-chem
)	O
during	O
action	O
potential	O
repolarization	O
,	O
and	O
inhibition	O
of	O
the	O
inward	O
currents	O
contributing	O
to	O
EAD	O
and	O
arrhythmia	O
formation	O
.	O

Adrenergic	O
agonists	O
suppress	O
the	O
proliferation	O
of	O
microglia	O
through	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
.	O

The	O
effects	O
of	O
several	O
cyclic	B-chem
adenosine	I-chem
monophosphate	E-chem
(	O
cAMP	S-chem
)	O
-	O
elevating	O
agents	O
on	O
the	O
proliferation	O
of	O
cultured	O
rat	O
microglia	O
were	O
investigated	O
by	O
immunocytochemical	O
staining	O
with	O
an	O
antibody	O
against	O
proliferating	B-geneY
cell	I-geneY
nuclear	I-geneY
antigen	E-geneY
(	O
PCNA	S-geneY
)	O
.	O

Epinephrine	S-chem
,	O
isoproterenol	S-chem
,	O
forskolin	S-chem
and	O
8Br	B-chem
-	I-chem
cAMP	E-chem
suppressed	O
the	O
microglial	O
proliferation	O
.	O

A	O
beta2	O
-	O
selective	O
agonist	O
terbutaline	S-chem
but	O
not	O
a	O
beta1	O
-	O
selective	O
agonist	O
dobutamine	S-chem
mimicked	O
the	O
effect	O
of	O
the	O
above	O
cAMP	S-chem
-	O
elevating	O
agents	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
selective	O
beta	O
-	O
receptor	O
antagonist	O
oxprenolol	S-chem
and	O
a	O
beta2	O
-	O
selective	O
antagonist	O
acebutalol	S-chem
,	O
but	O
not	O
a	O
beta1	O
-	O
selective	O
antagonist	O
butoxamine	S-chem
,	O
counteracted	O
the	O
suppressive	O
effects	O
of	O
the	O
beta	O
-	O
agonists	O
on	O
microglial	O
proliferation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
beta	O
-	O
agonists	O
suppress	O
the	O
proliferation	O
of	O
microglia	O
by	O
elevating	O
intracellular	O
cAMP	S-chem
level	O
through	O
an	O
action	O
on	O
beta2	B-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
.	O

Apoptosis	O
induced	O
neurotoxicity	O
of	O
Di	B-chem
-	I-chem
n	I-chem
-	I-chem
butyl	I-chem
-	I-chem
di	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chlorobenzohydroxamato	I-chem
)	I-chem
Tin	I-chem
(	I-chem
IV	I-chem
)	E-chem
via	O
mitochondria	O
-	O
mediated	O
pathway	O
in	O
PC12	O
cells	O
.	O

The	O
severe	O
toxicity	O
of	O
antitumor	O
organotin	B-chem
(	I-chem
IV	I-chem
)	E-chem
compounds	O
limits	O
their	O
application	O
in	O
clinic	O
,	O
however	O
,	O
the	O
toxic	O
mechanism	O
is	O
still	O
unclear	O
.	O

Di	B-chem
-	I-chem
n	I-chem
-	I-chem
butyl	I-chem
-	I-chem
di	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
chlorobenzohydroxamato	I-chem
)	I-chem
Tin	I-chem
(	I-chem
IV	I-chem
)	E-chem
(	O
DBDCT	S-chem
)	O
,	O
an	O
antitumor	O
agent	O
with	O
high	O
activity	O
and	O
obvious	O
neurotoxicity	O
was	O
chosen	O
as	O
a	O
typical	O
diorganotin	B-chem
(	I-chem
IV	I-chem
)	E-chem
compound	O
to	O
investigate	O
its	O
neurotoxic	O
mechanism	O
using	O
PC12	O
cells	O
and	O
comprehensive	O
methods	O
.	O

Treatment	O
with	O
DBDCT	S-chem
resulted	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
growth	O
inhibition	O
of	O
PC12	O
cells	O
.	O

The	O
changes	O
in	O
cell	O
morphology	O
were	O
observed	O
using	O
light	O
microscopy	O
,	O
fluorescence	O
microscopy	O
and	O
transmission	O
electron	O
microscopy	O
.	O

PC12	O
cell	O
apoptosis	O
induced	O
by	O
DBDCT	S-chem
was	O
confirmed	O
by	O
annexin	O
V	O
/	O
propidium	B-chem
iodide	E-chem
staining	O
,	O
and	O
characterized	O
by	O
cleavage	O
of	O
caspase	B-geneY
-	I-geneY
9	E-geneY
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
proteins	O
.	O

DBDCT	S-chem
induced	O
the	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
and	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
.	O

DBDCT	S-chem-MU-1
up	O
-	O
regulated	O
the	O
expression	O
of	O
Bax	S-geneY-C3-2
,	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
Bcl	B-geneY-C4-2
-	I-geneY-C4-2
2	E-geneY-C4-2
,	O
and	O
significantly	O
increased	O
the	O
ratio	O
of	O
Bax	S-geneY-C3-2
/	O
Bcl	B-geneY-C3-2
-	I-geneY-C3-2
2	E-geneY-C3-2
.	O

DBDCT	S-chem-C3-1
also	O
caused	O
the	O
phosphorylation	O
of	O
JNK	S-geneN-C3-2
and	O
p38	S-geneN-C3-2
(	O
MAPK	S-geneN-C3-2
)	O
.	O

In	O
rats	O
exposed	O
to	O
DBDCT	S-chem
,	O
apoptosis	O
was	O
also	O
observed	O
in	O
brain	O
,	O
as	O
shown	O
by	O
the	O
detection	O
of	O
cleaved	O
caspase	B-geneY
-	I-geneY
9	E-geneY
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
proteins	O
and	O
increased	O
TUNEL	O
positive	O
staining	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
demonstrated	O
that	O
DBDCT	S-chem
caused	O
the	O
neurotoxicity	O
by	O
inducing	O
apoptosis	O
via	O
mitochondria	O
-	O
mediated	O
pathway	O
.	O

Oral	O
l	B-chem-C3-1
-	I-chem-C3-1
glutamine	E-chem-C3-1
increases	O
active	O
GLP	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
(	O
7	O
-	O
36	O
)	O
amide	S-chem
secretion	O
and	O
improves	O
glycemic	O
control	O
in	O
stretpozotocin	S-chem
-	O
nicotinamide	S-chem
induced	O
diabetic	O
rats	O
.	O

l	B-chem
-	I-chem
glutamine	E-chem
is	O
a	O
non	O
-	O
essential	O
amino	B-chem
acid	E-chem
.	O

It	O
decreased	O
blood	O
sugar	S-chem
,	O
stimulated	O
insulin	S-geneN
secretion	O
in	O
type	O
2	O
diabetic	O
patients	O
.	O

The	O
objective	O
of	O
the	O
present	O
investigation	O
was	O
to	O
evaluate	O
l	B-chem-C3-1
-	I-chem-C3-1
glutamine	E-chem-C3-1
increases	O
glucagon	B-geneY-C3-2
like	I-geneY-C3-2
peptide	I-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
(	O
GLP	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
)	O
(	O
7	O
-	O
36	O
)	O
amide	S-chem
secretion	O
in	O
streptozotocin	S-chem
-	O
nicotinamide	S-chem
(	O
STZ	S-chem
-	O
NTM	S-chem
)	O
induced	O
diabetic	O
Sprague	O
Dawley	O
rats	O
.	O

Molecular	O
docking	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
molecular	O
basis	O
for	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
agonistic	O
activity	O
.	O

Type	O
2	O
diabetes	O
was	O
induced	O
in	O
overnight	O
fasted	O
Sprague	O
Dawley	O
rats	O
pre	O
-	O
treated	O
with	O
nicotinamide	S-chem
(	O
100mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
followed	O
by	O
20min	O
after	O
administration	O
of	O
streptozotocin	S-chem
(	O
55mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

The	O
rats	O
were	O
divided	O
into	O
;	O
I	O
-	O
nondiabetic	O
,	O
II	O
-	O
diabetic	O
control	O
,	O
III	O
-	O
sitagliptin	S-chem
(	O
5mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
IV	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
250mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
V	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
500mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
and	O
VI	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
1000mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
.	O

The	O
l	B-chem
-	I-chem
glutamine	E-chem
and	O
sitagliptin	S-chem
treatment	O
was	O
8week	O
.	O

Plasma	O
glucose	S-chem
was	O
estimated	O
every	O
week	O
.	O

Body	O
weight	O
,	O
food	O
and	O
water	O
intake	O
were	O
recorded	O
daily	O
.	O

Glycosylated	O
haemoglobin	S-geneN
,	O
lipid	O
profile	O
,	O
plasma	O
and	O
colonic	O
active	O
(	O
GLP	B-geneY
-	I-geneY
1	E-geneY
)	O
(	O
7	O
-	O
36	O
)	O
amide	S-chem
,	O
mRNA	O
expression	O
of	O
proglucagon	O
GLP	B-geneY
-	I-geneY
1	E-geneY
,	O
plasma	O
and	O
pancreatic	O
insulin	S-geneN
,	O
histology	O
of	O
pancreata	O
and	O
biomarkers	O
of	O
oxidative	O
stress	O
(	O
superoxidase	B-geneN
dismutase	E-geneN
,	O
reduced	O
glutathione	S-chem
,	O
malondialdehyde	S-chem
,	O
glutathione	B-geneN
peroxidase	E-geneN
,	O
glutathione	B-geneN
S	I-geneN
transferase	E-geneN
)	O
were	O
measured	O
after	O
8week	O
.	O

In	O
acute	O
study	O
,	O
the	O
rats	O
were	O
divided	O
into	O
I	O
-	O
glucose	S-chem
(	O
2.5g	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
II	O
-	O
sitagliptin	S-chem
(	O
5mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
III	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
250mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
IV	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
500mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
and	O
V	O
-	O
l	B-chem
-	I-chem
glutamine	E-chem
(	O
1000mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
.	O

Plasma	O
glucose	S-chem
,	O
active	O
GLP	B-geneY
-	I-geneY
1	E-geneY
(	O
7	O
-	O
36	O
)	O
amide	S-chem
concentration	O
and	O
insulin	S-geneN
levels	O
were	O
measured	O
after	O
glucose	S-chem
loading	O
.	O

The	O
docking	O
data	O
indicated	O
that	O
l	B-chem
-	I-chem
glutamine	E-chem
bind	O
to	O
the	O
GLP	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
.	O
l	B-chem-C3-1
-	I-chem-C3-1
glutamine	E-chem-C3-1
decreased	O
plasma	O
glucose	S-chem
,	O
increased	O
plasma	O
and	O
pancreatic	O
insulin	S-geneN-C3-2
,	O
increased	O
plasma	O
and	O
colonic	O
active	O
GLP	B-geneY-C3-2
-	I-geneY-C3-2
1	E-geneY-C3-2
(	O
7	O
-	O
36	O
)	O
amide	S-chem
secretion	O
as	O
well	O
as	O
decreased	O
oxidative	O
stress	O
in	O
streptozotocin	S-chem
-	O
nicotinamide	S-chem
induced	O
diabetic	O
rats	O
.	O

Ovarian	O
Expression	O
of	O
Insulin	B-geneY
-	I-geneY
Like	I-geneY
Peptide	I-geneY
3	E-geneY
(	O
INSL3	S-geneY
)	O
and	O
Its	O
Receptor	O
(	O
RXFP2	S-geneY
)	O
During	O
Development	O
of	O
Bovine	O
Antral	O
Follicles	O
and	O
Corpora	O
Lutea	O
and	O
Measurement	O
of	O
Circulating	O
INSL3	S-geneY
Levels	O
During	O
Synchronized	O
Estrous	O
Cycles	O
.	O

Insulin	B-geneY
-	I-geneY
like	I-geneY
peptide	I-geneY
3	E-geneY
(	O
INSL3	S-geneY
)	O
,	O
a	O
major	O
product	O
of	O
testicular	O
Leydig	O
cells	O
,	O
is	O
also	O
expressed	O
by	O
the	O
ovary	O
,	O
but	O
its	O
functional	O
role	O
remains	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
quantified	O
expression	O
of	O
INSL3	S-geneY
and	O
its	O
receptor	O
RXFP2	S-geneY
in	O
theca	O
interna	O
cell	O
(	O
TIC	O
)	O
and	O
granulosa	O
cell	O
compartments	O
of	O
developing	O
bovine	O
antral	O
follicles	O
and	O
in	O
corpora	O
lutea	O
(	O
CL	O
)	O
.	O

INSL3	S-geneY
and	O
RXFP2	S-geneY
mRNA	O
levels	O
were	O
much	O
higher	O
in	O
TIC	O
than	O
granulosa	O
cell	O
and	O
increased	O
progressively	O
during	O
follicle	O
maturation	O
with	O
INSL3	S-geneY
peaking	O
in	O
large	O
(	O
11	O
-	O
18	O
mm	O
)	O
estrogen	S-chem
-	O
active	O
follicles	O
and	O
RXFP2	S-geneY
peaking	O
in	O
9	O
-	O
to	O
10	O
-	O
mm	O
follicles	O
before	O
declining	O
in	O
larger	O
(	O
11	O
-	O
18	O
mm	O
)	O
follicles	O
.	O

Expression	O
of	O
both	O
INSL3	S-geneY
and	O
RXFP2	S-geneY
in	O
CL	O
was	O
much	O
lower	O
than	O
in	O
TIC	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
confirmed	O
abundant	O
expression	O
of	O
INSL3	S-geneY
mRNA	O
and	O
protein	O
in	O
TIC	O
.	O

These	O
observations	O
indicate	O
follicular	O
TIC	O
rather	O
than	O
CL	O
as	O
the	O
primary	O
site	O
of	O
both	O
INSL3	S-geneY
production	O
and	O
action	O
,	O
implying	O
a	O
predominantly	O
autocrine	O
/	O
paracrine	O
role	O
in	O
TIC	O
.	O

To	O
corroborate	O
the	O
above	O
findings	O
,	O
we	O
showed	O
that	O
in	O
vitro	O
exposure	O
of	O
TIC	O
to	O
a	O
luteinizing	O
concentration	O
of	O
LH	S-geneN
greatly	O
attenuated	O
expression	O
of	O
both	O
INSL3	S-geneY
and	O
its	O
receptor	O
while	O
increasing	O
progesterone	S-chem
secretion	O
and	O
expression	O
of	O
STAR	S-geneY
and	O
CYP11A1	S-geneY
.	O

Moreover	O
,	O
in	O
vivo	O
,	O
a	O
significant	O
cyclic	O
variation	O
in	O
plasma	O
INSL3	S-geneY
was	O
observed	O
during	O
synchronized	O
estrous	O
cycles	O
.	O

INSL3	S-geneY
and	O
estradiol	B-chem
-	I-chem
17β	E-chem
followed	O
a	O
similar	O
pattern	O
,	O
both	O
increasing	O
after	O
luteolysis	O
,	O
before	O
falling	O
sharply	O
after	O
the	O
LH	S-geneN
surge	O
.	O

Thus	O
,	O
theca	O
-	O
derived	O
INSL3	S-geneY
,	O
likely	O
from	O
the	O
dominant	O
preovulatory	O
follicle	O
,	O
is	O
detectable	O
in	O
peripheral	O
blood	O
of	O
cattle	O
,	O
and	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
luteinization	O
induced	O
by	O
the	O
preovulatory	O
LH	S-geneN
surge	O
.	O

Collectively	O
,	O
these	O
findings	O
underscore	O
the	O
likely	O
role	O
of	O
INSL3	S-geneY
as	O
an	O
important	O
intrafollicular	O
modulator	O
of	O
TIC	O
function	O
/	O
steroidogenesis	O
,	O
while	O
raising	O
doubts	O
about	O
its	O
potential	O
contribution	O
to	O
CL	O
function	O
.	O

Metformin	S-chem-C4-1
-	O
mediated	O
downregulation	O
of	O
p38	S-geneN-C4-2
mitogen	B-geneN-C4-2
-	I-geneN-C4-2
activated	I-geneN-C4-2
protein	I-geneN-C4-2
kinase	E-geneN-C4-2
-	O
dependent	O
excision	O
repair	O
cross	O
-	O
complementing	O
1	O
decreases	O
DNA	O
repair	O
capacity	O
and	O
sensitizes	O
human	O
lung	O
cancer	O
cells	O
to	O
paclitaxel	S-chem
.	O

Metformin	S-chem
,	O
an	O
extensively	O
used	O
and	O
well	O
-	O
tolerated	O
drug	O
for	O
treating	O
individuals	O
with	O
type	O
2	O
diabetes	O
,	O
has	O
recently	O
gained	O
significant	O
attention	O
as	O
an	O
anticancer	O
drug	O
.	O

On	O
the	O
other	O
hand	O
,	O
paclitaxel	S-chem
(	O
Taxol	S-chem
)	O
is	O
a	O
new	O
antineoplastic	O
drug	O
that	O
has	O
shown	O
promise	O
in	O
the	O
treatment	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

High	O
expression	O
levels	O
of	O
excision	B-geneY
repair	I-geneY
cross	I-geneY
-	I-geneY
complementary	I-geneY
1	E-geneY
(	O
ERCC1	S-geneY
)	O
in	O
cancers	O
have	O
been	O
positively	O
associated	O
with	O
the	O
DNA	O
repair	O
capacity	O
and	O
a	O
poor	O
prognosis	O
in	O
NSCLC	O
patients	O
treated	O
with	O
platinum	S-chem
-	O
containing	O
chemotherapy	O
.	O

In	O
this	O
current	O
study	O
,	O
paclitaxel	S-chem-C3-1
was	O
found	O
to	O
increase	O
phosphorylation	O
of	O
mitogen	B-geneN-C3-2
-	I-geneN-C3-2
activated	I-geneN-C3-2
protein	I-geneN-C3-2
kinase	E-geneN-C3-2
(	O
MAPK	O
)	O
kinase	O
3	O
/	O
6	O
(	O
MKK3	B-geneN
/	I-geneN
6	E-geneN
)	O
-	O
p38	S-geneN-C3-2
MAPK	S-geneN-C3-2
as	O
well	O
as	O
protein	O
and	O
mRNA	O
levels	O
of	O
ERCC1	S-geneY-C3-2
in	O
H1650	O
and	O
H1703	O
cells	O
.	O

Moreover	O
,	O
paclitaxel	S-chem-C3-1
-	O
induced	O
ERCC1	S-geneY-C3-2
protein	O
and	O
mRNA	O
levels	O
significantly	O
decreased	O
via	O
the	O
downregulation	O
of	O
p38	S-geneN-C4-2
activity	O
by	O
either	O
a	O
p38	S-geneN-C4-2
MAPK	S-geneN-C4-2
inhibitor	O
SB202190	S-chem-C4-1
or	O
p38	S-geneN
knockdown	O
with	O
specific	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
.	O

Specific	O
inhibition	O
of	O
ERCC1	S-geneY
with	O
siRNA	O
was	O
found	O
to	O
enhance	O
the	O
paclitaxel	S-chem
-	O
induced	O
cytotoxic	O
effect	O
and	O
growth	O
inhibition	O
.	O

Furthermore	O
,	O
metformin	S-chem-C4-1
was	O
able	O
to	O
not	O
only	O
decrease	O
the	O
paclitaxel	S-chem-C3-1
-	O
induced	O
p38	S-geneN-MU-2
MAPK	S-geneN-MU-2
-	O
mediated	O
ERCC1	S-geneY-MU-2
expression	O
,	O
but	O
also	O
augment	O
the	O
cytotoxic	O
effect	O
induced	O
by	O
paclitaxel	S-chem
.	O

Finally	O
,	O
expression	O
of	O
constitutive	O
activate	O
MKK6	S-geneY
or	O
HA	O
-	O
p38	S-geneN
MAPK	S-geneN
vectors	O
in	O
lung	O
cancer	O
cells	O
was	O
able	O
to	O
abrogate	O
ERCC1	S-geneY-C4-2
downregulation	O
by	O
metformin	S-chem-C4-1
and	O
paclitaxel	S-chem-C4-1
as	O
well	O
as	O
cell	O
viability	O
and	O
DNA	O
repair	O
capacity	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
inhibition	O
of	O
the	O
p38	S-geneN-C4-2
MAPK	S-geneN-C4-2
signaling	O
by	O
metformin	S-chem-C4-1
coupled	O
with	O
paclitaxel	S-chem
therapy	O
in	O
human	O
NSCLC	O
cells	O
may	O
be	O
a	O
clinically	O
useful	O
combination	O
,	O
which	O
however	O
will	O
require	O
further	O
validation	O
.	O

Tamoxifen	S-chem-MU-1
represses	O
miR	B-geneN-C4-2
-	I-geneN-C4-2
200	E-geneN-C4-2
microRNAs	O
and	O
promotes	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
by	O
up	O
-	O
regulating	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Myc	E-geneY-C3-2
in	O
endometrial	O
carcinoma	O
cell	O
lines	O
.	O

Although	O
tamoxifen	S-chem
(	O
TAM	S-chem
)	O
,	O
a	O
selective	O
estrogen	B-geneY
receptor	E-geneY
modulator	O
,	O
has	O
been	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
hormone	O
-	O
responsive	O
breast	O
cancer	O
,	O
its	O
estrogen	S-chem
-	O
like	O
effect	O
increases	O
the	O
risk	O
of	O
endometrial	O
cancer	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
TAM	S-chem
-	O
induced	O
endometrial	O
carcinoma	O
still	O
remain	O
unclear	O
.	O

In	O
this	O
report	O
,	O
we	O
explored	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
TAM	S-chem
-	O
induced	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
ECC	O
-	O
1	O
and	O
Ishikawa	O
endometrial	O
cancer	O
cell	O
lines	O
and	O
found	O
miR	B-geneN
-	I-geneN
200	E-geneN
is	O
involved	O
in	O
this	O
process	O
via	O
the	O
regulation	O
of	O
c	B-geneY
-	I-geneY
Myc	E-geneY
.	O

When	O
treated	O
with	O
TAM	S-chem
,	O
ECC	O
-	O
1	O
and	O
Ishikawa	O
cells	O
were	O
characterized	O
by	O
higher	O
invasiveness	O
and	O
motility	O
and	O
underwent	O
EMT	O
.	O
miR	B-geneN-C4-2
-	I-geneN-C4-2
200	E-geneN-C4-2
,	O
a	O
miRNA	O
family	O
with	O
tumor	O
suppressive	O
functions	O
in	O
a	O
wide	O
range	O
of	O
cancers	O
,	O
was	O
found	O
reduced	O
in	O
response	O
to	O
TAM	S-chem-C4-1
treatment	O
.	O

Consistent	O
with	O
zinc	B-geneY
finger	I-geneY
E	I-geneY
-	I-geneY
box	I-geneY
binding	I-geneY
homeobox	I-geneY
2	E-geneY
,	O
which	O
was	O
confirmed	O
as	O
a	O
direct	O
target	O
of	O
miR	B-geneY
-	I-geneY
200b	E-geneY
in	O
endometrial	O
cancer	O
cell	O
lines	O
,	O
some	O
other	O
key	O
factors	O
of	O
EMT	O
such	O
as	O
Snail	S-geneY-C3-2
and	O
N	B-geneY-C3-2
-	I-geneY-C3-2
cadherin	E-geneY-C3-2
increased	O
,	O
whereas	O
E	B-geneY-C4-2
-	I-geneY-C4-2
cadherin	E-geneY-C4-2
decreased	O
in	O
the	O
TAM	S-chem-MU-1
-	O
treated	O
cells	O
,	O
contributing	O
to	O
TAM	S-chem
-	O
induced	O
EMT	O
in	O
these	O
endometrial	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
c	B-geneY
-	I-geneY
Myc	E-geneY
directly	O
binds	O
to	O
and	O
represses	O
the	O
promoter	O
of	O
miR	B-geneN
-	I-geneN
200	E-geneN
miRNAs	O
,	O
and	O
its	O
up	O
-	O
regulation	O
in	O
TAM	S-chem-C4-1
-	O
treated	O
endometrial	O
cancer	O
cells	O
leads	O
to	O
the	O
down	O
-	O
regulation	O
of	O
miR	B-geneN-C4-2
-	I-geneN-C4-2
200	E-geneN-C4-2
and	O
eventually	O
to	O
EMT	O
.	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
TAM	S-chem-MU-1
can	O
repress	O
the	O
miR	B-geneN-C4-2
-	I-geneN-C4-2
200	E-geneN-C4-2
family	O
and	O
induce	O
EMT	O
via	O
the	O
up	O
-	O
regulation	O
of	O
c	B-geneY-C3-2
-	I-geneY-C3-2
Myc	E-geneY-C3-2
in	O
endometrial	O
cancer	O
cells	O
.	O

These	O
findings	O
describe	O
a	O
possible	O
mechanism	O
of	O
TAM	S-chem
-	O
induced	O
EMT	O
in	O
endometrial	O
cancer	O
and	O
provide	O
a	O
potential	O
new	O
therapeutic	O
strategy	O
for	O
it	O
.	O

Dexamethasone	S-chem
-	O
mediated	O
changes	O
in	O
adipose	O
triacylglycerol	S-chem
metabolism	O
are	O
exaggerated	O
,	O
not	O
diminished	O
,	O
in	O
the	O
absence	O
of	O
a	O
functional	O
GR	B-geneN
dimerization	I-geneN
domain	E-geneN
.	O

The	O
glucocorticoid	B-geneY
(	I-geneY
GC	I-geneY
)	I-geneY
receptor	E-geneY
(	O
GR	S-geneY
)	O
has	O
multiple	O
effector	O
mechanisms	O
,	O
including	O
dimerization	O
-	O
mediated	O
transactivation	O
of	O
target	O
genes	O
via	O
DNA	O
binding	O
and	O
transcriptional	O
repression	O
mediated	O
by	O
protein	O
-	O
protein	O
interactions	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
developing	O
selective	O
GR	S-geneY
modulators	O
that	O
would	O
dissociate	O
adverse	O
effects	O
from	O
therapeutic	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mouse	O
has	O
a	O
mutation	O
in	O
the	O
dimerization	O
domain	O
of	O
GR	S-geneY
and	O
has	O
been	O
shown	O
to	O
have	O
attenuated	O
transactivation	O
with	O
intact	O
repression	O
.	O

To	O
understand	O
the	O
role	O
of	O
GR	S-geneY
dimerization	O
-	O
dependent	O
targets	O
in	O
multiple	O
tissues	O
,	O
we	O
measured	O
metabolic	O
fluxes	O
through	O
several	O
disease	O
-	O
relevant	O
GC	O
target	O
pathways	O
using	O
heavy	O
water	O
labeling	O
and	O
mass	O
spectrometry	O
in	O
wild	O
-	O
type	O
and	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
administered	O
the	O
potent	O
GC	O
dexamethasone	S-chem
(	O
DEX	S-chem
)	O
.	O

Absolute	O
triglyceride	S-chem
synthesis	O
was	O
increased	O
in	O
both	O
wild	O
-	O
type	O
and	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
by	O
DEX	S-chem
in	O
the	O
inguinal	O
and	O
epididymal	O
fat	O
depots	O
.	O

GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
showed	O
an	O
exaggerated	O
response	O
to	O
DEX	S-chem
in	O
both	O
depots	O
.	O

De	O
novo	O
lipogenesis	O
was	O
also	O
greatly	O
increased	O
in	O
both	O
depots	O
in	O
response	O
to	O
DEX	S-chem
in	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
,	O
but	O
not	O
wild	O
-	O
type	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
inhibitory	O
effect	O
of	O
DEX	S-chem
on	O
bone	O
and	O
skin	O
collagen	O
synthesis	O
rates	O
was	O
greater	O
in	O
wild	O
-	O
type	O
compared	O
with	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
.	O

Wild	O
-	O
type	O
mice	O
were	O
more	O
sensitive	O
to	O
DEX	S-chem
-	O
dependent	O
decreases	O
in	O
insulin	S-geneN
sensitivity	O
than	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
.	O

Wild	O
-	O
type	O
and	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
were	O
equally	O
sensitive	O
to	O
DEX	S-chem
-	O
dependent	O
decreases	O
in	O
muscle	O
protein	O
synthesis	O
.	O

Chronic	O
elevation	O
of	O
GCs	O
in	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
results	O
in	O
severe	O
runting	O
and	O
lethality	O
.	O

In	O
conclusion	O
,	O
some	O
metabolic	O
effects	O
of	O
GC	O
treatment	O
are	O
exaggerated	O
in	O
adipose	O
tissue	O
of	O
GR	S-geneY
(	O
dim	O
/	O
dim	O
)	O
mice	O
,	O
suggesting	O
that	O
selective	O
GR	S-geneY
modulators	O
based	O
on	O
dissociating	O
GR	S-geneY
transactivation	O
from	O
repression	O
should	O
be	O
evaluated	O
carefully	O
.	O

Evaluation	O
of	O
flutamide	S-chem
genotoxicity	O
in	O
rats	O
and	O
in	O
primary	O
human	O
hepatocytes	O
.	O

Flutamide	S-chem-C4-1
,	O
an	O
effective	O
competitive	O
inhibitor	O
of	O
the	O
androgen	B-geneY-C4-2
receptor	E-geneY-C4-2
used	O
orally	O
for	O
palliative	O
treatment	O
of	O
prostatic	O
carcinoma	O
and	O
regulation	O
of	O
prostatic	O
hyperplasia	O
was	O
evaluated	O
for	O
its	O
genotoxic	O
effects	O
in	O
the	O
intact	O
rat	O
and	O
in	O
primary	O
cultures	O
of	O
human	O
hepatocytes	O
.	O

Negative	O
responses	O
were	O
obtained	O
in	O
all	O
the	O
in	O
vivo	O
assays	O
as	O
well	O
as	O
in	O
the	O
in	O
vitro	O
assay	O
.	O

In	O
rats	O
given	O
a	O
single	O
oral	O
dose	O
of	O
500	O
mg	O
/	O
kg	O
flutamide	S-chem
,	O
fragmentation	O
and	O
repair	O
of	O
liver	O
DNA	O
were	O
absent	O
,	O
and	O
no	O
increase	O
was	O
observed	O
in	O
the	O
frequency	O
of	O
micronucleated	O
hepatocytes	O
.	O

In	O
the	O
liver	O
of	O
rats	O
given	O
flutamide	S-chem-C3-1
as	O
initiating	O
agent	O
at	O
the	O
dose	O
of	O
500	O
mg	O
/	O
kg	O
/	O
week	O
for	O
6	O
successive	O
weeks	O
,	O
gamma	B-geneN-C3-2
-	I-geneN-C3-2
glutamyltraspeptidase	E-geneN-C3-2
-	O
positive	O
foci	O
were	O
detected	O
only	O
in	O
3	O
of	O
10	O
rats	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
promoting	O
effect	O
on	O
the	O
development	O
of	O
aberrant	O
crypt	O
foci	O
in	O
rats	O
given	O
100	O
mg	O
/	O
kg	O
flutamide	S-chem
on	O
alternate	O
days	O
for	O
8	O
successive	O
weeks	O
.	O

In	O
primary	O
cultures	O
of	O
human	O
hepatocytes	O
from	O
one	O
male	O
and	O
one	O
female	O
donor	O
DNA	O
fragmentation	O
as	O
measured	O
by	O
the	O
Comet	O
assays	O
,	O
and	O
DNA	O
repair	O
synthesis	O
as	O
revealed	O
by	O
quantitative	O
autoradiography	O
,	O
were	O
absent	O
after	O
a	O
20	O
hr	O
exposure	O
to	O
flutamide	S-chem
concentrations	O
ranging	O
from	O
18	O
to	O
56	O
microM	O
.	O

Taken	O
as	O
a	O
whole	O
,	O
our	O
results	O
seem	O
to	O
indicate	O
that	O
flutamide	S-chem
is	O
a	O
non	O
-	O
genotoxic	O
drug	O
.	O

Effect	O
of	O
hormonal	O
agents	O
on	O
monocyte	B-geneY
chemotactic	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
expression	O
by	O
endometrial	O
epithelial	O
cells	O
of	O
women	O
with	O
endometriosis	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
hormonal	O
agents	O
used	O
in	O
the	O
medical	O
treatment	O
of	O
endometriosis	O
,	O
such	O
as	O
danazol	S-chem
and	O
GnRH	S-geneY
agonist	O
,	O
exert	O
direct	O
regulatory	O
action	O
on	O
monocyte	B-geneY
chemotactic	I-geneY
protein	I-geneY
-	I-geneY
1	E-geneY
(	O
MCP	B-geneY
-	I-geneY
1	E-geneY
)	O
expression	O
by	O
endometrial	O
epithelial	O
cells	O
.	O

DESIGN	O
:	O
Primary	O
cultures	O
of	O
epithelial	O
cells	O
isolated	O
from	O
human	O
endometrium	O
were	O
exposed	O
to	O
different	O
concentrations	O
of	O
cytokines	S-geneN
and	O
steroid	S-chem
hormone	O
analogs	O
.	O

Expression	O
of	O
MCP	B-geneY
-	I-geneY
1	E-geneY
was	O
analyzed	O
at	O
the	O
levels	O
of	O
protein	O
and	O
messenger	O
RNA	O
.	O

SETTING	O
:	O
Gynecology	O
clinic	O
and	O
laboratory	O
of	O
endocrinology	O
of	O
reproduction	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
Women	O
presenting	O
for	O
infertility	O
or	O
pelvic	O
pain	O
in	O
whom	O
endometriosis	O
was	O
diagnosed	O
by	O
using	O
laparoscopy	O
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Endometrial	O
tissue	O
biopsy	O
performed	O
at	O
laparoscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Secretion	O
of	O
MCP	B-geneY
-	I-geneY
1	E-geneY
protein	O
was	O
measured	O
by	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
mRNA	O
steady	O
-	O
state	O
levels	O
were	O
measured	O
by	O
performing	O
Northern	O
blot	O
analysis	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
Buserelin	B-chem-C5-1
acetate	E-chem-C5-1
,	O
a	O
GnRH	S-geneY-C5-2
agonist	O
(	O
0.1	O
-	O
10	O
ng	O
/	O
mL	O
)	O
,	O
had	O
no	O
significant	O
effect	O
on	O
MCP	B-geneY
-	I-geneY
1	E-geneY
expression	O
,	O
whereas	O
danazol	S-chem-C4-1
(	O
10	O
(	O
-	O
7	O
)	O
-	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
a	O
testosterone	S-chem-C4-1
analog	O
,	O
and	O
dexamethasone	S-chem-C4-1
,	O
an	O
anti	O
-	O
inflammatory	O
glucocorticoid	O
hormone	O
(	O
10	O
(	O
-	O
12	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
showed	O
a	O
direct	O
and	O
a	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
MCP	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
expression	O
.	O

This	O
effect	O
occurred	O
at	O
the	O
level	O
of	O
protein	O
and	O
mRNA	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
The	O
findings	O
of	O
the	O
study	O
may	O
affect	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
hormonal	O
treatments	O
act	O
on	O
endometriosis	O
and	O
influence	O
its	O
clinical	O
manifestations	O
.	O

N2	B-chem
-	I-chem
acetylphenelzine	E-chem
:	O
effects	O
on	O
rat	O
brain	O
GABA	S-chem
,	O
alanine	S-chem
and	O
biogenic	O
amines	S-chem
.	O

The	O
neurochemical	O
properties	O
of	O
N2	B-chem
-	I-chem
acetylphenelzine	E-chem
were	O
compared	O
with	O
those	O
of	O
phenelzine	S-chem
in	O
a	O
rat	O
model	O
.	O

N2	B-chem
-	I-chem
Acetylphenelzine	E-chem
is	O
a	O
relatively	O
potent	O
inhibitor	O
of	O
monoamine	B-geneN
oxidase	I-geneN
-	I-geneN
A	I-geneN
and	I-geneN
-	I-geneN
B	E-geneN
and	O
causes	O
increases	O
in	O
whole	O
-	O
brain	O
levels	O
of	O
noradrenaline	S-chem
and	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
,	O
and	O
decreases	O
in	O
homovanillic	B-chem
acid	E-chem
,	O
5	B-chem
-	I-chem
hydroxyindole	I-chem
-	I-chem
3	I-chem
-	I-chem
acetic	I-chem
acid	E-chem
,	O
and	O
3,4	B-chem
-	I-chem
dihydroxyphenylacetic	I-chem
acetic	E-chem
after	O
acute	O
i.p	O
.	O
administration	O
of	O
the	O
drug	O
.	O

Phenelzine	S-chem-C4-1
is	O
a	O
more	O
potent	O
monoamine	B-geneN-C4-2
oxidase	E-geneN-C4-2
inhibitor	O
than	O
is	O
N2	B-chem-C4-1
-	I-chem-C4-1
acetylphenelzine	E-chem-C4-1
.	O

The	O
most	O
marked	O
difference	O
in	O
the	O
profile	O
was	O
that	O
N2	B-chem
-	I-chem
acetylphenelzine	E-chem
had	O
no	O
effect	O
on	O
whole	O
brain	O
levels	O
of	O
the	O
amino	B-chem
acid	E-chem
neurotransmitters	O
alanine	S-chem
and	O
gamma	B-chem
-	I-chem
aminobutyric	I-chem
acid	E-chem
,	O
whereas	O
phenelzine	S-chem
caused	O
dramatic	O
increases	O
.	O

Acetylation	O
of	O
phenelzine	S-chem-C4-1
at	O
the	O
N2	S-chem-C4-1
position	O
presumably	O
interferes	O
with	O
the	O
inhibition	O
of	O
the	O
transaminase	S-geneN-C4-2
enzymes	O
for	O
gamma	B-chem-C4-1
-	I-chem-C4-1
aminobutyric	I-chem-C4-1
acid	E-chem-C4-1
and	O
alanine	S-chem-C4-1
.	O

Decreased	O
serum	O
concentrations	O
of	O
25	B-chem
-	I-chem
hydroxycholecalciferol	E-chem
are	O
associated	O
with	O
increased	O
risk	O
of	O
progression	O
to	O
impaired	O
fasting	O
glucose	S-chem
and	O
diabetes	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
association	O
between	O
vitamin	B-chem
D	E-chem
status	O
and	O
the	O
risk	O
of	O
incident	O
impaired	O
fasting	O
glucose	S-chem
(	O
IFG	O
)	O
and	O
diabetes	O
in	O
a	O
population	O
-	O
based	O
cohort	O
of	O
diabetes	O
-	O
free	O
subjects	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
historical	O
prospective	O
cohort	O
study	O
of	O
subjects	O
from	O
the	O
Clalit	O
Health	O
Services	O
database	O
,	O
which	O
includes	O
information	O
on	O
nearly	O
4	O
million	O
people	O
,	O
diabetes	O
-	O
free	O
subjects	O
aged	O
40	O
-	O
70	O
years	O
with	O
serum	O
25	B-chem
-	I-chem
hydroxycholecalciferol	E-chem
(	O
25	B-chem
-	I-chem
OHD	E-chem
)	O
measurements	O
available	O
were	O
followed	O
for	O
2	O
years	O
to	O
assess	O
the	O
development	O
of	O
IFG	O
and	O
diabetes	O
in	O
five	O
25	B-chem
-	I-chem
OHD	E-chem
subgroups	O
:	O
≥	O
25	O
,	O
25.1	O
-	O
37.5	O
,	O
37.6	O
-	O
50	O
,	O
50.1	O
-	O
75	O
,	O
and	O
>	O
75	O
nmol	O
/	O
L	O
.	O

RESULTS	O
The	O
baseline	O
cohort	O
included	O
117,960	O
adults	O
:	O
83,526	O
normoglycemic	O
subjects	O
and	O
34,434	O
subjects	O
with	O
IFG	O
.	O

During	O
follow	O
-	O
up	O
,	O
8,629	O
subjects	O
(	O
10.3	O
%	O
of	O
the	O
normoglycemic	O
group	O
)	O
developed	O
IFG	O
,	O
and	O
2,162	O
subjects	O
(	O
1.8	O
%	O
of	O
the	O
total	O
cohort	O
)	O
progressed	O
to	O
diabetes	O
.	O

A	O
multivariable	O
model	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
population	O
group	O
,	O
immigrant	O
status	O
,	O
BMI	O
,	O
season	O
of	O
vitamin	B-chem
D	E-chem
measurement	O
,	O
LDL	S-geneN
and	O
HDL	S-geneN
cholesterol	S-chem
,	O
triglycerides	S-chem
,	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
history	O
of	O
hypertension	O
or	O
cardiovascular	O
disease	O
,	O
Charlson	O
comorbidity	O
index	O
,	O
smoking	O
,	O
and	O
socioeconomic	O
status	O
revealed	O
an	O
inverse	O
association	O
between	O
25	B-chem
-	I-chem
OHD	E-chem
and	O
the	O
risk	O
of	O
progression	O
to	O
IFG	O
and	O
diabetes	O
.	O

The	O
odds	O
of	O
transitioning	O
from	O
normoglycemia	O
to	O
IFG	O
,	O
from	O
normoglycemia	O
to	O
diabetes	O
,	O
and	O
from	O
IFG	O
to	O
diabetes	O
in	O
subjects	O
with	O
a	O
25	B-chem
-	I-chem
OHD	E-chem
level	O
≤	O
25	O
nmol	O
/	O
L	O
were	O
greater	O
than	O
those	O
of	O
subjects	O
with	O
a	O
25	B-chem
-	I-chem
OHD	E-chem
level	O
>	O
75	O
nmol	O
/	O
L	O
[	O
odds	O
ratio	O
1.13	O
(	O
95	O
%	O
CI	O
1.03	O
-	O
1.24	O
)	O
,	O
1.77	O
(	O
1.11	O
-	O
2.83	O
)	O
,	O
and	O
1.43	O
(	O
1.16	O
-	O
1.76	O
)	O
,	O
respectively	O
]	O
.	O

CONCLUSIONS	O
Vitamin	B-chem
D	E-chem
deficiency	O
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
IFG	O
and	O
diabetes	O
.	O

Antithrombotic	O
and	O
profibrinolytic	O
activities	O
of	O
isorhamnetin	B-chem
-	I-chem
3	I-chem
-	I-chem
O	I-chem
-	I-chem
galactoside	E-chem
and	O
hyperoside	S-chem
.	O

The	O
potential	O
anticoagulant	O
activities	O
of	O
two	O
single	O
compounds	O
,	O
isorhamnetin	B-chem
-	I-chem
3	I-chem
-	I-chem
O	I-chem
-	I-chem
galactoside	E-chem
(	O
IMG	S-chem
)	O
and	O
hyperoside	S-chem
,	O
from	O
Oenanthe	O
javanica	O
,	O
were	O
tested	O
.	O

The	O
anticoagulant	O
activities	O
were	O
investigated	O
by	O
measuring	O
activated	O
partial	O
thromboplastin	S-geneY
time	O
(	O
aPTT	O
)	O
and	O
prothrombin	S-geneY
time	O
(	O
PT	O
)	O
,	O
and	O
the	O
ability	O
to	O
inhibit	O
production	O
of	O
thrombin	S-geneY
and	O
activated	B-geneY
factor	I-geneY
X	E-geneY
(	O
FXa	S-geneY
)	O
was	O
investigated	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

And	O
,	O
the	O
effects	O
of	O
the	O
compounds	O
on	O
expression	O
of	O
plasminogen	B-geneY
activator	I-geneY
inhibitor	I-geneY
type	I-geneY
1	E-geneY
(	O
PAI	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
tissue	B-geneY
-	I-geneY
type	I-geneY
plasminogen	I-geneY
activator	E-geneY
(	B-geneY
t	I-geneY
-	I-geneY
PA	E-geneY
)	O
were	O
tested	O
in	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
(	I-geneY
TNF	I-geneY
)	I-geneY
-	I-geneY
α	E-geneY
activated	O
HUVECs	O
.	O

Treatment	O
with	O
IMG	S-chem-C4-1
and	O
hyperoside	S-chem-C4-1
resulted	O
in	O
significantly	O
prolonged	O
aPTT	O
and	O
PT	O
and	O
inhibition	O
of	O
the	O
activities	O
of	O
thrombin	S-geneY-C4-2
and	O
FXa	S-geneY-C4-2
,	O
and	O
IMG	S-chem-MU-1
or	O
hyperoside	S-chem-C4-1
inhibited	O
production	O
of	O
thrombin	S-geneY-MU-2
and	O
FXa	S-geneY-C4-2
in	O
HUVECs	O
.	O

In	O
accordance	O
with	O
these	O
anticoagulant	O
activities	O
,	O
both	O
agents	O
elicited	O
anticoagulant	O
effects	O
in	O
mouse	O
.	O

In	O
addition	O
,	O
treatment	O
with	O
IMG	S-chem-C4-1
and	O
hyperoside	S-chem-C4-1
resulted	O
in	O
inhibition	O
of	O
TNF	B-geneY-C4-2
-	I-geneY-C4-2
α	E-geneY-C4-2
-	O
induced	O
production	O
of	O
PAI	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
,	O
and	O
treatment	O
with	O
IMG	S-chem-C4-1
resulted	O
in	O
significant	O
reduction	O
of	O
the	O
PAI	B-geneY-C4-2
-	I-geneY-C4-2
1	E-geneY-C4-2
to	O
t	B-geneY-C4-2
-	I-geneY-C4-2
PA	E-geneY-C4-2
ratio	O
.	O

The	O
anticoagulant	O
and	O
profibrinolytic	O
effects	O
of	O
IMG	S-chem
were	O
greater	O
than	O
those	O
of	O
hyperoside	S-chem
,	O
indicating	O
positive	O
regulation	O
of	O
its	O
anticoagulant	O
function	O
by	O
the	O
methoxy	S-chem
group	O
of	O
IMG	S-chem
.	O

IMG	S-chem
and	O
hyperoside	S-chem
possess	O
antithrombotic	O
activities	O
and	O
offer	O
bases	O
for	O
development	O
of	O
a	O
novel	O
anticoagulant	O
.	O

